<SEC-DOCUMENT>0001193125-26-263731.txt : 20260609
<SEC-HEADER>0001193125-26-263731.hdr.sgml : 20260609
<ACCEPTANCE-DATETIME>20260609160845
ACCESSION NUMBER:		0001193125-26-263731
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		91
FILED AS OF DATE:		20260609
DATE AS OF CHANGE:		20260609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclerion Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001755237
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831895370
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295175
		FILM NUMBER:		261076146

	BUSINESS ADDRESS:	
		STREET 1:		301 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-621-7722

	MAIL ADDRESS:	
		STREET 1:		301 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d111069ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ck0001755237="http://www.cyclerion.com/20260331" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-4/A</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden167030477" contextRef="P01_01_2026To03_31_2026">S-4/A</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2026To03_31_2026" id="ixv-59443">0001755237</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2026To03_31_2026" id="ixv-59444">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2024To08_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-01</xbrli:startDate> <xbrli:endDate>2024-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2024To05_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-05-01</xbrli:startDate> <xbrli:endDate>2024-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_28_2023To07_28_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-28</xbrli:startDate> <xbrli:endDate>2023-07-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_22_2024To07_22_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-22</xbrli:startDate> <xbrli:endDate>2024-07-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_04_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-02-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_07_2025To05_07_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-05-07</xbrli:startDate> <xbrli:endDate>2025-05-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_LicenseAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_OptionAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PurchaseAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:PurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ck0001755237:InterestAndOtherIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:CyclerionLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_LicenseAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:LicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_OptionAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_PurchaseAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:PurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ck0001755237:InterestAndOtherIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaMaterialPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:CyclerionLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-12-13</xbrli:startDate> <xbrli:endDate>2024-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2025To12_01_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-12-01</xbrli:startDate> <xbrli:endDate>2025-12-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ck0001755237:TisentoTherapeuticsHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_28_2023_MinimumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:WeightedAverageInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_28_2023_MinimumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TerminalDeclineRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_28_2023_TreasuryRateMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TreasuryRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_28_2023_MaximumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TerminalDeclineRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_28_2023_MaximumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:WeightedAverageInvestmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-07-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_OptionAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaMaterialPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-03-21</xbrli:startDate> <xbrli:endDate>2025-03-21</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-21</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_07_2025_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-05-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-09-19</xbrli:startDate> <xbrli:endDate>2025-09-19</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaResearchLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-03</xbrli:startDate> <xbrli:endDate>2021-06-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-03</xbrli:startDate> <xbrli:endDate>2021-06-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-02-01</xbrli:startDate> <xbrli:endDate>2026-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-03</xbrli:startDate> <xbrli:endDate>2026-01-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_03_2026To01_03_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:MedsteerCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-03</xbrli:startDate> <xbrli:endDate>2026-01-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-01-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_06_2026To01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-06</xbrli:startDate> <xbrli:endDate>2026-01-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_OptionAgreementMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:MedsteerCollaborationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_PerformanceSharesMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaMaterialPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2026To03_31_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-01-01</xbrli:startDate> <xbrli:endDate>2026-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesSeedPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesSeedPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-04-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2026To04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_CyclerionTherapeuticsIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:CyclerionTherapeuticsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-01</xbrli:startDate> <xbrli:endDate>2026-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2026To04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-01</xbrli:startDate> <xbrli:endDate>2026-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001755237</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;"> </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">As filed with the Securities and Exchange Commission on June 9, 2026 </div></div></div> <div style="text-align: right; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">No. 333-295175 </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;">&#160;</div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 16pt; font-weight: bold; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">UNITED <div style="display:inline;">STATES</div> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 16pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 12pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 17pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 17pt; letter-spacing: 0px; top: 0px;display:inline;">AMENDMENT NO. 1 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 17pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 17pt; letter-spacing: 0px; top: 0px;display:inline;">to</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 17pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 17pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 17pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden167030477;display:inline;">S-4</div></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 17pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">REGISTRATION STATEMENT</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bolder;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 11pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 11pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 22pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2026To03_31_2026" id="ixv-60769">CYCLERION THERAPEUTICS, INC.</ix:nonNumeric></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Exact name of registrant as specified in its charter) </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 7pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 34%;"/>
<td style="vertical-align: bottom;"/>
<td style="width: 32%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 32%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: center; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2026To03_31_2026" format="ixt-sec:stateprovnameen" id="ixv-60770">Massachusetts</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2026To03_31_2026" id="ixv-60771">2834</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2026To03_31_2026" id="ixv-60772">83-1895370</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(State or other jurisdiction of</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(Primary Standard Industrial</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">Classification Code Number)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(I.R.S. Employer</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">Identification No.)</div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2026To03_31_2026" id="ixv-146"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">245 First Street, 18</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">th Floor</div></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2026To03_31_2026" id="ixv-60773">Cambridge</ix:nonNumeric>, </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2026To03_31_2026" format="ixt-sec:stateprovnameen" id="ixv-60774">Massachusetts</ix:nonNumeric> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2026To03_31_2026" id="ixv-60775">02142</ix:nonNumeric></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2026To03_31_2026" id="ixv-60776">857</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2026To03_31_2026" id="ixv-60777">327-8778</ix:nonNumeric></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-60778">Regina Graul, Ph.D.</ix:nonNumeric></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">President and Chief Executive Officer </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-177"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">245 First Street, 18</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">th Floor</div></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-60779">Cambridge</ix:nonNumeric>, </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" format="ixt-sec:stateprovnameen" id="ixv-60780">Massachusetts</ix:nonNumeric> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-60781">02142</ix:nonNumeric></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-60782">857</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-60783">327-8778</ix:nonNumeric></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 7pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Copies of all communications, including communications sent to agent for service, should be sent to: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 50%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="text-align: center; vertical-align: top;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">William J. Michener, Esq.<br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Zachary Blume, Esq.</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">Ropes&#160;&amp; Gray LLP<br/>Prudential Tower<br/>800 Boylston Street<br/>Boston, Massachusetts 02199<br/>(617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">951-7000</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: center; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Ryan A. Murr, Esq.<br/>Branden C. Berns, Esq.<br/>Gibson, Dunn&#160;&amp; Crutcher LLP<br/>One Embarcadero Center, Suite 2600<br/>San Francisco, California 94111<br/>(415) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">393-8373</div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Approximate date of commencement of proposed sale of the securities to the public:</div></div> As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box&#8194;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-accelerated</div> filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 16%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 60%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 19%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 2%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2026To03_31_2026" format="ixt-sec:entityfilercategoryen" id="ixv-60784">Non-accelerated filer</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9746;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2026To03_31_2026" format="ixt:fixed-true" id="ixv-60785">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/>
<td colspan="2" style="height: 1.5pt;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2026To03_31_2026" format="ixt:fixed-false" id="ixv-60786">&#9744;</ix:nonNumeric></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;">Exchange Act Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">13e-4(i)</div> (Cross-Border Issuer Tender Offer)&#8194;&#9744; </div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;">Exchange Act Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">14d-1(d)</div> (Cross-Border Third-Party Tender Offer)&#8194;&#9744; </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div> </div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXPLANATORY NOTE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuances of (i)&#160;all shares of Cyclerion Common Stock in exchange for each share of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), (ii) all Cyclerion Warrants in exchange for Korsana Warrants (including Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), (iii) all shares of Cyclerion Series B Preferred Stock in exchange for shares of Korsana Series Seed Preferred Stock, (iv)&#160;all options to purchase shares of Cyclerion Common Stock in exchange for Korsana Options, (v)&#160;all Cyclerion RSUs in exchange for Korsana RSUs, (vi)&#160;all shares of Cyclerion Common Stock issuable upon exercise of Cyclerion Warrants issued in exchange for Korsana Warrants, (vii)&#160;all shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock issued in exchange for Korsana Series Seed Preferred Stock, (viii)&#160;all shares of Cyclerion Common Stock issuable upon exercise of options to purchase shares of Cyclerion Common Stock issued in exchange for Korsana Options, and (ix)&#160;all shares of Cyclerion Common Stock issuable upon settlement of Cyclerion RSUs issued in exchange for Korsana RSUs, are intended to be covered by this registration statement on Form <span style="white-space:nowrap">S-4</span> of which this proxy statement/prospectus is a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no difference between (A)&#160;the shares of Cyclerion Common Stock that will be issued in exchange for each share of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), (B) the shares of Cyclerion Common Stock that will be issuable upon the exercise of Cyclerion Warrants issued in exchange for Korsana Warrants, (C)&#160;the shares of Cyclerion Common Stock that will be issuable upon conversion of Cyclerion Series B Preferred Stock issued in exchange for each share of Korsana Series Seed Preferred Stock, (D)&#160;the shares of Cyclerion Common Stock that will be issuable upon the exercise of options to purchase shares of Cyclerion Common Stock issued in exchange for Korsana Options, and (E)&#160;the shares of Cyclerion Common Stock that will be issuable upon the settlement of Cyclerion RSUs that will be issued in exchange for Korsana RSUs. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">REFERENCES TO ADDITIONAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus incorporates important business and financial information about Cyclerion Therapeutics, Inc. that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (&#8220;SEC&#8221;) website (<span style="font-style:italic">www.sec.gov</span>) or upon your written or oral request by contacting 245 First Street, 18<sup style="font-size:75%; vertical-align:top">th</sup> Floor, Cambridge, MA 02142, Attention: Secretary, or by calling (857) <span style="white-space:nowrap">327-8778.</span> Cyclerion also maintains a website at <span style="font-style:italic">www.cyclerion.com</span>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. However, the information contained in or accessible through Cyclerion&#8217;s website is not part of the accompanying proxy statement/prospectus or the registration statement of which the accompanying proxy statement/prospectus forms a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">To ensure timely delivery of these documents, any request should be made no later than&#8195;&#8195;&#8195;&#8195;, 2026 to receive them before the Cyclerion Shareholders Meeting. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional details about where you can find information about Cyclerion, please see the section titled &#8220;<span style="font-style:italic">Where You Can Find More Information</span>&#8221; beginning on page&#160;435 of the accompanying proxy statement/prospectus. </p></div>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div style="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt)"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary proxy statement/prospectus is not complete and may be changed. Cyclerion Therapeutics, Inc. may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></span></p></div><div style="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt)"> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">PRELIMINARY PROXY STATEMENT/PROSPECTUS </span></span></p> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED JUNE 9, 2026 </span></span></p> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">


<img src="g111069g00a01.jpg" alt="LOGO" style="width:2.22327in;height:0.971699in"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">


<img src="g111069g00a02.jpg" alt="LOGO" style="width:3.07547in;height:0.654087in"/>
</td></tr>
</table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PROPOSED MERGER </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">YOUR VOTE IS VERY IMPORTANT </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the Shareholders of Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc., </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion Therapeutics, Inc., a Massachusetts corporation (&#8220;Cyclerion&#8221;), and Korsana Biosciences, Inc., a Delaware corporation (&#8220;Korsana&#8221;), entered into an Agreement and Plan of Merger and Reorganization on April&#160;1, 2026, which agreement was subsequently amended on April&#160;17, 2026 (as amended, the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp., a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Korsana will merge with and into Cariboos Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Korsana Biosciences Operating Company, LLC&#8221; and Cyclerion will change its name to &#8220;Korsana Biosciences, Inc.&#8221; The term &#8220;Combined Company&#8221; when used in the accompanying proxy statement/prospectus refers to the post-Merger corporate structure including Korsana Biosciences, Inc. (f/k/a Cyclerion Therapeutics, Inc.) as the parent entity and Korsana Biosciences Operating Company, LLC as its wholly-owned subsidiary. </p> <div> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the First Merger (the &#8220;First Effective Time&#8221;, and the date on which the closing of the Merger occurs, the &#8220;Closing Date&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement: (i)&#160;each then-outstanding share of Korsana common stock, $0.0001 par value per share, of Korsana (the &#8220;Korsana Common Stock&#8221;) and Korsana Series A Preferred Stock, $0.0001 par value per share (&#8220;Korsana Series A Preferred Stock&#8221;) (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing described below), excluding any shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares, will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock, no par value per share (the &#8220;Cyclerion Common Stock&#8221;), equal to the exchange ratio as described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Exchange Ratio</span>&#8221; beginning on page&#160;169 of the accompanying proxy statement/prospectus (the &#8220;Exchange Ratio&#8221;); provided, that in the event the aggregate number of shares of Cyclerion Common Stock issuable to a holder of Korsana capital stock (when aggregated with all of the shares of the Cyclerion Common Stock outstanding then beneficially owned by such person and its affiliates (as calculated pursuant to Section&#160;13(d) of the Securities Exchange Act of 1934, as amended, and <span style="white-space:nowrap">Rule&#160;13d-3&#160;promulgated</span> thereunder) immediately after giving effect to the issuance of the merger consideration) would result in the issuance of shares of Cyclerion Common Stock to a holder in excess of a specified percentage (initially set at a percentage up to 9.99%) of the total outstanding shares of Cyclerion Common Stock (such specified percentage, a &#8220;Beneficial Ownership Limitation&#8221;), then Cyclerion will issue to any such holder (x)&#160;shares of Cyclerion Common Stock up to such holder&#8217;s Beneficial Ownership Limitation and (y)&#160;in lieu of any shares in excess of such holder&#8217;s Beneficial Ownership Limitation, <span style="white-space:nowrap">pre-funded</span> warrants (&#8220;Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants&#8221;) to purchase a number of shares of Cyclerion Common Stock upon exercise of such Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants equal to such excess shares; (ii)&#160;each then-outstanding share of Korsana Series Seed Preferred Stock, $0.0001 par value per share (&#8220;Korsana Series Seed Preferred Stock&#8221; and, together with the Korsana Series A Preferred Stock, the &#8220;Korsana Preferred Stock&#8221;), excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Series B <span style="white-space:nowrap">non-voting</span> convertible preferred stock, no par value per share (&#8220;Cyclerion Series B Preferred Stock&#8221;), equal to the Exchange Ratio divided by 1,000; (iii) each then-outstanding option (a &#8220;Korsana Option&#8221;) to purchase shares of Korsana Common Stock will be converted into and become an option to purchase shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), </p></div> </div> <p style="clear:both; font-size:1pt; height:0">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Treatment of Korsana</span><span style="font-style:italic"> Options</span>&#8221; beginning on page&#160;172 of the accompanying proxy statement/prospectus; (iv)&#160;each then-outstanding restricted stock unit (a &#8220;Korsana RSU&#8221;) for shares of Korsana Common Stock will be converted into and become a restricted stock unit (a &#8220;Cyclerion RSU&#8221;) for shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Korsana</span><span style="font-style:italic"> Restricted Stock Units</span>&#8221; beginning on page&#160;173 of the accompanying proxy statement/prospectus; and (v)&#160;each then-outstanding warrant to purchase shares of Korsana Common Stock (each, a &#8220;Korsana Warrant&#8221;) will be converted into a warrant to purchase shares of Cyclerion Common Stock on the existing terms and conditions (each, a &#8220;Cyclerion Warrant&#8221;), subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Treatment of Korsana</span><span style="font-style:italic"> Warrants</span>&#8221; beginning on page&#160;173 of the accompanying proxy statement/prospectus. </p> </div> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock that is issued and outstanding at the First Effective Time will remain issued and outstanding and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Prior to the First Effective Time, the Cyclerion board of directors (the &#8220;Cyclerion Board&#8221;) will accelerate the vesting of all options to purchase shares of Cyclerion Common Stock (&#8220;Cyclerion Options&#8221;) and all restricted stock awards (&#8220;Cyclerion RSAs&#8221;). Each outstanding Cyclerion Option with an exercise price per share equal to or less than the volume weighted average closing trading price of a share of Cyclerion Common Stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five consecutive trading days ending three trading days prior to the Calculation Date (as defined in the Merger Agreement), as reported by Bloomberg L.P. (the &#8220;Cyclerion Closing Price&#8221; and such Cyclerion Options, <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;In-the-Money</span></span> Cyclerion Options&#8221;), will be cancelled at the First Effective Time and such holder thereof will receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying the excess of the Cyclerion Closing Price over the exercise price per share of the Cyclerion Common Stock underlying such Cyclerion Option by the number of shares of the Cyclerion Common Stock underlying such Cyclerion Option (&#8220;Cyclerion Stock Option Cash Consideration&#8221;). Each Cyclerion Option with an exercise price greater than the Cyclerion Closing Price (an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;Out-of-the-Money</span></span></span> Cyclerion Option&#8221;) will be cancelled for no consideration. The vesting of each Cyclerion RSA will be accelerated in full. </p> <div> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on Cyclerion&#8217;s and Korsana&#8217;s capitalization as of March&#160;31, 2026 and assuming Cyclerion&#8217;s net cash as of closing being equal to $0, each share of Korsana Common Stock and Korsana Series A Preferred Stock is currently estimated to be entitled to receive approximately 1.1009 shares of Cyclerion Common Stock. Each share of Korsana Series Seed Preferred Stock will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock, equal to the Exchange Ratio divided by 1,000. The estimated Exchange Ratio does not give effect to the proposed Cyclerion reverse stock split and is subject to adjustment based on Cyclerion&#8217;s estimated net cash at the closing of the First Merger as described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Exchange Ratio</span>&#8221; beginning on page&#160;169 of the accompanying proxy statement/prospectus. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, on April&#160;1, 2026, Korsana entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional and accredited investors for the purchase of shares of Korsana Common Stock and <span style="white-space:nowrap">Pre-Funded</span> Warrants to purchase shares of Korsana Common Stock (the &#8220;Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants&#8221;) for an aggregate purchase price of approximately $380.0&#160;million, immediately prior to the closing of the Merger (referred to herein as the &#8220;Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing&#8221;). The shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants that are issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing will be converted into the right to receive a number of shares of Cyclerion Common Stock and Cyclerion Pre-Funded Warrants, respectively, equal to the Exchange Ratio described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Exchange Ratio</span>&#8221; beginning on page&#160;169 of the accompanying proxy statement/prospectus. Korsana and the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing have also agreed to enter into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) at the closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Korsana Common Stock that are held by the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing from time to time pursuant to Rule 415 under the Securities Act (&#8220;Rule 415&#8221;). The Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is more fully described in the sections titled &#8220;<span style="font-style:italic">Agreements Related to the Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">S</span><span style="font-style:italic">ecurities Purchase</span><span style="font-style:italic"> Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Agreements Related to the Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Registration Rights Agreement</span>&#8221; beginning on pages&#160;188 and&#160;190, respectively, of the accompanying proxy statement/prospectus. </p> </div> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, based on the estimated Exchange Ratio as described in the accompanying proxy statement/prospectus, Cyclerion securityholders as of immediately prior to the Merger are expected to own </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately 1.5% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), and former holders of Korsana securities (including those issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) are expected to own approximately 98.5% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Cyclerion&#8217;s net cash as of closing being equal to $0. Under certain circumstances described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger</span> <span style="font-style:italic">Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Exchange Ratio</span>&#8221; beginning on page&#160;169 of the accompanying proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if Cyclerion&#8217;s net cash as of closing is less than or greater than $0. </p> </div> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Cyclerion Common Stock are currently listed on Nasdaq under the symbol &#8220;CYCN.&#8221; Cyclerion plans to file an initial listing application for the Combined Company with Nasdaq. After completion of the Merger, Cyclerion will be renamed &#8220;Korsana Biosciences, Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;KRSA.&#8221; It is a condition to the consummation of the Merger that Cyclerion will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that Cyclerion will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. However, in the event that the shares of Cyclerion Common Stock to be issued in the Merger are not approved for listing on Nasdaq, it is possible that Cyclerion and Korsana may mutually agree to waive the applicable condition and nonetheless proceed with completion of the Merger. If such condition is waived, Cyclerion will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of shareholders prior to proceeding with the Merger. Accordingly, you are advised that Cyclerion shareholders will not have certainty regarding the listing of the Combined Company&#8217;s shares at the time you are asked to vote at the annual meeting described below. On&#8195;&#8195;&#8195;&#8195;, 2026, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Cyclerion Common Stock was $&#8195;&#8195;&#8195;&#8195; per share. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion shareholders are cordially invited to attend the annual meeting of Cyclerion (the &#8220;Cyclerion Shareholders Meeting&#8221;) to be held on&#8195;&#8195;&#8195;&#8195;, 2026, at&#8195;&#8195;&#8195;&#8195;a.m. Eastern Time, unless postponed or adjourned to a later date, in order to obtain the shareholder approvals necessary to complete the Merger and related matters. At the Cyclerion Shareholders Meeting, Cyclerion will ask its shareholders to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">1.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve (i)&#160;the issuance of shares of Cyclerion Common Stock, including the shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, which will represent more than 20% of the shares of Cyclerion Common Stock outstanding immediately prior to the First Merger, to stockholders of Korsana pursuant to the Merger Agreement, a copy of which is attached as <span style="font-style:italic">Annex A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of Cyclerion resulting from the First Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">2.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve articles of amendment to the restated articles of organization of Cyclerion, as amended (the &#8220;Cyclerion Articles&#8221;), to increase the number of shares of Cyclerion Common Stock that Cyclerion is authorized to issue from 400,000,000 shares to&#8195;&#8195;&#8195;&#8195;shares, in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">H</span> to the accompanying proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">3.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve an amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock at a ratio in the range of one new share for every&#8195;&#8195;&#8195;&#8195;shares and one new share for every&#8195;&#8195;&#8195;&#8195;shares (or any number in between), in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">I</span> to the accompanying proxy statement/prospectus, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the Cyclerion Board and the Korsana board of directors (the &#8220;Korsana Board&#8221;) prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by Cyclerion shareholders, determined solely by the Cyclerion Board (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">4.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve (A)&#160;the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by domestication (&#8220;Proposal No. 4A&#8221;) and (B)(i) the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and (ii)&#160;the adoption of the memorandum and articles of association of the Combined Company (the &#8220;Cayman Articles&#8221;), substantially in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">K</span> to the accompanying proxy statement/prospectus (&#8220;Proposal No. 4B&#8221; and together with Proposal No. 4A, the &#8220;Redomestication Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;); </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">5.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Elect Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D., and Dina Katabi, Ph.D., to the Cyclerion Board and to hold office until Cyclerion&#8217;s annual meeting of shareholders in 2027, and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No.&#160;5&#8221;), provided that if the Merger is consummated, the composition of the Cyclerion Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">6.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ratify the appointment of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2026 (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">7.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve the Korsana Biosciences, Inc. 2026 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">8.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve the Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal No.&#160;8&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">9.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve, on an advisory basis, certain compensation arrangements for Cyclerion&#8217;s named executive officers that are based on or otherwise relate to the Merger (the &#8220;Merger Compensation Proposal&#8221; or &#8220;Proposal No.&#160;9&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">10.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve, on an advisory basis, the compensation of Cyclerion&#8217;s named executive officers (the <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;Say-on-Pay</span></span> Proposal&#8221; or &#8220;Proposal No.&#160;10&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">11.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve an adjournment of the Cyclerion Shareholders Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;11&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">12.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Transact such other business as may properly come before the shareholders at the Cyclerion Shareholders Meeting or any adjournment or postponement thereof. </p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the accompanying proxy statement/prospectus, current directors and officers of Cyclerion who in the aggregate owned approximately 24.2% of the outstanding shares of Cyclerion capital stock on an as-converted to Cyclerion Common Stock basis as of March&#160;31, 2026, and certain Korsana stockholders (solely in their respective capacities as Korsana stockholders) who in the aggregate owned approximately 43.9% of the outstanding shares of Korsana capital stock as of March&#160;31, 2026, are parties to stockholder support agreements with Cyclerion and Korsana, respectively, whereby such stockholders have agreed to vote in favor of the adoption of the Merger Agreement and the approval of the Merger and related transactions contemplated by the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on <span style="white-space:nowrap">Form&#160;S-4</span> of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Korsana stockholders holding a sufficient number of shares of Korsana capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After careful consideration, each of the Cyclerion and the Korsana boards of directors has approved the Merger Agreement and has determined that it is advisable to consummate the Merger. The Cyclerion Board has approved the proposals described in the accompanying proxy statement/prospectus and recommends that its shareholders vote &#8220;FOR&#8221; the proposals described in the accompanying proxy statement/prospectus. </p> <div> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">More information about Cyclerion, Korsana, the Merger Agreement and transactions contemplated thereby and the foregoing proposals are contained in the accompanying proxy statement/prospectus. Cyclerion urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 33 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS. </p> </div> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion and Korsana are excited about the opportunities the Merger brings to Cyclerion&#8217;s shareholders and Korsana&#8217;s stockholders and thank you for your consideration and continued support. </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Regina Graul, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Jonathan Violin, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">President and Chief Executive Officer</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-style:italic">Chief Executive Officer and President</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Cyclerion Therapeutics, Inc.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-style:italic">Korsana Biosciences, Inc.</span></td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">The accompanying proxy statement/prospectus is dated&#8195;&#8195;&#8195;&#8195;, 2026, and is first being mailed to Cyclerion&#8217;s shareholders on or about&#8195;&#8195;&#8195;&#8195;, 2026. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CYCLERION THERAPEUTICS, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">245 First Street, 18th Floor </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cambridge, MA 02142 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTICE OF ANNUAL MEETING OF SHAREHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the shareholders of Cyclerion Therapeutics, Inc.: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOTICE IS HEREBY GIVEN</span> that a virtual annual meeting of shareholders (the &#8220;Cyclerion Shareholders Meeting&#8221;) will be held on&#8195;&#8195;&#8195;&#8195;,&#8195;&#8195;&#8195;&#8195;, 2026 at&#8195;&#8195;&#8195;&#8195; a.m. Eastern Time, unless postponed or adjourned to a later date. The Cyclerion Shareholders Meeting will be held exclusively online. You will be able to attend and participate in the Cyclerion Shareholders Meeting online by visiting <span style="font-style:italic">www.virtualshareholdermeeting.com/</span>&#8195;&#8195;&#8195;&#8195;, where you will be able to listen to the meeting live, submit questions and vote. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Cyclerion Shareholders Meeting will be held for the following purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">1.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve (i)&#160;the issuance of shares of Cyclerion Common Stock, including the shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, which will represent more than 20% of the shares of Cyclerion Common Stock outstanding immediately prior to the First Merger, to stockholders of Korsana pursuant to the terms of the Merger Agreement, a copy of which is attached as <span style="font-style:italic">Annex A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of Cyclerion resulting from the First Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">2.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve articles of amendment to the restated articles of organization of Cyclerion, as amended (the &#8220;Cyclerion Articles&#8221;), to increase the number of shares of Cyclerion Common Stock that Cyclerion is authorized to issue from 400,000,000 to&#8195;&#8195;&#8195;&#8195;, in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">H</span> to this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">3.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve an amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock at a ratio in the range of one new share for every&#8195;&#8195;&#8195;&#8195;shares and one new share for every&#8195;&#8195;&#8195;&#8195;shares (or any number in between), in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">I</span> to this proxy statement/prospectus, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the Cyclerion Board and the Korsana Board prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by Cyclerion shareholders, determined solely by the Cyclerion Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">4.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve (A)&#160;the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by domestication and (B)(i) the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and (ii)&#160;and, as a special resolution for the purposes of Cayman Islands law, the Cayman Articles, substantially in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">K</span> to this proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">5.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D., and Dina Katabi, Ph.D., to the Cyclerion Board and to hold office until Cyclerion&#8217;s annual meeting of shareholders in 2027, and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, provided that if the Merger is consummated, the composition of the Cyclerion Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">6.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify the appointment of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2026; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">7.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the Korsana Biosciences, Inc. 2026 Stock Incentive Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">8.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve the Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">9.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve, on an advisory basis, certain compensation arrangements for Cyclerion&#8217;s named executive officers that are based on or otherwise relate to the Merger; </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">10.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve, on an advisory basis, the compensation of Cyclerion&#8217;s named executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">11.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve an adjournment of the Cyclerion Shareholders Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">12.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the shareholders at the Cyclerion Shareholders Meeting or any adjournment or postponement thereof. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These proposals are collectively referred to as the &#8220;Proposals.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board has fixed&#8195;&#8195;&#8195;&#8195;, 2026 as the record date (the &#8220;Record Date&#8221;) for the determination of shareholders entitled to notice of, and to vote at, the Cyclerion Shareholders Meeting and any adjournment or postponement thereof. Only holders of record of shares of Cyclerion Common Stock at the close of business on the Record Date are entitled to notice of, and to vote at, the Cyclerion Shareholders Meeting. At the close of business on&#8195;&#8195;&#8195;&#8195;, 2026, Cyclerion had &#8195;&#8195;&#8195;&#8195;shares of common stock outstanding and entitled to vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Your vote is important. The affirmative vote of a majority of the votes properly cast by the holders of Cyclerion Common Stock in person or represented by proxy at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No.&#160;1 and Proposal No.&#160;5. The affirmative vote of a majority of the shares entitled to vote on the subject matter at the Cyclerion Shareholders Meeting is required for approval of Proposal No.&#160;2, and Proposal No.&#160;3. The affirmative vote of not less than <span style="white-space:nowrap">two-thirds</span> of the shares entitled to vote on the subject matter at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No. 4A. The affirmative vote of not less than two-thirds of the votes properly cast by the holders of Cyclerion Common Stock in person or represented by proxy at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No. 4B. The number of affirmative votes exceeding the number of votes opposing the matter, assuming a quorum is present, is required for the approval of Proposal No.&#160;6, Proposal No.&#160;7, Proposal No.&#160;8, Proposal No.&#160;9, Proposal No.&#160;10 and Proposal No.&#160;11. Approval of each of Proposal No.&#160;1, Proposal No.&#160;2, and Proposal No.&#160;3 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2, and 3, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such conditions. The approvals of Proposal Nos. 4A, 4B, 7, 8, and 9 are not conditions to the completion of the Merger, however, each of these proposals is conditioned on the consummation of the Merger and will not be implemented if the Merger is not consummated. Approvals of Proposal Nos. 3, 5, 6, 10, and 11 are requested whether or not the Merger is consummated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">All shareholders are cordially invited to attend the annual meeting. Even if you plan to attend the Cyclerion Shareholders Meeting, Cyclerion requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the Cyclerion Shareholders Meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the Cyclerion Shareholders Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE CYCLERION BOARD HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO CYCLERION AND ITS SHAREHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE CYCLERION BOARD RECOMMENDS THAT CYCLERION SHAREHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Important Notice Regarding the Availability of Proxy Materials for the Cyclerion Shareholders Meeting to Be Held on&#8195;&#8195;&#8195;&#8195;, 2026 at&#8195;&#8195;&#8195;&#8195;a.m. Eastern Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy statement/prospectus, which also serves as the annual report to shareholders in connection with the annual meeting, is available at <span style="font-style:italic">www.cyclerion.com.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Cyclerion Board of Directors, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regina Graul, Ph.D. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;&#8195;&#8195; , 2026 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:94%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_1">QUESTIONS AND ANSWERS ABOUT THE MERGER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_2">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_3">MARKET PRICE AND DIVIDEND INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_4">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_6">THE ANNUAL MEETING OF CYCLERION SHAREHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_7">THE MERGER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">134</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_8">THE MERGER AGREEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_9">AGREEMENTS RELATED TO THE MERGER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">188</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_10">CYCLERION DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_11">CYCLERION EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_12">CYCLERION <span style="white-space:nowrap">NON-EMPLOYEE</span> DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_13">CYCLERION EQUITY COMPENSATION PLAN INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_14">KORSANA EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_15">KORSANA DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_16">MATTERS BEING SUBMITTED TO A VOTE OF CYCLERION SHAREHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_17">PROPOSAL NO. 1&#8201;-&#8201;THE NASDAQ STOCK ISSUANCE PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_18">PROPOSAL NO. 2&#8201;-&#8201;THE AUTHORIZED SHARE INCREASE PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_19">PROPOSAL NO. 3&#8201;-&#8201;THE REVERSE STOCK SPLIT PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_20">PROPOSAL NO. 4&#8201;-&#8201;THE REDOMESTICATION PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_21">PROPOSAL NO. 5&#8201;-&#8201;THE DIRECTOR ELECTION PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_22">PROPOSAL NO. 6&#8201;-&#8201;THE AUDITOR RATIFICATION PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_23">PROPOSAL NO. 7&#8201;-&#8201;THE STOCK PLAN PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_24">PROPOSAL NO. 8&#8201;-&#8201;THE ESPP PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_25">PROPOSAL NO. 9&#8201;-&#8201;THE MERGER COMPENSATION PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_26">PROPOSAL NO. 10&#8201;-&#8201;THE <span style="white-space:nowrap"><span style="white-space:nowrap">SAY-ON-PAY</span></span> PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_27">PROPOSAL NO. 11&#8201;-&#8201;THE ADJOURNMENT PROPOSAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_28">CYCLERION&#8217;S BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_29">KORSANA&#8217;S BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_30">CYCLERION&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_31">KORSANA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_32">MANAGEMENT FOLLOWING THE MERGER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">379</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_33">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_34">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_35">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_36">DESCRIPTION OF CYCLERION CAPITAL STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_37">COMPARISON OF RIGHTS OF HOLDERS OF CYCLERION CAPITAL STOCK AND<br/>KORSANA CAPITAL STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_38">PRINCIPAL SHAREHOLDERS OF CYCLERION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_39">PRINCIPAL STOCKHOLDERS OF KORSANA</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_40">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_41">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_42">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_43">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">435</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:94%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_44">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2027 ANNUAL MEETING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_45">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_46">ANNEX A: AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, AND THE AMENDMENT THERETO</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">A-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_47">ANNEX B: OPINION OF GEMINI VALUATION SERVICES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">B-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_48">ANNEX C: FORM OF CYCLERION SHAREHOLDER SUPPORT AGREEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">C-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_49">ANNEX D: FORM OF KORSANA STOCKHOLDER SUPPORT AGREEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">D-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_50">ANNEX E: FORM OF <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">E-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_51">ANNEX F: FORM OF CVR AGREEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_52">ANNEX G: FORM OF ARTICLES OF AMENDMENT TO THE RESTATED ARTICLES OF ORGANIZATION OF CYCLERION THERAPEUTICS, INC. TO DESIGNATE SERIES B PREFERRED STOCK</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="white-space:nowrap">G-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_53">ANNEX H: FORM OF ARTICLES OF AMENDMENT TO THE RESTATED ARTICLES OF ORGANIZATION OF CYCLERION THERAPEUTICS, INC. TO REFLECT INCREASE IN AUTHORIZED SHARES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">H-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_54">ANNEX I: FORM OF ARTICLES OF AMENDMENT TO THE RESTATED ARTICLES OF ORGANIZATION OF CYCLERION THERAPEUTICS, INC. TO REFLECT REVERSE STOCK SPLIT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">I-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_55">ANNEX J: PLAN OF DOMESTICATION*</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">J-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_56">ANNEX K: FORM OF CAYMAN ISLANDS MEMORANDUM AND ARTICLES OF ASSOCIATION*</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">K-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx111069_57">ANNEX L: APPRAISAL RIGHTS (SECTION 262 OF THE DELAWARE GENERAL CORPORATION LAW)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">L-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ANNEX M: RESOLUTIONS OF THE CYCLERION BOARD FOR THE CAYMAN REDOMESTICATION*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">M-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ANNEX N: CAYMAN ISLANDS SERIES A CERTIFICATE OF DESIGNATION*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">N-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ANNEX O: CAYMAN ISLANDS SERIES B CERTIFICATE OF DESIGNATION*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">O-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ANNEX P: FORM OF KORSANA BIOSCIENCES, INC. 2026 STOCK INCENTIVE <br/>PLAN*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">P-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ANNEX Q: FORM OF KORSANA BIOSCIENCES, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">Q-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ANNEX R: FORM OF CYCLERION THERAPEUTICS, INC. PROXY CARD*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">R-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To be filed by amendment </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_1">QUESTIONS AND ANSWERS ABOUT THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.&#160;3 of this proxy statement/prospectus. </span></p> <div> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following section provides answers to frequently asked questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What is the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: On April&#160;1, 2026, Cyclerion, Korsana, First Merger Sub and Second Merger Sub entered into the Merger Agreement, which agreement was subsequently amended on April&#160;17, 2026. A copy of the Merger Agreement, including the amendment thereto, is attached as <span style="font-style:italic">Annex A</span><span style="font-style:italic"> </span>to this proxy statement/prospectus. The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, First Merger Sub will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the First Merger. Korsana will then merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. This entire transaction is referred to in this proxy statement/prospectus as the Merger. In connection with the Merger, Cyclerion will change its corporate name to &#8220;Korsana Biosciences, Inc.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: Why are the two companies proposing to merge? </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Cyclerion and Korsana believe that combining the two companies will result in a company with a promising pipeline, a strong leadership team and substantial capital resources, focused on developing novel therapies to reduce the burden of neurodegenerative diseases. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s</span><span style="font-style:italic"> Reasons for the Merger</span>&#8221; and &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Korsana</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s Reasons for the Merger</span>&#8221; beginning on pages 142 and 146, respectively, of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What will happen to Cyclerion if, for any reason, the Merger does not close? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Cyclerion has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed Merger. In the event the Merger does not close, Cyclerion will have a limited ability to continue its current operations without obtaining additional financing. Although the Cyclerion Board may elect, among other things, to attempt to complete another strategic transaction if the Merger does not close, the Cyclerion Board may instead divest all or a portion of Cyclerion&#8217;s business or take steps necessary to liquidate or dissolve Cyclerion&#8217;s business and assets if a viable alternative strategic transaction is not available. If Cyclerion decides to dissolve and liquidate its assets, Cyclerion would be required to pay all of its contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available cash left to distribute to shareholders after paying the obligations of Cyclerion and setting aside funds for reserves. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: Why am I receiving this proxy statement/prospectus? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: You are receiving this proxy statement/prospectus because you have been identified as a shareholder of Cyclerion as of the applicable Record Date, and you are entitled to vote to approve the matters set forth herein. This document serves as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a proxy statement of Cyclerion used to solicit proxies for the Cyclerion Shareholders Meeting to vote on the matters set forth herein; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a prospectus of Cyclerion used to offer (i)&#160;all shares of Cyclerion Common Stock in exchange for each share of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), (ii) all Cyclerion Warrants in exchange for Korsana Warrants (including Korsana Pre-Funded Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), (iii) all shares of Cyclerion Series B Preferred Stock in exchange for shares of Korsana Series Seed Preferred Stock, (iv)&#160;all options to purchase shares of Cyclerion Common Stock in exchange for Korsana Options, (v)&#160;all Cyclerion RSUs in exchange for Korsana RSUs, (vi)&#160;all shares of Cyclerion Common Stock issuable upon exercise of Cyclerion Warrants issued in exchange for Korsana Warrants, (vii)&#160;all shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock issued in exchange for Korsana Series Seed Preferred Stock, (viii)&#160;all shares of Cyclerion Common Stock issuable upon exercise of options to purchase shares of Cyclerion Common Stock issued in exchange for Korsana Options, and (ix)&#160;all shares of Cyclerion Common Stock issuable upon settlement of Cyclerion RSUs issued in exchange for Korsana RSUs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the annual report of Cyclerion provided in connection with the special meeting in lieu of annual meeting. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What is the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: In connection with the Merger, Korsana entered into the Securities Purchase Agreement with certain investors named therein, including, among others, Fairmount, Venrock Healthcare Capital Partners, General Atlantic, TCGX, Forbion, Wellington Management, Commodore Capital, RA Capital Management, RTW Investments, Vivo Capital, Janus Henderson Investors, Foresite Capital, J.P. Morgan Life Sciences Private Capital, SR One, Sanofi Ventures, Kalehua Capital, Spruce Street Capital, and other leading investment management firms, pursuant to which such investors agreed to purchase shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants for an aggregate purchase price of approximately $380.0&#160;million. Shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants issued pursuant to this financing transaction will be converted into shares of Cyclerion Common Stock and Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants, in accordance with the Exchange Ratio and the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately after the First Merger, the shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing are expected to represent approximately 57.7% of the outstanding shares of common stock of the Combined Company (on a fully-diluted basis). Korsana and the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing have also agreed to enter into a Registration Rights Agreement at the closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Cyclerion Common Stock that are held by the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing from time to time pursuant to Rule 415. The closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more complete description of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, please see the sections titled &#8220;<span style="font-style:italic">Agreements Related to the Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">S</span><span style="font-style:italic">ecurities Purchase</span><span style="font-style:italic"> Agreement</span>&#8221; and &#8220;<span style="font-style:italic">&#8212; </span><span style="font-style:italic">Registration Rights Agreement</span>&#8221; beginning on pages 188 and 190 of this proxy statement/prospectus, respectively. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What proposals will be voted on at the Cyclerion Shareholders Meeting in connection with the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite shareholder vote at the Cyclerion Shareholders Meeting in order for the Merger to close: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The Nasdaq Stock Issuance Proposal</span> to approve (i)&#160;the issuance of shares of Cyclerion Common Stock, including the shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, which will represent more than 20% of the shares of Cyclerion Common Stock outstanding </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immediately prior to the First Merger, to stockholders of Korsana, pursuant to the Merger Agreement, a copy of which is attached as <span style="font-style:italic">Annex A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of Cyclerion resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">Authorized Share Increase Proposal</span> to approve an amendment to the Cyclerion Articles to increase the number of shares of Cyclerion Common Stock that Cyclerion is authorized to issue from 400,000,000 to&#8195;&#8195;&#8195;&#8195;, in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">H</span> to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">Reverse Stock Split Proposal</span> to approve an amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock at a ratio in the range of one new share for every&#8195;&#8195;&#8195;&#8195;shares and one new share for every&#8195;&#8195;&#8195;&#8195;shares (or any number in between), with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the Cyclerion Board and the Korsana Board prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by Cyclerion shareholders, determined solely by the Cyclerion Board, in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">I</span> to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The Redomestication Proposal</span> to approve (A)&#160;the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by domestication and (B)(i) the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and (ii)&#160;the adoption of the Cayman Articles. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of each of Proposal Nos. 1, 2, and 3 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2, and 3, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such conditions. The issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, and Cyclerion Series B Preferred Stock in connection with the Merger and the change of control of Cyclerion resulting from the Merger will not take place unless Proposal Nos. 1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to increase the number of authorized shares of Cyclerion Common Stock will not take place unless Proposal Nos.&#160;1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock, will not take place unless Proposal Nos. 1, 2, and 3 are approved by the requisite Cyclerion shareholders. However, the Cyclerion Board may determine to effect the reverse stock split, if approved by Cyclerion shareholders, following the Shareholders Meeting, even if Proposal Nos. 1 and 2 are not approved or the Merger is not otherwise completed. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the requirement of obtaining Cyclerion shareholder approval of Proposal Nos. 1, 2, and 3, the closing of the Merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Conditions to the Completion of the Merger</span>&#8221; beginning on page 183 of this proxy statement/prospectus. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presence, by attending or being represented by proxy, at the Cyclerion Shareholders Meeting of the holders of a majority of the shares of Cyclerion Common Stock outstanding and entitled to vote at the Cyclerion Shareholders Meeting is necessary to constitute a quorum at the meeting for the Proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What proposals are to be voted on at the Cyclerion Shareholders Meeting, other than the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal and the Authorized Share Increase Proposal? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: At the Cyclerion Shareholders Meeting, the holders of Cyclerion Common Stock will also be asked to consider the following proposals: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The Director Election Proposal</span> to elect Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D., and Dina Katabi, Ph.D., to serve until </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cyclerion&#8217;s 2027 annual meeting of shareholders, or until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The Auditor Ratification Proposal</span> to ratify the selection of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2026; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;7</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The Stock Plan Proposal</span> to approve the Korsana Biosciences, Inc. 2026 Stock Incentive Plan; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;8</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The ESPP Proposal</span> to approve the Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;9</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The Merger Compensation Proposal</span> to approve, on an advisory basis, certain compensation arrangements for Cyclerion&#8217;s named executive officers that are based on or otherwise relate to the Merger; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;10 &#8211; </span><span style="font-weight:bold">The <span style="white-space:nowrap"><span style="white-space:nowrap">Say-on-Pay</span></span> Proposal</span> to approve, on an advisory basis, the compensation of Cyclerion&#8217;s named executive officers; and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proposal No.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1</span><span style="font-weight:bold">1</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">-</span><span style="font-weight:bold">&#8201;</span><span style="font-weight:bold">The Adjournment Proposal</span> to approve an adjournment of the Cyclerion Shareholders Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The approvals of Proposal Nos. 4A, 4B, 5, 6, 7, 8, 9, 10, and 11 are not a condition to the Merger. However, the implementation of Proposal Nos. 7, 8, and 9 are conditioned on the consummation of the Merger. Cyclerion does not expect that any matter other than the Proposals will be brought before the Cyclerion Shareholders Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presence, by attending or being represented by proxy, at the Cyclerion Shareholders Meeting of the holders of a majority of the shares of Cyclerion Common Stock outstanding and entitled to vote at the Cyclerion Shareholders Meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What shareholder votes are required to approve the Proposals at the Cyclerion Shareholders Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: The affirmative vote of a majority of the votes properly cast by the holders of Cyclerion Common Stock in person or represented by proxy at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No.&#160;1 and Proposal No.&#160;5. The affirmative vote of a majority of the shares entitled to vote on the subject matter at the Cyclerion Shareholders Meeting is required for approval of Proposal No.&#160;2, and Proposal No.&#160;3. The affirmative vote of not less than <span style="white-space:nowrap">two-thirds</span> of the shares entitled to vote on the subject matter at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No. 4A. The affirmative vote of not less than two-thirds of the votes properly cast by the holders of Cyclerion Common Stock in person or represented by proxy at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No.&#160;4B. The number of affirmative votes exceeding the number of votes opposing the matter, assuming a quorum is present, is required for the approval of Proposal No.&#160;6, Proposal No.&#160;7, Proposal No.&#160;8, Proposal No.&#160;9, Proposal No.&#160;10 and Proposal No.&#160;11. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of each of Proposal No.&#160;1, Proposal No.&#160;2, and Proposal No.&#160;3 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2, and 3, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such conditions. The issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, and Cyclerion Series B Preferred Stock in connection with the Merger and the change of control of Cyclerion resulting from the Merger will not take place unless Proposal Nos. 1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to increase the number of authorized shares of Cyclerion Common Stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will not take place unless Proposal Nos. 1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock, will not take place unless Proposal Nos. 1, 2, and 3 are approved by the requisite Cyclerion shareholders. However, the Cyclerion Board may determine to effect the reverse stock split, if approved by Cyclerion shareholders, following the Shareholders Meeting, even if Proposal Nos. 1 and 2 are not approved or the Merger is not otherwise completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Proposal Nos. 4A, 4B, 7, 8, and 9 are each conditioned on the consummation of the Merger. Therefore, if Proposal Nos. 1, 2, and 3 are not approved or the Merger is not consummated, Proposal Nos. 4A, 4B, 7, 8, and 9 will each have no effect, even if approved by Cyclerion shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What are Cyclerion contingent value rights? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Immediately prior to the First Effective Time, Cyclerion and the designated rights agent (&#8220;Rights Agent&#8221;) are expected to enter into a Contingent Value Rights Agreement (the &#8220;Cyclerion CVR Agreement&#8221;), pursuant to which holders of Cyclerion Common Stock and Cyclerion Series A Preferred Stock as of the close of business on the last business day prior to the day on which the First Effective Time occurs will receive one contingent value right (each, a &#8220;Cyclerion CVR&#8221;) for each outstanding share of Cyclerion Common Stock or Cyclerion Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Cyclerion CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of Cyclerion&#8217;s <span style="white-space:nowrap">pre-Merger</span> legacy assets (the &#8220;Cyclerion Legacy Assets&#8221;), net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the Merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of Cyclerion Legacy Assets other than those Cyclerion Legacy Assets described in the following clauses (ii)&#160;and (iii), upon the second (2nd) anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#8217;s right to receive payments under that License Agreement, dated June&#160;3, 2021, between Cyclerion and Akebia Therapeutics, Inc. (the &#8220;Akebia License Agreement&#8221;), the earlier of (A)&#160;the fifteenth (15th) anniversary of the date of entry into the Cyclerion CVR Agreement and (B)&#160;the expiration pursuant to its terms or earlier termination by Akebia of the Akebia License Agreement, and (iii) with respect to the sale, transfer or other disposition of the equity interests of Tisento Therapeutics Holdings, Inc. (&#8220;Tisento&#8221;) beneficially owned by Cyclerion, the earliest of (A)&#160;nine (9) months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the Legacy Assets Transaction Period (as defined in the Cyclerion CVR Agreement), the Combined Company shall expend up to $50,000 (the &#8220;CVR Expense Cap&#8221;) for costs and expenses associated with the retention of an employee or consultant of Cyclerion for the purpose of business development efforts related to Cyclerion Legacy Assets and related activities, including seeking and negotiating and, with the prior written consent of Combined Company (not to be unreasonably withheld, conditioned or delayed), executing agreements with respect to Cyclerion Legacy Assets, which amount shall be included as a deduction in the determination of Cyclerion&#8217;s net cash in accordance with the Merger Agreement. At the end of the Legacy Assets Transaction Period, the amount, if any, by which the CVR Expense Cap exceeds the aggregate amount of costs and expenses associated with the retention of an employee or consultant of Cyclerion will constitute net proceeds under the Cyclerion CVR Agreement and will be payable as CVR proceeds to the CVR holders in accordance with the terms of the Cyclerion CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contingent payments under the Cyclerion CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the Cyclerion CVRs. In the event that no such proceeds are received, holders of the Cyclerion CVRs will not receive any payment pursuant to the Cyclerion CVR Agreement. There can be no assurance that any holders of Cyclerion CVRs will receive any payments with respect thereto. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The right to the contingent payments contemplated by the Cyclerion CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the Cyclerion CVR Agreement. The Cyclerion CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The Cyclerion CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Cyclerion or any of its affiliates. No interest will accrue on any amounts payable in respect of the Cyclerion CVRs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What will Cyclerion securityholders receive in the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Each share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock that is issued and outstanding at the First Effective Time of the Merger will remain issued and outstanding and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Prior to the First Effective Time, the Cyclerion Board will accelerate the vesting of all Cyclerion Options and Cyclerion RSAs. Each outstanding Cyclerion Option with an exercise price less than or equal to the Cyclerion Closing Price will be cancelled at the First Effective Time and such holder thereof will receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying the excess of the Cyclerion Closing Price over the exercise price per share of the Cyclerion Common Stock underlying such Cyclerion Option by the number of shares of the Cyclerion Common Stock underlying such Cyclerion Option. The vesting of each Cyclerion RSA will be accelerated in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, Cyclerion securityholders as of immediately prior to the Merger are expected to own approximately 1.5% of the outstanding shares of the Combined Company on a fully-diluted basis, former Korsana securityholders, excluding holders of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants purchased in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, are expected to own approximately 40.8% of the outstanding shares of the Combined Company on a fully-diluted basis, and Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing are expected to represent approximately 57.7% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis, subject to certain assumptions, including, but not limited to, Cyclerion&#8217;s Net Cash as of Closing being $0. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more complete description of the treatment of Cyclerion securities in the Merger, please see the sections titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Merger Consideration</span>,&#8221; &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Exchange Ratio</span>,&#8221; and &#8220;<span style="font-style:italic">Market Price and Dividend Information</span>&#8221; beginning on pages 168, 169 and 32, respectively, of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What will Korsana securityholders receive in the Merger? </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), excluding any shares to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Common Stock and/or Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants, as applicable, equal to the Exchange Ratio (described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Exchange Ratio</span>&#8221; beginning on page 169 of this proxy statement/ prospectus), (ii) each then-outstanding share of Korsana Series Seed Preferred Stock, excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock equal to the Exchange Ratio divided by 1,000; (iii)&#160;each then-outstanding Korsana Option will be converted into and become an option to purchase shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement, (iv)&#160;each then-outstanding Korsana RSU will be converted into and become a Cyclerion RSU on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement, and (v)&#160;each then-outstanding and unexercised </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Korsana Warrant (including Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) will be converted into a Cyclerion Warrant, subject to adjustment as set forth in the Merger Agreement. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more complete description of the treatment of Korsana securities in the Merger, please see the&#160;sections titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Merger Consideration</span>,&#8221; and &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Exchange Ratio</span>&#8221; beginning on pages 168 and 169 of this proxy statement/prospectus. For a description of the effect of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing on Korsana&#8217;s current securityholders, please see the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Securities Purchase Agreement</span>&#8221; beginning on page 188 of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: Will the common stock of the Combined Company trade on an exchange? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Shares of Cyclerion Common Stock are currently listed on Nasdaq under the symbol &#8220;CYCN.&#8221; </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion intends to file an initial listing application for the common stock of the Combined Company with Nasdaq. After completion of the Merger, Cyclerion will be renamed &#8220;Korsana Biosciences, Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;KRSA.&#8221; It is a condition to the consummation of the Merger that Cyclerion will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that Cyclerion will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties; however, if such condition is waived, Cyclerion will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of shareholders prior to proceeding with the Merger. Accordingly, you are advised that Cyclerion shareholders will not have certainty regarding the listing of the Combined Company&#8217;s shares at the time you are asked to vote at the Cyclerion Shareholders Meeting. For more information, please see the section entitled &#8220;<span style="font-style:italic">Risk Factors</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Risks Related</span><span style="font-style:italic"> to the </span><span style="font-style:italic">Merger</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">-</span><span style="font-style:italic"> Cyclerion</span><span style="font-style:italic"> and </span><span style="font-style:italic">Korsana</span><span style="font-style:italic"> may mutually agree to waive the condition to the </span><span style="font-style:italic">Merger</span><span style="font-style:italic"> requiring approval </span><span style="font-style:italic">for</span><span style="font-style:italic"> listing on Nasdaq, and if such condition is waived, the Combined Company</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s stock may not be listed on Nasdaq following completion of the </span><span style="font-style:italic">Merger</span>.&#8221; on page 33 of this proxy statement/prospectus. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On&#8195;&#8195;&#8195;&#8195;, 2026, the last trading day before the date of this proxy statement/prospectus, the closing sale price of Cyclerion Common Stock was $&#8195;&#8195;&#8195;&#8195;per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: Who will be the directors of the Combined Company immediately following the Merger? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Immediately following the Merger, the Combined Company&#8217;s board of directors will be composed of six members, all six of whom will have been designated by Korsana. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the First Effective Time, the Cyclerion Board will appoint the following Korsana designees: Andrew Gottesdiener,&#8195;&#8195;&#8195;&#8195;, Tomas Kiselak, Michelle Pernice, Nimish Shah, and Dr.&#160;Jonathan Violin to the board of directors of the Combined Company, and concurrent therewith all of Cyclerion&#8217;s current directors will resign from their positions as directors of the Cyclerion Board effective as of the First Effective Time. Mr.&#160;Kiselak is expected to be appointed as Chair of the board of directors of the Combined Company. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Cayman Redomestication is effected, the Combined Company will have a staggered structure of three classes following the completion of the Merger. See the section titled &#8220;<span style="font-style:italic">Management Following the Merger</span>&#8221; for additional information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: Who will be the executive officers of the Combined Company immediately following the Merger? </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Immediately following the Merger, the executive management team of the Combined Company is expected to consist of the following members of the Korsana executive management team: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jonathan Violin, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer and President</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Mark Vignola, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Madelyn Zeylikman</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">General Counsel and Secretary</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: As a Cyclerion shareholder, how does the Cyclerion Board recommend that I vote? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: The Cyclerion Board, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of Cyclerion and its shareholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement and approved the issuance of shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, in connection with the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, respectively; and (iii)&#160;recommends that Cyclerion&#8217;s shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; each of the Proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What risks should I consider in deciding whether to vote in favor of the Merger? </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: You should carefully review the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 33 of this proxy statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the Combined Company&#8217;s business will be subject, and risks and uncertainties to which each of Cyclerion and Korsana, as independent companies, are subject. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: When do you expect the Merger to be consummated? </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: The Merger is anticipated to close in the third quarter of 2026, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Conditions to the Completion of the Merger</span>&#8221; beginning on page 183 of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: Why is Cyclerion seeking approval for the redomestication to the Cayman Islands (the &#8220;Cayman Redomestication&#8221;)? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: The Cyclerion and Korsana boards of directors believe that there are several reasons why the Cayman Redomestication is in the best interests of Cyclerion and Cyclerion&#8217;s shareholders. The Cyclerion Board believes the Cayman Redomestication may help the Combined Company attract and retain qualified management by reducing the risk of lawsuits being filed against the Combined Company and its directors and officers. Cyclerion and Korsana believe that for the reasons described in this proxy statement/prospectus, in general, Cayman Islands law will provide greater protection to the Combined Company and its directors and officers than Massachusetts law. Additionally, the Cyclerion Board believes that the Cayman Redomestication will give the Combined Company more flexibility and predictability in various corporation transactions. For more information, please see the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Redomestication Proposal</span>&#8221; below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: How will the Cayman Redomestication affect the rights of the Combined Company&#8217;s shareholders? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Your rights as a shareholder currently are governed by Massachusetts law and the provisions of the restated articles of organization of Cyclerion, and Cyclerion&#8217;s amended and restated bylaws. As a result of the Cayman Redomestication, you will become a shareholder of the Combined Company with rights governed by Cayman </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Islands law and the provisions of the Cayman Articles, in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">K</span> to this proxy statement/prospectus, which differ in certain respects from your current rights. These important differences are discussed and summarized in this proxy statement/prospectus under &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Redomestication</span><span style="font-style:italic"> Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Effects</span><span style="font-style:italic"> of the Cayman Redomestication</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Comparison of Rights of Holders</span><span style="font-style:italic"> of the </span><span style="font-style:italic">Massachusetts </span><span style="font-style:italic">Corporation Capital</span> <span style="font-style:italic">Stock</span><span style="font-style:italic"> and the </span><span style="font-style:italic">Cayman Company Share Capital</span>&#8221; beginning on page 237 of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What are the U.S. federal income tax considerations of the Cayman Redomestication to the Combined Company&#8217;s stockholders? </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A:<span style="font-style:italic"> </span>Subject to the limitations and qualifications described in the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Redomestication Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax Considerations</span><span style="font-style:italic"> of the Cayman Redomestication</span>&#8221; beginning on page 260 of this proxy statement/prospectus, Cyclerion intends that the Cayman Redomestication qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. As a result, a U.S. Holder (as defined therein) of the Combined Company stock (as defined therein) will not recognize gain or loss upon the Cayman Redomestication. For a more detailed discussion of the U.S. federal income tax considerations of the Cayman Redomestication, see the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Redomestication Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax Considerations</span><span style="font-style:italic"> of the Cayman Redomestication</span>&#8221; beginning on page 260 of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What do I need to do now? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Cyclerion urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference, and to consider how the Merger affects you. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Shareholder of Record: Shares Registered in Your Name </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a shareholder of record, you may vote at the Cyclerion Shareholders Meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time, the form of which is attached as <span style="font-style:italic">Annex R </span>to this proxy statement/prospectus. Whether or not you plan to attend the Cyclerion Shareholders Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote even if you have already voted by proxy. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote, attend the Cyclerion Shareholders Meeting via the Internet and vote during the meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the Cyclerion Shareholders Meeting, we will vote your shares as you direct. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote over the telephone, dial toll-free&#8195;&#8195;&#8195;&#8195;using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number found on the Notice. Your vote must be received by&#8195;&#8195;&#8195;&#8195;, 2026 at 11:59 p.m. Eastern Time to be counted. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote through the Internet, go to <span style="font-style:italic">www.proxyvote.com</span> to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be received by&#8195;&#8195;&#8195;&#8195;, 2026 at 11:59 p.m. Eastern Time to be counted. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Beneficial Owner: Shares Registered in the Name of Broker or Bank </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice containing voting instructions from that organization rather than from Cyclerion. Simply follow the voting instructions in the Notice to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker or bank. To vote at the Cyclerion Shareholders Meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What if I return a proxy card or otherwise vote but do not make specific choices? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the Nasdaq Stock Issuance Proposal, &#8220;For&#8221; the Authorized Share Proposal, &#8220;For&#8221; the Reverse Stock Split Proposal, &#8220;For&#8221; the Redomestication Proposal, &#8220;For&#8221; the Director Election Proposal, &#8220;For&#8221; the Auditor Ratification Proposal, &#8220;For&#8221; the Stock Plan Proposal, &#8220;For&#8221; the ESPP Proposal, &#8220;For&#8221; the Merger Compensation Proposal, &#8220;For&#8221; the <span style="white-space:nowrap"><span style="white-space:nowrap">Say-on-Pay</span></span> Proposal and &#8220;For&#8221; the Adjournment Proposal. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What happens if I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable? </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: If you are a shareholder of record and fail to return your proxy card or otherwise vote, your shares will not be voted. If you are a beneficial owner of Cyclerion Common Stock and fail to provide proxy instructions, your shares will not be voted on <span style="white-space:nowrap">non-routine</span> matters. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: If my Cyclerion shares are held in &#8220;street name&#8221; by my broker and I do not provide my broker or bank with voting instructions, what happens? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent will only be able to vote your shares with respect to proposals considered to be &#8220;routine.&#8221; Your broker, bank or other agent is not entitled to vote your shares with respect to <span style="white-space:nowrap">&#8220;non-routine&#8221;</span> proposals, which Cyclerion refers to as a &#8220;broker <span style="white-space:nowrap">non-vote.&#8221;</span> Whether a proposal is considered routine or <span style="white-space:nowrap">non-routine</span> is subject to stock exchange rules and final determination by the stock exchange. Even with respect to routine matters, some brokers are choosing not to exercise discretionary voting authority. As a result, Cyclerion urges you to direct your broker, bank or other agent how to vote your shares on all proposals to ensure that your vote is counted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What are broker <span style="white-space:nowrap">non-votes</span> and do they count for determining a quorum? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Generally, a &#8220;broker <span style="white-space:nowrap">non-vote&#8221;</span> occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s) with respect to such shares on how to vote and does not have discretionary authority to vote on the matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker <span style="white-space:nowrap">non-votes,</span> if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Cyclerion Shareholders Meeting. Broker <span style="white-space:nowrap">non-votes,</span> if any, will have no effect on Proposal Nos. 1, 4B, 5, 6, 7, 8, 9, 10, and 11 and will have the same effect as a vote &#8220;AGAINST&#8221; Proposal Nos. 2, 3, and 4A. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: May I revoke and/or change my vote after I have submitted a proxy or provided proxy instructions? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Cyclerion shareholder of record, unless such shareholder&#8217;s vote is subject to a support agreement, may revoke and/or change their vote at any time before their proxy is voted at the Cyclerion Shareholders Meeting in one of four ways: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You may submit another properly completed proxy with a later date by mail or via the internet. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You can provide your proxy instructions via telephone at a later date. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You may send a notice that you are revoking your proxy over the Internet, following the instructions provided on your proxy card. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You may attend the Cyclerion Shareholders Meeting and vote during the meeting. Simply attending the Cyclerion Shareholders Meeting will not, by itself, revoke your proxy and/or change your vote. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What are the material U.S. federal income tax considerations of the Merger to a U.S. Holder of Korsana Common Stock and Korsana Preferred Stock? </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Subject to the limitations and qualifications described in the section titled &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax Considerations</span><span style="font-style:italic"> of the </span><span style="font-style:italic">Merger</span>&#8221; beginning on page 161 of this proxy statement/prospectus, each of Cyclerion and Korsana intend that the Merger qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) for U.S. federal income tax purposes. Assuming the Merger so qualifies, a U.S. Holder of Korsana stock (as defined therein) will not recognize gain or loss upon the exchange of its Korsana stock for Cyclerion stock. For a more detailed discussion of the U.S. federal income tax considerations of the Merger, see the section titled &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax Considerations</span><span style="font-style:italic"> of the </span><span style="font-style:italic">Merger</span>&#8221; beginning on page 161. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What are the material U.S. federal income tax consequences of the issuance of the Cyclerion CVRs, including any distributions of Cyclerion capital stock under the Cyclerion CVRs? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: Although the U.S. federal income tax treatment of the Cyclerion<span style="font-weight:bold"> </span>CVRs is uncertain and the matter is not free from doubt, the Combined Company intends to treat a holder&#8217;s receipt of the Cyclerion CVRs as a distribution of property with respect to the holder&#8217;s existing shares of Cyclerion capital stock for U.S. federal income tax purposes. Please review the information in the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger&#8212;Cyclerion CVR Agreement&#8212;Material U.S. Federal Income Tax Consequences of the Cyclerion CVRs to Holders of Cyclerion Capital Stock</span>&#8221; for a discussion of the material U.S. federal income tax consequences of the Cyclerion CVRs to holders of Cyclerion capital stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: What are the U.S. federal income tax considerations of the reverse stock split to a U.S. Holder of Cyclerion Common Stock? </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: A U.S. Holder of Cyclerion Common Stock should not recognize gain or loss upon the reverse stock split, except to the extent such holder receives cash in lieu of a fractional share of Cyclerion Common Stock, and subject to the discussion in the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;3</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Reverse Stock Split Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax Considerations</span><span style="font-style:italic"> of the </span><span style="font-style:italic">Reverse Stock Split</span>&#8221; beginning on page 230 of this proxy statement/prospectus. Please review the information in the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;3</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Reverse Stock Split Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax Considerations</span><span style="font-style:italic"> of the </span><span style="font-style:italic">Reverse Stock Split</span>&#8221; beginning on page 230 of this proxy statement/prospectus for a more complete description of the U.S. federal income tax considerations of the reverse stock split to a U.S. Holder of Cyclerion Common Stock. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Q: Who can help answer my questions? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A: If you are a Cyclerion shareholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Banks and Brokers Call: </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Stockholders Call Toll Free: </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_2">PROSPECTUS SUMMARY </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the Cyclerion Shareholders Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;<span style="font-style:italic">Where You Can Find More Information</span>&#8221; beginning on page 435 of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.&#160;3 of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Companies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is a preclinical biotechnology company focused on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Cyclerion&#8217;s current strategic focus is centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression (&#8220;TRD&#8221;), which Cyclerion believes represents a substantial clinical and commercial opportunity. Over the past year, Cyclerion has refined its strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized <span style="white-space:nowrap">CYC-126,</span> an individualized therapy for TRD as its foundational development program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s executive offices are located at 245 First Street, 18th Floor, Cambridge, MA 02142. Its telephone number is (857) <span style="white-space:nowrap">327-8778.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Korsana is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer&#8217;s disease (&#8220;AD&#8221;). Korsana&#8217;s lead product candidate, <span style="white-space:nowrap">KRSA-028,</span> is an anti-amyloid beta (&#8220;A&#223;&#8221;) antibody that combines the proprietary Therapeutic Targeting (&#8220;THETA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>&#8221;) platform informed by clinical and regulatory learnings from other anti-A&#223; products that have achieved regulatory approval or are in late-stage clinical trials. <span style="white-space:nowrap">KRSA-028</span> was designed to build upon the success of these prior products while addressing shortcomings that limit their clinical and commercial success, such as the ability to penetrate the brain. Korsana believes that <span style="white-space:nowrap">KRSA-028</span> has the potential to rapidly clear amyloid plaques resulting in meaningful impacts on clinical symptoms in AD patients, and to do so while avoiding adverse effects associated with the specific designs of prior products. After Korsana completes good laboratory practice ("GLP") toxicity studies, it intends to submit a Clinical Trial Notification (&#8220;CTN&#8221;) in Australia or a Clinical Trial Application (&#8220;CTA&#8221;) in New Zealand by the end of 2026 and an Investigational New Drug (&#8220;IND&#8221;) application in the United States in the first quarter of 2027. Pharmacokinetic data in healthy volunteers is anticipated by <span style="white-space:nowrap">mid-year</span> 2027 and interim <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data in AD patients is anticipated by the end of 2027. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. See &#8220;<span style="font-style:italic">Risk Factors &#8211; Risks Related to Korsana &#8211; Risks Related to Korsana&#8217;s Discovery, Development, and Commercialization &#8211; Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Korsana&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Korsana may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span>&#8221; </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">AD is a progressive and devastating neurodegenerative disease that slowly destroys cognition and leads to progressive impairment in patients&#8217; ability to conduct activities of daily living. Prevalence increases with age; up to <span style="white-space:nowrap">one-third</span> of people over age 85 have symptoms. There are seven million people suffering from AD in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States, a number that is expected to double by 2050 due to an aging population. AD is the seventh-leading cause of death in the United States with an estimated 500,000 deaths every year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Until recently, approved treatments for AD addressed only symptoms and had no impact on the course of the disease. That situation changed after the approval of antibody-based therapeutics that targeted A&#223;. Clinical trials of these therapeutics have provided clear evidence that antibody-mediated depletion of A&#223; in the brain correlates with a reduction in the rate of cognitive decline in symptomatic AD. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> was designed using clinical and regulatory learnings from these pioneering antibody-based therapeutics, together with Korsana&#8217;s proprietary combination of antibody engineering technologies, with the goal of improving clinical efficacy and safety profiles. <span style="white-space:nowrap">KRSA-028</span> targets what is believed to be the most clinically relevant form of A&#223; and is designed to improve brain uptake while reducing effects on reticulocytes. It was also designed with physicochemical properties and stability intended to enable potent anti-A&#223; activity to the brain via subcutaneous injections. Key features of <span style="white-space:nowrap">KRSA-028&#8217;s</span> design include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating a proprietary transferrin receptor (&#8220;TfR&#8221;) based shuttle designed to potentially improve delivery to the brain, which Korsana believes may also help reduce or avoid the treatment-related complications known as amyloid-related imaging abnormalities (&#8220;ARIA&#8221;), associated with the two approved disease-modifying therapies </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Targeting <span style="white-space:nowrap">3-pyroglutamate</span> A&#223; (&#8220;3pE-A&#223;&#8221;), a form of A&#223; that is enriched in amyloid plaques that is believed to contribute to plaque formation in AD </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating Fc domain modifications designed to potentially improve half-life and reduce the potential for hematologic adverse events seen with other antibodies that incorporate <span style="white-space:nowrap">TfR-based</span> shuttles, while potentially preserving antibody-mediated immune function believed to contribute to amyloid plaque clearance </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enabling subcutaneous formulation through potentially favorable solubility, viscosity, and stability characteristics </p></td></tr></table> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary THETA technology used to create <span style="white-space:nowrap">KRSA-028</span> combines the benefits of <span style="white-space:nowrap">TfR-mediated</span> shuttling to the brain with Fc modifications to extend half-life and spare reticulocytes from destruction shown to be caused by third-party <span style="white-space:nowrap">TfR-shuttled</span> investigational products. The THETA technology was designed to retain phagocytic capacity, the mechanism by which the two approved disease-modifying products are thought to clear amyloid plaques from the brain. Korsana believes that the THETA platform will lead to meaningful improvements in the ability to deliver therapeutic modalities, such as antibodies, to the brain, while minimizing the frequency of adverse events associated with other <span style="white-space:nowrap">TfR-based</span> shuttle systems. Korsana intends to expand its pipeline by advancing other product candidates that incorporate THETA technology. Korsana anticipates disclosing details on its next product candidate in late 2026 or 2027. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana was founded in 2024 and launched to research and develop brain-targeted antibody candidates licensed from Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) and led by industry veterans with extensive experience in drug discovery and development. Fairmount has launched a series of companies based on assets licensed from Paragon, including Apogee Therapeutics, Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, Crescent Biopharma, and Damora Therapeutics. Members of Korsana&#8217;s executive team and other employees have extensive experience in the manufacture and development of antibodies and AOCs, including management and oversight of externalized research and development activities. Paragon and Paragon Laboratories perform research services for Korsana to discover and evaluate potential antibody and AOC product candidates, which could be licensed for further development, manufacture and commercialization by Korsana. Korsana separately performs certain GLP toxicity studies and pre-clinical IND enabling activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has entered into a License Agreement with Paragon (the &#8220;Paragon License Agreement&#8221;); (ii) an Antibody Discovery and Option Agreement with Paragon and Parasa Holding LLC (&#8220;Parasa&#8221;) (the &#8220;Paragon </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ADOA&#8221;); (iii) a Platform Option Agreement with Paragon and Parasa (the &#8220;Paragon POA&#8221;); and (iv) an Antibody Oligo Conjugate (&#8220;AOC&#8221;) Research Letter Agreement with Paragon Laboratories, Inc. (&#8220;Paragon Laboratories&#8221;) (the &#8220;Paragon Research Letter Agreement&#8221; and, together with the Paragon License Agreement, the Paragon ADOA, and the Paragon POA, the &#8220;Paragon Agreements&#8221;). As described in more detail in this proxy statement/prospectus, as of the date of this proxy statement/prospectus, Korsana has exercised the option for Research Program 002 (including KRSA-028) pursuant to the Paragon ADOA and has entered into the Paragon License Agreement covering Research Program 001 and Research Program 002. Korsana has not exercised its option or licensed any other program under the Paragon ADOA, Paragon POA, or the Paragon Research Letter Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Paragon identifies, evaluates, and develops antibodies against one or more mutually agreed therapeutic targets and a mutually agreed brain transit target, in accordance with research plan(s) mutually agreed to by Paragon and Korsana. The Paragon ADOA covers multiple research programs, including two research programs targeting A&#223; as the therapeutic target and TfR1 as the brain transit target (&#8220;Research Program 001&#8221; and &#8220;Research Program 002&#8221;, respectively, and collectively, the &#8220;A&#223; Research Programs&#8221;), with the ability to add additional programs by mutual agreement. Each research program is overseen and coordinated by a joint development committee consisting of two employees from Korsana and two employees from Paragon, with Korsana and Paragon each having one vote with respect to decisions of the committee. Under the Paragon ADOA, Korsana has the exclusive option, on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis (each, an &#8220;ADOA Option&#8221;), to negotiate and enter into a license agreement (each, a &#8220;License&#8221;) granting Korsana (a)&#160;an exclusive, worldwide license to the product-specific intellectual property from the applicable program and (b)&#160;a <span style="white-space:nowrap">non-exclusive,</span> worldwide license to certain incorporated platform technology, including THETA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana exercised the ADOA Option for Research Program 002, nominated KRSA-028 as the development candidate for Research Program 002, and entered into the Paragon License Agreement with respect to the A&#223; Research Programs. Pursuant to the Paragon License Agreement, Paragon granted Korsana a worldwide, royalty-bearing, exclusive (even as to Paragon and its affiliates) and sublicensable license under certain licensed antibody transport vehicle technology, to develop, manufacture and commercialize antibody products and antibody transport vehicle products directed to A&#223; and TfR1, and related non-exclusive licenses under certain transit antibody technology, patents and know-how. The exclusive license covers certain derived antibodies, derived antibody transport vehicles and related products within the scope of the Paragon License Agreement. In addition, any additional antibody transport vehicles discovered, generated, identified or characterized by Paragon under the A&#223; Research Programs are included as licensed antibody transport vehicles under the Paragon License Agreement, subject to the express exclusions and limitations set forth in the Paragon License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon License Agreement, Korsana is responsible for development, manufacturing, regulatory and commercialization activities for licensed products and is obligated to use commercially reasonable efforts to develop and seek regulatory approval for at least one licensed product in the United States and at least one other major market country. Korsana is required to make milestone payments to Paragon upon the achievement of specified development and regulatory milestones and to pay Paragon tiered royalties in the low- to mid-single digits on annual net sales of licensed products, subject to specific reductions. If a product candidate, including certain combination products, is developed by Korsana as a bona fide back-up or substitute product to another royalty product for the same licensed therapeutic target, the same licensed transit target, if applicable, and the same indication, it would be considered a back-up royalty product for which no duplicate milestone payments are owed to Paragon, subject to specified limitations. The agreement expires on a product-by-product and country-by-country basis upon expiration of the applicable royalty term, unless earlier terminated, and may be terminated by Korsana for convenience upon 60 days&#8217; prior written notice. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s principal executive offices are located at 203 Crescent Street, Bldgs. #3/3A/4, Suite 503, Waltham, MA 02453, and its telephone number is (781) <span style="white-space:nowrap">516-2325.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">First Merger Sub </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">First Merger Sub is a direct, wholly owned subsidiary of Cyclerion and was formed solely for the purpose of carrying out the Merger. First Merger Sub&#8217;s executive offices are located at 245 First Street, 18th Floor, Cambridge, MA 02142. Its telephone number is (857) <span style="white-space:nowrap">327-8778.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Second Merger Sub </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Second Merger Sub is a direct, wholly owned subsidiary of Cyclerion and was formed solely for the purpose of carrying out the Merger. Second Merger Sub&#8217;s executive offices are located at 245 First Street, 18th Floor, Cambridge, MA 02142. Its telephone number is (857) <span style="white-space:nowrap">327-8778.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Merger (see page 134) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, and in accordance with the Delaware General Corporation Law (&#8220;DGCL&#8221;) and the Delaware Limited Liability Company Act (&#8220;DLLCA&#8221;), (i) at the First Effective Time, First Merger Sub will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the First Merger and (ii)&#160;immediately following the First Merger and as part of the same overall transaction as the First Merger, Korsana will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cyclerion&#8217;s Reasons for the Merger (see page 142) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of its evaluation of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement (the &#8220;Contemplated Transactions&#8221;), the Cyclerion Board held numerous meetings, consulted with Cyclerion management, its legal counsel and its financial advisor and reviewed and assessed a significant amount of information and, in reaching its decision to approve the Merger, the Merger Agreement and the Contemplated Transactions, as described later in this proxy statement/prospectus under the section titled &#8220;<span style="font-style:italic">The Merger-Cyclerion&#8217;s Reasons for the Merger</span>.&#8221; </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Korsana</span><span style="font-weight:bold">&#8217;</span><span style="font-weight:bold">s </span><span style="font-weight:bold">Reasons </span><span style="font-weight:bold">for</span><span style="font-weight:bold"> the Merger</span> <span style="font-weight:bold">(see page 146)</span> </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of reaching its decision to approve the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, the Korsana Board consulted with Korsana&#8217;s senior management, legal counsel, and financial advisors, and considered a wide variety of factors. Ultimately, the Korsana Board concluded that a merger with Cyclerion, together with the additional financing committed from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, was the best option to generate capital resources to support the advancement of Korsana&#8217;s pipeline and fund the combined organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional factors the Korsana Board considered included the following (which factors are not necessarily presented in any order of relative importance): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">as a public company, Korsana expects to have broader access to capital and a wider range of investors to support the preclinical and clinical development of its pipeline than would be available if Korsana continued to operate as a privately-held company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing will generate capital resources to fund the Combined Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential benefits from increased public market awareness of Korsana and its pipeline; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical and current information concerning Korsana&#8217;s business, including its financial performance and condition, operations, management, and preclinical and clinical data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competitive nature of the industry in which Korsana operates; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board&#8217;s fiduciary duties to Korsana stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board&#8217;s belief that no alternatives to the Merger, together with the additional financing committed from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, were reasonably likely to create greater value for Korsana stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Korsana Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board&#8217;s expectation that the Merger, together with the additional financing committed from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an initial public offering; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expected financial position, operations, management structure, and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and clinical trials); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the business, history, operations, financial resources, and credibility of Cyclerion; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of appraisal rights under the DGCL to holders of Korsana capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Korsana capital stock as determined by the Delaware Court of Chancery; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms and conditions of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the shares of Cyclerion Common Stock issued to Korsana stockholders, including shares of Cyclerion Common Stock issued in exchange for shares of Korsana Common Stock sold in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, will be registered on a Form <span style="white-space:nowrap">S-4</span> registration statement and will become freely tradable for Korsana stockholders who are not affiliates of Korsana and who are not parties to <span style="white-space:nowrap">lock-up</span> agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Support Agreements, pursuant to which certain directors, officers, and stockholders of Korsana and Cyclerion, respectively, have agreed, solely in their capacity as stockholders of Korsana and Cyclerion, respectively, to vote all of their shares of Korsana capital stock or Cyclerion Common Stock in favor of the adoption or approval, respectively, of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Korsana Biosciences, Inc. prior to or upon the closing of the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the likelihood that the Merger will be consummated on a timely basis. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana Board also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that the Merger or the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing might not be completed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Exchange Ratio used to establish the number of shares of Cyclerion Common Stock to be issued to Korsana stockholders in the Merger is fixed, except for adjustments due to Cyclerion&#8217;s Net Cash balance, the amount of proceeds from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and outstanding capital stock at Closing, and thus the relative percentage ownership of Cyclerion shareholders and Korsana stockholders in the Combined Company immediately following the completion of the Merger is similarly fixed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential effect of the termination fee of up to $10.736&#160;million payable by Korsana; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential reduction of Cyclerion&#8217;s Net Cash prior to the closing; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Cyclerion could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs, time and effort involved in connection with completing the Merger, related disruptions, or potential disruptions to Korsana&#8217;s business and related administrative challenges associated with combining the companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the additional expenses and obligations to which Korsana&#8217;s business will be subject following the Merger as a public company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;Risk Factors&#8221; in this proxy statement/prospectus. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the Cyclerion Board of Directors (see page 129) </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and declared that the issuance of shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, Cyclerion and its shareholders. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and declared that it is advisable and in the best interests of Cyclerion and its shareholders to approve the amendment to the Cyclerion Articles to effect the increase in authorized shares. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and declared that it is advisable and in the best interests of Cyclerion and its shareholders to approve the amendment to the Cyclerion Articles to effect the reverse stock split, if necessary. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Reverse Stock Split Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is fair to, in the best interests of, and advisable to, Cyclerion and its shareholders to approve (A)&#160;the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by domestication and (B)(i) the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and (ii)&#160;the adoption of the Cayman Articles, as described in this proxy statement/prospectus. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Redomestication Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to elect Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D., and Dina Katabi, Ph.D., to serve on the Cyclerion Board and to hold office until Cyclerion&#8217;s annual meeting of shareholders in 2027, provided that if the Merger is consummated, the composition of the Cyclerion Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; each director nominee named in the Director Election Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to ratify the selection of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2026. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Auditor Ratification Proposal as described in this proxy statement/prospectus. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve the 2026 Stock Incentive Plan, as described in this proxy statement/prospectus. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve the 2026 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve certain compensation arrangements for Cyclerion&#8217;s named executive officers that are based on or otherwise relate to the Merger. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve, on an advisory basis, the compensation of Cyclerion&#8217;s named executive officers. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the <span style="white-space:nowrap"><span style="white-space:nowrap">Say-on-Pay</span></span> Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that adjourning the Cyclerion Shareholders Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, Cyclerion and its shareholders and has approved and adopted the proposal. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus. </p></td></tr></table> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Cyclerion&#8217;s Directors and Executive Officers in the Merger (see page 155) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Cyclerion Board with respect to approving the Merger, shareholders should be aware that Cyclerion&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Cyclerion shareholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">under the terms of the Merger Agreement, (i)&#160;prior to the closing of the Merger, the Cyclerion Board will accelerate the vesting of all equity awards of Cyclerion then outstanding but not then vested or exercisable, regardless of whether requirements for performance-based vesting have been met, and cancel each option to acquire shares of Cyclerion Common Stock with an exercise price per share greater than Cyclerion Closing Price and (ii)&#160;at the closing of the First Merger, <span style="white-space:nowrap"><span style="white-space:nowrap">(a)&#160;In-the-Money</span></span> Cyclerion Options will be cancelled and converted into the right to receive cash as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Treatment of Cyclerion Options and Cyclerion Restricted Stock Awards</span>&#8221; beginning on page 155 of this proxy statement/prospectus and (b)&#160;each other option to acquire shares of Cyclerion Common Stock will be cancelled for no consideration; and </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s President and Chief Executive Officer will receive severance benefits in accordance with the terms of the amended employment agreement that she entered into with Cyclerion in connection with the Merger, as described in further detail in the section of this proxy statement/prospectus titled &#8220;<span style="font-style:italic">Interests of </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s</span><span style="font-style:italic"> </span><span style="font-style:italic">Directors and Executive Officers in the Merger</span>.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Cyclerion shareholders approve the Merger as contemplated by this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Korsana&#8217;s Directors and Executive Officers in the Merger (see page 157) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Korsana Board with respect to approving the Merger, stockholders should be aware that Korsana&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Korsana stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">as of April&#160;1, 2026, Korsana&#8217;s current <span style="white-space:nowrap">non-employee</span> directors and executive officers beneficially owned, in the aggregate, approximately 44.6% of the shares of Korsana capital stock, which for purposes of this subsection excludes any Korsana shares issuable upon exercise or settlement of Korsana options and restricted stock units held by such individual; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Fairmount Healthcare Fund II L.P. (&#8220;Fairmount Fund II&#8221;), an affiliate of Tomas Kiselak and Michelle Pernice (Korsana directors) and Jonathan Violin (Korsana director and Chief Executive Officer and President), currently holds shares of Korsana capital stock and has agreed to purchase Korsana Common Stock and Korsana Pre-Funded Warrants in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Venrock Healthcare Capital Partners, an affiliate of Andrew Gottesdiener and Nimish Shah (Korsana directors), currently holds shares of Korsana capital stock and has agreed to purchase Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in connection with the Merger, each option to purchase shares of Korsana Common Stock and each Korsana restricted stock unit held by Korsana&#8217;s executive officers and directors, whether or not vested, will be converted into an option to purchase shares of the Combined Company&#8217;s common stock or a restricted stock unit of the Combined Company, respectively, on the same terms and conditions (including any vesting and acceleration provisions); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s directors and executive officers are expected to become directors and executive officers of the Combined Company upon completion of the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Korsana stockholders approve the Merger as contemplated by this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Opinion of Gemini to the Cyclerion Board (see page B-1) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion retained Gemini Valuation Services, LLC (&#8220;Gemini&#8221;) as its financial advisor in connection with the Merger and the other transactions contemplated by the Merger Agreement. On March&#160;31, 2026, Gemini rendered to the Cyclerion Board its oral opinion, which was subsequently confirmed by a written opinion addressed to the Cyclerion Board, dated March&#160;31, 2026, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Gemini in preparing its opinion, the Exchange Ratio was fair, from a financial point of view, to Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the written opinion of Gemini, dated March&#160;31, 2026, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Gemini in preparing its opinion, is attached as <span style="font-style:italic">Annex B</span> to this proxy statement/prospectus and is incorporated herein by reference. <span style="font-weight:bold">Gemini</span><span style="font-weight:bold">&#8217;</span><span style="font-weight:bold">s financial advisory services and opinion were provided </span><span style="font-weight:bold">for</span><span style="font-weight:bold"> the information and assistance of the </span><span style="font-weight:bold">Cyclerion</span><span style="font-weight:bold"> Board (in their capacity as directors and not in any other capacity) in connection with and </span><span style="font-weight:bold">for</span><span style="font-weight:bold"> purposes of the </span><span style="font-weight:bold">Cyclerion</span><span style="font-weight:bold"> Board</span><span style="font-weight:bold">&#8217;</span><span style="font-weight:bold">s consideration of the </span><span style="font-weight:bold">Merger</span><span style="font-weight:bold"> and the opinion of </span><span style="font-weight:bold">Gemini</span><span style="font-weight:bold"> addressed only the fairness, from a financial point of view, as of the date thereof, to </span><span style="font-weight:bold">Cyclerion</span> <span style="font-weight:bold">of the Exchange Ratio</span> <span style="font-weight:bold">pursuant to the</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-weight:bold">terms of the Merger Agreement. The opinion of </span><span style="font-weight:bold">Gemini</span><span style="font-weight:bold"> did not address any other term or aspect of the Merger Agreement or the </span><span style="font-weight:bold">Merger</span><span style="font-weight:bold"> and does </span><span style="font-weight:bold">not constitute a recommendation to any shareholder of Cyclerion as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">The full text of the written opinion of Gemini should be read carefully in its entirety for a description of the assumptions made and limitations upon the review undertaken by Gemini in preparing its opinion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview of the Merger Agreement and Agreements Related to the Merger Agreement </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Merger</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Consideration</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 168) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), excluding shares of Korsana capital stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Common Stock and/or Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants, as applicable, equal to the Exchange Ratio (described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement &#8212; Exchange Ratio</span>&#8221; beginning on page&#160;169 of this proxy statement/prospectus), (ii) each then-outstanding share of Korsana Series Seed Preferred Stock (excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares) will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then-outstanding Korsana Option will be converted into and become an option to purchase shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement, (iv)&#160;each then-outstanding Korsana RSU will be converted into and become a Cyclerion RSU on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement, and (v)&#160;each then-outstanding and unexercised Korsana Warrant (including Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) will be converted into a Cyclerion Warrant, subject to adjustment as set forth in the Merger Agreement. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, Cyclerion securityholders as of immediately prior to the Merger are expected to own approximately 1.5% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis and former holders of Korsana securities are expected to own approximately 98.5% of the outstanding shares of capital stock of the Combined Company on a fully-diluted basis. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if Cyclerion&#8217;s Net Cash as of Closing is less than or greater than $0. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Treatment</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">of</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Korsana</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Options</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 172) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, Cyclerion will assume Korsana&#8217;s 2025 Equity Incentive Plan and each option to purchase shares of Korsana Common Stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of Cyclerion Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Korsana Option assumed by Cyclerion may be exercised solely for shares of Cyclerion Common Stock; (ii)&#160;the number of shares of Cyclerion Common Stock subject to each outstanding Korsana Option assumed by Cyclerion will be determined by multiplying (A)&#160;the number of shares of Korsana Common Stock that were subject to such Korsana Option assumed by Cyclerion, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Cyclerion Common Stock; and (iii)&#160;the per share exercise price of each Korsana Option assumed by Cyclerion will be determined by dividing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(A)&#160;the per share exercise price of such Korsana Option, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Korsana Option assumed by Cyclerion will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Korsana Option will otherwise remain unchanged. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Korsana stock option shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Cyclerion Common Stock subsequent to the First Effective Time. In addition, the Combined Company&#8217;s compensation committee will succeed to the authority and responsibility of the Korsana Board as administrator of Korsana&#8217;s 2025 Equity Incentive Plan. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Treatment of Korsana Warrants</span></span><span style="font-weight:bold"> </span>(see page 173) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each Korsana Warrant that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a Cyclerion Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Korsana Warrant assumed by Cyclerion may be exercised solely for shares of Cyclerion Common Stock; (ii)&#160;the number of shares of Cyclerion Common Stock subject to each outstanding Korsana Warrant assumed by Cyclerion will be determined by multiplying (A)&#160;the number of shares of Korsana Common Stock issuable upon exercise of the Korsana Warrant that were subject to such Korsana Warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounded up to the next whole share of Cyclerion Common Stock to the extent the aggregate amount of fractional shares of Cyclerion Common Stock such holder would otherwise be entitled to is equal to or exceeds 0.50; and (iii)&#160;the per share exercise price for the Cyclerion Common Stock issuable upon exercise of each Korsana Warrant assumed by Cyclerion will be determined by dividing (A)&#160;the per share exercise price of Cyclerion Common Stock subject to such Korsana Warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Korsana Warrant assumed by Cyclerion will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Korsana Warrant will otherwise remain unchanged. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Korsana Warrant shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Cyclerion Common Stock subsequent to the First Effective Time. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Korsana</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Restricted</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Stock</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Units</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 173) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, Cyclerion will assume Korsana&#8217;s 2025 Equity Incentive Plan and each Korsana RSU that is outstanding immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into a Cyclerion RSU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Korsana RSU assumed by Cyclerion may be settled solely for shares of Cyclerion Common Stock; and (ii)&#160;the number of shares of Cyclerion Common Stock subject to each outstanding Korsana RSU assumed by Cyclerion will be determined by multiplying (A)&#160;the number of shares of Korsana Common Stock that were subject to such Korsana RSU assumed by Cyclerion, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number up to the next whole number of shares of Cyclerion Common Stock to the extent the aggregate amount of fractional shares of Cyclerion Common Stock such holder of the assumed restricted stock units would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down. Each Korsana RSU assumed by Cyclerion will otherwise continue in full force and effect and the term, settlement, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vesting schedule, acceleration rights and other terms and conditions of such Korsana RSU will otherwise remain unchanged. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Korsana RSU shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Cyclerion Common Stock subsequent to the First Effective Time. In addition, the Combined Company&#8217;s compensation committee will succeed to the authority and responsibility of the Korsana Board as administrator of the Korsana 2025 Equity Incentive Plan. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Treatment</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">of</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Cyclerion Common Stock</span></span><span style="font-weight:bold"><span style="font-style:italic">, </span></span><span style="font-weight:bold"><span style="font-style:italic">Cyclerion</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"><span style="font-style:italic">Options and Cyclerion Restricted Stock Awards</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page&#160;174) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as contemplated by the proposed increase in the number of authorized shares of Cyclerion Common Stock described in Proposal No.&#160;2 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding Cyclerion Common Stock described in Proposal No.&#160;3 of this proxy statement/prospectus, Cyclerion Common Stock will remain unaffected by the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, prior to the Closing, the Cyclerion Board will accelerate the vesting of all equity awards of Cyclerion then outstanding but not then vested or exercisable. At the First Effective Time, (i)&#160;each <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Cyclerion Option will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Cyclerion Closing Price over the exercise price per share of Cyclerion Common Stock underlying such Cyclerion Option by (B)&#160;the number of shares of Cyclerion Common Stock underlying such Cyclerion Option and (ii)&#160;each <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">Out-of-the-Money</span></span></span> Cyclerion Option will be cancelled for no consideration. The vesting of each Cyclerion RSA will be accelerated in full. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Conditions to the </span></span><span style="font-weight:bold"><span style="font-style:italic">Completion</span></span><span style="font-weight:bold"><span style="font-style:italic"> of the </span></span><span style="font-weight:bold"><span style="font-style:italic">Merger</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page&#160;183) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To complete the Merger, Cyclerion shareholders must approve Proposal No.&#160;1, Proposal No.&#160;2, and Proposal No.&#160;3 (unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waive such conditions) and Korsana stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Non-</span></span><span style="font-weight:bold"><span style="font-style:italic">Solicitation</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page&#160;179) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains <span style="white-space:nowrap">non-solicitation</span> provisions prohibiting Cyclerion and Korsana from soliciting a competing transaction. Each of Cyclerion and Korsana has agreed that, subject to certain exceptions, Cyclerion and Korsana and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize or permit any of the directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives retained by it or any of its subsidiaries to, directly or indirectly: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">solicit, initiate, or knowingly encourage, induce, or facilitate the communication, making, submission or announcement of, any Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">furnish any <span style="white-space:nowrap">non-public</span> information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to certain exceptions set forth in the Merger Agreement, approve, endorse, or recommend any Acquisition Proposal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publicly propose to do any of the foregoing. </p></td></tr></table> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Boa</span></span><span style="font-weight:bold"><span style="font-style:italic">rd </span></span><span style="font-weight:bold"><span style="font-style:italic">Recommendation Change</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 181) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Korsana Board nor Cyclerion Board may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of (i)&#160;a material development or change in circumstances, or (ii)&#160;with respect to a superior offer that did not result from a material breach of the Merger Agreement (each of (i)&#160;and (ii), an &#8220;Intervening Event&#8221;), if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such party has provided at least four business days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, after the other party shall have delivered to such party a written offer to alter the terms or conditions of the Merger Agreement during the four-business day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new three-business day period following such notification during which the parties would be obligated to comply again with the requirements described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in recommendation. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Termination of the Merger Agreement </span></span>(see page 184) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Either Cyclerion or Korsana may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Termination </span></span><span style="font-weight:bold"><span style="font-style:italic">Fee</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 184) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger Agreement is terminated under certain circumstances, Cyclerion could be required to pay Korsana a termination fee of $235,000 or Korsana could be required to pay Cyclerion a termination fee of $10,736,000. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Support Agreements</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 188) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain stockholders of Korsana (solely in their respective capacities as Korsana stockholders) holding approximately 43.9% of the outstanding shares of Korsana capital stock have entered into support agreements with Cyclerion and Korsana to vote all of their shares of Korsana capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby (the &#8220;Korsana Support Agreements&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors and officers of Cyclerion holding approximately 24.2% of the outstanding shares of Cyclerion capital stock as of March&#160;31, 2026 on an <span style="white-space:nowrap">as-converted</span> to Cyclerion Common Stock basis have entered into support agreements with Cyclerion and Korsana to vote all of their shares of Cyclerion Common Stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the Reverse Stock Split and against any alternative Acquisition Proposals (the &#8220;Cyclerion Support Agreements&#8221;). </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up</span> </span></span><span style="font-weight:bold"><span style="font-style:italic">Agreements</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 188) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain executive officers, directors and stockholders of Korsana have entered into <span style="white-space:nowrap">lock-up</span> agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Cyclerion Common Stock or any securities convertible into or exercisable or exchangeable for Cyclerion Common Stock, currently or thereafter owned, but excluding, as applicable, shares purchased by existing Korsana stockholders in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing (including any shares of Cyclerion Common Stock issuable upon exercise of Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in exchange for Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants sold in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), until 180 days after the First Effective Time. Approximately 42.4 million shares of Cyclerion Common Stock (or approximately 113.8 million shares of Cyclerion Common Stock, if the Cyclerion Series B Preferred Stock is converted and the Korsana Pre-Funded Warrants held by such executive officers, directors and stockholders of Korsana are exercised) are expected to be subject to such lock-up agreements following the closing of the Merger, subject to the Reverse Stock Split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Cyclerion CVR Agreement</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 190) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the First Effective Time, Cyclerion and the Rights Agent are expected to enter into the Cyclerion CVR Agreement, pursuant to which holders of Cyclerion Common Stock and Cyclerion Series A Preferred Stock as of the close of business on the last business day prior to the day on which the First Effective Time occurs will receive one Cyclerion CVR for each outstanding share of Cyclerion Common Stock or Cyclerion Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Cyclerion CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of Cyclerion Legacy Assets, net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the Merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of all Cyclerion Legacy Assets other than those Cyclerion Legacy Assets described in the following clauses (ii)&#160;and (iii), upon the second (2nd) anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#8217;s right to receive payments under the Akebia License Agreement, the earlier of (A)&#160;the fifteenth (15th) anniversary of the date of entry into the Cyclerion CVR Agreement and (B)&#160;the expiration pursuant to its terms or earlier termination by Akebia Therapeutics, Inc. of the Akebia License Agreement, and (iii)&#160;with respect to the sale, transfer or other disposition of the equity interests of Tisento that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement, dated May&#160;13, 2023, by and among Cyclerion, Tisento and JW Cycle, Inc., the earliest of (A)&#160;nine (9) months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the Legacy Assets Transaction Period (as defined in the Cyclerion CVR Agreement), the Combined Company shall expend up to the CVR Expense Cap for costs and expenses associated with the retention of an employee or consultant of Combined Company for the purpose of business development efforts related to Cyclerion Legacy Assets and related activities, including seeking and negotiating and, with the prior written consent of the Combined Company (not to be unreasonably withheld, conditioned or delayed), executing agreements with respect to Cyclerion Legacy Assets, which amount shall be included as a deduction in the determination of Cyclerion&#8217;s net cash in accordance with the Merger Agreement. At the end of the Legacy Assets Transaction Period, the amount, if any, by which the CVR Expense Cap exceeds the aggregate amount of costs and expenses associated with the retention of an employee or consultant of Cyclerion will constitute net proceeds under the Cyclerion CVR Agreement and will be payable as CVR proceeds to the CVR holders in accordance with the terms of the Cyclerion CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contingent payments under the Cyclerion CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the Cyclerion CVRs. In the event that no such proceeds are received, holders of the Cyclerion CVRs will not receive any payment pursuant to the Cyclerion CVR Agreement. There can be no assurance that any holders of Cyclerion CVRs will receive any payments with respect thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right to the contingent payments contemplated by the Cyclerion CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the Cyclerion CVR Agreement. The Cyclerion CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The Cyclerion CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Cyclerion or any of its affiliates. No interest will accrue on any amounts payable in respect of the Cyclerion CVRs. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Securities Purchase Agreement and Registration Rights Agreement</span></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>(see page 188) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors of Korsana entered into the Securities Purchase Agreement with Korsana, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Korsana Common Stock or, in lieu thereof, Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants, representing an aggregate commitment of approximately $380.0&#160;million in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants that are issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing will be or will have the right to be, respectively, converted into shares of Cyclerion Common Stock in the Merger. The Securities Purchase Agreement contains customary representations and warranties of Korsana and also contains customary representations and warranties of the purchaser parties thereto. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities Purchase Agreement also contemplates Korsana and the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing entering into the Registration Rights Agreement at the closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Cyclerion Common Stock that are held by the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing from time to time pursuant to Rule 415. Approximately 196.0&#160;million shares of Cyclerion Common Stock (or approximately 260.9 million shares of Cyclerion Common Stock, if the Cyclerion Pre-Funded Warrants are exercised) are expected to be registrable securities under the Registration Rights Agreement following the closing of the Merger, subject to the Reverse Stock Split. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Management Following the Merger (see page 379) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age as of April 1, 2026 and position of each of the individuals who are expected to serve as executives and directors of the Combined Company following completion of the Merger: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:59%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Age</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Violin, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer, President and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Vignola, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Madelyn Zeylikman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">51</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">General Counsel and Secretary</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors:</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Gottesdiener</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">35</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">39</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle Pernice</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">38</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimish Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
</table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Federal Income Tax Considerations of the Merger (see page 161) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in detail in the section titled &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">U.S. Federal Income Tax Considerations of the Merger</span>&#8221; beginning on page&#160;161 of this proxy statement/prospectus and subject to the limitations and qualifications described therein, Korsana and Cyclerion intend the Merger to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. Assuming the Merger so qualifies, a U.S. Holder of Korsana stock (as defined therein) will not recognize gain or loss upon the exchange of its Korsana stock for Cyclerion stock. For a more detailed discussion of the U.S. federal income tax considerations of the Merger, see the section titled &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">U.S. Federal Income Tax Considerations of the Merger</span>,&#8221; beginning on page&#160;161 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Federal Income Tax Considerations of the Cayman Redomestication (see page&#160;260) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations and qualifications described in the section titled &#8220;<span style="font-style:italic">Proposal </span><span style="font-style:italic">No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4&#8212;</span><span style="font-style:italic"> </span><span style="font-style:italic">The Redomestication Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax Considerations</span><span style="font-style:italic"> of the Cayman Redomestication,</span>&#8221; Cyclerion intends that the Cayman Redomestication qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. Assuming the Cayman Redomestication so qualifies, a U.S. Holder of the Combined Company stock will not recognize gain or loss upon the Cayman Redomestication. For a more detailed discussion of the U.S. federal income tax considerations of the Cayman Redomestication, please see the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4 &#8212; The Redomestication Proposal &#8212; </span><span style="font-style:italic">U.S. Federal Income Tax</span><span style="font-style:italic"> </span><span style="font-style:italic">Considerations</span><span style="font-style:italic"> of the Cayman Redomestication.</span>&#8221; </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Factors (see page 33) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both Cyclerion and Korsana are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to the Proposed Merger </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Failure to complete, or delays in completing, the potential Merger could materially and adversely affect Cyclerion&#8217;s results of operations, business, financial results and/or common stock price; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Exchange Ratio will not change or otherwise be adjusted based on the market price of Cyclerion Common Stock; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, to Korsana stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by Cyclerion shareholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Korsana stockholders. Failure to obtain these approvals would prevent the closing of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Cyclerion completes the Merger, the Combined Company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the Combined Company&#8217;s shareholders or restrict the Combined Company&#8217;s operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion is expected to be deemed a shell company. As a result, if Cyclerion completes the Merger, the Combined Company may be subject to more stringent reporting requirements, offering limitations and resale restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Some of the Cyclerion and Korsana directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion shareholders and Korsana stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to the Proposed Reverse Stock Split </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The reverse stock split may not increase the Combined Company&#8217;s stock price over the long term; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The reverse stock split may decrease the liquidity of the Combined Company&#8217;s common stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The reverse stock split may lead to a decrease in the Combined Company&#8217;s overall market capitalization. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Cyclerion </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As Cyclerion is a biopharmaceutical company with a limited operating history and no products approved for commercial sale, valuing Cyclerion&#8217;s business and predicting its prospects are challenging. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s business has incurred significant losses and Cyclerion anticipates that, if it continue to progress the development of its product candidates, Cyclerion will continue to incur significant losses for the foreseeable future. Cyclerion has never generated revenue from product sales and may never be profitable. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There is substantial doubt about Cyclerion&#8217;s ability to continue as a going concern. If Cyclerion is not able to complete the proposed Merger and Cyclerion continues to progress the development of its product candidates, Cyclerion will need to raise additional funding in the near term, which may not be available on acceptable terms, if at all, to continue as a going concern and advance its product candidates. Failure to obtain capital when needed may force Cyclerion to delay, limit or terminate product development efforts or operations altogether. Raising additional capital would dilute Cyclerion&#8217;s existing shareholders, restrict Cyclerion&#8217;s operations or cause it to relinquish valuable rights. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Cyclerion continues to progress the development of its product candidates, Cyclerion&#8217;s approach to the discovery and development of product candidates for the treatment of serious diseases may never lead to marketable products. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Research and development of biopharmaceutical products is inherently risky. If Cyclerion continues to progress the development of its product candidates, Cyclerion may encounter substantial delays in its activities, including Cyclerion&#8217;s planned clinical studies, or Cyclerion may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities in the development of products to treat patients with serious diseases. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Cyclerion, assuming Cyclerion continues to progress the development of its product candidates, or Tisento, Akebia or any other future licensees, as applicable, are ultimately unable to obtain regulatory approval for the product candidates, Cyclerion will be unable to generate product revenue and Cyclerion&#8217;s business will be substantially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Cyclerion continues to progress the development of its product candidates, obtaining and maintaining regulatory approval of product candidates in one jurisdiction does not mean that there will be success in obtaining regulatory approval of Cyclerion&#8217;s product candidates in other jurisdictions. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Cyclerion continues to progress the development of its product candidates, Cyclerion may not succeed in its pursuit of capital, capabilities, and transactions for the development and commercialization of Cyclerion&#8217;s future clinical stage assets, which would affect Cyclerion&#8217;s financial condition.</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Cyclerion or its licensors, licensees or Tisento are unable to adequately protect proprietary technologies, or obtain and maintain issued patents that are sufficient to protect their respective product candidates, others could compete against Cyclerion, its licensees and Tisento more directly, which would have a material adverse impact on Cyclerion&#8217;s business, prospects, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s prospects for success depend on our ability to retain Regina Graul, Cyclerion&#8217;s President and Chief Executive Officer and in the future to attract, retain and motivate qualified personnel. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If Cyclerion fails to maintain proper and effective internal controls, Cyclerion&#8217;s ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm Cyclerion&#8217;s business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion could be delisted from Nasdaq, which would seriously harm the liquidity of Cyclerion&#8217;s stock and ability to raise capital. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Korsana </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Even if the Merger and Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing are successful, Korsana will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Korsana&#8217;s ability to continue as a going concern; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana has never generated any revenue from product sales and may never be profitable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana is a preclinical-stage biotechnology company with a limited operating history on which to assess its business; it has not initiated, conducted, or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Korsana or its current or future collaborators are unable to complete development of or commercialize Korsana&#8217;s product candidates, or experience significant delays in doing so, Korsana&#8217;s business will be materially harmed; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana is substantially dependent on the success of its lead program, <span style="white-space:nowrap">KRSA-028,</span> and its anticipated clinical trials of such programs may not be successful; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana currently relies on licensing arrangements with Paragon through the Paragon License Agreement and research collaborations with Paragon through the Paragon ADOA and Paragon Research Letter Agreement. If Korsana is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Korsana&#8217;s business could be negatively impacted; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In order to successfully implement Korsana&#8217;s plans and strategies, Korsana will need to grow the size of its organization and it may experience difficulties in managing this growth; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana does not currently own any issued patents or pending patent applications. Therefore, Korsana&#8217;s ability to obtain and protect its patent rights, and protect other proprietary rights, is uncertain, exposing Korsana to the possible loss of competitive advantage; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. If Korsana is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Korsana will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Risks Related to the Cayman Redomestication</span></span> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Currently, Cyclerion is governed by Massachusetts law, the Cyclerion Articles, and the Cyclerion Bylaws, but upon effectiveness of the Cayman Redomestication the Combined Company will be governed by Cayman Islands law and the Cayman Articles, provisions of which have anti-takeover implications. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Because the Combined Company&#8217;s Cayman Articles designate the courts of the Cayman Islands as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by shareholders, this could limit your ability to obtain a favorable judicial forum for disputes with the Combined Company or the Combined Company&#8217;s directors, officers, or other employees. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to the Combined Company </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of the Combined Company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Combined Company may incur losses for the foreseeable future and may never achieve profitability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Provisions that will be in the Combined Company&#8217;s articles of organization and bylaws and provisions under Massachusetts law could make an acquisition of the Combined Company more difficult and may prevent attempts by its shareholders to replace or remove its management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">After completion of the Merger, holders of Combined Company Series B Preferred Stock will have the ability to significantly influence all matters submitted to the Combined Company shareholders for approval; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks and other risks are discussed in greater detail under the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 33 of this proxy statement/prospectus. Cyclerion and Korsana both encourage you to read and consider all of these risks carefully. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory Approvals (see page&#160;182) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, Cyclerion must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, to Korsana&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the Merger is conditioned on the expiration or termination of any applicable waiting period (and any extension thereof) under the HSR Act and the absence of any law or order restraining, enjoining, or otherwise prohibiting the consummation of the Merger. The HSR Act provides that certain transactions may not be completed until notification and report forms are furnished to the U.S. Department of Justice (&#8220;DOJ&#8221;) and the U.S. Federal Trade Commission (&#8220;FTC&#8221;) and the HSR Act waiting period is terminated or expires. On April 22, 2026, Cyclerion and Korsana each filed a notification and report form under the HSR Act with the DOJ and the FTC. The applicable waiting period required under the HSR Act expired at 11:59 p.m., Eastern Time, on May 22, 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nasdaq Stock Market Listing (see page&#160;163) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion intends to file an initial listing application for the common stock of the Combined Company with Nasdaq. After completion of the Merger, Cyclerion will be renamed &#8220;Korsana Biosciences, Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;KRSA.&#8221; It is a condition to the consummation of the Merger that Cyclerion will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that Cyclerion will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties; however, if such condition is waived, Cyclerion will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of shareholders prior to proceeding with the Merger. Accordingly, you are advised that Cyclerion shareholders will not have certainty regarding the listing of the Combined Company&#8217;s shares at the time you are asked to vote at the Cyclerion Shareholders Meeting. For more information, please see the section entitled &#8220;<span style="font-style:italic">Risk Factors</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Risks Related</span><span style="font-style:italic"> to the </span><span style="font-style:italic">Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> and </span><span style="font-style:italic">Korsana</span><span style="font-style:italic"> may mutually agree to waive the condition to the </span><span style="font-style:italic">Merger</span><span style="font-style:italic"> requiring approval </span><span style="font-style:italic">for</span><span style="font-style:italic"> listing on Nasdaq, and if such condition is waived, the Combined Company</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s stock may not be listed on Nasdaq following completion of the </span><span style="font-style:italic">Merger</span><span style="font-style:italic">.</span>&#8221; on page&#160;33 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anticipated Accounting Treatment (see page&#160;164) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is expected to be treated by Cyclerion as a reverse merger and is expected to be accounted for as an <span style="white-space:nowrap">in-substance</span> reverse recapitalization of Cyclerion by Korsana in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) as, at close, the transaction is, in essence, the issuance of equity by Korsana for Cyclerion&#8217;s net assets, consisting of nominal assets and liabilities before the Merger. For accounting purposes, Korsana is considered to be acquiring the assets and liabilities of Cyclerion in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Korsana&#8217;s equity holders will own a substantial majority of the voting rights in the Combined Company; (ii)&#160;Korsana&#8217;s largest stockholder will retain the largest interest in the Combined Company; (iii)&#160;Korsana will designate all of the initial members of the board of directors of the Combined Company; and (iv)&#160;Korsana&#8217;s executive management team will become the management of the Combined Company. The Combined Company will be named Korsana Biosciences, Inc. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accordingly, the Merger is expected to be treated as the equivalent of Korsana issuing stock to acquire the net assets of Cyclerion. As a result of the Merger, the net assets of Cyclerion will be stated at fair value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Korsana. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital.</span></span> See the &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal Rights and Dissenters&#8217; Rights (see page&#160;164) </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, Cyclerion shareholders are not entitled to appraisal rights in connection with the Merger. Korsana stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of Rights of Holders of Cyclerion Capital Stock and Korsana Capital Stock (see page&#160;413) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is incorporated under the laws of the Commonwealth of Massachusetts and thus is currently subject to the MBCA and Korsana is incorporated under the laws of the State of Delaware and thus subject to the DGCL and accordingly, the rights of their respective stockholders are not identical due to differences in the law of the jurisdiction in which each entity is incorporated and due to differences in governing documents. If the Merger is completed, Korsana stockholders will become shareholders of Cyclerion, and their rights will be governed by the MBCA, the Cyclerion Articles and the Cyclerion Bylaws, in each case as they may be amended, including by Proposal Nos. 2 and 3 if approved by Cyclerion shareholders. The extent to which the rights of Korsana stockholders will change as a result of the Merger is further affected by Proposal No.&#160;4, which, if approved and the Cayman Redomestication is effected, would result in Cyclerion shareholders (including former Korsana stockholders) no longer being governed by the MBCA and Cyclerion&#8217;s existing organizational documents, but instead by the Cayman Articles and the Cayman Islands Companies Act. For a comparison of stockholder rights under these respective regimes, see the section titled &#8220;<span style="font-style:italic">Comparison of Rights</span><span style="font-style:italic"> of </span><span style="font-style:italic">Holders of </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> Capital Stock</span><span style="font-style:italic"> and </span><span style="font-style:italic">Korsana</span><span style="font-style:italic"> Capital Stock</span>&#8221; beginning on page&#160;413, and, assuming the Cayman Redomestication is completed, the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Redom</span><span style="font-style:italic">estication</span><span style="font-style:italic"> Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Effects</span><span style="font-style:italic"> of the </span><span style="font-style:italic">Redomestication</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Comparison of Rights of Holders</span><span style="font-style:italic"> of the </span><span style="font-style:italic">Massachusetts</span><span style="font-style:italic"> Corporation Capital Stock</span><span style="font-style:italic"> and the </span><span style="font-style:italic">Cayman Company Share Capital</span>&#8221; beginning on page&#160;237. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Proposal No.&#160;4 is approved by Cyclerion shareholders and the Merger is completed, the Combined Company will effect the Cayman Redomestication pursuant to the Plan of Domestication as set forth in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">J</span> to this proxy statement/prospectus, and, upon completion of the Cayman Redomestication, the rights of Cyclerion shareholders and the rights of Korsana stockholders who become the Combined Company stockholders pursuant to the Merger will no longer be governed by the Cyclerion Articles, Cyclerion&#8217;s amended and restated bylaws and the MBCA, and instead will be governed by the Cayman Articles, in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">K</span> to this proxy statement/prospectus, and the Cayman Islands Companies Act. For a comparison of rights of holders of the Combined Company capital stock as a Massachusetts corporation and the Combined Company share capital as a Cayman Islands exempted company limited by shares assuming the completion of the Cayman Redomestication, see the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">The Redomestication Proposal</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Effects</span><span style="font-style:italic"> of the Cayman Redomestication</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Comparison of Rights of Holders</span><span style="font-style:italic"> of the</span><span style="font-style:italic"> </span><span style="font-style:italic">Massachusetts</span><span style="font-style:italic"> Corporation Capital Stock</span><span style="font-style:italic"> and the </span><span style="font-style:italic">Cayman Company Share Capital</span>&#8221; beginning on page&#160;237 of this proxy statement/prospectus. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_3">MARKET PRICE AND DIVIDEND INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Common Stock is currently listed on the Nasdaq Capital Market under the symbol &#8220;CYCN.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price of the Cyclerion Common Stock on March&#160;31, 2026, the last day of trading prior to the announcement of the Merger, as reported on The Nasdaq Capital Market, was $1.55 per share. The closing price of the Cyclerion Common Stock on&#8195;&#8195;&#8195;&#8195;, 2026, as reported on The Nasdaq Capital Market, was $&#8195;&#8195;&#8195;&#8195;per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the market price of the Cyclerion Common Stock is subject to fluctuation, the market value of the shares of the Cyclerion Common Stock that the Korsana stockholders will be entitled to receive in the Merger may increase or decrease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is a private company, and its shares of common stock and preferred stock are not publicly traded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming approval of Proposal Nos. 1, 2, and 3 and successful application for initial listing with Nasdaq, following the consummation of the Merger, shares of Cyclerion Common Stock will trade on Nasdaq under Cyclerion&#8217;s new name, &#8220;Korsana Biosciences, Inc.,&#8221; and new trading symbol &#8220;KRSA.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&#8195;&#8195;&#8195;&#8195;, 2026, there were approximately&#8195;&#8195;&#8195;&#8195;registered holders of record of the Cyclerion Common Stock. As of&#8195;&#8195;&#8195;&#8195;, 2026, Korsana had&#8195;&#8195;&#8195;&#8195;holders of record of Korsana Common Stock,&#8195;&#8195;&#8195;&#8195;holders of record of Korsana Series Seed Preferred Stock, and&#8195;&#8195;&#8195;&#8195;holders of record of Korsana Series A Preferred Stock. For detailed information regarding the beneficial ownership of certain Cyclerion and Korsana stockholders, see the sections of this proxy statement/prospectus titled &#8220;<span style="font-style:italic">Principal </span><span style="font-style:italic">Share</span><span style="font-style:italic">holders of </span><span style="font-style:italic">Cyclerion</span>,&#8221; &#8220;<span style="font-style:italic">Principal Stockholders of </span><span style="font-style:italic">Korsana</span>&#8221; and &#8220;<span style="font-style:italic">Principal S</span><span style="font-style:italic">hare</span><span style="font-style:italic">holders of the Combined Company</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividends </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion has never declared or paid any cash dividends on the Cyclerion Common Stock and does not anticipate paying cash dividends on the Cyclerion Common Stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the Combined Company&#8217;s then-current board of directors and will depend upon a number of factors, including the Combined Company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has never paid or declared any cash dividends on Korsana capital stock. If the Merger does not occur, Korsana does not anticipate paying any cash dividends on the Korsana capital stock in the foreseeable future, and Korsana intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the Korsana Board and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors the Korsana Board deems relevant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_4">RISK FACTORS </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Combined Company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of Cyclerion Common Stock. You should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</span><span style="font-style:italic">435</span><span style="font-style:italic">&#160;of this proxy statement/prospectus for further information. Moreover, some of the factors, events and contingencies discussed below may have occurred in the past, but the disclosures below are not representations as to whether or not the factors, events or contingencies have occurred in the past and instead reflect our beliefs and opinions as to the factors, events, or contingencies that could materially and adversely affect us in the future. </span></p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Proposed Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to complete, or delays in completing, the potential Merger could materially and adversely affect Cyclerion&#8217;s results of operations, business, financial results, and/or common stock price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;1, 2026, Cyclerion and Korsana entered into the Merger Agreement, which agreement was subsequently amended on April&#160;17, 2026, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the First Merger and, immediately following the First Merger and as part of the same overall transaction as the First Merger, Korsana will merge with and into Second Merger Sub as part of the Second Merger, with Second Merger Sub continuing as a wholly owned subsidiary of Cyclerion and the surviving entity of the Second Merger. Consummation of the Merger is subject to certain closing conditions, a number of which are not within Cyclerion&#8217;s control. Any failure to satisfy these required conditions to closing may prevent, delay or otherwise materially adversely affect the completion of the transaction. Cyclerion cannot predict with certainty whether or when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that it will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, its business, which may materially adversely affect its results of operation and its business. Uncertainty as to whether the Merger will be completed in a timely manner or at all may affect Cyclerion&#8217;s ability to retain and motivate existing employees. Uncertainty as to whether the Merger will be completed in a timely manner or at all could adversely affect Cyclerion&#8217;s business and its relationship with collaborators, suppliers, vendors, regulators, and other business partners. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the conditions to the Merger are not satisfied or waived, the Merger may not occur. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the Merger is approved by the stockholders of Korsana and Cyclerion, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and described further in the section titled &#8220;The Merger Agreement&#8221; of this proxy statement/prospectus. Cyclerion cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion and Korsana may mutually agree to waive the condition to the Merger requiring approval for listing on Nasdaq, and if such condition is waived, the Combined Company&#8217;s stock may not be listed on Nasdaq following completion of the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Cyclerion agreed, to the extent required by the rules and regulations of Nasdaq, to use its commercially reasonable efforts to cause the shares of Cyclerion Common Stock being issued </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the Merger to be approved for listing on Nasdaq at or prior to the First Effective Time. Additionally, under the Merger Agreement, each of Cyclerion&#8217;s and Korsana&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties of various conditions, including that the shares of Cyclerion Common Stock to be issued in the Merger have been approved for listing (subject to official notice of issuance) on Nasdaq as of the closing of the Merger. In the event that the shares of Cyclerion Common Stock to be issued in the Merger are not approved for listing on Nasdaq, it is possible that Cyclerion and Korsana may mutually agree to waive the applicable condition and nonetheless proceed with completing the Merger. If such condition is waived, Cyclerion will not recirculate an updated proxy statement/prospectus, nor will it solicit a new vote of shareholders prior to proceeding with the Merger. If Cyclerion proceeds with the Merger in these circumstances, the Combined Company&#8217;s stock may not be listed on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Combined Company&#8217;s stock is not listed on Nasdaq following completion of the Merger, trading of the shares could be conducted in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the Combined Company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the Combined Company. Also, it may be difficult for the Combined Company to raise additional capital if the Combined Company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the Combined Company and could have a material adverse effect on the Combined Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Exchange Ratio for the Merger will not change or otherwise be adjusted based on the market price of Cyclerion Common Stock. </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applying the Exchange Ratio, based on Cyclerion&#8217;s and Korsana&#8217;s capitalization as of March&#160;31, 2026 and taking into account Cyclerion&#8217;s current cash position, each share of Korsana Common Stock is currently estimated to be entitled to receive approximately 1.1009 shares of Cyclerion Common Stock. Each share of Korsana Series Seed Preferred Stock will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock, equal to the Exchange Ratio divided by 1,000. Applying the Exchange Ratio, the former Korsana securityholders immediately before the Merger are expected to own approximately 98.5% of the aggregate number of shares of the Combined Company&#8217;s capital stock following the Merger (on a fully-diluted basis), and Cyclerion shareholders immediately before the Merger are expected to own approximately 1.5% of the aggregate number of shares of the Combined Company capital stock following the Merger (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Cyclerion&#8217;s Net Cash as of closing being equal to $0. In the event Cyclerion&#8217;s Net Cash is less than or greater than $0, the Exchange Ratio will be adjusted such that the number of shares issued to Korsana&#8217;s <span style="white-space:nowrap">pre-closing</span> securityholders will be decreased or increased, as applicable, and Cyclerion shareholders will own a smaller or larger percentage, as applicable, of the Combined Company following the consummation of the Merger. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the market price of Cyclerion&#8217;s stock before the completion of the First Merger will not affect the number of shares Korsana stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the First Merger, the market price of Cyclerion Common Stock increases from the market price on the date of the Merger Agreement, then Korsana stockholders could receive merger consideration with substantially more value for their shares of Korsana capital stock than the parties had negotiated when they established the Exchange Ratio. Similarly, if before the completion of the First Merger, the market price of Cyclerion Common Stock declines from the market price on the date of the Merger Agreement, then Korsana stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a price-based termination right. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The issuance of Cyclerion Common Stock, including the shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, to Korsana stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by Cyclerion shareholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Korsana stockholders. Failure to obtain these approvals would prevent the closing of the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before the Merger can be completed, Cyclerion shareholders must approve, among other things, the issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, to Korsana stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger, and Korsana stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, neither Cyclerion nor Korsana is obligated to complete the Merger if there is a material adverse effect affecting the other party between April&#160;1, 2026, the date of the Merger Agreement, and the closing of the Merger. However, certain types of causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes in general economic or political conditions, industry-wide changes, changes resulting from the announcement of the Merger, natural disasters, pandemics, other public health events or force majeure events and changes in U.S. generally accepted accounting principles. Therefore, if any of these events were to occur and adversely affect Cyclerion or Korsana, the other party would still be obliged to consummate the closing of the Merger notwithstanding such material adverse effect. If any such adverse effects occur and Cyclerion consummates the closing of the Merger, the stock price of the Combined Company may suffer. This in turn may reduce the value of the Merger to the shareholders of Cyclerion, Korsana or both. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the Merger is not completed, Cyclerion&#8217;s stock price may decline significantly. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Cyclerion Common Stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Cyclerion Common Stock will likely be volatile based on whether shareholders and other investors believe that Cyclerion can complete the Merger or otherwise raise additional capital to support Cyclerion&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of Cyclerion Common Stock has been and may be exacerbated by low trading volume. Additional factors that may cause the market price of Cyclerion Common Stock to fluctuate include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of the results of its future clinical trials, discussions with regulators, and regulatory approval decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the entry into, or termination of, key agreements, including commercial partner agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the loss of key employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future sales of Cyclerion Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general and industry-specific economic conditions that may affect Cyclerion&#8217;s research and development expenditures; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> fluctuations in financial results. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Cyclerion Common Stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Cyclerion completes the Merger, the Combined Company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the Combined Company&#8217;s shareholders or restrict the Combined Company&#8217;s operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, Korsana and Cyclerion entered into the Securities Purchase Agreement with certain investors, including existing investors of Korsana, pursuant to which the investors agreed to purchase, in the aggregate, approximately $380.0&#160;million of Korsana Common Stock and Korsana Pre-Funded Warrants in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing immediately prior to the closing of the Merger. The closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions. The Korsana Common Stock and Korsana Pre-Funded Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing will result in dilution to all securityholders of the Combined Company (i.e., both Cyclerion&#8217;s <span style="white-space:nowrap">pre-Merger</span> securityholders and former Korsana securityholders). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional financing may not be available to the Combined Company when it is needed or may not be available on favorable terms. To the extent that the Combined Company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the Combined Company, including Cyclerion&#8217;s <span style="white-space:nowrap">pre-Merger</span> securityholders and Korsana former securityholders. It is also possible that the terms of any new equity securities may have preferences over the Combined Company&#8217;s common stock. Any debt financing the Combined Company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the Combined Company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the Combined Company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the Combined Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a result of Cyclerion&#8217;s assumption of the Paragon ADOA in connection with the Merger, the Combined Company will be subject to the obligation to grant to Parasa on December&#160;31, 2026, warrants to purchase a number of shares equal to 1.00% of the outstanding shares of Cyclerion Common Stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Such warrants granted will result in further dilution to all securityholders of the Combined Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transfers of the Combined Company&#8217;s securities utilizing Rule 144 of the Securities Act may be limited. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of the Combined Company&#8217;s securities will be restricted from immediate resale. Holders should be aware that transfers of the Combined Company&#8217;s securities pursuant to Rule 144 may be limited as Rule 144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. Cyclerion&#8217;s expected disposal of Cyclerion&#8217;s historical assets and operations in connection with the Merger is expected to make Cyclerion a shell company. Cyclerion anticipates that following the consummation of the Merger, the Combined Company will no longer be a shell company. As a result, Cyclerion anticipates that holders will not be able to sell their restricted Combined Company securities pursuant to Rule 144 without registration until one year after Cyclerion files the Current Report on Form <span style="white-space:nowrap">8-K</span> following the closing that includes the required Form 10 information that reflects that the Combined Company is no longer a shell company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion is expected to be deemed a shell company. As a result, if Cyclerion completes the Merger, the Combined Company will be subject to more stringent reporting requirements, offering limitations and resale restrictions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s or the Combined Company&#8217;s expected disposal of Cyclerion&#8217;s historical assets and operations prior to or following the Merger is expected to make Cyclerion a shell company. As such, the Combined Company would be subject to the requirements applicable to shell company business combinations. The requirements applicable to shell company business combinations are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Combined Company will need to file a Form <span style="white-space:nowrap">8-K</span> to report the Form 10 type information after closing with the SEC reflecting its status as an entity that is not a shell company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion is not, and the Combined Company will not be, eligible to use a Form <span style="white-space:nowrap">S-3</span> until 12 full calendar months after closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Combined Company will need to wait at least 60 calendar days after closing to file a Form <span style="white-space:nowrap">S-8</span> for any equity plans or awards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Combined Company will be an &#8220;ineligible issuer&#8221; for three years following the closing, which will prevent the Combined Company from (i)&#160;incorporating by reference in its Form <span style="white-space:nowrap">S-1</span> filings, (ii)&#160;using a free writing prospectus, or (iii)&#160;taking advantage of well-known seasoned issuer status despite its public float; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">investors who (i)&#160;are affiliates of Korsana at the time the Merger is submitted for the vote or consent of Korsana stockholders, (ii)&#160;receive securities of the Combined Company in the Merger (i.e., Rule 145(c) securities), and (iii)&#160;publicly offer or sell such securities, will be deemed to be engaged in a distribution of such securities, and therefore to be underwriters with respect to resales of those securities, and accordingly such securities may not be included in the Form <span style="white-space:nowrap">S-1</span> resale registration statement anticipated to be filed after the closing of the Merger unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rule 144(i)(2) will limit the ability to publicly resell Rule 145(c) securities per Rule 145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the Combined Company per Rule 144 (i.e., holders of restricted securities and any affiliates of the public company are also affected) until one year after the Form 10 information is filed with the SEC. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing SEC requirements would increase the Combined Company&#8217;s time and cost of raising capital, offering stock under equity plans, and complying with securities laws. Further, such requirements will add burdensome restrictions on the resale of Combined Company shares by affiliates of Korsana and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Some of Cyclerion&#8217;s and Korsana&#8217;s directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors and executive officers of Cyclerion and Korsana have interests in the Merger that are different from, or in addition to, the interests of other Cyclerion shareholders generally. These interests with respect to Cyclerion&#8217;s directors and executive officers may include, among others, retention bonus payments, extension of exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, certain current members of the Korsana Board will continue as directors of the Combined Company after the First Effective Time, and, following the closing of the Merger, will be eligible to be compensated as <span style="white-space:nowrap">non-employee</span> directors of the Combined Company pursuant to Cyclerion&#8217;s <span style="white-space:nowrap">non-employee</span> director compensation policy that is expected to remain in place following the First Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board was aware of and considered those interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, and recommend the approval of the Merger Agreement to Cyclerion and Korsana stockholders. These interests, among other factors, may have influenced the directors and executive officers of each company to support or approve the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion shareholders and Korsana stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Combined Company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, Cyclerion shareholders and Korsana stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the Combined Company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Combined Company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of the Merger, Cyclerion&#8217;s current shareholders will generally own a smaller percentage of the Combined Company than their ownership of Cyclerion prior to the Merger. Immediately after the Merger, Cyclerion securityholders as of immediately prior to the Merger are expected to own approximately 1.5% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), and former holders of Korsana securities are expected to own approximately 98.5% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Cyclerion&#8217;s Net Cash as of closing being equal to $0. The Chief Executive Officer and President of Korsana will serve as the Chief Executive Officer and President of the Combined Company following the completion of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Merger Agreement is in effect, each party is generally prohibited from, among other things, soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry. In addition, Cyclerion&#8217;s current directors and executive officers have entered into support agreements pursuant to the terms of the Merger Agreement, and as an inducement to Korsana&#8217;s willingness to enter into the Merger Agreement, by which they have agreed to vote all of their shares of Cyclerion capital stock in favor of the Merger Agreement and the transactions contemplated thereby and against any competing proposals, subject to certain limited exceptions. These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the merger consideration in the combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because the lack of a public market for Korsana Common Stock makes it difficult to evaluate the fair market value of its capital stock, the value of Cyclerion Common Stock to be issued to Korsana stockholders may be more or less than the fair market value of Korsana Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding capital stock of Korsana is privately held and is not traded on any public market. The lack of a public market makes it difficult to determine the fair market value of Korsana capital stock. Because the percentage of Cyclerion&#8217;s equity to be issued to Korsana stockholders was determined based on negotiations between the parties, it is possible that the value of Cyclerion Common Stock and Cyclerion Series B Preferred </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock to be issued to Korsana stockholders will be more or less than the fair market value of Korsana capital stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Lawsuits may be filed against Cyclerion, Korsana, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against Cyclerion, the Cyclerion Board, Korsana, the Korsana Board and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and Cyclerion or Korsana may not be successful in defending against any such future claims. Lawsuits that may be filed against Cyclerion, the Cyclerion Board, Korsana, or the Korsana Board could delay or prevent the Merger, divert the attention of Cyclerion&#8217;s and Korsana&#8217;s management and employees from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> business and otherwise adversely affect Cyclerion and Korsana financially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion has never paid and, other than in connection with the Merger, does not intend to pay any cash dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion has never paid cash dividends on any of its capital stock. Cyclerion does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Cyclerion does not successfully consummate the Merger or another strategic transaction, the Cyclerion Board may decide to pursue a dissolution and liquidation of Cyclerion. In such an event, the amount of cash available for distribution to Cyclerion shareholders, if any, will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities, as to which Cyclerion can give you no assurance. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Merger will be completed. If the Merger is not completed, the Cyclerion Board may decide to pursue a dissolution and liquidation of Cyclerion. In such an event, the amount of cash available for distribution to Cyclerion shareholders, if any, will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as Cyclerion funds its operations while pursuing the Merger. In addition, if the Cyclerion Board were to approve and recommend, and Cyclerion shareholders were to approve, a dissolution and liquidation of Cyclerion, Cyclerion would be required under Massachusetts law to pay Cyclerion&#8217;s outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to shareholders. Cyclerion&#8217;s commitments and contingent liabilities may include obligations under Cyclerion&#8217;s employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control of Cyclerion, litigation against Cyclerion, and other various claims and legal actions arising in the ordinary course of business, and other unexpected and/or contingent liabilities. As a result of this requirement, a portion of Cyclerion&#8217;s assets would need to be reserved pending the resolution of such obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cyclerion may be subject to litigation or other claims related to a dissolution and liquidation of Cyclerion. If a dissolution and liquidation were to be pursued, the Cyclerion Board, in consultation with Cyclerion&#8217;s advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of Cyclerion Common Stock could lose all or a significant portion of their investment in the event of liquidation, dissolution or winding up of Cyclerion. A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to Cyclerion shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion and its shareholders will not have any right to make damage claims against Korsana for the breach of any representation, warranty or covenant made by Korsana in the Merger Agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that all of the representations, warranties and covenants of the parties contained therein shall not survive the closing of the Merger, except for those covenants contained therein that by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their terms apply or are to be performed in whole or in part after the Closing, and then only with respect to breaches occurring after the closing of the Merger. Accordingly, there are no remedies available to the parties with respect to any breach of the representations, warranties, covenants or agreements of the parties to the Merger Agreement after the Closing of the Merger, except for covenants to be performed in whole or in part after the Closing. As a result, Cyclerion and its shareholders will have no remedy available to them if the Merger is consummated and it is later revealed that there was a breach of any of the representations, warranties and covenants made by Korsana at the time of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Cyclerion cannot assure you that the due diligence conducted in relation to Korsana has identified all material issues or risks associated with Korsana, its business or the industry in which it competes. Furthermore, Cyclerion cannot assure you that factors outside of its or Korsana&#8217;s control will not later arise, or that any previously identified risks will not materialize in a manner inconsistent with the preliminary analysis. As a result of these factors, following the closing of the Merger, the Combined Company may be exposed to liabilities and incur additional costs and expenses and it may be forced to later write-down or write off assets, restructure its operations, or incur impairment or other charges. Cyclerion and its shareholders have no indemnification rights against Korsana or its stockholders under the Merger Agreement. Accordingly, any shareholders of Cyclerion that remain stockholders of the Combined Company following the Merger could suffer a reduction in the value of their securities. Such shareholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by Cyclerion&#8217;s directors or officers of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the registration statement or proxy statement/prospectus relating to the Merger contained an actionable material misstatement or material omission. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion&#8217;s shareholders potentially may not receive any payment on the Cyclerion CVRs and the Cyclerion CVRs may otherwise expire valueless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contemplates that, at or prior to the First Effective Time, Cyclerion and the Rights Agent (as defined in the Cyclerion CVR Agreement) will execute and deliver the Cyclerion CVR Agreement, pursuant to which each person who was a shareholder of record of Cyclerion&#8217;s capital stock as of the close of business on the last business day prior to the day on which the First Effective Time occurs will be entitled to receive a Cyclerion CVR, issued by Cyclerion subject to and in accordance with the terms and conditions of the Cyclerion CVR Agreement. Pursuant to the Cyclerion CVR Agreement, each CVR holder is entitled to certain rights to receive a pro rata portion of the proceeds, if any, received by Cyclerion as a result of the disposition of the Cyclerion Legacy Assets during specified periods of time. Such proceeds are subject to certain permitted deductions. The right of Cyclerion&#8217;s shareholders to derive any value from the Cyclerion CVRs will be contingent solely upon the disposition of such Cyclerion Legacy Assets within the time periods specified in the Cyclerion CVR Agreement or any other contingencies as provided in the Cyclerion CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion may not be able to achieve successful results from the disposition of such Cyclerion Legacy Assets as described above. If this is not achieved for any reason within the time periods specified in the CVR Agreement, no payments will be made under the Cyclerion CVRs, and the Cyclerion CVRs will expire valueless. For more information see the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger &#8212; Cyclerion CVR Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The tax treatment of the Cyclerion CVRs is uncertain. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company intends to treat the issuance of the Cyclerion CVRs to the persons who prior to completion of the Merger were Cyclerion shareholders as a distribution of property with respect to Cyclerion capital stock. However, the U.S. federal income tax treatment of the CVRs is uncertain. There is no legal authority directly addressing the U.S. federal income tax treatment of contingent value rights with characteristics similar to the Cyclerion CVRs. Therefore, it is possible that the issuance of the Cyclerion CVRs may be treated as a distribution of equity with respect to Cyclerion capital stock, as an &#8220;open transaction,&#8221; or as a &#8220;debt instrument&#8221; for U.S. federal income tax purposes, and such questions are inherently factual in nature. For more information regarding the U.S. federal income tax consequences of the Cyclerion CVRs, see the section titled </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;<span style="font-style:italic">Agreements Related to the Merger &#8212; Cyclerion CVR Agreement &#8212; Material U.S. Federal Income Tax Consequences of the Cyclerion CVRs to Holders of Cyclerion Capital Stock</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Proposed Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The reverse stock split could result in a significant devaluation of Cyclerion&#8217;s market capitalization and the trading price of Cyclerion Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Cyclerion expects that the reverse stock split will result in an increase in the market price of Cyclerion Common Stock, Cyclerion cannot assure stockholders that the reverse stock split, if implemented, will increase the market price of Cyclerion Common Stock in proportion to the reduction in the number of shares of Cyclerion Common Stock outstanding or result in a permanent increase in the market price. Accordingly, the total market capitalization of Cyclerion Common Stock after the reverse stock split may be lower than the total market capitalization before such reverse stock split and, in the future, the market price of Cyclerion Common Stock following such reverse stock split may not exceed or remain higher than the market price prior to the corresponding reverse stock split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effect the reverse stock split may have upon the market price of Cyclerion Common Stock cannot be predicted with any certainty. The market price of Cyclerion Common Stock is dependent on many factors, including Cyclerion&#8217;s business and financial performance, general market conditions, prospects for future success and other factors detailed from time to time in the reports Cyclerion files with the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The reverse stock split may result in some stockholders owning &#8220;odd lots&#8221; that may be more difficult to sell or require greater transaction costs per share to sell. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reverse stock split may result in some stockholders owning &#8220;odd lots&#8221; of less than 100 shares of Cyclerion Common Stock on a post-split basis. These odd lots may be more difficult to sell, or require greater transaction costs per share to sell, than shares in &#8220;round lots&#8221; of even multiples of 100 shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The reverse stock split may not generate additional investor interest. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Cyclerion Board believes that a higher stock price may help generate investor interest, there can be no assurance that the reverse stock split will result in a per share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of Cyclerion Common Stock may not necessarily improve. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The reverse stock split may not increase the Combined Company&#8217;s stock price over the long term. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of the reverse stock split are to (i)&#160;increase the <span style="white-space:nowrap">per-share</span> market price of Cyclerion Common Stock above the minimum bid price requirement under the Nasdaq rules so that the listing of Cyclerion<span style="font-weight:bold"> </span>and the shares of Cyclerion Common Stock being issued in the Merger on Nasdaq will be approved and (ii)&#160;increase the number of authorized and unissued shares available for future issuance in connection with the Merger, though such increase will not alone be sufficient to complete the Merger. It cannot be assured, however, that the reverse stock split will accomplish any increase in the per share market price of Cyclerion Common Stock for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of Cyclerion Common Stock will proportionally increase the market price of Cyclerion Common Stock, it cannot be assured that the reverse stock split will increase the market price of Cyclerion Common Stock by a multiple of the reverse stock split ratio mutually agreed by Cyclerion<span style="font-weight:bold"> </span>and Korsana, or result in any permanent or sustained increase in the market price of Cyclerion Common Stock, which is dependent upon many factors, including Cyclerion&#8217;s<span style="font-weight:bold"> </span>business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of Cyclerion Common Stock might meet the listing requirements for Nasdaq initially after the reverse stock split, it cannot be assured that it will continue to do so. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The reverse stock split may decrease the liquidity of the Combined Company&#8217;s common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Cyclerion<span style="font-weight:bold"> </span>Board believes that the anticipated increase in the market price of the Combined Company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its shareholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the Combined Company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the Combined Company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the Combined Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The reverse stock split may lead to a decrease in the Combined Company&#8217;s overall market capitalization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should the market price of the Combined Company&#8217;s common stock decline after the reverse stock split, the percentage decline will be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the Combined Company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the Combined Company, as measured by its stock capitalization, will be reduced. In some cases, the <span style="white-space:nowrap">per-share</span> stock price of companies that have effected reverse stock splits subsequently declined back to <span style="white-space:nowrap">pre-reverse</span> split levels, and accordingly, it cannot be assured that the total market value of the Combined Company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the Combined Company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Cyclerion </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this &#8220;Risks Related to Cyclerion&#8221; section to &#8220;Cyclerion,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Cyclerion and its subsidiaries. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Position and Capital Needs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">As we are a biopharmaceutical company with a limited operating history and no products approved for commercial sale, valuing our business and predicting our prospects are challenging. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company that was incorporated in 2018. Our business was conducted within Ironwood Pharmaceuticals, Inc. prior to that time, and we had no history as an independent company prior to the completion of the separation which occurred in 2019. Prior to the announcement of the Merger, we were seeking to develop new products for treatment resistant depression. We have also developed a pipeline of sGC stimulators, but we have no products approved for commercial sale, and we have never generated revenue from product sales nor has Tisento or Akebia ever generated product sales from products incorporating our compounds. Our operating activities to date have been limited primarily to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, pursuing partnership opportunities and obtaining licenses we deem necessary for our treatment resistant depression candidate, and conducting early-stage clinical trials for our product candidates. In light of the proposed Merger, we have stopped the development of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not obtained marketing approval for any of our product candidates; engaged on our own or through a third party, in commercial scale manufacturing or conducted sales and marketing activities necessary for the successful commercialization of our product candidates. Our short operating history offers limited insight into our prospects for success or even viability. If we continue to progress the development of our product candidates, we expect our operating performance to fluctuate. We will encounter challenges frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields and we have not yet demonstrated an ability to successfully navigate such challenges. If we do not successfully address the challenges </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we face or we are not able to complete the proposed Merger, our business, prospects, financial condition and results of operations will be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business has incurred significant losses and we anticipate that, if we continue to progress the development of our product candidates, we will continue to incur significant losses for the foreseeable future. We have never generated revenue from product sales and may never be profitable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business has incurred operating losses due to costs incurred in connection with our research and development activities and general and administrative expenses associated with our operations. Our net losses for the years ended December&#160;31, 2025 and 2024 were $3.5&#160;million and $3.1&#160;million, respectively. We expect to incur significant losses for at least the next several years, and for these losses to significantly increase, if we continue our research activities and conduct development of, and seek regulatory approvals for, our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue from our current and any potential future product candidates and achieve profitability depends on our ability, alone or with strategic partners, to complete the development of, and obtain the necessary regulatory and essential pricing and reimbursement approvals to commercialize, our product candidates. If we continue to progress the development of our product candidates, we do not know when, if ever, we will generate revenues from sales of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, our expenses would increase beyond expectations if we are required by the FDA, the EMA, or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently anticipate. Even if one or more of the product candidates that we develop is approved for commercial sale, we may never generate revenue in amounts sufficient to achieve and maintain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">There is substantial doubt about our ability to continue as a going concern. </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">If we are not able to complete the proposed </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Merger</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> and we continue to progress the development of our product candidates, w</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">e will need to raise additional funding in the near term, which may not be available on acceptable terms, if at all</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">,</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> to continue as a going concern and advance our product candidates. Failure to obtain capital when needed may force us to delay, limit or terminate our product development efforts or operations altogether. Raising additional capital would dilute our existing shareholders, restrict our operations or cause us to relinquish valuable rights.</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is substantial doubt regarding our ability to continue as a going concern. As of December&#160;31, 2025, we had unrestricted cash and cash equivalents of approximately $3.2&#160;million. Our management believes that such cash and cash equivalents will not be sufficient to fund our operating expenses and capital requirements until the completion of the Merger. If we are not able to complete the proposed Merger and we continue to progress the development of our product candidates, we will require significant additional funding to advance any of our product candidates beyond the short term and to sustain our operations. In the event that we are unable to raise the capital necessary, we may need to curtail our operations or cease operations altogether. Because there is substantial doubt about our ability to continue as a going concern for a reasonable period of time, an investment in our common stock is highly speculative and holders of our common stock could suffer a total loss of their investment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also seek to raise such capital through public or private financing of our securities, royalty financing or debt financing. Raising funds in the current economic environment is, and may in the future, continue to be challenging, and such financing may not be available in sufficient amounts or on acceptable terms, if at all. The terms of any financing may harm existing shareholders. The issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute the ownership of existing shareholders.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell shares or other equity securities in one or more other transactions, or issue stock, stock options or other securities pursuant to our current equity plans, investors may be materially diluted by such subsequent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuances. We will need significant additional capital in the near term to continue our current plans. No assurance can be given that we will be able to obtain such funds upon favorable terms and conditions, if at all. Failure to do so could have a material adverse effect on our business. To the extent we raise additional capital by issuing equity securities, our stockholders would likely experience substantial dilution. We may sell common stock, preferred stock, convertible securities or other equity or convertible securities in one or more transactions that may include voting rights (including the right to vote as a series on particular matters), preferences as to dividends and liquidation, antidilution, and conversion and redemption rights, subject to applicable law, and at prices and in a manner we determine from time to time. Such issuances and the exercise of any convertible securities will dilute the percentage ownership of our stockholders and may affect the value of our capital stock and could adversely affect the rights of the holders of such stock, thereby reducing the value of such stock. Moreover, any exercise of convertible securities may adversely affect the terms upon which we will be able to obtain additional equity capital, since the holders of such convertible&#160;securities can be expected to exercise them at a time when we would, in all likelihood, not be able to obtain any needed capital on terms more favorable to us than those provided in such convertible securities.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Incurring debt, if available, would result in increased fixed payment obligations, and we may agree to restrictive covenants, such as limitations on our ability to incur additional debt or limitations on our ability to acquire, sell or license intellectual property rights that could impede our ability to conduct our business. In the event we are unable to raise financing, we may need to reduce or cease operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, we also intend to seek funds through collaborations, strategic alliances, or licensing arrangements with third parties. Such agreements may adversely impact retained rights to our assets, technologies, future revenue streams and programs, especially those that receive regulatory approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Development and Clinical Testing of Our Products and Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, our approach to the discovery and development of product candidates for the treatment of serious diseases may never lead to marketable products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of drug therapies presents unique challenges, including an imperfect understanding of the biology, a frequent lack of translatability of nonclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect that may be too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance. If we are unable to complete the proposed Merger and continue to progress the development of our product candidates, our future success would be highly dependent on the successful development of our technology and our current and any potential future product candidates. The scientific evidence to support the feasibility of developing our current product candidates is both preliminary and limited. If we continue to progress the development of our product candidates but do not successfully develop and commercialize product candidates, we will not become profitable and the value of our common stock may decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and development of biopharmaceutical products is inherently risky. If we continue to progress development of our product candidates, we may encounter substantial delays in our activities, including our planned clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities in the development of products to treat patients with serious diseases. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress development of our product candidates, our business will depend heavily on the successful development, clinical testing, regulatory approvals and commercialization of our lead product candidate for treatment resistant depression, praliciguat <span style="white-space:nowrap">(out-licensed</span> to Akebia), any potential future <span style="white-space:nowrap">out-licensing</span> of olinciguat, and any future potential product candidates we may acquire or license as well as both the product candidates we have sold to Tisento (the &#8220;Transferred Assets&#8221;). Any of our current or potential product candidates will require regulatory approval.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical and clinical studies that our product candidates are both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate benefit-risk profile for its intended use in its intended patient population. In some instances, significant variability in safety or efficacy appear in different clinical studies of the same product candidate due to numerous factors, including changes in study protocols, differences in the number and characteristics of the enrolled study participants, variations in the dosing regimen and other clinical study parameters or the dropout rate among study participants. Product candidates in later stages of clinical studies often fail to demonstrate adequate safety and efficacy despite promising nonclinical testing and early clinical studies. Companies in the biopharmaceutical industry often suffer significant setbacks in both early and later-stage clinical studies as most product candidates that begin clinical studies are never approved for commercialization by regulatory authorities. Favorable results in earlier stage trials may not be replicated in later stage trials. If we continue to progress the development of our product candidates and fail to produce positive results in our clinical trials, the development timeline, regulatory approval and commercialization prospects of our assets and, correspondingly, our business and financial prospects, would be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In the event of difficulties in enrolling participants in any clinical studies conducted on our product candidates, those clinical trials could be delayed or prevented from proceeding. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying participants to participate in any clinical studies of our product candidates would be critical to the success of those clinical trials. The timing of any clinical studies will depend in part on the speed at which participants can be recruited to participate in testing these product candidates. Estimates of the prevalence of target indications may vary considerably. Determining the incidence of these conditions, including in specific geographies or demographic groups, would be challenging. The lower the actual prevalence of these conditions, the more challenges would be encountered enrolling participants in those clinical studies, which could delay development of those product candidates. Clinical trial enrollment may also encounter difficulties for a variety of other reasons. The number of participants eligible for a clinical trial may be substantially limited by stringent eligibility criteria in a study protocol, such as the inclusion of biomarker-driven identification or other highly specific criteria related to stage of disease progression or to specific patient reported outcome measures. The number of participants required to power the statistical analysis of the study&#8217;s endpoints may be very large leading to an extended enrollment period. Issues such as the proximity of participants to a study site, the complexity of the study design, the ability to recruit investigators with appropriate skill and experience, competing clinical studies for similar therapies or targeting similar participants, perceptions of the benefit-risk profile of the product candidate relative to other available therapies or product candidates, and ability to obtain and maintain institutional review board (&#8220;IRB&#8221;), or ethics committee (&#8220;EC&#8221;) approvals and participant consents all could have a substantial impact on the timing of clinical trial enrollment. If sufficient participants cannot be enrolled in clinical studies in a timely way, obtaining study results would be delayed, which may harm our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we, </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">assuming we continue to progress the development of our product candidates, or </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Tisento, </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Akebia</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">or</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> any other future licensees, as applicable, are ultimately unable to obtain regulatory approval </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">for</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> the product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product candidate cannot be commercialized until the appropriate regulatory authorities have reviewed and approved the product candidate. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical studies and depends upon numerous factors, including the type and complexity of the product candidates involved. Regulatory authorities have substantial discretion in the approval process and may refuse to accept an application for review or may decide that data are insufficient for approval and require additional nonclinical, clinical, or other information (e.g., product quality data or manufacturing controls). No regulatory approval for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any of our product candidates we own, licensed to Akebia or sold to Tisento has been requested or obtained, and it is possible that none of these existing product candidates or any product candidates we, if we continue to progress the development of our product candidates, or our licensees or Tisento may seek to develop in the future will ever obtain regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any ongoing clinical studies may not be completed on schedule, and any planned clinical studies may not begin on schedule, if at all. The completion or commencement of clinical studies can be delayed or prevented for a number of reasons, including, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory bodies may not authorize us or our investigators to commence planned clinical studies, or require that ongoing clinical studies be suspended through imposition of clinical holds; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative results from ongoing studies or other industry studies involving product candidates modulating the same or similar mechanism of action; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or contract research organizations (&#8220;CRO&#8221;), and clinical study sites, the terms of which can be subject to considerable negotiation and may vary significantly among different CROs and study sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical studies, for example delays in the manufacturing of sufficient supply of finished drug product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties obtaining EC or IRB approval(s) to conduct a clinical study at a prospective site or sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">challenges in recruiting and enrolling participants in clinical studies, the proximity of participants to study sites, eligibility criteria for the clinical study, the nature of the clinical study protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical study programs for similar indications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severe or unexpected drug-related side effects experienced by participants in a clinical study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the presence of unanticipated metabolites in participants in a clinical study may require considerable nonclinical and clinical assessment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, our licensees or Tisento may decide, or regulatory authorities may require the conduct of additional clinical studies or abandonment of product development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in validating, or inability to validate, any endpoints utilized in a clinical study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory bodies may disagree with a clinical study&#8217;s design and the interpretation of data from clinical studies, or may change the requirements for approval even after it has reviewed and commented on the design for clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reports from nonclinical or clinical testing of other competing candidates that raise safety or efficacy concerns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cutbacks in funding for the FDA may result in delays in reviewing and approving applications; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties retaining participants who have enrolled in a clinical study but may be prone to withdraw due to rigors of the clinical studies, lack of efficacy, side effects, personal issues, or loss of interest. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical study may be suspended or terminated by us, our licensees, Tisento, the FDA or other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comparable authorities, the IRBs or ECs overseeing a clinical study, a data and safety monitoring board overseeing the clinical study, or other regulatory authorities due to a number of factors, including, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to conduct the clinical study in accordance with regulatory requirements or clinical protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inspection of the clinical study operations or study sites by the FDA or other regulatory authorities that reveals deficiencies or violations that require undertaking corrective action, including in response to the imposition of a clinical hold; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unforeseen safety issues, including any that could be identified in ongoing studies, adverse side effects or lack of effectiveness; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in government regulations or administrative actions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">problems with clinical supply materials; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of adequate funding to continue clinical studies. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, our product candidates may cause side effects or adverse events that are presented in the product labeling approved by regulatory authorities. Some may result in label restrictions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, our current and any potential future product candidates may cause serious side effects which could cause us, our licensees, Tisento, or regulatory authorities to interrupt, delay or halt clinical studies and could result in restrictive label language or delay or denial of regulatory approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, changes in regulatory requirements, FDA guidance or unanticipated events during nonclinical studies and clinical studies of our product candidates, which may result in changes to nonclinical or clinical study protocols or additional nonclinical or clinical study requirements, which could result in increased costs and could delay development timelines. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, changes in regulatory requirements, FDA guidance or unanticipated events during nonclinical studies and clinical studies may force amendment to nonclinical studies and clinical study protocols or the FDA may impose additional nonclinical studies and clinical study requirements. Amendments or changes to clinical study protocols would require resubmission to the FDA and IRBs for review and approval, which may increase the cost or delay the&#160;timing or successful completion of clinical studies. Similarly, amendments to nonclinical studies may increase the cost or delay the timing or successful completion of those nonclinical studies. In the event of delays in completing, or the termination of, any of nonclinical or clinical studies, or if it is required that additional nonclinical or clinical studies be conducted, the commercial prospects for product candidates may be harmed and our ability to generate product revenue will be delayed for those product candidates we retain our <span style="white-space:nowrap">out-license</span> or to realize value in our equity position in Tisento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, obtaining and maintaining regulatory approval of product candidates in one jurisdiction does not mean that there will be success in obtaining regulatory approval of our product candidates in other jurisdictions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, compliance with the numerous and varying safety, efficacy and other regulatory requirements of other countries is required. If we continue to progress the development of our product candidates, obtaining and maintaining regulatory approval of product candidates in one jurisdiction does not guarantee that obtaining or maintaining regulatory approval in any other jurisdiction will be possible, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or other comparable foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical or clinical studies, as studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. The marketing approval processes in other countries may implicate all of the risks detailed above regarding FDA approval in the United States, as well as other risks. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price intended to be charged for a product candidate is also subject to approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs and could delay or prevent the introduction of product candidates in certain countries. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair the ability to market product candidates in such countries. Any such impairment would reduce the size of the potential market, which could have a material adverse impact on our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, data/market exclusivity may be more limited than we expect based upon the competitive landscape and other factors outside of our control that may occur during development or after approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, there are many types of data/market exclusivity mechanisms that we or our licensees may seek to secure for our product candidates. Many of these have risk of loss of exclusivity if the competitive landscape changes or regulations are revised. If we, our licensees or Tisento seek and are awarded orphan drug designation in the US and/or the EU based upon criteria in effect at the time, this designation may be rescinded if a similar drug or another therapy that confers a significant benefit over these product candidates is subsequently approved. If these product candidates were to fail to obtain orphan drug status, or lose such status after it is obtained, or the marketing exclusivity that such status provides, our business, prospects, financial condition and results of operations could be materially harmed. There are other types of data/market exclusivity rights granted after approval that may not confer exclusivity anticipated if the competitive landscape changes and our business, prospects, financial condition and results of operations could be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Reliance on Licensees, Tisento and Other Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, w</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">e may not succeed in our pursuit of capital, capabilities, and transactions </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">for</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> the development and commercialization of our future clinical stage assets, which would affect our financial condition.</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">&#160;</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, we will seek capital, capabilities, and transactions to advance the development of our product candidate for treatment resistant depression and other product candidates we may acquire rights to in the future. There can be no assurance that this process will result in any effective negotiations toward, reaching terms of, executing agreements relating to, or completing any transaction or that any such transaction will be successful. Failure to complete any of the&#160;foregoing efforts would materially adversely affect our business, prospects, financial condition and results of operations.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Akebia may not be successful in developing any therapies through the praliciguat <span style="white-space:nowrap">out-license</span> and we may not realize any future revenue from the <span style="white-space:nowrap">out-license.</span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;3, 2021, we entered into the Akebia License Agreement relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound praliciguat and other related products and forms thereof enumerated in such agreement. Under the agreement, Akebia is responsible for all research, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development, regulatory, and commercialization activities for certain products. On December&#160;13, 2024, we and Akebia entered into Amendment #1 to License Agreement (the &#8220;2024 Amendment&#8221;) to the original Akebia License Agreement. Under the terms of the 2024 Amendment, Akebia paid the Company (i) $1.25&#160;million in December 2024 and an additional $0.5&#160;million in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. Pursuant to the terms of the Akebia License Agreement, as amended, Akebia will pay Cyclerion tiered royalties ranging from <span style="white-space:nowrap">mid-single</span> digit to twenty percent of net sales. Cyclerion&#8217;s obligations to deliver certain drug products have also ceased. The agreement may be terminated by either party in the event of a material breach by the other party or by us in the event of certain patent disputes. There can be no assurances that the agreement will result in any therapies or that it will not be terminated prior to the realization by us of any remaining eligible revenues or that Akebia will be able to successfully bring any of the licensed product candidates to market due to financial limitations or other business factors in the future or if Akebia is unable to raise additional capital on favorable terms, if at all. Akebia may at any time terminate the Akebia License Agreement upon 180 days written notice, subject to Akebia&#8217;s obligation to grant Cyclerion a <span style="white-space:nowrap">non-exclusive,</span> royalty-free license, with the right to grant multiple tiers of sublicenses, to certain licensed compounds or products as defined in the Akebia License Agreement as well as certain rights to regulatory submissions, product trademarks, contracts with third party suppliers and certain other rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tisento may not be successful in developing any therapies and we may not realize any future value from the Tisento common stock we received under the Asset Purchase Agreement with Tisento.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investment in Tisento is subject to all of the risks associated with an earlier stage biotechnology company. The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that Tisento&#8217;s technology, development experience and scientific knowledge provide it with competitive advantages, it may face potential competition from many different sources, including large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and commercialization of similar products. Any investigational products that Tisento may successfully develop and commercialize will compete with new immunotherapies that may become available in the future. As a result, our investment in Tisento is risky and our equity interest in Tisento could be significantly diluted in the future if Tisento seeks to raise additional capital or is unable to raise additional capital on favorable terms, if at all. If Tisento suffers adverse effects, it may not be able to continue as a going business concern, and we may lose our entire investment. Tisento is a privately-held company and there is no public market for its securities. As a result, it may be difficult to sell any of our securities position in Tisento in the near term, if at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We lack operational control over Tisento. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investment in Tisento represents a minority or passive stake and we may have little to no participation, input or control over the management, policies, and operations of Tisento. Further, we may lack sufficient ownership of voting securities to impact, without the vote of additional equity holders, any matters submitted to stockholders or members of such business for a vote. There is inherent risk in making minority equity investments in companies over which we have little to no control. Without control of the management and decision-making of these businesses, we cannot control their direction, strategy, policies and business plans, and we may be powerless to improve any declines in their performance, operating results and financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, any collaboration or license arrangements that we enter into in the future may not be successful, which could impede our ability to develop and commercialize our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, we may seek additional collaboration or license arrangements for the commercialization, and/or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration or license arrangements. We face significant challenges in seeking appropriate partners. Moreover, collaboration and license arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement such arrangements. The terms of any collaborations, licenses or other arrangements that we may establish may not be favorable to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, any future collaboration or license arrangements that we enter into may not be successful. The success of such arrangements will depend heavily on the efforts and activities of our partners. Collaboration and license arrangements are subject to numerous risks, including that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partners have significant discretion in determining the efforts and resources that they will apply to collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a partner with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partners may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaboration and license arrangements may be terminated, and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or any potential future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partners may own or <span style="white-space:nowrap">co-own</span> intellectual property covering products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaboration or license arrangements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a partner&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, we expect in the future to rely on third parties to conduct any nonclinical or clinical studies for any existing or potential future product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, necessary regulatory approvals for or commercialization of any potential future product candidates may not be obtainable and our business could be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have the infrastructure or internal resources and capabilities to independently conduct nonclinical or clinical studies. If we continue to progress the development of our product candidates, we expect to rely on contract laboratories, medical institutions, clinical investigators, licensees and other third parties, such as CROs, to conduct nonclinical studies on any future discovery compounds and product candidates and clinical studies on product candidates. We expect to rely heavily on such parties for execution of nonclinical and clinical studies and as a result that we will only be able to control certain aspects of their activities. As a result, if we continue to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
progress the development of our product candidates, we expect we will have limited direct control over the conduct, timing and completion of our nonclinical and clinical studies and the management of data developed through these studies. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors may materially impede the willingness or ability of third parties to complete quality nonclinical and clinical studies and may subject us to unexpected cost increases that are beyond our control. Nevertheless, we may&#160;be responsible for ensuring that each of any future nonclinical and clinical studies is conducted in accordance with any applicable protocol, legal, regulatory and scientific requirements and standards, and our reliance on CROs and other third parties does not necessarily relieve us of our regulatory responsibilities. We, and any future CROs and other third parties are required to comply with regulations and guidelines, such as GLPs, good clinical practices ("GCPs"), and current Good Manufacturing Practices. These regulations are enforced by the FDA and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces compliance to regulations through periodic inspections of clinical study sponsors, principal investigators, and third parties. If the FDA determines there was a failure to comply with the regulations, the clinical data generated in any clinical studies may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require the performance of additional clinical studies before approving any marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any potential future nonclinical studies, clinical studies or product manufacturing will comply with these regulations. Our failure or the failure of our CROs or other third parties to comply with these regulations may require the repeat of those clinical studies, which would delay the regulatory approval process and could also result in enforcement action up to and including civil and criminal penalties. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we or our current licensee or any future licensees may design or approve the designs of our product candidate clinical studies, CROs and other third parties conduct those clinical studies. As a result, if we continue to progress the development of our product candidates many important aspects of the execution of the development programs for our product candidates may be outside of our direct control. In addition, the CROs, or other third parties, may not perform all of their obligations under arrangements with us or our licensees or in compliance with regulatory requirements, but we may remain responsible and are subject to enforcement action that may include civil penalties and criminal prosecution for any violations of FDA laws and regulations during the conduct of clinical studies. If we continue to progress the development of our product candidates and the CROs, or our licensees, do not perform clinical studies in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development and commercialization of our product candidates may be delayed, or our development program materially and irreversibly harmed. We may not be able to control the amount and timing of resources these CROs or our licensees devote to our clinical products.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any relationships with these third-party CROs terminate, arrangements with alternative CROs may not be achievable. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to required clinical protocols, regulatory requirements or for other reasons, any clinical studies such CROs are associated with may be extended, delayed or terminated, and required regulatory approval for or successful commercialization of our product candidates may not be obtainable. As a result, we believe that our financial results and the commercial prospects for our product candidates in the approved indication would be harmed, our costs could increase and our ability to generate revenue could be delayed or lost. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates then except as <span style="white-space:nowrap">out-licensed,</span> we must rely completely on third-party suppliers to manufacture any nonclinical and clinical drug supplies for our product candidates, and we intend to rely on third parties to produce commercial supplies of any product candidates that are approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have, nor do we plan to acquire, the infrastructure or capability to internally manufacture the drug supply of our current or any potential future product candidates, for use in the conduct of our nonclinical and clinical studies. We lack the internal resources and the capability to manufacture any product candidates on any scale. If we continue to progress the development of our product candidates, we expect to depend on third-party contract manufacturing organizations, or CMOs, for all our requirements of raw materials, drug substances and drug product for any future nonclinical studies and clinical trials. We do not have long-term supply agreements in place with any CMO and we expect that any potential future product candidates will be individually contracted under a services agreement on a purchase order basis. If we continue to progress the development of our product candidates, we expect to rely on CMOs for the supply of later-stage development and commercialization, as well as for the supply of any other discovery compounds or product candidates that we may identify, and we may not be able to enter into long-term supply agreements with such CMOs on favorable terms. As a further result, we are subject to price fluctuations for any clinical drug supplies. If the prices charged by these CMOs increase, our business, prospects, financial condition and results of operations could be materially harmed. We expect in the future to apply industry risk management practices to minimize the impact to nonclinical and clinical timelines associated with delays to our clinical supplies. However, these delays could still lead to clinical trials delays that could adversely impact our business.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any facilities which may be used by contract manufacturers to manufacture the active pharmaceutical ingredient and final drug product must complete a <span style="white-space:nowrap">pre-approval</span> inspection by the FDA and other comparable foreign regulatory agencies to assess compliance with applicable requirements, including current GMP, after we submit our new drug application, or NDA, or relevant foreign regulatory submission to the applicable regulatory agency. If the FDA or an applicable foreign regulatory agency determines now or in the future that these facilities are noncompliant, we may need to find alternative manufacturing facilities, which would impede our ability to develop, obtain regulatory approval for or market our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our anticipated reliance on third parties if we continue to progress the development of our product candidates requires us to share our confidential information, including trade secrets and <span style="white-space:nowrap">know-how,</span> which increases the possibility that our confidential information will be misappropriated or disclosed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we will seek to involve third party licensees and collaborators on potential future product candidates if we continue to progress the development of our product candidates, we expect we will rely on third parties to manufacture our product candidates, and because we expect to collaborate with various CROs and other third parties to conduct our nonclinical studies and clinical trials, we must, at times, share our trade secrets or <span style="white-space:nowrap">know-how</span> with them. We seek to protect our confidential information, including <span style="white-space:nowrap">know-how</span> and trade secrets, in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors and consultants prior to beginning our collaborations or disclosing confidential information to such parties. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets and <span style="white-space:nowrap">know-how.</span> Despite these contractual provisions, the need to share our confidential information with third parties increases the risk that confidential information such as trade secrets and <span style="white-space:nowrap">know-how</span> becomes known by our competitors, is inadvertently incorporated into the technology of others, or is disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our confidential information including know-how and trade secrets, a competitor&#8217;s discovery of our confidential information or other unauthorized use or disclosure could impair our competitive position and may have a material adverse effect on our business, prospects, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we or our licensors, licensees or Tisento are unable to adequately protect proprietary technologies, or obtain and maintain issued patents that are sufficient to protect their respective product candidates, others could compete against us, our licensees and Tisento more directly, which would have a material adverse impact on our business, prospects, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend in part on our licensors, licensees and Tisento&#8217;s ability to obtain and maintain patent and other proprietary protection in the United States and other countries for commercially important technology, inventions and <span style="white-space:nowrap">know-how</span> related to our business, defend and enforce patents, should they issue, preserve the confidentiality of trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our product candidates and compositions, their methods of use and any other inventions that are important to the development of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have 22 issued U.S. patents, 12 pending U.S. patents applications and numerous foreign patents and pending patent applications. Patent families are filed either as utility U.S. patents or under an international patent law treaty (PCT) that provides a unified procedure for filing a single initial patent application to seek patent protection for an invention simultaneously in each of the 158 contracting states, followed by the process of entering national phase, which requires a separate application in each of the member states in which national patent protection is sought. We also rely on patents issued to licensors providing patent licenses for our treatment resistant depression candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;<span style="font-style:italic">Cyclerion</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s </span><span style="font-style:italic">Business</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Intellectual Property</span>.&#8221; We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology and pharmaceutical companies, including ours, involve complex legal and factual questions, which in recent years have been the subject of much litigation, and, therefore, the issuance, scope, validity, enforceability and commercial value of any patent claims that we may obtain cannot be predicted with&#160;certainty. Patent applications may not be granted as issued patents in any particular jurisdiction and, even if they do, these patents may not include claims with a sufficient scope to protect our product candidates or otherwise provide any competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if patent applications are issued, competitors and other third parties may infringe, misappropriate or otherwise violate patents and other intellectual property rights. We may not be able to prevent infringement, misappropriation or other violations of intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. To counter infringement or unauthorized use, filing infringement claims may be required, which can be expensive and time-consuming and divert the attention of management and key personnel from business operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, patents, if issued, may be challenged, deemed unenforceable, invalidated or circumvented in the United States and abroad. U.S. patents and patent applications may also be subject to interference, derivation, <span style="white-space:nowrap">ex-parte</span> <span style="white-space:nowrap">re-examination,</span> post-grant review, or inter-partes review proceedings, supplemental examination and challenges in district or other courts. Interference proceedings provoked by third parties or brought by us or our licensees may be necessary to determine the priority of inventions with respect to patents or patent applications. An unfavorable outcome could require ceasing the use of the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer a license on commercially reasonable terms. Involvement in litigation or interference proceedings may fail and, even if successful, may result in substantial costs, and distract management and other employees. Furthermore, an adverse decision in an interference or derivation proceeding can result in a third party receiving the <span style="white-space:nowrap">sought-out</span> patent right, which in turn could affect the ability to develop, market or otherwise commercialize our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents may also be subjected to opposition, post-grant review or comparable proceedings lodged in various foreign, both national and regional, patent offices or courts. Such proceedings could result in revocation or amendment of patents in such a way that they no longer cover our product candidates or competitive products. In addition, such proceedings may be costly. Thus, any patents, should they issue, may not provide any protection against competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, though a patent, if it were to issue, is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide adequate protection to exclude competitors from making similar products. Even if a patent issues and is held to be valid and enforceable, competitors may be able to design around or circumvent our patents, such as by using <span style="white-space:nowrap">pre-existing</span> or newly developed technology or products in a <span style="white-space:nowrap">non-infringing</span> manner. If these developments were to occur, they could have a material adverse effect on our business, prospects, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any litigation to enforce or defend patent rights, even if successful, would be costly and time-consuming and would divert the attention of management and key personnel from business operations. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, proceedings to enforce or defend any patents, if and when issued, put those patents at risk of being invalidated, held unenforceable or not infringed, or interpreted narrowly. Such proceedings could also provoke third parties to assert counterclaims, including that some or all of the claims in one or more patents are invalid, not infringed or unenforceable. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or <span style="white-space:nowrap">non-enablement.</span> Grounds for unenforceability assertions of a patent include allegations that someone connected with prosecution of the patent application that matured into the patent withheld relevant information from the U.S. Patent and Trademark Office, or the USPTO, or made a misleading statement, during prosecution of the patent application. In an infringement proceeding, a court may disagree with allegations and refuse to stop the other party from using the technology at issue on the grounds that patents do not cover the technology in question or may decide that a patent is invalid or unenforceable. An adverse result in any litigation, defense or post-grant proceedings could result in one or more patents being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim&#160;proceedings or developments. If securities analysts or investors perceive these results to be negative, it would have a material adverse effect on the price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, there cannot be certainty that there is no invalidating prior art, of which we, our licensees and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, at least part, and perhaps all, of the patent protection on our product candidates could be lost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any patents, if and when issued, covering our product candidates are invalidated or found not infringed or unenforceable, our business, prospects, financial condition and results of operations could be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend in part on our ability to operate without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. Other parties may allege that our product candidates or the use of our technologies or technologies licensed by us infringe or otherwise violate patent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions, materials, formulations, methods of manufacture or methods for treatment related to our product candidates. Because patent applications can take many years to issue, third parties may have currently pending patent applications which may later result in issued patents that our product candidates may infringe, or which such third parties claim are infringed by our technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain and cannot be adequately quantified in advance. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either does not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our product candidates. In addition, if any such claim were successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing our product candidates. Any claim relating to intellectual property infringement that is successfully asserted against us may require us to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing another party&#8217;s patents, for past use of the asserted intellectual property and royalties and other consideration going forward if we are forced to take a license. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks coming to fruition could have a material adverse effect on our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property we own or license from third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our employee, consultants, <span style="white-space:nowrap">non-academic</span> outside scientific collaborators and other advisors enter into confidentiality and intellectual property assignment agreements with us or have entered into confidentiality and intellectual property assignment agreements with Ironwood or third parties licensing intellectual property to us. We seek to have inventions assigned to us by the parties rendering services whenever possible. Our <span style="white-space:nowrap">in-bound</span> licenses seek&#160;to insure that all of the intellectual property licensed to us is owned by the licensor. However, we may not be able to enter into these agreements with all parties (for example with academic collaborators) or these agreements may not be honored and may not effectively assign intellectual property rights to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, or we may have to <span style="white-space:nowrap">in-license</span> intellectual property owned by another party. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions over the lifetime of owned patents and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications For <span style="white-space:nowrap">in-bound</span> licensed intellectual property rights, failure to maintain compliance with such requirements would adversely impact our rights as regards those patents and applications. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors or other third parties might be able to enter the market earlier than would otherwise have been the case and this circumstance could have a material adverse effect on our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and our licensees and Tisento may not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications and we may not timely file foreign patent applications. Thus, for each of the patent families that are believed to provide coverage for our product candidates, we, and our licensees, will need to decide whether and where to pursue protection outside the United States. Filing and prosecuting patent applications and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and so it is unlikely to pursue and maintain patents in all countries worldwide. As such, competitors may use technologies in jurisdictions where patent protection is not pursued and obtained to develop their own products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some foreign countries may not protect intellectual property rights to the same extent as the laws of the United States. Consequently, it may not be possible to prevent third parties from practicing our inventions in all countries outside the United States even if there is a patent in that jurisdiction. Further, a competitor may export otherwise infringing products to territories where patent protection exists, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even pursuing and obtaining issued patents in particular jurisdictions, patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology or pharmaceuticals. This could make it difficult to stop the infringement of patents, if obtained, or the misappropriation of or marketing of competing products in violation of other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis, which is an expensive and time-consuming process with uncertain outcomes.&#160;Accordingly, patent protection might not be sought in certain countries, and there will not be a benefit of patent protection in such countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce patent rights in foreign jurisdictions could result in substantial costs and divert efforts and attention from other aspects of our business, could put patents at risk of being invalidated or interpreted narrowly, could put patent applications at risk of not issuing, and could provoke third parties to assert claims. We, or our licensees, may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that developed or licensed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we, or our licensees, do not obtain additional protection under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidates, our business, prospects, financial condition and results of operations may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of the U.S. patents owned may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent term extension as compensation for patent term lost during the FDA regulatory review process. A maximum of five years can be restored to the eligible patent. In all cases, the total patent life for the product with the patent extension cannot exceed 14 years from the product&#8217;s approval date, or in other words, 14 years of potential marketing time. However, an extension might not be granted because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If unable to obtain a patent term extension or the term of any such extension is less than we request, the duration of patent protection obtained for our product candidates may not provide any meaningful commercial or competitive advantage, competitors may obtain approval of competing products earlier than they would otherwise be able to do so, and our ability to generate revenues could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, if we continue to progress the development of our product candidates, our success will be heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has enacted and implemented wide-ranging patent reform legislation: the Leahy-Smith America Invents Act, or the America Invents Act. The America Invents Act includes a number of significant changes to U.S. patent law. These provisions affect the way patent applications will be prosecuted and may also affect patent litigation. It is not yet clear what, if any, impact the America Invents Act will have on the operation of certain elements of our product candidates. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents that may issue from our patent applications, all of which could have a material adverse effect on our business, prospects, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on these and other decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce any patents that may issue in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to damages resulting from claims that we or our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current employee and any employees we may hire in the future may have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We also engage and, in the future, intend to engage advisors and consultants who are concurrently employed at universities or who perform services for other entities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that we or our employees, advisors or consultants or third parties from whom we license certain technologies have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third party. We may be subject to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims that an employee, advisor or consultant performed work for us that conflicts with that person&#8217;s obligations to a third party, such as an employer, and thus, that the third party has an ownership interest in the intellectual property arising out of work performed for us. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which would materially harm our commercial development efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Future Commercialization of Our Current or Potential Future Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The incidence and prevalence for target patient populations of our current and any potential future product candidates we may acquire have not been established with precision. If we continue to progress the development of our product candidates and the market opportunities for our current and potential future product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incidence and prevalence for all the conditions we aim to address with our current and any potential future programs vary considerably. Projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. If we continue to progress the development of our product candidates, the total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates, if approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would harm our results of operations and our business. Further, even if significant market share for our product candidates is obtained, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates and are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates, if approved, we may not be successful in commercializing those product candidates if and when they are approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have an infrastructure for the sale, marketing, market access, patient service and distribution of pharmaceutical products. In order to market our product candidates, if approved by the FDA or any other regulatory authority outside the United States, we must build our sales, marketing, managerial and other <span style="white-space:nowrap">non-technical</span> capabilities, or arrange with third parties to perform these services. There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product candidate launch. If we continue to progress the development of our product candidates and commercialization is delayed or does not occur, we would have prematurely or unnecessarily incurred such expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, any product candidate revenue or the profitability of that revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may fail to enter into </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, or if we are unable to do so on commercially reasonable terms, we will not be successful in commercializing our product candidates if approved and our business, prospects, financial condition and results of operations will be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we continue to progress the development of our product candidates and ultimately obtain regulatory approval for our product candidates, our product candidates may not achieve broad market acceptance by patients, physicians, healthcare payors or others in the medical community, which would limit the revenue that we generate from their sales. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, the future commercial success of our product candidates, if approved by the FDA or other applicable regulatory authorities outside the United States, will depend upon the awareness and acceptance of our product candidates among the medical community, including patients, physicians and healthcare payors. If we continue to progress the development of our product candidates and any of our product candidates are approved but do not achieve an adequate level of acceptance by patients, physicians, healthcare payors and others in the medical community, we may not generate sufficient revenue to become, or remain, profitable. Market acceptance of our product candidates, if approved, will depend on a number of factors, including, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the efficacy and safety of our approved product candidates as demonstrated in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical indications and labeling claims for our product candidates that are approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations or warnings contained in the labeling approved for our product candidates by the FDA or other applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any restrictions on the use of our product candidates together with other medications or restrictions on the use of our products in certain types of patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any adverse effects associated with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size of the target patient population, and the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety, efficacy, cost and other potential advantages of our approved product candidates compared to other available therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to generate cost effectiveness data that supports a profitable price; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain sufficient reimbursement and pricing by third-party payors and government authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of patients to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> in the absence of sufficient payor coverage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our sales and marketing strategies; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publicity concerning our product candidates or competing products and treatments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates and our product candidates are ultimately approved but do not achieve an adequate level of acceptance by patients, physicians and payors, we may not generate sufficient revenue from our product candidates to become or remain profitable. Before granting reimbursement approval, healthcare payors may require us to demonstrate that our product candidates, in addition to treating these target indications, also provide incremental health benefits to patients. Efforts to educate the medical community and third-party payors about the benefits of our product candidates may require significant resources and may never be successful. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably, if we continue to progress the development of our product candidates. Price controls may be imposed in certain markets, which may harm our future profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, market acceptance and sales of any approved product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors and government authorities and may be affected by existing and future health care reform measures and cost-cutting measures at the federal and state level currently proposed for Medicaid and other programs. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require the provision of supporting scientific, clinical and cost-effectiveness data for the use of our product candidates to the payor. We or our partners may not be able to provide&#160;data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of our product candidates. In addition, in the United States, third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. As a result, if we continue to progress the development of our product candidates significant uncertainty exists as to whether and how much third-party payors will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between <span style="white-space:nowrap">low-priced</span> and high-priced member states, can further reduce prices. In some countries, we or our partners may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with healthcare and other regulations, we could face substantial penalties and our business, prospects, financial condition and results of operations could be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidates that we may evaluate in clinical studies are subject to certain federal and state healthcare laws and regulations that may affect our business. These laws and regulations include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal healthcare program anti-kickback laws, which prohibit, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, as an inducement or reward for their past, current or potential future prescribing, purchase, use, recommending for use, referral, formulary placement, or dispensing of our product candidates; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product and medical device research, development, and marketing, prohibits manufacturers from marketing or promoting such products prior to approval; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">state law equivalents of the above federal laws, such as anti-kickback laws, state transparency laws, state laws limiting interactions between pharmaceutical manufacturers and members of the healthcare industry and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. For example, if we conduct clinical studies in any of the member states of the European Union, the processing of personal data in the European Economic Area, or the EEA, is subject to the 1995 Data Protection Directive, imposing strict obligations and restrictions on the ability to collect, analyze and transfer personal data. In May 2018, the General Data Protection Regulation, or the GDPR, took effect, increasing our obligations with respect to clinical studies conducted in the EEA and increasing the scrutiny applied by clinical study sites located in the EEA to transfers of personal data from such sites to countries that are considered by the European Commission to lack an adequate level of data protection, such as the United States. The compliance obligations&#160;imposed by the GDPR may increase our cost of doing business. In addition, the GDPR imposes substantial fines for breaches of data protection requirements, and it confers a private right of action on data subjects for breaches of data protection requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other laws, rules or regulations that apply to us, we will be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could impede our ability to operate our business and our financial results. We cannot be certain that compliance programs will address all areas of potential exposure and the risks in this area cannot be entirely eliminated, particularly because the requirements and government interpretations of the requirements in this space are constantly evolving. Any action against us for violation of these laws, rules or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business, as well as damage our business or reputation. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, fraud and reporting laws may prove costly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face significant competition in an environment of rapid technological and scientific change, and our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may harm our ability, or a licensee&#8217;s ability, to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success depends on our ability, or a licensee&#8217;s ability, to demonstrate and maintain a competitive advantage with respect to the design, development and commercialization of our product candidates. In many cases, our product candidates that may be commercialized will compete with existing, market-leading products. The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that are developed or commercialized in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing, and commercialization. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates do not obtain regulatory approvals in target indications prior to these or any other competing product candidates, or if our product candidates do not demonstrate superior efficacy, safety or tolerability compared to these and any other approved therapeutics for our target indications, then those product candidates may not be able to compete effectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical studies, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we or our licensees could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our product candidates infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price that could be charged, for any of our product candidates that may be developed and commercialized. See &#8220;<span style="font-style:italic">-Risks Related to Our Intellectual Property Rights</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The impact of healthcare reform and other governmental and private payor initiatives, as well as the Inflation Reduction Act of 2022, may harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, the method of delivery or payment for health care products and services could harm our business, operations and financial condition. There is significant interest in promoting health care reform, as evidenced by the enactment in the United States of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act in 2010 and in reducing the costs of certain prescription drugs as evidenced by the Inflation Reduction Act of 2022. It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect: the demand for any drug products for which we may obtain regulatory approval; our ability to set a price that we believe is fair for our product candidates; our ability to obtain coverage and reimbursement approval for a product; our ability to generate revenues and achieve or maintain profitability; and the level of taxes that we are required to pay. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates, our future growth may depend, in part, on our, or a licensee&#8217;s, ability to commercialize any current and potential future product candidates outside the United States, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, our future profitability may depend, in part, on our or a licensee&#8217;s ability to commercialize our current and any potential future product candidates outside the United States for which we may rely on partnerships with third parties. If we commercialize our product candidates outside the United States, we would be subject to additional risks and uncertainties, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the customers&#8217; ability to obtain reimbursement for our product candidates outside the United States; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to gain reimbursement in foreign markets at a price that is profitable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to directly control commercial activities because we are relying on third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">import or export licensing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">longer accounts receivable collection times; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">longer lead times for shipping; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">language barriers for technical training; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced protection of intellectual property rights in some foreign countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the existence of additional potentially relevant third-party intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency exchange rate fluctuations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign sales of our product candidates could also be harmed by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to generate meaningful revenues in jurisdictions outside of the United States may be limited due to the strict price controls and reimbursement limitations imposed by governments outside of the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some countries, we or our licensees may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies, or to meet other criteria for pricing approval. If reimbursement of a product candidate, if approved, is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, prospects, financial condition and results of operations could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we continue to progress the development of our product candidates and any of our product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or (an &#8220;ANDA&#8221;), seeking approval of a generic copy of an approved, small-molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a new drug application (&#8220;NDA&#8221;) that references the FDA&#8217;s prior approval of the small-molecule innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity. These include, subject to certain exceptions, the period during which an <span style="white-space:nowrap">FDA-approved</span> drug is subject to orphan drug exclusivity. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic or NDA applicant that seeks to market its product before expiration of the patents must include in the ANDA a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming <span style="white-space:nowrap">non-infringement</span> of, the listed patent or patents. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, if we continue to progress the development of our product candidates and any of our product candidates are approved, competitors could file ANDAs for generic versions of our small-molecule drug products or NDAs that reference our small-molecule drug products, respectively. If there are patents listed for our small-molecule drug products in the Orange Book, those ANDAs and NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we or our licensees may develop or license. Moreover, if any of our patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Business Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Our prospects </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">for</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> success depend on our ability to retain Regina Graul, our President and Chief Executive Officer and in the future to attract, retain and motivate qualified personnel.</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on Regina Graul, Ph.D. who is currently our sole employee. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our success also depends on our ability in the future to attract, retain and motivate highly skilled junior, <span style="white-space:nowrap">mid-level</span> and senior managers as well as junior, <span style="white-space:nowrap">mid-level</span> and senior scientific and medical personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to attract or retain qualified management and scientific personnel in the future due to the competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than what we may be able to offer. The failure to succeed in nonclinical&#160;or clinical studies may make it more challenging to recruit and retain qualified personnel. In addition, in order to induce employees to continue their employment with us, we have provided equity awards that vest over time and the value to our employees of such equity awards may be significantly affected by movements in our stock price that are beyond our control and may be at any time insufficient to counteract more lucrative offers from other companies. If we are unable to attract and retain high quality personnel, the rate and success at which we can develop and commercialize product candidates will be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of our current and any potential future product candidates in clinical studies and any sale thereof, if approved, exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with our product candidates. For example, we may be sued if any such product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we become subject to product liability claims and cannot successfully defend ourselves against them, we could incur substantial </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things: withdrawal of subjects from our clinical studies; substantial monetary awards to patients or other claimants; decreased demand for our product candidates or any future product candidates following marketing approval, if obtained; damage to our reputation and exposure to adverse publicity; increased FDA warnings on product labels; litigation costs; distraction of management&#8217;s attention from our primary business; loss of potential revenue; and the inability to successfully commercialize our product candidates or any potential future product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain product liability insurance coverage for our clinical studies through both domestic and international insurance policies, subject to an annual coverage limit. Nevertheless, our insurance coverage may be insufficient to reimburse us for any expenses or losses we may suffer if a judgment or settlement exceeds available insurance proceeds. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including if insurance coverage becomes increasingly expensive. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may not be able to obtain this product liability insurance on commercially reasonable terms. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or series of claims brought against us could cause our stock price to decline and, if we are unsuccessful in defending such a claim or claims and the resulting judgments exceed our insurance coverage, our business, prospects, financial condition and results of operations could be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our product candidates, if approved, or require us to suspend or abandon our commercialization efforts of any approved product candidates. Even in a circumstance in which we do not believe that an adverse event is related to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Securities Exchange Act of 1934, or The Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the Nasdaq Capital&#160;Market. We are a &#8220;smaller reporting company.&#8221; For so long as we remain a smaller reporting company, we will be exempt from Section&#160;404(b) of the Sarbanes-Oxley Act, which requires auditor attestation to the effectiveness of internal control over financial reporting. As a smaller reporting company, we are exempt from compliance with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on the exemptions available to us as a smaller reporting company. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are, however, subject to Section&#160;404(a) of the Sarbanes-Oxley Act. Beginning with our annual report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2024, we must include a management assessment of the effectiveness of our internal control over financial reporting. As of the expiration of our smaller reporting </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company status, we will be broadly subject to enhanced reporting and other requirements under the Exchange Act and Sarbanes-Oxley Act. We have engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There can be no assurances that in future periods we will be able to timely conclude that our internal control over financial reporting is effective as required by Section&#160;404(a). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our business, prospects, financial condition and results of operations could be harmed, our investors could lose confidence in our reported financial information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unfavorable global economic and political conditions could harm our business, prospects, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations could be harmed by general conditions in the global economy and in the global financial markets as well as adverse economic conditions caused by political unrest or loss of government funding for product candidates. A severe or prolonged economic downturn and severe political disruption could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our information technology systems or data, or those of CRO and other third parties upon which we rely, are or were compromised, we could experience adverse impacts resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; interruptions to our commercial operations, clinical trials or other operations; harm to our reputation; loss of revenue or profits; loss of sales and other adverse consequences. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and our third-party service providers may process proprietary, confidential, and sensitive data, including personal data (such as health-related data and data related to our clinical trials), intellectual property, and trade secrets (collectively, sensitive information). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase. These threats are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), &#8220;hacktivists&#8221;, organized criminal threat actors, sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyberattacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products. We and the third parties upon which we rely may be subject to a variety of other evolving threats, including, but not limited to, social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), <span style="white-space:nowrap"><span style="white-space:nowrap">denial-of-service</span></span> attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, attacks enhanced or facilitated by artificial intelligence, and other similar threats. In particular, ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, ability to provide our products, disruption of clinical trials, loss of data (including data related to clinical trials), loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws prohibit such payments). Additionally, hybrid and remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit, and in public locations. Future or past business transactions (such as acquisitions or integrations) could also expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon third parties and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email, and other functions. We also rely on third parties to provide certain products, including active pharmaceutical ingredients, to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. While we may be entitled to damages if the third parties upon which we rely fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. We may share or receive sensitive information with or from third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information security systems (such as our hardware and/or software, including that of third parties upon which we rely), but we may not be able to detect, mitigate, and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security&#160;obligations require us to implement and maintain specific security measures, industry-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standard or reasonable security measures to protect our information technology systems and sensitive information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable data security and public company disclosure obligations may require us to notify relevant stakeholders of certain security incidents, including affected individuals, customers, regulators and investors. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss and other similar harms. For example, the loss of clinical trial data from completed or ongoing clinical trials for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether a cybersecurity incident is reportable to our investors may not be straightforward, may take considerable time to determine, and may be subject to change as the investigation of the incident progresses, including changes that may significantly alter any initial disclosure that we provide. Moreover, experiencing a material cybersecurity incident and any mandatory disclosures could lead to negative publicity, loss of customer, investor or partner confidence in the effectiveness of our cybersecurity measures, diversion of management&#8217;s attention, governmental investigations, lawsuits, and the expenditure of significant capital and other resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. In addition, our insurance coverage may not be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices or that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Sensitive information of us or our customers could also be leaked, disclosed, or revealed as a result of or in connection with our employee&#8217;s, personnel&#8217;s, or vendor&#8217;s use of generative AI technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employee or future employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and applicable foreign regulators, provide accurate information to the FDA and applicable foreign regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately and/or disclose unauthorized activities to us. In particular, research and development, commercialization and business arrangements in the healthcare industry are subject to considerable laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict, regulate or prohibit a wide range of activities pertaining to clinical trials including the informed consent process, data integrity and conducting the study in accordance with the investigational plan, and for approved products, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have&#160;a significant impact on our business, including the imposition of significant fines or other sanctions, possible exclusions from participation in Medicare, Medicaid and other U.S. federal healthcare programs, contractual damages and reputational harm. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and any contract manufacturers and suppliers we engage, are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act, or the FCPA, and other worldwide anti-bribery laws. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the FCPA, which prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations. In some countries in which we operate, the pharmaceutical and life sciences industries are exposed to a high risk of corruption associated with the conduct of clinical trials and other interactions with healthcare professionals and institutions. Any such activities could expose us to potential liability under the FCPA, which may result in us incurring significant criminal and civil penalties and to potential liability under the anti-corruption laws and regulations of other jurisdictions in which we operate. In addition, the costs we may incur in defending against an FCPA investigation could be significant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Ownership of Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We could be delisted from Nasdaq, which would seriously harm the liquidity of our stock and ability to raise capital. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;1, 2022, the Company received a notice from the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) notifying the Company that the closing bid price for the Company&#8217;s common stock listed on Nasdaq has been below the minimum $1.00 per share required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Requirement&#8221;).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a period of 180 calendar days, or until November&#160;28, 2022, to regain compliance with the Bid Price Requirement. The Company did not regain compliance with the Bid Price Requirement by the initial compliance date. On November&#160;29, 2022, however, Nasdaq notified the Company of its eligibility for an additional 180 calendar day period, or until May&#160;29, 2023 (the &#8220;Extended Compliance Date&#8221;), to regain compliance with the Bid Price Requirement. Nasdaq&#8217;s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the exception of the Bid Price Requirement, and the Company&#8217;s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. Effective November&#160;25, 2022, the Company transferred its listing of the Company&#8217;s common stock from the Nasdaq Global Market to the Nasdaq Capital Market, a continuous trading market that operates in substantially the same manner as the Nasdaq Global Market. The Company&#8217;s common stock continues to trade under the symbol &#8220;CYCN&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We effected a 20:1 reverse stock split in May 2023. As a result, we have regained compliance with the Bid Price Requirement. If the Company does not regain compliance with the Bid Price Requirement in the future, the Company&#8217;s stock will again be subject to delisting. As a result of amendments in October 2024 to the Nasdaq delisting procedures, NASDAQ now may automatically delist companies which conduct multiple reverse stock splits in any <span style="white-space:nowrap">12-month</span> period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement, including initiating a reverse stock split. However, there can be no assurance that the Company will be able to maintain compliance with the Bid Price Requirement, would receive sufficient shareholder support for a reverse stock split, or will otherwise be in compliance with other Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2026, Nasdaq refiled with the SEC an application to allow Nasdaq to delist certain companies from the Nasdaq Capital Market and Nasdaq Global Market where companies with a market value of listed securities below $5&#160;million for 30 consecutive business days face immediate suspension and delisting, without the usual compliance period or automatic stay (the &#8220;Proposed Market Value Rule&#8221;). The SEC has requested comments on the proposed application. The comment period for public comments ended on February&#160;19, 2026, after which time the SEC may elect to accept the Nasdaq proposal. If approved by the SEC, the rule will become effective within 45 days of publication in the Federal Register, or within up to 90 days if extended by the SEC pursuant to Section&#160;19(b)(2) of the Exchange Act. Currently, the Company would not meet the requirements of the Proposed Market Value Rule and if the Proposed Market Value Rule is approved, the Company may not meet the requirements under the Proposed Market Value Rule to maintain its current listing on the Nasdaq Capital Market. The loss of the Company&#8217;s listing on the Nasdaq Capital Market would result in the Company&#8217;s common stock trading on the OTC Market, which could adversely affect the market price of the Company&#8217;s common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our common stock may fluctuate widely and you could lose all or part of your investment in our common stock as a result. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price for our common stock has fluctuated widely, and may in the future fluctuate widely, depending upon many factors, some of which are beyond our control, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to raise additional capital on a timely basis and the terms on which we raise any capital; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a relatively low public float for our shares of common stock, which could cause trades of small blocks of shares to have a significant impact on the price of our shares of common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results and timing of nonclinical studies and clinical studies of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the commercial performance of our product candidates, those <span style="white-space:nowrap">out-licensed</span> to third parties and the Transferred Assets sold to Tisento, if approved, as well as the costs associated with such activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of clinical studies of our competitors&#8217; products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to adequately protect our trade secrets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commencement or termination of any strategic partnership or licensing arrangement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments with respect to our product candidates or our competitors&#8217; products, including any developments, litigation or public concern about the safety of such products; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements concerning product development results, including clinical trial results, the introduction of new products or intellectual property rights of us or others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated fluctuations in our financial condition and our quarterly and annual operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">deviations in our operating results from any guidance we may provide or the estimates of securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sufficiency, additions and departures of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the passage of legislation or other regulatory developments affecting us or our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuations in the valuation of companies perceived by investors to be comparable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our common stock by us, our insiders or our other shareholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcement or expectation of additional financing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publication of research reports by securities analysts about us or our competitors or our industry and speculation regarding our company or our stock price in the financial or scientific press or in online investor communities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in market conditions in the pharmaceutical and biotechnology sector; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Nasdaq&#8217;s rules, which impose certain continued listing requirements, including a minimum $1 bid price, and the Proposed Market Value Rule, such that a failure to meet these requirements would lead Nasdaq to take further steps to delist our common stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in general market and economic conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, results of operations, financial condition and prospects. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price for our common stock is particularly volatile. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our common stock is characterized by significant price volatility when compared to seasoned issuers, and we expect that our stock price will continue to be more volatile than those of a seasoned issuer. Several factors cause the volatility in our share price. We are a speculative or &#8220;risky&#8221; investment due to our short operating history, lack of revenues and the uncertain success (including of regulatory approval) of any of our product candidates. As a consequence of this risk, more risk-averse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares of our common stock more quickly and at greater discounts than would be the case with the stock of a seasoned issuer. Plaintiffs have, in the past, initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may in the future be the target of such litigation. Securities litigation could result in substantial costs and liabilities and could divert management&#8217;s attention and resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We run the risk of inadvertently being deemed an investment company required to register under the Investment Company Act of 1940.</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We run the risk of inadvertently being deemed an investment company required to register under the Investment Company Act of 1940 (the &#8220;Investment Company Act&#8221;) because a significant portion of our assets </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consists of investments in companies in which we own less than a majority interest. The risk varies depending on events beyond our control, such as significant appreciation or depreciation in the market value of certain of our publicly traded holdings, adverse developments with respect to our ownership of certain of our subsidiaries, transactions involving the sale of certain assets and our participation in any partnership or other fund established to finance future broadband and real estate projects in which we may engage. If we are deemed to be an inadvertent investment company, we may seek to rely on a safe harbor under the Investment Company Act that would provide us a <span style="white-space:nowrap">one-year</span> grace period to take steps to avoid being deemed to be an investment company. In order to ensure we avoid being deemed an investment company, we have taken, and may need to continue to take, steps to reduce the percentage of our assets that constitute investment assets under the Investment Company Act. These steps have included, among others, selling marketable securities that we might otherwise hold for the long term and deploying our cash in <span style="white-space:nowrap">non-investment</span> assets. We may be forced to sell our investment assets at unattractive prices or to sell assets that we otherwise believe benefit our business in the future to remain below the requisite threshold. We may also seek to acquire additional <span style="white-space:nowrap">non-investment</span> assets to maintain compliance with the Investment Company Act, and we may need to incur debt, issue additional equity or enter into other financing arrangements that are not otherwise attractive to our business. Any of these actions could have a material adverse effect on our results of operations and financial condition.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we can make no assurance that we would successfully be able to take the necessary steps to avoid being deemed to be an investment company in accordance with the safe harbor. If we were unsuccessful, then we would have to register as an investment company, and we would be unable to operate our business in its current form. We would be subject to extensive, restrictive, and potentially adverse statutory provisions and regulations relating to, among other things, operating methods, management, capital structure, indebtedness, dividends, and transactions with affiliates. If we were deemed to be an investment company and did not register as an investment company when required to do so, there would be a risk, among other material adverse consequences, that we could become subject to monetary penalties or injunctive relief, or both, that we would be unable to enforce contracts with third parties, and/or that third parties could seek to obtain rescission of transactions with us undertaken during the period in which we were an unregistered investment company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. The issuance of additional guidance related to existing or future tax laws, or changes to tax laws or regulations proposed or implemented by the current or a future U.S. presidential administration, Congress, or taxing authorities in other jurisdictions, including jurisdictions outside of the United States, could materially affect our tax obligations and effective tax rate. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes may adversely impact our business, financial condition, results of operations, and cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of taxes we pay in different jurisdictions depends on the application of the tax laws of various jurisdictions, including the United States, to our international business activities, tax rates, new or revised tax laws, or interpretations of tax laws and policies, and our ability to operate our business in a manner consistent with our corporate structure and intercompany arrangements. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for pricing intercompany transactions pursuant to our intercompany arrangements or disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a challenge or disagreement were to occur, and our position was not sustained, we could be required to pay additional taxes, interest, and penalties, which could result in <span style="white-space:nowrap">one-time</span> tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. Our financial statements could fail to reflect adequate reserves to cover such a contingency. Similarly, a taxing authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years of research activities conducted outside the United States. Unless the United States Department of the Treasury issues regulations that narrow the application of this provision to a smaller subset of our research and development expenses or the provision is deferred, modified, or repealed by Congress, in future years we may experience a material decrease in our cash flows from operations and an offsetting similarly sized increase in our net deferred tax assets over these amortization periods. The actual impact of this provision will depend on multiple factors, including the amount of research and development expenses we will incur and whether we conduct our research and development activities inside or outside the United States and our overall net operating loss position. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be subject to limitations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current law, our federal net operating losses (&#8220;NOLs&#8221;) generated in tax years beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. As of December&#160;31, 2025, we had federal NOLs of $211&#160;million. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the&#160;corporation&#8217;s ability to use its <span style="white-space:nowrap">pre-change</span> NOL carryforwards and other <span style="white-space:nowrap">pre-change</span> U.S. tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. It is possible that we have experienced an ownership change in the past. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control, as well as the issuance of additional securities if we are successful in raising equity capital. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, our federal NOL carryforwards may be subject to a percentage limitation if used to offset income in tax years following an ownership change. In addition, it is possible that we have in the past undergone, and in the future may undergo, additional ownership changes that could limit our ability to use all of our <span style="white-space:nowrap">pre-change</span> NOL carryforwards and other <span style="white-space:nowrap">pre-change</span> tax attributes (such as research tax credits) to offset our post-change income or taxes. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOL carryforwards and other tax attributes, which would harm our future operating results by effectively increasing our future tax obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We maintain our cash at financial institutions, often in balances that exceed federally insured limits. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain the majority of our cash and cash equivalents in accounts at banking institutions in the United States that we believe are of high quality. Cash held in these accounts often exceeds the FDIC insurance limits. If such banking institutions were to fail, we could lose all or a portion of amounts held in excess of such insurance limitations. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts fail to initiate or maintain coverage of our stock, publish a negative report or change their recommendations regarding our stock adversely, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us, our business, our market or our competitors. Currently, no industry analysts cover our stock. If securities or industry analysts fail to initiate coverage of our stock, the lack of exposure to the market could cause our stock price or trading volume to decline. If any of the analysts who cover us or may cover us in the future publish a negative report or change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any analyst who covers us or may cover us in the future were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not expect to pay any cash dividends for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid cash dividends and we do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our operations. In addition, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have anti-takeover provisions in our articles of organization and bylaws and are subject to provisions of Massachusetts law that may frustrate any attempt to remove or replace our current board of directors or to effect a change of control or other business combination involving our company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated articles of organization and bylaws and certain provisions of Massachusetts law may discourage certain types of transactions involving an actual or potential change of control of our company that might be beneficial to us or our security holders. For example, our bylaws grant our directors the right to adjourn any meetings of shareholders. Our board of directors also may issue shares of any class or series of preferred stock in the future without shareholder approval and upon such terms as our board of directors may determine. The rights of the holders of our&#160;common stock will be subject to, and may be harmed by, the rights of the holders of any class or series of preferred stock that may be issued in the future. Massachusetts state law also prohibits us from engaging in specified business combinations unless the combination is approved or consummated in a prescribed manner. These provisions, alone or together, could delay hostile takeovers and changes in control of our company or changes in our management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our articles of organization designate the state and federal courts located within the Commonwealth of Massachusetts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders, which could discourage lawsuits against us and our directors and officers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated articles of organization designate the state and federal courts located within the Commonwealth of Massachusetts as the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our shareholders, creditors or other constituents, any action asserting a claim arising pursuant to any provision of the Massachusetts Business Corporation Act, or the MBCA, or any action asserting a claim governed by the internal affairs doctrine, in all cases subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. In addition, our articles of organization provide that unless our board of directors consents in writing to the selection of an alternative forum, the U.S. federal district courts shall be the exclusive forum for the resolutions of any complaint asserting a cause of action arising under the U.S. federal securities laws. This exclusive forum provision may limit the ability of our shareholders to bring a claim in a judicial forum that such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders find favorable for disputes with us or our directors or officers, which may discourage such lawsuits against the company and our directors and officers. Alternatively, if a court outside of Massachusetts were to find this exclusive forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings described above, we may incur additional costs associated with resolving such matters in other jurisdictions, which could harm our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Korsana </p> <div> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Korsana&#8217;s Limited Operating History, Financial Position and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana is a preclinical stage biotechnology company with a limited operating history on which to assess its business; Korsana has not completed any clinical trials, and it has no products approved for commercial sale, which may make it difficult to evaluate its current business and likelihood of success and viability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is a preclinical stage biotechnology company with a limited operating history. Since its inception, Korsana has incurred operating losses with no corresponding revenue and has utilized substantially all of its resources to identify and develop its product candidates, organize and staff its company, and provide other general and administrative support for its operations. Korsana has no significant experience as a company in initiating, conducting, or completing preclinical studies or clinical trials. In part because of this lack of experience, Korsana cannot be certain that its preclinical studies or clinical trials will begin or be completed on time, if at all. In addition, Korsana has not yet demonstrated an ability to obtain regulatory approvals, manufacture a commercial-scale product, or arrange for a third party to do so on its behalf, or conduct sales, marketing, and distribution activities necessary for successful product commercialization. Consequently, any predictions about Korsana&#8217;s future success or viability may not be as accurate as they could be if Korsana had a longer operating history. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as Korsana&#8217;s business grows, Korsana may encounter unforeseen expenses, restrictions, difficulties, complications, delays, and other known and unknown factors. Korsana will need to transition at some point from a company with an early research and development focus to a company capable of supporting larger scale clinical trials and eventually commercial activities. Korsana may not be successful in such a transition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing are successful, Korsana will require substantial additional capital to finance its operations in the future. If Korsana is unable to raise such capital when needed, or on acceptable terms, Korsana may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing biotechnology products is a long, time-consuming, expensive, and uncertain process that takes years to complete. Korsana expects its expenses to increase in connection with its ongoing activities, particularly as Korsana conducts preclinical studies and clinical trials of, and seeks regulatory approval for, its product candidates, and advances discovery efforts with respect to its research and development programs, and advances any future programs and product candidates that Korsana may license. Even if one or more of the programs that Korsana develops is approved for commercial sale, Korsana anticipates incurring significant costs associated with sales, marketing, manufacturing, and distribution activities to launch any such product. Korsana&#8217;s expenses could increase beyond expectations if Korsana is required by the FDA or other regulatory agencies to perform preclinical studies or clinical trials in addition to or more expansive than those that Korsana currently anticipates. Because the design and outcome of Korsana&#8217;s planned and anticipated clinical trials are highly uncertain, Korsana cannot reasonably estimate the actual amount of funding that will be necessary to successfully complete the development and commercialization of any program Korsana develops. Korsana&#8217;s future capital requirements depend on many factors, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, design, progress, results, and costs of discovery and preclinical and clinical development for Korsana&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of completing clinical and commercial-scale manufacturing activities; </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining, defending, and enforcing Korsana&#8217;s intellectual property and proprietary rights, and defending intellectual property-related claims, including claims of infringement, misappropriation, or other violations of third-party intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs, timing, and outcome of the regulatory review of Korsana&#8217;s product candidates and obtaining the requisite regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of Korsana&#8217;s future commercialization activities, either on its own or in collaboration with others, including product sales, marketing, manufacturing, and distribution for any product candidate for which Korsana receives regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue, if any, received from commercial sales of product candidates for which Korsana receives regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of Korsana&#8217;s current or future collaborations, including its collaboration with Paragon and Paragon Laboratories pursuant to the Paragon ADOA and Paragon Research Letter Agreement, respectively, and the success of the Paragon License Agreement and any future license agreements Korsana enters into with Paragon; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s ability to establish and maintain additional collaborations on favorable terms, if at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which Korsana acquires or <span style="white-space:nowrap">in-licenses</span> products, intellectual property, and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of operational, financial and management information systems and associated personnel; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of operating as a public company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, Korsana will require substantial additional funding to continue its operations. As of December&#160;31, 2025, Korsana had $154.1&#160;million in cash and cash equivalents. Korsana expects that its existing cash and cash equivalents, and investments, combined with the gross proceeds of approximately $380.0&#160;million from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, will be sufficient to fund the Combined Company&#8217;s operating expenses and capital expenditure requirements into 2029. Even if the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing are successful, Korsana will still need to raise additional capital to continue to fund its operations in the future. If Korsana is unable to raise additional capital when needed, that could raise substantial doubt about Korsana&#8217;s ability to continue as a going concern. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements, or other sources, and adequate additional financing may not be available to Korsana on acceptable terms, or at all. Such financing may dilute Korsana&#8217;s stockholders or the failure to obtain such financing may restrict Korsana&#8217;s operating activities. Any additional fundraising efforts may divert Korsana&#8217;s management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect Korsana&#8217;s business. To the extent that Korsana raises additional capital through the sale of equity or convertible debt securities, the ownership interest of Korsana&#8217;s stockholders will be diluted, and the terms may include liquidation or other preferences and anti-dilution protections that adversely affect the rights of Korsana&#8217;s stockholders. Debt financing may result in the imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect Korsana&#8217;s business. If Korsana raises additional funds through upfront payments or milestone payments pursuant to future collaborations with third parties, Korsana may have to relinquish valuable rights to Korsana&#8217;s product candidates, or grant licenses on terms that are not favorable to Korsana. Korsana&#8217;s ability to raise additional capital may be adversely impacted by global macroeconomic conditions and volatility in the credit and financial markets in the United States and worldwide. Korsana&#8217;s failure to raise capital as and when needed or on acceptable terms would have a negative impact on Korsana&#8217;s financial condition and Korsana&#8217;s ability to pursue its business strategy, and Korsana may have to delay, reduce the scope of, suspend, or eliminate one or more of its product candidates, clinical trials, or future commercialization efforts or cease Korsana&#8217;s operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana expects to continue to incur losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. Korsana has no products approved for sale, has not generated any revenue </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">
from its product candidates, and may never generate revenue or become profitable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biotechnology product development is a highly speculative undertaking and entails substantial upfront capital expenditures and significant risks that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. Korsana has no products approved for commercial sale, has not generated any revenue from product sales to date, and continues to incur significant research and development and other expenses related to Korsana&#8217;s ongoing operations. Korsana does not expect to generate product revenue unless or until Korsana successfully completes preclinical and clinical development and obtains regulatory approval for, and then successfully commercializes, at least one of its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may never succeed in these activities and, even if it does, may never generate revenues that are significant or large enough to achieve profitability. If Korsana is unable to raise sufficient additional capital to advance a product candidate to commercialization or generate sufficient revenue through the sale of any approved products, Korsana may be unable to continue operations without additional funding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana incurred significant net losses in each period since it commenced operations in November 2024. Korsana generated net losses of $35.7&#160;million for the period from November 2024 (inception) to December&#160;31, 2025. As of December&#160;31, 2025, Korsana had an accumulated deficit of $35.7&#160;million. Korsana expects to continue to incur losses for the foreseeable future. Korsana&#8217;s operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. Korsana anticipates that its expenses will increase substantially if and as Korsana: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advances its existing and future product candidates through preclinical and clinical development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks to identify additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintains, expands, enforces, defends, and protects Korsana&#8217;s intellectual property portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks, obtains, and maintains regulatory approvals for Korsana&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks to identify, establish, and maintain additional collaborations and license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">makes milestone payments to Paragon under the Paragon License Agreement and Paragon ADOA, and to Paragon Laboratories under the Paragon Research Letter Agreement, and under any additional future collaboration or license agreements that Korsana enters into; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ultimately establishes a sales, marketing, and distribution infrastructure to commercialize any drug products for which Korsana may obtain regulatory approval, either on its own or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">generates revenue from commercial sales of product candidates for which Korsana receives regulatory approval, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">hires additional personnel, including research and development, clinical, and commercial personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adds operational, financial, and management information systems and personnel, including personnel to support Korsana&#8217;s product development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquires or <span style="white-space:nowrap">in-licenses</span> products, intellectual property, and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishes clinical and commercial-scale current good manufacturing practices (&#8220;cGMP&#8221;) capabilities through a third-party or Korsana&#8217;s own manufacturing facility; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">operates as a public company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Korsana&#8217;s expenses will increase if, among other things, it is required by the FDA or other regulatory authorities to perform clinical trials or studies in addition to, or different than, those that Korsana currently anticipates, there are any delays in completing Korsana&#8217;s clinical trials or the development of any of its product candidates, or there are any third-party challenges to Korsana&#8217;s intellectual property or Korsana needs to defend against any intellectual property-related claim. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Korsana obtains regulatory approval for, and is successful in commercializing, one or more of Korsana&#8217;s product candidates, Korsana expects to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. Korsana may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect its business. The size of Korsana&#8217;s future net losses will depend, in part, on the rate of future growth of Korsana&#8217;s expenses and its ability to generate revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s failure to become profitable would decrease its value and could impair its ability to raise capital, maintain its research and development efforts, expand its business, and/or continue its operations. A decline in the value of the Combined Company&#8217;s stock could also cause stockholders to lose all or part of their investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Korsana&#8217;s Discovery, Development, and Commercialization </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana faces competition from entities that have developed or may develop product candidates for the diseases addressed by Korsana&#8217;s product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of drugs is highly competitive. Korsana&#8217;s product candidates, if approved, will face significant competition and Korsana&#8217;s failure to effectively compete may prevent it from achieving significant market penetration. Korsana competes with a variety of multinational biopharmaceutical companies, specialized biotechnology companies, and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. If approved for the treatment of patients with Alzheimer&#8217;s disease, <span style="white-space:nowrap">KRSA-028</span> would compete with two anti-amyloid antibody therapies that have been approved by the FDA for treatment of early Alzheimer&#8217;s disease: lecanemab (Leqembi), marketed by Eisai and Biogen, and donanemab (Kisunla), marketed by Eli Lilly. Korsana is aware of several companies with product candidates in clinical development for the treatment of patients with Alzheimer&#8217;s disease, including Roche (including Genentech, its wholly owned subsidiary), Lilly, Eisai, Biogen, AbbVie, Merck, Sanofi, Bristol Myers Squibb, Voyager Therapeutics, Denali Therapeutics, Acumen, Alzheon, AC Immune, and others. Many of the companies with which Korsana is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and commercialization than Korsana does, and are further along in the clinical development and/or commercialization process. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Korsana&#8217;s competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Korsana in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, raising capital, enrolling patients in clinical trials, establishing and defending rights to intellectual property, as well as in acquiring technologies complementary to, or necessary for, Korsana&#8217;s product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s competitors have developed or are developing, and may in the future develop, product candidates or products competitive with Korsana&#8217;s product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any potential new treatments, including those currently under clinical development. Korsana&#8217;s success will depend partially on its ability to develop and commercialize products that have a competitive safety, efficacy, dosing, and/or presentation profile. Korsana&#8217;s commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, less expensive, or have a more attractive dosing profile or presentation than the products Korsana develops, or if competitors develop products or biosimilars that enter the market more quickly than Korsana and gain market acceptance. Conversely, the lack of commercial success of other competing therapies may raise concerns about the financial viability of Korsana&#8217;s product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because of the competitive landscape for Alzheimer&#8217;s disease, Korsana may also face competition for establishing clinical trial sites and enrolling patients. Patient enrollment will depend on many </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
factors, including if potential clinical trial patients choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for product candidates that are under development for the same indications as Korsana&#8217;s product candidates. An increase in the number of approved products for the indications Korsana is targeting with its product candidates will likely further exacerbate this competition. Korsana&#8217;s inability to enroll a sufficient number of patients could, among other impacts, delay Korsana&#8217;s development timeline, which may further harm Korsana&#8217;s competitive position. </p> <p style="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s programs are in the preclinical and clinical stages of development and may fail in development or suffer delays that materially and adversely affect Korsana&#8217;s viability. If Korsana or its future collaborators are unable to complete development of or commercialize Korsana&#8217;s product candidates, or experience significant delays in doing so, Korsana&#8217;s business will be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has no commercially approved products. Korsana&#8217;s programs are in the preclinical and clinical stages of development, and Korsana has not completed any clinical trials. As a result, Korsana expects it will be many years before Korsana commercializes any product candidate, if ever. Korsana&#8217;s ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, Korsana&#8217;s product candidates, either alone or with third parties, and Korsana cannot guarantee that it will ever obtain regulatory approval for any of its product candidates. Korsana has not yet demonstrated its ability to complete any clinical trials, obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on Korsana&#8217;s behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of any product candidate, Korsana or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of the product candidate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana or its collaborators may experience delays in initiating or completing preclinical studies or clinical trials. Korsana or its collaborators also may experience numerous unforeseen events during, or as a result of, any future preclinical studies or clinical trials that Korsana could conduct that could delay or prevent Korsana&#8217;s ability to receive regulatory approval or commercialize its product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators, such as the FDA, institutional review boards (&#8220;IRBs&#8221;), or comparable foreign regulatory authorities may not authorize Korsana or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective clinical research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites may deviate from the trial protocol, fail to conduct trials in a compliant manner, or drop out of a trial, which may require that Korsana add new clinical trial sites or investigators or otherwise negatively impact the timing or integrity of Korsana&#8217;s clinical trial(s); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results and Korsana may decide, or regulators may require Korsana, to conduct additional preclinical studies or clinical trials or Korsana may decide to abandon a product development program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of subjects required for clinical trials of any product candidates may be larger than Korsana can anticipate, and enrollment in these clinical trials may be slower than Korsana anticipates or subjects may drop out of these clinical trials or fail to return for post-treatment <span style="white-space:nowrap">follow-up</span> at a higher rate than Korsana anticipates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to Korsana in a timely manner, or at all, or may deviate from the clinical trial protocol or suffer other quality or performance issues that negatively impact the timing or integrity of Korsana&#8217;s clinical trial(s); </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana may elect to, or regulators, IRBs or ethics committees may require that Korsana or its investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in Korsana&#8217;s clinical trials are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials of any of Korsana&#8217;s product candidates may be greater than Korsana anticipates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the quality of Korsana&#8217;s product candidates or other materials necessary to conduct clinical trials of Korsana&#8217;s product candidates may be inadequate to initiate or successfully complete a given clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana may be unable to manufacture sufficient quantities of its product candidates for use in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reports from clinical testing of other therapies may raise safety or efficacy concerns about Korsana&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana may fail to establish an appropriate safety profile for a product candidate based on preclinical or clinical data for such product candidate as well as data emerging from other therapies in the same class as such product candidate; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory authorities may require Korsana to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting Korsana to initiate a clinical trial. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA. Commencing clinical trials in jurisdictions outside of the United States is similarly subject to acceptance by the applicable regulatory authority of clinical trial documentation following discussions with such authority. In the event that the FDA or other applicable regulatory authority requires Korsana to complete additional preclinical studies or Korsana is required to satisfy other FDA or foreign regulatory authority requests, respectively, prior to commencing clinical trials, the start of Korsana&#8217;s first clinical trial for a product candidate may be delayed. Even after Korsana receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree as to whether Korsana has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Korsana&#8217;s trial design or the clinical endpoints selected, which may require Korsana to complete additional preclinical studies or clinical trials, delay the enrollment of Korsana&#8217;s clinical trials or impose stricter approval conditions than Korsana currently expects. There are analogous processes and risks applicable to clinical trial applications in other countries, including but not limited to Canada, New Zealand, Australia, countries in the EU, and countries in Asia. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may not have the financial resources to continue development of its product candidates if Korsana experiences any issues that delay or prevent regulatory approval of, or Korsana&#8217;s ability to commercialize, its product candidates. Korsana or its future collaborators&#8217; inability to complete development of, or commercialize Korsana&#8217;s product candidates, or significant delays in doing so, could have a material and adverse effect on Korsana&#8217;s business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana is substantially dependent on the success of <span style="white-space:nowrap">KRSA-028,</span> and Korsana&#8217;s anticipated clinical trials for such product candidate may not be successful. </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s future success is substantially dependent on its ability to timely obtain regulatory approval for, and then successfully commercialize, <span style="white-space:nowrap">KRSA-028.</span> Korsana is initially investing a majority of its efforts and financial resources into the research and development of this program. After Korsana completes GLP toxicity studies, it plans to submit a CTN in Australia or a CTA in New Zealand by the end of 2026 and an IND in the United States in the first quarter of 2027. Pharmacokinetic data in healthy volunteers is anticipated by <span style="white-space:nowrap">mid-year</span> </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2027 and interim <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data in Alzheimer&#8217;s disease patients is anticipated by the end of 2027. The success of <span style="white-space:nowrap">KRSA-028</span> depends on demonstrating one or more clinical advantages over other approved <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibody products or product candidates in clinical development, which may include favorable data on amyloid plaque clearance, slowing of cognitive decline or disease progression, reduced rates of amyloid-related imaging abnormalities (&#8220;ARIA&#8221;), improved hematologic safety, and/or a convenient <span style="white-space:nowrap">low-volume</span> subcutaneous route of administration. Korsana&#8217;s belief that <span style="white-space:nowrap">KRSA-028</span> will show favorable clinical data is based in part on the assumption that the increased brain penetration observed in mice and <span style="white-space:nowrap">non-human</span> primates (&#8220;NHPs&#8221;) through the use of the proprietary THETA platform, which confers binding to the transferrin receptor (&#8220;TfR1&#8221;), will translate to humans. If Korsana&#8217;s Phase 1 clinical trial of <span style="white-space:nowrap">KRSA-028</span> or additional clinical trials do not demonstrate adequate brain delivery or improvements versus the limitations of other TfR1-based approaches, the clinical and commercial potential of <span style="white-space:nowrap">KRSA-028</span> will be significantly and adversely affected. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s product candidates will require evaluation of preclinical, clinical, and manufacturing activities, preclinical and clinical development, regulatory approval in multiple jurisdictions, substantial investment, and significant marketing efforts before Korsana generates any revenues from product sales. Korsana is not permitted to market or promote its product candidates before it receives regulatory approval from the FDA and comparable foreign regulatory authorities, and Korsana may never receive such regulatory approvals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of Korsana&#8217;s product candidates will depend on a variety of factors. Korsana does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Korsana&#8217;s intellectual property rights, potential threats from the intellectual property rights of third parties and the manufacturing, marketing, distribution, and sales efforts of any future collaborator. Accordingly, Korsana cannot assure you that it will ever be able to generate revenue through the sale of these product candidates, even if approved. If Korsana is not successful in obtaining regulatory approval for and commercializing <span style="white-space:nowrap">KRSA-028</span> or future product candidates, or is significantly delayed in doing so, Korsana&#8217;s business will be materially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s product candidates are based on novel technology in fields that have seen limited success in drug development, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has focused its research and development efforts on addressing neurodegenerative diseases. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are few effective therapeutic options available for patients with neurodegenerative diseases, such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease. Korsana&#8217;s future success is highly dependent on the successful development of its THETA<sup style="font-size:75%; vertical-align:top">&#8482;</sup> platform and its product candidates for treating neurodegenerative diseases. Developing and, if approved, commercializing Korsana&#8217;s product candidates for treatment of neurodegenerative diseases subjects it to a number of challenges, including engineering product candidates to cross the blood brain barrier (&#8220;BBB&#8221;) to enable optimal concentration of the therapeutic in the brain and obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s approach to the treatment of neurodegenerative diseases aims to identify and select targets with a link to neurodegenerative diseases; to identify and develop molecules that engage the intended target; to, where possible, identify and develop biomarkers, which are biological molecules found in blood, other bodily fluids, or tissues that are signs of a normal or abnormal process or of a condition or disease, to select patient populations and demonstrate, where possible, target engagement, pathway engagement, and impact on disease progression of its molecules; and to engineer its molecules to cross the BBB and act directly in the brain. This strategy may not prove to be successful. Korsana may not be able to discover, develop, and utilize biomarkers to demonstrate target engagement, pathway engagement, and the impact on disease progression of its product candidates. Korsana cannot be sure that its approach will yield satisfactory therapeutic products that are safe and effective, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scalable, or profitable. Moreover, public perception of drug safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to novel treatments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korsana does not achieve its projected development objectives in the time frames Korsana announces and expects, the commercialization of its product candidates may be delayed which may harm Korsana&#8217;s reputation and prospects, increase its expenses, and cause its stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Korsana estimates the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which Korsana sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the initiation of Korsana&#8217;s Phase 1 clinical trial of <span style="white-space:nowrap">KRSA-028,</span> the timing for receipt of clinical data, and the timing for the submission of regulatory filings. From time to time, Korsana may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to Korsana&#8217;s estimates, in many cases for reasons beyond Korsana&#8217;s control. If Korsana does not meet these milestones as publicly announced, or at all, Korsana&#8217;s prospects and reputation may be adversely affected, and its stock price may decline. Additionally, delays relative to Korsana&#8217;s projected timelines are likely to cause overall expenses to increase, which may require Korsana to raise additional capital sooner than expected and prior to achieving targeted development milestones. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s approach to the discovery and development of its product candidates is unproven, and Korsana may not be successful in its efforts to build a pipeline of product candidates with commercial value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s approach to the discovery and development of its product candidates leverages established mechanisms of action and incorporates advanced antibody engineering to optimize half-life and other properties designed to overcome limitations of existing therapies, including increased binding affinity, and transferrin receptor (&#8220;TfR&#8221;) shuttling for delivering large molecule drugs across the BBB, enabling higher drug concentration inside the brain. Korsana&#8217;s product candidates are purposefully designed to improve upon existing product candidates and products while maintaining the same, established mechanisms of action. However, the scientific research that forms the basis of Korsana&#8217;s efforts to develop differentiated product candidates using half-life extension technologies, effector function modification, and/or the TfR-based THETA technology to deliver large molecule drugs across the BBB, is ongoing and may not result in viable product candidates. Korsana has no clinical data on product candidates using TfR-based THETA technology in neurodegenerative diseases and demonstrating whether they are safe or effective for long-term treatment in humans. Korsana also has no clinical data to indicate whether its antibody engineering designed to optimize half-life and modify effector function enhances brain exposure or translates into improved safety, tolerability, convenience, or efficacy in humans. The long-term safety and efficacy of Korsana&#8217;s product candidates compared to currently approved products is unknown. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may ultimately discover that utilizing half-life extension technologies, effector function modulation, and the TfR-based THETA technology to target <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span> for Korsana&#8217;s specific indications and any product candidates resulting therefrom do not possess certain properties required for therapeutic effectiveness. Korsana currently has only preclinical data regarding the increased half-life properties, effector function modulation, and targeting mechanism of Korsana&#8217;s product candidates, and the same results may not be seen in humans. In addition, product candidates using half-life extension technologies and effector function modulation, or that are designed to bind to <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span> and clear amyloid plaques, may demonstrate different chemical, pharmacological and biological properties in patients than they do in laboratory studies. This technology and any product candidates resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective, or harmful ways. Many product candidates that appeared highly promising in preclinical studies or in early-stage clinical trials have failed when advanced into, or further in, clinical development. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other companies are developing drug products that target A<span style="FONT-FAMILY:SYMBOL">b</span> or utilize TfR-mediated delivery technologies for central nervous system indications, or that utilize half-life extension technology and/or effector function modulation for other targets. The failure of those companies to demonstrate the safety and/or efficacy of their product candidates may be harmful to Korsana&#8217;s business, financial condition, results of operations, and prospects. Conversely, if those companies are successful in demonstrating safety and/or efficacy of their product candidates, these competitive products may instead gain and hold the applicable market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Korsana may in the future seek to discover and develop product candidates that are based on novel targets and technologies that are unproven. If Korsana&#8217;s discovery or business development activities fail to identify novel targets or technologies for drug development, or such targets or technologies prove to be unsuitable for treating human disease, Korsana may not be able to develop viable additional product candidates. Korsana and its future collaborators may never receive approval to market and commercialize any product candidate. Even if Korsana or a future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as Korsana intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from Korsana&#8217;s product candidates prove to be ineffective, unsafe, or commercially unviable, Korsana&#8217;s product candidates and pipeline would have little, if any, value, which would have a material and adverse effect on Korsana&#8217;s business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Korsana&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Korsana may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, Korsana must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of Korsana&#8217;s product candidate in humans. Korsana&#8217;s clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Furthermore, a failure of one or more clinical trials can occur at any clinical trial phase. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. In addition, Korsana expects to rely on patients to provide feedback on subjective measures, including disease severity and quality of life, which are inherently difficult to evaluate. These measures can be influenced by factors outside of Korsana&#8217;s control and can vary widely from day to day for a particular patient, and from patient to patient and from site to site within a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana cannot be sure that the FDA or comparable foreign regulatory authorities will agree with Korsana&#8217;s clinical development plans. Korsana plans to use the data from healthy volunteers from its Phase 1 clinical trial of <span style="white-space:nowrap">KRSA-028</span> to support additional clinical development. However, there is no guarantee the data from such Phase 1 trial will support additional development. If the FDA or comparable foreign regulatory authorities require Korsana to conduct additional trials or enroll additional healthy volunteers or patients, Korsana&#8217;s development timeline may be delayed. Korsana cannot be sure that submission of an IND or similar foreign application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other <span style="font-style:italic">in vivo</span> or <span style="font-style:italic">in vitro</span> data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval or positive ethics committee opinions at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of Korsana&#8217;s product candidates for use in clinical trials or the inability to do any of the foregoing; failure by Korsana&#8217;s CROs, other third parties or Korsana to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practice (&#8220;GCP&#8221;) requirements or regulatory guidelines; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements, guidance or clinical trial plans that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to new or larger-scale facilities and delays or failure by Korsana&#8217;s CMOs or Korsana to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana could also encounter delays if a clinical trial is suspended or terminated by Korsana, by the IRBs or ethics committees of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Korsana&#8217;s clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Korsana is required to conduct additional clinical trials or other testing of its product candidates beyond those that Korsana currently contemplates, if Korsana is unable to successfully complete clinical trials of its product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, Korsana&#8217;s business and results of operations would be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may encounter difficulties enrolling patients in its clinical trials, and its clinical development activities could thereby be delayed or otherwise adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their protocols depends, among other things, on Korsana&#8217;s ability to enroll a sufficient number of patients who remain in the trial until its conclusion. Korsana may experience difficulties in patient enrollment in clinical trials for a variety of reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size and nature of the patient population; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly specific criteria related to stage of disease progression, which may limit the patient populations eligible for Korsana&#8217;s clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size of the study population required for analysis of the trial&#8217;s primary endpoints; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proximity of patients to a trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design of the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s ability to recruit clinical trial investigators with the appropriate competencies and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in enrolling patients in Korsana&#8217;s clinical trials caused by worldwide economic conditions, including pandemics or other public health outbreaks and other geopolitical events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing clinical trials for similar therapies or targeting patient populations meeting Korsana&#8217;s patient eligibility criteria; </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">availability of approved products that target the patient populations that Korsana is seeking to enroll; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions of the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s ability to obtain and maintain patient consents; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that Korsana may not be able to collect data from patients for any reason. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana or its partners may encounter difficulties or delays in enrollment of its clinical trials due to the availability of newly approved therapies and competing products. For example, lecanemab received FDA approval for the treatment of Alzheimer&#8217;s disease in 2023, and donanemab received FDA approval for the treatment of Alzheimer&#8217;s disease in July 2024. As a result, Korsana or its partners&#8217; ability to enroll participants in clinical trials for Alzheimer&#8217;s disease may be hampered if potential participants choose to instead avail themselves of approved therapies<span style="font-style:italic">.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preliminary, &#8220;topline&#8221; or interim data from Korsana&#8217;s clinical trials that Korsana announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Korsana may publicly disclose preliminary or topline data from its preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a more comprehensive review of the data. Korsana also makes assumptions, estimations, calculations, and conclusions as part of its analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that Korsana reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, Korsana may also disclose interim data from its preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from Korsana&#8217;s clinical trials continue other treatments. Further, others, including regulatory authorities, may not accept or agree with Korsana&#8217;s assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and of Korsana as a company. In addition, the information Korsana chooses to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Korsana determines is material or otherwise appropriate information to include in Korsana&#8217;s disclosure. As a result, you or others may have reached different conclusions based on such extensive information in comparison to Korsana&#8217;s publicly disclosed conclusion regarding a particular preclinical study or clinical trial. If the preliminary, topline, or interim data that Korsana reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Korsana&#8217;s ability to obtain approval for, and commercialize, Korsana&#8217;s product candidates may be harmed, which could harm Korsana&#8217;s business, operating results, prospects, or financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s future clinical trials or those of its future collaborators may reveal significant adverse events or undesirable side effects not seen in Korsana&#8217;s preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval, or limit commercial potential or market acceptance of any of Korsana&#8217;s product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results of Korsana&#8217;s clinical trials could reveal a high or unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. Korsana has not yet completed any clinical trials in humans. If significant adverse events or other side effects are observed in any of Korsana&#8217;s future clinical trials, Korsana </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may have difficulty recruiting patients to such trials, patients may drop out of Korsana&#8217;s trials, or Korsana may be required to abandon the trials or Korsana&#8217;s development efforts of one or more product candidates altogether. For example, treatment-emergent adverse events (&#8220;TEAEs&#8221;) have been reported in approximately 85% of expansion cohort participants in Roche&#8217;s Brainshuttle AD study, an ongoing Phase 1/2 clinical trial investigating trontinemab in patients with prodromal or mild to moderate Alzheimer&#8217;s disease, including ARIA, anemia, infusion-related reactions, and one fatal case of cerebral macrohemmorrhage. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because <span style="white-space:nowrap">KRSA-028</span> will have a similar mechanism of action as trontinemab, it is possible that patients in Korsana&#8217;s future clinical trials could exhibit TEAEs of similar or worse frequency or severity. Korsana, the FDA or other applicable regulatory authorities, or an IRB or ethics committee, may suspend any clinical trials of any product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to Korsana&#8217;s tolerability versus other therapies. In addition, an extended half-life could prolong the duration of undesirable side effects, which could also inhibit market acceptance. TEAEs could also affect patient recruitment or the ability of enrolled subjects to complete Korsana&#8217;s clinical trials or could result in potential product liability claims. Potential side effects associated with Korsana&#8217;s product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from Korsana&#8217;s product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm Korsana&#8217;s business, financial condition, results of operations, and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if Korsana successfully advances its product candidates or any future product candidate through clinical trials, such trials will only include a limited number of patients and limited duration of exposure to Korsana&#8217;s product candidates. As a result, Korsana cannot be assured that adverse effects of Korsana&#8217;s product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using Korsana&#8217;s product candidates over a multi-year period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may expend its limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Korsana has limited financial and managerial resources, Korsana focuses its research and development efforts on certain selected programs. For example, Korsana is initially focused primarily on its initial product candidate, KRSA-028. As a result, Korsana may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Korsana&#8217;s resource allocation decisions may cause Korsana to fail to capitalize on viable commercial products or profitable market opportunities. Korsana&#8217;s spending on current and future research and development product candidates for specific indications may not yield any commercially viable product candidates. If Korsana does not accurately evaluate the commercial potential or target market for a particular product candidate, Korsana may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for Korsana to retain sole development and commercialization rights to such product candidate. In addition, Korsana may select product candidates amongst a variety of potential product candidates, and the product candidates Korsana selects may fail to be viable commercial products or the product candidates Korsana does not select may have a greater likelihood of success. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any approved products resulting from Korsana&#8217;s current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors, and others in the </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">
medical community necessary for commercial success and Korsana may not generate any future revenue from the sale or licensing of such products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if regulatory approval is obtained for a product candidate resulting from one of Korsana&#8217;s current or future programs, Korsana may not gain market acceptance among physicians, healthcare professionals, patients, healthcare payors, or the medical community. Korsana may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. Market acceptance will depend on many factors, including factors that are not within Korsana&#8217;s control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are two approved disease-modifying therapeutic products and additional product candidates in later stages of clinical development for the treatment of Alzheimer&#8217;s disease, including Leqembi (marketed by Eisai and Biogen) and Kisunla (marketed by Lilly). However, <span style="white-space:nowrap">KRSA-028</span> is designed to have improved brain penetration and contains modifications that are known to increase the half-life of antibodies in circulation; to date, no such disease-modifying therapy with these design modifications has been approved by the FDA for the treatment of Alzheimer&#8217;s disease, though several such agents are in clinical development. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt a biologic that incorporates effector function modification and half-life extension for Korsana&#8217;s targeted indication, and Korsana may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by Korsana or its existing or future collaborators. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance of Korsana&#8217;s product candidates may be negatively impacted by potential poor performance of Korsana&#8217;s competitors, including the occurrence of serious adverse events in such competitors&#8217; clinical trials or failure by such competitors to obtain and maintain regulatory approval for their product candidates. Additionally, although Korsana believes that the improved dosing and convenience it expects its product candidates to provide will improve market acceptance of such product candidates and that Korsana&#8217;s product candidates will have a competitive efficacy profile, Korsana&#8217;s predictions may not be accurate and other competitive products may instead gain and hold the applicable market. Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. Korsana cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies, or private insurers will determine that Korsana&#8217;s product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any current or future product candidate is approved but does not achieve an adequate level of acceptance by such parties, Korsana may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of Korsana&#8217;s programs may compete with Korsana&#8217;s other programs, which could negatively impact Korsana&#8217;s business and reduce Korsana&#8217;s future revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is developing <span style="white-space:nowrap">KRSA-028</span> for the treatment of Alzheimer&#8217;s disease and may in the future develop programs for additional neurodegenerative disease indications. However, developing multiple product candidates for neurodegenerative disease indications may negatively impact Korsana&#8217;s business if the product candidates compete with each other. For example, if multiple product candidates are conducting clinical trials at the same time, they could compete for the enrollment of patients. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit Korsana&#8217;s future revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s research and development efforts are concentrated in the field of neurodegenerative diseases, which has historically experienced a high rate of clinical failure. If the scientific basis for Korsana&#8217;s approach proves insufficient or the field experiences setbacks, Korsana&#8217;s entire pipeline could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has concentrated its research and development efforts on therapeutics for neurodegenerative diseases, with its lead product candidate, <span style="white-space:nowrap">KRSA-028,</span> targeting Alzheimer&#8217;s disease. The neurodegenerative disease field has historically experienced a high rate of clinical trial failure compared to other therapeutic areas, and a number of companies have invested significant resources in the development of neurodegenerative disease </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates without obtaining regulatory approval. If the scientific basis for Korsana&#8217;s approach to treating neurodegenerative diseases, including the use of TfR-based THETA technology to deliver therapeutics across the blood brain barrier, proves to be flawed or insufficient, Korsana&#8217;s entire pipeline could be rendered nonviable. Because Korsana&#8217;s pipeline is concentrated in a single therapeutic area, Korsana does not have the benefit of diversification across multiple therapeutic areas that could offset failures in any one program. A setback in one program could have a disproportionate impact on Korsana&#8217;s business, financial condition, results of operations, and prospects relative to a company with a more diversified pipeline. Adverse developments in the neurodegenerative disease field generally, including safety signals or clinical failures by other companies developing therapies for similar indications, could negatively affect investor sentiment, regulatory scrutiny, and patient enrollment for Korsana&#8217;s clinical trials, regardless of the merits of Korsana&#8217;s own product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana plans to conduct clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana plans to conduct the single ascending dose (SAD) portion of its Phase 1 clinical trial of <span style="white-space:nowrap">KRSA-028</span> in healthy participants in Australia or New Zealand, and Korsana may choose to conduct the multiple ascending dose (MAD) portion of its Phase clinical trial of KRSA-028 in AD patients and future clinical trials outside the United States in whole or in part, including potentially in the UK, EU, or Canada. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on Korsana&#8217;s determination that the trials also complied with all applicable U.S. laws and regulations. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the relevant jurisdiction, as applicable. If the FDA or any comparable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt Korsana&#8217;s development of the applicable product candidates or delay or prevent regulatory approval for commercialization in the applicable jurisdiction. Even if the FDA or any comparable foreign regulatory authority accepted such data, it could require Korsana to modify its planned clinical trials to receive clearance to initiate such trials in the United States or the relevant jurisdiction, as applicable, or to continue such trials once initiated. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, conducting international clinical trials presents additional risks that may delay completion of Korsana&#8217;s clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit Korsana&#8217;s ability to conduct its clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Korsana&#8217;s Reliance on Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana relies on collaborations and licensing arrangements with third parties, including Paragon. If Korsana is unable to maintain these collaborations or licensing arrangements, or if these collaborations or licensing arrangements are not successful, Korsana&#8217;s business could be negatively impacted. </span></p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana relies on its collaboration with Paragon and Paragon Laboratories for a substantial portion of its discovery capabilities and for the rights necessary to develop and commercialize its product candidates. In the future, Korsana could also rely on additional licensing arrangements with third parties. For example, Korsana has </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entered into the Paragon ADOA, the Paragon POA, the Paragon Research Letter Agreement, and the Paragon License Agreement. However, Paragon or Paragon Laboratories could terminate these agreements under certain circumstances, including Korsana&#8217;s failure to make any payments owed to Paragon under the agreement or any uncured material breach of the agreement by Korsana, in which event Korsana may lose intellectual property rights and may not be able to develop or commercialize the product candidates covered by that agreement, including <span style="white-space:nowrap">KRSA-028.</span> </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations or licensing arrangements that Korsana enters into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of Korsana&#8217;s collaborators or licensors experiences delays in performance of, or fails to perform, their obligations under their agreement with Korsana, disagrees with Korsana&#8217;s interpretation of the terms of such agreement, or terminates their agreement with Korsana, Korsana&#8217;s pipeline and product candidates and development timeline could be adversely affected. If Korsana fails to comply with any of the obligations under its collaborations or license agreements, including payment terms and diligence terms, Korsana&#8217;s collaborators or licensors may have the right to terminate such agreements, in which event Korsana may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by Korsana&#8217;s agreements or may face other penalties under Korsana&#8217;s agreements. Korsana&#8217;s collaborators and licensors may also fail to properly maintain or defend the intellectual property Korsana has licensed from them, if required by Korsana&#8217;s agreement with them, leading to the potential invalidation of Korsana&#8217;s intellectual property, or they may even infringe upon Korsana&#8217;s intellectual property rights, any of which could subject Korsana to litigation or arbitration, which would be time-consuming and expensive and could harm Korsana&#8217;s ability to commercialize its product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Korsana&#8217;s product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Korsana&#8217;s. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of Korsana&#8217;s strategy, Korsana plans to evaluate additional opportunities to enhance its capabilities and expand its development pipeline or add development or commercialization capabilities. Korsana may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require Korsana to incur <span style="white-space:nowrap">non-recurring</span> and other charges, increase Korsana&#8217;s near and long-term expenditures, issue securities that dilute Korsana&#8217;s existing stockholders or disrupt Korsana&#8217;s management and business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that Korsana considers attractive. These companies may have a competitive advantage over Korsana due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies may be unwilling to assign or license rights to Korsana, whether they perceive Korsana to be a competitor or for other reasons. Whether Korsana reaches a definitive agreement for a collaboration will depend, among other things, upon Korsana&#8217;s assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. Korsana may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If Korsana fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, Korsana may not be able to further develop its product candidates or bring them to market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks associated with the <span style="white-space:nowrap">in-licensing</span> or acquisition of product candidates could cause substantial delays in the preclinical and clinical development of Korsana&#8217;s product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has relied and continues to rely on Paragon, and expects to rely on Korsana&#8217;s future licensing partners, to (i)&#160;conduct research and development in accordance with the applicable protocol, legal, regulatory, and scientific standards, (ii)&#160;accurately report the results of all preclinical studies conducted prior to Korsana&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensing or acquisition of the relevant product candidates, and (iii)&#160;correctly collect and interpret the data from these studies. If the research and development processes or the results of the development programs prior to Korsana&#8217;s licensing or acquisition of Korsana&#8217;s product candidates prove to be unreliable, this could result in increased costs and delays in the development of Korsana&#8217;s product candidates, which could adversely affect any future revenue from such product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may also acquire or <span style="white-space:nowrap">in-license</span> additional product candidates for preclinical or clinical development in the future as Korsana continues to build its pipeline. The risks associated with acquiring or <span style="white-space:nowrap">in-licensing</span> product candidates could result in delays in the commencement or completion of Korsana&#8217;s preclinical studies and clinical trials, if they are ever commenced or completed, and Korsana&#8217;s ability to generate revenues from its product candidates may be delayed. Please see the section titled &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Korsana&#8217;s Intellectual Property&#8212;If Korsana is unable to obtain or maintain necessary rights to its programs through acquisitions and <span style="white-space:nowrap">in-licenses,</span> Korsana&#8217;s business may be materially harmed</span>&#8221; below for additional information regarding such risks. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana currently relies, and plans to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, Korsana may not be able to obtain regulatory approval of or commercialize Korsana&#8217;s product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has utilized and plans to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support Korsana&#8217;s preclinical studies and clinical trials under agreements with Korsana. Korsana will rely heavily on these third parties over the course of its preclinical studies and clinical trials, and Korsana controls only certain aspects of their activities. As a result, Korsana will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if Korsana was relying entirely upon its own staff. Nevertheless, Korsana is responsible for ensuring that each of its studies and trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and Korsana&#8217;s reliance on these third parties does not relieve Korsana of its regulatory responsibilities. Korsana and its third-party contractors and CROs are required to comply with GCP, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of Korsana&#8217;s product candidates in clinical development. If Korsana or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in Korsana&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Korsana to perform additional clinical trials before approving Korsana&#8217;s marketing applications. Korsana cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Korsana&#8217;s clinical trials comply with GCP. In addition, Korsana&#8217;s clinical trials must be conducted with products manufactured in accordance with cGMP. Korsana&#8217;s failure to comply with these requirements may require Korsana to repeat clinical trials, which would delay the regulatory approval process. Moreover, Korsana&#8217;s business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws, and foreign equivalents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any third parties conducting Korsana&#8217;s clinical trials will not be its employees and, except for remedies available to Korsana under its agreements with such third parties, Korsana cannot control whether they devote sufficient time and resources to Korsana&#8217;s programs. These third parties may encounter challenges hiring and retaining sufficient qualified personnel or they may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including Korsana&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on Korsana&#8217;s behalf and the timing thereof and could lead to products that compete directly or indirectly with Korsana&#8217;s current or future product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to Korsana&#8217;s clinical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protocols or regulatory requirements or for other reasons, Korsana&#8217;s clinical trials may be extended, delayed or terminated and Korsana may not be able to complete development of, obtain regulatory approval of or successfully commercialize its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Korsana plans to rely on foreign CROs and CMOs, including WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics (Hong Kong)&#8221;), for formulation and manufacturing of Korsana&#8217;s Phase 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. Foreign CMOs may be the target of U.S. legislation, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to Korsana, delay the procurement or supply of such material, restrict or even prohibit Korsana&#8217;s ability to work with such CMOs, or have an adverse effect on Korsana&#8217;s ability to secure significant commitments from governments to purchase potential therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on Korsana&#8217;s collaborators in China which could have an adverse effect on Korsana&#8217;s business, financial condition, results of operations, and prospects. In addition, the United States government has imposed significant tariffs on imports from China and other countries and may impose more restrictions on goods, including biologically derived substances, manufactured in or imported from China or other countries or impose other restrictions on companies&#8217; ability to work with Chinese or other foreign counterparties. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United States and the UK, could also negatively impact Korsana&#8217;s ability to manufacture its product candidates for its planned clinical trials or have an adverse effect on its ability to secure government funding, which could adversely affect Korsana&#8217;s financial condition and cause Korsana to delay its clinical development programs. Furthermore, if one or more of Korsana&#8217;s collaborators or vendors in China is deemed to be a biotechnology company of concern under the BIOSECURE Act, Korsana&#8217;s operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while Korsana has established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting Korsana&#8217;s collaborators in China could introduce delays into the development program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana relies on the use of third-party CMOs to manufacture Korsana&#8217;s product candidates, and Korsana expects to continue to rely on third-party CMOs to produce Korsana&#8217;s products, if approved. Korsana&#8217;s business could be adversely affected if Korsana is unable to use third-party manufacturing sites or if the third-party manufacturers encounter difficulties in production. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana does not currently own any facility that may be used as Korsana&#8217;s clinical-scale manufacturing and processing facility and must rely on CMOs to manufacture Korsana&#8217;s product candidates. Korsana has not yet caused its product candidates to be manufactured on a commercial scale and may not be able to do so for any of Korsana&#8217;s product candidates, if approved. Korsana currently has a single source for its supply of Korsana&#8217;s product candidates. If there should be any disruption in such supply arrangement, including any adverse events affecting Korsana&#8217;s sole supplier, or if Korsana experiences delays or difficulties in transferring, or is unable to successfully transfer, Korsana&#8217;s manufacturing processes, it could have a negative effect on the clinical development of Korsana&#8217;s product candidates and other operations while Korsana works to identify and qualify an alternate supply source. Korsana has limited control over the manufacturing process of, and may be dependent on, Korsana&#8217;s contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of Korsana&#8217;s product candidates. Beyond periodic audits, Korsana has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance, and qualified personnel. If the FDA or another applicable regulatory authority does not approve these facilities for the manufacture of Korsana&#8217;s product candidates or withdraws any approval in the future, Korsana may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and delays and materially adversely affect Korsana&#8217;s ability to develop, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain regulatory approval for or market its product candidates, if approved. Korsana, or its future contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of member states of the European Union (&#8220;EU Member States&#8221;) or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMP. Despite Korsana&#8217;s efforts to audit and verify regulatory compliance, one or more of Korsana&#8217;s third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. Korsana&#8217;s failure, or the failure of Korsana&#8217;s CMOs, to comply with applicable regulations could result in sanctions being imposed on Korsana, including fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Korsana&#8217;s product candidates or products, if approved, and harm Korsana&#8217;s business and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, Korsana&#8217;s CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, intellectual property disputes or as a result of labor disputes or unstable political environments. If any CMOs on which Korsana will rely fail to manufacture quantities of Korsana&#8217;s product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a commercially reasonable cost, Korsana&#8217;s business, financial condition, and prospects could be materially and adversely affected. In addition, Korsana&#8217;s CMOs are responsible for transporting temperature-controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, Korsana&#8217;s integrity and purity specifications. Korsana and any of its CMOs may also face product seizure or detention or refusal to permit the import or export of products. Korsana&#8217;s business could be materially adversely affected by business disruptions to Korsana&#8217;s third-party providers that could materially adversely affect Korsana&#8217;s anticipated timelines, potential future revenue and financial condition and increase Korsana&#8217;s costs and expenses. Each of these risks could delay or prevent the completion of Korsana&#8217;s preclinical studies and clinical trials or the approval of any of Korsana&#8217;s product candidates by the FDA or comparable foreign regulatory authorities, result in higher costs or adversely impact commercialization of Korsana&#8217;s product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Korsana&#8217;s Business and Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In order to successfully implement its plans and strategies, Korsana will need to grow the size of its organization and Korsana may experience difficulties in managing this growth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana expects to experience significant growth in the number of its employees and the scope of Korsana&#8217;s operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, and regulatory affairs. To manage its anticipated future growth, Korsana must continue to implement and improve its managerial, operational, financial, and personnel systems, expand Korsana&#8217;s facilities, and continue to recruit and train additional qualified personnel. Due to its limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, Korsana may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana is highly dependent on its key personnel and anticipates hiring new key personnel. If Korsana is not successful in attracting and retaining highly qualified personnel, Korsana may not be able to successfully implement its business strategy. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon its ability to attract and retain highly qualified managerial, scientific, and medical personnel. Korsana is highly dependent on Korsana&#8217;s managerial, scientific, and medical personnel. Although Korsana has entered into employment agreements with Korsana&#8217;s executive officers, each of them may terminate their employment with </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korsana at any time. Korsana does not maintain &#8220;key person&#8221; insurance for any of Korsana&#8217;s executives or other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees. The loss of the services of Korsana&#8217;s executive officers or other key employees could impede the achievement of Korsana&#8217;s research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key personnel may be difficult and may take an extended period of time. If Korsana does not succeed in attracting and retaining qualified personnel, it could materially adversely affect Korsana&#8217;s business, financial condition, and results of operations. Korsana could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in Korsana&#8217;s employee recruitment and retention efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where Korsana would be subject to additional regulatory burdens and other risks and uncertainties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates, if approved, in foreign markets for which Korsana may rely on collaboration with third parties. Recent and ongoing changes in the United States trade policy with foreign countries, including the continued uncertainty surrounding U.S. tariffs and potential retaliatory measures by foreign governments, may disrupt the global supply chain for biopharmaceutical products. For example, in September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity. It is not yet clear whether these tariffs would apply to the importation of active pharmaceutical ingredients and possibly bulk drug products that are intended for use in clinical trials and not for commercial sale, which could increase the costs of materials for Korsana&#8217;s clinical trials. Any direct tariffs, if imposed on pharmaceutical products, may result in increased costs for raw materials and contract manufacturing services, reduced ability to source critical CMOs, and a delay in Korsana&#8217;s development timelines. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is not permitted to market or promote any of its product candidates before Korsana receives regulatory approval from the applicable foreign regulatory authority, and Korsana may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, Korsana must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing, and distribution of Korsana&#8217;s product candidates, if approved, and Korsana cannot predict success in these jurisdictions. If Korsana fails to comply with the regulatory requirements in international markets and receive applicable regulatory approvals, Korsana&#8217;s target market will be reduced and Korsana&#8217;s ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if Korsana obtains approval of its product candidates and ultimately commercialize its product candidates in foreign markets, Korsana would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Korsana competes achieve the forecasted growth, Korsana&#8217;s business may not grow at similar rates, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Korsana&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Korsana competes meet its size estimates and growth forecasts, Korsana&#8217;s business may not grow at similar rates, or at all. Korsana&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which Korsana gains regulatory approval, the accepted price for the product, the ability to obtain coverage and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement and whether Korsana owns the commercial rights for that territory. If the number of its addressable patients is not as significant as Korsana estimates, the indication approved by regulatory authorities is narrower than Korsana expects or the treatment population is narrowed by competition, physician choice, or treatment guidelines, Korsana may not generate significant revenue from sales of such products, even if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on its behalf may engage in misconduct or other improper activities. Misconduct by these parties could include intentional, reckless, or negligent conduct or disclosure of unauthorized activities to Korsana that violates FDA regulations, including those laws requiring the reporting of true, complete, and accurate information to the FDA, manufacturing standards, federal and state healthcare laws and regulations, and laws that require the true, complete, and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Korsana&#8217;s reputation. Korsana has adopted a code of conduct, but it is not always possible to identify and deter misconduct by these parties and the precautions Korsana takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Korsana from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s internal information technology systems, or those of any of its CROs, manufacturers, other contractors or consultants, third party service providers, or existing or future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of Korsana&#8217;s proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to Korsana&#8217;s brand and material disruption of Korsana&#8217;s operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of its business, Korsana and the third parties upon which Korsana relies collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, &#8220;Process&#8221;) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, &#8220;Sensitive Information&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures in an effort to protect systems that store Korsana&#8217;s information, given their size and complexity and the increasing amounts of information maintained on Korsana&#8217;s internal information technology systems and those of Korsana&#8217;s third-party CROs, other contractors (including sites performing Korsana&#8217;s clinical trials), third party service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by Korsana&#8217;s employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise Korsana&#8217;s system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, Korsana&#8217;s data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some actors now engage and are expected to continue to engage in cyber-attacks, including without </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Korsana, and the third parties upon which Korsana relies, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt Korsana&#8217;s systems and operations. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Korsana&#8217;s operations, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Korsana may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration, or dissemination of, or damage to, Korsana&#8217;s data or applications, or for it to be believed or reported that any of these occurred, Korsana could incur liability and reputational damage and the development and commercialization of its product candidates could be delayed. Further, Korsana&#8217;s insurance policies may not be adequate to compensate Korsana for the potential losses arising from any such disruption in, or failure or security breach of, Korsana&#8217;s systems or third-party systems where information important to Korsana&#8217;s business operations or commercial development is stored. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s remote workforce may create additional risks for its information technology systems and data because Korsana&#8217;s employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose Korsana to additional cybersecurity risks and vulnerabilities, as Korsana&#8217;s systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Korsana has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Korsana may be unable in the future to detect vulnerabilities in its information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, Korsana may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require Korsana to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana relies on third-party service providers and technologies to operate critical business systems to Process Sensitive Information in a variety of contexts. Korsana&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If its third-party service providers experience a security incident or other interruption, Korsana could experience adverse consequences. While Korsana may be entitled to damages if its third-party service providers fail to satisfy their privacy or security-related obligations to Korsana, any award may be insufficient to cover its damages, or Korsana may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and Korsana cannot guarantee that third parties&#8217; infrastructure in Korsana&#8217;s supply chain or Korsana&#8217;s third-party partners&#8217; supply chains have not been compromised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korsana (or a third party upon whom Korsana relies) experiences a security incident or is perceived to have experienced a security incident, Korsana may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on Processing Sensitive Information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in Korsana&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting Korsana&#8217;s platform, deter new customers from products, and negatively impact Korsana&#8217;s ability to grow and operate Korsana&#8217;s business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in Korsana&#8217;s contracts are sufficient to protect Korsana from liabilities, damages, or claims related to its data privacy and security obligations. Korsana cannot be sure that its insurance coverage will be adequate or sufficient to protect Korsana from or to mitigate liabilities arising out of Korsana&#8217;s privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect Korsana&#8217;s operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana, and third parties Korsana works with, are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. In addition, Korsana is and may become subject to the terms of contractual obligations related to privacy, data protection, and data security. Korsana&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by Korsana or third parties related to Korsana to comply with such laws, regulations and obligations could increase Korsana&#8217;s compliance and operational costs, expose Korsana to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on Korsana&#8217;s business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korsana fails to comply with environmental, health and safety laws and regulations, Korsana could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of Korsana&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Korsana&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, Korsana may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Korsana&#8217;s research, development, or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service (&#8220;IRS&#8221;) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect the Combined Company&#8217;s stockholders or Korsana. Korsana assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where Korsana has operations to determine the potential effect on its business and any assumptions Korsana has made about its future taxable income. Korsana cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on Korsana&#8217;s business if they were to be enacted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the United States enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside the United States. On July&#160;4, 2025, the U.S. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Congress enacted the One Big Beautiful Bill Act, which includes a provision restoring the immediate deductibility of domestic research and development expenditures. The impact of this newly enacted law on Korsana&#8217;s tax position will depend on how the provision is implemented and interpreted by the IRS and other regulatory authorities. In addition, Korsana has no assurance as to whether, when and how this provision may be subject to further amendment or repeal. Such changes, among others, may adversely affect Korsana&#8217;s effective tax rate, results of operations, and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may acquire businesses, product candidates, or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that Korsana believes will complement or augment its existing business. If Korsana acquires businesses with promising markets or technologies, Korsana may not be able to realize the benefit of acquiring such businesses if Korsana is unable to successfully integrate them with its existing operations and company culture. Korsana may encounter numerous difficulties in developing, manufacturing, and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent Korsana from realizing their expected benefits or enhancing Korsana&#8217;s business. There is no assurance that, following any such acquisition, Korsana will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on Korsana&#8217;s business and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana maintains its cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect Korsana&#8217;s ability to pay its operational expenses or make other payments. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s cash held in <span style="white-space:nowrap">non-interest-bearing</span> and interest-bearing accounts exceeds the FDIC insurance limits. If such banking institutions were to fail, Korsana could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank in March 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that Korsana may experience in the future or inability for a material time period to access Korsana&#8217;s cash and cash equivalents could have an adverse effect on Korsana&#8217;s ability to pay its operational expenses or make other payments, which could adversely affect Korsana&#8217;s business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Korsana&#8217;s Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s intellectual property portfolio is at an early stage. Therefore, its ability to obtain and protect its patent rights, and protect other proprietary rights, is uncertain, exposing it to the possible loss of competitive advantage. </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana will rely upon a combination of patents, trademarks, trade secret protection, copyrights and confidentiality agreements, licenses, and its agreements with Paragon and Paragon Laboratories to protect the intellectual property related to Korsana&#8217;s programs and technologies and to prevent third parties from competing unfairly with Korsana. Korsana&#8217;s success depends in large part on its ability to obtain and maintain patent protection for Korsana&#8217;s product candidates and their uses, as well as Korsana&#8217;s ability to operate without infringing on or violating the proprietary rights of others. If Korsana is unable to obtain patent protection with respect to <span style="white-space:nowrap">KRSA-028,</span> or any future product candidates, Korsana&#8217;s business, financial condition, results or operations and prospects could be materially harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s intellectual property portfolio is at an early stage. Korsana does not currently own any issued patents or pending patent applications. With respect to Research Program 002 (including <span style="white-space:nowrap">KRSA-028)</span> and Research Program 001, Paragon has filed provisional patent applications in the United States directed to (i)&#160;antibodies targeting A&#223; and (ii)&#160;antibodies targeting both A&#223; and TfR1, including applications covering </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
composition of matter, pharmaceutical formulations, and methods of using such antibodies, which Korsana has exclusively licensed from Paragon pursuant to the Paragon License Agreement. With respect to the THETA technology, Paragon has filed provisional patent applications in the United States directed to antibodies targeting TfR1, including applications covering composition of matter, pharmaceutical formulations, and methods for using such antibodies or compounds, such as bispecific antibodies, comprising such antibodies, which Korsana has non-exclusively licensed from Paragon pursuant to the Paragon License Agreement. Paragon, or Korsana, with respect to licensed project antibody transport vehicle patents for which Korsana has the first right, but not the obligation, to prepare, file, prosecute and maintain patent applications, intends to file one or more <span style="white-space:nowrap">non-provisional</span> patent applications claiming priority to these provisional patent applications. However, Korsana cannot provide assurances that such <span style="white-space:nowrap">non-provisional</span> patent application(s) will be filed, nor whether such <span style="white-space:nowrap">non-provisional</span> patent application(s), if filed, will issue, the breadth of any resulting issued patent(s), or whether any issued patent(s) will be found to be invalid, unenforceable, or will be challenged by third parties. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any issued patents may not afford sufficient protection of Korsana&#8217;s product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, or invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products, or product candidates. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that Korsana may license or own covering Korsana&#8217;s product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO. If Korsana does not obtain patent coverage for the work Korsana is conducting, or if Korsana obtains such rights but they are invalidated or rendered unenforceable, Korsana may be unable to exclude competitors from pursuing and marketing the same or similar product candidates. Other risks Korsana faces if it is not able to obtain and maintain patent coverage for Korsana&#8217;s product candidates are the reduction in valuation of its product candidates, and ultimately of Korsana as a company, by potential investors, and Korsana&#8217;s inability to assert claims for infringement against third parties or counterclaim against such third parties or negotiate more advantageous settlement parameters. Further, if Korsana encounters delays in its clinical trials or delays in obtaining regulatory approval, the period of time during which Korsana could market its product candidates under patent protection would be reduced. Thus, the patents that Korsana may own or license may not afford Korsana any meaningful exclusivity period or competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Korsana may not be able to obtain or protect Korsana&#8217;s intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of at least certain patents, trade secrets, or other intellectual property. Filing, prosecuting, maintaining, and defending patents on product candidates and other related inventions worldwide would be expensive and Korsana&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, Korsana may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if Korsana or its licensor files patent applications to obtain such rights. Korsana&#8217;s competitors may operate in countries where Korsana does not have patent protection and may be able to freely use its technologies and discoveries in such countries, at least to the extent not forbidden by law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of its technology and product candidates, Korsana may also rely on trade secrets, including unpatented <span style="white-space:nowrap">know-how,</span> technology, and other proprietary information, to maintain Korsana&#8217;s competitive position. Any disclosure, either intentional or unintentional, by Korsana&#8217;s employees, the employees of third parties with whom Korsana shares its facilities or third-party consultants and vendors that Korsana engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of Korsana&#8217;s trade secrets or proprietary information could enable competitors to duplicate or surpass Korsana&#8217;s technological achievements, thus eroding Korsana&#8217;s competitive position in its market. In order to protect its proprietary technology and processes, Korsana relies in part on confidentiality agreements with its collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Korsana may need to share its proprietary information, including trade secrets, with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future business partners, collaborators, contractors, and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while Korsana undertakes reasonable efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, Korsana may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of Korsana&#8217;s proprietary rights and failure to obtain or maintain trade secret protection could adversely affect Korsana&#8217;s competitive business position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, if Korsana&#8217;s trademarks and trade names are not registered or adequately protected, then Korsana may not be able to build name recognition in its markets of interest and Korsana&#8217;s business may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korsana is unable to obtain or maintain necessary rights to its programs through acquisitions and <span style="white-space:nowrap">in-licenses,</span> Korsana&#8217;s business may be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Korsana&#8217;s development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of Korsana&#8217;s business will depend in part on its ability to acquire, <span style="white-space:nowrap">in-license,</span> or use these third-party proprietary rights. Korsana may be unable to acquire or <span style="white-space:nowrap">in-license</span> any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that Korsana identifies as necessary for its programs. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that Korsana may consider attractive or necessary. These established companies may have a competitive advantage over Korsana due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Korsana to be a competitor may be unwilling to assign or license rights to Korsana. Korsana also may be unable to license or acquire third-party intellectual property rights on terms that would allow Korsana to make an appropriate return on Korsana&#8217;s investment or at all. If Korsana is unable to successfully obtain rights to required third-party intellectual property rights or maintain intellectual property rights Korsana obtains in the future, Korsana may have to abandon development of the relevant program, which could have a material adverse effect on Korsana&#8217;s business, financial condition, results of operations, and prospects. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has the right to control prosecution, defense, maintenance, and enforcement of patents exclusively <span style="white-space:nowrap">in-licensed</span> under the Paragon License Agreement. However, there may be times when rights for patents and patent applications relating to Korsana&#8217;s product candidates are controlled by Korsana&#8217;s future licensors or collaboration partners, including with respect to patents <span style="white-space:nowrap">non-exclusively</span> <span style="white-space:nowrap">in-licensed</span> under the Paragon License Agreement. If Korsana, Paragon or any of Korsana&#8217;s future licensors (including Paragon Laboratories) or collaboration partners fail to prosecute, defend, maintain and enforce such patents and patent applications in a manner consistent with Korsana&#8217;s best interests, including by payment of all applicable fees for patents covering its product candidates, Korsana could lose its rights to the intellectual property or its exclusivity with respect to those rights, Korsana&#8217;s ability to develop and commercialize those product candidates may be adversely affected and Korsana may not be able to prevent competitors from making, using and selling competing products. In addition, even if Korsana has the right to control prosecution of patents and patent applications Korsana has licensed to and from third parties, including under future license agreements with Paragon or Paragon Laboratories following the point at which such control is assumed, Korsana may still be adversely affected or prejudiced by actions or inactions of Paragon, additional licensees, or licensors and their counsel prior to the date upon which Korsana assumes control over patent prosecution. For example, Paragon is currently responsible for the prosecution, defense, maintenance, and enforcement of patents related to Research Program 003, for which Korsana has not exercised its ADOA Option or entered into a license agreement. Pursunt to the Paragon License Agreement, Korsana has the first right, but not the obligation, to prepare, file, prosecute and maintain certain licensed project antibody transport vehicle patents for Research Program 002, including KRSA-028, and Research Program 001, but Paragon retains control over patent prosecution for certain <span style="white-space:nowrap">non-exclusively</span> licensed transit antibody technology, including the THETA technology, and other Paragon-controlled patents. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s future licensors may not be the sole and exclusive owners of all rights in the patents Korsana may <span style="white-space:nowrap">in-license.</span> If other third parties have rights to Korsana&#8217;s future <span style="white-space:nowrap">in-licensed</span> patents, they may be able to license such patents to Korsana&#8217;s competitors, and Korsana&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Korsana&#8217;s competitive position, business, financial condition, results of operations, and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that Korsana may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if Korsana is able to obtain a license, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving Korsana&#8217;s competitors access to the same technologies licensed to Korsana. In that event, Korsana may be required to expend significant time and resources to redesign Korsana&#8217;s product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Korsana is unable to do so, Korsana may be unable to develop or commercialize the affected product candidates, which could harm Korsana&#8217;s business, financial condition, results of operations, and prospects significantly. Korsana cannot provide any assurances that third-party patents do not exist which might be enforced against Korsana&#8217;s product candidates, manufacturing methods or future products or methods resulting in either an injunction prohibiting Korsana&#8217;s manufacture or future sales, or, with respect to its future sales, an obligation on Korsana&#8217;s part to pay royalties and/or other forms of compensation to third parties, which could be significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise between Korsana and Korsana&#8217;s future licensors regarding intellectual property subject to a license agreement, including (but not limited to): the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which Korsana&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; Korsana&#8217;s right to sublicense patents and other rights to third parties; Korsana&#8217;s right to transfer or assign the license; the inventorship and ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by Korsana&#8217;s future licensors and Korsana and Korsana&#8217;s partners; and the priority of invention of patented technology. If Korsana or its future licensors breach the terms of Korsana&#8217;s license agreements, such breach may have a material adverse effect on Korsana&#8217;s business and the commercialization efforts for its programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may be subject to intellectual property lawsuits or may need to file lawsuits to protect Korsana&#8217;s intellectual property, which could result in substantial costs and liability and prevent Korsana from commercializing Korsana&#8217;s potential products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess Korsana&#8217;s freedom to operate and guarantee that Korsana can operate without infringing on or violating third party rights. If certain of Korsana&#8217;s product candidates are ultimately granted regulatory approval, patent rights held by third parties could be alleged to render one or more of Korsana&#8217;s product candidates infringing. If a third party successfully brings a claim against Korsana, and Korsana&#8217;s rights are not held invalid or unenforceable, Korsana may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret misappropriation) brought against Korsana, whether or not successful, may cause Korsana to incur significant legal expenses and divert the attention of Korsana&#8217;s management and key personnel from other business concerns. Korsana cannot be certain that future patents, if filed and issued, owned, or licensed by Korsana will not be challenged by others, whether in the course of litigation or in agencies like the USPTO. Some of Korsana&#8217;s competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Korsana can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Korsana&#8217;s ability to raise funds. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate Korsana&#8217;s future patents, trademarks, copyrights, or other intellectual property. To counter infringement or other violations, Korsana may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against Korsana, including claims alleging that Korsana infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents Korsana asserts is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that Korsana&#8217;s patents do not cover the technology. Similarly, if Korsana asserts trademark infringement claims, a court or administrative body may determine that the marks Korsana has asserted are invalid or unenforceable or that the party against whom Korsana has asserted trademark infringement has superior rights to the marks in question. In such a case, Korsana could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if Korsana is successful, any award of monetary damages or other remedy Korsana receives may not be commercially valuable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Korsana may be required to protect its future patents, if filed and issued, through procedures created to attack the validity of a patent at the USPTO. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Korsana&#8217;s patent rights, which could adversely affect Korsana&#8217;s competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if Korsana&#8217;s product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against Korsana&#8217;s future licensees or customers and other parties with whom Korsana has business relationships and Korsana may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require Korsana to initiate or defend protracted and costly litigation on behalf of licensees or other parties regardless of the merits of such claims. If any of these claims succeed, Korsana may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products Korsana uses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to Korsana&#8217;s intellectual property rights, there is a risk that some of Korsana&#8217;s confidential information could be compromised by disclosure during this type of litigation or other proceedings. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s success will depend in part on Korsana&#8217;s and Korsana&#8217;s current and future licensors&#8217; ability to obtain, maintain and enforce patent protection for Korsana&#8217;s licensed intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s success will depend in part on its, Paragon&#8217;s, and Korsana&#8217;s future licensors&#8217; (including Paragon Laboratories&#8217;) ability to obtain, maintain and enforce patent protection for its licensed intellectual property. Currently, pursuant to the Paragon License Agreement, Korsana has the first right, but not the obligation, to prosecute and maintain certain licensed project antibody transport vehicle patents for Research Program 002 (including KRSA-028) and Research Program 001, and Paragon controls the prosecution, maintenance, enforcement, and defense of certain other licensed patents, including licensed transit antibody patents and other Paragon-controlled patents. Korsana, Paragon and Korsana&#8217;s future licensors may not successfully prosecute the patent applications that cover its product candidates. Even if patents are issued in respect of these patent applications, Korsana, Paragon, and Korsana&#8217;s future licensors (including Paragon Laboratories) may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than Korsana would. Without protection for any <span style="white-space:nowrap">in-licensed</span> intellectual property, other companies might be able to offer substantially identical products for sale, which could adversely affect Korsana&#8217;s competitive business position and harm its business prospects. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may be subject to claims that Korsana has wrongfully hired an employee from a competitor or that Korsana&#8217;s employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology industry, in addition to Korsana&#8217;s employees, Korsana engages the services of consultants to assist Korsana in the development of Korsana&#8217;s product candidates. Many of these consultants, and many of Korsana&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including Korsana&#8217;s competitors or potential competitors. Korsana could in the future be subject to claims that Korsana or Korsana&#8217;s employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Korsana tries to ensure that its employees and consultants do not use the intellectual property, proprietary information, <span style="white-space:nowrap">know-how</span> or trade secrets of others in their work for Korsana, Korsana may become subject to claims that it caused an employee to breach the terms of his or her <span style="white-space:nowrap">non-competition</span> or <span style="white-space:nowrap">non-solicitation</span> agreement, or that Korsana or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Korsana may litigate to defend against these claims, even if Korsana is successful, litigation could result in substantial costs and could be a distraction to management and other employees. If Korsana&#8217;s defenses to these claims fail, in addition to requiring Korsana to pay monetary damages, a court could prohibit Korsana from using technologies or features that are essential to Korsana&#8217;s product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Korsana&#8217;s reputation, its ability to form strategic alliances or sublicense Korsana&#8217;s rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Korsana&#8217;s business, results of operations and financial condition. Even if Korsana is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing Korsana&#8217;s ability to protect its products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of Korsana&#8217;s owned and <span style="white-space:nowrap">in-licensed</span> patent applications and the maintenance, enforcement, or defense of Korsana&#8217;s owned and <span style="white-space:nowrap">in-licensed</span> issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation increased the uncertainties and costs surrounding the prosecution of Korsana&#8217;s patent applications and the enforcement or defense of Korsana&#8217;s issued patents, all of which could have a material adverse effect on Korsana&#8217;s business, financial condition, results of operations, and prospects. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact Korsana&#8217;s ability to enforce its proprietary technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in <span style="font-style:italic">Amgen, Inc. v. Sanofi</span> (&#8220;<span style="font-style:italic">Amgen</span>&#8221;) recently held that Amgen&#8217;s patent claims to a class of antibodies </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided 26 exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that Korsana will be granted U.S. patents with composition of matter claims as broad as Amgen&#8217;s directed to antibodies functionally defined by their ability to bind a particular antigen. Even if Korsana is granted claims directed to functionally defined antibodies, it is possible that a third party may challenge Korsana&#8217;s patents, when issued, relying on the reasoning in <span style="font-style:italic">Amgen</span> or other precedential court decisions. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Korsana&#8217;s patent rights and its ability to protect, defend and enforce its patent rights in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the U.S. Supreme Court&#8217;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. Korsana cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. Geopolitical instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement, or defense of issued patents. In addition, the Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Korsana does not currently own or license any European patents or applications, if Korsana obtains or licenses such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on Korsana&#8217;s business and its ability to commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time and may adversely affect Korsana&#8217;s ability to enforce or defend the validity of any European patents Korsana may obtain. Korsana may decide to opt out from the UPC any future European patent applications that Korsana may file and any patents Korsana may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for <span style="white-space:nowrap">non-compliance</span> and brought under the jurisdiction of the UPC. Korsana cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Korsana decides to opt out of the UPC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment, and other requirements imposed by governmental patent agencies, and Korsana&#8217;s patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. If Korsana fails to maintain any future patents and patent applications, if filed and issued, covering Korsana&#8217;s product candidates, its competitive position would be adversely affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect Korsana&#8217;s ability to develop and market its products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana cannot guarantee that any of Korsana&#8217;s patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Korsana be certain that it has identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of Korsana&#8217;s product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent, the patent&#8217;s prosecution history and in some cases certain extrinsic evidence of the meaning of terms in a claim. Korsana&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Korsana may incorrectly determine that its products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Korsana&#8217;s determination of the expiration date of any patent in the United States or abroad that Korsana considers relevant may be incorrect. Korsana&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, Korsana cannot be certain that others have not filed patent applications for technology covered by Korsana&#8217;s future issued patents or its pending applications, if filed, or that Korsana is the first to invent the technology. Korsana&#8217;s competitors may have filed, and may in the future file, patent applications covering Korsana&#8217;s products or technology similar to Korsana&#8217;s. Any such patent application may have priority over Korsana&#8217;s future patent applications or patents, if filed and issued, which could require Korsana to obtain rights to issued patents covering such technologies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may become subject to claims challenging the inventorship or ownership of Korsana&#8217;s patents, if issued, and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may be subject to claims that former employees, collaborators or other third parties have an interest in Korsana&#8217;s future patents, if filed and issued, or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being invalid or unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Korsana&#8217;s programs or as a result of questions regarding <span style="white-space:nowrap">co-ownership</span> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, Korsana may enter into agreements to clarify the scope of Korsana&#8217;s rights in such intellectual property. If Korsana fails in defending any such claims, in addition to paying monetary damages, Korsana may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Korsana&#8217;s business. Even if Korsana is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that Korsana&#8217;s licensors are not the sole and exclusive owners of the patents Korsana <span style="white-space:nowrap">in-licensed.</span> If other third parties have ownership rights or other rights to Korsana&#8217;s <span style="white-space:nowrap">in-licensed</span> patents, they may be able to license such patents to Korsana&#8217;s competitors, and its competitors could market competing products and technology. This could have a material adverse effect on Korsana&#8217;s competitive position, business, financial condition, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect Korsana&#8217;s competitive position of its product candidates for an adequate amount of time. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from Korsana&#8217;s earliest U.S. <span style="white-space:nowrap">non-provisional</span> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Korsana&#8217;s product candidates are obtained, once the patent life has expired, Korsana may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, Korsana&#8217;s owned and licensed patent portfolio may not provide Korsana with sufficient rights to exclude others from commercializing products similar or identical to Korsana&#8217;s. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s technology licensed from various third parties may be subject to retained rights. </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s future licensors may retain certain rights under the relevant agreements with Korsana, including the right to use or license the licensed technology outside of the scope of Korsana&#8217;s license, use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Korsana&#8217;s licensors limit their use of the technology to these uses, and Korsana could incur substantial expenses to enforce its rights to its licensed technology in the event of misuse. In addition, while there are certain restrictions on Paragon&#8217;s ability to develop products that could be competitive with Korsana&#8217;s as more fully described in &#8220;<span style="font-style:italic">Korsana&#8217;s Business </span>&#8212;<span style="font-style:italic"> Paragon Agreements</span>&#8221; beginning on page&#160;312 of this proxy statement/prospectus, these restrictions may not prevent the possible future license or development by Paragon of certain technology that could lead to product candidates competitive with Korsana&#8217;s. This could have a material adverse effect on Korsana&#8217;s competitive position, business, financial condition, results of operations, and prospects. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. If Korsana is not able to obtain, or if there are delays in obtaining, required regulatory approvals for Korsana&#8217;s product candidates, Korsana will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive, and typically takes many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Korsana cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, Korsana cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Korsana&#8217;s product candidates, including <span style="white-space:nowrap">KRSA-028,</span> Korsana must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials that its product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Korsana&#8217;s product candidates may not be effective, may be only moderately effective, may prove to have undesirable or unintended side effects, toxicities, or other characteristics, or may fail to improve on the applicable standard of care, any of which may preclude Korsana from obtaining regulatory approval. The FDA and comparable foreign regulatory authorities have discretion in the approval process and may refuse to accept any application or may decide that Korsana&#8217;s data is insufficient for approval and require additional preclinical, clinical, or other data. Korsana&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Korsana&#8217;s clinical trials; Korsana may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for Korsana&#8217;s proposed indication; the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by participants in Korsana&#8217;s clinical trials or by individuals using drugs similar to its product candidates; Korsana may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh Korsana&#8217;s safety risks; the FDA or comparable foreign regulatory authorities may disagree with Korsana&#8217;s interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of Korsana&#8217;s product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and Korsana may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Korsana&#8217;s product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which Korsana contracts for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Korsana&#8217;s clinical data insufficient for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the FDA or applicable foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Korsana failing to obtain regulatory approval to market Korsana&#8217;s product candidates, which would significantly harm Korsana&#8217;s business, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korsana was to obtain approval, regulatory authorities may approve any of Korsana&#8217;s product candidates for fewer or more limited indications than Korsana requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If Korsana is not able to obtain, or if there are delays in obtaining, required regulatory approvals for Korsana&#8217;s product candidates, Korsana will not be able to commercialize, or will be delayed in commercializing, this could have a material adverse effect on Korsana&#8217;s competitive position, business, financial condition, results of operations, and prospects. In addition, the FDA and foreign regulatory authorities may undergo leadership changes, change their policies, issue additional regulations, or revise existing regulations, or take other actions, such as those implemented by the Department of Government Efficiency, which may impact Korsana&#8217;s clinical development plans or prevent or delay approval of Korsana&#8217;s product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon Korsana that could delay Korsana&#8217;s ability to obtain approvals and increase the costs of compliance. Since the start of President Trump&#8217;s administration in 2025, U.S. policy changes have been implemented at a rapid pace and additional changes are likely. It is difficult to predict how executive actions that may be taken under the current administration may affect the FDA&#8217;s ability to exercise its regulatory authority. If any actions impose constraints on the FDA&#8217;s ability to engage in routine oversight and product review activities in the normal course, Korsana&#8217;s business may be negatively impacted. Additionally, federal government could adopt legislation, regulations or policies that adversely affect Korsana&#8217;s business or create a more challenging and costly environment to pursue the development, approval, and commercialization of Korsana&#8217;s product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may not be able to meet requirements for the chemistry, manufacturing, and control of Korsana&#8217;s product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to receive approval of Korsana&#8217;s products by the FDA and comparable foreign regulatory authorities, Korsana must show that it and Korsana&#8217;s contract manufacturing partners are able to characterize, control and manufacture Korsana&#8217;s drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that Korsana&#8217;s drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Korsana is not able to meet the chemistry, manufacturing, and control requirements, Korsana may not be successful in getting Korsana&#8217;s products approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s product candidates for which Korsana intends to seek approval as biologics may face competition from biosimilars sooner than anticipated. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <span style="white-space:nowrap">FDA-licensed</span> reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes that any of Korsana&#8217;s product candidates approved as biologics under a BLA should qualify for the <span style="white-space:nowrap">12-year</span> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider Korsana&#8217;s product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for <span style="white-space:nowrap">non-biological</span> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if Korsana receives regulatory approval of Korsana&#8217;s product candidates, Korsana will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and Korsana may be subject to penalties if it fails to comply with regulatory requirements or experience unanticipated problems with its product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that Korsana may receive for Korsana&#8217;s product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions, or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve Korsana&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Comparable foreign regulatory authorities may impose similar requirements. In addition, if the FDA or comparable foreign regulatory authorities approve Korsana&#8217;s product candidates, Korsana&#8217;s product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as <span style="white-space:nowrap">on-going</span> compliance with cGMPs and GCPs for any clinical trials that Korsana conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs. If Korsana or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or Korsana, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, delays or restrictions on Korsana&#8217;s ability to conduct clinical trials or delays or refusal to grant a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing authorization, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, suspension, withdrawal or variation of any marketing authorization that has been granted, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. Similar penalties may apply in case of failure by Korsana or by any of Korsana&#8217;s third-party partners, including suppliers, manufacturers and distributors, to comply with FDA and EU laws and the related national laws of individual EU Member States and other applicable regulatory authorities governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of a marketing authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements, including administrative, civil or criminal penalties. The occurrence of any event or penalty described above may inhibit Korsana&#8217;s ability to commercialize its product candidates and generate revenue and could require Korsana to expend significant time and resources in response and could generate negative publicity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Disruptions at the FDA, the SEC and other government agencies and regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of Korsana&#8217;s business may rely, which could negatively impact its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review regulatory filings and Korsana&#8217;s ability to commence human clinical trials can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC, and other government agencies on which Korsana&#8217;s operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies or comparable foreign regulatory authorities may also slow the time necessary for the review and approval of applications for clinical trial or marketing authorization, which would adversely affect Korsana&#8217;s business. For example, in recent years, including in 2018, 2019 and 2025, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Additionally, action by the Trump administration to limit federal agency budgets or personnel may result in reductions to the FDA&#8217;s budget, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting Korsana&#8217;s ability to progress development of its product candidates or obtain regulatory approval for its product candidates. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process Korsana&#8217;s regulatory submissions, which could have a material adverse effect on its business. Further, future government shutdowns could impact Korsana&#8217;s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue Korsana&#8217;s operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process Korsana&#8217;s regulatory submissions, which could have a material adverse effect on Korsana&#8217;s business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may face difficulties from healthcare and regulatory legislative reform measures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of Korsana&#8217;s product candidates. Korsana cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, the Trump administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription drugs. If </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Korsana is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Korsana is not able to maintain regulatory compliance, Korsana may lose any regulatory approval that it may have obtained and it may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose Korsana to penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers may expose Korsana to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Korsana conducts its operations, including how it researches, markets, sells and distributes its product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that Korsana&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If Korsana&#8217;s operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to Korsana, it may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Korsana&#8217;s operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if Korsana is successful in defending against any such actions that may be brought against it, Korsana&#8217;s business may be impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if Korsana is able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, Korsana may not be able to offer such product candidates at competitive prices, which would seriously harm Korsana&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana intends to seek approval to market Korsana&#8217;s product candidates in both the United States and in selected foreign jurisdictions. If Korsana obtains approval in one or more foreign jurisdictions for Korsana&#8217;s product candidates, Korsana will be subject to rules and regulations in those jurisdictions. Korsana&#8217;s ability to successfully commercialize any product candidates that Korsana may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over Korsana&#8217;s products in an attempt to reduce their costs, which may reduce Korsana&#8217;s commercial opportunity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Korsana can face criminal liability and other serious consequences for violations, which can harm Korsana&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which Korsana conducts activities. Governmental regulation of the import or export of Korsana&#8217;s drug candidates, or Korsana&#8217;s failure to obtain any required import or export authorization for its candidates, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when applicable, could harm international operations. Furthermore, export control laws and economic sanctions prohibit the provision of certain items, technology, and services to countries, governments, and persons targeted by sanctions programs. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. Korsana may engage third parties to sell Korsana&#8217;s products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. Korsana has direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. Korsana can be held liable for the corrupt or other illegal activities of Korsana&#8217;s employees, agents, contractors, and other collaborators, even if Korsana does not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Governments outside the United States tend to impose strict price controls, which may adversely affect Korsana&#8217;s revenue, if any. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some countries, particularly EU Member States, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between <span style="white-space:nowrap">low-priced</span> and high-priced EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, Korsana or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of Korsana&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Korsana&#8217;s business, financial condition, results of operations, or prospects could be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If Korsana seeks and is unable to obtain accelerated approval, the amount, size, and duration of Korsana&#8217;s clinical trials could be greater than planned, which could increase the expense, reduce the likelihood, and/or delay the timing of obtaining necessary regulatory approvals. Even if Korsana receives accelerated approval, if confirmatory trials do not verify clinical benefit, or if Korsana does not comply with rigorous post-approval requirements, such authorities may withdraw accelerated approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may seek accelerated approval, or other expedited development, review, or approval status, for Korsana&#8217;s product candidates. Even if granted, there is no guarantee that receiving an expedited development, review or approval status from the FDA will lead to a faster development or regulatory review or approval process, and such status does not increase the likelihood that Korsana&#8217;s product candidates will ultimately receive marketing approval. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. If Korsana chooses to pursue accelerated approval, there can be no assurance that the FDA will agree that Korsana&#8217;s proposed primary endpoint is an appropriate surrogate endpoint. Similarly, there can be no assurance that after subsequent FDA feedback that Korsana will continue to pursue accelerated approval or any other form of expedited development, review, or approval, even if Korsana initially decides to do so. Furthermore, if Korsana submits an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require Korsana to conduct further studies or trials prior to considering Korsana&#8217;s application or granting approval of any type. Korsana might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval might not be granted because Korsana&#8217;s submission is deemed incomplete by the FDA. Accelerated approval may be contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s predicted effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA may require that any such confirmatory study be initiated or substantially underway prior to the submission of an application for accelerated approval. Even if Korsana receives accelerated approval from the FDA, Korsana will be subject to rigorous post-approval requirements, including submission to the FDA of all promotional materials prior to their dissemination. The FDA could withdraw accelerated approval for multiple reasons, including Korsana&#8217;s failure to conduct any required post-approval study with due diligence, or the inability of such study to confirm the drug&#8217;s predicted clinical benefit relative to its risks. A failure to obtain accelerated approval or any other form of expedited review or approval for a product candidate could result in a longer time period prior to commercializing such product candidate, increase the cost of development of such product candidate, and harm Korsana&#8217;s competitive position in the marketplace. Comparable considerations apply outside of the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana may become exposed to costly and damaging liability claims, when testing a product candidate in the clinical stage or at the commercial stage, and Korsana&#8217;s product liability insurance may not cover all damages from such claims. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While Korsana currently has no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose Korsana to liability claims. These claims may be made by patients that use the product or product candidate, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against Korsana, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for Korsana&#8217;s products or any prospects for commercialization of Korsana&#8217;s products. Although Korsana intends to obtain product liability insurance for Korsana&#8217;s future clinical trials, it is possible that its liabilities could exceed Korsana&#8217;s insurance coverage or that in the future Korsana may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against Korsana for uninsured liabilities or in excess of insured liabilities, Korsana&#8217;s assets may not be sufficient to cover such claims and Korsana&#8217;s business operations could be impaired. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Litigation costs and the outcome of litigation could have a material adverse effect on Korsana&#8217;s business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Korsana may be subject to litigation claims through the ordinary course of Korsana&#8217;s business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal information, contractual relations with collaborators and licensors and intellectual property rights. Litigation to defend Korsana against claims by third parties, or to enforce any rights that Korsana may have against third parties, could result in substantial costs and diversion of Korsana&#8217;s resources, causing a material adverse effect on Korsana&#8217;s business, financial condition, results of operations, or cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s business could be adversely affected by economic downturns, inflation, fluctuating interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on Korsana&#8217;s results of operations and financial condition. </span></p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, fluctuating interest rates, and uncertainty about economic stability. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs imposed by the U.S. government and potential retaliatory measures by foreign governments and other barriers to trade, especially in light of recent comments and executive orders made by the Trump administration, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), government shutdowns, tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, Korsana and its business partners and suppliers. For example, the <span style="white-space:nowrap">COVID-19</span> pandemic resulted in widespread unemployment, economic slowdown, and extreme volatility in the capital markets. In addition, the U.S. has imposed and taken action to pause, resume or adjust tariffs on imports from a number of countries. Since February 2025, the United States government has imposed various tariffs on imports from most countries, including tariffs on imports from China and South Korea. In September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity. It is not yet clear whether these tariffs would apply to the importation of active pharmaceutical ingredients and possibly bulk drug products that are intended for use in clinical trials and not for commercial sale, which could increase the costs of materials for Korsana&#8217;s clinical trials. There still remains substantial uncertainty about the duration of existing tariffs and whether additional tariffs may be imposed, modified, or suspended. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Uncertainty and political tensions as a result of trade policies could reduce trade volume, investment, technological exchange, and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. The Federal Reserve has raised interest rates multiple times in recent years in response to concerns about inflation and it may raise them again. High interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect Korsana&#8217;s business or the third parties on whom Korsana relies. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect Korsana by increasing its costs, including labor and employee benefit costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on Korsana&#8217;s results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Cayman Redomestication </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Currently, Cyclerion is governed by Massachusetts law, Cyclerion Articles and Cyclerion Bylaws, but upon effectiveness of the Cayman Redomestication the Combined Company will be governed by Cayman Islands law and the Cayman Articles, provisions of which have anti-takeover implications. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Upon effectiveness of the Cayman Redomestication, the Combined Company&#8217;s organizational documents will change and the Combined Company and its organizational documents will be governed by Cayman Islands law rather than Massachusetts law. Provisions that will be included in the Cayman Articles may discourage, delay, or prevent a merger, acquisition, or other change in control of the Combined Company that shareholders may consider favorable, including transactions in which its ordinary shareholders might otherwise receive a premium price for their ordinary shares. These provisions could also limit the price that investors might </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be willing to pay in the future for the Combined Company&#8217;s ordinary shares, thereby depressing the market price of its ordinary shares. In addition, because the Combined Company board of directors will be responsible for appointing the members of the Combined Company management team, these provisions may frustrate or prevent any attempts by the Combined Company shareholders to replace or remove its current management by making it more difficult for shareholders to replace members of the Combined Company board of directors. Among other things, these provisions will: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">introduce the use of a classified board of directors such that not all members of the Combined Company board of directors are elected at one time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow the authorized number of the Combined Company directors to be changed only by resolution of its board of directors, subject to the terms of the Cayman Series B Certificate of Designation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit the manner in which shareholders can remove directors from the Combined Company&#8217;s board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide for advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at shareholder meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit who may call a general meeting of shareholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize the Combined Company board of directors to issue preferred shares without shareholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the share ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Combined Company board of directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require a special resolution passed by the affirmative vote of not less than <span style="white-space:nowrap">two-thirds</span> of the votes cast at a general meeting of the Combined Company will be required to amend provisions of the Cayman Articles. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon effectiveness of the Cayman Redomestication, the Cayman Series B Certificate of Designation (as defined below) relating to the Cayman Series B Preferred Shares (as defined below) may delay or prevent a change in control of the Combined Company. At any time while at least 30% of the originally issued Cayman Series B Preferred Shares remain issued and outstanding, the Combined Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Shares, (i)&#160;consummate (x) any Fundamental Transaction (as defined in the Cayman Series B Certificate of Designation) or (y)&#160;any merger or consolidation of the Combined Company with or into another entity or any stock sale to, or other business combination in which the Combined Company shareholders immediately before such transaction do not hold at least a majority of the Combined Company&#8217;s capital stock immediately after such transaction, (ii)&#160;increase the size of the Combined Company board of directors, (iii)&#160;adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless such adoption, amendment or repeal has been approved by the unanimous vote of the Combined Company board of directors, or (iv)&#160;retain or replace the Combined Company&#8217;s registered independent public accounting firm, independent compensation consultant or corporate counsel. This provision of the Cayman Series B Certificate of Designation may make it more difficult for the Combined Company to enter into any of the aforementioned transactions, even potential change of control transactions that could offer a premium over the market value of the Combined Company to the ordinary shareholders, as it would require the separate consent of the majority of the issued and outstanding Cayman Series B Preferred Shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because the Cayman Articles designate the courts of the Cayman Islands as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by the Combined Company&#8217;s shareholders, this could limit your ability to obtain a favorable judicial forum for disputes with the Combined Company or its directors, officers, or other employees. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Articles will provide that unless the Combined Company consents in writing to the selection of an alternative forum, the courts of the Cayman Islands shall have exclusive jurisdiction over any claim or dispute </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arising out of or in connection with the Cayman Articles or otherwise related in any way to each shareholder&#8217;s shareholding in the Combined Company, including but not limited to (i)&#160;any derivative action or proceeding brought on behalf of the Combined Company, (ii)&#160;any action asserting a claim of breach of any fiduciary or other duty owed by any of the Combined Company&#8217;s current or former director, officer or other employee to the Combined Company or its shareholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Act or the Cayman Articles, or (iv)&#160;any action asserting a claim against the Combined Company governed by the internal affairs doctrine (as such concept is recognized under the laws of the United States of America) and that each shareholder irrevocably submits to the exclusive jurisdiction of the courts of the Cayman Islands over all such claims or disputes. The forum selection provision in Cayman Articles will not apply to actions or suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or any claim for which the federal district courts of the United States of America are, as a matter of the laws of the United States of America, the sole and exclusive forum for determination of such a claim. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Articles will also provide that, without prejudice to any other rights or remedies that the Combined Company may have, each of the Combined Company&#8217;s shareholders acknowledges that damages alone would not be an adequate remedy for any breach of the selection of the courts of the Cayman Islands as exclusive forum and that accordingly the Combined Company shall be entitled, without proof of special damages, to the remedies of injunction, specific performance or other equitable relief for any threatened or actual breach of the selection of the courts of the Cayman Islands as exclusive forum. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This choice of forum provision may increase a shareholder&#8217;s cost and limit the shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Combined Company or its directors, officers, or other employees, which may discourage lawsuits against the Combined Company and its directors, officers, and other employees. Any person or entity purchasing or otherwise acquiring any of the Combined Company&#8217;s shares or other securities, whether by transfer, sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; memorandum and articles of association or other charter documents has been challenged in legal proceedings. It is possible that a court could find this type of provisions to be inapplicable or unenforceable, and if a court were to find this provision in the Cayman Articles to be inapplicable or unenforceable in an action, the Combined Company may incur additional costs associated with resolving the dispute in other jurisdictions, which could have adverse effect on the Combined Company&#8217;s business and financial performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Combined Company </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If any of the events described in &#8220;Risks Related to Cyclerion&#8221; or &#8220;Risks Related to Korsana&#8221; occur, those events could cause potential benefits of the Merger not to be realized. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the Merger, the Combined Company will be susceptible to many of the risks described in the sections herein entitled &#8220;<span style="font-style:italic">Risks Related to Cyclerion</span>&#8221; and &#8220;<span style="font-style:italic">Risks Related to Korsana</span>.&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the Combined Company could be adversely affected in a material way. This could cause the market price of the Combined Company common stock to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of the Combined Company common stock is expected to be volatile, and the market price of the common stock may drop following the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of the Combined Company common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the Combined Company common stock to fluctuate include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of clinical trials and preclinical studies of the Combined Company&#8217;s product candidates, or those of the Combined Company&#8217;s competitors or the Combined Company&#8217;s existing or future collaborators; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed financial and development projections the Combined Company may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed the financial and development projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the Combined Company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the Combined Company or its competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actions taken by regulatory agencies with respect to the Combined Company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the Combined Company&#8217;s ability to obtain patent protection for its technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits, including patent or shareholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if securities or industry analysts do not publish research or reports about the Combined Company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of securities by the Combined Company or its securityholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the Combined Company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of the Combined Company common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships, or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the introduction of technological innovations or new therapies that compete with the products and services of the Combined Company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> fluctuations in the Combined Company&#8217;s financial results. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the Combined Company common stock. In addition, a recession, depression, or other sustained adverse market event could materially and adversely affect the Combined Company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the Combined Company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the Combined Company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition, and cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Combined Company may incur losses for the foreseeable future and may never achieve profitability. </span></p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The Combined Company will need to successfully complete significant research, development, testing, and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several years. Even if the Combined Company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the Combined Company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The Combined Company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the Combined Company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or <span style="white-space:nowrap">in-licensing</span> or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the Combined Company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The Combined Company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company will require substantial additional funds to conduct the costly and time-consuming clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of <span style="white-space:nowrap">KRSA-028</span> and Korsana&#8217;s future programs and future product candidates. The Combined Company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the Combined Company shareholders&#8217; ownership interests or inhibit the Combined Company&#8217;s ability to achieve its business objectives. If the Combined Company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of its common shareholders. In addition, any debt financing may subject the Combined Company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If the Combined Company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances, or licensing arrangements with third parties, the Combined Company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams, or research programs or grant licenses on terms that may not be favorable to it. Even if the Combined Company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the Combined Company or its shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Combined Company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company will incur significant legal, accounting, and other expenses as a public company that Korsana did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The Combined Company&#8217;s management team will consist of the executive officers of Korsana prior to the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the Combined Company complies with all of these requirements. Any changes the Combined Company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the Combined Company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Upon completion of the Merger, failure by the Combined Company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Merger, Cyclerion, under the new name &#8220;Korsana Biosciences, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, Cyclerion agreed to use its commercially reasonable efforts to cause the shares of Cyclerion Common Stock being issued in the Merger (including any common stock issuable upon conversion of the Cyclerion Series B Preferred Stock) to be approved for listing on Nasdaq at or prior to the First Effective Time. Based on information currently available to Cyclerion, Cyclerion anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the closing of the Merger unless it effects a reverse stock split. The Cyclerion Board intends to effect a reverse stock split of the shares of Cyclerion Common Stock at a ratio of between &#8195;&#8195;&#8195;&#8195;to &#8195;&#8195;&#8195;&#8195;. In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the Combined Company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the Combined Company that its shares of common stock will not be listed on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a potential delisting from Nasdaq, if the Combined Company common stock is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-</span></span> counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the Combined Company common stock; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the Combined Company common stock. Also, it may be difficult for the Combined Company to raise additional capital if the Combined Company common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the Combined Company common stock and could have a material adverse effect on the Combined Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the Combined Company will be subject to additional laws and regulations affecting public companies that will increase the Combined Company&#8217;s costs and the demands on management and could harm the Combined Company&#8217;s operating results and cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that the Combined Company file with the SEC, annual, quarterly, and current reports with respect to the Combined Company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule <span style="white-space:nowrap">12b-2</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Exchange Act, in at least the near term, the Combined Company may take advantage of exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the Combined Company&#8217;s periodic reports and proxy statements. Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the Combined Company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting, and other expenses to do so. If the Combined Company is not able to comply with the requirements in a timely manner or at all, the Combined Company&#8217;s financial condition or the market price of the Combined Company common stock may be harmed. For example, if the Combined Company or its independent auditor identifies deficiencies in the Combined Company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the Combined Company could face additional costs to remedy those deficiencies, the market price of the Combined Company stock could decline or the Combined Company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the Combined Company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided the Combined Company continues to be listed on Nasdaq, the Combined Company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that the Combined Company maintain effective disclosure controls and procedures and internal control over financial reporting. The Combined Company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form <span style="white-space:nowrap">10-K</span> filing for that year, as required by Section&#160;404 of the Sarbanes- Oxley Act. As a private company, Korsana has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the Combined Company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The Combined Company may experience difficulty in meeting these reporting requirements in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company may discover weaknesses in its system of internal control over financial reporting that could result in a material misstatement of its financial statements. The Combined Company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Combined Company is not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the Combined Company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The unaudited pro forma condensed combined financial information for Cyclerion and Korsana included in this proxy statement/prospectus are preliminary, and the Combined Company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma financial information for Cyclerion and Korsana included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the Combined Company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results of operations that would have been realized had the entities been combined during the period presented. The Combined Company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The Exchange Ratio reflected in this proxy statement/prospectus is preliminary. The final Exchange Ratio could differ materially from the preliminary Exchange Ratio used to prepare the pro forma adjustments. For more information see the section titled &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; beginning on page 392. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions that will be in the Combined Company&#8217;s articles of organization and bylaws and provisions under Massachusetts law could make an acquisition of the Combined Company more difficult and may prevent attempts by its shareholders to replace or remove its management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions that will be included in the Combined Company&#8217;s articles of organization and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of the Combined Company that shareholders may consider favorable, including transactions in which its common shareholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the Combined Company common stock, thereby depressing the market price of its common stock. In addition, because the Combined Company board of directors will be responsible for appointing the members of the Combined Company management team, these provisions may frustrate or prevent any attempts by the Combined Company shareholders to replace or remove its current management by making it more difficult for shareholders to replace members of the Combined Company board of directors. Among other things, these provisions will: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow the authorized number of the Combined Company directors to be changed only by resolution of its board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit the manner in which shareholders can remove directors from the Combined Company&#8217;s board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide for advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at shareholder meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require that shareholder actions must be effected at a duly called shareholder meeting or by the unanimous written consent of all shareholders in lieu of such a meeting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limit who may call a special meeting of shareholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize the Combined Company board of directors to issue preferred stock without shareholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Combined Company board of directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require the approval of the holders of at least a majority of the votes that all Combined Company shareholders would be entitled to cast to amend or repeal certain provisions of the Combined Company&#8217;s articles of organization or bylaws. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the provisions of the Cyclerion Articles, as amended, relating to the Combined Company&#8217;s Series B Preferred Stock may delay or prevent a change in control of the Combined Company. At any time while at least 30% of the originally issued Series B Preferred Stock remains issued and outstanding, the Combined Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (i)&#160;consummate (x) any Fundamental Transaction (as defined in the Cyclerion Articles, as amended) or (y)&#160;any merger or consolidation of the Combined Company with or into another entity or any stock sale to, or other business combination in which the Combined Company shareholders immediately before such transaction do not hold at least a majority of the Combined Company&#8217;s capital stock immediately after such transaction, (ii)&#160;increase the size of the Combined Company board of directors, (iii)&#160;adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unless such adoption, amendment or repeal has been approved by the unanimous vote of the Combined Company board of directors, or (iv)&#160;retain or replace the Combined Company&#8217;s registered independent public accounting firm, independent compensation consultant or corporate counsel. This provision of the Series B Certificate of Designation may make it more difficult for the Combined Company to enter into any of the aforementioned transactions, even potential change of control transactions that could offer a premium over the market value of the Combined Company to the common shareholders, as it would require the separate consent of the majority of the holders of the Series B Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Proposal No.&#160;4 is approved by Cyclerion shareholders and the Merger is completed, the Combined Company will effect the Cayman Redomestication pursuant to the Plan of Domestication as set forth in the form attached as <span style="font-style:italic">Annex J </span>to this proxy statement/prospectus, and, upon completion of the Cayman Redomestication, the rights of Cyclerion shareholders and the rights of Korsana stockholders who become the Combined Company shareholders pursuant to the Merger will no longer be governed by the Cyclerion Articles, Cyclerion Bylaws and the MBCA, and instead will be governed by the Cayman Articles, in the form attached as <span style="font-style:italic">Annex K </span>to this proxy statement/prospectus, and the Cayman Islands Companies Act. See &#8220;<span style="font-style:italic">Risks Related to the Cayman Redomestication &#8212; Currently, Cyclerion is governed by Massachusetts, Cyclerion Articles and Cyclerion</span> <span style="font-style:italic">Bylaws, but upon effectiveness of the Cayman Redomestication the Combined Company will be governed by Cayman Islands law and the Cayman Articles, provisions of which have anti-takeover implications</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The articles of organization, as amended, of the Combined Company will provide that, unless the Combined Company consents in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between Combined Company and its shareholders, which could limit its shareholders&#8217; ability to obtain a favorable judicial forum for disputes with the Combined Company or its directors, officers, employees, or shareholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The articles of organization, as amended, of the Combined Company will provide that, unless the Combined Company consents in writing to the selection of an alternative forum, a state or federal court located within the Commonwealth of Massachusetts shall be the sole and exclusive forum for (a)&#160;any derivative action or proceeding brought on behalf of the Combined Company, (b)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Combined Company to the Combined Company or the Combined Company&#8217;s shareholders, (c)&#160;any action asserting a claim arising pursuant to any provision of the MBCA or any successor statute, or (d)&#160;any action asserting a claim governed by the internal affairs doctrine, in all cases subject to the court having personal jurisdiction over the indispensable parties named as defendants, which for purposes of this risk factor refers to herein as the &#8220;Massachusetts Forum Provision.&#8221; The Massachusetts Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange Act. In addition, the articles of organization, as amended, of the Combined Company will provide that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing Massachusetts Forum Provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Massachusetts Forum Provision may impose additional costs on shareholders of the Combined Company in pursuing any such claims, particularly if the shareholders do not reside in or near the Commonwealth of Massachusetts or were permitted to select another jurisdiction. Additionally, the forum selection clauses in the articles of organization, as amended, of the Combined Company may limit its shareholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with the Combined Company or its directors, officers, employees, or shareholders, which may discourage such lawsuits against the Combined Company and its directors, officers, employees, and shareholders even though an action, if successful, might benefit its shareholders. Alternatively, if a court were to find the Massachusetts Forum Provision contained in the Combined Company&#8217;s articles of organization, as amended, to be inapplicable or unenforceable in an action, the Combined Company may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect its business, financial condition, and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Proposal No.&#160;4 is approved by Cyclerion shareholders and the Merger is completed, the Combined Company will effect the Cayman Redomestication pursuant to the Plan of Domestication as set forth in the form </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attached as <span style="font-style:italic">Annex J</span> to this proxy statement/prospectus, and, upon completion of the Cayman Redomestication, the rights of Cyclerion shareholders and the rights of Korsana stockholders who become the Combined Company shareholders pursuant to the Merger will no longer be governed by the Cyclerion Articles, Cyclerion Bylaws and the MBCA, and instead will be governed by the Cayman Articles, in the form attached as <span style="font-style:italic">Annex K</span> to this proxy statement/prospectus, and the Cayman Islands Companies Act. See &#8220;<span style="font-style:italic">Risks Related to the Cayman Redomestication &#8212; Because the Cayman Articles designate the courts of the Cayman Islands as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by the Combined Company&#8217;s shareholders, this could limit your ability to obtain a favorable judicial forum for disputes with the Combined Company or its directors, officers or other employees.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion and Korsana do not anticipate that the Combined Company will pay any cash dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current expectation is that the Combined Company will retain its future earnings, if any, to fund the growth of the Combined Company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the Combined Company common stock will be your sole source of gain, if any, for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">An active trading market for the Combined Company common stock may not develop and its shareholders may not be able to resell their shares of common stock for a profit, if at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, there had been no public market for shares of Korsana capital stock. An active trading market for the Combined Company shares of common stock may never develop or be sustained. If an active market for the Combined Company common stock does not develop or is not sustained, it may be difficult for the Combined Company shareholders to sell their shares at an attractive price or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of shares by existing shareholders could cause the Combined Company stock price to decline. </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If existing securityholders of Cyclerion and Korsana sell, or indicate an intention to sell, substantial amounts of the Combined Company common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the Combined Company could decline. Based on shares outstanding as of March&#160;31, 2026 for Cyclerion and Korsana, after giving effect to the estimated Exchange Ratio and the shares of Korsana Common Stock to be issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the anticipated Cyclerion Reverse Stock Split, the Combined Company is expected to have outstanding a total of approximately 206.8&#160;million shares of common stock immediately following the completion of the Merger (or approximately 293.7&#160;million shares of common stock after giving effect to the conversion of the Cyclerion Series B Preferred Stock and the exercise of Cyclerion Pre-Funded Warrants). Approximately 164.4&#160;million shares (or approximately 179.9&#160;million, if certain Korsana Pre-Funded Warrants are exercised) will be freely tradeable upon completion of the Merger, and an additional approximately 42.4&#160;million shares (or approximately 113.8&#160;million, if the Cyclerion Series B Preferred Stock is converted and the remaining Korsana Pre-Funded Warrants are exercised) will become available for sale in the public market beginning 180 days after the closing of the Merger as a result of the expiration of <span style="white-space:nowrap">lock-up</span> agreements between Cyclerion on the one hand and certain securityholders of Korsana on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, shares of common stock that are subject to outstanding warrants, options or restricted stock units will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the Combined Company common stock could decline. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">After completion of the Merger, holders of Combined Company Series B Preferred Stock will have the ability to significantly influence all matters submitted to the Combined Company shareholders for approval. </span></p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Merger, and giving effect to the issuance of the shares of Korsana Common Stock and the Korsana Pre-Funded Warrants prior to the closing of the Merger pursuant to the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, it is anticipated that holders of Combined Company Series B Preferred Stock will, in the aggregate, beneficially own approximately 36.6% of the Combined Company&#8217;s outstanding shares of common stock (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Cyclerion&#8217;s net cash as of closing being $0. As a result, if these shareholders were to choose to act together, they would be able to significantly influence all matters submitted to the Combined Company shareholders for approval, as well as the Combined Company management and affairs. For example, these shareholders, if they choose to act together, would significantly influence the election of directors and approval of any merger, consolidation, or sale of all or substantially all of the Combined Company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the Combined Company on terms that other shareholders may desire. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">After completion of the Merger, Preferred Directors elected by the holders of Cyclerion Series B Preferred Stock will have the ability to control or significantly influence all matters submitted to the Combined Company board of directors for approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, pursuant to the Cyclerion Articles, as amended, at all times when at least 30% of the originally issued Cyclerion Series B Preferred Stock remains issued and outstanding: (i)&#160;the holders of Cyclerion Series B Preferred Stock, exclusively and voting together as a separate class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect four directors (the &#8220;Preferred Directors&#8221;); and (ii)&#160;the holders of Cyclerion Common Stock and of any other class or series of voting stock (including the Cyclerion Series B Preferred Stock), exclusively and voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect the balance of the total number of directors of Cyclerion (the <span style="white-space:nowrap">&#8220;At-Large</span> Directors&#8221;). Each Preferred Director is entitled to three votes on each matter presented to the Combined Company board of directors. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, it is expected Mr. Gottesdiener, Mr. Kiselak, Ms. Pernice, and Mr. Shah will be elected as the four Preferred Directors by the holders of Cyclerion Series B Preferred Stock. These four Preferred Directors will represent approximately 86% of the total votes of the Combined Company board of directors. As a result, these four Preferred Directors would be able to control or significantly influence all matters submitted to the Combined Company board of directors for approval, including business plans and policies and the appointment and removal of the Combined Company&#8217;s officers. The holders of Cyclerion Series B Preferred Stock will thereby have influence with respect to the composition of the Combined Company board of directors and, to the extent they influence the actions of the Preferred Directors, if at all, actions of the Combined Company board of directors. Entities affiliated with Fairmount and Venrock Healthcare Capital Partners are expected to be the sole holders of 92% of Cyclerion Series B Preferred Stock following the completion of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana expects that the decision to enter into or amend any agreement with Paragon will be subject to the approval of the Combined Company board of directors. As noted above, the Combined Company board of directors will include four Preferred Directors that are affiliated with and elected by Fairmount and Venrock Healthcare Capital Partners, two of whom are affiliated with Fairmount, in addition to Dr.&#160;Violin. As a result, Fairmount may exert influence on the decisions of the Combined Company board of directors and the Combined Company management, including as it relates to agreements with Paragon and decisions to exercise options or enter into license agreements thereunder, which interests may differ from the interests of the Combined Company shareholders given Fairmount&#8217;s interest in the Combined Company and Paragon, and indirect interest in Parasa. All directors of the Combined Company will owe fiduciary duties pursuant to Massachusetts law, and directors of the Combined Company will be expected to comply with their respective fiduciary duties under Massachusetts law relevant to related party transactions. If the Cayman Redomestication is effected, all directors of the Combined Company will owe fiduciary duties pursuant to Cayman Islands law, and directors of the Combined Company will be expected to comply with their respective fiduciary duties under Cayman Islands law relevant to related party transactions. See the section titled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4 &#8212; The Redomestication Proposal &#8212; Effects of the Cayman Redomestication &#8212; Comparison of Shareholder Rights under Massachusetts and Shareholder Rights</span> </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="font-style:italic">under Cayman Islands Law &#8212; Fiduciary Duties and Business Judgment</span>&#8221; beginning on page&#160;252 of this proxy statement/prospectus. Following the completion of the Merger, Korsana anticipates that the Combined Company will adopt a related party transaction approval policy and the Combined Company&#8217;s audit committee will be responsible for the review, consideration and approval or ratification of related party transactions. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the Combined Company, its business or its market, its stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the Combined Company common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the Combined Company common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the Combined Company will not have any control over the analysts or the content and opinions included in their reports. The price of the Combined Company common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the Combined Company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company will have broad discretion over the use of the cash and cash equivalents of the Combined Company and the proceeds from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. You may not agree with the Combined Company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The Combined Company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the Combined Company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the Combined Company&#8217;s cash resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Combined Company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Cyclerion and Korsana has incurred losses during its history, and the Combined Company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2025, Cyclerion had federal NOL carryforwards of approximately $211&#160;million. As of December&#160;31, 2025, Korsana had federal NOL carryforwards of approximately $31.5&#160;million. Under current law, U.S. federal NOLs incurred in tax&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such NOL carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections&#160;382 and 383 of the Code, U.S. federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more shareholders or groups of shareholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50&#160;percentage points over their lowest ownership&#160;percentage within a rolling three-year period. The Combined Company&#8217;s ability to utilize its NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the Combined Company earns taxable income, such limitations could result in increased future income tax liability to the Combined Company, and the Combined Company&#8217;s future cash flows could be adversely affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in tax law could adversely affect the Combined Company&#8217;s business and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company is subject to federal, state, and local income and other taxes in the United States and in foreign jurisdictions because of the scope of its operations. New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. For example, the U.S. government recently enacted legislation commonly referred to as the One Big Beautiful Bill Act that (along with prior U.S. federal tax reform legislation) has resulted in significant changes to the taxation of business entities, including, among other changes, the imposition of minimum taxes and excise taxes, changes to the taxation of income derived from international operations, changes in the deduction and amortization of research and development expenditures, and limitations on the deductibility of business interest. Future guidance from the IRS and other taxing authorities with respect to this and other legislation may affect the Combined Company, and certain aspects of such legislation could be repealed or modified in future legislation or sunset in future years. In addition, it is uncertain if and to what extent various states will conform to federal law. To the extent that any such changes in tax laws and regulations have a negative impact on the Combined Company, including as a result of related uncertainty, its business, financial condition, results of operations and cash flows may be materially and adversely impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unfavorable global economic conditions could adversely affect the Combined Company&#8217;s business, financial condition, results of operations or cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the Combined Company&#8217;s business, including weakened demand for the Combined Company&#8217;s product candidates and the Combined Company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the Combined Company&#8217;s suppliers, possibly resulting in supply disruption, or cause the Combined Company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the Combined Company&#8217;s business and the Combined Company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains statements that constitute forward-looking statements within the meaning of the federal securities laws in relation to Cyclerion, Korsana, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding Cyclerion&#8217;s or Korsana&#8217;s expectations, hopes, beliefs, intentions, or strategies regarding the future. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Cyclerion, Korsana or the proposed transaction will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Cyclerion&#8217;s or Korsana&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. In addition to other factors and matters contained in this document, Cyclerion and Korsana believe the following factors could cause actual results to differ materially from those discussed in the forward-looking statements: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the conditions to the closing of the Merger are not satisfied, including the failure to obtain stockholder approval required to complete the Merger and transactions contemplated thereby; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s and Korsana&#8217;s ability to meet expectations regarding the timing and completion of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is not completed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">uncertainties as to the timing and costs of the consummation of the Merger and the ability of each of Cyclerion and Korsana to consummate the Merger and the transactions contemplated thereby, including the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">uncertainties with obtaining the requisite approvals of the stockholders of each of Cyclerion and Korsana and the e&#64256;ectiveness of the registration statement to be filed with the SEC in connection with the Merger and the <span style="white-space:nowrap">Pre-Closing</span> Financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks related to Cyclerion&#8217;s continued listing on the Nasdaq until closing of the proposed Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expectations regarding the strategies, prospects, plans expectations and objectives of management of Cyclerion or Korsana for future operations of the Combined Company following the closing of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of the Combined Company to recognize the benefits that may be derived from the Merger, including the commercial or market opportunity of the product candidates of Korsana and the Combined Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that the CVR holders may never receive any proceeds pursuant to the Cyclerion CVR Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Cyclerion shareholders will not receive any dividend of cash prior to the closing of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks related to Cyclerion&#8217;s and Korsana&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, uncertainties regarding the impact any </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
delay in the closing of the Merger would have on the anticipated cash resources of the Combined Company upon closing and other events and unanticipated spending and costs that could reduce the Combined Company&#8217;s cash resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the accuracy of the parties&#8217; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that under the terms of the Merger Agreement, Cyclerion and Korsana are restrained from soliciting other acquisition proposals during the pendency of the Merger, except in certain circumstances; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of the announcement or pendency of the Merger on Cyclerion&#8217;s or Korsana&#8217;s business relationships, operating results and business generally, including disruption of Cyclerion&#8217;s and Korsana&#8217;s management&#8217;s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Merger Agreement may be terminated in circumstances that require Cyclerion or Korsana to pay a termination fee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any legal proceedings that may be instituted against Cyclerion, Korsana or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of Cyclerion and Korsana to protect their respective intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competitive responses to the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legislative, regulatory, political and economic developments beyond the parties&#8217; control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the initiation, timing and success of clinical trials for Korsana&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">success in retaining, or changes required in, Cyclerion&#8217;s and Korsana&#8217;s officers, key employees or directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s public securities&#8217; potential liquidity and trading; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory actions with respect to Cyclerion&#8217;s and Korsana&#8217;s product candidates or their respective competitors&#8217; products and product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s ability to manufacture their product candidates in conformity with the FDA&#8217;s requirements and to scale up manufacturing of their product candidates to commercial scale, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">uncertainties regarding the capabilities and potential of the THETA platform and Korsana&#8217;s pipeline programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s reliance on third-party contract development and manufacturer organizations to manufacture and supply product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of Korsana&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expected potential benefits of strategic collaboration with third parties and Korsana&#8217;s ability to attract collaborators with development, regulatory and commercialization expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s ability to successfully commercialize product candidates, if approved, and the rate and degree of market acceptance of such product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments and projections relating to Korsana&#8217;s competitors or industry. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize, or should any of Cyclerion&#8217;s or Korsana&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that Cyclerion or Korsana considers immaterial or which are unknown. You are urged to carefully review the disclosures Cyclerion and Korsana make concerning these risks and other factors that may affect Cyclerion&#8217;s and Korsana&#8217;s business and operating results under the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 33 of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by Cyclerion and incorporated by reference herein. Please see the section titled &#8220;<span style="font-style:italic">Where You Can Find More Information</span>&#8221; beginning on page 435 of this proxy statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of Cyclerion, Korsana or the Combined Company could differ materially from the forward-looking statements. Any public statements or disclosures by Cyclerion and Korsana following this proxy statement/prospectus that modify or impact any of the forward-looking statements contained in this proxy statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. Cyclerion and Korsana do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law to do so. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_6">THE ANNUAL MEETING OF CYCLERION SHAREHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Date, Time and Place </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Shareholders Meeting will be held on&#8195;&#8195;&#8195;&#8195;, 2026, commencing at&#8195;&#8195;&#8195;&#8195;a.m. Eastern Time, unless postponed or adjourned to a later date. The Cyclerion Shareholders Meeting will be held exclusively online. You will be able to attend and participate in the Cyclerion Shareholders Meeting online by visiting <span style="font-style:italic">www.virtualshareholdermeeting.com</span><span style="font-style:italic">/</span>&#8195;&#8195;&#8195;&#8195;, where you will be able to listen to the meeting live, submit questions and vote. Cyclerion is sending this proxy statement/prospectus to its shareholders in connection with the solicitation of proxies by the Cyclerion Board for use at the Cyclerion Shareholders Meeting and any adjournments or postponements of the Cyclerion Shareholders Meeting. This proxy statement/prospectus is first being furnished to Cyclerion shareholders on or about&#8195;&#8195;&#8195;&#8195;, 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purpose of the Cyclerion Shareholders Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purposes of the Cyclerion Shareholders Meeting are: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">1.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve (i)&#160;the issuance of shares of Cyclerion Common Stock, including the shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, which will represent more than 20% of the shares of Cyclerion Common Stock outstanding immediately prior to the First Merger, to stockholders of Korsana, pursuant to the Merger Agreement, a copy of which is attached as <span style="font-style:italic">Annex A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of Cyclerion resulting from the First Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No.&#160;1&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">2.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve articles of amendment to the restated articles of organization of Cyclerion, as amended (the &#8220;Cyclerion Articles&#8221;), to increase the number of shares of Cyclerion Common Stock that Cyclerion is authorized to issue from 400,000,000 shares to&#8195;&#8195;&#8195;&#8195;shares, in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">H</span> to this proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal No.&#160;2&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">3.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve an amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock at a ratio in the range of one new share for every&#8195;&#8195;&#8195;&#8195;shares and one new share for every&#8195;&#8195;&#8195;&#8195;shares (or any number in between), in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">I</span> to this proxy statement/prospectus, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the Cyclerion Board and the Korsana Board prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by Cyclerion shareholders, determined solely by the Cyclerion Board (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No.&#160;3&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">4.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve (A)&#160;the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by domestication (&#8220;Proposal No. 4A&#8221;) and (B)(i) the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and (ii)&#160;the adoption of the memorandum and articles of association of the Combined Company (the &#8220;Cayman Articles&#8221;), substantially in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">K</span> to this proxy statement/prospectus (&#8220;Proposal No. 4B&#8221; and together with Proposal No. 4A, the &#8220;Redomestication Proposal&#8221; or &#8220;Proposal No.&#160;4&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">5.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Elect Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D., and Dina Katabi, Ph.D., to the Cyclerion Board and to hold office until Cyclerion&#8217;s annual meeting of shareholders in 2027, and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No.&#160;5&#8221;), provided that if the Merger is consummated, the composition of the Cyclerion Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">6.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ratify the appointment of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2026 (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No.&#160;6&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">7.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve the Korsana Biosciences, Inc. 2026 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No.&#160;7&#8221;); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">8.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve the Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal No.&#160;8&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">9.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve, on an advisory basis, certain compensation arrangements for Cyclerion&#8217;s named executive officers that are based on or otherwise relate to the Merger (the &#8220;Merger Compensation Proposal&#8221; or &#8220;Proposal No.&#160;9&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">10.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve, on an advisory basis, the compensation of Cyclerion&#8217;s named executive officers (the <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;Say-on-Pay</span></span> Proposal&#8221; or &#8220;Proposal No.&#160;10&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">11.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Approve an adjournment of the Cyclerion Shareholders Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No.&#160;11&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">12.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Transact such other business as may properly come before the shareholders at the Cyclerion Shareholders Meeting or any adjournment or postponement thereof. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of each of Proposal No.&#160;1, Proposal No.&#160;2, and Proposal No.&#160;3 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2, and 3, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such conditions. The issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, and Cyclerion Series B Preferred Stock in connection with the Merger and the change of control of Cyclerion resulting from the Merger will not take place unless Proposal Nos. 1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to increase the number of authorized shares of Cyclerion Common Stock will not take place unless Proposal Nos. 1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock, will not take place unless Proposal Nos. 1, 2, and 3 are approved by the requisite Cyclerion shareholders. However, the Cyclerion Board may determine to effect the reverse stock split, if approved by Cyclerion shareholders, following the Shareholders Meeting, even if Proposal Nos. 1 and 2 are not approved or the Merger is not otherwise completed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendation of the Cyclerion Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cyclerion Board recommends that you vote: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and declared that the issuance of shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, Cyclerion and its shareholders. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and declared that it is advisable and in the best interests of Cyclerion and its shareholders to approve the amendment to the Cyclerion Articles to effect the increase in authorized shares. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and declared that it is advisable and in the best interests of Cyclerion and its shareholders to approve the amendment to the Cyclerion Articles to effect the reverse stock split, if necessary. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Reverse Stock Split Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is fair to, in the best interests of, and advisable to, Cyclerion and its shareholders to approve (A)&#160;the redomestication of Cyclerion from </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the Commonwealth of Massachusetts to the Cayman Islands by domestication and (B)(i) the redomestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation and (ii)&#160;the adoption of the Cayman Articles, as described in this proxy statement/prospectus. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Redomestication Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to elect Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D., and Dina Katabi, Ph.D., to serve on the Cyclerion Board and to hold office until Cyclerion&#8217;s annual meeting of shareholders in 2027, provided that if the Merger is consummated, the Cyclerion Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to ratify the selection of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2026. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Auditor Ratification Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve the 2026 Stock Incentive Plan, as described in this proxy statement/prospectus. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve the 2026 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve certain compensation arrangements for Cyclerion&#8217;s named executive officers that are based on or otherwise relate to the Merger. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that it is advisable to, and in the best interests of, Cyclerion and its shareholders to approve, on an advisory basis, the compensation of Cyclerion&#8217;s named executive officers. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the <span style="white-space:nowrap"><span style="white-space:nowrap">Say-on-Pay</span></span> as described in this proxy statement/prospectus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board has determined and believes that adjourning the Cyclerion Shareholders Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, Cyclerion and its shareholders and has approved and adopted the proposal. The Cyclerion Board recommends that Cyclerion shareholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Record Date and Voting Power </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders of record of Cyclerion Common Stock at the close of business on the Record Date of&#8195;&#8195;&#8195;&#8195;, 2026, are entitled to notice of, and to vote at, the Cyclerion Shareholders Meeting. At the close of business on&#8195;&#8195;&#8195;&#8195;, 2026, there were&#8195;&#8195;&#8195;&#8195;registered holders of record of Cyclerion Common Stock and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
there were&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock issued and outstanding. Each share of Cyclerion Common Stock entitles the holder thereof to one vote on each matter submitted for shareholder approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting and Revocation of Proxies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy accompanying this proxy statement/prospectus is solicited on behalf of the Cyclerion Board for use at the Cyclerion Shareholders Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, as of the Record Date referred to above, your shares were registered directly in your name with the transfer agent for Cyclerion Common Stock, Computershare Trust Company, N.A., then you are a shareholder of record. As a shareholder of record, you may vote at the Cyclerion Shareholders Meeting or vote by proxy. Whether or not you plan to attend the Cyclerion Shareholders Meeting, we urge you to vote by proxy over the telephone or on the Internet as instructed below or return the proxy card we may mail to you to ensure your vote is counted, the form of which is attached hereto as <span style="font-style:italic">Annex </span><span style="font-style:italic">R</span><span style="font-style:italic"> </span>to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The procedures for voting are as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a shareholder of record, you may vote at the Cyclerion Shareholders Meeting. Alternatively, you may vote by proxy by using the accompanying proxy card, over the Internet or by telephone. Whether or not you plan to attend the Cyclerion Shareholders Meeting, Cyclerion encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the Cyclerion Shareholders Meeting, you may still attend the Cyclerion Shareholders Meeting and vote. In such case, your previously submitted proxy will be disregarded. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to Cyclerion before the annual meeting, we will vote your shares as you direct. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You can vote by proxy over the telephone by calling the toll-free number found on the proxy card. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You can vote by proxy over the Internet by following the instructions provided on the proxy card. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from Cyclerion. Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote at the Cyclerion Shareholders Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion provides Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent will only be able to vote your shares with respect to proposals considered to be &#8220;routine.&#8221; Your broker, bank or other agent is not entitled to vote your shares with respect to <span style="white-space:nowrap">&#8220;non-routine&#8221;</span> proposals. As a result, Cyclerion urges you to direct your broker, bank or other agent how to vote your shares on all proposals to ensure that your vote is counted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abstentions and broker <span style="white-space:nowrap">non-votes,</span> if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Cyclerion Shareholders Meeting. Abstentions will be counted towards the vote totals for each proposal, will have the same effect as a vote &#8220;AGAINST&#8221; Proposal Nos. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2, 3, and 4A and will have no effect on Proposal Nos. 1, 4B, 5, 6, 7, 8, 9, 10, and 11. Broker <span style="white-space:nowrap">non-votes,</span> if any, will have no effect on Proposal Nos. 1, 4B, 5, 6, 7, 8, 9, 10, and 11 and will have the same effect as a vote &#8220;AGAINST&#8221; Proposal Nos. 2, 3, and 4A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All properly executed proxies that are not revoked will be voted at the Cyclerion Shareholders Meeting and at any adjournments or postponements of the Cyclerion Shareholders Meeting in accordance with the instructions contained in the proxy. <span style="font-weight:bold">If a holder of </span><span style="font-weight:bold">Cyclerion</span><span style="font-weight:bold"> Common Stock</span><span style="font-weight:bold"> executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted </span><span style="font-weight:bold">&#8220;</span><span style="font-weight:bold">FOR</span><span style="font-weight:bold">&#8221;</span><span style="font-weight:bold"> all of the proposals in accordance with the recommendation of the </span><span style="font-weight:bold">Cyclerion</span><span style="font-weight:bold"> Board.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Required Vote </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence at the Cyclerion Shareholders Meeting of the holders of a majority of the shares of Cyclerion Common Stock outstanding and entitled to vote at the Cyclerion Shareholders Meeting is necessary to constitute a quorum at the meeting. Abstentions and broker <span style="white-space:nowrap">non-votes,</span> if any, will be counted towards the presence of a quorum. The affirmative vote of a majority of the votes properly cast by the holders of Cyclerion Common Stock in person or represented by proxy at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No.&#160;1 and Proposal No.&#160;5. The affirmative vote of a majority of the shares entitled to vote on the subject matter at the Cyclerion Shareholders Meeting is required for approval of Proposal&#160;No.&#160;2, and Proposal No.&#160;3. The affirmative vote of not less than <span style="white-space:nowrap">two-thirds</span> of the shares entitled to vote on the subject matter at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No. 4A. The affirmative vote of not less than two-thirds of the votes properly cast by the holders of Cyclerion Common Stock in person or represented by proxy at the Cyclerion Shareholders Meeting, assuming a quorum is present, is required for approval of Proposal No. 4B. The number of affirmative votes exceeding the number of votes opposing the matter, assuming a quorum is present, is required for the approval of Proposal No.&#160;6, Proposal No.&#160;7, Proposal No.&#160;8, Proposal No.&#160;9, Proposal No.&#160;10, and Proposal No.&#160;11. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of each of Proposal No.&#160;1, Proposal No.&#160;2, and Proposal No.&#160;3 is a condition to the completion of the Merger. Therefore, the Merger cannot be consummated without the approval of Proposal Nos. 1, 2 and 3, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such conditions. The issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, and Cyclerion Series B Preferred Stock in connection with the Merger and the change of control of Cyclerion resulting from the Merger will not take place unless Proposal Nos. 1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to increase the number of authorized shares of Cyclerion Common Stock will not take place unless Proposal Nos. 1, 2, and 3 are approved by Cyclerion shareholders and the Merger is consummated. The amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock, will not take place unless Proposal Nos. 1, 2, and 3 are approved by the requisite Cyclerion shareholders. However, the Cyclerion Board may determine to effect the reverse stock split, if approved by Cyclerion shareholders, following the Shareholders Meeting, even if Proposal Nos. 1 and 2 are not approved or the Merger is not otherwise completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Proposal Nos. 4A, 4B, 7, 8, and 9 are each conditioned on the consummation of the Merger. Therefore, if Proposal Nos. 1, 2, and 3 are not approved or the Merger is not consummated, Proposal Nos. 4A, 4B, 7, 8, and 9 will each have no effect, even if approved by Cyclerion shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221; votes, abstentions and broker <span style="white-space:nowrap">non-votes,</span> if any, as applicable to each proposal. Abstentions and broker <span style="white-space:nowrap">non-votes,</span> if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Cyclerion Shareholders Meeting. Abstentions will be counted towards the vote totals for each proposal, will have the same effect as a vote &#8220;AGAINST&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Proposal&#160;Nos.&#160;2, 3, and 4A and will have no effect on Proposal Nos. 1, 4B, 5, 6, 7 8, 9, 10, and 11. Broker <span style="white-space:nowrap">non-votes,</span> if any, will have no effect on Proposal Nos. 1, 4B, 5, 6, 7, 8, 9, 10, and 11 and will have the same effect as a vote &#8220;AGAINST&#8221; Proposal Nos. 2, 3, and 4A. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion directors and officers beneficially holding approximately 24.2% of the outstanding shares of Cyclerion Common Stock as of March&#160;31, 2026 have entered into Cyclerion Support Agreements with Cyclerion and Korsana to vote all of their shares of Cyclerion Common Stock in favor of Proposal No.&#160;1, Proposal No.&#160;2, and Proposal No.&#160;3, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form <span style="white-space:nowrap">S-4</span> of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Korsana stockholders holding a sufficient number of shares of Korsana capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Solicitation of Proxies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to solicitation by mail, the directors, officers, employees and agent of Cyclerion may solicit proxies from Cyclerion shareholders by personal interview, telephone, email, fax or otherwise. Cyclerion and Korsana will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Cyclerion Common Stock for the forwarding of solicitation materials to the beneficial owners of Cyclerion Common Stock. Cyclerion will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, the Cyclerion Board does not know of any business to be presented at the Cyclerion Shareholders Meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Cyclerion Shareholders Meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_7">THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page 168 of this proxy statement/prospectus describe the material aspects of the Merger and the Merger Agreement. While Cyclerion and Korsana believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. See the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 435 of this proxy statement/prospectus. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following chronology is a summary description of the background of the negotiations and the proposed merger and does not purport to document every discussion among representatives of Cyclerion, Korsana or other parties. In addition to formal meetings of the Cyclerion Board, Cyclerion&#8217;s management had periodic and other informal discussions with members of the Cyclerion Board throughout the process, and Cyclerion&#8217;s management held periodic calls with various advisors, and ultimately with Korsana and its advisors. The terms of the Merger Agreement are the result of extensive <span style="white-space:nowrap">arm&#8217;s-length</span> negotiations among Cyclerion&#8217;s and Korsana&#8217;s management and members of the Cyclerion Board and the Korsana Board, as well as with Cyclerion&#8217;s and Korsana&#8217;s respective financial advisors and legal counsel. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Cyclerion Board,&#8201;assisted by Cyclerion management and outside advisors,&#8201;regularly considers and reviews the strategy, performance and prospects of Cyclerion with a view toward maximizing shareholder value. These reviews have included, from time to time, discussions of opportunities and risks associated with Cyclerion&#8217;s development programs, its financial condition, strategic relationships and market conditions generally, as well as strategic alternatives, financing opportunities, business collaborations and licensing opportunities potentially available to Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion was spun out of Ironwood Pharmaceuticals, Inc. in April 2019 as a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (&#8220;sGC&#8221;) for treatment of central nervous system diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April 2019 and July 2023, Cyclerion conducted multiple clinical trials in connection with the development of its sGC stimulators for treatment of various indications. In order to narrow such efforts, in June 2021, Cyclerion out licensed certain assets pursuant to the Akebia License Agreement. In early 2023, the Cyclerion Board determined to shift Cyclerion&#8217;s strategy from developing sGC stimulators to building a new pipeline targeting neuropsychiatric diseases and in July 2023, Cyclerion sold zagociguat and CY3018 to Tisento. In connection with such sale, Cyclerion discontinued clinical development programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between July 2023 and January 2025, the Cyclerion Board held periodic meetings to review Cyclerion&#8217;s financial position, capital requirements and financing strategy and consider opportunities and strategies for obtaining sufficient capital to continue its shift toward building a new therapeutic pipeline including development programs targeting neuropsychiatric diseases. During this time, members of Cyclerion management evaluated assets in multiple therapeutic areas with the goal of identifying products and opportunities directed at addressing patient needs and increasing shareholder value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;7, 2025, at a meeting of the Cyclerion Board, including Dr.&#160;Regina Graul, Cyclerion&#8217;s President and Chief Executive Officer, Ms.&#160;Rhonda Chicko, Cyclerion&#8217;s Chief Financial Officer, and Mr.&#160;Keith Ouellette, a representative of CFGI, LLC, Cyclerion&#8217;s accounting, finance and tax advisor, in attendance, Dr.&#160;Graul and Ms.&#160;Chicko presented a preliminary operating plan and budget for fiscal year 2025, which included a proposed development plan focused around acquiring rights to a product candidate and pipeline for therapeutic treatments of treatment resistant depression (&#8220;TRD&#8221;) and an initial financing strategy designed to support such development </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
plan. The Cyclerion Board discussed these initiatives and directed Cyclerion&#8217;s management to continue to refine the proposed development plan and to evaluate financing alternatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;20, 2025, Cyclerion entered into a patent option agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) (the &#8220;MIT Option Agreement&#8221;), pursuant to which MIT granted Cyclerion the exclusive right to negotiate an exclusive license agreement with respect to certain patent rights held by MIT related to therapeutic product candidates for the treatment of depression. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;3, 2025, at a meeting of the Cyclerion Board, including Dr.&#160;Graul, with members of Cyclerion&#8217;s management, including Ms.&#160;Chicko, and Mr.&#160;Ouellette in attendance, members of the Cyclerion Board and Cyclerion&#8217;s management reviewed Cyclerion&#8217;s financial position and projected cash runway. Dr.&#160;Graul and Ms.&#160;Chicko then presented a proposed updated financing strategy, which included the establishment of an <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;at-the-market&#8221;</span></span> equity program to be used for opportunistic equity financing transactions and certain <span style="white-space:nowrap">non-dilutive</span> capital sources, including potential asset-related transactions. The Cyclerion Board then directed Cyclerion&#8217;s management to continue pursuing multiple financing channels in parallel. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;4, 2025, at a meeting of the Cyclerion Board, including Dr.&#160;Graul, with members of Cyclerion&#8217;s management, including Ms.&#160;Chicko, and Mr.&#160;Ouellette in attendance, members of the Cyclerion Board and Cyclerion&#8217;s management reviewed updates to Cyclerion&#8217;s proposed development program for the product candidate that is the subject of the MIT Option Agreement, including engagement and feedback with regulatory authorities, and reviewed Cyclerion&#8217;s financial position and financing activities. Members of the Cyclerion Board, including Dr.&#160;Graul, and members of Cyclerion&#8217;s management, including Ms.&#160;Chicko, and Mr.&#160;Ouellette discussed a strategy of identifying intellectual property rights for the development of a medical device development program as a companion to Cyclerion&#8217;s proposed drug development program prior to pursuing a larger financing transaction as well as potential asset-related transactions. The Cyclerion Board directed management to continue advancing efforts to identify potential development programs while pursuing financing alternatives and strategic opportunities in parallel. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;19, 2025, following the exercise of its option under the MIT Option Agreement and negotiations with MIT, Cyclerion entered into a patent license agreement (the &#8220;MIT License Agreement&#8221;) with MIT, pursuant to which MIT granted Cyclerion a license to develop and commercialize certain anesthetic-based investigational therapy products for the treatment of neuropsychiatric disorders, including depression. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;3, 2025, at a meeting of the Cyclerion Board, including Dr.&#160;Graul, and members of Cyclerion&#8217;s management, including Ms.&#160;Chicko, and Mr.&#160;Ouellette in attendance, members of the Cyclerion Board and Cyclerion&#8217;s management reviewed updates to Cyclerion&#8217;s financial position and projected cash runway, including the impact of an anticipated Phase 2 <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> trial and related device development program activities. The Cyclerion Board discussed the juxtaposition between the amount of required capital for the proposed development plan presented by Dr.&#160;Graul and Ms.&#160;Chicko and the availability of financing to meet these capital requirements. As a result of the potential challenges funding Cyclerion&#8217;s development plans, in addition to exploring potential financing transactions, the Cyclerion Board also directed Cyclerion&#8217;s management to continue to evaluate strategic alternatives and to determine a process for reviewing and evaluating inbound expressions of interest regarding reverse merger opportunities that Cyclerion may receive as a result of its financial position. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between October&#160;3, 2025 and December&#160;11, 2025, members of Cyclerion&#8217;s management met with representatives of 16 financial advisors to discuss advising Cyclerion on a potential financing transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;16, 2025, Cyclerion&#8217;s management received an unsolicited indication of interest from a representative of Company A, a privately held biotech company developing therapies for metabolic disorders, regarding a potential reverse merger transaction (the &#8220;Company A Proposal&#8221;). The Company A Proposal provided for the acquisition of all of Company A&#8217;s outstanding equity securities by Cyclerion in exchange for shares of Cyclerion common stock at a ratio determined by agreed valuations of Cyclerion and Company A and </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an equity financing of at least $25&#160;million. Cyclerion&#8217;s valuation in the Company A Proposal was $20&#160;million. The Company A Proposal did not provide for payments to Cyclerion&#8217;s shareholders upon divestiture of Cyclerion Legacy Assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;26, 2025, members of the Cyclerion Board received correspondence from a representative of Company A requesting a response by October&#160;31, 2025 as to whether Cyclerion intended to move forward with Company A&#8217;s proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on October&#160;26, 2025, Cyclerion engaged a scientific advisor, Tim Surgenor of Red Sky Partners, LLC, to assist with review and evaluation of the Company A Proposal and related diligence. Later that day, Cyclerion&#8217;s management notified the full Cyclerion Board of the response deadline received from Company A. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between October&#160;26, 2025 and October&#160;29, 2025, members of Cyclerion&#8217;s management and Mr.&#160;Surgenor conducted scientific, regulatory, financial and strategic diligence on Company A. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;29, 2025, Dr.&#160;Graul and Ms.&#160;Chicko met with Mr.&#160;Surgenor and Michael Higgins, a member of the Cyclerion Board, to discuss concerns related to the proposed financing terms of the Company A Proposal, which were subsequently communicated to the other members of the Cyclerion Board. Following consideration of the concerns raised by Dr.&#160;Graul, Ms.&#160;Chicko, Mr.&#160;Surgenor and Mr.&#160;Higgins, the Cyclerion Board determined that it was not in the best interests of Cyclerion or Cyclerion&#8217;s shareholders to move forward with the Company A Proposal, due to their belief that such a transaction would not provide greater value to Cyclerion&#8217;s shareholders than continuing operations as an independent company. In coming to this decision, the Cyclerion Board noted that Company A&#8217;s development programs, including the underlying technology and science, were early stage and the target indications were both highly competitive. Company A had limited cash resources on hand and the future of the combined company would have been dependent on completion of a concurrent financing of at least $25&#160;million and up to $55&#160;million, which was not secured. The Cyclerion Board directed Cyclerion&#8217;s management to notify Company A of Cyclerion&#8217;s decision not to move forward. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;31, 2025, Company A was notified of Cyclerion&#8217;s decision not to proceed with the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;20, 2025, at a meeting of the Cyclerion Board with Dr.&#160;Graul, Ms.&#160;Chicko and Mr.&#160;Ouellette, in attendance, Dr.&#160;Graul and Ms.&#160;Chicko presented a comprehensive overview of Cyclerion&#8217;s capital requirements for its proposed drug and device development programs, indicating that approximately $20 to $25&#160;million in capital would be necessary to fund operations through a key clinical inflection point and approximately $50&#160;million would be necessary to reach full Phase 2 <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data. Dr.&#160;Graul and Ms.&#160;Chicko also presented a few alternatives for obtaining the necessary capital to fund such operations and identified two out of the 16 potential financial advisors with whom Cyclerion had met over the prior two months that had expressed interest in being engaged for such financing transactions. The Cyclerion Board discussed these capital requirements relative to Cyclerion&#8217;s recent difficulties in identifying substantial investor interest and directed Cyclerion&#8217;s management to move forward with negotiations to engage a financial advisor in connection with pursuing a private placement transaction or transactions to obtain the required capital for the drug and device development programs while also continuing to evaluate strategic alternatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on November&#160;20, 2025, members of Cyclerion&#8217;s management received a proposed engagement letter from one of the two prospective financial advisors, which included a proposal for a financing transaction involving the sale of registered equity. Following further discussions with the first prospective financial advisor and the direction of the Cyclerion Board to pursue a private placement transaction, Cyclerion decided not to move forward with engaging the first prospective financial advisor for the financing transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between November&#160;24, 2025 and December&#160;11, 2025, Cyclerion negotiated an engagement letter with the second prospective financial advisor, Lucid Capital Markets, LLC (&#8220;Lucid&#8221;). On December&#160;11, 2025, Cyclerion and Lucid entered into an engagement letter pursuant to which Lucid agreed to assist with the evaluation and </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
execution of a potential private placement financing transaction. The engagement letter did not provide for Lucid&#8217;s participation in negotiations related to an acquisition transaction, such as the Mergers, and Lucid did not participate in such negotiations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;19, 2025, at a meeting of the Cyclerion Board with Dr.&#160;Graul, Ms.&#160;Chicko, representatives of Lucid, and a representative of one of Cyclerion&#8217;s legal advisors, Gennari Aronson, LLP in attendance, Lucid provided an overview of the proposed financing transaction process, including target investor profiles, anticipated transaction structure and a potential timeline for execution. The Cyclerion Board discussed the proposed process and timeline and directed Cyclerion&#8217;s management to proceed with the financing transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between January&#160;20, 2026 and March&#160;9, 2026, Cyclerion and Lucid contacted approximately 90 institutional investors and conducted approximately 50 diligence sessions, including 17 formal management presentations. None of the investors contacted agreed to serve as lead investor in the proposed private placement transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;28, 2026, Cyclerion&#8217;s management received an unsolicited indication of interest from representatives of an advisor to Company B, a privately held biotech company developing therapies for treatment of chronic pain, about a potential reverse merger transaction (the &#8220;Company B Proposal&#8221;). The Company B Proposal provided for the acquisition of all of Company B&#8217;s outstanding equity interests by Cyclerion in exchange for shares of Cyclerion common stock and <span style="white-space:nowrap">non-voting</span> preferred stock at a ratio determined by agreed-upon valuations of Cyclerion and Company B and a concurrent private placement of at least $50&#160;million. Cyclerion&#8217;s valuation in the Company B Proposal was $8&#160;million. The Company B Proposal did not provide for payments to Cyclerion&#8217;s shareholders upon divestiture of Cyclerion Legacy Assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;3, 2026, Cyclerion and Company B entered into a mutual confidentiality agreement that did not include a standstill provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between February&#160;3, 2026 and March&#160;1, 2026, members of Cyclerion&#8217;s management conducted scientific, regulatory, financial and strategic diligence on Company B. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;2, 2026, Cyclerion&#8217;s management received an unsolicited indication of interest from an investor in Company&#160;C, a privately held biotechnology company, about a potential transaction (the &#8220;Company C Proposal&#8221;). The Company C Proposal provided for the sale of Cyclerion preferred stock holding voting rights equal to 65% of Cyclerion&#8217;s outstanding shares to an investor in Company C for a purchase price of $10&#160;million. The Company C Proposal provided for payments to Cyclerion&#8217;s shareholders upon divestiture of Cyclerion Legacy Assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;4, 2026, at a meeting of the Cyclerion Board with Dr.&#160;Graul, Ms.&#160;Chicko and Mr.&#160;Ouellette in attendance, Dr.&#160;Graul presented an overview of the Company B Proposal and their initial diligence findings. Following review of diligence findings and discussion with Cyclerion management, the Cyclerion Board determined not to pursue a reverse merger transaction with Company B due to risks related to a potential longer development timeline than the assumed timeline embedded in Company B&#8217;s valuation model, limited interaction with and guidance from regulatory agencies, including the FDA, unproven product scalability and substantial anticipated capital requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&#160;Graul contacted a representative of Company D, a public royalty aggregator, to discuss a potential royalty financing transaction on March&#160;5, 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;6, 2026, a representative from Wedbush Securities Inc. (&#8220;Wedbush&#8221;), the financial advisor to Korsana, contacted Dr.&#160;Graul to express interest in a reverse merger transaction between Cyclerion and Korsana. The expression of interest from Korsana delivered by Wedbush was unsolicited. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;9, 2026, Cyclerion and Company D entered into a mutual confidentiality agreement, which did not include a standstill. Cyclerion began providing diligence materials to Company D to assess interest in assets. Company D did not follow up on a potential transaction following initial diligence review. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on March&#160;9, 2026, representatives of Wedbush and Cyclerion had an introductory meeting by videoconference. Following this meeting, a representative of Wedbush delivered to Dr.&#160;Graul an initial draft of a term sheet for a proposed reverse merger transaction between Cyclerion and Korsana (the &#8220;Initial Korsana Term Sheet&#8221;), which Cyclerion&#8217;s management subsequently shared with the Cyclerion Board. The Initial Korsana Term Sheet provided for the acquisition of all outstanding shares of Korsana capital stock by Cyclerion in exchange for shares of Cyclerion common stock at a ratio determined by agreed valuations of Cyclerion and Korsana and a concurrent private placement into Korsana of at least $150&#160;million (the &#8220;PIPE financing&#8221;). The Initial Korsana Term Sheet also provided for a to be determined valuation of Korsana, noting that Korsana&#8217;s latest post-money valuation on the date of the Final Korsana Term Sheet was $240&#160;million and a proposed $8&#160;million valuation of Cyclerion, which would be adjusted upward or downward, <span style="white-space:nowrap"><span style="white-space:nowrap">dollar-for-dollar,</span></span> based on the amount of net cash above or below $0, respectively, held by Cyclerion at the closing of the Merger. The Initial Korsana Term Sheet did not provide Cyclerion shareholders the right to receive contingent payments post-closing in connection with the divestiture of Cyclerion Legacy Assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;9, 2026, and March&#160;10, 2026, Dr.&#160;Graul and Ms.&#160;Chicko spoke with the Cyclerion Board about the Initial Korsana Term Sheet and met with representatives from Cyclerion&#8217;s legal counsel, Ropes&#160;&amp; Gray LLP (&#8220;Ropes&#160;&amp; Gray&#8221;) to discuss the Initial Korsana Term Sheet, including the proposed Cyclerion valuation and potential to add a mechanism for contingent payments to Cyclerion&#8217;s shareholders via a contingent value rights (&#8220;CVR&#8221;) agreement (the &#8220;CVR Agreement&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;10, 2026, Cyclerion and Korsana entered into a mutual confidentiality agreement that did not include a standstill and began exchanging diligence materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on March&#160;10, 2026, a representative of Cyclerion sent a revised term sheet to Wedbush (the &#8220;Revised Korsana Term Sheet&#8221;). The Revised Korsana Term Sheet provided for a valuation of Cyclerion of $12&#160;million and the issuance of CVRs to Cyclerion&#8217;s shareholders at the closing of the Merger, which would represent the right to receive payments received in connection with the divestiture of Cyclerion Legacy Assets on a pro rata basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between March&#160;10, 2026 and March&#160;12, 2026, Cyclerion&#8217;s management conducted initial scientific, regulatory, financial and strategic diligence on Korsana through review of materials provided in a virtual data room and discussions with representatives of Korsana&#8217;s management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;11, 2026, members of Cyclerion&#8217;s management and Korsana&#8217;s management and representatives of Wedbush held a meeting by videoconference to discuss Cyclerion&#8217;s asset portfolio, cash runway and other background diligence items. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on March&#160;11, 2026, Cyclerion and Company C entered into a mutual confidentiality agreement that did not include a standstill for the purposes of enabling Cyclerion&#8217;s management to review materials and conduct scientific, regulatory, financial and strategic diligence, after which members of Cyclerion&#8217;s management were granted access to diligence materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between March&#160;11, 2026, and March&#160;12, 2026, members of Cyclerion&#8217;s management conducted scientific, regulatory, financial and strategic diligence on Company C. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following that meeting, also on March&#160;11, 2026, a representative of Wedbush sent Cyclerion&#8217;s management a further revised term sheet (the &#8220;Final Korsana Term Sheet&#8221;). The Final Korsana Term Sheet provided for (i)&#160;a to be determined valuation of outstanding Korsana equity, noting that Korsana&#8217;s latest post-money valuation on the date of the Final Korsana Term Sheet was $240&#160;million, (ii)&#160;a valuation of Cyclerion equal to $10&#160;million, which would be adjusted upward or downward, <span style="white-space:nowrap"><span style="white-space:nowrap">dollar-for-dollar,</span></span> based on the amount of net cash above or below $0, respectively, held by Cyclerion at the closing of the Merger, (iii)&#160;the issuance of CVRs to Cyclerion&#8217;s shareholders at or prior to the Closing for the purpose of distributing payments received in connection with the </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
divestiture of Cyclerion Legacy Assets and (iv)&#160;a concurrent private placement into Korsana of at least $150&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;13, 2026, at a meeting of the Cyclerion Board with Dr.&#160;Graul, Ms.&#160;Chicko and Mr.&#160;Ouellette in attendance, Dr.&#160;Graul presented initial diligence findings with respect to Company C to the Cyclerion Board. Following review of initial diligence findings, the Cyclerion Board determined not to pursue a transaction with Company C due to concerns regarding the lack of capital and liquidity included in the proposed transaction, which would likely result in a need for additional capital raises in the near term and the dilutive effect the transaction would have on Cyclerion&#8217;s shareholders, as well as concerns related to the sufficiency of Company C&#8217;s organizational depth to support the complexity of Company C&#8217;s proposed development strategy. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on March&#160;13, 2026, the Cyclerion Board convened at a meeting at which Dr.&#160;Graul, Ms.&#160;Chicko and Mr.&#160;Ouellette and representatives from Ropes&#160;&amp; Gray were present. Cyclerion&#8217;s management presented the Final Korsana Term Sheet and its initial diligence findings on Korsana and provided an overview of Cyclerion&#8217;s available strategic alternatives, including limited opportunities for financing transactions. The Cyclerion Board reviewed and assessed the Final Korsana Term Sheet as being a potential alternative to previously discussed alternative financing transactions, as well as the previously proposed transactions with Company A, Company B and Company C. The Cyclerion Board also discussed the relative merits and risks of the transactions contemplated by the Final Korsana Term Sheet, the Company A Proposal, the Company B Proposal, the Company C Proposal and potential alternative financing transactions if Cyclerion were to remain a standalone company, including the respective value to Cyclerion shareholders, financing needs, and risks to completion of a merger and obtaining sufficient financing to get to a critical inflection point in connection with Cyclerion&#8217;s proposed drug and device development programs. Following discussion, the Cyclerion Board determined the transactions contemplated by the Final Korsana Term Sheet represented the best available alternative for Cyclerion and its shareholders and directed Cyclerion management to execute the term sheet and negotiate a transaction with Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;16, 2026, Cyclerion and Korsana entered into the Final Korsana Term Sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on March&#160;16, 2026, Dr.&#160;Graul informed an investor in Company C that Cyclerion was not interested in moving forward with the Company C Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2026, Cyclerion&#8217;s management and representatives from Ropes&#160;&amp; Gray met with representatives of Korsana&#8217;s management and representatives of Wedbush and Gibson, Dunn&#160;&amp; Crutcher LLP (&#8220;Gibson Dunn&#8221;), Korsana&#8217;s legal advisor, to discuss the timeline for signing definitive agreements related to the proposed transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between March&#160;18, 2026 and March&#160;31, 2026, representatives of Cyclerion&#8217;s management team conducted further business and financial due diligence with respect to Korsana, its business and the market for its pipeline products, and Korsana&#8217;s management and advisors conducted diligence of Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;19, 2026, Terrence McGuire, a board observer of Tisento and a former director of Cyclerion, on behalf of the board of directors of Tisento, contacted Dr.&#160;Graul with an unsolicited offer to purchase all equity securities of Tisento beneficially owned by Cyclerion (the &#8220;Tisento Proposal&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;20, 2026, at an executive session of a meeting of the Cyclerion Board in which Dr.&#160;Graul, Ms.&#160;Chicko and Mr.&#160;Ouellette were present and one member of Cyclerion&#8217;s Board, Dr.&#160;Peter Hecht, recused himself due to a conflict of interest in connection with Dr.&#160;Hecht&#8217;s position as Chief Executive Officer of Tisento, the Cyclerion Board and members of Cyclerion&#8217;s management discussed the Tisento Proposal, including whether the sale transaction contemplated thereby was in the best interests of the Cyclerion shareholders. Following discussion, the Cyclerion Board determined that the purchase price offered in the Tisento Proposal was not an acceptable price for 10% of the equity interests of Tisento and devalued the ownership potential for such an early-stage </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company. The Cyclerion Board directed Dr.&#160;Graul to inform Tisento of its decision not to move forward with the sale of Tisento equity and further directed members of Cyclerion&#8217;s management to identify potential transactions and interested counterparties for the sale of the equity securities of Tisento beneficially owned by Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;22, 2026, Gibson Dunn delivered an initial draft of the Merger Agreement and the CVR Agreement to Ropes&#160;&amp; Gray. Between March&#160;22, 2026, and March&#160;31, 2026, the parties and their respective advisors negotiated the terms and conditions of the transaction documentation. Key points of negotiation on the Merger Agreement included (i)&#160;termination provisions and related fees payable upon the occurrence of certain events by Cyclerion and Korsana and (ii)&#160;procedures for determining Cyclerion&#8217;s net cash position, including deductions for certain fees and expenses. With respect to the CVR Agreement, the key point of negotiation revolved around the length of the post-closing period that Cyclerion shareholders may receive contingent payments, the period of time that dispositions of Cyclerion Legacy Assets could occur, the level of efforts Korsana would need to use to effect such disposition and the ability of a Cyclerion representative to facilitate such disposition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;23, 2026, Dr.&#160;Graul informed Mr.&#160;McGuire of Cyclerion&#8217;s decision not to move forward with the Tisento Proposal at that time, while asking that representatives of Cyclerion and Tisento keep lines of communication open in the event Tisento is willing to offer a higher price for the Tisento equity held by Cyclerion that better aligns the view of the Cyclerion Board of the Tisento equity&#8217;s potential value. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;24, 2026, representatives of Gibson Dunn delivered to Ropes&#160;&amp; Gray drafts of certain ancillary agreements and documents relating to the Merger, the terms of which the parties negotiated through March&#160;31, 2026, including the Parent Support Agreement, Company Support Agreement, <span style="white-space:nowrap">Lock-Up</span> Agreement, Parent Articles of Amendment, which contained the potential terms of the preferred stock to be issued in the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on March 24, 2026, a representative of Ropes&#160;&amp; Gray contacted Gemini Valuation Services, LLC (&#8220;Gemini&#8221;) regarding a potential engagement of Gemini to serve as a financial advisor in connection with the Contemplated Transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;25, 2026, Cyclerion entered into a confidentiality agreement with Gemini. Following the execution of that agreement, Dr.&#160;Graul provided representatives of Gemini with access to certain materials related to the Contemplated Transaction, including the most recent draft of the Merger Agreement and other diligence information requested by Gemini to complete its analysis in connection with the provision of an opinion, if requested by the Cyclerion Board, regarding the fairness, from a financial point of view, of the Exchange Ratio. Representatives of Gemini agreed to complete the work necessary to determine if it would be able to deliver such an opinion. Gemini subsequently provided Cyclerion with an update on any potential conflicts that Gemini might have related to the potential engagement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;27, 2026, the Cyclerion Board held a meeting with Dr.&#160;Graul, Ms.&#160;Chicko, Mr.&#160;Ouellette and representatives of Ropes&#160;&amp; Gray to discuss the status of the reverse merger negotiations, including Merger Agreement and CVR Agreement terms, diligence review of Korsana and asset disposition options for Cyclerion Legacy Assets. The Cyclerion Board reviewed the proposed transaction timeline and Cyclerion&#8217;s existing cash resources, and the terms of the proposed PIPE financing for the transaction, including the potential dilution to Cyclerion shareholders as a result of the proposed PIPE financing, and provided guidance on the terms being negotiated in the transaction documents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;30, 2026, Dr.&#160;Graul, members of Korsana&#8217;s management and representatives of Gemini met via videoconference to provide Gemini with additional information on the Contemplated Transactions and answer questions from Gemini related to its fairness analysis. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on March&#160;30, 2026, the Cyclerion Board held a meeting with Dr.&#160;Graul, Ms.&#160;Chicko, Mr.&#160;Ouellette and representatives from Ropes&#160;&amp; Gray in attendance. At the meeting, a representative of Ropes&#160;&amp; Gray presented an overview of the key terms of the Merger Agreement, the CVR Agreement and other transaction documents, </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including the CVR term, the Exchange Ratio, a mandatory dividend term in the Merger Agreement, and treatment of outstanding Cyclerion equity awards in connection with the Merger. Following discussion of the key issues and alternative approaches to each, the Cyclerion Board directed Cyclerion management and the representatives of Ropes&#160;&amp; Gray to seek to finalize negotiations of the transaction documents and provided guidance on how to proceed with negotiations of certain key terms, including eliminating the mandatory dividend and ensuring that the CVR term in the CVR Agreement is sufficiently long to ensure that Cyclerion shareholders have an opportunity to receive payments under the Akebia License Agreement and in connection with the disposition of equity interests of Tisento held by Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2026, Dr.&#160;Graul, Ms.&#160;Chicko and members of Korsana&#8217;s management and representatives of Wedbush, Gibson Dunn and Ropes&#160;&amp; Gray had a videoconference to discuss the merger consideration calculation, including an update on the valuation of outstanding Korsana equity, which, based upon Korsana&#8217;s latest post-money valuation as determined by conversations with potential investors in the PIPE financing, was agreed to be equal to $268.4&#160;million, and to receive an update on PIPE subscriptions, which were expected to be approximately $380&#160;million to date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on March&#160;31, 2026, Cyclerion entered into an engagement letter with Gemini in advance of the Cyclerion Board&#8217;s meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2026, the Cyclerion Board held a meeting by videoconference, at which Dr.&#160;Graul, Ms.&#160;Chicko, Mr.&#160;Ouellette and representatives of Ropes&#160;&amp; Gray and Gemini were present. Representatives of Ropes&#160;&amp; Gray provided any updates to negotiations of the terms of the Merger Agreement, the CVR Agreement and other ancillary documents associated with the proposed Merger since the previous day&#8217;s meeting. Representatives of Ropes&#160;&amp; Gray then reminded the Cyclerion Board of its fiduciary duties under Massachusetts law, which had been discussed with the Cyclerion Board throughout the process. Gemini then reviewed its financial analyses with respect to Cyclerion, Korsana and the proposed Merger. Thereafter, at the request of the Cyclerion Board, Gemini orally rendered its opinion to the Cyclerion Board (which was subsequently confirmed in writing by delivery of Gemini&#8217;s written opinion dated March&#160;31, 2026, addressed to the Cyclerion Board), as to, as of such date, the fairness, from a financial point of view, to Cyclerion of the Exchange Ratio. Representatives of Cyclerion management and Ropes&#160;&amp; Gray responded to questions from the Cyclerion Board and, after further discussion, the Cyclerion Board provided guidance regarding certain key terms that had not been resolved and adjourned the meeting, indicating that it would consider the final terms and conditions following further negotiations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the morning of April&#160;1, 2026, the Cyclerion Board reviewed updates to the transaction documents made subsequent to the Cyclerion Board meeting during the prior day and unanimously: (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Cyclerion and its shareholders; (ii)&#160;adopted, approved and declared advisable the Merger Agreement, the CVR Agreement, the Cyclerion Support Agreement, the Korsana Support Agreement, the <span style="white-space:nowrap">Lock-Up</span> Agreement and the Contemplated Transactions, including the Merger and issuance of shares of Cyclerion common stock, Cyclerion Series B Preferred Stock and the Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants pursuant to the terms of the Merger Agreement and the issuance of CVRs pursuant to the CVR Agreement in connection with the merger; and (iii)&#160;recommended that Cyclerion&#8217;s shareholders vote in favor of the Parent Shareholder Matters, including the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later on April&#160;1, 2026, the parties entered into the Merger Agreement and the related ancillary documents, other than the CVR Agreement which will be entered into in connection with Closing and the private placement investors executed and delivered the Korsana Securities Purchase Agreement for the PIPE financing. Cyclerion and Korsana then issued a joint press release announcing the execution of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;17, 2026, the parties entered into the amendment to the Merger Agreement to reflect the appropriate voting standard for shareholder approval of the Redomestication Proposal and to remove approval of the Redomestication Proposal from the list of closing conditions to the Merger. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cyclerion&#8217;s Reasons for the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of its evaluation of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement (the &#8220;Contemplated Transactions&#8221;), the Cyclerion Board held numerous meetings, consulted with Cyclerion management, its legal counsel and its financial advisor and reviewed and assessed a significant amount of information and, in reaching its decision to approve the Merger, the Merger Agreement and the Contemplated Transactions, the Cyclerion Board considered the following factors, among others and not necessarily presented in any order of relative importance: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s business, financial performance (both past and prospective) and its financial condition, results of operations (both past and prospective), market capitalization and the need for and inability to raise material amounts of additional capital, business and strategic objectives, including the development of Cyclerion&#8217;s lead neuropsychiatric program, as well as the risks and timing of accomplishing those objectives, including if Cyclerion were to remain an independent company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possible alternatives to the Merger and the Contemplated Transactions available to Cyclerion, the range of possible benefits and risks to Cyclerion&#8217;s shareholders of those alternatives and the timing and the likelihood of accomplishing the goals of any of such alternatives, and the Cyclerion Board&#8217;s assessment that the Merger presented a superior opportunity for Cyclerion&#8217;s shareholders to any such alternatives; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the comprehensive and thorough process of reviewing and analyzing potential strategic alternatives undertaken by the Cyclerion Board and management, including the exploration of potential licensing or other disposition of key assets and financing transactions, such as a private investment in public equity, an <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> equity offering or convertible security financing, and the Cyclerion Board&#8217;s belief that no commercially viable alternative financing, strategic investment, merger, asset sale or licensing transaction was reasonably available to Cyclerion that could reasonably be expected to advance Cyclerion&#8217;s development program to a meaningful value inflection point within the required timeframe; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Cyclerion Board&#8217;s assessment of potential candidates for a strategic transaction, and in particular, the Cyclerion Board&#8217;s view that Korsana was the most attractive and promising candidate, and the Cyclerion Board&#8217;s belief that the Merger would create more value for Cyclerion&#8217;s shareholders than any of the other proposals that the Cyclerion Board had received or Cyclerion could create as a standalone company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the process undertaken by the Cyclerion Board in pursuit of a strategic transaction, including the proposed Merger, in each case considering the current market dynamics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prospects of and risks associated with the other potential strategic counterparties, including multiple reverse merger candidates, that had made proposals for a strategic transaction with Cyclerion based on the scientific, regulatory, financial and strategic due diligence conducted by Cyclerion&#8217;s management and Cyclerion&#8217;s advisors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Cyclerion Board&#8217;s belief, based in part on the scientific, regulatory, financial and strategic due diligence process conducted by Cyclerion&#8217;s management and reviewed with the Cyclerion Board, that Korsana&#8217;s assets and development programs present a scientifically credible market opportunity with the potential to create meaningful value for the shareholders of the Combined Company and an opportunity for Cyclerion&#8217;s shareholders to participate in the future potential growth of the Combined Company, notwithstanding the risks inherent in early-stage development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential for Cyclerion&#8217;s shareholders to receive certain cash payments following the Closing pursuant to the Cyclerion CVR Agreement, which the Cyclerion Board believed preserves for Cyclerion&#8217;s shareholders the potential value from a sale, license or other disposition of any Cyclerion Legacy Assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s current market capitalization, potential dilution from future financings and uncertainty regarding the availability of sufficient capital required to support its plans and objectives to a </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
meaningful value inflection point on terms acceptable to Cyclerion were it to remain an independent company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial market conditions at the time of the signing of the Merger Agreement, including Cyclerion&#8217;s inability to raise financing in a private investment in public equity financing, market prices, volatility and the then-current trading information with respect to Cyclerion common stock, and the possibility that Cyclerion common stock could be delisted from the Nasdaq and only trade through the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> markets, if at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the financial analysis presented by Gemini to the Cyclerion Board on March&#160;31, 2026 and Gemini&#8217;s opinion, dated March&#160;31, 2026, to the Cyclerion Board that, as of such date and based upon and subject to the qualifications, limitations, assumptions and other matters set forth therein, the Exchange Ratio was fair, from a financial point of view, to Cyclerion (as more fully described in the section titled &#8220;<span style="font-style:italic">The Merger&#8212;Opinion of Cyclerion&#8217;s Financial Advisor</span>&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the anticipated strength of Korsana&#8217;s investment base and the potential for the aggregate commitment represented in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing of approximately $380.0&#160;million to fund the balance sheet of the Combined Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the <span style="white-space:nowrap">pre-Merger</span> Cyclerion shareholders are anticipated (if Cyclerion&#8217;s net cash is equal to $0 when calculated pursuant to the terms of the Merger Agreement) to own approximately 1.5% of the fully diluted equity interests of the Combined Company as of the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">following the Merger, if completed, the <span style="white-space:nowrap">pre-Merger</span> Cyclerion shareholders will continue to own Cyclerion common stock and Cyclerion Series A preferred stock, and the Cyclerion Board&#8217;s belief that this continuing equity interest will provide the existing Cyclerion shareholders with an opportunity to participate following the Merger in the potential equity value of the Combined Company, which will focus on Korsana&#8217;s development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Cyclerion Board&#8217;s belief that the terms of the Merger Agreement and the related agreements, including the parties&#8217; respective representations, warranties and covenants, the conditions to their respective obligations to close the Merger and the termination rights of the parties, are reasonable under the circumstances, including: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the belief that, as a result of <span style="white-space:nowrap">arm&#8217;s-length</span> negotiations with Korsana, Cyclerion and its representatives negotiated the most favorable Exchange Ratio to which Korsana was willing to agree, and that the other terms of the Merger Agreement include the most favorable terms to Cyclerion in the aggregate to which Korsana was willing to agree; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the calculation of the Exchange Ratio, Cyclerion net cash at the Closing and the estimated number of shares of Cyclerion common stock, Cyclerion Series B Preferred Stock and Cyclerion <span style="white-space:nowrap">pre-funded</span> warrants to purchase shares of Cyclerion common stock to be issued in the Merger (in addition to Cyclerion equity awards to be issued in the Merger), and the fact that the relative valuation of Cyclerion, and thus the relative percentage ownership of Cyclerion&#8217;s shareholders immediately following the Closing, is subject to change based on the amount of Cyclerion net cash at the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and customary nature of the conditions to Cyclerion&#8217;s and Korsana&#8217;s respective obligations to complete the Merger and the likelihood that the Merger will be completed on a timely basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of Cyclerion under the Merger Agreement to consider unsolicited acquisition proposals under certain circumstances and for the Cyclerion Board to potentially change its recommendation in favor of such a proposal should Cyclerion determine such proposal to constitute, or be reasonably likely to result in, a superior offer or upon the occurrence of any other intervening event; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the belief by the Cyclerion Board of the reasonableness of the potential termination fee of $235,000 payable by Cyclerion if the Merger Agreement is terminated in certain circumstances; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the belief by the Cyclerion Board of the reasonableness of the potential termination fee of $10,736,000 payable by Korsana, depending on the circumstances of the termination, which the Cyclerion Board believed would provide deterrence for competing acquisition proposals and provide Cyclerion with compensation for the time, expense and disruption associated with negotiating the transaction if the Merger is not completed under such specified circumstances; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">Lock-Up</span> Agreements, pursuant to which certain executive officers, directors and stockholders of Korsana have agreed not to transfer their shares of common stock of the Combined Company for the <span style="white-space:nowrap">180-day</span> period after the effective time of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana support agreements, pursuant to which certain stockholders of Korsana, solely in their capacities as stockholders, have agreed to execute a written consent or vote all of their shares of Korsana capital stock in favor of the Merger and against any competing proposals; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Cyclerion support agreements, pursuant to which certain stockholders of Cyclerion, solely in their capacities as stockholders, have agreed, to vote all of their shares of Cyclerion common stock in favor of the Proposals and against any competing proposals. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of its deliberations, the Cyclerion Board also considered, among other things, a variety of risks, uncertainties, and other countervailing factors related to entering into the Merger, the Merger Agreement and the Contemplated Transactions, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that the Merger will not be consummated in a timely manner or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential adverse effects of the public announcement of the Merger on Cyclerion&#8217;s business, including the potential volatility of the trading price of Cyclerion common stock resulting from, among other things, (i)&#160;potential impact of matters relating to Korsana and its financial condition, operating results, development programs and prospects and (ii)&#160;the fact that Korsana is not currently a public company and, as a result, there is no established trading market or market prices for Korsana common stock and limited information related to Korsana is publicly available. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that any Cyclerion Legacy Assets remaining after the Closing will not be monetized and the consequential potential that Cyclerion shareholders will not receive any consideration under the Cyclerion CVRs and the Cyclerion CVRs may otherwise expire valueless; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Korsana will not be able to complete the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing on the terms or amounts contemplated or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that certain provisions of the Merger Agreement could have the effect of discouraging competing proposals involving Cyclerion, including the restrictions on Cyclerion&#8217;s ability to solicit alternative acquisition proposals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that, under certain circumstances, Cyclerion may be required to pay to Korsana a termination fee of $235,000, and the potential effects of such termination fee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the substantial challenges to which the ability of the Combined Company to execute on its business plan will be subject, some of which will be beyond the control of the Combined Company, including risks and challenges relating to execution, technology, regulatory matters, funding needs and the fact that the Combined Company is not anticipated to generate any material amount of revenue in the near future, risks relating to the development and/or commercialization of Korsana&#8217;s development program, including that such development programs may not generate acceptable clinical data in the future or be successfully developed into products that are marketed </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and sold, as well as other scientific, regulatory and financial risks and uncertainties as to the extent to which the Combined Company will be able to successfully execute its business plan on a timely basis, if at all, and achieve its projections; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of Korsana under the Merger Agreement to consider unsolicited acquisition proposals under certain circumstances and for the Korsana Board to potentially change its recommendation in favor of such a proposal should Korsana determine such proposal to constitute, or be reasonably likely to result in, a superior offer or upon the occurrence of any other intervening event; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of the Cyclerion Board under the Merger Agreement to potentially change its recommendation in the case of an intervening event (subject to the terms of the Merger Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the strategic direction of the Combined Company following the completion of the Merger, which will be determined by the Combined Company&#8217;s board, which is not expected to include a representative of the current Cyclerion Board, and the Combined Company&#8217;s management, which is not expected to include any current Cyclerion officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the substantial fees and expenses incurred or that may be incurred by Cyclerion or the Combined Company associated with completing the Merger and the Contemplated Transactions, including the costs associated with any potential transaction related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility of disruptive shareholder demands or litigation following announcement of the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Merger may not be completed despite the parties&#8217; efforts or that the Closing may be unduly delayed and the effects on Cyclerion as a standalone company because of such failure or delay, including that a more limited range of alternative strategic transactions may be available to Cyclerion in such an event and that Cyclerion may experience additional significant challenges associated with its need to raise additional capital through the public or private sale of equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that under certain circumstances, Cyclerion will not be entitled to receive a termination fee from Korsana even in the event that the Merger is not consummated as a result of circumstances which are not under Cyclerion&#8217;s control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the dilution to the existing shareholders of Cyclerion upon the consummation of the Merger and the Contemplated Transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that the Cyclerion net cash, as more fully described below under the caption &#8220;<span style="font-style:italic">The Merger Agreement&#8212;Calculation of Cyclerion&#8217;s Net Cash</span>&#8221; in this proxy statement/prospectus, may be less than $0 at the determination time, which would reduce the relative percentage ownership of Cyclerion&#8217;s existing equityholders in the Combined Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the interests that Cyclerion&#8217;s directors and executive officers have with respect to the transactions that are or may be different from, or in addition to, the interests of Cyclerion&#8217;s shareholders generally, including those interests described in the sections entitled &#8220;<span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Interests of Cyclerion&#8217;s </span><span style="font-style:italic">Directors and Executive Officers in the Merger</span>&#8221; beginning on page&#160;155 in this proxy statement/prospectus; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the various other risks associated with the Combined Company and the Contemplated Transactions, including those described in the sections entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and &#8220;<span style="font-style:italic">Cautionary Note Regarding Forward-Looking Statements</span>&#8221; beginning on pages&#160;33 and 125, respectively, in this proxy statement/prospectus. </p></td></tr></table> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information and factors considered by the Cyclerion Board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by the Cyclerion board of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In light of the variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the Cyclerion Board did not find it useful or practicable to and did not attempt to, quantify, assign or rank any relative or specific weights to the various factors that it considered in reaching its determination that the Merger, the Merger Agreement and the Contemplated Transactions are advisable and in best interests of Cyclerion and Cyclerion&#8217;s shareholders. In considering the factors described above, individual members of the Cyclerion Board may have given different weight to different factors. The Cyclerion Board did not undertake to make any specific determination as to whether any particular factor, or any aspect of any particular factor, was favorable or unfavorable to the ultimate determination of the Cyclerion Board, but rather the Cyclerion Board conducted an overall analysis of the factors described above, including discussions with and questioning of Cyclerion management and representatives of the Cyclerion&#8217;s legal and financial advisors. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This explanation of the reasoning of the Cyclerion Board and all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed in the section titled &#8220;<span style="font-style:italic">Cautionary Note Regarding Forward-Looking Statements</span>&#8221; beginning on page&#160;125. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korsana&#8217;s Reasons for the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of reaching its decision to approve the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, the Korsana Board held numerous meetings, consulted with Korsana&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, the Korsana Board concluded that a merger with Cyclerion, together with the additional financing committed from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, was the best option to generate capital resources to support the advancement of Korsana&#8217;s pipeline and fund the combined organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional factors the Korsana Board considered included the following (which factors are not necessarily presented in any order of relative importance): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the preclinical and clinical development of Korsana&#8217;s pipeline, compared to the capital and investors Korsana could otherwise gain access to if it continued to operate as a privately-held company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing will generate capital resources to fund the Combined Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential benefits from increased public market awareness of Korsana and its pipeline; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical and current information concerning Korsana&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competitive nature of the industry in which Korsana operates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board&#8217;s fiduciary duties to Korsana stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board&#8217;s belief that no alternatives to the Merger, together with the additional financing committed from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, were reasonably likely to create greater value for Korsana stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Korsana Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board&#8217;s expectation that the Merger, together with the additional financing committed from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an IPO; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expected operations, management structure and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and clinical trials); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the business, history, operations, financial resources and credibility of Cyclerion; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of appraisal rights under the DGCL to holders of Korsana capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Korsana capital stock as determined by the Delaware Court of Chancery; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms and conditions of the Merger Agreement, including the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the determination that the expected relative percentage ownership of Cyclerion shareholders and Korsana stockholders in the combined organization was appropriate, based on the Korsana Board&#8217;s judgment and assessment of the approximate valuations of Cyclerion (including the value of the Net Cash Cyclerion is expected to provide to the combined organization) and Korsana (including the value of the amount of proceeds from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expectation that the Merger will be treated as a reorganization for U.S. federal income tax purposes, with the result that the Korsana stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes with respect to the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the limited number and nature of the conditions of the obligation of Cyclerion to consummate the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights of Korsana under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Korsana receive a superior offer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights of Korsana under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the conclusion of the Korsana Board that the potential termination fees payable by Cyclerion or Korsana to the other party, and the circumstances when such fee may be payable, were reasonable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the shares of Cyclerion Common Stock issued to Korsana stockholders, including shares of Cyclerion Common Stock issued in exchange for shares of Korsana Common Stock sold in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, will be registered on a Form <span style="white-space:nowrap">S-4</span> registration statement and will become freely tradable for Korsana stockholders who are not affiliates of Korsana and who are not parties to <span style="white-space:nowrap">lock-up</span> agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Support Agreements, pursuant to which certain directors, officers and stockholders of Korsana and Cyclerion, respectively, have agreed, solely in their capacity as stockholders of Korsana and Cyclerion, respectively, to vote all of their shares of Korsana capital stock or Cyclerion Common Stock in favor of the adoption or approval, respectively, of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Korsana Biosciences, Inc. prior to or upon the closing of the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the likelihood that the Merger will be consummated on a timely basis. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana Board also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Korsana and the ability of Korsana to </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
obtain financing in the future in the event the Merger is not completed; the possibility that the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing might not be completed or completed in accordance with the terms of the Merger Agreement and the potential adverse effect of the public announcement of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing on the reputation of Korsana and the ability of Korsana to obtain financing in the future in the event the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is not completed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Exchange Ratio used to establish the number of shares of Cyclerion Common Stock to be issued to Korsana stockholders in the Merger is fixed, except for adjustments due to Cyclerion&#8217;s net cash balances, the amount of proceeds from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and outstanding capital stock at closing, and thus the relative percentage ownership of Cyclerion shareholders and Korsana stockholders in the combined organization immediately following the completion of the Merger is similarly fixed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential reduction of Cyclerion&#8217;s Net Cash prior to the closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that Cyclerion could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of Cyclerion to obtain the required shareholder vote or the failure of Korsana to close the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, and the potential adverse effect on the reputation of Korsana and the ability of Korsana to obtain financing in the future in the event the Merger is not completed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs involved in connection with completing the Merger, the time and effort of Korsana senior management required to complete the Merger, the related disruptions or potential disruptions to Korsana&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Korsana, and related administrative challenges associated with combining the companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the additional expenses and obligations to which Korsana&#8217;s business will be subject to following the Merger that Korsana has not previously been subject to, and the operational changes to Korsana&#8217;s business, in each case that may result from being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post-closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that future sales of common stock by existing Cyclerion shareholders may cause the price of Cyclerion Common Stock to fall, thus reducing the potential value of Cyclerion Common Stock received by Korsana stockholders following the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;Risk Factors&#8221; in this proxy statement/prospectus. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by the Korsana Board in its consideration of the Merger Agreement, the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Korsana&#8217;s senior management and legal counsel, the Korsana Board concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, the Korsana Board unanimously approved the Merger Agreement, the Merger, the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and the other transactions contemplated by the Merger Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Opinion of Gemini, Cyclerion&#8217;s Financial Advisor, to the Cyclerion Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2026,&#160;Gemini&#160;Valuation Services, LLC (&#8220;Gemini&#8221;) rendered its opinion to the Cyclerion Board, as to the fairness, from a financial point of view, of the Exchange Ratio pursuant to the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">The summary of the opinion in this proxy statement/prospectus is qualified in its entirety by reference to the full text of the written opinion, which is included as&#160;Annex&#160;B&#160;to this proxy statement/prospectus and sets forth the procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered by Gemini in preparing its opinion. The opinion was addressed to the Cyclerion Board for the use and benefit of the members of the Cyclerion Board (in their capacities as such) in connection with the Cyclerion Board&#8217;s evaluation of the Merger Agreement. Neither the opinion nor the summary of the opinion and related analyses set forth in this proxy statement/prospectus is intended to and they do not constitute advice or a recommendation to any of the shareholders of Cyclerion or any other security holders as to how such holder should vote or act with respect to any matter relating to the Contemplated Transactions or otherwise. Gemini&#8217;s opinion should not be construed as creating any fiduciary duty on Gemini&#8217;s part to Cyclerion, any other party to the Merger Agreement, any security holder of Cyclerion or such other party, any creditor of Cyclerion or such other party, or any other person. Gemini&#8217;s opinion was just one of the several factors the Cyclerion Board took into account in making its determination to approve the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini&#8217;s opinion only addressed whether, as of the date of the opinion, the Exchange Ratio was fair, from a financial point of view, to Cyclerion. It did not address any other terms, aspects, or implications of the transaction or the Merger Agreement, including, without limitation, (i)&#160;any term or aspect of the transaction that was not susceptible to financial analysis, or (ii)&#160;fairness to any other security holders of Cyclerion, Korsana or any other person or any creditors or other constituencies of Cyclerion, Korsana or any other person. Gemini expressed no opinion as to (1)&#160;what the value of shares of Cyclerion common stock actually would be when issued to the Korsana shareholders in the Merger Agreement, (2)&#160;the price at which shares of Korsana common stock or any other security of Korsana may be issued or sold in the Korsana Private Placement, or (3)&#160;the prices at which Korsana stock or Cyclerion common stock may trade, be purchased or sold at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini&#8217;s opinion did not address the relative merits of the transaction as compared to any alternative transaction or business strategy that might exist for Cyclerion and did not constitute a recommendation to any Cyclerion shareholder as to how such shareholder should vote with respect to any matter. At the direction of the Cyclerion Board, Gemini did not offer any opinion as to (i)&#160;the material terms of the Merger Agreement or the form of the Contemplated Transactions or any other contractual arrangement that the parties may enter into in connection with the Contemplated Transactions or (ii) the fairness of the Contemplated Transactions to, or any consideration that may be received in connection therewith by, the individual shareholders, nor did Gemini offer any opinion as to the relative fairness of the consideration to be received by different shareholders or the merits of the underlying decision by the Cyclerion Board or Cyclerion to engage in or consummate the transaction. The financial and other terms of the transaction were determined pursuant to negotiations between the parties to the Merger Agreement and were not determined by or pursuant to any recommendation from Gemini. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini&#8217;s analyses and opinion were necessarily based upon market, economic, and other conditions as they existed on, and could be evaluated as of, the date of the opinion. Accordingly, although subsequent developments could arise that would otherwise affect its opinion, Gemini did not assume any obligation to update, review, or reaffirm its opinion to the Cyclerion Board or any other person or otherwise to comment on or consider events occurring or coming to Gemini&#8217;s attention after the date of its opinion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, Gemini made such reviews, analyses, and inquiries as Gemini deemed necessary and appropriate under the circumstances. Among other things, Gemini: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reviewed the financial statements of Korsana for the fiscal years ended December&#160;31, 2024 and December&#160;31, 2025; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reviewed information relating to the business, assets, liabilities, business plan and prospects of Korsana furnished to Gemini by Cyclerion, and the assumptions underlying those; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Conducted discussions with members of senior management and representatives of Korsana concerning the foregoing matters, as well as the business and prospects of Korsana generally, and the assumptions underlying those; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reviewed publicly available financial and stock market data, including valuation levels, for certain other companies in lines of business of Korsana that Gemini deemed relevant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reviewed a draft copy, received by Gemini on March&#160;28, 2026, of the Merger Agreement (the &#8220;Draft Merger Agreement&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Conducted such other financial studies and analyses and considered such other information as Gemini deemed appropriate. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at its opinion, Gemini, with the Cyclerion Board&#8217;s consent, relied upon and assumed, without independently verifying, the accuracy and completeness of all of the financial, legal, regulatory, tax, accounting and other information that was supplied to, discussed with, or reviewed by Gemini, and Gemini, with the Cyclerion Board&#8217;s consent, further relied upon such information being complete and accurate in all material respects. At the direction of the Cyclerion Board, Gemini did not make or obtain any independent evaluations or appraisals of Cyclerion&#8217;s or Korsana&#8217;s assets or liabilities (including any contingent, derivative, or <span style="white-space:nowrap">off-balance-sheet&#160;assets</span> and liabilities) and did not perform or obtain any analysis with respect to the dissolution or liquidation value of such assets or liabilities. At the direction of the Cyclerion Board, Gemini also used the assumptions provided by Cyclerion&#8217;s and Korsana&#8217;s management for the purposes of its analysis and delivering its opinion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini was advised that, given that Cyclerion&#8217;s assets and liabilities are comprised of cash (net of liabilities) and Cyclerion Legacy Assets (which currently are contemplated to be disposed) and that Cyclerion is not expected to have any continuing business operations on a standalone basis other than those incidental to Cyclerion&#8217;s status as a publicly traded company, the management of Cyclerion has not prepared financial forecasts relating to Cyclerion. Accordingly, Gemini did not perform a financial analysis of Cyclerion, the Cyclerion Legacy Assets or the CVRs, and did not ascribe any value to the Cyclerion Legacy Assets or the CVRs. Based upon the terms underlying the Exchange Ratio set forth in the Draft Merger Agreement, Gemini assumed the equity value of Cyclerion to be $10.0&#160;million, and Cyclerion Net Cash at Closing to be $0. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini assumed, with the Cyclerion Board&#8217;s consent, that the representations and warranties of all parties to the Merger Agreement were true and correct, that each party to the Merger Agreement will perform all of the covenants and agreements required to be performed by such party, that all conditions to the consummation of the Merger will be satisfied without waiver thereof, and that the Merger will be consummated in a timely manner in accordance with the terms described in the Merger Agreement, without any modifications or amendments thereto or any adjustment to the Exchange Ratio. In rendering its opinion, Gemini also assumed, with the consent of the Cyclerion Board, that the final executed form of the Merger Agreement would not differ in any material respect from the draft that Gemini examined along with the discussion on the draft. Gemini has not been authorized to and has not solicited indications of interest in a possible transaction with Cyclerion from any party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini did not evaluate the solvency or creditworthiness of Cyclerion, Korsana or any other party to the transaction, or whether Cyclerion, Korsana or any other party to the transaction is paying or receiving reasonably equivalent value in the transaction under any applicable foreign, state, or federal laws relating to bankruptcy, insolvency, fraudulent transfer, or similar matters, nor did Gemini evaluate, in any way, the ability of Cyclerion, Korsana or any other party to the transaction to pay its obligations when they come due. Gemini did not physically inspect Cyclerion&#8217;s or Korsana&#8217;s properties or facilities and did not make or obtain any evaluations or appraisals of Cyclerion&#8217;s or Korsana&#8217;s assets or liabilities (including any contingent, derivative, or <span style="white-space:nowrap">off-balance-sheet</span> assets and liabilities). Gemini did not attempt to confirm whether Cyclerion or Korsana had good title to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their respective assets. Gemini&#8217;s role in reviewing any information was limited solely to performing such reviews as it deemed necessary to support its own advice and analysis and was not on behalf of the Cyclerion Board, Cyclerion, or any other party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini assumed, with the Cyclerion Board&#8217;s consent, that the Contemplated Transactions, including the Merger, would be consummated in a manner that complies in all respects with applicable foreign, federal, state, and local laws, rules, and regulations and that, in the course of obtaining any regulatory or third party consents, approvals, or agreements in connection with the transaction, no delay, limitation, restriction, or condition would be imposed that would have an adverse effect on Cyclerion, Korsana or the Contemplated Transactions. Gemini also assumed, with the Cyclerion Board&#8217;s consent that the transaction would be consummated on the terms set forth in the Merger Agreement, without waiver, modification, or amendment of any term, condition, or agreement thereof material to Gemini&#8217;s analyses or opinion. Gemini also assumed that the representations and warranties of the parties to the Merger Agreement contained therein were true and correct and that each such party would perform all of the covenants and agreements to be performed by it under the Merger Agreement. Gemini offered no opinion as to the contractual terms of the Merger Agreement or the likelihood that the conditions to the consummation of the Merger Agreement, set forth in the Merger Agreement, including, without limitation, any of the ancillary transactions, would be satisfied. Gemini further assumed that for U.S. federal tax income purposes, the Merger Agreement would qualify as a reorganization within the meaning of Section&#160;368 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with preparing its opinion, Gemini performed a variety of financial analyses. The following is a summary of the material financial analyses performed by Gemini in connection with the preparation of its opinion. It is not a complete description of all analyses underlying such opinion. The preparation of an opinion is a complex process involving various determinations as to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances. As a consequence, neither Gemini&#8217;s opinion nor the respective analyses underlying its opinion is readily susceptible to partial analysis or summary description. In arriving at its opinion, Gemini assessed as a whole the results of all analyses undertaken by it with respect to the opinion. While it took into account the results of each analysis in reaching its overall conclusions, Gemini did not make separate or quantifiable judgments regarding individual analyses and did not draw, in isolation, conclusions from or with regard to any individual analysis or factor. Therefore, Gemini believes that the analyses underlying the opinion must be considered as a whole and that selecting portions of its analyses or the factors it considered, without considering all analyses and factors underlying the opinion collectively, could create a misleading or incomplete view of the analyses performed by Gemini in preparing the opinion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implied multiple ranges and implied value reference ranges indicated by Gemini&#8217;s analyses are not necessarily indicative of actual values nor predictive of future results, which may be significantly more or less favorable than those suggested by such analyses. Much of the information used in, and accordingly the results of, Gemini&#8217;s analyses are inherently subject to substantial uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of the material financial analyses performed by Gemini in connection with the preparation of its opinion includes information presented in tabular format. The tables alone do not constitute a complete description of these analyses. Considering the data in the tables below without considering the full narrative description of the analyses, as well as the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses Gemini performed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of its analyses, Gemini reviewed a number of financial metrics, including the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Equity Value</span>&#160;&#8212;&#160;generally the value as of a specified date of the relevant company&#8217;s outstanding equity securities (taking into account its options and other outstanding convertible securities) plus the value as of such date of its net debt (the value of its outstanding indebtedness, preferred stock and minority interests less the amount of cash on its balance sheet). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selected Transactions Analysis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Merger and Acquisition Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini considered certain financial data and the financial terms of the following business transactions, each, involving target companies within the neurology and other relevant segments of the biotechnology industry. The financial data reviewed included the Equity Value, value of capital raised prior to each selected transaction and the related market value of invested capital multiple (&#8220;MVIC Multiples&#8221;). The selected transactions were: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Date Announced</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Phase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Acquirer</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Equity<br/>Value<br/>($m)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Raised&#160;to<br/>Date<br/>($m)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market<br/>Value of<br/>Invested<br/>Capital<br/>Multiple</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">January&#160;20, 2026</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">RAPT&#160;Therapeutics,&#160;Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">GSK plc</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.0x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">December&#160;26, 2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Gracell Biotechnologies Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">AstraZeneca plc</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.1x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">October&#160;14, 2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Longboard&#160;Pharmaceuticals,<br/>Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">H.&#160;Lundbeck&#160;A/S</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.1x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">September&#160;9, 2025</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Tourmaline Bio, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Novartis AG</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.9x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">April&#160;10, 2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Alpine&#160;Immune&#160;Sciences,&#160;Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Vertex&#160;Pharmaceuticals<br/>Incorporated</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">508</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9.7x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">January&#160;7, 2026</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Ventyx Biosciences, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Eli Lilly and Company</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.6x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">September&#160;17, 2025</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">89bio, Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Roche</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.4x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Average</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">610</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.1x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Median</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.0x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini looked at the above transactions within neurology and other relevant segments within the biotechnology industry that Gemini deemed to be relevant based on its professional judgement and experience. Gemini believes that the groups of companies listed above have business models similar to Korsana but noted that none of these companies has the same management, composition, size, operations, financial profile or combination of businesses as Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of the above transactions, each of the selected target comparable companies were clinical- stage, whereas Korsana Biosciences remains a preclinical company. Gemini nevertheless viewed these transactions as relevant reference points because all seven companies are development-stage biotechnology platforms with no meaningful commercial revenue whose valuations were primarily driven by the quality and differentiation of their pipelines, the magnitude of the unmet medical need and the perceived probability of advancing through later-stage clinical development, rather than by near-term cash flow. In evaluating Korsana, Gemini also considered that the selected target companies and Korsana share capital-intensive therapeutic areas (CNS and immune-mediated diseases), blue-chip investor syndicates and large pre-transaction/private financings, which are key drivers of public market appetite for development-stage biotechnology companies. However, Gemini recognizes that the clinical-stage target companies had already generated human data and, in some cases, had defined regulatory pathways, whereas Korsana&#8217;s program is pre-IND and supported only by preclinical data today; accordingly, the clinical-stage target company multiples represent directional, upper-bound benchmarks and Gemini applied a qualitative discount to Korsana&#8217;s valuation to reflect its earlier stage of development, greater technical and regulatory risk, and longer time to potential commercialization. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected transactions had an average and median MVIC Multiple of 4.1x and 3.0x, respectively. Korsana has raised $175&#160;million prior to the Merger and the value of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing as of March&#160;31, 2026, was expected to be $380&#160;million. Based on the observed MVIC Multiples in the selected transactions, which were further adjusted for comparison with the Cyclerion-Korsana (as discussed above), Korsana&#8217;s Equity Value was estimated as follows: </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Valuation Analysis (in $m)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Median</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Average</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korsana Invested Capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MVIC Multiple</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.0x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.0x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Funding</span> Valuation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impending Financing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Public Listing </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini considered certain financial data and the financial terms of the following business transactions, each, involving companies undergoing an initial public offering (&#8220;IPO&#8221;). Each of these four companies is within the neurology and other relevant segments of the biotechnology industry. The financial data reviewed included the total amount of investment raised prior to the public offering, the total amount of investment raised in connection with the public offering, the public offering valuation of the selected company, and the <span style="white-space:nowrap">pre-public</span> offering valuation of the selected company, and the resulting MVIC Multiples determined from comparing <span style="white-space:nowrap">pre-money</span> valuation of the selected companies to each company&#8217;s respective valuation following their respective public offering. The selected transactions were: </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:25%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">IPO Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Phase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br/>Raise<br/><span style="white-space:nowrap">(Pre-</span><br/>Public<br/>Deal)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Public&#160;Deal<br/>Raise</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Public&#160;Deal<br/>Valuation</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Pre-Money</span><br/>Valuation</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market<br/>Value of<br/>Invested<br/>Capital<br/>Multiple</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">June&#160;7, 2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Rapport&#160;Therapeutics,&#160;Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.9x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">September&#160;15,&#160;2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Neumora&#160;Therapeutics,&#160;Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.8x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">January&#160;7, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Amylyx&#160;Pharmaceuticals,&#160;Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">883</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.4x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">June&#160;28, 2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Alumis Inc.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Clinical</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">638</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.0x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Average</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">206</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,074</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.8x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Median</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.8x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini looked at the above transactions within neurology and other relevant segments within the biotechnology industry. Gemini believes that the groups of companies listed above have business models similar to those of Korsana but noted that none of these companies has the same management, composition, size, operations, financial profile or combination of businesses as Korsana. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time of their initial public offerings, each of the selected comparable companies were clinical-stage, whereas Korsana Biosciences remains a preclinical company. Gemini nevertheless viewed these IPOs as relevant reference points because all four companies are development-stage biotechnology platforms with no meaningful commercial revenue whose valuations were primarily driven by the quality and differentiation of their pipelines, the magnitude of the unmet medical need and the perceived probability of advancing through later-stage clinical development, rather than by near-term cash flow. In evaluating Korsana, Gemini also considered that the selected IPO issuers and Korsana share capital-intensive therapeutic areas (CNS and immune-mediated diseases), blue-chip investor syndicates and large pre-IPO/private financings, which are key drivers of public market appetite for development-stage biotechnology companies. However, Gemini recognizes that the clinical-stage issuers had already generated human data and, in some cases, had defined regulatory pathways, whereas Korsana&#8217;s program is pre-IND and supported only by preclinical data today; accordingly, the clinical-stage IPO multiples represent directional, upper-bound benchmarks and Gemini applied a qualitative discount to Korsana&#8217;s valuation to reflect its earlier stage of development, greater technical and regulatory risk, and longer time to potential commercialization. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected transactions had an average and median MVIC Multiple of 2.8x and 2.8x, respectively. Korsana has raised $175&#160;million prior to the Merger and the value of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing as of March&#160;31, 2026, was expected to be $380&#160;million. Based on the observed MVIC Multiples in the selected transactions, which were further adjusted for comparison with the Cyclerion-Korsana transaction (as discussed above), Korsana&#8217;s Equity Value was estimated as follows: </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:78%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Valuation Analysis (in $m)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Median</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Average</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korsana Invested Capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MVIC Multiple</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.3x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.8x</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Funding</span> Valuation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impending Financing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Concluded Equity Value </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the above determined equity value ranges for Korsana and averaging the low and high ranges under each valuation method, the enterprise value for Korsana is estimated to range between $753&#160;million and $891&#160;million. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:84%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Valuation Range (in $m)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Low</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom">High</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comparable Transactions: M&amp;A</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">$730</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">$905</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comparable Transactions: Public Listing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">$777</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">$876</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Relative Valuation Analysis </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gemini compared the above calculated equity value of Korsana against the value of contribution by Cyclerion&#8217;s shareholders to the Merger Agreement below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Merger Agreement, Cyclerion is offering approximately 98.5% of post transaction outstanding common stock to the common stockholders and debt holders of Korsana while Cyclerion shareholders will retain approximately 1.5% of the post transaction outstanding common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the above analyses, Gemini noted that, the implied contribution made by the holders of Cyclerion common stock is lower than the aggregate value of the post-Closing equity position received by the holders of Cyclerion common stock pursuant to the Merger Agreement. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of Korsana&#8217;s outstanding equity, as set forth in the Merger Agreement, was equal to $268.4 million. The aggregate amount of investor commitments received in connection with the Korsana Pre-Closing Financing was expected to be approximately $380&#160;million as of March&#160;31, 2026, the date on which Gemini delivered its opinion. Based upon these two inputs, the Company Valuation (as defined in the Merger Agreement) was determined to be $648.4 million. Accordingly, based upon the range of Korsana equity values determined by Gemini&#8217;s analysis of $730 million to $905 million, the valuation of Korsana determined in accordance with the Merger Agreement, was fair, from a financial point of view, to Cyclerion and as a result, the Exchange Ratio under the Merger Agreement was fair, from a financial point of view, to Cyclerion. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Matters Relating to Gemini&#8217;s Opinion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of a fairness opinion is a complex analytical process involving various determinations as to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a fairness opinion is not readily susceptible to summary description. In arriving at its opinion, Gemini did not draw, in isolation, conclusions from or with regard to any factor or analysis that it considered. Rather, Gemini made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of the analyses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Gemini opinion was one of the many factors taken into consideration by the Cyclerion Board in making its determination to approve the Merger Agreement. Consequently, the analyses as described above should not be viewed as determinative of the opinion of the Cyclerion Board with respect to the Exchange Ratio in the Merger Agreement or of whether the Cyclerion Board would have been willing to agree to a different exchange ratio. The Exchange Ratio in the Merger Agreement was determined through <span style="white-space:nowrap">arm&#8217;s-length</span> negotiations between Cyclerion and Korsana and was approved by the Cyclerion Board. Neither Gemini nor any of its affiliates recommended any specific exchange ratio to Cyclerion or the Cyclerion Board or that any specific exchange ratio constituted the only appropriate exchange ratio for the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of its financial advisory business, Gemini regularly is engaged in the evaluation of businesses and their securities in connection with mergers, acquisitions, corporate restructurings, private placements and other purposes. Gemini is a recognized advisory firm that has substantial experience in providing financial advice in connection with proposed mergers, acquisitions, sales of companies, businesses and other assets and other transactions. Gemini regularly undertakes valuation engagements in connection with public offerings, private placements, business combinations and similar transactions. Gemini may provide financial advisory and other financial services to Cyclerion and/or Korsana or other participants in the merger in the future, for which Gemini may receive compensation. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the two years preceding the date of Gemini&#8217;s written opinion, Gemini did not have a commercial or investment banking relationship with Cyclerion or Korsana and has not received any compensation for prior work performed. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For services rendered in connection with the delivery of its opinion, Cyclerion paid Gemini an advisory fee, a portion of which was paid upon the signing of the engagement letter and the balance of which was paid following delivery of Gemini&#8217;s opinion. As of the date hereof, Gemini&#8217;s fee has been fully paid. No portion of Gemini&#8217;s fee was contingent upon the closing of the Merger or upon the conclusions reached in its written opinion.&#160;Cyclerion also agreed to reimburse Gemini for its reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket&#160;expenses</span></span> incurred in connection with its services and will indemnify Gemini against certain liabilities arising out of its engagement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion selected Gemini to render a fairness opinion in connection with the Merger based on Gemini&#8217;s professional qualifications, as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">The Gemini opinion does not constitute a recommendation to the Cyclerion Board or any Cyclerion</span> <span style="font-weight:bold">shareholder as to how the Cyclerion Board, such shareholder or any other person should vote or otherwise</span> <span style="font-weight:bold">act with respect to the Merger or any other matter, including whether or not any Cyclerion shareholder</span> <span style="font-weight:bold">should enter into any voting, support, stockholder or other agreements, arrangements or understandings in connection with the Merger</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Cyclerion&#8217;s Directors and Executive Officers in the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Cyclerion Board with respect to approving the Merger, shareholders should be aware that Cyclerion&#8217;s current directors and officers have interests in the Merger that are different from, or in addition to, the interests of Cyclerion&#8217;s shareholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that Cyclerion&#8217;s shareholders approve the Merger as contemplated by this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Treatment of Cyclerion Options and Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, prior to the closing of the Merger, the Cyclerion Board will accelerate the vesting of all equity awards of Cyclerion then outstanding but not then vested or exercisable, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regardless of whether requirements for performance-based vesting have been met, and cancel each option to acquire shares of Cyclerion Common Stock with an exercise price per share greater than the Cyclerion Closing Price. At the closing of the First Merger, <span style="white-space:nowrap"><span style="white-space:nowrap">(i)&#160;In-the-Money</span></span> Cyclerion Options will be cancelled and converted into the right to receive an amount in cash without interest, less applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Cyclerion Closing Price over the exercise price per share of the Cyclerion Common Stock underlying such option by (B)&#160;the number of shares of Cyclerion Common Stock underlying such option and (ii)&#160;each other option to acquire shares of Cyclerion Common Stock will be cancelled for no consideration. The vesting of each Cyclerion RSA will be accelerated in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth information regarding the Cyclerion stock options held as of&#8195;&#8195;&#8195;&#8195;, 2026 by each of Cyclerion&#8217;s executive officers and <span style="white-space:nowrap">non-employee</span> directors. No Cyclerion executive officer or <span style="white-space:nowrap">non-employee</span> director holds any restricted stock awards. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:52%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Participant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of<br/>Vested<br/>Options<br/>Held (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Weighted<br/>Average<br/>Exercise&#160;Price<br/>of Vested<br/>Options ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of<br/>Unvested<br/>Options<br/>Held (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Weighted<br/>Average<br/>Exercise<br/>Price of<br/>Unvested<br/>Options&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina Graul, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rhonda Chicko</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Errol De Souza, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Hecht, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Higgins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Hyman, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dina Katabi, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential Payments upon Termination or Change in Control </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Graul is subject to an amended and restated offer letter with Cyclerion (the &#8220;A&amp;R Graul Offer Letter&#8221;), which provides that, in the event Dr.&#160;Graul&#8217;s employment is terminated by Cyclerion without &#8220;cause&#8221;, or for &#8220;good reason&#8221; (each as defined in the A&amp;R Graul Offer Letter and as described in more detail in the section titled &#8220;<span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> Executive Compensation</span>&#8221; on page 207), subject to Dr.&#160;Graul&#8217;s execution and <span style="white-space:nowrap">non-revocation</span> of a release, the executive is entitled to (i)&#160;nine months of salary continuation, (ii)&#160;an amount equal to twelve months of health insurance premium contributions at the same monthly rate that Cyclerion provides reimbursement for such health insurance premium contributions immediately prior to the termination date, in the case of (i)&#160;and (ii), payable in a lump sum on the first regularly scheduled payroll date following the effectiveness of a release via payroll, and (iii)&#160;full acceleration of any unvested Cyclerion equity awards. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the A&amp;R Graul Offer Letter, Dr.&#160;Graul will be entitled, at the Cyclerion Board&#8217;s discretion, to receive a bonus of up to $150,000 payable upon the consummation of transaction resulting in a change of control of Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger will constitute a &#8220;change in control&#8221; for purposes of the A&amp;R Graul Offer Letter. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Golden Parachute Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth in the table below is intended to comply with Item 402(t) of Regulation <span style="white-space:nowrap">S-K,</span> which requires disclosure of compensation that each named executive officer could receive that is based on or otherwise relates to the Merger. This compensation is referred to as &#8220;golden parachute&#8221; compensation by the applicable SEC disclosure rules, and in this section Cyclerion uses such term to describe the Merger-related compensation payable to Cyclerion&#8217;s named executive officers. For additional details regarding the terms of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payments and benefits described below, see the discussion above. This Merger-related compensation is subject to a <span style="white-space:nowrap">non-binding</span> advisory vote of Cyclerion shareholders, as set forth in Proposal No.&#160;9 to this proxy statement/prospectus. See the section entitled &#8220;<span style="font-style:italic">Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;9</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">The Merger Compensation Proposal</span>&#8221; on page 277. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts indicated below are estimates based on multiple assumptions that may or may not actually occur or be accurate on the relevant date, including assumptions described below, and do not reflect certain compensation actions that may occur before the consummation of the Merger. For purposes of calculating such amounts, the Company has assumed: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relevant price per share of Cyclerion Common Stock is $4.61 per share, which is the average closing market price of Cyclerion Common Stock over the first five business days following the first public announcement of the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Merger is consummated on April&#160;9, 2026; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a termination of Dr.&#160;Graul&#8217;s employment by Cyclerion without cause or by Dr.&#160;Graul for good reason (in each case, as defined in the A&amp;R Graul Offer Letter) occurred on April&#160;9, 2026. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="26" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Golden Parachute Payments</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Cash<br/>($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Equity<br/>($)(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Pension/<br/>NQDC<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Perquisites/<br/>Benefits<br/>($)(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Tax<br/>Reimbursement<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Other<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina Graul, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">315,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">200,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">48,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">563,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rhonda Chicko</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">27,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">27,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reported in the &#8220;Cash&#8221; column represents a lump sum cash payment of nine months of base salary payable pursuant to the A&amp;R Graul Offer Letter, as discussed in further detail above. This amount is a &#8220;double trigger&#8221; payment. No amount is included with respect to the potential bonus that Dr. Graul may receive in connection with a change in control (up to $150,000) because this bonus is at the discretion of the Board. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reflect the acceleration value of unvested option and restricted stock awards held by the named executive officers. The amounts reported in this column are attributable to single-trigger arrangements (i.e., the amounts are triggered by the change in control alone) and represent, as they relate to option awards, the difference between $4.61 and the exercise price of the applicable option, multiplied by the number of shares of Clyclerion Common Stock subject to unvested options as of April&#160;9, 2026, and, as they relate to restricted stock awards, $4.61 multiplied by each share of restricted Cyclerion Common Stock outstanding as of April&#160;9, 2026. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amount reported represents the estimated cost of 12 months of health insurance premiums contributions payable pursuant to the A&amp;R Graul Offer Letter, as discussed in further detail above. This amount is a &#8220;double trigger&#8221; payment. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interests of Korsana&#8217;s Directors and Executive Officers in the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Korsana Board with respect to approving the Merger, stockholders should be aware that Korsana&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Korsana stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Korsana stockholders approve the Merger as contemplated by this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana Ownership Interests </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2026, Korsana&#8217;s current <span style="white-space:nowrap">non-employee</span> directors and executive officers beneficially owned, in the aggregate approximately 44.6% of the shares of Korsana capital stock, which for purposes of this </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsection excludes any Korsana shares issuable upon exercise or settlement of Korsana Options and Korsana RSUs held by such individual. Each of Korsana&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<span style="font-style:italic">Agreements</span><span style="font-style:italic"> </span><span style="font-style:italic">Related</span><span style="font-style:italic"> </span><span style="font-style:italic">to</span><span style="font-style:italic"> </span><span style="font-style:italic">the Merger &#8212; Support Agreements</span>&#8221; beginning on page 188 of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, Fairmount Fund II, Venrock Healthcare Capital Partners, and Jonathan Violin currently hold shares of Korsana capital stock. Three of Korsana&#8217;s directors (Mr.&#160;Kiselak, Ms.&#160;Pernice, and Dr.&#160;Violin) and one of Korsana&#8217;s executive officers (Dr.&#160;Violin) have current or historical affiliations or associations with Fairmount. Two of Korsana&#8217;s directors (Dr.&#160;Gottesdiener and Mr.&#160;Shah) are affiliated with Venrock Healthcare Capital Partners. The table below sets forth the ownership of Korsana capital stock by Fairmount Fund II, Venrock Healthcare Capital Partners, and Jonathan Violin as of March&#160;31, 2026. Fairmount Fund II and Venrock Healthcare Capital Partners have also agreed to purchase Korsana Common Stock and Korsana Pre-Funded Warrants in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. For a more detailed discussion of these relationships, please see the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions of the Combined Company &#8212; </span><span style="font-style:italic">Korsana</span><span style="font-style:italic"> Transactions &#8212; </span><span style="font-style:italic">Korsana</span><span style="font-style:italic"> <span style="white-space:nowrap">Pre-Closing</span> Financing</span>&#8221; beginning on page 386 of this proxy statement/prospectus. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:63%"/>

<td style="vertical-align:bottom;width:23%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Stockholder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares&#160;of&#160;Capital&#160;Stock&#160;held</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fairmount Healthcare Fund II L.P.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Venrock Healthcare Capital Partners</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,700,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Violin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 22,500,000 shares of Korsana Common Stock issuable upon conversion of 10,000,000 shares of Korsana Series Seed Preferred Stock and 12,500,000 shares of Korsana Series A Preferred Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 21,700,000 shares of Korsana Common Stock issuable upon conversion of 9,200,000 shares of Korsana Series Seed Preferred Stock and 12,500,000 shares of Korsana Series A Preferred Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These shares of restricted stock vest as to 25% on June&#160;1, 2026 and thereafter in approximately equal monthly installments for 36 months, subject to Dr.&#160;Violin&#8217;s continued service through the applicable vesting date. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Violin Anti-Dilution Provision </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the consulting agreement and offer letter between Korsana and Dr.&#160;Violin, Korsana is obligated to issue additional options to purchase shares of Korsana Common Stock in order to maintain Dr.&#160;Violin&#8217;s ownership in Korsana at approximately 5% on a fully-diluted basis until Korsana has raised an aggregate of $200&#160;million in financing following the effective date of his consulting agreement. The options granted to Dr.&#160;Violin on October&#160;27, 2025 were in partial satisfaction (with respect to $151&#160;million in financing) of such obligation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each option to purchase shares of Korsana Common Stock that is outstanding and unexercised immediately prior to the First Effective Time under Korsana&#8217;s 2025 Equity Incentive Plan and that, following assumption by Cyclerion at the First Effective Time, will be eligible to be registered on Form <span style="white-space:nowrap">S-8,</span> whether or not vested, will be converted into an option to purchase shares of Cyclerion Common Stock. Cyclerion will assume Korsana&#8217;s 2025 Equity Incentive Plan and each such outstanding option to purchase shares of Korsana Common Stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of Korsana&#8217;s 2025 Equity Incentive Plan and the terms of the stock option agreement by which such option to purchase shares of Korsana Common Stock is evidenced. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth information regarding the Korsana stock options held as of March 31, 2026 by each of Korsana&#8217;s current executive officers and <span style="white-space:nowrap">non-employee</span> directors. The number of shares of common stock underlying such options and the exercise price will be adjusted appropriately to reflect the Exchange Ratio. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Participant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of<br/>Vested<br/>Options<br/>Held (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Weighted<br/>Average<br/>Exercise&#160;Price<br/>of Vested<br/>Options ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Unvested<br/>Options<br/>Held (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Weighted<br/>Average<br/>Exercise<br/>Price of<br/>Unvested<br/>Options&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Violin, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,054,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Vignola, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,221,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Madelyn Zeylikman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">733,121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Gottesdiener</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle Pernice</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimish Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korsana Management Following the Merger </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the section captioned &#8220;Management Following the Merger&#8221; beginning on page&#160;379 of this proxy statement/prospectus certain of Korsana&#8217;s directors and executive officers are expected to become the directors and executive officers of the Combined Company upon the closing of the Merger. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indemnification and Insurance </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the indemnification and insurance provisions related to the Korsana directors and officers under the Merger Agreement, please see the section titled &#8220;<span style="font-style:italic">The Merger Agreement &#8212; Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page&#160;182 of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Form of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL and DLLCA, (i)&#160;at the First Effective Time, First Merger Sub will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the First Merger and (ii)&#160;immediately following the First Merger and as part of the same overall transaction as the First Merger (the &#8220;Second Effective Time&#8221;), Korsana will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Merger Consideration and Adjustment </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and excluding shares to be cancelled pursuant to the Merger Agreement and dissenting shares) will be automatically converted solely into the right to receive a number of shares of Cyclerion Common Stock or Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants equal to the Exchange Ratio (described in more detail in the section titled &#8220;<span style="font-style:italic">The Merger Agreement &#8212; Exchange Ratio</span>&#8221; beginning on page&#160;169 of this proxy statement/prospectus), (ii) each then-outstanding share of Korsana Series Seed Preferred Stock (excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares) will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then-outstanding Korsana Option will be converted into and become an option to purchase shares of Cyclerion Common Stock on the existing terms and conditions (including with </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement, (iv)&#160;each then-outstanding Korsana RSU will be converted into and become a Cyclerion RSU on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement, and (v)&#160;each then-outstanding and unexercised Korsana Warrant (including Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) will be converted into a Cyclerion Warrant, subject to adjustment as set forth in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares of Cyclerion Common Stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of Cyclerion Common Stock resulting from the conversion of shares of Korsana Common Stock (including shares of Korsana Common Stock issued in the Korsana Pre-Closing Financing) shall be issued as follows: (i)&#160;one share of Cyclerion Common Stock if the aggregate amount of fractional shares of Cyclerion Common Stock of any individual holder of Korsana capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of Cyclerion Common Stock if the aggregate amount of fractional shares of Cyclerion Common Stock of any individual holder of Korsana capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Cyclerion Series B Preferred Stock that a holder of Korsana Series Seed Preferred Stock would otherwise be entitled to receive will be aggregated with all fractional shares of Cyclerion Series B Preferred Stock issuable to such holder and rounded up to the nearest whole share of Cyclerion&#8217;s Series B Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Procedures for Exchanging Stock Certificates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or prior to the closing date, Cyclerion and Korsana will select an exchange agent (the &#8220;Exchange Agent&#8221;) and, at the First Effective Time, Cyclerion will deposit with the Exchange Agent evidence of book-entry shares representing the shares of Cyclerion Common Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Korsana Common Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) and Korsana Series A Preferred Stock (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of Cyclerion Series B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Korsana Series Seed Preferred Stock calculated in accordance with the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the First Effective Time, the Exchange Agent will mail to each record holder of Korsana Common Stock, Korsana Series A Preferred Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares)&#160;(i) a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates and identifying the record holder&#8217;s book-entry shares in exchange for the merger consideration. Upon delivery to the Exchange Agent of a duly executed letter of transmittal in accordance with the Exchange Agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates and identification of book-entry shares, if applicable, and delivery to the Exchange Agent of such other documents as may be reasonably required by the Exchange Agent or Cyclerion, the record holder of such stock certificates or book-entry shares, as applicable, will be entitled to receive in exchange therefor book-entry shares representing the number of whole shares of Cyclerion Common Stock or Cyclerion Series B Preferred Stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Korsana Common Stock or Korsana Series Seed Preferred Stock will be cancelled. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the First Effective Time, each certificate or book-entry share representing Korsana Common Stock, Korsana Series Seed Preferred Stock or Korsana Series A Preferred Stock that has not been surrendered will represent only the right to receive shares of Cyclerion Common Stock or Cyclerion Series B Preferred Stock, as applicable, issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">HOLDERS OF KORSANA CAPITAL STOCK SHOULD NOT SEND IN THEIR KORSANA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF KORSANA STOCK CERTIFICATES. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">First Effective Time and Second Effective Time </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Korsana stockholders and the approval by the Cyclerion shareholders of the issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The First Merger will become effective upon the filing of a certificate of merger (the &#8220;First Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by Cyclerion and Korsana and specified in the First Certificate of Merger. The Second Merger will become effective upon the filing of a certificate of merger (the &#8220;Second Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by Cyclerion and Korsana and specified in the Second Certificate of Merger. Neither Cyclerion nor Korsana can predict the exact timing of the consummation of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory Approvals </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, Cyclerion must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, to Korsana&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is subject to the requirements of the HSR Act and the related rules and regulations, which provide that certain transactions may not be completed until notification and report forms have been furnished to the DOJ and the FTC and until certain waiting periods have been terminated or have expired. The HSR Act requires Cyclerion and Korsana to observe a <span style="white-space:nowrap"><span style="white-space:nowrap">30-calendar-day</span></span> waiting period after the submission of their respective HSR notification and report forms before consummating the Merger. The waiting period may be shortened if the reviewing agency grants &#8220;early termination&#8221; of the waiting period or lengthened if the acquiring person (here Cyclerion) voluntarily withdraws and refiles to allow a second <span style="white-space:nowrap"><span style="white-space:nowrap">30-calendar-day</span></span> waiting period, or if the reviewing agency issues a request for additional information or documentary material (a &#8220;Second Request&#8221;) prior to the expiration of the initial waiting period, the parties must observe a second <span style="white-space:nowrap"><span style="white-space:nowrap">30-calendar-day</span></span> waiting period, which begins to run only after each of the parties has substantially complied with the Second Request. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 22, 2026, Cyclerion and Korsana each filed a notification and report form under the HSR Act with the DOJ and the FTC. The applicable waiting period required under the HSR Act expired at 11:59 p.m., Eastern Time, on May 22, 2026. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Federal Income Tax Considerations of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of Korsana Common Stock and of Korsana Preferred Stock (collectively, &#8220;Korsana stock&#8221;) of the Merger. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <span style="white-space:nowrap">non-U.S.</span> tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. Korsana has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to a U.S. Holder that holds Korsana stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including, without limitation, the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&#160;451(b) of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. expatriates and former citizens or long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. Holders whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Korsana stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks, insurance companies and other financial institutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts or regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers or traders in securities or other persons that elect to use a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting for their holdings in Korsana stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations or governmental organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons deemed to sell Korsana stock under the constructive sale provisions of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who hold or receive Korsana stock pursuant to the exercise of any employee stock option or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-qualified</span> retirement plans; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that own, or have owned, actually or constructively, more than 5% of Korsana stock; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds Korsana stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Korsana stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the Merger arising under U.S. federal estate or gift tax laws, the laws of any state, local or <span style="white-space:nowrap">non-U.S.</span> taxing jurisdiction or any applicable income tax treaty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Korsana stock that, for U.S. federal income tax purposes, is or is treated as any of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Korsana and Cyclerion intends that the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code. Assuming the Merger so qualifies, a U.S. Holder will not recognize gain or loss upon the exchange of its Korsana stock for Cyclerion Common Stock or Cyclerion Series B Preferred Stock (collectively, &#8220;Cyclerion stock&#8221;). A U.S. Holder will have the same aggregate basis in its Cyclerion stock after the Merger as such U.S. Holder had in the corresponding Korsana stock immediately prior to the Merger. A U.S. Holder&#8217;s holding period in the Cyclerion stock immediately following the Merger will include such U.S. Holder&#8217;s holding period in the corresponding Korsana stock immediately prior to the Merger. If a U.S. Holder holds different blocks of Korsana stock (generally, Korsana stock acquired on different dates or at different prices), such U.S. Holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of Cyclerion stock received in the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each U.S. Holder is urged to consult its tax advisor regarding the U.S. federal income tax considerations of the Merger in light of its personal circumstances and the considerations to them under state, local and <span style="white-space:nowrap">non-U.S.</span> tax laws and other federal tax laws. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each U.S. Holder who receives Cyclerion stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. Holder who owned immediately before the Merger at least one percent (by vote or value) of the total outstanding stock of Korsana or who owned securities in Korsana with a basis of $1,000,000 or more is required to attach a statement to its tax return for the year in which the Merger is consummated that contains the information listed in Treasury Regulation <span style="white-space:nowrap">Section&#160;1.368-3(b).</span> Such statement must include the U.S. Holder&#8217;s tax basis in such U.S. Holder&#8217;s Korsana stock surrendered in the Merger, the fair market value of such Korsana stock, the date of the Merger, and the name and employer identification number of each of Korsana and Cyclerion. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nasdaq Stock Market Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Cyclerion Common Stock are currently listed on Nasdaq under the symbol &#8220;CYCN.&#8221; Cyclerion has agreed to use commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&#160;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Cyclerion Common Stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to the Cyclerion Articles effecting the proposed reverse stock split, certified by the Secretary of the Commonwealth of Massachusetts, to Nasdaq on the closing date of the Merger; and (d)&#160;to the extent required by Nasdaq Marketplace Rule 5110, assist Korsana in preparing and filing an initial listing application for the Cyclerion Common Stock issued to Korsana stockholders (including any common stock issuable upon conversion of the Cyclerion Series B Preferred Stock) (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Merger Agreement, each of Cyclerion&#8217;s and Korsana&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the closing of the Merger, of various conditions, including that the Nasdaq Listing Application shall have been approved. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Nasdaq Listing Application is approved, Cyclerion anticipates that the common stock of the Combined Company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;KRSA.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the Combined Company must maintain a bid price of $4.00 or higher for a certain period of time following the proposed reverse stock split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anticipated Accounting Treatment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is expected to be treated by Cyclerion as a reverse merger and is expected to be accounted for as an <span style="white-space:nowrap">in-substance</span> reverse recapitalization of Cyclerion by Korsana in accordance with U.S. GAAP as, at close, the transaction is, in essence, the issuance of equity for Cyclerion&#8217;s net assets, consisting of nominal assets and liabilities before the Merger. For accounting purposes, Korsana is considered to be acquiring the assets and liabilities of Cyclerion in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Korsana&#8217;s equity holders will own a substantial majority of the voting rights in the Combined Company; (ii)&#160;Korsana&#8217;s largest stockholder will retain the largest interest in the Combined Company; (iii)&#160;Korsana will designate all of the initial members of the board of directors of the Combined Company; and (iv)&#160;Korsana&#8217;s executive management team will become the management of the Combined Company. The Combined Company will be named Korsana Biosciences, Inc. Accordingly, the Merger is expected to be treated as the equivalent of Korsana issuing stock to acquire the net assets of Cyclerion. As a result of the Merger, the net assets of Cyclerion will be stated at fair value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Korsana. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital.</span></span> See the &#8220;<span style="font-style:italic">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal Rights and Dissenters&#8217; Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, Cyclerion shareholders are not entitled to appraisal rights in connection with the Merger. Korsana stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below is not a complete summary regarding Korsana&#8217;s stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <span style="font-style:italic">Annex L</span> in this proxy statement/prospectus. Stockholders intending to exercise appraisal rights should carefully review <span style="font-style:italic">Annex L</span>. Failure to follow precisely any of the statutory procedures set forth in <span style="font-style:italic">Annex L</span> may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Korsana stockholders exercise their appraisal rights under Delaware law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&#160;262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten days after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger is completed, within ten days after the effective date of the Merger, Korsana will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Korsana capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Korsana within 20 days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Korsana of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Korsana capital stock held by such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder. Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to c/o Korsana Biosciences, Inc., 203 Crescent Street, Bldgs. #3/3A/4, Suite 503, Waltham, MA 02453, and should be executed by, or on behalf of, the record holder of shares of Korsana capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ALL DEMANDS MUST BE RECEIVED BY KORSANA WITHIN 20 DAYS AFTER THE DATE KORSANA MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Korsana capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Korsana capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be effective, a demand for appraisal by a holder of shares of Korsana capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Korsana. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold your shares of Korsana capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time within 60 days after the First Effective Time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding nor joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Korsana. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the merger consideration for your shares of Korsana capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120 days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10 days after the stockholder&#8217;s written request is received by the surviving corporation or within 10 days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120 days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and Cyclerion, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20 days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In <span style="font-style:italic">Weinberger v. UOP, Inc.</span>, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In <span style="font-style:italic">Cede</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&amp; Co. v. Technicolor, Inc.</span>, the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In <span style="font-style:italic">Weinberger</span>, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the First Effective Time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120 days after the First Effective Time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60 days after the First Effective Time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Korsana capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60 days after the First Effective Time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_8">THE MERGER AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement, including the amendment thereto, is attached to this proxy statement/prospectus as Annex A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about Cyclerion, Korsana, First Merger Sub or Second Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Merger Agreement contains representations and warranties that Cyclerion, First Merger Sub, and Second Merger Sub, on the one hand, and Korsana, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Merger Agreement. While Cyclerion and Korsana do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies, and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Cyclerion or Korsana, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Cyclerion, First Merger Sub, Second Merger Sub and Korsana and are modified by the disclosure schedules. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, the DLLCA, and the MBCA, at the Closing, First Merger Sub, a wholly owned subsidiary of Cyclerion, will merge with and into Korsana, with Korsana surviving the First Merger as a wholly owned subsidiary of Cyclerion (the &#8220;First Merger&#8221;). Immediately following the First Merger, and as part of the same overall transaction, Korsana will merge with and into Second Merger Sub, a wholly owned subsidiary of Cyclerion, with Second Merger Sub surviving the Second Merger as the surviving entity (the &#8220;Second Merger&#8221;). Upon completion of the Second Merger, Second Merger Sub will be renamed &#8220;Korsana Biosciences Operating Company, LLC.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Completion and Effectiveness of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by Korsana stockholders and the approval by Cyclerion shareholders of the issuance of Cyclerion Common Stock and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the Closing. The Merger will become effective upon the filing of certificates of Merger with the Secretary of State of the State of Delaware or at such later time as is agreed by Cyclerion and Korsana and specified in the certificates of Merger. Neither Cyclerion nor Korsana can predict the exact timing of the consummation of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Merger Consideration </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Korsana Common Stock and Korsana Series A Preferred Stock (including </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), excluding shares of Korsana capital stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Common Stock and/or, in the event that they would receive, pursuant to the Exchange Ratio, a number of shares of Cyclerion Common Stock, that (when aggregated with all securities then beneficially owned by such person and its affiliates (as calculated pursuant to Section&#160;13(d) of the Exchange Act and Rule <span style="white-space:nowrap">13d-3</span> promulgated thereunder)) would be in excess of a set beneficial ownership limitation applicable to such holder, Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants, equal to the Exchange Ratio (described in more detail below), and (ii)&#160;each then-outstanding share of Korsana Series Seed Preferred Stock, excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement. No fractional shares of Cyclerion Common Stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of Cyclerion Common Stock resulting from the conversion of shares of Korsana capital stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) shall be issued as follows: (i)&#160;one share of Cyclerion Common Stock if the aggregate amount of fractional shares of Cyclerion Common Stock such holder of Korsana capital stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii)&#160;no shares of Cyclerion Common Stock if the aggregate amount of fractional shares of Cyclerion Common Stock such holder of Company Capital Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exchange Ratio </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exchange Ratio is calculated using a formula intended to allocate existing Cyclerion and Korsana securityholders a percentage of the Combined Company. Based on Cyclerion&#8217;s and Korsana&#8217;s capitalization as of&#160;March&#160;31, 2026, the Exchange Ratio was estimated to be equal to approximately 1.1009 shares of Cyclerion Common Stock for each share of Korsana Common Stock. This estimate is subject to adjustment prior to the closing of the Merger for Cyclerion&#8217;s Net Cash as of 11:59 p.m. on the business day prior to the anticipated closing date (the &#8220;Cash Determination Time&#8221;) (and as a result, Cyclerion securityholders could own less, and Korsana securityholders (including, for this purpose, investors in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) could own more, or vice versa, of the Combined Company). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the estimates set forth above, after giving effect to the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, and certain other assumptions, immediately following the completion of the Merger, Cyclerion securityholders would own approximately 1.5% of the capital stock of the Combined Company post-Merger on a fully-diluted basis, and Korsana securityholders, including shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants purchased in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, would own approximately 98.5% of the capital stock of the Combined Company post-Merger on a fully-diluted basis. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if Cyclerion&#8217;s Net Cash as of Closing is less than or greater than $0. There can be no assurance that any of these assumptions will be accurate at Closing when the final Exchange Ratio is determined. For more information on the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, please see the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger &#8212; Securities Purchase Agreement</span>&#8221; beginning on page&#160;188 of this proxy statement/prospectus. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exchange Ratio formula is the quotient obtained (rounded to four decimal places) by dividing number of Korsana Merger Shares by the Korsana Outstanding Shares, in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Aggregate Valuation&#8221; means the sum of (i)&#160;the Korsana Valuation and (ii)&#160;the Cyclerion Valuation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Post-Closing Cyclerion Shares&#8221; means the quotient determined by dividing (i)&#160;the Cyclerion Outstanding Shares by (ii)&#160;the Cyclerion Allocation Percentage. The estimated Exchange Ratio for purposes of the unaudited pro forma condensed combined financial information was derived on a fully-diluted basis as of December&#160;31, 2025 for Cyclerion and March&#160;31, 2026 for Korsana,<sup style="font-size:75%; vertical-align:top"> </sup>using </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
a stipulated value of Korsana of $268.4&#160;million (excluding the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) and of Cyclerion of $10&#160;million. For more information, see &#8220;Unaudited Pro Forma Condensed Combined Financial Information.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Cyclerion Allocation Percentage&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by dividing (i)&#160;the Cyclerion Valuation by (ii)&#160;the Aggregate Valuation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Cyclerion Outstanding Shares&#8221; means, without duplication, (including, without limitation, the effects of the Nasdaq Reverse Split, if completed, prior to the First Effective Time) the total number of shares of Cyclerion capital stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis and as converted to Cyclerion Common Stock basis and assuming, without limitation or duplication, (i)&#160;the issuance of shares of Cyclerion Common Stock in respect of all <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Cyclerion Options, warrants or other rights or commitments to receive shares of Cyclerion Common Stock or Cyclerion preferred stock (or securities convertible or exercisable into shares of Cyclerion Common Stock or Cyclerion preferred stock, but excluding any Cyclerion capital stock issued as Merger Consideration), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time, and (ii)&#160;the settlement in shares of Cyclerion Common Stock of Cyclerion RSAs outstanding as of immediately prior to the First Effective Time on a net settlement basis. Notwithstanding any of the foregoing, no <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">Out-of-the-Money</span></span></span> Cyclerion Options shall be included in the total number of shares of Cyclerion Common Stock outstanding for purposes of determining the Cyclerion Outstanding Shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Cyclerion Valuation&#8221; means (i) $10,000,000, minus (ii)&#160;the amount by which Net Cash is less than $0, plus (iii)&#160;the amount by which Cyclerion&#8217;s Net Cash exceeds $0. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Korsana Allocation Percentage&#8221; means the percentage (rounded to four decimal places) determined by subtracting the Cyclerion Allocation Percentage from 100%. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Korsana Equity Value&#8221; means $268,400,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Korsana Merger Shares&#8221; means the product determined by multiplying (i)&#160;the Post-Closing Cyclerion Shares by (ii)&#160;the Korsana Allocation Percentage. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Korsana Outstanding Shares&#8221; means, without duplication, the total number of shares of Korsana capital stock outstanding immediately prior to the First Effective Time (including any shares of Korsana Common Stock or Korsana Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), expressed on a fully diluted and <span style="white-space:nowrap"><span style="white-space:nowrap">as-converted-to-Korsana</span></span> Common Stock basis assuming, without limitation or duplication, the exercise of all Korsana Options, Korsana RSUs, Korsana Warrants or other rights or commitments to receive shares of Korsana Common Stock or Korsana Preferred Stock (or securities convertible or exercisable into shares of Korsana Common Stock or Korsana Preferred Stock), whether conditional or unconditional or vested or unvested, that are outstanding as of immediately prior to the First Effective Time; provided that &#8220;Korsana Outstanding Shares&#8221; shall exclude any Korsana Options, Korsana RSUs, Korsana Warrants and any other equity awards issued under the Korsana 2025 Equity Incentive Plan (including any shares of Korsana Common Stock issuable upon the exercise of such Korsana Options, Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants or other equity awards) issued to directors, employees, consultants or other service providers following the date of the Merger Agreement but prior to the Closing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Korsana Valuation&#8221; means (i)&#160;the Korsana Equity Value, plus (ii)&#160;the amount of proceeds actually received by the Korsana from the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Calculation of Cyclerion&#8217;s Final Net Cash </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, Cyclerion&#8217;s &#8220;Net Cash&#8221; means, as of 11:59 p.m. Eastern Time on the last business day prior to the anticipated closing date, the sum (without duplication) of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Cyclerion&#8217;s unrestricted cash, cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in Cyclerion&#8217;s SEC filings or Cyclerion&#8217;s balance sheet (including any proceeds actually received from the sale, license, transfer, disposition, divestiture or other monetization transaction or winding down of Cyclerion&#8217;s legacy business) (each, a &#8220;Cyclerion Legacy Transaction&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain Cyclerion prepaid expenses set forth in Cyclerion&#8217;s disclosure letter, if any; minus the sum (without duplication) of the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Cyclerion&#8217;s unpaid consolidated short-term and long-term contractual obligations and liabilities accrued at the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Cyclerion&#8217;s SEC filings and its balance sheet; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(d)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The aggregate amount (without duplication) of all fees and expenses incurred by Cyclerion prior to the First Effective Time in connection with the negotiation, execution and delivery of the Merger Agreement and the contemplated transactions or any Cyclerion Legacy Transaction, including: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of Cyclerion in connection with the transactions contemplated by the Merger Agreement or any Cyclerion Legacy Transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">50% of the fees paid to the SEC in connection with filing this registration statement and any amendments and supplements thereto, with the SEC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">50% of the fees and expenses incurred in connection with the printing, mailing and distribution of this proxy statement and any amendments and supplements thereto; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">50% of all filing fees required to be paid by the parties in connection with any notification and report forms required to be filed under the HSR Act or any notification or other document required to be filed in connection with the Merger under any applicable foreign law relating to antitrust or competition matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">50% of any Nasdaq fees related to the continued listing of Cyclerion, the listing transactions contemplated by the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any costs and fees associated with making the distribution of the CVRs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any bonus, retention payments, severance, <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control</span></span> payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that are due or payable to any director, officer, employee or consultant as a result of the consummation of the contemplated transactions or any Cyclerion Legacy Transaction, together with any payroll taxes associated therewith; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to Section&#160;6.7 of the Merger Agreement; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all costs and expenses associated with the <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend, to the extent declared and unpaid as of the First Effective Time. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(e)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any accrued and unpaid taxes of Cyclerion and its subsidiaries for tax periods (or portions thereof) ending on or before the closing date, in accordance with the terms of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(f)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All costs and expenses relating to the winding down of the Cyclerion legacy business, including any Cyclerion Legacy Transaction, and further including any costs incurred by the Combined Company following the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(g)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts paid to holders of <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Cyclerion Options pursuant to Section&#160;6.6(d) of the Merger Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(h)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend amount, to the extent not declared and paid prior to the delivery of the Cyclerion&#8217;s Net Cash schedule. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No later than five business days before the date of the Cyclerion Shareholders Meeting set forth in the Proxy Statement, Cyclerion will deliver to Korsana a Net Cash schedule setting forth, in reasonable detail, Cyclerion&#8217;s good faith estimated calculation of its Net Cash as of 11:59 p.m. on the business day prior to the anticipated closing date, prepared and certified, via certificate in the form reasonably acceptable to Korsana, by Cyclerion&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and <span style="white-space:nowrap">back-up</span> materials used or useful in preparing the Net Cash schedule. No later than three business days after delivery of such Net Cash schedule (the last day of such period referred to as the response date), Korsana will have the right to dispute any part of the Net Cash schedule by delivering a written notice to that effect to Cyclerion (referred to herein as a &#8220;dispute notice&#8221;). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Cyclerion&#8217;s Net Cash calculation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korsana disputes the Net Cash schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of Net Cash. If the parties are unable to negotiate an agreed-upon determination of the disputed items or component thereof within three days after the delivery of the dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by Cyclerion and Korsana. The determination of the amount of Net Cash made by such auditor shall be final and binding on Cyclerion and Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s Net Cash balance is subject to numerous factors, some of which are outside of Cyclerion&#8217;s control. The actual amount of Net Cash will depend significantly on the timing of the Closing. In addition, the Closing could be delayed if Cyclerion and Korsana are not able to agree upon the amount of Cyclerion&#8217;s Net Cash as of the Cash Determination Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Treatment of Korsana Options </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each Korsana Option that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of Cyclerion Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Korsana Option assumed by Cyclerion may be exercised solely for shares of Cyclerion Common Stock; (ii)&#160;the number of shares of Cyclerion Common Stock subject to each outstanding Korsana Option assumed by Cyclerion will be determined by multiplying (A)&#160;the number of shares of Korsana Common Stock that were subject to such Korsana Option assumed by Cyclerion, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Cyclerion Common Stock; and (iii)&#160;the per share exercise price of each Korsana Option assumed by Cyclerion will be determined by dividing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(A)&#160;the per share exercise price of such Korsana Option, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Korsana Option assumed by Cyclerion will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Korsana Option will otherwise remain unchanged. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent provided under the terms of a Korsana Option assumed by Cyclerion in accordance with the terms of the Merger Agreement, such Korsana Option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Korsana Common Stock subsequent to the First Effective Time. Following the completion of the Merger, the Combined Company&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of the Korsana Board or any committee thereof with respect to each Korsana Option assumed by Cyclerion in accordance with the terms of the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korsana Restricted Stock Units </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, Cyclerion will assume Korsana&#8217;s 2025 Equity Incentive Plan and each Korsana RSU that is outstanding immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into a Cyclerion RSU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Korsana RSU assumed by Cyclerion may be settled solely for shares of Cyclerion Common Stock; and (ii)&#160;the number of shares of Cyclerion Common Stock subject to each outstanding Korsana RSU assumed by Cyclerion will be determined by multiplying (A)&#160;the number of shares of Korsana Common Stock that were subject to such Korsana RSU assumed by Cyclerion, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number up to the next whole number of shares of Cyclerion Common Stock to the extent the aggregate amount of fractional shares of Cyclerion Common Stock such holder of the assumed restricted stock unit would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down. Each Korsana RSU assumed by Cyclerion will otherwise continue in full force and effect and the term, settlement, vesting schedule, acceleration rights and other terms and conditions of such Korsana RSU will otherwise remain unchanged. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Korsana RSU shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Cyclerion Common Stock subsequent to the First Effective Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Treatment of Korsana Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each Korsana Warrant that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a Cyclerion Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Korsana Warrant assumed by Cyclerion may be exercised solely for shares of Cyclerion Common Stock; (ii)&#160;the number of shares of Cyclerion Common Stock subject to each outstanding Korsana Warrant assumed by Cyclerion will be determined by multiplying (A)&#160;the number of shares of Korsana Common Stock issuable upon exercise of the Korsana Warrant that were subject to such Korsana Warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounded up to the next whole share of Cyclerion Common Stock to the extent the aggregate amount of fractional shares of Cyclerion Common Stock such holder would otherwise be entitled to is equal to or exceeds 0.50; and (iii)&#160;the per share exercise price for the Cyclerion Common Stock issuable upon exercise of each Korsana Warrant assumed by Cyclerion will be determined by dividing (A)&#160;the per share exercise price of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cyclerion Common Stock subject to such Korsana Warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. Each Korsana Warrant assumed by Cyclerion will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Korsana Warrant will otherwise remain unchanged. To the extent provided under the terms of a Korsana Warrant assumed by Cyclerion in accordance with the terms of the Merger Agreement, such Korsana Warrant shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of Cyclerion Common Stock subsequent to the First Effective Time. In addition, the Cyclerion Board or a committee thereof will succeed to the authority and responsibility of the Korsana Board or any committee thereof with respect to each Korsana Warrant assumed by Cyclerion in accordance with the terms of the Merger Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cyclerion Common Stock, Cyclerion Preferred Stock, Cyclerion Options and Cyclerion Restricted Stock Awards </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as contemplated by the proposed increase in the number of authorized shares of Cyclerion Common Stock described in Proposal No.&#160;2 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding Cyclerion Common Stock described in Proposal No.&#160;3 of this proxy statement/prospectus, Cyclerion Common Stock will remain unaffected by the Merger. Cyclerion Series A Preferred Stock will remain unaffected by the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, prior to the closing of the Merger, the Cyclerion Board will accelerate the vesting of all equity awards of Cyclerion then outstanding but not then vested or exercisable, and cancel each Cyclerion option that is not an <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Cyclerion Option. At the closing of the First Merger, (i)&#160;each <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Cyclerion Option will be cancelled and converted into the right to receive an amount in cash without interest, less applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Cyclerion Closing Price over the exercise price per share of the Cyclerion Common Stock underlying such option by (B)&#160;the number of shares of Cyclerion Common Stock underlying such option and (ii)&#160;each other option to acquire shares of Cyclerion Common Stock will be cancelled for no consideration. The vesting of each Cyclerion RSA will be accelerated in full. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Procedures for Exchanging Korsana Stock Certificates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or prior to the closing date, Cyclerion and Korsana will select an exchange agent (the &#8220;Exchange Agent&#8221;) and, at the First Effective Time (as defined herein), Cyclerion will deposit with the Exchange Agent evidence of book-entry shares representing the shares of Cyclerion Common Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of Cyclerion Series B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Korsana Series Seed Preferred Stock calculated in accordance with the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the First Effective Time, the Exchange Agent will mail to each record holder of Korsana Common Stock and Korsana Series A Preferred Stock (including shares of Korsana Common Stock issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) (excluding shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares) and each record holder of Korsana Series Seed Preferred Stock who will receive Cyclerion Series B Preferred Stock issuable in exchange for such Korsana Series Seed Preferred Stock pursuant to the terms, and calculated in accordance with, the Merger Agreement (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the merger consideration. Upon delivery to the Exchange Agent of a duly executed letter of transmittal in accordance with the Exchange Agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certificates, if applicable, and delivery to the Exchange Agent of such other documents as may be reasonably required by the Exchange Agent or Cyclerion, the record holder of such stock certificates or book-entry shares, as applicable, will be entitled to receive in exchange therefor book-entry shares representing the number of whole shares of Cyclerion Common Stock or Cyclerion Series B Preferred Stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Korsana Common Stock, Korsana Series Seed Preferred Stock, or Korsana Series A Preferred Stock will be cancelled. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the First Effective Time, each certificate representing Korsana Common Stock, Korsana Series Seed Preferred Stock, or Korsana Series A Preferred Stock that has not been surrendered will represent only the right to receive shares of Cyclerion Common Stock or Cyclerion Series B Preferred Stock, as applicable, issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">HOLDERS OF KORSANA COMMON STOCK, KORSANA SERIES SEED PREFERRED STOCK, OR KORSANA SERIES A PREFERRED STOCK SHOULD NOT SEND IN THEIR KORSANA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF KORSANA STOCK CERTIFICATES. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Officers of Cyclerion Following the Merger </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, each of the directors and officers of Cyclerion will resign effective as of the First Effective Time and the Cyclerion Board will thereafter consist of a total of six new directors designated by Korsana. Korsana has designated Andrew Gottesdiener&#8195;&#8195;&#8195;&#8195;, Tomas Kiselak, Michelle Pernice, Nimish Shah, and Dr.&#160;Jonathan Violin to serve as members of the Cyclerion Board. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon the Closing, Jonathan Violin, Ph.D. will serve as Chief Executive Officer and President of the Combined Company, Mark Vignola, Ph.D. will serve as Chief Financial Officer of the Combined Company, and Madelyn Zeylikman will serve as General Counsel and Secretary. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Amendment of the Cyclerion Articles </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion agreed to amend the Cyclerion Articles to (i)&#160;change Cyclerion&#8217;s name to &#8220;Korsana Biosciences, Inc.&#8221;, (ii) effect the proposed reverse stock split, if needed, (iii)&#160;increase the number of shares of Cyclerion Common Stock that Cyclerion is authorized to the amount proposed in this proxy statement/prospectus, such amount determined by Korsana as being sufficient to allow for consummation of the Contemplated Transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Representations and Warranties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations and warranties of Cyclerion, First Merger Sub and Second Merger Sub, on one hand, and Korsana, on the other hand, for a transaction of this type relating to, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">corporate organization and power, subsidiaries and similar corporate matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">organizational documents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authority to enter into the Merger Agreement and the related agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">votes required for completion of the Merger and approval of the proposals that will come before the Cyclerion Shareholders Meeting and that will be the subject of the Korsana stockholder approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the Merger would not contravene the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any encumbrances on the parties&#8217; assets or require the consent of any third party; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">capitalization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial statements and, with respect to Cyclerion, documents filed with the SEC and the accuracy of information contained in those documents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">material changes or events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">title to assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real property and leaseholds; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">material contracts, including the validity of material contracts to which the parties or their subsidiaries are a party and any default of such contracts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory compliance, permits and restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal proceedings and orders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">tax matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employee and labor matters and benefit plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">environmental matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">insurance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fees owed to financial advisors and similar fees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain transactions or relationships with affiliates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privacy and data security; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trade control laws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to Korsana, ownership of Cyclerion capital stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to Cyclerion, the valid issuance in the Merger of Cyclerion Common Stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger. The accuracy of the representations and warranties of each of Cyclerion and Korsana form the basis of certain of the conditions to the obligations of Cyclerion and Korsana to complete the Merger, subject to materiality thresholds. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Covenants; Conduct of Business Pending the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion has agreed that, except as contemplated or permitted by the Merger Agreement, as required by law, or unless Korsana has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Cyclerion will, and will cause its subsidiaries to, use commercially reasonable efforts to conduct their business and operations in the ordinary course consistent with past practices and in material compliance with all applicable laws, regulations and certain material contracts and continue to pay material outstanding accounts payable and other material current liabilities (including payroll) when due and payable. Cyclerion has also agreed that, subject to certain limited exceptions and except as contemplated or permitted by the Merger Agreement, as required by law, or unless Korsana has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, it will not, and will not cause or permit any of its subsidiaries to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">declare, accrue, set aside or pay any dividend (other than the <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend, if any, and the Closing Distribution, as defined in the Merger Agreement) or make any other distribution </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of Cyclerion Common Stock from terminated employees, directors or consultants of Cyclerion or in connection with the payment of the exercise price or withholding taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under any Cyclerion equity incentive plan in accordance with the terms of such award in effect on the date of the Merger Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">except as required to give effect to anything in contemplation of the Closing, amend any of its organization documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any capital stock or other security (except for Cyclerion Common Stock issued upon the valid exercise of outstanding Cyclerion Options or Cyclerion RSUs, as applicable), any option, warrant or right to acquire any capital stock or any other security or any instrument convertible into or exchangeable for any capital stock or other security; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">form any subsidiary or acquire any equity interest or other interest in any other entity or enter into any joint venture with any other entity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lend money to any person or entity (except for the advancement of reasonable and customary expenses to employees, directors and consultants in the Ordinary Course of Business); incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others; or, other than the incurrence or payment of expenses pursuant to the terms of the Merger Agreement, make any capital expenditure or commitment in excess of 100,000; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt, establish or enter into certain agreements, plans or arrangements relating to employment or benefits matters; cause or permit any such agreement, plan or arrangement to be amended other than as required by law or in order to make amendments for purposes of Section&#160;409A of the Code; pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its employees, directors or consultants; increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or hire or terminate any officer, employee or consultant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell, assign, transfer, license, sublicense or otherwise dispose of any intellectual property of Cyclerion (other than pursuant to <span style="white-space:nowrap">non-exclusive</span> licenses in the ordinary course of business or pursuant to the consummation of any Parent Legacy Transaction); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make, change or revoke any material tax election; file any amended income or other material tax return; or adopt or change any material accounting method in respect of taxes; enter into any material tax closing agreement or settle any material tax claim or assessment; consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment; or surrender any material claim for refund; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">waive, settle or compromise any pending or threatened legal proceeding against Cyclerion or any of its subsidiaries, other than waivers, settlements or agreements for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and that do not impose any material restrictions on the operations or businesses of Cyclerion or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Cyclerion or any of its subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">forgive any loans to any person, including its employees, officers, directors or affiliate; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">terminate or modify in any material respect, or fail to exercise renewal rights to, any material insurance policy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">materially change pricing or royalties or other payments set or charged by Cyclerion or any of subsidiaries to its customers or licensees; or agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to Cyclerion or any of subsidiaries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or fail to repay when due any material obligation, including accounts payable and accrued expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into, amend in a manner adverse to Cyclerion or terminate any Cyclerion material contract outside of the ordinary course of business; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">agree, resolve or commit to do any of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement does not give Korsana the right, directly or indirectly, to control or direct the operations of Cyclerion prior to the First Effective Time. Prior to the First Effective Time, Cyclerion shall exercise, consistent with the terms and conditions of the Merger Agreement, complete unilateral control and supervision over its business operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing restrictions, Cyclerion is expressly permitted to engage in a Parent Legacy Transaction and is expressly permitted to declare and pay the <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has agreed that, except as contemplated or permitted by the Merger Agreement or the Securities Purchase Agreement, as required by law, or unless Cyclerion shall have provided its written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Korsana will use commercially reasonable efforts to conduct its business and operations in the ordinary course consistent with past practices and in material compliance with all applicable laws, regulations and certain contracts. Korsana has also agreed that, subject to certain limited exceptions without the consent of Cyclerion, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, it will not: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for shares of Korsana Common Stock from terminated employees, directors or consultants of Korsana); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">except as required to give effect to anything in contemplation of the Closing, amend any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other than in ordinary course of business, sell, issue, grant, or authorize any of the foregoing actions with respect to the shares of Korsana capital stock outstanding as of the date of the Merger Agreement: any capital stock or other security of Korsana (except for shares of outstanding Korsana Common Stock issued upon the valid exercise or settlement of Korsana Options); any option, warrant or right to acquire any capital stock or any other security; or any instrument convertible into or exchangeable for any capital stock or other security of Korsana; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other than in ordinary course of business, acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; or guarantee any debt securities of others; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any lien with respect to such assets or properties, except in ordinary course of business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property of Korsana, other than in the ordinary course of business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">waive, settle or compromise any pending or threatened legal proceeding against Korsana, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Korsana or any equitable relief on, or the admission of wrongdoing by Korsana; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other than in the ordinary course of business: (A)&#160;make, change or revoke any material tax election; (B)&#160;file any amended income or other material tax return; (C)&#160;adopt or change any material accounting method in respect of taxes; (D)&#160;enter into any material tax closing agreement, settle any material tax claim or assessment; (E)&#160;consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment; or (F)&#160;surrender any material claim for refund; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into, amend in a manner adverse to Korsana or terminate any Korsana material contract, outside of the ordinary course of business; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">agree, resolve or commit to do any of the foregoing. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Solicitation</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Cyclerion and Korsana has agreed that, except as described below, Cyclerion and Korsana and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors, agents or representatives retained by it or any of its subsidiaries to, directly or indirectly: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal (as defined below) or Acquisition Inquiry (as defined below) or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">furnish any <span style="white-space:nowrap">non-public</span> information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approve, endorse or recommend any Acquisition Proposal, subject to the terms of the Merger Agreement; execute or enter into any letter of intent or any contract contemplating or otherwise relating to an Acquisition Transaction; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publicly propose to do any of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#8220;Acquisition Inquiry&#8221; means, with respect to a Party, an inquiry, indication of interest or request for <span style="white-space:nowrap">non-public</span> information (other than an inquiry, indication of interest or request for information made or submitted by Korsana, on the one hand, or Cyclerion, on the other hand, to the other Party) that could reasonably be expected to lead to an Acquisition Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#8220;Acquisition Proposal&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than any Cyclerion Legacy Transaction, any Interim Financing, or the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) involving: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&#160;in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (ii)&#160;in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, before obtaining the applicable approvals of Cyclerion shareholders or Korsana stockholders required to consummate the Merger, each party may furnish <span style="white-space:nowrap">non-public</span> information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with, any third party in response to a bona fide written Acquisition Proposal, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in a Superior Offer (and is not withdrawn), if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such party&#8217;s board of directors concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least two business days prior to furnishing any <span style="white-space:nowrap">non-public</span> information or entering into discussions with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention to furnish <span style="white-space:nowrap">non-public</span> information to, or enter into discussions with, such third party; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such party receives from the third party an executed confidentiality agreement containing provisions at least as favorable to such party as those contained in the confidentiality agreement between Cyclerion and Korsana; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least two business days prior to furnishing any <span style="white-space:nowrap">non-public</span> information to a third party, such party furnishes the same <span style="white-space:nowrap">non-public</span> information to the other party to the extent not previously furnished. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;Superior Offer&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a)&#160;was not obtained or made as a direct or indirect result of a breach of this Agreement, (b)&#160;is on terms and conditions that the Cyclerion Board or Korsana Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Cyclerion&#8217;s shareholders or Korsana&#8217;s stockholders, as applicable, than the terms of the Merger, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that each party will promptly (and in no event later than one business day after such party receives any such Acquisition Proposal or Acquisition Inquiry) advise the other party of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Recommendation Change </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, subject to certain exceptions described below, both Korsana and Cyclerion agreed that their respective board of directors may not withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of such party&#8217;s board of directors in a manner adverse to the other party except for in limited circumstances described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the approval of the Merger by each party&#8217;s respective stockholders, if (i)&#160;such party has received a bona fide written Acquisition Proposal that the such party&#8217;s board of directors determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;a material development or change in circumstances (other than any such event, development or change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, or (B)&#160;the fact, in and of itself, that such party meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or (C), solely with respect to Cyclerion, a Cyclerion Legacy Transaction) that affects the business, assets or operations of such party and occurs or arises after the date the Merger Agreement was executed (each, an &#8220;Intervening Event&#8221;), such party&#8217;s board of directors may amend, withdraw, or modify its recommendation in a manner adverse to the other party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a change of its recommendation due to a Superior Offer, such party&#8217;s board of directors must first: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negotiate with the other party in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, during the required four business day notice period and provide the other party with certain information regarding such Superior Offer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the other party delivers a written offer to alter the terms or conditions of the Merger Agreement during the required four business day notice period, the party considering a change in the recommendation of its board of directors must redetermine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of a change of its recommendation due to an Intervening Event, such party&#8217;s board of directors must first promptly notify the other party, in writing, at least four business days before making a change in its recommendation, stating the material facts and circumstances related to the applicable material development or change in circumstance and that such party&#8217;s board of directors intends to make a change in its recommendation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Annual Meeting of Cyclerion&#8217;s Shareholders and Written Consent of Korsana&#8217;s Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of Cyclerion Common Stock for the purpose of considering and voting to approve the Merger Agreement and the transactions contemplated thereby (including the Merger) and amendments to the Cyclerion Articles as further described herein (the &#8220;Required Cyclerion Shareholder Vote&#8221;). The Cyclerion Shareholders Meeting will be held as promptly as practicable after this registration statement on Form <span style="white-space:nowrap">S-4</span> is declared effective under the Securities Act, and in any event no later than 45 days after the effective date of this registration statement on Form <span style="white-space:nowrap">S-4.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after this registration statement on Form <span style="white-space:nowrap">S-4</span> has been declared effective, and no later than two business days thereafter, Korsana is required to obtain the approval by written consent from the holders of a majority of the outstanding shares of Korsana capital stock, voting together as a single class on an <span style="white-space:nowrap">as-converted</span> basis, and the holders of a majority of the outstanding shares of Korsana Preferred Stock, voting as a separate class, to (x)&#160;adopt and approve the Merger Agreement and the Merger or the transactions contemplated thereby (including the Merger), (y) acknowledge that the approval given thereby is irrevocable and that such stockholders are aware of their rights to demand appraisal for their shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (z)&#160;acknowledge that by their approval of the Merger, they are not entitled to appraisal rights with respect to their shares in connection with the Merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL (the &#8220;Required Korsana Stockholder Vote&#8221;). Reasonably promptly following receipt of such consents, Korsana will prepare, and cause to be mailed to its stockholders who did not execute such consents, a notice in accordance with the DGCL. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulatory Approvals </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party agreed to use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indemnification and Insurance for Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, Cyclerion and the surviving entity in the Merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the First Effective Time, a director or officer of Cyclerion or Korsana, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of Cyclerion or of Korsana, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL or the MBCA, as applicable. From and after the First Effective Time, Cyclerion and the surviving corporation in the Merger will also fulfill Cyclerion&#8217;s and Korsana&#8217;s indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the First Effective Time, a director or officer of Cyclerion or Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The certificate of formation and limited liability company agreement of the surviving entity will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the Cyclerion Articles and the Cyclerion Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the First Effective Time, Cyclerion will maintain director and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Cyclerion. In addition, Cyclerion will secure and purchase a six year &#8220;tail policy&#8221; on Cyclerion&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the First Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Pre-Closing</span> Cash Dividend </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is required if and to the extent it reasonably expects Cyclerion&#8217;s Net Cash to exceed $5,000,000, and it may otherwise elect to, in each case, prior to the First Effective Time, declare and pay a dividend on the shares of Cyclerion Common Stock and Cyclerion Preferred Stock outstanding (excluding for the avoidance of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
doubt any shares of Cyclerion capital stock issuable pursuant to the Merger) up to an amount by which Cyclerion&#8217;s Net Cash will exceed $0. Cyclerion does not expect to pay a <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Cyclerion and Korsana has agreed to use its reasonable best efforts to cause to be taken all actions necessary to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Cyclerion and Korsana have further agreed that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion will use its commercially reasonable efforts to maintain its listing on Nasdaq and cause the shares of Cyclerion Common Stock being issued in the Merger to be approved for listing on Nasdaq at or prior to the First Effective Time; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion will keep Korsana reasonably informed regarding any shareholder litigation against Cyclerion or any of its directors relating to the Merger Agreement or the transactions contemplated thereby. Cyclerion will (i)&#160;give Korsana the opportunity to participate in the defense, settlement or prosecution of any such litigation (ii)&#160;consult with Korsana with respect to the defense, settlement and prosecution of any such litigation and (iii)&#160;consider in good faith Korsana&#8217;s advice with respect to such litigation. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conditions to the Completion of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the Closing, of various conditions, which include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any applicable waiting periods (or any extensions thereof) under the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended, (if applicable) and any applicable foreign law relating to antitrust or competition matters shall have expired or otherwise been terminated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there must not have been issued, and remain in effect, any order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any governmental authority of competent jurisdiction, and there must not be any law, statute, ordinance, rule, code, regulation, order, judgment, injunction, decree or other legally enforceable requirement in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana shall have obtained the Required Korsana Stockholder Vote; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion shall have obtained the Required Cyclerion Shareholder Vote; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the initial listing application for Cyclerion Common Stock on Nasdaq shall have been approved by Nasdaq; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the registration statement on Form <span style="white-space:nowrap">S-4,</span> of which this proxy statement/prospectus is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any stop order or any proceeding seeking a stop order that has not been withdrawn. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each party&#8217;s obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the other party&#8217;s representations and warranties being true and correct as of the Closing Date, subject to applicable materiality qualifiers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the other party to the Merger Agreement must have performed or complied with in all material respects all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the First Effective Time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the lack of a material adverse effect that is continuing with respect to the other party; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the other party having delivered certain certificates and other documents required under the Merger Agreement for the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to Cyclerion&#8217;s obligation to complete the Merger, the <span style="white-space:nowrap">lock-up</span> agreements executed by certain securityholders of Korsana continuing to be in full force and effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to Cyclerion&#8217;s obligation to complete the Merger, the Securities Purchase Agreement being in full force and effect and proceeds of not less than $150,000,000 having been received by Korsana or will be received by Korsana substantially concurrently with the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to Korsana&#8217;s obligation to complete the Merger, certain Cyclerion agreements have been terminated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to Korsana&#8217;s obligation to complete the Merger, Cyclerion must have filed articles of amendment with the Secretary of the Commonwealth of Massachusetts, containing at least such amendments as are necessary to consummate the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to Korsana&#8217;s obligation to complete the Merger, if Cyclerion declares the <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend, the <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend amount having been deposited by Cyclerion with Cyclerion&#8217;s transfer agent for distribution to holders of Cyclerion Common Stock as of the record date of the <span style="white-space:nowrap">Pre-Closing</span> Cash Dividend. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination and Termination Fee </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of the Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement may be terminated at any time before the First Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by mutual written consent of Cyclerion and Korsana; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either Cyclerion or Korsana, if the Merger has not been consummated by October&#160;1, 2026 (the &#8220;End Date&#8221;) (subject to possible extension as provided in the Merger Agreement); provided, however, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of the Merger Agreement; provided, further, that if (i)&#160;the SEC has not declared this registration statement on Form <span style="white-space:nowrap">S-4</span> effective, or (ii)&#160;the waiting periods (and extensions thereof) applicable to the Merger under the HSR Act have not expired or otherwise been terminated, by the date that is 90 days prior to the End Date, then either party may extend the End Date for an additional 90 days by notice to the other party; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either Cyclerion or Korsana, if a court of competent jurisdiction or governmental entity has issued a final and <span style="white-space:nowrap">non-appealable</span> order, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Merger or any of the transactions contemplated by the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(d)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Cyclerion, if the Korsana Required Stockholder Vote has not been obtained within two business days of the registration statement on Form <span style="white-space:nowrap">S-4,</span> of which this proxy statement/prospectus is a part, becoming effective; provided further, however, that this right to terminate the Merger Agreement will not be available to Cyclerion once Korsana obtains such stockholder approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(e)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by either Cyclerion or Korsana, if the Cyclerion Shareholders Meeting has been held and completed and Cyclerion shareholders have taken a final vote on the Merger Proposals set forth herein to be considered at the Cyclerion Shareholders Meeting, and the Merger Proposals have not been approved by Cyclerion shareholders; provided that this right to terminate the Merger Agreement will not be available to Cyclerion where Cyclerion&#8217;s action or failure to act has been a principal cause of the failure to obtain the Cyclerion shareholder approval at the Cyclerion Shareholders Meeting and such action or failure to act constitutes a breach of the Merger Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(f)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Korsana, at any time prior to obtaining the approval by Cyclerion shareholders of the Merger Proposals set forth herein to be considered at the Cyclerion Shareholders Meeting, if any of the following circumstances shall occur: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion fails to include in this proxy statement/prospectus the Cyclerion Board&#8217;s recommendation that Cyclerion shareholders vote to approve the Merger Proposals set forth herein to be considered at the Cyclerion Shareholders Meeting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Cyclerion Board, or any committee thereof, makes a Cyclerion board recommendation change in a manner adverse to Korsana (or publicly proposes to do so), or adopts, approves or recommends any Acquisition Proposal (or publicly proposes to do so); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(g)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Cyclerion, at any time prior to obtaining the Korsana Required Stockholder Vote, if any of the following circumstances shall occur: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board makes a board recommendation change in a manner adverse to Cyclerion; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Korsana Board or any committee thereof publicly approves, endorses or recommends any Acquisition Proposal; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(h)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Korsana, if a Form 25 has been filed with respect to the Cyclerion Common Stock by Cyclerion or Nasdaq or any other cessation of listing of the Cyclerion Common Stock on Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Korsana, if Cyclerion, First Merger Sub or Second Merger Sub have breached any of their representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Cyclerion, First Merger Sub or Second Merger Sub has become inaccurate, in either case such that the conditions to the Closing would not be satisfied as of time of such breach or inaccuracy; provided that Korsana is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; provided, further, if such breach or inaccuracy is curable, then Korsana shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a <span style="white-space:nowrap">30-day</span> period after delivery of written notice of such breach or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top;text-align:left">
inaccuracy from Korsana to Cyclerion, First Merger Sub or Second Merger Sub and Korsana&#8217;s intention to terminate pursuant to this paragraph and (ii)&#160;Cyclerion, First Merger Sub and Second Merger Sub (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of such written notice (it being understood that Korsana shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Cyclerion, First Merger Sub or Second Merger Sub is cured prior to such termination becoming effective); </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(j)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Cyclerion, if Korsana has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Korsana has become inaccurate, in either case such that the conditions to the Closing would not be satisfied as of time of such breach or inaccuracy; provided that Cyclerion is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; provided, further, if such breach or inaccuracy is curable, then Cyclerion shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a <span style="white-space:nowrap">30-day</span> period after delivery of written notice of such breach or inaccuracy from Cyclerion to Korsana and Cyclerion&#8217;s intention to terminate pursuant to this paragraph and (ii)&#160;Korsana ceasing to exercise commercially reasonable efforts to cure such breach following delivery of such written notice (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Korsana is cured prior to such termination becoming effective); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(k)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">by Cyclerion (at any time prior to obtaining the Cyclerion Required Shareholder Vote), concurrently with Cyclerion&#8217;s entering into a definitive agreement for a Superior Offer, subject to certain conditions. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination Fees Payable by Cyclerion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion must pay Korsana a termination fee of $235,000 if (i)&#160;the Merger Agreement is terminated by Cyclerion or Korsana pursuant to clause (e)&#160;above or by Korsana pursuant to clause (f)&#160;above, (ii) at any time after the date of the Merger Agreement and prior to the Cyclerion Shareholders Meeting, an Acquisition Proposal with respect to Cyclerion will have been publicly announced, disclosed or otherwise communicated to the Cyclerion Board (and will not have been withdrawn), and (iii)&#160;within 12 months after the date of such termination, Cyclerion enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination Fees Payable by Korsana </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana must pay Cyclerion a termination fee of $10.736&#160;million if (i)&#160;the Merger Agreement is terminated by Cyclerion pursuant to clause (d)&#160;or (g) above (ii)&#160;at any time after the date of the Merger Agreement and before obtaining the Korsana Required Stockholder Vote, an Acquisition Proposal with respect to Korsana will have been publicly announced, disclosed or otherwise communicated to the Korsana Board (and will not have been withdrawn), and (iii) within 12 months after the date of such termination, Korsana enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Amendment and Waiver </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement may be amended by the parties to the Merger Agreement by action taken or authorized by their respective boards of directors at any time, whether before or after the approval of the Merger Agreement by either party&#8217;s stockholders has been obtained; provided, that after approval of the Merger Agreement has been obtained by either party&#8217;s stockholders, no amendment may be made that pursuant to applicable law requires further approval or adoption by the stockholders of either party, without such further approval or adoption. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party, to the extent permitted by applicable law. No failure or delay on the part of any party with respect to the exercise of any right or power under the Merger Agreement will operate as a waiver of such right or power. Furthermore, no single or partial exercise of any such right or power will preclude any other or further exercise thereof or of any other right or power. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Fees and Expenses </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides all fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby shall be paid by the party incurring such expenses, except as described above in the section titled &#8220;<span style="font-style:italic">The Merger Agreement&#160;&#8212; Termination and Termination Fee</span>&#8221; beginning on page&#160;184 of this proxy statement/prospectus, and except that Cyclerion and Korsana will share equally in any fees and expenses incurred in relation to (i)&#160;the filings with the SEC of the registration statement on <span style="white-space:nowrap">Form&#160;S-4</span> (including any financial statements and exhibits) and any related amendments or supplements and paid to a financial printer or the SEC and (ii)&#160;the printing, mailing and distribution of the proxy statement/prospectus and any amendments and supplements. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_9">AGREEMENTS RELATED TO THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Support Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Korsana stockholders beneficially holding approximately 43.9% of the outstanding shares of Korsana capital stock have entered into Korsana Support Agreements with Cyclerion and Korsana to vote all of their shares of Korsana capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative Acquisition Proposals. Cyclerion directors and officers beneficially holding approximately 24.2% of the outstanding shares of Cyclerion Common Stock as of March&#160;31, 2026 have entered into Cyclerion Support Agreements with Cyclerion and Korsana to vote all of their shares of Cyclerion Common Stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the reverse stock split and against any alternative Acquisition Proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the support agreements does not purport to be complete and is qualified in its entirety by the full text of the form of Cyclerion Support Agreement and the form of Korsana Support Agreement, which are attached to this proxy statement/prospectus as <span style="font-style:italic">Annex C </span>and <span style="font-style:italic">Annex D</span>, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Lock-Up</span> Agreements </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain executive officers, directors and stockholders of Korsana have entered into <span style="white-space:nowrap">lock-up</span> agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of Cyclerion Common Stock or any securities convertible into or exercisable or exchangeable for Cyclerion Common Stock, currently or thereafter owned, but excluding, as applicable, shares purchased by existing Korsana stockholders in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing (including any shares of Cyclerion Common Stock issuable upon exercise of Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants issued in exchange for Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants sold in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing), until 180 days after the First Effective Time. Approximately 42.4 million shares of Cyclerion Common Stock (or approximately 113.8 million shares of Cyclerion Common Stock, if the Cyclerion Series B Preferred Stock is converted and the Korsana Pre-Funded Warrants held by such executive officers, directors and stockholders of Korsana are exercised) are expected to be subject to such lock-up agreements following the closing of the Merger, subject to the Reverse Stock Split. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana stockholders who have executed <span style="white-space:nowrap">lock-up</span> agreements beneficially owned, in the aggregate, approximately 43.9% of the outstanding shares of Korsana capital stock as of March&#160;31, 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the <span style="white-space:nowrap">lock-up</span> agreements does not purport to be complete and is qualified in its entirety by the full text of the form of <span style="white-space:nowrap">lock-up</span> agreement, which is attached to this proxy statement/prospectus as <span style="font-style:italic">Annex E</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Securities Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors entered into the Securities Purchase Agreement with Korsana, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Korsana Common Stock or, in lieu thereof, Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants, representing an aggregate commitment of approximately $380.0&#160;million in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. Under the Securities Purchase Agreement, the number of shares of Korsana Common Stock or Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants, as applicable, shall be determined at a purchase price per share or <span style="white-space:nowrap">pre-funded</span> warrant equal to (i)&#160;a valuation for Korsana equal to $268.4&#160;million, divided by (ii)&#160;the number of fully diluted shares of Korsana Common Stock outstanding immediately prior to the First Effective Time (including the securities being issued under the Securities Purchase Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants will have an exercise price per share equal to $0.0001 (as adjusted from time to time as provided in the form of Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrant) and may be exercised at any time and from time to time after the original issue date. The Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants do not expire. The foregoing description of the form of Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrant does not purport to be complete and is qualified in its entirety by the full text of the form of Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrant, which is filed as Exhibit 4.2 to the registration statement of which this proxy statement/prospectus forms a part. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants that are issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing will be or will have the right to be, respectively, converted into shares of Cyclerion Common Stock in the Merger. Accordingly, by approving Proposal No.&#160;1 relating to the Merger, Cyclerion shareholders will also be approving the issuance of shares of Cyclerion Common Stock to be issued in exchange for all shares of Korsana Common Stock and upon exercise of Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants that are sold in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities Purchase Agreement contains customary representations and warranties of Korsana and also contains customary representations and warranties of the purchaser parties thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each purchaser&#8217;s obligation to purchase shares of Korsana Common Stock and/or Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants from Korsana pursuant to the Securities Purchase Agreement is subject to the satisfaction or waiver of certain conditions, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s representations and warranties in the Securities Purchase Agreement being true and correct in all respects as of the effective date of the Securities Purchase Agreement and true and correct in all material respects as of the closing date for the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, subject to certain exceptions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana having performed and complied in all material respects with the obligations and conditions required to be performed or complied with by it; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no injunction having been issued prohibiting the consummation of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the securities under the Securities Purchase Agreement having been obtained and in full force and effect; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana having furnished all required materials to Cyclerion&#8217;s transfer agent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no material adverse effect shall have occurred that is continuing, since the date of the Securities Purchase Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an opinion from Company counsel, dated as of the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of a compliance certificate by an authorized officer of Korsana; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of a secretary&#8217;s certificate by the secretary of Korsana; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana having delivered the Registration Rights Agreement required by the Securities Purchase Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">this registration statement on Form <span style="white-space:nowrap">S-4</span> shall have been become effective under the Securities Act, no stop order shall be suspending the effectiveness of this registration statement and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Nasdaq Listing Application shall have been approved by Nasdaq; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the satisfaction or waiver of all conditions to the Closing set forth in the Merger Agreement (other than the condition regarding the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and other than those conditions which, by their nature, are to be satisfied at the Closing of the transactions contemplated by the Merger) and the Closing being set to occur substantially concurrently with the closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s obligation to sell shares of Korsana Common Stock or Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants, as applicable, to each purchaser pursuant to the Securities Purchase Agreement is subject to the satisfaction or waiver of certain conditions, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the representations and warranties made by the purchasers being true and correct as of the closing date of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, subject to certain exceptions; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each purchaser having performed and complied with all obligations and conditions required to be performed or complied with by each purchaser; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no injunction having been issued prohibiting the consummation of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each investor having delivered the Registration Rights Agreement required by the Securities Purchase Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana having received payment in full from each investor as required by the Securities Purchase Agreement, subject to certain exceptions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of Securities Purchase Agreement is filed as Exhibit 10.3 to this registration statement on Form <span style="white-space:nowrap">S-4</span> of which this proxy statement/prospectus is a part, and the foregoing description of the Securities Purchase Agreement is qualified in its entirety by reference thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration Rights Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities Purchase Agreement contemplates Korsana and the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing entering into the Registration Rights Agreement at the closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Korsana Common Stock that are held by the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing from time to time, including the shares of Cyclerion Common Stock issued in exchange for shares of Korsana Common Stock sold in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing or underlying Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants issued upon conversion of the Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants sold in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement, the Combined Company will agree to prepare and file a resale registration statement covering the resale of the Cyclerion Common Stock within 30 calendar days of the Closing pursuant to Rule 415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the earlier of the date that all registrable securities covered by such registration statement (i)&#160;have been sold thereunder or pursuant to Rule 144 of the Securities Act (&#8220;Rule 144&#8221;), (ii) may be sold without volume or <span style="white-space:nowrap"><span style="white-space:nowrap">manner-of-sale</span></span> restrictions pursuant to Rule 144 and without the requirement for the Combined Company to be in compliance with the current public information requirement under Rule 144, (iii) have been exchanged for unrestricted shares of Cyclerion Common Stock under an effective registration statement on Form <span style="white-space:nowrap">S-4,</span> if available, or if unavailable, another appropriate form filed with the SEC, subject to certain exceptions, and (iv)&#160;five years after the date of the Registration Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registration Rights Agreement also provides that the Combined Company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of Registration Rights Agreement is filed as Exhibit 10.4 to this registration statement on Form <span style="white-space:nowrap">S-4</span> of which this proxy statement/prospectus is a part, and the foregoing description of the Registration Rights Agreement is qualified in its entirety by reference thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cyclerion CVR Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the First Effective Time, Cyclerion and the Rights Agent are expected to enter into the Cyclerion CVR Agreement, pursuant to which holders of Cyclerion Common Stock and Cyclerion Series A Preferred Stock as of the close of business on the last business day prior to the day on which the First Effective Time occurs will receive one Cyclerion CVR for each outstanding share of Cyclerion Common Stock or Cyclerion Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Cyclerion CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of Cyclerion&#8217;s <span style="white-space:nowrap">pre-Merger</span> legacy assets, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the Merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of all <span style="white-space:nowrap">pre-Merger</span> legacy assets other than those <span style="white-space:nowrap">pre-Merger</span> legacy assets described in the following clauses (ii)&#160;and (iii), upon the second (2nd) anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#8217;s right to receive payments under the Akebia License Agreement, the earlier of (A)&#160;the fifteenth (15th) anniversary of the date of entry into the Cyclerion CVR Agreement and (B)&#160;the expiration pursuant to its terms or earlier termination by Akebia. of the Akebia License Agreement, and (iii)&#160;with respect to the sale, transfer or other disposition of the equity interests of Tisento that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement, dated May&#160;13, 2023, by and among Cyclerion, Tisento and JW Cycle, Inc., the earliest of (A)&#160;nine (9) months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the Legacy Assets Transaction Period (as defined in the Cyclerion CVR Agreement), the Combined Company shall expend up to the CVR Expense Cap for costs and expenses associated with the retention of an employee or consultant of Combined Company for the purpose of business development efforts related to Cyclerion&#8217;s legacy assets and related activities, including seeking and negotiating and, with the prior written consent of the Combined Company (not to be unreasonably withheld, conditioned or delayed), executing agreements with respect to legacy assets, which amount shall be included as a deduction in the determination of Cyclerion&#8217;s net cash in accordance with the Merger Agreement. At the end of the Legacy Assets Transaction Period, the amount, if any, by which the CVR Expense Cap exceeds the aggregate amount of costs and expenses associated with the retention of an employee or consultant of Cyclerion will constitute net proceeds under the Cyclerion CVR Agreement and will be payable as CVR proceeds to the CVR holders in accordance with the terms of the Cyclerion CVR Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contingent payments under the Cyclerion CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the Cyclerion CVRs. In the event that no such proceeds are received, holders of the Cyclerion CVRs will not receive any payment pursuant to the Cyclerion CVR Agreement. There can be no assurance that any holders of Cyclerion CVRs will receive any payments with respect thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right to the contingent payments contemplated by the Cyclerion CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the Cyclerion CVR Agreement. The Cyclerion CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The Cyclerion CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Cyclerion or any of its affiliates. No interest will accrue on any amounts payable in respect of the Cyclerion CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Cyclerion CVR Agreement does not purport to be complete and is qualified in its entirety by the full text of the form of Cyclerion CVR Agreement, which is attached hereto as <span style="font-style:italic">Annex F</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material U.S. Federal Income Tax Consequences of the Cyclerion CVRs to Holders of Cyclerion Capital Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations relating to the receipt of the CVRs by Cyclerion shareholders pursuant to the Cyclerion CVR Agreement. This section applies only to persons that hold their Cyclerion capital stock as capital assets for U.S. federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S. federal income taxation that may be relevant to holders in light of their particular circumstances or status including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts; regulated investment companies; <span style="white-space:nowrap">tax-exempt</span> organizations or governmental organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other integrated transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that have a functional currency other than the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that actually or constructively own five percent or more of Cyclerion voting shares or five percent or more of the total value of all classes of shares of Cyclerion; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">taxpayers that are subject to the <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> accounting rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who hold shares of Cyclerion capital stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to special tax accounting rules as a result of any item of gross income with respect to Cyclerion capital stock being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that hold securities in Cyclerion as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Cyclerion capital stock who exercise dissenters&#8217; rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who acquired their shares of Cyclerion capital stock pursuant to the exercise of options or otherwise as compensation or through a <span style="white-space:nowrap">tax-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former citizens or long-term residents of the United States. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S. federal taxes other than those pertaining to U.S. federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S. state or local or <span style="white-space:nowrap">non-U.S.</span> taxation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any entity or arrangement classified as a partnership for U.S. federal income tax purposes holds Cyclerion capital stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. If you are a partner of a partnership or other pass-through entity holding Cyclerion capital stock, you should consult your tax advisors regarding the tax consequences of the receipt of the Cyclerion CVRs and distributions of Cyclerion capital stock pursuant to the Cyclerion CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the following discussion does not address the tax consequences of transactions effectuated before, after or at the same time as the receipt of the Cyclerion CVRs, whether or not they are in connection with the receipt of the Cyclerion CVRs, including, without limitation, the merger and the reverse stock split, except as specifically provided below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion CVRs generally may not be transferred or assigned except for certain permitted transfers; accordingly, this discussion assumes the Cyclerion CVRs are not transferable or assignable and does not address any consequences of transferring, assigning or otherwise disposing of the Cyclerion CVRs or any interest therein. No ruling from the IRS has been or will be requested in connection with the distribution of the Cyclerion CVRs. Cyclerion shareholders should be aware that the IRS could adopt a position contrary to that set forth in this discussion and which could be sustained by a court. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE RECEIPT OF THE CYCLERION CVRS ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <span style="white-space:nowrap">NON-U.S.</span> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, a &#8220;U.S. holder&#8221; is a beneficial owner of Cyclerion capital stock that is for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">corporation (or other entity that is treated as a corporation for U.S. federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United States or any state thereof or the District of Columbia or otherwise treated as a U.S. tax resident for U.S. federal income tax purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate whose income is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust if (1)&#160;a U.S. court can exercise primary supervision over the administration of such trust and one or more U.S. persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S. person. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Receipt of Cyclerion CVRs by Cyclerion U.S. Holders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the matter is not free from doubt, the Combined Company intends to treat the receipt of Cyclerion CVRs and the Cyclerion reverse stock split as separate transactions for U.S. federal income tax purposes, and the following discussion assumes this treatment will be respected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is substantial uncertainty as to the tax treatment of Cyclerion CVRs. Specifically, there is no authority directly addressing whether contingent value rights with characteristics similar to the Cyclerion CVRs should be treated as a distribution of property with respect to the corporation&#8217;s stock, a distribution of equity, a &#8220;debt instrument&#8221; or an &#8220;open transaction&#8221; for U.S. federal income tax purposes. Under applicable U.S. tax principles, such questions are inherently factual in nature. As a result, it is not possible to express a definitive conclusion as to the U.S. federal income tax treatment of the receipt of the Cyclerion CVRs or receipt of payments (if any) pursuant to the Cyclerion CVRs. Based on the specific characteristics of the Cyclerion CVRs, Cyclerion intends to report the issuance of the Cyclerion CVRs as a distribution of property with respect to its stock. Cyclerion U.S. Holders are urged to consult their tax advisors regarding the tax consequences to them of the receipt of Cyclerion CVRs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, Cyclerion intends to report the issuance of the Cyclerion CVRs to Cyclerion U.S. Holders as a distribution of property with respect to its stock. Each Cyclerion U.S. Holder will be treated as receiving a distribution in an amount equal to the fair market value of the Cyclerion CVR issued to such Cyclerion U.S. Holder on the date of the issuance. This distribution generally should be treated first as a taxable dividend to the extent of the Cyclerion U.S. Holder&#8217;s<span style="font-style:italic">&#160;pro rata</span>&#160;share of Cyclerion&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as <span style="white-space:nowrap">a&#160;non-taxable&#160;return</span> of capital to the extent of the Cyclerion U.S. Holder&#8217;s basis in its Cyclerion capital stock, and finally as capital gain from the sale or exchange of Cyclerion capital stock with respect to any remaining value. Cyclerion U.S. Holders will receive a <span style="white-space:nowrap">Form&#160;1099-DIV&#160;notifying</span> them of the portion of the Cyclerion CVR value that is treated as a dividend for U.S. federal income tax purposes. Although Cyclerion will estimate the value of the Cyclerion CVRs for purposes of reporting on <span style="white-space:nowrap">Form&#160;1099-DIV&#160;to</span> Cyclerion U.S. Holders, the value of the Cyclerion CVRs is uncertain and the IRS or a court could determine that the value of the Cyclerion CVRs at the time of issuance was higher. In such case, the Cyclerion U.S. Holders could be treated as having additional income or gain upon receipt of the Cyclerion CVRs as described above. A Cyclerion U.S. Holder&#8217;s initial tax basis in such holder&#8217;s Cyclerion CVR should equal the fair market value of such Cyclerion CVR on the date of their issuance. The holding period of such Cyclerion CVR should begin on the day after the date of issuance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the above treatment, the Combined Company intends to treat any future payments received by a Cyclerion U.S. Holder on a Cyclerion CVR as <span style="white-space:nowrap">a&#160;non-taxable&#160;return</span> of such Cyclerion U.S. Holder&#8217;s adjusted tax basis in the Cyclerion CVR to the extent thereof, and payments in excess of such amount as ordinary income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the treatment of such future payments is uncertain and alternative treatments are possible. One such possible treatment is that a Cyclerion CVR could be treated as one or more &#8220;debt instruments.&#8221; If that were to be the case, then payments received with respect to the Cyclerion CVRs could be treated as payments in repayment of a &#8220;debt instrument,&#8221; except to the extent interest is imputed under the Code. If those rules were to apply, interest generally should be imputed under complex rules. In such a case, a Cyclerion U.S. Holder would be required to include any such interest in income on an annual basis, whether or not currently paid. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that the issuance of the Cyclerion CVRs could be treated as a distribution of equity for U.S. federal income tax purposes, in which case Cyclerion U.S. Holders should not recognize gain or loss as a result of the issuance of the Cyclerion CVRs. Depending on the fair market value of the Cyclerion CVRs on the date of their issuance, each Cyclerion U.S. Holder&#8217;s tax basis in such holder&#8217;s Cyclerion capital stock would be allocated between such holder&#8217;s Cyclerion capital stock and such holder&#8217;s Cyclerion CVRs. The holding period of such Cyclerion CVRs should include the Cyclerion U.S. Holder&#8217;s holding period of such holder&#8217;s Cyclerion capital stock. Future payments on a Cyclerion CVR received by a Cyclerion U.S. Holder could be treated as dividends to the extent of the Cyclerion U.S. Holder&#8217;s pro rata share of Cyclerion&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as <span style="white-space:nowrap">a&#160;non-taxable&#160;return</span> of capital to the extent of the Cyclerion U.S. Holder&#8217;s basis in the Cyclerion CVR, and finally as capital gain from the sale or exchange of the Cyclerion CVR with respect to any remaining value. As discussed above, Cyclerion does not intend to report the issuance of the Cyclerion CVRs as a distribution of equity and the IRS may disagree with any Cyclerion U.S. Holder reporting the Cyclerion CVR issuance as a distribution of equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that the issuance of the Cyclerion CVRs could be treated as subject to the &#8220;open transaction&#8221; doctrine if the value of the Cyclerion CVRs on the closing date cannot be &#8220;reasonably ascertained.&#8221; If the receipt of Cyclerion CVRs were treated as an &#8220;open transaction&#8221; for U.S. federal income tax purposes, each Cyclerion U.S. Holder should not immediately take the Cyclerion CVRs into account in determining whether such holder must recognize income, if any, on the receipt of the Cyclerion CVRs and such holder would take no tax basis in the Cyclerion CVRs. Rather, the Cyclerion U.S. Holder&#8217;s U.S. federal income tax consequences would be determined at the time future payments, if any, with respect to the Cyclerion CVRs are received or deemed received, based on whether the Cyclerion CVRs are treated as a distribution of property or of equity, in accordance with the Cyclerion U.S. Holder&#8217;s regular method of accounting. As discussed above, Cyclerion does not intend to report the issuance of the Cyclerion CVRs as an open transaction and the IRS may disagree with any Cyclerion U.S. Holder reporting the Cyclerion CVR issuance as an open transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion CVRs should generally be treated as capital assets for U.S. federal income tax purposes once issued. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Receipt of Cyclerion CVRs by <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holders</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, <span style="white-space:nowrap">a&#160;&#8220;Non-U.S.&#160;Holder&#8221;</span> means a beneficial owner of Cyclerion capital stock that is neither a U.S. Holder nor a partnership (or other pass-through entity) for U.S. federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, there is substantial uncertainty as to the tax treatment of Cyclerion CVRs and payments made thereunder. Cyclerion intends to report the issuance of the Cyclerion CVRs to <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holders</span> as a distribution of property with respect to its stock. Each <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> will be treated as receiving a distribution in an amount equal to the fair market value of the Cyclerion CVR issued to such <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> on the date of the issuance. This distribution generally should be treated first as a taxable dividend to the extent of the <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder&#8217;s</span><span style="font-style:italic">&#160;pro rata</span>&#160;share of Cyclerion&#8217;s current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as <span style="white-space:nowrap">a&#160;non-taxable</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
return of capital to the extent of the <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder&#8217;s</span> basis in its Cyclerion capital stock, and finally as capital gain from the sale or exchange of Cyclerion capital stock with respect to any remaining value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if any portion of the distribution of Cyclerion CVRs made <span style="white-space:nowrap">to&#160;Non-U.S.&#160;Holders</span> is treated as a dividend for U.S. federal income tax purposes (as described above), such dividend will be subject to withholding at a rate of 30% (or at a lower rate under an applicable income tax treaty). Under the terms of the Cyclerion CVR Agreement, Cyclerion and the rights agent are permitted to deduct all applicable withholding taxes from the distribution of a Cyclerion CVR to <span style="white-space:nowrap">a&#160;Non-U.S.&#160;Holder</span> and from any payments under the Cyclerion CVR to <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;Non-U.S.&#160;Holder.&#160;Non-U.S.&#160;Holders</span></span> should be aware that the U.S. federal income tax treatment of payments on the Cyclerion CVR is unclear, as described in more detail above, but Cyclerion intends to take the position that such payments will be treated as U.S. source income subject to U.S. withholding tax at a 30% rate, or at a lesser treaty rate. Under the Cyclerion CVR Agreement, Cyclerion and the rights agent are authorized to withhold this tax from payments <span style="white-space:nowrap">to&#160;Non-U.S.&#160;Holders.</span> To the extent that any payments made to <span style="white-space:nowrap">a&#160;Non-U.S.&#160;Holder</span> on a Cyclerion CVR are treated as interest (subject to certain exemptions for amounts treated as &#8220;portfolio interest&#8221; under the Code) or dividends, such amounts will be subject to U.S. federal withholding tax at a 30% rate, or at a lesser treaty rate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding, if the issuance of the Cyclerion CVRs is effectively connected with a <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder&#8217;s</span> conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> maintains a permanent establishment in the United States to which the distribution of the Cyclerion CVRs is attributable), the <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> will be exempt from U.S. federal withholding tax and the distribution of the Cyclerion CVRs generally will be subject to U.S. federal income tax on a net income basis in the same manner as if such <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> were a U.S. Holder. To claim the exemption, the <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> must furnish to the applicable withholding agent a valid IRS <span style="white-space:nowrap">Form&#160;W-8ECI&#160;(or</span> applicable successor form), certifying that the distribution is effectively connected with the <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder&#8217;s</span> conduct of a trade or business within the United States. A <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) of all or a portion of its effectively connected earnings and profits for the taxable year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any portion of the issuance of the Cyclerion CVRs is treated as capital gain from the sale or exchange of Cyclerion capital stock, such gain generally will not be subject to U.S. federal income tax unless (i)&#160;such gain is effectively connected with the conduct by a <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> of a trade or business in the United States (and, if an income tax treaty applies, the gain is generally attributable to a U.S. permanent establishment maintained by such <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder),</span> (ii) in the case of gain realized by a <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> that is an individual, such <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> is present in the United States for 183 days or more in the taxable year of the sale and certain other conditions are met or (iii)&#160;Cyclerion is or has been a USRPHC for U.S. federal income tax purposes and, if the shares are &#8220;regularly traded on an established securities market,&#8221; such <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> owned, directly or indirectly, at any time during the five-year period ending on the date of the distribution, more than 5% of the shares of Cyclerion capital stock and such <span style="white-space:nowrap">Cyclerion&#160;Non-U.S.&#160;Holder</span> is not eligible for any treaty exemption. The shares will be considered &#8220;regularly traded&#8221; if they are traded on an established securities market located in the United States and are regularly quoted by brokers or dealers making a market in the shares. Cyclerion believes it is not, and has not been, a USRPHC for U.S. federal income tax purposes. In addition, although not free from doubt, Cyclerion believes that Cyclerion common shares currently should be considered to be regularly traded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description does not discuss all of the tax considerations that may be applicable to <span style="white-space:nowrap">a&#160;Non-U.S.&#160;Holder</span> of Cyclerion <span style="white-space:nowrap">CVRs.&#160;Non-U.S.&#160;Holders</span> are urged to consult their own tax advisors to determine the U.S. federal, state, local <span style="white-space:nowrap">and&#160;non-U.S.&#160;income</span> and other tax considerations that may be relevant to them in light of their particular circumstances. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Alternative Treatment of the Receipt of Cyclerion CVRs and the Cyclerion Reverse Stock Split as a Single Recapitalization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding Cyclerion&#8217;s position that the receipt of Cyclerion CVRs and the Cyclerion reverse stock split are appropriately treated as separate transactions, it is possible that the IRS or a court could determine that the receipt of the Cyclerion CVRs and the Cyclerion reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes. In such case, the tax consequences of the receipt of Cyclerion CVRs and the Cyclerion reverse stock split would differ from those described above and would depend in part on many of the same considerations described above, including whether the Cyclerion CVRs should be treated as property, equity or debt instruments or should be subject to the &#8220;open transaction&#8221; doctrine. In general, if the Cyclerion CVRs are treated as property and are not subject to the &#8220;open transaction&#8221; doctrine, then a Cyclerion U.S. Holder should recognize gain (but not loss) equal to the lesser of (i)&#160;the fair market value of the Cyclerion CVRs received, and (ii)&#160;the excess (if any) of (A)&#160;the sum of (1)&#160;the fair market value of the Cyclerion CVRs received and (2)&#160;the fair market value of the Cyclerion shares received in the Cyclerion reverse stock split (treating fractional shares as received for this purpose), over (B)&#160;the Cyclerion U.S. Holder&#8217;s adjusted tax basis in the Cyclerion capital stock surrendered in the Cyclerion reverse stock split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PLEASE CONSULT YOUR TAX ADVISOR WITH RESPECT TO THE PROPER CHARACTERIZATION OF THE RECEIPT OF THE CYCLERION CVRS. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_10">CYCLERION DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of April&#160;15, 2026, concerning Cyclerion&#8217;s directors and executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s directors and executive officers as of April&#160;15, 2026 are as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:52%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Regina M. Graul, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">President, Chief Executive Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Rhonda Chicko</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Chief Financial Officer and Secretary</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Errol B. De Souza, Ph.D.<sup style="font-size:75%; vertical-align:top"> (1) (2)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">72</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Chairman of the Board of Directors</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Peter M. Hecht, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">62</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Michael J. Higgins<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">63</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Steven E. Hyman, M.D.<sup style="font-size:75%; vertical-align:top">(1)(3)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">73</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dina Katabi, Ph.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">54</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Director</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Audit Committee </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Compensation Committee </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Nominating and Corporate Governance Committee </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers and Employee Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Regina Graul, Ph.D.</span> has served on the Cyclerion Board since August 2024, as Cyclerion&#8217;s President since December 2023 and as Cyclerion&#8217;s President and Chief Executive Officer since August 2024. Before joining Cyclerion as President, Dr.&#160;Graul served as vice president, program executive at EQRx Therapeutics, Inc. from February 2021 where she led multiple portfolios and cross-functional research and development teams in oncology. From April 2019 through February 2021, Dr.&#160;Graul served as senior director, global development leader at Cyclerion and lead the olinciguat franchise. From 2004 through February 2021, Dr.&#160;Graul served in numerous roles of increasing responsibility across the organization at Ironwood Pharmaceuticals, Inc., most recently as the head of internal innovation and senior director of research and development. Dr.&#160;Graul did her post-doctoral work at MIT, received her Ph.D. in synthetic organic chemistry from Rice University and a B.A. in chemistry from Saint Anselm College. Dr.&#160;Graul brings extensive drug research and development experience in the <span style="white-space:nowrap">bio-pharmaceutical</span> industry over the past 22 years, which makes her a valuable member of the Cyclerion Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Rhonda M. Chicko, C.P.A.</span> is a consultant to Cyclerion and has served as its Chief Financial Officer since January 2024. Ms.&#160;Chicko has been consulting as a chief financial officer to various life science companies since October&#160;2019. Ms.&#160;Chicko previously served as chief financial officer of Scholar Rock from April&#160;2018 through October&#160;2019 and vice president of finance at Editas Medicine from September&#160;2015 through March&#160;2018. From 2005 to 2015, Ms.&#160;Chicko worked at Ironwood Pharmaceuticals, Inc. in financial roles of increasing responsibility, culminating as senior director, finance and tax. Earlier in her career, Ms.&#160;Chicko held a range of positions at investment management and accounting firms, including Wellington Management Company, LLP and PricewaterhouseCoopers, LLP. Ms.&#160;Chicko holds a M.S.T. from Bentley University and a B.S. in accounting from Le Moyne College. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Errol B. De Souza, Ph.D</span><span style="font-weight:bold"><span style="font-style:italic">.</span></span><span style="font-weight:bold"></span>&#160;has served as a member of the Cyclerion Board since April&#160;2021 and is the current Chairman of the Cyclerion Board. Dr.&#160;De Souza was the executive chairman of Neuphoria Therapeutics Inc. (formerly known as Bionomics Limited) from November&#160;2018 to December&#160;2022, <span style="white-space:nowrap">non-executive</span> chairman from January&#160;2023 to June 2023 and a member of its board of directors until November&#160;2023. Previously, Dr.&#160;De Souza served as president, chief executive officer, and member of the board of directors of several companies, including Neuropore Therapies, Inc. from January&#160;2017 to December 2019, Biodel, Inc. from March&#160;2010 to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
January&#160;2016, Archemix Corp from April&#160;2003 to March&#160;2009 and Synaptic Pharmaceutical Corporation from September&#160;2002 to March&#160;2003. From September&#160;1998 to September&#160;2002, Dr.&#160;De Souza held senior vice president roles at Hoechst Marion Roussel Pharmaceuticals, Inc. and Aventis Pharmaceuticals, Inc. He was also founder, chief scientific officer and member of the board of directors at Neurocrine Biosciences, Inc. from October&#160;1992 to August&#160;1998 and head of CNS Diseases Research at DuPont Merck from May&#160;1990 to October&#160;1992. Dr.&#160;De Souza is currently a member of the board of directors of Alector Inc. and Royalty Pharma, Inc. He has previously served on the board of directors of Catalyst Biosciences, Inc., Targacept, Inc., IDEXX Laboratories, Palatin Technologies, Inc. and a number of private company boards. Dr.&#160;De Souza received a B.A. in physiology and a Ph.D. in endocrinology from the University of Toronto. Dr.&#160;De Souza brings extensive strategic and CNS experience as an executive in the <span style="white-space:nowrap">bio-pharmaceutical</span> industry, having founded companies and served as executive chairman, president, and chief executive officer of several private and public <span style="white-space:nowrap">bio-pharmaceutical</span> companies, each of which make him a valuable member of the Cyclerion Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Peter M. Hecht, Ph.D</span><span style="font-weight:bold">.</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span>has been a member of the Cyclerion Board since Cyclerion commenced operations as an independent company in April&#160;2019 and was Cyclerion&#8217;s Chief Executive Officer from April&#160;2019 to November&#160;2023. Dr.&#160;Hecht presently serves as the chief executive officer of Tisento Therapeutics, Inc., a privately-held biotechnology company and as a member of its board of directors. Previously, he served as the chief executive officer of Ironwood Pharmaceuticals, Inc. and as a member of its board of directors from its founding in 1998 to March 2019. Under Dr.&#160;Hecht&#8217;s leadership, the Ironwood Pharmaceuticals, Inc. team built a robust pipeline and grew it into a commercial biotechnology company that discovered, developed, and is now commercializing LINZESS<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#160;- the blockbuster branded prescription market leader in its class. Prior to <span style="white-space:nowrap">co-founding</span> Ironwood Pharmaceuticals Inc, Dr.&#160;Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr.&#160;Hecht also serves on the boards of directors of Kallyope Inc. and Mythic Therapeutics, both privately held biotechnology companies. Dr.&#160;Hecht earned a B.S. in Mathematics and an M.S. in Biology from Stanford University, and a Ph.D. in molecular biology from the University of California at Berkeley. Dr.&#160;Hecht&#8217;s experiences as the founder of several innovative biotechnology companies, his tenure as the chief executive officer and a board member of each of Microbia, Ironwood Pharmaceuticals, Inc., Cyclerion and Tisento Therapeutics, Inc., and his extensive scientific background make him a valuable member of the Cyclerion Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Michael J. Higgins</span><span style="font-weight:bold"></span>&#160;has been a member of the Cyclerion Board since November&#160;2023. Mr.&#160;Higgins was appointed chairman of the board of directors of Voyager Therapeutics, Inc., in June&#160;2019 and also served as Voyager Therapeutics, Inc.&#8217;s interim president and chief executive officer from June&#160;2021 to March&#160;2022. Mr.&#160;Higgins has served as chairman of the board of directors of Pulmatrix, Inc., since April&#160;2020, and has served as a member of the boards of directors of Nocion Therapeutics, Inc., a privately held biopharmaceutical company, since September&#160;2020; Camp4 Therapeutics Corporation, since October&#160;2017; Sea Pharmaceuticals, LLC, a privately held pharmaceutical company, since October&#160;2016; and KinDex Pharmaceuticals, Inc., a privately held biotechnology company, since March&#160;2016. Mr.&#160;Higgins previously served as a member of the board of directors of Genocea Biosciences Inc. from February&#160;2015 to May&#160;2022. Mr.&#160;Higgins is a serial entrepreneur who has helped launch and build numerous companies during his career. He served as <span style="white-space:nowrap"><span style="white-space:nowrap">entrepreneur-in-residence</span></span> at Polaris Partners, an investment company, from 2015 to 2020. From 2003 to 2014 he served as senior vice president, chief operating officer at Ironwood Pharmaceuticals, Inc. Prior to 2003, Mr.&#160;Higgins held a variety of senior business positions at Genzyme Corporation, including vice president of corporate finance and vice president of business development. Mr.&#160;Higgins earned a B.S. from Cornell University and an M.B.A. from the Amos Tuck School of Business at Dartmouth College. Mr.&#160;Higgins&#8217; financial and business expertise, including his diversified background as an executive officer in public pharmaceuticals companies, qualifies him to serve as a member of the Cyclerion Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Steven E. Hyman, M.D.</span> has served as a member of the Cyclerion Board since July&#160;2022. Dr.&#160;Hyman is a Distinguished Service Professor and Harald McPike Professor of Stem Cell and Regenerative Biology at Harvard University and a Core Institute Member of the Broad Institute of MIT and Harvard where he directs the Broad Program in Brain Health. Dr.&#160;Hyman also serves as chairman of the board of directors of the Charles A. Dana Foundation (NY). In the private sector, Dr.&#160;Hyman is founder of Emugen Therapeutics, a director of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Voyager Therapeutics, <span style="white-space:nowrap">Q-State</span> Biosciences and Vesalius, and serves on the scientific advisory boards of Janssen and <span style="white-space:nowrap">F-Prime</span> Capital. From 2001 to 2011, Dr.&#160;Hyman served as Provost (Chief Academic Officer) of Harvard University, and from 1996 to 2001, as Director of the National Institute of Mental Health (NIMH), a component of the US National Institutes of Health. Dr.&#160;Hyman has served as Editor of the Annual Review of Neuroscience (2002-2016), founding President of the International Neuroethics Society (2008-2013), President of the Society for Neuroscience (2015), and President of the American College of Neuropsychopharmacology (2018). Dr.&#160;Hyman is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine. Dr.&#160;Hyman received his B.A. from Yale College, an M.A. from the University of Cambridge, which Dr.&#160;Hyman attended as a Mellon fellow studying history and philosophy of science, and an M.D. from Harvard Medical School. Dr.&#160;Hyman brings a deep expertise as a world-renowned leader in neuroscience leading large-scale, collaborative research programs aimed to discover and develop novel biomarkers and therapeutics for neuropsychiatric diseases, each of which make him a valuable member of the Cyclerion Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Dina Katabi</span><span style="font-weight:bold">, </span><span style="font-weight:bold">Ph.D</span><span style="font-weight:bold">.</span><span style="font-weight:bold"></span>&#160;has been a member of the Cyclerion Board since November&#160;2023. Dr.&#160;Katabi is the <span style="white-space:nowrap">co-founder</span> and president of Emerald Innovations, a health analytics company that specializes in digital health solutions for passive, contactless in-home monitoring. Dr.&#160;Katabi is also the inaugural Thuan and Nicole Pham Professor of Electrical Engineering and Computer Science and the Director of the Massachusetts Institute of Technology&#8217;s Center for Wireless Networks and Mobile Computing. Dr.&#160;Katabi is a MacArthur Fellow and a member of the National Academy of Engineering (NAE), the National Academy of Sciences (NAS), and the American Association of Arts and Sciences (AAAS). Dr.&#160;Katabi&#8217;s research focuses on advanced wireless sensing, applied machine learning, and digital health. Several startups have been spun out of Dr.&#160;Katabi&#8217;s lab. Dr.&#160;Katabi has received three honorary degrees from the American University of Beirut, the American University of Cairo, and the Catholic University of America. Dr.&#160;Katabi received her Ph.D. and M.S. in computer science from MIT and her B.S. from Damascus University. Dr.&#160;Katabi&#8217;s scientific background and experiences make her a valuable member of the Cyclerion Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independence of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required under the listing standards of the Nasdaq Capital Market, a majority of the members of a listed company&#8217;s Board of Directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the Board of Directors. The Cyclerion Board consults with Cyclerion&#8217;s counsel to ensure that the Cyclerion Board&#8217;s determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and Cyclerion, its senior management and its independent auditors, the Cyclerion Board has affirmatively determined that the following four directors satisfy the independence standard established by the Nasdaq listing standards, as well as the Corporate Governance Guidelines adopted by the Cyclerion Board: Drs. Hyman, Katabi and De Souza and Mr.&#160;Higgins. In making this determination, the Cyclerion Board found that none of these individuals had a material or other disqualifying relationship with Cyclerion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cyclerion Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board has an independent Chairman, Dr.&#160;De Souza, who has authority, among other things, to call and preside over Cyclerion Board meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Cyclerion Board. Accordingly, the Cyclerion Board Chairman has substantial ability to shape the work of the Cyclerion Board. Cyclerion believes that separation of the positions of Board Chairman and Chief Executive Officer or President reinforces the independence of the Cyclerion Board in its oversight of the business and affairs of Cyclerion. In addition, Cyclerion believes that having an independent Board Chairman creates an environment that is more conducive to objective evaluation and oversight of management&#8217;s performance, increasing management accountability and improving the ability of the Cyclerion Board to monitor whether management&#8217;s actions are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the best interests of Cyclerion and its shareholders. As a result, Cyclerion believes that having an independent Board Chairman can enhance the effectiveness of the Cyclerion Board as a whole. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of the Cyclerion Board in Risk Oversight </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the Cyclerion Board&#8217;s functions is informed, tailored oversight of Cyclerion&#8217;s risk management process. The Cyclerion Board oversees risk directly through the Cyclerion Board as a whole, as well as through various Cyclerion Board standing committees that address risks specific to their respective areas of oversight. In particular, the Cyclerion Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion has implemented and continues to refine an enterprise risk management process. On an ongoing basis, Cyclerion identifies key risks, assess their potential impact and likelihood, and, where appropriate, implement operational measures and controls or purchase insurance coverage in order to help ensure adequate risk mitigation. Periodically, key risks, status of mitigation activities, and potential new or emerging risks are reported to and discussed with senior management and further addressed with the Cyclerion Board, as necessary. On at least an annual basis, a long-term comprehensive enterprise risk management update is provided to the Cyclerion Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s Audit Committee has the responsibility to consider and discuss Cyclerion&#8217;s major financial and IT risk exposure and the approach management uses to monitor and control this exposure, including guidelines and policies to govern the risk management processes. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of our internal audit function. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s Nominating and Corporate Governance Committee monitors the effectiveness of Cyclerion&#8217;s Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s Compensation Committee oversees and reviews Cyclerion&#8217;s compensation policies and programs to ensure that they encourage an appropriate balance of risk and reward, and that they align management&#8217;s incentives with those of Cyclerion&#8217;s shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Meetings of the Board of Directors, Attendance and Overboarding </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board met eight times and acted by written consent on several occasions in 2025. No director attended less than 75% of the meetings of the Cyclerion Board and its committees on which he or she served. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as provided in Cyclerion&#8217;s Corporate Governance Guidelines, all directors are expected to be able to dedicate sufficient time to ensure the diligent performance of his or her duties on Cyclerion&#8217;s behalf, including attending Cyclerion Board and applicable committee meetings as well as the annual meetings of shareholders. All of Cyclerion&#8217;s directors attended the 2025 annual meeting of shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s Corporate Governance Guidelines also provide that directors should not serve on more than a total of four public company boards of directors and that directors who hold the position of Chief Executive Officer of a public company should not serve on more than a total of two public company boards of directors (including the board of his or her own company). Cyclerion also expects that each director will avoid circumstances that create an actual or perceived conflict of interest and has a process in place to appropriately evaluate any perceived conflict of interest. Cyclerion&#8217;s Nominating and Corporate Governance Committee and the Cyclerion Board regularly evaluate its directors&#8217; commitments at other public companies to confirm compliance with Cyclerion&#8217;s overboarding policy, discussed above, and to ensure that they are able to devote sufficient time to their duties at Cyclerion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information Regarding Committees of the Cyclerion Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board has three committees: (a)&#160;an Audit Committee, (b)&#160;a Compensation Committee and (c)&#160;a Nominating and Corporate Governance Committee, each of which operates pursuant to a charter adopted by the Cyclerion Board. The following table provides membership of each Cyclerion Board committee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:41%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td style="width:38%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Audit</span><br/><span style="font-weight:bold">Committee</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Compensation</span><br/><span style="font-weight:bold">Committee</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Nominating and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Corporate Governance</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Committee</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Errol B. De Souza, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">I</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">C</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael J. Higgins.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">C</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">I</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven E. Hyman, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">I&#8201;&#8201;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">C</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dina Katabi, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">I</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:95%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-size:10pt">C=</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Committee Chairperson</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">I=</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Independent Committee Member</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a description of the Cyclerion Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. Each such committee has authority to engage legal counsel or other experts or consultants, as it deems necessary to carry out its responsibilities. The Cyclerion Board has determined that each member of each such committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to Cyclerion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Audit Committee</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee of the Cyclerion Board was established by the Cyclerion Board in accordance with Section&#160;3(a)(58)(A) of the Exchange Act, to oversee Cyclerion&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee is responsible for, among other duties: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and Cyclerion&#8217;s independent registered public accounting firm Cyclerion&#8217;s annual and quarterly financial statements, earnings releases and related disclosures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing with management and Cyclerion&#8217;s independent registered public accounting firm the quality and adequacy of internal controls and internal auditing procedures, including any material weaknesses in either; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing with management and Cyclerion&#8217;s independent registered public accounting firm any significant risks or exposures facing Cyclerion and the related mitigation plans, and reviewing Cyclerion&#8217;s compliance with such mitigation plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and Cyclerion&#8217;s independent registered public accounting firm the quality and acceptability of Cyclerion&#8217;s accounting policies and all material correcting adjustments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing, retaining, overseeing and approving the compensation for and, when necessary, terminating Cyclerion&#8217;s independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving all audit services and all permitted <span style="white-space:nowrap">non-audit,</span> tax and other services to be performed by Cyclerion&#8217;s independent registered public accounting firm, in each case, in accordance with the Audit Committee&#8217;s <span style="white-space:nowrap">pre-approval</span> policy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing with Cyclerion&#8217;s independent registered public accounting firm its independence and ensuring that it receives the written disclosures regarding these communications required by the Public Company Accounting Oversight Board; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving all related party transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to the Cyclerion Board whether the audited financial statements should be included in Cyclerion&#8217;s annual report and preparing the report of Cyclerion&#8217;s Audit Committee required by SEC rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with Cyclerion&#8217;s independent registered public accounting firm all material communications between Cyclerion&#8217;s management and Cyclerion&#8217;s independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, updating and recommending to the Cyclerion Board changes to Cyclerion&#8217;s Code of Business Conduct and Ethics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing the integrity of Cyclerion&#8217;s information technology systems, processes and data and reviewing and assessing with management the adequacy of security for such technology systems, processes and data; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing procedures for the receipt, retention, investigation and treatment of accounting related complaints and concerns. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee is currently composed of three directors: Mr.&#160;Higgins, who serves as Chair, Dr.&#160;De Souza and Dr.&#160;Hyman. Each member of the Audit Committee is financially literate and has accounting or related financial management expertise. The Audit Committee met five times during fiscal year 2025. The Cyclerion Board has adopted a written Audit Committee charter that is available to shareholders on Cyclerion&#8217;s website at <span style="font-style:italic">www.cyclerion.com</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of Cyclerion&#8217;s Audit Committee are independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii)&#160;of the Nasdaq rules). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board has also determined that Mr.&#160;Higgins qualifies as an &#8220;audit committee financial expert,&#8221; as defined under applicable SEC rules. The Cyclerion Board made a qualitative assessment of Mr.&#160;Higgins&#8217; level of knowledge and experience based on a number of factors, including his formal education and prior experience at public reporting companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Cyclerion Board acts on behalf of the Cyclerion Board to, among other things, administer Cyclerion&#8217;s compensation policies and human resources philosophy, and to enable Cyclerion to attract and motivate qualified personnel and advise the Cyclerion Board regarding, and facilitate the Cyclerion Board&#8217;s oversight of, the compensation of members of the Cyclerion Board and Cyclerion&#8217;s CEO and other executive officers. The Compensation Committee is responsible for, among other duties: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to the Cyclerion Board annually, corporate goals and objectives relevant to executive officer compensation and evaluating and approving the performance of executive officers in light of those goals and objectives; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving executive officer compensation, including salary, bonus and incentive compensation, deferred compensation, perquisites, equity compensation, benefits provided upon retirement, severance or other termination of employment and any other forms of executive compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving Cyclerion&#8217;s President and Chief Executive Officer&#8217;s compensation based on its evaluation of Cyclerion&#8217;s President and Chief Executive Officer&#8217;s performance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and making recommendations to the Cyclerion Board, or approving, any contracts or other transactions with Cyclerion&#8217;s current or former executive officers, including consulting arrangements, employment contracts, severance or termination arrangements and loans to employees; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing and administering Cyclerion&#8217;s incentive compensation plans and equity-based plans and recommending to the Cyclerion Board the adoption of new incentive compensation plans and equity-based plans and any amendments to Cyclerion&#8217;s existing plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the compensation and benefits paid to directors for service on the Cyclerion Board the committees thereof and recommending any changes in such compensation and benefits to the Cyclerion Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing Cyclerion&#8217;s management succession and development plans, including plans with respect to Cyclerion&#8217;s Chief Executive Officer and President; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management any compensation related material required to be included in Cyclerion&#8217;s filings with the SEC and recommending to the Cyclerion Board whether such compensation related material should be included in such filings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee is currently composed of two directors: Dr.&#160;De Souza, who serves as Chair and Mr.&#160;Higgins. All members of Cyclerion&#8217;s Compensation Committee are independent (as independence is currently defined in Rule 5605(d)(2) of the Nasdaq listing standards), and each of whom qualifies as a <span style="white-space:nowrap">&#8220;non-employee</span> director&#8221; (within the meaning of Rule <span style="white-space:nowrap">16b-3</span> of the Exchange Act) and an &#8220;outside director&#8221; (within the meaning of Section&#160;162(m) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)). The Compensation Committee met three times and acted by written consent on several occasions during fiscal year 2025. The Cyclerion Board has adopted a written Compensation Committee charter that is available to shareholders on Cyclerion&#8217;s website at <span style="font-style:italic">www.cyclerion.com</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, the Compensation Committee meets twice per year and with greater frequency if necessary. The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with the Chief Executive Officer and President. The Compensation Committee does not currently retain a compensation consultant. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer and President may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding her compensation or individual performance objectives. Under the Compensation Committee&#8217;s charter, it has the authority to obtain, at the expense of the Company, advice and assistance from compensation consultants and legal, accounting or other advisors that the Compensation Committee considers necessary or appropriate in the performance of its duties. In particular, the Compensation Committee has the authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation Committee, and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence; however, there is no requirement that such independence assessment be undertaken when the advisers role is limited to consulting on broad based plans generally available to all salaried employees, or providing <span style="white-space:nowrap">non-customized</span> information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee of the Board of Directors is responsible for, among other duties: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying individuals qualified to become members of the Cyclerion Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to the Cyclerion Board the persons to be nominated for election as directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assisting the Cyclerion Board in recruiting such nominees; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to the Cyclerion Board qualified individuals to serve as committee members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performing an annual evaluation of the Cyclerion Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating the need and, if necessary, creating a plan for the continuing education of Cyclerion&#8217;s directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating and approving any requests from Cyclerion&#8217;s executive officers to serve on the board of directors of another for-profit company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assessing and reviewing Cyclerion&#8217;s Corporate Governance Guidelines and recommending any changes to the Cyclerion Board. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is composed of two directors: Dr.&#160;Hyman, who serves as Chair, and Dr.&#160;Katabi. Each member of the Nominating and Corporate Governance Committee is independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met three times during fiscal 2025 and took action by written consent once. The Cyclerion Board has adopted a written Nominating and Corporate Governance Committee charter that is available to shareholders on Cyclerion&#8217;s website at <span style="font-style:italic">www.cyclerion.com</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is the policy of the Cyclerion Board that directors should possess strong personal and professional ethics, integrity and values, demonstrate a keen understanding of, and enthusiasm for, Cyclerion, its business and its industry, and be committed to representing the long-term interests of Cyclerion&#8217;s shareholders. The composition of the Cyclerion Board should also encompass a range of talents, ages, skills, diversity, business experience and clinical/scientific expertise sufficient to provide sound and prudent oversight with respect to the operations and interests of Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering potential nominees for director, the Nominating and Corporate Governance Committee looks to maintain a balance of perspectives, qualifications, qualities and skills on the Cyclerion Board, and will look for nominees who exhibit, among other qualities: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the highest professional and personal ethics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broad experience in business, the biopharmaceutical industry, government or science; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to provide insights and practical wisdom based on their experience and expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commitment to enhancing shareholder value; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sufficient time to carry out their duties effectively (their service on other boards of public companies should be limited as set forth in Cyclerion&#8217;s Corporate Governance Guidelines); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with legal and regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to develop a good working relationship with other Cyclerion Board members and contribute to the Cyclerion Board&#8217;s working relationship with senior management of Cyclerion; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">except in exceptional cases, satisfy the independence standards established by the Nasdaq listing standards. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the foregoing, there are no stated minimum criteria for director nominees, although the Nominating and Corporate Governance Committee may also consider such other factors as it may deem are in the best interests of Cyclerion and its shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is committed to inclusion and diversity within the Cyclerion Board and confirms that its policy of <span style="white-space:nowrap">non-discrimination</span> based on race, color, religion, gender, national origin, ethnicity, age, disability, veteran status, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pregnancy, marital status, sexual orientation or any other reason prohibited by applicable law applies in the assessment and selection of all director candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee may use any process it deems appropriate for the purpose of evaluating candidates that is consistent with the policies set forth in the Cyclerion Organizational Documents, Cyclerion&#8217;s Corporate Governance Guidelines and Cyclerion&#8217;s policy, which process may include, without limitation, personal interviews, background checks, written submissions by the candidates and third-party references. Although the Nominating and Corporate Governance Committee may seek candidates that have different qualities and experiences at different times in order to maximize the aggregate experience, qualities and strengths of the Cyclerion Board members, nominees for each election or appointment of directors shall be evaluated using a substantially similar process and under no circumstances shall the Nominating and Corporate Governance Committee evaluate nominees recommended by a shareholder of Cyclerion pursuant to a process substantially different than that used for other nominees for the same election or appointment of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Shareholder Communications with the Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board will consider any written or electronic communication from Cyclerion&#8217;s shareholders to the Cyclerion Board, a committee of the Cyclerion Board or any individual director. Any shareholder who wishes to communicate to the Cyclerion Board, a committee of the Cyclerion Board or any individual director should submit written or electronic communications to our secretary at our principal offices, which shall include contact information for such shareholder. All communications from shareholders received shall be forwarded by Cyclerion&#8217;s secretary to the appropriate recipient(s) on a periodic basis, but in any event no later than the Cyclerion Board&#8217;s next scheduled meeting. The appropriate recipient(s) will consider and review carefully any communications from shareholders forwarded by Cyclerion&#8217;s secretary. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Governance Guidelines, Code of Business Conduct and Ethics, Insider Trading Policy and Clawback Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board has adopted Corporate Governance Guidelines that set forth the responsibilities of the Cyclerion Board and the qualifications and independence of its members and the members of its standing committees. In addition, the Cyclerion Board adopted a Code of Business Conduct and Ethics setting forth standards applicable to all of Cyclerion&#8217;s directors, officers and employees. The Corporate Governance Guidelines and Code of Business Conduct and Ethics are available on Cyclerion&#8217;s website at <span style="font-style:italic">www.cyclerion.com</span>. Cyclerion expects that any amendment to the code, or any waivers of its requirements, which apply to Cyclerion&#8217;s Chief Executive Officer or President, Chief Financial Officer, Chief Accounting Officer, or Corporate Controller, if any, will be disclosed on Cyclerion&#8217;s website. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion has adopted an Insider Trading Prevention Policy that applies to all of Cyclerion&#8217;s employees, officers and directors, including its Chief Executive Officer and other executive officers, which prohibits such individuals from purchasing financial instruments, or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in market value of Cyclerion&#8217;s common stock, such as prepaid variable forward contracts, equity swaps, collars, forward sale contracts and exchange funds. Cyclerion&#8217;s Insider Trading Prevention Policy also prohibits Cyclerion from transacting in its securities unless in compliance with applicable U.S. securities laws, rules and regulations and applicable stock exchange listing standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s insider trading compliance officer, as designated by the Cyclerion Board, a committee thereof or an executive officer of Cyclerion (the &#8220;Compliance Officer&#8221;) assists with implementing, interpreting and enforcing Cyclerion&#8217;s Insider Trading Prevention Policy, <span style="white-space:nowrap">pre-clearing</span> trading activities of certain people, and <span style="white-space:nowrap">pre-approving</span> any <span style="white-space:nowrap">10b5-1</span> plans; provided that if the designated Compliance Officer&#8217;s service with Cyclerion is terminated, or no one else has been designated as a Compliance Officer by the Cyclerion Board, a committee thereof or an executive officer of Cyclerion, then Cyclerion&#8217;s outside general counsel will be deemed to be the Compliance Officer for the purposes of Cyclerion&#8217;s Insider Trading Prevention Policy. Cyclerion&#8217;s Insider </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trading Prevention Policy is included as Exhibit 19 to Cyclerion&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2025, filed with the SEC on March&#160;30, 2026. Cyclerion will furnish to any person without charge, upon written request, a copy of Cyclerion&#8217;s Insider Trading Prevention Policy and requests may be directed to Cyclerion&#8217;s secretary at its principal executive offices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board has adopted a Clawback Policy that applies to Executive Officers (as defined in the Clawback Policy). The Clawback Policy is included as Exhibit 97.1 to Cyclerion&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2025, filed with the SEC on March&#160;30, 2026. Cyclerion will furnish to any person without charge, upon written request, a copy of the Clawback Policy and requests may be directed to Cyclerion&#8217;s secretary at its principal executive offices. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_11">CYCLERION EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Cyclerion,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Cyclerion and its subsidiaries. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a smaller reporting company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. These include, but are not limited to, reduced disclosure obligations regarding executive compensation in our proxy statements, including the requirement to include a Compensation Discussion and Analysis, and provide information relating to the ratio of total compensation of our Chief Executive Officer or President to the median of the annual total compensation of all of our employees. We have elected to comply with the scaled disclosure requirements applicable to smaller reporting companies. As a smaller reporting company, we are permitted to limit reporting of compensation disclosure to our principal executive officer and our two other most highly compensated executive officers, which we refer to as our &#8220;named executive officers&#8221; or our &#8220;NEOs.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation awarded to, earned by, and paid to our named executive officers with respect to the years ended December&#160;31, 2025 and December&#160;31, 2024. Regina M. Graul, Ph.D., our President and Chief Executive Officer, joined the Company on December&#160;1, 2023 and Rhonda M. Chicko, a consultant who serves as our Chief Financial Officer, commenced services to the Company in January&#160;2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:38%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name and Principal Position</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Salary</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Bonus</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Equity</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Severance&#160;and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Separation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">All Other</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina M. Graul, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">420,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">52,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">572,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">President and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">390,831</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">323,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">35,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">874,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rhonda M. Chicko <sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">355,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53,553</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">408,978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer and Corporate Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects cash bonuses paid to Dr.&#160;Graul in 2024 and 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects (i)&#160;the fair value of a stock option award on the date of grant issued in 2024 and 2025 calculated in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification Topic 718, Compensation&#8212;Stock Compensation, and (ii)&#160;the value of restricted stock awards based on the market value of the Company&#8217;s Common Stock on the date of grant in 2024. Each of the option grant and stock awards vest over a four-year period. For a discussion of the assumptions used in the valuation of awards, see Note&#160;7 to our consolidated and combined financial statements for the year ended December&#160;31, 2025, included in our Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> that we filed with the SEC on March&#160;30, 2026. All values reported exclude the effects of potential forfeitures. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of amounts for reimbursement for medical insurance premiums, the employer contribution to the Company&#8217;s 401(k) plan for Dr.&#160;Graul and a work from home stipend. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Chicko currently serves as a consultant to the Company and does not receive employee benefits. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of our Board of Directors determines our executives&#8217; compensation and determines the compensation of our named executive officers. For 2025, our Compensation Committee reviewed and discussed management&#8217;s proposed compensation. The three primary elements of our executive officer compensation program for Dr.&#160;Graul, our President and Chief Executive Officer, are annual base salary, <span style="white-space:nowrap">non-equity</span> incentive plan compensation, and long-term equity incentive compensation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Annual Base Salary and Employment Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Graul joined the Company and became President on December&#160;1, 2023. Her base salary was initially set at $372,000 per year and increased in August&#160;2024 to $420,000 per year. She received a <span style="white-space:nowrap">one-time</span> cash bonus of $75,000 in January 2024 and a <span style="white-space:nowrap">one-time</span> cash bonus of $50,000 in December&#160;2024 and a <span style="white-space:nowrap">one-time</span> cash bonus of $20,000 in January 2025 and $80,000 in October 2025. In the event that Dr.&#160;Graul&#8217;s employment is terminated by the Company without &#8220;cause&#8221; (as defined in her offer letter, as amended), Dr.&#160;Graul is entitled to nine months base salary, twelve months of health insurance premiums, and any Company equity or equity-based awards held shall immediately accelerate and become fully vested and exercisable. Ms.&#160;Graul is also entitled to a bonus of up to $150,000 if the Company consummates a merger or other transaction after which the holders of its common stock immediately before the merger or other transaction do not directly or indirectly beneficially own more than 50% of the voting power of the Company&#8217;s (or its successor&#8217;s or the Company&#8217;s ultimate parent&#8217;s) equity securities (a &#8220;<span style="text-decoration:underline">Change of Control</span>&#8221;) as determined by the Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&#160;Chicko joined the Company in January&#160;2024 as our Chief Financial Officer. Ms.&#160;Chicko performs her services on a part-time basis as an independent consultant and is compensated on an hourly basis for her services. In August 2025, Ms.&#160;Chicko received a stock option to purchase up to 25,000 shares, subject to certain vesting requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual base cash compensation of our named executive officers have been determined and approved (and are periodically reviewed) by our Compensation Committee in order to compensate our named executive officers for the satisfactory performance of duties to the Company. For Ms.&#160;Graul, annual base salary is intended to provide a fixed component of compensation, reflecting her skill set, experience, roles and responsibilities. Cash compensation for our named executive officers have been set at levels deemed necessary to attract and retain individuals with superior talent and are in line with cash compensation for similar roles at our peer group companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Restricted Stock Grants to Dr.&#160;Graul </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Graul was granted 50,000 shares of restricted stock of the Company under the Company&#8217;s 2019 Equity Plan, pursuant to the terms and conditions of the Company&#8217;s standard form of restricted stock agreement (the &#8220;Initial Restricted Stock Grant&#8221;). The shares of the Initial Restricted Stock Grant vest based on her continued employment by the Company on each vest date: 10,000 shares of the Initial Restricted Stock Grant vested on December&#160;1, 2023, and an additional 833 shares of the Initial Restricted Stock Grant vest on the first day of each subsequent month, for forty-seven (47)&#160;successive months, with the remaining 849 shares of the Initial Restricted Stock Grant vesting on December&#160;1, 2027, subject to continued service through each such vesting date. Pursuant to the Company&#8217;s 2019 Equity Plan, the Compensation Committee may accelerate the vesting of all unvested restricted shares at its option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on January&#160;1, 2024, Dr.&#160;Graul was granted an additional 50,000 shares of restricted stock of the Company under the Company&#8217;s 2019 Equity Plan, pursuant to the terms and conditions of the Company&#8217;s standard form of restricted stock agreement (the &#8220;Second Restricted Stock Grant&#8221;). The shares issued under the Second&#160;Restricted Stock Grant vest based on Dr.&#160;Graul&#8217;s continued employment by the Company on each vest date: 10,000 shares of the Second Restricted Stock Grant vested on January&#160;1, 2024, an additional 833&#160;shares of the Second Restricted Stock Grant vest on the first day of each subsequent month, for forty-seven (47)&#160;successive months, and the remaining 849 shares of the Second Restricted Stock Grant vest on January&#160;1, 2028, subject to continued service through each such vesting date. Pursuant to the Company&#8217;s 2019 Equity Plan, the Compensation Committee may accelerate the vesting of all unvested restricted shares at its option. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Equity-Based Awards </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards granted to our named executive officers are designed to align the interests of our named executive officers with those of our shareholders. Vesting of equity awards is generally tied to each officer&#8217;s continuous service with us and serves as an additional incentive measure.&#160;Our executives </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally are awarded an initial new hire grant upon commencement of employment and are typically awarded annual grants in line with the practice of our peer group. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance.&#160;We generally avoid granting stock options, stock appreciation rights or similar option-like instruments in relation to the disclosure of material <span style="white-space:nowrap">non-public</span> information except to new hires or in connection with the promotion of any employee to a new position.&#160;No option was granted within four business days before and one business day after the filing of a periodic report or the filing of furnishing of a current report on Form <span style="white-space:nowrap">8-K</span> that contains material nonpublic information (other than disclosure of a material new option award grant under Item 5.02(e) of Form <span style="white-space:nowrap">8-K).</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards as of December&#160;31, 2025 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">Grants of Plan-Based Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name of Optionee</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exercisable&#160;Stock</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Options</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Per&#160;Share&#160;Option</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exercise Price</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina M. Graul, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">19,771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">August&#160;4,&#160;2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rhonda Chicko<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">August&#160;6, 2035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of an incentive stock option granted in August&#160;2024 to purchase up to 55,849 shares of the Corporation&#8217;s common stock pursuant to the 2019 Equity Incentive Plan. These 55,849 shares vest ratably in monthly installments over a <span style="white-space:nowrap">48-month</span> period commencing August&#160;31, 2024 and ending August&#160;4, 2028, provided that Dr.&#160;Graul remains employed by the Company on such applicable vesting date, subject to certain exemptions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of a <span style="white-space:nowrap">non-qualified</span> stock option granted in August&#160;2025 to purchase up to 25,000 shares of the Corporation&#8217;s common stock pursuant to the 2019 Equity Incentive Plan. This option provided for immediate vesting of 8,750 shares from with the remaining unvested shares vesting ratably over a 30 month period commencing on August&#160;31, 2025 and ending February&#160;29, 2028, provided that Ms.&#160;Chicko remains a consultant by the Company on such applicable vesting date, subject to certain exemptions. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:36%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number&#160;of&#160;securities</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">underlying&#160;the&#160;award</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exercise&#160;price</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of&#160;the&#160;award</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($/share)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant&#160;date&#160;fair</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">value of the</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">award&#160;($/share)</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina M. Graul, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">08/05/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">55,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rhonda Chicko</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">08/07/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="16"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">Grants of Plan-Based Restricted Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name of Restricted Stock Recipient</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Restricted</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Award</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vested</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Restricted</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Unvested</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Restricted</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(#)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Market&#160;Value&#160;of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Shares of Stock</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">That Have Not</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Yet Vested<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina M. Graul, Ph.D.<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">59,151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">51,878</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Market value is based on the closing price for the Company&#8217;s Common Stock as reported by Nasdaq on December&#160;31, 2025 of $1.27 per share. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of a restricted Common Stock award granted to Dr.&#160;Graul on December&#160;1, 2023 and a second restricted Common Stock award granted on January&#160;1, 2024 in consideration for her services as an employee of the Company. These shares of restricted Common Stock provided for immediate vesting of 10,000 shares from each award with the remaining unvested shares vesting ratably over a 48 month period from the date of grant, subject to certain exemptions. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Retirement Benefits and Other Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Graul is eligible for certain benefits, including reimbursement for health insurance premiums, a work from home stipend, and certain other benefits. In addition, we maintain a 401(k) plan intended to qualify as a <span style="white-space:nowrap">tax-qualified</span> plan under Section&#160;401 of the U.S. Internal Revenue Code of 1986, as amended, which Dr.&#160;Graul is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible to participate in on the same basis as our other employees. The 401(k) plan has a 75% matching Company contribution on the first $8,000 of an employee&#8217;s annual contribution. Dr.&#160;Graul did not participate in, or otherwise receive any other benefits under any pension, retirement or deferred compensation plan sponsored by us (other than our 401(k) plan, as mentioned above) during 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pay Versus Performance </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are providing the following disclosure, as it applies to smaller reporting companies, regarding executive &#8220;Compensation Actually Paid&#8221; (&#8220;CAP&#8221;), as calculated under applicable SEC rules, for our principal executive officer(s) (&#8220;PEO(s)&#8221;) and our other named executive officers <span style="white-space:nowrap">(&#8220;non-PEO</span> NEOs&#8221;) and certain financial performance measures for the fiscal years ended December&#160;31, 2025, 2024 and 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the CAP to our PEO(s) and the CAP to our <span style="white-space:nowrap">non-PEO</span> NEOs, we are required to make various adjustments to the total compensation amounts that have been reported in the Summary Compensation Table (&#8220;SCT&#8221;), as the SEC&#8217;s valuation methods for this section differ from those required in the SCT. Information regarding the methodology for calculating CAP to our PEO(s) and the CAP to our <span style="white-space:nowrap">non-PEO</span> NEOs, including details regarding the amounts that were deducted from, and added to, the SCT totals to arrive at the values presented for CAP, are provided in the footnotes to the table. Note&#160;that for <span style="white-space:nowrap">non-PEO</span> NEOs, compensation is reported as an average. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a smaller reporting company and is not required to disclose the total shareholder return for our peer group or to disclose the company-selected measure or the tabular list of our most important financial performance measures. Information presented in this section will not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, except as we may specifically do so by reference to this section. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pay Versus Performance </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:16%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold"><span style="font-style:italic">(a)</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(b)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(c)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(d)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(e)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(f)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(g)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic">Year<sup style="font-size:75%; vertical-align:top">(1)</sup></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Summary</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Table Total</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For First</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Summary</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Table Total</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">For Second</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually Paid</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">To First PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually Paid</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">To Second</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Average</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Summary</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Table Total</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">for</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-PEO</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Named</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Executive</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Officers</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Average</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually Paid</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">to</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-PEO</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Named</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Executive</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Officers</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Initial Fixed</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">$100</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Investment</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Based on</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Shareholder</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Return</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Net Income</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Loss)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Thousands)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2025</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">572,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">443,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">408,978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">369,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,528</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2024</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">874,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">857,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,057</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2023</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">147,361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">82,954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">181,931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(62,468</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">559,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">383,419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,263</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Deductions from, and additions to, total compensation as reported in the SCT by year to calculate CAP include: </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reconciliation of Summary Compensation Table Total to Compensation Actually Paid for PEO </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:9%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:24%"/>

<td style="vertical-align:bottom"/>
<td style="width:2%"/>

<td style="vertical-align:bottom"/>
<td style="width:8%"/>

<td style="vertical-align:bottom"/>
<td style="width:8%"/>

<td style="vertical-align:bottom"/>
<td style="width:7%"/>

<td style="vertical-align:bottom"/>
<td style="width:8%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom"/>
<td style="width:6%"/>

<td style="vertical-align:bottom"/>
<td style="width:8%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">PEO</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Summary</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Table</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">for PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exclusion of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock<br/>Awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">from</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Summary</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Table</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">for PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Inclusion<br/>of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Year-End</span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fair<br/>Value</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Equity</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Granted</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">During<br/>Year</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">That</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Remained</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Outstanding</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">and</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Unvested<br/>as</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Last Day<br/>of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">for PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Inclusion<br/>of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Change In</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fair Value</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">from</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Last Day of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Prior Year<br/>to</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Last Day of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Outstanding</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">and<br/>Unvested</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Equity</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Granted in</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Any Prior</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">for PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Inclusion</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vesting</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fair</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value<br/>of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Granted</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">During</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year<br/>that</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vested</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">During</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year<br/>for</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Inclusion</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of<br/>Change</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">in Fair</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Value</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">from<br/>Last</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Day</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Prior</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">to<br/>Vesting</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Unvested</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Equity</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Granted</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">in any</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Prior</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year<br/>that</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Vested</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">During</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year<br/>for</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">PEO</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exclusion</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fair<br/>Value</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">at</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Last<br/>Day</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Prior<br/>Year</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Equity</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Forfeited</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">During</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Year<br/>for</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">Paid to<br/>PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" colspan="3" rowspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina M. Graul, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer,</span></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">President</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">572,153</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">(108,053)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">(20,383)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">443,717</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">874,823</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">(323,665)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">242,360</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">(3,901)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">72,954</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">(4,756)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">857,815</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">147,361</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">(124,330)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">134,000</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">24,900</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">&#8212;&#8194;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:right">181,931</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount represents our net loss for the year as reported on our Annual Report on Form <span style="white-space:nowrap">10-K.</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reconciliation of Summary Compensation Table Total to Compensation Actually Paid for <span style="white-space:nowrap">Non-PEO</span> NEOs </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Summary Compensation Table Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">408,978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">559,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Minus): Grant Date Fair Value of Equity Awards Granted in Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(53,553</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus: Fair Value at Fiscal Year End of Outstanding and Unvested Equity Awards Granted in the Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus/(Minus): Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Fiscal Years</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus/(Minus): Change in Fair Value as of the Vesting Date of Equity Awards Granted in Prior Fiscal Years that Vested in the Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(26,909</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Minus): Fair Value as of the Prior Fiscal Year End of Equity Awards Granted in Prior Fiscal Years that Failed to Meet Vesting Conditions in the Fiscal Year</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(148,950</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Actually Paid</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">369,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">383,419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Description of Relationship Between PEOs and <span style="white-space:nowrap">Non-PEO</span> NEO Compensation Actually Paid and Company Total Shareholder Return (&#8220;TSR&#8221;) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the relationship between the average Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our <span style="white-space:nowrap">Non-PEO</span> NEOs, and the Company&#8217;s cumulative TSR from December&#160;31, 2022 through December&#160;31, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:30%"/>

<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Average&#160;Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually Paid to</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">our PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Average&#160;Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually Paid to our</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-PEO</span> NEOs</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cumulative&#160;TSR&#160;of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">$100 Invested Over</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">the Three Most</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Recently&#160;Completed</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fiscal Years</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">572,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">355,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9.68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">551,158</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">113,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">559,278</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excludes severance payment to Ms.&#160;Gault in 2023 of $214,000 and a separation payment to Ms.&#160;Gjino of $204,000. Ms.&#160;Gault and Ms.&#160;Gjino were our two <span style="white-space:nowrap">Non-PEO</span> NEOs in 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Description of Relationship Between PEOs and <span style="white-space:nowrap">Non-PEO</span> NEO Compensation Actually Paid and Net Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the relationship between the Average Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our <span style="white-space:nowrap">Non-PEO</span> NEOs, and our Net Income (Loss) during the two most recently completed fiscal years. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:32%"/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Average&#160;Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually Paid to</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">our PEO</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Average&#160;Compensation</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Actually Paid to our</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-PEO</span> NEOs</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Net&#160;Income&#160;(Loss)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">for the Three Most</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Recently&#160;Completed</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fiscal Years</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">572,153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">355,425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,528</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">551,158</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">249,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,057</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">113,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">559,278</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,263</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excludes severance payment to Ms.&#160;Gault in 2023 of $214,000 and a separation payment to Ms.&#160;Gjino of $204,000. Ms.&#160;Gault and Ms.&#160;Gjino were our two <span style="white-space:nowrap">Non-PEO</span> NEOs in 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_12">CYCLERION <span style="white-space:nowrap">NON-EMPLOYEE</span> DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide compensation to our <span style="white-space:nowrap">non-employee</span> directors that is designed to enable us to attract and incentivize high quality directors, provide them with compensation at a level that is consistent with our compensation objectives and encourage their ownership of our stock to further align their interests with those of our shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation awarded to, earned by, and paid to our <span style="white-space:nowrap">non-employee</span> directors for the year ended December&#160;31, 2025: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:60%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Fees&#160;Earned&#160;or</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Paid in Cash</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Option</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Restricted</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Stock</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Awards<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Total</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">($)</p></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Errol B. De Souza, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter M. Hecht, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael F. Higgins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven E. Hyman, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dina Katabi, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">On June&#160;14, 2022, each <span style="white-space:nowrap">non-employee</span> director (other than Mr.&#160;Higgins, Dr.&#160;Hyman and Dr.&#160;Katabi) was granted an annual stock option award to purchase 500 shares of the Company&#8217;s Common Stock having an exercise price per share equal to the closing price on the grant date or $10.60 per share. These stock option awards vested in full on the first anniversary of the grant date subject to the terms and conditions of the stock option award agreement and are all outstanding as of December&#160;31, 2024. On July&#160;25, 2022, in connection with Dr.&#160;Hyman joining the Board, he was granted a <span style="white-space:nowrap">pro-rata</span> annual stock option award to purchase 887 shares of the Company&#8217;s Common Stock and an initial stock option award to purchase 2,000 shares of the Company&#8217;s Common Stock, each at an exercise price per share equal to the closing price on the grant date or $15.50 per share. Dr.&#160;Hyman&#8217;s annual stock option award vests in full on the first anniversary of the grant date and his initial stock option award vests in 36 equal monthly installments over a three-year period following the date of grant, in each case, subject to the terms and conditions of the stock option award agreement and are all outstanding as of December&#160;31, 2024. On May&#160;15, 2023, each of Dr.&#160;De Souza and Dr.&#160;Hyman was granted an annual stock option award to purchase 1,000 shares of the Company&#8217;s Common Stock having an exercise price per share equal to the closing price on the grant date or $3.82 per share. These stock option awards vested in full on the first anniversary of the grant date subject to the terms and conditions of the stock option award agreement and are all outstanding as of December&#160;31, 2025. The amounts in the above table reflect the fair value of stock option awards on the date of grant calculated in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification Topic 718, Compensation&#8212;Stock Compensation. For a discussion of the assumptions used in the valuation of awards, see Note&#160;8 to our consolidated and combined financial statements for the year ended December&#160;31, 2025, included in our Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> that we filed with the SEC on March 30, 2026. All values reported exclude the effects of potential forfeitures. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Company granted restricted stock awards during the year ended December&#160;31, 2023 to the members of the Board of Directors for their services as members of the Board of Directors. These director restricted stock awards were issued in November&#160;2023, with each director (other than Mr.&#160;McGuire) receiving an award of 20,000 shares of restricted Common Stock. Dr.&#160;De Souza, as Chairman of the Board of Directors, received an additional grant of 30,000 shares of restricted Common Stock for his services as Chairman of the Board of Director. All of these grants provided for an initial vesting of a portion of the shares with the remainder vesting ratably over a <span style="white-space:nowrap">42-month</span> period, subject to earlier vesting as set forth in the 2019 Equity Plan. Compensation expense is recognized over the applicable service period. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_13">CYCLERION EQUITY COMPENSATION PLAN INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides certain information regarding Cyclerion&#8217;s equity compensation plans in effect as of December&#160;31, 2025: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:39%"/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Plan Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of&#160;securities<br/>to be issued upon<br/>exercise of<br/>outstanding options,<br/>warrants and rights<br/>(a)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Weighted&#160;average<br/>exercise price of<br/>outstanding<br/>options, warrants<br/>and rights</span><br/><span style="font-weight:bold">(b)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of&#160;securities<br/>remaining available<br/>for future issuance<br/>under equity<br/>compensation plans<br/>(excluding securities<br/>reflected in column<br/>(a)) (c)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">297,762</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">149.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">382,900</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">297,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">382,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes shares issuable upon exercise of outstanding options under Cyclerion&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) and Amended and Restated 2010 Equity Incentive Plan (the &#8220;2010 Plan&#8221;). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 291,952 shares available under the 2019 Plan and 2010 Plan and 90,948 shares available under Cyclerion&#8217;s 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;). An annual increase to be added on the date of each annual meeting of the stockholders of Cyclerion, the number of shares reserved under the 2019 Plan is automatically increased by 4% of the total number of shares of stock outstanding on a fully diluted basis as of the close of business on the immediately preceding business day, or a lesser number of shares as may be determined by the Cyclerion Board. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_14">KORSANA EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the Merger, the executive officers of Korsana will become executive officers of the Combined Company. This section sets forth the fiscal year 2025 compensatory arrangements for the following executive officers of Korsana (the &#8220;Korsana NEOs&#8221;): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Appointment Date</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jonathan Violin</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Director; Chief Executive Officer, President and Secretary<sup style="font-size:75%; vertical-align:top">(2)</sup></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">August 25, 2025</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Kyle Breidenstine</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">Senior Vice President, Finance and Treasurer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">September 10, 2025</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mark Vignola, Korsana&#8217;s Chief Financial Officer, and Madelyn Zeylikman, Korsana&#8217;s General Counsel and Secretary, were not appointed until 2026 and thus did not earn any compensation during 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Violin was appointed on August&#160;26, 2025. From August&#160;1, 2025 until December&#160;31, 2025, Dr.&#160;Violin provided services to Korsana as a consultant. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the total compensation awarded to, earned by, and paid to the Korsana NEOs for the 2025 fiscal year. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Salary<br/>($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Bonus<br/>($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Stock<br/>Awards<br/>($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Awards ($)<sup style="font-size:75%; vertical-align:top">(4)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Jonathan Violin</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Director; Chief Executive Officer, President and Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2025</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">250,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">125,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">565,596</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">3,237,057</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">4,177,653</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Kyle Breidenstine </p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Senior Vice President, Finance and Treasurer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2025</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">100,527</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">78,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">310,202</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">$</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">489,229</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount in this column for 2025 for Dr.&#160;Violin represents consulting fees paid for services provided to Korsana. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column represent (i)&#160;annual cash bonus compensation paid for performance in 2025, as described in more information under &#8220;<span style="font-style:italic">Narrative to Summary Compensation Table</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">Annual Bonuses</span>&#8221; below, and (ii)&#160;a $40,000 signing bonus paid to Mr.&#160;Breidenstine in connection with his appointment, as described in more information under &#8220;<span style="font-style:italic">narrative to </span><span style="font-style:italic">Summary Compensation Table</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">NEO Agreements&#8212;Mr.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;Breidenstine</span>&#8221; below. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column represent the aggregate grant date fair value of restricted stock awarded to the Korsana NEOs during 2025, calculated in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 (&#8220;FASB ASC Topic 718&#8221;) based on a per share value of $0.57. See Note 7 to Korsana&#8217;s financial statements included elsewhere in this proxy statement/prospectus for more information on the assumptions used in calculating such amounts. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column represent the aggregate grant date fair value of stock options awarded to the Korsana NEOs during 2025, calculated in accordance with FASB ASC Topic 718. See Note 7 to Korsana&#8217;s financial statements included elsewhere in this proxy statement/prospectus for more information on the assumptions used in calculating such amounts. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Base Salary </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base salary for each Korsana NEO was established in connection with the commencement of their services or employment with Korsana after taking into account market compensation rates, responsibilities, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
experience. Korsana expects to review base salaries for the Korsana NEOs annually and may adjust salaries from time to time to realign with market levels after taking into account individual responsibilities, internal equity, performance, and experience. During 2025, Dr.&#160;Violin received a monthly consulting fee of $50,000 (which was not <span style="white-space:nowrap">pro-rated</span> for partial months) and his annual base salary, effective as of January&#160;1, 2026, is $600,000. During 2025, the annual base salary for Mr.&#160;Breidenstine was $330,000. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Annual Bonus </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Korsana NEO is eligible to participate in Korsana&#8217;s annual bonus program with target bonuses equal to 50% of his base consulting fee for Dr.&#160;Violin and 35% of base salary for Mr.&#160;Breidenstine. For 2025, each of Dr.&#160;Violin&#8217;s and Mr.&#160;Breidenstine&#8217;s target bonus was <span style="white-space:nowrap">pro-rated</span> based on their respective service commencement date with Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2025 bonuses were paid out based on a holistic evaluation of Korsana&#8217;s performance and the Korsana NEOs&#8217; contributions to Korsana during 2025. Based on such performance, the Korsana Board approved the payment of annual bonuses at 100% of target in the amounts set forth in the &#8220;<span style="font-style:italic">Summary Compensation Table</span>&#8221; above, which were paid in 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Long-Term Incentives </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s equity grant program is intended to align the interests of the Korsana NEOs with those of Korsana&#8217;s stockholders and to motivate them to make important contributions to Korsana&#8217;s performance. In connection with their commencement of services with Korsana, on October&#160;27, 2025: (i) Dr.&#160;Violin purchased 1,000,000 shares of restricted stock at $0.86 per share, representing the fair market value on such date, which shares vest 25% on June&#160;1, 2026 and monthly thereafter through June&#160;1, 2029; and (ii)&#160;Mr.&#160;Breidenstine received options to purchase 484,337 shares of Korsana Common Stock, which vest 25% on September&#160;10, 2026 and monthly thereafter until September&#160;10, 2029. In addition, on October&#160;27, 2025, Dr.&#160;Violin received options to purchase 5,054,217 shares of Korsana Common Stock, which vest 25% on June&#160;1, 2026 and monthly thereafter until June&#160;1, 2029. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">NEO Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the commencement of their services and/or employment with Korsana, Korsana entered into a consulting agreement and/or offer letters with each of the Korsana NEOs, as described below. For purposes of the following descriptions, &#8220;cause,&#8221; &#8220;change in control,&#8221; and &#8220;good reason&#8221; have the meanings provided under the respective offer letter. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dr.&#160;Violin </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the commencement of his employment with Korsana, Dr.&#160;Violin provided services pursuant to a consulting agreement with Korsana. Under the consulting agreement, Dr.&#160;Violin received monthly consulting fees equal to $50,000 per month and an initial opportunity to purchase shares of restricted stock, as described above under &#8220;<span style="font-style:italic">Long-Term Incentives</span>.&#8221; In addition, Korsana will periodically grant stock options sufficient to maintain Dr.&#160;Violin&#8217;s ownership at approximately 5% on a fully-diluted basis until Korsana has raised an additional $200&#160;million in financing following the effective date of his consulting agreement, to vest in equal monthly installments after the applicable date of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his employment, Dr.&#160;Violin&#8217;s consulting agreement automatically terminated and he entered into an offer letter with Korsana, effective January&#160;1, 2026, which provides for <span style="white-space:nowrap">at-will</span> employment. Dr.&#160;Violin&#8217;s offer letter provides for an annual base salary of $600,000 and an annual target bonus equal to 50% of his base salary. The offer letter also provides for the same periodic grants of stock options as described above under his consulting agreement. The options granted to Dr.&#160;Violin on October&#160;27, 2025 were in partial satisfaction (with respect to $151&#160;million in financing) of such obligation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dr.&#160;Violin&#8217;s offer letter, in the event of Dr.&#160;Violin&#8217;s termination by Korsana without cause more than three months before or more than 12 months following a change in control of Korsana, he is eligible for the following severance benefits, subject to his execution and <span style="white-space:nowrap">non-revocation</span> of a release of claims: (i)&#160;severance payments equal to 12 months of his base salary, (ii)&#160;any earned but unpaid bonus for the year prior to the year of termination, (iii)&#160;if such termination occurs prior to June&#160;1, 2026, acceleration of his outstanding equity awards that were scheduled to vest on June&#160;1, 2026 and if such termination occurs on or after June&#160;1, 2026, the acceleration of 30% of the unvested portion of his time-based equity awards, and (iv)&#160;Korsana-subsidized continued health coverage for up to 12 months. Upon a termination by Korsana without cause or his resignation for good reason within three months before or within 12 months following a change in control of Korsana, he will instead be eligible to receive (i)&#160;severance payments equal to 18 months of his base salary, (ii)&#160;any earned but unpaid bonus for the year prior to the year of termination, (iii)&#160;full acceleration of his outstanding time-based equity awards, and (iv)&#160;Korsana-subsidized continued health coverage for up to 18 months. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Mr.&#160;Breidenstine </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his employment, Mr.&#160;Breidenstine entered into an offer letter which provides for <span style="white-space:nowrap">at-will</span> employment. Mr.&#160;Breidenstine&#8217;s offer letter provides for an annual base salary of $330,000, an annual target bonus equal to 35% of his base salary, <span style="white-space:nowrap">pro-rated</span> for 2025, and a <span style="white-space:nowrap">one-time</span> signing bonus of $40,000, which is subject to repayment in the event Mr.&#160;Breidenstine is terminated for cause or resigns within 12 months. The offer letter also provides for an initial grant of stock options as described above under &#8220;<span style="font-style:italic">Long-Term Incentives</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Mr.&#160;Breidenstine&#8217;s offer letter, in the event of his termination by Korsana without cause before or more than 12 months following a change in control of Korsana, he is eligible for the following severance benefits, subject to his execution and <span style="white-space:nowrap">non-revocation</span> of a release of claims: (i)&#160;severance payments equal to nine months of his base salary, (ii)&#160;any earned but unpaid bonus for the year prior to the year of termination, and (iii)&#160;Korsana-subsidized continued health coverage for up to nine months. Upon a termination by Korsana without cause or his resignation for good reason within 12 months following a change in control, he will also receive full acceleration of his outstanding time-based equity awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at 2025 Fiscal <span style="white-space:nowrap">Year-End</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by each of the Korsana NEOs as of December&#160;31, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Exercise<br/>Price<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Shares or<br/>Units of<br/>Stock That<br/>Have Not<br/>Vested (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Market<br/>Value of<br/>Shares or<br/>Units of<br/>Stock<br/>That Have<br/>Not<br/>Vested<br/>($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Violin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom;text-align:right">5,054,217<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(2)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/26/2035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,000,000<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(3)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">860,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle Breidenstine</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom;text-align:right">484,337<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(4)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">0.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10/26/2035</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column reflect the value of restricted stock as of December&#160;31, 2025, based on a per share price of $0.86. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The options vest as to 25% on June&#160;1, 2026 and thereafter in approximately equal monthly installments for 36 months, subject to Dr.&#160;Violin&#8217;s continued service through the applicable vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">These shares of restricted stock vest as to 25% on June&#160;1, 2026 and thereafter in approximately equal monthly installments for 36 months, subject to Dr.&#160;Violin&#8217;s continued service through the applicable vesting date. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The options vest as to 25% on September&#160;10, 2026 and thereafter in approximately equal monthly installments for 36 months, subject to Mr.&#160;Breidenstine&#8217;s continued service through the applicable vesting date. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Narrative Disclosure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Retirement Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana provides employees, including the Korsana NEOs, the opportunity to participate in a <span style="white-space:nowrap">tax-qualified</span> defined contribution 401(k) retirement plan; however, Korsana did not provide any matching or other contributions under such plan in 2025. Korsana does not provide any <span style="white-space:nowrap">non-qualified</span> deferred compensation plans or defined benefit plans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2025 Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana also maintains a 2025 Equity Incentive Plan, the purpose of which is to advance the interests of Korsana&#8217;s stockholders by enhancing Korsana&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to Korsana and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of Korsana&#8217;s stockholders. Korsana&#8217;s 2025 Equity Incentive Plan provides for the issuance of up to 20,584,336 shares of Korsana Common Stock (of which 8,140,038 shares remain available for issuance as of March&#160;30, 2026), which may be granted as stock options, restricted stock, restricted stock units and other stock-based awards to eligible employees, officers, directors, consultants and advisors of Korsana on such terms and conditions as approved by the Korsana Board or any committee appointed by the Korsana Board to administer Korsana&#8217;s 2025 Equity Incentive Plan. No grants will be made under Korsana&#8217;s 2025 Equity Incentive Plan following consummation of the Merger. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_15">KORSANA DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2025, pursuant to the terms of a consulting agreement between Korsana and Ms.&#160;Pernice, Korsana granted Ms.&#160;Pernice stock options to acquire 138,889 shares of Korsana Common Stock, which vest 25% on November&#160;8, 2025 and monthly thereafter until November&#160;8, 2028. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No members of the Korsana Board received any cash retainers or other fees during 2025, and no members, other than Ms.&#160;Pernice, received any other compensation during 2025. Korsana did not implement a formal non-employee director compensation policy during 2025. It is expected that the Combined Company will implement a <span style="white-space:nowrap">non-employee</span> director compensation program that is expected to include an annual cash retainer and annual equity grants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2025 Director Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation for each person who served as a <span style="white-space:nowrap">non-employee</span> member of the Korsana Board during 2025. Directors who also serve as employees received no additional compensation for their service as directors. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option&#160;Awards<br/>($)<sup style="font-size:75%; vertical-align:top">(1) </sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Gottesdiener</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nilesh Kumar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle Pernice</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">88,954</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">88,954</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimish Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Harwin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported represent the aggregate grant date fair value of the stock options awarded to Korsana <span style="white-space:nowrap">non-employee</span> directors during 2025, calculated in accordance with FASB ASC Topic 718. See Note 7 to Korsana&#8217;s financial statements included elsewhere in this proxy statement/prospectus for more information on the assumptions used in calculating such amounts. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2025, Ms.&#160;Pernice held outstanding options to acquire 138,889 shares of Korsana Common Stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_16">MATTERS BEING SUBMITTED TO A VOTE OF CYCLERION SHAREHOLDERS </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_17">PROPOSAL NO. 1&#8201;-&#8201;THE NASDAQ STOCK ISSUANCE PROPOSAL </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cyclerion Shareholders Meeting, Cyclerion will ask its shareholders to approve (i)&#160;the issuance of shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, to the stockholders of Korsana pursuant to the Merger Agreement, which shares of Cyclerion Common Stock will represent more than 20% of the shares of Cyclerion Common Stock outstanding immediately prior to the First Merger and (ii)&#160;the change of control of Cyclerion resulting from the First Merger, pursuant to Nasdaq Listing Rules&#160;5635(a) and 5635(b), respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the First Merger, Cyclerion securityholders as of immediately prior to the First Merger are expected to own approximately 1.5% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), and former holders of Korsana securities are expected to own approximately 98.5% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Cyclerion&#8217;s net cash as of closing being equal to $0. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down, including if Cyclerion&#8217;s net cash as of closing is less than or greater than $0. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion will assume outstanding and unexercised Korsana Options to purchase shares of Korsana Common Stock, Korsana RSUs, and Korsana Warrants to purchase shares of Korsana Common Stock, and such securities will be converted into options to purchase shares of Cyclerion Common Stock, Cyclerion RSUs and Warrants to purchase shares of Cyclerion Common Stock, as applicable, subject to certain adjustments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of, reasons for and other aspects of the Merger Agreement and the Merger are described in detail in the section of this proxy statement/prospectus titled &#8220;<span style="font-style:italic">The</span><span style="font-style:italic"> </span><span style="font-style:italic">Merger</span><span style="font-style:italic"> </span><span style="font-style:italic">Agreement</span>.&#8221; A copy of the Merger Agreement, including the amendment thereto, is attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">A</span><span style="font-style:italic"> </span>to this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reason for the Proposal </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(a)(1), a company listed on Nasdaq is required to obtain shareholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of Cyclerion Common Stock in the Merger exceeds the 20% under the Nasdaq Listing Rules and is expected to represent approximately 98.5% of Cyclerion Common Stock on a fully-diluted basis immediately following the Merger. Accordingly, in order to ensure compliance with Nasdaq Listing Rule 5635(a)(1), Cyclerion must obtain the approval of Cyclerion shareholders for the issuance of these shares of common stock in the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain shareholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of Cyclerion. Accordingly, in order to ensure compliance with Nasdaq Listing Rule 5635(b), Cyclerion must obtain the approval of Cyclerion shareholders of the change of control resulting from the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such condition. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Authorized Share Increase Proposal or the Reverse Split Proposal are not approved or the other closing conditions under the Merger Agreement are not satisfied or waived, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Cyclerion shareholders have agreed to vote any shares of Cyclerion Common Stock owned by them in favor of the Nasdaq Stock Issuance Proposal. See &#8220;<span style="font-style:italic">Agreements Related to the Merger</span><span style="font-style:italic">&#160;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic"> </span><span style="font-style:italic">Support</span><span style="font-style:italic"> </span><span style="font-style:italic">Agreements</span>&#8221; beginning on page&#160;188 of this proxy statement/prospectus for more information. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Nasdaq Stock Issuance Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_18">PROPOSAL NO. 2&#8201;-&#8201;THE AUTHORIZED SHARE INCREASE PROPOSAL </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cyclerion Shareholders Meeting, Cyclerion will ask its shareholders to approve an amendment to the Cyclerion Articles to increase the number of authorized shares of Cyclerion Common Stock (the &#8220;Cyclerion Share Increase Amendment&#8221;). On&#8195;&#8195;&#8195;&#8195;, 2026, the Cyclerion Board approved a proposal to amend the Cyclerion Articles to increase the number of authorized shares of Cyclerion Common Stock from 400,000,000 shares to&#8195;&#8195;&#8195;&#8195;, which would also have the effect of increasing the total number of authorized shares from 500,000,000, including Cyclerion preferred stock, to&#8195;&#8195;&#8195;&#8195;(the &#8220;Cyclerion Share Increase&#8221;), in the form attached as <span style="font-style:italic">Annex H</span> to this proxy statement/prospectus. As of&#8195;&#8195;&#8195;&#8195;, 2026, there were&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock issued and outstanding, and&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock reserved for issuance. Accordingly, approximately&#8195;&#8195;&#8195;&#8195;shares of the total number of Cyclerion Common Stock currently authorized remain available for issuance or may be reserved for issuance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Form of the Cyclerion Share Increase Amendment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Share Increase Amendment would amend and restate the first paragraph of Article III of the Cyclerion Articles in its entirety as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;State the total number of shares and par value, if any, of each class of stock that the corporation is authorized to issue. All corporations must authorize stock. If only one class or series is authorized, it is not necessary to specify any particular designation. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:24%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:20%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:20%"/>

<td style="vertical-align:bottom"/>
<td style="width:18%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:10%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="3" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Without Par Value</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">With Par Value</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">TYPE</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">NUMBER OF SHARES</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">TYPE</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">NUMBER&#160;OF&#160;SHARES</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">PAR&#160;VALUE</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center">Common</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center">Preferred</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">100,000,000</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation is authorized to issue&#8195;&#8195;&#8195;&#8195;million shares of capital stock of which&#8195;&#8195;&#8195;&#8195;million are &#8220;Common Stock&#8221; and 100&#160;million shares are &#8220;Preferred Stock.&#8221;&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Background and Reasons for the Cyclerion Share Increase Amendment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Articles currently authorizes the issuance of up to 400,000,000 shares of Cyclerion Common Stock and 100,000,000 shares of preferred stock. As of the close of business on&#8195;&#8195;&#8195;&#8195;, 2026, there were&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock issued and outstanding, and&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock reserved for issuance. Accordingly, &#8195;&#8195;&#8195;&#8195;shares of the total number of Cyclerion Common Stock currently authorized remain available for issuance or may be reserved for issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in greater detail in the section of this proxy statement/prospectus titled &#8220;<span style="font-style:italic">The Merger Agreement</span>,&#8221; pursuant to the Merger Agreement, Cyclerion will be required to issue shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, to Korsana stockholders and to assume Korsana&#8217;s 2025 Equity Incentive Plan and outstanding Korsana Options, Korsana RSUs, and Korsana Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Cyclerion Common Stock currently authorized and unissued and not reserved for issuance is not sufficient for (i)&#160;the issuance of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, pursuant to the Merger Agreement and (ii)&#160;the assumption of Korsana&#8217;s 2025 Equity Incentive Plan and Korsana Options, Korsana RSUs, and Korsana Warrants. In addition, there will not be sufficient shares of Cyclerion Common Stock available for issuance in connection with possible future acquisitions, equity and equity-based financings, possible future awards under employee benefit plans and other corporate purposes that the Cyclerion Board may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determine to be desirable. Therefore, the Cyclerion Board has determined that the Cyclerion Share Increase Amendment is in the best interests of Cyclerion and its shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Cyclerion Share Increase Amendment is approved by shareholders, upon its effectiveness, and without giving effect to the proposed reverse stock split described in Proposal No.&#160;3 of this proxy statement/prospectus, Cyclerion will have a total of&#8195;&#8195;&#8195;&#8195;authorized shares of Cyclerion Common Stock, with&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock issued and outstanding (as of&#8195;&#8195;&#8195;&#8195;, 2026), and&#8195;&#8195;&#8195;&#8195;shares reserved for issuance (as of&#8195;&#8195;&#8195;&#8195;, 2026), leaving a balance of&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock authorized and unissued and not reserved for any specific purpose. Such outstanding share amounts will be correspondingly adjusted to the extent the proposed reverse stock split is effected prior to effectiveness of the Cyclerion Share Increase Amendment, but the reverse stock split will not change the number of authorized shares of common or preferred stock. The Cyclerion Share Increase Amendment will have no effect on the authorized shares of Cyclerion Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for (i)&#160;the issuance of shares of Cyclerion Common Stock, including shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock, and (ii)&#160;the issuance of shares of Cyclerion Common Stock that may result from the assumption of Korsana&#8217;s 2025 Equity Incentive Plan and outstanding options to purchase Korsana Common Stock, Korsana RSUs, and Korsana Warrants, each pursuant to the terms of the Merger Agreement, Cyclerion does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Possible Effects of the Cyclerion Share Increase Amendment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Cyclerion Share Increase Amendment is approved and becomes effective, the additional authorized shares would be available for issuance at the discretion of the Cyclerion Board and without further shareholder approval, except as may be required by law or Nasdaq rules. The additional shares of authorized Cyclerion Common Stock would have the same rights and privileges as the shares of Cyclerion Common Stock currently issued and outstanding. Holders of Cyclerion Common Stock have no preemptive rights. The Cyclerion Share Increase would not change the number of shares of common stock outstanding, nor will it have any immediate dilutive effect; however, the issuance of additional shares of Cyclerion Common Stock authorized by the Cyclerion Share Increase may, among other things, have a dilutive effect on earnings per share and on shareholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of Cyclerion Common Stock, or the perception that these sales might occur, could adversely affect the prevailing market price of Cyclerion Common Stock or limit Cyclerion&#8217;s ability to raise additional capital. Cyclerion shareholders should recognize that, as a result of this proposal, they will own a smaller percentage of shares relative to the total authorized shares of the company than they presently own. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the Cyclerion Share Increase Amendment is approved and becomes effective, it will increase the number of unissued authorized shares, which could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Cyclerion Board or contemplating a tender offer or other transaction for the combination of Cyclerion with another company. However, the Cyclerion Share Increase Amendment is not being proposed in response to any effort of which Cyclerion is aware to accumulate shares of Cyclerion Common Stock or obtain control of Cyclerion, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to the Cyclerion Board and shareholders. Other than the proposals being submitted to the Cyclerion shareholders for their consideration at the Cyclerion Shareholders Meeting, the Cyclerion Board does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of Cyclerion. For more information, please see the section titled &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to the Combined Company</span>&#8221; beginning on page&#160;114 of this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal or Dissenters&#8217; Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the MBCA, shareholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the Cyclerion Share Increase Amendment or the Cyclerion Share Increase. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Effectiveness of Amendment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Cyclerion Share Increase Amendment is approved by the shareholders at the Cyclerion Shareholders Meeting, it will become effective upon the filing of a certificate of amendment, a copy of which is attached as <span style="font-style:italic">Annex H</span> to this proxy statement/prospectus, with the Secretary of the Commonwealth of Massachusetts or such later effective date and time as specified in the certificate of amendment in accordance with Massachusetts law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of the Cyclerion Articles and the certificates of amendment to the Cyclerion Articles are available as exhibits to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is conditioned upon the approval of the Authorized Share Increase Proposal, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such condition. Notwithstanding the approval of the Authorized Share Increase Proposal, if the Nasdaq Stock Issuance Proposal or the Reverse Split Proposal are not approved or the other closing conditions under the Merger Agreement are not satisfied or waived, the actions contemplated by the Authorized Share Increase Proposal will not be effected. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Cyclerion shareholders have agreed to vote any shares of Cyclerion Common Stock owned by them in favor of the Authorized Share Increase Proposal. See &#8220;<span style="font-style:italic">Agreements Related to the Merger &#8212; Support Agreements</span>&#8221; beginning on page&#160;188 of this proxy statement/prospectus for more information. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Authorized Share Increase Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUTHORIZED SHARE INCREASE PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_19">PROPOSAL NO. 3&#8201;-&#8201;THE REVERSE STOCK SPLIT PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cyclerion Shareholders Meeting, Cyclerion will ask its shareholders to approve an amendment to the Cyclerion Articles to effect a reverse stock split of Cyclerion&#8217;s issued and outstanding common stock at a ratio in the range of one new share for every&#8195;&#8195;&#8195;&#8195;shares and one new share for every&#8195;&#8195;&#8195;&#8195;shares outstanding (or any number in between), to be determined mutually by the Cyclerion Board and the Korsana Board (the &#8220;Split Ratio&#8221;). The final Split Ratio and effectiveness of such amendment and the abandonment of such amendment will be mutually agreed by the Cyclerion Board and the Korsana Board prior to the First Effective Time, assuming this proposal is approved by Cyclerion&#8217;s shareholders. On&#8195;&#8195;&#8195;&#8195;, 2026, the Cyclerion Board adopted resolutions approving the proposed articles of amendment to the Cyclerion Articles in the form attached as <span style="font-style:italic">Annex</span><span style="font-style:italic"> </span><span style="font-style:italic">I</span><span style="font-style:italic"> </span>to this proxy statement/prospectus. If this articles of amendment is filed with the Secretary of the Commonwealth of Massachusetts, upon its effectiveness (the &#8220;Reverse Stock Split Effective Time&#8221;), it will effect the reverse stock split by the Split Ratio but will not increase the par value of Cyclerion Common Stock. At the Reverse Stock Split Effective Time, the issued and outstanding shares of Cyclerion Common Stock immediately prior to the Reverse Stock Split Effective Time will automatically without further action on the part of Cyclerion be combined into a smaller number of shares in accordance with the final Split Ratio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By approving the Reverse Stock Split Proposal, Cyclerion shareholders will approve the amendment to the Cyclerion Articles pursuant to which any whole number of issued and outstanding shares of Cyclerion Common Stock, between and including&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;, would be combined into one share of Cyclerion Common Stock, and will authorize the Cyclerion Board to file the articles of amendment. As of&#8195;&#8195;&#8195;&#8195;, 2026, 400,000,000 shares of Cyclerion Common Stock were authorized,&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock were outstanding, and no shares of Cyclerion Common Stock were held in treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reverse stock split will not change the number of authorized shares of Cyclerion Common Stock or preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All holders of Cyclerion Common Stock will be affected proportionately by the reverse stock split. No fractional shares of Cyclerion Common Stock will be issued as a result of the reverse stock split. Instead, Cyclerion shareholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;<span style="font-style:italic">No Fractional Shares</span>.&#8221; Each Cyclerion shareholder will hold the same percentage of the outstanding Cyclerion Common Stock immediately following the reverse stock split as that Cyclerion shareholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in Cyclerion shareholders receiving cash in lieu of fractional shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reasons for the Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board approved the proposal approving the amendment to the Cyclerion Articles effecting the reverse stock split for the following reasons: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board believes effecting the reverse stock split will result in an increase in the minimum bid price of Cyclerion Common Stock and reduce the risk of a delisting of Cyclerion Common Stock from Nasdaq in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board believes a higher stock price may help generate investor interest in Cyclerion, and ultimately the Combined Company, and help Cyclerion attract and retain employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board believes a higher stock price may increase trading volume in Cyclerion Common Stock and facilitate future financings by the Combined Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board believes that the resulting increase in the number of authorized and unissued shares available for future issuance will be necessary for the issuance of shares to the shareholders of Korsana pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, the </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
issuance of shares of Cyclerion Common Stock that may result from the assumption of Korsana&#8217;s 2025 Equity Incentive Plan and outstanding options to purchase Korsana Common Stock, Korsana RSUs, and Korsana Warrants, pursuant to the Merger Agreement, and ultimately the consummation of the Merger; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cyclerion Board believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the desired results of the reverse stock split. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Requirements for Listing on Nasdaq </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion Common Stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;CYCN.&#8221; Cyclerion intends to file an initial listing application pursuant to the terms of the Merger Agreement for the Combined Company to list the securities of the Combined Company on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a <span style="white-space:nowrap">non-Nasdaq</span> entity, resulting in a change of control of the issuer and potentially allowing the <span style="white-space:nowrap">non-Nasdaq</span> entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require Cyclerion to have, among other things, a $4.00 per share minimum bid price for a certain number of trading days preceding the closing of the Merger. Therefore, the reverse stock split may be necessary in order to satisfy Nasdaq requirements and consummate the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is a condition to the consummation of the Merger that Cyclerion will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that Cyclerion will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in Cyclerion&#8217;s management being able to issue more shares without further shareholder approval. The reverse stock split will not affect the number of authorized shares of Cyclerion capital stock, which will continue to be authorized pursuant to the Cyclerion Articles. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Increased Investor Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On&#8195;&#8195;&#8195;&#8195;, 2026, Cyclerion Common Stock closed at $&#8195;&#8195;&#8195;&#8195;per share. An investment in Cyclerion Common Stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, the Cyclerion Board believes that most investment funds are reluctant to invest in lower priced stocks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of Cyclerion Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion cannot predict whether the reverse stock split will increase the market price for Cyclerion Common Stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the market price per share of Cyclerion Common Stock after the reverse stock split will rise in proportion to the reduction in the number of shares of Cyclerion Common Stock outstanding before the reverse stock split; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the reverse stock split will result in a per share price that will increase the ability of Cyclerion to attract and retain employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of time for the Combined Company&#8217;s common stock to be approved for listing by Nasdaq. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Cyclerion Common Stock will also be based on the performance of Cyclerion, and after the Merger, on the performance of the Combined Company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of Cyclerion Common Stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of Cyclerion may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of Cyclerion Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effects of the Reverse Stock Split </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the reverse stock split is implemented, after the Reverse Stock Split Effective Time, the issued and outstanding shares of Cyclerion Common Stock immediately prior to the Reverse Stock Split Effective Time will automatically, without further action on the part of Cyclerion, be combined into a smaller number of shares proportionately based on the Split Ratio and each Cyclerion shareholder will own a reduced number of shares of Cyclerion Common Stock. The reverse stock split will affect all Cyclerion shareholders uniformly and will not affect any shareholder&#8217;s percentage ownership interests in Cyclerion, except that Cyclerion shareholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares. After the reverse stock split, each share of Cyclerion Common Stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the Cyclerion Common Stock now authorized, and Cyclerion Common Stock issued pursuant to the reverse stock split will remain fully paid and <span style="white-space:nowrap">non-assessable.</span> The reverse stock split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; covered by Rule <span style="white-space:nowrap">13e-3</span> under the Exchange Act. Cyclerion will continue to be subject to the periodic reporting requirements of the Exchange Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effect on Shares of Cyclerion Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reverse stock split will not change the number of authorized shares of Cyclerion Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the Reverse Stock Split Effective Time, Cyclerion Common Stock would have a new committee on uniform securities identification procedures number, which is used to identify Cyclerion Common Stock. Cyclerion Common Stock is currently registered under Section&#160;12(b) of the Exchange Act and Cyclerion is subject to the periodic reporting and other requirements of the Exchange Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effect on Cyclerion Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reverse stock split will not change the number of authorized shares of Cyclerion preferred stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Reduction in Stated Capital </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reverse stock split will not affect the par value of Cyclerion Common Stock. As a result, after the Reverse Stock Split Effective Time, the stated capital on Cyclerion&#8217;s balance sheet attributable to Cyclerion Common Stock will be reduced proportionately based on the Split Ratio, subject to a minor adjustment in respect of the treatment of fractional shares, and the additional <span style="white-space:nowrap">paid-in</span> capital account will be credited with the amount by which the stated capital is reduced. Cyclerion shareholders&#8217; equity, in the aggregate, will remain unchanged. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Effect on Equity Plans and Outstanding Derivative and Convertible Securities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options and warrants to purchase or acquire, as applicable, shares of Cyclerion Common Stock, and the number of shares reserved for issuance pursuant to Cyclerion&#8217;s existing equity incentive, stock option and employee stock purchase plans will be reduced proportionately based on the Split Ratio. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If (i)&#160;the Cyclerion shareholders approve the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal, (ii)&#160;the Cyclerion Board and the Korsana Board mutually agree that a reverse stock split is necessary, and (iii)&#160;the Cyclerion Board still believes that a reverse stock split is in the best interests of Cyclerion and its shareholders, Cyclerion will file the articles of amendment to the Cyclerion Articles with the Secretary of the Commonwealth of Massachusetts at such time as the Cyclerion Board has determined to be the appropriate Reverse Stock Split Effective Time at the Split Ratio. If the Reverse Stock Split Proposal is approved and the Nasdaq Stock Issuance Proposal is not approved by Cyclerion shareholders, the Cyclerion Board and the Korsana Board may mutually agree to delay effecting the reverse stock split without resoliciting shareholder approval or abandon effecting the reverse stock split; otherwise, the Cyclerion Board may, in its sole discretion, delay without resolicitation of shareholder approval or abandon effecting the reverse stock split. Beginning at the Reverse Stock Split Effective Time, each stock certificate representing <span style="white-space:nowrap">pre-split</span> shares will be deemed for all corporate purposes to evidence ownership of post-split shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Beneficial Owners of Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the implementation of the reverse stock split, Cyclerion intends to treat shares held by shareholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered shareholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding Cyclerion Common Stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered shareholders for processing the reverse stock split and making payment for fractional shares. If a shareholder holds shares of Cyclerion Common Stock with a bank, broker, custodian or other nominee and has any questions in this regard, shareholders are encouraged to contact their bank, broker, custodian or other nominee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registered Holders of Common Stock in Book-Entry Form </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of Cyclerion&#8217;s registered holders of common stock hold some or all of their shares electronically in book-entry form with Cyclerion&#8217;s transfer agent, Equiniti. These shareholders do not hold physical stock certificates evidencing their ownership of Cyclerion Common Stock. However, they are provided with a statement reflecting the number of shares of Cyclerion Common Stock registered in their accounts. If a shareholder holds registered shares in book-entry form with Cyclerion&#8217;s transfer agent, no action needs to be taken to receive post-reverse stock split shares or payment in lieu of fractional shares, if applicable. If a shareholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the shareholder&#8217;s address of record indicating the number of shares of Cyclerion Common Stock held following the reverse stock split. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Registered Holders of Common Stock in Certificate Form </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the Reverse Stock Split Effective Time, the Cyclerion shareholders will be notified that the reverse stock split has been effected. Cyclerion expects that the Cyclerion transfer agent will act as Exchange Agent for purposes of implementing the exchange of stock certificates. Holders of <span style="white-space:nowrap">pre-split</span> shares will be asked to surrender to the Exchange Agent certificates representing <span style="white-space:nowrap">pre-</span> split shares held in certificated form in exchange for certificates representing post-split shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by Cyclerion. No new certificates will be issued to a shareholder until such shareholder has surrendered such shareholder&#8217;s outstanding certificate(s) together with the properly completed and executed letter of transmittal to the Exchange Agent. Any <span style="white-space:nowrap">pre-split</span> shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post-split shares. <span style="font-weight:bold">Shareholders</span><span style="font-weight:bold"> </span><span style="font-weight:bold">should</span><span style="font-weight:bold"> </span><span style="font-weight:bold">not</span><span style="font-weight:bold"> </span><span style="font-weight:bold">destroy</span><span style="font-weight:bold"> </span><span style="font-weight:bold">any</span><span style="font-weight:bold"> </span><span style="font-weight:bold">stock</span><span style="font-weight:bold"> </span><span style="font-weight:bold">certificate(s) and should not submit any certificate(s) unless and until requested to do so</span><span style="font-style:italic">.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Fractional Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued in connection with the reverse stock split. Shareholders of record who otherwise would be entitled to receive fractional shares because they hold a number of <span style="white-space:nowrap">pre-split</span> shares not evenly divisible by the number of <span style="white-space:nowrap">pre-split</span> shares for which each post-split share is to be reclassified, will be entitled, upon surrender to the Exchange Agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction of a share to which the shareholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the articles of amendment to the Cyclerion Articles effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders should be aware that, under the escheat laws of the various jurisdictions where shareholders reside, where Cyclerion is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by Cyclerion or the Exchange Agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, shareholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Anti-Takeover Effect </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Cyclerion Board or contemplating a tender offer or other transaction for the combination of Cyclerion with another company, the reverse stock split is not being proposed in response to any effort of which Cyclerion is aware to accumulate shares of Cyclerion Common Stock or obtain control of Cyclerion, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to the Cyclerion Board and shareholders. Other than the proposals being submitted to the Cyclerion shareholders for their consideration at the Cyclerion Shareholders Meeting, the Cyclerion Board does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of Cyclerion. For more information, please see the section titled &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to the Combined Company</span>&#8221; beginning on page 114 of this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Federal Income Tax Considerations of the Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of Cyclerion Common Stock of the reverse stock split. The discussion does not purport to be a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <span style="white-space:nowrap">non-U.S.</span> tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. Cyclerion has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the reverse stock split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to a U.S. Holder that holds Cyclerion Common Stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including without limitation the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&#160;451(b) of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. expatriates and former citizens or long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. Holders whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding Cyclerion Common Stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks, insurance companies and other financial institutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts or regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers or traders in securities or other persons that elect to use a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting for their holdings in Cyclerion Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations or governmental organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons deemed to sell Cyclerion Common Stock under the constructive sale provisions of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who hold or receive Cyclerion Common Stock pursuant to the exercise of any employee stock option or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-qualified</span> retirement plans; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that own, or have owned, actually or constructively, more than 5% of Cyclerion Common Stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds Cyclerion Common Stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Cyclerion Common Stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the reverse stock split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Cyclerion Common Stock that, for U.S. federal income tax purposes, is or is treated as any of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the reverse stock split arising under U.S. federal estate or gift tax laws, the laws of any state, local or <span style="white-space:nowrap">non-U.S.</span> taxing jurisdiction or any applicable income tax treaty. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tax Considerations of the Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposed reverse stock split is intended to qualify as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes pursuant to Section&#160;368(a)(1)(E) of the Code. As a result, a U.S. Holder generally should not recognize gain or loss upon the proposed reverse stock split, except with respect to cash received in lieu of a fractional share of Cyclerion Common Stock, as discussed below. A U.S. Holder&#8217;s aggregate adjusted tax basis in the shares of Cyclerion Common Stock received pursuant to the proposed reverse stock split should equal the aggregate adjusted tax basis of the shares of the Cyclerion Common Stock surrendered (excluding any portion of such basis that is allocated to any fractional share of Cyclerion Common Stock), and such U.S. Holder&#8217;s holding period in the shares of Cyclerion Common Stock received should include the holding period in the shares of Cyclerion Common Stock surrendered. U.S. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Cyclerion Common Stock surrendered to the shares of Cyclerion Common Stock received in a recapitalization pursuant to the proposed reverse stock split. Each U.S. Holder of shares of Cyclerion Common Stock acquired on different dates and at different prices is urged to consult its tax advisor regarding the allocation of the tax basis and holding period of such shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash in Lieu of Fractional Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder that receives cash in lieu of a fractional share of Cyclerion Common Stock pursuant to the proposed reverse stock split should recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S. Holder&#8217;s tax basis in the shares of Cyclerion Common Stock surrendered that is allocated to such fractional share of Cyclerion Common Stock. Such capital gain or loss should be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for Cyclerion Common Stock surrendered exceeded one year at the Reverse Stock Split Effective Time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tax Reporting Regarding the Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a) of the Code, each U.S. Holder who receives shares of Cyclerion Common Stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. Holder who owned at least five percent (by vote or value) of the total outstanding stock of Cyclerion or who owned securities in Cyclerion with a basis of $1,000,000 or more are required to attach a statement to their tax returns for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulations <span style="white-space:nowrap">Section&#160;1.368-3(b).</span> Such statement must include the holder&#8217;s tax basis in the U.S. Holder&#8217;s Cyclerion Common Stock and the fair market value of such stock. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">This discussion of U.S. federal income tax considerations of the reverse stock split is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the reverse stock split to you may be complex and will depend </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">
on your specific situation and on factors that are not within Cyclerion&#8217;s knowledge or control. Each prospective investor is urged to consult its tax advisor with respect to the application of U.S. federal income tax laws to its specific situation as well as any tax considerations arising under the U.S. federal estate or gift tax rules or under the laws of any state, local, <span style="white-space:nowrap">non-U.S.</span> or other taxing jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information Reporting and Backup Withholding </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of cash made in lieu of a fractional share of Cyclerion Common Stock may, under certain circumstances, be subject to information reporting and backup withholding. To avoid backup withholding, each holder of Cyclerion Common Stock that does not otherwise establish an exemption should furnish its taxpayer identification number and comply with the applicable certification procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld will be allowed as a credit against the holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Holders of Cyclerion Common Stock should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Appraisal or Dissenters&#8217; Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the MBCA, shareholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the proposed amendment to the Cyclerion Articles to effect the reverse stock split. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is conditioned upon the approval of the Reverse Stock Split Proposal, unless, to the extent permitted by applicable law, each of Cyclerion, the Merger Subs, and Korsana waives such condition. Notwithstanding the approval of the Reverse Stock Split Proposal, if the Nasdaq Stock Issuance Proposal or the Authorized Share Increase Proposal are not approved or the other closing conditions under the Merger Agreement are not satisfied or waived, the actions contemplated by the Reverse Stock Split Proposal will not be effected. However, the Cyclerion Board may determine to effect the Reverse Stock Split Proposal, if approved by the Cyclerion shareholders, following the Shareholders Meeting, even if the Merger is not otherwise completed. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Cyclerion shareholders have agreed to vote any shares of Cyclerion Common Stock owned by them in favor of the Reverse Stock Split Proposal. See &#8220;<span style="font-style:italic">Agreements</span><span style="font-style:italic"> </span><span style="font-style:italic">Related</span><span style="font-style:italic"> </span><span style="font-style:italic">to</span><span style="font-style:italic"> </span><span style="font-style:italic">the</span><span style="font-style:italic"> </span><span style="font-style:italic">Merger</span><span style="font-style:italic"> </span><span style="font-style:italic">&#8212;</span><span style="font-style:italic"> </span><span style="font-style:italic">Support </span><span style="font-style:italic">Agreements</span>&#8221; beginning on page 188 of this proxy statement/prospectus for more information. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Reverse Stock Split Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE REVERSE STOCK SPLIT PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_20">PROPOSAL NO. 4&#8201;-&#8201;THE REDOMESTICATION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cyclerion annual meeting, Cyclerion shareholders will be asked to approve (i)&#160;pursuant to the MBCA, the domestication of Cyclerion from a corporation organized under the laws of the Commonwealth of Massachusetts (the &#8220;Massachusetts Corporation&#8221;) to an exempted company incorporated under the laws of the Cayman Islands (the &#8220;Cayman Company&#8221;) and to adopt resolutions approving the domestication (the &#8220;Cayman Redomestication Resolutions&#8221;) included as <span style="font-style:italic">Annex M </span>to this proxy statement/prospectus &#8212; Proposal No. 4A &#8212; and (ii)&#160;pursuant to the Companies Act, the transfer by way of continuation of Cyclerion from the Massachusetts Corporation to the Cayman Company and to adopt the Cayman Redomestication Resolutions and as a special resolution the Cayman Articles (as defined below) &#8212; Proposal No. 4B, as more fully described in this Proposal No.&#160;4. The proposed domestication of the Massachusetts Corporation to a Cayman Company pursuant to this Proposal 4 is referred to herein as the &#8220;Cayman Redomestication.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Principal Terms of the Cayman Redomestication </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Cayman Redomestication is approved by Cyclerion shareholders and the Merger is completed, the Cayman Redomestication will be effected by the Combined Company through a domestication pursuant to Section&#160;9.20 of the MBCA, and the Cayman Company will continue its existence as an exempted company limited by shares under the Companies Act, as amended, of the Cayman Islands (the &#8220;Companies Act&#8221;), as set forth in the plan of domestication (the &#8220;Plan of Domestication&#8221;), included as <span style="font-style:italic">Annex J </span>to this proxy statement/prospectus. Approval of the Redomestication Proposal will constitute approval of the Plan of Domestication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the adoption of the Plan of Domestication, upon the effectuation of the Cayman Redomestication: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Combined Company will continue its existence as a Cayman Islands exempted company and will continue to operate its business under the name &#8220;Korsana Biosciences, Inc.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The internal affairs of the Combined Company will cease to be governed by Massachusetts law and will instead be governed by Cayman Islands law (including but not limited to the Companies Act). See &#8220;<span style="font-style:italic">Effects of the Cayman Redomestication &#8212; Comparison of Shareholder Rights under Massachusetts</span> <span style="font-style:italic">and Cayman Islands Law</span>&#8221; below. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Combined Company will cease to be governed by Cyclerion&#8217;s restated articles of organization (as amended, the &#8220;Massachusetts Articles&#8221; or the &#8220;Cyclerion Charter&#8221;) and Cyclerion&#8217;s amended and restated bylaws (the &#8220;Massachusetts Bylaws&#8221; or the &#8220;Cyclerion Bylaws&#8221;) and will instead be governed by the provisions of the proposed Cayman Islands memorandum and articles of association (the &#8220;Cayman Articles&#8221;), a form of which is included as <span style="font-style:italic">Annex K </span>to this proxy statement/prospectus. See &#8220;<span style="font-style:italic">Effects of the Cayman Redomestication &#8212; Comparison of Rights of Holders of the Massachusetts</span> <span style="font-style:italic">Corporation Capital Stock and the Cayman Company Share Capital </span>&#8220; below. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Cayman Redomestication will not result in any change in the Combined Company&#8217;s business, management, obligations, assets, or liabilities (other than as a result of the transaction costs related to the Cayman Redomestication). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Combined Company will continue to be treated as a U.S. corporation for all purposes under the Code. See &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations of the Cayman Redomestication &#8212; U.S. Tax Status of the Cayman Company after the Cayman Redomestication&#8221; below</span>. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding share of common stock of the Massachusetts Corporation will be automatically converted into one ordinary share of the Cayman Company (each a &#8220;Cayman Share&#8221;, together the &#8220;Cayman Shares&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding share of any series of the preferred stock of the Massachusetts Corporation will be automatically converted into one share of the corresponding series of the preferred shares of the Cayman Company. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Shareholders of the Combined Company will not be required to exchange their existing stock certificates (if any) for new share certificates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each outstanding option or right to acquire shares of common stock of the Massachusetts Corporation will continue in existence in the form of and will automatically become an option or right to acquire an equal number of Cayman Shares under the same terms and conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Shares resulting from the Cayman Redomestication will continue to be traded on Nasdaq under the symbol &#8220;KRSA.&#8221; The Cayman Redomestication is not expected to cause any interruption in the trading of such Cayman Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cyclerion shareholders approve the Cayman Redomestication and the Merger is completed, Cyclerion and Korsana anticipate that the Cayman Redomestication will become effective as soon as practicable following the Merger (the &#8220;Cayman Redomestication Effective Time&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Redomestication may be delayed by Cyclerion&#8217;s board of directors or the Combined Company&#8217;s board of directors, or the Plan of Domestication may be terminated and abandoned by action of Cyclerion&#8217;s board of directors or the Combined Company&#8217;s board of directors, at any time prior to the Cayman Redomestication Effective Time, whether before or after the approval by Cyclerion&#8217;s shareholders, if Cyclerion&#8217;s board of directors or the Combined Company&#8217;s board of directors determines for any reason that such delay or abandonment would be in the best interests of Cyclerion and its shareholders or the Combined Company and its shareholders, as the case may be, including if the Merger is not completed for any reason. In addition, Cyclerion or the Combined Company may face legal challenges to the Cayman Redomestication, including, among others, shareholder challenges under Massachusetts law, seeking to delay or prevent the Cayman Redomestication. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reasons for the Cayman Redomestication </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s board of directors and Korsana&#8217;s board of directors believe that there are several reasons the Cayman Redomestication is in the best interests of the Combined Company and its shareholders. In particular, Cyclerion&#8217;s board of directors and Korsana&#8217;s board of directors believe that the Cayman Redomestication will allow the Combined Company to take advantage of certain provisions of the corporate laws of the Cayman Islands. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Redomestication will potentially reduce the risk of opportunistic and frivolous shareholder demands and litigation for the Combined Company and its directors and officers, which may allow the Combined Company&#8217;s directors and officers to focus on the Combined Company&#8217;s business and save it the cost of such demands and litigation. The frequency and cost of claims directed towards directors and officers of Massachusetts corporations increases the risk facing directors and officers of public companies in exercising their duties. If the Combined Company were to be targeted by opportunistic and frivolous shareholder demands or lawsuits, the costs or other consequences of responding to or defending such claims could potentially be borne by the Combined Company&#8217;s shareholders through, among other things, indemnification obligations, distraction to the Combined Company&#8217;s management and employees, and increased insurance premiums. Cyclerion&#8217;s board of directors expects fewer opportunistic and frivolous books and records inspection demands under Cayman Islands law as shareholders generally do not have statutory rights to inspect or obtain copies of the register of shareholders or other corporate records under the Companies Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Redomestication will potentially provide the Combined Company&#8217;s directors and officers with greater protection, which may help the Combined Company attract and retain highly qualified management personnel. Massachusetts law generally authorizes a corporation to adopt provisions eliminating or limiting the personal liability of directors or officers to the corporation for monetary damages for breach of fiduciary duty, except for liability for any breach of the director&#8217;s duty of loyalty to the corporation or its shareholders, acts or omissions not in good faith or involving intentional misconduct or knowing violations of law or any improper distributions to shareholders under the MBCA, or any transaction from which the director derived any improper personal benefit. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In most cases, under Cayman Islands law, the Cayman Company will be the proper plaintiff in any claim based on a breach of duty owed to it, and a claim against (for example) the Cayman Company&#8217;s directors or officers usually may not be brought by a shareholder. In principle, a shareholder does not have a direct right of action against directors of the Cayman Company. However, based on Cayman Islands authorities and English authorities (which will be of persuasive authority in the Cayman Islands), there are exceptions to the foregoing principle such that a shareholder may be entitled to bring a derivate action on behalf of the Cayman Company, but only in limited circumstances, including but not limited to: the Cayman Company acts or proposes to act illegally or ultra vires; the act complained of (although not ultra vires) could be affected if duly authorized by a special resolution that has not been obtained; and those who control the Cayman Company are perpetuating a &#8220;fraud on the minority&#8221;. A shareholder may have a direct right of action against the Cayman Company where the individual rights of that shareholder have been or will be infringed. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cayman Islands law does not specifically restrict a Cayman Islands exempted company from exculpating its directors or officers from liability for negligence or a breach of duty, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to limit liability against willful default, willful neglect, actual fraud, or the consequences of committing a crime. In light of the above, the Cayman Redomestication is expected to limit the circumstances in which direct claims may be brought by shareholders against the directors and officers of the Cayman Company as a matter of Cayman Islands law. There is currently no known pending claim or litigation against any of Cyclerion&#8217;s directors or officers for breach of fiduciary duty related to their service as directors or officers of Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Redomestication could also potentially provide the Combined Company with greater flexibility to consider and engage in certain types of corporate transactions that might provide shareholders with an opportunity to realize greater value for their shares in the Combined Company that the Combined Company&#8217;s board of directors determines to be in the best interests of the Combined Company. Under Part I, Title XV, Chapter 110F of the Massachusetts General Laws, a business combination between a corporation and an interested shareholder is prohibited unless it satisfies certain conditions, one or more of which may be impractical in certain instances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not provide a list of statutory facts that directors and officers may consider in making takeover decisions or decisions in relation to corporate transactions. Under Cayman Islands law, in making decisions, directors are required to comply with their fiduciary duties to the company, including duties of loyalty, honesty, fidelity, good faith and acting in the best interests of the company. Directors must also act with skill, care and diligence with a standard measured against both objective and subjective tests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the Cayman Redomestication may allow the Combined Company to accomplish certain types of transactions with a reduced risk of litigation or a court overturning the business decisions of the Combined Company&#8217;s board of directors, to the detriment of the Combined Company and its shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such transactions potentially implicating the fairness standard under Massachusetts law are currently being discussed or considered by the Cyclerion&#8217;s board of directors. Consequently, the Cayman Redomestication is not being proposed to prevent a change in control, or as a response to any present attempt known to the Cyclerion&#8217;s board of directors to acquire control of Cyclerion or obtain representation on the Cyclerion&#8217;s board of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Risks Associated with the Cayman Redomestication </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Cayman Redomestication will result in all or any of the benefits described in this proxy statement/prospectus, including the benefits of or resulting from the transfer by way of continuation of the Combined Company into the Cayman Islands or the application of Cayman Islands law to the internal affairs of the Combined Company. See &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to the Cayman Redomestication</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Effects of the Cayman Redomestication </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Redomestication will effect a change in the legal domicile of the Combined Company and other changes, the most significant of which are described below. Following the Cayman Redomestication, the Combined Company will be governed by the Companies Act instead of the MBCA, and the Combined Company will be governed by the Cayman Articles. Approval of this Proposal No.&#160;4 will constitute the approval and adoption of the Cayman Articles. The Massachusetts Articles and the Massachusetts Bylaws will no longer be applicable following completion of the Cayman Redomestication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summaries below do not purport to be complete and are subject to, and qualified in their entirety by reference to, the Companies Act, the Cayman Articles, the MBCA, the Massachusetts Articles and Massachusetts Bylaws, which you should carefully read, together with this entire document and the other referenced documents for a more complete understanding of the differences between being a shareholder of the Massachusetts Corporation before the Cayman Redomestication and being a shareholder of the Cayman Company following the completion of the Cayman Redomestication. Copies of the Cayman Articles, the Cayman Series A Certificate of Designation (as defined below), Cayman Series B Certificate of Designation (as defined below), the Massachusetts Articles, the Massachusetts Bylaws, the Massachusetts Series A Articles of Amendment (as defined below), the Massachusetts Series B Articles of Amendment (as defined below), the form of certificate of amendment to effect the proposed reverse stock split described in Proposal No.&#160;3 and the form of certificate of amendment to effect the increase in the number of authorized shares of Cyclerion common stock described in Proposal No.&#160;2 are included as <span style="font-style:italic">Annex K, Annex N, Annex O, Exhibit 3.1 (as amended by Exhibit 3.2 and Exhibit 3.3), Exhibit 3.4, Exhibit 3.3, Annex G, Annex I, and Annex H</span>, respectively, to this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of Rights of Holders of the Massachusetts Corporation Capital Stock and the Cayman Company Share Capital </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Articles differ in many respects from the Massachusetts Articles and Massachusetts Bylaws. The differences between the rights of shareholders of the Massachusetts Corporation under the Massachusetts Articles and Massachusetts Bylaws and their rights as shareholders of the Cayman Company immediately after the Cayman Redomestication under the Cayman Articles are summarized below. The following summary gives effect to the proposed increase in the number of authorized shares of Cyclerion common stock described in Proposal No.&#160;2 and the proposed reverse stock split described in Proposal No.&#160;3. The summary below is not intended to be relied upon as an exhaustive list of all differences or a complete description of the differences between the MBCA, the Massachusetts Articles, and the Massachusetts Bylaws, on the one hand, and the Cayman Articles, the Companies Act, and the common law of the Cayman Islands, on the other hand. The summary below is qualified in its entirety by reference to the actual text of the MBCA, the Massachusetts Articles, the Massachusetts Bylaws, the Cayman Articles, and the Companies Act. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Organizational Documents</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The rights of Massachusetts Corporation shareholders are governed by the Massachusetts Articles, the Massachusetts Bylaws and the MBCA.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The rights of Cayman Company shareholders will be governed by the Cayman Articles, the Companies Act, and the common law of the Cayman Islands.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Authorized Capital Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Massachusetts Corporation is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that the Massachusetts Corporation is authorized to issue is&#8195;&#8195;&#8195;&#160;, of which&#8195;&#8195;&#8195;&#160;shares are common stock, each having no par value per share, and 100,000,000 shares are</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The authorized share capital of the Cayman Company under the Cayman Articles is US$50,000 divided into &#8195;&#8195;&#8195;&#8195;&#8220;ordinary shares,&#8221; having a par value of US$0.0001 per share; and 100,000,000 &#8220;preferred shares,&#8221; having a par value of US$0.0001 per share. The Cayman Company may increase its authorized share capital through an ordinary</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">preferred stock, each having no par value per share. The preferred stock may be issued from time to time in one or more series.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Massachusetts Corporation preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Massachusetts Corporation entitled to vote thereon, without a separate vote of the holders of the preferred stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of preferred stock.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">resolution passed by the affirmative vote of a simple majority of the votes cast at a general meeting (an &#8220;ordinary resolution&#8221;).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Common Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Massachusetts Corporation&#8217;s authorized common stock consists of&#8195;&#8195;&#8195;&#160;shares of common stock, no par value per share.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each holder of a share of Massachusetts Corporation common stock is entitled to one vote for each such share held of record on the applicable record date on each matter properly submitted to the stockholders for their vote.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Company&#8217;s authorized Cayman Shares will consist of&#8195;&#8195;&#8195;&#8195;Cayman Shares, par value US$0.0001 per share.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each holder of Cayman Shares will carry the right to receive notice of, to attend and to vote at any Cayman Company general meeting.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Preferred Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Massachusetts Corporation preferred stock consists of 100,000,000 shares of preferred stock, each having no par value per share. The voting rights of preferred stockholders can vary depending on the series of preferred stock issued. The Massachusetts Corporation Board is authorized to determine the voting powers, full or limited, or no voting powers for each series of preferred stock.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500,000 shares of Massachusetts Corporation preferred stock are designated as Series A Convertible Preferred Stock (&#8220;Massachusetts Series A Preferred Stock&#8221;) pursuant to articles of amendment to the Massachusetts Articles (the &#8220;Massachusetts Series A Articles of Amendment&#8221;). Holders of Massachusetts Series A Preferred Stock are not entitled to vote at any meetings of Massachusetts Corporation shareholders. Each share of Massachusetts Series A Preferred Stock is convertible into one share of Massachusetts Corporation common stock.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, the Massachusetts Corporation&#8217;s board of directors (the &#8220;Massachusetts Corporation Board&#8221;) intends to designate &#8195;&#8195;&#8195;&#8195;shares of undesignated preferred stock as</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Company&#8217;s authorized preferred shares will consist of 100,000,000 preferred shares, par value US$0.0001 per share.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cayman Articles will provide that, whenever the capital of the Cayman Company is divided into different classes (and as otherwise determined by the board of directors) the rights attached to any such class may, subject to any rights or restrictions for the time being attached to any class, only be materially adversely varied or abrogated with the consent in writing of the holders of simple majority of the issued Cayman Shares or preferred shares of the relevant class, or with the sanction of a resolution passed at a separate meeting of the holders of the Cayman Shares or preferred shares of such class by a simple majority of the votes cast at such a meeting. The directors may vary the rights attaching to any class without the consent or approval of shareholders; provided that the rights will not, in the determination of the directors, be materially adversely varied or abrogated by such action.</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Massachusetts Series B Preferred Stock through an articles of amendment to the Massachusetts Articles in the form attached as Annex H (the &#8220;Massachusetts Series B Articles of Amendment&#8221;). No shares of Massachusetts Series B Preferred Stock are currently authorized or outstanding. Except as otherwise required by the Massachusetts Series B Articles of Amendment or law, the Massachusetts Series B Preferred Stock will not have voting rights. The Massachusetts Series B Articles of Amendment provides for certain voting rights in relation to the election of directors as discussed under &#8220;- Structure of Board of Directors; Term of Directors; Election of Directors&#8221; below. As long as shares of Massachusetts Series B Preferred Stock are outstanding, Massachusetts Corporation will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Massachusetts Series B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to Massachusetts Series B Preferred Stock, (b)&#160;alter or amend the description of rights of Massachusetts Series B Preferred Stock set forth in its articles of organization, (c)&#160;amend its articles of organization, bylaws or other charter documents in any manner that adversely affects any rights of the holders of Massachusetts Series B Preferred Stock, (d)&#160;file any articles of amendment, description of rights, preferences, limitations and relative rights of any series of Massachusetts Corporation preferred stock (as defined in the Massachusetts Series B Articles of Amendment), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of Massachusetts Series B Preferred Stock, (e)&#160;issue further shares of the Massachusetts Series B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Massachusetts Series B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Massachusetts Series B Preferred Stock remains issued and outstanding, (i)&#160;consummate either (A)&#160;a Fundamental Transaction (as defined in the Massachusetts Series B Articles of Amendment) or (B)&#160;any merger or consolidation of the Massachusetts Corporation or other business combination in which the shareholders of the Massachusetts Corporation immediately before such transaction do not hold at least a majority of the capital stock of the Massachusetts Corporation immediately after such transaction, (ii)&#160;increase the size of the Massachusetts Corporation Board, (iii)&#160;adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless approved by the unanimous vote of the</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Articles will also provide that the rights conferred upon the holders of the Cayman Shares or preferred shares of any class shall not, unless otherwise expressly provided by the terms of issue of the relevant class, be deemed to be materially adversely varied or abrogated by the creation, allotment or issue of Cayman Shares or preferred shares ranking pari passu with them, subsequent to them, with preferred rights (including enhanced voting rights) or the redemption or purchase of any of the relevant class by the Cayman Company.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Company&#8217;s board of directors (the &#8220;Cayman Company Board&#8221;) will designate 500,000 preferred shares as Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Shares (the &#8220;Cayman Series A Preferred Shares&#8221;) through a certificate of designation in the form attached as <span style="font-style:italic">Annex N </span>(the &#8220;Cayman Series A Certificate of Designation&#8221;). Except as otherwise provided for in the Cayman Articles, the Cayman Series A Certificate of Designation or at law, a holder of Cayman Series A Preferred Shares will not have voting rights.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Assuming the Massachusetts Corporation Board designates&#8195;&#8195;&#8195;&#8195;shares of the Massachusetts Corporation&#8217;s preferred stock as the Massachusetts Series B Preferred Stock through the Massachusetts Series B Certificate of Designation, upon the effectiveness of the Cayman Redomestication and the Cayman Articles, the Cayman Company Board will designate&#8195;&#8195;&#8195;&#8195;preferred shares as Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Shares (the &#8220;Cayman Series B Preferred Shares&#8221;) through a certificate of designation in the form attached as <span style="font-style:italic">Annex O </span>(the &#8220;Cayman Series B Certificate of Designation&#8221;). Except as otherwise provided for in the Cayman Articles, the Cayman Series B Certificate of Designation or at law, a holder of Cayman Series B Preferred Shares will not have voting rights other than in relation to the election of directors as discussed under &#8220;&#8212; <span style="font-style:italic">Structure of Board of Directors; Term of Directors; Election of Directors</span>&#8221; below. In addition, as long as any Cayman Series B Preferred Shares are issued and outstanding, the Cayman Company will not, without the affirmative vote of the holders of a simple majority of the then issued and outstanding Cayman Series B Preferred Shares: (a)&#160;alter or change adversely the powers, preferences or rights given to Cayman Series B Preferred Shares, or&#160;alter or amend the rights, powers, preferences and other terms of the Cayman</p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Massachusetts Corporation Board, or (iv)&#160;retain or replace the Massachusetts Corporation&#8217;s registered independent public accounting firm, independent compensation consultant or corporate counsel, or (g)&#160;enter into any agreement with respect to any of the foregoing. Following the closing of the Merger, each share of Massachusetts Series B Preferred Stock then outstanding will be convertible, at any time and from time to time, at the option of the holder of Massachusetts Series B Preferred Stock, into a number of shares equal to 1,000 shares of Massachusetts Corporation common stock, subject to certain limitations, including that a holder of Massachusetts Series B Preferred Stock is prohibited from converting shares of Massachusetts Series B Preferred Stock into shares of Massachusetts Corporation common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 19.99%) of the total number of shares of Massachusetts Corporation common stock issued and outstanding immediately after giving effect to such conversion.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Series B Preferred Shares set forth in the Cayman Series B Certificate of Designation, amend or repeal any provision of, or add any provision to, the Cayman Articles and the Cayman Series B Certificate of Designation, or&#160;file any articles of amendment, description of rights, preferences, limitations and relative rights of any series of Preferred Shares (as defined in the Cayman Series B Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of Cayman Series B Preferred Shares, (b)&#160;issue further Cayman Series B Preferred Shares or increase or decrease (other than by conversion) the number of authorized Cayman Series B Preferred Shares, (c)&#160;at any time while at least 30% of the originally issued Cayman Series B Preferred Shares remains issued and outstanding, (i)&#160;consummate either (A)&#160;a Fundamental Transaction (as defined in the Cayman Series B Certificate of Designation) or (B)&#160;any merger or consolidation of the Cayman Company or other business combination in which the shareholders of the Cayman Company immediately before such transaction do not hold at least a majority of the shares in the capital of the Cayman Company immediately after such transaction, (ii)&#160;increase the size of the Cayman Company Board, (iii)&#160;adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless approved by the unanimous vote of the Cayman Company Board, or (iv)&#160;retain or replace the Cayman Company&#8217;s registered independent public accounting firm, independent compensation consultant or corporate counsel, or (d)&#160;enter into any agreement with respect to any of the foregoing.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Number and Qualification of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The number of Massachusetts Corporation directors shall be not less than three directors and may be increased or decreased to a size fixed exclusively by vote of a majority of the directors then serving. No decrease in the authorized number of directors constituting the Massachusetts Corporation Board will shorten the term of any incumbent director. Directors need not be stockholders of the Massachusetts Corporation. Following the completion of the Merger, the Combined Company&#8217;s Board is expected to consist of&#8195;&#8195;&#8195;&#8195;members.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The size of the Cayman Company Board will be fixed by the Cayman Company Board and may be increased or decreased at any time by the affirmative vote of a simple majority of the voting power of the Cayman Company Board present, or in accordance with terms set out in the Cayman Articles. No decrease in the authorized number of directors constituting the Cayman Company Board will shorten the term of any incumbent director. Directors need not be shareholders of the Cayman Company. The Cayman Company Board is expected to consist of&#8195;&#8195;&#8195;&#8195;members.</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Structure of Board of Directors; Term of Directors; Election of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each annual meeting of shareholders, directors shall be elected for a full term of set to expire at the next annual meeting of shareholders. Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by statute, the Massachusetts Articles or the Massachusetts Bylaws, when a quorum is present, (i)&#160;in the event there are at least as many directorships as nominees, directors shall be elected by a majority of the votes properly cast and entitled to vote generally on the election of directors or (ii)&#160;in the event there are more nominees than directorships, directors shall be elected by a plurality of the votes properly cast and entitled to vote generally on the election of directors.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, at all times when at least 30% of the originally issued Massachusetts Series B Preferred Stock remains issued and outstanding: (i)&#160;the holders of Massachusetts Series B Preferred Stock, exclusively and voting together as a separate class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect four directors (&#8220;Massachusetts Preferred Directors&#8221;); and (ii)&#160;the holders of Massachusetts Corporation common stock and of any other class or series of voting stock (including the Massachusetts Series B Preferred Stock), exclusively and voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect the balance of the total number of directors of the Massachusetts Corporation. Each Massachusetts Preferred Director shall be entitled to three votes on each matter presented to the Massachusetts Corporation Board.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Company Board will be divided into three classes designated as: Class&#160;I, Class&#160;II, and Class&#160;III. The Cayman Company Board will be authorized to assign directors already in office to such classes in accordance with a resolution or resolutions adopted by the Cayman Company Board. At the first annual general meeting of shareholders following the date of adoption of the Cayman Articles, the term of office of the Class&#160;I directors shall expire and Class&#160;I directors shall be elected for a full term of three years. At the second annual general meeting of shareholders following the date of adoption of the Cayman Articles, the term of office of the Class&#160;II directors shall expire and Class&#160;II directors shall be elected for a full term of three years. At the third annual general meeting of shareholders following the date of adoption of the Cayman Articles, the term of office of the Class&#160;III directors shall expire and Class&#160;III directors shall be elected for a full term of three years. At each succeeding annual general meeting of shareholders, directors shall be elected for a full term of three years to succeed the directors of the particular class whose terms expire at such annual general meeting. Notwithstanding the foregoing provisions, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal. Any election of directors by shareholders shall be determined by a plurality of the votes properly cast on the election of directors.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">At all times when at least 30% of the originally issued Cayman Series B Preferred Shares remains issued and outstanding: (i)&#160;the holders of record of the Cayman Series B Preferred Shares, exclusively and voting together as a separate class on an <span style="white-space:nowrap">as-converted</span> to Cayman Shares basis, shall be entitled to elect four directors (&#8220;Cayman Preferred Directors&#8221;); and (ii)&#160;the holders of the Cayman Shares and of any other class or series of voting shares (including the Cayman Series B Preferred Shares), exclusively and voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to Cayman Shares basis, shall be entitled to elect the balance of the total number of directors of the Cayman Company, provided, however, for administrative convenience, the initial Cayman Preferred Directors may also be appointed by the Cayman Company Board in connection with the approval of the initial issuance of Cayman Series B Preferred Shares without a separate</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">action by the holders of Cayman Series B Preferred Shares. Each Cayman Preferred Director shall be entitled to three votes on each matter presented to the Cayman Company Board.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Removal of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any series of preferred stock, at any special meeting of Massachusetts Corporation shareholders called at least in part for such purpose, any director may by the affirmative vote of the holders of at least a majority of the shares entitled to vote for the election of directors, be removed for cause. The Massachusetts Corporation Board may remove any director or directors, for cause, at a meeting of the Massachusetts Corporation Board by vote of a majority of directors then in office.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, any Massachusetts Preferred Director may be removed without cause only by the affirmative vote of the holders of a majority of the Massachusetts Series B Preferred Stock.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights and restrictions of holders of any series of preferred shares to remove directors specified by the Cayman Articles or any certificate of designation, any individual director or the Cayman Company Board may only be removed with cause by an ordinary resolution. In addition, the Cayman Company Board is authorized to remove any director or directors, for cause, by the affirmative vote of a simple majority of directors present or in accordance with the terms set out in the Cayman Articles.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">At all times when at least 30% of the originally issued Cayman Series B Preferred Shares remains issued and outstanding, any Cayman Preferred Director may be removed without cause only by the affirmative vote of the holders of a majority of the Cayman Series B Preferred Shares, given either at a special meeting of such shareholders duly called for that purpose or pursuant to a written consent of shareholders.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Vacancies on the Board of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any series of preferred stock, any vacancies on the Massachusetts Corporation Board resulting from death, resignation, disqualification, removal or other causes, and any newly created directorships resulting from any increase in the number of directors, shall be filled exclusively by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Massachusetts Corporation Board, and not by the shareholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, at all times when at least 30% of the originally issued Massachusetts Series B Preferred Stock remains issued and outstanding, any vacancies of a Massachusetts Preferred Director directorship resulting from death, resignation, disqualification, removal, or other causes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to the rights of the holders of any series of preferred shares, including pursuant to any certificate of designation, any vacancies on the Cayman Company Board resulting from death, resignation, disqualification, removal or other causes, and any newly created directorships resulting from any increase in the number of directors, shall, unless the Cayman Company Board determines by resolution that any such vacancies or newly created directorships shall be filled by the shareholders as permitted in accordance with the Cayman Articles and any certificate of designation, be filled only by the affirmative vote of a simple majority of the voting power of the directors present, or by unanimous written consent of all directors, or by a sole remaining director and not by the shareholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified.</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">shall be filled by the affirmative vote of the holders of a majority of the Massachusetts Series B Preferred Stock.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">If the holders of the Cayman Series B Preferred Shares fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect pursuant to the Cayman Series B Certificate of Designation, then any directorship not so filled shall remain vacant until such time as the holders of the Cayman Series B Preferred Shares fill such directorship in accordance with the Cayman Series B Certificate of Designation.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Shareholder Action by Written Consent</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Any action required or permitted to be taken by the Massachusetts Corporation shareholders may be taken without a meeting if evidenced by consents signed by all Massachusetts Corporation shareholders entitled to vote on the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">A resolution in writing signed by all the shareholders entitled to receive notice of and to attend and vote at general meetings of the Cayman Company (or being corporations by their duly authorized representatives) shall be as valid and effective as if the same had been passed at a general meeting of the Cayman Company duly convened and held for the purposes of passing a special resolution or an ordinary resolution.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Quorum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">At all meetings of stockholders, except where otherwise provided by statute or by the Massachusetts Articles or the Massachusetts Bylaws, at any meeting of Massachusetts Corporation shareholders, a majority of the votes entitled to be cast on a matter by a voting group shall constitute a quorum with respect to that voting group for action on that matter. In the absence of a quorum, any meeting of shareholders may be adjourned, from time to time, either by the chairperson of the meeting or by a majority of the votes cast on the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">At all meetings of shareholders, except where otherwise provided by the Cayman Articles or any certificate of designation, the holders of record of <span style="white-space:nowrap">one-third</span> of the issued and outstanding shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at any meeting of shareholders. If less than a quorum is present at a meeting, the holders of shares representing a simple majority of the voting power present at the meeting or the presiding officer or chairman may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided for in the Cayman Articles. A meeting will be adjourned until quorum is present. At such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the original meeting.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Special Meetings of Shareholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Special meetings of the Massachusetts Corporation shareholders may be called, for any purpose as is a proper matter for shareholder action under the Massachusetts Articles, the Massachusetts Bylaws and the MBCA, by (i)&#160;subject to certain conditions, holders of at least forty percent (40%) of all the votes entitled to be cast on any issue to be considered at the proposed special meeting, or (ii)&#160;the Massachusetts Corporation Board pursuant to a resolution adopted by a majority of the directors at a meeting of directors where a quorum is</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to certain conditions set forth in the Cayman Articles, general meetings of the Cayman Company may be called, for any purpose as is a proper matter for shareholder action under Cayman Islands law, by (i)&#160;the Cayman Company Board or (ii)&#160;the holders of at least 40% of all the votes entitled to be cast on any issue to be considered at the proposed general meeting delivered to an executive officer of the Cayman Company at the principal executive offices of the Cayman Company.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">present or by unanimous written consent of the Massachusetts Corporation Board.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Massachusetts Corporation Board or an officer designed by the Massachusetts Corporation Board shall determine the time and place of such special meeting. Upon determination of the time and place of the meeting, the Massachusetts Corporation secretary shall cause a notice of meeting to be given to the Massachusetts Corporation shareholders entitled to vote, in accordance with the Massachusetts Bylaws. No business may be transacted as such special meeting other than the business specified in the notice of meeting. Special meetings called by Massachusetts Corporation shareholders will be scheduled not fewer than sixty (60)&#160;nor more than ninety (90)&#160;days after the date of delivery of a written request to the Massachusetts Corporation secretary for such meeting to be called by shareholders holding at least forty percent (40%) of the votes entitled to be cast on any issue to be considered at the proposed special meeting, subject to certain conditions in the Massachusetts Bylaws.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cayman Company Board shall determine the date, time, and place (and, if the general meeting is to be a hybrid meeting or an electronic meeting, the details of the electronic facilities for attendance and participation by electronic means at the general meeting) of such meeting, if any. Upon such determination, the Cayman Company Board or executive officer of the Cayman Company shall cause a notice of general meeting to be given to the Cayman Company shareholders entitled to vote, in accordance with the Cayman Articles.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Notice of Shareholder Meetings</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of Massachusetts Corporation shareholders shall be given not less than seven (7)&#160;nor more than sixty (60)&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting. Notice of any special meeting requested by Massachusetts Corporation shareholders in accordance with the Massachusetts Bylaws shall be given in writing or electronic transmission within thirty (30)&#160;days of the date of delivery of a written request for such special meeting to be called. Notice delivered to Massachusetts Corporation shareholders of shareholder meetings will specify the date, place and time of such meeting and the purposes of such meeting.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by law, a notice of each meeting of shareholders stating the time, date and place of such meeting (and, if the meeting is to be a hybrid meeting or an electronic meeting, the details of the electronic facilities for attendance and participation by electronic means at the meeting) by which shareholders and proxy holders may be deemed to be present in person and vote at any such meeting shall be given not less than seven (7)&#160;nor more than sixty (60)&#160;days before the date of the meeting to each shareholder entitled to vote at such meeting as of the record date for such meeting, such notice to specify, in the case of general meetings, the business, purpose or purposes for which the meeting has been called . No business may be transacted at an annual general meeting otherwise than specified in the notice of annual general meeting.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The accidental omission to give notice of a meeting to or the <span style="white-space:nowrap">non-receipt</span> of a notice of a meeting by any shareholder shall not invalidate the proceedings at any meeting.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Advance Notice Requirements for Shareholder Proposals</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nominations of persons for election to the Massachusetts Corporation Board may be made at an annual meeting or special meeting of shareholders, and the proposal of business to be considered by the</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Nominations of persons for election to the Cayman Company Board and the proposal of business to be considered by the shareholders may be made at an annual general meeting of shareholders: (i) pursuant</p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">shareholders may be made at an annual meeting of shareholders, by any Massachusetts Corporation shareholder who was a shareholder of record at the time of giving the shareholder&#8217;s notice, who is entitled to vote at the meeting and who complied with the notice procedures set forth in the Massachusetts Bylaws. Such notice must be received by the Massachusetts Corporation not later than the close of business on the ninetieth (90th) day no earlier than the close of business on the one hundred twentieth (120th) day prior to the first anniversary of the preceding year&#8217;s annual meeting, in the case of an annual meeting nomination, and not later than the close of business on the later of the ninetieth (90th) day prior to such meeting or the tenth (10th) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Massachusetts Corporation Board to be elected at such meeting, in the case of a special meeting nomination.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to the Cayman Company&#8217;s notice of meeting of shareholders (with respect to business other than nominations); (ii) brought specifically by or at the direction of the Cayman Company Board; or (iii) by any shareholder of the Cayman Company who was a shareholder of record at the time of giving the shareholders&#8217; notice provided for in the Cayman Articles below, who is entitled to vote at the meeting and who complied with the notice procedures set forth in Cayman Articles. Such notice must be received by the Cayman Company not later than the close of business on the ninetieth day and no earlier than the close of business on the one hundred twentieth day prior to the first anniversary of the preceding year&#8217;s annual meeting, or if no annual meeting was held in the preceding year, not later than the close of business on the later of the ninetieth day prior to such meeting or the tenth day following the day on which public announcement is first made of the date of such meeting.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">For director nominations or other business to be properly brought before an annual general meeting by a shareholder, the shareholder must (i)&#160;have given Timely Notice in writing and (ii)&#160;must comply with the requirements in the Cayman Articles as to the contents of the Timely Notice.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Amendment of Certificate of Incorporation and Memorandum of Association</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Massachusetts Articles may be amended by the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment at a duly constituted meeting of shareholders called expressly for such purpose.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Articles will consist of a memorandum of association and articles of association.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to the Companies Act and the rights attaching to the various classes, including pursuant to any certificate of designation, the Cayman Company may at any time and from time to time by i) a majority of not less than <span style="white-space:nowrap">two-thirds</span> of the shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the Cayman Company of which notice specifying the intention to propose the resolution as a special resolution has been duly given and where a poll is taken regard shall be had in computing a majority to the number of votes to which each shareholder is entitled or ii) approved in writing by all of the shareholders entitled to vote at a general meeting of the Cayman Company in one or more instruments each signed by one or more of the shareholders (a &#8220;special resolution&#8221;) alter or amend the memorandum of association and articles of association forming a part of the Cayman Articles, in whole or in part.</p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Amendment of Bylaws and Articles of Association</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Except as otherwise provided by law, the Massachusetts Bylaws may be adopted, amended, or repealed by the Massachusetts Corporation Board. Any adoption, amendment, or repeal of the Massachusetts Bylaws by the Massachusetts Corporation Board pursuant to a resolution adopted by a majority of the directors at a meeting of directors where a quorum is present or by unanimous written consent of the Massachusetts Corporation Board. The Massachusetts Bylaws may also be adopted, amended, or repealed by the shareholders votes cast in favor representing a majority of the votes entitled to be cast on the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Articles will consist of a memorandum of association and articles of association.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to the Companies Act and the rights attaching to the various classes, including pursuant to any certificate of designation, the Cayman Company may at any time and from time to time by special resolution alter or amend the articles of association forming a part of the Cayman Articles in whole or in part.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Limitation on Director and Officer Liability</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Directors shall not be liable to the Massachusetts Corporation or its shareholders for damages for any breach of fiduciary duty, except to the extent that the elimination or limitations of liability is not permitted under law.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Act does not restrict the authority of a Cayman exempted company to indemnify its directors, officers, employees, or agents.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cayman Articles provide that no Indemnified Person (as defined below) shall be liable: (a)&#160;for the acts, receipts, neglects, defaults or omissions of any other director or officer or agent of the Cayman Company; or (b)&#160;for any loss on account of defect of title to any property of the Cayman Company; or (c)&#160;on account of the insufficiency of any security in or upon which any money of the Cayman Company shall be invested; or (d)&#160;for any loss incurred through any bank, broker or other similar Person; or (e)&#160;for any loss occasioned by any negligence, default, breach of duty, breach of trust, error of judgement or oversight on such Indemnified Person&#8217;s part; or (f)&#160;for any loss, damage or misfortune whatsoever which may happen in or arise from the execution of discharge of the duties, powers, authorities, or discretions of such Indemnified Person&#8217;s office or in relation thereto; unless the same shall happen through such Indemnified Person&#8217;s own actual fraud, willful default or willful neglect as determined by a court of competent jurisdiction.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Indemnification</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Massachusetts Corporation will indemnify and hold harmless its directors and officers from and against any and all claims and liabilities to which he or she may be or become subject by reason of being or having been a director or officer of the Massachusetts Corporation or by reason of alleged acts or omissions as a director or officer of the Massachusetts Corporation, in each case, to the fullest extent permitted by applicable law and will reimburse each such officer and director for any and all</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Cayman Articles provide that, to the fullest extent permitted by law, every director (including any alternate director appointed pursuant to the provisions of the Cayman Articles), secretary, assistant secretary, or other officer (but not including the Cayman Company&#8217;s auditors) and the personal representatives of the same (each an &#8220;Indemnified Person&#8221;) shall be indemnified and secured harmless out of the assets and funds of the Cayman Company</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">legal and other expenses reasonably incurred in connection with such claims, whether or not such person has ceased to be a director or officer at or prior to the time such person is indemnified, held harmless or reimburse. These obligations to indemnify, hold harmless and reimburse directors and officers include payment by the Massachusetts Corporation of expenses incurred in defending a civil or criminal action or proceeding in advance of the final disposition of such action or proceeding.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Massachusetts Corporation will also indemnify and hold harmless persons who serve at the Massachusetts Corporation&#8217;s express written request as directors or officers of another organization, if such entity fails, directly or through insurance, to cover such costs and expenses; provided that, such other entity will be the full indemnitor or insurer of first resort for any such liabilities, expenses or other losses and only thereafter will the Massachusetts Corporation be required to pay indemnification or advancement of any such liabilities, expenses or other losses.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The rights conferred on any person by the Massachusetts Articles will be in addition to and not exclusive of any other rights to which any officer or director of the Massachusetts Corporation may otherwise be lawfully entitled.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">against all actions or proceedings whether threatened, pending or completed, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such Indemnified Person, other than by reason of such Indemnified Person&#8217;s own actual fraud, willful default or willful neglect as determined by a court of competent jurisdiction, (i)&#160;in or about the conduct of the Cayman Company&#8217;s business or affairs (including as a result of any mistake of judgment), (ii) in the execution or discharge of his or her duties, powers, authorities or discretions, or (iii)&#160;in respect of any actions or activities undertaken by an Indemnified Person provided for and in accordance with the provisions set out above (inclusive) including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such Indemnified Person in defending or otherwise being involved in, (whether successfully or otherwise) any civil proceedings concerning the Cayman Company or its affairs in any court whether in the Cayman Islands or elsewhere.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each shareholder waives any claim or right of action they might have, whether individually or by or in the right of the Cayman Company, against any director or officer on account of any action taken by such director or officer, or the failure of such director or officer to take any action in the performance of his or her duties with or for the Cayman Company; provided that such waiver shall not extend to any matter in respect of any actual fraud, willful default or willful neglect which may attach to such director or officer.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Company will pay the expenses (including attorneys&#8217; fees) incurred by an Indemnified Person in defending any proceeding in advance of its final disposition; provided, however, that such payment of expenses in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by the Indemnified Person to repay all amounts advanced if it should be ultimately determined that the Indemnified Person is not entitled to be indemnified under the Cayman Articles or otherwise.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The rights to indemnification and advancement of expenses conferred on any Indemnified Person as set out above will not be exclusive of any other rights that any Indemnified Person may have or hereafter acquire pursuant to an agreement with the Cayman Company or otherwise.</p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Conversion Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Massachusetts Corporation common stock is neither convertible nor redeemable.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Massachusetts Series A Preferred Stock have the right to convert such shares into shares of Massachusetts Corporation common stock at any time at a ratio of 1 share of Massachusetts Series A Preferred Stock to 1 share of Massachusetts Corporation common stock.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">When the Massachusetts Series B Preferred Stock is issued in connection with the Merger, the holders of the Massachusetts Series B Preferred Stock will have the right to convert such shares into Massachusetts Corporation common stock at any time at a ratio of 1 share of Massachusetts Series B Preferred Stock to 1,000 shares of Massachusetts Corporation common stock, subject to certain limitations, including that a holder of Massachusetts Series B Preferred Stock is prohibited from converting shares of Massachusetts Series B Preferred Stock into shares of Massachusetts Corporation common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 19.99%) of the total number of shares of Massachusetts Corporation common stock issued and outstanding immediately after giving effect to such conversion.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Cayman Series A Certificate of Designation, each Cayman Series A Preferred Shares then issued and outstanding shall be convertible, at any time and from time to time, at the option of the holder thereof, at a ratio of 1 Cayman Series A Preferred Share to 1 Cayman Share, subject to adjustment for share splits, combinations and similar events provided for in the Cayman Series A Certificate of Designation.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In accordance with the Cayman Series B Certificate of Designation, each Cayman Series B Preferred Shares then issued and outstanding shall be convertible, at any time and from time to time, at the option of the holder thereof, at a ratio of 1 Cayman Series B Preferred Share to 1,000 Cayman Shares, subject to certain limitations, including that a holder of Cayman Series B Preferred Shares will be prohibited from converting Cayman Series B Preferred Shares into Cayman Shares if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 19.99%) of the total number of Cayman Shares issued and outstanding immediately after giving effect to such conversion.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Preemptive Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Massachusetts Corporation shareholders do not have preemptive rights. Thus, if additional shares of Massachusetts Corporation common stock are issued, the current holders of Massachusetts Corporation common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cayman Company shareholders will not have preemptive rights. Thus, if additional Cayman Shares are issued, the current holders of Cayman Shares will own a proportionately smaller interest in a larger number of outstanding Cayman Shares to the extent that they do not participate in the additional issuance.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Distributions to Shareholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subject to preferences that may be applicable to any outstanding shares of Massachusetts Corporation preferred stock, the holders of Massachusetts Corporation common stock are entitled to receive ratably such dividends as may be declared by the Massachusetts Corporation Board out of legally available funds.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Subject to the Companies Act, the Cayman Articles, and any certificate of designation, and except as otherwise provided by the rights attached to any shares, the directors may resolve to declare dividends (including interim dividends) and other distributions on shares in issue and authorize payment of the dividends or other distributions out of the funds of the Cayman Company lawfully available therefor. All dividends shall be declared and paid according to the amounts paid up on the Cayman Shares, but if</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and for so long as nothing is paid up on any of the Cayman Shares, dividends may be declared and paid according to the par value of the Cayman Shares. Dividends may be paid in cash, in property, or in shares.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Cayman Islands company may only make distributions by way of a dividend out of its profits, retained earnings, and/or share premium account.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Where dividends are paid from share premium, a statutory solvency test applies immediately following payment such that the company shall be able to pay its debts as they fall due in the ordinary course of business. Where dividends are paid from profits or retained earnings directors are also required to assess solvency, although the test is not expressly set out in the Companies Act.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Exclusive Forum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Massachusetts Articles provide that unless the Massachusetts Corporation Board consents in writing to the selection of an alternative forum, a state or federal court located within the Commonwealth of Massachusetts shall be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Massachusetts Corporation; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Massachusetts Corporation to the Massachusetts Corporation or its shareholders; (iii)&#160;any action asserting a claim against the Massachusetts Corporation arising pursuant to any provision of the MBCA or any successor statute; or (iv)&#160;any action asserting a claim against the Massachusetts Corporation governed by the internal affairs doctrine.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cayman Articles will provide that, unless the Cayman Company consents in writing to the selection of an alternative forum, the courts of the Cayman Islands shall have exclusive jurisdiction over any claim or dispute arising out of or in connection with the Cayman Articles or otherwise related in any way to each member&#8217;s shareholding in the Cayman Company, including but not limited to:</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(a) any derivative action or proceeding brought on behalf of the Cayman Company; (b)&#160;any action asserting a claim of breach of any fiduciary or other duty owed by any current or former director, officer, or other employee of the Cayman Company to the Cayman Company or the members; (c)&#160;any action asserting a claim arising pursuant to any provision of the Companies Act, the Cayman Articles; or (d)&#160;any action asserting a claim against the Company concerning its internal affairs.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Registration Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than in connection with the Merger, the Massachusetts Corporation shareholders do not have any registration rights.</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, the Massachusetts Corporation will enter into a registration rights agreement with the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, pursuant to which, among other things, the Combined Company will agree to prepare and file a resale registration statement covering the resale of certain shares of Massachusetts</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Assuming the Massachusetts Corporation enters into a registration rights agreement with the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, the Cayman Company will have comparable obligations pursuant to the registration rights agreement.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Massachusetts Corporation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Cayman Company</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Corporation common stock within 30 business days of the Closing pursuant to Rule 415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act. The registration rights agreement also provides that the Combined Company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Stock Transfer Restrictions Applicable to Shareholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Shares of Massachusetts Corporation common stock are transferable in the manner prescribed by the MBCA.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Transfer of Cayman Shares in record form may be subject to the restrictions that may be set out from time to time in the Cayman Articles, including, without limitation, the receipt of an instrument of transfer in such form as the directors may in their absolute discretion approve and such other evidence as the directors may reasonably require to show the right of the transferor to make the transfer.</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Comparison of Shareholder Rights under Massachusetts and Shareholder Rights under Cayman Islands Law </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Act and the common law of the Cayman Islands are similar in many respects to the statutory corporate laws of Massachusetts, as governed by the MBCA. However, there are certain differences that may affect the rights of a shareholder or shareholder of the Combined Company, as well as the corporate governance of the Combined Company. The following are brief summaries of material differences between the current rights of shareholders of the Massachusetts Corporation under the MBCA and the rights of shareholders of the Cayman Company following completion of the Cayman Redomestication under the Companies Act. This section does not include a complete description of all differences among such rights, nor does it include a complete description of such rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Increasing or Decreasing Authorized Capital Stock or Share Capital </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Massachusetts law, shareholders must approve an amendment to the corporation&#8217;s charter to increase or decrease the number of authorized shares in accordance with the provisions of the applicable statute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, the memorandum and articles of association of a Cayman Islands exempted company sets the authorized share capital. Any changes made to the authorized share capital of a Cayman Islands exempted company will require an ordinary resolution and any amendment to the memorandum and articles of association of a Cayman Islands exempted company will require a special resolution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA provides that, unless a company opts out of such provision, the terms of directors of a public Massachusetts company shall be staggered by dividing the directors into three groups, as nearly equal in number as possible, with only one group of directors being elected each year. The board of directors of a public Massachusetts company may unilaterally opt back into the default requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Companies Act does not provide for the classification of directors into classes with staggered terms of office, Cayman Islands law allows companies to implement a classified board structure through their articles of association. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cumulative Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Massachusetts law, cumulative voting for directors entitles each shareholder to multiply the number of votes they are entitled to cast by the number of directors for whom they are entitled to vote and cast the product for a single candidate or distribute the product among two or more candidates. Cumulative voting may enable a minority shareholder or group of shareholders to elect at least one representative to the board of directors where such shareholders would not be able to elect any directors without cumulative voting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the MBCA does not generally grant shareholders cumulative voting rights, a Massachusetts corporation may provide in its certificate of incorporation or bylaws for cumulative voting in the election of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Act does not provide for cumulative voting as a mechanism for electing directors and if a Cayman Islands exempted company wants to allow cumulative voting, it must explicitly set out in its articles of association. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Massachusetts Articles do not provide for cumulative voting in the election of directors. Similarly, the Cayman Articles do not provide for cumulative voting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Vacancies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, subject to the articles of organization or the bylaws and the rights of any holders of any outstanding series of preferred stock, vacancies on the board of directors, including those resulting from any increase in the authorized number of directors, may be filled by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum. Any director so appointed will hold office for the remainder of the term of the director no longer on the board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, there is no statutory rule governing how board of director vacancies may be filled. Instead, the process is governed by a Cayman Islands exempted company&#8217;s articles of association, which generally give the remaining directors discretion to appoint a replacement until the next annual meeting or for the remainder of the term, and may also require shareholder approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, subject to the articles of organization or the bylaws and the rights of any holders of any outstanding series of preferred stock, the shareholders may remove one or more directors with or without cause. In the case of directors of a public corporation whose terms are staggered pursuant to Section&#160;8.06(b) of the MBCA, shareholders may effect, by the affirmative vote of a majority of the shares outstanding and entitled to vote in the election of directors, the removal of any director or directors or the entire board of directors only for cause. If a director is elected by a voting group of shareholders, only the shareholders of that voting group may participate in the vote to remove him. If cumulative voting is authorized, a director may not be removed by the shareholders if the number of votes sufficient to elect him under cumulative voting is voted against his removal. If cumulative voting is not authorized, a director may be removed by the shareholders only if the number of votes cast to remove him exceeds the number of votes cast not to remove him. A director may be removed by the shareholders or the directors only at a meeting called for the purpose of removing him. Currently, under the Massachusetts Articles, except as otherwise determined by the Massachusetts Corporation Board in establishing a series of preferred stock, any director or directors may be removed from office for cause at any special meeting of the shareholders called at least in part for such purpose by the affirmative vote of the holders of at least a majority of the stock entitled to vote for the election of directors. In addition, the Massachusetts Corporation Board is authorized to remove any director or directors, for cause, at a meeting of the board of directors, by vote of a majority of directors then in office. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, there is no statutory right for shareholders to remove directors. Instead, the removal process is governed by a Cayman Islands exempted company&#8217;s articles of association. Under the Cayman Articles, subject to the rights and restrictions of holders of any series of preferred shares to remove directors specified by the Cayman Articles or any certificate of designation, neither the Cayman Company Board nor any individual director may be removed without cause. Subject to the rights and restrictions of holders of any series of preferred shares to remove directors specified by the Cayman Articles or any certificate of designation, any individual director or the Cayman Company Board may be removed with cause by an ordinary resolution of the shareholders or the affirmative vote of a simple majority of the directors present. Additionally, under the Cayman Certificate of Designation for the Cayman Series B Preferred Shares, any Cayman Preferred Director may be removed without cause only by the affirmative vote of the holders of a simple majority of the Cayman Series B Preferred Shares. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fiduciary Duties and Business Judgment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Massachusetts law, members of the board of directors are entitled to rely in good faith upon information, opinions, reports, or statements, including financial statements and other financial data, if prepared or presented by officers or employees of the corporation whom the director reasonably believes to be reliable and competent with respect to the information, opinions, reports or statements presented or legal counsel, public accountants, or other persons retained by the corporation, as to matters involving skills or expertise the director reasonably believes are matters (i)&#160;within the particular person&#8217;s professional or expert competence or (ii)&#160;as to which the particular person merits confidence. A director is not liable for any action taken as a director, or any failure to take any action, if he performed the duties of his office in compliance with this section. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, directors owe fiduciary duties to the company, including duties of loyalty, honesty, fidelity, good faith and acting in the best interests of the company. Directors must also act with skill, care and diligence with a standard measured against both objective and subjective tests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to Massachusetts law, Cayman Islands law permits directors to rely on information, opinions, reports, and statements prepared by officers, employees, committees or professional advisors, provided such reliance is reasonable and made in good faith. As a matter of Cayman Islands law, a director is under a general fiduciary duty to avoid conflicts of interest and Cayman Islands courts will generally defer to directors&#8217; decisions if made in good faith, for a proper purpose and without conflicts of interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Flexibility for Decisions, Including Takeovers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA does not provide a list of statutory factors that corporate directors and officers may consider in making takeover decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not provide a list of statutory facts that directors and officers may consider in making takeover decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, directors owe fiduciary duties to the company, including duties of loyalty, honesty, fidelity, good faith and acting in the best interests of the company. Directors must also act with skill, care and diligence with a standard measured against both objective and subjective tests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation on Personal Liability of Directors and Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA authorizes a corporation to adopt a charter provision eliminating or limiting the personal liability of directors and officers to the corporation for monetary damages for breach of fiduciary duty, except for liability for, any breach of the director&#8217;s or officer&#8217;s duty of loyalty to the corporation or its shareholders, acts or omissions not in good faith or involving intentional misconduct or knowing violations of law or any improper distributions to shareholders under the MBCA, or any transaction from which the director derived any improper personal benefit. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not specifically restrict a Cayman Islands exempted company from exempting its directors or officers from liability for negligence or a breach of duty or a breach of trust, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to limit liability against willful default, willful neglect, actual fraud, or the consequences of committing a crime. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, the Cayman Company will be the proper plaintiff in any claim based on a breach of duty owed to it, and a claim against (for example) the Cayman Company&#8217;s directors or officers usually may not be brought by a shareholder. In principle, a shareholder does not have a direct right of action against directors of the Cayman Company. However, based on Cayman Islands authorities and English authorities (which will be of persuasive authority in the Cayman Islands), there are exceptions to the foregoing principle such that a shareholder may be entitled to bring a derivate action on behalf of the Cayman Company, but only in limited circumstances, including but not limited to: the Cayman Company acts or proposes to act illegally or ultra vires; the act complained of (although not ultra vires) could be affected if duly authorised by a special resolution that has not been obtained; and those who control the Cayman Company are perpetuating a &#8220;fraud on the minority&#8221;. A shareholder may have a direct right of action against the Cayman Company where the individual rights of that shareholder have been or will be infringed. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indemnification </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA has statutory mechanisms that permit corporations to indemnify directors, officers, employees, and agents in similar circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Massachusetts Articles provide that the liability of Massachusetts Corporation directors for damages for any breach of fiduciary duty shall be limited to the fullest extent permitted by law. The Massachusetts Articles also provides that the Massachusetts Corporation will indemnify, and advance funds to and reimburse expenses of, Massachusetts Articles directors and officers that have been appointed the Massachusetts Corporation Board to the fullest extent permitted by law, and that the Massachusetts Corporation may indemnify, and advance funds to and reimburse expenses of, such other officers and employees as determined by the Massachusetts Corporation Board. The right of indemnification provided under the Massachusetts Bylaws is in addition to and not exclusive of any other rights to which any of the Massachusetts Corporation directors, officers or any other persons may otherwise be lawfully entitled. The Massachusetts Corporation has also entered into indemnification agreements with Massachusetts Corporation directors and officers, and the Massachusetts Corporation carries insurance policies insuring Massachusetts Corporation directors and officers against certain liabilities that they may incur in their capacity as directors and officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part 8 of the MBCA authorizes the provisions, described above, that are contained in the Massachusetts Articles and the Massachusetts Bylaws. In addition, Sections 8.30 and 8.42 of the MBCA provide that if an officer or director discharges his or her duties in good faith and with the care that a person in a like position would reasonably exercise under similar circumstances and in a manner the officer or director reasonably believes to be in the best interests of the corporation, he or she will not be liable for such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, the Cayman Company will be the proper plaintiff in any claim based on a breach of duty owed to it, and a claim against (for example) the Cayman Company&#8217;s directors or officers usually may not be brought by a shareholder. In principle, a shareholder does not have a direct right of action against directors of the Cayman Company. However, based on Cayman Islands authorities and English authorities (which will be of persuasive authority in the Cayman Islands), there are exceptions to the foregoing principle such that a shareholder may be entitled to bring a derivate action on behalf of the Cayman Company, but only in limited circumstances, including but not limited to: the Cayman Company acts or proposes to act illegally or ultra vires; the act complained of (although not ultra vires) could be affected if duly authorised by a special resolution that has not been obtained; and those who control the Cayman Company are perpetuating a &#8220;fraud on the minority&#8221;. A shareholder may have a direct right of action against the Cayman Company where the individual </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights of that shareholder have been or will be infringed. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the statutory indemnification mechanism in Massachusetts law, no corporation may indemnify a party unless it decides that indemnification is proper. Under the MBCA, the corporation through its shareholders, directors or independent legal counsel will determine whether the conduct of the person seeking indemnity conformed to the statutory provisions governing indemnity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Act does not restrict the authority of a Cayman Islands exempted company to indemnify its directors, officers, employees, or agents, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, actual fraud, or the consequences of committing a crime. The Cayman Articles provide for indemnification for every director and officer of the Cayman Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Advancement of Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA permits a corporation to advance expenses relating to the defense of any proceeding to directors and officers contingent upon such individuals&#8217; commitment to repay any advances unless it is determined ultimately that such individuals are entitled to be indemnified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not restrict the authority of a Cayman Islands exempted company to advance expenses incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding, but there is no statutory provision expressly requiring or governing advancement of expenses. Instead, the ability to advance expenses is typically addressed in a Cayman Islands exempted company&#8217;s articles of association. The Cayman Articles provide for expense advancement provisions for indemnified persons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both the MBCA and the Companies Act do not have a specific statute governing either the establishment of director compensation, or the fairness of director compensation. The Combined Company&#8217;s board of directors after the Cayman Redomestication will establish the compensation of its directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Action by Written Consent of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA provides that, unless the articles of organization or the bylaws provide otherwise, any action required or permitted to be taken at a meeting of the directors or a committee thereof may be taken without a meeting if all members of the board or committee, as the case may be, consent to the action in writing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Act does not prescribe rules for the written consent of directors and the process is governed by a Cayman Islands exempted company&#8217;s articles of association which typically allows board decisions to be made by unanimous written consent in lieu of a meeting of the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Massachusetts Articles or Massachusetts Bylaws, nor the Cayman Articles, limit the type or nature of a board action taken by written consent. A resolution in writing passed by the directors of the Cayman Company will be required to be executed by all the directors or committee thereof, entitled to receive notice of meetings of directors or committee thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Actions by Written Consent of Shareholders and Shareholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA provides that any action required or permitted to be taken at a meeting of the shareholders may be taken without a meeting if the action is taken either: (1)&#160;by all shareholders entitled to vote on the action; or (2)&#160;to the extent permitted by the articles of organization, by shareholders having not less than the minimum </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of votes necessary to take the action at a meeting at which all shareholders entitled to vote on the action are present and voting. In addition, the MBCA requires the corporation to give notice of the taking of corporate action without a meeting by less than unanimous written consent to those shareholders who did not consent in writing at least seven days before the action pursuant to the consent is taken. Any action required or permitted to be taken by the Massachusetts Corporation shareholders may be taken without a meeting if evidenced by consents signed by all Massachusetts Corporation shareholders entitled to vote on the matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, there is no statutory restriction on shareholder action by written consent and the process is governed by a Cayman Islands exempted company&#8217;s articles of association. The Cayman Articles provide that an ordinary resolution or a special resolution in writing signed by all shareholders entitled to receive notice of and to attend and vote at a general meeting of the Cayman Company will be as valid and effective as if such resolution had been passed at a meeting of the shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividends and Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless further restricted in the certificate of incorporation, the MBCA permits a corporation to declare and pay dividends unless, if the corporation is a going concern, the corporation would not be able to pay its existing and reasonably foreseeable debts, liabilities and obligations, whether or not liquidated, matured, asserted or contingent, as they become due in the usual course of business or the corporation&#8217;s total assets would be less than the sum of its total liabilities plus, unless the articles of organization permit otherwise, the amount that would be needed, if the corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Act and the Cayman Articles, the directors, by resolution, may declare dividends on shares in issue and authorize payment out of the funds of the Cayman Company lawfully available therefor. The directors may, subject to the preference of any classes of shares, authorize a dividend at such time and of such an amount as they think fit if they are satisfied that the Cayman Company will, have sufficient profits, retained earnings and/or share premium lawfully available therefor and, immediately after the payment of the dividend, satisfy the solvency test (that is, if the directors can determine based on the facts at the time that the company can in the future, following the payment of the dividend, pay its debts as they fall due in the ordinary course of business). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restrictions on Business Combinations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Massachusetts law provides certain protections to shareholders in connection with certain business combinations, which can be found in Chapter 110F of the MBCA, Cayman Islands law does not provide equivalent statutory protections to shareholders. Under Cayman Islands law, any specific provisions relating to business combinations needs to be set out expressly in the articles of association of a Cayman Islands exempted company. See &#8220;<span style="font-style:italic">Shareholder and Shareholder Vote for Mergers and Other Corporation Reorganizations</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Massachusetts Corporation is subject to the provisions of Chapter 110F of the MBCA. In general, Chapter 110F prohibits a publicly held Massachusetts corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested shareholder&#8221; for a three-year period following the time that this shareholder becomes an interested shareholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested shareholder. An &#8220;interested shareholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested shareholder status, five percent or more of the corporation&#8217;s voting stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Chapter 110F, a business combination between a corporation and an interested shareholder is prohibited unless it satisfies one of the following conditions: before the shareholder became interested, the corporation&#8217;s board of directors approved either the business combination or the transaction which resulted in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholder becoming an interested shareholder; upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 90% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the shareholder became interested, the business combination was approved by the corporation&#8217;s board of directors of the corporation and authorized at an annual or special meeting of the shareholders by the affirmative vote of at least <span style="white-space:nowrap">two-thirds</span> of the outstanding voting stock which is not owned by the interested shareholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Massachusetts corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original articles of organization or an express provision in its articles of organization or bylaws resulting from a shareholders&#8217; amendment approved by at least a majority of the outstanding voting shares. The Massachusetts Corporation has not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of the Massachusetts Corporation may be discouraged or prevented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shareholder and Shareholder Vote for Mergers and Other Corporate Reorganizations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, a merger, share exchange and sale of all or substantially all assets of a corporation must be approved by the board of directors and, unless (1)&#160;a greater percentage vote is required by the corporation&#8217;s articles of organization, <span style="white-space:nowrap">by-laws,</span> or board, or (2)&#160;a lesser percentage vote is required by the articles of organization, the merger, share exchange or sale of assets must be approved by <span style="white-space:nowrap">two-thirds</span> of all the shares entitled to vote on the matter. The articles of organization may provide for a lesser vote than <span style="white-space:nowrap">two-thirds</span> but not less than a majority of the shares entitled to vote on the matter. The Massachusetts Articles provide that a merger, consolidation, or sale of substantially all of the assets of the corporation may be approved by a majority of all of the shares entitled to vote on the matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, a company may merge with another company (wherever incorporated, provided that such merger is not prohibited by the laws of the jurisdiction of incorporation of that company) pursuant to the Companies Act. A merger under Cayman Islands law requires the approval by a special resolution, which in the context of a general meeting of the Cayman Company requires (i)&#160;not less than a <span style="white-space:nowrap">two-thirds</span> majority of the votes cast by such shareholders attending and voting in person or, where proxies are allowed, by proxy at a quorate general meeting of the Cayman Company and where a poll is taken, regard shall be had in computing a majority to the number of votes to which each shareholder is entitled or (ii)&#160;the written resolution of all shareholders entitled to vote at such general meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No shareholder resolution is required for a merger between a parent company (i.e., a company that holds issued shares that together represent 90% of the votes at a general meeting of the subsidiary company) and its subsidiary company, provided the parent company is the surviving entity and a copy of the plan of merger (including the memorandum and articles of association of the company) is given to every member of each subsidiary company to be merged unless that member agrees otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, a Cayman Islands exempted company may be acquired through a tender offer by a third party. Where the holders of 90% or more in value of a class of the Cayman Company&#8217;s shares (excluding any shares already beneficially owned by the offeror) have within four months of the making of an offer accepted an offer for their shares in the Cayman Company, the remaining shareholders in that class may be statutorily required to also transfer their shares by notice given at any time within two months of the expiry of the four month period, unless, within one month, the <span style="white-space:nowrap">non-tendering</span> shareholders can obtain a Cayman court order otherwise providing. If the offeror has acquired acceptances of 90% of all the Cayman Company&#8217;s shares but does not exercise its &#8220;squeeze out&#8221; right, then the <span style="white-space:nowrap">non-accepting</span> shareholders have no statutory right to require the offeror to acquire their shares on the same terms as the original offer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Cayman Islands exempted company may also be acquired by way of a Cayman Islands court-approved scheme of arrangement under the Companies Act. A scheme of arrangement is a compromise or arrangement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">256 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which may be entered into between a company and one or more classes of shareholders requires. In order to become binding and effective in accordance with its terms, the scheme of arrangement requires the approval of shareholders representing 75% or more by value of the shares of each class comprised in the scheme, in each case at the relevant meeting or meetings, and an order of the Grand Court of the Cayman Islands sanctioning the scheme of arrangement. A scheme of arrangement, if approved by the requisite statutory majorities and sanctioned by the Grand Court of the Cayman Islands, is binding on all of the shareholders of each class, including any dissenting shareholders. There is currently no cross class cramdown available under Cayman Islands law. Shares held by the acquiring party are likely to be considered to belong to a separate class for the purposes of approving the scheme. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Appraisal or Dissenter&#8217;s Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, shareholders have appraisal rights in the event of certain corporate actions such as a merger, share exchange or action that materially and adversely affects the rights of a shareholder. If a proposed corporate action requiring appraisal rights is submitted to vote at a shareholder meeting, a shareholder who wishes to assert appraisal rights must: (1)&#160;deliver to the corporation, before the vote is taken, written notice of intent to demand payment for shares if the proposed action is effected; and (2)&#160;not vote any shares in favor of the proposed action. The corporation is required to pay fair value to a shareholder exercising appraisal rights for the shares held by such shareholder. If fair value is unsettled, the MBCA provides for resolution of fair value in a single equitable proceeding in a court in the county in Massachusetts where the corporation&#8217;s principal office or registered office is located. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, under Cayman Islands law, shareholders of a Cayman Islands exempted company do not have statutory appraisal rights; provided that in the event of a statutory merger under the Companies Act a shareholder shall be entitled to receive the fair value of their shares upon dissenting from such merger. Rights of a dissenting shareholder are not available in certain circumstances, for example, to dissenters holding shares of any class in respect of which an open market exists on a recognized stock exchange or recognized interdealer quotation system at the relevant date and where the consideration for such shares to be contributed are shares of any company listed on a national securities exchange or shares of the surviving or consolidated company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mechanics and timing procedures vary somewhat between Massachusetts and the Cayman Islands, but both require technical compliance with specific notice and payment protocols. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special Meetings of Shareholders and General Meetings of Shareholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA permits special meetings of shareholders to be called by the board of directors or by any other person authorized in the certificate of incorporation or bylaws to call a special shareholder meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, there is no statutory right for shareholders to call a general meeting where the articles of association provide for the calling of meetings. Where the articles of association provide for calling of meetings, the ability to convene such a meeting will be governed by the company&#8217;s articles of association. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Meetings Pursuant to Petition of Shareholders and Shareholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA provides that a shareholder of a corporation may apply to superior court of the county where a corporation&#8217;s principal office or, if none, in the Commonwealth of Massachusetts, its registered office is located if an annual meeting was not held within the earlier of six months after the end of the corporation&#8217;s fiscal year or 15 months after its last annual meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, there is no statutory provision allowing shareholders to petition a court to compel a general meeting and Cayman Islands exempted companies are not required to hold annual general meetings, unless otherwise set out expressly in the articles of association of a Cayman Islands exempted company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">257 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adjournment of Shareholder and Shareholder Meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, if a meeting of shareholders is adjourned due to lack of a quorum and the adjournment is for more than 120 days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting must be given to each shareholder of record entitled to vote at the meeting. At the adjourned meeting the corporation may transact any business that might have been transacted at the original meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, the adjournment of shareholder meetings is not regulated by statute and is instead governed by a Cayman Islands exempted company&#8217;s articles of association. Typically, a Cayman Islands exempted company&#8217;s articles provide that if a meeting is not quorate, it may be adjourned to a later date without requiring new notice. There is no statutory requirement to provide notice of an adjourned meeting unless otherwise set out expressly in the articles of association of a Cayman Islands exempted company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Duration of Proxies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MBCA, a proxy executed by a shareholder will remain valid for a period of eleven months, unless the proxy provides for a longer period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, there is no statutory equivalent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Quorum and Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA provides that the certificate of incorporation and bylaws may establish quorum and voting requirements. If the certificate of incorporation and bylaws are silent as to specific quorum and voting requirements: (a)&#160;a majority of the votes entitled to be cast on a matter constitutes a quorum for action on a matter; (b)&#160;favorable action on a matter, other than the election of directors, is taken by a voting group if the votes cast within the group favoring the action exceed the votes cast opposing the action; (c)&#160;directors are elected by a plurality of the votes cast by the shares entitled to vote in the election at a meeting at which a quorum is present.; and (d)&#160;where a separate vote by a class or series is required, majority of the votes entitled to be cast on the matter by the voting group constitutes a quorum of that voting group for action on that matter and, favorable action on a matter, other than the election of directors, is taken by a voting group if the votes cast within the group favoring the action exceed the votes cast opposing the action. A bylaw dealing with quorum or voting requirements for shareholders, including additional voting groups, may not be adopted, amended, or repealed by the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, quorum requirements are not regulated by statute and are instead governed by a Cayman Islands exempted company&#8217;s articles of association. Business may only be transacted at a meeting of shareholders of a Cayman Islands exempted company if a quorum is present. The Cayman Articles provide that the holders of record of <span style="white-space:nowrap">one-third</span> of the issued and outstanding shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at any meeting of shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shareholder and Shareholder Inspection Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MBCA provides that upon five days written notice a shareholder of a corporation is entitled to inspect and copy, during regular business hours at the office where they are maintained, copies of any of the following records of the corporation: (1)&#160;articles of organization and bylaws, (2)&#160;resolutions adopted by the board of directors creating one or more classes or series of shares and fixing their rights and preferences, (3)&#160;minutes and written consents of all shareholders&#8217; meetings for the past three years, (4)&#160;all written communications to shareholders generally within the past three years, including financial statements furnished, (5)&#160;a list of the names and business addresses of the corporation&#8217;s current directors and officers, and (6)&#160;the corporation&#8217;s most recent annual report delivered to the secretary of state. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">258 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, shareholders generally do not have any rights to inspect or obtain copies of the register of shareholders or other corporate records of a company, though directors may from time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of a Cayman Islands exempted company or any of them will be open to the inspection of shareholders not being directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What Doesn&#8217;t Change After Cayman Redomestication? </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from being governed by the Cayman Articles, the Companies Act, and the common law of the Cayman Islands, following completion of the Cayman Redomestication, the Combined Company will continue to exist in the form of a Cayman exempt company and will continue to be treated as a U.S. corporation for all purposes under the Code. By virtue of the Cayman Redomestication, all of the rights, privileges and powers of the Massachusetts Corporation, and all property, real, personal, and mixed, and all debts due to the Massachusetts Corporation, as well as all other things and causes of action belonging to the Massachusetts Corporation, will remain vested in the Cayman Company and will be the property of the Cayman Company. In addition, all debts, liabilities, and duties of the Massachusetts Corporation will remain attached to the Cayman Company and may be enforced against the Cayman Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Change in the Business </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Redomestication will not result in any change in the Combined Company&#8217;s business, management, obligations, assets, or liabilities (other than as a result of the transaction costs related to the Cayman Redomestication). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company&#8217;s management, including all directors and officers, will remain the same in connection with the Cayman Redomestication and will have the same positions with the Cayman Company. To the extent that the Cayman Redomestication will require the consent or waiver of a third party, the Combined Company will use commercially reasonable effects to obtain such consent or waiver before completing the Cayman Redomestication. Cyclerion and Korsana do not expect that any such required consent will impede the Combined Company&#8217;s ability to redomesticate to the Cayman Islands. The Cayman Redomestication will not otherwise adversely affect any of the Combined Company&#8217;s material contracts with any third parties, and the Combined Company&#8217;s rights and obligations under such material contractual arrangements will continue as rights and obligations of the Cayman Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Stock Exchange Listing or Securities Act Consequences </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company will continue to be a publicly held company following completion of the Cayman Redomestication, and the Cayman Shares will continue to be listed on Nasdaq and traded under the symbol &#8220;KRSA&#8221;. We expect that the Cayman Shares will trade under a new CUSIP. The Combined Company will continue to file required periodic reports and other documents with the SEC. Except as related to the implementation of a new CUSIP, there is not expected to be any interruption in the trading of the Cayman Shares as a result of the Cayman Redomestication. The Combined Company and its shareholders will be in the same respective positions under the federal securities laws after the Cayman Redomestication as the Combined Company and its shareholders were prior to the Cayman Redomestication. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Material Accounting Implications </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effecting the Cayman Redomestication will not have any material accounting implications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Exchange of Stock Certificates Required </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders will not be required to exchange their existing stock certificates (if any) for new share certificates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">259 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Federal Income Tax Considerations of the Cayman Redomestication </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of the Combined Company common stock and the Combined Company convertible preferred stock (the &#8220;Combined Company stock&#8221;) of the Cayman Redomestication, and, subject to the limitations, qualifications, and assumptions described herein and in the opinion filed as Exhibit 8.1 hereto, insofar as it describes matters of federal income tax law or conclusions with respect thereto, constitutes the opinion of Gibson, legal counsel to Korsana. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <span style="white-space:nowrap">non-U.S.</span> tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. The Combined Company has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the Cayman Redomestication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to a U.S. Holder that holds the Combined Company stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including without limitation the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&#160;451(b) of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. expatriates and former citizens or long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. Holders whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding the Combined Company stock as part of a hedge, straddle, or other risk-reduction strategy or as part of a conversion transaction or other integrated investment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks, insurance companies, and other financial institutions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts or regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">brokers, dealers or traders in securities or other persons that elect to use a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting for their holdings in the Combined Company stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations or governmental organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons deemed to sell the Combined Company stock under the constructive sale provisions of the Code; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who hold or receive the Combined Company stock pursuant to the exercise of any employee stock option or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-qualified</span> retirement plans; and </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">persons that own, or have owned, actually or constructively, more than 5% of the Combined Company stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds the Combined Company stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Combined Company stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the Cayman Redomestication<span style="font-weight:bold">.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">260 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of the Combined Company stock that, for U.S. federal income tax purposes, is or is treated as any of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the Cayman Redomestication arising under U.S. federal estate or gift tax laws, the laws of any state, local or <span style="white-space:nowrap">non-U.S.</span> taxing jurisdiction or any applicable income tax treaty</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Tax Status of the Cayman Company after the Cayman Redomestication </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;7874 of the Code, the Combined Company after the Cayman Redomestication is and will continue to be treated as a U.S. corporation for all purposes under the Code. As such, the Combined Company after the Cayman Redomestication is subject to U.S. federal income tax on the Combined Company&#8217;s worldwide taxable income (regardless of whether such income is &#8220;U.S. source&#8221; or &#8220;foreign source&#8221;) and is required to file a U.S. federal income tax return annually with the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Cayman Redomestication </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this registration statement, Gibson, legal counsel to Korsana, will deliver an opinion that, subject to the limitations, qualifications, and assumptions described herein and in the opinion filed as Exhibit 8.1 hereto, the Cayman Redomestication will qualify as a &#8220;reorganization&#8221; for U.S. federal income tax purposes pursuant to Section&#160;368(a)(1)(F) of the Code. As a result, a U.S. Holder will not recognize gain or loss upon the proposed Cayman Redomestication. A U.S. Holder will have the same aggregate basis in its Combined Company stock after the Cayman Redomestication as such U.S. Holder had in the corresponding Combined Company stock immediately prior to the Cayman Redomestication. A U.S. Holder&#8217;s holding period in the Combined Company stock immediately following the Cayman Redomestication will include such U.S. Holder&#8217;s holding period in the corresponding the Combined Company stock immediately prior to the Cayman Redomestication. Each U.S. Holder of shares of the Combined Company stock acquired on different dates and at different prices is urged to consult its tax advisor regarding the allocation of the tax basis and holding period of such shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tax Reporting Regarding the Cayman Redomestication </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each U.S. Holder that receives shares of the Combined Company stock in the Cayman Redomestication is required to retain permanent records pertaining to the Cayman Redomestication and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. Holder who owned at least five percent (by vote or value) of the total outstanding stock of the Combined Company stock or who owned securities in the Combined Company stock with a basis of $1,000,000 or more is required to attach a statement to their tax returns for the year in which the Cayman Redomestication is consummated that contains the information listed in Treasury Regulations <span style="white-space:nowrap">Section&#160;1.368-3(b).</span> Such statement must include the U.S. Holder&#8217;s tax basis in the holder&#8217;s Combined Company stock and the fair market value of such stock. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">261 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">This discussion of U.S. federal income tax considerations of the Cayman Redomestication is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax considerations of the Cayman Redomestication to a holder may be complex and will depend on such holder&#8217;s specific situation and on factors that are not within Cyclerion&#8217;s knowledge or control. Each holder is urged to consult its tax advisor with respect to the application of U.S. federal income tax laws to its specific situation as well as any tax considerations arising under the U.S. federal estate or gift tax rules or under the laws of any state, local, <span style="white-space:nowrap">non-U.S.,</span> or other taxing jurisdiction</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulatory Matters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consummation of the Cayman Redomestication does not require any Cayman Islands regulatory approval but certain documents will be required to be filed with the Cayman Islands Registrar of Companies including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A director&#8217;s undertaking confirming that the Cayman Company is able to pay its debts as they become due in the ordinary course of business together with a statement of the Cayman Company&#8217;s assets and liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A sworn affidavit from a director stating that the Cayman Company is not in liquidation, subject to insolvency proceedings, or in the process of being wound up in any jurisdiction together with certain other declarations required under the Companies Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A certificate good standing provided by the Secretary of the Commonwealth of Massachusetts immediately prior to the Cayman Redomestication in together with the charter documents of the Massachusetts Corporation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A formal notice of continuation to be filed with the Cayman Islands Registrar of Companies, notifying it of the Cayman Company&#8217;s intent to continue as a Cayman Islands exempted company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A directors&#8217; resolution resolving to change the domicile of the Massachusetts Corporation from Massachusetts to the Cayman Islands. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the above requirements are satisfied, the Cayman Islands Registrar of Companies will issue a Certificate of Continuation, which serves as evidence that the Cayman Company has been duly registered in the Cayman Islands and migrated out of Massachusetts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consummation of the Cayman Redomestication requires the filing of the Plan of Domestication with Secretary of the Commonwealth of Massachusetts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No other regulatory or governmental approvals or consents will be required in connection with the Cayman Redomestication. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Appraisal Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our Massachusetts Corporation Common Stock are not entitled to appraisal rights with respect to the Cayman Redomestication described in this proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legal Proceedings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Cyclerion may become subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of the date of this proxy statement/prospectus, Cyclerion is not currently a party to any claim or litigation, the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on Cyclerion because of defense and settlement costs, diversion of management resources and other factors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">262 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Enforcement of Civil Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cayman Islands has a different body of securities laws as compared to the United States and may provide less protection to investors. Additionally, Cayman Islands companies may not have standing to sue before the Federal courts of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is uncertainty as to whether the courts of the Cayman Islands will recognize and enforce against the us, our directors and/or executive officers in the United States judgments obtained in the United States courts predicated upon the civil liability provisions of the securities laws of the United States.&#160;The courts of the Cayman Islands may be unlikely (i)&#160;to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state; and (ii)&#160;in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States (and the Cayman Islands are not a party to any treaties for the reciprocal enforcement or recognition of such judgments with the United States), the courts of the Cayman Islands may, by an action commenced on the judgment obtained in the United States in the courts of the Cayman Islands, recognize and enforce, without retrial of the merits at common law, a foreign money judgment of a foreign court of competent jurisdiction provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, the court must have had proper jurisdiction over the parties subject to such judgment as a matter of Cayman Islands conflict of law rules, and such judgment must be: final and conclusive and for a liquidated sum, and must not be in respect of multiple damages, taxes or a fine or penalty, or other charges of a like nature, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy), no new admissible evidence relevant to the action is submitted prior to the rendering of the judgment by the courts of the Cayman Islands; and there is due compliance with the correct procedures under the laws of the Cayman Islands. A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interest of Certain Persons </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s board of directors believes that the corporate laws of the Commonwealth of Massachusetts and the Cayman Islands are substantially comparable as to the rights of shareholders, at least on balance of the relevant considerations against one another and as relevant to the Combined Company. As part of its process, Cyclerion&#8217;s board of directors considered if domestication to the Cayman Islands would convey any <span style="white-space:nowrap">non-ratable</span> benefits on any of the Combined Company&#8217;s directors or officers and did not identify any such <span style="white-space:nowrap">non-ratable</span> benefits. However, others may allege, and shareholders should be aware in voting on the Redomestication Proposal and the Cayman Redomestication Resolutions, that the Combined Company&#8217;s directors and executive officers may be considered to have interests in the Cayman Redomestication that are different from, or in addition to, the interests of the shareholders generally to the extent that it might afford them greater limitations on liability under the common law of the Cayman Islands for acts in their capacities as directors or officers occurring after the Cayman Redomestication. Cyclerion&#8217;s board of directors has considered these potential interests, among other matters, in reaching the decision to approve the Cayman Redomestication and to recommend that Cyclerion&#8217;s shareholders vote in favor of this proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposal No. 4A: To approve the domestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by domestication pursuant to the MBCA and adopt the Cayman Redomestication Resolutions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Cayman Redomestication and the adoption of the Cayman Redomestication. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">263 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposal No. 4B: To resolve as a special resolution that: (i)&#160;the domestication of Cyclerion from the Commonwealth of Massachusetts to the Cayman Islands by way of continuation pursuant to the Companies Act and the Cayman Redomestication Resolutions be approved; and (ii)&#160;with effect from the registration of Cyclerion in the Cayman Islands, the memorandum of association and articles of association in the form presented to the Cyclerion Annual Meeting (with such further consequential amendments as may be deemed necessary by the Cyclerion Board) be and are adopted as the memorandum of association and articles of association of the Cayman Company with the name of the company as set out therein. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of Proposal No. 4B. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Cyclerion shareholders have agreed to vote any shares of Cyclerion Common Stock owned by them in favor of the Redomestication Proposal. See &#8220;<span style="font-style:italic">Agreements Related to the Merger &#8212; Support Agreements</span>&#8221; beginning on page 188 of this proxy statement/prospectus for more information. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; EACH OF PROPOSALS NOS. 4A AND 4B AND THE ADOPTION OF THE CAYMAN REDOMESTICATION RESOLUTIONS. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">264 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_21">PROPOSAL NO. 5&#8201;-&#8201;THE DIRECTOR ELECTION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s Bylaws provide that the Cyclerion Board shall consist of no less than three directors (except when there are fewer than three shareholders), and that the number of directors may be increased or decreased at any time by a vote of a majority of the directors then in office. The Cyclerion Board currently consists of six directors, all of whose current terms will expire at the Cyclerion Shareholders Meeting. The following individuals are being nominated to serve on the Cyclerion Board: Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D., and Dina Katabi, Ph.D. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For information about each of the nominees and the Cyclerion Board generally, please see &#8220;Cyclerion Directors, Officers and Corporate Governance&#8221; elsewhere in this registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If elected, the nominees will hold office until the next Annual Meeting and until a respective successor is elected and has been qualified, or until such director resigns or is removed from office. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion shareholders should understand, however, that if the Merger is consummated, the approval of the director nominees named in the Director Election Proposal will only have an effect until the completion of the Merger because the composition of the Cyclerion Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. Following the Merger, the Combined Company&#8217;s board of directors will consist of six members designated by Korsana, including Andrew Gottesdiener,&#8195;&#8195;&#8195;&#8195;, Tomas Kiselak, Michelle Pernice, Nimish Shah, and Dr.&#160;Jonathan Violin. All of Cyclerion&#8217;s current directors are expected to resign from their positions as directors of Cyclerion, effective by the closing of the Merger. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is <span style="font-weight:bold">not</span> conditioned upon the election of the director nominees named in the Director Election Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the election of the director nominees named in the Director Election Proposal. However, if the nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as the Cyclerion Board may designate. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE DIRECTOR NOMINEES NAMED IN THE DIRECTOR ELECTION PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">265 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_22">PROPOSAL NO. 6&#8201;-&#8201;THE AUDITOR RATIFICATION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cyclerion Shareholders Meeting, Cyclerion will ask its shareholders to ratify the appointment by the audit committee of the Cyclerion Board (the &#8220;Cyclerion audit committee&#8221;) of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2026. Ernst&#160;&amp; Young LLP has served as Cyclerion&#8217;s independent registered public accounting firm since 2019. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Cyclerion&#8217;s Bylaws nor other governing documents or law require shareholder ratification of the selection of Ernst&#160;&amp; Young LLP as Cyclerion&#8217;s independent registered public accounting firm. However, the Cyclerion audit committee has requested the Cyclerion Board submit the selection of Ernst&#160;&amp; Young LLP to the shareholders for ratification as a matter of good corporate practice. If the shareholders fail to ratify the selection, the Cyclerion audit committee of the will reconsider whether or not to retain that firm. Even if the selection is ratified, the Cyclerion audit committee in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best interests of Cyclerion and its shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A representative of Ernst&#160;&amp; Young LLP is expected to be present at the Cyclerion Shareholders Meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from Cyclerion shareholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Principal Accountant Fees and Services </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents aggregate fees billed to Cyclerion for the fiscal years ended December&#160;31, 2025 and 2024 by Ernst&#160;&amp; Young LLP, Cyclerion&#8217;s principal accountant. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">FISCAL YEAR ENDED<br/>DECEMBER&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">385,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">385,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">70,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">455,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">400,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit fees were for professional services rendered for the audit of Cyclerion&#8217;s annual financial statements and reviews of interim financial statements included in Cyclerion&#8217;s quarterly reports on Form <span style="white-space:nowrap">10-Q,</span> including accounting consultations, as well as for services that are normally provided in connection with regulatory filings or engagements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the services of Ernst&#160;&amp; Young LLP for the years ended December&#160;31, 2025 and 2024 described above were <span style="white-space:nowrap">pre-approved</span> by the Cyclerion audit committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee <span style="white-space:nowrap">Pre-Approval</span> Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion audit committee has adopted a policy for the <span style="white-space:nowrap">pre-approval</span> of audit and <span style="white-space:nowrap">non-audit</span> services rendered by Cyclerion&#8217;s independent registered public accounting firm, Ernst&#160;&amp; Young LLP. The policy generally <span style="white-space:nowrap">pre-approves</span> specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. <span style="white-space:nowrap">Pre-approval</span> may also be given as part of the Cyclerion audit committee&#8217;s approval of the scope of the engagement of the independent auditor or on an individual, explicit, <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis before the independent auditor is engaged to provide each service. The <span style="white-space:nowrap">pre-approval</span> of services may be delegated to one or more of the Cyclerion audit committee&#8217;s members, but the decision must be reported to the full Cyclerion audit committee at its next scheduled meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion audit committee has determined that the rendering of services other than audit services by Ernst&#160;&amp; Young&#160;LLP is compatible with maintaining the principal accountant&#8217;s independence. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">266 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee Report </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion audit committee has reviewed and discussed the audited financial statements for the fiscal year ended December&#160;31, 2025 with management of Cyclerion and Ernst&#160;&amp; Young LLP, Cyclerion&#8217;s independent registered public accounting firm. The Cyclerion audit committee has also received from, and discussed with, Cyclerion&#8217;s independent registered public accounting firm the written disclosures and other communications that Cyclerion&#8217;s independent registered public accounting firm is required to provide to the Cyclerion audit committee, including, the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) and the SEC. The Cyclerion audit committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants&#8217; communications with the Cyclerion audit committee concerning independence and has discussed with the independent registered public accounting firm the accounting firm&#8217;s independence. Based on the foregoing, the Cyclerion audit committee has recommended to the Cyclerion Board that the audited financial statements be included in Cyclerion&#8217;s Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> for the fiscal year ended December&#160;31, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By the Audit Committee of the Board of Directors of Cyclerion Therapeutics, Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael J. Higgins, Chair </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Errol B. De Souza, Ph.D. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steven E. Hyman, M.D. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is <span style="font-weight:bold">not</span> conditioned upon the approval of the Auditor Ratification Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Auditor Ratification Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUDITOR RATIFICATION PROPOSAL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material in this report is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference in any filing of Cyclerion under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">267 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_23">PROPOSAL NO. 7&#8201;-&#8201;THE STOCK PLAN PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cyclerion Shareholders Meeting, Cyclerion will ask its shareholders to approve the Korsana Biosciences, Inc. 2026 Stock Incentive Plan (the &#8220;2026 Stock Plan&#8221;) to be effective on the closing date of the Merger. The 2026 Stock Plan was approved by the Cyclerion Board on&#8195;&#8195;&#8195;&#8195;, 2026, subject to stockholder approval and the consummation of the Merger. If the 2026 Stock Plan is approved by stockholders and the Merger is consummated, no further awards will be granted under Cyclerion&#8217;s 2019 Equity Incentive Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the 2026 Stock Plan is to promote and closely align the interests of employees, officers, <span style="white-space:nowrap">non-employee</span> directors and other individual service providers of the Combined Company and its stockholders by providing stock-based compensation and other performance-based compensation. The objectives of the 2026 Stock Plan are to attract and retain the best available employees, officers, <span style="white-space:nowrap">non-employee</span> directors and other individual service providers for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the Combined Company through incentives that are consistent with the Combined Company&#8217;s goals and that link the personal interests of participants to those of the Combined Company&#8217;s stockholders. The 2026 Stock Plan allows for the grant of stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), other stock-based awards and incentive bonuses (collectively, &#8220;Awards&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of the 2026 Stock Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of the 2026 Stock Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2026 Stock Plan, a copy of which is attached as <span style="font-style:italic">Annex P </span>to this proxy statement/prospectus. Stockholders are urged to read the 2026 Stock Plan in its entirety. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2026 Stock Plan will be administered by the compensation committee of the Combined Company board of directors, or another committee designated by the Combined Company board of directors to administer the 2026 Stock Plan, which is referred to herein as the &#8220;Administrator.&#8221; The Administrator will have broad authority, subject to the provisions of the 2026 Stock Plan, to administer and interpret the 2026 Stock Plan and Awards granted thereunder. All decisions and actions of the Administrator will be final. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Subject to 2026 Stock Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial share pool under the 2026 Stock Plan will be&#8195;&#8195;&#8195;&#8195;% of the total number of shares of outstanding capital stock immediately following the consummation of the Merger (including Combined Company common stock, preferred stock and unexercised <span style="white-space:nowrap">pre-funded</span> warrants), subject to certain adjustments in the event of a change in the Combined Company&#8217;s capitalization. The shares that may be issued under the 2026 Stock Plan will be automatically increased on January&#160;1 of each year beginning in 2027 and ending with a final increase on January&#160;1, 2036 in an amount equal to&#8195;&#8195;&#8195;&#8195;% of the diluted stock (including Combined Company common stock, preferred stock and unexercised <span style="white-space:nowrap">pre-funded</span> warrants) on the preceding December&#160;31, unless a lower, or no, increase is determined by the Administrator. Only&#8195;&#8195;&#8195;&#8195;shares of Combined Company common stock may be issued under the 2026 Stock Plan as incentive stock options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Combined Company common stock issued under the 2026 Stock Plan may be either authorized and unissued shares or previously issued shares acquired by the Combined Company. On termination or expiration of an Award under the 2026 Stock Plan, in whole or in part, the number of shares of Combined Company common stock subject to such Award but not issued thereunder or that are otherwise forfeited back to the Combined Company will again become available for grant under the 2026 Stock Plan. Additionally, shares retained or withheld in payment of any exercise price, purchase price, or tax withholding obligation of an Award will again become available for grant under the 2026 Stock Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">268 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&#8195;&#8195;&#8195;&#8195;, 2026, the closing price of a share of Cyclerion Common Stock was $&#8195;&#8195;&#8195;&#8195;per share, as reported on Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current or prospective employees, officers, <span style="white-space:nowrap">non-employee</span> directors, and other independent service providers of the Combined Company and its subsidiaries will be eligible to participate in the 2026 Stock Plan, if selected by the Administrator. Following the Merger, it is expected that approximately employees (including&#8195;&#8195;&#8195;&#8195;executive <span style="white-space:nowrap">officers),&#8195;&#8195;&#8195;&#8195;non-employee</span> directors and&#8195;&#8195;&#8195;&#8195;other individual service providers of the Combined Company will be eligible to participate in the 2026 Stock Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate dollar value of equity-based (based on the grant date fair market value of equity-based Awards) and cash compensation granted under the 2026 Stock Plan or otherwise to any <span style="white-space:nowrap">non-employee</span> director for service on the board may not exceed $&#8195;&#8195;&#8195;&#8195;during any full calendar year following the effective date; provided, however, that in the calendar year in which a <span style="white-space:nowrap">non-employee</span> director first joins the board or during any calendar year in which a <span style="white-space:nowrap">non-employee</span> director is designated as Chairman of the Board or Lead Director, the maximum aggregate dollar value of equity-based and cash compensation granted to the <span style="white-space:nowrap">non-employee</span> director may be up to $&#8195;&#8195;&#8195;&#8195;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Types of Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Stock Options</span>. All stock options granted under the 2026 Stock Plan will be evidenced by a written agreement with the participant, which provides, among other things, whether the option is intended to be an incentive stock option or a <span style="white-space:nowrap">non-qualified</span> stock option, the number of shares subject to the option, the exercise price, exercisability (or vesting), the term of the option, which may not generally exceed ten years, and other terms and conditions. Subject to the express provisions of the 2026 Stock Plan, options generally may be exercised over such period, in installments or otherwise, as the Administrator may determine. The exercise price for any stock option granted may not generally be less than the fair market value of the Combined Company common stock subject to that option on the grant date. The exercise price may be paid in cash or such other method as determined by the Administrator, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares issuable under an option, the delivery of previously owned shares, or withholding of shares deliverable upon exercise. The 2026 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price of a previously awarded option or cancel and <span style="white-space:nowrap">re-grant</span> or exchange such option for cash or a new Award with a lower (or no) exercise price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Stock Appreciation Rights</span>. SARs may be granted alone or in conjunction with all or part of a stock option. Upon exercising a SAR, the participant is entitled to receive the amount by which the fair market value of the Combined Company common stock at the time of exercise exceeds the exercise price of the SAR. This amount is payable in Combined Company common stock, cash, restricted stock, or a combination thereof, at the Administrator&#8217;s discretion. The 2026 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price of a previously awarded SAR or cancel and <span style="white-space:nowrap">re-grant</span> or exchange such SAR for cash or a new Award with a lower (or no) exercise price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Restricted Stock and RSUs</span>. Awards of restricted stock consist of shares of stock that are transferred to the participant subject to restrictions that may result in forfeiture if specified conditions are not satisfied. RSUs result in the transfer of shares of cash or stock to the participant only after specified conditions are satisfied. The Administrator will determine the restrictions and conditions applicable to each award of restricted stock or RSUs, which may include performance vesting conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Other Stock-Based Awards</span>. Other stock-based awards are Awards denominated in or payable in, valued in whole or in part by reference to, or otherwise based on or related to, the value of Combined Company common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">269 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Incentive Bonuses</span>. Each incentive bonus will confer upon the participant the opportunity to earn a payment, which may be subject to vesting or performance criteria established by the Administrator. Payment of the amount due under an incentive bonus may be made in cash or shares, as determined by the Administrator. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Performance Criteria </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may specify certain performance criteria which must be satisfied before Awards will be granted or will vest. The performance goals may vary from participant to participant, group to group, and period to period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards generally may not be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated by a participant other than by will or the laws of descent and distribution, and each option or SAR may be exercisable only by the participant during his or her lifetime. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clawback </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards will be subject to recoupment in accordance with any clawback policy adopted by the Combined Company (or any successor or other clawback policy adopted by the Combined Company). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adjustments Upon a Change in Capitalization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change in capitalization of the Combined Company, including any reorganization, reclassification, combination of shares, stock split, reverse stock split, <span style="white-space:nowrap">spin-off,</span> dividend or distribution (other than quarterly cash dividends), the share pool and outstanding Awards will be equitably adjusted by the Administrator. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change in control of the Combined Company, the Administrator may (i)&#160;provide for the assumption of outstanding Awards, (ii)&#160;issue substitute awards, (iii)&#160;accelerate vesting or waive any forfeiture conditions, (iv)&#160;accelerate the exercisability of the award, (v)&#160;make any other adjustments to outstanding Awards as deemed to be appropriate or (vi)&#160;provide for the cancellation and <span style="white-space:nowrap">cash-out</span> of outstanding Awards; however, if Awards are not assumed, continued or substituted for, then all outstanding Awards will become fully vested and exercisable (with performance based on target or actual achievement as determined by the Administrator). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment and Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company board of directors will have the right to amend, alter, suspend, or terminate the 2026 Stock Plan at any time, provided certain enumerated material amendments may not be made without stockholder approval. No amendment or alteration to the 2026 Stock Plan or an Award or Award agreement will be made that would materially impair the rights of the holder, without such holder&#8217;s consent; however, no consent will be required if the Administrator determines in its sole discretion and prior to the date of any change in control that such amendment or alteration either is required or advisable in order for the Combined Company, the 2026 Stock Plan, or such Award to satisfy any law or regulation or to meet the requirements of or avoid adverse financial accounting consequences under any accounting standard, or is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately compensated. The 2026 Stock Plan will automatically terminate as to the grant of future awards, unless earlier terminated by the Combined Company board of directors, on&#8195;&#8195;&#8195;&#8195;, 2036. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">270 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Federal Income Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the U.S. federal income tax treatment applicable to the Combined Company and the participants who receive Awards under the 2026 Stock Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary expressly does not discuss the income tax laws of any state, municipality, or <span style="white-space:nowrap">non-U.S.</span> taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S. federal income tax law. Because individual circumstances may vary, each participant is urged to consult their tax advisor concerning the tax implications of Awards granted under the 2026 Stock Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Incentive Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under the 2026 Stock Plan may be either incentive stock options, which are intended to satisfy the requirements of Section&#160;422 of the Code, or <span style="white-space:nowrap">non-qualified</span> stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the optionee will recognize long-term capital gain in an amount equal to the excess of (i)&#160;the amount realized upon the sale or other disposition of the purchased shares over (ii)&#160;the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two years after the date of grant or less than one year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii)&#160;the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the optionee makes a disqualifying disposition of the purchased shares, then the Combined Company (or, if applicable, the affiliate employer) will be entitled to an income tax deduction for the taxable year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The Combined Company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nonqualified Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No taxable income is recognized by an optionee upon the grant of a <span style="white-space:nowrap">non-qualified</span> stock option. The optionee in general will recognize ordinary income, in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The Combined Company (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised <span style="white-space:nowrap">non-qualified</span> stock option. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No taxable income is recognized upon receipt of a SAR. The participant will recognize ordinary income in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares on the exercise date over the base price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The Combined Company (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the SAR. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">271 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant who receives unvested shares of Combined Company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when the restrictions constituting a substantial risk of forfeiture lapse, an amount equal to the excess of (i)&#160;the fair market value of the shares on the vesting date over (ii)&#160;the amount paid (if any) for the shares. The participant may, however, elect under Section&#160;83(b) of the Code to include as ordinary income in the year the unvested shares are issued an amount equal to the excess of (a)&#160;the fair market value of those shares on the issue date over (b)&#160;the amount paid (if any) for such shares. If the Section&#160;83(b) election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The Combined Company (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Units, Other Stock-Based Awards, Incentive Bonuses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, no taxable income is recognized upon the grant of RSUs, other stock-based awards or incentive bonuses. The participant will recognize ordinary income in the year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The Combined Company (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Deductibility of Executive Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;162(m) of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1.0&#160;million. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2026 Stock Plan will be subject to the $1.0&#160;million annual deduction limitation. The Administrator of the 2026 Stock Plan may grant Awards under the 2026 Stock Plan that are or may become <span style="white-space:nowrap">non-deductible</span> when it believes doing so is in the best interests of the Combined Company and its stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Plan Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible participants under the 2026 Stock Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the Administrator. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is <span style="font-weight:bold">not</span><span style="font-weight:bold"> </span>conditioned upon the approval of the Stock Plan Proposal. However, the Stock Plan Proposal is conditioned on the consummation of the Merger. Notwithstanding the approval of the Stock Plan Proposal, if the Merger is not completed, the actions contemplated by the Stock Plan Proposal will not be effected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the Stock Plan Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">272 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_24">PROPOSAL NO. 8&#8201;-&#8201;THE ESPP PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cyclerion Shareholders Meeting, Cyclerion will ask its shareholders to approve the Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan (the &#8220;2026 ESPP&#8221;) to be effective on the closing date of the Merger. The 2026 ESPP was approved by the Cyclerion Board on&#8195;&#8195;&#8195;&#8195;, 2026, subject to stockholder approval and the consummation of the Merger. If the 2026 ESPP is approved by stockholders and the Merger is consummated, Cyclerion&#8217;s 2019 Employee Share Purchase Plan will be terminated and no further shares will be issued thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the 2026 ESPP is to provide employees of the Combined Company and its designated subsidiaries with an opportunity to purchase shares of the Combined Company common stock through accumulated contributions. The 2026 ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, <span style="white-space:nowrap">sub-plans</span> that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of <span style="white-space:nowrap">non-U.S.</span> subsidiaries of the Combined Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of the ESPP </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of the 2026 ESPP is not intended to be complete and is qualified in its entirety by the complete text of the 2026 ESPP, a copy of which is attached as <span style="font-style:italic">Annex Q </span>to this proxy statement/prospectus. Stockholders are urged to read the 2026 ESPP in its entirety. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2026 ESPP will be administered by the compensation committee of the Combined Company board of directors or another committee designated by the Combined Company board of directors to administer, which is referred to herein as the &#8220;ESPP Administrator.&#8221; All questions of interpretation of the 2026 ESPP are determined by the ESPP Administrator, whose decisions are final and binding upon all participants. The ESPP Administrator may delegate, subject to applicable law, its responsibilities under the 2026 ESPP to one or more other persons. The ESPP Administrator may adopt rules or procedures relating to the operation and administration of the 2026 ESPP to accommodate the specific requirements of local laws and procedures, including to adopt <span style="white-space:nowrap">sub-plans</span> for participants outside of the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Subject to ESPP </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial share pool under the 2026 ESPP will be the lesser of (i)&#8195;&#8195;&#8195;&#8195;% of the total number of shares of outstanding capital stock immediately following the consummation of the Merger (including Combined Company common stock, preferred stock and unexercised <span style="white-space:nowrap">pre-funded</span> warrants) or (ii)&#8195;&#8195;&#8195;&#8195;shares, subject to certain adjustments in the event of a change in the Combined Company&#8217;s capitalization. The shares that may be issued under the 2026 ESPP will be automatically increased on January&#160;1 of each year beginning in 2027 and ending with a final increase on January&#160;1, 2036 in an amount equal to the lesser of&#8195;&#8195;&#8195;&#8195;% of the diluted stock (including Combined Company common stock, preferred stock and unexercised <span style="white-space:nowrap">pre-funded</span> warrants) on the preceding December&#160;31 or&#8195;&#8195;&#8195;&#8195;, unless a lower, or no, increase is determined by the ESPP Administrator. Shares of Combined Company common stock issued under the 2026 ESPP may either be shares of authorized but unissued Combined Company common stock, Combined Company common stock held as treasury shares, or Combined Company common stock acquired in an open-market transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the total number of shares to be purchased by all participants on any exercise date (as defined below) exceeds the number of shares remaining available for issuance under the 2026 ESPP, the ESPP Administrator may make a pro rata allocation of the remaining available number of shares in as uniform a manner as possible and as the ESPP Administrator determines to be equitable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">273 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&#8195;&#8195;&#8195;&#8195;, 2026, the closing price of a share of Cyclerion Common Stock was $&#8195;&#8195;&#8195;&#8195;per share, as reported on Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All employees of the Combined Company or a designated subsidiary of the Combined Company (as defined in the 2026 ESPP) who customarily work for more than 20 hours per week and more than five months in any calendar year and satisfy the requirements set forth in the 2026 ESPP will be eligible to participate in the 2026 ESPP. However, any employee who would own (or pursuant to Section&#160;424(d) of the Code would be deemed to own) more than 5% of the voting power or value of the Combined Company common stock immediately after a grant under the 2026 ESPP is not eligible to participate, and no participant may purchase more than $25,000 of Combined Company common stock in any one calendar year. Following the Merger, it is expected that approximately&#8195;employees will be eligible to participate in the 2026 ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Offering Periods </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2026 ESPP is generally implemented by a series of &#8220;offering periods&#8221; which will not exceed 27 months. The offering periods under the 2026 ESPP will be established by the ESPP Administrator. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Payroll Deductions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To participate in an offering period, an eligible employee must execute and submit a properly completed subscription agreement on or before a date determined by the ESPP Administrator prior to the applicable enrollment date. Once enrolled in the 2026 ESPP, a participant can purchase shares of Combined Company common stock with payroll deductions at the end of the applicable offering period. Once an offering period is over, a participant is automatically enrolled in the next offering period unless the participant chooses to withdraw from the 2026 ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each subscription agreement will request a deduction in an amount expressed as a whole percentage between&#8195;&#8195;&#8195;&#8195;% and&#8195;&#8195;&#8195;&#8195;% and all payroll deductions will be credited to the eligible employee&#8217;s account. The maximum permissible contribution by any participant for all offering periods during any calendar year is $25,000. No interest will be paid on any amount held in the account of any eligible employee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Option Grant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first trading day of each offering period, each eligible employee automatically will be granted an option to acquire shares of Combined Company common stock on the exercise date. All participants granted options under the 2026 ESPP will have the same rights and privileges consistent with the requirements set forth in Section&#160;423 of the Code. No eligible employee will be permitted to purchase more than&#8195;&#8195;&#8195;&#8195;shares of Combined Company common stock during each purchase period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchase Price </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The price per share at which shares are purchased under the 2026 ESPP is determined by the ESPP Administrator, but in no event will be less than 85% of the fair market value of the Combined Company common stock on the first or the last trading day of the offering period, whichever is lower. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise of Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the end of each offering period, unless the participant has withdrawn from the 2026 ESPP, payroll deductions are applied automatically to purchase shares of Combined Company common stock at the price described above. The number of shares purchased is determined by dividing the payroll deductions by the applicable purchase price, rounded down to the nearest whole share. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">274 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any payroll deductions accumulated in a participant&#8217;s account that are not sufficient to purchase a full share will be retained in the participant&#8217;s account for the subsequent option period (subject to earlier withdrawal in accordance with the terms of the 2026 ESPP). Any other amounts of payroll deductions in a participant&#8217;s account that are not used for the purchase of shares of Combined Company common stock, whether because of the participant&#8217;s withdrawal, because the amount would enable the participant to purchase more than the maximum number of shares, or for any other reason, will be returned to the participant, without interest, as soon as administratively practicable after such withdrawal, exercise date or other event, as applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cancellation and Withdrawal </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participants may cancel all (but not less than all) of their option and terminate their subscription agreement by delivering a written notice revoking their subscription to the Combined Company or by following an electronic or other withdrawal procedure determined by the ESPP Administrator. Upon such termination and cancellation, the balance in the participant&#8217;s account will be returned to the participant, without interest, as soon as administratively practicable thereafter. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of Employment or Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the termination of a participant&#8217;s employment with the Combined Company (or a designated subsidiary, as applicable) for any reason or if a participant loses eligibility to participate in the 2026 ESPP, the participant&#8217;s option will be deemed cancelled, the balance in the participant&#8217;s account will be returned to the participant (or his or her estate or designated beneficiary in the event of the participant&#8217;s death), without interest, as soon as administratively practicable, and the participant will have no other rights under the 2026 ESPP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rights to purchase Combined Company common stock under the 2026 ESPP may not be transferred by a participant and may be exercised during a participant&#8217;s lifetime only by the participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adjustments Upon a Change in Capitalization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any reorganizations, recapitalizations, stock splits, reverse stock splits, stock dividends, extraordinary dividends or distributions, or similar events, the ESPP Administrator will appropriately adjust the number and class of shares available under the 2026 ESPP and the applicable purchase price of such shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Merger or Other Corporate Transaction </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a merger, sale, or other similar corporate transaction involving the Combined Company, each outstanding option will be assumed or an equivalent option substituted by the successor corporation or a parent or subsidiary of the successor corporation. If the successor corporation refuses to assume or substitute for the option, the offering period with respect to which such option relates will be shortened by setting a new exercise date on which such offering period shall end. The new exercise date will occur before the date of the Combined Company&#8217;s proposed merger, sale, or other similar corporate transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment and Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP Administrator may amend, suspend or terminate the 2026 ESPP at any time and, in the event of a termination of the 2026 ESPP, may terminate all outstanding offering periods (and return each participant&#8217;s account balance to the participant) or allow outstanding offering periods to expire in accordance with their terms. The 2026 ESPP will continue in effect until terminated by the ESPP Administrator. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">275 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Federal Income Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the 2026 ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options under the 2026 ESPP will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more <span style="white-space:nowrap">sub-plans</span> are established for employees of <span style="white-space:nowrap">non-U.S.</span> subsidiaries, the tax rules may be different than discussed below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2026 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the 2026 ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the 2026 ESPP at the beginning of an option period or upon its exercise on the exercise date at the end of an option period. Upon the disposition of shares acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the employee holds shares acquired under the 2026 ESPP for at least two years from the grant date of his or her option and at least one year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first day of the option period) exceeded the exercise price for the option, or (ii)&#160;the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long-term capital gain or loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short-term or long-term capital gain or loss depending on the length of time the employee has held the shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company is not entitled to any deduction with respect to the difference between the fair market value of the Combined Company common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the Combined Company (or, if applicable, the affiliate employer) is entitled to a tax deduction for any ordinary income recognized by the participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Plan Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The benefits that will be received by or allocated to eligible employees under the 2026 ESPP cannot be determined at this time because the amount of payroll deductions contributed to purchase shares of Combined Company common stock under the 2026 ESPP is entirely within the discretion of each participant (subject to the limitations discussed above). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is <span style="font-weight:bold">not </span>conditioned upon the approval of the ESPP Proposal. However, the ESPP Proposal is conditioned on the consummation of the Merger. Notwithstanding the approval of the ESPP Proposal, if the Merger is not completed, the actions contemplated by the ESPP Proposal will not be effected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the ESPP Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE ESPP PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">276 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_25">PROPOSAL NO. 9&#8201;-&#8201;THE MERGER COMPENSATION PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;14A of the Exchange Act and Rule <span style="white-space:nowrap">14a-21(c)</span> thereunder, Cyclerion is seeking <span style="white-space:nowrap">non-binding,</span> advisory shareholder approval of certain compensation arrangements for Cyclerion named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item 402(t) of Regulation <span style="white-space:nowrap">S-K</span> in the section titled &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic"> &#8212; Interests of </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s</span><span style="font-style:italic"> Directors and Executive Officers in the Merger &#8212; </span><span style="font-style:italic">Golden Parachute Compensation</span>&#8221; beginning on page 156 of this proxy statement/prospectus. At the Cyclerion Shareholders Meeting, Cyclerion will therefore ask its shareholders to adopt the following resolution: </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;RESOLVED: That certain compensation arrangements for Cyclerion named executive officers in connection with the Merger, as disclosed pursuant to Item 402(t) of Regulation <span style="white-space:nowrap">S-K</span> in the section titled &#8220;</span><span style="font-weight:bold"><span style="font-style:italic">The Merger</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> &#8212; Interests of </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Cyclerion</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">&#8217;</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">s</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"> Directors and Executive Officers in the Merger &#8212; </span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Golden Parachute Compensation</span></span><span style="font-weight:bold">&#8221; in the proxy statement/prospectus, are hereby APPROVED on a <span style="white-space:nowrap">non-binding,</span> advisory basis.&#8221; </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the vote is advisory in nature only, it will not be binding on Cyclerion. Accordingly, to the extent Cyclerion is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed, regardless of the outcome of the advisory vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is <span style="font-weight:bold">not</span> conditioned upon the approval of the Merger Compensation Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Merger Compensation Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE MERGER COMPENSATION PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">277 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_26">PROPOSAL NO.&#160;10 &#8211; THE <span style="white-space:nowrap"><span style="white-space:nowrap">SAY-ON-PAY</span></span> PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;14A of the Exchange Act requires that Cyclerion provide its shareholders with the opportunity to vote to approve, on a <span style="white-space:nowrap">non-binding,</span> advisory basis, not less frequently than once every three years, the compensation of Cyclerion&#8217;s named executive officers as disclosed in this proxy statement/prospectus in accordance with the compensation disclosure rules of the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s compensation programs are designed to effectively align Cyclerion&#8217;s executives&#8217; interests with the interests of Cyclerion&#8217;s shareholders by focusing on long-term equity incentives that correlate with the growth of sustainable long-term value for Cyclerion&#8217;s shareholders. Cyclerion&#8217;s shareholders are urged to read the section titled &#8220;Cyclerion Executive Officer and Director Compensation&#8221; in this proxy statement/prospectus, which discusses how Cyclerion&#8217;s executive compensation policies and practices implement Cyclerion&#8217;s compensation philosophy and contains tabular information and narrative discussion about the compensation of Cyclerion&#8217;s named executive officers. The Compensation Committee of the Cyclerion Board (the &#8220;Cyclerion Compensation Committee&#8221;) believes that the objectives of Cyclerion&#8217;s executive compensation program, as they relate to Cyclerion&#8217;s named executive officers, are appropriate for a company of Cyclerion&#8217;s size and stage of development and that its compensation policies and practices help meet those objectives. In addition, the Cyclerion Compensation Committee believes that Cyclerion&#8217;s executive compensation program, as it relates to Cyclerion&#8217;s named executive officers, achieves an appropriate balance between fixed compensation and variable incentive compensation. The Cyclerion Board and the Cyclerion Compensation Committee believe that Cyclerion&#8217;s policies and practices are effective in implementing Cyclerion&#8217;s compensation philosophy and in achieving Cyclerion&#8217;s compensation program goal. Accordingly, Cyclerion is asking its shareholders to approve the compensation of Cyclerion&#8217;s named executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote on this resolution is not intended to address any specific element of compensation; rather, the vote relates to the compensation of Cyclerion&#8217;s named executive officers, as described in this proxy statement/prospectus in accordance with the compensation disclosure rules of the SEC. Accordingly, Cyclerion is asking its shareholders to vote on the following resolution at the Cyclerion Shareholders Meeting: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">&#8220;RESOLVED, that the compensation paid to the Cyclerion&#8217;s named executive officers, as disclosed in Cyclerion&#8217;s proxy statement/prospectus related to its 2026 Annual Meeting of Shareholders, pursuant to the compensation disclosure rules of the SEC, including the compensation tables and the related material disclosed in the proxy statement/prospectus is hereby APPROVED on a <span style="white-space:nowrap">non-binding,</span> advisory basis.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the vote is advisory in nature only, it will not be binding on Cyclerion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is <span style="font-weight:bold">not</span> conditioned upon the approval of the <span style="white-space:nowrap"><span style="white-space:nowrap">Say-on-Pay</span></span> Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the <span style="white-space:nowrap"><span style="white-space:nowrap">Say-on-Pay</span></span> Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE <span style="white-space:nowrap"><span style="white-space:nowrap">SAY-ON-PAY</span></span> PROPOSAL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">278 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_27">PROPOSAL NO. 11&#8201;-&#8201;THE ADJOURNMENT PROPOSAL </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cyclerion fails to receive a sufficient number of votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal, Cyclerion may propose to adjourn the Cyclerion Shareholders Meeting, for a period of not more than 60 days, for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal. Cyclerion currently does not intend to propose adjournment at the Cyclerion Shareholders Meeting if there are sufficient votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal, and/or the Reverse Stock Split Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger is <span style="font-weight:bold">not</span> conditioned upon the approval of the Adjournment Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight:bold">FOR</span>&#8221; the approval of the Adjournment Proposal. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE CYCLERION BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL, IF NECESSARY. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">279 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_28">CYCLERION&#8217;S BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Cyclerion,&#8221; the &#8220;Company&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Cyclerion and its subsidiaries. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview and Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the announcement of the Merger, we were focused on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Our strategic focus has been centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression (&#8220;TRD&#8221;), which we believe represents a substantial clinical and commercial opportunity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Primary Focus on New Potential Treatment for Treatment Resistant Depression </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past year, we refined our strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and, prior to the announcement of the Merger, prioritized <span style="white-space:nowrap">CYC-126,</span> an individualized therapy for TRD as our foundational development program.</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In September 2025, we entered into a license agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) for intellectual property supporting this program (the &#8220;MIT License Agreement&#8221;). Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $4.4&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, we are required to pay MIT varying percentages of income received as consideration for any sublicenses granted. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In January 2026, we entered into a collaboration and <span style="white-space:nowrap"><span style="white-space:nowrap">option-to-license</span></span> agreement with Medsteer SAS (&#8220;Medsteer&#8221;) to access certain technology, data assets, and technical <span style="white-space:nowrap">know-how</span> related to drug delivery and physiological monitoring. Under the terms of the Collaboration Agreement, the Company paid to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $3.7&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have been advancing development planning, regulatory strategy, and commercial positioning for this program. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In February 2026, we received notice from the FDA confirming prior informal communications that <span style="white-space:nowrap">CYC-126</span> will be regulated under the FDA&#8217;s Center for Drug Evaluation and Research (&#8220;CDER&#8221;), with the FDA&#8217;s Center for Devices and Radiologic Health (&#8220;CDRH&#8221;) providing input and reviews as applicable. We believe that the FDA feedback provided clear guidance that the Company believes will help enable an FDA IND submission. The FDA guidance supported continued advancement of the planned Phase 2 study design, leveraging <span style="white-space:nowrap">FDA-approved</span> anesthetics and their well-established nonclinical and clinical safety data. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have also recently announced the formation of a Clinical Advisory Board with the appointment of five internationally recognized key leaders in neuropsychiatry anesthesiology clinical care, and clinical development. This advisory board will provide strategic guidance and support key decision making regarding clinical development as Cyclerion seeks to advance <span style="white-space:nowrap">CYC-126</span> for TRD and builds a pipeline across neuropsychiatric diseases. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">280 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the announcement of the Merger, <span style="white-space:nowrap">CYC-126</span> was being developed as a potential anesthetic-based therapy for neuropsychiatric indications, including TRD. The system is designed to deliver anesthetic agents while monitoring brain activity to support individualized dosing through a patient feedback loop. The Company believes this approach may provide a differentiated treatment option for patients with TRD. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">CYC-126</span> consists of two generic intravenous anesthetic agents, propofol and dexmedetomidine, administered through a personalized delivery system intended to operate as a clinical decision support tool for an anesthesiologist. The treatment would be expected to be delivered in a hospital-based setting, such as a procedure room or post-anesthesia care unit (&#8220;PACU&#8221;), followed by a short recovery period in the PACU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Major depressive disorder (&#8220;MDD&#8221;) is a prevalent psychiatric illness characterized by episodes of depressed mood, cognitive disturbances, and diminished interest or pleasure in activities lasting for at least two weeks. A subset of patients with MDD who do not achieve an adequate response after at least two antidepressant treatments are considered to have treatment-resistant depression. It is estimated that more than <span style="white-space:nowrap">one-third</span> of patients with medication-treated MDD meet criteria for TRD, representing approximately 2.8 to 3&#160;million adults in the United States. Patients with TRD experience higher hospitalization rates, increased suicide risk, greater psychiatric comorbidity, and limited effective treatment options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Propofol and dexmedetomidine have an established clinical safety database as widely used anesthetic agents. Additionally, several early-phase clinical studies have suggested that propofol may have rapid-acting antidepressant effects in patients with TRD. Cyclerion is developing <span style="white-space:nowrap">CYC-126</span> to incorporate a proprietary, technology-enabled delivery approach designed to achieve and maintain specific electroencephalogram (&#8220;EEG&#8221;) states. The Company believes that controlled sedation may modulate communication among brain regions that are dysregulated in patients with TRD. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In parallel with the advancement of our neuropsychiatric strategy, Cyclerion continues to evaluate opportunities related to our legacy soluble guanylate cyclase (&#8220;sGC&#8221;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions intended to maximize shareholder value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Background </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded in 2018 to focus on the treatment of serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. Since that time, our strategy for Cyclerion has changed and our sGC assets zagociquat and CY3018 were sold in 2023 to Tisento, we <span style="white-space:nowrap">out-licensed</span> praliciguat in 2021. We also entered into a <span style="white-space:nowrap">non-binding</span> license option agreement for olinciguat in 2024 which was terminated in 2025. Our prior strategy to conduct research and development on sGC stimulators has been discontinued and we do not intend to internally pursue research and development or commercialization with any sGC asset. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table is a high-level summary of our historical sGC portfolio: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:18%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Program</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Indication(s)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Description</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top">Zagociguat <span style="white-space:nowrap">(CNS-penetrant)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome), cognitive impairment</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Zagociguat is a <span style="white-space:nowrap">CNS-penetrant</span> sGC stimulator that has shown rapid improvements across a range of endpoints reflecting multiple domains</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top">Sold to Tisento as part of the Asset Purchase Agreement in July 2023. On January&#160;8, 2026, Tisento announced completion of enrollment</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">281 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:18%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:27%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:26%"/>

<td style="vertical-align:bottom"/>
<td style="width:24%"/></tr>

<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:1.5pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:1.5pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:bottom"><span style="font-weight:bold">Program</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Indication(s)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Description</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:bottom"><span style="font-weight:bold">Status</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">&#160;</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">associated with schizophrenia, and Alzheimer&#8217;s Disease with Vascular Pathology (ADV)</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">of disease activity, including mitochondrial disease-associated biomarkers.</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top">in PRIZM, a global phase 2b study of zagociguat for the treatment of MELAS. Zagociguat received Fast Track designation in June 2025 from the U.S. Food and Drug Administration for the treatment of MELAS.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">CY3018 <span style="white-space:nowrap">(CNS-penetrant)</span></td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Neuropsychiatric disorders</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">CY3018 is a <span style="white-space:nowrap">CNS-penetrant</span> sGC stimulator in preclinical development that has potential for the treatment of neuropsychiatric diseases and disorders.</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top">Sold to Tisento as part of the Asset Purchase Agreement in July 2023.</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; padding-left:8pt;vertical-align:top">Praliciguat (peripheral)</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Focal Segmental Glomerulosclerosis (FSGS)</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Praliciguat is a systemic sGC stimulator that is licensed to Akebia for the treatment of a rare kidney disease.</td>
<td style=" BORDER-LEFT:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; padding-right:2pt;vertical-align:top"><span style="white-space:nowrap">Out-licensed</span> to Akebia in 2021 and renegotiated terms effective December 2024. In December 2025, Akebia announced that the first patient has been dosed in a Phase 2 clinical trial of praliciguat. In February 2026, we received a $1,000,000 milestone payment from Akebia tied to the commencement of the</td></tr>
<tr style="font-size:1pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; padding-left:8pt;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000;height:6pt">&#160;</td>
<td colspan="2" style="BORDER-LEFT:0.75pt solid #000000; BORDER-TOP:0.75pt solid #000000; BORDER-RIGHT:0.75pt solid #000000;height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-left:8pt;vertical-align:top">Olinciguat (peripheral)</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Cardiovascular diseases</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">Olinciguat is a vascular sGC stimulator</td>
<td style=" BORDER-LEFT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000; BORDER-BOTTOM:0.75pt solid #000000; padding-right:2pt;vertical-align:top">Cyclerion entered into an exclusive <span style="white-space:nowrap">non-binding</span> license option agreement in July 2024 but terminated it in 2025. Cyclerion is currently exploring potential license opportunities.</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">282 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the status of sGC stimulator assets that are either licensed or may be divested to other entities: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a03.jpg" alt="LOGO" style="width:6.04605in;height:1.10526in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Akebia License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;3, 2021, we entered into a License Agreement with Akebia (the &#8220;Akebia License Agreement&#8221;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the Akebia License Agreement. Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the <span style="white-space:nowrap">out-licensed</span> praliciguat products. In 2021, Akebia paid a $3.0&#160;million upfront payment to us upon signing of the Akebia License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;13, 2024, we announced that Cyclerion and Akebia <span style="white-space:nowrap">re-negotiated</span> a mutually beneficial amendment to Akebia&#8217;s exclusive license agreement for praliciguat, a systemic sGC stimulator. Under this new license amendment, we will receive $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million is due in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat at an earlier date than as originally agreed between the parties. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using Praliciguat. Pursuant to the terms of amendment, upon initiation (defined as first patient dosed) of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to us and this payment was received in February 2026. We are eligible to receive additional milestone cash payments of up to approximately $557.5&#160;million in total related to potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, we are eligible to receive certain higher-tiered sales-based royalties ranging from <span style="white-space:nowrap">mid-single-digits</span> to twenty percent.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the Akebia License Agreement will expire on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis upon the expiration of the last royalty term, which ends upon the longest of (i)&#160;the expiration of the patents licensed under the Akebia License Agreement, (ii)&#160;the expiration of regulatory exclusivity for such product, and (iii) 10 years from first commercial sale of such product. Akebia may terminate the Akebia License Agreement in its entirety or only with respect to a particular licensed compound or product upon 180 days&#8217; prior written notice to&#160;Cyclerion, subject to certain obligations to license back to Cyclerion licensed compounds and candidates and related assets. The parties also have customary termination rights, subject to a cure period, in the event of the other party&#8217;s material breach of the Akebia License Agreement or in the event of certain additional circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2026, Akebia announced that the first patient was dosed in a Phase 2 clinical trial evaluating praliciguat for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of praliciguat, an oral soluble guanylate cyclase (sGC) stimulator, in approximately 60 adult patients.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is not responsible for the conduct of this study, and there can be no assurance regarding the timing, outcome, or potential commercialization of praliciguat. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">283 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tisento Asset Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;11, 2023, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with an investor group that included Peter Hecht (our former CEO), JW Celtics Investment Corp and JW Cycle Inc. which subsequently changed their names to Tisento Therapeutics Holdings Inc. (&#8220;Tisento Parent&#8221;) and Tisento Therapeutics Inc. (&#8220;Tisento&#8221;). Upon the closing in July 2023, following receipt of approval by the Cyclerion stockholders of the transactions contemplated by the Asset Purchase Agreement, we sold to Tisento certain assets (the &#8220;Transferred Assets&#8221;) and Tisento assumed certain liabilities relating thereto. In consideration for such sale and assumption, at the closing we received proceeds of $8.0&#160;million as cash consideration, $2.4&#160;million as reimbursement for certain operating expenses related to such assets for the period between signing and closing of the Asset Purchase Agreement, and shares of common stock of Tisento Parent comprising 10% of the then issued and outstanding equity securities of Tisento Parent immediately following such closing, subject to certain protections against future potential dilution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Asset Purchase Agreement, we agreed not to compete with Tisento through July 2028 either alone or directly or indirectly with or through any affiliate or third party, initiate investigational new drug (&#8220;IND&#8221;)-enabling preclinical development, develop, commercially manufacture, commercialize, or otherwise exploit any compound or product that is (A)&#160;a <span style="white-space:nowrap">CNS-penetrant</span> sGC stimulator, (B)&#160;developed for the treatment of a program indication, and (C)&#160;reasonably expected to compete with any compound or product in a purchased program for the treatment of a program indication (any such compound or product, a &#8220;Cyclerion Competing Product&#8221;) anywhere in the world, or (ii)&#160;license, convey, grant, or otherwise transfer any rights to any third party to initiate <span style="white-space:nowrap">IND-enabling</span> preclinical development, develop, commercially manufacture, commercialize, or otherwise exploit a Cyclerion Competing Product anywhere in the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;27, 2025, Tisento Therapeutics announced that the first patient had been dosed in its global Phase 2b PRIZM study. The study is investigating the impact of once-daily oral zagociguat treatment on fatigue, cognitive impairment, and other key aspects of the rare mitochondrial disease MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). In June 2025, Tisento announced that it had received from the U.S, FDA &#8220;Fast Track Designation&#8221; for MELAS, lactic acidosis and certain Stroke-like Episodes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PRIZM - a <span style="font-weight:bold">P</span>hase 2b <span style="font-weight:bold">R</span>andomized, Placebo-Controlled Trial <span style="font-weight:bold">I</span>nvestigating <span style="font-weight:bold">Z</span>agociguat in <span style="font-weight:bold">M</span>ELAS - is evaluating the efficacy and safety of oral zagociguat 15 mg or 30 mg compared to placebo when administered once-daily for 12 weeks in participants with genetically and phenotypically defined MELAS. The PRIZM study has a crossover design, with two <span style="white-space:nowrap">12-week</span> treatment periods separated by a <span style="white-space:nowrap">4-week</span> washout period. All participants will receive zagociguat during one of the <span style="white-space:nowrap">12-week</span> periods and placebo during the other. Participants who complete the study may be eligible for an open-label extension study. PRIZM is a global study that will enroll approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. See ClinicalTrials.gov (NCT06402123) for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2026, Tisento announced completion of enrollment in the global Phase 2b PRIZM clinical trial evaluating oral zagociguat for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). The study enrolled approximately 43 participants, and Tisento has indicated that <span style="white-space:nowrap">top-line</span> results are expected in the fourth quarter of 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion does not control the conduct of this study and cannot provide assurance regarding its outcome or timing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Olinciguat </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, we entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">284 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid us an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and we were provided notice on October&#160;23, 2025 that the Optionee was terminating the Option Agreement. We are currently exploring potential strategic opportunities for olinciguat. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We protect the intellectual property and proprietary technology that we believe is important to our business, including by pursuing and maintaining U.S. and foreign patents that cover our product candidates and compositions, their methods of use and the processes for their preparation, as well as any other relevant inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We expect to also rely on licenses for patented intellectual property owned by third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, improvements and <span style="white-space:nowrap">know-how</span> related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have 22 issued U.S. patents, 12 pending U.S. patents applications and numerous foreign patents and pending patent applications related to our sGC programs. Patent families are filed either as utility U.S. patents or under an international patent law treaty (PCT) that provides a unified procedure for filing a single initial patent application to seek patent protection for an invention simultaneously in each of the 158 contracting states, followed by the process of entering national phase, which requires a separate application in each of the member states in which national patent protection is sought. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our TRD strategy, we have licensed a patent application from MIT. We also hold an option to license certain technology owned by Medsteer, a leading technology provider of closed loop anesthesia delivery systems, under the Collaboration Agreement. The patent application licensed from MIT has not yet been granted. If we continue to progress the development of our product candidates, we intend to apply for certain U.S. and foreign patents related to our TRD product strategy.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The technology underlying our sGC patents and pending patent applications has been developed by us and was not acquired from any <span style="white-space:nowrap">in-licensing</span> agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intellectual property portfolios for our most advanced product candidates in the sGC space (praliciguat and olinciguat) are summarized below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Praliciguat Patent Portfolio </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our praliciguat patent portfolio includes 14 U.S. issued patents, 9 pending U.S. patent applications, and numerous patents and pending patent applications in foreign jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the U.S. patents, US 9,481,689, which will expire in 2034, is directed to praliciguat and pharmaceutical compositions thereof. The term of this U.S. patent may be eligible for patent term extension as described below. Three other U.S. patents, US 8,748,442, US 9,139,564, and 10,189,809, expire in 2031, and provide&#160;generic coverage of praliciguat and intermediates used in the preparation of praliciguat, as well as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">285 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compounds related to praliciguat, respectively. A fifth U.S. patent, US 10,183,021 will expire in 2034 and is directed to the treatment of resistant hypertension with praliciguat or combinations of praliciguat and known anti-hypertensives. A sixth U.S. patent, US 10,639,308 will expire in 2034 and is directed to the treatment of diabetic nephropathy with praliciguat or combinations of praliciguat with other agents. The seventh U.S. patent, US 10,927,136 covers phosphorus prodrugs of praliciguat and will expire in 2037. The eighth U.S. Patent, US 11,389,449, is directed to the treatment of metabolic syndrome with praliciguat and will expire in 2038. The ninth U.S. Patent, US 11,357,777, is directed to the treatment of a severe form of liver disease named nonalcoholic steatohepatitis (NASH) with praliciguat and other compounds and will expire in 2039. The tenth to fourteenth U.S. Patents, US 11,319,308 (expiring in 2039), US 11,773,089 (expiring in 2037), US 11,274,096 (expiring in 2039), US 11,708,361 (expiring in 2039) and US 12,275,724 (expiring in 2039) are directed to the syntheses of praliciguat or of intermediates useful in the manufacture of praliciguat.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two pending U.S. patent applications that, if issued, will expire in 2031 and 2034, respectively, provide generic coverage for praliciguat composition of matter. Two additional U.S. patent applications that, if issued, will expire in 2037 and 2039, respectively, provide coverage for methods of large-scale preparation of praliciguat. We also have a pending U.S. application directed to a praliciguat formulation, that, if issued, will expire in 2036. Another pending U.S. application is directed to phosphorous prodrugs of praliciguat and, if issued, will expire in 2037. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another of the U.S. pending applications is directed to methods of treating diabetic nephropathy with praliciguat, and if issued, will expire in 2040 or later. Another of the U.S. pending applications is directed to the use of certain sGC stimulators, including praliciguat for the treatment of HFpEF in post-menopausal women and, if issued, will expire in 2042. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we have eight granted European patents expiring between 2031 and 2039. Each of these patents is validated in multiple countries or registered in multiple countries as a European Unitary Patent. We hold nine granted Japanese patents expiring between 2031 and 2040. We also have numerous patent applications pending in foreign jurisdictions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Olinciguat Patent Portfolio </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our olinciguat patent portfolio includes 16 U.S. issued patents, five pending U.S. patent applications and numerous patents and pending applications in foreign jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the U.S. patents, US 9,586,937, which will expire in 2034, is directed to olinciguat and pharmaceutical compositions thereof. The term of this U.S. patent may be eligible for patent term extension as described below. Three other U.S. patents, US 8,748,442, US 9,139,564, and US 10,189,809, expire in 2031, and provide generic coverage of olinciguat, intermediates used in the preparation of olinciguat, and compounds related to olinciguat, respectively. The fifth U.S. patent, US 10,517,874, which will expire in 2034 is directed to the treatment of SCD using olinciguat alone or in combinations with other therapeutic agents. The sixth and seventh U.S. issued patents, US 10,889,577, and US 11,572,358, will expire in 2037 and are directed to polymorphs of olinciguat. The eighth issued patent, US 11,207,323, will expire in 2034 and provides coverage for stereoisomers of olinciguat. Seven more U.S. issued patents, US 11,319,308 (expiring in 2039), US 11,773,089 (expiring in 2037), US 11,274,096 (expiring in 2039), US 11,834,444 (expiring in 2038), US 12,030,874 (expiring in 2039), US 12,247,025 (expiring in 2037 ), and US 12,275, 724 (expiring in 2039) are directed to the chiral syntheses of olinciguat or the syntheses of intermediates useful in the manufacture of olinciguat. The last U.S. issued patent, US 11,357,777, is directed to the treatment of NASH with olinciguat and other compounds and will expire in 2039. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One pending U.S. patent application, if issued, will expire in 2037 and provides additional coverage for polymorphs of olinciguat. Two pending U.S. patent applications, if issued, will expire in 2031 and 2034, respectively, and provides generic coverage for olinciguat. One pending U.S. patent application is directed to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">286 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processes and synthetic intermediates for preparing olinciguat and, will expire in 2037. A fifth pending U.S. patent application is directed to the treatment of heart failure with preserved ejection fraction (HFpEF) in post-menopausal women with olinciguat and other sGC stimulators. If issued, the corresponding patent will expire in 2042.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we have nine granted European patents expiring between 2031 and 2039 each of them validated in multiple countries or registered in multiple countries as Unitary European Patents; eight granted Japanese patents&#160;expiring between 2031 and 2039; seven granted Chinese patents expiring between 2031 and 2039; and a large number of issued patents in other foreign jurisdictions, expiring between 2031 and 2039. We also have numerous pending patent applications in foreign jurisdictions. Some of these patents may be eligible for patent term extension or the foreign jurisdiction equivalent, depending on the jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent Term </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a <span style="white-space:nowrap">non-provisional</span> patent application, assuming that all applicable maintenance or annuity fees are paid. In the United States, and China, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the respective patent offices, in examining and granting a patent, or, in the US, the term may be shortened if a patent is terminally disclaimed over an earlier-filed patent. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in that country, and the validity and enforceability of the patent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the term of a U.S. patent that covers an US Food and Drug Administration (FDA)-approved drug may be eligible for patent term extension under the Drug Price Competition and Hatch-Waxman Act, to account for some of the time the drug is under development and regulatory review after the patent is granted. For a drug for which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for extension of the term of one U.S. patent that includes at least one claim covering the composition of matter of an <span style="white-space:nowrap">FDA-approved</span> drug (drug substance or drug product), an <span style="white-space:nowrap">FDA-approved</span> method of treatment using the drug and/or a method of manufacturing the <span style="white-space:nowrap">FDA-approved</span> drug. The extended patent term cannot exceed the shorter of five years beyond the <span style="white-space:nowrap">non-extended</span> expiration of the patent or 14 years from the date of the FDA approval of the drug. Some foreign jurisdictions, including Europe, Japan, and China, have similar patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trade Secrets and Proprietary Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely upon unpatented trade secrets and <span style="white-space:nowrap">know-how</span> and continuing technological innovation to develop and maintain our competitive position. We typically rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We protect our proprietary information, including trade secrets and <span style="white-space:nowrap">know-how,</span> by establishing confidentiality agreements with our commercial partners, collaborators, scientific advisors, employees and consultants and invention assignment agreements with our employees, consultants, scientific advisors and contractors. These agreements generally provide that all confidential information developed or made known during the course of an individual or entities&#8217; relationship with us must be kept confidential during and after the relationship. These agreements also typically provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. These agreements are designed to protect our proprietary information and, in the case of the invention </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">287 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. However, these agreements may be breached, and we may not have adequate remedies for any breach. We also take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <span style="white-space:nowrap">know-how</span> and inventions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">United States Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA regulates medical products, including prescription drugs under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations. Products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and regulations requires the expenditure of substantial time and financial resources. Failure to&#160;comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including imposition of a clinical hold, refusal by the FDA to approve applications, withdrawal of an approval, import/export delays, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, debarment, or civil or criminal investigations and penalties brought by the FDA, the Department of Justice, State Attorneys General, or other governmental entities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be approved and marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of extensive nonclinical laboratory and animal studies conducted in accordance with applicable regulations, including GLP regulations and applicable requirements for the humane use of laboratory animals; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may commence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an independent institutional review board (&#8220;IRB&#8221;) to proceed with initiating the clinical trial at each corresponding investigational site. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCPs and other clinical-trial related regulations to establish the safety and efficacy of the product for each proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation and submission to the FDA of an NDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of one or more FDA inspections such as <span style="white-space:nowrap">pre-approval</span> inspection(s) of the manufacturing facility or facilities at which the product, or components thereof, are made to assess compliance with current GMP; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payment of user fees for FDA review of the NDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA acceptance, review and approval of the NDA, which may include an Advisory Committee review. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and approval process requires substantial time, effort and financial resources and the receipt and timing of any approval is uncertain. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">288 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nonclinical and Clinical Trials in Support of an NDA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any drug product candidate in humans, the product candidate must undergo rigorous nonclinical testing. Nonclinical studies include laboratory evaluations of the product candidate, as well as in vitro and animal studies to assess the potential safety and efficacy of the product candidate. The conduct of nonclinical studies that determine the product safety information for administration to humans must comply with federal regulations and requirements, including GLP regulations. The sponsor must submit the results of the nonclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical study protocol, to the FDA as part of an IND, which must become effective before clinical trials in a given indication may be commenced. The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the content of the IND or the conduct of the proposed trial(s) as outlined in the IND prior to that time. In such a case, the IND sponsor must resolve any outstanding concerns with the FDA before the clinical trial(s) can proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators in accordance with GCP requirements. Each clinical trial must be reviewed and approved by an IRB for the sites at which the trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution. The IRB also approves the informed consent form, including a privacy statement, which must be provided to each clinical trial participant or his or her legal representative, and must monitor the clinical trial until completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are typically conducted in three sequential phases prior to approval, which may overlap or be combined: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 1.</span> Phase 1 clinical trials generally involve a small number of healthy participants or disease-affected participants who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability and safety of the drug. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 2.</span> Phase 2 clinical trials usually involve studies in a limited population of participants with a disease or disorder to evaluate the efficacy of the product candidate for specific indications, determine dosage tolerance and optimal dosage, and identify possible adverse effects and safety risks. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 3.</span> Phase 3 clinical trials generally involve a larger number of participants at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use, to establish the overall benefit/risk profile of the product and to provide an adequate basis for product approval by the FDA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Phase 4.</span> Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be required to be conducted after approval to gain additional experience from the treatment of participants in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations, or when otherwise requested by the FDA. Failure to conduct the Phase 4 clinical trials per the plan required by the FDA could result in enforcement action or withdrawal of approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing new information and changes such as the results of clinical trials, new nonclinical studies, new product quality data, or changes to manufacturing controls must be submitted at least annually to the FDA and more frequently if serious adverse events occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on various grounds, including a finding that the research participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the requirements of the IRB or if the drug has been associated with unexpected serious harm to participants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">289 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
There are also requirements related to registration and reporting of certain clinical trials and completed clinical trial results to public registries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Submission and Review of an NDA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required nonclinical and clinical testing, the results of nonclinical studies and clinical trials, together with detailed information on the product&#8217;s manufacture, composition, quality controls and proposed labeling, among other things, are submitted to the FDA in the form of an NDA, requesting approval to market the product for one or more indications. The application must be accompanied by a significant user fee payment, which typically increases annually, although waivers may be granted in limited cases (e.g., for products that have received an Orphan Designation). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval and may require additional nonclinical or clinical studies, or other information (e.g., product quality data or manufacturing controls) before it accepts the filing. If an NDA has been accepted for filing, which occurs 60 days after submission, the FDA sets a user fee goal date that informs the applicant of the specific date by which the FDA intends to complete its review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original NDAs, the FDA has ten months from the filing date in which to complete its review of a standard application, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process may be significantly extended by FDA requests for additional information and clinical data or clarification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews NDAs to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with current GMP to assure and preserve the product&#8217;s identity, strength, quality and purity. Before approving an NDA, the FDA typically will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities comply with current GMP. Additionally, the FDA will frequently inspect one or more clinical trial sites for compliance with GCPs and integrity of the data supporting safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the approval process, the FDA will also prepare an integrated benefit-risk assessment and determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks and to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS. A REMS that includes elements to assure safe use, or ETASU, can substantially increase the costs of commercializing a drug. The FDA could also require a special warning, known as a boxed warning, to be included in the product label in order to highlight a particular safety risk. Boxed warnings may limit the type of advertising for a drug. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to risk, benefit and interpretation of clinical trial data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, FDA will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug and is accompanied by specific prescribing information for specific conditions of use. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the submission identified by the FDA and may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either amend the NDA with data to address the raised concerns, resubmit the NDA addressing all the deficiencies identified in the letter, engage in dispute resolution with the FDA about the identified deficiencies in the CRL, or withdraw the application. Even with submission of this additional information, the FDA may ultimately decide that the <span style="white-space:nowrap">re-submitted</span> application does not satisfy the regulatory criteria for approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">290 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than 200,000 individuals in the United States, or in other limited cases. Orphan drug designation must be requested before submitting an NDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, though companies developing orphan drugs may be eligible for certain incentives, including tax credits for qualified clinical testing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same active component parts for the same indication for seven years from the date of such approval, except in limited circumstances. Competitors, however, may receive approval of different active component parts for the same indication or obtain approval for the same active component parts for a different indication. If one of our product candidates designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Review and Approval Application Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has various programs that are intended to expedite development and approval of drugs intended for the treatment of serious or life-threatening diseases or conditions and that demonstrate the potential to address unmet medical needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An application may be eligible for a &#8220;fast track&#8221; designation for a product that is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. Fast track designation provides opportunities for more frequent interactions with the FDA review team and permits FDA to consider sections of the NDA on a rolling basis before the complete application is submitted.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy&#8221;. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An application may be eligible for &#8220;accelerated approval&#8221; where the product candidate is intended to treat a serious or life-threatening illness and provides meaningful therapeutic benefit over existing treatments; applications eligible for accelerated approval may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA requires a sponsor to conduct confirmatory studies to verify the predicted effect on IMM or another clinical endpoint, and the product may be subject to expedited withdrawal procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an NDA is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if the FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. Under priority review, the FDA must review an application in six months, compared to ten months for a standard review. A product may be eligible for more than one expedited approval program. Even if a product qualifies for one or more of these programs, however, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, these expedited review pathways do not change the standards for approval and may not ultimately expedite the development or approval process. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">291 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Patent</span> Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent exclusivity, the holder of the NDA for the listed drug may be entitled to a period of <span style="white-space:nowrap">non-patent</span> exclusivity, during which the FDA cannot approve an ANDA for approval of a generic or 505(b)(2) application that relies on the listed drug as protected by regulatory exclusivity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An NDA for a new chemical entity may receive five years of exclusivity, whereby the FDA will not accept for filing, with limited exceptions, a product seeking to rely upon the FDA&#8217;s findings of safety or effectiveness for such new chemical entity. An ANDA containing a paragraph IV patent certification can be filed after four years. Alternatively, an NDA may obtain a three-year period of <span style="white-space:nowrap">non-patent</span> market exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pediatric Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of <span style="white-space:nowrap">non-patent</span> marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed patents in the case of drugs. This <span style="white-space:nowrap">six-month</span> exclusivity may be granted if a sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims and some manufacturing and supplier changes, are subject to prior FDA review and approval. There also are continuing annual user fee requirements for marketed products and the establishments where such products are manufactured, as well as new application fees for certain supplemental applications. The FDA may impose a number of post-approval requirements as a condition of approval of an NDA, such as Phase 4 clinical trials or a REMS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA&#160;and such state agencies for compliance with current GMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from current GMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain current GMP compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may issue enforcement letters or withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay product distribution and require significant time and financial expenditures. Later discovery of previously unknown safety issues with a product, including adverse events of unanticipated severity or frequency, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include: </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">292 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or other enforcement-related letters of clinical holds on post-approval clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications, in accordance with the provisions of the approved label and FDA guidance. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses, and a company that is found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses may be subject to significant liability, including investigation by federal and state authorities. Additionally, all promotional material must be truthful and <span style="white-space:nowrap">non-misleading,</span> and present balanced information regarding the risks and benefits of the drug product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Regulatory Requirements</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the U.S., our abilities to develop and market a product, if we continue to progress the development of our product candidates, are contingent upon receiving approval and ultimately marketing authorization from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from jurisdiction to jurisdiction. At present, foreign marketing authorizations are applied for at a national level, although within the E.U. registration procedures are available to companies wishing to market a product in more than one E.U. member state.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to U.S. federal and foreign anti-corruption laws. Those laws include the U.S. Foreign Corrupt Practices Act, or FCPA, which prohibits U.S. corporations and their representatives from offering, promising, authorizing, or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA encompasses certain healthcare professionals in many countries. We are also subject to similar laws of other countries that have enacted anti-corruption laws and regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pediatric Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, companies developing a new medicinal product must agree to a Pediatric Investigation Plan, or PIP, with the European Medicines Agency (EMA) and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The MAA for the product must include the results of pediatric clinical trials conducted in accordance&#160;with the PIP, unless a waiver applies or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Where the MAA includes the results of all pediatric studies conducted in accordance with the PIP and the results are reflected in the approved summary of product characteristics, the holder of a patent or supplementary protection certificate is entitled to receive a <span style="white-space:nowrap">six-month</span> extension of the protection under a supplementary protection certificate or, in the case of orphan medicinal products, the product is eligible for a <span style="white-space:nowrap">two-year</span> extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">293 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the US, under Pediatric Research Equity Act (PREA), a pediatric development plan is required to accompany an NDA for all drugs, except those receiving <span style="white-space:nowrap">non-oncology</span> Orphan Drug Designation. This may include waiver or deferral of pediatric studies. The Best Pharmaceuticals for Children Act (BPCA) also allows for agreement with FDA on a pediatric written request that, if fulfilled, may extend data exclusivity for the molecule for an additional 6 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our plans for a potential new drug candidate for TRD under consideration may be applicable for the treatment of pediatric patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite our belief that, if we continue to progress the development of our product candidates, the potential product that we intend to develop and commercialize in TRD will be differentiated, we will face competition from many different sources. Potential competition includes major/specialty pharmaceutical, biopharmaceutical, device and biotechnology companies, academic institutions, governmental agencies and medical research organizations. Additionally, we would expect that, if approved, our product will compete with the standard of care and any new therapies that may become available in the future. Several biopharmaceutical companies have therapies in clinical development for TRD and we are aware that many more are investigating treatments for TRD (e.g., psychedelic-related therapies are currently in development for TRD but have not yet been approved). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TRD is a disease with high unmet need and is associated with multiple serious public health implications. The FDA and the EMA have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment). A number of published sources estimate that at least 30% of persons with depression meet this definition. There are many treatment paradigms that have been employed for the management of TRD. In general, these treatment paradigms /therapies can be bucketed into categories of: pharmacotherapies, somatic therapies and psychotherapeutic approaches. It is well known that the majority of these treatments have serious limitations despite their benefit. Many companies have developed or are seeking to develop new treatments for TRD. Leading companies in TRD market include Janssen (Johnson&#160;&amp; Johnson) with Spravato, alongside major pharmaceutical firms Eli Lilly, AbbVie, Pfizer, and Novartis. Specialized biotechs like Compass Pathways and Axsome Therapeutics are actively developing novel therapies, including psychedelic compounds and rapid-acting agents. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pharmacotherapies</span>: antidepressants and antipsychotics indicated for use in major depressive disorder are frequently prescribed, combined or augmented with a second agent to treat TRD. Additionally, mood stabilizers (e.g. lithium) are utilized as treatments, alone or in combination for TRD. Only two pharmacotherapies are approved for TRD in the U.S.: Spravato (esketamine), marketed by Janssen (a subsidiary of Johnson&#160;&amp; Johnson) and Symbyax (olanzapine/fluoxetine hydrochloride capsules), developed by Eli Lilly and Company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Somatic Therapies</span>: multiple somatic therapies are used for the management of TRD such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Psychotherapeutic Approaches</span>: manual-based psychotherapies are not proven to be efficacious as a standalone intervention in TRD, but their efficacy in combination with antidepressants has been noted. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is highly competitive within and across therapeutic categories and indications. There are many public and private biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the research and development and commercialization of products that&#160;may be similar to our product candidates or address similar markets. In addition, the number of companies seeking to develop and commercialize products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">294 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitive advantage in the markets we target. The success of all of our product candidates, if approved, will likely depend upon their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors may have greater financial resources and broader expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors could also compete with us in establishing clinical trial sites and participant registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition can also impact Tisento (in which we hold an equity interest), as well as companies which we have <span style="white-space:nowrap">out-licensed</span> or seek to <span style="white-space:nowrap">out-license</span> our product candidates. To date, the product candidates we have sold to Tisento or <span style="white-space:nowrap">out-licensed</span> to Akebia are either in early stage clinical or <span style="white-space:nowrap">pre-clinical</span> stages or not yet received any approval allowing for the commercial sale of these product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Manufacturing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. If we continue to progress the development of our product candidates, we intend to depend on third-party contract manufacturing organizations, or CMOs, for all our requirements of raw materials, drug substance and drug products for clinical trials and nonclinical research. If we continue to progress the development of our product candidates, we intend to continue to rely on CMOs for the supply of our retained assets for all stages of clinical development and commercialization, as well as for the supply of any other product candidates that we may identify. We require all our CMOs to conduct manufacturing activities in compliance with current GMP requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Human Capital Resources </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a small, innovative company, if in the future we elect to start growing our internal operations, our success will depend on attracting, retaining and motivating highly skilled and experienced scientific, medical and other personnel. We plan to provide compensation and benefits programs which may include competitive salaries, potential annual discretionary bonuses, stock awards, a 401(k) plan with employer match, healthcare and insurance benefits, health savings and flexible spending accounts, unlimited vacation time, among other benefits. Our employees will be further guided by our code of conduct and our cultural values of seeking to serve patients, acting with integrity, empowering people and innovating for solutions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employee Profile </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2025, we had one employee and several consultants, including our Chief Financial Officer. We may in the future seek to expand our employee base, hire additional consultants and also outsource certain functions to other firms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in the Commonwealth of Massachusetts on September&#160;6, 2018. Our principal executive offices are located at 245 First Street, Riverview II, 18<sup style="font-size:75%; vertical-align:top">th</sup> Floor, Cambridge, MA 02142. Our telephone number is (857) <span style="white-space:nowrap">327-8778.</span> Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;CYCN.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">295 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Available Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our internet website address is www.cyclerion.com. In addition to the information contained in this proxy statement/prospectus supplement, information about us can be found on our website. Our website and information included in or linked to our website are not part of this proxy statement/prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our annual reports on Form <span style="white-space:nowrap">10-K,</span> quarterly reports on Form <span style="white-space:nowrap">10-Q,</span> current reports on Form <span style="white-space:nowrap">8-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission, or the SEC. The SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#8217;s website is www.sec.gov. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">296 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_29">KORSANA&#8217;S BUSINESS </p> <div> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korsana Overview </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer&#8217;s disease (&#8220;AD&#8221;). Korsana&#8217;s lead product candidate, <span style="white-space:nowrap">KRSA-028,</span> is an anti-amyloid beta (&#8220;A<span style="FONT-FAMILY:SYMBOL">b</span>&#8221;) antibody that combines the proprietary Therapeutic Targeting (&#8220;THETA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>&#8221;) platform with clinical and regulatory learnings from other <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> products that have achieved regulatory approval or are in late-stage clinical trials. <span style="white-space:nowrap">KRSA-028</span> was designed to build upon the success of these prior products while addressing shortcomings that limit their clinical and commercial success, such as the ability to penetrate the brain. Korsana believes that <span style="white-space:nowrap">KRSA-028</span> has the potential to rapidly clear amyloid plaques resulting in meaningful impacts on clinical symptoms in AD patients, and to do so while avoiding adverse effects associated with the specific designs of prior products. After Korsana completes GLP toxicity studies, it intends to submit a Clinical Trial Notification (&#8220;CTN&#8221;) in Australia or a Clinical Trial Application (&#8220;CTA&#8221;) in New Zealand by the end of 2026 and an Investigational New Drug (&#8220;IND&#8221;) application in the United States in the first quarter of 2027. Pharmacokinetic data in healthy volunteers is anticipated by <span style="white-space:nowrap">mid-year</span> 2027 and interim <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data in AD patients is anticipated by the end of 2027. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. See &#8220;<span style="font-style:italic">Risk Factors &#8211; Risks Related to Korsana &#8211; Risks Related to Korsana&#8217;s Discovery, Development, and Commercialization &#8211; Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Korsana&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Korsana may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.&#8221;</span> </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AD is a progressive and devastating neurodegenerative disease that slowly destroys cognition and leads to progressive impairment in patients&#8217; ability to conduct activities of daily living. Prevalence increases with age; up to <span style="white-space:nowrap">one-third</span> of people over age 85 have symptoms. There are seven million people suffering from AD in the United States, a number that is expected to double by 2050 due to an aging population. AD is the seventh-leading cause of death in the United States with an estimated 500,000 deaths every year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until recently, approved treatments for AD addressed only symptoms and had no impact on the course of the disease. That situation changed after the approval of antibody-based therapeutics that targeted A<span style="FONT-FAMILY:SYMBOL">b</span>. Clinical trials of these therapeutics have provided clear evidence that antibody-mediated depletion of A<span style="FONT-FAMILY:SYMBOL">b</span> in the brain correlates with a reduction in the rate of cognitive decline in symptomatic AD. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> was designed using clinical and regulatory learnings from these pioneering antibody-based therapeutics, together with Korsana&#8217;s proprietary combination of antibody engineering technologies, with the goal of improving clinical efficacy and safety profiles. <span style="white-space:nowrap">KRSA-028</span> targets what is believed to be the most clinically relevant form of A<span style="FONT-FAMILY:SYMBOL">b</span> and is designed to improve brain uptake while reducing effects on reticulocytes. It was also designed with physicochemical properties and stability intended to enable potent <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> activity to the brain via subcutaneous injections. Key features of <span style="white-space:nowrap">KRSA-028&#8217;s</span> design include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating a proprietary TfR based shuttle designed to potentially improve delivery to the brain, which Korsana believes may also help reduce or avoid the treatment-related complications known as ARIA associated with the two approved disease-modifying therapies </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Targeting <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span>, a form of A<span style="FONT-FAMILY:SYMBOL">b</span> that is enriched in amyloid plaques that is believed to contribute to plaque formation in AD </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating Fc domain modifications designed to potentially improve half-life and reduce the potential for hematologic adverse events seen with other antibodies that incorporate TfR-based shuttles, while potentially preserving antibody-mediated immune function believed to contribute to amyloid plaque clearance </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">297 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enabling subcutaneous formulation through potentially favorable solubility, viscosity, and stability characteristics. </p></td></tr></table> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary THETA technology used to create <span style="white-space:nowrap">KRSA-028</span> combines the benefits of TfR-mediated shuttling to the brain with Fc modifications to extend half-life and spare reticulocytes from destruction shown to be caused by third-party TfR-shuttled investigational products. The THETA technology was designed to retain phagocytic capacity, the mechanism by which the two approved disease-modifying products are thought to clear amyloid plaques from the brain. Korsana believes that the THETA platform will lead to meaningful improvements in the ability to deliver therapeutic modalities, such as antibodies, to the brain, while minimizing the frequency of adverse events associated with other TfR-based shuttle systems. Korsana intends to expand its pipeline by advancing other product candidates that incorporate THETA technology. Korsana anticipates disclosing details on its next product candidate in late 2026 or 2027. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana was founded in 2024 and launched to research and develop brain-targeted antibody candidates licensed from Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) and led by industry veterans with extensive experience in drug discovery and development. Fairmount has launched a series of companies based on assets licensed from Paragon, including Apogee Therapeutics, Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, Crescent Biopharma, and Damora Therapeutics. Members of Korsana&#8217;s executive team and other employees have extensive experience in the manufacture and development of antibodies and AOCs, including management and oversight of externalized research and development activities. Paragon and Paragon Laboratories performs research services for Korsana to discover and evaluate potential antibody and AOC product candidates, which could be licensed for further development, manufacture and commercialization by Korsana. Korsana separately performs certain GLP toxicity studies and pre-clinical IND enabling activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has entered into a License Agreement with Paragon (the &#8220;Paragon License Agreement&#8221;); (ii) an Antibody Discovery and Option Agreement with Paragon and Parasa Holding LLC (&#8220;Parasa&#8221;) (the &#8220;Paragon ADOA&#8221;); (iii) a Platform Option Agreement with Paragon and Parasa (the &#8220;Paragon POA&#8221;); and (iv) an Antibody Oligo Conjugate (&#8220;AOC&#8221;) Research Letter Agreement with Paragon Laboratories, Inc. (&#8220;Paragon Laboratories&#8221;) (the &#8220;Paragon Research Letter Agreement&#8221; and, together with the Paragon License Agreement, the Paragon ADOA, and the Paragon POA, the &#8220;Paragon Agreements&#8221;). As described in more detail in this proxy statement/prospectus, as of the date of this proxy statement/prospectus, Korsana has exercised the option for Research Program 002 (including KRSA-028) pursuant to the Paragon ADOA and has entered into the Paragon License Agreement covering Research Program 001 and Research Program 002. Korsana has not exercised its option or licensed any other program under the Paragon ADOA, Paragon POA, or the Paragon Research Letter Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Paragon identifies, evaluates, and develops antibodies against one or more mutually agreed therapeutic targets and a mutually agreed brain transit target, in accordance with research plan(s) mutually agreed to by Paragon and Korsana. The Paragon ADOA covers multiple research programs, including two research programs targeting A&#223; as the therapeutic target and TfR1 as the brain transit target (&#8220;Research Program 001&#8221; and &#8220;Research Program 002&#8221;, respectively, and collectively, the &#8220;A&#223; Research Programs&#8221;), with the ability to add additional programs by mutual agreement. Each research program is overseen and coordinated by a joint development committee consisting of two employees from Korsana and two employees from Paragon, with Korsana and Paragon each having one vote with respect to decisions of the committee. Under the Paragon ADOA, Korsana has the exclusive option, on a program-by-program basis (each, an &#8220;ADOA Option&#8221;), to negotiate and enter into a license agreement (each, a &#8220;License&#8221;) granting Korsana (a) an exclusive, worldwide license to the product-specific intellectual property from the applicable program and (b) a non-exclusive, worldwide license to certain incorporated platform technology, including THETA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana exercised the ADOA Option for Research Program 002, nominated KRSA-028 as the development candidate for Research Program 002, and entered into the Paragon License Agreement with respect to the A&#223; Research Programs. Pursuant to the Paragon License Agreement, Paragon granted Korsana a worldwide, royalty-bearing, exclusive (even as to Paragon and its affiliates) and sublicensable license under certain licensed antibody </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">298 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transport vehicle technology, to develop, manufacture and commercialize antibody products and antibody transport vehicle products directed to A<span style="FONT-FAMILY:WINGDINGS">&#232;</span> and TfR1, and related non-exclusive licenses under certain transit antibody technology, patents and know-how, which includes the THETA technology. The exclusive license covers certain derived antibodies, derived antibody transport vehicles and related products within the scope of the Paragon License Agreement. In addition, any additional antibody transport vehicles discovered, generated, identified or characterized by Paragon under the A<span style="FONT-FAMILY:WINGDINGS">&#232;</span> Research Programs are included as licensed antibody transport vehicles under the Paragon License Agreement, subject to the express exclusions and limitations set forth in the Paragon License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon License Agreement, Korsana is responsible for development, manufacturing, regulatory and commercialization activities for licensed products and is obligated to use commercially reasonable efforts to develop and seek regulatory approval for at least one licensed product in the United States and at least one other major market country. Korsana is required to make milestone payments to Paragon upon the achievement of specified development and regulatory milestones and to pay Paragon tiered royalties in the low- to mid-single digits on annual net sales of licensed products, subject to specific reductions. If a product candidate, including certain combination products, is developed by Korsana as a bona fide back-up or substitute product to another royalty product for the same licensed therapeutic target, the same licensed transit target, if applicable, and the same indication, it would be considered a back-up royalty product for which no duplicate milestone payments are owed to Paragon, subject to specified limitations. The agreement expires on a product-by-product and country-by-country basis upon expiration of the applicable royalty term, unless earlier terminated, and may be terminated by Korsana for convenience upon 60 days&#8217; prior written notice. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korsana&#8217;s Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana intends to become a leading biopharmaceutical company addressing the needs of patients suffering from neurodegenerative diseases. Korsana&#8217;s strategy is to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Obtain clinical <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data with <span style="white-space:nowrap">KRSA-028</span> in a Phase 1/2 trial. </span><span style="white-space:nowrap">KRSA-028</span> was designed to build on the mechanisms of pioneering anti-A<span style="FONT-FAMILY:SYMBOL">b</span> therapeutics and the clinical and regulatory precedents they have established. Korsana believes that it can efficiently obtain clinical <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data demonstrating the potential of <span style="white-space:nowrap">KRSA-028</span> to provide meaningful benefits in AD patients in a Phase 1/2 trial, a combined single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) trial in healthy participants and AD participants respectively. After Korsana completes GLP toxicity studies, it anticipates submitting a CTN in Australia or a CTA in New Zealand by the end of 2026 to support the SAD portion of the trial in healthy participants and an IND in the United States in the first quarter of 2027 to support the MAD portion of the trial in AD patients, with interim results in AD patients becoming available by the end of 2027. </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Expand its portfolio of product candidates.</span> The THETA platform technology has potential advantages over other technologies designed to shuttle therapeutics to the brain. Korsana intends to expand its portfolio by advancing additional product candidates that incorporate this technology with the potential to transform the treatment of neurodegenerative diseases. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Maximize the value of <span style="white-space:nowrap">KRSA-028</span> by exploring its potential in treating presymptomatic AD.</span> Data generated with other <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> therapeutics suggests that their ability to slow disease progression is more pronounced when administered early in the course of the disease. Ongoing third-party Phase 3 trials aim to confirm these findings. Korsana believes that the properties of <span style="white-space:nowrap">KRSA-028,</span> including dosing convenience and specific modifications designed to reduce the likelihood of adverse events seen with other products, position it as an attractive candidate for early-stage and potentially presymptomatic AD. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Build a preeminent biotechnology company initially focused on neurodegenerative diseases. </span>Korsana is assembling a team of experts dedicated to bringing life-changing therapies to patients suffering from neurodegenerative diseases. Korsana plans to apply this expertise to support the development of <span style="white-space:nowrap">KRSA-028</span> and other THETA product candidates as well as to identify product candidates that address other unmet needs in this field. </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">299 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Growing Unmet Need in Treating Neurodegenerative Diseases </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neurodegenerative diseases are progressive conditions in which nerve cells lose their function and eventually die. Because these neurons are rarely replaced, neurodegeneration is generally considered to be irreversible. Although genetics can increase the risk of developing a neurodegenerative disease, in most instances the exact cause is not known. Age is a common risk factor for diseases such as AD; Parkinson&#8217;s disease (&#8220;PD&#8221;); amyotrophic lateral sclerosis (&#8220;ALS&#8221;); frontotemporal lobar degeneration (&#8220;FTLD&#8221;); Huntington&#8217;s disease (&#8220;HD&#8221;); and others. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a04.jpg" alt="LOGO" style="width:6.12264in;height:3.33333in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 1. The prevalence of a number of neurodegenerative diseases increases with age</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The world&#8217;s population is undergoing a demographic shift as the proportion of older adults increases. From 2020 to 2050, the global population aged 60 years and over is projected to increase from one billion to 2.1&#160;billion. Increases in life expectancy mean these adults are also living longer, with the number of people aged 80 and over expected to triple to 426&#160;million. These trends suggest that the prevalence of neurodegenerative diseases and their impact on society will continue to grow. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Society bears a heavy burden from the increasing cost of neurodegenerative disease care. For example, between 2015 and 2050, the global costs of caring for patients with dementia alone are expected to increase nearly tenfold to $9.12 trillion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent technological advancements in diagnostics and in the ability to deliver therapeutics to the central nervous system (&#8220;CNS&#8221;), have enabled the discovery and approval of some of the first therapeutics that have meaningful impacts on slowing the rate of progression of AD, the most prevalent of neurodegenerative diseases. Korsana believes that these findings provide an opening to develop therapies with improved efficacy and safety for AD while providing a template that can be applied to the discovery of therapeutics for other neurodegenerative diseases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">KRSA-028</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> is an <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibody that targets <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span>, a modified form of A<span style="FONT-FAMILY:SYMBOL">b</span> that is prevalent in amyloid plaques in AD patients. <span style="white-space:nowrap">KRSA-028</span> is further distinguished from other A<span style="FONT-FAMILY:SYMBOL">b</span> therapeutics through the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">300 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incorporation of THETA platform technology which enables increased brain exposure by means of an endogenous protein shuttle system. <span style="white-space:nowrap">KRSA-028</span> was engineered to be delivered subcutaneously in order to increase patient convenience and to reduce the overall impact of treatment on the healthcare system. After Korsana completes GLP toxicity studies, it intends to submit a CTN for <span style="white-space:nowrap">KRSA-028</span> in Australia or a CTA in New Zealand by the end of 2026 and an IND in the United States in the first quarter of 2027. Korsana anticipates that interim <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data will be available by the end of 2027. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Alzheimer&#8217;s Disease Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Alzheimer&#8217;s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills and eventually prevents patients from carrying out even simple tasks. Its symptoms include cognitive dysfunction, memory abnormalities, progressive impairment in activities of daily living and a host of behavioral and neuropsychiatric symptoms. The exact cause of AD is unknown; however, genetic and environmental factors are established contributors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The hallmark neuropathologic changes of AD are diffuse plaques marked by extracellular A<span style="FONT-FAMILY:SYMBOL">b</span> protein. Deposition of A<span style="FONT-FAMILY:SYMBOL">b</span> is an early event in the development of AD. A<span style="FONT-FAMILY:SYMBOL">b</span> is derived from proteolytic cleavage of amyloid precursor protein (&#8220;APP&#8221;). Normal processing of APP results in the secretion of A<span style="FONT-FAMILY:SYMBOL">b</span> protein in multiple forms: a predominant <span style="white-space:nowrap">40-amino</span> acid form, known as A<span style="FONT-FAMILY:SYMBOL">b</span>40, and a less abundant <span style="white-space:nowrap">42-amino</span> acid form known as A<span style="FONT-FAMILY:SYMBOL">b</span>42. A<span style="FONT-FAMILY:SYMBOL">b</span>42 is more prone to aggregation and has been shown to be enriched in A<span style="FONT-FAMILY:SYMBOL">b</span> plaques in AD. In addition, approximately 25% of the total A<span style="FONT-FAMILY:SYMBOL">b</span>42 in plaques has an altered form of the amino acid glutamate known as pyroglutamate (&#8220;pE&#8221;), at position 3. This altered form of A<span style="FONT-FAMILY:SYMBOL">b</span>42, <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span>, is highly prone to the type of <span style="white-space:nowrap">AD-associated</span> amyloid clustering known as oligomerization and is believed to be a key driver in AD pathogenesis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">One of the most common initial symptoms of AD is memory impairment, in particular, the ability to recall recent events. As AD progresses, the cognitive dysfunction it brings leads to deficits both in executive function and in problem solving. Patients become less organized and less motivated. As the disease progresses, an inability to complete tasks emerges, followed subsequently by deficits in language. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In late-stage disease, behavioral and psychological symptoms, such as apathy, social disengagement and irritability are common. Some patients develop agitation, aggression, wandering, and psychosis. AD patients frequently develop sleep disorders and 10% to 20% experience seizures. The average life expectancy after a diagnosis of AD has been reported to be between eight and ten years. Patients generally succumb to terminal-stage complications that relate to advanced debilitation, such as dehydration, malnutrition, and infection. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">AD is a highly prevalent and costly disease </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">While estimates of the prevalence of AD vary, the Alzheimer&#8217;s Association estimates that there are seven million people in the United States suffering from AD and that this number is projected to double by 2050. AD is the seventh-leading cause of death in the United States and is associated with an estimated 500,000 deaths a year. According to the Alzheimer&#8217;s Association, in the United States alone, 1 in 9 persons over the age of 65 have AD. In people aged 85 and above, that rate increases to 1 in 3 persons. Globally, AD affects some 60&#160;million patients. This number does not include the estimated<span style="font-style:italic"> </span><span style="white-space:nowrap">6-fold</span> of additional people who unknowingly harbor the disease in its presymptomatic biological form. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition to its debilitating effect on patients&#8217; cognition and <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> functioning, AD places a significant burden on the healthcare system. The costs of healthcare and long-term care for patients with AD in the United States was estimated to be $384&#160;billion in 2025, with this cost expected to grow to more than $1 trillion by 2050 as the population ages. <span style="white-space:nowrap">Two-thirds</span> of this cost is borne by Medicare and Medicaid. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Indirect costs of care associated with AD include caregiver burden and associated healthcare utilization and costs. It has been estimated that over 80% of caregiving for a patient with AD is informal care by family and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">301 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
friends. Providing care to a patient with AD is financially, physically, and emotionally burdensome to the caregiver. Caregiving for patients with AD is unique compared with caregiving in other disease states due to the long duration of disease, and the progressive, unrelenting decline in cognitive and physical functioning. In the United States, over 11&#160;million caregivers provide unpaid care for people with AD or other dementias. The Alzheimer&#8217;s Association estimates that, in 2024, these caregivers provided 19.2&#160;billion hours of care valued at $414&#160;billion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Treatments for AD </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There are currently no cures for AD, despite many clinical trials of numerous agents based on a wide range of mechanisms. Two classes of symptomatic therapies are approved for the treatment of AD: acetylcholinesterase inhibitors and glutamatergic modulators. The approved acetylcholinesterase inhibitors donepezil, galantamine, and rivastigmine are designed to slow the degradation of acetylcholine, helping to preserve neuronal communication. Approved glutamatergic modulators, such as memantine, are designed to block sustained, <span style="white-space:nowrap">low-level</span> activation of the <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">N-methyl-D-aspartate</span></span></span> (&#8220;NMDA&#8221;) receptor. These drugs provide temporary benefit, but they do not slow or halt neuronal death and do not represent a change in the underlying course of disease. In addition, antidepressants and antipsychotics are often prescribed <span style="white-space:nowrap">off-label</span> to treat the symptoms of severe AD when patients suffer from agitation, aggressive behaviors, psychosis and depression. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The biology of AD is complex, involving progressive, interactive and destructive processes that lead to neuronal dysfunction and cell death. The pharmaceutical industry has taken notice of the unmet need by developing therapies intended to be disease-modifying rather than simply targeting symptom relief. Indeed, there are more than 80 product candidates currently in Phase 2 or Phase 3 trials aimed at altering the course of AD progression. Recent drug candidates under development for AD include those focused on A<span style="FONT-FAMILY:SYMBOL">b</span> synthesis or clearance from the brain, the synthesis, phosphorylation, or clearance from the brain of tau protein, chronic inflammation, vascular dysfunction, metabolic dysregulation and neurotoxicity. However, most of these drug candidates have so far failed to demonstrate significant benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Clinical trials of three <span style="white-space:nowrap">FDA-approved</span> <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibodies have demonstrated that reductions in amyloid plaques provide meaningful clinical benefit in AD. The most significant clinical outcomes have been reported for lecanemab, marketed as Leqembi<sup style="font-size:75%; vertical-align:top">&#174;</sup> by Biogen and Eisai, and donanemab, marketed as Kisunla<sup style="font-size:75%; vertical-align:top">&#174;</sup> by Eli Lilly. Both of these therapies slow AD progression by almost 30%, a modest but meaningful impact on disease progression that is projected to lead to benefits in healthcare-related resource utilization. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a05.jpg" alt="LOGO" style="width:5.91824in;height:2.58491in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 2. Lecanemab and donanemab slow the rate of AD disease progression by about 30% </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">302 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">An important observation from clinical trials of <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibodies is the correlation between the degree of A<span style="FONT-FAMILY:SYMBOL">b</span> plaque removal and the impact on disease progression. Antibodies such as solanezumab and crenezumab, which had minimal impact on A<span style="FONT-FAMILY:SYMBOL">b</span> plaque removal, did not lead to meaningful effects on clinical symptoms. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a06.jpg" alt="LOGO" style="width:4.89623in;height:3.07547in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 3. Increased reduction in amyloid plaques across multiple Phase 3 clinical trials is associated with reduced rate of cognitive decline. The sizes of the bubbles represent the number of patients. </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure adapted from 2023 Boxer (Cell). </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">A challenge associated with approved <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> therapies is the risk that patients treated with them may develop neurological complications referred to as ARIA. Although the mechanisms underlying ARIA remain incompletely understood, the occurrence of these adverse events appears to be linked to vascular amyloid deposition. In clinical studies, approximately 15% to 25% of patients treated with <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> therapies developed ARIA. ARIA consists of two forms: a form associated with hemorrhage, known as <span style="white-space:nowrap">ARIA-H;</span> and a form associated with edema, known as <span style="white-space:nowrap">ARIA-E.</span> While ARIA occurs at a low rate in AD patients, <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibodies increase rates of ARIA by damaging blood vessels. Increased <span style="white-space:nowrap">ARIA-H</span> is correlated with worsening cognition although symptoms can be avoided if <span style="white-space:nowrap">ARIA-H</span> is detected early and treatment suspended. <span style="white-space:nowrap">ARIA-E</span> is associated with symptoms that include worsening of cognition, headache, and gait disturbance, which can be severe enough to lead to hospitalization. <span style="white-space:nowrap">Anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> therapies carry a black box warning due to the risk of serious or life-threatening complications from ARIA. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">303 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a07.jpg" alt="LOGO" style="width:3.86792in;height:3.19182in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 4. Treatment with <span style="white-space:nowrap">anti-A</span></span><span style="FONT-FAMILY:SYMBOL">b</span><span style="font-style:italic"></span><span style="font-style:italic"> antibodies is associated with the development of <span style="white-space:nowrap">ARIA-E</span> and <span style="white-space:nowrap">ARIA-H</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Monitoring for ARIA requires regular cerebral MRI imaging during the first six months of <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> therapy, which is when the vast majority of ARIA events occur. This, combined with the need to administer these therapies by intravenous infusion, results in a high burden on patients, caregivers, and the healthcare system. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a08.jpg" alt="LOGO" style="width:6.08176in;height:2.4434in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 5. Treatment regimens for Leqembi and Kisunla based on their FDA approved labels </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Leqembi and Kisunla received FDA approval in 2023 and 2024, respectively, and had combined annual revenue of about $900&#160;million in 2025. Both are expected to become multi-billion-dollar products despite the documented risk of ARIA. Korsana believes that therapies offering improved efficacy and greater tolerability can benefit from the growing awareness of disease-modifying anti-amyloid therapies that these early entrants have generated among patients, caregivers, and healthcare providers and can not only address the current patient population but also expand the addressable AD market. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">304 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana&#8217;s solution, <span style="white-space:nowrap">KRSA-028</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> is an <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibody designed to improve AD treatment by addressing key limitations of existing therapies. <span style="white-space:nowrap">KRSA-028</span> is designed to increase the delivery of <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> activity to the brain through convenient subcutaneous injections while minimizing the risk of ARIA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key features of <span style="white-space:nowrap">KRSA-028&#8217;s</span> design are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating a proprietary TfR based shuttle designed to potentially improve delivery to the brain, which may potentially avoid the high local concentrations thought to be associated with the development of ARIA </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Targeting <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span>, a form of A<span style="FONT-FAMILY:SYMBOL">b</span> that is believed to contribute to plaque formation in AD </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating Fc domain modifications designed to potentially improve half-life and reduce the potential for hematologic adverse events </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enabling subcutaneous formulation through potentially favorable solubility, viscosity, and stability </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pairing of a novel TfR1-targeting domain with a proprietary combination of Fc modifications designed to improve pharmacokinetics, spare reticulocytes from destruction, and preserve amyloid phagocytosis is a key differentiator for <span style="white-space:nowrap">KRSA-028,</span> and has been named the &#8220;Therapeutics Targeting&#8221; platform, or &#8220;THETA&#8221; platform. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a09.jpg" alt="LOGO" style="width:5.97833in;height:2.54598in"/>
 </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 6. Design of <span style="white-space:nowrap">KRSA-028</span> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Increased brain exposure through shuttling </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A challenge with most biotherapeutics is that the blood-brain barrier severely limits the ability of these molecules to enter the brain. Although the brain is highly vascularized, molecules such as antibodies are unable to readily cross the blood-brain barrier, limiting their therapeutic potential. Approved <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibodies aducanumab, lecanemab and donanemab all face this problem. To compensate for poor brain permeability, doses of these drugs can approach or exceed 1000 mg to achieve significant reductions in A<span style="FONT-FAMILY:SYMBOL">b</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These high levels limit the administration of the highest doses to intravenous infusions. The first subcutaneous product, Leqembi Iqlik<sup style="font-size:75%; vertical-align:top">&#8482;</sup>, is approved by the FDA as a maintenance therapy for AD. Weekly subcutaneous doses of Leqembi Iqlik result in serum levels of lecanemab that are approximately half of those achieved with biweekly intravenous dosing of 10 mg/kg, which is the dosage recommended for the first 18 months of treatment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">305 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A method for overcoming the limitations posed by the blood-brain barrier is to take advantage of the natural process that is used to shuttle substances such as transferrin across the barrier. In this process, referred to as receptor-mediated transcytosis, a substance to be transported binds to specific receptors on cells that face blood capillaries. Upon binding, the receptor-ligand complexes are transported through the cell and the ligand is released into the brain. There is a well-documented precedent for using TfR to shuttle biotherapeutics across the blood-brain barrier, including the shuttling of an <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibody in clinical development. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a10.jpg" alt="LOGO" style="width:5.82075in;height:3.27358in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 7. TfR-mediated transcytosis provides a mechanism to transport antibodies across the blood-brain barrier </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gantenerumab is an <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibody originally developed by Genentech/Roche that does not contain a shuttle domain. Gantenerumab failed to significantly slow AD progression in two Phase 3 trials. One of the challenges with gantenerumab was that it was associated with a high rate of ARIA. Despite a dose titration regimen that was intended to minimize adverse events, up to 26% of patients experienced ARIA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roche used TfR technology to create trontinemab, a molecule designed to overcome these limitations. Trontinemab was designed to improve the <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> activity of gantenerumab through the attachment of a protein domain engineered to use the TfR to shuttle it across the blood-brain barrier. Trontinemab was shown to have two properties that differentiated it from gantenerumab: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The CNS exposure of drug, as measured by the ratio of drug in the cerebrospinal fluid, or CSF, compared to plasma, was eight-fold higher after a dose of 10 mg/kg trontinemab compared to what was previously observed after a 20 mg/kg dose of gantenerumab. Importantly, treatment with trontinemab led to more rapid reductions in amyloid levels in AD patients. Over 90% of patients treated with 3.6 mg/kg trontinemab achieved amyloid-negative status by week 28, whereas only 28% of patients treated with 510 mg gantenerumab achieved amyloid-negative status by week 116. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">306 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a11.jpg" alt="LOGO" style="width:5.99057in;height:2.45283in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 8. Trontinemab led to higher brain exposure and more rapid reductions in amyloid than historic results with gantenerumab </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Despite higher brain exposure, trontinemab was associated with a decreased risk of ARIA compared to gantenerumab. This reduction of ARIA is believed to result from trontinemab largely avoiding exposing vascular tissue in the brain to high levels of <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibodies. Although the mechanisms underlying ARIA remain incompletely understood, the occurrence of these adverse events appears to be linked to vascular amyloid deposition. Both the lower doses of trontinemab and its ability to be shuttled across the blood-brain barrier may reduce the frequency of ARIA by limiting vascular amyloid exposure. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> was designed with a proprietary TfR-based shuttle domain to increase brain penetration and reduce ARIA risk. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pre-clinical studies of KRSA-028 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana conducted multiple in vitro analytical similarity assessments comparing KRSA-028 to reference material generated by Paragon intended to model both investigational as well as marketed disease-modifying immunotherapies for AD. The assessments included measurements of brain penetration, half-life, and effect on reticulocytes in non-human primates and in vitro activity in cellular uptake of 3pE-A<span style="FONT-FAMILY:SYMBOL">b</span> fibrils, and the results are described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In both mice and NHPs, <span style="white-space:nowrap">KRSA-028</span> resulted in higher levels in the brain than equivalent doses of trontinemab, which Paragon generated based on published information. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a12.jpg" alt="LOGO" style="width:5.84591in;height:2.47484in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">307 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 9. <span style="white-space:nowrap">KRSA-028</span> had higher brain penetration in mice and NHPs than trontinemab </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Targeting <span style="white-space:nowrap">3pE-A</span></span><span style="FONT-FAMILY:SYMBOL">b</span><span style="font-style:italic"></span><span style="font-style:italic"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Analysis of amyloid plaques identified that a significant portion of A<span style="FONT-FAMILY:SYMBOL">b</span> protein contains modified amino acids. Approximately 25% of the total A<span style="FONT-FAMILY:SYMBOL">b</span>42 in plaques has an altered form of the amino acid glutamate known as pE at position 3. This altered form of A<span style="FONT-FAMILY:SYMBOL">b</span>42, <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span>, is highly prone to the type of <span style="white-space:nowrap">AD-associated</span> amyloid clustering known as oligomerization and is believed to be a key driver in AD pathogenesis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Donanemab, an <span style="white-space:nowrap"><span style="white-space:nowrap">anti-3pE-A</span></span><span style="FONT-FAMILY:SYMBOL">b</span> antibody, is associated with both a greater reduction in amyloid plaques and reduced rate of clinical decline in AD than other <span style="white-space:nowrap">anti-A</span><span style="FONT-FAMILY:SYMBOL">b</span> antibodies that do not target <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span>. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> was designed to target the same epitope or region of <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span> as donanemab and remternetug, a <span style="white-space:nowrap">follow-on</span> antibody to donanemab currently being developed by Eli Lilly. <span style="font-style:italic">In vitro</span> assays found that <span style="white-space:nowrap">KRSA-028</span> had similar potency and activity in cellular uptake of <span style="white-space:nowrap">3pE-A</span><span style="FONT-FAMILY:SYMBOL">b</span> fibrils as donanemab and remternetug, both of which Paragon generated based on published information. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a13.jpg" alt="LOGO" style="width:4.47153in;height:2.67569in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 10. <span style="white-space:nowrap">KRSA-028</span> had similar activity in a cellular 3pE-A&#223; uptake assay as donanemab </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fc engineering </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incorporation of a TfR shuttle domain into other biotherapeutics has a known potential advantage: it has been shown to increase biodistribution of various investigational biotherapeutics to the brain. However, incorporation of TfR shuttle technology also has a potential drawback: it typically decreases the overall half-life of the biotherapeutic due to the expression of the TfR in other tissues. Molecules that are recognized by the transferrin receptor in those tissues can be taken out of circulation by receptor-mediated endocytosis and degradation, thus reducing the amount of therapeutic molecules that are transferred into the brain. These other tissues include both cells that are part of the hematopoietic or blood-forming system such as bone-marrow cells as well as cells found in other tissues throughout the body. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antibody-based therapeutics that include a TfR shuttle domain face another challenge: their binding to TfR on blood cells known as reticulocytes triggers the destruction of these reticulocytes by the immune system. This process is driven by interactions with the antibody&#8217;s Fc domain. This destruction of reticulocytes results in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">308 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development of treatment-related anemia. Clinical results reported for trontinemab, an <span style="white-space:nowrap">anti-A&#223;</span> antibody containing a TfR-based shuttle domain, found that between 10% and 20% of treated patients experienced anemia. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a14.jpg" alt="LOGO" style="width:5.07222in;height:0.509028in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 11. Trontinemab treatment was associated with a risk of anemia </span></p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> was engineered to incorporate proprietary changes to its Fc domain to both improve its half-life in circulation and to reduce its propensity to cause anemia &#8211; without impairing its ability to cause phagocytosis of A&#223; plaques. Studies in NHPs demonstrate the impact of these changes on half-life and on anemia compared to trontinemab, which Paragon generated based on published information. <span style="white-space:nowrap">KRSA-028</span> had a <span style="white-space:nowrap">2.5-fold</span> longer half-life and did not lead to any reductions in reticulocytes compared to trontinemab. Korsana believes that both of these effects provide competitive advantages over trontinemab and other <span style="white-space:nowrap">anti-A&#223;</span> antibody product candidates that are designed to use a TfR-based shuttle domain. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a15.jpg" alt="LOGO" style="width:5.92138in;height:2.59119in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 12. Fc modifications incorporated into <span style="white-space:nowrap">KRSA-028</span> improve its half-life and reduce the depletion of reticulocytes in NHPs</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Improvement in properties to facilitate subcutaneous dosing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All <span style="white-space:nowrap">FDA-approved</span> therapies require burdensome administration and associated MRI monitoring. Kisunla requires monthly intravenous infusions and is not available as a subcutaneous formulation. Leqembi is available as a subcutaneous formulation, called Leqembi Iqlik, but maintenance dosing at 360 mg requires an initial <span style="white-space:nowrap">18-month</span> treatment course of intravenous infusions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> was designed to have the stability, viscosity, and solubility to specifically enable its delivery subcutaneously, thereby providing convenience for patients and reducing burdens on the healthcare system. Korsana believes <span style="white-space:nowrap">KRSA-028</span> should be compatible for development as a drug-device combination product using a marketed autoinjector. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">309 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initial comparisons of the projected pharmacokinetics of <span style="white-space:nowrap">KRSA-028</span> and that of trontinemab from clinical trials suggest that the exposure of a monthly 250 mg intravenous dose of trontinemab could be matched by a monthly subcutaneous dose of approximately 150 mg of <span style="white-space:nowrap">KRSA-028.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g00a16.jpg" alt="LOGO" style="width:3.94653in;height:2.99306in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Figure 13. Exposure levels of 150 mg <span style="white-space:nowrap">KRSA-028</span> delivered subcutaneously are projected to be equivalent to an intravenous doses of 250 mg trontinemab</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Competitive positioning of <span style="white-space:nowrap">KRSA-028</span> </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes that <span style="white-space:nowrap">KRSA-028&#8217;s</span> combination of key features &#8211; TfR-mediated delivery across the blood-brain subcutaneous delivery &#8211; provides the potential to deliver meaningful clinical activity. Although <span style="white-space:nowrap">KRSA-028</span> has yet to enter clinical development, Korsana believes that its preclinical profile offers the potential to have a number of competitive advantages over approved <span style="white-space:nowrap">anti-A&#223;</span> therapeutics and those in late-stage clinical development, including the potential to reduce ARIA risk, avoid anemia, and provide a differentiated subcutaneous administration profile. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical development of <span style="white-space:nowrap">KRSA-028</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approvals of other <span style="white-space:nowrap">anti-A&#223;</span> antibody therapeutics have, Korsana believes, provided a clear path for clinical development and established precedents for regulatory approval. Critical elements for the development of AD therapies are the availability of quantitative assessments of both amyloid levels in the brain and of clinical disease severity. A clear correlation between amyloid levels and disease severity has established that amyloid depletion can serve as an early biomarker for clinical activity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amyloid levels in the brain can be measured <span style="white-space:nowrap">non-invasively</span> using radiopharmaceuticals that specifically bind to amyloid and can be detected by positron emission tomography (&#8220;PET&#8221;). Although this technology has been available for over twenty years, it is only in the last decade or so that improved imaging agents such as florbetapir F18, marketed as Amyvid<sup style="font-size:75%; vertical-align:top">&#174;</sup> by Eli Lilly; flutemetamol F18, marketed as Vizamyl<sup style="font-size:75%; vertical-align:top">&#174;</sup> by GE Healthcare; and florbetaben F18, marketed as Neuraceq<sup style="font-size:75%; vertical-align:top">&#174;</sup> by Lantheus, became widely used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plaque density is often reported in Centiloids (&#8220;CL&#8221;), a standardized, <span style="white-space:nowrap">100-point</span> scale designed to quantify A&#223; plaque density in AD PET scans, anchoring a value of 0 CL as amyloid-negative and 100 CL as typical AD. It harmonizes data across different PET tracers, scanners, and analysis pipelines to ensure comparable, actionable results. The adoption of this standard within the field has enabled comparisons of data obtained across multiple sites as well as longitudinally collected data. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">310 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical efficacy is often measured by the Clinical Dementia Rating Sum of Boxes <span style="white-space:nowrap">(&#8220;CDR-SB&#8221;),</span> an <span style="white-space:nowrap">18-point</span> validated tool measuring both cognitive and functional impairment in AD. It sums scores from six domains: memory, orientation, judgment, community affairs, home/hobbies, and personal care. <span style="white-space:nowrap">CDR-SB</span> is accepted as a sensitive, standard outcome measure in clinical trials. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After Korsana completes GLP toxicity studies, it plans to submit a CTN in Australia or a CTA in New Zealand by the end of 2026 and an IND in the United States in the first quarter of 2027. Korsana has initiated interactions with the FDA regarding its clinical development plans for KRSA-028 and is in the process of collecting and analyzing FDA responses. Pending regulatory approval, the first-in-human (&#8220;FIH&#8221;), Phase 1/2 clinical trial is designed as an integrated SAD/MAD study in healthy adult participants and AD patients, respectively. The SAD portion of the study in healthy participants is expected to provide valuable data on safety, tolerability, pharmacokinetics, and CSF exposure by <span style="white-space:nowrap">mid-year</span> 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reduction in A&#223; levels observed in AD patients treated with other potent <span style="white-space:nowrap">anti-A&#223;</span> antibodies, such as trontinemab, is both rapid and highly reproducible across patients. In a Phase 1/2 trial, trontinemab led to a dose-dependent reduction in centiloids that exceeded a <span style="white-space:nowrap">70-point</span> change by day 50, an effect that was clearly distinguished from controls. Approximately a dozen patients were included in the treatment arm. Korsana believes that interim clinical <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data for <span style="white-space:nowrap">KRSA-028</span> can be obtained in the MAD portion of the FIH Phase 1/2 trial in AD patients by the end of 2027. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes that completion of its dose-ranging clinical trial in 2028 will provide the necessary pharmacologic and <span style="white-space:nowrap">anti-A&#223;</span> activity to enable a Phase 3 pivotal trial of <span style="white-space:nowrap">KRSA-028.</span> Korsana also believes that the properties of <span style="white-space:nowrap">KRSA-028,</span> such as its potential dosing convenience, low rate of ARIA, and avoidance of reticulocyte destruction, are well-aligned with its potential use to treat patients with presymptomatic AD. Support for this comes from a previous analysis conducted by Eli Lilly that demonstrated that the ability of donanemab to slow cognitive decline was more pronounced in patients with earlier stages of AD. Extrapolation of these findings by researchers at Eli Lilly suggested that treatment of patients with presymptomatic AD may delay or even stop disease progression. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preclinical programs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana intends to develop additional product candidates that incorporate the TfR shuttle and accompanying engineered Fc domain, which together are referred to as the THETA platform. Korsana anticipates disclosing details of its next program either in late 2026 or in 2027. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korsana&#8217;s Team, Investors, and Paragon Collaboration </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana was founded in 2024 and launched to research and develop brain-targeted antibody candidates licensed from Paragon, an antibody discovery engine founded by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) and led by industry veterans with extensive experience in drug discovery and development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is led by an experienced management team. Korsana&#8217;s President and CEO, Jonathan Violin, Ph.D., who also serves as a Director of the Company, brings deep experience in company building, business strategy, and product development. Dr.&#160;Violin previously served as interim CEO of Crescent Biopharma and the President and CEO of Viridian Therapeutics, which he also <span style="white-space:nowrap">co-founded.</span> He previously served as founding CEO of Dianthus Therapeutics and <span style="white-space:nowrap">co-founder</span> and CEO of Quellis Bioscience. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mark Vignola, Ph.D., Korsana&#8217;s Chief Financial Officer, has over 15 years of experience as a strategic financial leader to biotech companies and a strong track record of advancing companies through major inflection points. He most recently served as the Chief Financial Officer of Terns Pharmaceuticals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kyle Breidenstine, Korsana&#8217;s Senior Vice President, Finance and Treasurer, has nearly twenty years of experience in strategic finance, accounting, and operations. He most recently served as Vice President, Finance at PepGen. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">311 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Madelyn Zeylikman, Korsana&#8217;s General Counsel, has over twenty years of legal experience in the life sciences industry. She most recently served as General Counsel at Kiniksa Pharmaceuticals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana completed financings totaling&#160;$175&#160;million in its Series Seed and Series A financing from a syndicate of healthcare investors led by Fairmount, Venrock Healthcare Capital Partners, Wellington Management and TCGX, with participation by J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital, and others. Additionally, Korsana has secured financing commitments that, upon closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, are expected to result in total gross proceeds of $380&#160;million from a syndicate of healthcare investors led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, Wellington Management, Commodore Capital, RA Capital Management, RTW Investments, Vivo Capital, Janus Henderson Investors, Foresite Capital, J.P. Morgan Life Sciences Private Capital, SR One, Sanofi Ventures, Kalehua Capital, Spruce Street Capital, and other leading investment management firms. The financing includes Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Paragon Agreements </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Paragon Antibody Discovery and Option Agreement </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;5, 2025, Korsana entered into the Paragon ADOA with Paragon and Parasa. Under the Paragon ADOA, Paragon identifies, evaluates, and develops antibodies against one or more mutually agreed therapeutic targets and a mutually agreed brain transit target. The Paragon ADOA covers Research Program 001 and Research Program 002, each targeting A&#223; and TfR1 (collectively, the &#8220;A&#223; Research Programs&#8221;), and one undisclosed research program 003, with the ability to add additional programs by mutual agreement. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Korsana has the exclusive option, on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis (each, an &#8220;ADOA Option&#8221;), to negotiate and enter into a license agreement (each, a &#8220;License&#8221;) granting Korsana (a)&#160;an exclusive, worldwide license to the product-specific intellectual property from the applicable program and (b)&#160;a <span style="white-space:nowrap">non-exclusive,</span> worldwide license to certain incorporated platform technology. ADOA Options are exercisable at Korsana&#8217;s sole discretion during the applicable option period, with no separate exercise payment. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon signing, Korsana became obligated to reimburse Paragon approximately $18.8&#160;million for <span style="white-space:nowrap">pre-development</span> costs incurred through September&#160;5, 2025. For each research program, Korsana is also required to pay Paragon a research initiation fee and certain third-party costs and internal resource fees. As of March 31, 2026, Korsana has recorded an aggregate of $40.1&#160;million of operating expenses under the Paragon ADOA for development costs. On a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis, Korsana is also required to make <span style="white-space:nowrap">one-time,</span> <span style="white-space:nowrap">non-refundable</span> milestone payments of up to $46.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination. Any License will incorporate the same milestone obligations, with milestones not achieved prior to License execution no longer payable under the Paragon ADOA. Under any License, Korsana would be required to make tiered royalty payments in the low to <span style="white-space:nowrap">mid-single</span> digit percentage range based on annual net sales, subject to certain reductions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;19, 2026, Korsana exercised its ADOA Option with respect to Research Program 002. Korsana made a $5.0&#160;million milestone payment to Paragon in March 2026 related to the nomination of KRSA-028 as the development candidate for Research Program 002. On June&#160;8, 2026, Korsana entered into the Paragon License Agreement with Paragon with respect to the A<span style="FONT-FAMILY:WINGDINGS">&#232;</span> Research Programs, as described in more detail below. Korsana&#8217;s ADOA Option with respect to research program 003 remains unexercised. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon ADOA continues on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis until the earliest of completion of the applicable research plan activities, expiration of the option period, or failure to execute a License within a specified period following option exercise. Korsana may terminate any research program or the Paragon ADOA in its entirety at any time for any reason, subject to certain termination fees. Each party has the right to terminate upon the other party&#8217;s uncured material breach or bankruptcy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">312 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Korsana will grant Parasa warrants on each of December&#160;31, 2025 and December&#160;31, 2026 to purchase shares equal to 1.00% of Korsana&#8217;s outstanding capital stock on a fully diluted basis as of the grant date, at an exercise price equal to fair market value. If Korsana undergoes an initial public offering or reverse merger, Parasa will instead receive warrants from the resulting public parent on equivalent terms. Each warrant is exercisable for 10 years from the grant date, with <span style="white-space:nowrap">pro-ration</span> if the research term ends before <span style="white-space:nowrap">year-end.</span> On December&#160;31, 2025, Korsana issued Parasa a warrant to purchase 1,102,561 shares of common stock at $0.86 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Paragon Platform Option Agreement </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;16, 2025, Korsana entered into the Paragon POA with Paragon and Parasa, in connection with the Paragon ADOA. Under the Paragon POA, Korsana may designate up to four target combinations (each consisting of one or two therapeutic targets and TfR1 as the transit target) to be exclusively reserved during the option period (the &#8220;POA Option Period&#8221;). As of the effective date, the initial reserved target list includes one undisclosed target combination. Korsana may also obtain rights to designate up to two additional target combinations upon payment of $2.0&#160;million each. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon is obligated to notify Korsana if Paragon or its affiliates develop research plans for, plan to license, or enter into negotiations with third parties regarding antibodies directed to target combinations that include TfR1 as the transit target but are not then on a reserved target list. Upon receipt of such notice, Korsana has a specified period to elect to designate that target combination as a reserved target combination, subject to applicable limits. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to limited exceptions, Paragon has agreed not to develop, license, or commercialize antibodies directed to any Korsana-reserved target combination during the POA Option Period, which ends on the earlier of the fifth anniversary of the Paragon POA or exercise or expiration of Korsana&#8217;s last POA Option. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the POA Option Period, Korsana has an option (a &#8220;POA Option&#8221;) for each reserved target combination to either (a)&#160;enter into an antibody discovery and option agreement on terms materially consistent with the Paragon ADOA or (b)&#160;enter directly into a license agreement (a <span style="white-space:nowrap">&#8220;POA-License&#8221;)</span> upon payment of a $5.0&#160;million exercise fee. Under any <span style="white-space:nowrap">POA-License,</span> Korsana would be required to make <span style="white-space:nowrap">one-time,</span> <span style="white-space:nowrap">non-refundable</span> milestone payments of up to $41.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination, and tiered royalty payments in the low to <span style="white-space:nowrap">mid-single</span> digit percentage range based on annual net sales, subject to certain reductions. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon POA continues until expiration of the POA Option Period. Each party has the right to terminate upon the other party&#8217;s uncured material breach or bankruptcy. Korsana may terminate at any time for any reason. As of the date of this proxy statement/prospectus, Korsana has not exercised any POA Options or made any payments under the Paragon POA. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Paragon Research Letter Agreement </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 3, 2026, Korsana entered into the Paragon Research Letter Agreement with Paragon Laboratories. Under the terms of the Paragon Research Letter Agreement, the parties agreed to initiate a research program (the &#8220;AOC Research Program&#8221;) focused on an undisclosed target combination, in an effort to identify, evaluate and develop antibody oligonucleotide conjugates (&#8220;AOCs&#8221;) directed to such target combination (the &#8220;Research AOCs&#8221;). The AOC Research Program will be conducted in accordance with a research plan that the parties will use specified efforts to agree upon within a specified period following the effective date of the Paragon Research Letter Agreement (the &#8220;AOC Research Plan&#8221;). During the AOC Research Term (as defined below), each party will use specified efforts to conduct and complete the research activities assigned to it under the AOC Research Plan, and Paragon Laboratories will provide Korsana with periodic updates regarding the Research AOCs identified under the AOC Research Plan. The AOC Research Program will continue until the earliest of (a) the </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">313 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date that the aggregate costs paid or owing by Korsana to Paragon Laboratories meet or exceed a budgeted cap, (b) completion of the activities set forth in the AOC Research Plan, and (c) such other mutually agreed date (such period, the &#8220;AOC Research Term&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon Research Letter Agreement, Korsana has a nontransferable, exclusive option during the AOC Research Term and, provided that Korsana is not in material breach, for an additional specified period thereafter (collectively, the &#8220;AOC Option Period&#8221;), to either (i) enter into an antibody oligo conjugate discovery and option agreement for the AOC Research Program (the &#8220;AOC-DOA Option&#8221;), or (ii) enter into a license agreement for the AOC Research Program (the &#8220;AOC-License Option&#8221; and, with the AOC-DOA Option, either referenced hereinafter as the &#8220;AOC Option&#8221;). Korsana may exercise the AOC Option only once for the AOC Research Program, without payment of a separate exercise fee. The AOC Option terminates upon the earliest of: a permitted early termination of the AOC Research Program, the expiration of the AOC Option Period without Korsana having exercised the AOC Option, and, if Korsana has exercised the AOC Option, the failure of the parties to finalize a Definitive Agreement (as defined below) or elect the applicable dispute resolution procedures within the required timeframe. Following termination of the AOC Option, Paragon Laboratories is free to license or grant rights in the Research AOCs to third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Korsana&#8217;s exercise of the AOC Option, the parties will negotiate for a specified period toward a definitive agreement (the &#8220;Definitive Agreement&#8221;). If Korsana exercises the AOC-DOA Option, the Definitive Agreement would provide for, among other things, the continuation of the AOC Research Program, payment by Korsana of a research initiation fee, and an exclusive option for Korsana to enter into separate license agreement(s) consistent with the license described below. If Korsana exercises the AOC-License Option, the Definitive Agreement would be a license agreement granting Korsana, its affiliates, and sublicensees the right to develop, manufacture, and commercialize the Research AOCs for any and all uses worldwide, under an exclusive license to the Research AOCs as a whole and any therapeutic nucleic acid component included in a Research AOC, and a non-exclusive license to any platform elements incorporated into such Research AOCs. Any such license agreement would include a one-time upfront license fee. If the parties are unable to reach agreement on the Definitive Agreement within the specified negotiation period, either party may elect to resolve the dispute in accordance with procedures set forth in the Paragon ADOA, as applied <span style="font-style:italic">mutatis mutandis</span>. As between the parties, Paragon Laboratories owns all intellectual property generated under or in connection with the AOC Research Program, and Korsana has assigned all of its rights therein to Paragon Laboratories. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Paragon Laboratories&#8217; performance of the AOC Research Program and the grant of the AOC Option to Korsana, Korsana is required to reimburse Paragon Laboratories for certain third-party costs and internal resource fees, which may not exceed a budget cap set forth in the AOC Research Plan unless increased by mutual written agreement. All payments under the Paragon Research Letter Agreement are non-refundable and non-creditable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Research Letter Agreement will continue until the expiration of the AOC Option, unless terminated earlier in accordance with the terms thereof. The Paragon Research Letter Agreement and the AOC Research Program may be terminated by either party upon prior written notice if the other party commits a material breach and fails to cure within such notice period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Paragon License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;8, 2026, Korsana entered into the Paragon License Agreement with Paragon for certain antibody transport vehicle compounds discovered, generated, identified or characterized by Paragon in the course of performing Research Program 001 and Research Program 002 under the Paragon ADOA, including KRSA-028, together with certain related antibodies, antibody transport vehicles and products comprising the foregoing. The Paragon License Agreement is consistent with the pre-negotiated terms agreed to upon execution of the Paragon ADOA. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">314 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon License Agreement, Paragon granted Korsana a royalty-bearing, worldwide, exclusive and sublicensable license under certain licensed project antibody transport vehicle technology to develop, manufacture, commercialize and otherwise exploit licensed antibodies, licensed antibody transport vehicles, derived antibodies, derived antibody transport vehicles and related products in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the &#8220;field&#8221;) and worldwide (the &#8220;territory&#8221;). Paragon also granted Korsana certain royalty-bearing, worldwide, non-exclusive and sublicensable licenses under certain transit antibody technology, other licensed patents and other licensed know-how to develop, manufacture, commercialize and otherwise exploit specified licensed products in the field and territory. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Paragon License Agreement, Korsana is solely responsible for, and has sole authority and control over, all aspects of the development, manufacturing and commercialization of products under the licensed programs, including regulatory strategy, communications, filings and activities, including clinical trials. Korsana is required to use commercially reasonable efforts to develop and seek regulatory approval for at least one licensed product in the United States and at least one other major market country and, following receipt of regulatory approval for a licensed product in a given country, to commercialize such licensed product in such country. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the applicable exclusivity period, Paragon is restricted from directly or indirectly conducting activities, including granting licenses to third parties, to develop, manufacture, commercialize or otherwise exploit antibody transport vehicles directed to both A&#226; and TfR1, subject to specified exceptions, including for certain change-of-control and acquired programs. The exclusivity period continues until the earlier of the fifth anniversary of the effective date and the occurrence of specified exclusivity termination events tied to Korsana&#8217;s failure to achieve certain diligence milestones, subject to cure and extension mechanics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Paragon License Agreement, Korsana is obligated to pay Paragon up to $46.0 million per product based on the achievement of specified development and regulatory milestones. If a product candidate, including certain combination products, is developed by Korsana as a bona fide back-up or substitute product another royalty product for the same licensed therapeutic target, the same licensed transit target, if applicable, and the same indication, it would be considered a back-up royalty product for which no duplicate milestone payments are owed to Paragon, subject to specified limitations. Korsana is obligated to pay Paragon up to $23.0 million per product for certain Korsana-developed products that are not licensed products from Research Program 001 or Research Program 002 and are directed to the applicable licensed target or target combination based on the achievement of specified development and regulatory milestones. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other key terms of the Paragon License Agreement include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana will pay Paragon tiered royalties in the low- to mid-single digits based on annual net sales of licensed products in the field and territory, subject to a specified reduction if there is no valid claim covering the product in the country. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The royalty term ends, on a product-by-product and country-by-country basis, on the later of the twelfth anniversary of the first commercial sale of such product in such country and the expiration of the last-to-expire valid patent claim covering such product in such country. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana has the right to grant sublicenses under the Paragon License Agreement, provided that each sublicense is in writing and consistent with the relevant terms, conditions and restrictions of the Paragon License Agreement, Korsana provides Paragon with a copy of each sublicense agreement and any amendments within 30 days following execution, subject to permitted redactions, and Korsana remains responsible for all payments and obligations due under the Paragon License Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With respect to certain patents licensed to Korsana under the Paragon License Agreement, Korsana has the first right, but not the obligation, to prepare, file, prosecute and maintain such patents at its sole expense, subject to Paragon&#8217;s review, comment and backup prosecution rights. Paragon retains control over the preparation, filing, prosecution and maintenance of certain other patents owned or controlled by Paragon. </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">315 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana may terminate the Paragon License Agreement in its entirety or on a country-by-country or royalty product-by-royalty product basis for any or no reason upon 60 days&#8217; prior written notice to Paragon. The Paragon License Agreement may also be terminated by either party upon the other party&#8217;s uncured material breach or, to the extent permitted by law, upon the other party&#8217;s insolvency or bankruptcy. </p></td></tr></table> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">WuXi Biologics Master Services Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2024, Korsana entered into a biologics master services agreement (the &#8220;WuXi Biologics MSA&#8221;) with WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics (Hong Kong)&#8221;). The WuXi Biologics MSA governs certain development activities and good manufacturing practice (&#8220;GMP&#8221;) manufacturing and testing for the <span style="white-space:nowrap">KRSA-028</span> program, as well as potential future programs, on a work order basis. Under the WuXi Biologics MSA, Korsana is obligated to pay WuXi Biologics (Hong Kong) a service fee and all <span style="white-space:nowrap">non-cancellable</span> obligations in the amount specified in each work order associated with the agreement for the provision of services. WuXi Biologics (Hong Kong) is obligated to, among other things, (i)&#160;perform manufacturing services in accordance with applicable standards and law using personnel with appropriate qualifications, and to manufacture product in accordance with cGMP, (ii)&#160;comply with confidentiality and invention assignment provisions, (iii)&#160;notify Korsana of regulatory visits or inspections and provide redacted copies of any report or written communication received from such authorities in connection therewith and (iv)&#160;assign to Korsana all right, title and interest in and to all intellectual property created or developed in connection with the provision of the services, and all intellectual property relating to such inventions, subject to certain exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The WuXi Biologics MSA terminates on the later of (i)&#160;December&#160;12, 2029 or (ii)&#160;the completion of services under all work orders executed by the parties prior to December&#160;12, 2029, unless terminated earlier; provided that Korsana may extend the term continuously for additional <span style="white-space:nowrap">two-year</span> periods upon written notice to WuXi Biologics (Hong Kong) at least thirty (30)&#160;days prior to the expiration of the then-current term. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. Korsana can terminate the WuXi Biologics MSA or any work order (i)&#160;at any time upon 30 days&#8217; prior written notice, or (ii)&#160;immediately upon written notice if WuXi Biologics (Hong Kong) fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order (i)&#160;at any time upon six months&#8217; prior notice with reasonable cause, provided however that if WuXi Biologics (Hong Kong) terminates a work order in such manner, no termination or cancellation fees shall be paid by Korsana and (ii)&#160;immediately for cause upon (a)&#160;the other party&#8217;s material breach that remains uncured for 30 days after notice of such breach, (b)&#160;the other party&#8217;s bankruptcy, or (c)&#160;a force majeure event that prevents performance for a period of at least 90 days. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has entered into various work orders pursuant to the WuXi Biologics MSA for ongoing manufacturing work related to <span style="white-space:nowrap">KRSA-028.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">WuXi Cell Line License Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;2, 2024, Korsana entered into a cell line license agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi Biologics Ireland&#8221;). Under the Cell Line License Agreement, Korsana received a <span style="white-space:nowrap">non-exclusive,</span> worldwide, sublicensable license to certain of WuXi Biologics Ireland&#8217;s <span style="white-space:nowrap">know-how,</span> cell line, biological materials and media and feeds to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further commercialize certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics Ireland under the Cell Line License Agreement (the &#8220;WuXi Biologics Ireland Licensed Products&#8221;). <span style="white-space:nowrap">KRSA-028</span> is manufactured using a cell line licensed under the Cell Line License Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the license, Korsana incurred a <span style="white-space:nowrap">non-refundable</span> license fee of $0.15&#160;million. Additionally, if Korsana manufactures all of its commercial supplies of bulk drug product for a particular WuXi </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">316 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Biologics Ireland Licensed Product with a manufacturer other than WuXi Biologics Ireland or its affiliates, it is required to make royalty payments to WuXi Biologics Ireland in an amount equal to a fraction of a single digit percentage of global net sales of the applicable WuXi Biologics Ireland Licensed Product manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If Korsana manufactures part of its commercial supplies of bulk drug product for a particular WuXi Biologics Ireland Licensed Product with WuXi Biologics Ireland or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. If Korsana manufactures all of its commercial supplies of bulk drug product for a particular WuXi Biologics Ireland Licensed Product with WuXi Biologics Ireland or its affiliates, then no Royalty is payable. Korsana has the option, at any time, to pay WuXi Biologics Ireland a <span style="white-space:nowrap">non-refundable</span> <span style="white-space:nowrap">lump-sum</span> royalty buyout payment on a drug <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-drug</span></span> product basis to extinguish future Royalty obligations with respect to such drug product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&#160;by Korsana upon six months&#8217; prior written notice and its payment of all undisputed amounts due to WuXi Biologics Ireland through the effective date of termination, (ii)&#160;by WuXi Biologics Ireland for a material breach by Korsana that remains uncured for 60 days after written notice, (iii)&#160;by WuXi Biologics Ireland if Korsana fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&#160;by either party upon the other party&#8217;s bankruptcy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;2, 2026, Korsana entered into Amendment No.&#160;1 to the Cell Line License Agreement with WuXi Biologics Ireland. The amendment expands the scope of the Cell Line License Agreement to include certain additional proprietary cell lines developed by WuXi Biologics Ireland through genetic engineering of the original host cell line. The amendment updates the license grant in the Cell Line License Agreement to encompass cell lines derived from the original host cell line or such engineered cell lines. The license fee applies regardless of which licensed cell line is used. All other terms of the Cell Line License Agreement remain in full force and effect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Overview </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana strives to protect the proprietary programs and technologies that it believes are important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its programs, its methods of use and manufacture, and other inventions. Korsana will rely upon a combination of patents, trademarks, trade secret protection, copyrights and confidentiality agreements, licenses, and its agreements with Paragon and Paragon Laboratories to protect the intellectual property related to Korsana&#8217;s programs and technologies and to prevent third parties from competing unfairly with Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana does not currently own any issued patents or pending patent applications. With respect to Research Program 002 (including <span style="white-space:nowrap">KRSA-028)</span> and Research Program 001, Paragon has filed provisional patent applications in the United States directed to: (i)&#160;antibodies targeting A&#223; and (ii)&#160;antibodies targeting both A&#223; and TfR1, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, which Korsana has exclusively licensed from Paragon pursuant to the Paragon License Agreement. With respect to the THETA technology, Paragon has filed provisional patent applications in the United States directed to antibodies targeting TfR1, including applications covering composition of matter, pharmaceutical formulations, and methods for using such antibodies or compounds, such as bispecific antibodies, comprising such antibodies, which Korsana has non-exclusively licensed from Paragon pursuant to the Paragon License Agreement. Korsana controls patent prosecution for patents exclusively licensed under the Paragon License Agreement, including those covering the entirety of KRSA-028, and Paragon controls patent prosecution for patents non-exclusively licensed from Paragon pursuant to the Paragon License Agreement, including those specific to the THETA technology. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A provisional patent application is an application filed in the USPTO for the purpose of securing an early date of priority for the applicant&#8217;s invention. The provisional application must include a written description of what the inventor has discovered, along with a drawing of the invention, but need not include patent claims, statements concerning or disclosing the prior art, or certain other formalities. A provisional patent application allows for an effective filing date to be established with regard to an invention, but once a provisional patent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">317 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application is filed, either a corresponding <span style="white-space:nowrap">non-provisional</span> patent application or a petition to convert the provisional patent application into a <span style="white-space:nowrap">non-provisional</span> patent application must be filed within 12 months or such effective filing date will be lost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum term of a U.S. patent, excluding extensions and adjustments, begins on the effective filing date of the first <span style="white-space:nowrap">non-provisional</span> application claiming the patented invention and ending 20 years from that date. In essence, a provisional patent application provides a patent applicant two principal advantages over filing a <span style="white-space:nowrap">non-provisional</span> application. First, it allows the applicant to secure an earlier priority date for its invention than that of an equivalent <span style="white-space:nowrap">non-provisional</span> application&#8212;up to one year earlier than the filing date of a related <span style="white-space:nowrap">non-provisional</span> application. Second, since the term of a patent runs from the effective filing date of the first <span style="white-space:nowrap">non-provisional</span> application but does not begin upon filing a provisional application, filing a provisional application provides the applicant an additional year&#8217;s time to refine that invention before filing a related <span style="white-space:nowrap">non-provisional</span> application without surrendering the earlier priority date. Securing an earlier priority date both ensures that later inventors cannot obtain a patent to the same invention and provides protection against certain arguments that developments in the field arising after the priority date should prevent or invalidate the applicant&#8217;s invention. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korsana or Paragon timely file <span style="white-space:nowrap">non-provisional</span> patent applications in the United States and in countries outside of the United States with regard to <span style="white-space:nowrap">KRSA-028</span> provisional patent applications and these <span style="white-space:nowrap">non-provisional</span> patent applications result in issued patents, such patents are expected to expire in 2046, without taking potential patent term adjustment or patent term extension into consideration. If Paragon timely files <span style="white-space:nowrap">non-provisional</span> patent applications in the United States and in countries outside of the United States with regard to the THETA technology-related provisional patent applications and these <span style="white-space:nowrap">non-provisional</span> patent applications result in issued patents, such patents are expected to expire in 2046, without taking potential patent term adjustment or patent term extension into consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding the risks related to Korsana&#8217;s intellectual property, see the section titled &#8220;<span style="font-style:italic">Risk Factors</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">&#8212;</span><span style="font-style:italic">&#8201;</span><span style="font-style:italic">Risks Related to </span><span style="font-style:italic">Korsana</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s</span><span style="font-style:italic"> Intellectual Property</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other IP Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, Korsana relies upon unpatented trade secrets, <span style="white-space:nowrap">know-how</span> and continuing technological innovation to develop and maintain its competitive position. However, trade secrets and <span style="white-space:nowrap">know-how</span> can be difficult to protect. Korsana seeks to protect its proprietary information, in part by executing confidentiality agreements with its collaborators and scientific advisors, and <span style="white-space:nowrap">non-competition,</span> <span style="white-space:nowrap">non-solicitation,</span> confidentiality and invention assignment agreements with its employees and consultants. Korsana has also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements Korsana enters into are designed to protect its proprietary information and the agreements or clauses requiring assignment of inventions to it are designed to grant it ownership of technologies that are developed through its relationship with the respective counterparty. Korsana cannot guarantee, however, that it has executed such agreements with all applicable counterparties, that such agreements will not be breached, or that these agreements will afford it adequate protection of its intellectual property and proprietary rights. For more information, please see the section titled &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to </span><span style="font-style:italic">Korsana</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s</span><span style="font-style:italic"> Intellectual Property</span>&#8221; in this proxy statement/prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Commercial </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of Korsana&#8217;s product candidates be approved for commercialization, Korsana intends to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable Korsana to realize the full commercial value of its programs. Given Korsana&#8217;s stage of development, it has not yet established a commercial organization or distribution capabilities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">318 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana does not own or operate, and currently has no plans to establish, any manufacturing facilities. All of its preclinical and clinical drug supply development, manufacturing, storage, distribution, and testing are outsourced to third-party manufacturers and facilities. Korsana&#8217;s manufacturing strategy enables it to more efficiently direct financial resources to the research, development, and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities. As Korsana&#8217;s programs advance through development, it expects to enter into longer-term commercial supply agreements with key suppliers and manufacturers to fulfill and secure its supply needs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana expects to face intense competition from other biopharmaceutical companies that are developing agents for the treatment of neurodegenerative diseases, including Alzheimer&#8217;s disease. Korsana believes the key competitive factors affecting the success of its product candidates, if approved, will include efficacy, safety profile, method of administration (including the potential for subcutaneous self-injection versus intravenous infusion), blood-brain barrier penetration, cost of treatment, level of promotional activity, and intellectual property protection. Many of Korsana&#8217;s competitors have significantly greater financial, manufacturing, marketing, sales, distribution and technical resources and more experience in research and development, clinical trials, regulatory matters, and commercialization than Korsana does. These competitors also compete with Korsana in recruiting and retaining qualified scientific and management personnel and in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Korsana&#8217;s programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved for the treatment of patients with Alzheimer&#8217;s disease, <span style="white-space:nowrap">KRSA-028</span> would compete with two anti-amyloid antibody therapies that have been approved by the FDA for treatment of early Alzheimer&#8217;s disease: lecanemab (Leqembi), marketed by Eisai and Biogen, and donanemab (Kisunla), marketed by Eli Lilly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is aware of several companies with product candidates in clinical development for the treatment of patients with Alzheimer&#8217;s disease, including Roche (including Genentech, its wholly owned subsidiary), Lilly, Eisai, Biogen, AbbVie, Merck, Sanofi, Bristol Myers Squibb, Voyager Therapeutics, Denali Therapeutics, Acumen, Alzheon, AC Immune, and others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond Korsana&#8217;s Alzheimer&#8217;s disease program, Korsana is advancing a pipeline of THETA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>-enabled therapies for other undisclosed neurodegenerative diseases with high unmet need. Korsana expects to face competition from companies developing disease-modifying therapies across a range of neurodegenerative indications, many of which have substantially greater resources and experience than Korsana does. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those Korsana is developing. Korsana, along with its third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which Korsana wishes to conduct studies or seek approval or licensure of its product candidates. Generally, before a new therapeutic product can be marketed, considerable data demonstrating a biological product candidate&#8217;s quality, safety, purity and potency, must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. For biological product candidates, potency is similar to efficacy and is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">319 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-marketing may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications from the sponsor, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on Korsana&#8217;s company and its products or product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Biologics Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, biological products (or &#8220;biologics&#8221;) are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical site before the trial is commenced; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice (&#8220;GCP&#8221;) requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation of and submission to the FDA of a biologics license application (&#8220;BLA&#8221;), after completion of all pivotal clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA Advisory Committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA <span style="white-space:nowrap">pre-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical and Clinical Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to beginning any clinical trial with a product candidate in the United States, Korsana must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">320 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. In April 2025, the FDA published a roadmap to reduce animal testing in preclinical safety studies, including those required in INDs, with scientifically validated new approach methodologies (&#8220;NAMs&#8221;). An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <span style="white-space:nowrap">30-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <span style="white-space:nowrap">so-called</span> Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">321 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">BLA Submission and Review </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan (&#8220;PSP&#8221;) within sixty days after an <span style="white-space:nowrap"><span style="white-space:nowrap">end-of-Phase</span></span> 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted, except that the PREA will apply to an original BLA for a new active ingredient that is orphan-designated if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that the FDA determines to be substantially relevant to the growth or progression of a pediatric cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">322 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <span style="white-space:nowrap">pre-</span> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation of Combination Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain therapeutic products are comprised of multiple components, such as drug components, biologic components, and device components, that would normally be subject to different regulatory frameworks by the FDA and frequently regulated by different centers at the FDA. These products are known as combination products. Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug/biologic-device combination product is attributable to the drug or biological product, the FDA center responsible for premarket review of the drug or biological product would have primary jurisdiction for the combination product. The FDA has also established the Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. A combination product with a primary mode of action attributable to the drug or biologic component generally would be reviewed and approved pursuant to the drug or biologic approval processes set forth in the FDCA. In reviewing the new drug application (NDA) or BLA for such a product, however, FDA reviewers would consult </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">323 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with their counterparts in the FDA&#8217;s Center for Devices and Radiological Health to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products with both device and drug/biologic components are subject to cGMP requirements applicable to both drugs and devices, including the Quality Management System Regulation applicable to medical devices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by Korsana pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, and potency or effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Korsana and its third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Korsana and any third-party manufacturers that it may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on post-approval clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal of the FDA to permit the import or export of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mandated modification of promotional materials and labeling and the issuance of corrective information; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">324 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising, and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Korsana and approved by the FDA. Such <span style="white-space:nowrap">off-label</span> uses are common across medical specialties. Physicians may believe that such <span style="white-space:nowrap">off-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <span style="white-space:nowrap">off-label</span> use of their products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biosimilars and Reference Product Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Affordable Care Act (&#8220;ACA&#8221;) includes a subtitle called the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an <span style="white-space:nowrap">FDA-approved</span> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an <span style="white-space:nowrap">FDA-approved</span> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. The FDA has issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">325 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the <span style="white-space:nowrap">42-month</span> period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <span style="white-space:nowrap">six-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <span style="white-space:nowrap">FDA-issued</span> &#8220;Written Request&#8221; for such a study. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and continues to be interpreted and implemented by the FDA. On December&#160;20, 2020, Congress amended the PHSA as part of the <span style="white-space:nowrap">COVID-19</span> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the <span style="white-space:nowrap">12-year</span> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent Term Extension </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., after a BLA is approved, owners of relevant drug patents may apply for up to a five-year patent extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as <span style="white-space:nowrap">one-half</span> the time between the later of the effective date of an IND and issue date of the patent for which extension is sought, and the submission date of a BLA, plus the time between BLA submission date and the BLA approval date up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14 years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent in question. However, Korsana may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Some, but not all, foreign jurisdictions possess patent term extension or other additional patent exclusivity mechanisms that may be more or less stringent and comprehensive than those of the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Healthcare Laws and Compliance Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse, and transparency laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The AKS prohibits, among other things, persons, and entities from knowingly and willfully soliciting, receiving, offering, or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">326 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are a number of statutory exceptions and regulatory safe harbors protecting some common commercial activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, for persons in a position to refer or recommend federally reimbursable healthcare business may be alleged to be intended to induce prescribing, purchasing or recommending, and may be subject to scrutiny if they do not qualify for an exception or regulatory safe harbor. Qualifying for a statutory exception or regulatory safe harbor requires satisfying all of the criteria for the exception or safe harbor. Korsana&#8217;s practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS, but it does increase the risk of regulatory scrutiny. Ultimately, the legality of the arrangement will be evaluated on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCA, which can be enforced through civil whistleblower or qui tam actions, prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics, and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is also subject to federal price reporting laws and federal consumer protection and unfair competition laws. Federal price reporting laws require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/ or discounts on approved products. Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If Korsana&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Korsana may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">327 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of its operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Data Privacy and Security </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information and could apply to Korsana&#8217;s operations or the operations of its partners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing regulations impose data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and HITECH on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA <span style="white-space:nowrap">non-compliance.</span> A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that Korsana submits electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to Korsana may be delayed or denied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, state health information privacy laws, such as California&#8217;s Confidentiality of Medical Information Act and Washington&#8217;s My Health My Data Act, that govern the privacy and security of health-related information, specifically, may apply even when HIPAA does not and impose additional requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even when HIPAA and state health information privacy laws do not apply, according to the FTC and state attorneys general, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the Federal Trade Commission Act and state consumer protection laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain state laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020, govern the privacy and security of personal information, including </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">328 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
health-related information in certain circumstances, some of which are more stringent than HIPAA in various ways. Numerous other states have passed similar laws, but many differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CCPA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, and affords rights to California residents in relation to their personal information. Health information falls under the CCPA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked, directly or indirectly, with a particular consumer or household and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CCPA and numerous other comprehensive privacy laws that have passed or are being considered in other states, as well as at the federal and local levels, exempt PHI that is subject to HIPAA; and others exempt covered entities and business associates subject to HIPAA altogether, further complicating compliance efforts, and increasing legal risk and compliance costs for Korsana and the third parties upon whom Korsana relies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Korsana&#8217;s use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence and machine learning, controlling for data bias, and antidiscrimination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Coverage and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S. and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Korsana&#8217;s ability to successfully commercialize its product candidates, if approved, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow it to establish or maintain pricing sufficient to realize a sufficient return on its investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product candidate for which Korsana obtains regulatory approval. Sales of any approved product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of Korsana&#8217;s product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a <span style="white-space:nowrap"><span style="white-space:nowrap">plan-by-plan</span></span> basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require Korsana to provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">329 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a covered benefit under its health plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safe, effective, and medically necessary; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost-effective; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">neither experimental nor investigational. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices, and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the U.S. government, state legislatures, and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. On August&#160;29, 2023, HHS announced the list of the first ten drugs subject to price negotiations. These price negotiations occurred in 2024. In January 2025, CMS announced a list of 15 additional Medicare Part D drugs that will be subject to price negotiations. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision requires drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition, beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Korsana cannot be sure that reimbursement will be available for any product candidate that it may commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">330 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union (&#8220;EU&#8221;) provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of Korsana&#8217;s product candidates. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and Korsana expects there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cost and creating a new manufacturer discount program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">331 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January&#160;1, 2021. In May 2025, the Trump Administration renewed the idea of international reference pricing through an executive order entitled &#8220;Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,&#8221; which, among other things, directs the HHS and other agencies to communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for U.S. patients in line with comparably developed nations and to facilitate <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> purchasing programs. The HHS subsequently issued guidance indicating the MFN target price will be the lowest price paid in an Organisation for Economic <span style="white-space:nowrap">Co-operation</span> and Development country with a gross domestic product (&#8220;GDP&#8221;) per capita of at least 60% of the U.S. GDP per capital. In addition, in December 2025, CMS proposed new drug payment models to lower drug prices for Medicare beneficiaries; under the models, CMS would explore potential adjustments to Medicare drug inflation rebate calculations by comparison to international drug pricing information. It is currently unclear whether and to what extent these measures will be implemented and what impact any such implementation would have on Korsana&#8217;s business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, Korsana expects government authorities to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the U.S. have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm Korsana&#8217;s business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for its drugs or put pressure on its drug pricing, which could negatively affect Korsana&#8217;s business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Government Regulation Outside of the United States </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, Korsana is subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of its products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not Korsana obtains FDA approval for a product, it must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">332 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation in the European Union </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">European Data Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The processing of personal data, including health-related personal data in the European Economic Area (&#8220;EEA&#8221;) is mainly governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), and related data protection laws in individual EEA countries. In the United Kingdom, the processing of personal data is mainly governed by the GDPR as incorporated into UK law pursuant to the European Union (Withdrawal) Act 2018 (the &#8220;UK GDPR&#8221;). The GDPR and UK GDPR impose a number of strict obligations and requirements for the processing, including collecting, analyzing and transferring, of personal data of individuals in the EEA or in the UK, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR and UK GDPR include requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the personal data breaches which may have to be notified to the national data protection authorities and data subjects, the measures to be taken when engaging processors, and obligations relating to the security and confidentiality of the personal data. EEA countries may also impose additional requirements in relation to the processing of health, genetic and biometric data through their national legislation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the EEA that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). When relying on the appropriate safeguards, data exporters, with the assistance of the data importers, are also required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the safeguards in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential equivalence. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. With regard to the transfer of data from the EEA to the United States, on July&#160;10, 2023, the EC adopted its adequacy decision for the <span style="white-space:nowrap">EU-US</span> Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With regard to the transfer of data from the EEA to the UK, based on the EC&#8217;s adequacy decision of June&#160;28, 2021 and subsequent renewals, personal data may continue to flow freely from the EEA to the UK on the basis that the UK is deemed to provide an adequate level of data protection until December&#160;27, 2031. The adequacy decisions will automatically expire unless renewed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to transfers from the UK to other countries, these transfers are also subject to specific transfer rules under the UK regime. These UK international transfer rules broadly mirror the EU GDPR rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (&#8220;UK Addendum&#8221;) and a document setting out transitional provisions. The IDTA and UK Addendum came into force on March&#160;21, 2022 and are the primary <span style="white-space:nowrap">UK-approved</span> mechanisms for putting in place appropriate safeguards for UK restricted transfers, subject to transitional arrangements for legacy SCCs. Regarding transfers from the UK to the EEA, the UK Information Commissioner&#8217;s Office (&#8220;ICO&#8221;) guidance indicates that organizations do not need new arrangements. With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the UK Extension to the <span style="white-space:nowrap">EU-US</span> Data Privacy Framework, the <span style="white-space:nowrap">UK-US</span> Data Bridge, which came into force on October&#160;12, 2023. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">333 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">UK-US</span> Data Bridge recognizes the United States as offering an adequate level of data protection where the recipient is a U.S. organization certified to the <span style="white-space:nowrap">EU-US</span> Data Privacy Framework and participating in the UK Extension to the <span style="white-space:nowrap">EU-US</span> Data Privacy Framework. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with the requirements of the GDPR or UK GDPR and the related national data protection laws of the EEA countries may result in significant monetary fines for noncompliance of up to &#8364;20&#160;million or &#163;17.5&#160;million (as applicable), 4% of the total worldwide annual turnover (for higher-tier infringements). This is enforced by ICO and is entirely separate from fines under EU GDPR. In addition, violations of national laws can trigger additional, administrative penalties, investigations, corrective orders, temporary or definitive bans, and, in some jurisdictions, and a number of criminal offenses for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data protection authorities from the different EEA countries may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, there are specific requirements relating to processing health data from clinical trials, including public disclosure obligations provided in the EU Clinical Trials Regulation No.&#160;536/2014 (&#8220;CTR&#8221;), European Medicines Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against Korsana, harm to Korsana&#8217;s reputation, and adversely impact its business and operating results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Drug and Biologic Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CTR, a sponsor is able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the Clinical Trials Information System or &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an <span style="white-space:nowrap">&#8220;opt-out&#8221;</span> from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU database, including a layperson&#8217;s summary. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory and CTIS serves as the single entry point for submission of clinical trial-related information and data. As of January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive need to comply with the CTR and have to be transitioned to CTIS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the National Competent Authority and to the Ethics Committees of the EU member state where they occur. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">334 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Drug Marketing Authorization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA. To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be used or sold in the UK, a drug must have an effective MA granted by the Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;) under the Human Medicines Regulations 2012 (SI 2012/1916), as amended. MA applications are submitted electronically via the MHRA Submissions Portal. Under the MHRA&#8217;s national assessment procedure, the MHRA generally aims to reach a decision within 210 <span style="white-space:nowrap">&#8220;clock-on&#8221;</span> days, excluding any &#8220;clock-stops&#8221; while the applicant prepares responses to MHRA questions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;30, 2023, the MHRA published detailed guidance on its recently announced new International Recognition Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January&#160;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations, and renewals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Centralized Authorization Procedure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the European Medicines Agency (&#8220;EMA&#8221;) that is valid for all EU Member States as well as in the three additional EEA Member States (Norway, Iceland, and Liechtenstein). The centralized procedure is compulsory for specific medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy, or tissue engineered medicines) and medicinal products with a new active substance indicated for the treatment of certain diseases (HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune diseases and other immune dysfunctions, and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&#160;20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">335 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety, and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Decentralized Authorization Procedure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&#160;they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&#160;they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&#160;they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Risk Management Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October&#160;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">MA Validity Period </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAs have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">336 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA. Following Windsor Framework changes, which became effective January&#160;1, 2025, European Commission Union authorizations are no longer valid in Northern Ireland and centrally authorized products are instead authorized by the MHRA under <span style="white-space:nowrap">UK-wide</span> marketing authorizations; existing licenses for product licensed by the MHRA that covers Great Britain only become geographically valid <span style="white-space:nowrap">UK-wide</span> while retaining their license number/prefix. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&#160;31, 2020 and ending on December&#160;31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining member states of the EU, the three year period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exceptional Circumstances/Conditional Approval </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. Once a conditional MA has been granted, the MA holder must fulfil specific obligations within defined timelines. A conditional MA is valid for one year and must be renewed annually, but it can be converted into a standard MA once the MA holder fulfils the obligations imposed and the complete data confirm that the medicine&#8217;s benefits continue to outweigh its risks. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Data and Market Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. Innovative medicinal products, referred to as New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An additional <span style="white-space:nowrap">non-cumulative</span> <span style="white-space:nowrap">one-year</span> period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the <span style="white-space:nowrap">10-year</span> marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative <span style="white-space:nowrap">one-year</span> period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">337 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant <span style="white-space:nowrap">pre-trial</span> tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation and negotiations are still ongoing. The timing for finalization of these negotiations and entry into force are unclear. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current drafts envisage: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a shortening of the periods of data exclusivity from eight to six years (with transferrable vouchers for an additional year of market protection as an incentive for the development of new antibiotics), </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">earlier regulatory guidance and extension of market exclusivity for orphan medicines (depending on certain conditions), </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">four-year data exclusivity for additional indications of existing products, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">rules governing the availability of products (including shortage prevention plans and some supply obligations for manufacturers). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted a MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a <span style="white-space:nowrap">two-</span> year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. From January&#160;1, 2025, EU pediatric requirements are addressed via Windsor Framework categorization: for Category 2 products, both UK and EU pediatric requirements apply, and an <span style="white-space:nowrap">EU-agreed</span> PIP must also be in place (unless waived). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PRIME Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">338 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Products from <span style="white-space:nowrap">small-and</span> <span style="white-space:nowrap">medium-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling <span style="white-space:nowrap">non-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A <span style="white-space:nowrap">kick-off</span> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure by Korsana or by any of its third-party partners, including suppliers, manufacturers and distributors, to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal, or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of a MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact Korsana&#8217;s profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn, or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">339 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More generally, <span style="white-space:nowrap">non-compliance</span> with pharmacovigilance obligations can lead to the variation, suspension, or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC (repealed by Directive 2017/1572 on January&#160;31, 2022), Regulation (&#8220;EC&#8221;) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;) These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. Amendments or replacements of at least Directive 2001/83/EC and Regulation (EC) No 726/2004 are part of the reform proposal for European pharmaceutical legislation. Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations, and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;27, 2025, the Council of the EU approved a framework for compulsory licensing of crisis-relevant products (including medicinal products) in crisis situations. While the proposal focuses on voluntary agreements with intellectual property rights holders, it includes rules on compulsory licensing as a measure of last resort upon activation / declaration of a crisis or emergency mode. The European Parliament has not yet voted on the proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sales and Marketing Regulations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advertising and promotion of Korsana&#8217;s products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising, and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute <span style="white-space:nowrap">off-label</span> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all <span style="white-space:nowrap">off-label</span> promotion is prohibited. <span style="white-space:nowrap"><span style="white-space:nowrap">Direct-to-consumer</span></span> advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines, and imprisonment. These laws may further limit or restrict the advertising and promotion of Korsana&#8217;s products to the general public and may also impose limitations on its promotional activities with healthcare professionals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following Brexit, the requirements to display the common logo no longer apply to <span style="white-space:nowrap">UK-based</span> online sellers, except for those established in Northern Ireland. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">340 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Corruption Legislation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act 2010. Due to the Bribery Act 2010&#8217;s <span style="white-space:nowrap">far-reaching</span> territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed. The Bribery Act 2010 is comprised of four offenses that cover (i)&#160;individuals, companies and partnerships that give, promise, or offer bribes, (ii)&#160;individuals, companies, and partnerships that request, agree to receive or accept bribes, (iii)&#160;individuals, companies and partnerships that bribe foreign public officials, and (iv)&#160;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten years and in some cases both. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulations in the UK and Other Markets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The UK formally left the EU on January&#160;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement, which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The UK government has adopted the Medicines and Medical Devices Act 2021 (the MMDA) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines, and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korsana fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">341 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation of Medicinal Products in Australia </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Australian Therapeutic Goods Administration (&#8220;TGA&#8221;) and the National Health and Medical Research Council (&#8220;NHMRC&#8221;) set the GCP requirements for clinical research in Australia. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the regulations, standards and codes set by the TGA and NHMRC is mandatory. Under the Therapeutic Goods Act 1989 (Cth) and the Therapeutic Goods Regulations 1990 (Cth), it is a condition (amongst other conditions) of all clinical trials involving investigational medicinal products to comply with the National Statement on Ethical Conduct in Research Involving Humans, published by the NHMRC (the &#8220;National Statement&#8221;), and the Guideline for Good Clinical Practice published by the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;ICH Guidelines&#8221;). The ICH Guidelines have been adopted in Australia and must be complied with across all fields of clinical research involving therapeutic goods, including those related to pharmaceutical quality, nonclinical and clinical data requirements, and trial designs. The basic requirements for preclinical data to support a <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> trial under ICH Guidelines are applicable in Australia. Requirements related to adverse event reporting in Australia are generally similar to those required in other major jurisdictions, although reporting timeframes may differ to other jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials conducted using &#8220;unapproved therapeutic goods&#8221; in Australia, being those which have not yet been evaluated by the TGA for quality, safety, and efficacy (and including unapproved indications of therapeutic goods which have otherwise been approved for use in Australia) must occur pursuant to either the Clinical Trial Notification Scheme (&#8220;CTN Scheme&#8221;) or the Clinical Trial Approval Scheme (&#8220;CTA Scheme&#8221;). In each case, the trial is supervised by a Human Research Ethics Committee (&#8220;HREC&#8221;), an independent review committee constituted in accordance with the National Statement that ensures the protection of rights, safety and well-being of human subjects involved in a clinical trial. An HREC reviews, approves and provides continuing oversight of trial protocols (including any amendments), methods and materials intended to be used in obtaining and documenting informed consent of the clinical trial subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CTN Scheme broadly involves: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to an HREC, of all material relating to the proposed clinical trial, including the trial protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the HREC reviews the scientific validity of the trial design, the balance of risk versus harm of the therapeutic good, the ethical acceptability of the trial process, and approves the trial protocol. The HREC is also responsible for monitoring the conduct of the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the institution or organization at which the trial will be conducted (the &#8220;Approving Authority&#8221;) giving final approval for the conduct of the trial at the site, in terms no less restrictive to those advised by the HREC; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the investigator submitting a &#8216;Notification of Intent to Conduct a Clinical Trial&#8217; form (&#8220;CTN Form&#8221;) to the TGA. The CTN Form must be signed by the sponsor, the principal investigator, the chairman of the HREC and a person responsible from the Approving Authority. The TGA does not review any data relating to the clinical trial however CTN trials cannot commence until the trial has been notified to the TGA. It is the responsibility of the sponsor to ensure that all relevant approvals are in place before supplying the &#8220;unapproved&#8221; therapeutic goods in clinical trials in Australia. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CTA Scheme: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment, which includes payment of relevant fees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the TGA will undertake a preliminary assessment to ensure that there is sufficient data to begin evaluation. If critical data is missing, the TGA may request further information; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">342 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a sponsor must forward any comments made by the TGA delegate to the HREC(s) at the sites where the trial will be conducted; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the HREC is responsible for considering the scientific and ethical issues of the proposed trial protocol. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor cannot commence a trial under the CTA Scheme until written advice has been received from the TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval for inclusion in the Australian Register of Therapeutic Goods (&#8220;ARTG&#8221;) is required before a therapeutic good (including pharmaceutical product) may be marketed (or supplied, imported, exported, or manufactured) in Australia. Exceptions apply to therapeutic goods/pharmaceutical products that are supplied, imported, and exported to and from Australia for the purposes of a clinical trial, on the basis that certain conditions are met (e.g., the trial is conducted in accordance with the CTN or CTA Scheme). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a sponsor decides to register a therapeutic good/pharmaceutical product in Australia, in order to obtain registration of the product on the ARTG, it is required that (amongst others): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sponsor submits appropriate documentation, including the outcomes of clinical trials and studies, to allow the TGA to assess the quality, safety, and efficacy of the therapeutic product/ pharmaceutical product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sponsor submits evidence which demonstrates that the manufacture of the therapeutic product/ pharmaceutical product complies with the applicable GMP requirements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TGA has the ultimate discretion to decide whether to include the therapeutic product/ pharmaceutical product in the ARTG. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation of Medical Products in New Zealand </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials in New Zealand are regulated under the Medicines Act 1981 (&#8220;Medicines Act&#8221;) and Medicines Regulations 1984. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New Zealand Medicines and Medical Devices Safety Authority (&#8220;Medsafe&#8221;) is the regulatory authority that administers the application and approval process for medicines and clinical trials in New Zealand (under delegation from the Director-General of Health). Approval from Medsafe is required in the following two circumstances: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">before a medicine can be distributed in New Zealand &#8212; see &#8220;Approval for Distribution&#8221; below; however, there is an exemption from this approval requirement for medicines that are imported or manufactured for the sole purpose of use in a clinical trial (including pharmacokinetic, bioequivalence and <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> studies); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">for all clinical trials involving unapproved medicines carried out in New Zealand; however, if a medicine is already approved by Medsafe for distribution in New Zealand, then there is no separate requirement to obtain approval for clinical trials with that medicine (including if the medicine is being tested for a use not provided for under its existing authorization). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medsafe also expects all clinical trials to be carried out in accordance with internationally accepted standards for good clinical practice as published by the EMA in its Guideline for Good Clinical Practice, to the extent that these standards are compatible with the Medicines Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">343 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Approval Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trial approval process requires submission of an online application to Medsafe. The application must include information about the nature of the medicine, the purpose of the trial, details of the investigators conducting the trial, written consent to nomination from each investigator, copies of information supplied to the investigators, a protocol of the trial, and details of the sites and facilities used. The application must be made by the actual or intended importer, manufacturer, packer, or supplier of the medicine in New Zealand. Once approved, the applicant becomes the &#8220;sponsor&#8221; and assumes responsibility and legal liability for the trial in New Zealand. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an application is received, Medsafe provides it to the Health Research Council of New Zealand (&#8220;HRC&#8221;). One of two HRC standing committees will consider the application and make a recommendation to Medsafe as to whether the clinical trial should be approved (with or without conditions) or declined. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Standing Committee on Therapeutic Trials considers pharmaceutical medicine trial applications, while the Gene Technology Advisory Committee considers applications for trials involving gene and other biotechnology therapies. Both standing committees undertake a similar scientific assessment process, and consider factors such as trial protocol and design, data collection, and general compliance with the Guideline for Good Practice before making a recommendation to Medsafe. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Ethical Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medsafe expects all clinical trials to be approved by the Health and Disability Ethics Committee (&#8220;HDEC&#8221;), regardless of whether Medicines Act approval is required. HDEC reviews and approves applications and provides ongoing oversight of clinical trials to ensure alignment with good ethical practice. HDEC approval can be sought before, during, or after Medicines Act approval is sought from Medsafe. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Registration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A clinical trial&#8217;s sponsor may register a trial with the Australian New Zealand Clinical Trials Registry (&#8220;ANZCTR&#8221;), an online public registry of clinical trials undertaken in New Zealand, Australia, and elsewhere. While not mandatory, the ANZCTR is a recognized part of the World Health Organisation Registry Network and registration is encouraged by the World Health Organisation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Approval for Distribution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a sponsor decides to distribute the new medicine product in New Zealand after the clinical trial, the sponsor must apply for distribution approval. This is separate to the approval process for clinical trials and involves submitting an application to Medsafe for consideration. Medsafe assesses the safety, efficacy, quality, and risk profile of the medicine, and makes a recommendation to the Minister of Health as to whether the medicine should be approved for distribution (in practice, the Minister follows Medsafe&#8217;s recommendation). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, local, state, and federal laws, including in the United States, regarding such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect Korsana&#8217;s business. These and other laws govern Korsana&#8217;s use, handling and disposal of various biological, chemical, and radioactive substances used in, and wastes generated by, Korsana&#8217;s operations. If Korsana&#8217;s operations result in contamination of the environment or expose individuals to hazardous or biohazardous substances, Korsana could be liable for damages, environmental remediation, and/or governmental fines. Korsana believes that it is in material compliance with applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">344 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
environmental laws and occupational health and safety laws that continued compliance therewith will not have a material adverse effect on its business. Korsana cannot predict, however, how changes in these laws may affect its future operations. Korsana may incur significant costs to comply with such laws and regulations now or in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Properties and Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana currently operates as a virtual company and does not maintain physical corporate offices. Korsana&#8217;s employees currently work remotely. In March 2026, Korsana entered into a lease agreement pursuant to which it will lease approximately 9,164 square feet of office space in Waltham, Massachusetts to serve as Korsana&#8217;s corporate headquarters. This lease is expected to commence in the third quarter of 2026 and has a term of four years. Korsana believes this arrangement supports its current and near-term future anticipated needs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Korsana may be involved in legal proceedings arising in the ordinary course of its business. Korsana is not presently a party to or aware of any legal proceedings that, in the opinion of management, would have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on Korsana due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&#160;15, 2026, Korsana had 19 employees, all of whom were employed full time. None of Korsana&#8217;s employees are represented by a labor union or covered under a collective bargaining agreement. Korsana considers its relationship with its employees to be good. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">345 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_30">CYCLERION&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion of Cyclerion&#8217;s financial condition and results of operations in conjunction with the financial statements and the related notes thereto and other financial information included elsewhere in this proxy statement/prospectus. The following discussion contains forward-looking statements that reflect Cyclerion&#8217;s current plans, estimates and beliefs. Cyclerion&#8217;s historical results are not necessarily indicative of the results that may be expected for any period in the future. Cyclerion&#8217;s actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement/prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Cyclerion,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Cyclerion and its subsidiaries. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview and Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Our current strategic focus is centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression (&#8220;TRD&#8221;), which we believe represents a substantial clinical and commercial opportunity. Over the past year, we have refined our strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized <span style="white-space:nowrap">CYC-126,</span> an individualized therapy for TRD as our foundational development program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2025, we entered into a license agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) for intellectual property supporting this TRD program. In January 2026, we also entered into a collaboration and <span style="white-space:nowrap"><span style="white-space:nowrap">option-to-license</span></span> agreement with Medsteer SAS (&#8220;Medsteer&#8221;), a developer of anesthesia delivery and monitoring technologies. This agreement provides Cyclerion with access to Medsteer&#8217;s technical expertise, data assets, and intellectual property relating to technology-enabled drug delivery and physiological monitoring, and grants us the right, but not the obligation, to obtain additional rights under specified conditions. We intend to evaluate these capabilities as part of our broader development strategy for our TRD program. Given the substantial unmet medical need in TRD, the stage of clinical development, and the potential commercial opportunity, we believe this program is well positioned to serve as the foundation of our future development efforts. The program team is currently advancing an integrated clinical, regulatory, and commercial strategy for this TRD program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In parallel with the advancement of our neuropsychiatric strategy, Cyclerion continues to evaluate opportunities related to our legacy soluble guanylate cyclase (&#8220;sGC&#8221;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions intended to maximize shareholder value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;1, 2026 Cyclerion entered into the Merger Agreement with Korsana, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, pursuant to which Korsana will become a wholly owned subsidiary of Cyclerion and Cyclerion will operate under the name Korsana Biosciences, Inc. following the Merger. Cyclerion anticipates that the Merger will close in the third quarter of 2026, subject to certain closing conditions, along with the concurrent Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. Following the Merger, the current business of Korsana will become the primary business of Cyclerion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">346 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on its current operating plan, Cyclerion expects that its current cash and cash equivalents will fund its operations until the closing of the contemplated Merger, which is subject to approval by its shareholders and the shareholders of Korsana and other customary closing conditions; however, Cyclerion has based this estimate on assumptions that may prove to be wrong, and Cyclerion could use its capital resources sooner than Cyclerion expects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion CVR Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the First Effective Time, Cyclerion will enter into the CVR Agreement with the Rights Agent pursuant to which <span style="white-space:nowrap">Cyclerion&#8217;s&#160;pre-Merger&#160;shareholders</span> will receive one CVR for each outstanding share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock held by such shareholder on such date. Each CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of <span style="white-space:nowrap">Cyclerion&#8217;s&#160;pre-Merger&#160;legacy</span> assets, net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the Merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of <span style="white-space:nowrap">all&#160;pre-Merger&#160;legacy</span> assets other than <span style="white-space:nowrap">those&#160;pre-Merger&#160;legacy</span> assets described in the following clauses (ii)&#160;and (iii), upon the second (2<sup style="font-size:75%; vertical-align:top">nd</sup>) anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#8217;s right to receive payments under the Akebia License Agreement, the earlier of (A)&#160;the fifteenth (15<sup style="font-size:75%; vertical-align:top">th</sup>) anniversary of the date of entry into the CVR Agreement and (B)&#160;the expiration or earlier termination by Akebia Therapeutics, Inc. of the Akebia License Agreement pursuant to its terms, and (iii)&#160;with respect to the sale, transfer or other disposition of the equity interests of Tisento that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement, dated May&#160;13, 2023, by and among Cyclerion, Tisento and JW Cycle, Inc., the earliest of (A)&#160;nine (9)&#160;months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any holders of CVRs will receive any payments with respect thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expense.</span> Research and development expenses are incurred in connection with the discovery and development of our product candidates. These expenses consist primarily of the following costs: compensation, benefits and other employee-related expenses, research and development-related facilities, third-party contracts relating to manufacturing, nonclinical studies, clinical trial activities. All research and development expenses are charged to operations as incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, we entered into a license agreement with Akebia relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a $3.0&#160;million upfront payment to us upon signing of the license agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;13, 2024, we announced that Cyclerion and Akebia <span style="white-space:nowrap">re-negotiated</span> a mutually beneficial amendment to Akebia&#8217;s exclusive license agreement for praliciguat. Under this new license amendment, we received $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was paid in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat at an earlier date than as originally agreed between the parties. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using Praliciguat. Pursuant to the terms of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">347 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendment, upon initiation (defined as first patient dosed) of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to us and the payment was received in February 2026. We are eligible to receive additional milestone cash payments of up to approximately $557.5&#160;million in total related to potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, we are eligible to receive certain higher-tiered sales-based royalties ranging from <span style="white-space:nowrap">mid-single-digits</span> to twenty percent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2025, we entered in a Material Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Akebia relating to purchase additional development materials (the &#8220;Additional Development Materials&#8221;) by Akebia for Akebia&#8217;s use pursuant to the license agreement. Akebia paid $0.8&#160;million to us for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025 and we recognized revenue of $0.8&#160;million during the year ended December&#160;31, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, we entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid us an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and we were provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. We are currently exploring potential license opportunities for olinciguat. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zagociguat and CY3018 are orally administered <span style="white-space:nowrap">CNS-penetrant</span> sGC stimulators. On July&#160;28, 2023, Tisento purchased zagociguat and CY3018 in exchange for $8.0&#160;million in cash consideration, $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and 10% of all of Tisento Parent&#8217;s outstanding equity securities at the time of closing. Research and development expenses decreased significantly after July&#160;28, 2023, due to sale of the Transferred Assets which resulted in a reduction of research and development efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;27, 2025, Tisento announced that the first patient had been dosed in its global Phase 2b PRIZM study. The study is investigating the impact of once-daily oral zagociguat treatment on fatigue, cognitive impairment, and other key aspects of the rare mitochondrial disease MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis,&#160;and Stroke-like Episodes). On June&#160;17, 2025, Tisento announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to zagociguat for the treatment of MELAS.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PRIZM - a Phase 2b Randomized, Placebo-Controlled Trial Investigating Zagociguat in MELAS - is evaluating the efficacy and safety of oral zagociguat 15 mg or 30 mg compared to placebo when administered once-daily for 12 weeks in participants with genetically and phenotypically defined MELAS. The PRIZM study has a crossover design, with two <span style="white-space:nowrap">12-week</span> treatment periods separated by a <span style="white-space:nowrap">4-week</span> washout period. All participants will receive zagociguat during one of the <span style="white-space:nowrap">12-week</span> periods and placebo during the other. Participants who complete the study may be eligible for an open-label extension study. PRIZM is a global study with plans to enroll approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. Tisento announced its first patient was dosed in the study in January 2025. In August 2025, Tisento announced that the first patient was enrolled in Tisento&#8217;s open-label extension study in MELAS and in January 2026, Tisento announced that it completed enrollment in PRIZM. Further information regarding the study is available at ClinicalTrials.gov (NCT06402123). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;19, 2025, Cyclerion and the Massachusetts Institute of Technology (&#8220;MIT&#8221;) entered into a Patent License Agreement (the &#8220;MIT License Agreement&#8221;) pursuant to which MIT granted to us an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">348 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, we paid a nominal upfront license fee and patent reimbursement fee. Thereafter, we are also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $4.4&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, we are required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. We recorded research and development expense of $0.1&#160;million for the year ended December&#160;31, 2025, which consisted of upfront fees, patent reimbursement fees and transaction costs related to the license. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;3, 2026, we and Medsteer SAS (&#8220;Medsteer&#8221;) entered into a Collaboration and Option Agreement (the &#8220;Collaboration Agreement&#8221;) pursuant to which Medsteer granted to us (i)&#160;a <span style="white-space:nowrap">non-exclusive,</span> worldwide, royalty-free, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#8220;Option&#8221;), exercisable at our sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, in <span style="white-space:nowrap">multi-bed</span> or intensive unit wards, or in the context of medical transport. We may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an additional two years at our option and upon payment of a nominal fee or by mutual agreement of us and Medsteer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Collaboration Agreement, the Company will pay to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $3.7&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to evaluate other activities aimed at enhancing shareholder value, which may potentially include collaborations, licenses, mergers, acquisitions, and/or other targeted investments. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses of continuing operations, employee and facility related costs allocated to research and development expense, and discovery and preclinical phase programs, for the three months ended March&#160;31, 2026 and 2025 and the years ended December&#160;31, 2025 and 2024. The product pipeline expenses related primarily to external costs associated with nonclinical studies and clinical trial costs. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:58%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three&#160;Months&#160;Ended<br/>March&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel and related internal costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> 7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securing regulatory approvals for new drugs is a lengthy and costly process. Any failure by us or our partners to obtain, or any delay in obtaining, regulatory approvals would materially adversely affect our product candidate development efforts and our business overall. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">349 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the inherent uncertainties of pharmaceutical product development, we cannot estimate with any degree of certainty how our programs will evolve, and therefore the amount of time or money that would be required to obtain regulatory approval to market them. As a result of these uncertainties surrounding the timing and outcome of any approvals, we are currently unable to estimate precisely when, if ever, our discovery and development candidates will be approved.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we continue to progress the development of our product candidates, the successful development of any current or potential future product candidates is highly uncertain and subject to a number of risks. Please refer to &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to </span><span style="font-style:italic">Cyclerion</span>&#8221;, in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to determine the duration and costs to complete current or future nonclinical and clinical stages of any current or potential future product candidates, including as licensed to third parties, or when, or to what extent, we may generate revenues from the commercialization and sale of any current or potential future product candidates. Development timelines, probability of success and development costs vary widely. We anticipate that we will make determinations as to which additional programs to pursue and how much funding to direct to each program on an ongoing basis in response to the data from the studies of each product candidate, the competitive landscape and ongoing assessments of such product candidate&#8217;s commercial potential. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expense.</span> General and administrative expenses consist primarily of compensation, benefits and other employee and <span style="white-space:nowrap">non-employee</span> related expenses for personnel in our administrative, finance, legal, information technology, business development, and human resource functions. Other costs include the legal costs of pursuing patent protection of our intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. We record all general and administrative expenses as incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of these financial statements requires us to make certain estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. We base our estimates on our historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from our estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our application of accounting policies requires significant judgments and estimates on the part of management and is the most critical to aid in fully understanding and evaluating our reported financial results. Our significant accounting policies are more fully described in Note 2, <span style="font-style:italic">Summary of Significant Accounting Policies</span>, of the consolidated financial statements elsewhere in this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All research and development expenses are expensed as incurred. We defer and capitalize nonrefundable advance payments we make for research and development activities until the related goods are received or the related services are performed. See Note 2, <span style="font-style:italic">Summary of Significant Accounting Policies</span>, of the consolidated financial statements appearing elsewhere in this proxy statement/prospectus. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations for the Three Months Ended March 31, 2026 and March 31, 2025 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The revenue and expenses reflected in the consolidated financial statements may not be indicative of revenue and expenses that will be incurred by us in the future. The following discussion summarizes the key factors we believe are necessary for an understanding of our consolidated financial statements. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">350 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:63%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three&#160;Months&#160;Ended<br/>March 31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from option agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(81</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(81</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1928</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,671</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">109</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,209</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,457</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,752</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">120</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and other comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,177</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,429</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,748</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Revenue</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue from option agreement. </span>On July 22, 2024, we entered into the Option Agreement with the Optionee, which the Optionee had the Option to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. We recognized revenue of $0.1 million related to the Option extension fee and expense reimbursement during the three months ended March 31, 2025. The Option Agreement was terminated in October 2025 and no revenue was recognized during the three months ended March 31, 2026.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Expenses</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and development expense.</span> The increase in research and development expense of approximately $0.7 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025, was primarily driven by increases of approximately $0.6 million in professional consulting and approximately $0.1 million in license option fee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and administrative expense.</span> The increase in general and administrative expenses of approximately $1.0 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily driven by increases of approximately $0.3 million in professional consulting and $0.9 million in corporate legal fees, offset by a decrease of $0.1 million in patent fees and $0.1 million in insurance expense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest income.</span> Interest income was not changed significantly for the three months ended March 31, 2026, compared to the three months ended March 31, 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Results of Operations for the Years Ended December 31, 2025 and December 31, 2024</span> </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The revenue and expenses reflected in the consolidated financial statements may not be indicative of revenue and expenses that will be incurred by us in the future. The following discussion summarizes the key factors we believe are necessary for an understanding of our consolidated financial statements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">351 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Revenues and Expenses </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from license agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from purchase agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">XX</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from option agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,074</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">235</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cost and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,973</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,628</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,345</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(80</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(38</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from settlement of account payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(363</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from insurance recovery</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">XX</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">153</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,528</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,057</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(471</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue from license agreement. </span>On December&#160;13, 2024, we entered into the 2024 Amendment with Akebia providing for payments aggregating $1.75&#160;million all of which was recognized in revenue during the year ended December&#160;31, 2024. $1.25&#160;million of this amount was paid in December 2024 and the remaining $0.5&#160;million was paid in September 2025. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to us. We recognized revenue and accounts receivable of $1.0&#160;million during the year ended December&#160;31, 2025, and the $1.0&#160;million payment was received in February 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenues from purchase agreement</span>. In September 2025, we entered into the<span style="font-style:italic"></span>&#160;Purchase Agreement with Akebia. Akebia paid $0.8&#160;million to us for the purchase of Additional Development Materials during the year ended December&#160;31, 2025. The Additional Development Materials were delivered to Akebia as of December&#160;31, 2025 and we recognized revenue of $0.8&#160;million during the year ended December&#160;31, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue from option agreement. </span>On July&#160;22, 2024, we entered into the Option Agreement with the Optionee, under which the Optionee had the Option to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. We recognized revenue of $0.2&#160;million related to the Option fee payment and expense reimbursement during the year ended December&#160;31, 2024 and we recognized revenue of $0.3&#160;million related to the Option extension fee, amendment fee and expense reimbursement during the year ended December&#160;31, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and development expenses. </span>The increase in research and development expenses of approximately $0.7&#160;million for the year ended December&#160;31, 2025 compared to the year ended December&#160;31, 2024 was driven by an increase of $0.1&#160;million in license fees, $0.6&#160;million in professional consulting to support the research and&#160;development efforts related to <span style="white-space:nowrap">CYC-126,</span> and $0.1&#160;million in outside service fees, offset by a decrease of $0.1&#160;million in stock compensation expenses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">352 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and administrative expenses.</span> The increase in general and administrative expenses of approximately $0.7&#160;million for the year ended December&#160;31, 2025 compared to the year ended December&#160;31, 2024 was primarily driven by an increase of $0.8&#160;million in professional consulting, $0.1&#160;million in outside service fee and $0.7&#160;million in corporate legal fees, offset by a decrease of $0.3&#160;million in patent fees, $0.2&#160;million in insurance expense, $0.1&#160;million in board member fees and $0.3&#160;million in employee-related expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest and other income, net.</span> Interest and other income decreased by approximately $0.1&#160;million for the year ended December&#160;31, 2025 compared to the year ended December&#160;31, 2024 primarily attributable to the reduction in interest rates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain from settlement of account payable. </span>During the year ended December&#160;31, 2024, we reached a settlement agreement with a vendor for a disputed account payable and recorded a gain of $0.4&#160;million on settlement of account payable. No such transaction occurred during the year ended December&#160;31, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain from insurance recovery. </span>During the year ended December&#160;31, 2025, we recorded approximately $1.3&#160;million of insurance recoveries related to loss of advanced intermediated GMP finished materials covered by several policies with third-party insurers. No such gain was recognized during the year ended December&#160;31, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have been funded primarily from sales of our equity securities, payments received in connection with the sale of assets to Tisento, milestone payments from Akebia and an option to license payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2025, we closed on a private placement of 499,998 shares of our common stock, pursuant to a Stock Purchase Agreement, for total gross proceeds of approximately $1.375&#160;million. We also incurred transaction costs of $0.1&#160;million during the year ended December&#160;31, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;4, 2025, we filed a Registration Statement on Form <span style="white-space:nowrap">S-3</span> (the &#8220;2025 Shelf&#8221;) with the SEC in relation to the registration of common stock, preferred stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $25.0&#160;million. The amount we can sell in any twelve-month period under the 2025 Shelf, which was declared effective in February 2025, cannot exceed <span style="white-space:nowrap">one-third</span> of the value of our public float. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;7, 2025, we entered into an &#8220;at the market&#8221; equity offering program (the &#8220;ATM Program&#8221;) pursuant to a Sales Agreement (the &#8220;2025 Sales Agreement&#8221;) by and between us and Guggenheim Securities LLC (&#8220;Guggenheim Securities&#8221;). Pursuant to the terms of the 2025 Sales Agreement, we can sell, from time to time, shares of our common stock, having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as our agent, subject to the application of General Instruction I.B.6 of Form <span style="white-space:nowrap">S-3</span> (&#8220;Instruction I.B.6&#8221;) pertaining to primary offerings by certain registrants, including shares of common stock offered directly by the Company (the &#8220;ATM Shares&#8221;).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the ATM Program to fund the development of product candidates and for other general corporate purposes, including funding potential new clinical programs and product candidates. financing our existing businesses and operations and expanding our businesses and operations through new product development programs and additional hires. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Sales Agreement, Guggenheim Securities will use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon our instructions. We have provided Guggenheim Securities with customary indemnification rights, and Guggenheim Securities will be entitled to a commission of 3.0% of the gross proceeds of the ATM Shares sold under the Sales Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">353 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of the ATM Shares will be made pursuant to a previously filed and effective registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-284690).</span> ATM Shares may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Sales of the ATM Shares, if any, will be made at&#160;market prices by any method that is deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Capital Market or any other trading market for our common stock. We have no obligation to sell any of the ATM Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Instruction I.B.6, in no event will we sell ATM Shares with a value exceeding more than <span style="white-space:nowrap">one-third</span> of our &#8220;public float&#8221; (the aggregate market value of our outstanding common stock held by <span style="white-space:nowrap">non-affiliates)</span> in any twelve-month period so long as our public float remains below $75.0&#160;million. During the year ended December&#160;31, 2025, we sold 715,220 ATM Shares for net proceeds of $2.1&#160;million. On January&#160;6, 2026, we sold 405,000 ATM Shares for net proceeds of $0.8&#160;million. The Company exhausted all sales under the that may currently be made pursuant to Instruction I.B.6. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;19, 2023, we sold 225,000 shares of our common stock, pursuant to a Common Stock Purchase Agreement, and 351,037 shares of Series A Preferred Stock, to our former CEO, for total gross proceeds of approximately $5&#160;million. There were no material fees or commissions related to the transaction. Such Series A Convertible Preferred Stock is convertible into shares of our common stock on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-to-one</span></span> basis. Our shareholders approved such convertibility on July&#160;19, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;28, 2023, we closed the transactions contemplated by the Asset Purchase Agreement receiving proceeds of $8.0&#160;million as cash consideration, approximately $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 programs for the period between signing and closing of the transaction, and 10% of all of Tisento Parent&#8217;s outstanding equity securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to complete the Merger, our ability to continue to fund our operations and meet capital needs will depend on our ability to generate cash from operations and access to capital markets and other sources of capital, as further described below. We anticipate that, if we continue to progress the development of our product candidates, our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes.</p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 31, 2026, we had approximately $2.8&#160;million of unrestricted cash and cash equivalents. Our cash equivalents include amounts held in U.S. government money market funds. We invest cash in excess of immediate requirements in accordance with our investment policy, which requires all investments held by us to be at least &#8220;AAA&#8221; rated or equivalent, with a remaining final maturity when purchased of less than twelve months, so as to primarily achieve liquidity and capital preservation. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Going Concern </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluated whether there are conditions and events, considered in the aggregate, which raise substantial doubt about our ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing our analysis, management excluded certain elements of our operating plan that cannot be considered probable. Under ASC <span style="white-space:nowrap">205-40,</span> the future receipt of potential funding from future partnerships, equity or debt issuances, and the potential milestones from the Akebia </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">354 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement cannot be considered probable at this time because these plans are not entirely within our control and/or have not been approved by the Board of Directors as of the date of these consolidated financial statements.</p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred recurring losses since our inception, including net losses of $3.2 million for the three months ended March 31, 2026 and $3.5&#160;million for the year ended December&#160;31, 2025. In addition, as of March&#160;31, 2026, we had an accumulated deficit of $274.2&#160;million. We expect that our cash and cash equivalents as of March&#160;31, 2026, will be sufficient to fund operations into the third quarter of 2026, however, we will need to obtain additional funding to sustain operations as we expect to continue to generate operating losses for the foreseeable future. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flows </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The following is a summary of cash flows for the periods presented: </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:63%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months Ended<br/>March 31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,176</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(968</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(66</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(66</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(550</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:62%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="14"><span style="font-weight:bold">(dollars in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,314</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,333</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(24</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flows used in Operating Activities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities of $1.2 million for the three months ended March 31, 2026 was primarily a result of our $3.2 million net loss from operations. The net loss was offset by a decrease in accounts receivable of $1.0 million and an increase in accrued expenses and other current liabilities of $0.9 million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities of $1.0 million for the three months ended March 31, 2025 was primarily a result of our $1.4 million net loss from operations. The net loss was offset by non-cash stock-based compensation expense of $0.1 million, a decrease in prepaid expenses of $0.2 million, an increase in accounts payable of $0.1 million and an increase in accrued expenses and other current liabilities of $0.1 million. </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $3.3&#160;million for the year ended December&#160;31, 2025 was primarily a result of our $3.5&#160;million net loss from operations. The net loss was also adjusted by an increase in accounts receivable of $0.4&#160;million and a decrease in accrued expenses and other current liabilities of $0.1&#160;million. The net loss was offset by <span style="white-space:nowrap">non-cash</span> stock-based compensation expense of $0.4&#160;million, an increase of accounts payable of $0.1&#160;million and an increase of accrued research and development costs of $0.2&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $4.3&#160;million for the year ended December&#160;31, 2024 was primarily a result of our $3.1&#160;million net loss from operations. The net loss was also adjusted by gain from settlement of accounts payable of $0.4&#160;million, an increase in accounts receivable of $0.6&#160;million, a decrease in accounts payable, accrued expenses and other current liabilities of $1.0&#160;million. The net loss was offset by <span style="white-space:nowrap">non-cash</span> stock-based compensation expense of $0.6&#160;million.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">355 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flows from Financing Activities </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investment activities of $0.1 million for the three months ended March 31, 2026 was due to purchase of lab equipment acquired during the three months ended March 31, 2026. There was no investing activity in the three months ended March 31, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the three months ended March 31, 2026 of $0.8 million was due to the net proceeds received from ATM related to the issuance of 405,000 shares of our common stock under the ATM. Net cash provided by financing activities for the three months ended March 31, 2025 of $1.4 million was due to cash received from the 2025 Equity Private Placement related to issuance of 499,998 shares common stock at a purchase price of $2.75 per share. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&#160;31, 2025 of $3.3&#160;million was due to $1.2&#160;million net proceeds received from the 2025 Cyclerion Private Placement related to the issuance of 499,998 shares of our common stock at a purchase price of $2.75 per share and $2.1&#160;million net proceeds received from ATM related to the issuance of 715,220 shares of our common stock under the ATM. There was no financing activity incurred during the year ended December&#160;31, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Funding Requirements </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to complete the Merger, we expect our expenses to fluctuate as we continue to maintain <span style="white-space:nowrap">out-license</span> opportunities and potentially seek to broaden our portfolio through <span style="white-space:nowrap">in-licensing</span> of complementary assets. We expect that our cash and cash equivalents as of March 31, 2026, will be sufficient to fund operations through the closing of the Merger. As a result, if we are unable to complete the Merger, we will need to obtain additional funding to sustain operations as we expect to continue to generate operating losses for the foreseeable future. Failure to obtain necessary capital when needed may delay development of any current or potential future product candidates, or our ability to continue our operations. Because there is substantial doubt about our ability to continue as a going concern for a reasonable period of time, an investment in our common stock is highly speculative; holders of our common stock could suffer a total loss of their investment. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the many risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our expenses will fluctuate, and our future funding requirements will depend on, and could increase or decrease significantly as a result of many factors, including the: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">scope, progress, results and costs of researching and developing our current and any potential future product candidates, and any preclinical studies and clinical trials we may conduct; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs, timing and outcome of regulatory review of any current and any potential future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of future activities, including medical affairs, manufacturing and distribution, of any current or potential future product candidates for which we receive marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost and timing of necessary actions to support our strategic objectives; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or potential future product candidates, if any. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in any of these or other variables with respect to the development of any current or potential future product candidates could significantly change the costs and timing of the development of that product candidate.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">356 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend primarily on our ability to complete the proposed transaction with Korsana. If we do not complete the proposed transaction with Korsana and until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties, of which there can be no assurance. To the extent that we raise additional capital through the sale of equity or convertible debt securities, outstanding equity ownership may be materially diluted, and the terms of securities sold in such transactions could include liquidation and other preferences and rights that adversely affect the rights of holders of common stock. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in increased fixed payment obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, as to which raise there can be no assurances, we may have to relinquish rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we do not complete the Merger and are unable to raise funds, we may need to cease operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Commitments and Obligations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Tax-related</span> Obligations </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We exclude assets, liabilities or obligations pertaining to uncertain tax positions from our contractual commitments and obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of March 31, 2026, we had no uncertain tax positions. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Separation Benefits </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the separation benefit of the former Chief Financial Officer, we paid $0.1&#160;million each in May 2024 and August 2024. We have no further separation benefits obligation as of March&#160;31, 2026. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established for the purpose of facilitating <span style="white-space:nowrap">off-balance</span> sheet arrangements (as that term is defined in Item 303(a)(4)(ii) of Regulation <span style="white-space:nowrap">S-K)</span> or other&#160;contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships. We enter into guarantees in the ordinary course of business related to the guarantee of our own performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of new accounting pronouncements see Note 2, <span style="font-style:italic">Summary of Significant Accounting Policies</span>, of the consolidated financial statements appearing elsewhere in this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">357 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_31">KORSANA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion of Korsana&#8217;s financial condition and results of operations in conjunction with the financial statements and the related notes thereto and other financial information included elsewhere in this proxy statement/prospectus. The following discussion contains forward-looking statements that reflect Korsana&#8217;s current plans, estimates and beliefs. Korsana&#8217;s historical results are not necessarily indicative of the results that may be expected for any period in the future. Korsana&#8217;s actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement/prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview&#8195; </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer&#8217;s disease (&#8220;AD&#8221;). Korsana&#8217;s lead product candidate, <span style="white-space:nowrap">KRSA-028,</span> is an anti-amyloid beta (&#8220;A&#223;&#8221;) antibody that combines the proprietary Therapeutic Targeting (&#8220;THETA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>&#8221;) platform informed by clinical and regulatory learnings from other <span style="white-space:nowrap">anti-A&#223;</span> products that have achieved regulatory approval or are in late-stage clinical trials. <span style="white-space:nowrap">KRSA-028</span> was designed to build upon the success of these prior products while addressing shortcomings that limit their clinical and commercial success, such as the ability to penetrate the brain. Korsana believes that <span style="white-space:nowrap">KRSA-028</span> has the potential to rapidly clear amyloid plaques resulting in meaningful impacts on clinical symptoms in AD patients, and to do so while avoiding adverse effects associated with the specific designs of prior products. After Korsana completes GLP toxicity studies, it intends to submit a Clinical Trial Notification (&#8220;CTN&#8221;) in Australia or a Clinical Trial Application (&#8220;CTA&#8221;) in New Zealand by the end of 2026 and an Investigational New Drug (&#8220;IND&#8221;) application in the United States in the first quarter of 2027. Pharmacokinetic data in healthy volunteers is anticipated by <span style="white-space:nowrap">mid-year</span> 2027 and interim <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data in AD patients is anticipated by the end of 2027. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. See &#8220;<span style="font-style:italic">Risk Factors &#8211; Risks Related to Korsana &#8211; Risks Related to Korsana&#8217;s Discovery, Development, and Commercialization &#8211; Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Korsana&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Korsana may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span>&#8221; </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AD is a progressive and devastating neurodegenerative disease that slowly destroys cognition and leads to progressive impairment in patients&#8217; ability to conduct activities of daily living. Prevalence increases with age; up to <span style="white-space:nowrap">one-third</span> of people over age 85 have symptoms. There are seven million people suffering from AD in the United States, a number that is expected to double by 2050 due to an aging population. AD is the seventh-leading cause of death in the United States with an estimated 500,000 deaths every year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until recently, approved treatments for AD addressed only symptoms and had no impact on the course of the disease. That situation changed after the approval of antibody-based therapeutics that targeted Ab. Clinical trials of these therapeutics have provided clear evidence that antibody-mediated depletion of A&#223; in the brain correlates with a reduction in the rate of cognitive decline in symptomatic AD. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">KRSA-028</span> was designed using clinical and regulatory learnings from these pioneering antibody-based therapeutics, together with Korsana&#8217;s proprietary combination of antibody engineering technologies, with the goal of improving clinical efficacy and safety profiles. <span style="white-space:nowrap">KRSA-028</span> targets what is believed to be the most clinically relevant form of A&#223; and is designed to improve brain uptake while reducing effects on reticulocytes. It </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">358 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was also designed with physicochemical properties and stability intended to enable potent <span style="white-space:nowrap">anti-A&#223;</span> activity to the brain via subcutaneous injections. Key features of <span style="white-space:nowrap">KRSA-028&#8217;s</span> design include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating a proprietary transferrin receptor, or TfR, based shuttle designed to potentially improve delivery to the brain, which Korsana believes may also help reduce or avoid the treatment-related complications known as amyloid-related imaging abnormalities, or ARIA, associated with the two approved disease-modifying therapies </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Targeting <span style="white-space:nowrap">3-pyroglutamate</span> Ab, or <span style="white-space:nowrap">3pE-Ab,</span> a form of A&#223; that is enriched in amyloid plaques that is believed to contribute to plaque formation in AD </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Incorporating Fc domain modifications designed to potentially improve half-life and reduce the potential for hematologic adverse events seen with other antibodies that incorporate TfR-based shuttles, while potentially preserving antibody-mediated immune function believed to contribute to amyloid plaque clearance </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Enabling subcutaneous formulation through potentially favorable solubility, viscosity, and stability characteristics </p></td></tr></table> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary THETA technology used to create <span style="white-space:nowrap">KRSA-028</span> combines the benefits of TfR-mediated shuttling to the brain with Fc modifications to extend half-life and spare reticulocytes from destruction shown to be caused by third-party TfR-shuttled investigational products. The THETA technology was designed to retain phagocytic capacity, the mechanism by which the two approved disease-modifying products are thought to clear amyloid plaques from the brain. Korsana believes that the THETA platform will lead to meaningful improvements in the ability to deliver therapeutic modalities, such as antibodies, to the brain, while minimizing the frequency of adverse events associated with other TfR-based shuttle systems. Korsana intends to expand its pipeline by advancing other product candidates that incorporate THETA technology. Korsana anticipates disclosing details on its next product candidate in late 2026 or 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its inception in November 2024, Korsana has devoted substantially all of its resources to raising capital, organizing and staffing Korsana, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties, and providing general and administrative support for these operations. Korsana does not have any programs approved for sale and has not generated any revenue from product sales. To date, Korsana has funded its operations primarily with proceeds from the issuance of convertible preferred stock. In November 2024, Korsana received $10.0&#160;million in gross proceeds from the issuance of Series A preferred stock, subsequently reclassified to Series Seed preferred stock in September 2025. Additionally in September 2025, Korsana received $15.0&#160;million in gross proceeds from the issuance of Series Seed preferred stock and $151.0&#160;million in gross proceeds from the issuance of Series A preferred stock to various investors. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has incurred operating losses since inception. Korsana&#8217;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Korsana may develop. Korsana generated net losses of $13.5 million and $0.1 million for the three months ended March 31, 2026, and March 31, 2025. Korsana generated net losses of $35.6&#160;million and $0.1&#160;million for the year ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. As of March&#160;31, 2026, Korsana had an accumulated deficit of $49.2&#160;million. Korsana expects to continue to incur significantly increased expenses for the foreseeable future if and as it: </p> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advances its existing and future research and development and discovery-related development of its programs 001 and 002 (A&#223; and TfR1) (together the &#8220;A&#223; program&#8221;) and its undisclosed program 003; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks and identifies additional research programs and product candidates and initiates discovery- related activities and preclinical studies for those programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completes future preclinical studies for Korsana&#8217;s pipeline; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pursues investigational new drug applications or comparable foreign applications that allow commencement of Korsana&#8217;s planned clinical trials or future clinical trials for any programs Korsana may develop; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">359 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiates enrollment and successfully completes clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pursues positive results from Korsana&#8217;s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">hires research and development, clinical, manufacturing and commercial personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adds operational, financial and management information systems and personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experiences any delays, challenges, or other issues associated with the preclinical and clinical development of Korsana&#8217;s programs, including with respect to its regulatory strategies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develops, maintains and enhances a sustainable, scalable, reproducible and transferable clinical and commercial-scale current good manufacturing practices (&#8220;cGMP&#8221;) capabilities through a third-party or Korsana&#8217;s own manufacturing facility for the programs Korsana may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seeks, obtains and maintains regulatory approvals for any product candidates for which Korsana successfully completes clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which Korsana may obtain regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">generates revenue from commercial sales of product candidates for which Korsana receives regulatory approval, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintains safety, tolerability and efficacy profile of any product Korsana may develop in additional indications following approval in one indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintains, expands, enforces, defends and protects Korsana&#8217;s intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products Korsana may develop and defends any intellectual property-related claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">further acquires or <span style="white-space:nowrap">in-licenses</span> product candidates or programs, intellectual property and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintains Korsana&#8217;s current collaborations and establishes and maintains any future collaborations, including making milestone, royalty or other payments thereunder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the outcome of any of these variables with respect to the development of programs that Korsana may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the U.S. Food and Drug Administration or another comparable regulatory authority were to require Korsana to conduct clinical trials beyond those that Korsana currently anticipates will be required to complete clinical development and obtain regulatory approval of one or more product candidates, or if Korsana experiences significant delays in Korsana&#8217;s preclinical studies or clinical trials, Korsana would be required to expend significant additional financial resources and time to advance and complete clinical development. Korsana may never obtain regulatory approval for any of its product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana will not generate revenue from product sales unless and until it successfully initiates and completes clinical development and obtains regulatory approval for any product candidates. If Korsana obtains regulatory approval for any of its product candidates and does not enter into a commercialization partnership, it expects to incur significant expenses related to developing Korsana&#8217;s commercialization capability to support product sales, manufacturing, marketing, and distribution. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2026, Korsana had cash and cash equivalents of $134.2&#160;million. Based on its current operating plan, Korsana has concluded its existing cash and cash equivalents will be sufficient to fund its operating plan for at least 12 months after the date Korsana&#8217;s financial statements for the period ended March&#160;31,&#160;2026 are available to be issued. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;1, 2026, Korsana entered into an Agreement and Plan of Merger (as subsequently amended on April&#160;17, 2026, the &#8220;Merger Agreement&#8221;) with Cyclerion Therapeutics Inc. (&#8220;Cyclerion&#8221;) and Cariboos Merger Sub Corp and Cariboos Merger Sub II, LLC, wholly owned subsidiaries of Cyclerion, pursuant to which, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">360 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation (the &#8220;First Merger&#8221;). Immediately following the First Merger and as part of the same overall transaction, Korsana will merge with and into Cariboos Merger Sub II, LLC (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), with Cariboos Merger Sub II, LLC being the surviving entity of the Second Merger. In connection with the Merger, Merger Sub II will change its corporate name to &#8220;Korsana Biopharma Operating Company, LLC&#8221; and Cyclerion will change its name to &#8220;Korsana Biosciences, Inc.&#8221; Cyclerion following the Merger is referred to herein as the &#8220;Combined Company.&#8221; The Combined Company will be led by Korsana&#8217;s management team and remains focused on discovering and developing novel therapies designed to reduce the burden of neurodegenerative diseases, starting with Alzheimer&#8217;s disease. In connection with the Merger, Korsana and Cyclerion entered into the Subscription Agreement with certain institutional and accredited investors, pursuant to which such investors have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the Merger, shares of Korsana common stock and <span style="white-space:nowrap">pre-funded</span> warrants for an aggregate purchase price of $380.0&#160;million in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. The closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and is expected to occur immediately prior to the closing of the Merger. The proceeds from the Subscription Agreement are expected to advance the Combined Company&#8217;s pipeline and will be used for research and development, business development, working capital, and other general corporate purposes. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana estimates that its existing cash and cash equivalents as of the date of this proxy statement/prospectus, together with the net proceeds from the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, will be sufficient to enable Korsana to fund its operating expenses and capital expenditure requirements into 2029. Korsana has based this estimate on assumptions that may prove to be wrong, Korsana&#8217;s operating plan may change as a result of many factors currently unknown to Korsana and Korsana could exhaust its available capital resources sooner than Korsana expects. See the sections titled &#8220;&#8212; <span style="font-style:italic">Liquidity and Capital Resources</span>&#8221; below and &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to Korsana&#8217;s Limited Operating History, Financial Position and Capital Requirements</span>&#8221; beginning on page 75 of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impact of General Economic Risk Factors on Korsana&#8217;s Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Uncertainty in the global economy presents significant risks to Korsana&#8217;s business. Korsana is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, fluctuating interest rates, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the responses thereto, and supply chain disruptions. While Korsana is closely monitoring the impact of the current macroeconomic and geopolitical conditions on all aspects of Korsana&#8217;s business, including the impacts on participants in any future clinical trials and its employees, suppliers, vendors and business partners and Korsana&#8217;s future access to capital, the ultimate extent of the impact on Korsana&#8217;s business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Korsana&#8217;s control and could exist for an extended period of time. Korsana will continue to evaluate the nature and extent of the potential impacts to its business, results of operations, liquidity and capital resources. For additional information, see the section titled &#8220;Risk Factors &#8212; Risks Related to Korsana&#8217;s Business and Operations.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, Korsana has not generated revenue from any sources, including product sales, and does not expect to generate any revenue from the sale of products in the foreseeable future. If Korsana&#8217;s development efforts for its product candidates are successful and result in regulatory approval, Korsana may generate revenue in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">361 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future from product sales or payments from future collaboration or license agreements that Korsana may enter into with third parties, or any combination thereof. Korsana cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of Korsana&#8217;s product candidates. Korsana may never succeed in obtaining regulatory approval for any of its product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s operating expenses consist of (i)&#160;research and development expenses and (ii)&#160;general and administrative expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred in connection with the research and development of Korsana&#8217;s programs. These expenses include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Korsana&#8217;s behalf and services rendered under the Paragon ADOA (as defined below) for research programs, the A&#223; program and undisclosed program 003; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses incurred in connection with continuing Korsana&#8217;s current research programs and discovery-phase development of any programs Korsana may identify, including under future agreements with third parties, such as consultants and contractors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">personnel-related expenses, including recruiting costs, salaries, bonuses, benefits and equity-based compensation expense. </p></td></tr></table> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana expenses research and development costs as incurred. For the three months ended March 31, 2026, Korsana recognized $8.8&#160;million of expenses in connection with services provided by Paragon under the Paragon ADOA in Korsana&#8217;s condensed consolidated statements of operations and comprehensive loss. For the three months ended March 31, 2025, Korsana recognized less than $0.1 million of expenses in connection with services provided by Paragon for the 001 program and stock compensation. For the year ended December 31, 2025, Korsana recognized $31.3 million of expenses in connection with services provided by Paragon under the Paragon ADOA in Korsana&#8217;s consolidated statements of operations and comprehensive loss. There were no expenses recognized during the period November&#160;8, 2024 (inception) to December&#160;31, 2024 related to the Paragon ADOA. See the section titled &#8220;Contractual Commitments and Obligations&#8221; below for further details on Korsana&#8217;s research plans. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana expects its research and development expenses will increase substantially for the foreseeable future as Korsana continues to invest in research and development activities related to the continued development of Korsana&#8217;s programs, developing any future programs, including investments in manufacturing, as Korsana advances any program Korsana may identify and continue to conduct clinical trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related expenses, including recruiting costs, salaries, bonuses, benefits and equity-based compensation, for individuals in Korsana&#8217;s executive, finance, legal, operations, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters and patent-related activities, insurance costs, information technology, and professional and consulting fees associated with accounting, audit, tax and investor and public relations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana expects that its general and administrative expenses will increase substantially for the foreseeable future as Korsana increases its headcount and establishes office space to support its expected growth. Korsana also expects to incur increased expenses associated with becoming a public company, including transactional costs and increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Korsana also expects to incur additional intellectual property-related expenses as Korsana files patent applications to protect innovations arising from its research and development activities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">362 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other income </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income includes interest income of $1.3 million earned for the three months ended March 31, 2026 and $0.1 million for the three months ended March 31, 2025. Other income includes interest income of $1.6&#160;million earned for the year ended December&#160;31, 2025 and less than $0.1&#160;million for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. Other income relates to interest earned on Korsana&#8217;s money market accounts. The increase in interest income relates to an increase in the cash and cash equivalents balance from the issuance of Korsana&#8217;s Series A convertible preferred stock in September 2025. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Taxes </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No provision for income taxes was recorded for the three months ended March 31, 2026 and for the three months ended March 31, 2025. No provision for income taxes was recorded for the year ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (inception) through December&#160;31, 2024. Korsana has recorded a full valuation allowance against its net deferred tax assets at the various balance sheet dates, as Korsana believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date and expectation of future losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations for the Three Months Ended March&#160;31, 2026 and March 31, 2025 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s condensed consolidated statements of operations and comprehensive loss for the periods presented (in thousands): </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three&#160;Months<br/>Ended<br/>March&#160;31,&#160;2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months<br/>Ended<br/>March&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(14,760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(143</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(13,510</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(73</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $8.8&#160;million for the three months ended March 31, 2026 and less than $0.1&#160;million for the three months March&#160;31, 2025. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s research and development expenses incurred for the periods presented (in thousands): </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:75%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months<br/>Ended<br/>March&#160;31,&#160;2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months<br/>Ended<br/>March&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development costs by selected program / platform:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A&#223; program <sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,897</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Undisclosed program 003 <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development costs:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation) <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">956</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $7.1&#160;million for the three months ended March 31, 2026 and $0 for the three months ended March&#160;31, 2025. </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">363 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $1.5&#160;million for the three months ended March 31, 2026 and $0 for the three months ended March&#160;31, 2025 </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $0.2&#160;million for the three months ended March 31, 2026 and less than $0.1&#160;million for the three months ended March&#160;31, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of less than $0.1&#160;million for the three months ended March 31, 2026 and $0 for the three months ended March&#160;31, 2025. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $11.5&#160;million for the period ended March 31, 2026 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$7.1&#160;million of research and development expense due to Paragon for services rendered under the Paragon ADOA for the A&#223; program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.5&#160;million of research and development expense due to Paragon for services rendered under the Paragon ADOA for undisclosed program 003; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.0&#160;million of personnel-related costs related to recruiting costs, salaries, benefits, and other compensation-related costs, including stock-based compensation expense of $0.3&#160;million of which $0.2&#160;million of stock-based compensation expense related to the 2026 Parasa Warrant Obligation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.6&#160;million of research and development expense due to an increase in chemistry, manufacturing, and development costs for the A&#223; program, including $0.2&#160;million of toxicology testing for the A&#223; program with a third-party contract research organization; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.3&#160;million of other research and development expense related to chemistry, manufacturing, and development costs with a third-party contract development and manufacturing organization. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $0.1&#160;million for the three months ended March&#160;31, 2025 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Less than $0.1&#160;million of research and development expense due to third party services rendered for the A&#223; program; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Less than $0.1&#160;million of stock-based compensation expense. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s total general and administrative expenses for the periods presented (in thousands): </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months<br/>Ended<br/>March&#160;31,&#160;2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months<br/>Ended<br/>March&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $3.3&#160;million for the three months ended March 31, 2026 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.7&#160;million of professional and consulting fees associated with accounting, audit, investor and public relations, and legal fees due to an increase in Korsana&#8217;s business activity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.4&#160;million of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based compensation of $0.4&#160;million; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.2&#160;million of other business expenses. </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">364 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were less than $0.1&#160;million for three months ended March&#160;31, 2025 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Less than $0.1&#160;million of professional and consulting fees associated with accounting, audit, tax and insurance; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Less than $0.1&#160;million of other business expenses. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations for the Year Ended December&#160;31, 2025 and Period from November&#160;8, 2024 (Inception) to December&#160;31, 2024 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s statements of operations and comprehensive loss for the periods presented (in thousands): </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Period from<br/>November&#160;8,&#160;2024<br/>(Inception) to<br/>December&#160;31,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">37,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(37,291</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(109</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(35,642</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $31.2&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $1.2&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s research and development expenses incurred for the periods presented (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year&#160;Ended<br/>December&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Period&#160;from<br/>November&#160;18,&#160;2024<br/>(Inception) to<br/>December&#160;31,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extemal research and development costs by selected program / platform :</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A&#223; program <sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">27,003</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Undisclosed program 003 <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development costs:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation) <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">365 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $26.4&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $3.9&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $0.9&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of less than $0.1&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $32.8&#160;million for the year ended December&#160;31, 2025 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$26.4&#160;million of research and development expense due to Paragon for services rendered under the Paragon ADOA for the A&#223; program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$3.9&#160;million of research and development expense due to Paragon for services rendered under the Paragon ADOA for undisclosed program 003; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.6&#160;million of personnel-related costs related to recruiting costs, salaries, benefits, and other compensation-related costs, including stock-based compensation expense of $0.9&#160;million of which $0.8&#160;million of stock-based compensation related to the 2025 Parasa Warrant Obligation; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.6&#160;million of research and development expense due to an increase in chemistry, manufacturing, and development costs for the A&#223; program, including $0.4&#160;million of toxicology testing for the A&#223; program with a third-party contract research organization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.2&#160;million of other research and development expense related to chemistry, manufacturing, and development costs with a third-party contract development and manufacturing organization; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.1&#160;million of research and development expense due to an increase in chemistry, manufacturing, and development costs for undisclosed program 003, including $0.1&#160;million of toxicology testing for undisclosed program 003 with a third-party contract research organization. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were less than $0.1&#160;million for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Less than $0.1&#160;million of stock-based compensation expense. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s total general and administrative expenses for the periods presented (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:65%"/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Period from<br/>November&#160;8,&#160;2024<br/>(Inception) to<br/>December&#160;31,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting fees<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related (including stock-based compensation)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees related to patent<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">620</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $0.5&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">366 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $0.6&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes related party amount of $0.1&#160;million for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $4.5&#160;million for the year ended December&#160;31, 2025 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$2.4&#160;million of professional and consulting fees associated with accounting, audit, investor and public relations, and legal fees due to an increase in Korsana&#8217;s business activity, including $0.5&#160;million reimbursed to Paragon and the chief executive officer for such services provided; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$1.3&#160;million of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based compensation of $0.7&#160;million; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.6&#160;million of legal fees due to Paragon associated with patent-related activities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$0.2&#160;million of other business expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were less than $0.1&#160;million for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024 and consisted primarily of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Less than $0.1&#160;million of corporate legal fees and legal fees associated with patent-related activities. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sources of Liquidity </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its inception, Korsana has incurred significant operating losses. Korsana expects to incur significant expenses and operating losses for the foreseeable future as Korsana continues the preclinical development of its programs and commences clinical development of the A&#223; program and undisclosed program 003. Korsana has not yet commercialized any products and Korsana does not expect to generate revenue from sales of products for several years, if at all. To date, Korsana has primarily funded its operations with proceeds from the issuance of Series Seed and Series A preferred stock. In November 2024, Korsana issued and sold 8,000,000 shares of Series A convertible preferred stock (subsequently reclassified to Series Seed preferred stock in September 2025) at a purchase price of $1.25 per share, for total gross proceeds of $10.0&#160;million. In September 2025, Korsana received $15.0&#160;million in gross proceeds from the issuance of Series Seed preferred stock and $151.0&#160;million from the issuance of Series A preferred stock. As of March 31, 2026, Korsana had cash and cash equivalents of $134.2&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows for the Three Months Ended March&#160;31, 2026 and March 31, 2025 </span></p> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s cash flows for the periods presented (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months<br/>Ended<br/>March&#160;31,&#160;2026</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Three Months<br/>Ended<br/>March&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(19,477</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(165</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(19,877</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(41</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">367 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Net Cash Used in Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March 31, 2026, net cash used in operating activities was $19.5&#160;million, which was primarily attributable to a net loss of $13.5&#160;million and decreases in operating assets and liabilities of $6.6&#160;million, partially offset by <span style="white-space:nowrap">non-cash</span> charges of $0.7&#160;million. <span style="white-space:nowrap">Non-cash</span> charges consisted of $0.7&#160;million in stock-based compensation expense. The changes in operating assets and liabilities primarily consisted of a $0.2&#160;million decrease in accounts payable, $6.0&#160;million decrease in accrued expenses and other current liabilities, and $0.5&#160;million increase in prepaid expenses and other current assets. The decrease in accounts payable, and accrued expenses and other current liabilities was primarily due to repayment of vendor invoicing. The increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses with Korsana&#8217;s contract research organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2025, net cash used by operating activities was less than $0.1&#160;million, which was primarily attributable to a net loss of $0.1&#160;million, partially offset by increases in operating assets and liabilities of less than $0.1&#160;million and <span style="white-space:nowrap">non-cash</span> charges of less than $0.1&#160;million. <span style="white-space:nowrap">Non-cash</span> charges consisted of less than $0.1&#160;million in stock-based compensation expense. The changes in operating assets and liabilities consisted of $0.2&#160;million increase in accounts payable and accrued expenses and other current liabilities and $0.2&#160;million decrease in prepaid expenses and other current assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Net Cash Used in Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2026, net cash used in investing activities was $0.2&#160;million, which is attributable to $0.2&#160;million purchase of property and equipment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Net Cash Used in Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&#160;31, 2026, net cash used in financing activities was $0.2&#160;million, which is attributable to $0.2&#160;million of deferred offering cost payments in connection with Korsana&#8217;s proposed merger transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows for the Year Ended December 31, 2025 and Period from November 8, 2024 (Inception) to December 31, 2024 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes Korsana&#8217;s cash flows for the periods presented (in thousands): </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:61%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended<br/>December&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Period from<br/>November&#160;8,&#160;2024<br/>(Inception) to<br/>December&#160;31,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(22,406</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">166,433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,064</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">144,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Net Cash Used in Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2025, net cash used in operating activities was $22.4&#160;million, which was primarily attributable to a net loss of $35.6&#160;million, partially offset by <span style="white-space:nowrap">non-cash</span> charges of $1.6&#160;million and changes in operating assets and liabilities of $11.6&#160;million. <span style="white-space:nowrap">Non-cash</span> charges consisted of $1.6&#160;million in stock-based compensation expense. The changes in operating assets and liabilities primarily consisted of a $0.1&#160;million increase in accounts payable, $12.0&#160;million increase in accrued expenses and other current liabilities, partially offset by $0.5&#160;million increase in prepaid expenses and other current assets. The increase in accounts payable, and accrued expenses and other current liabilities was primarily due to an increase in Korsana&#8217;s business activity, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">368 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including $10.6&#160;million of additional accrued expenses and other current liabilities related to the research and development activities conducted by Paragon on behalf of Korsana, as well as vendor invoicing and payments. The increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses with Korsana&#8217;s contract research organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From November&#160;8, 2024 (inception) to December&#160;31, 2024, net cash provided by operating activities was less than $0.1&#160;million, which was primarily attributable to a net loss of $0.1&#160;million, offset by <span style="white-space:nowrap">non-cash</span> charges of $0.1&#160;million and changes in operating assets and liabilities of $0.1&#160;million. <span style="white-space:nowrap">Non-cash</span> charges consisted of $0.1&#160;million in stock-based compensation expense. The changes in operating assets and liabilities consisted of $0.1&#160;million increase in accounts payable, accrued expenses and other current liabilities. The increase in accounts payable, accrued expenses and other current liabilities was primarily due to an increase in Korsana&#8217;s business activities, as well as vendor invoicing and payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Net Cash Provided by Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2025, net cash provided by financing activities was $166.4&#160;million, consisting of $15.0&#160;million of net proceeds from the issuance of Korsana&#8217;s Series Seed convertible preferred stock, $150.6&#160;million of net proceeds from the issuance of Korsana&#8217;s Series A convertible preferred stock, and $0.9&#160;million of net proceeds from the issuance of Korsana&#8217;s restricted stock awards (&#8220;RSAs&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From November&#160;8, 2024 (inception) to December&#160;31, 2024, net cash provided by financing activities was $10.1&#160;million, consisting of $10.0&#160;million of net proceeds from the issuance of Korsana&#8217;s Series A convertible preferred stock, subsequently reclassified to Series Seed convertible preferred stock during the year ended December&#160;31, 2025, and $0.1&#160;million of proceeds from the issuance of restricted stock awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future Funding Requirements </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, Korsana has not generated any revenue from product sales. Korsana does not expect to generate revenue from product sales unless and until Korsana successfully completes preclinical and clinical development of, receives regulatory approval for, and commercializes a product candidate. Korsana does not know when, or if, that will occur. Korsana expects its expenses to increase substantially in connection with its ongoing activities, particularly as Korsana advances the preclinical activities and studies and initiates clinical trials. In addition, if Korsana obtains regulatory approval for any programs, Korsana expects to incur significant expenses related to product sales, marketing, and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Further, Korsana expects to incur additional costs associated with operating as a public company. The timing and amount of Korsana&#8217;s operating expenditures will depend largely on the factors set out above. For more information, see the section titled &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related To Korsana&#8217;s Limited Operating History, Financial Position and Capital Requirements</span>&#8221; beginning on page&#160;75 of this proxy statement/prospectus. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s funding requirements and timing and amount of its operating expenditures will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rate of progress in the development of Korsana&#8217;s existing and future research and development and discovery-related development of its A&#223; program and undisclosed program 003; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of additional research programs and product candidates and discovery-related activities and preclinical studies for those programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability of Korsana to successfully file investigational new drug applications or comparable foreign applications and obtain authorization to commence Korsana&#8217;s planned clinical trials or future clinical trials for any programs Korsana may develop the costs of enrollment and successful completion of clinical trials; </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">369 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs necessary to pursue positive results from Korsana&#8217;s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of hiring research and development, clinical, manufacturing and commercial personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of adding operational, financial and management information systems and personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of developing, maintaining and enhancing sustainable, scalable, reproducible and transferable clinical and commercial-scale cGMP capabilities through a third-party or Korsana&#8217;s own manufacturing facility for the programs Korsana may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of future commercialization activities, including establishing sales, marketing and distribution infrastructure to commercialize any programs, for any of Korsana&#8217;s product candidates for which Korsana receives regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue, if any, received from commercial sales of Korsana&#8217;s product candidates for which Korsana receives marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of preparing, maintaining, expanding, enforcing, defending and protecting Korsana&#8217;s intellectual property rights and protection or regulatory exclusivity for any products Korsana may develop and defending any intellectual property-related claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and payment of milestone, royalty or other payments Korsana must make pursuant to its existing and potential future collaborations and licensing arrangements with third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs Korsana incurs in maintaining business operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company, including costs of audit, legal, regulatory and <span style="white-space:nowrap">tax-</span> related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing technological and market developments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which Korsana acquires or invests in businesses, products and technologies, including entering into licensing or collaboration arrangements for programs. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential programs and product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and Korsana may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, Korsana&#8217;s programs, if approved, may not achieve commercial success. Korsana&#8217;s commercial revenues, if any, will be derived from sales of products that Korsana does not expect to be commercially available for many years, if ever. Accordingly, Korsana will need to obtain substantial additional funds to achieve its business objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate additional funds may not be available to Korsana on acceptable terms, or at all. Korsana does not currently have any committed external source of funds. To the extent that Korsana raises additional capital through the sale of equity or convertible debt securities, ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Korsana&#8217;s existing stockholders. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Korsana&#8217;s ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute ownership interests. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">370 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Korsana raises additional funds through strategic collaborations or licensing arrangements with third parties, Korsana may have to relinquish valuable rights to its technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to Korsana. If Korsana is unable to raise additional funds through equity or debt financings when needed, Korsana may be required to delay, limit or terminate its product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that Korsana would otherwise prefer to develop and market itself. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;31, 2026, Korsana had cash and cash equivalents of $134.2&#160;million. Korsana expects that the existing cash that and cash equivalents, which was primarily raised from Series Seed and Series A convertible preferred stock financings, will be sufficient to fund Korsana&#8217;s operating plans for at least twelve months from the date these financial statements are available to be issued. Korsana estimates that its existing cash and cash equivalents as of the date of this proxy statement/prospectus, together with the net proceeds from the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, will be sufficient to enable Korsana to fund Korsana&#8217;s operating expenses and capital expenditure obligations requirements through 2029. Korsana has based this estimate on assumptions that may prove to be wrong, Korsana&#8217;s operating plan may change as a result of many factors currently unknown to Korsana and Korsana could exhaust its available capital resources sooner than Korsana expects. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Contractual Obligations and Other Commitments Paragon Antibody Discovery and Option Agreement </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2025, Korsana entered into an Antibody Discovery and Option Agreement with Paragon and Parasa (the &#8220;Paragon ADOA&#8221;). Under the Paragon ADOA, Paragon identifies, evaluates, and develops antibodies against one or more mutually agreed therapeutic targets and a mutually agreed brain transit target. The Paragon ADOA covers Research Program 001 and Research Program 002, each targeting A&#223; and TfR1 (collectively, the &#8220;A&#223; Research Programs&#8221;), and one undisclosed research program 003, with the ability to add additional programs by mutual agreement. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Korsana has the exclusive option, on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis (each, an &#8220;ADOA Option&#8221;), to negotiate and enter into a license agreement (each, a &#8220;License&#8221;) granting Korsana (a)&#160;an exclusive, worldwide license to the product-specific intellectual property from the applicable program and (b)&#160;a <span style="white-space:nowrap">non-exclusive,</span> worldwide license to certain incorporated platform technology. ADOA Options are exercisable at Korsana&#8217;s sole discretion during the applicable option period, with no separate exercise payment. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon signing, Korsana became obligated to reimburse Paragon approximately $18.8&#160;million for <span style="white-space:nowrap">pre-development</span> costs incurred through September&#160;5, 2025. For each research program, Korsana is also required to pay Paragon a research initiation fee and certain third-party costs and internal resource fees. As of March 31, 2026, Korsana has recorded an aggregate of $40.1&#160;million of operating expenses under the Paragon ADOA for development costs. On a program-by-program and product-by-product basis, Korsana is also required to make one-time, non-refundable milestone payments of up to $46.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination. Any License will incorporate the same milestone obligations, with milestones not achieved prior to License execution no longer payable under the Paragon ADOA. Under any License, Korsana would be required to make tiered royalty payments in the low to mid-single digit percentage range based on annual net sales, subject to certain reductions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;19, 2026, Korsana exercised its ADOA Option with respect to Research Program 002. Korsana made a $5.0&#160;million milestone payment to Paragon in March 2026 related to the nomination of KRSA-028 as the development candidate for Research Program 002. On June&#160;8, 2026, Korsana entered into the Paragon License Agreement with Paragon with respect to the A&#223; Research Programs, as described in more detail below. Korsana&#8217;s ADOA Option with respect to program 003 remains unexercised. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon ADOA continues on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis until the earliest of completion of the applicable research plan activities, expiration of the option period, or failure to execute a License within a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">371 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified period following option exercise. Korsana may terminate any research program or the Paragon ADOA in its entirety at any time for any reason, subject to certain termination fees. Each party has the right to terminate upon the other party&#8217;s uncured material breach or bankruptcy. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Parasa will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of Korsana&#8217;s outstanding capital stock on a fully diluted basis as of the grant date, at an exercise price equal to fair market value. The grant dates for the issuance of the warrants was on December 31, 2025 and expected to be on December 31, 2026. Parasa&#8217;s research and discovery related activities have a service inception date preceding the grant dates, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, the Company accrues compensation cost for the warrants expected to be granted to Parasa as the related services are provided based on the estimated fair value of the warrants at each interim reporting date, with cumulative adjustments recognized for changes in fair value through the respective grant date. When the Company entered into the Paragon ADOA with Parasa, the underlying terms and conditions of the warrant agreements had not been executed and it was uncertain whether the final terms and conditions would result in liability- or equity-classified warrants. Given the uncertainty related to the terms and conditions of the warrant agreements and the determination of liability or equity classification prior to the grant dates, the Company initially accrues the costs for the warrants as a liability. If Korsana undergoes an initial public offering or reverse merger, Parasa will instead receive warrants from the resulting public parent on equivalent terms. Each warrant is exercisable for 10 years from the grant date, with <span style="white-space:nowrap">pro-ration</span> if the research term ends before <span style="white-space:nowrap">year-end.</span> On December&#160;31, 2025, Korsana issued Parasa a warrant to purchase 1,102,561 shares of common stock at $0.86&#160;per share. Upon the grant of the warrant and the finalization of the terms and conditions, the Company concluded that equity classification was appropriate, resulting in a reclassification of the award from liability to equity on December 31, 2025. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana concluded that the rights obtained under the Paragon ADOA represent an asset acquisition whereby the underlying assets comprise <span style="white-space:nowrap">in-process</span> research and development assets with no alternative future use. The Paragon ADOA did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the <span style="white-space:nowrap">in-process</span> research and development assets, which represent a group of similar identifiable assets. All of the upfront consideration paid by Korsana was allocated to the <span style="white-space:nowrap">in-process</span> research and development assets acquired and was immediately expensed as part of research and development expenses on the consolidated statement of operations and comprehensive loss. The research initiation fees represent a <span style="white-space:nowrap">one-time</span> cost on a research <span style="white-space:nowrap">program-by</span> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of <span style="white-space:nowrap">on-going</span> development costs, monthly development cost fees and additional development expenses incurred by Paragon are recognized as research and development expense when incurred. Amounts paid as reimbursements for administrative activities incurred by Paragon are recognized as general and administrative expense when incurred. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Korsana recorded total expense of $8.8 million during the three months ended March 31, 2026 for amounts owed to Paragon across all Research Programs, including $3.6 million of research and development work completed by Paragon, $5.0 million for the achievement of a development candidate milestone, and $0.2 million of stock-based compensation related to the 2026 Parasa Warrant Obligation. An amount of $3.6&#160;million was unpaid by Korsana at March 31, 2026 and is included in related party accrued expenses and other current liabilities within Korsana&#8217;s condensed consolidated balance sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Korsana recorded expense of $31.3&#160;million during the year ended December&#160;31, 2025 for amounts owed to Paragon across all Research Programs, including $18.8&#160;million of upfront payments made to cover the cost of development work completed by Paragon prior to the effective date and $2.0&#160;million of Research Initiation Fees. A total of $30.3&#160;million was recognized as research and development expense and $1.0&#160;million was recognized as general and administrative expense in Korsana&#8217;s consolidated statements of operations and comprehensive loss during the year ended December&#160;31, 2025. An amount of $10.6&#160;million was unpaid by Korsana at December&#160;31, 2025 and was included in related party accrued expenses and other current liabilities within Korsana&#8217;s consolidated balance sheet. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">372 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> </div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Paragon Platform Option Agreement </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 16, 2025, Korsana entered into the Platform Option Agreement with Paragon and Parasa (the &#8220;Paragon POA&#8221;), in connection with the Paragon ADOA. Under the Paragon POA, Korsana may designate up to four target combinations (each consisting of one or two therapeutic targets and a transit target) to be exclusively reserved during the option period (the &#8220;POA Option Period&#8221;). As of the effective date, the initial reserved target list includes one undisclosed target combination. Korsana may also obtain rights to designate up to two additional target combinations upon payment of $2.0&#160;million each. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the POA Option Period, Korsana has an option ( a &#8220;PPOA Option&#8221;) for each reserved target combination to either (a)&#160;enter into an antibody discovery and option agreement on terms materially consistent with the Paragon ADOA or (b)&#160;enter directly into a license agreement (a <span style="white-space:nowrap">&#8220;POA-License&#8221;)</span> upon payment of a $5.0&#160;million exercise fee. Under any <span style="white-space:nowrap">POA-License,</span> Korsana would be required to make <span style="white-space:nowrap">one-time,</span> <span style="white-space:nowrap">non-refundable</span> milestone payments of up to $41.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination, and tiered royalty payments in the low to <span style="white-space:nowrap">mid-single</span> digit percentage range based on annual net sales, subject to certain reductions. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon POA continues until expiration of the POA Option Period. Each party has the right to terminate upon the other party&#8217;s uncured material breach or bankruptcy. Korsana may terminate at any time for any reason. As of the date of this proxy statement/prospectus, Korsana has not exercised any POA Options or made any payments under the Paragon POA. </p> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Paragon Research Letter Agreement</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 3, 2026, Korsana entered into a research letter agreement (the &#8220;Paragon Research Letter Agreement&#8221;) with Paragon Laboratories, Inc. (&#8220;Paragon Laboratories&#8221;). Under the terms of the Paragon Research Letter Agreement, the parties agreed to initiate a research program (the &#8220;AOC Research Program&#8221;) focused on an undisclosed target combination, in an effort to identify, evaluate and develop antibody oligonucleotide conjugates (&#8220;AOCs&#8221;) directed to such target combination (the &#8220;Research AOCs&#8221;). The AOC Research Program will be conducted in accordance with a research plan that the parties will use specified efforts to agree upon within a specified period following the effective date of the Paragon Research Letter Agreement (the &#8220;AOC Research Plan&#8221;). During the AOC Research Term (as defined below), each party will use specified efforts to conduct and complete the research activities assigned to it under the AOC Research Plan, and Paragon Laboratories will provide Korsana with periodic updates regarding the Research AOCs identified under the AOC Research Plan. The AOC Research Program will continue until the earliest of (a) the date that the aggregate costs paid or owing by Korsana to Paragon Laboratories meet or exceed a budgeted cap, (b) completion of the activities set forth in the AOC Research Plan, and (c) such other mutually agreed date (such period, the &#8220;AOC Research Term&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon Research Letter Agreement, Korsana has a nontransferable, exclusive option during the AOC Research Term and, provided that Korsana is not in material breach, for an additional specified period thereafter (collectively, the &#8220;AOC Option Period&#8221;), to either (i) enter into an antibody oligo conjugate discovery and option agreement for the AOC Research Program (the &#8220;AOC-DOA Option&#8221;), or (ii) enter into a license agreement for the AOC Research Program (the &#8220;AOC-License Option&#8221; and, with the AOC-DOA Option, either referenced hereinafter as the &#8220;AOC Option&#8221;). Korsana may exercise the AOC Option only once for the AOC Research Program, without payment of a separate exercise fee. The AOC Option terminates upon the earliest of: a permitted early termination of the AOC Research Program, the expiration of the AOC Option Period without Korsana having exercised the AOC Option, and, if Korsana has exercised the AOC Option, the failure of the parties to finalize a Definitive Agreement (as defined below) or elect the applicable dispute resolution procedures within the required timeframe. Following termination of the AOC Option, Paragon Laboratories is free to license or grant rights in the Research AOCs to third parties. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">373 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Korsana&#8217;s exercise of the AOC Option, the parties will negotiate for a specified period toward a definitive agreement (the &#8220;Definitive Agreement&#8221;). If Korsana exercises the AOC-DOA Option, the Definitive Agreement would provide for, among other things, the continuation of the AOC Research Program, payment by Korsana of a research initiation fee, and an exclusive option for Korsana to enter into separate license agreement(s) consistent with the license described below. If Korsana exercises the AOC-License Option, the Definitive Agreement would be a license agreement granting Korsana, its affiliates, and sublicensees the right to develop, manufacture, and commercialize the Research AOCs for any and all uses worldwide, under an exclusive license to the Research AOCs as a whole and any therapeutic nucleic acid component included in a Research AOC, and a non-exclusive license to any platform elements incorporated into such Research AOCs. Any such license agreement would include a one-time upfront license fee. If the parties are unable to reach agreement on the Definitive Agreement within the specified negotiation period, either party may elect to resolve the dispute in accordance with procedures set forth in the Paragon ADOA, as applied <span style="font-style:italic">mutatis mutandis</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As between the parties, Paragon Laboratories owns all intellectual property generated under or in connection with the AOC Research Program, and Korsana has assigned all of its rights therein to Paragon Laboratories. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Paragon Laboratories&#8217; performance of the AOC Research Program and the grant of the AOC Option to Korsana, Korsana is required to reimburse Paragon Laboratories for certain third-party costs and internal resource fees, which may not exceed a budget cap set forth in the AOC Research Plan unless increased by mutual written agreement. All payments under the Paragon Research Letter Agreement are non-refundable and non-creditable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Research Letter Agreement will continue until the expiration of the AOC Option, unless terminated earlier in accordance with the terms thereof. The Paragon Research Letter Agreement and the AOC Research Program may be terminated by either party upon prior written notice if the other party commits a material breach and fails to cure within such notice period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-style:italic">Paragon License Agreement</span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;8, 2026, Korsana entered into a license agreement with Paragon for certain antibody transport vehicle compounds discovered, generated, identified or characterized by Paragon in the course of performing Research Program 001 and Research Program 002 under the Paragon ADOA, including KRSA-028, together with certain related antibodies, antibody transport vehicles and products comprising the foregoing (the &#8220;Paragon License Agreement&#8221;). The Paragon License Agreement is consistent with the pre-negotiated terms agreed to upon execution of the Paragon ADOA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon License Agreement, Paragon granted Korsana a royalty-bearing, worldwide, exclusive and sublicensable license under certain licensed project antibody transport vehicle technology to develop, manufacture, commercialize and otherwise exploit licensed antibodies, licensed antibody transport vehicles, derived antibodies, derived antibody transport vehicles and related products in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the &#8220;field&#8221;) and worldwide (the &#8220;territory&#8221;). Paragon also granted Korsana certain royalty-bearing, worldwide, non-exclusive and sublicensable licenses under certain transit antibody technology, other licensed patents and other licensed know-how to develop, manufacture, commercialize and otherwise exploit specified licensed products in the field and territory. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Paragon License Agreement, Korsana is solely responsible for, and has sole authority and control over, all aspects of the development, manufacturing and commercialization of products under the licensed programs, including regulatory strategy, communications, filings and activities, including clinical trials. Korsana is required to use commercially reasonable efforts to develop and seek regulatory approval for at least one licensed product in the United States and at least one other major market country and, following receipt of regulatory approval for a licensed product in a given country, to commercialize such licensed product in such country. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">374 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the applicable exclusivity period, Paragon is restricted from directly or indirectly conducting activities, including granting licenses to third parties, to develop, manufacture, commercialize or otherwise exploit antibody transport vehicles directed to both A&#223; and TfR1, subject to specified exceptions, including for certain change-of-control and acquired programs. The exclusivity period continues until the earlier of the fifth anniversary of the effective date and the occurrence of specified exclusivity termination events tied to Korsana&#8217;s failure to achieve certain diligence milestones, subject to cure and extension mechanics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Paragon License Agreement, Korsana is obligated to pay Paragon up to $46.0 million per product based on the achievement of specified development and regulatory milestones. If a product candidate, including certain combination products, is developed by Korsana as a bona fide back-up or substitute product to another royalty product for the same licensed therapeutic target, the same licensed transit target, if applicable, and the same indication, it would be considered a back-up royalty product for which no duplicate milestone payments are owed to Paragon, subject to specified limitations. Korsana is obligated to pay Paragon up to $23.0 million per product for certain Korsana-developed products that are not licensed products from Research Program 001 or Research Program 002 and are directed to the applicable licensed target or target combination based on the achievement of specified development and regulatory milestones. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other key terms of the Paragon License Agreement include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana will pay Paragon tiered royalties in the low- to mid-single digits based on annual net sales of licensed products in the field and territory, subject to a specified reduction if there is no valid claim covering the product in the country. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The royalty term ends, on a product-by-product and country-by-country basis, on the later of the twelfth anniversary of the first commercial sale of such product in such country and the expiration of the last-to-expire valid patent claim covering such product in such country. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana has the right to grant sublicenses under the Paragon License Agreement, provided that each sublicense is in writing and consistent with the relevant terms, conditions and restrictions of the Paragon License Agreement, Korsana provides Paragon with a copy of each sublicense agreement and any amendments within 30 days following execution, subject to permitted redactions, and Korsana remains responsible for all payments and obligations due under the Paragon License Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With respect to certain patents licensed to Korsana under the Paragon License Agreement, Korsana has the first right, but not the obligation, to prepare, file, prosecute and maintain such patents at its sole expense, subject to Paragon&#8217;s review, comment and backup prosecution rights. Paragon retains control over the preparation, filing, prosecution and maintenance of certain other patents owned or controlled by Paragon. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana may terminate the Paragon License Agreement in its entirety or on a country-by-country or royalty product-by-royalty product basis for any or no reason upon 60 days&#8217; prior written notice to Paragon. The Paragon License Agreement may also be terminated by either party upon the other party&#8217;s uncured material breach or, to the extent permitted by law, upon the other party&#8217;s insolvency or bankruptcy. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korsana considers Paragon, Paragon Laboratories, Parasa and Fairmount to be related parties. See the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions of the Combined Company &#8212; Korsana Transactions</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Significant Judgments and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations is based on Korsana&#8217;s financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires Korsana to make estimates and assumptions that affect the reported amounts </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">375 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Korsana&#8217;s estimates are based on its historical experience and on various other factors that Korsana believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Korsana&#8217;s significant accounting policies are described in more detail in Note 2 to its financial statements for the year ended December&#160;31, 2025 and for the period ended November&#160;8, 2024 (inception) to December&#160;31, 2024, as well as any new significant accounting policies described in Note 2 to its financial statements for the three months ended March 31, 2026, included elsewhere in this proxy statement/prospectus, Korsana believes the following accounting policies used in the preparation of Korsana&#8217;s financial statements require the most significant judgments and estimates. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Contract Costs Accruals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of Korsana&#8217;s research and development expenses, with a substantial portion of Korsana&#8217;s ongoing research and development activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and Korsana&#8217;s related party Paragon. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana accrues for expenses resulting from obligations under its Paragon ADOA and Paragon POA by and among Korsana, Paragon and Parasa, and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to Korsana. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. Korsana makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to Korsana&#8217;s accruals could materially affect its results of operations. As of March&#160;31, 2026, Korsana has not experienced any material deviations between accrued and actual research and development expenses. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana measures stock-based awards granted to employees, directors, and <span style="white-space:nowrap">non-employees</span> in the form of stock options and restricted stock awards (&#8220;RSAs&#8221;), based on their fair value on the date of the grant using the Black-Scholes option-pricing model. Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to <span style="white-space:nowrap">non-employees</span> with service-based vesting conditions is recognized in the same manner as if Korsana had paid cash in exchange for the goods or services. Korsana accounts for forfeitures as they occur. Korsana classifies its stock-based compensation expenses in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model uses inputs that are determined by the board of directors on the date of grant and assumptions Korsana makes for the volatility of stock-based awards, the expected term of stock- based awards, the risk-free interest rate for a period that approximates the expected term of Korsana&#8217;s stock-based awards and its expected dividend yield. Korsana has historically been a private company and lacks </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">376 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company-specific historical and implied volatility information of Korsana&#8217;s stock. Therefore, Korsana estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of Korsana&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Korsana has estimated a 0% dividend yield based on the expected dividend yield and the fact that Korsana has never paid, and does not expect to pay, any cash dividends in the foreseeable future. See Note 7 to Korsana&#8217;s financial statements included elsewhere in this proxy statement/prospectus for information concerning certain of the specific assumptions Korsana used in applying the Black-Scholes option-pricing model to determine the estimated fair value of its stock options granted in the periods presented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Determination of Fair Value of Common Stock </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for Korsana&#8217;s common stock as of March 31, 2026, the estimated fair value of stock-based awards has been determined by Korsana&#8217;s board of directors as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that Korsana believed were relevant. In addition, the board of directors considered various objective and subjective factors to determine the fair value of Korsana&#8217;s share-based awards as of each grant date, including: </p> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prices at which Korsana sold shares of Korsana Preferred Stock and preferences of the Korsana Preferred Stock relative to its stock-based awards at the time of each grant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s common stock valuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the progress of Korsana&#8217;s research and development programs, including the status of discovery-phase studies for Korsana&#8217;s product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s stage of development and business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">external market conditions affecting the biotechnology industry and trends within the biotechnology industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The lack of an active public market for Korsana&#8217;s common stock and Korsana Preferred Stock at the grant dates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s common stock valuations were prepared using a recent transactions method, including an option pricing method (&#8220;OPM&#8221;). Under this method, Korsana used the observed transaction price from a recent preferred stock financing and solved for the total equity value that results in that preferred stock price, using an OPM that allocates value across the capital structure based on the rights and preferences of each equity class. The resulting total equity value was then allocated to the common stock and preferred stock based on their respective economic rights, resulting in an estimated fair value of the common stock as of the valuation date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Korsana had used significantly different assumptions or estimates, the fair value of Korsana&#8217;s common stock and its stock-based compensation expense could have been materially different. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a public trading market for Korsana&#8217;s common stock has been established, it is no longer necessary for the board of directors to estimate the fair value of Korsana&#8217;s common stock in connection with its valuation and accounting for granted stock-based awards or other such awards Korsana may grant, as the fair value of its common stock is determined based on the quoted market price of Korsana&#8217;s common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">377 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recently Issued Accounting Pronouncements </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact Korsana&#8217;s financial position, results of operations or cash flows is disclosed in Note 2 to Korsana&#8217;s financial statements as of March&#160;31, 2026 included elsewhere in this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented Korsana did not have, nor does Korsana currently have, any <span style="white-space:nowrap">off-balance</span> sheet arrangements as defined in the rules and regulations of the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Quantitative and Qualitative Disclosures About Market Risks </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inflation Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Korsana believes the effects of inflation, if any, on its business, results of operations, financial condition or financial statements included elsewhere in this proxy statement/prospectus have been immaterial. Korsana cannot assure you its business will not be affected in the future by inflation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">378 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_32">MANAGEMENT FOLLOWING THE MERGER </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Merger, the business and affairs of the Combined Company will be managed under the direction of the Combined Company&#8217;s board of directors. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company&#8217;s board of directors will initially be fixed at six members, consisting of five current Korsana board members, namely Andrew Gottesdiener, &#8195;&#8195;&#8195;, Tomas Kiselak, Michelle Pernice, Nimish Shah, and Dr.&#160;Jonathan Violin. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each executive officer of the Combined Company will serve at the discretion of the Combined Company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed Combined Company&#8217;s directors or executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of Cyclerion&#8217;s current directors are expected to resign from their positions as directors of Cyclerion, effective as of the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age as of April&#160;1, 2026 and position of each of the individuals who are expected to serve as executives and directors of the Combined Company following completion of the Merger: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:44%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Age</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic">Executive Officers</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Violin, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">50</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer, President and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Vignola, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Madelyn Zeylikman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">51</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">General Counsel and Secretary</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors:</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Gottesdiener</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">35</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">39</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle Pernice</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">38</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimish Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td></tr>
</table> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers and Employee Director </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Jonathan Violin, Ph.D.</span> Dr.&#160;Violin has served as Korsana&#8217;s Chief Executive Officer and President since August 2025 and as a member of the Korsana Board since September 2025. Prior to joining Korsana, Dr.&#160;Violin served as the interim Chief Executive Officer and President of Crescent Biopharma, Inc. (Nasdaq: CBIO) from October 2024 to March 2025. Dr.&#160;Violin has served as President, Chief Executive Officer and member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company, from January 2021 to February 2023, and he previously served as President and Chief Operating Officer of Viridian from October 2020 until January 2021. Dr.&#160;Violin was the <span style="white-space:nowrap">Co-Founder</span> of Viridian&#8217;s predecessor and led its operations from April 2020 to its acquisition. Dr.&#160;Violin has served as a member of the board of directors of Crescent Biopharma, Inc. (Nasdaq: CBIO) since October 2024 and Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotechnology company he <span style="white-space:nowrap">co-founded,</span> since July 2019. Dr.&#160;Violin also <span style="white-space:nowrap">co-founded</span> Quellis Biosciences, Inc., a biotechnology company (acquired by Astria Therapeutics, Inc. (Nasdaq: ATXS), formerly Catabasis Pharmaceuticals, Inc.), in 2018 and served on the Astria Therapeutics board of directors from January 2021 until its acquisition by BioCryst Pharmaceuticals in January 2026. Prior to that, Dr.&#160;Violin <span style="white-space:nowrap">co-founded</span> and helped lead Trevena Inc. (Nasdaq: TRVN), a biotechnology company, in various roles from 2008 until November 2018, including most recently as Senior Vice President, Scientific Affairs and Investor Relations Officer. Dr.&#160;Violin </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">379 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received a Ph.D. from the Department of Pharmacology in the Biomedical Sciences Program at the University of California, San Diego, a M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes that Dr.&#160;Violin is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his extensive experience and innovations in the field of biotechnology, leadership experience as CEO of several public biotechnology companies, and his academic expertise and accomplishments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Mark Vignola, Ph.D.</span> Dr.&#160;Vignola has served as Korsana&#8217;s Chief Financial Officer since March 2026. Prior to joining Korsana, Dr.&#160;Vignola served as the Chief Financial Officer of Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company, from August 2020 to February 2025, where he led the company&#8217;s crossover financing, initial public offering, and multiple <span style="white-space:nowrap">follow-on</span> offerings. Previously, Dr.&#160;Vignola was the Chief Financial Officer at Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company where he led several financing rounds, from May 2019 to May 2020. Earlier in his career, Dr.&#160;Vignola was Head of Corporate Development and Investor Relations at Intercept Pharmaceuticals, Inc. and a biotechnology equity research analyst at Needham&#160;&amp; Company. Dr.&#160;Vignola earned his B.S. in Biology from Boston College and his Ph.D. in Molecular Genetics and Microbiology from Duke University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Madelyn Zeylikman</span>. Ms.&#160;Zeylikman has served as Korsana&#8217;s General Counsel and Secretary since January 2026. Prior to joining Korsana, Ms.&#160;Zeylikman served in senior legal roles at Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA), a biopharmaceutical company, from August 2020 to September 2025, including as General Counsel and Secretary beginning in May 2021, supporting the successful launch of the Kiniksa&#8217;s first commercially approved drug and advising on key business transactions. Ms.&#160;Zeylikman also held senior legal roles at Verastem, Inc. (Nasdaq: VSTM) and NxStage Medical, Inc., and began her career as a transactional attorney in the life sciences group at Ropes&#160;&amp; Gray LLP. Ms.&#160;Zeylikman holds a J.D. from the University of California, Berkeley, and a B.S. in Biology from Duke University. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Andrew Gottesdiener</span>. Dr.&#160;Gottesdiener has served as a member of the Korsana Board since November 2024. Dr.&#160;Gottesdiener is a partner at Venrock Healthcare Capital Partners, an investment firm, in its New York office, where he focuses on healthcare investments. Dr.&#160;Gottesdiener is also a <span style="white-space:nowrap">co-founder</span> of Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical stage biotechnology company, and has served as a member of Apogee&#8217;s board since 2022. Prior to joining Venrock Healthcare Capital Partners full-time in September 2018, Dr.&#160;Gottesdiener earned his M.D. from Weill Cornell Medical College during which time he received an HHMI summer fellowship for basic science research. He also has an M.B.A. from Columbia Business School. Dr.&#160;Gottesdiener received an A.B. in Economics from Washington University in St. Louis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes Dr.&#160;Gottesdiener is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his extensive experience in the biotechnology industry providing leadership in biotechnology investments and his medical and research background. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Tomas Kiselak</span>. Mr.&#160;Kiselak has served as a member of the Korsana Board since November 2024. Mr.&#160;Kiselak is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he <span style="white-space:nowrap">co-founded</span> in April 2016. Prior to Fairmount, he was a managing director at RA Capital Management, LLC, a healthcare and life science investment firm. Mr.&#160;Kiselak currently serves as the chairman of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN) and has been a member of Viridian&#8217;s board since October 2020, and has served as a director for Apogee Therapeutics, Inc. (Nasdaq: APGE) since June 2023, Jade Biosciences, Inc. (Nasdaq: JBIO) since April 2025, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since June 2023, Zenas BioPharma, Inc. (Nasdaq: ZBIO) since September 2020, and several private companies. Mr.&#160;Kiselak previously served as a director of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) from September 2023 until March 2025. He received a B.S. in Neuroscience and Economics from Amherst College. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">380 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes Mr.&#160;Kiselak is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his experience advising and serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Michelle Pernice</span>. Ms.&#160;Pernice has served as a member of the Korsana Board since November 2024. Ms.&#160;Pernice is an Operating Partner at Fairmount Funds Management LLC, a healthcare investment firm. Prior to joining Fairmount in October 2023, Ms.&#160;Pernice served in global regulatory roles for numerous pharmaceutical and biotechnology companies, including Pardes Biosciences from 2021 to 2023, Dynavax Technologies Corp., a commercial-stage biopharmaceutical company, from 2019 to 2021, Amgen Inc. (Nasdaq: AMGN), a global biotechnology company from 2014 to 2019, and Novartis AG (NYSE: NVS), a global pharmaceutical company, from 2012 to 2014, including development strategy across all phases of development, multiple modalities, and notable approvals. Ms.&#160;Pernice received her PharmD from St. John&#8217;s University and completed a post-PharmD fellowship through Rutgers University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes Ms.&#160;Pernice is qualified to serve as a member of the Combined Company&#8217;s board of directors because of her experience advising biotechnology companies and her background in global regulatory and development strategy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Nimish Shah</span>. Mr.&#160;Shah has served as a member of the Korsana Board since November 2024. Mr.&#160;Shah is a Partner at Venrock Healthcare Capital Partners, an investment firm, where he focuses on the firm&#8217;s public and crossover biotech investments. Mr.&#160;Shah joined Venrock Healthcare Capital Partners in 2013 and has invested in public and private healthcare companies since 2010. Mr.&#160;Shah is also a <span style="white-space:nowrap">co-founder</span> and a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical stage biotechnology company, where he has served since 2022. Mr.&#160;Shah previously served as a director for Instil Bio, Inc. (Nasdaq: TIL) until December 2021 and as a board observer for LianBio (Nasdaq: LIAN), Biohaven Ltd. (NYSE: BHVN), Viridian Therapeutics, Inc. (Nasdaq: VRDN), and Dianthus Therapeutics, Inc. (Nasdaq: DNTH). Mr.&#160;Shah holds a B.S. in Pharmacy from Rutgers College of Pharmacy, an M.P.H. from the Mailman School of Public Health at Columbia University, and an M.B.A. from Columbia Business School. He is a member of the Columbia Business School Healthcare and Pharmaceutical Management Advisory Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana believes that Mr.&#160;Shah is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his extensive investment management and finance experience in the healthcare sector, as well as his experience serving on the boards of directors of numerous other biotechnology companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Composition of the Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Board currently is declassified, with directors serving <span style="white-space:nowrap">one-year</span> terms. Following the completion of the Merger, if the Cayman Redomestication is effected, pursuant to the Cayman Articles, the Combined Company&#8217;s board of directors will be divided into three classes, with directors serving three-year terms and Class&#160;I directors holding initial terms expiring at the 2027 annual meeting of stockholders, Class&#160;II directors holding initial terms expiring at the 2028 annual meeting of stockholders and Class&#160;III directors holding initial terms expiring at the 2029 annual meeting of stockholders. The Class&#160;I directors will be &#8195;&#8195;&#8195;&#8195;and &#8195;&#8195;&#8195;&#8195;, the Class&#160;II directors will be &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195; , and the Class&#160;III directors will be &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;. See &#8220;<span style="font-style:italic">Risk Factors &#8212; </span><span style="font-style:italic">Risks Related</span><span style="font-style:italic"> to the Cayman </span><span style="font-style:italic">Redomestication</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Currently</span><span style="font-style:italic">, </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> is governed by Massachusetts law, </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> Articles and </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> Bylaws</span><span style="font-style:italic">, but upon effectiveness of the Cayman </span><span style="font-style:italic">Redomestication</span><span style="font-style:italic"> the Combined Company will be governed by Cayman Islands law and the Cayman Articles, provisions of which have anti-takeover implications.</span>&#8221;<span style="font-style:italic"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, pursuant to the Cyclerion Articles, as amended, at all times when at least 30% of the originally issued Cyclerion Series B Preferred Stock remains issued and outstanding: (i)&#160;the holders of Cyclerion Series B Preferred Stock, exclusively and voting together as a separate class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect four Preferred Directors; and (ii)&#160;the holders of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">381 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cyclerion Common Stock and of any other class or series of voting stock (including the Cyclerion Series B Preferred Stock), exclusively and voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect the balance of the total number of directors of Cyclerion. Each Preferred Director shall be entitled to three votes on each matter presented to the Combined Company board of directors. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, it is expected that Dr.&#160;Gottesdiener, Mr.&#160;Kiselak, Ms.&#160;Pernice and Mr.&#160;Shah will be elected as the four Preferred Directors by the holders of Cyclerion Series B Preferred Stock, and &#8195;&#8195;&#8195;and Dr.&#160;Violin will be elected as the two <span style="white-space:nowrap">At-Large</span> Directors. The four Preferred Directors will, in the aggregate, represent approximately 86% of the total votes of the Combined Company board of directors. As a result, the four Preferred Directors would be able to control or significantly influence all matters submitted to the Combined Company board of directors for approval, including business plans and policies and the appointment and removal of the Combined Company&#8217;s officers. See &#8220;<span style="font-style:italic">Risk Factors &#8212; Risks Related to the Combined Company &#8212; After </span><span style="font-style:italic">completion</span><span style="font-style:italic"> </span><span style="font-style:italic">of</span><span style="font-style:italic"> </span><span style="font-style:italic">the</span><span style="font-style:italic"> </span><span style="font-style:italic">Merger</span><span style="font-style:italic">,</span><span style="font-style:italic"> </span><span style="font-style:italic">Preferred</span><span style="font-style:italic"> </span><span style="font-style:italic">Directors</span><span style="font-style:italic"> </span><span style="font-style:italic">elected</span><span style="font-style:italic"> </span><span style="font-style:italic">by</span><span style="font-style:italic"> </span><span style="font-style:italic">the</span><span style="font-style:italic"> </span><span style="font-style:italic">holders</span><span style="font-style:italic"> </span><span style="font-style:italic">of</span><span style="font-style:italic"> </span><span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> </span>Series B Preferred Stock will have the ability to control or significantly influence all matters submitted to the Combined Company board of directors for approval.&#8221; </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Independence </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq listing rules have objective tests and a subjective test for determining who is an &#8220;independent director.&#8221; The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on information provided by each proposed director concerning her or his background, employment and affiliations, Cyclerion and Korsana expect that the Combined Company&#8217;s board of directors will determine that &#8195;&#8195;&#8195;&#8195;, Dr. Gottesdiener, Mr. Kiselak, Ms. Pernice and Mr. Shah qualify as &#8220;independent directors&#8221; as defined under Nasdaq listing rules. Jonathan Violin, Korsana&#8217;s current Chief Executive Officer, is not expected to qualify as an independent director of the Combined Company. In making these determinations, the Combined Company&#8217;s board of directors will consider the current and prior relationships that each director has with Cyclerion and Korsana and all other facts and circumstances that the Combined Company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each Combined Company director in the Merger, any relevant related party transactions and the beneficial ownership of securities of Cyclerion, Korsana or the Combined Company by each Combined Company director. See also the sections titled &#8220;<span style="font-style:italic">The Merger</span><span style="font-style:italic"> &#8212; </span><span style="font-style:italic">Interests of </span><span style="font-style:italic">Korsana</span><span style="font-style:italic">&#8217;</span><span style="font-style:italic">s</span><span style="font-style:italic"> Directors</span><span style="font-style:italic"> and</span><span style="font-style:italic"> </span><span style="font-style:italic">Executive</span><span style="font-style:italic"> </span><span style="font-style:italic">Officers</span><span style="font-style:italic"> </span><span style="font-style:italic">in</span><span style="font-style:italic"> </span><span style="font-style:italic">the</span><span style="font-style:italic"> </span><span style="font-style:italic">Merger</span>,&#8221; &#8220;<span style="font-style:italic">Certain</span><span style="font-style:italic"> </span><span style="font-style:italic">Relationships</span><span style="font-style:italic"> </span><span style="font-style:italic">and</span><span style="font-style:italic"> </span><span style="font-style:italic">Related</span><span style="font-style:italic"> </span><span style="font-style:italic">Party</span><span style="font-style:italic"> </span><span style="font-style:italic">Transactions</span><span style="font-style:italic"> </span><span style="font-style:italic">of</span><span style="font-style:italic"> </span><span style="font-style:italic">the</span><span style="font-style:italic"> </span><span style="font-style:italic">Combined Company</span>&#8221; and &#8220;<span style="font-style:italic">Principal Stockholders of </span><span style="font-style:italic">Korsana</span>&#8221; beginning on pages&#160;157, 385 and 428, respectively, of this proxy statement/prospectus for additional information. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Leadership Structure </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, Mr. Kiselak is expected to serve as Chair of the Combined Company&#8217;s board of directors (&#8220;Chair&#8221;). Although the Combined Company&#8217;s governance documents will not require that the Combined Company separate the Chief Executive Officer and Chair positions, Korsana believes that having the positions be separate is the appropriate leadership structure for the Combined Company at this time as it helps facilitate independent board oversight of management and allows the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the Combined Company&#8217;s board of directors. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana Board recognizes that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer and Chair, might be appropriate. Accordingly, the Combined </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">382 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#8217;s board may periodically review its leadership structure. At any time when a <span style="white-space:nowrap">non-independent</span> director is serving as Chair, Korsana anticipates that the independent directors of the Combined Company will designate a lead independent director to preside at all meetings of the board of directors of the Combined Company at which the Chair is not present, preside over executive sessions of the independent directors, which will occur regularly throughout each year, serve as a liaison between the Chair and independent directors, and perform such additional duties as the Combined Company&#8217;s board of directors may otherwise determine and delegate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Committees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, Cyclerion and Korsana anticipate that the Combined Company&#8217;s board of directors will establish an audit committee, a compensation committee and a nominating and governance committee (&#8220;governance committee&#8221;), each of which will operate pursuant to a charter adopted by the Combined Company&#8217;s board of directors. Cyclerion and Korsana believe that following the completion of the Merger the functioning and composition of these committees of the Combined Company will comply with the requirements of Nasdaq listing rules and SEC rules and regulations. The Combined Company&#8217;s board of directors may also establish other committees from time to time to assist the Combined Company and its board of directors. Each of the audit committee, compensation committee and the governance committee is expected to have the responsibilities described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, the members of the Combined Company&#8217;s audit committee are expected to be&#8195;&#8195;&#8195;&#8195;,Dr.&#160;Gottesdiener and Mr.&#160;Shah, each of whom is expected to qualify as an independent director for audit committee purposes as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve on the Combined Company&#8217;s audit committee.&#8195;&#8195;&#8195;&#8195;is expected to chair the audit committee. In addition, the Combined Company&#8217;s board of directors is expected to determine that&#8195;&#8195;&#8195;&#8195;is an &#8220;audit committee financial expert&#8221; as defined under the rules of the SEC. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of the Combined Company&#8217;s audit committee will be to oversee the Combined Company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will oversee the system of internal controls established by management and the Combined Company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Merger, the members of the Combined Company&#8217;s compensation committee are expected to be&#8195;&#8195;&#8195;&#8195;and Mr.&#160;Kiselak, each of whom is expected to qualify as an independent director for compensation committee purposes as defined under the rules of the SEC and the applicable Nasdaq listing rules. Mr.&#160;Kiselak is expected to chair the compensation committee. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of the Combined Company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the Combined Company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the Combined Company&#8217;s executive officers, evaluating the performance of these officers in light of the goals and objectives and setting or recommending to the Combined Company&#8217;s board of directors the officers&#8217; compensation. The compensation committee will also administer and make recommendations to the Combined </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">383 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans to executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Governance Committee </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Merger, the members of the Combined Company&#8217;s governance committee are expected to be Dr.&#160;Gottesdiener and Ms. Pernice, each of whom is expected to qualify as an independent director as defined under applicable Nasdaq listing rules. Ms.&#160;Pernice is expected to chair the governance committee. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company&#8217;s governance committee will be responsible for engaging in succession planning for the Combined Company&#8217;s board of directors, developing and recommending to the Combined Company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the Combined Company&#8217;s board of directors regarding candidates for election or reelection to the Combined Company&#8217;s board of directors at each annual stockholders&#8217; meeting. In addition, the governance committee will be responsible for overseeing corporate governance matters. The governance committee will also be responsible for overseeing the structure, composition and functioning of the Combined Company&#8217;s board of directors and its committees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the expected members of the Combined Company&#8217;s compensation committee has at any time been one of the officers or employees of the Combined Company. None of the Combined Company&#8217;s expected executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the Combined Company&#8217;s board of directors or compensation committee following the completion of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, the Combined Company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the Combined Company&#8217;s directors, officers and employees. The full text of the Combined Company&#8217;s Code of Conduct and Ethics will be posted on the Combined Company&#8217;s website at <span style="font-style:italic">www.korsana.com</span>. It is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The Combined Company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable Nasdaq and SEC rules. The Combined Company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the Combined Company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the Combined Company&#8217;s website to be part of this proxy statement/prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">384 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_33">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Korsana&#8217;s and Cyclerion&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<span style="font-style:italic">Management Following the Merger</span>,&#8221; &#8220;<span style="font-style:italic">Korsana</span><span style="font-style:italic"> Executive Compensation</span>&#8221; and &#8220;<span style="font-style:italic">Cyclerion</span><span style="font-style:italic"> Executive Compensation</span>,&#8221; the following is a description of each transaction involving Cyclerion since January&#160;1, 2024, each transaction involving Korsana since November&#160;8, 2024 (inception) and each currently proposed transaction in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">either Korsana or Cyclerion has been or is to be a participant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Korsana&#8217;s or Cyclerion&#8217;s total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years, as applicable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any of Korsana&#8217;s or Cyclerion&#8217;s directors, executive officers or holders of more than 5% of Korsana&#8217;s or Cyclerion&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cyclerion Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described below, there have been no transactions since January&#160;1, 2024 to which Cyclerion has been a participant in which the amount involved exceeded or will exceed $120,000 (which amount is less than one percent of the average of Cyclerion&#8217;s total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years), and in which any of Cyclerion&#8217;s directors, executive officers or holders of more than 5% of capital stock, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements that are described under &#8220;Cyclerion Executive Compensation&#8221; and &#8220;Cyclerion <span style="white-space:nowrap">Non-Employee</span> Director Compensation.&#8221; Cyclerion also entered into indemnification agreements with its directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cyclerion March 2025 Private Placement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;21, 2025, Cyclerion entered into a Stock Purchase Agreement (the &#8220;PIPE Purchase Agreement&#8221;) with the investors named therein, including Peter M. Hecht, Ph.D. and Michael J. Higgins, who serve as members of the Cyclerion Board (each, a &#8220;PIPE Investor&#8221; and collectively, the &#8220;PIPE Investors&#8221;) for the private placement of 499,998&#160;shares (the &#8220;PIPE Shares&#8221;) of Cyclerion Common Stock, at an offering price of $2.75 per PIPE Share (the &#8220;Cyclerion Private Placement&#8221;). The Cyclerion Private Placement closed on March&#160;25, 2025 and the gross proceeds of the Cyclerion Private Placement were $1.375&#160;million, before deducting expenses. Dr.&#160;Hecht and Mr.&#160;Higgins purchased 181,818 and 9,090 shares of Cyclerion&#8217;s Common Stock in the Cyclerion Private Placement, respectively. In connection with the Cyclerion Private Placement, Cyclerion and the PIPE Investors entered into a Registration Rights Agreement, dated March&#160;21, 2025, pursuant to which Cyclerion agreed to register the resale of the PIPE Shares pursuant to a registration statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Korsana Transactions </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Eight of Korsana&#8217;s stockholders or their affiliates are, or are expected to be as of immediately following the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, beneficial holders of more than 5% of Korsana&#8217;s capital stock: Fairmount, Venrock Healthcare Capital Partners, TCGX, Wellington Management, J.P. Morgan Life Sciences Private Capital, FMR LLC, Janus Henderson Investors and Forbion.Three of Korsana&#8217;s directors (Mr.&#160;Kiselak, Ms.&#160;Pernice, and Dr.&#160;Violin) and one of Korsana&#8217;s executive officers (Dr.&#160;Violin) have current or historical affiliations or associations with Fairmount. Two of Korsana&#8217;s directors (Dr.&#160;Gottesdiener and Mr.&#160;Shah) are affiliated with Venrock Healthcare Capital Partners. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">385 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Korsana deems Paragon, Paragon Laboratories, and Parasa related parties, because Fairmount beneficially owns more than 5% of Paragon and Paragon Laboratories, appointed the board of directors of Paragon and Paragon Laboratories, and has the contractual right to approve the appointment of any executive officers of Paragon and Paragon Laboratories. Parasa is an entity formed by Paragon as a vehicle to hold equity in Korsana in order to share profits with certain employees of Paragon. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Initial Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, Korsana completed a financing of Korsana restricted common stock and issued and sold (i) 2,500,000 shares of Korsana restricted common stock to Paragon and (ii) 2,500,000 shares of Korsana restricted common stock to Parasa, in each case, at a purchase price of $0.02 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Series Seed Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, Korsana completed a financing of an aggregate of 8,000,000 shares of Korsana Series Seed Preferred Stock at a purchase price of $1.25 per share. In September 2025, Korsana completed a financing of an additional aggregate of 12,000,000 shares of Korsana Series Seed Preferred Stock at a purchase price of $1.25 per share. The following table summarizes the purchases of Korsana Series Seed Preferred Stock by related persons: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:70%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Purchaser</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares&#160;of&#160;Korsana<br/>Series&#160;Seed&#160;Preferred<br/>Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total<br/>Purchase<br/>Price</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fairmount Healthcare Fund II, L.P.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Venrock Healthcare Capital Partners</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Series A Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2025, Korsana completed a financing of an aggregate of 75,500,000 shares of Korsana Series A Preferred Stock at a purchase price of $2.00 per share. The following table summarizes the purchases of Korsana Series A Preferred Stock by related persons: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Purchaser</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares&#160;of&#160;Korsana<br/>Series&#160;A&#160;Preferred&#160;Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total<br/>Purchase<br/>Price</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fairmount Healthcare Fund II, L.P.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Venrock Healthcare Capital Partners</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">25,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with TCGX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Wellington Management</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, on April&#160;1, 2026, Korsana entered into the Securities Purchase Agreement with certain investors to effect the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. Pursuant to the Securities Purchase Agreement, the investors agreed to purchase an estimated aggregate of 118,022,392 shares of Korsana Common Stock and 43,444,829 Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants, at an estimated price of $2.3534 per share of common stock and $2.3533 per <span style="white-space:nowrap">pre-funded</span> warrant, for aggregate gross proceeds of approximately $380.0&#160;million. The aggregate purchase price of $380.0&#160;million is fixed, while the purchase price per share or <span style="white-space:nowrap">pre-funded</span> warrant and the aggregate number of shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants to be purchased is subject to change pursuant to the terms of the Securities Purchase Agreement. Please see the section titled &#8220;<span style="font-style:italic">Agreements Related to the Merger &#8212; Securities Purchase Agreement</span><span style="font-style:italic">.</span>&#8221; The closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. The table below sets forth the number of shares of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">386 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants expected to be purchased by related persons at the closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing (based on the currently estimated purchase price per share or <span style="white-space:nowrap">pre-funded</span> warrant, as applicable). </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Participant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares of<br/>Korsana<br/>Common&#160;Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap">Pre-funded</span><br/>Warrants of<br/>Korsana</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total<br/>Purchase<br/>Price</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Fairmount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,481,413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,387,120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">74,997,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Venrock Healthcare Capital Partners</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,594,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,900,469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">59,998,233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with FMR LLC</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,747,413</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,999,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with TCGX</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,518,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,229,285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,999,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Forbion</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,622,844</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,999,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Wellington Management</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,373,706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,999,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Janus Henderson Investors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,824,224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,999,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with J.P. Morgan Life Sciences Private Capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,974,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,999,944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div> <div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Paragon Agreements </span></p> </div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Paragon Antibody Discovery and Option Agreement </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;5, 2025, Korsana entered into the Paragon ADOA with Paragon and Parasa. Under the Paragon ADOA, Paragon identifies, evaluates, and develops antibodies against one or more mutually agreed therapeutic targets and a mutually agreed brain transit target. The Paragon ADOA covers Research Program 001 and Research Program 002, each targeting A&#223; and TfR1 (collectively, the &#8220;A&#223; Research Programs&#8221;), and one undisclosed research program 003, with the ability to add additional programs by mutual agreement. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Korsana has the exclusive option, on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis (each, an &#8220;ADOA Option&#8221;), to negotiate and enter into a license agreement (each, a &#8220;License&#8221;) granting Korsana (a)&#160;an exclusive, worldwide license to the product-specific intellectual property from the applicable program and (b)&#160;a <span style="white-space:nowrap">non-exclusive,</span> worldwide license to certain incorporated platform technology. ADOA Options are exercisable at Korsana&#8217;s sole discretion during the applicable option period, with no separate exercise payment. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon signing, Korsana became obligated to reimburse Paragon approximately $18.8&#160;million for <span style="white-space:nowrap">pre-development</span> costs incurred through September&#160;5, 2025. For each research program, Korsana is also required to pay Paragon a research initiation fee and certain third-party costs and internal resource fees. On a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis, Korsana is also required to make <span style="white-space:nowrap">one-time,</span> <span style="white-space:nowrap">non-refundable</span> milestone payments of up to $46.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination. Any License will incorporate the same milestone obligations, with milestones not achieved prior to License execution no longer payable under the Paragon ADOA. Under any License, Korsana would be required to make tiered royalty payments in the low to <span style="white-space:nowrap">mid-single</span> digit percentage range based on annual net sales, subject to certain reductions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;19, 2026, Korsana exercised its ADOA Option with respect to Research Program 002. Korsana made a $5.0&#160;million milestone payment to Paragon in March 2026 related to the nomination of KRSA-028 as the development candidate for Research Program 002. On June&#160;8, 2026, Korsana entered into the Paragon License Agreement with Paragon with respect to the A&#223; Research Programs, as described in more detail below. Korsana&#8217;s ADOA Option with respect to program 003 remains unexercised. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon ADOA continues on a <span style="white-space:nowrap"><span style="white-space:nowrap">program-by-program</span></span> basis until the earliest of completion of the applicable research plan activities, expiration of the option period, or failure to execute a License within a specified period following option exercise. Korsana may terminate any research program or the Paragon ADOA in its entirety at any time for any reason, subject to certain termination fees. Each party has the right to terminate upon the other party&#8217;s uncured material breach or bankruptcy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">387 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2026, Korsana has recorded an aggregate of $40.1 million of operating expenses under the Paragon ADOA. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon ADOA, Korsana will grant Parasa warrants on each of December&#160;31, 2025 and December&#160;31, 2026 to purchase shares equal to 1.00% of Korsana&#8217;s outstanding capital stock on a fully diluted basis as of the grant date, at an exercise price equal to fair market value. If Korsana undergoes an initial public offering or reverse merger, Parasa will instead receive warrants from the resulting public parent on equivalent terms. Each warrant is exercisable for 10 years from the grant date, with <span style="white-space:nowrap">pro-ration</span> if the research term ends before <span style="white-space:nowrap">year-end.</span> On December&#160;31, 2025, Korsana issued Parasa a warrant to purchase 1,102,561 shares of common stock at $0.86 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Paragon Platform Option Agreement </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;16, 2025, Korsana entered into the Paragon POA with Paragon and Parasa, in connection with the Paragon ADOA. Under the Paragon POA, Korsana may designate up to four target combinations (each consisting of one or two therapeutic targets and TfR1 as the transit target) to be exclusively reserved during the option period (the &#8220;POA Option Period&#8221;). As of the effective date, the initial reserved target list includes one undisclosed target combination. Korsana may also obtain rights to designate up to two additional target combinations upon payment of $2.0&#160;million each. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon is obligated to notify Korsana if Paragon or its affiliates develop research plans for, plan to license, or enter into negotiations with third parties regarding antibodies directed to target combinations that include TfR1 as the transit target but are not then on a reserved target list. Upon receipt of such notice, Korsana has a specified period to elect to designate that target combination as a reserved target combination, subject to applicable limits. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to limited exceptions, Paragon has agreed not to develop, license, or commercialize antibodies directed to any Korsana-reserved target combination during the POA Option Period, which ends on the earlier of the fifth anniversary of the Paragon POA or exercise or expiration of Korsana&#8217;s last POA Option. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the POA Option Period, Korsana may exercise has an option ( a&#8220; POA Option&#8221;) for each reserved target combination to either (a)&#160;enter into an antibody discovery and option agreement on terms materially consistent with the Paragon ADOA or (b)&#160;enter directly into a license agreement (a <span style="white-space:nowrap">&#8220;POA-License&#8221;)</span> upon payment of a $5.0&#160;million exercise fee. Under any <span style="white-space:nowrap">POA-License,</span> Korsana would be required to make <span style="white-space:nowrap">one-time,</span> <span style="white-space:nowrap">non-refundable</span> milestone payments of up to $41.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination, and tiered royalty payments in the low to <span style="white-space:nowrap">mid-single</span> digit percentage range based on annual net sales, subject to certain reductions. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon POA continues until expiration of the POA Option Period. Each party has the right to terminate upon the other party&#8217;s uncured material breach or bankruptcy. Korsana may terminate at any time for any reason. As of the date of this proxy statement/prospectus, Korsana has not exercised any POA Options or made any payments under the Paragon POA. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span>As of March&#160;31, 2026, Korsana has not recorded any operating expenses under the Paragon POA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"></span><span style="font-weight:bold"></span><span style="font-style:italic">Paragon Research Letter Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 3, 2026, Korsana entered into the Paragon Research Letter Agreement with Paragon Laboratories. Under the terms of the Paragon Research Letter Agreement, the parties agreed to initiate a research program (the &#8220;AOC Research Program&#8221;) focused on an undisclosed target combination, in an effort to identify, evaluate and develop antibody oligonucleotide conjugates (&#8220;AOCs&#8221;) directed to such target combination (the &#8220;Research </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">388 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
AOCs&#8221;). The AOC Research Program will be conducted in accordance with a research plan that the parties will use specified efforts to agree upon within a specified period following the effective date of the Paragon Research Letter Agreement (the &#8220;AOC Research Plan&#8221;). During the AOC Research Term (as defined below), each party will use specified efforts to conduct and complete the research activities assigned to it under the AOC Research Plan, and Paragon Laboratories will provide Korsana with periodic updates regarding the Research AOCs identified under the AOC Research Plan. The AOC Research Program will continue until the earliest of (a) the date that the aggregate Costs (as defined below) paid or owing by Korsana to Paragon Laboratories meet or exceed a budgeted cap, (b) completion of the activities set forth in the AOC Research Plan, and (c) such other mutually agreed date (such period, the &#8220;AOC Research Term&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon Research Letter Agreement, Korsana has a nontransferable, exclusive option during the AOC Research Term and, provided that Korsana is not in material breach, for an additional specified period thereafter (collectively, the &#8220;AOC Option Period&#8221;), to either (i) enter into an antibody oligo conjugate discovery and option agreement for the AOC Research Program (the &#8220;AOC-DOA Option&#8221;), or (ii) enter into a license agreement for the AOC Research Program (the &#8220;AOC-License Option&#8221; and, with the AOC-DOA Option, either referenced hereinafter as the &#8220;AOC Option&#8221;). Korsana may exercise the AOC Option only once for the AOC Research Program, without payment of a separate exercise fee. The AOC Option terminates upon the earliest of: a permitted early termination of the AOC Research Program, the expiration of the AOC Option Period without Korsana having exercised the AOC Option, and, if Korsana has exercised the AOC Option, the failure of the parties to finalize a Definitive Agreement (as defined below) or elect the applicable dispute resolution procedures within the required timeframe. Following termination of the AOC Option, Paragon Laboratories is free to license or grant rights in the Research AOCs to third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Korsana&#8217;s exercise of the AOC Option, the parties will negotiate for a specified period toward a definitive agreement (the &#8220;Definitive Agreement&#8221;). If Korsana exercises the AOC-DOA Option, the Definitive Agreement would provide for, among other things, the continuation of the AOC Research Program, payment by Korsana of a research initiation fee, and an exclusive option for Korsana to enter into separate license agreement(s) consistent with the license described below. If Korsana exercises the AOC-License Option, the Definitive Agreement would be a license agreement granting Korsana, its affiliates, and sublicensees the right to develop, manufacture, and commercialize the Research AOCs for any and all uses worldwide, under an exclusive license to the Research AOCs as a whole and any therapeutic nucleic acid component included in a Research AOC, and a non-exclusive license to any platform elements incorporated into such Research AOCs. Any such license agreement would include a one-time upfront license fee. If the parties are unable to reach agreement on the Definitive Agreement within the specified negotiation period, either party may elect to resolve the dispute in accordance with procedures set forth in the Paragon ADOA, as applied <span style="font-style:italic">mutatis mutandis</span>. As between the parties, Paragon Laboratories owns all intellectual property generated under or in connection with the AOC Research Program, and Korsana has assigned all of its rights therein to Paragon Laboratories. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Paragon Laboratories&#8217; performance of the AOC Research Program and the grant of the AOC Option to Korsana, Korsana is required to reimburse Paragon Laboratories for certain third-party costs and internal resource fees. Which may not exceed a budget cap set forth in the AOC Research Plan unless increased by mutual written agreement. All payments under the Paragon Research Letter Agreement are non-refundable and non-creditable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Paragon Research Letter Agreement will continue until the expiration of the AOC Option, unless terminated earlier in accordance with the terms thereof. The Paragon Research Letter Agreement and the AOC Research Program may be terminated by either party upon prior written notice if the other party commits a material breach and fails to cure within such notice period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2026, Korsana paid a $1.0 million research initiation fee under the Paragon Research Letter Agreement. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">389 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Paragon License Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;8, 2026, Korsana entered into the Paragon License Agreement with Paragon for certain antibody transport vehicle compounds discovered, generated, identified or characterized by Paragon in the course of performing Research Program 001 and Research Program 002 under the Paragon ADOA, including KRSA-028, together with certain related antibodies, antibody transport vehicles and products comprising the foregoing. The Paragon License Agreement is consistent with the pre-negotiated terms agreed to upon execution of the Paragon ADOA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Paragon License Agreement, Paragon granted Korsana a royalty-bearing, worldwide, exclusive and sublicensable license under certain licensed project antibody transport vehicle technology to develop, manufacture, commercialize and otherwise exploit licensed antibodies, licensed antibody transport vehicles, derived antibodies, derived antibody transport vehicles and related products in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the &#8220;field&#8221;) and worldwide (the &#8220;territory&#8221;). Paragon also granted Korsana certain royalty-bearing, worldwide, non-exclusive and sublicensable licenses under certain transit antibody technology, other licensed patents and other licensed know-how to develop, manufacture, commercialize and otherwise exploit specified licensed products in the field and territory. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Paragon License Agreement, Korsana is solely responsible for, and has sole authority and control over, all aspects of the development, manufacturing and commercialization of products under the licensed programs, including regulatory strategy, communications, filings and activities, including clinical trials. Korsana is required to use commercially reasonable efforts to develop and seek regulatory approval for at least one licensed product in the United States and at least one other major market country and, following receipt of regulatory approval for a licensed product in a given country, to commercialize such licensed product in such country. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the applicable exclusivity period, Paragon is restricted from directly or indirectly conducting activities, including granting licenses to third parties, to develop, manufacture, commercialize or otherwise exploit antibody transport vehicles directed to both A&#226; and TfR1, subject to specified exceptions, including for certain change-of-control and acquired programs. The exclusivity period continues until the earlier of the fifth anniversary of the effective date and the occurrence of specified exclusivity termination events tied to Korsana&#8217;s failure to achieve certain diligence milestones, subject to cure and extension mechanics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Paragon License Agreement, Korsana is obligated to pay Paragon up to $46.0 million per product based on the achievement of specified development and regulatory milestones. If a product candidate, including certain combination products, is developed by Korsana as a bona fide back-up or substitute product to another royalty product for the same licensed therapeutic target, the same licensed transit target, if applicable, and the same indication, it would be considered a back-up royalty product for which no duplicate milestone payments are owed to Paragon, subject to specified limitations. Korsana is obligated to pay Paragon up to $23.0 million per product for certain Korsana-developed products that are not licensed products from Research Program 001 or Research Program 002 and are directed to the applicable licensed target or target combination based on the achievement of specified development and regulatory milestones. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other key terms of the Paragon License Agreement include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana will pay Paragon tiered royalties in the low- to mid-single digits based on annual net sales of licensed products in the field and territory, subject to a 30% reduction if there is no valid claim covering the product in the country. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The royalty term ends, on a product-by-product and country-by-country basis, on the later of the twelfth anniversary of the first commercial sale of such product in such country and the expiration of the last-to-expire valid patent claim covering such product in such country. </p></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">390 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana has the right to grant sublicenses under the Paragon License Agreement, provided that each sublicense is in writing and consistent with the relevant terms, conditions and restrictions of the Paragon License Agreement, Korsana provides Paragon with a copy of each sublicense agreement and any amendments within 30 days following execution, subject to permitted redactions, and Korsana remains responsible for all payments and obligations due under the Paragon License Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">With respect to certain patents licensed to Korsana under the Paragon License Agreement, Korsana has the first right, but not the obligation, to prepare, file, prosecute and maintain such patents at its sole expense, subject to Paragon&#8217;s review, comment and backup prosecution rights. Paragon retains control over the preparation, filing, prosecution and maintenance of certain other patents owned or controlled by Paragon. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana may terminate the Paragon License Agreement in its entirety or on a country-by-country or royalty product-by-royalty product basis for any or no reason upon 60 days&#8217; prior written notice to Paragon. The Paragon License Agreement may also be terminated by either party upon the other party&#8217;s uncured material breach or, to the extent permitted by law, upon the other party&#8217;s insolvency or bankruptcy. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, Korsana has not recorded any operating expenses under the Paragon License Agreement. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana Indemnification Agreements and Insurance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has entered into an indemnification agreement with each of its directors and officers and purchased directors&#8217; and officers&#8217; liability insurance. The indemnification agreements require Korsana to indemnify its directors and officers to the fullest extent permitted under Delaware law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana Restricted Stock Grants to Directors and Executive Officers </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has entered into a restricted stock purchase agreement with Dr.&#160;Violin, Director and Chief Executive Officer and President, as more fully described in the sections titled &#8220;<span style="font-style:italic">Korsana</span><span style="font-style:italic"> Executive</span> <span style="font-style:italic">Compensation</span>&#8221; and &#8220;<span style="font-style:italic">Korsana</span><span style="font-style:italic"> Director Compensation</span>&#8221; beginning on pages&#160;215 and 219, respectively, of this proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Korsana Policies for Approval of Related Party Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana does not have a formal policy regarding approval of transactions with related parties. Following the completion of the Merger, Korsana anticipates that the Combined Company will adopt a related party transaction approval policy and the Combined Company&#8217;s audit committee will be responsible for the review, consideration and approval or ratification of related party transactions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">391 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_34">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Defined terms included below shall have the same meaning as terms defined and included in the Company&#8217;s definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on June&#160;9, 2026. </span></p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;1, 2026, Korsana entered into a Merger Agreement with Cyclerion and Cariboos Merger Sub Corp and Cariboos Merger Sub II, LLC, both wholly owned subsidiaries of Cyclerion, which agreement was subsequently amended on April&#160;17, 2026, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp merged with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation (the &#8220;First Merger&#8221;). Immediately following the First Merger and as part of the same overall transaction, Korsana merged with and into Cariboos Merger Sub II, LLC (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), with Cariboos Merger Sub II, LLC being the surviving entity of the Second Merger. The closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and is expected to occur immediately prior to the closing of the Merger. As such, the pro forma adjustments reflect the Merger and the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. The Merger is expected to close during the third quarter of 2026, following the effectiveness of Cyclerion registration statement on Form <span style="white-space:nowrap">S-4</span> and receipt of approval by the stockholders of each of Korsana and Cyclerion, in the latter case pursuant to the Cyclerion Special Meeting. In connection with the Merger, Cariboos Merger Sub II, LLC will change its corporate name to &#8220;Korsana Biosciences Operating Company, LLC&#8221; and Cyclerion will change its name to &#8220;Korsana Biosciences, Inc.&#8221; Cyclerion following the Merger is referred to herein as the &#8220;Combined Company.&#8221; The Combined Company will be led by Korsana&#8217;s management team and remain focused on discovering and developing novel therapies designed to reduce the burden of neurodegenerative diseases, starting with Alzheimer&#8217;s disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Korsana common stock (including shares of Korsana common stock issued in connection with the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock equal to the Exchange Ratio, (ii)&#160;each-then-outstanding share of Cyclerion Series A preferred stock will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock, (iii)&#160;each then-outstanding share of Korsana Series Seed preferred stock will be converted into the right to receive a number of shares of newly created Cyclerion Series B <span style="white-space:nowrap">non-voting</span> Preferred Stock, which are each convertible into 1,000 shares of Cyclerion common stock, equal to the Exchange Ratio divided by 1,000, (iv) each-then-outstanding share of Korsana Series A preferred stock will be automatically converted into the right to receive a number of shares of Cyclerion common stock equal to the Exchange Ratio, as well as a right to receive a <span style="white-space:nowrap">pre-funded</span> warrant to purchase Korsana common stock that will be converted into a <span style="white-space:nowrap">pre-funded</span> warrant to purchase Cyclerion common stock, subject to adjustment as set forth in the form of the <span style="white-space:nowrap">pre-funded</span> warrant, (v)&#160;each then-outstanding option to purchase Korsana common stock will be assumed by Cyclerion and will be converted into an option to purchase shares of Cyclerion common stock, adjusted for the Exchange Ratio, (vi)&#160;each then-outstanding warrant to purchase Korsana common stock will be assumed by Cyclerion and will be converted into a warrant to purchase shares of Cyclerion common stock, adjusted for the Exchange Ratio, (vii)&#160;each then-outstanding share of Korsana restricted stock will be assumed by Cyclerion, subject to adjustment as set forth in the Merger Agreement, (viii)&#160;each then-outstanding <span style="white-space:nowrap">pre-funded</span> warrant to purchase shares of Korsana common stock will be converted into a <span style="white-space:nowrap">pre-funded</span> warrant to purchase shares of Cyclerion common stock, subject to adjustment as set forth in the Merger Agreement and the form of <span style="white-space:nowrap">pre-funded</span> warrant, (ix)&#160;the vesting of each option to acquire shares of Cyclerion common stock that is issued and outstanding will be accelerated, each <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> option will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Cyclerion Closing Price over the exercise price per share of Cyclerion common stock underlying such Cyclerion option by (B)&#160;the number of shares of Cyclerion common stock underlying such Cyclerion option, and each <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">out-of-the-money</span></span></span> option will be cancelled for no consideration; and (x)&#160;the vesting of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">392 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each unvested Cyclerion restricted stock award will be accelerated, and all vested and unsettled Cyclerion restricted stock awards will be cancelled and converted into the right to receive a number of shares of Cyclerion common stock equal to the number of unsettled shares of Cyclerion common stock underlying such Cyclerion restricted stock award. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exchange Ratio is currently estimated to be approximately 1.1009 shares of Cyclerion common stock for each share of Korsana common stock on the closing date. Under the Exchange Ratio formula, the former Korsana stockholders immediately before the effective time, including those purchasing shares and <span style="white-space:nowrap">pre-funded</span> warrants in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, will own approximately 98.5% of the outstanding common stock of the Combined Company, and the stockholders of Cyclerion immediately before the effective time will own approximately 1.5% of the outstanding common stock of the Combined Company, which give effect to (a)&#160;Cyclerion net cash as of the closing of the Merger being $0, (b) Korsana closing the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing for an aggregate gross purchase price of approximately $380.0&#160;million, (c)&#160;a valuation for Cyclerion equal to $10.0&#160;million based on net cash of $0 at closing, and (d)&#160;a valuation for Korsana equal to $268.4&#160;million plus $380.0&#160;million of assumed proceeds in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, in each case as further described in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under U.S. GAAP. For further details related to the accounting for the Merger, please see Notes&#160;1 and 3 below. All share amounts have been adjusted to reflect the estimated Exchange Ratio of 1.1009 shares of Cyclerion common stock for each share of Korsana common stock, unless otherwise stated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of Cyclerion and Korsana as of March&#160;31, 2026 and depicts the accounting of the Merger and <span style="white-space:nowrap">Pre-Closing</span> Financing transactions (collectively, the &#8220;transaction&#8221;) prepared pursuant to Article 11 of Regulation <span style="white-space:nowrap">S-X.</span> The unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2026 for Cyclerion and Korsana and for the year ended December&#160;31, 2025 for Cyclerion and Korsana, combine the historical results of Cyclerion and Korsana for those periods and depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January 1, 2025. Collectively, the pro forma balance sheet transaction accounting adjustments and the pro forma statements of operations transaction accounting adjustments are referred to as the &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments.&#8221; </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical unaudited financial statements of Korsana as of and for the three months ended March 31, 2026, and the related notes included elsewhere in the proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical unaudited financial statements of Cyclerion as of and for the three months ended March&#160;31, 2026, and the related notes included elsewhere in the proxy statement/prospectus; </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical audited financial statements of Korsana as of and for the year ended December&#160;31, 2025, and the related notes included elsewhere in the proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the historical audited financial statements of Cyclerion as of and for the year ended December&#160;31, 2025, and the related notes included elsewhere in the proxy statement/prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the section titled &#8220;Korsana&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation,&#8221; and other financial information relating to Korsana included elsewhere in the proxy statement/prospectus; and </p></td></tr></table> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the section titled &#8220;Cyclerion&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and other financial information relating to Cyclerion included elsewhere in the proxy statement/prospectus. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">393 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the closing of the Merger, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had Cyclerion and Korsana been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">394 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED </p> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BALANCE SHEET AS OF MARCH&#160;31, 2026 </p> </div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(In thousands) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:56%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Historical</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">5(A)<br/>Cyclerion<br/>Therapeutics,<br/>Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">5(B)<br/>Korsana<br/>Biosciences<br/>Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Transaction<br/>Accounting<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Notes</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Pro&#160;Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,823</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">134,162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(a)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">483,516</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">380,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(c)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(28,919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(d)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,757</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(e)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,257</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(g)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(j)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(f)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">135,109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">346,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">484,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted Cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other investment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,350</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(h)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,231</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(d)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> 8,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">137,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> 339,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">485,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> &#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(148</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(g)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,109</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(g)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, current</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability, related party</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,766</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,257</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other liabilities, non-current</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, non-current</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">937</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">937</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,257</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korsana Series Seed convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(24,964</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(b)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korsana Series A convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">150,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(150,573</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(b)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cyclerion Series B non-voting convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(b)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cyclerion Series A convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cyclerion common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korsana common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(b)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(c)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">280,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">150,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(b)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">500,859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">379,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(c)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(30,150</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(d)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(j)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(283,072</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(i)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(274,197</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(49,240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(513</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(a)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(49,588</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,757</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(e)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(f)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(348</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(j)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">283,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(i)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(5,350</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">(h)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(47,026</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">491,525</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">451,290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> 8,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">137,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> 339,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">485,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">395 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF </p> <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2026 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(In thousands, except share and per share amounts) </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Historical</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">6(A)<br/>Cyclerion<br/>Therapeutics,<br/>Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">6(B)<br/>Korsana<br/>Biosciences<br/>Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Transaction<br/>Accounting<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Note</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Note</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,209</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(14,760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(17,969</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;<br/></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>32<br/></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;<br/></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;<br/></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>1,250<br/></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;<br/></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;<br/></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>1,282<br/></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;<br/></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,177</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(13,510</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(16,687</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>5,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>270,586,687</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>6</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>(d)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>22,018</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>6</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>(d)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(0.76</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(12.20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(0.06</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold"></span>(57.04</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">396 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OPERATIONS FOR THE YEAR ENDED DECEMBER&#160;31, 2025 </p> </div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(In thousands, except share and per share amounts) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Historical</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">6(C)<br/>Cyclerion<br/>Therapeutics,<br/>Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">6(D)<br/>Korsana<br/>Biosciences<br/>Inc.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Transaction<br/>Accounting<br/>Adjustments</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Note</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Pro Forma<br/>Combined</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Note</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from license agreements</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from purchase agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from option agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,074</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,074</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">959</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">33,744</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,088</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">(a)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,709</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">(b)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">(c)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">37,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">45,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(4,973</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(37,291</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(43,379</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from insurance recovery</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,649</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,528</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(35,642</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,115</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(40,285</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,920,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">269,562,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">(d)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted- average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">(d)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1.11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(12.20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(0.14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(138.16</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">397 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_35">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">1. Description of the Merger </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;1, 2026, Korsana entered into the Merger Agreement with Cyclerion, Cariboos Merger Sub Corp and Cariboos Merger Sub II, LLC, which agreement was subsequently amended on April&#160;17, 2026, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp will merge with and into Korsana, with Korsana surviving as a wholly owned subsidiary of Cyclerion and the surviving corporation of the First Merger, and, immediately following the First Merger and as part of the same overall transaction, Korsana will merge with and into Cariboos Merger Sub II, LLC, with Cariboos Merger Sub II, LLC being the surviving entity of the Second Merger.&#160;The Merger, including the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, is expected to close during the third quarter of 2026 following the effectiveness of Cyclerion&#8217;s registration statement on Form <span style="white-space:nowrap">S-4</span> and receipt of approval by the stockholders of each of Korsana and Cyclerion, in the latter case pursuant to the Cyclerion Special Meeting. In connection with the Merger, Cariboos Merger Sub II, LLC will change its corporate name to &#8220;Korsana Biopharma Operating Company, LLC&#8221; and Cyclerion changed its name to &#8220;Korsana Biosciences, Inc.&#8221; Cyclerion following the Merger is referred to herein as the &#8220;Combined Company.&#8221; Subject to the terms and conditions of the Merger Agreement, at closing of the Merger: </p> </div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each then-outstanding share of Korsana common stock (including shares of Korsana common stock issued in connection with the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing) will be converted into the right to receive a number of shares of Cyclerion common stock equal to the Exchange Ratio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each-then-outstanding share of Cyclerion Series A preferred stock will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each then-outstanding share of Korsana Series Seed preferred stock will be converted into the right to receive a number of shares of newly created Cyclerion Series B <span style="white-space:nowrap">non-voting</span> preferred stock, which are each convertible into 1,000 shares of Cyclerion common stock, equal to the Exchange Ratio divided by 1,000; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">d)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each-then-outstanding share of Korsana Series A preferred stock will be automatically converted into the right to receive to a number of shares of Cyclerion common stock equal to the Exchange Ratio, as well a right to receive a <span style="white-space:nowrap">pre-funded</span> warrant to purchase Korsana common stock that will be converted into a <span style="white-space:nowrap">pre-funded</span> warrant to purchase Cyclerion common stock, subject to adjustment as set forth in the form of the <span style="white-space:nowrap">pre-funded</span> warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">e)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each then-outstanding option to purchase Korsana common stock will be assumed by Cyclerion and will be converted into an option to purchase shares of Cyclerion common stock, adjusted for the Exchange Ratio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">f)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each then-outstanding warrant to purchase shares of Korsana common stock will be converted into a warrant to purchase shares of Cyclerion common stock, adjusted for the Exchange Ratio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">g)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each then-outstanding share of Korsana restricted stock will be assumed by Cyclerion, subject to adjustment as set forth in the Merger Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">h)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">each then-outstanding <span style="white-space:nowrap">pre-funded</span> warrant to purchase shares of Korsana common stock will be converted into a <span style="white-space:nowrap">pre-funded</span> warrant to purchase shares of Cyclerion common stock, subject to adjustment as set forth in the form of <span style="white-space:nowrap">pre-funded</span> warrant. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Korsana restricted stock outstanding and unvested immediately prior to Closing (&#8220;Korsana Restricted Stock&#8221;) that is assumed by Cyclerion in the Merger will remain unvested to the same extent and will be subject to the same repurchase option, risk of forfeiture or other condition under any applicable restricted stock purchase agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, the Cyclerion Board will take actions to accelerate the vesting of certain outstanding equity awards including options to purchase Cyclerion common stock and restricted stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">398 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awards held by a current employee, director or consultant of Cyclerion as of the closing of the Merger. The acceleration of vesting of Cyclerion options and restricted stock awards occurs upon a modification of the awards as a result of the Merger. The incremental fair value associated with the modification to accelerate vesting has been included as an adjustment to the unaudited pro forma condensed combined financial information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each option to acquire shares of Cyclerion common stock with an exercise price less than or equal to the Cyclerion Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A)&#160;the excess of the Cyclerion Closing Price over the exercise price per share of Cyclerion common stock underlying such Cyclerion option by (B)&#160;the number of shares of Cyclerion common stock underlying such Cyclerion option, and each option with an exercise price greater than the Cyclerion Closing Price to acquire shares of Cyclerion common stock will be cancelled for no consideration. The incremental fair value of Cyclerion options associated with the modification to accelerate vesting and the cancelation of certain stock options for no consideration has been included as an adjustment to the unaudited pro forma condensed combined financial information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Merger, Cyclerion securityholders as of immediately prior to the Merger will own approximately 1.5% of the outstanding capital stock of the Combined Company on a fully diluted basis, former Korsana securityholders, excluding shares purchased in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, will own approximately 40.8% of the outstanding capital stock of the Combined Company on a fully diluted basis, and shares and <span style="white-space:nowrap">pre-funded</span> warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing will own approximately 57.7% of the outstanding capital stock of the Combined Company on a fully diluted basis. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana stockholders are expected to receive approximately 303,313,421 shares on a fully diluted basis in connection with the Merger, including (i) 13,699,861 shares of Cyclerion common stock and stock options subject to vesting terms, based on the number of shares of Korsana common stock outstanding immediately prior to the Merger, including Korsana restricted stock, (ii)&#160;the shares of common stock and <span style="white-space:nowrap">pre-funded</span> warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, (iii)&#160;Korsana Series Seed <span style="white-space:nowrap">non-voting</span> preferred stock as of March&#160;31, 2026, which will be exchanged into shares of newly created Cyclerion Series B non-voting Preferred Stock, which will be convertible into 1,000 shares of Cyclerion common stock, equal to the Exchange Ratio divided by 1,000, and (iv)&#160;Korsana Series A preferred stock outstanding as of March&#160;31, 2026, which will be convertible into shares of Cyclerion common stock, as well as a right to receive a <span style="white-space:nowrap">pre-funded</span> warrant to purchase Korsana common stock that will be converted into a <span style="white-space:nowrap">pre-funded</span> warrant to purchase shares of Cyclerion common stock, subject to adjustment set forth the form of the <span style="white-space:nowrap">pre-funded</span> warrant. These estimates are subject to certain inputs, which include, but are not limited to, (a)&#160;Cyclerion&#8217;s net cash as of the closing of the Merger being approximately $0, (b) Korsana closing the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing for an aggregate purchase price of approximately $380.0&#160;million, (c)&#160;a valuation for Cyclerion equal to $10&#160;million based on net cash of $0 at closing, and (d)&#160;a valuation for Korsana equal to $268.4&#160;million, in each case as further described in the Merger Agreement. The following table summarizes the pro forma number of shares of common stock of the Combined Company outstanding following the consummation of the transactions: </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:56%"/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Pro Forma</span><br/><span style="font-weight:bold">(Assuming&#160;Cyclerion&#8217;s&#160;Net&#160;Cash</span><br/><span style="font-weight:bold">at Closing or $0)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Equity&#160;Capitalization&#160;Summary&#160;(fully&#160;diluted&#160;bas&#160;is)<br/>Upon Consummation of the Merger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of&#160;Shares&#160;Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">%<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korsana stockholders<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">125,554,178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cyclerion stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,681,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in the Subscription Agreement<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">177,759,243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">57.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common stock of the combined company</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">307,994,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">100.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 17,042,183 <span style="white-space:nowrap">pre-funded</span> warrants issued upon the conversion of Series A preferred stock after reflecting the estimated Exchange Ratio. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">399 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 47,828,409 <span style="white-space:nowrap">pre-funded</span> warrants issued in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing after reflecting the estimated Exchange Ratio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1) approval by Cyclerion stockholders of the issuance of Cyclerion common stock, including shares of Cyclerion common stock issuable upon conversion of the Cyclerion Preferred Stock, and the other transactions proposed under the Merger Agreement, (2)&#160;approval by the requisite Korsana stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the listing application to be submitted in connection with the Merger, and (4)&#160;the effectiveness of this registration statement. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreement for Cyclerion&#8217;s employee includes entitlement to a transaction bonus and severance of which will be treated as <span style="white-space:nowrap">pre-Merger</span> compensation expense of Cyclerion, which will be assumed by the Combined Company at the closing of the Merger to the extent they are not yet settled in cash beforehand by Cyclerion. Additionally, Cyclerion&#8217;s current Directors&#160;&amp; Officers (&#8220;D&amp;O&#8221;) policy will be fully utilized at the closing of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Private Financing Transaction &#8212; Subscription Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, on April&#160;1, 2026, Korsana and Cyclerion entered into the Subscription Agreement with certain institutional and accredited investors, pursuant to which such investors have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the Merger, 118,022,392 shares of Korsana common stock and 43,444,829 <span style="white-space:nowrap">pre-funded</span> warrants before giving effect to the Exchange Ratio, at an purchase price of $2.3534 per share and $2.3533 per warrant, for an aggregate purchase price of $380.0&#160;million in a private placement. The closing of the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and is expected to occur immediately prior to the closing of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Contingent Value Rights Agreement </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Effective Time of the Merger, Cyclerion will enter into a Contingent Value Rights Agreement (&#8220;CVR Agreement&#8221;) whereby which Cyclerion&#8217;s <span style="white-space:nowrap">pre-Merger</span> shareholders will receive one contingent value right (each a &#8220;CVR&#8221;) for each outstanding share of Cyclerion common stock and Cyclerion preferred stock held by such shareholder on such date. Each CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of Cyclerion&#8217;s <span style="white-space:nowrap">pre-Merger</span> legacy assets, net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the Merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of all <span style="white-space:nowrap">pre-Merger</span> legacy assets other than those <span style="white-space:nowrap">pre-Merger</span> legacy assets described in the following clauses (ii)&#160;and (iii), upon the second anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#8217;s right to receive payments under that License Agreement, dated June&#160;3, 2021, between Cyclerion and Akebia Therapeutics, Inc. (the &#8220;Akebia License Agreement&#8221;), the earlier of (A)&#160;the fifteenth anniversary of the date of entry into the CVR Agreement and (B)&#160;the expiration or earlier termination by Akebia Therapeutics, Inc. of the Akebia License Agreement pursuant to its terms, and (iii)&#160;with respect to the sale, transfer or other disposition of the shares of common stock of Tisento Therapeutics Holdings, Inc. (&#8220;Tisento&#8221;) that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement, dated May&#160;13, 2023, by and among Cyclerion, Tisento and JW Cycle, Inc., the earliest of (A)&#160;nine months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh anniversary of the Closing Date. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Asset CVR and the Tisento CVR payments are not probable or reasonably estimable at this time. The Company will continue to assess probability for both CVR payments on a quarterly basis and will record a derivative liability when probable and reasonably estimable. Additionally, the Company has </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">400 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preliminarily determined that the fair value of Tisento investment is not material given the current lack of observable pricing, the early state of Tisento&#8217;s development activities and the significant uncertainty regarding its potential value. Therefore, the Company has reduced the Tisento investment to zero for purposes of the pro forma financial information as presented in adjustment 5(h) below. The Company will continue to assess observable and unobservable data points to consider fair value estimates through closing of the transaction. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2. Basis of Presentation </p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <span style="white-space:nowrap">S-X.</span> The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Company upon consummation of the Merger. The unaudited pro forma condensed combined statement of operations data for the three months ended March 31, 2026 and the unaudited proforma condensed combined statement of operations for the year ended December&#160;31, 2025 give effect to the Merger as if it had been consummated on January&#160;1, 2025. The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2026 gives effect to the Merger and combines the historical balance sheets of Cyclerion and Korsana if the Merger had been consummated on March&#160;31, 2026. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i)&#160;changes in initial assumptions in the determination of the accounting acquirer and related accounting, (ii)&#160;changes in the amount of Cyclerion net cash to be assumed at the closing date, and (iii)&#160;other changes in Cyclerion&#8217;s assets and liabilities, which are expected to be completed after the closing of the Merger, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the Combined Company&#8217;s future results of operations and financial position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the preparation of the accompanying unaudited pro forma combined financial information, Management is not aware of any material differences between Korsana&#8217;s accounting policies and the accounting policies of Cyclerion. Following the consummation of the Merger, Korsana will conduct a more detailed review of Cyclerion&#8217;s accounting policies. As a result, Korsana may identify differences between the accounting policies of the two companies that, when conformed, could have had a material impact on the accompanying unaudited pro forma combined financial information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3. Accounting for the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for under U.S. GAAP as a reverse recapitalization of Cyclerion by Korsana, as the transaction is, in essence, the issuance of equity for Cyclerion&#8217;s net assets, which will primarily consist of nominal operations and nominal other net assets immediately before the Merger. Under this method of accounting, Korsana will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Immediately prior to the Merger, Korsana is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana stockholders own a substantial majority of the voting rights in the Combined Company through existing ownership and additional interest through the Subscription Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s largest stockholder retains the largest interest in the Combined Company (19.4%); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana designated the initial members of the Combined Company board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana&#8217;s executive management team became the management of the Combined Company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Combined Company will be renamed &#8220;Korsana Biosciences, Inc.&#8221; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">401 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of Korsana being the accounting acquirer, Korsana&#8217;s assets and liabilities will be recorded at their <span style="white-space:nowrap">pre-combination</span> carrying amounts. Cyclerion&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time of the Merger. The Company has preliminarily determined that the fair value of Tisento investment is not material given the current lack of observable pricing, the early state of Tisento&#8217;s development activities and the significant uncertainty regarding its potential value. Therefore, the Company has reduced the carrying value of the Tisento investment to $0 for purposes of the pro forma financial information as presented in adjustment 5(h) below. The Company will continue to assess observable and unobservable data points to consider fair value estimates through closing of the transaction. The Company determined that the carrying value of the other acquired operating assets and liabilities approximates fair value, with no goodwill or other intangible assets recorded. Any difference between the consideration transferred and the fair value of the net assets of Cyclerion following the determination of the actual consideration transferred for Cyclerion will be reflected as an adjustment to additional <span style="white-space:nowrap">paid-in</span> capital. For periods prior to closing of the Merger, the historical financial statements of Korsana will become the historical financial statements of the Combined Company. The Merger will not be accounted for as a business combination under Accounting Standard Codification No.&#160;805, Business Combinations. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">4. Shares of Cyclerion Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Korsana Stockholders upon Closing of the Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the Merger, all outstanding shares of Korsana common stock, on a fully-diluted basis, will be exchanged for shares of Cyclerion common stock based on the Exchange Ratio of 1.1009 shares of Cyclerion common stock for each share of Korsana common stock, determined in accordance with the terms of the Merger Agreement. Each share of Korsana Series Seed preferred stock will be convertible into the right to receive a number of shares of newly created Cyclerion Series B <span style="white-space:nowrap">non-voting</span> Preferred Stock, equal to the Exchange Ratio divided by 1,000 (and each such share of newly created Cyclerion Series B <span style="white-space:nowrap">non-voting</span> Preferred Stock has the right to convert into 1,000 shares of Cyclerion common stock, subject to certain limitations). The estimated number of shares of Cyclerion common stock that Cyclerion expects to issue to Korsana&#8217;s stockholders assumes Cyclerion net cash at the closing of the Merger is $0 and is determined as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korsana common stock outstanding as of March&#160;31, 2026 <sup style="font-size:75%; vertical-align:top">(l)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korsana convertible preferred stock to be issued in exchange of Korsana <span style="white-space:nowrap">non-voting</span> convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korsana convertible preferred stock to be issued in exchange of Korsana common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">60,019,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korsana convertible preferred stock to be issued in exchange of Korsana <span style="white-space:nowrap">pre-funded</span> warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,480,230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korsana common stock to be issued upon exercise of Korsana stock options <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,444,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Korsana common stock to be issued upon exercise of Korsana warrants<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,102,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated shares of Korsana common stock to be issued in connection with the Subscription Agreements, see Note 5(c)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">118,022,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Korsana <span style="white-space:nowrap">pre-funded</span> warrants to be issued in connection with the Subscription Agreements, see Note 5(c)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">43,444,829</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Korsana fully diluted shares prior to the closing of the merger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">271,514,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Exchange Ratio</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.1009</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">402 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:79%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fully diluted shares to be issued to Korsana stockholders and Investors participating in Subscription Agreements upon closing of the merger</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">303,313,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares of Korsana common stock outstanding as of March&#160;31, 2026, including 1,000,000 shares of unvested Korsana restricted stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the outstanding options as of March&#160;31, 2026 to acquire Korsana common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the outstanding warrants as of March&#160;31, 2026 to acquire Korsana common stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">5. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of March&#160;31, 2026 </p> </div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows: </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pro forma notes: </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(A) Derived from the unaudited balance sheet of Cyclerion as of March&#160;31, 2026 included elsewhere in the proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(B) Derived from the unaudited balance sheet of Korsana as of March&#160;31, 2026 included elsewhere in the proxy statement/prospectus. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pro forma Balance Sheet Transaction Accounting Adjustments: </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(a) To reflect incremental compensation expense of $0.5&#160;million related to severance payments resulting from <span style="white-space:nowrap">pre-existing</span> employment agreement or from approval from the Cyclerion Board that will be incurred prior to the closing of the Merger. The pro forma adjustment is reflected as a decrease in cash of $0.5&#160;million for the severance payments made subsequent to March&#160;31, 2026 and an increase to accumulated deficit of $0.5&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(b) To reflect the conversion of all outstanding shares of Korsana Series A preferred stock, with a carrying amount of $150.6&#160;million, to Cyclerion common stock and <span style="white-space:nowrap">pre-funded</span> warrants, as well as to reflect the reclassification of all outstanding Korsana Series Seed preferred stock, with a carrying value of $25.0&#160;million, to newly created Cyclerion Series B preferred stock outside of stockholder&#8217;s equity (deficit). The Company&#8217;s Series&#160;B Non-Voting Convertible Preferred Stock are classified within temporary (mezzanine) equity under ASC&#160;480 and ASC 480-10-S99. Although the Series B Preferred Stock is not mandatorily redeemable, certain provisions may require the Company to transfer cash or other assets upon the occurrence of events not solely within the Company&#8217;s control. For example, the Series B Preferred Stock includes fundamental transaction provisions pursuant to which, upon the occurrence of certain merger, change-in-control, or other similar transactions, holders may receive cash or other non-equity consideration in lieu of common shares. The occurrence of such transactions is not solely within the control of the Company and may involve shareholder approval. The conversion of the Korsana Series A preferred stock is recorded at the issuance of Cyclerion common stock at par value with the remaining amount recorded to additional <span style="white-space:nowrap">paid-in</span> capital. </p> </div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(c) To reflect the issuance of 118,022,392 shares of Korsana common stock and 43,444,829 <span style="white-space:nowrap">pre-funded</span> warrants, prior to giving effect to the Exchange Ratio, pursuant to the Subscription Agreement, for an aggregate purchase price of $380.0&#160;million. The issuance of shares in connection with the Subscription Agreement are recorded as the issuance of Korsana common stock at par value with the remaining amount recorded to additional <span style="white-space:nowrap"><span style="white-space:nowrap">paid-in-capital.</span></span> </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(d) To reflect estimated transaction costs of $28.9&#160;million, not yet reflected in the historical financial statements, that are expected to be incurred by Korsana in connection with the Merger and <span style="white-space:nowrap">Pre-Closing</span> Financing, and $1.2 million reflected in the historical financial statements as deferred offering costs, such as </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">403 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
advisory, legal and auditor fees, as a reduction in cash in the unaudited pro forma condensed combined balance sheet. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets of Cyclerion, these direct and incremental costs are treated as a reduction of the net proceeds received within additional <span style="white-space:nowrap">paid-in</span> capital. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(e) To reflect estimated transaction costs of $2.8&#160;million, not yet reflected in the historical financial statements, which are expected to be incurred by Cyclerion in connection with the Merger, such as advisory, legal and auditor fees and including the estimated $0.7&#160;million cost of a D&amp;O tail policy, as a reduction in cash and an increase in accumulated deficit of $2.8&#160;million in the unaudited pro forma condensed combined balance sheet. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(f) To derecognize $0.3&#160;million of Cyclerion&#8217;s prepaid expenses and other current assets consisting of $0.2&#160;million of prepaid expenses related to software that will not be fully utilized and $0.1&#160;million of prepaid insurance primarily related to the current Cyclerion&#8217;s D&amp;O insurance policy that will be fully utilized at the closing of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(g) To derecognize $1.3&#160;million of Cyclerion&#8217;s accrued expenses consisting of $0.2&#160;million of accrued research and development and $1.1&#160;million of accrued professional and consulting fees that will be paid prior to the closing of the Merger. </p> </div> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(h) To reflect the elimination of Cyclerion&#8217;s historical equity investment of $5.3&#160;million given the current lack of observable pricing, the early state of Tisento&#8217;s development activities and the significant uncertainty regarding its potential value. The Company has preliminarily determined the fair value of the Tisento investment to be $0 and will continue to assess observable and unobservable data points to consider fair value estimates through closing of the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(i) To reflect the recapitalization of Korsana and the derecognition of accumulated other comprehensive income and the accumulated deficit of Cyclerion, which is reversed to additional paid-in capital. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The derecognition of accumulated deficit of Cyclerion of $283.1 million is determined as follows (in thousands): </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:83%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit of Cyclerion as of March 31, 2026</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">274,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation expense related to Cyclerion severance payments, see Note 5(a)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preliminary estimated transaction costs of Cyclerion, see Note 5(e)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derecognition of Cyclerion prepaid expenses, see Note&#160;5(f)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of equity investment, see Note 5(h)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total adjustment to derecognize the accumulated deficit of Cyclerion</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">283,072</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> </div> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5(j) To reflect the one-time postcombination stock compensation expense of $0.3 million in general and administrative expense related to the acceleration of equity awards pursuant to a modification to accelerate vesting of certain Cyclerion stock options and restricted stock awards per the terms of the Merger Agreement, and a one-time cash payment of less than $0.1 million to settle certain in-the-money stock options. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">404 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><span style="font-weight:bold">6.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations and Comprehensive Loss </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows: </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pro forma notes: </span></p> <div> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(A) Derived from the unaudited condensed consolidated statements of operations and comprehensive loss of Cyclerion for the three months ended March 31, 2026 included elsewhere in the proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(B) Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of Korsana for the three months ended March 31, 2026 included elsewhere in the proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(C) Derived from the audited consolidated statements of operations and comprehensive loss of Cyclerion for the year ended December&#160;31, 2025 included elsewhere in the proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(D) Derived from the audited consolidated statement of operations and comprehensive loss of Korsana for the year ended December&#160;31, 2025 included elsewhere in the proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana and Cyclerion did not record any provision or benefit for income taxes during the year ended December&#160;31, 2025 nor for the three months ended March 31, 2026 because each company incurred a <span style="white-space:nowrap">pre-tax</span> loss in 2025 and expects to incur a pre-tax loss in 2026 and each company maintained a full valuation allowance on its deferred tax assets. Accordingly, the Company has not reflected any income tax effects related to the pro forma adjustments as it continues to expect a full valuation allowance will be required following the transaction. </p> </div> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pro forma Statements of Operations Transaction Accounting Adjustments: </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(a) To reflect incremental compensation expense related to severance payments recorded in general and administrative expenses of $0.5&#160;million, resulting from <span style="white-space:nowrap">pre-existing</span> employment agreement or from approval from the Cyclerion Board that will be incurred upon the closing of the Merger, corresponding to the adjustment described in Note 5(a) as if it was made on January&#160;1, 2025. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(b) To reflect the derecognition of Cyclerion&#8217;s prepaid expenses and other current assets of $0.3&#160;million related to $0.2&#160;million of software that will not be fully utilized, and prepaid insurance of $0.1&#160;million primarily related to the current Cyclerion D&amp;O policy that will be fully utilized at the closing of the Merger, corresponding to the adjustment made in Note 5(f) as if it was made on January&#160;1, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(c) To reflect the <span style="white-space:nowrap">one-time</span> postcombination stock compensation expense of $0.3&#160;million in general and administrative expense pursuant to a modification to accelerate vesting of certain stock options and restricted stock awards, and the <span style="white-space:nowrap">one-time</span> cash payment above fair value to settle certain <span style="white-space:nowrap"><span style="white-space:nowrap">in-the-money</span></span> stock options corresponding to the adjustment made in Note 5(j) as if it was made on January&#160;1, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6(d) The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the three months ended March 31, 2026 and the year ended December&#160;31, 2025. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the Combined Company for the respective periods. Pro forma weighted average shares outstanding includes the <span style="white-space:nowrap">pre-funded</span> warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. Shares of newly created Cyclerion Series B <span style="white-space:nowrap">non-voting</span> Preferred Stock share the same characteristics as common stock and have no substantive preference attributed to them and, accordingly, have been considered a class of common stock in the computation of net loss per share regardless of their legal form. Net loss is allocated to common stock based on its proportional ownership on an <span style="white-space:nowrap">as-converted</span> basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">405 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma weighted average shares have been calculated as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:74%"/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">March&#160;31, 2026</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">Basic&#160;and&#160;Diluted</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders (in thousands)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(15,430</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Series B <span style="white-space:nowrap">non-voting</span> convertible preferred stockholders (in thousands)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1,256</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical weighted average number of Cyclerion common shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,205,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Cyclerion common stock issued to Korsana stockholders upon close of Merger, assuming consummation of the Merger as of January&#160;1, 2025<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">266,381,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma combined weighted average number of common shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">270,586,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma combined weighted average number of shares of Series B non-voting convertible preferred stock outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(0.06</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(57.04</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">December&#160;31,&#160;2025</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">Basic&#160;and&#160;Diluted</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders (in thousands)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(37,243</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Series B non-voting convertible preferred stockholders (in thousands)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(3,042</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical weighted average number of Cyclerion common shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,181,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of Cyclerion common stock issued to Korsana stockholders upon close of Merger, assuming consummation of the Merger as of January 1, 2025<sup style="font-size:75%; vertical-align:top">(1) </sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">266,381,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma combined weighted average number of common shares outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">269,562,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma combined weighted average number of shares of Series B non-voting convertible preferred stock outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> (0.14)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Series B <span style="white-space:nowrap">non-voting</span> convertible preferred stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"> (138.16)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the estimated shares of Cyclerion common stock and <span style="white-space:nowrap">pre-funded</span> warrants issued to Korsana stockholders at the closing of the Merger, excluding (i)&#160;the outstanding and unvested Korsana restricted </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">406 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="vertical-align:top;text-align:left">
stock and options to purchase Korsana common stock at the closing of the Merger that were converted to the right to receive 1,100,900 shares of the Cyclerion common stock as of March&#160;31, 2026 and December&#160;31, 2025, and 12,598,961 options to purchase shares of Cyclerion common stock as of March 31, 2026 and December&#160;31, 2025 after reflecting the estimated Exchange Ratio, (ii)&#160;the outstanding shares of Korsana Series Seed preferred stock that were exchanged for 22,018 shares of newly created Cyclerion Series B Preferred Stock as of March 31, 2026 and December&#160;31, 2025, and (iii)&#160;the outstanding warrants to purchase Korsana common stock at the closing of the Merger that were converted to the right to receive 1,213,850 warrants to purchase shares of Cyclerion common stock as of March 31, 2026 and December&#160;31, 2025, after reflecting the estimated Exchange Ratio. The shares of Cyclerion common stock issued in exchange for shares of Korsana restricted stock and options to purchase shares of Cyclerion common stock issued in exchange for options to purchase shares of Korsana common stock are subject to the same vesting and forfeiture conditions, applicable, as they were prior to the Merger. </td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">407 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_36">DESCRIPTION OF CYCLERION CAPITAL STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following description of Cyclerion capital stock and provisions of the Cyclerion Articles and Cyclerion Bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Massachusetts corporate law. Copies of these documents are filed as exhibits to the registration statement of which this proxy/prospectus forms a part. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized Capital Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion&#8217;s authorized capital stock consists of 400,000,000 shares of common stock and 100,000,000 shares of preferred stock, 500,000 of which preferred stock is designated as Cyclerion Series A Preferred Stock and the rest of which preferred stock is undesignated. As of March&#160;30, 2026, there were 4,330,314 shares of common stock outstanding and 351,037 shares of Cyclerion Series A Preferred Stock outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to shares of preferred stock outstanding, holders of outstanding shares of Cyclerion Common Stock are entitled to receive dividends out of assets legally available at the times and in the amounts as the Cyclerion Board may from time to time determine. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding share of Cyclerion Common Stock is entitled to one vote on all matters submitted to a vote of shareholders. Holders of shares of Cyclerion Common Stock have no cumulative voting rights. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preemptive Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion Common Stock is not entitled to preemptive or other similar subscription rights to purchase any of Cyclerion securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conversion or Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion Common Stock is neither convertible nor redeemable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon Cyclerion&#8217;s liquidation, the holders of Cyclerion Common Stock would be entitled to receive pro rata Cyclerion&#8217;s assets which are legally available for distribution, after payment of all debts and other liabilities and subject to the prior rights of any holders of the Cyclerion Series A Preferred Stock or any other preferred stock then outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Listing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion Common Stock is listed on the Nasdaq Capital Market under the trading symbol &#8220;CYCN.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transfer Agent and Registrar </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for Cyclerion Common Stock is Computershare Trust Company, N.A. Its address is 150 Royall Street, Canton, Massachusetts 02021 and its telephone number is <span style="white-space:nowrap">(800)&#160;522-6645.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">408 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to limitations of the MBCA and the Cyclerion Articles and Cyclerion Bylaws, the Cyclerion Board may, without further action by Cyclerion shareholders, from time to time, direct the issuance of additional shares of preferred stock in series and may, at the time of issuance, determine the designations, powers, preferences, privileges and relative participating, optional or special rights, any or all of which may be greater than the rights of Cyclerion Common Stock, as well as the qualifications, limitations or restrictions thereof, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of shares constituting each class or series; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voting rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">rights and terms of redemption, including sinking fund provisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dividend rights and rates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">terms concerning the distribution of assets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conversion or exchange terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">redemption prices and terms; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">liquidation preferences. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion will specify the following terms relating to any class or series of preferred stock offered: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the title and stated value of the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of shares of the preferred stock offered, the liquidation preference per share and the offering price of the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the dividend rate(s), period(s) or payment date(s) or method(s) of calculation applicable to the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether dividends are cumulative or <span style="white-space:nowrap">non-cumulative</span> and, if cumulative, the date from which dividends on the preferred stock will accumulate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Cyclerion&#8217;s right, if any, to defer payment of dividends and the maximum length of any such deferral period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the procedures for auction and remarketing, if any, for the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the provisions for a sinking fund, if any, for the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the provision for redemption, if applicable, of the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any listing of the preferred stock on any securities exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock, including the conversion price or manner of calculation and conversion period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voting rights, if any, of the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether interests in the preferred stock will be represented by depositary shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a discussion of any material or special United States federal income tax considerations applicable to the preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the class or series of preferred stock as to dividend rights and rights upon the liquidation, dissolution or winding up of our affairs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">409 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Satisfaction of any dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of Cyclerion Common Stock. Holders of shares of preferred stock may be entitled to receive a preference payment in the event of our liquidation before any payment is made to the holders of shares of Cyclerion Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Series A Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Cyclerion Series A Preferred Stock (i)&#160;is convertible at the option of the holder into one share of Cyclerion Common Stock, subject to adjustment for stock splits, combinations and similar events, (ii)&#160;is entitled to participate in any dividends paid to holders of Cyclerion Common Stock on an <span style="white-space:nowrap">as-converted</span> basis, and (iii)&#160;is entitled to a payment of $0.01 liquidation preference per share, before any amounts are paid to holders of Cyclerion Common Stock, upon the liquidation, dissolution or winding up of Cyclerion, and thereafter will participate in any liquidation distributions to holders of Cyclerion Common Stock on an <span style="white-space:nowrap">as-converted</span> basis. The Cyclerion Series A Preferred Stock has no voting rights except as required by law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Effects of Our Organizational Documents </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Cyclerion Articles and the Cyclerion Bylaws contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of the Cyclerion Board but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control is approved by the Cyclerion Board. These provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Action by written consent; special meetings of shareholders</span>. The Cyclerion Bylaws provide that shareholder action can be taken only at an annual or special meeting of shareholders or by the unanimous written consent of all shareholders in lieu of such a meeting. The Cyclerion Articles and the Cyclerion Bylaws also provide that, except as otherwise required by law, special meetings of the shareholders can only be called pursuant to a resolution adopted by a majority of the Cyclerion Board or holders of at least 40% of Cyclerion&#8217;s then outstanding common stock. Except as described above, shareholders are not permitted to call a special meeting or to require the Cyclerion Board to call a special meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Advance notice procedures</span>. The Cyclerion Bylaws contain an advance notice procedure for shareholder proposals to be brought before an annual meeting of Cyclerion&#8217;s shareholders, including proposed nominations of persons for election to the Cyclerion Board. Shareholders at an annual meeting are only able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Cyclerion Board or by a shareholder who was a shareholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given Cyclerion&#8217;s Secretary timely written notice, in proper form, of the shareholder&#8217;s intention to bring that business before the meeting. Although the Cyclerion Bylaws do not give the Cyclerion Board the power to approve or disapprove shareholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the Cyclerion Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of Cyclerion. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Proxy Access</span>. The Cyclerion Bylaws provide that a shareholder or a group of shareholders meeting certain conditions may nominate candidates for election as a director at an annual meeting of our shareholders using &#8220;proxy access&#8221; provisions. These provisions allow one or more shareholders (up to 20, collectively), owning at least 3% of Cyclerion&#8217;s outstanding common stock continuously for at least three years, to nominate for election to the Cyclerion Board and to be included in Cyclerion&#8217;s proxy materials up to the greater of two individuals or 20% of the Cyclerion Board, subject to the provisions included in the Cyclerion Bylaws, including the provision of timely written notice to Cyclerion&#8217;s Secretary. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">410 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Number of directors and filling vacancies; election of directors</span>. The Cyclerion Articles provide that the number of directors is established by the Cyclerion Board. Furthermore, any vacancy on the Cyclerion Board, however occurring, including a vacancy resulting from an increase in the size of the Cyclerion Board, may only be filled by the affirmative vote of a majority of the directors on the Cyclerion Board then in office. The ability of the Cyclerion Board to increase the number of directors and fill any vacancies may make it more difficult for Cyclerion&#8217;s shareholders to change the composition of the Cyclerion Board. The Cyclerion Bylaws provide that a majority of the votes properly cast for the election of a director shall effect such election unless there are more nominees than directorships, in which case a plurality standard shall apply. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Authorized but unissued shares.</span> Cyclerion&#8217;s authorized but unissued shares of common stock and preferred stock are available for future issuance without shareholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of Cyclerion&#8217;s common stock by means of a proxy contest, tender offer, merger or otherwise. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Exclusive forum.</span> The Cyclerion Articles require, to the fullest extent permitted by law, that derivative actions brought in the name of Cyclerion, actions against Cyclerion&#8217;s directors, officers and employees for breach of a fiduciary duty and other similar actions may be brought only in specified courts in the Commonwealth of Massachusetts. Although Cyclerion believes this provision benefits Cyclerion by providing increased consistency in the application of Massachusetts law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against Cyclerion&#8217;s directors and officers. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Provisions under Massachusetts Law </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions Regarding Business Combinations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is subject to the provisions of Chapter 110F of the MBCA. In general, Chapter 110F prohibits a publicly held Massachusetts corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, five percent or more of the corporation&#8217;s voting stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Chapter 110F, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, the corporation&#8217;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 90% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the shareholders by the affirmative vote of at least <span style="white-space:nowrap">two-thirds</span> of the outstanding voting stock which is not owned by the interested shareholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Massachusetts corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original articles of organization or an express provision in its articles of organization or bylaws resulting from a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">411 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. Cyclerion has not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of Cyclerion may be discouraged or prevented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions Regarding a Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;8.06(b) of the MBCA provides that, unless a company opts out of such provision, the terms of directors of a public Massachusetts company shall be staggered by dividing the directors into three groups, as nearly equal in number as possible, with only one group of directors being elected each year. Cyclerion has opted out of this default requirement for a classified board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;8.06(c)(2) of the MBCA, however, the Cyclerion Board may unilaterally opt back into default requirements under Section&#160;8.06(b) of the MBCA and become a classified board of directors without the approval of the Cyclerion shareholders. Sections 8.06(d) and (e)&#160;of the MBCA provide that when a board of directors is so classified, (i)&#160;shareholders may remove directors only for cause, (ii)&#160;the number of directors shall be fixed only by the vote of the board of directors, (iii)&#160;vacancies and newly created directorships shall be filled solely by the affirmative vote of a majority of the remaining directors and (iv)&#160;a decrease in the number of directors will not shorten the term of any incumbent director. If the Cyclerion Board opts into this classified structure in the future, these provisions are likely to increase the time required for shareholders to change the composition of the Cyclerion Board. For example, at least two annual meetings would generally be necessary for shareholders to effect a change in a majority of the members of the Cyclerion Board. As a result, the ability of the Cyclerion Board to adopt a classified structure in the future without the approval of Cyclerion shareholders could have the effect of discouraging a potential acquirer from making a tender offer for a majority of the outstanding voting interest of Cyclerion&#8217;s capital stock or otherwise attempting to obtain control of Cyclerion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Articles provide that the liability of Cyclerion&#8217;s directors for damages for any breach of fiduciary duty shall be limited to the fullest extent permitted by law. The Cyclerion Bylaws also provide that Cyclerion will indemnify, and advance funds to and reimburse expenses of, Cyclerion&#8217;s directors and officers that have been appointed by the Cyclerion Board to the fullest extent permitted by law, and that Cyclerion may indemnify, and advance funds to and reimburse expenses of, such other officers and employees as determined by the Cyclerion Board. The right of indemnification provided under the Cyclerion Bylaws is in addition to and not exclusive of any other rights to which any of Cyclerion&#8217;s directors, officers or any other persons may otherwise be lawfully entitled. Cyclerion has also entered into indemnification agreements with its directors and officers, and Cyclerion carries insurance policies insuring its directors and officers against certain liabilities that they may incur in their capacity as directors and officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part 8 of the MBCA authorizes the provisions, described above, that are contained in the Cyclerion Articles and the Cyclerion Bylaws. In addition, Sections 8.30 and 8.42 of the MBCA provide that if an officer or director discharges his or her duties in good faith and with the care that a person in a like position would reasonably exercise under similar circumstances and in a manner the officer or director reasonably believes to be in the best interests of the corporation, he or she will not be liable for such action. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">412 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_37">COMPARISON OF RIGHTS OF HOLDERS OF CYCLERION CAPITAL STOCK AND </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">KORSANA CAPITAL STOCK </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger is completed, Korsana stockholders will receive shares of Cyclerion Common Stock, Cyclerion <span style="white-space:nowrap">Pre-Funded</span> Warrants, and shares of Cyclerion Series B Preferred Stock, pursuant to the terms of the Merger Agreement. Prior to or upon the closing of the Merger, assuming that Proposal Nos. 2 and 3 are approved by Cyclerion&#8217;s shareholders, the Cyclerion Articles will be amended to increase the number of shares of Cyclerion Common Stock that Cyclerion is authorized to issue from 400,000,000 to&#8195;&#8195;&#8195;&#8195;, and to effect the proposed reverse stock split, as set forth in the forms of certificates of amendment attached as <span style="font-style:italic">Annex</span><span style="font-style:italic"> </span><span style="font-style:italic">H</span>, and <span style="font-style:italic">Annex </span><span style="font-style:italic">I</span> to this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is incorporated under the laws of the Commonwealth of Massachusetts, and the rights of its shareholders are generally governed by the Massachusetts Business Corporation Act (&#8220;MBCA&#8221;), as well as its articles of organization and bylaws. Korsana is incorporated under the laws of the State of Delaware, and the rights of its stockholders are generally governed by the DGCL, as well as its articles of organization or certificates of incorporation and bylaws. Upon completion of the Merger, Korsana stockholders will become shareholders of Cyclerion, and their rights thereafter will be governed by the MBCA, the Cyclerion Bylaws, and the Cyclerion Articles, each as may be amended in connection with the Merger, including as contemplated by Proposal Nos. 2 and 3. The material differences between the rights of Korsana stockholders prior to the Merger and their rights as Cyclerion shareholders after the Merger &#8212; taking into account the amendments to the Cyclerion Articles and Cyclerion Bylaws that would be effected if Proposal Nos. 2 and 3 are approved &#8212; are described in the immediately following paragraph. </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material differences between the current rights of Korsana stockholders under the Korsana Charter and Korsana Bylaws and their rights as Cyclerion shareholders, after the Merger, under the Cyclerion Articles and Cyclerion Bylaws, both as will be in effect immediately following the completion of the Merger and assuming that Proposal Nos. 2 and 3 are approved by Cyclerion&#8217;s shareholders, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL, the MBCA and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of Cyclerion or Korsana before the Merger and being a shareholder of the Combined Company following the completion of the Merger. For more information on how to obtain these documents, see the section titled &#8220;<span style="font-style:italic">Where You Can Find More</span><span style="font-style:italic"> </span><span style="font-style:italic">Information</span>&#8221; beginning on page&#160;435 of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Proposal No.&#160;4 is approved by Cyclerion shareholders and the Merger is completed, the Combined Company will effect the Cayman Redomestication pursuant to the Plan of Domestication as set forth in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">J</span><span style="font-style:italic"> </span>to this proxy statement/prospectus, and, upon completion of the Cayman Redomestication, the rights of Cyclerion shareholders and the rights of Korsana stockholders who become Combined Company shareholders pursuant to the Merger will no longer be governed by the Cyclerion Articles, the Cyclerion Bylaws and the MBCA and instead will be governed by the Cayman Articles, in the form attached as <span style="font-style:italic">Annex&#160;</span><span style="font-style:italic">K</span><span style="font-style:italic"> </span>to this proxy statement/prospectus, and the Cayman Islands Companies Act. For a comparison of rights of holders of the Combined Company capital stock as a Massachusetts corporation and the Combined Company share capital as a Cayman Islands exempted company limited by shares, assuming the completion of the Cayman Redomestication, see the section titled &#8220;<span style="font-style:italic">Proposal </span><span style="font-style:italic">No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;4 &#8212; The Redomestication Proposal &#8212; </span><span style="font-style:italic">Effects</span><span style="font-style:italic"> of the Cayman Redomestication&#160;&#8212; </span><span style="font-style:italic">Comparison of Rights of</span><span style="font-style:italic"> </span><span style="font-style:italic">Holders</span><span style="font-style:italic"> </span><span style="font-style:italic">of the</span><span style="font-style:italic"> </span><span style="font-style:italic">Massachusetts </span><span style="font-style:italic">Corporation</span><span style="font-style:italic"> </span><span style="font-style:italic">Capital</span><span style="font-style:italic"> </span><span style="font-style:italic">Stock</span><span style="font-style:italic"> </span><span style="font-style:italic">and</span><span style="font-style:italic"> </span><span style="font-style:italic">the</span><span style="font-style:italic"> </span><span style="font-style:italic">Cayman</span><span style="font-style:italic"> </span><span style="font-style:italic">Company</span><span style="font-style:italic"> </span><span style="font-style:italic">Share</span><span style="font-style:italic"> </span><span style="font-style:italic">Capital</span>&#8221; beginning on page&#160;237 of this proxy statement/prospectus. </p> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">413 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">Cyclerion</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">Korsana</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Organizational Documents</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The rights of Cyclerion shareholders are governed by Cyclerion&#8217;s restated articles of organization (as amended, the &#8220;Cyclerion Articles&#8221;), Cyclerion&#8217;s amended and restated bylaws (the &#8220;Cyclerion Bylaws&#8221;) and the Massachusetts Business Corporation Act (the &#8220;MBCA&#8221;).</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The rights of Korsana&#8217;s stockholders are governed by Korsana&#8217;s second amended and restated certificate of incorporation (the &#8220;Korsana Charter&#8221;), Korsana&#8217;s bylaws (the &#8220;Korsana Bylaws&#8221;) and the DGCL. Rights of certain holders of Korsana preferred stock are governed by the Amended and Restated Investors&#8217; Rights Agreement (the &#8220;Korsana IRA&#8221;), the Amended and Restated Right of First Refusal and <span style="white-space:nowrap">Co-Sale</span> Agreement (the &#8220;Korsana ROFR Agreement&#8221;), and the Amended and Restated Voting Agreement, each dated as of September&#160;15, 2025.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Authorized Capital Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cyclerion is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Cyclerion is authorized to issue is 500,000,000, of which 400,000,000 shares are common stock, each having no par value per share, and 100,000,000 shares are preferred stock, each having no par value per share. The preferred stock may be issued from time to time in one or more series. The number of authorized shares of Cyclerion preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of Cyclerion entitled to vote thereon, without a separate vote of the holders of the preferred stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of preferred stock.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korsana is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Korsana is authorized to issue is 217,863,552, of which 122,363,552 shares are common stock, par value $0.0001 per share, and 95,500,000 shares are preferred stock, par value $0.0001 per share. The number of authorized shares of Korsana Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Korsana preferred stock that may be required under the Korsana Charter) the affirmative vote of the holders of shares of Korsana capital stock representing a majority of the votes represented by all outstanding shares of Korsana capital stock entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Common Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cyclerion authorized common stock consists of 400,000,000 shares of common stock, no par value per share.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each holder of a share of Cyclerion Common Stock is entitled to one vote for each such share held of record on the applicable record date on each matter properly submitted to the stockholders for their vote.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Korsana&#8217;s authorized common stock consists of 122,363,552 shares of common stock, par value $0.0001 per share.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Each holder of a share of Korsana Common Stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders (and written actions in lieu of meetings).</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Preferred Stock</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cyclerion preferred stock consists of 100,000,000 shares of preferred stock, each having no par value per share. The voting rights of preferred stockholders can vary depending on the series of preferred stock issued. The</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korsana&#8217;s 95,500,000 shares of preferred stock consist of 20,000,000 shares of preferred stock designated as shares of &#8220;Series Seed Preferred Stock,&#8221; and 75,500,000 shares of preferred stock</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">414 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion Board is authorized to determine the voting powers, full or limited, or no voting powers for each series of preferred stock.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">500,000 shares of Cyclerion preferred stock are designated as Series Convertible A Preferred Stock (&#8220;Cyclerion Series A Preferred Stock&#8221;). Holders of Cyclerion Series A Preferred Stock are not entitled to vote at any meetings of Cyclerion shareholders. Each share of Cyclerion Series A Preferred Stock is convertible into one share of Cyclerion Common Stock.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, the Cyclerion Board intends to designate&#8195;&#8195;&#8195;&#8195;shares of undesignated preferred stock as Cyclerion Series B Preferred Stock through an articles of amendment to the Cyclerion Articles in the form attached as <span style="font-style:italic">Annex </span><span style="font-style:italic">G</span> to this proxy statement/prospectus (the &#8220;Articles of Amendment&#8221;). No shares of Cyclerion Series B Preferred Stock are currently authorized or outstanding. Except as otherwise required by the Articles of Amendment or law, the Cyclerion Series B Preferred Stock will not have voting rights. The Articles of Amendment provides for certain voting rights in relation to the election of directors as discussed under &#8220;- <span style="font-style:italic">Structure of Board of Directors; Term of Directors; Election of Directors</span>&#8221; below. As long as shares of Cyclerion Series B Preferred Stock are outstanding, Cyclerion will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Cyclerion Series B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to Cyclerion Series B Preferred Stock, (b)&#160;alter or amend the description of rights of Cyclerion Series B Preferred Stock set forth in its articles of organization, (c)&#160;amend its articles of organization, bylaws or other charter documents in any manner that adversely affects any rights of the holders of Cyclerion Series B Preferred Stock, (d)&#160;file any articles of amendment, description of rights, preferences, limitations and relative rights of any series of Cyclerion preferred stock (as defined in the Articles of Amendment), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of Cyclerion Series B Preferred Stock, (e)&#160;issue further shares of the Cyclerion Series B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Cyclerion Series B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Cyclerion Series B Preferred Stock remains issued and outstanding, (i)&#160;consummate either (A)&#160;a Fundamental Transaction (as defined in the Articles of Amendment) or (B)&#160;any merger or consolidation of Cyclerion or other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">designated as shares of &#8220;Series A Preferred Stock.&#8221; On each matter voted on at a meeting of stockholders (and written actions in lieu of meetings), each holder of a share of Korsana preferred stock is entitled to cast the number of votes equal to the number of whole shares of Korsana Common Stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Holders of Korsana preferred stock vote together with holders of Korsana Common Stock as a single class and on an <span style="white-space:nowrap">as-converted</span> to common stock basis.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">415 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">business combination in which the shareholders of Cyclerion immediately before such transaction do not hold at least a majority of the capital stock of Cyclerion immediately after such transaction, (ii)&#160;increase the size of the Cyclerion Board, (iii)&#160;adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless approved by the unanimous vote of the Cyclerion Board, or (iv)&#160;retain or replace Cyclerion&#8217;s registered independent public accounting firm, independent compensation consultant or corporate counsel, or (g)&#160;enter into any agreement with respect to any of the foregoing. Following the closing of the Merger, each share of Cyclerion Series B Preferred Stock then outstanding will be convertible, at any time and from time to time, at the option of the holder of Cyclerion Series B Preferred Stock, into a number of shares equal to 1,000 shares of Cyclerion Common Stock, subject to certain limitations, including that a holder of Cyclerion Series B Preferred Stock is prohibited from converting shares of Cyclerion Series B Preferred Stock into shares of Cyclerion Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 19.99%) of the total number of shares of Cyclerion Common Stock issued and outstanding immediately after giving effect to such conversion.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Number and Qualification of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The number of Cyclerion directors shall be not less than three directors and may be increased or decreased to a size fixed exclusively by vote of a majority of the directors then serving. No decrease in the authorized number of directors constituting the Cyclerion Board will shorten the term of any incumbent director. Directors need not be stockholders of Cyclerion. Following the completion of the Merger, the Combined Company is expected to consist of six members.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The number of directors of Korsana is established from time to time by the Korsana Board. The Korsana Board currently consists of six members. Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office, unless, at the time of such decrease, there are vacancies on the board which are eliminated by the decrease.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Structure of Board of Directors; Term of Directors; Election of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each annual meeting of shareholders, directors shall be elected for a full term of set to expire at the next annual meeting of shareholders. Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by statute, the Cyclerion Articles or the Cyclerion Bylaws, when a quorum is present, (i)&#160;in the event there are at least as many</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korsana directors shall be elected at the annual meeting of stockholders by such stockholders as have the right to vote on such election. Election of directors need not be by written ballot. Each director shall hold office for a term of one year and until his or her successor is elected and qualified, or until such director&#8217;s earlier resignation or removal. All elections shall be determined by a plurality of the votes cast, except as otherwise required by law.</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">416 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">directorships as nominees, directors shall be elected by a majority of the votes properly cast and entitled to vote generally on the election of directors or (ii)&#160;in the event there are more nominees than directorships, directors shall be elected by a plurality of the votes properly cast and entitled to vote generally on the election of directors.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, at all times when at least 30% of the originally issued Cyclerion Series B Preferred Stock remains issued and outstanding: (i)&#160;the holders of Cyclerion Series B Preferred Stock, exclusively and voting together as a separate class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect four Preferred Directors; and (ii)&#160;the holders of Cyclerion Common Stock and of any other class or series of voting stock (including the Cyclerion Series B Preferred Stock), exclusively and voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect the balance of the total number of directors of Cyclerion. Each Preferred Director shall be entitled to three votes on each matter presented to the Cyclerion Board.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The holders of record of the shares of Korsana Series Seed Preferred Stock, voting together exclusively and as a separate class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, are entitled to elect four directors of Korsana (the &#8220;Series Seed Preferred Directors&#8221;). The holders of record of the shares of Series A Preferred Stock, voting together exclusively and as a separate class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, are entitled to elect one director (the &#8220;Series A Preferred Director&#8221;). The holders of record of the shares of common stock and of any other class or series of voting stock (including the Korsana preferred stock), exclusively and voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, shall be entitled to elect one director (the &#8220;At Large Director&#8221;).</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Removal of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of any series of preferred stock, at any special meeting of Cyclerion shareholders called at least in part for such purpose, any director may by the affirmative vote of the holders of at least a majority of the shares entitled to vote for the election of directors, be removed for cause. The Cyclerion Board may removal any director or directors, for cause, at a meeting of the Cyclerion Board by vote of a majority of directors then in office.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, any Preferred Director may be removed without cause only by the affirmative vote of the holders of a majority of the Cyclerion Series B Preferred Stock.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Any director may be removed, with or without cause, by the holders of a majority of shares of the class or series of capital stock entitled to elect such director, voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to common stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Vacancies on the Board of Directors</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subject to the rights of the holders of any series of preferred stock, any vacancies on the Cyclerion Board resulting from death, resignation, disqualification, removal or other causes, and any newly created directorships resulting from any increase in the number of directors, shall be filled exclusively by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Cyclerion Board, and not by the shareholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Any director may resign at any time upon notice given in writing or by electronic transmission to Korsana. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any director seat other than those required to be filled by a particular class or series of stockholders pursuant to the Korsana Charter can be filled by the vote or written consent in lieu of a meeting of a majority of the remaining director(s), although less than a quorum. Vacancies and newly created directorships resulting from any increase in</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">417 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such director&#8217;s successor shall have been elected and qualified.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Following the completion of the Merger, at all times when at least 30% of the originally issued Cyclerion Series B Preferred Stock remains issued and outstanding, any vacancies of a Preferred Director directorship resulting from death, resignation, disqualification, removal or other causes shall be filled by the affirmative vote of the holders of a majority of the Cyclerion Series B Preferred Stock.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">If the holders of shares of a class or series of stock entitled to elect one or more directors fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as such holders elect a person to fill such directorship.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Stockholder Action by Written Consent</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Any action required or permitted to be taken by the Cyclerion shareholders may be taken without a meeting if evidenced by consents signed by all Cyclerion shareholders entitled to vote on the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered to Korsana, a written consent signed by a sufficient number of stockholders to take action is delivered to Korsana.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Quorum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">At all meetings of stockholders, except where otherwise provided by statute or by the Cyclerion Articles or the Cyclerion Bylaws, at any meeting of Cyclerion shareholders, a majority of the votes entitled to be cast on a matter by a voting group shall constitute a quorum with respect to that voting group for action on that matter. In the absence of a quorum, any meeting of shareholders may be adjourned, from time to time, either by the chairperson of the meeting or by a majority of the votes cast on the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Except as otherwise provided by the DGCL or the Korsana Charter, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes. Where a separate vote by a class or series is required, a majority of the voting power of the shares of such class or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">418 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">quorum. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Special Meetings of Shareholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special meetings of the Cyclerion shareholders may be called, for any purpose as is a proper matter for shareholder action under the Cyclerion Articles, the Cyclerion Bylaws and the MBCA, by (i)&#160;subject to certain conditions, holders of at least forty percent (40%) of all the votes entitled to be cast on any issue to be considered at the proposed special meeting, or (ii)&#160;the Cyclerion Board pursuant to a resolution adopted by a majority of the directors at a meeting of directors where a quorum is present or by unanimous written consent of the Cyclerion Board.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cyclerion Board or an officer designed by the Cyclerion Board shall determine the time and place of such special meeting. Upon determination of the time and place of the meeting, the Cyclerion secretary shall cause a notice of meeting to be given to the Cyclerion shareholders entitled to vote, in accordance with the Cyclerion Bylaws. No business may be transacted as such special meeting other than the business specified in the notice of meeting. Special meetings called by Cyclerion shareholders will be scheduled not fewer than sixty (60)&#160;nor more than ninety (90)&#160;days after the date of delivery of a written request to the Cyclerion secretary for such meeting to be called by shareholders holding at least forty percent (40%) of the votes entitled to be cast on any issue to be considered at the proposed special meeting, subject to certain conditions in the Cyclerion Bylaws.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Korsana Board or the Chief Executive Officer if one is elected, or the President, and shall be held at such place, date, and time as they or he or she shall fix.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Notice of Shareholder Meetings</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of Cyclerion shareholders shall be given not less than seven (7)&#160;nor more than sixty (60)&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting. Notice of any special meeting requested by Cyclerion shareholders in accordance with the Cyclerion Bylaws shall be given in writing or electronic transmission with thirty (30)&#160;days of the date of delivery of a written request for such special meeting to be called. Notice delivered to Cyclerion shareholders of shareholder meetings will specify the date, place and time of such meeting and the purposes of such meeting.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Except as otherwise provided by the DGCL or the Korsana Charter, notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, shall be given not less than 10 days nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">419 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Advance Notice Requirements for Shareholder Proposals</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nominations of persons for election to the Cyclerion Board may be made at an annual meeting or special meeting of shareholders, and the proposal of business to be considered by the shareholders may be made at an annual meeting of shareholders, by any Cyclerion shareholder who was a shareholder of record at the time of giving the shareholder&#8217;s notice, who is entitled to vote at the meeting and who complied with the notice procedures set forth in the Cyclerion Bylaws. Such notice must be received by Cyclerion not later than the close of business on the ninetieth (90<sup style="font-size:75%; vertical-align:top">th</sup>) day no earlier than the close of business on the one hundred twentieth (120<sup style="font-size:75%; vertical-align:top">th</sup>) day prior to the first anniversary of the preceding year&#8217;s annual meeting, in the case of an annual meeting nomination, and not later than the close of business on the later of the ninetieth (90<sup style="font-size:75%; vertical-align:top">th</sup>) day prior to such meeting or the tenth (10<sup style="font-size:75%; vertical-align:top">th</sup>) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Cyclerion Board to be elected at such meeting, in the case of a special meeting nomination.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Neither the Korsana Charter nor the Korsana Bylaws contain advance notice requirements for stockholder proposals.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Amendment of Articles of Organization and Certificate of Incorporation</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Cyclerion Articles may be amended by the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment at a duly constituted meeting of shareholders called expressly for such purpose.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Korsana Charter may be amended pursuant to Section&#160;242 of the DGCL; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the holders of at least a majority of the outstanding shares of preferred stock, voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to common stock basis (the &#8220;Requisite Holders&#8221;), is required to (i)&#160;amend, alter or repeal of any provision of the Korsana Charter, (ii)&#160;create or issue any capital stock unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences or (iii)&#160;increase the authorized number of shares of preferred stock or any additional class or series of capital stock of Korsana unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Amendment of Bylaws</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Except as otherwise provided by law, the Cyclerion Bylaws may be adopted, amended or repealed by the Cyclerion Board. Any adoption, amendment or repeal of the Cyclerion Bylaws by the Cyclerion Board pursuant to a resolution adopted by a majority of the directors at a meeting of directors where a quorum is present or by unanimous written consent of the Cyclerion Board. The Cyclerion Bylaws may also be adopted, amended or</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Korsana Bylaws may be amended or repealed by the Korsana Board or by the stockholders; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the Requisite Holders is required (in addition to any other vote required by law or the Korsana Charter) to amend, alter or repeal any provision of the Korsana Bylaws.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">420 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">repealed by the shareholders votes cast in favor representing a majority of the votes entitled to be cast on the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Limitation on Director Liability</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Directors shall not be liable to Cyclerion or its shareholders for damages for any breach of fiduciary duty, except to the extent that the elimination or limitations of liability is not permitted under law.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Korsana Charter provides that, to the fullest extent permitted by law, a director or officer of Korsana shall not be personally liable to Korsana or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of Korsana shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Indemnification</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion will indemnify and hold harmless its directors and officers from and against any and all claims and liabilities to which he or she may be or become subject by reason of being or having been a director or officer of Cyclerion or by reason of alleged acts or omissions as a director or officer of Cyclerion, in each case, to the fullest extent permitted by applicable law and will reimburse each such officer and director for any and all legal and other expenses reasonably incurred in connection with such claims, whether or not such person has ceased to be a director or officer at or prior to the time such person is indemnified, held harmless or reimburse. These obligations to indemnify, hold harmless and reimburse directors and officers include payment by Cyclerion of expenses incurred in defending a civil or criminal action or proceeding in advance of the final disposition of such action or proceeding.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion will also indemnify and hold harmless persons who serve at Cyclerion&#8217;s express written request as directors or officers of another organization, if such entity fails, directly or through insurance, to cover such costs and expenses; provided that, such other entity will be the full indemnitor or insurer of first resort for any such liabilities, expenses or other losses and only thereafter will Cyclerion be required to pay indemnification or advancement of any such liabilities, expenses or other losses.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The rights conferred on any person by the Cyclerion Articles will be in addition to and not exclusive of any other rights to which any officer or director of Cyclerion may otherwise be lawfully entitled.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Korsana Charter (i)&#160;permits Korsana to indemnify, to the fullest extent permitted by applicable law, any director or officer of Korsana, and (ii)&#160;authorizes Korsana to indemnify, to the extent permitted by the DGCL, any employee or agent of Korsana, who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (for purposes of this paragraph, a &#8220;proceeding&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of Korsana or is or was serving at the request of Korsana as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such proceeding. Korsana is required to indemnify a director or officer in connection with a proceeding initiated by such person only if the proceeding was authorized by the Korsana Board.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Korsana Bylaws require Korsana to indemnify, to the fullest extent permitted by Delaware law, except in certain circumstances, each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (for purpose of this paragraph, a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director or an officer of Korsana or is or was</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">421 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">serving at the request of Korsana as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (for purpose of this paragraph, an &#8220;indemnitee&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee. The Korsana Bylaws also provide that an indemnitee will have the right to be paid by Korsana expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition, provided, however, that, if the DGCL requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer shall be made only upon delivery to Korsana of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses. The Korsana Bylaws also provide that the rights to indemnification and advancement of expenses shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Korsana Charter, the Korsana Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Conversion Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Cyclerion Series A Preferred Stock have the right to covert such shares into shares of Cyclerion Common Stock at any time at a ratio of 1 share of Cyclerion Series A Preferred Stock to 1 share of Cyclerion Common Stock.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">When Cyclerion Series B Preferred Stock is issued in connection with the Merger, the holders of Cyclerion Series B Preferred Stock will have the right to convert such shares into Cyclerion Common Stock at any time at a ratio of 1 share of Cyclerion Series B Preferred Stock to 1,000 shares of Cyclerion Common Stock, subject to certain limitations, including that a holder of Cyclerion Series B Preferred Stock is prohibited from converting shares of Cyclerion Series B Preferred Stock into shares of Cyclerion Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 19.99%) of the total number of shares of Cyclerion Common Stock issued and outstanding immediately after giving effect to such conversion.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Korsana Charter provides that holders of preferred stock have the right to convert such shares into shares of common stock, at the option of the holder, at any time, at a conversion rate in accordance with the terms set forth in the Korsana Charter. In addition, upon the earliest to occur of (i)&#160;immediately prior to the closing of the sale of shares of common stock to the public at a price of at least $4.00 per share (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm- commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $75,000,000 of gross proceeds, net of the underwriting discount and commissions, to Korsana and in connection with such offering the shares of Korsana Common Stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Korsana Board; (ii)&#160;immediately prior to the closing of a</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">422 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">business combination pursuant to which Korsana becomes a public company under the terms set forth in the Korsana Charter; and (iii)&#160;the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders, all outstanding shares of preferred stock will automatically be converted into shares of common stock at the then effective conversion rate as calculated in accordance with the Korsana Charter.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Right of First Refusal</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Certain stockholders party to the Korsana ROFR Agreement wishing to transfer any shares of Korsana capital stock (other than any shares of preferred stock or common stock that are issued or issuable upon conversion of preferred stock) must first provide Korsana with the right to purchase such shares. In such an event, if Korsana does not elect to exercise its right of first refusal in full, certain stockholders party to the Korsana ROFR Agreement have a secondary refusal right to purchase all or any portion of such shares of Korsana capital stock which are proposed for sale or transfer and not purchased by Korsana pursuant to its right of first refusal.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Right of <span style="white-space:nowrap">Co-Sale</span></span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Certain stockholders party to the Korsana ROFR Agreement have a right of <span style="white-space:nowrap">co-sale</span> with respect to any Korsana capital stock proposed to be transferred or sold that is not either purchased by Korsana by exercise of its right of first refusal (as further described above) or by any Korsana stockholder by exercise of their secondary refusal right (as further described above), each pursuant to the Korsana ROFR Agreement.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Preemptive Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Cyclerion shareholders do not have preemptive rights. Thus, if additional shares of Cyclerion Common Stock are issued, the current holders of Cyclerion Common Stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korsana stockholders do not have preemptive rights. Thus, if additional shares of Korsana Common Stock are issued, the current holders of Korsana Common Stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Distributions to Stockholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subject to preferences that may be applicable to any outstanding shares of Cyclerion preferred stock, the holders of Cyclerion Common Stock are entitled to receive ratably such dividends as may be declared by the Cyclerion Board out of legally available funds.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Korsana shall not declare, pay or set aside any dividends (other than dividends on shares of common stock payable in shares of common stock) unless holders of preferred stock first receive, or simultaneously receive, a dividend on each</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">423 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">outstanding share of preferred stock in an amount calculated in accordance with the Korsana Charter.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Exclusive Forum</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">The Cyclerion Articles provide that unless the Cyclerion Board consents in writing to the selection of an alternative forum, a state or federal court located within the Commonwealth of Massachusetts shall be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of Cyclerion; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Cyclerion to Cyclerion or its shareholders; (iii)&#160;any action asserting a claim against Cyclerion arising pursuant to any provision of the MBCA or any successor statute; or (iv)&#160;any action asserting a claim against Cyclerion governed by the internal affairs doctrine.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The Korsana Charter provides that, unless Korsana consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Korsana, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Korsana to Korsana or Korsana&#8217;s stockholders, (iii)&#160;any action asserting a claim against Korsana, its directors, officers or employees arising pursuant to any provision of the DGCL, the Korsana Charter or the Korsana Bylaws or (iv)&#160;any action asserting a claim against Korsana, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Korsana, except for, as to each of (i)&#160;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. These provisions may impose additional costs on Korsana&#8217;s stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, these provisions may limit Korsana&#8217;s stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with Korsana or its directors, officers or other employees, which may discourage such lawsuits against Korsana and its directors, officers and other employees even though an action, if successful, might benefit its stockholders.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Registration Rights</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than in connection with the Merger, Cyclerion shareholders do not have any registration rights.</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, Cyclerion will enter into the Registration Rights Agreement with the investors participating in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing, pursuant to which, among other things, the Combined</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Under the Korsana IRA, certain holders of Korsana capital stock that are party to the Korsana IRA, have certain registration rights, including the right to demand that Korsana file a registration statement, so called &#8220;demand&#8221; registration rights, or request that their shares be covered by a registration statement that Korsana is otherwise filing, <span style="white-space:nowrap">so-called</span></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">424 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company will agree to prepare and file a resale registration statement covering the resale of certain shares of Cyclerion Common Stock within 30 business days of the Closing pursuant to Rule 415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act. The Registration Rights Agreement also provides that the Combined Company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#8220;piggyback&#8221; registration rights. The registration rights granted under the Korsana IRA will terminate upon the earlier of: (i)&#160;the closing of a Deemed Liquidation Event (as such term is defined in the Korsana Charter), (ii) such time after Korsana&#8217;s initial public offering when all registrable securities could be sold under Rule 144 of the Securities Act or a similar exemption without limitation during a three-month period without registration or (iii)&#160;the third anniversary of Korsana&#8217;s initial public offering.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-style:italic">Share Transfer Restrictions Applicable to Shareholders</span></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Shares of Cyclerion Common Stock are transferable in the manner prescribed by the MBCA.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Transfers of shares of Korsana capital stock are subject to restrictions set forth in the Korsana Bylaws, Korsana ROFR Agreement and Korsana IRA.</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">425 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_38">PRINCIPAL SHAREHOLDERS OF CYCLERION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;30, 2026, Cyclerion had 4,330,314 shares of Cyclerion Common Stock issued and outstanding. The table below shows certain information about the beneficial ownership of Cyclerion Common Stock, as of March&#160;30, 2026, by:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of Cyclerion&#8217;s directors, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of Cyclerion&#8217;s named executive officers, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of Cyclerion&#8217;s directors and executive officers as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with SEC rules, Cyclerion has included in the column &#8220;Number of Shares Beneficially Owned&#8221; all shares of Cyclerion Common Stock over which the person has sole or shared voting or investment power as of March&#160;30, 2026, and all shares of Cyclerion Common Stock that the person has the right to acquire within 60 days after March&#160;30, 2026 through the exercise of any stock options. All shares that a person has a right to acquire within 60 days of March&#160;30, 2026 are deemed outstanding for the purpose of computing the percentage beneficially owned by the person, but are not deemed outstanding for the purpose of computing the percentage beneficially owned by any other person. Unless otherwise indicated, each person has the sole power (or shares the power with a spouse) to invest and vote the shares of Cyclerion Common Stock listed opposite the person&#8217;s name. Where applicable, ownership is subject to community property laws. Our inclusion of shares in this table as beneficially owned is not an admission of beneficial ownership of those shares by the person listed in the table. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of beneficial ownership in the table below is based on 4,330,314 shares of Common Stock outstanding plus 351,037 shares of Common Stock that may be issued upon conversion of shares of our preferred stock purchased by Dr.&#160;Hecht in May&#160;2023, each as of March&#160;30, 2026. The address of all named executive officers and directors is 245 First Street, 18th Floor, Cambridge, MA 02142. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name of Beneficial Owner</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number of<br/>Shares of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Beneficially</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Owned</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">Percentage<br/>of Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Named Executive Officers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Errol B. De Souza, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">52,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter M. Hecht, Ph.D.<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,021,224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael F. Higgins<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">30,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven E. Hyman, M.D.<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">23,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dina Katabi, Ph.D.<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regina M. Graul, Ph.D.<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">124,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rhonda M. Chicko<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All executive officers and directors as a group (7&#160;persons)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold">1,286,258</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">&#160;</span></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><span style="font-weight:bold">26.6</span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold">%&#160;</span></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Denotes less than 1% </p></td></tr></table> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This table is based upon information supplied by officers, directors and shareholders known by us to be beneficial owners of more than 5%&#160;of our Common Stock, information obtained from Schedules 13G or 13D filed with the SEC and based on information publicly available reporting beneficial ownership of our Common Stock. Unless otherwise noted below, no shareholder has had any position, office or other material relationship with us or any of our predecessors or affiliates within the past three years. </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 20,000 shares of Common Stock issued on November&#160;30, 2023 as restricted Common Stock for services as a member of the Company&#8217;s Board of Directors, of which 13,759 of these shares are vested through March&#160;30, 2026 and the remaining 6,241 shares vest ratably on a monthly basis through June&#160;1, 2027, provided that Dr.&#160;De Souza remains as a director of the Company on each such applicable vesting </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">426 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
date, subject to certain exemptions, (ii) 30,000 shares of Common Stock issued on November&#160;30, 2023 as restricted Common Stock for services as Chairman of the Board of Directors, of which 20,625 of these shares are vested through March&#160;30, 2026 and the remaining 9,375 shares vest ratably on a monthly basis through June&#160;1, 2027, provided that Dr.&#160;De Souza remains as Chairman of the Board of Directors of the Company on each such applicable vesting date subject to certain exemptions, and (iii)&#160;an additional 2,500 shares of Common Stock that underlie stock options that are currently exercisable or will be exercisable within the next 60 days. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 559,203 shares of Common Stock held directly by Dr.&#160;Hecht, (ii)&#160;an additional 110,984 shares of Common Stock that underlie stock options that are currently exercisable or will be exercisable within 60 days, and (iii) 351,037 shares of Common Stock that may be issued upon conversion of shares of our preferred stock purchased by Dr.&#160;Hecht in May&#160;2023. These shares of preferred stock have no voting rights but may be converted into our Common Stock by the holder at any time. The shares of Common Stock held directly by Dr.&#160;Hecht&#160;include (i) 20,000 shares of Common Stock issued on November&#160;30, 2023 as restricted Common Stock for services as a member of our Board, of which 13,759 shares are vested as of March&#160;30, 2026 and the remaining 6,241 shares vest ratably on a monthly basis through June&#160;1, 2027, provided that Dr.&#160;Hecht remains as a director of the Company on each such applicable vesting date, subject to certain exemptions, (ii) 15,000 shares of Common Stock issued on December&#160;1, 2023 as restricted Common Stock, of which 8,764 shares are vested as of March&#160;30, 2026 and the remaining 6,236 shares vest ratably on a monthly basis through November&#160;1, 2027, provided that Dr.&#160;Hecht remains as a consultant to or a director of the Company on each such applicable vesting date, subject to certain exemptions, and (iii)&#160;15,000&#160;shares of Common Stock issued on January&#160;2, 2024 as restricted Common Stock, of which 8,613 shares are vested as of March&#160;30, 2026 and the remaining 6,387 shares vest ratably through November&#160;1, 2027, provided that Dr.&#160;Hecht remains as a consultant to or a director of the Company on each such applicable vesting date, subject to certain exemptions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 10,740 shares of Common Stock held directly by Mr.&#160;Higgins, and (ii) 20,000 shares of Common Stock issued on November&#160;30, 2023 as restricted Common Stock for services as a member of the Company&#8217;s Board of Directors, of which 13,759 of these shares are vested as of March&#160;30, 2026 and the remaining 6,241 shares vest ratably on a monthly basis through June&#160;1, 2027, provided that Mr.&#160;Higgins remains as a director of the Company on each such applicable vesting date, subject to certain exemptions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 3,887 shares of Common Stock that underlie stock options that are currently exercisable or will be exercisable within 60 days (ii) 20,000 shares of Common Stock issued as restricted Common Stock on November&#160;30, 2023 for services as a member of the Company&#8217;s Board of Directors, of which 13,759 of these shares are vested as of March&#160;30, 2026 and the remaining 6,241 shares vest ratably on a monthly basis through June&#160;1, 2027, provided that Dr.&#160;Hyman remains as a director of the Company on each such applicable vesting date, subject to certain exemptions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 20,000 shares of Common Stock issued as restricted Common Stock on November&#160;30, 2023 for services as a member of the Company&#8217;s Board of Directors, of which 13,759 of these shares are vested as of March&#160;30, 2026 and the remaining 6,241 shares vest ratably on a monthly basis through June&#160;1, 2027 provided that Dr.&#160;Katabi remains as a director of the Company on each such applicable vesting date, subject to certain exemptions. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 50,000 shares of Common Stock issued to Dr.&#160;Graul as restricted Common Stock on December&#160;1, 2023, of which 32,491&#160;of the shares vested as of March&#160;30, 2026 and the remaining 17,509 shares vesting ratably through December&#160;1, 2027, provided that Dr.&#160;Graul remains as an employee of the Company on each such applicable vesting date, subject to certain exemptions, (ii) 50,000 shares of Common Stock issued to Dr.&#160;Graul as restricted Common Stock on January&#160;1, 2024, with 31,658 of the shares vested as of March&#160;30, 2026 and the remaining 18,342 shares vesting ratably through January&#160;1, 2028, subject to certain exemptions; and (iii)&#160;an option to acquire 55,849 shares of Common Stock with 24,423 shares exercisable or which will become exercisable within 60 days with the remainder vesting monthly through July&#160;2028. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 18 shares owned directly by Ms.&#160;Chicko and (ii)&#160;an option to acquire 25,000 shares of Common Stock with 13,466 shares exercisable or which will become exercisable within 60 days with the remainder vesting monthly through February&#160;2028. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">427 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_39">PRINCIPAL STOCKHOLDERS OF KORSANA </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information known to Korsana regarding beneficial ownership of Korsana capital stock on an <span style="white-space:nowrap">as-converted</span> to Korsana Common Stock basis as of April&#160;1, 2026 for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person or group of affiliated persons, who is known by Korsana to be the beneficial owner of more than 5% of Korsana capital stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of Korsana&#8217;s directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each Korsana named executive officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of Korsana&#8217;s executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to Korsana&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of the date of this table. Shares of Korsana Common Stock that an individual has the right to acquire within 60 days of the date of this table are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To Korsana&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The percentage of beneficial ownership shown prior to the Merger and Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing in the table below is based on 101,500,000 shares of Korsana Common Stock deemed to be outstanding as of the date of this table, assuming the conversion of all outstanding shares of Korsana Preferred Stock into shares of Korsana Common Stock. The following table does not reflect any shares of Korsana Common Stock or Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants that such holders have agreed to purchase in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">428 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address for each beneficial owner is c/o Korsana Biosciences, Inc., 203 Crescent Street, Bldgs. #3/3A/4, Suite 503, Waltham, MA 02453. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage<br/>of Shares<br/>Outstanding<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">5% or Greater Stockholders</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fairmount Healthcare Fund II, L.P.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities&#160;Affiliated&#160;with&#160;Venrock&#160;Healthcare Capital Partners<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,700,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with TCGX<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with J.P. Morgan Life Sciences Private Capital<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Wellington Management<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Sanofi Ventures<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Janus Henderson Investors<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Named Executive Officers and Directors</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Gottesdiener</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomas Kiselak<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michelle Pernice<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Violin<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,263,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Vignola</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Madelyn Zeylikman</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nimish Shah<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,700,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (7&#160;persons)<sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">47,318,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">45.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 22,500,000 shares of Korsana Common Stock issuable upon conversion of 10,000,000 shares of Korsana Series Seed Preferred Stock and 12,500,000 shares of Korsana Series A Preferred Stock held directly by Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount Fund II&#8221;). Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) serves as investment manager for Fairmount Fund II. Fairmount Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II&#8217;s portfolio. Because Fairmount Fund II has divested itself of voting and investment power over the securities it holds and may not revoke that delegation on less than 61 days&#8217; notice, Fairmount Fund II disclaims beneficial ownership of the securities it holds. As managers of Fairmount, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II. Fairmount, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 4,166,166 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCP EG&#8221;), (ii) 8,333,334 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by Venrock Healthcare Capital Partners XP, L.P. (&#8220;VHCP XP&#8221;) (iii) 627,840 shares of Korsana Common Stock issuable upon conversion of Korsana Series Seed Preferred Stock held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP III&#8221;), (iv) 62,720 shares of Korsana Common Stock issuable upon conversion of Korsana Series Seed Preferred Stock held by VHCP <span style="white-space:nowrap">Co-Investment</span> Holdings III, LLC (&#8220;VCHP <span style="white-space:nowrap">Co-III&#8221;),</span> (v) 4,000,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series Seed Preferred Stock held by VHCP XP, and (vi) 4,509,440 shares of Korsana Common Stock issuable upon conversion of Korsana Series Seed Preferred Stock held by VCHP EG. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">429 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
the sole general partner of VHCP EG. VHCP Management III, LLC (&#8220;VHCPM III&#8221;) is the sole general partner of VHCP III and the sole manager of VHCP <span style="white-space:nowrap">Co-III.</span> VHCP Management XP, LLC (&#8220;VHCPM XP&#8221;) is the sole general partner for VHCP XP. Dr.&#160;Bong Koh and Nimish Shah are the voting members of VHCPM III, VHCPM EG and VHCPM XP. Dr.&#160;Koh, Mr.&#160;Shah, VHCPM III, VHCPM EG and VHCPM XP disclaim beneficial ownership over all shares held by VHCP III, VHCP <span style="white-space:nowrap">Co-III,</span> VHCP EG and VHCP XP, except to the extent of their respective indirect pecuniary interests therein. The principal business address of each of the foregoing persons is 7 Bryant Park, 23rd Floor, New York, New York 10018. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 10,000,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by TCG Crossover Fund II, L.P. (&#8220;TCGX&#8221;). TCG Crossover GP II, LLC, the General Partner of TCGX, and Chen Yu, Managing Partner of TCG Crossover GP II, LLC, have shared voting and dispositive power over the securities held by TCGX. The address for each of TCGX, TCG Crossover GP II, LLC and Chen Yu is 245 Lytton Ave., Suite 350, Palo Alto, California 94301. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 8,530,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by 270 Life Sciences Private Capital Master Fund I <span style="white-space:nowrap">SCA-RAIF,</span> (ii) 1,240,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by 270 Life Sciences Private Capital Employee Fund I LP and (iii) 230,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by J.P. Morgan Growth Equity Division Holdings Inc. 270 Life Sciences Private Capital Master Fund I <span style="white-space:nowrap">SCA-RAIF</span> is duly represented and acting through its managing general partner (actionnaire g&#233;rant commandit&#233;), 270 Life Sciences Private Capital Fund I GP (Lux) S.&#224;.r.l. J.P. Morgan Growth Equity Division Holdings is the sole general partner of 270 Life Sciences Private Capital Employee Fund I LP. The address for each of these entities is 390 Madison Avenue, Floor 27, New York, NY 10172. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 7,500,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. (&#8220;Wellington Biomedical Fund&#8221;) and (ii) 500,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by Wellington Private Investments Opportunities SPV 2, LLC (&#8220;WPIO&#8221;). Wellington Management Company LLP, a registered investment adviser under the Investment Advisers Act of 1940, as amended (&#8220;WMC&#8221;), is the investment advisor to Wellington Biomedical Fund and WPIO. Wellington Biomedical Innovation II GP L.P. is the general partner of Wellington Biomedical Fund. Wellington Alternative Investments LLC (&#8220;WAI&#8221;) is the Manager of WPIO and Wellington Management Investment, Inc. is the Managing Member of WAI. WMC is an indirect subsidiary of Wellington Management Group LLP. Wellington Management Group LLP and WMC may be deemed beneficial owners with shared voting and investment power over the shares held by Wellington Biomedical Fund and WPIO. Additional information about WMC is available in its Form ADV filed with the SEC. The address of all entities referenced in this footnote is 280 Congress Street, Boston, MA 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 7,500,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by Sanofi Ventures LLC. The corporate address for Sanofi Ventures LLC is 100 Morris Street, Morristown, New Jersey 07960. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 7,500,000 shares of Korsana Common Stock issuable upon conversion of Korsana Series A Preferred Stock held by Janus Henderson Biotech Innovation Master Fund Limited (&#8220;Janus Master Fund&#8221;). Such shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC (&#8220;Janus&#8221;), an investment adviser registered under the Investment Advisers Act of 1940, as amended, who acts as investment adviser for Janus Master Fund and has the ability to make decisions with respect to the voting and disposition of the shares subject to the oversight of the board of directors of Janus Master Fund. Under the terms of its management contract with Janus Master Fund, Janus has overall responsibility for directing the investments of Janus Master Fund in accordance with the investment objective, policies, and limitations. Janus Master Fund has one or more portfolio managers appointed by and serving at the pleasure of Janus whom make decisions with respect to the disposition of the shares. The portfolio managers for Janus Master Fund are Andrew Acker, Daniel S. Lyons, and Agustin Mohedas. The business address of each of the aforementioned parties is c/o Janus Henderson Investors US LLC, 151 Detroit Street, Denver, Colorado 80206. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">430 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (a)&#160;vested options to acquire 49,190 shares of common stock and (b)&#160;options to acquire 5,787 shares of common stock that will vest within 60 days of the date of this table. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(9)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (a)1,000,000 shares of restricted common stock and (b)&#160;options to acquire 1,263,554 shares of common stock that will vest within 60 days of the date of this table. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(10)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See notes 1, 2, 8 and 9. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">431 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_40">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;3 of this proxy statement/prospectus</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding beneficial ownership of the Combined Company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on&#8195;&#8195;&#8195;&#8195;, 2026 for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person or group of affiliated persons, who is expected by Cyclerion and Korsana to be the beneficial owner of more than 5% of the Combined Company&#8217;s common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person expected to be a director of the Combined Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person expected to be a named executive officer of the Combined Company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of the Combined Company&#8217;s expected directors and executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to the Combined Company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of&#8195;&#8195;&#8195;&#8195;, 2026. Shares of the Combined Company&#8217;s common stock that an individual or entity has the right to acquire within 60 days of&#8195;&#8195;&#8195;&#8195;, 2026 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To Cyclerion&#8217;s and Korsana&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table lists applicable percentage ownership based on&#8195;&#8195;&#8195;&#8195;shares of common stock expected to be outstanding upon consummation of the Merger, after giving effect to the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing and prior to giving effect to the anticipated Cyclerion reverse stock split and includes&#8195;&#8195;&#8195;&#8195;shares of unvested restricted common stock. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60 days, including upon the exercise of stock options and warrants. These stock options and warrants shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the Combined Company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Merger, Cyclerion securityholders as of immediately prior to the Merger are expected to own approximately&#8195;&#8195;&#8195;&#8195;% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), and former holders of Korsana securities are expected to own approximately&#8195;&#8195;&#8195;&#8195;% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, Cyclerion&#8217;s Net Cash as of closing being equal to $&#8195;&#8195;&#8195;&#8195;. There can be no assurances any of these assumptions will be accurate at closing when the final Exchange Ratio is determined. The table below assumes that, based on Cyclerion&#8217;s and Korsana&#8217;s capitalization as of&#8195;&#8195;&#8195;&#8195;, 2026, the Exchange Ratio is estimated to be equal to approximately&#8195;&#8195;&#8195;&#8195;shares of Cyclerion Common Stock for each share of Korsana Common Stock, prior to giving effect to the anticipated Cyclerion reverse stock split. The estimated Exchange Ratio was derived on a fully-diluted basis, using a stipulated value of Korsana of $268.4&#160;million and of Cyclerion of $10&#160;million, assuming Net Cash of $&#8195;&#8195;&#8195;&#8195;as of Closing. The final Exchange Ratio is subject to adjustment prior to the closing of the Merger based upon Cyclerion&#8217;s Net Cash at Closing and the aggregate proceeds from the sale of Korsana Common Stock and Korsana <span style="white-space:nowrap">Pre-Funded</span> Warrants in the Korsana <span style="white-space:nowrap">Pre-Closing</span> Financing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">432 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address for each beneficial owner is c/o Korsana Biosciences, Inc., 203 Crescent Street, Bldgs. #3/3A/4, Suite 503, Waltham, MA 02453. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage<br/>of Shares<br/>Outstanding<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><span style="font-weight:bold"><span style="font-style:italic">5% or Greater Stockholders</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic">Named Executive Officers and Directors</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; persons)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">433 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_41">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ropes&#160;&amp; Gray LLP will pass upon the validity of the securities offered by this proxy statement/prospectus. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_42">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Cyclerion Therapeutics, Inc. at December&#160;31, 2025 and 2024, and for each of the two years in the period ended December&#160;31, 2025, included in the Proxy Statement of Cyclerion Therapeutics, Inc., which is referred to and made a part of this Prospectus and Registration Statement, have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about Cyclerion Therapeutics, Inc.&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Korsana Biosciences, Inc. at December&#160;31, 2025 and 2024, and for the year ended December&#160;31, 2025 and the period from November&#160;8, 2024 (inception) to December&#160;31, 2024, included in the Proxy Statement of Cyclerion Therapeutics, Inc., which is referred to and made a part of this Prospectus and Registration Statement, have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">434 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_43">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and current reports, proxy statements, and other information with the SEC electronically, and the SEC maintains a website that contains Cyclerion&#8217;s filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <span style="font-style:italic">www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion also makes available free of charge on or through its website at <span style="font-style:italic">www.cyclerion.com</span>, its Annual Reports on Form <span style="white-space:nowrap">10-K,</span> Quarterly Reports on Form <span style="white-space:nowrap">10-Q,</span> Current Reports on Form <span style="white-space:nowrap">8-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Cyclerion electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Cyclerion are inactive textual references and except as specifically incorporated by reference into this proxy statement/prospectus, information on those websites is not part of this proxy statement/prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion has filed with the SEC a registration statement on Form <span style="white-space:nowrap">S-4,</span> of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of Cyclerion Common Stock (including the shares of Cyclerion Common Stock issuable upon conversion of Cyclerion Series B Preferred Stock) to be issued to Korsana stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about Cyclerion and Cyclerion Common Stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules and regulations of the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyclerion has supplied all information contained in this proxy statement/prospectus relating to Cyclerion and Korsana has supplied all information contained in this proxy statement/prospectus relating to Korsana. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to request documents from Cyclerion or Korsana, please send a request in writing or by telephone to either Cyclerion or Korsana at the following addresses: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center">Cyclerion Therapeutics, Inc.<br/>245 First Street, 18th Floor<br/>Cambridge, MA 02142<br/>Attn: Secretary<br/>Tel: (857) <span style="white-space:nowrap">327-8778</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Korsana Biosciences, Inc.<br/>203 Crescent Street, Bldgs. #3/3A/4, Suite 503</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Waltham, MA 02453<br/>Attn: Secretary</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Tel: (781) <span style="white-space:nowrap">516-2325</span></p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cyclerion has filed its Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2025 with the SEC. It is available free of charge at the SEC&#8217;s web site at www.sec.gov. Upon written request by a Cyclerion shareholder, Cyclerion will mail without charge a copy of its Annual Report on Form <span style="white-space:nowrap">10-K,</span> including the financial statements, but excluding exhibits to the Annual Report on Form <span style="white-space:nowrap">10-K.</span> Exhibits to the Annual Report on Form <span style="white-space:nowrap">10-K</span> are available upon payment of a reasonable fee, which is limited to Cyclerion&#8217;s expenses in furnishing the requested exhibit. All requests should be directed to Cyclerion&#8217;s Secretary, 245 First Street, 18th Floor, Cambridge, MA 02142 . </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a Cyclerion shareholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact, &#8195;&#8195;&#8195;, at the following telephone number: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Banks and Brokers Call: &#8195;&#8195;&#8195; </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Stockholders Call Toll Free: &#8195;&#8195;&#8195; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">435 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx111069_44">SHAREHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2027 ANNUAL MEETING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Bylaws provide that, for shareholder nominations to the Cyclerion Board at an annual meeting of shareholders, the shareholder must have given timely notice thereof in writing to the Secretary at Cyclerion Therapeutics, Inc., 245 First Street, 18th Floor, Cambridge, MA 02142. To be timely for the 2027 annual meeting of shareholders, the shareholder&#8217;s notice must be delivered to us not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the anniversary date of the prior year&#8217;s annual meeting of shareholders, except that if the 2027 annual meeting of shareholders is set for a date that is more than 30 days before or after such anniversary date, Cyclerion must receive the notice not later than the close of business on the 60th day prior to the date of the annual meeting (provided that, if fewer than 65 days&#8217; notice or prior public disclosure of the date of the 2027 annual meeting of shareholders is given or made to the shareholders, notice by the shareholder to be timely must be so received no later than the close of business on the 15th day following the day of such notice or public disclosure). Assuming the date of Cyclerion&#8217;s 2027 annual meeting of shareholders is not so advanced or delayed, shareholders who wish to make a proposal or a director nomination for the 2027 annual meeting of shareholders must notify Cyclerion no earlier than&#8195;&#8195;&#8195;&#8195;, 2027 and no later than&#8195;&#8195;&#8195;&#8195;, 2027. Such notice must provide certain information about the director nominees, as provided in the Cyclerion Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other shareholder proposals to be considered at an annual meeting of Cyclerion shareholders, the Cyclerion Bylaws provide that the shareholder must, in addition to any other applicable requirements, comply with the requirements of Rule <span style="white-space:nowrap">14a-8</span> of the Exchange Act. Shareholder proposals submitted pursuant to Rule <span style="white-space:nowrap">14a-8</span> of the Exchange Act must be received no later than the close of business on&#8195;&#8195;&#8195;&#8195;, 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to satisfying the foregoing requirements of the Cyclerion Bylaws, to comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees other than the Cyclerion&#8217;s nominees for the 2027 annual meeting of shareholders must provide notice that sets forth the information required by Rule <span style="white-space:nowrap">14a-19</span> under the Exchange Act </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Availability of Bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Cyclerion Bylaws may be obtained by accessing Cyclerion&#8217;s filings on the SEC&#8217;s website at <span style="font-style:italic">www.sec.gov</span>. You may also contact Cyclerion&#8217;s corporate secretary at Cyclerion&#8217;s principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Householding of Proxy Materials </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single set of the proxy materials addressed to those shareholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for shareholders and cost savings for companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Cyclerion Shareholders Meeting, a number of brokers with account holders who are Cyclerion shareholders will be &#8220;householding&#8221; the proxy materials. A single set of the proxy materials will be delivered to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of the proxy materials, please notify your broker or Cyclerion. Direct your written request to Secretary at Cyclerion Therapeutics, Inc., 245 First Street, 18th Floor, Cambridge, MA 02142. Cyclerion undertakes to promptly deliver a separate set of the proxy materials upon receiving your written request. Shareholders who currently receive multiple copies of the proxy materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">436 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:DefinedContributionPlanTypeExtensibleList" id="hidden167030863" contextRef="P01_01_2025To12_31_2025">http://fasb.org/us-gaap/2025#QualifiedPlanMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd"/></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div id="tx111069_45" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">INDEX TO CYCLERION THERAPEUTICS, INC.&#8217;S FINANCIAL STATEMENTS </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Years Ended December 31, 2025 and 2024 </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 96%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_1">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_2">Consolidated Balance Sheets as of December&#160;31, 2025 and 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_3">Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2025 and 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_4">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2025 and 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_5">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2025 and 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_6">Notes to the Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Three Months Ended March 31, 2026 and 2025 </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_6a" style="display:inline;">Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_6b" style="display:inline;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-26</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_6c" style="display:inline;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-27</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_6d" style="display:inline;">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-28</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_6e" style="display:inline;">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-29</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">INDEX TO KORSANA BIOSCIENCES, INC.&#8217;S FINANCIAL STATEMENTS </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Years Ended December 31, 2025 and 2024 </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_7" style="display:inline;">Report of Independent Registered Public Accounting Firm (PCAOB ID# 00042)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_8" style="display:inline;">Consolidated Balance Sheets as of December&#160;31, 2025 and 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_9" style="display:inline;">Consolidated Statements of Operations and Comprehensive Loss for the Year Ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (Inception)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-46</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_10" style="display:inline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity for the Year Ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (Inception) to December&#160;31, 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-47</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_11" style="display:inline;">Consolidated Statements of Cash Flows for the Year Ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (Inception) to December&#160;31, 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_12" style="display:inline;">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Three Months Ended March 31, 2026 and 2025 </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_13" style="display:inline;">Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-74</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_14" style="display:inline;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-75</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_15" style="display:inline;">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-76</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_16" style="display:inline;">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-77</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_17" style="display:inline;">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">F-78</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-1 </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin111069_1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Report of Independent Registered Public Accounting Firm </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To the Shareholders and the Board of Directors of Cyclerion Therapeutics, Inc. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Opinion on the Financial Statements </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have audited the accompanying consolidated balance sheets of Cyclerion Therapeutics, Inc. (the Company) as of December&#160;31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December&#160;31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December&#160;31, 2025, in conformity with U.S. generally accepted accounting principles. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s Ability to Continue as a Going Concern </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations, has limited financial resources, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis for Opinion </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Critical Audit Matter </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">opinion on the consolidated&#160;financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 22%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 76%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Assessment of indicators of impairment of investment in Tisento Therapeutics Holdings Inc.</div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Description of the Matter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As discussed in Notes 2 and 4 to the consolidated financial statements, as of December&#160;31, 2025, the Company had recognized an Other investment of $5.4&#160;million which was accounted for as a financial instrument without a readily determinable fair value. Such investment was recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment was measured at cost less any impairment recorded or adjustments for observable price changes. As of December&#160;31, 2025, no impairment loss was recognized.</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Auditing the Company&#8217;s assessment of indicators of impairment of the Other investment was complex and required significant judgment in applying our audit procedures and in the evaluation of the results of the procedures performed to determine if any impairment indicators were present. In addition, there was a significant degree of subjectivity in evaluating the relevance and reliability of the audit evidence obtained.</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">How We Addressed the Matter in Our Audit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">We performed audit procedures to test management&#8217;s evaluation of events or changes in circumstances that might be indicators of impairment of the Company&#8217;s Other investment. Such procedures included, among others: (i)&#160;evaluating the appropriateness of management&#8217;s assessment of indicators of impairment; (ii)&#160;independently obtaining and assessing evidence, including from external sources, to corroborate management&#8217;s judgments and evaluating contrary evidence; (iii)&#160;reading the minutes of the Company&#8217;s Board of Directors meetings; and (iv)&#160;performing inquiries of management of Tisento Therapeutics Holdings Inc. and the Company regarding their knowledge of impairment indicators.</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have served as the Company&#8217;s auditor since 2018. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Boston, Massachusetts </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">March&#160;30, 2026 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div> <div id="fin111069_2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Consolidated Balance Sheets </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">(In thousands, except share and per share data)</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60792">3,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60793">3,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60794">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60795">556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60796">384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60797">421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60798">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60799">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60800">4,635</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60801">4,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60802">5,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60803">5,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60804">9,985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60805">9,575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60806">508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60807">390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:AccruedResearchAndDevelopmentCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60808">198</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:AccruedResearchAndDevelopmentCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60809">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60810">194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60811">283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60812">900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60813">725</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (Note 6)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60814">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60815">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock, <ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2025" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-60816"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-60817">no</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60818"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60819">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60820"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60821"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60822"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60823">351,037</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Series A convertible preferred stock issued and outstanding at December&#160;31, 2025 and 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60824">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60825">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2025" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-60826"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-60827">no</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60828"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60829">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2025 and 2024; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60830">3,925,314</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60831">2,710,096</ix:nonFraction> shares issued at December&#160;31, 2025 and 2024, respectively; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60832">3,821,236</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60833">2,545,922</ix:nonFraction> shares outstanding at December&#160;31, 2025 and 2024, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60834">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60835">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60836">280,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60837">276,342</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60838">271,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60839">267,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60840">9,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60841">8,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities and stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60842">9,985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60843">9,575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Th</div>e accompanying notes are an integral part of these consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-4 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div> <div id="fin111069_3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">(In thousands, except per share data)</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 84%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenues:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenue from license agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To12_31_2025_LicenseAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60844">1,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To12_31_2024_LicenseAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60845">1,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenue from purchase agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To12_31_2025_PurchaseAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60846">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To12_31_2024_PurchaseAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60847">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenue from option agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To12_31_2025_OptionAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60848">274</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To12_31_2024_OptionAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60849">250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60850">2,074</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60851">2,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cost and expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60852">959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60853">286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60854">6,088</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60855">5,342</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total cost and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60856">7,047</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60857">5,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60858">4,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60859">3,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60860">128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60861">208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gain from settlement of account payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:GainLossFromSettlementOfAccountPayable" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60862">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:GainLossFromSettlementOfAccountPayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60863">363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gain from insurance recovery</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60864">1,317</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60865">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60866">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60867">571</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60868">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60869">3,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-60870"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-60871">1.11</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-60872"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-60873">1.21</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60874"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60875">3,181</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60876"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60877">2,518</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other comprehensive loss:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60878">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60879">3,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other comprehensive loss:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign currency translation adjustment loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60880">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60881">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60882">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60883">3,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The</div> accompanying notes are an integral part of these consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-5 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div> <div id="fin111069_4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Consolidated Statements of Stockholders&#8217; Equity </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;">(In thousands, except share data)</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 34%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated<br/> other<br/> comprehensive</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total<br/> Stockholders&#8217;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2023</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60884">2,474,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60885">351,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60886">275,717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60887">264,417</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60888">12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60889">11,288</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60890">3,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60891">3,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Vesting of restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60892">71,763</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense related to issuance of stock options and restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60893">625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60894">625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60895">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60896">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Release of foreign currency translation adjustment upon liquidation of a subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment" contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60897">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment" contextRef="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60898">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60899">2,545,922</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60900">351,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60901">276,342</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60902">267,492</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60903">8,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock - private placement, net of issuance cost</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60904">499,998</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60905">1,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60906">1,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock - ATM</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60907">715,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60908">2,077</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60909">2,077</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60910">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60911">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Vesting of restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60912">60,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense related to issuance of stock options and restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60913">441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60914">441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60915">3,821,236</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60916">351,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60917">280,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60918">271,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60919">9,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">The</div> accompanying notes are an integral part of these consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-6 </div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div> <div id="fin111069_5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Consolidated Statements of Cash Flows </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 84%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CASH FLOWS FROM OPERATING ACTIVITIES:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60920">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60921">3,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Gain from settlement of account payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:GainLossFromSettlementOfAccountPayable" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60922">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="ck0001755237:GainLossFromSettlementOfAccountPayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60923">363</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60924">441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60925">625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60926">444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60927">556</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60928">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60929">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60930">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60931">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60932">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60933">445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60934">146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60935">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60936">89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60937">515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60938">3,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60939">4,333</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CASH FLOWS FROM FINANCING ACTIVITIES:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from ATM</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:ProceedsFromAtTheOffer" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60940">2,077</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:ProceedsFromAtTheOffer" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60941">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from private placement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60942">1,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60943">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance costs paid for private placement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="ck0001755237:IssuanceCostsPaidForPrivatePlacement" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60944">130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:IssuanceCostsPaidForPrivatePlacement" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60945">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60946">3,322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60947">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effect of exchange rate changes on cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-60948">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60949">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net increase (decrease) in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60950">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-60951">4,339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents, beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60952">3,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60953">7,571</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents, end of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60954">3,240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60955">3,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Th</div>e accompanying notes are an integral part of these consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-7 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div> <div id="fin111069_6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Notes to the Consolidated Financial Statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div><ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030589" id="ixv-32792"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Nature of Business </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nature of Operations </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Cyclerion Therapeutics, Inc. (&#8220;Cyclerion&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221;) became an independent public company on April&#160;1, 2019 after Ironwood Pharmaceuticals, Inc. completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">tax-free</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">spin-off</div> of their sGC business. Cyclerion has one employee as of December&#160;31, 2025 and also relies on a team of specialist consultants for its operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion is focused on building a new pipeline of innovative therapeutics to address serious neuropsychiatric diseases. The Company&#8217;s current strategic focus is centered on the development of a novel therapeutic approach for treatment-resistant depression (&#8220;TRD&#8221;), which represents a substantial clinical and commercial opportunity. Over the past year, the Company has refined its strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CYC-126,</div> an individualized therapy for TRD as its foundational development program. In September 2025, the Company entered into a license agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) for intellectual property supporting this program (see Note 11), and in January 2026 entered into a collaboration and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">option-to-license</div></div> agreement with Medsteer SAS (&#8220;Medsteer&#8221;) to access certain technology, data assets, and technical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> related to drug delivery and physiological monitoring. The Company is advancing development planning, regulatory strategy, and commercial positioning for this program and intends to initiate a Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">proof-of-concept</div></div> study in Australia in the second half of 2026. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In parallel with the advancement of its neuropsychiatric strategy, Cyclerion continues to evaluate opportunities related to its legacy soluble guanylate cyclase (&#8220;sGC&#8221;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions designed to maximize shareholder value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. (&#8220;Akebia&#8221;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a&#160;$<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60956">3.0</ix:nonFraction> million&#160;upfront payment to the Company upon signing of the license agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;13, 2024, Cyclerion announced that Cyclerion and Akebia have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-negotiated</div> a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator.&#160;Under this new license amendment, Cyclerion will receive&#160;$<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-60957">1.75</ix:nonFraction> million&#160;in amendment payments, of which $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-60958">1.25</ix:nonFraction>&#160;million was paid in December 2024 and an additional payment of $<ix:nonFraction name="ck0001755237:RemainingAdditionalUpFrontPayment" contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60959">0.5</ix:nonFraction>&#160;million was received in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated (defined as first patient dosed) Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis&#160;(&#8220;FSGS&#8221;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $<ix:nonFraction name="ck0001755237:DevelopmentMilestonePayment" contextRef="P12_01_2025To12_01_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60960">1.0</ix:nonFraction>&#160;million development milestone payment would be due to us and it was received in February 2026. The Company is eligible to receive additional milestone cash payments of up to approximately&#160;$<ix:nonFraction name="ck0001755237:PaymentOfCashMilestone" contextRef="P01_01_2025To12_31_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60961">557.5</ix:nonFraction> million&#160;in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher-tiered sales-based royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single-digits</div> to twenty percent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-8</ix:exclude></div></div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_167030589" continuedAt="TextSelectionAppend_167030589_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030589_1" continuedAt="TextSelectionAppend_167030589_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030589_2" continuedAt="TextSelectionAppend_167030589_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030589_3" continuedAt="TextSelectionAppend_167030589_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $<ix:nonFraction name="ck0001755237:OptionFee" contextRef="P08_01_2024To08_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-60963">150,000</ix:nonFraction> in August 2024 and subsequent fees totaling $<ix:nonFraction name="ck0001755237:SubsequentFees" contextRef="P08_01_2024To08_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-60964">80,000</ix:nonFraction> to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company is currently exploring potential license opportunities for olinciguat. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Zagociguat is a clinical-stage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-penetrant</div> sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-targeted</div> sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. On July&#160;28, 2023, the Company sold <div style="display:inline;">z</div>agociguat and CY3018 to Tisento Therapeutics, Inc. (&#8220;Tisento&#8221;), a newly formed private company focused on their development, in exchange for $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P07_28_2023To07_28_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60965">8.0</ix:nonFraction>&#160;million in cash consideration, $<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_28_2023To07_28_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60966">2.4</ix:nonFraction>&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-60967">10</ix:nonFraction>% of all of Tisento&#8217;s parent&#8217;s outstanding equity securities (&#8220;Tisento Parent&#8221;). </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Cyclerion GmbH, a wholly owned subsidiary, was incorporated in Zug, Switzerland on May&#160;3, 2019. The functional currency is the Swiss franc. Cyclerion GmbH was liquidated and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">de-registered</div> in May 2024. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Securities Corporation, a wholly owned subsidiary, was incorporated in Massachusetts on November&#160;15, 2019 and was granted securities corporation status in Massachusetts. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Purchase Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2023, the Company entered into a stock purchase agreement with the Company&#8217;s former Chief Executive Officer (the &#8220;CEO&#8221;) pursuant to which he invested $<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-60968">5</ix:nonFraction>&#160;million in cash for <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-60969">225,000</ix:nonFraction> shares of common stock and <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-60970">351,037</ix:nonFraction> shares of Series A Convertible Preferred Stock of the Company at a price of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-60971">8.68</ix:nonFraction> per share (after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">1-for-20</div></div> reverse stock split the Company implemented on May&#160;15, 2023). The Series A Convertible Preferred Stock is convertible into shares of the Company&#8217;s common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">one-to-one</div></div> basis. The closing of the equity investment took place on May&#160;19, 2023, and (to comply with Nasdaq listing requirements) the Company&#8217;s shareholders approved such convertibility on July&#160;19, 2023. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025 Equity Private Placement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;21, 2025, the Company entered into a Stock Purchase Agreement (the &#8220;2025 Equity Private Placement&#8221;) for a private placement of <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-60972">499,998</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-60973">2.75</ix:nonFraction> per share for total gross proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="6" format="ixt:num-dot-decimal" id="ixv-60974">1.375</ix:nonFraction>&#160;million. The closing of the 2025 Equity Private Placement occurred on March&#160;25, 2025. The Company incurred transaction costs of $<ix:nonFraction name="ck0001755237:TransactionCostsSaleOfTransferredAssets" contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60975">0.1</ix:nonFraction>&#160;million for the 2025 Equity Private Placement. The Shares issued were not registered under the Securities Act of 1933, as amended, or any state securities laws and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act as a transaction not involving a public offering. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the 2025 Equity Private Placement, the Company entered into a Registration Rights Agreement with the investors, dated March&#160;21, 2025, pursuant to which the Company agreed to register the resale of the Shares pursuant to a registration statement which was filed with the SEC and declared effective by the SEC on May&#160;15, 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">At-the-Market</div></div> Offering </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;4, 2025, the Company filed a Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> (the &#8220;Shelf&#8221;) with the Securities and Exchange <div style="display:inline;">Commission</div> (the &#8220;SEC&#8221;) in relation to the registration of common stock, preferred </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><ix:exclude><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-9</div></ix:exclude></div><div style="margin-top: 1em; margin-bottom: 1em"></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_167030589_4" continuedAt="TextSelectionAppend_167030589_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030589_5" continuedAt="TextSelectionAppend_167030589_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030589_6" continuedAt="TextSelectionAppend_167030589_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030589_7" continuedAt="TextSelectionAppend_167030589_8"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $<ix:nonFraction name="ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice" contextRef="PAsOn02_04_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60976">25.0</ix:nonFraction>&#160;million.&#160;The Registration Statement was declared effective by the SEC in February 2025. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On May&#160;7, 2025, the Company and Guggenheim Securities, LLC (&#8220;Guggenheim Securities&#8221;) entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the &#8220;Shares&#8221;), having an aggregate offering price of up to $<ix:nonFraction name="ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice" contextRef="PAsOn05_07_2025_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-60977">20,000,000</ix:nonFraction> from time to time through or to Guggenheim Securities, acting as the Company&#8217;s agent, subject to the application of General Instruction I.B.6 of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Form&#160;S-3&#160;(&#8220;Instruction</div> I.B.6&#8221;) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company will pay Guggenheim Securities cash commission of <ix:nonFraction name="ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" contextRef="P05_07_2025To05_07_2025" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-60978">3.0</ix:nonFraction>% of the gross proceeds of the Shares sold under the Sales Agreement. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2025, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-60979">715,220</ix:nonFraction> shares of its common stock for net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60980">2.1</ix:nonFraction>&#160;million under the Sales Agreement, after deducting commissions paid to Guggenheim Securities of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60981">0.1</ix:nonFraction>&#160;million. </div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-32892"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#8217;s financial position and the results of its operations for the fiscal years presented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation and Cyclerion GmbH which was dissolved in May 2024. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. </div></div> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At each reporting period, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> Going Concern, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> the future receipt of potential funding from future partnerships, equity or debt issuances, certain cost reduction measures and the potential milestones from the Akebia agreement cannot be considered probable at this time because these plans are not entirely within the Company&#8217;s control and/or have not been approved by the Board of Directors as of the date of these consolidated financial statements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-10</ix:exclude></div></div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_167030589_8" continuedAt="TextSelectionAppend_167030589_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030589_9" continuedAt="TextSelectionAppend_167030589_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030589_10" continuedAt="TextSelectionAppend_167030589_11"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030589_11"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company expects that its cash and cash equivalents as of December&#160;31, 2025, will be sufficient to fund operations through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-2026,</div> however the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements <div style="letter-spacing: 0px; top: 0px;display:inline;">have </div>been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. </div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030588" id="ixv-32926"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Summary of Significant Accounting Policies </div></div> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-32929"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Segment Information </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.&#160;The Company&#8217;s president and chief executive officer, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews the Company&#8217;s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews net loss, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-operating</div> expenses and operating expenses excluding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> stock based compensation expense. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ConsolidationVariableInterestEntityPolicy" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-32935"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Variable Interest Entities </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii)&#160;the parties&#8217; contractual rights and responsibilities pursuant to any contractual agreements and (iii)&#160;which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements at the time that determination is made. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-32940"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Investment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for an identical or a similar investment of the same issuer, the Company will measure the equity security at fair value as of the date that the observable transaction occurred in accordance with ASC Topic 321, Investments-Equity Securities. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030557" id="ixv-32945"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of consolidated financial statements in accordance with U.S. generally accepted <div style="display:inline;">accounting</div> principles (&#8220;GAAP&#8221;) requires the Company&#8217;s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-11</ix:exclude></div></div> </ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_167030557" continuedAt="TextSelectionAppend_167030557_1"><ix:continuation id="TextSelection_167030588" continuedAt="TextSelectionAppend_167030588_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_1" continuedAt="TextSelectionAppend_167030588_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_2" continuedAt="TextSelectionAppend_167030588_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030588_3" continuedAt="TextSelectionAppend_167030588_4"><ix:continuation id="TextSelectionAppend_167030557_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company&#8217;s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period <div style="display:inline;">in</div> which they become known. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-32974"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and Cash Equivalents </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-32979"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair Value of Investment Instruments </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1 &#8212; Quoted prices in active markets for identical assets or liabilities. </div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2 &#8212; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </div></div></td></tr></table> </ix:nonNumeric> <div style="clear:both;max-height:0pt;"></div> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33017"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign Currency Translation Adjustment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The functional currency of the Company&#8217;s former foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company&#8217;s former foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company&#8217;s former foreign subsidiary was included as a foreign currency translation adjustment in the consolidated statements of stockholders&#8217; equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measurement</div> of intercompany balances are recorded in the consolidated statements of operations. </div> </ix:nonNumeric><ix:nonNumeric name="ck0001755237:RelatedPartyAccountsReceivablePolicyPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030553" id="ixv-33024"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts Receivable </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-12</ix:exclude></div></div></ix:nonNumeric></ix:continuation> </div></div><ix:continuation id="TextSelection_167030553" continuedAt="TextSelectionAppend_167030553_1"><ix:continuation id="TextSelectionAppend_167030588_4" continuedAt="TextSelectionAppend_167030588_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_5" continuedAt="TextSelectionAppend_167030588_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_6" continuedAt="TextSelectionAppend_167030588_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030588_7" continuedAt="TextSelectionAppend_167030588_8"><ix:continuation id="TextSelectionAppend_167030553_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">significant outstanding invoices. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had <div style="display:inline;">significant</div> write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December&#160;31, 2025 or 2024. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33052"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenue </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (&#8220;ASC 606&#8221;), it performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1)&#160;license agreement, (2)&#160;purchase agreement and (3)&#160;option to license agreement which are fully described in Note 11, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">License and Option Agreement</div></div>. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33060"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Costs </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33067"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and Administrative Expenses </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel and outside consultants providing the Company&#8217;s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company&#8217;s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030586" id="ixv-33072"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income taxes </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is primarily subject to U.S. Federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-13</ix:exclude></div></div></ix:nonNumeric></ix:continuation> </div></div><ix:continuation id="TextSelection_167030586" continuedAt="TextSelectionAppend_167030586_1"><ix:continuation id="TextSelectionAppend_167030588_8" continuedAt="TextSelectionAppend_167030588_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_9" continuedAt="TextSelectionAppend_167030588_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_10" continuedAt="TextSelectionAppend_167030588_11"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030588_11" continuedAt="TextSelectionAppend_167030588_12"><ix:continuation id="TextSelectionAppend_167030586_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;more-likely-than-not&#8221;</div> of being sustained by the applicable tax authority. Tax positions not deemed to meet a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion&#8217;s income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December&#160;31, 2025, and 2024. The Company&#8217;s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December&#160;31, 2025 and 2024, the Company has <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-60986"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-60987">no</ix:nonFraction></ix:nonFraction> accruals for interest or penalties related to income tax matters. </div></ix:continuation><ix:nonNumeric name="ck0001755237:PatentCostsPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33102"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent Costs </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $<ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2025To12_31_2025_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60988">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2024To12_31_2024_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60989">0.6</ix:nonFraction>&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. </div></div> </ix:nonNumeric><ix:nonNumeric name="ck0001755237:InterestAndOtherIncomePolicyPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33107"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest and Other Income, Net </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the year ended December&#160;31, 2025 and 2024, interest and other income, net consisted of a $<ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60990">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="P01_01_2024To12_31_2024_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-60991">0.2</ix:nonFraction>&#160;million of interest income related to interest generated from the Company&#8217;s cash and cash equivalents balances, respectively. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33112"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Subsequent Events </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company considers events or transactions that have occurred after the balance sheet date of December&#160;31, 2025, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K.</div> See Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events</div></div>. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030582" id="ixv-33119"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December&#160;31, 2025 and 2024, that had a material effect on its consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2025, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2025-05,</div> Financial Instruments&#8212;Credit Losses (Topic 326), which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with its annual report for fiscal 2027. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-14</ix:exclude></div></div></ix:nonNumeric></ix:continuation> </div></div><div style="text-align: center;"><ix:continuation id="TextSelection_167030582" continuedAt="TextSelectionAppend_167030582_1"><ix:continuation id="TextSelectionAppend_167030588_12" continuedAt="TextSelectionAppend_167030588_13"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_13" continuedAt="TextSelectionAppend_167030588_14"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030588_14" continuedAt="TextSelectionAppend_167030588_15"><ix:exclude><div style="font-size: 10pt; text-align: left; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030588_15"><ix:continuation id="TextSelectionAppend_167030582_1"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Adopted Accounting Pronouncements </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with its annual report for fiscal 2025 and interim periods thereafter on a retrospective basis. The adoption did not have a material effect on the consolidated financial statements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09,</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09</div> requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than PBEs, the requirements will be effective for annual periods beginning after December&#160;15, 2025. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December&#160;31, 2025 and continuing to provide the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-ASU</div> disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December&#160;31, 2025, the Company adopted this new ASU and it only impacts the Company&#8217;s income tax disclosures with no impact to its operations, cash flows, or financial condition. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption. </div></div></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030581" id="ixv-33156"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Fair Value of Financial Instruments </div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33159"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December&#160;31, 2025 and December&#160;31, 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 60%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60993">3,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60994">3,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60995">3,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60996">3,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2024:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60997">3,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60998">3,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-60999">3,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61000">3,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2025 and 2024, there were no transfers between levels. The fair value of the Company&#8217;s cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-15</ix:exclude></div></div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_167030581" continuedAt="TextSelectionAppend_167030581_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030581_1" continuedAt="TextSelectionAppend_167030581_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030581_2" continuedAt="TextSelectionAppend_167030581_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030581_3" continuedAt="TextSelectionAppend_167030581_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030581_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company believes the carrying amounts of its accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair value due to the <div style="display:inline;">short-term </div>nature of these amounts. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:InvestmentTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33528"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Other Investment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;28, 2023, the Company closed the transactions contemplated by the Asset Purchase Agreement receiving proceeds of $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P07_28_2023To07_28_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61002">8.0</ix:nonFraction>&#160;million as cash consideration, approximately $<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_28_2023To07_28_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61003">2.4</ix:nonFraction>&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 programs for the period between signing and closing of the transaction, and <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-61004">10</ix:nonFraction>% of all of Tisento Parent&#8217;s outstanding equity securities which fair value was determined to be $<ix:nonFraction name="ck0001755237:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61005">5.3</ix:nonFraction>&#160;million at the time of closing. The Company&#8217;s investment in Tisento Parent does not provide it with significant influence over Tisento Parent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has determined that the Company&#8217;s investment in Tisento Parent is an equity security, whereby such investment does not give the Company a controlling financial interest or significant influence over the investee.&#160;Further, the Company assessed the accounting for its investment in Tisento Parent in accordance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">with&#160;ASC&#160;810-10,&#160;Consolidation&#8212;Overall.&#160;After</div> determining that no scope exception applies under the guidance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">of&#160;ASC&#160;810-10-15-12&#160;and&#160;ASC&#160;810-10-15-17,&#160;the</div></div></div></div></div></div> Company&#160;concluded that it has a variable interest in Tisento Parent through its investment in Tisento Parent common stock. Tisento Parent does not have sufficient equity to finance its activities without additional subordinated financial support as Tisento Parent is a startup entity in its early stages of raising funds and will require significant capital to advance its programs to commercial stage. Therefore, the Company concluded that its investment in Tisento Parent is a variable interest entity (&#8220;VIE&#8221;) in accordance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">with&#160;ASC&#160;810-10-15-14(a)&#160;and&#160;is</div></div></div> subject to potential consolidation under the VIE model. However, all activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance are directed by the Tisento Parent board and the board approves decisions by a simple majority. Based on the board composition, the Company determined that no one party has control over the Tisento Parent board and power is not shared because the activities that most significantly affect Tisento Parent and its subsidiary&#8217;s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Tisento Parent board. Therefore, because the Company controls no director of Tisento Parent, the Company cannot unilaterally direct any of the activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance. Accordingly, the Company does not hold a controlling financial interest in Tisento Parent. Because both criteria (a)&#160;and (b)&#160;above have to be met for the application of the guidance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in&#160;ASC&#160;810-10-25-44B&#160;and&#160;criteria</div></div></div> (a)&#160;has not been met, The Company concluded that it should not consolidate Tisento under the VIE model. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, the Company has accounted for the investment as a financial instrument without a readily determinable fair value. Such investment is recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment is measured at cost less any impairment recorded or adjustments for observable price changes. An impairment loss is recognized in the consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of December&#160;31, 2025, <ix:nonFraction name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61006">no</ix:nonFraction> impairment loss was recognized. The Company considers the cost of the investment to be the maximum exposure to loss as a result of its involvement with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-affiliated</div> entity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The initial fair value of the investment in Tisento Parent was determined by reference to the risk-adjusted net assets value using the discounted cash flow method. The estimated net assets value of Tisento Parent includes the cash generated/used from the operations and the proceeds from equity financing. Valuations were derived by reference to observable valuation measures for comparable companies or transactions, including weighted <div style="display:inline;">average</div> cost of capital (<ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="PAsOn07_28_2023_MinimumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-61007">21</ix:nonFraction>% to <ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="PAsOn07_28_2023_MaximumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-61008">23</ix:nonFraction>%), terminal decline rate (<ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="PAsOn07_28_2023_MinimumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-61009">25</ix:nonFraction>% to <ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="PAsOn07_28_2023_MaximumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-61010">75</ix:nonFraction>%) and the discount rate referenced by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-year</div> treasury rate of <ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="PAsOn07_28_2023_TreasuryRateMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-61011">4.01</ix:nonFraction>%. </div> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-16</div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33563"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Accrued Expenses and Other Current Liabilities </div></div> <ix:nonNumeric name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33566"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 66%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61012">143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61013">220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61014">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61015">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61016">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61017">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61018">194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61019">283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33691"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. Commitments and Contingencies </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Other Funding Commitments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company may enter into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have any significant cancellation penalties. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Guarantees </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-61020"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-61021">no</ix:nonFraction></ix:nonFraction>t have any liabilities recorded for these obligations as of December&#160;31, 2025 or December&#160;31, 2024. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Separation Benefits </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As part of the separation benefit of the former Chief Financial Officer, the Company paid $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P08_01_2024To08_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61022"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P05_01_2024To05_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61023">0.1</ix:nonFraction></ix:nonFraction>&#160;million each in May 2024 and August 2024. The Company has <ix:nonFraction name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61024"><ix:nonFraction name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61025">no</ix:nonFraction></ix:nonFraction> further separation benefits obligation as of December&#160;31, 2025 and 2024. </div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030577" id="ixv-33711"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. Share-based Compensation Plans </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;) and the 2019 Equity Incentive Plan (&#8220;2019 Equity Plan&#8221;). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options, restricted stock awards (&#8220;RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion also mirrored two of Ironwood Pharmaceuticals, Inc. (&#8220;Ironwood&#8221;) existing plans, the <div style="display:inline;">Amended</div> and Restated 2005 Stock Incentive Plan (&#8220;2005 Equity Plan&#8221;) and the Amended and Restated 2010 Employee, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-17</ix:exclude></div></div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_167030577" continuedAt="TextSelectionAppend_167030577_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030577_1" continuedAt="TextSelectionAppend_167030577_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030577_2" continuedAt="TextSelectionAppend_167030577_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030577_3" continuedAt="TextSelectionAppend_167030577_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Director and Consultant Equity Incentive Plan (&#8220;2010 Equity Plan&#8221;). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pro-rata</div> share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs. </div><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33740"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table provides share-based compensation reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 82%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2025To12_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61027">29</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61028">91</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2025To12_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61029">412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61030">534</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61031">441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61032">625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Stock options granted under the Company&#8217;s equity plans generally have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ten-year</div> term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. </div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-33851"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of stock option activity for the year ended December&#160;31, 2025 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number<br/> of&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Average<br/> Intrinsic<br/> Value (in<br/> thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61033">335,448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61034">158.98</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61035">4.7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61036">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61037">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61038">2.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61039">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61040">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled or forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61041">62,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61042">140.44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61043">297,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61044">149.73</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61045">4.9</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61046">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61047">232,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61048">187.20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61049">4.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61050">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the years ended December&#160;31, 2025 and 2024, the Company granted stock options to purchase an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61051">25,000</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61052">55,849</ix:nonFraction> shares, respectively, at weighted average grant date fair values per option share of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61053">2.14</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61054">2.80</ix:nonFraction> respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-61055"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-61056">no</ix:nonFraction></ix:nonFraction> options exercised during the year ended December&#160;31, 2025 and 2024. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options held by the Company&#8217;s employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> is $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61057">0.1</ix:nonFraction>&#160;million and the weighted average period over which that expense is expected to be recognized is <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61058">3.03</ix:nonNumeric> years. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-18</ix:exclude></div></div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_167030577_4" continuedAt="TextSelectionAppend_167030577_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030577_5" continuedAt="TextSelectionAppend_167030577_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030577_6" continuedAt="TextSelectionAppend_167030577_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030577_7"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-34155"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion during the years ended December&#160;31, 2025 and 2024 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 77%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-61060">3.79</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-61061">3.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="-2" scale="-2" format="ixt:fixed-zero" id="ixv-61062">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="-2" scale="-2" format="ixt:fixed-zero" id="ixv-61063">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected option term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2025To12_31_2025" format="ixt-sec:duryear" id="ixv-61064">5.4</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-61065">6.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected stock price volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-61066">141.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-61067">111.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the years ended December&#160;31, 2025 and 2024, expected volatility was estimated using an average of the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has granted certain employees performance-based options to purchase shares of common stock. These options are subject to performance-based milestone vesting. During the year ended December&#160;31, 2025 and 2024, there were <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-61068"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61069">no</ix:nonFraction></ix:nonFraction> shares that vested as a result of performance milestone achievements. <ix:nonFraction name="ck0001755237:ShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61070"><ix:nonFraction name="ck0001755237:ShareBasedCompensationExpense" contextRef="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61071">No</ix:nonFraction></ix:nonFraction>&#160;share-based compensation expense related to these performance-based options was recognized during the years ended December&#160;31, 2025, and 2024, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted Stock Awards </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61072">No</ix:nonFraction> RSA was granted during the year ended December&#160;31, 2025. The Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61073">65,000</ix:nonFraction>&#160;RSAs during the year ended December&#160;31, 2024. The fair value of all RSAs is based on the market value of the Company&#8217;s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period. </div></div> <ix:nonNumeric name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-34247"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of RSA activity for the years ended December&#160;31, 2025 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number<br/> of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61074">164,174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61075">2.56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61076">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61077">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61078">60,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61079">2.52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61080">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61081">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61082">104,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61083">2.57</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested RSAs held by the Company&#8217;s directors is $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61084">0.2</ix:nonFraction>&#160;million and the weighted average period over which that expense is expected to be recognized is <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2025To12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61085">1.69</ix:nonNumeric> years. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-19</div></div> </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-34388"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Loss per share </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-34391"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61086">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61087">3,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating net loss per share &#8212; basic and diluted (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61088"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61089">3,181</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61090"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61091">2,518</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61092"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61093">1.11</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61094"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61095">1.21</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company excludes potential shares of common stock related to Preferred Stock, stock options and RSAs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030570" id="ixv-61096">The following table sets forth potential shares that were considered anti-dilutive for the years ended December&#160;31, 2025 and 2024: </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_167030570"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61097">351,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61098">351,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61099">297,762</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61100">335,448</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61101">104,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61102">164,174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61103">752,877</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61104">850,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation></ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030575" id="ixv-34642"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. Income Taxes </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-34645"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of net income (loss) before income tax expense are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Domestic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61105">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61106">3,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61107">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61108">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61109">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61110">3,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-34753"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows after adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on a retrospective basis&#160;(in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pretax loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61111">3,528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61112">3,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">US Federal Statutory Tax Rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61113">741</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-61114">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61115">642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-61116">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign tax effects</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61117">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="-2" scale="-2" format="ixt:fixed-zero" id="ixv-61118">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61119">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-61120">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-deductible</div> items</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61121">571</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-61122">16.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61123">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-61124">2.9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61125">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="-2" scale="-2" format="ixt:fixed-zero" id="ixv-61126">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61127">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-61128">0.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61129">170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-61130">4.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61131">566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-61132">18.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61133">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-61134">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61135">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-61136">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-20</ix:exclude></div></div> </ix:nonNumeric></div></div><div style="text-align: center;"><ix:continuation id="TextSelection_167030575" continuedAt="TextSelectionAppend_167030575_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030575_1" continuedAt="TextSelectionAppend_167030575_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030575_2" continuedAt="TextSelectionAppend_167030575_3"><ix:exclude><div style="font-size: 10pt; text-align: left; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030575_3" continuedAt="TextSelectionAppend_167030575_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s effective tax rate differs from the statutory rate primarily due to continued losses and the maintenance of a full valuation allowance on deferred tax assets, resulting in zero income tax expense for the period. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-35045"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets (liabilities) consist of the following as of December&#160;31, 2025 and 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61138">57,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61139">53,281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61140">10,385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61141">10,383</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61142">6,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61143">7,122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Capitalized research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61144">8,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61145">12,370</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangibles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61146">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61147">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61148">83,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61149">83,156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61150">83,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61151">83,156</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61152">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61153">&#8212;</ix:nonFraction>&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has evaluated the positive and negative evidence bearing upon the possible realization of its deferred tax assets. Management has considered the Company&#8217;s history of operating losses, in addition to the expected timing of the reversal of existing temporary differences and concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company will not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved at December&#160;31, 2025 and December&#160;31, 2024. Management reevaluates the positive and negative evidence on a quarterly basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The valuation allowance increased by approximately $<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61154">0.2</ix:nonFraction>&#160;million during the year ended December&#160;31, 2025 primarily due to increases in capitalized research and development expenses, net operating losses, tax credit carryforwards and deferred tax assets related to share-based compensation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At December&#160;31, 2025 and 2024, Cyclerion has federal net operating loss carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-61155">211</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-61156">195</ix:nonFraction>&#160;million, respectively, to offset future federal taxable income that will be carried forward indefinitely until utilized. As of December&#160;31, 2025 and 2024, Cyclerion had state net operating loss carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-61157">212</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-61158">196</ix:nonFraction>&#160;million, respectively, to offset future state taxable income, which will <ix:nonNumeric name="us-gaap:OtherInformationPertainingToIncomeTaxes" contextRef="P01_01_2025To12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="ixv-61159">begin to expire in 2039 and will continue to expire through 2045</ix:nonNumeric>. Cyclerion also had tax credit carryforwards of approximately $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61160">10.8</ix:nonFraction>&#160;million as of December&#160;31, 2025, to offset future federal and state income taxes. <ix:nonNumeric name="us-gaap:OtherInformationPertainingToIncomeTaxes" contextRef="P01_01_2025To12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-61161">Federal credits begin to expire in 2039 and will continue to expire through 2044. State credits begin to expire in 2034 and continue through 2039</ix:nonNumeric>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s ability to use its operating loss carryforwards and tax credits to offset future taxable income could be subject to restrictions under Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Internal Revenue Code&#8221;). These potential restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Changes in stock ownership may occur that would create these limitations on the Company&#8217;s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has not as yet conducted a study of its research and development credit carry forwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are <div style="display:inline;">being</div> presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><ix:exclude><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-21</div></ix:exclude></div><div style="margin-top: 1em; margin-bottom: 1em"></div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_167030575_4" continuedAt="TextSelectionAppend_167030575_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030575_5" continuedAt="TextSelectionAppend_167030575_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030575_6" continuedAt="TextSelectionAppend_167030575_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030575_7"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon audit, taxing authorities may challenge all or part of an uncertain income tax position. While Cyclerion has no history of tax audits since its inception on a standalone basis, it may be subject to tax audits by federal and state taxing authorities in the future. Accordingly, Cyclerion regularly assesses the outcome of potential examinations in each of the taxing jurisdictions when determining the adequacy of the amount of unrecognized tax benefit recorded. Cyclerion had <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-61162"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61163">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits as of December&#160;31, 2025 and 2024. Cyclerion will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December&#160;31, 2025 and 2024, no interest or penalties have been accrued. There are <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61164"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61165">no</ix:nonFraction></ix:nonFraction> current federal or state income tax audits in progress. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-35298"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Defined Contribution Plan </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has established a defined contribution <div style="-sec-ix-hidden:hidden167030863;display:inline;">401(k) Savings Plan</div> which allows eligible employees to contribute from <ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="P01_01_2025To12_31_2025_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-61166">1</ix:nonFraction>% to <ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-61167">100</ix:nonFraction>% of their compensation, subject to certain IRS limits. The Company&#8217;s contributions to the plan are at the sole discretion of the board of directors. Currently, the Company provides a matching contribution of <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-61168">75</ix:nonFraction>% of the employee&#8217;s contributions, up to $<ix:nonFraction name="ck0001755237:DefinedContributionPlanEmployerMatchingContributionMaximum" contextRef="P01_01_2025To12_31_2025" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61169">6,000</ix:nonFraction> annually. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Included in compensation expense is de minimis related to the defined contribution 401(k) Savings Plan for the years ended December&#160;31, 2025 and 2024, respectively. </div></div> </ix:nonNumeric><ix:nonNumeric name="ck0001755237:LicenseAgreementsTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" continuedAt="TextSelection_167030618" id="ixv-35306"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. License and Option Agreement </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent License Agreement </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2025, the Company and MIT entered into a Patent License Agreement (the &#8220;MIT License Agreement&#8221;) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, the Company paid a nominal upfront license fee and patent reimbursement fee. Thereafter, the Company is also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $<ix:nonFraction name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61170">4.4</ix:nonFraction>&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, the Company is required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recorded research and development expense of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61171">0.1</ix:nonFraction>&#160;million for the year ended December&#160;31, 2025, which consisted of upfront fees, patent reimbursement fees and transaction costs related to the license. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia License Agreement </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;3, 2021, the Company and Akebia entered into a License Agreement (the &#8220;Akebia License Agreement&#8221;) relating to the exclusive worldwide license by the Company to Akebia of its rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-22</ix:exclude></div></div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_167030618" continuedAt="TextSelectionAppend_167030618_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030618_1" continuedAt="TextSelectionAppend_167030618_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030618_2" continuedAt="TextSelectionAppend_167030618_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030618_3" continuedAt="TextSelectionAppend_167030618_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the &#8220;Products&#8221;). Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Akebia paid a $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61173">3.0</ix:nonFraction>&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> payment to the Company upon signing of the License Agreement. On December&#160;13, 2024, the Company and Akebia entered into Amendment #1 to the License Agreement (the &#8220;2024 Amendment&#8221;) to the original License Agreement between the parties dated June&#160;3, 2021. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the 2024 Amendment, Akebia paid $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-61174">1.75</ix:nonFraction>&#160;million in amendment payments, of which $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-61175">1.25</ix:nonFraction>&#160;million was paid in December 2024 and an additional payment of $<ix:nonFraction name="ck0001755237:AdditionalUpFrontPayment" contextRef="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61176">0.5</ix:nonFraction>&#160;million was paid in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $<ix:nonFraction name="ck0001755237:DevelopmentMilestonePayment" contextRef="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61177">1.0</ix:nonFraction>&#160;million development milestone payment would be due to the Company and which was received in February 2026. Pursuant to the terms of the Akebia License Agreement, as amended, Cyclerion is eligible to receive additional potential future development, regulatory, and commercialization milestone payments up to $<ix:nonFraction name="ck0001755237:CommercializationMilestonePayments" contextRef="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61178">557.5</ix:nonFraction>&#160;million in total, and Akebia will pay Cyclerion tiered royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit to twenty percent of net sales. Cyclerion&#8217;s obligations to deliver certain drug products have also ceased. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Akebia License Agreement, the Company determined the Akebia License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the Akebia License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined that the grant of license to its patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-evaluate</div> the probability of achievement of the milestones and any related constraints each reporting period. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia Material Purchase Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;3, 2025, the Company and Akebia entered into a Material Purchase Agreement (the &#8220;Purchase Agreement&#8221;) relating to the purchase of additional development materials (the &#8220;Additional Development Materials&#8221;) by Akebia for Akebia&#8217;s use pursuant to the Akebia License Agreement. Akebia paid $<ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61179">0.8</ix:nonFraction>&#160;million to the Company for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined the Purchase Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the Akebia License Agreement or the Amendment. The delivery of the Additional Development Materials by the Company represents a single performance obligation and consideration was recognized upon delivery. The Company recognized revenue of $<ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61180">0.8</ix:nonFraction>&#160;million during the year ended December&#160;31, 2025. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-23</ix:exclude></div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_167030618_4" continuedAt="TextSelectionAppend_167030618_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030618_5" continuedAt="TextSelectionAppend_167030618_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167030618_6" continuedAt="TextSelectionAppend_167030618_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167030618_7"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Option Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $<ix:nonFraction name="ck0001755237:OptionFee" contextRef="P08_01_2024To08_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61182">150,000</ix:nonFraction> in August 2024 and subsequent fees totaling $<ix:nonFraction name="ck0001755237:OptionAdditionalFee" contextRef="P07_22_2024To07_22_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61183">80,000</ix:nonFraction> to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2025To12_31_2025" escape="true" id="ixv-35377"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. Subsequent Events </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;6, 2026, the Company sold <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61184">405,000</ix:nonFraction> shares of common stock under the Sales Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_06_2026To01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61185">0.8</ix:nonFraction>&#160;million. The Company exhausted all sales under the 2025 Shelf. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;3, 2026, the Company and the Medsteer, SAS (&#8220;Medsteer&#8221;) entered into a Collaboration and Option Agreement (the &#8220;Collaboration Agreement&#8221;) pursuant to which Medsteer granted to the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(i)&#160;a&#160;non-exclusive,&#160;worldwide,</div> royalty-free, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#8220;Option&#8221;), exercisable at the Company&#8217;s sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in&#160;multi-bed&#160;or</div> intensive unit wards, or in the context of medical transport. <ix:nonNumeric name="ck0001755237:DebtInstrumentsOptionsExercisePeriod" contextRef="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="ixv-61186">The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an addition two years at the Company&#8217;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer.</ix:nonNumeric> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the terms of the Collaboration Agreement, the Company will pay to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61187">3.7</ix:nonFraction>&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-24</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div><div id="fin111069_6a" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Condensed Consolidated Balance Sheets </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands except share and per share data) </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Unaudited) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 78%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,<br/> 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61188">2,823</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61189">3,240</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61190">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61191">1,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61192">255</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61193">384</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61194">11</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61195">11</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61196">3,089</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61197">4,635</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61198">66</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61199">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61200">5,350</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61201">5,350</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61202">8,505</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61203">9,985</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61204">457</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61205">508</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:AccruedResearchAndDevelopmentCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61206">148</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:AccruedResearchAndDevelopmentCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61207">198</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61208">1,109</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61209">194</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61210">1,714</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61211">900</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (Note&#160;6)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61212">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61213">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred stock, <ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2025" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61214"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2026" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61215">no</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2026" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61216"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61217">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61218"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2026_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61219"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2026_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61220"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61221">351,037</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Series&#160;A convertible preferred stock issued and outstanding at March&#160;31, 2026 and December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61222">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61223">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2026" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61224"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2025" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61225">no</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61226"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2026" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61227">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2026 and December&#160;31, 2025; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2026" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61228">4,330,314</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61229">3,925,314</ix:nonFraction> shares issued at March&#160;31, 2026 and December&#160;31, 2025, respectively; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2026" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61230">4,241,260</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2025" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61231">3,821,236</ix:nonFraction> shares outstanding at March&#160;31, 2026 and December&#160;31, 2025, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61232">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61233">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div> capital</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61234">280,988</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61235">280,105</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61236">274,197</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61237">271,020</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61238">6,791</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61239">9,085</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities and stockholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61240">8,505</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61241">9,985</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-25 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div> <div id="fin111069_6b" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Condensed Consolidated Statements of Operations and Comprehensive Loss </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands except per share data) </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Unaudited) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 84%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months<br/> Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenues:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenue from option agreement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2026To03_31_2026_OptionAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61242">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To03_31_2025_OptionAgreementMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61243">81</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61244">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61245">81</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cost and expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61246">730</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61247">36</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61248">2,479</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61249">1,502</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total cost and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61250">3,209</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61251">1,538</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61252">3,209</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61253">1,457</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61254">32</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61255">28</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other income, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61256">32</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61257">28</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss and other comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61258">3,177</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61259">1,429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61260"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61261">0.76</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61262"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61263">0.56</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61264"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61265">4,205</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61266"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61267">2,556</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div><div id="fin111069_6c" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Condensed Consolidated Statements of Stockholders&#8217; Equity </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands except share data) </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Unaudited) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 44%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total<br/> Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61268">2,545,922</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61269">351,037</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61270">276,342</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61271">267,492</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61272">8,850</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61273">1,429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61274">1,429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock - private placement, net of issuance cost</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61275">499,998</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61276">1,245</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61277">1,245</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vesting of restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61278">15,024</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense related to issuance of stock options and restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61279">114</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61280">114</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at March&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61281">3,060,944</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61282">351,037</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61283">277,701</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61284">268,921</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61285">8,780</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="8" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="8" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total<br/> Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61286">3,821,236</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61287">351,037</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61288">280,105</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61289">271,020</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61290">9,085</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of common stock - ATM</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2026To03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61291">405,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2026To03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61292">825</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61293">825</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2026To03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61294">3,177</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61295">3,177</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vesting of restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="P01_01_2026To03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61296">15,024</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense related to issuance of stock options and restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2026To03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61297">58</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61298">58</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balance at March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61299">4,241,260</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61300">351,037</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61301">280,988</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61302">274,197</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61303">6,791</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-27 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div><div id="fin111069_6d" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Condensed Consolidated Statements of Cash Flows </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Unaudited) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 84%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months<br/> Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CASH FLOWS FROM OPERATING ACTIVITIES:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61304">3,177</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61305">1,429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61306">58</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61307">114</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61308">1,000</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61309">25</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61310">129</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61311">165</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61312">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61313">5</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61314">51</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61315">93</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61316">50</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61317">2</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61318">915</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61319">121</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61320">1,176</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61321">968</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CASH FLOWS FROM INVESTING ACTIVITIES:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchases of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61322">66</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61323">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61324">66</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61325">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CASH FLOWS FROM FINANCING ACTIVITIES:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from ATM</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:ProceedsFromAtTheOffer" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61326">825</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:ProceedsFromAtTheOffer" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61327">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from private placement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61328">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61329">1,375</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61330">825</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61331">1,375</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net (decrease) increase in cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61332">417</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61333">407</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents, beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61334">3,240</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61335">3,232</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents, end of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61336">2,823</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61337">3,639</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-28 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Therapeutics, Inc. </div></div><div id="fin111069_6e" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Notes to the Condensed Consolidated Financial Statements </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(Unaudited) </div></div><ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" continuedAt="TextSelection_167031197" id="ixv-37770"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Nature of Business </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nature of Operations </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion Therapeutics, Inc. (&#8220;Cyclerion&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221;) became an independent public company on April&#160;1, 2019 after Ironwood Pharmaceuticals, Inc. completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">tax-free</div></div> <div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">spin-off</div> of their sGC business. Cyclerion has one employee as of March&#160;31, 2026 and also relies on a team of specialist consultants for its operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion has historically focused on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Prior to the proposed Merger, its&#160;strategic focus was centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression (&#8220;TRD&#8221;), which it believes represents a substantial clinical and commercial opportunity. Over the past year, the Company has refined our strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, The Company has evaluated multiple opportunities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">prioritized&#160;CYC-126,&#160;an</div> individualized therapy for TRD as its foundational development program. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In September 2025, the Company entered into a license agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) for intellectual property supporting this TRD program. In January 2026, the Company also entered into a collaboration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">and&#160;option-to-license&#160;agreement</div></div> with Medsteer SAS (&#8220;Medsteer&#8221;), a developer of anesthesia delivery and monitoring technologies. This agreement provides the Company with access to Medsteer&#8217;s technical expertise, data assets, and intellectual property relating to technology-enabled drug delivery and physiological monitoring, and grants the Company the right, but not the obligation, to obtain additional rights under specified conditions. The Company intends to evaluate these capabilities as part of our broader development strategy for our TRD program. Given the substantial unmet medical need in TRD, the stage of clinical development, and the potential commercial opportunity, the Company believe this program is well positioned to serve as the foundation of our future development efforts. The program team is currently advancing an integrated clinical, regulatory, and commercial strategy for this TRD program. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In parallel with the advancement of our neuropsychiatric strategy, the Company continues to evaluate opportunities related to potentially monetizing its legacy soluble guanylate cyclase (&#8220;sGC&#8221;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions intended to maximize shareholder value. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. (&#8220;Akebia&#8221;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61338">3.0</ix:nonFraction>&#160;million upfront payment to the Company upon signing of the license agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">On December&#160;13, 2024, Cyclerion announced that Cyclerion and Akebia had <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-negotiated</div> a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under this new license amendment, Cyclerion received $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-61339">1.75</ix:nonFraction>&#160;million in amendment payments, of which $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-61340">1.25</ix:nonFraction>&#160;million was paid in December 2024 and the remaining additional payment of $<ix:nonFraction name="ck0001755237:RemainingAdditionalUpFrontPayment" contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61341">0.5</ix:nonFraction>&#160;million was received in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated (defined as first patient dosed) Phase&#160;2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using praliciguat. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-29</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_167031197" continuedAt="TextSelectionAppend_167031197_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_1" continuedAt="TextSelectionAppend_167031197_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_2" continuedAt="TextSelectionAppend_167031197_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031197_3" continuedAt="TextSelectionAppend_167031197_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $<ix:nonFraction name="ck0001755237:DevelopmentMilestonePayment" contextRef="P01_01_2023To12_31_2023_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61343">1.0</ix:nonFraction>&#160;million development milestone payment was received in February 2026. The Company is eligible to receive additional milestone cash payments of up to approximately $<ix:nonFraction name="ck0001755237:PaymentOfCashMilestone" contextRef="P01_01_2026To03_31_2026_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61344">557.5</ix:nonFraction>&#160;million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher-tiered sales-based royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single-digits</div> to twenty percent. Payment of these sums are reserved for Cyclerion stockholders under the &#8220;Cyclerion CVR Agreement&#8221; described below. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $<ix:nonFraction name="ck0001755237:OptionFee" contextRef="P08_01_2024To08_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61345">150,000</ix:nonFraction> in August 2024 and subsequent fees totaling $<ix:nonFraction name="ck0001755237:SubsequentFees" contextRef="P08_01_2024To08_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61346">80,000</ix:nonFraction> to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company is currently exploring potential license opportunities for olinciguat. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Zagociguat is a clinical-stage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-penetrant</div> sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-targeted</div> sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. On July&#160;28, 2023, the Company sold Zagociguat and CY3018 to Tisento Therapeutics, Inc. (&#8220;Tisento&#8221;), a newly formed private company focused on their development, in exchange for $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P07_28_2023To07_28_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61347">8.0</ix:nonFraction>&#160;million in cash consideration, $<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_28_2023To07_28_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61348">2.4</ix:nonFraction>&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-61349">10</ix:nonFraction>% of all of Tisento&#8217;s parent&#8217;s outstanding equity securities (&#8220;Tisento Parent&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025 Equity Private Placement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;21, 2025, the Company entered into a Stock Purchase Agreement (the &#8220;2025 Equity Private Placement&#8221;) for a private placement of <ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61350">499,998</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61351">2.75</ix:nonFraction> per share for total gross proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="6" format="ixt:num-dot-decimal" id="ixv-61352">1.375</ix:nonFraction>&#160;million. The closing of the 2025 Equity Private Placement occurred on March&#160;25, 2025. The Company incurred transaction costs of $<ix:nonFraction name="ck0001755237:TransactionCostsSaleOfTransferredAssets" contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61353">0.1</ix:nonFraction>&#160;million for the 2025 Equity Private Placement. The Shares issued were not registered under the Securities Act of 1933, as amended, or any state securities laws and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act as a transaction not involving a public offering. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the 2025 Equity Private Placement, the Company entered into a Registration Rights Agreement with the investors, dated March&#160;21, 2025, pursuant to which the Company agreed to register the resale of the Shares pursuant to a registration statement which was filed with the SEC and declared effective by the SEC on May&#160;15, 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">At-the-Market</div></div> Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On February&#160;4, 2025, the Company filed a Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $<ix:nonFraction name="ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice" contextRef="PAsOn02_04_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61354">25.0</ix:nonFraction>&#160;million. The Registration Statement was declared effective by the SEC in February 2025. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-30</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_167031197_4" continuedAt="TextSelectionAppend_167031197_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_5" continuedAt="TextSelectionAppend_167031197_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_6" continuedAt="TextSelectionAppend_167031197_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031197_7" continuedAt="TextSelectionAppend_167031197_8"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">On May&#160;7, 2025, the Company and Guggenheim Securities, LLC (&#8220;Guggenheim Securities&#8221;) entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the &#8220;Shares&#8221;), having an aggregate offering price of up to $<ix:nonFraction name="ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice" contextRef="PAsOn05_07_2025_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61356">20,000,000</ix:nonFraction> from time to time through or to Guggenheim Securities, acting as the Company&#8217;s agent, subject to the application of General Instruction I.B.6 of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> (&#8220;Instruction I.B.6&#8221;) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company will pay Guggenheim Securities cash commission of <ix:nonFraction name="ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" contextRef="P05_07_2025To05_07_2025" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-61357">3.0</ix:nonFraction>% of the gross proceeds of the Shares sold under the Sales Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2025, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61358">715,220</ix:nonFraction> shares of its common stock for net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61359">2.1</ix:nonFraction>&#160;million under the Sales Agreement, after deducting commissions paid to Guggenheim Securities of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61360">0.1</ix:nonFraction>&#160;million. During the three months ended March&#160;31, 2026, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2026To03_31_2026_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61361">405,000</ix:nonFraction> shares of common stock under the Sales Agreement for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2026To03_31_2026_SalesAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61362">0.8</ix:nonFraction>&#160;million. The Company exhausted all sales under the 2025 Shelf. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Merger Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On April&#160;1, 2026, Cyclerion entered into a Plan of Merger and Reorganization (as amended, the &#8220;Merger Agreement&#8221;) with Korsana, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, pursuant to which among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp., a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Korsana will merge with and into Cariboos Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Korsana Biosciences Operating Company, LLC&#8221; and Cyclerion will change its name to &#8220;Korsana Biosciences, Inc.&#8221;. Cyclerion anticipates that the Merger will close in the third quarter of 2026, subject to certain closing conditions, along with&#160;the concurrent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Korsana&#160;Pre-Closing&#160;Financing</div> described below. Following the Merger, the current business of Korsana will become the primary business of Cyclerion. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">At the closing of the First Merger (the &#8220;First Effective Time&#8221;, and the date on which the closing of the Merger occurs, the &#8220;Closing Date&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement: (i)&#160;each then-outstanding share of common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61363">0.0001</ix:nonFraction> par value per share, of Korsana (the &#8220;Korsana Common Stock&#8221;) and Series A Preferred Stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61364">0.0001</ix:nonFraction> par value per share of Korsana (&#8220;Korsana Series A Preferred Stock&#8221;) (including shares of Korsana Common Stock issued in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing described below), excluding any shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares, will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock, no par value per share (the &#8220;Cyclerion Common Stock&#8221;), equal to the exchange ratio as described in the Merger Agreement (the &#8220;Exchange Ratio&#8221;); provided, that in the event the aggregate number of shares of Cyclerion Common Stock issuable to a holder of Korsana capital stock (when aggregated with all of the&#160;shares of the Cyclerion Common Stock outstanding then beneficially owned by such person and its affiliates (as calculated pursuant to Section&#160;13(d) of the Securities Exchange Act of 1934, as amended, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;13d-3</div> promulgated&#160;thereunder) immediately after giving effect to the issuance of the merger consideration) would result in the issuance of shares of Cyclerion Common Stock to a holder in excess of a specified percentage (initially set at a percentage up to <ix:nonFraction name="ck0001755237:DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" contextRef="P04_01_2026To04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_CyclerionTherapeuticsIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-61365">9.99</ix:nonFraction>%) of the total outstanding shares of Cyclerion Common Stock (such specified percentage, a &#8220;Beneficial Ownership Limitation&#8221;), then Cyclerion will issue to any such holder (x)&#160;shares of Cyclerion Common Stock up to such holder&#8217;s Beneficial Ownership Limitation and (y)&#160;in lieu of any shares in excess of such holder&#8217;s Beneficial Ownership <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Limitation,&#160;pre-funded&#160;warrants</div> (&#8220;Cyclerion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) to purchase a number of shares of Cyclerion Common Stock upon exercise of such Cyclerion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants equal to such excess shares; (ii)&#160;each then-outstanding share of Korsana Series </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-31</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_167031197_8" continuedAt="TextSelectionAppend_167031197_9"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_9" continuedAt="TextSelectionAppend_167031197_10"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_10" continuedAt="TextSelectionAppend_167031197_11"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031197_11" continuedAt="TextSelectionAppend_167031197_12"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Seed Preferred Stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesSeedPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-61367">0.0001</ix:nonFraction> par value per share (&#8220;Korsana Series Seed Preferred Stock&#8221; and, together with the Korsana Series A Preferred Stock, the &#8220;Korsana Preferred Stock&#8221;), excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">B&#160;non-voting&#160;convertible</div> preferred stock, no par value per share (&#8220;Cyclerion Series B Preferred Stock&#8221;), equal to the Exchange Ratio divided by 1,000; (iii) each then-outstanding option (a &#8220;Korsana Option&#8221;) to purchase shares of Korsana Common Stock will be converted into and become an option to purchase shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement; (iv)&#160;each then-outstanding restricted stock unit for shares of Korsana Common Stock will be converted into and become a restricted stock unit for shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement; and (v)&#160;each then-outstanding warrant to purchase shares of Korsana Common Stock will be converted into a warrant to purchase shares of Cyclerion Common Stock on the existing terms and conditions, subject to adjustment as set forth in the Merger Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Each share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock that is issued and outstanding at the First Effective Time will remain issued and outstanding and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Prior to the First Effective Time, the Cyclerion board of directors will accelerate the vesting of all options to purchase shares of Cyclerion Common Stock (&#8220;Cyclerion Options&#8221;) and all restricted stock awards (&#8220;Cyclerion RSAs&#8221;). Each outstanding Cyclerion Option with an exercise price per share equal to or less than the volume weighted average closing trading price of a share of Cyclerion Common Stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five consecutive trading days ending three trading days prior to the Calculation Date (as defined in the Merger Agreement), as reported by Bloomberg L.P. (the &#8220;Cyclerion Closing Price&#8221;), will be cancelled at the First Effective Time and such holder thereof will receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying the excess of the Cyclerion Closing Price over the exercise price per share of the Cyclerion Common Stock underlying such Cyclerion Option by the number of shares of the Cyclerion Common Stock underlying such Cyclerion Option. Each Cyclerion Option with an exercise price greater than the Cyclerion Closing Price will be cancelled for no consideration. The vesting of each Cyclerion RSA will be accelerated in full. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Based on Cyclerion&#8217;s capitalization as of December&#160;31, 2025 and Korsana&#8217;s capitalization as of March&#160;31, 2026 and assuming Cyclerion&#8217;s net cash as of closing being equal to $<ix:nonFraction name="ck0001755237:NetCashOnCapitalization" contextRef="P01_01_2026To03_31_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61368">0</ix:nonFraction>, each share of Korsana Common Stock and Korsana Series A Preferred Stock is currently estimated to be entitled to receive approximately <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-61369">1.1009</ix:nonFraction> shares of Cyclerion Common Stock. Each share of Korsana Series Seed Preferred Stock will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock, equal to the Exchange Ratio divided by 1,000. The estimated Exchange Ratio does not give effect to the proposed Cyclerion reverse stock split and is subject to adjustment based on Cyclerion&#8217;s estimated net cash at the closing of the First Merger. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In connection with the Merger, on April&#160;1, 2026, Korsana entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional and accredited investors for the purchase of shares of Korsana Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants to purchase shares of Korsana Common Stock (the &#8220;Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="P04_01_2026To04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61370">380.0</ix:nonFraction>&#160;million, immediately prior to the closing of the Merger (referred to herein as the &#8220;Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing&#8221;). The shares of Korsana Common Stock and Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants that are issued in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing will be converted into the right to receive a number of shares of Cyclerion Common Stock and Cyclerion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants, respectively, equal to the Exchange Ratio. Korsana and the investors participating in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing have also agreed to enter into a registration rights agreement at the closing of the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Korsana Common Stock that are held by the investors participating in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing from time to time pursuant to Rule 415 under the Securities Act. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-32</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_167031197_12" continuedAt="TextSelectionAppend_167031197_13"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_13" continuedAt="TextSelectionAppend_167031197_14"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_14" continuedAt="TextSelectionAppend_167031197_15"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031197_15" continuedAt="TextSelectionAppend_167031197_16"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Based on its current operating plan, Cyclerion expects that its current cash and cash equivalents will fund its operations until the closing of the contemplated Merger, which is subject to approval by its shareholders and the shareholders of Korsana and other customary closing conditions; however, Cyclerion has based this estimate on assumptions that may prove to be wrong, and Cyclerion could use its capital resources sooner than Cyclerion expects. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion CVR Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">At or prior to the first merger, Cyclerion will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a designated rights agent (the &#8220;Rights Agent&#8221;), pursuant to which Cyclerion&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> shareholders will receive one CVR for each outstanding share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock held by such shareholder on such date. Each CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of Cyclerion&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-Merger</div> legacy assets, net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> legacy assets other than those <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> legacy assets described in the following clauses (ii)&#160;and (iii), upon the second (2nd) anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#8217;s right to receive payments under the Akebia License Agreement, the earlier of (A)&#160;the fifteenth (15th) anniversary of the date of entry into the CVR Agreement and (B)&#160;the expiration or earlier termination by Akebia Therapeutics, Inc. of the Akebia License Agreement pursuant to its terms, and (iii)&#160;with respect to the sale, transfer or other disposition of the equity interests of Tisento that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement, dated May&#160;13, 2023, by and among Cyclerion, Tisento and JW Cycle, Inc., the earliest of (A)&#160;nine (9)&#160;months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any holders of CVRs will receive any payments with respect thereto. </div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-37937"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The condensed consolidated financial statements and the related disclosures are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. Additionally, certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2025, which was filed with the SEC on March&#160;30, 2026. </div></div></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#8217;s financial position and the results of its operations for the interim periods presented. The results of operations for the three months ended March&#160;31, 2026 and 2025 are not necessarily indicative of the results that may be expected for the full year or any other subsequent interim period. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation, Cyclerion Australia Pty Ltd., Cariboos Merger Sub Corp. and Cariboos Merger Sub II, LLC. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-33</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_167031197_16" continuedAt="TextSelectionAppend_167031197_17"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_17" continuedAt="TextSelectionAppend_167031197_18"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031197_18" continuedAt="TextSelectionAppend_167031197_19"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031197_19"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">At each reporting period, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> Going Concern, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> the future receipt of potential funding from future partnerships, license payments, equity or debt issuances, certain cost reduction measures and the achievement of potential milestone payments from Akebia cannot be considered probable at this time because these plans are not entirely within the Company&#8217;s control and/or have not been approved by the Board of Directors as of the date of these condensed consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expects that its cash and cash equivalents as of March&#160;31, 2026, will be sufficient to fund operations into the third quarter of 2026, however the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. If the Merger is not consummated, the Company believes that its cash and cash equivalents as of March&#160;31, 2026 would be adequate to fund its operating expenses into the third quarter of 2026. However, in order to continue development of its programs, the Company would need to secure substantial additional funding in the future, from one or more equity or debt financings, collaborations, or other sources. Additional funding may not be available to the Company on acceptable terms, or at all. The Company&#8217;s Board of Directors may also decide to pursue a dissolution and liquidation in lieu of continuing program development in the event the Merger is not consummated. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-34 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-37989"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Summary of Significant Accounting Policies </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The accounting policies of the Company are set forth in Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies</div></div> to the consolidated financial statements contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2025. </div></div><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-37997"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">New Accounting Pronouncements </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the interim condensed consolidated financial statements, the Company did not adopt any new accounting pronouncements during the three months ended March&#160;31, 2026 that had a material effect on its condensed consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#8217;s condensed consolidated financial statements upon adoption. </div></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-38004"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Fair Value of Financial Instruments </div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-38007"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 61%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;March&#160;31,&#160;2026:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61373">2,610</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61374">2,610</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61375">2,610</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61376">2,610</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61377">3,072</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61378">3,072</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61379">3,072</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61380">3,072</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the three months ended March&#160;31, 2026 and 2025, there were no transfers between levels. The fair value of the Company&#8217;s cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company believes the carrying amounts of its accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these amounts. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:InvestmentTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" continuedAt="TextSelection_167031218" id="ixv-38385"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Other Investment </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company has determined that the Company&#8217;s investment in Tisento Parent is an equity security, whereby such investment does not give the Company a controlling financial interest or significant influence over the investee. Further, the Company assessed the accounting for its investment in Tisento Parent in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10,</div> Consolidation&#8212;Overall. After determining that no scope exception applies under the guidance </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-35</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_167031218" continuedAt="TextSelectionAppend_167031218_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031218_1" continuedAt="TextSelectionAppend_167031218_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031218_2" continuedAt="TextSelectionAppend_167031218_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031218_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10-15-12</div></div></div> and ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10-15-17,</div></div></div> the Company concluded that it has a variable interest in Tisento Parent through its investment in Tisento Parent common stock. Tisento Parent does not have sufficient equity to finance its activities without additional subordinated financial support as Tisento Parent is a startup entity in its early stages of raising funds and will require significant capital to advance its programs to commercial stage. Therefore, the Company concluded that its investment in Tisento Parent is a variable interest entity (&#8220;VIE&#8221;) in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10-15-14(a)</div></div></div> and is subject to potential consolidation under the VIE model. However, all activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance are directed by the Tisento Parent board and the board approves decisions by a simple majority. Based on the board composition, the Company determined that no one party has control over the Tisento Parent board and power is not shared because the activities that most significantly affect Tisento Parent and its subsidiary&#8217;s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Tisento Parent board. Therefore, because the Company controls no director of Tisento Parent, the Company cannot unilaterally direct any of the activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance. Accordingly, the Company does not hold a controlling financial interest in Tisento Parent. Because both criteria (a)&#160;and (b) above have to be met for the application of the guidance in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;810-10-25-44B</div></div></div> and criteria (a)&#160;has not been met, the Company concluded that it should not consolidate Tisento under the VIE model. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Accordingly, the Company has accounted for the investment as a financial instrument without a readily determinable fair value. Such investment is recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment is measured at cost less any impairment recorded or adjustments for observable price changes. An impairment loss is recognized in the consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of March&#160;31, 2026, <ix:nonFraction name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61382">no</ix:nonFraction> impairment loss was recognized. The Company considers the cost of the investment to be the maximum exposure to loss as a result of its involvement with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-affiliated</div> entity. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-38426"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Accrued Expenses and Other Current Liabilities </div></div><ix:nonNumeric name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-38429"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 70%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,<br/> 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61383">984</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61384">143</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61385">21</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61386">13</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61387">104</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61388">38</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61389">1,109</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="PAsOn12_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61390">194</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" continuedAt="TextSelection_167031208" id="ixv-38556"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. Commitments and Contingencies </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Other Funding Commitments </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the normal course of business, the Company enters into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have any significant cancellation penalties. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Indemnification Obligations </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-36</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_167031208" continuedAt="TextSelectionAppend_167031208_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031208_1" continuedAt="TextSelectionAppend_167031208_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031208_2" continuedAt="TextSelectionAppend_167031208_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031208_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is <div style="display:inline;">unlimited</div>. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of March&#160;31, 2026 and December&#160;31, 2025. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" continuedAt="TextSelection_167031256" id="ixv-38593"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. Share-based Compensation Plans </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;) and the 2019 Equity Incentive Plan (&#8220;2019 Equity Plan&#8221;). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options, restricted stock awards (&#8220;RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion also mirrored two of Ironwood Pharmaceuticals, Inc. (&#8220;Ironwood&#8221;) existing plans, the Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Equity Plan&#8221;) and the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (&#8220;2010 Equity Plan&#8221;). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pro-rata</div> share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs. </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-38601"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table provides share-based compensation reflected in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2026 and 2025 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 79%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2026To03_31_2026_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61392">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2025To03_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61393">12</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2026To03_31_2026_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61394">58</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2025To03_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61395">102</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61396">58</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61397">114</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Stock options granted under the Company&#8217;s equity plans generally have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ten-year</div> term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-37</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_167031256" continuedAt="TextSelectionAppend_167031256_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031256_1" continuedAt="TextSelectionAppend_167031256_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031256_2" continuedAt="TextSelectionAppend_167031256_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031256_3"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-38741"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of stock option activity for the three months ended March&#160;31, 2026, is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number<br/> of&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Average<br/> Intrinsic<br/> Value (in<br/> thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61399">297,762</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61400">149.73</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61401">4.9</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61402">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-61403">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61404">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61405">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61406">&#8212;</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled or forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61407">17,355</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61408">203.65</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61409">280,407</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61410">146.39</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61411">4.9</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61412">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61413">220,760</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61414">181.20</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61415">4.2</ix:nonNumeric></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-61416">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61417"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61418">no</ix:nonFraction></ix:nonFraction> options exercised during the three months ended March&#160;31, 2026 and 2025. As of March&#160;31, 2026, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options is $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61419">0.1</ix:nonFraction>&#160;million and the weighted average period over which that expense is expected to be recognized is <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61420">2.86</ix:nonNumeric> years. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has granted certain former employees performance-based options to purchase shares of common stock. These options are subject to performance-based milestone vesting. During the three months ended March&#160;31, 2026 and 2025, there were&#160;<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2025To03_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-61421"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2026To03_31_2026_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-61422">no</ix:nonFraction></ix:nonFraction> shares that vested as a result of performance milestone achievements. <ix:nonFraction name="ck0001755237:ShareBasedCompensationExpense" contextRef="P01_01_2025To03_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61423"><ix:nonFraction name="ck0001755237:ShareBasedCompensationExpense" contextRef="P01_01_2026To03_31_2026_PerformanceSharesMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61424">No</ix:nonFraction></ix:nonFraction> share-based compensation expense related to these performance-based options was recognized during the three months ended March&#160;31, 2026 and 2025, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted Stock Awards </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61425"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-61426">No</ix:nonFraction></ix:nonFraction> RSA was granted during the three months ended March&#160;31, 2026 and 2025. The fair value of all RSAs is&#160;based on the market value of the Company&#8217;s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period. </div></div><ix:nonNumeric name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-39057"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of RSA activity for the three months ended March&#160;31, 2026 is as follows:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number<br/> of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-61427">104,078</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61428">2.57</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-61429">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61430">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61431">15,024</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61432">2.52</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61433">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-61434">&#8212;</ix:nonFraction>&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61435">89,054</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-61436">2.59</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2026, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested RSAs is $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61437">0.2</ix:nonFraction>&#160;million and the weighted average period over which that expense is expected to be recognized is <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-61438">1.45</ix:nonNumeric> years. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-38 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-39212"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Loss per share </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-39215"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61439">3,177</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-61440">1,429</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating net loss per share &#8212; basic and diluted (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61441"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61442">4,205</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61443"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61444">2,556</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61445"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61446">0.76</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61447"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-61448">0.56</ix:nonFraction></ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company excludes shares of common stock related to Preferred Stock, stock options and RSAs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" continuedAt="TextSelection_167031249" id="ixv-61449">The following table sets forth potential shares that were considered anti-dilutive for the three months ended March&#160;31, 2026 and 2025: </ix:nonNumeric></div></div><ix:continuation id="TextSelection_167031249"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2026To03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61450">351,037</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2025To03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61451">351,037</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61452">280,407</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61453">329,458</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61454">89,054</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61455">149,150</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2026To03_31_2026" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61456">720,498</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-61457">829,645</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:nonNumeric><div style="clear:both;max-height:0pt;"></div><ix:nonNumeric name="ck0001755237:LicenseAgreementsTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" continuedAt="TextSelection_167031199" id="ixv-39489"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. Option/License Agreement </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent License Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2025, the Company and MIT entered into a Patent License Agreement (the &#8220;MIT License Agreement&#8221;) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, the Company paid a nominal upfront license fee and patent reimbursement fee. Thereafter, the Company is also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $<ix:nonFraction name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61458">4.4</ix:nonFraction>&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, the Company is required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61459"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="P01_01_2026To03_31_2026_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-61460">No</ix:nonFraction></ix:nonFraction> expense was recognized for the three months ended March&#160;31, 2026 and 2025 related to the license. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-39</ix:exclude> </div></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_167031199" continuedAt="TextSelectionAppend_167031199_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031199_1" continuedAt="TextSelectionAppend_167031199_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031199_2" continuedAt="TextSelectionAppend_167031199_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031199_3" continuedAt="TextSelectionAppend_167031199_4"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia License Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;3, 2021, the Company and Akebia entered into a License Agreement (the &#8220;Akebia License Agreement&#8221;) relating to the exclusive worldwide license by the Company to Akebia of its rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the &#8220;Products&#8221;). Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Akebia paid a $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61462">3.0</ix:nonFraction>&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> payment to the Company upon signing of the License Agreement. On December&#160;13, 2024, the Company and Akebia entered into Amendment #1 to the License Agreement (the &#8220;2024 Amendment&#8221;) to the original License Agreement between the parties dated June&#160;3, 2021. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Under the terms of the 2024 Amendment, Akebia paid $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-61463">1.75</ix:nonFraction>&#160;million in amendment payments, of which $<ix:nonFraction name="ck0001755237:UpFrontPaymentReceived" contextRef="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-4" scale="6" format="ixt:num-dot-decimal" id="ixv-61464">1.25</ix:nonFraction>&#160;million was paid in December 2024 and an additional payment of $<ix:nonFraction name="ck0001755237:AdditionalUpFrontPayment" contextRef="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61465">0.5</ix:nonFraction>&#160;million was paid in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of&#160;certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $<ix:nonFraction name="ck0001755237:DevelopmentMilestonePayment" contextRef="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61466">1.0</ix:nonFraction>&#160;million development milestone payment would be due to the Company and which was received in February 2026. Pursuant to the terms of the Akebia License Agreement, as amended, Cyclerion is eligible to receive additional potential future development, regulatory, and commercialization milestone payments up to $<ix:nonFraction name="ck0001755237:CommercializationMilestonePayments" contextRef="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61467">557.5</ix:nonFraction>&#160;million in total, and Akebia will pay Cyclerion tiered royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit to twenty percent of net sales. Cyclerion&#8217;s obligations to deliver certain drug products have also ceased. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Akebia License Agreement, the Company determined the Akebia License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the Akebia License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined that the grant of license to its patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-evaluate</div> the probability of achievement of the milestones and any related constraints each reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia Material Purchase Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;3, 2025, the Company and Akebia entered into a Material Purchase Agreement (the &#8220;Purchase Agreement&#8221;) relating to the purchase of additional development materials (the &#8220;Additional Development Materials&#8221;) by Akebia for Akebia&#8217;s use pursuant to the Akebia License Agreement. Akebia paid $<ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61468">0.8</ix:nonFraction>&#160;million to the Company for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:exclude>F-40</ix:exclude> </div></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_167031199_4" continuedAt="TextSelectionAppend_167031199_5"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031199_5" continuedAt="TextSelectionAppend_167031199_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_167031199_6" continuedAt="TextSelectionAppend_167031199_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_167031199_7"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined the Purchase Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the Akebia License Agreement or the Amendment. The delivery of the Additional Development Materials by the Company represents a single performance obligation and consideration was recognized upon delivery. <ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2025To03_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-61470"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2026To03_31_2026_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-61471">No</ix:nonFraction></ix:nonFraction> revenue was recognized under the Purchase Agreement during three months ended March&#160;31, 2026 and 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Option Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $<ix:nonFraction name="ck0001755237:OptionFee" contextRef="P08_01_2024To08_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61472">150,000</ix:nonFraction> in August 2024 and subsequent fees totaling $<ix:nonFraction name="ck0001755237:OptionAdditionalFee" contextRef="P07_22_2024To07_22_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-61473">80,000</ix:nonFraction> to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company recognized revenue of $<ix:nonFraction name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="P01_01_2025To03_31_2025" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61474">0.1</ix:nonFraction>&#160;million related to the extension fee payment and expense reimbursement for the three months ended March&#160;31, 2025.</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Medsteer Collaboration Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On January&#160;3, 2026, the Company and the Medsteer, SAS (&#8220;Medsteer&#8221;) entered into a Collaboration and Option Agreement (the &#8220;Collaboration Agreement&#8221;) pursuant to which Medsteer granted to the Company (i)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div> worldwide, royalty-free, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#8220;Option&#8221;), exercisable at the Company&#8217;s sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">multi-bed</div> or intensive unit wards, or in the context of medical transport. The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an additional two years at the Company&#8217;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer. Under the terms of the Collaboration Agreement, the Company recognized $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2026To03_31_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61475">0.1</ix:nonFraction>&#160;million research and development expense during the three months ended March&#160;31, 2026, which is related to the upfront payment paid to Medsteer and other transaction costs. Medsteer will be eligible to receive up to $<ix:nonFraction name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="P01_03_2026To01_03_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-61476">3.7</ix:nonFraction>&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and&#160;royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2026To03_31_2026" escape="true" id="ixv-39567"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Subsequent Events </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">As described above, on April&#160;1, 2026, the Company entered into the Merger Agreement (which was subsequently amended on April&#160;17, 2026) with Korsana, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, pursuant to which Korsana will become a wholly owned subsidiary of the Company and the Company will operate under the name Korsana Biosciences, Inc. following the merger. The Company anticipates that the merger will close in the third quarter of 2026, subject to certain closing conditions, along with the concurrent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Korsana&#160;pre-closing&#160;financing.</div> Following the merger, the current business of Korsana will become the primary business of the Company. </div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-41 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">INDEX TO KORSANA BIOSCIENCES, INC.&#8217;S FINANCIAL STATEMENTS </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 95%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_7" style="display:inline;">Report of Independent Registered Public Accounting Firm (PCAOB ID# 00042)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_8" style="display:inline;">Consolidated Balance Sheets as of December&#160;31, 2025 and 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-45</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_9" style="display:inline;">Consolidated Statements of Operations and Comprehensive Loss for the Year Ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (Inception)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-46</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_10" style="display:inline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity for the Year Ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (Inception) to December&#160;31, 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-47</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_11" style="display:inline;">Consolidated Statements of Cash Flows for the Year Ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (Inception) to December&#160;31, 2024</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-48</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin111069_12" style="display:inline;">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-49</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-42 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin111069_7" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Report of Independent Registered Public Accounting Firm<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#160;</div> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the Stockholders and the Board of Directors of Korsana Biosciences, Inc.<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#160;</div></div></div> </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Opinion on the Financial Statements </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have audited the accompanying consolidated balance sheets of Korsana Biosciences, Inc. (the Company) as of December&#160;31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; (deficit) equity and cash flows for the year ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2025 and 2024, and the results of its operations and its cash flows for the year ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024 in conformity with U.S. generally accepted accounting principles. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis for Opinion </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Critical Audit Matter </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for the Antibody Discovery and Option Agreement </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 14%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 84%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Description of the Matter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">As described in Note 9 to the consolidated financial statements, during September 2025, the Company entered into an Antibody Discovery and Option Agreement (the &#8220;Paragon ADOA&#8221;) with Paragon and Parasa, both related parties, for certain research programs being developed by Paragon. The Company recorded expense of $31.3&#160;million during the year ended December&#160;31, 2025 for amounts incurred under the Paragon ADOA. The Company concluded that the arrangement represented the acquisition of in-process research and development assets with no alternative future use, resulting in the upfront consideration being expensed as</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-43 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">research and development costs upon execution of the agreement. All amounts paid as reimbursements to Paragon for ongoing development activities are recognized as research and development expenses as incurred. The Company also evaluated the classification of the warrants issued to Parasa and concluded that the warrants were equity classified.</div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;">Auditing management&#8217;s evaluation of the recognition of acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development and the classification of warrants issued was especially challenging and required significant audit effort and judgment due to the complex assessment of provisions within the Paragon ADOA under authoritative guidance and the related party nature of the transaction.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">How We Addressed the Matter in Our Audit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">To evaluate the Company&#8217;s accounting for the Paragon ADOA and warrants, our audit procedures included, among others, reading the agreements, discussing the contractual terms with management, and evaluating management&#8217;s technical accounting analysis for consistency with the agreement and applicable accounting guidance.</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have served as the Company&#8217;s auditor since 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Philadelphia, Pennsylvania </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">April 17, 2026 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-44 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin111069_8" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 77%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">154,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">461</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">154,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">154,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Long term liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Accrued other liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">13,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">78</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (Note 10)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Series Seed (formerly known as Series A) convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of December 31, 2025 and 2024; 20,000,000 and 8,000,000 shares issued and outstanding as of December&#160;31, 2025 and 2024, respectively; liquidation preference of $25,000 and $10,000 as of December 31, 2025 and 2024, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">24,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Series A convertible preferred stock, $0.0001 par value; 75,500,000 and no shares authorized as of December&#160;31, 2025 and 2024, respectively; 75,500,000 and no shares issued and outstanding as of December&#160;31, 2025 and December&#160;31, 2024, respectively; liquidation preference of $151,000 and $0 as of December 31, 2025 and 2024, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">150,573</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; (deficit) equity:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, $0.0001 par value; 122,363,552 and 35,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 6,000,000 and 5,000,000 shares issued and outstanding as of December 31, 2025 and 2024, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">153</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; (deficit) equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(33,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities, convertible preferred stock and stockholders&#8217; (deficit) equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">154,596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(1)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $10,565 as of December&#160;31, 2025 and $0 as of December&#160;31, 2024 (see Note 12). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-45 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin111069_9" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/>December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period&#160;from&#160;November&#160;8,<br/>2024 (Inception) to<br/>December 31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">32,785</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,506</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">37,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">109</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(37,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(109</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other income:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss and comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share attributable to common stockholders, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(12.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(0.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,920,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,509,434</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(1)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $31,248 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024 (see Note 12). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(2)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $1,203 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024 (see Note 12). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-46 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin111069_10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except share amounts) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 42%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in&#160;Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total&#160;Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">(Deficit) Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-right: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of November 8, 2024 (inception)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">99</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of Series Seed (formerly known as Series A) convertible preferred stock. net of issuance costs of $35</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of December 31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">153</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of Series Seed convertible preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of Series A convertible preferred stock, net of issuance costs of $427</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">75,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">150,573</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Issuance of restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">792</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">792</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Grant of the Parasa warrant</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">816</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">816</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of December 31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">95,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">175,537</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,761</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,730</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(33,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-right-color: rgb(0, 0, 0); border-right-width: 0.75pt; border-right-style: solid;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-47 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin111069_11" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 69%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/>December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period from<br/>November&#160;8,&#160;2014<br/>(Inception) to<br/>December&#160;31,&#160;2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,608</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(461</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash (used in) provided by operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(22,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">860</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="text-align: right; vertical-align: bottom;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of Series Seed convertible preferred stock, net of issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Proceeds from issuance of Series A convertible preferred stock, net of issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">150,573</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">166,433</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net increase in cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">144,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents at beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents at end of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">154,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(1)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $10,565 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024 (see Note 12). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-48 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin111069_12" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">1.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nature of the Business and Basis of Presentation </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Background and Basis of Presentation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Korsana Biosciences, Inc. and subsidiary (&#8220;Korsana&#8221; or the &#8220;Company&#8221;) is a biotechnology company that was established and incorporated under the laws of the state of Delaware on November&#160;8, 2024. Korsana was founded and launched to research and develop antibody candidates licensed from Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;). As of December&#160;31, 2025, the Company operated as a virtual company and did not maintain a corporate headquarters or other significant facilities. Korsana was formed to develop therapies built on Therapeutic Targeting (THETA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">TM</div>), a next generation blood-brain barrier (BBB) platform, with an initial focus on neurodegenerative disorders, including its lead product candidate, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">KRSA-028,</div> an anti-amyloid beta (&#8220;A&#223;&#8221;) antibody that combines the proprietary Therapeutic Targeting (&#8220;THETA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#8482;</div>&#8221;) platform informed by clinical and regulatory learnings from other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">anti-A&#223;</div> products that have achieved regulatory approval or are in late-stage clinical trials. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, the ability to complete preclinical and clinical trials, the ability to obtain regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s potential product candidates will require approval from the U.S. Federal Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential product candidates will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential product candidates, if approved, will be accepted in the marketplace, that any future product candidates can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product candidates will be successfully marketed, if at all. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On April&#160;1, 2026, the Company entered into an Agreement and Plan of Merger with Cyclerion Therapeutics Inc. (&#8220;Cyclerion&#8221;) and Cariboos Merger Sub Corp and Cariboos Merger Sub II, LLC, both wholly owned subsidiaries of Cyclerion, which agreement was subsequently amended on April&#160;17, 2026 (as amended, the &#8220;Merger Agreement&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation (the &#8220;First Merger&#8221;). Immediately following the First Merger and as part of the same overall transaction, Korsana will merge with and into Cariboos Merger Sub II, LLC (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), with Cariboos Merger Sub II, LLC being the surviving entity of the Second Merger. In connection with the Merger, Cariboos Merger Sub II, LLC will change its corporate name to &#8220;Korsana Biopharma Operating Company, LLC&#8221; and Cyclerion will change its name to &#8220;Korsana Biosciences, Inc.&#8221; The combined company will be led by the Company&#8217;s management team and will remain focused on discovering and developing novel therapies designed to reduce the burden of neurodegenerative diseases, starting with Alzheimer&#8217;s disease. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subject to the terms and conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Korsana common stock (including shares of Korsana common stock issued in connection with the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing described below) will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock equal to the Exchange Ratio as defined in the Merger Agreement, (ii)&#160;each then-outstanding share of Korsana Series Seed preferred stock will be converted into the right to receive a </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-49 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">number of shares of Cyclerion Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-voting</div> Preferred Stock, which are each convertible into 1,000 shares of Cyclerion common stock, equal to the Exchange Ratio divided by 1,000, (iii) each-then-outstanding share of Korsana Series A preferred stock will be automatically converted into the right to receive to a number of shares of Cyclerion common stock equal to the Exchange Ratio, as well a right to receive a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase Korsana common stock that will be converted into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase Cyclerion common stock, subject to adjustment as set forth in the form of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant, (v)&#160;each then-outstanding option to purchase Korsana common stock will be assumed by Cyclerion and will be converted into an option to purchase shares of Cyclerion common stock, adjusted for the Exchange Ratio, (vi)&#160;each then-outstanding warrant to purchase Korsana common stock will be assumed by Cyclerion and will be converted into a warrant to purchase shares of Cyclerion common stock, subject to adjustment as set forth in the Merger Agreement, (vii)&#160;each then-outstanding share of Korsana restricted stock will be assumed by Cyclerion, subject to adjustment as set forth in the Merger Agreement, (viii)&#160;each then-outstanding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase shares of Korsana common stock will be converted into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase shares of Cyclerion common stock, subject to adjustment as set forth in the Merger Agreement and the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the Merger, on April&#160;1, 2026, Korsana and Cyclerion entered into Subscription Agreements with certain institutional and accredited investors, pursuant to which such investors have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the Merger, shares of Korsana common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants at an estimated purchase price of $2.3534 per share and $2.3533 per warrant, for an aggregate purchase price of $380.0&#160;million in a private placement (the &#8220;Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing&#8221;). Shares of the Company&#8217;s common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing will be converted into shares of Cyclerion common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase share of Cyclerion common stock in accordance with the Exchange Ratio at the effective time of the close of the transaction. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by Cyclerion&#8217;s stockholders, (2)&#160;approval by the Company&#8217;s stockholders, (3)&#160;Nasdaq&#8217;s approval of the listing application to be submitted in connection with the Merger, and (4)&#160;the effectiveness of Cyclerion&#8217;s registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-4.</div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the date that the consolidated financial statements are issued. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Since its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its potential product candidates and starts to generate revenue, it expects to incur significant expenses related </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-50 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">to developing its internal commercialization capability to support product sales, marketing, and distribution. As a result, the Company will need substantial additional funding to support its operations. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statements do not include any adjustments that may result if the Company is not able to continue as a going concern. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred net losses of $35.6&#160;million and $0.1&#160;million during the year ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024, respectively. As of December&#160;31, 2025 and 2024, the Company had an accumulated deficit of $35.7&#160;million and $0.1&#160;million, respectively. As of December&#160;31, 2025, the Company had $154.1&#160;million in cash and cash equivalents. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s management expects that the existing cash and cash equivalents that were primarily raised from Series Seed and Series A convertible preferred stock financings (see Note 5) will be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the date these consolidated financial statements are available to be issued. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Summary of Significant Accounting Policies </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In December 2025, the Company formed Korsana Securities Corporation, which is a wholly owned subsidiary based in the United States, to hold the Company&#8217;s marketable securities. All intercompany balances and transactions have been eliminated in consolidation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company operates and manages its business as a single operating and reporting segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information for purposes of evaluating financial performance and allocating resources (see Note 13). </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-51 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash balances at an accredited financial institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is dependent on third-party organizations to research, develop, manufacture, and process its potential product candidates for its development programs. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note 9). </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of an investment in a money market fund. Interest income associated with the cash equivalents is recorded as other income in the consolidated statements of operations and comprehensive loss. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1 &#8212; Quoted prices in active markets that are identical assets or liabilities. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2 &#8212; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3).&#160;The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their relatively short maturity periods. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Classification of Convertible Preferred Stock </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has classified the Series Seed convertible preferred stock and Series A convertible preferred stock (together the &#8220;Convertible Preferred Stock&#8221;) outside of stockholders&#8217; deficit on the Company&#8217;s </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-52 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Convertible Preferred Stock is not redeemable, except in the event of deemed liquidation (see Note 5). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the Convertible Preferred Stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the Convertible Preferred Stock would be made only when a deemed liquidation event becomes probable. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Contract Costs Accruals </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third-party service providers, including contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related party Paragon (see Note 9). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accrues for expenses resulting from obligations under its Antibody Discovery and Option Agreement (the &#8220;Paragon ADOA&#8221;) and Platform Option Agreement (the &#8220;Paragon POA&#8221;) by and among the Company, Paragon and Parasa Holding LLC (&#8220;Parasa&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of December&#160;31, 2025 and 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development costs are expensed as incurred. Research and development costs include amounts reimbursed to Paragon under the Paragon ADOA (see Note 9), salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative Expenses </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, and professional fees. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-53 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Commitments and Contingencies </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company may be subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the consolidated balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December&#160;31, 2025 and 2024, no liabilities were recorded for loss contingencies (see Note 10). </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company grants stock options and restricted stock awards (&#8220;RSAs&#8221;) that are subject to service-based vesting conditions. Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services. Forfeitures are accounted for as they occur. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company also has RSAs that are subject to performance-based vesting conditions relating to the achievement of a specified amount of Series A convertible preferred stock financing. Accruals of compensation cost for an award with a performance condition shall be based on the probable outcome of that performance condition. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company measures all stock-based awards granted to employees, directors, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The fair values of restricted stock awards and options are based on the fair value of the Company&#8217;s common stock on the date of grant. The Company&#8217;s common stock valuations were prepared using a recent transactions method, including an option pricing method (&#8220;OPM&#8221;). Under this method, the Company used the observed transaction price from a recent preferred stock financing and solved for the total equity value that results in that preferred stock price, using an OPM that allocates value across the Company&#8217;s capital structure based on the rights and preferences of each equity class. The resulting total equity value was then allocated to the common stock and preferred stock based on their respective economic rights, resulting in an estimated fair value of the Company&#8217;s common stock as of the valuation date. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of common stock and stock-based compensation expense could have been materially different. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-54 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share Attributable to Common Stockholders </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company applies the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method when computing net loss per share attributable to the Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its Convertible Preferred Stock to be participating securities as, in the event a dividend is paid on common stock, the holders of Convertible Preferred Stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potentially dilutive securities. For purposes of this calculation, the Company&#8217;s outstanding warrants, outstanding Convertible Preferred Stock, stock options to purchase common stock, and unvested RSAs are considered potentially dilutive common shares. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company generated a net loss for the period presented. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-step</div> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-55 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company will recognize interest and/or penalties related to unrecorded tax benefits in income tax expense as they arise. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncement Not Yet Adopted </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div> Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">220-40):</div> Disaggregation of Income Statement Expenses (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> require public entities to disclose specified information about certain costs and expenses. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> is effective for the Company&#8217;s annual reporting period beginning after December&#160;15, 2026 and interim reporting periods beginning after December&#160;27, 2027, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements. </div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">3.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair Value Measurements </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following tables present the Company&#8217;s fair value hierarchy for financial assets and liabilities measured (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">149,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">149,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">149,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">149,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents consist of money market funds, which were valued by the Company based on quoted market prices, which represent a Level&#160;1 measurement within the fair value hierarchy. There were no transfers between Level&#160;1, Level&#160;2, or Level&#160;3 during the year ended December&#160;31, 2025. The Company did not have any financial assets or liabilities that were determined to be Level&#160;1, Level&#160;2, or Level&#160;3 measurements within the fair value hierarchy as of December&#160;31, 2024. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">4.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued Expenses and Other Current Liabilities </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 66%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/>2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/>2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional and consulting <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">827</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued employee compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12,313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(1)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $10,333 as of December&#160;31, 2025 and $0 as of December&#160;31, 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-56 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(2)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $232 as of December&#160;31, 2025 and $0 as of December&#160;31, 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">5.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible Preferred Stock </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On November&#160;21, 2024, the Company issued a total of 8,000,000 shares of the initial Series A Convertible Preferred Stock to Fairmount Healthcare Fund II L.P. (Fairmount Fund II), an affiliate fund of Fairmount, as well as to Venrock Healthcare Capital Partners EG L.P., Venrock Healthcare Capital Partners III, L.P., VHCP <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-Investment</div> Holdings III, LLC, Venrock Associates IX, L.P. and Venrock Partners IX, L.P., (collectively known as &#8220;Venrock&#8221;) at a purchase price of $1.25 per share for gross proceeds of $10.0&#160;million. Of the 8,000,000 shares of initial Series A Convertible Preferred Stock issued, 4,000,000 shares of Series A Convertible Preferred Stock were issued to Fairmount Fund II and 4,000,000 shares of Series A Convertible Preferred Stock were issued to Venrock, both of which are considered related parties (see Note 12). </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;11, 2025 (the &#8220;Additional Closing Date&#8221;), the Company issued an additional 12,000,000 shares of the initial Series A Convertible Preferred Stock to Fairmount Fund II and Venrock, at a purchase price of $1.25 per share for gross proceeds of $15.0&#160;million (the &#8220;Additional Closing&#8221;). Of the 12,000,000 shares of initial Series A Convertible Preferred Stock issued, 6,000,000 shares of Series A Convertible Preferred Stock were issued to Fairmount Fund II and 6,000,000 shares of Series A Convertible Preferred Stock were issued to Venrock. Additionally, the Company and its stockholders decided to seek additional capital funding by authorizing up to 75,500,000 shares of a new series of preferred stock of the Company to be designated as the new &#8220;Series A Convertible Preferred Stock&#8221;. The Board of Directors amended the Amended and Restated Certificate of Incorporation (&#8220;ARCI&#8221;) to (i)&#160;change the name of the Company to &#8220;Korsana Biosciences, Inc.&#8221; from &#8220;Korsa Biosciences, Inc.&#8221;; (ii) reclassify each outstanding share of initial Series A Convertible Preferred Stock into a share of preferred stock of the Company to be designated as &#8220;Series Seed Convertible Preferred Stock&#8221; (collectively with the new Series A Convertible Preferred Stock, the &#8220;Convertible Preferred Stock&#8221;), which resulted in the reclassification of 20,000,000 shares of the initial Series A Convertible Preferred Stock issued and outstanding into shares of Series Seed Convertible Preferred Stock; (iii)&#160;designate the rights, preferences, privileges, and restrictions of the new Series A Convertible Preferred Stock, and facilitate the issuance and sale of such shares; and (iv)&#160;authorize 122,363,552 shares of common stock of the Company, $0.0001 par value per share and 95,500,000 shares of preferred stock of the Company, $0.0001 par value per share, of which 20,000,000 shares will be designated as Series Seed Convertible Preferred Stock and 75,500,000 shares will be designated as Series A Convertible Preferred Stock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;15, 2025, the Company entered into the new Series A Preferred Stock Purchase Agreement to issue certain investors shares of Series A Convertible Preferred Stock, $0.0001 par value per share, at a purchase price of $2.00 per share. The Company issued 75,500,000 shares of the Series A Convertible Preferred Stock for gross proceeds of $151.0&#160;million. Of the 75,500,000 shares of Series A Convertible Preferred Stock issued, 12,500,000 shares were issued to Fairmount and 12,500,000 shares were issued to Venrock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The holders of the Convertible Preferred Stock have the following rights and preferences: </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Voting </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The holders of Convertible Preferred Stock are entitled to vote, together with the holders of the Company&#8217;s common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-57 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">stockholders entitled to vote on such matter. A majority vote of the holders of Convertible Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws in a manner that adversely affects the rights of the Convertible Preferred Stock, reclassify common stock or establish another class of capital stock (unless the same ranks junior to the Convertible Preferred Stock with respect to its rights), create shares that would rank senior to or authorize additional shares of Convertible Preferred Stock, declare a dividend or make a distribution. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the holders of record of the shares of Series Seed Preferred Stock, voting together exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> to Common Stock basis, shall be entitled to elect four directors of the Company. The holders of record of the shares of Series A Preferred Stock, voting together exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> to Common Stock basis, shall be entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Convertible Preferred Stock), exclusively and voting together as a single class, are entitled to elect one director of the Company. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Each share of Convertible Preferred Stock is convertible into common shares at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Convertible Preferred Stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of the firm-commitment underwritten public offering of the Company&#8217;s common stock or the closing of a reverse merger transaction at which the price is at least $4.00 per share resulting in at least $75.0&#160;million of gross proceeds to the Company, net of the underwriting discounts or commissions, or (ii)&#160;the vote or written consent of the holders of a majority of the outstanding shares of Convertible Preferred Stock, voting as a single class. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The conversion ratio of Convertible Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $1.25 per share for the Series Seed Convertible Preferred Stock and $2.00 per share for the Series A Convertible Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The conversion price is currently $1.25 per share for the Series Seed Convertible Preferred Stock and $2.00 per share for the Series A Convertible Preferred Stock. As of December&#160;31, 2025 and 2024, each outstanding share of Convertible Preferred Stock was convertible into common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">one-for-one</div></div> basis. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Convertible Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Convertible Preferred Stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Convertible Preferred Stock calculated based on the respective original issue price of the Series A Convertible Preferred Stock and Series Seed Convertible Preferred Stock. Dividends are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cumulative.</div> For the year ended December&#160;31, 2025 and for the period November&#160;8, 2024 (inception) through December&#160;31, 2024, no dividends had been declared or paid by the Company. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-58 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Convertible Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Convertible Preferred Stock are entitled to an amount equal to the greater of (i)&#160;the applicable original issue price per share of the Convertible Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Convertible Preferred Stock in preference to any distributions to common stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unless the holders of a majority in voting power of the then outstanding shares of Convertible Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redemption </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Convertible Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">6.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common Stock </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025 and 2024, the Company has the authority to issue a total of 122,363,552 and 35,000,000 shares of common stock, respectively, at a par value of $0.0001 per share. As of December&#160;31, 2025 and 2024, the Company had 6,000,000 and 5,000,000 shares of common stock, respectively, issued and outstanding in connection with RSAs. Unvested RSAs are considered legally issued and outstanding shares of common stock. Each share of common stock entitles the holder to one vote, together with the holders of Convertible Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors, subject to the dividend rights of the holders of Convertible Preferred Stock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025 and 2024, there are 105,358,748 and 8,000,000 shares of common stock reserved for issuance for the potential conversion of shares of Convertible Preferred Stock into common stock and the exercise of outstanding stock options and warrants to common stock. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-59 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025 and 2024, the Company had common stock reserved for future issuance as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/>2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,<br/>2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issuable upon conversion of Company Series Seed Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">20,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issuable upon conversion of Company Series A Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">75,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issuable upon exercise of warrants under the Parasa Warrant Obligation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,102,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding and issued stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,756,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total shares of common stock reserved</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">105,358,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">7.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-Based Compensation </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2025 Equity Incentive Plan </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;11, 2025, the Board of Directors approved the 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock-based awards to employees, officers, directors, consultants, and advisors. The 2025 Plan is administered by the Board of Directors, or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2025 Plan generally vest over four years, subject to the participant&#8217;s continued service, and expire after ten years. Upon adoption, the 2025 Plan authorized 20,584,336 shares of common stock reserved for issuance under the plan. As of December&#160;31, 2025, the total number of shares of common stock reserved for issuance under the 2025 Plan was 20,584,336 shares, with 10,828,149 shares of common stock available for future grants. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Option Valuation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option- pricing model. The Company is a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-60 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the year ended December&#160;31, 2025: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 70%;"/>
<td style="width: 26%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December<br/>31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">87.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity for the year ended December&#160;31, 2025: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 35%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number&#160;of&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted&#160;Average<br/>Exercise<br/>Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted&#160;Average<br/>Remaining<br/>Contractual Term<br/>(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding balance as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,756,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding balance as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,756,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest, December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,756,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">67,886</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted average grant-date fair value of stock options granted for the year ended December&#160;31, 2025 was $0.64. For the year ended December&#160;31, 2025, there was no intrinsic value related to outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock. There were no stock options granted during the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Awards </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;8, 2024, the Company&#8217;s Board of Directors approved the Restricted Stock Notice and Restricted Stock Purchase Agreement, under which Korsana issued and sold 5,000,000 RSAs to Paragon at a price of $0.02 per share. Paragon subsequently contributed 2,500,000 RSAs to Parasa, an entity formed by Paragon as a vehicle to hold equity in the Company. The RSAs have performance-based vesting conditions only, which include a performance condition related to achieving a specified amount of Series A convertible preferred stock financing. The Company considers the probability of achieving the relevant performance condition and recognizes expense when the Company concludes it is probable that the performance condition will be achieved. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-61 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;21, 2024, the Company raised gross proceeds of $10.0&#160;million in connection with the initial Series A Convertible Preferred Stock financing (see Note 5). Upon the initial issuance of Series A Convertible Preferred Stock to Fairmount and Venrock, 40% of the RSAs became vested under the performance condition and the Company recognized stock-based compensation expense associated with these RSAs. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;11, 2025, the Company raised gross proceeds of $15.0&#160;million in connection with the Series A Convertible Preferred Stock Additional Closing (see Note 5). Upon the additional issuance of the initial Series A Convertible Preferred Stock to Fairmount and Venrock, 100% of the RSAs became vested under the performance condition and the Company recognized stock-based compensation expense associated with these RSAs. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;27, 2025, the Company issued and sold 1,000,000 RSAs to the Company&#8217;s chief executive officer, a venture partner at Fairmount during the year ended December&#160;31, 2025, in exchange for executive services and such issuance was determined to be a related party transaction (see Note 12). The RSAs issued and sold to the Company&#8217;s chief executive officer have service-based vesting conditions and vest over a four-year period, during which time all unvested shares are subject to forfeiture and the Company&#8217;s repurchase right in the event the holder&#8217;s services with the Company voluntarily or involuntarily terminate. The RSAs issued and sold to the Company&#8217;s chief executive officer were granted from the 2025 Plan. As these unvested RSAs are similar to early exercises of stock options, cash proceeds received for unvested RSAs issued to the Company&#8217;s chief executive officer were initially recorded as a liability and are reclassified to equity as vesting occurs. As of December&#160;31, 2025, $0.3&#160;million and $0.5&#160;million, respectively, was recorded in accrued expenses and other current liabilities and accrued other liabilities, noncurrent on the Company&#8217;s consolidated balance sheet related to the unvested RSAs held by the chief executive officer subject to vesting and repurchase rights under the terms of the RSA agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the RSA activity for the year ended December&#160;31, 2025: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 54%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number&#160;of&#160;RSAs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted&#160;Average<br/>Grant&#160;Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested balance as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested balance as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024, the Company recorded stock-based compensation expense of $0.2&#160;million and $0.1&#160;million, respectively, related to the RSAs in the consolidated statements of operations and comprehensive loss as general and administrative and research and development expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Parasa Warrant Obligation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In September 2025, the Company entered into the Paragon ADOA with Paragon and Parasa (see Note 9). Under the terms of the Paragon ADOA, Parasa will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&#160;31, 2025 and December&#160;31, 2026, with an exercise price equal to the fair market value of the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-62 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">underlying shares on the grant date as determined by the Board of Directors (the &#8220;Parasa Warrant Obligation&#8221;). If the term with respect to all research programs ends prior to the end of a calendar year, the warrant for such calendar year shall be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pro-rated</div> for that calendar year. The grant dates for the issuance of warrants was on December&#160;31, 2025 (the &#8220;2025 Parasa Warrant Obligation&#8221;) and expected to be on December&#160;31, 2026 (the &#8220;2026 Parasa Warrant Obligation&#8221;) (if the term with respect to all research programs is still active), respectively, as all terms of the award, including number of shares and exercise price, will be known by all parties on those dates. Parasa&#8217;s research and discovery related activities have a service inception date preceding the grant dates, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, the Company records a liability for the warrants expected to be granted to Parasa as the related services are provided, with the value of the liability based on the estimated fair value of the warrants at each interim reporting date. For the year ended December&#160;31, 2025, $0.8&#160;million was recognized as stock-based compensation expense related to the 2025 Parasa Warrant Obligation within research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss. On December&#160;31, 2025, the fair value of the warrant obligation of $0.8&#160;million was reclassified from accrued expenses to stockholders&#8217; equity on the consolidated balance sheet when the Company settled the 2025 Parasa Warrant Obligation by issuing Parasa a warrant to purchase 1,102,561 shares of Company Common Stock at an exercise price of $0.86 per share. The warrant has a term of 10 years, is fully vested, and is exercisable in part or full at any time during the term of the warrant. As of December&#160;31, 2025, the warrant issued under the 2025 Parasa Warrant Obligation is outstanding and unexercised. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the assumptions used in calculating the fair value of the warrant: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">87.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statements of operations and comprehensive loss (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 50%;"/>
<td style="width: 21%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 21%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/>December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period&#160;from&#160;November</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">8, 2024 (Inception) to<br/>December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">680</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,608</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025, total unrecognized compensation cost related to the unvested stock options was $4.9&#160;million, which is expected to be recognized over a weighted average period of approximately 3.5 years. As of December&#160;31, 2025, total unrecognized compensation cost related to the unvested RSAs was $0.5&#160;million to be recognized over a weighted average period of approximately 3.4 years. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-63 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the consolidated statements of operations and comprehensive loss (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 50%;"/>
<td style="width: 21%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 21%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/>December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period&#160;from&#160;November</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">8, 2024 (Inception) to<br/>December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Parasa Warrant Obligation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">816</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,608</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">8.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income Taxes </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The domestic and foreign components of the Company&#8217;s loss before income taxes were as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/>December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period from<br/>November&#160;8,&#160;2024<br/>(Inception) to<br/>December&#160;31,<br/>2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">U.S.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table is a reconciliation of the U.S. federal statutory rate of 21% to the Company&#8217;s effective rate for the year ended December&#160;31, 2025: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 78%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">U.S. Federal Statutory Tax Rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(7,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State and Local Income Tax, Net of Federal (National) Income Tax Effect</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign Tax Effects</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effect of Changes in Tax Laws or Rates Enacted in the Current Period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effect of Cross-Border Tax Laws</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax Credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">R&amp;D Credit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(463</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in valuation allowances</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7,901</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(22.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nontaxable or Nondeductible Items</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Permanent Adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in Unrecognized Tax Benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other Adjustments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-64 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the period from November&#160;8, 2024 (Inception) to December&#160;31, 2024, the effective income tax rate differs from the statutory federal income tax rate as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 75%;"/>
<td style="width: 20%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period from<br/>November&#160;8,&#160;2024<br/>(Inception) to<br/>December&#160;31,<br/>2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Federal statutory income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">State income taxes, net of federal benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(10.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Permanent differences</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(12.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the years ended December&#160;31, 2025 and 2024, the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s operating losses since inception have been generated in the United States. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Components of the Company&#8217;s deferred tax assets consisted of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and Development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">937</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accruals and Reserves</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research&#160;&amp; Experimental Expenditures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Based Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">368</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Capitalized License Fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">526</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,252</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(10,252</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025 and 2024, the Company had federal net operating loss carryforwards of $31.5&#160;million and less than $0.1&#160;million, respectively, which may be available to offset future taxable income. The federal net operating losses carryforward indefinitely, but may only be used to offset 80% of annual taxable income. As of December&#160;31, 2025 and 2024, the Company had state net operating loss carryforwards of $26.2&#160;million and less than $0.1&#160;million, respectively. The state net operating losses expire beginning in 2044. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025 and 2024, the Company also had federal research and development tax credit carryforwards of $0.5&#160;million and $0, respectively, which may be available to offset future tax liabilities. As of December&#160;31, 2025 and 2024, the Company had state research and development tax credit carryforwards of $0.6&#160;million and $0, respectively. The federal tax credit carryforwards expire beginning in 2045 while the state tax credits carryforwards expire beginning in 2040. A full valuation allowance has been provided against the Company&#8217;s research and development tax credit carryforwards and, if an adjustment is required, this adjustment would result in an adjustment to the deferred tax asset established for the research and development tax credit carryforwards and the valuation allowance. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-65 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 (&#8220;IRC&#8221;), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards, research and development tax credit carryforwards, or the federal orphan drug credits would be subject to an annual limitation under Section&#160;382. Any limitation may result in expiration of a portion of the net operating loss carryforwards, research and development tax credit carryforwards, or the federal orphan drug credits before utilization. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has evaluated the positive and negative evidence bearing upon the realizability of the deferred tax assets. As of December&#160;31, 2025 and 2024, based on the Company&#8217;s historical operating losses, the Company has concluded that it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December&#160;31, 2025 and 2024. The valuation allowance for deferred tax assets as of December&#160;31, 2025 and 2024 was $10.3&#160;million and less than $0.1&#160;million, respectively. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The valuation allowance increased by $10.3&#160;million and less than $0.1&#160;million during the years ended December&#160;31, 2025 and 2024, respectively. The change during the year ended December&#160;31, 2025 was primarily due to the increase in the capitalized research and experimental expenditures, research and development tax credit and net operating loss carryforwards. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025 and 2024, the Company had no accrued interest or penalties related to unrecorded tax benefits. The Company did not have any uncertain tax positions as of December&#160;31, 2025 and 2024. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The federal and state income tax returns are generally subject to tax examinations for the tax years ended December&#160;31, 2024 through present. To the extent that the Company has tax attribute carryforwards, the tax years in which the attributes were generated may still be adjusted upon examination by the Internal Revenue Services or State tax authorities to the extent utilized in a future period. The Company is not currently under examination by any tax authorities. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">9.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Paragon Antibody Discovery and Option Agreement</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bolder;display:inline;"><div style="font-style: normal; background: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Paragon Antibody Discovery and Option Agreement </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In September 2025, the Company entered into the Paragon ADOA with Paragon and Parasa. Under the Paragon ADOA, Paragon identifies, evaluates, and develops antibodies against one or more mutually agreed therapeutic targets and a mutually agreed brain transit target. The Paragon ADOA covers Research Program 001 and Research Program 002, each targeting A&#223; and TfR1 (together the &#8220;A&#223; program&#8221;), and one undisclosed research program 003, with the ability to add additional programs by mutual agreement. The Company&#8217;s lead product candidate, KRSA-028, was developed from program 002. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-66 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Under the Paragon ADOA, Korsana has the exclusive option (each, an &#8220;ADOA Option&#8221;), on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Program-by-Program</div></div> basis, to enter into a separate agreement with Paragon consistent with a set of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-negotiated</div> terms to further develop, manufacture and commercialize the resulting antibody transport vehicle compounds (each, a &#8220;License Agreement&#8221;). If the Company exercises an ADOA Option and finalizes a related License Agreement, it will be required, on a program-by-program and product-by-product basis, to make one-time, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> milestone payments of up to $46.0&#160;million per product upon the achievement of specified clinical development and regulatory milestones, which amount is reduced by 50% for independently developed products directed to the same target combination. Additionally, the Company will be required to make tiered royalty payments in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">low-to-mid</div></div> single-digits beginning on the first commercial sale of each developed product. From time to time, the Company can choose to add additional targets by mutual agreement with Paragon. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Under the terms of the Paragon ADOA, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Korsana (each, a &#8220;Research Program&#8221;), and certain administrative activities. The Paragon ADOA requires Korsana, Paragon, and Parasa to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities may include performing preclinical studies. Korsana is required to pay a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> nonrefundable, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-creditable</div> fee of $1.0&#160;million (the &#8220;Research Initiation Fee&#8221;) within 30 days following finalization of the Research Plan for each such Research Program. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Korsana will reimburse Paragon for the costs of performing the development activities set forth in the Research Plan, plus an agreed-upon margin charged by Paragon. Korsana made an upfront payment to Paragon when they entered into the Paragon ADOA to cover the cost of work completed by Paragon for the selected Research Programs prior to the effective date. Each Research Program is overseen and coordinated by a joint development committee consisting of two employees from Korsana and two employees from Paragon, with Korsana and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parasa have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Parasa will deliver to Korsana a data package that includes sequence information for all then-existing antibodies and information directed to such target. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless terminated earlier, the Paragon ADOA shall continue in force on a Research Program- <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">by-Research</div> Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such ADOA Option is not exercised by the Company; (ii)&#160;if the Company exercises its ADOA Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30 days, the expiration of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the Paragon ADOA). The Company may terminate the Paragon ADOA or any Research Program at any time for any or no reason upon 30 days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancellable</div> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon ADOA or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Paragon ADOA or any Research Program upon (i) 30 days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> period and (ii)&#160;the other party&#8217;s bankruptcy. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon ADOA, provided that any milestone set in the Paragon ADOA that </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-67 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon ADOA and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Korsana pursuant to the Paragon ADOA for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Korsana would also be required to make royalty payments to Paragon in the low single-digit percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">product-by-product</div></div> and country- <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">by-country</div> basis upon the later of the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">last-to-expire</div></div> valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the Paragon ADOA, Korsana will grant Parasa warrants on each of December&#160;31, 2025 and December&#160;31, 2026, to purchase a number of shares equal to 1.00% of Korsana&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Korsana common stock on each respective grant date. Parasa is an entity formed by Paragon as a vehicle to hold equity in Korsana in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon ADOA other than to receive such warrants (see Note 7). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company concluded that the rights obtained under the Paragon ADOA represent an asset acquisition whereby the underlying assets comprise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development assets with no alternative future use. The Paragon ADOA did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development assets, which represent a group of similar identifiable assets. All of the upfront consideration paid by Korsana was allocated to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development assets acquired and was immediately expensed as part of research and development expenses on the consolidated statement of operations and comprehensive loss. The research initiation fees represent a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> cost on a research <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">program-by</div> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">on-going</div> development costs, monthly development cost fees and additional development expenses incurred by Paragon are recognized as research and development expense when incurred. Amounts paid as reimbursements for administrative activities incurred by Paragon are recognized as general and administrative expense when incurred. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the Paragon ADOA, the Company recorded expense of $31.3&#160;million during the year ended December&#160;31, 2025 for amounts owed to Paragon across all Research Programs, including $18.8&#160;million of upfront payments made to cover the cost of development work completed by Paragon prior to the effective date and $2.0&#160;million of Research Initiation Fees. A total of $30.3&#160;million was recognized as research and development expense and $1.0&#160;million was recognized as general and administrative expense in the Company&#8217;s consolidated statements of operations and comprehensive loss during the year ended December&#160;31, 2025. An amount of $10.6&#160;million was unpaid by Korsana at December&#160;31, 2025 and is included in related party accrued expenses and other current liabilities within the Company&#8217;s consolidated balance sheet. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Paragon Platform Option Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In October 2025, the Company entered into the Platform Option Agreement with Paragon and Parasa (the &#8220;Paragon POA&#8221;) in connection with the Paragon ADOA. Pursuant to the Paragon POA, the Company will have an exclusive option to enter into either a separate Antibody Discovery and Option Agreement or a separate </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-68 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">License Agreement with Paragon and Parasa, enabling the Company with the right to add, remove, or replace specific target combinations and further develop, manufacture and commercialize the resulting antibody transport vehicle compounds. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following designation of a target combination, the Company may elect their option to enter into a separate Antibody Discovery and Option Agreement or a separate License Agreement with Paragon and Parasa, the terms of which will be finalized in connection with the option exercise. If the Company elects to enter into a License Agreement (a &#8220;POA License&#8221;), it will be required to make a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> payment to Paragon of $5.0&#160;million for the license option exercise fee. Under any POA License, Korsana would be required to make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> milestone payments of up to $41.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination, and tiered royalty payments in the low to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit percentage range based on annual net sales, subject to certain reductions.. These payments are intended to fund the research to be performed by Paragon and Parasa under either an Antibody Discovery and Option Agreement or License Agreement. As of December&#160;31, 2025, the Company has not exercised its option and no amounts were expensed related to the Paragon POA during the year ended December&#160;31, 2025. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will also have an exclusive option to designate up to two additional reserved target combinations. If the Company exercises its option, it will be required to make a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> payment to Paragon of $2.0&#160;million for the additional reserved target option exercise fee. A separate additional reserved target option exercise fee is due and payable to Paragon each time that the Company exercises an additional reserved target option. </div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">10.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and Contingencies </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">401(k) Plan </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company maintains a defined-contribution plan under Section&#160;401(k) of the Internal Revenue Code of 1986 (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-tax</div> basis. Matching contributions to the 401(k) Plan may be made at the discretion of management. For the year ended December&#160;31, 2025 and for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024, the Company has not recorded any expense related to 401(k) Plan match contributions. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Indemnification Agreements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31, 2025 and 2024. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-69 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legal Proceedings </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of December&#160;31, 2025 and 2024, the Company was not a party to any material legal proceedings or claims. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">11.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net Loss per Share </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 57%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/>December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period from<br/>November&#160;8,&#160;2024<br/>(Inception) to<br/>December&#160;31,<br/>2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,920,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,509,434</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss attributable to common stockholders, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(12.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(0.06</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted-average common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti-dilutive effect: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/>December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period from<br/>November&#160;8,&#160;2024<br/>(Inception) to<br/>December&#160;31,<br/>2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">95,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,756,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding and issued warrant to Parasa</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,102,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">106,358,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">11,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-70 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">12.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Related Party Transactions </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fairmount, Venrock, Paragon, and Parasa have been identified as related parties of Korsana and have engaged in material transactions with the Company. The ownership of outstanding shares of stock of Korsana, assuming the conversion of preferred stock into common stock, is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 55%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 21%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,&#160;2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fairmount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Venrock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Paragon</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Parasa</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fairmount currently has two representatives appointed to Korsana&#8217;s Board of Directors. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. Parasa is an entity formed by Paragon as a vehicle to hold equity in Korsana in order to share profits with certain employees of Paragon. Additionally, Venrock has two representatives appointed to Korsana&#8217;s Board of Directors. The Company entered into significant related party transactions with Fairmount, Paragon and Parasa during 2024 and 2025 related to the issuance of Convertible Preferred Stock to Fairmount (see Note 5), the issuance of RSAs and warrants to Paragon and Parasa (see Note 7), the issuance of RSAs to the Company&#8217;s chief executive officer who was a venture partner at Fairmount as of December&#160;31, 2025 (see Note 7), and the Paragon ADOA and Paragon POA (see Note 9) transactions. Other than the issuance of Convertible Preferred Stock in 2024 and 2025 (see Note 5), the Company did not have any other significant related party transactions with Venrock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Additionally, as of December&#160;31, 2025, there were five investors who participated in the Series A convertible preferred stock raise in September 2025 &#8211; an investor who owns 9.9%, an investor with two separate funds who collectively owns 9.6%, an investor with two separate funds who collectively owns 7.9%, and two investors who each own 7.4% of outstanding shares of common stock in the Company, assuming the conversion of preferred stock into common stock. Other than the issuance of Convertible Preferred Stock in 2025, the Company did not have any other significant related party transactions with these investors. </div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">13.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Segment Reporting </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has one reportable segment relating to the research and development of its research programs. The Company&#8217;s CODM, its Chief Executive Officer, manages the Company&#8217;s operations on a company-wide basis for the allocation of resources and the assessment of performance. The Company&#8217;s measure of segment profit or loss used to assess performance and allocate resources is net loss. The CODM uses net loss to evaluate loss generated from the Company&#8217;s business activities in deciding how to allocate company resources and in monitoring budget versus actual results. Assets are also managed on a company-wide basis. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-71 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below is a summary of the segment loss, including significant segment expenses that are reviewed by the CODM (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 44%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December<br/>31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Period&#160;from&#160;November&#160;8,<br/>2024 (Inception) to<br/>December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A&#223; program research and development costs <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">27,003</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Second undisclosed program 003 research and development costs <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative personnel costs (including stock-based compensation)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development personnel costs (including stock-based compensation)&#160;<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(3)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">1,557</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other general and administrative costs <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(4)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,232</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other research and development costs <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(5)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">( 1,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">35,642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(1)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $26,411 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(2)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $3,936 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(3)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $862 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(4)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $1,203 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;">(5)</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $39 for the year ended December&#160;31, 2025 and $0 for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">14.</div></div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Subsequent Events </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has evaluated events and transactions occurring subsequent to December&#160;31, 2025 through April 17, 2026, the date at which the consolidated financial statements are available to be issued. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;19, 2026, the Company exercised its ADOA Option with respect to Research Program 002, and is currently negotiating the related License Agreement. The Company made a $5.0 million milestone payment to Paragon in March 2026 related to the nomination of KRSA-028 as the development candidate for Research Program 002. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-72 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On April&#160;3, 2026, the Company entered into an Antibody Oligo Conjugate Research Letter Agreement with Paragon Laboratories, Inc. to initiate a Research Program focused on the development of antibody oligonucleotide conjugates directed to a selected target. The Paragon Research Letter Agreement provides for reimbursement of research costs and monthly research fees, and grants the Company an exclusive Option to enter into either an antibody oligonucleotide conjugate discovery and option agreement for an upfront research initiation fee of $1.0&#160;million, or a license agreement for the Research Program for an upfront license fee of $5.0&#160;million. At this time, the Company has not exercised either Option related to the Paragon Research Letter Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"> </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-73 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div id="fin111069_13" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED CONSOLIDATED BALANCE SHEETS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 82%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">134,162</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">154,135</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">947</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">461</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">135,109</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">154,596</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> asset</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,097</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">165</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">96</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,231</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">137,698</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">154,596</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 176</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">7,398</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">12,313</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating lease liability, current</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">160</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Warrant liability, related party</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">208</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">7,766</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">12,489</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Long term liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Accrued other liabilities, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">484</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">538</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Operating lease liability, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">937</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">9,187</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">13,027</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Commitments and contingencies (Note 11)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Series Seed (formerly known as Series A) convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of March&#160;31, 2026 and December&#160;31, 2025; 20,000,000 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025; liquidation preference of $25,000 as of March&#160;31, 2026 and December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">24,964</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">24,964</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Series A convertible preferred stock, $0.0001 par value; 75,500,000 shares authorized as of March&#160;31, 2026 and December&#160;31, 2025; 75,500,000 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025; liquidation preference of $151,000 as of March&#160;31, 2026 and December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">150,573</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">150,573</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stockholders&#8217; deficit:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock, $0.0001 par value; 122,363,552 shares authorized as of March&#160;31, 2026 and December&#160;31, 2025; 6,000,000 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,213</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,761</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(49,240</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(35,730</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(47,026</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(33,968</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">137,698</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">154,596</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(1)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $3,582 as of March&#160;31, 2026 and $10,565 as of December&#160;31, 2025 (see Note 13). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-74 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div id="fin111069_14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except share and per share amounts) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months<br/>Ended<br/>March&#160;31,&#160;2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months<br/>Ended<br/>March&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 11,477</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 99</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3,283</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">44</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">14,760</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">143</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(14,760</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(143</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other income:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,250</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">70</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total other income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,250</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">70</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss and comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(13,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share attributable to common stockholders, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(2.70</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(0.04</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">5,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(1)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $8,790 and $23 for the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively (see Note 13). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 48pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-75 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div id="fin111069_15" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands, except share amounts) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 39%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Convertible<br/>Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-left: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in&#160;Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total&#160;Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">(Deficit) Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; border-left: 0.75pt solid rgb(0, 0, 0); padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">8,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 9,964</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">5,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 153</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(88</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 66</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of March&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">8,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 9,964</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">5,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 176</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> (161</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 16</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">95,500,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">175,537</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">6,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,761</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(35,730</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(33,968</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">452</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">452</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(13,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(13,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Balances as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">95,500,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">175,537</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">6,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,213</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(49,240</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(47,026</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-76 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div id="fin111069_16" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(In thousands) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 73%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months<br/>Ended<br/>March&#160;31,&#160;2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Ended<br/>March&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(13,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">660</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Prepaid expenses and other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(486</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(216</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(176</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">194</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other liabilities <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(5,965</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">31</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(19,477</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from investing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Purchases of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(165</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(165</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash flows from financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Payment of deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(235</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net cash used in financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(235</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net decrease in cash, cash equivalents, and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(19,877</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash, cash equivalents, and restricted cash at beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">154,135</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">10,108</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash, cash equivalents, and restricted cash at end of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">134,258</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">10,067</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Supplemental disclosure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred offering costs included in accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 996</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Operating lease liability arising from obtaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> 1,097</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(1)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes change in related party amount of $(6,983) and $0 for the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively (see Note 13). </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-77 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div id="fin111069_17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Nature of the Business and Basis of Presentation </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Background and Basis of Presentation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Korsana Biosciences, Inc. and subsidiary (&#8220;Korsana&#8221; or the &#8220;Company&#8221;) is a biotechnology company that was established and incorporated under the laws of the state of Delaware on November&#160;8, 2024. Korsana was founded and launched to research and develop antibody candidates licensed from Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;). The Company historically operated as a virtual company and did not maintain a corporate headquarters or other significant facilities. As of March&#160;31, 2026, the Company entered into an operating lease agreement for office space located in Waltham, Massachusetts. Korsana was formed to develop therapies built on Therapeutic Targeting (THETA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">TM</div>), a next generation blood-brain barrier (BBB) platform, with an initial focus on neurodegenerative disorders, including its lead product candidate, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">KRSA-028,</div> an anti-amyloid beta (&#8220;A<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;display:inline;">b</div>&#8221;) antibody that combines the proprietary Therapeutic Targeting (&#8220;THETA<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">&#8482;</div>&#8221;) platform with well-validated aspects from other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">anti-A</div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;display:inline;">b</div> products that have achieved regulatory approval or are in late-stage clinical trials. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, the ability to complete preclinical and clinical trials, the ability to obtain regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s potential product candidates will require approval from the U.S. Federal Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential product candidates will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential product candidates, if approved, will be accepted in the marketplace, that any future product candidates can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product candidates will be successfully marketed, if at all. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On April&#160;1, 2026, the Company entered into an Agreement and Plan of Merger with Cyclerion Therapeutics Inc. (&#8220;Cyclerion&#8221;) and Cariboos Merger Sub Corp and Cariboos Merger Sub II, LLC, both wholly owned subsidiaries of Cyclerion, which agreement was subsequently amended on April&#160;17, 2026 (as amended, the &#8220;Merger Agreement&#8221;), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation (the &#8220;First Merger&#8221;). Immediately following the First Merger and as part of the same overall transaction, Korsana will merge with and into Cariboos Merger Sub II, LLC (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), with Cariboos Merger Sub II, LLC being the surviving entity of the Second Merger. In connection with the Merger, Cariboos Merger Sub II, LLC will change its corporate name to &#8220;Korsana Biopharma Operating Company, LLC&#8221; and Cyclerion will change its name to &#8220;Korsana Biosciences, Inc.&#8221; The combined company will be led by the Company&#8217;s management team and will remain focused on discovering and developing novel therapies designed to reduce the burden of neurodegenerative diseases, starting with Alzheimer&#8217;s disease. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Subject to the terms and conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Korsana common stock (including shares of Korsana common stock issued in connection with the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing described below) will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock equal to the Exchange Ratio as defined in the Merger Agreement, (ii)&#160;each </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-78 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">then-outstanding share of Korsana Series Seed preferred stock will be converted into the right to receive a number of shares of Cyclerion Series B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-voting</div> Preferred Stock, which are each convertible into 1,000 shares of Cyclerion common stock, equal to the Exchange Ratio divided by 1,000, (iii) each-then-outstanding share of Korsana Series A preferred stock will be automatically converted into the right to receive to a number of shares of Cyclerion common stock equal to the Exchange Ratio, as well a right to receive a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase Korsana common stock that will be converted into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase Cyclerion common stock, subject to adjustment as set forth in the form of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant, (v)&#160;each then-outstanding option to purchase Korsana common stock will be assumed by Cyclerion and will be converted into an option to purchase shares of Cyclerion common stock, adjusted for the Exchange Ratio, (vi)&#160;each then- outstanding warrant to purchase Korsana common stock will be assumed by Cylcerion and will be converted into a warrant to purchase shares of Cyclerion common stock, subject to adjustment as set forth in the Merger Agreement, (vii)&#160;each then-outstanding share of Korsana restricted stock will be assumed by Cyclerion, subject to adjustment as set forth in the Merger Agreement, (viii)&#160;each then-outstanding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase shares of Korsana common stock will be converted into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant to purchase shares of Cyclerion common stock, subject to adjustment as set forth in the Merger Agreement and the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrant. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In connection with the Merger, on April&#160;1, 2026, Korsana and Cyclerion entered into Subscription Agreements with certain institutional and accredited investors, pursuant to which such investors have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the Merger, shares of Korsana common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants at an estimated purchase price of $2.3534 per share and $2.3533 per warrant, for an aggregate purchase price of $380.0&#160;million in a private placement (the &#8220;Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing&#8221;). Shares of the Company&#8217;s common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing will be converted into shares of Cyclerion common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-funded</div> warrants to purchase share of Cyclerion common stock in accordance with the Exchange Ratio at the effective time of the close of the transaction. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by Cyclerion&#8217;s stockholders, (2)&#160;approval by the Company&#8217;s stockholders, (3)&#160;Nasdaq&#8217;s approval of the listing application to be submitted in connection with the Merger, and (4)&#160;the effectiveness of Cyclerion&#8217;s registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-4.</div></div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#8217;s financial position and the results of its operations for the interim periods presented. The results of operations for the three months ended March&#160;31, 2026 and 2025 are not necessarily indicative of the results that may be expected for the full year or any other subsequent interim period. The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Korsana Securities Corporation. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-79 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the date that the condensed consolidated financial statements are issued. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Since its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its potential product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution. As a result, the Company will need substantial additional funding to support its operations. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statements do not include any adjustments that may result if the Company is not able to continue as a going concern. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred net losses of $13.5&#160;million and $0.1&#160;million during the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. As of March&#160;31, 2026, the Company had an accumulated deficit of $49.2&#160;million. As of March&#160;31, 2026, the Company had $134.2&#160;million in cash and cash equivalents. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s management expects that the existing cash and cash equivalents that were primarily raised from Series Seed and Series A convertible preferred stock financings (see Note 5) will be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the date these condensed consolidated financial statements are available to be issued. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Summary of Significant Accounting Policies </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company&#8217;s significant accounting policies are disclosed in Note 2 to its audited financial statements as of and for the year ended December&#160;31, 2025 and as of December&#160;31, 2024 and for the period from November&#160;8, 2024 (inception) to December&#160;31, 2024 and the related notes disclosed elsewhere in this definitive proxy statement/prospectus on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-4.</div> Since the date of those financial statements, there have been no changes to the Company&#8217;s significant accounting policies except as noted below. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-80 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Cash, Cash Equivalents, and Restricted Cash </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following represents the Company&#8217;s cash, cash equivalents, and restricted cash (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 61%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,&#160;2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,&#160;2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">134,162</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">10,067</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">96</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total cash, cash equivalents, and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">134,258</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">10,067</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. As of March&#160;31, 2026, the Company&#8217;s restricted cash relates to a letter of credit for its office lease in Waltham, Massachusetts and is included in other assets in the Company&#8217;s condensed consolidated balance sheet. The carrying value of the restricted cash approximates fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Property and Equipment </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;text-indent: 0px;">
<tr>
<td style="width: 40%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Estimated Useful Life (Years)</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Leasehold&#160;improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="text-align: center; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">Lesser&#160;of&#160;the&#160;life&#160;of&#160;the&#160;asset&#160;or&#160;remaining&#160;lease&#160;term</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Furniture and fixtures</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="text-align: center; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">5 years</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Computer software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="text-align: center; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3 years</div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Deferred Offering Costs </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company capitalizes certain legal, professional, accounting, and other third-party fees that are directly associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> equity financings as deferred offering costs until such financings are consummated. After the consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the common or preferred stock or in stockholders&#8217; deficit as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital generated as a result of the offering. Should the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. As of March&#160;31, 2026, deferred offering costs of $1.2&#160;million were recorded as other assets in the condensed consolidated balance sheet. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Leases </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company evaluates arrangements entered into to determine whether or not it includes a lease. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) asset and a current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise its option. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining lease term. The </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-81 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Company determines the present value of lease payments using the implicit rate, if it is readily determinable, or the incremental borrowing rate for the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to discount lease payments. The incremental borrowing rate represents an estimated rate of interest that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. For operating leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. As of March&#160;31, 2026, the Company has one operating lease and no finance leases. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The Company accounts for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components related to operating leases for office space as a single lease component. The Company has elected that costs associated with leases having an initial term of 12&#160;months or less are recognized in the condensed consolidated statement of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Recently Issued Accounting Pronouncement Not Yet Adopted </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div> Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">220-40):</div> Disaggregation of Income Statement Expenses <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;ASU&#160;2024-03&#8221;).</div> The amendments in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> require public entities to disclose specified information about certain costs and expenses. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03</div> is effective for the Company&#8217;s annual reporting period beginning after December&#160;15, 2026 and interim reporting periods beginning after December&#160;27, 2027, with early adoption permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Fair Value Measurements </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following tables present the Company&#8217;s fair value hierarchy for financial assets and liabilities measured (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">130,293</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">130,293</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">130,293</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">130,293</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 62%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149,096</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149,096</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149,096</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149,096</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents consist of money market funds, which were valued by the Company based on quoted market prices, which represent a Level&#160;1 measurement within the fair value hierarchy. There were no transfers </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-82 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">between Level&#160;1, Level&#160;2, or Level&#160;3 during the three months ended March&#160;31, 2026 and the year ended December&#160;31, 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Accrued Expenses and Other Current Liabilities </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 70%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,<br/>2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31,<br/>2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued research and development <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">5,082</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">10,784</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued professional and consulting <div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,532</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">827</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued employee compensation and benefits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">391</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">371</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">393</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">331</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">7,398</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">12,313</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(1)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $3,582 as of March&#160;31, 2026 and $10,333 as of December&#160;31, 2025. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(2)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amount of $0 as of March&#160;31, 2026 and $232 as of December&#160;31, 2025. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Convertible Preferred Stock </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On November&#160;21, 2024, the Company issued a total of 8,000,000 shares of the initial Series A Convertible Preferred Stock to Fairmount Healthcare Fund II L.P. (Fairmount Fund II), an affiliate fund of Fairmount, as well as to Venrock Healthcare Capital Partners EG L.P., Venrock Healthcare Capital Partners III, L.P., VHCP <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-Investment</div> Holdings III, LLC, Venrock Associates IX, L.P. and Venrock Partners IX, L.P., (collectively known as &#8220;Venrock&#8221;) at a purchase price of $1.25 per share for gross proceeds of $10.0&#160;million. Of the 8,000,000&#160;shares of initial Series A Convertible Preferred Stock issued, 4,000,000 shares of Series A Convertible Preferred Stock were issued to Fairmount Fund II and 4,000,000 shares of Series A Convertible Preferred Stock were issued to Venrock, both of which are considered related parties (see Note 13). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;11, 2025 (the &#8220;Additional Closing Date&#8221;), the Company issued an additional 12,000,000&#160;shares of the initial Series A Convertible Preferred Stock to Fairmount Fund II and Venrock, at a purchase price of $1.25 per share for gross proceeds of $15.0&#160;million (the &#8220;Additional Closing&#8221;). Of the 12,000,000 shares of initial Series A Convertible Preferred Stock issued, 6,000,000 shares of Series A Convertible Preferred Stock were issued to Fairmount Fund II and 6,000,000 shares of Series A Convertible Preferred Stock were issued to Venrock. Additionally, the Company and its stockholders decided to seek additional capital funding by authorizing up to 75,500,000 shares of a new series of preferred stock of the Company to be designated as the new &#8220;Series A Convertible Preferred Stock&#8221;. The Board of Directors amended the Amended and Restated Certificate of Incorporation (&#8220;ARCI&#8221;) to (i)&#160;change the name of the Company to &#8220;Korsana Biosciences, Inc.&#8221; from &#8220;Korsa Biosciences, Inc.&#8221;; (ii) reclassify each outstanding share of initial Series A Convertible Preferred Stock into a share of preferred stock of the Company to be designated as &#8220;Series Seed Convertible Preferred Stock&#8221; (collectively with the new Series A Convertible Preferred Stock, the &#8220;Convertible Preferred Stock&#8221;), which resulted in the reclassification of 20,000,000 shares of the initial Series A Convertible Preferred Stock issued and outstanding into shares of Series Seed Convertible Preferred Stock; (iii)&#160;designate the rights, preferences, privileges, and restrictions of the new Series A Convertible Preferred Stock, and facilitate the issuance and sale of such shares; and (iv)&#160;authorize 122,363,552 shares of common stock of the Company, $0.0001 par value per share and 95,500,000 shares of preferred stock of the Company, $0.0001 par value per share, of which 20,000,000 shares will be designated as Series Seed Convertible Preferred Stock and 75,500,000 shares will be designated as Series A Convertible Preferred Stock. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-83 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;15, 2025, the Company entered into the new Series A Preferred Stock Purchase Agreement to issue certain investors shares of Series A Convertible Preferred Stock, $0.0001 par value per share, at a purchase price of $2.00 per share. The Company issued 75,500,000 shares of the Series A Convertible Preferred Stock for gross proceeds of $151.0&#160;million. Of the 75,500,000 shares of Series A Convertible Preferred Stock issued, 12,500,000 shares were issued to Fairmount and 12,500,000 shares were issued to Venrock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The holders of the Convertible Preferred Stock have the following rights and preferences: </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Voting </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The holders of Convertible Preferred Stock are entitled to vote, together with the holders of the Company&#8217;s common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. A majority vote of the holders of Convertible Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws in a manner that adversely affects the rights of the Convertible Preferred Stock, reclassify common stock or establish another class of capital stock (unless the same ranks junior to the Convertible Preferred Stock with respect to its rights), create shares that would rank senior to or authorize additional shares of Convertible Preferred Stock, declare a dividend or make a distribution. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In addition, the holders of record of the shares of Series Seed Preferred Stock, voting together exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> to Common Stock basis, shall be entitled to elect four directors of the Company. The holders of record of the shares of Series A Preferred Stock, voting together exclusively and as a separate class on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> to Common Stock basis, shall be entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Convertible Preferred Stock), exclusively and voting together as a single class, are entitled to elect one director of the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Conversion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Each share of Convertible Preferred Stock is convertible into common shares at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Convertible Preferred Stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of the firm-commitment underwritten public offering of the Company&#8217;s common stock or the closing of a reverse merger transaction at which the price is at least $4.00&#160;per share resulting in at least $75.0&#160;million of gross proceeds to the Company, net of the underwriting discounts or commissions, or (ii)&#160;the vote or written consent of the holders of a majority of the outstanding shares of Convertible Preferred Stock, voting as a single class. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The conversion ratio of Convertible Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $1.25 per share for the Series Seed Convertible Preferred Stock and $2.00 per share for the Series A Convertible Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The conversion price is currently $1.25 per share for the Series Seed Convertible Preferred Stock and $2.00 per share for the Series A Convertible Preferred Stock. As of March&#160;31, 2026, each outstanding share of Convertible Preferred Stock was convertible into common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">one-for-one</div></div> basis. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-84 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Dividends </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Convertible Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Convertible Preferred Stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Convertible Preferred Stock calculated based on the respective original issue price of the Series A Convertible Preferred Stock and Series Seed Convertible Preferred Stock. Dividends are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cumulative.</div> For the three months ended March&#160;31, 2026 and March&#160;31, 2025, no dividends had been declared or paid by the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Liquidation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Convertible Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Convertible Preferred Stock are entitled to an amount equal to the greater of (i)&#160;the applicable original issue price per share of the Convertible Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Convertible Preferred Stock in preference to any distributions to common stock will share rateably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unless the holders of a majority in voting power of the then outstanding shares of Convertible Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Redemption </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Convertible Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. Common Stock </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2026 and December&#160;31, 2025, the Company has the authority to issue a total of 122,363,552 shares of common stock, respectively, at a par value of $0.0001 per share. As of March&#160;31, 2026 and December&#160;31, 2025, the Company had 6,000,000 shares of common stock issued and outstanding in connection with restricted stock awards (&#8220;RSAs&#8221;), respectively. Unvested RSAs are considered legally issued and outstanding shares of common stock. Each share of common stock entitles the holder to one vote, together with the holders of Convertible Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors, subject to the dividend rights of the holders of Convertible Preferred Stock. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-85 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2026 and December&#160;31, 2025, the Company had common stock reserved for future issuance as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 64%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,<br/>2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31,<br/>2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issuable upon conversion of Company Series Seed Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">20,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">20,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issuable upon conversion of Company Series A Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">75,500,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">75,500,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Shares issuable upon exercise of warrants under the Parasa Warrant Obligation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,102,561</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,102,561</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding and issued stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">11,444,298</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">8,756,187</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total shares of common stock reserved</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">108,046,859</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">105,358,748</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. Stock-Based Compensation </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">2025 Equity Incentive Plan </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;11, 2025, the Board of Directors approved the 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock-based awards to employees, officers, directors, consultants, and advisors. The 2025 Plan is administered by the Board of Directors, or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2025 Plan generally vest over four years, subject to the participant&#8217;s continued service, and expire after ten years. Upon adoption, the 2025 Plan authorized 20,584,336 shares of common stock reserved for issuance under the plan. As of March&#160;31, 2026, the total number of shares of common stock reserved for issuance under the 2025 Plan was 20,584,336 shares, with 8,140,038&#160;shares of common stock available for future grants. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Stock Option Valuation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option-pricing model. The Company is a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-86 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards during the three months ended March&#160;31, 2026: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 71%;"/>
<td style="width: 25%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">6.0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">86.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3.8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Stock Options </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the stock option activity for the three months ended March&#160;31, 2026: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 48%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number of<br/>Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted&#160;Average<br/>Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding balance as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">8,756,187</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.86</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">9.8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,688,111</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.86</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">9.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding balance as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">11,444,298</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.86</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">9.7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">6,294</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested and expected to vest, March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">11,444,298</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.86</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">9.7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">6,294</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">106,838</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.86</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">9.6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted average grant-date fair value of stock options granted during the three months ended March&#160;31, 2026 was $0.64. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock. There were no stock options granted during the three months ended March&#160;31, 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Restricted Stock Awards </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;8, 2024, the Company&#8217;s Board of Directors approved the Restricted Stock Notice and Restricted Stock Purchase Agreement, under which Korsana issued and sold 5,000,000 RSAs to Paragon at a price of $0.02 per share. Paragon subsequently contributed 2,500,000 RSAs to Parasa Holding LLC (&#8220;Parasa&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company. The RSAs have performance-based vesting conditions only, which include a performance condition related to achieving a specified amount of Series&#160;A convertible preferred stock financing. The Company considers the probability of achieving the relevant performance condition and recognizes expense when the Company concludes it is probable that the performance condition will be achieved. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On November&#160;21, 2024, the Company raised gross proceeds of $10.0&#160;million in connection with the initial Series A Convertible Preferred Stock financing (see Note 5). Upon the initial issuance of Series A Convertible Preferred Stock to Fairmount and Venrock, 40% of the RSAs became vested under the performance condition and the Company recognized stock-based compensation expense associated with these RSAs. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-87 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;11, 2025, the Company raised gross proceeds of $15.0&#160;million in connection with the Series&#160;A Convertible Preferred Stock Additional Closing (see Note 5). Upon the additional issuance of the initial Series A Convertible Preferred Stock to Fairmount and Venrock, 100% of the RSAs became vested under the performance condition and the Company recognized stock-based compensation expense associated with these RSAs. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On October&#160;27, 2025, the Company issued and sold 1,000,000 RSAs to the Company&#8217;s chief executive officer, a venture partner at Fairmount, in exchange for executive services and such issuance was determined to be a related party transaction (see Note 13). The RSAs issued and sold to the Company&#8217;s chief executive officer have service-based vesting conditions and vest over a four-year period, during which time all unvested shares are subject to forfeiture and the Company&#8217;s repurchase right in the event the holder&#8217;s services with the Company voluntarily or involuntarily terminate. The RSAs issued and sold to the Company&#8217;s chief executive officer were granted from the 2025 Plan. As these unvested RSAs are similar to early exercises of stock options, cash proceeds received for unvested RSAs issued to the Company&#8217;s chief executive officer were initially recorded as a liability and are reclassified to equity as vesting occurs. As of March&#160;31, 2026, $0.4&#160;million and $0.5&#160;million, respectively, was recorded in accrued expenses and other current liabilities and accrued other liabilities, noncurrent on the Company&#8217;s condensed consolidated balance sheet related to the unvested RSAs held by the chief executive officer subject to vesting and repurchase rights under the terms of the RSA agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the RSA activity for the three months ended March&#160;31, 2026: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 63%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number of<br/>RSAs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted&#160;Average<br/>Grant Date<br/>Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested balance as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.57</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested balance as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.57</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the three months ended March&#160;31, 2026 and March&#160;31, 2025, the Company recorded stock-based compensation expense of less than $0.1&#160;million, respectively, related to the RSAs in the condensed consolidated statements of operations and comprehensive loss as general and administrative and research and development expense. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Parasa Warrant Obligation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">In September 2025, the Company entered into the Antibody Discovery and Option Agreement (the &#8220;Paragon ADOA&#8221;) with Paragon and Parasa (see Note 9). Under the terms of the Paragon ADOA, Parasa will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&#160;31, 2025 and December&#160;31, 2026, with an exercise price equal to the fair market value of the underlying shares on the grant date as determined by the Board of Directors (the &#8220;Parasa Warrant Obligation&#8221;). If the term with respect to all research programs ends prior to the end of a calendar year, the warrant for such calendar year shall be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pro-rated</div> for that calendar year. The grant dates for the issuance of warrants was on December&#160;31, 2025 (the &#8220;2025 Parasa Warrant Obligation&#8221;) and expected to be on December&#160;31, 2026 (the &#8220;2026 Parasa Warrant Obligation&#8221;) (if the term with respect to all research programs is still active), respectively, as all terms of the award, including number of shares and exercise price, will be known by all parties on those dates. Parasa&#8217;s research and discovery related activities have a service inception date </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-88 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">preceding the grant dates, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, the Company records a liability for the warrants expected to be granted to Parasa as the related services are provided, with the value of the liability based on the estimated fair value of the warrants at each interim reporting date. For the three months ended March&#160;31, 2026, $0.2&#160;million was recognized as stock-based compensation expense related to the 2026 Parasa Warrant Obligation expected to be granted to Parasa on December&#160;31, 2026 within research and development expense in the Company&#8217;s condensed consolidated statement of operations and comprehensive loss. On December&#160;31, 2025, the fair value of the warrant obligation of $0.8&#160;million was reclassified from accrued expenses to stockholders&#8217; equity on the condensed consolidated balance sheet when the Company settled the 2025 Parasa Warrant Obligation by issuing Parasa a warrant to purchase 1,102,561 shares of Company Common Stock at an exercise price of $0.86 per share. The warrant issued on December&#160;31, 2025 has a term of 10 years, is fully vested, and is exercisable in part or full at any time during the term of the warrant. As of March&#160;31, 2026, the warrant issued under the 2025 Parasa Warrant Obligation is outstanding and unexercised. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the assumptions used in calculating the fair value of the 2026 Parasa Warrant Obligation: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 78%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,&#160;2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected term (years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">10.0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">86.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4.2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">0.0</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">%&#160;</div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the condensed consolidated statements of operations and comprehensive loss (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 50%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">279</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">381</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">660</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2026, total unrecognized compensation cost related to the unvested stock options was $6.3&#160;million, which is expected to be recognized over a weighted average period of approximately 3.9 years. As of March&#160;31, 2026, total unrecognized compensation cost related to the unvested RSAs was $0.4&#160;million, which is expected to be recognized over a weighted average period of approximately 3.2 years. As of March&#160;31, 2026, total unrecognized compensation cost related to the 2026 Parasa Warrant Obligation was $0.6&#160;million, which is expected to be recognized over approximately 0.8 years. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-89 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the condensed consolidated statements of operations and comprehensive loss (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 50%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">35</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">417</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Parasa Warrant Obligation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">208</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">660</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Income Taxes </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">There was no income tax provision recorded for the three months ended March&#160;31, 2026 or March&#160;31, 2025 and, therefore, the Company&#8217;s effective income tax rate was 0.0% for the three months ended March&#160;31, 2026 and March&#160;31, 2025. The effective income tax rate for the three ended March&#160;31, 2026 differed from the 21% federal statutory rate primarily due to the valuation allowance maintained against the Company&#8217;s net deferred tax assets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">9. Paragon Agreements</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bolder;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Paragon Antibody Discovery and Option Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">In September 2025, the Company entered the Paragon ADOA with Paragon and Parasa. Under the Paragon ADOA, Paragon identifies, evaluates, and develops antibodies against one or more mutually agreed therapeutic targets and a mutually agreed brain transit target. The Paragon ADOA covers Research Program 001 and Research Program 002, each targeting A<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;display:inline;">b</div> and TfR1 (together the &#8220;A<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;display:inline;">b</div> program&#8221;), and one undisclosed research program 003, with the ability to add additional programs by mutual agreement. The Company&#8217;s lead product candidate, KRSA-028, was developed from program 002. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Under the Paragon ADOA, Korsana has the exclusive option (each, an &#8220;ADOA Option&#8221;), on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">Program-by-Program</div></div> basis, to enter into a separate agreement with Paragon consistent with a set of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-negotiated</div> terms to further develop, manufacture and commercialize the resulting antibody transport vehicle compounds (each, a &#8220;License Agreement&#8221;). If the Company exercises an ADOA Option and finalizes a related License Agreement, it will be required on a program-by-program and product-by-product basis, to make one-time, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> milestone payments of up to $46.0&#160;million per product upon the achievement of specified clinical development and regulatory milestones, which amount is reduced by 50% for independently developed products directed to the same target combination. Additionally, the Company will be required to make tiered royalty payments in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">low-to-mid</div></div> single-digits beginning on the first commercial sale of each developed product. From time to time, the Company can choose to add additional targets by mutual agreement with Paragon. On March&#160;19, 2026, the Company exercised its ADOA Option for Research Program 002. The Company made a $5.0 million milestone payment to Paragon in March 2026 related to the nomination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">KRSA-028</div> as the development candidate for Research Program 002. On June&#160;8, 2026, the Company entered into a license agreement with respect to the A<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;display:inline;">b</div> program (see Note 15). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the terms of the Paragon ADOA, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Korsana (each, a &#8220;Research Program&#8221;), and certain administrative activities. The Paragon ADOA requires Korsana, Paragon, and Parasa to develop a research plan for each target that includes </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-90 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">design, modelling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities may include performing preclinical studies. Korsana is required to pay a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> nonrefundable, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-creditable</div> fee of $1.0&#160;million (the &#8220;Research Initiation Fee&#8221;) within 30 days following finalization of the Research Plan for each such Research Program. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Korsana will reimburse Paragon for the costs of performing the development activities set forth in the Research Plan, plus an agreed-upon margin charged by Paragon. Korsana made an upfront payment to Paragon when they entered into the Paragon ADOA to cover the cost of work completed by Paragon for the selected Research Programs prior to the effective date. Each Research Program is overseen and coordinated by a joint development committee consisting of two employees from Korsana and two employees from Paragon, with Korsana and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parasa have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Parasa will deliver to Korsana a data package that includes sequence information for all then-existing antibodies and information directed to such target. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Unless terminated earlier, the Paragon ADOA shall continue in force on a Research Program- <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">by-Research</div> Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;if the Company exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30 days, the expiration of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the Paragon ADOA). The Company may terminate the Paragon ADOA or any Research Program at any time for any or no reason upon 30 days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancellable</div> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon ADOA or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Paragon ADOA or any Research Program upon (i) 30 days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> period and (ii)&#160;the other party&#8217;s bankruptcy. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon ADOA, provided that any milestone set in the Paragon ADOA that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon ADOA and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Korsana pursuant to the Paragon ADOA for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Korsana would also be required to make royalty payments to Paragon in the low single-digit percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">product-by-product</div></div> and country- <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">by-country</div> basis upon the later of the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">last-to-expire</div></div> valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the Paragon ADOA, Korsana granted on December&#160;31, 2025 and will grant on December&#160;31, 2026, Parasa warrants to purchase a number of shares equal to 1.00% of Korsana&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Korsana common stock on each respective grant date. Parasa is an entity formed by Paragon as a </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-91 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">vehicle to hold equity in Korsana in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon ADOA other than to receive such warrants (see Note 7). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The Company concluded that the rights obtained under the Paragon ADOA represent an asset acquisition whereby the underlying assets comprise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development assets with no alternative future use. The Paragon ADOA did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development assets, which represent a group of similar identifiable assets. All of the upfront consideration paid by Korsana was allocated to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in-process</div> research and development assets acquired and was immediately expensed as part of research and development expenses on the condensed consolidated statement of operations and comprehensive loss. The research initiation fees represent a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> cost on a research <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">program-by</div> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">on-going</div> development costs, monthly development cost fees and additional development expenses incurred by Paragon are recognized as research and development expense when incurred. Amounts paid as reimbursements for administrative activities incurred by Paragon are recognized as general and administrative expense when incurred. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the Paragon ADOA, the Company recorded total expense of $8.8&#160;million during the three months ended March&#160;31, 2026 for amounts owed to Paragon across all Research Programs, including $3.6&#160;million of research and development work completed by Paragon, $5.0&#160;million for the achievement of a development candidate milestone, and $0.2&#160;million of stock-based compensation expense related to the 2026 Parasa Warrant Obligation. An amount of $3.6&#160;million was unpaid by Korsana at March&#160;31, 2026 and is included in related party accrued expenses and other current liabilities within the Company&#8217;s condensed consolidated balance sheet. Further, an amount of $0.2&#160;million related to the 2026 Parasa Warrant Obligation is included in warrant liability, related party within the Company&#8217;s condensed consolidated balance sheet. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Paragon Platform Option Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In October 2025, the Company entered into the Platform Option Agreement with Paragon and Parasa (the &#8220;Paragon POA&#8221;) in connection with the Paragon ADOA. Pursuant to the Paragon POA, the Company will have an exclusive option to enter into either a separate Antibody Discovery and Option Agreement or a separate License Agreement with Paragon and Parasa, enabling the Company with the right to add, remove, or replace specific target combinations and further develop, manufacture and commercialize the resulting antibody transport vehicle compounds. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Following designation of a target combination, the Company may elect their option to enter into a separate Antibody Discovery and Option Agreement or a separate License Agreement with Paragon and Parasa, the terms of which will be finalized in connection with the option exercise. If the Company elects to enter into a License Agreement (a &#8220;POA License&#8221;), it will be required to make a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div></div> <div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> payment to Paragon of $5.0&#160;million for the license option exercise fee. Under any POA License, Korsana would be required to make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time,</div></div> <div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> milestone payments of up to $41.0&#160;million per product, reduced by 50% for independently developed products directed to the same target combination, and tiered royalty payments in the low to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit percentage range based on annual net sales, subject to certain reductions. These payments are intended to fund the research to be performed by Paragon and Parasa under either an Antibody Discovery and Option Agreement or License Agreement. As of March&#160;31, 2026, the Company has not exercised its option and no amounts were expensed related to the Paragon POA during the three months ended March&#160;31, 2026. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-92 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">The Company will also have an exclusive option to designate up to two additional reserved target combinations. If the Company exercises its option, it will be required to make a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div></div> <div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> payment to Paragon of $2.0&#160;million for the additional reserved target option exercise fee. A separate additional reserved target option exercise fee is due and payable to Paragon each time that the Company exercises an additional reserved target option. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Leases </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In March 2026, the Company entered into a noncancelable operating lease agreement for office space located in Waltham, Massachusetts. The lease commenced in March 2026 and is set to expire in October 2030. Rent payment is expected to commence in the fourth quarter of 2026. The Company provided the landlord with a letter of credit for the security deposit in the amount of $0.1&#160;million, which is recorded within restricted cash on the condensed consolidated balance sheet. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of the lease payments, the Company used it incremental borrowing rate when measuring operating lease liabilities as discount rates were not implicit or readily determinable. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2026, the Company had $1.1&#160;million of operating lease ROU assets, short term lease liabilities of $0.2&#160;million and long term lease liabilities of $0.9&#160;million on its condensed consolidated balance sheets. As of March&#160;31, 2026, the operating lease arrangement had a remaining lease term of 4.6 years and an incremental borrowing rate of 9.8%. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2026, the total remaining operating lease payments included in the measurement of lease liabilities was as follows (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 68%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Period ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2026 (remaining 9 months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">64</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2027</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">384</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2028</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">393</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2029</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">402</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2030</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">342</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total undiscounted lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,585</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total undiscounted unearned tenant improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(137</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Less: Imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(351</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total present value of operating lease liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,097</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. Commitments and Contingencies </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">401(k) Plan </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company maintains a defined-contribution plan under Section&#160;401(k) of the Internal Revenue Code of 1986 (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-tax</div> basis. Employer contributions to the 401(k) Plan may be made at the discretion of management. For the three months ended March&#160;31, 2026 and March&#160;31, 2025, the Company has recorded less than $0.1&#160;million and no expense, respectively, related to 401(k) Plan employer contributions. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-93 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Indemnification Agreements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March&#160;31, 2026. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Legal Proceedings </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of March&#160;31, 2026, the Company was not a party to any material legal proceedings or claims. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. Net Loss per Share </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 51%;"/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(13,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted-average common shares outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">5,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss attributable to common stockholders, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(2.70</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(0.04</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted-average common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-94 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti-dilutive effect: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 50%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Convertible preferred stock (as converted to common stock)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">95,500,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">8,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock options to purchase common stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">11,444,298</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested restricted stock awards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding and issued warrant to Parasa</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,102,561</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">109,046,859</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">11,000,000</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">13. Related Party Transactions </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Paragon and Parasa have been identified as related parties of Korsana and have engaged in material transactions with the Company for the three months ended March&#160;31, 2026. The Company entered into significant related party transactions with the Paragon ADOA and Paragon POA (see Note 9) transactions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">14. Segment Reporting </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has one reportable segment relating to the research and development of its research programs. The Company&#8217;s CODM, its Chief Executive Officer, manages the Company&#8217;s operations on a company-wide basis for the allocation of resources and the assessment of performance. The Company&#8217;s measure of segment profit or loss used to assess performance and allocate resources is net loss. The CODM uses net loss to evaluate loss generated from the Company&#8217;s business activities in deciding how to allocate company resources and in monitoring budget versus actual results. Assets are also managed on a company-wide basis. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-95 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The table below is a summary of the segment loss, including significant segment expenses that are reviewed by the CODM (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 53%;"/>
<td style="width: 18%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 17%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/>March&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;">A<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;display:inline;">b</div> program research and development costs&#160;<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">8,897</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Second undisclosed program 003 research and development costs&#160;<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(2)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,488</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative personnel costs (including stock-based compensation)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,428</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development personnel costs (including stock-based compensation)&#160;<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(3)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">956</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other general and administrative costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,855</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">44</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other research and development costs&#160;<div style="font-size: 75%; vertical-align: top;display:inline;font-size:8.3px">(4)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">136</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">76</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(1,250</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(70</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">13,510</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(1)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $7,080 and $0 for the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(2)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $1,488 and $0 for the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(3)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $208 and $23 for the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; text-align: left; vertical-align: top;"><div style="display:inline;">(4)</div></td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Includes related party amounts of $14 and $0 for the three months ended March&#160;31, 2026 and March&#160;31, 2025, respectively. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">15. Subsequent Events </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has evaluated events and transactions occurring subsequent to March&#160;31, 2026 through June&#160;9, 2026, the date at which the condensed consolidated financial statements are available to be issued. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On April&#160;3, 2026, the Company entered into an Antibody Oligo Conjugate Research Letter Agreement with Paragon to initiate a Research Program focused on the development of antibody oligonucleotide conjugates directed to a selected target. The Research Letter Agreement provides for reimbursement of research costs and monthly research fees, and grants the Company an exclusive option to enter into either an antibody oligonucleotide conjugate discovery and option agreement for an upfront research initiation fee of $1.0&#160;million, or a license agreement for the Research Program for an upfront license fee of $5.0&#160;million. In June 2026, Korsana paid a $1.0&#160;million research initiation fee. At this time, the Company has not exercised either option related to the Research Letter Agreement. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-96 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bolder;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">KORSANA BIOSCIENCES, INC. </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(UNAUDITED) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">On June&#160;8, 2026, the Company entered into a license agreement with Paragon for Research Programs 001 and 002, the A<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;display:inline;">b</div> program, consistent with those terms under the Paragon ADOA, as further described in Note 9. The license agreement included the requirement to make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> milestone payments to Paragon of up to $46.0&#160;million upon the achievement of specified clinical development and regulatory milestones, which amount is reduced by 50% for independently developed products directed to the same target combination, as well as tiered royalty payments in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">low-to-mid</div></div> single-digits beginning on the first commercial sale of each developed product. The $5.0&#160;million milestone payment made to Paragon in March 2026 related to the nomination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">KRSA-028</div> as the development candidate for program 002 will not be owed again under the license agreement. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-97 </div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_46">Annex A </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="ii111069_1a"><span id="ii111069_1aa"></span>Annex A </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Confidential </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Execution Version </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">among: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">KORSANA BIOSCIENCES, INC.; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CARIBOOS MERGER SUB CORP.; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CARIBOOS MERGER SUB II, LLC; and </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CYCLERION THERAPEUTICS, INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Dated as of April&#160;1, 2026 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:82%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Page</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_1">Section&#8199;1. Definitions and Interpretative Provisions </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_2">Definitions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">1.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_3">Other Definitional and Interpretative Provisions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_4">Section&#8199;2. Description of Transaction </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_5">The Merger</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_6">Effects of the Merger</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_7">Closing; First Effective Time; Second Effective Time</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_8">Organizational Documents; Directors and Officers</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_9">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_10">Closing of the Company&#8217;s Transfer Books</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.7</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_11">Surrender of Company Capital Stock</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_12">Calculation of Parent Net Cash and Company Valuation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.9</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_13">Contingent Value Right</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.10</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_14">Further Action</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.11</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_15">Intended Tax Treatment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.12</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_16">Withholding</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">2.13</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_17">Appraisal Rights</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_18">Section&#8199;3. Representations and Warranties of the Company </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_19">Due Organization; Subsidiaries</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_20">Organizational Documents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_21">Authority; Binding Nature of Agreement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_22">Vote Required</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_23"><span style="white-space:nowrap">Non-Contravention;</span> Consents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_24">Capitalization</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.7</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_25">Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_26">Absence of Changes</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.9</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_27">Absence of Undisclosed Liabilities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.10</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_28">Title to Assets</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.11</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_29">Real Property; Leasehold</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.12</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_30">Intellectual Property</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.13</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_31">Agreements, Contracts and Commitments</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.14</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_32">Compliance; Permits; Restrictions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.15</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_33">Legal Proceedings; Orders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.16</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_34">Tax Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.17</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_35">Employee and Labor Matters; Benefit Plans</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.18</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_36">Environmental Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.19</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_37">Insurance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.20</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_38">No Financial Advisors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.21</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_39">Transactions with Affiliates</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.22</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_40">Privacy and Data Security</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.23</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_41">Trade Control Laws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.24</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_42">Ownership of Parent Capital Stock</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">3.25</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_43">No Other Representations or Warranties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_44">Section&#8199;4. Representations and Warranties of Parent, First Merger Sub and Second Merger Sub </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_45">Due Organization; Subsidiaries </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:82%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Page</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_46">Organizational Documents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_47">Authority; Binding Nature of Agreement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_48">Vote Required</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_49"><span style="white-space:nowrap">Non-Contravention;</span> Consents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_50">Capitalization</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.7</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_51">SEC Filings; Financial Statements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_52">Absence of Changes</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.9</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_53">Absence of Undisclosed Liabilities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.10</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_54">Title to Assets</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.11</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_55">Real Property; Leasehold</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.12</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_56">Intellectual Property</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.13</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_57">Agreements, Contracts and Commitments</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.14</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_58">Compliance; Permits; Restrictions</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.15</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_59">Legal Proceedings; Orders</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.16</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_60">Tax Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.17</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_61">Employee and Labor Matters; Benefit Plans</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.18</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_62">Environmental Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.19</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_63">Insurance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.20</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_64">Transactions with Affiliates</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.21</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_65">No Financial Advisors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.22</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_66">Valid Issuance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.23</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_67">Privacy and Data Security</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.24</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_68">Trade Control Laws</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">4.25</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_69">No Other Representations or Warranties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_70">Section&#8199;5. Certain Covenants of the Parties </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_71">Operation of Parent&#8217;s Business</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">5.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_72">Operation of the Company&#8217;s Business</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">5.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_73">Access and Investigation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">5.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_74">No Solicitation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">5.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_75">Notification of Certain Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_76">Section&#8199;6. Additional Agreements of the Parties </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_77">Registration Statement, Proxy Statement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_78">Company Stockholder Written Consent</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_79">Parent Shareholder Meeting</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_80">Efforts; Regulatory Approvals</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_81">Company Options; Company RSUs; Company Warrants</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_82">Employee Benefits</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.7</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_83">Indemnification of Officers and Directors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_84">Disclosure</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.9</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_85">Listing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.10</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_86">Tax Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.11</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_87">Legends</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.12</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_88">Officers and Directors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.13</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_89">Termination of Certain Agreements and Rights</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.14</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_90">Section&#160;16 Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.15</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_91">Allocation Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.16</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_92">Parent SEC Documents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.17</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_93">Obligations of Merger Subs</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:82%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center">Page</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.18</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_94">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.19</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_95">Company <span style="white-space:nowrap">Pre-Closing</span> Financing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">6.20</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_96">Termination of Certain Agreements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_97">Section&#8199;7. Conditions Precedent to Obligations of Each Party </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">7.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_98">Regulatory Approvals</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">7.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_99">No Restraints</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">7.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_100">Stockholder Approval</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">7.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_101">Listing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">7.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_102">Effectiveness of Registration Statement</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_103">Section&#8199;8. Additional Conditions Precedent to Obligations of Parent and Merger Subs </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">8.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_104">Accuracy of Representations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">8.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_105">Performance of Covenants</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">8.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_106">Documents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">8.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_107">No Company Material Adverse Effect</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">8.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_108">Company Stockholder Written Consent</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">8.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_109">Company <span style="white-space:nowrap">Pre-Closing</span> Financing</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_110">Section&#8199;9. Additional Conditions Precedent to Obligation of the Company </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_111">Accuracy of Representations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_112">Performance of Covenants</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_113">Documents</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_114">No Parent Material Adverse Effect</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_115">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_116">Parent Articles of Amendment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">9.7</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_117">Termination of Agreements</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_118">Section&#8199;10. Termination </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_119">Termination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_120">Effect of Termination</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">10.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_121">Expenses; Termination Fees</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt" colspan="5"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#anxa111069_122">Section&#8199;11. Miscellaneous Provisions </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">A-82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="2"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.1</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_123"><span style="white-space:nowrap">Non-Survival</span> of Representations and Warranties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.2</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_124">Amendment</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.3</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_125">Waiver</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.4</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_126">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.5</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_127">Applicable Law; Jurisdiction; WAIVER OF RIGHT TO TRIAL BY JURY</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.6</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_128">Assignability</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.7</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_129">Notices</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.8</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_130">Cooperation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.9</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_131">Severability</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.10</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_132">Other Remedies; Specific Performance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">11.11</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#anxa111069_133">No Third-Party Beneficiaries</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">A-85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Exhibits:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Exhibit&#160;A-1</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of Parent Shareholder Support Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Exhibit&#160;A-2</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of Company Stockholder Support Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exhibit B</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of <span style="white-space:nowrap">Lock-Up</span> Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exhibit C</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of Subscription Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Exhibit&#160;D-1</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit A thereto, incorporated by reference into this Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Exhibit&#160;D-2</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Second Certificate of Merger, incorporated by reference into this Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of Parent Articles of Amendment Schedule</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of CVR Agreement</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit G</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Form of Pre-Funded Warrant</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">T<small style="font-weight:inherit;font-style:unset;text-decoration:unset">HIS</small> A<small style="font-weight:inherit;font-style:unset;text-decoration:unset">GREEMENT</small> <small style="font-weight:inherit;font-style:unset;text-decoration:unset">AND</small> P<small style="font-weight:inherit;font-style:unset;text-decoration:unset">LAN</small> <small style="font-weight:inherit;font-style:unset;text-decoration:unset">OF</small> M<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ERGER</small> <small style="font-weight:inherit;font-style:unset;text-decoration:unset">AND</small> R<small style="font-weight:inherit;font-style:unset;text-decoration:unset">EORGANIZATION</small> </span>(this &#8220;<span style="font-weight:bold">Agreement</span>&#8221;) is made and entered into as of April&#160;1, 2026, by and among <span style="font-weight:bold">C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">YCLERION</small> T<small style="font-weight:inherit;font-style:unset;text-decoration:unset">HERAPEUTICS</small>, I<small style="font-weight:inherit;font-style:unset;text-decoration:unset">NC</small>.</span>, a Massachusetts corporation (&#8220;<span style="font-weight:bold">Parent</span>&#8221;), <span style="font-weight:bold">C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ARIBOOS</small> M<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ERGER</small> S<small style="font-weight:inherit;font-style:unset;text-decoration:unset">UB</small> C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ORP</small>.</span>, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<span style="font-weight:bold">First</span> <span style="font-weight:bold">Merger Sub</span>&#8221;), <span style="font-weight:bold">C<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ARIBOOS</small> M<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ERGER</small> S<small style="font-weight:inherit;font-style:unset;text-decoration:unset">UB</small> II, LLC</span>, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;<span style="font-weight:bold">Second</span> <span style="font-weight:bold">Merger Sub</span>&#8221; and, together with First Merger Sub, &#8220;<span style="font-weight:bold">Merger Subs</span>&#8221; and each, a &#8220;<span style="font-weight:bold">Merger Sub</span>&#8221;), and <span style="font-weight:bold">K<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ORSANA</small> B<small style="font-weight:inherit;font-style:unset;text-decoration:unset">IOSCIENCES</small>, I<small style="font-weight:inherit;font-style:unset;text-decoration:unset">NC</small>.</span>,<span style="font-weight:bold"> </span>a Delaware corporation (the &#8220;<span style="font-weight:bold">Company</span>&#8221;). Certain capitalized terms used in this Agreement are defined in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span>. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">R<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ECITALS</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#8220;<span style="font-weight:bold">First</span> <span style="font-weight:bold">Merger</span>&#8221;) in accordance with this Agreement and the DGCL. Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;<span style="font-weight:bold">Second Merger</span>&#8221; and, together with the First Merger, the &#8220;<span style="font-weight:bold">Merger</span>&#8221;), with Second Merger Sub being the surviving entity of the Second Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. The Parties intend that, (i)&#160;the First Merger and the Second Merger, taken together, will constitute an integrated transaction described in Rev. Rul. <span style="white-space:nowrap">2001-46,</span> <span style="white-space:nowrap">2001-2</span> C.B. 321 that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and (ii)&#160;this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations Sections <span style="white-space:nowrap">1.368-2(g)</span> and <span style="white-space:nowrap">1.368-3(a).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. The Parent Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&#160;adopted, approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement, and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the shareholders of Parent vote to approve this Agreement and thereby approve the Parent Shareholder Matters, including the Contemplated Transactions, and against any competing proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The First Merger Sub Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions, and against any competing proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. The sole member of the Second Merger Sub has (i)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions, and against any competing proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. The Company Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, each of the officers and directors set forth on <span style="text-decoration:underline">Section </span><span style="text-decoration:underline">A</span> of the Parent Disclosure Letter (solely in their capacity as shareholders of Parent) are executing support agreements in favor of the Company in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit <span style="white-space:nowrap">A-1</span></span> (the &#8220;<span style="font-weight:bold">Parent Shareholder Support Agreement</span>&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Parent Capital Stock in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, and, if deemed necessary by Parent, an amendment to Parent&#8217;s articles of organization and bylaws to effect the Contemplated Transactions, and against any competing proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders of the Company listed on <span style="text-decoration:underline">Section A</span> of the Company Disclosure Letter (solely in their capacity as stockholders of the Company), collectively representing the Required Company Stockholder Vote, are executing support agreements in favor of Parent in substantially the form attached hereto as Exhibit <span style="white-space:nowrap">A-2</span> (the &#8220;<span style="font-weight:bold">Company Stockholder Support Agreement</span>&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions, and against any competing proposals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s and the Company&#8217;s willingness to enter into this Agreement, the stockholders, officers and directors of the Company listed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;B</span> of the Company Disclosure Letter are executing <span style="white-space:nowrap">lock-up</span> agreements in substantially the form attached hereto as Exhibit B (the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Lock-Up</span> Agreement</span>,&#8221; and collectively, the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Lock-Up</span> Agreements</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">K. It is expected that, within two (2)&#160;Business Days following the date the Registration Statement is declared effective under the Securities Act, the holders of shares of Company Capital Stock sufficient to adopt and approve this Agreement and the Merger as required under the DGCL and the Company&#8217;s certificate of incorporation and bylaws will execute and deliver an action by written consent adopting this Agreement, in form and substance reasonably acceptable to Parent, in order to obtain the Required Company Stockholder Vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">L. Concurrently with the execution and delivery of this Agreement, certain investors have executed a Securities Purchase Agreement in the form attached hereto as Exhibit C among the Company and the Persons named therein (including as may be amended, restated and/or superseded from time to time, collectively, the &#8220;<span style="font-weight:bold">Subscription Agreement</span>&#8221;), pursuant to which such Persons have agreed to purchase, in the amounts set forth therein, shares of Company Common Stock and <span style="white-space:nowrap">pre-funded</span> warrants to purchase Company Common Stock immediately prior to the First Effective Time (the &#8220;<span style="font-weight:bold">Company <span style="white-space:nowrap">Pre-Closing</span> Financing</span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, intending to be legally bound, agree as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_1">Section&#160;1. <span style="text-decoration:underline">Definitions</span><span style="text-decoration:underline"> and Interpretative Provisions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_2">1.1 <span style="text-decoration:underline">Definitions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">(a)</span> <span style="text-decoration:underline"></span>For purposes of this Agreement (including this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1</span>): </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acceptable Confidentiality Agreement</span>&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, <span style="white-space:nowrap">non-solicitation</span> or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with Parent relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Accrued <span style="white-space:nowrap">Pre-Closing</span> Tax Amount</span>&#8221; means any accrued and unpaid Taxes of Parent and its Subsidiaries for Tax periods (or portions thereof) ending on or before the Closing Date either (a)&#160;for which the applicable Tax Returns have not been filed as of the Closing Date or (b)&#160;that have been shown as due but not paid on Tax Returns that have been filed as of the Closing Date, in each case, (1)&#160;determined on a <span style="white-space:nowrap"><span style="white-space:nowrap">jurisdiction-by-jurisdiction</span></span> basis, which amount may not be less than zero with respect to any Tax in any jurisdiction or period, (2)&#160;computed without taking into account any refunds or overpayments (or credits in lieu thereof), (3) computed taking into account estimated payments, Tax attribute carryovers and carryforwards solely to the extent that such payments, carryovers, or carryforwards are available to reduce Taxes or taxable income, as applicable, for such period at a &#8220;more likely than not&#8221; or higher level of comfort, (4)&#160;determined in accordance with the past accounting methods and practices of Parent and its Subsidiaries, except to the extent that any such method or practice is not supportable at a &#8220;more likely than not&#8221; or higher level of comfort, (5)&#160;determined by excluding any Tax credits transferred pursuant to Section&#160;6418 of the Code (or any corresponding, similar or analogous provision of state, local or <span style="white-space:nowrap">non-U.S.</span> Law), and (6)&#160;with respect to any period that includes but does not end on the Closing Date, the amount allocated to the portion of such period ending on or before the Closing Date shall be: (i)&#160;in the case of Taxes that are based upon or related to income, sales, proceeds, profits, receipts, wages, compensation, or similar items and all other Taxes that are not imposed on a periodic basis, be deemed equal to the amount of such Taxes which would be payable if the taxable period of Parent and its Subsidiaries ended as of the close of business on the Closing Date based on an interim closing of the books (except that exemptions, allowances, and deductions that are otherwise calculated on an annual basis (including depreciation and amortization deductions, other than with respect to property placed in service after the Closing) shall be apportioned on a daily basis); and (ii)&#160;in the case of Taxes not described in clause (i), imposed on a periodic basis, be deemed equal to the amount of such Taxes for the entire period (or, in the case of such Taxes determined on an arrears basis, the amount of such Taxes for the immediately preceding period), multiplied by a fraction the numerator of which is the number of calendar days in the period ending on the Closing Date and the denominator of which is the number of calendar days in the entire period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acquisition Inquiry</span>&#8221; means, with respect to a Party, an inquiry, indication of interest or request for <span style="white-space:nowrap">non-public</span> information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that could reasonably be expected to lead to an Acquisition Proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acquisition</span> <span style="font-weight:bold">Proposal</span>&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acquisition</span> <span style="font-weight:bold">Transaction</span>&#8221; means any transaction or series of related transactions (other than any Parent Legacy Transaction or the Company <span style="white-space:nowrap">Pre-Closing</span> Financing) involving: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&#160;in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (ii)&#160;in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Affiliate</span>&#8221; shall have the meaning given to such term in Rule 145 under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Affordable Care Act</span>&#8221; means the Patient Protection and Affordable Care Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Anticipated Closing Date</span>&#8221; means the anticipated Closing Date, as agreed upon by Parent and the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Business</span> <span style="font-weight:bold">Day</span>&#8221; means any day other than (a)&#160;Saturday or Sunday; or (b)&#160;a day on which banks in the Commonwealth of Massachusetts are authorized or obligated to be closed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">COBRA</span>&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Section&#160;6 of Title I of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Code</span>&#8221; means the Internal Revenue Code of 1986, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Associate</span>&#8221; means any current employee, independent contractor, officer or director of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Board</span>&#8221; means the board of directors of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Capital Stock</span>&#8221; means the Company Common Stock and the Company Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Capitalization Representations</span>&#8221; means the representations and warranties of the Company set forth in <span style="text-decoration:underline">Sections 3.6(a)</span> and <span style="text-decoration:underline">3.6(d)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Common Stock</span>&#8221; means the common stock, $0.0001 par value per share, of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Contract</span>&#8221; means any Contract: (a)&#160;to which the Company is a Party, (b)&#160;by which the Company is or may become bound or under which the Company has, or may become subject to, any obligation or (c)&#160;under which the Company has or may acquire any right or interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Employee Plan</span>&#8221; means any Employee Plan that the Company (a)&#160;sponsors, maintains, administers, or contributes to, (b)&#160;may reasonably be expected to have any Liability, or (c)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of the Company (or their spouses, dependents, or beneficiaries), but excluding any Employee Plan in which the Company participates that is sponsored by any professional employer organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Fundamental Representations</span>&#8221; means the representations and warranties of the Company set forth in <span style="text-decoration:underline">Sections 3.1(a)</span>, <span style="text-decoration:underline">3.2</span>, <span style="text-decoration:underline">3.3</span>, <span style="text-decoration:underline">3.4</span>, <span style="text-decoration:underline">3.5(a)(i)</span>, and <span style="text-decoration:underline">3.20</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company IP Rights</span>&#8221; means all Intellectual Property rights that are owned or purported to be owned by, assigned to, exclusively licensed to, or controlled by the Company that are necessary for, or used or held for use in, the operation of the business of the Company as presently conducted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company IP Rights Agreement</span>&#8221; means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential information provided under confidentiality agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Key Employee</span>&#8221; means any executive officer of the Company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Material Adverse Effect</span>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company, taken as a whole; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a)&#160;the announcement of this Agreement or the pendency of the Contemplated Transactions (provided, that this clause (a)&#160;will be disregarded for purposes of any representation or warranty the purpose of which is to expressly address the consequences of the execution and delivery of this Agreement, the consummation of the Contemplated Transactions, or the performance of the obligations hereunder or thereunder), (b) the taking of any action, or the failure to take any action, by the Company that is required to undertake, or refrain from undertaking (as applicable), to comply with the terms of this Agreement, (c)&#160;any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d)&#160;any change in generally accepted accounting principles in the United States (&#8220;<span style="font-weight:bold">GAAP</span>&#8221;) or applicable Law or the interpretation thereof, (e)&#160;general economic or political conditions or conditions generally affecting the industries in which the Company operates, or (f)&#160;any change in the cash position of the Company which results from operations in the Ordinary Course of Business; except in each case with respect to clauses (c), (d) and (e), to the extent disproportionately affecting the Company relative to other similarly situated companies in the industries in which the Company operates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Merger Shares</span>&#8221; means the product determined by <span style="font-style:italic"><span style="text-decoration:underline">multiplying</span></span> (a)&#160;the Post-Closing Parent Shares <span style="font-style:italic"><span style="text-decoration:underline">by</span></span> (b)&#160;the Company Allocation Percentage, in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Aggregate Valuation</span>&#8221; means the sum of (i)&#160;the Company Valuation, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (ii)&#160;the Parent Valuation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Company Allocation Percentage</span>&#8221; means the percentage (rounded to four decimal places) determined by <span style="font-style:italic"><span style="text-decoration:underline">subtracting</span></span> (i)&#160;the Parent Allocation Percentage <span style="font-style:italic"><span style="text-decoration:underline">from</span></span> (ii)&#160;100&#160;percent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Company Equity Value</span>&#8221; means $268,400,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Company Outstanding Shares</span>&#8221; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Company <span style="white-space:nowrap">Pre-Closing</span> Financing), expressed on a fully diluted and <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-converted-to-Company</span></span></span> Common Stock basis assuming, without limitation or duplication, the exercise of all Company Options, Company RSUs, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock), whether conditional or unconditional or vested or unvested, that are outstanding as of immediately prior to the First Effective Time; provided that &#8220;Company Outstanding Shares&#8221; shall exclude any Company Options, Company RSUs, Company Warrants and any other equity awards issued under the Company Stock Plan (including any shares of Company Common Stock issuable upon the exercise of such Company Options, Company Warrants or other equity awards) issued to directors, employees, consultants or other service providers following the date hereof but prior to the Closing (collectively, the &#8220;<span style="font-weight:bold">Service Provider Grants</span>&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Company Valuation</span>&#8221; means (i)&#160;the Company Equity Value, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (ii)&#160;the amount of proceeds actually received by the Company from the Company <span style="white-space:nowrap">Pre-Closing</span> Financing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Exchange Ratio</span>&#8221; means the ratio (rounded to four decimal places) equal to the quotient obtained by dividing (i)&#160;the Company Merger Shares by (ii)&#160;the Company Outstanding Shares. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Parent Allocation Percentage</span>&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by <span style="font-style:italic"><span style="text-decoration:underline">dividing</span></span> (i)&#160;the Parent Valuation <span style="font-style:italic"><span style="text-decoration:underline">by</span></span> (ii)&#160;the Aggregate Valuation. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Parent Outstanding Shares</span>&#8221; means, without duplication, (including, without limitation, the effects of the Nasdaq Reverse Split, if completed, prior to the First Effective Time) the total number of shares of Parent Capital Stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis and as converted to Parent Common Stock basis and assuming, without limitation or duplication, (i)&#160;the issuance of shares of Parent Common Stock in respect of all In the Money Parent Options, warrants or other rights or commitments to receive shares of Parent Common Stock or Parent Preferred Stock (or securities convertible or exercisable into shares of Parent Common Stock or Parent Preferred Stock, but excluding any Parent Capital Stock issued as Merger Consideration), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time, and (ii)&#160;the settlement in shares of Parent Common Stock of Parent Restricted Stock Awards outstanding as of immediately prior to the First Effective Time on a net settlement basis as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.6(e)</span>. Notwithstanding any of the foregoing, no Out of the Money Parent Options shall be included in the total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Parent Valuation</span>&#8221; means (i) $10,000,000, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (ii)&#160;the amount by which Parent Net Cash is less than $0, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (iii)&#160;the amount by which Parent Net Cash exceeds $0. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-weight:bold">Post-Closing Parent Shares</span>&#8221; mean the quotient determined by <span style="font-style:italic"><span style="text-decoration:underline">dividing</span></span> (i)&#160;the Parent Outstanding Shares <span style="font-style:italic"><span style="text-decoration:underline">by</span></span> (ii)&#160;the Parent Allocation Percentage. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Options</span>&#8221; means options or other rights to purchase shares of Company Capital Stock issued by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Preferred Stock</span>&#8221; means the shares of the Company&#8217;s capital stock designated as preferred stock, including the Company Series Seed Preferred Stock and Company Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Registered IP</span>&#8221; means all Company IP Rights that are owned or exclusively licensed by the Company that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications and registrations for any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Series A Preferred Stock</span>&#8221; means a series of the Company&#8217;s preferred stock designated as Series A Preferred Stock, $0.0001 par value per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Series Seed Preferred Stock</span>&#8221; means a series of the Company&#8217;s preferred stock designated as Series Seed Preferred Stock, $0.0001 par value per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company RSU</span>&#8221; means each restricted stock unit award for shares of Company Capital Stock issued by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Stock Plan</span>&#8221; means the Company&#8217;s 2025 Equity Incentive Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Triggering Event</span>&#8221; shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote: (a)&#160;the Company Board shall have made a Company Board Adverse Recommendation Change; (b)&#160;the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (c)&#160;the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Warrants</span>&#8221; means warrants (including any <span style="white-space:nowrap">pre-funded</span> warrants) to purchase shares of Company Capital Stock issued by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Confidentiality</span> <span style="font-weight:bold">Agreement</span>&#8221; means the mutual <span style="white-space:nowrap">non-disclosure</span> agreement dated as of March&#160;10, 2026, between the Company and Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Consent</span>&#8221; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contemplated</span> <span style="font-weight:bold">Transactions</span>&#8221; means the Merger and the other transactions contemplated by this Agreement (other than any Parent Legacy Transaction and the Parent Articles of Amendment), including the CVR Agreement, the Company <span style="white-space:nowrap">Pre-Closing</span> Financing and the Nasdaq Reverse Split (to the extent applicable and deemed necessary or advisable by Parent and the Company). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Contract</span>&#8221; means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Delisting Event</span>&#8221; means (i)&#160;the filing of a Form 25 with respect to the shares of Parent Common Stock by Parent or Nasdaq with the SEC, (ii)&#160;any other cessation of listing of the Parent Common Stock on Nasdaq, whether or not a Form 25 has been filed yet, or (iii)&#160;thirty (30) days after formal notification by Nasdaq of its determination to delist the shares of Parent Common Stock from Nasdaq unless, during such thirty (30)&#160;day period, Parent has received notice from Nasdaq that Nasdaq has withdrawn its formal notification or otherwise determined not to delist the shares of Parent Common Stock from Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">DGCL</span>&#8221; means the General Corporation Law of the State of Delaware, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">DLLCA</span>&#8221; means the Delaware Limited Liability Company Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Effect</span>&#8221; means any effect, change, event, circumstance, or development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Employee Plan</span>&#8221; means (a)&#160;an &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA whether or not subject to ERISA; (b)&#160;other plan, program, policy or arrangement providing for stock options, restricted stock awards, stock purchases, equity-based compensation, bonuses (including any annual bonuses and retention bonuses) or other incentives, severance pay, deferred compensation, employment, compensation, change in control or transaction bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits), pension benefits, profit-sharing benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits, dental benefits, vision benefits, and all other employee benefit plans, agreements, and arrangements, not described in (a)&#160;above; and (c)&#160;all other plans, programs, policies or arrangements providing compensation to employees, consultants and <span style="white-space:nowrap">non-employee</span> directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Encumbrance</span>&#8221; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Enforceability Exceptions</span>&#8221; means the (a)&#160;Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b)&#160;rules of law governing specific performance, injunctive relief and other equitable remedies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Entity</span>&#8221; means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Environmental</span> <span style="font-weight:bold">Law</span>&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">ERISA Affiliate</span>&#8221; means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity or part of the same &#8220;controlled group&#8221; as such Entity under Sections 414(b), (c), (m) or (o)&#160;of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">ERISA</span>&#8221; means the Employee Retirement Income Security Act of 1974, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Exchange</span> <span style="font-weight:bold">Act</span>&#8221; means the Securities Exchange Act of 1934, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">First Merger Sub Board</span>&#8221; means the board of directors of First Merger Sub. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governmental Authority</span>&#8221; means any: (a)&#160;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b)&#160;federal, state, local, municipal, foreign, supra-national or other government, (c)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority) or (d)&#160;self-regulatory organization (including Nasdaq). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Governmental Authorization</span>&#8221; means any: (a)&#160;permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law or (b)&#160;right under any Contract with any Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Hazardous Materials</span>&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or <span style="white-space:nowrap">by-products.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">HSR Act</span>&#8221; means the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">In the Money Parent Option</span>&#8221; shall mean Parent Options with an exercise price equal to or less than the Parent Closing Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Intellectual Property</span>&#8221; means: (a)&#160;United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisionals, continuations, <span style="white-space:nowrap"><span style="white-space:nowrap">continuations-in-part,</span></span> reissues, extensions, supplementary protection certificates, reexaminations, term extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures and inventions (collectively, &#8220;<span style="font-weight:bold">Patents</span>&#8221;), (b) trademarks, service marks, trade names, domain names, corporate names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration thereof and goodwill associated therewith, (c)&#160;copyrights, including registrations and applications for registration thereof, (d)&#160;software, including all source code, object code and related documentation, (e)&#160;formulae, customer lists, trade secrets, <span style="white-space:nowrap">know-how,</span> confidential information and other proprietary rights and intellectual property, whether patentable or not, and (f)&#160;all United States and foreign rights arising under or associated with any of the foregoing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">IRS</span>&#8221; means the United States Internal Revenue Service. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Knowledge</span>&#8221; means, (a)&#160;with respect to an individual, that such individual is actually aware of the relevant fact or that such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment responsibilities, and (b)&#160;with respect to any Person that is an Entity the Knowledge of any executive officer of such Person as of the date such knowledge is imputed. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Law</span>&#8221; means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Legal Proceeding</span>&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other Governmental Authority or any arbitrator or arbitration panel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">MBCA</span>&#8221; means the Massachusetts Business Corporation Act, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Minimum Concurrent Investment Amount</span>&#8221; means $150,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Multiemployer</span> <span style="font-weight:bold">Plan</span>&#8221; means a &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001(a)(3) of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Multiple Employer Plan</span>&#8221; means a &#8220;multiple employer plan&#8221; within the meaning of Section&#160;413(c) of the Code or Section&#160;3(40) of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Multiple Employer Welfare Arrangement</span>&#8221; means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Nasdaq Reverse Split</span>&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Nasdaq</span>&#8221; means The Nasdaq Stock Market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Order</span>&#8221; means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court or Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Ordinary</span> <span style="font-weight:bold">Course of Business</span>&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Organizational Documents</span>&#8221; means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b)&#160;all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Out of the Money Parent Options</span>&#8221; shall mean Parent Options with an exercise price greater than the Parent Closing Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Articles of Amendment Schedule</span>&#8221; means a schedule to the Parent Articles of Amendment in the form attached hereto as Exhibit E. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Associate</span>&#8221; means any current employee, independent contractor, officer or director of Parent or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Balance Sheet</span>&#8221; means the audited balance sheet of Parent as of December&#160;31, 2025, included in Parent&#8217;s Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2025, as filed with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Board</span>&#8221; means the board of directors of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Capital Stock</span>&#8221; means the Parent Common Stock and the Parent Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Capitalization Representations</span>&#8221; means the representations and warranties of Parent and Merger Subs set forth in <span style="text-decoration:underline">Sections 4.6(a)</span> and <span style="text-decoration:underline">4.6(d)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Closing Price</span>&#8221; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5)&#160;consecutive trading days ending three (3)&#160;trading days immediately prior to the Calculation Date as reported by Bloomberg L.P. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Common Stock</span>&#8221; means the common stock, no par value per share, of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Contract</span>&#8221; means any Contract: (a)&#160;to which Parent is a party, (b)&#160;by which Parent or any Parent IP Rights or any other asset of Parent is or may become bound or under which Parent has, or may become subject to, any obligation or (c)&#160;under which Parent has or may acquire any right or interest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Convertible Preferred Stock</span>&#8221; means the series of Parent&#8217;s <span style="white-space:nowrap">non-voting</span> convertible preferred stock, no par value per share, with the rights, preferences, powers and privileges specified in the Parent Articles of Amendment Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Employee Plan</span>&#8221; means any Employee Plan that Parent or any of its Subsidiaries (a)&#160;sponsors, maintains, administers, or contributes to, (b)&#160;may reasonably be expected to have any Liability, or (c)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of Parent or any of its Subsidiaries (or their spouses, dependents, or beneficiaries), but excluding any Employee Plan in which the Parent or any of its Subsidiaries participates that is sponsored by any professional employer organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Fundamental Representations</span>&#8221; means the representations and warranties of Parent and Merger Subs set forth in <span style="text-decoration:underline">Sections</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.1(a)</span>, <span style="text-decoration:underline">4.2</span>, <span style="text-decoration:underline">4.3</span>, <span style="text-decoration:underline">4.4</span>, <span style="text-decoration:underline">4.5(a)(i)</span>, and <span style="text-decoration:underline">4.21</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent IP Rights Agreement</span>&#8221; means any Contract governing, related or pertaining to any Parent IP Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent IP Rights</span>&#8221; means all Intellectual Property owned, licensed or controlled by Parent that is necessary for, or used or held for use in, the operation of the business of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent</span> <span style="font-weight:bold">Key Employee</span>&#8221; means (i)&#160;an executive officer of Parent; and (ii)&#160;any employee of Parent that reports directly to the Parent Board or to an executive officer of Parent. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Legacy Business</span>&#8221; means the business of Parent as conducted at any time prior to the date of this Agreement, including but not limited to business related to the assets listed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1(a)</span> of the Parent Disclosure Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Material Adverse Effect</span>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a)&#160;the announcement of this Agreement or the pendency of the Contemplated Transactions (provided, that this clause (a)&#160;will be disregarded for purposes of any representation or warranty the purpose of which is to expressly address the consequences of the execution and delivery of this Agreement, the consummation of the Contemplated Transaction or the performance of the obligations hereunder or thereunder), (b) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c) the taking of any action, or the failure to take any action, by Parent that it is required to undertake, or refrain from undertaking (as applicable), to comply with the terms of this Agreement, (d)&#160;any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or any governmental or other response or reaction to any of the foregoing, (e)&#160;any change in GAAP or applicable Law or the interpretation thereof, (f)&#160;general economic or political conditions or conditions generally affecting the industries in which Parent or any of its Subsidiaries operates, or (g)&#160;failure to achieve or maintain any minimum level of Parent Net Cash; except, in each case with respect to clauses (d), (e) and (f), to the extent materially and disproportionately affecting Parent or any of its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent or any of its Subsidiaries operates. Notwithstanding the above, a Delisting Event shall constitute a Parent Material Adverse Effect, provided that the Company has not refused or unreasonably delayed its consent to reasonable actions by Parent to maintain the listing of Parent Common Stock on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Net Cash</span>&#8221; means without duplication, (a)&#160;Parent&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, including any proceeds actually received from any Parent Legacy Transaction prior to the Calculation Date, <span style="font-style:italic"><span style="text-decoration:underline">plus</span></span> (b)&#160;the prepaid expenses set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;1.1(b)</span> of the Parent Disclosure Letter, if any, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span><span style="font-style:italic"> </span>(c)&#160;the sum of unpaid consolidated short-term and long-term contractual obligations and liabilities accrued by Parent as of the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (d)&#160;the aggregate amount (without duplication) of all fees and expenses incurred by Parent prior to the First Effective Time in connection with the negotiation, execution and delivery of this Agreement and the Contemplated Transactions or any Parent Legacy Transaction, including: (i)&#160;any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of Parent in connection with the Contemplated Transactions or any Parent Legacy Transaction; (ii) 50% of the fees paid to the SEC in connection with filing the Registration Statement and any amendments and supplements thereto, with the SEC; (iii) 50% of the fees and expenses incurred in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements thereto, (iv) 50% of all Antitrust Fees, (v) 50% of any Nasdaq Fees, (vi)&#160;any CVR Fees, (vii)&#160;any bonus, retention payments, severance, <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control</span></span> payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that are due or payable to any director, officer, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee or consultant as a result of the consummation of the Contemplated Transactions or any Parent Legacy Transaction, together with any payroll Taxes associated therewith; (viii)&#160;the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.7</span>, and (ix)&#160;all costs and expenses associated with any dividend of any excess Parent Net Cash, in each case, to the extent unpaid as of the First Effective Time, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (e)&#160;all remaining rent payments and fees and expenses associated with terminating the Parent Real Estate Leases, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (f)&#160;the Accrued <span style="white-space:nowrap">Pre-Closing</span> Tax Amount, <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span> (g)&#160;all costs and expenses relating to the winding down of Parent Legacy Business, including the sale, license or other disposition of any or all of the Parent Legacy Business (including, for clarity, any <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control</span></span> payments, Contract termination or breakage costs or similar payment obligations that are due or payable to any Person to effect the winding down of Parent Legacy Business) to the extent unpaid as of the Closing, including any costs incurred by the Company (including the Surviving Entity) following the Closing <span style="font-style:italic"><span style="text-decoration:underline">minus</span></span><span style="font-style:italic"> </span>(h)&#160;the Parent Stock Option Cash Consideration, minus (i)&#160;to the extent not declared and paid prior to delivery of the Parent Net Cash Schedule, the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend Amount (if any). For avoidance of doubt, the calculation of Parent Net Cash may result in a number below $0. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Options</span>&#8221; means options or other rights to purchase shares of Parent Common Stock, including those granted by Parent pursuant to any Parent Stock Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Preferred Stock</span>&#8221; means the shares of Parent Capital Stock designated as preferred stock, no par value per share, including the Parent Convertible Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Registered IP</span>&#8221; means all Parent IP Rights that are owned or exclusively licensed by Parent that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications for any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Restricted Stock Award</span>&#8221; means an award of restricted shares of Parent Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Parent Triggering Event</span>&#8221; shall be deemed to have occurred if, prior to the approval of this Agreement and the Contemplated Transactions by Parent&#8217;s shareholders and subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(c)</span>: (a) Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation, (b)&#160;the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation Change or subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(e)</span>, publicly proposed, endorsed or recommended any Acquisition Proposal or (c)&#160;Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.4</span>). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Party</span>&#8221; or &#8220;<span style="font-weight:bold">Parties</span>&#8221; means the Company, Merger Sub and Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permitted Alternative Agreement</span>&#8221; means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a Superior Offer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permitted Encumbrance</span>&#8221; means (a)&#160;any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith by the appropriate proceedings and for which adequate reserves will be or have been made on the Company Financial Statements or the Parent Balance Sheet, as applicable, in accordance with GAAP (in a manner reasonably consistent with the manner in which such items were historically determined), (b) minor <span style="white-space:nowrap">non-monetary</span> liens that have arisen in the Ordinary Course of Business and that neither (in any case or in the aggregate): (i) result from a breach of Contract or violation of Law in any material respect nor (ii)&#160;materially detract from the value of the assets subject thereto or materially impair the operations of the Company or Parent, as applicable, (c)&#160;statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements, (d)&#160;deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law, (e)&#160;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materials or supplies for amounts that are not yet due and payable and (f)&#160;liens arising under applicable securities Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Person</span>&#8221; means any individual, Entity or Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Personal Information</span>&#8221; means any data or information that constitutes &#8220;personal information,&#8221; &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;protected health information,&#8221; or any analogous term under applicable Law, including any such information that identifies, relates to, describes, is linked to, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with any identified or identifiable individual or household. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Privacy Laws</span>&#8221; mean, collectively, (a)&#160;all Laws governing privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including any such legally binding requirements set forth in regulations and agreements containing consent orders published by regulatory authorities of competent jurisdiction such as the U.S. Federal Trade Commission, U.S. Federal Communications Commission, or state data protection authorities, including HIPAA, Section&#160;5 of the Federal Trade Commission Act, the Controlling the Assault of <span style="white-space:nowrap">Non-Solicited</span> Pornography And Marketing Act, the Telephone Consumer Protection Act and U.S. state consumer protection and data breach notification Laws, and (b)&#160;any legally binding requirements of any self-regulatory organizations governing data privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including the Payment Card Industry Data Security Standard. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Representatives</span>&#8221; means with respect to a Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and other representatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Sarbanes-Oxley Act</span>&#8221; means the Sarbanes-Oxley Act of 2002. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">SEC</span>&#8221; means the United States Securities and Exchange Commission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Securities Act</span>&#8221; means the Securities Act of 1933, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Subsequent Transaction</span>&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Subsidiary</span>&#8221; means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a)&#160;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body or (b)&#160;at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Superior</span> <span style="font-weight:bold">Offer</span>&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a)&#160;was not obtained or made as a direct or indirect result of a breach of this Agreement, (b)&#160;is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Parent&#8217;s shareholders or the Company&#8217;s stockholders, as applicable, than the terms of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Contemplated Transactions, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax Return</span>&#8221; means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tax</span>&#8221; means any U.S. federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, environmental tax, excise tax, ad valorem tax, transfer tax, conveyance tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, social security tax, customs duty, licenses tax, alternative or <span style="white-space:nowrap">add-on</span> minimum or other tax or similar charge, duty, levy, fee, tariff, impost, obligation or assessment in the nature of a tax (whether imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Treasury Regulations</span>&#8221; means the United States Treasury regulations promulgated under the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each of the following terms is defined in the Section&#160;set forth opposite such term: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:52%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:46%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Terms</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Section</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">AAA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(f)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Accounting Firm</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(f)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Preamble</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Allocation Certificate</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.15</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Antitrust Fees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.4(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Assumed Option</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.5(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Assumed RSU Award</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.5(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Assumed Warrant</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.5(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Balance Sheet Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Beneficial Ownership Limitation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(h)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Calculation Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Capitalization Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.6(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Certificate of Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Certifications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Closing Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Closing</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company 409A Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.17(j)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Board Adverse Recommendation Change</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Board Recommendation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Disclosure Letter</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Section&#160;3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Financial Statements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Intervening Event</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Material Contract</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.13(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Material Contracts</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.13(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Product Candidates</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Real Estate Leases</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.11</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:52%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:46%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Terms</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Section</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Regulatory Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Required <span style="white-space:nowrap">S-4</span> Information</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.1(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Stockholder Consent Review Period</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Stockholder Support Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Stockholder Written Consents</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Termination Fee</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">10.3(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Valuation Calculation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Valuation Delivery Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Valuation Determination Time</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Valuation Dispute Notice</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Valuation Response Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company Valuation Schedule</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Company</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Preamble</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Costs</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">CVR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.9(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">CVR Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.9(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">CVR Fees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.9(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">D&amp;O Indemnified Parties</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dispute Notice</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dissenting Shares</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.13(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Drug/Device Regulatory Agency</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Employment-Related Laws</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.17(k)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">End Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">10.1(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Exchange Agent</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">FDA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">FDCA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">First Certificate of Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">First Effective Time</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">First Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">First Step Surviving Corporation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.1</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Form <span style="white-space:nowrap">S-4</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.1(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Intended Tax Treatment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.11</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Liability</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Lock-Up</span> Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Lock-Up</span> Agreements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Merger Consideration</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)(iii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Merger Subs</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Preamble</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nasdaq Fees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nasdaq Listing Application</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.9</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Notice Period</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Ordinary Course Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.16(g)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent 409A Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.17(j)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Articles of Amendment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.4(b)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Board Adverse Recommendation Change</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.3(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Board Recommendation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.3(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Common Stock Payment Shares</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Disclosure Letter</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Section&#160;4</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Intervening Event</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.3(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Legacy Transaction</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.1(c)(i)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Material Contract</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.13(a)</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:52%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:46%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Terms</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Section</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Net Cash Calculation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Net Cash Schedule</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Notice Period</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.3(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.14(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.1(c)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend Amount</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.1(c)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Product Candidates</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.14(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Real Estate Leases</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.11</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Regulatory Permits</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.14(d)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent SEC Documents</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.7(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Shareholder Matters</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.3(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Shareholder Meeting</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.3(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Shareholder Support Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Parent Stock Plans</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.6(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">PHSA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.14(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Post-Closing Welfare Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.6(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Pre-Closing</span> Period</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">5.1(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">Pre-Funded</span> Warrants</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Privacy Policies</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.22</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proxy Statement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.1(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Registration Statement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.1(a)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Remaining Entitlement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(a)(ii)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Required Company Stockholder Vote</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.4</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Required Parent Shareholder Vote</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">4.4</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Response Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.8(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">SEC Documents</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.16</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Second Certificate of Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Second Effective Time</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.3</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Second Merger</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Securities</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.5(g)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Stockholder Notice</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.2(b)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Subscription Agreement</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Recital</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Surviving Entity</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2.1</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Tax Certificates</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.10(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Transaction Litigation</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">6.4(c)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">WARN Act</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">3.17(k)</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_3">1.2 <span style="text-decoration:underline">Other Definitional and Interpretative Provisions</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules are to Sections, Exhibits and Schedules of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract (except for references to any agreements or Contracts listed on the Parent Disclosure Letter or Company </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disclosure Letter) are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. The Exhibits to this Agreement, the Parent Disclosure Letter and the Company Disclosure Letter are integral parts of the interpretation of this Agreement, but only Exhibit <span style="white-space:nowrap">D-1</span> (including Exhibit A to such Exhibit) and Exhibit <span style="white-space:nowrap">D-2</span> are incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, <span style="white-space:nowrap">re-enacted</span> thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Company Disclosure Letter and the Parent Disclosure Letter shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4</span>, respectively. The disclosures in any section or subsection of the Company Disclosure Letter or the Parent Disclosure Letter shall qualify other sections and subsections in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4</span>, respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation, that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been (a)&#160;posted to and continuously made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions or (b)&#160;delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_4">Section&#160;2. <span style="text-decoration:underline">Description of Transaction</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_5">2.1 <span style="text-decoration:underline">The Merger</span>. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;<span style="font-weight:bold">First Step</span> <span style="font-weight:bold">Surviving Corporation</span>&#8221;). Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;<span style="font-weight:bold">Surviving Entity</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_6">2.2 <span style="text-decoration:underline">Effects of the Merger</span>. The First Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. As a result of the First Merger, the Company will become a wholly owned subsidiary of Parent. The Second Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_7">2.3 <span style="text-decoration:underline">Closing; First Effective Time</span><span style="text-decoration:underline">; Second Effective Time</span>. Unless this Agreement is earlier terminated pursuant to the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10</span>, and subject to the satisfaction or waiver of the conditions set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9</span>, the consummation of the Merger (the &#8220;<span style="font-weight:bold">Closing</span>&#8221;) shall take place remotely, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;8</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9</span>, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;<span style="font-weight:bold">Closing Date</span>.&#8221; Immediately </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the Closing on the Closing Date, Parent shall file the Parent Articles of Amendment with the office of the Secretary of the Commonwealth of Massachusetts. At the Closing, (i)&#160;the Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance attached hereto as <span style="text-decoration:underline">Exhibit <span style="white-space:nowrap">D-1</span></span> and incorporated herein by reference (the &#8220;<span style="font-weight:bold">First</span> <span style="font-weight:bold">Certificate of Merger</span>&#8221;) and (ii)&#160;the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance attached hereto as <span style="text-decoration:underline">Exhibit <span style="white-space:nowrap">D-2</span></span> and incorporated herein by reference (the &#8220;<span style="font-weight:bold">Second Certificate of Merger</span>&#8221; and together with the First Certificate of Merger, the &#8220;<span style="font-weight:bold">Certificate of Merger</span>&#8221;). The First Merger shall become effective at the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#8220;<span style="font-weight:bold">First</span> <span style="font-weight:bold">Effective Time</span>&#8221;). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the &#8220;<span style="font-weight:bold">Second Effective Time</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_8">2.4 <span style="text-decoration:underline">Organizational Documents; Directors and Officers</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the First Effective Time: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in the Merger to read as set forth on <span style="text-decoration:underline">Exhibit A</span> to the First Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The bylaws of the First Step Surviving Corporation shall be identical to the bylaws of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and such bylaws; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Corporation, shall be such persons as are set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.12</span> of the Company Disclosure Letter, unless otherwise designated by the Company prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">(b)</span> <span style="text-decoration:underline">At the Second Effective Time: </span> </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be amended to (A)<span style="text-decoration:underline"></span>&#160;change the name of the Surviving Entity to &#8220;Korsana Biosciences Operating Company LLC,&#8221; and (B)&#160;make such other changes as are directed by the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that following the Second Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving Entity to &#8220;Korsana Biosciences Operating Company LLC&#8221;; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The articles of organization of Parent shall be identical to the articles of organization of Parent immediately prior to the Second Effective Time, until thereafter amended as provided by the MBCA and such articles of organization; provided, however, that immediately prior to the Second Effective Time, Parent shall file articles of amendment to its articles of organization to (i)<span style="text-decoration:underline"></span>&#160;change the name of Parent to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#8220;Korsana Biosciences, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split, (iii) increase the number of shares of Parent Capital Stock that Parent is authorized to issue to a number determined by the Company, in its sole discretion, such amount to be sufficient to allow for consummation of the Contemplated Transactions, (iv)<span style="text-decoration:underline"></span>&#160;redomicile Parent from the Commonwealth of Massachusetts to such jurisdiction as may be determined by the Company, (v)<span style="text-decoration:underline"></span>&#160;designate shares of Parent Preferred Stock as the Parent Convertible Preferred Stock and (vi)<span style="text-decoration:underline"></span>&#160;make such other changes as are mutually agreeable to Parent and the Company (such amendment, the &#8220;<span style="font-weight:bold">Parent Articles of Amendment</span>&#8221;); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) The directors and officers of Parent, each to hold office in accordance with the articles of organization and bylaws of Parent, shall be as set forth in <span style="text-decoration:underline">Section&#160;6.12</span>; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The directors and officers of Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability company agreement of Second Merger Sub, shall be as set forth in&#160;Section 6.12&#160;after giving effect to the provisions of<span style="text-decoration:underline"></span>&#160;Section 6.12, or such other persons as shall be designated by the Company prior to Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_9">2.5 <span style="text-decoration:underline">Conversion of </span><span style="text-decoration:underline">Company, First Merger Sub and Second Merger Sub Equity Securities</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the First Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Subs, the Company or any stockholder of the Company or shareholder of Parent: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) subject to <span style="text-decoration:underline">Section&#160;2.5(c)</span> and <span style="text-decoration:underline">Section&#160;2.5(a)(iii)</span> below, each share of Company Capital Stock (including any shares of Company Capital Stock issued pursuant to the Company <span style="white-space:nowrap">Pre-Closing</span> Financing) outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to <span style="text-decoration:underline">Section&#160;2.5(a)(i)</span><span style="font-style:italic"> </span>and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio (the &#8220;<span style="font-weight:bold">Parent Common Stock Payment Shares</span>&#8221;); provided, however, that, in the event the aggregate number of shares of Parent Common Stock issuable to any holder of Company Capital Stock at the Closing would result in the issuance of shares of Parent Common Stock in an amount (when aggregated with all Securities then beneficially owned by such Person and its affiliates (as calculated pursuant to Section&#160;13(d) of the Exchange Act and Rule <span style="white-space:nowrap">13d-3</span> promulgated thereunder)) in excess of such holder&#8217;s Beneficial Ownership Limitation (if any), Parent shall issue to any such holder of Company Capital Stock (x)&#160;shares of Parent Common Stock up to such holder&#8217;s Beneficial Ownership Limitation, and (y)&#160;in lieu of any shares of Parent Common Stock in excess of the Beneficial Ownership Limitation (such excess shares, the &#8220;<span style="font-weight:bold">Remaining Entitlement</span>&#8221;), <span style="white-space:nowrap">pre-funded</span> warrants, substantially in the form attached hereto as Exhibit G (&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Pre-Funded</span> Warrants</span>&#8221;), to purchase a number of shares of Parent Common Stock upon exercise of such <span style="white-space:nowrap">Pre-Funded</span> Warrants equal to the Remaining Entitlement, in such manner to provide any such holder of Company Capital Stock with the same economic effect as contemplated by this Agreement; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5(c)</span> and notwithstanding <span style="text-decoration:underline">Section&#160;2.5(a)(ii)</span> above, each share of Company Series Seed Preferred Stock outstanding immediately prior to the First Effective Time (excluding shares of Company Series Seed Preferred Stock to be canceled pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5</span><span style="text-decoration:underline">(</span><span style="text-decoration:underline">a)(i)</span> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x)<span style="text-decoration:underline"></span>&#160;the Exchange Ratio <span style="font-style:italic"><span style="text-decoration:underline">divided by</span></span> (y) 1,000 (such shares of Parent Convertible Preferred Stock, together with the Parent Common Stock Payment Shares and <span style="white-space:nowrap">Pre-Funded</span> Warrants described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5(a)(ii)</span>, the &#8220;<span style="font-weight:bold">Merger Consideration</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Capital Stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued in exchange for such shares of Company Capital Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Capital Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Capital Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (on a per position basis) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with <span style="text-decoration:underline">Section&#160;2.7</span> and any accompanying documents as required therein: (i)&#160;one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Capital Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii)&#160;no shares of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Capital Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Parent Preferred Stock that a holder of Company Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Preferred Stock issuable to such holder and any remaining fractional shares shall be, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with <span style="text-decoration:underline">Section&#160;2.7</span> and any accompanying documents as required therein, rounded up to the nearest whole share of Parent Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) All Company Options (including any Service Provider Grants) outstanding immediately prior to the First Effective Time shall be treated in accordance with <span style="text-decoration:underline">Section&#160;6.5(a)</span>. All Company Warrants outstanding immediately prior to the First Effective Time shall be treated in accordance with&#160;<span style="text-decoration:underline">Section 6.5(c)</span>. All Company RSUs outstanding immediately prior to the First Effective Time shall be treated in accordance with&#160;<span style="text-decoration:underline">Section 6.5(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Each share of common stock, $0.0001 par value per share, of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.0001 par value per share, of the First Step Surviving Corporation. Each book entry share of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) If, between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Company Options, Company RSUs, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) For purposes of this Agreement, the &#8220;<span style="font-weight:bold">Beneficial Ownership Limitation</span>&#8221; may be set at the discretion of each holder of Company Capital Stock to a percentage designated by such Person to the Company between 0% and 19.99% of the number of shares of the Parent Common Stock outstanding immediately after giving effect to the issuance of the Merger Consideration (collectively, the &#8220;<span style="font-weight:bold">Securities</span>&#8221;); provided that such percentage shall be set at 9.99% for any holder of Company Capital Stock that does not make such designation to the Company at least ten (10)&#160;Business Days prior to the Closing. Notwithstanding the foregoing, by written notice to the Surviving Entity, any Person may reset the Beneficial Ownership Limitation percentage to a higher or lower percentage, not to exceed 19.99%; provided that any increase will not be effective until the sixty-first (61st) day after such written notice is delivered to the Surviving Entity. Upon such a change by any Person of the Beneficial Ownership Limitation, the Beneficial Ownership Limitation may not be further amended by such Person without first providing the minimum notice required by this <span style="text-decoration:underline">Section&#160;2.5(h)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_10">2.6 <span style="text-decoration:underline">Closing of the Company&#8217;s Transfer Books</span>. At the First Effective Time: (a)&#160;all Company Capital Stock outstanding immediately prior to the First Effective Time shall be treated in accordance with <span style="text-decoration:underline">Section&#160;2.5(a)</span>, and all holders of certificates representing Company Capital Stock that were outstanding immediately prior to the First Effective Time shall cease to have any rights as stockholders of the Company and (b)&#160;the stock transfer books of the Company shall be closed with respect to all Company Capital Stock outstanding immediately prior to the First Effective Time. No further transfer of any such Company Capital Stock shall be made on such stock transfer books after the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_11">2.7 <span style="text-decoration:underline">Surrender of Company Capital Stock</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date, Parent and the Company shall jointly select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;<span style="font-weight:bold">Exchange Agent</span>&#8221;). At the First Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Parent Capital Stock issuable pursuant to <span style="text-decoration:underline">Section&#160;2.5(a)</span> in exchange for Company Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the First Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i)&#160;a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that (A)&#160;delivery of physical stock certificates representing shares of Company Capital Stock, (the &#8220;<span style="font-weight:bold">Company Stock Certificates</span>&#8221;) shall be effected, and risk of loss and title shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent), and (B)&#160;a holder of uncertificated shares of Company Capital Stock shall not be required to deliver Company Stock Certificates and in lieu thereof, the Exchange Agent shall receive an &#8220;agent&#8217;s message&#8221; in customary form (or such other evidence, if any, as the Exchange Agent may require, with respect to such uncertificated shares of Company Capital Stock) and (ii)&#160;instructions for effecting the surrender of Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for book-entry shares of Parent Capital Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A)&#160;the holder of such Company Stock Certificate or uncertificated shares of Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Capital Stock) that such holder has the right to receive pursuant to the provisions of <span style="text-decoration:underline">Section&#160;2.5(a)</span> and <span style="text-decoration:underline">Section&#160;2.5(c)</span> and (B)&#160;the Company Stock Certificate or uncertificated shares of Company Capital Stock so surrendered shall be canceled. Until surrendered as contemplated by this <span style="text-decoration:underline">Section&#160;2.7(b)</span>, each Company Stock Certificate or uncertificated shares of Company Capital Stock shall be deemed, from and after the First Effective Time, to represent only the right to receive book-entry shares of Parent Capital Stock representing the Merger Consideration. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Capital Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the lost, stolen or destroyed Company Stock Certificate or any Parent Capital Stock issued in exchange therefor as Parent may reasonably request. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No dividends or other distributions declared or made with respect to Parent Capital Stock with a record date after the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Capital Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or uncertificated shares of Company Capital Stock or provides an affidavit of loss or destruction in lieu thereof in accordance with this <span style="text-decoration:underline">Section&#160;2.7</span> (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Any shares of Parent Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Company Capital Stock as of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Capital Stock who have not theretofore surrendered their Company Stock Certificates or uncertificated shares of Company Capital Stock in accordance with this <span style="text-decoration:underline">Section&#160;2.7</span> shall thereafter look only to Parent for satisfaction of their claims for Parent Capital Stock and any dividends or distributions with respect to shares of Parent Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No Person shall be liable to any holder of any Company Capital Stock or to any other Person with respect to any shares of Parent Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_12">2.8 <span style="text-decoration:underline">Calculation of Parent Net Cash and Company Valuation</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) No later than five (5)&#160;Business Days before the date of the Parent Shareholder Meeting set forth in the Proxy Statement (the &#8220;<span style="font-weight:bold">Calculation Date</span>&#8221;), Parent will deliver to the Company a schedule (the &#8220;<span style="font-weight:bold">Parent</span> <span style="font-weight:bold">Net Cash Schedule</span>&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of the components of Parent Net Cash (the &#8220;<span style="font-weight:bold">Parent</span> <span style="font-weight:bold">Net Cash Calculation</span>,&#8221; and the date of delivery of such schedule being the &#8220;<span style="font-weight:bold">Parent Net Cash Schedule Delivery Date</span>&#8221;) as of 11:59 p.m. on the Business Day prior to the Anticipated Closing Date (the &#8220;<span style="font-weight:bold">Cash</span> <span style="font-weight:bold">Determination Time</span>&#8221;) prepared and certified, via certificate in the form reasonably acceptable to the Company, by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible) as reasonably requested by the Company, the work papers and <span style="white-space:nowrap">back-up</span> materials used or useful in preparing the Parent Net Cash Schedule and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel and its accountants and counsel during Parent&#8217;s normal business hours and upon reasonably advanced written notice. The Parent Net Cash Calculation shall include Parent&#8217;s determination, as of the Cash Determination Time, of the defined terms in <span style="text-decoration:underline">Section&#160;1.1(b)</span> necessary to calculate the Exchange Ratio. During the period beginning on the Parent Net Cash Schedule Delivery Date and ending on the Calculation Date, the Company shall have an opportunity to review the Parent Net Cash Schedule and Parent shall reasonably cooperate with the Company in good faith to respond to any questions regarding the Parent Net Cash Schedule raised by the Company; provided that this shall in no way limit or otherwise affect the Company&#8217;s remedies under this Agreement or otherwise, or constitute an acknowledgement by the Company of the accuracy of the amounts reflected therein. Notwithstanding anything else in this Agreement, the Company may require Parent to deliver a new Parent Net Cash Schedule if the Closing Date is more than twenty (20)&#160;days after the Calculation Date, which date of delivery shall be deemed the &#8220;Calculation Date&#8221; hereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No later than the Calculation Date, the Company will deliver to Parent a schedule (the &#8220;<span style="font-weight:bold">Company Valuation Schedule</span>&#8221;) setting forth, in reasonable detail, the Company&#8217;s good faith, estimated calculations of the components of the Company Valuation (the &#8220;<span style="font-weight:bold">Company Valuation Calculation</span>,&#8221; and the date of delivery of such schedule being the &#8220;<span style="font-weight:bold">Company Valuation Delivery Date</span>&#8221;) as of 11:59 p.m. on the last </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business Day prior to the Anticipated Closing Date (the &#8220;<span style="font-weight:bold">Company Valuation Determination Time</span>&#8221;) prepared and certified, via certificate in the form reasonably acceptable to Parent, by the Company&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for the Company). The Company shall make available to Parent (electronically to the greatest extent possible) as reasonably requested by Parent, the work papers and <span style="white-space:nowrap">back-up</span> materials used or useful in preparing the Company Valuation Schedule and, if reasonably requested by Parent, the Company&#8217;s internal finance personnel and its accountants and counsel during the Company&#8217;s normal business hours and upon reasonably advanced written notice. During the period after the delivery of the Company Valuation Schedule and prior to the Closing, Parent shall have an opportunity to review the Company Valuation Schedule and the Company shall reasonably cooperate with Parent in good faith to respond to any questions regarding the Company Valuation Schedule raised by Parent; provided, that this shall in no way limit or otherwise affect the Parent&#8217;s remedies under this Agreement or otherwise, or constitute an acknowledgement by Parent of the accuracy of the amounts reflected therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No later than three (3)&#160;Business Days after the Parent Net Cash Schedule Delivery Date (the last day of such period, the &#8220;<span style="font-weight:bold">Response Date</span>&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;<span style="font-weight:bold">Dispute Notice</span>&#8221;). Any Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Parent Net Cash Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) No later than three (3)&#160;Business Days after the Company Valuation Delivery Date (the last day of such period, the &#8220;<span style="font-weight:bold">Company Valuation Response Date</span>&#8221;), Parent shall have the right to dispute any part of the Company Valuation Calculation by delivering a written notice to that effect to the Company (a &#8220;<span style="font-weight:bold">Company Valuation Dispute Notice</span>&#8221;) and any Company Valuation Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Company Valuation Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if on the Response Date, the Company fails to deliver a Dispute Notice as provided in <span style="text-decoration:underline">Section&#160;2.8(c)</span>, then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) If, on or prior to the Company Valuation Response Date, Parent notifies the Company in writing that it has no objections to the Company Valuation Calculation or, if on the Company Valuation Response Date, Parent fails to deliver a Company Valuation Dispute Notice as provided in <span style="text-decoration:underline">Section&#160;2.8(d)</span>, then the Company Valuation Calculation as set forth in the Company Valuation Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon the Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement. If Parent delivers a Company Valuation Dispute Notice on or prior to the Company Valuation Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of the components of the Company Valuation, which agreed upon Company Valuation amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash as of the Cash Determination Time pursuant or the components of Company Valuation as of the Company Valuation Determination Time, in each case pursuant to <span style="text-decoration:underline">Section&#160;2.8(g)</span> within three days after delivery of the Dispute Notice or the Company Valuation Dispute Notice, as applicable (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Parent Net Cash or Company Valuation shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company. If the parties are unable to select an independent auditor within five (5)&#160;days, then either Parent or the Company may thereafter request that either the Boston, Massachusetts Office of the American Arbitration Association or the New York, New York Office of the American Arbitration Association (&#8220;<span style="font-weight:bold">AAA</span>&#8221;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA, the &#8220;<span style="font-weight:bold">Accounting Firm</span>&#8221;). Parent and the Company shall promptly deliver to the Accounting Firm the work papers and <span style="white-space:nowrap">back-up</span> materials used in preparing the Parent Net Cash Schedule and the Dispute Notice and the Company Valuation Schedule and the Company Valuation Dispute Notice, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five (5)&#160;Business Days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; provided, however, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash or the components of the Company Valuation made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time or the components of the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration:underline">Section&#160;2.8(h)</span>. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash or the Company Valuation that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Net Cash amount or the components of the Company Valuation. If this <span style="text-decoration:underline">Section&#160;2.8(h)</span> applies as to the determination of the Parent Net Cash at the Cash Determination Time or to the determination of the components of the Company Valuation at the Company Valuation Determination Time, as applicable, upon resolution of the matter in accordance with this <span style="text-decoration:underline">Section&#160;2.8(h)</span>, the Parties shall not be required to determine Parent Net Cash or the Company Valuation again even though the Closing may occur later than the Anticipated Closing Date, except that either Parent and the Company may request a redetermination of Parent Net Cash or the Company Valuation if the Closing Date is more than thirty (30)&#160;days after the Anticipated Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_13">2.9 <span style="text-decoration:underline">Contingent Value Right</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Prior to the First Effective Time, Parent shall declare a distribution (the &#8220;<span style="font-weight:bold">Closing Distribution</span>&#8221;) to holders of Parent Common Stock and Parent Preferred Stock of record as of immediately prior to the First Effective Time (including, for the avoidance of doubt, those shares of Parent Common Stock with respect to Parent Restricted Stock Awards accelerated pursuant to <span style="text-decoration:underline">Section&#160;6.6(e))</span> of the right to receive one contingent value right (each, a &#8220;<span style="font-weight:bold">CVR</span>&#8221;) for each outstanding share of Parent Common Stock or Parent Preferred Stock held by such stockholder as of such date (less applicable withholding taxes), each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement in the form attached hereto as Exhibit F (the &#8220;<span style="font-weight:bold">CVR Agreement</span>&#8221;). The record date for the Closing Distribution shall be the close of business on the Business Day prior to the date on which the First Effective Time occurs and the payment date for which shall be three (3)&#160;Business Days after the First Effective Time; provided that the payment of such distribution may be conditioned upon the occurrence of the First Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent and the Exchange Agent shall, at or prior to the First Effective Time, duly authorize, execute and deliver the CVR Agreement, subject to any reasonable revisions to the CVR Agreement that are requested by such Exchange Agent and are reasonably acceptable to the Company and Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent shall pay all costs and fees associated with any action contemplated by this <span style="text-decoration:underline">Section&#160;2.9</span> (the &#8220;<span style="font-weight:bold">CVR Fees</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_14">2.10 <span style="text-decoration:underline">Further Action</span>. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of First Merger Sub, in the name of Second Merger Sub, in the name of the Surviving Entity and otherwise) to take such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_15">2.11 <span style="text-decoration:underline">Intended Tax Treatment</span>. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, the First Merger and the Second Merger, taken together, are intended to constitute an integrated transaction described in Rev. Rul. <span style="white-space:nowrap">2001-46,</span> <span style="white-space:nowrap">2001-2</span> C.B. 321 that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code (the &#8220;<span style="font-weight:bold">Intended Tax Treatment</span>&#8221;). The Parties adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_16">2.12 <span style="text-decoration:underline">Withholding</span>. Each of the Exchange Agent, Parent and the Surviving Entity shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement to any Person such amounts as are required to be deducted or withheld from such consideration under applicable Law; provided that, with respect to any <span style="white-space:nowrap">non-compensatory</span> amounts, the Exchange Agent, Parent and the Surviving Entity shall use commercially reasonable efforts to promptly notify such Persons of any intention to withhold any portion of such consideration and cooperate with any requests by such Persons to reduce or eliminate any such withholding to the extent permitted by applicable Law. To the extent such amounts are so deducted or withheld and remitted to the appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. All payments made under this agreement that constitute compensation to employees for services for Tax purposes shall be made through the payroll of the Surviving Entity or Parent, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_17">2.13 <span style="text-decoration:underline">Appraisal Rights</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the First Effective Time and which are held by stockholders or owned by beneficial owners who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#8220;<span style="font-weight:bold">Dissenting Shares</span>&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in <span style="text-decoration:underline">Section&#160;2.5</span> attributable to such Dissenting Shares. Such stockholders or beneficial owners shall be entitled to receive payment of the fair value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders or beneficial owners fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders or owned by beneficial owners who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in <span style="text-decoration:underline">Sections 2.5</span> and <span style="text-decoration:underline">2.7</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company shall give Parent prompt written notice of any demands by dissenting stockholders or beneficial owners received by the Company, withdrawals of such demands and any other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
instruments served on the Company and any material correspondence received by the Company in connection with such demands, and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. The Company shall not, except with Parent&#8217;s prior written consent, not to be unreasonably withheld, delayed or conditioned, make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_18">Section&#160;3. <span style="text-decoration:underline">Representations and Warranties of the Company</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the written disclosure document delivered by the Company to Parent (the &#8220;<span style="font-weight:bold">Company Disclosure Letter</span>&#8221;) concurrently with the execution of this Agreement, the Company represents and warrants to Parent and Merger Subs as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_19">3.1 <span style="text-decoration:underline">Due Organization; Subsidiaries</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has all necessary power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted, (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)&#160;to perform its obligations under all Contracts by which it is bound. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit sharing interest of any nature in, or control, directly or indirectly, any other Entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed and is not obligated to make, nor is the Company bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_20">3.2 <span style="text-decoration:underline">Organizational Documents</span>. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the Company. The Company is not in breach or violation of its Organizational Documents in any material respect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_21">3.3 <span style="text-decoration:underline">Authority; Binding Nature of Agreement</span>. The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions, subject to obtaining the Required Company Stockholder Vote (as defined below). The Company Board has (a)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (b)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (c)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_22">3.4 <span style="text-decoration:underline">Vote Required</span>. The affirmative vote (or written consent) of&#160;the holders of (a)&#160;a majority of the shares of Company Capital Stock outstanding on the record date, voting as a single class on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">an&#160;as-converted&#160;basis,</span> and (b)&#160;the holders of a majority of the shares of Company Preferred Stock outstanding on the record date and entitled to vote thereon, voting as a separate class, is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions (collectively, the &#8220;<span style="font-weight:bold">Required Company Stockholder Vote</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_23">3.5 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-Contravention;</span> Consents</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Assuming the accuracy of representations set forth in <span style="text-decoration:underline">Section&#160;4.5</span> hereof, except (i)&#160;as set forth in <span style="text-decoration:underline">Section&#160;3.5(a)</span> of the Company Disclosure Letter, (ii)&#160;the Required Company Stockholder Vote, (iii)&#160;compliance with any applicable requirements of the HSR Act (if applicable) and (iv)&#160;the filing of the Certificate of Merger required by the DGCL or DLLCA and the filing of the Parent Articles of Amendment required by the MBCA, neither (x)&#160;the execution, delivery or performance of this Agreement by the Company, nor (y)&#160;the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) contravene, conflict with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which the Company, or any of the assets owned or used by the Company, is subject; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to the business of the Company, or any of the assets owned, leased or used by the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Company Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C)&#160;accelerate the maturity or performance of any Company Material Contract or (D)&#160;cancel, terminate or modify any term of any Company Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except for (i)&#160;the Required Company Stockholder Vote, (ii)&#160;the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA and the filing of the Parent Articles of Amendment with the Secretary of the Commonwealth of Massachusetts pursuant to the MBCA, (iii)&#160;compliance with any applicable requirements of the HSR Act (if applicable) and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, and (iv)&#160;as set forth in <span style="text-decoration:underline">Section&#160;3.5(b)</span> of the Company Disclosure Letter, the Company was not, is not, nor will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&#160;the execution, delivery or performance of this Agreement or (y)&#160;the consummation of the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements or any of the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_24">3.6 <span style="text-decoration:underline">Capitalization</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of the Company consists of (i) 122,363,552 shares of Company Common Stock of which 6,000,000 shares have been issued and are outstanding as of the date hereof, and (ii) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
95,500,000 shares of Company Preferred Stock of which 95,500,000 shares have been issued and are outstanding as of the date hereof. The Company does not hold any shares of its capital stock in its treasury. As of the date of this Agreement, the Company Capital Stock is held by the Persons and in the amounts set forth in <span style="text-decoration:underline">Section&#160;3.6(a)</span> of the Company Disclosure Letter, which further sets forth for each such Person (i)&#160;the&#160;name of such Person and the number of shares held, (ii)&#160;the class and series of such shares, (iii)&#160;the number of the applicable book-entry positions representing such shares or the number of the certificate representing such shares, and (iv)&#160;whether such Person is or has ever been an employee. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. There are no declared or accrued but unpaid dividends with respect to any shares of the Company Capital Stock and the Company has never declared or paid any dividend or other distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding Company Capital Stock as set out in <span style="text-decoration:underline">Section&#160;3.6(a)</span> of the Company Disclosure Letter have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents, arising under applicable securities Laws or Encumbrances created by Parent. None of the outstanding Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Company Capital Stock or other securities. <span style="text-decoration:underline">Section&#160;3.6(b)</span> of the Company Disclosure Letter accurately and completely describes all repurchase rights held by the Company with respect to Company Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company has reserved 20,584,336 shares of Company Common Stock for issuance to officers, directors, employees and consultants of the Company pursuant to the Company Stock Plan. As of the date hereof, 12,444,298 shares of Company Common Stock remain available for issuance pursuant to the Company Stock Plan. Except for the Company Stock Plan and as set forth on <span style="text-decoration:underline">Section&#160;3.6(c)</span> of the Company Disclosure Letter, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. <span style="text-decoration:underline">Section&#160;3.6(c)</span> of the Company Disclosure Letter sets forth the following information with respect to each Company Option and Company RSU outstanding as of the date hereof: (i)&#160;the name of the holder, (ii)&#160;the number of shares of Company Common Stock subject to such Company Option or Company RSU as of the date hereof, (iii)&#160;the exercise price of such Company Option, (iv)&#160;the date on which such Company Option or Company RSU was granted, (v)&#160;the applicable vesting schedule, including any acceleration provisions, (vi)&#160;the date on which such Company Option expires, (vii)&#160;whether such Company Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii)&#160;the Stock Plan pursuant to which such Company Option or Company RSU was granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth on <span style="text-decoration:underline">Section&#160;3.6(d)</span> of the Company Disclosure Letter, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any Company Capital Stock or other securities of the Company, (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which the Company is or may become obligated to sell or otherwise issue any Company Capital Stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All outstanding Company Capital Stock, Company Options, Company RSUs and other securities of the Company have been issued and granted in compliance in all material respects with (i)&#160;all applicable securities laws and other applicable Law and (ii)&#160;all requirements set forth in applicable Contracts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company Capital Stock are uncertificated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_25">3.7 <span style="text-decoration:underline">Financial Statements</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has delivered to Parent accurate and complete copies of its unaudited financial statements for the period ended December&#160;31, 2025 (the &#8220;<span style="font-weight:bold">Balance Sheet Date</span>&#8221;) (collectively, the &#8220;<span style="font-weight:bold">Company Financial Statements</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii)&#160;transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii)&#160;access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal controls consistent with the practices of similarly situated private companies over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Section&#160;3.7(c)</span> of the Company Disclosure Letter lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and <span style="white-space:nowrap">&#8220;off-balance</span> sheet arrangements&#8221; (as defined in Item 303(c) of Regulation <span style="white-space:nowrap">S-K</span> under the Exchange Act) effected by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Neither the Company nor its independent auditors have identified (i)&#160;any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii)&#160;any fraud, whether or not material, that involves the Company, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii)&#160;any claim or allegation regarding any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_26">3.8 <span style="text-decoration:underline">Absence of Changes</span>. Except as set forth on <span style="text-decoration:underline">Section&#160;3.8</span> of the Company Disclosure Letter, since the Balance Sheet Date, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&#160;Company Material Adverse Effect or (b)&#160;action, event or occurrence that would have required consent of Parent pursuant to <span style="text-decoration:underline">Section&#160;5.2(b)</span> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_27">3.9 <span style="text-decoration:underline">Absence of Undisclosed Liabilities</span>. Since the Balance Sheet Date, the Company does not have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;<span style="font-weight:bold">Liability</span>&#8221;), except for: (a)&#160;Liabilities disclosed, reflected or reserved against (or to be disclosed, reflected or reserved against) in Company Financial Statements, (b)&#160;normal and recurring current Liabilities that have been incurred by the Company since the date hereof in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of the Company under Company Contracts, (d)&#160;Liabilities incurred in connection with the Contemplated Transactions, and (e)&#160;Liabilities described in <span style="text-decoration:underline">Section&#160;3.9</span> of the Company Disclosure Letter. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_28">3.10 <span style="text-decoration:underline">Title to Assets</span>. The Company owns and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including all tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_29">3.11 <span style="text-decoration:underline">Real Property; Leasehold</span>. The Company does not own and has never owned any real property, nor is the Company party to any agreement to purchase or sell any real property. The Company has made available to Parent (a)&#160;an accurate and complete list of&#160;all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;<span style="font-weight:bold">Company</span> <span style="font-weight:bold">Real Estate Leases</span>&#8221;), each of which is in full force and effect, with no existing material default thereunder by the Company or to the Company&#8217;s Knowledge, the other party thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_30">3.12 <span style="text-decoration:underline">Intellectual Property</span>.<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section&#160;3.12(a)</span> of the Company Disclosure Letter is an accurate, true and complete listing of all Company Registered IP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Section&#160;3.12(b)</span> of the Company Disclosure Letter accurately identifies (i)&#160;all Company Contracts pursuant to which any Company IP Rights are licensed to the Company (other than (A)&#160;any <span style="white-space:nowrap">non-customized</span> software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between Company and its employees in Company&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Section&#160;3.12(c)</span> of the Company Disclosure Letter accurately identifies each Company Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company IP Rights (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Company IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for the Company&#8217;s benefit). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company is not bound by, and no Company IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the Company to use, exploit, assert or enforce any Company IP Rights anywhere in the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Company exclusively owns all right, title and interest to and in Company IP Rights (other than (i)&#160;Company IP Rights licensed to the Company, or <span style="white-space:nowrap">co-owned</span> rights each as identified in <span style="text-decoration:underline">Section&#160;3.12(e)</span> of the Company Disclosure Letter, (ii)&#160;any <span style="white-space:nowrap">non-customized</span> software that (A)&#160;is licensed to the Company solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services and (iii)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) All documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any Intellectual Property for the Company has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to the Company and confidentiality provisions protecting trade secrets and confidential information of the Company. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the Knowledge of the Company, no current or former stockholder, officer, director or employee of the Company has any claim, right (whether currently exercisable, or exercisable in the future) or interest to or in any Company IP Rights purported to be owned by the Company. To the Knowledge of the Company, no employee of the Company is (A)&#160;bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for the Company or (B)&#160;in breach of any Contract with any former employer or other Person concerning Company IP Rights purported to be owned by the Company or confidentiality provisions protecting trade secrets and confidential information comprising Company IP Rights purported to be owned by the Company. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution were used, directly or indirectly, to develop or create, in whole or in part, any Company IP Rights in which the Company has an ownership interest, except for any such funding or use of facilities or personnel that does not result in such Governmental Authority or institution owning such Company IP Rights or the right to receive royalties or other remuneration for the practice of such Company IP Rights as of the date of this Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The Company has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that the Company holds, or purports to hold, as confidential or a trade secret. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) The Company has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Company IP Rights to any other Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company has delivered or made available to Parent, a complete and accurate copy of all Company IP Rights Agreements. With respect to each of the Company IP Rights Agreements: (i)&#160;each such agreement is valid and binding on the Company and in full force and effect, (ii)&#160;the Company has not received any written notice of termination or cancellation under such agreement, or received any written notice of breach or default under such agreement, which breach has not been cured or waived and (iii)&#160;the Company, and to the Knowledge of the Company, no other party to any such agreement, is not in breach or default thereof in any material respect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by the Company does not violate any license or agreement between the Company and any other third party, and, to the Knowledge of the Company, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company, no third party is infringing upon any Patents owned by Company within the Company IP Rights, or otherwise violating any Company IP Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) As of the date of this Agreement, Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, enforceability, claim construction, ownership or right to use, sell, offer for sale, license or dispose of any Company IP Rights. The Company has not received any written notice asserting that any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that the Company has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. None of the Company IP Rights is subject to any outstanding order of, judgment of, decree of or agreement with any Governmental Authority that limits the ability of the Company to exploit any Company IP Rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each item of Company Registered IP is and at all times has been filed and maintained in compliance in all material respects with all applicable Law and all filings, payments and other actions required to be made or taken to maintain such item of Company Registered IP in full force and effect have been made by the applicable deadline. To the Knowledge of the Company, all Company Registered IP that is issued or granted is valid and enforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) To the Knowledge of the Company, no trademark (whether registered or unregistered) or trade name owned, used or applied for by the Company conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has or purports to have an ownership interest has been impaired as determined by the Company in accordance with GAAP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Except as set forth in <span style="text-decoration:underline">Sections&#160;3.12(b)</span>, <span style="text-decoration:underline">3.12(c)</span> or <span style="text-decoration:underline">3.12(k)</span> of the Company Disclosure Letter or as contained in <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;off-the-shelf&#8221;</span></span> license agreements entered into in the Ordinary Course of Business by the Company, (i)&#160;the Company is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole, and (ii)&#160;the Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) The Company is not party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Company IP Rights, result in breach of, default under or termination of such Contract with respect to any Company IP Rights, or impair the right of the Company or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_31">3.13 <span style="text-decoration:underline">Agreements, Contracts and Commitments</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section 3.13(a)</span> of the Company Disclosure Letter lists the following Company Contracts in effect as of the date of this Agreement other than the Subscription Agreement (each, a &#8220;<span style="font-weight:bold">Company Material Contract</span>&#8221; and collectively, the &#8220;<span style="font-weight:bold">Company Material Contracts</span>&#8221;): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) each Company Contract containing (A)&#160;any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Company&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision or (D)&#160;any <span style="white-space:nowrap">non-solicitation</span> provision; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) each Company Contract (A)&#160;pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, or (B)&#160;pursuant to which the Company granted any Person an exclusive license under any Company IP Rights; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $250,000 pursuant to its express terms and not cancelable without penalty; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company or of a product; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $250,000 after the date of this Agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $250,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $250,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any <span style="white-space:nowrap">pre-clinical</span> or clinical development activities of the Company, (C)&#160;any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course of Business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement in excess of $250,000 pursuant to its express terms; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) each Company Contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Company in excess of $1,000,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) each Company Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which the Company has outstanding obligations to pay consideration in excess of $250,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) any other Company Contract that is not terminable at will (with no penalty or payment) by the Company, and (A)&#160;which involves payment or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $250,000 in the aggregate, or obligations after the date of this Agreement in excess of $250,000 in the aggregate or (B)&#160;that is material to the business or operations of the Company taken as a whole; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) Company Real Estate Leases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such a manner, and, if such Company Material Contract provides for a cure period, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company or such other party fails to have cured such breach, violation or default, so that any other party or the Company, as the case may be, is permitted to modify, cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse Effect. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_32">3.14 <span style="text-decoration:underline">Compliance; Permits; Restrictions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company is, and has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the Company. There is no agreement or Order binding upon the Company which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except for matters regarding the U.S. Food and Drug Administration (or any successor agency thereto) (&#8220;<span style="font-weight:bold">FDA</span>&#8221;) or other comparable Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or medical device products (&#8220;<span style="font-weight:bold">Drug/Device Regulatory Agency</span>&#8221;), the Company holds all required Governmental Authorizations for the operation of the business of the Company as currently conducted (the &#8220;<span style="font-weight:bold">Company Permits</span>&#8221;). <span style="text-decoration:underline">Section&#160;3.14(b)</span> of the Company Disclosure Letter identifies each Company Permit. The Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Entity or its Subsidiaries, as applicable, immediately after the Second Effective Time on terms substantially identical to those enjoyed by the Company as of the date of this Agreement and immediately prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) There are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company of the Federal Food, Drug, and Cosmetic Act (&#8220;<span style="font-weight:bold">FDCA</span>&#8221;), the Public Health Service Act (&#8220;<span style="font-weight:bold">PHSA</span>&#8221;), FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of the Company as currently conducted, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the &#8220;<span style="font-weight:bold">Company Product Candidates</span>&#8221;) (collectively, the &#8220;<span style="font-weight:bold">Company Regulatory Permits</span>&#8221;), and no such Company Regulatory Permit has been (i)&#160;revoked, withdrawn, suspended, cancelled or terminated or (ii)&#160;modified in any adverse manner, other than immaterial adverse modifications. <span style="text-decoration:underline">Section&#160;3.14(d)</span> of the Company Disclosure Letter identifies each Company Regulatory Permit. The Company has timely maintained and is in compliance in all material respects with the Company Regulatory Permits and has not received any written notice or correspondence or, to the Knowledge of the Company, other communication from any Drug/Device Regulatory Agency regarding (A)&#160;any material violation of or failure to comply materially with any term or requirement of any Company Regulatory Permit or (B)&#160;any revocation, withdrawal, suspension, cancellation, termination or material modification of any Company Regulatory Permit. The Company has made available to Parent all </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material information requested by Parent in the Company&#8217;s possession or control relating to material Company Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following (to the extent there are any): (x) adverse event reports; preclinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y)&#160;similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information is accurate and complete in all material respects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All clinical, preclinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company, or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated, were, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, in accordance in all material respects with the applicable protocols and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. The Company has not received any written notices, correspondence or other communications from any Drug/Device Regulatory Agency, Governmental Authority, institutional review board, ethics committee or safety monitoring committee requiring, or to the Knowledge of the Company threatening to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, the Company or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of the Company, on behalf of the Company has been disqualified from participating in studies involving the Company Product Candidates, and to the Knowledge of the Company, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company is not, and to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate, is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products, including Company Product Candidates, by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither the Company, nor any of its officers, directors, employees or agents have been debarred or excluded from participation in any federal healthcare programs. The Company has not, and to the Knowledge of the Company, no contract manufacturer, nor their respective officers, employees or agents, with respect to any Company Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto or a comparable policy of any other Drug/Device Regulatory Agency. None of the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii)&#160;any similar applicable Law. To the Knowledge of the Company, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) All manufacturing operations conducted by, or to the Knowledge of the Company, for the benefit of the Company in connection with any Company Product Candidate have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211 and <span style="white-space:nowrap">600-610</span> and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Neither the Company nor, to the Knowledge of the Company, any manufacturing site of a contract manufacturer or laboratory, with respect to any Company Product Candidate, (i)&#160;is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii)&#160;has received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting material noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of the Company, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_33">3.15 <span style="text-decoration:underline">Legal Proceedings; Orders</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) There is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves the Company or any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or (ii)&#160;that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) There is no Order to which the Company, or any of the material assets owned or used by the Company, is subject. To the Knowledge of the Company, no officer or Company Key Employee is subject to any Order that prohibits such officer or Company Key Employee from engaging in or continuing in any conduct, activity or practice relating to the Company or any material assets owned or used by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_34">3.16 <span style="text-decoration:underline">Tax Matters</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by the Company under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no written claim has been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is subject to taxation by that jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All material amounts of Taxes due and owing by the Company (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause (a)&#160;of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of the Company. The Company has not granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect, other than waivers resulting from automatically granted extensions of time to file Tax Returns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company has not been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code in the last five (5)&#160;years. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The Company is not a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary commercial Contracts entered into in the Ordinary Course of Business the primary purpose of which does not relate to Tax (an &#8220;<span style="font-weight:bold">Ordinary Course Agreement</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The Company has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is the Company). The Company has no Liability for the Taxes of any Person under Treasury Regulations <span style="white-space:nowrap">Section&#160;1.1502-6</span> (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) The Company has not entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations <span style="white-space:nowrap">Sections&#160;1.6011-4(b)(2)</span> or <span style="white-space:nowrap">301.6111-2(b)(2).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) The Company is not aware of any facts or circumstances and has not taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_35">3.17 <span style="text-decoration:underline">Employee and Labor Matters; Benefit Plans</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an employee of the Company, whether full- or part-time, such employee&#8217;s annual salary (or if hourly, hourly rate), most recent annual bonus received, and current annual bonus opportunity. No Company Key Employee has indicated to the Company that he or she intends to resign or retire as a result of the transactions contemplated by this Agreement or otherwise. The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an individual independent contractor engaged by the Company, such contractor&#8217;s rate of compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The employment of the Company&#8217;s employees is terminable by the Company at will. The Company has made available to Parent accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing its employees, and there are no labor organizations representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Section&#160;3.17(d)</span> of the Company Disclosure Letter lists all Company Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of the Company to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to Parent). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Each Company Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Company Employee Plan or the exempt status of any related trust. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Each Company Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the Knowledge of the Company, threatened with respect to any Company Employee Plan. All payments and/or contributions required to have been made with respect to all Company Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Company Employee Plan and applicable Law except as would not be material to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6)&#160;years, maintained, contributed to or been required to contribute to (i)&#160;any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;a Multiemployer Plan, (iii)&#160;any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv)&#160;any Multiple Employer Plan, or (v)&#160;any Multiple Employer Welfare Arrangement. Neither the Company nor any of its ERISA Affiliates has in the past six (6)&#160;years incurred any liability under Title IV of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) No Company Employee Plan provides for, and the Company has not promised to provide any, medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (i)&#160;pursuant to COBRA or an analogous state law requirement or (ii)&#160;continuation coverage through the end of the month in which such termination or retirement occurs. The Company does not sponsor or maintain any self-funded medical or long-term disability benefit plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) No Company Employee Plan is subject to any law of a foreign jurisdiction outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Each Company Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;<span style="font-weight:bold">Company</span> <span style="font-weight:bold">409A Plan</span>&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Company 409A Plan is or, when made in accordance with the terms of the Company 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) The Company is, and has been, in material compliance with all applicable federal, state and local laws, rules and regulations respecting employment, employment practices, terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, retaliation and harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee and workplace safety and health, wages (including overtime wages), compensation, hours of work, &#8220;plant closings&#8221; and &#8220;mass layoffs&#8221; within the meaning of the Worker Adjustment and Retraining Act of 1988 or similar state or local law (the &#8220;<span style="font-weight:bold">WARN Act</span>&#8221;), labor practices or disputes, restrictive covenants, employment agreements, workers&#8217; compensation and long-term disability policies, leaves of absence and worker privacy (collectively, &#8220;<span style="font-weight:bold">Employment-Related Laws</span>&#8221;), and in each case, with respect to employees of the Company: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of the Company, threatened or reasonably anticipated against or involving the Company or any trustee of the Company relating to any employee, contingent worker, director, employment agreement or Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of the Company, there are no material pending or threatened or reasonably anticipated claims or actions against the Company or any trustee under any workers&#8217; compensation policy or long-term disability policy. The Company is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) The Company has no material liability with respect to any misclassification, since its incorporation, of: (i)&#160;any Person as an independent contractor rather than as an employee, (ii)&#160;any employee leased from another employer or (iii)&#160;any employee currently or formerly classified as exempt from overtime wages. The Company has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has the Company been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) To the Company&#8217;s Knowledge, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, by or with respect to any Company Associates. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Company&#8217;s Knowledge, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) The Company is not, nor has the Company been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of the Company including charges of unfair labor practices or discrimination complaints. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) There is no contract, agreement, plan or arrangement to which the Company is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to Section&#160;4999 or Section<span style="text-decoration:underline"></span>&#160;409A of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) The Company is not a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_36">3.18 <span style="text-decoration:underline">Environmental Matters</span>. The Company has complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse Effect. The Company has not received any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#8217;s compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company: (i)&#160;no current or prior owner of any property leased or controlled by the Company has received any written notice or other communication relating to property owned or leased at any time by the Company, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with or violated any Environmental Law relating to such property and (ii)&#160;the Company has no material liability under any Environmental Law. The Company has made available all environmental site assessments, environmental audits and other material environmental documents in the Company&#8217;s possession or control relating to the Company, including the Company&#8217;s business and current or former facilities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_37">3.19 <span style="text-decoration:underline">Insurance</span>.<sup style="font-size:75%; vertical-align:top"> </sup>The Company has delivered to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, the Company has not received any notice or other communication regarding any actual or possible: (i)&#160;cancellation or invalidation of any insurance policy or (ii)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against the Company, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_38">3.20 <span style="text-decoration:underline">No Financial Advisors</span>. Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.20</span> of the Company Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_39">3.21 <span style="text-decoration:underline">Transactions with Affiliates</span>. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.21</span> of the Company Disclosure Letter describes any material transactions or relationships between, on one hand, the Company and, on the other hand, any (a)&#160;executive officer or director of the Company or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b)&#160;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (c)&#160;to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item&#160;404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b)&#160;or (c)&#160;that is of the type that would be required to be disclosed under Item&#160;404 of <span style="white-space:nowrap">Regulation&#160;S-K</span> under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_40">3.22 <span style="text-decoration:underline">Privacy and Data Security</span>.<sup style="font-size:75%; vertical-align:top"> </sup>The Company is and has at all times been in compliance with all applicable Privacy Laws and the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with the Company in connection with the operation of the Company&#8217;s business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, the Company (a)&#160;has implemented and maintains reasonable written policies and procedures that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information (the &#8220;<span style="font-weight:bold">Privacy Policies</span>&#8221;) and (b)&#160;has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, no Legal Proceeding has been asserted or threatened against the Company by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of the Company, there have been no data security incidents or data breaches or other adverse events or incidents that have resulted in any unauthorized access, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of the Company or any service provider acting on behalf of the Company, in each case, where such incident, breach or event resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Company Contract. To the Knowledge of the Company, the Company is not a &#8220;covered entity&#8221; or a &#8220;business associate&#8221; as those terms are defined under the Health Insurance Portability and Accountability Act, as amended. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_41">3.23 <span style="text-decoration:underline">Trade Control Laws</span>. Since the Company&#8217;s incorporation, the Company have been in material compliance with all applicable anti-corruption, import, export control, and economic and trade sanctions laws, regulations, statutes, and orders, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the Export Administration Regulations, the International Traffic in Arms Regulations, and the regulations administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (the &#8220;<span style="font-weight:bold">Trade Laws</span>&#8221;) and have obtained, or are otherwise qualified to rely upon, all material import and export licenses, consents, notices, waivers, approvals, orders, authorizations, registrations, declarations or other authorizations from, and made any filings with, any Governmental Authority required for (a)&#160;the import, export, and reexport of products, services, software and technologies and (b)&#160;releases of technologies and software to foreign nationals (the &#8220;<span style="font-weight:bold">Trade Approvals</span>&#8221;). There are no pending or threatened claims against the Company, nor any actions, conditions, facts, or circumstances that would reasonably be expected to give rise to any material future claims with respect to the Trade Laws or Trade Approvals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_42">3.24 <span style="text-decoration:underline">Ownership of Parent Capital Stock</span>. None of the Company, their directors or, to the Knowledge of the Company, any of its officers, Affiliates, or employees of the Company or any of its controlled Affiliates (a)&#160;has owned any shares of Parent&#8217;s capital stock; or (b)&#160;has been an &#8220;interested stockholder&#8221; (as defined in Chapter 110F of the MBCA) of Parent, in each case during the three years prior to the date hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_43">3.25 <span style="text-decoration:underline">No Other Representations or Warranties</span>. The Company hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty with respect to Parent or with respect to any other information provided to the Company, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4</span> (in each case as qualified and limited by the Parent Disclosure Letter)) none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_44">Section&#160;4. <span style="text-decoration:underline">Representations and Warranties of Parent, First Merger Sub and </span><span style="text-decoration:underline">Second Merger Sub</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except (i)&#160;as set forth in the written disclosure document delivered by Parent to the Company (the &#8220;<span style="font-weight:bold">Parent Disclosure Letter</span>&#8221;) concurrently with the execution of this Agreement or (ii)&#160;as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A)&#160;without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B)&#160;excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in the Parent SEC Documents shall be deemed to be disclosed in a section of the Parent Disclosure Letter only to the extent that is readily apparent from a reading of such Parent SEC Documents that is applicable to such section or subsection of the Parent Disclosure Letter, Parent, First Merger Sub and Second Merger Sub represent and warrant to the Company as follows: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_45">4.1 <span style="text-decoration:underline">Due Organization; Subsidiaries</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent is a corporation duly incorporated, validly existing and in good standing under the Laws of the Commonwealth of Massachusetts and has all necessary corporate power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted, (ii)<span style="text-decoration:underline"></span>&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)<span style="text-decoration:underline"></span>&#160;to perform its obligations under all Contracts by which it is bound. Merger Sub is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware, and has all necessary corporate power and authority: (i)<span style="text-decoration:underline"></span>&#160;to conduct its business in the manner in which its business is currently being conducted, (ii)<span style="text-decoration:underline"></span>&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)<span style="text-decoration:underline"></span>&#160;to perform its obligations under all Contracts by which it is bound. Since the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date of its incorporation, Merger Subs have not engaged in any activities other than in connection with or as contemplated by this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each of Parent and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth on <span style="text-decoration:underline">Section&#160;4.1(c)</span> of the Parent Disclosure Letter, Parent has no Subsidiaries other than Merger Subs, and Parent does not own any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or control, directly or indirectly, any other Entity other than Merger Subs. Except as set forth on <span style="text-decoration:underline">Section&#160;4.1(c)</span> of the Parent Disclosure Letter, Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Parent has not agreed and is not obligated to make, nor is Parent bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_46">4.2 <span style="text-decoration:underline">Organizational Documents</span>. Parent has delivered to the Company accurate and complete copies of Parent&#8217;s Organizational Documents. Parent is not in breach or violation of its Organizational Documents in any material respect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_47">4.3 <span style="text-decoration:underline">Authority; Binding Nature of </span><span style="text-decoration:underline">Agreement</span>. Parent and each Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions, subject to obtaining the Required Parent Shareholder Vote. The Parent Board has: (a)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (b)&#160;adopted, approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (c)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the shareholders of Parent vote to approve the Contemplated Transactions, and, if deemed necessary by Parent and the Company, the amendment to the articles of organization of Parent to (i)&#160;change the name of Parent to &#8220;Korsana Biosciences, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split and (iii)&#160;make such other changes as are mutually agreeable to Parent and the Company pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of First Merger Sub and its sole stockholder, (y)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions. The sole member of Second Merger Sub has: (A)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and the sole member; and (B)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company and the accuracy of the representations set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.24</span>, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_48">4.4 <span style="text-decoration:underline">Vote Required</span>. Assuming the accuracy of the representations set forth in <span style="text-decoration:underline">Section&#160;3.24</span>, the affirmative vote of a majority of the shares of Parent Common Stock properly cast is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve this Agreement, the Contemplated Transactions, and thereby approve (a)&#160;the issuance of Parent Common Stock that represent (or are convertible into) more than twenty percent (20%) of the shares of Parent Common Stock outstanding immediately prior to the First Effective Time to the Company stockholders in connection with the Contemplated Transactions and the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change of control of Parent resulting from the Contemplated Transactions, in each case pursuant to the Nasdaq rules and (b)&#160;clauses (ii) through (vi)&#160;of the definition of &#8220;Parent Articles of Amendment&#8221; (collectively, the &#8220;<span style="font-weight:bold">Required Parent Shareholder Vote</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_49">4.5 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-Contravention;</span> Consents</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to obtaining the Required Parent Shareholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger required by the DGCL or DLLCA and the filing of the Parent Articles of Amendment pursuant to the MBCA, and assuming the accuracy of the representations set forth in <span style="text-decoration:underline">Section&#160;3.5</span> hereof, neither (x)&#160;the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y)&#160;the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of the assets owned or used by Parent or its Subsidiaries, is subject; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries or that otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Parent Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Parent Material Contract, (C)&#160;accelerate the maturity or performance of any Parent Material Contract or (D)&#160;cancel, terminate or modify any term of any Parent Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except for (i)&#160;any Consent set forth on <span style="text-decoration:underline">Section&#160;4.5(a)</span> of the Parent Disclosure Letter under any Parent Contract, (ii)&#160;the Required Parent Shareholder Vote, (iii)&#160;the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA and the filing of the Parent Articles of Amendment with the Secretary of the Commonwealth of Massachusetts pursuant to the MBCA, (iv)&#160;compliance with any applicable requirements of the HSR Act (if applicable) and (v)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, neither Parent nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&#160;the execution, delivery or performance of this Agreement or (y)&#160;the consummation of the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Parent Board and the First Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Chapter 110F of the MBCA are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_50">4.6 <span style="text-decoration:underline">Capitalization</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized Parent Capital Stock consists of (i)&#160;400,000,000 shares of Parent Common Stock, no par value per share, of which 4,330,314 shares have been issued and are outstanding as of March&#160;30, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2026 (the &#8220;<span style="font-weight:bold">Capitalization Date</span>&#8221;), and (ii) 100,000,000 shares of Parent Preferred Stock, no par value per share, of which 351,037 shares have been designated as Series A Convertible Preferred Stock and are issued and outstanding as of the Capitalization Date. Parent does not hold any shares of Parent Capital Stock in its treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. <span style="text-decoration:underline">Section&#160;4.6(b)</span> of the Parent Disclosure Letter accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except for the 2019 Equity Incentive Plan and Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (as may be amended from time to time, the &#8220;<span style="font-weight:bold">Parent Stock Plans</span>&#8221;), the Parent 2019 Employee Stock Purchase Plan and except as set forth on <span style="text-decoration:underline">Section&#160;</span><span style="text-decoration:underline">4.6(c)</span> of the Parent Disclosure Letter, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the Capitalization Date, Parent has reserved 589,952 shares of Parent Common Stock for issuance under the Parent Stock Plans, 282,809 shares have been reserved for issuance upon exercise or settlement of Parent Options, as applicable, granted under the Parent Stock Plans, and 306,905 shares remain available for future issuance pursuant to the Parent Stock Plans. As of the Capitalization Date, Parent has reserved 90,948 shares of Parent Common Stock for future issuance pursuant to the Parent 2019 Employee Stock Purchase Plan. <span style="text-decoration:underline">Section&#160;4.6(c)</span> of the Parent Disclosure Letter sets forth the following information with respect to each Parent Option and Parent Restricted Stock Award outstanding as of the Capitalization Date, as applicable: (i)&#160;the name of the holder, (ii)&#160;the number of shares of Parent Common Stock subject to such Parent Option and Parent Restricted Stock Awards as of the Capitalization Date, (iii)&#160;the exercise price of such Parent Option, (iv)&#160;the date on which such Parent Option or Parent Restricted Stock Award was granted, (v)&#160;the applicable vesting schedule, (vi)&#160;the date on which such Parent Option expires, and (vii)&#160;whether such Parent Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except for outstanding shares of (x)&#160;Parent Preferred Stock, (y)&#160;Parent Options or Parent Restricted Stock Awards, or (z)&#160;as set forth on <span style="text-decoration:underline">Section&#160;4.6(d)</span> of the Parent Disclosure Letter, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of Parent Capital Stock or other securities of Parent, (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of Parent Capital Stock or other securities of Parent, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent. Except as set forth on <span style="text-decoration:underline">Section&#160;4.6(d)</span> of the Parent Disclosure Letter, there are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of Parent Common Stock, Parent Options and Parent Restricted Stock Awards, and other securities of Parent have been issued and granted in compliance in all material respects with (i)&#160;all applicable securities laws and other applicable Law and (ii)&#160;all requirements set forth in applicable Contracts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) With respect to Parent Options and Parent Restricted Stock Awards granted, to the Knowledge of Parent, except as would be material to Parent, (i)&#160;each grant of a Parent Option or Parent Restricted Stock Award was duly authorized no later than the date on which the grant of such Parent Option and Parent Restricted Stock Award was by its terms to be effective (the &#8220;<span style="font-weight:bold">Parent Grant Date</span>&#8221;) by all necessary corporate action, including, as applicable, approval by the Parent Board (or a duly constituted and authorized committee thereof) or duly authorized officer and any required stockholder approval by the necessary number of votes or written consents, (ii)&#160;each Parent Option and Parent Restricted Stock Award grant was made in accordance with the terms of the Parent Stock Plan pursuant to which it was granted and all other applicable Law and regulatory rules or requirements, and (iii)&#160;the per share exercise price of each Parent Option was not less than the fair market value of a share of Parent Common Stock on the applicable Parent Grant Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_51">4.7 <span style="text-decoration:underline">SEC Filings; Financial Statements</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Since January&#160;1, 2023, Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act (the &#8220;<span style="font-weight:bold">Parent SEC Documents</span>&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i)&#160;Rule <span style="white-space:nowrap">13a-14</span> under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC Documents (collectively, the &#8220;<span style="font-weight:bold">Certifications</span>&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this <span style="text-decoration:underline">Section&#160;4.7</span> the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i)&#160;complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii) fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof or as required by GAAP, SEC rule or policy or applicable Law, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent&#8217;s auditor has at all times since its engagement by Parent as Parent&#8217;s auditor been: (i)&#160;a registered public accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation <span style="white-space:nowrap">S-X</span> under the Exchange Act and (iii)&#160;to the Knowledge of Parent, in compliance with subsections (g)&#160;through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth on <span style="text-decoration:underline">Section&#160;4.7(d)</span> of the Parent Disclosure Letter (&#8220;<span style="font-weight:bold">Prior Nasdaq Notice</span>&#8221;), Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents. Parent has delivered to Company true, correct and complete copies of all material notices, correspondence and communications (including any deficiency notices, staff determinations, compliance plans, hearing requests or determinations) between Parent and Nasdaq during the past two years relating to Parent&#8217;s compliance with Nasdaq listing standards. The matters underlying the Prior Nasdaq Notice have been fully and finally resolved and Parent has received a determination from Nasdaq in writing that Parent has regained compliance with the applicable listing standards and that the matters underlying the Prior Nasdaq Notice have been so fully and finally determined. No hearing, appeal, monitoring period, exception, probationary status, compliance plan, or other remedial or supervisory condition is pending or remains in effect with respect to the matters underlying the Prior Nasdaq Notice. Parent is not currently subject to any panel monitor, grace period, or other conditional listing status arising out of the Prior Nasdaq Notice. No facts or circumstances exist that would reasonably be expected to give rise to a recurrence of the deficiency underlying the Prior Nasdaq Notice. As of the date hereof, no delisting determination has been issued and no trading suspension in respect of Parent&#8217;s securities is in effect. Parent has timely filed all reports required to be filed by it under the Exchange Act, and such filings comply in all material respects with applicable requirements of the SEC and Nasdaq listing standards. Parent is in compliance in all material respects with Nasdaq listing standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Since January&#160;1, 2023, there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&#160;that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#8217;s transactions and dispositions of assets, (ii)<span style="text-decoration:underline"></span>&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)<span style="text-decoration:underline"></span>&#160;that receipts and expenditures are made only in accordance with the authorization policy and (iv)<span style="text-decoration:underline"></span>&#160;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness of Parent&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#8217;s auditors and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure)<span style="text-decoration:underline"></span>&#160;(A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B)<span style="text-decoration:underline"></span>&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s or its Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent&#8217;s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Parent&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Parent&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_52">4.8 <span style="text-decoration:underline">Absence of Changes</span>. Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.8</span> of the Parent Disclosure Letter, between the Balance Sheet Date and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&#160;Parent Material Adverse Effect or (b)&#160;action, event or occurrence that would have required consent of the Company pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(b)</span> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_53">4.9 <span style="text-decoration:underline">Absence of Undisclosed Liabilities</span>. Since the Balance Sheet Date, neither Parent nor any of its Subsidiaries has any Liability except for: (a)&#160;Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b)&#160;normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d)&#160;Liabilities incurred in connection with the Contemplated Transactions, and (e)&#160;Liabilities described in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.9</span> of the Parent Disclosure Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_54">4.10 <span style="text-decoration:underline">Title to Assets</span>. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including all tangible assets reflected on the Parent Balance Sheet or in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_55">4.11 <span style="text-decoration:underline">Real Property</span>; Leasehold. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to any agreement to purchase or sell any real property. Parent has made available to the Company (a)&#160;an accurate and complete list of&#160;all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;<span style="font-weight:bold">Parent</span> <span style="font-weight:bold">Real Estate Leases</span>&#8221;), each of which is in full force and effect, with no existing material default thereunder by Parent or its Subsidiaries or, to Parent&#8217;s Knowledge, the other party thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_56">4.12 <span style="text-decoration:underline">Intellectual Property</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section&#160;4.12(a)</span> of the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Section&#160;4.12(b)</span> of the Parent Disclosure Letter accurately identifies (i)&#160;all Parent Contracts pursuant to which any Parent IP Rights are licensed to Parent (other than (A)&#160;any <span style="white-space:nowrap">non-customized</span> software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between Parent and its employees in Parent&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to Parent are exclusive or nonexclusive. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Section&#160;4.12(c)</span> of the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent IP Rights (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Parent IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent&#8217;s benefit). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Neither Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any Parent IP Rights anywhere in the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Parent or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i)&#160;Parent IP Rights licensed to Parent, or <span style="white-space:nowrap">co-owned</span> rights each as identified in <span style="text-decoration:underline">Section&#160;4.12(e)</span> of the Parent Disclosure Letter, (ii)&#160;any <span style="white-space:nowrap">non-customized</span> software that (A)&#160;is licensed to Parent solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries&#8217; products or services and (iii)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) All documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Parent and its Subsidiaries. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any claim, right (whether currently exercisable, or exercisable in the future), or interest to or in any Parent IP Rights purported to be owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a)&#160;bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b)&#160;in breach of any Contract with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such Subsidiary. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) No funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Parent and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Parent or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Parent IP Rights to any other Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Parent has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any material respect, and, to the Knowledge of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any Parent IP Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) As of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) To the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance with GAAP (in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Except as may be set forth in the Contracts listed on <span style="text-decoration:underline">Section&#160;4.12(b)</span>, <span style="text-decoration:underline">4.12(c)</span> or <span style="text-decoration:underline">4.12(k)</span> of the Parent Disclosure Letter or as contained in <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;off-the-shelf&#8221;</span></span> license agreements entered into in the Ordinary Course of Business by Parent, (i)&#160;Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and (ii)&#160;Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Neither Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Parent IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_57">4.13 <span style="text-decoration:underline">Agreements, Contracts and Commitments</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Section&#160;4.13</span> of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement other than a Parent Employee Plan (each, an &#8220;<span style="font-weight:bold">Parent Material Contract</span>&#8221; and collectively, the &#8220;<span style="font-weight:bold">Parent Material Contracts</span>&#8221;): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) each Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting or independent contractor services, not terminable by Parent on thirty (30)&#160;calendar days&#8217; or less notice without liability; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) each Parent Contract containing (A)&#160;any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision or (D)&#160;any <span style="white-space:nowrap">non-solicitation</span> provision; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) each Parent Contract (A)&#160;pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B)&#160;pursuant to which Parent granted any Person an exclusive license under any Parent IP Rights; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries, or of a product; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) each Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any <span style="white-space:nowrap">pre-clinical</span> or clinical development activities of Parent, (C)&#160;any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Parent or such Subsidiary or (D)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Parent Contracts entered into in the Ordinary Course of Business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement in excess of $100,000 pursuant to its express terms; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) each Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound (other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary in excess of $100,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) any Parent Real Estate Lease; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) a Contract disclosed in or required to be disclosed in <span style="text-decoration:underline">Section&#160;4.12(b)</span> or <span style="text-decoration:underline">Section&#160;4.12(c)</span> of the Parent Disclosure Letter; or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) any other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, and (A)&#160;which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B)&#160;that is material to the business or operations of Parent and its Subsidiaries taken as a whole. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent&#8217;s Knowledge as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and, if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_58">4.14 <span style="text-decoration:underline">Compliance; Permits; Restrictions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent and each of its Subsidiaries is, and since January&#160;1, 2025, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the &#8220;<span style="font-weight:bold">Parent Permits</span>&#8221;). <span style="text-decoration:underline">Section&#160;4.14(b)</span> of the Parent Disclosure Letter identifies each Parent Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit. The rights and benefits of each Parent Permit, if any, will be available to Parent and the Surviving Entity immediately after the Second Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and immediately prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) There are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Each of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the &#8220;<span style="font-weight:bold">Parent Product Candidates</span>&#8221;) (the &#8220;<span style="font-weight:bold">Parent Regulatory Permits</span>&#8221;), and no such Parent Regulatory Permit has been (i)&#160;revoked, withdrawn, suspended, cancelled or terminated or (ii)&#160;modified in any adverse manner other than immaterial adverse modifications. <span style="text-decoration:underline">Section&#160;4.14(d)</span> of the Parent Disclosure Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January&#160;1, 2025, received any written notice or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A)&#160;any material violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B)&#160;any revocation, withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available to the Company all material information requested by the Company in Parent&#8217;s or its Subsidiaries&#8217; possession or control relating to material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following (to the extent there are any): (x) adverse event reports; <span style="white-space:nowrap">pre-clinical,</span> clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y)&#160;similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information is accurate and complete in all material respects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All clinical, <span style="white-space:nowrap">pre-clinical</span> and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since January&#160;1, 2025, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January&#160;1, 2025, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers, employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii)&#160;any similar applicable Law. To the Knowledge of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of its officers, employees or agents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) All manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with any Parent Product Candidate, since January&#160;1, 2025, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory, with respect to any Parent Product Candidate, (i)&#160;is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii)&#160;has, since January&#160;1, 2025, received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting material noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_59">4.15 <span style="text-decoration:underline">Legal Proceedings; Orders</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) There is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used by Parent or any of its Subsidiaries or (ii)&#160;that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_60">4.16 <span style="text-decoration:underline">Tax Matters</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no written claim has been made by a Governmental Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries is subject to taxation by that jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Each of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause (a)&#160;of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Parent or any of its Subsidiaries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect, other than waivers resulting from automatically granted extensions of time to file Tax Returns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Neither Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Parent or its Subsidiaries) under Treasury Regulations <span style="white-space:nowrap">Section&#160;1.1502-6</span> (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Neither Parent nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations <span style="white-space:nowrap">Sections&#160;1.6011-4(b)(2)</span> or <span style="white-space:nowrap">301.6111-2(b)(2).</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Neither Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_61">4.17 <span style="text-decoration:underline">Employee and Labor Matters; Benefit Plans</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries, such employee&#8217;s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly, hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such contractor&#8217;s name, duties and rate of compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The employment of Parent&#8217;s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Section&#160;4.17(d)</span> of the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to the Company). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Each Parent Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Each Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Employee Plan and applicable Law except as would not be material to Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6)&#160;years, maintained, contributed to or been required to contribute to (i)&#160;any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;a Multiemployer Plan, (iii)&#160;any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv)&#160;any Multiple Employer Plan, or (v)&#160;any Multiple Employer Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has in the past six (6)&#160;years incurred any liability under Title IV of ERISA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) No Parent Employee Plan provides for, and neither Parent nor any of its Subsidiaries has promised to provide any, medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (i)&#160;pursuant to COBRA or an analogous state law requirement or (ii)&#160;continuation coverage through the end of the month in which such termination or retirement occurs. Parent does not sponsor or maintain any self-funded medical or long-term disability benefit plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) No Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Each Parent Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;<span style="font-weight:bold">Parent 409A Plan</span>&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms of the Parent 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Parent is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director, employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or any trustee of any Subsidiary of Parent under any workers&#8217; compensation policy or long-term disability policy. Parent is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) Parent has no material liability with respect to any misclassification within the past three (3)&#160;years of: (i)&#160;any Person as an independent contractor rather than as an employee, (ii)&#160;any employee leased from another employer or (iii)&#160;any employee currently or formerly classified as exempt from overtime wages. In the past three (3)&#160;years, Parent has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) To the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) Parent is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) There is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to Section&#160;4999 or Section&#160;409A of the Code. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) Neither Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) (i) result in the payment of any &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code or (ii) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_62">4.18 <span style="text-decoration:underline">Environmental Matters</span>. Since January&#160;1, 2025, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January&#160;1, 2025, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with Parent&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent: (i)&#160;no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received since January&#160;1, 2025, any written notice or other communication relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii)&#160;neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. Parent has made available all environmental site assessments, environmental audits and other material </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
environmental documents in the Parent&#8217;s possession or control relating to the Parent and its Subsidiaries, including the Parent&#8217;s and its Subsidiaries&#8217; business and current or former facilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_63">4.19 <span style="text-decoration:underline">Insurance</span>.<span style="font-weight:bold"> </span>Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs). Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January&#160;1, 2025, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i)&#160;cancellation or invalidation of any insurance policy or (ii)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_64">4.20 <span style="text-decoration:underline">Transactions with Affiliates</span>. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K</span> promulgated by the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_65">4.21 <span style="text-decoration:underline">No Financial Advisors</span>. Except as set forth on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.21</span> of the Parent Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_66">4.22 <span style="text-decoration:underline">Valid Issuance</span>. The Parent Common Stock to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common Stock issuable upon (a)&#160;exercise of any Assumed Warrant, (b)&#160;exercise of any <span style="white-space:nowrap">Pre-Funded</span> Warrant, and (c)&#160;conversion of any Parent Preferred Stock, upon issuance in accordance with the terms of the applicable Assumed Warrant, <span style="white-space:nowrap">Pre-Funded</span> Warrant and Parent Articles of Amendment (respectively), will be validly issued, fully paid and nonassessable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_67">4.23 <span style="text-decoration:underline">Privacy and Data Security</span>. Parent and its Subsidiaries are and since January&#160;1, 2025, have been in compliance with all applicable Privacy Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with Parent or any of its Subsidiaries in connection with the operation of Parent&#8217;s and its Subsidiaries&#8217; business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, Parent (i)&#160;has implemented and maintains reasonable Privacy Policies that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii)&#160;has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Personal Information. To the Knowledge of Parent, there have been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Parent Contract. To the Knowledge of Parent, Parent is not a &#8220;covered entity&#8221; or a &#8220;business associate&#8221; as those terms are defined under the Health Insurance Portability and Accountability Act, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_68">4.24 <span style="text-decoration:underline">Trade Control Laws</span>. Since March&#160;1, 2023, Parent and its Subsidiaries have been in material compliance with all applicable Trade Laws and have obtained, or are otherwise qualified to rely upon, all material Trade Approvals. There are no pending or threatened claims against the Parent or its Subsidiaries, nor any actions, conditions, facts or circumstances that would reasonably be expected to give rise to any material future claims with respect to the Trade Laws or Trade Approvals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_69">4.25 <span style="text-decoration:underline">No Other Representations or Warranties</span>. Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company makes any express or implied representation or warranty with respect to the Company or with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in <span style="text-decoration:underline">Section&#160;3</span> (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_70">Section&#160;5. <span style="text-decoration:underline">Certain Covenants of the Parties</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_71">5.1 <span style="text-decoration:underline">Operation of Parent&#8217;s Business</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in <span style="text-decoration:underline">Section&#160;5.1(a)</span> of the Parent Disclosure Letter, (iii)&#160;as required by applicable Law, or (iv)&#160;unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to <span style="text-decoration:underline">Section&#160;10</span> and the First Effective Time (the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Pre-Closing</span> Period</span>&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x)&#160;conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Parent Material Contracts and (y)&#160;continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in <span style="text-decoration:underline">Section&#160;5.1(b)</span>&#160;of the Parent Disclosure Letter, (iii)&#160;as required by applicable Law, or (iv)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the <span style="white-space:nowrap">Pre-Closing</span> Period, Parent shall not, nor shall it cause or permit any of Subsidiaries to, do any of the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) declare, accrue, set aside or pay any dividend (other than the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend Amount, if any, and the Closing Distribution) or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent or in connection with the payment of the exercise price or withholding Taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under any Parent equity incentive plan in accordance with the terms of such award in effect on the date of this Agreement); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A)&#160;any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Awards, as applicable), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) (A) lend money to any Person (except for the advancement of reasonable and customary expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or guarantee any indebtedness for borrowed money, (C)&#160;guarantee any debt securities of others or (D)&#160;other than the incurrence or payment of expenses pursuant to the terms of this Agreement, make any capital expenditure or commitment in excess of $100,000; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) (A) adopt, establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B)&#160;cause or permit any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with Section&#160;409A of the Code, (C)&#160;pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire any officer, employee or consultant; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to <span style="white-space:nowrap">non-exclusive</span> licenses in the Ordinary Course of Business or pursuant to the consummation of any Parent Legacy Transaction); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) other than in the Ordinary Course of Business: (A)&#160;make, change or revoke any material Tax election; (B)&#160;file any amended income or other material Tax Return; (C)&#160;adopt or change any material accounting method in respect of Taxes; (D)&#160;enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E)&#160;consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F)&#160;surrender any material claim for refund; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) forgive any loans to any Person, including its employees, officers, directors or Affiliate; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) (A) materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B)&#160;agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of Subsidiaries; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) delay or fail to repay when due any material obligation, including accounts payable and accrued expenses; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) enter into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) agree, resolve or commit to do any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding any provision herein to the contrary (including the foregoing provisions of this <span style="text-decoration:underline">Section&#160;5.1</span>), Parent: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) may engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of the Parent Legacy Business (including terminating its Parent Real Estate Leases and other Parent Contracts) (each, a &#8220;<span style="font-weight:bold">Parent Legacy Transaction</span>&#8221;) and, in connection with any Parent Legacy Transaction, (A)&#160;establish one or more Subsidiaries to hold assets of the Parent Legacy Business, (B)&#160;transfer to any such Subsidiary any or all of the assets of the Parent Legacy Business and the liabilities and obligations related thereto, and (C)&#160;take such other steps that are reasonably necessary to prepare for a Parent Legacy Transaction; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that to the extent any Parent Legacy Transaction results in material obligations of Parent that will extend beyond Closing (other than the right of Parent to receive proceeds as a result of such Parent Legacy Transaction), such terms shall be reasonably acceptable to the Company and any such post-Closing obligations shall be a reduction to Parent Net Cash; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) shall, if and to the extent Parent reasonably expects the Parent Net Cash to exceed $5,000,000, and may otherwise elect to, in each case, prior to the First Effective Time, declare and pay a dividend on the shares of Parent Common Stock and Parent Preferred Stock outstanding (excluding for the avoidance of doubt any shares of Parent Capital Stock issuable pursuant to the Contemplated Transactions) up to an amount, to be determined in accordance with <span style="text-decoration:underline">Section&#160;2.8</span>, equal to the aggregate of Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $0 (such dividend, the &#8220;<span style="font-weight:bold">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend</span>&#8221; and such amount, the &#8220;<span style="font-weight:bold">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend Amount</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_72">5.2 <span style="text-decoration:underline">Operation of the Company&#8217;s Business</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except (i)&#160;as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in <span style="text-decoration:underline">Section&#160;5.2(a)</span> of the Company Disclosure Letter, (iii)&#160;as required by applicable Law, (iv)&#160;with respect to any Company <span style="white-space:nowrap">Pre-Closing</span> Financing, which is expressly permitted, or (v)&#160;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the <span style="white-space:nowrap">Pre-Closing</span> Period the Company shall use commercially reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Company Material Contracts. For the avoidance of doubt, during the <span style="white-space:nowrap">Pre-Closing</span> Period, Ordinary Course of Business, with respect to the Company, shall also include such <span style="white-space:nowrap">build-out,</span> expansion, and development activities as are customary and reasonable for biotechnology companies at a stage of development substantially similar to that of the Company as of the date hereof, including, without limitation, activities relating to personnel hiring and retention, laboratory and office expansion, clinical and regulatory infrastructure development, manufacturing <span style="white-space:nowrap">scale-up</span> (including engagement of contract development and manufacturing organizations), implementation of quality and compliance systems, and other operational capability enhancements; <span style="text-decoration:underline">provided</span>,&#160;<span style="text-decoration:underline">however</span>, that nothing in this <span style="text-decoration:underline">Section&#160;5.2</span> shall be construed to permit the Company to take any action that is expressly prohibited or restricted by the terms of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except (i)&#160;as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in <span style="text-decoration:underline">Section&#160;5.2(b)</span> of the Company Disclosure Letter, (iii)&#160;as required by applicable </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Law, (iv)&#160;in connection with any Company <span style="white-space:nowrap">Pre-Closing</span> Financing, which is expressly permitted, or actions taken in the Ordinary Course of Business, or (v)&#160;with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the <span style="white-space:nowrap">Pre-Closing</span> Period, the Company shall not do any of the following: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) other than in the Ordinary Course of Business, sell, issue, grant, or authorize any of the foregoing actions with respect to the shares of Company Capital Stock outstanding as of the date of this Agreement: (A)&#160;any capital stock or other security of the Company (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options or Company Warrants), (B) any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security of the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) other than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) (A) lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, or (C)&#160;guarantee any debt securities of others; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) sell, assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to <span style="white-space:nowrap">non-exclusive</span> licenses); </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) waive, settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) other than in the Ordinary Course of Business: (A)&#160;make, change or revoke any material Tax election; (B)&#160;file any amended income or other material Tax Return; (C)&#160;adopt or change any material accounting method in respect of Taxes; (D)&#160;enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E)&#160;consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F)&#160;surrender any material claim for refund; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) enter into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) agree, resolve or commit to do any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_73">5.3 <span style="text-decoration:underline">Access and Investigation</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the <span style="white-space:nowrap">Pre-Closing</span> Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a)&#160;provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (b)&#160;provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (c)&#160;permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d)&#160;make available to the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this <span style="text-decoration:underline">Section&#160;5.3</span> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything herein to the contrary in this <span style="text-decoration:underline">Section&#160;5.3</span>, no access or examination contemplated by this <span style="text-decoration:underline">Section&#160;5.3</span> shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; <span style="text-decoration:underline">provided</span> that such Party or its Subsidiary (i)&#160;shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii)&#160;shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii)&#160;shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_74">5.4 <span style="text-decoration:underline">No Solicitation</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and the Company agrees that, during the <span style="white-space:nowrap">Pre-Closing</span> Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly: (i)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any <span style="white-space:nowrap">non-public</span> information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii)&#160;engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry (other than to inform such Person of the existence of the provisions in this <span style="text-decoration:underline">Section&#160;5.4</span>), (iv) approve, endorse or recommend any Acquisition Proposal, (v)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or (vi)&#160;publicly propose to do any of the foregoing; <span style="text-decoration:underline">provided, however</span>, that, (x)&#160;any public disclosures made in compliance with <span style="text-decoration:underline">Section&#160;6.3</span>(e) shall not constitute a violation of this <span style="text-decoration:underline">Section&#160;5.4</span> and (y)&#160;notwithstanding anything contained in this <span style="text-decoration:underline">Section&#160;5.4</span> and subject to compliance with this <span style="text-decoration:underline">Section&#160;5.4</span>, prior to the approval of this Agreement by a Party&#8217;s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company, or the Required Parent Shareholder Vote in the case of Parent), such Party may furnish <span style="white-space:nowrap">non-public</span> information regarding such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which such Party&#8217;s board of directors determines in good faith, after consultation with such Party&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&#160;such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B)&#160;the board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the board of directors&#8217; fiduciary duties under applicable Law, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(C)&#160;at least two&#160;(2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, such Party gives the other Party written notice of the identity of such Person and of such Party&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D)&#160;such Party receives from such Person an executed Acceptable Confidentiality Agreement and (E)&#160;at least two&#160;(2) Business Days prior to furnishing any such nonpublic information to such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this <span style="text-decoration:underline">Section&#160;5.4</span> by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this <span style="text-decoration:underline">Section&#160;5.4</span> by such Party for purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the <span style="white-space:nowrap">Pre-Closing</span> Period, then such Party shall promptly (and in no event later than one&#160;(1) Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person within twenty-four (24)&#160;hours following the execution and delivery of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_75">5.5 <span style="text-decoration:underline">Notification of Certain Matters</span>. During the <span style="white-space:nowrap">Pre-Closing</span> Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a)&#160;any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c)&#160;such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d)&#160;the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in <span style="text-decoration:underline">Section&#160;7</span>, <span style="text-decoration:underline">Section&#160;8</span> or <span style="text-decoration:underline">Section&#160;9</span>, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company in this Agreement or (y)&#160;determining whether any condition set forth in <span style="text-decoration:underline">Section&#160;7</span>, <span style="text-decoration:underline">Section&#160;8</span> or <span style="text-decoration:underline">Section&#160;9</span> has been satisfied. Any failure by either Party to provide notice pursuant to this <span style="text-decoration:underline">Section&#160;5.5</span> shall not be deemed to be a breach for purposes of <span style="text-decoration:underline">Section&#160;8.2</span> or <span style="text-decoration:underline">Section&#160;9.2</span>, as applicable, unless such failure to provide such notice was made with such Party&#8217;s Knowledge that such failure to provide notice would reasonably be expected to constitute a breach of this <span style="text-decoration:underline">Section&#160;5.5</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_76">Section&#160;6. <span style="text-decoration:underline">Additional Agreements of the Parties</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_77">6.1 <span style="text-decoration:underline">Registration Statement, Proxy Statement</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable after the date of this Agreement, Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form <span style="white-space:nowrap">S-4</span> (the &#8220;<span style="font-weight:bold">Form <span style="white-space:nowrap">S-4</span></span>&#8221;), in which a proxy statement relating to the Parent Shareholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;<span style="font-weight:bold">Proxy Statement</span>&#8221;) shall be included as a part (the Proxy Statement and the Form <span style="white-space:nowrap">S-4,</span> collectively, the &#8220;<span style="font-weight:bold">Registration Statement</span>&#8221;), in connection with the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration under the Securities Act of the shares of Parent Common Stock (including any Parent Common Stock issuable upon (I)&#160;conversion of the Parent Convertible Preferred Stock or (II)&#160;exercise of any Assumed Warrant) to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form <span style="white-space:nowrap">S-4</span> pursuant to applicable Law. Parent shall use commercially reasonable efforts to (i)&#160;cause the Registration Statement to comply with applicable rules and regulations promulgated by the SEC, (ii)&#160;cause the Registration Statement to become effective as promptly as practicable, and (iii)&#160;respond promptly to any comments or requests of the SEC or its staff related to the Registration Statement. Parent shall use commercially reasonable efforts to take all actions required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions (including any Parent Common Stock issuable upon (I)&#160;conversion of the Parent Convertible Preferred Stock or (II)&#160;exercise of any Assumed Warrant). Each of the Parties shall reasonably cooperate with the other Party and furnish all information concerning itself and its Affiliates, as applicable, to the other Parties that is required by law to be included in the Registration Statement as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and Proxy Statement. In furtherance and not in limitation of the foregoing, Parent shall use its reasonable best efforts to file the Form <span style="white-space:nowrap">S-4</span> no later than 30 Business Days following the date hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith)&#160;(i) will comply as to form in all material respects with the requirements of applicable U.S. federal securities laws, and (ii)&#160;other than with respect to information supplied by or on behalf of the Company to Parent for inclusion in the Registration Statement, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company to Parent for inclusion in the Registration Statement will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither Party makes any covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other Party or any of its Representatives regarding such other Party or its Affiliates for inclusion therein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s shareholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If at any time before the First Effective Time, (i)&#160;Parent, Merger Subs or the Company (A)&#160;become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, (B)&#160;receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C)&#160;receives SEC comments on the Registration Statement, or (ii)&#160;the information provided in the Registration Statement has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent shareholders) or otherwise addressing such SEC request or comments and each Party and shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1)&#160;that the Registration Statement has become effective, (2)&#160;of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuable in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon (I)&#160;conversion of the Parent Convertible Preferred Stock or (II)&#160;exercise of any Assumed Warrant) for offering or sale in any jurisdiction, or (3)&#160;any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
orders of the SEC relating to the Registration Statement. The Company and Parent shall each pay 50% of (i)&#160;the fees paid in connection with filing the Registration Statement and any amendments and supplements thereto, and (ii)&#160;the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company that is required by Law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement (collectively, the &#8220;<span style="font-weight:bold">Company </span><span style="font-weight:bold">Required <span style="white-space:nowrap">S-4</span> Information</span>&#8221;). Without limiting the foregoing, the Company will use commercially reasonable efforts to cause to be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no later than the date on which the Registration Statement is filed with the SEC (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent may file the Registration Statement, or any amendment or supplement thereto, without the prior consent of the Company, <span style="text-decoration:underline">provided</span> that Parent has included the Company Required <span style="white-space:nowrap">S-4</span> Information in the Registration Statement in substantially the same form as it was provided to Parent by the Company pursuant to this <span style="text-decoration:underline">Section&#160;6.1</span>; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">further</span>, that if the prior consent of the Company is not obtained then, notwithstanding anything else herein, the Company makes no covenant or representation regarding the portion of such information supplied by or on behalf of the Company to Parent for inclusion in such Registration Statement that the Company reasonably identifies prior to such filing of the Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_78">6.2 <span style="text-decoration:underline">Company Stockholder Written Consent</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2)&#160;Business Days thereafter, the Company shall obtain the approval by written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of the DGCL, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii)&#160;acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (iii)&#160;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the &#8220;<span style="font-weight:bold">Company Stockholder Written Consents</span>&#8221;). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Reasonably promptly following receipt of the Required Company Stockholder Vote, the Company shall prepare and mail a notice (the &#8220;<span style="font-weight:bold">Stockholder Notice</span>&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent, if any. The Stockholder Notice shall (i)&#160;be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b) of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii)&#160;provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of the DGCL and the certificate of incorporation and bylaws of the Company and (iii)&#160;include a description of the appraisal rights of the Company&#8217;s stockholders available under the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this <span style="text-decoration:underline">Section&#160;6.2(b)</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be subject to Parent&#8217;s advance review (the period of time starting upon delivery of any such materials to Parent and ending upon resolution of any good faith comments raised by Parent, the &#8220;<span style="font-weight:bold">Company Stockholder Consent Review Period</span>&#8221;), and the Company shall consider in good faith any comments raised by Parent in connection with Parent&#8217;s review. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company agrees that, subject to <span style="text-decoration:underline">Section&#160;6.2(d)</span>: (i) the Company Board shall recommend that the Company&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in <span style="text-decoration:underline">Section&#160;6.2(a)</span> (the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;<span style="font-weight:bold">Company Board Recommendation</span>&#8221;) and (ii)&#160;the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary contained in <span style="text-decoration:underline">Section&#160;6.2(c)</span>, and subject to compliance with <span style="text-decoration:underline">Section&#160;5.4</span> and <span style="text-decoration:underline">Section&#160;6.2</span>, if at any time prior to approval and adoption of this Agreement by the Required Company Stockholder Vote, (i)&#160;the Company receives a bona fide unsolicited written Acquisition Proposal that did not result from a breach of <span style="text-decoration:underline">Section&#160;5.4</span> or <span style="text-decoration:underline">Section&#160;6.2</span> and that the Company Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;as a result of a material development or change in circumstances (other than any such event, development or change to the extent (A)&#160;known or reasonably foreseeable to the Company, the Company Board or any of its executive officers as of the date of this Agreement or (B)&#160;related to (1)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, (2)&#160;any events, developments or changes relating to Parent or Merger Subs, or (3)&#160;the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a &#8220;<span style="font-weight:bold">Company Intervening Event</span>&#8221;), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a &#8220;<span style="font-weight:bold">Company Board Adverse Recommendation Change</span>&#8221;) if, but only if, (x)&#160;in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i)&#160;the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii)&#160;the Company has, during the Notice Period (as defined below), negotiated with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii)&#160;if, Parent has delivered to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); provided that (1)&#160;Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four (4)&#160;Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;<span style="font-weight:bold">Notice Period</span>&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2)&#160;during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least three (3)&#160;Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration:underline">Section&#160;6.2(d)</span> and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions) or (y)&#160;in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change, and the Company shall have given Parent two (2)&#160;Business Days thereafter to propose revisions to the terms of this Agreement or make other proposals so that such Company Intervening Event would no longer necessitate a Company Board Adverse Recommendation Change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with <span style="text-decoration:underline">Section&#160;6.2(a)</span> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry or Company Intervening Event, or by any Company Board Adverse Recommendation Change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_79">6.3 <span style="text-decoration:underline">Parent Shareholder Meeting</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock to consider and vote to approve (I)&#160;the issuance of shares of Parent Common Stock that represent (or are convertible into) more than twenty percent (20%) of the shares of Parent Common Stock outstanding immediately prior to the First Effective Time to the Company stockholders in connection with the Contemplated Transactions and the change of control of Parent resulting from the Contemplated Transactions, in each case pursuant to the Nasdaq rules and (II)&#160;clauses (ii) through (vi)&#160;of the definition of &#8220;Parent Articles of Amendment&#8221; (collectively, the &#8220;<span style="font-weight:bold">Parent Shareholder Matters</span>&#8221; and such meeting, the &#8220;<span style="font-weight:bold">Parent Shareholder Meeting</span>&#8221;). The Parent Shareholder Meeting shall be held as promptly as practicable after the date that the Registration Statement is declared effective under the Securities Act, and in any event, no later than forty-five (45)&#160;days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Shareholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Shareholder Meeting, or a date preceding the date on which the Parent Shareholder Meeting is scheduled, Parent reasonably believes that (i)&#160;it will not receive proxies sufficient to obtain the Required Parent Shareholder Vote, whether or not a quorum would be present, (ii)&#160;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Shareholder Meeting or (iii)&#160;that the failure to postpone or adjourn the Parent Shareholder Meeting would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Shareholder Meeting as long as the date of the Parent Shareholder Meeting is not postponed or adjourned more than an aggregate of 45 days in connection with any postponements or adjournments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent agrees that (i)&#160;the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Shareholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <span style="text-decoration:underline">Section&#160;6.3(a)</span> above and (ii)&#160;the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s shareholders vote to approve the Parent Shareholder Matters (the recommendation of the Parent Board being referred to as the &#8220;<span style="font-weight:bold">Parent Board Recommendation</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary contained in Section&#160;6.3(b), and subject to compliance with <span style="text-decoration:underline">Section&#160;5.4</span> and <span style="text-decoration:underline">Section&#160;6.3</span>, the Parent Board may withhold, amend, withdraw or modify the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parent Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company (a &#8220;<span style="font-weight:bold">Parent Board Adverse Recommendation Change</span>&#8221;) if, at any time prior to approval and adoption of this Agreement by the Required Parent Shareholder Vote, (i)&#160;Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer or (ii)&#160;as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, (B)&#160;the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations, or (C)&#160;any Parent Legacy Transaction) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a &#8220;<span style="font-weight:bold">Parent Intervening Event</span>&#8221;), if, but only if, (x)&#160;in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i)&#160;the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii)&#160;Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined below), negotiated with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (iii)&#160;if, after the Company has delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); <span style="text-decoration:underline">provided</span> that (1)&#160;the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4)&#160;Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;<span style="font-weight:bold">Parent</span> <span style="font-weight:bold">Notice Period</span>&#8221;), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2)&#160;during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent&#8217;s shareholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3)&#160;Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration:underline">Section&#160;6.3(c)</span> and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y)&#160;in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Parent&#8217;s obligation to call, give notice of and hold the Parent Shareholder Meeting in accordance with <span style="text-decoration:underline">Section&#160;6.3(a)</span> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i)&#160;complying with Rules <span style="white-space:nowrap">14d-9</span> and <span style="white-space:nowrap">14e-2(a)</span> promulgated under the Exchange Act; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that any disclosure made by Parent or the Parent Board pursuant to Rules <span style="white-space:nowrap">14d-9</span> and <span style="white-space:nowrap">14e-2(a)</span> shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii)&#160;complying with Item 1012(a) of Regulation <span style="white-space:nowrap">M-A</span> promulgated under the Exchange Act; (iii)&#160;informing any Person of the existence of the provisions contained in <span style="text-decoration:underline">Section&#160;5.4</span>; or (iv)&#160;making any disclosure that the Parent Board (or a committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law or by any listing or trading rules or regulations of Nasdaq; provided that, in the case of (iv), Parent shall provide the Company with a reasonable opportunity to review any such disclosure not less than two (2)&#160;Business Days prior to the making thereof (to the extent practicable) and shall consider in good faith any comments from the Company thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_80">6.4 <span style="text-decoration:underline">Efforts; Regulatory Approvals</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Parties shall use commercially reasonable efforts to obtain all regulatory approvals required by applicable Law to consummate the Contemplated Transactions. In addition, and without limiting the generality of the foregoing, each Party (i)&#160;shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii)&#160;shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii)&#160;shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Parties shall prepare and file, if required, (a)&#160;the notification and report forms required to be filed under the HSR Act within fifteen (15)&#160;Business Days after the date of this Agreement and (b)&#160;any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters, no later than fifteen (15)&#160;Business Days after the date the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection with antitrust or competition matters. Parent and the Company shall each pay 50% of all filing fees required to be paid by the Parties in connection with any notification and report forms required to be filed under the HSR Act or any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters (collectively, &#8220;<span style="font-weight:bold">Antitrust Fees</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Without limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (&#8220;<span style="font-weight:bold">Transaction Litigation</span>&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i)&#160;give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; <span style="text-decoration:underline">provided</span> that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely affect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii) consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii)&#160;consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_81">6.5 <span style="text-decoration:underline">Company Options; Company RSUs; Company Warrants</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option (including any Service Provider Grants), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to purchase shares of Parent Common Stock (an &#8220;<span style="font-weight:bold">Assumed Option</span>&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be equal to (i)&#160;the number of shares of Company Common Stock subject to the respective Company Option immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&#160;the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option immediately prior to the First Effective Time divided by (B)&#160;the Exchange Ratio; provided that in the case of any Company Option to which Section&#160;421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section&#160;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;424(a) of the Code; provided further, that in the case of any Assumed Option to which Section&#160;409A of the Code applies as of the First Effective Time, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) At the First Effective Time, each award of Company RSU (including any Service Provider Grants), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into a restricted stock unit award to acquire shares of Parent Common Stock (an &#8220;<span style="font-weight:bold">Assumed RSU Award</span>&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company RSU as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). Each such Assumed RSU Award shall represent the right to receive, upon settlement, that number of shares of Parent Common Stock as is equal to: (i)&#160;the number of shares of Company Common Stock subject to the respective Company RSU immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock; <span style="text-decoration:underline">provided</span>, that in the case of any Assumed RSU Award to which Section&#160;409A of the Code applies as of the First Effective Time, the number of shares of Parent Common Stock subject to such restricted stock unit and the terms and conditions governing such restricted stock unit shall be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) At the First Effective Time, each Company Warrant (including any <span style="white-space:nowrap">pre-funded</span> Company Warrant issued pursuant to the Company <span style="white-space:nowrap">Pre-Closing</span> Financing), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an &#8220;<span style="font-weight:bold">Assumed Warrant</span>&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i)&#160;the number of shares </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio (rounded up to the next whole share of Parent Common Stock to the extent the aggregate amount of fractional shares of Parent Common Stock such holder of Assumed Warrants would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down), and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&#160;the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B)&#160;the Exchange Ratio. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_82">6.6 <span style="text-decoration:underline">Employee Benefits</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on <span style="text-decoration:underline">Section&#160;4.17(d)</span> or contemplated by Section&#160;5.1(b) of the Parent Disclosure Letter, subject to the provisions of such agreements. The parties acknowledge and agree that the Merger shall not constitute a &#8220;change in control&#8221; (or term of similar import) under any Company Employee Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) From and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an &#8220;employee welfare benefit plan&#8221; as defined in Section&#160;3(1) of ERISA (each, a &#8220;<span style="font-weight:bold">Post-Closing Welfare Plan</span>&#8221;) in which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i)&#160;waive all limitations as to <span style="white-space:nowrap">pre-existing</span> conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the same extent that such <span style="white-space:nowrap">pre-existing</span> conditions, waiting periods, required physical examinations and exclusions would not have applied or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii)&#160;provide each such current or former Parent employee and his or her eligible dependents with credit for any <span style="white-space:nowrap">co-payments</span> and deductibles paid in the plan year that includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such Post-Closing Welfare Plan in satisfying any applicable <span style="white-space:nowrap">co-payment</span> or deductible requirements under such Post-Closing Welfare Plan for the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Parent 401(k) Plan</span>. Unless directed otherwise by the Company in writing no less than three (3)&#160;Business Days before the Closing Date, Parent shall have, at least one (1)&#160;Business Day prior to the Closing Date, (i)&#160;ceased contributions to, and adopted written resolutions (or taken other necessary and appropriate action(s)) to terminate any Parent Employee Plan that is intended to qualify under Section&#160;401(a) of the Code with a cash or deferred arrangement described in Section&#160;401(k) of the Code (collectively, the &#8220;<span style="font-weight:bold">401(k) Plans</span>&#8221;) in compliance with such 401(k) Plan&#8217;s terms and the requirements of applicable Law, (ii)&#160;made all employee and employer contributions to the 401(k) Plans for all periods of service prior to the Closing Date, including such contributions that would have been made on behalf of 401(k) Plan participants had the Merger not occurred (regardless of any service or <span style="white-space:nowrap"><span style="white-space:nowrap">end-of-year</span></span> employment requirements) but prorated for the portion of the plan year that ends on the Closing Date, and (iii) 100% vested all participants under the 401(k) Plans, with such termination, contributions and vesting effective no later than one (1)&#160;day prior to the Closing Date. Parent shall provide the Company copies of all such corporate actions or documentation related to the same at least three (3)&#160;Business Days before their adoption or approval for the Company&#8217;s reasonable review and comment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Parent Options</span>. As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or exercisable shall become immediately vested (with all performance conditions associated with such Parent Options, if any, deemed satisfied in full) and exercisable in full. At the First Effective Time, each In the Money Parent Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive (i)&#160;an amount in cash without interest, less any applicable tax withholding, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equal to the product obtained by multiplying (A)&#160;the excess of the Parent Closing Price over the exercise price per share of the Parent Common Stock underlying such Parent Option by (B)&#160;the number of shares of the Parent Common Stock underlying such Parent Option (such amount, the &#8220;<span style="font-weight:bold">Parent Stock Option Cash Consideration</span>&#8221;). Parent shall cause the Surviving Entity to pay the Parent Stock Option Cash Consideration, less applicable withholdings, at or within ten (10)&#160;Business Days after the First Effective Time. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no consideration. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">Parent Restricted Stock Awards</span>. As of immediately prior to the First Effective Time, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that the vesting of each outstanding and unvested Parent Restricted Stock Award shall be accelerated in full effective as of immediately prior to the First Effective Time, contingent on the occurrence of the Closing. Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying the legally-required withholding rate for such holder in connection with such issuance by the number of shares of Parent Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_83">6.7 <span style="text-decoration:underline">Indemnification of Officers and Directors</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;<span style="font-weight:bold">D&amp;O Indemnified Parties</span>&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;<span style="font-weight:bold">Costs</span>&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL or the MBCA, as applicable. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; <span style="text-decoration:underline">provided</span> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL or the MBCA, as applicable, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the D&amp;O Indemnified Parties&#8217; rights with regards to counsel, following the First Effective Time, the D&amp;O Indemnified Parties shall be entitled to continue to retain Ropes&#160;&amp; Gray LLP or such other counsel selected by the D&amp;O Indemnified Parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Organizational Documents of the Surviving Entity shall contain, and Parent shall cause the Organizational Documents of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) From and after the First Effective Time, (i)&#160;the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arising out of matters occurring at or prior to the First Effective Time and (ii)&#160;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) From and after the First Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a six (6)&#160;year prepaid &#8220;D&amp;O tail policy&#8221; for the <span style="white-space:nowrap">non-cancelable</span> extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six (6)&#160;years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except that Parent will not commit or spend on such &#8220;D&amp;O Tail policy&#8221; annual premiums in excess of 250% of the annual premiums paid by Parent in its last full fiscal year prior to the date hereof for Parent&#8217;s current policies of directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific amount), and if such premiums for such &#8220;D&amp;O tail policy&#8221; would exceed 250% of such annual premium, then Parent shall purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such &#8220;D&amp;O tail policy.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this <span style="text-decoration:underline">Section&#160;6.7</span> in connection with their enforcement of the rights provided to such persons in this <span style="text-decoration:underline">Section&#160;6.7</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The provisions of this <span style="text-decoration:underline">Section&#160;6.7</span> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) In the event Parent or the Surviving Entity or any of their respective successors or assigns (i)&#160;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this <span style="text-decoration:underline">Section&#160;6.7</span>. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this <span style="text-decoration:underline">Section&#160;6.7</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_84">6.8 <span style="text-decoration:underline">Disclosure</span>. The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form <span style="white-space:nowrap">8-K</span> announcing the execution and delivery of this Agreement. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any public disclosure regarding the Contemplated Transactions unless: (a)&#160;the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b)&#160;such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; provided, however, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public statements made by the Company or Parent in compliance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.8</span>. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2(d)</span> or pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.3(e)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_85">6.9 <span style="text-decoration:underline">Listing</span>. At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b)&#160;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and to submit a copy of the amendment to Parent&#8217;s articles of organization effecting the Nasdaq Reverse Split, certified by the Secretary of the Commonwealth of Massachusetts, to Nasdaq on the Closing Date; and (d)&#160;to the extent required by Nasdaq Marketplace Rule 5110, assist the Company in preparing and filing an initial listing application for the Parent Capital Stock on Nasdaq (including any Parent Common Stock issuable upon conversion thereof) (the &#8220;<span style="font-weight:bold">Nasdaq Listing Application</span>&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its Representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.9</span>. The Company and Parent shall each pay 50% of Nasdaq fees associated with any action contemplated by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.9</span>, including any fees related to the engagement of a consultant (the &#8220;<span style="font-weight:bold">Nasdaq Fees</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_86">6.10 <span style="text-decoration:underline">Tax Matters</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Parties shall use reasonable best efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section&#160;1313(a) of the Code. The Parties shall comply with the recordkeeping and information reporting requirements imposed on them to support the Intended Tax Treatment, including, but not limited to, those set forth in Treasury Regulation Section&#160;1.368-3. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that could reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that could reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Registration Statement and Proxy Statement, (i)&#160;the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions and limitations), (ii) Parent shall use its reasonable best efforts to cause Ropes&#160;&amp; Gray LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions and limitations), and (iii)&#160;Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Ropes&#160;&amp; Gray LLP (or such other nationally </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Registration Statement and Proxy Statement shall have been declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable such advisors to render such opinions (the &#8220;<span style="font-weight:bold">Tax Certificates</span>&#8221;). Each of Parent and the Company shall use its reasonable best efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax Certificates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Parent and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer, recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_87">6.11 <span style="text-decoration:underline">Legends</span>. Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent for purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_88">6.12 <span style="text-decoration:underline">Officers and Directors</span>. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall take all necessary action so that the Persons listed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.12</span> of the Company Disclosure Letter are elected or appointed, as applicable, to the positions of officers or directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.12</span> of the Company Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the Company shall designate a successor. Notwithstanding the foregoing, at any time prior to the Second Effective Time, the Company shall have a right to amend <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.12</span> of the Company Disclosure Letter, with respect to officers and directors of Parent and Surviving Entity, in its sole discretion. The Company shall use reasonable best efforts to cause each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a <span style="white-space:nowrap">Lock-Up</span> Agreement prior to Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_89">6.13 <span style="text-decoration:underline">Termination of Certain </span><span style="text-decoration:underline">Agreements</span><span style="text-decoration:underline"> and Rights</span>. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration rights agreements, <span style="white-space:nowrap">co-sale</span> agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Capital Stock, respectively (collectively, the &#8220;<span style="font-weight:bold">Investor Agreements</span>&#8221;), including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of Parent or the Surviving Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_90">6.14 <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;16</span><span style="text-decoration:underline"> Matters</span>. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule <span style="white-space:nowrap">16b-3</span> promulgated under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_91">6.15 <span style="text-decoration:underline">Allocation </span><span style="text-decoration:underline">Information</span>. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior to the First Effective Time)&#160;(a) each holder of (i)&#160;Company </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Capital Stock, (ii)&#160;Company Options, (iii)&#160;Company RSUs, and (iv)&#160;Company Warrants, (b)&#160;such holder&#8217;s name and address, (c)&#160;with respect to holders of Company Capital Stock, the number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d)&#160;the number of shares of Parent Capital Stock, Assumed Options, Assumed RSU Awards, and Assumed Warrants to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock, Company Options, Company RSUs and Company Warrants held by such holder as of immediately prior to the First Effective Time (the &#8220;<span style="font-weight:bold">Allocation Certificate</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_92">6.16 <span style="text-decoration:underline">Parent SEC Documents</span>. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (&#8220;<span style="font-weight:bold">SEC Documents</span>&#8221;). As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by Parent with the SEC (a)&#160;shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b)&#160;shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_93">6.17 <span style="text-decoration:underline">Obligations of Merger Sub</span><span style="text-decoration:underline">s</span>. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_94">6.18 <span style="text-decoration:underline">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend</span>. If Parent declares the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend, then, prior to the First Effective Time, Parent shall deposit the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend Amount with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock and to the holders of the shares of Parent Preferred Stock, in each case, outstanding as of the record date of the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_95">6.19 <span style="text-decoration:underline">Company <span style="white-space:nowrap">Pre-Closing</span> Financing</span>. In the event the structure of the Company <span style="white-space:nowrap">Pre-Closing</span> Financing either violates applicable Law or prevents or materially delays Parent from causing the Registration Statement to become effective in a timely manner, and in any event sixty (60)&#160;days prior to the End Date, then Parent and the Company shall, and shall use their reasonable best efforts to cause the investors in the Company <span style="white-space:nowrap">Pre-Closing</span> Financing, to cause the Company <span style="white-space:nowrap">Pre-Closing</span> Financing to be amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Parent Capital Stock substantially contemporaneously with the Closing in a manner which preserves to the extent possible, the amount of funds ultimately received by Parent and its Subsidiaries, and the number of Parent shares ultimately held by the investor in respect of such amounts as though the Company <span style="white-space:nowrap">Pre-Closing</span> Financing has been consummated by its terms. In the event that all conditions in the Subscription Agreements have been satisfied, the Company shall use its reasonable best efforts to take, or to cause to be taken, all actions required, necessary or that it otherwise deems to be proper or advisable to consummate the transactions contemplated by the Subscription Agreements on the terms described therein, including using its reasonable best efforts to enforce its rights under the Subscription Agreements to cause such investors to pay to (or as directed by) the Company the applicable purchase price under each such investor&#8217;s applicable Subscription Agreement in accordance with its terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_96">6.20 <span style="text-decoration:underline">Termination of Certain Agreements</span>. Promptly following the date hereof, Parent will take all action necessary to terminate each of those agreements listed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.20</span> of the Parent Disclosure Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_97">Section&#160;7. <span style="text-decoration:underline">Conditions Precedent to Obligations of Each Party</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_98">7.1 <span style="text-decoration:underline">Regulatory Approvals</span>. Any applicable waiting periods (or any extensions thereof) under the HSR Act and any applicable foreign Law relating to antitrust or competition matters shall have expired or otherwise been terminated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_99">7.2 <span style="text-decoration:underline">No Restraints</span>. No Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_100">7.3 <span style="text-decoration:underline">Stockholder Approval</span>. (a)&#160;Parent shall have obtained the Required Parent Shareholder Vote (but solely with respect to such items as are necessary to consummate the transactions contemplated by this Agreement) and (b)&#160;the Company shall have obtained the Required Company Stockholder Vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_101">7.4 <span style="text-decoration:underline">Listing</span>. The Nasdaq Listing Application shall have been approved by Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_102">7.5 <span style="text-decoration:underline">Effectiveness of Registration Statement</span>. The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or Legal Proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_103">Section&#160;8. <span style="text-decoration:underline">Additional Conditions Precedent to Obligations of Parent and Merger Subs</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_104">8.1 <span style="text-decoration:underline">Accuracy of Representations</span>. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are de minimis, individually or in the aggregate, (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_105">8.2 <span style="text-decoration:underline">Performance of Covenants</span>. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_106">8.3 <span style="text-decoration:underline">Documents</span>. Parent shall have received the following documents, each of which shall be in full force and effect: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i)&#160;that the conditions set forth in <span style="text-decoration:underline">Sections&#160;8.1</span>, <span style="text-decoration:underline">8.2</span>, <span style="text-decoration:underline">8.4</span> and <span style="text-decoration:underline">8.5</span> have been duly satisfied and (ii)&#160;that the information (other than emails and addresses) set forth in the Allocation Certificate delivered by the company in accordance with <span style="text-decoration:underline">Section&#160;6.15</span> is true and accurate in all respects as of the Closing Date; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) a certificate pursuant to Treasury Regulations Sections <span style="white-space:nowrap">1.1445-2(c)</span> and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&#160;1.897-2(h), in each case, in form and substance reasonably acceptable to Parent; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the Company Valuation Schedule; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) the Allocation Certificate; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) the <span style="white-space:nowrap">Lock-Up</span> Agreements, duly executed by the Persons listed on Section B of the Company Disclosure Letter, which shall be in full force and effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_107">8.4 <span style="text-decoration:underline">No Company Material Adverse Effect</span>. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_108">8.5 <span style="text-decoration:underline">Company Stockholder Written Consent</span>. The Company Stockholder Written Consent executed by the stockholders of the Company collectively constituting the Required Company Stockholder Vote shall have been obtained and remain in full force and effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_109">8.6 <span style="text-decoration:underline">Company <span style="white-space:nowrap">Pre-Closing</span> Financing</span>. The Subscription Agreement shall be in full force and effect and proceeds of not less than the Minimum Concurrent Investment Amount shall have been received by the Company or will be received by the Company substantially concurrently with the Closing in connection with the consummation of the transactions contemplated by the Subscription Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_110">Section&#160;9. <span style="text-decoration:underline">Additional Conditions Precedent to Obligation of the Company</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_111">9.1 <span style="text-decoration:underline">Accuracy of Representations</span>. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are de minimis, individually or in the aggregate, (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b)&#160;for those </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_112">9.2 <span style="text-decoration:underline">Performance of Covenants</span>. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_113">9.3 <span style="text-decoration:underline">Documents</span>. The Company shall have received the following documents, each of which shall be in full force and effect: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) a certificate executed by an executive officer of Parent certifying that the conditions set forth in <span style="text-decoration:underline">Sections</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9.1</span><span style="text-decoration:underline">, </span><span style="text-decoration:underline">9.2</span> and <span style="text-decoration:underline">9.4</span> have been duly satisfied; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) written resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.12</span> hereof; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the Parent Net Cash Schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_114">9.4 <span style="text-decoration:underline">No Parent Material Adverse Effect</span>. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_115">9.5 <span style="text-decoration:underline">Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend</span>. If Parent declares the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend, then the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend Amount shall have been deposited by Parent with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent <span style="white-space:nowrap">Pre-Closing</span> Dividend. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_116">9.6 <span style="text-decoration:underline">Parent Articles of Amendment</span>. The Parent Articles of Amendment shall have been duly filed with the Secretary of the Commonwealth of Massachusetts, containing at least such amendments as are necessary to consummate the transactions contemplated by this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_117">9.7 <span style="text-decoration:underline">Termination of Agreements</span>. Parent shall have terminated each of those agreements listed on <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.20</span> of the Parent Disclosure Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_118">Section&#160;10. <span style="text-decoration:underline">Termination</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_119">10.1 <span style="text-decoration:underline">Termination</span>. This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Shareholder Matters by Parent&#8217;s shareholders, unless otherwise specified below): </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Parent and the Company<span style="text-decoration:underline">;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) by either Parent or the Company if the Merger shall not have been consummated by October&#160;1, 2026 (subject to possible extension as provided in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.1(b)</span>, the &#8220;<span style="font-weight:bold">End Date</span>&#8221;); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the right to terminate this Agreement under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10.1(b)</span> shall not be available to the Company or Parent if such Party&#8217;s (or in the case of Parent, Merger Subs&#8217;) action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement; provided further, however, that, in the event that (i)<span style="text-decoration:underline"></span>&#160;the SEC has not declared effective under the Securities Act the Registration Statement or (ii)<span style="text-decoration:underline"></span>&#160;the waiting periods (and extensions thereof) applicable to the Merger under the HSR Act have not expired or otherwise been terminated by the date which is ninety (90)<span style="text-decoration:underline"></span>&#160;days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date for an additional ninety (90)<span style="text-decoration:underline"></span>&#160;days by notice to the other Party;<span style="text-decoration:underline"> </span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) by either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2)&#160;Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that if the Registration Statement becomes effective during or immediately prior to the beginning of Company Stockholder Consent Review Period, the two (2)&#160;Business Day period set forth herein shall be tolled until the end of the Company Stockholder Consent Review Period; <span style="text-decoration:underline">provided further</span>, <span style="text-decoration:underline">however</span>, that once the Required Company Stockholder Vote has been obtained (whether timely or not), Parent may not terminate this Agreement pursuant to this <span style="text-decoration:underline">Section&#160;10.1(d)</span>; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) by either Parent or the Company if (i)&#160;the Parent Shareholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s shareholders shall have taken a final vote on the Parent Shareholder Matters and (ii)&#160;the Parent Shareholder Matters shall not have been approved at the Parent Shareholder Meeting (or at any adjournment or postponement thereof) by the Required Parent Shareholder Vote; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the right to terminate this Agreement under this <span style="text-decoration:underline">Section&#160;10.1(e)</span> shall not be available to Parent where the failure to obtain the Required Parent Shareholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) by the Company (at any time prior to the approval of the Parent Shareholder Matters by the Required Parent Shareholder Vote) if a Parent Triggering Event shall have occurred; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) by Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote) if a Company Triggering Event shall have occurred; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) by the Company, if a Delisting Event occurs; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section&#160;9.1</span> or <span style="text-decoration:underline">Section&#160;9.2</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; <span style="text-decoration:underline">provided</span> that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">further</span>, that if such inaccuracy in Parent&#8217;s or Merger Subs&#8217; representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section&#160;10.1(i)</span> as a result of such particular breach or inaccuracy until the earlier of (A)&#160;the expiration of a thirty (30)&#160;day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration:underline">Section&#160;10.1(i)</span> and (B)&#160;Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration:underline">Section&#160;10.1(i)</span> (it being understood that the Company shall not be permitted to terminate this Agreement pursuant to this Section&#160;10.1(i) as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration:underline">Section&#160;8.1</span> or <span style="text-decoration:underline">Section&#160;8.2</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; <span style="text-decoration:underline">provided</span> that Parent is not then in material breach of any representation, warranty, covenant or agreement under </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this Agreement; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">further</span>, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section&#160;10.1(j)</span> as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a thirty (30)&#160;day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration:underline">Section&#160;10.1(j) </span>and (ii)&#160;the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration:underline">Section&#160;10.1(j)</span> (it being understood that Parent shall not be permitted to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section&#160;10.1(j)</span> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) by Parent (at any time prior to the approval of the Parent Shareholder Matters by the Required Parent Shareholder Vote) and following compliance with all of the requirements set forth in the proviso to this <span style="text-decoration:underline">Section&#160;10.1(k)</span>, upon the Parent Board authorizing Parent to enter into a Permitted Alternative Agreement; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that Parent shall not enter into any Permitted Alternative Agreement unless: (i)&#160;Parent shall have complied in all material respects with its obligations under <span style="text-decoration:underline">Section&#160;5.4</span> and <span style="text-decoration:underline">Section&#160;6.3</span>, (ii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law and (iii)&#160;Parent shall concurrently pay to the Company the Company Termination Fee in accordance with <span style="text-decoration:underline">Section&#160;10.3(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Party desiring to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section&#160;10.1</span> (other than pursuant to <span style="text-decoration:underline">Section&#160;10.1(a)</span> shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_120">10.2 <span style="text-decoration:underline">Effect of Termination</span>. In the event of the termination of this Agreement as provided in <span style="text-decoration:underline">Section&#160;10.1</span>, this Agreement shall be of no further force or effect; provided, however, that (a)&#160;this <span style="text-decoration:underline">Section&#160;10.2</span>, <span style="text-decoration:underline">Section&#160;10.3</span> and <span style="text-decoration:underline">Section&#160;11</span> (other than <span style="text-decoration:underline">Section&#160;11.8</span>) and the related definitions of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b)&#160;the termination of this Agreement and the provisions of <span style="text-decoration:underline">Section&#160;10.3</span> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_121">10.3 Expenses; Termination Fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth in this <span style="text-decoration:underline">Section&#160;10.3</span> and <span style="text-decoration:underline">Section&#160;6.9</span>, all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated; it being clarified that the Company and Parent shall each pay 50% of (i)&#160;the fees paid in connection with filing the Registration Statement and any amendments and supplements thereto, and (ii)&#160;the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If (i)&#160;this Agreement is terminated by Parent or the Company pursuant to <span style="text-decoration:underline">Section&#160;10.1(e)</span> or by the Company pursuant to <span style="text-decoration:underline">Section&#160;10.1(f)</span>, (ii) at any time after the date of this Agreement and prior to the Parent Shareholder Meeting, a bona fide third party Acquisition Proposal for a change of control transaction with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been publicly withdrawn) and (iii)&#160;within twelve (12)&#160;months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction (excluding in each case any transactions occurring in connection with the liquidation, dissolution and winding up of Parent), then Parent shall pay to the Company, within ten (10)&#160;Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $235,000 (the &#8220;<span style="font-weight:bold">Company Termination Fee</span>&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If (i)&#160;this Agreement is terminated by Parent pursuant to <span style="text-decoration:underline">Section&#160;10.1(d)</span> or to <span style="text-decoration:underline">Section&#160;10.1(g)</span>, (ii) at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, an Acquisition Proposal with respect to the Company shall have been publicly announced, disclosed or otherwise communicated to the Company Board (and shall not have been publicly withdrawn) and (iii)&#160;within twelve (12)&#160;months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10)&#160;Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction, a nonrefundable fee in an amount equal to $10,736,000 (the &#8220;<span style="font-weight:bold">Parent Termination Fee</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) If either Party fails to pay when due any amount payable by it under this Section&#160;10.3, then (i)&#160;such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this <span style="text-decoration:underline">Section&#160;10.3</span> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Parties agree that, subject to <span style="text-decoration:underline">Section&#160;10.2</span>, the payment of the fees and expenses set forth in this <span style="text-decoration:underline">Section&#160;10.3</span> shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this <span style="text-decoration:underline">Section&#160;10.3</span>, it being understood that in no event shall either Parent or the Company be required to pay the individual fees or damages payable pursuant to this <span style="text-decoration:underline">Section&#160;10.3</span> on more than one occasion. Subject to <span style="text-decoration:underline">Section&#160;10.2</span>, following the payment of the fees and expenses set forth in this <span style="text-decoration:underline">Section&#160;10.3</span> by a Party, (i)&#160;such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii)&#160;no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii)&#160;all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x)&#160;the agreements contained in this <span style="text-decoration:underline">Section&#160;10.3</span> are an integral part of the Contemplated Transactions, (y)&#160;without these agreements, the Parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this <span style="text-decoration:underline">Section&#160;10.3</span> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that nothing in this <span style="text-decoration:underline">Section&#160;10.3(e)</span> shall limit the rights of the Parties under <span style="text-decoration:underline">Section&#160;11.10</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" id="anxa111069_122">Section&#160;11. <span style="text-decoration:underline">Miscellaneous Provisions</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_123">11.1 <span style="text-decoration:underline"><span style="white-space:nowrap">Non-Survival</span> of Representations and Warranties</span>. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First Effective Time and this <span style="text-decoration:underline">Section&#160;11</span> shall survive the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_124">11.2 <span style="text-decoration:underline">Amendment</span>. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s stockholders or before or after obtaining the Required Parent Shareholder </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Vote); provided, however, that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Subs and Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_125">11.3 <span style="text-decoration:underline">Waiver</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_126">11.4 <span style="text-decoration:underline">Entire </span><span style="text-decoration:underline">Agreement</span><span style="text-decoration:underline">; Counterparts; Exchanges by Electronic Transmission</span>. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; provided, further, that only Exhibit <span style="white-space:nowrap">D-1</span> (including Exhibit A to such Exhibit) and Exhibit <span style="white-space:nowrap">D-2</span> are incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_127">11.5 <span style="text-decoration:underline">Applicable Law; Jurisdiction</span><span style="text-decoration:underline">; WAIVER OF RIGHT TO TRIAL BY JURY</span>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws, except to the extent the provisions of the Laws of the Commonwealth of Massachusetts are mandatorily applicable to the fiduciary duties of the board of directors or officers of Parent; <span style="text-decoration:underline">provided</span>, that the provisions of this Agreement related to the filing of the Parent Articles of Amendment with the office of the Secretary of the Commonwealth of Massachusetts which by their nature are governed by the Laws of the Commonwealth of Massachusetts shall be governed and construed in accordance with the Laws of the Commonwealth of Massachusetts. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;11.5</span>, (c) waives any objection to laying venue in any such action or proceeding in such courts, (d)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;11.7</span> of this Agreement and (f)&#160;irrevocably and unconditionally waives the right to trial by jury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_128">11.6 <span style="text-decoration:underline">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; provided, however, that </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_129">11.7 <span style="text-decoration:underline">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one&#160;(1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c)&#160;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Parent or Merger Subs: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Cyclerion Therapeutics, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">245 First Street, 18th Floor </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142 </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attention: Regina Graul, Ph.D. </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Email: *** </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Ropes&#160;&amp; Gray LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Prudential Tower, 800 Boylston Street </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Boston, MA 02199 </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attention: Zachary R. Blume; William J. Michener </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Email: *** </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to the Company: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Korsana Biosciences, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">221 Crescent Street Building 23, Suite 105 </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attention: Maddy Zeylikman </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Email: *** </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&#160;&amp; Crutcher LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">One Embarcadero Center, Suite 2600 </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94111 </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attention: Ryan Murr, Branden Berns, Evan Shepherd </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Email: *** </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_130">11.8 <span style="text-decoration:underline">Cooperation</span>. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_131">11.9 <span style="text-decoration:underline">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_132">11.10 <span style="text-decoration:underline">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" id="anxa111069_133">11.11 <span style="text-decoration:underline">No Third-Party Beneficiaries</span>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.7</span>) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Remainder of page intentionally left blank] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">I<small style="font-weight:inherit;font-style:unset;text-decoration:unset">N</small> W<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ITNESS</small> W<small style="font-weight:inherit;font-style:unset;text-decoration:unset">HEREOF</small>,</span> the Parties have caused this Agreement to be executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CYCLERION THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer and President</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CARIBOOS MERGER SUB CORP.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CARIBOOS MERGER SUB II, LLC</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer and President</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Agreement and Plan of Merger and Reorganization]</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">I<small style="font-weight:inherit;font-style:unset;text-decoration:unset">N</small> W<small style="font-weight:inherit;font-style:unset;text-decoration:unset">ITNESS</small> W<small style="font-weight:inherit;font-style:unset;text-decoration:unset">HEREOF</small>,</span> the Parties have caused this Agreement to be executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">KORSANA BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Jonathan Violin</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jonathan Violin</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Agreement and Plan of Merger and Reorganization]</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit <span style="white-space:nowrap">A-1</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Parent Shareholder Support Agreement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit <span style="white-space:nowrap">A-2</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Company Stockholder Support Agreement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit B </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of <span style="white-space:nowrap">Lock-Up</span> Agreement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit C </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Subscription Agreement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit D-1 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of First Certificate of Merger </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit <span style="white-space:nowrap">D-2</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Second Certificate of Merger </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit E </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of Parent Articles of Amendment Schedule </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit F </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of CVR Agreement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">Exhibit G </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Confidential</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Execution Version</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">THIS AMENDMENT TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </span>(this &#8220;<span style="font-weight:bold">Amendment</span>&#8221;) is entered into as of April&#160;17, 2026, by and among Cyclerion Therapeutics, Inc., a Massachusetts corporation (&#8220;<span style="font-weight:bold">Parent</span>&#8221;), Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;<span style="font-weight:bold">First Merger Sub</span>&#8221;), Cariboos Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (&#8220;<span style="font-weight:bold">Second Merger Sub</span>&#8221; and, together with First Merger Sub, &#8220;<span style="font-weight:bold">Merger Subs</span>&#8221; and each, a &#8220;<span style="font-weight:bold">Merger Sub</span>&#8221;), and Korsana Biosciences, Inc., a Delaware corporation (the&#160;&#8220;<span style="font-weight:bold">Company</span>&#8221;), and this Amendment amends that certain Agreement and Plan of Merger and Reorganization, entered into as of April&#160;1, 2026, by and among the Parent, Merger Subs and the Company (the &#8220;<span style="font-weight:bold">Merger Agreement</span>&#8221;). Capitalized terms used in this Amendment but not defined herein shall have the meanings given such terms in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;11.2</span> of the Merger Agreement, the parties hereto wish to amend the Merger Agreement as specified herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, Parent, Merger Subs and the Company agree as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">1.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Amendment to Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.4</span>. <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.4</span> of the Merger Agreement is deleted and replaced in its entirety with the following: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;4.4 <span style="text-decoration:underline">Vote Required</span>. Assuming the accuracy of the representations set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.24</span>, (a) the affirmative vote of a majority of the shares of Parent Common Stock properly cast is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve the issuance of Parent Common Stock that represent (or are convertible into) more than twenty percent (20%) of the shares of Parent Common Stock outstanding immediately prior to the First Effective Time to the Company stockholders in connection with the Contemplated Transactions and the change of control of Parent resulting from the Contemplated Transactions, in each case pursuant to the Nasdaq rules, (b)&#160;the affirmative vote of a majority of all shares of Parent Common Stock entitled to vote is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve clauses (ii), (iii) and (v)&#160;of the definition of &#8220;Parent Articles of Amendment,&#8221; and (c)&#160;the affirmative vote of <span style="white-space:nowrap">two-thirds</span> of all shares of Parent Common Stock entitled to vote is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve clause (iv)&#160;of the definition of &#8220;Parent Articles of Amendment&#8221; (collectively, the &#8220;<span style="font-weight:bold">Required Parent Shareholder Vote</span>&#8221;).&#8221; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">2.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Acknowledgment</span>. The parties hereby acknowledge and agree that (i)&#160;the approval contemplated by clause (iv)&#160;of the definition of &#8220;Parent Articles of Amendment&#8221; is not necessary to consummate the transactions contemplated by the Merger Agreement, as such phrase is used in Section&#160;7.3 thereof and (ii)&#160;Parent&#8217;s failure to obtain the approval contemplated by clause (iv)&#160;of the definition of &#8220;Parent Articles of Amendment,&#8221; in and of itself, shall not give rise to the Company&#8217;s ability to terminate the Merger Agreement pursuant to Section&#160;10.1(e) of the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">3.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Other Terms.</span> All of the provisions of this Amendment shall be effective as of the date hereof. Except as specifically provided for in this Amendment, all of the terms of the Merger Agreement shall remain unchanged and are hereby confirmed and remain in full force and effect, and the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;11</span> of the Merger Agreement are incorporated herein by reference and shall apply to the terms and provisions of this Amendment and the parties hereto, <span style="font-style:italic">mutatis mutandis</span>. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">4.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Effect of Amendment</span>. Whenever the Merger Agreement is referred to in the Merger Agreement or in any other agreements, documents or instruments, such reference shall be deemed to be to the Merger Agreement as amended by this Amendment. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">5.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Counterparts</span>. This Amendment may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Amendment (in counterparts or otherwise) by all parties hereto by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Amendment. </p></td></tr></table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">[</span><span style="font-weight:bold"><span style="font-style:italic">Remainder of page intentionally left blank</span></span><span style="font-weight:bold">] </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Parent, Merger Subs and the Company have caused this Amendment to be executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CYCLERION THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Regina Graul</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name: Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title: Chief Executive Officer and President</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CARIBOOS MERGER SUB CORP.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Regina Graul</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name: Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title: President</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CARIBOOS MERGER SUB II, LLC</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Regina Graul</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name: Regina Graul</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title: Chief Executive Officer and President</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">KORSANA BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Violin</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name: Jonathan Violin</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title: Chief Executive Officer</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[Signature Page to Amendment No. 1]</span> </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_47">Annex B </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OPINION OF GEMINI VALUATION SERVICES </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Annex B </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OPINION OF GEMINI VALUATION SERVICES </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:62%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:37%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:right"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">1100 Glendon Ave, 905</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Los Angeles, CA 90024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:right"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">T: <span style="white-space:nowrap"><span style="white-space:nowrap">310-696-4001</span></span></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">F: <span style="white-space:nowrap"><span style="white-space:nowrap">310-696-4007</span></span></p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Strictly Confidential </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&#160;31, 2026 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion Therapeutics, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">245 First Street, 18th Floor </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02142 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have requested the opinion (the &#8220;Opinion&#8221;) of Gemini Valuation Services, LLC (&#8220;GVS&#8221; and, for the avoidance of doubt, all references to pronouns such as &#8220;we&#8221; and &#8220;our&#8221;) as to the fairness from a financial point of view, of the Exchange Ratio (as defined in the Agreement and Plan of Merger and Reorganization (the &#8220;Agreement&#8221;) to be entered into by Cyclerion Therapeutics Inc. (the &#8220;Parent&#8221;), Cariboos Merger Sub Corp. (&#8220;First Merger Sub&#8221;), Cariboos Merger Sub II, LLC (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Sub&#8221;) and Korsana Biosciences, Inc. (&#8220;Korsana&#8221; or the &#8220;Company&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the terms and subject to the conditions of the Agreement, among other things, (i)&#160;the Company will merge with and into First Merger Sub, with the Company as the surviving entity (the &#8220;First Merger&#8221;) and (ii)&#160;immediately following the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). Pursuant to the terms and subject to the conditions set forth in the Agreement, (a)&#160;each outstanding share of Company common stock and Company preferred stock designated as &#8220;Series A Preferred Stock&#8221; will be converted into the right to receive a number of shares of Parent common stock equal to the Exchange Ratio; provided, that in the event the aggregate number of shares of Cyclerion common stock issuable to holders of Company capital stock would result in the issuance of shares of Parent common stock to a holder in excess of a specified percentage of total outstanding shares of Parent common stock, then the Parent will issue to any such holder (x)&#160;shares of Parent common stock up to such holder&#8217;s specified percentage and (y)&#160;in lieu of any shares in excess of such holder&#8217;s specified percentage, <span style="white-space:nowrap">pre-funded</span> warrants (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;), to purchase a number of shares of Cyclerion common stock upon exercise of such <span style="white-space:nowrap">Pre-Funded</span> Warrants equal to such excess shares, (b)&#160;each outstanding share of Company preferred stock designated as &#8220;Series Seed Preferred Stock&#8221; will be converted into the right to receive a number of shares of Parent Convertible Preferred Stock (as defined in the Agreement) equal to (x)&#160;the Exchange Ratio divided by (y) 1,000, (c) each outstanding option to purchase shares of Company capital stock will be assumed by the Parent, subject to adjustment as set forth in the Agreement, (d)&#160;each outstanding restricted stock unit award for shares of Company capital stock will be assumed by the Parent, subject to adjustment as set forth in the Agreement and (e)&#160;each outstanding warrant to purchase shares of Company capital stock will be assumed by the Parent, subject to adjustment as set forth in the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Opinion does not address the Parent&#8217;s underlying business decision to effect the Merger or the relative merits of the Merger as compared to any alternative business strategies or transactions that might be available to the Parent and does not constitute a recommendation to any shareholder of the Parent as to how such shareholder should vote with respect to the Merger or any other matter. At your direction, we have not been asked to, nor do we, offer any opinion as to (i)&#160;the material terms of the Agreement or the form of the Merger or any other contractual arrangement that the parties may enter into in connection with the Merger or (ii)&#160;the fairness of the Merger to, or any consideration that may be received in connection therewith by, the individual shareholders, nor do we offer any Opinion as to the relative fairness of the consideration and the consideration to be received by different shareholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed, with your consent, that the representations and warranties of all parties to the Agreement are true and correct, that each party to the Agreement and Plan of Merger will perform all of the covenants and agreements required to be performed by such party, that all conditions to the consummation of the Merger will be satisfied without waiver thereof, and that the Merger will be consummated in a timely manner in accordance with the terms described in the Agreement, without any modifications or amendments thereto or any adjustment to the Exchange Ratio. In rendering this Opinion, we have also assumed, with your consent, that the final executed form of the Agreement does not differ in any material respect from the draft that we have examined along with the discussion on the draft. We have not been authorized to and have not solicited indications of interest in a possible transaction with the Parent from any party. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In arriving at our Opinion, we have, among other things: (i)&#160;reviewed the financial statements of the Company; (ii)&#160;reviewed certain internal information relating to the business, assets, liabilities, business plan and prospects of the Company furnished to us by the Parent; (iii)&#160;conducted discussions with members of senior management and representatives of the Parent concerning the matters described in clauses (i)&#160;and (ii) of this paragraph, as well as the business and prospects of the Company generally; (iv)&#160;reviewed publicly available financial and stock market data, including valuation levels, for certain other companies in lines of business of the Company that we deemed relevant; (v)&#160;reviewed a preliminary draft of the Agreement, dated March&#160;28, 2026; and (vi)&#160;conducted such other financial studies and analyses and took into account such other information as we deemed appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our review, we have not assumed any responsibility for independent verification of any of the financial, legal, regulatory, tax accounting and other information supplied to, discussed with, or reviewed by us for the purpose of this Opinion and have, with your consent, relied on such information being complete and accurate in all material respects. In addition, at your direction we have not made any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, <span style="white-space:nowrap">off-balance-sheet,</span> or otherwise) of the Parent or Korsana, nor have we been furnished with any such evaluation or appraisal. You have directed us to use the assumptions provided by management of Korsana and the Parent for the purposes of our analysis and this Opinion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Opinion is necessarily based on economic, monetary, market and other conditions as in effect on, and the information made available to us as of, the date hereof. In addition, you have not asked us to address, and this Opinion does not address, the fairness to, or any other consideration of, any class of creditors or other constituencies of the Parent, other than the shareholders of the Parent. We also do not express any Opinion as to the fairness of the amount or nature of any compensation to be received by any of the Parent&#8217;s officers, directors or employees, or any class of such persons, relative to the consideration or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Opinion is for the use and benefit of the Board of Directors of the Parent in the evaluation of the Merger. Based upon and subject to the foregoing, it is our opinion that, as the date hereof, the Exchange Ratio is fair from a financial point of view to the Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Very truly yours, </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:100%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">GEMINI VALUATION SERVICES</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">/s/ Nathan Johnson</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By: Nathan Johnson</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Its: Managing Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="padding-bottom:2pt ;vertical-align:top">Date: 03/31/2026</td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">B-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_48"><span id="ii111069_401"></span>Annex C </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM CYCLERION SUPPORT AGREEMENT </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Annex C </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">CONFIDENTIAL </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Final Form </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PARENT SUPPORT AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Support Agreement (this &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;) is made and entered into as of April&#160;1, 2026, by and among Korsana Biosciences, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;), Cyclerion Therapeutics, Inc., a Massachusetts corporation (&#8220;<span style="text-decoration:underline">Parent</span>&#8221;), and the undersigned shareholder of Parent (the &#8220;<span style="text-decoration:underline">Shareholder</span>&#8221; and each of the Shareholder, Company, and Parent a &#8220;<span style="text-decoration:underline">Party</span>&#8221; and, collectively, the &#8220;<span style="text-decoration:underline">Parties</span>&#8221;). Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">RECITALS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;<span style="text-decoration:underline">First </span><span style="text-decoration:underline">Merger Sub</span>&#8221;) and Cariboos Merger Sub II, LLC a Delaware limited liability company (the &#8220;<span style="text-decoration:underline">Second Merger Sub</span>&#8221;), have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), pursuant to which (i)&#160;the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii)&#160;the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, the Shareholder is the beneficial owner (as defined in Rule <span style="white-space:nowrap">13d-3</span> under the Exchange Act) of such number of shares of Parent Capital Stock as indicated in <span style="text-decoration:underline">Appendix A</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a condition and inducement to the willingness of the Company to enter into the Merger Agreement, Parent has required that Shareholder enter into this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, intending to be legally bound, the Parties hereby agree as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline">Certain Definitions</span>. For all purposes of this Agreement, the following terms shall have the following respective meanings: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<span style="text-decoration:underline">Constructive Sale</span>&#8221; means, with respect to any security, (i)&#160;a short sale with respect to such security, (ii)&#160;entering into or acquiring a derivative contract with respect to such security, (iii)&#160;entering into or acquiring a futures or forward contract to deliver such security or (iv)&#160;entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly changing the economic benefits or risks of ownership of such security. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#8220;<span style="text-decoration:underline">Shares</span>&#8221; means (i)&#160;all shares of Parent Capital Stock and any other equity securities of Parent beneficially owned by the Shareholder as of the date hereof, including such securities indicated in <span style="text-decoration:underline">Appendix A</span>, (ii)&#160;all additional shares of Parent Capital Stock acquired, whether beneficially owned or of record, by the Stockholder during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date, and (iii)&#160;any shares of capital stock or other equity securities of Parent that such Shareholder acquires or with respect to which such Shareholder otherwise acquires sole or shared voting power (including any proxy), whether beneficial or of record, or otherwise owned by such Shareholder after the execution and delivery of this Agreement and expiring on the Expiration Date, whether by exercise of any Parent Options or otherwise, including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#8220;<span style="text-decoration:underline">Transfer</span>&#8221; or &#8220;<span style="text-decoration:underline">Transferred</span>&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of an Encumbrance, lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Transfer and Voting Restrictions</span>. The Shareholder covenants to Parent and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise permitted by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2(d)</span>, during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Shareholder shall not Transfer any of the Shareholder&#8217;s Shares, publicly announce its intention to Transfer any of its Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Shareholder will not commit any act that would restrict the Shareholder&#8217;s legal power, authority and right to vote all of the Shares held by the Shareholder or otherwise prevent or disable the Shareholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, and as otherwise permitted by this Agreement, the Shareholder shall not enter into any voting agreement with any person or entity with respect to any of the Shareholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case which has the effect of limiting or affecting the Shareholder&#8217;s legal power, authority or right to vote the Shareholder&#8217;s Shares in favor of the Parent Shareholder Matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Entity, the Stockholder will not enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect Transfer of any right, title or interest (including any right or power to vote to which the holder thereof may be entitled whether such right or power is granted by proxy or otherwise) to any Shares or take any action that would reasonably be expected to make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of restricting the Stockholder&#8217;s legal power, authority and right to vote all of the Shares or would otherwise prevent or disable such Stockholder from performing any of such Stockholder&#8217;s obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything else herein to the contrary, the Shareholder may, at any time, Transfer Shares (i)&#160;by will or other testamentary document or by intestacy to the legal representative, heir, beneficiary or a member of the immediate family of the Shareholder or, if the Shareholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Shareholder, (ii)&#160;to such Shareholder&#8217;s Affiliates (in each case, directly or indirectly), (iii) to any trust or other entity for the direct or indirect benefit of the Shareholder or the immediate family of the Shareholder (or, if the Shareholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Shareholder) or otherwise for estate tax or estate planning purposes, (iv)&#160;in the case of a Shareholder who is not a natural person, by pro rata distributions from the Shareholder to its members, partners, or shareholders pursuant to the Shareholder&#8217;s organizational documents, (v)&#160;pursuant to applicable Law or by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement and (vi)&#160;pursuant to the exercise of any option to purchase any Parent Capital Stock, including in order to pay the exercise price of such option or otherwise satisfy taxes applicable thereto; <span style="text-decoration:underline">provided</span>, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y)&#160;the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto. Any action taken in violation of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2(a)</span> through <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2(d)</span> shall be null and void ab initio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Shareholder to exercise any option or any other right to acquire any shares of Parent Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Agreement to Vote Shares</span>. The Shareholder covenants to Parent and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Until the Expiration Date, at every meeting of the Shareholders of Parent called to vote upon the Parent Shareholder Matters, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the shareholders of Parent, the Shareholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Shareholder (A)&#160;in favor of the Parent Shareholder Matters, and (B)&#160;against any Acquisition Proposal.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Shareholder is the beneficial owner, but not the record holder, of Shares, the Shareholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Shareholder&#8217;s Shares in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any <span style="white-space:nowrap">split-up,</span> reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">Action in Shareholder Capacity Only</span>. The Shareholder is entering into this Agreement solely in the Shareholder&#8217;s capacity as a record holder and beneficial owner, as applicable, of its Shares and not in the Shareholder&#8217;s capacity as a director or officer of Parent. Nothing herein shall limit or affect the Shareholder&#8217;s ability to exercise the Shareholder&#8217;s fiduciary duties as an officer or director of Parent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">Irrevocable Proxy</span>. The Shareholder hereby revokes (or agrees to cause to be revoked) any proxies that the Shareholder has heretofore granted with respect to its Shares. In the event and to the extent that the Shareholder fails to vote the Shares in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> at any applicable meeting of the shareholders of Parent or pursuant to any applicable written consent of the shareholders of Parent, the Shareholder shall be deemed to have irrevocably granted to, and appointed, the Company as his, her or its proxy and <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> (with full power of substitution), for and in its name, place and stead, to (a)&#160;attend any all meetings of the Parent shareholders with respect to any of the matters specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> and (b)&#160;vote, express consent, dissent or grant, withhold or issue instructions to the record holder to vote his, her or its Shares in any action by written consent of Parent shareholders or at any meeting of Parent shareholders called with respect to any of the matters specified in, and in accordance and consistent with, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein (including the next sentence), the Shareholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable (and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of the Shareholder, as applicable) and shall not be terminated by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9</span>. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date. The Shareholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to file this proxy and any substitution or revocation with the Secretary of Parent. The Shareholder hereby affirms that the proxy set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5</span> is given in connection with and granted in consideration of and as an inducement to the Company to enter into </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Merger Agreement and that such proxy is given to secure the obligations of the Shareholder under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span>. With respect to any Shares that are owned beneficially by the Shareholder but are not held of record by the Shareholder (other than shares beneficially owned by the Shareholder that are held in the name of a bank, broker or nominee), the Shareholder shall take all action necessary to cause the record holder of such Shares to grant the irrevocable proxy and take all other actions provided for in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5</span> with respect to such Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">No Solicitation</span>. The Shareholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that Parent is prohibited from taking pursuant to Section&#160;5.4 of the Merger Agreement and Section&#160;5.4 of the Merger Agreement is hereby incorporated by reference <span style="font-style:italic">mutatis mutandis</span>. The Stockholder hereby represents and warrants that the Stockholder has read Section&#160;5.4 of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <span style="text-decoration:underline">Documentation and Information</span>. The Shareholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Shareholder&#8217;s identity and ownership of the Shares and the nature of the Shareholder&#8217;s commitments and obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <span style="text-decoration:underline">Representations and Warranties of the Shareholder</span>. The Shareholder hereby represents and warrants to Parent and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) The Shareholder is the beneficial or record owner of the shares of Parent Capital Stock indicated in <span style="text-decoration:underline">Appendix A</span> (each of which shall be deemed to be &#8220;held&#8221; by the Shareholder for purposes of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> unless otherwise expressly stated with respect to any shares in <span style="text-decoration:underline">Appendix A</span>), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement and Encumbrances arising under applicable securities or community property laws); and (ii)&#160;the Shareholder does not beneficially own any securities of Parent other than the shares of Parent Capital Stock and rights to purchase shares of Parent Capital Stock set forth in <span style="text-decoration:underline">Appendix A</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise provided in this Agreement, the Shareholder has full power and authority to (i)&#160;make, enter into and carry out the terms of this Agreement and (ii)&#160;vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Shareholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Shareholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shareholder&#8217;s Shares, deposited any of the Shareholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Shareholder&#8217;s legal power, authority or right to vote the Shareholder&#8217;s Shares on any matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Agreement has been duly and validly executed and delivered by the Shareholder and (assuming the due authorization, execution and delivery by the other Parties) constitutes a valid and binding agreement of the Shareholder enforceable against the Shareholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Shareholder and the performance by the Shareholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or, if applicable, any provision of an organizational document (including a certificate of incorporation) to or by which the Shareholder is a party or bound, or any applicable law to which the Shareholder (or any of the Shareholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Shareholder&#8217;s ability to perform its obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The execution, delivery and performance of this Agreement by the Shareholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Shareholder&#8217;s ability to perform its obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Shareholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Shareholder&#8217;s own choosing. The Shareholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Shareholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Shareholder understands that such Shareholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Shareholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Shareholder understands and acknowledges that the Company, Parent and the Merger Subs are entering into the Merger Agreement in reliance upon the Shareholder&#8217;s execution, delivery and performance of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) With respect to the Shareholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Shareholder, threatened against, the Shareholder or any of the Shareholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Shareholder to perform its obligations hereunder or to consummate the transactions contemplated hereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <span style="text-decoration:underline">Termination</span>. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a)&#160;such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof, (b)&#160;the First Effective Time, (c)&#160;the amendment of the Merger Agreement, without the prior written consent of the Shareholder, in a manner that affects the economics or material terms of the Merger Agreement in a manner that is adverse to the Shareholder and (d)&#160;the time this Agreement is terminated upon the written agreement of the Shareholder, the Company and Parent (the &#8220;<span style="text-decoration:underline">Expiration Date</span>&#8221;); <span style="text-decoration:underline">provided</span><span style="font-style:italic">, </span><span style="text-decoration:underline">however</span><span style="font-style:italic">,</span> that (i)<span style="text-decoration:underline">&#160;Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10</span> shall survive the termination of this Agreement, and (ii)&#160;the termination of this Agreement shall not relieve any Party from any liability for any material and willful breach of this Agreement prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <span style="text-decoration:underline">Miscellaneous Provisions</span>.<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Amendments</span>. No amendment of this Agreement shall be effective against any Party unless it shall be in writing and signed by each of the Parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span>. This Agreement constitutes the entire agreement between the Parties and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the Parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Applicable Law; Jurisdiction.</span> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws, except to the extent the provisions of the laws of the Commonwealth of Massachusetts are mandatorily applicable to the Merger or the fiduciary duties of the board of directors or officers of Parent and provided, that the provisions of this Agreement which by their terms are governed by the laws of the Commonwealth of Massachusetts shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts. In any action or proceeding between any of the Parties arising out of or relating to this Agreement, each of the Parties: (i)&#160;irrevocably and unconditionally consents and submits to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i)&#160;of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10(c)</span>, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (v)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;10(h)</span> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Assignment</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated (except pursuant to the Merger) by such Party without the prior written consent of the other Parties, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Parties&#8217; prior written consent shall be void and of no effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">No Third-Party Rights</span>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <span style="text-decoration:underline">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <span style="text-decoration:underline">Specific Performance</span>.<sup style="font-size:75%; vertical-align:top"> </sup>Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <span style="text-decoration:underline">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i)&#160;one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii)&#160;upon delivery in the case of delivery by hand or (iii)&#160;on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A)&#160;if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section&#160;11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B)&#160;if to the Shareholder, to the Shareholder&#8217;s address, electronic mail address or facsimile shown below Shareholder&#8217;s signature to this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <span style="text-decoration:underline">Confidentiality</span>. Except to the extent required by applicable Law or regulation, the Shareholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Contemplated Transactions in strict confidence and shall not divulge any such information to any third person, except to the extent such information has been publicly disclosed by the Company or Parent in connection with their entry into the Merger Agreement and this Agreement; provided, however, that the Shareholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided, that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Shareholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to Parent, this Agreement, the Contemplated Transactions, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing Party shall make reasonable efforts to consult with the Company and Parent to the extent practicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <span style="text-decoration:underline">Interpretation</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, <span style="white-space:nowrap">re-enacted</span> thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of Page Left Intentionally Blank</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">COMPANY:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">KORSANA BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic"></span>[<span style="font-style:italic">Signature Page to Parent Shareholder Support Agreement</span>]<span style="font-style:italic"></span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">PARENT:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CYCLERION THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic"></span>[<span style="font-style:italic">Signature Page to Parent Shareholder Support Agreement</span>]<span style="font-style:italic"></span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SHAREHOLDER], </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in his/her capacity as the Shareholder: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature:<span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address: </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic"></span>[<span style="font-style:italic">Signature Page to Parent Shareholder Support Agreement</span>]<span style="font-style:italic"></span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Appendix A </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">C-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_49"><span id="ii111069_1b"></span>Annex D </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM KORSANA SUPPORT AGREEMENT </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Annex D </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">CONFIDENTIAL </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Final Form </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COMPANY SUPPORT AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Support Agreement (this &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;) is made and entered into as of April&#160;1, 2026, by and among Korsana Biosciences, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;), Cyclerion Therapeutics, Inc., a Massachusetts corporation (&#8220;<span style="text-decoration:underline">Parent</span>&#8221;), and the undersigned stockholder of the Company (the &#8220;<span style="text-decoration:underline">Stockholder</span>&#8221; and each of the Stockholder, Company, and Parent a &#8220;<span style="text-decoration:underline">Party</span>&#8221; and, collectively, the &#8220;<span style="text-decoration:underline">Parties</span>&#8221;). Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">RECITALS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;<span style="text-decoration:underline">First Merger Sub</span>&#8221;), and Cariboos Merger Sub II, LLC a Delaware limited liability company (the &#8220;<span style="text-decoration:underline">Second Merger Sub</span>&#8221;), have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), pursuant to which (i)&#160;the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii)&#160;the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule <span style="white-space:nowrap">13d-3</span> under the Exchange Act) of such number of shares of Company Capital Stock as indicated in <span style="text-decoration:underline">Appendix A</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a condition and inducement to the willingness of Parent to enter into the Merger Agreement, Parent has required that Stockholder enter into this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, intending to be legally bound, the Parties hereby agree as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline">Certain Definitions</span>. For all purposes of this Agreement, the following terms shall have the following respective meanings: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#8220;<span style="text-decoration:underline">Constructive Sale</span>&#8221; means, with respect to any security, (i)&#160;a short sale with respect to such security, (ii)&#160;entering into or acquiring a derivative contract with respect to such security, (iii)&#160;entering into or acquiring a futures or forward contract to deliver such security or (iv)&#160;entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly changing the economic benefits or risks of ownership of such security. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#8220;<span style="text-decoration:underline">Shares</span>&#8221; means (i)&#160;all shares of Company Capital Stock and any other equity securities of the Company beneficially owned by the Stockholder as of the date hereof, including such securities indicated in <span style="text-decoration:underline">Appendix A</span>, (ii)&#160;all additional shares of Company Capital Stock acquired, whether beneficially or of record, by the Stockholder during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date, and (iii)&#160;any shares of Company Capital Stock or other equity securities of the Company that are issued to such Stockholder or such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy), whether beneficial or of record, or otherwise owned by such Stockholder after the execution and delivery of this Agreement and expiring on the Expiration Date, whether by exercise of any Company Options or otherwise, including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#8220;<span style="text-decoration:underline">Transfer</span>&#8221; or &#8220;<span style="text-decoration:underline">Transferred</span>&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of an Encumbrance, lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Transfer and Voting Restrictions</span>. The Stockholder covenants to Parent and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise permitted by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2</span><span style="text-decoration:underline">(c)</span>, during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, publicly announce its intention to Transfer any of its Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case which has the effect of limiting or affecting the Stockholder&#8217;s legal power, authority or right to execute and deliver the Company Stockholder Written Consents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Entity, the Stockholder will not enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect Transfer of any right, title or interest (including any right or power to vote to which the holder thereof may be entitled whether such right or power is granted by proxy or otherwise) to any Shares or take any action that would reasonably be expected to make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of restricting the Stockholder&#8217;s legal power, authority and right to vote all of the Shares or would otherwise prevent or disable such Stockholder from performing any of such Stockholder&#8217;s obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i)&#160;by will or other testamentary document or by intestacy to the legal representative, heir, beneficiary or a member of the immediate family of the Stockholder or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder, (ii)&#160;to such Stockholder&#8217;s Affiliates (in each case, directly or indirectly), (iii) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (iv)&#160;in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (v)&#160;purchased from the Company pursuant to the Company <span style="white-space:nowrap">Pre-Closing</span> Financing on or about the Closing Date (including any shares of the Company issued upon conversion of any <span style="white-space:nowrap">pre-funded</span> warrants of Parent), (vi) pursuant to applicable Law or by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement and (vii)&#160;pursuant to the exercise of any option to purchase any Company Capital Stock or settlement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any restricted stock units, including in order to pay the exercise price of such option or otherwise satisfy taxes applicable thereto; <span style="text-decoration:underline">provided</span>, that in the cases of clauses (i)-(vi), (x) such Transferred Shares shall continue to be bound by this Agreement and (y)&#160;the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto. Any action taken in violation of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2(a)</span> through <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2(</span><span style="text-decoration:underline">d</span><span style="text-decoration:underline">)</span> shall be null and void ab initio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Company Capital Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Agreement to Vote Shares</span>. The Stockholder covenants to Parent and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Until the Expiration Date, at every meeting of the stockholders of the Company, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A)&#160;in favor of the adoption and approval of the Merger Agreement, (B)&#160;in favor of approval of the Contemplated Transactions, (C)&#160;against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Contemplated Transactions and (D)&#160;against any Acquisition Proposal.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any <span style="white-space:nowrap">split-up,</span> reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">Action in Stockholder Capacity Only</span>. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and/or beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of the Company. Nothing herein shall limit or affect the Stockholder&#8217;s ability to exercise the Stockholder&#8217;s fiduciary duties as an officer or director of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">Irrevocable Proxy</span>. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, as his, her or its proxy and <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> (with full power of substitution), for and in its name, place and stead, to (a)&#160;attend any all meetings of the Company stockholders with respect to any of the matters specified in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> and (b)&#160;vote, express consent, dissent or grant, withhold or issue instructions to the record holder to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting of the Company&#8217;s stockholders called with respect to any of the matters specified in, and in accordance and consistent with, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> of this Agreement. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein (including the next sentence), the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable (and as such shall survive and not be affected by the death, incapacity, mental illness or insanity of the Stockholder, as applicable) and shall not be terminated by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9</span>. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall automatically terminate on the Expiration Date. The Stockholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to file this proxy and any substitution or revocation with the Secretary of Company. The Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5</span> is given in connection with and granted in consideration of and as an inducement to Parent and the Merger Subs to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span>. With respect to any Shares that are owned beneficially by the Stockholder but are not held of record by the Stockholder (other than shares beneficially owned by the Stockholder that are held in the name of a bank, broker or nominee), the Stockholder shall take all action necessary to cause the record holder of such Shares to grant the irrevocable proxy and take all other actions provided for in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5</span> with respect to such Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">No Solicitation</span>. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that the Company is prohibited from taking pursuant to Section&#160;5.4 of the Merger Agreement and Section&#160;5.4 of the Merger Agreement is hereby incorporated by reference <span style="font-style:italic">mutatis mutandis</span>. The Stockholder hereby represents and warrants that the Stockholder has read Section&#160;5.4 of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <span style="text-decoration:underline">Documentation and Information</span>. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <span style="text-decoration:underline">No Exercise of Appraisal Rights; Waivers</span>. The Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Contemplated Transactions that Stockholder may have by virtue of, or with respect to, any Shares under any applicable Law (including all rights under Section&#160;262 of the DGCL, a copy of which is attached hereto as <span style="text-decoration:underline">Appendix B</span>) and (b)&#160;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Authority, which (i)&#160;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii)&#160;alleges that (A)&#160;the execution and delivery of this Agreement by the Stockholder breaches any duty that such Stockholder has (or may be alleged to have) to the Company or to the other Company stockholders, (B)&#160;the approval of the Merger Agreement by the Company Board breaches any fiduciary duty of the Company Board or any member thereof, or (C)&#160;the Contemplated Transactions constitute a breach of any fiduciary duty of the Company Board or any member thereof; <span style="text-decoration:underline">provided</span>, that (x)&#160;the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company and (y)&#160;the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <span style="text-decoration:underline">Representations and Warranties of the Stockholder</span>. The Stockholder hereby represents and warrants to Parent and the Company as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) The Stockholder is the beneficial owner of the shares of Company Capital Stock indicated in <span style="text-decoration:underline">Appendix A</span> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3</span> unless otherwise expressly stated with respect to any shares in <span style="text-decoration:underline">Appendix A</span>), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement, any <span style="white-space:nowrap">lock-up</span> agreement entered into by and between the Stockholder, the Company and Parent, and Encumbrances arising under applicable securities or community property laws); and (ii)&#160;the Stockholder does not beneficially own any securities of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company other than the shares of Company Capital Stock and rights to purchase shares of Company Capital Stock set forth in <span style="text-decoration:underline">Appendix A</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i)&#160;make, enter into and carry out the terms of this Agreement and (ii)&#160;vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other Parties) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or, if applicable, any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Entity) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and the Merger Subs are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <span style="text-decoration:underline">Certain Agreements</span>. Each Stockholder, by this Agreement, and with respect to such Stockholder&#8217;s Shares, severally and not jointly, hereby agrees to terminate, subject to the occurrence of, and effective immediately prior to, the First Effective Time any stockholder agreements, voting agreements, registration rights agreements, <span style="white-space:nowrap">co-sale</span> agreements and any other similar Contracts between the Company and holders of Company </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Capital Stock, including rights under any letter agreement providing for redemption rights, put rights, purchase rights, information rights, rights to consult with and advise management, inspection rights, preemptive rights, board of directors observer rights or rights to receive information delivered to the board of directors or other similar rights not generally available to stockholders of the Company between the Stockholder and the Company, including Investor Agreements, but excluding, for the avoidance of doubt, any rights the Stockholder may have that relate to any indemnification, commercial, development or employment agreements or arrangements between such Stockholder and the Company or any subsidiary of the Company, which shall survive in accordance with their terms. Each Stockholder hereby terminates and waives all rights of first refusal, redemption rights and rights of notice of the Merger and the other transactions contemplated by the Merger Agreement, effective as of immediately prior to, and contingent upon, the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <span style="text-decoration:underline">Termination</span>. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a)&#160;such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof, (b)&#160;the First Effective Time and (c)&#160;the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;<span style="text-decoration:underline">Expiration Date</span>&#8221;); <span style="text-decoration:underline">provided</span><span style="font-style:italic">, </span><span style="text-decoration:underline">however</span><span style="font-style:italic">,</span> that (i)&#160;<span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;12</span> shall survive the termination of this Agreement and (ii)&#160;the termination of this Agreement shall not relieve any Party from any liability for any material and willful breach of this Agreement prior to the First Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <span style="text-decoration:underline">Miscellaneous Provisions</span>.<sup style="font-size:75%; vertical-align:top"> </sup> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <span style="text-decoration:underline">Amendments</span>. No amendment of this Agreement shall be effective against any Party unless it shall be in writing and signed by each of the Parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <span style="text-decoration:underline">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span>. This Agreement constitutes the entire agreement between the Parties and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the Parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <span style="text-decoration:underline">Applicable Law; Jurisdiction.</span> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement, each of the Parties: (i)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i)&#160;of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;12(c)</span>, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (v)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;12</span><span style="text-decoration:underline">(h)</span> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Assignment</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated (except pursuant to the Merger) by such Party without the prior written consent of the other Parties, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Parties&#8217; prior written consent shall be void and of no effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <span style="text-decoration:underline">No Third-Party Rights</span>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <span style="text-decoration:underline">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <span style="text-decoration:underline">Specific Performance</span>.<sup style="font-size:75%; vertical-align:top"> </sup>Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <span style="text-decoration:underline">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i)&#160;one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii)&#160;upon delivery in the case of delivery by hand or (iii)&#160;on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A)&#160;if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section&#160;11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B)&#160;if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <span style="text-decoration:underline">Confidentiality</span><span style="text-decoration:underline">. </span>Except to the extent required by applicable Law or regulation, the Stockholder shall hold any <span style="white-space:nowrap">non-public</span> information regarding the Company, this Agreement, the Merger Agreement and the Contemplated Transactions in strict confidence and shall not divulge any such information to any third person, except to the extent such information has been publicly disclosed by the Company or Parent in connection with their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (<span style="text-decoration:underline">provided</span> that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to the Company, Parent, the Merger Subs, this Agreement, the Contemplated Transactions, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing Party shall make reasonable efforts to consult with the Company and Parent to the extent practicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <span style="text-decoration:underline">Interpretation</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, <span style="white-space:nowrap">re-enacted</span> thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of Page Left Intentionally Blank</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">COMPANY:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">KORSANA BIOSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Signature Page to Company Stockholder Support Agreement</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">PARENT:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">CYCLERION THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Signature Page to Company Stockholder Support Agreement</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written. </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">[STOCKHOLDER], </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">in his/her capacity as the Stockholder: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Signature: <span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Address: </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Signature Page to Company Stockholder Support Agreement</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Appendix A </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Appendix B </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">D-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_50"><span id="ii111069_1c"></span>Annex E </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM OF <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Annex E </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Confidential </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Final Form </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">LOCK-UP</span> AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&#160;1, 2026 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyclerion Therapeutics, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">245 First Street, 18<sup style="font-size:75%; vertical-align:top">th</sup> Floor </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02142 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Regina Graul, Ph.D. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: *** </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned signatory of this <span style="white-space:nowrap">lock-up</span> agreement (this &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Lock-Up</span> Agreement</span>&#8221;) understands that Cyclerion Therapeutics, Inc., a Massachusetts corporation (including any successor thereto, &#8220;<span style="text-decoration:underline">Parent</span>&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of April&#160;1, 2026 (as the same may be amended from time to time, the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;) with CARIBOOS MERGER SUB CORP., a Delaware corporation and a wholly owned subsidiary of Parent, CARIBOOS MERGER SUB II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Korsana Biosciences, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">1.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated by the Merger Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;<span style="text-decoration:underline">Restricted Period</span>&#8221;); <span style="text-decoration:underline">provided</span>, that if a registration statement covering the shares of Company Common Stock and <span style="white-space:nowrap">pre-funded</span> warrants of the Company issued and sold in connection with the Company <span style="white-space:nowrap">Pre-Closing</span> Financing (other than any shares or <span style="white-space:nowrap">pre-funded</span> warrants of the Company held by affiliates of the Company or, following the Closing, affiliates of Parent) has not been declared effective by the SEC prior to the end of such <span style="white-space:nowrap">180-day</span> period, then the Restricted Period shall end on such later date upon which such registration statement is first declared effective; <span style="text-decoration:underline">provided further</span>, <span style="text-decoration:underline">that</span>, this <span style="white-space:nowrap">Lock-Up</span> Agreement shall terminate immediately upon the undersigned&#8217;s termination of employment with Parent or its subsidiaries: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">a.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon (i)&#160;exercise of Parent Options, (ii) settlement of Parent Restricted Stock Units or (iii)&#160;any warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the undersigned, except as set forth below (collectively, the &#8220;<span style="text-decoration:underline">Undersigned&#8217;s Shares</span>&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">b.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (a)&#160;above or this clause (b)&#160;is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">c.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">d.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">except for any support agreement entered into as of the date hereof by the undersigned with Parent and the Company, grant any proxies or powers of attorney with respect to any Parent Common Stock, deposit any Parent Common Stock into a voting trust or enter into a voting agreement or similar arrangement or commitment with respect to any Parent Common Stock; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">e.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">publicly disclose the intention to do any of the foregoing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">2.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The restrictions and obligations contemplated by this <span style="white-space:nowrap">Lock-Up</span> Agreement shall not apply to: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">a.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">transfers of the Undersigned&#8217;s Shares: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">i.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a natural person, (A)&#160;to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (each, a &#8220;<span style="text-decoration:underline">Family Member</span>&#8221;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B)&#160;to the undersigned&#8217;s estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C)&#160;as a bona fide gift or a charitable contribution, (D)&#160;by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E)&#160;to any partnership, corporation or limited liability company which is controlled by or under common control with the undersigned and/or by any such Family Member(s); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">ii.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is an Entity, (A)&#160;to another Entity that is an affiliate (as defined under Rule <span style="white-space:nowrap">12b-2</span> of the Exchange Act) of the undersigned, including investment funds or other entities that controls or manages, is under common control or management with, or is controlled or managed by, the undersigned, (B)&#160;as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule <span style="white-space:nowrap">13d-3</span> of the Exchange Act) of the Undersigned&#8217;s Shares or (D)&#160;transfers or dispositions not involving a change in beneficial ownership; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">iii.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">if the undersigned is a trust, to any grantors or beneficiaries of the trust; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">provided</span> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to Sections 2(a)(i)(A), 2(a)(i)(E) or 2(a)(ii)(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a <span style="white-space:nowrap">lock-up</span> agreement in the form of this <span style="white-space:nowrap">Lock-Up</span> Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">b.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the exercise of Parent Options (including a net or cashless exercise of a Parent Option), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; <span style="text-decoration:underline">provided</span> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">c.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">transfers to Parent in connection with the net settlement of any Parent Restricted Stock Unit or other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; <span style="text-decoration:underline">provided</span> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">d.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the establishment of, or amendment to, a trading plan pursuant to Rule <span style="white-space:nowrap">10b5-1</span> under the Exchange Act for the transfer of shares of Parent Common Stock; <span style="text-decoration:underline">provided</span> that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">e.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">the disposition (including a forfeiture or repurchase) to Parent of any shares of Parent Common Stock issued pursuant to a Parent Restricted Stock Award or otherwise granted pursuant to the terms of any employee benefit plan or restricted stock purchase agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">f.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">transfers, distributions, sales or other transactions by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public offering by Parent, in each case following the date of the Closing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">g.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">transfers pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent; <span style="text-decoration:underline">provided</span> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this <span style="white-space:nowrap">Lock-Up</span> Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">h.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">transfers pursuant to an order of a court or regulatory agency; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">i.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">transfers by the undersigned of shares of Parent Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company, if any, purchased from the Company on or about the Closing Date but prior to the Closing; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and <span style="text-decoration:underline">provided</span>, further, that, with respect to each of (b), (c), and (d)&#160;above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section&#160;16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under Section&#160;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to this <span style="white-space:nowrap">Lock-Up</span> Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For purposes of this <span style="white-space:nowrap">Lock-Up</span> Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of Parent&#8217;s voting securities if, after such transfer, Parent&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of Parent (or the surviving entity). </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">3.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any attempted transfer in violation of this <span style="white-space:nowrap">Lock-Up</span> Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this <span style="white-space:nowrap">Lock-Up</span> Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this <span style="white-space:nowrap">Lock-Up</span> Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">4.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this <span style="white-space:nowrap">Lock-Up</span> Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">5.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this <span style="white-space:nowrap">Lock-Up</span> Agreement. The undersigned understands that Parent and the Company are proceeding with the transactions contemplated by the Merger Agreement in reliance upon this <span style="white-space:nowrap">Lock-Up</span> Agreement. The Company is an intended third-party beneficiary of this <span style="white-space:nowrap">Lock-Up</span> Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">6.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any and all remedies herein expressly conferred upon Parent or the Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Parent or the Company or of any one remedy will not preclude the exercise of any other remedy. The undersigned agrees that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur to Parent and/or the Company in the event that any of the provisions of this <span style="white-space:nowrap">Lock-Up</span> Agreement were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that Parent and the Company shall be entitled to an injunction or injunctions to prevent breaches of this <span style="white-space:nowrap">Lock-Up</span> Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Parent or the Company is entitled at Law or in equity, and the undersigned waives any bond, surety or other security that might be required of Parent or the Company with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at Law or that any award of specific performance is not an appropriate remedy for any reason at Law or in equity. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">7.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In the event that any holder of securities of Parent that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same percentage of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of such securities held by such holder on the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Pro-Rata</span> Release</span>&#8221;); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that such <span style="white-space:nowrap">Pro-Rata</span> Release shall not be applied unless and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock subject to a substantially similar agreement. In the event of any <span style="white-space:nowrap">Pro-Rata</span> Release, Parent shall promptly (and in any event within two (2)&#160;Business Days of such release) inform each relevant holder of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock of the terms of such <span style="white-space:nowrap">Pro-Rata</span> Release. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">8.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Upon the release of any of the Undersigned&#8217;s Shares from this <span style="white-space:nowrap">Lock-Up</span> Agreement, Parent will reasonably cooperate with the undersigned to facilitate the timely preparation and delivery of certificates or the establishment of book-entry positions at Parent&#8217;s transfer agent representing the Undersigned&#8217;s Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this <span style="white-space:nowrap">Lock-Up</span> Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">9.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned understands that this <span style="white-space:nowrap">Lock-Up</span> Agreement is irrevocable and is binding upon the undersigned&#8217;s heirs, legal representatives, successors and assigns. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">10.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This <span style="white-space:nowrap">Lock-Up</span> Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties arising out of or relating to this <span style="white-space:nowrap">Lock-Up</span> Agreement, each of the parties: (i)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)&#160;agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance with foregoing clause (i)&#160;of this paragraph, (iii)&#160;waives any objection to laying venue in any such action or Legal Proceeding in such courts, (iv)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v)&#160;agrees that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;11</span> of this <span style="white-space:nowrap">Lock-Up</span> Agreement. This <span style="white-space:nowrap">Lock-Up</span> Agreement constitutes the entire agreement between the parties to this <span style="white-space:nowrap">Lock-Up</span> Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">THE PARTIES HERETO HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY ACTION OR LEGAL PROCEEDING RELATED TO OR ARISING OUT OF THIS <span style="white-space:nowrap">LOCK-UP</span> AGREEMENT, ANY DOCUMENT EXECUTED IN CONNECTION HEREWITH AND THE MATTERS CONTEMPLATED HEREBY AND THEREBY. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">11.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or sent by overnight courier (providing proof of delivery), by electronic transmission (providing confirmation of transmission) to the Company or Parent, as the case may be, in accordance with Section&#160;11.7 of the Merger Agreement and to the undersigned at his, her or its address or email address (providing confirmation of transmission) set forth on the signature page hereto (or at such other address for a party as shall be specified by like notice). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">12.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This <span style="white-space:nowrap">Lock-Up</span> Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed <span style="white-space:nowrap">Lock-Up</span> Agreement (in counterparts or otherwise) by Parent, the Company and the undersigned by electronic transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this <span style="white-space:nowrap">Lock-Up</span> Agreement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[SIGNATURE PAGE FOLLOWS] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Very truly yours,</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Print Name of Stockholder: [NAME]</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="font-size:1px; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Signature (for individuals):</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="font-size:1px; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Signature (for entities):</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Signature Page to Lock-Up Agreement</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:86%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Accepted and Agreed by <span style="font-weight:bold">PARENT</span>:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><span style="font-size:10pt">Name:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><span style="font-size:10pt">Title:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Signature Page to Lock-Up Agreement</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">E-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_51">Annex F </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM OF CVR AGREEMENT </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Annex F </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">CONFIDENTIAL </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Final Form </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONTINGENT VALUE RIGHTS AGREEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <span style="font-weight:bold">CONTINGENT VALUE RIGHTS AGREEMENT </span>(this &#8220;<span style="font-weight:bold">Agreement</span>&#8221;), dated as of [__], 2026, is entered into by and between Cyclerion Therapeutics, Inc., a Massachusetts corporation (the &#8220;<span style="font-weight:bold">Company</span>&#8221;), and [__], a [__], as the &#8220;Rights Agent&#8221; (as defined herein), and [__], a [__], solely in its capacity as the initial representative, agent and attorney in fact of the Holders (the &#8220;<span style="font-weight:bold">Representative</span>&#8221;). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">RECITALS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the Company, Cariboos Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;<span style="font-weight:bold">First Merger Sub</span>&#8221;), Cariboos Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (&#8220;<span style="font-weight:bold">Second Merger Sub</span>&#8221;), and Korsana Biosciences, Inc., a Delaware corporation (&#8220;<span style="font-weight:bold">Korsana</span>&#8221;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of April&#160;1, 2026 (the &#8220;<span style="font-weight:bold">Merger Agreement</span>&#8221;), pursuant to which First Merger Sub will merge with and into Korsana, with Korsana surviving the First Merger as a wholly-owned Subsidiary of the Company, and immediately following the First Merger and as part of the same overall transaction as the First Merger, Korsana will merge with and into Second Merger Sub (the &#8220;<span style="font-weight:bold">Second Merger</span>&#8221; and, together with the First Merger, the &#8220;<span style="font-weight:bold">Merger</span>&#8221;), with Second Merger Sub being the surviving entity of the Second Merger; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, pursuant to the Merger Agreement, and in accordance with the terms and conditions thereof, the Company has agreed to issue to the Holders (as defined herein) contingent value rights as hereinafter described; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the parties to this Agreement have done all things reasonably necessary to make the contingent value rights, when issued pursuant to the Merger Agreement and hereunder, the valid obligations of the Company and to make this Agreement a valid and binding agreement of the Company, in accordance with its terms; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the initial Holders desire that the Representative act as their agent for the purposes of accomplishing the intent and implementing the provisions of this Agreement and facilitating the consummation of the transactions contemplated hereby and performing the other services described in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE 1 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DEFINITIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;1.1 </span><span style="font-weight:bold"><span style="text-decoration:underline">Definitions</span></span>. Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement. The following terms have the meanings ascribed to them as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Acting Holders</span>&#8221; means, at the time of determination, the Holders of more than 35% of the outstanding CVRs, as reflected on the CVR Register. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Assignee</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5</span>. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Code</span>&#8221; means the Internal Revenue Code of 1986, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Company Shares</span>&#8221; means shares of Parent Common Stock (including, for the avoidance of doubt, those shares of Parent Common Stock with respect to Parent Restricted Stock Awards accelerated pursuant to Section&#160;6.6(e) of the Merger Agreement) and shares of Parent Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CVR</span>&#8221; means a contingent contractual right of Holders to receive CVR Proceeds pursuant to the Merger Agreement and this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CVR Expense Cap</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.2</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CVR Payment Amount</span>&#8221; means, for a given Holder, an amount equal to the product of (a)&#160;the CVR Proceeds and (b)&#160;(i) the total number of CVRs entitled to receive such CVR Proceeds held by such Holder divided by (ii)&#160;the total number of CVRs entitled to receive such CVR Proceeds held by all Holders, in each case of clauses (i)&#160;and (ii), as reflected on the CVR Register as of the close of business on the date prior to the date of payment (rounded down to the nearest whole cent). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CVR Payment Date</span>&#8221; means a date that is no later than thirty (30)&#160;days following the receipt of the corresponding portion of Gross Proceeds by the Company or any of its Affiliates, pursuant to which CVR Proceeds are payable to Holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CVR Payment Notice</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CVR Proceeds</span>&#8221; means, without duplication, 100% of the Net Proceeds in the case of any Legacy Assets Transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">&#8220;CVR Register</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.3(b)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">CVR Term</span>&#8221; means the period beginning on the Closing Date and ending upon the second (2nd) anniversary of this Agreement; <span style="text-decoration:underline">provided</span>, that, (i)&#160;with respect to the Legacy Assets Transaction Agreement set forth on <span style="text-decoration:underline">Schedule 1.1</span><sup style="font-size:75%; vertical-align:top">1</sup> hereto, the CVR Term shall automatically extend until the earlier of the (A)&#160;fifteenth (15th) anniversary of this Agreement and (B)&#160;the expiration or earlier termination by Akebia Therapeutics, Inc. of such Legacy Assets Transaction Agreement pursuant to its terms, and (ii)&#160;with respect to the Tisento Shares, the CVR Term shall extend until the end of the Legacy Assets Transaction Period with respect to the Tisento Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Gross Proceeds</span>&#8221; means, without duplication, the sum of all cash consideration actually received by the Company during the CVR Term in consideration for a Legacy Assets Transaction pursuant to a Legacy Assets Transaction Agreement (including any cash actually received upon the sale by the Company or its Affiliates of any equity securities received as consideration in a Legacy Assets Transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Holder</span>&#8221; means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Legacy Assets</span>&#8221; means all of the Company&#8217;s and the Company&#8217;s Subsidiaries&#8217; right, title and interest in and to the tangible and intangible assets of the Company or any of its Subsidiaries as of immediately prior to the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Legacy Assets Transaction</span>&#8221; means the sale, transfer, license or other disposition by the Company or any of its Affiliates of all or any part of any Legacy Asset to any third party (including any sale or disposition of equity securities in any Subsidiary of the Company that holds any right, title or interest in or to any Legacy Assets). </p><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">1</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">Note to Draft</span>: Schedule to list the Akebia License Agreement. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Legacy Assets Transaction Agreement</span>&#8221; means a definitive agreement, contract or other definitive arrangement entered into by the Company or any of its Affiliates providing for a transaction or series of transactions regarding a Legacy Assets Transaction, in each case, as set forth on <span style="text-decoration:underline">Schedule 1.2</span><sup style="font-size:75%; vertical-align:top">2</sup> hereto or entered into during the Legacy Assets Transaction Period. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Legacy Assets Transaction Period</span>&#8221; means the period commencing on the Closing Date and ending on the first (1st) anniversary of the Closing Date; provided that, with respect to the Tisento Shares, the Legacy Assets Transaction Period shall extend until the earliest of (A)&#160;nine (9) months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the Sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Loss</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(g)</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Net Proceeds</span>&#8221; means, during the CVR Term, the Gross Proceeds minus Permitted Deductions, as calculated in a manner consistent with GAAP. For clarity, (i)&#160;if Permitted Deductions exceed the Gross Proceeds as it relates to any payment event, as applicable, any excess Permitted Deductions shall be applied against Gross Proceeds in a subsequent payment event, as applicable; and (ii)&#160;if any of the Gross Proceeds or Permitted Deductions are not in U.S. dollars, currency conversion to U.S. dollars shall be made by using the exchange rate prevailing at the JPMorgan Chase Bank or its successor entity on the due date of receipt of such Gross Proceeds or due date of payment of relevant Permitted Deductions, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Notice</span>&#8221; has the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Officer&#8217;s Certificate</span>&#8221; means a certificate signed by the chief executive officer and the chief financial officer of the Company, in their respective official capacities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Party</span>&#8221; means the Company or the Rights Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permitted Deductions</span>&#8221; means the sum of: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) any applicable Tax (including any applicable value added or sales taxes or withholding taxes) imposed on or with respect to Gross Proceeds and payable by (or withheld from) the Company or any of its Affiliates (regardless of whether the due date for such Taxes arises during or after the Legacy Assets Transaction Period) and, without duplication, any income or other similar Taxes payable by the Company or any of its Affiliates that would not have been incurred by the Company or any of its Affiliates but for the Gross Proceeds; <span style="font-style:italic">provided</span> that, for purposes of calculating income Taxes incurred by the Company or its Affiliates in respect of the Gross Proceeds, any such income Taxes shall be computed based on the gain recognized by the Company or its Affiliates from the Legacy Assets Transaction after reduction for any net operating loss carryforwards or other Tax attributes of the Company or its Affiliates in existence as of the Closing Date that are available to offset such gain after taking into account any limits of the usability of such attributes, including under Section&#160;382 of the Code as determined by the Company&#8217;s tax advisers (and for the sake of clarity such income taxes shall be calculated without taking into account any net operating losses or other tax attributes generated by the Company or its Affiliates after the Closing Date); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any reasonable and documented expenses incurred by the Company or any of its Affiliates in respect of its performance of this Agreement following the Closing Date or in respect of its performance of any Contract in connection with any Legacy Asset (in each case, to the extent such expenses are not included in the determination of the Parent Net Cash in accordance with the Merger Agreement), including any costs related to </p><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><sup style="font-size:75%; vertical-align:top">2</sup>&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">Note to Draft</span>: Schedule to list the Akebia License Agreement and any Parent Legacy Transaction entered into prior to Closing, if any. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the prosecution, maintenance or enforcement by the Company or any of its Subsidiaries of intellectual property rights (but excluding any costs related to a breach of this Agreement, including costs incurred in litigation in respect of the same); </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any reasonable and documented expenses incurred or accrued by the Company or any of its Affiliates in connection with (i)&#160;the negotiation, entry into and closing of any Legacy Assets Transaction of any Legacy Asset or (ii)&#160;the maintenance and enforcement costs related to the CVRs (including fees and expenses related to the Rights Agent), including any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee, service fee or other fee, commission or expense owed to any broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party in relation thereto, and the CVR Expenses Cap to the extent not included in the determination of the Parent Net Cash in accordance with the Merger Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) any Losses incurred or reasonably executed to be incurred by the Company or any of its Affiliates arising out of any third-party claims, demands, actions, or other proceedings relating to or in connection with any Legacy Assets Transaction, including indemnification obligations of the Company or any of its Affiliates set forth in any Legacy Assets Transaction Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any proceeds in consideration for a Legacy Assets Transaction pursuant to a Legacy Assets Transaction Agreement included in the final determination of the Parent Net Cash in accordance with the Merger Agreement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) any royalties or other amounts payable by the Company or any of its Affiliates to any third party in connection with any Legacy Assets; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) any Liabilities borne by the Company or any of its Affiliates pursuant to Contracts related to Legacy Assets, including costs arising from the termination thereof (in each case, only to the extent not included in the calculation of Parent Net Cash); and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) any Liabilities existing or incurred during the CVR Term that would have been required to be included in the calculation of the Parent Net Cash to the extent not taken account in the calculation of the Parent Net Cash in accordance with the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Permitted Transfer</span>&#8221; means a transfer of CVRs (a)&#160;upon death of a Holder by will or intestacy; (b)&#160;pursuant to a court order; (c)&#160;by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (d)&#160;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent allowable by DTC; or (e)&#160;as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.6</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Rights Agent</span>&#8221; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent will have become the Rights Agent pursuant to the applicable provisions of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Sale of Tisento</span>&#8221; means (i)&#160;the sale of all or substantially all of the assets of Tisento on a consolidated basis to an unrelated person or entity, (ii)&#160;a merger, reorganization or consolidation pursuant to which the holders of Tisento&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&#160;the sale of all, or substantially all, of the outstanding equity interests of Tisento to an unrelated person, entity or group thereof acting in concert, or (iv)&#160;any other transaction in which the owners of Tisento&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of Tisento or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from Tisento. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tisento</span>&#8221; means Tisento Therapeutics Holdings Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold">Tisento Shares</span>&#8221; means the equity interests of Tisento owned by the Company. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE 2 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONTINGENT VALUE RIGHTS </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.1 </span><span style="font-weight:bold"><span style="text-decoration:underline">Holders of CVRs; Appointment of Rights Agent</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The CVRs represent the rights of Holders to receive CVR Proceeds pursuant to this Agreement. The initial Holders will be the holders of Company Shares as of immediately prior to the Effective Time. One CVR will be issued with respect to each Company Share that is outstanding as of immediately prior to the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company hereby appoints the Rights Agent to act as Rights Agent for the Company in accordance with the express terms and conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.2 </span><span style="font-weight:bold"><span style="text-decoration:underline"><span style="white-space:nowrap">Non-transferable</span></span></span>. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. The CVRs will not be listed on any quotation system or traded on any securities exchange. Any attempted sale, assignment, transfer, pledge, encumbrance or disposition of CVRs, in whole or in part, in violation of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2</span> shall be void ab initio and of no effect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.3 </span><span style="font-weight:bold"><span style="text-decoration:underline">No Certificate; Registration; Registration of Transfer; Change of Address</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The CVRs will be issued in book-entry form only and will not be evidenced by a certificate or other instrument. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent shall create and maintain a register (the &#8220;<span style="font-weight:bold">CVR Register</span>&#8221;) for the purpose of registering CVRs and Permitted Transfers. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from the Company. The CVR Register will initially show one position for Cede&#160;&amp; Co. representing Company Shares held by DTC on behalf of the street holders of the Company Shares held by such holders as of immediately prior to the Effective Time. The Rights Agent will have no responsibility whatsoever directly or indirectly to the street name holders with respect to transfers of CVRs. With respect to any payments or issuances to be made under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4</span> below, the Rights Agent will accomplish the payment to any former street name holders of Company Shares by sending one <span style="white-space:nowrap">lump-sum</span> payment or issuance to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution of payments or Company Shares by DTC to such street name holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Subject to the restrictions on transferability set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2</span>, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer in form reasonably satisfactory to the Rights Agent pursuant to its guidelines or procedures, including a guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program, duly executed and properly completed by the Holder thereof, the Holder&#8217;s attorney duly authorized in writing, the Holder&#8217;s personal representative or the Holder&#8217;s survivor, and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2</span>), register the transfer of the CVRs in the CVR Register. The Company and Rights Agent may require evidence of payment of a sum sufficient to cover any stamp, documentary, registration, or other Tax or governmental charge that is imposed in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with any such registration of transfer (or evidence that such Taxes and charges are not applicable). The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement that requires the payment by a Holder of a CVR of applicable taxes or charges unless and until the Rights Agent is satisfied that all such taxes or charges have been paid. All duly transferred CVRs registered in the CVR Register will be the valid obligations of the Company and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR will be valid until registered in the CVR Register. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written notice and proper validation of the identity of such Holder, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form, promptly record the change of address in the CVR Register. The Company, the Acting Holders or the Representative may make a written request to the Rights Agent for a list containing the names, addresses and number of CVRs of the Holders that are registered in the CVR Register. Upon receipt of such written request from the Acting Holders or the Representative, as applicable, the Rights Agent shall promptly deliver a copy of such list to the Acting Holders or the Representative, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Company Shares as of immediately prior to the Effective Time (the &#8220;<span style="font-weight:bold">Record Time</span>&#8221;). Subject to the terms and conditions of this Agreement and the Company&#8217;s prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable tax withholding, to each holder of Company Shares as of the Record Time by the mailing of a statement of holding reflecting such CVRs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.4 </span><span style="font-weight:bold"><span style="text-decoration:underline">Payment Procedures</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If a Legacy Assets Transaction Agreement is entered prior to the end of the Legacy Assets Transaction Period, then the Company shall promptly deliver to the Rights Agent (with a copy to the Representative) written notice indicating that a Legacy Assets Transaction Agreement has been entered into and a copy of the Legacy Assets Transaction Agreement and any ancillary agreements thereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On or prior to each CVR Payment Date and subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6</span>, the Company shall deliver to the Rights Agent (with a copy to the Representative)&#160;(i) written notice indicating that (A)&#160;the Holders are entitled to receive one or more payments with respect to CVR Proceeds; (B)&#160;the source and trigger event for such payment of CVR Proceeds; and (C)&#160;if applicable, a detailed calculation of Gross Proceeds (including any calculations and/or supporting documentation applicable to any allocation determination for consideration related or not related to a Legacy Asset), Net Proceeds and any Permitted Deductions used to calculate such CVR Proceeds with reasonable supporting detail for such Permitted Deductions (such notice, a &#8220;<span style="font-weight:bold">CVR Payment Notice</span>&#8221;), (ii) a letter of instruction setting forth, for each CVR, the CVR Payment Amount with respect thereto (including each component included in the calculation thereof) and (iii)&#160;any other letter of instruction reasonably required by the Rights Agent. On or prior to any CVR Payment Date and subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6</span>, the Company shall deliver to the Rights Agent the CVR Payment Amounts required by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.6</span>. All amounts delivered by the Company hereunder shall be delivered in U.S. dollars. For the avoidance of doubt, the Company shall have no further liability in respect of the relevant CVR Payment Amount upon delivery of such CVR Payment Amount in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(b)</span> and the satisfaction of each of the Company&#8217;s obligations set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(b)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span>. With respect to cash deposited by the Company with the bank or financial institution designated by the Rights Agent (which shall be Wells Fargo, U.S. Bank or another bank or financial institution of substantially equivalent national reputation and financial standing), the Rights Agent agrees to cause such bank or financial institution to establish and maintain a separate demand deposit account therefor in the name of the Rights Agent for the benefit of the Company. The Rights Agent will only draw upon cash in such account(s) as required from time to time in order to make payments as required under this Agreement and any applicable Tax withholding payments pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7(b)</span> herein. The Rights Agent shall have no </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsibility or liability for any diminution of funds that may result from any deposit made by the Rights Agent in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4(b)</span>, including any losses resulting from a default by any bank, financial institution or other third party, in the absence of fraud, bad faith or willful misconduct by or on behalf of the Rights Agent. The Rights Agent may from time to time receive interest in connection with such deposits. The Rights Agent shall not be obligated to pay such interest to the Company, the Representative, any Holder or any other party. The Rights Agent is acting as an agent hereunder and is not a debtor of the Company in respect of cash deposited hereunder. For the avoidance of doubt, the Company and Representative acknowledge that (i)&#160;the Rights Agent is not a bank or a trust company, (ii)&#160;the Rights Agent is not acting in any sort of capacity as an &#8220;escrow&#8221; or similar agent hereunder, and (iii)&#160;nothing in this Agreement shall be construed as requiring the Rights Agent to perform any services that would require registration with any governmental authority as a bank or a trust company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Rights Agent will promptly, and in any event within ten (10)&#160;Business Days after receipt of the CVR Payment Notice as well as any letter of instruction reasonably required by the Rights Agent, send each Holder at its registered address a copy of the CVR Payment Notice (at the Company&#8217;s sole cost and expense) and, following the applicable CVR Payment Date, promptly (and in any event within thirty (30)&#160;days following such CVR Payment Notice) pay the CVR Payment Amount to each of the Holders by check mailed to the address of each Holder as reflected in the CVR Register as of the close of business on the CVR Payment Date; provided, that with respect to any such Holder that is due an amount in excess of $100,000 in the aggregate who has provided the Rights Agent wiring instructions in writing as of the close of business on the date of the CVR Payment Notice, by wire transfer of immediately available funds to the account specified on such instruction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Any portion of the CVR Payment Amount that remains undistributed to a Holder twelve (12)&#160;months after the applicable CVR Payment Date will be delivered by the Rights Agent to the Company, upon demand, and any Holder will thereafter look only to the Company for payment of the CVR Payment Amount, without interest, but such Holder will have no greater rights against the Company than those accorded to general unsecured creditors of the Company under applicable Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) None of the Company, any of its Affiliates, or the Rights Agent will be liable to any Person in respect of the CVR Payment Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. If, despite the Company&#8217;s, any of its Affiliates&#8217; or the Rights Agent&#8217;s commercially reasonable efforts to deliver the CVR Payment Amount to the applicable Holder, the CVR Payment Amount has not been paid prior to two (2)&#160;years after the applicable CVR Payment Date (or immediately prior to such earlier date on which the CVR Payment Amount would otherwise escheat to any Governmental Body), the CVR Payment Amount will become the property of the Company, to the extent permitted by applicable Law, free and clear of all claims or interest of any Person previously entitled thereto. If the CVR Payment Amount does not become the property of the Company as per applicable Law upon transfer by the Rights Agent, such Holder will thereafter look only to the Company for payment of the CVR Payment Amount, without interest, and the Company will be responsible for escheatment to the applicable Governmental Body. The Rights Agent will not be responsible for escheatment of abandoned property except in the case that the Company is unable to provide the Rights Agent with the applicable wire instructions to transfer such property to the Company before the CVR Proceeds would escheat to the applicable Governmental Body. In addition to and not in limitation of any other indemnity obligation herein, the Company agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.5 </span><span style="font-weight:bold"><span style="text-decoration:underline">No Voting, Dividends or Interest; No Equity or Ownership Interest</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If and when issued, the CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs to any Holder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If and when issued, the CVRs will not represent any equity or ownership interest in the Company or in any constituent company to the Merger. It is hereby acknowledged and agreed that a CVR shall not constitute a security of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in this Agreement shall be construed as conferring upon any Holder, by virtue of the CVRs, any rights or obligations of any kind or nature whatsoever as a shareholder of the Company or any of its Subsidiaries either at law or in equity. The rights of any Holder and the obligations of the Company and its Affiliates and their respective officers, directors and controlling Persons are contract rights limited to those expressly set forth in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) It is hereby acknowledged and agreed that the CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of the Company&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. Each Holder acknowledges that it is highly possible that no Legacy Assets Transaction will occur prior to the expiration of the Legacy Assets Transaction Period and that there will not be any Gross Proceeds that may be the subject of a CVR Payment Amount. It is further acknowledged and agreed that neither the Company nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.5(d)</span> is an essential and material term of this Agreement and that in no event shall the Company, its board of directors or its officers and Affiliates be deemed to have any fiduciary or similar duties to any Holder by virtue of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.6 </span><span style="font-weight:bold"><span style="text-decoration:underline">Ability to Abandon CVR</span></span>. A Holder may at any time, at such Holder&#8217;s option, abandon all of such Holder&#8217;s remaining rights represented by CVRs by transferring such CVR to the Company or a Person nominated in writing by the Company (with written notice thereof from the Company to the Rights Agent) without consideration in compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by the Company of such transfer and cancellation. Nothing in this Agreement is intended to prohibit the Company or its Affiliates from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;2.7 </span><span style="font-weight:bold"><span style="text-decoration:underline">Tax Matters</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and the Representative intend that, for all U.S. federal and applicable state and local income tax purposes, (i)&#160;the issuance of the CVRs pursuant to Section&#160;2.1 of this Agreement is intended to be treated as a distribution of property (and not debt or equity of the Company) by the Company to its shareholders governed by Code Section&#160;301 and (ii)&#160;any CVR Payment Amount (if any) is intended to be treated as a contractual payment pursuant to the rights afforded by this Agreement to the Holder and not as a distribution by the Company in respect of stock in the Company. The Company and its Affiliates (including the Company after the Merger) shall (and the Company shall instruct the Rights Agent to) report to the extent required by applicable Law for all Tax purposes in a manner consistent with the foregoing, and none of the parties will take any position to the contrary on any U.S. federal, state and local Tax Returns or for other U.S. federal and applicable state and local income tax purposes, unless otherwise required by changes in applicable Law or a &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code (or a similar determination under applicable state or local Law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In addition to any Permitted Deductions, the Company and its Affiliates (including the Company after the Merger) and the Rights Agent shall be entitled to, and the Company will instruct the Rights Agent or its applicable Affiliate to, deduct and withhold, or cause to be deducted or withheld, from each CVR Payment Amount or any other amounts otherwise payable pursuant to this Agreement such amounts as may be required to be deducted and withheld therefrom under applicable Tax Law. Prior to making (or causing to be made) any Tax deduction or withholding pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7(b)</span>, the Rights Agent will (and the Company shall instruct the Rights Agent to) provide the opportunity for the Holders to provide properly completed and duly executed Internal Revenue Service Forms <span style="white-space:nowrap">W-9</span> or applicable Form <span style="white-space:nowrap">W-8,</span> as applicable, or any other reasonably appropriate </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forms or information from Holders in order to eliminate or reduce withholding. The Rights Agent shall and the Company shall (or shall cause its applicable Affiliate to), as applicable, promptly and timely remit, or cause to be promptly and timely remitted, any amounts withheld in respect of Taxes to the appropriate Governmental Body. To the extent any amounts are so deducted, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made. Promptly following such withholding, the Company will (or will instruct its applicable Affiliate or the Rights Agent to) deliver to the Person to whom such amounts would otherwise have been paid reasonably acceptable evidence of such withholding. Any amounts not withheld by the Company or the Paying Agent on the issuance of CVRs to the Holders or any payments to the Holders under this Agreement (including CVR Payment Amounts) and subsequently determined to have been required to be withheld by the Company by any relevant governmental entity shall be paid by the Holders through a deduction from future CVR Payment Amounts payable to the applicable Holder(s). In connection with the distribution of CVRs to the Holders, the Company, the Paying Agent and the Representative shall be entitled to make reasonable estimations of the Company&#8217;s &#8220;earnings and profits&#8221; (as such term is defined for federal income tax purposes (including the adjustments described in Section&#160;312 of the Code), and shall be entitled to adopt the withholding tax procedures described in Treasury Regulation <span style="white-space:nowrap">Section&#160;1.1441-3(c)(2)(ii)</span> in connection with the foregoing). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE 3 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THE RIGHTS AGENT </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.1 </span><span style="font-weight:bold"><span style="text-decoration:underline">Certain Duties and Responsibilities</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent such liability arises as a result of the willful misconduct, bad faith or gross negligence of the Rights Agent (in each case as determined by a final <span style="white-space:nowrap">non-appealable</span> judgment of court of competent jurisdiction). Notwithstanding anything in this Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees paid by the Company to the Rights Agent in connection with this Agreement (but not including reimbursable expenses and other charges) during the eighteen (18)&#160;months immediately preceding the event for which recovery from the Rights Agent is being sought. Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company or Korsana. The Rights Agent may (but shall not be required to) enforce all rights of action under this Agreement and any related claim, action, suit, audit, investigation or proceeding instituted by the Rights Agent may be brought in its name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on the CVR Register. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.2 </span><span style="font-weight:bold"><span style="text-decoration:underline">Certain Rights of Rights Agent</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent may rely and will be protected by the Company in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other paper or document reasonably believed by it to be genuine and to have been signed or presented by or on behalf of the Company or, with respect to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.3(d)</span>, the Representative. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking or omitting any action hereunder, the Rights Agent may rely upon an Officer&#8217;s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of bad faith, gross negligence or willful misconduct (each as determined by a final <span style="white-space:nowrap">non-appealable</span> judgment of a court of competent jurisdiction) on its part, not incur any liability and shall be held harmless by the Company for or in respect of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence of bad faith, gross negligence or willful misconduct (in each case, as determined by a final, <span style="white-space:nowrap">non-appealable</span> judgment of a court of competent jurisdiction) on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss, liability, damage, judgment, fine, penalty, cost or expense (each, a &#8220;<span style="font-weight:bold">Loss</span>&#8221;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#8217;s performance of its obligations under this Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection with the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been determined by a final <span style="white-space:nowrap">non-appealable</span> decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s gross negligence, bad faith or willful misconduct; provided that this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2(g)</span> shall not apply with respect to income, receipt, franchise or similar Taxes levied against the Rights Agent by a Governmental Authority. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The Company agrees (i)&#160;to pay the fees of the Rights Agent in connection with the Rights Agent&#8217;s performance of its obligations hereunder as set forth in <span style="text-decoration:underline">Exhibit A</span> and agreed upon in writing by the Rights Agent and the Company on or prior to the date of this Agreement, and (ii)&#160;to reimburse the Rights Agent for all reasonable and documented <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder, including all stamp and transfer Taxes (and excluding for the avoidance of doubt, any income, receipt, franchise or similar Taxes levied against the Rights Agent by a Governmental Authority) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that the Company will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent for the fees of counsel in connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of Section&#160;2.4(a), Section&#160;2.4(b) or Section&#160;3.2(g), if the Company is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Rights Agent shall have no responsibility to the Company, any holders of CVRs, any holders of Company Shares or any other Person for interest or earnings on any moneys held by the Rights Agent pursuant to this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Rights Agent shall not be subject to, nor be required to comply with, or determine if any Person has complied with, the Merger Agreement or any other agreement between or among any the Company, Korsana or Holders, even though reference thereto may be made in this Agreement, or to comply with any notice, instruction, direction, request or other communication, paper or document other than as expressly set forth in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Subject to applicable Law, (i)&#160;the Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may buy, sell or deal in any securities of the Company or Korsana or become peculiarly interested in any transaction in which such parties may be interested, or contract with or lend money to such parties or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement, and (ii)&#160;nothing herein will preclude the Rights Agent from acting in any other capacity for the Company or for any other Person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) In the event the Rights Agent reasonably believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Rights Agent hereunder, the Rights Agent shall, as soon as practicable, provide notice to the Company, and the Rights Agent, may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to the Company or any Holder or any other Person for refraining from taking such action, unless the Rights Agent receives written instructions from the Company or such Holder or other Person which eliminate such ambiguity or uncertainty to the reasonable satisfaction of the Rights Agent; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to the Company or Korsana resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Rights Agent shall not be liable for or by reason of any statements of fact or recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by the Company only. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) The Rights Agent shall act hereunder solely as agent for the Company and shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by the Company, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (a)&#160;any guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing; or (b)&#160;any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) The Rights Agent shall not be liable or responsible for any failure of the Company to comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable regulation or law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The obligations of the Company and the rights of the Rights Agent under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2</span>, <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.1</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4</span> shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.3 </span><span style="font-weight:bold"><span style="text-decoration:underline">Resignation and Removal; Appointment of Successor</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent may resign at any time by written notice to the Company. Any such resignation notice shall specify the date on which such resignation will take effect (which shall be at least thirty (30)&#160;days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (x)&#160;the date so specified and (y)&#160;the appointment of a successor Rights Agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least thirty&#160;(30) days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If the Rights Agent resigns, is removed or becomes incapable of acting, the Company will promptly appoint a qualified successor Rights Agent. Notwithstanding the foregoing, if the Company fails to make such appointment within a period of thirty (30)&#160;days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance of such appointment in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.3(c)</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.4</span>, become the Rights Agent for all purposes hereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2</span>. Each notice will include the name and address of the successor Rights Agent. If the Company fails to send such notice within ten (10)&#160;Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything to the contrary in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.3</span>, unless consented to in writing by the Representative, the Company will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Rights Agent will reasonably cooperate with the Company and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;3.4 </span><span style="font-weight:bold"><span style="text-decoration:underline">Acceptance of Appointment by Successor</span></span>. Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to the Company and to the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; <span style="font-style:italic">provided</span> that upon the request of the Company or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE 4 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">COVENANTS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.1 </span><span style="font-weight:bold"><span style="text-decoration:underline">List of Holders</span></span>. The Company will furnish or cause to be furnished to the Rights Agent, in such form as the Company receives from the Company&#8217;s transfer agent (or other agent performing similar services for the Company), the names and addresses of the Holders within fifteen (15)&#160;Business Days following the Closing Date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.2 </span><span style="font-weight:bold"><span style="text-decoration:underline">No Obligations of Public Company</span></span>. Notwithstanding anything herein to the contrary, and for the avoidance of doubt, (a)&#160;the Company and its Affiliates shall have the power and right to control all aspects of their businesses and operations (and all of their assets and products), and subject to its compliance with the terms of this Agreement, the Company and its Affiliates may exercise or refrain from exercising such power and right as it may deem appropriate and in the best overall interests of the Company and its Affiliates and its and their stockholders, rather than the interest of the Holders, (b)&#160;none of the Company or any of its Affiliates (or any directors, officer, employee, or other representative of the foregoing) owes any fiduciary duty or similar duty to any Holder in respect of the Legacy Assets, and (c)&#160;following the Legacy Assets Transaction Period, the Company shall be permitted to take any action in respect of the Legacy Assets in order to satisfy any wind-down and termination Liabilities of the Legacy Assets. For the avoidance of doubt, during and after the Legacy Assets Transaction Period, the Company shall not be required to use any efforts to pursue one or more Legacy Assets Transactions with respect to the Legacy Assets. Without limiting the foregoing, during the Legacy Assets Transaction Period, the Company shall expend up to $50,000 (the &#8220;<span style="font-weight:bold">CVR Expense Cap</span>&#8221;) for costs and expenses associated with the retention of an employee or consultant of the Company for the purpose of business development efforts related to the Legacy Assets and related activities, including seeking and negotiating and, with the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed), executing Legacy Transaction Agreements, which amount shall be included as a deduction in the determination of the Parent Net Cash in accordance with the Merger Agreement. Notwithstanding anything to the contrary in this Agreement, at the end of the Legacy Assets Transaction Period, the amount, if any, by which the CVR Expense Cap exceeds the aggregate amount of costs and expenses associated with the retention of an employee or consultant of Parent for the purpose of business development efforts related to the Legacy Assets and related activities, including seeking and negotiating and, with the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed), executing Legacy Transaction Agreements, shall constitute Net Proceeds and shall be payable as CVR Proceeds to the Holders in accordance with the terms of this Agreement. Notwithstanding anything to the contrary in this Agreement, the Company shall use commercially reasonable efforts to not, and shall use commercially reasonable efforts to cause its Affiliates not to, (i)&#160;take any action or (ii)&#160;fail to take any action, in either case, with the primary purpose of avoiding, or intended to prevent or materially delay, (x)&#160;during the Legacy Assets Transaction Period, the entry into any Legacy Assets Transaction Agreement or (y)&#160;during the CVR Term, the receipt of Gross Proceeds or the payment of any CVR Proceeds. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.3 </span><span style="font-weight:bold"><span style="text-decoration:underline">Books and Records</span></span>. Until the end of the CVR Term, the Company shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable the Rights Agent to confirm the applicable CVR Payment Amount payable hereunder in accordance with the terms specified in this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.4 </span><span style="font-weight:bold"><span style="text-decoration:underline">Audits</span></span>. Until the expiration of this Agreement and for a period of one (1)&#160;year thereafter, the Company shall keep complete and accurate records in sufficient detail to support the accuracy of the payments due hereunder. The Representative shall have the right to cause an independent accounting firm reasonably acceptable to the Company to audit such records for the sole purpose of confirming payments for a period covering not more than the date commencing with the first CVR Payment Date and ending on the last day of the CVR Term. The Company may require such accounting firm to execute a reasonable confidentiality agreement with the Company prior to commencing the audit. The accounting firm shall disclose to Rights Agent or the Representative, as applicable, only whether the reports are correct or not and the specific details concerning any discrepancies. No other information shall be shared. Such audits may be conducted during normal business hours upon reasonable prior written notice to the Company, but no more than frequently than once per year. No accounting period of the Company shall be subject to audit more than one time by the Representative, as applicable, unless after an accounting period has been audited by the Representative, as applicable, the Company restates its financial results for such accounting period, in which event the Representative, as applicable, may conduct a second audit of such accounting period in accordance with this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.4</span>. Adjustments (including remittances of underpayments or overpayments disclosed by such audit) shall be made by the Company to reflect the results of such audit, which adjustments shall be paid promptly following receipt of an invoice therefor. Whenever such an adjustment is made, the Company shall promptly prepare a certificate setting forth such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjustment, and a brief, reasonably detailed statement of the facts, computation and methodology accounting for such adjustment to the extent not already reflected in the audit report and promptly file with the Rights Agent a copy of such report and promptly deliver to the Rights Agent a revised CVR Payment Notice for the applicable CVR Proceeds. The Rights Agent shall be fully protected in relying on any such report and on any adjustment or statement therein contained and shall have no duty or liability with respect to, and shall not be deemed to have knowledge of any such adjustment or any such event unless and until it shall have received such report. The Representative shall bear the full cost and expense of such audit unless such audit discloses an underpayment by the Company of ten percent (10%) or more of the CVR Payment Amount due under this Agreement, in which case the Company shall bear the full cost and expense of such audit. The Rights Agent shall be entitled to rely on any audit report delivered by the independent accounting firm pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.4</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.5 </span><span style="font-weight:bold"><span style="text-decoration:underline">Representative</span></span>. Certain Holders may enter into an engagement agreement (the &#8220;Representative Engagement Agreement&#8221;) with the Representative and provide direction to the Representative in connection with its services under this Agreement and the Representative Engagement Agreement (such Holders, including their individual representatives, collectively hereinafter referred to as the &#8220;Advisory Group&#8221;). Neither the Representative nor its members, managers, directors, officers, contractors, agents and employees nor any member of the Advisory Group (collectively, the &#8220;Representative Group&#8221;), shall be liable to any Holder for any action or failure to act in connection with the acceptance or administration of the Representative&#8217;s responsibilities hereunder or under the Representative Engagement Agreement, unless and only to the extent such action or failure to act constitutes gross negligence, fraud, willful breach or willful or intentional misconduct. The Holders shall indemnify, defend and hold harmless the Representative Group from and against any and all losses, claims, damages, liabilities, fees, costs, expenses (including fees, disbursements and costs of counsel and other skilled professionals and in connection with seeking recovery from insurers), judgments, fines, amounts paid in settlement (collectively, the &#8220;Representative Expenses&#8221;) incurred without gross negligence, fraud, willful breach or willful or intentional misconduct on the part of the Representative and arising out of or in connection with the acceptance or administration of its duties hereunder or its duties (or any duties of any member of the Advisory Group) under the Representative Engagement Agreement. Such Representative Expenses may be recovered first, from the Representative Expense Fund, second, from any distribution of CVR Payment Amounts otherwise distributable to the Holders at the time of distribution, and third, directly from the Holders. The immunities and rights to indemnification shall survive the resignation or removal of the Representative or its duties (or any duties of any member of the Advisory Group) under the Representative Engagement Agreement or any termination of this Agreement or the Representative Engagement Agreement. The Holders acknowledge that the Representative shall not be required to expend or risk its own funds or otherwise incur any financial liability in the exercise or performance of any of its powers, rights, duties or privileges or pursuant to this Agreement or the transactions contemplated hereby or thereby. Furthermore, the Representative shall not be required to take any action unless the Representative has been provided with funds, security or indemnities which, in its reasonable determination, are sufficient to protect the Representative against the costs, expenses and liabilities which may be incurred by the Representative in performing such actions. The powers, immunities and rights to indemnification granted to the Representative Group hereunder: (i)&#160;are coupled with an interest and shall be irrevocable and survive the death, incompetence, bankruptcy or liquidation of any Holder and shall be binding on any successor thereto, and (ii)&#160;shall survive the delivery of an assignment by any Holder of the whole or any fraction of his, her or its interest in the CVR Proceeds. Following the designation of the Representative, the Company shall promptly wire the Representative Expense Amount to the Representative, which shall be held by the Representative in a segregated client account and shall be used (A)&#160;for the purposes of paying directly or reimbursing the Representative for any Representative Expenses incurred pursuant to this Agreement or the Representative Engagement Agreement, or (B)&#160;as otherwise determined by the Advisory Group (such fund, the &#8220;Representative Expense Fund&#8221;). The Representative is not providing any investment supervision, recommendations or advice and shall have no responsibility or liability for any loss of principal of the Representative Expense Fund other than as a result of its gross negligence, fraud, willful breach or willful or intentional misconduct. The Representative is not acting as a withholding agent or in any similar capacity in connection with the Representative Expense Fund and has no tax reporting or income distribution obligations with respect to the Representative Expense Fund. The Holders will not receive any interest on the Representative </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Expense Fund and assign to the Representative any such interest. Subject to the prior written approval of the Advisory Group, the Representative may instruct the Rights Agent to contribute funds to the Representative Expense Fund from the CVR Payment Amounts otherwise distributable to any Holders, on a pro rata basis. As soon as reasonably determined by the Representative that the Representative Expense Fund is no longer required to be withheld, the Representative shall distribute the remaining Representative Expense Fund, if any, to the Rights Agent for further distribution to the Holders in such proportions as though the amount of the remaining Representative Expense Fund constituted CVR Proceeds hereunder (provided, that, any amounts remaining from the amounts contributed to the Representative Expense Fund from the CVR Payment Amounts otherwise distributable to any Holders pursuant to the previous sentence shall first be distributed to such Holders in proportion to such Holders&#8217; respective contributions). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.6 </span><span style="font-weight:bold"><span style="text-decoration:underline">Payment of CVR Payment Amounts</span></span>. The Company shall, promptly following receipt of a payment of CVR Proceeds, deposit with the Rights Agent, for payment to the Holders in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4</span>, the aggregate amount necessary to pay the CVR Payment Amount to each Holder; provided, that the Company shall aggregate multiple payments of CVR Proceeds until the aggregate amount reaches $250,000 and that such exception does not apply to the final payment of CVR Proceeds which shall occur no later than thirty (30)&#160;days following the applicable CVR Payment Date; provided, that the Company shall provide the Representative with written notice within five (5)&#160;Business Days each time Gross Proceeds are received but held pending the aggregation threshold set forth in this proviso. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;4.7 </span><span style="font-weight:bold"><span style="text-decoration:underline">Prohibited Actions</span></span>. Unless approved by the Representative (not to be unreasonably withheld, conditioned or delayed), prior to the end of the CVR Term, the Company shall not grant any lien, security interest, pledge or similar interest solely in respect of any Legacy Assets or any Net Proceeds separate and apart from any other assets of the Company. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE 5 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDMENTS </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.1 </span><span style="font-weight:bold"><span style="text-decoration:underline">Amendments Without Consent of Holders or Rights Agent</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company, at any time and from time to time, may (without the consent of any Person, other than the Rights Agent, with such consent not to be unreasonably withheld, conditioned or delayed) enter into one or more amendments to this Agreement for any of the following purposes: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) to evidence the succession of another person to the Company and the assumption of any such successor of the covenants of the Company; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) to add to the covenants of the Company such further covenants, restrictions, conditions or provisions as the Company and the Rights Agent will consider to be for the protection and benefit of the Holders; <span style="font-style:italic">provided</span> that in each case, such provisions do not adversely affect the interests of the Holders; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to cure any ambiguity, to correct or supplement any provision in this Agreement that may be defective or inconsistent with any other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement; <span style="font-style:italic">provided</span> that, in each case, such provisions do not adversely affect the interests of the Holders; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act and the rules and regulations promulgated thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) as may be necessary or appropriate to ensure that the Company is not required to produce a prospectus or an admission document in order to comply with applicable Law; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) to cancel the CVRs (i)&#160;in the event that any Holder has abandoned its rights in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.6</span>, (ii) in order to give effect to the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.7</span> or (iii)&#160;following a transfer of such CVRs to the Company or its Affiliates in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.2</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.3</span>; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) as may be necessary or appropriate to ensure that the Company complies with applicable Law; or </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) to effect any other amendment to this Agreement for the purpose of adding, eliminating or changing any provisions of this Agreement, <span style="font-style:italic">provided</span> that, in each case, such additions, eliminations or changes do not adversely affect the interests of the Holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the execution by the Company of any amendment pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span>, the Company will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.2 </span><span style="font-weight:bold"><span style="text-decoration:underline">Amendments with Consent of Holders</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In addition to any amendments to this Agreement that may be made by the Company without the consent of any Holder pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1</span>, with the consent of the Representative (whether evidenced in a writing or taken at a meeting of the Holders), the Company and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the execution by the Company and the Rights Agent of any amendment pursuant to the provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.2</span>, the Company will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;5.3 </span><span style="font-weight:bold"><span style="text-decoration:underline">Effect of Amendments</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the execution of any amendment under this <span style="text-decoration:underline">Article 5</span>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of the Company which states that the proposed supplement or amendment is in compliance with the terms of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5</span>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ARTICLE 6 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">MISCELLANEOUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.1 </span><span style="font-weight:bold"><span style="text-decoration:underline">Notices to Rights Agent and to the Company</span></span>. All notices, requests and other communications (each, a &#8220;<span style="font-weight:bold">Notice</span>&#8221;) to any party hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery in person, by FedEx or other internationally recognized overnight courier service or (c)&#160;on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to the Rights Agent, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[__] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[__] </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[__] </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[__] </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to the Company, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Korsana Biosciences, Inc. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">203 Crescent Street, Buildings 3/3A/4, Suite 503 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Waltham, Massachusetts 02453 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Maddy Zeylikman </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: <span style="text-decoration:underline">maddy.zeylikman@korsana.com</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy, which shall not constitute notice, to: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&#160;&amp; Crutcher LLP </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">One Embarcadero Center, Suite 2600 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94111 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Ryan Murr, Branden Berns, Evan Shepherd </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: rmurr@gibsondunn.com, bberns@gibsondunn.com, eshepherd@gibsondunn.com </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address or facsimile number as such party may hereafter specify for the purpose by notice to the other parties hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.2 </span><span style="font-weight:bold"><span style="text-decoration:underline">Notice to Holders</span></span>. All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other Holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.3 </span><span style="font-weight:bold"><span style="text-decoration:underline">Entire Agreement</span></span>. As between the Company and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.4 </span><span style="font-weight:bold"><span style="text-decoration:underline">Merger or Consolidation or Change of Name of Rights Agent</span></span>. Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.3</span>. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.5 </span><span style="font-weight:bold"><span style="text-decoration:underline">Successors and Assigns</span></span>. This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, the Company and the Rights Agent and their respective successors and assigns. Except for assignments pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span>, the Rights Agent may not assign this Agreement without the Company&#8217;s prior written consent. Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;5.1(a)(ii</span>) and <span style="text-decoration:underline">Article 6</span> hereof, the Company may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more of its Affiliates or to any Person with whom the Company is merged or consolidated, or any entity resulting from any merger or consolidation to which the Company shall be a party (each, an &#8220;<span style="font-weight:bold">Assignee</span>&#8221;); <span style="font-style:italic">provided</span>, that in connection with any assignment to an Assignee, the Company shall agree to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remain liable for the performance by the Company of its obligations hereunder (to the extent the Company exists following such assignment). The Company or an Assignee may not otherwise assign this Agreement without the prior consent of the Representative (such consent not to be unreasonably withheld, conditioned or delayed). Any attempted assignment of this Agreement in violation of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5</span> will be void <span style="font-style:italic">ab initio</span> and of no effect. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.6 </span><span style="font-weight:bold"><span style="text-decoration:underline">Benefits of Agreement; Action by Representative</span></span>. Nothing in this Agreement, express or implied, will give to any Person (other than the Company, the Rights Agent, the Holders and their respective permitted successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Company, the Rights Agent, the Holders and their permitted successors and assigns. The Holders will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Representative (at the instruction of the Acting Holders) will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.7 </span><span style="font-weight:bold"><span style="text-decoration:underline">Governing Law</span></span>. This Agreement and the CVRs will be governed by, and construed in accordance with, the laws of the State of Delaware without regard to the conflicts of law rules of such state. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.8 </span><span style="font-weight:bold"><span style="text-decoration:underline">Jurisdiction</span></span>. In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (a)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware; (b)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.8</span>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; and (e)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.1</span> or <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2</span> of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;6.9 <span style="text-decoration:underline">WAIVER OF JURY TRIAL</span>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I)&#160;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II)&#160;EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III)&#160;EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV)&#160;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <span style="text-decoration:underline">SECTION 6.9</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.10 </span><span style="font-weight:bold"><span style="text-decoration:underline">Severability Clause</span></span>. In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written Notice to the Company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.11 </span><span style="font-weight:bold"><span style="text-decoration:underline">Counterparts; Effectiveness</span></span>. This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.12 </span><span style="font-weight:bold"><span style="text-decoration:underline">Termination</span></span>. This Agreement will automatically terminate and be of no further force or effect and, except as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;3.2</span>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor, upon the expiration of the CVR Term. The termination of this Agreement will not affect or limit the right of Holders to receive the CVR Proceeds under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;2.4</span> to the extent earned and received within the time frames set forth herein and prior to the termination of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement until such payment of CVR Proceeds have been made, if applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.13 </span><span style="font-weight:bold"><span style="text-decoration:underline">Funds</span></span>. All funds received by Rights Agent under this Agreement that are to be distributed or applied by Rights Agent in the performance of services hereunder (the &#8220;<span style="font-weight:bold">Funds</span>&#8221;) shall be held by the Rights Agent, as agent for the Company, and deposited in one or more bank accounts to be maintained by the Rights Agent in its name as agent for the Company. Until paid pursuant to the terms of this Agreement, the Rights Agent shall hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1&#160;billion or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&#8217;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall, in the absence of bad faith, gross negligence or willful misconduct (each as determined by a final <span style="white-space:nowrap">non-appealable</span> judgment of a court of competent jurisdiction) on its part, have no responsibility or liability for any diminution of the Funds that may result from any deposit made by the Rights Agent in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party. The Rights Agent may from time to time receive interest, dividends or other earnings in connection with such deposits. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.14 </span><span style="font-weight:bold"><span style="text-decoration:underline">Further Assurance by Company</span></span>. The Company agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, documents, instruments and assurances as may reasonably be required or requested by the Rights Agent or the Representative for the carrying out or performing by the Rights Agent or the Representative of the provisions of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Section</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;6.15 </span><span style="font-weight:bold"><span style="text-decoration:underline">Construction</span></span>. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, whenever the context requires: singular terms will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and feminine genders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words &#8220;without limitation.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Unless stated otherwise, &#8220;Article&#8221; and &#8220;Section&#8221; followed by a number or letter mean and refer to the specified Article or Section of this Agreement. The term &#8220;Agreement&#8221; and any reference in this Agreement to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this Agreement or any other agreement or document includes, and is a reference to, this Agreement or such other agreement or document as it may have been, or may from time to time be, amended, restated, replaced, supplemented or novated and includes all schedules to it. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:30 p.m. on the last day of the period, if the last day of the period is a Business Day, or at 4:30 p.m. on the next Business Day if the last day of the period is not a Business Day. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless otherwise specified. The parties hereto and the Company have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) All references herein to &#8220;$&#8221; are to United States Dollars. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of page intentionally left blank</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">IN WITNESS WHEREOF</span>, each of the parties has caused this Agreement to be executed as of the day and year first above written. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CYCLERION THERAPEUTICS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#8195;&#8195;&#8195;]</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Signature Page to CVR Agreement</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Schedule 1.1 </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Schedule 1.2 </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_52">Annex G </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM OF ARTICLES OF AMENDMENT TO THE RESTATED ARTICLES OF ORGANIZATION OF CYCLERION THERAPEUTICS, INC. TO DESIGNATE SERIES B PREFERRED STOCK. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g55a01.jpg" alt="LOGO" style="width:6.31947in;height:8.17613in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">D The Commonwealth of Massachusetts William Francis Galvin PC Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 FORM MUST BE TYPED Articles of Amendment FORM MUST BE TYPED (General Laws Chapter 156D, Section 10.06; 950 CMR 113.34) (1) Exact name of corporation: (2) Registered o? ce address: (number, street, city or town, state, zip code) (3) Th ese articles of amendment a? ect article(s: (specify the number(s) of article(s) being amended (I-VI)) (4) Date adopted: (month, day, year) (5) Approved by: (check appropriate box) &#174; the incorporators. &#174; the board of directors without shareholder approval and shareholder approval was not required. &#174; the board of directors and the shareholders in the manner required by law and the articles of organization. (6) State the article number and the text of the amendment. Unless contained in the text of the amendment, state the provisions for implementing the exchange, reclassi? cation or cancellation of issued shares. Article I is being amended and restated in its entirety to read as follows: &#8220;The exact name of the corporation is [] (the &#8220;Corporation&#8221;).&#8221; Article III is being amended to indicate that [ ] shares of Preferred Stock have been designated as Series B Non-Voting Convertible Preferred Stock, as set forth in Article IV. Article IV is being amended as set forth in Attachment IV to add the preferences, rights and limitations of Series B Non-Voting Convertible Preferred Stock. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g55a02.jpg" alt="LOGO" style="width:6.31947in;height:8.17613in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">To change the number of shares and the par value, * if any, of any type, or to designate a class or series, of stock, or change a designation of class or series of stock, which the corporation is authorized to issue, complete the following: Total authorized prior to amendment: WITHOUT PAR VALUE WITH PAR VALUE TYPE NUMBER OF SHARES TYPE NUMBER OF SHARES PAR VALUE Total authorized after amendment: WITHOUT PAR VALUE WITH PAR VALUE TYPE NUMBER OF SHARES TYPE NUMBER OF SHARES PAR VALUE (7) Th e amendment shall be eff ective at the time and on the date approved by the Division, unless a later eff ective date not more than 90 days from the date and time of fi ling is specifi ed: *G.L. Chapter 156D eliminates the concept of par value, however a corporation may specify par value in Article III. See G.L. Chapter 156D, Section 6.21, and the comments relative thereto. Series A Convertible Preferred Series A Convertible Preferred 500,000 Series B Non-Voting Convertible Preferred </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g55a03.jpg" alt="LOGO" style="width:6.31947in;height:8.17613in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">Signed by: , (signature of authorized individual) &#174; Chairman of the board of directors, &#174; President, &#174; Other o?cer, &#174; Court-appointed ?duciary, on this day of , . </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g55z04.jpg" alt="LOGO" style="width:6.31947in;height:8.17613in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">COMMONWEALTH OF MASSACHUSETTS William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Articles of Amendment (General Laws Chapter 156D, Section 10.06; 950 CMR 113.34) I hereby certify that upon examination of these articles of amendment, it appears that the provisions of the General Laws relative thereto have been complied with, and the ? ling fee in the amount of $ having been paid, said articles are deemed to have been fi led with me this day of, 20 , at a.m./p.m. time E? ective date: (must be within 90 days of date submitted) WILLIAM FRANCIS GALVIN Secretary of the Commonwealth Filing fee: Minimum ? ling fee $100 per article amended, stock increases $100 per 100,000 shares, plus $100 for each additional 100,000 shares or any fraction thereof. Examiner TO BE FILLED IN BY CORPORATION Name approval Contact Information: C M Telephone: Email: Upon ? ling, a copy of this ? ling will be available at www.sec.state.ma.us/cor. If the document is rejected, a copy of the rejection sheet and rejected document will be available in the rejected queue. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Confidential </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right"><span style="font-style:italic">Final Form </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ATTACHMENT IV </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DESCRIPTION OF SERIES B CONVERTIBLE PREFERRED STOCK </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">E.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="text-decoration:underline">Designation and Amount of Series B Preferred Stock</span>. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This series of Preferred Stock shall be designated as &#8220;Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock&#8221; and the number of shares constituting the Corporation&#8217;s Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock</span></span>&#8221;) shall be [__] shares, which are being issued pursuant to the terms of the Agreement and Plan of Merger, dated as of the date hereof, by and among the Corporation, Cariboos Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Corporation, Cariboos Merger Sub II, LLC, a Delaware limited liability company and Korsana Biosciences, Inc., a Delaware corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Merger Agreement</span></span>&#8221;). The Series B <span style="white-space:nowrap">Non-VotingPreferred</span> Stock shall have the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in these Restated Articles of Organization that are applicable to the Preferred Stock of all classes and series, set forth below: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1. <span style="text-decoration:underline">Definitions</span>. For the purposes of this section, the following terms shall have the following meanings: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Affiliate</span></span>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act of 1933, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Business Day</span></span>&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to&#160;close. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Buy-In</span></span></span>&#8221; shall have the meaning set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.2</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Closing Sale Price</span></span>&#8221; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors of the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Commission</span></span>&#8221; means the United States Securities and Exchange Commission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221; means the Corporation&#8217;s common stock, no par value, and stock of any other class of securities into which such securities may hereafter be reclassified or changed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Conversion Shares</span></span>&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock in accordance with the terms hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Exchange Act</span></span>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Holder</span></span>&#8221; means a holder of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Person</span></span>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Trading Day</span></span>&#8221; means a day on which the principal Trading Market is open for business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-weight:bold"><span style="font-style:italic">Trading Market</span></span>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2. <span style="text-decoration:underline">Designation, Amount and Par Value</span>. The series of Preferred Stock shall be designated as the Corporation&#8217;s Series B <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock</span></span>&#8221;) and the number of shares so designated shall be [__]. Each share of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall have no par value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3. <span style="text-decoration:underline">Dividends</span>. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock (on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-if-converted-to-Common-Stock</span></span></span></span> basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4. <span style="text-decoration:underline">Voting Rights</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1 Except as otherwise provided herein or as otherwise required by the the Massachusetts Business Corporation Act (M.G.L. c. 156D) (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Mass Law</span></span>&#8221;), the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall have no voting rights. However, as long as any shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock or alter or amend the rights, powers, preferences and other terms of the Preferred Stock set forth herein (this &#8220;<span style="font-weight:bold"><span style="font-style:italic">Description of Rights</span></span>&#8221;), amend or repeal any provision of, or add any provision to, the Articles of Incorporation (including this Description of Rights) or Amended and Restated Bylaws of the Corporation, or file any articles of amendment, descriptions of rights, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Articles of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, (iii)&#160;at any time while at least 30% of the originally issued Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock remains issued and outstanding, (A)&#160;consummate (I) any Fundamental Transaction (as defined below) or (II)&#160;any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a majority of the capital stock of the Corporation immediately after such transaction, (B)&#160;increase the size of the Board of Directors of the Corporation, (C)&#160;adopt, amend or repeal any written delegation of authority policy, corporate authority matrix or similar document, framework or schedule unless such adoption, amendment or repeal has been approved by the unanimous vote of the Board of Directors of the Corporation or (D)&#160;retain or replace the Corporation&#8217;s registered independent public accounting firm, independent compensation consultant or corporate counsel or (iv)&#160;enter into any agreement with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to any of the foregoing. Holders of shares of Common Stock acquired upon the conversion of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.2 Any vote required or permitted under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.1</span> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting, provided that the consent is executed by Holders representing a majority of the outstanding shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3 <span style="text-decoration:underline">Election of Directors</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">4.3.1 At all times when at least 30% of the originally issued Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock remains issued and outstanding, (i)&#160;the holders of record of the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, exclusively and voting together as a separate class on an <span style="white-space:nowrap">as-converted</span> to Common Stock basis, shall be entitled to elect four directors of the Corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Preferred </span></span><span style="font-weight:bold"><span style="font-style:italic">Directors</span></span>&#8221;); and (iii)&#160;the holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock), exclusively and voting together as a single class on an <span style="white-space:nowrap">as-converted</span> to Common Stock basis, shall be entitled to elect the balance of the total number of directors of the Corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">At-Large</span> Directors</span></span>&#8221;); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, for administrative convenience, the initial Preferred Directors may also be appointed by the Board of Directors in connection with the approval of the initial issuance of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock without a separate action by the holders of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">4.3.2 Any Preferred Director elected as provided in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.3.1</span> may be removed without cause by, and only by, the affirmative vote of the holders of a majority of the shares of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">4.3.3 If the holders of shares of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.3.1</span> (and to the extent any of such directorships is not otherwise filled by a director appointed in accordance with the proviso in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.3.1</span>), then any directorship not so filled shall remain vacant until such time as the holders of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock fill such directorship in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;4.3.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">4.3.4 At any meeting held for the purpose of electing a Preferred Director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall constitute a quorum for the purpose of electing such Preferred Director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">4.3.5 Each Preferred Director shall be entitled to [three] votes on each matter presented to the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5. <span style="text-decoration:underline">Rank; Liquidation</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">5.1 The Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall rank on parity with the Common Stock, the Corporation&#8217;s Series A Convertible Preferred Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">5.2 Upon any liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Corporation, whether voluntary or involuntary (a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Liquidation</span></span>&#8221;), each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid <span style="font-style:italic">pari passu</span> with all holders of Common Stock, plus </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall be treated as if it were a Liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6. <span style="text-decoration:underline">Conversion</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.1 <span style="text-decoration:underline">Reserved</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.2 <span style="text-decoration:underline">Conversion at Option of Holder</span>. Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span> and <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.3</span>, each share of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (each, an &#8220;<span style="font-weight:bold"><span style="font-style:italic">Optional Conversion</span></span>&#8221;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <span style="font-weight:bold"><span style="text-decoration:underline">Annex A</span></span> (a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Notice of Conversion</span></span>&#8221;), duly completed and executed. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;<span style="font-weight:bold"><span style="font-style:italic">DTC</span></span>&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;<span style="font-weight:bold"><span style="font-style:italic">DWAC Delivery</span></span>&#8221;). The date on which an Optional Conversion shall be deemed effective (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Conversion Date</span></span>&#8221;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2)&#160;Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.3 <span style="text-decoration:underline">Conversion Ratio</span>. The &#8220;<span style="font-weight:bold"><span style="font-style:italic">Conversion Ratio</span></span>&#8221; for each share of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Conversion</span></span>&#8221;) of each share of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.4 <span style="text-decoration:underline">Beneficial Ownership Limitation</span>. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, and a Holder shall not have the right to convert any portion of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.2</span>, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in this Description of Rights) with respect to the Series B Preferred Stock, such Holder (or any of such Holder&#8217;s Affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section&#160;13(d) or Section&#160;16 of the Exchange Act and the applicable rules and regulations of the Commission, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;<span style="font-weight:bold"><span style="font-style:italic">Attribution Parties</span></span>&#8221;)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock subject to the Notice of Conversion, with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span>, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#8220;beneficial ownership&#8221; and &#8220;beneficially own&#8221; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span>, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A)&#160;the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B)&#160;a more recent public announcement by the Corporation that is filed with the Commission, or (C)&#160;a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two (2)&#160;Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;<span style="font-weight:bold"><span style="font-style:italic">Beneficial Ownership Limitation</span></span>&#8221; shall initially be set at the discretion of each Holder to a percentage designated by such Holder on its signature page to the Purchase Agreement or otherwise between 0% and 19.99% of the number of shares of the Common Stock outstanding or deemed to be outstanding as of the applicable measurement date, and such percentage shall be set at 19.99% for any Holder that does not make such designation in the Purchase Agreement or otherwise. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation (email being sufficient), (i) the Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage, not to exceed 19.99%, which increase will not be effective until the sixty-first (61st) day after such written notice is delivered to the Corporation, and (ii)&#160;the Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage. Upon such a change by a Holder of the Beneficial Ownership Limitation, not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span>. Notwithstanding the foregoing, (x)&#160;at any time following notice of a Fundamental Transaction, the Holder may waive and/or change the Beneficial Ownership Limitation effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation and (y)&#160;at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&#8217;s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&#8217;s Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4 </span>shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Securities in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Purchaser for any purpose including for purposes of Section&#160;13(d) or Rule <span style="white-space:nowrap">16a-1(a)(1)</span> of the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.5 <span style="text-decoration:underline">Mechanics of Conversion</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">6.5.1 <span style="text-decoration:underline">Delivery of Certificate or Electronic Issuance</span>. Upon Conversion not later than two (2)&#160;Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Share Delivery Date</span></span>&#8221;), the Corporation shall either: (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, or (b)&#160;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the account of the Holder&#8217;s prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock unsuccessfully tendered for conversion to the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">6.5.2 <span style="text-decoration:underline">Obligation Absolute</span>. Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span>, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span>, in the event a Holder shall elect to convert any or all of its Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span>, issue Conversion Shares upon a properly noticed conversion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">6.5.3 <span style="text-decoration:underline">Cash Settlement</span>. If, at any time after the the initial issuance of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, the Corporation fails to deliver to a Holder such certificate or certificates, or electronically deliver (or instruct its transfer agent to electronically deliver) such shares in the case of a DWAC Delivery, pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span> on or prior to the third (3rd) Trading Day after the Share Delivery Date applicable to such conversion (other than a failure caused by (i)&#160;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&#160;the application of the Beneficial Ownership Limitation, then, unless the Holder has rescinded the applicable Notice of Conversion pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span>, the Corporation shall, at the request of the Holder, pay an amount equal to the Fair Value (as defined below) of such undelivered shares, with such payment to be made within two Business Days from the date of request by the Holder, whereupon the Corporation&#8217;s obligations to deliver such shares underlying the Notice of Conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares. For purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.3</span>, the &#8220;Fair Value&#8221; of shares shall be fixed with reference to the last reported Closing Sale Price on the principal Trading Market on which the Common Stock is listed as of the Trading Day immediately prior to the date on which the Notice of Conversion is delivered to the Corporation. For the avoidance of doubt, the cash settlement provisions set forth in this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.3</span> shall be available irrespective of the reason for the Corporation&#8217;s failure to timely deliver Conversion Shares (other than a failure caused by (i)&#160;materially incorrect or incomplete information provided by Holder to the Corporation or (ii)&#160;the application of the Beneficial Ownership Limitation, including due to limitations set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.6</span>, due to applicable Trading Market rules. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">6.5.4 <span style="text-decoration:underline"><span style="white-space:nowrap">Buy-In</span> on Failure to Timely Deliver Certificates</span>. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span> (other than a failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Buy-In</span></span></span>&#8221;), then the Corporation shall (A)&#160;pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x)&#160;such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&#160;the product of (1)&#160;the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2)&#160;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&#160;at the option of such Holder, either reissue (if surrendered) the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock equal to the number of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span>. For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a <span style="white-space:nowrap">Buy-In</span> with respect to an attempted conversion of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&#160;of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&#160;Trading Days after the occurrence of a <span style="white-space:nowrap">Buy-In,</span> indicating the amounts payable to such Holder in respect of such <span style="white-space:nowrap">Buy-In</span> together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock as required pursuant to the terms hereof or the cash settlement remedy set forth in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.3</span>; provided, however, that the Holder shall not be entitled to both (i)&#160;require the reissuance of the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii)&#160;receive the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.1</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">6.5.5 <span style="text-decoration:underline">Reservation of Shares Issuable Upon Conversion</span>. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7</span>) upon the conversion of all outstanding shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and <span style="white-space:nowrap">non-assessable.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">6.5.6 <span style="text-decoration:underline">Fractional Shares</span>. No fractional shares of Common Stock shall be issued upon conversion of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares of Common Stock that a Holder of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock the Holder seeks to convert into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">6.5.7 <span style="text-decoration:underline">Transfer Taxes</span>. The issuance of certificates for shares of the Common Stock upon conversion of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">6.6 <span style="text-decoration:underline">Status as Stockholder</span>. Upon each Conversion Date, (i)&#160;the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Description of Rights. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7. <span style="text-decoration:underline">Certain Adjustments</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">7.1 <span style="text-decoration:underline">Stock Dividends and Stock Splits</span>. If the Corporation, at any time while this Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock is outstanding: (A)&#160;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock) with respect to the then outstanding shares of Common Stock; (B)&#160;subdivides outstanding shares of Common Stock into a larger number of shares; or (C)&#160;combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.1</span> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">7.2 <span style="text-decoration:underline">Fundamental Transaction</span>. If, at any time while this Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock is outstanding, (A)&#160;the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, <span style="white-space:nowrap">spin-off,</span> share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&#160;any tender offer or exchange offer by the Corporation is completed pursuant to which more than 50% of the Common Stock not held by the Corporation is exchanged for or converted into other securities, cash or property, or (D)&#160;the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.1</span>) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;<span style="font-weight:bold"><span style="font-style:italic">Fundamental Transaction</span></span>&#8221;), then, upon any subsequent conversion of this Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of Common Stock (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Alternate Consideration</span></span>&#8221;). For </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new description of terms, certificate of designations or similar with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7.2</span> and ensuring that this Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">7.3 <span style="text-decoration:underline">Calculations</span>. All calculations under this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7</span> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;7</span>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8. <span style="text-decoration:underline">Redemption</span>. The shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law, nor shall the foregoing limit the Holder&#8217;s rights under <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.5.3</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9. <span style="text-decoration:underline">Transfer</span>. A Holder may transfer any shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock together with the accompanying rights set forth herein, held by such Holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&#160;do and perform, or cause to be done and performed, all such further acts and things, and (ii)&#160;execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;9</span>. The transferee of any shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10. <span style="text-decoration:underline">Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock Register</span>. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;11</span>), a register for the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock, in which the Corporation shall record (i)&#160;the name, address, and electronic mail address of each holder in whose name the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock have been issued and (ii)&#160;the name, address, and electronic mail address of each transferee of any shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock or his, her or its legal representatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11. <span style="text-decoration:underline">Notices</span>. Any notice required or permitted by the provisions of this Description of Rights to be given to a Holder of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the Mass Law, and shall be deemed sent upon such mailing or electronic transmission. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">12. <span style="text-decoration:underline">Book-Entry; Certificates</span>. The Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder&#8217;s shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder&#8217;s shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. To the extent that any shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13. <span style="text-decoration:underline">Lost or Mutilated Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock Certificate</span>. If a Holder&#8217;s Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">14. <span style="text-decoration:underline">Waiver</span>. Any waiver by the Corporation or a Holder of a breach of any provision of this Description of Rights shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Description of Rights or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Description of Rights on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Description of Rights. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Description of Rights to the contrary, any provision contained herein and any right of the Holders of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock granted hereunder may be waived as to all shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">15. <span style="text-decoration:underline">Severability</span>. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">16. <span style="text-decoration:underline">Status of Converted Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock</span>. If any shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. Any share of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">[<span style="font-style:italic">Remainder of Page Intentionally Left Blank</span>] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ANNEX A </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">NOTICE OF CONVERSION </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES B <span style="white-space:nowrap">NON-VOTING</span> CONVERTIBLE PREFERRED STOCK) </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock indicated below, represented in book-entry form, into shares of common stock, no par value (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221;), of Cyclerion Therapeutics, Inc., a Massachusetts corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Corporation</span></span>&#8221;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in the Articles of Amendment (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Articles of Amendment</span></span>&#8221;) filed by the Corporation with the Secretary of the Commonwealth of Massachusetts on [__], 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A)&#160;conversion of the remaining, unconverted Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B)&#160;exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in <span style="text-decoration:underline">Section</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;6.4</span> of the Attachment IV of the Articles of Amendment, is _____%. For purposes hereof, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section&#160;13(d) of the Exchange Act and the applicable regulations of the Commission. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONVERSION CALCULATIONS: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:81%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:18%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date to Effect Conversion:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock owned prior to Conversion:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series B <span style="white-space:nowrap">Non-Voting</span> Preferred Stock to be Converted:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Common Stock to be Issued:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address for delivery of physical certificates:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For DWAC Delivery, please provide the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:100%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Broker No.:<span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Account No.:<span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;</span></p></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[HOLDER]</p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">&#160;</td></tr>
</table></div>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_53">Annex H </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a01.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">D The Commonwealth of Massachusetts William Francis Galvin PC Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 FORM MUST BE TYPED Articles of Amendment FORM MUST BE TYPED (General Laws Chapter 156D, Section&#160;10.06; 950 CMR 113.34) (1) Exact name of corporation:____________________________________________________________________________ (2) Registered o&#64259;&#8195;ce address:______________________________________________________________________________ (number, street, city or town, state, zip code)&#160;(3) Th ese articles of amendment a&#64256; ect article(s): ______________________________________________________________ (specify the number(s) of article(s) being amended <span style="white-space:nowrap">(I-VI))</span> (4) Date adopted: ______________________________________________________________________________________ (month, day, year)&#160;(5) Approved by: (check appropriate box) &#174; the incorporators. &#174; the board of directors without shareholder approval and shareholder approval was not required. &#174; the board of directors and the shareholders in the manner required by law and the articles of organization. (6)&#160;State the article number and the text of the amendment. Unless contained in the text of the amendment, state the provisions for implementing the exchange, reclassifi cation or cancellation of issued shares. P.C. c156ds1006950c11334 01/13/05 </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a02.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">To change the number of shares and the par value, * if any, of any type, or to designate a class or series, of stock, or change a designation of class or series of stock, which the corporation is authorized to issue, complete the following: Total authorized prior to amendment: WITHOUT PAR VALUE WITH PAR VALUE TYPE NUMBER OF SHARES TYPE NUMBER OF SHARES PAR VALUE Common 400,000,000 Preferred 99,500,000 Series A Convertible Preferred 500,000 Series B Convertible Preferred [&#8226;] Total authorized after amendment: WITHOUT PAR VALUE WITH PAR VALUE TYPE NUMBER OF SHARES TYPE NUMBER OF SHARES PAR VALUE Common [&#8226;] Preferred 99,500,000 Series A Convertible Preferred 500,000 (7) Th e amendment shall be eff ective at the time and on the date approved by the Division, unless a later eff ective date not more than 90 days from the date and time of fi ling is specifi ed: *G.L. Chapter 156D eliminates the concept of par value, however a corporation may specify par value in Article III. See G.L. Chapter 156D, Section 6.21, and the comments relative thereto. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a03.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">Signe d by: ___________________________________________________________________________________________, (signature of authorized individual) &#174; Chairman of the board of directors, &#174; President, &#174; Other o&#64259;&#8195;cer, &#174; Court-appointed fi duciary, on this _________________________day of_________________________________________ , _____________________. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a04.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">COMMONWEALTH OF MASSACHUSETTS William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Articles of Amendment (General Laws Chapter 156D, Section&#160;10.06; 950 CMR 113.34) I hereby certify that upon examination of these articles of amendment, it appears that the provisions of the General Laws relative thereto have been complied with, and the fi ling fee in the amount of $______ having been paid, said articles are deemed to have been fi led with me this _______ day of _____________, 20_____ , at _______a.m./p.m. time E&#64256; ective date:_________________________________________________ (must be within 90 days of date submitted) WILLIAM FRANCIS GALVIN Secretary of the Commonwealth Filing fee: Minimum fi ling fee $100 per article amended, stock increases $100 per 100,000 shares, plus $100 for each additional 100,000 shares or any fraction thereof. Examiner TO BE FILLED IN BY CORPORATION Name approval Contact Information: C ___________________________________________________________ M ___________________________________________________________ ___________________________________________________________ Telephone: ___________________________________________________ Email: ______________________________________________________ Upon fi ling, a copy of this fi ling will be available at www.sec.state.ma.us/cor. If the document is rejected, a copy of the rejection sheet and rejected document will be available in the rejected queue. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_54">ANNEX I </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a05.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">D The Commonwealth of Massachusetts William Francis Galvin PC Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 FORM MUST BE TYPED Articles of Amendment FORM MUST BE TYPED (General Laws Chapter 156D, Section&#160;10.06; 950 CMR 113.34) (1) Exact name of corporation:____________________________________________________________________________ (2) Registered office address:______________________________________________________________________________ (number, street, city or town, state, zip code)&#160;(3) Th ese articles of amendment aff ect article(s): ______________________________________________________________ (specify the number(s) of article(s) being amended <span style="white-space:nowrap">(I-VI))</span> (4) Date adopted: ______________________________________________________________________________________ (month, day, year)&#160;(5) Approved by: (check appropriate box) &#174; the incorporators. &#174; the board of directors without shareholder approval and shareholder approval was not required. &#174; the board of directors and the shareholders in the manner required by law and the articles of organization. (6)&#160;State the article number and the text of the amendment. Unless contained in the text of the amendment, state the provisions for implementing the exchange, reclassifi cation or cancellation of issued shares. P.C. c156ds1006950c11334 01/13/05 </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a06.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">To change the number of shares and the par value, * if any, of any type, or to designate a class or series, of stock, or change a designation of class or series of stock, which the corporation is authorized to issue, complete the following: Total authorized prior to amendment: WITHOUT PAR VALUE TYPE NUMBER OF SHARES Common 400,000,000 Preferred 99,500,000 500,000 TYPE NUMBER OF SHARES PAR VALUE Total authorized after amendment: WITHOUT PAR VALUE WITH PAR VALUE TYPE NUMBER OF SHARES TYPE NUMBER OF SHARES PAR VALUE Common [&#8226;] Preferred 99,500,000 [&#8226;] (7) Th e amendment shall be eff ective at the time and on the date approved by the Division, unless a later eff ective date not more than 90 days from the date and time of fi ling is specifi ed: *G.L. Chapter 156D eliminates the concept of par value, however a corporation may specify par value in Article III. See G.L. Chapter 156D, Section 6.21, and the comments relative thereto. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a07.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">Signed by: ___________________________________________________________________________________________, (signature of authorized individual) &#174; Chairman of the board of directors, &#174; President, &#174; Other o&#64259;&#8195;cer, &#174; Court-appointed fi duciary, on this _________________________day of_________________________________________ , _____________________. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g111069g99a08.jpg" alt="LOGO" style="width:6.31944in;height:8.1781in"/>
 </p> <p style="font-family:Times New Roman; font-size:0.5pt"><span style="color:#FFFFFF">COMMONWEALTH OF MASSACHUSETTS William Francis Galvin Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512 Articles of Amendment (General Laws Chapter 156D, Section&#160;10.06; 950 CMR 113.34) I hereby certify that upon examination of these articles of amendment, it appears that the provisions of the General Laws relative thereto have been complied with, and the fi ling fee in the amount of $______ having been paid, said articles are deemed to have been fi led with me this _______ day of _____________, 20_____ , at _______a.m./p.m. time E&#64256; ective date:_________________________________________________ (must be within 90 days of date submitted) WILLIAM FRANCIS GALVIN Secretary of the Commonwealth Filing fee: Minimum fi ling fee $100 per article amended, stock increases $100 per 100,000 shares, plus $100 for each additional 100,000 shares or any fraction thereof. Examiner TO BE FILLED IN BY CORPORATION Name approval Contact Information: C ___________________________________________________________ M ___________________________________________________________ ___________________________________________________________ Telephone: ___________________________________________________ Email: ______________________________________________________ Upon fi ling, a copy of this fi ling will be available at www.sec.state.ma.us/cor. If the document is rejected, a copy of the rejection sheet and rejected document will be available in the rejected queue. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right" id="tx111069_57">Annex L </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECTION 262 OF THE DELAWARE GENERAL CORPORATION LAW </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#167; 262. Appraisal rights </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with subsection (d)&#160;of this section and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c) of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Appraisal rights shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation, conversion, transfer, domestication or continuance authorized pursuant to and in accordance with the provisions of &#167; 265 or &#167; 388 of this title): </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) <span style="font-style:italic">Provided, however</span>, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for the conversion, transfer, domestication or continuance (or, in the case of a merger pursuant to &#167; 251(h) of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f) of this title. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title to accept for such stock anything except: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or continuance, or depository receipts in respect thereof; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">L-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange or held of record by more than 2,000 holders; </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) [Repealed.] </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title or a transfer, domestication or continuance effected pursuant to &#167; 390 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Appraisal rights shall be perfected as follows: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) If a proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c) of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation, conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section, of the date that the merger, consolidation or conversion has become effective; or </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) If the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting or converted entity within 10 days after </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">L-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation who is entitled to appraisal rights of the approval of the merger, consolidation, conversion, transfer, domestication or continuance and that appraisal rights are available for any or all shares of such class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, shall, also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice, demand in writing from the surviving, resulting or converted entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i)&#160;each such constituent corporation or the converting, transferring, domesticating or continuing corporation shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1) or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">L-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d) of this section and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person who has complied with the requirements of subsections (a)&#160;and (d) of this section, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2) of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3) of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10 days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section, whichever is later. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication or continuance the shares of the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1&#160;million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">L-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(h) After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation, conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer, domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(j) The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(k) Subject to the remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, either within 60 days after such effective date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">L-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consolidation, conversion, transfer, domestication or continuance, as set forth in subsection (e)&#160;of this section. If a petition for an appraisal is not filed within the time provided in subsection (e)&#160;of this section, the right to appraisal with respect to all shares shall cease. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(l) The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">L-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;20. Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Massachusetts </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cyclerion Articles provide that the liability of Cyclerion&#8217;s directors for damages for any breach of fiduciary duty shall be limited to the fullest extent permitted by law. The Cyclerion Bylaws provide that Cyclerion will indemnify, and advance funds to and reimburse expenses of, Cyclerion&#8217;s directors and officers that have been appointed by the Cyclerion Board to the fullest extent permitted by law, and that Cyclerion may indemnify, and advance funds to and reimburse expenses of, such other officers and employees as determined by the Cyclerion Board. The right of indemnification provided under the Cyclerion Bylaws is in addition to and not exclusive of any other rights to which any of Cyclerion&#8217;s directors, officers or any other persons may otherwise be lawfully entitled. Cyclerion has also entered into indemnification agreements with our directors and officers, and Cyclerion carries insurance policies insuring its directors and officers against certain liabilities that they may incur in their capacity as directors and officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part 8 of the MBCA authorizes the provisions, described above, that are contained in the Cyclerion Articles and the Cyclerion Bylaws. In addition, Sections 8.30 and 8.42 of the MBCA provide that if an officer or director discharges his or her duties in good faith and with the care that a person in a like position would reasonably exercise under similar circumstances and in a manner the officer or director reasonably believes to be in the best interests of the corporation, he or she will not be liable for such action. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana is a corporation under the DGCL. Section&#160;145(a) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(b) of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b) of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Korsana Charter contains provisions that limit or eliminate the personal liability of Korsana&#8217;s directors or officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. These limitations of liability do not alter director or officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. In addition, the Korsana Bylaws provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana will indemnify its directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Korsana will advance expenses, including attorneys&#8217; fees, to its directors and officers in connection with legal proceedings relating to their service for or on behalf of Korsana, subject to limited exceptions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana has entered into indemnification agreements with its directors and executive officers. These agreements provide that Korsana will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law. Korsana will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines, and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and Korsana will indemnify its directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of Korsana or in furtherance of Korsana&#8217;s rights. Additionally, certain of Korsana&#8217;s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s services as a director referenced herein. Nonetheless, Korsana has agreed in the indemnification agreements that Korsana&#8217;s obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Korsana also intends to maintain general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;21. Exhibits and Financial Statement Schedules </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibit Index </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A list of exhibits filed with this registration statement on Form <span style="white-space:nowrap">S-4</span> is set forth on the Exhibit Index and is incorporated herein by reference. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Financial Statements </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements filed with this registration statement on Form <span style="white-space:nowrap">S-4</span> are set forth on the Financial Statement Index and are incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;22. Undertakings </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned registrant hereby undertakes: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(iii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Provided, however</span>, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The registrant undertakes that every prospectus: (i)&#160;that is filed pursuant to paragraph (a)(5) immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3) of the Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item 4, 10(b), 11, or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1&#8224;*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii111069_1a">Agreement and Plan of Merger and Reorganization, dated as of April&#160;1, 2026, by and among Cyclerion Therapeutics, Inc., Cariboos Merger Sub Corp., Cariboos Merger Sub II, LLC, and Korsana Biosciences, Inc. (included in Annex A to the proxy statement/prospectus and incorporated herein by reference).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii111069_1aa">Amendment No.&#160;1 to Agreement and Plan of Merger and Reorganization, dated as of April&#160;16, 2026, by and among Cyclerion Therapeutics, Inc., Cariboos Merger Sub Corp., Cariboos Merger Sub II, LLC, and Korsana Biosciences, Inc. (included in Annex A to the proxy statement/prospectus and incorporated herein by reference).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000110465919018720/a19-7436_1ex4d1.htm">Restated Articles of Organization of Cyclerion Therapeutics, Inc. (incorporated herein by reference to Exhibit 4.1 to Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed on March&#160;29, 2019 (File <span style="white-space:nowrap">No.&#160;333-230615)).</span> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000114036123024768/brhc20052986_ex3-1.htm">Articles of Amendment to Amended and Restated Articles of Incorporation dated May&#160;15, 2023 (incorporated by reference to Exhibit 3.1 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on May&#160;15, 2023 (File <span style="white-space:nowrap">No.&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000114036123026621/brhc20053546_ex3-1.htm">Articles of Amendment to Amended and Restated Articles of Incorporation dated May&#160;19, 2023 (incorporated by reference to Exhibit 3.1 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on May&#160;25, 2023 (File No.&#160;001 - 38787)).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000110465919018720/a19-7436_1ex4d2.htm">Amended and Restated Bylaws of Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 to Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed on March&#160;29, 2019 (File <span style="white-space:nowrap">No.&#160;333-230615)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex35.htm">Second Amended and Restated Certificate of Incorporation of Korsana Biosciences, Inc. (incorporated by reference to Exhibit 3.5 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex36.htm">Bylaws of Korsana Biosciences, Inc. (incorporated by reference to Exhibit 3.6 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/cycn-ex4_1.htm">Description of Securities Registered pursuant to Section&#160;12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.1 to Annual Report on Form 10-K filed on March&#160;30, 2026 (File <span style="white-space:nowrap">No.&#160;001-38787)).</span> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex42.htm">Form of Korsana Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Opinion of Ropes&#160;&amp; Gray LLP.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;8.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Tax Opinion of Gibson, Dunn &amp; Crutcher LLP</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii111069_401">Form of Cyclerion Support Agreement (included in Annex C to the proxy statement/prospectus and incorporated herein by reference).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii111069_1b">Form of Korsana Support Agreement (included in Annex D to the proxy statement/prospectus and incorporated herein by reference).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex103.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.3 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April&#160;1, 2026) (File <span style="white-space:nowrap">No.&#160;001-38787)).</span> </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex104.htm">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.4 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April&#160;1, 2026) (File <span style="white-space:nowrap">No.&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii111069_1c">Form of <span style="white-space:nowrap">Lock-Up</span> Agreement (included in Annex E to the proxy statement/prospectus and incorporated herein by reference).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000104746919000876/a2237620zex-10_10.htm">Form of Stock Option Agreement under the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to Form 10 filed on March<span style="text-decoration:underline"></span>&#160;4, 2019 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000104746919000876/a2237620zex-10_11.htm">Form of <span style="white-space:nowrap">Non-Employee</span> Director Restricted Stock Agreement under the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.11 to Form 10 filed on March<span style="text-decoration:underline"></span>&#160;4, 2019 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000104746919000876/a2237620zex-10_12.htm">Form of Restricted Stock Unit Agreement under the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Form 10 filed on March<span style="text-decoration:underline"></span>&#160;4, 2019 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001755237/000110465919018720/a19-7436_1ex4d5.htm">Cyclerion Therapeutics, Inc. Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan and forms of agreement thereunder (incorporated by reference to Exhibit 4.5 to Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed on March<span style="text-decoration:underline"></span>&#160;29, 2019 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-230615)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10&#8224;&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000156459021039205/cycn-ex102_241.htm">License Agreement, dated as of June<span style="text-decoration:underline"></span>&#160;3, 2021, by and between Cyclerion Therapeutics, Inc. and Akebia Therapeutics, Inc (incorporated by reference to Exhibit 10.2 to Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed on July<span style="text-decoration:underline"></span>&#160;29, 2021 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11&#8224;&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312524280125/d856941dex101.htm">Amendment #1 to License Agreement by and between the Company and Akebia Therapeutics, Inc. dated December<span style="text-decoration:underline"></span>&#160;13, 2024 (incorporated by reference to Exhibit 10.1 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on December<span style="text-decoration:underline"></span>&#160;17, 2024 (File No. 001-38787)). </a></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000114036121021236/nt10025805x1_ex10-1.htm">Common Stock Purchase Agreement, dated as of June<span style="text-decoration:underline"></span>&#160;3, 2021, by and between Cyclerion Therapeutics, Inc. and the Investors named therein (incorporated by reference to Exhibit 10.1 to Registration Statement on Form <span style="white-space:nowrap">S-3</span> filed on June<span style="text-decoration:underline"></span>&#160;16, 2021 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-257145)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13&#8224;&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312525277749/cycn-ex10_1.htm">Patent License Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;19, 2025, by and between Cyclerion Therapeutics, Inc. and Massachusetts Institute of Technology (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed on November<span style="text-decoration:underline"></span>&#160;12, 2025 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787))</span></a>.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex107.htm">Amended and Restated Offer Letter to Regina Graul (incorporated by reference to Exhibit 10.7 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April 1, 2026 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000095017025103123/cycn-ex10_1.htm">Consulting Agreement with Rhonda Chicko dated August<span style="text-decoration:underline"></span>&#160;4, 2025 (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed on August<span style="text-decoration:underline"></span>&#160;5, 2025 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787))</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16&#8224;&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001755237/000119312526132193/cycn-ex10_14.htm">Collaboration and Option Agreement, dated as of January<span style="text-decoration:underline"></span>&#160;3, 2026, by and between Cyclerion Therapeutics, Inc. and Medsteer, SAS (incorporated by reference to Exhibit 10.14 to Annual Report on Form <span style="white-space:nowrap">10-K</span> filed on March<span style="text-decoration:underline"></span>&#160;30, 2026 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787))</span></a>.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312525115089/d51125dex11.htm">Sales Agreement by and between Cyclerion Therapeutics, Inc. and Guggenheim Securities, LLC, dated May<span style="text-decoration:underline"></span>&#160;7, 2025. (incorporated by reference to Exhibit 1.1 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on May<span style="text-decoration:underline"></span>&#160;7, 2025 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787)).</span></a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312525062612/d926001dex102.htm">Registration Rights Agreement, dated March<span style="text-decoration:underline"></span>&#160;21, 2025, by and among Cyclerion Therapeutics, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.2 to Current Report on Form <span style="white-space:nowrap">8-K</span> filed on March<span style="text-decoration:underline"></span>&#160;25, 2025 (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-38787)</span></a>).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1019.htm">Korsana Biosciences, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.19 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1020.htm">Form of Restricted Stock Purchase Agreement of Korsana Biosciences, Inc. (incorporated by reference to Exhibit 10.20 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.21#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1021.htm">Form of Stock Option Agreement under Korsana Biosciences, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.21 to Registration Statement on Form S-4 filed on April&#160;20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.22#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1022.htm">Form of Indemnification Agreement between Korsana Biosciences, Inc. and its directors and officers (incorporated by reference to Exhibit 10.22 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.23#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1023.htm">Consulting Agreement, dated August&#160;1, 2025, by and between Korsana Biosciences, Inc. and Jonathan Violin (incorporated by reference to Exhibit 10.23 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.24#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1024.htm">Offer Letter, effective as of January&#160;1, 2026, by and between Korsana Biosciences, Inc. and Jonathan Violin (incorporated by reference to Exhibit 10.24 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.25#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1025.htm">Offer Letter, dated March&#160;5, 2026, by and between Korsana Biosciences, Inc. and Mark Vignola (incorporated by reference to Exhibit 10.25 to Registration Statement on Form S-4 filed on April&#160;20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.26#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1026.htm">Offer Letter, dated December&#160;15, 2025, by and between Korsana Biosciences, Inc. and Madelyn Zeylikman (incorporated by reference to Exhibit 10.26 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:87%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.27#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1027.htm">Offer Letter, dated August&#160;14, 2025, by and between Korsana Biosciences, Inc. and Kyle Breidenstine (incorporated by reference to Exhibit 10.27 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.28&#8224;&#8224;&#8224;*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex1028.htm">Antibody Discovery and Option Agreement, effective as of September&#160;5, 2025, by and among Paragon Therapeutics, Inc., Parasa Holding LLC, and Korsana Biosciences, Inc.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.29&#8224;&#8224;&#8224;**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Paragon License Agreement, dated June&#160;8, 2026, by and between Paragon Therapeutics, Inc. and Korsana Biosciences, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.30&#8224;&#8224;&#8224;*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex1030.htm">Platform Option Agreement, effective as of October&#160;16, 2025, by and among Paragon, Parasa Holding LLC, and Korsana Biosciences, Inc.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.31&#8224;&#8224;*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex1031.htm">Paragon Research Letter Agreement, dated April 3, 2026, by and between Paragon Laboratories, Inc. and Korsana Biosciences, Inc.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.32&#8224;&#8224;*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex1032.htm">Cell Line License Agreement, effective as of December&#160;2, 2024, by and between Korsana Biosciences, Inc. and WuXi Biologics Ireland Limited.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.33&#8224;&#8224;*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex1033.htm">Amendment No. 1 to Cell Line License Agreement, effective as of March 2, 2026, by and between Korsana Biosciences, Inc. and WuXi Biologics Ireland Limited.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.34&#8224;&#8224;&#8224;*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex1034.htm">Biologics Master Services Agreement, dated as of December&#160;12, 2024, by and between Korsana Biosciences, Inc. and WuXi Biologics (Hong Kong) Limited.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.35</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1032.htm">Warrant to Purchase Common Stock, issued on December&#160;31, 2025 by Korsana Biosciences, Inc. to Parasa Holding LLC (incorporated by reference to Exhibit 10.32 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex231.htm">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm of Cyclerion Therapeutics, Inc.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex232.htm">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm of Korsana Biosciences, Inc.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.3**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Consent of Ropes&#160;&amp; Gray LLP (included in Exhibit 5.1).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#ii111069_sig">Power of Attorney (incorporated by reference to Exhibit&#160;99.5 to Registration Statement on Form&#160;S-4 filed on April&#160;20, 2026 (File No.&#160;333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex991.htm">Consent of Jonathan Violin to serve as a director of Cyclerion Therapeutics, Inc., to be renamed Korsana Biosciences, Inc. (incorporated by reference to Exhibit 99.1 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex992.htm">Consent of Tomas Kiselak to serve as a director of Cyclerion Therapeutics, Inc., to be renamed Korsana Biosciences, Inc. (incorporated by reference to Exhibit 99.2 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex993.htm">Consent of Michelle Pernice to serve as a director of Cyclerion Therapeutics, Inc., to be renamed Korsana Biosciences, Inc. (incorporated by reference to Exhibit 99.3 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex994.htm">Consent of Andrew Gottesdiener to serve as a director of Cyclerion Therapeutics, Inc., to be renamed Korsana Biosciences, Inc. (incorporated by reference to Exhibit 99.4 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex995.htm">Consent of Nimish Shah to serve as a director of Cyclerion Therapeutics, Inc., to be renamed Korsana Biosciences, Inc. (incorporated by reference to Exhibit 99.5 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175)). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;99.6*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d111069dex996.htm">Consent of Gemini Valuation Services, LLC.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Instance Document.</td></tr></table> </div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Schema.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Calculation Linkbase.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Definition Linkbase.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Label Linkbase.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">XBRL Taxonomy Extension Presentation Linkbase.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File. Formatted in Inline XBRL and contained in exhibit 101.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1755237/000119312526162177/d111069dexfilingfees.htm">Filing Fee Table (incorporated by reference to Exhibit 107 to Registration Statement on Form S-4 filed on April 20, 2026 (File No. 333-295175). </a></td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">**</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To be filed by amendment. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">#</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#8224;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule <span style="white-space:nowrap">24b-2</span> under the Exchange Act for any exhibits or schedules so furnished. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#8224;&#8224;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;customarily and actually treated as private or confidential. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="ii111069_sig">SIGNATURES </p> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form <span style="white-space:nowrap">S-4</span> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on June 9, 2026. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">CYCLERION THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ REGINA GRAUL</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">Regina Graul, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-style:italic">President and Chief Executive Officer</span></td></tr>
</table></div> <div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant and in the capacities indicated on June 9, 2026. </p> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:51%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/<small style="font-weight:inherit;font-style:unset;text-decoration:unset">S</small>/ REGINA GRAUL, PH.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Regina Graul, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">President, Chief Executive Officer and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Rhonda Chicko</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer (Principal Financial</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Officer and Principal Accounting Officer)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Errol De Souza, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Peter Hecht, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Michael Higgins</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Steven Hyman, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Dina Katabi, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td></tr>
</table> </div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:11%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:88%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="vertical-align:top"/></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">*&#160;By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ REGINA GRAUL, PH.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Regina Graul, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Attorney-in-Fact</td></tr>
</table> </div> <div> </div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>2
<FILENAME>d111069dex1028.htm
<DESCRIPTION>EX-10.28
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.28</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.28 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND
(II)&nbsp;IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANTIBODY
DISCOVERY AND OPTION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> A<SMALL>NTIBODY</SMALL> D<SMALL>ISCOVERY</SMALL> <SMALL>AND</SMALL>
O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (&#8220;<B>Agreement</B>&#8221;) is entered into and effective as of September&nbsp;5, 2025 (the &#8220;<B>Effective Date</B>&#8221;), by and among Paragon Therapeutics, Inc., a
Delaware corporation (&#8220;<B>Paragon</B>&#8221;), Parasa Holding LLC, a Delaware limited liability company (&#8220;<B>Parasa</B>&#8221;) and Korsa Biosciences, Inc., a Delaware corporation (&#8220;<B>Korsa</B>&#8221;). Paragon, Parasa and Korsa
are also referred to herein individually as a &#8220;<B>Party</B>&#8221;, or collectively as the &#8220;<B>Parties</B>.&#8221; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B><B> </B>Paragon has developed and is continuing to develop proprietary platform technology for (a)&nbsp;the
discovery and development of antibodies against therapeutically relevant targets, and (b)&nbsp;the delivery of therapeutic agents across the blood-brain barrier through receptor-mediated transcytosis; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> Korsa desires to engage Paragon to perform, and Paragon is willing to perform, certain research activities to
discover, generate, identify, characterize and develop one or more antibody transport vehicle compounds containing a first antibody directed to one or more mutually agreed therapeutic targets of interest to Korsa and a second antibody directed to a
certain mutually agreed transit target of interest to Korsa; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> Korsa will have an exclusive option to
enter into separate license agreements with Paragon to further develop, manufacture and commercialize the resulting antibody transport vehicle compounds, all on the terms and subject to the conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> </B><B>T<SMALL>HEREFORE</SMALL></B><SMALL><B></B></SMALL><B>, </B>in consideration of the foregoing premises and the
mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINED TERMS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> &#8220;<B>Achievement of Development Candidate</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, the first to occur of: (a)&nbsp;nomination by Korsa&#8217;s Board of Directors of a Royalty Product as a &#8220;Development Candidate&#8221; (&#8220;<B>Nomination of a
DC</B>&#8221;); and (b)&nbsp;the initiation by or on behalf of Korsa or its Affiliate or sublicensee of a toxicology study with respect to a Royalty Product that employs applicable then-current good laboratory practice standards, the results of
which are intended to be submitted as part of an IND (&#8220;<B>GLP Tox Initiation</B>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> &#8220;<B>Actual Quarterly
Costs</B>&#8221;<B> </B>shall have the meaning provided in Section&nbsp;5.2(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> &#8220;<B>Affiliate</B>&#8221; shall mean any entity controlled by, controlling,
or under common control with a Party hereto. For the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control&#8221;) means the direct or indirect
ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business
entity. Notwithstanding the foregoing, (a)&nbsp;with respect to either Party, Affiliates of such Party do not include [***] or its Affiliates other than such Party and its subsidiaries, (b) [***], and (c) [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> &#8220;<B>Agreement</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> &#8220;<B>Antibody</B>&#8221; shall mean any molecule, including [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> &#8220;<B>Antibody Product</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any product that comprises or contains any Project Antibody or any Derived Antibody thereof, other than as part of a Multispecific
Antibody or a Multispecific Antibody Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> &#8220;<B>Applicable Law</B>&#8221; shall mean any national, supra-national,
federal, state or local laws, rules, guidances and regulations, in each case, as applicable to the subject matter and the party at issue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> &#8220;<B>ATV</B>&#8221;<B> </B>shall mean a compound that comprises or contains: (a)&nbsp;with respect to a Single Therapeutic
Target Research Program, (i)&nbsp;an Antibody that is Directed To a Therapeutic Target (the &#8220;<B>Therapeutic Antibody</B>&#8221;), and (ii)&nbsp;an Antibody that is Directed To a Brain Transit Target (together with any multispecific Antibody
format, including, e.g., Fc substitutions within such a format, for such compound, the &#8220;<B>Transit Antibody</B>&#8221;); and (b)&nbsp;with respect to a Dual Therapeutic Target Research Program, (i)&nbsp;a first Therapeutic Antibody,
(ii)&nbsp;a second Therapeutic Antibody, and (iii)&nbsp;a Transit Antibody. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> &#8220;<B>ATV Product</B>&#8221; shall mean, on a
Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any product that comprises or contains any Project ATV or any Derived ATV thereof, other than as part of a Multispecific ATV
or a Multispecific ATV Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> &#8220;<B>ATV Production Activities</B>&#8221; shall have the meaning provided in
Section&nbsp;2.1(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B> &#8220;<B>Background IP</B>&#8221; shall mean all Patents and
<FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by a Party (a)&nbsp;as of the Effective Date, or (b)&nbsp;that otherwise arise outside of and independently of this Agreement. Paragon&#8217;s Background IP includes the Paragon Platform
Technology and any Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B> &#8220;<B>Bankruptcy Code</B>&#8221; shall
have the meaning provided in Section&nbsp;9.5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B> &#8220;<B>Bankruptcy Event</B>&#8221; shall have the meaning provided in
Section&nbsp;9.5. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B> &#8220;<B>Brain Transit Target</B>&#8221; shall mean a protein molecule (such as the human transferrin
receptor) that (a)&nbsp;[***], and (b)&nbsp;[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B> &#8220;<B>Budget</B>&#8221; shall mean the agreed budget for the activities set
forth in the Research Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B> &#8220;<B>Business </B><B>Day</B>&#8221; shall mean any day other than Saturday, Sunday, or other
national holidays in the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B> &#8220;<B>Calendar Quarter</B>&#8221; shall mean the respective periods of three
(3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30, and December 31. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>
&#8220;<B>Calendar Year</B>&#8221; shall mean each successive period of twelve (12)&nbsp;months commencing on January&nbsp;1 and ending on December 31. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B> &#8220;<B>Change of Control</B>&#8221; shall mean, with respect to any entity, any of the following: (a)&nbsp;the sale or
disposition of all or substantially all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b)&nbsp;(i) the acquisition by a Third Party, alone or together with any of its Affiliates, other than an
employee benefit plan (or related trust) sponsored or maintained by such entity or any of its Affiliates, of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity or its direct or indirect parent entity
that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity (a &#8220;<B>Parent Entity</B>&#8221;), or (ii)&nbsp;the acquisition, merger or
consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i)&nbsp;or (ii), an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of
voting capital stock of such entity or its Parent Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital
stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation, and in each case of (a)&nbsp;or (b), whether through a
single transaction or a series of related transactions, but excluding any and all bona fide financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile of such entity). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B> &#8220;<B>CMC Activities</B>&#8221; shall mean, with respect to a particular Project ATV (or components thereof) and Research
Program, chemistry, manufacturing and control activities sufficient to produce a full data set from transfection into a stable pool through to quality assurance released clinical grade drug product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B> &#8220;<B>CMC Activities Package</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(d)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B> &#8220;<B>CMC Estimated Timeline</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(d)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B> &#8220;<B>CMC Fee</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(d)(i). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B> &#8220;<B>CMC Monthly Fee</B>&#8221; shall mean, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, if Paragon is performing CMC Activities under this Agreement, the CMC Monthly Fee set forth on <U>Exhibit C</U> applicable to such CMC
Activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B> &#8220;<B>CMC Project ATV</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(d)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B> &#8220;<B>CMC Substitution Project ATV</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(d)(ii). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B> &#8220;<B>Commercialize</B>&#8221; or &#8220;<B>Commercializing</B>&#8221; shall mean to market, promote, distribute, offer for
sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize a product. When used as a noun, &#8220;<B>Commercialization</B>&#8221; means any and all activities involved in Commercializing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B> &#8220;<B>Confidential Information</B>&#8221; of a Party shall mean any and all <FONT STYLE="white-space:nowrap">non-public</FONT>
scientific, business, regulatory, or technical information that is disclosed or made available by or on behalf of one Party (the &#8220;<B>Disclosing Party</B>&#8221;) to any other Party (a &#8220;<B>Receiving Party</B>&#8221;) in connection with
this Agreement, whether in writing, orally, visually or otherwise. Notwithstanding any provision of this Agreement to the contrary, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT>
Program basis, all (a)&nbsp;Paragon Platform Technology and Transit Antibody Technology shall be the Confidential Information of Paragon, and (b)&nbsp;Project ATV Inventions and Project ATV Technology shall be the Confidential Information of all
Parties, and each Party shall be deemed as both the &#8220;Disclosing Party&#8221; and the &#8220;Receiving Party&#8221; with respect thereto; <I>provided, that</I> if, with respect to a particular Research Program, Korsa does not exercise the
Option or the Parties do not enter into the License Agreement in accordance with this Agreement, then the Project ATV Technology for such Research Program shall thereafter be the Confidential Information of Paragon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B> &#8220;<B>Control</B>&#8221; (including any variations such as<B> </B>&#8220;<B>Controlled</B>&#8221;<B> </B>and
&#8220;<B>Controlling</B>&#8221;) shall mean, with respect to any technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under such
technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party or requiring a payment. Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed to
&#8220;Control&#8221; any technology or Intellectual Property Rights that (a)&nbsp;prior to the consummation of a Change of Control of such Party, is owned or <FONT STYLE="white-space:nowrap">in-licensed,</FONT> or (b)&nbsp;after the consummation of
a Change of Control of such Party, becomes owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> (to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder and
without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((a)
or (b)), by a Third Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party after the Effective Date as the result of an assignment of this Agreement in connection
with a Change of Control unless prior to the consummation of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B> &#8220;<B>Cost Advance</B>&#8221; shall have the meaning provided in
Section&nbsp;5.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B> &#8220;<B>Cover</B>&#8221; or &#8220;<B>Covering</B>&#8221; shall mean, with respect to a Patent, that,
in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B> &#8220;<B>Deliverables</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(e)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B> &#8220;<B>Derived Antibody</B>&#8221; shall, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in Section&nbsp;1.35 as applicable to a Research Program. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B> &#8220;<B>Derived Antibody Patent</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any Patent that Covers the composition of matter of, or any method of specifically making or using, any Derived Antibody. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B> &#8220;<B>Derived ATV</B>&#8221;<B> </B>shall mean, with respect to a Project ATV, any ATV that consists of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> a Therapeutic Antibody as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) with respect to a Project ATV for a Single Therapeutic Target Research Program, a Therapeutic Antibody that is Directed To the applicable
Selected Therapeutic Target (and no other Targets), which Therapeutic Antibody may be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Project Antibody included in such Project ATV; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a monospecific Therapeutic Antibody that is derived from or constitutes a Modification of the Project Antibody
included in such Project ATV, that in each case has [***] (a &#8220;<B>Derived Antibody</B>&#8221; for a Single Therapeutic Target Research Program); or </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) with respect to a Project ATV for a Dual Therapeutic Target Research Program, a first Therapeutic Antibody that is Directed To the first
applicable Selected Therapeutic Target (and no other Targets) and a second Therapeutic Antibody that is Directed To the second applicable Selected Therapeutic Target (and no other Targets), one or both of which first and second Therapeutic
Antibodies may be as under clause (a)(i)(x) or (y)&nbsp;above applied <I>mutatis mutandis </I>(each a &#8220;<B>Derived Antibody</B>&#8221; for a Dual Therapeutic Target Research Program); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> a Transit Antibody that is Directed To the applicable Selected Transit Target (and no other Targets), which Transit Antibody may be:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Transit Antibody included in such Project ATV; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a Transit Antibody that is derived from or constitutes a Modification of the Transit
Antibody included in such Project ATV, that in each case has [***] (a &#8220;<B>Derived Transit Antibody</B>&#8221;); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any other
Transit Antibody (an &#8220;<B>Other Transit Antibody</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For avoidance of doubt, with respect to a Project ATV, any ATV that consists of
(1)&nbsp;the Project Antibody included in such Project ATV or a Derived Antibody with respect to such Project Antibody, and (2)&nbsp;a Transit Antibody Directed To the applicable Selected Transit Target, will be deemed a Derived ATV, irrespective of
origin of any of the components of such ATV, and whether or not such ATV utilizes the same Project ATV Technology or Transit Antibody Technology as the Project ATV from which it was derived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B> &#8220;<B>Derived ATV Patent</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any Patent that Covers the composition of matter of, or any method of specifically making or using, any Derived ATV or any component
thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B> &#8220;<B>Derived Transit Antibody</B>&#8221; shall, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in Section&nbsp;1.35 as applicable to a Research Program. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B> &#8220;<B>Develop</B>&#8221; or<B> </B>&#8220;<B>Developing</B>&#8221;<B> </B>shall<B> </B>mean to discover, evaluate, test,
research or otherwise develop a product. When used as a noun, &#8220;<B>Development</B>&#8221; means any and all activities involved in Developing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B> &#8220;<B>Development Costs</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, (a) [***] (such amounts, the &#8220;<B>Third Party Costs</B>&#8221;), and (b) [***] (such development fees, the &#8220;<B>Development
Fees</B>&#8221;, and the development fees to be paid in any given Calendar Year during the Research Program, the &#8220;<B>Annual Development Fees</B>&#8221;); in each case ((a) and (b)) to the extent consistent with the Research Plan (including
[***]). For clarity, Development Costs shall exclude the CMC Fee but shall include any Third Party Costs paid by Paragon with respect to the performance of the CMC Activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B> &#8220;<B>Directed To</B>&#8221; shall mean, with regard to an Antibody or product, that such Antibody or product is developed or
designed to (a) [***], and (b) [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B> &#8220;<B>Dispute</B>&#8221; shall have the meaning provided in Section&nbsp;11.7. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B> &#8220;<B>Dual Therapeutic Target Research Program</B>&#8221; shall have the meaning provided in Section&nbsp;1.105. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B> &#8220;<B>Effective Date</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B> &#8220;<B>Election Notice</B>&#8221; shall have the meaning provided in Section&nbsp;4.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B> &#8220;<B>Equity Grant</B>&#8221; shall have the meaning provided in Section&nbsp;5.8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B> &#8220;<B>FDA</B>&#8221; shall mean the United States Food and Drug
Administration, or a successor federal agency thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B> &#8220;<B>Field</B>&#8221; shall mean the prophylaxis, palliation,
treatment and diagnosis of human disease and disorders in all therapeutic areas. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B> &#8220;<B>Final Deliverable</B>&#8221; shall,
on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in the Research Plan for such Research Program. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B> &#8220;<B>GLP Tox Initiation</B>&#8221; shall have the meaning provided in Section&nbsp;1.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B> &#8220;<B>Indemnified Party</B>&#8221;<B> </B>shall have the meaning provided in Section&nbsp;10.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B> &#8220;<B>Indemnifying Party</B>&#8221; shall have the meaning provided in Section&nbsp;10.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B> &#8220;<B>Intellectual Property Rights</B>&#8221; shall mean any and all proprietary rights provided under (a)&nbsp;patent law,
including any Patents, (b)&nbsp;copyright law, or (c)&nbsp;any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in <FONT STYLE="white-space:nowrap">Know-How,</FONT> or the expression
or use thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B> &#8220;<B>JDC</B>&#8221;<B> </B>shall have the meaning provided in Section&nbsp;3.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B> &#8220;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#8221; shall mean all technical information and <FONT
STYLE="white-space:nowrap">know-how</FONT> in any tangible or intangible form, including (a)&nbsp;inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids,
nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing
or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b)&nbsp;all data, instructions, processes, formulae, strategies, and expertise, whether
biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding the foregoing, <FONT
STYLE="white-space:nowrap">Know-How</FONT> excludes Patent claims. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B> &#8220;<B>Korsa</B>&#8221; shall have the meaning provided
in the first paragraph of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B> &#8220;<B>Korsa</B><B> Indemnitee</B>&#8221; shall have the meaning provided in
Section&nbsp;10.2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B> &#8220;<B>Korsa IP</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(c)(ii). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B> &#8220;<B>Korsa Product</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, individually or collectively, as applicable, Project Antibodies, Derived Antibodies, Antibody Products, Project ATVs, Derived ATVs and
ATV Products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B> &#8220;<B>License Agreement</B>&#8221; shall have the meaning provided in Section&nbsp;4.4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B> &#8220;<B>License Agreement Dispute</B>&#8221; shall have the meaning provided in
Section&nbsp;4.4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B> &#8220;<B>Licensed Transit Antibody Patents</B>&#8221; shall, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in Section&nbsp;1.62. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B> &#8220;<B>Licensed Transit Antibody Technology</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, (a)&nbsp;the Transit Antibody Inventions relating specifically and solely to the composition of matter of, or any method of using, making or manufacturing, any Transit
Antibody included in a Project ATV, (b)&nbsp;the Transit Antibody Patents that Cover the composition of matter of, or any method of using, making or manufacturing, any Transit Antibody included in a Project ATV (&#8220;<B>Licensed Transit Antibody
Patents</B>&#8221;), (c) the Transit Antibody Information, and (d)&nbsp;the Transit Antibody Results relating specifically and solely to any Transit Antibody included in a Project ATV. For clarity, if the Parties execute the License Agreement for a
Research Program and the Research Term for such Research Program continues following execution of such License Agreement, any Licensed Transit Antibody Technology under such Research Program first conceived, reduced to practice or otherwise
generated following the execution of such License Agreement shall be <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed to Korsa under such License Agreement as described in <U>Exhibit B</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B> &#8220;<B>Losses</B>&#8221; shall have the meaning provided in Section&nbsp;10.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B> &#8220;<B>MAA</B>&#8221; shall mean (a)&nbsp;a New Drug Application in the United States, as defined in the United States Federal
Food, Drug and Cosmetics Act, and applicable regulations promulgated thereunder by the FDA, (b)&nbsp;a Biologics License Application in the United States, as defined in the United States Public Health Service Act, or (c)&nbsp;any application filed
with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B>
&#8220;<B>Manufacture</B>&#8221; or &#8220;<B>Manufacturing</B>&#8221; shall mean to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store a product or any component thereof, as
applicable. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing a product or any component thereof, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B> &#8220;<B>Milestone</B>&#8221; shall have the meaning provided in Section&nbsp;5.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B> &#8220;<B>Milestone Payment</B>&#8221; shall have the meaning provided in Section&nbsp;5.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B> &#8220;<B>Modification</B>&#8221; shall mean, with respect to an Antibody, a modification of such Antibody, including an ScFv or
Fab, or the heavy chain or light chain independently, or segments thereof, or any pegylated version (whether or not including sequence changes), any fusion protein, chimeric protein, peptide, siRNA, polynucleotide, affinity matured Antibody,
mutagenized (e.g., by random mutagenesis, <I>in vitro</I> selection or site directed mutagenesis, or by a single round of mutagenesis or selection or multiple iterations of mutagenesis or selection, in each case including any associated
substitutions) Antibody, or any fragment of such Antibody. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B> &#8220;<B>Multispecific Antibody</B>&#8221; shall mean, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any Antibody that is comprised of (a) [***], and (b) [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B> &#8220;<B>Multispecific Antibody Product</B>&#8221; means any product that comprises or contains any Multispecific Antibody. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B> &#8220;<B>Multispecific ATV</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any ATV that is comprised of (a)&nbsp;a Project ATV or a Derived ATV, and (b)&nbsp;one (1) or more Antibodies or moieties that are
Directed To one (1)&nbsp;or more Targets other than the applicable Selected Therapeutic Target(s) and Selected Transit Target. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B>
&#8220;<B>Multispecific ATV Product</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any product that comprises or contains any Multispecific ATV.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B> &#8220;<B>Nomination of a DC</B>&#8221; shall have the meaning provided in Section&nbsp;1.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B> &#8220;<B>Notice of Dispute</B>&#8221; shall have the meaning provided in Section&nbsp;11.7(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B> &#8220;<B>Option</B>&#8221; shall have the meaning provided in Section&nbsp;4.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B> &#8220;<B>Option Period</B>&#8221; shall have the meaning provided in Section&nbsp;4.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B> &#8220;<B>Other Transit Antibody</B>&#8221; shall, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in Section&nbsp;1.35 as applicable to a Research Program. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B> &#8220;<B>Other Transit Antibody IP</B>&#8221; shall mean any Intellectual Property Rights owned or controlled by Paragon and its
Affiliates that relate to or Cover the composition of matter of, or any method of using, making or manufacturing, any Other Transit Antibody. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B> &#8220;<B>Paragon</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B> &#8220;<B>Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</B>&#8221; shall, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in Section&nbsp;2.1(c)(i). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B> &#8220;<B>Paragon Indemnitee</B>&#8221; shall have the meaning provided in Section&nbsp;10.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B> &#8220;<B>Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#8221; shall mean
<FONT STYLE="white-space:nowrap">(a)&nbsp;Know-How</FONT> relating to antibody-based product (including Antibodies, antibody-drug conjugates, Transit Antibodies and ATVs) discovery and development, (b)&nbsp;all methods, materials and other <FONT
STYLE="white-space:nowrap">Know-How</FONT> used in the foregoing, and (c)&nbsp;platforms embodying, components, component steps and other portions of any of the foregoing in (a)&nbsp;or (b), in each case of (a)&nbsp;through (c) that are Controlled
by Paragon or its Affiliates prior to or during the Term. The Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> shall exclude <FONT STYLE="white-space:nowrap">Know-How</FONT> included in the Transit Antibody Technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B> &#8220;<B>Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT>
Improvement</B>&#8221; shall<B> </B>mean all <FONT STYLE="white-space:nowrap">Know-How</FONT> developed or discovered through or as a result of the activities performed by or on behalf of Paragon under a Research Program that constitutes an
improvement, enhancement, modification, substitution, or alteration to the Paragon Platform Technology; <I>provided, however</I>, (a)&nbsp;the Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> Improvements shall exclude <FONT
STYLE="white-space:nowrap">Know-How</FONT> included in the Transit Antibody Technology, and (b)&nbsp;to the extent any of the <FONT STYLE="white-space:nowrap">Know-How</FONT> developed or discovered under the Research Program specifically and solely
relates to a Project ATV, such <FONT STYLE="white-space:nowrap">Know-How</FONT> (other than the <FONT STYLE="white-space:nowrap">Know-How</FONT> included in the Transit Antibody Technology) will be considered Project ATV Technology, and in each case
not Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> Improvements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B> &#8220;<B>Paragon Platform
Patents</B>&#8221; shall mean all Patents that Paragon or its Affiliates Control prior to or during the Term that Cover Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> or Paragon Platform
<FONT STYLE="white-space:nowrap">Know-How</FONT> Improvements. The Paragon Platform Patents shall exclude Transit Antibody Patents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B> &#8220;<B>Paragon Platform Technology</B>&#8221; shall mean Paragon Platform <FONT STYLE="white-space:nowrap">Know-How,</FONT>
Paragon Platform <FONT STYLE="white-space:nowrap">Know-How</FONT> Improvements, and Paragon Platform Patents.<B> </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B>
&#8220;<B>Parasa</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B>
&#8220;<B>Party</B>&#8221; or &#8220;<B>Parties</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B> &#8220;<B>Patents</B>&#8221; shall mean (a)&nbsp;unexpired patents and patent applications, (b)&nbsp;any and all divisionals,
continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, substitutions, registrations, <FONT STYLE="white-space:nowrap">re-examinations,</FONT> revalidations,
extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c)&nbsp;any and all foreign equivalents of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89</B> &#8220;<B>Phase I Trial</B>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R.
&#167;312.21(a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B> &#8220;<B>Phase II
Trial</B>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B> &#8220;<B>Phase III Trial</B>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R.
&#167;312.21(c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92</B> &#8220;<B><FONT
STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs</B>&#8221; shall have the meaning provided in Section&nbsp;5.2(e). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.93</B> &#8220;<B>Project Antibody</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, a Therapeutic Antibody that is included in a Project ATV. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.94</B> &#8220;<B>Project ATV</B>&#8221; shall mean, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, any and all ATVs that comprise or contain (a)&nbsp;(i) with respect to a Single Therapeutic Target Research Program, a Therapeutic Antibody
that is Directed To the applicable Selected Therapeutic Target (and no other Targets), or (ii)&nbsp;with respect to a Dual Therapeutic Target Research Program, a first Therapeutic Antibody that is Directed To the first applicable Selected
Therapeutic Target (and no other Targets) and a second Therapeutic Antibody that is Directed To the second applicable Selected Therapeutic Target (and no other Targets), and (b)&nbsp;a Transit Antibody that is Directed To the Selected Transit Target
(and no other Targets), and that in each case are discovered, generated, identified or characterized by Paragon in the course of performing the applicable Research Program. For clarity, Project ATVs do not include (x)&nbsp;Therapeutic Antibodies
that are Directed To a Target other than the applicable Selected Therapeutic Target(s), and (y)&nbsp;Transit Antibodies that are Directed To a Brain Transit Target other than the applicable Selected Transit Target. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.95</B> &#8220;<B>Project ATV Information</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, electronic files containing a description of the Project ATVs discovered, generated, identified or characterized under a Research Program, including the sequences of all
Therapeutic Antibodies included in the Project ATVs but excluding any Transit Antibody Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.96</B> &#8220;<B>Project ATV
Invention</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, (a)&nbsp;any invention or discovery, whether or not patentable, that was discovered or
reduced to practice by or on behalf of Paragon under a Research Program that constitutes the composition of matter of (i)&nbsp;any Project ATV as a whole, or (ii)&nbsp;any Project Antibody included in a Project ATV, and (b)&nbsp;all Intellectual
Property Rights therein that are Controlled by Paragon or its Affiliates. Project ATV Inventions expressly exclude any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under a
Research Program that (x)&nbsp;constitutes Transit Antibody Inventions, or (y)&nbsp;does not specifically and solely relate to a Project ATV (including linkers with broader applicability to ATVs), and all Intellectual Property Rights in the
foregoing that are Controlled by Paragon or its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.97</B> &#8220;<B>Project ATV Patents</B>&#8221; shall mean, on a
Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, all Patents that Cover the composition of matter of (a)&nbsp;any Project ATV as a whole, or (b)&nbsp;any Project Antibody
included in a Project ATV, including Patents with the following claims: (i)&nbsp;claims to the Project Antibody included in a Project ATV; (ii)&nbsp;claims to the Project Antibody included in a Project ATV with any Transit Antibody included in a
Project ATV; and (iii)&nbsp;specific picture claims to the Project ATVs, that are in each case Controlled by Paragon or its Affiliates. Project ATV Patents shall exclude Transit Antibody Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.98</B> &#8220;<B>Project ATV Samples</B>&#8221; shall, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in Section&nbsp;2.1(e)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.99</B> &#8220;<B>Project ATV Selection Criteria</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, those criteria agreed to by the Parties in the Research Plan that establish that a Project ATV is suitable for clinical testing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.100</B> &#8220;<B>Project ATV Technology</B>&#8221; shall mean, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, (a)&nbsp;the Project ATV Inventions, (b)&nbsp;the Project ATV Patents, (c)&nbsp;the Project ATV Information and Results, and (d)&nbsp;all
Intellectual Property Rights therein that are Controlled by Paragon and its Affiliates, but excluding in each case any Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP. For clarity, if the Parties execute the License Agreement for a
Research Program and the Research Term for such Research Program continues following execution of such License Agreement, any Project ATV Technology under such Research Program first conceived, reduced to practice or otherwise generated following
the execution of such License Agreement shall be exclusively licensed to Korsa under such License Agreement as described in <U>Exhibit B</U>. The Project ATV Technology shall exclude the Paragon Platform Technology, the Transit Antibody Technology,
the Other Transit Antibody IP and the Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.101</B> &#8220;<B>Regulatory
Approval</B>&#8221; shall mean all clearances, approvals (including approval of an MAA as well as any applicable pricing and/or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially
distribute, sell and market a pharmaceutical or biologic product in a country or territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.102</B> &#8220;<B>Regulatory
Authority</B>&#8221; shall mean any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture, marketing
or sale of a pharmaceutical or biologic product in a country or region, including the FDA in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.103</B>
&#8220;<B>Representatives</B>&#8221; of a Party shall mean such Party&#8217;s and its Affiliates&#8217; officers, directors, employees, contractors, subcontractors, agents and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.104</B> &#8220;<B>Research Plan</B>&#8221; shall, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, have the meaning provided in Section&nbsp;2.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.105</B> &#8220;<B>Research Program</B>&#8221; shall mean each research program agreed to by the Parties to (a)&nbsp;discover, generate,
identify and characterize ATVs that include Transit Antibodies Directed To the Selected Transit Target (and no other Targets) and either (i)&nbsp;Therapeutic Antibodies Directed To a single, mutually agreed Therapeutic Target (and no other Targets)
(a &#8220;<B>Single Therapeutic Target Research Program</B>&#8221;), or (ii)&nbsp;Therapeutic Antibodies Directed To two mutually agreed Therapeutic Targets (and no other Targets) (a &#8220;<B>Dual Therapeutic Target Research Program</B>&#8221;),
and in each case to perform such additional activities with respect to such ATVs, and (b)&nbsp;conduct certain other activities to develop Transit Antibody Technology, including with respect to Transit Antibodies that may be Directed To Brain
Transit Targets other than the Selected Transit Target, in each case of (a)&nbsp;and (b) as set forth in the applicable Research Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.106</B> &#8220;<B>Research Term</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, the period of time beginning on the agreement by the Parties on the Research Plan for such Research Program and continuing until
completion of the activities under such Research Plan or such other date mutually agreed upon by the Parties; <I>provided, that</I> (a)&nbsp;if Korsa does not exercise the Option for such Research Program in accordance with Section&nbsp;4.3 prior to
expiration of the applicable Option Period, then upon such expiration the Research Term shall automatically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminate and Paragon shall have no obligation to perform any activities under such Research Plan thereafter, or (b)&nbsp;if Korsa exercises the Option during the applicable Option Period in
accordance with Section&nbsp;4.3 but (i)&nbsp;the Parties are unable to finalize and execute a License Agreement and (ii)&nbsp;neither Party has delivered notice of a License Agreement Dispute during the applicable [***] period in accordance with
Section&nbsp;4.4, then upon the expiration of such period the Research Term shall automatically terminate and Paragon shall have no obligation to perform any activities under such Research Plan thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.107</B> &#8220;<B>Results</B>&#8221; shall mean, on a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, the data, results, analysis, conclusions, outcomes, information, documentation, and reports that are generated by or on behalf of
Paragon in performance of a Research Program with respect to the Project ATVs, excluding Project ATVs, Project ATV Inventions, Project ATV Patents, the Project ATV Information and Transit Antibody Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.108</B> &#8220;<B>Royalty Product</B>&#8221; shall have the meaning provided in <U>Exhibit B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.109</B> &#8220;<B>Selected Therapeutic Target</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.110</B> &#8220;<B>Selected Transit Target</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.111</B> &#8220;<B>Shares</B>&#8221; shall mean shares of common stock, par value $0.0001, of Korsa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.112</B> &#8220;<B>Single Therapeutic Target Research Program</B>&#8221; shall have the meaning provided in Section&nbsp;1.105. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.113</B> &#8220;<B>Target</B>&#8221; shall mean a protein molecule that (a) [***], and (b) [***]. Targets shall include Therapeutic
Targets and Brain Transit Targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.114</B> &#8220;<B>Term</B>&#8221; shall have the meaning provided in Section&nbsp;9.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.115</B> &#8220;<B>Territory</B>&#8221; shall mean worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.116</B> &#8220;<B>Therapeutic Antibody</B>&#8221; shall have the meaning provided in Section&nbsp;1.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.117</B> &#8220;<B>Therapeutic Target</B>&#8221; shall mean a protein molecule that (a) [***], and (b) [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.118</B> &#8220;<B>Third Party</B>&#8221; shall mean any person or entity other than Paragon, Parasa or Korsa or an Affiliate of any of
Paragon, Parasa or Korsa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.119</B> &#8220;<B>Third Party Claim</B>&#8221; shall have the meaning provided in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.120</B> &#8220;<B>Transit Antibody</B>&#8221; shall have the meaning provided in Section&nbsp;1.8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.121</B> &#8220;<B>Transit Antibody Information</B>&#8221; shall mean, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, electronic files containing the sequences of all Transit Antibodies included in the Project ATVs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.122</B> &#8220;<B>Transit Antibody Invention</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, (a)&nbsp;any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under a Research Program that
constitutes the composition of matter of any Transit Antibody or that relates to Transit Antibody discovery or development or methods of using, making or manufacturing Transit Antibodies or their components, and (b)&nbsp;all Intellectual Property
Rights therein that are Controlled by Paragon or its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.123</B> &#8220;<B>Transit Antibody Patents</B>&#8221; shall mean,
on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, all Patents that Cover the composition of matter of, or any method of using, making or manufacturing, any Transit
Antibody, including Patents with the following claims: (a)&nbsp;claims to the Transit Antibody included in a Project ATV; and (b)&nbsp;claims to the Transit Antibody included in a Project ATV with any second monospecific or multispecific Antibody
(other than any such claims that expressly recite the sequence of the Project Antibody included in a Project ATV), that are in each case Controlled by Paragon or its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.124</B> &#8220;<B>Transit Antibody</B> <B>Results</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, the data, results, analysis, conclusions, outcomes, information, documentation, and reports that are generated by or on behalf of Paragon in performance of a Research
Program to the extent relating to Transit Antibodies, including the Transit Antibody Information but excluding Transit Antibodies, Transit Antibody Inventions and Transit Antibody Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.125</B> &#8220;<B>Transit Antibody Technology</B>&#8221; shall mean, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, (a)&nbsp;the Transit Antibody Inventions, (b)&nbsp;the Transit Antibody Patents, (c)&nbsp;the Transit Antibody Information and the Transit Antibody Results, and (d)&nbsp;all
Intellectual Property Rights therein that are Controlled by Paragon and its Affiliates. The Transit Antibody Technology shall exclude the Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP and the Other Transit Antibody IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.126</B> &#8220;<B>Valid Claim</B>&#8221; shall mean, with respect to particular Patent in a particular country, (a)&nbsp;a claim of an
issued and unexpired patent (including the term of any patent term extension, supplemental protection certificate, renewal or other similar extension) in such country within such Patent that has not been abandoned or revoked, or held unpatentable,
invalid or unenforceable in a final decision of a court or other governmental authority of competent jurisdiction from which no appeal may be taken, or has been taken before the expiry of the permitted time period, and that has not been disclaimed,
denied or admitted to be invalid or unenforceable through reissue, <FONT STYLE="white-space:nowrap">re-examination,</FONT> disclaimer or otherwise, or (b)&nbsp;a claim within a patent application in such country within such Patent that has not been
pending more than [***] years from the earliest priority date of such claim and which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDUCT OF RESEARCH PROGRAM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 Research Program. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Overview</B>. The Parties intend to initiate one or more Research Programs, each focused on (i)&nbsp;discovering, generating,
identifying and characterizing one or more ATV candidates that comprise or contain (x) (1)&nbsp;with respect to a Single Therapeutic Target Research Program, a Therapeutic Antibody Directed To a single, mutually agreed Therapeutic Target (and no
other Targets), or (2)&nbsp;with respect to a Dual Therapeutic Target Research Program, a first Therapeutic Antibody Directed To the first mutually agreed Therapeutic Target (and no other Targets) and a second Therapeutic Antibody Directed To the
second mutually agreed Therapeutic Target (each Therapeutic Target that is the subject of a Research Program, a &#8220;<B>Selected Therapeutic Target</B>&#8221;), and (y)&nbsp;a Transit Antibody Directed To a mutually agreed Brain Transit Target
(the &#8220;<B>Selected Transit Target</B>&#8221;), and (ii)&nbsp;conducting certain other activities to develop Transit Antibody Technology, including with respect to Transit Antibodies that may be Directed To Brain Transit Targets other than the
Selected Transit Target, in each case of (i)&nbsp;and (ii) as further set forth in the Research Plan for such Research Program. As of the Effective Date, the Parties have agreed to the Research Programs listed on <U>Exhibit A</U>, labeled as
&#8220;<B>Research Program 001</B>,&#8221; &#8220;<B>Research Program 002</B>&#8221; and &#8220;<B>Research Program 003</B>.&#8221; The Parties acknowledge and agree that Research Program 003 is [***], and references to a Research Programs with
respect to Research Program 003 shall be interpreted accordingly. Additional Research Programs may be added to this Agreement by mutual written agreement of the Parties, it being understood that each Party may accept or reject a new Research Program
in its sole discretion and no Party shall be obligated under this Agreement to agree to any further Research Programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>Research Plan. </B>No later than [***] after the Effective Date (or, in the case of any Research Program added after the Effective Date, no later than [***] after the Parties&#8217; written agreement on such additional Research Program), the
Parties will agree on a research plan, to the extent a research plan has not been previously agreed upon, for each Research Program that will include design, modeling, synthesis, evaluation, and other mutually agreed activities (&#8220;<B>Research
Plan</B>&#8221;). The Research Plan shall also provide for the use of any Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP or Korsa IP and the performance of any CMC Activities that have been agreed by the Parties for a Research
Program. For clarity, if at the end of such [***] period (or any extension thereof mutually agreed in writing)&nbsp;(i) the Parties have not agreed on the Research Plan for a Research Program, or (ii)&nbsp;Korsa has not paid Paragon the Research
Initiation Fee for a Research Program, Paragon shall have no obligations to Korsa with respect to such Research Program or the corresponding ATVs that include Therapeutic Antibodies Directed To the Selected Therapeutic Target(s) and Transit
Antibodies Directed To the Selected Transit Target. Once the Parties agree on the Research Plan and Korsa pays the Research Initiation Fee for a Research Program, Paragon and Parasa shall conduct research under such Research Program during the
Research Term in an effort to (1)&nbsp;discover, generate, identify or characterize Project ATVs for further Development, Manufacture and Commercialization (&#8220;<B>ATV Production Activities</B>&#8221;), (2) perform certain other activities with
respect to the Project ATVs, including Development and Manufacturing activities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to the Project ATVs, and (3)&nbsp;conduct certain other activities to develop Transit Antibody Technology, in each case of (1)&nbsp;through (3) (inclusive) if and as set forth in the
applicable Research Plan (which other activities, for clarity, may be performed following Korsa&#8217;s exercise of the Option or execution of a License Agreement for such Research Program). The Parties may amend a Research Plan upon mutual written
agreement. Paragon and Parasa will use [***] to conduct and complete the activities set forth in a Research Plan on the timelines set forth in such Research Plan and in compliance with the Budget for such Research Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) Use of Other Technology. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Parties desire for Paragon to use Third Party Intellectual Property Rights Controlled by Paragon (e.g., huMab murine
models, linkers or technology relating to Transit Antibodies) (&#8220;<B>Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP</B>&#8221;) in the conduct of a Research Program, then (x)&nbsp;such use shall be set forth in the Research Plan
for such Research Program, and (y)&nbsp;Korsa shall be responsible for paying to Paragon as part of the Development Fees the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If the Parties desire for Paragon to use (x)&nbsp;Intellectual Property Rights owned by Korsa or its Affiliates, or
(y)&nbsp;Intellectual Property Rights <FONT STYLE="white-space:nowrap">in-licensed</FONT> by Korsa or its Affiliates from Third Parties (e.g., linkers or technology relating to Transit Antibodies) ((x) and (y)&nbsp;collectively,
&#8220;<B>Korsa</B><B> IP</B>&#8221;) in the conduct of a Research Program, then (1)&nbsp;such use shall be set forth in the Research Plan for such Research Program, (2)&nbsp;Korsa shall be responsible for obtaining any necessary licenses and rights
with respect to any <FONT STYLE="white-space:nowrap">in-licensed</FONT> Korsa IP to enable Paragon and Parasa to access and use such <FONT STYLE="white-space:nowrap">in-licensed</FONT> Korsa IP to conduct such Research Program in accordance with the
applicable Research Plan, and (3)&nbsp;Korsa shall be responsible for all costs to provide Paragon with the right to access and use such Korsa IP in the conduct of such Research Program. During the Research Term for any Research Program in which
Korsa IP is used, Korsa hereby grants to Paragon and Parasa a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable (to Paragon&#8217;s and Parasa&#8217;s Third Party service providers, subcontractors, consultants and other agents
performing activities on behalf of Paragon or Parasa under the Research Program), royalty-free and fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license under the Korsa IP to access and use the Korsa IP to conduct such Research Program in
accordance with the applicable Research Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) CMC Activities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Korsa may request that Paragon perform CMC Activities for a particular Project ATV in furtherance of a Research Program by
selecting one (1)&nbsp;Project ATV from such Research Program (the &#8220;<B>CMC Project ATV</B>&#8221;) and a CMC Activities package from the options set forth on <U>Exhibit</U><U></U><U>&nbsp;C</U> (the &#8220;<B>CMC Activities Package</B>&#8221;)
and delivering written notice thereof to Paragon during the applicable Research Term. Following receipt of such notice, if Paragon, in its sole discretion, agrees in writing to perform such CMC Activities for the CMC Project ATV, then the Parties
shall, through the JDC, mutually agree on an amendment to the Research Plan for such Research Program that shall include (1)&nbsp;the CMC Activities to be performed by Paragon for the CMC Project ATV, (2)&nbsp;an updated Budget that includes the
total fee corresponding to the mutually agreed CMC Activities Package as set forth on <U>Exhibit C</U> (the &#8220;<B>CMC Fee</B>&#8221;) and any estimated Third Party Costs to be incurred by Paragon in the performance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the CMC Activities as part of the Development Fees, and (3)&nbsp;the estimated number of months until completion of the CMC Activities corresponding to the mutually agreed CMC Activities
Package as set forth on <U>Exhibit C</U> (the &#8220;<B>CMC Estimated Timeline</B>&#8221;). If CMC Activities are completed prior to the end of the CMC Estimated Timeline, the total CMC Fee related to the CMC Activities will still be payable to
Paragon. Any portion of the CMC Fee that was not billed prior to completion of the CMC Activities shall be invoiced to Korsa upon completion of the CMC Activities. If Korsa requests any material changes to the scope of any CMC Activities, and
Paragon, in its sole discretion, agrees to such changes, or the Parties otherwise agree to changes to the scope of any CMC Activities, then the Parties shall, through the JDC, mutually agree on an amendment to the applicable Research Plan, which
shall include such changes, and any adjustments to the CMC Fee (and corresponding CMC Monthly Fee) to account for the impact of such changes on Paragon&#8217;s costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The JDC shall oversee the performance of the CMC Activities and shall have the authority to determine whether, based on the
progress of such CMC Activities, the CMC Activities should be performed with respect to a different Project ATV. If the JDC makes such determination, Korsa shall have the <FONT STYLE="white-space:nowrap">one-time</FONT> right, exercisable upon
written notice within [***] of the JDC&#8217;s determination, to substitute the CMC Project ATV with a different Project ATV (such Project ATV, the &#8220;<B>CMC Substitution Project ATV</B>&#8221;). If Paragon agrees, in its sole discretion, to
perform the CMC Activities for the CMC Substitution Project ATV, the Parties shall update the applicable Research Plan, a new CMC Fee and CMC Estimated Timeline shall apply to such CMC Activities, and any unpaid portion of the CMC Fee for the CMC
Activities for the original CMC Project ATV shall be waived. If Paragon does not agree to proceed with CMC Activities for the CMC Substitution Project ATV, the Parties shall amend the applicable Research Plan so that it does not require the
performance of any CMC Activities or further payment of the CMC Fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) Deliverables; Project ATV Samples. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> On a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis
following completion of the ATV Production Activities set forth in the applicable Research Plan, Paragon and Parasa will deliver to Korsa a data package that includes the Project ATV Information, the Transit Antibody Information and the Results for
the then-existing Project ATVs for such Research Program (the &#8220;<B>Deliverables</B>&#8221;). Additionally, upon request by Korsa, and at [***] cost and expense, Paragon and Parasa shall provide to Korsa samples of the Project ATVs for such
Research Program that have been expressed in accordance with the applicable Research Plan (&#8220;<B>Project ATV Samples</B>&#8221;) to enable Korsa to evaluate the Option. Following completion of a Research Program, Paragon shall deliver to Korsa
the Final Deliverable for such Research Program, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> During the Option Period with respect to each Research Program,
Korsa will review the Deliverables and Project ATV Samples for such Research Program to determine whether [***] Project ATV for such Research Program meets the applicable Project ATV Selection Criteria. If Korsa determines that [***] Project ATV for
such Research Program meets the applicable Project ATV Selection Criteria, then Korsa shall so notify Paragon in writing prior to the end of the applicable Option Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Conduct of Research Program. </B>On a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis during the applicable Research Term,<B> </B>Paragon and Parasa shall (i)&nbsp;perform the activities assigned to it under the
applicable Research Plan in a professional, diligent and good scientific manner, in compliance with all Applicable Law, and in compliance with such Research Plan; (ii)&nbsp;ensure that its Representatives and subcontractors diligently perform such
Research Program in a manner in accordance with generally accepted industry practices by appropriately trained personnel who are experienced in the relevant fields and in compliance with Applicable Law; (iii)&nbsp;keep Korsa fully informed regarding
the progress and results of such Research Program; (iv)&nbsp;promptly provide Korsa with any additional information regarding such Research Program that Korsa reasonably requests; (v)&nbsp;participate in teleconference(s) at a time(s) agreed upon by
the Parties to provide an update to Korsa on the performance of such Research Program; and (vi)&nbsp;give Korsa prompt written notice with respect to information known or believed by Paragon and Parasa to be likely to materially impede or otherwise
adversely affect the performance of such Research Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Subcontractors. </B>Paragon and Parasa may perform the
activities under each Research Program through one or more subcontractors; <I>provided, that</I> Paragon and Parasa shall at all times be fully responsible for the compliance of such subcontractors with this Agreement and for the performance of
their obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Research Books and Records; Audit</B>.<B> </B>Paragon shall maintain complete and
accurate records related to the activities performed by Paragon under each Research Program. All such books and records shall be retained by Paragon and Parasa on a Research <FONT STYLE="white-space:nowrap">Program-by-Research</FONT> Program basis
until the later of: (a) [***] after the end of the applicable stage of research; and (b)&nbsp;such longer period as may be required by Applicable Law. Upon Korsa&#8217;s request and at [***] expense, Paragon shall provide copies of such records or
such records shall be made available for Korsa&#8217;s reasonable review, audit and inspection upon reasonable notice and with reasonable frequency. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Joint Development Committee</B>. The Parties will establish a single Joint Development Committee (the
&#8220;<B>JDC</B>&#8221;) to oversee and coordinate the activities under each Research Program in accordance with the remainder of this 2.3. The JDC shall be comprised of two (2)&nbsp;employees from Korsa and two (2)&nbsp;employees from Paragon,
with each Party designating one (1)&nbsp;such employee as its JDC <FONT STYLE="white-space:nowrap">co-chairperson.</FONT> Subject to the foregoing, each Party shall appoint its respective representatives to the JDC from time to time, and may change
its representatives, in its sole discretion, effective upon notice to the other Parties designating such change. Representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to and ongoing
familiarity with the activities to be performed under each Research Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>JDC Meetings</B>. The JDC shall meet in accordance with a schedule established
by mutual written agreement of the Parties no less frequently than once every three (3)&nbsp;months, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, until the end of
the period specified in Section&nbsp;3.4. The JDC may meet by means of teleconference, videoconference or other similar means, as jointly determined by the Parties. As appropriate, additional employees or consultants may from time to time attend the
JDC meetings as nonvoting observers; <I>provided, that</I> any such consultant shall agree in writing to comply with the confidentiality obligations under this Agreement; and <I>provided, further</I> <I>that</I> no Third Party personnel may attend
unless otherwise agreed by all Parties. Each Party shall bear its own expenses related to the attendance of the JDC meetings by its representatives. Each Party may also call for special meetings to resolve particular matters requested by such Party.
Paragon shall be responsible for keeping minutes of each JDC meeting that record in writing all decisions made, action items assigned or completed and other appropriate matters. Paragon shall send meeting minutes to all members of the JDC within
[***] after a meeting for review. Each member shall have [***] from receipt in which to comment on and to approve/provide comments to the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time
period, does not notify the drafting Party that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>JDC Functions</B>. The JDC&#8217;s responsibilities are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Developing, reviewing, overseeing and coordinating the activities under each Research Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Periodically reviewing the progress of activities under each Research Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Updating or modifying each Research Plan; <I>provided, that</I> such update or modification does not obligate any Party to perform
any task or expend any resources outside of or beyond its obligations under the applicable Budget; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Reviewing performance
against the applicable Budget and timeline for each Research Program periodically (at least [***]), and periodically meeting to review and (subject to mutual approval of the Parties) approving any discovery project Budget deviation where such
deviation is greater than [***] percent [***]%); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Reviewing the reconciliation of Actual Quarterly Costs at the end of each
Calendar Quarter for each Research Program; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Determining whether the Project ATV Selection Criteria for a Research Program are
not achievable for any reason and therefore such Research Program no longer warrants further research; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> Determining
whether, based on the progress of the CMC Activities for a CMC Project ATV, the CMC Activities should be performed with respect to a different Project ATV. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>JDC Decision Making and Disputes</B>. The JDC will endeavor to make decisions
by consensus, with each of Korsa and Paragon having one vote. If consensus is not reached by the Parties&#8217; Representatives pursuant to such vote, then disputes relating to: (a)&nbsp;the reconciliation of Actual Quarterly Costs, as set forth in
Section&nbsp;5.2(c), will be resolved in accordance with Section&nbsp;11.6; (b) technical or scientific decisions in the course of operationalizing a Research Program, including the nature of activities to be performed by Paragon and Parasa
thereunder and the determination as to whether the CMC Activities should be performed with respect to a different Project ATV, shall be finally decided by [***]; and (c)&nbsp;the Budget for each Research Program (except with respect to the CMC Fee,
which is determined in accordance with Section&nbsp;2.1(c)(ii)), and all other matters not covered by clauses (a)&nbsp;or (b), shall be finally decided by [***]. For clarity, and notwithstanding the creation of the JDC, each Party shall retain the
rights, powers and discretion granted to it hereunder, and the JDC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing.
The JDC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JDC shall be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided
by the JDC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JDC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B>
<B>Disbandment</B>. The JDC shall remain in effect from the date on which it is established in accordance with Section Article 3 until, on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT>
Program basis, the expiration of the applicable Research Term. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION; LICENSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Grant of Option.</B> Subject to the terms and conditions of this Agreement, on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, Paragon hereby grants to Korsa, during the Term and subject to delivery of the Election Notice in accordance with Section&nbsp;4.3, an exclusive option
(&#8220;<B>Option</B>&#8221;) to be granted an exclusive license under the Project ATV Technology and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under the Licensed Transit Antibody Technology, in each case, for the applicable
Research Program, to Develop, Manufacture and Commercialize Korsa Products in the Field in the Territory as further described on <U>Exhibit B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Limited</B><B> License Grant During Option Period.</B> Subject to the terms and conditions of this Agreement, on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, and effective only during the Term, Paragon hereby grants to Korsa (a)&nbsp;a limited, exclusive, royalty-free license, without the right to
sublicense, under the Project ATV Technology for such Research Program and, to the extent Controlled by Paragon for this purpose and applicable, the Paragon <FONT STYLE="white-space:nowrap">In-Licensed</FONT> IP for such Research Program, and
(b)&nbsp;a limited, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free license, without the right to sublicense, under the Licensed Transit Antibody Technology for such Research Program, in each case solely to evaluate the Option
and for the purpose of allowing Korsa to determine whether to exercise the Option with respect to such Research Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Option </B><B>Exercise.</B> On a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, Korsa may, in its sole discretion, exercise the Option for a Research Program by delivering written notice of such exercise to Paragon (&#8220;<B>Election Notice</B>&#8221;)
at any time during the period beginning on the initiation of activities under such Research Program and ending [***] following Korsa&#8217;s receipt of the Deliverables for such Research Program, or such longer period as agreed upon by the Parties
(&#8220;<B>Option Period</B>&#8221;). If Korsa fails to exercise the Option for a Research Program in accordance with this Section&nbsp;4.3 prior to expiration of the applicable Option Period, then, upon such expiration, such Option shall terminate
and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>License Agreement Execution After Option Exercise. </B>Within ninety (90)&nbsp;days
of Korsa&#8217;s exercise of the Option with respect to a Research Program as set forth in Section&nbsp;4.3, subject to any extension as mutually agreed by the Parties, the Parties shall use reasonable efforts to finalize and execute a definitive
written agreement consistent with the economic and other terms set forth in <U>Exhibit B</U> (the &#8220;<B>License Agreement</B>&#8221;). If the Parties, despite using reasonable efforts to reach definitive agreement on the terms of the License
Agreement, are unable to finalize and execute the License Agreement within such ninety (90)&nbsp;day period (as may be extended), then either Party may elect to resolve such dispute (a &#8220;<B>License Agreement Dispute</B>&#8221;) in accordance
with <U>Exhibit</U><U></U><U>&nbsp;D</U> by providing written notice thereof to the other Party within [***] following the end of such ninety <FONT STYLE="white-space:nowrap">(90)-day</FONT> period. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAYMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Research Initiation Fee</B>. Korsa shall pay to Paragon a <FONT STYLE="white-space:nowrap">one-time</FONT>
nonrefundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> fee of One Million Dollars ($1,000,000) for each Research Program (each such fee, a &#8220;<B>Research Initiation Fee</B>&#8221;) no later than thirty (30)&nbsp;days following
finalization of the Research Plan for each such Research Program. For clarity, the Research Initiation Fees are nonrefundable, <FONT STYLE="white-space:nowrap">non-creditable,</FONT> and separate from any Development Costs (including the <FONT
STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs) or Cost Advance paid or owing with respect to each Research Program. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Development Costs</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The monthly rate for the Development Fees (the &#8220;<B>Monthly Rate</B>&#8221;) shall be determined and charged on a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program and calendar <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-by-calendar</FONT></FONT> month basis. For the period
beginning on the Effective Date and continuing through December&nbsp;31, 2025, the Monthly Rate for each Research Program in a particular calendar month shall be [***]. Paragon shall have the right to adjust the Monthly Rate on a [***] basis to
account for inflation and other increases in costs by providing written notice thereof to Korsa at least [***] prior to the end of the [***].</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> On a quarterly and Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT>
Program basis, unless Korsa has already paid a Cost Advance for the prior Calendar Quarter in accordance with Section&nbsp;5.2(c), Paragon will deliver an invoice to Korsa for the Development Costs incurred by Paragon in the performance of each
Research Program during such Calendar Quarter, including [***] and any [***] incurred during such Calendar Quarter in a manner consistent with the applicable Budget, and Korsa will pay such amount within [***] after receipt of Paragon&#8217;s
invoice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> At Paragon&#8217;s request, on a quarterly and Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, Korsa will advance to Paragon any Development Costs contemplated in the applicable Budget, including [***], and any [***] reasonably
expected to be incurred by Paragon in the performance of such Research Program during the upcoming Calendar Quarter in accordance with applicable Research Plan and Budget (less any <FONT STYLE="white-space:nowrap">pre-payments</FONT> for Third Party
Costs from earlier Calendar Quarters that Paragon reasonably anticipates will be carried over to such upcoming Calendar Quarter) (the &#8220;<B>Cost Advance</B>&#8221;). Paragon&#8217;s request for the Cost Advance for an upcoming Calendar Quarter
will be made by delivering an invoice to Korsa prior to the start of such Calendar Quarter, and Korsa will pay the Cost Advance within [***] after receipt of Paragon&#8217;s invoice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Within [***] after the end of each Calendar Quarter in which any Third Party Costs have been paid, Paragon will calculate and
provide to Korsa a written reconciliation on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis of its actually-incurred Third Party Costs (incurred in a manner consistent
with the Budget) for the prior Calendar Quarter for which any Third Party Costs have been paid (&#8220;<B>Actual Quarterly Costs</B>&#8221;) against the Third Party Costs paid for that Calendar Quarter, including reasonable documentation of such
Actual Quarterly Costs. The form of such reconciliation shall be subject to JDC review and approval. If the amounts paid for Third Party Costs for a Research Program exceed the Actual Quarterly Costs for such Research Program, then Paragon will
credit such excess payment against Development Costs contemplated in the applicable Budget for such Research Program and reasonably expected to be incurred by Paragon in the performance of such Research Program during any upcoming Calendar Quarter
and Korsa will deduct such amount from its next quarterly invoice. If the amounts paid for Third Party Costs for a Research Program are less than the Actual Quarterly Costs for such Research Program, then Paragon will invoice Korsa for the
difference and Korsa will pay such amount together with its next quarterly invoice for such Research Program. If no further amounts will be owed to Paragon hereunder, Paragon will refund such amount. For clarity, the above reconciliation will not
apply to Development Fees for a Research Program. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding Sections 5.2(a), 5.2(b), 5.2(c) and 5.2(d) to the contrary,
the Parties acknowledge that Paragon has incurred (i)&nbsp;approximately $11,016,135 in Development Costs through July&nbsp;31, 2025, and (ii)&nbsp;certain additional Development Costs between August&nbsp;1, 2025 and the Effective Date, as a result
of work performed by Paragon at risk on Research Programs 001, 002, and 003 (the costs described in (i)&nbsp;and (ii), the &#8220;<B><FONT STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs</B>&#8221;). Korsa shall reimburse
Paragon for the <FONT STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs within [***] after Korsa&#8217;s receipt of a written invoice that details the <FONT STYLE="white-space:nowrap">Pre-Effective</FONT> Date Development Costs.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> If a Research Plan requires Paragon to perform CMC Activities in furtherance of the applicable Research Program, then Korsa
shall pay to Paragon the CMC Monthly Fee until the full amount of the CMC Fee has been paid. On a quarterly and Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, Paragon will
deliver an invoice to Korsa for the CMC Monthly Fees accrued for the prior Calendar Quarter, and Korsa will pay such amount within [***] after receipt of Paragon&#8217;s invoice. For clarity, the CMC Fee is separate from any Development Costs or
Cost Advance paid or owing with respect to a Research Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> All payments made by Korsa under this Section&nbsp;5.2 shall be <FONT
STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable</FONT> except as otherwise provided in Section&nbsp;5.2(d) with respect to reconciling excess amounts paid for Third Party Costs which cannot
otherwise be credited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Milestones</B>. On a Royalty
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Royalty</FONT></FONT> Product basis, Korsa shall make the following <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT>
and <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payments to Paragon (or to such other designee(s), as designated by Paragon) as set forth below (each payment, a &#8220;<B>Milestone Payment</B>&#8221;), based on the achievement
of the corresponding milestone set forth below (each, a &#8220;<B>Milestone</B>&#8221;) by Korsa, its Affiliates, or its sublicensees with respect to each such Royalty Product. Korsa shall, within [***] after it or its Affiliates achieve a
Milestone, or within [***] after it learns that its or its Affiliate&#8217;s sublicensee has achieved a Milestone, notify Paragon of the achievement of such Milestone in writing. Following receipt of such notice, Paragon shall invoice Korsa for such
Milestone Payment, and Korsa shall make such Milestone Payment to Paragon or Paragon&#8217;s designee within [***] after receipt of Paragon&#8217;s invoice. Each Milestone Payment shall be paid no more than once per Royalty Product, and
Korsa&#8217;s total Milestone Payments hereunder per Royalty Product (together with any such Milestone Payments per each such Royalty Product achieved and payable pursuant to a subsequently executed License Agreement) shall not exceed <FONT
STYLE="white-space:nowrap">Forty-Six</FONT> Million Dollars ($46,000,000). For avoidance of doubt, upon achievement of any Milestone for a Royalty Product, all prior unachieved Milestones for such Royalty Product shall be deemed thereby achieved
and, if the Milestone Payment for any such prior Milestone has not previously been paid, it shall thereupon also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid. The Parties acknowledge and agree
that once the License Agreement for a Research Program has been executed and is effective, any Milestone for a Royalty Product under such Research Program set forth in this Agreement that (a)&nbsp;has not yet been achieved, and (b)&nbsp;is
duplicated in such License Agreement, together with the corresponding Milestone Payment, shall no longer be achievable and payable under the terms of this Agreement and shall only be achievable and payable under the terms of such License Agreement.
Additionally, for the avoidance of doubt, if a Milestone with respect to a Royalty Product is achieved and paid by Korsa pursuant to this Agreement, then there shall be no Milestone Payment due for the achievement of such Milestone for such Royalty
Product under a subsequently executed License Agreement for the applicable Research Program, notwithstanding the inclusion of the same Milestone in <U>Exhibit B</U> hereto or in such License Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Regulatory/Development Milestones per Royalty Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Regulatory/Development Milestones per Royalty Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[***]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Section&nbsp;5.3, on a Royalty
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Royalty</FONT></FONT> Product basis, if Korsa ceases all Development of a first Royalty Product after the Achievement of a Development Candidate for such first Royalty
Product and, thereafter, Korsa&#8217;s Board of Directors nominates a second Royalty Product as a development candidate that is (x)&nbsp;a bona fide <FONT STYLE="white-space:nowrap">back-up</FONT> to such first Royalty Product, and (y)&nbsp;for the
same Selected Therapeutic Target(s), the same Selected Transit Target and the same indication (a &#8220;<B><FONT STYLE="white-space:nowrap">Back-Up</FONT> Royalty Product</B>&#8221;), then [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B>Financial Records</B><B>.</B> Paragon shall keep complete and accurate books of account and records in sufficient detail to
enable the Development Costs and Milestones payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Paragon, for at least [***] following the end of the [***] to which such books and
records pertain, and Korsa shall be entitled to inspect such books and records at Paragon&#8217;s offices upon Korsa&#8217;s reasonable request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B>Manner and Method of Payment</B>. All cash payment amounts hereunder are expressed in U.S. dollars (USD) unless otherwise
specified. Each payment shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless otherwise specified in writing by Paragon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B> <B>Tax</B>. Each Party shall be responsible for paying its own respective taxes in connection with any activities that it performs
and any payments that it receives under this Agreement. The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary in order for any Party to not pay or withhold tax or to pay or withhold tax at a reduced
rate under an applicable income tax treaty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B> <B>Late Payments</B>. In the event that any cash payment due for any undisputed
amount under this Agreement is not made when due, then the cash payment shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported by the <I>Wall Street Journal</I> (U.S., Western
Edition) or, if lower, the maximum legal annual interest rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B> <B>Equity Grants</B>. Except as expressly agreed otherwise by
the Parties in writing, upon completion of each of the Calendar Years ending December&nbsp;31, 2025 and December&nbsp;31, 2026, Korsa will grant to Parasa a warrant to purchase a number of Shares equal to 1.00% of the outstanding Shares as of the
date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred stock, stock options, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or
similar instruments), with an exercise price equal to the fair market value of the underlying Shares on the date of the grant as determined by the board of directors of Korsa (each grant, an &#8220;<B>Equity Grant</B>&#8221;); <I>provided, that</I>
if Korsa undergoes an initial public offering or a reverse merger transaction the rights and obligations of this Section&nbsp;5.8 shall continue and Parasa shall be entitled to warrants from the ultimate public company parent to purchase a number of
shares of such parent equal to 1.00% of the outstanding shares of the parent as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred
stock, stock options, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or similar instruments), as applicable. Such warrants will be exercisable for a period of ten (10)&nbsp;years following the date of the grant. Each Equity Grant shall
be effected on the last Business Day of each applicable Calendar Year and the corresponding grant date shall be such date. If the Term with respect to all Research Programs ends prior to the end of a Calendar Year, the Equity Grant for such Calendar
Year shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for such Calendar Year and such Equity Grant shall be effected within five (5)&nbsp;Business Days of the end of the Term with respect to all Research Programs. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL
PROPERTY RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1 Ownership.</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Background IP</B>. As between the Parties, each Party will retain all right, title and interest in and to all of its Background
IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Project ATV Technology, Paragon Platform Technology and Transit Antibody Technology.</B> Subject to the rights and
licenses granted to Korsa in this Agreement, as between the Parties, Paragon or its Affiliates shall own all right, title and interest in and to all Project ATV Technology, Paragon Platform Technology and Transit Antibody Technology, irrespective of
inventorship. Korsa agrees to assign and hereby assigns to Paragon all of Korsa&#8217;s right, title and interest in and to the Project ATV Technology, Paragon Platform Technology and Transit Antibody Technology, including any and all Intellectual
Property Rights therein. Korsa shall execute and deliver, and shall cause its Affiliates to execute and deliver, such additional documents, instruments, conveyances and assurances and take any such further actions as may be reasonably required to
ensure that all right, title and interest in the Project ATV Technology, Paragon Platform Technology and Transit Antibody Technology is effectively assigned to and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held by Paragon. Korsa and its Affiliates shall cause all of its and their employees who, in each case, generated, conceived of or created any Project ATV Technology, Paragon Platform Technology
and Transit Antibody Technology to assign without additional consideration all ownership rights in such Project ATV Technology, Paragon Platform Technology and Transit Antibody Technology to Paragon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 Patent Prosecution, Maintenance and Enforcement &#8211; Project ATV Patents. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis,
prior to execution of a License Agreement for a Research Program, Paragon shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain or enforce any applicable Project ATV Patents at Paragon&#8217;s sole expense, and
Korsa shall reasonably cooperate and assist Paragon in such preparation, filing, prosecution, maintenance and enforcement, at Paragon&#8217;s request. On a Research
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis following execution of a License Agreement for a Research Program, (i)&nbsp;with respect to any applicable Project ATV Patents that
have been filed prior to the execution of such License Agreement, the Parties&#8217; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project ATV Patents shall be as set forth therein and Korsa
shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and maintenance of any such Project ATV Patents in accordance with the terms of such License Agreement, and (ii)&nbsp;with respect to any applicable
Project ATV Patents that have not been filed prior to the execution of such License Agreement, (1)&nbsp;Paragon, at its sole expense, shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain and enforce such Project
ATV Patents until the date on which the Final Deliverable for such Research Program is delivered to Korsa, and during such period Paragon shall provide Korsa with drafts of all proposed filings to any patent office with respect to such Project ATV
Patents in reasonably adequate time before submission of such filings for Korsa&#8217;s review and comment, and (2)&nbsp;following the date on which the Final Deliverable for such Research Program is delivered to Korsa, the Parties&#8217; respective
rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project ATV Patents shall be as set forth in such License Agreement and Korsa shall reimburse Paragon for any costs and expenses actually incurred by
Paragon in the prosecution and maintenance of any such Project ATV Patents in accordance with the terms of such License Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Korsa covenants and agrees that it will not file or prosecute any Patents Covering any Project Antibody, Derived Antibody, Project
ATV, Derived ATV or any component thereof, including any Project ATV Inventions, or any Transit Antibody Inventions, during the Term of this Agreement except as permitted under a License Agreement for the applicable Research Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Defense of Claims Brought by Third Parties.</B> If a Party becomes aware of any actual or potential claim that the Development,
Manufacture or Commercialization of any Project Antibody, Derived Antibody, Antibody Product, Multispecific Antibody, Multispecific Antibody Product, Project ATV, Derived ATV, ATV Product, Multispecific ATV, Multispecific ATV Product or any
component thereof infringes or in the future will infringe the Intellectual Property Rights of any Third Party, such Party will promptly notify the other Parties. In any such instance, the Parties will [***] thereafter meet (which may be through the
JDC) to discuss [***] regarding the best response to such notice. Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the License Agreement (to the extent applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> <B>No Implied Licenses.</B> Except as expressly set forth herein, no right or
license under any Patents, <FONT STYLE="white-space:nowrap">Know-How</FONT> or Intellectual Property Right of any Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly
provided in this Agreement or a License Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROTECTION OF CONFIDENTIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Confidentiality.</B> Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the
Term and for [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the
Disclosing Party. The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#8217;s Representatives who have a need for such information; <I>provided, that</I> the Receiving Party shall advise
such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as stringent as those contained in
this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of
its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. The Receiving Party shall promptly notify the Disclosing
Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>
<B>Exceptions.</B> The Receiving Party&#8217;s obligations under Section&nbsp;7.1 shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a)&nbsp;is now, or hereafter
becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available; (b)&nbsp;is known by the Receiving Party at the time of receiving such information from the Disclosing Party;
(c)&nbsp;is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d)&nbsp;is independently discovered or developed by the Receiving Party, without the aid, use or application of
any Confidential Information of the Disclosing Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Authorized Disclosure.</B> Notwithstanding the provisions of this Article 7,
the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable
Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange; <I>provided, that</I> the Receiving Party
shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at [***] request and expense, shall cooperate with the Disclosing Party&#8217;s efforts to contest such requirement, to obtain a protective order
requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential Information; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> reasonably necessary to file or prosecute patent applications, prosecute or defend litigation or otherwise establish rights or
enforce obligations under this Agreement, in each case, in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B>No Requirement to Disclose
Paragon Platform Technology or Transit Antibody Technology.</B> Notwithstanding anything to the contrary in this Agreement, Paragon will not be required to disclose any of the Paragon Platform Technology or Transit Antibody Technology to Korsa other
than as required to be included in the Deliverables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B>Use of Names.</B> No Party shall use any other Party&#8217;s name or
trademarks in any advertising, sales, or promotional material or in any publication without the prior written consent of such other Party or Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B>Confidentiality of this Agreement.</B> This Agreement and its terms are considered Confidential Information of all Parties, and
each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the applicable other Party, except as expressly permitted by Section&nbsp;7.3 or Section&nbsp;7.7, and
except that each Party may disclose this Agreement and its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations by such Third Parties or in confidential financing
documents; <I>provided</I>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth in this Article 7 (<I>provided,
that</I> the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7</B>
<B>Publicity.</B> Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, no Party shall issue a press release announcing that they have entered into an ATV discovery partnership, without the other
Parties&#8217; prior written consent, which shall not be unreasonably withheld. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>Mutual Representations and Warranties.</B> Each Party represents and warrants to each other that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate
or other power and authority to enter into this Agreement and to carry out the provisions hereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> it is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not
and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>Paragon Representations, Warrants and Covenants</B>. Paragon hereby represents, warrants and covenants to Korsa that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it will perform its activities under each Research Program with due care and in accordance with (i)&nbsp;Applicable Law,
(ii)&nbsp;the terms and conditions contained herein and the applicable Research Plan, and (iii)&nbsp;generally prevailing industry standards; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> neither it nor any of its Affiliates have entered or will enter, directly or indirectly, into any contract or any other transaction
with any Third Party or Affiliate that conflicts or derogates from its undertakings under this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> it has the right,
power and authority to use the Paragon Platform Technology in performance of each Research Plan and the performance of its obligations under this Agreement, in each case in accordance with the terms hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under each Research Program has
assigned and has executed an agreement assigning its entire right, title and interest in and to Project ATV Technology and Transit Antibody Technology to Paragon; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> there are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries initiated or written notices
received that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets or business, which would, individually or in the aggregate, have a material adverse effect on, or
materially prevent, Paragon&#8217;s ability to perform under this Agreement or to grant the Option or other rights granted to Korsa under this Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> none of Paragon, its Representatives, or any other person used by Paragon in the performance of this Agreement has been or is
(i)&nbsp;debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. &#167; 335a, (ii)&nbsp;listed by any government or regulatory agencies as
ineligible to participate in any Federal healthcare programs (as that term is defined in 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(f))</FONT> or government procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> programs, or
excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii)&nbsp;convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. Paragon
agrees to inform Korsa in writing promptly if Paragon or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is
pending or threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Disclaimer.</B> EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY
DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF
THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B> <B>Term.</B> The term of this Agreement (&#8220;<B>Term</B>&#8221;) shall commence on the Effective Date and, subject to earlier
termination in accordance with this Article 9, shall continue on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis until the expiration or termination of the applicable
Research Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B>Termination of Agreement for Material Breach.</B> Each Party shall have the right to terminate this
Agreement in its entirety or a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis upon thirty (30)&nbsp;days&#8217; prior written notice to the other Parties upon or after the
material breach of any provision of this Agreement by any other Party if the breaching Party has not cured such breach by the end of such thirty (30)&nbsp;day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B> <B>Termination for Convenience.</B> Korsa shall have the right to terminate this Agreement in its entirety or a Research <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis for any reason or no reason upon thirty (30)&nbsp;days&#8217; prior written notice to Paragon; <I>provided, that</I> (a)&nbsp;Korsa will pay
Paragon any unpaid fees due for Development Costs accrued prior to such effective termination date for any terminated Research Program, (b)&nbsp;Korsa will pay Paragon any <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations
reasonably incurred by Paragon in connection with its activities under any terminated Research Program, as evidenced by Paragon&#8217;s records, and (c)&nbsp;if the Research Plan for any terminated Research Program includes CMC Activities, and if
the aggregate amount of the CMC Monthly Fees paid by Korsa as of the effective date of termination for such Research Program is less than three-fourths (3/4) of the total CMC Fee, then Paragon will invoice Korsa for the difference between
three-fourths (3/4) of the total CMC Fee and the aggregate amount of the CMC Monthly Fees paid by Korsa as of the effective date of termination, which shall be payable by Korsa on a <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT
STYLE="white-space:nowrap">non-creditable</FONT> basis within [***] of receipt in accordance with Section&nbsp;5.5. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4</B> <B>Termination for Delay</B>. Paragon shall have the right to terminate this
Agreement on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis immediately upon written notice to Korsa if, as a result any action or failure to act by Korsa or its
Affiliates, a Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a period of four (4)&nbsp;consecutive months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B> <B>Termination for a Bankruptcy Event. </B><B></B>Each Party will have the right to terminate this Agreement in the event of a
Bankruptcy Event with respect to any other Party. &#8220;<B>Bankruptcy Event</B><B>&#8221;</B><B> </B>means the occurrence of any of the following: (a)&nbsp;the institution of any bankruptcy, receivership, insolvency, reorganization or other similar
proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended, or under any similar laws or statutes of the
United States or any state thereof (the &#8220;<B>Bankruptcy Code</B>&#8221;),<B> </B>where in the case of involuntary proceedings, such proceedings have not been dismissed or discharged within [***] after they are instituted, (b)&nbsp;the
insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c)&nbsp;the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not
involving the Bankruptcy Code, (d)&nbsp;the appointment of a receiver for all or substantially all of a Party&#8217;s assets, or (e)&nbsp;any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6</B> <B>Disposal of Confidential Information.</B> In the event this Agreement in its entirety or any Research Program expires or is
terminated and the Parties have not entered into a License Agreement with respect to any expired or terminated Research Program, each Party shall return to the applicable other Party all Confidential Information of such other Party (including all
copies thereof) in such Party&#8217;s possession related to such expired or terminated Research Program; <I>provided, however</I>, that each Party may retain one copy of such other Party&#8217;s Confidential Information in such Party&#8217;s secure
archives for the sole purpose of monitoring compliance with its obligations hereunder or Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7</B> <B>Accrued Rights;
Survival.</B> The expiration or termination of this Agreement for any reason shall not release any Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is
attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude any Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with
respect to breach of this Agreement. In the event of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions:
Article 5, Article 7, Article 10 and Article 11, as well as Sections 2.3, 6.1, 6.2, 6.4, 9.3, 9.6 and 9.7. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B> <B>By </B><B>Korsa</B><B>.</B> Korsa hereby agrees to defend, indemnify, and hold harmless Paragon, Parasa, their Affiliates and
their Representatives (each, a &#8220;<B>Paragon Indemnitee</B>&#8221;) from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense and attorneys&#8217; fees (collectively,
&#8220;<B>Losses</B>&#8221;), to which any Paragon Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#8220;<B>Third Party Claim</B>&#8221;)<B> </B>to the extent such Losses result from: (a)&nbsp;the negligence or willful misconduct of any Korsa Indemnitee in the performance of this Agreement;
or (b)&nbsp;the breach by any Korsa Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Paragon Indemnitee or the breach by Paragon of this Agreement, or where such
Losses are subject to indemnification pursuant to Section&nbsp;10.2 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2</B> <B>By Paragon.</B> Paragon hereby agrees to
defend, indemnify, and hold harmless Korsa, its Affiliates and its and their Representatives (each, an &#8220;<B>Korsa</B><B> Indemnitee</B>&#8221;) from and against any and all Losses to which any Korsa Indemnitee may become subject as a result of
any Third Party Claim to the extent such Losses result from: (a)&nbsp;the negligence or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (b)&nbsp;the breach by any Paragon Indemnitee of this Agreement; except, in
each case, to the extent such Losses result from the negligence or willful misconduct of any Korsa Indemnitee, the breach by Korsa of this Agreement, or where such Losses are subject to indemnification pursuant to Section&nbsp;10 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B> <B>Indemnification Procedure. </B><B></B>In connection with any Third Party Claim for which a Party (the &#8220;<B>Indemnified
Party</B>&#8221;)<B> </B>seeks indemnification from another Party (the &#8220;<B>Indemnifying Party</B>&#8221;)<B> </B>pursuant to this Agreement, the Indemnified Party will: (a)&nbsp;give the Indemnifying Party prompt written notice of the Third
Party Claim; <I>provided, however, </I>that failure to provide such notice will not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure;
(b)&nbsp;cooperate with the Indemnifying Party, at the Indemnifying Party&#8217;s expense, in connection with the defense and settlement of the Third Party Claim; and (c)&nbsp;permit the Indemnifying Party to control the defense and settlement of
the Third Party Claim; <I>provided, however, </I>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&#8217;s prior written consent, which will not be unreasonably withheld or delayed, in the event that such
settlement materially adversely impacts the Indemnified Party&#8217;s rights or obligations. Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its
selection and at its own expense.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B> <B>Limitation of Liability.</B> EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 7 OR FOR
INDEMNIFICATION CLAIMS UNDER ARTICLE 10, IN NO EVENT SHALL ANY PARTY BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE
POSSIBILITY OF SUCH DAMAGES. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B>
<B>Independent Contractor Relationship.</B> Each of Paragon&#8217;s and Parasa&#8217;s relationship with Korsa is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture or
employer-employee relationship. No Party is an agent of any other Party or authorized to make any representation, contract or commitment on behalf of any other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B> <B>Force Majeure. </B>No Party will be charged with any liability for delay or
failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor
disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law. The Party affected will give prompt written notice to the other Parties of the nature of the cause of any material delay or failure to perform,
its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and
will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give prompt written notice to the other Parties of such resumed performance. If any such failure or delay in a
Party&#8217;s performance hereunder continues for more than [***], any of the other Parties may terminate this Agreement upon written notice to the affected Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B> <B>Entire Agreement; Amendment.</B> This Agreement, together with all Exhibits attached hereto, constitutes the final, complete,
and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. This Agreement (including its Exhibits) may not be changed,
modified, amended, or supplemented except by a written instrument signed by all Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B>
<B><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></B> The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or
right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if
applicable, for a particular period of time and shall be signed by such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5</B> <B>Severability.</B> Should one or more of the
provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and
the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.6</B> <B>Assignment.</B> Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior
written consent of the other Parties (which consent shall not be unreasonably withheld); <I>provided, however</I>, that any Party may assign this Agreement and its rights and obligations hereunder without the other Parties&#8217; consent to its
successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of the Parties under this Agreement shall be binding upon
and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out
the intent of this section. Any assignment not in accordance with this Agreement shall be void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.7</B> <B>Dispute</B><B> Resolution.</B><B> </B>The Parties recognize that a <I>bona
fide </I>dispute as to certain matters may arise from time to time during the Term relating to any Party&#8217;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including
disputes relating to alleged breach or termination of this Agreement (but excluding any License Agreement Disputes or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the
Parties&#8217; respective Intellectual Property Rights) (hereinafter, a &#8220;<B>Dispute</B>&#8221;).<B> </B><B></B>In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute
or disagreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Party claiming that such a Dispute exists will give notice in writing (a &#8220;<B>Notice of
Dispute</B>&#8221;)<B> </B>to the other Parties of the nature of the Dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Dispute will be referred to the then Chief
Executive Officer or Chief Operating Officer of Paragon and the then Chief Executive Officer or President of Korsa who will meet no later than [***] following the initial receipt of the Notice of Dispute and use reasonable efforts to resolve the
Dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If, within [***] of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any
reason, the meeting described in Section&nbsp;11.7(b) hereof has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered
by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this Section&nbsp;11.7(c). The arbitration will be conducted by a
panel of three arbitrators. Within [***] after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [***] of their
appointment, who will serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least [***] of dispute resolution experience (which may include judicial experience) or legal or business experience in the
biotech or pharmaceutical industry. If any Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [***] period, JAMS will make the necessary appointments for
such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <I>ex </I><I>parte</I><I> </I>communication with its appointed arbitrator. The place of arbitration will be in Boston, Massachusetts or such other venue as the
Parties may mutually agree. The arbitration proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted in English translation accompanied by the original or a
true copy thereof. The arbitrators have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed by the Federal Arbitration Act, 9
U.S.C. &#167;&#167;1 <I>et seq., </I>and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant to this
Section&nbsp;11.7 will be deemed the Confidential Information of all Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Nothing in this Section&nbsp;11.7 will preclude either Party from seeking
equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any
arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. No remedy referred to in this Agreement is intended to be exclusive, but each will be cumulative and in addition to any
other remedy referred to in this Agreement or otherwise available under Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> The Parties agree that any disputes
relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights (which, for clarity, excludes License Agreement Disputes) will be submitted
to a court of competent jurisdiction in the country in which such Intellectual Property Rights were granted or arose; <I>provided, however</I>, that, in the case where such country is the United States, the sole jurisdiction and venue for all
actions, suits and proceedings arising out of any such dispute shall be the federal courts located in Boston, Massachusetts, and each Party hereby (i)&nbsp;irrevocably and unconditionally waives any objection to the laying of venue of any such
action, suit or proceeding in the federal courts of Boston, Massachusetts, and (ii)&nbsp;agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.8</B> <B>Governing Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts without reference to conflicts of laws principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.9</B> <B>Notices.</B> Any notice to be given under this Agreement
must be in writing and delivered either in person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior
written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a)&nbsp;the date of actual receipt; (b)&nbsp;if delivered by express courier, the next Business Day the express courier regularly makes
deliveries; or (c)&nbsp;if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to any other Party in accordance with this Section&nbsp;11.9, the Party
shall send a copy of such notice by email to such other Party. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Paragon or Parasa:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paragon Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">221 Crescent Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Building 23, Suite 105</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Waltham, MA 02453</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Korsa:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Korsa Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">221 Crescent Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Building 23, Suite 105</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Waltham MA 02453</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: [***]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.10</B> <B>Interpretation.</B> Except where the context expressly requires otherwise,
(a)&nbsp;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &#8220;include&#8221;,
&#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&nbsp;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word
&#8220;shall&#8221;, (d)&nbsp;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or
otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#8217;s or entity&#8217;s successors and
assigns, (f)&nbsp;the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g)&nbsp;all
references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h)&nbsp;the word &#8220;notice&#8221; means notice in writing (whether or
not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i)&nbsp;provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221;
&#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding <FONT
STYLE="white-space:nowrap">e-mail</FONT> and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement
or successor law, rule or regulation thereof, and (k)&nbsp;the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;or&#8221;. The headings of clauses contained in this Agreement preceding the
text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and
uncertainties in this Agreement, if any, shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the
English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English
language. To the extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any Research Plan, the terms and conditions of this Agreement will prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.11</B> <B>No Third Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the Parties and their successors
and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.12</B> <B>Counterparts.</B> This Agreement may be executed in counterparts, each of
which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as
original signatures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.13</B> <B>Expenses</B>. Each Party shall pay its own costs, charges and expenses incurred in connection with
the negotiation, preparation, and completion of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.14</B> <B>Binding Effect</B>. This Agreement shall be binding upon
and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.15</B>
<B>Construction</B>. The Parties hereto acknowledge and agree that: (a)&nbsp;each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rule of construction to the
effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c)&nbsp;the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in
a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.16</B>
<B>Cumulative Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available
under law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Remainder of page left intentionally blank; signature page follows.] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the Parties hereto
have executed this Antibody Discovery and Option Agreement on the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARAGON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>K<SMALL>ORSA</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Susanna High</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Violin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Susanna High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Violin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, President and Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARASA</SMALL> H<SMALL>OLDING</SMALL> LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Susanna High</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Susanna High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Antibody Discovery and Option Agreement] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>3
<FILENAME>d111069dex1030.htm
<DESCRIPTION>EX-10.30
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.30</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.30 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLATFORM OPTION
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> P<SMALL>LATFORM</SMALL> O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL>
(&#8220;<B>Agreement</B>&#8221;) is entered into and effective as of October&nbsp;16, 2025 (the &#8220;<B>Effective Date</B>&#8221;), by and among Paragon Therapeutics, Inc., a Delaware corporation (&#8220;<B>Paragon</B>&#8221;), Parasa Holding LLC,
a Delaware limited liability company (&#8220;<B>Parasa</B>&#8221;), and Korsana Biosciences, Inc., a Delaware corporation (&#8220;<B>Korsana</B>&#8221;). Paragon, Parasa and Korsana are also referred to herein individually as a
&#8220;<B>Party</B>&#8221;, or collectively as the &#8220;<B>Parties</B>.&#8221; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B><B> </B>the Parties are party to that certain Antibody Discovery and Option Agreement, dated as of
September&nbsp;5, 2025 (the &#8220;<B>Existing ADOA</B>&#8221;), pursuant to which Korsana is funding certain research activities to be undertaken by Paragon and Parasa, including the development of proprietary platform technology for the delivery
of therapeutic agents across the blood-brain barrier through receptor-mediated transcytosis; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> as
partial consideration for such funding, Korsana will have an exclusive option to enter into one or more agreements with Paragon to develop, manufacture and commercialize antibody transport vehicle compounds utilizing such proprietary platform
technology, all on the terms and subject to the conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>
</B><B>T<SMALL>HEREFORE</SMALL></B><SMALL><B></B></SMALL><B>, </B>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties, intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINED TERMS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>
&#8220;<B>Acquired Program</B>&#8221; shall have the meaning provided in Section&nbsp;2.4(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> &#8220;<B>Acquiring
Entity</B>&#8221; means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party&#8217;s Affiliates, other than the applicable entity Party in the definition of Change of Control and such Party&#8217;s
Affiliates immediately prior to the closing of such Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> &#8220;<B>Additional Reserved Target
Combination</B>&#8221; shall have the meaning provided in Section&nbsp;2.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> &#8220;<B>Additional Reserved Target Exercise
Notice</B>&#8221; shall have the meaning provided in Section&nbsp;2.3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> &#8220;<B>Additional Reserved Target
Limit</B>&#8221; shall have the meaning provided in Section&nbsp;2.3(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> &#8220;<B>Additional Reserved Target List</B>&#8221;
shall have the meaning provided in Section&nbsp;2.2(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> &#8220;<B>Additional Reserved Target Option</B>&#8221; shall have the meaning
provided in Section&nbsp;2.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> &#8220;<B>Additional Reserved Target Option Exercise Fee</B>&#8221; shall have the meaning
provided in Section&nbsp;4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> &#8220;<B>Additional Reserved Target Option Exercise Notice</B>&#8221; shall have the meaning
provided in Section&nbsp;2.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> &#8220;<B>Additional Reserved Target ROFR Notice</B>&#8221; shall have the meaning provided
in Section&nbsp;2.3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B> &#8220;<B>Additional Target Nomination Period</B>&#8221; shall have the meaning provided in
Section&nbsp;2.3(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B> &#8220;<B>ADOA Agreement</B>&#8221; shall have the meaning provided in Section&nbsp;3.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B> &#8220;<B>ADOA Option</B>&#8221; shall have the meaning provided in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B> &#8220;<B>Affiliate</B>&#8221; shall mean any entity controlled by, controlling, or under common control with a Party hereto. For
the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control&#8221;) means the direct or indirect ownership of more than fifty percent (50%) of the
voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding the foregoing, (a)&nbsp;with
respect to either Party, Affiliates of such Party do not include [***] or its Affiliates other than such Party and its subsidiaries, and [***] shall not be deemed to be a Parent Entity of either Party, (b) [***], and (c) [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B> &#8220;<B>Agreement</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B> &#8220;<B>Antibody</B>&#8221; shall mean any molecule, including [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B> &#8220;<B>Applicable Law</B>&#8221; shall mean any national, supra-national, federal, state or local laws, rules, guidances and
regulations, in each case, as applicable to the subject matter and the party at issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B> &#8220;<B>ART Option Exercise <FONT
STYLE="white-space:nowrap">Cut-Off</FONT> Date</B>&#8221; shall have the meaning provided in Section&nbsp;2.3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>
&#8220;<B>ART ROFR Period</B>&#8221; shall have the meaning provided in Section&nbsp;2.3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B> &#8220;<B>ATV</B>&#8221;<B>
</B>shall mean a compound that comprises or contains: (a)&nbsp;one or more Antibodies that are each Directed To a Therapeutic Target (the &#8220;<B>Therapeutic Antibody</B>&#8221;), and (b)&nbsp;an Antibody that is Directed To a Brain Transit Target
(together with any multispecific Antibody format, including, e.g., Fc substitutions within such a format, for such compound, the &#8220;<B>Transit Antibody</B>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B> &#8220;<B>Bankruptcy Code</B>&#8221; shall have the meaning provided in
Section&nbsp;7.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B> &#8220;<B>Bankruptcy Event</B>&#8221; shall have the meaning provided in Section&nbsp;7.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B> &#8220;<B>Brain Transit Target</B>&#8221; shall mean a protein molecule (such as the human transferrin receptor) that
(a)&nbsp;[***], and (b)&nbsp;[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B> &#8220;<B>Business </B><B>Day</B>&#8221; shall mean any day other than Saturday, Sunday,
or other national holidays in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B> &#8220;<B>Calendar Quarter</B>&#8221; shall mean the respective periods of
three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30, and December 31. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>
&#8220;<B>Change of Control</B>&#8221; shall mean, with respect to any entity, any of the following: (a)&nbsp;the sale or disposition of all or substantially all of the assets of such entity or its direct or indirect controlling Affiliate to a Third
Party; or (b)&nbsp;(i) the acquisition by a Third Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by such entity or any of its Affiliates, of more than fifty percent
(50%) of the then-outstanding shares of voting capital stock of such entity or its direct or indirect parent entity that is an Affiliate that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%) of the
then-outstanding shares of voting capital stock of such entity (a &#8220;<B>Parent Entity</B>&#8221;), or (ii)&nbsp;the acquisition, merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of
clause (i)&nbsp;or (ii), an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock of such entity or its Parent Entity, as the case may be, immediately prior to such
acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or
consolidation, as the case may be, immediately after such acquisition, merger or consolidation, and in each case of (a)&nbsp;or (b), whether through a single transaction or a series of related transactions, but excluding any and all bona fide
financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile of such entity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B> &#8220;<B>COC Program</B>&#8221; shall have the meaning provided in Section&nbsp;2.4(b)(ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B> &#8220;<B>Commercialize</B>&#8221; or &#8220;<B>Commercializing</B>&#8221; shall mean to market, promote, distribute, offer for
sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize a product. When used as a noun, &#8220;<B>Commercialization</B>&#8221; means any and all activities involved in Commercializing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B> &#8220;<B>Confidential Information</B>&#8221; of a Party shall mean any and all <FONT STYLE="white-space:nowrap">non-public</FONT>
scientific, business, regulatory, or technical information that is disclosed or made available by or on behalf of one Party (the &#8220;<B>Disclosing Party</B>&#8221;) to any other Party (a &#8220;<B>Receiving Party</B>&#8221;) in connection with
this Agreement, whether in writing, orally, visually or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B> &#8220;<B>Control</B>&#8221; (including any variations such as<B>
</B>&#8220;<B>Controlled</B>&#8221;<B> </B>and &#8220;<B>Controlling</B>&#8221;) shall mean, with respect to any technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant
a license or a sublicense of or under such technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party or requiring a payment. Notwithstanding the foregoing, a Party and its
Affiliates shall not be deemed to &#8220;Control&#8221; any technology or Intellectual Property Rights that (a)&nbsp;prior to the consummation of a Change of Control of such Party, is owned or <FONT STYLE="white-space:nowrap">in-licensed,</FONT> or
(b)&nbsp;after the consummation of a Change of Control of such Party, becomes owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> (to the extent such technology or Intellectual Property Rights are developed outside of the scope of the
activities conducted hereunder and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party immediately before such Change of Control, or any Confidential Information of
the other Party), in each case ((a) or (b)), by a Third Party that becomes an Affiliate of such Party after the effective date of the applicable agreement as a result of such Change of Control or an assignee of such Party as the result of an
assignment of the applicable agreement in connection with a Change of Control unless prior to the consummation of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property
Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B> &#8220;<B>Cover</B>,&#8221; &#8220;<B>Covered</B>&#8221; or &#8220;<B>Covering</B>&#8221; shall mean, with respect to
a Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent or a pending claim included in
such Patent if such pending claim were to issue in an issued Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B> &#8220;<B>Cure Period</B>&#8221; shall have the meaning
provided in <U>Exhibit C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B> &#8220;<B>Definitive Agreement</B>&#8221; shall have the meaning provided in Section&nbsp;3.3.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B> &#8220;<B>Definitive Agreement Dispute</B>&#8221; shall have the meaning provided in Section&nbsp;3.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B> &#8220;<B>Derived Funded Transit Antibody</B>&#8221; shall have the meaning provided in <U>Exhibit</U><U></U><U>&nbsp;C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B> &#8220;<B>Derived Funded Transit Antibody Patent</B>&#8221; shall mean any Patent that Covers the composition of matter of, or any
method of specifically making or using, any Derived Funded Transit Antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B> &#8220;<B>Develop</B>&#8221; or<B>
</B>&#8220;<B>Developing</B>&#8221;<B> </B>shall<B> </B>mean to discover, evaluate, test, research or otherwise develop a product. When used as a noun, &#8220;<B>Development</B>&#8221; means any and all activities involved in Developing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B> &#8220;<B>Diligence Milestone</B>&#8221; shall have the meaning provided in
<U>Exhibit C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B> &#8220;<B>Directed To</B>&#8221; shall mean, with regard to an Antibody or product, that such Antibody or
product is developed or designed to (a) [***], and (b) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B> &#8220;<B>Dispute</B>&#8221; shall have the meaning provided in
Section&nbsp;9.7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B> &#8220;<B>Effective Date</B>&#8221; shall have the meaning provided in the first paragraph of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B> &#8220;<B>Exclusive Target Combination</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B> &#8220;<B>Existing ADOA</B>&#8221; shall have the meaning provided in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B> &#8220;<B>FDA</B>&#8221; shall mean the United States Food and Drug Administration, or a successor federal agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B> &#8220;<B>Field</B>&#8221; shall mean the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all
therapeutic areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B> &#8220;<B>Funded Transit Antibody</B>&#8221; shall mean a Transit Antibody that (a)&nbsp;is Directed To
the Selected Transit Target (and no other Targets), and (b)&nbsp;was discovered, generated, identified, characterized or developed by or on behalf of Paragon or its Affiliates under a Funding Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B> &#8220;<B>Funded Transit Antibody IP</B>&#8221; shall mean Funded Transit Antibody
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Funded Transit Antibody Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B> &#8220;<B>Funded Transit Antibody <FONT
STYLE="white-space:nowrap">Know-How</FONT></B>&#8221; shall mean any and all <FONT STYLE="white-space:nowrap">Know-How</FONT> that (a)&nbsp;is&nbsp;Controlled by Paragon and its Affiliates, (b)&nbsp;was discovered, generated or developed under a
Funding Agreement, and (c)&nbsp;relates to a Funded Transit Antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B> &#8220;<B>Funded Transit Antibody Patents</B>&#8221;
shall mean any and all Patents that (a)&nbsp;are&nbsp;Controlled by Paragon and its Affiliates, and (b)&nbsp;Cover the composition of matter of, or any method of using, making or manufacturing, any Funded Transit Antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B> &#8220;<B>Funding Agreement</B>&#8221; shall mean (a)&nbsp;the Existing ADOA, (b)&nbsp;any ADOA Agreement executed pursuant to the
terms of this Agreement, and (c)&nbsp;any other definitive written agreement between Paragon or its Affiliate and Korsana pursuant to which Paragon or its Affiliate discovers, generates, identifies, characterizes or develops Transit Antibodies in
the performance of research or development activities funded by Korsana. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B> &#8220;<B>General Multispecific License</B>&#8221;
shall have the meaning provided in Section&nbsp;2.4(b)(i)(B). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B> &#8220;<B>GLP Tox Initiation</B>&#8221; shall mean the initiation by or on behalf
of Korsana or its Affiliate or sublicensee of a toxicology study with respect to a Licensed ATV Product that employs applicable then-current good laboratory practice standards, the results of which are intended to be submitted as part of an IND.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B> &#8220;<B>Indemnified Party</B>&#8221;<B> </B>shall have the meaning provided in Section&nbsp;8.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B> &#8220;<B>Indemnifying Party</B>&#8221; shall have the meaning provided in Section&nbsp;8.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B> &#8220;<B>Initial Reserved Target Combination</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B> &#8220;<B>Initial Reserved Target Exercise Notice</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B> &#8220;<B>Initial Reserved Target Limit</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B> &#8220;<B>Initial Reserved Target List</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B> &#8220;<B>Initial Reserved Target ROFR Notice</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B> &#8220;<B>Initial Target Nomination Period</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B> &#8220;<B>Intellectual Property Rights</B>&#8221; shall mean any and all proprietary rights provided under (a)&nbsp;patent law,
including any Patents, (b)&nbsp;copyright law, or (c)&nbsp;any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in <FONT STYLE="white-space:nowrap">Know-How,</FONT> or the expression
or use thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B> &#8220;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#8221; shall mean all technical information
and <FONT STYLE="white-space:nowrap">know-how</FONT> in any tangible or intangible form, including (a)&nbsp;inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors,
plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or
marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b)&nbsp;all data, instructions, processes, formulae, strategies, and
expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding the
foregoing, <FONT STYLE="white-space:nowrap">Know-How</FONT> excludes Patent claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B> &#8220;<B>Korsana</B>&#8221; shall have
the meaning provided in the first paragraph of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B> &#8220;<B>Korsana Indemnitee</B>&#8221; shall have the meaning provided in
Section&nbsp;8.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B> &#8220;<B>License Agreement</B>&#8221; shall have the meaning provided in Section&nbsp;3.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B> &#8220;<B>License Option</B>&#8221; shall have the meaning provided in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B> &#8220;<B>License Term Sheet</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B> &#8220;<B>Licensed ATV Product</B>&#8221; shall mean any product that comprises an ATV comprising or consisting of (a)&nbsp;one or
more Therapeutic Antibodies that are Directed To the applicable Selected Therapeutic Target(s) (and no other Targets), and (b)&nbsp;a Funded Transit Antibody or a Derived Funded Transit Antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B> &#8220;<B>Losses</B>&#8221; shall have the meaning provided in Section&nbsp;8.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B> &#8220;<B>MAA</B>&#8221; shall mean (a)&nbsp;a New Drug Application in the United States, as defined in the United States Federal
Food, Drug and Cosmetics Act, and applicable regulations promulgated thereunder by the FDA, (b)&nbsp;a Biologics License Application in the United States, as defined in the United States Public Health Service Act, or (c)&nbsp;any application filed
with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B>
&#8220;<B>Manufacture</B>&#8221; or &#8220;<B>Manufacturing</B>&#8221; shall mean to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store a product or any component thereof, as
applicable. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing a product or any component thereof, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B> &#8220;<B>Modification</B>&#8221; shall mean, with respect to an Antibody, a modification of such Antibody, including an ScFv or
Fab, or the heavy chain or light chain independently, or segments thereof, or any pegylated version (whether or not including sequence changes), any fusion protein, chimeric protein, peptide, siRNA, polynucleotide, affinity matured Antibody,
mutagenized (e.g., by random mutagenesis, <I>in vitro</I> selection or site directed mutagenesis, or by a single round of mutagenesis or selection or multiple iterations of mutagenesis or selection, in each case including any associated
substitutions) Antibody, or any fragment of such Antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B> &#8220;<B>Modification Technology</B>&#8221; shall have the
meaning provided in <U>Exhibit</U><U></U><U>&nbsp;C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B> &#8220;<B>Net Sales</B>&#8221; shall have the meaning provided in
<U>Exhibit C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B> &#8220;<B>Nomination of a DC</B>&#8221; shall mean the&nbsp;nomination by Korsana&#8217;s Board of
Directors of a Licensed ATV Product as a &#8220;Development Candidate&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B> &#8220;<B>Notice of Dispute</B>&#8221; shall
have the meaning provided in Section&nbsp;9.7(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B> &#8220;<B>Option</B>&#8221; shall have the meaning provided in
Section&nbsp;3.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B> &#8220;<B>Option Exercise Fee</B>&#8221; shall have the meaning provided in
Section&nbsp;4.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B> &#8220;<B>Option Exercise Notice</B>&#8221; shall have the meaning provided in Section&nbsp;3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B> &#8220;<B>Option Period</B>&#8221; shall mean the period commencing on the Effective Date and ending on the earlier of
(a)&nbsp;the fifth anniversary of the Effective Date, and (b)&nbsp;the later of (i)&nbsp;if Korsana has not exercised any Additional Reserved Target Option during the Initial Target Nomination Period, the exercise by Korsana of its Option for the
last of the Initial Reserved Target Combinations, and (ii)&nbsp;if Korsana has exercised one or both of its Additional Reserved Target Options, the ART Option Exercise <FONT STYLE="white-space:nowrap">Cut-Off</FONT> Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B> &#8220;<B>Paragon</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B> &#8220;<B>Paragon Exclusivity Obligations</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B> &#8220;<B>Paragon Exclusivity Period</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B> &#8220;<B>Paragon Exclusivity Termination Event</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B> &#8220;<B>Paragon</B><B> Indemnitee</B>&#8221; shall have the meaning provided in Section&nbsp;8.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B> &#8220;<B>Parasa</B>&#8221; shall have the meaning provided in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B> &#8220;<B>Parent Entity</B>&#8221; shall have the meaning provided in Section&nbsp;1.26. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B> &#8220;<B>Party</B>&#8221; or &#8220;<B>Parties</B>&#8221; shall have the meaning provided in the first paragraph of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89</B> &#8220;<B>Patents</B>&#8221; shall mean (a)&nbsp;unexpired patents and patent applications, (b)&nbsp;any and all
divisionals, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> reissues, renewals, substitutions, registrations, <FONT STYLE="white-space:nowrap">re-examinations,</FONT>
revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c)&nbsp;any and all foreign equivalents of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B> &#8220;<B>Phase I Trial</B>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R.
&#167;312.21(a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B> &#8220;<B>Phase II
Trial</B>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92</B> &#8220;<B>Phase III Trial</B>&#8221; shall mean a human clinical trial in any
country of the type described in 21 C.F.R. &#167;312.21(c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.93</B> &#8220;<B>Regulatory Approval</B>&#8221; shall mean all clearances, approvals (including approval of an MAA as well as any
applicable pricing and/or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical or biologic product in a country or territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.94</B> &#8220;<B>Regulatory Authority</B>&#8221; shall mean any supranational, multinational, federal, national, state, provincial or
local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture, marketing or sale of a pharmaceutical or biologic product in a country or region, including the FDA in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.95</B> &#8220;<B>Representatives</B>&#8221; of a Party shall mean such Party&#8217;s and its Affiliates&#8217; officers,
directors, employees, contractors, subcontractors, agents and consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.96</B> &#8220;<B>Reserved Target Combination</B>&#8221;
shall mean an Initial Reserved Target Combination or an Additional Reserved Target Combination, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.97</B>
&#8220;<B>Reserved Target List</B>&#8221; shall mean the Initial Reserved Target List or the Additional Reserved Target List, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.98</B> &#8220;<B>Royalty Product</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.99</B> &#8220;<B>Royalty Rate</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.100</B> &#8220;<B>Royalty Term</B>&#8221; shall have the meaning provided in <U>Exhibit C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.101</B> &#8220;<B>Selected Therapeutic Target</B>&#8221; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.102</B> &#8220;<B>Selected Transit Target</B>&#8221; shall mean human transferrin receptor protein 1 (TfR1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.103</B> &#8220;<B>Target</B>&#8221; shall mean a protein molecule that (a) [***], and (b) [***]. Targets shall include Therapeutic
Targets and Brain Transit Targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.104 </B>&#8220;<B>Target Combination</B>&#8221; shall have the meaning provided in
Section&nbsp;2.1(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.105</B> &#8220;<B>Term</B>&#8221; shall have the meaning provided in Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.106</B> &#8220;<B>Territory</B>&#8221; shall mean worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.107</B> &#8220;<B>Therapeutic Antibody</B>&#8221; shall have the meaning provided in Section&nbsp;1.20. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.108</B> &#8220;<B>Therapeutic Target</B>&#8221; shall mean a protein molecule that (a)
[***], and (b) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.109</B> &#8220;<B>Third Party</B>&#8221; shall mean any person or entity other than Paragon, Parasa or Korsana
or an Affiliate of any of Paragon, Parasa or Korsana. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.110</B> &#8220;<B>Third Party Claim</B>&#8221; shall have the meaning provided
in Section&nbsp;8.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.111</B> &#8220;<B>Transit Antibody</B>&#8221; shall have the meaning provided in Section&nbsp;1.20. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.112</B> &#8220;<B>Valid Claim</B>&#8221; shall mean, with respect to particular Patent in a particular country, (a)&nbsp;a claim of an
issued and unexpired patent (including the term of any patent term extension, supplemental protection certificate, renewal or other similar extension) in such country within such Patent that has not been abandoned or revoked, or held unpatentable,
invalid or unenforceable in a final decision of a court or other governmental authority of competent jurisdiction from which no appeal may be taken, or has been taken before the expiry of the permitted time period, and that has not been disclaimed,
denied or admitted to be invalid or unenforceable through reissue, <FONT STYLE="white-space:nowrap">re-examination,</FONT> disclaimer or otherwise, or (b)&nbsp;a claim within a patent application in such country within such Patent that has not been
pending more than seven (7)&nbsp;years from the earliest priority date of such claim and which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESERVATION
OF TARGET COMBINATIONS; EXCLUSIVITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 Initial Reserved Targets. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Initial Reserved Target List.</B> Subject to this Section&nbsp;2.1 and Section&nbsp;2.4, during the [***] period following the
Effective Date (the &#8220;<B>Initial Target Nomination Period</B>&#8221;), Korsana shall have the right to designate up to four (4)&nbsp;Target combinations consisting of (i)&nbsp;one (1) or two (2) (but no more than two (2)) Therapeutic Targets
(each such Therapeutic Target, a &#8220;<B>Selected Therapeutic Target</B>&#8221;), and (ii)&nbsp;the Selected Transit Target (each such combination, a &#8220;<B>Target Combination</B>&#8221;), to be exclusively reserved for Korsana during the
Option Period (each, an &#8220;<B>Initial Reserved Target Combination</B>,&#8221; and the list of the Initial Reserved Target Combinations, the &#8220;<B>Initial Reserved Target List</B>&#8221;). Target Combinations may be added, removed or replaced
on the Initial Reserved Target List in accordance with this Section&nbsp;2.1; <I>provided, that</I> in no event may there be more than the following number of Initial Reserved Target Combinations on the Initial Reserved Target List at any given
time: (A)&nbsp;four (4), or (B)&nbsp;if Korsana has exercised an Option with respect to one or more Initial Reserved Target Combinations in accordance with Section&nbsp;3.2 as of such time, then the number equal to four (4)&nbsp;minus the total
number of such exercised Options (the &#8220;<B>Initial Reserved Target Limit</B>&#8221;). Notwithstanding the foregoing, with respect to an Initial Reserved Target Combination for which Korsana has exercised its Option, if (x)&nbsp;in the case of
an ADOA, Korsana terminates such ADOA for convenience following a determination by the applicable joint development committee that the selection criteria for an applicable ATV under the research program for such Reserved Target Combination are not
achievable and therefore no longer warrants further research, or (y)&nbsp;in the case of a License </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, Korsana terminates such License Agreement for convenience following a good faith determination by the board of directors of Korsana that a target product profile for an applicable ATV
for such Reserved Target Combination is not achievable and therefore no longer warrants further research, and, as of the effective date of such termination, (i)&nbsp;the Initial Target Nomination Period has not expired, and (ii)&nbsp;Korsana is not
in breach of the applicable Definitive Agreement and has satisfied all financial obligations to Paragon thereunder, then Korsana shall have the right (but not the obligation) to designate one (1)&nbsp;replacement Target Combination (including
pursuant to its rights under Section&nbsp;2.1(c)) for addition to the Initial Reserved Target List in place of the Initial Reserved Target Combination that is the subject of such terminated Definitive Agreement. As of the Effective Date, the Initial
Reserved Target List consists of the Target Combination set forth on <U>Exhibit A</U>, which is an Initial Reserved Target Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Changes to the Initial Reserved Target List.</B> During the Initial Target Nomination Period, Korsana may provide Paragon with
written notice of a Target Combination that Korsana desires to add to or remove from the Initial Reserved Target List, or written notice to replace an existing Initial Reserved Target Combination on the Initial Reserved Target List. The Target
Combination that is the subject of such written notice shall, subject to the Initial Reserved Target Limit, be deemed added to, removed from or replaced on the Initial Reserved Target List, as applicable, as of the date of such notice by Korsana. If
Korsana exercises an Option with respect to an Initial Reserved Target Combination in accordance with Section&nbsp;3.2 but, subject to compliance with Section&nbsp;3.3 by the Parties, the Parties do not enter into a Definitive Agreement with respect
thereto, then the applicable Initial Reserved Target Combination shall be deemed to be removed from the Initial Reserved Target List as of the expiration of the Parties&#8217; obligations under Section&nbsp;3.3, the vacancy on the Initial Reserved
Target List caused by such removal may not be filled with another Target Combination and Paragon shall have no further obligations to Korsana under this Article 2 with respect to such Initial Reserved Target Combination (including under
Section&nbsp;2.1(c) and Section&nbsp;2.3(c) below). If an Initial Reserved Target Combination is replaced on the Initial Reserved Target List with another Target Combination (including any replacement made in accordance with Section&nbsp;2.1(c)),
then Paragon shall have no further obligations to Korsana under this Article 2 with respect to such replaced Initial Reserved Target Combination (including under Section&nbsp;2.1(c) and Section&nbsp;2.3(c) below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Right of First Refusal. </B>During the Initial Target Nomination Period and subject to the last two sentences of
Section&nbsp;2.1(b), Paragon shall promptly notify Korsana in writing if Paragon or any of its Affiliates (i)&nbsp;have developed a descriptive research plan (x)&nbsp;similar in breadth and detail to the Research Plans for Research Program 001 and
Research Program 002 under the Existing ADOA, and (y)&nbsp;relating to the discovery, generation, identification or characterization of ATVs Directed To a Target Combination that is not then currently on the Initial Reserved Target List,
(ii)&nbsp;have a <I>bona fide</I> plan to license or grant rights to a Third Party to ATVs Directed To a Target Combination that is not then currently on the Initial Reserved Target List, or (iii)&nbsp;enters into <I>bona fide</I> negotiations with
a Third Party pursuant to an offer to or from any Third Party relating to the foregoing (i)&nbsp;or (ii) (an &#8220;<B>Initial Reserved Target ROFR Notice</B>&#8221;). Korsana shall have [***] from receipt of the Initial Reserved Target ROFR Notice
to elect to designate the Target Combination that is the subject of the Initial Reserved Target ROFR Notice as an Initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Reserved Target Combination by providing written notice thereof to Paragon (an &#8220;<B>Initial Reserved Target Exercise Notice</B>&#8221;). If the Initial Reserved Target Limit has been reached
at the time such notice is being issued by Korsana to Paragon, then the Initial Reserved Target Exercise Notice shall also indicate which Target Combination should be removed and replaced by the Target Combination that is the subject of the Initial
Reserved Target ROFR Notice, and Paragon shall have no further obligations to Korsana under this Article 2 with respect to such removed Target Combination. If Korsana provides an Initial Reserved Target Exercise Notice to Paragon during such [***]
period, then subject only to the Initial Reserved Target Limit, such Target Combination shall be deemed to be an Initial Reserved Target Combination and shall be added to the Initial Reserved Target List as of the date of such notice by Korsana and,
if applicable, shall replace the Target Combination designated by Korsana to be removed from the Initial Reserved Target List. If Korsana does not provide an Initial Reserved Target Exercise Notice during such [***] period, then Paragon shall have
no further obligations to Korsana under this Article 2 with respect to such Target Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Option for Additional Reserved
Targets. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Grant of Option.</B> Subject to the terms and conditions of this Agreement, including this Section&nbsp;2.2 and
Section&nbsp;3.1, Paragon hereby grants to Korsana, during the Initial Target Nomination Period and subject to (i)&nbsp;delivery of an Additional Reserved Target Option Exercise Notice in accordance with Section&nbsp;2.2(b), and (ii)&nbsp;payment of
the applicable Additional Reserved Target Option Exercise Fee to Paragon in accordance with Section&nbsp;4.1, the option (each, an &#8220;<B>Additional Reserved Target</B> <B>Option</B>&#8221;) to obtain the right to designate in accordance with
Section&nbsp;2.3 up to two (2)&nbsp;Target Combinations (in addition to the Initial Reserved Target Combinations) to be exclusively reserved for Korsana during the Option Period (each, an &#8220;<B>Additional Reserved Target Combination</B>,&#8221;
and the list of the Additional Reserved Target Combinations, the &#8220;<B>Additional Reserved Target List</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>Exercise of Option.</B> During the Initial Target Nomination Period, Korsana may, in its sole discretion, exercise one or both of the Additional Reserved Target Options by (i)&nbsp;delivering written notice of such exercise to Paragon (each, an
&#8220;<B>Additional Reserved Target Option Exercise Notice</B>&#8221;), and (ii)&nbsp;making payment to Paragon of the Additional Reserved Target Option Exercise Fee in accordance with Section&nbsp;4.1. If Korsana declines to or fails to exercise
either or both of the Additional Reserved Target Options in accordance with this Section&nbsp;2.2(b) prior to expiration of the Initial Target Nomination Period, then, upon such expiration, such Additional Reserved Target Option or both Additional
Reserved Target Options shall terminate and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 Additional Reserved Targets. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Additional Reserved Target List.</B> If Korsana has exercised one or both of the Additional Reserved Target Options in accordance
with Section&nbsp;2.2(b), then subject to this Section&nbsp;2.3 and Section&nbsp;2.4, during the [***] period following the expiration of the Initial Target Nomination Period (the &#8220;<B>Additional Target Nomination Period</B>&#8221;), Korsana
shall have the right to designate up to one (1)&nbsp;Additional Reserved Target Combination, if Korsana exercised only one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of its Additional Reserved Target Options or two (2)&nbsp;Additional Reserved Target Combinations, if Korsana exercised both of its Additional Reserved Target Options, in each case, to be added
to the Additional Reserved Target List. Target Combinations may be added to the Additional Reserved Target List in accordance with this Section&nbsp;2.3; <I>provided, that</I> in no event may there be more than the following number of Additional
Reserved Target Combinations on the Additional Reserved Target List at any given time: (x)&nbsp;the total number of Additional Reserved Target Options exercised by Korsana (i.e., one (1)&nbsp;or two (2)), or (y)&nbsp;if Korsana has exercised an
Option with respect to one or more Additional Reserved Target Combinations in accordance with Section&nbsp;3.2 as of such time, then the number equal to the number set forth in subsection (x)&nbsp;above minus the total number of such exercised
Options (the &#8220;<B>Additional Reserved Target Limit</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Changes to the Additional Reserved Target List.</B>
During the Additional Target Nomination Period, Korsana may provide Paragon with (i)&nbsp;written notice of a Target Combination that Korsana desires to add to the Additional Reserved Target List, or (ii)&nbsp;written notice to replace an existing
Additional Reserved Target Combination on the Additional Reserved Target List with a Target Combination presented to Korsana under an Additional Reserved Target ROFR Notice, provided that Korsana&#8217;s substitution right under the foregoing clause
(ii)&nbsp;shall terminate, as applicable, (A)&nbsp;on the date of Korsana&#8217;s exercise of an Option for one (1)&nbsp;Additional Reserved Target Combination, if Korsana exercised only one of its Additional Reserved Target Options or (B)&nbsp;on
the date of Korsana&#8217;s exercise of an Option for a second Additional Reserved Target Combination, if Korsana exercised both of its Additional Reserved Target Options (the date in (A)&nbsp;or (B), as applicable, the &#8220;<B>ART Option Exercise
<FONT STYLE="white-space:nowrap">Cut-Off</FONT> Date</B>&#8221;); <I>provided further </I>that Korsana may not replace an existing Additional Reserved Target Combination on the Additional Reserved Target List with a Target Combination for the [***].
The Target Combination that is the subject of such written notice shall, subject to the Additional Reserved Target Limit, be deemed to be added to or replaced on the Additional Reserved Target List, as applicable, as of the date of such notice by
Korsana. If Korsana exercises an Option with respect to an Additional Reserved Target Combination in accordance with Section&nbsp;3.2 but, subject to compliance with Section&nbsp;3.3 by the Parties, the Parties do not enter into a Definitive
Agreement with respect thereto, then the applicable Additional Reserved Target Combination shall be deemed to be removed from the Additional Reserved Target List as of the expiration of the Parties&#8217; obligations under Section&nbsp;3.3, the
vacancy on the Additional Reserved Target List caused by such removal may not be filled with another Target Combination, and Paragon shall have no further obligations to Korsana under this Article 2 with respect to such Additional Reserved Target
Combination (including under Section&nbsp;2.3(c) below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Right of First Refusal. </B>During the Additional Target
Nomination Period and continuing until the ART Option Exercise <FONT STYLE="white-space:nowrap">Cut-Off</FONT> Date (the &#8220;<B>ART ROFR Period</B>&#8221;), Paragon shall promptly notify Korsana in writing if Paragon or any of its Affiliates
(i)&nbsp;have developed a descriptive research plan (x)&nbsp;similar in breadth and detail to the Research Plans for Research Program 001 and Research Program 002 under the Existing ADOA, and (y)&nbsp;relating to the discovery, generation,
identification or characterization of ATVs with respect to a Target Combination that is not then currently on the Initial Reserved Target List or the Additional Reserved Target List, (ii)&nbsp;have a <I>bona fide</I> plan to license or grant rights
to a Third Party to ATVs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to a Target Combination that is not then currently on the Initial Reserved Target List or the Additional Reserved Target Combination, or (iii)&nbsp;enters into <I>bona fide</I>
negotiations with a Third Party pursuant to an offer to or from any Third Party relating to the foregoing (i)&nbsp;or (ii); <I>provided, however</I>, that, at such time during the ART ROFR Period that, as applicable, Korsana has designated one
(1)&nbsp;Additional Reserved Target Combination, if Korsana has exercised only one of its Additional Reserved Target Options or Korsana has designated two (2)&nbsp;Additional Reserved Target Combinations, if Korsana exercised both of its Additional
Reserved Target Options in accordance with Section&nbsp;2.3(a), then Paragon shall no longer be obligated under this Section&nbsp;2.3(c) to notify Korsana in writing if Paragon or any of its Affiliates engages in the activities set forth in the
foregoing clause (i), (ii) or (iii)&nbsp;involving a Target Combination for the prophylaxis, palliation, treatment and diagnosis of human diseases and disorders in oncology (each such notice, an &#8220;<B>Additional Reserved Target ROFR
Notice</B>&#8221;). Korsana shall have [***] from receipt of the Additional Reserved Target ROFR Notice to elect to designate the Target Combination that is the subject of the Additional Reserved Target ROFR Notice as an Additional Reserved Target
Combination by providing written notice thereof to Paragon (an &#8220;<B>Additional Reserved Target Exercise Notice</B>&#8221;). If Korsana provides an Additional Reserved Target Exercise Notice to Paragon during such [***] period, then subject only
to the Additional Reserved Target Limit, such Target Combination shall be deemed to be an Additional Reserved Target Combination and shall be added to the Additional Reserved Target List as of the date of such notice by Korsana. If Korsana does not
provide an Additional Reserved Target Exercise Notice during such [***] period, then Paragon shall have no further obligations to Korsana under this Article 2 with respect to such Target Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4 Exclusivity for Reserved Target Combinations. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Exclusivity.</B> Subject to the terms of this Section&nbsp;2.4, to the maximum extent permissible under Applicable Law, during
the Option Period on a Reserved Target <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Combination-by-Reserved</FONT></FONT> Target Combination basis following the addition of such Reserved Target Combination to the Reserved Target
List, Paragon shall not, and shall ensure that each of its Affiliates does not, directly or indirectly, conduct any activity, either on its own or with or through, for the benefit of, or sponsored by, any Third Party, including granting any license
to any Third Party that would permit such Third Party, to Develop, manufacture, commercialize or otherwise exploit any ATVs Directed To a Reserved Target Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Exceptions to Exclusivity</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) On a [***] basis, it will not be a violation of Section&nbsp;2.4(a) if: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) Paragon or its Affiliate, directly or through a Third Party, (1)&nbsp;[***], (2) [***], or (3) [***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) Paragon or its Affiliate, directly or through a Third Party, [***] (1) [***], and (2) [***]; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) without limiting the proviso clause of subsection (B)&nbsp;above, a Third Party uses
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding anything in Section&nbsp;2.4(a) to the contrary, if a Change of Control occurs with respect to Paragon or
its Parent Entity, and the Acquiring Entity as of the Change of Control is engaged prior to the date of such Change of Control, or becomes engaged after the date of such Change of Control, in a program or product that would otherwise violate
Section&nbsp;2.4(a) (each, a &#8220;<B>COC Program</B>&#8221;), then (A)&nbsp;Section&nbsp;2.4(a) shall not apply with respect to such COC Program, and (B)&nbsp;such Acquiring Entity will be permitted to continue such COC Program after such Change
of Control and such continuation will not constitute a violation of Section&nbsp;2.4(a), provided that with respect to such COC Program (1)&nbsp;no Funded Transit Antibody IP, Modification Technology (including Derived Funded Transit Antibody
Patents), or Confidential Information of Korsana or Confidential Information of both Parties under a Funding Agreement is used by or on behalf of such Acquiring Entity in connection with such COC Program, and (2)&nbsp;such Acquiring Entity
institutes commercially reasonable technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (1)&nbsp;are met, including by creating &#8220;firewalls&#8221; between the personnel working on the COC Program
and the personnel performing any work for Korsana under any Funding Agreement between Paragon or any of its Affiliates and Korsana on any ATVs Directed To one or more Targets, as applicable, that are the same as that of such COC Program, or having
access to data from activities performed under any such Funding Agreement or Confidential Information of Korsana or Confidential Information of Paragon applicable to the COC Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Notwithstanding anything in Section&nbsp;2.4(a) to the contrary, Paragon or its Parent Entity shall be permitted to acquire a Third
Party entity that is engaged prior to the date of such acquisition, or becomes engaged after the date of such acquisition but solely pursuant to rights it holds under agreements existing prior to the date of such acquisition, in a program or product
that would otherwise violate Section&nbsp;2.4(a) (each, an &#8220;<B>Acquired Program</B>&#8221;), and such acquisition will not constitute a violation of Section&nbsp;2.4(a) as long as such program or product (or rights thereto) is not the sole
asset of such entity, in which case, (i)&nbsp;Section 2.4(a) shall not apply with respect to such Acquired Program, and (ii)&nbsp;Paragon or its Parent Entity, as applicable, will be permitted to continue such Acquired Program after such acquisition
and such continuation will not constitute a violation of Section&nbsp;2.4(a), provided that with respect to such Acquired Program (A)&nbsp;no Funded Transit Antibody IP, Modification Technology (including Derived Funded Transit Antibody Patents), or
Confidential Information of Korsana or Confidential Information of both Parties under a Funding Agreement is used by or on behalf of Paragon or its Parent Entity, as applicable, in connection with such Acquired Program, and (B)&nbsp;Paragon or its
Parent Entity, as applicable, institutes commercially reasonable technical and administrative safeguards to ensure the requirements set forth in the foregoing clause (A)&nbsp;are met, including by creating &#8220;firewalls&#8221; between the
personnel working on the Acquired Program and the personnel performing any work for Korsana under any Funding Agreement between Paragon or any of its Affiliates and Korsana on any ATVs Directed To one or more Targets, as applicable, that are the
same as that of such Acquired Program, or having access to data from activities performed under any such Funding Agreement or Confidential Information of Korsana or Confidential Information of Paragon applicable to the Acquired Program. For the
avoidance of doubt, the exclusivity covenants of Section&nbsp;2.4(a), and the permitted exception under this Section&nbsp;2.4(b)(iii), do not apply to [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>
<B>Grant of Option.</B> Subject to the terms and conditions of this Agreement, including this Article 3, on a Reserved Target <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Combination-by-Reserved</FONT></FONT> Target Combination
basis, Paragon hereby grants to Korsana during the Option Period and subject to (a)&nbsp;delivery of the Option Exercise Notice in accordance with Section&nbsp;3.2, and (b)&nbsp;if applicable, payment of the applicable Option Exercise Fee to Paragon
in accordance with Section&nbsp;4.2, an exclusive option (an &#8220;<B>Option</B>&#8221;) to either (i)&nbsp;enter into an antibody discovery and option agreement with Paragon and Parasa to discover, generate, identify and characterize one or more
ATVs Directed To the applicable Reserved Target Combination as further described on <U>Exhibit B</U> (the &#8220;<B>ADOA Option</B>&#8221;), or (ii)&nbsp;enter into a license agreement to Develop, Manufacture and Commercialize, use, make, have made,
sell, offer for sale, have sold, import, export and otherwise exploit ATVs Directed To the applicable Reserved Target Combination as further described on <U>Exhibit</U><U></U><U>&nbsp;C</U> (the &#8220;<B>License Option</B>&#8221;). For clarity,
Korsana may exercise each Option only once for each Reserved Target Combination. Contemporaneously with its exercise of an Option for a Reserved Target Combination, Korsana shall select either the ADOA Option or the License Option but not both for
such Reserved Target Combination. For clarity, any exclusive rights to be granted to Korsana under the ADOA Option or the License Option with respect to a Reserved Target Combination shall be subject to the same exceptions to exclusivity described
in Section&nbsp;2.4(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Option </B><B>Exercise.</B> On a Reserved Target <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Combination-by-Reserved</FONT></FONT> Target Combination basis, during the Option Period, Korsana may, in its sole discretion, exercise an Option for a Reserved Target Combination by (a)&nbsp;delivering written notice of
such exercise to Paragon and selecting either the ADOA Option or the License Option for such Reserved Target Combination (&#8220;<B>Option </B><B>Exercise Notice</B>&#8221;), and (b)&nbsp;if applicable, making payment of the Option Exercise Fee in
accordance with Section&nbsp;4.2. If Korsana fails to exercise any or all of its Options for the applicable maximum Reserved Target Combinations in accordance with this Section&nbsp;3.2 as of the date of expiration of the Option Period, then, upon
such expiration, such unexercised Options shall terminate and be of no further force or effect and Paragon shall have no obligations to Korsana under this Agreement with respect to such Reserved Target Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Definitive Agreement Execution After Option Exercise. </B>Within ninety (90)&nbsp;days of Korsana&#8217;s exercise of an Option
with respect to a Reserved Target Combination as set forth in Section&nbsp;3.2, subject to any extension as mutually agreed by the Parties, the Parties shall use reasonable efforts to finalize and execute a definitive written agreement consistent
with either (a)&nbsp;in the case that such Option is exercised as an ADOA Option, the economic and other terms set forth in <U>Exhibit B</U> (an &#8220;<B>ADOA Agreement</B>&#8221;), or (ii)&nbsp;in the case that such Option is exercised as a
License Option, the economic and other terms set forth in <U>Exhibit C</U> (a &#8220;<B>License Agreement</B>,&#8221; and each ADOA Agreement and License Agreement shall also be referred to hereunder as an &#8220;<B>Definitive Agreement</B>&#8221;).
If the Parties, despite using reasonable efforts to reach definitive agreement on the terms of the applicable Definitive Agreement, are unable to finalize and execute such Definitive Agreement within such ninety (90)&nbsp;day period (as may be
extended), then either Party may elect to resolve such dispute (a &#8220;<B>Definitive Agreement Dispute</B>&#8221;) in accordance with <U>Exhibit</U><U></U><U>&nbsp;D</U> by providing written [***] notice thereof to the other Party within [***]
following the end of such ninety <FONT STYLE="white-space:nowrap">(90)-day</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAYMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>
<B>Additional Reserved Target Option Exercise Fee</B>. Concurrently with Korsana&#8217;s delivery of a written notice that Korsana is exercising an Additional Reserved Target Option in accordance with Section&nbsp;2.2(b), Korsana shall pay to
Paragon a <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment of Two Million Dollars ($2,000,000) (the &#8220;<B>Additional Reserved Target Option Exercise Fee</B>&#8221;). For
clarity, a separate Additional Reserved Target Option Exercise Fee is due and payable each time that Korsana exercises an Additional Reserved Target Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Option Exercise Fee for a License Agreement</B>. On a Reserved Target <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Combination-by-Reserved</FONT></FONT> Target Combination basis, concurrently with Korsana&#8217;s delivery of an Option Exercise Notice for such Reserved Target Combination in accordance with Section&nbsp;3.2, Korsana
shall pay to Paragon a <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment of Five Million Dollars ($5,000,000) only if Korsana has selected the License Option for such Reserved
Target Combination (the &#8220;<B>Option Exercise Fee</B>&#8221;). For clarity, each Option Exercise Fee is nonrefundable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> and separate from any amounts that are payable by Korsana to Paragon
under the applicable License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Manner and Method of Payment</B>. All cash payment amounts hereunder are expressed
in U.S. dollars (USD) unless otherwise specified. Each payment shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless otherwise specified in writing by Paragon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B>Tax</B>. Each Party shall be responsible for paying its own respective taxes in connection with any activities that it performs
and any payments that it receives under this Agreement. The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary in order for any Party to not pay or withhold tax or to pay or withhold tax at a reduced
rate under an applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B>Late Payments</B>. In the event that any cash payment due for any undisputed
amount under this Agreement is not made when due, then the cash payment shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported by the <I>Wall Street Journal</I> (U.S., Western
Edition) or, if lower, the maximum legal annual interest rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROTECTION OF CONFIDENTIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Confidentiality.</B> Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the
Term and for [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the
Disclosing Party. The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#8217;s Representatives who have a need for such information; <I>provided, that</I> the Receiving Party shall advise
such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as stringent as those contained in
this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of
its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. The Receiving Party shall promptly notify the Disclosing
Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>
<B>Exceptions.</B> The Receiving Party&#8217;s obligations under Section&nbsp;5.1 shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a)&nbsp;is now, or hereafter
becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available; (b)&nbsp;is known by the Receiving Party at the time of receiving such information from the Disclosing Party
(provided that, in the case of any Party as the Receiving Party, the exception of this clause (b)&nbsp;shall not apply to any Confidential Information of the Disclosing Party provided to such Receiving Party or any of its Affiliates under the
Existing ADOA or another Funding Agreement); (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d)&nbsp;is independently discovered or developed by the Receiving Party,
without the aid, use or application of any Confidential Information of the Disclosing Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Authorized Disclosure.</B>
Notwithstanding the provisions of this Article 5, the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable
Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange; <I>provided, that</I> the Receiving Party
shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the [***] request and expense, shall cooperate with the Disclosing Party&#8217;s efforts to contest such requirement, to obtain a protective order
requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential Information; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> reasonably necessary to prosecute or defend litigation or otherwise establish
rights or enforce obligations under this Agreement, in each case, in accordance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B>Use of Names.</B> No
Party shall use any other Party&#8217;s name or trademarks in any advertising, sales, or promotional material or in any publication without the prior written consent of such other Party or Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B>Confidentiality of this Agreement.</B> This Agreement and its terms are considered Confidential Information of all Parties, and
each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the applicable other Party, except as expressly permitted by Section&nbsp;5.3 or Section&nbsp;5.6, and
except that each Party may disclose this Agreement and its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations by such Third Parties or in confidential financing
documents; <I>provided</I>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth in this Article 5 (<I>provided,
that</I> the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B>
<B>Publicity.</B> Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, no Party shall issue a press release announcing that they have entered into this Agreement without the other Parties&#8217; prior
written consent, which shall not be unreasonably withheld. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>Mutual Representations and Warranties.</B> Each Party represents and warrants to each other that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate
or other power and authority to enter into this Agreement and to carry out the provisions hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> it is duly authorized to
execute and deliver this Agreement and to perform its obligations hereunder; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> this Agreement is legally binding upon it,
enforceable in accordance with its terms, and does not and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Paragon Representations, Warrants and Covenants</B>. Paragon hereby represents,
warrants and covenants to Korsana that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it has the right, power and authority to grant to Korsana the Options and other rights
granted to Korsana under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> neither it nor any of its Affiliates have entered or will enter, directly or
indirectly, into any contract or any other transaction with any Third Party or Affiliate that conflicts or derogates from its undertakings under this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> there are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries initiated or written notices
received that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets or business, which would, individually or in the aggregate, have a material adverse effect on, or
materially prevent, Paragon&#8217;s ability to perform under this Agreement or to grant the Options or other rights granted to Korsana under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Disclaimer.</B> EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS
OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR
ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Term.</B> The term of this Agreement (&#8220;<B>Term</B>&#8221;) shall commence on the Effective Date and, subject to earlier
termination in accordance with this Article 7, shall continue until the expiration of the Option Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Termination of
Agreement for Material Breach.</B> Each Party shall have the right to terminate this Agreement in its entirety upon thirty (30)&nbsp;days&#8217; prior written notice to the other Parties upon or after the material breach of any provision of this
Agreement by any other Party if the breaching Party has not cured such breach by the end of such thirty (30)&nbsp;day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B>
<B>Termination for Convenience.</B> Korsana shall have the right to terminate this Agreement in its entirety for any reason or no reason upon ninety (90)&nbsp;days&#8217; prior written notice to Paragon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B>Termination for a Bankruptcy Event. </B><B></B>Each Party will have the right to terminate this Agreement in the event of a
Bankruptcy Event with respect to any other Party. &#8220;<B>Bankruptcy Event</B><B>&#8221;</B><B> </B>means the occurrence of any of the following: (a)&nbsp;the institution of any bankruptcy, receivership, insolvency, reorganization or other similar
proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or chapter of the United States Bankruptcy Code, as amended, or under any similar laws or statutes of the United States or any state thereof (the &#8220;<B>Bankruptcy Code</B>&#8221;),<B>
</B>where in the case of involuntary proceedings, such proceedings have not been dismissed or discharged within [***] after they are instituted, (b)&nbsp;the insolvency or making of an assignment for the benefit of creditors or the admittance by a
Party of any involuntary debts as they mature, (c)&nbsp;the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d)&nbsp;the appointment of a receiver for all or
substantially all of a Party&#8217;s assets, or (e)&nbsp;any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B>Disposal of Confidential Information.</B> In the event this Agreement expires or is terminated, each Party shall return to the
applicable other Party all Confidential Information of such other Party (including all copies thereof) in such Party&#8217;s possession; <I>provided, however</I>, that each Party may retain one copy of such other Party&#8217;s Confidential
Information in such Party&#8217;s secure archives for the sole purpose of monitoring compliance with its obligations hereunder or Applicable Law or in accordance with the terms of another existing agreement between the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B>Accrued Rights; Survival.</B> The expiration or termination of this Agreement for any reason shall not release any Party from
any liability or obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this
Agreement preclude any Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of expiration or any termination of this Agreement, the following
provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: Article 1, Article 3 (except in the case of a termination of this Agreement by Paragon in accordance with 7.2 or
Section&nbsp;7.4 or by Korsana in accordance with Section&nbsp;7.3, in which case Article 3 shall not survive), Article 4 (to the extent relating to payment obligations that accrued prior to the effective date of expiration or termination of this
Agreement), Article 5, Article 8 and Article 9, as well as Section&nbsp;2.4 (solely in the event that on the date of expiration of the Option Period the parties are negotiating a Definitive Agreement or are engaged in a Definitive Agreement Dispute,
in each case, for one or more Reserved Target Combinations for which Korsana has exercised an Option prior to such date of expiration in accordance with Section&nbsp;3.2 and only, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, until the earlier of (a)&nbsp;the parties executing such Definitive Agreement, (b)&nbsp;the expiration of the [***] period referenced in
Section&nbsp;3.3, without either Party delivering a notice of a Definitive Agreement Dispute, and (c)&nbsp;the resolution of the Definitive Agreement Dispute in accordance with Exhibit D), Section&nbsp;6.3, Section&nbsp;7.5, this Section&nbsp;7.6.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>By Korsana.</B> Korsana hereby agrees to defend, indemnify, and hold harmless Paragon, Parasa, their Affiliates and their
Representatives (each, a &#8220;<B>Paragon Indemnitee</B>&#8221;) from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense and attorneys&#8217; fees (collectively,
&#8220;<B>Losses</B>&#8221;), to which any Paragon Indemnitee may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
become subject as a result of any claim, demand, action, or other proceeding by any Third Party (&#8220;<B>Third Party Claim</B>&#8221;)<B> </B>to the extent such Losses result from: (a)&nbsp;the
negligence or willful misconduct of any Korsana Indemnitee in the performance of this Agreement; or (b)&nbsp;the breach by any Korsana Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or
willful misconduct of any Paragon Indemnitee or the breach by Paragon of this Agreement, or where such Losses are subject to indemnification pursuant to Section&nbsp;8.2 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>By Paragon.</B> Paragon hereby agrees to defend, indemnify, and hold harmless Korsana, its Affiliates and its and their
Representatives (each, an &#8220;<B>Korsana Indemnitee</B>&#8221;) from and against any and all Losses to which any Korsana Indemnitee may become subject as a result of any Third Party Claim to the extent such Losses result from: (a)&nbsp;the
negligence or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (b)&nbsp;the breach by any Paragon Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or
willful misconduct of any Korsana Indemnitee, the breach by Korsana of this Agreement, or where such Losses are subject to indemnification pursuant to Section&nbsp;8.1 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Indemnification Procedure. </B><B></B>In connection with any Third Party Claim for which a Party (the &#8220;<B>Indemnified
Party</B>&#8221;)<B> </B>seeks indemnification from another Party (the &#8220;<B>Indemnifying Party</B>&#8221;)<B> </B>pursuant to this Agreement, the Indemnified Party will: (a)&nbsp;give the Indemnifying Party prompt written notice of the Third
Party Claim; <I>provided, however, </I>that failure to provide such notice will not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure;
(b)&nbsp;cooperate with the Indemnifying Party, at the Indemnifying Party&#8217;s expense, in connection with the defense and settlement of the Third Party Claim; and (c)&nbsp;permit the Indemnifying Party to control the defense and settlement of
the Third Party Claim; <I>provided, however, </I>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&#8217;s prior written consent, which will not be unreasonably withheld or delayed, in the event that such
settlement materially adversely impacts the Indemnified Party&#8217;s rights or obligations. Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its
selection and at its own expense.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B> <B>Limitation of Liability.</B> EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 5 OR FOR
INDEMNIFICATION CLAIMS UNDER ARTICLE 8, IN NO EVENT SHALL ANY PARTY BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE
POSSIBILITY OF SUCH DAMAGES. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B>
<B>Independent Contractor Relationship.</B> Each of Paragon&#8217;s and Parasa&#8217;s relationship with Korsana is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture or
employer-employee relationship. No Party is an agent of any other Party or authorized to make any representation, contract or commitment on behalf of any other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B>Force Majeure. </B>No Party will be charged with any liability for delay or
failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor
disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law. The Party affected will give prompt written notice to the other Parties of the nature of the cause of any material delay or failure to perform,
its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and
will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give prompt written notice to the other Parties of such resumed performance. If any such failure or delay in a
Party&#8217;s performance hereunder continues for more than [***], any of the other Parties may terminate this Agreement upon written notice to the affected Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B> <B>Entire Agreement; Amendment.</B> This Agreement, together with all Exhibits attached hereto, constitutes the final, complete,
and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. This Agreement (including its Exhibits) may not be changed,
modified, amended, or supplemented except by a written instrument signed by all Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4</B>
<B><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></B> The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or
right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if
applicable, for a particular period of time and shall be signed by such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B> <B>Severability.</B> Should one or more of the
provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and
the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6</B> <B>Assignment.</B> Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior
written consent of the other Parties (which consent shall not be unreasonably withheld, conditioned or delayed); <I>provided, however</I>, that any Party may assign this Agreement and its rights and obligations hereunder without the other
Parties&#8217; prior consent to an Affiliate or to its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of
a Party under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of such Party, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and
permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7</B> <B>Dispute</B><B> Resolution.</B><B> </B>The Parties recognize that a <I>bona fide
</I>dispute as to certain matters may arise from time to time during the Term relating to any Party&#8217;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes
relating to alleged breach or termination of this Agreement (but excluding any Definitive Agreement Disputes or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the
Parties&#8217; respective Intellectual Property Rights) (hereinafter, a &#8220;<B>Dispute</B>&#8221;).<B> </B><B></B>In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve it: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Party claiming that such a Dispute exists will give notice in writing (a &#8220;<B>Notice of Dispute</B>&#8221;)<B> </B>to the
other Parties of the nature of the Dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Dispute will be referred to the then Chief Executive Officer or Chief
Operating Officer of Paragon and the then Chief Executive Officer or President of Korsana who will meet no later than [***] following the initial receipt of the Notice of Dispute and use reasonable efforts to resolve the Dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If, within [***] of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting
described in Section&nbsp;9.7(b) hereof has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to
its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this Section&nbsp;9.7(c). The arbitration will be conducted by a panel of three
arbitrators. Within [***] after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [***] of their appointment, who will
serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least [***] of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical
industry. If any Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [***] period, JAMS will make the necessary appointments for such arbitrator(s) or the
chairman. Once appointed by a Party, such Party will have no <I>ex parte </I>communication with its appointed arbitrator. The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The
arbitration proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted in English translation accompanied by the original or a true copy thereof. The arbitrators
have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;1 <I>et seq., </I>and
judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant to this Section&nbsp;9.7 will be deemed the
Confidential Information of all Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Nothing in this Section&nbsp;9.7 will preclude either Party from seeking equitable
relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if
necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. No remedy referred to in this Agreement is intended to be exclusive, but each will be cumulative and in addition to any other remedy
referred to in this Agreement or otherwise available under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(<SMALL>E</SMALL>)</B> The Parties agree that any disputes
relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights (which, for clarity, excludes Definitive Agreement Disputes) will be
submitted to a court of competent jurisdiction in the country in which such Intellectual Property Rights were granted or arose; <I>provided, however</I>, that, in the case where such country is the United States, the sole jurisdiction and venue for
all actions, suits and proceedings arising out of any such dispute shall be the federal courts located in Boston, Massachusetts, and each Party hereby (i)&nbsp;irrevocably and unconditionally waives any objection to the laying of venue of any such
action, suit or proceeding in the federal courts of Boston, Massachusetts, and (ii)&nbsp;agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.8</B> <B>Governing Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts without reference to conflicts of laws principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.9</B> <B>Notices.</B> Any notice to be given under this Agreement
must be in writing and delivered either in person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior
written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a)&nbsp;the date of actual receipt; (b)&nbsp;if delivered by express courier, the next Business Day the express courier regularly makes
deliveries; or (c)&nbsp;if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. Together with any notice provided by a Party to any other Party in accordance with this Section&nbsp;9.9, the Party shall
send a copy of such notice by email to such other Party. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Paragon or Parasa:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paragon Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">221 Crescent Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Building 23, Suite 105</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Waltham, MA 02453</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Korsana:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Korsana Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">221 Crescent Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Building 23, Suite 105</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Waltham MA 02453</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: [***]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.10</B> <B>Interpretation.</B> Except where the context expressly requires otherwise,
(a)&nbsp;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &#8220;include&#8221;,
&#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&nbsp;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word
&#8220;shall&#8221;, (d)&nbsp;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or
otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#8217;s or entity&#8217;s successors and
assigns, (f)&nbsp;the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g)&nbsp;all
references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h)&nbsp;the word &#8220;notice&#8221; means notice in writing (whether or
not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i)&nbsp;provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221;
&#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding <FONT
STYLE="white-space:nowrap">e-mail</FONT> and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement
or successor law, rule or regulation thereof, and (k)&nbsp;the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;or&#8221;. The headings of clauses contained in this Agreement preceding the
text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and
uncertainties in this Agreement, if any, shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the
English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English
language. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.11</B> <B>No Third Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the Parties and
their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.12</B> <B>Counterparts.</B> This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all
of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.13</B> <B>Expenses</B>. Each Party shall pay its own costs, charges and expenses
incurred in connection with the negotiation, preparation, and completion of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.14</B> <B>Binding Effect</B>. This
Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.15</B> <B>Construction</B>. The Parties hereto acknowledge and agree that: (a)&nbsp;each Party and its counsel reviewed and negotiated
the terms and provisions of this Agreement and have contributed to its revision; (b)&nbsp;the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this
Agreement; and (c)&nbsp;the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.16</B> <B>Cumulative Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly
stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Remainder of page left intentionally blank; signature page follows.] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the Parties hereto
have executed this Platform Option Agreement on the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARAGON</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>K<SMALL>ORSANA</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Susanna High</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Violin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Susanna High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Violin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, President and Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARASA</SMALL> H<SMALL>OLDING</SMALL> LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Susanna High</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Susanna High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Platform Option Agreement] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>4
<FILENAME>d111069dex1031.htm
<DESCRIPTION>EX-10.31
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.31</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.31 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g111069g0605101842264.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">To:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Korsana Biosciences, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">221 Crescent Street, Building 23, Suite 105 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attn: Jonathan
Violin, CEO </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>AOC Research Letter Agreement</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April&nbsp;3, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Jonathan, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Antibody Oligo Conjugate (AOC) Research Letter Agreement (this &#8220;<B>Agreement</B>&#8221;) is entered into and effective as of the
date of last signature below (the &#8220;<B>Effective Date</B>&#8221;), by and between Paragon Laboratories, Inc., a Delaware corporation (&#8220;<B>Paragon</B>&#8221;), and Korsana Biosciences, Inc., a Delaware corporation
(&#8220;<B>Korsana</B>,&#8221; and with Paragon, each a &#8220;<B>Party</B>&#8221; and collectively the &#8220;<B>Parties</B>&#8221;). This Agreement sets forth the terms and conditions under which the Parties will initiate a research program (the
&#8220;<B>Research Program</B>&#8221;) focused on the targets described on the attached <U>Exhibit</U><U></U><U>&nbsp;A</U> (the &#8220;<B>Selected Targets</B>&#8221;), in an effort to identify, evaluate and develop antibody oligonucleotide
conjugates directed to the Selected Targets (the &#8220;<B>Research AOCs</B>&#8221;) (and, for clarity, no other targets). In consideration of the foregoing, the mutual covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>1 Research
Program. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> The Research Program shall commence on the Effective Date and continue until the earliest of: (a)&nbsp;the date
that the aggregate Costs (as defined below) paid or owing by Korsana to Paragon under <U>Section</U><U></U><U>&nbsp;3</U> meet or exceed the Budget Cap (as defined below), (b) completion of the activities set forth in the Research Plan (as defined
below), and (c)&nbsp;such other mutually agreed date by the Parties in writing (any such period, the &#8220;<B>Research Term</B>&#8221;). During the Research Term of the Research Program, (i)&nbsp;each Party will use [***] to conduct and complete
the research activities assigned to it as set forth in the research plan for such Research Program in accordance with this Agreement (the &#8220;<B>Research Plan</B>&#8221;), (ii)&nbsp;Paragon will provide Korsana with [***] updates regarding the
Research AOCs identified under the Research Plan (the &#8220;<B>Deliverables</B>&#8221;) to enable Korsana to evaluate the Option (as defined below), and (iii)&nbsp;Paragon will notify Korsana reasonably in advance of the estimated date when the
aggregate Costs paid or owing by Korsana to Paragon under <U>Section</U><U></U><U>&nbsp;3</U> will meet or exceed the Budget Cap. Korsana shall have the right to use the Deliverables for the Research Program during the Option Period (as defined in
<U>Section</U><U></U><U>&nbsp;2</U> below) internally for the sole purpose of determining whether to exercise the Option and for no other purpose. The Research Plan shall be governed by this Agreement, and this Agreement will control over any
conflicting term in the Research Plan except to the extent the Research Plan expressly states otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221 Crescent Street, BLDG 23 STE 105
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">paragontherapeutics.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> The Parties shall use [***] to agree on a Research Plan for the Research Program
that will include design, modeling, synthesis, evaluation, and other mutually agreed activities no later than [***] after the Effective Date. Once completed, the initial Research Plan shall be attached as <U>Exhibit B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2</B> <B>Option</B>. Subject to the terms and conditions of this Agreement, Paragon hereby grants to Korsana a nontransferable (except as
permitted under <U>Section</U><U></U><U>&nbsp;12</U>), exclusive option (the &#8220;<B>Option</B>&#8221;) during the Research Term and, provided that Korsana is not in material breach of this Agreement, for an additional [***] thereafter
(collectively, the &#8220;<B>Option Period</B>&#8221;) to either (a)&nbsp;enter into an antibody oligo conjugate discovery and option agreement for the Research Program as further described in this <U>Section</U><U></U><U>&nbsp;2</U> (the &#8220;<B><FONT
STYLE="white-space:nowrap">AOC-DOA</FONT> Option</B>&#8221;), or (b)&nbsp;enter into a license agreement for the Research Program as further described in this <U>Section</U><U></U><U>&nbsp;2</U> (the &#8220;<B>License Option</B>&#8221;). Korsana may
exercise the Option by providing written notice to Paragon during the Option Period and, following Paragon&#8217;s receipt of such notice, the Parties shall negotiate for a three (3)&nbsp;month period (or such other longer mutually agreed period by
the Parties in writing) (the &#8220;<B>Negotiation Period</B>&#8221;) a definitive written agreement [***] and on customary and reasonable terms, which terms shall provide for (1)&nbsp;in the case that such Option is exercised as an <FONT
STYLE="white-space:nowrap">AOC-DOA</FONT> Option, (i)&nbsp;the continuation of the Research Program, (ii)&nbsp;economic terms that shall include a research initiation fee of One Million Dollars ($1,000,000), and (iii)&nbsp;an exclusive option for
Korsana to enter into separate license agreement(s) consistent with the license described in the following <U>clause (2)(</U><U>i</U><U>)</U> (excluding, for the avoidance of doubt, the upfront license fee described in <U>clause (2)(ii)</U>) (an
&#8220;<B><FONT STYLE="white-space:nowrap">AOC-DOA</FONT> Agreement</B>&#8221;), or (2)&nbsp;in the case that such Option is exercised as a License Option, (i)&nbsp;a license agreement with Paragon for Korsana, its Affiliates (as defined under the
ADOA (as defined in <U>Section</U><U></U><U>&nbsp;7</U> below)), and (sub)licensees to develop, manufacture, and commercialize the resulting Research AOCs for any and all uses worldwide ([***]), and (ii)&nbsp;economic terms that shall include a <FONT
STYLE="white-space:nowrap">one-time</FONT> upfront license fee of Five Million Dollars ($5,000,000) (a &#8220;<B>License Agreement</B>,&#8221; and each of an <FONT STYLE="white-space:nowrap">AOC-DOA</FONT> Agreement or a License Agreement shall also
be referred to hereunder as a &#8220;<B>Definitive Agreement</B>&#8221;). For clarity, Korsana may exercise the Option only once for the Research Program. If the Parties, despite negotiating [***], are unable to finalize and execute a Definitive
Agreement prior to the expiration of the Negotiation Period, then either Party may elect, by providing written notice thereof to the other Party within [***] of the expiration of the Negotiation Period, to resolve such dispute in accordance with the
procedures set forth on Exhibit D of the ADOA (as defined in <U>Section</U><U></U><U>&nbsp;7</U>) interpreted as applying <I>mutatis mutandis</I> to this Agreement in order to determine which Party&#8217;s proposed Definitive Agreement is the most
commercially reasonable under the circumstances and best gives effect to the economic and other terms described in this <U>Section</U><U></U><U>&nbsp;2</U>. The Option for the Research Program shall terminate and be of no force or effect, and
Paragon shall be free to license or grant any other rights under the Research AOCs of the Research Program to a third party, upon the earliest of (x)&nbsp;in the event that the Research Program is terminated in accordance with
<U>Section</U><U></U><U>&nbsp;8</U>, the effective date of such termination, (y)&nbsp;in the event that Korsana fails to exercise the Option for the Research Program in accordance with this <U>Section</U><U></U><U>&nbsp;2</U> prior to expiration of
the Option Period, the expiration of the Option Period, and (z)&nbsp;in the event that Korsana exercises the Option for the Research Program in accordance with this <U>Section</U><U></U><U>&nbsp;2</U> during the Option Period in accordance with this
<U>Section</U><U></U><U>&nbsp;2</U> but (i)&nbsp;the Parties are unable to finalize and execute a Definitive Agreement during the Negotiation Period and (ii)&nbsp;neither Party has delivered notice that it is electing the foregoing dispute
resolution procedures during the applicable [***] period in accordance with this <U>Section</U><U></U><U>&nbsp;2</U>, the expiration of such [***] period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3</B> <B>Costs</B>. As consideration for Paragon&#8217;s performance hereunder of the Research Program and the grant of the Option to
Korsana, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-by-quarter</FONT></FONT> basis during the Research Term, Korsana shall (a)&nbsp;reimburse Paragon for the [***] in the performance of the Research Program [***]
(the &#8220;<B>Third Party Costs</B>&#8221;), and (b)&nbsp;[***] (the &#8220;<B>Fees</B>,&#8221; and together with the Third Party Costs, the &#8220;<B>Costs</B>&#8221;); provided, that the maximum aggregate Costs to be paid by Korsana, including
the Costs paid for work performed (whether </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by Paragon personnel or contract research organizations or other third parties) prior to the Effective Date as described below, for the Research Program shall not exceed the amount set forth in
the Research Plan (as such amount may be increased during the Research Term solely by mutual written agreement of the Parties, the &#8220;<B>Budget Cap</B>&#8221;) unless otherwise agreed by the Parties in writing. On a [***] basis, Paragon will
deliver an invoice to Korsana for the Costs incurred by Paragon in the performance of the Research Program during such [***], and Korsana will pay such Costs within [***] after receipt of such invoice. Paragon shall have the right to adjust the
Fees, no more than [***], to account for inflation and other reasonable increases in costs by providing written notice thereof to Korsana at least [***] in advance of such increase. Notwithstanding this <U>Section</U><U></U><U>&nbsp;3</U> to the
contrary, the Parties acknowledge that Paragon has incurred (i)&nbsp;approximately Fifty-Five Thousand Dollars ($55,000) through February&nbsp;28, 2026 and (ii)&nbsp;certain additional Costs between March&nbsp;1, 2026 and the Effective Date, as a
result of work performed by Paragon (itself or through contract research organizations or other third parties) at risk on the Research Program, and Korsana shall reimburse Paragon for such Costs within [***] after Korsana&#8217;s receipt of a
written invoice that details such Costs. All payments made by Korsana under this <U>Section</U><U></U><U>&nbsp;3</U> shall be <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4</B> <B>Payments</B>. Each cash payment hereunder shall be in U.S. dollars (unless otherwise specified) made by electronic funds transfer
in immediately available funds to a bank and account designated in writing by Paragon. Late payments shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported by the <I>Wall
Street Journal</I> (U.S., Western Edition) or, if lower, the maximum annual interest rate permitted by law. Each Party shall be responsible for paying its own respective taxes in connection with this Agreement and will commit [***] to reduce the
respective taxes payable by the other Party hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5</B> <B>Records</B>. Paragon shall maintain complete and accurate records,
books, and accounts of all transactions and activities covered by this Agreement, including of all Third Party Costs and Fees under the Research Program. Upon Korsana&#8217;s reasonable request and at [***] expense during the term of this Agreement
and for [***] thereafter, Paragon shall provide Korsana access to those records, books, and accounts at the location where they are stored to enable Korsana to verify the Costs payable under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6</B> <B>IP Rights</B>. As between the Parties, (a)&nbsp;each Party will retain all right, title, and interest in and to all of its
background intellectual property, and (b)&nbsp;Paragon shall own all right, title, and interest in and to (i)&nbsp;all Research AOCs and other physical materials and deliverables generated under the Research Program or as a result of work performed
prior to the Effective Date on the Research Program, including all intellectual property rights therein, (ii)&nbsp;all inventions and data generated, conceived or reduced to practice by or on behalf of either Party under the Research Program or as a
result of work performed prior to the Effective Date on the Research Program, including all intellectual property rights therein, and (iii)&nbsp;all materials, inventions, data and other intellectual property generated, conceived or reduced to
practice in connection with Korsana&#8217;s use of the Deliverables during the Option Period, including all intellectual property rights therein, in each case of (i)&nbsp;through (iii) (inclusive), irrespective in each case of inventorship ((i),
(ii), and (iii)&nbsp;collectively, &#8220;<B>Research Program Results</B>&#8221;). Korsana agrees to assign and hereby assigns to Paragon all of Korsana&#8217;s right, title, and interest in and to the Research Program Results, and shall execute and
deliver such additional documents and take any such further actions as may be reasonably required to ensure that all such rights, title, and interests are effectively assigned to and held by Paragon. Korsana shall cause all of its employees, service
providers and other representatives who generated, conceived of or created any Research Program Results to assign without additional consideration all ownership rights in such Research Program Results to Paragon. Prior to execution of a Definitive
Agreement for the Research Program, Paragon shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforce patents covering the Research Program Results at Paragon&#8217;s sole cost and expense, and Korsana shall reasonably cooperate and assist Paragon in such preparation, filing, prosecution,
maintenance, and enforcement, at Paragon&#8217;s request and cost and expense. Except as expressly set forth in this Agreement, no right or license under any intellectual property rights of a Party is granted or shall be granted to the other Party
by implication hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7</B> <B>Confidentiality</B>. The confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> terms
set forth in that certain Antibody Discovery and Option Agreement by and among Paragon, Korsana and Parasa Holding LLC, and dated September&nbsp;5, 2025 (as in effect on the Effective Date of this Agreement, the &#8220;<B>ADOA</B>&#8221;) shall be
interpreted as applying <I>mutatis mutandis</I> to this Agreement. Notwithstanding the foregoing, (a)&nbsp;this Agreement and its terms are considered Confidential Information (as defined under the ADOA) of both Parties, and (b)&nbsp;the Research
AOCs, Deliverables, and Research Program Results are considered the Confidential Information of both Parties, and each Party shall be deemed as both the Disclosing Party and Receiving Party (each as defined under the ADOA) with respect thereto;
provided, that if Korsana does not exercise its Option or the Parties do not enter into a Definitive Agreement for the Research Program in accordance with <U>Section</U><U></U><U>&nbsp;2</U>, then the Research AOCs, Deliverables, and Research
Program Results for the Research Program shall thereafter be the Confidential Information of Paragon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8</B> <B>Term</B>. This
Agreement shall commence on the Effective Date and, unless terminated earlier, shall continue until the expiration of the Option for the Research Program in accordance with <U>Section</U><U></U><U>&nbsp;2</U>. This Agreement (and the Research
Program) may be terminated by either Party upon thirty (30)&nbsp;days&#8217; prior written notice (or ten (10)&nbsp;days prior written notice in the case of a payment breach) if the other Party commits a material breach of this Agreement and fails
to cure such breach within thirty (30)&nbsp;days (or ten (10)&nbsp;days in the case of a payment breach) of such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9</B>
<B>Effects of Termination</B>. Upon expiration of the Research Term, the Research Program shall automatically terminate, and Paragon shall have no further obligations to perform any work under the Research Program, unless the Parties agree in
writing to increase the Budget Cap. The expiration or termination of this Agreement for any reason shall not release any Party from any liability or obligation that has already accrued to any other Party. In the event of expiration or any
termination of this Agreement, the following provisions of this Agreement shall survive in accordance with their respective terms and conditions: <U>Sections 3</U> and <U>4</U> (solely with respect to any payment obligations that accrued prior to
such expiration or termination of this Agreement but have not been paid), <U>Section</U><U></U><U>&nbsp;5</U>, <U>Section</U><U></U><U>&nbsp;6</U>, <U>Section</U><U></U><U>&nbsp;7</U>, this <U>Section</U><U></U><U>&nbsp;9</U>, and <U>Sections 10</U>
to <U>14</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10</B> <B>Indemnity</B>. Each Party (the &#8220;<B>Indemnifying Party</B>&#8221;) agrees to defend, indemnify, and hold
harmless the other Party, its Affiliates (as defined under the ADOA), and its and their respective representatives and subcontractors from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense
and attorneys&#8217; fees, arising out of any claim, demand, action, or other proceeding by any third party to the extent resulting from: (a)&nbsp;the negligence or willful misconduct of any Indemnifying Party in the performance of this Agreement;
or (b)&nbsp;the material breach by any Indemnifying Party of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11</B> <B>Disclaimer</B>. EXCEPT AS EXPRESSLY SET FORTH
HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE,
<FONT STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. EXCEPT FOR LIABILITY FOR BREACH OF <U>SECTION 7</U> OR FOR INDEMNIFICATION
CLAIMS UNDER <U>SECTION 10</U>, IN NO EVENT SHALL ANY PARTY BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12</B> <B>Assignment</B>. Neither this Agreement nor any rights or obligations hereunder
may be assigned by any Party without the prior written consent of the other Parties (which consent shall not be unreasonably withheld, conditioned, or delayed); provided, however, that any Party may assign this Agreement and its rights and
obligations hereunder without the other Party&#8217;s consent to an Affiliate (as defined under the ADOA) or to the successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of
stock, sale of assets, or otherwise. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this
<U>Section</U><U></U><U>&nbsp;12</U> shall be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13</B> <B>Governing Law</B>. This Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14</B>
<B>Miscellaneous</B>. Paragon&#8217;s relationship with Korsana is that of an independent contractor, and neither Party is an agent of the other Party. This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and
exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements relating to its subject matter. No modification or amendment of this Agreement or any Exhibit
shall be effective unless set forth in a written instrument signed by both Parties. Any notice to be given hereunder must be in writing and delivered either in person, by internationally recognized express courier, or by email to the Party to be
notified at the address(es) identified below, or at any address such Party has previously designated by prior written notice to the other. This Agreement may be executed in counterparts (by facsimile or PDF signatures), each of which shall be deemed
an original, but all of which together shall be deemed to be one and the same agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">If to Paragon:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Paragon Laboratories, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">221 Crescent Street Building 23, Suite 105</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attn: [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email: [***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">If to Korsana:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Korsana Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">221 Crescent Street, Building 23, Suite 105</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Waltham, MA 02453</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attn: [***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Email: [***]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please indicate Korsana&#8217;s acceptance of and agreement to the terms of this Agreement by
returning a signed copy by email to the attention of Paragon Legal at [***]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ARAGON</SMALL> L<SMALL>ABORATORIES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;3, 2026</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><I>ACCEPTED AND AGREED:</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">K<SMALL>ORSANA</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Violin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Violin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;3, 2026</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>5
<FILENAME>d111069dex1032.htm
<DESCRIPTION>EX-10.32
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.32 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS
NOT MATERIAL AND (II)&nbsp;IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CELL LINE LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Cell
Line License Agreement (&#8220;Agreement&#8221;), effective as of December&nbsp;2, 2024 (&#8220;EFFECTIVE DATE&#8221;), is entered and made by and between <B>WuXi Biologics Ireland Limited</B>, having an address at Dundalk Science&nbsp;&amp;
Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, &#8220;<B>WuXi Biologics</B>&#8221;) and <B>KORSA Biosciences, Inc. </B>a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham,
MA 02453 (&#8220;Licensee&#8221;). WuXi Biologics and Licensee may be referred to herein individually as a &#8220;Party&#8221; and collectively as the &#8220;Parties.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Affiliate&#8221; </B>of a person means any other person that directly or indirectly Controls, is
Controlled by, or is under common Control with, the person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Client Product&#8221; </B>means the [***] of interest to Licensee, which is designated by the
Licensee to be produced by the Licensed Cell Line. Each different Client Product covered under this Agreement shall be specified in Appendix I. An amendment to this Agreement is required for each new Client Product produced by the Licensed Cell
Line. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Confidential Information</B>&#8221; of a Party (the &#8220;<B>Disclosing Party</B>&#8221;) means all <FONT
STYLE="white-space:nowrap">non-</FONT> public scientific, technical, financial regulatory or business information and materials disclosed by or on behalf of the Disclosing Party to the other Party (the &#8220;<B>Receiving Party</B>&#8221;) or its
Related Persons (defined below) in connection with this Agreement. Confidential information shall be identified as confidential in writing or, if disclosed verbally or by observation, summarized in writing and submitted to the Receiving Party within
[***] of the oral or visual disclosure thereof; provided, however, information need not be labeled or marked &#8220;confidential&#8221; to be deemed Confidential Information hereunder, if under the circumstances it is, or should be, understood to be
confidential. The Confidential Information of both Parties includes the existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this
Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Construct</B>&#8221; means a [***] developed by WuXi Biologics that is used for delivering genetic
code and for transfecting and/or transforming the Host Cell Line for purposes of creating the Licensed Cell Line. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Control</B>&#8221; over an entity means (a)&nbsp;owning 50% or more of the voting securities or other
ownership interests of such entity or (b)&nbsp;having the power to direct the management or policies of such entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Drug Product&#8221; </B>means the final dosage form which contains Client Product, in association
with other active or inactive ingredients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Drug Substance&#8221; </B>means bulk Client Product, which has not yet been packaged into its final
dosage form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Host Cell Line&#8221; </B>means the proprietary host cell line developed by WuXi Biologics, and
designated by WuXi Biologics as the [***]-Cell Line, that is used to make the Licensed Cell Line. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Licensed Cell Line&#8221; </B>means a transformed or transfected (using WuXi Biologics&#8217;
Construct(s)) version of the Host Cell Line that produces the Client Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Licensed <FONT STYLE="white-space:nowrap">Know-How&#8221;</FONT> </B>means any <FONT
STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information owned or controlled by WuXi Biologics that is used or incorporated in the Process, and that is necessary or useful to operate the Process
as further described in the Technology Transfer Package. The word &#8220;control&#8221; when used in connection with Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> includes both exclusively and
<FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed <FONT STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information, as well a right of WuXi Biologics to transfer such <FONT
STYLE="white-space:nowrap">know-how</FONT> and <FONT STYLE="white-space:nowrap">non-public</FONT> information to Licensee. As used in this definition <FONT STYLE="white-space:nowrap">&#8220;know-how&#8221;</FONT> means all confidential and
proprietary commercial, technical, scientific and other <FONT STYLE="white-space:nowrap">know-how</FONT> and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures,
experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
preclinical, clinical, safety, manufacturing and quality control data and <FONT STYLE="white-space:nowrap">know-how,</FONT> and including study designs and protocols). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Marketing Authorization Approval</B>&#8221; means, with respect to a country or extra-national
territory, any and all approvals (including a New Drug Application or Biologics License Application approved by the FDA), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or
market a product in such country or some or all of such extra-national territory, including any pricing or reimbursement approvals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Materials&#8221; </B>means the biological materials, including the Licensed Cell Line, provided to
Licensee pursuant to the license granted under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Media and Feeds&#8221; </B>means any proprietary media and feeds used in the Process.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Net Sales</B>&#8221; means the amount earned and recognized as revenue by Licensee and its Affiliates
or sublicensees for bona fide sales of Client Product to a third-party ([***]), less: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Net Sales will not include [***]. Such amounts will be determined from the books and records of [***], maintained in accordance with GAAP
consistently applied. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Process&#8221; </B>means a process for manufacture of Client Product utilizing Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> Materials and Media and Feeds as described in the Technology Transfer Package. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Regulatory Authority</B>&#8221; means any applicable supranational, national, regional, state or
local regulatory agency, department, bureau, commission, council, or other government entity involved in regulating development of and granting regulatory approval for a pharmaceutical product, including the FDA and EMA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Related Persons&#8221; </B>means a Party&#8217;s Affiliates and their respective directors, officers,
employees and agents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Research Cell Bank</B>&#8221; is a [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Technology Transfer Package&#8221; </B>means all information and data describing the Process,
together with all Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> Materials and Media and Feeds necessary or useful for the development and manufacture of Client Product using the Licensed Cell Line and/or the Process.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Third Party&#8221; </B>means any person other than the Parties to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#8220;Third Party Manufacturer&#8221; </B>means (i)&nbsp;a Third Party whose primary business is contract
manufacturing, or (ii)&nbsp;a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing of Client Product and/or Drug Product by such Third Party for Licensee or such sublicensee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>License</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WuXi Biologics hereby grants to Licensee and its Affiliates a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide license, with the right to grant sublicenses as provided in Section&nbsp;2.3, to the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Licensed Cell Line, Materials,
and Media and Feeds, for the purpose of conducting the Process, including the following licensed activities: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, import, sell and otherwise use Client Product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further
commercialize Drug Substance and Drug Product for any and all purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Licensee or its Affiliates may contract with a Third Party Manufacturer for the limited purpose of
developing and manufacturing Client Product on behalf of the Licensee or its Affiliates, provided that, such Third Party Manufacturers are bound by the contract to comply with the confidentiality and use terms of this Agreement, and that the
Licensee or its Affiliates will remain liable for any Third Party Manufacturers&#8217; breach of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the benefit of doubt, a Third Party Manufacturer cannot manufacture Client Product, Drug Substance or Drug
Product utilizing the Licensed Cell Line and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> without first being contracted with a Licensee, its Affiliates or sublicensee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Third Party Manufacturer that has been granted a sublicense cannot grant, issue or transfer a sublicense to
another Third Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions of this Agreement, Licensee shall have the right to grant sublicenses to a
Third Party for the rights granted to Licensee under this Agreement. Each sublicense agreement shall be in writing and provided that the applicable sublicensee is bound by all applicable terms and conditions of this Agreement, and Licensee or its
Affiliates shall remain liable for any sublicensee&#8217;s breach of this Agreement. Licensee shall inform WuXi Biologics in writing any and all such sublicenses. [***]. Licensee will notify WuXi Biologics in writing of any sublicense agreement with
a sublicensee within [***] of the execution of such agreement. Any sublicense granted by Licensee to any rights licensed to it hereunder will terminate [***] upon the termination of the license by WuXi Biologics under the terms of this Agreement;
provided, that such sublicensed rights will not terminate if, as of the effective date of such termination, a sublicensee is not in material default of its obligations under its sublicense agreement, and within [***] of such termination, the
sublicensee agrees in writing to be bound directly to WuXi Biologics under a license agreement substantially similar to this Agreement with respect to the rights sublicensed hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as expressly provided in this Agreement, nothing in this Agreement shall be deemed to have granted
Licensee (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual property, <FONT STYLE="white-space:nowrap">Know-How</FONT> or information owned or controlled by WuXi Biologics.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invoicing of License fees will commence from [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Transfer of Materials and Licensed Know-How</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">WuXi Biologics shall notify Licensee in writing within [***] following the date on which WuXi Biologics completes transfection of the Host Cell
Line to generate the Licensed Cell Line. Thereafter, [***] upon written request and the completion of due payment by Licensee (and in any event within [***] following designation of a Third Party Manufacturer), WuXi Biologics shall disclose, make
available, and conduct a full transfer, and shall cause its Affiliates to disclose, make available, and conduct a full </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
transfer to Licensee, its Affiliates, or any one or more of its Third Party Manufacturers designated by Licensee, all Materials and Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> that
is necessary or reasonably useful for Licensee and Third Party Manufacturers to solely develop and manufacture the Client Product. The Parties shall agree to a schedule for such transfer of the Materials and Licensed
<FONT STYLE="white-space:nowrap">Know-How.</FONT> WuXi Biologics will provide [***] assistance to enable such Third Party Manufacturer to manufacture Client Product, provided, however, it is the Third Party Manufacturer&#8217;s full responsibility
to manufacture such Client Product after the transfer, WuXi Biologics will not be responsible for the Third Party Manufacturer&#8217;s success or failure to manufacture any Client Products. Initiation of such technology transfer will be determined
by Licensee. WuXi Biologics will be reimbursed for such activities by Licensee on [***] rate. WuXi Biologics will provide [***] requested ongoing technical support if requested by Licensee with such support reimbursed [***] rate basis. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>License Fee</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license granted in Section&nbsp;2 of this Agreement, and the representation and warranty set forth in Section&nbsp;10
of this Agreement, Licensee agrees to pay WuXi Biologics a fixed <FONT STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee of USD 150,000 for the Licensed Cell Line used in Client
Product. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Cell Line Royalties.</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Licensee manufactures all of its commercial supplies of the applicable Drug Substance using manufacturing
facilities other than WuXi Biologics&#8217; or its Affiliates&#8217; manufacturing facilities, Licensee shall pay to WuXi Biologics a Royalty of [***]% on the applicable Drug Product&#8217;s global Net Sales sold by Licensee, its Affiliates, or
sublicensees, paid to WuXi Biologics [***]. If Licensee manufactures part of its commercial supplies of the applicable Drug Substance using WuXi Biologics&#8217; or its Affiliates&#8217; manufacturing facilities, the Royalty shall be reduced
accordingly on a [***] basis, depending on [***]. If Licensee manufactures all of its commercial supplies of the applicable Drug Substance by WuXi Biologics or its Affiliates, no Royalty is applicable and no Royalty payment shall be due hereunder.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Licensee, or its sublicensee or assignee may, at any time, pay to WuXi Biologics, on a Drug <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Drug</FONT></FONT> Product basis, a fixed <FONT STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> royalty buyout payment as
set forth below. Once WuXi Biologics has received the royalty buyout payment from Licensee, or its sublicensee or assignee, future royalty obligations with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
respect to such Drug Product will be extinguished. No royalty payments already paid shall be creditable to royalty buyout payments and no previously accrued obligations will be affected.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For [***], Licensee shall pay to WuXi Biologics a buyout payment of [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For [***], Licensee shall pay to WuXi Biologics a buyout payment of [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For clarity, all buyout payments are based upon [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Payment Terms</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee shall pay WuXi Biologics&#8217; undisputed invoice(s) within [***] of receipt by Licensee. Such payments will be made by wire transfer
to the account designated by WuXi Biologics. Invoices must be submitted, and payment must be made, [***]. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Bank Account Details</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unless the Parties otherwise mutually agree in writing, and such mutual agreement is set forth in a particular invoice, Licensee shall pay each
invoice by wire transfer to the account designated by WuXi Biologics. With respect to Net Sales invoiced in U.S. dollars, the Net Sales and the amounts due hereunder will be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency
other than U.S. dollars, payments will be calculated based on standard methodologies employed by Licensee or its Affiliates or sublicensees for consolidation purposes for the [***] for which remittance is made for Royalties. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Restriction</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee agrees that no attempt will be made by or on behalf of Licensee to modify or reverse engineer the Licensed Cell Line or attempt to
reverse engineer, recreate or assemble the Construct(s). Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used the Licensed Cell Line for any purpose other than as provided hereunder,
including operating the Process, the manufacture of Client Product, Drug Substance and Drug Product, and for other purposes reasonably related to securing Marketing Authorization Approval for the Client Product and/or Drug Product. Licensee shall
not transfer the Licensed Cell Line to any Third Party except to a permitted sublicensee, as described in Section&nbsp;2.2 above, permitted Third Party Manufacturer, or an assignee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnity</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Licensee</U> agrees to indemnify, hold harmless and defend WuXi Biologics, its Affiliates, and their
respective directors, officers, employees and agents harmless (collectively, &#8220;WuXi Indemnitees&#8221;) from and against any and all liabilities and damages (including reasonable attorneys&#8217; fees) resulting from any and all claims from any
Third Party (&#8220;Claims&#8221;) to the extent arising from the use of the Licensed Cell Line, Client Product, Drug Substance or Drug Product by Licensee; except to the extent WuXi Biologics is obligated to indemnify Licensee in accordance with
Section&nbsp;9.2 of this Agreement, and provided further that Licensee shall have no obligation to indemnify any such Claims that arise from WuXi Biologics&#8217; (i) negligence or intentional misconduct in connection with the Licensed Cell Line
(ii)&nbsp;material breach of this Agreement (including the representations and warranties set forth in Section&nbsp;10); or (iii)&nbsp;Host Cell Line components of the Licensed Cell Line or any Media and Feeds. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">WuXi Biologics will indemnify Licensee, its Affiliates, its sublicensees and their respective directors,
officers, employees and agents, and their respective successors, heirs and assigns (collectively, &#8220;Licensee Indemnitees&#8221;), and defend and hold each of them harmless, from and against any and all Losses in connection with any and all
Third-Party Claims against Licensee Indemnitees to the extent arising from or occurring as a result of: (i)&nbsp;the breach by WuXi Biologics of any provision of this Agreement; or (ii)&nbsp;any negligence or willful misconduct on the part of any
WuXi Indemnitee in connection with the Host Cell Line components of the Licensed Cell Line, except in each case to the extent Licensee is obligated to indemnify WuXi Biologics in accordance with Section&nbsp;9.1 of this Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each party must notify the other party within [***] of receipt of any claims made for which the other party might be
liable hereunder. The indemnifying party will have the sole right to defend, negotiate, and settle such claims. The indemnified party will be entitled to participate in the defense of such matter and to employ counsel at its expense to assist in
such defense. No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party&#8217;s written consent; provided, however, that the indemnifying party will have final decision-making authority regarding
all aspects of the defense of any claim. The party seeking indemnification will provide the indemnifying party with such information and assistance as the indemnifying party may reasonably request, at the expense of the indemnifying party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Limitation of Liability. NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR
OTHERWISE) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT,
HOWEVER CAUSED, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-USE</FONT> OBLIGATIONS IN SECTION 11. NOTHING IN THIS SECTION 9.4
IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Representations and Warranties</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">10.1 WuXi Biologics represents and warrants that: (i)&nbsp;it is a corporation duly organized validly existing and in good standing under the
laws of the Republic of Ireland; (ii)&nbsp;the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of WuXi Biologics; (iii)&nbsp;the performance of WuXi Biologics&#8217;
obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv)&nbsp;WuXi Biologics will not before the termination of this
Agreement enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement; (v)&nbsp;WuXi Biologics has sufficient facilities, experienced personnel and other capabilities
reasonably suited to enable it to perform its obligations under this Agreement; (vi)&nbsp;WuXi Biologics has the right to grant the licenses or sublicenses, as the case may be, therefor granted under this Agreement; (vii)&nbsp;WuXi Biologics is the
sole and exclusive owner of the Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> and Licensed Cell Line, or otherwise has the right to license the Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> and Licensed Cell Line and grant
rights to Licensee as set forth in this Agreement and during the Term of the Agreement, (viii)&nbsp;to the best of its knowledge WuXi Biologics is and will remain entitled to grant to Licensee the licenses and rights specified or contemplated by
this Agreement, and to the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> , (ix) as of the Effective Date, neither WuXi Biologics nor any of its Affiliates has received any notice challenging WuXi Biologics&#8217; ownership or right to
use the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in relation to the Licensed Cell Line and, Host Cell Line component of the Licensed Cell Line, (x)&nbsp;to the best of WuXi Biologics&#8217;s knowledge, there are no valid grounds for
any claim against WuXi Biologics or any of its Affiliates except for any claims caused by Licensee&#8217;s DNA sequence related to the Client Product incorporated into the Licensed Cell Line. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">10.2 Licensee represents and warrants that: (i)&nbsp;it is a corporation duly organized
validly existing and in good standing under the laws of the Commonwealth of Massachusetts; (ii)&nbsp;the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Licensee;
(iii)&nbsp;the performance of Licensee&#8217;s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a party; (iv)&nbsp;Licensee
has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (v)&nbsp;Licensee will not before the termination of this Agreement enter into any
agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">10.3
Disclaimer of Warranties. OTHER THAN AS PROVIDED IN THIS AGREEMENT, THE LICENSED <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> AND LICENSED CELL LINES ARE PROVIDED AND LICENSED TO LICENSEE &#8220;AS IS&#8221;, THE PARTIES MAKE NO REPRESENTATIONS
AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT THERETO OR TO THE PRODUCTS, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSEVALIDITY OF THE RIGHTS LICENSED
HEREUNDER, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Confidentiality</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.1 Subject to the exceptions listed below, during the term of this Agreement and for [***] thereafter, the Receiving Party shall, and shall
ensure that its Related Persons will, (a)&nbsp;maintain the Disclosing Party&#8217;s Confidential Information in confidence, (b) not use such Confidential Information other than in connection with this Agreement, and (c)&nbsp;not disclose such
Confidential Information to any Third Party other than (i)&nbsp;those of its Related Persons that have a need to know such Confidential Information in connection with the Activities conducted pursuant to the Agreement and are obligated to maintain
such Confidential Information in confidence and (ii)&nbsp;to the extent required by applicable law or judicial order, or to the extent reasonably necessary to prosecute or defend litigation or arbitration in relation to this Agreement, and, in
either case, only after the Receiving Party gives the Disclosing Party [***] advance written notice of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
requirement and [***] with the Disclosing Party&#8217;s efforts to limit or avoid such disclosure, to seek a protective order or secure confidential treatment of the Confidential Information,
and/or to seek any other remedies available to the Disclosing Party at law or in equity. Notwithstanding the foregoing, the existence of this Agreement and its <FONT STYLE="white-space:nowrap">non-technical</FONT> terms may be disclosed
confidentially in connection with a potential financing, collaboration or acquisition or in discussion with a potential acquirer of Client Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.2 The Receiving Party&#8217;s obligations set forth in Section&nbsp;11.1 do not apply to Confidential Information if (a)&nbsp;the
information is public knowledge or becomes public knowledge after disclosure through no act or omission of the Receiving Party or any of its Related Persons, (b)&nbsp;the information can be shown by the Receiving Party to have been lawfully in its
possession prior to disclosure, (c)&nbsp;the information was rightfully received on a <FONT STYLE="white-space:nowrap">non-confidential</FONT> basis from a Third Party that was not obligated to maintain the information in confidence, or (d)&nbsp;the
Receiving Party can show that equivalent information was developed independently by the Receiving Party without reference to the Disclosing Party&#8217; Confidential Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.3 Licensee may disclose the Confidential Information of WuXi Biologics to a Third Party for the purpose of exercising Licensee&#8217;s
license rights hereunder (including disclosure to potential Third Party sublicensees), provided that Licensee shall, prior to such disclosure, ensure that each Third Party to which disclosure is to be made is made aware of the obligations contained
in this Agreement and agrees to be subject to obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> no less onerous than those contained in this Agreement. Any breaches of the obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> contained in this Agreement by such Third Party shall be treated as a breach of such obligations by Licensee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.4 Notwithstanding anything to the contrary in this Agreement, a Party may disclose this Agreement and its terms, and material developments
or material information generated under this Agreement, in securities filings with the U.S. Securities and Exchange Commission (or equivalent foreign agency) and any rules of stock exchanges where the Parties may be listed to the extent required by
applicable law after complying with the procedure set forth in this Section&nbsp;11.4. In such event, unless otherwise required to comply with applicable law, the Party seeking such disclosure will prepare a draft confidential treatment request and
proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">will [***] give its input in a [***] in order to allow the Party seeking disclosure to file
its request within the timelines proscribed by applicable laws and regulations. The Party seeking such disclosure shall exercise [***] to obtain confidential treatment of this Agreement from the U.S. Securities and Exchange Commission (or equivalent
foreign agency) as represented by the redacted version reviewed by the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">11.5 The provisions of this Section&nbsp;11 shall
survive termination or expiry of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12.1. <U>Voluntary Termination by Licensee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Licensee shall have the right to terminate this Agreement upon at least six (6)&nbsp;months prior written notice to WuXi Biologics, and upon
payment of all undisputed amounts due to WuXi Biologics through such termination effective date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12.2 <U>Termination for Default</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Nonpayment</U>. In the event Licensee fails to pay any undisputed amounts due and payable to WuXi Biologics hereunder, and fails to make
such payments within thirty (30) days after receiving written notice of such failure, WuXi Biologics may terminate this Agreement [***] upon written notice to Licensee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Material Breach</U>. In the event Licensee commits a material breach of its obligation under this Agreement and fails to cure that
breach within sixty (60)&nbsp;days after receiving written notice thereof, WuXi Biologics may terminate this Agreement [***] upon written notice to Licensee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12.3 <U>Termination Upon Bankruptcy</U>. If either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a
receiver or trustee over all or substantially all of its property, files a petition or commences a proceeding under any bankruptcy or insolvency act in any state or country or has any such petition or application filed against it which is not
discharged within [***] of the filing thereof, then the other Party may thereafter terminate this Agreement effective [***] upon written notice to such Party. All rights and licenses granted under or pursuant to this Agreement by WuXi Biologics are,
and will otherwise be deemed to be, for purposes of the relevant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
provisions of the Bankruptcy and Insolvency Act, R.S.C. 1985, c. <FONT STYLE="white-space:nowrap">B-3</FONT> (&#8220;BIA&#8221;), including Sections 65.11(7), 65.13(9), 72.1 and 246.1 of the BIA;
and the relevant provisions of the Companies&#8217; Creditors Arrangement Act, R.S.C. 1985, c. <FONT STYLE="white-space:nowrap">C-36</FONT> (&#8220;CCAA&#8221;), including Sections 32(6) and 36(8) of the CCAA (the BIA and CCAA being referred to
collectively as the &#8220;Insolvency Legislation&#8221;), a grant of a &#8220;right to use&#8221; &#8220;intellectual property&#8221; as used in the Insolvency Legislation. The Parties agree that Licensee and its Affiliates and sublicensees, as
licensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without limiting Licensee&#8217;s rights
under the Insolvency Legislation, if WuXi Biologics becomes insolvent or makes an assignment for the benefit of its creditors or there is filed by or against it any bankruptcy, receivership, reorganization or similar proceeding pursuant to or under
the Insolvency Legislation or otherwise, Licensee will be entitled to a copy of any and all information specified in the Technology Transfer Package unless WuXi Biologics, or its trustee or receiver, elects within [***] to continue to perform all of
its obligations under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12.4 Expiration or termination of this Agreement for any reason will not relieve either party of any
obligation accruing prior to such expiration or termination, including section 5 (Cell Line Royalties) shall survive termination or expiry of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.1 <U>Assignment</U>. This Agreement may not be assigned or otherwise transferred by either Party (subject to Licensee&#8217;s right to
sublicense its rights hereunder) without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; <I>provided, however</I>, that a Party may, without such consent, assign this Agreement
in its entirety (a)&nbsp;to an Affiliate, or (b)&nbsp;to a Third Party in connection with a merger, acquisition, consolidation or a sale involving all or substantially all of the assets or business of such Party. Any attempted assignment or transfer
in violation of this Section&nbsp;13.1 shall be void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.2 <U>Regulatory Assistance</U>. WuXi Biologics will provide assistance to
Licensee, and any sublicensee, in respect of Licensee&#8217;s or such sublicensee&#8217;s regulatory filing activities for the Client Product and/or Drug Product, at Licensee&#8217;s or such sublicensee&#8217;s reasonable cost and expense on [***]
rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.3 <U>Governing Law</U>. The laws of the State of New York, USA, without regard to any
choice of law principle that would require the application of the law of another jurisdiction, govern all matters relating to this Agreement and the enforcement thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The parties expressly reject any application to this Agreement of (a)&nbsp;the United Nations Convention on Contracts for the International
Sale of Goods; and (b)&nbsp;the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April&nbsp;11, 1980. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.4 <U>Arbitration.</U> The parties shall engage in good faith consultation to resolve any dispute arising out of or in connection with this
agreement. Such consultation will begin [***] after one party has delivered to the other party a request for consultation. If the dispute cannot be resolved within [***] following the date on which the request for consultation is delivered, then
either party may submit the dispute to JAMS International Arbitration Rules (&#8220;Arbitration&#8221;). The Arbitration tribunal will consist of three arbitrators. Within [***] after the commencement of the Arbitration, each Party shall select one
person to act as arbitrator, each of whom must be a practicing or retired attorney or judge have at least [***] of litigation experience within the biopharmaceutical industry. The two arbitrators so selected shall select the chair within [***] of
the commencement of the Arbitration, whom must a practicing or retired attorney or judge have at least [***] of litigation experience within the biopharmaceutical industry. If the arbitrators selected by the Parties are unable or fail to agree upon
the third arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration Rules. All arbitrators shall serve as neutral, independent and impartial arbitrators. (ii)&nbsp;The
Arbitration shall be conducted in accordance with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration will be Manhattan, New York. The official language of the arbitration will be English. The
arbitration proceedings will be confidential, and the arbitrator may issue appropriate protective orders to safeguard each party&#8217;s Confidential Information. During the course of arbitration, the parties shall continue to implement the terms of
this agreement. The arbitral award will be final and binding upon the parties, and the party to the award may apply to a court of competent jurisdiction for enforcement of the award. Notwithstanding the foregoing, each party has the right to
institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the arbitrator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">13.5 <U>Counterparts</U>. This Agreement may be executed in two (2)&nbsp;or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures
shall be deemed to bind each Party hereto as if they were the original signatures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties hereto have caused this AGREEMENT to be duly executed as of the Effective
Date set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WuXi Biologics Ireland Limited</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>KORSA Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Chen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Evan Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chris Chen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Evan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 of 17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Appendix I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Service Agreements for Client Products </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Client Product Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Contract (e.g., Master Service Agreements)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effective Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 of 17 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>6
<FILENAME>d111069dex1033.htm
<DESCRIPTION>EX-10.33
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.33</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.33 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND
(II)&nbsp;IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT
NO. 1 TO THE CELL LINE LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT</B> (&#8220;<B>Amendment</B>&#8221;), effective
as of March&nbsp;2, 2026 (the &#8220;<B>Amendment Effective Date</B>&#8221;), is entered into and made by and between <B>WuXi Biologics Ireland Limited</B>, having an address at Dundalk Science&nbsp;&amp; Technology Park, Mullagharlin, Dundalk, Co
Louth A91 X56F, Ireland (&#8220;<B>WuXi Biologics</B>&#8221;), and <B>Korsana Biosciences, Inc.</B>, having its principal place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (&#8220;<B>Licensee</B>&#8221;). WuXi
Biologics and Licensee may be referred to herein individually as a &#8220;<B>Party</B>&#8221; and collectively as the &#8220;<B>Parties</B>.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, WuXi Biologics and Licensee (then known as KORSA Biosciences, Inc.) have entered into that certain Cell Line License Agreement, dated as of
December&nbsp;2, 2024 (the &#8220;<B>License Agreement</B>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties now desire to amend the License Agreement to enable
additional cell lines to be licensed by Licensee as set forth herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing, of the mutual promises set forth
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending legally to be bound, hereby agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;1.4 of the License Agreement defining the Construct is hereby deleted in its entirety and replaced
with the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.4 &#8220;<B>Construct</B>&#8221; means a [***] developed by WuXi Biologics that is used for
delivering genetic code and for transfecting and/or transforming the Host Cell Line or the Engineered WuXia Cell Line for purposes of created the Licensed Cell Line. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;1.9 of the License Agreement defining the Licensed Cell Line is hereby deleted in its entirety and
replaced with the following: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.9 &#8220;<B>Licensed Cell Line</B>&#8221; means the cell line developed by WuXi Biologics
which produces the Client Product. Licensed Cell Line includes: the Host Cell Line alone, or an Engineered WuXia Cell Line based on the Host Cell Line; WuXi Biologics&#8217; proprietary Construct component; and the sequence encoding the recombinant
protein. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Section&nbsp;1.22 (and subsections) is hereby added to the License Agreement as follows:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.22 &#8220;<B>Engineered WuXia Cell Line</B>&#8221; means a proprietary cell line developed by WuXi Biologics through
the genetic engineering of the Host Cell Line, including but not limited to the following, and including their progeny, modified, and unmodified derivatives: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1.22.1 &#8220;<B>WuXia RidGS Cell Line</B>&#8221; means the Engineered WuXia Cell Line which [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1.22.2 &#8220;<B>WuXia TrueSite Cell Line</B>&#8221; means the Engineered WuXia Cell Line which [***]. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2.1 of the License Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.1 WuXi Biologics hereby grants to Licensee and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
worldwide license, with the right to grant sublicenses as provided in Section&nbsp;2.3, to the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and the Licensed Cell Line (whether derived from the Host Cell Line or an Engineered WuXia Cell
Line), Materials, and Media and Feeds, for the purpose of conducting the Process, including the following licensed activities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, import, sell and otherwise use Client Product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further
commercialize Drug Substance and Drug Product for any and all purposes </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;4 of the License Agreement is hereby deleted in its entirety and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>4. License Fee</B>. As consideration for the license granted in Section&nbsp;2 of this Agreement, and the
representations and warranties set forth in Section&nbsp;10 of this Agreement, Licensee agrees to pay WuXi Biologics a fixed <FONT STYLE="white-space:nowrap">non-creditable,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee
of USD 150,000 for the Licensed Cell Line used in Client Product. [***]. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as expressly modified by this Amendment, the License Agreement shall remain unchanged and in full force
and effect in accordance with its terms and the Parties hereby ratify and reaffirm the License Agreement as amended hereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Amendment may be executed in any number of counterparts, with each counterpart constituting an original,
but all of which shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment by electronic transmission (including .pdf file) shall be effective as delivery of a manually executed
counterpart of this Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any capitalized term used in this Amendment and not otherwise defined herein shall have the meaning given to
that term in the License Agreement. This Amendment and the rights and obligations of the Parties hereto shall be governed, construed, and enforced in accordance with the governing law as stated in the License Agreement </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
BECAUSE THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be duly executed as of the Amendment Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WuXi Biologics Ireland Limited</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Korsana Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Zhisheng Chen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Angela She</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Zhisheng Chen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Angela She</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VP R&amp;D Strategy and Operations</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>7
<FILENAME>d111069dex1034.htm
<DESCRIPTION>EX-10.34
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.34</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.34 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS
NOT MATERIAL AND (II)&nbsp;IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOLOGICS MASTER SERVICES AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
Biologics Master Services Agreement (this &#8220;<B>Agreement</B>&#8221;) is dated and effective as of December&nbsp;12, 2024 (the &#8220;<B>Effective Date</B>&#8221;) and is between <B>KORSA Biosciences, Inc., </B>a Delaware corporation, with an
office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (&#8220;<B>Client</B>&#8221;) and <B>WuXi Biologics (Hong Kong) Limited</B>, with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong
Kong (&#8220;<B>Provider</B>&#8221;), each of Client and Provider being a &#8220;<B>Party,</B>&#8221; and collectively the &#8220;<B>Parties</B>.&#8221; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Client discovers and develops biologics. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider coordinates the biologics development and manufacturing services, including those provided by certain
affiliated operating companies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties desire that Provider or its Affiliates provide services to Client on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">project-by-project</FONT></FONT> basis. The services for each project (the &#8220;<B>Services</B>&#8221;) will be provided pursuant to a separate and distinct contract (a &#8220;<B>Work
Order</B>&#8221;) that incorporates certain terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties therefore agree as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Affiliate</B>&#8221; of a Person means any other Person that directly or indirectly Controls, is
controlled by, or is under common Control with, the Person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Applicable Law</B>&#8221; means all applicable laws, regulations and current Good Manufacturing
Practice (cGMP) and other official guidelines and directives of any Authority relevant to the Services performed under this Agreement, and the supply, use, marketing or sale of the Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Authority</B>&#8221; means any government regulatory authority responsible for granting approvals for
the performance of Services under this Agreement or for issuing regulations pertaining to the Manufacture and/or use of Product in the intended country of use, including the FDA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Cell Line</B>&#8221; means the cell line that has been developed to produce a Product.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Certificate of Analysis</B>&#8221; means a certificate of analysis for testing of Specifications of a
Product in a form agreed to by the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Certificate of Compliance</B>&#8221; means a document issued by WuXi Biologics attesting that a
Product Batch has been manufactured in compliance with cGMP (as applicable) and that Manufacturing Batch records have been reviewed and approved by WuXi Biologics&#8217; Quality Assurance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Certificate of Testing</B>&#8221; means a certificate for testing of selected Specifications of a
Product in a form agreed by both Parties, for the selected testing performed by WuXi Biologics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Confidential Information</B>&#8221; of a Party (the &#8220;<B>Disclosing</B> <B>Party</B>&#8221;)
means all information and materials disclosed by or on behalf of the Party to the other Party (the &#8220;<B>Receiving Party</B>&#8221;) or its Related Persons (as defined below) in connection with this Agreement that is reasonably considered to be
confidential and is not generally available to the public, and permits the Disclosing Party to obtain a business advantage over any third party(ies) that do not know or use such information. The Confidential Information of both Parties includes the
existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this Agreement. All data and information developed by either party relating
specifically to the Products, including Cell Line validation data generated by Provider under Work Orders, constitutes Client&#8217;s Confidential Information. Confidential Information excludes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that at the time of disclosure to Receiving Party is in the public domain (through no act or
omission of Receiving Party); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that was known by Receiving Party prior to receipt from Disclosing Party (as proven by Receiving
Party&#8217;s written records); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that is disclosed to Receiving Party by a third party without an obligation of confidentiality and
having the legal right to do so (as proven by Receiving Party&#8217;s written records); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">information that is independently developed by Receiving Party without any benefit of, and not being derived or
arising from, Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Control</B>&#8221; over a Person means (a)&nbsp;owning 50% or more of the voting securities or other
ownership interests of the Person or (b)&nbsp;having the power to direct the management or policies of the Person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Facility</B>&#8221; means the facility(ies) of Provider identified in the applicable Work Order.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>FDA</B>&#8221; means the United States Food and Drug Administration, and any successor agency having
substantially the same functions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Intellectual Property</B>&#8221; means patents and patent applications, trademarks and applications,
trade names, service marks, domain names, copyrights and copyright applications and registrations, schematics, industrial models, inventions, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, computer software programs and other
intangible proprietary information including Confidential Information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Person</B>&#8221; means an individual, a corporation, a partnership, an association, a trust or other
entity or organization, including a government or political subdivision or an agency thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Product</B>&#8221; means the drug substance, drug product, or a part or derivative of the drug
substance or drug product, that is manufactured through the Services or to be produced by a Cell Line. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;<B>Specifications</B>&#8221; means the list of tests, references to any analytical procedures and
appropriate acceptance criteria which are numerical limits, ranges or other criteria for tests described in order to establish a set of criteria to which Product at any stage of Manufacture should conform to be considered acceptable for its intended
use that are provided by or approved by Client, as such specifications are amended or supplemented from time to time by Client in writing. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Work Orders</B>. Provider shall provide the Services to Client pursuant to each Work Order that is entered
into during the term of this Agreement. The preferred form of Work Order is provided in <B>Exhibit A</B>. Each Work Order will automatically incorporate the terms of this Agreement and be a separate and distinct agreement. If there is a
contradiction between a provision of this Agreement and a Work Order, then the provision in this Agreement will take precedence unless the Work Order specifically states that it takes precedence over such named provision, in which case such
precedence shall be limited in application to the Services under such Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Manufacturing</B>. Both Parties will comply with the manufacturing terms in <B>Exhibit B</B>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Affiliates</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider may delegate or subcontract the Services, or any part thereof, to an Affiliate of Provider listed on
Exhibit C for the provision of Services described. If the Services are provided by an Affiliate, then references to Provider in this Agreement will be deemed to be references to the Affiliate with the necessary modifications. Provider shall be
liable for the performance of the Affiliate to the same extent as if the performance was that of Provider. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Affiliate of a Party may enter into a Work Order instead of the Party. If a Work Order is entered into by an
Affiliate, then references to the Party in this Agreement will be deemed to be references to the Affiliate with the necessary modifications. The Party shall be liable for the performance of the Affiliate to the same extent as if the performance was
that of the Party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONTRACT PRICE; PAYMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Contract Price</B>: Client shall pay Provider the undisputed fees in the amount and manner provided in the
applicable Work Order (the &#8220;<B>Contract Price</B>&#8221;). The Contract Price may be charged in accordance with a <FONT STYLE="white-space:nowrap">lump-sum</FONT> or other pricing structure as agreed by the Parties. The Contract Price will
include [***]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expenses</B>. Client shall reimburse Provider for reasonable and documented expenses that are
(a)&nbsp;authorized by Client, (b)&nbsp;described in the applicable Work Order, or (c)&nbsp;described in this Agreement, including Sections [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestones</B>. If a Work Order includes a payment for completion of a project stage or other milestone,
then Provider shall notify Client [***] after the milestone is achieved. Client will be deemed to have agreed that the milestone was achieved unless it notifies Provider otherwise within [***] of receiving such notice. Each milestone payment is
designed to reflect the fair value of the corresponding Services, and is not dependent on any other milestone unless otherwise specified in the Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment</B>. Client shall pay undisputed amounts in each of Provider&#8217;s invoices within [***] of
receipt by wire transfer to the account designated by Provider. Provider shall submit invoices to Client via email, attention: [***]. All payments made under this Agreement and any Work Order will be made [***]. The Contract Price is exclusive of,
and Client shall pay, any applicable taxes (other than taxes on Provider&#8217;s income) and other fees of any nature imposed by or under the authority of any government authority. Client may withhold any payment that the Client disputes [***]
provided that Client informs Provider of such dispute within the original time for payment, in which case the Parties will meet to resolve the dispute [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Clawbacks</B>. Other than as agreed by the parties, under this Agreement or an applicable Work Order, the
Contract Price and other payments under this Agreement and any applicable Work Order are <FONT STYLE="white-space:nowrap">non-cancelable</FONT> and <FONT STYLE="white-space:nowrap">non-refundable,</FONT> provided that Provider shall refund any <FONT
STYLE="white-space:nowrap">pre-payments</FONT> made for Services not performed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment Default</B>. In the event of an overdue undisputed amount (a &#8220;<B>Payment Default</B>&#8221;),
interest of [***]% will accrue [***] on the overdue payment as of the date of the Payment Default. If the Payment Default is not rectified within [***] after Client&#8217;s receipt of notice of such Payment Default, then it will be deemed an
incurable material breach of the applicable Work Order, and Provider may terminate the Work Order pursuant to Section&nbsp;11.3.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Review</B>. At [***], each Party to a Work Order may propose a prospective adjustment of the Contract
Price to reflect documented changes in pricing factors including foreign exchange fluctuation, cost reductions and efficiency increases, inflation or deflation and changes in the price of raw materials. The Parties shall negotiate [***] with the aim
of identifying a mutually acceptable amendment of the Work Order. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROVISION OF SERVICES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Specifications</B>. Provider shall provide all the Services at the Facility or other facilities agreed by
both parties and in accordance with the Specifications of the applicable Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Qualifications</B>. Provider shall ensure that the persons that provide the Services (the
&#8220;<B>Personnel</B>&#8221;) (a) have the appropriate skills, training and experience and (b)&nbsp;are bound by confidentiality obligations consistent with the terms of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance</B>. Provider shall provide the Services in compliance with Applicable Law and applicable Good
Practice (&#8220;<B>GxP</B>&#8221;) guidelines in all material respects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">On-Site</FONT> Monitoring</B>. Representatives of Client may, [***], visit
the facilities where the Services are provided and consult informally during such visits with appropriate Personnel in order to monitor the Services. The representatives will be bound by rules applicable to the facilities and may, [***], be
prohibited from entering or only given limited access to certain areas within the facilities. Provider may require that Client or the representatives execute an agreement that regulates the representatives&#8217; conduct during its visit. Client
shall be responsible for all expenses incurred in connection with such visits [***], and all its personnel must be subject to the same level of confidentiality as in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Inspections</B>. Provider will permit visits and/or inspections by regulatory Authorities of any
country as required by Applicable Law, and will permit Client or its agents to be present and participate in any visit or inspection by such regulatory Authority of the Facility (to the extent it relates in any way to any Product) or the
manufacturing process. Provider will give as much advance notice as possible to Client of any such visit or inspection. Provider will provide Client with a redacted (only to protect confidential information of Provider&#8217;s other customers and
remove the contents not related to the Client&#8217;s project ) copy of any report or other written communication received from such Authority in connection with such visit or inspection, and any written communication received from any regulatory
Authority relating to the Product, the Facility (if it relates to or affects the development and/or manufacture of Product) or the manufacturing process, within [***] after receipt, and will consult with, and unless legally prohibited by regulatory
Authorities, seek approval from, Client before responding to each such communication if time permits. Provider will provide Client with a copy of its final responses within [***] after submission. [***]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Facility</B>. Provider will not change the location of such Facility or use any additional facility for the
performance of manufacturing Services under this Agreement without at least [***] prior written notice to, and prior written consent from, Client, which consent will not be unreasonably withheld or delayed (it being understood and agreed that Client
may withhold consent pending satisfactory completion of a quality assurance audit and/or regulatory impact assessment of the new location or additional facility, as the case may be). Provider will maintain, [***], the Facility and all Equipment
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
required for the Manufacture of Product in a state of repair and operating efficiency consistent with the requirements of cGMP (if applicable) and all Applicable Law. Provider will be responsible
for performing all validation of the Facility, Equipment and cleaning and maintenance processes employed in the Manufacturing Process in accordance with cGMP (if applicable), Provider&#8217;s SOPs, the applicable Quality Agreement (if any), and
Applicable Law. Provider will be responsible for obtaining, [***], any Facility or other licenses or permits, and any regulatory and government approvals necessary for the performance of Services by Provider under this Agreement. [***], Provider
will provide Client with copies of all such approvals, and Client will have the right to use any and all information contained in such approvals in connection with regulatory approval and/or commercial development of Product. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SOURCING OF MATERIAL </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Materials</B>. Provider shall, [***], purchase all materials necessary for the Services (the
&#8220;<B>Materials</B>&#8221;). If a Material is not commercially available, then Client may elect to (a)&nbsp;supply, [***], the Material to Provider; or (b)&nbsp;amend the applicable Work Order to permit the use of a commercially available
substitute. Provider shall perform the market research and propose a list of vendors in compliance with Applicable Law and applicable GxP in all material respects, [***]. Provider shall take the inventory risk of the selected materials, such as the
damages to pass through materials caused by improper storage or pollutions, [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Client Materials</B>. If a Material is to be supplied by Client (a &#8220;<B>Client Material</B>&#8221;),
then Client shall provide the Client Material [***] in a timely manner and provide such information as may be required by Provider or Applicable Law concerning the stability, storage and safety requirements of the Client Material. Provider shall
ensure that the Client Material will be (a)&nbsp;used solely for the purpose of providing the Services, (b)&nbsp;only distributed to Personnel on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">need-to-know</FONT></FONT> basis
for the provision of the Services and (c)&nbsp;preserved and protected in a manner consistent with the specifications of the applicable Work Order and any relevant standard operating procedures or other instructions provided by Client. Client will
at all times retain title to and ownership of the Client Materials, Product, any intermediates and components of Client Materials or Product, and any work in process at each and every stage of the Manufacturing Process. Provider will provide within
the Facility an area or areas where the Client Materials, Product, any intermediates and components of Client Materials or Product, and any work in process are segregated and stored in accordance with the Specifications and cGMP (if applicable), and
in such a way as to be able at all times during the period of the Agreement or applicable Work Order to clearly distinguish such materials from products and materials belonging to Provider, or held by it for a third party&#8217;s account. Provider
will ensure that Client Materials (which are under Provider&#8217;s control), Product, any intermediates and components of Product, and any work in process are free and clear of any liens or encumbrances arising from disputes with any third party.
Provider will at all times during the period of the Agreement or applicable Work Order take such measures as are required to protect the Client Materials, Product, any intermediates and components of any Client Materials or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Product, and any work in process from loss, damage and theft at all stages of the Manufacturing Process. Client agrees that it is responsible to insure such items against theft, damage or loss
and under no circumstances shall Provider be liable for loss or damage to any such items. The foregoing agreement does not limit the Provider&#8217;s liability for Client Materials&#8217;(for clarity, such Client Materials should be specified in the
applicable Work Orders) loss or damage solely resulting from Provider&#8217;s gross negligence or willful misconduct while the Services are being performed or while such Client Materials are in the Provider&#8217;s care. Provider will [***] notify
Client if at any time it believes any Product or Client Materials, or any intermediates and components of any Client Materials or Product, or any work in process have been damaged, lost or stolen. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unused Client Materials and Other Materials</B>. Provider shall, [***], return, destroy or otherwise dispose
of unused Client Materials [***] after the earlier of (a)&nbsp;completion of the Services for which the Client Materials were provided, (b)&nbsp;termination of the applicable Work Order, or (c)&nbsp;receipt of written instructions from Client
pertaining to its disposition. Provider may dispose of other unused Materials at its sole discretion upon [***] prior written notice to Client, and Client may elect during the [***] period to have the Client Materials transferred to Client.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECORDS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Storage for Records</B>. All materials, data and documentation obtained or generated by Provider in the
course of providing the Services, including all computerized records and files (&#8220;<B>Records</B>&#8221;), will be maintained in a secure area in accordance with industry standards and Applicable Law, [***]. While it is the Parties&#8217; intent
that Provider shall retain ownership of any Provider IP or Provider Confidential Information contained in the Records, the Records with exclusion of the Provider IP and Provider Confidential Information are the sole and exclusive property of Client
and Client shall be able to use the Records, unencumbered, for purposes related to the Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Retention of Records</B>. Upon termination of the applicable Work Order, Provider shall, at Client&#8217;s
option, (a)&nbsp;destroy the Records, (b)&nbsp;deliver the Records to Client, or (c)&nbsp;retain the Records for [***] and then destroy the Records. If the Records are to be destroyed, then Provider shall give [***] notice to Client, and Client may
elect during the [***] period to have the Records transferred to Client. Notwithstanding the foregoing, the Records may be retained solely to the extent as required by Applicable Law or as otherwise necessary for regulatory or insurance purposes.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Storage for Product</B>. All the Products shall be stored in Provider&#8217;s facilities for [***] after
Provider&#8217;s issuance of a Certificate of Compliance with 1) a Certificate of Analysis (if full lot release testing is performed by Provider) or 2) a Certificate of Testing (if Client requests only selected lot release testing to be performed by
Provider), as applicable, and a monthly storage fee for Products shall be charged after the [***] period. Client agrees that the commercial value and/or cost of replacement or remanufacture of any Products provided to Provider for storage is a
matter that, as between Client and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Provider, is within the sole and exclusive knowledge of Client. Client agrees that it is responsible to insure such items against damage or loss and shall purchase appropriate insurance to cover
its Products stored in Provider&#8217;s facilities. [***]. Transportation of Product by Provider on behalf of Client shall be made at the sole risk and expense of Client, notwithstanding the use of any INCOTERMS delivery term on any waybill or other
documentation relating to the transportation. Provider shall not be liable for the actions or omission of any delivery services or carriers or freight forwarders. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ownership</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in this Agreement, (i)&nbsp;Provider has no ownership rights in any Intellectual
Property that is owned by Client, or licensed by any third party to Client, or any of its Affiliates, including Product, (&#8220;<B>Client IP</B>&#8221;) and (ii)&nbsp;Client has no ownership rights in any Intellectual Property that is owned by
Provider, or licensed by any third party to Provider, or any of its Affiliates (&#8220;<B>Provider IP</B>&#8221;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider shall ensure that each of the Personnel vests in Provider, or its applicable Affiliate, any and all
rights that such person(s) might otherwise have in the Intellectual Property created or developed in connection with the provision of the Services, and all Intellectual Property relating to such inventions (excluding moral rights) (&#8220;<B>Project
IP</B>&#8221;). Improvements, modifications, and derivatives of Client IP constitute Project IP. Provider hereby assigns and shall assign (and require its Affiliates to assign) all right, title and interest in Project IP to Client. Client will,
[***], have sole control of filing and prosecuting applications for, and maintenance and enforcement of, patents for Project IP. Provider shall, [***], use [***] to assist Client to obtain, maintain and enforce the Project IP. Client shall use [***]
to [***] notify Provider of any patents granted for Project IP. Provider will be responsible for all payments to be made to Personnel of Provider and its Affiliates in accordance with any Applicable Law requiring remuneration for inventions. For the
avoidance of doubt, Provider has no right to file, prosecute, maintain, protect, defend, or enforce Intellectual Property claiming that covers any Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the foregoing, Intellectual Property created or developed in connection with the provision of
the Services (i)&nbsp;that relates solely to Provider IP, (ii)&nbsp;that relates to experimental methods independent of Client IP and Project IP, or (iii)&nbsp;that relates to manufacturing processes generally, in each case without reliance or
reference to Client IP or Project IP (collectively, &#8220;<B>Manufacturing Improvements</B>&#8221;) is Provider IP and not Project IP. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Licenses</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider acknowledges and agrees that it does not acquire a license or any other right to Client IP except for
the limited purpose of carrying out its duties and obligations under this Agreement and that such limited, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> license will expire upon the completion of such duties and obligations or the
termination or expiration of this Agreement, whichever is the first to occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Provider hereby grants and shall ensure that each applicable Affiliate will grant and hereby does grant, to
Client and its applicable Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> perpetual, irrevocable, royalty-free, <FONT STYLE="white-space:nowrap">non-transferable(except</FONT> in the case of Section&nbsp;14.2) and sublicensable
(through multiple tiers) license to Client and its Affiliates to use Provider IP solely to develop, Manufacture, have Manufactured, distribute, offer for sale, sell, and otherwise dispose of Product. Provider may, at its discretion, grant to Client
the right to use Manufacturing Improvements under mutually satisfactory terms to be negotiated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Licenses</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">In the provision of Services under this Agreement, Provider may recommend to incorporate into the process or deliverables some specific
Provider IP that needs an additional license. Prior to incorporation of such IP into the process and deliverables, Provider shall submit to Client a written list of such IP, describing it in reasonable detail. Within [***] of Client&#8217;s receipt
of the information noted in the preceding sentence, Client will notify Provider of its decision as to whether to incorporate such IP into the process or deliverables. Provider shall not incorporate such IP into the process or deliverables without
Client&#8217;s express written consent. For any specific Provider IP included in the process or deliverables for which Provider has failed to notify Client and/or for which Client has not expressly consented to the inclusion thereof, Client&#8217;s
rights to such IP shall be the same as Client&#8217;s rights in the process or deliverables. If Client agrees that some specific Provider IP may be incorporated in the process or deliverables or may be necessary for Client&#8217;s full utilization
of the deliverables, both parties shall discuss [***] regarding such license required. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]<B>-Cell Line License</B>. If Client agrees to use Provider&#8217;s [***]-Cell Line for the manufacture of
Product, then Client shall purchase from Provider a worldwide, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> sublicensable (through multiple tiers), <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to research, develop, make,
have made, and commercialize the Product (the &#8220;<B>License</B>&#8221;). The terms of the License to Provider&#8217;s [***]-Cell Line, including license fees and potential royalties, will be separately negotiated as a separate definitive
agreement (&#8220;<B>License Agreement</B>&#8221;). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATIONS AND WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual</B>. Each Party represents and warrants that (a)&nbsp;it validly exists under the laws of the
jurisdiction in which it was organized, (b)&nbsp;it has the full power, right and authority to execute and deliver this Agreement and to perform its obligations under this Agreement, (c)&nbsp;this Agreement once executed will constitute a legal,
valid and binding agreement enforceable against it and (d)&nbsp;its performance of this Agreement will not conflict with any obligations it may have to any other person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Infringement</B>. Client represents and warrants that, to the best of its knowledge, the use of Client
Intellectual Property and Client Materials in the performance of Services in accordance with this Agreement will not infringe the Intellectual Property rights of any third party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Provider Representations and Warranties</B>. Provider represents and warrants to Client that
(i)&nbsp;neither it nor any of the Personnel involved in the Services has been debarred, or, to the best of its knowledge, is under consideration for debarment, by the United States Food and Drug Administration from working in or providing services
to any pharmaceutical or biotechnology company pursuant to the Generic Drug Enforcement Act of 1992 or any other governmental authority pursuant to analogous laws; (ii)&nbsp;to the best of its knowledge, the Provider IP will not violate the
intellectual property rights of any third party and it will [***] notify Client in writing should it become aware of any claims asserting such violation; and (iii)&nbsp;at the time of delivery to Client, the Product Manufactured under this Agreement
will have been Manufactured in accordance with cGMP (if applicable) and all other Applicable Law, the Manufacturing Process, the applicable Quality Agreement, and Specifications. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compliance with Law</B>. Each Party represents and warrants that it shall, and shall ensure that each of its
Affiliate will, comply with all Applicable Law in connection with performance of this Agreement and any Work Orders. Each Party shall [***] notify the other Party upon becoming aware of a breach of this Section. Breach of this Section with respect
to the U.S. Foreign Corrupt Practices Act or any other applicable anti-bribery law will be deemed an incurable material breach for purposes of Section&nbsp;11.3(b). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNIFICATION; LIMITATION ON LIABILITY; INSURANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Claims Against Client</B>. Provider shall defend, indemnify and hold Client and its Affiliates
and its directors, officers, employees, agents and consultants and legal, financial, accounting and other advisors (&#8220;<B>Related Persons</B>&#8221;) harmless from and against any and all liabilities and damages (including reasonable
attorneys&#8217; fees) (&#8220;<B>Losses</B>&#8221;) resulting from any third party claims, demands, suits or proceedings (&#8220;<B>Claims</B>&#8221;) to the extent arising out of or relating to (a)&nbsp;its performance of the Services, (b)&nbsp;a
material breach of this Agreement by Provider, (c)&nbsp;a material violation of Applicable Law by Provider or any of its Related Persons, or (d)&nbsp;the gross negligence, recklessness or willful misconduct of Provider or any of its Related Persons
during the course of activities carried out in connection with this Agreement (except to the extent that such Losses are within the scope of the indemnification obligation of Client under Section&nbsp;9.2). The indemnification obligations set forth
in this Section&nbsp;9.1 do not apply to the extent that the Loss arises in whole or in part from the gross negligence, recklessness or willful misconduct of Client or any of its Related Persons or Client&#8217;s material breach of this Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Claims Against Provider</B>. Client shall defend, indemnify and hold Provider and its Related
Persons harmless from and against any and all Losses resulting from any Claims to the extent arising out of or relating to (a)&nbsp;Client&#8217;s use of Project IP or deliverables produced in accordance with this Agreement and the written
instructions of Client that were provided or produced under a Work Order (including use of any license under Provider IP), or Provider&#8217;s appropriate or proper use of Client Materials or Client IP provided by Client for use in the Services or
due to compliance to any written instructions provided by Client for use in the Services; (b)&nbsp;a material breach of this Agreement by Client , (c) a material violation of Applicable Law by Client or any of its Related Persons, (d)&nbsp;the gross
negligence, recklessness or willful misconduct of Client or any of its Related Persons during the course of activities carried out in connection with this Agreement, or (e)&nbsp;development or manufacture, use, handling, storage, or other
disposition of Products by or on behalf of Client or any of its Affiliates, sublicensees, agents or contractors (except by Provider), including Claims and threatened Claims based on product liability, bodily injury, risk of bodily injury, death or
property damage or the failure to comply with any Applicable Law; except to the extent that such Losses are within the scope of the indemnification obligation of Provider under Section&nbsp;9.1;. The indemnification obligations set forth in this
Section&nbsp;9.2 do not apply to the extent that the Loss arises in whole or in part from the negligence, recklessness or willful misconduct of Provider or any of its Related Persons, or Provider&#8217;s material breach of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Intellectual Property Claims</B>. Client shall defend, indemnify and hold Provider and its Related Persons
harmless from and against Losses resulting from Claims to the extent arising out of or related to infringement of any third party Intellectual Property rights in connection with the Services or the Product and where the infringement would not have
occurred but for Provider&#8217;s reliance upon Client&#8217;s written requirements, specifications and Client IP. To the extent Claims that are based on Provider IP independent of the Services or Product under this Agreement or Provider&#8217;s
breach of this Agreement, Client shall not be required to defend, indemnify, and hold Provider and its Related Persons harmless from those Losses. Provider shall defend, indemnify and hold Client and its Related Persons harmless from and against
Losses resulting from Claims to the extent arising out of or related to infringement of any Intellectual Property rights related to the Services and that are based on Provider IP. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defense</B>. Each Party shall notify the other Party within [***] upon learning of a Claim that is subject
to indemnification pursuant to Sections 9.1, 9.2, or 9.3 (but failure to notify shall not relieve the indemnifying Party of its indemnification obligations unless such failure materially prejudices its ability to defend the claim). The indemnifying
Party shall control, [***], the defense of the Claim [***] with counsel of its choice. The indemnified Party shall use [***] to cooperate in the defense at the indemnifying Party&#8217;s request and expense, and may participate in the Claim [***].
No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party&#8217;s written consent; provided that, if a settlement contains an absolute waiver of liability for the indemnified party, and each party
has acted in compliance with the requirements of this Section&nbsp;9.4, then the indemnified party&#8217;s consent will be deemed given. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitations on Liability</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NEITHER PARTY WILL BE LIABLE UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) FOR SPECIAL,
INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, HOWEVER CAUSED, EVEN IF THE
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF THE CONFIDENTIALITY AND <FONT STYLE="white-space:nowrap">NON-USE</FONT> OBLIGATIONS, OR FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. NOTHING IN THIS SECTION
IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance</B>. Each Party shall ensure that insurance coverage is carried and maintained with a financially
sound and reputable insurer against loss from such risks and in such amounts as is sufficient to support its obligations under this Agreement. Each Party shall provide a copy of the applicable insurance policy if requested by the other Party.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY AND PUBLICITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality</B>. During the term of this Agreement and for [***] thereafter (other than with respect to
trade secrets, which shall remain confidential for so long as they are protected under Applicable Law), the Receiving Party shall, and shall ensure that it, its Affiliates, and its Related Persons will, (a)&nbsp;maintain the Confidential Information
of the Disclosing Party in confidence, (b)&nbsp;not use the Confidential Information of the Disclosing Party other than solely in connection with this Agreement and (c)&nbsp;not disclose the Confidential Information of the Disclosing Party to any
third party other than (i)&nbsp;those of its Related Persons that have a need to know the Confidential Information in connection with the Services and are obligated to maintain the Confidential Information in confidence on terms at least as strict
as those contained herein, and (ii)&nbsp;notify the Disclosing Party of any unauthorized disclosure of its Confidential Information [***] upon becoming aware of such disclosure. Notwithstanding the foregoing, Client may disclose the existence of
this Agreement and Confidential Information of Provider confidentially in connection with a potential financing or acquisition or collaboration, provided, however, Client shall be liable for the acts and consequences of such disclosure.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return of Confidential Information</B>. Upon termination of this Agreement, and if requested in writing by
the Disclosing Party within [***] thereafter, the Receiving Party shall cause all Confidential Information of the Disclosing Party to be [***] destroyed or returned to the Disclosing Party; provided, however, that the Receiving Party may, subject to
its obligations of confidentiality hereunder, retain (a)&nbsp;a single secure copy of any Confidential Information for legal archival purposes, and (b)&nbsp;electronic <FONT STYLE="white-space:nowrap">back-up</FONT> files that have been created by
routine archiving and <FONT STYLE="white-space:nowrap">back-up</FONT> procedures need not be deleted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publicity</B>. Each Party shall not, and shall ensure that its Related Persons will not, use the name,
symbols or marks of the other Party or any of its Affiliates in any advertising or publicity material or make any form of representation or statement that would constitute an express or implied endorsement by the other Party or any of its Affiliates
of any commercial product or service, without the other Party&#8217;s or Affiliate&#8217;s prior written consent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audits</B>. Provider and its Affiliates may have in the past provided, and may currently or in the future
provide, services to other customers that are similar to the Services. Provider is absolutely committed to protecting Client&#8217;s Confidential Information and Intellectual Property, and shall not use such Confidential Information or Intellectual
Property for the benefit of any person other than Client. In order to protect the Confidential Information of Client and the confidential information of other customers, Provider shall use [***] to ensure that other customers do not seek the
disclosure of Confidential Information of Client, and Client hereby agrees it shall not seek the disclosure of confidential information of other customers of Provider. Notwithstanding the foregoing, if Client wishes to conduct an audit that relates
to services provided to another customer for purposes of confirming that Client&#8217;s Intellectual Property is adequately protected, then Provider shall use [***] to seek the other customer&#8217;s approval to waive confidentiality obligations to
the extent necessary to allow Client to conduct the audit in a manner that does not involve disclosure of the other customer&#8217;s confidential information to Client. If another customer wishes to conduct an audit that relates to the Services for
purposes of confirming that the other customer&#8217;s Intellectual Property is adequately protected, then Client shall discuss whether to waive Provider&#8217;s confidentiality obligations to Client to the extent necessary to allow the other
customer to conduct the audit in a manner that does not involve disclosure of Client&#8217;s Confidential Information to the other customer. Such audits may involve an independent auditor designated by Provider and paid for by the person seeking the
audit. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Agreement</B>. The term of this Agreement commences on the Effective Date and, unless earlier terminated
pursuant to this Section&nbsp;11, will expire on the later of (a)&nbsp;five (5) years from the Effective Date; or (b)&nbsp;the completion of Services under all Work Orders executed by the parties prior to the fifth anniversary of the Effective Date.
The term of this Agreement may be extended by Client continuously for additional [***] periods upon written notice to Provider at least [***] prior to the expiration of the then-current term. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Client will have the right, in its sole discretion, to terminate this Agreement or Work Order (a)&nbsp;upon
thirty (30)&nbsp;days&#8217; prior written notice to Provider; or (b)&nbsp;immediately upon written notice if Provider fails to obtain or maintain any material governmental licenses or approvals required in connection with the Services. Client shall
pay off Provider for the Services rendered and the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations occurred prior to the termination date; provided that Provider will use [***] to mitigate such
<FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations if applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Work Orders</B>. Work Orders are subject to the terms of this Agreement and are not affected by the
termination of this Agreement unless such Work Order is terminated together with the Agreement. The term of each Work Order commences on the date indicated in the Work Order and will, unless terminated earlier in accordance with this Agreement,
terminate upon completion of the Services. Notwithstanding the foregoing, either Party may terminate a Work Order: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at any time with six (6)&nbsp;months&#8217; advance notice to the other Party, provided, however, Provider
shall provide sufficient evidence to prove that there is reasonable cause to terminate the Work Order and discuss with Client [***] prior to the termination; provided further, if Provider terminates a Work Order pursuant to this clause 11.3.1, then
no termination or cancellation fees shall be paid by Client, Provider shall continue to provide Services for the irrelative Work Orders; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">immediately upon notice to the other Party if </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.3.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a material breach of the Work Order by the other Party remains uncured thirty (30)&nbsp;days after notice of
the material breach was received by such other Party; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.3.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for
or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law (which proceedings remain undismissed for [***]); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.3.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Force Majeure Event occurs that will, or continues to, prevent performance (in whole or substantial part) of
this Agreement or any pending Work Order by the other party for a period of at least ninety (90)&nbsp;days. In the case of a Force Majeure Event relating solely to a pending Work Order, the right to terminate will be limited to such Work Order.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival</B>. Upon termination of this Agreement or a Work Order, all outstanding rights and obligations
between the Parties arising out of or in connection with this Agreement or the Work Order, as the case may be, will [***] terminate, other than any obligations that (a)&nbsp;matured prior to the effective date of the termination or (b)&nbsp;by its
nature are intended to survive, including Sections 2.1, 4.2, 4.3, 4.6, 6.1, 6.2, 11.4, 11.5 and Articles 1, <FONT STYLE="white-space:nowrap">7-10,</FONT> 12 and 14. Provider will, upon receipt of a termination notice from Client, [***] cease
performance of the applicable Services and will take all reasonable steps to mitigate the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection therewith. Within [***] after the
<FONT STYLE="white-space:nowrap">close-out</FONT> of a Work Order, Provider will provide to Client a written </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
itemized statement of all work performed by it in connection with the terminated Work Order, an itemized breakdown of the payments associated with that work, and a final invoice for that Work
Order. If Client has <FONT STYLE="white-space:nowrap">pre-paid</FONT> to Provider more than the amount in a final invoice then Provider agrees to [***] refund that money to Client, or to credit the excess payment toward another existing or future
Work Order, at the election of Client. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Fee.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">If a Work Order is terminated early by Client under Section&nbsp;11.2 or 11.3, then Client shall pay Provider for the Services rendered in
accordance with the terms of this Agreement and all <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations in connection with the Services to the extent specified in the applicable Work Order; provided that Provider will use [***] to
mitigate such <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If <FONT STYLE="white-space:nowrap">non-manufacturing</FONT> Services, as specified in the applicable Work
Order, are terminated by Provider due to Client&#8217;s material breach pursuant to Section&nbsp;11.3.2, then Provider may charge Client a termination fee equal to [***] of the remaining value of such
<FONT STYLE="white-space:nowrap">non-manufacturing</FONT> Services within the Work Order as liquidated damages in connection with the redeployment of reserved Personnel and administrative overhead and costs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If manufacturing Services are terminated by Provider due to Client&#8217;s material uncured breach or at
Client&#8217;s request, Client may be charged cancellation fees as specified in Section&nbsp;12; If manufacturing Services (manufacturing run(s) including <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing, GMP manufacturing, and
engineering run) are terminated by Provider due to a Client request to cancel or due to a termination of the applicable Work Order by Provider because of Client&#8217;s uncured material breach pursuant to Section&nbsp;11.3.2, Client shall be charged
cancellation fees as specified in Section&nbsp;12 below. If Client requests to 1) postpone or reschedule, or 2) materially change the production scale or batch size of, a manufacturing run originally scheduled under an executed Work Order or Change
Order and/or this Agreement, the same cancellation terms in Section&nbsp;12 will apply, <I>provided that no cancellation fees will be charged in where such termination results from Provider&#8217;s breach of this Agreement, or its negligence or
willful misconduct</I>. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CANCELLATION TERMS FOR MANUFACTURING SERVICES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cancellation of <FONT STYLE="white-space:nowrap">non-GMP</FONT> Drug Substance Manufacturing</B>. If a
notice to cancel a <FONT STYLE="white-space:nowrap">non-GMP</FONT> drug substance manufacturing batch in an executed Work Order and/or this Agreement is received, Provider will make [***] to find an alternative customer or project to fill the
manufacturing slot. In the case where no alternative customer or project can be identified to fill the slot(s), charges for cancelling the related work under this Agreement (&#8220;<B>Cancellation Charge(s)</B>&#8221;) will be applied based on the
following: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] except the cost of raw materials purchased by Provider under the applicable Work Order for such <FONT
STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation
notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***] prior to the scheduled vial thaw. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing batch fee plus the cost of raw
materials purchased by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***]; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of a <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch fee plus the cost of raw materials purchased
by Provider under the applicable Work Order for such <FONT STYLE="white-space:nowrap">non-GMP</FONT> batch, if the cancellation notice is received [***]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cancellations for Drug Substance cGMP Manufacturing Run or Engineering Run</B>. If a notice to cancel a drug
substance cGMP manufacturing run or an engineering run in an executed Work Order and/or this Agreement (as the case may be) is received, Provider will use [***] to find an alternative customer or project (but excluding any project under existing
contract with Provider) for the manufacturing slot. In the case where no alterative customer or project can be identified to fill the slot(s), Cancellation Charge(s) will be applied based on the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] except the cost of raw materials purchased by Provider under the applicable Work Order for purposes of
such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled vial thaw or anytime thereafter. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cancellation for Drug Product cGMP Manufacturing Run or Engineering Run</B>. If a notice to cancel a cGMP
drug product manufacturing run or an engineering run in an executed Work Order and/or this Agreement (as the case may be) is received, Provider will use [***] to find an alternative customer or project but excluding any project under existing
contract with Provider) to fill the manufacturing slot(s). In the case where no alternative customer or project can be identified to fill the slot(s), Cancellation Charge(s) will be applied based on the following: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***], except the cost of raw materials purchased by Provider under the applicable Work Order for purposes of
such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] of the cGMP manufacturing run or engineering run batch fee plus the cost of raw materials purchased by
Provider under the applicable Work Order for purposes of such cGMP manufacturing run or engineering run, if the cancellation notice is received [***] before the scheduled manufacturing run or anytime thereafter. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHIPPING </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All materials to be provided by Provider to Client will be delivered FCA (carrier named by Client) (Incoterms
2020), including Product and other deliverables produced under a Work Order, returned Client Materials, returned Records and returned Confidential Information. For the avoidance of doubt, FCA (carrier named by Client) means Provider is responsible
for handing over the materials, cleared for export, to a carrier named by Client. Client assumes risk at hand over and pays all costs as specified in Incoterms 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All materials to be provided by Client to Provider will be delivered DDP (site designated by Provider)
(Incoterms 2020), including Client Materials. For the avoidance of doubt, DDP (site designated by Provider) means Client is responsible for delivery to and unloading at the site designated by Provider and pays all costs including import duties and
taxes. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure</B>. &#8220;<B>Force Majeure</B>&#8221; means and includes such circumstances or occurrences
which are beyond the reasonable control of the Party that materially prevent such Party from performing any of such Party&#8217;s obligations under this Agreement (other than the payment of money), and that are not caused by the Party&#8217;s
negligence, which may include, but not limited to, acts of God; pandemic(such as <FONT STYLE="white-space:nowrap">Covid-19),</FONT> strikes and labour problems affecting an entire industry or region; lightning, fire, flood, washout, storm, or other
actions of the elements; government actions, including embargos, sanctions, prohibitions; and war, civil disturbances or other imposition of sanctions by a governmental authority with jurisdiction over a Party. Neither Party shall be liable for <FONT
STYLE="white-space:nowrap">non-fulfilment</FONT> of its obligations or in breach under this Agreement if such <FONT STYLE="white-space:nowrap">non-fulfilment</FONT> is due to Force Majeure for the duration of such Force Majeure. Each Party shall use
[***] to mitigate adverse consequences in the event of such Force Majeure. A Party that is prevented from performing any of its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
obligations due to Force Majeure will [***] give notice to the other Party of the event and the obligations as to which performance is prevented or delayed. If a Force Majeure situation continues
for more than [***], the unaffected Party may terminate any affected Work Order upon notice to the affected Party, without penalty or liability (including without limitation penalties described in Section&nbsp;12). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment; Novation</B>. This Agreement may not be assigned by a Party without the prior written consent of
the other Party; provided, however, that (i)&nbsp;a Party may assign this Agreement to any of its Affiliates with net worth or insurance commensurate with such Party&#8217;s obligations and sufficient capacity and personnel, without such consent,
but with notice to the other Party; and (ii)&nbsp;Client may, without Provider&#8217;s consent, assign this Agreement (a)&nbsp;to a third party in connection with the transfer or sale of all or substantially all of its assets or the line of business
or Product to which this Agreement relates; (b)&nbsp;to a successor entity or acquirer in the event of a merger, consolidation or change of control. Any purported assignment in violation of this Section is void. This Agreement binds the
Parties&#8217; successors and assigns. Notwithstanding anything to the contrary in this Agreement, upon written notice from Client that Client has executed an exclusive license as to all or substantially all of the Client&#8217;s assets or Product
to which one or more Work Orders relates, Provider shall, and hereby does (and Client, by providing such notice, also shall, and hereby does): (i) novate this Agreement and the applicable Work Orders to the Client&#8217;s exclusive licensee, on a
form of novation agreement provided by Client and reasonably accepted by Provider (which acceptance shall not be unreasonably withheld, conditioned, or delayed) at the time of such novation; and (ii)&nbsp;enter into a new agreement that is an exact
copy of this Agreement and includes only those Work Orders that are not subject to the novation in clause (i). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices</B>. All notices, requests, demands and other formal or legal communications required under this
Agreement must be in writing and will be deemed to have been given or made and sufficient in all respects when delivered by reputable international courier to the following addresses: </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>To Client: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">KORSA
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">221 Crescent Street, Suite 105, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Waltham, MA 02453 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Attn:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>To Provider: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">WuXi Biologics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">800 Qifan Road,
No.4 3F </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">Pudong District, Shanghai, China 200137 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Attn:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent Contractor</B>. The Parties are independent contractors, and nothing contained in this Agreement
may be deemed or construed to create a partnership, joint venture, employment, franchise, agency, fiduciary or other relationship between the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></B>. During the term of this Agreement and for
[***] thereafter, Client shall not directly or indirectly induce or solicit (or authorize or assist in the taking of any such actions by any third party) any employee or consultant of Provider or any of its Affiliates that have provided Services
under this Agreement to leave his or her employment or business association. Hiring advertisements and efforts not directed at a particular individual do not constitute a solicitation in violation of this Section&nbsp;14.5. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing Law</B>. The laws of the State of New York, USA, without regard to any choice of law principle
that would require the application of the law of another jurisdiction, govern all matters relating to this Agreement and the enforcement thereof. The parties expressly reject any application to this Agreement of (a)&nbsp;the United Nations
Convention on Contracts for the International Sale of Goods; and (b)&nbsp;the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April&nbsp;11, 1980.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Arbitration</B>. The Parties shall engage in [***] consultation to resolve any dispute arising out of or in
connection with this Agreement. Such consultation will begin [***] after one Party has delivered to the other Party a request for consultation. If the dispute cannot be resolved within [***] following the date on which the request for consultation
is delivered, then either Party may submit the dispute to the JAMS International Arbitration Rules (&#8220;<B>Arbitration</B>&#8221;). The Arbitration tribunal will consist of three arbitrators. Within [***] after the commencement of the
Arbitration, each Party shall select one person to act as arbitrator, each of whom must be a practicing or retired attorney or judge having at least [***] of litigation experience within the biopharmaceutical industry. The two arbitrators so
selected shall select the chair within [***] of the commencement of the Arbitration, whom must a practicing or retired attorney or judge having at least [***] of litigation experience within the biopharmaceutical industry. If the arbitrators
selected by the Parties are unable or fail to agree upon the third arbitrator within the allotted time, the third arbitrator shall be appointed by JAMS in accordance with the JAMS International Arbitration Rules. All arbitrators shall serve as
neutral, independent and impartial arbitrators. The Arbitration shall be conducted in accordance with the expedited procedures set forth in the JAMS International Arbitration Rules. The place of arbitration will be New York City. The official
language of the arbitration will be English. The arbitration proceedings </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
will be confidential, and the arbitrator may issue appropriate protective orders to safeguard each Party&#8217;s Confidential Information. During the course of arbitration, the Parties shall
continue to implement the terms of this Agreement including all Work Orders then in effect. The arbitral award will be final and binding upon the Parties, and the Party to the award may apply to a court of competent jurisdiction for enforcement of
the award. Notwithstanding the foregoing, each Party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the arbitrator. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement; <FONT STYLE="white-space:nowrap">Non-Reliance</FONT></B>. This Agreement, together with
each Work Order, contains the entire agreement between the Parties with respect to the subject matter of this Agreement. Prior agreements are hereby superseded. For the avoidance of doubt, prior confidentiality obligations are superseded to the
extent that they cover Confidential Information. Each Party disclaims that it is relying on any representations or warranties other than those set forth in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment</B>. No modification or waiver of any term of this Agreement or any other form of amendment to
this Agreement will be binding unless made expressly in writing and signed by both Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Third Party Beneficiaries</B>. The provisions of this Agreement are for the sole benefit of the Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver</B>. The waiver by either Party of any breach of any term of this Agreement will not constitute a
waiver of any other breach of the same or any other term. Failure or delay on the part of either Party to fully exercise any right under this Agreement will not constitute a waiver or otherwise affect in any way the same or any other right.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability</B>. If any provision in this Agreement is held to be invalid, illegal or unenforceable in any
respect, then (a)&nbsp;the provision will be replaced by a valid and enforceable provision that achieves as far as possible the intention of the Parties and (b)&nbsp;all other provisions of this Agreement will remain in full force and effect as if
the original agreement had been executed without the invalidated, illegal or unenforceable provision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent Counsel</B>. Each Party has had the opportunity to consult independent counsel, and as such,
this Agreement will not be construed to have been drafted by one Party or the other but will be construed as having been jointly drafted when interpreting its provisions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">14.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts</B>. This Agreement may be executed in one or more counterparts, each of which will be deemed
an original, but all of which together constitute one and the same instrument. Executed counterparts may be exchanged by facsimile or <FONT STYLE="white-space:nowrap">e-mail</FONT> in PDF or similar electronic format. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, this Agreement was executed on the date stated in the introductory clause. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WuXi Biologics (Hong Kong) Limited</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>KORSA Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Chen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Evan Thompson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chris Chen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Evan Thompson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A &#8211; Form of Work Order </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WORK ORDER (NUMBER [</B>&#9679;<B></B><B>]) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This work order is dated [&#9679;] and is between KORSA Biosciences, Inc. (&#8220;<B>Client</B>&#8221;) and [WuXi Biologics (Hong Kong) Limited]
(&#8220;<B>Provider</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Biologics Master Services Agreement between KORSA Biosciences, Inc. and WuXi Biologics (Hong Kong)
Limited, dated [&#9679;] (the &#8220;Master Services Agreement&#8221;), are hereby incorporated by reference into this Work Order. Any modifications to the Master Services Agreement will be deemed to be references to this Work Order automatically.
Each capitalized term used but not defined in this Work Order has the meaning given in the Master Services Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Title</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>[Project title] </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>[Description of the Services including deliverables and specifications] </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tasks and Timeframe</B>. Provider shall complete the Services in accordance with the following schedule:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Task</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Completion Date</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Client Materials </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>[Description of the Client Materials to be provided by Client to Provider that are necessary to perform the Services] </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reporting and Transfer of Data and Results </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>[Description of how data and results should be reported and transferred to Client, including electronic protocols for secure transmission of
data and instructions for physical handling and shipping of materials if chemicals are being synthesized or other materials are to be transferred to Client] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Additional Requirements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>[Any additional requirements such as additional obligations of the parties that do not appropriately fit into the task list and special
handling of materials] </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES; PAYMENT SCHEDULE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Terms</B>. Expenses, milestones, payment and default and other general terms are provided in
Section&nbsp;3 of the Master Services Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Contract Price and Upfront Payment</B>. The Contract Price will be USD [&#9679;]. On signing of this Work
Order, Client shall pay Provider [&#9679;] % of the Contract Price as a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestones</B>. The table below lists milestones and related information. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Deliverable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Payment</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>[Description including work required, criteria for achievement and timeline]</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment Instructions</B>. Unless an invoice provides otherwise, Client shall pay the invoice in USD by wire
transfer to the account listed below (as may be amended from time to time): </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Beneficiary Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Beneficiary Address</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Beneficiary Bank Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="10"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Bank Address</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="9">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Branch Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">[***]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Bank Account Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Bank Code</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&#8195;&#8195;Branch Code</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>SWIFT Address</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMUNICATIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Technical Communications</B>. All technical communications required under this Work Order are to be sent via
reputable international courier or email and addressed as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If to Client: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: [&#9679;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.: [&#9679;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [&#9679;]
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If to Provider: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#9679;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: [&#9679;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.: [&#9679;] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [&#9679;]
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, this Work Order is executed on the date stated in the introductory clause. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KORSA Biosciences, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>WuXi Biologics (Hong Kong) Limited</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&#8195;&#8195;&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B &#8211; Manufacturing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C: Affiliates of Provider </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>d111069dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#8220;Experts&#8221; and to the use of our report dated March&nbsp;30, 2026, included in the Proxy
Statement of Cyclerion Therapeutics, Inc. that is made a part of Amendment No. 1 to the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-4</FONT> No.&nbsp;333-295175) and Prospectus of Cyclerion Therapeutics, Inc. for the registration
of shares of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 9, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>9
<FILENAME>d111069dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#8220;Experts&#8221; and to the use of our report dated April&nbsp;17, 2026 with respect to the
consolidated financial statements of Korsana Biosciences, Inc. included in the Proxy Statement of Cyclerion Therapeutics, Inc. that is made a part of Amendment No.&nbsp;1 to the Registration Statement
<FONT STYLE="white-space:nowrap">(Form&nbsp;S-4</FONT> No.&nbsp;333-295175) and Prospectus of Cyclerion Therapeutics, Inc. for the registration of shares of its common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, Pennsylvania </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 9, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>10
<FILENAME>d111069dex996.htm
<DESCRIPTION>EX-99.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF GEMINI VALUATION SERVICES, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the use of our opinion letter, dated March&nbsp;31, 2026, to the Board of Directors of Cyclerion Therapeutics, Inc., included as Annex B to the proxy statement / prospectus which forms a part of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> of Cyclerion Therapeutics, Inc., to be filed on the date hereof, and to the references to such opinion in such proxy statement / prospectus under the captions: &#8220;Prospectus Summary - Opinion of Gemini to
the Cyclerion Board,&#8221; &#8220;The Merger - Background of the Merger&#8221; and &#8220;The Merger - Opinion of Gemini, Cyclerion&#8217;s Financial Advisor, to the Cyclerion Board of Directors.&#8220; In giving such consent, we do not admit that
we come within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder, nor do we thereby admit that we are
experts with respect to any part of such Registration Statement within the meaning of the term &#8220;expert&#8221; as used in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GEMINI VALUATION SERVICES, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nathan Johnson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Authorized Signatory</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Los Angeles, CA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">June&nbsp;9, 2026</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>ck0001755237-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-June-2026 [05:34:42] {PM}-->
<schema targetNamespace="http://www.cyclerion.com/20260331" elementFormDefault="qualified" xmlns:ck0001755237="http://www.cyclerion.com/20260331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.cyclerion.com/role/CoverPage" id="CoverPage">
        <link:definition>1001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" id="CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/NatureOfBusiness" id="NatureOfBusiness">
        <link:definition>1007 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>1008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>1009 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/OtherInvestment" id="OtherInvestment">
        <link:definition>1010 - Disclosure - Other Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>1011 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>1012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlans" id="ShareBasedCompensationPlans">
        <link:definition>1013 - Disclosure - Share-based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/LossPerShare" id="LossPerShare">
        <link:definition>1014 - Disclosure - Loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>1015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/DefinedContributionPlan" id="DefinedContributionPlan">
        <link:definition>1016 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/LicenseAndOptionAgreement" id="LicenseAndOptionAgreement">
        <link:definition>1017 - Disclosure - License and Option Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>1018 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>1019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <link:definition>1020 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>1021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansTables" id="ShareBasedCompensationPlansTables">
        <link:definition>1022 - Disclosure - Share-based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/LossPerShareTables" id="LossPerShareTables">
        <link:definition>1023 - Disclosure - Loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>1024 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/NatureOfBusinessDetails" id="NatureOfBusinessDetails">
        <link:definition>1025 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" id="SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails">
        <link:definition>1026 - Disclosure - Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" id="SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>1027 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails" id="FairValueOfFinancialInstrumentsDetails">
        <link:definition>1028 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails" id="OtherInvestmentAdditionalInformationDetails">
        <link:definition>1029 - Disclosure - Other Investment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>1030 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>1031 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails" id="ShareBasedCompensationPlansDetails">
        <link:definition>1032 - Disclosure - Share-based Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails" id="ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails">
        <link:definition>1033 - Disclosure - Share-based Compensation Plans - Schedule of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails" id="ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails">
        <link:definition>1034 - Disclosure - Share-based Compensation Plans - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails" id="ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails">
        <link:definition>1035 - Disclosure - Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails" id="ShareBasedCompensationPlansSummaryOfRsaActivityDetails">
        <link:definition>1036 - Disclosure - Share-based Compensation Plans - Summary of RSA activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" id="LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails">
        <link:definition>1037 - Disclosure - Loss per share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails" id="LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails">
        <link:definition>1038 - Disclosure - Loss per share - Schedule Of Earnings Per Share Diluted By Common Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" id="IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails">
        <link:definition>1039 - Disclosure - Income Taxes - Schedule of Components of Net Income Loss Before Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
        <link:definition>1040 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" id="IncomeTaxesReconciliationOfIncomeTaxesDetails">
        <link:definition>1041 - Disclosure - Income Taxes - Reconciliation of income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" id="IncomeTaxesDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>1042 - Disclosure - Income Taxes - Deferred tax assets (liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/DefinedContributionPlanDetails" id="DefinedContributionPlanDetails">
        <link:definition>1043 - Disclosure - Defined Contribution Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails" id="LicenseAndOptionAgreementAdditionalInformationDetails">
        <link:definition>1044 - Disclosure - License and Option Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
        <link:definition>1045 - Disclosure - Subsequent Events (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk" >
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CoverPage" roleURI="http://www.cyclerion.com/role/CoverPage"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#NatureOfBusiness" roleURI="http://www.cyclerion.com/role/NatureOfBusiness"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPolicies"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#FairValueOfFinancialInstruments" roleURI="http://www.cyclerion.com/role/FairValueOfFinancialInstruments"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#OtherInvestment" roleURI="http://www.cyclerion.com/role/OtherInvestment"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilities"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CommitmentsAndContingencies" roleURI="http://www.cyclerion.com/role/CommitmentsAndContingencies"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#ShareBasedCompensationPlans" roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlans"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#LossPerShare" roleURI="http://www.cyclerion.com/role/LossPerShare"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#IncomeTaxes" roleURI="http://www.cyclerion.com/role/IncomeTaxes"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#DefinedContributionPlan" roleURI="http://www.cyclerion.com/role/DefinedContributionPlan"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#LicenseAndOptionAgreement" roleURI="http://www.cyclerion.com/role/LicenseAndOptionAgreement"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#SubsequentEvents" roleURI="http://www.cyclerion.com/role/SubsequentEvents"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#FairValueOfFinancialInstrumentsTables" roleURI="http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsTables"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#ShareBasedCompensationPlansTables" roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansTables"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#LossPerShareTables" roleURI="http://www.cyclerion.com/role/LossPerShareTables"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#IncomeTaxesTables" roleURI="http://www.cyclerion.com/role/IncomeTaxesTables"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#NatureOfBusinessDetails" roleURI="http://www.cyclerion.com/role/NatureOfBusinessDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#FairValueOfFinancialInstrumentsDetails" roleURI="http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#OtherInvestmentAdditionalInformationDetails" roleURI="http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#ShareBasedCompensationPlansDetails" roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails" roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails" roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails" roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#ShareBasedCompensationPlansSummaryOfRsaActivityDetails" roleURI="http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" roleURI="http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails" roleURI="http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" roleURI="http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#IncomeTaxesReconciliationOfIncomeTaxesDetails" roleURI="http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" roleURI="http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#DefinedContributionPlanDetails" roleURI="http://www.cyclerion.com/role/DefinedContributionPlanDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#LicenseAndOptionAgreementAdditionalInformationDetails" roleURI="http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="ck0001755237-20260331.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"  />
        <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"  />
        <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"  />
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CoverPage" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_937" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_937" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_938" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_937" xlink:to="loc_dei_DocumentInformationDocumentAxis_938" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_939" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_938" xlink:to="loc_dei_DocumentDomain_939" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_942" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_937" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_942" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_943" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_942" xlink:to="loc_dei_AddressTypeDomain_943" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_944" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_943" xlink:to="loc_dei_BusinessContactMember_944" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_940" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_937" xlink:to="loc_dei_DocumentInformationLineItems_940" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_102" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityRegistrantName_102" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_103" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_DocumentType_103" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_107" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityFilerCategory_107" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_108" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntitySmallBusiness_108" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_111" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityEmergingGrowthCompany_111" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_116" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityCentralIndexKey_116" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_120" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_AmendmentFlag_120" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_123" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityTaxIdentificationNumber_123" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_125" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityIncorporationStateCountryCode_125" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_126" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressAddressLine1_126" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_128" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressCityOrTown_128" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_129" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressStateOrProvince_129" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_130" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressPostalZipCode_130" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_131" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_CityAreaCode_131" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_132" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_LocalPhoneNumber_132" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_941" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityPrimarySicNumber_941" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_945" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_ContactPersonnelName_945" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_143" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_148" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_143" xlink:to="loc_us-gaap_AssetsAbstract_148" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_149" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_AssetsCurrentAbstract_149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_146" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_146" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_152" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_158" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_163" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_OtherAssetsCurrent_163" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_167" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_149" xlink:to="loc_us-gaap_AssetsCurrent_167" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_946" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_946" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments_160" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_OtherLongTermInvestments_160" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_168" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_148" xlink:to="loc_us-gaap_Assets_168" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_154" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_143" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_154" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_145" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_154" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_145" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_147" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_145" xlink:to="loc_us-gaap_AccountsPayableCurrent_147" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_ck0001755237_AccruedResearchAndDevelopmentCurrent_153" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_145" xlink:to="loc_ck0001755237_AccruedResearchAndDevelopmentCurrent_153" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent_159" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_145" xlink:to="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent_159" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_164" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_145" xlink:to="loc_us-gaap_LiabilitiesCurrent_164" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_151" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_154" xlink:to="loc_us-gaap_CommitmentsAndContingencies_151" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_157" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_154" xlink:to="loc_us-gaap_StockholdersEquityAbstract_157" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_144" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_157" xlink:to="loc_us-gaap_PreferredStockValue_144" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_150" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_157" xlink:to="loc_us-gaap_CommonStockValue_150" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_156" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_157" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_156" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_161" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_157" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_161" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_169" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_157" xlink:to="loc_us-gaap_StockholdersEquity_169" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_162" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_154" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_162" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_171" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_174" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_171" xlink:to="loc_us-gaap_StatementTable_174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_172" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_172" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SeriesaConvertiblePreferredStockMember" xlink:label="loc_ck0001755237_SeriesaConvertiblePreferredStockMember_175" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_ck0001755237_SeriesaConvertiblePreferredStockMember_175" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementLineItems_176" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_173" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_173" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_177" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_177" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_178" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockSharesIssued_178" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_180" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_180" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_182" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_182" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_183" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockSharesIssued_183" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_184" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_184" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_186" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_196" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_186" xlink:to="loc_us-gaap_StatementTable_196" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_190" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_srt_ProductOrServiceAxis_190" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_189" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_190" xlink:to="loc_srt_ProductsAndServicesDomain_189" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementMember" xlink:label="loc_ck0001755237_LicenseAgreementMember_192" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_189" xlink:to="loc_ck0001755237_LicenseAgreementMember_192" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PurchaseAgreementMember" xlink:label="loc_ck0001755237_PurchaseAgreementMember_202" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_189" xlink:to="loc_ck0001755237_PurchaseAgreementMember_202" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionAgreementMember" xlink:label="loc_ck0001755237_OptionAgreementMember_209" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_189" xlink:to="loc_ck0001755237_OptionAgreementMember_209" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_201" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_us-gaap_StatementLineItems_201" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_191" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_201" xlink:to="loc_us-gaap_RevenuesAbstract_191" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_198" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_191" xlink:to="loc_us-gaap_Revenues_198" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_207" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_191" xlink:to="loc_us-gaap_OperatingExpensesAbstract_207" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_188" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_188" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_200" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_200" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_208" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_OperatingExpenses_208" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_211" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_OperatingIncomeLoss_211" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_197" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_OtherNonoperatingIncome_197" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_GainLossFromSettlementOfAccountPayable" xlink:label="loc_ck0001755237_GainLossFromSettlementOfAccountPayable_206" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_ck0001755237_GainLossFromSettlementOfAccountPayable_206" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_213" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_213" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_210" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_210" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_214" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_NetIncomeLoss_214" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_215" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_EarningsPerShareAbstract_215" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_193" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_215" xlink:to="loc_us-gaap_EarningsPerShareBasic_193" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_203" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_215" xlink:to="loc_us-gaap_EarningsPerShareDiluted_203" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:label="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_187" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_187" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_199" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_199" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_195" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" xlink:to="loc_us-gaap_NetIncomeLoss_195" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_205" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_205" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_194" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_205" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_194" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_934" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_934" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_219" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_222" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_219" xlink:to="loc_us-gaap_StatementTable_222" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_220" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_222" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_220" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_223" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_220" xlink:to="loc_us-gaap_EquityComponentDomain_223" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_224" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_CommonStockMember_224" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_227" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_PreferredStockMember_227" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_229" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_229" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_231" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_RetainedEarningsMember_231" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_233" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_233" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_225" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_222" xlink:to="loc_us-gaap_StatementLineItems_225" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_221" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_221" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_226" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_226" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" xlink:label="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare_228" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare_228" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" xlink:label="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue_230" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue_230" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_232" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_232" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_234" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_234" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_235" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_NetIncomeLoss_235" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_236" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_236" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_239" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_239" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" xlink:label="loc_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment_240" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment_240" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_241" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_241" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_242" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_242" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_244" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_247" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_247" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_251" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_247" xlink:to="loc_us-gaap_ProfitLoss_251" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_257" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_247" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_GainLossFromSettlementOfAccountPayable" xlink:label="loc_ck0001755237_GainLossFromSettlementOfAccountPayable_245" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_257" xlink:to="loc_ck0001755237_GainLossFromSettlementOfAccountPayable_245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_252" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_257" xlink:to="loc_us-gaap_ShareBasedCompensation_252" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_249" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_249" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_255" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_261" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_261" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_267" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_267" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:label="loc_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment_272" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" xlink:to="loc_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment_272" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_275" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_263" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_275" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_269" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_247" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_269" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_253" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_253" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_254" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_253" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_254" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_266" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_253" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_266" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ProceedsFromAtTheOffer" xlink:label="loc_ck0001755237_ProceedsFromAtTheOffer_250" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259" xlink:to="loc_ck0001755237_ProceedsFromAtTheOffer_250" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_256" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_256" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_IssuanceCostsPaidForPrivatePlacement" xlink:label="loc_ck0001755237_IssuanceCostsPaidForPrivatePlacement_262" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259" xlink:to="loc_ck0001755237_IssuanceCostsPaidForPrivatePlacement_262" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_259" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_265" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_244" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_265" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_271" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_271" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_274" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_274" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_277" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_277" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/NatureOfBusiness" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_300" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_301" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_300" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPolicies" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_303" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_304" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_303" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_304" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/FairValueOfFinancialInstruments" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_309" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_310" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_309" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/OtherInvestment" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_315" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock_316" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_315" xlink:to="loc_us-gaap_InvestmentTextBlock_316" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilities" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_321" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_322" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_321" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_322" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CommitmentsAndContingencies" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_324" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_325" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_324" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlans" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_330" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_331" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_330" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_331" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LossPerShare" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_333" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_334" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_333" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_334" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxes" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_336" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_337" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_336" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_337" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/DefinedContributionPlan" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_339" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_340" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_339" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_340" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LicenseAndOptionAgreement" >
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementAbstract" xlink:label="loc_ck0001755237_LicenseAgreementAbstract_345" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementsTextBlock" xlink:label="loc_ck0001755237_LicenseAgreementsTextBlock_346" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001755237_LicenseAgreementAbstract_345" xlink:to="loc_ck0001755237_LicenseAgreementsTextBlock_346" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SubsequentEvents" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_356" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_357" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_356" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_357" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_359" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_360" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_361" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_361" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_362" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_362" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_363" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_363" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_364" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_UseOfEstimates_364" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_365" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_365" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_366" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_366" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_367" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_367" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" xlink:label="loc_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock_368" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock_368" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_369" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_369" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_370" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_370" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_371" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_371" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_372" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_372" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PatentCostsPolicyTextBlock" xlink:label="loc_ck0001755237_PatentCostsPolicyTextBlock_373" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_ck0001755237_PatentCostsPolicyTextBlock_373" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" xlink:label="loc_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock_374" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock_374" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_375" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_375" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_376" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_359" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_376" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_381" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_382" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_381" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_382" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_391" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_392" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_391" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_398" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_399" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_398" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_399" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_400" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_398" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_400" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_401" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_398" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_401" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_402" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_398" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_402" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LossPerShareTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_404" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_405" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_404" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_405" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_406" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_404" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_406" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesTables" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_408" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_409" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_408" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_409" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_410" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_408" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_410" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_411" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_408" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_411" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/NatureOfBusinessDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_416" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_418" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_416" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_418" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_432" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_432" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_417" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_432" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_417" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TisentoTherapeuticsHoldingsIncMember" xlink:label="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_421" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_417" xlink:to="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_421" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_437" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_srt_ConsolidatedEntitiesAxis_437" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_425" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_437" xlink:to="loc_srt_ConsolidatedEntitiesDomain_425" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_KorsanaBiosciencesIncMember" xlink:label="loc_ck0001755237_KorsanaBiosciencesIncMember_949" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_425" xlink:to="loc_ck0001755237_KorsanaBiosciencesIncMember_949" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CyclerionTherapeuticsIncMember" xlink:label="loc_ck0001755237_CyclerionTherapeuticsIncMember_955" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_425" xlink:to="loc_ck0001755237_CyclerionTherapeuticsIncMember_955" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_442" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_442" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_442" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" xlink:label="loc_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember_443" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424" xlink:to="loc_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember_443" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_445" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_445" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_426" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_445" xlink:to="loc_us-gaap_EquityComponentDomain_426" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_427" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_426" xlink:to="loc_us-gaap_CommonStockMember_427" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_447" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_StatementClassOfStockAxis_447" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_438" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_447" xlink:to="loc_us-gaap_ClassOfStockDomain_438" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_431" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_438" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_431" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SeriesSeedPreferredStockMember" xlink:label="loc_ck0001755237_SeriesSeedPreferredStockMember_956" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_438" xlink:to="loc_ck0001755237_SeriesSeedPreferredStockMember_956" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_950" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_950" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_951" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_950" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_951" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_952" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_951" xlink:to="loc_us-gaap_SubsequentEventMember_952" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_449" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_srt_RangeAxis_449" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_440" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_449" xlink:to="loc_srt_RangeMember_440" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_450" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_440" xlink:to="loc_srt_MaximumMember_450" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_452" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_452" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_422" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_452" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_422" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SalesAgreementMember" xlink:label="loc_ck0001755237_SalesAgreementMember_430" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_422" xlink:to="loc_ck0001755237_SalesAgreementMember_430" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_455" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_TypeOfArrangementAxis_455" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_455" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CyclerionLicenseAgreementMember" xlink:label="loc_ck0001755237_CyclerionLicenseAgreementMember_420" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" xlink:to="loc_ck0001755237_CyclerionLicenseAgreementMember_420" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaLicenseAgreementMember" xlink:label="loc_ck0001755237_AkebiaLicenseAgreementMember_433" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" xlink:to="loc_ck0001755237_AkebiaLicenseAgreementMember_433" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_457" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_ClassOfStockLineItems_457" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PaymentOfCashMilestone" xlink:label="loc_ck0001755237_PaymentOfCashMilestone_429" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_PaymentOfCashMilestone_429" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_UpFrontPaymentReceived" xlink:label="loc_ck0001755237_UpFrontPaymentReceived_436" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_UpFrontPaymentReceived_436" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_RemainingAdditionalUpFrontPayment" xlink:label="loc_ck0001755237_RemainingAdditionalUpFrontPayment_963" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_RemainingAdditionalUpFrontPayment_963" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionFee" xlink:label="loc_ck0001755237_OptionFee_444" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_OptionFee_444" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SubsequentFees" xlink:label="loc_ck0001755237_SubsequentFees_446" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_SubsequentFees_446" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DevelopmentMilestonePayment" xlink:label="loc_ck0001755237_DevelopmentMilestonePayment_448" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_DevelopmentMilestonePayment_448" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_451" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_451" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_454" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_OperatingExpenses_454" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_456" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_456" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_458" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_458" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_459" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_SharesIssued_459" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_460" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PreferredStockSharesIssued_460" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_461" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_461" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_462" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_462" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_466" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_466" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_463" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_463" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" xlink:label="loc_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice_464" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice_464" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" xlink:label="loc_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock_465" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock_465" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_467" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_467" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TransactionCostsSaleOfTransferredAssets" xlink:label="loc_ck0001755237_TransactionCostsSaleOfTransferredAssets_468" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_TransactionCostsSaleOfTransferredAssets_468" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_953" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_953" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" xlink:label="loc_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares_954" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares_954" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_NetCashOnCapitalization" xlink:label="loc_ck0001755237_NetCashOnCapitalization_957" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_NetCashOnCapitalization_957" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_958" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_958" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_959" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_959" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_470" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_470" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_471" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475" xlink:to="loc_us-gaap_PatentsMember_471" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_479" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_479" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_473" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_479" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_473" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_InterestAndOtherIncomeMember" xlink:label="loc_ck0001755237_InterestAndOtherIncomeMember_476" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_473" xlink:to="loc_ck0001755237_InterestAndOtherIncomeMember_476" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_472" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" xlink:to="loc_us-gaap_ProfessionalFees_472" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_478" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" xlink:to="loc_us-gaap_InterestAndOtherIncome_478" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_482" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_483" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_482" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_512" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_512" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_518" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_518" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_518" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_514" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521" xlink:to="loc_us-gaap_MoneyMarketFundsMember_514" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_524" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_524" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_520" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_524" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_520" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_519" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_520" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_519" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_526" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_526" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_526" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_516" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_516" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_527" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_527" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_522" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_527" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_522" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_578" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_578" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_584" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xlink:to="loc_srt_RangeAxis_584" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_592" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_584" xlink:to="loc_srt_RangeMember_592" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_598" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_592" xlink:to="loc_srt_MinimumMember_598" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_599" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_592" xlink:to="loc_srt_MaximumMember_599" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_588" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xlink:to="loc_us-gaap_ValuationTechniqueAxis_588" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_581" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_588" xlink:to="loc_us-gaap_ValuationTechniqueDomain_581" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_WeightedAverageInvestmentMember" xlink:label="loc_ck0001755237_WeightedAverageInvestmentMember_583" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_581" xlink:to="loc_ck0001755237_WeightedAverageInvestmentMember_583" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TerminalDeclineRateMember" xlink:label="loc_ck0001755237_TerminalDeclineRateMember_587" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_581" xlink:to="loc_ck0001755237_TerminalDeclineRateMember_587" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TreasuryRateMember" xlink:label="loc_ck0001755237_TreasuryRateMember_590" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_581" xlink:to="loc_ck0001755237_TreasuryRateMember_590" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_591" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_591" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_580" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_591" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_580" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TisentoTherapeuticsHoldingsIncMember" xlink:label="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_582" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_580" xlink:to="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_582" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xlink:to="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_579" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_579" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_586" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_OperatingExpenses_586" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_589" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_589" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" xlink:label="loc_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1_593" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1_593" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_596" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_596" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaap_InvestmentOwnedPercentOfNetAssets_597" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_InvestmentOwnedPercentOfNetAssets_597" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_626" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_627" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_626" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_627" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_628" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_626" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_628" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_629" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_626" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_629" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent_630" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_626" xlink:to="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent_630" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_632" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_633" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_632" xlink:to="loc_us-gaap_SeveranceCosts1_633" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_634" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_632" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_634" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_635" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_632" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_635" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_672" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_672" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_674" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_AwardTypeAxis_674" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_674" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_694" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" xlink:to="loc_us-gaap_RestrictedStockMember_694" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_703" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" xlink:to="loc_us-gaap_PerformanceSharesMember_703" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_706" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" xlink:to="loc_us-gaap_EmployeeStockOptionMember_706" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_683" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_683" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_678" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_683" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_678" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_688" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_VestingAxis_688" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_676" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_688" xlink:to="loc_us-gaap_VestingDomain_676" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_692" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_srt_TitleOfIndividualAxis_692" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_692" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_680" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675" xlink:to="loc_srt_DirectorMember_680" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_695" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_srt_RangeAxis_695" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_689" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_695" xlink:to="loc_srt_RangeMember_689" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_693" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_693" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ShareBasedCompensationExpense" xlink:label="loc_ck0001755237_ShareBasedCompensationExpense_709" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_ck0001755237_ShareBasedCompensationExpense_709" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_710" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_710" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_711" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_711" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_714" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_714" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_715" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_715" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_716" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_716" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_718" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_718" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_723" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_725" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_723" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_725" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_724" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_725" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_724" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_726" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_724" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_726" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_728" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_726" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_728" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_730" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_726" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_730" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_729" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_729" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_727" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_729" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_727" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_732" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_732" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_734" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737" xlink:to="loc_us-gaap_AwardTypeAxis_734" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_749" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745" xlink:to="loc_us-gaap_EmployeeStockOptionMember_749" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_735" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_735" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_741" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_741" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_746" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_746" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_750" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_750" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_753" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_753" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_755" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_755" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_733" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_733" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_739" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_739" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_744" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_744" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_933" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_933" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_752" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_752" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_736" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_736" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_742" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_742" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_751" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_751" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_754" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_754" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_757" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_758" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_757" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_758" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_759" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_757" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_759" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_760" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_757" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_760" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_761" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_757" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_761" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_763" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_763" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_765" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_AwardTypeAxis_765" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_777" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774" xlink:to="loc_us-gaap_RestrictedStockMember_777" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_764" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_764" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_769" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_769" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_773" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_773" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_776" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_776" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_779" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_779" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_766" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_766" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_771" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_771" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_775" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_775" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_778" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_778" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_780" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_780" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_782" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_785" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_782" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_783" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_785" xlink:to="loc_us-gaap_NetIncomeLoss_783" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" xlink:label="loc_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract_788" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_782" xlink:to="loc_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract_788" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_784" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract_788" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_784" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_787" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract_788" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_787" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_790" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_782" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_790" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_786" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_790" xlink:to="loc_us-gaap_EarningsPerShareBasic_786" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_789" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_790" xlink:to="loc_us-gaap_EarningsPerShareDiluted_789" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_792" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_792" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_796" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_796" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_796" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_795" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" xlink:to="loc_us-gaap_EmployeeStockOptionMember_795" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_800" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" xlink:to="loc_us-gaap_RestrictedStockMember_800" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_801" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_801" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_797" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_801" xlink:to="loc_us-gaap_EquityComponentDomain_797" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_798" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_797" xlink:to="loc_us-gaap_PreferredStockMember_798" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_803" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_803" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_799" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_803" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_799" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:label="loc_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits_802" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_803" xlink:to="loc_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits_802" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_935" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_806" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_935" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_806" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_807" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_935" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_807" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_808" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_935" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_808" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_810" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_815" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_810" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_815" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_811" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_815" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_811" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_812" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_811" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_812" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_817" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812" xlink:to="loc_us-gaap_DomesticCountryMember_817" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_820" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_820" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativesByContractTypeAxis" xlink:label="loc_us-gaap_CreditDerivativesByContractTypeAxis_818" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_815" xlink:to="loc_us-gaap_CreditDerivativesByContractTypeAxis_818" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativesContractTypeDomain" xlink:label="loc_us-gaap_CreditDerivativesContractTypeDomain_816" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditDerivativesByContractTypeAxis_818" xlink:to="loc_us-gaap_CreditDerivativesContractTypeDomain_816" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_815" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_814" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_814" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_819" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_OperatingLossCarryforwards_819" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_822" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_822" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInformationPertainingToIncomeTaxes" xlink:label="loc_us-gaap_OtherInformationPertainingToIncomeTaxes_823" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_OtherInformationPertainingToIncomeTaxes_823" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_825" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_825" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_826" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_826" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_828" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_831" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_828" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_831" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_829" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_831" xlink:to="loc_us-gaap_DebtInstrumentAxis_829" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_836" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_829" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_836" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_831" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_832" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_832" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_834" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_834" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_835" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_835" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_837" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_837" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_838" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_838" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_839" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_839" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_840" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_840" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_841" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_841" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_842" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_842" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_843" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_843" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_844" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_844" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_845" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_845" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_846" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_846" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_848" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_848" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_849" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_849" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_851" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_851" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_852" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_852" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_853" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_853" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_854" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_854" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_855" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_855" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_856" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_856" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_857" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_850" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_857" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/DefinedContributionPlanDetails" >
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="loc_ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_859" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_860" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_859" xlink:to="loc_us-gaap_DefinedContributionPlanTable_860" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_861" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_860" xlink:to="loc_srt_RangeAxis_861" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_866" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_861" xlink:to="loc_srt_RangeMember_866" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_868" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_866" xlink:to="loc_srt_MinimumMember_868" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_869" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_866" xlink:to="loc_srt_MaximumMember_869" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_860" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTypeExtensibleList" xlink:label="loc_us-gaap_DefinedContributionPlanTypeExtensibleList_862" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_us-gaap_DefinedContributionPlanTypeExtensibleList_862" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_864" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_864" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_865" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_865" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" xlink:label="loc_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum_867" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum_867" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementAbstract" xlink:label="loc_ck0001755237_LicenseAgreementAbstract_892" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001755237_LicenseAgreementAbstract_892" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_898" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" xlink:to="loc_us-gaap_TypeOfArrangementAxis_898" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_898" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PatentLicenseAgreementMember" xlink:label="loc_ck0001755237_PatentLicenseAgreementMember_894" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_PatentLicenseAgreementMember_894" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaResearchLicenseAgreementMember" xlink:label="loc_ck0001755237_AkebiaResearchLicenseAgreementMember_900" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_AkebiaResearchLicenseAgreementMember_900" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" xlink:label="loc_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember_903" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember_903" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaMaterialPurchaseAgreementMember" xlink:label="loc_ck0001755237_AkebiaMaterialPurchaseAgreementMember_906" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_AkebiaMaterialPurchaseAgreementMember_906" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_MedsteerCollaborationAgreementMember" xlink:label="loc_ck0001755237_MedsteerCollaborationAgreementMember_947" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_MedsteerCollaborationAgreementMember_947" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_902" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_902" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_899" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_902" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_899" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_895" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_899" xlink:to="loc_us-gaap_SubsequentEventMember_895" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_896" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_896" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionFee" xlink:label="loc_ck0001755237_OptionFee_901" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_OptionFee_901" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionAdditionalFee" xlink:label="loc_ck0001755237_OptionAdditionalFee_904" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_OptionAdditionalFee_904" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_907" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_907" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_UpFrontPaymentReceived" xlink:label="loc_ck0001755237_UpFrontPaymentReceived_908" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_UpFrontPaymentReceived_908" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AdditionalUpFrontPayment" xlink:label="loc_ck0001755237_AdditionalUpFrontPayment_909" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_AdditionalUpFrontPayment_909" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DevelopmentMilestonePayment" xlink:label="loc_ck0001755237_DevelopmentMilestonePayment_910" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_DevelopmentMilestonePayment_910" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CommercializationMilestonePayments" xlink:label="loc_ck0001755237_CommercializationMilestonePayments_911" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_CommercializationMilestonePayments_911" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_912" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_912" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_913" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_Revenues_913" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_948" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_CostsAndExpenses_948" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
        </link:presentationLink>
        <link:presentationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_920" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_926" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_920" xlink:to="loc_us-gaap_SubsequentEventTable_926" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_924" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_926" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_924" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_925" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_924" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_925" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_922" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_925" xlink:to="loc_us-gaap_SubsequentEventMember_922" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_928" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_926" xlink:to="loc_srt_StatementScenarioAxis_928" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_930" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_928" xlink:to="loc_srt_ScenarioUnspecifiedDomain_930" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_931" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_926" xlink:to="loc_us-gaap_SubsequentEventLineItems_931" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_921" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_us-gaap_CommonStockSharesIssued_921" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_927" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_927" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DebtInstrumentsOptionsExercisePeriod" xlink:label="loc_ck0001755237_DebtInstrumentsOptionsExercisePeriod_929" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_ck0001755237_DebtInstrumentsOptionsExercisePeriod_929" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_UpFrontPaymentReceived" xlink:label="loc_ck0001755237_UpFrontPaymentReceived_932" />
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_ck0001755237_UpFrontPaymentReceived_932" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        </link:presentationLink>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"  />
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"  />
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CoverPage" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_940" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_937" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_DocumentInformationTable_937" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis_938" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_937" xlink:to="loc_dei_DocumentInformationDocumentAxis_938" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_939" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_938" xlink:to="loc_dei_DocumentDomain_939" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain_939_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_938" xlink:to="loc_dei_DocumentDomain_939_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_942" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_937" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_942" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_943" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_942" xlink:to="loc_dei_AddressTypeDomain_943" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_943_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_942" xlink:to="loc_dei_AddressTypeDomain_943_default" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_944" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_943" xlink:to="loc_dei_BusinessContactMember_944" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_102" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityRegistrantName_102" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_103" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_DocumentType_103" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_107" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityFilerCategory_107" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_108" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntitySmallBusiness_108" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_111" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityEmergingGrowthCompany_111" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_116" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityCentralIndexKey_116" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_120" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_AmendmentFlag_120" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_123" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityTaxIdentificationNumber_123" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_125" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityIncorporationStateCountryCode_125" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_126" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressAddressLine1_126" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_128" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressCityOrTown_128" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_129" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressStateOrProvince_129" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_130" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityAddressPostalZipCode_130" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_131" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_CityAreaCode_131" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_132" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_LocalPhoneNumber_132" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_941" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_EntityPrimarySicNumber_941" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_945" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_940" xlink:to="loc_dei_ContactPersonnelName_945" use="optional" order="25" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_176" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_174" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_StatementTable_174" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_172" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_172" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_179_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SeriesaConvertiblePreferredStockMember" xlink:label="loc_ck0001755237_SeriesaConvertiblePreferredStockMember_175" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_179" xlink:to="loc_ck0001755237_SeriesaConvertiblePreferredStockMember_175" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_173" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_173" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_177" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_177" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_178" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockSharesIssued_178" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_180" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_180" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_181" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_182" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_182" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_183" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockSharesIssued_183" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_184" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_176" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_184" use="optional" order="13" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_201" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_191" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_201" xlink:to="loc_us-gaap_RevenuesAbstract_191" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_198" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_191" xlink:to="loc_us-gaap_Revenues_198" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_207" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_191" xlink:to="loc_us-gaap_OperatingExpensesAbstract_207" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_188" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_188" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_200" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_200" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_208" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_OperatingExpenses_208" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_211" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_OperatingIncomeLoss_211" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_197" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_OtherNonoperatingIncome_197" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_GainLossFromSettlementOfAccountPayable" xlink:label="loc_ck0001755237_GainLossFromSettlementOfAccountPayable_206" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_ck0001755237_GainLossFromSettlementOfAccountPayable_206" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_213" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_213" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_210" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_210" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_195" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" xlink:to="loc_us-gaap_NetIncomeLoss_195" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_215" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_EarningsPerShareAbstract_215" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_193" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_215" xlink:to="loc_us-gaap_EarningsPerShareBasic_193" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_203" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_215" xlink:to="loc_us-gaap_EarningsPerShareDiluted_203" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:label="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_187" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_187" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_199" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_216" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_199" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_205" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_205" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_194" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_205" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_194" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_934" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_217" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_934" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_196" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_201" xlink:to="loc_us-gaap_StatementTable_196" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_190" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_196" xlink:to="loc_srt_ProductOrServiceAxis_190" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_189" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_190" xlink:to="loc_srt_ProductsAndServicesDomain_189" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_189_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_190" xlink:to="loc_srt_ProductsAndServicesDomain_189_default" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementMember" xlink:label="loc_ck0001755237_LicenseAgreementMember_192" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_189" xlink:to="loc_ck0001755237_LicenseAgreementMember_192" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PurchaseAgreementMember" xlink:label="loc_ck0001755237_PurchaseAgreementMember_202" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_189" xlink:to="loc_ck0001755237_PurchaseAgreementMember_202" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionAgreementMember" xlink:label="loc_ck0001755237_OptionAgreementMember_209" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_189" xlink:to="loc_ck0001755237_OptionAgreementMember_209" use="optional" order="30" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_225" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_222" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StatementTable_222" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_220" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_222" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_220" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_223" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_220" xlink:to="loc_us-gaap_EquityComponentDomain_223" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_223_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_220" xlink:to="loc_us-gaap_EquityComponentDomain_223_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_224" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_CommonStockMember_224" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_227" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_PreferredStockMember_227" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_229" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_229" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_231" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_RetainedEarningsMember_231" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_233" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_223" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_233" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_221" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_221" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_226" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_226" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" xlink:label="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare_228" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare_228" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" xlink:label="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue_230" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue_230" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_232" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_232" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_234" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_234" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_235" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_NetIncomeLoss_235" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_236" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_236" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_237" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_239" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_239" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" xlink:label="loc_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment_240" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_225" xlink:to="loc_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment_240" use="optional" order="20" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/NatureOfBusinessDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_457" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_418" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_418" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_432" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_432" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_417" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_432" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_417" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_417_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_432" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_417_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TisentoTherapeuticsHoldingsIncMember" xlink:label="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_421" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_417" xlink:to="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_421" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_437" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_srt_ConsolidatedEntitiesAxis_437" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_425" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_437" xlink:to="loc_srt_ConsolidatedEntitiesDomain_425" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_425_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_437" xlink:to="loc_srt_ConsolidatedEntitiesDomain_425_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_KorsanaBiosciencesIncMember" xlink:label="loc_ck0001755237_KorsanaBiosciencesIncMember_949" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_425" xlink:to="loc_ck0001755237_KorsanaBiosciencesIncMember_949" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CyclerionTherapeuticsIncMember" xlink:label="loc_ck0001755237_CyclerionTherapeuticsIncMember_955" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_425" xlink:to="loc_ck0001755237_CyclerionTherapeuticsIncMember_955" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_442" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_442" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_442" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_442" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424_default" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" xlink:label="loc_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember_443" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_424" xlink:to="loc_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember_443" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_445" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_445" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_426" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_445" xlink:to="loc_us-gaap_EquityComponentDomain_426" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_426_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_445" xlink:to="loc_us-gaap_EquityComponentDomain_426_default" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_427" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_426" xlink:to="loc_us-gaap_CommonStockMember_427" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_447" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_StatementClassOfStockAxis_447" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_438" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_447" xlink:to="loc_us-gaap_ClassOfStockDomain_438" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_438_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_447" xlink:to="loc_us-gaap_ClassOfStockDomain_438_default" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_431" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_438" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_431" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SeriesSeedPreferredStockMember" xlink:label="loc_ck0001755237_SeriesSeedPreferredStockMember_956" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_438" xlink:to="loc_ck0001755237_SeriesSeedPreferredStockMember_956" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_950" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_950" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_951" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_950" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_951" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_951_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_950" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_951_default" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_952" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_951" xlink:to="loc_us-gaap_SubsequentEventMember_952" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_449" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_srt_RangeAxis_449" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_440" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_449" xlink:to="loc_srt_RangeMember_440" use="optional" order="29" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_440_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_449" xlink:to="loc_srt_RangeMember_440_default" use="optional" order="30" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_450" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_440" xlink:to="loc_srt_MaximumMember_450" use="optional" order="31" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_452" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_452" use="optional" order="32" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_422" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_452" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_422" use="optional" order="33" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_422_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_452" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_422_default" use="optional" order="34" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SalesAgreementMember" xlink:label="loc_ck0001755237_SalesAgreementMember_430" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_422" xlink:to="loc_ck0001755237_SalesAgreementMember_430" use="optional" order="35" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_455" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_418" xlink:to="loc_us-gaap_TypeOfArrangementAxis_455" use="optional" order="36" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_455" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" use="optional" order="37" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_455" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419_default" use="optional" order="38" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CyclerionLicenseAgreementMember" xlink:label="loc_ck0001755237_CyclerionLicenseAgreementMember_420" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" xlink:to="loc_ck0001755237_CyclerionLicenseAgreementMember_420" use="optional" order="39" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaLicenseAgreementMember" xlink:label="loc_ck0001755237_AkebiaLicenseAgreementMember_433" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419" xlink:to="loc_ck0001755237_AkebiaLicenseAgreementMember_433" use="optional" order="40" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PaymentOfCashMilestone" xlink:label="loc_ck0001755237_PaymentOfCashMilestone_429" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_PaymentOfCashMilestone_429" use="optional" order="41" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_UpFrontPaymentReceived" xlink:label="loc_ck0001755237_UpFrontPaymentReceived_436" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_UpFrontPaymentReceived_436" use="optional" order="42" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_RemainingAdditionalUpFrontPayment" xlink:label="loc_ck0001755237_RemainingAdditionalUpFrontPayment_963" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_RemainingAdditionalUpFrontPayment_963" use="optional" order="43" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionFee" xlink:label="loc_ck0001755237_OptionFee_444" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_OptionFee_444" use="optional" order="44" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SubsequentFees" xlink:label="loc_ck0001755237_SubsequentFees_446" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_SubsequentFees_446" use="optional" order="45" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DevelopmentMilestonePayment" xlink:label="loc_ck0001755237_DevelopmentMilestonePayment_448" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_DevelopmentMilestonePayment_448" use="optional" order="46" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_451" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_451" use="optional" order="47" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_454" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_OperatingExpenses_454" use="optional" order="48" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_456" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_456" use="optional" order="49" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_458" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_458" use="optional" order="50" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_459" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_SharesIssued_459" use="optional" order="51" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_460" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PreferredStockSharesIssued_460" use="optional" order="52" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_461" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_461" use="optional" order="53" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_462" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_462" use="optional" order="54" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_466" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_466" use="optional" order="55" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_463" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_463" use="optional" order="56" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" xlink:label="loc_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice_464" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice_464" use="optional" order="57" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" xlink:label="loc_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock_465" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock_465" use="optional" order="58" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_467" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_467" use="optional" order="59" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TransactionCostsSaleOfTransferredAssets" xlink:label="loc_ck0001755237_TransactionCostsSaleOfTransferredAssets_468" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_TransactionCostsSaleOfTransferredAssets_468" use="optional" order="60" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_953" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_953" use="optional" order="61" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" xlink:label="loc_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares_954" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares_954" use="optional" order="62" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_NetCashOnCapitalization" xlink:label="loc_ck0001755237_NetCashOnCapitalization_957" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_ck0001755237_NetCashOnCapitalization_957" use="optional" order="63" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_958" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_958" use="optional" order="64" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_959" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_457" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_959" use="optional" order="65" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_474" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_471" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_475" xlink:to="loc_us-gaap_PatentsMember_471" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_479" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_477" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_479" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_473" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_479" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_473" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_473_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_479" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_473_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_InterestAndOtherIncomeMember" xlink:label="loc_ck0001755237_InterestAndOtherIncomeMember_476" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_473" xlink:to="loc_ck0001755237_InterestAndOtherIncomeMember_476" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_472" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" xlink:to="loc_us-gaap_ProfessionalFees_472" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_478" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_480" xlink:to="loc_us-gaap_InterestAndOtherIncome_478" use="optional" order="11" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_527" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_527" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_518" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_518" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_518" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_518" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_514" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_521" xlink:to="loc_us-gaap_MoneyMarketFundsMember_514" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_524" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_524" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_520" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_524" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_520" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_520_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_524" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_520_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_519" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_520" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_519" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_526" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_517" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_526" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_526" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_526" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513_default" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_516" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_513" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_516" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_522" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_527" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_522" use="optional" order="14" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_584" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xlink:to="loc_srt_RangeAxis_584" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_592" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_584" xlink:to="loc_srt_RangeMember_592" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_592_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_584" xlink:to="loc_srt_RangeMember_592_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_598" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_592" xlink:to="loc_srt_MinimumMember_598" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_599" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_592" xlink:to="loc_srt_MaximumMember_599" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_588" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xlink:to="loc_us-gaap_ValuationTechniqueAxis_588" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_581" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_588" xlink:to="loc_us-gaap_ValuationTechniqueDomain_581" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_581_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_588" xlink:to="loc_us-gaap_ValuationTechniqueDomain_581_default" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_WeightedAverageInvestmentMember" xlink:label="loc_ck0001755237_WeightedAverageInvestmentMember_583" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_581" xlink:to="loc_ck0001755237_WeightedAverageInvestmentMember_583" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TerminalDeclineRateMember" xlink:label="loc_ck0001755237_TerminalDeclineRateMember_587" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_581" xlink:to="loc_ck0001755237_TerminalDeclineRateMember_587" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TreasuryRateMember" xlink:label="loc_ck0001755237_TreasuryRateMember_590" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_581" xlink:to="loc_ck0001755237_TreasuryRateMember_590" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_591" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_585" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_591" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_580" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_591" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_580" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_580_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_591" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_580_default" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TisentoTherapeuticsHoldingsIncMember" xlink:label="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_582" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_580" xlink:to="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember_582" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_579" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_579" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_586" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_OperatingExpenses_586" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_589" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_589" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" xlink:label="loc_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1_593" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1_593" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_596" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_596" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaap_InvestmentOwnedPercentOfNetAssets_597" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems_594" xlink:to="loc_us-gaap_InvestmentOwnedPercentOfNetAssets_597" use="optional" order="22" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_674" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_AwardTypeAxis_674" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_674" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_674" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_694" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" xlink:to="loc_us-gaap_RestrictedStockMember_694" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_703" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" xlink:to="loc_us-gaap_PerformanceSharesMember_703" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_706" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_687" xlink:to="loc_us-gaap_EmployeeStockOptionMember_706" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_683" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_683" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_678" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_683" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_678" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_678_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_683" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_678_default" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_688" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_us-gaap_VestingAxis_688" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_676" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_688" xlink:to="loc_us-gaap_VestingDomain_676" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_676_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_688" xlink:to="loc_us-gaap_VestingDomain_676_default" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_692" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_srt_TitleOfIndividualAxis_692" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_692" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_692" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675_default" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_680" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_675" xlink:to="loc_srt_DirectorMember_680" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_695" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677" xlink:to="loc_srt_RangeAxis_695" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_689" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_695" xlink:to="loc_srt_RangeMember_689" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_689_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_695" xlink:to="loc_srt_RangeMember_689_default" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_693" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_693" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ShareBasedCompensationExpense" xlink:label="loc_ck0001755237_ShareBasedCompensationExpense_709" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_ck0001755237_ShareBasedCompensationExpense_709" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_710" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_710" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_711" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_711" use="optional" order="24" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_712" use="optional" order="25" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_714" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_714" use="optional" order="26" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_715" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_715" use="optional" order="27" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_716" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_716" use="optional" order="28" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_718" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_698" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_718" use="optional" order="29" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_729" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_725" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_729" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_725" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_724" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_725" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_724" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_726" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_724" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_726" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_726_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_724" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_726_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_728" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_726" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_728" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_730" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_726" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_730" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_727" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_729" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_727" use="optional" order="7" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_734" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_737" xlink:to="loc_us-gaap_AwardTypeAxis_734" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_734" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_749" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_745" xlink:to="loc_us-gaap_EmployeeStockOptionMember_749" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_735" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_735" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_741" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_741" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_746" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_746" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_750" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_750" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_755" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_755" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_733" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_733" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_739" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_739" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_744" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_744" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_752" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_752" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_736" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_736" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_742" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_747" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_742" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_751" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_751" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_754" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_740" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_754" use="optional" order="22" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_765" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_AwardTypeAxis_765" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_765" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_777" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_774" xlink:to="loc_us-gaap_RestrictedStockMember_777" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_764" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_764" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_769" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_769" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_773" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_773" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_776" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_768" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_776" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_770" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_766" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_766" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_771" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_771" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_775" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_775" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_778" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_778" use="optional" order="15" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_803" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_803" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_796" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_796" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_796" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_796" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_795" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" xlink:to="loc_us-gaap_EmployeeStockOptionMember_795" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_800" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_794" xlink:to="loc_us-gaap_RestrictedStockMember_800" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_801" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_793" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_801" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_797" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_801" xlink:to="loc_us-gaap_EquityComponentDomain_797" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_797_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_801" xlink:to="loc_us-gaap_EquityComponentDomain_797_default" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_798" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_797" xlink:to="loc_us-gaap_PreferredStockMember_798" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_799" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_803" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_799" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:label="loc_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits_802" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_803" xlink:to="loc_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits_802" use="optional" order="12" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_815" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_815" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_811" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_815" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_811" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_812" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_811" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_812" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_812_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_811" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_812_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_817" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812" xlink:to="loc_us-gaap_DomesticCountryMember_817" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_820" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_812" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_820" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativesByContractTypeAxis" xlink:label="loc_us-gaap_CreditDerivativesByContractTypeAxis_818" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_815" xlink:to="loc_us-gaap_CreditDerivativesByContractTypeAxis_818" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativesContractTypeDomain" xlink:label="loc_us-gaap_CreditDerivativesContractTypeDomain_816" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditDerivativesByContractTypeAxis_818" xlink:to="loc_us-gaap_CreditDerivativesContractTypeDomain_816" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativesContractTypeDomain" xlink:label="loc_us-gaap_CreditDerivativesContractTypeDomain_816_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditDerivativesByContractTypeAxis_818" xlink:to="loc_us-gaap_CreditDerivativesContractTypeDomain_816_default" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_814" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_814" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_819" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_OperatingLossCarryforwards_819" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_822" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_822" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInformationPertainingToIncomeTaxes" xlink:label="loc_us-gaap_OtherInformationPertainingToIncomeTaxes_823" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_OtherInformationPertainingToIncomeTaxes_823" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_825" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_825" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_826" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_821" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_826" use="optional" order="15" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_831" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_831" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_829" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable_831" xlink:to="loc_us-gaap_DebtInstrumentAxis_829" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_836" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_829" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_836" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_836_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_829" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_836_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_832" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_832" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_834" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_834" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_835" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_835" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_837" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_837" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_838" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_838" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_839" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_839" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_840" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_840" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_841" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_841" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_842" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_842" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_843" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_843" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_844" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_844" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_845" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_845" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_846" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_833" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_846" use="optional" order="17" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/DefinedContributionPlanDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_860" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_us-gaap_DefinedContributionPlanTable_860" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_861" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_860" xlink:to="loc_srt_RangeAxis_861" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_866" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_861" xlink:to="loc_srt_RangeMember_866" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_866_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_861" xlink:to="loc_srt_RangeMember_866_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_868" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_866" xlink:to="loc_srt_MinimumMember_868" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_869" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_866" xlink:to="loc_srt_MaximumMember_869" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTypeExtensibleList" xlink:label="loc_us-gaap_DefinedContributionPlanTypeExtensibleList_862" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_us-gaap_DefinedContributionPlanTypeExtensibleList_862" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_864" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_864" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_865" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_865" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" xlink:label="loc_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum_867" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_863" xlink:to="loc_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum_867" use="optional" order="10" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_898" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" xlink:to="loc_us-gaap_TypeOfArrangementAxis_898" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_898" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_898" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PatentLicenseAgreementMember" xlink:label="loc_ck0001755237_PatentLicenseAgreementMember_894" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_PatentLicenseAgreementMember_894" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaResearchLicenseAgreementMember" xlink:label="loc_ck0001755237_AkebiaResearchLicenseAgreementMember_900" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_AkebiaResearchLicenseAgreementMember_900" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" xlink:label="loc_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember_903" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember_903" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaMaterialPurchaseAgreementMember" xlink:label="loc_ck0001755237_AkebiaMaterialPurchaseAgreementMember_906" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_AkebiaMaterialPurchaseAgreementMember_906" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_MedsteerCollaborationAgreementMember" xlink:label="loc_ck0001755237_MedsteerCollaborationAgreementMember_947" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_893" xlink:to="loc_ck0001755237_MedsteerCollaborationAgreementMember_947" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_902" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_897" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_902" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_899" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_902" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_899" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_899_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_902" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_899_default" use="optional" order="12" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_895" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_899" xlink:to="loc_us-gaap_SubsequentEventMember_895" use="optional" order="13" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_896" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_896" use="optional" order="14" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionFee" xlink:label="loc_ck0001755237_OptionFee_901" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_OptionFee_901" use="optional" order="15" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionAdditionalFee" xlink:label="loc_ck0001755237_OptionAdditionalFee_904" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_OptionAdditionalFee_904" use="optional" order="16" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_907" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_907" use="optional" order="17" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_UpFrontPaymentReceived" xlink:label="loc_ck0001755237_UpFrontPaymentReceived_908" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_UpFrontPaymentReceived_908" use="optional" order="18" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AdditionalUpFrontPayment" xlink:label="loc_ck0001755237_AdditionalUpFrontPayment_909" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_AdditionalUpFrontPayment_909" use="optional" order="19" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DevelopmentMilestonePayment" xlink:label="loc_ck0001755237_DevelopmentMilestonePayment_910" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_DevelopmentMilestonePayment_910" use="optional" order="20" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CommercializationMilestonePayments" xlink:label="loc_ck0001755237_CommercializationMilestonePayments_911" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_ck0001755237_CommercializationMilestonePayments_911" use="optional" order="21" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_912" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_912" use="optional" order="22" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_913" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_Revenues_913" use="optional" order="23" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_948" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_905" xlink:to="loc_us-gaap_CostsAndExpenses_948" use="optional" order="24" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_931" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_926" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_us-gaap_SubsequentEventTable_926" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_924" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_926" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_924" use="optional" order="2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_925" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_924" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_925" use="optional" order="3" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_925_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_924" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_925_default" use="optional" order="4" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_922" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_925" xlink:to="loc_us-gaap_SubsequentEventMember_922" use="optional" order="5" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_928" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_926" xlink:to="loc_srt_StatementScenarioAxis_928" use="optional" order="6" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_930" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_928" xlink:to="loc_srt_ScenarioUnspecifiedDomain_930" use="optional" order="7" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_930_default" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_928" xlink:to="loc_srt_ScenarioUnspecifiedDomain_930_default" use="optional" order="8" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_921" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_us-gaap_CommonStockSharesIssued_921" use="optional" order="9" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_927" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_927" use="optional" order="10" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DebtInstrumentsOptionsExercisePeriod" xlink:label="loc_ck0001755237_DebtInstrumentsOptionsExercisePeriod_929" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_ck0001755237_DebtInstrumentsOptionsExercisePeriod_929" use="optional" order="11" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_UpFrontPaymentReceived" xlink:label="loc_ck0001755237_UpFrontPaymentReceived_932" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_931" xlink:to="loc_ck0001755237_UpFrontPaymentReceived_932" use="optional" order="12" />
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember" />
          <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="loc_us-gaap_QualifiedPlanMember" order="1.0" />
        </link:definitionLink>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"  />
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" >
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent" use="optional" order="3" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_ck0001755237_AccruedResearchAndDevelopmentCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ck0001755237_AccruedResearchAndDevelopmentCurrent" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="6" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="8" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="9" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="10" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="11" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="12" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="13" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="14" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="15" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherLongTermInvestments" use="optional" order="16" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="17" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ProceedsFromAtTheOffer" xlink:label="loc_ck0001755237_ProceedsFromAtTheOffer" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ck0001755237_ProceedsFromAtTheOffer" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_IssuanceCostsPaidForPrivatePlacement" xlink:label="loc_ck0001755237_IssuanceCostsPaidForPrivatePlacement" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ck0001755237_IssuanceCostsPaidForPrivatePlacement" use="optional" order="6" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_GainLossFromSettlementOfAccountPayable" xlink:label="loc_ck0001755237_GainLossFromSettlementOfAccountPayable" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ck0001755237_GainLossFromSettlementOfAccountPayable" use="optional" order="8" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="9" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="10" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="11" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="12" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" use="optional" order="13" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="14" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:label="loc_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" use="optional" order="15" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" use="optional" order="16" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" order="17" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_GainLossFromSettlementOfAccountPayable" xlink:label="loc_ck0001755237_GainLossFromSettlementOfAccountPayable" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_ck0001755237_GainLossFromSettlementOfAccountPayable" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="6" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="7" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="8" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="9" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" order="10" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="11" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="4" weight="1" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" use="optional" order="5" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="6" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="7" weight="-1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" use="optional" order="2" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" use="optional" order="3" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits" use="optional" order="4" weight="-1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="1" />
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
        </link:calculationLink>
        <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link" >
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationDocumentAxis" xlink:label="loc_dei_DocumentInformationDocumentAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationDocumentAxis" xml:lang="en-US">Document Information, Document [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis" xlink:to="lab_dei_DocumentInformationDocumentAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentDomain" xlink:label="loc_dei_DocumentDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentDomain" xml:lang="en-US">Document [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain" xlink:to="lab_dei_DocumentDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaap_OtherLongTermInvestments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermInvestments" xml:lang="en-US">Other Long-Term Investments</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermInvestments" xml:lang="en-US">Other investment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_ck0001755237_AccruedResearchAndDevelopmentCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AccruedResearchAndDevelopmentCurrent" xml:lang="en-US">Accrued Research And Development Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AccruedResearchAndDevelopmentCurrent" xml:lang="en-US">Accrued research and development costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_ck0001755237_AccruedResearchAndDevelopmentCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AccruedResearchAndDevelopmentCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of liabilities.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xml:lang="en-US">Accrued Expenses And Other Liabilities Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lab_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" xml:lang="en-US">Amount of accrued expenses and other liabilities current.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at March 31, 2026 and December 31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, no par value, 400,000,000 shares authorized at March 31, 2026 and December 31, 2025; 4,330,314 and 3,925,314 shares issued at March 31, 2026 and December 31, 2025, respectively; 4,241,260 and 3,821,236 shares outstanding at March 31, 2026 and December 31, 2025, respectively</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Paid-in capital</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SeriesaConvertiblePreferredStockMember" xlink:label="loc_ck0001755237_SeriesaConvertiblePreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_SeriesaConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_SeriesaConvertiblePreferredStockMember" xlink:to="lab_ck0001755237_SeriesaConvertiblePreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_SeriesaConvertiblePreferredStockMember" xml:lang="en-US">SeriesA convertible preferred stock.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shared outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ending balance (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementMember" xlink:label="loc_ck0001755237_LicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_LicenseAgreementMember" xml:lang="en-US">Revenue from license agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_LicenseAgreementMember" xlink:to="lab_ck0001755237_LicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PurchaseAgreementMember" xlink:label="loc_ck0001755237_PurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_PurchaseAgreementMember" xml:lang="en-US">Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_PurchaseAgreementMember" xml:lang="en-US">Revenue from purchase agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_PurchaseAgreementMember" xlink:to="lab_ck0001755237_PurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_PurchaseAgreementMember" xml:lang="en-US">Purchase agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionAgreementMember" xlink:label="loc_ck0001755237_OptionAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_OptionAgreementMember" xml:lang="en-US">Option Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_OptionAgreementMember" xml:lang="en-US">Revenue from option agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_OptionAgreementMember" xlink:to="lab_ck0001755237_OptionAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_OptionAgreementMember" xml:lang="en-US">Option Agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Total revenues</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Cost and expenses:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total cost and expenses</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Interest income</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_GainLossFromSettlementOfAccountPayable" xlink:label="loc_ck0001755237_GainLossFromSettlementOfAccountPayable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_GainLossFromSettlementOfAccountPayable" xml:lang="en-US">Gain Loss from Settlement of Account Payable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_GainLossFromSettlementOfAccountPayable" xml:lang="en-US">Gain from settlement of account payable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ck0001755237_GainLossFromSettlementOfAccountPayable" xml:lang="en-US">Gain from settlement of account payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_GainLossFromSettlementOfAccountPayable" xlink:to="lab_ck0001755237_GainLossFromSettlementOfAccountPayable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_GainLossFromSettlementOfAccountPayable" xml:lang="en-US">Gain (loss) from settlement of account payable.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xml:lang="en-US">Gain on Business Interruption Insurance Recovery</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xml:lang="en-US">Gain from insurance recovery</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:to="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss per share:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share - Basic</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share - Diluted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:label="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xml:lang="en-US">Earnings Per Share Basic and Diluted Other Disclosure [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xml:lang="en-US">Weighted average shares used in calculating:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:to="lab_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xml:lang="en-US">Earnings per share basic and diluted other disclosure.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares used in calculating net loss per share - basic</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares used in calculating net loss per share - Diluted</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xml:lang="en-US">Other comprehensive loss:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive loss:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustment loss</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Paid-in capital</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated deflicit</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Beginning balance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Ending balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" xlink:label="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" xml:lang="en-US">Stock Issued During Period Issuance of Common Stock Net of Issuance Cost, Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" xml:lang="en-US">Issuance of common stock - private placement, net of issuance cost (in share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" xlink:to="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" xml:lang="en-US">Stock issued during period issuance of common stock net of nssuance cost, share.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" xlink:label="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" xml:lang="en-US">Stock Issued During Period Issuance of Common Stock Net of Issuance Cost, Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" xml:lang="en-US">Issuance of common stock - private placement, net of issuance cost</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" xlink:to="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" xml:lang="en-US">Stock issued during period issuance of common stock net of issuance cost, value</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock - ATM (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Sale of shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock - ATM</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Vesting of restricted stock awards (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation expense related to issuance of stock options and restricted stock awards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" xlink:label="loc_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" xml:lang="en-US">Release Of Foreign Currency Translation Adjustment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" xml:lang="en-US">Release of foreign currency translation adjustment upon liquidation of a subsidiary</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" xlink:to="lab_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" xml:lang="en-US">Release of foreign currency translation adjustment..</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:label="loc_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" xml:lang="en-US">Increase Decrease In Accrued Research And Development</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" xml:lang="en-US">Accrued research and development costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" xlink:to="lab_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" xml:lang="en-US">The increase (decrease) during the reporting period in accrued research and development expense.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ProceedsFromAtTheOffer" xlink:label="loc_ck0001755237_ProceedsFromAtTheOffer" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_ProceedsFromAtTheOffer" xml:lang="en-US">Proceeds from at the Offer</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_ProceedsFromAtTheOffer" xml:lang="en-US">Proceeds from ATM</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_ProceedsFromAtTheOffer" xlink:to="lab_ck0001755237_ProceedsFromAtTheOffer" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_ProceedsFromAtTheOffer" xml:lang="en-US">Proceeds from at the offer.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from private placement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from stock purchase agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_IssuanceCostsPaidForPrivatePlacement" xlink:label="loc_ck0001755237_IssuanceCostsPaidForPrivatePlacement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_IssuanceCostsPaidForPrivatePlacement" xml:lang="en-US">Issuance Costs Paid for Private Placement</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_IssuanceCostsPaidForPrivatePlacement" xml:lang="en-US">Issuance costs paid for private placement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_IssuanceCostsPaidForPrivatePlacement" xlink:to="lab_ck0001755237_IssuanceCostsPaidForPrivatePlacement" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_IssuanceCostsPaidForPrivatePlacement" xml:lang="en-US">Issuance costs paid for private placement.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Nature of Business</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaap_InvestmentTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTextBlock" xml:lang="en-US">Investment [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTextBlock" xml:lang="en-US">Other Investment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Compensation Plans</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Loss per share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Defined Contribution Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementAbstract" xlink:label="loc_ck0001755237_LicenseAgreementAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_LicenseAgreementAbstract" xml:lang="en-US">License Agreement [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_LicenseAgreementAbstract" xlink:to="lab_ck0001755237_LicenseAgreementAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_LicenseAgreementAbstract" xml:lang="en-US">License agreement abstract.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_LicenseAgreementsTextBlock" xlink:label="loc_ck0001755237_LicenseAgreementsTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_LicenseAgreementsTextBlock" xml:lang="en-US">License Agreements [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_LicenseAgreementsTextBlock" xml:lang="en-US">License and Option Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_LicenseAgreementsTextBlock" xlink:to="lab_ck0001755237_LicenseAgreementsTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_LicenseAgreementsTextBlock" xml:lang="en-US">The entire disclosure for license agreements.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Variable Interest Entities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Investment Instruments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" xlink:label="loc_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" xml:lang="en-US">Related Party Accounts Receivable Policy Policy [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" xml:lang="en-US">Accounts Receivable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" xlink:to="lab_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for related party accounts receivable.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative Expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PatentCostsPolicyTextBlock" xlink:label="loc_ck0001755237_PatentCostsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs Policy [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_PatentCostsPolicyTextBlock" xlink:to="lab_ck0001755237_PatentCostsPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_PatentCostsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for patent costs.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" xlink:label="loc_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" xml:lang="en-US">Interest And Other Income Policy Policy [Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" xml:lang="en-US">Interest and Other Income, Net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" xlink:to="lab_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for interest and other income.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued/Adopted Accounting Pronouncements</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of stock option activity</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of weighted-average assumptions used in estimating the fair value of the stock options</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US">Summary of RSA activity</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Common Share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xml:lang="en-US">Schedule of earnings per share diluted by common class</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Components of Net Income Loss Before Income Tax Expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Summary of reconciliation of income taxes computed using the U.S. federal statutory rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of deferred tax assets (liabilities)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TisentoTherapeuticsHoldingsIncMember" xlink:label="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_TisentoTherapeuticsHoldingsIncMember" xml:lang="en-US">Tisento Therapeutics Holdings Inc [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_TisentoTherapeuticsHoldingsIncMember" xml:lang="en-US">Tisento Therapeutics Holdings Inc</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_TisentoTherapeuticsHoldingsIncMember" xlink:to="lab_ck0001755237_TisentoTherapeuticsHoldingsIncMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_TisentoTherapeuticsHoldingsIncMember" xml:lang="en-US">Tisento therapeutics holdings inc.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_KorsanaBiosciencesIncMember" xlink:label="loc_ck0001755237_KorsanaBiosciencesIncMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_KorsanaBiosciencesIncMember" xml:lang="en-US">Korsana Biosciences Inc [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_KorsanaBiosciencesIncMember" xml:lang="en-US">Korsana</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_KorsanaBiosciencesIncMember" xlink:to="lab_ck0001755237_KorsanaBiosciencesIncMember" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CyclerionTherapeuticsIncMember" xlink:label="loc_ck0001755237_CyclerionTherapeuticsIncMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_CyclerionTherapeuticsIncMember" xml:lang="en-US">Cyclerion Therapeutics Inc [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_CyclerionTherapeuticsIncMember" xml:lang="en-US">Cyclerion</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_CyclerionTherapeuticsIncMember" xlink:to="lab_ck0001755237_CyclerionTherapeuticsIncMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" xlink:label="loc_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" xml:lang="en-US">Two Thousand Twenty Five Equity Private Placement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" xml:lang="en-US">2025 Equity Private Placement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" xlink:to="lab_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" xml:lang="en-US">Two thousand twenty five equity private placement member.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SeriesSeedPreferredStockMember" xlink:label="loc_ck0001755237_SeriesSeedPreferredStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_SeriesSeedPreferredStockMember" xml:lang="en-US">Series Seed Preferred Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_SeriesSeedPreferredStockMember" xml:lang="en-US">Series Seed Preferred Stock</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_SeriesSeedPreferredStockMember" xlink:to="lab_ck0001755237_SeriesSeedPreferredStockMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SalesAgreementMember" xlink:label="loc_ck0001755237_SalesAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_SalesAgreementMember" xml:lang="en-US">Sales Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_SalesAgreementMember" xlink:to="lab_ck0001755237_SalesAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_SalesAgreementMember" xml:lang="en-US">Sales agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CyclerionLicenseAgreementMember" xlink:label="loc_ck0001755237_CyclerionLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_CyclerionLicenseAgreementMember" xml:lang="en-US">Cyclerion License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_CyclerionLicenseAgreementMember" xml:lang="en-US">Cyclerion</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_CyclerionLicenseAgreementMember" xlink:to="lab_ck0001755237_CyclerionLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_CyclerionLicenseAgreementMember" xml:lang="en-US">Cyclerion license agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaLicenseAgreementMember" xlink:label="loc_ck0001755237_AkebiaLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AkebiaLicenseAgreementMember" xml:lang="en-US">Akebia License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AkebiaLicenseAgreementMember" xml:lang="en-US">Akebia</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AkebiaLicenseAgreementMember" xlink:to="lab_ck0001755237_AkebiaLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AkebiaLicenseAgreementMember" xml:lang="en-US">Akebia license agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Nature of Business</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PaymentOfCashMilestone" xlink:label="loc_ck0001755237_PaymentOfCashMilestone" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_PaymentOfCashMilestone" xml:lang="en-US">Payment Of Cash Milestone</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_PaymentOfCashMilestone" xml:lang="en-US">Additional milestone cash payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_PaymentOfCashMilestone" xlink:to="lab_ck0001755237_PaymentOfCashMilestone" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_PaymentOfCashMilestone" xml:lang="en-US">Payment of cash milestone.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_UpFrontPaymentReceived" xlink:label="loc_ck0001755237_UpFrontPaymentReceived" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_UpFrontPaymentReceived" xml:lang="en-US">Up Front Payment Received</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_UpFrontPaymentReceived" xml:lang="en-US">Up front payment received</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_UpFrontPaymentReceived" xlink:to="lab_ck0001755237_UpFrontPaymentReceived" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_UpFrontPaymentReceived" xml:lang="en-US">Up Front Payment Received.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionFee" xlink:label="loc_ck0001755237_OptionFee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_OptionFee" xml:lang="en-US">Option Fee</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_OptionFee" xml:lang="en-US">Option fee</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_OptionFee" xlink:to="lab_ck0001755237_OptionFee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_OptionFee" xml:lang="en-US">Option fee</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_SubsequentFees" xlink:label="loc_ck0001755237_SubsequentFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_SubsequentFees" xml:lang="en-US">Subsequent Fees</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_SubsequentFees" xml:lang="en-US">Subsequent fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_SubsequentFees" xlink:to="lab_ck0001755237_SubsequentFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_SubsequentFees" xml:lang="en-US">subsequent fees</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DevelopmentMilestonePayment" xlink:label="loc_ck0001755237_DevelopmentMilestonePayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_DevelopmentMilestonePayment" xml:lang="en-US">Development Milestone Payment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_DevelopmentMilestonePayment" xml:lang="en-US">Development milestone payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_DevelopmentMilestonePayment" xlink:to="lab_ck0001755237_DevelopmentMilestonePayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_DevelopmentMilestonePayment" xml:lang="en-US">Development milestone payment.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Cash consideration transferrred</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Outstanding equity securities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xml:lang="en-US">Equity Securities, FV-NI</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xml:lang="en-US">Equity investment in cash</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Common stock shares issued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Common stock share purchase price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" xlink:label="loc_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" xml:lang="en-US">Maximum Amount Of Aggregate Initial Offering Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" xml:lang="en-US">Maximum amount of aggregate initial offering price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" xlink:to="lab_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" xml:lang="en-US">Maximum amount of Aggregate initial offering price.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" xlink:label="loc_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" xml:lang="en-US">Cash Commission Percentage Of Gross Proceeds Of Sales Of Common Stock</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" xml:lang="en-US">Cash commission of gross proceeds of sales of common stock, percentage</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" xlink:to="lab_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" xml:lang="en-US">Cash commission percentage of gross proceeds of sales of common stock.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Commissions paid</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TransactionCostsSaleOfTransferredAssets" xlink:label="loc_ck0001755237_TransactionCostsSaleOfTransferredAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_TransactionCostsSaleOfTransferredAssets" xml:lang="en-US">Transaction Costs Sale of Transferred Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001755237_TransactionCostsSaleOfTransferredAssets" xml:lang="en-US">Transaction costs associated with sale of transferred assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_TransactionCostsSaleOfTransferredAssets" xlink:to="lab_ck0001755237_TransactionCostsSaleOfTransferredAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_TransactionCostsSaleOfTransferredAssets" xml:lang="en-US">Transaction costs sale of transferred assets.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" xlink:label="loc_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" xml:lang="en-US">Debt Instrument Convertible Threshold Percentage of Outstanding Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" xml:lang="en-US">Percentage of outstanding shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" xlink:to="lab_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" xml:lang="en-US">Debt instrument convertible threshold percentage of outstanding shares.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_NetCashOnCapitalization" xlink:label="loc_ck0001755237_NetCashOnCapitalization" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_NetCashOnCapitalization" xml:lang="en-US">Net Cash On Capitalization</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_NetCashOnCapitalization" xml:lang="en-US">Net cash on capitalization</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_NetCashOnCapitalization" xlink:to="lab_ck0001755237_NetCashOnCapitalization" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_NetCashOnCapitalization" xml:lang="en-US">Net cash on capitalization.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Number of common shares</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xml:lang="en-US">Aggregate purchase price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_RemainingAdditionalUpFrontPayment" xlink:label="loc_ck0001755237_RemainingAdditionalUpFrontPayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_RemainingAdditionalUpFrontPayment" xml:lang="en-US">Remaining Additional Up Front Payment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_RemainingAdditionalUpFrontPayment" xml:lang="en-US">Remaining additional up front payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_RemainingAdditionalUpFrontPayment" xlink:to="lab_ck0001755237_RemainingAdditionalUpFrontPayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_RemainingAdditionalUpFrontPayment" xml:lang="en-US">Remaining additional up front payment.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_InterestAndOtherIncomeMember" xlink:label="loc_ck0001755237_InterestAndOtherIncomeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_InterestAndOtherIncomeMember" xml:lang="en-US">Interest And Other Income [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_InterestAndOtherIncomeMember" xml:lang="en-US">Interest and other income, net</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_InterestAndOtherIncomeMember" xlink:to="lab_ck0001755237_InterestAndOtherIncomeMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_InterestAndOtherIncomeMember" xml:lang="en-US">Represents information pertaining to transactions recorded in interest and other income.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Legal and other fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndOtherIncome" xml:lang="en-US">Interest and Other Income</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestAndOtherIncome" xml:lang="en-US">Interest income generated from cash and cash equivalents balances</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US">Income tax, penalties and interest accrued</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money market funds</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Recurring</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Total cash equivalents</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xml:lang="en-US">Equity Method Investment [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_WeightedAverageInvestmentMember" xlink:label="loc_ck0001755237_WeightedAverageInvestmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_WeightedAverageInvestmentMember" xml:lang="en-US">Weighted Average Investment [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_WeightedAverageInvestmentMember" xml:lang="en-US">Weighted average investment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_WeightedAverageInvestmentMember" xlink:to="lab_ck0001755237_WeightedAverageInvestmentMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_WeightedAverageInvestmentMember" xml:lang="en-US">Weighted average investment.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TerminalDeclineRateMember" xlink:label="loc_ck0001755237_TerminalDeclineRateMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_TerminalDeclineRateMember" xml:lang="en-US">Terminal Decline Rate [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_TerminalDeclineRateMember" xml:lang="en-US">Terminal decline rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_TerminalDeclineRateMember" xlink:to="lab_ck0001755237_TerminalDeclineRateMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_TerminalDeclineRateMember" xml:lang="en-US">Terminal decline rate.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_TreasuryRateMember" xlink:label="loc_ck0001755237_TreasuryRateMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_TreasuryRateMember" xml:lang="en-US">Treasury Rate [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_TreasuryRateMember" xml:lang="en-US">Treasury rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_TreasuryRateMember" xlink:to="lab_ck0001755237_TreasuryRateMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_TreasuryRateMember" xml:lang="en-US">Treasury rate.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems" xml:lang="en-US">Investment Holdings, Other than Securities [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems" xlink:to="lab_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" xlink:label="loc_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" xml:lang="en-US">Available-for-Sale Securities, Continuous Unrealized Loss Position, Fair Value 1</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" xml:lang="en-US">Fair value of outstanding equity securities</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" xlink:to="lab_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" xml:lang="en-US">Available-for-sale securities, continuous unrealized loss position, fair value 1.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xml:lang="en-US">Impairment loss on other investments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaap_InvestmentOwnedPercentOfNetAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedPercentOfNetAssets" xml:lang="en-US">Investment Owned, Net Assets, Percentage</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentOwnedPercentOfNetAssets" xml:lang="en-US">Net assets percentage</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="lab_us-gaap_InvestmentOwnedPercentOfNetAssets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Professional fees</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee compensation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xml:lang="en-US">Other</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Payment to former chief financial officer</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xml:lang="en-US">Separation benefits obligation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss Contingency Accrual</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Liabilities recorded for indemnification provisions</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">us-gaap_AwardTypeAxis</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock Awards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PerformanceSharesMember" xml:lang="en-US">Performance Shares [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PerformanceSharesMember" xml:lang="en-US">Performance stock options</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title and Position [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title and Position [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Plans</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number of shares vested</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_ShareBasedCompensationExpense" xlink:label="loc_ck0001755237_ShareBasedCompensationExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_ShareBasedCompensationExpense" xml:lang="en-US">Share Based Compensation Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001755237_ShareBasedCompensationExpense" xml:lang="en-US">Share based compensation expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_ShareBasedCompensationExpense" xlink:to="lab_ck0001755237_ShareBasedCompensationExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_ShareBasedCompensationExpense" xml:lang="en-US">Share based compensation expense</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized share-based compensation expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Expected period to recognize the expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value per option share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Total intrinsic value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized share-based compensation expense</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Options</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at beginning of the year (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at end of the year (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at beginning of the year (in dollars per share)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding as of December&#160;31, 2025</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected option term (in years)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Unvested at the beginning of the period (in shares)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Unvested the end of the period (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited (in shares)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Unvested at the beginning of the period (in dollars per share)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Unvested restricted common stock at the end of the period (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Granted (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Vested (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Numerator:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" xlink:label="loc_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" xml:lang="en-US">Earnings Per Share Basic and Diluted1 [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" xml:lang="en-US">Denominator:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" xlink:to="lab_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" xml:lang="en-US">Earnings per share basic and diluted1.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xml:lang="en-US">Net loss per share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive securities excluded from the calculation of diluted loss per share</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:label="loc_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xml:lang="en-US">Dilutive securities, effect on basic earnings per share, options and restrictive stock units</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" xlink:to="lab_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Total</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Pretax loss</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativesByContractTypeAxis" xlink:label="loc_us-gaap_CreditDerivativesByContractTypeAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditDerivativesByContractTypeAxis" xml:lang="en-US">Credit Derivatives Contract Type [Axis]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditDerivativesByContractTypeAxis" xml:lang="en-US">Credit Derivatives Contract Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditDerivativesByContractTypeAxis" xlink:to="lab_us-gaap_CreditDerivativesByContractTypeAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditDerivativesContractTypeDomain" xlink:label="loc_us-gaap_CreditDerivativesContractTypeDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditDerivativesContractTypeDomain" xml:lang="en-US">Credit Derivatives Contract Type [Domain]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditDerivativesContractTypeDomain" xml:lang="en-US">Credit Derivatives Contract Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditDerivativesContractTypeDomain" xlink:to="lab_us-gaap_CreditDerivativesContractTypeDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Income Taxes</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherInformationPertainingToIncomeTaxes" xlink:label="loc_us-gaap_OtherInformationPertainingToIncomeTaxes" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherInformationPertainingToIncomeTaxes" xml:lang="en-US">Other Information Pertaining to Income Taxes</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherInformationPertainingToIncomeTaxes" xml:lang="en-US">Income tax credit expiration description</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInformationPertainingToIncomeTaxes" xlink:to="lab_us-gaap_OtherInformationPertainingToIncomeTaxes" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Accrued interest or penalties</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">US Federal Statutory Tax Rate</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign tax effects</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Non-deductible items</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xml:lang="en-US">Tax credits</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">US Federal Statutory Tax Rate, Percent</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign tax effects, Percent</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Non-deductible items, Percent</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Tax credits, Percent</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance, Percent</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income Tax Expense (Benefit), Percent, Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred tax assets:</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credit carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share-based compensation</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Deferred Tax Assets Capitalized Research And Development Costs</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Capitalized research and development</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangibles</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred tax assets</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="loc_ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US">Not Found During Migration Deprecated Concept Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lab_ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xml:lang="en-US">Not Found During Migration Deprecated Concept Defined Contribution Pension And Other Postretirement Plans Disclosure Abstract</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Defined Contribution Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanTypeExtensibleList" xlink:label="loc_us-gaap_DefinedContributionPlanTypeExtensibleList" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanTypeExtensibleList" xml:lang="en-US">Defined Contribution Plan, Type [Extensible Enumeration]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanTypeExtensibleList" xml:lang="en-US">401 (k) Savings Plan</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTypeExtensibleList" xlink:to="lab_us-gaap_DefinedContributionPlanTypeExtensibleList" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Percent of compensation eligible employees may elect to contribute</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Matching contribution (as a percent of employee's contributions)</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" xlink:label="loc_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" xml:lang="en-US">Defined Contribution Plan Employer Matching Contribution Maximum</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" xml:lang="en-US">Maximum amount of employer matching contribution</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" xlink:to="lab_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" xml:lang="en-US">The maximum amount per employee of the employer's matching contributions.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_PatentLicenseAgreementMember" xlink:label="loc_ck0001755237_PatentLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_PatentLicenseAgreementMember" xml:lang="en-US">Patent License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_PatentLicenseAgreementMember" xml:lang="en-US">Patent License Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_PatentLicenseAgreementMember" xlink:to="lab_ck0001755237_PatentLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_PatentLicenseAgreementMember" xml:lang="en-US">Patent license agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaResearchLicenseAgreementMember" xlink:label="loc_ck0001755237_AkebiaResearchLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AkebiaResearchLicenseAgreementMember" xml:lang="en-US">Akebia Research License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AkebiaResearchLicenseAgreementMember" xml:lang="en-US">Akebia Research License Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AkebiaResearchLicenseAgreementMember" xlink:to="lab_ck0001755237_AkebiaResearchLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AkebiaResearchLicenseAgreementMember" xml:lang="en-US">Akebia Research License Agreement Member.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" xlink:label="loc_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" xml:lang="en-US">Amendment Akebia Research License Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" xml:lang="en-US">Amendment Akebia Research License Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" xlink:to="lab_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" xml:lang="en-US">Amendment Akebia Research License Agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AkebiaMaterialPurchaseAgreementMember" xlink:label="loc_ck0001755237_AkebiaMaterialPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AkebiaMaterialPurchaseAgreementMember" xml:lang="en-US">Akebia Material Purchase Agreement [Member]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AkebiaMaterialPurchaseAgreementMember" xml:lang="en-US">Akebia Material Purchase Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AkebiaMaterialPurchaseAgreementMember" xlink:to="lab_ck0001755237_AkebiaMaterialPurchaseAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AkebiaMaterialPurchaseAgreementMember" xml:lang="en-US">Akebia Material Purchase Agreement.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_MedsteerCollaborationAgreementMember" xlink:label="loc_ck0001755237_MedsteerCollaborationAgreementMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_MedsteerCollaborationAgreementMember" xml:lang="en-US">Medsteer Collaboration Agreement [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_MedsteerCollaborationAgreementMember" xlink:to="lab_ck0001755237_MedsteerCollaborationAgreementMember" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_OptionAdditionalFee" xlink:label="loc_ck0001755237_OptionAdditionalFee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_OptionAdditionalFee" xml:lang="en-US">Option Additional Fee</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_OptionAdditionalFee" xml:lang="en-US">Option additional fee</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_OptionAdditionalFee" xlink:to="lab_ck0001755237_OptionAdditionalFee" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_OptionAdditionalFee" xml:lang="en-US">Option additional fee.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue recognized</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_AdditionalUpFrontPayment" xlink:label="loc_ck0001755237_AdditionalUpFrontPayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_AdditionalUpFrontPayment" xml:lang="en-US">Additional Up Front Payment</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_AdditionalUpFrontPayment" xml:lang="en-US">Additional up front payment</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_AdditionalUpFrontPayment" xlink:to="lab_ck0001755237_AdditionalUpFrontPayment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_AdditionalUpFrontPayment" xml:lang="en-US">Additional up front payment.</link:label>
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_CommercializationMilestonePayments" xlink:label="loc_ck0001755237_CommercializationMilestonePayments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_CommercializationMilestonePayments" xml:lang="en-US">Commercialization Milestone Payments</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_CommercializationMilestonePayments" xml:lang="en-US">Commercialization milestone payments</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_CommercializationMilestonePayments" xlink:to="lab_ck0001755237_CommercializationMilestonePayments" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_CommercializationMilestonePayments" xml:lang="en-US">Commercialization milestone payments.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xml:lang="en-US">Payment of additional development materials</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpenses" xml:lang="en-US">Costs and Expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
          <link:loc xlink:type="locator" xlink:href="ck0001755237-20260331.xsd#ck0001755237_DebtInstrumentsOptionsExercisePeriod" xlink:label="loc_ck0001755237_DebtInstrumentsOptionsExercisePeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001755237_DebtInstrumentsOptionsExercisePeriod" xml:lang="en-US">Debt Instruments, Options, Exercise Period</link:label>
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001755237_DebtInstrumentsOptionsExercisePeriod" xml:lang="en-US">Exercise period</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001755237_DebtInstrumentsOptionsExercisePeriod" xlink:to="lab_ck0001755237_DebtInstrumentsOptionsExercisePeriod" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001755237_DebtInstrumentsOptionsExercisePeriod" xml:lang="en-US">Debt instruments, options, exercise period.</link:label>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember" />
          <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QualifiedPlanMember" xml:lang="en-US">Qualified Plan [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QualifiedPlanMember" xlink:to="lab_us-gaap_QualifiedPlanMember" />
        </link:labelLink>
      </link:linkbase>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <element name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ck0001755237_AccruedResearchAndDevelopmentCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SeriesaConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_SeriesaConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
  <element name="LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_LicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="PurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_PurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="OptionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_OptionAgreementMember" substitutionGroup="xbrli:item" />
  <element name="GainLossFromSettlementOfAccountPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_GainLossFromSettlementOfAccountPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" substitutionGroup="xbrli:item" />
  <element name="StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare" substitutionGroup="xbrli:item" />
  <element name="StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ReleaseOfForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IncreaseDecreaseInAccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ProceedsFromAtTheOffer" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_ProceedsFromAtTheOffer" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IssuanceCostsPaidForPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_IssuanceCostsPaidForPrivatePlacement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="LicenseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_LicenseAgreementAbstract" substitutionGroup="xbrli:item" />
  <element name="LicenseAgreementsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_LicenseAgreementsTextBlock" substitutionGroup="xbrli:item" />
  <element name="RelatedPartyAccountsReceivablePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_PatentCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="InterestAndOtherIncomePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="TisentoTherapeuticsHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_TisentoTherapeuticsHoldingsIncMember" substitutionGroup="xbrli:item" />
  <element name="KorsanaBiosciencesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_KorsanaBiosciencesIncMember" substitutionGroup="xbrli:item" />
  <element name="CyclerionTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_CyclerionTherapeuticsIncMember" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyFiveEquityPrivatePlacementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember" substitutionGroup="xbrli:item" />
  <element name="SeriesSeedPreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_SeriesSeedPreferredStockMember" substitutionGroup="xbrli:item" />
  <element name="SalesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_SalesAgreementMember" substitutionGroup="xbrli:item" />
  <element name="CyclerionLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_CyclerionLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="AkebiaLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_AkebiaLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="PaymentOfCashMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_PaymentOfCashMilestone" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="UpFrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_UpFrontPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="OptionFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_OptionFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="SubsequentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_SubsequentFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="DevelopmentMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_DevelopmentMilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="MaximumAmountOfAggregateInitialOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock" substitutionGroup="xbrli:item" />
  <element name="TransactionCostsSaleOfTransferredAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_TransactionCostsSaleOfTransferredAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares" substitutionGroup="xbrli:item" />
  <element name="NetCashOnCapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_NetCashOnCapitalization" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="RemainingAdditionalUpFrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_RemainingAdditionalUpFrontPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="InterestAndOtherIncomeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_InterestAndOtherIncomeMember" substitutionGroup="xbrli:item" />
  <element name="WeightedAverageInvestmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_WeightedAverageInvestmentMember" substitutionGroup="xbrli:item" />
  <element name="TerminalDeclineRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_TerminalDeclineRateMember" substitutionGroup="xbrli:item" />
  <element name="TreasuryRateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_TreasuryRateMember" substitutionGroup="xbrli:item" />
  <element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_ShareBasedCompensationExpense" substitutionGroup="xbrli:item" />
  <element name="EarningsPerShareBasicAndDiluted1Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_EarningsPerShareBasicAndDiluted1Abstract" substitutionGroup="xbrli:item" />
  <element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" substitutionGroup="xbrli:item" />
  <element name="DefinedContributionPlanEmployerMatchingContributionMaximum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PatentLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_PatentLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="AkebiaResearchLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_AkebiaResearchLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="AmendmentAkebiaResearchLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="AkebiaMaterialPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_AkebiaMaterialPurchaseAgreementMember" substitutionGroup="xbrli:item" />
  <element name="MedsteerCollaborationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ck0001755237_MedsteerCollaborationAgreementMember" substitutionGroup="xbrli:item" />
  <element name="OptionAdditionalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_OptionAdditionalFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="AdditionalUpFrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_AdditionalUpFrontPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="CommercializationMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_CommercializationMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="DebtInstrumentsOptionsExercisePeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ck0001755237_DebtInstrumentsOptionsExercisePeriod" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g111069g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1BD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &(<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"C_P  1" $D IL# 2(  A$! Q$!_\0 '0 !  $% 0$!
M      @! P4&!P0) O_$ $@0  $# P$%!00$#0(& @,!  $  @,$!1$&!Q(A
M,5$($T%AD2(R<;$4<G.!%2,S-#4V-T)2=*'!T22R&$-38H*35%4E8Y+A_\0
M&P$!  ,! 0$!              $#! (%!@?_Q  \$0 " 0," P4%!P($!P
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MX:UH7M0<$6$Z"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG^$JNG_9I7QNYL<0O1=F;]!*/+*YY7<\&Y7NX?5(>2OGWBSMQ;X?JKR:D/\
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MX!7E1<3BY1:3P2G@\M'2"'+W^U*[FXKU *J+FC1A0AR06$')R>6$1%:0$1$
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MS2YS1_$>7S7!&-+W!HYDX"]"WARPSZG+-QV8Z!N&NKQ]&H_Q=-&09YCR:/\
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MOI;+4S#,CMP>?-4TNT]W>/EL[=OXLZ=I"'GD9I]XI&?\S/P7X;=Q*<00R/\
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M1.?=+C3T^..ZYXSZ*)^J]O>J+SOQT!CMT!\(^+O5<WEJ[QJ2O#))JJNJ9#@
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MWTS:+O74U9<J&&HJ*<_BW/;G"MI5.[9&"(.S38Y>M6/;45D<E#;N?>/;@N^
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M$;_K-!5AMIM[3D45.#]0+W(@+<<,<0Q'&U@\@KB(@"(B (B( B(@"(B (B(
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M:JF;(WGX_%>I?6T:L:U-5(/*>J,,HN+PPB(K2 B(@"(B (B( B(@"(B (B(
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M!$0#=;T";K>@1$ W6] FZWH$1 -UO0)NMZ!$0#=;T";K>@1$ W6] FZ.@1$
MW1T";K>@1$ W6] FZWH$1 -UO0)NMZ!$0#=;T";K>@1$ W6] FZWH$1 -UO0
M)NMZ!$0#=;T";K>@1$ W6] FZWH$1 -UO0)NMZ!$0#=;T";K>@1$ W6] FZW
MH$1 -UO0)NMZ!$0#=;T";K>@1$ W6] FZWH$1 -UO0)NMZ!$0#=;T";K>@1$
M W6] FZWH$1 -UO0)NMZ!$0#=;T";K>@1$ W6] FZWH$1 -UO0)NMZ!$0#=;
MT";K>@1$ W6] FZWH$1 -UO0)NMZ!$0#=;T";K>@1$ W6] FZWH$1 -UO0)N
MMZ!$0#=;T";K>@1$ W6] FZWH$1 -UO0)NMZ!$0#=;T";K>@1$ W6] FZWH$
31 -UO0)NMZ!$0#=;T"JB(#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g111069g00a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1>,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %V\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM0QVBGD_<4P\<-/-RXM^)5[>J^2Z76JK9W%TDSRXDK+;/+$_4.K*"A8TN89
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MZAV46]^1*756WZT4<+X[+'[JFZGAW +@.M-<7K5U4Z2Z5!\#GQ86\&C[%K&
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MZ_2FMGT[7?NJ9H;C/6N9K(:BKG7*^U]8\Y,LI(/<L>M<5A8*F\L(B+IP(B(
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M $1$ 1$0%N>95%4\RJ+IP(B( O:/R0O%>T?DA 835/P<_P!):8MSU0/]7/\
M26F!::?$\[JO,(B*TS!$1 $1$!4#>( ZSA=!LU.*>@C;UD<5I5F@-1<8F8X
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-NG B(@"]H_)"(@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g111069g00a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1(H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $@L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*/_  !$( 4P'%@,!(@ "$0$#$0'_Q  =  $  @,! 0$!
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M4(_E/_TG#W^&?_ME&EY?RG_Z3A[_  S_ /;*-/5])^J'A>O_ '2  Z7&
M                            G/!9XF+OR#5?PD'4G'!;XF+OR#5?PD&4
MQI_9+HJ_52  V<X                               "<<"OX2+3Z)OV3
MR$O\=WI)MP*_A(M/HF_8O(2_QW>DQH_95_S_ -NBO]5/_7R #9S@
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M<\%OB8N_(-5_"9WOPEMZ?]D(.IX%!>GX9U?,@ )5
M          G' K^$BT^B;]D\@Y..!7\)%I]$W[%YE?\ URW]-^R$)?X[O2?)
M]/\ '=Z3Y-8^&,_(  @                               @3"8\)'_TQ
M^0J7^(AQ,>$CEPQ^0J7^(AQC8_%OZC\@ &SG
M      ( @3'R_5/ 5^#6V?XIOVKP. K\&ML_Q3?M7@\*O\I?3VOPA"/Y3_\
M2</?X9_^V4:7E_*?_I.'O\,__;*-/4])^J'A^O\ W2  Z7&
M                   G/!;XF+OR#5?PD&4G/!;XF+OR#5?PD&4QI_9+HJ_5
M2  V<X                               "<<"OX2+3Z)OV+R$O\ '=Z2
M;<"OX2+3Z)OV+R$O\=WI,:/V5?\ /_;HK_53_P!?( -G.
M                 (3'A(Y<,?D*E_B(<A,>$CEPQ^0J7^(QN?E2Z+7X5(<
M#9S@          DO!U+'!BJEDFD9&Q&OS<]<D3P5\I)TJZ;6Y<*CNB'B'9Y2
M:::*^ GEY"LT!G5;S.6U-WIB(2JZW5UNQ[55])(UR-GSTFKFBMV9_P"1/>$2
M[VRZ<'R55%-"E1531RR0H]-)%S5.3//D0ID\(JM1.)X6HOS3U1RMZLM_?[@W
MM%'0UMO;41MC5S)JED:IDB\Z_6:=MAHL#V2MFJ:N">ZU$+X6,@D;(UJ/;DNU
MJ\Z%7 KVJO,9\2MWJ?%6/,/N>5TTSY'KFYRYJIC -HC$8<TSF<R  E
M   A,<3_ (/,%_\ 6_MD(<A,<3_@\P7_ -;^V0RK_.ET6OUU_P#WVAP -7.
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M^^F>B>M4$U1'R115/Q#E@ZCL/7EL"S.M%Q2%-NFM,_1]>1RQ%43\(JHFGY
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M8@ ;N0     3G@M\3%WY!JOX2#*3G@M\3%WY!JOX2#*8T_LET5?JI  ;.<
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MPY/>+;<;W4NIU722ZS->NBU,]F6?.GEYS.(GJS]-8F.C$?*N0%!W1\/.J^0
M!4  !"8XG_!Y@O\ ZW]LA#D)CB?\'F"_^M_;(95_G2Z+7ZZ__OM#@ :N<
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M@Y..!7\)%I]$W[%YE?\ URW]-^R$)?X[O2?)]/\ '=Z3Y-8^&,_(  @
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MGPRX@-RX>WV>%.ZFKYTI8]XD^&-35\Z4L>\2?#+B W+G*?;[/"G4X&KXG_\
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M@YYJF9S+KIIBF,0Y^*O&IO0[]QP3O8J\:F]#OW'!*K
M                 Z%GY*[\6?\ N.>="S\E=^+/.>
M                 '0L'WUA_2_54YZ\IT+!]]8?TOU5.>O*
M                        WKK_ &3\79^\T3>NO]D_%V?O T0
M                         -ZK^]E!_P S]8T3>J_O90?\S]8#1
M                            Z%GY*[\6><\Z%GY*[\6>!SP
M                         .A8/OK#^E^JISSH6#[ZP_I?JJ!SUY5 7E
M                                  ;UU_LGXNS]YHF]=?[)^+L_>:(
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M+]53GG0L'WUA_2_54#GKR@+R@
M-ZZ_V3\79^\T3>NO]D_%V?O-$
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M7E\5#* /AT4;E17,:JIR*J<A\K!"KE<L4:JOET4,H ^.+9DB:#<D7--G(?8
M           ="P??6']+]53\^?RF_P"<PW_U'_:/T'8/OK#^E^JI^?/Y3?\
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M%4^'J6:)ICR  Q;           '0L'WUA_2_54YYT+!]]8?TOU5 YZ\H"\H
M                                  #>NO\ 9/Q=G[S1-ZZ_V3\79^\T
M0                                   EU@^]4/I=_JH%@^]4/I=_JH
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M*=8A/!A67&JI*UM94.JJ*-[4I)G1)$KF9+FNCEFFWG)L:51C"E$SYR  JL
M           .A8/OK#^E^JI6O"?@!<;NMJI<DH>X^,_\CC-/3T?_ ')EEH_Y
MEE6#[ZP_I?JJ<_RDQ./A$Q$^)49J#=UD3<OM!J#=UD3<OM"\P7[E7*G:IX49
MJ#=UD3<OM!J#=UD3<OM"\P.Y5R=JE1FH-W61-R^T&H-W61-R^T+S [E7)VJ5
M&:@W=9$W+[0:@W=9$W+[0O,#N5<G:I49J#=UD3<OM!J#=UD3<OM"\P.Y5R=J
ME1FH-W61-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0:@W=9$W+[0O,#N5<G
M:I49J#=UD3<OM!J#=UD3<OM"\P.Y5R=JE1FH-W61-R^T&H-W61-R^T+S [E7
M)VJ5&:@W=9$W+[0:@W=9$W+[0O,#N5<G:I49J#=UD3<OM!J#=UD3<OM"\P.Y
M5R=JE1FH-W61-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0:@W=9$W+[0O,#
MN5<G:I49J#=UD3<OM#-5?R?'P<5_\S([C(TD_H.66?D_G"[3>NO]D_%V?O'<
MJY.U3P_/VH-W61-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0:@W=9$W+[0O
M,#N5<G:I49J#=UD3<OM!J#=UD3<OM"\P.Y5R=JE1FH-W61-R^T&H-W61-R^T
M+S [E7)VJ5&:@W=9$W+[0:@W=9$W+[0O,#N5<G:I49J#=UD3<OM!J#=UD3<O
MM"\P.Y5R=JE1FH-W61-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0:@W=9$W
M+[0O,#N5<G:I49J#=UD3<OM!J#=UD3<OM"\P.Y5R=JE1FH-W61-R^T&H-W61
M-R^T+S [E7)VJ5&:@W=9$W+[0:@W=9$W+[0O,#N5<G:I49J#=UD3<OM!J#=U
MD3<OM"\P.Y5R=JE1FH-W61-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0S2_
MR?'QTT$W^TR+QNEL[AY,ER_]0NTWJO[UT'_,_6'<JY.U2_/VH-W61-R^T&H-
MW61-R^T+S [E7)VJ5&:@W=9$W+[0:@W=9$W+[0O,#N5<G:I49J#=UD3<OM!J
M#=UD3<OM"\P.Y5R=JE1FH-W61-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0
M:@W=9$W+[0O,#N5<G:I49J#=UD3<OM!J#=UD3<OM"\P.Y5R=JE1FH-W61-R^
MT&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0:@W=9$W+[0O,#N5<G:I49J#=UD3<
MOM!J#=UD3<OM"\P.Y5R=JE1FH-W61-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$
MW+[0:@W=9$W+[0O,#N5<G:I49J#=UD3<OM!J#=UD3<OM"\P.Y5R=JE1FH-W6
M1-R^T&H-W61-R^T+S [E7)VJ5&:@W=9$W+[0V*3^3V^H2?+$R-XJ-9/Z#GGE
MY/YPNLZ%GY*[\6>.Y5R=JE^?-0;NLB;E]H-0;NLB;E]H7F!W*N3M4J,U!NZR
M)N7V@U!NZR)N7VA>8'<JY.U2HS4&[K(FY?:#4&[K(FY?:%Y@=RKD[5*C-0;N
MLB;E]H-0;NLB;E]H7F!W*N3M4J,U!NZR)N7V@U!NZR)N7VA>8'<JY.U2HS4&
M[K(FY?:%88HL*X9Q=5VA:GNKN;1^ZZ&AI:3$=R9KERY<I^PC\M<+=//5<+%W
MAI6*^5[HFHB?\%AI9N3U>65VW&/"*-22>=M/3)I2N7+F/T/P5\'D6'8$K;@U
MLEPD:G/]SYTV.5%\A\\%7!Y%AZE977%BK<W9[,_YOE3+8Y478663>O35)9LQ
M3&9  <SI              Z%@^^L/Z7ZJG/.A8/OK#^E^JH'/7E 7E
M                              ;UU_LGXNS]YHF]=?[)^+L_>:(
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M?B16_P"GD+%1,D0PQ4D$53-41QHV:;1XQW][),D_R,XCQ&"8S.0
M ="S\E=^+/.>="S\E=^+/.>                                   '0
ML'WUA_2_54YZ\IT+!]]8?TOU5.>O*
M     WKK_9/Q=G[S1-ZZ_P!D_%V?O T0
M      -ZK^]E!_S/UC1-ZK^]E!_S/U@-$
M       #H6?DKOQ9YSSH6?DKOQ9X'/             "-TN$J&+%M??Y&K)5
MU"L5BJJIH91Z"^7;FGU$D!,3A$QD !"0                Z%@^^L/Z7ZJG
M/.A8/OK#^E^JH'/7E 7E                                    ;UU_
MLGXNS]YHF]=?[)^+L_>:(                                   2ZP?
M>J'TN_U4"P?>J'TN_P!5 '/Q5XU-Z'?N."=[%7C4WH=^XX(
M                      ="S\E=^+/.>="S\E=^+/.>
M                   '0L'WUA_2_54YZ\IT+!]]8?TOU5.>O*
M                          WKK_9/Q=G[S1-ZZ_V3\79^\#1
M                          WJO[V4'_,_6-$WJO[V4'_,_6 T0
M                           .A9^2N_%GG/.A9^2N_%G@<\
M                        #H6#[ZP_I?JJ<\Z%@^^L/Z7ZJ@<]>4!>4
M                                !O77^R?B[/WFB;UU_LGXNS]YH@
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ME( BW>*L\UVAWBK/-=HE( BW>*L\UVAWBK/-=HE( BW>*L\UVAWBK/-=HE(
MBW>*L\UVAWBK/-=HE( BW>*L\UVAWBK/-=HE( BW>*L\UVAWBK/-=HE( BW>
M*L\UVAWBK/-=HE( X%JM-335T<TNAH-SSR7ZE0U>\57YKM$I $6[Q5GFNT.\
M59YKM$I $6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59Y
MKM$I $6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59YKM$
MI $6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59YKM$I $
M6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59YKM$I $6[Q5GFNT.\59YKM$I $6[Q
M5GFNT;-=:*F;N?0XOP(6L7-?*A( !%N\59YKM#O%6>:[1*0!%N\59YKM#O%6
M>:[1*0!%N\59YKM#O%6>:[1*0!%N\59YKM#O%6>:[1*0!%N\59YKM#O%6>:[
M1*0!%N\59YKM#O%6>:[1*0!%N\59YKM#O%6>:[1*0!%N\59YKM#O%6>:[1*0
M!%N\59YKM#O%6>:[1*0!%N\59YKM#O%6>:[1*0!%N\59YKM#O%6>:[1*0!%N
M\59YKM#O%6>:[1*0!%N\59YKM#O%6>:[1*0!%N\59YKM&S/:*E]%2Q-XO2CT
M]+;SKF2  1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5G
MFNT2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT
M2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D
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M2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D
M1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D 1;O
M%6>:[0[Q5GFNT2D 1;O%6>:[0[Q5GFNT2D :EJIWTM#'#+EIMSSR7ZU!M@
M  &8          9@       9@
M
M
M
M
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M9[DEDAA:QST:Y<M)43;EFN7I(CYQ)GPL( $@
M
M
M                                #2O%R@M-"^KJM+BFJB+HY9[5R\JH
M;%+40U4#9J:5DL3O%>Q<T7;D!E
M
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M3]3TT\53 R:"1LD;TS:YJYHIE71-,XEM17%49AD !1<
M
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MC51>?8AU !HS6BVSU4=3-;Z22ICRT)7PM5[,N3)<LTR\AO)DB; @
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M$[++44<]=2-\%)V9KQ:(B>,JK^<_2AY=5/3.'ITU=49  56
M
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M%C/F7W@7"%OPC9XJ*A8BN:U$=(J;7*B99YDD .&9R[HC  "$@
M
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M[^\^-%7_ #-@ ?$<;(TT8V-8WF:F2'V
M
M                                           $2X5/_!5=Z6?K(?C/
M@_PG<,87B&@H6.XG2^ZR(F:-3)5YTY<E/VWCBV37;#M11TS5=)(YFQ,N1')F
M:^ L'6_!ME906]%7+-7/7/-WA.7RJO\ >-**^F&55'5+W F$+=A&S1T-OB:C
MF^,_:JN7->=57RDE ,\Y:1&  !(
M
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MFU       )R    \@
M
M
M
9                             #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g111069g00a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a04.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1R\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ')\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@#Z <M P$B  (1 0,1 ?_$ !P
M 0 " @,!               !!@4' @,$"/_$ % 0  (! P(#!0,)!@0$!@ "
M"P ! @,$$04&$B$Q!Q-!49$4%F$5(C)24U1Q<I(((S,T-H$U0G.Q)%5TH1<E
M0T1BP2:"T2=%8Y/A\#=DPO'_Q  : 0$! 0$! 0$              0(#! 4&
M_\0 )Q$! 0 " P$! 0 #  ,!  ,   $"$0,2(3$$01,B410R84(5<8'_V@ ,
M P$  A$#$0 _ /J=R2.MU&NA,UU.I''+*JY]XQWC..>0R3L.7>,GO&<,C))D
M.?>2'>2.&6,LO:CEWC'>,XY&2=AR[QCO&<<C([#EWC'>2..1D3(<^\D.\D<,
ML99>U'+O&.\9QR,D[#EWC)[R1PR,EF5'/O)#O)'#+&1VHY=XQWC..1DG8<^\
MD.\D<,C++VHY]Y(CO)''+&1V'+O&.\D<<C))D.?>2'>2.&6,LO:CEWDAWC..
M1DG8<N\9/>2.&1DLRHY]Y(=Y(X98R.U'+O&.\9QR,D[#GWDAWDCAEC++VHY]
MY(CO&<<L9'8<N\8[R1QR,DF0Y]Y(=Y(X98RR]J.7>2'>,XY&1V'+O&.\D<<C
M(F0Y]Y(=Y(X98RQVHY=XQWC..1DG8<^\D.\D<,C++,J.?>2([QG'(R.U'+O&
M.\D<<C).PY]Y(=Y(X98RR]J.7>2'>,XY&1V'+O&.\D<<C(F0Y]Y(=Y(X98RQ
MVHY=XQWC..1DG8<^\8[R1PR,LLRHY]Y(CO&<<L9'8<N\8[QG'(3)V'/O)#O)
M'#+&67M1R[R0[QG'(R.PY=XQWDCCD9$R'/O)#O)'#+&6.U'+O)#O&<<C).PY
M]XQWDCAD999E1S[R1'>,XY8R.PY=XQWC..1DG8<^\D.\D<,L99>U'/O)$=XS
MCD9'8<N\8[R1QR,B9#GWDAWDCAEC+':CEWDAWC..1DG8<N\D3WDCAD999E1S
M[R0[QG#+&1V'+O&.\9QR,D[#GWDAWDCAEC++VHY]Y(CO&<<C([#EWC)[R1PR
M,B94<^\D.\D<,L98[4<N\D.\9QR,D[#EWDB>\D<,C++,J.?>2([R1QRQD=J.
M7>,=XSCD9)V'/O)#O)'#(RR]J.?>2([QG'+&1V'+O&.\9QR,D[#GWDAWDCAE
MC++VHY=Y(=XSCD9)V'+O)$]Y(X9&6694<^\D.\D<,L9':CEWC'>,XY&2=AS[
MR0[R1PR,LO:CGWDB.\9QRQD=AR[QCO&<<C).PY]Y(=Y(X98RR]J.?>,CO&<<
MC).PY=Y(GO)'#(RRS(<^\D.\D<,L9':CEWC'>,XY&2=AR[R1/>2.&1EE[4<^
M\D1WC..6,CL.7>,=Y(XY&2=AS[R0[R1PRQDO:CGWC([QG'(R3L.7>2)[R1PR
M,LLRHY]Y(CO)''+&1VHY=XQWC..1DG8<N\D3WDCAD99>U'/O)$=Y(XY8R.U'
M+O&.\9QR,D[#GWDAWDCAD99>U'/O)$=XSCD9'8<N\9/>2.&1EB9#GWDB.\D<
M<L98[4<N\8[QG'(R3L.7>2)[R1PR,LO:CGWDB.\D<<L9':CEWC'>,XY&2=AS
M[R0[R1PR,LO:CGWDB.\9QRQD=AR[QD]Y(X9&23(<^\D.\D<,L9+VHY=XQWC.
M.1DG8<N\D3WDCAD99>U'/O)$=Y(XY8R.U'+O&.\9QR,D[#GWDAWDCAEC++VH
MY]Y(CO&<<C([#EWC)[R1PR,DF0Y]Y(=Y(X98R7M1R[QCO&<<C).PY=XR>\D<
M,C++,AS[R1'>2..6,CM1R[QCO&<<C).PYJ;.R$LIGG\3NI=&;QRV$_$Z3NGX
MG2C.0(DCQ)((")#  @$ 9  9&0 &0 !((  9  !       !$D "2  &0@ )!
M  #(  ( "2   R  3)( $D  ,@ "00  R  R$ !)   9  )DD    &0 !((
M!C( #(0 $@@    "  D@ !D  2"  &0  0 $@@ !D  $ !)   9  D$  QD
M!D( "00  R  )( $D  !D "00  R  "  D$  ,@ "2 !)#  9&0 !)  DC(
M ( "00  R  )( $D,  ,@ "2 !)  #(0 $D  !D  $ !)#  #( !$D "2  &
M1D "2   R  )( $D  ,C( !$D "2  &0  1)  #(  ( "2   R  1)  D@ !
MD  $20 &1D  $ !)  #(R  1)  D@ !D  2"  8  !  20  &0 ")( $D  ,
M@! #OH]&=!WT>C-8?1$_$Z4=T_$Z4*'B20P02&0   (
M
M
M
M
M                                  ! ( =]'HSH.^CT9K#Z(GXG2CNG
MXG2A08#!D
M
M
M
M
M      @$ .^CT9T'?1Z,UA]$3\3I1W3\3I0H,!@R
M                  $ A !)
M
M                                           8  -8
M
M                                          (! #OH]&=!WT>C-8?1
M$_$Z4=T_$Z4*# 8,@                                3%9()B\=! :
MQXD+#Z,TIVS]J57:]=V]@XNLNJ9B^QSM<N=R:R[74W&*:Y<_$WU\V/H&*(?(
M1:<>)=&LFMNVS=]UM/1*5S9)<<Y-<S(V2FGXC'Q/D*CVY[DJ-JC0[S\N6=D.
MW+<M&:=>UE&&>;:9KK:/K@&INR[M9LMSS5K<R4+E^;-LKFLKFGS)9H  9
M                                                         !$
MN9.%YGFU.M*VL*]:/TH1RCY<W1VVZY8:U7M:$(M1DTN;-3'8^JUAOJ,'R.NV
MO=.,^QU,>?#(SFT.WF]^4Z=#6*?!3DTO$O4?3N"%CS,'#7J5[MN>HV4E)<'$
MCYFU?MPUZAJEQ;T8)J$W%)-B8['UHFF\9)/D9=M>Z8KB]CJ8_*RT;*[=ZM74
M*=#7(=VI-1\1T'TB#RZ5?V^HV4+FUFI0FL\F>OH9LT!!) H  @
M                                         B2$\$_@ 7D&L=0O,TGV
MT]J-;:]Q.UL7%UHX\2P;KY$I&@>QOM:N=RZTK/47&*:Y/)O]/BAQ+H-".7F,
M&MNV;>%WM/2(W%FDY9\3%]B_:!?;MC_QD5UP77@VXB4LDOJ0NC;Z(FA'@,Q\
M9(T[VM]K%+:]=V5BU.YP:AEVO[MNFZE&UJ.'@TF:Z70^P4D^CR1R/E_9?;K?
M0U*G;ZW!PA)I/J?2>C:E1U.QIW%O)2A-)F;C8/=A8()1!
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M0IYY\2:-Y]F_:-I^[*$(PJ)7+7.+9+CH;  7F3DR(
M   @$ .^CT9T'?1Z,UA]$3\3I1W3\3I0H,!@R
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ME["+V #FH
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MTRB9^588!)!D
M      Y0>,G$F(@\NK7:LM.N;AX7!!R/B+>MW6WMOFO&ES4I</H?2_;ON=Z'
MMNI&E)*=2+B^9H#L+=BMTN^U24>!MOFSKC/ZBOV=O7V-O&T@^7$UGU/MK:FI
MPU71J%>D\KA63Y6_:#EIUUJ$-0TZ<6X_5?Q9LW]FK=3OM$]@K2S53RN8L_HX
M?M1\MM0_,_\ 8KG[+;_=\O,LG[42SMF'XO\ V*Y^RY']U_\ F%G@^ED^9U76
M?9*RCUX7@[>A$L.+4GR.<OJOAWM752EON<K_ (G!5,_VR;[[/]>VA=Z+0ME1
MIJKP*,G)>)[NU+LSTS==1W%*K"-VEC$6:*U?LEW/H]2<K.I45*/-..3K+M%_
MWWV24];UB%WH%2GW>>+"9M[LRT*]T+1G;7[3DL8Y_ ^2]+W?N79VHPC<5:LN
M%X:FW@^LNR_=\=V:*KAXXX)*6/P,Y2P7, '-0
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M*XJQC.OCQ1L^*4(X2Y$RR4 !S
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MDCN3ST.=NU0P200
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MF5_@R )(,*  @
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MVK9PIVL(NHE]/',FY(+-94>YLZ%)+'!!+T/1(<DL$/J85  (
M       ! ( =]'HSH.^CT9K#Z(GXG2CNGXG2A08#!D
M            ( !GD  )R0 !.6,D "<LA  3EC)
M                                                   38 #+&0 &
M1_8 !D
M  +X  3ED  ,DY( $Y";1  GB?FQQ,@ 3EC+( $Y(0
M                                     )R^A  9?F,@ 3DCQ  G+&60
M &1E^8 $\7Q8RR -AED\3\V0!L3E^9&6  R                        $
M @!WT>C.@[Z/1FL/HB?B=*.Z?B=*%!@,&0
M
M
M
M
M                              " 0 [Z/1G0=]'HS6'T1/Q.E'=/Q.E"
M@P&#(
M
M
M
M
M ! ( =]'HSH.^CT9K#Z(GXG2CNGXG2A08#!D
M                         "&TNK2_N!("P^C3   AM+JTOQ8$@A-/HT_P
M)P !&5]9>H33Z23_ +@2"&TNK2_$)I]&G^# D#_8A-/HT_P D   #C4G&G!R
MF\175@<O $4Y1J4U*+S%]&2
M               !X75I?B0FGTDG_<"0,  !@AM+JTOQ D   1E/HT_P#:2Y
MM+\0)!":?1I_@QE>+2 D      P
M               1Q1^M'U D   "&XK_ #+U D!<^CR/[H "$T^DD_[D@ 1E
M+JTOQ":?1I_W D!X75I?B0FGT:?X 2",I=6E^)( #!/(" ,   ,
M                                      $-I=6E^+)6'T:?X  "4! (
MREU:7XA-/HT_P D AN*ZRCZ@2 N?1IC\>0 $<4?K1]20 (>%U:033Z23_N!(
M#Y+FR$T^DD_P8$@AM+JTOQ)7/H    (! #OH]&=!WT>C-8?1$_$Z4=T_$Z4*
M# 8,@!@                                +F !R.+6     !      '
MAUO4*>EZ;6NZTDHPBVCYCUKM'W%N76*U'0:=9QI-_0EY&X^WJ\G9[(K2A+&7
M@UE^S3I]*XA=W-2*<GE9.F/D1[>R[M/OZ6L_).OQG"><9F_B?0M*<:M*-2#S
M&2RCY [6U'2.TNC*WCP\4E_N?5NV*SK;?L)OJZ47_P!C.46/5JM[#3["K<U7
MB,(MGS)KO:+N#<NN5;/0:=9\$FOF/R9]([GL?E#1+FAQ8S!\SY+V]KJV%O*X
ME6I*JG.3SU-8HM>U.T?7-O:]3L-QTZL>/[1F^=?U^%KM7Y4@^4H<2Q^!\O:G
MJJ[1=]V\Z=-4%'Q1NCM:K?)/9A3M8OBG"FEE?@Q9Z-0Q[2-S:C?7/R=3KU:<
M9M)J1=.S3<^Z;W<UO2U*VKQMW])R?(U?V<[FNM"LZTX:7[2I2;XFC=G9?VD:
M9KU^K.O:T[6[?S4EUR6CR]JN\;^KN*WT?2IU(3G'FX/',Q>PMXZMI>ZZ.DZK
M4JU%5?6;S@X]IFD7^D;XM=9MZ$JM"*RV8?;]M?Z[O6CJ]:W=*WHYXI>!9[!M
M_M;W='1]"E0M:C5Y52X%'J>WLKI:@]#IW6I5:DY5HJ24WT-2U)5=Z]H%*/6S
MM:G!)^&$SZ!TVO9VU&G:4:L/W:X4LF*,@"<939"63"I2,#O6I.EHE>5.33QX
M&?17=]?X#7_ L'LVI.4]"M93>6X+F91]3$[1_P  M/R(R[ZBB  0       8
M          8                2&        ,   !,>I$IJFI3ET2R3$\FL
M3=/3;J2\*<O]BP:&[5>U"\>JK2= 4YU7E9@_')5-([1-R;9U.A\O4ZZIU>:X
MWE&'[.8K4^UR<;CYR5277\2^?M*:=1IV5O5C!)P22.DB-\[;U:EK6D6]W2::
MJ04G\#)8YFK/V>+Z5WM!*;SP))&U'T;,571>W5.TMJE:M+AA!9;9\O\ :-VL
M75;<U.VTRM.-.$E%\#QGF7SMQWLZ5NM%TR2E<5N68OFN9\^[IVS6T6_T^M<R
M;JW#4GG\36,1]H;'O9WFU;"YKMN<Z2;;*;VH=I6G;>TZXHT+A.\QR2ZY,YLR
MG5J=GMA"@WQN@L8_ TEO'LNO)VNIZOJE>;X9.48OR))Z,_V$[TO]QZE<RNJU
M24,Y49/)ENUG==]\M6FCZ5.<*E;*S!X*-^S/1[O5KN"Z)M?]RS]J^E7VF;NL
M-7MJ$JE*FVY/R+J;$=E^\M1L=>JZ7J]2I4;DDG-]#U:QNC4-8[0J%GIU:I&W
MHU>":B^1K^A.]G?7FN5J+I1IRXE\2_\ 8M94ZEY>:S?M1[Z?'!R8L&\+>+A1
MA&3RTN;.S!UT*].M#BISC*/P9TN^ME6[IU8<?EDPKU+EX'7<5."E*:71'8N:
MRN://><[6I^#$'CT#4GJ"N.*..[GPF496]DK]W>^?>LLC8I$  @
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MOG?6SJ-8,B5[9C_X!E@% !]6"          3D"
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M13QUP=SY=2Z$9&.9XKK4[.V;5:M&+\LG;9W="Z7%0JQE^# ] #!
M 74E@,\AU( $\B,<A)J*S)X1Y*M_1AE*2;-XX7+XNJ]> >*GJ-*75X/53J0J
MK,'D987$T[$!CER(R8T@P&%U F/0\6M1<]*NHKKW<O\ 8]@G%3IR@^DE@L'Q
MSV82]B[79]]\U.H^OXFP/VFKRG*RMZ49)N231YNU/LUU&UUE:KMZG/O4V_W?
MXE6LMD;KW7JMM'6Z==4J:2S/..1T\^HW%^SU;>Q;.XJOS5))KT-AZKJ,(:9<
M3MYJ4U%XP5^YT*KIFR58Z:FKB%+A7#UR43LMTC<=/6:JUOOI6SF^4\XP9_\
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M  $# P2/,:$ E+ED?B40,$\L<F@QH0 ,$ G (Y>: ($@" 3_ '0*(!( @ $
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M81DKFX=;/1F6&"2 NJ.J\_E:OX'<NIT7G\O4_ 08'972^_U66/Q96]D_^_\
M]9ED?44B#DN:("9!B-V+&@W7Y2C]C[S6O_S?_9>-V?X#=?E91^Q_^-??C_\
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MT9T'?2Z,UA]$3\3I1W3\3I0H,!@R'@2B/ 9%$A>(( 9  $H<R!E@3S"(RQD
M  )"^)&6,L   "     2N@( $D  "?#D0$\ ,$^I&6,L"<9!&63D 0
M    1/X$+J3A / @ED    !."&@!/1$(D" ,@   !7]^?T_<?E,^8#?G]/W'
MY2P>G9W].V?Y$9<Q&SOZ=L_R(RXH  @
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M.>9RTKUX.N[_ ):?X';%IQY/*.J[_EI_@(*_LOIJ/^LRR%;V7TU'_699!2
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MK<O^$U494Q6Y?\*JB#Q[+_DZGXEA*]LS^4J?B6$4@^K ?5@@
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M2I^)82O;+_E*GXEA%(/JP'U8( ")8$                           !@
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M8^)U7/\ !J?@=L?$ZKG^#4_ L%?V3]+4O]=_[ED?5E;V3]+4O]=_[ED?5BD
M@"#DDD0I99  Y-X7(XI^8\#B!SXEY$IG62N@'82<(]3F4<&@LKD<P!Q6<_ E
MK)()1PZ$-MDRZD 1@8)           1Z@=-S;0N*;C-9*QJ&C3IR<J66O)%N
M"2._%SWC>?EX,>3ZU].VJPSQ0:.M4IOI%E_J6M*I])'5#3[>+RHH]4_8\G_@
M:4VC9UZGT8,S6E:/PM3K<_@9^G1IP^C'!V8PCCG^NY33MQ_CQQNZX0IJFDH]
M$<T%T!Y=[>V30@P,X(( ;        2R2! !*Z," 20  & )70@E$% QFY/\
M":IDS&[C_P )K"#';)_E:WXEC*YLG^6K_F+&+](/JP'U8(&? Y>!Q   CQ+!
M,?'!/%A$! & ""5T(SE]$  <61@D 0EYDQ60 'B        $"5T8'FO;=5Z#
MBN;15KFC*C-QDL%QB>2_L87,6_\ ,=.//7UZ?S\W3RJFN1)Z*]G4HS::;1T,
M]$NWTL<IE-Q 8)X'-8@N95VXHR&FVLJU5/'S5XG*PTV=9KC6$6&A1C0@HQ1R
MSSGQY>?]$QFL792BJ<%%$OJ,L@X/G6[KD<0"( (8          !+(
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M,!OG^G;O\I8.W9C_ /P[:?D1FGU,)LS^G+3\B,V*  (
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M99X@B  0        %R)RR !.6,L@ 3EC)  -Y               !.?499
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MS<7^%53*&,W#_A=4S!CME?R]?\2QE<V5_+U_Q+&*#ZL!]00
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M)6>9!E4G=1Z,Z#NI?1+A]"?B=*.Z?B=*%!@,&0!/@04  0 ,$X&A
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M?7].W7X&?1@-]?T[=?E+!V[,_IRT_(C-&%V7_3MG^1&:%  $ # P  P3@:$
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MYD9&0)Y#!"9RP(.(.7"<6L  "4DP(!.$.28$(GD%U9'B !R2SU(:P!
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MQ+&5O97\"O\ F+*A2"^)&"2" "1R @# 0    ,#   D" 2 (!(6 (
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MEE<RHU$DW@LMI6C6AE%26,?$RNB7&*G WR,91Z>#DU>M9_ .4>:.+.3WBY
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MPQADY&0(PQ@G)#9      %R(K_P)_@216?[B98*WL?Z6J?Z[+.RK[(^EJO\
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MEG1+5)<U@ZU;6[YRHTV_RG:0S,\'#V6V^PI_I'LMM]A3_2<P78X>RVWV%/\
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M#T)[JC]E#T.0 X]U2^RAZ#NJ7V4/0Y ;'&-.FGF,(I_@<UG#(1($+J8_</\
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M=;^'/\"P5K9#_>ZK_P!0RT%7V1_&U7_J&6E]!2( !
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MZ,UA]$3\3I.Z?B=*%!@,&1*Z,(+HR4!Q
M 2%TR02N@@XSBI+F>"MI]*IEM/)D0C6],7"9?6"EID,\E(XK2X/JI&>P/[#L
MY_X,6(I:726,Y,E0MX4UR1VI$BY;;PXYC\3'H2NIQ2)(Z)'D3CD0T!)UU9JG
M2G.3Y163L.FYIJM;5:3_ ,\7$04#4NTFPLKNI0E7MDXO'.H>3_Q5T[[Q:_\
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M0V=LB7[[5?\ J)%K3Y%3V-COM5_ZB1:^6.1FK  &0
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M_+JOX'O/#KG^'5?P,3ZK#;)_AW/YBS%9V1_#NOS%F%(/JP'U8(
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M.%X&=*M-MJ-I<UI4J%>$YKK%'J-,=DE:M4W'6=>3;E%O#-SFK-  #( #  #
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MM *OWNJ^;]!WNJ^;] NUG!6.]U7ZS]!WNJ_6?H0VLXP5CO=5^L_0=]JOUGZ
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M;]VZ47*7#R2-/;4I:T[BO["I495'SE*)O#4*]"A;R=RTJ>.>3ITMV=2GQV?
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M'L>O_>_^PT=UOP,%0]CU_P"]_P#8>QZ_][_[#1W6[A'"5'V/7_O?_8>QZ_\
M>_\ L-'=;T<H<I+D4[V/<'WK_L%9[@RO^*_[$OQ+FVYI67:KJ>KA:-=Z79;E
M]G^;>8_L>SV+<_WW_L>;+Z^3R7_9>,/R&'Y%(]BW-]]_[#V+<WWW_L9ZL+OA
MC#*1[%N;[[_V(]BW-]]_[#0O&'Y##\BC^Q;F^^_]A[#N;[[_ -BZ%XP_(G#\
MBC^P[F^^_P#8>P[F^^_]@+QA^0P_(H_L.YOOO_8>P[F^^_\ 8@O&'Y##\BC^
MP[F^^_\ 8CV+<RY^V9_L47<'ATB%U3MTKV?'/S/<2@ " $ @!WTNC.@[Z71F
ML/HB?B=*.Z?B=*%!DHCQ)1(*UOK29:IHU:%-9J*/(I6SMSST.$K+4:,XJ')-
MKD;;X4XLPVI[>L-0EFO36?@BRBC[OW@M1LG9Z?2G.53E\U9,SV>Z#.RT:3N(
MXG6CS3,W8;9TZQGQ4*7->:,U%)+"Q@O8:;G4NMJ[JN*[I3=M4GU2Y8+#K^_*
M%?2JE*SA-UJD<))%WU'3K;4(.-Q!-?@8VUVEI=O552%/,ESYI&=HK?9=HU>@
MZU_=P:G6\S8;HTFVY0@_[$4H0I048))+R.39=JZY4:?"TH12?DC46Y+&[T'<
MTM2I4Y2HSEE\*SR-PKFCSW=E2NZ;A6@I)^:)L5&EO^R]DX^"2GCI@J%G;7.Z
MMT.\5*<:$7E<2P;!>S-,X^/N^?4S5A94+&BJ=O!12^!9EI'CK;<L+AJ=:BI3
MPED\.H[6TV%A7E"@N)1>"S1?(XU$IPE&2Y-8&U:5V%H]&MNFXA7HONXY:RC<
M=M;PMJ:IT4HQ1YK/2;6TKRK4(<,WU9[R;!-C$?%+T )L,0^JO08A]5>@ V&(
M?57H,0^JO0 NQ$HQ<7B*]"L:M3X:W18+0C#:]1Q#C1O"O/\ HQWBP./@@E\$
M3T(.CYVD\O)#E\" %,?@,?@ #1CX(<O)  3R\D0E\$ W@!".9KDBTZ70X:"R
MD5NUBYU%A99<;2*C1BO@8RT]7Y<?;4Q44NB)^;]5>@9!S>XQ'R7H,1\EZ $#
MACY(<"\D!D!P+R0X8^2]!E@!B/DO08CY+T  G$/)>@Q#R7H0 )Q#R7H1PQ\E
MZ  3R(?4  NC,#OO^F[S\IGET9@=]_TW>?E+!SV1_3=G^1&<?0P>R/Z;L_R(
MSCZ"_1  (-==KE*YN*=G2MZ<YISP\(M6RK9VF@T*<H\,EU1F*M&G6QWD4\=,
MG**45A))%V.6$V:S[0]!N87U/4K&#<XOB>#9?3H)I5(8DDU\1*-9T=_UZ>G.
MC.SK^T)8SP>)Y]D:-=:CK=35-0A))\TI&R'I%G*7&Z4>+KT/33IPIQX814<>
M2+:.6$WC"P3PQ\D2EA$&1X]9<UHUXX)N:I2PEYX9KOLJT^O'4K^XN:,HN3RG
M)&T,*46I<TUS1UT:-.CGNHJ.>N$:G@[<Y70K>]],K7^ES=NWWD4\8+)GD.33
MST)/!JK;F[[K1K;V2_M:\W#DGPL\>H5[_>&JT8*A5IVL)9:DL<C:M;3;2X>9
MTH\7X'=;6M&W6*<(K\$7=1T:191L+"G;TTDHH]J<ET&/0$VIDG*(9!!RR==9
M<5&2^!S\ O%,N-]6*?=0X*LD^IUIK!D]9H\%5S2Y,Q9]'&[FW?'V)RAE$!%5
M/(+!&!@+I/+R&5Y$ J:.1*( $C)Q!%TE,#H &3-Z#2>>-F%IQS+!:]-I=U;+
MES9RYKK%SSOCTMO(\&/$8/#_ %QB,_$)^;& D4<LHAOR9 P0,_$+\1A^1,>H
M #Q&  _L,@ F)#\" !PJ_P .7X',X5?X<OP+!6=C?S&K?]1+_<M3ZE4V-_,:
MM_U$BUL4@G@XRA&<91J+,62/ D%5U/8VE7M:57NG&<N?)X._1MG:9IE55:=+
M,UT;>2QY8+;L,+&.6"O:YM/3M5J.I6I?/\UR+""2Z%2TS8NEVE55'2XI)\LO
M);*,(4::A!)170D%V.3?(AODL$ ;&,UG1++5J7#=TE)^97*?9[I4:O$X2<4^
MG$78#8\NG6%O84%2MH*$4L<CCJNF6VIT'2NX*<? ]@)L4I=GNE]\Y<#X<].(
MLVE:3::925.UIJ*/>"[$\N9"74$Y((R_@,OX %V&7\"4^I!*(*]NF'[A/QR5
M=+X%XUNAWMK+X+)2IY4FGX,^M^3+<T^/^W'63C@ 'M>'820 ;",$@&T8&"0-
M&T8&"0-&T)'*$<S27F%T/5IE)U;J,4LF,\M8UKCF\M+?I,."VC^![EG'0Z[>
MGP4HKX',^%G=Y6OT/'CUQD3G\!G\"!@PVG/X#)"6>@ Y<1&?P(PP78G/X#/X
M$8&&03G\">?DCCAH98'+GY(9_ XY $IKQ(?4( 2>'6?\/K?@>X\6M?X=5_ L
M&"V/]&\_,6HJVQOHWGYBT"_1*.JXEBC/'-X.WX$8Y/R)!J3;VG5ZV^+JO6I3
M4(S>&T;;?0ZZ=O2A-SC%*3\<'/S+L8K<VFO5-'KT(/$Y1Y-&LMNZMJ&UKJK;
MWE"M5IIXBU')N-/!YKBQH7/\6G%_' E&KMQ;FO-Q4O8K"VK4U/E)N.$7+8&@
MO1],3J1Q6FOG&>MM-M;>6:5.*?G@]JY9-;'#@@^L5G\#SZA:1N;*M1PL36#T
M$YRFL&!IF-'4-H:Y4K4Z,ZEO4?-06>1FM0W[4N+6=*VLJZJ26$^ V/4MZ5:+
M56$9+XH\M/2;2G/BC2CG\#4J*)V>[>N'=5=1U"/SJO/$C83T^VE]*E!O\#OC
M&,(XBDEX8.<>:%RVJM;NTVB]#NE1H)SX'C"*SV4:;*%";N:#C)/EQ(V15BI1
M:ES3ZG71I0H_PXJ*^")L=L>7(-\R 03R)31Q) P^X89I*217\XZ%NU*BJMNU
MY%3FN&4EY,]'%\?2_)EO'3CEC+ .KUZ,L98 -&6,L &C+&6 #1EC+ !HRQE@
M T'*BN*HE\3BCU6%/CKQ2Y\R7XF5DE6BQIJG;+ESP=T<8(2Q!+X#P/);Z^+E
M=W:<H91 )ME.4.7P(!=B?0<B 02L$X.(RP.6!@XY8RP.6!@XY8RP#QGD
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M#KJ_0E^!F"L[&_F=6_ZB1:O$JFQOYG5O^HD6OQ+2!!+P00
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M%O\ <5ZLW%9NI2S\13[2]S6E2G?W<D[";3\>@OP?2J1#,3M;5HZSHUO>P_\
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MHVML;^9U;_J)%L15-C?S.K?&XD6Q&:L<0 9
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MM9_P^K^![&>/6/\ #ZOX$&"V+_[S\Y:2J[%_][^<M1*0?5@/JP0
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MRF>\&8'?7]-WGY2P<MD?T[9_D1G&8/9'].6GY$9QBB  0  @ &     !(
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M!V%5V._^)U9?_P"1+_<M<7U*KL=_\5J__42+4,B  ,@
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M2I2?S<],99;-Q]E6CZSJ#N:N82;RU'Q+;MS0;/0;*-O912BEAO'47+<&79"
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M(($B.2!/@ (!.1D"#BSD%'(T.,3EX#AP0-""8@$T)Y @#0CQ!(*.(.6"< <
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ML(UO[Y:>Y/E/T9/OCI_E/T9FYZ=9J3_X6E^DX^P6GW:E^E'TO'HFV%]\=/\
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M09[0X_N<F51X],I=W12/<L8.5^OJ<4UA$$CD0S+H9" 11(  @9# #(R 38
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MZLXV-*>8IMK*_ W:C-\$&$WI_3-[^4S9A-Z?TU>_E$$;+_IVS_(9WP,%LO\
MIVT_(9U]!?I$  @      7B  8\24^7,AC0  "6$0$\ 21GX  ,A  22GCH<
M1DHQFN4>.DI117O$N56FJE*47XE7U"WE0JM8^:>S@SEFG7')Y0/ >!V=
M            !#H'R.=&#G))+(7;(:+;\==3QR18L81Y=/H*A22\6CU>!XN7
M/M7GRNZ@ '%D             3'Q%7^'/\!'Q%7^'/\  L%2V/\ S>K_ /42
M+85+8_\ -ZO_ -1(MHH  @                        F/B8G7[;O;=N*R
MUS,JCKJP[R$H^:.G%GTRVY\F'?&QKV2:;1",GK%D[>LVE\UF,1]KCS[3;X'+
MC<,M5 YG('1A (\22H         > 4DFDWU%\7&;=UK2E6K*$5S+Q8TNZMX1
M2YX,-M^Q?#WM1+/@6."PD?*_5S3*]8^Q^/AZ3LF/3F&2B)X2R^1XGN1X$8$9
MQDOFM,D!'J#CQ1SCB6240!@ARC'Z32_$E<^:?(N@P,$3G&"S.22^(@U)9BTU
M\!H3@G!PE4@I<+G%2\LG),@D>8'F!!YM6_D:OX'I/+JG\A5_ L%>V']*_P#S
MEK*GL/Z5_P#G+8*0?5@/JP0$ !L,C/P  9^ S\  &0  R  )( +L  0
M    @2N@'&<%4BXRZ%<U.QE2J.4%\TLI$Z<:D<329TPRT[<7+<*I+6&0N98[
MK2(3;=/J8Z>DUXODHX_$[S.5]#']&%C&OD3'FCW+3*\N6(G?;Z/6?TN%+\1W
MD:O-C)]8N$7*6(]66#2;!4TJE3JST6FG4J#S)9D>]8X<8.=Y/^/'S?H[>8H7
M+*0().+QH )((!)                       " 0 [Z71G0=]+HS6'T1/Q.
ME'=/Q.E"@P&#(E=""5T(*  (                       D<@(1U5Z:JP<6
MCM.$I*";8E2Q7;^RE3;DER,74G&&>)X+!J-[%1<8X95=0HSK2<HL[XOE_HUC
M_P"I5OX0>#R5-0;^@>:K1G#.4V=.'^!T?/RY,GJ=]4(]NJ>9Y2 Y]\O^O9&^
MJ>9ZZ-_'_-U,0DSG&G.71,S6\.3)8*5>$UU/5;T'6EB*R8.UMJG)M\BQZ575
M!XET,V>/;PWM?]F<TRT5&&9+F>+6=K:;J]=5KRDI37BT96VK1J0^:T4KM5WS
M;[4T:M)S7M#CR2?,Y[M?6PDD\8?M5W9I6V-NU;*@X.HX\"C$UI^SAMZZK[BK
M:Q4IN-)MOFO,IVVK6KO_ '%[;K%[3IVW'Q<,YGU3LR&BZ=9PL=+N*,Y)+*BU
MEB^-,SJM6WL[&M7JQ@E&+>6CY:H4JW:#VE8<<VU.IP_#DS<O;YK+TO:4N[EB
M<FUR>/ JG[,^DJ>EUM2JQ_>RJ93:+CY-C=VDV-/3K"C;THJ*IQ2Y'JZIG&K5
MC2A*=2245S;9C++<.FW=:=*C<TYU(Y^:I<S/U34M(LJCE=5*$)U8K*?#S/EK
MM?W1J.JZA/3IT)T[2$^#,HX6#>NL=JVDZ;KGR9=4ZD)YQQ2Y(K7;1+0;S9T[
MJC4H]_465PXST9J2Q&;[([*TTS9#]CJ1G.5)MJ+\<'S?J/RU'?MQ=6EK5E4C
M5EPMQ^)M#]G;4JUMHEU4N%4G;P;Y=>1=]N[YVIJ&XIVT*$*5PI-.52*QDORC
M5>E]IVNZ%JM"GKM&4:$FNL5_^@VMOFR6_-B0KZ;AU))227@:_P#VEKG3*U:U
MC92I2JM+'=X\S9'8#;UZ>TJ?M*;C**QDNQIJKI>OZC9T=#E0J*%/$,N/+D6#
M=U6K:Z3IVV;6>:M2*A44?,WONF]LM$TBXO:M*FN!=>%)FB=D6%?7=<U#7J\6
MZ="3G3R-[&U-D5-(VKH5M;W%S0IW$HKC3EAY+O87UM?TN\M*L*L?.+R?)ME9
MSW5K&L3N:\X*WF^%*3+]V :K<4]6U+3I3E.E2EPQR\F<H-]^+,)O3^FKW\IG
M&8/>G]-7OY3"HV7_ $[:?D,Z^A@ME_T]:?D1G? E^D0
M         .4>1X]3ME7IMI<T>OP'^QK'+KZLNE-K4Y4Y-,ZX]"R:A8*JG.G]
M(KU:$J<W&2/?AG,H[8Y2^.(("9II(          8!',)-OD4VYQCQ/!F](L6
MDJDUT.K2]/XOGU%A&<AB*2BN1YN;DU-1SSR_@"?BB#R.8"<# TB
M    $IX(J_PY?@!/^'(L%2V-_.:O_P!3(MI4MC_SFL?]3(MRZ,40 "
M                   B40B<@>2^M87-&46EGP*9?VD[6LXR7(OR9X=0L:=U
M!J:YGK_/S_X_KR?I_/.2;GU1@^A[+_3ZMM4>$W$\2\GU/J89S.;CXV>%PNJ
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MD$<@%VG &>1 $@9Y!/S" #(* \03D@@GP(&0                      $
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M'U8#ZL$
M                 " 0 [Z71G0=]+HS6'T1/Q.E'=/Q.D43X@A G\$@G*2Y
MF+O];LK%XK5H9\DQ!DF2C':?K5E>O%&M#/DV9#*\.8$D'FO+ZA9PXJ]2,<>#
M9C[?<^FUZO=QK1XGYL@S((A*-2*E"2<7XHD: DXG"YN*-M3XZU2,8KS98.T&
M$CNC3)5>!5HYSC.3+6]Q2N(*=&<9Q?DP.U/S& 1.480<I-)+J)!)#/'::M:7
M5>5&C44JB\$>QBS0  @$I\B !R\,GEOJRHTF\GI;Q%Y*]K%QQ3<$^1K&.?+G
MUQ8VO-U)R>3K'@#K/'R[=@ *!!(P!      ,@   !E]'N>&2A)F?B\Q*;1EP
MS31:;&JJE-<SEE'M_/GN:KU$CP!C3UH!/@0 R202BP0,A@@9   ?B  R%X@
M3X&#WI_35Y^4S9A-Z?TU>?E+!&R_Z>M/R(SG@8/9?]/6GY$9SP(0
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M)?\ !5?P/2>74OY*K^!8*YL/^)J'YRV%3V)_$U#\Y;!E](/JP'U8(
M
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M@JG>0X<9ZFD]SW\*^^X.@^7'U1K6T;R@\P4O!K)2.T3<OR?93MK5MUI?->/
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MVI?R53\#TGGU'^2J_@6"M[$_B:A^<MA4]A_Q=0_U"V"D'U8#ZL$
M
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MB,YX$(
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M@I!]6 ^K!
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MMI^0SG@0@
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M"L[#YU=0_P!0MV"H;"_C:C_J%N%^D  0
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MJ]_*9I2Y&$WJ_P#\-7OY3,5&R_Z=L_R&<?0P6RW_ /AZS_(9U]!1  (
M
M  F/B14^BR8^)%3Z++!4MC?S^L?]3+_<N'BRG[&_G]8_ZF7^Y</%EHX  R
M                       QR"Z ;T*UN&U^<ZJ17G](O]Y05>C*+6>12=0M
M7;5FI966?5_+R]IJOC_KX>N7:/, XCA/:\.G'Q))P1@L0 P       CE"#G)
M175G'\#,Z!8RJUE4G'YJ\SGR\DPCMQ<=SNF<T2T[BWPUUYF28BE%82Z!\SXG
M)EVNWWN/#ICH !S;             !$D(D"%U.C4?Y.K^#.]'3?_ ,G5_ L%
M7V%_&U'_ %"W%1V%_&U'_4+<*  (
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MI_35[^4Q%<=E_P!/6GY$9WP,%LO^GK3\B,\^@H@ $
M                                                3'Q(J?19,?$B
MI]%E@J6QOY_6/^IE_N7#Q93]C?S^L?\ 4R_W+AXLM'  &0
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MCZE_J%O\"TB  9
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MU>?E,X8/>G]-7GY1!&ROZ>M?R(SG@8/97]/6OY49WP%$  @
M                                                     "8^)%3Z
M+)CXD5/HLL%2V-_/ZQ_U,O\ <N'BRG[&_G]8_P"IE_N7#Q9:.  ,@
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M4=A_Q]2_U"W"D  0
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MY3.>!@]E?T]:?D,YX"@ "
M                            "$^<6%U#^BRP5+8_*_UG_J9?[EO\2G[(
M_G]9_P"IE_N6]"D0 "
M                       B2$2!".F^YVE7\&=QTWO\I5_*RP5?87.OJ7^H
M6[!4-@_S&I_ZA;Q?I !]6"
M                                ! ( =]+HSH.^ET9K#Z(GXG2CNGXG
M2A08#!D2N@2?4+H%+S**QN_;3UM0G2N)4:D.CB4ET]Q[?K/NY5;FE%^.3:>H
M:A;6-/CN:JA'XE*UG?5LG*C8QC<-\L)9+$<=)[0J<I1I:G35"?1Y+S9W5&\H
M1JV\U*$EE,TQ4VW>[DO55G:.WC)YSC!MG;6E/2=-I6[DY.*QD7'0RRZ&F]^U
M9W^[:%G5;=)3Z&Y/ U7VEZ1<T=0HZG:4W)QEEX+BK8FDZ9;6EA3HTZ<5'A-:
M;^LZ>D:Y;7=J^!RJ+BP9;1NT*V]@A&YDHUHK'"T4C>FJ76JZA1JS@XT'-<+\
MRR5&U]7U#CV?6K-\Y4O_ **!V?STNC"K<ZIP-R;^D6FMI]Q?[-I4*&7*4<<C
M#[<[/:GL_P#QLWAOZ+?0@M5C<;<O*G#;PI2EGX%EH4:=&FHT8J,%T2-1;NVI
M7T&,;S3JDDH\VD_(O'9_J\M4T6G*K)NHN3R3^;5:402/$R()70-H1_% 0S&Z
MY+AMC)O\48;7WFEC*-2.7-YC6!Z@B+Y=43GXHZQ\Q&"<#/Q0S\44,# S\4,_
M% ,# S\4,_% ,# S\4,_% ,# S\4,_% ,# S\4,_% , 9^*(S\4!. @0NH'L
ML9\-9%II/-.+*C;O%6);;?'<QY^'F<\WM_+?KGR!/(<C#UF!@C'Q0Q\4!.!@
MAX\UZC^Z D@?W0S^ #'(#(Y>9 ")011!A=Y_TU>?E,T87>G]-7GY0.&ROZ?M
M/R(SSZ&!V5_3UK^1&>?04B  0
M                                \0_HL>)#^BRP5/9'\_K7_4R_W+<B
MH;(_G]9_ZF7^Y;T*1  (
M                        ")(1($'3>?RE3\IW'5>?RM3\K+!5MA?S&I_Z
MA;BH[#_F-2_U"W#+Z0?5@/JP0
M                                   (! #OI=&=!WTNC-8?1$_$Z4=T
M_$Z4*# 8,AX$I)A=!DHH/:+;V]>O;JYOE;TUUB_$\NB5]J:?!<56C.HO\V"U
M;AVY;:W*#N/\IA'V=V'D:1DX;PT*FE&%U!)=,(SUE>4;VA&K;S4X2YIHI_\
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M-&/U^TE?:3<6\>LU@#Q;*S[O6OY$9[P,9M^TE8Z71H3ZPC@R1
M                                                           !
M_E9..1'^5E@J.R/Y_6O^IE_N6_HBH[+A*%_K&5R=S)_]RW/IU%(@ $
M                                                          !$
M_P"Q  '5>+_A:GY6=IU77\M47P8@JVPOYG4O]0MY4MBTY0N=2XEC-0MF1O9#
MQ8
M              0" '?2Z,Z#OI=&:P^B)^)TH[I^)TH4& P9#P'@2NA!0)R0
M,@2G@-@+Q(()R1D 3R^!&!D9 E<B/[(D %R _ > V()RL$  $"4('@>#5X.5
MNSW]#JN8\=-HU&<YO'2G26&T1@[[ZFZ562/.GR.T]CY.4U=)()( $H@ <@1D
M9 @        E$$H  .O0(R&E4^*LFRRQY12,/H=!NGQ/J9DY95]+\^.L0 &'
M<    <@ )(
M                               E$! #IM[6C;RJ2HP47-\4OBSO071D
M
M           AI--/HR0!TV]M2MW-T8*+F\OXG<
M                                                    " 0 [Z71
MG0=]+HS6'T1/Q.E'=/Q.E"@P&#(E=""5T(*  ( 8          G/P(    "8
MD$KH((#7S240BHP>L6_-S2Y&%PLEPNJ*J4FF5:ZHNG5DF=,:\/Z./5VZ" #3
MS  *             "/$]%G2[VJHI9.F*R\(SNBVC@^.74SE=.G%AVR9.SI*
ME32QX'<^I*9#ZG*OIR:F@ $4  $@  020
M
M
M
M                          " 0 [Z71G0=]+HS6'T1/Q.E'=/Q.E"@P&#
M(E=""5T(*  (                !*9  E]0@& ?/D8S4[)5(.4>N#)H/FL,
MN-9SPF4U5*JTY0;3."^)9+_3U5RX\F5^K3E2DU)'69/F\G%<*X )C)MR0 "*
M     !*(" DE? A<S(Z?9.LTWT)O2XX7*ZCCI]I*I44GT+)0I\$4D1;4(THI
M([6^9RMV^EQ<72()?0DXOJ9=0     SR&0 &0P
M
M
M
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M:;E)U$9FE1C2CB*.S\"#%NWLPXYA\2AT(R,F72)SR(
M
M
M
M                                               $ @!WTNC.@[Z7
M1FL/HB?B=*.Z?B=*&0, &1*Z$! H  @                        E!8$1
MCJ% N387Q& B'%-'"5*,NJ.S R7::CH=K3?@%:TUX'<F3CXC:=8Z5;P7@<XQ
M2Z(YX"0W5F,@@&A@BB^)!+Z$
M
M
M
M                                  @$ .^ET9T'?2Z,UA]"?-/"9TJ+
M\GZ &K/0X9>3'#+R?H 9T'#+R?H.&7D_0 :#AEY/T'#+R?H -!PR\GZ#AEY/
MT &@X9>3]!PR\GZ #0<,O)^@X9>3] !H.&7D_0<,O)^@ T'#+R?H.&7D_0 :
M#AEY/T'#+R?H -!PR\GZ#AEY/T &@X9>3]!PR\GZ #0<,O)^@X9>3] !H.&7
MD_0<,O)@#0<+\GZ#AEY/T &@X9>3'#+R?H -!PR\GZ#AEY/T &@X9>3]!PR\
MGZ #0<,O)^@X9>3] !H.&7D_0<,O)^@ T'#+R?H.&7D_0 :#AEY/T'#+R?H
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MGZ #0<,O)^@X9>3] !H.&7D_0<,O)^@ T'#+R?H.&7D_0 :#AEY/T'#+R?H
M-!PR\GZ#AEY/T &@X9>3]!PR\GZ #0<,O)^@X9>3] !H.&7D_0<,O)^@ T'#
M+R?H.&7D_0 :#AEY/T'#+R?H -!PR\GZ#AEY/T &@X9>3]!PR\GZ #0<,O)^
M@X9>3] !H.&7D_0<,O)^@ T'#+R?H.&7D_0 :#AEY/T'#+R?H -!PR\GZ#AE
MY/T &@X9>3]!PR\GZ #0<,O)^@X9>3] !H.&7D_0<,O)^@ T'#+R?H.&7D_0
M :#AEY/T'#+R?H -!PR\GZ#AEY/T &@X9>3] HOR?H -!PR\GZ'=3Y)Y -8P
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g111069g00a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a05.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1C^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &.$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"C_P  1" ,(!N\# 2(  A$! Q$!_\0 '0 !  (" P$!
M      8'! 4! @,("?_$ %L0  $# P$$! @("P0'!@4$ P ! @,$!1$&!Q(A
M,1-!47$(%"(R-V&1LA47-5)6=(&Q%B,S0E-R<W6AP=%4DI/A)"4T0U5BE"8V
M.(+"\"=$8]+Q&%>BLV3#XO_$ !H! 0$! 0$! 0             " 0,$!0;_
MQ  W$0$!  (! P(#!P,$ @(" P   0(1 Q(A,01!$S)1(D)A<:&QP8&1\ 4C
MT>$4,U+Q%5-#<I+_V@ , P$  A$#$0 _ /JD
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MA 039;=M25M#64FL+?+3UU)+N-G6/=9.WJ<U>OD3MO(FS55C=P !C0
M
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MDGCA1%@N4<2I'(G8J\LF]%]_+/B2^/"S  0Z
M
M                                                    !PO,Y.%
MI6G_ /$E5_46_P C$OUS^+S:?>:I$W:&YT3JAK>2+,B?Y$YBT14-VIS:J6J9
MT$E.D/0;G%%3''.?49&T70M/K%UL=,](W4E0V1R[N=YB<VE8WMC/PLO]=_\
MVFSOE?RL_I_FD7H[.ZU;#KE+.G^FU]*^LJ%ZU>_C]RH:73M/-5>#5/'39Z3Q
M>1W#L1V5_@6[JBS.N^F*VU0/;"L\"Q-<J91O#'(UVSW2S]-:-I[)6R,JNC:Y
MKW(W".157A@W*]4S_'6OZ;,)TW#\-[:+P?ZREJ=F=LCIG,Z2#>CE:B\4=GK(
MIX1M1#45NFK; YKK@^K:K4;YS4WD,R^;&ZJGN516:+O]39O&7;TL+<JS[.*&
MTT/LE@M%UCO.H+A/>+PWBV2;S6+VHA6\<LYR6^^].>LIA>.3\&BVQ1?]MMGT
M<GE8J$1<][2Y+K\EU?[%WW*0_7FB*C4FI-/7.&K9 RV3=(YCF95Z93@BYX<B
M:5<*STDT*+NK(Q6Y[,H<\N_%T^^[^KK)KDW[:G\J=\%[AI>])G_YU?N/;8G_
M -^->?723[)-$5&B+374E35,JEJ*A9D5K-W"8Y<R.5FRJZTNMY;WI[4$M%3U
M,Z3U%/NYW^.53GR.MREY/PLU^W_#ACC9Q_C+;^M_Y:>5$7PI8\IRI/\ _66%
MMF]&=_\ JZF#^ -4NUMNKUK&= D'1=!N<<[F[G.?Y$DUS8Y=1Z4N5IAE2&2J
MBW&O5,HW[#EGWX\9/:?S7IGSV_E^RN]&5EGHM@U(_4L;WVIT:LF1K5<N%<O8
M1VBV25WBD-UV>ZNJ(*6H:DD;'N5,-YHF4_F6KI71D5OT%#IJ[*RLA1BLD5&[
MJ.15SR*^EV-W^VRK!I?5]916U554A=E=WCR3"H=<LI>3*R^7GX\+.+'&SQ&;
MLHU?J3\+Z_2.KGQU573,WV5+$3.$3DN.?>7*WD0?9WL]I-(+453ZF:ONE5A9
MJJ=<N7U(3A.1&=EUK^J^.6;W_0 !#H
M
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M5ANJ7F\W&HNUYW<)-,O!G<ATQRGO>WTKGEC?:=_JLD '%W
M
M
M
M
M
M
M
M
M
M
M
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MKZ)JYDIF.SN(I<VC=00:FTY17:E3=94,1RMSYJ]:%7'MM,R[ZK=@ E0
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MK34^F]5T.F->1PS/K/R%9$[*.7UET(N2KCKO[,QRWV<@ E0
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M3QR*O2Q8PK'IS124H4[X-\:K9[]4PM5E#/<'NIT7EN^HN)O(9S5[?@87<[@
M(6      7DH"\E H*XUT6E/"(FN%\7HJ&X4R10SN3R4543^F/M)[M(UI8J'1
MUQ1:Z&>2>%T,443D<Y[E3")A# U]<=+7S5%/H[4]!(LTS.D@JG8:U%5%\UW:
M:.[[/=';.]/72\11=-6LA<D"U+T<J.5,)NH;=7CDR]O'XLFYR6X^^OZ,[P89
MGR;/'->N4952(B=G$MTK/P>+5+;-G-*ZI8K)*J1\^%3"X5>!9ATYOGKGP_)
M ')U      BNJ-"6?4]XHZ^\QR5'BB*D<*NPQ57K5.LE0$[799N:JCM Q,@V
M_P"J8H6(R-E,C6M1."(CFEU5=)!5PK%51,EC7CNO3*%,:'_\0NK/J_\ ZFEQ
M76XT]KM\];6R-CIX6J][E7'!"\K]C"WZ?\LU]O*3Z_Q'>:6&BI7R2N;%!$U7
M*J\$:U"G-&R)K?;)6ZGMZ+\$6Z+Q6.94QTS\<<>H\8JR];8:E\$?26G2$;\2
M.Y2529Y9["WM.V6WZ?M<%NM,#(*6%,-:WK]:]JC&='VKY_SNFWJ^S/'^=FT
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M<>TKCUCEACKOV[_G/X<\Y<YE=]N_Z?\ *]6\CDZPYZ)F]YV$R=CDZP
M                       =95W8GJG4BJ4]X/,;9GZKKG?E9KB]%7U(I<3T
MWF.1>M,%+;$:Z&T:FU9I^KD;%4I7.EC:]<;[55>17'YRGX?S$Y^)?Q_BMYX1
M-.V39I62KYT$L<K5]:*3?2,SJC3%JF?YSZ6-5_NH5UX1EVA32$=FBD:ZNKZB
M.-L2+EV,\\%F:>I5HK'04JIA88&,7[&H@Q_]=_/^#+YY^7\M@ "5
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M>H .;H
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M72/S:BJ7S>YO''M+)&#9E<9J)N,MW1.0 )4
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M7M5[V0.X;C<IE/6>=NNM70*Q(I'NB;_NW<4#%B@QK?5-K*9DS,X<G)>HR0T
M         '"KCK.L<C)$58WM<B<,HN3'N_"UUJIP7H7\4_54J7P7YI9M'79T
MTLDCDN4B(KW*Y43=;PXFR=MIM[Z7*G(! 8H          !3S;*QSG-:]JN3F
MB+G!Z%(;&)I9-J^OF232O8V5-UKGJJ-\I>2=1LFY:FW5D7>@" Q0
M  !T9*QSU:U[5<G-$7BAW*&V33S/VY:SCDFE?&W>PUSU5$\KJ0V3<J;==E\@
M Q0          !Y]*S?W%>W?^;GB>A0U[GF;X3MKB2:5(EIVJK$>NZODNZN1
MN..TVZ7R #%           'FZ5B2(Q9&H]>3<\3T*%UC/,WPF]-Q-FE2)U.S
M+$>NZO"3JY%8S:<KI?2<@$Y E0          !YOE8Q41[VMSRRN,GHI1?A(3
MS0WW170S2QHZJ>B[CU;GBSG@W&;NDY74VO1 <-Y')B@
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MR,<]S6O:KDYHB\4.Y2&RJ:5^VS7K'RRNC9(NZUSU5$\KJ3J+O-LTG&[@ #%
M       !PIR<*!T;*QSU:U[5<G-$7BAZ(4-LHGF?MWUQ')-*Z-F_NL<]51/+
M3DA?*<C<II.-V  Q0        %Y +R \^E8C]Q7MWU_-SQ]AW0H:^SS)X4MH
MA2:5(5I458T>NZOXI_5R+Y:;9I.-WMR #%         Z@ /-96(]&.>U'KR;
MGBIW0H;:#/,WPBM*Q,FE;$Z-F6->J-7SN:%\IS-LTF9;VY !B@
M>;Y6,QOO:U5X)E<9/1"D/"/FEBN.C>AFDC1U>B.W'JW*;S>>"ZZ7_9H?U$^X
MVS4VF7=L>@ ,4
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M&8^  $J                                            R
M      "%[9_1?J/ZJOWH8FPCT3Z>_9.]]QE[9_1?J/ZJOWH8NPCT3Z>_9.]]
MQ?W$??3JHACJ(G1RM1S')A44AUYT]+3*Z6D19(>:M3FTFHZB%J^M=WJ*!V&J
MKH\\6.)A;+O35R(C'HR7K8[@IK[UIYE2KIJ3#)>:MZG$2>V6EG5KD6.5B]74
M7+,OF<;CEAWP\?3_ (6=D$1M6I'MQ'7)OMY;Z<_M)333QU$:21/1S5ZT,RQN
M/E6'+CGX>H )=
M                  '"X(_>-3TUO<YJ)ON3@JYPB%8XW*ZQ1GR8\<ZLKJ)"
M")6W6=-4R;CVHGK:O(E4,C98FO8[+7)E%-SX\L+K*:3Q<V'+-X7;N "'4  #
M(*\VDZYK=*WNPT5)2P3,N$R1R.D545J91.&"P6+EJ*O6)WG4S??3L ,H&@&1
MD !E!D !E!E  &4&4  909  9&4  9&0 &4&4  90QZ^9:>BGF:B*Z.-ST1>
MO"*IENILDWV9 (3LEU?5:RT]/<*ZGAIY8ZE\*-B55143KXDVRA5QN-U62R^
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M>6-I:I<-21/,>O\ (<GI=SKX;N?K&8\GMEVJS@=6.:YJ*U45%Y*AV/&Z@
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M@=LIV@KNEUU6S;6*C2JTL"4D</2),BKOJN,\N18:+P-UVE^I[V?3_P"W( ,
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MN &4&4#0#(
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M[F7E9\28V;WK]627IRRE\;_>KE9R.3RHT<E+$C_.W$SWX/4X.T[@ #0
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MKV;;1*[4E]=;KA2P,58UD8^'/#'/.5]9>?H>7#&Y7Q&3EQMTM  'D=
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M)C;0M3G&YO)Q4L*S6VCM5$REML$<%,WBUC$X<1VDNO=FK;/P9P (=
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MB-\<KT1%:[D2)%3!XLY)EJ/I\-RRPER\N0 2Z@
M                               =7,1R8<B*G8IV 'FR%D?F-:WN0]$
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MEGAA%^PWNB]F-\GU'!?]?7-M?5T_E0P(N6L=V]A<V B8-G)?++QRC4P@ (6
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M  8T        (IKCG3=RDK(IKCG3=R@14WVCOE-WZBFA-]H[Y3=^HH$W
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MPI%PL\NF'-AGXK-!QO'*+DEU   !QDYR  R$
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MP=\>27M>U3D'5KT<U'-5%1>2IQ.R'E=
M                             =0 '"*,@<@XR<HN0         !QD#D
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MJ1\R-7IL<%[.U"9IR/G\N/3E<=/L>FSN?',K=[  <WH
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M55>"]YUY_18<6%RF6[$X<MRNM+A !\YW
M  !2*7;4=33ULL,,<;4C7=57<<@2L$(_"BN^;#_=_P Q^%%=\V'^[_F!+ZVK
MBHX%EG=NM3^)'9=5_C%Z*#R.K/,TERNE1<=Q)U:B,Y(U,& @%@VB\07%%:WR
M)4YL7^1LRL*:=]-.R:)</8N4-Q^$]=\V'^[_ )@3<$(_"BN^;#_=_P SM%JF
ML21%?'$YO6U$PJ@34\JMZQTLKV^<UJJ@I95F@CD5,;[4=CL.M?\ [#4?LW?<
M9EVE;/+YXM.T+:C?ZBN_!^W457!3S.C5R1M3&%5$YKZC/DUGM:M#%K;SI^!]
M#%Y4J1L;G'V+D]/!_OEJM<-_9<KC2TKW5CE:V65&JJ;R]JEDZCU[I>BLU5--
M>**9J1N3HXY$>YRXY(B';.]$[3VG[.'']OS?>_N\--:YAU-H2KO=N:D=3!$]
M7Q/3S)&HO!3ML?U+7ZJT9%<[KT7C3Y7L7HV[J81>' KC8S2S+H;6=SZ)\5)7
M.E? UR8\G"\4]I)-@E5XCLC\:Z-\O123/W&)ESL+R1!E)C<_RG]%8VV8_G9^
M:V<C)1/_ ,5-;1OKK?4T^GZ+?7HH9%<R16IVX13OH_56L-,:ZHM+ZUFAK8JU
M%6&I:N\[/;GL[R9QV]O<O))W]OJO1%.,D(VKZX;HG3[:F*%*BOJ']%31+R5W
M:I73*3:]44Z:@^$*6-%9TJ6U7+R3CC=Y95/63C-S?LJW5U[K]0XR0+2&T6DN
MVAJF^5\:TTM"UR5<2IYKV\\=Y *:LVG;0H5N=DJ:>Q6ISU=3(Y[FND9U*N$7
M)O1=V?0ZYK:_$7)7&I]872V[5;%I^FZ'X/K(D?+O,R[.\J<%^PU&B=8:DL^J
MH-+:]AC=/4-S25L:\),=2]I'=LMTFL^V/3=924KJNI;3(D4+>;G*]V$]I6..
ML\=]Y=_M4W+>&7M9_P Q] 9&5*%N-)M=MK9;^^OI)F-3I76YCU5&MZTQR_B6
M1HS7%)?M"_A!*G0I"QWC,>?,>WSD)N.I;OQY5,MW6O*99"+DH"FO^T3:6Z>I
MTM+#9;1&]4BE>Y6ND^U$7)L+!K/5>BM2T-AV@I%54E9Y-/7QJJ^5ZUZS9QV]
MO?Z)O))W]EX X:N>*<CDAT                      BFN.=-W*2LBFN.=-
MW*!%3?:.^4W?J*:$WVCOE-WZB@3<       %8;0=K-/IJ\? ULMTUUNJ-WG1
M1\$;V(IVV?[58-2W7X'NEMFM=V5JN2&7BCT]1I]C]+#5[0]=W"H8V2J94MC8
M]R95K>/+V(8GA"026ZOL%YLS4CNZ5"0QO:G%5=E$R7-3IEF^K7Z^$7=ZK+XW
M^GE*M>;1=/Z#ADIZ>&.6Y2+EM+3,1,N[78-_LZK[M=-,T]=?X4@K)U=)T:?F
ML5?)3V8(ML^V4VZT3-O%\<MTODWXR26?BUCEX^2G\RST1$1$1,(@NL9KS2;R
MN_$<@ A8          (7MG]%^H_JJ_>AB["/1/I[]D[WW&5MG]%^H_JJ_>AB
M["/1/I[]D[WW%_<1]]/@ 0L               !YSP13QJR9C7M7J5",W/33
MF.6:W.PJ<=Q5Q[%)4 (?0:AJ*.1(+@Q7(W@JKYR?U)325<-7$DD#T<U?X'A<
M+935S%2:--[J>G-"+U5LKK-(L](]SXDZVI]Z 38$=M&HXZA4CK-V*3DCNI20
MM<CD16JBHO)4 YPAU>U',<BHBY3K.QUE_)NQV 4[K&@EIZ]SG-RB<%_J1Y$5
M5PB*JJ3Q]'5R.=TE/._C^<Q5.B6Z=.5')_AK_0^WP^L^'A,;-ORW/Z#XO)<Y
MVVZ:96KME*R6*-57\[*<"54>J(UPVIA5J]K>)@Z9IZAER1)H96Q[JYWFJB<B
M0U5GHJG._"B.7\YO!3YO-G,L[<GV?3<6>'')A?'U>U)<::J3\3*U?4O!3+1>
M)%ZG3#F*KZ.H7*=3N!A]->;8OE)(YB=J;R'/HE^6N_QLL?GQ_LFH(Q2:I3@V
MKA5J]K3=TESI*I$Z&=JN7JSA2+AE/+KARX9^*S <(IR2Z  4 #KO)GFASO)V
MH!R#A%1>2Y[CE                    'G44\51&K)V->U>I4/0 :[X$MW]
MDC_B/@2W?V6/^)L0!K'V.WJU42F8U53@J=1"[G;I[?,YDK55GYKTY*A8YU?&
MQZ8>U')V*F0*RIX):AZ,A8YSE[$)G;+!2Q4C&U<+))N;E7J]1N8X8H_R<;6]
MR8.^ -<EDMW]EC_B/@2W?V6/^)L0!C4E!2TBJM/"QBKUHAD@ 43X2M+'6UVE
MZ6;/135'1OPO'"JB&U9X/VCG,15\?RJ9_+?Y&^VH:'K=6W"QU%%54\#:"=)7
MI*BJKDRB\,=Q8$:8:U%ZD1"L<M8:GG=<[CO.V^-1$]';.M.:2>LUHH4;4[N[
MT\B[S\=Y ?"9_P!GTK]?_H7;@KW:UHBMUG'9FT-5! M#4],_I45=Y.'!,=QN
M&7^YC<O:Q5QDPRD]Y?V8.U76URT_):+/I^&)]UN2HR-\OFL]9'I=$[0*JEJ9
MK_K;Q:G1JO<D"81$Z^I"9[2MGD6LJ2D?'6/HKI1\8*AB9POK(=!LLUG<V+2:
MIUO--;%PCHH-Y5>G9Q1#,=:OU3EO<^C4^#3'B'5L<4JS*C]ULB\W\^/VFS\&
MN:%DNIZ1^$KFU>^]%YJWC@D>RC9Q5Z$N]W<VLAJ+=58Z%F%Z1N%_.ZC%UCLI
MJ*J^R7[1MXDLMVD3$F,]&_U\.1>6<ZM_62(QX[,=>\MJ8:IU%I^S76V4][Z/
MQZJ=NTN8-]V<]2XX<2EM.VNY7#:OJVBI-23V2M?*UZ)'&URS-X]O9_,GNBMF
M5?37ME[UM>77NYP<*;GN1^OCUF7M#V70:END=YM5?+:KW$G">+D]4Y9,EQPL
MOX6?Y_9=F6<L_)K;OH#4,MMJ&73:#6^)/8K9>D@8C=WUJ>&J[-3V+8#<J"BK
MDKZ>.%NY.G)R;[3"AV4ZOO"I3:PUG+56W**Z&'>R_P!2Y1,%@:NT>VX[/JO3
M5F=%2M?"V*)7HNZU$5%XX[C,_ELVKBGVY;/#$V)U--4[,K$M(K=UD&XY$ZG(
MO$@FO9&UOA :4AHG(L].Q5F5OYJ<5X_8>L&R/4MFM-)'I35+K;4K&C:N-%=T
M4COG-X90EFSC9K!I:JFNERK9+I?)_/JI/S?4TZ6X_$O)OZ_Y^3EC,OA3CU[3
M_/S0O2CV47A'7YEP5&RU$*] KOL7"?8A>D[V1PO?(Y&L:U555Y8(%M'V:4FK
MIH:^FJI+;>8%S'51<U]2D-79?K^XIXG>M=.?;'\)&Q[RN5O9A40Y3[6$Q\63
M3K=XY6^U>VP1S:O6.MJZB7%ODJD2-$X(JEW$<T)I&W:-LC+;:T<K<[TDK_.D
M=UJI(QE9VD]I(S"7O;[W8 "5@                  &!?\ Y"N/U:3W5,\P
M+_\ (5Q^K2>ZHC*JSP6/1[6?O&7W6%Q%.^"QZ/:S]XR^ZPN(K/YJS#Y0 $J
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MS7*A]!;)M4S:BLLK*YR+64KD8YWSTZG#U?H[QSXDNX<?+U=D[ !\]V
M                        Q*FVT=2_?GIV/=VJAE@#7? EN_LD?\1\"6[^
MRQ_Q-B (S?[#'XNDEOB:U[/.:GYR$3<QS'*U[51R<,*6D>3J>%SMYT3%7M5
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ML(]$^GOV3O?<96V?T7ZC^JK]Z&+L(]$^GOV3O?<7]Q'WT^ !"P
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MJJO4O!3*SEJ\2+U6EW(JNI)T3_E=_4Q$^&;8O%)',3_S)@=$ORT^-GC\^/\
M9JJATS*B5KW2-5'+P55[5//I)/TC_P"\IA:KO<\\N,[KU3J_-0C<5941O1S9
M7?:O,^GP^DRY,.KP^%S^MPXL[A.ZR=*/F==4\J16;J[W%53U$U:N2([/[GXY
M3/C<G),M]7:A+T/F<TLSLOL^[Z2S+BF6-WL !R>D
M            P,  !@ !A!@ !A!A  &   P,(  P,(  &
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M#T<GI>'#&V9]_P"CGCR96^%TIR 3D#YSN
M     8&  &$&$  8&  &!A  &$&$  8&  &$&
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MN]&/J,?&?:I,#QIJB*H9O0R->WU*>QS>B78
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MG:A7J?1Y\<Z_,[,X^29=DV 0'A=0
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MN4-#5Z9I)&JM/O0O]3LH:R2.\VAJJQZR0MZT\I$ F((U;]3Q/PVL8L;OG(G
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MN/DZYO6@ $N@
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M0^%R<>7'ETY3N]<LLW  $-
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MJ_>AB["/1/I[]D[WW&5MG]%^H_JJ_>AB["/1/I[]D[WW%_<1]]/@ 0L
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M\USX9\2]VP SP&3ROH
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M]CNQ2V45%3*'EYN'+ARZ<G3'*93<<@ Y*
M                                           BFN.=-W*2LBFN.=-W
M*!%3?:.^4W?J*:$WVCOE-WZB@3<        X.'/1K5<[@U$RJE+7+:S?;E=Z
MNET3IV6Y4]*]8W3[N454Y]:"3=U&6R3=76$7)1_X>[3OH4_^Y_\ ]%H:&N-U
MNE@AJ;_0K05SE<CH%3&ZB+PZU*N%DVF9RW20  E8          (7MG]%^H_J
MJ_>AB["/1/I[]D[WW&5MG]%^H_JJ_>AB["/1/I[]D[WW%_<1]]/@ 0L
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MQ3?VZ^TE7AKG=%)\UQ-X[.Z\.?'+M>U;<'".1414XHO8<H0[    9"*  R$
M                                                &!?_ )"N/U:3
MW5,\P+_\A7'ZM)[JB,JK/!8]'M9^\9?=87$4[X+'H]K/WC+[K"XBL_FK,/E
M 2H                       !UD:CV.:O6F"M[C224=5)%*U4X\%7K3M+*
MP8]9105;=VHC:]/7S0"M#<Z9N$5OJ)$J$5J283>["2TUDH(G[S8$547AGB+M
M9:>N8JHU&2HG!S?Y@;..1DC$=&Y'-7BBH=B#0SU]AJ$CD15ASRYM7N)9;;E3
MU\2.A?Y2)Q:O- ,T       '"IE%1>1J7:8L;G.<ZT6]7.7*JM.WBOL-N#9E
M<?%-;:?\%[%_P>W_ /3L_H>U'8;515"3T=NHX)D3"/CA:UR?:B&R!MSRO;;-
M00X5,G():K;:-L\I[O'+<;0Q(;DGE*UG!)?Z*1S9]K^JM=8EFU,YR1HNXV67
M.]&O+"^HNS!"=H6AJ74E(Z6F8V&Y,3R).2.]3CV\/J,<L?A<W>?7Z.66%EZL
M4SAFCFB;)$]KV.3+7(N45#N4+H_5UQT3<GV?4+)?%&NQAR96/CS;VH7E0UD%
M=2QU-)*V6&1-YKVKE%0X\_I\N&_67Q589S)D  X+
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M\_HYS+D6TBY!PTY/F.X
M         !IM6Z@I],Z?J[O6QR24],B.>V-,N5,XX&Y(EM2O3=/Z&NE>Z"*H
M<R/=9'*W+7.7@F4,MU&R;:JQ[7](W;<:RY-IY'?F3X8J?Q)K0W:@KF;U'6T\
M[?\ Z<B+]Q3>@-C]GN=C@N^IHUJ;A7MZ9S&>1&Q%Y(B)ZCC5>PVG@I)JG1UP
MK*&K:BN2%)%W7KV)V'7.88W5<<+GE-KQWD.44^7M')M+=:G5UBNZUB4KW13T
M4SD<]CVKA6JBEO[)M?2:NIZNDN=,E'>*)=V>'CQ]:?:+QZWJ^&SDWYBPB*:X
MYTW<I*T(IKCG3=RG-T14WVCOE-WZBFA-]H[Y3=^HH$W       !&K!HRV6.Y
MW:OHNGZ>YNWI]]^4Z^2=7,A]1L*TC/42S/\ ']^1RO=B?AE5SV%JX..HV6SP
MRS?E4_Q"Z/[+A_C_ .18&DM.T6E[-%;+9TOBT:JK>D=O+Q7/,W&?6$4WJMFM
MLZ9.^G( )4   J9(_K]/^Q=Z^JR?<I(#0Z[C?+I"\1Q,<][J5Z-:U,JJX7DA
M.?RU?'\T1#P=/1?0?M)/>+-3D5OX/]-44>S:AAJX)8)4DD562L5KD\KL4LA.
M1WYO_97#B^4(MM$HM1U]B2+1]?'0W'I4599,8W>M.**2D8.4[+LV^;==6#:E
M3:1NDU^U'35-K9"JU$+4;E[<\O-0M381Z*-/_LG>^XR=LR8V7ZC^JK]Z&-L(
M]$^GOV3O?<=+=XHF.LD^ !S=
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MOP6/1[5YY_"$ONL+C*=\%GT?5G[QE]UA<0S^:F'RP !*P
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MEPRQF.Y[+QLN],@ '%0
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M/1/I[]D[WW&5MG]%^H_JJ_>AB["/1/I[]D[WW%_<1]]/@ 0L
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M[4.R<BMJ629]3$UKY7*KTX(J]I9#/-0C/#H=>'F^+OLY !#L
M            XW4[#E$1.2     ,"_\ R%<?JTGNJ9Y@7_Y"N/U:3W5$956>
M"QZ/:S]XR^ZPN(IWP6/1[6?O&7W6%Q%9_-68?*  E0
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M&ZNWU:@-=9+Q0WFD2IMM0R:)>>ZO%/4J=1L4/S%EEU7O  8
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M96WRZXR3P$4UQSINY25D4UQSINY25(J;[1WRF[]130F^T=\IN_44";@
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MZ>_9.]]QE;9_1?J/ZJOWH8NPCT3Z>_9.]]Q?W$??3X $+
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M_P A7'ZM)[JB,JK/!8]'M9^\9?=87$4[X+'H]K/WC+[K"XBL_FK,/E  2H
M                                     !PY."\"M*__ &Z?*8\M2S%(
MKJ&Q2/F=4TB;V]Q<S^8$5-]HUSDN3T;Q:K.)K&6ZL>_=;32Y];<&RTY5-MMP
M?%5MW%?Y.\OYI@FX.&JBM147**<F@        8ESM])<J5]/701S0NYM>F3+
M'4;+9W@JJHV<V!-8T]&V&=*>2F?4*Q)>&\CVHGV<>1*[EH2PUUI2@\29"QGF
M/C3#FKVY/6I](%%^[Y?_ .QI)3T<G/R?9O5?",<9W[/G^Z6+4.SJN2MME0Z>
MB5>+FM56JG8]O\RP=#;1Z&_-;3UVY25^$3=5WDO[E)Y-&R6)T<K&O8Y,*UR9
M14*NUOLN@JU?6V#_ $>I3REA3S57U=BG><W'ZB=/-VOU1TW#OCX6FU<IDY*)
MTOK^[:8K$M>I(I)(&+NJLF=^-/YH71:+I1W:D;46^H9-$Y,Y:O+O/-S>GSX?
M/CZKQSF3. 0'!8                                             C
M&T*>_P!/IN>72<39;HUR*QKFHJ*F>/!35PZKNEJV<NOVH[;(E? Q'34T;<*O
M%$X(3L\YDC6-_3;O1X\K>Y8]8WJ6&MU4-#MQT7<HT;=Z>IHG+PW:FGWT]J9,
M]:399JM=YJ6:69Z<VN2-_P#)3:7)VSR]5;Z6LDLD]4G!4RU'(I'[EL/TC<]^
M:VRS4KW<=Z"1'(G<7]GSK3G]KQO:6:#T'8-(U-5/IWI$94IY373=(B=Q,RN]
MEVSR70]36)\+35U/,GDMDSY)8@SN[YVW":GC0137'.F[E)6137'.F[E(6BIO
MM'?*;OU%-";[1WRF[]10)N       #AR(YJHO%%*;O.SW5-AO57<MG-VBIH:
MERR24-1Q9O+S5$7@7%)(V*-[WKAK4557U%(_A]K;5-QK?P(L\#K;3RK$D\[L
M;ZISZS<=[[,RUKNZNL&US4,;J"^W>@H*"3R97P-:CU;UHFZ2+6FA;S76"T:;
MTU714-FC;N5BKY\C?5ZU7*_::;Q[;#_PNV?XO^99FB7WN2PPNU/%%#<E5=]L
M2Y;C/#^!=\>SGC>_NR]-6B"Q62CMM(F(:>-&(O;ZS9@$6VW==)))J  ,:
M     A>V?T7ZC^JK]Z&+L(]$^GOV3O?<96V?T7ZC^JK]Z&+L(]$^GOV3O?<7
M]Q'WT^ !"P
M        8CY'+O-<B*WDJ*AB)1TJ/WTIH=[MW#:*QJJN40XZ)G8@'A'([*-\
MG=Y81,&'<K'25N\[=Z.7YS>!M$8U%RB)D[ 0>2CNEED5\#G+%\YO%%[T-M;-
M2PRX96)T4GSOS5)$J9147BAI;GI^FK$<Z-$BE7K1."@;B)[9&[S'(YJ\E13L
M0=8;G9'[[=YT2+U<6J;JVZDIZA494)T,G:O)0-\#JQ[7MWFJBM7K0[
M            O(!>0$;UK;'5]OS&BN5B*BHG85+56V9C]R6#I$1<IY.\A>M1
M64T#T;/,QBJF<.4TUP6U2RP.1\"KTB;^%ZL+_D>[TOJ\N&=.MQ\GUWH,/49=
M?5JH;H&P/=4ND= R-B*BN\E$X=BEE0T%)$]'QTL#'MY.2-$5#'IJRW0M1D$T
M#45>35YFR;Q0\_/RY<N?57L])Z?'@X^C&[8TE!22O5\E-"]Z\U=&BJIV?24[
MX4B?!$Z-O)BL143[#W!Q>IX0TL$+7-B@B8UWG(UB)GO.L5#212(^.F@8].2M
M8B*:?5^KK1I2CZ>[U*,<[A'$WB^1>Q$*_?4:ZU^G^@,_!NR/X)+(J^,/;VHG
M4;)M-LB?WV[:;M".EO%3;H'.7CTN[O*O=S52)5.UW2+XW4U!'67-S>"04]&Y
M4X=F41#*T[LCT[:Y/&*YDMVK%XNEK%W\N[<$ZI;=1TJ(E+2P1=7D1HAO8[JQ
MIMH5RG5RV39_=F*[AO31-B12D]3;-]:7F_7&XLT[)"VJE=*D:/;Y.>KF?8J(
M#<<^GPG+CZO-4M8M1W^P6"V4%VT%6U/B5/' DD*-D54:B)G^!NJ?;%9X<)>[
M7>+1U9J:551%_P#+DL\\9Z:&H:K9X8Y&KS1[44S<OF*F-GBM)8M9:>ON$M=V
MI9WXST>^B/3_ ,J\20-5%XHN4(-J/9;IF](KTHDH:GFD])Y#L]JD8;:M=Z#5
MS[54?A+:6\5@G<J3,3U+UC4O@W9Y7""(:(U[:-5M=#3O=37*/A-13INR,5.?
M#K0ER=9-FFR[<@ -           ,"_\ R%<?JTGNJ9Y@7_Y"N/U:3W5$956>
M"QZ/:S]XR^ZPN(IWP6/1[6?O&7W6%Q%9_-68?*  E0
M                       >'3HBKP4#T;Y[S3:BLZ5T*RP(B5#$_O)V&T29
M$<JX7B=V3(]V$1>($9TY=U@=XE7.5NZN&J[J]1*TXH1W4EF6I1:FE3\<B>4B
M=?\ F>>F[RCVMI*MRI*G!KEZ_4!)@       %Y%>W_:C;++>*JW5%'622P.W
M7.8C<+PSPXEA=16^HME=+>KW5W&2Y3Q.J';RL:Q%1.&#T>G^%U7XWA&?5K[+
M12;4[6_4M/<O$:WHHZ5\"MPW*JKD7//EP-];-K-JN%QIJ.*AK6R5$B1M<Y&X
M157KXFM^)>C_ .+5/^&AE6G9'26ZYTE:RZ5#W4\K9$:K$PN%Y'KROH[//[N4
M^(LY.LY.&G)\QZ&CU-IBV:BI717&G:Y^/(E;P>Q?4I3-RT_J79]7NKK7*^2B
M1?RC.+53L>T^@CI+&V5CF2-1S')A45,HIZ>'U.7%]F]\?HC+"9=_=!M$;1K=
M?]RFJU2DN'S'\&O7_E7^1/&KE,E4ZXV71U2OKM/*D%2GE+#R:Y?4O4IHM+Z]
MN>E:GX*U/!,^)B[J.?G?;_5#MEZ?#FG7P7^B)G<>V:\P:^RW:BO%&VIMT[)H
MG=B\4]2IU&P0\-EEU7;R+R4I3:%M O\ 9=75U!;ZF!E-$C-QKX4<J9:BKQ[R
MZ^HU%;IRT5U2^HK+;333OQO/>Q%5<<$.WI^3#CRWR8[B,Y;.U43\:FJO[92_
M].TRK7M/U/47.DAEJZ98Y)F,<B4[4X*N%++K=,V5NJK= VUTB1/IY7.;T?!5
M1S,+_%3>1Z4L4<C7QVFD:]JHYKDC3**>W+U/IY/_ %^?R<YAG]6Z8=CAIR?+
M=P                                  " ;<JBJIMF5ZDH7*Q_1HUSDY
MHU5XD_(SM&K6V_1=TJ):!;A&V)6OIDYR-7@J$Y>&X^55:;V%:>N>E;?525=8
ME;40ME=.QR<UXXP=5V+:FLCLZ4U:^-B+G<F16JOLX&EV=[9J?3D:VF[T-6RU
M1*J4SW\9(FY\Q<\T3J+GLNTC2MV:Q:>\4K'NY,D>C7'ISN>[9X>;#HUJ^6NV
M8P:XI:BK@UM+!- Q$\7EC5%WN_'\RP3QIJNGJF[U-/%,WM8Y'?<>QRRNW;&:
M"*:XYTW<I*R*:XYTW<I*D5-]H[Y3=^HIH3?:.^4W?J*!-P       >%7&V:E
MFC>N&O8K57L144I395K/3VDV7#3=TN=*Q\%5(^*H:[,<C57MZE]1>#VHYCFJ
MG!4PI5EVV?[-:.J?\)QTD,[W*YR23X7*^HW"ZMW[ISELFO9*/C(TA](;?_BH
M2"T7.BN]&VKME3%4TS\HV2-<HN.95*Z,V3(BJK[?A/\ _)+"T+3V2EL,<.F'
M1NMC'.1BQNWFYSQPO>59-=F2Y;[I" "%@          A>V?T7ZC^JK]Z&+L(
M]$^GOV3O?<96V?T7ZC^JK]Z&+L(]$^GOV3O?<7]Q'WT^ !"P
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M57CAV>:'T5L\U3%JNP4U8Q42?HV+,U%\URIQ+O']FY8W>O+G.3[4QRFM^$J
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MWP6/1[6?O&7W6%Q%9_-68?*  E0
M       >/BZ97RE/8 >/BZ?.4Y9"C'9SD]0 (OJ.S+EU91Y1R<7M3[T)0<*F
M45%3@!H=.7E*QJ4\ZXJ&IP7YR?U-^1'4%I=1RK7466HBY<B?FKVH;73]W;<(
M]R3A.WGZ_6!N0               #0ZITM;=24W17"+RV^9*W@YIO@5CE<+O
M&]V6;[50%SL&H]G=<ZNM<RS4*KQD:F4QV/0L+1.T>W7_ *.FJD\4N#N&XJY:
M]?\ E7^1.I8VRL<R1J/8Y,*BIE%0JW6NR^"7I;CIYRTU2S\9T+?-54X^3V*>
MV<W'ZB=/-VOU_P"7+IN'?'PM7* I72&TZKH*EMNU1&Y4:J,Z94P]OZR%P4E=
M2U5*E33SQR0*F=]KDP>;F]/GPW63ICG,O#4U_P#WRM?U6;WF$@(97W^TIK&W
M*MQIL,@E8[\8G!RN9A/X*3&.1DK$?&]KV+Q16KE%,Y,;)CN>W\F-\NP .2@
M                                 #HY&N:J.1%1>U#N0S:W?)]/Z!NU
M=1JK:E(]R)R?FN=PR9;ILFWGJVOT'3R^+ZEFLS95_,GW=XT#MEFS[4](RX6N
M&-(I?,GHYE1J]W41*R;)[4[9_->]0K)7W>HIUJ>D<]?)RF4[^!Z:4TO<]2[%
MK-'8K@^AK:65\\;FJJ;ZIG"<#K<9CN;[S6_ZN,RN6KKM5A[.-G-)H:JK'T-P
MJZF*H1/(G5%W.[!/"NMC>L:G45LJ+?>FJR^6UW0U*+^=C\XL4S/>^]VKCUKL
M$4UQSINY25D4UQSINY2%HJ;[1WRF[]130F^T=\IN_44";@       QJ^5T%%
M42M3*LC<Y/L15* T1L[M^L]-W746H'5%5<JJ298OQJHD>,XX(?0LL:21O8Y,
MM<BHOVE3Z"M>I-)ZJJK%)2)4::J)))XJEJ_D][CNJ;C]Z3SKLG+VOMONB&@M
MEFFM5Z!298YH+NQ9(GSLD7SVN5,JU>'4A;&R62C71=)#0P,@2F<^GE8W](QR
MM<OVJF?M*WH:K4NS.ZWJ@@L%3=;;6SNFI)(%\U7<>/VJ6/LHLE79=+-;<F[E
M;5S25<K/FJ]RKC^)URRF6-RWVNO[N4QN.4Q^F_[>R9@ XNX          (7M
MG]%^H_JJ_>AB["/1/I[]D[WW&5MG]%^H_JJ_>AB["/1/I[]D[WW%_<1]]/@
M0L
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M_P#(5Q^K2>ZHC*JSP6/1[6?O&7W6%Q%.^"QZ/:S]XR^ZPN(K/YJS#Y0 $J
M                                              =7-1[5:Y$5%YHI
M#KU;9;54MJZ+>2/.>'YO^1,SI+&V6-T<C4<QR85% U]CN;+C39542=O![?YF
MS(1=*.:RUZ5%*JI"Y>"IU>I24VFX1W"F21BX<G!S>Q0,X
M   1;6&B;9J6!WC$?0U:)Y$\:8<G?VH4'?X+II>MJ[(^N>D?!7-C>NZY%XIP
M[CZEZCY[VV6J:DU:^N<U>@JV-5KL<$5J85/X'T_]/Y;<OAY7LX<V/;JBON:J
MO->TLG8]JJKH[Y!::B9TE%4*K6-<N=QW5@K9#<Z-JZ:@U/;JFN?N4\4J.>J)
MG!]3GXYR<=ECSX75V^JT.3&H*VGKJ=D]),R:)Z91S5R9)^8UKL]X
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MK*PF[=_1.=U)KZO#\.-IG7H)W]Y/_N+,T77W6Y6.&IO]O6W5SE5'TZKG=3/
MSOA>VX_V^D_QF_U,FFGBJ(TD@D9(Q>3F.R@M[>&2=_+V !*P          0O
M;/Z+]1_55^]#%V$>B?3W[)WON,K;/Z+]1_55^]#%V$>B?3W[)WON+^XC[Z?
M A8
M                 ,.M9#4,=#/&CVFA=IRE5^4EE1O9E"3.A1SE7*G'0-[5
M UU/;Z.*GZ!($<UW-5QE347#3,D2K+;I%7''=5<*G<I*$@:BYRIZ@0ZAOU50
M/2&X1O<B=:^<G]234%QIJZ-'4\B*O6U>:'-=;Z>M9NU$:.7J=UI]I&*ZP5-$
M]9[?*YR)QPBX<@$QR")6_4LD3NBN$:KC@KT3"_:2>EJH:F-'PO:YJ]B@>P
M        $1VDZ/BU?8O%VR>+W"G>DU)4)SCD3EQ[%)<,&RZ99M6.A]>R4M6W
M36MT2WWVG1(V2O7$=4B<$<UW:I85?0TESHWT];!%44\B<6/:CD4TVL]%V?5U
M(D5VIT66/*PU#/)DB7M12!J[7>S]G1M;^$]E9YJKGQAC>Q5ZS=3)DMQ\I=8M
MF>E+)</':"U0MJ.:.>F]CNSR)CN^2J=7(@6FMJNG+RYL4M0ZWU:\%@J_Q;L]
M?,G%/64U2B+3SQ2HO+<>BF9;]S'7LCUET'8+-?I[Q;Z)(J^;*ODWLYSS)0O(
MXR<Y,WVTW7>U%=4Z!L&J*^"MO-$D]1"W=8[>QA,Y)+!"V&%D4:88QJ-:G8B'
MKDZ2S1PM5TLC6-3K<N$&^VF^^T4U)LZTSJ*H2>Z6N%\R+E7L3=5R^M4YFXL&
MG[7I^C2FM%'#31(B9W&HBKWKUFBU-M*TW86JV:N94U&/)@IG(][OL12),U%K
M?76\S3E%\ 6MW!:RJ:JRN1>MJ=14EUKV1;CO?ND6O=H=)89/@JU(MRU%/Y$%
M'#Y2M5>2O7J0XV8:(EL'C=WO,WC-_N"[]1)S1G7NM7L,W0VSZU:6<ZJ1'5MX
MERLU?4>5*]5YX5>2$R1,#<G:-DM[T0 $J           ,"__ "%<?JTGNJ9Y
M@7_Y"N/U:3W5$956>"QZ/:S]XR^ZPN(IWP6/1[6?O&7W6%Q%9_-68?*  E0
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MZYTXYZ-2[4V57">6A?P>3_XUG5/JD@.K7HYJ.:N47BBIUG8YJ
M        *_VZ5T]!LSN[Z5RL?(U(]YO-$5>)8!%]I%/;*O1ETIK[4,IJ&6/<
M=,_DQ5Y+[<$Y-Q\HMH.TV30.SF*\,B8V=]*DT\[O.>Y>.,D!V=:$CVFONFJ-
M62U3F5,KFTT;7[J(U.LPH- Z\O5GI+"V[TU5IEKMZ.H9(BM<S[_L+:OVH;1L
MITE;8*B">2!J=#&D+,Y<B9X]F3T9V2Y9[[WM/P_SP\^$[3#7:>?Q_P \H_L3
MJ:FRZDU#HZIJ7U%/;I%=2N>N7(Q<</XEQ%+[!Z.NNUZOVL;C Z!+E(J0-<F%
MW>'\."%T$\F^V_.IO\U\?OKQOM^0137'.F[E)6137'.F[E.;HBIOM'?*;OU%
M-";[1WRF[]10)N       "L;OL6TQ=;G4U]4M;T]0]7OW9L)E?L(O+LPV<1Z
MACLJU]0MU>F4@;/EWV\"[:][XZ*H?'Q>V-RM[\*51L%LEOJ+=5:AJ8V3WJ>J
ME229_%S./F^HK"WO-]I$9R>?>UI]5;--G6EFTCKW55U,RJ?T<;UE54SZ^!;>
MBK);]/V"FHK.]SZ+'21N<[>54=QSG[3)O]GM]YMLM+=:6&H@5J_E&HN[ZT["
M)[$IYI='+#*]SXJ6JF@A<JYS&UZHW^' V6W&[OAEDQRG;RL  $.@
M  (7MG]%^H_JJ_>AB["/1/I[]D[WW&5MG]%^H_JJ_>AB["/1/I[]D[WW%_<1
M]]/@ 0L
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MX+'H]K/WC+[K"XBG?!8]'M9^\9?=87$5G\U9A\H "5
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M^YQO=T]M_P!2Y))=1RG#&%9:>2DM-%3S8Z2*%C'8[41$4SCC!R?+MW=O0
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MH7+O;O7C!:>EK+!I^Q4=MIN+(&85V.+G=:_:IML($3!5R[:9,>^P $J
M     !"]L_HOU']57[T,781Z)]/?LG>^XRML_HOU']57[T,781Z)]/?LG>^X
MO[B/OI\ "%@
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MA\H "5
M  -5?K4VX0(K?)F9YKNWU&BL=U?;)7TE>BM8B]?YO^1,B"ZLE22ZN:C43<:B
M*O:!OEU'0)+P<]4Y;R-X&VI:J&JB22"1KV+UH5B;?3%6^GN3&97HY?)5 )Z
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MM#731HY*UBJF>28<2-KT<B*U45%ZT)RGV<2>:[  YJ
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M1Z)]/?LG>^XO[B/OI\ "%@
M                                                    U6H;9\(4
MB)'^59Q;Z_40>:EGA>K)(GM<G:A9,DJ,7"HJGD^1CE3+<X7K0"+:9M+Y:CQF
MH8YC(U\E')YRDQ1#R2=O!$13V0!@8  XPASA  &!A  &!A  &$&
M            &!?_ )"N/U:3W5,\P+_\A7'ZM)[JB,JK/!8]'M9^\9?=87$4
M[X+'H]K/WC+[K"XBL_FK,/E  2H
M                       (9JZA?'5^,M:JQO3"KV*3,ZR1MD8K7M1S5YHH
M%6F5;9VTM;%/(Q7-:N<(35;);UFSXLWEG'49%5;*6IIN@?$UK4\W=3"H!ZT5
M7#5P]) ]'-^XR$(/4T=;8JCIJ=RK#GSDY+WH2&S7N&O8C'N1D_6U>ON VX"
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M5?O0Q=A'HGT]^R=[[C*VS^B_4?U5?O0Q=A'HGT]^R=[[B_N(^^GP (6
M
M                #..L        #RDBWW9R=?%_6>X \$@QUGNG(
M                           8%_\ D*X_5I/=4SS O_R%<?JTGNJ(RJL\
M%CT>UG[QE]UA<13O@L>CVL_>,ONL+B*S^:LP^4 !*@
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MCT3Z>_9.]]Q?W$??3X $+
M                                     .KGHWF!V.'.1.:GBZ15X)P.
M@9MZ.E[$.J*KG)E3J=HT\LUC( !B@
M           # O\ \A7'ZM)[JF>8%_\ D*X_5I/=41E59X+'H]K/WC+[K"XB
MG?!8]'M9^\9?=87$5G\U9A\H "5
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M^H_JJ_>AB["/1/I[]D[WW&5MG]%^H_JJ_>AB["/1/I[]D[WW%_<1]]/@ 0L
M
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M_(5Q^KR>ZHC*JSP6/1[6?O&7W6%Q%.^"SZ/:S]XR^ZPN(K/YJS#Y0 $J
M
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M
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MA<93O@L^CZL_>,ONL+B&?S5N'RP !*@
M                                          '5S4<U6N:BHO-%ZRO]
M0PQ0766.!B,:B(N/6J%A$2U=;G],E7$Q7-5,/PG+'6!&#9Z=J'T]UAW57=>N
MZY.TUAF6N9M'7PS3L<K6KGE@R"QT.3SIYHYXFR1/1S')E%0]#0
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M^XC[Z?  A8                     ZR>8IX97M/>3S%,=#8RN<KVC*]IP
MQSE>T97M. !SE>T97M. !SE>T97M. !SE>T97M. !SE>T97M. !SE>T97M.
M!SE>T97M. !SE>T97M. !SE>T97M. !SE>T97M. !SE>T97M. !SE>T97M.
M!SE>T97M. !SE>T97M.                  &53DH '.5[1E>TX '.5[1E>
MTX '.5[1E>TX '.5[3C*]H'4!DQ^8AR<1^8AR8H
M   ,>MHJ>NIW05L$4\+N;)&HYJ_8ID #1_@EI[_@EM_Z9G]#M#I:Q0RMDALU
MO9(Q<M<VG:BHO:G W0-W6:CA$.0#&A@7_P"0KC]6D]U3/,"__(5Q^K2>ZHC*
MJSP6/1[6?O&7W6%Q%.^"QZ/:S]XR^ZPN(K/YJS#Y0 $J
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M>AB["/1/I[]D[WW&5MG]%^H_JJ_>AB["/1/I[]D[WW%_<1]]/@ 0L
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M1&55G@L>CVL_>,ONL+B*=\%CT>UG[QE]UA<16?S5F'R@ )4
M                                       <*J(BJJX0#DX<Y&IERX,6
M:L:W*1\5[3#DE?(OE*5,;6,N:L1,I&F?68;WN>N7+E3J"Y-!U&=;E\EZ&"9=
MN7RW)ZC,O SP$ZP<V@       !XOEW7*W=S@]CQ?#O/5V]C('19O*S@[,GRY
M$5H\7_YU]@;3X5%5RJ![\SRJJ>.IA=%,U',=S/5 !";A05-DJ?&:1RK#G@O9
MZE)%9;Q#<(D3*,G3FQ?Y&QEC;(Q6/:CFKS14(C>+/+;Y5J[>Y>C1<JB<V_Y
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M[)WON+^XC[Z?  A8                     ZR>8ICH9$GF*8Z&QE  &
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MC:!4I!IV9F?*F<C/L,#9E2[EOJ*A4PZ1R-^Q#!VI569J2F1>35>J?<;NWR?
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M[Z8(3KRN==+M'0TF7MA1<HG6[K/?9[61T-%=)9W(UL>%7*F?^))Z?KOS*_\
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M6=KAC.28?7LXS/*X7-?J*BIE.1R>%!&Z*AIXY%R]L;6KWX/<Y7M767<  8T
M  =0'4!DQ^8AR<1^8AR8J                                !@7_P"0
MKC]6D]U3/,"__(5Q^K2>ZHC*JSP6/1[6?O&7W6%Q%.^"QZ/:S]XR^ZPN(K/Y
MJS#Y0 $J                                               9QS '
M"KCF>,M4QG!/*4P99WR*N5X=A4QM&9-5-;P9Q4P9)7R+Y2_8= 7)I@ #0
MR*!<3]Z&.>M*N)VF7P-J@ .30                X5J*F%XIV'( BE^L2QN
M6JH$5%3BK&]7K0][!?DFQ3UJXE3@UZ_G$D([?[$D^:BB1&S)Q5J<-[_,"0YX
M')$[#>W0/2EN"N3CAKW=7>2MCD<U%:J.1>.44#DQY97->J)C@9!T?$URY7F!
MX=,_U#IG>H[K"U,<SLD#>U0/1JY:BG(1,(       </\Q>XY.'^8O<!^?2?*
MR_6?_6??UM^3Z;]DW[CX!3Y67ZS_ .L^_K;\GTW[)OW'?F]GGX/=D  X/0
M           !%-<<Z;N4E9%-<<Z;N4"*F^T=\IN_44T)OM'?*;OU% FX
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MZ.:O8>Y!D=6:>K=U?*A5?L<G]276ZNAKX$E@=WHO- ,E_-.\['1_YO>=P
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MG2?!M?35?1KNR=#(C]U>Q<<C.#  !H     #J Z@,F/S$.3B/S$.3%0
M                           ,"_\ R%<?JTGNJ9Y@7_Y"N/U:3W5$956>
M"QZ/:S]XR^ZPN(IWP6/1[6?O&7W6%Q%9_-68?*  E08U?^1^TR3&K_R/VFSR
M-< #JP
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M]9*KK;K_ #W%TM!>VTU(N,0] URIV\53K.F>75V<L,.G=2,'#>7'BIR<G8
M           "*:XYTW<I*R*:XYTW<H$5-]H[Y3=^HIH3?:.^4W?J*!-P
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M56)BO\Y6HJ]^#N<76=P=0'4&LF/S$.3B/S$.3%0
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M!6ZG;A]/:X5>O_*J?YX+J<N553=[PQM\]_W[-QG3GE)XFO[^[@ $N@   0!
M/2F_+L[S;)R-33?EV=YMDY'/(@ "6@           'C+,K7JU$ [O_-[SN8J
MS*O4G Y2=W8@&2#AJY1%.0                           $4UQSINY25D
M4UQSINY0(J;[1WRF[]130F^T=\IN_44";@       AVEM-76TWJ^5E?>YZVG
MKG(M/ ]SE2GY\$RO#FG(@55LGUA-5321[0+@QCWJYK4DD\E%7ES,^_[/]955
MUK:NDUBE-2R/5[(NB5=QO8032UFU[J:X5C+9J9ZVRGD6+QU[<->Y.>ZA>$WW
ME]G/.ZWN>Z4?%'K/_P#<.X?XDG]3#NN@=>Z;MM1=*+7555.IF+*L,JO=OHG4
MB*JH>MXV?;1*.@EGH]6)5RL;O=$C=U78[%+%V2RS56B*-];7>/U"JY)7N;A4
M<CE16JGJ7@5;=6RIDFY+&9LTO-5?]&VVX7"-65<D>)$5,95%QG!*#I%&V-NZ
MQK6M[$3!W.>5EML=<9J:  8T       !"]L_HOU']57[T,781Z)]/?LG>^XR
MML_HOU']57[T,781Z)]/?LG>^XO[B/OI\ "%@                    #K)
MYBF.AD2>8ICH;&4  8     .#D #@'(              *@O-ANEXV\6^NFH
M*AMHH(<MJ7-\ASD3.,]ZEO\ :/M!N_LS'Z,UWN7U  8T   X5,M5%Y*F#D 4
M&_3>M=G>JKE==,T3+U;ZU55T.5RF5RF4Y\#K>HMI&TN%MLKK3'8+;OHLSG*J
M;WV+Q4OY.'6"IEVDLWI-QW;9=;:G2MD@T[8*.UTGY.G8C=[&-Y>M3:G(,MMN
MZV22:@ #&@       !P<@   !P<@      #J Z@,F/S$.3B/S$.3%0
M                          ,"_P#R%<?JTGNJ9Y@7_P"0KC]6D]U1&55G
M@L>CVL_>,ONL+B*=\%CT>UG[QE]UA<16?S5F'R@ )4&-7_D?M,DQJ_\ (_:;
M/(UP .K      /&MG2DHYZA454C8KL)UX/8(!\TWJ>X7:Y3UE3#.]\CE5,L7
M@F>"&YI-8ZIHZ:.GI7OCAC3#6MIDX?P+]X?-9_=0</FM_NH>^^MQLF-PFI_G
MT<?A7>]HW)1UUZT0R*HG<EPFAWM]/)7>QZBK[!>M0:+EJJ1UO?*LBY5LB.5$
M7YR*A>N?L.,IUHB]Z'#C]1T;QN.Y?95PW)W\*8T[I2[ZFOWPG?8WQ4RN21RR
M)Q?V-1.PN=C6L8UK$1&M3")V(ASDXR3S<UY;-]I/8QPZ>_NK37=RK]0W-FG;
M&R5(][\?,J*C5QU9[";Z8LM/8+3#14R(JMXR/QA7N[5-IP[$3N0&9<N\)A)J
M?NWI^UU54^M*2LLVNH;]XE)5T7!R[B9X]ATIZ:XZYU?37">CDI+93X5.E3J1
M<X[U+;1>''"_8,]G#NX'6>JLQG;O)K;,N/=O?R81$1$3"(F$0UVH;>ZZ6>II
M(IWP2R-\B1JXW7=1L0>66R[CI.RC;=5ZHT5<9W2TLT['+AZ/RYDGKR=[Y=M0
M:Y=!2,M21L8[*;C5PB]JJI>&<IA<*GK0(N.2(G<F#V?^7-]5PG5]7'X=G:7L
MCFE[2NE]*N@>[?FC:Z5ZI\[')"M=GU%-<M?NJZB&1K&.?-E[51,YX?>78@X8
MX(B=R8.>'J+CU6SODV\<N,Q^B&;2]+2ZAH(YJ+=\;I\JUJ_GHO406QZKU#I:
MD6W2VUTK&>8V9KLL[L%VCAV-7O1%-X_4=.'P\YN-RPZKN>5'T.G;_K*])5W1
MDD,"JF])(F$1O8U"Z*"AAHK?%14Z8AC9T:)]ADY^PX(YN>\LD\2>QCATW?N^
M;7V:KJ-024<<$N7U#F(JL7")O+Q+?UQ:VTFSJ:AIF*J0,8B(U,Y5%X\"9\.Q
MOL0<./#)TY?5WDN/;P8\<QMJB=F&G9+CJ*.:IA>VFI<2.WVJF5ZD+GU#4NH[
M%<*AB*KHX7*U$YJN#8<$Y(B=R8..HCGY[S93*SL<>'0IS8];Y9=1U5941/:D
M;%5%>U4RJJ8^UM9Z_5;8(HI7LB8UB*C55.*EU\.I$3N3!SE.MK5^Q#I_Y?\
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MC4TWY=G>;9.1SR(  EH          !T=$URJJIQ.X \^A9V#H6=AZ !@
M                         (IKCG3=RDH?*QF-][6KZUP136LC'K3;CFNP
MB\ER!&#?:.^4W?J*:$WFD'-9<G*]R-3<7BJX G(.C9HW.PU['+V(IW
M/&JA6>EFBSCI&*W/9E"D=F^M;?H9];I752K03T]0]\=1(F&2,5<HN5ZR],FF
MOFG;/>X]V[V^FJ41,(Z1B*J?:;C=6_BS*;GY(I?MKVD;?;IIJ:Z05TVZNY!3
MN1[GKU)P4SMD%KJ;;I"-]:U635LLE8L?S$D<KD3V*A&+N[9AH:1U0^GMZUC.
M+8V)TC\^KG@G6@=1?A1IZ*Z)2NI62N<C(W<]U%5$7[4+GRVXH^].I(P <W0
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M@Z-O8#3'!D=&WL'1M[ :8X,CHV]@Z-O8#3'!D=&WL'1M[ :<Q^8AR$3" QH
M                               8%_\ D*X_5I/=4SS O_R%<?JTGNJ(
MRJL\%CT>UG[QE]UA<13O@L>CVL_>,ONL+B*S^:LP^4 !*@QJ_P#(_:9)C5_Y
M'[39Y&N !U8      P$(16Z^;#M&@TG!0+,]Z(LE0DGF=?(3O=1ENINIO@8(
MEK+6$VGKS:;?3VJ:N?7/W5>Q51(DSC*\"7*F. ]MF^^G  #0$5V@:LDTG04L
MT%MEN,L\J1I''E,>M<(2:G>Z6FAD>W<<]C7*WYJJG(3O-LWWT]  &@  # (1
M?=?);=?6_3$-O6IEJMU7S))CHT7U=W$2;NHRV26U-P%3F T
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MV$>B?3W[)WON+^XC[Z?  A8
M
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M)SQE2ZEYK@WM<9E/<QW,KC?8" (8MZ4WY=G>;9.1J:;\NSO-LG(YY$  2T
M                                             !U6-JO1ZM3>3DO8
M=DX          ,'&ZF,'( BFJ]GVG-3Q.2Z6]BR<TE9Y+D7MR9FB=.QZ6L<5
MK@J):B&)SE8Z7SL*N<?8;\(F#9;)J,LENP &-          !"]L_HOU']57[
MT,781Z)]/?LG>^XRML_HOU']57[T,781Z)]/?LG>^XO[B/OI\ "%@
M
M
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MI(S;K4D\2&,N[;[T" (8MZ4WY=G>;9.1J:;\NSO-LG(YY$  2T
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MI\ "%@
M
M      !K=035L%EK9+7!XQ6MB588\XWG=7$RW4;)MVN%ZMEM<UEQN-'2O=YJ
M3S-8J]V5,NGGCJ(FR02LEC<F4>QR.1?M0HS3NQAVHH9[KM!J:QUTJ)%<D,<J
M8B;V95%/#9_'5:)VO2:4H:V:MM$T2R(Q[M[HEY_8=9A+>G?=RN5^;79?X .;
MH&!?_D*X_5I/=4SS O\ \A7'ZM)[JB,JK/!8]'M9^\9?=87$4[X+'H]K/WC+
M[K"XBL_FK,/E  2H,:O_ "/VF28U?^1^TV>1K@ =6
M     .D[%EIY8VN5BO:K=Y$SC*<R);/-"P:+;<%CKI*Z:MDZ1\DD:,5/5P4F
M $NMZ99OR  -     '"M1[7-<B.:J85%3FA5U[V+VJLKI:JSW2NL\DKMY[8/
M*:O;A,I@M("=KMEFYJJXTKLAL]FKXZ^X5=5>*V-<L?4KAK5[=WC]Y8X!MMOE
MF.,Q\  ,4                      0! /2F_+L[S;)R-33?EV=YMDY'/(@
M "6@
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M:ZRS;.+'0W*%8*N*'RXU7*MRY53/KPJ$RPG8@P5<MS4B9CJ[M  2L
M
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ML'12?HW>PVP'6::GHI/T;O8<=%)\QWL-N!UFFL@C>DS%5JHB+V&S3D 3;MH
M#
M           #1WG2EAO,O2W2TT=3)\Z2-%4 #86RVT=KI6P6ZEAIH6\$9&U&
MH9@ \DF@
M
M                  :*\:4L-ZE26ZVFCJI$_.DC15]IL+9;:.UTS:>W4L--
M"WDR)J-0 ;[:9KW9H #0
M
3                      ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g111069g00a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a06.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1T@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)$-B-#93<R4G-T22P? 8)G2"D\+A\2B#HK+_Q  ; 0$  P$! 0$
M     0(#! 4&!__$ #81 0$  @$$ 0,"!0(%! ,!   ! A$#!!(A,4$%$U$B
M810R0G&!D:$&%2,SP;'1X? 60_%2_]H # ,!  (1 Q$ /P#U2
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MGRNQY5&ZE9'14C'-BE1=\ZZ78F.TW*:3[#\EH\JM"7&W<_8*Y6>UW[0WA47
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MQ\1[M19##:LVMD=M=4)J&1BJJ*I/93[F*UP1'B!FE-BEM8_235D_LP0[]]?
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MM+K7V*HN-A,Y;I. $!5<
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M<@"O,'P2JQ[*;I=)JIDD56Y7(Q$[BPT )MW[1,9CZ#A#D$) @ #Q  !   "
M         $"H  0  $      G<  \.H  >!$N)N,3Y9C$MLIIFP2/<B\SDZ=
M%):"9=>46;FFHQ2UR6:P45OED21\$:,5R>)MP"$R: H      !P<@  @ #P
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MC15]EJ:3O*+/3R ("0
M
M
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MC#_<[\R/E+TR@" E
M
M
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M>F4 0$H
M
M
M                                              .%[E.3A0/,JW"\
MYUQI=1QU;H*:V3_Z?,NE1/L_P2+]I&WU] ZBR>AK%B2D5K%8BZ5>JFMSS ,C
MQ_,ILAQ%5<D[N=_*O7?_ -*::XV+/\[JH**\-6.A1R*]'+I-)XG1->+*YO,W
M+'H#AY=Y;YAMKN,_22>%'._(DAJ,4M,5CQ^BMU.[FCIXT8B^9MS"^W1/7D !
M"0          <.\/F>9Y?YD8?[G?F>F'>'S/,\O\R,/]SOS(^4O3* ("4
M
M
M
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M1AW]9?S*_*7IE $!(
M
M
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ME[;QNI4R?_MWCUWX]3V$O@>:)EW^TC%OZR_F56>F $!(
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MK$:#YCTK4TNT\SZ,'<
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MXD2 $6[3))Z<.\/F>9Y?YD8?[G?F>F'>'S/,\O\ ,C#_ '._,CY6>F4 0$H
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M7^9&'^YWYGIAWA\SS/+_ #(P_P!SOS(^4O3* ("4
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MU>Y4/HJOA7F;:EB6ZX2(DB>XJ^):B+M-GS7/PY<.=QR?5]/SX\^$SQ  8M@
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MK>HR&>R\298;M7,9;*J/E@C<[W7;[R9-HMTL@'7#413LYH9&2-\VKL[-D)
MJZ154 #5S7VABD5CY41R'Q](K?\ ^-^ &W!B4-QIZU%6G?S(AE@#A?$Y.%[E
M \F2X]#D_%^Z4&37#L8>T58G<W<G72%@/X(8DK51;TY$_P#,;^I&,VX2US\A
MN%UGN*0,FE5[%5Z(NOO-31<,KC<E6*COO:2+W-27K^9T[W/%<LFKYCTUBMJI
MK)8:.WT4G:T\#.5CU7>T-NAH,%M<]EQ:WV^K>LDT$:-<Y>]5V;]#GOMTX^@
M$)          !P[P^9YGE_F1A_N=^9Z8=X?,\SR_S(P_W._,CY2],H @)0
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M5"VH)$EB;(Q=M<FT.+EP[*^@Z/J/O8>?<=@ ,G8                 ;
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ME;?%+)5:5M.]=-C0^+SBUH;>[.ZGCAY)G<LT#'(J(4_C<-W'33_E_)V]V_\
M[50=HS7O(?:+M-IW%TU5OQNERV.RK:HG=HSFYO(K?/[-#8\CFIJ9=Q.7F:GU
M?L+\/4X\N7;K7C;/FZ3+AQN6Y=72/! #I<KMI:B2CJ65$+E:]B[VAZ1P6^,O
M=CAEWN1J:<>:2?<(;V^@NZT;W_PIM:13A^H<'W>/NGN/0^F]1]KE[;ZJ^T[@
M$ZIT!\X^H<*J(BKY% \;\E=77-MIII%2&+_4UXJ7/EEQ;:\?K*ISD:K8UY=^
M9Y0K*I]=7U%7(JJZ5ZKLZ.GP[LMWX>7]4ZB\?'V3W76U$:B(G@<@'<^<
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MTM(YK$V]R-3S5='FB1S7?M(0JQR.3F7JB[\2ORN]-( @)0
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MYE%WIE  2
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MPJ:B2JF?+,Y7.<N^IWW6NEKZR261RJF^AAG?Q\?9'SW5=1>;+]@ &CE  0@
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M^QZ::XL9^RAOV@M_OBBWW<A5J%N_M"TZ]K15'@B<I47@=?!_VWSOU&:ZBN0
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MYGE_F1A_N=^9'REZ90! 2@
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M=DJO2[;#(B[7E39GH0[A[4N?2.A<NT:3%.X\_.=N5CZ;I^3[G',@ %6P
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MYGE_F1A_N=^9Z8=X?,\SR_S(P_W._,CY2],H @)0
M                                                          4
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M          <.\/F>9Y?YD8?[G?F>F'>'S/,\O\R,/]SOS(^4O3* ("4
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ME0W1 N*$Z^CPQ(ND7KHY^JS^WQ99*Y745SM7*JN7:JIP ?,.4  2
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MBB1>KG+I#S3!5T];^T7#+22MEC55]IO=WE5GI]  2
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MD5"(GCHN4%LOJ//?E7'Z7T^/P@]GX<6F@1.T19E3ZR(2ZBH*:BCY*6%D;?\
MI31E Y,^7/D_FNW9Q\/'Q_R30@ ,VH          "]QJKM8+==6*VLI8W[\5
M:FS:@(LE]JON?!^U5+G.IY7P[\$1-$=JN"TJ(OHU7M?M+R!I.7.>JYL^BX,_
M>*@V<&+@KDYJINOF;6BX*Q(Y%J:QVO'1<X)O-G?E7'Z?P8_TH'8>&-EM;T>^
M-*AZ>+VH36EI(*2-(Z>)D;$[D:FCO!G;;[=.''CA-8S0 "%P
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MWU'+M.=R[7O/73O \SR_S(P_W+^919Z90! 2
M                                   '4ZHA:NG2QHJ>;D/N3W'?(J.V
M4<-SS2MAKYI5A15TWM.5$+2;=73=/.:97*ZF,VMMDL;T562-<B>*+LY9(Q_N
M/:[Y+LJ))9+3?JVAMU1))2O:NUYN;7^3ZPV^U=L@K5CI9JQC7;<[>^4GL=.7
MTV]MRQRWZU\>UN*Y&IM51$^T^(YXI%5(Y&.5/)=D4=._,;"BT$ZTBJ[3_/Y$
M:AI'V_*Z2FL,\C^S;RU*O<NM^/>1,67'T<RF4RRUE-^/[?FK4 ;OE3?>"KA
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M*=J)#$QB)W::=X
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MI5C8C3-3H $N'>'S/,\O\R,/]SOS/3#O#YGF>7^9&'^YWYD?*7IE $!*
M                                                       ?,GNN
M^13]MMD5TS>MAG=+&W:]6="XE0QHJ&GCF=*R)J2+WN1.I;'+3KZ;JOX>9:]V
M(Z['*&RVJNDIFN?(]B[<[JI%<(54QN\=%1=^1:;V->Q6O1%:O>AT14-/%&YD
M<3&M=WHB=XF7Y7PZRS#+'/S;9?\ 17.$WG]RXS).^EEE8LR[5J=QU7JNCO.0
MVQ]A5>U54=,C$UT\=EEMH:=L*PMA8D2][==%/BEME)22+)3T\<;UZ;1">Z;V
MT_C>/ORY>WS=_/C_ "RX]HQN^_2'(!1YKKGF9#"^1ZZ:U-JI1&=W^6\761C'
MJE,SV41%+"XH7Q;;;64\?OS;3Y%+[5555[UZJ;<>/R^C^C=))/OY?X  :O>
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MZ'I/M3OS]M^/#7FN0!L]%H    -@ -C8 #8V
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M._,CY2],H @)0
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MH\ZH68Y(Q\4_M3-C7F1?F7N4R[<]^?"=_*TP?+-\J<WO:ZGT=[0
M
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MP[P^9YGE_F1A_N=^9Z8=X?,\SR_S(P_W._,CY2],H @)0
M                                                    =4_^B_PZ
M'8YR-3:KI"'93D/(JTM&NU_J<AQ];UW'T7%>3D__ *Z.FZ?/GS[<%7OM+YKK
M5NF7V>T547SZFUIZ:*!NF-3?F=ZKM55>]>H/S[ZC]7ZCK\KW76/X?92W6C8
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M-(V2JIUIY5[V*N]&6;R[\K  )
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M=KF;- JJJ.:OVE%GJE $[@2
M                       '#G(U%55TB=Z@<G',B=ZH1>^Y?24+'-IW-EE^
MSP('<,KN58Y=2K&W_I.+FZ[CXO'NJ7DD6S-<J6%5229J*AB.R*V-=I:INRF'
MU,\BJLDSW*OFIUL:LDB)U55.'/ZKE/,Q\*3DN5U(M;(LCA;2\E%(CW/Z*J>!
M!GN5[E<]=N7O4ZHF<D:(=A\3]2^H9]=RW/+U/4?:=%TTX.*3Y^0 'G.P
M       CU\H>15G8G15ZH2$ZJB))H7L=UVAZ/TOK\^AZB<DOCY_LF72$NWHM
M3!;I;+!8>UJYVLEEZ\OB0"W6.IN-S]#IT5%7Q^PL.V<+Z18VK<YY)7IX(O0_
M5;R8\F,RQOBO(^M=1)A.&>ZZ;EQ2C5[H;91R2/7HUR]QK'3YGD+$8J>CT[^Y
MS>G0LJVXW:[?&UD%)%[/BYNU-NQC6-Y6HB)Y(9OFU84/#!\KD==Z^2H3O5NR
M86?$;/:T3T>D8JITVY-D@ 'S'&R-O+&QK4\D31]
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MB=#/._'TT  2
M                   %6<0<IO53?F8UB;/^.5-S2KW,;LM,IO,ZFKP?/ER3
MT=U3;ZMO93HQ-JQ-]Y;#VIG=1CXK<\KM.376T72?TNKBI$GC8B[15)CPXRBE
MR-LJU-(E)>(?9F:K=*O4@=CSVP5W%NKNOIC(:1U"V/FE7E]I$[C:8?617[BQ
M672S,=^[6P<CWHFFN=OO+V?EGC?Q5QG#_<=\CDX?[COD9-U:W;_<)3$,N[?[
MA*8@$LPKW'DJ\R*X5[CR5>8!2E>+'#*^95E"7"V5S88$C1O*KM=2ZCA4VA..
M5Q\Q7+&935>+;9B%\N>9RX]17!7SP+J5R.Z)W[_(V7$CAW?L/H65DEP<^C<J
M-<]'+T53>Y7:,FX?<1JN^VBCEJXJIZR?PVJJ*G7HNC$RO(LRXF)!9Y;'-1P/
M>G-["HGS.G=MW\.;MDEGR]!<*FJS +,BR]JO8)[>][ZJ2TT&"6:2P8G;;9,J
M+)3Q(QRIYF_.:^W5CZ#6WZZ-L]NEJWP2SHQ-\D2;<IL@J(J:5$5"$JXH.*=/
M6UD-,VQW:-97<O,^+2)\R*X?&E'QJKV2>RZ>+G:BEW=G&G5&-3_!6_$7"KA6
M7FCR+&7M;=J;3>S<NFO;]JFF-GIGEC??M]<?)F18')SN1.:9B(GGWD@X8PO@
MPFV,D14=V:+H@=;B669M<Z-,O9!16ZE]KLX'\W:.^U"QK[^]:"UQ18Y2PS2L
M1&HV1W*B(1?7:8^;<FAXQW:Y6[%9H[-33SU,WL?PDVK4\2KILEMMIX<5MJI+
M'<H9ZB+<TSXNBO\ %54]"6_MY*.):Z-C:A6^VU.J(II\\L\UXQ2X4%"R/TF:
M/E9S)I-C'*3Q3+&WS%<_L[9''/9$M3:*I:]BJ]9E;["_9LNA"%<)<=K<:Q=E
M#<VQI4-<J^QU)J1G9;=)XY9CJM%F>,T.5V9]MNC>:G>J*OS0\UXUCM%B_'RG
MH+8FH&JJ)]YZO=X?,\T2_P R$/\ <[\RB[TRG< @)
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M'5VNV7^B<YKD<G=]I9%DJ%JK52SKWR1HY2<.7NRN)+NZ9H -E@
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M+3*\N,KU*"/X'<ZF\8G;J^O8K*F:-'/:J:TNU) 9ZTTEW-@ "0
M<.\/F>9Y?YD8?[G?F>F'>'S/,\O\R,/]SOS(^4O3* ("4
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M%C?[[KJ22>=4IX%YNRUWJ2"&-L4;6,336]$0TX^.XYW*ID\OL '0L
M
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M+.SF8U6ZTGR-J:'!JNFKL6M]10TRTM-)'MD6M<J;4WR=QC?;HGH !"0
M     <.\/F>9Y?YD8?[G?F>F'>'S/,\O\R,/]SOS(^4O3* ("4
M                                              !3F=R]I?YTW[JZ
M+=FJH(4599HV:^LY$*7RJ:*HOU7) ]'L5W>BGF_4_P#MS^[+E]-2 #PF(  "
M]QM:%VX43R-49MM?IZM\SA^H\??PVSX>E](Y?M=3)?GPV( /FGV8
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MWOY_LFR=P,6UR.EH87O]Y4ZF4>SCEW26/(RQ[;8  L@
M
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MW&W+>5UE=V>/*)]0RDQUC-XS4OX?,,:11-8WN1-(?80'I2:\//WL
M
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M;DN4%+)5/:Y&]FQ-KU/-V#7^?*..--<IJ26F5VUY7MUXE%GKI $!(
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M7/OQ_P QO0:^EJ])RR*9[?:;M$71\YS]-R<-UE'V'2];Q=3CO&^?PY !SNL
M    #@[(89)G(V)CG+]B$HL&,222)+6MTQ.YIU])T/-U><PXL?\ V8\W4<?!
MCO.M?CUDEKYVR2M5($7>U3O+'IX6PQ-C8FFM32(<4\+(8T9&U&M3P.T_0_IG
MTSCZ#CU/.5]U\OU?5Y=3EN^H  ]1Q@
M
M                           4_?JY,4XGONUZC>^VU4?9Q2(FTB=OO4N
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M>%U+&])[A523RKU5J]Q-+?8;=;]+2TL;')XZZFT '"(B>"(<@
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MDZ( >YQ<.'#CV<<U'GYYY9WNRNZ  T4
M
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MQC]J_%:7 :VNN&)VZINS5;6R1\TJ*FNNU)"?+$:U.5J(B)X(A]&5:R:@  D
M         '#O#YGF>7^9&'^YWYGIAWA\SS/+_,C#_<[\R/E+TR@" E
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M0
M
M   "KN(&67F6^,QO$6+^\53<LJ]T:;[RT2F\RJ*K!\^7)O19*FWU;.RGY$VK
M$WWE\/:F=U'1B]SR^SY/=K1>JIMQJ8Z1)XFL7:+O_!-.'65TV1Q2-J*1*.[0
M+RS1.:B.^9 ,>SNQ5_%NLNSJQE/2.H6QHZ7I[6NXVF'U4%]XM5MULJ*MM2'D
M?(G<YV^\ME/RSQOXJXCA_N.^1R</]QWR,FZM;M_N$IB&7=O]PE,0"685[CR5
M>9%<*]QY*O, I2/%S,<VLF4I2XW1.EHNS1W,C47K]Q=QU20QO7;HVN7S5"<;
MJHRFX\I^N#/_ $Y*)*=%JU721<B;_([+QQ7XC6C3;G1K3.=[O.Q$W^!Q07Z+
M#^,]TJ\CIG.@DD5(E5ONIUTJ&UXY<0;)D]FBMUHC=+7.>U62(G=]AT:F_3FW
M=7RO?A_<JV[8C;:ZZ-1M7-%S/1//9(B*<+8JF+ [,RN:K9VP)S(O?WDK.>^W
M3CZ  0D          '#O#YGF>7^9&'^YWYGIAWA\SS/+_,C#_<[\R/E+TR@"
M E           !'L\?R8W4JGV$A-#F\?:8]4I]A;#^:+\?\ -%*IU 3HJIY
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MP:J>T$JST<,KN][453O/B&-(HFQM]UJ:0^ST8U  2
M
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M*GB?1TT*1I21) WEBY4Y4\D.XZ9Z7  2
M
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MIS0U,573,F@55B>FV[31WG#&M8U&L1&HG@B')TQ8
M
M                                           JO.<KR";)TL&()&VK
MC;SROD3:(A:A469MKL.S;Z3TE+)5TU6U(9VM3:M3?>6P]J9^D;CS3B'1UD]-
M/20UDD/5[8V^!(>$^>7+*<AJJ:MM3*5L+?:D1NEWON/FEO\ !9>),E5=9?1J
M"X4J/8^3HU%\ABMRI:[B]5KC[VOMBP;E='[BOVG4TNM>F<W+[7$</]QWR.3A
M_N.^1BW5K=O]PE,0R[M_N$IB 2S"O<>2KS(KA7N/)5Y@#A>B*<G"@4'BV97&
MX<4LG6>H>E+;X7HR)7>ST1>NBL;Q#?:BT5N:I<IFQLJ=-C1R^9-<[X89)!E]
M;5XX]_87%5[16JG3?>BDOR+AW5>J:CQVB:CJI9&NF5->?4Z)E)Z<W;;N7X6!
MPUNDUXPFTU]2NYIH45R^?71)T-)AMG_<.-4%L1=^CQ(S9NS"^W1CZ#5Y%<Y;
M5;):JGI)*N1B;2)G>IM!I"$JPMO$JZUE=!3OQ.OA9*[E61R]&_:1[$XTH>-E
M;'+[+ZB)7M1?D7?I/(KWB+@]1=[A37NP3^C7NFTC7?TN3R4TQRGIG<;[]L?C
M]41P8&Y'JFWSL:U/->I(^&<#Z?"K9'(FG=DBD(;@N291=:63.*R-]%2IMD,&
MD1SO-40L#(8;O#;(XL:6".9FFHDB)I$(NM=I-[N2-<<KQ66G":AU ]T<DJHQ
M7M[VHJG."X;99<.HW5E+%633Q(]\TK4<[:IYDENEC;D&-.MM]:USYH^616)W
M+YH5S;\5S['J*2U6*X4[[=M4C=,B*]K>[O5?(F>M;19^K>MNKAF^IMO%*\V2
M&IDEML<2O8QSMHQ=]R%TH07AS@Z8VL]=73.J+M4]9I%_)"=)XE<KN^%N.63R
MX=UUM-GF>5$_^TA#I-)S+W?,]+N\/F>:)?YD8?[G?F4^5WID! 2
M     =%92Q5=.^&=J.8Y.J*=X J?*\1DM[WST:<T*KO7D0]>BJB]%3S/0TD;
M9&JU[4<U?!2(7W"J6MYI*7^%*OW'5Q\_QD[.+J/C-5 -K<K!7T$SF/@>]J+[
MR)T-6]KF+I[5:ODIU2R^G7++Z< ;!9(!L[H:6HFUV,+W[\D(V.DS;/;9KI5M
M@@:O7O7R))CV%5%9J6M1T<?DO12Q+-9:2UQHE/&G-]94ZF')SS'Q/;GY.HF/
MB>V)C&/4]GIVHUJ.F7WG*;X XK;;NN"Y7*[H "$
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M5.&[9G]Q;"JI&KEVB%K(:]/E<L/*<;N  -U@
M
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M=<9UGJEA17R*N^9=^9*4(MPQH*BVX-:*2M14GCA1'(O?LE)A?;HQ]  (2#0
M#0T  T     X=X?,\SR_S(P_W._,],.\/F>9Y?YD8?[G?F1\I>F4 0$H
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MGM >&]MG2JKKC50NC=,]>5')I>\GR#0)X^.<>/;"34T  ND
M
M                                                 '34T\-3&K)X
MVR,7P<FR,W/A_CER:Y*FW,7??RKHE@)EL](LE]JBNG ZRS/5UNJ)Z1?#3MZ.
M_A_PPJ<6RR2Z3W-U8QT79M1R:5O4M8$]^6M*_;QEVX<JHU53JI&[ED$]%*Z.
M6D5$7N7S)*8-TMT5? YDB)S>"E5U>54WI$[I=:YO ZC*N-#+03K')M4\%,0#
M;6:\+;&N1(N?9+[173UL?:2P=DU>[9',=L:U#FSU"?P^]$\R9QL:QB-8B(B
M<^!6F3<1ZBT<1*+&V6Q\T4[459TWTZ%F*4IQ4XF4&(9>RGFQYM=5,C1S:C75
M-^!;&;JN5U&@R?C RVY%<*)<32?L)59VG*OM?::^#CEV,B/BQ#E=YHU3IGXV
MV.>9\L^'1/F>NW*K>JJ=;^-%@8U>;"X6K]K=&TQ_9CW?BIECW'JDK;G34EQM
MSZ-)G(U'.\U+PAD;+"R1B[:]J.3Y*4O-@%LXB6['\BH8VVI4U,Z)K>_2]WX%
MS4L784T,2+OLV(W?R31EGKX:8=WR[  4:           X=X?,\SR_P R,/\
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M7=FQ&[4QY=:C'EUJ,T &+
M
M
M                 !A7.WQ5T"LD3VO!2/6O&W-JW+4IN-J^S]I+@!\QL;&Q
M&L32(?0  TUUQJTW2I](KZ**:9$US.;M=&Y.%'HT\I8NEC7C)<H<ACB@HX)%
M; QR::JIO1(_VA?HLE@CEM*TO[S:]O*R%$ZI_@DG%'A]B]ZO'I<URI[?<%3V
MD5VMKYD4MG#7$Z6M967K)*>IAA]KEY^_7^3HEE_4YNVS>.EQ\)YGS\/K+)(Q
M&.6!-HB:UU4EZ&NL$M#-:*9]I5BT2LU$K.[1L3"^W1CX@ "$@   ;3>MIL
M#Y5[$72N:B_,#Z 147N '#O#YGF>7^9&'^YWYGI=W@>:)?YD8?[E_,CY2],H
M @)0             ,:XT;*ZD?3RJY&/32JU=*:3&\.M=@JIZFC8]T\WO/D7
MF4D@)F5DTF9634$ !" Q;G04]SHI:6LC22&1-.13* /2"MX86%K6Q_\ $+"U
MW,D2R+R_<32EIXZ6!D,#&LC8B(B(G<=P+7*Y>ZM<KE[H "JH  !'[]B=LOE9
M3U-?&YTL#N9BHO<I( 3+9YB9;/,?,;48Q&IW(FD/H A
M
M
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M
M
M
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M[\RGRL],H @)
M
M
M                                                   #S+Q9JH:+
MCW::BJ>D<,;&JYR^"'IKQ*HXG\,++D=W_?-WKUI>5B,5? OQV2^5.26SPJGB
M_?;;<>+^.UU'51RTL*1]I(U>B=2:?M!Y99+OP]EI;=7Q3SK(U48U? ZW\!\=
M;1+6R723T9&\_:KW:\R,T?#_  *X5ZT,5_>KU7E:JIT<II^GX^&7ZI[^5V\&
M/_9K8O\ R$_-2;&HQ.RQ8_C]%;*9ZOBIV<K7+XFW,;[;XS4  0D
M '#O#YGF>7^9&'^YWYGIAWA\SS/+_,C#_<[\R/E+TR@" E
M
M
M
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MW._,],.\/F>9Y?YD8?[G?F1\I>F4 0$H
M
M
M
M            -/DF2VO'*3TF[U38(O/O4>RW3G+JN2@QFZ54#N66&!SVKY*B
M%=_L\91<LGL%;-=JAT\D<RM17>1O:+B%B&7QS6JDN22+4M6)6JU6[V8U)!C?
M"3'ZERS\D;W*_E5=JY5+R:FOEG;YWOPL<&HQ6]Q9!8J2YTZ*V*H;S-3RZFW*
M-)Y    "KT  TU'DUKK;Q/:Z:I22LA]]B)W&Y&B78#YED9%&Y\CD:QJ;55\$
M*^EXQ8A%/)$ZNE58W<CE;"JIOYDR6^D7*3VL,&!9KM1WF@CK+?,DL$B;1R&>
MA"7#O#YGF>7^9&'^YWYGIAWA\SS/+_,C#_<[\R/E+TR@" E
M
M
M
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M\VX%CU1C''&EH*NI?4R-VBO<NU[RB[U\@ )
M
M
M
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M9YGE_F1A_N=^97Y6>F4 0$H
M
M
M
M  4\[\9L.R2X\18+Q8(D7LHD1CO)3T0I47'+B/48G#%06=J.N,W7?>K4^1?C
MWOPIR:UY0?M^+3>G:K^!J<HLO$S);2^ANFYJ95YE:NN\OCA3=;I><2@JKY%R
M52KK:MTKD\RLN(?$?)<5SQD<L'+:.=&\NNCD\]FDMMU(RN,DW;5J\+[=4VC!
M;30UK4;/##RO3R7:DK3N,"QW&*[6FFKH-=G.Q'IHST,;[;ST  A(
M  .'>'S/,\O\R,/]SOS/3#O#YGF:H5&_M'PJ[ZR_F1\I>FD 3N!*
M
M
M
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M*WR2=T*=O+1+XM\BSL R>+*L?@KF-6.;7++&O]+D\"+CKRG'/=TD@ *K@
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M<;KZM]D65&]NE'YM[]?<6#PRRUN66))WL[.JA7LYF+]9!<=39,]W28  JN
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M>:SCE>*>##G4,<C7U%<J1QM:N]DBX8VQ]JPVWT\J:DY.9R>6RO\ 0O\ UI4
M"C0     !L'55ME=32MIW(V56JC'*G1%\ .S9J,EQV@R.C]%N;'NA1=Z1=$*
M_<O$;M%5+_0\G-O79>!85KCJHZ*)E?(V6I1/;<U-(JDZU\JR[\6*"R>UTEFX
MPX[1V^%L4#',TB(B>)8/'JH=!@-6C=^VJ-71"^(&O7C8O[F_F6-Q>MCKI@MR
MCC3;XV<Z)YZ-+[QVRD\9:9?#&)L6#6EL::18&JOW(0"T_P /CS5-9T1\;E=]
MI)>#N0TM=@M.KI6M=1L2.7FZ:TA&<%<F0<6[M=Z/;Z.F58DD[D52)XM3?,QT
MNH &;8           CW$&=:?#;O(U%54IW)^!(34Y72K6XY<J9J;=) YJ)]N
MB9[1?2 ?L[M1<.>]4]I\JJJ_Y-%Q1_@\8,8DCZ/=K:I\U-GP"KH:6WW&SS/1
ME32S+MKEUM-FJR-[<IXUVN*B7M(;>J)*].Y.\UG\U8_T2+T !BW
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ML^XF.-X];L>H4I;9 V-G]3O%R^:J;<$W*U68R>8A^9</[3E$\514K-353/\
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M(-$]UUI68R78 "%@
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M3,1Z?9M#.*?_ &:+O+=,,E9*JKZ/*C$^6BX"N4U=+8W<V  A8
M
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M^:KJ:%4EE=S.Y7:39)K!AUFL5JFM]MI&Q02MY7Z[U36N\MER2^E<>.SVH_\
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M%X$/X68_]'L2I*9Z<LKF(]Z?;HF!GE=VM<)K$ !58
M
M              :ZMLMLKIDEK:&FGD1-(Z2-'*AFT\,<$38H6-CC:FD:U-(A
MV &@                          =-530U42Q5,3)8U[VO3:*=%#;*&A5R
MT5'! J]ZQL1OY&: "       V
M                         PH+5005+JB&C@9.[JLC6(CE_P F: "=P
M               ^)8V2L<R1J.8Y-*BIM%.JCHZ:CC6.D@CACWOE8W2&0
M                    8M304E5(U]3312O8NVJ]J*J&4 "(B)I.B
M
M
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M0#Z15_UD'TBK_K(!/P0#Z15_UD-ACUYJZNZ,AF<G(J 2\
M
M
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M/5_U$ U(-M]'J_ZB#Z/5_P!1 -2#;?1ZO^H@^CU?]1 -2#;?1ZO^H@^CU?\
M40#4@VWT>K_J(/H]7_40#4@VWT>K_J(/H]7_ %$ U(-M]'J_ZB#Z/5_U$ U(
M-M]'J_ZB#Z/5_P!1 -2#;?1ZO^H@^CU?]1 -2#;?1ZO^H@^CU?\ 40#4@VWT
M>K_J(/H]7_40#4@VWT>K_J(/H]7_ %$ U(-M]'J_ZB#Z/5_U$ U(-M]'J_ZB
M#Z/5_P!1 -2;;$_][9\E'T>K_J(;''K/5TET;-,U$8B 2\
M
M
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M0V
M
M
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MZ9G,E)KVF+]I/D[CA$Z')E;MM)H !"0
M
M
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M[)=*C$5M.3]@J]EV7\'NT1"CQ;.<<AGMN.U5');G*O(Z;WFHI<((F5A<(K_
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M@ 56
1                  !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g111069g00a07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a07.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[2"B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ((4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9G9F<3T4G5C?,1F(YMF ?.EF944\<T2HYCVHYJIY44^ADUC>
M
M
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M_P"OM);@V:W:BN,LCZF1J.AD>CVJQSL9])?N^DL^\ZPVO!PQ<L:J^5#DS:@
M
M
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M7\N6F?W7\Q398UIWK^7/3/[K^8III\6>IP;*1>YM]"'8ZQ>YM]"'8S:
M
M
M                                                         ,
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MXF.1R?:@,ON  D
M
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M:=NT-\L])<:9KFPU#$>U'=41>\6G4V9SP36*9W<63 !DU
M
M
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M:+TB8^*7@ S:
M
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MY<D:=5,P!M3U1LUZ  (6
M                     #(R1ROU#XE7O@DBXF(O5%,E;KO2URXA?[+\U>2G
M/TO:G9=75G1K>-J)QC@WMV;5K6+S7<R("*#H,
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MXGN1J<N\CW76_+)[]V>?_<?JE(#5RB*GE!@^L
M
M       %;ZJ=B\S(8J*9\3D=&Y45.X]^K78O<_I,-QGY+VZLQVK4F/S3]WLN
MS4B=&L3TA9NF+KZHT:]IA)6<EQY3-(N2N-%5KH;HD2>UE3"EC(?H7L/MENU]
MEB;SFT;I>:]H=GC0UIB.$[W( .P^(
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MKG4=+<KC/4T\$KDCCD7*,Y^04C;F8Z1DM;9B)^.%X  A8
M                                              57K%V+[/Z3"<9E
M-:.Q?ZA/.82/BD<C&(KG+R1$/R[MM,]IU/6?N]SV6O\ 8IZ0E>A*9:FZ]I_=
MB3)92$?T9:%MMO1TR8GEYN3N)"B'NO8O9)[+V6(M&)G?+ROM+7C6UYFO"-P
M#KO@
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M''0:TU#20JYT<#EC:J]<(I;2BFU;$[\(U)OBN>&8;'  Q;@
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M*14SPX55.MGU7:+O4=A0U;9)?S<848,PS@ (2
M                                      !K3O7\N>F?W7\Q398UIWK^
M7/3/[K^8III\6>IP;*1>YM]"'8ZQ>YM]"'8S:!!]U?@BE^N_V)PO0@VZJ_\
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MEPCU=%GO:JHOVFQWD*\JMK+7+K>/4]/5U5-5M<CECBPC'+YQI7V;3%N$Q_\
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MS5KE<]LBIA,KY!I3LVF9YQ@U(FU8B.N4V !5<
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M#4XVIR3D9=JY1%[RB\.0
M                     UIWK^7/3/[K^8ILL:T[U_+GIG]U_,4TT^+/4X-E
M(O<V^A#L=8O<V^A#L9M \]914U:Q&54+)6HN41R9YGH!,3,;X1,1,8EB_4&U
M?J-/_D0Y]0;5^HT_^1#)@MWE^LL^YT_RQ^C&>H-J_4:?_(@]0;5^HT_^1#)@
M=Y?K)W.G^6/T8SU!M7ZC3_Y$'J#:OU&G_P B&3 [R_63N=/\L?HQGJ#:OU&G
M_P B!EBMC7(YM# CD7**C$,F!WE^LG<Z?Y8_03DG(8 *-3"   ,(  P   P
M P@P  P       !@
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M3@V4B]S;Z$.QUB]S;Z$.QFT
M
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MOYJ?8:U;U<M\M,)A.79?S%-J6B9W0QO68C?+96+W-OH0['6+W-OH0[&#<
M
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MIG]U_,4TT^+/4X-E(O<V^A#L=8O<V^A#L9M
M
M
M                                             -:=Z_ESTS^Z_F*;
M+&M.]?RYZ9_=?S%--/BSU.#92+W-OH0['6+W-OH0[&;0
M
M
M                           #(10 &1^P                      &M
M.]?RYZ9_=?S%-EC6G>OY<],_NOYBFFGQ9ZG!LI%[FWT(=CK%[FWT(=C-H
M                 8VY7:"AE9'+E5=W>0"-:LW-L&F+HE!<9)5GPBJC&Y1O
MI)9:KC372@AK**1)()6HYKD[B@]]]#3UL[M36ASJF-Z(DT36Y5N$Z^@B&TNX
MU9I2Y1456]9;3,]$>UR^Y9\J%]G,;G2CL==71B^E.9YMML@QM1>[?36M+C+5
M1)1JU')+Q<E13YV'4-LOL;WVJJ94(SD[A7H1LSC.-SFLL#C)R5 !5P<<2 <@
MXXD&0.0='RLC3^T>UOI7!V:Y')EJHJ>8#D'"K@YRG> !QQ(%7 '(.$7)R !Q
MQ#('(..)!D#D''$<*]J8RJ)Z5 [ )S
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MC6G>OY<],_NOYBFFGQ9ZG!LI%[FWT(=CK%[FWT(=C-H
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MC^J;^!6>$/EU9V-'3M'Q>MG)J(<@%7P@
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M@91VJFCIZ=J>U8G7TF21!:8Q%8X05B<S:W&0 %5@
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MZG!LI%[FWT(=CK%[FWT(=C-H                   =7QL?A7L:Y4Z93)V
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MTR35.@
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M],_NOYBFRQK3O7\N>F?W7\Q333XL]3@V4B]S;Z$.QUB]S;Z$.QFT
M                  !'M:7*>T6SQNAACDJ%<C,N3R?L,#%K"OGM;Y601-J>
MV6+LU5>283F3JH@BJ&<,S&O;G.')D\R6JA1SG)2Q9<N57AZ@11UYO*MG:U]*
MU\,:+A<JKE4\U/J:[O?7QR-IT=0O1%7G_:(O<3=MOI&N5S8(^+&,X\APMNHU
M>YRT\?$Y<JN.H$2L^J:^O==X74[(YZ2)KV)SYJI\W:DN[639ABXV\,;6<\\2
MIGB]!-(Z*F8^1[((VND1&N5$YJB=X6BINT618&<2X15P!'*R]W&DM$4CH&.J
MU56N;SQDQ,&I;Q76]U92M@1.Q<[@5%SQ(N,$\?31/]O&UR9SS3RGSAH*6)BL
MC@C:WGR1._J!!4UG<4[%OBC7/[%'RHC5Y+GGS]![FWR\=HL[889(%X7-C15X
ME:I+64=,UJHV"-$7_P"TY91T[7HYL3$<B81<>0""U^K;E!;O'XHX7,=(D:1+
MG+>>%53*T%[KI[U$R3L6T;T5$QE7*I('6NA<QS74L2M7JBM.\=!2QR-DC@8C
MVIA%1.@$6O.HJ^GIHY*5L&6HYTG$J\L+C!F-+U%3<+>RIKVQ+(Y<M1O/A/>Z
MVT;^+BIXW97*Y0^]/3Q4[>&%C6-[D ^H
M              \D]?%#(K'JN4/GZJ0=ZF,NWOQQXSZ:Z59C+X[Z]HM,0S_J
MI!WJ/52#O4P +=S57WB[/^JD'>H]5(.]3  =S4]XNS_JI!WJ/52#O4P '<U/
M>+L_ZJ0=ZCU4@[U, !W-3WB[/^JD'>H]5(.]3  =S4]XNS_JI!WJ/52#O4P
M'<U/>+L_ZJ0=ZCU4@[U, !W-3WB[/^JD'>H]5(.]3  =S4]XNS_JI!WJ/52#
MO4P '<U/>+L_ZJ0=ZGTIZZ*:3@9G)'#VVCWTA6VE6(F5J:]IM$2D( /F?8
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M*1>YM]"'8ZQ>YM]"'8S:
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MC+7(J+,_M:US%]K&GDSY"TK71Q6^@AI:=,11-1K2D1FNUU7F?Q;+U  A(
M                !PH'.3HLT37<+I&([N5R9*DW2US=VWZ'2NCHDENTK>*6
M3R1H5K?+-J?3&L]-+?KRM5)63M56,Y(WGS12^G3;F.43P5O;9SC?,;VT_$F<
M93)R4UNXW5]EN<&I;!/VENIHFI-38ZIY54L+0>IH-5Z=I[E3IPJ]$1[?S78Y
MH1%<UVHY<2;1%HK/-(P$Z JL                   :T[U_+GIG]U_,4V6-
M:=Z_ESTS^Z_F*::?%GJ<&RD7N;?0AV.L7N;?0AV,V@
M
M         "/7;WXX\1[;M[\<>(^ZGAAS-3Q2  LH
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MSU.#92+W-OH0['6+W-OH0[&;0
M           <(IRJ@ ,C( #)QD#D'&3E  .,G*
M        $>NWOQQXCVW;WXX\1]U/##F:GBD !90
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MXF,0W$B]S;Z$.QUC]S;Z$.QBV
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M2+W-OH0['6+W-OH0[&;4
M   ZN3V*G8X=[52)X#7+9KY:-2^F3_YFQR&N.S/RT:E],G_S-CD-K^"G_P P
MK/FZGK+S7&I;1T%142*B,B8KUSYD-?=H*9VM=S;IJ>X-5\=(O#"B\T1W0LO?
M.ZNM>W=Q>QW"^9.R14\YC?!TM$=OV^@GX<2U3UD>J^7G@KH[MK4Z;H^?^D:O
M"M.LY^4?[6BU#"ZLTQ;-46UU%=X$EB7VKNCFKWHIFT3 4SQE>-RJK+LO:*"Y
M1U5?<KC<XH7<45/5/RR-3'7QS=>[BTMBA3_P6SKVU1CVKWHO)I-MT=2?DUI6
MIJ(<+5S?V-.WRN>O),'DVETNNGM.]I4HJW&M7MZAZ]5<J9P:TM,_CF=U>'K_
M *X_HSM6(_#$;[?;_?#]49UCJO4%RUC^2&AEAI)8&<<]6],I'YL'GL>L=3Z3
MU=2:=UO+!7-K?<*R).'FJ],'DV^5+9OEJF"O>C)JEK70\:XXD\Q\M\'-K]PM
M)45&Y'U3)>)R,YJQ,]5)TL9TXG?M<?K]C4CS,3C9X?3[KY:N410=($5(6(O5
M&ID[F32                           1Z[>_''B/;=O?CCQ'W4\,.9J>*
M0 %E                      /E475EGC\:E8Y[4Y8;U/J835_P0OI+Z=8O
M:*SPEGJWG3I-Z\8>WUR*3]2F'KCTGZE,5JB<CG"'W_T_0Z?5R?ZOVK\WTA9/
MKCTGZE,/7'I/U*8K;"#"#^GZ'3ZG]7[5^;Z0LGUQZ3]2F'KCTGZE,5MA!A!_
M3]#I]3^K]J_-](63ZX])^I3#UQZ3]2F*VP@P@_I^AT^I_5^U?F^D+)]<>D_4
MIAZX])^I3%;8080?T_0Z?4_J_:OS?2%D^N/2?J4P]<>D_4IBML(,(/Z?H=/J
M?U?M7YOI"R?7'I/U*8>N/2?J4Q6V$&$']/T.GU/ZOVK\WTA9/KCTGZE,/7'I
M/U*8K;"#"#^GZ'3ZG]7[5^;Z0LGUQZ3]2F'KCTGZE,5MA!A!_3]#I]3^K]J_
M-](63ZX])^I3#UQZ3]2F*VP@P@_I^AT^I_5^U?F^D+)]<BD_4IR4Z?NS+S0)
M511NC:JXP[J48O12W=N/BZSZ2GQ]M[)I:.GM4C>Z/LSM^OVC5V-2=V.B4@ Y
M+O@          '"G)P[_ % JK=K;=^J:R*YV"L;1WR!.'B1_#Q)Y\&:O>B7Z
MCV_@LMZE1]?'$G]MG.)$3&<D$ME94VO?JY>KM5)34M0U?%D>[$;TQ]A><;VO
M;Q,5'-7HJ+E"<?VHCE._T1G^Y/6-WJUM=HK=9U&FGUN+%M:?V?&K^7!Z>I=^
MWVEH-(Z<@MT'LGHB.D=^<[RJ29#CO+3J3,3'7BK&G$3GH[)T 3H"BX     X
MX6]R#A;W(<@#CA;W(<X0 #CA3N0(B)T0Y       -:=Z_ESTS^Z_F*;+&M.]
M?RYZ9_=?S%--/BSU.#92+W-OH0['6+W-OH0[&;0
M                      X=[53D 5]I#;6FTYJ^XW^&NFFDK%=F)R(B-RN2
MP#G )F9F(B>1SF>J);CZ-BUM9&VV>LEI8TD2171HBJN/(9G3-HBL5FIK= ]S
MXX&\*.7JIE (F8B:QPE$Q$S%IXP'"G((2A^H=%17[4UONEPK)7T]$O''1X3@
MX_SE)>U$QCR(<X B=V.2,;\H-K_;BV:NECJG2S4-SC3A95T[N%Z)W'QT'ME;
M=+5+ZV:HGN=R=R\:J7<3D3N0G^!@FMIK&(1:L6WR)T !"P
M            (]=O?CCQ'MNWOQQXC[J>&',U/%( "R@
M    &$U?\$+Z3-F$U?\ !"^DUT?,JQ[3Y5O1 F]#DX;T.3M/,0  )
M              '"]%+=VX^+K/I*5$O12W=N/BZSZ2G/]I>3\W7]B_Y$^B4@
M X#U8          !PIR *0W1VQU-JZ_R5$%PI&435S"UZJCF?Z& BVAU]&Q&
MQZE:UJ=$25?Z&QP+5M-8V85M6+3F6N?K2;@_]3I_%7^A;NV5ANNG].I1WRM\
M<JT>J]IG/(EX)[R9B81&G$3D3H "BX                  !K3O7\N>F?W7
M\Q398UIWK^7/3/[K^8III\6>IP;*1>YM]"'8ZQ>YM]"'8S:
M
M               (]=O?CCQ'MNWOQQXC[J>&',U/%( "R@
M       &$U?\$+Z3-F$U?\$+Z371\RK'M/E6]$";T.3AO0Y.T\Q   D
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M398UIWK^7/3/[K^8III\6>IP;*1>YM]"'8ZQ>YM]"'8S:
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MDA<=ID=+;J9\BY>Z-%52A%Z%\V7X)I/JT.7[3I6M:[,8=OV)JWO>^W,SP>T
M'(>A                  !'KM[\<>(]MV]^./$?=3PPYFIXI  64
M               PFK_@A?29LPFK_@A?2:Z/F58]I\JWH@3>AR<-Z')VGF(
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MTS^Z_F*;+&M.]?RYZ9_=?S%--/BSU.#92+W-OH0['6+W-OH0[&;0
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M5W(^+C_IH;]E\ZOJ^7MW^/?TE4B= $Z ]0\.
MX7H7S9?@FD^K0H9>A?-E^":3ZM#E>U?#5WO87COZ0]H .*](
M      "/7;WXX\1[;M[\<>(^ZGAAS-3Q2  LH                     !A
M-7_!"^DS9A-7_!"^DUT?,JQ[3Y5O1 F]#DX;T.3M/,0  )
M       '"]%+=VX^+K/I*5$O12W=N/BZSZ2G/]I>3\W7]B_Y$^B4@ X#U8
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MN>F?W7\Q398UIWK^7/3/[K^8III\6>IP;*1>YM]"'8ZQ>YM]"'8S:
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M%E.Y6JA;4K_9BM9SQ^O)33M_>VK1CA].:N/!SBA304<B-:D\CU65<<U7*]3
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MY'Q<?]-"5$5W(^+C_IH;]E\ZOJ^7MW^/?TE4B= $Z ]0\.
M          X7H7S9?@FD^K0H9>A?-E^":3ZM#E>U?#5WO87COZ0]H .*](
M                "/7;WXX\1[;M[\<>(^ZGAAS-3Q2  LH
M        !A-7_!"^DS9A-7_!"^DUT?,JQ[3Y5O1 F]#DX;T.3M/,0  )
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ME^":3ZM"AEZ%\V7X)I/JT.5[5\-7>]A>._I#V@ XKT@
M (]=O?CCQ'MNWOQQXC[J>&',U/%( "R@                     &$U?\$+
MZ3-F$U?\$+Z371\RK'M/E6]$";T.3AO0Y.T\Q   D
M  <+T4MW;CXNL^DI42]%+=VX^+K/I*<_VEY/S=?V+_D3Z)2 #@/5@
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MO12W=N/BZSZ2E1+T4MW;CXNL^DIS_:7D_-U_8O\ D3Z)2 #@/5@
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MA#L9M        $9KO?3_ $GG/17>^G^D\Y]U>$.7?Q2  LJ
M        !A=7? S_ *2&:,+J[X&?])#31\<,>T>5;T0).@"= =MYD
M                !PO0OFR_!-)]6A0R]"^;+\$TGU:'*]J^&KO>PO'?TA[0
M <5Z0                  $>NWOQQXCVW;WXX\1]U/##F:GBD !90
M               #":O^"%])FS":O^"%])KH^95CVGRK>B!-Z')PWH<G:>8@
M  2                     .%Z*6[MQ\76?24J)>BEN[<?%UGTE.?[2\GYN
MO[%_R)]$I !P'JP                        >0 ",:WT;0:PIH*:ZNE\7
MB>C^!BXXO,OF*P\(:T4-DV[HZ.UTL5-3LG1$:Q,>12]EZ%,>%%\2J?\ Q"?@
MI&<8B.L+TB)MF>D_:4_VR^(5C_PK/P*P\*:576RS4N5X7U"*J%G[9?$*Q_X5
MGX%7^%+"J6RRU*(N&5"(JFVK_D1G\W[L-+R?E^RX=(T[*73=NAC1$:R!J)]A
M"?"'I6U&W58YV,Q.1Z?L)QI29)].VZ5JHJ.@8N4]!!_"'JFT^W-8UV,RN1B?
MM,M?.U/7/[K]GQLQCI^S+[+U+ZK;>R/DRKD@1,_M4FQ"=EZ9U-MM9&O1458$
M7"^DFQKK^;;U9Z'EQ@/-7UM-00.FK)V01)U>]<(>DC&X>DXM9Z=FM,]5)2LD
M<B]I&U%5,+GH91\6D\-SV)JJQ8^%J3^(AKWNW74MPWLTS-0U$=1&BQ(KHURF
M>T7D2'_AMM__ %%7?PF_U*[U#HN'0VZFG;93ULM8R26*59)&\*HO'C'^AM2*
MQ.Z6-YMC?#<"+W-OH0['6+W-OH0[&+<       !&:[WT_P!)YST5WOI_I/.?
M=7A#EW\4@ +*@                     875WP,_P"DAFC"ZN^!G_20TT?'
M#'M'E6]$"3H G0';>9                        <+T+YLOP32?5H4,O0O
MFR_!-)]6ARO:OAJ[WL+QW](>T '%>D                  !'KM[\<>(]MV
M]^./$?=3PPYFIXI  64                      PFK_@A?29LPFK_@A?2:
MZ/F58]I\JWH@3>AR<-Z')VGF(  $@                    #A>BEN[<?%U
MGTE*B7HI;NW'Q=9])3G^TO)^;K^Q?\B?1*0 <!ZL
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MN[<?%UGTE.?[2\GYNO[%_P B?1*0 <!ZL
M             -:=Z_ESTS^Z_F*;+&M.]?RYZ9_=?S%--/BSU.#92+W-OH0[
M'6+W-OH0[&;0       !&:[WT_TGG/17>^G^D\Y]U>$.7?Q2  LJ
M             !A=7? S_I(9HPNKO@9_TD--'QPQ[1Y5O1 DZ )T!VWF0
M                    '"]"^;+\$TGU:%#+T+YLOP32?5H<KVKX:N]["\=_
M2'M !Q7I                   1Z[>_''B/;=O?CCQ'W4\,.9J>*0 %E
M                   ,)J_X(7TF;,)J_P""%])KH^95CVGRK>B!-Z')PWH<
MG:>8@  2                     .%Z*6[MQ\76?24J)>BEN[<?%UGTE.?[
M2\GYNO[%_P B?1*0 <!ZL
M -:=Z_ESTS^Z_F*;+&M.]?RYZ9_=?S%--/BSU.#92+W-OH0['6+W-OH0[&;0
M       !&:[WT_TGG/17>^G^D\Y]U>$.7?Q2  LJ
M !A=7? S_I(9HPNKO@9_TD--'QPQ[1Y5O1 DZ )T!VWF0
M        '"]"^;+\$TGU:%#+T+YLOP32?5H<KVKX:N]["\=_2'M !Q7I
M               1Z[>_''B/;=O?CCQ'W4\,.9J>*0 %E
M       ,)J_X(7TF;,)J_P""%])KH^95CVGRK>B!-Z')PWH<G:>8@  2
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M^;+\$TGU:%#+T+YLOP32?5H<KVKX:N]["\=_2'M !Q7I
M   1Z[>_''B/;=O?CCQ'W4\,.9J>*0 %E                      ,)J_X
M(7TF;,)J_P""%])KH^95CVGRK>B!-Z')PWH<G:>8@  2
M     .%Z*6[MQ\76?24J)>BEN[<?%UGTE.?[2\GYNO[%_P B?1*0 <!ZL
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MQ\76?24J)>BEN[<?%UGTE.?[2\GYNO[%_P B?1*0 <!ZL
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MN[<?%UGTE.?[2\GYNO[%_P B?1*0 <!ZL
M             -:=Z_ESTS^Z_F*;+&M.]?RYZ9_=?S%--/BSU.#92+W-OH0[
M'6+W-OH0[&;0       !&:[WT_TGG/17>^G^D\Y]U>$.7?Q2  LJ
M             !A=7? S_I(9HPNKO@9_TD--'QPQ[1Y5O1 DZ )T!VWF0
M                    '"]"^;+\$TGU:%#+T+YLOP32?5H<KVKX:N]["\=_
M2'M !Q7I                   1Z[>_''B/;=O?CCQ'W4\,.9J>*0 %E
M                   ,)J_X(7TF;,)J_P""%])KH^95CVGRK>B!-Z')PWH<
MG:>8@  2                     .%Z*6[MQ\76?24J)>BEN[<?%UGTE.?[
M2\GYNO[%_P B?1*0 <!ZL
M -:=Z_ESTS^Z_F*;+&M.]?RYZ9_=?S%--/BSU.#92+W-OH0['6+W-OH0[&;0
M       !&:[WT_TGG/17>^G^D\Y]U>$.7?Q2  LJ
M !A=7? S_I(9HPNKO@9_TD--'QPQ[1Y5O1 DZ )T!VWF0
M        '"]"^;+\$TGU:%#+T+YLOP32?5H<KVKX:N]["\=_2'M !Q7I
M               1Z[>_''B/;=O?CCQ'W4\,.9J>*0 %E
M       ,)J_X(7TF;,)J_P""%])KH^95CVGRK>B!-Z')PWH<G:>8@  2
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M^;+\$TGU:%#+T+YLOP32?5H<KVKX:N]["\=_2'M !Q7I
M   1Z[>_''B/;=O?CCQ'W4\,.9J>*0 %E                      ,)J_X
M(7TF;,)J_P""%])KH^95CVGRK>B!-Z')PWH<G:>8@  2
M     .%Z*6[MQ\76?24J)>BEN[<?%UGTE.?[2\GYNO[%_P B?1*0 <!ZL
M                              R@R      #6G>OY<],_NOYBFRQK3O7
M\N>F?W7\Q333XL]3@V4B]S;Z$.QUB]S;Z$.QFT        1FN]]/])YST5WO
MI_I/.?=7A#EW\4@ +*@                     875WP,_Z2&:,+J[X&?\
M20TT?'#'M'E6]$"3H G0';>9                        <+T+YLOP32?5
MH4,O0OFR_!-)]6ARO:OAJ[WL+QW](>T '%>D                  !'KM[\
M<>(]MV]^./$?=3PPYFIXI  64                      PFK_@A?29LPFK
M_@A?2:Z/F58]I\JWH@3>AR<-Z')VGF(  $@                    #A>BE
MN[<?%UGTE*B7HI;NW'Q=9])3G^TO)^;K^Q?\B?1*0 <!ZL
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MS^<IS_:?D_-V/8G^1/HE(&1DX#U8!D9  9&0 &1D
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MCC6-%5<]>9<[5Y$X_#%^4Y^B)G%IISC$_JY 3H"$@
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M9KM3UB/U70BY!PAR52
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MPU*\L1/U6U?_ !;GF8^6%D[C[@6W1%N2:L5):I_N4#785Q2U3OAK6HF=/;;
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MT%;I:>)J35#$DEDQ[)R^=28BMZ;>,8G'JB=JEHKG.8SZ(3MUO;57"]0VC5E
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MST:JVDG9G@3HBE*36\SIXWXS'R6M%J1MYYQGYMCDZ )T!DU
M                                                        &N7A
M&.:W7FFG.<C6I(U555PB<R]*._6EM)"BW2ARC&_^^WN])!]V-K':\N%+4MN?
MB?8-X<=GQ9('_P -S_\ J)?X2_U+Z>.[V;=9^K.^>\VJ](7TE_M*KA+I0JJ^
M1)V_U(WN_:)+[M]<H*5.TE[/M&(WGQ8*LA\'*2.:.3\HG+PN1WN2_P!2_P"A
MI?%;?!2N7C2.-L:JOEPF"-2E9KNG>MIWMM;XW*,V%U=86V)M@OC:6EN-(Y6H
ML[43C3/>OE+-OVH](V6WRU=5/;7,8W*,CX'.=YD1"+:ZV2LFHZR6MHY'V^LD
MYN<SFU5[\$=L?@ZT$%2C[O=IJN%%1>S8G!GTEYM&IOF<2SBLZ>Z(S"Q]N]3T
M>KK345=NM4U!3+EK72,1J2=>:8*2TO<?6ZWGKV7M%@HZYSFI(J<L*OL5-E+/
M;*2T6Z&AM\+8::)O"QC>A&]P-O;-K:F:VYQ*RH9[2>-<.3S><KM174VJQNX?
M);9FVGLVX\63J]76&EH'5<MWH^Q1O%E)FJJ_LZD!V_W)NNLM07>*CH84L](U
M59.F>)W7">DC%/X.$#:WBJ+[*^EXO<T9A<=V2Y-&Z3M>DK2VWVB#@B3FYRKE
MSU[U48I$3.<YC=_)F\XC&&N.W-NL&I->7E^LZEOC"3/[.&H?AJ\^]2V[O+M]
MHJQ33PMMJ\+55D<?"]SG>3H>'7FQMJU'<9:^W53[?53.XI,)Q-7OY&.TSX/=
MIH:ALMZKYKAPN148F6-7S*6S%J1&<8C")K-;S:(SF<HAX.M?'6[DW.I1J1]N
MQSFLQT0R_A'?'K2_I3_YDXTQM/#IO73[[:JY(J1S5;XIV?3/G/5N1ML[6-]M
M=Q;<?%O$L>PX.+BYY+5O7;TK1PK_ +5C3F*:M9XVS^RQ*;WO%]!/P->?" ^4
MC2_UB?BAL1$W@B:W.>%$0KK<';9=6:EM=U2X^+)1.XECX,\7/O\ V&6G,1K4
MM/")7U*S;1O2.,P\>_MEGN^W;W4C%DEIN&3A1,KCRF,V6UEIRZZ:IK?</$J:
MXTC$C>R=K6\2)Y<J7"L$<E-V,K4?&K>%R+T5"G=9[#6>]5DM5::J2VSR.XG(
MB<3/V(*6V=JL\)W_ #3>LS$3'&$LU5J_2&G+=)55,E!.YJ9;% C'N=YDP930
M]\@U%IMEQI+=+;X)<\,<C4153OY%9:;\'JU452V:\W":O1KD<C$3A:OF4NNE
MI(:2B92TL;8H8V<#&M3DB$VBL5F(G,RBLVF8S&(:^>#W\I6IO2__ .1=.XO+
M1%Z_PS_P(SMWMJ[2.IKG=EN/C*5BK_9]GP\.5SU)OJ2V>K%BKK>DG9>,Q+'Q
MXSC/E*ZWXJ1$=(AII[M6UIX3;*G_  5?BW=?\02GP@ODQNG_ /'\3W;4:#=H
M2VU5(ZN\<[>3M.+@X<&5W#TPNK=+U5H2I\66;']IP\6,>8MVBT7MFOP_97LT
M;'BZS]Y17;*:6GV:AEIVJZ5E.Y6HG?@J39FT:9U%<[K/K"IBDKDD7ABJ7HU,
M=^5-B-$Z<33>F*:SOG2I;$U6J_AQQ)Z"M]9["VR]7%]7::U]N?([,C,<35]'
M<7M>.^O;E+'3T[1H4I/&&1U-<= Z)T_(E-';GR<#DACBX7N5RIRZ$'\%ZJ9/
M?KV_VKI5XT;W(N23:6\'^RV][9;U5S7&1JY1.;6?M0SNA-K$TAJRLNE!<$6C
MGY)3=G[5.[)-+5K-LSG,%Z6O%<1C$PK+?.Y.M&[UKKT:K_%TC>YK>JHG4O>R
MZVL%TM;*V"Z4C8U;ER/E1KFKY45%YD8UCM>W4FMJ.^RU[610(U'4ZQYXT3SD
M7U/X/MNN-R=4VFY24$;W<3XE3B3.?)W&=)CNXI/Q;:F9U)O7AB/LC6Y5YBW%
MW)L]IT^OC,-([B?*U/8Y\ILI1Q=A2Q1)_<:C?L(7MWMM9=$QO?0L=-62>VJ)
M.;O0G<A.4Z$S-8K%*\OO*M8F;3>P #-H
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MI*SK8-.T5L6;MEIF(SCQC/[!2T1I6K/&9S]"\3.I68Y1/W4CX2'QTTM]+_\
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M&T0)%$G5?*Y>]5*UV*9O$YG&(^:UMNT;$QN_AFDZ  R:@
M                                                         P
MP  &!@ !@  ,(,  ,(,  !A     8&     8&  &!@ !@8  8&  &
M                                 !@     P  P,  ,#  # P@ #"#"
M  ,#  #   #  #   #  # P  P,  ,  !@
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MXX&^3/G)XG0Z0M:R-&,1$:U,(B'<B]HM.8W)I6:QB9R  JL
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M:5F45WLF9_-PF"L8U-.;8QB?U3.=.]:Q.8F%C@90&38
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M)(X6M<G[40K2:Q'XHRG4BTS^"<,NWH G0%%P
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M[M1-Q-^'-F:VHMM"Y4X53+5:WO\ VE^IH[3B)\!6W[NS^A?3C8T\V_\ 6_\
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M'XH7O%IF9I.(90 %%P
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M5:ZBVCM5WU4R_0U,]%6(Y'KV/)%5%ZDYNEK9<;)46V>1W9SQ+$YZ=<*F,F1
MXUV.1&ZVW'%#MN-!T6AJ.JIZ">69M0]'N63R<B8@$VM-IS*(B(X(9N)M_0ZW
M92-KZB6'Q=_&WL_*2JW4C:&B@IHU561,1B*OEP>D$1.(V8X$QF<@4 )0:_[<
M6^\ZRI=1SU$S:JG1J-8WVJ\/0G*<D )S.(KRA&-^US_@ !"0
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M#62\7BLN,]=4MEJ9%D<U.B*O[3P)X.>G_P!?JOL_[EX@B+3$8A,TB9S*CO\
MAST_^OU7V?\ <M#3>EZ:PZ82R4TCW4Z-<WB=UYDA F\VK-9X2B*5BT6B-\(=
MH#0=%HQUP=0SRRK62=H_C\BY\A,4 (F9GBM%8KP8S45EI+_:*FW7"-'T\[>%
M<^3SD8VZVYI=#R5/J?75,T,W6*1?8HO>A.@*S-<XYDQ$XSR  0D
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M;0Q.>SB3*91"&;):QNFLK)655X[#M8IEC;V+.%,$5B;9QR3:T5QGFLD 9(2
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M<2BMHM&8  56
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M5[LDTVMJUK-!V:5SE<O8-1<^9"M=^E_\SCY3O6MNU8^,?6-R5@)T!1<
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M/ND;7?Z")VM*)GE,Q_!.[5F(YQ$_/F]@ *+@
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M"(B>0K7\.E$=9F?ER3.)U9F.41'SYN0 57
M                                    80 !A   &  &!@    /%>:26
MMMT]/!,L$DC>%)$\AY-*6*FT]:(Z&D15:WV3GKU>Y>JJ9@"-V?B3O   P  &
M!@       808  8&     8&  &#Q7=]5';JEUOC;)5HQ>R:Y<(KL<CV@B8S&
M$Q.)RKS:O1]79FUUVU C'WZOD5TKT7B1K?(B%AIT&$!:ULJQ&  $)
M                      #"   ,  ,#  # P  P,  ,#   80 !@8  ^<S5
M=$]K'<+E141>Y3 :/TM3Z?\ &Y4D=/653^TEF<O-?-Z"1@1NX$[P8  80  ,
M#        P@P  &  &$  # P  P836'JHMAJV6*-CZ][%;'QNPB*OE,V,$3&
M8PF)Q.4-VQTBS2E@;%,C77&=5EJI4YJYZKE>?<3(8!>UIM.94K6*QB  %5@
+           !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g111069g00a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a08.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[19.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %C$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!!(A,5&Q$Q5!4F%QD04B@:'!X10R-'+1\"/Q)#.R0D/B_]H # ,!  (1 Q$
M/P#]4@&)\S6N5%1>0&4&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&
M<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q
M#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1
MXAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAOD
MH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&
M#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?
M)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XA
MODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&
M<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q
M#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1
MXAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAOD
MH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&
M#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?
M)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XA
MODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&
M<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q
M#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1
MXAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAOD
MH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&
M#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?
M)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XA
MODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&
M<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q
M#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1
MXAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAOD
MH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&<&#Q#?)1XAODH&3O
M&>ER#O6?WD-)5W55 $@#6@FV^2Y?8ILHNX      -*?_ &KC=-*?_:N Q@
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MFZ>I.90NQAN3CU1K:/.6FVL@RQ"DLC.3=^%W)$\BU8WM$SIU< %4@
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MIU;LG;:9I=&RY2OE:22.\%:C<JN=#Z$?NB;.0O--1U4B^YZ+F "BX
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M75_&:2M29#2K8D?+(K^-D$VR_):]?G;\NFYUL6KHK.P %5A#8@FV^2[IYFN
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M.D(0V$TY2Q&7S&1JNE6?)R-DGXW;HBHFR;)Z":SJ9^7ZPB>L)D $)
M $.?:EU=D<AFY=-:*A;-D6IM:O.3>*HB^SJ[U'0')Q-<W=4W3;=#FT78]AX9
M[$M?+9R%T[UDD[JWP\3E]*[(376^J)WKHMFB]+U-+8I:U97SV97=[:M2\Y)Y
M%ZN<O^A/%3TMH:KIW).NU\IE[3U8L?!;LK(S9?3MMUY%M%NO5%8U&G@ (6
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M79R(ODI]X?'08G%5,?41R05HVQ,XEW79$VYBLZB?C_O^$3&YC_?]]K< !58
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MG/54V-D :GAW^2>\>'?Y)[S; &IX=_DGO'AW^2>\VP!J>'?Y)[QW#_)/>;8
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M'?Y)[S; &IX=_DGO'AW^2>\VP!J>'?ZO>/#O\D]YM@#4\._R3WCP[_)/>;8
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M-1$39.@:B(FR=#T
M
M
M
M
M               7H !J,B5[U_NFTQJ-39.@:B)R0]
M
M
M     !0NUO7;M$XF"6"MXBU8?P,1R[-;YJHB-KX\=LEHK7O*^@HO9GVB8_6M
M16Q[5\E$U%FK.7G_ (F^:%Z3H-:+X[8[36T:D  4 !N@  ;@ -P     ;@
M     ;@ -T
M
M
M
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MJ3!J0X^K#:=9BKQLG<BHYZ)S4VRK!.O8  (
M
M
M
M
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M6)=^/DU4&X)SX]]]SRS&_&72  4>4
M
M
M
M
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MK%1-MD]0%A
M
M
M
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M(C6HFR(B;(AXD3$5%1C=TYHNQ]H &P 'FQZ
M
M
M
M
M
M
M
M
M
M
M
M
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MVVWF2'8#W?P-F.X14B\9\A%ZHG"FQ>^"GHYR4F?Q'4P 90
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M7?P?J(' ^U?-9K47:%BM"XB]+2@E8Q;DD*JUSN)-UW5/0C4Z>E5*OVO:8OZ
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ML]CF2HUM"4XK%RO%(CW[M=(B+\XG=4V6Y/'MAQ.HZ^-G1Z*LK7-=NGD,D?\
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M/G/GE:GM5"R]F&%N8+3$=3(L1D_>/<K47?9%<JH1GKCKNM8U,3]1;@ 9
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MJ\M]U]7L+X[1$1,^QSO69F8CVNJQ-1K4:G1$V/H\;Z3TXNX
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MSC-)H^XU8Y+<KIT8J;*U%Z;E\,_$3$Y;3"0 '
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M3[2$K]F^EX)6R,QC%<U=TXG*J%P!>,EZQJ)D8X8601-CB8UD;4V1J=$0R %
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M)W IT'9MI>&5LC,8Q7-7=.)RJA;:\+((FQ0L:R-B;-:U-D1#(";7M?\ FG8
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MF>G1W1?>:&.[/M-4+"3U\9'WB<T5RJNQ:P7C)>(U$SH>-39-NB>1Z 4
M
M
M
M
M
M
M
M
M
M
M       #YE>V.-SWKLUJ;JOJ ^@8*5N"[79/5E9-"]-VO8[=%^TS@
M
M
M
M
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MI:V#QMO+21+POD@1&PM=Y=XJ[+]FYI9=]G5^:M86I9EJX:DJ-OSQ+L^=Z_\
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MI)\IC_ V]U_Y/WB/Y)TYIYE674VLD<J?D;NF^V_C&%^V0\5$!6\1,S-8_/\
MRC<G<OU\*ZS3H>)O(QJI6XT;NJ]4XO40.$S^I[>3AAR6F/!57;\<_B6OX>7D
MG4N.R#9 B+1$:TK^J<IFL=W'P+AOA/CWX_YY(^#RZ]3W2V4S.1;8^&\-\&*Q
M4[M.^23C\^G0G]D&R YHY=:_%3\YGM34\E-#C=,^-JMVX)_$M9Q<O)2=Q-R]
M9PT=F]1\+=5JJZMQH[A7GLG%Z^7O)/8;(";1,:THD6I=8.G8Q^C^&-7(BO\
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MQ-7DJ;\!3<OIO\G=0387&UU\#J-\#8YN+E7[I561B[^A47=/6JB#'-)Z1/\
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MOY$@4_LQM8W(8!^1Q>.;CG6IWK9A;T[YJ\+E3;EZ.J%P$QIFO7EM,  (5
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M;;_SQ%P*UBM)PT<U%E);^0NVHH7PQK9EXD8URHKMD1$_NH64AQR3$ZB/9
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M?4X57OH[B2KOZ$VV,FJ,EJ6E;C9@,#!D8%;NZ22VD2M7RV5 F>:?^/<>/?\
M5LXC2]#%8"SAZBSMK3K(Y[U?\M5?\Y=]O6>,TOCV:4=IZ-9FT'1+"JH_Y?"O
M7GMU^PR:7N9J[5F?J#%18V9K]F,CG2;B;MUW1$V(/)9K6L-^Q'0TK4L56O5(
MI77T8KT\]MN1&M]".>;3&^O?O'=J9[1[LIJ;3U5]1KM/XRL]KN-45'+P\+4V
M^SJ2VF- X/3MU]RE#+):7=&RSOXW,1?0WR0F4L9+X!2PM%GPIW/$M7O?D]YM
M\WC\M_25FAF];RW:\=O2=2&NZ1K99$R".5C57FY$VY[)Z"=RGFR7KRQ/2.G=
M*LT?BH]6+J*)LS,@YO"_A?LQ_+;=6^E2.SG9IIW,9-UZQ#/#+(N\K().!DO^
M)-N9-ZGN9FE3C?@,7%DK"OV?').D2(WGSW]W(T=,9/4]V])'GL!7QU9(]VRQ
MVTE57;]-D3RWYD0BMLFN>+?FV+^D\5<PU;%=RL%"N]CV10JC4W:NZ;\N?-#:
MR^"J9:SCIK?>*ZA-W\36NV3BVVYIZ2*U)E-4T\CW6"T]7R%3@1>^DN)$O%SW
M3AV]A*Z:M96YCN]SN.CQ]OB5.YCF[U-O0N^Q/Q5GGBL6W^?B7<'4N9S'Y6?O
M%LT6/;"G%\E./;=53SY%>S?9GIW+9-UZ6*Q!,]=Y6UI>[;+_ (DVYF.WG-<Q
MVYF5](U)8&O5L<BY!$5S=^2[;<MT]!:+EC)1X-\]:BR7))'Q-K++PM5_]WB_
MU'9:)R8]:M^;/B,;4Q-"&ECX605H4V8QJ<D-W<I.)S6M)\C!%D-+5*U1SD22
M9M]'JQ/2NVW,F=4W<W2@A=I_$PY*5SE1[))TBX4\]]N84G'/-J9CK\83HW*Q
MI;):ENVIFZ@P4&-A:Q%C?':297.WZ;;)MR,.H<KJNIDECPFG:U^IPHJ327$B
M7?RVV&CT<\W+N/K"VC<B=.6<I;QB39O'QT+JN5%@CF[U-D7DO%MZ2N?#>MOA
M#NOR4J>%[WA[WQZ;\&_SMMO+GL1I$8YF9CIT^,+R"'U):RU/&I+@\;'D+G&U
M%ADF2).'GNO%MZ.1%Z;RNJKF2[K.:>KX^IP*O?1W$E7B]";; BDS7FZ?5; 5
MC5&2U+1N1,T_@H,E YF[Y)+:1*UV_3;9=^6R[FUI:[FKU:9^H,5%C9FOVC9'
M.DO$W;KNB<@<D\O-T^J=!1\EF]:PW[$='2E2Q5:]4BE=?1JO;Z%5-N19FV,@
MN$[]:3$R7<\7AN]^3Q[?-XO;Z03CF-=OK"2W0%&Q^;UO+>@CN:4J05G/1))&
MWT<K&[\UVVYD]J>YF:5-DF Q<62L*_9T<DZ1(C?/?8G29QS$Q&X^L)L%6TSD
M]3W;KX\]@*^/KHS=LL=M)55WEML>:FR>IZ=YD>"T_7R-96[NDDMI$J.\ME0C
M1Z.>;EZ?6%J&Y"Z8MYB[1D?GL9%CK*/5&Q1SI*BM\]ROWLWK>.[8CJ:3J35V
MO5(Y%R"-5[=^2JFW+<$8YF9C<?6%Z!&OL9!N$6=E)CLCW/%X;O/DJ_;YO%_J
M5G&9K6LU^O'?TI4KU7/1)96WT>K&^E=MN8TBN.;;[=/C"\ @M4W,W2K0NT_B
M8LE,YRI(R2PD*-3SW5%W-72V2U)=MSLU!@H,; UF[)([22J]V_3;;ER!%)Y>
M;I]5G!4M297553)+%@].UK]/@14FDN)$O%Z4X=B6TW:RMS&++G,='C[G&J=S
M',DJ<*=%XMO2":3%>;I]82X*%/G==,GD;#I"G)$CE1CUR*)Q)OR7;8M>3L9"
M'#23T:3+&01B*VNZ3@17>E.+_4:3..:ZZQU^,)(%*PV8UE8R,$63TO5J4W+M
M),V\CU:FWEMS)75-_/465UT_AX<DYRKWJ26$AX$]&VZ+N-$XYB>7<?6%@!6]
M+9#45V6=-082#&L:B=VL=I)>-?=R-3/Y;5M3)R18;3=:]21$X9WW4C5W+G\G
M;S&B,<S;EZ?6%O!$X"SE+6)2;,8^.E>W=O79-WB>KY6WI*O)G==I,]K-(4W1
MHY4:Y<BB;IY[;$Z*XYF9C<=/C"_ BLW8R=;$.GQ5".Y?1$VKOEX$5?3\H@L'
MF-7V<I!%E],U:5%V_>6&74D5G)=OD[<^>R$(C',QOI]87('Q&]KTW8Y')YH?
M2A052MZMN9I%CQVGZ6]BTU4\=(O\U6];DZJODB$'J74^3R&?73>CV-\;&K5N
MWI$WCJM7GMMZ7*A?8&N;&U)'<3T1$5VVVZ^9+KRSCU:WT1NE<7/A\)7I6[LU
MZ>-/ESS+NKE]/V$L 0YS,S.Y  $
M
M
M
M
M                     :V2_HZU^B=^Y39/B9[8X7OD^8UJJ[V A0^PU'M[
M.:"2HY']Y+OQ=?\ :.\R0=J_Q.LX\#B*JW$B:K[UEKOD5T]";^EV_H,VF-78
M#5#[-/!V%G[IF\B-B<Q&HJJFV^R<R4T]@,?I^M)!BZZ0LD>LCUW57/<J\U55
MYJ2T7F.>UKQUGV?-(1PQLDDD9&QLC]N)R)LKO:OI,H!#.
M
M
M
M
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M6S?B(.2QZSX7W_-?04+XR:_U;-^(@^,FO]6S?B(.2QZSX7W_ #7T%"^,FO\
M5LWXB#XR:_U;-^(@Y+'K/A??\U]!0OC)K_5LWXB#XR:_U;-^(@Y+'K/A??\
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M6S?B(.2QZSX7W_-?04+XR:_U;-^(@^,FO]6S?B(.2QZSX7W_ #7T%"^,FO\
M5LWXB#XR:_U;-^(@Y+'K/A??\U]!0OC)K_5LWXB#XR:_U;-^(@Y+'K/A??\
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M_NH/#P_0Q_=0R@&H8O#P_0Q_=0>'A^AC^ZAE -0Q>'A^AC^Z@\/#]#']U#*
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MH U$  "0
M
M
M
M
M
M
M                                   %7U!GK.-R20Q)&Z/@1VRI[23P
MF9ARD:\"\,S?G,4J&NW<.=1/_E-_>I%X.T^#*U71NV59&M7UHJ['Q$_;'$<+
M]HWQVGFIS:UX?)[\?9],O#5O$:MIU@'B=5/3[=X
M
M
M
M
M                                         YGVA/X<^GZ%O[U(W3-:
M2]FJS(]]FO1[E\D1=R8UCC;65U:VO39NO<,5SE^:U-UZEDTKC:&-2:"O*V:Y
M'LD[O2U5]'J/C:_95^*X^^28U2+=9_2'TMN-IP_!UK$_>F.RPMY'I@GLPUW1
M)/*R-97<#$<NW$[R0S(?9/FGH   *:[K<#+;*RRM2=[5>V/TJB=5 V $
M
M
M
M
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MS3D8Z.LQKW[ILU43HJ$20L0" A8
M
M
M
M
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M.JX( G0$)
M
M
M
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MFN02K91B21R*S=B*B+M[20VZ*>-8C$7A1$W\D/I"$@
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-4*V0FKOCL/X51C4Z&>?M**ZY\=HB9B-S'C^+M'!3;?+>L_C^RZ( G0'I,0
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M'V\75GEV[R1B.=MR3<OP_&US9)Q\LUF(WUC717+PLXJ1?FB8WKHW0 ;68
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MLBG5K47T(=^&X_+ERUB]8BM]Z\?N^+EGX2F/',UF>:NM^'7P6P!.@/7><
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M3N?$LS48JK&B;\2;="@8R:&;5U%U>DM-J(J<"IMOR7F8/M?E]-A[;W'COO\
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M^73U5TCE<J(J;KY;FK@N.RY[Q7)6(BT<T:\-^UGXKA<>*LS29W6=3O\ 1.@
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MN/RY[UC)6(BT3,:\(GVN7$\)3%29I,S-9U/X^"R  ]=YP
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MN#C5O3VJJK^PM3KRS/L5OTYHCVOT=0A;6J0PL39L;&L1/8AG/&GIQ[N\=
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M;3U[]I8HS6S8\M[>$=OG"TPP10J]8HVL5Z[NX4VW4R 'L1$1TAYTS,]P $H
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M602]D[2VK+?F\MD0LP,=/LW#6T6G<Z[;F9CZ2TVX[+:)B-1OPB(  >@Q@
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MC?U:F-IPX^I'6KILQB;<^JFV ;Z5BD16O:&.UIM,S/< !9
M
M
M
M
M
M
M
M
M
M                                                          &X
M
M
M
M
M
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MPN_^_,:1$K+OS!7L3?MT\@F*S#FR2O175[*)LDR)U14]#D+"B[D+
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MLX!S[N%_G*&_'-17HB>ET:^A?3MZ1HB5I0&"A:BO4XK-=W%%*U'-7U&<A(
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M9 E"9W4^.P<T<5]TR/D;Q-X(E?R^PSX'.TLY#)+0616QNX7<;%9S^TE-CS9
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MA7\+J[%YBZE2DZ=9E:KDXX7-39/6IESNI\=A)HXK[ID>]O$G!$KN7V$WL>;
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MY8<EIQL4KV-DO(UZ-7;B39>2EI-*_-2BEJMNK$DCY.&#C3=5?ZO6;H
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M'(6Y>LPC?1T< %5@
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MSQ,;=F/<U.)J+Z-R4/G"K==C85RB1I;5-WHSHB^1NA/2"$@
M                     P6:=:UP^)KPS</3O&([;WF'X(QOU?3_  6_P-T
M:7P1C?J^G^"W^ ^",;]7T_P6_P #= &.O7AKLX*\4<3.O"QJ-3]AD
M        ,5FM!9:C;,$4S47=$D8CD3WFO\$8WZOI_@M_@;H TO@C&_5]/\%O
M\!\$8WZOI_@M_@;H PUJM>JU6UH(H6KU2-B-W]QF       !K3T*=A_'8J5Y
M7[;<3XT<O[4-D :7P1C?J^G^"W^ ^",;]7T_P6_P-T :7P1C?J^G^"W^!MQQ
MLB8C(V-8QJ;(UJ;(A]         #3=B<<YRJZA455ZJL+>?[#SX(QOU?3_!;
M_ W0!I?!&-^KZ?X+?X'W#C:,,B20TZT<B=',B:BI]NQM
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M(G1[(T14^TW !K6J-2VK5MUH9E;R3O&([;WGM2G6J(Y*M>*%'=>[8C=_<;
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MIMMY;&4 :,6)QT4C7QT*K'M7='-B:BHOJY&>U4KVF(RU!%,Q%W1)&HY/VF<
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M151KD^9"S?DC$7H$-V'3U1N<FRLJOGM.V1G>+ND2?\*>@F4"'H2
M
M
M
M
M                                                  8K37.K2M9\
KY6*B;>PR@"I:!T[:PU>6?)69);<W+@5ZJC&[\D]I;0 1&@       '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g111069g00a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a09.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1O^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &^$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MZD#UKC8_6:C;"W3]PM-336UD4H%1+"YF''H,D>E1O3]#J39WJVJ?'8ZJXPR
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MOC:6>Q4=MO,Y<6SPPM^^.QDC>^$">?+HK@5'[/M$7RNUN-2WZD;01-E=.(2
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MM<UL@P2,*SUCJ&GE;1OI$UABF$1%@=(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 %X7 SB@J328\)$;N%D9&_@X]N%[H@90%ZT[K_6
M]=20WRF93P0$@.(#&-SU=@'F5=NF[3%8['1VV Y93QAF]^<>T_*MDBVR9G-*
M-4D88M/'$W*[;\0B(L3<(B(#"O=O9=;164$CBQM3$Z(N'5N01D*D[78]HNC:
MZ?WL9[X0.&Z-YYE80.A#2005?*+7'E<$U5IF&7 LC4K::\"BJ#0VJM7:LAO&
MKFLI86%I<WD"6M.0QK1G'K[U>J(F3*\E7W$X<,<5URV$1%D;!$7G-/%  9I6
M1@\@7N ^E >B+B-[9&!T;FN:>A:<@KK++'"S>ED8QO3+C@(#NBZQ2QS,WXGM
M>S\YIR%V0!$1 $1$ 1%Y2U,$3PR6>)CST:YX!* ]40<QR7#W-8PN>X-:.9).
M $!RB\X9XIP3#+'(!R)8X''R+T0!$1 $1$!'=H=MJ;OHRZT%!'Q*F>,-8W.,
MG>!Z^I1S8IINYZ;L]P@O%.())9P]@#@[(W<=BL5%HLC4'#N9D\*>19.]!$19
MFH1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$!2FT'\>FF/U:?_FO5UJE-H/X]-,?JT_\ S7JZUT9ORP_8Y--^?)^X
M1$7.=81$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&-IWX!7S]V?\
M0I.HIM4)&@KS@_\ T'?0KX_SHSS?Z<OV-=L._%U0?KR?SE3Q078F,;.[=C\Z
M3^8J=*V;_4E^Y73_ .E']D$1%D;!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MF&L8ZXPC+X,$. ]8QVA-K\!NCP[ZFT1:F^:BM-B?3LNU;'3/G)$32"2_&.@
M/>%E72Z4-JI34W*JAIH!^5([&?,.\IM?@-T>>>AF(M'9=76&]U!@M=TIZB;]
M&"6N/H!QGU*#;:-076S773\=KKI:9D[G"4,(\K#F]?E*O#%*4MG1F>3-&$-_
M5?(M5%J+EJ2TVJNI:&XUL<%74XX4;@27Y.!T'>O:^WRVV&E94W>J92P/?PVO
M<"078)QR'F*KM?@:;X\\]#8HM3<M1VFVBB-=6QPBL($!<#]\SC&.7G'58S=9
M:==<A;VWBD-63C<#^6>[>Z>U%"3Y2(>2"X;-^BT%1K+3U/<_>^>[TK*O.Z6%
MW0]Q/0?*MU4U,-+3OJ*F5D4#!O.D>[#0._*AQ:ZHE3B^C/5%'[7K33MTK!24
M%WII:@G 9DM)/FR.:D".+CU0C*,N8NPBU%3J:S4MT?;JFX00UC&<1T;R6X;W
MY/+VKQM>K[!=)98Z"[4LKX@7/&]NX ZGGC(4[)5=$=I&ZLWJ+16K5UANU<:.
MW72FGJ1G[VTD$X[L]?4ME<[E16NE-3<:J*F@'+?D=@9[AWE'%ITT2IQ:M/@R
MT6BLVK[!>JCP>V72GGG[(P2UQ] .,^I9%\U%:K$^G;=JV.F=4$B(.!.\1C/0
M><)LE=5R1OC6Z^#:HH[)K?3<=P\!?>:05.]N[N\<9[M[I[5K-J6L6Z7L#W4<
M\(NDH'@\;VEV\,@%P[.04QQR;4:ZD2S0C%ROH35%6/CH+ALLK:N@N>_>::E:
M^9[ 0Z-Y=Z,+OL_US14^B:"JU5>6"LF?)ATIR]P#B!R Z<E=X))-_.C-:F#D
MEXJRRT6JFN=/6Z=JJ^UU3)H^ ]\<L9R,AI]J@6RG6#SHNNNFJKF]S(ZTPB:8
M$[HW&D#D.\E56)N+?@7EFC&2B^\M)%C15]-+;A7,F::0Q\42]FYC.?D6-8K[
M;;]3R3VBJ;50QNW'/:T@ ]W,*E/J:;E=6;)%!MK>K:K2EBA?;FM\,J9.&Q[Q
MD,[2<*!.BVHT]O%X;7&HAW1+P8WM>2WKR:!S] 6T,#E'<VD<^34J$MJ3=>!>
MR*+Z?U-)+HKWYOE-+1301N,\;XRPY;V@'O58TE]V@:ZGJ*C3TC:&WQN(800P
M'S9.<E1' Y7;I(F>IC%*DVWW%[(JDT-J?5-OU8W3NK89)S(W+)FLWBWN)<.K
M>Q6VJY,;@Z9?%E656N BUUZOELL< FNU;#2QGIOGF?0.I59;5];N%IM%5I2\
M?>Y9W,D= [F< <B#S'5,>*61I(C+FCB3;[BWD6-5UM-0T9J:ZHB@A:,NDD<&
M@?*M/:M:Z=NM8*6@N]-+4$X#,EI<>X9 R?0JJ+:M(T<XITV2%%BW.XT=KI75
M-QJ8J: =7R.P%J+5K73MUJFTU!=Z:6=QPUF2TN/<,@911DU:0<XITWR2%%!M
MH]5/3U]D;!J2.S!\C@Z-S7'PCFWD, __ &5)+EJ&U6NNI:*X5L<%54XX3' ^
M7SQUQ@<^]3L=)KO*]HK:?%&U11Z#6NFY[AX##>:1]23@-#N1/F=T/RK<U];3
M6^E?4UT\<$#!ESY'8 4.+7#193BU:9D(HW!KG34])/4PWBF=# ,R'GEHSC.,
M9[0MY;JVGN-%#5T4HFIIF[S'@'#AW\T<9+JA&<9='9D(B*I8(B( B(@"(B +
MYI9<Z?3.V2KK;F)&4\53)OD-R0".1QVKZ66AO>C[#>ZMM3=+;%/.WEODD$^G
M!YK?!E6.U+HSFU.&65)Q?*=E6;<KO4773=CK;8^;WEJLO><$9=^2'#Y5CTUW
MT)0Z%=';J&&HOD]*80TP%\PE<TC.\1RP3GDKI=9K<ZTBV.I(C0!NX(2,M 6O
MLNC-/V6I-1;;9##-^?DN(]&25I'/!0VT^/\ O)E+39'-SM<KO[OV*K]S9(P5
M=\CSY;F1. \P+L_2%A[+P#MGNN1T-3_.KHL^F;/9JE]1:Z"*FF>W=<YA/,9S
MCJNU#INT4%RDN%'0Q15DF]O2M)R<G)[4EJ(MR==41#2RC&";_*S'UY:'WS2-
MTM\..-+$>&#VN',>T*E-E>O:?1D5;:KY35#8S*7AS&Y<QV "T@X[E?EZ=6,M
M-8^V!CJYL3C"'C(+\<@51%-K^WSWB3QXTY#X1%^7%&6O#A^<TD*=/^*$HM6O
M4C5-0R1FG3]#0;0]13:GU;17!U++34>ZQE*)!ASXP\^4?225-MO]EJ)[?:+M
M!&7PP1\&4M'P<\P3YE&KS72;2->6T6.WR14E,UD(\GDQ@<7%SL<FCFOHY\$<
ME.8)6-DB+=TM<,@CSK3+D[)P==.XRPXNW61-W?>4/0Z@V<LTQ%/4V6!]U9%A
MU.8G>5(!^=TP3VJ<['YZ&XV^IN%!IJ&S->1'OQR%W&QW9 Y#*W#MG>E751J#
M9H.)G>^$[&>_&5*((8X(FQ0,;'&T8:UHP %ADRQE&HWSXLZ<."<9)SKCP1\S
MZ<N]-I7:Q75=U$C((9ZAC]UN\1G> Y?(I9MWHG7JS6?45N8^2D$9:X[O-K7<
MP2K/O&C-/WBN\,N5LAFJ>UY+@3Z<'FMQ%14T5"VC9"P4K6[@B(RW=[E=ZF.Z
M,TN49QTDMDL<GP^A1=%J+9TW3+*BHL<#KJV/#J;A.\I_ZW3'G4SV4F@O5GN%
M31::ALK)F< R1O+A,,'. 0.0RM\=G>E35>$&S0<3.?A.QGT94H@ACIX6Q01M
MCC:,-:T8 5,F:+C4;_EE\.GG&5SKCP1\W:'O!V=:[KJ>^PR,@<'0R%C<EOE
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M5/5/NTD,K98N67 .WO)QR +L#KR4TU=;YKKI>[6^EW>/4TTD4>^<#><T@9*
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MKY'V<4L]7K2UQTH=OB7>)'8 #E?7"\C60C"?X>\]WV?DE/&U+N"(BY#O"(B
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MROK))!5 NP0\.)'/N&!S*W>OJFMU#M"LFCXZR:DM<U.ZKK> \L?*T9\C>',
M^9;C;;9;A?M"S45HI7U549XG"-A . [)/-8VN--7:+5-HU;IV%M56T49@GHG
M.W.-&<YW3WJ$_$EQINNG![6;0E3I?5]%5:6JS!I^2-[*^@J:B27)P=U\>]GG
MG&<D=JKNX:JT[J;6M\9K>XU[;102"FH[?3LJ USA\.1YB',Y!QDJ>44>IM5:
MPM-PN5NJ+#9K9OR&GDG!DJ9", .#3C='7FL2*T7[0NJ[Q7V*U.O5FNSQ/)3Q
M2-9-#*!SQO8!!YJ4_'J0UX=#2;/-0VVAVCT]FTE7W"KTW7TSSX/51S8I)F^4
M-UTH!P0#RSVKSV?:3@U5>M:&_5-;-;8KO.R*DCJ7Q,WMXY<=P@GLQSPISIIV
MJKUJGWUNT$MELL,!CBMSI&O?-(3\-^,@8'3![ETV66:X6BHU6ZXTSX!5W::H
M@+B#OQEQPX81NK"C=61K9]2?^/:WT/6S5-98Z4-,+)IG%[&/'-@>"' <NPK5
M;#]/6VGT9J&[0P/;7LEJJ9LG&>0(PT8&[G=]>,J8Z0L5RH]J6L[E54CXJ"M9
M"*>8D8DP#G'/*T^SBV7^PVW4&G:^QSB*:6IGAKFR,,;PYN&MQG.3A+X?\!+I
M_)K=AVC:*\Z7M]]O<M955T-0YU*34O#(6L=R:&@X()'/(*R[Q;-/S:@N\VT[
M45'-*Z8^ 4$-QDC;3P#X.6M+3OD=>JEFQBT5]CT#14-UIGTU6Q\A=&X@D N)
M'10[3-HO.DJV[4]7HP7ZIJ:V2HBN@?$=YKCRWB_F,>9+ML527!UV.3TEYJ]:
MZ;CK*JXZ:B=&*432/#FQO#\M#CAP'DA==A>F[73:5NUWAIWMN#9JJG$G&>1N
M#H-TG=]>,K<[,;)J*UZ\U36Z@H&11W-L,L<L#@Z)I;O>0.WEO =.Q<;-J&_6
M&FO&G:^QSBG?/4S17!LC#&\.R6C&<Y*-]:$5TOYD7L6HZ^P[ Y:NW2N%QGK7
M4L$IYECGOQGGV@9QY\*4U&R:B@L#JF*Y74:GCBXANGADA>Z0#)RW>W<=F,9Q
MVK L>S^XW+8S4:>N$9H+GX0Z>#B$'=>';S2<9Y'IZUL9;YKRHL?O/XJ.9=71
M\%]>:EG@W3!>.>]ZL(WSP0EQ^)=Q#-=:AN6HMB>G*Y\ICNCKI% ^1O+,C1(W
M/R@%;[:-HBCTWH^HU);:VYMU%1-9,ZN?62.=,<C>WFD[N#W !=M5: N-#LPT
MY8;5"ZOJZ2XPU%06$#\\O=S[,E3?:M;*R[[/;O06V!U1630[L<32 7'([TW=
M*)VNG?@2*RU#ZNT4-3+_ &DT#)'>DM!*@6T>B@J]141U5?Z6W:29 =ZD\,=!
M)4SDGX6,9:!CH[KE3NP0R4]CM\,[2R6.GC8]I["&@$*MM76*YT>TJ341TZ-2
MVZ:C;3L@#F;U,X'F0U_+!Z^LJD>I>70B=HN=EL6UJPT.@KG/)::\.BJZ;C22
MQ;PR06E^<].PE;6.QOU)MTU;15M95,L[*>!\U/!,Z/C'AQX:7-((;S)(!'0+
MM<[+JFY[0=)WUVGV45KHY2SP6%[2^%IZO?C [>@ST4LTU9+C2[7=676HI7LM
M]7! V"8D8>6L8"!SSU!5V_Z&:5\?,T.EZ$Z/VONL%KJ:KWEK*%U0VEFF=*(G
M-Q\$NR>T]JP]!V>':C[\:@U5-5U%.*V2GM]+'4R0LIXVXPX!A&7<^OF4KJK)
M<7[9J*[MI7FVLM\D+I\C >2W [^PK2V&WZBV<UMUH;78Y+Y9:VI?5TQIY6L?
M3N=U8X.(\GD.82_#J35=>AB;*[7/9MK.L*">KFJV14T ADG?OOX>3N@GMQT5
MR*KMG%HU'%M#U)>M14+:5E?!#PMQX<UN"?(SW@8RK15)]2^-4BFM'7=UAL.T
MFZ1@.DI;A,]@/3>W1CVX63I79M1:@TM1WC4E;<ZN_P!? VJ-7X9(PP.>-YH8
MUI#0!D=0>GJ6?I/2-9-:]<6Z[T[Z:*ZULIA><'>8YO)PQYUC:?N.M=,:?@T_
M)I:2Y3T<8IZ>N@J&")[1R:Y^3D<L9QW*]^!1+]1#ZFYWFY;,[G+73RU-XTG<
MVR-GSATL;7 ^5CKRZ^9;+;%6UNK+;IRDL%26O%%+>Y2P\RV-@W1ZR7!339[H
M6:SZ1NM#>Y8YJZ[OEDJBSFT;X(W1WX!6CV,Z0N]IKKQ+J*G,8AA;;:(N(._
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MKY9:NJ?54SJ:9C'PEW5K@X@8Z<PMEHK35XFO>H=37\"WW*ZPMIJ>")X>ZEC
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M*;V.'<N//I(S5QX9Z.E]H3Q-1GRBUT76-XDC:]O1P!"[+QSZ$(B( B(@"(B
M(B( B(@"(B (B( B(@"(B *OZW0%PI;_ '"[:2U)+9I+@X/J87TC:F-[Q^4
MXC!5@(I3HAI,B>C-%PZ>KZ^Z55=/<[W<,"IK)@&[P'1K6CDUH[E+$1&["5=
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M/CHIB!/DG&[AIY'U8\_:IU<KK<+WL*J:VZ>55/;@OW<;X$F <*8#9QI(57A
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MVP9>RENHY]1@6>&UNB@/<^62O=?YKN8Y(Z&.)T6^1@2./8._&%] ( &@!H
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MB(@"(B *=Z)M(A@\-G;]]?RCR.@[U'M+VDW*N&^/O$?-Y_HK*:T,:&M #0,
M!>?K<]+LX_R>M[,TUOMI?P<HB+RSW B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M+31.=WEJU]3*UN8H&B.,=C1A;PC((4=G862N:>Q2Y-JFRJA%.TCS1$4$A$1
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MN5H#0 !@#D$1#"UETJ?_ *+#^M]2S:N<01$_E'H%H'$N<2>9*D@X1$0@(B(
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MYH.!\JQM4V0:@MG@$E944L#W@S< @&1G/+">P'*V=-!'34\4$#0R*)H8QH[
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MW=E6*2H-)PP.-PW;GP?SL8777EOK9]LNG:F&CJ9*:,0[\K(G%C</=G+@,!7
MB+.TTZ[J#TR::OJ[*?N]NK7[>:"L91U#J1H;F81NW!]Z(^%C"R-MU!65EWTJ
MZCI*BH;'.\O,49>&C>CZX'+H5;"(L[4HNNBHEZ9.,HWU=E/;7;=6U6MM+2TM
M'4311EF^^.)S@W[X.I Y+OMQM%RGN-BNMOHI:N&D)$C8AO.!W@1R'/L*MY$C
MG<=O'0B6E4E+G\U>A"+U'+K;9Q6&IH)*"HEC=)'#,?*8YO,9Y#KCVJO-A5%4
M7K4T]WN#W2BVT[*:$N[#N[H'J:T_*K.U[9=07JF;36&[Q4%/(PLJ&O9DO![C
M@D>K"R=!Z5IM(V-M#3O,LKG<2:4C&^_T=@Q@*ZR*.)I=_H4EA<\T9-<+O\?
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MAI8J*C@I:=N[%"P1L'< ,!,TX[%"/CW%=/"?:.<[Z5S7]CV1$7,=H1$0!$1
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M]: RZ. 00AOY1YE>Z(A(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M"OG5MWH)ZZ>&FD=PVR.;&9.6^W/(J"4S,1$0D(B]Z&EEK:J*GIVETLC@UH"
MW^A+"Z\75KIF$TD)WI#V'S*Z6@-:&M& !@!:[3MJCLUJAI(\%S1E[@/A.[2M
MD2 "3T"DJ>-7.((2[\H\@M"]Q>XN<<DKWKJCCRDCX(Y!8R (B(0$1$ 1%RT%
MQ  YE >]% 9Y@W\D<R?,M\T!H  P O"B@$$0'Y1ZE>Z$A$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MV?/>%:NS33AI*?WRK(R)Y!]Z:X<VM[_6M[0Z1LM'+Q(:)A>#D%Y+L?*M\
M , *!86NNE0 WA,/,_"694S"&%S^WL]*T$CR]Y<XY)*D@ZHB(0$1$ 1$0!;.
MU4W_ -9_0?!^M8=) 9Y0T=.TK?,:&-#6C ') <HB(2$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M+=6">)\9,H(#VD9Y+!P>+68<<;VJ+-U-9-)EG*K;1,D1%ZYY01$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M)B6U.D9OW6-3_P"4W_P2_4GW6-4?Y3=_!+]2G^EM70W(LIJW$57@ ._)D/\
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MV' :!V9SGO*B&"4DWTHF>JA"2CR[5\%\(J*TMM U-:]:T]CU41*V6=M.\.:
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M9[QO$?0K4V::!@TA322S2"HN4W]I*!R:.YJT]MV=7"EVF2:D?5TYI75,LPB
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M/QO[/_UJC^0J0:HU]1V6\-L]%05]YO&YQ7TE P.=&SL+B2 /65H-?_C?V?\
MIJ/Y"HGIJCU+5;6MH$%FO]':JWPB.1S*FA$[I8<'<+27#  (^4("R]-:^HKU
M7S6R>BK;9>HF&3P"M8&2/;WM.<'IV%;#0^JZ35M@-TI(9J9C)9(9(IL;\;F'
M!!P3YCZU6M38[@S:II>75&LZ*IN\(>^GI*>U.C=+'SWLN:2&CSN6HO\ >Y=G
MMZVA6:GY.ND;+A:V@9+I)W")^/0[GCN" L>U;3[+6V"[WN=D]';+?4NIN-*
M>.X?F $DYY?*L%VU:&EC;5W?3-_MMI/_ .OSP#AC/0D EP'I"@VT[3TVEMG.
MA[=3SLIHJ>X0FJJ)8]]C)#^6\=H#OH4HU39-9#3-P??==VAEHX#O"'FSC CQ
MS/)^?D0$IUOM!M.DK;:[A5MEJ:.X2!D4M/APP1D.Z\P?,N+7KR*:UW2Y7BT7
M*R6^AC;*9JYK6B5KLX+0"3V=.O,*IM76^GI] ;+Z.*N]\Z1MQ8(ZDPNAXK-[
M(.X[F.6.JM7;!=;99M#U$MXMC;I!)+%#'1N.ZV20N\G)[ ",^I :>IVMQ4M&
MVXU>EM0065V"+@^%O#W3T=C>W@/4I;?]8VBR:9BOM5.7T,X9P.$TN=,7_!:T
M=I*K+:.[79V=7>2_2Z<M5N%-A\-,V29Y'+#,NP >S(RM;5.W--[$YJS'O6R>
M 3%Q\D2&)O#)^1R EEWVRTMDMSJR^:9OUOC< :?CQ-''\P.]@''/!PI7J+7%
MIL%FM]?7F7B5X;X+2QMWYIG. (:UHZGF%$O=-R4C-E=:VK+>(Z:,0 ]=_/9Z
MLJ':Y9<7;1=F@I+A!;C);>'25-1!QHVSD<QNDCF06 <^T("QZ+:;3MKZ:EU!
M8KQ815/$<,U=&WAO<>@WFDXSYULM7:ZH]/W*FM<%%6W6[U##)'143 Y^X.KB
M20 /25 -I6G]2OTQ)'K#7EMAMCY8QO,LQ+M_>\D-W7%V<]P6?J.QP737% =-
MZH?:]9TE W>;)2N='/!Y/,@@#KCD#D=HY("6Z6U]27J]/LU;;KA9[PV/C-I*
MY@#GL_.:02#\JF*J:U:FU78-:6:R:YI+56&Y[[*:X4.0\$<\.:0,#T?*K90%
M>77:K;:'5%ST]';;C67:C+ R"G8'&<N:'>3SY  \R<+9Z0U]0:ANM1:):2LM
M=ZIV\22AK6!K]W\X$$@CT%1+0SJ$;>->-E=&*]S*?A GF6\-N<)JOAS>Z&TD
MR@+360T<KJO=ZMB(?C/K(^4(#9?=;I)[K=+9:[!>;E76ZH?#-%3,:<-:<;^2
M<8)Z#KR6WU'M!H[/6TEM@MUPN5[J(A,+?2,#I&,[W$G ]944V%Q,&K-I$NZ.
M(;MND^8;_P!:]]#.;%MRUS%6<JR2"G? '=L(SG'K(]B D^E=>T=]N51:ZB@K
MK5>86<0T-:P->YO>T@D'U%;#1&JJ75MMJ*NE@FIG4]1)32PS8WFO8<'H3Z5
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M@V;3]=<J& X?5,):T><^2<#TE0L,VVDNA9ZC'&*DWPRTGN:QI<]P:T#)).
MNL$T4[-Z"5DC<XRQP(]BAE3J6AU3LWOE=;BX-\"G:^-PYL=N.Y%5[H"\U5EV
M07*>AHYZJ5]7)']YSF(%C?+. >05HX&T_&Z*2U,8R27*:LO(5=,9>$*B$R]-
MS?&?D7LOGC8G307#4,4];:*VHJ1(^07/BOX3"&YW7#&"?2>U?0ZC-C[*6VRV
MGS/-'=5'DRI@?,Z)DT;I6]6!P+AZDCJ8)9'1Q31OD;\)K7 D>D*FM%_CXO\
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MCUC)IRKL,,WOD\5 N$<CIB!\'X/Y.%:NSS15#HBV55';YI9_")S.^24#>Y@
M-Y=@ 6!J?9U27>]&\6ZYW"RW-[=V2>A>&\3'3>':4W+H-KJ^\BMCL^H(]KUN
MN&I+UISWQ%))&^EH!(R6:+!P2".8#L=3V+)V#PQMKM:S!HXCKJYI=YAE2S1F
MA:'35;57%]55W*[U30R6NK';TA:.P=PZ?(LG1FDJ?2S[LZFJ99S<*HU3^( -
MPGL&.Q')4T3&+33(G-?'#7M]CT3I9MRN\38XKE73UG!8WEY+!O9SC'0 =.U:
M#34EX?M]+K^*&.M=:G9BI'EP8W>;@.) R5,[_LXCK]05-XM%]NECK*IK14FB
M> )L="0>U=;)LQMUFU-27RCKZUU;'&Z.=TS@\U&\<DN)Y]B6J(VRLP-@N'6*
M_23C_P 2=>*CPLGX1=RQGU?U4;LFY#M9VCNL^Z)A;2X;GZ7'TYPO.H?I^ZZM
MOLTVH:S0MYBGX-3$:ID3:MH Q(-[ .?-D]O:LK8E::5NN=3W*S">6R\-E-#5
MR@XJ7@Y<\./PN8/-3TME5W(U&QJFUS)HJ%^EZ[3$5&Z5Y>VIBE,W$SSWR.W^
MBWNF+-/3W;6K]6WRR.%73L%;%;B]H@=T#W!PY$C"D-?LMIA<JJLT]?+K8?"W
M;\\5"\"-Y[3CL4@TKHRUZ=M-30PM?5&K)=535!WWSD]2XJ')%HP:X97%CM^O
MM-V.G@LTMFU5I@1GA1D\.1T&.3<D8(Q^LK"V:7ZWZATG35=JM[;; USHC2-:
M&MB<T\V@  8SYE&QLG%.R2EM>JK]06EY/^PQ3#A@'J!V@*=Z<LE%IZST]LMD
M7#I8!AH/,D]I)[25$FFB8)IF)KS\"K[^Y2_RE0OW/D,8T35/W1O253VN/> U
MN/I*L6]4#+K:*R@E>YC*F)T+G-Z@.&,A:K0^EH-)69UNI:B6HC=*Z7?D !R0
M!CEZ%>,TL3CWV9RQMYE/N2*VV,5<=NKM<U4V>!3$2N#>?)IE)P/0%[V^]WO4
M^G;O<K=):;'9?OG$:(M^9QW>>>@R>\J;:3T/1:=GO,C*B6J;<R.*R5HP!Y7+
ME^L5'Z;8Y9X*Q[Q75[J-SMXTN^ P^8]ZW>3&Y.3^1S+#FC",5\^\BNRG\5NL
M_P!G+_R2MALI_$]?_P!>?_EM4RT[L^I+'9[S;:>NJ'T]R8YCMYK<Q[S2W(]1
M]BR=-:)I;%I6ML<-7-+#5%Y=(\ .;O-#>6/0HGF@]U=[1./3SCMM=$T178")
M#H6O$!Q+X0_<_6W1A8EKHMJS;E3&NJVFD$C>*-^#FW//H,]%/M"Z4I](6J2A
MI:B6H8^4RET@ .2 ,<O0I&LYYEODTD[\37'IWV<8R;37@RE=%?CXO_ZLW\S4
MV3?C7U9Z9O\ G*>VG0]+;=9UNHXZN=]15!X=$X#=;O$'EV]B:9T/2V#4MSO,
M%7/++7%Y=&\ -;O.WN6%I+-!IKY)&<,$TXM]S;(1LY_'%JC]F[^9JC])2:@J
M=JVI8;)=(+;7NFD._4 '?9O>2!EI[,>I6U8=%TUGU5<;Y%53235K2UT;@-UN
M2#R[>Q8NLMGELU-7,KG33T5<T;IFIR 7#SJ5GCN?@TD5>FGL7BFWU_N1G3.A
MM10Z[I[[>+U;JR:++9Q$2'D;I & T#N4\UZV5VC+R*?>XIIG[N[UZ+6:-T!;
M],U3ZN.IJJNK<,&2=^?8I@]K7L<UX#FN&"#VA8Y,ES3ZU_!T8<.V#BU5_.SY
MZV9VS5E?IN4Z>U!0T-$V1PD@E:"X'M)\@\CZ58NR?2E7I&W7(7"NHJFGJ'-D
M8ZG<2UN <YR!YEBW'9!::BMFGHKA74$<Q+GPPN&Z<_T6\;H.C@TE-8*"LJJ:
M&9V9)@[>>[S<^Q:Y<T9II/K\C##@GC:;7*^?]CY_OLEIDUO/<*>CE?IX5@$@
M;R:[GEV/3S..Y7]M GIZK9C=)J)S'4LE'O1%G3=QRPNU%H"U4NCI=/'>D@DR
MYTSFC?WS^5Z0O>Q:-I[9I2HT_-5SUE%*'-!EP',:[J!CY4R9H3IKN_H,.GG!
M23_Y+Z,@MG$KO<^U0IL\3@O^#UQO^5[,J/[/[/JVYZ._\%U%;Z2UDR,?3RM&
M6Y//>.X>O7JK*T;LZHM,5<\L5?554,L;HN!-C< /7DM35;';2^JE?1W&X4=/
M*=YU/&X;I5EF@MROJ[Z%7I\CVNNBKK1I)]+5FEMD6HZ:MJZ6I;,^.2-U.XEH
M&^W/4!239!!&W91!Y(^^MJ'/Y=3ON'/U +=OT1;QHV?3E/+/%33 ;TI.\_(<
M#GGZ%GZ7T[#I_3,5E@GDEAC:]HD> ''><3V>E93RJ4&KYNS;'@<)IUQMKU*L
MV-4E-7Z"U)1U\P@I99BQTCC@,\D<_E6NI[)K&P626>P7JCNMA8'ES ]LD>X"
M<@M>.7G 5H:4T%;[!9;A:W2R5M+6N+I!,T=V,<O0HZ_8U;-][:>[7*&D<<FG
M:\%N.Y:K/#=)WP_D8>[9%"*KE+QHU]1J5VI]BEYJ)*:.FDA B<V(88</;S [
M/0HQ<F3NV!6DPAQC;6/,N/S=]^/;A7#+HNVC1T^G*/?IJ25N'/;@OSO Y/>>
M2]]/:4HK1I5E@>3648#P[C-&7!Q).1ZU59H17'C9H]-DF_Q/_C5_.S%TA4VO
M[GM"]CX1;V48$O,8'D^4#Z\JJ-F[)QH37<C0X4#H'<+NWMUV<>K=4RDV-VDS
MN$-SN,5&XY-,UXW3YE-3INA9I::PT;/!J.2%T.6 9&\,%WG*CM(13IW;)[+)
M-IR54G_)"?<^P,&B*E^Z,R5+P[EU :/K6F]SIY-7J=H^"'0X'KD5DZ(TO!I.
MS.MU+42U$9D,F_( #D@<N7H6%H31%+I":XR4M7/4&M+"X2 #=W=[IC]91++%
M[_G5$PP2B\=K\MV>^TW\7]__ '1_T*M==EX]SWI\9<*9PH14[OZ/(SGS9W5<
MUVH(;I;*JAJ@3!41NB?CK@C"BNFM 4]ITY76*ON59=[94L$38:O!$+ .36^;
MM]2PBTCJE%MFUU2R@\1;FV41"W"@?CD-T,W#C Z=V%H=A3ZE^S&S&K+R0PB/
M?Z\,'R?5C"UK-D4+HXZ*JU-?*FRL(Q;I)AP]T=&D]2%95)3Q4E-%3TT;8X(F
MAC&-& UH&  H;25()-NV5O[HIH?LVG:[H:F$'^)9>U%LU-L6NK+>-TMH&,PT
M=&>2'?\ #E2+76EX-76%UJJJB6GC=(R3?C )RTYQS6X\$B=0>!S-$L!BX3FO
M&0YN,$$>A$Z2#C;94VDZ+:,[2ML%IN&CVVPTK."TPRGR-WH<#&>_SY4,N%LJ
MK7LJFIY[M;[C0/OT+IS;W.,,,9<2YG,# W\<E8_W)8X&RTUKU1?;?:I'$NH8
M9AP\'JT=P4OI](V>#29TXRD:;68C$Z,\R[/,N)_.SSSWJ^Y(IL;-9M6BHG[,
MKXV<1>#"D)9TP"/@X]BJC51#=A6SU[CAK;A2$GN&[(IN_8]3ST<E!6ZCO55;
M TMAI)I Z.(XY'SX\ZD<F@K74:"I]*5SI:BB@C:QDIP'@MZ.'<5":1+BY6:W
M;S+'%LMO7$>&[[&M;GM)<.2CNH-U^T+9C'7#_81 71[_ ,$S<,[OKR&X]2V-
M5L>IKA:I*&[ZBO-P8&[E.:B0.$ \S>A/I4MU)HZW:@T]36JN,H%,&&"HC.[)
M$]HP'-/8432X#3?)YZO?IR"ZV&:_1!]?X5N6\M#B\2$=F[V8[^2K"@CU74;7
M]9'3E398*QG":??*-[G&''D[F[V=_J4^TWL[AME[ANUUO-ROE;3M+:=]<\.$
M(/7='?YUDZPT%1ZAN4%TIZVLM-WA;N-K*)VZ\M[G=Z)I<$N+?)!ZFS:J?M"T
MU6:GOFF8JN&0B.*D$K)IX\C>;S',>GDKG=G=..N%#M):!IK'=9+K6W&NO-V<
MSABJKG!SF-[FCL4R59.R8*BL/<]AGB=6.EW??)U?.:S/P]_>_*[>_P!JCVG&
M10:ZVI^\F!)X'O-X?Z7$G3UJ87O9E35=[J;I9[S<['459S5"B>&MF]([#UY^
M=9NB=GMMTA=;C6VZ>=_AL;(WLEP>;<^5GJ2<\\JVY<LJHOA>!JO<[MIALIM)
MIMTR.=*9SCF9.([.]Y\8]6%'M,PVZ>Z[5*2IJ12V&24-DE')D;W-(>1V<N2D
M=?LL@]\*NHL-_NUBAJW;\]-1/ C<[M('8I-IW2-IL6GY+/2P<2EF#N.9?*=,
M7##B\]I*.2Y?B%%\)]Q6MLI-H&FK!3PTWO+JS3,< X;,B.1].&^2.8P1N]F"
MO/:#?*#4&PZEK[51BAI350L%*&AHB+9,%H Y8!'8I W9*((745%JN_TUG.1X
M R8;@:>K<]<+?WO05LN.C(--4[Y*.AA<QS#& 7>2<\\]_:FY61ME31'-HM/%
M4;4]G;)F![6NJ'@$=H#"%Y[>P!XFR#D]MZA <.H!/-3:]:7@NNI+'>9:B6.:
MU<3AQM W7[X .?D7GK725/JIMK%34RP> 5;*MG# .\YO8<]BA27!9Q=,BNG]
MU^W?4QK@#.R@IQ1E_41X&]N__+>]JQMH3*0;8M O8&>&E\P?CX19N'&5C;2I
M['5:]HZ"]5-7IRNBI^)17R.81L?GJPDC QSZGM\ZT-DM%KJMJ^GS8;Q4:AJ*
M/B5%PN;I.* -TM:W?'D]O0%62[_D5;[OF7\B(LC8(B( B(@"(B (B( B(@"Q
M;J2+76$$@B%Y!'ZI64L>Y,=);JIC 7/=$]H [2053)^1E\?YD0G9;-+-)<N+
M*]^!'C><3CX2GRA.S>V5MO?<#6TTD(>&;N^,9QO9^E39<'LB,HZ2*FN>?ZL[
M?:CC+52<>G']$$1%Z1YY5^L-#U0K):NT1B:&1V\86_"8?-WA17Q;O __ *;4
M_P "GFK->>!5,E):6,DEC.Z^5W-H/<!VJ+^/E\)/WZ+^!02C5C3EX^+:G^!/
M%R\?%M3_  +9^/E\_3Q?P+GQ\OGZ:/\ @0DU?BY>/BZI_@7M3:5O51*&-M\S
M<_E/&Z!ZUG>/E\_31_P+VI=H-XBE#I3#*SM:68SZT')/]%Z=;8*!S9'-?52G
M,CV]/, I"M1IF_4]^H3/ "R1AQ)&3S:?J6W4E3'N-%!<:"HHZM@DIYV&-[3V
M@C"^:=5[*=06FLE][Z5]QHBX\.2'F['^\WJ"OIJIGBI:>6>HD;'#$TO>]QP&
MM R250NJMM=?+5RQ:=@BAI6DALTS=YSQWX[$!7_B1J;XCKOFBGB1J7XCKOFB
MM]]UW5?^*@^:_P"Z?==U7_BH/FO^Z@@T/B1J;XDKOFBGB1J;XCKOFBM]]UW5
M?^*@^:_[I]UW5?\ BH/FO^Z Q;!LQU-=:MD4EODHH2?*FJ!NAH[\=2OI72]B
MI-.62GME W$40YN/5[CU<?2515@VU7JFJV>^\,%72DX<&-W'@=X*OVRW2DO-
ML@K[=,)J:9N\UP]H/G!Y*23-1$0!$1 $1$!IM87R'3NGJRXSD9B8=QI_*?V#
MY5\I6>AK=7:KC@!=)55LQ=(\\\9.7$^@*P_="ZB\*O$%FIY#PJ5N]* >1>>P
M^@+?>YYTN:>BFU#4M\NH!AIP1T:#Y3O61CU*3-_B=%L66V4UGME/0T4;8X86
M!H &,^=9J(H- B(@.LT3)HGQ3,:^-X+7-<,@CN*^<-K^SLZ>G-TM$9=:Y7>6
MT<^ X_T7TBO"NI(:ZCFI:J-LD$K2Q[7#((*$-64+L1U][WS-L5XF(I'G_9Y'
M'E&[\WT%?0(((R.87RCM.T9/I&]GA!SK=.2ZGD[O]T^<*T-F.TRC.DJEE_J6
MQU5LBWLO=SF9T&.]V<#'G"DK%]S)7M1UI!I&P2O:]KKC,"RGCSSR?RCY@OD>
MKJ9:NJEJ*F1TDTKB][W'))/4K<ZVU+4ZIU!4W&J)#7G$<>>3&#H%H%!H<HB(
M#A$1 <HB[1L=(]K(VESW'  &22@-AINRU>H+Q3VZWQE\TSL9QR:.TGS+[$T?
MIZETQ8::VT;0&QMR]X&"]_:XJ*[&M##2MD%37,'OK5 .DR.<0[&^GO5B(0%4
M.U_5^\39;;,0!SJ'L/7_ '?K4LVEZK9IZTF&!P-?4M+8V@\V#M<OGJ1[I'N>
M\ESB<DGM0'&3VGFLN@KY:1XW7$Q]K3T6&BE<%)PCDCMDK1,Z.KBJF!T3N>.;
M3U"R%"()7PO#XW%KAW*26V[1U&&2X9)YSR*UC.^I\[K/9DL5SQ<Q_H;-$1:'
MDA2/1=A==J\23-_V2(Y?G\KS+4V:W372OCIJ<9<X\SV-':2KGM=#%;J&*F@&
M&L&,]Y[U2<JX/3]FZ/MY;Y_E7J930&M :  .0 1$6!]0$1$ 1$0'A731TU%4
M3SC>BCC<]XQG( R5@:=NE%=()9+='PV,=NN&X&Y.%ZZD_!^Y_NTG\I4:V5_W
M;6_MA]"X,N>4=7#$NC3.['@C+2SROJFB;(B+O.$(B( B(@"(B UFIK+2ZBL-
M;:+@9!25<?#D,3MUV/,>:^>-IVQC3&FV6$VZ2XDUMQCI9>+.'>0[.<>2,%?3
M2J[;M_9:1_\ >H/ZH#VTCLDTOH.[.OUL?<G3P0O!$LHD&Z1S\D-!)PJ\TS==
M-:WVNW>HU%#<*XMF@9:620S-;!AH)) P&>4,^5U7T<JKV7?C/VC_ +Q3?\H(
M"O\ 0>RO3^NKKJZMO;JYLU/=I8&"GF#!NX!Y@M/>N-H^SZ@V64%+J#1]\KZ.
MLBJ(P:66?>-0"X#&!C(Y\P05XZ+V8Q:WO&KJV2_7.VF"[2P\.D< UW(')\_-
M8UAT7;-(;4Z2V;0)JVOCED:^U5DLA-.\_FO!SSS@=W1 ?0&HK]76S2T%?;[3
M/=+A.&-CI82!Y;AG+B>C1VE5GL9=?SM6U8-6U#);H*2(N;&[+(FEV0QOF&2K
MP    Y!5-HC\>VM_W6'Z4!;*IBR[2X9-L5ZH*FIN3[<(HZ:E@%+)NLEWL.)
M'($_E'EW%7.JNTO^/O5__M],@)-J;:#I[3E=X%<*N1]: '.IZ:%\\C0>A+6
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MZN5TM1,\O>]QYDE>"D.MM*5^E+Q+1UT3N%O'@S8\F1O80?Z*/(2$1<( BY1
M%L],V2KU#>J:VT$9?-,X#/8T=KCY@M=%&^61L<;2Y[CAK0.9*^J-C6A&Z5M
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MEBM%X;:[C6B"K+-_#F.W0.\NQ@=.]8UGVA:9N]Q%#0W-CJAQPT/8Y@<>X$@
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MP0M;]U'2/A7@_OJ-_>W=[A/W/XL8QYUG7RET_8M)5 N-+#%;&0B.1K& %XZ
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M=UVZ[=Y8.5*U2FR7(VH:MP,G,V!_^]6;<:7:)6SW.KJ;M!9:6G),3 X!CQU
M!_J5>>%;Z3KH9X]1+9N:MV^A;Q(:"2< <R5IK#J6VWVLKZ>US<?P)S62O (;
MO'/(9Z]%7F@]07[6>BKQ3&O93W*F<UK*H-Y[I!//'H/RJ.[$;9>)K[<)J6Z"
M&EIJAOA<6/\ S'PO^_RI[NDI;GRA[TY2AL7$BV=/:NI[W?;G:X:.KADH7%KI
M)6@,?AQ;Y//S*2JK=GFH;E6ZYU737&NEEHJ-[^%&[&(P'N'+U!:NCO>K]?7B
MO&G:]EKM--(6,E+>9[@>I)[4E@_$^Y*B8:G\*OEMLN9%5FC-57RVZP=I;5TC
M9YGMS3U#6XWNO;V@X/R+337W5E?M.N]BLMQ#(R7!O&&60,&"7 =_9ZU5:>5M
M7W62]5&DZ?6J^9=B*FK'J#4NF]HE/I_4=Q%QAJ@W=>1^=T([N8*N54R8W"OF
M:XLJRITJH(B+,U"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B +&NC2ZV5C
M6@DF%X ';Y)62O*KF\'I)IL9X;'/QWX&56=;79:%[E1"-F%+/3R7'CPR1[PC
MQOM(S\)3Q1[2>HC?G50,'"X(;V]<Y^I2%<?LV..&FC'%*USS_+.OVA*<M1)Y
M%3XX_@+&N7]W5?[)_P!!62L>Y?W=5_LG_05W'$?/#NI7 7+OA'TKA06"!$0!
M$1 3?9+^$%1^[G^9JME5-LE_""H_=S_,U6RI1#()MN_%U<?UH_Y@OEI?4NV[
M\75Q_6C_ )@OEI05"(B (B( OH3W-OX,W7]\_P"AJ^>U]">YM_!FZ_OG_0U$
M$6XB(I)"\ZF9M/3RS2'#(VEQ/F 7HH;M=NOO3H.Y2-=NRS-$#/2[E]&4#X/F
MJ\U51J75DTHR^:LJ Q@'G.&_T7UOIZ@9:['0T,0PR"%L8'H"^:]B-J]\]>4C
MWMWHJ0&=WI'(>T^Q?4BEE(+O"(B@N$1$ 1$0!$1 $1$ 41USL_LVKX<UL1AK
M&_ J8<!X\Q[QZ5+D0%'4NP"G;59J;W(^GS\%D(:XCTDGZ%;>F].VW3MI9;K9
M3MCIQ\+/,O/:7'M*VR("D]I^QV"J;4732K.%4_#?1-^"_O+.X^;HJ:L]KDIY
MW25D;HY8W%H8\8(([POL'456^AL5?4Q?#BA<YOIPOEJ>5\\\DLKBZ1[BYQ/:
M4!YHB(#E<+E<*0<KA$0 *9;-M).U%=!)4,<+? X&5W3>/YH4?T_9ZF]W.*CH
MV%SWD9/8T=I*^EM/6BGLEJ@H:1H#(QS/:X]I*@&?%&R*-L<;0UC0 UH& !W+
MLB( B(@"(B (B( B(@"(B UVI/P?N?[M)_*5&ME?]VUO[8?0I=<J;PRWU--O
M;O&C='GNR,+6:6L7O%33Q";B\1X=G'3EA>?EP3EK,>5+\*3._%FA'23Q-\MH
MW:(B] X B(@"(B (B(#SJ9XJ:GDGJ)&10QM+WO><!K1U)/<M4W5-A>(2V\V\
MB8[L>)V^6>F!SYKSUY^!5^_<9OY"JWV':5M-=IT76X4;*BK;4$1ODR=S=QC"
MVACBX.<CGR99K(L<5U+6NEZMEJ##<[A2T@?\'C2AF?E6115E-70">BJ(JB$]
M'QN#@?6%\WVZ[0736-ZK[]8Z^_>66QPP-+FPC)',#S 8]:D6SBIK;3J:]/H;
M3<[?99:62:.&IB=ACVMSU(QURM9:;:NO)A#6[I+CA_4N*XW^T6VH;!<+G1TT
MSO@LEF:UQ]1*@5!JR[5&V.>R>&M?: TED0C9^C#OA8SU\ZC^R/3ENU;+>KSJ
M&'PZ<U)C:V5QP.6<X]8"Q=(VN&S;=9J"F+C!$'\,..2UICR!GS9PK1Q0CNCU
M:166;)/9+HF_^V773WFV5-QEM]/7TLM=%GB0,D!>W'7(ZA<U%XMU-<8:"HKJ
M:*MF ,<#Y 'O'/H.IZ%5'H<C[NVH>?5LW\S5[ZW(.W/37FBC_FD6?8+=MONL
MU6I>S=7?1;-QN5%;(.-<:N"EB_/F>&CVKSMEWMUU876RNIJMHZF&0/Q\BJ1]
M-%K#;36T%ZS-0V^%QCIR<-.-T=/_ )9]2G-IV>V>T:B-VM?'I7;H;P(GXC^3
MMSW*LL<(+\3YJR\,L\C;BN$Z^9(;I>;9:0TW.OI:0.Z<:4,S\JR**LIJZ!L]
M%415$+NCXW!P/K"^=:>Z4]TUM>ZZ_6*OOVY)PXHH&ES8@"X<P/1R]:D6R<UU
M'K^KCH[3<[?8ZQCBV&IB<&QD#(YD8ZY^5:2TVV+=\HRAK-TTJX;KYEWJI-K^
MM;U:+S3V[351PY8H#451;$R0AO9\(''($^M6Q/*R""260AK(VESB>P#F50^D
M=2V&XZHU1=]15D=.VM'!IV2@G[WT[ >P!4T\;;DU=%]5.DH)TV6]H:\F_P"E
MK?<'N#I98QQ,?GCD54=1JG7]UUI>[3INL$@I)Y0V(Q0-W8VOW1S>.?9VY6YV
M 76,&\61DXEB@EXU.>PL)P2/9\JA=)1ZBK=IFIV:3J13UC9YW/=OAN6<7IS!
M[<+?'C49S32_DYLF:4\>-IOGK74W=SU5M*TEP:W4;(I*-SPS=>R$@^;,?,%2
MS:;K.OH=$6B\Z>J#2NK9&G)C:\[I83C#@1V*M+?%=M5:IBL&L[W/ Z*7'"F_
M*=W-/3)[,J=;?*.&@T-:*2E;N00U+8V-[@&. 5G&.^":5_+H4C.?93E%NOF^
M;+.LE4^>P4-75O!>^F9+(\@#F6@D\E3-IVF7R;6].^IJ,:<J:U\$;#"P#=S@
M>5C>R,M/52[6E^%CV3TA:[$]721T\>.N2SF?D^E5U>JO3AV46JBH[C"Z]4CV
MU!8 [>+W$[XSC'+/_"L\.-<MJ[=&NHRM-*,JI7^_R/HU%H="W87O2EMKM[>>
M^(!Y_P!X<BM\N-K:Z9Z$9*24EWFJGU'9H)ZB">ZT4<U.,RL=,T&/TC/+JHSK
M&\U,[;54:>U7:+=2RN=O.G<QPJ,$##"0>G,<N]0*CLE'?MN-XI;E%QJ5@=*Z
M,YW7$-:!GY5[;<Z"EM<FE*.WP,IZ:-TH9&P8 \IA77##%3C'O:_L<,\\WCE*
MN$Z^?4NBON-';J?C7"K@IHOSY7AH]J\;7>[7=2X6RXTE66]1#*U^/D*J7;%:
M[GXSV^ZFV272T0QM#H&ASF@\\Y Y^M8>B;EHJLUE15-+35EEKVXC9 '8B>_S
MXY\^F"JK G#<7>J:R;&DOW);>]37:EVO6JR056[;)XPZ2'AL.3AQ^%C/8.U3
M>:_6F"Y-M\URI&5SB *=TH#R3T&[G*I+:]<ZJS[4Z2NM[ ^KCIFB)I&?*.\T
M<NWJM]L'I:2X/NUXKW.GOXGW9#+\*-I'(@=F3D>I6GA79J?R]2F//+M98UX]
M_@7"B(N,] (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( M%3:0L%+>GW:"UP,N#CO&49Y'O S@'S@+>HI4FNA5Q4NJ"(B@L%
MK=20W">PUT=EJ!37)T1\'E+0X-?V<B"/-S[ULD0%+:8VVVJWVF.W;0Q6VR_T
MHX-5Q:1SFS/'+?;N-P,]<8&#T6#I&J@UIMJBU+I:VSTMEIJ-T-36OA,0JGGI
M@=O4=>?)796VN@KGAU;0TM0X<@9HFO(^4+W@@BIXFQ4\3(HF\@QC0T#U! ?,
MFBM,:(L=PO5EVFT?@=RAJWOIJNHJIH8:F$]"US7!N>7IY_)8&RR@T@[6M=4:
M)TZ]E)2P<,WDUDSV2.<1F-C'DAPY#RLJUJV@HZYK6UM)3U+6]!-&'X^4+UIX
M(::)L5/%'%$WHR-H:!Z@@/GNS:>J]3['=<6ZWMWZHWNIE8S.-\LW';H].,+S
ML%%L;?IR">\4[:.YQ1!M31SUM2R?B 8< S?R<GI@+Z'IJ:"E:YM-#%"U[B]P
MC8&@N/4G':L>:TVZ:H\(FM]))/G/$="TNSZ<90%(7/3PJMB/A.FM,2V=C+@R
MZ-M[JA\\DL;' %YW^8):,[O/D!WJ67O:[:G:=B?I26&YZAJ=R.GMN'%X>2,B
M1HP6@<^Y6@L2&V4$%2ZH@HJ6.H=UE9$T./K R@*LVOU3K;=]G5SO<D,$--<"
M:J=H(BC)8.?,G Y'JO+7-=2W+:ELYK*">.HI9C*Z.6,Y:X=X*MVKI:>LA,57
M!%/$3DLE8'-^0KHVWT33 6T=.#!RBQ$W[W^KRY>I 4MMJJ:K1NLHM36^)[F7
M:V2VE^YT%1S,+CWGL] 69K#0%5%L$@L-OI^-6TK(ZF6)G(RO!WGCSGF?D5PU
M--!5-8VI@BF:QP>T2,#@'#H1GM\Z]4!\[TM-L5?8!6RTH96-BRZ@?6U(J-_'
M-@9OY)SRY<E:FR"CI:31=.^@T^_3]/4O=.VB?4/G< >CG%W,$@ X4G=:;<ZI
M%2ZWTAJ <\4PMWL]^<96:@(%MIL55?-&O%"QTDU+(*CAM&2\ $$#U'/J5<6>
MJV9"RTHN=HJG74-:R:%AGWB_H7<G >?^B^A%B^]M#QN-X%3<7.=_A-WL^G"Z
M,>?;':[_ (='+ETV^>]5_*LK7:126ZCV-216:FDIJ NB?'%('!S0Z4$YWN?4
M]JV-D_$D?_;YOI<I_400U$1BJ(HY8SU8]H<#ZBC:>%L' ;%&(<8X8:-W'=CH
MJ]K^&OG9;L/QN2\**FV*T9N.S"[T33NNJ7S0@]Q<P#^JA.DH='6JGJZ#7MKJ
M([K#*<./%\H=@&X<>OVKZ.IJ:"EC+*:&*%A.=V-@:,^@+SJ*"CJ7A]324\SQ
MT=)&''VA:+4<R\'X,R>D_#%6K7BK15]+8-/WW0-]9HNV5-%-51-!$XD'$+';
MP:-XD=F.7>M=L]VA6S3&CQ:KU'50W*C=(&0&)V9,N+@ <<N9QS5TL:UC0UC0
MUHY  8 6/-;Z.>42STE/)(/RWQM)^4A5[9-.,E:Z]2WN\HM2@TG5=."&R7R;
M5NSB\54=KJJ-SZ>1K(Y<$O\ )/-N.9'J"ANRVOH;KH&MTHR5XNLS9L1F-P !
M'++NG8KL:T-:&M  '( +P@H:2GE,D%+!%([JYD8:3ZPH65*+BEWVBSP2<E)O
MNIE.;-];46CK-+8=40U-%4TLKRQW"+@\$YQR[<Y\WG7KL\I*S4.T.ZZL?2R4
MUN(<V'BC!?ENZ,>KF5;U30TE4X.JJ6"8CH9(P['RKW:UK&!K&AK0,  8 4RS
MKEI<LK'326U2E:CT*8V -'OUJ=V.>^P?\3E="\*:CIJ9SS34\,)?\(QL#=[T
MX7NL\L^TEN-<&+LH*%E*[2?QRZ8__<_\PK.]T!33M9I^YQQ/D@HYW<0M&=W.
MZ1_*5:LM'32SLFEIX7S,^#(Y@+F^@KUEC9-&Z.5C7L=R+7#(/J6BSTXNNAE+
M3;E-7^9V45M9UQ;=3:2@I;,*F8-E9+/(8G-;%@$8)(YG)[%QM+_$_I#T0_\
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MZ;P^16:B=O+I\J#TT>OSL(B+$Z B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+'N5;3VV@J*RMD$5- POD>>P!
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M5U-IO6UEAM==61F2DFII3)%+@$EN>_ * F%%J2V5FHZVQ4\SG7*DB;--&6$
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MS_=I/Y2HULK_ +MK?VP^A>=ES3CK<>)/\+3/0Q88/1Y,C7*:)LB(O1//"(B
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MG8DY8Z9P.1[,+R=HZPNTQ#IYUO:;-$064W$?@$.WASSO=>?5 :3:B -CE^
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M%&7@_P"YSY7V3G&URO[=WB75LG_%[9?V)_F*A_NA8Y!2Z?J2TFEBJG"0]@)
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MDFY0S;5X5_DIAU6GQP49X=S\;_P1^COL\^DY;JZ*,3,:YP8,[O(J*_="K_\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=S+M[KDY^1)98MSYZ]"(8)Q6-5TZF7M(OE#8-+SU5QI&5L;W")E._X,CSG
M)P<<@3ZE5NT%]]J=G=/47**U6^W%\9IZ2E82X@YP=XGER[E<.KM.TFJ+)+;:
M_>#'$/8]O5CQT</;\J@4>QR%]KDI*Z_5E40,4Q>T[D'/F0S>(/L3!/'!)M\V
M3J<>6;:BN&B.Z]/_ .8[2^?TL7_+>IC<Z*"+8>8VQ,W1;628Q^46@Y].2LF[
M;.S<M#V[3DMV<!1RA[:@4_-P < -W>Y?"ZY[%(*S3HJ=%G3_ (26M\%;2\?<
MST &]NY\W3*2RQI)/OL1PSN3:ZQ2*<JWSGW/5'PR2SPK$GZO$?\ UPK%MD%K
M&R$!C8? S;W.<>6"_=.2?/O+::?T;26W1GBY6R>'4K@]KW.9N;P<XNZ9.",]
M?,HI2['J>&26%]\KI+4XEPH>89GL)\K!^12\D)6FZYLK'#DA32O\-?L>'N<L
M>+=TQT\,_P"AJF>TW\ KW^[N739]H]FCJ"KI8JPU39YN*"8]S=Y 8ZG/1;?4
MUJ%\L-;;3,814QF/B!N]NY[<9&5E.<7FW+I9MBQRC@V/K1$=A5.R'9]2/:UH
M?+)(YQ'4^40,^H*);+HFS;3]8Q/)#7B=IQW&7"M+1>GQIC3U/:FU!J1"7'B%
MFYG)STR5I=-:!BLVI;S=9*[PIER$@? Z'=#0YV\1G)SW=%?M8W-WUZ%.QE6-
M5TZ_0@%-IG5^EZFN\2J^EN5"Z3RXV.C<X'N<UW(''G4DV7ZB]];+?*">U4UN
MK*-CA*(&;H><.!R.P@CO7:KV2LBJY9-/:@K[/#+S?%#O$'UAS5)]):+H-,V>
MIHZ-SGSU+2)JEX\IYQCIV#GT5LF6$H\NW^U?4IBP9(3X5+GOM?P?--!:;O66
M"NKZ=CI+30S!TK"[R=XXYX[>0&?2OJ?25RI+MIRWUEN:QE/)$W$;.D9 P6^H
M\EIM$:&@TU8[A:YJKP^"M>7/WHMSD6AI&,GN7;9]HZ71\553MNKZRCE<',A=
M#N<(]I!R<YY?(F?+'*G\N@TN">!JUU7/R/;:@^=F@+XZD)$HISS'7=R-[_AR
MM#L'AHO$"%T#8S.^:05)P,[V]R!_^.ZK$FC9-$^*5K7QO:6N:X9!!Z@JLZ_9
M) VKEDT_>ZZSP3?VL$67-=YN3AR\QRLL<HN#A)US9MEA-9%DBKXJC4;-=R/:
M[J:*V8][MQV\&_!#MYN/^I==C_XR=7?KS?\ ."LG1^E;=I6@=3VYA+Y#O2S/
MYND/G^I:O2&AVZ=U'=KLVO=4&O<]QB,6[N;S][KDY[NBTEFB]W[)&4<$XN'R
M;;^5DLKJB*DHJBIJ3B"&-TDAQGR0"3R] 506.]7+4=GO=3IZV6BS6;RVSRO:
M9)7N#<GER'0CT95PU$,=33RP3L#XI6ECVGHX$8(58TFQZDIJR81WJN;:IG9?
M1-RT/'8'.#N?R+/#*"3W=3741R2:V]#1;%OP"U7SR,/_ .65N/<[TL7BI<9R
MQIDDJW1N..9:&-Y>TJ0:3T"S3E#>J."X&6FN(<&L,..#D$==X[W(CNZ+8;/M
M)MT?9IK>VL-6))S-OF/<QD 8QD_FK3+EC)3I]6C+!@G%PW+HF5;LS,D%\UU'
M1Y:YD$W#:WL<'.QA:O972ZNJ;7<#I6IML4)FW9VU+6EY./.T\O\ NK:T;H5F
MF[]=;F*\U/AY),1AW=S+L]<G*T]UV3P27*>KL%YK+*)\\:* $M=D]!APP/-S
M6G;P;:\:[C):;(HQ==+Z.NIH[)I"]Z8TMK&2[OI#%54;W-$#R?*P<\L#"S=A
ME)#]SJYRF-I?--*UY(SD!C<#T?6I7:M#4UMTK<+-!6U+_#(G1OFE<7[N1C(;
MG ZKWT1I%NEM-36AM8:D22/?Q3'N8W@!C&3W=ZSGF4HR5\VC;'IW&<77"3[R
M#>Y[IH3IV\2&-A>Z;<+B.K=WHL/83RI]6 <@,<OXU8.S_1K=(6RKHVUQJQ42
M<3?,6YN\L8QDK&T-H1NE679K;@ZJ\/QG,.YN?"\YS\)3/+%[^>M%<>"<>SM=
M+LK_ &*7&FM.D]4UU<SB4T+FN>S&=[D1CUE>S[C=;WL\NU90T-HLVGW,D=N,
M87R2$'!'4 9/;A332.SFDL5ENULJZQU?37'&_F+AEH /3F?2M1;=CU+3.DAJ
MKU6U-L<XO%%S8S>["<.P?D"L\N-R<K[T4C@S*$85W/\ [^QE; #_ /D&/WF3
M^BLA1C9_I5VD;1);Q7&LC=(9&DQ</=SU'4Y4G7+FDI3;1VZ>+ACC&75!$19F
MP1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0$3VF?@ZS]NWZ'+?V3^Y:#]WC_E"T&TS\'6?MV_0
MY;^R?W+0?N\?\H7FXO\ ?9/_ ,K^YZ&3_90__3_L9J(B](\\(B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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ME0U+R\T\3]V:G>.6<=H*M);E))]Y6+V[6UW&=M\8*36VAJ^E %=X26 MY.<
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MVE;J'8QP''Y.:C&QYSC;*YI^"V1N/D*WVT:J%+I"NY@.E#8F^?)Y^S*Q]F-
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MCJMO8K';+#1"DLU#!1TX.=R)N,GSGJ?6L[CP_I8_X@G'A_2Q_P 03<O$C:_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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*V<FT$1%TG.?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g111069g00a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a10.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1V$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '6<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\2BC)V1U_\0 &P$!  ,! 0$!              $" P0%!@?_Q  W$0$  @(
M! ((!@(" @,! 0   0(#$002(3%!4043(C)A<9&A,X&QP='P%.$C0A7Q)#12
M8I+_V@ , P$  A$#$0 _ .J41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MHCDE^#BP?5FKG?NFOA''U&+TN71')+\'%@^K-5)7JEJ(B-!$1 1$0$1$!$1
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M$L!W?;O*VXK6U4,-LMM+0TK0R&GC;&QHX  *Z4Y+<UIF%L5>6L1(B(J-!$1
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M-7._=-?"./J,7I<NB.27X.+!]6:J2O5+41$:"(B B(@(B("(B B(@(B("(B
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M$0$1$!$1 6N:'D=TO2WYUU?'55$QE,PCFDVHPXG/#"V,BF)F)W")B+1J7@
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M1&9S.;>UQ8]IZ"%D<K2.KDF)K.I>H@.41 B(@(B("(B B(@(B("(O'.#6Y*
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MP-/79MTI278;.S<\#TA:UMMP9^&G'[4=899$16<HB(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M5'37"XTM//)[F.24-<?-E9(;QG.1T%#;U$1$B(B B(@(B("(B B(@(B("(B
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M>$V[2Q-!H'5M]P^[5CJ.%V_9>_:/\N5GJ+D7H&9-9<YY#T\VP-4RT9K&AU-
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MJAK(F07>A<&543,[!SP>S/Q3A")3%$12N(B("(B B(@(B("(B B(@(B("(B
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M72R"2GG8)&.'2TC(5=:DY'K^+=52:9KI#S3B9;>YYXMXNC\W$=BVVI6B1$1
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MJ(J)=N#W$RT#[WK/G-]"E2BN@?>]9\YOH4J6M>SS>)_%D1$5F B(@(B("(B
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M*1U%:Z>&3_,#<OW_ !CO*N:BGAJ6AM1$V0 Y&T."A&FS!J=U!7&CU';Y;:[
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M2U3?N;/@SI?I7?HH1W6/O/3?TLW]+5-^YL^#.E^E=^BA5M1$1 1$0$1$!$1
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M)Y=6#_5V(_M<$4O.JS+6- "VAIF]431^2QVJR3:FLXE\\3?_ #+*QC9C:WJ
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MG'-_)E=/\HFJ[.]ADN1N$ :&OIJEH+7 #& >A3*TW?2.JM])*[2%]<[:</\
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MZR,?8IQI6M=6VECGM:#&3'EO @=(6V*>NG'QU8FL6AET7B+9Y@B(@(B("(B
MB(@(B("(B B(@(B(.5>Z:^$<?48O2Y=$<DOP<6#ZLU<[]TU\(X^HQ>ERZ(Y)
M?@XL'U9JI*]4M1$1H(B("(B H+RR2ANDXH"-\]7"P?S9_13I17E$TW4:DLT4
M5#-'%5TTS:B(2YV'$9\%V.O/%([LL]9MCM%>^I:MZ5=:=B$^M-/L<,@3N?CR
M,*H5EDUE2DYTQWP!TT]6PY\QPLWR<62^5&J8+A=[/-:Z:C8[ G>USI'NW;@.
M@=:WM>)C3YC@O1_$8\];7KJ(?%K/.ZBU54'_ %+BX?RM:%E@L2QE59;G=X*^
MVUX$E9)-'/%3NDCE:[>""!NZL+V6_P!"QKLOE$F-T9A<'./4!CBJUF-.WB,=
MYR6G24<DA$EDN,__ #;A,?-E3A1'DKMU3;='4K*Z%\-1*YTSXWC#FEQS@CK4
MN63W,<<M8@1$1<41U"<ZVM(ZJ.<_^9H4N40ON_7=N'5;YC__ '&(I9D5#[FW
M_P!]+E+_ ,NPR?FYRF 42NHQJ#4,GR+#Z72?LBL-7Z=&S8Z$?]TU?.HSBQ5W
MT956QC9L]$.J%OH5'4W_  .L[6@?FH6=#Z/;LZ3LS>JCB_H"RZQVFV[.G;4W
MJI(OZ LBI6@1$1(H[J_1MDU9%&V]48EEB!$4[#LR,SU.'1V*1(D=$3$3TESU
MJ+D2NM&V66Q5T=?$,ED,W@2>3/ K555%/1UDE'7P24M7&<.BD&"/W7;2PVH]
M,V?4=,Z&\4$-2",!Y&'M\CAO"Z\7&9*>]UAYN?T9BR;FGLRX\6\.YOT]L4]?
MJ68G:J :2G:1P8TY<[SD#[$NO(+32UK#:[Y/34+C[9#+&)'@?[79'YK;UBM=
M-9;126ZB;LT]-&(V9XG'2>U7XGBHRUBM6? \!;!>;WZ^2^1$7"]85M<6U+Z&
M=M"]C*HL(C<\9 =UJY11,;C26L:VVU]@IN<JJ0RP$ETL\3]L[1XN<.*^HWLE
M8U\;@YCAD$=(6RRT.:0X9!&""M>WRA%HOG,PL:VBJF&6(#XCA[H>3>"/.OF?
M2?HRN*LYL7YO2X;BIO/)90Z,*.7Q^U6>U^Z:6@'_ '9W?GA9NNJFTL1<3X9]
MR.LJST=:);]>F3O#N\*=XEEDQND>#D,!\N\KR.%PVSY:TKYNS)>*5FTMMP;7
M,1[?NM@9\N%]IGI1?>P\"!$12D1$X#).!UHA97>O9;J"2H>,XW-'6>A:PJIY
M*JHDGF=M/><DK+ZKNQN%:Z&)W^&B.!_N/6L&LK3MZG#8N2NY[RK45,^KJ8X8
M_=./V!3^BIF4E,R&,;FCCUE8K3-M-+!S\S<3R#<#\4+.*(AGFR<TZCL(B*6(
MB(@(B("(B B(@(B("(B B(@(B("(B# ZP]XQ?/414NUA[QB^>HBHEVX/<3+0
M/O>L^<WT*5**Z!][UGSF^A2I:U[/-XG\61$168"(B B(@(BIRS10_P";+''\
MYP""HB^8WLE;F)[7CK:<KZ0$1$!$1 1$0$1$!$1 1$0$1$!$1!KL0WK26HKW
M64=J-UHKI,V<&*0-?&X C!SY5D8[GJ^ZQN%+:*:UM(QSM7+MGS-"F:(CE07U
MBU5UD;)JN^U5>P;^]H?:HL^0<5*[/9[=9J806NC@I8QT1MP3Y3Q5^B$1$"(M
M<\L^M+CI*WT,=F9"*NL>YO/2C:$;6C?AO242V,H+I(&YZ]U+=/\ 2@+*-G:6
MC?Z5I8\K&M' CU4@'S:5O[K%VC7>I[3%.RBNI8)Y732'F6$N<>)WIM676R]7
M*;^4W63@<WV8?-B8/T68T;KG5EXO4=JJ;[**>9CGOE$;><&.AKL;OL*1U1:\
M5B;2Z4P>HI@]16I7VZL>/"U!>S_^( ] 5)UC>_W=ZO3O_P 8X>A6Y9<O^?B^
M+;^"F.M:<];4)/AW&[N\M=)^ZS_)\9K=J.IM8JZF>CDIN?8VHD,A8X. ."=^
M-ZB:Z7Q<73);EAL1$"*'4(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B(-!=UC[STW]+-_2U3?N;/@SI?I7?HH1W6/O/3?TLW]+5-^Y
ML^#.E^E=^BA5M1$1 1$0$1$!$1 1$0$1$!$1 3"(@P]5INVU%29S"8Y2<ET3
MBW/EPGK>H\8VZC'TBS"*-0TC+>.FT9GT=;9*@U ,[)]G9VP_?QR,^3]5B*IM
M1;)715T<KHFGP:@-RUP[<<%/<+QS&O:0YH(/$%1-8:5XF\>]U06.:.09CD:X
M=AROO._B%*C:+>2X]YPY=O/@C>O@V.VDY-'%]BKRRT_R*^2+N<&C)('E5"6N
MIHL[4S/(#DJ8MLUN;PHX?Y5]P6NA@=M0TD#'<<A@4\LG^37R:GUAK6GTY212
MRT=6\S9$1YLAKB.C)6,JZG4&I=-4]STO<8&O=OEIL#:'^W/6MS7RST%ZM\E'
M<Z6*H@>"-E[<X[1U%<V:@L&H>3>_FJM[*AUNV]IKX\NCD9G@_' ^5898FO?L
M]7T?;%Q$<M=5R1VWVGX+NBU9J^R.=#/8!++P<_F79/G"KC4?*#>'?X.V<RW@
M=J+'I4CT_P J]EKXVMN)=;Y\>$9 7,)["%+*34%IKL&FO%$\'H9*W/V<56L1
M/:S;+DMCGVN'B)\^ND)H-"7R\%DNKKS*Z/B::%^ .P[L*7V73%DLDIEMU$P5
M!W<X3M//G*RKYX(VYVB[M)W'SK#7;4--10N<^>%@'1M@ >5RO%:T<=LV?B/9
M\/*.D*UX8=@U#2&NB&2"< MZ<K757RAT---+3T]//.T.(,K -D;_ "JVK*NZ
M<H-ZCMUHGD9:H]]3.T%K,>D]@6P)-,TMMMT<=!#$T01[+O SSF.OM5=S?W>S
MKK3%PT17-UM/AY?-2H-04%ZL4DM!,'^#L%O2#VA9:H(9+0.R-EKPT[^S"U;J
M.T.M<T=VM$)CJ(M\\$0.S.WKP.E2RTWVW7JWME@J6 $#:8YV'1GM'8E;^%NZ
MF3AZQ'/BZU_3YI2/!NS]KA)%@=N"OAF(J^:-Q\"H&V#VC<5%Y[U!$Q[:BH8U
MT0R)3(&CR[RL#ZY;AJ2J=;M-QM?(T^'6.R&1]HSQ4S>(4IPM[1OM'FFM!*8:
M"XY< ^,EH)\BR#Y6QV8&%P+6QC!S^:B-GTA(_GS=*Z>KJ-K#B]Y:.'4%=MTK
M!+!S<%9/2U#3CP)7;B.PG@4B9GP1:N+?O?9)7NB<R"F@< U_'9._'2J^(*.'
M#=F*(=?2H<+/?K?()!-35S![KP3&_'FW*[[WJJ@!SWB!S3D .VG>?*MS*6Q5
M\+;A(8.<JW%^VZ.F&YN!@N[5X:>"!V8H0^4]>\_:591U]9&T"2!DH'2UV%]>
MJDW!M']L@4L^6RZ<^2,%U3*6]38QP5M)-2//MG?3_,[]%]"OJ#OYF%OE>?V7
MTVKJ7>Y93Y^<?V1.ICNHM=:P#M,(^>'(VHI =FCH3*[_ &QX'VE7!;7R\33Q
MCKP25ZRC>YP[XJI'_P"UO@C\D.BB>_G-)EE@IHL>YXE8H2$O+62R2G_:,#[5
M(3'2QXVQ&,?**PKYRZ1S:9A=O]T1AH4+5GX*,5-(Z0O>6L/;X1_-2_10<VTO
M:\@N$KLD*)2MG$;BZ=D8Q\4*::1@YBQ4^XASQMN)XDD\5?%W<_&S_P ?YLLB
M(NAY0B(@(B("(B B(@(B("(B B(@(B(.5>Z:^$<?48O2Y=$<DOP<6#ZLU<[]
MTU\(X^HQ>ERZ(Y)?@XL'U9JI*]4M1$1H(B("(B B(@)A$1 #C@A.>.]$0$1$
M2(B("@NL;A26;6-NKKK4,I:*2ADIVS2'#><VVNV<^0%3I:IY2HX;CKFDHZV-
MD]/!;S,R-XRT/=)C:QUX&%?%C]9>*QXN?B,L8<<WGP9AFM--/]S?* _^*%80
MS1WV35U7:7=]0>IC:6.6/>V23PW$-/3C:"B[M.65_NK51G_P@LSHDBR4VKX;
M8.]Z>"C94QQ,W-CD(?D@=&<#[%T9N$MBKS3+CX7CZY[\D1IKNUW&CCH*>-]3
M"R1C US'N#7-(X@@\$NTT-;0NI:::.6>=[(V,8X$N)<-P"UQWO%6$U-6T35$
MQVY)';RYQXDJO1$V>MI[A;?:*NGD:^.1O$'*F>!O%>;:M?2>.;\FI[Z=KVN)
MT%LHX7C#HX6,(ZB&@*Y5K:9GU-JHIY=\DL#'N\I:"5=+C>K B(B1$1 1$0$1
M$!$1 18:QZBH[Q55-/3"1KX2<;8P)&@XVF]8RLRJUO6\;K.R8FLZD4!Y3JSF
M:RT1Q$&9O.28ZA@#_P!>13:OK:>WTLE362LBA8,ESCCS>5:LNU]M6H9))+K1
M3T$@&S!6PG;<QN=VVS_^?%</I"]9Q3BYHB;=MM^%K//SZW$,2R&:MF9+,V2:
MG8\&9K#ASF]("VOINXVFHI8Z:U&.$,;NI\;#FCR%:X%-76F-U0PQW&VG&*BE
M=M^=S1O:KF&:CN!9+$\<\S>U[3A[3V$+P>%XG)Z.F:9*=)_O2?%Z&7%7B8W6
M6V.A% K7J&Y6UHCK6NN5/G_,! E:/)P=Z5*[5?+==&CO.J8Z0\8G>#(WRM.]
M?1\/QF'B(W2?R\7F9,%\?O0R2(BZV0HWK&[FCIA2P.]NE'A=C5G:ZJBHZ62>
M=VRQ@6KKC625U9+42DDN.X=0Z J6EU<+BY[<T]H6RRVG*#ONL#Y&YACWG/2>
MA8VGA?43LBB&7/. I_;Z1E'2LA8!N&\]95(=N;)RQJ.ZX7J(I<0B(@(B("(B
M B(@(B("(B B(@(B("(B B(@P.L/>,7SU$5+M8>\8OGJ(J)=N#W$RT#[WK/G
M-]"E2BN@?>]9\YOH4J6M>SS>)_%D1$5F B(@+QQ#6ESB&M&\D\ O5$>5&O?1
M:4DCA)$M7*VF#@<8SQ/V!4R7C'2;SX+TKSVBL>*,:FUC6W2IEI[-.ZEM["6F
MH9[N4CCLGH':L31V)E:1/7NEF!Z99'.<[[2OBUTC7RQP, ;$P#=V!2@#9  W
M +X;B..S<1:;3;IY/=QXJ8XU$+!MHIX6_P""?/2.Z'02N:?LSA96TZEK;1.V
M"^2&IM[B&MK,>'&?^\[.U4E\O8V2-S)&AS'#!!X$*W#<?FX>VXG<>2N3#3)&
MIAL6)[)8VR1N#XWC::YIR".M?2@^@JJ2AK9[)*YSJ?!FI'..<-Z6>;H4X7VG
M#YZ\1CC)7Q>+EQSCM-9$1%LS$1$!$1 1$0$1$!$1 1$0$1$!$1 6D^Z7'^'T
M^[_O9&_DMV*)<IMDLMXTO4'4#V014S3+%4%^R8WXW$'MX80<H83>I9I:V:&F
MM?.:AO\ <H:WG'#FXX)"-G.X[F](6=CH.2J/W5RO,W_@3C]%"K6ZD')S((]=
M6[) VV2-W^13"./DF:/\J]R_^'/^ZR]JJ.2>"&H=%153)QC8;.R7GGG/^EDY
MSY%,=U,E>:DQM+L(H]ZIZ(=_]RZC?Y0_]9$-=HP^YTO>G_/P/3(M-SY/(]1B
MCOEK]4@+FCBX#SKYTI*V7E! A<'AE \2;)SLY<W&?*HZZMTE@[.B:Y_SWL_^
MM2WDZO&GGUM1;K59C9:U[.<,;PWVYHZ0X$YQG@HG>NS?A<>*,D37)$SY0GR(
MBH]41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0:"[
MK'WGIOZ6;^EJF_<V?!G2_2N_10CNL?>>F_I9OZ6J;]S9\&=+]*[]%"K:B(B
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M\)(X0'#R%:VX^;5FO*Y\?HJ*7B_-VEE\ # X#<B(N![ B(B1$1 1$0$1$!"
M00=X1$&M:ZVOL5PEIWAK:"5Y?3/S@-ZV?J%0FJX(FDOD;Y!O*V36T=/70F&L
M@CFB/Q7C*B]9R?V>>7;A-13CI;'(<'[2OG>+]#6R9)OAF(WX/0Q<;$5U=KVM
MGFN-8V&FC<^>0[,43>/E*W#IVVMM%EI*%IR8F ./6[I/VKXL]AMMH'^!IF,D
MQ@R'>X^<K*+O]'>CXX2)F9W:6'$<1Z[I':!6]=1TU?3F&L@CFB/Q7C..T=15
MPB]*8WTES=D%N.EJZ@D+[-)WS2<333/\-OS'=(["L(Z>"1X@JXW0SG_2G;LN
M6U5;5E#2UL>Q5P13-ZGM!7D<5Z'Q9IFU/9G[.O%QEZ=+=6IVT%7:YG5%BG="
M\G?'Q8_L<W@5<54C'AFS1T]),1F=L PUS^DK/7JQ"RR.K:2J=WJ[P12R>%LN
MZ"T\?,HR<DDG>2G <+FX?FKEG<>#MI:F7VZP*9Z7I.]Z#G'MQ)*<[^KH4<L5
M%W[7M:YN8V^$_P BG30  !N W!>E#+B+_P#5](B*7*(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B# ZP]XQ?/414KUK(V*VQOD.RUK\DJ)PGGZ?GXO"B()
MVO(JS+NX?W%_9[K=[9SPHZ.DFAD((=))@[ED?75J#Q;0_?%1Z&]T4<;6F0;N
MT!5/5^A_Y@_F'[KYG-Z4XFF2U:STB9\%[<-CM.[1U9WUU:@\6T/WQ3UU:@\6
MT/WQ6"]7Z'_F#^8?NGJ]0?\ ,'\P_=9?^7XOS^RO^)B\F=]=.H/%M#]\4]=5
M_P#%M#]\5@O5ZA_YH_F'[KWU>H/^:/YA^Z?^7XOS^Q_B8O)FSJG4/1;K?]\5
M\G5.I-DXMUNVN@\\5AO5ZA_YH_F'[KX=?Z, [+FD_.'[I_Y;B_/['^)B\F'D
M@JH:VJFK>:%3/*9G"+W#2>I9IUP?)1PQ4C><KZAXABC'RCTGL WK$5UPBJI^
M<,D31P VQN6<Y,:)E9JFKN&TU[*.G$3,'(#WDY(\P_-8\)AMQ?$Q%_'K+3+>
M,6.9CP3[35AI;%1B.G:'U+P#-4.WOE=TDE9=$7W%:Q6.6O9X,S-IW(B(I0(B
M("(B B(@(B("(B B(@(B("(B B(@(B(&3UE,GK1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0%B-3Z=MNI;;)17:G9*QP\%^/#C/6T]"RZ(-/Z7OMST!?V:8U=,Z6T
M3NV;=<7;QGH8YW1U+< [#D+#ZLT]1:GL=3;+C&US)6D,>1DQ.Z'#M"@O(O>[
ME!)<M'ZG?*Z\6IV8I)#_ )L' $'IQZ"@VDB(@(B("(B B(@(B("(B B(@(B(
M"(B B(@T%W6/O/3?TLW]+5-^YL^#.E^E=^BA'=8^\]-_2S?TM4W[FSX,Z7Z5
MWZ*%6U$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$06]=1
MT]=3OIZR".>!XPZ.1H<#YBM0:XY&*:4R7'2DLM)6AW."G+_ \C#Q;OZR?,MS
MHJ7QUO&I=/#<7EX6W-BG7Z.8Z?E%O]A+K=?+8V>IBPP.<3&[_JZ#Y=RF%ELM
MSU#5TUYU5#%$R ;5'21G+03OVW<<G@I1RL:"AU-;7U5' /56,>#@AO.-ZCT9
MZLJ"\D>JI=MVG;S([OB(8I7N&]P!(+#U$8Z5R\LUORWGIX/?];3B.'G/PU8B
MT>]Y_E\&R:=K9=L/ .[!:>I1FX:6;;7RUE@FDIR[>ZF(VX3VAO$>8A2:9KH9
M>=CW@<1UA7'@R,W;VN"WFL2\NF6U)W7M+7\5/=)'9>^@'7B-^_\ Z2?U56,/
M:X1SRRP2 [G0C#7>3.5(YZ%LCW-<2R5ON7-XX[5C:REF:U[9&!X;X0>T[]W8
MJ:TZHR1;HI2RRR,\(MJ8QT#W07@<T[Q+,SK!W^G*M6STCL9>89.DM5U1T\]?
M)S-O?)/)V  #RDH:Y8ZO#-(Y[F0N;(X#.R(R3CS%9NPZ<=/1B2YNEC#G9; T
MXPWMZ5F[!93::<]\%LE5)O>\>@=BRJWIC\9>=GXN=S7'V\V$J-,6Z8 -;+$!
M\A_[Y7U1::M=*TXIQ(X_&D.3^RS"+3ECR<OK\DQKFG3'-L=L:\N;10Y\BOX8
MHX6[,,;(V]31A?2*=:9S,SWEZO$1$"(B B(@(B("(B B(@(B("(B B(@(B("
M(B#E7NFOA''U&+TN71')+\'%@^K-7._=-?"./J,7I<NB.27X.+!]6:J2O5+4
M1$:"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B*PO=:*"V3SD^%C9;Y3P4$1-IU"&:ONCJVO=3L/M$#B!CI=TE8!"2
MXDN)+B<DGK5_9*3ORXQ1GW#?"=Y LN[V:Q&.NO)*-/4 HJ(%X]ND\)W9U!95
M> 87JEP3,VG<B(B($1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!%^43_@)
M^<HQ8O\ LZSYK_25)^43_@+O*HQ8_P#LZWYK_25E?WGHX/P/S86TR/@IB#8+
M;7!SBX2SEVUY-P5[WV?_ )1LWVO_ &5_8*JFCM4+9*B%CQG(<\ \5D._:3^*
MI_O&_NOF,OI#B*7M6L](GRAI?#2UIF88#OIW_P HV;[7_LO>^G?_ "C9OM?^
MRSW?M)_%4_W@_=._:3^*I_O L_\ R7$^?VA3U%/+[RP/?3O_ )1LWVO_ &3O
MEW_RC9OM?^RS_?U)_%4_W@3OVE_BH/O G_DN)\_M!ZBGE^J/]].Z=(V;[7_L
MO'5P;QTI91YW_LI#WY3'_P"(A_G"\-11NW.FISV;83_R7$^<?2#U%/+[RCS;
ME#\;2EE/DD</T4^Y-;A3UU!<&4]LI[<^"<-?' <M=EH(.<*"7/FN^W<QL[&[
MAP65T57266]L=4EK+=<L1%Q^+*,[!/8=X^Q=OHWTEDOGBF68U/PACQ/#U]7,
MU[MJ]:]1%]2\<1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 6K>5MITW>['K6B&)X)FT57M#+7P/)XCK!Z5M)
M13E4MD=VY/KW2RMSBG=(SL<W>/0@DU+/'4TT51 X/BE8'L<.D$9550SD;N'J
MCR;6.4N+GLAYEQ/6TX_13- 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!H+NL?>>
MF_I9OZ6J;]S9\&=+]*[]%".ZQ]YZ;^EF_I:IOW-GP9TOTKOT4*MJ(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/,+0'+MI>2T72GU
M/:&F+;ES,6;@R3H=Y_3Y5T L??;33WJTU5OK6AT$["QW9V^59Y:<]=.S@.+G
MA,T7\.TQYP@VB[]%J73M/69;SQ ;,P'W+\;UDZ8F"7F';V'>T]78M':2NE1H
M?7-5:*AQ[R=,87AWEP'+>M5'SL0<P^$-[2%ECOS5^+T>-X>,&3I[MNL*5>"Q
MS91P&YRI2[VA[>+=_E5U"X5-,0_<3N<.U6L6YKHSQ:<>97<M9\)?>GHJ:&]/
MIYH(GQU3><87-!PX<0/,IG#!%""((F1@_): H$*@4<L-2\ ][2 DGY)W$_FM
M@QN#AEIR#ORKT<W%;W$^:C5L\ .ZE:%9)PVFD%8YPPXCJ6M7'+Y1$4@B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B#E7NFOA''U&+TN71')+\'%@^K-
M7._=-?"./J,7I<NB.27X.+!]6:J2O5+41$:"(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H)K6XNGJ^\VG$<)\+'25-
MJF404\LKB &-+MZU/42NGGDE><N>XN*I:77P=-VFT^"FI=I*EYJD?.X>%*=W
MD45IXS-.R-HR7. 6Q((Q%"R-HPUH  5(=/$6U'*J(B*7((B("(B B(@(O%Z@
M(B("(B B(@(B("(B B(@(B("(B"+<HG_  )WE49L7_9UOS7^DJ3\HG_ 3\Y1
MBQ_]G6?-?Z2LK>\]'!^#^:0<G%FME;IXS5ENI)Y3,X;<D0<?M*E/K:L?B>W_
M '#?V6%Y+/\ LO\ ^,]3!;8Z5Y8Z/,XJTQFMU\6)];5C\3T'W#?V3UM6/Q/0
M?<-_999%?DKY.?FMYL1ZV;%XGM_W#?V7GK8L7B:W_<-_99A$Y*^1SV\V']:]
MA\34'W#50KM/:;I:.:>JM%O$,;2YY,#> \RSZA7*S5/CTY!2QG'?E2V%WS1D
MD>A99IIBQVO,=H7Q\U[17?=KVQ0-J'CFF<W!+(Z1D?0QA.YOV*65%-%44SZ>
M5H,;AC'5U%8FP-'/R$# #<!9Q? VO-K3?QE[VM1I]VG5E79Y(Z2_L=448\%E
M>QN2/G@>E3""^VJ=@=%<:5S3_P!X%#.@@\%1=2T[SE\$1/:T+VL'IS)CKRWC
MF<>3@J6G<=$HO>L;/:J=TAJ14R#_ $J?PW?EP6:MM7'7T%/5PAPBF8'M#A@X
M*U;>XVMHF4M-$T254K80&MZ"<G\@MK4T+:>GBAC&&1M# !T !>SZ/XR_%Q:\
MQJ(<7$8:X=1$[E51$7I.41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0%8WR(3V6X1$9#J=X_P#*5?*UN;@RVU;CP$+S
M_P"4H-:]S@]WK$J('.SS%=*P#J&5M1:I[G+P](7.4>YDN4Q ZMZVLA B(@(B
M("(B B(@(B("(B B(@(B("(B#07=8^\]-_2S?TM4W[FSX,Z7Z5WZ*$=UC[ST
MW]+-_2U3?N;/@SI?I7?HH5;41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$&CNZ(TH#30ZBH(]F6)P94; XCH=YBLCR7ZC]6;)$
MR=^9F#''JXA;4NU!#<K;4T=2QLD,\;F.:X9&\+E[14E;I36]19ZC+'<YS>P[
MI</<GS_JN7)'J[\WA+Z'@[?YG"6PS[U.L?)OG(@JL<&2=/:J58SFIQ*/C;G!
M5&O974;98SQ&<=(/4J@'.THSO.,'RA:.#>IVL:F)DF0\ L>-APQT%9[154^2
MWR4M0XNFI'F,D\2WB#]BP@&W&6G<1N\A5_I>9K+O*PC#IH03VEI_8A37I*,T
M;QS"6JSJV8?M#I5X#E4ZAFU$>L;UM#SE@O%Z5XK*B(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B(.5>Z:^$<?48O2Y=$<DOP<6#ZLU<[]TU\(X^HQ>ER
MZ(Y)?@XL'U9JI*]4M1$1H(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B(A&]<5G,VUE.T^',['F4"4@UM5&>\&(>Y@:&^
M?I4?Z%E;N];AJ\N.&9TI#SMSVR/!B;M>?H4S6$TI2\S;S,X>%,<^8+-I##-;
MFO(B(C(1$0%;5E9!2,VIY .H=)5C=[PVD)BA&U/C?U-46GFDJ)2^5Q>\]93;
MHQ8)OUGLS=3J-Q.*:$8ZWG>K1U^K2=SHQV;*L8Z9Q&7''8JHIV8Z53FAUQAQ
MQX+V+4-4T^&R-X\F%EJ*^4U0X-?F)Y^5P^U1IU,/BD@JA)&YA\+@IBVU;8*6
M^#8(.1D;QV+U1"U7F2D]KFS)#^84K@F9-$V2([3'#<5:'%DQ6QSU5$1$9B(B
M B(@(B("(B B(@(B((ORB?\  C\Y1BQ?]G6?-?Z5)N43_@1\JC-C_P"SK?FO
M])65_>>C@_!_-+^2O_LO_P",]3!0_DL_[+_^,]3!=&/W8>5Q?XUOF(B*[G$1
M$!0'E;R*.RO^(VL()\K=RGRPFL;)ZOV*:C8X,G!$D+S\5XX%8<5CG+AM2/&&
MN&\4O%I:XL+@*B1O6U9U0^CJ)8*N2.5G-5=._8FC/0?U!4JI:AE3%MQGL(Z0
MO@+5FEIK;O#W^\;A57H16;YIZNX"UVIHDKWMVBX^XA;\IQ_3BKX\=LMHI2-S
M*LS%8W+):6B]4-4N?L9AM[,EW1SCNCS#TJ?K%:;L\=DMK::-YDE<3)-*>,CS
MQ*RJ^XX+AO\ &PQC\?%X>?+ZV\V\!$1=;$1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%B-73][:6N\V<;%+(<_])67
M4%Y;+F;7R;7AS-\D[!3L':\X067<_4G>W)I12$>%42R3'SN/[+8ZC7)I0.MN
M@;%2O&'MI6.<.TC/ZJ2H"(B B(@(B("(B B(@(B("(B B(@(B(-!=UC[STW]
M+-_2U3?N;/@SI?I7?HH1W6/O/3?TLW]+5-^YL^#.E^E=^BA5M1$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%A:C2UGJ+\R]3T
M$,ER8T-9,X;V@<-W#/:LTBB8B5JWM7W9TA]9#%;+Q)$"&LJ_;(P>&U\8>@KY
M@\">5GQ3O:L_?[8+E0.8PAM0P[<3_DN"CH@N<TC6PT19,PX>^4X8?)UJDPZ\
M=XM7K/52JG1TVU),YK&?*=N"N=,1-KKL:R%Q,$#"P. W.<[CO[ /S5U26:MF
MKHY+B8!3QG:$;=^T>W*DD43(F;$;6L:. :,!36OC*N3-$5Y8\7V.)0\$17<C
M'2MV9"%\*\JV;@X*T5X5>(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@Y5[IKX1Q]1B]+ET1R2_!Q8/JS5SOW37PCCZC%Z7+HCDE^#BP?5FJDKU2U$1
M&@B(@(B("(B B(@(B("(B B(@(B("(B($1$2(B("(B B(@(B("(B B(@(B("
M(B J=1((H))#P8TN^P*HL/JRJ[ULD^#X4N(QYU$II7FM$-=U4[JFIFGD.72.
M+B538TR/:QONG$ +P;AA9+3M.*BZ1;0RUGAE9/9F8K&TTI813T\<0X,:&JLO
M%ZI><(B("QM[K^\J4\V1SS]S1U=JOII6Q1/D><-:,E0:NJGU=2^5YX\!U!-M
M\&+GG<]H4#M/<227./2KN"$,&3O<OFEBP-LC?T*X65I>@(B*@+QS0X8< 0O4
M4BQFC,;MWN2LC8KBZDG$4CO:''!!Z#UJD]H>TM(W*Q>TM>05I6=JVK%XU+80
M.=XX+U833=>9X33RG,D8W'K"S:N\R])I/+(B(BHB(@(B("(B B(@(B((MRB?
M\!=Y5&;'_P!G6_-?Z2I)RD.#+ <]+L*-6OVK30+MWM;G?;E96]YZ.#\'\TPY
M*_\ LO\ ^,]3!1'DN86Z4C<?CRN<%+ET8_=AY7%_C7^8B\17<[U$1 14:BJI
MZ89J9XHOGN 4>KM94$+9&4<<U7.P#+&M+ ,\,EV.I6K6;3J%;WK2.:TZA7U'
MI.VWUW.U#)(*L# J8#LOQU'H(\JCHT#<::3-#?&%O_?4^_SX*^*O5EW>&RQM
MIZ:-AVG,#=HN'2"3^BV#33-GIXYHR"R1H<".D$+#BO1N.TQ.:D;E/#>D.?<8
MK=D/&BZNH %??)@SI921"//_ %')4CLMFH+- Z*W4[8@_>]V2Y[SUN<=Y611
M5P\+AP?AUB&U\U\GO2(B+=D(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M$\24D+QTL"KK'V)VU:H.P8606D/)M&K3 B(B!$1 7B]1!!N4:KDGDH[13/\
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M=+11-AIXQAK&\ KE%[^YUIYW+&]^(B(H2(B("(B B(@(B("(B B(@(B("(B
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MT\;-J;SH1$70R$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M'2Q4U,P1P1-#&,'  < L'KMX%FIXOC3UM-&T=?M@/Z*1*58CK*SN].VJM59
M\ M?$X>?&Y:YTL\NMTL+M_-R.:MHD9!'6M6Z=:8JNYPG<63'TE97[P[^%GV+
M1\DDY)YB(;I2D^#',"T=65/UKCDU/-ZBO$77AV/.5L=;8O=<7'1K-/QU^@B(
MM'&C>HM)T]XJ&U,,[J2K^,]K=H/'1D+XM>DHZ=VU<:M]=@@M86[#!CK&3GSE
M29%S3P>"V3ULUCF;1GR17DB>@!@+U$72Q$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!$N5@9Y.-0_57+5U![PIOHF^A;2Y5QG
MDXU%]4>M66[_ (?2_1,]"UQ>+Y[T[_T_/]EMJ'_A$_SH_P#]1JG=\/\ _D*L
M[;?%_4H)J+_@U1Y6?UM4[OGPA5/_ /SHOZE-O>A3T=_]2_S_ (5U\\FG_;/5
MX^J_T.7T%\\FF[6NKQ_MI?Z7*MNSKX#\3\FR$1%F]D1$002Z'F^5:F_[VTO
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M631$57<(B((9KD"/4>DYS_$RQ9\K/[+-+!\JT;H;!37:.6%DMJJ!5-9*<";
M(+ >L]"@C.56[5#0:/1M<<C(YR39_13%9MVAG>]:>].D_GQ'KBQO/&6"HB_(
M']%I73+LVLL_Y<TD?\KR%.-+:IKKSKFSMU%:S:6,$G>F';7.R$;VD]&[.Y:[
MUS4/TIJ^ZVJPF.JI1*9WNGW<W(\ESF#'$#*F,5YGEUU5]=CK3GF>C.U(VJ:9
MO6QP_(K<')7/WSR=:?E)R32M'V$C]%S#-J.]RL<T.I(MH8RUI)_-=+\D-=2U
M_)Y9WT5.::*)AA,1=M;+FN(=OZ<G?YU-\-\?O1I&+B,>:9C'.])BB(J-Q$1
M1$0$1$!$1 1$0$1$!$1 1$0:"[K'WGIOZ6;^EJF_<V?!G2_2N_10CNL?>>F_
MI9OZ6J;]S9\&=+]*[]%"K:B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(! ((*QSV[+W ]"R*M:
MMN\.Z]RF$2M41%9 B(@(B("(B B(@(B("(B B(@(B(.5>Z:^$<?48O2Y=$<D
MOP<6#ZLU<[]TU\(X^HQ>ERZ(Y)?@XL'U9JI*]4M1$1H(B("(B B(@(B("(B
MB(@(B("(B(<^ZP$O)GRQ4E\HVD6B]'8J ?<@DX=]APY= L<'M#FG+7#(/8H9
MRN:29J_1E71M8#60^WTSND/'1YQD*)<CO*/;_6&Z'4M:REJ[/_AYG3N\)[1N
M:0.)/1YE"L=&X46'TGJ*BU1:&W.UE[J5SW,:YPP3@XSA9A2L(B(D1$0$1$!$
M1 1$0$1$!$1 1$0$(!!!X%$1#5U_I11WBIA:/ VMIOD.]8_H4MU_2XEIZIK=
MQ&PX]O0HDL9C4O9PWYZ1*>V2H[YMD#\Y<&[+O*%?J+Z.J?"FIG=/AM_52A3#
MCR5Y;3 B(B@J51"R>%T4K=ICA@A5400F[6U]OEXET3O<OQ^2M89C'NXA3R:)
MDT;HY6A[#N(*C5QL,K'%U)X;#\3I"B8=V+B(M&K]UFQ[7C+3E?2L)(Y(7EKV
MN8X=>Y>B:0?&*SY72OE0EG#<AF\]:MB]SN+B5=T=LJJK?'&0T_&=N"F*HF8K
M&Y6C0Z1^!ESW'<.M2VRVIM&T2R[YR/Y>Q5;5:XJ%F<!\QXOPL@KQ#BS9^;V:
M]GJ\5A<[Q06QF:VI9&>AN<N/F4<J-935 <+3;97C@)93LC[$FT0SIAO?K$)D
M%[@K77?>HZH$S7!E,"?<QM5K+;JJ3?57BI=_UD?JJ\_P;1POG:&SAO7N%JP6
MIGQ+I49^E/[JM!1W*FWTEYJ!Y3D?JHYY\B>%CPM]FS$6OZ>[ZBHI/;'0U\74
M?!<LM1ZSI=K8NE/+12=;AM-/G"M%X4MPUX[=?DE:*A1U4%9"):65DL9X%IRJ
MRLYYZ=)%';_SMYJC9*27FX=G:K9&\6L/Q!VE9:L-1,TPTCN;)W&8CW/D'254
MH**&B@YJ!O$[3G'>7N/$D]*E$]52EIXJ6FBIZ=@9#$T,8T<  JJ(H2#BM:TN
M_4M\(/\ K?J5LH<1E:OLKN<NEWDZ'3'?YRJ7\'7PO:\_+]63T1OUS6GH$:V:
MM;<G;=O5=U?QPT#TK9*TP^ZY>/\ Q?R@1$6KB$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6+K+Q'276GHY68$H
M_P PG<#T!911S7%.'VMM2![; \$.["J7F8KN&N&M;7BMO%(T5I:IS4VZGF/%
M[ 3Y5=>=7B=QMG,:G4O41$0(B(->\N+"='4\G1%<('GR9*PV3UE2KE<I^?T!
M<CC/-;$ODP5% <@$=.]>GZ/[6AX7I>/:K/S6%P&+OIV7_EW.'\\C]5 .5VG%
M+REWUC1N>Z.7^9@*V!=R&-HIG<(JVG?G_P 1JAO+JS8Y4:[=NDI87_D1^BTM
MTXJ/C#''[7 VCRG^$$71/<\3\YH&6+IAKIF_:05SL5NCN>+S2T%BOL-9,(\5
MP<P<<Y8%7TAJ,<3/FT]#Q,YIK'DW<%ZL(W4]K)QS[AVEI61HJ^EK0333LDQT
M [_L7D1:L]I?1VQWK&YA=(B*S,1$0$1$!$1 1$0$1$!$1 1$0:"[K'WGIOZ6
M;^EJF_<V?!G2_2N_10CNL?>>F_I9OZ6J;]S9\&=+]*[]%"K:B(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("^)F;<9'2OM$&,PO%6J&[,AQP.]45=41$0$1$!$1 1$0$1$!$1 1
M$0$1$'*O=-?"./J,7I<NB.27X.+!]6:N=^Z:^$<?48O2Y=$<DOP<6#ZLU4E>
MJ6HB(T$1$!$1 1$0$1$!$1 1$0$1$!$1!$^4?4%XT]9#46"QU%VJ79'M0VA%
M_N+1O(\BXNOM=4W*\UM97L$=5/*9)6-;L .)W[NA=^K7^N^2C3FK7SU4M.:.
MZ2#WU!X)<[K<W@5"DPQ'<S5(FY-FQ@C:AJ9&D=6];76L^1/2%TT53W>UW(LD
MI^?YR"9G"0$#?CH6S%*:B(B+"(B B(@(B("(B B(@(B("(B B(@QNH:+O^U3
M1-]V!M-\H6L,8W'<>E;A\O!:PU'2BCO%1$T883MM\A6=H\7=P5^]%.R5(I;E
M#(X^"3LGR%3T;^'!:T!QPXJ=V&L[\M['..7L\%RK#7B*_P#9D41%+E$1$!>+
MU$%.2&*7_,C:[RC*MG6NC<<F!GV*]1$Q:8[2MHZ&FC]Q!&#U[*N  !@<%ZL9
M?[Q3V6B-14Y))PQ@XN*3.DQ%KSJ.LKRKJZ>CA,M7/'#&.+GN 4.N>I:VY%]/
M9H70P'<:J08R/]JQ<XFO4O?]Z.(V[XH <-8WM5Q:*:OU%-S%I'>U$P[+ZDCA
MV +*;3/2'93#3''-?P^D?RL&4U#12\Y5S]\59Z'G:<3V#BLG34E^N#FLM]IE
M@C/^K4C8 '7@J=V#2%JM#VS10\]5C>9Y3M.SUCH"D8X*]<7FY\OI"-^Q&_G_
M  UM3\G]?4OV[I=G-'R*<''VE9!G)O:L>VSU<A[7J<HKQBJY;<;FG_MKY(3[
M&]CQN%0.T2*C+R;T&R>]JVLA/1X65/$4^KKY(CC,\?\ :6L9M%WVA:[O&N@J
MV#@R7(=Y%B*AU73C8O=IG@;P,ACVH_M&Y;E7S*QLD;F/:'-.X@C(*K.*/!M3
MC[_]XW]FD:>FYF455AK>;>#M;#7Y:[L(4GL^K62/;3WF$T4YX2.W1N\ZR=ZT
M)1R%]397&@K./@[V.[".A0J5[^?=;+]3"*H/#/N7=H*RU-'=6^/B8\_UC^6R
MV.:YH<PAS3P(W@KZ6N[==ZG3<S(JASI[0XX!.]T1_4+8%/-'40,FA>'Q2 .:
MX=(6E;;<N7#./Y*B(BED^)7;$4C_ )+25J[2V]M<_P"5,5LF[/YJUUK_ ),#
MS_Y2M<:6&+7(\_'D<5G?O#MX6/8M/R9WDL&W<[U+T;8;G[5L5:_Y)&YIKM)T
MNF"V ML/N0XN.G_GM_? 1$6CC$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0?+W-8QSWN#6M&2XG  7S!-'/$V6"1DD;AD/
M800?(0K>\T+;I:*V@D<6MJH70DCHR"%J3DDU+ZVJVIT;J.3F:BGE+:9[O<NR
M3NSV[B%2U^6T1/BZ<7#SEQVM7O'A\/-N=$&_>-Z*[F%A-9.#;!4 G>[ 'VK-
M'=Q(!\JB=^G-XN\%KIG9B8[:E([/V6>2=5UYM^'KN\3X1U9S3K"RRT@<,'8!
M4&Y<;=<YK#27.SRU EM\NV^.'.7-/3NZEF=?:M=HNEMTYMSZF@DD$4TC'XYD
M=&[I4DMU=27BU15E$]M11U,>TP]#@>A1,1:)Q[:TF^&U>(UTF?["EIRXPW:Q
MT5;3S,F;+$UQ>PY&UC>/M627-&A.4&?1U^KJ*KC=)9)*IXYH;S"=KBWS<0NC
M[?64]PHH:NBE;-3S-#XWMX$)ARQDCXIXW@[\-?K[L]I7"C-!K6U55YJ+7,Z6
MCJXW[#&U+=@2_-RI'(]L<;WO.&-:7./4 M-5=U@Y0J"]UU-2"FK+/A]-4M]T
MYH)W'KX95<V2::Y>YP>"N;FF\=(UU\IGM\VR.4)G.:&O[3P[SD/V#*U[;Y.>
MM]+*#[N)COM 4@M]=4:OY)[A%SA-<ZED@D.-[G ?J%KW1-1<*W2YD[\M,#+<
MP12FH<\. :, D =6%W\#QF.F^:=;C;R/2GHOB,L>Q&YK.I_;ZLCK!_-:<K)1
M_I;$G\KP?T4?Y?X\:_HZ@>YGMD9!Z\/=^X6)N5ZN]^=46N&:A-'(=A\L<;AM
M-Z=Y.Y2*[::.IYJ:2[ZK:^X1Q\Q V.GR!U-)W#BF3TCAMGK:L[B##Z"XNG"W
MIDC4SVC_ -=FKRMP]SG!2S,U(VKBC>&/BD!>!N\'!]"P&E.2]M[J*ZAJ;Y-2
MW*F=@Q\PT@CAE8S40KN3R>X6"UW>.I[^8.^W1M\,8X-SCP=W0"HXOTCBRXO9
MB>Z_HOT%Q./B9K:T1.OC\/@Z990VVJ@#XJ>FDB=P<P @^<+#5VEFQYFM,SX)
MP<X)W'LRM8Z%Y6[+9++0VJ2W5D;(6[+I X.W])ZU.+URJ:>H;,*VCJ._9GC+
M*>/<X^7/!>?&3%>NY>U;A>*PY.6M9G?W9NS7J85'>-X88:G@QSA@/4C"A<-Q
MH=::49>+82)8LD9]TQPXM*SVF;CZH6QCWG,T9YN3R]:TI;KRS/R<N;'TYM:F
M.DQY2RR(BU<PB(@(B("(B B(@(B("(B#07=8^\]-_2S?TM4W[FSX,Z7Z5WZ*
M$=UC[STW]+-_2U3?N;/@SI?I7?HH5;41$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$04*EFU'
MD<0K)9-PR"%CW M<0>A6JB7PB(I0(B("(B B(@(B("(B B(@(B(.5>Z:^$<?
M48O2Y=$<DOP<6#ZLU<[]TU\(X^HQ>ERZ(Y)?@XL'U9JI*]4M1$1H(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("CVL+
M8RJM\E3&P=\1#)/26J0KQ[6O8YCQEI&".M1,;6I>:6BT-/K.:4J^9K3 [W$O
M#RK'W:B=07">G<TAK7> >MO0K6)YCD;(PX<T@A8O7F(O7YME(J%%4,JZ6.:,
M@APZ.@JNK//["(B B(@(B\04:ZJBHJ26HJ'AL<;=HDK7;I9+Y6.N5P\"F9GF
M(3P:.LK(:QK3=;G#::9Y-/"=NI(X$] 5CWI->[C%9K?X,30#/(.#&CH65IW.
MG?@QQCKS6Z3/VA=V.S5&JZASN<=!:(7;+B.,Q'$#L6T[=14]!2,IZ2)L43!@
M!J^+3006R@AI*1@9#$, #I[5]UM;3443Y*N>.%C07$O<!N6]*<L?%Y?$<1.:
M=1[L=F(J]766CNTENJ:UD=1'C;R/!:>HGKP<K-4M3!5PB6EFCFB/!\;@X'SA
M<^WFHI+A=*ZLMMPHZV.>9S]EK]F3!.[P78S@8'F5O#5W2Q.AGM)J:3VP;1:T
M\W@\=H<"KN9T@CB&M)<0 !DDK3UHY1KM3R8KV0UL!&YS0&/SZ%L/3E^HM36Z
M9T#7LP3%)%)@.&[R\-Z!6ZFI(0UM+'/6R.. *=F0.TDX&.T96$ONLJR@J*:F
M;01QRU <6ODDVF[NC<!O6%J]1PV,U%KD9B:B&P 3G:'%NSCCNQU*':HU;SUH
M-354DTTT&71[#N:#"=V3CPL>=7QZYHYNS/+S32>2=2D];J2Z.!=6W7F0X^"V
M/$8\@Z2MB:1KI[A8*.>K8]DY;LOVQ@N+3C:\^,^=<IS:NNU2QL=-S5.\;P^"
M/:E_G.7+>?()<+S5V:N@OC:Q_-2AT,U2#EX<-X!/'!'YKLXK'%:Q,5B-?5YW
M YIM>8FTVW\.C:16#U-IVDOU)S=0-B9N^.9ONF%9Q>'@O/F(F-2]>E[4GFK.
MI::EAEH:V2RWAH>_9\"0CP91V=JNM.7)UAK6V^LD<ZAG=[0\_P"F<\"IMK?3
MK;];<Q897P>%!)PP>H]BULUANE!)35C=BN@):X$8+7#I7-:LTE[>'+7B,?7\
M_P"6T O5&]%7<U]!WK4NQ6TW@/;TD#@5(PM(G<;<5Z32TUEAM63.CM$L3 ,S
M@Q[1Z,J%VUO>=N%-[IP!\+HWJ7ZP]XQ?/4243$3+LX?I323\E]*ZDH*UCW!Q
M,@.0IJHKH'WO6?.;Z%*EM2-5>;Q4[RVF1$16<XB(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B HEK?0=IU;&U]8Q\%:P>UU,
M6YX\O6I:BBU8M&I7QY+8K<U)U+4U+H+6MH88[1K+:@'!D['$_GE5W:4Y1*EA
M9-K"")I^1$<K:2Q>H[AZG6R21A'.N\%GE64XJUC?7ZNNO&9;VUJ-S_\ S'\-
M*7#0%SDN0I1JFOK*LGPBPN#0?MZ%=.AU'R35D%=5SB\66H.Q.X [<9\IX?JM
MM:7MC:*B;/(-JJF&T]YX[^A1_E?O=#;]*U%#5,CGJ*QICCA=O_ZCU86,XXI6
M<DSIV4XN^;+&#7-$])Z1U_C2054%KUCIAT;RVHM];$' @[V](/80M7:#N[]!
M:QFTA<JQE3:IG;=+4;0#6$]!ZNHCK4'Y*GW>HNTVGZ6NDI8Z@;<@<\AH:W>2
M/-U*RY4)K2+I'0V-\E4ZDR)ZO/@N>>(;CH!Z5G.>;:O$=G5BX"*7MPUK;K/7
MMV\I_O=EY[C9;+J#4=FN5"+S0U<Y?!) 0'LD)/ ^?&[I"HZ<U7JC0I%/%!++
M0.RYM)5,.6@]/6.'0ONZV(C3E!-06.NIKC!LS=][W<[NSD]H."%G+QJVFOUD
MLMUEEC9?:.00U49&'$#/A8Z1^ZPYYC=HG6G7RUM$5FO-$])WYQ'2>G;:YI.6
M:X7.FJH9++ ^-T3FR<U(0YK2""=_E4-T7KJ;3MBN=KIJ6)YK7YYV0[V#&,?8
MOG6(M5]OYFT]2LMD!]W)O:UQZ3@</,L91;%-234MUM//M)/-5L>6N:[HR>!;
MV%+9+3/O=E\7#88IJ*:WJ=?V4PTE5:L@L=7-8LFWMD)G#!X0.,D^3"P6G=.5
M6M;E<&6F:. M:9'QRO(YQV>C'6=ZP4.H;G;^?I;?<:FGII? D9'(0U_1O"R4
M$6H--5C)HLT=0&;0<",[+AQ\X659B(CFWIM;'>+6Y)B)GM_OS9">YPVFC%KJ
M;3WK5POV)JB.3:VL=0X?FMJ:>NV@(+9!6&JIQ4P,!=SV0\N X[/#*TNR>^5-
M%4QQND?3R?YKFLSGRG"HP6*1L$\M1+LB*,O+=H#=U;^)4TRQ2=Q&U,W"1EKR
MVM-?E/=*M>:_II]0.K])&>EG>TLEF.!MYW9 \BS/(1IBWWV:XW>\M96S12!D
M;)7;7A$9+B.GCA0>@TA<:C2E3?I:<MHXSX#MPSOQGR*R;07*WVRGN$!E@9.W
M;.SEN1G<1UA7C)-;<UX1;!2^*<.&^I[;[ST\&Z.6;15HCL%3>:6!E)50[((C
M: V3)QPZ/*K;DNY,+34Z<I[G?834RUC-MD1) B;T<.)/%:V[\U/7Z1K7ON,U
M39VD"1L\NU@YZ =_V+=W)=K*TW'2]#2.J8Z>LHHFPRQRN#<X& YN>(*Z<<X\
MF3<QKH\SB*\1PW#<E;;Z]9CPC79$=/MEY->4,6*9[I;%=R.9)W!CSN'Y[O.%
M/-LZ:OKPX$T%5O&SP:<_HL!R\TK:K1T%VHWL=-;JADK9&.!P"<<?+A9VNO5O
MFY/:2ZW, LFIF/C:.)D+=P"UUR[C?;K#DM:<U:9)C<V]F?G':4QC>U[ ]A#F
M.&0YIR"OI:MT%;]4-MIN#*OVNJ.U'!([<UO6 >"V-:6UC:)HN3F.J<G.QP[%
MKBR<\;UIQ<1@C#:8BT3I>(B+5S"(B B(@(B("(B B(@T%W6/O/3?TLW]+5-^
MYL^#.E^E=^BA'=8^\]-_2S?TM4W[FSX,Z7Z5WZ*%6U$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!6E6S#MH=*NU3G9MQN'2IA"P7B]*\5D"(B B(@(B("(B B(@(B("(B#
ME7NFOA''U&+TN71')+\'%@^K-7._=-?"./J,7I<NB.27X.+!]6:J2O5+41$:
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@BVNJ 2T;*Q@\.(X=VM*@ZV[40LJ*>2&098\8*U7<J1]#62P2C>T[C
MUA9VCQ>AP>3=>2?!FM(U@:^2E><!WA,\O2I2M;0RO@E;)&</:<@K8%OJ6U=+
M',SXPWCJ*K!GIJ>9<HB*6 B(@*POM>VVVFIJG_$8=GR]"OU$=?RB:.AMS3X4
M\H<[YH46G4-,-(O>(E&;</4ZT3U=1GGIO#.>))X!;$Y-[.ZWV7OFH9BJK#SK
MR>(!X!0F2F=<KY:[9&0&/>))/FM6XHFAD;6-&&M& JXJ]=M./RS%8KY]?X?0
MX* ZXLS:IUR%:UC(JR(115SAM=[NZB.@'K[5/E\O8U[7->T.:=Q!W@KH>2Y<
MO')?J6VTYGCI67" ;P^D=MDCH('$^98*COFH=.RNI1+4TE.\ F"H9ELG9ARZ
M@?;:BSR.J+*2^FQX="X^#Y6'XI[.![%<24UHU3;FOJJ6&K@.0!*SPF'@1U@H
MAS;'JF@J'AU?0.I"!E\M$< ^5AW?8I\S2H%;2-LE34P5$FP75C7%AD<_PL%N
M>AJD-TY&=.5E=%/3&HI(@\&6G8[:9(WY._>,^56>IZ"'1$\%PL%PD=*)0WU.
MJ).<C(.XD'BW 1+XN7)K=1<GRTMP;5B?!EFJ7':#AV#BLI1\EM*7-]4ZV2IB
M^-$UNRUXZBKO0^N'W:L-#=VPPU3SF%\>0U_^W?TC\U/004& L6D;%9&XMMKI
MX3P+MC+CYRL\T!HP!@=07J)O?=$1$=($1$2\*UER@T8M-_I[JP8AJ_:INH.Z
M"MG+"ZPMC;M8*JG<T.?L%S.QP&Y4O7<.GA<OJLD3/:>DM9,E-KU'1W!CO:9G
M"&4#A@]*V2M6,)KM-R-<,2QM((Z0YJV!IJM]4+'1U!.7NC <>T;BL<<^#TN*
MKTBWET6FL/>,7SU$5+=8>\8OGJ)*\F#W$RT#[WK/G-]"E2BN@?>]9\YOH4J6
MM>SS>)_%D1$5F B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@>5:SY4J74,=7%<*"036V)HS3CB'=)[5LM0C6>N*:PW$
MVVKMTLPDAVV2G&PYW4L<_+R3S3IU\%S^MCU=>:?)BJ3E3IZ>AYNXVVH@K&,&
MRSXKMV[CP6O:6Y4^J]9]_:GK&PT49V@T@X+1P:,*87&T=ZZ4N.HKWB:MJ(R*
M:([VQ[0W'[.'4M>66IH[5IBYU553LJJRI+::BC=G(=OR[=U;EYU[7O:*WGIW
M_P#;W^'QX:4O?#'M=MQ]];\O-C.4F[Q/UA/4V.KQ$UO-1OA&P&LP1L_9N50W
M6P4/)L;=11OEO=:]KJF5S<!@!SLCL]*J7?2E)IR:RC4DD@[Z;WQ5-8/"8P\&
M#M*LM/:(N.IYY:NUQPT=M,A$<E5*&@#/ 'B5:.;<].KJB</JZ[GV8UU\])[)
MRHWJ6VTU!;*5L;VPLB!#=HG  W9"AFJM)7ZBH!J.[M;$^JEQS9&'DD$YQT<%
MB+=<K]8+W44EJJY._!(8LQ;+RX@_%)!_)>ZAK;]6U(AU+55H>#M;-1D$=N-R
MK:TVCVYW)AX?U5X]5$1$]_.6P.3C46F([9L7&UNJ;O'[AFSEKAV*[U9JR"_7
M"W6Y] *&@IY@^=K!G/E Z@L!<=+6BTZ4M5ZT]>FS7.*4.E<Q^_)WC XC"RW)
MOJBQT%;<6ZHAD,E9_P#%3-VFD=(/:>M1NW3%O4,+4Q^UQ-(FTQ\][^$?=CN5
M.V:=J;W;C8'04T,T.U.]@W9ZRWH.[@H>V6H,#63S/E+1@%QS@#@%DM1RT5;J
M.NJ+2PMHGOQ"W.?!'5Y5L736A+1J31;!1U#H+_"[;=(3[D]#2/D]JSF+9[S6
MKHC+7@\-9R;GY]X^:':>O5WNU)!IZT5,362.V!$ UI?OSO/2J>N*"NHW4%BN
M])!35KGAS:H.]TPDC>1T9]"C=?;I;1J&HI[I++1U4#B1/#O >.!W='D5>EU$
MRXW"IJM5R5-=.*7FJ>1N 6N'N<]@&?M4Q&H[]5^7VN>D1R]^D==^?Q3K4U==
M]-:%?IVZL$M'*UG>M5&<M<,YP#TA8Z:_7/5]BMNF=/T %/1TX$U0[_:,DEWQ
M1N46N]TNEXHZ.C?4/FI*9A$,0&YO7Y2I7I.ON>D-%5%;! R>VW*)\3WCBQ^]
MO'HQGSK2MXO\G/?!ZFL3J)OOIY;GQ^>D1M%J$T+WU,DG,AQ:YK.SI5&@I8'E
MDL[Y&1,J&LG+>+6GI'V+8]FHH+1HVQW[#)6F1S:AG$.WG<?*%!-31 U=37VZ
MEFI[153%L0D.02-^,]/6L9B:SU=>/+ZR9B.W;?QCHS/*#:J73UM9!9M3"O@K
M,<Y2-=O#>()&<=2NJ74S;G;].6FYM[UH;<&LD<,N#QD>$0.G&Y9'D2T)'?*Y
MUZNS62V^F<610D^[?VCJ&5=U%GT_<[GJB:XU4=NIX';%*8SC#LG&&CB/!X=J
MVM6TQ$QTB7'&7%6TX[;M-/'XST\/%MR+5^FH[>R:.[4;:9@#0 _>WH QQ4@C
M<U\;7L<#&X;0<.!'6N3]+6R.\ZBH[7/5-A$SBWG0W)QU[^M;;')37M9S+=45
M8@X;/A</)M873AXC+>-Q7?YO*XKT=P^"T5MEU,^<;_1(M:ZZI[(8J.UB.X76
M9X:R"-V0W)Z2%+J*266C@DJ8^:F>P%\><[+B-X45T?R?6C34HJ(Q)55P_P!>
M;'@^0="F'E73BB_6U_H\_B)PQ$4P]=>,^/Y>3U$1:N41$0$1$!$1 1$0:"[K
M'WGIOZ6;^EJF_<V?!G2_2N_10CNL?>>F_I9OZ6J;]S9\&=+]*[]%"K:B(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@L)V[,CE25Y5MRW: X*S5X5$1$!$1 1$0$1$!$1
M 1$0$1$'*O=-?"./J,7I<NB.27X.+!]6:N=^Z:^$<?48O2Y=$<DOP<6#ZLU4
ME>J6HB(T$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 47UO;>>IA61 ;<6Y^!Q;UJ4+YD8V2-S'@%K@01UJ)C:V.
M\TM%H:@"D&E+@(I'4LI\%YRP]O4L9>*!]NN$L#P=D'+'=85FUSF.#FG#FG(/
M4LNSUYB,E6REZK*T5C:VBCE!\,##QU%7JEY\QJ=2(B(/% ;_ "BHUIL Y%/%
M]A*GZUHSP]7W=YZ' *EW5PL=;3\&:Y/J?OO6-QJW'(I8A$T=I/\ ;\UL\<%K
MKD@&V+U,=[G5 &?,MBC@M,7NN/CYWFF/+7Z/'N#6ESB T;R2M5<I/*?!0VBH
MBTQ.VHKFNV'R!AV8APVLD8*V'J2W>J]CKJ 2&-T\18' D8/1YES.8JBR7.2F
MKZ<;49,4\+F[GL.XCSC>#Y%HXTZY(>4BYW:H]0[D^.>ND#GP5$SMG('Q3@;S
MU+;]BMSK;1NCEFYZ:1[I)'[.SDGJ'1T+E5FF+G3ZFI_4,/=3N?S])5DX:8P>
M)/01P(XY74.E[R+M0^W 1UL7@S1$[P?E>0II3GKS<N^K)7%E1)0U#:)[8ZDL
M<(W.X!V-Q^U:]JK/!=K3(SFCWXTD2F49?M](S^8/!;+49U5;YH8IKI:HV.K&
MQG;C<2&R #=D#I&Y%VC;S.[3X;-5/<R2,[4,C?=.>.C=P(/$+<7)EKJEUC;W
MX88*^G $\3NG_<.PK6MQH#=;74QW.9U2:H\[(X'#8Y /!>P=&#Q'2,Y6M;)7
MW;2.I(9Z=KXJZ%P!C R)6GH[0>A=U>#]F8F?:[QY/,MZ0]J)K'L]I\W90.46
M/L-<ZY6FCK)()*=\\37NBD;LN:2.!"R"X7IB(B O'#(QUKU>%!IF*(TE_O%
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M$1H(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MR*[<G%5B9G'X]WF8>!O:(KFGW9Z>>FSN3W4/J_88I)QLUT($=0P_* XCL*E
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MG>$ W=DCM.52;2MBCJXZV-TE4=EL;W[N;P=^[K4BN.CJJ'DYCU&RH]IVP.:
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M+T*,Z;U'5W'3,E9=6PPL@D;$'[6SWRX\ !T=JJS39+II7!SWD9V1Q/0&CJZ
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MZHO9-'TU)(VHN#S658WY><M'F4H&X8&X#< O45XB([.:^2V2=VD1$4J"(B#
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M7QEYG:P^[:2<J\O-_GN='34DM+ WF1ALC8PUY'43TJ]Y/]7T-DC=0ZMM??5
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MW"S-+3QTM-'! T-BC:&M Z %51 3"(@8W(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#XF;MQD+'E9-6-0W9D/4=
MZM5$J*+TA>*4"(B B(@(B("(B#E7NFOA''U&+TN71')+\'%@^K-7._=-?"./
MJ,7I<NB.27X.+!]6:J2O5+41$:"(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B J%?.VEH:F>1NTR*-SR.L $X5=1GE N
M(I+!/31$.JZS_#QL!WC:W%WD WJF2\4K-I\$UK-K16&OH-4/E8R:FT[9XF/
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M8RAYZ61_/UDYVI9G#!/8.H#J5]'&R)FS&QK&]31@+[4LM"(BA(B(@(B("(B
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MVNUG_4E9B63YK3P\I6Z-$Z"@L-0ZX7*H]4+J]G-[99B.)IXM8WMZRIJ
M . 757B<E:<D2X[<#AMDG+:/X8726F+9I:V-H[13B-N!MRG>^0];BLTO47.[
M(C79&-?Z:;J2R/AC [\CWP.)P >D'RX6HM1:=N^G(:'GR-J'PHI8^O.<9["N
MA%87JUP7>WRTE2T%KAX)Z6GH(7-FX>+[M'=Z'"<?;#$8[=:[:(LM[]<?+/8:
MN=NQ(V)K'YZ7!AWA5-26.DT-K2JGNUL[^TS<G$EX:=J$DY.".&"?.KNRZ'BN
M=SJY:&JDH[_;7YB(W-DXX)Z0=W%9.YZDU#0T4UJU58V7&%S=ESW-W$=8< 02
MN>L[KN_U>K>VLD5Q=HC4QO4Z[Q,2AFJ+?I:."*Y:-O)8X'PX'R$2,/6,X..Q
M1"^W"MN3((ZZN;5F$9C><%S1U$\5E7VFP0P22O-QA>T$@%K' =F=RP,5JJ*X
MO?1T\CP/^6"3]BY;^]TZ;>I@BL5]J=Z\9[_5LWDMU/J7O26WV4PU3*=H>*>7
M < >.SUC*N-6U%->6R>N'3%11U_\53Y;O[01@A:FHJJY6*O;-3234\\1W.&6
MN;_ZZEL6+EEO1@8RJIZ&=VS[IT!.UVG>M:7CEY;3^[ES\)>,OK<-8Z_'4_[8
M.EIJN2A?0P7&G? _P13U3< =H=T'SK'56E;U8X^_'Q-,#?CLD:]I^PKZNFIG
M5U1-.RWPL?,<D,86M![%7H[)J^X1!U):[@(G<"Z-P:?M641S1J(VZHFV/VK3
M$1+Q^M[O66EUMFGAEIVLPT2,&6CL*M=,\U R3ONDC>*EAC8^;(# ?C#M[5CM
M16>Y6NM$-VI#!5/&ULXV21UXPK<5U73O93U +N;&PUKN@=GVJ+1;\VM*XYK[
M&M3Y,W!77:@AN-EM4\D]+. )6PM+@X#T#K6:T)JYFC73/CHFR5$HP]TP(('4
M%'M.7YUEK9*B"=T4[AL%P;D8*FENUU2R2;=VI;9<&;O!GC:UWF(2M]3WF&.?
M',Q-9I%HGOUU,_WYJK^46CENU5=ZBFDDK2T"GC<08XSPSYNA16_S6FOMC;B*
MVIDU YY=*Q\?@D$\,]84NL-QTG>M<F2YPT=+1%NQ!3M;X!=VD>=1W7(L[M1U
MM/8J5C:%CMAK@<Y(XD=F5:TSR\\SN/[U988I&2,=:S6=1/PUY,+0:>HZ^PU5
MQDN=/3U;"&QTCCX;SU]@5;3E^O&AKESM#-"UTK 7LRU[7CH!QTK[T/8J>]:I
M9:;A4NIF/)]L#@".P9W9*ENL.2.ML0%?;\7>AB.W)%LEKP.H@'>/(K4K:8YJ
MQV7RYL5;SARV][PF.GU_E"]0:I=J.[<Y40"E@J'M[Y9 3X>#OP"MD7SE0MD.
MCS8K/:JIFU3][LYX  -QC/:5%*ZS6:]V(W+35)/076C>.^:,/,C6-W^V#._'
MH7M':]6SBWWNHMXO%,QP8R-OMF-D\'!N\>=6K::[BOBQR4PY(K-HURSVF==?
M#^[6U)%J>A;;:FGI'6XO<(XIY!@DD\<%;!K]&ZPM] ZXSZQ:V<#:V#P<>H;O
MT64Y8JUT5FL;IXFQ5;I&.,(=G9.-X\F5F[3::_41BK+Z][*0 &* ;MKS="VQ
MXHK:U(^#@S<7:V.N:8B-[WTWX_%K>WZTO5+?K7-K:![J"-VRVIC9AN>OJ*WW
M0U<%?21U5'*R:GE;M,>PY!"L+OIZVW:S26NKIF&E<W  &]AZQVK4]@NM9R7Z
MK=8+S))-8*IP=33N^)DX#O)T$>=;QO#/M3N)\7%>*<;7_BC5H\/"8^'Q;N1>
M-<U[0YC@YI&06G(*]72\L1$0$1$!$1 1$0:"[K'WGIOZ6;^EJF_<V?!G2_2N
M_10CNL?>>F_I9OZ6J;]S9\&=+]*[]%"K:B(B B(@(B("(B O"<(XX&3P4!OV
MH*JX5;H+9.Z"AC=LNE9N=*>D ] 7/Q/$X^&ISY):XL-LMN6J;/KJ9D[87SQ"
M9QP&%XR3Y%<A:PTY1PG4UN:&^Y+Y22<DD-.#GRK9[>"IP?$_Y6/UFM=4Y\/J
M;<N]BINFC;)S9D8'\=G._P"Q5%K_ %]0PRWNGD>#E\/$.(((.XC'E5^*S_X^
M*<FMZ1AQ^MOR;3_*]&\+75EO]9:I]BME?5VYQWO><R0CKSTC\UL*&1LL39(G
M->QPRUP.XA1PO%8^)KS8Y,N&V*=6?:(BZ60B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*WJVY8#U*X7C@""#TI QI7
MB^G#9<0>A?*NJ(B("(B B(@(B(.5>Z:^$<?48O2Y=$<DOP<6#ZLU<[]TU\(X
M^HQ>ERZ(Y)?@XL'U9JI*]4M1$1H(B("(B B(B!$7CG!N]Q ':4'J+!W'5VG[
M=(8ZR\T,<PXQ"4.?_*W)4<DY3J.6H,-ML]VJB/\ 4?#S,9_ZG?LK5I:WNQM2
M^6E.MITGZ+!:3U$S4$%2[O62DGIY.;DB>X.QNR"".(6=43$Q.I6K:+1NO81$
M4+"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@QU^NT-EMLE;4M>Z-A#<,&
M223A8V+6MA>WPZ]D3AQ9(TM(_)96^4 N5HJZ/IEC+6D]#N@_:M:VMXJ:-O/M
M8Z>,\W+D<'C<5Y?I#C<G!S$Q&XEU</@IFB=SUA);IKF#9:RPT[[A*XX+\%L<
M?:2>*CT5,7UDE?7.;/<)-SI<8P/DM'0%<@ ##0 .Q>KYWB_2.7BNEND>3T,6
M"F+MW8V^0-DI-O RT_D5GN2FYR.IJFT3N![UPZ ])C/1YEC:QH?2RM=PV2L9
MHE[HM:6US7$<ZV2%PZQLY_16]%9YQ<3$>%NB.)I%\4_!N-$1?:/%$1$!$1!\
MR,$C',=[EPP5J>N@[VK9X?D/("VTH!K>E$-T$S6X$PR>TA4M#KX.VK37S8*D
ME,-3%(TX+7 Y6Q8W![&N'!P!6M?2IWI^H-1:H7.]TT;)\RI#IXBO2)9%$7R]
MP:QSG' :"2I<KU>K5]DU7KG44,]98[38W6\3/CB?42/:YP:XC. >Q96UZHO]
M#?:*V:PME%3FO);33T4A<S: SLNR<J_)/9EZVJ=HO"0T9<0/*@.[.=RHU>HO
MG: ."0#Y5ZB'J+Y#@20""0O20#Q'VH/47@<#P(/D*P+=1Q2ZO-AACVGQT_?$
MLN=S=^ WRJ8ZSJ"9B(W+/HODN &\@>7I7N=RA+U%\APW#(R>&_BOI!@=8>\8
MOGJ(J7:P]XQ?/4142[<'N)EH'WO6?.;Z%*E%= ^]ZSYS?0I4M:]GF\3^+(B(
MK,!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!6%^<66&YN:2'-I92".@[!5^K:YT
M[JNV5E,P@/GA?$">&7-(_5!SAIMC6V"@ :![2T\.Q9'9'4/L6.M\==:Z.*@K
MK/=F5-,WFGAE&][21NR' 8(5QWW+XKO'X"3]E47.R.H?8K2[L:ZUU8+01S3N
MCL7UWW+XKO'X"3]E2J365T#Z2DL]W?/..;8#1O:,G=DDC ""RT6XS:;HYI3M
MRR N>\[RXY.\K-[(ZA]BQ]';+AIB#U'KK9<I):4E@F@I7R1RC.=IK@.&]5^^
MY?%=X_ 2?LB(7.R.H?8FPUVYS6EIW$$<5;=]R^*[Q^ D_9>=]SC.Q:+S(_H:
M*&3)/5O")9G1_*JRRZ:H+8;:Z4TK#'M\YC.'%9@\M+-^+0<]LJJ7735/:^1G
M:K+?!%=&4S72/V1MM<7YWGKP<*GJ.U4$-GT3)#1P,?/40B5S6 %X(Z>M2A%M
M0WG4?*1414MNHN;B@>)80QN1&X<'%Q]"M(*]C*9YKRVGJ8263Q.."QXW$871
M]-!#3QAE/%'$W'!C0WT*QJ+!:*BXMKY[;225C>$SHP7)I+4ND-%W#4S1570R
MVVT$^!&T8FJ&=!S\4'[5MZR6BWV2B;26JEBIH&C@P;W=I/$GRJ_&X8'!%((B
M("(B O%ZB#7E#&*7E8J61[FS1.<?.U;#[%KO3A-;REW:I.]L+2T'JSN_1;$*
MPX?M,_&79QOO5B>_+#4^N*^75^J(-)6L!M+&_;K)@W>-DYQY-WVKZY/;_;:#
M4]PL@C]3XHG&*%LYP7[)X[^D[RMG0T5-!/+/#3Q1S2_YCVM <[RE:_U/I>VZ
MBUD^"X1O&8P1)$=EP..M9WQVK,7CK.W1ASX\E)PVC58C[^;.Z^T=1:KM3F/8
MQE:P;4$[0-K..!/2"N9835Z;U"-NE8:JF?OBGC#FD\,%IXK:-]NNL-!UM/;X
M[Q3U\4FZ"-[1(\-SAH(.\=2AM[L.L;O=ZJON%DK):N9VUD1;AU 8*Y\]HO.Z
MQ/-'=ZGHZML%)KDO$TMVZ_RFUKY0M/WVADME]MT%J+FY;40L&RUXZ< ;E\V_
ME-&FK=547/LN :"*5[79P>C/9V+7-;:KK0S14U^H3;F/&SSLD&=W6,<?M4[T
M]8^35]%S==<ZN2I=QDE+HP#V #AY52N2\VZS$3'Y+Y.'X>E?=FU9\(Z_GO\
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M+Q7U5I.Y6Y^+,^.LHAP@G?LR1]C7<"/*HE6ZGCI+A);WVZN?<&'!@B8'[_G
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M7RXZ>I156FOGHW<V'.V'>"2!TM.XJDK0E^H;-<(KG:I;U0OHJ!CWN;S^[;E
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M-!:=K;+5:@K+D8C4W&L=.WFW;6&?%!W<5[H#3]=9IKW574PFJKZHRCFG[0V
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MUR8UH)?#T/QT[)_(E:]U#:&:=NHBIGMDLM:.>M\K?<!IW\V#V<1V+<1 (+7
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M6Y^VHW]VN;F;UI2UTVG]84D-RT\^01PU<8W-R=P<%)Z=D<5/'' T-B:T!@'
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M>%D!9RWRF>@IICO,D;7'RD*M-<TNC#R3FO%.D_E_>Z=46EJ)P:Y]6Z<<<,(
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MN'.=ZO,C6;B_9(:3V+LQY(O'1X^?!;%/6%^B(M& B(@(B("(B B(@(B("(B
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M3N"QLS+!R;/-/8MB[ZJ>,/J9AM,IATD=7D&]0N]/J[W/+47:OJIZEY#N<+R
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M; +E61&)U%LG.PW:R6X&[?D[SUKH6P76>:@'/10Q59D#74C&%IA!Z#U^7@M
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M)&>)6&IK#/I_E'N]39K2Z.VU-K\'O:(-CYUN<-P-V2MI(IFTS,SY[5BL1&D
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M1UQXMC^_:HF-PTQ9.2T6[MJ>JEO\84?W[?W4HTI<K/#3R32W6WMD><8=4L!
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M/Q<?[IZX++XYMGXN/]URI[">MO%\7XAJ>PGK;Q?%^(:AMU7ZX++XYMGXN/\
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<W'RD1 [W'RD[W'RD1 Y@#XQ59FX(B(>HB(/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g111069g00a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a11.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1A04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &#,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"C_P  1" +@!P4# 2(  A$! Q$!_\0 '  !  (" P$
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MR0';=W?V1YK6Z=HP6ORC-2SSQMD?6HL=%S#?E)Y1N/?M^U7$QC8V[,:UH[[
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MUNY*-Q&3V'7HLI6Z1INE;+;W"YW"H*WK_7>F-087!:DJTGR6[,;!;:WI+&7
M';;IN-U-.).J]04<OC<#I''^-D;H+C8E8?"B:/?VW[_@M9'IVD4UKV%D[A<;
MA43DM1<2=#/J9'5#Z.0Q$D[(I_#: 8P3MOT4GXIZ_P AI3,:?@QE5EN/(B0>
M%M[3W] P ^74ID>E<1G6M\"T-PM=G\U1P.+FR&4G;!5CV!<?4G8 >]4MG]1<
M4-)UVY[-,Q\V+#FF>M&T?P32>V_?[U[?E"Y+,W=&X^;&P0OP5IL4TTKOI->7
M-,8'V[IE>A,^Y=]>9LT,<K-^1[0X?85Z;A5;C=7YW37#B?+:QI0MNQEL52"$
M_P"MW #!T6E98XP6(/C5K,=$TMYACRT;[>G?NJX:L*>B+LW"YW"@&&US)F.'
M.1S<4#:^2I12-FKOZB.9@Z@^Y0G%:EXDZWPL&1TY#1Q]1K #)( 76)!](M![
M-WZ?<IE>O87,J1>NX3<*M^$FN+NI:&3KY^&.OE,7)X=GDZ-/?K^I1INJ=>:Z
MM6Y]$15<?A:\IBCL6 "Z<@[$C?R3*[HF=59=FX3<*MN'VK<X[/6=,ZTKPPY>
M*/QH9HOH6&;[;CWJ-6];ZSSFK<_IC3,%1D]2P0VV]O2*(#L=^[B4R.Z+G56R
M[MPN=U6$.J=18[5FDL#F!5=/>AD=<=&W^<W;;E6[XM:DNZ4T=-E,:V(V&311
M@2#<;.=L5*V[?6BIV33<+C<*L^(^N[VEM-Z=R<,4<ANO8)VEN^X+-]F_>HIJ
M'4W$W"5!JBY7HMPP<USZ( +HXR?,]]^RN1\>XF=?DO?<+G=4CD=0\1L[CY-0
M::AJ4\*QIEA@F:'23, WYCOZJ8:?UT_(<+OE1)3=)8C@<Y]>)I)=(TENP'?N
M$<6E84DW1/MUYSRMB@DD.Y#&EQV]RH^E>XN9^A'EZ?Q?CX)!SQU'L',YOEOO
MUZJ7\--6W]4Z8RS<U7C@RE"22M.U@Z$AO=246DWR$9)M=I)M$ZGIZNP4>6QS
M)HZSWN8!,W9V[3L5OP=^R^9N%%_6^0T;%C-&05ZM:M+(9;M@;\SR[?E:#[E9
M7##6^8R&>OZ9U?5CKYJFP/#X^@F;Z@?>%N4*;HS'$M:EGGLH[#JJG+K*;338
MIQ>BKBRYY;_!EI(&P/KU4A/4*!T]26Y.+]W3[HJ_P.*@VP'AG\)S;CH3Z=5B
M*MT;DZ5]WW)XT]USNJ/BUSK?4>:SN#TU4J-FHW98G7)!LV.,'9HV/=W0K/T%
MK'5-37ATEK=E=]F2$RP6(AMS@?9T]55!M$<TF7"#NHY)JRBW6K-,&.?X<ZO\
M)#^7V.7TWW[J1!4-K_)Y3&<<X'8"DV[DY\9X,$;CLUI)^D[W !2"MT).HWW?
M<OEI&RYW"HFWJW7^B,SCI=8BE;Q-^=L+C"T#P23Y$*;ZUU9>PVLM+8RFV%U7
M)R\LQ<W<[;'M^"N5Z=I,ZUO@3_=-PHGQ/SUO3.DILGCQ&;#)X(P)!N-GRM:?
MU$K1<4=<W](G3SZ=9EEMZ4QR1;>T\\OLM;Z$N(446ZHUF2OL+)W3<*A=0ZMX
MD:59!J'.0T78:21K9*<8'-$T^_OO[UE9G4/$F]CI=2X6&I4PL;#-%5D:'221
M#KS'[1U5R/<SGUHO#=-PH'7UTZ7A5'JR.D^:=U?G%:,$[R;\I'3KMOO]RA,,
M_%_)TF9:N_'5HW,\5E,L',1W .Y[IE=M/@7,J37$O+<)N%77#S7%S4N@KN5M
MP1P9*FZ2*5@^CSM&X.WV$*%:?U;Q&UYA(;.G8J-&.(<LUB1O^MDW.X:#V &R
M9';7(9E5E];A 0JTX3:TRF:&:Q>J(8XLSB).27PQL'MV/7;[BHGCM4<0M=S7
MKFD9,?1QE:=T+&R .>_;UW^Y,CNB9U1>^Z#KV4$X7YW4F4@OU=7XSX'=J2!C
M96MV9,#YC[%.F]E&J-)V<HB*%"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@&X3<*IN)?$7(:3UA4H0PPRT7P-E>"
MW=Y)+AL#]P63H74>J)/C?*:N@^!XF&'QHFNC#3Z[ _9^U=NHEDS\#S_J8=9U
M?$M#<)N%0T&M.(&J'V,AIFG&S&PO(:WE!W \MSW.RG/"W7;M5UK-?(0M@R=3
MI*UO9W7N!Y*SZ/.,6WPW[#.'TO#G)15Z[/@^XL#=-PJ1R.L==:ASEVMI3'&M
M5JNVWFCV<X;D DN]=NRV?"[7>9R6HK>G]2PL%R!I(>UO*=P0"".WFK^FGEO3
MG7$BZ9!RRT^5UI9;>X7&X50Z[XA9@:K.FM'UV376^P^0CF(=MN0!V&P[E8>G
M]::SQ.IJN+U9CS-%.X R11;EH/\ .W;TV4CT>;CFT++I<(R<==-&ZT1/=2ZZ
MQN U#0P]R*RZS<Y?#<QH+1NX@;G?U4L:=AU5!<<K1I\1<#:;&93%$QX8.[MI
M"=EZ:DUQQ PLD65O48*N-F=M'"YH=T/8./<'9=%T;/"+CN[.<NE]7B3C+5*M
MNXOK<)N%"<KKRKCM P:BD8"ZQ$UT,._TI#_-_P#Y]%7(U=Q(...H!4A^*MO$
MY.0;<GKMWV]ZYPP)2N]*TU.L^E0A56[5Z<N9?NX3<*&X'7-+):&DU$\"-L$3
MG3Q;_1>.X_\ Y]56N(UQQ U-9FOX"C ZA [8Q<HV/NW/4E(]'FVT]*YB72H1
M46M;VHLVAKO&7=8SZ;BBLB]#S<SW,')[(W/7=2]?.G#"_-D^-$]RW :]B5LI
MDB_H.Y>H_4OHOR3'PEAN*7(G1,9XRDWP;2[C39#46/HYJAB9I2;UPGPXVC<@
M ;[GT"Y^4./.HQA&R\]_PO&<UHW#&^\^15<16,M6XY6#'CY7T;(9"ZR^$EK&
MB/?V7=AU7;A_/EH>)NH(+-"1E*S(Z3X3)"03R@!H#O158*J^RS/ZAYJ__5%N
M;CU7.X53Z^U=JCY3C :1H.\0,YG3OCZ./<[$]-@M+@=?ZKQ&KZF#U=!$XV'M
M:2  YH=T!!'0J1Z-.4;5=W$U/ID(2RM/E=:%Y;A-PJGXE<0\EI76%&A7@BFI
M21,DD;R[O=NXC8'[@HYG-=Z]T[=J9#.4H(,=8=LV#E!&W?;?N#LK#HTYI-5J
M,3IF'!M.]-]"^MPFX5$:@U]K>6A\H,;193P#7#E+VAQ<"=MW>>VZW][7^9L<
M,JFI,5! ++9"RTQS2YHVW!(_;]ZCZ--)/MH1Z9AMM*]KVW786SN%BY.XRC0L
M6Y@XQPQF1P:.I &_1:+1.HAGM'U,O8+&/=&3-R]FEO?]B@.E=9YC6&)U5);C
M@9C:]=[8RQNQ).^PW^P+/4R^+_\ .YT_40^&O\MB>Z'UC0UA4LV,9'.QD#^1
MPF:&DG;?IU4G;T"IC\G*:.OIO-33.#(XY@YSCV #=R5BVM>ZOU7F+E?0]2,4
MJSMO%(!+O>2>G7T77$Z/_P!CC#9<SSX72_\ IC.>K?(O+<*(9/7N,Q^L*^G)
MHK)NSE@:YK 6>UVW.ZB.AN(F5^48TYK&JRO?<>6.5HY=SZ$=NOJFIM2RU>+^
M.Q0Q^/DCD,7\.^$&5N^_9RD>CM3RRUT-2Z4GAYHNM4MBW-QLM#K'4M/2F'.1
MR$<KX ]K-HF[G<J&\6-?7<#=JX? 0MER=D [EO,6[G8 #U*KSB%EM9MTM\ U
MC28(9Y6NBL-VW#@=^4[)A='<Z;V8Q^EQP\T8[I<M%RLO[3&:KZAPU?)TFR-K
MSC=HD&SN^RVRA'!D[<.\3_5=_F*FKW;,<1W 7+%BH3E%<#O@3>)AQD]VCMN$
MW5%T.)^J,EELEB<=CZ]J\)',K<K=@P D%SON7IIG7VJ<9K:O@M811GX2X-Z-
M +-^Q!'<+K^EGV<S@^FX=\=ZNM"[^8+G<*I>(.O<Q%J<:;TC69-? 'B/<W?8
MGR'D.XZK7X#7^I<'J>GA=<UHVMM$!LP&Q;N=@=QT(WZ+,>C3E&UX<34NF8<9
M.+O3CP+JW"XY@JXXL:]GTPVM0P\;)<I:/LAPWY!]GF3NHC:UMK[2V)DL:CQ\
M3XYQM!,6CV']P' >HW2'1Y3CF7'S+B=*AAR<7>F_9WEZ[A<[A5UIW6]VQPU?
MJ&Y5^$7 YS6PUV'VCOL.@W4%?JKB78QDN=BK1Q8Q@,A9X8&S1WZ'KLD>CR;:
M;2HDNEP45))N]=%P+^W"P8,Q0L9&6A!;BEMQ,YWQL<"6C?;KMV4'TQK/)ZCX
M=7<I2J,=EX.:,1-&[7N'F!]A50\+<EJ"IJVT_#TO'FGD:VX"W?PV%_M'O]JW
M#HK>92=-&,3IL8Y'%6I%\7=<XVIK.'34D5DWI0"UP8"SJ">^_N4LW"JC,:CE
M@XR4L0*%!T;VM/PAT(,PW:3T<LENN<G0XI.T[EHX!1F.U>0-V=UZMW/GYA9Z
MEM+*N%FUTA1<LSTNBS]QNN-PJ[XL:VM:6CH5L2V*3(VI  V0;[-ZCM]NR\^(
M.NK>EL'CH8XHI\]=:T!FWLM/F=OM.VRQ'!E))KB;ETB$')/AJRR">A4=UMJN
MCI#%QWLC',^%\HB B;N=R"?7W*JI-::^TM)7O:IIQOQLSP'#E +0?>.Q^U3;
MB%.S4&A:\F/Q/QL^Z6_!V^43G ^V?LZK?4.+5ZI\CFNDJ<9*.C2XH]\WQ*Q&
M(Q.(R%F"VZ')LYX0Q@) ]_536I,VS7BF9N&R-#AOWV/559K+3,SM*:=T_7Q/
MPVXV-D/PL]JVVW,[[^JM&C#\'JPP@[^&P,_ +.)&"C<>;\#6#+$<JGR7CQ,@
MG9<;A1[7^H1I?3%K)B,2R1[-8P]BXG8;JI:FI>)V4HC,8^"!]!P+FLC:T[@>
M[NIAX+FG*Z7:7%Z1'":C3;["^^8+ IYG'W;T].I:BFL0 &5D;@[D^W90ROJ+
M4=[AQ;ONQ#X,Y&"P0.80).H]H#["?P52\'LCGJNI)6XFD)X9YVBZXMW\-I/4
M]^BZ0Z,Y*5O8Y8G3%!P23^(^G-PFX51ZUUAJNQJJ3 Z1Q[F.C!YIY8SL\CJ2
M">FP6%I#7>J*6M:VG=70QF2P>4.#0'-)!(/3H1T68]'E*.95SKB;ETN$996G
MO5UI9;65S./Q+&.R-N*OXC@U@>X N)\@/-9X<"-POF7C'>S$W$&(6ZH9\&>&
MT/9_UK.;<'W]>BL//ZUU+A.']7*7J<-?*OG,;XI&= W?ITW6GT9Y(R3U9F/3
M$\2<6M(^W_1:^X7.ZC.)S5FWH&OF9 SX7)2%@@#V>;EW[>BC?";6]_4V)RMS
M,-@:*9W'A-VZ;$G]BY=5*I/^)VZ^-Q7\MBR=PN0050\>M-=:MOW7:2@KQTZT
MA9M[/-[M]U->&FH=39"S9HZIQ4D#X>C;(9RM<1W!_>MRZ/**MM=W$YPZ7"<J
M2=<ZT+#/8J-8[5U"[K"]IV*.<7*<0ED>YHY""=NAW4E/9?.^5R>:I<;<_7TQ
M498RENLR.-TGT(AN27N7&*MT>B;RJSZ(W3<*E,?JW6>CM18ZEK]M6SB\C)X3
M+L( \)_D#LI7;U;?QG%.M@;XA&*O5N>K)R[.\0'8MW\U<CTKB,ZUO@6!N%P3
MT4'XJ:KN:;H8V##,BDR^1MLK5XY!N""?:.WWC\5-(@_PFAY!?L.8CH"5FM++
M>M$>^5]$:X&EGQ3MONKFRUY:/#<T>AW[K8:ES=73N$M93(%WP>NPO<&CJ=O(
M>]5YQ49\3\1-#:B;[+#9=0G=Y<KQTW_$KOQRE?D#IO3D!//DKS/$:/\ PVGK
M]W5:4<R5<=/?T)FIN^'O[DUT+JNAK'!,RN+$K8'/<PLE&SFD'S"\\MK"ACM5
MXS3[XYY+U\.<SPV@M8!YN._10OAAR:>X@:NTP &0&5EZJS_A</:V_ +&TFTY
M_CMJ3).]NOB8&U(CY!Y[_L*N5-Z;5?OZF<SRN][KW]"4ZYXFZ?T;.VMD99)[
MCAS?!ZS>=X'J>O3[UZZ#XCX'6CY8L7-)';C',ZO.WD?MZ@>:\-)\/:F$S^8S
M%V5N1O7Y2]LDT8WB:?YH45U=4J.XV:79@HHX\C$Q\EXP#;:+;IS[)%1=(LG)
M6R>ZWUOA=&U(ILU8+7RDB*&,<SW[>C?^ZTVB>+&G-69 4:<D]6ZX$LAM,Y"\
M#TZ]?L42XF.KZ;XJ8K4VH:XLX)U;X.US@'>!)OOS<OGY_BM9J+.83B#K#3=;
M14+7W*MEMB:XU@C,<3=]Q[^X5A%-+M\B3DTWV>9] H@[(N9T"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( A[%$\D!\[
M\:(+$?%*C*;IQ[)8(Q%;(W$9!()Z>_\ :O;4VD;]FM6@U%Q&J2P2NYXFV 2T
MG;N/:]ZM_6>C\;JVBVODVN#F'>.5FP>S["H9B.".$IW63V[EJZQC@YL3P W[
M#ZA>_"QXJ"3=-=EGR\7HD^LDTK4NUK_9(W2T=+\-8F9>Q%<J5J;8B]H]F?IL
M ![U\[Z.L08;5.,S64QS_BA\YY"YI+6^\>O+N%]#:[T$S5K:L,V3GJ4JX&U>
M)@Y21V/X=%D9_0F,S&E(L$X>!# &^#*QHYF$>?W^:S@X\,--O5R>O<:Q^C3Q
M6E'116G:_0U/&6>*SPQOSUWMDBD#',>T[@CF'4+6<!\QCQH<5GV(8YZ\CS*U
M[@" 3N#]B\=<:;.EN#V1QK;TMR&-[3&Z5NQ8"X>S]BCV@^&>+U;HBA<EFFIW
M Y[7R1 'G&_3<*P4.IDF]+W^A)RQ/U$6EKEV^ICZ!_\ :W&?.7<7[50ML.YV
M]B#T'XGJO3@5<K8G5V<HY-[(+DA+6&0[;D..XW5O:)T?CM(XXUL<USGO.\DS
M]N=Y_<M-K/A?A=3V3;>9*=QWTI80/:^T>:/'@VX?XTE?<(]%Q(I37[K;KOX$
M$X\7*V5U#IS'8R1D]Z-[N;PCS%O,6@ [?82MIQ&P^E\K<QE#*YCXNU%'"R,2
M!I(/3^=Y=_/=2;1'"_$:6NFZR26Y< V;),!['O ]5GZXT%BM7LB-_GBLQ#9L
M\6P=MZ'U"RL6$<L(MTKU[S;Z/B34YR2N5:<-.TIC-NU7PWFJ20:EBNUI'^S$
MV4R ^O,QV_3W@J6<>+3LCP\PUPQEAFD9(6_T26%;3"\$\+1O1V;EVU>$;@YL
M<@ :=O(^H4\U+IRCJ'#28R^S_1W;<I9T+".Q"L\>&:+6K3WJC&%T;$RSB]$U
MHKLAV0SF/BX-!_PR$\V-;$T!XW+^3;EV]=U%.#'\F6I/M=_D6^Q7!'"TY9'V
M+MFUNTAC7@!K201OMY[*1Z3T#7TYIW(8F&[-/'<)+I'M +=QMT"D\3#4)J+N
MS>'A8SQ(2FJ44UN0O\FB-HP^;D '.;#&D[==@U1OC'7L1\4Z<AN&B)61^%:(
MZ1]2-_N*M[AYHF#1=*W7K7);+;$@D+I&@$;#;;HLS6.D,;JS'BMDV$%IW9*S
MH]A]Q5>/%8[Q%M_1(]%F^BK">C7J5%J;2.2L5(*^H>(M6:O*[FB98W+20.X]
MKT*N72-%V,TYCZ;K++1AB#1,P;!X\B% \-P3PM'(1V;=VU=9&X.;"\ -^_U"
MM..-L;&L8 UK1L !L %C'Q5**C%W]*.G1<!PDYRC3VW;*>X_2-HYG0V4N-/Q
M?5R7\._;<,WY2"?P/X*T,ADZ-?#SWI[$/P-L1>9"X<I;MZKG4.#HZ@Q4V.RT
M#9ZLHV+7#L?(CT(571<!<6)VLGSN6FQS3N*;I/9V]/L^Y>=4XY6>IVI9D8G"
MW C4/!O/4Y(]H,G8LOK!W0#<^PX?_4%'VZ@FUAH_2FD'E[\@^Z*U]OF(X=B=
M_NV7T+CJ%?'48:=*)D-:%H8QC1L  H=@.&F-PVNK^IX)Y'3VN;: M 9&7=R"
MM*:S.]O38C@ZTW]2%?E)8]M?2&G&Q&2#'U+K(Y'QC<Q-Y2 X?9LO&/A)#+CF
MWF:_RSJ;H_$$HF]GEVWWWW]%=&8Q53,8Z>AD8&3U9F\KV/&X*J<\ \:)C''G
M\NS&D[_ P_V=O3_^0I&6E,2CK:1@T\7B<9P(U8,!EY<K5E;,\SR,Y3S; $?J
M[JR.$[0.'&GMAM_H;%[7=&X^30]C2](? Z,L!@#HV@EH/G[RMGIC$,P. H8J
M*5TK*D0B#W#8N \RJY)I_3\B,6FGW_@V6RJ'A=/%C^)NO\?=<V.]-<;8C#SL
M9(R#L1O]H5OJD^)$&BM2:NGI9?*3Z?S]%H M[B,2L/4;.\^_JLPW^AJ>UG7C
MMDJ;]7:'H,D8^ZS(,D<T'<L:7L[_ &[%;'7VIM19'7<&CM'VJN,M-@^$6+MA
MH/LGL&;@_L5;SX#3[=<:5Q6ELC-G,C\,;9N77/\ $V8TM(&_IL#Y^:NGB!PS
MQNL;%>X^S8Q^2A'*VU6.SB/0K5**7>S%N3=<D4WQ:TWFL+IUD^J-;S96S)88
M(J0]EAZ]3MOY?8IQQ+ =Q$X:[@$>,>_VL65\Q.&DQ=J"WD[]N], &W)W<[HM
MCO[(/K]JE>5T)%DLKIF_8R$WC83JW9@VF/3OZ?16HS2K79_@RX-I]J_)B\<A
M_P#JNSW_ ,D?Y@HEQ-_D"Q6__A4?_P!%6?K+3\>I]-W<//.^".TSD,C!N6]=
M^RPLQHREEM#LTS=ED-5L$<(E;L' L V=]O1<HNE]4_ [-7X,KWC_  NFX<82
M8/D;5AL0.GDCZEC2-N8?8L.IPEAM8]MV#7^6DJ/;SB03^SM]NZL#2'#VI@M-
M7<)>O6,O3M.)<+?7E&VVP[J(/X!XL3%E?/9:''$[FHU_L_C_ .BZ*25I,YN+
MT='CI+%8?&<+M7G YN7,0RMF,DTC>79X:01[_M4QX)-#>%FG@ !_H_\ ^D5M
MX-'XZGH^73F.;\&I20NAYF@%WM#8N/J5DZ/P,>FM-4,/#,^>.I'R"1XV+NI.
MY_%24K3^GE95%JOKYT5'P_ADGU)Q3AK@F63F:P#S):Y1/A+H"'5.G#+!JS)X
M^S!*Z.>G"_E$9W]-_-7KI/14&G<]G,I#<EFDRL@D>QS0!&1Z>JC>JN#6)S&6
MER6-OW,-:FZS&F=FO/<G;HBDEIV+R$HWKVLT6C=&87!\286'5MW)9JO"7?!I
MAS>P3YNZ[?9NL[A.!\Y_$4[#?X7'U_24MX?\/,5HQL\E22:U>G_UMJP=WN]W
MN"R=,:,@P.H\_EXK<LTF7E;*^-S0!&1OT'KW5SZ[\/R9R/33B0S7DK*G&K1<
M]AXCB<R9@>X[#<@=%[?E(7ZT?#TUGS,$]BW"(V;C=VSMR=O0 *5\0-"X[6V/
MBKY%\L,T#N>&>'H^,J(UN".,9BKM>UEKURY8:UC;=CVW0M#@[9H/;?;99C5*
M^'K9N5IMKCZ4:CC, =):$! (-FOW_J!3/C7TX3Y_;_=F_P"9JS-6Z#KZCQF%
MI379H&XN1DC',:"7\HVV*V^L-/1ZETQ>PL\[H([48C,C!N6]0?\ LDVFJ7-O
M[##BXR3?)?DUNE@!PQQH  'Q6SM_\M5UH;4ATGP"DR\<0EFBDE;$P]B]TSFM
MW]VY5O8W$,HZ=@Q+97/CAK"L)".I ;R[K1830&/Q^AI=+6I7W:,O.'N>T!WM
M.+NGO!/3[$E)-R[?4D8M**?#T*]K:;U_F<9%D<[K^#'4I&>,^.DT-#&$;[<P
MV';[5W_)_;&S$ZS9#;=<8VX\"P\[ND')](_:LZEP'QD,[6V<[EK./:=Q3<_9
MFWH?=]RF&CM TM*39KXLG>*F1((K\H#8=AM[)\U92522XHD8NTWP(M^3;D*<
MW#QE6*6,6:]B42LW',-SN#^!6-#9@RWY1#7XQS964*+F6I&=1S$  $__ ,]E
M['@9BFXBK6JY:_4N0\P-N#9CI&DD[. []_5370>A\7HN@^#&-?)-*=YK$O5\
MA]Y5;BY9O?(14E'+[WLDX*JG'_\ ^1>2_P"4-_S-5K[*,P:0ABU[8U0+4AGF
MJBJ8"T<H (.^_??HN<73OO\ L;DKC2[/N0W@BT?'_$ [=3F']?O<L;4X_P#[
MA],^OP)_['J=Z.TA#IF[G+,-J2=V4MFT\/:!X9._0>HZKRR.BX+NN\=J=UN1
ML].$Q-@#1RN!WZD_>M)U)/L_%"M)+F_S9*V]E4M@ _E'5]P#MB';?BK; V46
MDT?"_7[-5?"I!.RJ:O@<HY=M^^ZS!T[?;]A-7&EV?=$(_*4_BOA_7XRB_P"Z
M\^*LC*VO^']F=P9 VP&E[N@!(/[U.>(6C(=9XVI3LVY*S:]AM@.8T'<CRZKU
MUOHO&ZPPC<=E.=H80Z.6/H]CAYA:C+*EW^A)1S7W$;X^6X&\/Y(C*P236ZPC
M;S#=VTS2=ON!*U?%L!VH>'(<-Q\8L[_8%Q6X&8UE65EO-Y*Y9W9X4TYYO! <
M''E:3Y[;;^A4UU1HV'/W\!:FMR0NQ$XG8UK0?$(VZ'T[+2<8UKQ,.,I9M-U1
M&?RB1_\ JPN__-C_ ,RDQ '#78  #%]O_M+VU[I6+6&G)L18LOK1R.:XR,:"
M1L=_-;'XI9\GOBGQ7>'\&^#>)MUVY>7=<G^QQ][';_)/D5%IS5$NDOR=\7D:
MT39;3MX( _Z(>^5X!=[@NK]+:[O8\7M2<1(Z-(Q^)(VFT-#6D;[;CE"L"CP_
MQL/#Z/25R1]NBUA;XC@ [<N+@1Z$$J(X[@3C(++/A^<RMZBP@MJ2/V9L.P/J
M%U<DY2?:<LK22--P(+#PRU3X4KIFBW+M([NX<C>I4N_)X '"S&;#NZ0_^9;;
M2?#ZIIJAFZ-&U(:F2D,@C+ !!N-B&^O39;30FEXM(Z:K8>O8?8CA+B)'C8G<
M[]@HY)WVUY%C%I)=K\RO]!.8SC)Q!=)T8&Q%W3RV.ZT X>XG4EBUFN&.J9<9
M+XSO%C:YP8).YV V('7WJUL%HV#$ZMSF>9:DEERO+SPN: UG+Z'S41SO!'%7
M<K/>Q65R&(=8<72QU7;-<3Z#ILBDM.XLHW?>>7"#/ZD&J,UI75EV')3T(FS,
MMQ$$;$@<I< -^^_7KW5MM<.H\PHMH'0N+T73GBQQEFGG=S36)SS22;=MSZ+T
MT]I,X?4>9RWQG:L_&+@[P)3[$/N;U4DTV(II$F+P.YZH7 =U%M1:0.9U1A<S
M\:VZPQKN;X-$?8FZ[^UU6=K+3YU+I^QBQ>GH^-M_#P'9[=COT6.!KB;P'<;A
M%B8BG\78NI3,KYO B;'XC_I/V&VY]ZRU65!$10!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!/)$0'S_P 96-EXLX5CP"UT,0/Z
M;E:7%&M-/H',1502X0$\H\VCO^I8NJN'E;4.J:>;FO30RUFM8(VM!#MB3W^]
M35T8>QS'@%KAL0?,+T3Q$X02W7J>3"P9+$Q'+:5?8^<.&V(S63TZ7XG6PQ,,
M3W<]3J.3_B[^:E7"[ 5\)F,GFH]34\P17>Z9D#?;)[DGK[BMGF>">%O9"6S4
MNVJ39'%SHHP"T?9Z!3#1^C,5I6A)6QT7,91M++)L7/\ M]R[8O2(RBW%[\*7
MW/-@=$G"45..W&W]BI].ZBU+Q O9!T>HZ^ H0$$QQ- D+23V/<[ =3NL'A3&
MR'B]=BCNNOM:R1OPEYW,IW;U4VO<$L'8RCK,5NW! ]Q<ZNS;;OV!\@MKBN&&
M/Q&J*^8Q=N6L(F!GP=K06N '7<^_9:Z["2:CHFN7Y,_IL=M.:MIW=_C@5WI2
MQ'AN/.3&5>V'Q7S,8^0[#=VQ;U]X5IY_7V PN7K8^W,^6U.0&^!'XG*20 #L
M=QONNFN>'6(U<]L]LR5[K6\HGBVW(]#ZK6Z1X28;3V2COOGGO68^L9F V:?7
M;U7)SPL11<[M*J.\</'PI2CAI4W=\OH0[C  _BGIC<;@MBZ'_P"85)ORA /D
M(.G_ .TL_P"ZWFJ] 5]0ZFQV9FNRPRT@T-C:T$.V=S=2MCKO2D6KL*,=8LR5
MV>().=C03T^W[5%BQ2P^S?Q-2P9MXO\ ^EIX44OKJO/+P7TG-$UQAA.\NW8;
M@@$_?^U96-P69MZ2AMGB)'!BW0AKHG@[1MVV+"-_+LKCQNEJ=72<.G['^ETV
M1>"3(T;N'K]J@+^!6&-HO;D[K:Y._A;#\-__ $76/2(/,FZUO:SSRZ)-99)7
MHD]:-/6TK\4\(]3Q8_+ULO'-RRAU8$!O*1N.Y\@MUP"R^/CT1)7DLP13P3/=
M(U[@" =MBK'PV"H8?$1XRC QE1C>7DV^EZ[^I*KW(<$L':R;K,-NW6@>=W01
M[;?8#Y!8ZZ,U*,WOQ.OZ>>$X3PTM%57S[2)Z#N5\AQWO6J;@ZO(9BQS>QZ=_
MU+Z"4!TWPRQVG]5#,X^S*UK8S&VN6CE&XVWW_6I\N?2)QFXY>"HZ]$PIX:EG
MW;;.O+]B%OFNR'LO.>LI'-:MS^HM?VM/8/*5L+7K\S3-*P%SRWOU/V] -NRA
MF8J.H<4L1!-FY,S8;-%XMAYWV=S?1[__ ,[JV]9<)L3J3+.R(LSTK$G^L\(
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M]PV4>@J_ N,V&@=F9,Q*V9GB67NW/-L>GW*S-5<(,-G<O)D&6;%*69W-*V(
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MKL!MNHI5&O=;_<KC<K]WM]B#:YUM<?DSI?1,0M:@E'\+.=O!I-[%SSZCT_\
MZ+:\/-&U]+5));-CX?G+9Y[EZ0[NE=Z#?LT>BA<W >%^1MW8]4Y6&:S(9)#&
M TG<[]2#U6PT_P '78?,U+_RKS%GX._G\*5QY7^X]5J.6JLR\UW1KXZU+-\=
MLO!J@13LIU(SCZ]@^QU(W< >A/[UQQNQF&PV/Q>4PT%:EGH[L+:[JP#'O!=U
M:0.XV4UU_P .\3K/P)KCYJMZ#<1VJYY7@>A/F%I-)<'<5A,O#D[^1O9BW!UB
M-MV[6'UVZ]4BUI;V$D[=+<LNJY[ZT3I1M(6 N'H=NJ]$"+F=$$1$ 1$0!$1
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MD%4<*EWHE:**?)>_]8+B?)>_]8+BE+F:Z[%^6_%>I*T44^2]_P"L%Q/DO?\
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MZP7$I<QUV+\M^*]25HHI\E[_ -8+B?)>_P#6"XE+F.NQ?EOQ7J2M%%/DO?\
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M,M^FP^\=#]ZDBE%L(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M\O?:$1%"A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M9]&M R('UY6@?]EGK$JMT:A>56$1%#01$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!<%<H@/,1-:]SVL:'N[D#J5W;V7*( B(@"(B (B( B(@"(B (B( B(@."
M.JZ,C:S?D:&[G<[#;<KT1 !V1$0'F&-#G.#0'.[D#NO1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MM.>UEVUS,'",F*%G7VW./3IZ("P-PFZTVDK<U[3&+MVG\\\U=DCW;;;DCJ5
MLOQ!NVM::?Q^$KSQ8B>Z:]BW-%RB9P!W8S?KL-NI6LKS93.95F+6W3<* :^S
M.<=G,7IS2LL%?(VV/GELS-YA#$WIN!ZD^Y8VD<QJ'$ZP^3.KKE>\^Q7-BG;B
MCY"_;?F:X=!N/L446T'*BR$7#5SNH:")NB (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B +#OMO$L^ N@ Z\WB[_=MM]ZS$0&HY,W_XE'\'+,H-N!K_ (>87'?V?"WV
MV^]9:("'ZQO>).VHP^RSVG?:LW1]_P 6JZI(?;BZM][5ES:>I32ODD$A>\[D
M\R]*6#J4[+9X/$#V_P#$@/2XW)&;_0WUA%M_\3???[EX<F;_ /$H_@Y;=$!Y
M51,(&BR6&;^<6=ON7JB("%<9+4]/AWEY*SRQ[HQ&7CNUKG $_@5[/L8_1.B(
M)J.+L6:L,<;? H0\\C]]AOMTW]25),MCZ^5QUFC=B$M:PPQR,/F"JUCTQQ!T
M_&VCIK.8ZYBV^S%\9,<986>300.NP]55LT9>]G;1.H<;E9=3S::Q5O#Y5S63
M3-RK?!CYB-@XM!.W3OTZJ'9K4F2PM5N6I:]DS-V*9C9Z<5;FJG=P#FAP&P&Q
MZ'=3F/AU>N87.MSF8=9S&6C8R2>-H9'&&'=K6C;LM%E=":]SNFI,3E<QBH:]
M=K1!%586B<M(Y?$.W0=/+S6U5^!AIUXF;F)M1YKBA9PN*SLN,Q_Q<R>0L8'.
M:2?YN_8GU6FR#\]9TIKS3^4SDUA^)8)&7&L ?+&6DF-WV[=3[U8.)TU?K<0+
M&=G=!\'EQT=7E:X\W.""?+LL*715VQ>UJZ2:%D.;A;%"022W9I&[AM[UENE2
MY>=E2>[Y_@AGQW>TKPYTC09GQ7ERL;'?#[; X58O#!Y&@=]NP63I35[L;K#%
MXN'5HU11R9=&[G9RRUI -P=P.K3U&RW%30^HYM(XJM<R%.MGL,\-H6:X)88@
MT- >"/,=UM-*X36<F7BNZMR]1L%<$1U,<TM9*3_.D)&Y^Q=&XMMF4I))$-T[
M7UCJ+2^1RYU;8IBI8L"O%'$T\X8X_3)[CIMLLO-:^O/TCI)K\I7Q%G,L+K.0
M>SF$+6CVBT?TB>@4ST?IJ[A]%W,3:="ZS,^RYI8XENTCG%N_3WK2C0.4BTAI
MZ&C>AJZAPS289A[43MQLYKNG5I"Q:X]AMI\.TT6D]5OIZDBQ-;5ORFIW()7"
M1[-I:\C6[@[@;%I7OHE^H\EIN_J*_J&R8J\=N.*HUHY7<O,&O<>Y(/4?8%(]
M-8364]R2WJS*4PUL+XXJE %L;G$?2>2-RMAHC3%C$Z.EPV3=&]TKY^<Q'<<K
MW'U\]BDGHZWH0NU>UFB^.LB.!4>7%R7XS.-;,;&_M\^WTOM6MOW]0Y+6N$Q&
M-S$E.&WAFSSR<H>6G?J]H/3F/;=> X?ZU=I>WIF3,T/B6*(Q5"UI$LC?YK7G
M;H!T'12O'Z3OU];XK+O?!\&JXH4GM#CS%^^^X&W9:=9F_>S,)2I+EZHB6#AU
M=ELIG],OU3-%'B7L<,@V%OCRA[=VM/EL-B2>YW61CL]GK>@7&?4%#'3U+\E2
MSD[0V<Z-CB-V-[%YV4PTWIRYC=7ZGREAT)KY(PF$-)+ARM(/-^*B-CAWGH\9
M%+CK=*/+5,I/>KB4%\3FR;C9PV[[%933W[/$VXUM[1KM+:DNT-?8?%UM3V=1
M8S)MD+WV8.3D+6D@L=L-PN=%X'4F8H99^,U&[$5HLE8,$<,0<9'<YW,A/EOY
M!;2IHO6-O5^G]0Z@R6/FEI/>V2M "V..-S2-V[C<N/O76GH[76&CNQX#,8Z*
M*[;EE>R=I=X+7..SF';OMY'S6FU]?[,I/CM_1+^&>H+.HM*PVK[6B]%(^M8Y
M/HF1CBTD?;MNL#3KSD>)>I+$O7X!'#4A']$$<SOQ)'X+?Z-T]#IC3U7&5WNE
M\,%TDK_I2/)W<X_:2M%CXCA^)V2;(.6#,UV2Q.]9(^CA]NVQ6=,SHTKRZFG;
MI'6E7*YR[BL]C*0O7#:#?@QF<]H:&M:YQVVV \@>_=;K35KY>:-?%F8W03-F
M=6MLKR%H<]CMCL1UY2M5?TYKG&Y&W'I7+T78JW,Z;;(<SY*Y=](,/IY@*8:.
MT_'IS!Q462NFDYG233.[R2..[G?>5/\ $5\1#N%=:#'7]<5:4388(,DYD<;!
ML&@,&P"].#M2O/H>X9HV.=;LSF<N /.2=CNM]H_3UK#Y34MBVZ)T>2O&S$&'
M?9A:!U]_11&QHK66*M9"GI/,48<+D)72/%AI,E<N^ER;!5NU7-+[()4[Y-_=
MF^X,.)T+!&>K(K$\;/ZHE< %I9FZDU!KK4N)H9Z7&8^LV%P?&P.>TEIZ-WZ#
MWJ>:1P4>G-/4\7"XR"!OM//=[B=W./VDE8&!P-NCJ_4&4F=$:]_PO"#2>8<H
MV.Z-K,V$GE2*[QC]8Y_2F1O/U,ZD[#RSP,,$(WM.B)]N0GR/;8>FZV4FH\YJ
M6AI+&8RZ,;;RU0VK5MC YS&M !#1ZDE273FE[V-TIG<;.^$SWK-J:,M<2T-D
M)Y=^G=0O4.,=IC":/A^.*N,U+1A=#!/,UQK2C;VF.=MT!Z;*II[]GV?Y(TUM
MV_=5Y&UT\-1X7B?1PF5STV4QTF.EGC,C UQ<'-'M[=R/(^]9G'.>5NF*54/<
MRM<OPP6"/.-Q.X^]1GA]-E,MQ9CO93+4LI/!BWME- $P5^9[>5@/J>I5LZDP
M=/4.&LXW(LYH)F[;CNT^3AZ$*2TRW[U98ZYDO>AD4Z%6KCHZE>")E1K P1AH
MY=OL58<.\74GSVN-/RP,GP4-N-T<#NK&N=NXM'W^2QLOHGB'9KU\5%GJ$F/K
MO#H+SB]EJ/;L=V]"0.G7NLO"Z6UAC-%YK!U!2AR4KRZ/*"4[V"XDN<[IN';(
MM+=^[1-Z5&=KB2#5.2H:2PT;)75[$5FY99L64XXW;ANX_GNVV ]-TDN-TQKC
M53WGE@MX]N0;_78"UW_9:C2^G>).GZM>E1&EH:;7 R<C7\\GJXGS<?4J1\3-
M%Y#4\N)EQT\,$D3S':+R1SP.VYFCI[D:2TOW[H)MZT17!T9--YC0N4<"WXSB
MEK7#MMO)(?$83[]R0I9PGA%BMF<\\?PF5O2/!/\ X;'%K/U K9<0=-6<[I&3
M'XJ1D%^$QR5)''8,>PC;M[MUE8_'S:?T5%1I&(6*=,-8YV_)SAO4GSVW1ST;
M]UO]RJ&J7N]B0*MM!0QY'B'K?(W6-?=K6F5(2X;F.(,!&WIOW4TTI8O7=.T+
M&6:UMZ2%KI@P;#FVZ[#T4:U5H[*.SLF?T?DF8_*RL$=F*8<T-D#Z)</(CU"B
M^%M,KU6A&M8:VT_8U#2JYO3.H!+1OL;7N_!PR,2;[ A_,-VG?LO#4%_4%'C)
MD'Z7Q=;(V'8R,2,GE,8:WG[C;W[+:LT=K'4DU4:VR]&.A6G9.*N.C(\1S3N.
M9SA^Q26EIRY!Q(O9YSHC2FHMK-:#[?,' ]1MV6HTJ^OV,--W]/N0# 7<]Q!U
MG3BS];'X@Z>M"Q+58YSK#W;>SMO_ #/?NL#B%JK3M[B!DZ.H+,@IX^BZK (X
MS(/'D&[G=.W*.4*Q=::5O7,WB\]IQ\$&8J/Y)3*2UL\!^DUVPZ^Y9G#C2\FF
M=-,JW7LFR,TK[-N4'</E>=R=SY=A]RB::OWJ:IK0AFB=0LSO!?+L,IEFHU9Z
MKG.&SG-:T\KB/+=NRG7#]K7Z"P < YIH0@@]=_8"T65T;D/E%G[6,?791S&/
M=#-&YQ!$X!#7[;=MCU6AQ&$XJT<74QD5W3L-6")L#9&M>Y[6@; ]MB>BK:E?
M;7Y)3C79?X([::VGI[BQCJHY:$#^:)@^BPNZD#[U>>-(^)ZI\O ;_E4:P>@J
M5#25["VY'6GY%K_AMAWTI7NWW=^OHHS%IOB53KMQ%3/8J3%M;X3;<L;OA#6=
MAY;$@>:DM5E[OL6-K7O^YWT=FX=.\/\ 4N5G(Y*^1MN ]7<^P'XD*L\7K'"8
ME^E,G1N3OS,5A[LF'0N:)FSNWDW<?Z)/3[%;-CAU(,/I[!PSMEQ5:T;>0?*?
M;L/&Y'3;S<=_N4VS>(@RV%N8VQ&TPV(71$;>1&RN91=[_P!>I,KDJ]Z^AE3O
M;)2D>P[M=&2"/,$*'<%A_P#JWQ._7_6_]5ZV^C,9D\;I&KC<O)%+<@C,/B1N
M)#FCHTGW[;+KP[P=G3ND*.+O.C=8AY^8QG=OM/<X;?<0LZ*TNS\EU=-]OX*T
MP^3U;0U7JQFF,'3R-=UQID?/.8RUW(.FRL?1.1U+?9;.J<15QKF%HA$$QDYQ
MUWWW[;=%#I-.<0<3J#,V--3X,4K\XFVM<Y>"&@>0]RE&BH];MNV#K"3$/J^'
M_!"D'!W/OY[^6RJ_:NY#7,^]_<DF6Q\>4QT].=\K(IF\KC$\L=M[B.RKKAIC
MJN)XDZWHXZ%D%:%M0-8WL/X/]NZM,=E$=/:<N8[7.J,Q.Z(U<EX'@AKCS#D9
ML>8?:LQ=7W%DKKO);N%6?'*"*UCM,U[#&R02YNLR1CAT<T\P(/W*5XB[DY=4
MYFK;$)QT#8C7<QI!W(/,''S/V>JPN(6G+FH8\&VDZ)II9.&Y)XAVW8PG<#;S
MZI']R;[!+6,DN3^Q$*5M^F:N>T7D)'.B;4EGQ<K_ .?"6DF/?S+?V+QFRTV,
MX?Z1\#5U'3A?3;O\)KB7QO9';KTV4SXFZ-9J_!/AA<(,G""ZI9WV+'>8W'78
M]BLS3NF:]?2^(QV:IT[D].NV(F2-LC0X  [<P53TM[Z?DC3NEMK^"!Z+U)8L
M:@KLL\2,3EH=G.=4BIB-SP 3]+?IMW4=XC9K':MTIJ+,39"H8J\)@Q=(S-YR
M>8!TQ9OOS'L/0?:KMCT[AXB3#B,?$X@M+HZ[&G8]"-P/10G6G"; 7],Y"MI_
M"8RIE)6;03EG+R.W'7<*YE=A19A:Q$LU'26H\/5&<JXO;QZ]9PD<?9&[F[="
MX;=EJY-16]1\1](78\)=Q51SIH ZZP1S2_P;B?9&^S1T[^:E^6T+-%IO&UM)
MV&8>]0>)HQ$2(9'[>T'@=P2NNE-*YZ74$>?UK=J6,A!$8:T%1I$40/=W7KS%
M:M6_J9IUX$-T_F,CI#$W]*6M)9*W<=)-X=N",&O8:[?VWO/;W]UD:,J29/\
M)^NU[#MI8HYW1.:?H.8XN:6GW$+;6=(:WJVKN/PV>JG W9'O<ZUS/L5VN[M8
M?3TW6TU;1CTOPPFPF&876)XO@-1G=TDDAVW_ %D_<LMW%UNZ-152UV5DCT+D
MI,OH_#9";_6V*D<C_P"L6C?]:WJU>EL:W#:=QN-;VJUXX=_4AH!_6MHI.LSH
ML+RJPB(LF@B(@"(B (B( B(@.I;N"' $'R5<GIQXC_Y,?^H%9"TQTY2.J1J
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MJP3.;V,D8<1^*R&L#6@-  '8!=D04!V1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 7!*Y5<\<]17,!I./XME=#8MS>#XK>[&[$G8^1Z+
M>'!SDHKB<\7$6%!SEP/+"G?CIJ';\UU_\SE98ZA?$U3*7Z=X7:UVQ'<!W\9L
MAYC]I\_O7USP_P O-GM'8K)60!//""_;S<#L3^I>CI'1GA).[/)T/IJZ0W&J
M9($1%Y#WA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MWF2WU/GLI=A<33PN,@Q^-A$-6%O*QH_:3YE2_AHM?%9!^'(/QUKT-_.CP/T
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M(<H? -]RT/VW<#[T5*VO>Q=75F++/+Q&R4,%:)\.E:<S9I)WMV-Z1AW:UG_
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M?+_TRK)5;<3?X^</O[?+_P!,K4-S,MBR0B!%DT$1$ 1$0!$1 $1$ 1$0!$1
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M.9>3'6JF0GGC:'.=! 7-&_8;K482FZBC$\2.&KDZ)NBK'YY<+^;<Q_\ AO\
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M!Y';J?/<^Y2P*-5HRIWJ%6W$W^/G#[^WR_\ 3*LAQ [G8*MN)1#M=\/MCO\
MZ?+_ -,JPW)+8LH(@[(LF@B(@"(B (B( B(@"(B (B( N"N4(" ^1^*\-Z'7
M>5^-.<O?+O&X[[%G\W97IP,KY*OH6(9/G#72N=7:_N(MAM^O=3NUCZ=MS76J
ML,Q:=VF1@=M]FZR T-    '8!>K%Z3UF&H5L>' Z'U6++%S79R.R(B\I[@B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MJYA/_8E>[+)X,HR6U,^9GBND1G%Z.T7\.R(.R+PGTPB(@"(B (B( B(@"(B
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M'XF@K+.4N!GA! &^_P#"!3F.*.,;1L:T>C1LN7QL>-GM#AZ%,VW851W[2O\
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MS^/G#[^WR_\ 3*L&]B32W+);V1 BP;"(B (B( B(@"(B (B( B(@"(B (B(
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MQ]F+(Q-K9C'R>!<A'9KQOU'N.VZ\;7$C3=7 ULL;HEIR%K7NBV<Z+?S>W?<
M'OT5>4V9K)XK5VH=+TI++,Y:9% R.4,>8&[M>\$]B1V^U:J[31G:FG[U)2S6
MMW*<4,10QKBW .;9B=)R_P"T2QMZ[?\ ".G5;S1N7NR9W56-RM@R.HVQ)"2
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MC<+V4;X;^+\A<%X^_B?!(]]^_921)+*VBQ=I,(B*%"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"K;B;_'SA]_;Y
M?^F59*K;B;_'SA]_;Y?^F5J&YF6Q9(1 BR:"(B (B( B(@"(B (B( B(@"(B
M KGC5KJ]H7$X^WCJ\$[[$YB<)2=@ -^FRL.N\R01O/=S051_Y6'\6<)_:W?Y
M5=U/_9(/ZC?V+37PIF$WF:/5$19-A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%I+!ZJ@B^/L7#8>T#E+NCV>[F'52)%+%&EH:;Q&/PDF(HT(:^/D:6/AC'*'
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M_P"F59*K;B;_ !\X??V^7_IE:AN9EL62$0(LF@B(@"(B (B( B(@"(B (B(
MB(@*,_*P_BSA/[6[_*KNI_[)!_4;^Q4C^5A_%G"?VMW^57=3_P!D@_J-_8MO
M]J,+]S/5$18-A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M8Y@>-^5PZA>O.SFY>8<WIOU0'9$W1 $0(@"(B (B( B(@"(B (B( B(@"(B
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ML#2X",[ JXE6W$W^/G#[^WR_],JPW,S6A9([(@19-A$1 $1$ 1$0!$1 $1$
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MS=4!E(N X$;@KG= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M( B(@"(B (B("C/RL/XLX3^UN_RJ[J?^R0?U&_L5(_E8?Q9PG]K=_E5W4_\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(#C=:EFHL<_47Q
M&RRU^2$)G=$WKRL!VZGR/7LLW(026J,\$,[Z\DC"ULK "6$^853Z6TY4TWQI
M%:FZ61\F)=+--*[F?(\R#=Q6HJW3]Z$;:6GO4N+R41U+Q#T_IW(? <C:D=;
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M8P0T CPW^GV+3PIM)4S*Q\--O,J[R=(H5\Z.D/SU'_=O_<GSHZ0_/4?]V_\
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M3Z/Z(#9(NK'M>-V.#AZ@KL@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MBJ@^:3+?6J?_ ,_[T^:3+?6J?_S_ +TZO#_GY,=;B_+\T6_N/4?BJBXBG_\
M7%I#_P"S_P!8KK\TF6^M4_\ Y_WJ-3Z;LZ9XG:8JW,@^^^6:*42.W]D>)MMU
M/N73"A!-M2O1G+&Q,222E"M5Q[3Z;"($7S3[(1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!6N&_ETU#_P KK_YG*R@JUPW\NFH?^5U_\SE906I;F8A$
M19-!$1 4A^4CC'>%BLK$-C$71N<!U\B/UK7\7*PS&@]-:IK@&5C&1S/'?8CI
M^#@?Q5E\7L;\9:!RC&MWDB8)F]/-IW4(X:,;JG@UD\(X[S0>)&T'R_GL/XG]
M2]^%B5AQE_%^3/E8^%>+.'\E?U19/#_,LSND\==#^:1T362>YX'52)4A^3AE
MRQN4PDY+9(W>,QI\O)P_8KO7EQX=7B.)[>BXO6X2D$1%R/0$1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 /):"SI\B5TU"W+!(3OL3TW6
M_1 1L2YVB?X:-EN,>;=MUETL_#/,V":&6"9W0!PZ;K<KH8V.<'.8TN'8D=0@
M.X1><[#)"]C7%KG @.'DM V#-43_  <C+3!Y./5 2-%'V:A\%W)D*DL!]=MP
MMM2R%6YO\'F:\^GG^" RD1$ 1$0!$1 =7,:X$. </0A8%G#4+&_/68#ZM'*?
MU+8H@,>E4CIUVPPAW(WMS'=8&4DRL-D.I11RP;#=I[[K;H@(^S4)B/+>I3PN
M'<@;A9U?-4+&W)8:UQ\G=#^M;!S0X$. (]"L&UAZ5G?GKL!/FT;% 9[2' $'
M<'L5RO.&)L,+(XQLUHV"U-Y^7AM/?6CBE@_FMWZH#=(H^-0OA.UZE-$?,@;A
M9U;-T+! ;8:UQ\G]$!LD0$;;CLB (B( B(@"(B (B( B(@"(B (B( B(@"(F
MX0!$W";H B;IN@")NB (B;H B)N@"(FZ (FZ( B)N$ 1$0!$1 :75^ BU+I^
MWBK$CHFS <LC>[' [AP^P@*$1Z'U;EK&/JZMU!1M86E,R<15JY9)8<P[MYR>
M@&X!.RM%%4ZV(TGN:BU#F#GZDE:>HW#MC<+$3V'Q7/\ YI:>P"A]S1^J,3E;
M]C16:HUJE^;QYJMZ O#'GNYA'7KZ%6.B)T&K(QH72QTW3MFS<=>R5Z=UFW9+
M>0/D/HWR \E[Q82>75<F7O21O9##X-.)F^\8)W<X[^9Z?@I B6[L5I16E_A]
MD9S?Q,-ZHS35ZZ;TK3&[X0QQ()8T[\O*2-]SUZJR8F!C T=   %V1+TH5K85
M;<3/X^</O[?+_P!,JR56W$W^/G#[^WR_],JPW)+8LD=D0(LF@B(@"(B (B(
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M-\>''$^A.C?]6+/!X;HE"(B\I[PB(@"(B (B( B(@"(B (B( B(@"(B (B(
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MI_DXRWV-_P P4Y4&XT_R<9;[&_Y@NF#_ .D>\X](_P#*7<S,TA_%;$_V:/\
M8MNM1I#^*V)_LT?[%MUUENSC#]J"(BAH(B( B(@"(B (B( JAXB_RQ:0_P#M
M?]8JWE4/$7^6+2'_ -K_ *Q7; _<^YGFZ3^Q=Z^Y>@1 B\)],(B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B TFMX76=)9:O';@INFKOB$\[N5C.8;;D_>JVRND,GI'2
M0S-#5V3DN8RLUS87.:*CVM'T!&!V(\]]U;.6QU7+8VQ0OQ-FJV&&.1CNQ!5?
MU>%+&V8X[VH<I=PT1!9CI7^QT[ G?<@>BU%UQHS)68EK(NRNL.'&1NL$3+-6
M>3E/82NC!V'W;K(XE$'B#P_;#_M(NO.P[\G)[7W*5:OT?0U+B(*-ATE<UG!]
M:: \KH7 ;#EV]RU6D.'L6$ROQKD\I;S.3:TQQ3VO_A-/<-&^P^U:4E=\C-.J
MYDX;YJ,:WR>IL=\#^2NGXLR7\WC^);9!X6VW+MS'KOU_!2@#9"%S1MJRG>'=
MS,7N+N?FU%BX\7?..A!KLG;, WF.QYATZJX@JUPO\NFH?^5U_P#,Y64%J6Y(
M;!$19-!$1 %1OY1F+=#-A\[ W9S'> ]P\B"7-_[J\E!N,^-^,N'F4:T<TD ;
M89_])W/ZMUVZ//)B)GFZ7A]9@R7O0RLG7CUIPY>R/:1UVH'L/_'MN/UA0'\G
MC*/J6,OIN\XLL0O\:-A]WLO'X['[UO?R?<J;VBW57NW?3F,?7R:0"/\ NH-K
M9S]%<9:^5CW95LN;,[EZ M=[+_\ N5Z(1_?@?5'DG/3#Z3]']3Z)!1=8W!S0
MYI!:1N"/-=EX3Z@1$0!$1 $1$ 1%XVYQ6J3SN!+8F.>0//8;H#U+@.Z<P7SA
M@9-2<3\OD"S/G'01'F9 'D; D[  ;;]NI6WHU]:Z%U31@EFN9G%2N D+&ND:
M&[[$]>Q'=>I]%KX7)9N1X5TVUF4'EY_T7P7 #J@(/95EQ]MV*FBHY*D\L#S9
M8.:-Y:=NOF%Y:5X@X3 Z-PL>:R+GW7P N:-Y']SU<N<<&4H9USH[2Z1&&)DE
MII=EIHM=B,U0R^-;?QUF.>HX$\[3VV[[^BQ\%J?$9Z6>/$7HK3X/]8&;^S^(
M7/*]=-CMGCIKN;E<;K3S:FQ$.;9AY;L;<D_;E@(/,=QN%5_$'B7+3UC1QF+O
M11T(I6BY*!N0=_::>G[%O#PI8CI(YXO2(847*3V+HYOM3<*O=>\0Z.*TBV]A
MKD$UNTW>H"#L\!W*YPZ>7O7EH;5T.=T3-'-D6SYEE222=H!#FG8[%.IGD<ZT
M0_48?6+#3U>I8X<#VZH' JE_R>[EJ[C=1?#+<\I:]@:Z60NY06N[;K=<*:L4
M&9S;H]2C,%SNL0+_ .!]H_TOPZ+4\#)*46]CGA=)ZR,9)?NOB6>.J*.#6NG@
MV\?C2OM1_P!HW)')UVV]YW]%C:=XA:=U!=^"8Z\#9)V:R1I:7?9OW7/JYU='
M9XL$ZS(EB+5Y_/X[3]$V\M997A!Y07=W'T \UH\7Q)TOD:EBQ#DF1L@&\@E:
M6N WVWV\U%"4E:198D(O*WJ3!-U@XC+4\Q19<QD[+%9^X;(W?8[=^Z[Y4<V,
MM@R^"#$[^$_H]#U^Y1IITS2:DK1E!P/9<JM.#=>*K7RGA:C&;!D:2[=_\%T[
M>TMIEN*6E<9;=6FR(DD:=G>"PO /VKI+":GECJ<8X\<BG/3ZDW1:C3FHL9J*
MJ;&(MLL1M.SMNA:?>/);<G8+FTXNF=HR4E<7:.-UR#NJ7UUQ-DJZVH8S&W(H
M\9%-&+DP&Y&SO;;VZ;#T5CV-8X"KC:N0GR4+*=IW+#*=]GGW=%T>#-).MSC'
MI&'*4HI[$A11F/7.!DU#%A8KHDOR?1:QI(WVWVW]=EXZEX@Z>T[;-7)7@+(V
MYHXVE[F_;MV65AS;JC;Q8)-N2T)8BCNF-9X34O,W$762RM&YB<.5X'KL5[6=
M686ME7XRQD(([S&\[HG$@@;;[[]NRCA).FM2K$@UF3T-XBA=+B=I:YDQ1@R3
M?%<[E:YS2&./H"I%F<WC\+1-S)VHJ]?R>\]_</5'"4=T(XL))N+6ALEQNH)3
MXLZ2M61"W(F,D[!TD9:W\5G<1=35\#I6S:;;9%9GC<*A[\[]MQM^U5X4TTFM
MS*Q\-IR4E2);S#?9<KYPX1FYFM25+=O5,PLME+G47O>73- W/NV5S:EU[I_3
MD_P?)WFML;;F*,%[A]H'9=,7 <)9%JSE@=*CBP>(]%WDI1:'3.KL-J6-SL1<
M9,YG5T9Z/;]H*[7]5X6AEVXNYD(8KY <(G;@[$$[[]O(KEDDG5:G=8D&LR>A
MO$44Q/$'3N5%\U+P+*3>>9[F$-#?4'S"Z7N(VF*>-BO/RD3X)7%L?A@ESB.^
MP[J]7.ZIDZ[#J\R)<BBDW$'3D.$@RLF1C%6;<1C;VR1W'+W6=I?5>(U-7?+A
M[39O#.SV$<KF_:"CPY)706+!M)-6S>HHOJ;7> TW,(<I>:V?OX3 7N ]X'9=
MM,:XP6II'18FZU\[1S&)X+7;>NQ[IU<LN:M!UL,V2U9)B=EQS!4UK[B7)3UG
M3QF.O114(9 +DK1N003NT]%M^)UFAGM,8VW4U,S%U'S$LL@O EZ'ITZK:P)5
M%O9G/]3!N2CJXEGCJBC$.?Q6G=.8IV5RD?A/A8QEE_-M*>7O]_?JI"RQ&^NV
M=CVF%S></WZ$=]USE%H[1FI=Y[(M-A=3XC-OL-Q5Z*R:_P#K2S?9OWE:"[Q3
MTI4OFI)D0Y[3RN>QA<P'[55AR;I(R\6$5F<E1.$6-0O5[]2.U2F9/7D',R1A
MW!"UV(U3A\OD)Z..OQ3VH-S)&W?=NQV\QZK.5ZZ;&LT=-=S=(B*&@B(@"(B
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M>Y_8I2O.Q!%9@DAG8V2*0%KFN'0@^2;;#O*^;F*&IYFR9+*U:F+#_P"#I^*
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M_'8OQ?@[<="\>+(7NW+COU*N(*M<-_+IJ'_E=?\ S.5E!:EN2"I!$19-!$1
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M&H,M:E9+5RM:.N8.7J UNQW/O4=JZ$U5C8/BO#:P=7P8W:QCZX=/$P_S6O\
M=Y%3->O&E^1E>W"S1ZJ^.<U3X;PY0V,9D[-IT=@CV7M_@MG'W$]5XSZ*9B.(
M%33V,RV3@QN5J/FM@V'.>\L([.[@G?JK"R>D'V+>DWPW9',PDQE>ZPXR23>Q
MR]7'S\UDW]-R6M=XW/BPQL52M) 8BWJXN(.^_P!R9E?C_1<NGA]R'Z"QC-)Z
M_P!2X&C<L?%3:$-QC;$A?X3R7 D;^73=5YE*F R%2_;KC5^=RS0^49.NQT<
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M6E3T'>HV)PVW>:(JT6Q)D=N.@6I:M5[U)A_#N:?(R/\ COA2 ]VSF2<W7O\
MP([K8:WD<WB[HAC7$-+9]P#T/19.6T;9SVF-,RT<@_&9C%1LDKS\G, 2P M<
M/0KQI:!S#]5X7/YO/-OW*8>)&B+D9RD; , [>\GNM6LW<V8=N.G)%;ZDQ[8,
M_E;&ML?J5\C[#W5LKCI3)#$S^9LT'IMYK=Z\Q6*U-I;1-QV2FR@=9BIFVUSH
MS(UWTB6^3NGVJ73:'U)C[EMFE]3MIXNU*Z5U:Q7$IB+OI<A/E[BO2]PWY-%4
M,-A<BZO;HV&VX[4K.;FE!W)<WWJ1DDEV5_8E%MOMLG6,I18VA!3K<W@PM#&\
MQW.WVJIJ&EX>(VH=29#/7;PBHWGT:E>&9T8A# /;V'F25;&*CMQ8Z"/(S,GM
MM;M)(QO*UQ]0/)4CG<O6PVM<^W#ZJ.FI99P;=:[5,D<KMO\ 6Q>\A9C>9FG6
M4Z:9C.(TMKBGD=16:C(<B8#?V,DI&S>C1WYB.G11ZXW&8>[B<II7'ZLIS?#8
MHY;>0YF12!SMB""=SNI5P^T<_4>BLT?C"TWX5D_AE.]*P<[W,VY9"T^1(/1;
MO+\.]4Z@KU_E!JN.:2K.R:"*&L(XB0=]W[=2=MUU32DK?+[(Y4W%UV_=G77^
M&=J+BE@L<^[:JU7XZ5\_P>0L=(T.'L[CU7GIG3L&F.)-W3=&U;?A\ABS.Z&:
M8NY'\Q:2T^\*<SZ<EFUOCL\;#.2M3?6=%MU<7$'??TZ+B33<CN(,6HO'8(F4
M34\'8\V_,7;[KFG22[_S_1UDK=]WX*HT;0K:-T5K//XH3?#JTTU>+GD+@ UV
MS3MZC?NM>-/F/&QY''8S73M3A@F;>='[$DG?J.?Z!/ZE9N(T'9J2Y^C>R$5K
M3V4=))\%\+ED8Y_?VEA5M$:NAA9BVZTD&$C C:6P 61&.S?$^SIOW6E+C?(S
MEX=YI]98^[J75NB*=Z>UCI+-.5UML+RQ_8%S-QVW*R-.X.'0W%2MBL19MNQN
M0QLD[X)I2\->QWTAOY[*:6]+/EU7@LK'9_@L97D@+)"7/DY@!OS?=YKO>TU)
M:U]CM0"PP0U:<E5T):=W%QWWW44OS^?Z*X_C\64U6KP:QFOY?/XW6%Z=]F1E
M=V.;_ P-:[8!OMCKTZ].ZV^>LYUG!8QY87JUVMDHH8)K0Y9GQ"4<CW#<]=CM
M]RE<NAM0XJ];.CM2,Q^/MRF:2K8KB41N<?:+#Y;^BS<SH6Q?T-'@G9>>S:^$
M,LR7+9+W/<'AQZ>0\@!T"*2T7#0*+MOO(IKC2E+2>C8W8^>W)/;R=1\\LTQ<
M7NY^IZ]MUO\ C:YS,'@>1Q:3E8 =CW'M*3ZVTU'JC3DN,DL/KO);)'.P;ECV
MG=KMOM4,O\/-1YFO2^4&IV7)J5EDT+60>'& -]R0/I.(Z>@2$M4V]G?V]"3B
M\C26Z?Y,"OH^#5^M=:196[<;1AM1AD$$QC!<8F^T=N_V+4:1T<W5VC[LV;RV
M2F?C)IZ=(-G+1&V,G9QV/M.Z]SZ!6SI[ 28K.:@OOG;(W)V&3-:!L6!K W8_
M@L31>EI=/Z?R6.DLLF?:M3V ]K2 T2=A]RDI:.N7F:4==>?D5S;R=?(\,M*'
M4>9R4;9FD25J+'/L7>7<;;@[[>96!H,P8?BCA:^!HZ@QN-R%>82Q94D-FY6[
MAS6DGJ.BF?S<9&K@]/LQ.995S.':]D=@Q<\;VO/4%I7?'Z!S?ROP^H\SJ/X?
M<I\['Q>#R1ACFD;, ['?U6U)6_J<\LJ2[B-:;T-4U;G-8/R]VV*L66D$=>O,
M8P';#=YV[GT4RX0V;4=+-86W9DMC#WG58K$AW<^/8. )\R-]EKFZ!U'C\IFK
M^GM2LI29*VZ>2-\'B,#3VV![.'JI=HC3$6E\2^LVQ);LSRNL6;,GTI9'=W'\
M%B]/HO'0Z5\5]K_)'\\'X#B70R[Y",?DJ[J<P)Z-D:"YI_!NRA>C,M;T_E\[
MF<K*XU\U2ER==I)V'(X[-'O(<U6GKS3GRHT]-CVS_!YBYKXIP-S&X'N/NW"U
MNIM"U\U7T] )?!BQ<K><#_XL0'M1GW$AOX*1:JGW?3_8DG=KO(16Q]O'?-^;
M[WB]?OS7;0YCT?*QSN7[@0/N65PVTAC:?$W5EN'X1XM&=C8MY21_",YG;CSZ
MJ>:FTW)E\W@+T4[(F8R=TSF$;EX+2-AZ=U@4-*Y3':]O9FEDXAC,ARNM5'Q;
MN+FMV!:[R6E+EIO^"..UZ[?DK;0.@:FJ<)FK64R%\,CR-IL$$,Q8R)P>?:V'
M<JQ>#%^S>T#1==F?/-$Z2'Q'G=S@QY:"3Z[ +.T)IB73>&O49;+)W6+<UD.:
MW;8/.X'W+VX?Z<DTOIYF-FG9.]LDDG.T$ \SR[_NHY:-=Q<OQ7WD8XQRXQS<
M96S.3R<==[G../QL;G36MA_P]@%$.&9BQ7%.E2PM//8[%7J4KWP90G^$<W8A
M[6DG96-K?260RV5Q^8T_E&X[+4V/B:^6+Q&/8[N"/N6LPV@\U7UKC=2Y?4/Q
MA;@BDAFC,/(SE<W8!@';KU*L&DM>TDTV].PG&HVVGX&^W'/;'<="X0N<=@';
M=.J^<<8S&X6U3GSS-4Z>ST4K'2Y&8NGKRG?KS$';E<OI/+4(<IC+5&SS>#8C
M,;N4['8C95K+P\U+<H'!Y'58GTX0(S&:P\=T8._*7_=W4PW3+-6C U/@8]4<
M9(ZDMVQ!2?A0^7X-(6&9OBNV;N/+LLC16-^3&L=4:>HVK,N,;19:BCGD+S&X
M@@@$J8U-*NKZZ9G8IF"LS&B@V#8\PV?N#OZ;=%WK:9?%K?)YR2=CH+E1E;P=
MNHY2=SO]ZB?PUV/[LK7Q9N[\61CA@]QX(0O>\EWP>S[1/7_62*"9C3]++\,-
M"6[QG=,ZQ!5);(1NQ[SO]_O4WH\.,[1IV<-5U0Z/34AD+*S8!XK0XDEG/Y-W
M/VK/M: M2</<5@*V29#>QLD<T-GP]V\[#N-V^BWF69R[5^3FXMJNQ_BB+Z@T
M'AF\5=)U@+7AOJ2$_P .[?\ @0P,Z_M]4R.;LZ>;Q/R-'_:HY86QNVWY2YC6
M[_=NIAG-)YK(7M-Y6MF((<QC(W13R&#>.=K]N?8>6^WZU[,T-#9EU4S*2MFJ
M9PMW8P$.C :!W]=QNLWI3[?OZ&TM=.S[%3_$#V8R/)8O':[^4O()1=<P&.63
MOL1S_1)_4OH'!36;.&I37X3#;?"QTL9[M?MU'XJOJ^AM6Q0,Q@UI*W"L 8PL
M@ L\@_F^)]G3?NK*J0BO6BA:Y[FQM#07N+G'8=R3W*LI)K0D(M;E0C -XB:[
MU/\ 'EZXS'XB=M2K5KS.C =R[F0[>>_9:#"6;NC:_$J6*T^W;I\C8IY#N[KN
M&EWO&ZL'.:'R;-27,WI'.?%-J_RBY%)$)(I-N@>!Y.V7CIOAL*#-2P9>^[)5
M\T )7/&S]]CN2?M[;=E$U5=GGH6OBOM\B,_-E$=)'/C.9,:A^#&X;HLNY>;E
MYMMOZ/\ V6!E[-S5^6X;ODLS4Y,A4D-A\+BUVVWM;>F__=28\/-3&A\1_+&0
M:=Y?"$8@'PCP^W)S^FW3=;^QH=@U#I>[0F9!2PD3H6PD$EP(V'5:4E>NW^S.
M5UV_Z*]KZ.93XF6-'T\KDH\!<QXNSP_"'%[G!Y&P=W /0GU6XT+6^3&;UIA(
M<G-%C*E=MB&6P\R?!]PX$]?3;=30Z6E/$INI_A+/!&/^!>!RGFWY^;FW6)-H
M<6LQJ>Q;L@U<S5;6+&#9S-M^N_WK&;2NS\Z&LJNUS7XLI',U<)-@KE_%-UEE
M,M$PR#+\KHX=_P"ENX_1^Y3V[?LWSPJM697.FG<UTAW/M'D'4K.?PXU/<PDF
M"R.K]\*(_#8R"L&2.:.P<[T^Q;>#0=IM71D<M^%S\"09"&'^% &PV]%T4E>_
M'U,99>7H1+3^AZ^L-0ZRDS%^_P# X<H^.*M#.YC [E!+CMW/;\%+."<UAN%R
M>-L69;+,;>EK122NYG%@<=@3]RW^D-/28*UGII)VS#)7W6VAH(Y 6@;'\%TT
M/IJ73ARYFL,G^'7'V6\K=N4.).Q_%84M*[%XZ?V:<?BM<WX:_P!&IXQS4FX2
ME!D\M=HUIK #H*+'.GM@ _P;.7J/4JK<!)6P>OM..TS0U'C:5Z4Q3#*$M9./
M<TDG=7'KW2UK/G&7,3D?B_+8V4RUIG,#V>T-G!S?L47DX=ZAOYW#9K-ZF;;N
MX^</$38.2(,\PT#S/J5<)I;DQ8MK0TV+T;!J_7.M1EK]]M""ZUK:L$Q8USBS
M<N.WW;+'P^9R&F]":TQ]6Y-*[%7?@E2:9Y<YC7G8=?<K0TOIV3#9K45Z2=DK
M<I9;88T#8L ;ML5J:&@(O U76RD[9ZV<L&;9@V,0Z[=?4'JHI*JX4OQ_97%Y
MK7-_G^BOM?<.*V!X>7LK1RF0?=\.-UITTY>RR"]NX+3T[]0KQP7_ +EH>?\
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M'R$&)Y+'QY\#^"?%7P9_BB3EY>7;;;;?SW[+SM8VQA\=PNH706V8;;6R-/\
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MY]FK!+8#K?A.:PN,?T 7 ;D=S]JLC7'\3\U_9)/\I6TCIUX_#Y*\3!'N6;,
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M&K6HL<+V2%>)L8?L?88[E'7=PW(] NLOWM&%^U,W&@H;<U*QF<J'QW<FX3>
MYVX@C V9&!Z@=3[R5*00>RH/,SN\+-Y0VIV:Q@R_P>K$V=P<V'=O*QL>^Q86
MDGMZJ^("XL!>-G;#?[5AK1,U%ZM,]%6W$SKKOA]_;Y?^F5-=38.IJ+#S8S(^
M+\&E+2[PI#&[H01LX=1U"J+-Z'Q&DN(&AY,1\+Y[%V1K_'L.E&PC/;?LD"3V
M+Q"($6381$0!$1 $1$ 1$0!$1 $1$ 1$0%&?E8?Q9PG]K=_E5W4_]D@_J-_8
MJ1_*P(&F<)U__:W?Y5=U/_9(/ZC?V+;_ &HPOW,]41%@V$1$ 1$0!$1 $1$
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MZ_8$RH*3-N_5&!C>YC\WC&O:=B#;C!!].ZR<?FL7D971X_)4K4C1S.;!.UY
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MU\SZYX=:@T=,\Y*HZ2F#[-N$<T9^WT^]=<++]3CBYOH3S\E/^..5'_\ !_\
MZ87T1K/'9/*:<MTL)>;0NS -;8(WY!OUV]^VZ^>/R4_XY97^Q_\ Z87T-K74
MU+2>G;66R7,880 &-^D]Q.P:/>L8O[CI@_M*LUWHVGHK"5,OA,E>AS;)XV!S
M[#WFVXGJTM)VZJR-5:ADQ&%KB&,2YF]RP5*V_5TKAW/_  MZDGT"K33^KM,Y
MC,P:DUCJ#'_#F#_0\>QQ,=,'S/3VI/4^7DM[F,-K2;7,VHL"<':JOKMAI_#7
M2?P49ZD@-VV))[^B-/:7OL$6MX^^TYX!QVZ]35%?(VWV[4.6>R29Q^D[E;N1
MZ#=6A9>]D$CXF&1[6DM9OMS'T5.<#7:C^.]3_#FXT4OC&4VC%S<XGV;T9N=N
M3[>JM7#9G'YJ.=^,M1V&02&*0L/T7#N%)Z^"^QJ&WU95M";44G&'#2ZAD9"V
MQ3F?#1B?S-@:"!U/\YQ\U<?795QGOY;=.?\ +Y_VA6/W26L8^^+"52?T^Q45
M>E:XD:OS;<A=LPZ:Q4_P6.K!(8_'D'1SG$;'8;+<X_0MO2^I<?:TI:E&*>XL
MO4K,[GMY?)[=]^H/DM+ALS'P[U=J"EJ)DE?$9*R;E.]R$Q[NZN8XCL>JW9XA
MLSN=QN-T2(\BU\H==M.8[PH(1WV/3VCY*J],NWN[,NM<V_NJ.:#W_/ADX^=Q
M8,/$0W?IOXA\E8@[*I,GJ/$Z;XUW[&<O14X9,3$QCI#T+N<G93K3FM-/ZCLR
MU\)E(+DT3.=[8SU#=]MUFFXKWQ94TF[]Z(D*(BR;"(B (B( B(@"(B (B( B
M(@"K;B;_ !\X??V^7_IE62JVXF_Q\X??V^7_ *96H;F9;%DA$"+)H(B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B UNI,O7P.#NY2X'N@JQF1S6#=SO<![U7D^O]5XVG'F,UI..O@7<KGNCL
MA\\3"?I.;_V5IRAI8>< M\]^RK35V4=K6V[2NG")J3B!E+[.L<# >L8/8O/;
MIV5CO1F6UF[U?K9F'Q.,GQ=-^2O95S6TJ[7<O/N.;<D]@!U6!IS6N7;J:M@=
M7X:/&W;C'259()O%CDY>I;OY$;+$SM.''\1M!5(V[58*]B*+F/F(P!]^RZ\3
M.NO>'PC_ -?\/>>G?EY.OW+:2M=IEW3["S@A.RX;V*B^N+NJJ?P/Y(XJGD.;
MG^$?")Q'R;;<NVY&^_7\%S6IT;HC.-Z\<M0?\KK_ .8J?JI] V,U:XM9^34M
M&O1R'Q="#%!)XC>7F.QWW*MA=6<4$1%DH1$0!$1 $1$ 5 \6]L!Q2QV8B<!S
M"*PYK>^[7;'\0%?X[]5\BZZM6KFKLM+?+C.)WMV=Y '8 >[9>SH4<TWW'S_^
M1GEPUSO['U3A<SC\W5-G%6H[$.^Q+.X/H0>H6P7S%P=ST>#U?$;5L5J-AACE
M+CLTG^;O]Z^FH)8YHFR0/9)&X=',=N#]ZY8^#U4JX'?HO2.OAFXG=$1<#TA$
M1 $1$ 1$0&'E<93RM-]7(UH[$#OYKQO^"IK5'#/*Z=MNRVBK,I9'[1A#MI&#
MOL/Z0]RO%%UP\66'ML<<;H\,5?%OSXE2Z%XMP7'Q4-3,^"V]^3X0![#C_P 0
M[M*MECFO:',<'-(W!!W!"A&N.&^(U,V2Q&P4\F1TGC'1Y_XF]C]O=5EC\_JO
MAID!2RT,EG%AW*UDAW:1ZQN\OL7;JX8VN'H^7H>=8V)T?3&U7/U/H5%H]+:I
MQ6IJ8L8NRU[@/;B/1[#Z$+<0SQ3!QAD9(&GE):0=CZ+S.+3IGMC)25IGHB(L
ME"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"SH_H-^Q8*SH_H-^Q21J)V6/=
MIU[U62M<ACG@D&SXY&AS2/L*R$639"=*<-\/I74MO+83Q(!9B,3Z^^[![6^X
M]/L4KR&.J9&OX%^M#9@W#O#E8'-W'GL5EHJVWN1)+8T0TAIT'?XCQG_X9G[E
MNF1MC8UC &M:-@ -@ NZ*6*HQJE&M4,QJP10F9_B2%C WG=YD[=RE&A5H-D;
M2K0P->[G<(V!O,[U.WFLE$*8[Z5:2W':?!$ZS&TM9*6CF:#W *]]ERB QKU"
MK?A,-VO#8B/\R5@</P*\\=BZ.-C,>/IUZK#W;#&& _@LU$!J\AI_$Y*?Q\AC
M:=J;;EYYH6O.WIN0NV-P6+QDKY,=CZE61PY7.AA:PD>G0+9(EDH!$1"A$1 $
M1$ 1=))&QL<Y[FM:T;DD[ !:?&ZJP63NNJ8_+T;-IO>*.4.=^"+4&[1<;K3Y
MC5&$PLS8LME:=25_T62RAI/W(#<HL:*]6EI_"HYXG5BWG$H<"W;UW6+B,]C,
MPV0XJ]6MB,[/\%X=R_:@LV:+'@NUYK4]:.:-T\ :9&-/5G-VW^U9" *MN)O\
M?.'W]OE_Z95DJMN)O\?.'W]OE_Z96H;F9;%DA$"+)H(B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B! $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0&FUEB[
M>:TW>QV/N&E8LL\,3@=6@]]ONW5;X?AQK##4(Z6+UBRM6C^BQE9H^\].I]ZN
M%<;!5-K8C5[D.U)HUVH,!CJUW(S1Y:B1)%?A]EXDVV)^P^86%I30=NIFX\UJ
M?,SYC)UVF.LYP#61-/0D#;N?53_9$4FB94]P!LA"(H:*PQW\N6H/^5U_\Q4_
M4 QW\N6H/^5U_P#,5/UT9R01$4 1$0!$1 $1$ 4+U?PXPFIK;K=ALM>V[8.E
M@('-]H[;J:(M1FX.XLS/#CB++)6BM;?!W3S\2ZO7-B.UW;9<_<[^\=ME I*^
ML^&4QDA<ZQC-^I&\D)^T?S5]#KAS6N:6O:'-/0APW!7:/29+26J[3S3Z'!ZP
M^%\T031G$W#:@9'#9E;1OG8&.4[-<?\ A<IX.HW\O55EK;A+C<S(^UAGLQMP
M[ES W^">?L'T?N41PVK=1\-[0Q6I:<END3S,<9"2UO;V'=B/<5KJH8BO">O(
MRL?$P76.M.:_)?:+1:9U9A]1PA^+N,>_;=T3O9>W[0MZO.XM.F>R,E)7%V$1
M%DH1$0!$1 %B93'4\I3DJY&O'8@>.K7C=9:*IT&D]&?-O$O2\FA,S7L8*Q;B
MJV6NV>"?8.^W)S#W+5\/-89/3V:8*WB6H+,@$M?Z1>2>X_XE]+YW$4\WC)Z&
M1B;+!*-B".H/D1Z$**:!X<8_2ENQ:=+\-M/=M%(]FWA,]![_ 'KW1Z3%X;4U
M;^Y\N?0IQQE+"=+[$XB=SQM<6EO,-]CW"[(B\)]0(HOJS6^.TQ<BK7Z^0EDD
M9X@-:LZ4 ;[=2.RT-;C!IZSUKU,S*.;DW;1<1OOMLB3>P;2W+&1=8GB2)CP"
M X!P!&QZKL@"(B (L&KEJ=K)W*%>826J8:9V@?0YM]@3Z]%UPF6@S%1UFJR=
MD;9'1;31EA):=B0#Y>] ;!$1 $1$ 1$0!%TGE9!!)-*>6.-I<X^@ W*P=.YB
MMG\/6R=#Q/@M@$QF1O*2 2-]ON0&Q1$4 1%JM2YRMI[&.O78[$D0<&\M>(R/
M)/N"%-JBKB7C#IZ'D\:IF8P]P:TOHN&Y/8*6:EU1C-.8^*WE9G1ME(;%&UI=
M)([OLUHZDJTT2T;M%&]*ZTP^II)HL?)-'9A;S2068C%(&^NQ\EB8[B+I[(YU
MN*J697S/>8XYO"<(9'CNUK^Q*4[HEJK)>BU6<S]+#24XK3I'6+<@BAAB87O>
M?7;T'F5M1U&Z%"(B@"+0X?56/R^:O8RFVR9J9(DD="1$X@['E=V.Q6^W5 1$
M0!%B97(U<50FNY"9L-:$<SWN[!8=_4%2G#C)'LL2-R$K(H?"B+MB[L7>@]Y0
M&W1$4 1%K\IF:.+GI0W9PR:[+X%=FVYD?WV'W>:H-@B(@"(B (B( B(H B(J
M B(@"+AS@UI<3L -UK=.YNIG\:V_C_$-=SW,:7MY2>4[$[>G1 ;-$6NJY>"S
ME[>.C9/XU9K7/>Z,AAW\@[S/10&Q1869R5?$8JWD+K^6M6C=+(0-SL!OT"[X
MJ]%D\;5O5P\0V(VRLYV[.Y2-QN%092(B@"(GDJ B(H BQ<KD*N*Q\]Z_,V&K
M"WF>]W8!85_/U*4&.EDCLR,OO:R'PHBXCF&X+O0>]4&W1$0!$1 $1867RE3$
M47V\A,(8&D-+CZD[ ;>I*@,U%PP\S01V(6GTQJ.CJ2&Y+C?%Y:EAU63Q&<IY
MV[;[>[JJ#<HM!CM6XK(ZFOX&I*]]^DP/F]GV #Y ^97K9U+CZ^I:^"<Z1U^6
M%U@AC=VQQCS>?)*!ND4%DXJ:8CONK&S8,;7^&;8KN, =VVY^W=27/Z@QN!QG
MQAD[+8JQ(#2!S%Y/8- [DI7$7P-JBBVE]=X;4=UU.DZS#;#><0VH'1.>WU;O
MW"E(1IH)WL$1% $1$ 1$0!9T?T&_8L%9T?T&_8I(U$[(B+)L(B( B(@"(B (
MB( B(@"(B (B( B(@"(B @?&:Q)%HF6O"]T9N3PU2X="&O> ?U*.<1](X?3&
MDZ>8PM*.K>Q%B"6.6/?=PYP' ^NX*F'%'$6LSI"S%CV>)<@>RS"S^FYC@[;[
M]ME <SJNYQ#IU-+T=/Y6G--/$;\UJ$LCAC8X.?U\]]M@MX=\.?E[LQ.N/+W^
M"Z(G\\37#S *AAT'IVM:R^7S;&79++C++/;/2)@'T1Y !;RSG8*FHJ.%-:TZ
M6S$Z1LK(]XFAODYWD536KM<-S&J;E'/T,Z-/4Y.1E2E6<1;<#U,KOZ/_  A9
M2;>A7HM3:Z8Q-RUPLU-#A(ICC;-R63%Q.WYGUN8=!OY.V.WVK-I9:M4S<FH,
M=C;53'TL8*TC)*SH3/.7#DC:"!N=^F_O4TT!J>CJ7&RG&XZY0@JN$0BLP>%T
MVZ<H]%X7(G9[6$-5T;FXO$D6)-V["6<[\@]X;U/V[+=_%3]Z5[[3-:6O>M^^
MPQ]&WL?A9G8[,92D-49!YM6H?$',7N[- ]   ![E.0=R51&:I6'?'.GSC[+]
M27,M\+KW1 >4P[M(?XFVP  (V5ZP B-H<=W  $^I66M%+W[X&EHVC$S66HX7
M'R7LK:BJ4XR ^64[-;N=A^LA53JO5>"U%K_0C,'E:MY\-V1TC87[EH,9V)5M
MY+'U,G4?5R-:&U6?MS12L#FG8[C<'WJK-:X#$X;7V@G8G&U*3I+T@>8(FLYA
MX9[[*PHD[HMP(@[(L&PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B'L@"+KS#<@N"YYV_TA^* Y1<<[
M?Z0_%.=O](?B@.47'.W^D/Q3G;_2'XH#QNR.AIV)&?29&YP^T JNN!.L,KK'
M3^1MYIT+IH;1B9X3.4<O*#_W5@Y-S?BZW[0_U3O/W%4Y^2J0-(Y@$@?Z>?\
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M=7XC4VFY;V8@G9E;8@EQT<(#(F<I)(=W) \U@ZMU;.[/7*TFM\7@J]=_+%%
MSX1*_P!3)T]G[%+<QA<ADN(N,NOCY,50IR<DO,-_'?N.@]P*@^&TKJO#TK6(
MJZ<P4TCG/<,S,_F<_??9Q;MN7?>LIVO?O_97H9$>L[^4X*Y[(VGLGM OI0S1
MLY?'+B& AOK[2\YXM7Z)TCB,D<I5^!TXH8I<8(1RAFPW]ON7?O7K7T/GAPVP
M6 ACBK7!?^$VY)"'-9RDN!('<%W+T6TMX?5NL9JM'4]2EBL14E;)-\&F,CK9
M;V _HM6]+=<_?Y,JZU]^Z1-\I7NY.G2=C;[J&TC)9"&!Q>SN6=>V_JMC:F,%
M::9K'2EC2X,9U+MO(+7"UDFZ@939CH_B@0<QN>+U#_)@;_W6V^U<SHNTKMVO
M,]0_TC-Z+R,./=]&6L]L\C1_Q,'4*5Z7SASV-??./N4(><B-MMG(][0/I<OD
M._X+<GJ"#V*TNL6Y%^FLA%A(O$ORQ&.(<W+L2-M]_<C>FP2UW(Q@XAK74DF=
MN;G$XZ5T..B_FR/;T?*?7KT'V+6\0+LLG$'"?)RD[+YO&,D?-3.S8V1R  .<
M\]&NZ=%/]+8F/":>H8Z(;"O"UKO>[;J?QW4-RV)U+@-:93/Z9I5,M#E(XV35
MII?"?$Y@V!#O3W+6EUR]^9G5IOF:W3'P_5.J<];RT#<3F:U%U&.F.I:U^^TA
M=_.&ZUV*QV6PN-PC=54J>*P>G#XIECE\1]N7;9O*!VW)*F^A=/Y6ID,GG-22
MP.RN0Y6^%7^A#&.S0?,]>ZX;0LZIU&ZSEJTL&$QLG+5JRL(-F7SE<#_-'9H^
MTHG6B]^[%7K[]Z>!'JFI\+B<_P#&^M+S*F8NQAM6HYI=\$@)]D.V'0GN25:,
M4C9HFR1N#HW@.:X'H0>H*IW46,S9SFI,;!ILWI,R]K8LH\ Q0P\H&Q.W0CKT
M5MXJH*&,J4PXN%>%L7,?/E&VZG"RK<@,^4U!K#.Y&EIG(,Q&,QK_  );9B$C
MY9?,-!Z !>6/RV?%'5F#RF6CCR6)9'+'DXHAUC>">K3TYO9/XKK7Q6KM(9/*
MLTYCZ.6Q^2LNLM,TQB=7>[OS=.H[+SN:-ST6B-1\\L=W4^<<WX0^(\K&-!V#
M6[^0&_XI_CIR\PG\6O/R-QP7JY"'0]2QDKS[1M[V&-<P-\(.<3MT[[[[_>L7
M5.5U#:XE4<#IRRRO R@Z>V][.9K"XD,=MYGIT"G.'I,QV*ITHALRO"R( >X
M*K:4VHY-<:KU#IRI4R,45AN,-6:0QEPC:#S-?[BX]%=')\M?0RK4>W3U-UI+
M*YW&:QR&G=19"+)1LJ_"X+7((R!OU#O(=U#LQK>Z76[<FOL53GA+S%CZ</C,
M<!OLUS]NI/N4KJ:)R]^CJ+(9JW%%G\O6-=C823'59Y,![GRW*C5C3.K;.E+&
M%J:4P.+<R'PG6XWASYQML>0;="[U)\T^Y>[8[ZWNY;5W#?2KA9%2SEY6,E@8
MP$2=SS=>P&VZE-.;,4-8Z<TX[*.LQ5:,EJ_(8PWQ1ORL!]-NO;T6-E,!G:4.
MB7XC&PW&8F(,FK23<G*XL#>;?;KMU6^PF'N?+K468R,(9%/7@J52';[L:"7G
MW=2M-I77-^B,I-I7R7]E9Y;B?\;9.X(=5,P-."5T<,;*3IGRAIVYG.VVV/H%
MOJ/$.]>X3YG+L>QV2JR_ X)XV<HF>7!K7AI[$[]ESC,%J_3M63!XS"X6]5\1
MYKY.=P!C8XD^VS;J1NM[F]+9&?$:<Q0E^&L9D(K.1L$-9N&;N^B .A=MT4^&
MJ[O[+K=]Y',]<US@<'BLSD<S7\=SX87XYD V>7=#N[OS>9VZ+TUAA\OJ'BQC
M*]+,NJ"C3^&M B#O@[B0P@;]R[KW]%,-9X6WF\YIYC(0[&UK#K%EQ/8AI#1M
MY]2L2CC\Y4XGY2^^C!+BK\$<8M^+L^%K ?9Y?/<G=%+CWAK2N[[D8U9J+,C6
MUG%6-1#351@8*<LE8.9:)'4EYZ#KN-O<K)TL<K\2P#/NK/OC<.DKG=D@WZ.'
MIN-BJ\RF-UO/1LX/)87%:@KR.>(<C9FY"QI)Y2YNW<;^6RL+2.+GPNF<=CK5
M@V9ZT08^7^D?=[E/\2_Y$/XE:DFH92"@S5&-P%?PN>25X\6PYV_0!FW0>\KQ
MX8:NLY";4%>WEH\Q1QL;969!L7A\X+27-(]VRQ+^F]08W6.7O4<#BL]%DGM?
M'9NR<KJP#0.4C8[MZ;]%UQ6EM2T-+ZS;+6K',Y20"$5R&QEA 'L^@ )47[7W
M>8_R1SIG*ZDLZ4@U5F\N:V+@;)9-9L32^RSF);S'R'8#;R41EXG6K<+LD-8Q
M4[(!DCQC<>]T?N8Y^VY/ENKBR&F66] G3C)/";\";6:_;?8M: #^(40IXS6U
MJM!AYL5AL7'$&QRY:(B1[V#S8PCHX@>:UI;HFM(L#2^4^.M.XW)F/PC;@9,6
M>A(ZA0_B5J.;'WZU&/4N-P,#F%\DL@\2=QWZ!K-N@]Y5@P1B&%D;-^5@#1Y*
MK<QI[/4-:9/)4=/8O/PY#EY);<O(ZML-N7J#[/GT6='+0UJHGMPQU;:R&0SE
M&?,19NC0A9-'D&Q>&23ONTCSVV[K35<GK3(Z%O:B?FX<=4A,MF$>"'OE8">4
M$]@/+U6RP.E]1T,3K>6U6K?&V3#6UA6(;$6\FP#?0#<CKZ+<Z@TU>=PSI:=Q
ML7-(YL$$_M;<K 09#^U5UP[#*[>TCF:RNMH=*4-36,I5I%W@%N-CAW\3G(&S
MG'KN=]]AV4OK9BW#Q"LX^]8#:+\8RTQAV C<#L\[KMK?!V\L[3M&I$'4(+L<
MUIQ.W+'&/9&WGN=E&.)N/GS.NL%CL3:;%-;K2U[KHSNZ.L2"X].Q.VP^U+MZ
M<W]ALM>S[F<W4EVUI_56I99RS#-BDAQL.PV>&@@R[]_:=V]P6KQ%S-5L;I_1
M^F3'7N_ 66;ER5O,( [KT'F3U4BU[IJU:T;1P&GX *XFABD (;R0 ^T??T7A
MJ##:@P^JCG]*5:E^.6LRM8I3R&,GDWY2QWWHJ^GHO[*[^O\ ?HCRPE_4.GM;
M4<%J#*1Y>GD8))()_"$<D;V#<@@=QLM90UMEQA<G<C(MW+V5=0Q4+V[-:.VY
MV[@=ULL9IW4-S*WM3ZB%891M-]?'X^N[=E?F'4EQ[N/JL=^C,M4T3IT8ML'Q
MYB9A<,,KO8E>1[;21^U%7^7O7T&O^/O3U(YQ.K:NQNF&5<KF8<G%F;$=1\38
M>0PO<?YA'<=QU5V4*S:E*O6C'L0QMC ]P&W_ &586\/K#5.I=-W-14*E#%T;
M'PA]6";Q"'MV(<XGON>P';JK2G+VP2NB;S2!I+1ZG;H$>D0M9%6XZ[J[5.H-
M2MQ66BQV$KVC6AL&$2/!8-G!@^WN2L>AQ#OXGAUD,GF9(K5R"\ZC6FY>5LQ'
M0/('IU/12O1F(R.$X?R5I(1\<2">=\?,.LSW.(&_X+22:$O?-YAJ-0P,S-"5
MMTLFZQR2]W-=]O9--N[^QKOW_P!$('$ZSCIHK[=6LS$A>T2XX4'1,+2>O(XC
MH1[U8N;RN=S^I;&"TO;CQT-*)DERZ^/G<'/&X8T'IOMU7EAZ&J<SE:K\QB\9
M@,;6?SRQUN666T?)NY&S6>OFL&Q)F<3K3.7M)LQ>7KW',9<@ELB-]25K=MSW
MZ;>2KK8BL]-+Y#4[.(5C"YG(QVJ>+I&:29C P3E_T"_T( *C&9UM;+[EI^O\
M73GA+W14*D'C,.W9I?MU)V\EM="8W):GP>N[ENY&,CE9G4XK,6XC 8W8<O\
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M'_>)/Q3Q8X<U>,C@T%Y'7[5D_#:W_C-0&-\6G_>)?Q3XM/\ O$OXK)^&UO\
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M4&+B\=4Q5&*ECH(Z]6(;,C8-@ LI$3<+0(B* (B( FR(@"(B (B( B(@"(B
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M9>CI'O+W$>FY\E*41.MB5>X;V1$0I6&._ERU!_RNO_F*GZ@&._ERU!_RNO\
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M-<9LHW)QQYV"M-3D<&N?$SD='N>_?J%'T3$JT5?\A@VD]"^D7$;@]C7-.[7
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MHG9$7#GM;])P'EU*R;.47#G-:"7.  \R4#@1N""/4(#E%PU[7#=K@1[BN=T
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MTU^9*/\ =!5M)D49,TOSD:.^L6/_ $S^Y/G(T=]8L?\ IG]RW7R(TU^9*/\
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MV5JM[+2Z6TMB=+4G5,)4;6B<[F=L27./J2>ZW8&RYM[)<#<4]6^(1$4-!$1
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M"P](:!@P.6ERMO)W<MDWQ^"VQ:(W8ST &P6\R;OE9E1:5$T'9$'0(N9T"(B
M)Y(B J3B?1MW^(^E:M;(/Q[+,,\1L1_3:.A(8?)Q 7..Q%C06N\%0H9C(Y#'
MYD31RU[TWB.C<QH<)&G8?85.=8Z3I:IHQ077RPS0/$L%B%W*^)X\P5K-*:"A
MPN6.5OY2]E\D(S%'/;(_@V'N&@ #KZK<72KO,23NS(T4YL.E)Q,X Q3VA*3Y
M?PKSU^[9:_@@".'M-Q&S))IWL_JF5Q"\,]PPBRF4O68L[E*=2\_GLTX' 1R'
M8 ]QN-P%-\/CJ^(QE:A29X=:O&(XV^@"BI+P+JV9B(BR:"(B (B("N)V_*3B
MWX+QST=/P"0M/T38D[?@W]JZ:T<V'BUHF6;9L3XK,3">W/LT[?;LI9@--PX?
M*9N_'/)+-E+ G?S@>QL-@T>Y>6MM(4-74(:]]\T4E>435YX7<KXG[;;@K2=-
M=GYW^YEQN_>VQ&N(#VR<0-$01$&P+;I2!W# QVY5D*$:3X>UL'FCF+N3NY;*
M",Q,GM.'L-/D !LINHZ2I%5MVPB(H4(B( >RK/BO$_.9? :9K%E:U;>^PR^=
M^>N(QN?#V(]H]OL5F$;A1S6>D*.JJU=MN6>O9K/\2"S [E?&[W%5:--D>S17
M5#%VM#\1<''D\C)J!^7:^M%:MC::L6@GV1OMRGS4FX.N:W$YJ$D>-%E; D'F
M"7;C]1"R],\/:^)R\>6R.3O9C)Q-+(9[;A_!-/?E  'WK%SW#*O?S-O)8W,Y
M+$S7/]I;5<.67R/0CH5MM/3WN82:U1B\&SXEW6]B+K7ESDQC(['8 $C[U9;>
MRU&E=/T=,X6OC,8QS:\0[N.[G$]W$^I6W"S)KAV>1N-\0B(LE"(B *I<16U/
M@,GEZVD(\3EL58N/E+Y;!8ZK(X[N:X#OL5;2K_,\,X+F8MW\;FLEBA==S6H:
MK@&RGMOU'0_8K'1DDM"L8JUF/AUJ:S;G%AORECDEF:-FO#9(P\CW;[C[E9O&
MJ2-_#RPUA!=/+"R+;S<7C;92"'1^*BTB_3;83\6/B,3FD^T=^I)/KOUW48Q/
M"FM5R%*:_F\GDJM%X?5J6'CDC([=AN=O>MYDWW5^/0QE:^M_GU+"J MKQ!W<
M-&_X+V7 &RY7,Z((B( NKVAS2#L0>A!\UV1 55J^)D'&G04<3&,C;7M<K6C8
M#IY!;+7)$?$+0\LIVA\:>,$]N8LZ?L*W^8TI!D]7X74$EF5DV,9(QD30.5_.
M-COYKTUGI6EJO%MIWGRQ.CD$L4T+MGQO'9P6K_;V>K(U=^^!&N)!\76.AH(C
MO/\ #)I-AW#!"[<_9V7' YS6:$?$X@2P7K3)@>[7>*X]?N(6=I3A[#A<U\;W
M\K>R^1;&88I;1'\&P]P  L+-<+:UW+7[F/S62Q<=]_/;KUG#DE=YGJ.F_N31
M+*35ZGIP9]O Y69G6&7)V71GR+>?R5@CLM;IW"U-/X>MC,<PLK0-Y6@G<GWD
M^JV2CWT*NT(B*%![+6YJM$<?<G,49F; \-D+1S $'< K9+RN0"S4F@<XM$C"
MPD>6XV4:M%6Y">"O7AKAOZCO\Q6NXG5XJV:T-'7B9$SXX#N5C0T;\KMSL%,]
M(8"/36GZF*@F?-%7:6A[P 3UW\EXZETU#GKN&L33R1'&6A:8U@&SR 1L?=U7
M1R6>^TQ7PM=Y&M=N$7$30\TQ#8/$L1@GMSF/HL;BHYLFKM UX]C8.3$C0.X:
MT;N/V;*6ZSTI1U9BFTLBZ6/PY!+%+"[E?&\=B"M-I;AU7P^;9E\AE+V7R,3#
M'#+;</X)I&VP 'ZTBTJO@22>M<2<-[+E -D6#81$0'!"K3BC!%7SF@8X(V1L
M^.VGE8T ;EKO_P"JLQ1_4VF8<]>PEF:Q)$[%VQ;8U@&SR 1L=_+JM1=23(]4
MUV,S<[F:."QTE[)SMA@9TW/4D^0 \S[E#L%2NZNU15U+EJSJF,H-<,94D'\(
M]SN\SQY=!T"V/$'0PU@_'N=EK5#X$\RL\ -.[_(G<>2PL1H#)T,E6M2ZSS-J
M.&0/=!)R<L@'D=AV2-+6]22O:M#KPH+66=6PN(\=F7E<\>>QV(/X+IPM/BZ@
MUO8B.]=^6<UI'8D,8#^M9&H^&\&3S=C*XW,9#$6[+0VP:KAM*!TZ@COLI'I'
M3=+2V%BQN-YS"QQ>Y\AW<]Q.Y<3ZE$U5]E?;T)3NNV_OZFZ1$6381$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
. 1$0!$1 $1$ 1$0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g111069g00a12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a12.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1H64&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$! 0$            &!P0%" ,! @G_Q !<$  ! P,! P,*$0L$ @(  @L
M 0(#! 4&$0<2(1,Q0147,E%587%RL=$(%"(T-38W<W1U@9&3HK+!X188.%-4
M5I*4H;/2(S-"4F*")$/")43PXO$F8V:#A*2T_\0 &P$!  (# 0$
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MJHG+Q)NN;WU3I+VM];3W"CAJZ*5LM/*U',>U>"H>6[8KM3^Y[;&IMWXS1+(
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MV*:\$3O'5.U5RLV?WM6KHO(*<BFT[/IC9FIH^U:YVJ:/  !L6I
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MY5LT35T<KY)>*F_7JJN%9(KY)GJJ:_\ %.A$[R(:P Z*(B(Q#D9F:IS( "4
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MM@E6%.>1&+N_.0/$ $@                      'UC7/<C6(KG*NB(B<5
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M!R\CHB^$JO9[@]=F%>K8$Y&AB5.6J%3@G>3MJ8VZ::K7_P!)X1+*[551>_\
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M8E>L=DC;=Z&2!)';K'\[7+VM4X'0EP;19Y9J!V/9&M#)&U%2*)R:ZZ<SF\_
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M95T:FJ<6JO1X2I] 5]VIQ,3/-;WVO:IJB(C'!>=+CN!8W#55URO?56&1J\C
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MF0:%?=HFF8F>,^*R-95%=-41B(Y0S9YV,O,D^ZDL;:A7Z=#DWM2_<NEQG/\
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M3MC<K6OD<NDFG_5.?0Q8MD^2OO$M ^".-D:(Y:ESM(U1>TI7[>WYEW=;WEE
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MT*7IZ&SUE>?&3R%)W;V5K??G_:4QHN35751T9W+,46J+F>>6* "YYP
M    "=;$O=#MW_MY%(*378W)R>T.U=]SD_H57O=U?)=I_>T_.'6  .?=8
M  !$MK/N?7KWA26D2VL^Y]>O>%++7\X^:J_[NKY2Y' !T+D@
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MM]5:Z^:BKX70U,+MU['=!BGIB<\8>.8QPD !(
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MB)KY*I4UT5RZJGW&-@%78<8H:^BK\NI;A35/,Q_#=X:+\Y#L#SNT.Q1V,9=
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M&J]BWSD;/78IFBW%,\WAU-=-R[553RD !:H
M       2;9E[?[!\,9Y3K\Y V9>W^P?#&>4Z_-3K_P"<?)O>R?=U?-$MK$+I
M\ O$;4556+71/"<CG:]ZB9/;I(I6HZ-ZHUR+THJG+6TO#*O%;S+K&KJ"9RNA
ME:G#37L5[YGH+D1FB5?:MJ9Q<CDAH -FTP          !8>#;1VXOC%9:'6Q
M:E:A7KRJ3;N[O)IS:*5X#"NBFN,5,[=VJU.U1/$Z0 9L
M
M                                          )ML;A=)GUO>U%5L:JK
ME[1"V,<]Z-8U7.5=$1$U55.A]D^&R8_:(:ZXPHROJY$<B+SQLX:(>;57(HMS
M_;V:&U-R]&.4<5N  T;I@     (WM'I75F$WB%C5<YU.Y41.\A)#PN#4?05#
M7)JU8W(J?(IE3.S,2QKIVJ9IZN(02O/,2K,>KDF6)SJ"I3E(96IZG1?^*]]"
M*'0T517&U#D:Z*K=4TU<X  9,0
M        3#9GF;<+N=75NH5K.7B2/=23<W=%UUYE(W>:U+E=ZVM2/D_3$KI=
MS77=U7FU,,&$41%4U1SEG-RJ:(HGE  #-@
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M*D>L+%W<?]!^(ZPL7=Q_T'XEW =[O=3=^G\OUE2/6%B[N/\ H/Q'6%B[N/\
MH/Q+N [W>ZF[]/Y?K*D>L+%W<?\ 0?B.L+%W<?\ 0?B7<!WN]U-WZ?R_65(]
M86+NX_Z#\1UA8N[C_H/Q+N [W>ZF[]/Y?K*D>L+%W<?]!^(ZPL7=Q_T'XEW
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M6%B[N/\ H/Q'6%B[N/\ H/Q+N [W>ZF[]/Y?K*D>L+%W<?\ 0?B.L+%W<?\
M0?B7<!WN]U-WZ?R_65(]86+NX_Z#\1UA8N[C_H/Q+N [W>ZF[]/Y?K*D>L+%
MW<?]!^(ZPL7=Q_T'XEW =[O=3=^G\OUE2/6%B[N/^@_$=86+NX_Z#\2[@.]W
MNIN_3^7ZRI'K"Q=W'_0?B.L+%W<?]!^)=P'>[W4W?I_+]94CUA8N[C_H/Q'6
M%B[N/^@_$NX#O=[J;OT_E^LJ1ZPL7=Q_T'XCK"Q=W'_0?B7<!WN]U-WZ?R_6
M5(]86+NX_P"@_$=86+NX_P"@_$NX#O=[J;OT_E^LJ1ZPL7=Q_P!!^(ZPL7=Q
M_P!!^)=P'>[W4W?I_+]94CUA8N[C_H/Q'6%B[N/^@_$NX#O=[J;OT_E^LJ1Z
MPL7=Q_T'XCK"Q=W'_0?B7<!WN]U-WZ?R_65(]86+NX_Z#\1UA8N[C_H/Q+N
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M-/%KK/V55[Y]QL376?LJKWS[C8E#U,2Z>M%\9OE,LQ+IZT7QF^4RP
M
M
M         !K[MV=-X_WH; U]V[.F\?[T V        !XUOK.?Q'>0]CQK?6<
M_B.\@&/8O8BD][0SC!L7L12>]H9P
M
M                                            &NL_957OGW&Q-=9^
MRJO?/N-B!B73UHOC-\IEF)=/6B^,WRF6
M
M                                                 -?=NSIO'^]#
M8&ONW9TWC_>@&P        /&M]9S^([R'L>-;ZSG\1WD Q[%[$4GO:&<8-B]
MB*3WM#.                  &BS?*;?AV.U-YN[G)30:>I8FKGN7F:G? WH
M-3C-^IK_ (U17N!KX:6JA29J2Z:M;WR!56VJS1233Q6J[5%FAD6*2YQPHL+5
M1=%7GU5$7O 6F#PM]9!<*&"LHY$EIYV))&].9S535%/<
M
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M:-B,W]]%E[73PU(E^5FWSN$O\DGG ZA!SUL(VF9AD^T.X6'+'0-2EII'/B;
MC'-D:YJ:*NO?4Z%
M
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M&
M                                                   :ZS]E5>^?
M<;$UUG[*J]\^XV(&)=/6B^,WRF68ET]:+XS?*98                   %1
M%314U0T6:V-;]BETM5.L<,M7 Z)KW-X-5>DWH C]AQR*DPFEQ^X)'.QE&E+,
MJ)P>F[HI6D>RO+J2URXY09>V/%Y'*G)NAUF9$JZJQ'=HNL :S&+)2X[8:*U6
M]N[34L:1M[_?^4V8 '+VQ'])/,?%J?[K3J$Y>V(_I)YCXM3_ '6G4(
M
M                                         #7W;LZ;Q_O0V!K[MV=-
MX_WH!L        #QK?6<_B.\A['C6^LY_$=Y ,>Q>Q%)[VAG&#8O8BD][0S@
M                !^98V31NCE8U\;DT5KDU1?D/T /S%%'#&V.%C8XVIHUK
M4T1$[R'@^WT;ZE*A])3NJ$YI5C:KD^734R0   ',VS']*7*/>7_98=,G,VS'
M]*7*/>7_ &6'3(
M
M   !KK/V55[Y]QL376?LJKWS[C8@8ET]:+XS?*99B73UHOC-\IE@
M                  !R]L1_23S'Q:G^ZTZA.7MB/Z2>8^+4_P!UIU"
M
M                                           U]V[.F\?[T-@:^[=G
M3>/]Z ;         \:WUG/XCO(>QXUOK.?Q'>0#'L7L12>]H9Q@V+V(I/>T,
MX                        #F;9C^E+E'O+_LL.F3F;9C^E+E'O+_LL.F0
M
M                                                 #76?LJKWS[C
M8FNL_957OGW&Q Q+IZT7QF^4RS$NGK1?&;Y3+
M    #E[8C^DGF/BU/]UIU"<O;$?TD\Q\6I_NM.H0
M
M                           &ONW9TWC_ 'H; U]V[.F\?[T V
M !XUOK.?Q'>0]CQK?6<_B.\@&/8O8BD][0SC!L7L12>]H9P
M           ',VS']*7*/>7_ &6'3)S-LQ_2ERCWE_V6'3(
M
M                                    !KK/V55[Y]QL376?LJKWS[C8
M@8ET]:+XS?*99B73UHOC-\IE@                          !R]L1_23S
M'Q:G^ZTZA.7MB/Z2>8^+4_W6G4(
M
M              #7W;LZ;Q_O0V!K[MV=-X_WH!L        #QK?6<_B.\A['
MC6^LY_$=Y ,>Q>Q%)[VAG&#8O8BD][0S@                        .9M
MF/Z4N4>\O^RPZ9.9MF/Z4N4>\O\ LL.F0
M
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MK5VY5:HJS53S7& "MZ
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M957OGW&Q-=9^RJO?/N-B!B73UHOC-\IEF)=/6B^,WRF6
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M(U7)X=>!95=KJIBF9X0\]O2VK5=5RBG%4\TA !6]
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MD[F.:YJPOT5JZHOJ6'31R9Z'VQKC>WZ[VAU2ZJ6DII&<LY-%?P:NO]3K,
M(OF/LKC?P[_\*DH(OF/LKC?P[_\ "I*
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MD4&W"N9;&M;"ZWL=5MCX-Y35=W73IT$Q&$Q5.5F  K6
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M'@:W4SM6YF9Y3R=%V;3[*_3331,Q-.=K,XX\?E_75V6 #6ND
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MVJ'DJ6+71%757*O.JKTJILP1,S/!,4Q'&  $)
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MB.( "$@                            #76?LJKWS[C8FNL_957OGW&Q
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M.:BM5%1>**G2#%D        Y>V(_I)YCXM3_ '6G4)R]L1_23S'Q:G^ZTZA
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M[*XW\.__  J2@B^8^RN-_#O_ ,*DH
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MFI71)IKVU,YIQX*Z:L^*3VFWT]JM\%%1M<VGA;NL:KE71.UJIE@&"P
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M_P"\='\SO,!-P0ZCVG8;6545-39!223RN1C&(CM7*O,G,3$
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M4[7*NO)KP1=47I+A BJ8)HAKL<M%/8;'16RCUY"EB;&U5YUT3G^4V(!BR
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MXY&\[7(BZ*AOR,[3O<]R+X#+]E32.T<J6'+MHUWM<5:S-:J-LFOJ5:BJFB^
MS^K>T=>?.*C^!/,:?9[[5*3PN\I(C=6M':JHB9CP<;J>U]5;O5T4U<(F?".K
M3V.\Y^RV1MHLRJ((-Y^D:,3@N\NO1TKJIG+?-I"(J_EQ4</_  3S'CC_ +%1
M>,_[2F>_L'>!2:=%9FF)PKN=LZNFN:8J\>D+5]#'DMZR3&KQ+D-QFN%1!6<D
MR2335$TYN"%R%"^A#]JV0_&*^0OHTL\W:TSF  $)
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M.DG]DFJ[1M6N-E6MEJ:"OH^J,<<B[W(/WU1S4[2+VBR8X*HGBL( %:T
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MLT:215[GL7F<V"14^R!* 8]OK(+A21U-*Y7PR)JU5:K=?D7B9
M
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MU=%TU1.!9>R"GPUL%7-B5-)3U2+N5,50KN6C7AP5'<="VJ>"JF.*Q@ 5+@
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M !#(
M                     #7W;LZ;Q_O0V!K[MV=-X_WH!L        #QK?6<
M_B.\A['C6^LY_$=Y ,>Q>Q%)[VAG&#8O8BD][0S@     "!9)0UU)M(LUYH*
M5*V*2!:&JC:]$?"QSD7E=%YT3I*_OEJOL$%SP^DLE5(ZINWIZCKFHG(1Q*J.
M75W0J:*FG?)KG%-D5'G-NO>-6CJCR=,ZGF8^=&-5JKKPUZ>'.?I,KSA'-Y;"
MXHV*J(KEKV<"R)PJF(G*PX&N9#&UZZN1J(J]\\ZNLIJ1J+53Q1(O-ON1-3VC
M57,:KDT<J(JIVC1Y=BEIRRA927J!TT3';[=UZL5%X]*>$PC^UGR53=,2MF3/
MDN6(9>VUTTM9Z9?33-1\?+,<OJVM54T777O$EV=4%LL65U=)57J>^Y-74R5$
MM8_16MB:NB,3BNB:]!7M3C6SZRU4UICMMWR&Y0/=R_I%7JD::\$71=.',6'L
M=I\+22X28I2STMP8C654-5O<K&G0FCNCP%D\E5,<5F@ J7        .9MF/Z
M4N4>\O\ LL.F3F;9C^E+E'O+_LL.F0*/]%Q[0;9\91^1Q6S.P;X$+$]%Y/&S
M!+:Q7-67T^QR1Z^J<B([F0I*ER^-)8F5]#44D<FC62/3A\IL=!<IHVMJ>CG>
MWM/<O;$VXSC/X;FZ>N:#WW[C\7R^4EFC8M2KG2/71D;$U<X_=S5%J*!475%E
MX+\A'+W)#0YS255RX4;H5;&]R>I:XV%VN:(F8ZPT.FLTWIB*N.(F<1SG'@_$
M-[;=,WQ9%I9Z9T5:Q5Y5--45R'=YPOE5927&>V4=MDCGN$E0SDN37547>3I.
MX+<R2.WTS)O]UL34=X=.)I]7&+D\<NO[*F)TT8HV>?!^JVJAHJ.:JJI$C@A8
MKWO7F1$355.?+IZ(:X55?,N*8SZ=MD3MWEZB16NDTYU1$_$NO/;7/>\,O5MI
M%TJ*FE?'&O?5.!QG9+S!C=$MIOL4U%74JJUT;XUU7CSF.GHHKJQ7.(6:^_>L
M6]JQ3M3EU=LRS^V[0+!4U--3NI*ZGU954DFBNC=IT+TIWS:[.6,_)&C56MYW
M]'_DI47H8K16NERC))Z>2GH;AHRG;(U45Z)KJY$[1)\FO-98-@=QK[;JVJ9$
M]C7I_P -Z3=5WR(I35$1,Q#U6YFJF)JC$IY4YKC-)7>DJB^VV*J1=U8G3M14
M7M<YOXY&2L1\;FO8O%'-75%.&K5BELJ;+'/4;\T\\:2.F5ZZ[RIKJ7OZ%.\5
MU;BMRM]7*^>"@J>3@E=QU:O'34NNZ>JU$35XO+I=?;U555%&?VKP !0]H
M
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M@
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M59(]'*JIT\Q-4U>***:(S-&.//":  Q6
M
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M0  AD
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MN=?L)K8;-.M-7USYWTDJNW=W5_!=>CF(3UK=LG[V?_[CO,!D[,?TI<H]Y?\
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M?5T?Z<Y7/3\KS !JW3@
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MD+Z.8GF^FT\H  0R
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M(?N>U_P]_D0J[1_TO7^G/_Z8_K\KS !JW3
M
M     UUG[*J]\^XV)KK/V55[Y]QL0,2Z>M%\9OE,LQ+IZT7QF^4RP
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MO+"?^A#]JV0_&*^0OHH7T(?M6R'XQ7R%]',3S?3:>4  (9
M
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M95714E8C4K*:"=&\R2QH[3YSUABCAC;'"QD<;>"-8FB)\AG-3"*?!^P 8,P
M      ',VS']*7*/>7_98=,G,VS']*7*/>7_ &6'3(%'^BX]H-L^,H_(XK9G
M8-\"%D^BX]H-L^,H_(XK9G8-\"&U[-Y5>CE_U'SM^OX?0 ;-S"/W;V[8A\.9
M]I#M@XGNWMVQ#X<S[2';!H=;[Z7=]C?!T>OWEK<F]K=V^"2_84XNV:^P$GO[
MSM')O:W=O@DOV%.+MFOL!)[^\L[/][Z*.W_A?6/RDU33PU,:QU$3)&+T.34\
MJ*W4=$JK24T42KSJUO$R@;G9C.<.-BNJ(V8G@\ZKUM-XCO(63Z$/W/:_X>_R
M(5M5>MIO$=Y"R?0A^Y[7_#W^1#6=I?Z?5TWZ<Y7/3\KS !JW3@
M
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MP^/[!W@4^GQ_8.\"EKRPG_H0_:MD/QBOD+Z*%]"'[5LA^,5\A?1S$\WTVGE
M "&0
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MJ^TO]/JZC].<KGI^5Y@ U;IP
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MG^ZTZA Y^]&%[ 8Q\8+]E"$(3?T87L!C'Q@OV4(0AM>S>57I^7+?J/G;]?P
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MC%?(7T<Q/-]-IY0  AD
M                                    !K[MV=-X_P!Z&P-?=NSIO'^]
M -@        >-;ZSG\1WD/8\:WUG/XCO(!CV+V(I/>T,XP;%[$4GO:&<
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MJKUM-XCO(63Z$/W/:_X>_P B&K[2_P!/JZC].<KGI^5Y@ U;IP
M
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M0_&*^0OHYB>;Z;3R@ !#(
M                                      #7W;LZ;Q_O0V!K[MV=-X_W
MH!L        #QK?6<_B.\A['C6^LY_$=Y ,>Q>Q%)[VAG&#8O8BD][0S@
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MU?:7^GU=1^G.5ST_*\P :MTX
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MA^,5\A?10OH0_:MD/QBOD+Z.8GF^FT\H  0R
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M2@*1]"K?[K<\*FH;A'/4TU%4OBAK7O14W=&JC.?5=-5X]]"[BA[0
M
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M:MD/QBOD+Z*%]"'[5LA^,5\A?1S$\WTVGE  "&0
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M6*Y.WHO0IG!$1$1$31$!6L"F]K.U^&R/ZEXPBUER94,AJIVM58J75VBM<O\
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MK2U4IX=55SNR>Y>=R]\WP!#(
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M.8GF^FT\H  0R
M                               U]V[.F\?[T-@:^[=G3>/]Z ;
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MGBN@ $,P
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M(7T4+Z$/VK9#\8KY"^CF)YOIM/*  $,@
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MJH
M           :ZS]E5>^?<;$UUG[*J]\^XV(&)=/6B^,WRF68ET]:+XS?*98
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MJ<&'9;C#=K31W"E76"JB;,Q>\Y-3,+E(
M                                      !K[MV=-X_WH; U]V[.F\?[
MT V        !XUOK.?Q'>0]CQK?6<_B.\@&/8O8BD][0SC!L7L12>]H9P
M                     ',VS']*7*/>7_98=,G,VS']*7*/>7_98=,@4?Z+
MCV@VSXRC\CBMF=@WP(63Z+CV@VSXRC\CBMF=@WP(;7LWE5Z.7_4?.WZ_A] !
MLW,(_=O;MB'PYGVD.V#B>[>W;$/AS/M(=L&AUOOI=WV-\'1Z_>6MR;VMW;X)
M+]A3B[9K[ 2>_O.T<F]K=V^"2_84XNV:^P$GO[RSL_WOHH[?^%]8_*5@ W3B
MWG5>MIO$=Y"R?0A^Y[7_  ]_D0K:J];3>([R%D^A#]SVO^'O\B&K[2_T^KJ/
MTYRN>GY7F<O^B;]UG$_@R_:<=0'+_HF_=9Q/X,OVG&OL^\I^<-_J_<5_*?L@
MF=RU45AJ%I]$C5$21R+ZI$UZ#[06NSKCC?\ 0IUA6'5TBHFNNG/J;^>)D\+X
MIFH^-Z:.:O2A&%P>@Y1=VIJV0*NJP(_U)N[ENK;VHC/!Q.GOV_8Q:JJFB8G.
M8\?^^CRV;OJ'6J5FJ.I&2N;&YR\>CAX";[(?=\@^+W>5I@45)!14S*>EC2.)
MG!&H9^R'W?(/B]WE:>?543;T\4RV79=Z+_:%5RF,1,3^'6  -0ZP    ^.[%
M? !].8-MDLN3[6WV"YRRMM-OI$FC@:[1LCU375>V0S'L?J\@IZJNGR*\0O6J
ME9N1S>I1$<J)SGO5;.'-E=6TV0W'T^QJ[LTRH[AIS=LU&J[3L1%5F*]FKEG$
M\);?2]F7YV;TT9IYXS'&&@LSY</CQG(;!-)3UTM;R$L37+NS,WUX*G2FB:'=
M2<QPWC.!NO\ 9J:JN5YJD:QSN1CB1$Y/1RZKQ[_$D%7A,\%)/*W*+XJQL<]$
M6;GT34QM]J6+,S:N5YG,^$]>7HFYV9?O1%RW1B,1XQTYNQ 4WZ%2KJ:S9J^2
MLJ):B1*R1N_*]7+IPZ5+D-RTX
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MP\ES07+=B-1,QB74  /<\0
M                          :^[=G3>/\ >AL#7W;LZ;Q_O0#8
M'C6^LY_$=Y#V/&M]9S^([R 8]B]B*3WM#.,&Q>Q%)[VAG
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MS7)X0,H
M          &NL_957OGW&Q-=9^RJO?/N-B!B73UHOC-\IEF)=/6B^,WRF6
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M)DL+I;#<Z6N8SLN2?JK?"G.;D                         :^[=G3>/\
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M0,\&KL.0VC(('362Y4M=$U='.@D1VGA-H
M     !KK/V55[Y]QL376?LJKWS[C8@8ET]:+XS?*99B73UHOC-\IE@
M                    !R]L1_23S'Q:G^ZTZA.7MB/Z2>8^+4_W6G4('/WH
MPO8#&/C!?LH0A";^C"]@,8^,%^RA"$-KV;RJ]/RY;]1\[?K^  &S<RTV6>Q<
M7PJ'[:'9=%ZS@][;Y#C3+/8N+X5#]M#LNB]9P>]M\AINT/>1\G9?I[X:K_=/
MVA['&5P]V;/?A;OMJ=FG&5P]V;/?A;OMJ4Z/WU+U]K_!U^GWAM0 ;]P0>FQ[
M](JE^+Y/[9YGIL>_2*I?B^3^V>+7^Z]6[[ ^*GY3]X=:$9VG>Y[D7P&7[*DF
M(SM.]SW(O@,OV5-([1R7L]]JE)X7>4D1'=GOM4I/"[RDB.CL>[I^4/G6M^(N
M?.?N'Q_8.\"GT^/[!W@4M>6$_P#0A^U;(?C%?(7T4+Z$/VK9#\8KY"^CF)YO
MIM/*  $,@  #E?%O7V0_&<WVU.J#E?%O7V0_&<WVU--V[\)ZPW'8?Q7I+?@
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M5?E L3T/ERKK?M3LJ6]S_P#7DY*5C>9S%Y]3ODX.]#5[L%D_]_LJ=X@
M                   #7W;LZ;Q_O0V!K[MV=-X_WH!L        #QK?6<_B
M.\A['C6^LY_$=Y ,>Q>Q%)[VAG&#8O8BD][0S@
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MV<>[91_$\W]QAT$<^[./=LI/B>;^XPZ".^[*^$H^7Y<)VI\77\_P  V#7@
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MPNAO4;.3DD18YHTYF2-[)$[Q+"K/0R6MENV0VE[7;RUCI*EW#F57;NGU2TP
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MMN^E F (?US<+_>6W?2GK2[1L0JZF&GILAM\D\STCC8V3BYRKHB)\H$K
M         #7W;LZ;Q_O0V!K[MV=-X_WH!L        #QK?6<_B.\A['C6^LY
M_$=Y ,>Q>Q%)[VAG&#8O8BD][0S@                   \:VJAHJ2:IJ7I
M'!$U7O<O,B(55UT[[46^6^6S#:BIQIBJJ57IA&ROC1=%D2/3FX*;W;M52T>R
MR^R0+H]8VLU[RN1%-E@E+#'LQL].UB<CU-8U6Z<%16<0-YC]WI+]9J2Z6Z3E
M*2JC21CN\O0O?-@4QL:O\>.[$ZJYU<<DM-;)9](V+ZI6(_F34T?YTF-]Q+I\
M[/.!J=F/Z4N4>\O^RPZ9.(L1VK6RR[8KQE\U#5R45:QS60M5N^W5&IQXZ=!;
M7YTF-]Q+I\[/.!L_1<>T&V?&4?D<5LSL&^!##VV;:K1GV-TEMM]NK::6&J9.
MKIE;HJ)KPX+WR*MVBVY&HGI2IX)ISM-CH;M%N*MN<.?[<TE[431[*G.,_A-P
M0GKC6[]DJOG:.N-;OV2J^=I[^]6?,T&ZM7_^<_1MKM[=L0^',^TAVP?S]KLU
MHI\@L=>VFG2.@J&S/:JIJY$5%T3YB_\ \Z3&^XET^=GG-/JJXKNS53/!U_9=
MJNSI::+D8F,_=>.3>UN[?!)?L*<7;-?8"3W]Y:UV]$WCM;:JVE99KFU\\+XD
M559HBN:J=OOE"8GE]'9K8ZFGIYY'K(Y^K%3313/15TV[F:IPJ[8L7+^GV+49
MG,+0!">N-;OV2J^=HZXUN_9*KYVFU[U9\SE=U:O_ /.?HF55ZVF\1WD+)]"'
M[GM?\/?Y$*!EVAV]\3V)25.KFJG.G:)7L0VTVC ,8J;9<;=6U,LM2Z9'0JW1
M$7HXJ:_77:+FSL3ET'8>EO:>*_:TXSC\NQCE_P!$W[K.)_!E^TXWOYTF-]Q+
MI\[/.5#M;VI6S-,TLEYHJ&K@@H85C>R56[SEU5>&GA/%:F(KB9ZMSJ:9KLUT
MT\YB?LE((3UQK=^R57SM'7&MW[)5?.TWO>K/F<-NK5__ )S]$V,C9#[OD'Q>
M[RM(#UQK=^R57SM/3"-I5NQ_:3'D=11U4E,VE6#DF*W?U54X]K3@>367[==O
M%,Y;7L;0ZBQJ-NY1B,2[J!SY^=)C?<2Z?.SSC\Z3&^XET^=GG-4ZIT&#GS\Z
M3&^XET^=GG'YTF-]Q+I\[/.!T&?'=BO@.??SI,;[B73YV><+Z*/&U14ZB73Y
MV><"'[-_8*I^&S_;4E13N*;2+=9[=+3ST=4]SZB29%:K=-'.540W'7>M/[!6
M?.WSG%ZWL[57-17731,Q,R[/1]HZ:WIZ**JXB8B%E&-<_8RL]Y?Y%*^Z[UI_
M8*SYV^<\JO:S:IJ2>)M#6(LD;F(JJWI30\]'9>KBJ)]G/T7U=IZ6:9C;A=OH
M2/<QD^&R^5"ZSCW8IMML^!8@ZTW"VUU3,M0^;?A5N[HO1Q4G_P"=)C?<2Z?.
MSSG>.%:K;M[O.,_ /O>9Y5FT7:M;,HVCVC(J6AJX::CIN1?'(K=YRZNXIIP_
MY&3UWK3^P5GSM\YS/;6BOZB]35:IS&/S+I>QM98L6:J;M6)S^(64"M>N]:?V
M"L^=OG'7>M/[!6?.WSFGW5J__P Y^C;[TTGGA:.SCW;*3XGF_N,.@CC#%=L-
MIL^T"&_S6^M?3QT,E*L;5;O;SG-77GYN!9GYTF-]Q+I\[/.=CV=;JM::BBN,
M3#D.T+E-W4UUT3F)=!GXY:+E.3Y1G*?]=Y-?F.:\G]$Y1U=DJ:;'+96TUTE3
M<AFG5JM8J].B+SD6?C^01TJW/\J;EU::WE5>LJ[F]SJW3M&>IUEK38]K.,L-
M-H[NIVO91G#KZ21D;=Z1[6-[;ET0^M<U[4<Q4<U>9474XVM6095M*<[JW>YZ
M6DH&I L=(NYRK_\ LNG2?FX9IF&"3OQVWWF2JIKFU$IYJA=Z2#5=%T4B-;9F
M]-C/[H)T5Z+47\?MEV2V:)SU8V1BO3G:CDU0_9Q]5V>_V&BDO%NR>Y.NE,WE
MGK)(JLDTXJFA-+3Z**SMMM*VYV:O=7)&U)G1*S<5^G%4U7F,M-J[6JB:K4YP
MC4Z2[I9BF[&,NC0<^?G28WW$NGSL\X_.DQON)=/G9YSTO,Z#!SY^=)C?<2Z?
M.SSC\Z3&^XET^=GG Z#.:_1BWZU-H;79):%M1=55:ADZN5O(,YNCGU[2\.!L
M?SI,;[B73YV><H_;OGUIVA7ZANEJI*NEDB@Y&5LZMXZ+JU4T7OJ!$\!O%OL.
M5V^XW>WI7TE/*CW1;RHO#I3MZ=I3HZ[>B(Q:KOECK(J*Y-BH7RN>BL;JJ.9N
MIIQ.4 !?FV';_69''!18=)56RBTUGD71LKW:\$147@AH-D.V'(<=R>DCN=PJ
M*^TU$B1SQ5#M]6HO_)JKQ14Y^^5$;/&*NDH,AMU7<X7ST4$[))HF+HY[$754
M37I _I8QR/8UR<RIJAK<H:U^-79KVHYJTDNJ*FJ+ZA2CF^BCQMK4:EDNFB)H
MG%GG,:Z^B;QVMM=92LLUS:Z>%\2*JLT17-5.WWP.3     '?WH?/<<Q?X.[^
MXXL(Y5V9>B"L>)X):+'66JX33T42L?)&K-URJY5X:KWR3_G28WW$NGSL\X'0
M8.?/SI,;[B73YV><?G28WW$NGSL\X'08.?/SI,;[B73YV><?G28WW$NGSL\X
M'08.?/SI,;[B73YV><?G28WW$NGSL\X'08**L?HD\?N]YH;=#9[DR6KG9 US
ME9HBN<B(J\>^7J                   &NL_957OGW&Q-=9^RJO?/N-B!B7
M3UHOC-\IEF)=/6B^,WRF6                      1W:+8%R?"+S9V.W9*
MJG<R-W:=SI_5"K;9M4?0X*EDKK)<&973P>D64"0/5)'(W=:Y':::::+SEZ'Y
M6-BOWU8W?_[:<0*UPC9[$[9/^3N0ME8MPWIZMD3MUS7/=OJB+QYE-'^;9@G:
MNO\ -)_B70 *7_-LP3M77^:3_$?FV8)VKK_-)_B70 *7_-LP3M77^:3_ !'Y
MMF"=JZ_S2?XET #C7T1NR_'L MEHGL"5G*54KF2<O*CTT1->'!"Q,"V 89>\
M*L5TK4N7IJLHHIY=RH1&[SFHJZ)N\VJEA[8=F4&TFBM]/47&6A2DD<]%8Q';
MVJ:=)+\5M#;!C=KM#)5F90TT=.DBIHKD:U$UT^0"J_S;,$[5U_FD_P 1^;9@
MG:NO\TG^)=  I?\ -LP3M77^:3_$?FV8)VKK_-)_B70 *7_-LP3M77^:3_$Y
M_P -P2SW;;E5XI5I4]2HYYXV[DFDFC$73U6G>[1W05/CFQJFLNT^?,F7::66
M6667TLL:(U-_7AKWM0-?^;9@G:NO\TG^(_-LP3M77^:3_$N@ 4O^;9@G:NO\
MTG^(_-LP3M77^:3_ !+H %+_ )MF"=JZ_P TG^)'-HNP/#;!@E^NU ER]-T5
M')/%RE0BMWFHJIJF[Q0Z+-1F%D9DF+W6RR3.@974[Z=9&IJK4<FFN@'->PG8
MSBV:X%#=[TE?Z;=/)&O(SHUNC5X<-U2P_P VS!.U=?YI/\2=;+<+BP+%8[)!
M5OJV,E?)RKVHU?5=&B$N I?\VS!.U=?YI/\ $?FV8)VKK_-)_B70 *7_ #;,
M$[5U_FD_Q'YMF"=JZ_S2?XET "E_S;,$[5U_FD_Q'YMF"=JZ_P TG^)=  I?
M\VS!.U=?YI/\1^;9@G:NO\TG^)=  I5_H;<$1CE1+KP3]J3_ !*=V*[,,?R_
M-<MM=W2K]*VR3=I^2E1KM.4<WBNBZ\$0[+<FK53MIH5WLVV8081DE_N\-QEJ
MGW9^\Z-[$:D?JG.X+T]D!'/S;,$[5U_FD_Q'YMF"=JZ_S2?XET "E_S;,$[5
MU_FD_P 1^;9@G:NO\TG^)=  I?\ -LP3M77^:3_$K;;[L>QC!\'2ZV-*[TVM
M2R+_ %ID>W=777AHG:.L2&[5L&BV@8PEGGK'T;$F;-RC&(Y?4Z\-%\(%);&-
MB.)9=LZM5ZNZ7#T[4\IRG)3HUOJ9'-31-U>A$)O^;9@G:NO\TG^)8>SC%(\*
MQ"AL,-2^J92[^DKV[JNWGN=S?^Q)0*7_ #;,$[5U_FD_Q'YMF"=JZ_S2?XET
M #G+)=ALV(5L-[V=MEK7L:L<U!4R)O/:O2UW#M<VAK+=L[RS:%404>3VIU@L
M\+^4E<K]Z233_BU.CPG4 //5I;5=V+U5/[H\7HIU5VBW-FFK]L^#A';S@UIP
M?.:*TV7TPM++31ROY9^\Y7*YR+QT3M'0K?0VX(K472Z\W[4G^)G;5=BU+G^4
M4UYGN\U&^&%L/)LB1R+NN5==5\);;4T1$[1Z'G4NOH;<%7GZK+__ )2?XC\V
MS!.U=?YI/\2Z !2_YMF"=JZ_S2?XC\VS!.U=?YI/\2Z !2_YMF"=JZ_S2?XC
M\VS!.U=?YI/\2Z !2_YMF"=JZ_S2?XGG/Z&K!WPO;$^ZQR*GJ7+4([1>WINE
MV "A+5Z&'%J=\BW&Y7*L:O8HU6Q;O]%U*NV\[,,?PF]8K2V1*ODKE*]D_+2H
M]=$=&B:<$T[)3LPKO:ILP@S^Y6*KGN,M&MK>Y[6L8CN4WE8O'7F[#^H$9C]#
M;@CHVJJ77541?72?XGZ_-LP3M77^:3_$N=C=UC6]I-#Z!2_YMF"=JZ_S2?XC
M\VS!.U=?YI/\2Z !2_YMF"=JZ_S2?XC\VS!.U=?YI/\ $N@ <8XGLQQ^Z;=K
M[B54E7U)HV/=%NRHDFJ;FFKM/_)>@N;\VS!.U=?YI/\ $D5AV7P6C:C=,S;<
MI9)JYKFK3*Q$:W7=Z?\ U+& I?\ -LP3M77^:3_$?FV8)VKK_-)_B70 *7_-
MLP3M77^:3_$?FV8)VKK_ #2?XET #G_+_0^85:L6NU?2I<_3%-322Q[U2BIO
M(U535-T@/H=MDV-Y[BUPK[\E;Z8@JN19R$R,3=W47BFB]LZNR"VMO%CK[:^1
M8FU<+X5>B:JW>14U(ILAV>0[.;'5VZGKY*UM1/RZO>Q&JGJ433AX (E^;9@G
M:NO\TG^(_-LP3M77^:3_ !+H %+_ )MF"=JZ_P TG^)E6GT/6$VNZ4=PI4N?
MIBEF9/'O5**F\UR.35-WFU0MX               U]V[.F\?[T-@:^[=G3>/
M]Z ;         \:WUG/XCO(>QXUOK.?Q'>0#'L7L12>]H9Q@V+V(I/>T,X
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M+);'56FYM<ZDJ6[DB-<K5T\*&NP#";1@MKFM]ACD93S2K,Y)'J]=[1$YU\"
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M&Q-=9^RJO?/N-B!B73UHOC-\IEF)=/6B^,WRF6
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MEE)X?3UV*[8I:+*YTNUPN],KJ.YZ;JM8SGBW>9$Z>!=@
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M]\^XV)KK/V55[Y]QL0,2Z>M%\9OE,LQ+IZT7QF^4RP
M            ?F6-DL;HY6H]CDT<UR:HJ=H_0 B5]P7'ZBR7"&DL%K2IDIY&
M1*E,Q/5*U43CIPXF!L8Q%<2PJAI:V@IZ:ZHQ6U#XVMWG^J54U<G.3P    (=
MM8AR2JPVJI,-8BW.H5(E>KT8K(UUWE15Z>CY28@"C\+ILYQ"T,H;/@-N9S++
M,MP:KYG]+G+TJI:%-:HL@M=%4998Z'J@UB[T,C6S)$JKQ1'+\A( !4.7[,8:
MW:/B]?;+';TLU*UZ5C6QL:U57FU;TEN0QLAB9'$QK(V(C6M:FB(B="'Z
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M30JV!S(&,5'=Y=.!88 CV!V"#'L9H*2.BIZ6H; Q*A(FHF\]$T555.=>^2$
M   (=M8AR2KPZJH\.8BW*H_TU?OHU6,7LE157G*_PFFSK#K,RWVC K<U.>69
MUP:KYG=+G+TJ7B (]26J+(+315&66.AZI;GJX9&MF2)=>9'+\A LNV90UFTO
M$KC;+);VV:DY3TZUL;&M75JZ:MZ>.A;P _,4;(8VQQ-:R-J:-:U-$1.T?H
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M/N-B!B73UHOC-\IEF)=/6B^,WRF6
M
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M)4K$NDB0RM?N+W]%X 9P      >%%64U=#RU%415$6JMWXGHY-4YTU0#W
M \**MI:^%9J*HAJ(D<K=^)Z.35%T5-4Z4 ]P     &'+=;?%#/++74S(J=VY
M*]TJ(D;NTY=>"F8U4<U%:J*B\45          /):F!*E*99H_3"MWTCWDWM.
MWIVCU                                           #76?LJKWS[C8
MFNL_957OGW&Q Q+IZT7QF^4RS$NGK1?&;Y3+
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M)^8S&)9TSF,@ (2                                   :^[=G3>/\
M>AL#7W;LZ;Q_O0#8        'C6^LY_$=Y#V/*L36DF1.EB^0#&L7L12>]H9
MQ@V)=;33=YB(9P
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M8O"^GQRV0RZ\HRFC:[7M[J&,\F<?RELP 8L@
M               &NL_957OGW&Q-;951RU2IS<II_0V0&#>]4MTCD_XJB_U,
MV-=YC5[::GE60I/2RQ+_ ,FJABV.HY:C2-_"6'U#T\ &P
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M0VAIZG6W79*G_P#1JC1LG_B[H4W"<>8
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M7PZ&S ,(AF%BKLAOEGIWL8ECIY/3%2JN365Z<6M1.UJFI+T1$1$3F0 G*(C
M "$@                                     ?B>1(H)'NYFHJG[-7=Y
M%G?'0Q*BNEXO_P#%H'ZQ^-64&^[5%D<K^)LC\QL2.-K&IHUJ:(?H :BO1UNJ
M_3T35= _U,S4Z/\ R-N?'-1S5:Y$5JIHJ+T@?(I&2QMDC<CF.35%3I/T:AU-
M/;7N?0-62!RZNA5>Q[Z&527*GG317I'(G!6/X*B@9H"*B\RZ@
M
M                                                          #\
M2S1Q-UD>UJ=]3637*2H<L5L9RCNF5>Q:![72L?#NP4S=^IEX-3_JG;4][?2I
M24S8]=YW.YW;4_%OH4IM9)'+)4/[*1?N,P           /.I@CJ8'Q2MWF.3
M1364M3+;Y6TM;JL2\(YNWWE-N?B>&.>)8Y6HYB\Z*!^T75-4Y@:KTC4T:ZT$
MJNC_ %4G%/D4^-N=3%HVIH9$=VV<4 VP-<EU9^IE_A4^]5&?J9?F4#8 U_51
MGZF7YE'51GZF7YE V -?U49^IE^91U49^IE^90-@#7]5&?J9?F4=5&?J9?F4
M#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91U49^IE^90-@#7]5&?J9?F4=5
M&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91U49^IE^90-@#7]5&?
MJ9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91U49^IE^90-
M@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91U49
M^IE^90-@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U49^I
ME^91U49^IE^90-@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V
M-?U49^IE^91U49^IE^90-@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZ
MF7YE V -?U49^IE^91U49^IE^90-@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7
MYE'51GZF7YE V -?U49^IE^91U49^IE^90-@#7]5&?J9?F4=5&?J9?F4#8 U
M_51GZF7YE'51GZF7YE V -?U49^IE^91U49^IE^90-@#7]5&?J9?F4=5&?J9
M?F4#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91U49^IE^90-@#7]5&?J9?F
M4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91U49^IE^90-@#7]
M5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91U49^IE^
M90-@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U49^IE^91
MU49^IE^90-@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE V -?U4
M9^IE^91U49^IE^90-@#7]5&?J9?F4=5&?J9?F4#8 U_51GZF7YE'51GZF7YE
M V -?U49^IE^93YU49^IE_A4#8@U;[L[FAHYY%\&A\TN57JCMVEB77FXNT ]
MZ^X-IW)#$G*U+NQ8GE46RA6GWYIUWZF3B]W:[R'I14$%)JL;=9%YWNXJIE
M     QZFBIZG_>B:Y>WIQ  PULL2+_I5%5$G:;)YQU'7]OK?XT\P #J.O[?6
M_P :>8=1U_;ZW^-/,  ZCK^WUO\ &GF'4=?V^M_C3S  .HZ_M];_ !IYAU'7
M]OK?XT\P #J.O[?6_P :>8=1U_;ZW^-/,  ZCK^WUO\ &GF'4=?V^M_C3S
M.HZ_M];_ !IYAU'7]OK?XT\P #J.O[?6_P :>8=1U_;ZW^-/,  ZCK^WUO\
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M[=?6JG:WT\P 'K%9Z5CMYZ/F=VY':F=&QL;=UC4:WM(@ 'Z
M
M
3                     '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g111069g00a13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a13.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1ML4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &T\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M4N'Q<K(&%31#4V*"DL+_V@ , P$  A$#$0 _ +4@
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MLMD1.O"OJ]!,5F>B)G"5P<)U.2$@
M
M
M       !J>["O;MQJ)8L\?D<F,? ;8>*]T++E:*RBDQP5$3HE^5,%-2)FDQ"
M^G/+:)E2+LX*SV5+>LO7GCX<H7J0^?<T=?MKN4YLS7=];ZK*<L=XQ'=4]2H7
M<TCK:QZFL\%=07"FP]J*^-TB(YB^**F3;FB^G6893$UU)B6T'#L$(]H#=6CL
M%@DME@KV27J9R)Q0/15A1.>55#P]FK6FK-6OKDOD[:BW4S41)G1X<KUZ)GH4
MIY^<=EK>;C/="G:"O?V8W9N25*N6EHWMIVHG@U$3./E529-.;]:#L=BI+72T
M=>R"&)(^%($Y\N:KS(5WUM:VG=^ZI5Q*M//*V=N?PF*B?\RQ6F-H=N+Y8**Y
M4MJ;)%/$U_$D[EPN.:=2-+/D8_GVIU,>4^"KVJ[[;)=R9KWI5DM/1.J6SQ->
MWA5BY15Y>C.2Y^L:OR[:6YU7_C6QS_G815'9=DDO-3;9(V0U5//W"\<KL.=Z
ME1>:9)9UW34]%M=>::C;PTT5O>V-.N&HWD1?$:$UC[V6T\SKQ:?O=57LL^ZK
M3?%2?43+VO\ ^H-#^-I]2D-=EGW5:;XJ3ZB9>U__ %!H?QM/J4MK^A3W?]RG
M#?J7]_\ VL3V-/Z!OGQS?J(8WO\ =AN_XTG[B9^QI_0-\^.;]1#6^['0[MW=
MST5/\X1R?!R+ZGZU/9'PA71C.C>/7\Y7CL7]"6_\7C_50I1VEO=>N/P,_50N
M9I*LAJM*VNI9*QT:TL;E>CDQ[1"DN_MS@NNZMVGI)&R0L>V-'-7**J)A2FI^
MM$>U?2_2GV0N9H+W.;/^(,_5*5Z$]V:@_*/_ !%T]!>YU9_Q!GZI2S0?NRT'
MH^R/_$:1_P"J^_%E'_I)]D?"5X=6V"UZEL<UNOL7>T+\.>G&K,8YHN4(CL]^
MVOVIJ;BVV5KGU,N%?&U5E<F/!%._M7:@KK/H6DIK?*^)*ZH[J5S5PO C57&?
MF(T[.&VNGM8T%?<+_P 55)#(D;:='XPF/;+XF6G$VFTQMAK;$1&>[6NT!N+:
M-?W"W2V>DFB2E8YKY941'/ST3'JPI/G9:<KMK(T<N429Z(1!VHK3IZP55CM6
MG:2FIY8HWNG2+'%A51&\2_(I+W985/8L3FG^G>3IX\G?'WNIJYYZ9^]I52O]
M+Y=N+7TB*OW:X.9\[\%[=+Z.L=BM-%2T=MI4[AB8D=$U7\7IXE3.2C[O=B__
M -M__P!#Z!Q?Z-OP%J;:-?OM!??6M'WUE^DZ  JLHKV@?=EN7QK"[=A_H.W_
M (O'^JA3+M.4#Z#=6JGX'(R9D<K5QU+-[5:]LFI=*4"P5T$=5!"R.:&21&N:
MY$1,\UZ#1_1QX&K^KGU?1E-V/<XU#^*/*P]DOW2)_P 7=]9./:!UE:;5MY<Z
M-*V&2NK8^YABC>CG<UYJN%Z8(=[']NDFUA<JW"]W!3X55]*J-#]2UO5]?J:W
MZ41Z_G"9>TW[D]P^,9]9"79,TY2W;5];<*V-LOV/B1T;7<T1[EPBX]6%)M[3
MGN3W#XQGUD)=DK4%/:]95UOJY&Q^7PHD:N7&7M7*)]8X?T[??8UOTZ_?=9'=
MK3U)J+05XI:N-KW,IWRQ.\6O:BJBHI5GLU72:T;H1T;7+W54BP2-\%Y]2UFZ
M5ZIK%H.]5=3*QG^;/9&CE]LY45$1"J/9KMLMVW3AJF([NZ;BG>J)RZC0_6GP
MQ]4ZWZ,>WZ-@[7='34>I+2E+300(^!RN[J-&Y7/5<=2:>S]:Z!VUVGZIU#2^
M4\#E[[NF\>>-W/BQDASMD9^V6R_B[OK)M[/3FNVBL&%3DQZ+\/&X:/Z5O;]3
M5]./9\F4W(T?IC4U R75;,0TJ*K)>]5G!GKXD>V?<W;?;FQ-M-DJYZN*-ZJJ
M1,XG.55ZJJXR:-VN]0UWV>H++'*YE"D/>N:BX1[LJG,V?9#:+25RT;07FYPI
M<*N=.-W$_P UBHOM<(1IYM6;1M!?$3$3O* -UM346KM;U5XME*ZEIYE;YKN2
MJJ>*EOI'*[8.17+E5LR_J%5-^66F'<FLI[##!%1TZ,C1L"(C>).O0M4[W I/
MR,OZA&WY:V/O:3?\Q7/WT5%V@U33:.U8EXJVND2&%_ Q/PG*G)#9]NHDW8WC
MCDU3+F.9'S/C1<<2-;E&-]'_ "4U#:O2::SUE16=\W<Q2*KI'8Y\*=<&[;A:
M>J-F]S;?<;(KO(T^ZTSG>*8PYJK\OZ36,1:LV]D??WT4C>+17WKG4\$-'2LA
M@8V.")O"UC4PB(G@4+W'O<5ZW7N%;=N-U&RL2-Z-Z]TUV,)\B*7ATK?*74^F
MZ*ZT;D6&JB1V,YX55.:?(4:UK;HK-NS6TUXA5U(EPXY6+RXHU=E>?K0SB)C6
MB)Z_[A>)B=*9CHL)3=H'05/;&6Z*BKDI&Q]TD20)P\.,8QDKS;;Y14&ZE-==
M/=Y#1)7(^)'IA48KNB_(N"U%%LSMQ5VZ.M@MC'TTD:2)(D[E3&,YSDTZQ6C9
M.ONS:2EC;%6-G[IC9)')Q/1?#FN>9>NVI%NZL[Z<UCI*PM)*DU/%*G21B.3Y
M4.XZ:6)D$$<,28CC:C&IZ$3DAW$3C.Q&<;@ (2
M
M
M               !PIR (]W1VLLNOX&OK6K3W"-JI'51)YWP.]*%=+WV<]9T
M=3P6M:6MA7.'MG1F/D7!<T$17'1/-MNJ3I#LUWRJJH9=354%)3H[,D<<G'(J
M>I43'Z2SFE--VS2UGBMMFIFP4\:>"<W+Z57Q4S0+\TXPKC?*.-W]K+?N%11N
M>_R:YP)B*H1.J?V7>E"!W;-;IV59*&R7&5:!?[O<%B8[/^SE/J+?@I%<=%IG
M/57O:GL_MLUS@N^K)V5=7$Y)&4[%XFH[TN54Y\R9M;VVHNFD+O;Z%C75-13/
MBB:JX155,(F? SP)OY]>6>A2>2W-'56+8K:35FDM>07.]44$5&R-[7.;.UZY
M5/0A(_:'T;>-::3I:&PP1S5$=0DCD?(C.6/2I*P%O.B(GM_RBGF3-H[_ $PA
MKLXZ$ONB+7=8-04\<+YY&NC1DB/RB)ZCIWOV836TR72S21T]V1,/21<-E1$Y
M>')2:P+^?,3/8IYF8CNJ1IK9?<S"VZINTMLM2\G,97*K%3Q3A:O[C\:Y[/-]
MAN5-'I6F;54K8F][/-4-:Y\GBN%Z%N@)\2-F TG;JFW:.MUOJV(VIAI6Q/:B
MY1'(W'4K7I79;6=OW&I+O54,#:*.L[YSDJ&*O#Q9SCJ6S!/-_4\IW1C^GY/L
MU'<W1-'KO2\MJK?,D1>\@E1.<;TZ*5LIMC=R+#=',L%;W,$F$=44U8L64]:9
M12X(*Q&)S"TSF,2JS?\ L[WF32\E5Y>MSU/),CG*^;S.#"Y3B=U7."2.SWI7
M4ND-/UEJU%110QK(LD3F2M?G/AR)>!:)QF/%68SCU*BKLGK7V1/LMY!!Y'Y?
MY1Q>4,]IQYSCKT+<QIAC47JB'($3BL5\"8S:;>( "$M(W/VZM6OK3Y-<&K%5
MQ\X*EB><Q?1\!6J]=G+65%/PVM:2MC55\]DR,Q\BX+F B*XZ)YML2IQI_LX:
MNKJC_MF2EH8D5,JLR/54\<8R6:VXT-;-"6)MOM;,N<O%-.Y/.D=Z5-M!;FG&
M%<;YE%':;]RBX?&,^LKGL5H"#7;+W"E3)2W&EC9)2SL<J<#L^."R_:&ME;=]
MLZZDM=)/5U3GL5(H6*YR\_0A''9-TS>[!=;XZ]6FMH&RQ,1CJB)6(Y<^&2NE
M$<U\_>RVK,Q2N/'YM7N.R6Y=XKV45WNCJJ@8OFS5%:LC&^M&KE?T$^[2;;T&
MWUF6"G7O[A/A:BH7\)?0GH0WX%HG$8A68S.41[\;63:_I*6HMLT<5QI&N1C9
M%PV1%\,X(XVMVKW(L6HK:M=5R4EFI9DE? VN5T;L+S3@1<<RT8(IYDYA-O.C
M$HKWMVJBW!HH9J61M/=J9,1R.]J]OH7D0M8=E=SJ25]O@N+[;;GJO$Z*N5(U
M_P#*U<_H+>@B(B$S.53-;]G.\4]/;ETRY*^I5B^6/EF1B<?^SGP)IL%@OWL+
MR6"Y4L<5W2B?2L8V1%:[DJ-7BZ<R2@3.]9I/241M:+=X5>V/VAU=I37U)=+U
M10Q4<;'(YS9VO7*IZ$4EC?C0TVN-#RTEO@CENT$C):97.1OBB.3*^EN?T$D@
M6\Z(B>Q7S9F8[H4[/.EM9Z.@J[7J2EC;;'?=(7-G:]6.\4PB]%,KO%L_;]?8
MKJ=Z4=YC9P-FQYLB>".Y?I)6 OY_4KYN<*?KL[NM1,?;:&OF6V>UX8[BK8U;
M_ARGU$E[.[$PZ3N4=XU#-'6W*)<PL9S9&JIUYIS4G4$Q:8W[HF,[.&I@Y (2
M
M
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M,5\ZO/'0MYMN662 R,@
M
M                                              (NWLVTK-PZ:BBI
M[MY)%3*KNZ<SB1[E\243C)$UB>J8F8Z(SVSVOLND-,)37.BHJFM>G%43RL1R
M+RZ)GHA4_<.BH?9/K:;23>*G6H1(6P\TXO\ 9^4LYOWH[56KX[?3Z7J$@ABX
MEFS.L:.ST3EU(#T+7+M%KQ\>L;&R:?"8E5.)T:+^$WP4FEN;5BUML?R3'+IS
M%=UOIZZ:RZ,6MG9WL]+1I(]BKCB<UO-,D0:6[1-'<;7>JN[VUE"^B:Q*>%DW
M&^H>[B3A1,?[*?.2EJ>XTUVVYN5=02)+2U%"^2-Z>**U2JG9CTY27_<226OA
M9-#0L[U&/3*<7/'+Y%)K$WU+5G;[E&:UTHMZ_HV.Y=H36]+7MJI;%3TUL5W*
M.6!Z*J>CC7^!.6TFYUMW!MTCH&I37"%$[ZF5V53UIZ4-@UU8**_Z5N%!6T\<
MD:P.X,I[541<*GH*<;"7&:Q;PVV")[D9-,ZFD1.CD7*#2Q:WDY]R+Q,5YX3A
MVO5_]AJ'\9_<IA.R/;+?6Z:O#J^BI:AS:EJ-66-KE3S?69OM=_U'H?QG]RE;
M=%6'65VI)Y-)0W&2G8[$BTLBM3B]?-/ IHSCG^_!IJ1F*_?BOFFG;#C^BK=]
M S^!^Z>QV>GG;+36VACE;S:^.%J*GP*B%*ET5NUGE27['XPO\Q)O9\TWKRUZ
MZ2?5,%U90=P],U,RN;Q<L<LJ:5C,LYG$+.IT!A=2ZHLVF*:.>_5\5%#([A8Z
M3.%7Y#7?9?T)_K+1?_E_ K$Y2WS)5/M=:J\IN5%IZG>BLI_NLR(OX2IR12S%
M+?*"ML?V7HJED] L:RME;T<U"B=RJEUUNL^6>5K8ZZM1O'(Y&HV/BQU7IR*\
MLWU(HM%HK2;MOU)MPENV(M5\[A4K^_[Z5_#S[MZ8:B_^O$D'L@ZE6>VW'3\S
MT5T#DGB3QPO4E?5K;!=-#UUD9<K=W3J58HVI4,Y*B<O'U%0]H[])HK<ZG>Z1
M.Y29U++A<HK57'UX4UI:+:MJ1TGI\O@SM7&E%N\??U7U\"CW:.N4URW4K*>1
MZK' YL+&YRB<D+O1/22-KFKEKDRB^DH?O<N-X+O^-)^XRQG4K$M8G&G:87+T
M7:K;8-&6VFBC@@@92L<]51$15X4RJE/=RH*:[[RU<6DHTE;)4-1GD_17?A*F
M/66*W,VYNFNK!9EM=YDH4IZ1&NA1RHV55:F,X($TQ>[ELQK5]#>+122O:N'S
M*S+W,7Q8XTB<ZW-;QGXLXVT<5WVA<^SQR0VVECG55E;$U'*OIQS/88_3]TIK
MU:*2XT+T?3U,:2,7U*9!>A%LYG)7&(PT;>K4BZ6V[NM?$]&5#F=S"O\ M.Y<
MO@YJ0?V0[*E9>;O?:EJODB:D;'N_M.ZFP]L>M='IBRT;7*B2U+GJGIPU?XF9
M[)5(V';N>=$PZ6J=E?4B(1H];W\-OO\ =.KTK7Q^_DVW>30-3N!8J:W4]S\A
M9%-WKTX.)).2HB*8;:/:*VZ-M<Z7FFHZZXR/7,[V(Y$9X(B+T):Z$;;X:<U'
MJC3L%OTK/W$_>H^1_?+'YJ9Y90KGDSR]TXY\1/95[?JCM$&Y=7#IID:,XF\3
M(?:I)A,HF/67(VZAJX-$66*X<7E+:9J/1W5/A*=4%#7;3Z]IJC6=ECK41>)K
MGKQHJ_VVKXJGK+H:5U%;]26*GNMKE22DE;E%_LJG5%^ TIBNEB)SO]5;SG4S
M,8V9@&DUFZVB:*KEIJK4-''/$Y6/8N<M5.J=#TV3<;2=\K4I+3>Z6IJ%17(Q
MBKG")E>J%8WZ)G;J]^M-1TFE=-UMWKWM;%3L5415]N[P:GPJ45U.M^UDR[:P
MN'$ZF;,D:O<N$3BSAC?@0DO=K4]QW4W"@TKIYSI+;%,C&\/1RIGB>OJ0WK?G
M3=%I78Z"U6Z-K(XIH^)R=7NQS<IG_;Y2?9'[]6D>EY./?]&.[&?]&7_XQGU&
M9[2.@]4:TJZ'[!0-FHJ2)SE9WB(KGJO@B^HPW8T14ME_RG_O&?462\#;6KF8
M]WP8:,XB?;/Q1-LAMM0Z?T7 E[L\'V6G57S]_&U[F^A.>? @3M.V&TV/7D#;
M+%'3K40][-%%R1KL^">&2S&ZFY-KT':7OJ)627.1BK3TR<U<OI7T(5AV\TO>
M]VM>ONUV;(^B27O:J=W)J)G/ W^!3?5U(F.S2,:=)SW6@V2=5/VSLBUJN67N
MEYNZXXEP5O[05)+H[>2*[VWB@[](ZMJMY)QHOG?47$HJ:*CI8J:G8C(8FHUK
M4\$0K/VS*-.\T]68Y\,D:K\J+_$G5O\ U8U(\32KYDTGP6*TG=67S3UON4:M
M5*F%LBXZ95.:?.95Q%79EKG5NU= CW96%[H_D125E0OJ1$6G#/3G-85][3.X
MLEDI*C2S;<DK+A2Y6H[Q45G/T8Y]"OVTNNUT#?IKFEM9<'R1+$C'.X>'*]47
M"EO-^K;12[;7ZKFI*>2ICI_,E=&BN;S\%ZH5Z[)UOH[AKFNBKZ6"IB2D54;,
MQ'HBY3GS,]&)YICO_P KZN.6)GIGZ+):5ULZ];:NU2M V%R0OE\F1^4\WPS@
MT#;#?:76>LJ6QNL,=(DW%]V;/Q*W"*O3'J)3UC2P4>A+S#20QPPMI).%D;4:
MU/-7P0J%V:?=@MJ?&?J.+Z>+:LQVQ]47B:Z,6[Y^C?.V>G^>Z>_P2?6AB]#[
MMSZ5VSH;+IBB6OOKGO>Y.!7MA;GJJ)U,IVS_ +^T]_@D^M#<.R=IVDI=%27G
MN6+754KF]ZJ95&)RPGH*:,9I;[[K:LXM7[[--TMVD+S27-*76%KA6-7HCWQ,
M6)T:>MJYR6=M=QIKI;H*VAD;+3SL1['IT5%*U=K[3E) EKO5- V.HE<Z*9S$
MQQ>**OK-R[)UUFN&W<U-,]7>1U"QLRO1JIG!:D\]9\85O$UM'A+%W#M#.HM<
M5%AGLD3*>&K6G=4NJ,8:BX5V,&N:J[1=X?JAM+I2BI7T#94CS,Q7.FYXRBY3
M!#.X<*U.Z-Z@3K)<'L^=Q=O1VAK!9K%;X(+51J^.-CN\?$USU=A.>53/4C3C
M-*WG_E-YQ>:0T_<[=BMT+8K#5UEDCJ*JX1<<L2S<*1.PBXZ+GJ;3M#K9VO=*
M_9=]"VB7O71]VU_&G+QSA"'>V8F*;3Z)TS)^XW'LF^Y>GXR_]Q.GBT7F?O=&
MI'+R1X_[0!VC_=AN7^*/]5"WEMO%)8-N*&YW&5(J6FH6/>Y?4WI\)4/M'^[#
M<O\ %'^JA8'=>UUUUV @AML;I98Z:&5[&]7,:G/EXE*SCA\QXM+Q%M>(GP^B
M.KWVB]2W.NDBTA98FPL=R=)$Z9SF^M$Q@ZK7VC-56JK;'JFS4[VO5.38W0.1
MOCA%SDU;8;<VW;?U%=#=J%TD=2J*LT;<R,QX? 33=[]M?NH^WMNE?''41.XF
M,E^Y.7/X+E]'RFF,8Y=V><YSLEC2.HJ#5%@I;M:Y4DIYVY3TM7Q1?6AF47*&
M T=INT:8M#:*P0MBHW+QIPOXD<J^.3/IT(MC.Q7.-P $)
M
M
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MZ'T@VDKVL2XRN5\_ [B3JN$R33SN:]^OW_M%O-BM*=/O_2N7^3KK[.>[H/\
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M5W#G\%,^!81.AJ>VNB*#0VG8[9;W.D?GCEF=UD=Z3;$-=28F=F5(Q  "BX
M
M
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M&#D <<(P<@#C X?A.0 P  &$.,'( XP,'( XP,'( 8&  "
M
M
M
M
M
M
M
M
M
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M)J0
M
M
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M'T3
M
M
M                                   I^>$_0 X1/4,'( (  !T5_P!X
MU/Q;OJ4[SHK_ +QJ?BW?4H'SST=[JEG_ "Q%^V0^B9\[-'>ZI9_RQ%^V0^B8
M
M
M
M                                       #HK_O&I^+=]2G>=%?]XU/
MQ;OJ4#YYZ.]U2S_EB+]LA]$SYV:.]U2S_EB+]LA]$P
M
M
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MFZ7%46JFC^Z*B8RJ+C(C%HF8[$YB8SW;@ @(2
M '17_>-3\6[ZE.\Z*_[QJ?BW?4H'SST=[JEG_+$7[9#Z)GSLT=[JEG_+$7[9
M#Z)@
M
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MQ\TS)T 0$       '&0.0?E7HB<U1/A.$E8O)'M7X% _8.,G(
M#HK_ +QJ?BW?4IWG17_>-3\6[ZE ^>>CO=4L_P"6(OVR'T3/G9H[W5+/^6(O
MVR'T3
M
M                              #  'FKJ&FKH'0UD+)HU_!>W)BZ725C
MI9VS0VZG;(U<HO G(SH+1>T1B)9VTJ6GFM$3+\M8C6HC<(B=$1#] %6@
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M ^>>CO=4L_Y8B_;(?1,^=FCO=4L_Y8B_;(?1,
M
M                     #SUU7'1TD]1.[@BB:KW.QG"(:"N[^GLKRJOS"17
M,:YJHY$5%Y*B^)BETW8U556SV]57_P#C,_@::<TCTXRTI-(]*&G>R]I_T5/T
M9ZK7NG8*^OAI6OFB65>%KI&83/@:=MW;:&IW/U+35%'32T\??<$3XFN:W$J(
MF$5,)R):CT[98WM?'::!KVKE')3L147YC?5KI4G&)_=MJ1I4G&)9-%ST.1@'
M(Y0
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MXU/Q;OJ4#YYZ.]U2S_EB+]LA]$SYV:.]U2S_ )8B_;(?1,
M
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M+T1?0LJ*?18
M                                          "]#4]2Z%L^I+@E7<DJ
M%F1B,3@DPB(GJ-L!:MIK.:RM6TUG,(1W.T%9=.Z:6NMS9TG[UK//DXDPOJ,W
MIW;#3U=8Z"JJ&5*RS0M>_$N$RJ? 9#?3^I#OCV?6IM6C/ZJVK\69]1U3K7\E
M$YWRZ9U;^2B<[Y-*Z=M^FZ)]+:XW-C>[C<KW<2N4S(!R3,S.9<LS-IS( "$
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MO680S:KANBZY4S:RE:E,LC4E58T3#<\_T$R-\#] \K5U?*3$\L1['16O+W
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M##GB[NZPLSZ<2HA]&#YV:.]U2S_EB+]LA]$P
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M[SY'Y1&M\5SGJ;<3I7FV8G;'BPM^,:.M;^GS3'3I*10<)GQ.3SG4
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M'PX(R82(##:3U-:M4VJ.XV2K94T[^2JWJU?0J>"F9+3&-I1$YZ  (2
M  '17_>-3\6[ZE.\Z*_[QJ?BW?4H'SST=[JEG_+$7[9#Z)GSLT=[JEG_ "Q%
M^V0^B8
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M5D:>?CU87/SJ;1H6C>^WM:^1F-[3A(=QO%OML3I*ZKBA8WKQ.Y_,:;<MU;'
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MI_:93RF?$Y /"?6@
M  JX.$7('("J<(N0.0$7(                            !DXR@'(
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MB_;(?1,^=FCO=4L_Y8B_;(?1,
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M1#.W&7GT=E+<%P\^C7'OM]4=4^U\%.U&P72IB3_8Y?4IV^QNGOU7?G+_ !)
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MC&_ AZCPK\5>;3,3L^\IP&CRQS5WQ'BC_P!C=/?JO_/7^(]C=/?JO_/7^)(
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M8D$7$V%D7 UK4Q_$D(BS;'9NUZ!OK[G07"JJ)'Q+$K)43&%5.?Z"4R]L;81
M "J0        Z*_[QJ?BW?4IWG17_>-3\6[ZE ^>>CO=4L_Y8B_;(?1,^=FC
MO=4L_P"6(OVR'T3
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M/M,>]$/YSOXG[@T'IN"9DL5JA;(QR.:N7<E3IXFS GRVI_E/[J1PFA'2D?M
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M/Q;OJ4[SHK_O&I^+=]2@?//1WNJ6?\L1?MD/HF?.S1WNJ6?\L1?MD/HF
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M\ALIK&V/]0;%^*L^HV<^;UIF;VYIS.7H5Z1@ !FD
M                       8  8&  &        %3(P  5$48  8.,(<@#CA
M0<*'( ''"AR .,(<X  XX4'"AR .$1$Z#A0Y '&$'"AR .,(<X  XX4'"AR
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M9D$=G7;"X:<DEU'J3+;I5,5&1.7B<UKL*JN7TJ3N6MM6M9G,Q"D;VM:.DR
MHL        '17_>-3\6[ZE.\Z*_[QJ?BW?4H'SST=[JEG_+$7[9#Z)GSLT=[
MJEG_ "Q%^V0^B8
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M&/W@YX]?[)9!@-&W.[72U+/?;:ENJ>)42-'\2.3T]>1GSGM6:S,2O&X "H
M                                  <9SX@<@        _,CT8Q7.7"(
MF5-7TGKVP:JN%;162K?/44:XF:Z)S.'GCJJ<Q&\X@G;=M0">(     <*H'(/
M+3UM/433Q03QR20+PR-:[*L7T+Z#U(
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MW5+/^6(OVR'T3/GAH^)R;IVA?,Q]EXOPT_\ &3UGT/
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MM\YEJNW55J*KLKWZLIHZ>K2148B)PJK?6G@;5@ X[VYK3.,-(C$8,)Z  52
M #SUSG,I)W,54<C'*BIX<BI+]=ZIXW?]OW'K_P",I:;5U1+2:9ND\#E;)'3O
M5JHSC5%POAXE-UC<JJOF_G(>S^%:=;1:;1GHY>)M,8PV'[>]4^_]Q^G4VS:G
M5NH+CKRUTE=>*VHII'.1\<DJN:[S%7H1CW;O]G\Y#.:'6>#5ELD@FEA>DR)Q
MPHCG87KRSZ#TM;1TYT[1$1T\'/2]N:,RN*#AO1.O0Y/E'I
M                 8O4ESDM%HFK(:9]4^-4Q$SJN5P!E 1O[(M?_JY5_I_@
M=%PW'N+:.9T=DGIWHG*63/"WUKR S=YUW;Z*YUEKD[V*HC:K4EQYJ+PY0CC0
MNII+5?*BJN57.^G?$]SV*Y7<;O#Y3"WVZS7NM6KJ(X6S.3SECPG%\)C>!?5\
MZ 6*TIJ.FU)2S3T<<C&Q/X%1_7.,F=(&TKK2NLD4-'24L$D/%ES&XXY%_B;E
M[(M=_JY5_I_@!(X(_M^OJVJK8*=]@JHVRO1BO7.&Y\>AOZ(!R  .JK^]9O\
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MTA>J)Z5E13Z,@
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ML1?2B'3J?BDWI->7KZV=>&BLYR_8 /)=(
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MB:U/0B2H?14^=FCO=4L_Y8B_;(?1,
M                  ?F1[8XW/>N&M3*J?HU+<^[/MFF)6P+_G%2Y(68Z\U+
M4K-[16.[+6U8TM.=2>S$[?,6^:BO&HJA'.;WOD]*J]$8GBA(9AM'6M+1IRBH
M\(CFL1S\>+EYJ8?<G4WV%M?D=$JONM9]S@C;U3/+B-;_ -74Q57@="U=.*SZ
M4[S[9WEKNM;C)K'4<.E+3(BTD;TDKIF],)^#G_US)(M-NI;3;X:*@B2*GB3#
M6H:_MSI=FG+*SOF(MQJ$XZE^<JKO1GU&UD:MH]"O2/O+LU+1Z%>D  ,60
M    #\2S118[V1C,].)R)DZ_+*7^\P_GH03VC;O2U%?;:"FGXJJFXUF:W\'.
M,?+R(:[Q_P#;=\YZG#_AOE=.+S;&?4Y[\1R6QA:'='6OV%H8K=9I(YKO7_<X
MN%R+W>>7%^GD>_;31U/IBU)+)B>Z52(^IJ%7B557GPHOH^LJ<KG*N55<^G);
MK:ZJAJ=!658)FRK'3LC?PKGA<B<T7UEN+X?\MHQ6L]9W]:-+4\I:9EM( /)=
M(
M                                  $;;KZ!OFKIZ:6Q:HJK,C&\$L;'
MN1CTY^"+U))!$Q$]4Q,QT:9MCM_;M!6E]-1/?45<Z\5152>VE=_ W->@!:9F
M>JL1CHCK0.WM1IC6VH[[-713QW5R*V)K%16<\\U)% (C:(CP3WF?$
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M.BO^\:GXMWU*!\\]'>ZI9_RQ%^V0^B9\[-'>ZI9_RQ%^V0^B8
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MIIQ6DYW:</IVK,S,,N #QG6
M
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M2G>=%?\ >-3\6[ZE ^>>CO=4L_Y8B_;(?1,^=FCO=4L_Y8B_;(?1,
M                                         #2=UZY\5B@MU.OW>XS-
M@PG7A\3\ZEND.AM$4]/3^=5=VD,+?%SL<W'AJ)H[UN<U[E1:&SP.<]R^U:\\
M%FC37>NJFY5+>.T6Q>[IV_@O=Z?WG9%8BL1;I&\_*'/P58U=;4XBW2-H]WUG
MX-DVOT\MFL*5%6W-RK5[Z=[O;<^B?(;B$3"80'+>TWF;2ZK6FTYD !54
M    /Q-(R&)\LCD:QB*YRKX(A^R.MZ+S/36:FLMMXEN%VD[EB-7FC?%?THAI
MI:<ZEXI"+3B,L+I#BUYN'4Z@G1_V,M:I'2,7HK_3^_YB7S!:)T_#IK3U-;X&
MX<U.*1?[3EZJ9TOQ&I%[>;TC:$4C$;@ ,%@
M
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MSHK_ +QJ?BW?4H'SST=[JEG_ "Q%^V0^B9\[-'>ZI9_RQ%^V0^B8
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M=';HT\]C$=*O]IZIS4ZZ?TM&;][;1[.[.?.MCP9T '(T
M
M                                                      !BM5V=
M+_IVX6ITJPI5Q+%WB)GASXX(XT/M-3:'TIJ.@EO*RP7&%R23R,1B1)PJBJ2U
M,CUB>D;N%ZHO"J^"E2-S]W-<6>ON^G+K2TR1/:^'C[KVS%RF4^0I:<9B.LPO
M7.T]HE[[-V=+#?F2RV?6K*UD;L/6!C'HU?0N%,C_ )*U-_K+-] G\2&]MMTK
M[H2CJZ>RPP/CJ7H]_&S/-#<7=H_6:M5$IZ1%]/=*:3CLSCUI2V2V_P!/:/UK
M4+:]5P72O;"^-]*U&\3>:95<+X8)Z*A]F.BO%XW0JM155/(V&1DCYID9PL5S
ME3DA;PM;/+7FZX1$QS6P  HL        '17_ 'C4_%N^I3O.BO\ O&I^+=]2
M@?//1WNJ6?\ +$7[9#Z)GSLT=[JEG_+$7[9#Z)@
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MO$ZD6OBO2-H12,1N  YU@
M
M                               </<UC5<]R-:G557"(82]VBS:@M]9#
M5,I94EB=&^9$:KF(J=<^!QKNW55VTA=J"WKBJJ(',CYXYKZR)=IMN]3Z=T?J
MJWW=Z.JZ^)S:=>^5W-6JG7P*SO%LQTC]_4M&V)B>_P!RW'0&W>D]&TM5!1R0
M53:AZ/5:IS)%;CT&U?8_3G]VM?YC"ICMA]Q5<JI.F%7^]*<>P-N+_>$_WI2T
MS,]5<87%H%H(T[F@6F:B<^"'A3]"'K*^;![9ZKT?JV:NU"]'TKJ=T:?=E?YR
MJF.7R%@RUHQC=$3U  52        '17_ 'C4_%N^I3O.BO\ O&I^+=]2@?//
M1WNJ6?\ +$7[9#Z)GSLT=[JEG_+$7[9#Z)@
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MYY6[@ Y%P
M
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M&I^+=]2@?//1WNJ6?\L1?MD/HF?.S1WNJ6?\L1?MD/HF
M                           $7[F<M>Z45>B.7]9#6->W1;_?:RJ5%?;K
M:[R:!J+_ *29?_6?D._?*Y,74%'%22XJ:2%>-47VJN7*?H/UINS05MTLEGBF
M[V"./[(54C>?%(O-$^3H>KIQ%:4O/:'E5O;1_,37TK6BL>^L;_LDW0%H^PNE
MZ.G>U$G<WO953Q<[FIL(:B(B(G1 >9:TVF;3W>EI:<:5(I7I  "JX
M  :]KZ_,T[I:NKW+]T1G!$B=5>O)"U*S>T5CNB9Q&6A:C8FN=U*2T-;Q6RSM
M66I7/)7>CY^%/G)>:B-1$1,(G)".]EK$^@L$EVK4<MPNC^^D<[KPYY(2(;\3
M:.:-.O2NWU5I&V9[@ .9<
M
M                                  #QWBWP7:U5=OJV\4%3$Z)Z>I4P
M>P_$TK((9)97(V-C5<YR]$1.I%HB8F)Z)B9B<PIOJ;8O7=NKZJUV)7UEDEDX
MV*DR,:[_ !-SU0F/3>VU=H[9NZ6RA?*Z_5,2R/=3KAW'CDUJH1ONKOS>;A?9
M+7H-7QTT3N!9V,XGRKZD\$-+BW(W2L$C:NMJ+DD2KE4J8E5J^KFA%?.I->T]
MTSM?/>.R=^SMM;5:2IYKWJ%%2]5:*G=N7*QM7"\U]*X)M(YV8W-H]PK+Q*U(
M+I F)X,__DGJ)&-;YSB65,8R !>:*A1=!>\^]U!9:>LL>EW>77MR+$Y\>5;
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MY'R[C:?DD]N^YP.=\*RID^C0
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MJ>"(?L Y&@
M
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M/HF?.S1WNJ6?\L1?MD/HF
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M_<RK2)ZSW  <RX
M
M                             #A[FL8Y[U1K6IE57P0KMN+VD(+/=I:#
M35#%7)$JM?42/5&Y1?!/$F;<FI=1Z$OL[%5',I7X5/@*Q=EW0EIU3=+I<K[3
M,JXZ542.*3FWB7Q7TE:Q-KS':(RM.*TYO&<-SV][2$%YNK+?JFWP4<4O)L['
M*K47UHI8:E@I4:V6EBA1KT1R.8U.:>DJEVI] V;3;;7=[#2,HEGD6*6.+DU5
M1,HI8+9NLDKMM;#-,Y7/6G:BJOJY&E<6I-N\3A28FMHCM+<P 52
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MLYG#*-?GF*X6E:U&M1K4PB)A$.0#PG8
M
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MXMWU*=YT5_WC4_%N^I0/GGH[W5+/^6(OVR'T3/G9H[W5+/\ EB+]LA]$P
M                                 '#W(QCG.7#6IE57P0#7M=ZDBTU8
MY*I<.J'KP0Q_VG&%VZM::>T[57>\.:RJJU6IF>Y,*QJ\T0PM%G<'7+ZJ1'+8
M;6O#&U>DDGI_]>"'MUI4U&I]00Z8MK^"FCQ)62-7P_LG773Q'D_?/L1QFO\
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MBV=F>GHWBT3,)< !\X[P
M
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M[E/:[7FE%:Y%1'=47_:0D_O8_P#Q&?.ATZWZ=/9\WG<'/]?7]L?"'[ !S/1
M   -"W*UJMFB2TV5%J+_ %6&11L3/=Y_"7UE]/3MJ6Y:HF8B,RQVZ6IJF>JA
MTGIQRNNE8J,F>Q<]TQ4Y].BX_0;9H72M)I.RLHJ;#YE\Z:;'.1QB-M=#LT[
MZXW)RU-]JVYJ)GKQ<*JN5:B_6IO)MK:E:U\EI](ZSXRK6)SS2  YEP
M
M
M                                  Z*_P"\:GXMWU*=YT5_WC4_%N^I
M0/GGH[W5+/\ EB+]LA]$SYV:.]U2S_EB+]LA]$P
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M\?\ 2L5F9S8 !RK@
M
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MW0)2VJG;&W\)_5SU]*J9=K4:U&M1$1.B(<F>KKS>.6L8KX+5KC>>H #!8
M
M
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MK75U?62]P])%E57*O'U5.7PDPZ7U/1:C9.Z@;*B0JB.XTQU SH
M
M                                 - WVODNG]L;S5TSE;,YB0M<BX5.
M)<9(:[-6VE@U-IJNN^I*)E?++,L;$D5?-]*\O'F21VI6N=M)7\**N)8U7U><
M>+LF*B[9N1%YI4N^I!I1$\\SZODF\XBL(DTMG;CM%.L]LD>VW35*0N8OBQW1
M/D+B%.MQT6H[3M,V!?.2K@1?A-X[2&DM<W34])<-),KYZ-T"1.CI)5:K7)GF
MJ90FDS.C69]<(O&-6T1ZI^*QN3HK_O&H^+=]2E'/M'W=][M0_3+_ #'YDT1N
MVC'*^W:@X$3GF9>GYQ UG1WNJV?\L1?MD/HED^9E#35TUXAIJ-DKKB^9(XVL
M7SUDXL(B>O))/VC[N^]VH?IE_F O5D9**_:/N[[W:A^F7^8?:/N[[W:A^F7^
M8"]61DHK]H^[OO=J'Z9?YA]H^[OO=J'Z9?Y@+U9&2BOVC[N^]VH?IE_F'VC[
MN^]VH?IE_F O5D9**_:/N[[W:A^F7^8?:/N[[W:A^F7^8"]61DHK]H^[OO=J
M'Z9?YA]H^[OO=J'Z9?Y@+U9.'NX6.=UPF2BWVC[N^]VH?IE_F./M'W=][M0?
M3+_,!(NIKNR\ZAKJO+D>YZM5KG<2MPN,)ZC&FM6C16XE! UKM(W.65'*Y9%<
MF5S\IE*NAU[0T4U36Z)K(X(6*^21SD1&M3FJJ>[3B]"*1'-V]?T?)<=^#<1?
M5MJ:?G9GU0R#U:UJJ]41/2IF;;>K?3TT+:/2?V08B?Z9[GN5RYY]$(EMNIKI
MJ:Y0VZU6J2JJY<]W!$_F["9/>FA-V&.=W%HOD+'+GAC?PI\R*9Z_&:45CE\[
M]X=WX9^%6T(MY;$YQMM,)RH]57Z%G%;M$4D*K[5W!G'SG=]MFX\J]W262*%O
M@UL:)^\@C[2-W?>[4'TR_P P^TC=[WOU#],O\QQ?FJ?_ !Q_+W*TY-J[>Z/H
MF"M7<VXJK98:U$=RX62-8GZ%/%0:.U?3523SZ?96.3PJ)$<GUD6?:1N][WZA
M^F7^8?:1N[[WZA^F7^8M''3$8BD0TYK].:4_TE3N72,X:"QVRDB\&1QL;CYE
M,-K9-;UUBD^VMK8;>QZ.7N%1$S_M8ZH0S]I&[OO?J'Z9?YCA=#;M/PDUJOTL
M>4RQ\N47X45Q6O%XM$\L1OVC=AJ:4WK-8M.99]**B1<]_P#I.VJBI:EZ.?.B
M*B8Y*?ENF=:I&QOL=URN3'$JS]?TG[^UK6>4_P#[<UV/CU/1_P#,]+U_P\6?
MP?6F8M.M.89'3&G%N]?Y/;FS5#L<3VQOX5X<^DWRCT"E.S$FE9*A<YXI:OFO
MS$+7'1.YTM<^:VZ;O%OB<B(D<,G3Y<GG^TC=WWNU#],O\QP<1QM[WSIVF(>K
MPO#3HZ?+J3S3XRLC06J:A:B4V@[>F.BO<UZ__EDS<%UU'3_>^EJ:+ECS'M;]
M15/[2-W?>[4/TR_S#[2-W?>[4/TR_P QQVO:W6<NJ(B.BV7VP:K_ -76?3(/
MM@U7_JZSZ9"IOVD;N^]VH?IE_F,7J*S[DZ;M_EU]9>Z*DXT9WLLRXXESA.OJ
M4JE<5;_JQ45$T]&B^'W9"#M36J2KOM;475)8ZR2172-ST7U>HA[2[-=ZIFFB
MT]-=Z^2%O%(V&=RJU.F5RIN.G=([F6ROFJ:W2UVN#I&\.)9.GKZJ::>K?2G-
M)PB:Q;:6<^P5+_;E^=!]@J7^W)\Z':E!N#A<Z KE7P^Z(>2Z67<2NMDU*FAK
MA%)(F.\;(F4-?SFO_G*GDJ>";]$W34]#INDAI[6M=3(GW&5\R(O!T1/T&=^V
M#5?^KK/ID*EQ:#W:AC;'%;+^QC>2-;+A$_\ R/U]I&[OO=J'Z9?YCFZM%LOM
M@U7_ *NL^F0?;!JO_5UGTR%3?M(W=][M0_3+_,/M(W=][M0_3+_,!;+[8-5_
MZNL^F0?;!JO_ %=9],A4W[2-W?>[4/TR_P P^TC=WWNU#],O\P%FM4ZDU9%:
MUQ:_(45V%F8Y'JB=?D^$B^XUU3<:EU16RK-.Y,*]43*D:/T+NV]BM?;=0.:J
M85%E7"__ )&S66Q[@VVV0TK]"W"=[$7,CI4R[F!G#8M-ZBOM%+3TUKF>^-CL
MI3HU%1WPFG>0[@?_ "_KOI4-;O\ H_<RX7-M90:8N]O<C.%4BEZ^OJ@%I$U!
MJO']76?3(=4^K;_0-;-<K!P4O$B.<R1'*GR%4OM(W=][M0_3+_,8/55NW TS
M2Q3:C^S-#!,[@8Z>9<.=UQU NHFX-NQ]ZUGY@]D&W?W6L_,*3:7M.NM5033:
M>CNM?%"Y&2.AE54:JIG"Y4S?L?;K>]%]^D_Z@+?>R#;O[K6?F#V0;=_=:S\P
MJ#['VZWO1??I/^H>Q]NM[T7WZ3_J L;KS7=+>:":VT]&]8G87O'NPJ.3U$<Y
M7"(JJJ)T3T&K633VZ5NAA@ETE5U,#%7/&U.-W_FR9OR'<#_Y?UWTJ 9JW5RT
MMSIJR9JSK Y'(U7=<=$R3#;=R[?50(Y])5-D1$XT:WB1%^$@">@W$="](-!5
MK)53S7.>CD1?@\35[KH[=FXU"2OL-T@1$PC(,,;\R. MC[(-N_NM9^8/9!MW
M]UK/S"H/L?;K>]%]^D_ZA['VZWO1??I/^H"WWL@V[^ZUGY@]D&W?W6L_,*@^
MQ]NM[T7WZ3_J'L?;K>]%]^D_Z@+?>R#;O[K6?F'AO6XD45NE=;:.=U2GM>];
MAJ>M2I_L?;K>]%]^D_ZCAVWNZKD5'6>^*B]463_J EW4-\J;]5-J:V.%LR)P
MJZ-N.)/68HP=GL^Y-'1-AK=%W&LE1?\ 2N>C5QX)@Q>J-3WW2LT$.HM+2V^6
M=JOC;+-S<B+A53" 2GI75==IY'1T$$#TD>BOXF^<[U9)2CW!H%8U9*2K1^.:
M(SH57K[7N%JJUTM58M-7&&@G;QMDA>BI*F>2HO)4,7['VZWO1??I/^H"WWL@
MV[^ZUGY@]D&W?W6L_,*@^Q]NM[T7WZ3_ *A['VZWO1??I/\ J M][(-N_NM9
M^8/9!MW]UK/S"H/L?;K>]%]^D_ZA['VZWO1??I/^H"WWL@V[^ZUGYAJNLMP:
M>X4E5;(J"1896<*O>[A<B_ 5K]C[=;WHOOTG_4;)IZP[FVVE=!7:0N->F<L>
M]R(YOJ5<KD#9>\?W21<2]VBY1N>2+Z3NH:A*>MIYY6K*V%Z.X,XZ+T]1B/(=
MP/\ Y?UWTJ'/D.X'_P OZ[Z5 )VL^YE%54_^<4<\<[5YLC\Y,>',]_L@V[^Z
MUGYA5._:1W3NE8DT>F[G1L:BM:R!>'EG/-<\U,;['VZWO1??I/\ J M][(-N
M_NM9^8/9!MW]UK/S"H/L?;K>]%]^D_ZA['VZWO1??I/^H"WWL@V[^ZUGY@]D
M&W?W6L_,*@^Q]NM[T7WZ3_J-4N\FJ;/=W6NZ3W&FN#51JP/E7B15Z>(%V[UN
M)%';IG6VCG6I1/-65N&IZU(KU#?*F^U25-;'"V9$PKHVXS\)$/L?;J21_P!$
M7QS')_XG)4_.-ETWIK<&ST/<2:(N55*JY=*^7FOR ;(;+I75E?8&+#000/;(
M]%?Q-\Y_JR:7Y#N!_P#+^N^E0US4VC=QKO50STFD;K0O8F%6.3/%Z%Z\@+K4
MDJS4L4KV\#GM1RM]&4Z';DHK]H^[OO=J'Z9?YA]H^[OO=J'Z9?Y@+U9&2BOV
MC[N^]VH?IE_F'VC[N^]VH?IE_F O5D9**_:/N[[W:A^F7^8?:/N[[W:A^F7^
M8"]61DHK]H^[OO=J'Z9?YA]H^[OO=J'Z9?Y@+U9&2BOVC[N^]VH?IE_F'VC[
MN^]VH?IE_F O5D9**_:/N[[W:A^F7^8U-*[5ZWS[#)6W7[*=\M/Y-W[N/O,X
MX>O7('T6!J>U-%=Z#0EJI]0R.=<&1^>CVX<SFO)W-<KZS;
M
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M:[N-_4+4/XC-^HH%+NS=[L-A_P 3_P!12^90SLW>[#8?\3_U%+Y@
M        "%>UO[EC?QZ/]5Y-1"O:W]RQGX]'^J\".>Q=_6"__BJ?KM+8%3^Q
M=_6"_P#XJGZ[2V                  KKVS_P"J]A_&W?JJ6**Z]L_^J]A_
M&W?JJ!U=BS^K^H_QIGZA8\KAV+/ZOZC_ !J/]0L>                 *F=
MM/\ K+IO\4D_7+9E3.VG_673?XI)^N!/>R'N4Z:_%4^M3>#1]D/<ITU^*I]:
MF\                 "C6_ON[5WQ\'_  EY2C6_ON[5WQ\'_"!>"D^]8?\
M WZCM.JD^]8?\#?J.T                 43@_[R#ORZ[]HI>PHG!_WCW?E
MUW[10+V
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M33O3+9(7H]J_*@'H ,.NJ+"EP\@6\VY*WBX>X\H9QY]&,Y S "+E,IS0
M
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MCI7NUG?G3*JRK3><J]<\:9+:%3^R'_7O4GQ*_M"V!T7Z5]C*.MO:  S6
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MVK':0 %%P
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MJZRGDI:QRY?-3*C5?\/+![]N]K--Z$5TMHIWR5CDX75,Z\3\>CU%Z3F:VO\
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ML@ *+
M
M
M
M
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M&#&:9O5+J"QT=TH7(Z"IC1Z>K/5#)DS$Q.)1$YC,  (2
M
M
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M@="]%QTY.+AFUYS$6\89UCEF:^L !FN
M
M
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M1(!OJ8B>6.S&F\3:>X #-<
M
M
M                                               <.:CFJUR(J*F%
M1?$QEFT_:++)/):;;2T;YUS*L$:,X_AQU  R@       !B;IIVSW6N@K+E;*
M2JJH,=U++$CG,PN>2KTY@ 99.280
M
5                        !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g111069g00a14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a14.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1#V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $-D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          #_
MX4 [:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B
M92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O,#<O,3 M,C(Z
M,#8Z-3,@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @
M(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H
M;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C8P,S0W.3PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A
M=6QT(CY-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@0V%R:6)O;W,@+2!3+30@
M7U)?1R!$<F%F=%\N9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(V+3 T+3$V5#(S.C S.C$V*S U.C,P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R
M<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R-BTP-"TQ-U0P,3HR,3HR,BLP-3HS,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#0M,3=4
M,#$Z,C$Z,C(K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,C4N," H5VEN9&]W<RD\
M+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O
M8F4Z9&]C:60Z<&AO=&]S:&]P.C1D868S.3=E+69B8C M9F8T,RUA,30S+69A
M-S)D83AE8S P-CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DEN<W1A;F-E240^>&UP+FEI9#HU9&5A,C(V-BTV.64P+61F-#(M8C)C,2TP
M96$P.3AF8SAD,6,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T
M;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.F8R.3DU8CDQ+3(R.&(M,&(T,2UB8C4U+6%A,3@P
M9C X-#0X93PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R-BTP-"TQ-U0P,3HQ.3HS,2LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#HS9&(Y96(T9"UC,S,V+3,U-#0M.31E82UA,3DW.3$P-V,Y,&4\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C8M,#0M,3=4,#$Z,C$Z,C(K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU9&5A,C(V-BTV.64P+61F-#(M
M8C)C,2TP96$P.3AF8SAD,6,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C8M,#0M,3=4,#$Z,C$Z,C(K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z.#1F,S<T-6$M,&4S-2TT,S5C+3EA-#<M93<X-3,T,#4W,S0Y/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,V1B.65B-&0M8S,S-BTS-30T+3DT
M96$M83$Y-SDQ,#=C.3!E/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.F8R.3DU8CDQ+3(R.&(M,&(T
M,2UB8C4U+6%A,3@P9C X-#0X93PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C@T9C,W-#5A
M+3!E,S4M-#,U8RTY830W+64W.#4S-# U-S,T.3PO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-
M;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*
M% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_;
M $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( )D%\@,!(@ "$0$#$0'_Q  <
M  $!  ,! 0$!            !P$%!@0# @C_Q !/$   !0("!P4$!@@$ P8'
M 0   0(#!001!B$'$A,7,5.A05%4<9,4(C)A"!4V0H&Q%B,S-5)RD9(E<\'1
M)F+A)"<W0X*R-$958W3"\/'_Q  : 0$  P$! 0               0(#! 4&
M_\0 -!$  @$# P0! @4$ 00#      $" P01$Q11$B$Q4D%A<04B,H&Q,T*1
MH33!T>'P(V*"_]H # ,!  (1 Q$ /P"[:3,05&&X-V0IBUU-E\%[7$A+37+&
MFY4*?4,4?3N7_!E47R+\Q_,G80]S\.MZ56EU3CEY.&XG.,\)E5+37+>!1ZAA
MOKEO!(]0Q*@'=LK?T1CJS]BJ[ZY;P2/4,-]<MX)'J&)4 ;&W]$-:?)5=]<MX
M)'J&&^N6\$CU#$J -C;^B&M/DJN^N6\$CU##?7+>"1ZAB5 &QM_1#6GR57?7
M+>"1ZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?T0UI\E5
MWURW@D>H8;ZY;P2/4,2H V-OZ(:T^2J[ZY;P2/4,-]<MX)'J&)4 ;&W]$-:?
M)5=]<MX)'J&&^N6\$CU#$J -C;^B&M/DJN^N6\$CU##?7+>"1ZAB5 &QM_1#
M6GR57?7+>"1ZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?
MT0UI\E5WURW@D>H8;ZY;P2/4,2H V-OZ(:T^2J[ZY;P2/4,-]<MX)'J&)4 ;
M&W]$-:?)5=]<MX)'J&&^N6\$CU#$J -C;^B&M/DJN^N6\$CU##?7+>"1ZAB5
M &QM_1#6GR57?7+>"1ZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H
M8E0!L;?T0UI\E5WURW@D>H8;ZY;P2/4,2H V-OZ(:T^2J[ZY;P2/4,-]<MX)
M'J&)4 ;&W]$-:?)5=]<MX)'J&&^N6\$CU#$J -C;^B&M/DJN^N6\$CU##?7+
M>"1ZAB5 &QM_1#6GR57?7+>"1ZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PW
MURW@D>H8E0!L;?T0UI\E5WURW@D>H8;ZY;P2/4,2H V-OZ(:T^2J[ZY;P2/4
M,-]<MX)'J&)4 ;&W]$-:?)5=]<MX)'J&&^N6\$CU#$J -C;^B&M/DJN^N6\$
MCU##?7+>"1ZAB5 &QM_1#6GR57?7+>"1ZAAOJEO!(]0Q*@#8V_HAK3Y+16:5
MI.GA**0]F2HZDU%L]?X;&-66FJ6\"CU#'&RWV.A?YW/S'."E*SH-/,5Y?\DR
MJSRNY5M]<MX)'J&&^N6\$CU#$J 7V-OZ(C6GR57?7+>"1ZAAOKEO!(]0Q*@#
M8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?T0UI\E5WURW@D>H8;ZY;P2/4,2
MH V-OZ(:T^2J[ZY;P2/4,-]<MX)'J&)4 ;&W]$-:?)5=]<MX)'J&&^N6\$CU
M#$J -C;^B&M/DJN^N6\$CU##?7+>"1ZAB5 &QM_1#6GR57?7+>"1ZAAOKEO!
M(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?T0UI\E5WURW@D>H8;ZY
M;P2/4,2H V-OZ(:T^2J[ZY;P2/4,-]<MX)'J&)4 ;&W]$-:?)5=]<MX)'J&&
M^N6\$CU#$J#(-C;^B&K4Y*KOKEO!(]0PWURW@4>H8E678,6,L[D&QM_1#6J<
ME6WURW@D>H8;ZY;P2/4,2DK_ "L,AL;?T0UI\E5WURW@4>H8;ZY;P*/[S$J+
MCV 5ROF&QM_1#6J<E5WURW@4>H8;ZY;P2/4,2HKVS -C;^B&M/DJN^N6\$CU
M##?7+>"1ZAB5 &QM_1#6GR57?7+>"1ZAAOKEO!(]0Q*B,L[AEJY!L;?T0UJG
M)5=]<MX%']YAOKEO H_O,2DKV[@+/@HC#8V_HAK3]BK;ZY;P2/4,-]<MX)'J
M&)58 V-OZ(:T^2J[ZY;P2/4,-]<MX)'J&)4 ;&W]$-:?)5=]<MX)'J&&^N6\
M$CU#$J -C;^B&M/DJN^N6\$CU##?7+>"1ZAB5 &QM_1#6GR57?7+>"1ZAAOK
MEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?T0UI\E5WURW@D>H8
M;ZY;P2/4,2H V-OZ(:T^2J[ZY;P2/4,-]<MX)'J&)4 ;&W]$-:?)5=]<MX)'
MJ&&^N6\$CU#$J -C;^B&M/DJN^N6\$CU##?7+>"1ZAB5 &QM_1#6GR57?7+>
M"1ZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?T0UI\E4/3
M7+$1G["CU#&TD]*\G11D=5IIB<55HUS2:[:@BQ_"?D.EQ%]G8#_*,4E94$U^
M5$JK/D[ ]-DMP]@1ZAC.^N6\"CU#$J :;*W]$0JM3V*KOKEO!(]0PWURW@D>
MH8E0"-C;^B&M/DJN^N6\$CU##?7+>"1ZAB5 &QM_1#6GR57?7+>"1ZAAOKEO
M!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?T0UI\E5WURW@D>H8;Z
MY;P2/4,2H V-OZ(:T^2J[ZY;P2/4,-]<MX)'J&)4 ;&W]$-:?)5=]<MX)'J&
M&^N6\$CU#$J -C;^B&M/DJN^N6\$CU##?7+>"1ZAB5 &QM_1#6GR57?7+>"1
MZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H8E0!L;?T0UI\E5WURW
M@D>H8;ZY;P2/4,2H/Q#8V_HAK3Y*IOKEO H_O,-]<MX%']YB5&1]XR6?:&QM
M_1#6J>Q5=]<MX)'J&&^N6\"C^\Q*OD&8;&W]$-:IR57?7+>!1_>8;ZY;P*/[
MS$J[,S#\2#8V_HAK5.2J[ZY;P2/4,-]<MX)'J&)58 V-OZ(:T^2J[ZY;P2/4
M,-]<MX)'J&)4!!L;?T0UI^Q5=]<MX)'J&&^N6\$CU#$JL7:%R/@&QM_1#6J<
ME5WURW@D>H8;ZY;P2/4,2H. ;&W]$-6?)5=]<MX%']YAOKEO!(]0Q*;&>9Y#
M(;&W]$-6IR57?7+>"1ZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PWURW@D>H
M8E0!L;?T0UI\E5WURW@D>H8;ZY;P2/4,2H V-OZ(:T^2J[ZY;P2/4,-]<MX)
M'J&)4 ;&W]$-:?)5=]<MX)'J&&^N6\$CU#$J -C;^B&M/DJN^N6\$CU##?7+
M>"1ZAB5 &QM_1#6GR57?7+>"1ZAAOKEO!(]0Q*@#8V_HAK3Y*KOKEO!(]0PW
MURW@D>H8E0!L;?T0UI\E5WURW@D>H8;ZY;P2/4,2H V-OZ(:T^2J[ZY;P2/4
M,-]<MX)'J&)4 ;&W]$-:?)5=]<MX)'J&&^N6\$CU#$J -C;^B&M/DJF^J6O_
M /!(]0Q0]%^+Z[%:EN/I)E+9YH([W'\T"Y_1V_9U/F.*_M:5.BY0CA]C:A4E
M*6&RX$96[0&<@'A'<3;3M]C:KR+\Q_,9<"'].:=OL;5>1?F/YD+@0^B_"OZ/
M[GGW/ZP =H#TCG  ,]@D&         X]H9EQ$   "0         &2L7$ 8 /
MF!&(   $@         =[96,P(KEGQ$  '     $@  6$   ';L,K@  6RS,.
M/   #@69@  #%AD2                              Z*6^QL+_.Y^8YP
M='+?8V%_G<_,<X,J/Z7]W_++2\F0 !J5
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M^97'Y8CL!2>+JB(=9JW*]YU1;8\D:U^!##=N-:<6LI)/L7TET)OSDBG?\@%
M5H_4[I)>P]3N**E2>N;O:E W]72:.8^7*%>8JW7TJ)I=01^ZE0W=U'MTIO*S
MVX*:;[Y^"0 *;B+1XW!XTBZ9:E5$/7+(DJX'QS(;[&^'\"X.?:37T594+J$W
M0TTKX2[Q7>0S%13?5P6T9=\_!,:'"TG6X>JIIME)4%/DIQ1VOY#0IS/(?TC$
M5>&CT55;[=%4IA$WVC)YK,];_<?SO(JIEU[[E A3=(I9FTE9YDGL(Q-M<2JR
MFFL89$Z:C%27R;3!^&Z[%$K[%'ILHBUEN*^%!?,=O):&Y"FH:AVCE:6K=:*Z
MVD$9&0XW"6+)+"_M7U;L[U!$2M8OZ?F*]HOC:Z-@96>KJGVQZL;-Q-,RO7,K
M]Y#&[JUJ7YHM)=L+DFBHR[/R0%230HTJ(R4D[&1C ^]<ZIZMJ'5IU%+6:C3W
M9\!\!Z"\&3\@  20                                    !A7PGY#I
M,1?9R _R3'-J^$_(=)B+[.0'^28SEY1*\'. 0 0N0  !(
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M*FXXSXJ8O820K]H6M252E&<O):K!0DT@  .@S
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MX.CEOL;"_P [GYCG!E1_2_N_Y9:7DR  -2H
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M]2D%\KC7  ZHK"P9MY>0  +$
M 85\)^0Z3$7V<@/\DQS:OA/R'28B^SD!_DF,Y>42O!S@$ $+D   2
M                              +%H?FZ"NP]6X1DG":74DO9K/@>MV#$
M;H6JV99!UU:P<8VK64LN*BOP$@:6IM1+;4I"TYDHN)&-C^D$RMDVG).L4UPU
M3=.PXI6U2,I2I2QGR:QJ+IZ9K)0\936'8G'L9]2TC2&J%1>T.ME\1G_L-QI-
MP37XOE:>;PZIJL8J&TDI)JMJ9<1$E>\9G<[GQ,^T>VCF9*B;-NDKZIE'\+;A
MD0;:4>EPEW7/?(U$V\KLROZ1Y*GPUHTH\*O.D](.-D2M4\D6.YW&=(R=70O
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M5U0]4+25DJ<4:C(>8K]O$+:AH4^C.2U2?6\@  =!F
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M><J&V54R]<DM%JDL_P#FSS%:EG4<%33RL8\X[_\ 4E55EMKODH#9VT]+\O\
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MM%?F.6WN76G*+6,&LZ73%/)\4)-:B2DC4H^PBS,;;]&9KV?;_5E5LK7UMF?
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M0U)E:G0:&R,NVW$<MA3##ND"=EUIJRIW"4;N:;ZUS,1N4IR3\1\L:;Z4^3B
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M04H5)RA&4<='SS]BTFEU23\FA4I1FHUF9FK(S,\S&"(C(P+,KC)9)'IG*6O
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M$V 4G<_/<QGJ&Y^>YC/4-];^Z&C/@FP"D[GY[F,]0W/SW,9ZAOK?W0T9\$V
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MR&0 &+>06\AD !BWD%O(9  8MY!;R&0 &+>06\AD !BWD%O(9  8MY!;R&0
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MA]+TDR^P^EVC4:$MH]Y3JKVR(33Z,,Z]'SDQAVN2NG-Y*W6V'#^ R["(Q^]
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M>@_?]?Y)&X&GH/W_ %_DD;@
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M6LMI%-;,C01EP,KC(^% 9G1,&?'43^0^XJ50
M                !IX?]ZR/\XW T\/^]9'^< ;@
M                        8/@=AD8,[$8 YG%6#H?$[C*YEA3JF<DF2K".
MXXP'!/8ECL.89I336J43M2YK&>R;OVB]R-8W14515/'9ME!K5Y$)SH6HCKCE
M\4U!ZSLG4JV1GQ2VD[$5^X7A+&7P3W2*+$T+<='T]&R5FF4$@OP'+:4YY<-
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M)-H:,TXAQBE&;7MQV[A64<#$2QGL1\M&0 !4
M                 &E5]IT_Y0W0TJOM.G_* &X   &JD_WO0?S&-J97,QJI
M,[2]!_,?Y#;$97, 2_2]HWK\>5\2;<@U3T%(K7<:4DS-9W[!1*2@;IJ1EA#;
M>JV@D%[I=A#VW(+D"[+ (SB;1#75NDYG%</),TA$:5.,J2=SL5CX=X]FC/1;
M782QO+3E37L5#=:DR)M"3(TW.XK5R"Y OR^"6\^26%HTK2TOJQA[<S[,;6IL
M-4];@?:/GI(T1IQ),IG821<BYQ%K.I^$[=]LQ5[D%R$8[)<$<LEFCK1S-P<R
MN7Q'B2HDJTTZA(2HR;-/S(Q\J?1A6M:7'L7G7LG3+X,$D];A;B*Q<@N0GYR/
MAKDEV.-&U;B'2)"XC8KFF6: B);2DF:E6.^1CZZ0='=;B?&<',T]:RPU'_$V
MI)FI7D*9<@N01_+C'P0UG.?DDV(=%]=)Z5X[%C=>RBGI=2[!I,U'8N\>/'.A
MVIDL5?I#A67.(DG%7>41'97>96[19;D%R GYR0QC0C4T&,8>>HYI3]13N$Y5
M*J2-2G3[;&/EC6$J7M/$%64M2IXC09NL-W_5)(CS5V"[&7$>1%!3-U:JI+#9
M5*BU5.V]XR[K@GB2?!#[H]=KD);I1T9UN,<30\G35S-.W0J2:D+29FJQW%3(
M\AFY",=T^"2<:8M']7CK#M)&T=8U3+962S6XDS([>0[##$8N&P]01[KA.+IF
MB;-19$=AM[D/RJQD)7;/U'G!*_I&P;LUHXJETR#744BTO)(BSL1YCH=$$LF8
MT=0E0A6NI-.EI>?WDY&.MJ&&ZFF<8>22VG$FE:3X&1C4X0PS&X4C51\,AQND
M-Q3FHM9JL9GG;Y"(]DT'WP<AB;!DKB32'&5E>IK]'Z R=2Q>^NX7 S(?G27@
MB5DIV+Q%A=YAN6H2-.H]\*TGV"G7^89 EC&">26:/\+U>$*>?G\4U=.<A77=
M=4C)#9$1Y7,<U]&>*J'5XAQ&ZDTMR%2HFC,OB21GF0L.)X*CQ)#5$7)[0Z1\
MB)9-JU3.QWXC[8>AZ.!B:>-C6ME24Z"0VF]S(O,2NV2'XP>Y*#+@/VDK7&;D
M%R   N07(  "Y!<@  +D%R   N07(  "Y!<@  +D%R   N07(  "Y!<@  +D
M%R   N07(  "Y!<@  +D%R   N07(  "Y!<@  +D%R   N07( :>@_?]?Y)&
MX&FH#_X@K_)(W-P  +D%R   N07(  "Y!<@  +D%R   N07(  "Y!<@  +D%
MR   N07(  "Y!<@  +D%R   N07(  "Y!<@!S>D'#SN)\,5473O)8<=--EJ*
MY%8[CW8=BUQ<#11[JD.J8:)!JMD=OD-M<@N0?0&CQ5"'-8>KXYLVVEU+1MDL
MTWM?M&,&PKD#AVACG5H<<IVR0I:2MK#>W(+D&?@'R>;)UI2%E=*B,A.]%A/1
M$E-X>K$ZAT[YO4]_O-J/B7XBCJS*UQJJR!HJN7II-PG$UE.6JE:%ZNL7<9=I
M"4\90&(XYR7@J^@:63:JAE39*,LB,QX\"P#V',,446\ZAY;"=4UI*Q'F.A06
MJ68_5R$+LL#XP2G%6BZM>FGY;"4RY$5=2?Z])7U%_.Q=HWVC[ ;>%C?JJBI7
M72E3F_4.<3/Y?(=Q<@N0GJ>,!]SE(2%FZ3$\M75\H53'5-O9Z6Q_J1TFP+EM
M_/(?>Y!<A .2P?AAV!DI^I>=:=3(U?M""2FQH*Q%8_Z#G=(E([B7%L'"TWO-
M4RO::DR/X2+@1_B*:>8U4= T<?(UM=3DOVFL42G5+5K?@7<0)X9.<Y-JTG5;
M2DN!%8?H8(R(AFY 0 "Y!<@  +D%R   N07(  "Y!<@  +D%R   N07(  "Y
M!<@  +D%R   N07(  "Y!<@  +D%R  :>'_>DC_.-Q<AI8@[2LE_. -T P1W
M*XS<@  +D%R   N07(  "Y!<@  +D%R   N07(  "Y!<@  +D%R   N07(
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MHNTB4>1#O4\!\VD);;)"2)*4E8B+L(?1)Y WE@R 7(+D(  +D%R   N07(
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MY  :;;2_*9ZAMI?E,]1N0 &FVTORF>H;:7Y3/4;D !IMM+\IGJ&VE^4SU&Y
M :;;2_*9ZAMI?E,]1N0 &FVTORF>H;:7[6F.HW('P ',,-RS=>^^3+6LNU[W
MM^ ]VVE[_LF>HVA?$/KVF --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R
M TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  T
MVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVV
ME^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVVE^
M4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVVE^4S
MU#;2_*9ZC<@ --MI?E,=0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVVE^4SU#
M;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVVE^4SU#;2
M_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVVE^4SU#;2_*
M9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVVE^4SU#;2_*9Z
MC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R  TVVE^4SU#;2_*9ZC<
M@ --MI?E,]0VTORF>HW( #3;:7Y3/4>&D;EF:NI=)EJ[AW.]QTX^9]H U*7I
M>W[)CJ,[:7Y3/4;=(_0 TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3
M;:7Y3/4-M+\IGJ-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:
M7Y3/4-M+\IGJ-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y
M3/4-M+\IGJ-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/
M4-M+\IGJ-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;67Y3'4-
MK+\ICJ-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;67Y3/4-M+
M\IGJ-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\I
MGJ-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ
M-R  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R
M  TVVE^4SU#;2_*9ZC<@ --MI?E,]0VTORF>HW( #3;:7Y3/4-M+\IGJ-R
DTVVE^4QU'GIF:\YI%14,H2C5L9I'0CY'V@#Z$>0#*>!  /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g111069g00a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a15.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1H 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRN55ZU7B=AZ^_,J]_P!UD]1QRWW*>8Z/9Z^&3.3VLWM11Z #T3R0
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M$M&M]!7'1]/2S7&II)FU#E:WH5<JICMRB%'.,6DWJ7C3E).45DM2I ("Y2X
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MN<CI55&IA,]2*-5V"ITS>YK76R123QHBJZ)5W5SYT0KMK:V;YEU3DX[=LB(
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MXZ<(KU4<>/;6'E8TB #W#YD
M
M                                                        %PV1
M5\E!M M#HUX32= ].U')CUX*>6/9M^?EB_O;/69U5>#7<:4':K%KBCJ+7WYE
M7O\ NLGJ..4Y(=C:^_,J]_W63U''*<D./V?\LCT?:WSQ\#T 'H'E
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M.AL*R5[[SG\VW[&_\Z+A_=5_U--2)R-M^QO_ #IN']U7_4T[\1_%+P/,P?\
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MA3BZ)JQ*URHN,IR7D5J3G&3E)NU]VA>E3I2A&,8J[6CR?DSGA4W7*BXRBXX
MR;E2.H+C54<BHKX)71*J=:HN#&/23NKH\=IQ=F  20
M>+R4Z_V9?F)9/[JSU'("\E.O]F7YB63^ZL]1Y_M#Y%XGJ>R?Y)>!9P >4>\
M     #1'LF/Y^Q_)D^XWN:(]DQ_/V/Y,GW'3@_YD<7M#_'EY?4TB #W#YH
M     ><)E>H$ #"YQA<^887]5?J    N ...2_4$   PO8OU D    #S\ 0
M!U<@+@ <^2*!< =>%    )        3*\D5?H!     X]:*@   !(
M (N .*<T4    D    85.:*GT! 0  "0        0  "0   !A>Q?J">4$
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M0XO9_P LCTO:WSQ\#T 'H'E
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M<T3R8-='33J*I':B<5:E*C-PEN  -#,
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MV9X'AI2I]'*4KZLRKUNEA&-K65C>_L@)XI-(V5(I(WJDJ91KD7'@&>RHB_\
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M+W_=G''Z>Y0X?9_RR/2]K?/'P/0 >B>4
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M]QO<T1[)C^?L?R9/N.G!_P R.+VA_CR\OJ:1 ![A\T
M
M
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M "Q4
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MIO9DK,  L0
M
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MV5R13.]=HWQ%!Z1_XCO7:-\10>D?^)<P.EJ=I\QU>EV5R12^]?HWQ%!Z1_\
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MTC_Q'>NT;XB@](_\2Y@=+4[3YCJ]+LKDBF=Z[1OB*#TC_P 1WKM&^(H/2/\
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M[*Y(IG>NT;XB@](_\1WKM&^(H/2/_$N8'2U.T^8ZO2[*Y(IG>NT;XB@](_\
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MTC_Q'>NT;XB@](_\2Y@=+4[3YCJ]+LKDBF=Z[1OB*#TC_P 1WKM&^(H/2/\
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M[*Y(IG>NT;XB@](_\1WKM&^(H/2/_$N8'2U.T^8ZO2[*Y(IG>NT;XB@](_\
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MTC_Q'>NT;XB@](_\2Y@=+4[3YCJ]+LKDBF=Z[1OB*#TC_P 1WKM&^(H/2/\
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MJ262,C4WP+4^;[S.I/>T7R$]1@ZF^!:GS?>9U)[VB^0GJ!)]0
M
M
M                        >.]ROF(G3'P>_P"==ZR6=[E?,1.F/@]_SKO6
M 2Z<@$Y        $/=/ABU_*=ZB8(>Z?#%K^4[U $P@"
M     #(  R$7(
M
M                       (33OOJY?/$V0FG??5R^> ,C4WP+4^;[S.I/>T
M7R$]1@ZF^!:GS?>9U)[VB^0GJ /J
M
M
M   #QWN5\Q$Z8^#W_.N]9+.]ROF(G3'P>_YUWK )=.0"<@       "'NGPQ:
M_E.]1,$/=/ABU_*=Z@"80!               #S> /0>;R#> /5Y&E=>;>(=
M):IK;-+I>Y5*TZHB3H_<21%3.416\O*;HWCY/IH)G;TL,3W<LN:BJ :+V7;:
M+GK?:C):>X&4=GDIEDCAD3,K'-1,JKNM%55ZC?:'/E QD7LNZUD;&L:EM3@U
M,)_-L.@P
M
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M>W'86:L[%4[F0 ""0
M
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MRBAMZN:DC]Y<N8Q5X^=3ILJ2
M                                                ?G>3R#?3M3ZR
MN7O1EKO%:ZKK%JNE5,+N3N:GU%'T+I"VWAU[2M?5JE+7/@CW9W)AB<C>-.$H
MN3EIW?\ 3AJ8BM"HJ:@G>]L^'D;<1V3TQ+5;X;900TE,LBPQ)AN^Y7+]:F68
M,[8WMGJ  "0                                    0FG??5R^>)LA-
M.^^KE\\ 9&IO@6I\WWF=2>]HOD)ZC!U-\"U/F^\SJ3WM%\A/4 ?4
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MW*)61U0 ""0
M
M                   #QWN5\Q$Z8^#W_.N]9+.]ROF(G3'P>_YUWK )=.0"
M<@       "'NGPQ:_E.]1,$/=/ABU_*=Z@"80!              >8/'QL>B
M(]J.1./%,GZ !^71M<U6N3*+S10UC6IAJ81.I#]  _"1,1ZN1J(Y>"NQQ/TB
M8/0 <_4G]+^M_P -3_;8= G/U)_2_K?\-3_;8= @
M
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M@#(U-\"U/F^\SJ3WM%\A/48.IO@6I\WWF=2>]HOD)Z@#Z@
M      B]2U]5:[%6UEOM\URJX8U=%20JB.E=V)G_ -=F3F_15XNMS]D7'=]3
MVI;).E$Z-\4BJB-\!<*JKVG4F#G#:IQV@W9.K=A_TJ;X>DJT]ALXL?BWA*+J
MI7T.B:6IBJ8DDIY62QKR<Q<H?8HVR2JBDTS#"QE+"]OA='"Y57&?=.SR55+R
M9U(;$G'@;X>KTU*-3B@ "AL
M
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M3"HY=_/$N&K[YMC9?)F:9LE*MJ:UJ0O<C7K(F$\)55R<?)@NU:ZX.Q6^G?\
MDQ:3^E_6_P"&I_ML.@3E;934:CJO9(R2ZTIV4]Z6@=TL;$1$1-QN[R5>K!U2
M5)
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MHE=*Z[LRT?:%!O9E+9??E]2\ Q**XTM=&CZ2IBF:O6UV3+3D8-6U.Q--70
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MUKW[[D1,NQC*]I]#R#ZT
M
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M!?<.\Y^I/Z7];_AJ?[;#H$Y^I/Z7];_AJ?[;#H$
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MYXFR$T[[ZN7SP!D:F^!:GS?>9U)[VB^0GJ,'4WP+4^;[S.I/>T7R$]0!]0
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MFCGB1\,C9&+Q1S5R?4\X^A68
M
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M=;L))&N47$;,G1)!(
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MI( &0 !D
M                                    'CO<KYB)TQ\'O^==ZR6=[E?,
M1.F/@]_SKO6 2Z<@$Y        $/=/ABU_*=ZB8(>Z?#%K^4[U $P@"
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M4G]+^M_PU/\ ;8= D$@
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MY%.9IK4T/T!E!D@ #*   9&0        ,@ #*#(
M                           !X[W*^8B=,?![_G7>LEG>Y7S$3ICX/?\
M.N]8!+IR 3D        0]T^&+7\IWJ)@A[I\,6OY3O4 3" (     5[7>H?Y
M,Z>GN#8%J)D<V**)%QOO<N$3)82 UQ88=1Z>J*">H6FRK9&3I_X;FKE%'B/
MU]J2MOE3==/V*V4EJIM2UE.ZJK:I8&R-IVIRQE.M>!=] 7NKN]IGCNC(V7&A
MG=2U'1>Y<YOZ2>14*=I^C]KJV\WBY:MLU7J*IIFTE/*FZV*%K<XRW/'CQ4MF
MS6WTMOL4C:>Z1W6HFG?-4U4:INOE<OA8QR1.PN[6_>/X,U>_[P_);DY )R!0
MT        R@!S]2?TOZW_#4_VV'0)S]2?TOJU?\ ^FI_ML.@0
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MZB[7GHG2^Y@C8Y7-8WZ4+2G'B>X,:E&-5Q<MV9M3KRI1DH[\O()R !L8@
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MH[*9/JJ-:%97@_\ GB?*U:$Z+M-?A^!Z G$&ID
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MD_I?5R?_ --3_;8= HF"I(
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M/J]R_)<J!9UHXEJ]SIU:F^C.2*?<-Y [(JRL<;=W<  D@
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MH:G^8K*>1/[,B*9N$EJC>-:G/Y9)^9F@_#9&N3+'-<G:BGZ12IH>@
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M'-/H]9T8"HZ+E5>B7KN.FHMJT31=ET_=ZV2*>CME7/"V5&J^.)53*+Q3)VU
MW\A'GGNH:ZV!_F1/_B$_^I#9*<B?:&(=6IL-?+<4H**OQ  //-0
M   >.7"9"E2UQ>)H616NW+FMJO!X<VM7ADQQ%>-"FYR-L/0E7J*G$P;G+-K"
M[=PT3E9:J5Z=T/7ATBYY)]1=Z:&."!D4+49&Q$:UJ=2&!IRTQ6BUQ4T:9=[I
M[OUG=:DH986A**=2I\\M>[N7@:XJO&=J=/Y(Z=_>_$)P !UG(
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MSWJ.)A5>SI+@]?WP/"K86=);6L>*T_?$S0 =!S
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M1.F/@]_SKO6 2Z<@$Y        $/=/ABU_*=ZB8(>Z?#%K^4[U $P@"
M$'K*CM-=8*N+4+D;;$1'3.5ZL1$1>U"<*5M?M=7==%5,-! M3)'+',Z!.<K6
MN15;]0!JUM+H#<66ETKJ26VIQ2KBCEZ-6_K)QY&X=GU+8H-.0NTNY76V95D8
MJO5RY7FBYXHOD(*DVIZ19;(^DK5IY&,1%I'0N21JHGN=W'/J,K9-3S-LE=62
M4KZ."OK9*JGIWMW7,C<O#*=6>>/*:.]F9JUT7E.0"<@9F@        !S]2?T
MOZW_  U/]MAT"<_4G]+^M_PU/]MAT"
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M6\CT ]$\X
M$)IWWU<OGB;(33OOJY?/ &1J;X%J?-]YG4GO:+Y">HP=3? M3YOO,ZD][1?(
M3U 'U   "\@ "'U+IRUZCH^Y[Q2-J&)Q:N51S5\BIQ0I3]DM*QZMHM0WRFIU
MX+$V?>3'9E4R;"N]?!:[=45M6_<@@:KWN[$0UM3[4KK6Q-J+9H6^U-'(F8IF
MLPCV]2\N1,;[BLK;RQZ:V>6&PU25<4$M57)_[S5R+(_Z,\$+@WK*WHK4%=?Z
M:IDN-BK;,Z)Z-;'5)A7IC.4\A94#O?,1M;(  @L      #GU/Z7:?X=_T*=!
M'/J?TO$_P[_H4 Z"                 !XYJ.:K7(BHO4I5:_2B15*UMCG=
M15F<JWFQ_D5"U@QK4(5E::_*\#:C7G1=X/7D_%%1IM3ST$S:;4E*ZD>O!L[>
M,;_IZC\WN]W:CBFJZ=+<ZWIQB<LJJYZ>3M7R%FK:.GKH'0U<+)8UX*UR9-.Z
MSHFVR]2T5.Z5*5B-=&QSE5$RG''TY/(]H5:^$I7VKK<]'YY9KD>M[/I4,75M
MLV>]:KRSR?,V)8+A>[@^FGE90+12<7+'(JN3ARQVEH-1[.+FM)>.@EG1E/*U
M?!<[";W5@VTU47BBHJ=IU^RL1UBCM-MO?<Y?:F'ZO6V4DENL?H 'I'F@
M
M                  ^<BJUCW(BN5$5<)U@% U7IFAIM2VF]4^]'4R5T;'M3
MW+LYX^?@;#-=5=VO%[K[93RZ<KJ2**L9*Z9Z*K41N?(;%0WJ[5HJ3S.'"=&Y
MSE35DVMUL]X !@=P           !X[W*^8B=,?![_G7>LEG>Y7S$3ICX/?\
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M]MAT"<_4G]+^M_PU/]MAT"
M     0NM?S2N_P#=G^HC=EGYBVOY"^M21UM^:-W_ +L_U%.LU^33VR2DJVX6
M=8U9"U>MZJN/JYG3"+G2V5O9YM:I&EBMN6B@_J?F_2_RQUQ36:!56W6QW2U3
MDY.>B\ON^LV7"QL<;6,1$:U$1$3J0J6S+3ZV:R=T5677"NQ-.YW-,IE$_?\
MO+@5K25]B.B-<%3DHNK4^:6?@MR\D%-5[<;[+W#2Z6M2[]SN[VQJU/T8U7FO
MG5/J-G5E1'2TLM1.Y&Q1,5[G+R1$3*FG-E])+K+7%RUK7M5::)[H*%CNK'#*
M>9/WJI?"Q46ZTM(_7<=4^RMYM+25E@T]IVAM=,G@4T:,5WZSNMWTKE24F_FW
M_)4_3>1^9OYM_P E3F<G)W9?0USL#_,B?_$)_P#4ALE.1K;8'^9$_P#B$_\
MJ0V2G(WQ7\TO$K#Y4  <Y8         +R*EK6[2-9':+<N]75:[F$_0;UJ3]
M[N,5JMD]7.O@QIP3]9>I"M:*MDU1/+?;GX554<8VK^@TX,7.4Y+#4]9:O@O^
M[COPE.,(O$U-(Z+B_P#FK)_3EIALUM92Q<7(F7N_6=UJ2AXWK/3LIPC3BH15
MDCCG.523G)W;  +E
M        0FG??5R^>)LA-.^^KE\\ 9&IO@6I\WWF=2>]HOD)ZC!U-\"U/F^\
MSJ3WM%\A/4 ?4     $#KND97:2N=-+#-.V2%4Z.'W;O-Y376FMH5]MUCHZ*
MLT1>'R4\;8M]B81R-3"+C'#@AL_5%WCL5AK;G,Q7LIHU?NIS7R&O+;IS7%^H
M8KK6ZSEMDM2U)8Z2DIFK'$U>*-55XJN.9,-]^XK+=8N>BM1U.H::HEJ[+66I
MT3T:C*GF],9RG!"R(4O9U>+K.ZZ674CXIKO:I6QR5$3=UL['-WF/QU+CFG:A
M=$#U$=  ""P &4  /PR6-ZN1CVN5JX5$7. ^:-CT:^1C7.Y(JX50#]G/J?TO
M$_P[_H4Z"RASZG]+M/\ #O\ H4 Z"                     7DI0M<5MHK
M(JFFD@FDN$#5;&]L3L(['+/6F2^KR/QN)^JF?,<V*H.O3=--*_%7.C"UU0J*
MHTW;@[% T_%IVMHX+<ZCE2IE;X3WQ.1=[''#C.DHKWI[P[;*ZX4*?^!+[IJ>
M12Y-:B+G")]!^EY&$, HQ2O:2T:5OS?S.B>/<I-VO%ZIN_XMY$%8]24-T=T:
M/Z&J3@Z&3P7(OWDZ0]ZT_079O_$0[LR>YFC\%[?I()C[]IIV*E'7:V_KM3\J
MSS]I;IJM#*LKKM+[K\7*]!2KYT79]E_9_FQ=1E.TKO\ *%M?0=)8FQU-4CD1
M8)'I&YJ=><D/_*B\^V24'M93=U;F_N]TIC&<<^6?(3/'T86U:?!-HK# 5IWT
M36MVD_4O0,*SS5<]$C[C3MIZC*YC:_>3'5Q,TZX2VHJ1RRCLMQ8 !8J
M
M                            >.]ROF(G3'P>_P"==ZR6=[E?,1.F/@]_
MSKO6 2Z<@$Y        $/=/ABU_*=ZB8(>Z?#%K^4[U $P@"     'QJH(:B
M-65$3)691=UZ90^Q3=K-VK+-HZIGMLO05,DD<"3XST2/<B*[ZAW(;LRWMDC1
M5C1[-YJ95N>*(?LU!8M*4%LU_/:XI:J6*NL2NJ97U#W/E<Z3"NRJ\%\V"S;)
MJBH6RU]#454E8RWULE+#/([><^-J\$5>M4Y%MG*_[K8HI9V_=+EY 3D"I<
M       Y^I/Z7];_ (:G^VPZ!.?J3^E_6_X:G^VPZ!
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MF>@\RAZ:F0
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M6(-"4G]+^M_PU/\ ;8= G/M&J.]E]6JU45/:U.*?-L.@B
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M8O\ ^Q6>E?\ B7.W4<%OH8*2CB;%3PM1C&-Y-1#(!:=6<\I2;"BEH  9D@
M  \5R(BJJX1 #!OES@M-MEJZA? ;P1$YN7J1"N:*MTM5/-?;DW_B*G^::OZ+
M##J%76&H^YF*OM10KO/5.4CO_7WE[BC;&UK&-1K6IA$3DB'G4_[NMTO^D=.]
M[WY:(]&I_:4>B_WEKW+<O/5GZ1,*>@'HGG
M                                A-.^^KE\\39":=]]7+YX R-2IFRU
M/F^\SJ3WM%\A/48.I?@6I\WWF=2>]8OD)Z@#Z@  !4X  %3U[IW3UTM-56:B
MHH)$@A5.G5J;[&\^"]1IRBNEGD[EI[?LS@JF2PK+3O>K=Z:-O#?Y>;ZS>.O+
M7/>M(W2WTF%GGA5K$5<97L-;U5TE@H-'ZA;:ZZFAM3G4-QAZ!=^)NZB*NZG-
MN6\T+4]Z?[K]RDUO7[H6;8Y<8[I8ZN>DT_3V2C2=61QPJGY14X.5?*BI@V A
M0-F=8VZWK4]TMT$T-DJIXUI^EC6/I'HQ$D>C5XX5<?47\2U)AH  5+ \5#T
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M7GPT?(YZN&J4<Y++CJN9]P ;F
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M+K@^&@<Y9GYWG;S&K^[)U.<_4G]+^M_PU/\ :8= E20
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MV&;6VOKMK*O:YU%3/6GH&OZNS">1%SYW&ZR,3_3BJ/#-^+_!VPS^(  XRX
M          *GKJYRPP0VRB5.[*Q=Q./%&\BQW.MAMU#-5U+MV*)N5\OD*CHR
MAJ+I<9K_ '-JY<N*9KOT6]J'!C)RDUAZ?S2U[EO?V1WX.G&*>(J?+'3O>Y?=
MEBTW9XK+;8Z:+B[W3W];G=I*@'93IQIQ4(JR1QU*DJDG.3NV  7*
M                                                  A=.^^;E\\3
M1":=]]7/YX R-2_ M3YOO,ZD]ZQ?(3U&#J7X%J?-]YG4GO6+Y">H ^H
M(+723KI*Z=QU+J:?H5W)6HJJU>U,<2B:9VM6F*PT4%UI+SW9%$V.55HWOWW(
MF%=GKR3NT_46H;);ZGVEL;ZN'H%?W:R=J="[/6Q>*_01=JUAK"2V4CW:"J)U
M=$Q5E[MB;O\ #W6,<,]A:*R?[Q*2>:1<-(:IMVIZ:>2UQ54<<#D8Y*B!8N*I
MG@B\R?*AH*34M757>MU)2);Z>:1J4=$LC7NB:C<*JJWM4MY$E8F+N@ ""P
M    .??^;QO^'?\ 0IN_4UMGO%AKK?25\UNGJ(UC;50M1SH\]:(IS9L]TQ)I
M'V2\%JFN<]S>RA<_NB9NZY<L7AC*\@#J8
M              'XFACGC5DT;9&+S:Y,H5BOT=$DZU%FJI;?/SPQ? 5?,6H&
M-;#TZR^-?GF;4<14HOX'^.146WF]6?P;S0+4P-YU%-QX=JH3=IOMNNJ)W'4L
M<_KC7@Y/H)-4RG$@+OI.VW%ZRHQU/4\TFA7"Y,.CKT?XY;2X/7G^3H53#UOY
M([+XK3E^"?!4$;J2QIX+F7>D;U+X,J)]YG6G5UNKI.@E<^DJDX+%,F%SY%ZR
MT<9"^S4^%\']GHRDL'.VW3^)<5]UJBP@(N4RG('6<@
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MM&35*E\D=._B_,  [#C
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MRTOJ*U:H]E-'<[#5I5T+Z!S&RHQS<JC%RF'(B@'3
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M$QCAR-/9V->,@YM)6,_:."6#FH)MW  /0//
M                                            /'>Y7S$3I?X/?\Z[
MUDL[W*^8B=+_  >_YUWK )<         A[K\,VOY3O43!#W7X9M?RG>H F
M    "F;7J^XVW0]7-:)7P5"R1QNF8F5B8YR(YR?07,USJK9S8:AUPNEXO=YI
MJ>15DF3N[<B:G9C'!/(%;>,[9'RH]E-HJ*2&:2]7^=\C$<Z5+@Y$>JIS+II>
MP4VG+;W%1SU<\6^K]ZJF65^5\J]1JZ#1&D8])+?:.^ZG=9XV*YJQ53\[J+C@
MS=S^XV'L]I;73:;A=8;C4W&@F59&3U$RR.7/-,JB*F.PTEO,X[BR@ S-
M     #GZD_I?UO\ AJ?[3#H$Y^I/Z7];_AJ?[3#H$
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M(UK4ZD/.C_=UMK_2&G>^/E]3T9?VE'9_WGKW+AY_0_8 /1/.
M                                                   !":=]]7/Y
MXFR$T[[ZN?SP!D:E^!:GS?>9U)[UB^0GJ,'4OP+4^;[S.I/>L7R$]0!]0
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M10M1K456+E<'1QS[_P WB?X=_P!"@'00
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M@
M'CO<KYB)TO\ ![_G7>LEG>Y7S$3I?X/?\Z[U@$N         0]U^&;7\IWJ)
M@A[K\,VOY3O4 3      !3-KUKJ[MHFI@H85J)(Y8YG0)SE:UR*K?J+F!IF.
MXU[1;5-(16R-LE6ZED8Q&K1N@<DC51/<[N#+V34LT5DKZN2E?1P5];)4T].]
M-U61N7AE.K//'E+>ZAI'2]*ZF@63]=6)GZS(+76?>547E?<  5+
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M4^6/J]R_).:2L[;-:61.PM1)X<S^M7*30!UTJ<:4%".B.6K4E5FYRU8 !<S
M
M  !":=]]7/YXFR$T[[ZN?SP!D:E^!:GS?>9U)[UB^0GJ,'4OP+4^;[S.I/>L
M7R$]0!]0     0FM;3+>]+7*W4[]R6HB5K5\I0['M/H++:*:V7NT7.BN%)&V
M!T,=,KFN5J8RU>Q<&P=67A+!IVONCH^E[FC5Z,_67L->6V':;>:"GN7ME8J1
MM2Q)60.I-]8VKQ1-Y5["T=Y66[B3NS*&KK:Z_:DJJ.2@BNTS'04TB8>C&-1J
M/<G4KL9^HOA7=&TVI*>GJ$U77T=9,KDZ)::'HT:W''/'B6(2U$=  "I8
M  '/O_-XG^'?]"G01S[_ ,WB?X=_T* =!
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MPKOH,*6,HU9;$'=^#-ZN$K4H[<U9>*_)(@ Z3F
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MO%$54\-4QR5$7RE]TG>+7=[<JV=JPL@7HY*=T2Q/A=^JYJIP4MHK%4[NY-
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M'9;7'%[JH>F],_K<Y28-,)1E%.K5^>6O=P7D9XNM&35*E\D=._B_,  [#C
M
M    !":=]]7/YXFR$T[[ZN?SP!D:E^!:GS?>9U)[UB^0GJ,'4OP+4^;[S.I/
M>L7R$]0!]0     1NI*.:X6*NI*9L+IIHU8U)TRQ5\OD-4VNDVCV*B@MJ7_3
M:-A:C(VSKX2-ZD^@V7KFXU-ITE=*ZB;O5$,*N9Y%[2EZ4V9Z9N6G:2NN3776
MLK(DGEJY9-YSG.3*X7JYEH97?A]RLE>Q;=$,U,VEJ%U946^>5SD6%U&U43=Q
MQSDLAK[96CK;<-2:>@JI*RW6NI8E-+([>5B/8CEC5>O=538(EK<1T  *E@
M :ZVA;6;+H^Z4%L]_P!QJI4C=!"],Q(JXR[L\QL54RBIVG-.WC1UITU/8*NW
MPJM9<+TL\\\G%[E<N<9[$[ OF2#^5LZ5C=OL:[M1%.?O^;Q/\._Z%+[M#7:,
MLU W0#+2VD2+,SZMWAJ[LPJ8Q@U!H%-2)[)J'^6JTJWCN%V_W*J;F[N+N\@R
M%H=2  $@
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M@GLU5L/O_.AX,L%-K:I/;7=^-2R@_$,L<S$?#(U[5Y*U<H?LZT[Z'&U;4
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M%XKSRJG+2Q=*K4E23^*.[\'54P=6G2C6:^%EI R,IQX\CI.4 (J*B*BIA0
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MX/::^:HWGP7#SWGU RF.8/?/  &4QS09  &4X\>0   RG:  ,IG&4SV#*=H
M    RF,Y&>.  !E.U   ,IQX\AD  9&4[0 !E,XSQ&4QG(  &4[>0  RG#CS
M   RF.8ZP  JHB*JJF$YC*<./,  #*8SG@  !E,9R  ,@  93M   RF,Y
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M;&HU'/3]9<9+T3/40T  *E@   4':QH*;7#;(D%;'2^U]4E0[?8KM].Q,%^
M[QW$5J&>XT&GJN:RT;*ZXPQ9AIWOW$D<G5DYOV?W:\7KV3,-9J.T^U-P=0N:
MZFWM["(Q<+GRG3%ZNM#9+947&ZU,=+10-WI)9.34.=].WZV:D]E3'<+'6,K*
M)U K4E8BHBJC%RG% #I4
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M5')1JC-W,>>''@N,=1A1:.F;IRU6M^H;LZ6BJ&3NJ^DQ)/NNRK7K^JO+!;0
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M!?Z[4OLF8;C=+-4V:I=0N:M)4M5'HB,7"\41>(!U(
M
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M]9+.]ROF(G2_P>_YUWK )<         A[K\,VOY3O43!#W7X9M?RG>H F
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MC;$Z1&IA?+S-C-7+4545,IR7J/0*DU-W2L,/1E1CLN5UNT  ,SH
M !&:BNL=GM4U5(J;R)AC?UG=2%)SC3BYRT1>G"522A'5E=UG5R76XTVGZ!ZJ
MZ1V]4JW]%J=1;:*DAH:)E-3-1L4;<(B%<T%9Y:6FEN5?EU=6^&JNYM:O''TE
MJ=[E?,<F#A*5\147Q2]%N7W9V8R<8VP]-_#'U>]_9%:V=_F^[^\R_P"HLQ6=
MG?YON_O,O^HLQ? ?XT/!&>._R)^+  .LY
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MV0FG??5S^> ,C4OP+4^;[S.I/>L7R$]1@ZE^!:GS?>9U)[UB^0GJ /J
M"%UK/7TVE;G-:&HZN9"JQ(J9XFL-)[)[%<=/T==-?KT^>IC2:58:WHF[[N+D
M1J)A..3:NJ%HVZ?KEN;I6T71+TJQ*J.1ODQQ-"0S;*(8]V&JOL;.>&RRHGK+
M0WV[BL]US=6B=)4.E*:IAMU97U39WH]RU=0LRM5$QP5>192@;(IM,S6^O=I*
M>MF@Z5.E6J>YRH['5O*I?Q*]\Q&UL@ "I8      '/O_ #>-_P ._P"A3H(Y
M]_YO$_P[_H4 Z"
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MK)9WN5\Q$Z7^#W_.N]8!+@        $/=?AFU_*=ZB8(>Z_#-K^4[U $P
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MB5K'QHQ,[B<."HF<X-@ Z'B9..S96\#SX^SH1GTBG*__ *8 !SGH
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M,N_]YF^@>-7>:BXQE,GI!(
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MV>5^'G]2\@Q+5<(+G0Q55*[>C>F?*B]BF6>Y&2DE*.C/#E%Q;C+5  %BH
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MOR?!,\?J+7L?MM5;='M2NIG4DE142U#:=R86)KG*J(J=7F+M@ =P !
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M/1D;GKR:BJ0^C=14^JM/4UWHXI8H)U<C62XWDW7*WJ\P!-
M
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MY6HJDN?.EIXJ6FBIZ=C8X8FHQC&\FHB81#Z$R:;;159+,  @D
M
M       A-3\K9_?8_O)LA-3\K9_?8_O)LYZ?\L_(Z*G\4//Z@ '0<X
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M<J[KD7MPBG1B5,*M:O2L3*(J9<B<%+6R*WS-!TG]+^M_PU/]IAT"<^T3FO\
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M+^>\K<^3D3W[LB.Y&\P8MJK&W&V4E;&BM941-E1%YHCDS]YE!JV03OF  0
M
M     >.54:Y6IE43@G:>@ J-1/>KG54,<]E6FABJ6R.DZ='81,]6"W &%&BZ
M;;<FV^-OLD;5JRJ))122X7^[8 !N8@           'CO<KYB)TO\'O\ G7>L
MEG>Y7S$3I?X/?\Z[U@$N         0]U^&;7\IWJ)@A[K\,VOY3O4 3
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M_D-[(^2Q=W.K^AH'/Z=T?1J[>:UW+*\L]IU8<_4G]+^M_P -3_:8= D$@
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MR;SO:_=8L  /?/!
M                                    !":=]]7/YXFR$T[[ZN?SP!D:
ME^!:GS?>9U)[UB^0GJ,'4OP+4^;[S.I/>L7R$]0!]0
M  0^KZ*ZW'3E=2:?N+;;<Y68AJG,WT8N>SRIE,]6<G.>@;9?+3[)J&DU1=FW
M:Y-H7*ZI:F$5JL7"<DY'44CV1QN?(YK&-17.<Y<(B)UJISQ15E+7^RU;/0U,
M-3"MO5$DA>CVJNXO6G  Z)   *!M&V;PZQJJ2=M<E L#7-5&P(_?RN<KQ0OX
M-*=65*6U!V9$HJ2LS2U%L*CIJR"=;\YZ1O:_=[EYX7./=&YXHHXF[L3&L;SP
MU,(?H%JN(J5K=([V(C",/E*KM TS/J:GLT=-410K0W*&N<LB*N\UF]EJ8Z^)
M';5MG\>MK4Q*:I[ANT"*D%4F<;J^Z8['-JH7L&.ZQ>Y0*_1=UH[G1WK2]PI*
M>\1T<=%41U<3GT]0QO)5W51R*G:A@U&SBOK+1?9+C=8:F_7=T2RS)&K(8F1N
MRD;&\5QSXKQ7)LT CN*SJ33D]UK=,S13QQMM-8E3(CD7PT1BMPGEXDS4VV&2
M"=M.UM+/(US4GB8U'L5?TD7',S0 :OJ]!ZBO530P:DN5FFH:*=DS:JGHW,K)
M=Q<HCG*NZW.$RK4+-IK3$]IGU.^6HBD2[53ZB-&HO@(K<87REJ [OW=^!O3_
M ']S-9LV>W.DTYI^.VW*ECO=EF=-!)+&Y\$F\BM<UR<%PJ+S0S[)I&]IJVKO
MU_N=)4355N[B=#31.8R)=Y5\#*JJIQYJN<E] _?L/WUN:OCT%J!FCZ&TI<K9
MW7::ML]!+T+]QS&KE$E3.<_),Z79]+<KOJBIO-5"L-[HZ>G<VG146*2-%RY,
M]65RG[S80'[]A^_<UY;-*ZJ[KHX;E=;,RW4KVNZ6BH594U"-Y->KE5K<]>ZA
M]IM*7^V7JYS:4NU#36ZZR]/4PU=.Z1T,JIASXE143CA.#N' OH *ULZT[/I;
M2U/:JNI;531O>YTS4QO;SE7*^7B?FSZ;GH=6:GNSYXW179($C8B+EG1Q[BY\
MZEG !KYVA*M=EU7I;NR#NF97*DV%W$S)O\N?(DK!I)]/J2[WB\OIJR6I9%3T
MS49E(8&)P3BG-5557!;P";Y6*9=]'2OU7#>+-+34C7TCZ.KB5BHDK5]RJ8ZT
M7//M*[0Z!U5%I>'2M1?[>ZPOCZ.HD93.[JW%7+HV.SN[JIPRJ91%-J@=Q'>?
M*DIXZ2EAIH&[L,+$C8WL:B80^H &@
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M_>%RV  S-         #GZD_I?UO^&I_M,.@3GZD_I?UO^&I_M,.@0
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MR/O.!_YJ_P#/W.]?X3_]+Z,L  .\X
M                                                   0FG??5S^>
M)LA-.^^KG\\ 9&I?@6I\WWF=2>]8OD)ZC!U+\"U/F^\SJ3WK%\A/4 ?4
M                $=J.RT>H;)66JYL>^DJF+'(C'JQ<>=%R<Y:,TM;='^R@
MBM-ECDCHV4#GHCWJ]<JQ<\5.GCGW_F\3_#O^A0#H(
M
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MB'GO"UG5Z7I%>UOEW<SO6*HJET6P[7O\V_D>,<CV-<F<*F4RF#T ] X
M
M                 0FG??5S^>)LA-.^^KG\\ 9&I?@6I\WWF=2>]8OD)ZC!
MU+\"U/F^\SJ3WK%\A/4 ?4                    $1JZ\26#3=QND%!47"
M2EA=*VF@3+Y%3J3_ -<CF797JVHUM[(ZGO-9;O:Z5]$^-8-]78W6+QRJ)ZCK
M$Y]_YO$_P[_H4 Z"
M
M                           !X[W*^8B=+_![_G7>LEG>Y7S$3I?X/?\
M.N]8!+@        $/=?AFU_*=ZB8(>Z_#-K^4[U $P      :NATIKBT7B]3
MZ>NUEBH[A5NJ=RI@>][57JRAM$$IV(:N:CT]I+:+865K*&]:?Q5U+ZN3?IY%
M\-V,X\G V+I:*]PVW=U-4T=37;Z^'2,5C-WJX+UDN"7*Y"C8  J6
M .?J3^E_6_X:G^TPZ!.?J3^E_6_X:G^TPZ!
M
M                                             !":=]]7/YXFR$T[
M[ZN?SP!D:E^!:GS?>9U)[UB^0GJ,'4OP+4^;[S.I/>L7R$]0!]0
M           #GW_F\3_#O^A3H(Y]_P";Q/\ #O\ H4 Z"
M
M                                                        !X[W
M*^8B=+_![_G7>LEG>Y7S$3I?X/?\Z[U@$N         0]U^&;7\IWJ)@A[K\
M,VOY3O4 3                        .?J3^E_6_X:G^TPZ!.?J3^E_6_X
M:G^TPZ!
M
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MXG^'?]"@'0(
M
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M.B>KO!1G),;IOVMVBZ2M]0ZFN&H+?3U3$3?B?+X355,X4M:Q6YJFD_I?UO\
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MGB;(33OOJY_/ &1J7X%J?-]YG4GO6+Y">HP=2_ M3YOO,ZD]ZQ?(3U 'U
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MM6?UE7/[+_XQWCM6?UE7/[+_ .,W\ #0/>.U9_65<_LO_C'>.U9_65<_LO\
MXS?P - ]X[5G]95S^R_^,=X[5G]95S^R_P#C-_  T#WCM6?UE7/[+_XQWCM6
M?UE7/[+_ .,W\ #0/>.U9_65<_LO_C'>.U9_65<_LO\ XS?P - ]X[5G]95S
M^R_^,P+]L>U9:;'<+BNT:YR=R4\D^YAZ;VZU5QG>\AT:16HZFTMMTU'>ZVFI
MJ>LC?"Y)IFQ[S53"HF5[% .7-C^C-5[1--3W9-=W.AZ.I=3]'O/?G"-7.=Y/
MUB]=X[5G]95S^R_^,V#LPMFD=&VA+%IR]4U3TLSI<.JXWR/>N.IOD1.KJ+Z
M:![QVK/ZRKG]E_\ &.\=JS^LJY_9?_&;^ !H'O':L_K*N?V7_P 8[QVK/ZRK
MG]E_\9OX &@>\=JS^LJY_9?_ !CO':L_K*N?V7_QF_@ :![QVK/ZRKG]E_\
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MTL:0])GP$7>SC"^1#KE4145%3*+S12,LE@M5C2H2SV^FHTG?TDO0L1N^[M4
MJ'>8T!^S5'_F_$=YC0'[-4?^;\380 ->]YC0'[-4?^;\1WF- ?LU1_YOQ-A
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M_P";\1WF- ?LU1_YOQ-A  U[WF- ?LU1_P";\1WF- ?LU1_YOQ-A  U[WF-
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MIWWU<_G@#(U+\"U/F^\SJ3WK%\A/48.I?@6I\WWF=2>]8OD)Z@#Z@
M             A-<7.2S:.O=R@_G:6CEE9\I&JJ?O.7)="PV_9%1[1H:ZL_E
M*LK:MTKI/!7,F,8.J=66OV[TQ=K7G=6LI9($7L5S51#EQ+GJFOT/2[+5TS6Q
M5L<S87UBM7H^C1^<\B%>[MKE;GG]BV5E?3._V^YU1IVM6XV&WUKO=5%.R1?.
MK44D##LU$ENM%%1(N4IX619\R8,PM*UW8I'3,  @D
M                             %.VB[.['KV&D;J!*A64BN='T4JLQGGG
MZBXE1VMW.JM&SJ^5=OCDDJT@Z.-L;55V7*C<HB=B*JE9.RN6@KNQIG8GLYL=
M=M!N.HK(RHCL5HJ%IZ+I)-]9Y6IASU7L[$\QTH478?:$LNRZP4ZQNCFD@2>5
M')AV^]=Y<^7C^XO1I++X>!G'/XN( !4L
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M         A[K\,VOY3O43!#W7X9M?RG>H F
M           "C;0M?IIBOM]IM=IJ+U?J_>=!10O1G@MYN<Y>2%Y-)UV6^RGM
MZS^Y=:7)#GMPN<$:M+]T9.YO]U+]LXUS2:VM]5)%2S4-;12]!54DV%=$].K*
M<T+<:3V(HKMIFT5\7O;NI$X<M[*F["VJ3XHC1M<  "             "C;0]
MH#=+5]MM%OM53>;[<=Y::CA<C,HG-7.7DG!?J+R4[:9JBTZ-M#;S7TL53<6K
MT-%&C$69[W<-UB\T3MP0R4?#9UK]NJJRY6NX6N>SWVW*G=-%,]'X1>2M<G-"
M\&J-BFG;PZON^M-5,Z"[7O=5E,B8Z&%/<HJ=N,&URS6G$JM]@ ""0
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M^\SJ3WK%\A/4 ?4                     83.<<0
M                                      %1%3"ID  )PY
M                                               (B)R1$"HB\TR
M                >.]ROF(G2_P>_P"==ZR6=[E?,1.E_@]_SKO6 2X
M   !#W7X9M?RG>HF"'NOPS:_E.]0!,
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M7M7=>U6IP<B]2D-H;9M;=*7.:Y]W7"Z7.2/H4J:Z7?<R/]5N$3"%Y OG<;K
M         A-.^^KG\\39":=]]7/YX R-2_ M3YOO,ZD]ZQ?(3U&#J7X%J?-]
MYG4GO6+Y">H ^H
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MDC%X*AE% T9)[2Z]U#IIB;M$Z-ERI&)R8CU5'M3R;R9^E2_D-;R4P ""0
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M99KNKJ7Z=VNT<$7"AU% Y9&]23Q)[I/.U4SYD-B$6R3)3S:  ()
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M8"'N7 E+5\0 ""0
M     #QZX8Y>Q"(TMQMKE[9'+^\S;M.E/;JB15PJ,5$\Y^+)!W-:X&*F';J*
MOG4 S@        "'O7Y.X6R7JZ7=^M"8(S44#IK8]T:9DB5)&_0 28/A0U#*
MNDBFC7+7M13[@
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MWSDP
M
M                                    "*NET6*3N2B3I:Q_!$ZF^50#
MX7-_MC<HJ"+C'$Y))UZDQR0G$3"83D8-IM[:"!45=^>1=Z1Z_I*9P
M   "HBHJ+Q10 "!H5]IK@ZDE7%).[>A>O)KNMI/&-<*.*NIG0S)P7BBIS:O:
MA%PUT]I<E/<LO@Y1SHG5V* 3H/S%(R5B/C<CFKQ14/T
M
M
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ML>W%O^-Q?640 %[]N+?\;B^L>W%O^-Q?640 %[]N+?\ &XOK'MQ;_C<7UE$
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M'MQ;_C<7UE$ !>_;BW_&XOK'MQ;_ (W%]91  7OVXM_QN+ZQ[<6_XW%]91
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3U$LQC8V(UC4:U.2(>@    __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g111069g00a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g00a16.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1^T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'Y<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*/_  !$( X($H ,!(@ "$0$#$0'_Q  =  $  @(# 0$
M            !@<%" $#! ()_\0 71   00! @,$ PD.! 0""  /  $" P0%
M!A$'$B$3,4%1%&%Q"!<B,E6!D9*Q%188(S4W0E)6<G.ALN$S=,'1)#9BDS14
M)28X0T138W6"E,+2)T5'\%=D@Z*CXO'_Q  : 0$  P$! 0
M 0(#!00&_\0 .!$!  (! 04$" 4$ P$! 0    $"$0,$$B$Q004R46%Q@9&A
ML<'1\!,4(C/A!A5"4A93\2,T0__:  P# 0 "$0,1 #\ VI
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M;=BL@^ J;]-W*G4D^G_= SQ:<LMR]5)\RQ42!8TV9)OY^6Q;\*V,H_%KG#9
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MEXH=%*K!2J15ZD38H(FHUC&)LB)Y'>1>T6GA'!;3K-8XSQ  47
M
M                                            ! ^.'YM\K^[_ **:
MD:/N:BI7I'Z3?>9<5FS_ $1O,[EW\>BFV_''\V^5_=_T4I3W*W_.=_\ RO\
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M*_UM+UXQ_F[S/\%?L4WVN<1'H^;S[)'/[Z*-]RLJ_?CD$WZ>C)O]*F']T?\
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MO&0 %%P
M
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MO-N:E:17D  HN
M                          ;@  -P    ;@
M
M
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M>'FTA8RF&K)4R-!O:L=&NR.1%Z[DQX#YZ74'#7%6;*[SL:L3E_=78"P0-QN
M W&X
M
M
M   #Y<QKMN9J+MU3=#Z &MWNN_\ &TO_ !'?:AL-B?R73_@L_I0UY]UW_CZ8
M_B.^U#8;$_DNG_!9_2@&O>AW1?A1YE'[=KV,W)_+<V*G_P "3]U36CB9-+PZ
MXZ4M6/@<N,M,[.1[4Z)S)LXL;5?&G2=+3$]K'Y2*Q;DC7L86;\RN5 *X]SW_
M ,X\1/W'?U.)%[E?L^RU.B;=IZ=)[=N93GW+NF[,6GLSF\E ^*;*RN5G.G5T
M:]=_I52+:)ST/"GBQGL7J!75\7>D=)%,Y%Y455544"_.)B?^H6=_RK_L()[E
MC\V47\9_VF$XV\7,+8TK+A],W&W\CD/Q2)"BKRING?[2P>"&GY-.<.,53L-5
MLZM65Z*G5%<NX$5XZ\6\APZRF.JT,?6M-LQJ]RRN5%39=NFQ5WX4>=^0L?\
M7?\ [FT>7T]B,Q(Q^5QM2X]B;-6:)'*U/5N8_P"\32O[/8S_ /%V_P"P&MJ>
MZBSVWY!Q_P!9_P#N3K@SQNRFO-6IB+N,J5HEB<_GB<Y5W3VEG930VEV8RXYN
M QJ*V%ZHJ5V].B^HU>]RXB-XMS-1$1$CE1$^<#<\
M
M
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MS
M
M
M          'CR_Y*N_P'_P!*FE_"#*69LO?Q36J^)JR2_N[*;HY?\E7OX#_Z
M5-.?<T1,GXK68I$1S'13(J?.>;:]FC:=*VE/5Z=DVBVS:L:E>BZ]"9C[EYB-
M)';03? =[?!2Y&/1S4<B[HI1NH\7)B<I+"J+R(Y58OJ+#X=9GT_'NK3._'0K
MTW7O0X78NTSHWG8]7GT^<.WVQLU=:D;7I<NOU3$ 'TSYL
M
M
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M&JK_ "+'0[.P[57:M&-2.?7TN1MNRVV75G3GET]#D 'K>0
M
M
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MI':FR1JT[]?N872#K@E;*QKV*BM<FZ*AV'UT<7RG(
M
M
M                          0_B-JG(Z7H5[&+PTV6DEDY'1Q[[M3SZ(0'
MWX-3_L%=^L[_ /-+N(7Q"U]C]&1UFV89K5VRNT-:!-W/4FLXX8RB8GGE!??@
MU/\ L%<^L[_\TPV+RN<U=Q9P64NZ<MXV&LQ8W*]%5O?W[[$A;Q@SKV\S- Y1
M6KW*K_\ _4R^E.).8S6<KT;>CK]"&5=EL2/W:WV]#:G"V8AC?]59B9X>CS6>
M #!N             /)E_P E7OX#_P"E33OW+WYW9_W)?M-Q,O\ DJ]_ ?\
MTJ:=^Y>_.[/^Y+]H&YX  ZY8VRQN9(U'-5-E14*6U?AEQ&5D:QKDKO7FC7U>
M1=O@8?4V(9E\9)"Y$[1$W8JIW*<SM388VO2_3WHY?1TNS-MG9-7CW9Y_5&>&
M^?6=JXZT]%>Q-XU5>JIY$^0H%BSXK(HNSF30N+HTUEHLOCF3QN17HB(]/)3R
M=B[=.I7\OJ=ZO+T?P]?;.Q1IV_'T^[;X_P LL!N#O.$
M
M
M                          51Q+@9A]?:;U7D&<^(J\T%A^W-V*N^*]4\
MMRURFN+F.DU-Q!TSIN]9F@P]ECY9&QNY>T<WPW\R:=^,??"<^Y%N[*P8];Z6
MDC:]NH<5RJFZ;VF)]JGJH:HP%^RRO2S6-L3N^+'%98YR_,BD'9P*T.QB)Z!.
MY4\73+NID].\)M*:?R\.2QE*2.U"N['+*J[?,6C<4_7C@GX *-
M   !Y,O^2KW\!_\ 2IIW[E[\[L_[DOVFXF7_ "5>_@/_ *5-._<O?G=G_<E^
MT#<\   O<H %?<1=/\\2Y.LBJ]J_C&HGAYD6T;G%PV1^'NL$JHCO5ZRYIXF3
M0OCD;S,>FRIYE-ZRP#L-=YHTWKR[JU?+U'S':NRWV;5C;-#AX^G^7TO96U4V
MG2G8]?U??DN.K.RQ"R6)R.8]-T5#M*VX=ZB5BMQMMV[?_=N5>[U%D-4[FQ;7
M7:M*-2OK]+B;9LMMEU9T[>KT.0 >MY0
M
M
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M=0
M
M                                       "O^)O$5NA7U>VQ5FW#,U5
M66/HUB[[;*O=N6 5/Q"?#=XI:4Q.8=_Z)>CYFQ.^)+,GQ=_,FL9M$(F<5F6
ML\88,I5WLZ&R-JNY.]T"O:OS\I%L7J_3+]0,R>+TCF*]JM(CI$I(JIOY.:B=
MQLW''''$C(V-:Q$V1J)T*DR*PXOCCCH\&J1R7:RKD(HU^"J(J;.5/,TI,;V(
MCQ9WB8KF9Y)MH77.)UC7D=CGR1V85VFK3-Y9(U]:$J*=EA@H>Z'IIC4:QUJ@
MYUIK$Z*OFOKZ(7$4G&(M'7_Q>,Q,UGH  JL          #R9?\E7OX#_ .E3
M3OW+WYW9_P!R7[3<3+_DJ]_ ?_2IIW[E[\[L_P"Y+]H&YX       "D U[I9
M9^TR%%OPT3=[$\2?;]#Y=LYJHNVR]YYMJV6FU:<Z=_\ QZ-EVF^RZD:E%*:3
MS+\)E$D=NL3O@O;_ *EST[45NNR:!Z/C>FZ*BE7\0<##CWNOUWL2-[OA,W[E
M\S%Z0UI%A)EAM3<U-R]4[^7UH<3LVVT;'K3LNI69K/*8C/W#L=IVV7:M&-JK
M>*VZQ,Q"Z]P5_/Q3P;$=V+I)-N[X*IN8ZWQ=IQKM7HOF\_A;'U<;+JS_ (OD
M9[3V2O/4A:.X*E=Q@C5OP<8]J^M^YU^^\GR<OTEXV/6G_%E/;&QQ_G[I6\"H
MO?>3Y.7Z?[CWWD^3E^D?DM;P/[QL?^_NE;NX*E;QAC1.N*>OK[38]%7B[3D7
M\?0?$GGS[E?RFM_JO':NR3__ $A:0*X3BQBM_P#!D0]4?%/ +_B/E3V-W(G9
MM6/\97CM'99X1J1[4]!#:G$C3]I_*RP]J_\ 4W8R<&K\+,F[;L2==NJE)TKQ
MSK+6NU:%N[>/;#/@QT.<QLSMHKL#E]3CUQ6H9=^RE8[;R4I,3'.&T7K;E+N!
M\H]%[E3Z3G<A9R#C<YW
M
M                                    $6UWHS':QQS(+ROBGA=SP6(E
MV?$[S124D'X@:2S&H[-63$ZBMXAD35:]L#U;S]>]=AU.B)+PWUO"Y(:FO+7H
MB=$YV?"V)5HCA[5TRZU<DMS9#,V6JV2[/U=\WDA$W\+=6\B\FOLIS>'-,[;[
M#!:/J:DT[Q0JXG5FI[TS)&\]9%F<^*QUZHN_<IM7]7Z<L9_3&]CDLC0G#V'3
MF7N9B[>FR67M*J+/+^@U5^*A/!L#*9F>;6(B  $)          !Y,O\ DJ]_
M ?\ TJ:=^Y>_.[/^Y+]IN)E_R5>_@/\ Z5-._<O?G=G_ ')?M W/   > ,;F
M<U2P]9TU^=L;$3N\5^8F(F9Q"MK16-ZTXAD=S#9W4V,PL2NO66-=X,1=W?05
M1JSB==NODKX=$KU^[M%^,J$&AAR&9M;1I-9F<OCNI[]+8)F-[4G$.#M7;M:S
MN;/&]/CT_E9N:XM=7,Q51>G<^1>B^LA&0UMG;R2-DNR-C?\ HLZ;$DP'"N];
M1LF3F2M&O56MZN0G>*X;X"FC%DA?8E;^E([O^8U_$V71X5C,O-&S]I[9QO;=
MCV>Z%$<V0O;M1UFQZMU<?:X;(MB[1].9D:^+FJALW4P^/J*BUJ<$:IXM8B*=
MEVE!;KO@GC:Z-R;*FQCJ]HWW9C2K$3TR]&C_ $]I[T3KWF8ZX_G+6&OB;$LK
M6.Y6(Y=N9? F6/X69*["DK;M9C')NU>J[F3U?IB3#2]K BOJ.7HOZOJ4[-'Z
MJDQ+O1[6\E5R]/-I\WI_U-M6GK3I;7$5]$<OX?47_HO8-31C6V69MY3/WQ>6
M+A!?W_&Y*MM_TM4[O>@L_*,7U5+:HW(+M=LU:1'L<G14/2G<=Z-NU;1F+.)/
M8FR5G$T]\J<]Z"S\HQ?54>]!9^48OJ*7&"?SNMXH_LVR?Z^^5*.X09+=>7)5
M=O#X+CHGX39:)/Q=NO*OJ14+RV&Q,;=K1U5GL39)_P 9]LJ%=PLS:-5>:!=O
M#<\4O#?43-N2JQ_L?_8V'V&Q>.T-6/!G/8&RSRS[6MMK0FH*R(LM%?\ \%VY
MC9].Y6%522A,NW?LW<VD5$4X5C5\$+QVC?K$,K?T]HSW;3[FJB4+\'5*EF/U
M\BH<+:OU]T6>S$J^',J&T\M6"5-I(F.3UM13R38/%SKO-0K/7_JC12T=H^-6
M,_T]CN:GN_EK;5U%EJ[.6*_81/6]5,A'KG4,;6HW(R(U/#S+VGTC@YW;OQ\2
M?NIL8N7AOII[G.]"<CE\I'$_G-&W>HC^S[93N:OOE5\'$S.Q<JN>R3;];Q,C
M6XM91LF]BM YGDQ.I+Y^%6$D:Y(WSQ*OBU478QMCA!31B^CY&PK_  YT3;^2
M#\39+<X1&S=K:?*^?7'S=%?B_$BIVV.E7SY7(9>OQ5P[T:LL<L>_?X[$6L\)
M,BUJK!<@<ODY5_V,3/PTSL:.5L;)-OU5[R?P]DMRG!^8[6T^]7/JCY+4@XB:
M=F>C&W%1R_K-V0R\.I</*U%;D:J>ITB(4#+HG4$355^.D1$\=S$S8J_#)RR5
M)T<G_0JD?D]&W=NF.V-KT_W=+W3#:*&_4F;S1687IYM>BG>U[7)NBHJ>TU6[
M7(5O@I)9B]2*J'?4U!E:KN:&].CO^IRK]I6>SI_QLO7^HJ_YZ<^UM'N$7YC7
M&OK[44+D5+ZN3OV5J=3+P<5LW'R\T-:3;Q=OU,Y[/U8Y8>FG;^RV[V8]2^ 5
M#2XO.1O_ !E#=W_TUZ?S4RU'BSBIG(VQ7GA]:HBI]IE.R:T?XO53M;9+\KK(
M!#X>(^G)%1OIJHY?!8U,O7U-B)V(YE^!$7]9VQC.G>O.'KIM&E?NVB?6S(/)
M7R-2Q_@68I/W7(IZ4>B^*?24:Q,3R?0.-^ARB[A(
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M)JFE6TWQATS8P3&5Y<ES16X8NB.;O\940TK,6MNQU9VB:QO3T7. #-J
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M7?X+_P"E33WW,&SN+DR>",EZ?.;AY?\ )5[^ _\ I4T[]R]^=V?]R7[0-SP
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MT[1+E:NSZNC.-2LP](&XW-V(
M                              .%0;'( ZGP,D^.QJ_,>*U@L9:55L4H
M)%_ZFF2!,3,<D36)YPB5_A_@KF_/5Y-_U%V,AIC3%+3K)FX]KD2545VZ[]QG
M07G5O,;LSP8UV;1K;?K6(GQP  S;@
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MP'_TJ:=^Y>_.[/\ N2_:;B9?\E7OX#_Z5-._<O?G=G_<E^T#<\
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M#EZW9>U:7&:YCRXI6#RU,A5N1H^M/'(U?%KD/2BG0K:+1F'@F)B<2Y 102@
M
M                                                   *FUK+7QW&
M;2M[)N;'4?!+$R63HULB]W7P+9*VXCSX?-:BQ6CLQC76?N@QTK)VNY5@5OBA
M->%HQ]\)^2+=V?OJ\.J[,>+XQ:9R+I6LJW*LE99-_@N7O3J<:YM1T.*VDI<:
M]J7+2NALM8O5T7145WSDGSW#_$YK2M3!V^T6.HUJ03([\8Q4\44QN@^%V-TM
MDWY)]FQD+W+R,EL.5RQIZMU+TFL3'EGUYS]5+1:8GASQZI6&@ ,V@
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M;INFRG**>EY@
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M?\E7OX#_ .E33OW+WYW9_P!R7[3<3+_DJ]_ ?_2IIW[E[\[L_P"Y+]H&YX
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M5IJ1FDYASKZ=].<7C$OL!%!HH
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MO?G=G_<E^T#<\
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MVTZ/>I/JXI$#JBGCF;S12,>WS:[<[4/=$Q/&'AF,<P $@
M
M       !67%_1FH-7/HLPN2BJ5X%YW-?T7G1>CD5.J%FE=\3M296M?QFF]+H
MQN8R:KM-)\6&-/C/$9S&.9/*<\D/BT1Q2B8D;-91[-[D5=U^PSFC],<0J.?K
M6,[J9ES'M7\9"B?&_D833>)R^G>,&.H9/.V,FZS1DF>YZ<K47NZ(9G#YC.:3
MXBI@L_;2]C,JYTE*;;9T;M_B&T3.8QCCGY_1A-8Q.<\,+: !BW
M   'DR_Y*O?P'_TJ:=^Y>_.[/^Y+]IN)E_R5>_@/_I4T[]R]^=V?]R7[0-SP
M
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M[NZ[;G4T=JT=?]NT2Y>KLVKH_N5F'L 0'H8
M                                                  %2\4YY=,ZW
MT_JU\+YL="CJMKD;NL;7=SBVB%<3M7XW2^'1M^KZ?/;7LX:2)NLR^6VR]!$X
MM$Q]]"8B8F)0*]K# 6>,F%RL>5J>@MQLC72K(B(URKW+Y*??W5CXB\5L5)AD
M<_%8/>5]G;X+WJO<BF>H\/=+Y7 P9>QI:*O>EA[5:G5.5WZNQ\\)M6T9;4^G
M9\$S3V3@^&E7EY4D;OMS(;5Q$XCG7/OS\,L9S,9F>$X^2TT !BV
M    'DR_Y*O?P'_TJ:=^Y>_.[/\ N2_:;B9?\E7OX#_Z5-._<O?G=G_<E^T#
M<\
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MW%1*UR&1R_HH[J9!'(J=%1?8=.EZWC-9RYMJ6I.+1AR!N"RH
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M@/\ Z5-._<O?G=G_ ')?M W/
M
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M;1H]^DLX#YCD9(Q',<CFKW*A];H>UXP#<
M                            ISBW#<U)KO3VDV79J6.LM?/.Z)>5ST;X
M;EQE&^Z$S5[#YG 6,3CUDOP*Z6.TU%56==E:J)T5%)KC?C*+=V<,RW@-I/;X
M5C,JOGZ9M_H9/3/"+3FGLS!DJ$N3=8A7=J365<WYTV*QBX\ZK;&U)-+Q/<G>
M[:1-R1Z"XOY_46J*>,NZ>CJP3+LZ5.?X/TFT5U,\)8VMIXXKQ !@W     !2
MFN)[-=:GU"[3NG%=C\.K4[>ZB*BKZD7_ &+E.% U:X%X)--\;,QBDF=.M>)$
M61W>Y>]5-ID[C73A_P#^TCJ7]U/L-BT[@ ->/=.:[U'I/-8F'3]U]>.:%SGH
MUN^Z[E)KQIU_\KS?]M -Z,O^2KO\!_\ 2IIW[EW\[L_[DOVD:DXRZ\EB?&_+
M3*UR*COQ:=RF?]RBYS^*7.]=W.@D55]8&ZH
M
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MZ&41R*G1=SK:>K34C>I.8<F^G;3G=M&)<@ T4
M                       C>M]58O26*]-R[E7F7EBB:WF?*[]5J$D*DUXV
MO+QDT@S+\OH/9R+$DGQ%E\._ION36-ZT51,XB9>)O%//64[>EH#)/IKU1R[;
MJGT$OX?Z^Q>K)9JK:LN.RE?K)4L-1'HGFGFA-D1&ILB;(4]KAL$7&?2BXI&I
M?>CDMI'W]EOWNV+UQ:V[CFI;>K6;9Y+D !FT      X4Y &NF@.GND=2_NH;
M%IW$$PO#>EBM>9#5,5R=]FXFSHG(G*GL)VG<!Y+N,HWG-==IU["MZ(LL:.V^
MD\WWNX;Y*H?_ (NS_8R@ P&5T_AVXNXJ8J@BI"]=_1V_JKZC4_W+B;<7)D3H
MB,E[O:;B9?\ )5[^ _\ I4T[]R]^=V?]R7[0-SP
M
M                                 "@ ?#XVO:K7M:Y%\%3<Q5[3>+N[
M=O59T_5^#]AF 4OITU(Q>,KTU+4G-9P@F2X>UY7*ZG86)5_1<FZ(1J]H?*5G
M.[-&3M3KNWH7 <;',U>Q=EU.,1CT.EH]L[5I<-[,>:@9:ERJJJ^*6-$7;FZH
M3_A@^[/Z3+8GD?"U$:C7+OU\R=3589VJV:)CT\G-W/FI3@J-5M>-K&JN^S4V
M,-E[&G9M>-2M\Q#;:NV/S.C.G:F)GJ]"=P"=P.ZX@
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M?\E7OX#_ .E33OW+WYW9_P!R7[0-SP
M
M
M                       @'%'1][.MHY73UE*N?QKN>O(O<]/%J^I2?G&R
M#EQ@\I4FS5W%BJU*UC2-2Q.B;+,U_1WKZ+L9?0FD]0Y+4GWTZ^6)M^-O9U*<
M:HK84WWWZ=-RUMAL7B^.,1Q4W,\)G@  HN             /)E_R5>_@/_I4
MT[]R]^=V?]R7[3<3+_DJ]_ ?_2IIW[E[\[L_[DOV@;G@
M
M
M                                    !#>(?$#&:(KP.OLFGLV%VA@A
M3X3O]D)D5-Q,JQXWB'I?4F2C23$P*Z"5SDW2%SOBO7U;DUC-HB43.*S+&LXX
MW)&HZ/1&3<U>Y>W3K_\ VF8TEQ6N9_.UL=+I2_29,NRSR3(YK?FV0GD>HL+)
M&CF96@K53=/Q[/\ <[JV8QEF9L5?(5)97=S63-<J_,BEHF/]5)S,=YD0 4:
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ML$C9(W)NUS5W10.T!
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MUGTU5YY;<#.:1[$W8WU*OF!+4 0
M
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M)L
M                                       !6FO':?R6O,'@<U@VY"Q:
MC>L<[G;)$B>KQ++*GXS8'463R.)MZ5I1NN5-WMMH[E=&N_Q?6BDU[T91.=V<
M)#[U6C/D*M_/_<SNG],8;3S7-P^/KU.;XRQMZK\Y4T5_C.R-&K1QS]OTG-3=
M?YF;TA>XGRY^LS4=*A'C%7\:Z-$YD3U=2\5GEE2;1''"V  9M
M  !Y,O\ DJ]_ ?\ TJ:=^Y>_.[/^Y+]IN)E_R5>_@/\ Z5-._<O?G=G_ ')?
MM W/
M
M                                                         ""\
M2M86<"E+&8.KZ9GLD_DK1*NR-\WKZD)T5+Q&N1Z>XGZ7SN13;&*R2J^54W2)
MSNY2:QFT1*)G%9F&.TK=UM0XH4<5JO+16&VJ<D_80?$:J=$1>B=?89O36K<W
MC-=3Z:U@QB^DN67'VH_BO;O\1?6>/)WZDW'7!68K,3H%Q<BI(CTV[SQ:AR,&
MK>,.GJN%>DS</S369F_%3=43EW-:_JFN8YQ.?;/TAG:<1:8GECY+I !BU
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M0
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M5/%PWT#0T-2L0T7ND?.J*^1_>NR 3)$V39 $
M
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ME33OW+WYW9_W)?M-Q,O^2KW\!_\ 2IIW[E[\[L_[DOV@;G@
M                                                  #8 ##WM,86
M]/VUO%U)9?UG1)NIDZM:&K"V*M$R*-O<UC=D0[0
M
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M]8>^YH?]HJ7U@)V"(8?B3I/,9&&AC<W5GMS+RQQM=U<I+T
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MQLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV
M-9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P
M6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?E
MQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/
M[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%
MJ'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<
M=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^QLV -9/P6H?EQWU/[#\%J'Y<=]3^
MQLV -'^-'"&/AWBJ5QF06TMB58]E;MMTWW,WPQX"Q:ST?3S;LJZ!9U<G9HW?
M;9=O(GONR_\ E;"_YE?Z2:^YE_-#B/;)_4!6_P""U#\N.^I_8?@M0_+COJ?V
M-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!
MK)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"
MU#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N
M.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_
M8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@M
M0_+COJ?V-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@M0_+C
MOJ?V-FP!K)^"U#\N.^I_8?@M0_+COJ?V-FP!K)^"U#\N.^I_8?@MP_+COJ_V
M-FP!^?7%'0K-%:Q9A&6EL(Y&+VBI^MM_N7-6]R_#-7BD^[;DYV([XOFF_D0_
MW3WYX8?9%_H;CXW\G5?X3/L UL_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7
M'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_
ML/P6H?EQWU/[&S8 UD_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_L/P6
MH?EQWU/[&S8 UD_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_L/P6H?EQ
MWU/[&S8 UD_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_L/P6H?EQWU/[
M&S8 UD_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_L/P6H?EQWU/[&S8
MUD_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_L/P6H?EQWU/[&S8 UD_!
M:A^7'?4_L/P6H?EQWU/[&S8 UD_!:A^7'?4_L%]RW"B*OW<?]3^QLV</^([V
M :+<(\:W$<>,9CT?VB5KCXN;SVW3<WJ0TET'_P"TK'_]RD_U-VD
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M:Y/=)Q*K51/NE)X>TW90\;,91CL=O'2K-FWW[1(FH[?V[;GL0
M                                               ?$KTCC>]WQ6IN
MH&)U'J?#Z;KI-FK\%1KNK4>[J[;R0P^G>)6E-06FUL9EX7V'+LV-WP57V;E%
M4].2\:.*>:LY6U)%AL5(V%(V+OS)UV3KT3?93(\7>"V.T[@Y-1:1FGIV<>B2
M.B1>BHG>N_?N!LJ"&\)=3+JG0^-R$NWI#HD;+MW<R=%)D
M                       #!Y_5.(P-JC6REMD,]V1(H&=ZN<8/BEKQFB,7
M%)'0FOWK+NSKP1_I.Z]_J-8]1)JJUQ)TOE=7IV+[ER-\%=%7\6WF3IU W41=
MT,=FLUCL'46UEKD-6!/TI';;F03N-8M=T;?%?C/+IOTM]?$8UOXQ6==T3OZ=
MW?T N7$<5='Y6\VI4S,"SN7E:C_@HJ^U2<-5'(BM7=%ZHJ>)K_Q"X!X.#2]B
MYIMTU3)4X^U8[=%YU;U7<E?N=-63:DT6V"\[FNT%[&1=]U5-UV M8
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M-.AM Q>9J*G<J;@<@
M         !X\O^2[?\)WV'L.FW$D]>6)>Y[5;](%'>Y88Q(]8O1=Y77V\W7R
M1VQ9W$]$70&=1>J>BOZ?,4IP:SU/0W$C56G,T]M3TVRV2%\J\K5VW1.J^>Y/
M..^N<5BM"9&K!=@ENVX^RCCC>CG=?'9 ,;[E%57ARJ*N^T[T3U?"4NHK7W/F
M ?@>'&/;*U6R66]NYJ]Z*O4LH
M   \UFC7LRQR6((Y'Q+S,<Y-^5?-#7OW0G3BAHA/_P":C_J0V--<_="?G1T1
M_FH_ZD V+_1^8U]X*1QKQJUM*Y4[;F<WOZ[<R&P2=WS&L]#*5N'?NA\N[+*M
M>CE&[,F?T;UZ[_2!L7G=ON+?W_\ D/\ L4H+W)2_\=K%J=R6&;)Y=Y:7$C6^
M'P6C<C;=?K2/="YL3&2(JN<J;)LFY!O<J8.6GIG(9BPUS9,G+S[*FW1%7J!>
M0                                   #<#Y541%55V1/%37SC+Q#DU+
M<=H71K?3+5MZ16)XOA(UN_PNJ?:?/%+7V6U/JN31.C++*J,7DN7%>C4:G<J(
MOJW)]PST9I?0U)%KVZD^2>GXZV^1JO<OCLH';0TS'I'A-8QD7^)'5<LCD\7;
M=2)^Y)8Q.'UYZ;=HN0E1?9LA;>397S&$NUZ\K)62Q.9NQR*F^WJ* ]S9J.MI
MG(YO26<E93M,LN?&DJ\J.7?94Z^P"S^/Z(O"W,;[+\%/M//[G%57A/B-UWZ.
M^TC7NEM:4(M%NPN.MPV,A>D:WLXG(]4;OU[B?\',,_ \.L-1F_Q6P\SO:O4"
M9@                                   1KB'G[.F=*W,K3J>ER5TYEC
M]7BH&*XM::S>J,#'2T]D4H3J_=\B]-V^10N!J9+@[KFO/JRHS(LON2)F05RK
MR=? O?AOQ+P^L<%'<])KU;2)M+7?(B*U?G\"I?=-:CQV?MX#3^'F;<O1VTD?
MV*\Z)OTVZ 9[W4\T=O1F!EC?O#-<8[=%Z*BH7'I-C(],XMD?Q$K,1-OW4*FX
MZ::GM<&ZG*QSK.,9'+LFZJBHFRDGX/:YP^:T-BT=D*\=NO V.:.21&N14395
MV^8"O_=*+RZ^T(K5V7MEZI^\AL%2_P#"0_N-^PULUSF:W$'CEIK%8ER6:V.D
M5TDK.K41.]=_:B&R\3>2-K/U41 /H
M                      &P %:\3N$.%UY99<L22T\@QO)V\/>Y/#<BNF/<
M[8G'9B&_ELI9R:Q*BMBD:B-7;NW+T 'S%&V.-K&-1K&ILB)X(?0
M                              *\U_PUBU;J;"Y>2\^N[&RMD2-&HO/L
MN^V_S%A@ B;(0;B7PSPVOJS&Y)'16H^D<\?QFDY % 8GW-F-@R$$V3SER[7A
M=ND#FHB*GDJE[8VE!CJ4-2G&V*")J-8UO@AZ0
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M58F(BHF_D7X *^X8<*\-H#M9:*OLWI6\KK$J?"V\D\BP4
M                                                         !PJ
M[ <@XYD\T',GF@'(..9/-#D                    .%4Y3N  XYM@CMP.0
M     '&X1=P.0  !PKD0Y1=P              #A5Z'*+N    !5V.-P.0$7
M<        X1VZ@<@      5=@ "+N  !PJ[ <@)U0     .$=NH'(!QS>P#D
M'"+N<@       X5VR[ <@)U0
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M/FT7/CY'\RXZW)7;NO<U'+L6HG<6O7=MB$4G->( "BX
M
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M$AT]IS'XJO\ $K1(S?S7Q7Z3+C4F)MPY&G&*\?O( "BX
M
M           !L        Y$<BHJ;HO>AX\;BZ.,9(S'5(*K)'<[TB8C4<[S7
M;Q/8                                 &P                V
M    VZ;  8ZE@L51N2VZ>.J06I?CRQQ(USO:ID438          -@  V
M#C9#HJ4:M-95J5XH5E?SR<C43F=YKZST       ^9(V2,<Q[4<QR;*B]RH>+
M&8;&XI'IC:%:HCUYG=C&C.9?7L>\    /+)CJ<MZ.[)5A=;C;RLF5B*]J>2*
M>H
M
M
M
M
M
M
M                                             #<;@ -P  &Z
M    ;H  W&X  ;@ -T           ;@         !N@               &X
M                                    -P     ;H  W        &Z
M-P                          &Z  $7<  -T&Z             W
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ME:D5ABLD5%>K5[TW),:6YJ5Y  *K                         !PY=DW
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MY4[T03)$/M%!&M"Y>UF,?:FNJQ7QV'QMY4VZ(O0DH #<XW Y 13C<#D'&XW
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MZD%N%T-J)DL3DV5KDW,71TKA*,_;5<= R7];95^TS8'($3;N
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M_BH;U7(^@P1QHK&<RH^79.]RIYG5_P#L<=^ZG]1/=/M1-,U$1-D]'3["]O\
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MN0E^/O09"LRQ3E;+"_N<TA.D&1RZGU,MQK73I+LG/U5&[?8=O"]7(W+-C_\
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M1$W7O4@6DI6:@U??S")S5X(FPPJOFO52?H3$8@SF0 $
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MGV^*]J[.:1_$\-<)C[;;"^D6'-7=K9G(J(OS(A-P(X<CFX:U&HB-39$\$.0
M,7C,-5Q]R[9KHJ26G\[]_!?4=<N J2ZAAS#N?TJ*-8T3=.79?'VF8V0; =-R
MK#<JR5[,;9(9$Y7-7Q0A$G"W!/M=JUUIK-]^S1Z<OV;D] \SR>"CBZE'&I2I
MQ)% C5;LWOZF)AH1:3TS:;1BFNLCYI>S>Y.9V_>G<24X<UKD5'(BHO@I$\<D
M<%+)7T+DE2]8L6*,KOA/JH[IOY=QGN&M>&SJ3)Y''5G08Y&)%#S)W]?[$KL:
M.P%B=9I<="LBKONB*B?09NI5@J0I%6B9%&G<UB;(6C@3Q8O':?K4<Y=RD4DJ
MSVMD>URIRI[.A]:CP-;/0P16I)6-AD21JQJB;JGGNAF-ALA PVHM/4L_CFU+
MW/R-7=KF+LY%/O3>#@P&-;2JR2OB:NZ+(J*O\D0RVPV$<!\JU'-5')NB]%W\
M2$Y7AIA+]QUA%L5U<NZMB<G*J_.BDX&PQU&+P6#HX2IZ/CX48WQ7O<[VJ>;&
M:;JX_-W,I#+,Z>U\=KE3E3KX=#.C8=<G3 8C4N#KY_&.HVY)61*Y'*L:HB]/
M:9<;#!'!TU(&UJT4#%561M1B;^2)L+E6&W6E@L,1\4B<KFKXH=VP$\>9'! E
MX6X+TKMN:UR;[]ESIR_9N33'TX*%2.M4C2.&--FM0]('3 X=W&'P. K866W)
M6DE>MF19'\ZHNRKY=#,C9!R& ETU474#,S%)-#::WE<V-41LG[R;$'U);T]F
M\O8K:CKSXRU!\%L[7?XB?06OL8K+Z?Q>6<CLA3BE<GZ2ILOTD83E4RX["V<G
MB\=I9LME63)+/8=UZ;^98NOL6W)X!*_+,^5)&K&D7ZV_CZC+XC!X[$L5N/J1
M0[]ZM3JOSF1Y4\B9Y85CFZJ,:PTX(W?&8Q&K\R&.U'@J^>J,KVI)6,9(DB+&
MJ(NZ>U#+IT&R">/%,<.#S^CL]"]&W=R<G9[^.VVQXM.86#!8Y*=5\KXT<KMY
M%15W5?4978 8*CIRK3U#;S$<LRV++>5[7*G*GLZ'GU-HS%:@>DEN-\<R)MVL
M2[.7V]"2[(",=!&-,:)Q.GYEFJLDEG[DDE5%5$]71#*YO#4LU36M?A22/P7Q
M1?-%,D"9X\R."%8WASAJ#+",6Q(^9BL1[W(JL1>_;H25<56DQ28Z=G:UD8D:
MH_O5$,AL-ASC!'#B@+N%F"=:[7FM(S?_  N=.7[-_P"9+\;BJ>-JK7HPMAC5
M.J-\? ]XV'3!URQ.G<)7P=::&J^5[))72JLBHJ[K[$[C*JU%147JB]#E$V $
M'R?#3"7KCK&]B!7+NYD3D1JK\Z'K;H/$1.IOJ)+6?5=S-<QR;N7U[H2W8;".
M'(GCS8#4FE,9J*-B7XW)*Q-FRL79R&,P/#S#8BVVRQ)IY6+NU9G(J(OL1$)E
ML-A'#D<V$U+IG'ZAKMCOQKS,^)(Q=G-,-A.'.%Q5MMAJ369&]6]LY%1%^9":
M 1PY$\>;&9S"TLU26K?BYX^]-EV5J^:*8#$<.\-C%F='VTLLC%9SR.158B^7
M0F0V($=^]2G][*X-9K'HJIMS[IS]^_?L9BG495H1U(W.6-C.1%7OV[CU;#8D
M8?3^!K8/TI*LDK_2)%E=SJB[*OET.N33M9^I69M9)O2FL[-&[IR;?09S8; 8
M+4FEL9J!B)>B7M&ILV5B[.0Q> X>X7#VVV8TFL2L7=BS.14:OGLB(3'8".'(
MGCS8S.86EFZ:ULA#VD>^Z+W*B^I2+4N%^"K66S.=:F1%W1DCTY?Y(3P".'&!
M\PQMBB;'&U&L:FR(G@AU7:L-VK+7LQMDAD3E<U?%#O YD<$"7A=@EM]MS6D9
MOOV7.G+]FY-,?2KT*D=:I&D<+$V:U#T@>1YH?J#A]A\U<=:E[:"9R[N6%R)S
M+\Z*9736F<=IZ!64(UYW?&D?U<[YS-@1PX03QYNFS%V]>2+G<SG:K>9O>F_D
M>/!8F##T4JUU>YO,KG/>N[G*J]ZF2V&R 1G/:-Q^7N^ENEM5;"IL]]>3DYT]
M?0S.'QE;$THZE)G+$SYU5?-5/:-A'#@/B9B21/8N^SDVZ$.DX=8>7&OJ2.L.
MYI%D27F3G:J^"+MW$T&PP,!I?2F-T[&Y*+'.D<FSI9%W<IV2Z=JRZCCS*R3>
MDL9R(U%3E5/H,WL-AGCD\F U+I3&:A:GIT2I*WNEC79R'AT[H+#X.REB%LL\
MS?BOF5%Y?9LA+=@(X<B>/-A]1Z=H:@JM@R$:KR+NUS5V<U?48'%<-L%0D616
MS6'>';.143Z$0FP$<#FPVFL#7T_4DK4Y9GQ.>K]I%1>7?P39.X\^0TI0O9^M
MEY>U2S!MLUJIRNV[E5-B0C8=<GDZ+5:&W6D@L,1\4B;.:OB0GWKL#Z4LJNM<
MF^_9<Z<OV;D]V!&,<3R1K'Z/QV/S;<G166%Z1]EV353D5/9MW]#VT<%7IU[T
M,<DJMN.<YZN5-TYM]]NGK,QL-D)\A@\;IJC1P2XCX<]1VZ.25455W]B$>CX7
M8)EI9E=9>S??LG/3E]G=N3W9!L.N3IA',;I+'XW-/R-%987.C[-86JG9[>S;
M<\,O#_$35;4$RSO2>59>=53F8J^70F.PV C>E]'XO3KGR4VODG<FRRRKN[;R
M/7<P%:WG:N5DDE2Q6:K6M:J<JHOGT,SL-AGJ,/#@J\6H9\PV25;,L:1*U53E
M1$^8^*^GJT&H9\PR25;$S.16JJ<J)]!F]AL@C@(GFM#8O*9=N2D=/#91R/58
MW(B.5//=/4>77FI<=5QMS&<_;7WL2-L")UW7N4FVQBI]/XN?)ID)J<;[:;?C
M')Y$8X;O1,3B<]6-X>XA<1IJO$]-II/QKT]:DG3N"(B)LB;("TSF<JQ&(  0
MD
M
M
B                                          ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g111069g0605101842264.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g0605101842264.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  U -,# 2(  A$! Q$!_\0
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M'P7X=B\+ZM):O:7$.G3.EM<(Q4_/#DKN!48( QD^M 'LE<]XD^(?A7P9Y?\
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M'JUI:0O/<%KSR&4*,X4;&W'\176USGQ%T2Z\2>!];TNR57N[NTDAB#MM!8C
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g111069g55a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g55a01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1G^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_   L("94': $!$0#_Q  =  $
M @(# 0$             !@<$!0(#" $)_\0 :!   0,# P(#! 0'" T(!P 3
M  $" P0%$082(0<Q$R)!"!11814R<9$6(T*!H;'1%U)5=).4P>$D,S0V-U16
M8G)SLK/P)28U8W6"@](80T13A)+")R@X162B\4;#9:.TT^)'9I6DX__:  @!
M 0  /P#U2
M
M
M
M
M
M
M
M
M
M
M
M
M
M ##NTKH:-[V8S\_L4\$OZJZG2=V&V_./_=O_ /,?4ZK:I3\BVX_U;_\ S#]U
M75'[VW?R;_\ S#]U;5&?J6[^3?\ ^8YMZLZJ;V9;?Y-__F)GI+VD+Y:Y60WB
MGHEI<<^!3N5W"83N_P")Z<Z>:^M6M[6VKMB5#,.6-R3,1J[D:URX1'+QYD)>
M
M                                                      8%[_Z/
M?_QZ*?FL[^Z'?8=M/%)4U$=/ F99'(QB8SE57"$E;TUU:YB/92\+_P!3)_Y#
MB_IQJYB96C<OV02_^0UE?IF_6MJNKK96[$Y5S:=^$_.K4-6U=V45%:J<*U>%
M0R]/WFOTM=FW2RR-CG8US<N8C_K<+PI[^Z::WH-;V)UPH'O3;*Z-8Y=B/\J)
MSAKEX\Q+@
M
M  8%[XH'_P#'HI^:[_[H=]AN="<:YL7\?I_]XT_16V?W%'^?]:F28-XM-'>*
M.2EN$2RP2)M<U'*W*9SW1?D>0_:&Z40Z2<MYL-.YE%A7S-:DDGF?)A/,Y51.
MZ%)-=N3/KZEO^R_J_P#!O5U10U;D=1.I)'HW+6^=7QIG*\]D7@]L
M
M                                              P+W_<#_P#CT4_-
M9W]T.^PW6A?[^;%_'Z?_ 'C3]%;9_<46/G^M3)!$NJMH;?=$5UO>Q'I(Z-<*
MF>ST7^@_/FIA6FN-; [CPYWM1/DBJAWV.K=07J*H8Y6JN&93X;D_8?I+0U3*
MRF;-%C:[/9<^IW@
M
M       &!>_[@?\ \>BGYK._NAWV&ZT)_?S8OX_3_P"\:?HK;/[AB_/^M3)!
MCW"))J5[')E%Q^L_.'53$CU7=&(F$]YE_P!MQJY'*V2%4[^(W]9^C.@9'2:8
MIG/55<KG]_\ 24D(
M
M        !@7O^X'_ /'HI^:SO[I=]ANM"_W\V+^/T_\ O&GZ*VS^X8OS_K4R
M08]?)X5*]R^F/UGYQ:K=XFJKHY/\9E_VW&JF3+X<=_$:?HOT^14TM3(Y,+N?
M_M*2,
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M:-*JXRK'"KD9N1JNY5%7LGV*?;)=J.]V]E;;I%DIGJJ-<K5;RBX7A3.
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M=:6IK:BEB<Y9H%1KT5N$15[?J,X&MH[U1UE6^F@>]96N<Q45JIRG<V0
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M<K7JJ)^8L[H]:+Q;-/I+?7T;I:J*&1ONRNPGEYSE$^)/0
M           #!O+'/H7HQ%5WR3Y*?GB[1.J?>'?\BW)5QW]SD_\ *<OP)U3_
M  +<?YG)_P"4^?@5JG^!;C_,Y/\ RC\"M4_P+<OYG)_Y3O@Z?:MJ'(C+761Y
M_?TLJ?\ T$[T=[/NIKV]'W"6AB@3NR99HW+QE/R/B>GNFO32RZ'I&);Z;PZI
M%5SGI,]Z*Y6HCOK?83L                'G#VS9GQVBP,9G:]E6CN/E$;S
MV3ZF*?2E3'&N7104K7<^NU_[#SAU7_POW;/;W^K_ -Y(>G=:_P!LL'_9D7])
M<-+_ '-%_H)^H[#3ZS_O/OO\0G_W;CPQIBAJKCU76CHY(V+/64T:K)VYPB>B
MGK;]SFTVW2-R;40(ZNJ(,5,C)G[7JF<*F>W?X'DG1M,RCZ[>[1)B**OJ8VIG
M.$1)$0]K:@END&@$DT_*R*Y-@@\)[V;T3EN[C"_DY]#QCTXN-PK>J[I;E(V2
MI;#,S+6(WC<OICXJI=OM(=/;3>*2.Y421+J![H8=JSN5WAX=_P"K3/&<<X)!
M[->@[II"QK)=7P;GMD8C&;T<F7HN51S4XX+J /#GM+UJU'4N))\JR%9XTX1.
M$D>>EX)89>B]O6!<HVBI$7G/.V,\F]"?\)\^?_<S_K0]>T?^&BI_[,3];2P0
M4'[1?5:LTJZEM5F=-#45"3QR/6%CVJJ(S;WY_*7T,NBZ9VW7W36W5MRB;)>*
MZA@G\9TSV-WO1KGJJ-X3//&#RU<+95Z+ZB24=!+$R:GGGC8Y,O:B-5[/RD^"
M'Z%69SGV>A<]<N=!&JK\]J'E;VSJ>-;Q25&/QJ4T+,Y]-\I9WL_4%.SHO(YC
M%17I5,7E>RJIYAI[=3T_5ZBIFL7PFU5)A-R^KF'I'VH;;3OZ?4WEXIF3OC\R
M\+L_20;V,[535"WVKE9F>%]*YKMRIA?QOI^8]6GA3VG:."GZA-\)JHDD3WNY
M5<JLLAZ7M%DH9NFK:1(E\%U0R145Z_6\-O.3RMT#HX9^I:Q3-56-@<Y,*J<I
M(PMGVR+;3MIJ*N1OX^2I:QR[E[)$[T_,;SV/:&"+2OOC&JD\T;VO=E>429V.
M/S%UZZOK=.:4NEU<DCO=*=\R(QJ*OE3/"+P>>>F>J:WJOJRXLO<BRVJ*I8R*
M%S&Q/;&]'*J*K/7RIZD1]HKI11:2;+=[2R**!ZNE>U9I'N7=*B)];C\KXEE>
MQ_<JVJTC5Q5,K71MKG-:B-1.$ACQZ%N=3*:*JTVD=0U7,\=BX1<<X4\9^S91
MP5?4+;.Q7(VF<].53E)(SU3[0-'%5Z)E\9,^&R9[>53GPW'G+V2J&"IUE423
M,57P^"]BY5,+O/;9X.ZP?X;J[^/S?K/;.C/[T+%_$8/]VT\.=?D_^R6Y/^I=
M_O93W'I1,6AOV_T(>-O:.PO69$]-])_LH>M.E[<:&HDCX7,N,_'Q''ECVH;E
MJ&752T-VJHI;5'4N;2QLB1JM16-W9=A,_>I<>D=,6G4O0NS4UZ:U(XK<C(W2
M2K&UJ*O.51?DA572CI%=XNI;KE2.IH[105TB1[UDR^-=Z-5J[<.3&.<GKY:1
MDE"RFG3<U&M1<+\"A=+:5LM'JZIMM_IW1I/+-4M>^5T;-JYQRJIZHI8-5T[T
M;4P2JV!)'(Q53;5N7LB_!QY Z9QMAZJTS(^&[H>/_$C/T /(OM?I_P I6K^,
M3?[+"\/9\_P:V;^*0_J4VW63_!U=<?&'_>L/,/LN_P"%U/\ 75?^[4]I%;]?
M/[R(_P"-)_NY#S)[-6G*K4U[EHVRP)2,IUDF8]5171^*U'(BHG?DOOJ]H.QV
M_IW61T-,Z-E'1U4D2+,]<+L<[U7GDI'V2DQK2M3_ *R#_P#2'M8 H3VCNK%S
MT74P6JP2205[_"E=*Z".2-8W;T5/-E<Y1/0[K#TVM6N.GE/57V!)[BLDCED2
M9\;?*KFMX;\L>AYCJ;14Z)ZHT5MADB\>&LID5S%5S?,K'I]9,^J'O71$\U5I
M>AFJG(^9R.W.1,(OG<>-^NZ__99D3_\ #Y__ *3V!TT_P>Z;_P"SX/\ 80D@
M!I=7ZCH=+V6>XW*39$QKE1-S45RHU783<J(J^5>#RUKWKVW4E!<*.DIKDR@J
MH'PQ^+3QHGF9M=ER.7UR1#V=-O[H<.SZOOE+_MJ7WI6X-L^L>IE:D$]1/'6Q
MNBCIV[WJNZ5%PWU[GGSJW>-6WZ]W"JOU/4PVIDTB0-GH_!<V)9%5J*NU,^G.
M2/Z==JAELG=IR&:2C21/$\.F67S83UVKCC!Z0]FW2E^I87WJ[5-*Z',T2QM1
MS9,JUOIM1/TE#:Y>K^J=.O\ U<'^T>^:+^YF_G_64[UATI1R:GLMXJJ9\T"U
M;9*CPW.RC&;,Y]$X1?4DENT;HFY4D-1#$B),U'(QU6[<GVHCCS)[3]@M=@OU
M%'9XEC9*R5S\R*_*H],=U/2/L\?X.;9_%:?_ '+3%]HK65TT?HV2KLDJPU6^
M+$BQ->U$5RHJ>8I'H!06'64LC=6/BDJI%E7F?P<_5QPBI\5)5JSH5I*S*Z:I
MEH*6-Z;(VS7"1J[\*J=U^1M.B71*WV^M@U#<'4E7&F)*5U-4R+ME9)PJ\(BI
MEOS/1!X\]I'7UZ?J1]D;4HRACGJ(5:Z%G+45F,.QGT+ TGTJT3K;IW:IV0QS
M7AU#!XSTK7X;*K6N=EK7+CUXP074G1*PMJDMEFN-G;<7IN3-P>[;A5W(J<KG
MA?0OSI-TUMFA+:K:2)J5$C_$<]DSWM7+6HOUO]$X]:M-LOFF6HR%TDK*B-ZX
M5WU6H[X&FT1IG1UWLC*B>-&3N<YJLDJE:["+CMN*\]IK1VG['I"DJ[/ K99)
M)&N<D[GHJ)&J^JKZH;;V./[WKE_JX/\ :E+:ZJUMXMVB[E5:>E9%71QHL;G1
M[T1=S4[*B^F3R3T.J*BOZ_TM5>%\2N=75;IW-;MS(L<JN7'&.54MSK1T#CU
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M_>2'N^R?]#4'\7C_ -E#RY[9O_2%+_J(?]J4M/H!_@57_2JOUJ>8O_ZU4?\
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MN\'ZY#T3TA_P=TW^E-_MN/(O5C_#TW^.T7^Q$>U-!?WI6_['_P"VX\<]=_\
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M[<)C[."S?9RZOW"]2?0=^<^JF:^&&&7$<:-5V_*X:U,]D/20
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M:W#=J<\H;'V?>C5VL-Q;=[S(^ED9)#,E/+3JUWEW93.?L]#TR
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M<D*^(QR2-C1ZHC55<854(GTIZ)V?1K?'J=EPJT5Z))-3HUV%5,<Y7M@DVMM
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M1TT\]/#5W-B(OO$L"-D1R.54=G*\]BU
M<$D;G&1XK/C^@>*SX_H.2/:O93Z   <)I60Q.DD7#&IE5QDT\FJK/&]S'U2H
MYJX5/"?^PX_A;9O\;7^2?^PV=!<*:OB\2DDWLSC.U4Y_.90
M  !QE:KXW-15:JIC*>A$*O0-ON%W;771Z5Z-?O;#4Q-D:WXHF[/"X3/V$KI*
M6GHX60TD$4$+&HUK(F(UK43A$1$]#N                            ,:
MXTRU=*^%LKXMZ*FYBX5,HJ?TD:L^@;117"2NK((+E5N5JI-54['O8YO9R.5%
M7/"<_)"6L:UC4:QJ-:G9$3"(?0                    #4:@LOTQ3^"ZKF
MIV+W\/\ *3&,+\N3%TUH^SV"%B4M#1K4M3S5*4[&R/YRF7(F>/Z"0@
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MR? ]%=(_:&;7U;J+62TM*JM<YBTM/*Y5=N:C455<[C"N_0>E&.1[<M['T
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M56N1<HK5PIZA]ESJ;4US&Z8NTC7I30OE8_8Y7JYTR8RY57*>?X'I<
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MNFK$J9)61-3W9<9?C'.?FA9M#515M*RH@55C?G"JGSQ_0=X
M                                     !A7C/N+\?\ '"GYJ/\ [J=]
MAN=$?W\6+^/T_P#O&GZ*VKF@B_/^M3*,.[VZ"[6V>AJ]W@3)M=M7"]\]_P Q
MX(ZPZ232&KY(8W(L-4^69OF5RXWN1,Y1"$S-1T>%/87LCW)\^A9:5R<)5S/[
M?*-"YM1UGT?8+E5Y1%@II)$SZJUBK_0?GGKF^R:IUE<;O.B(L_AJF&[?JQM;
MVRO[TU$$$E9604<&/%J';&Y[9^9[4]GKIS3:4TY#<E5RUEP@@DEQ(JM1S4=V
M143'UU+@!5_7'IS3ZUL4CF.5M<BQHBND5K-K55?1%7/)X2CD>WR20RN?W\K2
M1Z 6X4>L[164M+-A:N%';HE7RI(W/ZC]#+%6/K[5!4RM5KWYRBICLY4[?F,X
M                                   \F>U/IJ2PWNAU#;,8;'(^7Q%5
MWF?)CA,8_*^)SU9>G=6M*V^R:>:Z&5M)!#(ZL;M;XD?F=A6*Y<8QCC[B.]).
MJ#].Z-GL,L4BU+JU\^6Q(K=JM:WNKD7T^!Z5Z,:9?IK0]-05"M=,U\N58Y53
M#G*OJB'F[K/2Q0>TI2OCSN6X6]%RO^;$6)[7BYT99?MG_P!EIL-%?_<S/S_!
M3/UJ1'V27*EXU*B=EN"?J>1JVP1T'M%PR0HY5?-7.=Z\KXA;O56U:5BU9;M3
MZD2NDF@MT=,D5)(U'*U7/PNU53U<O.2B^K5W75O56GK712PN;111[9F;%PCU
M]$5?B6;[85O@2U6VK3=XTET@C=SQCPI/V(8U19Z5_LYVR7S[HX*][?-ZHZ4U
MW0^U4K^E.J9%W[IK:S?YOF_L</9EA2#6]]BB7R,KHT3/?ZKSUH>9/;%3-+_\
M+#_OG&=TIZ5:?U3H25]?[WXGO;F^2;:F$:Q?@OQ-QJS13-,](H[16/:_;<5G
M18GJJ96-Z=U1/A\"O_9IT9:M3V2G^DTGW1QR2M\.3;YDEPGI\R::MTCHO2.L
M**\79+C/4LJHIJ2*EF:YS98]KDWM7'"JB<)W*OJ+LE]]H:S5U-'+"Q]T5[&S
MMVN3*)W1%7X$C]L>F;*[34LR_C(Z27LO'UFF[UYI>VQ>SFVK:DWBNI*!RY?Q
ME5CS^LR/9<KY+5T<N]1 FYS+U(U$1,\>%"A$O8_AIY]65ERE=BM6EFAQNPFS
M?$O;[3TA6Z6M;+S=;ZU9?I&HHU@D3Q/+L1$[-_[J'EWHDUM'UKN<<:+L\"%.
M?3+HC)Z^:?O&FNK+M<6]]+-$^JBJHV,W2/8L#(U\[<(B<M^/W%H="=76;7-;
M65RPUT5]@\*2K61K61.D?O\ J(CE7'E7OCT+BOU"ZY6BII&*U'2HB(KEPG=%
M_H/$O3:I=I+KE.^N3#4J*S"HG=,/3UP>S[S!4W6P,;;GPMFD1CT655VX[^F3
MS+<.LFMK/J*.QR/M;G.8V7+:=53S+CNJHOZ";:WTOIRSZHAU3K1U34W=T\*,
MCMLJ821B(L:JQV.,,3//=2I-:W=NI?:!LEPIHIH&27>A5&5#=CDQX+>415^!
M8GMAM5MCTNCU3=FJ[=NT9,+'8$U;[.]KM3U1'26J!C%W*U/R5Y5$7X? HOIC
MJY.F-WU'85BE?.VX/8Q6L1[?)EO=5:OI\"^^F6D4M6E+M-5.15N=8E<FQR\(
M]&KSE$Q^DIKV6FHG5*L;Z9JT_2AK>N]II:?K=!3LW^'[O3+R[GEQ,_:NT[0V
MJT6>JI?%\62Y1L7<[*8\-W["XN@.5Z1Z?SWV3?[Z0L
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M\9SVW?(EELM%%;6(VBB6-$14^LJ^N?53/
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M=-:4IK)=I8Y/=&JC5C8J-RZ1SEPJHBKW0GP
M                         !A7CBA?_P >BGYJO_NEWV&7:*QULN]'<&(K
MG4TS)D:G==KD7^@O.#VEZZ&F9$VV56YN<NWQ\\_Z!US^TS=5:OAT-4U?]*-?
M_H(GJOKKJW4-%-10U<U+2S)M>Q\,3L\HJ<[,^A6*(JODD>NZ61RO>[XJO=3[
M#1U-TJDH+?3S5,[TW(V%BO=QWX3D_0WIMI*/1FG5M<4C9&K,Z;+45$Y1$]57
MX%<>UU(K.G5"B+RMQ:G_ .QE/&M.F(4_.6[[+,2/U],Y>[98%3[W'MT
M
M                                               PKQ_<+_\ CT4_
M-1_]TN^PY>G"97X'S;-_[AP1DR]H''8REKG\14,C\_!206#0.JM0RI'06:L1
MJ]Y&M1V.,_%#U)T5Z)TNDF1U]X6&MN*JY=SZ;8]C7,:FW.Y>RY^\N\I'VN(5
MDZ<T2M3*MN#7+]G@RGC*F7,#53Y_K+8]F"I;!U#6-RX66>!J<]^7'N,
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MBIJ:.AN5KI8WRR-C61T[W+YG8^'P4])6.X,NMK@K8\;9<XQVX<J?T&<
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MASG<N7TPB?!%+%M5QI+K015MNF;/2RYV2-141<*J+W^:*90
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M<]_]D9<Y<JO]D2%D
M    PKS_ '"_/_'"GYJO_NEWV&XT/_?O8OX_3_[QI^BEI_Z/B_/^M3+  !7/
M6CIQ1:ZL$B+&]MPIHY9*=T2L8KY-F&H]5:N4RB? \-7^T5NFKQ4VJ[-:RHIW
M^&J,=NY^U/M,-$Y1\;WQO3E',7"I^<W%NU?J*V,;'1U\[XVX1$DG>N$3A/RD
M.=?K+4ESC\.JKYV,_P"JG>GS_?*:1K5W*KG.D>O*N>N5^\[*"FGNE:VDH4:Z
M5V,HY<<9Q_2A[CZ'],X="V*!U7&Y+NYDD<V7L>W:LFY,*B?!$]2T
M                        5_U>TM<=06=9;$^1+G"U&PL\9(V+E[=V[_NY
M]314-^U=]!LM3Z:W_24+61-3+L*C$1%57;N_"FTT/TSH[7I"HL]P;)B:M=6*
M[<QSLJUJ81=O;CL5GHRS]1NG;DM-)2VZ:UJBHU]3.LDFYZHJ]G(GHOH6G<](
M5.J-#+0:A8C;@QDSHO!>F-ZHY&\KGXH5MHZFZCZ1IV::2DMC[>U/=X9)9E?*
MNY55554>B9\WP)WJK35]NW3ZIM2,C?7U],Z&9JR\-5>VU57C])D])M-W&QZ5
M2R7V*)&QQQPM1KT?E&HN<KV^!6E1HC6'3W657>]'Q034%3435$S*VH16Y>KD
M:B,:K>,._,6WHIE^N=+X^I8J>)[G+Y:=WEQM14X55]54J_I38-8=/KQ/:I*6
MB^CY6OJ=SY=[][E:F.%1,8;\#9:WTIJ2BZGS:@M3(JJWU,<5+X=7-N8GU=RH
MS*87R]_FIUT>G=5V/JE6WVFHK>VBN2T\#\O3#6M1J.5K45,+POQ._5/3^_U_
M4RBU)1Q1NIZ2M;5)NF1$PB-[M[^G8NNWOFDHX7U*-;,K<O1O9%^106KM*TU]
MZP6.:D\1D<-14)4['(S+E5?ER7]14[:6DA@8F$C8UGS7"8.U[&O;M>U'-^"I
MD\_V'1-YZ7:BDJ-/M2:T20+'BLF1Z^*YR*OE;M]&)S@W-FT#6:GU[+JK5#/#
MC6-CHFTTC=GB1JQ&^54<J<-7U.GJ9H._ZAZ@6^\6Z*)U)05D%6Q73(W.Q&9R
MB]TRU2Y;9)42T,+ZQK&U"MR]&=D7Y&MUM9_I_2MRM2;LU46SRN1J]T7NOV%1
M=%;/JO1^H*^T5=-1_1M54O<UZR;Y-C&NV]EPG9,\'?K?0FI+UU+H=24T$"Q4
MM&M+_;D:GUI%^JJY_+-_ULTO>=9Z;6SVF*)T;G12*JR(QVYJJJ\KQCL:W7/3
MZOUGHBGI*R-([K!7)4HZ"5K,M:QR(BN7/&7=C6:+K.I#64]DO%):VI"[=)(R
M5RR8<[]]O7/#O@79:8)*:WQ0S*JR-SE57/JJ]SC>K737BV5%!6MW03L5C\(F
M<?G12EH= :BT+J*HK]'HD]MFF6:5E;4(K68RC4:UNW"<]B42:PU/)2N924MM
M=7)A-KFNVY]?ROM,+273:>Y:?KH];/G]YJ:QT[60SM>U&*C53&4=CG=P:'0%
M)JSI[;);%404CZ>1[YT?+(LDFYR(F,HY$QY?@2+I)TXDTW73WVZ>*Z\ST[Z:
M1KI6R1[=[53'&<X8GK\2.WGIWJ"X]7EU5X4:4;YZ9[E2=$\L:1HOE[_D*;KK
M1HR^:QNVGIK9%$Z"U52U&5E1BX78O.>_U5[&=KO3%XOO3:"PT4<;JM]*L,R+
M(C<+Y<85>/13KL.EKQ1=*YM.U$<:5S:>&")$D1<[-N<N[>AQZ&Z/N^B:*[4]
MUC8U*VK6H3$J/7&W'IV-!TWZ<7S3W4B:^UD;$I'>/A?':[Z^<<)R?>H_3V_W
M_J)'?J**-8$IHX%_'(WZKE5>%Y-EU5Z:RW2]4VK-/K*Z]1U44T['S-9%X<3?
MAA%7EK>,_$P-1T&I.HD5LHKA%3PPPRK[W[K)X:^&]41<;E7/ER3.XZ0EMW2Z
M?2=@9O;)13TK5F>B.\^['F1$3NY?0TG172%XT3:[K#<8XTGF9 V)/%1Z*K-^
M<X_TD-;H;0E^LO4JYWNMBB2BKKC/6*J3(Y</WXPGI]9.#:=>>GL^MK4UU U5
MJV-8QKDD:S"(_*\JGS,_66A'7/IQ%8Z5KG3(^)ZJKVHN6IA?-@R>C&D)M*:)
M6V7%JK4.FD<Y[GI([:['&Y$^78K;573W4VE-=U.I-#PPR03+$Q[*J=$8D;6M
M5V&MVKG<PF]M@U3JS2][;>HZ>FGJZ.2*G]SD5GG5KF^JKCTY(!9=$ZK_  ;U
M3INHI:25U1%'3PRR2HZ1<*[*J_/"]N<$NZ96?4=JT?<;'<J>E9-!X<%.C'YR
MUJ87<N<9X^1V])-'W_2M^O$E?#"E+<KA+6*[Q4>J(Y%QC';G'!$(]&ZET-U%
M^F++!3RTDK)7O6JE1V'O<[LB*G&,&^ZMZ%U!K2HIY:2&%=O@O7$R,Y:JJO?[
M27=1[1>-2:3BI*>*'WSQU5S4?M3;L<G=5^:'WHM8KOI71]#8+M%$QM&V145K
MT>Y5=*Y_*IPO#O@6
M    ##NS7/HGHW&?ZE/SX?H+4*SNV^ZYQZJ__P IM=':'O\ !K"RRR>Z[8ZV
M![L*_LDC5_>GO2UL<RAB:_&Y,YQ]JF4   17J%H>VZWM24=T6=K6->C%B>C/
MK8SGA?@AYMU?[-5THWSU%@J:+W9KG*U*FH>KMO&.T??N5G<>F>I:"9T4KJ%R
MM54\CGKV7_1.JDZ=:EJ7[&+1)_I*]/\ Z2P-,>SAJ*Z,2>X55M2#*HJ1U#T=
MV1?6/YGI/IKTSL^@F/\ HIU4Y[T<U?&E1Z8<K5_>I^]0G0
M                        !&.H5QNULTY63V!*;W]L3G1>\-56;N,9QS@T
M'273MPI*:INM^=3K7W!S*MR4RKL1SD57<*G"9=PA8P             3@
M
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MS9QY5QP1GJ!U,O&G.J-ML$*Q.H*F@]Z54A1RYW2HGFS_ )B%TL7<QJ_%,GT
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M^(U$<K>415QRAO@
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M8L=H;1Q^!C+FKYFJ[#ESGG/J>EP
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M-M(V_1]FIH?Q:W%S71RS95JR9>JHFU57'&/N)H
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MOP)AT_LFO*O5CJS4E9<Z:AC='(V"==[55KFY;G=ZHB^GJ7@
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M:JM]+-*BY1\D37*B_:J?(S8HV11MCB8UC&HC6M:F$1/@<@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       JHB95
M41/F$5%3A<@    ZHJB&9VV*:-ZXSAKD4[0       O"<GQKFN^JY%^Q3Z
M
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M&U,K4,1#OIZB*H;NA>CV_%#G)(V-BO>J-:G=5,5;I1)WJ&'=3U4%1_:9&O\
ML.<LK(6[I7(UN<94QOI2B_QAARAN%+,_;%.USO@AE*J(F5[&(^Y4;)%8Z=B.
M1<*A\=<Z-J9=4,1#F^OI61>(Z9J,^)WQR-D;N8Y')\4.J>L@@<C9I6L551$1
M?B)JN"%$665K47XG4ESHU<B)4,55X,I'M5F]%\O?)C/N-(QRM?.Q%3A4./TI
M19Q[PS])D2U$44:22/1K%PN5.A;G1(N%J&&5&]LC=S%1S?BAR
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MSM=G'U<__48]BN-=9;ZZW7&2:>/8B-=)(OUG*BIQS\RQ
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MLP:&MVI;+6UM8][9(*A&(C6-5%S&B\Y3YGK*GB;!3Q1,^K&U&)]B)@[
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M;4--3^#%34:MSG+GKG]9EZ:TQ/'<'7"Y.7QG,V[6O1S>%3'ZB:
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MK7<\(:*GT!8J>Z+<(X'I.KW/[IC+LYXQ\R5,:C&HUO"(F$/H
M PGP "HB]T 5$7N@"HB]T083X#"? 83X 8R,)\!CC'H$3'8*F>X1$3L@"HB]
MT "(B=D /FU/@A]1$3L@/FU/@A]PGP0 (B)V 5$7N@&$^  PGP0^;4^"'W!\
MVI\$/H
M
M                                              -#K/4E'IFSRU=;
M-&QZL?X+'2-:Z5Z-54:U%7ERXX0P]&:C6ZZ?6\W%SJ2B='XNZIVQI&U%<BJK
MN$QP16KZO45;=JBU:<H*RZS1R.B6HH-D\;%1>%7:JX1<+@P;IU2N>F6NJ;[I
M^^242>=TONR,9&BKA$<Y41$Y5"TM/W>GOEHI+A2.3PZB)DNW<CE9N:CMJX]4
MR;    !?D4'I7K)5ZAZ@R6:*&MIX6TZ2^'+''QYF)\,_E%]NSM=M[XX*AUWU
M>30=VFI[U;+C/#(_PJ>1C&L8KD1%7"KC/<F/3?4\VK+4^YNI:JGI9FL? D[$
M3*+NSA4X7LA+@   1;76NK+HVVOJ;I64R3(B+'2^\,9+*FY&KM:Y45<9ROV$
M.AZA7J]PI5VBPWN"F7ANZDW(].Z.1<+E%14-IT_ZGT^JKTZSRVNOMU>V-TNR
ML1K'*UN$RC>^,KW^2D(HNL=;7]15L<<%=3QI"R3PY(F>KFI\,_E%^@    &L
MO=]M]DB\2YU4%-'C<KYI6QHB=NZJAJM+ZXLVIJF6&TU=/4+&]6*Z&=DB91,_
MDJIO[C7TUNI75%;-'#"U417R/1J<_-2H[I[0FEJ)&^&U:I55$Q!4Q.[Y_P [
MY%G:4OD>HK)#<H:>6G9(KD2.7ZR854_H-#KKJ/9=)S,I)9XJNYO=L2B@G8LZ
M.5$5J;%7.793"8YRA@:4U+?KS[_6SVZYT=*QK9(:>II=CU3G+4XY7@B-QZ[4
M\6I)]-PVBY_2R3+3LPUBJKT[X;W_ $&SK^J%STW1>^WS3U\FI,(YTJ4R,9'E
M41$<Y41$Y5"<Z+UM9=6T39K96TRRJNU8$J&/D:NU'*BHBKRF>23 C>M]86W2
M-M;57&6/+W^'''XK6N>_:JHU$5>57'"%?/ZK7%*5EY;I^^/M#\O7;3(J1L9]
M=7.QA$X7G/!9NDM04NI;%1W.C\K*B-)/"5R*YB+Z.Q]AN  :/5^IK?I6VQUM
MUFCB@?*D+5DD:Q%<J*N,N5$[-4[M*WZCU+8Z>ZVV1DE+/NV.8]KT7:Y6KRBJ
MG=%-L  :B^ZCM=B9ONM;2TK>$19YFQHJKGCS*GP4P])ZQM6J,_1-3#.B,5^8
MIF2)A%POU57U4VEZN]!9J*2IN573TT;6.>BS2MCW;4RN%54(50=6]/U5Q93/
MEC@@E>UD-5+41I%-GA58[.%QZX+ IYXJF".:FECFAD3<R2-R.:Y/BBIW0[%5
M$3*JB(0"_=5+!:ZSW>":.XN;E'K25$;_  W(JHK787A>.Q+-/WZW7^B2JM59
M3546=JK#,V1&N1$56JK57E,IP=.I=36C3=)[Q>+A1TK57:U)YV1JYV%5$3<J
M95<+P0&Q]0[IJJX4K[-9[O36V25O]D/ID=$YNY&N1'HBIWSZ\84M9B*C4W+E
M?B?32ZFU/:=.4JRW2NI8)-NYD,L[(WR)G"[4<J9(M;>K5@J;E%25SV6QLV5B
MFK)XXV2,1%5'M55Y:N.%3XDXK+E24=$E945,,=,N,2ND1K%SVY5<<E47;V@=
M+V]ZM8U:I4=MQ!4Q.]?](L?2>HH-16-+FR"6DBW.:K9\(J;>ZK\B-7?JOI^@
MN3J2":*N1CF^)-35$;V1M5$57N5%X:F>54ENGK];K_0,J[764U3&Y,_B9FR8
MY5.=JK\%-F1+7.O['HZCDEN5;3+4HW<RD2HC;-)YD1=K55%7']!$H^H%]NL:
M5-MT_?8*=43:CJ/=O1>4<BX7*85#8:$ZG0ZMN3K2VAK+;<6[EVU:-:YS6HF7
M(WOC.><>A%:WK]16.\MLU[M%SBK5<B[Y49&FURX3A512[Z6HBJH4E@>U[%7&
M6N14_05_U1ZJVK0+(6UD,M5-++X7AP/9N:NW<BJBJ?-+ZYJ]0:9J]004-?#1
M,A\>*.2)-TB)N14:J)A5\OZ2(TO7)+W=I+/:+/=67"!ZPR?BV/57<_DIE?R5
M]#=:<ZT6NIU!'8;U2U%KK4>^%TM<]D+5<Q%W.PJHN%5JH6Q&]LD;7QN1S'(B
MM<BY147U0^O<C&JYRHB)SE2%5O4[3%+5QTRW:WOG>YK4C;61;N>RXW9)MGC)
M%=0Z]T_8)GPW*YT,,S5QX<E5&QV<9QA51<F\L=TI[U:::XT3VR4U0W<QS'(Y
M%3..Z<+V([K'J!:=,L7Q7MJY4RCHH)6*]JHJ(J*F>%Y_0<-$]2+!JR1(**MI
MHJY7*Q*1]3&LRJC=RX8BYX1%S]BDS-9?+Y066E=-75,$2)QM?*UBJO..Z_(@
MEJZSZ=K+C[G6*EMD5$PM741Q[E541$3+N_)9<$T51$V6GD9+$[L]CD<B_G0B
MG4?5\.E;,Y[4=+73M>RFBB5JR/D1,HC6K]9>W&%,>T7VZ/Z>?3U9#5>\NIO&
M2F="C9FJF?*K<=S-T)K&BU322I Y&U=,C&5$3GM5['JBY1S47A45%RBDI
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M*>9_:_T_;:>WV6Y4],R.MJ*QWC2HJJKT1B8]<>B%M="45>D&FD:N%]V7"_\
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MQ3+%;KW<:R:1BMVMPQ)5;RN57NG94/2[51S4<U45%3**GJ?0
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M^U$.T
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M
M    ZZF".IIY(9FHZ.1JM<BIG**F#&MEL@MK7MID1K'8\J(B(F,]L?:9H
M           /CL[5VIE?0\^=1^D=XU3JY]W;'4)X,KWP;*B-$5'+\URA=NE*
M>KHK#0T==&C)*:GCA^LCE7:U$7*HOR-N   #XJ(O=$4^@  '2ZDIW3)*ZGA6
M5$PCU8F['PR=P           !CI14WO#I_ B69RHJOV)NRG;DR!A,YPF0%1%
M[HB@             Q;A0QU\#H9U58W(K7-X5%1?BBG.BI(:.G9#3QL8QK4;
MY6HF<)CT.\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  QI+A1QOV25=.U_[UTB(OZS(:Y')EJHJ?%#Z %X[G".:.7/A2,?A<+M<BG,
M ZEJ8$E\)9HO$SC9O3.?L.T  Z*BLI:=<5%3#$OP>]&_K.'TC18S[Y38^/BM
M_:<H:ZDFW>#502;>^R1%P=T<L<F?#>UV.^U<X.0      RF<93)U-J(72+&V
M:-9$7"M1R91?L.T  '!LT3I',;*Q7M[M1R93\QS
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M53@C.CNJEBU+(L:/;0R;G(C*F>-JJB(BYQGMR3\
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MQTU2QT%0D,<:N8YSE7+WY^LJ_!#U71NWTT2JBHNU/U':>4]<?_=/57\8M_\
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M(^@
M             H;IBUU#U1JZ:9%:^>HJ96YX54\Q:74>5D.EYGR.1K?$;ROV
MD-]F6HBEZ<;6/:KO?)5PB_Z)V]?7MFM%CI6.1TS[G&U&IWY:Y$X_.3705%+;
M])T%+.US9(T?E')A>7N7M^<B'M"U4%/T]N+9YFQJ^GD1J.7ZWU35]*K;I>Z]
M.;4E2VCDD]SA21RJJJB[4[\DDDU'I6OME19[E/0RVN+$$K7R^5$8J81?SM3U
M*8T0K=&:[?#J&9&V*I6:HB?4?BXT:N48B=\IPF%+;U-JFQ6[64=+/14SJU]
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M;C:G*HJ>I9^K.H=QTIJ=ED@T]+=(G1LE][2?PT3<N,;=B]L?$M
M
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MRLEKAM% E)3N<Z-'*[+L9Y^PSP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW/J2,
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M]7[7EA=9&QNZ8X?G9N@-%[)ZJO2M5=W]_F_4PN0
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MW8E-9I"#5W4>34"NC;2)2LC:QTBLDWL<G*M1%3'YS3S.8SVB-1*BXW14J/\
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M=WQZJGR)0
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M)W4   ^/>UC5<]R-:G=5.,4L<J*L3VO1.^U<G,
M  =CK;/$Z16-E8KT[M1>4.P
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M90
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M61J(N?C@Y@
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M7_3NV5&H]=5FJ)I)%IJ6MF]UR[<CXGH[:N%7+>')Q@N<
M
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M[T:CFKC&6KE%[)Z$FM%MIK5004E'&UD<3&LRC417;4QE<(F5X,P
M
M                              '%T4;G9<QJK\50Y            '1+
M212N5TC=R_-$7!V11-B;M9V^!S
M
M
M
M
M
M
M
M
M
M
M
M
M                                                (E/U"T_!JNFT
MY)4S)=:B5T,<?@NVJY._F[$M!K*^^4-#6)2U,CFS*Q'X1JKQG']!I+YU#T]9
M-0-LMPJ9F5[G,:C&PN<F7XV\IQZDN!':+6=FK+]5V:">1:^EE2&5BQ*B(Y<^
MO9>Q(@"+Z@UW8K#>&VRY5$K*MT:2HUL3G)M551.4^PE -#JG5EITP^A9=YI(
MUK'N9#LC5^53&<X[=T.J\ZTLUGM$-SKIY&4DL?BL<V)SE5O'HGVF1=-46NV:
M5;J*KE>VUNBBF1Z1JKMLBM1OE[_E(=^G+]0ZAMZUMKD?)!NVY<Q6KG"+V7Y*
MAM   :"NU=::&_4EFJ)I&UU4QSXFI&JHJ-SGGLG93?,<CFHY.RIE"-Z@UO9+
M!<FT%SGE94N8DB(V)SDPJJB<I]A]HM;66MU14Z>IYY%N=/ E1(Q8G(U&+MYW
M=ORD)(1:?7EB@U.[3\E1*ES;+'"K/"=C<_&WS=O5"4@
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MVD=*W"9>B8PJ+]OH2#II8+S88[A%>GT;XWK&E/[NYRKM3=G=E$YY3])-0
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MW)W5C'+VS\BB_9^H_P +=;:BU=<,M=5>[2Q)'Y4W1Y;RBY_>)ZGH\
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M+ZDT
M         !16@J>6S]67TM1&^)*N2IG:KVJW*>;GG["U_P *;8R\);IZFGAJ
M58LB-DG:U5;SSA5SZ%-ZST^_J%U(:^D8Z.G@IHY?'5JN8JL=C;EO&?,2SKI/
M%64]CMD3VNJ'72%KF-<BN:CFN3*IWQRA/](VY;3IZDHG+E8D=SA4[O5?7[3;
MJN$RO8\Z]3+A([K1IB6&BJ)(:62=LDK&JK6]^Z]D+"ZUU#G]'KIX,+Y99(('
M-C8F7+^-9V0A&K'SR]"ZAK:.=\R34WXE&+O7AOIW-#JBUW*;0L5^H:2IE;'/
M' M#'"Y\JXY5_"=BS-*ZMM&J9YJJ&QU4=2V)55JRJJJUJIZ)]J$(UI005EYI
M-0:7HIK;J)]3&ZJ2172O?&Q$1K?#7*)G:SG'ZS57>INUAU/0:AOMMKJY;G4L
M6;9 L?@MC5J*K^,(F/L[%OZ(NEIO%8^IM]IG@D56N=(LJO3G.%[X^)(];7*>
MSZ6N%?2TTU5-"UJMAA;N>[+D3A,+\3SQU(OUTU;I"JJW4=6JT[XXEI_!\Z^9
M%]$],FUZTU4M3IFW)1TD]0K::F:Y(FJ["IG*+CU0NS643KAIR=M(N]4Y\B;N
MR+\"L>@%X=^Y_56>JHYZ:JBCJ)E29-JJBKA$VKSZD:Z64M77W/6]"ZFGIGU-
MG?#')+&J(KG-1$QQSW[';TOU'4Z O%ULEYMM9+M6*.*?9X3)%\RKMRG.-R&U
MZYW26Y0:9JZ6@J7MV3/5K&JY4SX>,X0UVNYJZV2: U&VU5U;0T%H9[Q!#$Y7
M9<S:B*['E5%<G?X$TMFI[/6VQ*^BL%9+,W:U8HY5>Y%5$54PGPR5[<:"KL>I
M&7OIY')1L<U(Y*1L:U,BN<J[W>;=A.WV8/2M3&LM/+&BX5[5;G[4//.DZ>LZ
M==7+V^OI*BJHZBFBIV5#(U9&JJD;E5'*F%QA?N4RKU::C4W62GK:6*1M';Z^
MEK%J-BNCD:W9G#DXXPO/R,FP5,K>N.ID6FF\&2MID9-M\CO*N51?4O<I.^:U
MNEQO]RTY[C64T;JF6)DLL2;7M8Y51R<95%VD?Z5SRTF@M0TM123QU#KNY[6/
M:K7/;M9YD1>53CN2/HS-)%THK_'II895KI\12-5KE3"<X7T,?H)(]G2FMCGI
MIJ>794X9*BM<OYE(=I^W5UTZ3T:4U-/#/;8ZBK?"Z)5?(C7R+L1,915XP2OI
MKJJW7&T6FV7.P5L=?3NVXD>K'-<YZXRWA?@<^K\TB:TZ=LIJ*=T,53-N1K57
MPDS%]9?3\XZO3OCU3H*>.DGJ&,@GW^&BKLRQO"X[&EUQ+<M+]0](ZO;;:VNM
MU+;5=(R"%5VK(V1B-5V,(J;T[F'U]O[;I4T,])32R,=21JYS/,C5W/7:N/7D
MR>L3YY-;4#Z6DGJ(O#ID62)BN:G?/*&;UV69^M;0D5'43L2MIE5\;55$X[\&
M\ZPSO76FBECIY98X[[3.>]B91B9;ERKZ(1OJ8RMTYU&M^HO<ZFXVZLJTF<E-
M$JI"V-&9W.QCG*\_)2=4-ZMEZL-RK;;:YX)W-9(]5D5_+E7T^\U?0N>2*BUH
MZI@EA7Z7>K4D3:KTSW3/=#KZ%3/2\ZF9+2S0K)>JES5D14W)CNF>Z$=Z'UT]
MGU?6V^XT-33ND=/.V29BQHK5VHG=/DIZ&K)%BHYY6-5SF1N<C4[KA%X0H>MU
M?=M4T=UM\M%5T/N]*^5(YX4179:J83C.5R8U!<)$Z TM![E4)5Q452CH=J[T
M55DQEO?U-_1U3V>S9X*T\JU3K5*G@8\Z+EW&WODU5UHZV_=#:9MOIITJZ.W4
MS%ITC5\CW+LRB-1,\84R-"ZRM=?::*VW+3M=%<*")E&YLLBL=(YC$1SD;PN,
MHIA]2'W#1NOK;J6DMU974#;<D+HJ>)7*CGO?W=A4X3'!:>D=;0:CK$@IJ26-
MOAJY9%<CFHJ8XX]>2GNBDM18^HE30W*CJ(%]Q=B25BQHJN?'A.4[GHBND=#0
MU$K&.>YD;G(UJ95RHB\(4;>-97;4%IUO:9*.KHTIZ!R1Q30HCIE<U?*WC*K^
MTPM,U3F]"K_1.HJB*LCM[6+$Y%1[W>;A&]\EC=%)G2Z/HF20R1/CI*9KFO3"
MHOAIQ@K[I=<)K=U3NUNKJ*HA2JN=9-'-(U6-VX?A>4Y1<=_F;6V5#TZ^TDCZ
M>5E.EF>WQG)AF?$?QGMDB6D;A7]-=<S4EUH*NKI5IU5*ED2QQJY[D5$RJ=^%
MXR6+KZ_+>]&)4TU#4(BK)AN-RKAKD]"L)*.XS=*-&W&FH:J1:&MFJ:BE9"YT
MB,9(Y<+QY<HG"K\2R-"ZJLVH)K9(RQU5-6N>U<23+NA<JX17-_-ZFGN=-)9^
MLU!-49;#7UKGM<Y-J(B?->_<S.K-+;M5O]TJK?+3W2/='17"5[DC:U'HKE1J
M*B.1R(J(O/=#:=,;]=[;H2X3ZJD>]*"K2EIW21-@18$:QK53A,IE5YYS\3H]
MGNW*RQ5];(U6/6NE:B.147"M8I(.G?4)NLWJUMEKK=ACGYJ/\U43';YDZ!3]
MSZ5W&[=4Z74M9=*=U#15J54--X2HY$PF4W)W[>I;[&HQJ-;PB<(4MJ[H]45.
MMZ34.GZZ"A>SQGS->QTBO?)NY3.43ZRDIZ1Z!GT1;ZZ&JK(JJ2JK9*Q71M5O
M+VM3'/\ HD=ZR=*[AJV_PWRR7*"AKF0LIE=)$Z3+$<YRICMW5.<>AV:HZ55N
MH]6T]_DN,$<S)87N:^-V5;'CCCCT'5'I&_46HF:DT]60VV^-D9+)42M=+O\
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M3XH&M>CFN8K%SG//U5^\] @
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M1-NOU$U_T[=9:Y5W8WQ[<=L?T_>2L
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M6N5,X4[DY0
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M.=G;ZOKW1/F;$
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MJWE$5<+VY[FPIY+A5=5+U44E74NMULGIYZIJS*C61[45<-SSPCN$,*Z:GO\
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MJ=_S$UT?0.MUDBA?G*KOY5%[HGP-T
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M73>\1=0JV]2/IEAEIFQM3Q55<HK/3'^;\3>4^A)JSJ37:@NKVI$YL3HFPO\
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M[D7Z_<NV-J,8UB=FIA#Z
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M+*C=B*1)6[5QRF?VF53P^#3I$ST1<9-/#INE;>9KF]9/>)'M?P[C+>W&#>@
M %:]9]*W*_ML]PM4E,UUK661R3.<F=VQ$PB(N?JK\"/U]FK]:::@L-;X3'-@
M;3O<F6)E,+PN%_>_ M/25G;8=.6VV-7/NM-% JYSG8Q&]\)\#;@      U5U
MLE/<:V"IE5_B1-5K<.PG/_Y3:1MV,:U.R(B'T  T57INFJ[O!7SJ_P 2!SG,
MVNPGF[Y3!W7VQPWBB6CJ%=X#FM:NUV%X7*>GR0SK?1QT-.D,.[:F.ZY],?T&
M2
M
M
M
M
M
M
M
M
M
M
M
M
M
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MK6G]:SR0T<5;;IV,5ZQW%(XG*FY$[(]5YR6"
M
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MNUBIPG/IZDZT1%I75VLW7"AH/P:N#&,<^&XU3O$<UKFHC4:YWJN%3@]0@
M
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M/ZJTUKH^K%"_2"POJG3TK9_=I/&5(LIG*97"9QR>M0
M
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MHJ*YP35;X6(V-JKE529JK^A%.WJ_>&5.CK.VS:E]TJ645,U88D557'=>Z?\
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M8;
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MX&0[45<XRBJ6B
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M=E38YS5RGYOBI;(
M                                                           (
M#U@LSKCIM\E-&KZE)(T3&5X15]$-K643-7Z?9'4QN:UL^[;+EB\(J>G^D8=5
MH"WRZ6H+&V)J4E+.LR,65_JKL\]_RE,34O32W7C3]JM"1,2DH7R.:UTKTQO7
M*\IROYS*KM T4^E[9:XHV-?;8E93*LC]K%7'YU[>HTCH"ALM4E;41L?7-<CV
MR1RO5$7"HO"\>IE:;T3;[->:NYQ1(E5/.^9')(Y?K9SPO'JIJ])=-;?8-3RW
MN.)B5;WRN1[97KP_.>%X]3CHWIG;].Z@ENT<3/>7T[J?<V5[O*JHO9>/0VMC
MT726J[5ESA8U*RHIEIW/21R\*K?1>/R4.K3NDV6"EK:MS6OKY:=\;WQN<Y')
MW1$1?L0TG3_2E12:POU^J&M8VX> K6NW(]-B8Y14QZ>A/-16J&]V2LMM2U'0
MU+-CD5RIE,_%.2$T'2^@CL]=;ZJ*-\4JM2)&S/\ *U/15[G4_I-:5TM76=L#
M$94RLD7\?)CRJGKW]#KOW2*UW2@CA6&/Q&-8U%6>1$PW[#>:@OMML5A=';IX
MZATKUC\.GD;*Y-S5Y5,]N$*UL73RJ3IS;*>IA_Y2EGDCD7SHB-5S\*J8X3MS
M@MSI_8GZ7T?06FH?$KJ9)-SF*JM\TCG=UPOJ?-7WFDAT[=V4]93NK&TTFR-L
MC7/W;5PFW/*_(@G1#2E71?A'<KLC%;>E@G:U-S7)CQ%7<F$POF3L;S3O3QMC
MU?4W:C6%D-14R5$C?$>YRJ[=\4QZG92]-[?!K.*_-B8DK&2-5?%?GS9SQV]3
MCHWIM0:9ODMQI8V-D>DB925[OK=^%X-IIK1U'8;O/=8XV^\OIU@<YLCERW*.
MQA>/R2):NCK];WV"UP1R1VRGGCGD6:-6M>S"(Y&N:B\^92RK#:J:R6FGMU Q
M8Z:%%1C=RNQE55>5Y[JIG@
M
M      XRQME9M>F6_ XP0QP,V1-VMSG&<G8      %Y14*UTKTP9;;FZINU3
M%71>&K6L:US%1V45%RB_)?O+*.NHC\:GECSC>U6Y^U"OZ7IQC4]7<ZZJBG@E
MDC?'"C7-5FU.>47G)8%/#'3P,AA;MC8FUJ9SA#L #D1R*B]EX.BDHX*1NVG9
ML3MW5?UG>
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                         :^\
M7>DM-.LM9/#'C&$DD1F<KCU/LUWHJ6B2JN%53T<"XP^>5K&\]N5PG)T6W4EE
MNM0^"UW:WULK6+(K*>I9(Y$143.&JO'*?><J"]TM7<):)'QMJ8V;W1+(BO1.
M.[>Z=T-H# 6\VQ*]M"MRHDK7*K6T_CM\153NB-SG)G@    '&5Z1Q/>O9J*J
MD9TYK2@OM_KK32.B6HI(VR/1D[7KA<=VIRG<D%RJV4%OJ:N7'AP1ND=E<)A$
MSW]#1:.U?0ZIEN#*!T3EHU8V3PYFR8W;L9QV^JI)0
M
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M^][=S:6NY4=UI4J;=4,J(,JW>SME.Z&6
M
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MD\)%7=A.,?F[DGT?:*:RV=*2BF\:))'.W;=O*_(W8
M
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M/IDW@
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M/E5'.SM1%Y1/D24
M
M
M
M
M
M
M
M
M                                                           Z
M_&C\5(MZ>(J91#L,"6\4$5<M%)5,;5(U'K&N<X7U,\ Z:RJAHZ9]152)'"Q,
MN>O9/0XT593UL2R4LK96)ZH9         .JJJ8J2GDGJ'I'%&U7N<O9$1,JI
MT6RYT=T@2:@J&SQ*F4<W/V?T&8 <)9HXD_&.1IS
M
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MDK$W,=M7&5]3/T)>'7RPMJWXW>(YG"JO;'Q)"
M
M                  42R275_5FA6J:WW6@EGIG,1<M<B(_&47OZ$QUGJ>HA
MO='IJSQQNJ)J?QFYRQ41JJBHBY1.S31+35_3ZW37>Z5E344[U5BI-*LB(Y_9
M,)]A#NG_ +P[IFVXQ*L*+4RQI+&[:YRHBKM7UQQ^@E=FUS/8ND-@JJ]4?77"
M::E;O5S_ #+))MYSGT0P=,5&HWW"OO\ <%5EII494OVSJ[\6S*O\N<]FKQZF
M?BY]0Y:VIMU3/34U,J/IE@F6/Q6OS]9%7C&W]*D<UA<H)M7Z4L%RD?XE/ ^F
MG?A7.5S47*Y[+RG<D'3N*_U.NZ:HRKK'2MEA<JSK^]7;Y,_9Z%QUU7%14[II
MU5&)QE$R4M>M65=ZTV^_N>M-;W2>ZHZ%SD7?A?R<Y]>YA:/JJO372M*^IGEG
MJZJ6:E5)9%?A%15147OG@C&GXJK1^EM+ZJ@K:JIKKM5^[S03R*L;6ME=C&.>
M=B=U]5)=U<O=QN]CTA# JT\EZ?/3RI%(K43*L:F.?GZG5I.2JT=JO2-ECJ)J
MI+HKXZGQY%7PUC9E-N..=R_<AU:ON5\=U/IK/:I'O?5RSJQCIE:GE5RX[X[(
M<KK=-0:27\&8?[*O%R_LZ-*B=5VM1<.1'(N$3RKP;&@N-TL/5*ET]12OKG2V
MWWUZ54JKA5SE$YQA,<&BN=J_#GJ=<8IKC6TU)1VM*QG@/QND8YJ85%]/,I(>
MG&L+AJ+3-PIJIK8VTE%-4,F8]V]SD5>%55[<_H(_T_34^I:"T539)$I*:1*A
M[TJ517M21<HJ*O*<+P;K3\VH;KU-N,<2JMNM=5"Z9?'5/(Y,_55>?JKPAN;]
MJR>[5-X92KX=!9I5AJY6*YKVY<J-PF>>6KV(STXJ9;=:M4:GGJZB=*2XN6!D
MKU<US'JC4RG=/K=C%Z-TLEN?<]6WFMJO#9620MBWJ]F'HBIQW]16ZHU#K5GO
M-@C8D23)'Y9G1?57GNOS0O>QP5%/0)'5JJR[E7EV[C[2B>IUXJ+OU:H].T[6
MO;1W&D?(CE5-K7-CRJ9X_*,B:]5-FZFOM]'/))34M5"E8Q[W(D3%1JY:B+A>
M%7@RKIJ6OU7>-2I22.I[587-5TT+W,>YCT5<JBKRJ;%[$?;J>]WS2>H9J%RI
M#95CACD29S72-<_:CG97OA/3XF]M]3>^HNEHH[1+)$M'%'1U$D4RQN21J-5>
M57G[2;=39W6KI^UU5YG,DB8JKYLKC!D]'()*?1S62IARU$CN^>^";@
M
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M8UK4:B)A$P=H
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M3Z:BW[)'^*[>[=YE1$7]2&U
M
M
M
M
M
M
M
M
M
M
M                                                         /*U
M[N6N-6:XJJ&P14WA054U/E:ET:^5SE3\KX(;'\!NJ_\ [FE__P @O_F-/J2V
M=3-)4+;I<8J7W=)61+_9KG\N7X([Y'IG2UQ6Z6I*AR(BJ]6\9]#;@ JBMU/=
MJ?JS:K-)# E#44\TBO1SMWEW8]<>B>A:S%RQJ_%#Z#2ZNO\ #IVT35]1]2-C
MW_55?JM5?3[#[HV^Q:ETU0W>G_M54U7-\JIV<J=E^PW(
M
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M+P[]!.-(7.Z5D;FWE*?Q7*KF+ G&S"8S\\Y),
M
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M>^,^O)/>G^K*?65@6Z4E-5TT7C/A\.I8C7Y;ZX15XY)(
M
M                         :"YZ.L5SG\:NH?%DYY\:1O=<^CC%_<^TS_!
MG_\ L2_^8Y1:!TU%(CX[;AR>OCR_^8DS6HU,-3"'T U59I^V5E?%6U-+OJ8L
M['^(Y,9[\(N#DZPVUU2RH6F_&L3:UV]W"?>?*C3]LJ*AL\U-NE1NU'>(Y./O
M/M[L-MO<*172F\>/*.QO<WE.WU53XF3;+=2VRF2GH8O"A155&[E=ROS53[7T
M-/7PK#5Q^)&N>-RIW3'H8T=BMT=$M(RGQ3JU6*S>[LOSSGU#+%;F4CJ5E/B!
MR(U6[W<HG;G.3OMMMI+;&YE%%X;7+E4W*OZU-;)I&R27!*Y]%FJ1%1'^*_LO
M?C=CU-A<+51W&G2"LA\2),>7<Y.W;LI\MEHH;9&K*&#PF+G*;W.[_:JF/+IV
MURU:U,E+F=51=WB/].W&<>A5GM%OAE=I&ED@DFC6ZL;(UF>&JB9SCE"PM!6B
MW4>GJ*2AIEB1S<X5[E[.7XJI(:RFAK*9]/4LWQ/3#FY5,_<8%MT];+;-XM%2
M^%)E79\1SN53'JIRK;#;:V9):JFWR(FU%WN3C\R_,R:NW4M72^[5$6^'*+MW
M*G;YHN3 32]G2FC@2C_%1O\ $:WQ7\.^/<R;G9:"YQ01UT'BL@?XD:;W-VN^
M/"B>S4$]$RDE@W4[45J,WN3"+WYSD6JS4%I:YMO@\)'8SYW.SC..ZK\5.NIL
M%MJ:E*B:FW3(JJCO$<G*]^$4^W*PVVY1,CK:;Q6,:C&IO<W")V3A3);;Z9M-
M[ND7XG*+MW+Z?/(MMOIK;3^!11>%%N5VW<KN5[]U,H
M
M                                 U5UT[:KK*R2X4;9GL<CVJKG)A?C
MPIL*2FAHZ9D%,Q&0L3#6HN<':
M
M
M
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MXQZH;0 $#TMU(H+_ *I=9($8E0D;Y.'.5<-7'JU$_23P
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MERC<?I/ESU=8[7=$MU=7>%6+MQ'X3W?6[<HU4_20V\46FG=26SU5_K8KO[U
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M)L['.PC&;&YVHF$SRIN^DULIG=4.I"O;XK/>X<-D1%1.9?3!H- 05-+UKO\
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M?$F5W+ERO&#>:5Z<VK3>I9+S0NJUJ'P+"J2S[FX545>,?(G
M
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M<OHG^<6#11OAIF1RN:Y6HC45/@AW
M
M
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MT:IE',=E%.X    ^/<UC5<Y41J=U4Z*2NI:M7I2U$4RL=M=L<B[5^"F0
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M]0.IIEBE2CD5DC>[5PO)"?9XK:VJM-R;7U4E2Z)(&M<_['9_46TCVJ[;E,_
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MVJQ<KMR_C=V7MV,O2$.K*31Z:FGK[E<)I*>*IBHIZM58_<G+=RN7&-V>WH-
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MY(;?HQ?[XS6<^GKW55E9FGDJVS5-2Z143<UJ-PJKQW]?4O(
M                       \L5=-KS1VO:RX62QT=7#+5SSHM14-1%1RN1.$
M>B]E-W^Z+U67*_@O9_YQ_P#]32ZQU!U.UA9VV>LTS:XH5F9*LD50B/\ *OSD
M5/4]':3MS[9:4IY$5'(]SN51>_V&X *'MEJOVG>L%54R44?T7<:^>I69\K55
M&KOPJ(CL^J=T-C>*"[U'5RRW6&E8ZA@I)HWOWHF%7=CC.?5#JUI;KO-U=H+O
M0TD<U RUI ^1SVIA^Y^4PJY]4YP:6YZ;U)TYUBEQTY0LN5G6G2)7ULS/KN7E
M-J.:O&$YP7!HBON-QHUGKZ&FI&KN1$@[91?AE35]8K!7:@TI+!;(EEJ8V2/:
MW>UN5V.1$RJIZX(-IR74$736/2,]! VM=324LC?$17-5ZNQAV[;G#CMO/2/?
MH"-M*D_TY'3-3PD?&B*_*917??SDZJMVH;KT_;HU]! E0RFAI%VR)OS%MSYE
M=MSY#CJ'3FHM&VFFCTM Y]))$R2J>Z=L:MF[*F$<W/9.>?M,6UV6]67J;3WY
ME&QU MN\%\CI&_VQV<IA%S^<V>C:"[V[JM772LI6,H9K8E,V3Q$=E_B,7&$7
M/9%Y-;U"TEJ2R=2*S5NF*3WAM:Z&*5LD[&,;&QC,JB;D7.6&MU967ZZZRTQ=
M%H*=*9EU@F<YKT3#6N;E<*[/H>B+=4+5444SD1%>F>/M*5O6BKAICJ.W5-IC
M?/35%5-55?BRL1K%=G;AJ*BJGG7XF7+I^YZZU[:+W<J1D5!0LDA5T+VX5%:Y
M456N555<N3L8MBH;S3=6Z.YU=(QENIZ.6G21)$7U=MX1<^OP+O5$?&J+V<A0
MFK=,ZBT;U!DU)I2B;54U5#'1R>/,QC4;E'.5&HYJY\B&GU.Z]7'J99[NZBA2
M@=<Z5[I&O3AK=B.7&<_DKZ&ZOUBN]7U@HKU2TR/M7O\ !*LWB-1=C=F5VJN?
M1?0[=76>\3]6['=:>E:^VT]<LKY5D:BHWR<XSGT7T,SJEIB]4U]M&KM)4J5E
M32>+,^*65L<:NDPG*9:J\.7U)'H*^7K4$;8;M::"EC5=M2Z#NCT;E?RESYN,
M\E>6>@U9TNO51'043*BSU3WU3WU-0UV)'KM1$:UR<8:GIZDPZ@VJ^ZMZ>1?V
M*U+A'6LF\%DK4;L:CN<JOS^)K5T[5]0.G%)2W>-::XTE1)5,BIWMPJHCD;E7
M93"Y^)U6N?44>@5T?-00>]ST\U'*BR(KFI*KL*CMVW.'H8MYT3=;!TWI+7;*
M7Q*ZHIIHJACY&)A<^7E%1%^LOQ)W9OI"CZ56Z"FIHYKK14$,;Z:1R;%>B-14
M5<X7LOJ0:/35=>=:VB[VRF;;I::-[:V.A>V%CYW-=N5R9\RY7OS]I>=$Q\='
M R5561L;4<JKE55$YY*%I;;J^MNDUKU% Y('N=.S-4DB[<X;^4J)ZG'2]JOE
M%TO73]11QMN#:F2;P_$:OE5%PNY%QZ_$W.C;7=:#HRRU5%,UMS_LE%B\1%3S
M;MOF1<>J>IAVS1-=J#HO1V2NB=#=K?2SN@BBD9YI7*_:BN7*8Y3G*&OLE5JN
MAZ;7G2-TM=+'-1T?NU.OBHY\BNW*NYR.5/A\.Y)/9T97T]ONU/=(&02L6%C4
M:Y'9PCL]E4F/5ZRUFH.GEVMEMC62KG\+8U'HW.V9CEY7CLBD4Z<U-W_ ZJI;
MG20PUD=7L8QCLHK$8U,JN53.<G#H#17.P::KJ6]4[:>1]=+*U$>C\M5K$3ZJ
MK\%(_P!,M*7:JT/+8;U2I3/8V::/PY&.<LB\-3.53'F4ZM!5VL]'TU-I>ZV*
M@?3P/S%+/*V2172.W=T?C\KX%\6SQWV^-:MC8IW)YF,7AO/H51U I:J[/O-J
MK[30J^;,5MK-K73MS]9S7*J[%^KSP8.I=.7JEZ/5=C8V6KK9J6F9"V>=KE38
MYF<.SA.$,S5EMNE;T*?9X*9KKKX%(QL.]$1=CH]WF5<>B^OH:W4]/JVETE&F
MGZ5&X>Q'[*A(_-CG\I/D=%9:+S1]4%U)14,4MNDI&4N]\C43=E%7RY1?3O@V
M;:6\?NPW&\^Z1^X5-/!"V3>G*HK<\9SZ+Z'5UAT3>TU1!JK2\#ZNI2:.6IBD
MF8R-K(FMQPJHJYV\IE3?Z>OU]U#I^Z)6VFAI9W4_/@+C*KE.^Y35])+9<[14
M:S?<J=L2UDT3J;SH[>B(_/95QW3O@U_3O3-PJ*K6EJOU.E/17>Y+,R1CVN<K
M6O<]%3E<<HG=/4[-#0WWIS+<[4^BB=0U-;+51RS2(YVQ41K?JNX3RIQ@R^F.
MBZK3*U%_KXWLN3I'PMB<]CF+$[:N<ISG*+ZFBTIHFY7OI+%IR\0OIJNFJ9*V
M-L,K%57IN1J*[*IA=Q]T=<-7V?1=RTS=;72MGCI)\*Z9'O59-RIER/5/RC L
M6F[MJ/IS36]T'A7:ST\DT$4,K6^)*JNVM<Y5QCMV5"2]-+[JNFEH;%>+';HW
MTBMB?+O1\B95<KE'JBJ<>H%NO-3U-TQ<J6D8^EH9)5G<LC4VYQCA5ROYB8ZU
MJJQD5O=):J&NM+X$6J;5-1[4=QM3:J\\X]%(OTBTC=+/?)JU)*EEKFGFF6!)
MV^$U7-X1&(O9.,<<%HZBEEBMRN@:USU<B87[%*>Z=VZ]VSI7+:JVCCCK%94(
MC/$:[EV['*+CU-GT[H;I;^BE19Z^F9'<%I*MC8T>CLN>LFU,HN.<IZF?T&MU
MSM=A;37:F;!)'"UN$>CN=SO@JDZUA;I+OIBY4$**LE1$K&HBHBY^U>"H>DL%
M[TO+J"WW"CB8DM7B!72(Y7-;N3/E7CT-AT8MEUL]ZU!+=Z9L$-5<)9F.1Z.R
MU<X7A5P8'3'3EU^E+I0WBD;#15%?45#9&R-<Y47&WC*_#X&GT7+K/I[3+I^O
MLE#/0.>M2DU5*V5^]V$QY7XQAJ^A?MC=4OH&/KH60SJJYC8N6ISQZJ5EU^M=
MQO+=/16:!)Y*:L629%>C-K51.>53/YC2]1K%>+EHW2M+04C9:JE27WABR-;L
MSC'*KA>WH=6N;!>J[0.G:*CI&R55/0K',Q9&IM=EO&57"]E-Q?%U+;H='36Z
M)?<*.V,BKT\?:ULGAHU$VHY-W/JB*:'1.G;O8>J%'=[A2MCMLL4LTDWB-<J.
M>C\<(N?5/0Y=+M.7NT]0F5URI&Q47@2M\1)6NY5..$55,WII9KO;.IM=<+G2
MMAHGVIT+9$D:[,GB,5$PBJO9%Y,C2%NO%%UFOEUJJ1C+?/0QQ,D\1%RY/"SP
MBY_)7T.3+7=7]6]4U"TK/HFZMIH&S;V[E;X;6O5$SE%3GNAHHK?JSISK&]2V
M^U4U;9;K,B))5S-=B-F<*C4<F/K>J$[U5]*WSI5=8O<8(JVKIV+!%$Y&M=YD
M5>57"?G4Y=#J&OMMAJ:>ZPMAFWLVM1R.RB,1%Y15+&EE9$Q7R+AJ>N"B.@MB
MO5FN%6R]TC:>-\4J(YLC7KE59CLJ_!344]CU5TQU542VBVQ5]EDB2GCDK9VN
MRYVUSO*UR85%:J9P3_56G*OJ#H%C:VG2DJZ=):BFCI7-:UTS4>UK55<X1<I\
M/M(9:+GJ2Q],+UIJ]V^GB6DMT[$?XF]Z[T>Y<JCE3LY#(L%HGU#T8JZ2@:KZ
M]*"-L<:.1J.<JKPJKQZ?$Q:M=5W3I54Z8;:Z;WJDIHJ-K6RHCE5BMSE5=C/E
M-UJFV7NNZ+SVCW.-+HB4S61)(W"HU6;O-G'HOJ8FI[)=ZKHS)9X:5KKJM5%(
MD/B-1-J(W*[LX]%]27?@LNJ]"_1US62GECJG3L2%S<JJ-5$3*Y3'F(5TYN>L
M]+LH],7BQT'A0/RDLDJ229>_=W1ZIV<I]ZF:,U!1:XAUE8:9T]1+4135D3YV
M-C8R%K$3"915RC.4RIKNH%TU'J*NT9<'6VE;[K5NEE1C\(U-S/B[*_5]"_M.
M2OFL-!+*U&O?"U7(G9%P5)U#L=^H>IMDU+:J-D]'1MF=*Z25J(U7[D3R[D5?
MK>ARU-IZMZDW>C]]B6*WL@\.5\#VIAZ*KD3#E7/?X&?UUTPM7HN)UN:[Z1B?
M!"U[5:QVQ,_E<?=DE_3:TU%LL*-N,2)6K([+W.1[E;QA-R>G'8VVKF/ETO=X
M84W334DT<;>V7*QR(GWE.=*+#J*UZ<U9')2I#7S4#F4B-F;ETN'[>4=QRJ<Y
M0T>H+)JO46FT@K*3Q+C;(E1S75#7>9V,Y<KES]7T4FE?IFJU%T9CMCJ1B7NF
MH(:>/8K4<QR;=R(]>$[+V4U<_3V\5/22NMU12J^_QQ4\5',Z6-96-:K-R-D5
M?+PCO5,\_$L'I78ZRRV%T-UC5*K>F'/>CW8V-3NBKZHI(M1,JY+7*VWHJU'I
MAVWT7UR>?*ZR:MU-H&AM=QIEEO-+7+5R-=4M<J1HUR(NYSE1?K)QG)M=1VB\
M73IQI.@IZ1BW.CKG35,*2-1&,WOPN57"\*G95[G9KVPWNNT7I6EHJ1LE72+.
ML[%E:FW+D5O*KA?S'=KG1EXO&B='UUMA>MZL-*]4@;,QC%>](T5%55Y^JO93
M1ZPN.J;QT[?;JBVTR5=-314\J-E3*/:YN>5=A>47DNWI[6SU>F:-M3&R.2"&
M.)4;\F(1[KOIROU)HF2EM$2S5GC1JC-[6)M15RN7*B>I&+^MYU+TMBHW4<3;
MLRL15AC>B)L:BIG*KCU^)B,L-Y;TDHK;[HU;BRJE>^+Q&X1JH["YSCU3U/GX
M&72[='=/T38Y&7VSK/5LIXY6HUTB/D5C7.5<87+>R^IG].;]JN-*6SW>QVZ.
M>G<V.63>CGIN<JYW;U15P7/!O\%GB(B/PF43T4HR[4FK*K55UM=QA=]&UM9,
M^G5:E'9A1SE9A-RHG9.%0P-%6*^6O1=[L]51L955%R]XA9XK5W1HC4SE%PG9
M>";]":"NM.D:BW7:%(:M]7-(C$<CO*J-PN454]%(M2VR^:-ZI5-QIJ-DUOJ*
M)E+XDTC57*O:J\(J+^3\!U'LEZK^I5/<+92-FH?&IU=(LC6X1N-W"JB^AQU?
M9=2Z9ZBU^KM.4OO--<)8_>$FG:UC8V-;E4:CD7\E>.26RW"^:CT#?UJZ*".6
MII%2G9&_ARJCD5.7+CT[D!MVAKY>-!7FBFI5BND<<+*...9B;_-YLNSA.$^*
M$EZ<7_5;*FWV"]6.W1/HF>YQRH]'R*V.-4RJ[U3*[>3'U_;;C>VK;+Y:J-CW
MXE95)M?,UB*N&HY57#>_!/\ I99[E8]+-H[S-4S5/C/>CJB9)7;5QA,HJ\<=
MB(]:.GM3?JJAO-F9)-7P5,<LD?B,8W8QJ\Y7"KSCC)@ZH;>>H-':;=4T<42M
MJ46K2!Z)LC<NU53<JHO"YQR8VNM,UU!1Z)M5CA]X@LU:KY72/:UR,54=E>41
M>Z]BXM-K(MDHUF:C9-GF1/3DK+J=H^Y1:JM&JM.P+/56_P 9[FND8QBND\O/
M**O#E[*:O5UJNW43W*@EIT;2NIFQU;HI$162M7>J)N7GE$YY,3KEIV]W*XVZ
M.RTC:B&&ABB<YTK6*CFN?E.53T5"4]<9(DT52SNIX)&MJXDWO9E6JC7<I]A$
M=,ZZTO1,IIK[5MJWR2(R.>JIGS/W;N.=JJF#8ZFGU+<=4Q5MM:Z73%PJ&1QR
M+4;45F$:_P#%JY%3E'=TY.K1]LO.F]1:PW4<:4EV="VF>Z1JJY&->B\(O'UD
M[FRZ.6^ZV6ZZUGNE,V%M;5LDIU21';T19,KPJX[IW.KI+;+K:]::JJ[G3,AI
M:NYRS1/1Z.5S%63"X155.Z=S T):[U8]27JYST<:,?<JB2+=(U4<Q_"+A%SZ
MFFT#37RPI57Z^4D<U[\=]/$RHD25/ 7"HNY%54YW<9_,235ZZU==DK6T^RVS
M[(,-JD1N5[^7?WX7T,;1E@NFGM?7R26F:VW5](RFCE61JJKEVYX1>/7NARTA
M;KUI#JK>7NI&.M5>^&%L\LC7.VIC*HB+E%[]T.JML5Z7K/!=8Z5JVM:]LCI?
M%;G9QSMSG]!W)I>YZ-ZC5.H*&-\MMN59/653Y96X9N5VW#45%5,O^"FSM%CN
M6H^I=MU9=:5K*:@9+3Q['M5KF.:_:JM557/G-%T_LE]I.J5/<KE1LBH(VS-\
M1)6NQE'8X157U3T,W05GNU!U9?<KA2MBH%MKXDD21KEWK(BHF$7/;Y$NM-PU
M<[J/64=;;J=EB;1H^.=)D5RR99QMW_!7>GH6$
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MALSG8W/QP?=J;LX3/Q/H
M                                            5$7NF3XB(G9$3[#Z
M     B(BY1$                   "HBIRF3XC6M[-1/L0^@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?,GH2@ %7W[6]RMO4VWV%RN]TJ*)]0J)"U>4<Y$\R\_DEGQKN8U?BB*?0
M "$ZNU0^.YT=CM$K6W.L=)&QSD:YC'-PJ[NZIQGT4QM#SZLCNM33:DGIIHO>
M'I&L$2HB,1%QE=J>I/RI.K74&Y:3O45/1J](7-BSMA:_ERJB\K]A;8     !
M3^C.HUQNW4JIT_5J_P !M74PLS UJ;8T>J<]_P DN         $4ZCWVKT_8
M9*RASO8R1RX8COJM5>R_8=W36]SZCT/:;M5JJSU42O=EJ-7.Y4[)PG8DH
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M@EJ/<Y7P2Q0[9'.<BJGIE4[=BQJ&99Z2*5S',<YB*K7)A454[*=P
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M.Z&4          #IGJ88'-25^U7=N%4^2UD$2L223"O3*<+RAWHJ*B*G9>0
M   # N]XH;1$V2XS^"QV<+L<[.._9%.ZWUU-<:6.HHY/$A>FYKMJIE/L4R0
M  =,=5#)*Z-C\O:NU4PO"G<#H=5P-G\%7_C,;L87L=X
M               !&ET;;/?O?&04[*O;L\9L#4?MSG&[OCY$E
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MKM,B1R2JK6IY^$3.$3Y%\@HW4\U71]<)(XJRJ]W6U,7PEE79GQ$YQVS\R\@
M
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M:[%W4[7ND[X3NXL[IO2;:6*IHI)'T,B*YRS.R_>J(N$^78G0
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MHD;:>2::1K-SE?ER)CA4)%TBNNI[K95EU<Z!U5O>GXJ+PTPBICC"?,GP
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M:
M
M
M
M
M
M
M                               :^DO-#5U:TT$VZ9,^78Y.W?E4-@#B
MKVH["KR:YU]MS;BV@6=?>G/V(S8[O]N,&S!@T=UHZR9T5/+OD:JM5-JIRG?N
MAG &!)=Z*.N2C?-BH5R,V[%[KVYQCU,\US[W0,N<5O=.J5<JJC&;'<X[\XQZ
M&Q 5<(JKV0PZ2Z4E75/IX)=TS6[U;M5./SH9@!KKI>Z"US1Q5TZQOD3<U-CG
M93\R&?&]LD;7L7+7(BHOR4Y       &/7UM/04ZSU;]D2*B9PJ\K]AV4\\=1
M'XD+MS/CC!V X32-AB?)(N&,3*K\C'H+C2UZRI2R;UC5$=Y53&?M^PRP  8E
M;<:6AE@CJ9-CYE5&)M5<XQ\/M0RF.1[&N:N6JF44^@ !5PF5/C7([.%['T'S
M<F[;GG&3Z 8U?7TU QKJJ38UV<+M5?U';33QU,#)H7;HWIEJXQE#"NEZH+7)
M&RNG6-TB*K4V.=E$^Q#/AD;-$R2-<L>U'-7XHIR!@W6[4=J9$ZOF\)LK]C%V
MJ[*_F0R(*F*>!DT3MT;_ *JX5,G<BHJ93L   #IJ:J&F@EFF?MCB3+UPJX,>
MU7:BNK974$WBI$J-?Y5;A?SH9P!\<Y&]U^1] /CG(WNI]0    &'7W.DH-OO
M<NS<Y&)Y57E?L0S$5%3*   ^.<C6JYW"(F5-)9M5V>\U\M%;JM9:F-GB.9X3
MVX;E$SE41/5#>'743,IX))IG;8XVJYRXSA$,1;O1)1K5>-^(1J.5VQ>R_+&3
M+IYF5$$<T+MT<C4>U<8RB]CL   !AW"Y4MO;NJY?#3_15?U'1)?K=']>H5.,
M_4=V^XU-/K_3=0Y4AN"N5$S_ &B1/_I.2:\TZM5'3>_KXSWHQK? DY5>W.TW
M"WBB26&-9O/,[:Q-CN5^XSP     #XU[5541>4/H      -'>M5V>RU45/<J
MM89I'MC:WPGNRY>R91%-U%(V6-'QKEJ]E/J*BJJ>J&'3W6CJ*J6GBEW31/V/
M;M5,+]N/D9H        ,2ON-+04Z3U4FR)7;<[57G\WV'*W5U/<:1M31R>)"
MY51';53LN.RF2 #XYR-3*]C M%ZH+NQS[?/XK6N5JKL<WE._=/FAL
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M)HW75QTW9GHZVZ@E;1U"SNW/8Q&HF6JF$:OXQW=%]"];;HRP6?HY/25\E?\
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M=5WJ^/IG5U=#X+_"<_\ )?QY5:F.$0N<
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M7Y+DB/1W0,F@+!46Z6IBJ'2U3ZC=&CD1-R-3'/\ HD^
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M@;^,;VWHWCR_,]#VBJ6LME-4.:K5DB:_"_-J+_298
M
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M+60)](5'O&_W9?+YD=C&[GL6U0TZ4M'!3M5%2*-K,HF,X3!W
M
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MN-X
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M8U-JY=\._P!926
M                                                     &'5VFW5
MKT=64%)4.1,(LL+7JGWH9,44<+$9"QD;$[-:F$.%724]9&D=73Q3QHNY&RL1
MR9^.%^U3A1V^CH6[:*DIZ=N,8BC1GS]$,DZ9J6"9['S012/8N6.<Q%5J_)?0
M[FHC41$X1       8ZT%(M1[PM+3K/E%\3PTW93LN<9,@      '34TE/5;?
M>88Y4;VWM1V/O.R*-D4;61,:QC>$:U,(GYCD
M
M
M
M
M
M
M
M
M
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MIZ3IY;J*\6O7-\KJQ:N*%]+),]C=KLJJJJ+_ )J)^<V'M"W"IU=TQL-WC?)
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MI6U4D#FQ*EL5%1V/1=O!S]E%*I]#J6IDD>^WSRP/HT<_*-CP_LW\GTX+Y
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M39V+4L]KI;1014E#$V.*-J,3#4151/CA$,T
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MCY*<J>%L$+(H\[6IA,G8
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MJ*URM7S,ROY?;L>G8HVQ,1D:8:AR
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M1)%+0>:-6KA'1N^ST^&3T6
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MVGW"A;&V+Q'288W:F5QZ9^176KEUS^Z:SZ)2Y?0'C4^?#QX>W#=__P!62WP
M
M         ")=0]#6_6MJ]TJ]L,J2-D;.D2/<FW.$Y^TKYW1>[U_ATUWUW>ZR
MBC>DOASM1S7+ZIC=\%5/SEMZ:LE'IVRTUKML4<-)3[MC(V(UJ;G*Y<(GS539
M@                       TUVT[0W6Y4M970QS/IT<UB2,1W"FWB8V*-D<
M;4:QB(UJ)V1$.0
M
M
M
M
M
M
M
M
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M47:@DESAS&5<6YO&>45W'<VFF]96'44;5M=UH)Y51%6&.IC>]N>R*C57X$@
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MY*RM2.2I61J([>B*G*IW[]R>@
M'R1C9&.9(UKF.3#FN3**GP4JK5'1:@O-\J;I17RZ6>6H=OD9;U;$UV$1$SA.
M<87[U-KT^Z6VS1U745B5=1<JR9S7^/6-:Z1CD1R*J.QG*[N2P0
M                                0'7G3"VZRNT=?75=1#(QC(T;&UJI
MAJJJ=T^9/@        #A-'XL3F*JIGU0P[9:J:WNG=!&Q'S2+(]R,1%5R]U5
M4[F> J(J*BIE%*SUQTAMVJ+PZY172OM%2[:CG4&V-7(U,(BKC./4^:+Z06W3
M=Y=<Y[G77:J56.:ZO1LBL<U<HY%QE%X3DLT
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MN
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M&>*>]O;)$]]+,KX?#<Y%3&6HN?*A;
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M:*N@FI8DF<ZH:U&JBJB83#EYY)J
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MD?XCW;FIZ8553T-V
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^35V_P"/^Z;+35_U#5W9D5PL=QIJ=6N59)?JHN./0GR=DR
M
M
M
M                              #'KZR"@IG3U3]D351%7"KW^PBU-U)T
MQ50+/37+?3H[8K_=Y4\WPPK<DHMU=3W&E;44<GB0N541VU4[?)3$NVH+;:G(
MVOJ?"<KD:B>&YV55,IV135RZ[L-/+$RJKO#65R,C_$R+N7X<-X)'2U$573QS
MT[M\4B;FNPJ93\YV@
M
M           &-<863TCF2M1S55.%3/J4-T*;;:31-:Z[-:^-:V5$?)'XBYVL
MPG;[3GT/J;Y;- 5=QN+G/H&4M2L,DDJO<LJ.RB*F<XX=R=_16FK-:5BZHO4D
MCX*F)=D22;HD<R1&\,=E4X:OZ2U=3:1MM\IF1R1K3NC1RL= UK5RJ?%44VMB
MH&VNT4E"Q\DC8(T8CI%RY<?%3.
M
M                     ,:XRMAI'/?]5%3]90OL[,HK[IZKBD?*B-JY7>7C
MLC/BGS+#=?+%JNWW33MGDF6K;1RS(U8]B<IM[JF.[T*VZ(7N?1-V?H[4#8XO
M=8OQ?AHKW*^21KT17(N,8?\  NO4.JK=9*1LU6]Z>(CO#PQ795$]3&365NA@
MLSZR1[5NR+[MMC5=V,9S\.Z$EAD;+$V1GU7)E#D
M
M                                 #&N-%%<*1U/4;O#<J*NU<+P:/2V
MBK5IE[WVU:A5>CD7Q7H[OC/HGP0[;'I&VV:[2W&C6?WB2+P7;WHK=N47MC_-
M0RK]I^CO<;&5JR[6/1Z;'8YQCX&J9H*SMGII46JW0/21GXQ.Z+GGCY&SNFG*
M*Y5%MFJ5EWT#G.AVNPF5QG/'/9#;1,2*-K&YVM3"9.0
M
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M[OP6#32++%N7A<X.T
M
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M"0
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M(VJQLGB/3"+G*81<>JG&Y:8M%RK65=;2>+4,8D:/\1[<-3LF$7'J;D
M
M
M
M
M
M
M
M
M
M
M
F                                                _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g111069g55a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g55a02.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[15R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %54
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<H&1L7-TH;+!)#,U8G6S)C=#125$9(*B@_#Q&">$H\)E*#C_V@ ( 0$  #\
M_5(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 !KK6P(JIOKE
M.'0I]RSQQ?/7'\#ZCE;)\U<GV >-7514D+I9W;K&\57&3[AE9-&CXURU4RG
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M>B.1?J4^@          #7K:R&BB22I<K6*[=1<*O'_\ 5#UAD;-&CXURU3[
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MGZ_K-Y$PF$Z      ?,C$?&YCNA4P:M#;*6ADFDIXMQ\SMYZ[RKE>/:OUFX
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MK14=PIYJM&JY8F.R["=*X.H
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M]G&>'U*;^F]26K4<51)9JV*K9 _<D6//BN[.*'8
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M\NQRCEN\#&U"4U(D;EP]7MRWBJ\<%VZ7HJ2FL5O6EIH(=ZGC<O)QHW*JU./
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M8R5$LS5Y-[$<G^\CX\3RLK8+=\(+5='18I89*>FB;%"W<:S>9#Q1$X)Q7/\
M$\)*.JHMH&NJ6IA;7MN+(8:-:AR.W7<GA5;GYJY5.SH.YLZT*NF[7JF?43$B
MI+DD+U1R-D1B-5^<(W/Z2$WV>TMDI:6N33\C9(W2HLN[!R6'8_8F26
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M$E<M7(UZM5$QA,-3@24
M                        &$8U';R-3>Z,X,@         $<UWIMFJ;-\F
MU"R-@Y1LF8WHUV4SUJB]IX[/M,\TK,VU4ZO=2M>Z1%D>CG9<O:B)P)2
M                ?+F-=\YK5_:A]   'E4I(L2\CC?^LK[9[LWI]%W"2IH'
MU#M]CF*DTJ.3BK57H1/T4+&           !Y5<#*JEFIY<\G*Q8W8[%3"_U*
MPJ=ES**_37"R353?C3VK,UTZ-:B-1$3"(B?6333NF:6U*LZHZ2J?NJYTBH[#
MDST+CZR0
M
M
M
M
M
M
M
M
M
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M_B;(          .%/JNT07SY(EJ7)7\FDO)\FY4W5Z\XP=T
M
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MJHU<=1Q++J^TWF3<H)9'.X_.C5O0N/\ 4[Z.17*WK0R
M
M             ?GWX+3D;:JE>QTR_P"0]+7<':]VOW.V5?X.AIJ2.J9A-Q^\
MBQMXKQ_24U]2U%9H7:W1,M2PNI+O74M(])<O>C?P:+V87BO::=)I^CKMOUYG
MG=)OMKXW(C78XX_86+J[3\#YD6[2HZW1N=NLIW_A=WAVIC/00S9JUGR!M$AI
M=Y*&.XHR))/G[B.X9^OH)'\'+'R1J)$Z$N3O\J%B:MHIJ^SO@II(8Y%>U=Z5
MV&X0_.FU"DM]EO%%\D+.M8Z:)KG3*CF;B[V<8Z\HA)MK;.2VEV>9B^,^Z4;5
MSV8;[#=VOTR1[2M$SQN\:6\P(Y%7L=%T&CM/L%%=-JNDX:E94;/7RH_==CJ9
MT<#<V^4K+;IVAM=*J_%VTJQHKUR[".;CB1_:9IJ"VZ2L5]HG/^.TUMA5J2/R
MS+MU%X8['+UG6VQZMKZ2T6*QP)"C*RWP53W.9T.3Z\_5V'MM>TU36+0U->[8
MZ3X_RD#%Y5^687*KP1#A;6:V356C;-=GX9)/=XZ9R*F[XJ,?U<2=ZCT1;]*Z
M'NJVYTZR.HYV+RLF\F%8Y>Q#F;.[3;9=D=DN]Z=.L=IBGJVI Y$5=V1[EX+T
M_-[4(KL[HJ*ZZWU%K&1M2VAME0RJI6]#U:_?3BG0J\$Z%)%IM*O7-VU%5H^!
ME/35KF1-<JM?NJJJF4X\2,:MJ;ULZHZJS2NHWQW*3XXUS45^$1V$157&%X=B
MDDVP:2MK-D[*AKI]^62GD=XZ8RN%7J+ V/S.GTCOOQGXP].'\".?"3B672%M
M:BX_V]O_ &WD(K-'T]1L5MEYCD<E=;FU-:Q'2>*KHW2*U,8X_-3@:VHJFIO6
MQ?1]95K&VI?!5J[=\5N=_'#^1++%HRWVK9(ZZTSIUK:NBAFEWWHK-[ZDQT>,
MIPM%WNJTWLPUU=J?DW5%/61N8BMWDXO:WHRG:=S9UI2#5FDZ^6Z2*DD]2DOX
M%^ZB9:UW8O6I']'7>2[[.KC::M,31W*7=>QN&;C41$RO;_ Z.P;0=NN>E8[Q
M6/G^/?&'QKN289NM5%3ACI+RO2;UFKT7H6GD3_\ %3\X;&;+0Q:RU'<9%F62
MBI65+4:Y.*MPO1U]!)]'R>$#7^I6W!>3IK5- Z!&^(]4>CLYZ<_,3L-"RS5F
MDMM-+:J=87T%XK9][.7/:V-'*G'AA?&^L_0$JO6)5BW4=U;W0?GO:W8*:@T;
M<*FX2+)6.JVJQ:=^6(Q7="Y3IZ35U?4U=TV#0/J%B25+M&Q-W*)NHG]36VHZ
M6@M>C;1<J)[_ (X^Y-B=RC\LW4:]>"8Z<HA]ZULR)H_2^HVN_P#BCJ]7OR[\
M'ECG;N$QG\U.OM._J34ERETSH2D8M,VHO,LU-(YS51B9>UJ87/#I^LZ[] W9
M]TTK5TL]#_\ #Y7/J=Z1V'95N-SQ>/0O3@B4U VNVY6>"95W4JJMLNZN..Z[
MH_BALZ<M;=.;?K;14+E6FK7U=1)RCMYV]N2]'1PX(;&G;_)M VFI27%$9200
M2Q88W<>JL<JHO2O#B<^_VFFL.W1'4*R*JT#&_A'9X*Y/8>VMK6ESV[W&*9V(
M5HZ?YKL+^:AQYK/\E[;*VT4;O_A\]134[]]V7[CTCWL+CIXJ="WTK]+[:Y*.
MV.:M+5U\$<G*KO.W4QT=''QE._;)Z_5FTF]TSWTS*2T5SX51<M>Y'*]$QTY^
M9]1Y:@TK<M/Z,UA/624KJ2HK$GC2-ZJ]&+*W=1<HG'H(I9]-4]RV/:AFG<_E
M?CL:-W7X3&8UX\/K)9H"JGO>RJL^4%9F*Z+$WD^'BI&S']5/;X-^EJ&+0TEP
MB=-\9F=44Z[S_%W55/J^HE.SG9]#I34-?<HIDD=4TZ0JB2[V,*B]&$["Q0
M
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MR\U=NFI9J=(XVTRNWD=E%RN6IPX*6(
M
M            5]MFTU7ZKL5)0VQ[8I8:E)G/>U514W')C@B\>*'6V86VJL>C
MK?::_P :IIDDWY$:J-=O2.<F,HG4Y"5@
M
M
M
M
M
M
M
M
M
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MZTU73U35=2U$,S47"K&]')G^![           K"P?^;R_P#2U_[A9X
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M%_JIV                    1+:M^1%=^]'_G0T]COY+3_WIW^1A.0
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MF<$<N[CCCIX%B           J^P+_P#Q?7_I2_\ <+0
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M4;C"ICYJ)T9+-T3I^NLNI*J5M?3U- ^G1C(H4SNNWFJJYQ]2]98H
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MI6H<Y%DCW%W=UO5^U%)4          "K[!_YOK_TM?\ N%H
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MW;>Z.6%*E(6QK(Y..%?GH5>U"<;6J2MN>B;E:[93OFJ:N+=9NN1%14<U>O\
MB1G8%8[OINTUU'>J66&269KF\HY.A&XZE4ZNW*U7&_:'J;79Z=\U5+)$]-Q4
M1<(_*]./ZC8E:[C8])NH+O3OAJ?C#Y,/5%7=W6HG1GL4X'P@=/WS5%#;J"R4
M,LWQ>NBJG/C<GS4:]%3"JGZ2$WMUF9>=&-H+S2L;,]DK=V5J2<FJJY$=_)2
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M=6<)TD8KT7IPF.*HO^!8(          *PL'_ )OK_P!+7_N%G@
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MH1^M_:8YM:WQ\R/UO[3/-O6_Z$?K7VCFUK;'S(_6_M'-O6_Z$?K?VCFUK?\
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MY&$Y            !5VU'\K=(?WU?ZQEF4GXM'^ZAZ@
M          K"P_\ F^O_ $M?^X6>             57M13_QWIK^SD_U+.H?
MQ*G_ +-O]#V                         7H4JK9]PUUJW_J*_YI"U0
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MHHZB&HG?6R+%$D#$<K51$^=E4[3HS:D@HM(OO]='*VGC@Y=T>$1^.S"KC/\
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M<L:/C8]6R(B*F\W/4JG4 *UVV_B5D_OG^A,M'_DW0_N+_53L
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MQLFC9)A555XH=  K7;;^)63^^?Z$RT?^3=#^XO\ 53L
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M/[B_U4[                    (EM6_(BN_>C_SH:>QS\EI_P"]._R,)R
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MS7LWD<BIA4Z4/;3EFAL5NCHJ7<2&-J-8UC-U$1,]7\3B7305LN%YCNDL5/\
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M;RJM5[F1[F\J)C*\3M@%:[;?Q*R?WS_0F6C_ ,FZ']Q?ZJ=@
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MFE?/$7=O]T>$32OGB+NW^Z8\(NE//$7=O]TSX1-*^>(N[?[H\(FE?/$7=O\
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MCN\5D@MMP9/+\<3Q48Y.G@G2A:&DV.CT]1->F'(Q<I_%3K
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M=&5UYAH8IZO\/(R*)5I7(JN<J)QX]JEPVRNAN5##5TJN6&5,M5R87IQ_H;(
M               *OL"?_P 7E_Z6O_<+0             *KVH_EWIG^SD_U
M+.H?Q*G_ +-O]#V                         7@BE5;/ESKO5O_45_P T
MA:H            !6NV[\2L?]\_T)EH_\FZ']Q?ZJ=@
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M*-K%QQ\9TBKE>OH+L                !5^G_\ S>7_ *6O_<+0
M     *KVHK_X[TS_ &<G^I9U#^)4_P#9M_H>P
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M\O\ TM?^X6>             57M1_+O37]G)_J6=0_B5/_9M_H>P
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MAHZ9JMCC1SG;J95>ERJO2O6=$                %86#_S>7_I:_P#<+/
M           *KVH_EUIK^SD_U+.H?Q*G_LV_T/8
M    JK9_^7>K?^HK_FD+5             *UVV_B5D_OG^A,M'_DW0_N+_53
ML                    B6U;\B*[]Z/_.AI['4QI:;/E3O\C"<@
M    J_:DF=6:0_OJ_P!8RRZ3\6B_=0]0  >-5205;-RHC1[<*F%5>L^X(F00
MLBB;NQL1&M3L1#[  !JI;J1*IU2D*<LY=Y797I-H
MK"P?^;R_]+7_ +A9X            !5FU#\N]-?V<G^I9M#^)4_]FW^A[
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M?^2W+UE/:8QK_P EN7K*>T8U_P"27+UE/:$37_DMR]93VC&O_);EZRGM,_\
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MD:UPNJE=8TO-/61P)6-RZ29'(J9X\/V%[:7W/D&CY-45FZN,?M4Z@
M            (EM5_(FN_>C_ ,Z&IL>7.EY^.?\ :G?Y&$X            !
M5^U+/.S1_P#?5_K&672?BT7[J'J                           "L+!_Y
MO+_TM?\ N%G@            %5[4<\^],]G)R?ZEG4/XE3_V;?Z'L
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M_P#F\O\ TI?^X6>             57M1_+O37]G)_J6=0_B5/_9M_H>P
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M[%7'3D_4.O:6*IT2^.9,M;&CDX)THQ2OO@F3O79M3PKC<;+,Y%Z_]X7>
M             "K[!_YO+_TM?^X6@             55M1_+O3/]G)_J6?0_
MB5/_ &;?Z'L                         55L__+O5O_45_P TA:H
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MEW'*J85V4Z40L<                 %86%/_P"+ZY\UK_W"SP
M  "J]J/Y=::_LY/]2SJ'\2I_[-O]#V                         ZBJMG
MWY=ZM_ZBO^:0M4             K7;=^)63^^?Z$RT?^3=#^XO\ 53L
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M&1DLDCI7*Z17>,Y,+T_M) 1FVZ(LENN:W"E@E;4JU6*Y97*F%7/028
M            K"P\=KZ_]+7_ +A9X            !5>U'\N]-?V<G^I9U#^
M)4_]FW^A[                         %5;/\ \O-6_P#45_S2%J@
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ML'_F\O\ TM?^X6>             57M1_+O3/]G)_J6=0_B5/_9M_H>P
M                    '455L_7_ ,=ZM_ZBO^:0M4             K7;;^
M)63^^?Z$RT?^3=#^XO\ 53L                    B6U7\B*[]Z/\ SH:>
MQS\EI_[T[_(P@5YM]BUJS_XHD-BN<?C-GM\")*YK<X8K\*NZJNSC/4APIG:M
MH[-::K4:5,EL2M;RTD]7RR*U%<KLMWE5?%1>HDFL8=/5VG*F\:62!T%5!*BM
MBI^1:B-:K>A6HO2BGW)34<6P^W5"TE.DJT+U5W)IE5SVX(_#-4VVGT977E7/
MTZZ-SYDF=RD;(\-Q^#XY3*IPP3&Z:>T_=+%45%BK7TT5:ULS'4L7)81514QX
MJ8X&=C==?VU-307FB:D#)G-AJ'RH]ZL:W"+\Y<9QT&WM*NDM==V:>I)7M?)$
MV?\ !N5KN#G9X]'40C:W1U6BM74]^M&_!3SI%1.2-_)MXJKEX-5%SXB?47?=
M4CONEKC%0O61M72RPL5$W<JK7-Z_K[2H=CZ+H2]W2S:@3XI&UL4=.]WX1TCG
M*KE1=S*)\Y.PF.TZ6ONVE+A\@.D<YD3N,<G)[V<8SE4[%(.M MYM&FZ>VJY+
MU24J152QJC'I-A,Y>N,KP7BBK^TX]IIH'555%7P12212NCDY1B/57)G.5Z^)
MOV6URW_9O?FI3,J*N.Y-9"YVZKFL3=7"*[H3ZB1V".\ZEV=35,M R.]0U2PM
M<R1N_P DQ$_/5>CBO#)R]FKK)?\ 3\T%U2'G#$DDSD6#??R:81OCJB\,JG#)
MR]G-*M3>-7MFI8GSK:)$:CD1<KAN.*GOHU4I-(ZVHZREAIYH[:]&M:U%RJLD
M7I3AUH>T#%?9=!3U<+);=30N6H21$<UK51N/%Z^CJ13VEM3HY:V\6>/D+2R1
M9)608CC>CE\57,3"KTIU'!JZRX\V+E<*!J_$(9VLE:V3=8KE5,9;GBO%.."T
M=GE%IVJJJ>ZV%\:R-B6*1(Z?DTY3=17?FHJKQ3B6( 5?M2_*S2']]7^L99=)
M^+1?NH?E3;=>;3?]KEIM6H[C)0V:#EZ>I?$Q[\;KGXRW"Y\9$ZE)!L_TKLLO
MNHX&Z7OTE971,?&D7Q!8T7"<5571HG1]9K;;9+CJ/:92Z,H*ZLAH%M\52J03
M*SQFN>GS57=Z,=1SMK^R^GV<VZVW[2USKX*F6NCII(X7-A:L>Z]ZYW,*O%C>
M!U-L&N*S4&CM-06^MFHYZZYI3S_%)'QJL;M]JHJYXIT<%&L=A=)IC1<UYM%S
MN++E:(9:Y9FJQCWK&USV[SD1%5,HG0N2RO@^ZEGU#L_M_P >G?/6P0IRLDCG
M/>Y5>_&7.Z>"&QMYU#-I[9Q=IZ*=\%:L2+"^-SF.14D8BX<WHX*5;H38?1ZN
MTJEXO]SN'QZZLCK4G<K)'LY1J/7=<J*J)E5Z>T;$-;U>GK+>[?<ZR:M6"Y21
MPOJY'RN2-K6M1$7CA.'0<_91LMIMHMDJ]2ZDNMPJ*SXS-3LCE<V9J-;A6JBO
MRJ8WE_8='9&^NT+KB_Z9KKE6S45+9WUD3:B9S_PCG,7H1<)U\>DX&@]*R;7M
M876OU)7UK:-T#98HDD22-KF[L?!K\XZ%-FRQUNS';)2Z?M]952VFXW"FI6,E
ME5&M;EN=UK5PG&1>E#]5@                    K"P?^;R_P#2U_[A9X
M          !5>U'\N],_V<G^I9U#^)4_]FW^A[
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MWJ[_ *BO^:0M4             K7;;^)63^^?Z$RT?\ DW0_N+_53L
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M:C&YX(G#QFG?V2[*;I1:AKM1:W6!]TF?#-'\5F5S$>Q5ZE3@F$;_ (EY
M                 J^P_P#F^O\ TI?^X6@             57M1_+K37]G)
M_J6=0_B5/_9M_H>P                        "]!56S[\N]6_]17_ #2%
MJ@            %;;;?Q*R?WS_0F.C_R;H?W%_JIV
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M*%B1L15RN$3"'N                       "K[!_YOK_TI?^X6@
M      57M1_+S3/]G)_J6=0_B5/_ &;?Z'L
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M416JN.I"[[#2.H;334SW(YT;<*J='2IO
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:BH)H(JJJ@BEG=N1M?(UJN7AP1%7CTH;D3VR,1[516KT*A]
M
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MO1BQ<NW?15Z$QG)T?E*B^,10?&X.6ERC(]]-YV.G"=9M@
M
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MPZ"R9M"UK]:VZ^-O\C*2DEDD^(?%DP]')A&[^]PQ^PG0
M
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M<)VHB<LB(F%>G[<_S.)7:(U3H[4BU6DJFX5=#62OJ*BFA:D;$=Q1&KQX]/\
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MGF6>)%_!*Q4\5%X]&>@L<
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"Z/"E0_1P=_P#=";4Z'Z*#O_NCPIT/T4'?_='A2H?HX._^Z/"E0_10=_\
M='A2H?HH._\ NA-J5#]'!W_W1X4Z'Z*#O_NCPIT/T<'?_='A2H<?[N#O_NF/
M"G0_10=_]TSX4J'Z*#O_ +ICPIT/T4'?_=,^%*AQ_NX._P#NF/"G0_10=_\
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M -TQX4Z'Z*#O_NF?"E0_1P=_]T>%.A^B@[_[ICPIT/T4'?\ W1X4Z'Z*#O\
M[H\*=#]%!W_W3/A2H?HX._\ NCPI4/T4'?\ W1X4J'Z*#O\ [H\*5#]%!W_W
M1X4J'Z.#O_NCPI4/T<'?_='A2H?HH._^Z?3-J%"Y%7DX4Q^N^Z?/A2H?HH._
M^Z/"E0_10=_]T>%.A^B@[_[H\*5#]%!W_P!T>%*A^B@[_P"Z/"E0_1P=_P#=
M'A2H?HX._P#NCPI4/T<'?_='A2H?HX._^Z/"E0_1P=_]T)M2H5_].#O_ +H\
M*5#]'!W_ -T>%*A^C@[_ .Z8\*=#]'!W_P!TSX4Z'Z.#O_NF/"G0_10=_P#=
M,^%*AQ_NH._^Z$VI4/T<'?\ W1X4J''^[@[_ .Z/"E0_1P=_]T>%.A^C@[_[
MH\*5#]'!W_W1X4J'Z*#O_NCPI4/T<'?_ '1X4J'Z*#O_ +H\*=#]%!W_ -T>
M%.A^B@[_ .Z/"E0_1P=_]T>%*A^C@[_[H\*5#]%!W_W1X4J'Z.#O_NCPI4/T
M4'?_ '1X4J'Z.#O_ +H7:E0_1P=_]T>%*A^B@[_[H\*5#]'!W_W1X4J'Z*#O
M_NCPIT/T<'?_ '1X4J'Z*#O_ +H\*=#]%!W_ -T>%*A^B@[_ .Z/"E0X_P!W
M!W_W0FU*A^C@[_[H7:E0_1P=_P#='A3H?HX._P#NCPI4/T4'?_='A2H?HH._
M^Z/"E0_10=_]T>%.A^C@[_[H\*5#C_=P=_\ =";4J'Z*#O\ [H\*5#]'!W_W
M3*[4:%$_W<'?_=,>%*A^B@[_ .Z8\*=#]%!W_P!TSX4J'Z*#O_NA=J5#]%!W
M_P!TQX4Z'Z.#O_NF?"E0_10=_P#='A2HOHH._P#NF/"G0_10=_\ =,^%.A^B
M@[_[H\*5#]'!W_W1X4J'Z.#O_NCPI4/T<'?_ '1X4J'Z.#O_ +H\*5#]%!W_
M -T>%*A^B@[_ .Z/"E0_10=_]T>%.A^B@[_[H3:G0_1P=_\ ='A2H?HX._\
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M^CMM%3O^.)XT4#6+T=J(6%I%5=IRA5SE<NXO%?VJ=<
M $1VK?D17?O1_P"=#4V.?DM/_>G?Y&$Y          ,/<C&[SEPA\23,C^<N
M/X&7RL8F7+A/V&))F1XWUQGAT!\T;%:CEPKEPG#K,OE8SYRGDVL@=)N-?XV<
M8PI]25,4;T8]V'+T<%/I)XU<C4=Q5,]!]-D:YVZB\1OMWU;GQD3(8]KTRU<B
M1[8VJYRX1.)B*5DK=YBY3]AE\C6?.7!CE6;S6YXN3*&72-:Y&JO'I/.6JBB^
M>['\%,Q5$4J*K'9PF5X'S'5PR+AKL_P4]\\,GPZ5C6N<J\&]/ 12-E;EBY0^
MP85R)TGFE1&LBQH[QD3.,'J8<]K?G*8WVY:F?G=!EST:N%4^6RL<[=1>/[#[
M/F1[8T17+A%7!ATC6NW57B9?(UF-Y<9X(8Y5F43/%>C@95[4<C57BO0?*SQH
M[=5W']A\354,+D;(["JF>A3UC>U[<M7*'T          "K[!_P";R_\ 2U_[
MA:                   ,*]J.5,\43)\-F8YRM1>*?4925BN<U%XMZ3#9XW
M.<B.XMZ> 9/&]7(UV5:N%X&)*B.-CG.=AK>G@8AJ8IEQ&[*_L#*J%ZJC795/
MJ4^HYF29W%SCZCZ1[59OHOBGSRS-W.>'[#[:J.:BIT*85[4SE>@Q#,R9%6-<
MHBX7@?8,.<C>D\W5$;9$C5WC*J)C!ZF'.1K5<[H0^5D:B)E>E,H?3GHUN\J\
M#Y21JR;B+XV,X/L^7O:Q,N7"&.59AJYX.7"<#Z>Y&-57+A$/E9F(C55?G)E.
M =(UJ(JK]9ATS&KA5^OH,2U$47SW8_@?<4C96;S%RA]
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M:LT5Q?$Q6S9\5&,7KSUJI-=GNF[C8JR5)YZB>D=ONWIY^4=O+CA^S@3T
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MI.JKP5,=.>TM?36F*NQ:GJIJ.IJZFWO@1C?C4^_AV45>"8["<@
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MG8                   !$MJOY$5W[T?^=#3V._DM/_ 'IW^1A.0
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M;3N;N2P[CM]'<%SCHPO:6>          "K[#QVOK_P!+7_N%H
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M@                   $2VJ_D17?O1_YT-/8[^2T_\ >G?Y&$Y
M                                !6%A3&UY?^EK_P!PL\
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M83D            %7[4?RMT?_?5_K&672_BT?[J'J
M        "L+#_P";RX\UK_W"SP            "J]J/Y=Z:_LY"SJ'\2I_[-
MO]#V                         7H4JK9]^76K<='RBO\ FD+5
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M7 J9?&Q[VHBINJYJ+CB=4 K7;;^)6/\ OG^A,M'_ )-T/[B_U4[
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M*<%0M+9KI]CI9[]6,S5RU$DE.]=U?P+VHJ<<93YR\,E9;/8HTV\4KDBC;_\
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M4L*)(VHCY:1V6X;NI(J<./UH>>J;HMZU_16^D1$^3ZN"9ZO3&4=N+P7K./\
M"FJ8Z>VV#E,[KI)NA/J83#1-KM]SV;Z:JZKE4;#1-5NYA%PN.U"2:5OU'=DJ
M::@27<H7_%W<HW'%,IV\>@[X!6NVW\2LG]\_T)EH_P#)NA_<7^JG8
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M'\N],_V<G^I9U#^)4_\ 9M_H>P  (MJ;0]KU'6Q5-R6HY2)%:SDY-U,*N>/
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MM5SEPU$RJG'@U19*BX+00W.F?6(J-6)'>,BKC'\\H=D
MK"P?^;R_]+7_ +A9X            !5>U'\NM-?V<G^I9U#^)4_]FW^A[
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M_I:_]PM              JO:C^7>F?[.3_4LZA_$J?\ LV_T/8
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M7J/UCM)<Q=F>JG-QN?)-7U?JGE3?!)1?DV]._P#3<R#=_G*?H
M      %7V#_S?7_I2_\ <+0             *KVH_EWIG^SD_P!2SJ'\2I_[
M-O\ 0]@                        .HJK9_P#EWJW_ *BO^:0M4
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M391?'6145</X<.SI/T/L@T=S,T;0T$S7-K6Q[L^7-=Q1SE3BB<>#B;
M           J^P?^;Z_]+7_N%H             %5;4?R[TS_9R?ZEGT/XE3
M_P!FW^A[                         +T*55L^SS[U;_U%?\TA:H
M      !6NVW\2LG]\_T)EH_\FZ']Q?ZJ=@                   $1VK<-$
M5W[T?^=#4V.?DM/_ 'IW^1A.3"M1>E$7]IE$1.A$3]@Z3"-:BY1J)_ RJ(O2
MB#"8P$3'0,(G4@1$1,(G (B)T(,)G.$,*U%Z41?VF41$Z$1!A,YP@5$7I1
M   "K]J7Y6:/_OJ_UC++I/Q:+]U#U&$SG" PC43H1$_8ADPC6HN4:F?V'.U!
M:F7BVST4RJD4T;HW;JX7"IC@?5BM<-GME-14^\L<,;8TWERN&IA#?5K57*M3
M/[#)A6HO2B+_  ,]'0%1%Z410B(B<$P1671=#-J9MZD=-\89,DS41Z;N4^K'
MU=I*E3*<3"-1.A$3]ADPC6IT(B?P,F-UN<[J9_89                 *PL
M/_F^O_2E_P"X6>             57M1_+K37]G)_J6=0_B5/_9M_H>P
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MI,?W?[A#-;U6KG7ZPK<*BG=.VIS K8<(CLMZ?%X]1,8:[:"D$>Y64F[N\/\
M9_N'U\H;0_*Z3U?[@^/[0\_CE)ZO]P?']H?EE'ZO]P?*&T//"LI/5_N!*_:'
MY92>K_<'Q_:'Y92>K_<'RAM#\KI/5_N#X_M#\LI/5_N#X_M#\LI/5ON#X_M#
M\LI/5_N&/E#:'Y72>K?<'RAM#\LI/5ON&?E#:'UUE)ZO]PQ\H;0^JLI/5ON&
M4N&T/KK*3U?[@2X;0_*Z3U?[@^4-H?E=)ZO]P?*&T/KK*3U?[@^/[0_+*3U?
M[@^4-H>/QRD]7^X/C^T/RRD]7^X/C^T/RRD]7^X8^4-H?EE)ZM]P?*&T/RRD
M]7^X/E#:'A?]LI/5_N!+AM#\LI/5ON&?E#:'Y92>K_<'RAM#\KI/5_N#Y0VA
M^64GJ_W!\H;0_*Z3U?[@^/[0^/\ ME)ZO]P?']H>/QRD]7^X$K]H?EE)ZO\
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M^+1?NH>H                           *PL'_ )O+_P!+7_N%G@
M      %5[4/R[TS_ &<G^I9U#^)4_P#9M_H>P
M ,+\U2J]GJ_^.M6_]1__ +I"U0            "M=MOXE9/[Y_H3+1_Y-T/[
MB_U4[                    (EM5_(BN_>C_P Z&GL<_):?^]._R,-C:KK>
M+06FXKM/2K4MDJ6TZ,21&<5:YV<JB_HE0TOP@[[64S:FDV>W^>F<JHDL:*YJ
MXZ<*D>"8;.-ME'J>[36F\6UU@N$>XUL5?4M9)(Y[L-:C%1JYPJ+CKRA;ZJC4
M555$1.M3#7(Y,M5%3ZCY2:)7[B2,5^<;J.3)R=7:@IM,V.:Z5RL2")S6JKY$
MC3QEPG%>!7VR_:;=-;7US.;ERH[6U9&?&I$WHE<U$5/&W$3CE.LM=\T4;L22
M,:O8KD0^S#GM:J(YR(J\$RO2'*C457*B(G6H:Y')EJHJ=J'PV>)S]QLK%=T8
M1R9/0UZNJ9!!))E'*U%7=1>)"-DVT6+7]N=4Q4#Z/&_XKI4?\U43J1.TGX
M !5^U+\K='X\M7^L99=)^+1?NH4_M-VQ3Z9U-36&U6*LN=;4(_<2E>CG98Y<
MHC=U57@BJ6EIRNJ+A:X:BKI9J65[&N6.5,.3+45>I"/;3=3733-H=5VFS5UT
MD:YB<G2L5RX7.5X-7HP<_8YM)CVB6A:ME"^C<CGIN/E1ZX:J)U(G:6(
M                    "L+#_P";ZY\UK_W"SP            "J]J/Y=Z9_
MLY/]2SJ'\2I_[-O]#V                         7H*JV?_EWJW_J*_YI
M"U0            "M=MOXE9/[Y_H3+1_Y-T/[B_U4[
M  (CM6_(BN_>C_SH:FQS\EI_[T[_ ",(5\+QCG[,J'=3.+K"J_LY.4T=E6T'
M9W0:%HJ2[7FV05#'R*Z*3.4R]RIU=A7E\EM^L-O%#4Z%I(JFCH[C0SU%;2KE
M'QIR6<HJ)A$5')_ D6M-9:HOFU6X:0L5PKK>QM7\6^,12[R1HY$PNYP^OAD[
MNN=17S9GI6FM5?>JJ[76[PNCIZMSN1?3OBW=YR)XV5=OIUIC'61.LYPVO2?.
MQ-I=74U*0LJ'6I(E:[>?A%9O[R_-WNG=ZCUVJZGK->;%JNZ455+!#0NIJ:HI
MT?RB32;S5WU7AA>/1A3I[%[O6Z(V3U%^O-7++3,KW1)2R.W$57,8B.WN/]#C
MZ8DU!K.QOOM5M(J[)(QSHTH7QK*J[J91V]O-Z<]A+ME6U.MNNE;[:J]LTUVM
M5KJ:]U8^HR^3"JK4QN\,(Y$SE>@B^S2NUOM+K_C<.H[E:J6B<R=69Y9)TWL*
MWI;CYJ\>/2+[J_5MXUV[1-LNM?2SPU*TDM<R3>Z>ARLX=B\-XD>N=4WO9KIJ
M&PUMVJKK>+E BP5JOY%\*L5$=AOC9S^U",7:/4%CTN[4\6TZKKJEL4<ZVQ(5
M8Y5D5$5F_OK\W>7CCCNDUN>VF-NRV>\00.^4::6&!84J?'DRC=YV]N\.E>&"
M-II;:8[2DM\?JB[OGDD5&VU6<>3<F=[>WNCCV'5^"#NNTH]RX;)O3(K>O&\P
M_0@   !5^U+\K='_ -]7^L99=)^+1_NH?FR]QI)\)[3#5XYDK.'_ -LI/]M>
MUJ/9PVGIDMRUM1-"V5J)4\DN-Y6_HKV'5V8Z[@VCZ*J;DE,E(]LLD/(K+RJ^
M*U%SG=3]+L*S^!WPLDR)T8F_SL/T@                         "K[#_Y
MOK_TI?\ N%H             %5[4?RZTU_9R?ZEG4/XE3_V;?Z'L
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M2NE:723+I6:VJ9*1((WOADA56*CMW"*G[50Y.U:W6^?9R^Z:8CB^38'0PRI
MQ&,?(JIXSDX<<*A>5+M%TPNA(Z]+I ZF9&VF<[<?A)-Q/%Z"O?@AYETW).U,
M,59F\.C.^P_0P   !5^U+\K='_WU?ZQEETGXM%^ZA^;+VN/A/Z85%PO*5G^6
M4M3:ILLMNT6FB2NJ%I:AD;6-G9"U[VHCE=A%7MR=#1.BJ#06E)[;;E;*W>?*
MLBQHQ556HB]'[I4?P//^"S?LF_SL/T@                         "L+#
M_P";R_\ 2E_[A9X            !5>U'\N],_P!G)_J6=0_B5/\ V;?Z'L
M                       O0I56S]?_ !WJW_J*_P":0M4
MK7;;^)63^^?Z$RT?^3=#^XO]5.P                   ");5OR(KOWH_\
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MU@EE3YB\LG_YL/T>                         "L+#_YO+_TM?^X6>
M          57M0_+O37]G)_J6=0_B5/_ &;?Z'L
M    O!%*JV?<==:M7_\ R*_YI"U0            "M=MOXE8_P"^?Z$RT?\
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MHYBHYKDRBHN45#6K+C147X[64U/_ &LK6?U4]X9HIV;\,C)&=&\QR*G^!]@
M                        K"P_^;Z_]*7_ +A9X            !5>U'\N
M]-?V<G^I9U#^)4_]FW^A[                         +T*55L^3_QWJW_
M *BO^:0M4             K7;;^)63^^?Z$RT?\ DW0_N+_53L
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M86'_ ,WU_P"E+_W"SP            "J]J/Y=Z:_LY/]2SJ'\2I_[-O]#V
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MXD_^MG_JTND                         %86#_P WE_Z6O_<+/
M      *KVH_EWIG^SD+.H?Q*G_LV_P!#V                         ZB
MJMGWY=ZM_P"HK_FD+5             *UVV_B5D_OG^A,M'_ )-T/[B_U4[
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MU5J,T;*UB(C6O:B(G4G$@_P1?_*2/^^S_P!6EU
M    J^P?^;Z_]+7_ +A:             !5>U'\N]-?V<G^I9U#^)4_]FW^A
M[                         =156S[\N]6_P#45_S2%J@            %
M:[;?Q*R?WS_0F6C_ ,FZ']Q?ZJ=@                   $1VK?D17?O1_Y
MT-38[^2T_P#>G?Y&$AU58H-06M:.I7#4?RB>*B\414Z_VD V:?+6DK;!IVKM
MR<A!O.;/)(BN<Y[][&$7_F7^1Y:[TY=9-1P7NFAEJ$=,Q\E,Y[>3:UB-3K7H
M7=X_M./>])5\MPIKS3VYKEJ)%DDIT5B,BQC@G'H/336F[A67N2&XVB-E!,]$
M?E6.1&\>K)V--:)KFP:KM]PBD923UB_$'JK7<G"B\-Q,^*F$3AP(_IC3E=&V
MX6^YZ?IIY%J'<A43;CY$C3L7/!%QT?6=.Q:6N%3LVK[5-0\A5NN3I61-5O%B
M(W"]..I3G26*\SW)SDM#6HL>[OH]N>GHZ39BTO<ZA[+-54&XR!R2)4[S5>JK
M_'JWO\#4N&C;W-57*W00SMAI8\P3MD:CIU<W.%X\,+P)%LSM4T51'!<M.T5-
M56_<3XXC6++*[CESG)QSP_Q/C;+:+G=KU9TMM(L\#(Y&RN1R)NKE,=*\3I:R
MTU"FS.>GMEHI771U/#XK8V-<YR.9O>-V]/61/5NEKFEJH[C06Y)IH((X74F\
MU&.5>E5X]*9.QJNU5,^SQL-FL-+3U"U,:N@IT8Q.CQG=29. _3EVLMX;7R6:
M.[T<J-@Y&K<QT;%5<J]$5?G(B*G\5-Z;3%7X0*NLI+) RUNY+DT8C$8F$9O8
M;U<47J.E;-/5LUSUZQ;<RF974;8J22/=RYW)N3AQX*BJG3@XFG],UM39[O9:
M^PT]/6Q,9#3UZ(Q9WNRN7;V>"\$Z^LU;CIV_R_$:*&U<H^CCY#EN49OO5.&\
MO'I7!>MHC?%:J*.9N[(R%C7)V*C4R;0 *OVI?E9H_P#OJ_UC++I/Q:/]U#\U
M:OV?ZSH-KL>IM,VN>KA2HJ)U<D[(TR]7HGYR+T./TE;EF6WTJU3=RH6)JR-S
MG#L<4S^TK#;O1:ONUG=0:4MLE2USHW*^.H;&O2[*<7)]1T-@.E:[1VS]EKND
M+X:E*F63=>K57#L8^:JIU%C@                         K"P*GA>7_I:
M_P#<+/             *LVH?EUIK^SD_U+-H?Q*G_LV_T/8
M           !>@JK9^G_ ([U;_U%?\TA:H            !6NVW\2LG]\_T)
MEH_\FZ']Q?ZJ=@                   '!US:IKUIJIH:5,RR.8J<43H<B]
M*_L*PTG=-7:9H:BW_)5O>OQATC5=+E53")U._P"4[7/76'79K9WJ^\?#M8:M
M<_>=8K2KNU7KG_,?3M9:N<F'62U*GUR+[Q\\\=6[J-6QVG"=7*+[P;K'5K5\
M6QVI%^J1?>/OGIK!/_9K7WJ^\?":PU8CM[Y#M*+V[ZY_S'TW66KF_-LEJ3]D
MB^\836&K4_\ 8[2B_P!HOO#GCJ[>W_D2U;R]?*+G_,9366KMY7?(EJWEZ5Y1
M>/\ ^1ANL=6M<YS;':D<O2J2+E?_ ,@NL=6N7+K':E^M9%]XR[66KG-PMDM2
MIV+(OO&%UCJUS5:MCM2M[%D7'^8<\-6[N[\AVG=[.47'^8PNL-6N;NOL=I5$
M7.%D5?\ ^XRFL=6]5CM7>+[P366KFJJI9+4B]:I(OO&&ZPU:CE>ECM*.7BJI
M(N?\QE-8:MRKOD.TYZ<\HOO'TFM-8>9K9WJ^\.>NL/,UL[U?>,\]-8>9K9WJ
M^\.>FL/,UL[U?>,<]-8>9K9WJ^\1O4DFL-072U5_R50-^39N7PV;"+Q:O'+O
M^4D46LM7QQM8EGMB[J87\*OO'TFM-8+_ .S6SO5]XSSTUCYFMG>K[PYZ:P\S
M6SO5]XPFM=8>9K9WJ^\9YZ:P\S6SO5]XQSTUAYFMG>K[QGGIK#S-;.]7WC'/
M36'F:V=ZOO&>>FL/,UL[U?>,<]-8>9K9WJ^\936FL/,UL[U?>,<]=8>9K9WJ
M^\9YZ:P\S6SO5]X<]-8>9K9WJ^\.>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.
M]7WC'/76'F:V=ZOO&>>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.]7WASTUAYF
MMG>K[PYZ:P\S6SO5]X<]-8>9K9WJ^\.>FL/,UL[U?>,<]-8>9K9WJ^\.>FL.
MJS6SO5]XSSTUAYFMG>K[PYZ:P\S6SO5]XPFM=8+_ .S6SO5]X<]=8>9K9WJ^
M\9YZ:P\S6SO5]X<]-8>9K9WJ^\.>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.]
M7WC'/76'F:V=ZOO&>>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.]7WASTUAYFM
MG>K[PYZ:P\S6SO5]XQSTUAYFMG>K[QGGIK#S-;.]7WASTUAYFMG>K[QCGKK#
MC_\ !K9WJ^\9YZ:P\S6SO5]X<]-8>9K9WJ^\.>FL/,UL[U?>'/36'F:V=ZOO
M#GIK#S-;.]7WASTUAYFMG>K[PYZ:P\S6SO5]X<]-8>9K9WJ^\8YZ:P\S6SO5
M]X<]=8>9K9WJ^\1NAFUA1ZK6_P#R50+_ +,M+NK-XOSM[.-[)).>NL/,UL[U
M?>'/76'F:V=ZOO&>>FL/,UL[U?>,<]-8>9K9WJ^\9YZ:P\S6SO5]X<]-8>9K
M9WJ^\.>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.]7WASTUAYFMG>K[PYZ:P\S
M6SO5]X<]-8>9K9WJ^\.>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.]7WASTUAY
MFMG>K[QCGIK#/_!K9WJ^\9YZ:P\S6SO5]X<]-8>9K9WJ^\.>FL/,UL[U?>'/
M36'F:V=ZOO#GIK#S-;.]7WASTUAYFMG>K[PYZ:P\S6SO5]X<]-8>9K9WJ^\8
MYZZP\S6SO5]XRFM-8>9K9WJ^\1G4C]87^]6ZY_)= WXBUS<-FPB[W;EQ(H-9
M:OBA9&EGMB[C4:N95ZO_ +C[YZZP\S6SO5]X)K36/79K7WJ^\9YZ:P\S6SO5
M]X<]-8>9K9WJ^\.>FL/,UL[U?>,<]-88_P"#6SO5]XSSTUAYFMG>K[QCGKK#
MS-;.]7WC//36'F:V=ZOO&.>FL/,UL[U?>,\]-8>9K9WJ^\.>FL/,UL[U?>'/
M36'F:V=ZOO#GIK#S-;.]7WASTUAYFMG>K[PYZ:P\S6SO5]X<]-8>9K9WJ^\.
M>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.]7WASTUAYFMG>K[PYZ:P\S6SO5]X
MQSTUAYFMG>K[QGGIK#S-;.]7WASTUAYFMG>K[PYZ:P\S6SO5]X<]-8>9K9WJ
M^\.>FL/,UL[U?>'/36'F:V=ZOO&.>FL/,UL[U?>,\]-8>9K9WJ^\.>FL/,UL
M[U?>'/36'F:V=ZOO#GIK'S-;.]7WC'/36'F:V=ZOO&>>FL/,UL[U?>'/36'F
M:V=ZOO#GIK#S-;.]7WASTUAYFMG>K[QA-::P7_V:V=ZOO&>>FL/,UL[U?>,<
M]=8>9K9WJ^\.>FL/,UL[U?>,\]-8>9K9WJ^\.>FL/,UL[U?>'/36'F:V=ZOO
M#GIK#S-;.]7WC'/36/F:V=ZOO&>>FL/,UL[U?>'/36'F:V=ZOO&.>NL%14^1
MK9]7X5?>(S87ZPLEZNMS=:Z!WRC4?&,.FRB<7+PP[_F)/STUAU6:V=ZOO#GI
MK#S-;.]7WASTUAYFMG>K[PYZ:P\S6SO5]XQSUUAYFMG>K[QGGIK#S-;.]7WA
MSTUAYFMG>K[PYZ:P\S6SO5]XQSUUAYFMG>K[QGGIK#S-;.]7WC'/36'F:V=Z
MOO&>>FL/,UL[U?>'/36'F:V=ZOO#GIK#S-;.]7WASTUAYFMG>K[PYZ:P\S6S
MO5]XPFM=8>9K9WJ^\9YZ:P\S6SO5]X<]-8>9K9WJ^\.>FL/,UL[U?>'/36'F
M:V=ZOO#GIK#S-;.]7WASTUAYFMG>K[PYZ:P\S6SO5]XQSUUAYFMG>K[QGGIK
M#S-;.]7WC'/76'F:V=ZOO'"U-/JS6%1;*66V4,4=/4MD>Z.;"HU>"]*EQ6*C
M=06FFI7YWHVX7*YZU-X                    ^%AB5<K&Q5_=0B-;J^VQ3
M;L3$<S"?^CE20VBKHKK0,JZ2-.1>JHF^S"\%QT&YR4./]W'Z*',O-1\4Y'XO
M%"[?547+<F[2-CEI8I)(XT<YJ*OBH>W(P_1Q^B@Y&+Z-GHH<W4-TMU@MKJZX
MLW:=KD8JLCWERO1P/NQW"@O5#\;H6(Z'>5F7,1%RAMU2TU+32SS,8D<;5>[Q
M4Z$3*_T(BFM+;*Z:6GCS2P-Y215AX[J)E<?7P4D%CN=OO5(VIHF?@G-1R;\>
MZN%__8=)(853A''Z*#DH?HX_Y($BAZHX_P"2#DH<9Y./^2#D8?HX_10^')3M
M5$5L657'0AP;W=5MK+E4/AA^*T<2S.7D\KNHW>7]O0-&ZBM^IJ-T]&Q%W6L<
MN]'N_.SC^AS*;6MMEUA\@*S_ &E9GPM3D>&6YSQ_@33D8?HX_10<A%]$ST4,
M\C%]$ST4'(Q?1,]%!R,7T3/10)%&F<1L3/U&.0B^B9Z*&>1B^B9Z*#D8OHF>
MB@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH
M.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D
M8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+
MZ)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B
M9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>
MB@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH
M.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D
M8OHF>B@Y&+Z)GHH.1B^B9Z*&.0B^B9Z*&>2CQCDV8_=0<C%]$ST4'(Q?1,]%
M!R,7T3/10<C%]$ST4'(Q?1,]%!R,7T3/10<C%]$ST4'(Q?1,]%!R,7T3/10<
MC%]$ST4'(Q?1,]%!R,7T3/10<C%]$ST4'(Q?1,]%!R,7T3/10<C%]$ST4'(Q
M?1,]%!R,7T3/10<C%]$ST4'(Q?1,]%!R,7T3/10<C%]$ST4'(Q?1,]%!R,7T
M3/10<C%]$ST4'(Q?1,]%!R,7T3/10)%&G1&Q/X&.0B^B9Z*&>1B^B9Z*#D8O
MHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)
MGHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z
M*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@
MY&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1
MB^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8O
MHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)
MGHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>BACD8OHF>BAE8HU3C
M&Q?X(8Y&+Z)GHH9Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8O
MHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)
MGHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH.1B^B9Z
M*#D8OHF>B@Y&+Z)GHH.1B^B9Z*#D8OHF>B@Y&+Z)GHH8Y"+Z)GHH9;%&U<MC
M8B]J-0^P                    #\X7BSWO91<$N]@FHJBS3-2E=$W>FF1[
ME5RKT(F[AB=9+JO7]/76RGHM-1S0/FEY.-:UC<9=E..'+UJG\#2U'<M8:;LT
M=/<:FTR2/1[&.A8Y6[RY7CE$X<4/MMZO5AL6FKA'+1K47-'?&?%547=QC=3J
MZ3<N^JKKJ""GI;(^FAN,:*U[JIF&.<N,;N,KC@O5V&G>]4WZR6R&*_\ Q>9C
M(D21:2)<<,)TNQUEH:1K4K[1%.U['(YK53=7HRU%POUD-VH/I]0UG-:I1[Z:
M2)M2JQ83QFJ[K_AT8.%\':_,^*S6#<D8Z-LE5X[43\YC>W/7V'6^$35STNDJ
M!*=,MFK$BE\7.&+&_/[#M;(::G?LLM=*U56!\<S%X\<+*_/]3@7B_1TU^ATK
M9V2,?4RK3/?.U%:N,8PJ+GK7J.2NM[E:J74%H>D:UE'+R%/(D>8TW5PN\N<K
MT=AY4M\U!:=1V62XST#Z:JB69R0M7>XM7'3CKP;VF;S=:._OMMWEI/\ ;'/J
M8EC3"(SJRJXX\.K)[37VYNJGZ<II*:.N<BU39)6XCW>S/3GAV&A>[_JZV:5H
MGUTUL^-RUJ1*K8W;NZK78Z43L.->K5=8-5V.>Y3T;N5N-.Q>25W:G1E.Q"8W
M?4-;\L:SLD[HEMU/3-9"C6^.B/B5797^)!],?+.G7U5WMLU&MO9NR31N172J
MWCNHU,8SQ7K.O27&!=76C44[9%3QII&-1-]5>B]"9QU]IT([YJFZU=1=[#/;
M645-(Z)T=0QW*95>'!$5.A4ZRXZ1SWTD+IL<HK&J['1G'$]0
M
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M7*U%<KG>,J9XJJ]9]ZDT,E=7V^YVUT,%VI'NE2>1SE3?7''=XIU=AX7+9_\
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MD<_=5J-Z%5</1,8+&
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MU''VD8I_A 6Z2%4Y66[4#),<5QNQ=)^FP
M
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MKE7/']%31I](U>J]LE7J%^]%;(9::JIW.9OM>Z-(T5$7*87+5XX+X
M
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M,_!)E5=O93K1O ]-E6DKO:-3UUUNZU#5J*7D=R1R*B*CFXZ%7J:6J
M #0NEFMMU:B7.@IJM$3&)HT?PSGK/2WVRAMS-R@I(*=O9$Q&IV=1L311S,5D
MS&O9V.3*&O16RAH7*ZCI(('*F%6-B-X?_JA[SP13LW)XVR,[')E#PH[9142J
MM)200JO#,;$0B>L='TNHKS;:BHMT"NI95>VH6-KG)G=X\?W24QVNE2W04<\4
M<\44:1HDC45%1/J_@>U)0TM&U6TE/%"U>.&-1#-714U8S<JX(IF]CVHJ"DHZ
M:D9NTL$<+>G#&HABLH:6L:C:NGBF:BY1'M1>)FEI*>D8C*6".%B=",:B(>X
M
M
M
M
M
M
M
M
M
M                                              R      #SEJ(8G
M8EFC8N,X<Y$/0
M        #H/B66.%BOED8QB=+G*B(?3'M>F6.1R=J+DR
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M^CL-K:Q#';=J.C*RG:B2SW15DW4W5=A&=*EZ4$JST<4CDPKFHN,Y/<
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M4#%\2BIFIV)$U$SV]!M211R,W)(V.9^BYJ*AJT]IMU,]'4U!20N3KCA:U?\
M!#=-2JME!5O1]50TL[TXHZ2)KE3^:'W\2I>06!*:%(%1$6/<3=5$Z.'0?++?
M2,C=$RF@;"Y<NC2-$:Y?K3!]TM'3TB*E+!%"U5RK8V(U%7MX&O\ (ULY7E?D
MVBY3]/D&Y_G@V*BCIJF-(ZFGAFC1<HV1B.1%_8I\TE!1T?XI24\'5^"C1O\
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M?-13PU#-VHBCE;V/:COZGS2T=/2HJ4T$46>"[C$;G^1[@
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M-15_Q0VH8FPQHQN<)VGV     >+:6G;,DK8(DE3/CHQ-[^9[
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M?>UN>U<%!ZIHJ5OP@[#/2NWY/D^55P[/%>6R7RR>++8^5CY3=SN[R9QVX/4
M
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MFLY2.3"KXS%RA26V&[W*V:Q9\=@EJK!/+%$QM-%ET>6ION<[H1.GKX';UM)
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MKMH\6H4JJ7XLVW_%>2R[E-Y7J[/1C''M+"
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M8\I_\1H_66>TRNMK&BHBW"CX_P#U+/:836]C7_W"C]99[3*ZVLB+A;A1I_\
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M>4ZL)D@.RS3UZI5DN6J*^:LN#FNAS-3\D[=RU4Z%^I>HL8
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M?[0N@-+JO_!X?3?[1X/]+^9X?3?[1X/]+^9X?3?[3*:!TPF<6B'TW^TQX/\
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M#Z;_ &G0LNEK+9*A9[701T\JM5BN:YR\%5%QQ7M1#L@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;].24S+A+$QU0CE8CY$;G&,XST]*'9H:EE914]3$J+'-&V1JHN>"IE#V
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MH8ZRNCBEIHTW45C41517<>"X[.LN#3UR^5[-2U_)I%R[=[<1V]CBJ=/\#H@
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MM7&$3BG\"Y;#=+/RDEGMM7"^>B1&R0QMW=S/%.&,';
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M'*Z-S=YD;6*[.<(JH1K1NC)+1J2ZWFIFEY6OW%6)516M5O8J$Z
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MT9:[9=:BX4Z2K4SR\L]S]WB[CV-1>M>LD@
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M]@
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MFSX8YT>,,5%7I3HXYXENM5'(BM5%1>**@
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ML7C03*JU14%#+'! V)D;T=O.WE:J<<YSU(36EBY&FBBSG<8C<_L3!Z
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
K                                                     '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g111069g55a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g55a03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[0^ 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #V,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0E21H18C4F2Q,T568G)SA+/!&#93@B8T=9*3E<+C)X.CX>+P\?_:  @! 0
M/P#ZI
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                  &C:MQO:N:S
M&D:+-&7E31US5CW:;DTS$SO3TQ$]^QP9Q;J.HZC>T_5=)S,6Y19JO^+?CIB8
MB8C;;ICWS_@]G!_&^+Q-G7<;&LTVZJ+4W9F+T5]HF(](_%MH ./<R.8NI\-\
M>6]+Q[%^O$JLVZNJGIZ>JJJ8GO-,^[WNO7YJIL7*J(F:HIF8V]^SF7#/&NI9
MW,K7]"RZ+U&/A?9_#FN(B)ZZ8F=NV_K[W4
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MG7M$3U;],;>?DVX
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M[/O<-6<6S8M9,V[L8]'3$U[1.\]H[[3#;P
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MWKX(W*XMT]57D6KE-RGJI\D@
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MQ9R.%.76+517,W*LJW5,U535VJC_ /LZ9IV;9U#&B_CS5-N9F.\;>3T@
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MKUC=M7.W(MXO!-G'ZJ?$C)LTQ3O&^W>/)MG!>%<T_0Z;%W;JBNJ>V_K+.@
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M7,;CJB[;L7J=$MV8IFJ[1/1-VB?]NG]_EN[D
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MF)G>CJ[Q/[U_0](P]%POLNGV:;5KJFN8B9G>J?.>\_@R
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MT7\>OKM5QO35MMO"Z
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M1UQ'X;=O/UV9L
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M=_T9=<P;==K"Q[=W;Q*+=--6T[]XCNO
M                                                 *=,;[[1NJ
M
M
M               #%YW$.C8%R+>=J^GXUR>\4WLBBB?\)E8_TNX<_;^D_&6_
MFK3Q;P[55%-.OZ3-4^41F6]_^+,T5TUTQ515%5,^L3NJ"$W;=-,U373%-/G,
MSVA*BNFN-Z*HJCWQ.ZH +%&9C7+WA6\BS5=[^Q%<3/;\%\
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M:JBJB?*8GM*0
M                       /GGE7&W-S+_B,K_\ 4^AG+/Z1L;\$X'_VE;_\
MNZV/E'VX"T__ +5W_P RIN /GW5JHH_I \+5SWZ?M/:?7V;C/<5\#ZEQYQU@
MYNK8E6!IF-C56.BKIO47/:JFFJ8WC;SCT:WJ/$'$^K\>V^']'NYV)9MXG7%5
MG)F(]B9C]'>/P]6?M<9:O5>G0-/IR,[,LQ]JKR?M$TU^'/;;:?2)F/5Z-(XH
MXHQ[^N3<TK(RL'&P:[MK(KRXVKJB(F=H\XV[QO\ @M<N>),CBS4Z+\:WDV<J
MS<MUY6FQ757%J)JVBF:NT3%41OVCU4X<XMU6]S7U_3<JYD?=^-FQ;HZK\S3%
M/M^5/I':.S*:;Q+J?%W&.H8.E^/C8.F9=S$OW[5Z9C>-]IFGM[OQ<^Y=8^3I
MO.>+FI9=V_1UY6UR[WVC:N-O.6V8_&FLZ]D9.1AV+^/I]F[7CS>MY.\=5,^[
M:)[[P\6O\8<4X_*ZG4,S3\K3\^=0IM=LS>KHV_VH]/P8GB/7.)]-X1TGB&G4
M]1JKO:A&/<Q/M$Q$41%4S,U;]]^GRV]6R\S.*,_5N5^!J^E7+VGW,J;T3%B[
M.\13%=/GVW_1W9GDAA:I7P3I6H:AK69FU9%$S-N],ST;7*H\YF=]W30
M
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M
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M$T53;IB)VF%K2-*Q]+M31C4_I1$55;1$U;>L[1W\WO
M
M
M
M                               'SOQGSGUS&XGG2]!P<V[-,UTU>%C4
MW>]-4Q^,^4,9^5_CJ//1M6__ "V/I6,OG=Q?IW@W=0TO4K=BNY3;WKP*:(WG
M\9CW1+Z-X7U6G6]%L9]$33%R:HVG;?M5,>G[F5!@>(N*,'1(B+U47;TQO39M
MUT]=7?;M&^\L'G<>58./]JNZ3J-RSV]FBU&_?R9_A?B;3^(L/Q\&];ZHJFF;
M?B4U51,;;]HG\6;<VXLYC?<?&N'H=6+DU1?R[&-%RFFGI_UD4]]Y_P"TZ2
MTWB7C#['EW\'3K-V_EV=IK\*(KVB:=XG;SCSAJMOF;FZC]MTW3\/+M:KA4Q%
MVNNU3,355$S3M3Y_Y,]RQXKU/7K^J8NLX>59O855NB+MVQX=-R9Z]YI]\>S'
M^+?@
M              !\\\J^W-S+C_>,K_A4^AG+/Z1G;@G _P#M*W_Y=UL?*/\
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M44SZ[>>WS;IP[JD:UI%C/ILUV(N]7^KKGO&U4Q_Z,B
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M;7+<;_YNJZ+Q3H5O6<CA[&OXMC(Q*(KFQ%W>JGJVF.WIOU1_BVL
M
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MJHWB>F:HG?;>([,!;X JS.86?Q#/]1\>BW_R=NF>KHBB.F9B=_[+IP
M
M            1$1Y
M
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M3/E,3^Z50
M             ?*N@\%Z-QIS4R;.O6;MVW3>R:8BW<FCM$U3'E^+J/\ [/G
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M_-<HRK%=NJY1?M56Z?.J*XF(_FK8R+-^)FQ>MW(B=IZ*HG:?=V7
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M;NY&7>^TTQ3'3,4U4QVV_E+=P
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M^4=/^#K^/-4X]N:]XKFF)G?W[)@
M                                   \^HVZKNGY5NC>:Z[55,;>^8EQ
MSDYPMK?#W&.JYFHXV3]GR<>FU3-RCIB)WIWG\?)UKB2Q=R>']2L8\53>N8]=
M%$4QO,S-,[;.8\D^'=9X;UOB6O4\7(\+4+UJJBNY3TQ3%/B;[>_]*'7P
M  & X]C4ZN%-0HT*J]1J4T1X-5F-ZXGJC?;^6[%<L]"S-,TRN_K-R[?U#(JI
MO5U7J.FJFJ:8ZH\_?NVB=.QIS*<JJU3-ZF)B*MN\;[_-[
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       6XOVI
MN>'%RGK\NG?NN                  C=NT6J.J[7313[YG8HKIN4[T515'O
MA( 'ASM7T[ N1;S<W'L5S'5%-RN*9F/?_E+VTS%4;TS$PJ
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M\G9=-QKF)BTVKU^J_5']N8V>D
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M?#JJGIW\.WW\_-VT
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MT'7M-PM-TK&R\?)RK=BY=N7>F:*:MMZHC?O,;M_MS-5$3,;2J
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MUF_%SSF)]WX-DNXN/>KIJO6+5RJF=XFJB)F)]Z\
M              I%,1Y1$?NA4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
2                     ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g111069g55z04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g55z04.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[19"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %B4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*2HI&1\M,"TH,"4H*2C_P  +" F5!V@! 1$ _\0 '0 !  $% 0$!
M      8! @0%!P,("?_$ &(0  $# P," @0'"P<(!0H""P ! @,$!1$&$B$'
M,1-!%")180@5%C)QD=$7(T)458&3E*'2X5)35F)TDK$D)3,U-G*RP28T<X*S
M&#=#1$5C9'6#A/!&PO$G.&6BH\,HM.+_V@ ( 0$  #\ ^J0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD3ZN5T\BQMX3YKDPO*>1]'=/M84.LK%%74#W.>UD?CHL:L1'N:BJB9\CY_\
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M3<)O'HY(8V-6HE=,[<]S5\E1.V?(^GP
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M5/-7)QPI]<:/U19==4C;A;4J6-ROJS(UKO57'9%4F(
M                                                /@;X05IJ;)U%
MGFFB<C)_%G1R-7&'2R8[H?9O3&^0W_3$=33OWMB<D*KE.Z,8ODOO)81755;1
M76@OEFAE8^MBH9'K&CT5?68J)PBY\T\CXKZ5.=IOK!;J2OS"]*^F8]')MQE[
M5YW8QPI]]4\S*B%DL3D=&Y,HJ+E%.8?"2N,-'TMO,$KL/FB9M3*<XE8</^"5
M9*BIU4V\-B=Z/!53-5RH[\*!R)Y8_"3S)K\(2I=#U/M3&KRMJ1>W_O9"/_"]
MTO/4/H-0QQ[FMIH*3*;E7.97=L8\S16C6-;U(I+7I6%D\CJ6N9<)%="U&;&N
MVKA697/WSV8]YOOA<0Q6^W62WTC%93PUNYJ*N>59E>5Y\SM/P?Y5?TGT\BKV
M@=_XCCG&MJK=U_TE%GYMQ>G_  $(^%1I26PZAI+Y0-:U)W5%1*Y%<["O>G?*
M83YQ;IN[S]7+MIVRL9(E+!0MHYG3L1C5?%&K^',RN.$]Y=\,B-8-06J%.T=L
M@;Q[I9D/HCI_NJ>G<S4Y<]LK4_NGQ;+33:7ZHTD-:QT3F34ZJBM5.-S5_"P?
M?UDN,5UML593N1T<F<*BHO953R^@T'5JIBI>G&HGS/:U/0I<95$SZI\C?!_M
M<UVZJP7""-SZ>GKF.>Y$541%1WFG'D=N^$\B)2T*91,0KC/_ &C3JEGM=+>-
M!6>BKV+)3R45.KFHY6YPQJIRGO0^->HND+UTAU8E7;]B12TZ??X6.E8F][O5
M57MQGU$X.H_!NU%)JKJ5676I5SIWVV2-5<U&\-DC3LG!])W6D2NM=92+C%1"
M^+E<)ZS53_F?$-132=-.NL'C^I;HKC!O5G**Q-KEPY^/:OF33K5=*CJPR-FG
MMSJ2TNDDD\1B+ZKT:B85F[^2O?!J>CNOF:-TWJJR7!S_ $]'114NQK,-V[LY
M1RHJ_4IVGX/.G)K?2WJZUS,2W.I2LC=ZR91[57LJ(GX7EE"9=6/]BJO_ 'X_
M^-#Y+^##IJV:GUK54=Y@=-3I332(ULCF>LCF(G*+[U._5G1FAM^K67NPM@IF
M-6-'^-/(Y=C517=T5.[4.I5UYHH;97U<-5#,E+ ^=Z12-<J(UJK[?=YGRWIF
M'4NKNI^H=1Z7J(::)LD52UU3%G<F,)C#7(JY1?,A/7:P:DMU]@N^H)89YJAT
MLR/AC5$3&W.4VHGFA]2=!-3-U#H:@C1ZN=0TE- [AJ87PD]B^[S./_#3_P"L
MVO\ LO\ _=.J_!L_\W7_ -RO_A1G3*ZMIJ"%):R>*"-7;4=(]&IGV97Z"$=8
M9XJGIY7R02,DC6.7#FN147[T_P T/G+X'Z?](KIC^;A_\13[,/G?X7W^I:3^
MSR_\3#2?!IT'I_4VFJ^>\4CYI(WQ(U6S/9A%9E>RG2]5=)M(4ECFD@MTK7HY
MO/I,B^?TGS+\''*]3XD[HD4Z?L/O(TFN*3TW1][A1JN>ZBG1B)GNL;D3L?#'
M3I[M-]6;=2UR+"]+A1HY')C";V+^%CR4^_J:=E3 R:%R.C>F6JBYR<Y^$)<X
M*+IA?8)7(CYJ=-J93G#V^U3@?P1[/45&LG79(G>CP32-5RM7C=$['ECS)3\,
M5%]%S_\ #P?^*\S?@[=/-.ZAT%+7W2C?+5>ER1;DG>U-J-8J)A%QYJ3_ *9=
M,H]#ZKK*J@2%EN?2+"R-LCWN1RN8Y<[D[>JOF=1.6?"%J?1]'RIG&^FJ4_\
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MQTC5_"3CMW/T$
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M5CV.8J.[8W;=O;)!.D_2VZZDU,[4>K8*BG<D:(R"JII('M<Q[<+QM\D4^J@
M
M     "R:*.9FR5J.;WPI@4MBME++XM/111R8QN1#9 P*ZSV^ND:^KI8Y7MRJ
M*[RS_P#J,NGIXJ:)L<#$8QJ(B(GDB=CT5$5,+V*,8UB*C4PB\AC&L3#4PG<M
M9$QB88U$0JR-K/FM1"BQ,<N5:BJ7;6[=N./84\-FU6[4VKW0-C8QJHUJ(BAC
M&L148B(G<(QJ.W(B;NV2XQ*^VT=>B)64[)D3E-Q?145-11I'20MB8B8PTR"C
M6M:J[4QGE2B1L:[<C41?:7%C(F,7+&HBEYY5%/%4-VSQH]OL4OAB9#&V.)J-
M8U,(B>1Y.HZ=T[9EB:LK5RCO-#W+/!C\1'[$WIQDO+6L:U<M:B*-C=RNPFY?
M,(QJ.5R(FY?,>&S=NVIN]I5[&O:K7HBM7NA;%$R)%2-J-1?87.8UR8<F0U$:
MF$3"%/#9O5^U-R\9*O8UZ8<F4#6HUJ-:F$3R#6-:KE:F%7O[RCHVN5%<U%5
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M"K41K41J81.$0HV-C7;D:B+WR7&M=8K8ZH\=U%$LW;=CDV0
M
M
M
M
M
M
M
M
M
M
M
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MQ&<.=C'&[/FGD3,%KY&,^>]K?I7!<
M
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MZE:Q5PCG3-1%7V=S*BECFC1\+VR,7LYJY1?SEP
M
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MMYJ*BI?24CYO%EDSN594QQCCAV.Y]$@
M
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M3\$RJ6FUQ=/3FI DM#L8JKG<Y9680^M0
M
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MM/6FDE26CMM%32(J>M#3L8J_G1#:@
M
M    M:]KE5$[IW+@      #27W4]LL<L4=PDD8Z3.W:Q7=N_8VU+.RJI8:B%
M56.5B/:JICA4RAZF+37""IE\.)RJ[WI@R@ 4<Y&M5R]D*1R-D15;Y%P
M  !9-*V)FYZX0MI:B.J@;+"JJQV<93'G@OD>D<;GN^:U%53QI*N*J5_@JJ[<
M9RF#(
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M"=JX5/.-R'+/@UQ1TEQU8Q7HC6K3HFY??*=U:Y')EJHJ>U%*@
M
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MY^QU<
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ME^,V2+'75WC1N\)6HC<.[JJ(=6
M
M     !R2Q6G4-VUZM5J%:I]K8DD20RTVQJHBJK5W(B>TZV
M
M                            ::_:DMMD<UE=4QQS.1')&Y515:JJF>WN
M4T-7U!IZ%OB5U*V"!>$D=-QGR3YI*K-=:&\T+:RUU+*FF<JM21F<*J=^YF@
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M4)"]R,8YSEPUJ95?8A#Z'J#9[CJ2:RVN>*KJ848Z1&/5%:UVWG"I_63S)B
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MD5$W.]JFDL&O-/7RK?24%R@DJFL\1T35551N43/;VJA*
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M%\S@75ZU+8>I=))I)SK?*]:>.6"BQ"WPU7*YQC.51.#Z?
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MTT?7!S6:,8KEX]*9_P +B.]%[/3:EZ06J&I>YL4=;+-ZJ(NY4<Y,*B^7)O\
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MKGU5.GT=3%5P)- Y71JJHBJF#V
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M2HZ9E) D,6=B*J\GL
M
M
M
M
M
M
M
M
M
M
M
M
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M5B[%;V>YJ\+[VJ2<
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M7Z2I1%1<X5."J*B]E10Y4:F7*B)[5-=;[S1U]3/!3/5SX)'1/XXW)W_P-B
M
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M.<?G/4
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MO3+'(Y/:BY*@
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M_9(VI=&VH:REQXC&NSC*N7'"JG!T'7]CK-16&>V4=;Z(RHC='(OA;\HN,?\
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MON/HNAI_1J6.)5W/:U$<[MN5$Y4]P
M
M
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MZ)&U,J['8\J.X4M8JI33))A<+A%0R@ 8OQC2^E+3^,GC(J(K<+Y]C*
M    ,.JN='2S,BJ)T9(]R,:U47E5[(9B*BIE.P    !AU-SHZ:1(YYT8]4RB
M*BF2Z:-L:2.=AB^9;!413Q^)$]',SC/O/4+PAC+74R2.C65-[>Z87@K4UU-3
M1MDGE1C')E%5%Y/6&5DT39(W;F.1'(OM12\     'G431TT$DT[MD4;5<YWL
M1#&I[I15%.L\,Z.A1,J["]C+C>V2-KV+ECD1R+[44N
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M-ZYG=J>\:4OE0Y:NDJW4=(DCGR/D2)'HY57EJ+ZB+Y':P
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M*J_S7N0[4-.E@^$1IJKA_P#6JBOE>B]E56/]GTGTC32>-312_P MB.^M#T
M
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MR(G//\D^F8V)'&UC?FM1$0N
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M7<*B8Y<O!/@
M                             %1%147LI'*[1.GJ^IEJ*NW))-*Y7/=X
MTB95?H<;JWT%-;J=L%'%X<341J-W*O")A.YD@
M
M
M
M
M
M
M
M
M
M
M
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M\#T*F55E2HBRYS5^9MQG/9<G2M/5%15V*W5%;A*J6GC?+A,)N5J*O'TF>
M 65#_#@E>G=K5=]2'+^C_4>?6E?44U0CD=' Z7F%&=G-3VK_ "CJ8    -/J
M345%IZF2>X)*K%:YWWMJ*N$QGNJ>TS[96Q7&W4M;3[O!J8F3,W)A=KD14S^9
M3)
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MT!SVM^<Y$^E2J+E,IR@
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MZBCCHFRNVL=3)\Q5X3.TZ/;HI8+?30U$B2S1Q-8]Z)A'.1,*OYU,@
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M+6^62EIV,EEPKWIGUE3.//WFT
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M.]SYI*"![W.7*N<L;5557S4W
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M5#?$RUKO4RB>U,Y.\:(7.C+ J>=OI_\ PVFZ
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M<BICGPVD@
M   !K=3HYVFKLD:*KUI)4:B)G*[%.0=!F5=%J?4ZU\$K&U'H[8E6-43C=GO]
M*'<0         #YZZDT-P?UCAJ(('OIDJ*55<C%5,(C,\X/H2-R/8CDSA?:5
M                                              +)I$BB<]R*J)Y)
MW.#]*(*V#J5=W5,$K(IKG5R,<L:HFU4=CD[V
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M^<Y&IRO'=3,LMS@NU'Z13?,SM[HODB^7TF<
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M'&?,^E-)75U\TU;;F^+P754+95CW;MN?+.$S]1M@     :G5ZXTG>U]E#/\
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M.7*M54RJ=O+L9H
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ME5]N3W1$1$1$PB
M             LFABF1$FC9(B+E$<U%PI<UJ-:B-1$1/)$*@         H]J
M.8YJ]E3!R?4G3^YTVJ);WINJKG33M9%)$VH;&Q&-1.>Z+W1#?V?24M94Q5FH
MFODJ(GI(R.5S96L<U>%3.<+A$Y)TB(B81,(                  %3*87E"
MC6M;\UJ)]"&%5V>V5DB25=NHYWHJKNE@:Y<KWY5#R^3UE_)%N_5F?8/D]9?R
M1;OU9GV#Y/67\D6[]69]@73UF5>;1;E_^V9]@33UF3M:+=^K,^P+IZS*N5M%
MNS_9F?8$T_9D[6BW?JS/L"Z>LR][1;OU9GV!-/69%XM%N_5F?8/D_9OR1;OU
M9GV%66"SQOWQVFWM?_*2F8B_X&R    /"X4K:V@J:61RM9/$Z)RM[HCD5./K
M.1Q=/KUIW4574Z=GKJBEK',21)*EK&L:U/)$5/:I---:1AI*U;E7Q^)<'*DF
MZ5&O6-W.=KNZ=_:2\    '/.K6CJS6%O;10OG9$DD<N8I6M7+57V_22W2]'4
M4-J;#6;O%1[E]9R.7'TFV  5$5,+RAYQ010HO@Q,CRN5VM1,J>@
M                                                     (FS7UD?
MJB;3Z.J/C"*9L#D\+U=R]N<DL(KU2U'5:3T+<[U01P2U--X6UDR*K%W2M8N4
M147LY?,KTYU%+J:Q/K:AD;'MEV8C:J)\UJ^:K[24@   $<UY?*JP6.2LHHX9
M)&M>JI*BJG#57R5/8>'3#451JK15LO%9'#'453'.>V%%1J8>YO"*JKY>TE0
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MCO4*NUH^1EP@I8I&0ND7P&.:G#]OFY?(Z1754=%15%5/GPH(W2OPF5PB97_
MT.D-:VG5=3<8+0Z=9*!6)-XD>U/6W8Q[?FJ24        $;Z@WVJT[IY]?0Q
MPR3)(UFV9%5N%S[%3V&#TDU74ZRT='=JV*"*9TTD>V%JM;AJ^Q55?VDR  !R
M*MU!?-7.5VE(J1R,?SZ0KH_FKZWX7O0Z/I:>XU%H9)>8Z>.L5SD5L"KLQGCN
MJFV
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M#YSEOF?0?;L
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M-%7PM<V*J@9.QKNZ(YJ.1%^LRP
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M9Z)EMM%#0PHC8Z:!D+43.$1K41._T&6
M                                               >4-1#/N\&5C]J
MJU=JYPJ>1Z@                       H]K7L<QZ9:Y,*GM0U5!IRTV^XU
M5?1T4<595*U9I45<OV_-SSY&V
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MN['=[6]_SFAZ+25M3IVOJ;E+)+++7O?&Z3NC%8Q41/=W.@
M
M                      !4145%1%1>%12']3+G#;],U5 S:VIN%/-!3L1%
M3<]6X1$5.$Y<G?!SFU:3ETYT>U=<)%5M9<[?OD;A,M5B/1/61>?G&9\&EL+K
M!=%>C7*Y*=9,MSE=KN_M-5T3?.WJ'JF.)7)2K?*S<U'8;V=CCZCOX     ,:
MY/J(Z"H?1Q>-4HQ5CCW;=SO),^1Q+J76WZSVFIO%5<:^@JH?7AHHZEVR7<Y$
M5%5JX3;DNZLU]TJ.D5!<*:OK*6::VT<KUBG<U=SG1JJJJ+E5Y[G1NGE@JK1:
M8'U5WK*]96-DQ.Y5QEK>.57V$N      !KM0R5\5JE?::;TFL16[(O$1F>4S
MRON.$=3KU>])3QU?QK<'U+F-;Z$M2]&;55WKY1<9XP?1"=C@?5W4-^I.HE#;
MK955D-+-54\3EBJG,1&N1N5VHJ>TLOE;J/3G4J@MZ7*XUE#<ZZ.E19*MR)$B
M[<N1N[W]C.OTVH-(=1;(ZIN5PJ[==JU6>'-5.V1M;C.&[E_E=L';::5)Z>.5
MO9Z90Y3U[N,CJ"*QQ9WUT:/1$<J9V/1?H\O,]NIU34Z=Z+-J++NI:MK*7UJ=
M_A.555B.7<W'D0B^,U9)H)MYM]XNSJU*UL"T[:US4V;<J[=N]OD==Z5ZJ=K+
M1U->9(6P.EDD9L:Y7(FURIW4BGPA+W=;-;[ MFEJ(I*BM6-ZPSK$JICSPJ9(
M;JJXZCTY9M,7J.Z7*JDK9'+-2OJW(UJ-QQG=SD:NO>H;53Z9U-!<+A)#61OJ
M9Z+TMS8F8VX;WY3GV'>=,UKKEIRU5TC=KZJDBG<W.<*YB+C/GW-D
M
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M:FY$7*^>3/
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MJ*;&XQM;CZ"NUN,;4Q[,%4X[
M
M          'E/4P4^/2)XHL]M[T;GZST:Y'M1S%1S53**BY14*@      !41
M>X1,=@
M                                                      0.^]1:
M*W:MH+$QCI)YYEA>K'-5&*F.Z9RG<LUM:K7JJOMM-+6TGI.QZ-C6?#L\*J81
M<^1NH;];;-+;[+-/$R1D#6M596HF&ICS7/X)F1:DMSZ]*5U1"QZLWHKI6IQ]
M8MVHZ"NN#J*&6/QT9OV^(U5Q]&<^96]:BH;0^-M7+&U7N1O,C6XS]*FQH:N&
MMIFU%-(R2)V<.8Y'(N%QW0]P
M
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M7S^DV@
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ME@\-&N5V57YRDV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M70/W1N9O1?#<SC<J>?T$I
M
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MA\5LJM5WKHB)A/SF)I_6MLOMU=;Z)E2V=K'/59&(C<(N%[*OM),
M
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MJ-Y7LGTDETOIO2=NOOIEDF@?<O!6-495^(NS//JY7S\R9@
M
M                                'E5QNEI9HXW(U[V*UKE3.%5.YRE>
MD*)JZ;43*N!+A++',Z3#^7,1,<9QY>PW-WT#5WBXT%3<J^&9M*]7(W8K<YQG
MMCV(4INF=)2ZIM][@=&VIHW2.C7+UQN:J+PJX[+YE:GIQ#+K6CU*V6-*ZG21
M&N7=^&CD7C./PU\CWZD=-;1K>GC=7PM6OC:V-LSI'HB,157&&JB=W*>FA]$/
ML#'I6U,=2YS'QJK$5OJKCC]A&ZKHU14U^=7:>DBH(7M:Q\;W22*K4QE,N5>^
M"4ZDT%;[YI:"SU+&JE.CUA<KWHC'N1>>%RO?S,.'0#DT,FFJBIBDI$IWTZ(B
M.1$1V<\]_/VFYT;I6'3EE;;6*UT#8HXD1JNX1J83E5R7:8TA;-/5ESJ:"#PY
M:ZJ?52+XCW9>[.5Y5<=_+@CG4/I7:]65C+BUC(;K'&D<=0]\BHU-RJOJHN%S
MN7R\S>:'TG\G:=R3RLGGW+A[$5$1JHB8Q^93?W2WT]SHI:6K9OB>BHJ95.Z*
MGE])S"T]'X;(^OALT\--;ZF!84A7>]4W?.]9RJO)ZV#I%3T-AK+37S15%(^G
M=# UJO;X:NSE57.5[EU3TCI*JTVJAJ9(GLM37-HN7IX6Y45>R^MV3OGL;+5O
M36CU%9+12SJSTNVTZ003*YZ(WAJ*N$7G.WS/6_=-[=J#2<%HO365+X:>*GCD
M1[V(C6*U<>JJ>P\^GV@)M+5GCS5<4Z-W-8C&JFUJHB(G/T%VC.F]%IG44EVI
M]GBNC='PYZ\.5%\UQY'C4]1ZB*I=$W3%W<B)G<D:X_P*,ZD5#N^F+NGTQK]@
M7J34(Y4^2]WX_P#=K]@9U(J'+CY,7=/IC7["GW2:A'*BZ7NZ\_S:_859U(J'
MKCY,7=/>L:_86_=*J<+_ -%[O^C7["]G4B=RK_T8NZ?]Q?L+?NDU&?\ 9B[_
M *-?L'W2JC/^R]WQ_P!FOV%4ZE5'/_1>[_W%^PN3J1.K%7Y,7=%3^HOV%B=2
M:G/.E[O^C7["[[H]0K%7Y,79/^XOV%OW2JCRTO=_T:_87)U'J/#W?)B[YS_-
MK]A;]TJH_HM=_P"XOV%WW1ZC9N^3%W^CPU^PL^Z54_T7N_Z-?L+_ +I%1X>?
MDQ=\_P"XOV%J=2JC^B]W_1K]@^Z54?T7N_Z-?L*KU*J/Z+7C^XOV%7]1ZAJ_
M[,7=?_IK]A3[I-0JI_T7NZ?_ $U^PN=U(J&X_P"C%W7Z&+]A:G4FH5R)\E[O
M_<7[ [J14-7'R8NZY_\ =K]@;U)J%=A=+W?^XOV!W4FH:['R7NZ__37[ G4F
MH5?]F+O^C7[ _J34([":8NZ_]Q?L*+U)J/+2]W_1K]@^Z54?T7N_Z-?L+F=2
M*AW_ .6+NGTQK]A1.I51E472]WX_]VOV%6=1ZAW_ .6+NG_<7["Q.I51C_9>
M[Y_[-?L+V=1ZAV?^C%W3_P"FOV%J=2JC'^RUW_N+]A<SJ14*BYTQ=N/ZB_86
M_=*J,_[+W?\ 1K]A<WJ14*BK\F+OQ_[M?L+5ZDU&?]F+O^C7["OW2I\?[+W?
M^XOV%/NE5']%[O\ W%^PK]T>IVY^3-V_1K]A3[I51E?^BUW_ $:_87?=(J/#
M1WR8N_T;%^PI]TJ?'^RUW_N+]A5>I%0C47Y,7=?=L7["U>I50B?[+W?]&OV%
MSNI%0C<_)B[K_P#37["U>I51_1>[_HU^PK)U'J6I_LS=EY\HU^PHG4JHQSI:
M[Y_W%^P?=*J/Z+W?^XO'["K>I-0JX^3%W_N+]@?U(J&JB?)B[K]$:_8&]2:A
MRX^2]W3W^&OV%7=29VNQ\E[NOOV+]A1O4FH<N/DQ=T_^FOV!W4FH1RI\E[O_
M '%^P,ZD5"KA=,7?Z?#7[ O4F='*GR7NZ^_8OV%6=2*ARK_T8NZ)_N+]A1>I
M-0BK_P!%[OQ_47["GW2JC^B]W_1K]@3J54>>E[NO_P!-?L+F=1ZA47.F+O\
MW%^PL3J34^>E[O\ HU^PO;U(J'-5?DQ=TQ_[M?L+?NE3_P!%[O\ W%^PN3J1
M4*UR_)B[<>7AK]A:O4FH_HO=_P!&OV%[.I%0K55=,7?O_(7["S[I51C_ &7N
M_P"C7["]O4>H5F[Y,W;Z/#7["W[I-1_1>[_HU^PHO4JH_HO=_P!&OV#[I51C
M_9>[Y_W%^PO=U'J$:B_)B[KQVV+]A8O4JH\M+W?]&OV%[NH]0B9^3%W7W;%^
MPL7J549_V7N_Z-?L+G=1ZAO/R8NZ_0Q?L*-ZDU&41=+W?G_W:_8']2*AKD_Z
M,7=47_W:_8$ZDU"N1/DO=_T:_8'=2:AKL?)B[K_]-?L*?=*J/Z+W?]&OV!>I
M51_1>[_HU^PJSJ3.YRI\E[NG'FQ?L"]2JA'*GR7NZ^_8OV'K0=1)ZJOIZ9=-
M76-)9$8LCF+M;E>Z\=B>P2>+"UZM5NY,[5[H7@
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MD'\TT>B0?S;1Z'!_--*I2P)_Z-I3T2#^::/0X/YIH]#@_FFCT2#^::/0Z?\
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MMI8&JBI&U%3E#V3@
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MA'=;325\"M6*IB;*U6KE,*F3,.4=>-5UUDL[Z2RU,D-R<V.1GA/VOVJ]47_
MZ;;(I8:5&SS/F>JYW.[F4  #F-]U;->-9QZ=L$ZK&ZG\5U3"_EKVJ[+=OYD\
M_,V73JAU%05,D5]JZRKB\-RI)/\ RLMPG?V9)G=)_1;965&<>%"^3/LPU5.6
M]*]07;46M=0NJ*R=UKBC@=3M5^YF<8=C\Z*=;*.<UJ9<N"J*BHBIV4  H][8
MV.>]<-:F57V(<8TY?=0WGJS=:6FJJJ2ST%8C7M:_+$8N[&4]GJG: #0:WO[]
M-V7TZ*F2I=XK8]BOV]\\YPOL,O3]U6Z6QM7-$D"JY6[=V>QLT<U6[D7U?:&N
M1R9:N4*@XUIS55WO'5N"BBJ9_BJ-D[)6(_+-[=V,I[>Q+=,ZIJ*S4KK551;7
M*U\C55^5PG';'N)P
M                                           1GJ'J9=*:?2XI$V7[
M\V+:Y51.47V?00WI/8ZFT:5EO%6Q9[MLF8JRJCG*U%RB;\JN/53C)YZ*ZDU]
M[FO%--0QQU5'2+/L255^CGL-/=3ZBZVF_M]#B;76JD6=[$D=RN%5$5?L-AI?
MJ)4U^E;K<ZNBBB=04R38217;LJO?ZCQTCU,DNE@U)>;C2QTM+;%8K%:YST>U
MV>53&4[)Y'I3=1D^3EPN5PC93-WL=3;5<[Q(W*F'<)E.%[*94VK+M8M$55\N
MMO8W[^U86NFWH^)^W:[C*IW7@U'0>LU!<;945=X9*L?C2,1TE3XGDQ43NJ^:
MD^UO=8+1IJNGJ9/#:Z)\;7(BKZRL<J=OH.']*KI<K?IZLU+1T;:R*:GD5\TD
MNUVV-SLKSZRXVG4J'J!0LT';K[<WMIUK8G/B:C7O1RHJ\<)E/SFBTAU&K[UJ
M5*2"@BDM\TR-2H65<M:N>4:IU69ZLB<YJ95/(Y;HWJ56WK5%?15EOAIZ&DJ9
M:=\[9%<OJ[L>K[U1#,M?4.:ITG=;W)21-;27!U&UN]RHY$VX=[<^L:J^]4IJ
M/0$-[=:J:>:2XI1^CR/56X5JKNSCOP9O434M9ICI_234-L@I:FKJEI&T\+]C
M6*YLBHJ*WC.43ZR.R:EN-IZ.43+\QR5=PBJZ=[WS+(Y,N>B+E,YX5#SM&H9-
M%=/=/W"VT,-2VKA<L\KEV+AJ\*N.5[J;_5G4U;=IBQ5+K;35;KO2K-X$JKM7
M&..W;GS,S5NL7Z8T71W2@M5+&M32PSR1QKL1JN5O'"<XW&IO?4ZMIM,-NT%#
M&YJ-C1R>*Y$R['Y_,ZS;9Y:BE;)-&D;E\D7/D<9^$O:KO66JW34#9):9E?"K
MH_%1K>&R97"J>G5F]6^JZ;V=ULIX&P5]<M+"QD>QJ.<V1O"83"Y.<MBK:MVB
M-(2-<Q+9<6I5-1Z*CHY94<J.3.UR8=VY.@]?WP6/2UCL=)&QOI+)H(6M;M1,
M;.R)PG<Z5TPB?#T]T['*F'LH8D<F<\[4-+J77T;-0TVG; QE;>*EKW,A=NC^
M9E7>LJ(WA&KYG-J":JUQU9I(+M3M@BCI7PO;N21$<Q7KV7WJ=2K=7K7W!]NT
M]&VKD9#XRKE8U1$X7YV/:A#.G&KK_7VN6[5%*LC%ADQ&^I5S45KN_*^XV>G>
MJJW+3EFJ%I8DNE74+%-3;G*D;=[FHJ.QA>$1?SFQONLJNHN]';;#3MJ;A#,U
MM;#XBQI$CL;>5PCLIGLJD^MSIW4,#JR-(JA6IO8CMVU?9GS.>:EZB-EU*S36
MG6-K+@][X94571+'(U5RB*J(B]EYR8UAZB3W&QW9S:=BUM!5)2NCWNY5%1%Y
M7\_8AO0BU7>HNM9J%U+XK6U51#ETK5QE$7'*Y_".Z:@O=#8:!:NYS>#"KMC7
M;'.R["JB<(J^2G&]3=0[I=M&-NM!0L^*;DY])%,V96[G8<U4VKA4Y:O=,<&\
MZ85-#I7IQ;Z^X*R*NJF3-1-BN61S9'X17-1?=W-;J[6U]EN6F8K?1[8;K4K"
MUS*E6?A-;VRGM\RWJ9?KVE;I2PV3QI+I4)-%.QM0L:H]J,5,NRB+^%SDEESU
MC'I2PVBWWZ18;Q+1QKX;MTBN<U$1V7M14[HO.>3SZ9ZSN6I*FH944$<5,V5S
M4E27<N$3*<+[26ZLU!1Z:M#J^XR)'"CVQHNUSO67M\U%4C&G=27BFLTU9J&@
M;2QM1Z,=X_B[GIRC>%54X1>?<:O2_4>KK=%2:CO%#%1TTD$RT^V17H^1BN1&
MX3E,[5Y5#WCUF^X]*KC?*Q/1&U-OJ70*QSG>LU'IQYIV0@?3J[W"QZ7OVHX:
M1M13SP13RSODP["*["_RE[DFN_4^NI=.4-TBH8GTSZ=LLCUE<F,XQQW7N>VH
MNIM7:+79[HZBC6BJ**.ID>LCO5WHF.$Y7NGD9&KNHU99KE;4AHHY8*FC;4*J
MR*F%55\OS%G4+J*MJO\ 361;/1W!)88JA6SKE$W*ODJ8X-=UPU35V=U#9K!"
MD4RU4:KX,BPKM<UWLPG?![ZYOM_TMH&TTLL#UNE;-)2(JU/K;G[]OK(OO3S-
MMIC5;]-]/[=+J][J>MDBD5F]SIED<USN%<W/DK>YK]-=3*NOO,[W4<?Q*V1%
MDJO$<JL8N["HSOSCM@\KSU)K+C;;_6V"E9/0VF?P)9TE=&J+OPG"X7GW%WP?
M[<Z2CNESK(FI4R5CGL<N'.1'-1>'=_-39VJ>F?U6IFT^W/H4F<-QSN<=,
M
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MRJD5Z(VFHKKA7:AKG2+(RHE@B3>BM6-4:Y.%RN?67S.R@
M
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M8U&I^9,'H
M                                                    O*8,&BM=
M/1U+IX=^]S=JY7*8X^PS@"R>)LT3HWYVN[X,:V6V"W,E;3[\2.WNW+GDS
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M'L7)4MWMW;=S=W?&>2J/:JJB.153R12H
M
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M-QTB=<JK1U!7WBKDJ*N9LB/61/6XE<B9_,B$W
M
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M^I_XKR4
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MI*J=7[695K&HU%5$;][X3RR?17672+M9Z,BMS$>JQU#*A-J-5?58]//_ 'B
M?!KUO3P6"#2UYF;#=J9DM0^-VYS\.E3&51%3L]/,[\JHB*J]D(FS6E)-JJHL
ME,^.2HIY(V3-PY%9O1%3RQYG!(:F'_RF&Q;TW_&STQA?8IW_ %-K&AT]>:"B
MN,L<*537.1SD<JX3Z$-'U@TY8-2Z,DJ+I#3(JI$L=8L"/D8U7HN&JJ91%S^T
MT/P89:YVB+A%62S5#(KI-'')*_<J,1D>U$]B>XZAJ&V17:US4TS$?E%5J*U%
M];"HG?Z3YLZ"7F;IYK&?1VKWNM[(J?9 V1RO5TTLC'-;AF43*.7D^FKC1LN%
M(^)SU:U[7-W(G*93!\RQ5MQHNOLMC^.[@^WTUPI8V4SIG>&K7(U53;G&%R=/
MZV7A6,M6GJ-<ONB31>&U53.S8N/9Y^9N-.: L_R;M\=304J/DIHUJ&+ Q?$?
MM3*NXY7/F<:Z.5DFC.JU3I^I>ZGH:V:IJD9E=N$1R-]5O'X*$M^%741-T4FY
MR(BU%.J+CRW..LZ,J8:FR>+ _?'XCDSA3'355NJM0U-CCECEJ(FM66-6N^:Y
M$[Y3"_.0^?.KKKCT[ZH/O%LC?3TM^J88D1C_  VJD;&(N$:N>ZKW.W=*;9LM
MLM\>]SI[O''-)N\E3=Y]U^=YF3UA>V/IM?'O7#4B;E?^^TY]\%*:.:PZE6)V
MY$N7_P"BALNJMPI:7J#;(JB9&/=0*Y$PJ\;WG3+K9[??K*E%=:.GK*9[4<C)
MXDD:CL<.PJ8RF3Y1U927[H_7T]JB=4W#34TC(XWU4V&)+)E7*C&KPJ(B\X]I
M]0=/$C;H^WI"[=']\PN,?^D<2(
M                                                       P;U;H
MKK;I*2?_ $;U15X1>RY\S3: T=0Z+M,]#;W.>R6H=4*Y[6HJ*Y&ICA$X]5#$
MLN@+9:=83W^!7.J):;T=6*QFU$RU<\)G/JH3"5N^)[,JFY%3*>1S6Z=(K;<M
M0-O,]PKFUC96S-QLX<F,87&?)"4W73+;EIM+//55'A+$L3Y4<BO<B^:Y[D/T
M]T;M^GZB>>W7>YM?,]'O:CFM1RIGOA$SW-I-TTI*R[4M?77*OE6G:YJ1/<US
M'91>Z*GO/+7G2VWZTD@^,:NJIXX8&4[60[<*UKE5%PJ+SR9-OZ?-MU,M/!=[
MF]F<Y=*F?9_R*Z=Z<4-B@J&05M7423POIWRS*U7[7=^<>Y#!TUTGMVG*^:LM
MUPKEFF:C7Y5K<HBY3LB&1]S&@=JAE_DKJQU6V9LZ1JK5:CDQ[L^1.WQJZF6/
M<J*J8SGDYK+T=M3]2_'K*ZLCK?&?/ZFQ/6>JJO.,^:^9EWCI?1W>NIZRKN-=
MX].Q8V>LU>%]ZH2NML%/7V)+76*KX$V\N1'*NW&._'D5T[I^DL%J=04";(7/
M63AJ-Y5,>2)["%0](K;%J!+TEQKEK?51<JWE&JBHBKC/X*>9TJ!BQQ(U5553
MVFEU?IV+4ML?05$\T,$C7,?X2IRB^W/<CVBNFE#I"J66V5M6]KW(Y['[41V$
M5$RB(F>Y/CF>I^D-KU)=_C&X7"M2=&JQN-CL-W*N$545?PE)]:*'T"C\!99)
M><[I%RO9$_Y'--3]'J.IO7QO8ZRKM]2Z-L#H:160LV(JJJ\(G.<&XTOTVIK+
M=W79:VKFKI&HQ_BN:O"*BISC/X*>9.+E2I6T,],YRM;-&Z-53OA45/\ F<^L
MW26W6>]SW:BN%<E3,])'L16M:Y4SA%PF5[GM4]+J&HOT=Y=7UK:QCW2(C5;A
M%7OSC/F= IH_!IXHU<KMC4;E>ZX3N1S6>BK9JN)6W!B))M:U)6QM5Z(BJN,J
MB\<J29$1&X\L8(#JOI?:;[6K60SSVVH56KNHFLC54:F-JKC..R_F,1-%77P'
MTBU]9X+VJQ9?2/71%[K]*9-GH[I]1Z;CKWLJZFJJJR-&/FJ-KGM5,X5'8SGG
M]B&H^X_:_E%\>?&%<E=XJS?@?.7WXS^TWNL-"4>I[1#1U=341R10I$V>/;XB
M<HN<JG?@C[.G-54426VMKZWT)J(U'^,BN5&]N.WDAT&Q6FFLU VDHV-9&BY7
M#4;E<(F5QY\&P(MK71%LU5"STAJ4U4R1)4J8(VI*JHU41%<J9\_V(1ZGT-<[
M?$M-2W*NG@QA)):CUN>57]I?IOI906R_2WV>JJ9[C-)'*Y)=KD1S.V%QGV>9
ME7+IO27'4L=ZJ*^M6>*5\L<66JQJN[HF4RB$WIH? HXH455V,1N5]R'.KITC
MMEROC;M)<*Z&J:CFM\/8G#E55YQGS/35O2RCU5 R"YW&N9$U&HB,<U<[<X7"
MHOM,BV=.8[71K2TMWN3HE55RZ1$7GZ$,W1F@*+3%PFKHZRJK*B6/PW.J=KEQ
ME%SG&?)#)UOHRAU;+:WU[G)Z!,LK-K6KE5QWRB_R206RCCM]!!20_P"CA8C&
M\(G"?0:C6&FHM3V^2BJ:B>&"1NU_A*G/*+V7Z#2Z&Z<4.CJAS[;6U;V/>LCV
M/VHURJW'*(B9/#4O3"AU!=H[C67"M9/&Q8VHQ6JFW*KYI[R<6ZF]$I6P[W/V
M\(KERIJ-8Z4H-544--<$PD4J3-<C&JN414\T7VFQL-LCLUJ@H('O?'%NPY^,
MKERN\OI,\
M                                         #(      !17-;W5$^E2
MJ<]@41R*N$5%4J !E/:        "B.1>RHI4HBHJX14R5
M
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M8O1',@=3[&X=E,HN?+NGM.P
M                                                           Y
M;UUT95:CM#;E:MGQG;X7^CJJ.<J.<K>S4147MYH6=$M=LO\ 0NL]P26"Z6W9
M1.94(V-97,9A[F-3E4RU?(Q]<]3I:>6:FTXD\U1&NQ? C9-AR.5')CGR0SZ;
M7E9!9=MP94_&ZRY2%8FMD\/'SMG"XSGG!A6[4.K[=%6.OTTDB14[Y&R)2M8U
M7)RF%VISC/!H;%U%U1=[=0UU/Z4E(R19*J9U(S8Z)KO61'(W"<(O/!L;UU/K
MZJX4<>G(JR6*27#EA@9*BMXQRF?>:WJOJ74%0ND[?9:AT5?7QRMJ&.@:YS7Y
M9A'-PJM\^,'06ZAEL>G+10ULGCWF6CC1&0HW<KVM:CO4X7OGC!"8-2ZAO746
MU6J*O9Z)+%,LK%A9ZCFM<J(Y4;E%X[%UWZC7FDU;%9J-*J5W@J[9%3L>JJBN
M153C/X)B:BU[K"RZ6AK:F.N2I=6MB5?06IZBM5>RMQY=R9T&MY[QJ=U+:TF?
M1HUKO5C:Y,9:B\IGVDZNU?#:[;55M2Y$BIXGS.3*(JHU%5<9^@Y%/U%N]=37
M.\VYT])9:%GI'W^!G^41^R-V%1R\+Y^9KNK&K;A=.GEH6@G6.*\T*R21OC:K
MG\M5/)<?F)UTCLMRM&G;>ZKJ(GQ5-/#+M8U<I][3A<IWY(_U_P!65]GMK[;:
M'O96RQQS,5L;7\>(J+PJ*O9OL/"]UMRTMTNG6^5T#Z]U6QS7-:UOJ.1$1,*B
M>:+Y&BH+[<-%=*:26TMFI9)+JL;LQ([+58JJF'(O\E"<7#J&VATA25<[WMN<
M\KHO1U1B3-7UMJJQ?+A/+S0OZ7:IO6H;G<HKI#5QP0,8Z-T].D;795<[51.3
M;=7[Q)9>GM[JJ9RLJ64SG1NPBX5,>2\$-^#I8E99JN_5NV2KNSHJQ7M54RJM
M7*JG;S\N#LBHBIA3EE5KBMOFKDL&DY'POV.5U4^-DD+'L5VYJN3=AV$3CWH>
M&D.HU5J'3\LD/CMJ&2N3TE\3/#PB)ZO'&><FLTOU&O=TTK'7S/G:[+U6I?3L
M;&_:J^JBXQGC]BE\'4RYU>BJ6Z0+41O>LB^.^!FV7:KDVMXPJ\>7L-Q4ZUN3
M>F%%?4F='5RP5$CE?$Q%RQ78XQCR-$WJ5>4T;'=IG5$.V!)5EDIV-2;/FSC"
M_P 3TNO4F[-TW0W"E6HB?+3-EPZ!F9E7'K,3'*<^1)-4Z_?;;?:J.C@JJB]5
M])'4L;!&U[L?A99W\E[)P8>E-;W!=94^GKQ4+554],ZK18HV(UC<+AJX1%W)
MA?(T^ANI-VNNHZJW5;YZA(Z-U0FR!F$5'-3/"9\S9=-M=72]W6Y4]QEDEBIJ
M)]0V3PF-8JHK>RHGO4MT[KVY5^K-412RR+:[73Q5#<Q,1-NS<[#D3GLO=3,L
MVNJVYT.KZ^%M1Z)0TJ343EB;AR[7*NU4X=RWWGG1=1W1:=AGN+Y$K:J)KH&.
M:QKE7\+#>,]T,?1FO+O6UM947EM33VN&=6[ZB!L3=BHNU=V$3&<<Y-3U+UU?
MJ6QU$UKGDI7H]OALD@8KI&J[YS45%RW'F9_42X5=HZ81MK*Z"6Y33PR;6;=V
MQR?R<)[_ "-%K>6X: Z<T%JL\S8[A)<TW(QJ2>H]C_)R*O=$YP;NZ72Y:9Z-
MT<%^G1;A5K/2RKL1F_=XF$PJ)Y8[)DCUMU!5Z3Z;:<J[/XE.Z;Q_'^]H]96M
MD<J(F[//*]CMFB[G)>=*VNXS[O%J8&R.W-1JY7VHG"&Y
M
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MM\U-:+/4M621J.ECECE5KG)N[ICUN<G7+/016NV4U#3HC8H&(QJ)GA$^DRP
M
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M4U#34LLDE/ R.23&]S4Y=CL9
M
M     /*JIH*N%8JJ)DT2KE6O3*'C;;90VN!8;=204L2JKMD+$:F5\\)]!E@P
M[E:J"YM8VXT<%4UF5:DK$=MSWQD]Z6FAI(&04L3(86)M:QB81$]B(>H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  5<(4:Y'9QY<%0           4<Y&IS]!4   !5PF2C
M51R93L5
M                                         /*K8Z6DFC9\]S'-3RY5
M#@-'>;_-U8NVGI70I04]13Q(K7+OVO1%7G.,\^PG%+0:CLUYNM2BP/M<;VOC
M5\BN?M1%SQGN9&E]1774E)J2*K9 Q*69K*98VJU5:KE^=E5YPB&AZ0W*X_%F
MLYZM[7S4MYEBB155R;<HGM]ZDPZ7ZAN6I+17U-W9 R:&L? Q(6JU-B-:J9RJ
M\\J3'*>T#*>T YKU(U)60:EMNGJ%8T]/A<]5<BHJ*U57A<\?-/72FB);1J*B
MND=5520N8Z29LM1N1'O:J*B)CMRAT5%1>RC*>T  C^NXZM^F:Q;8K?3$V>'N
M7#?GMSG\V3G_ ,'WJ%4ZMM]RIKUX3;C!720QI#&K6K&UC.5RJ\Y53KD\S(6;
MY%PW.#@'1K7-[USJNKGN/@-M[*)\K/!:YCO$8YB)E%5>.5.EZ0U/<[MK"ZVZ
MKC@;14U.R2)S&*CE<N,Y7/O4G&0G/8YO8]8WJMU_4VB>*E2@CJIH4<V-4?M;
MOV\YQGU4\CI RGM"*B]@ ,I[0BHO90%7'<XEIY]9U+](J:Z=\-,L+UB6ED6)
M?%;ZJ(N<\<J2?2]EO&F^G5SI+A(CYXJ.H<QZRJ]=RHY4RI"ND.H[PS2E^J9G
M1R55'0+-$CLN17HKE3//;@Z7TXU!<K_;?'NK(&2>&UWWIJM3*JN>ZK["893V
M@93.,@'*>H6JYEU5!IRG<C6NGBBF7"HY&2(W.%SW];V&YTEHJ73FH:^J@J:F
M6DG5FWQZC?A$]V$P3U%SV&4SW0 X]?\ 6E5JF-:73+HU:S[XJRM5B\91><^]
M#>='+K>:VS1PWQL"2M;(Y5CSWW\<JJ^2FHZ@=1[KIO7EML\$=*M%5UL%-N?$
MYSL/1F>=R?RE\CI];<8:"TS7"K54@A8LCU:F5PGN.3S:[N]Z6]7&QMIG6ZTO
MPJRL5KE:[MQGGL2W2.O[?=M.U=PE>]/05CBJ<1JF'NPG"9Y3)#_EQ?;Q07"^
M6EE*ZWT54ZC57L<UV45,<9YX>G)T/I_JJFU=9'W"C<JL9,Z!<LV\HC57C_O$
ME 147LH[!%SV&0!E/:!E,9RAJ]25\MOL-;5T>QT\+-S$=RF<^9H.FNH[EJ&"
MY/NL<#'03(R/PF*W**B]\JI,U5$[JA\_=>;O=K;K>F^+Y&MI_0HU5%<J>LKW
M^2+]!] A.>P 1<]AD93VA.>P543NH&4]H(%UODJJ?IS>JJ@?MJ(HF[5W8Y\1
MOL/7HY75-=HJ@DK'(Z9*>#<J9[^&W/?WDX147LH7L<.OUSN-#UPJZ6&5%H?0
M(51%<JKN5S<\9P=Q "*B]E*(YJKA')GZ2JJB=U 543NIROX05;7T6GK=-;'H
MUZ3N5RJY4X1BKY*2?I15SUO3VRU%8Y%GDB<KES_7=[26@YQI76%YN>M%ME7%
M2MHD27UF1JCO5SCG/N.CY"<]@JX[A%SV&1E/:@"+GL,IGN@5<=P,I[0:?5]Z
MCT]IRLNLRXCIT:J^KN[N1O;\YQN]:BU3=+C3W.UI1K%X?WM%5R(K5RJ93/?"
MG:+35U%9;&R(C/&14:N4PG9,_P")S'I!U/N>K]1S6RYLI6JR&27[S$YOS7-1
M.5<OM)MU&U=!I*UT\\R^O52^CQ>HKO75JJF<+[B$1:UO5D=9:^]MI6T-UJ6T
M[5C8KG?.PO&>/,D^NM?TECM%!+ YRS7)DGHFZ-517-VISSQRY"+QZ\NNGJVR
M2Z@;3MH[PGBM6)BN<C$1%7SX^<AUZAJ8ZVBIZJ!56&>-LK%5,+M<F4_Q/8
M                                                     ^:;C65=
M'U^OJT2-57UE+NW-S^ W!TRPWB[5%3JR>K;&UU!X;J948J(JJCLY]O9#QZ7Z
MPNFJG:KANRP*VWU+(8?"CV\*K\YYY^:AJND[I*>DUQ5TV/28KY,C-W*<N1%X
M^A5)%T8U9==7Z?NE7=5@](IKC)2L\-FQ-C6L5,\]\N4@6D]5ZOUE9JF>);>C
MX9)5]:-6)AGU^TEG277]1J#1E557+'QA3133OV1;6[6KQA,]R*S:PU#<-,.U
M=;GT7@+%)4,;(S#_ +WE.6_2SVG2>DM]O&I-*TUUO7@?Y3&CHTC9M7YSD7*?
MF0FI\W]1[1=J[K;8H*!:=)Y6U"Q>(N$Q]\7GCV$XNVJY[554.F5VON,].UZ[
M&;F9;G=SG^HOD:^V:[J].7E(+RQ4MCXUD5T4.5WJN$Y54]AXU^K+I6:>AU#1
M1M575*0*BQ+G"9_!_,;:\ZJU56:5L-QT^RF;/45_A5*5,*I]Z151<)Y+P=/M
MCYY*&)]5M\947=M[=U,D&EUE4K2:;K)T[MV?M>U#Y\OL3^FNK*?4= F:1],K
M9%=]\7?(YWEQ[$\SK>M;C)=I(+30N8]SX652KY>:=T_P.==#H_BO7-PH*;_1
MQVV21N>>=\?F3[0VK[O=^HE]LEP6#T6CI8IHMD>%W.VYRN>>Y&+AK'4ERZEZ
M@TS0K1^CT[XXXM\>%]=J=W?2IG].=;7"+5]WTUJ'PEFIZB*GI_1X_5Y1V[*Y
M^CR&G^H5[K>K$VG:I:?T!*VI@9MBP[9'OV\Y[^JA@U6N-1W#JK3Z6IUI/1)O
M&^=%A?4\14];/]1"S2NJ-3TVM?DK=%HEEF@?7,6*-<;47:F7>WU5XP96C-67
MVS=09=*ZI6E5K:5:A/169Y<YNWUEQ[5\C-ONO+E:NJ=18F^%Z C(-GWO+LOV
MYRN?>IXZFU]=[1U46RQ+!Z!)-31-S%EWKHS=SG^LIK-0Z]U"_J?-IFC6E]$?
M5MIV[XN<.1/PL^\QJ36NH*'7DNE:I:55JZGT>!61Y3C.<NS]'D;/1>J[_0=3
M&:;O:TJQ5T]1X/@Q_@1M>O*^2^JAVHU&J8IIK9MI]N_Q$7UNV.3YZZ.6J_IH
M26MHG4?AQ).]-ZKG+5S[/<3CIEJNXZDZ<W5;JL*SMHJER^$S:GX2)Y^PC/2B
MY36?2FJKE0[?2Z2VNFCWIENYNY4RGYB5Z2ZA7B[:"O-TJE@]-I*-)F;8L-W*
MKO+//8C5EUAJK4VE]17%BT/CVW8D68U:GK9[IY]B4Z.ZFNFT)=;K=4<LEJ?#
M3RI%#^$JHU<)GE,J1.OUU?Y-*W'5]O=2>%257HK6OC];"JW\'/L?[3J_3*]W
M6_V1]9=TB1Z3.C1&,V\(C53C\ZDP/F3J/1UL_7J5U&L7$]&OKK_5C.B776LS
MK['IAB;JM)4IY\1Y:F[&,+GW^PU5+U!J]-W>[4%UC5*>GE1D+F0YRU,YRJJF
M?(LO&JKLR@GO='&UR,3QH46)556N7CCSX4ZSI:XONEDHZF5JME?#&YZ*W;ZR
MM15X_.;8^7>K6E[KT[O<5ZTDV%UO>QE.]LZK+)N57.<N,)QZJ<G<.F.LJ#5M
MBAJ*)96O=O562L1CD1'[>V5(3UU_VDT;_P#-HO\ %A,.J3E;TBU$YO=*"0A_
M0*"-_3ZI5ZK]]AA5_/N4YM0SOBT-U3BC3,?QRQ.WLG0[!T$IHG:$J&.5=KZM
M7+SY^'&0KX+=3*E)4T^$\%:R=V<>>UGF?0QR+JOK.^66_P!NMUK6F\&JKH*5
M?$CRN'MYYS[S4ZGU+JC0&K;2MS=0K9[M614S?"9OD1J*W?GMCYRX4D5ZUW'=
M;O0VJU(]S:F1T3U?'V3C'*+QYF-I/55UCOMVM,\;6LIZGP87>$J)M3/=WYB/
MZ8U3KC5MYO,=N=;$IZ"LDIOOD:M7A5Q[<]CNM&DJ4D"5&WQD8W?M[;L<X_.:
MO5=RFM5L;/3MW/=(C,;=W=%^PX]J?5NI]+5E+<:B2WK!5U$='M8S<]-W/;C"
M>JO)O^KNL[]8;G0T-F6E_P LK(J1GBQ[N7M\U^E2V_SZKM^@;S+>'6_QEH)U
MC\)%QN1CN_[# Z;,OMKZ>3W^K6D5\E)%-!LROMSE/SH;30_4:LK=.ZGNM^6/
MPK7.UC?!BPNU5QVSR8WI6I]46VHN5I]#22-Z-@\9JM]1>>4Y\E(QULAF?=Z)
MM7M6M2BASL^;\YV?VY)_K/5LJ:H=I^@P^5E.VJ5=F4QE6]T7WH8O3G5%SGU9
M6V2OBQ204WBL<V)4]97,_"\_G*=3(=K:[7"*>EM]J:SQ*ESH7NE9EJ9QCGR[
MJ0?ISK>YMUU=-.7I8'.94I3PK!'QZN_.5S[D,"'6NI;[U!NVG:=:/T>*OGIH
M]T>%VL5RIE?H:>&B];Z@OM[JM,S^B^E>-)X:I%M;MC]KL]^%\C<=)]=76JU'
M-IZ^>"M0U)9D6&+#=C>W.>_"F12ZS?K"YU4%N:Y:>GIEJ&J^/;ZS51.Z*O\
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M/IU;V:C6!:IBRJOH_P W.'8_9@QK)<+K6Z4T;;M,R4GJ+(RM2?OASTV[<?\
M>.UVB&:GME+%4[?'9&UK]O;<B<X,LY#HWJ!>[KU*^(JY:?T-6S.39%AWJYQS
MGW&CT]KO4FIM:5%B5:/P&0R2M^];5RU>.<FVZ-:UN]==:VR:A6!9Z6D?6.6"
M/#<;FHG.?>IL9=45NL+W6VS3;HO#IX4F1:ANWNB)W15\U*UEPU1I/1=RJ;FZ
MA62GI)9(?":KO7:CG<]N#0Z/U/JZLT^S5-U?;DM+(TJ7HQBI(K$5=V$]O'M*
MW#6-SK+/<K];HLMI=LE.CX5RK7NPG&>>"4T.H;O?;-;X:-D<=544T;I%FC5C
M4?M1SOH3N1_I9K*\5&L'Z?N[J9RO269%@9QAO'?/N4Q=.ZON>KKD^2B=3Q5,
M;G(YM0SP_48O/&5]IO+SK9]WO=3:+4BN=3PI4+OCXQV[HOO-5:M?W2@H[S#7
MPKX-#1OFC6.G5?6QN[YY-ET]NEVU"^BO%)-1)35+FOGCD7;*C$=A?5\EX.KF
MBUS8F:FTK7V>7YM2C$7UMOS7H[O^8^:](:DN'2_J ELU&Q'6?Q9WM=2Q^(Y(
MT:YC$5RXYRU,GU92U$=53LFA<CF/:CDY]J9. =&%7[JM5G\1D_XV%/A#3R.U
M7IV!R?>DN=,J+CW$F^$7%&FE[?W]2616\^>Q3G%=,^H7HQ#,F(TJ)D[8X62(
MFOPC((VZ7H7M7F&EDV<_[AU#ITJNZ?Z85>ZVNE5?T320@
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MB[&HW_D9X
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MGC#2PP2.?$S:YW"KE>3U<B.:J+RBGE!30T[GNA9M5ZY=RJY/8
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MG1NQ,9W+PI(K%<XKQ::>OIE:L4Z*YJM=N3NJ=_/L9P +7R,C^>Y&^7*ER<@
M                                                       %LLC8
MHGR2+M8QJN<OL1#1S:OL4*2K+<8VI$FY_JN]5/J-E:KI1W:E;4VZ=L\#DRCV
MHJ93\_T'E47NW4\_@S53&295-JHO=._D7UEWH:.)DM34-C8]J/:JHO*+V4Q[
M5J.TW:=8;=6LGE3/JM:J=N_=#;'*?A"15_R<H);9<ZB@D;5HKG0JJ*Y$8[U5
MPJ<&YZ97:6'I'172X2OJ)(:>>:1\CE57(U[UY7GR0@^E):GJ5JO5#G7":FHZ
M-T*TS<K*UN]KL[454QRPS.F6K);;J+5EFNM5+/%;JIM- ^6153:U9$54;SM[
M)P>&CJ2LZ@7O4U347.>*FH;I-31,=F5JLW*J8RJ83MP9?1_6,ZZANFF;A))/
M,RX3Q0222JJI'&WA$3'">JO&?,ZGJ"[P62WK5U*HD>]&<JJ<K^93BW3ZWU^L
M=(U&I*ZYU"2-\9K6/S(N6=EW*J?X&RZ5Z]FK- U[+C+(M?34T\R2R2JY[E15
MVIG''D:C3]#=+WT\K]85-?4>.^AEJ8&N7<K7LW(F'YSGU>^#:Z0U_53]*;]-
M-XGQA9Z)'NE695>]R[USG'"^K[S34]ONU3TZN>J):RI6MGA@JJ55=ES/$5%5
M&OSGL[W9.B=%M42ZFTU+Z0UR3T#VTDCG2*]7.:QN57CCGZ3H!JKEJ*U6R1&5
MU:R%ZHBHBHJ\<^Q/<IR;K_21I46FK>UJ(ESI<OQY(CCJE-JJRU-:ZD@KXWU+
M<98C79Y[>1L+C<*6VTSZBNF2&%B*YSE15PB=^QXVN]6^Z4[Y[?5-FA:B*KD1
M4PB]NZ>Y3"J=76*EF=%/<8V2-56JBM=W3OY&=47F@IX(IIJEK(Y&)(QRHO+5
M[+V/:"OIIX%FAF1T2.VJY$7N8ENU!:[E4K3T-8R:9&JY6HBIPGTI[S: U]RO
M5OMKXVUU4V%TB[6HJ*N5_,ABT.JK+7UJTE)<(Y:A';%8C79S[.QS#JU3-3JO
MHR2)B))X%4N43E?44ZM07*D8M#0/G:E9) U[8\+E41.5_8IZONU"RN2C=4-2
MI5GB)'A<[<XR>=SOMMM;T97U;(7*J-1%15Y7MV0S::HBJ84E@>CXU[*AC7R>
M:FLU=/2QK+/'"YS&([:KG(BX3/D?.E9>&:PO-TLUWN#Z2XM<D<%,_,JH]W=J
M=D3LAVWIKIZ?3VGX:>HKI*K=&Q&M>W;X>$7A.5]IS;7\=TL_5O3JLO-7)25,
M53*ZGRK6=G83OSCCZCINK]2-TQHSXWEC\5(VQ(K5?MSN5$[X7VG)]#66[:MT
M5/<Y;A4MN#:UT:.=Z[_#1J+C<JIQE>QZ4'4NH=T@HJ^2662YU58^E5'3NWM1
M?$PN['/9.#%?;KO!T\ME_95U/QA$^::I<CL/>R-7*B.=G.,-3Z#KG3"^KJ+1
M%JN,KE6>>)7O1SE<J>LJ=U[]B42R-BC<^1=K&IE5/GG3%\H;YU*O%->JU)H*
M>YS11P3HLC7,W/X1%[)PG!VF*33NEX%2!E);HJC$JI%%M1_EE<(;6VW&DN=.
ML]#,V:)';5<B*G.$7'/TH:VKU98Z-42IN$<>?:UWV&UH:RGKZ9M122I+"[*(
MY$7G'![.<C&JYRX:B9537-OEM=5)3MJV+,J[49A>_P!1?=+O06J#QKA4M@BQ
MNW.15X_,>MNN%+<8$FHIDEB5$5'(BIPJ93N:^Y:ILML<K:^OCA5.^6N7SQY)
M[3BOPC8&3UD=:Q$5B0Q,WX_KN^T[93ZFL]17K10UT;ZI&>(L:-=G;G&>WM5#
M<%'.1K5<Y<(B9534PZEM$UR6@BKHW5B.V+%M=G/L[8-A65E/1QK)4RI&Q$RJ
MKDX!UJKZ&Y]0].>@U#99FTDJ(C47/X6>YW*EK:>@LM&^LE2-J01Y547V(< Z
MN5='<>JD+Z"9LLR4$:+M147&]WFOTG4+O99Y]>U-8W5M531NB8B6UL;E8S&W
MUL[L<X]GF;R^:ZL-DNC;?<;A%#5+(R/8Y'9RY$5.R>Q4-7K>F;J'XDJ+=JB>
MTPPS*]? 8Y4J4RGJKRF$X7V]R5T+X[?9875-6LT<4:;JAR+EWO5.3QHM1VFM
MJDIJ6M9).J[48B+W^H][A>*"W2LBK:EL4CTW-145<I^8QK?J:SW&N2CHJZ.6
MI5%<D:-<BX3OW0V%=6T]!#XU7*D4><;E1>__ .$-147BW7K3EQ?;JEE1$ZEE
MY1%PJ;51>Z'*^@,+8=::I:Q$1J00<(F,'<R$=9H:I_3V\2T-=+1SQPY;)%G<
MBJYOGE#1?!ZK*VJTQ5-N%7-5RPNC9XDKE<J^IRO/M-/J"_3:OZGT&FZ*MEI:
M-U-*LJL<KF[V*Y>6\97A#&DN]3H/JG3VF6LFJK:ZA\96J]8V;W*J9V\\^KW,
M[4=76:LZJU&G:"X3Q45/;V5N6.56JJ.1JIMRG\ON:^W:EJ-&=7:RPS225-ND
M2"F@:Z16,8^3PU5R-YY]93N55.RFI9IY%PR)BO<ON1,G#K!45W4'7^HJ;TZ=
MENM52U&M5RR,<U^[\%53">H9?3O5E1:M=WC3-<Z2>):]\-/))*N(V,1W#6X7
M"<=LF-IY+CKG7E\2>JG2VVRY5%&L;G>(Q6M5VWA53'EQR>W1S5-<S559IRXN
MEF5\TTL<DDJKM8U,(B-]G'M-=H6:X:\O59<*V:;T&))H4BD?XK=[.R\XYY]A
MMNA.J+A57BKT[='S33T],ZJ\6657*J*]B(F/^][3M)KKG?+;:W,;7U3(7/7#
M45%7/U)[SD_PBDAN&G+95PJV2+PYGL?CR58^27]/M2VB#26E[=+71MK'V^%&
MQ*UV55(TSY8\E)I454--3^//(C(N/67WF%:+_:[PKTMM8RH5CE:[:BIA4[IR
MGO/"LU59:)VVJN$<:]N6N^PRX[Q0243:ME2U:9RJU'X7"JG<K17:AK6O6EJ&
MR(QNYV$7A#PCU%:I*]:)E:Q:I'(SP\+G*]D[&U+)YHZ>)TLSD;&WNJ^1JJ74
MUGJJGT>GKHWS<^JC7>7?R,FX7B@M_P#UVI;%PB\HJ]_H/*SZ@M=X>YELK&5#
MFMW*C45.,X\T]Z&T-;=K[;;2L:7&K9 LCMK=R*N5]G"'LESHUMWIZ3M]$VJ_
MQ,+C">9K9M86&%8DEN435E3+/5=S^PS*Z^VV@HF5=75LBIGL;(UZHN%:[&%[
M>]"LU\MT-O6NEJF-I4<C?$PN,KV\CWMMPI;E3>D4,S9H<JW<B*G*?2>&HJME
M%9*Z9\GAJV"16K[T:JG%.C599M1T\M3?Y8:^:2%5='4L63;A^W.53GA#K-/?
M]-VB*"WTU33TL35V1PQQJUJ9YPB(F/,V%=?K90TD=55U;(X)&JYKU1<*B=U[
M&5;ZZFN%.R>CE26)[4>UR(J914RB\FON.J+-;I',K:^.)S>Z*UR^>/)/::V_
M:^T_8YXXKA<(HG21I(W<CN6JJHB\(OL4P-<TR7ZVTTE!J:>TQI4QN\2%CEWX
MSEG"IPO_ ")=%-%2T>^:HWL3*K(Y%,2CU+:*RI2GIJZ.2951-J-=W7MY&1<;
MQ06U\3*ZI;"Z551B*BKG&,]OI0PZ+5=DK:WT2EN$<E3OV;$:[.[V=O<;L
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M2JFS&[&,]U[GT!8)GU-CMT\JJLDM-&]RJN>5:BJ9P
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M7+Z>GCB7*YY:U$_Y&:
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M9LT-CM<=+"KU541S]SMWK;41>?S&U
M                               !R>'J55+U1J]-/C?X,=7'3L=X28PJ
M<\YS^PZP   1G6^JH=.00QJR1U34H[P=J(J>JJ9RBJGM(UIJ^ZKJ-4V^*Y24
MC[56H^5B1PJCFQJURM1RXX7MDZ6
M
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M1SX(YIX4=5;?"8CMZ89A6KYG8]%5[J_3]&]\,T*MAC3;*W"_,0WH
M
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MHIHIHU162,1[51<\*F3T
M
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MZ&IJJ*+P897YRQN,83"^]3?P1,IX(X86HV.-J,:U/)$3"(7@
M
M                     !51J*J]D/'TJ'.-Z?4H])A_EI]0]*A_EI]2A*J%
M?PT^I1Z3#_+3ZE'I4/\ +3ZE'I,/\M/J4>E0_P M/J4>E0_RT^I1Z5#_ "T^
MI1Z3#_+3ZAZ5#_+3ZE'I4/\ +3ZE'I4/\M/J4)4P_P M/J4>DP_RT^I1Z3#_
M "T^I1Z5#_+3ZE'I4/\ +3ZE'I4/\M/J4>E0_P M/J4>E0_RT^I1Z5#G&],_
M0I[(N4R@
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M[?+TKA3H5-&L-/%$KG/5C$;N<N57"=U/0
M
M
M
M                 '*_E[=).H%/IR#PMT[)7MW1<89N\\^XWJWV]T6IHJ*X
M-A=3.A\3,4:JN><<_F)N  8-]N45HM5173MD='"B*J1MW.Y5$X3\Y@:1U)3:
MEHYZBCCG8R*7PE2:/8N<(O"9[<F]
M
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M
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MR)(UF@=&CL*[.,HF>Z'7P
M
M            $1$[!$1.P&.0,%-J9SCDKA,C"9SYC'(3@#"9
M
M
M
M
M
M
M
M
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M]ON$%?'OI]V/ZR8,LP9+I3,GFB<K]\6-W![4=7%5HY8MWJXSE,&0
M
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M*N.R$$^$!IR*MN%@G8KT>^659/75,_Z/L=0T-2-H])6B%F?5I8V\KGLTWH
M
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M6ZCS^)N_Q0Y_TSBU3)TRG6V5M*Q4I:?P6NAW+C:F/+G@GG1>GN-/;;K\;?\
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M'*K5:Y$[91.<D)^$Y"EMU5IFC=_U."TMB5?+U7.1.5^@^H[(J+9J#;V\"/\
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M5NFT\2QUE1$RKIHXW32MIXT:Z3*N3#<['87/F2_5.J*+6E@TO=[<NQLOBO=
M][5DC]9J(CD15QG:IUC2W^SEM_L[/\#9@
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M:[/")Y=_<>EJL]!:H_#MU*R!F=V&Y[XQY_0AGF!;;/06U56AIF0JJ*B[<_\
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MJB*CD14X5,IW]QF
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M)#<]%P5-)._PMTCF/9EJKACD\^>Z&^Z-HJ=-;&CGN>OAO]9RY5?OCB9@
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M\U#]013,I%EE5BOJDD3:OS>$<I/IJB*%421V%7W*>I:][68W+C)<U4<F4[
M
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M[I&JRJ5)'JJN5=\O?)TWHVJ.Z:6-4[+&_P#\1Q,P
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M8G4R3U*2HU$63.U,KM^<W]GL.@@
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MBN<JJW+]V_/_ '>WO)T
M                         1;5VB;9JB2)]SC>]8GMD;MD5OK-143M])(:
M"G]%HV0M_!SCG/=54C-7H.UU6IFWZ2-ZW!)63;O%5&[F8V\?]U"6MSM3=W*@
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZ=?HHW0T<$<F-[(VM7'M1#V
M
M
M
M       !$]4:UI+/4LI*=BUU8]NY(:=[7/X547U>_&#37+55[HJ3TQ*"ME9E
M$\)E/ZW/YB5Z0U!'J2T^G14\M,WQ'1^'(O/&.?VFZ
M
M                                     +97*QBN:U7*GDGF?.?11_QY
MU+NU?<I4DJ:.MJ:>%K_G(S#N$QY<GT8]C7LVN3+?88]MMU);8/!H8&PQ95=K
M<]U,H
M
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M!7.7")GNIMVN1R9:N4*@
M  %KV-D;MD:US?8Y,H8J6NWHN4H:7V_Z%OV&8B(B81$1/<
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MNAV;?CBI_N)]I;]RR'\LU7]Q/M'W+(?RS5?W$^T?<KA_+-5_<3[2^3I?$_\
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M?W$^T?<LA_+-5_<3[2Z#I=#%41R_'%4NQR.PK$YPOTG0X6>'&C,YQYEX
M
M
M
M
M
M
M
M
M
M
M
M
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M6Q[H,N_KK]A/Z:5)Z>*5OS9&HY/SID]
M
M                 6RQLEC5DK&O8O=KDRB_F-;\G;)E5^)[;ERY5?16<K]0
M^3ME_(]N_5F?8/D[9?R/;OU5GV#Y.V7\CV[]69]@^3ME_(]N_5F?8/D[9?R/
M;OU5GV#Y.V7\CV[]69]@^3ME_(]N_5F?8/D[9?R/;OU9GV#Y.V7\CV[]69]@
M^3ME_(]N_5F?8/D[9?R/;OU9GV#Y.V7\CV[]69]@^3ME_(]N_5F?8/D[9?R/
M;OU9GV#Y.V7\CV[]69]@^3ME_(]N_5F?8/D[9?R/;OU9GV#Y.V7\CV[]69]@
M^3ME_(]N_5F?8/D[9?R/;OU9GV#Y.V7\CV[]69]@33ME1R.2SVY%3LOHK/L-
MFQK6-1K$1K43"(B81$*@
M
M     %&N1V<>7!4H]R-3+BJ+E.
M
M                       ?.FN;O4Z)ZLVNX1*U]"ZFF=*CLO=N<KT3"91,
M=CZ$HZA*BAAJ,IB2-K_K3)\]-OE3J7J_*E5M91-MK7-\-%:[>DC4]JIC"J?1
M@
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M'X]2_IF_:52YT"JB)74JJO9$E;]IEHJ*F47*
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MJ?I;+%512^F088Y'8P[R4ZA!'X436=\%X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^DZK3L5D36N555/:7@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    *J(BJJX1"U)8U7A[5^A0LC$7"O:GTJ7(J.3**B_06OD9&F7O:U/:JX+D
M5%3*+E  O"94M;(QRJC7M<J=T1<X+@
M
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M5?+N=B**Y$[JB%0"BJB+A50J
M
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M4.].@]%\1[8T<J(CT5OJIQG.$.C:=?5R66D?<=_I:L^^;V[5SE>Z>1L0
M
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M4RG*
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M>R\DZ@C\*)K%<KMJ8RO=2\
M                        *F4PO8QVT-(V3Q&TL"/_ )21IGZS(
M
M
M
M
M
M
M
M
M
M                                         /*J>^.EF?&U7O:Q5:U.
MZKCA#E<75.IJ-6UNG&6>=E5221Q/D\7*JKTRGJ[>._M-S!K2Y4NHJ6UW"QU;
M8JJ5(F54CMK43C+L;>>Z>9T!%14147*+Y@ \:RH92TLT\JHC(F*]<KA,(F>_
MYB)U^LH:C0-??[0K)U@HYZE(X94?_HVN\\>UOL*=*=4S:LTQ3W"IA=#*]B.<
MQSD<J>LY/8GL)F
M
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M#;&[:DN_.Y%7V)["6
M
M          I(]L;'/>N&M155?8A\UQ7&TS?""OS:IT4NZMI$8CXU=SM;VX.O
M5UPTOIV[1RJZEI:FN?GU*=45ZMQW5K?+=Y^TY5;9:.?KY9JB)L:NFJZN2-^S
ME45CUS^TRW-H&_"3L+610ME<VK5V(^579-E5X-GJ1**FZ_6EM K*5ZV5RJL#
M-BJOB29[(;RLU;:I=85]GI*2B]/2VOE6H;$J2JW';=CM[LG/^@$L/R8OL"O^
M_-MU0YT>.$;GN>W3*>#[CVI$BVHQEDK%PB81$^^$EZ+W&V1]+:JHNJQ/ML%)
MOJ4EC5[/#S)G+<+E,9XP3[0-UTW=:.9^DV4;:=K6*_T:G6),*B[>-J>Q24@
M
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MFN'5]/Z3;+>VF\1/$<V=55&YYPFXGT&_PF^*B(_'*(7@
M                                                 8
M      P     , #    &    !@   80    8      P
M
M
M
M
M
M
M
M
M                                           >=1,V""2:1<,C:KW+
M[$1,J1ZCUO8JVX^@4M?')6(]K'1(UR*BN[)G&.3>5]9%0T<E54N1D$35?(Y?
MP43S-;8M46F^R2LM56RH6)4;)M1R;57/M1/8INP  #RJZF*DIWSU#T9$S&YR
M^7.#G5[ZKT-KK7-D@C=0LRCZE9')M7*HB;=N>>/K)3JO5MNTSI]EXN,S(Z1S
MF,1SLXRY,IV15-A17FCJK>VL9,WP'.V(["]_J,Z&5DS$?&[<U?,O
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MZ&H9)*W=E$1W&._="0@
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MK_;;['(^U5/I#8\;EV.;C.<?.1/8ILP
M                         "R9N^&1J=W-5#Y^TU<X;7U[U31U"KXE354<
M<>$SSM3[4.W:MF;3Z9N<TGS&0.<OU'&JMJU/2O6;VO<QDWH[VN:N%PLB*8O3
M_3M%=.D-_HJZ>H1DM3$JSM5%D9A8UPU51<<I^U2"1ZCNUIZ3W:%LJO@9=T1)
MGR.61,-:B)G/;@[/JS2M SIHVGAJ*E-DR5"3Y1)%=M5=N<=CEU?5U.H.A6FZ
MFNGE9,MWD171O7*HB/3NN3<ZWMD</2G1LT4LK9Z:JDE25%PYZHYZHCE[JAV;
MI5/)4]/[--.Y72/B<KE5<Y]=Q*SC?PD*:.73-0]_=L+$3]*TU?4S3U(SH/3U
ML;I(YFT5%A683NZ//EGS,GJVY5Z-QY55Q5PIS_N&#KR-9NC-"B2R1JET:N6+
MA?FO(_K")U3T=TNCJB=J_&DF7-=ROSS+UQ;8X>EFC)XI96STT\LJ2(N'/5'.
M5-R]U/?6GQM5]/\ 0U;3R+Z+'!4/K7>*J.V[F8XSZW92^IT]%K&YZ%=:9YXX
M:6F>VL5KDC57.C3'EZW**=VMSH;;2T-M5SEDC@;&BJF<[6XRJ^W@V0.:WFAM
M,=RO,TE76RUBVZ1/!DPZ)J;>')QW^U2(_!@DG=0SLDE>^%(G*U'.5>?$.\$
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MK4578\L<]B?P,\."-G\EJ-^I"\
M                      CVOK"_4^E:^SQOC8E2UJ*KU5$X>CNZ(OL-5TMT
M;-HNU5%%)+#(V6;Q/O;E=^"B>:)[";      @/4OI]'JVHMU;"]D=PMZR/IW
MR/<C4>[;RJ(BY3U$%NTC=YJ>EIK_ %5%-3PL2/%/N:N$3Z$\T0G%%3,I*6&"
M+.R-B,3*YX1,'L    <MNW3:NN'4)=3.J:3>L#(%3<Y%PBHO;;CR]ITRMA6H
MHJB%JHCI(W,15[95%0@>@NGSM.Z@N-UJ98I)JN-D:^&]R_-[<*B>PZ$
M    "CD1S51>RI@Y34=+ZJVZOJ+[I6HI:>6>-L#_ $I[G_>TVJJ8VJF<M0E5
MITK)Z?Z=>9(I:I%:Y%@<J)EJ\<8]B(2T90
M
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M=/3Z59IE9"QW.&+SE%Q\Y>QU#3%8^XZ;M-;,JK+4TD4SE5$1<N8BKPG'F;(
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MRO5C_8G1_P#\O7_AC.TZ&_V*T_\ _+Z?_P -INP
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MU*K=$:-<C,YMRKC/]6,[;H5=VB=/*J8S;J=<?_3:;L
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M1,(B)Y)@]P
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M#8H(V,8U$3#6HG;Z#V
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MOSA!#*V9NYF<9QR7@X3U!AEBZN:8ECJ)T;+=XD<S?ZN/4XP=V
M
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MOI+H(UEVIA-^U,X_/DS
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M.V^MCCE$.AM[)GN
M
M   <[USINLU1J*AAF:[XOH:B.=-[%VN3";D1R?G\R?4=-#1TT=/3,V0QIAK<
MJN$_.>P   !Q?JG;+Q=.H6GZ^WT%:ZEHX)HY7,@<Y%5<HG*)A#L%L1S;=2H]
M%:](F(J*F%1<&0
M
M           4PG/'<J
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
*          #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g111069g99a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a01.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M O_$ !D1 0$! 0$!               !$4$A,?_:  P# 0 "$0,1 #\ ]4@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                           &
M)=Y7P6FMFB=RR1P/>UWN5&JJ*!E@\,_AIX@_I)-_[O#_  #\-/$']))O_=X?
MX N/<P/#/X:>(/Z23?\ N\/\ _#3Q!_22;_W>'^ &/<P/$M'QVX@4[D5]YCG
M1/R9:2+2_L:BDZQ3TF*Z.9D>56>">%5TL]"JL>U/?R.54=^U 8]0 T>(979L
MNM:5]@K8ZJ'L]J='QK^:]J]47_YD-X$
M
M
M
M
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MX[42?]CNC5?$BKT;.Q-_UM14^*HT)7K8 !
M
M
M
M
M                                    ,&_?YCN/]&D_X5,XP;]_F.X_
MT:3_ (5 _.0W6$?^,[!_M"G_ .8TTINL(_\ &=@_VA3_ /,:&GZ'@ ,A'.(U
MCCR/!KW:I&(]T]*_P^G:1$YF+]CD0D85-HJ+V4#\UC:XG='V3)[3<XU5'4E5
M'-]C7(JI^PQ+M"E/=*R%.B1S/8GV.5#%#3]*6JCFHJ+M%ZH#68O.M3C5IG<N
MUEI(7JOUL139AD
M
M
M
M
M               #!OW^8[C_ $:3_A4SC!OW^8[C_1I/^%0/SD-UA'_C.P?[
M0I_^8TTINL(_\9V#_:%/_P QH:?H>  R &KRJYLLN,W:YRN1&TE+)-U][6JJ
M)]JZ _/>]R)+>:^1.SZB1R?:Y3"/JJJJJJNU4RK/0R7.[45! BK+53L@8B>]
MSD1/[0T_0?#HUBQ&QQN[LH8&K]D;3;G"")L$$<3$TQC4:B?!$T<PR
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M514M' WFDED72(G_ %7W)W4#-!C6ROIKG;Z>NH)F3TE1&DD4C%VCFJFT4R0
M                                "JB*FU1-]@
M5=)M>QH+1E]FO5UJ+?9JI;A+3+J>2G8KX8E]RR?1W\$55^ &_      :&]Y;
M9;-<::W5E8CKG4KJ&B@8Z69_QY&HJHG?JNDZ+U-ZQRN8URM5JJF^5>Z? #Z
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M34;ZRS/FFHD<K6U#H71LE5.B\BN1.9/BG0#<
M      - S+[-/D#[)15?KMSCZS0TK%D2%/?(Y/99]2JB_ WX
M
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M>KM>_P#Z:)6$
M                        #"OC5=9;@UJ*KEIY$1$[K[*F: /SK^;E[_\
MH-<O_=7_ -P^;E[_ /H-<O\ W5_]Q^B@"Z_.OYN7O_Z#7+_W5_\ </FY>_\
MZ#7+_P!U?_<?HH :_/BBP?*JYR-I,;O$N_-*.37[=:0L#$O1\RZ\2L?=VP66
MD5?:=.Y))-?!C5[_ %JA[' -0GAOPTL&!4JI:X5FKY&\LM;/I97I[D\FM^"?
M;LFP 0                                           H/TP9WMQ"QP
M-5?#DKE>Y/>K8W(G_$I?A4/I16*2[\,I*J!JNDME0RJ5$[\FE8[]G,B_8",+
MT2:B.7AM60MUXD-QD1R?6R-47_YO<>=>-/\ *KE']->3ST5LQAL>555CKY4C
MIKLC4A<Y=(D[=\J?[R*J?6C4(EQ+M55?.-U[M=OC62JJ[DL,;4]ZKK:_!.Z_
M +UZ=RC_ +WPO_I[?_Q60LDK[.8$I;WPYIVKM(KIX:+[]4TJ%@A QKG_ )MJ
M_P#4O_L4YUU73T-'-55DT<%-"Q7R2R+IK&IW55,>JF;4V2:=B.:V6G5Z(]-*
MB*W?5/)0/#'!JWU%UXDV:AI+A/;I9W2-]:@1/$8WPG\W+OLJMVB+Y;WY'LZE
MPC'[?BE78J:W0^H5$;FSH].9\RJG5[W+U5WGM>WEV/(7H\?RQ8[_ #YO^2\]
MPS_Y"3^:O]@6O"?!!-<6L:3W5?\ T4]JYC%>Y\?JXL7J:2EN;F*D<U2U7-9T
M\D3S]RKM$]RGBK@C_*YC?],_Z*>[9/\ )O\ J4%>(>!M545O&RQ5-=/)454M
M1*^261RN<]RQ/VJJO<N+TB^&MGN$4=YM;F4N25,J11TD;-K<'KY(U.ST3JKN
MVD]KWI0?"NZ267B-9ZZGI'5E0R9S(J=KT9XDCVN8U.9>B)S.3:^2'LW$,8J*
M6LDON2SLKLDJ&<KI&I^*I(^_@PHO9J>:]W+U4%:;@=@%5@6+OI[C725%;5.2
M:6!'[A@77T6)[_>[SZ>XL8 (  #QEZ4M5)4<6*F*155E-2PQ,3W(K5?_ &N4
M]*5<L<_!&>6%46)^.N<W7N]64H3TM[')29K;[PUB^KU]*D:N_P#MD:JBI^ZY
MG]9+^$&90WO@9D-CGE3Y2M-LJF<BKU? L;U8Y/@F^7X:3WA50>CS_+%CG\^7
M_DO/56-?RNYM_0[=_9,>:_1@LE5<N*-'7Q1N6DMD<DTTFNB*YCF-3?O57;U[
MD4]*8U_*[FW]#MW]DP*G0!B5MQIJ*:DAGD1)JN7PH(TZN>[2JND]R(BJJ^2(
M$5'Z0G%&Z8-ZE;;'3PI5UT+I/6Y/:\)$77LL[*OQ7:?!3(PS"+-G7!VV-O\
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M6/Y5X/Z)-_8AZ*](+^1[)/\ 51_\Y@.J.]$&"-^=W:9S462.W*C57RW(S?\
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M?3UCG?C&HU-\K_SDUV7O[]^0>C  $
M
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MNI/0  "
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MD!;K_/#;LKBBM5P>J-94,5?5Y'>Y=]6+]:JGQ0&+S 3JFT[ (
M                             X3,62-S$>YF_P IO=#14N&V&"ZK='6Y
ME3<O*JJW.J)6_P USU56I\$TA(
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M&.=\37)[EY%153X*NCE8[):[%2)2V6WTM#3]U93QHQ%7WKKNOQ4V
M
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MVGZ#TTOCT\4O(]GB,1W(]-.;M-Z5/)0E=@ "
M
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MW$#X$.<_A)C*N557U94Z^Y'N1">!
M
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M
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MYJJJKS\R)U3?D30
M
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M2S4T[$^/L<W_ ,D]H'@/A->F8_Q'Q^Y2N1D,=4UDCE_)8_;'+^QRGOP%  $
M%Z)M3S!/Z2-RH,IN<2VVCN-E94O;3*URQ2^&CE1%YNJ+M$WV\P/3X*GQ;CYA
M=ZY(ZRIGM%0[IRUC/8W\'MVFOBNBU:>:*H@CGIY&2PR-1['L7;7-5-HJ+YHJ
M <P
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MMFU?R>+'#))$CO=XC6JW^OH3:FGBJJ>*HII62P2M1\<C%VUS53:*B^:*$=@
M
M
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M+_>H5CN]>Q&Q1/33H(>BZ7W.<NE5/)$1/>7:$H  @
M
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MKNO9$UT3KT-?Q'Q'+,BSK'+Q;(+0RCL,ZS1-GJWH^HVYJKO4:HSZ.NZ^_P"
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MJ*6H=)XJ.>YW5KF-Y=;1.Z[^ 1-P
M
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M;$;^(@=[T1>KG)[UUKW;ZET@&@ "
M                      #&N=?26N@GK;C414U) U7R2RNY6M3XJ1*AS.Y7
MR#UK%\9J:NWNZQ5==.VC9,GYS&JCGJWXJU )L"NJSB>W'[A3TN<6*ML,=0[D
MBK?$;44KE]RR-ZM7ZT^/8L*&6.>%DL+VR1/:CF/8NT<B]E1?- .8
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MAC]<RKIT=RNTBM<QWN<U>J+]9N@
M
M
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M3VU6-D]8E7E;RNURKU]^T...W^V9';_7K'6,K*3G='XK$5$5R=T3:&%#$R;
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M3IL/Q]EOIY'3U$CUGJZIZ>U43.ZN>O\ T3R1$)&
M
M
M                                   !%N(V#VO.["ZVW9KF/8O/3U$?
MTX7^]/>GO3S_ &*D?QE<]Q:BCM=TMM/DU+ B,@KJ6J;#.K$[)(R32*NO-'?M
M[ED@"O,AH,MS6B?:IH(L9LTZ<E5)X[9ZN6->[&(WV&(J=%57*O7L2ZR6:CQK
M'X;98Z1K*>EB5L,/-KF7OU=[U7NOQ-J *DX>8OE5EXD9'?;I;J!M%?'HYR15
MG,^G1JJJ=.1.;OKR/F9XQEESXJV+)K=;:!U%9T=&R.2MY7U#7<R*[Z"\O1W;
MKV+< %5<6>']XOUUL^58E514.3VUJ-1LCO8E;U7EYM:VG,Y.J:5'*BZ-ECE5
MQ(NKZ>&_6ZTV.&-[73U,,WCR2M1=JV-G5K=]E5RKI%Z)LL, "KLKM>87O-<?
MN"V:WK9K-.^=M,MPT^>16JUDB^QI.7NB?%>I:( -VK454TNNJ%(OQ#-:3C!/
MFEHM=LAIZB-(:BC?7KN=O*C57:,TB^RU?/JA=P KVAFS6T7RZOFLK;M:J]S*
MB"..O8DE&]6-1\2\^D5G,BJBM]Z].NDP<"PZ\8=BM^=3T='/=KO5R5/J4<_A
MP4S7(J-8C^7KRI[D^'ELM  5AP,QC(<*QFHLM[HZ-S6ROJ(IX*GFYU=R^PK5
M:FNR]=_88&'8QEMKXJWS)ZZUV]**\(R)\<==S/IVHK4YOH:=T;VZ%O "H,CQ
M/+*+C"N:V"DHJ^C]7;2R4;ZGPI9&<NG:54Y4TNE3:^1L\LQV_<164=MO5"RQ
MX]%,V>JC6H;-452M[,3DVUC?>NU7MTZ%F ""\7L+ER_A]46.UNB@J&+')3-?
MT9MB]&KKLFMI^PTE+^$>Y854V6OLELMU4E$ZF6M=6),LWL*WV(FII'+[W/1$
M5=Z7L6J *MX)6/+,2PCY*O-LH$]7;)+3M96;D>]SN9&.TU6M3:K[2.7RZ&+P
MHQ?*\7R?)*RZVV@=2WVM]:<Z"MVZGVY[E32L3F^G\.Q;@ K_ (Y8=79O@DML
MM+XDK8YV5$;9'<K7JW:*W?ET<OVF=C'SCOMEFH,WL5%0T\E*M/.C*SQG5"JG
M*Y=-336JF_RE7J3( 5+@6/97PVCK+-1T$>0X^Z9TU')'4LAG@YN[7M?I%3SV
MB]]KYZ3:8EA5PESVMS?*_5V7.2+U>BHH'^(RDBUKJ_2<SU3?;I[3O?TL8 5#
M?\:RZKXQVO+Z6UV]:&VP.HVP.KM/F8OB)S[Y--7\9O77MWZF7QWQ3(\UM5!:
MK#2T:0P5#*M]145/)[34>WD1J-7\[>]EI@#$M,U9/;X9+G2QTE8J+XD,<OBM
M:N_)VDWTZ]O,^W2:K@H)9+=2LJZMNN2%\OA([KUV[2ZZ=>R]C* %)\,L3S?$
M\PR*[UULME3#?9_'F9%7*UT+N=SNFV>U]-WN+L  J/B#C&5WOB-CE]MMMMZT
M5CD5S6RUO*^H1515_(7EZ)\3YQ"Q;**CB%C&862@I;EZA!X4ULGJ48D;EYMN
M:Y4UOVN_?;472EN@"EKQC>=IQ2M&:P6NUU:MI5I)*".MY/ 8O-WD<WVEV_>T
M;\->:Y7$3A_D53E-MS;#*BDI<DAA;'5TLCU6*?2:5$<J)OI[/76T1%Z*A;X
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MJJ(CG+K>MHG0LT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7JO*C-HG9-[7:=^@%O@K?T?K[=,CX=Q7*^5;ZNLEJID61R(G1'=$TB(B(60
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M1.JH@ 'SG;^<G[3Z
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M3:[TODJ?!?\ J2XAEU]O,(49U5)(]Z^PF84
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MD<((HX(8XH6-9%&U&,:U-(U$Z(B',(
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M-9U<]$>]WO54*B/YLU$JZ5J)I/#TFOK.VHQ1&0/?#5*KVIM$<W2+]NSKS?\
M[[2Z[\B_VG9+29%/&L<DJ<CDTOM-3I]@';A]=+/!4T\SU>D;4<Q57:HG7H:6
MP6IMTDF:^58_#1%Z)O>R4V*T?)=++XCD?/(GM*G9$3R0BUAMTUPDF;!4+ K$
M155-]?V ;KYHQ?\ V6_]Q/[SEFC>2VTK=[Y7Z_J4XQ8[6,E8Y;BY4:J*J=>O
M]9V9Q_W"G_UO_12##HL894T4,Z53F.D8CM<FT3?VGRS553:[Q\G53U?$YW*F
MUVB*O94))9/\T4?^J;_81B^^WE<#6=7(Z-%U[]E$S !%
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MYNJ)K>O>2( <*=JM@C:Y-*C41?V$<R:VU=9<H)::%7L:Q$5>9$TO,J^:DF
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M $)M_P#[LS^X*\_>E+EE@ON)V6GLMXH:^9*Q9G,IIFR*UJ,<FW:7IU5.YO\
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MK1-@;.AJ6UE%3U+&2QMFC;(C)6*Q[45-Z<U>J+[T.\ (
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M[Z^]5)$
M
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M*YCN?JG;]J 6,"/85E5/EUL^4*&@N5+2.TL4E9"D?C-7\IG5=I\20@
M   #491DMGQ>VK7W^OAHJ9%TBO7:O7W-:G5R_!$ VX*VH.*K;O3K58_B.3W*
M@3M4QTS&,?\ %G,]%=]AGX/Q.M&77FLM%+1W2ANM)$LTU+6TZ1O:B*UJ^:]=
MN3I\0)T"I,1XR,RGB0S&*.RU-'$Q)O&EK'<LK7,1?9\--ZZIKJJEM@
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MWYF7B>1V[*K)!=;/-XM-+T5%33HW)W8Y/)R>[_H!MP
M
M
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M59I'>*O1S-:1.KO/R0T61-6K]++'FT_>FH-RJGE^+F7K]CF_M OP !
M
M
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M4K=L+I\7ME[?0V_Q%GJY9Z?UF>KEYD=SN>KV]=[5?L[(A9X @_"O"J_!;/\
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MERI74UPIHJFF<YKG12M1S55JHY-HO?2HBF2B(B(B)I$\@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2*RX?XE8'\><THG6BB6DM[():2)8DY8'Z8O,U/)=]3<8.J)Z2N?*O9*&)?\
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M4]ZHB[T;@K/(.$=LEOMDO&(NI\;N%OG1[WTM/[$T?FQ6(K4Z]M^:*N]EF!
M
M
M
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M%OA:U%B=35BSJYV^J*BM370D0
M
M    #29%B=CR1T3K[;8:[POH)+M4;]2;UOXF[ &/;Z*"WT<=+1L\."-%1C>9
M7:Z[[KU\S(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M974T"U$K6PN72)K34Z;<Y4=O347HB[UH": B]'G=BJ\;M][AGF6EN#E92Q)
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M>G55AD>Q'.C5>ZM5>V_@4_P[_P#2&XB?ZB#_ (6 ;SC9EUSL5)9K+C3FLO\
M?JE*6FE<FTA;M$<_Z]N:GVJOD13+,4S# K!)D]HS:[7:JH42:MI*]ROAF9OV
MN5JJO*B=_?K>E13+XH]>/7#=)/\ )(DJMW^=U_\ ^2R.)*,7AYE"2?0^2ZG?
M_P""<%9V*7N#(\;MMXI4Y8JV!LR-5=\JJG5OV+M/L-J5QZ.JN7@[CW/O?+-K
M?N\9^BQP@
M
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M$N\89;'V+B+9+_4W2E>](JV"%:AM4U7*J>VJIM>ND7W:WI2;_.[+_P!7-?\
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MB
M           (WE^%63+%I9+O3/6JI%YJ>J@E=%-$O^B]JHIRLN'6NUU456KJ
MZX5D2*D51<:N2J?'OHO)SJJ-77FB(I(@
M                                                           =
M-=5P4-'/5UDS(::!BR22/736-1-JJJ1G%KA<\FECO+EDM]B7VJ*E5J)+5-\I
M957Z+5[M8FE[*J^0$L        !%^*%W;8N']]N#JB6G?%2N2*2)W*])%]EF
ME]ZN5J'/AM0W&WX1:8;Y5U-9='0I+4RU$BO?SO\ :5NU_-WR_8!)0
M            (_%D4LF<38^VTUJ0Q4:53K@YNH5<KD1(T7S777OY+T D
M                                C^5Y%+8I[/#!::RXON-8RE5:=O2!
MJ]Y'KY(B=?V]20          5EPWJ;A>>(F;7-;G73V*EJ4M]'3R2JL22-1%
ME5K>W1R(B+[G*6: !%:J\5%MXBT-KJ)%?07>CD?3M5/\G/"J*]$^#F/1?K9\
M5)4
M
M
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MGB2AL\;TTOJK7;672]O$=U3X?66,
M
M
M
M                    !IKK8VUE_M%XAE\&KH%DC5>7:2PR)IS%^U&.1?)6
M_%3<@              &KI[#0Q7N:[NC?-<9&^&V:9ZO6)GYD:+T8WWZ[^>S
M:          #5NL-"^_-O$\;YZZ-JL@=*]7-IT5-+X;>S57S7NO;>NAM
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MTZ&_ 'QC6L8UC&HUK4TB(FD1/<?0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MHJIS+OV51R=D14UWZ]+(             <*B:.G@DFG>C(HVJ][E[-:B;55
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M_*CPJ_VC_P#3H3GZ3OT,)_VLW_H%7>  @
M
M
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MWVW>YOQ7IT7W&+F=R^9O&ZVY?<D?)C-SMJ4+JV-JO9 N^9-ZWT735^*.76]
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M?T7G7:)M=HB]O).NDT;S&<'GL_$S)<HDK8I8;M&QC(&L5'1\J-[KV7Z(12W
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MDC>Q565.>-VD5.WT/ZSEQ7P2HS=MA2FK8J7Y-K$JG>(Q7<Z)KHFNP5/0 $
M
M
M
M             (]EV.K>%H*VAF;2WJVRK-1U"IMJ*J:=&]/-CTZ*GU*G5"0@
M".W;#+#?+A3W.\6FGEN<;$9XS'.1R)^;S)I7)U7N;FW4%);*1E+;J6"EIF?1
MBA8C&I]B&2 (Y%CTE3F#K]=I8Y74K'06V!FU; QWTY%WWD=V]R(FNNU4D8
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M,Y_6$GW+#_>/FQG/ZPD^Y8?[R>@"!)C&<_K"3[EA_O'S8SG]82?<L/\ >3T
M0+YL9S^L)/N6'^\?-C.?UA)]RP_WD] $"^;&<_K"3[EA_O'S8SG]82?<L/\
M>3T 0+YL9S^L)/N6'^\?-C.?UA)]RP_WD] $"^;&<_K"3[EA_O'S8SG]82?<
ML/\ >3T 0+YL9S^L)/N6'^\?-C.?UA)]RP_WD] $"^;&<_K"3[EA_O'S8SG]
M82?<L/\ >3TZJNI@HZ>2HJYHH((TV^25R-:U/>JKT0"#_-C.?UA)]RP_WCYL
M9S^L)/N6'^\F=LN-%=:-E7;*N"KI7JJ-F@D1[':72Z5.B]45#* @7S8SG]82
M?<L/]X^;&<_K"3[EA_O)ZJHB*JJB(G=5,&U7FV7?QODJX4E:D+N25:>9LB,7
MW+I5TH$0^;&<_K"3[EA_O'S8SG]82?<L/]Y/3A)+'%R>+(QG.[E;S+KF7W)[
MU @OS8SG]82?<L/]X^;&<_K"3[EA_O)Z (%\V,Y_6$GW+#_>/FQG/ZPD^Y8?
M[R>@"!?-C.?UA)]RP_WCYL9S^L)/N6'^\GH @7S8SG]82?<L/]X^;&<_K"3[
MEA_O)VR1CWO:Q[7.8NG(B[5JZWU]W14"R,21L:O:DCD56M5>JHFMJB?:G[0(
M)\V,Y_6$GW+#_>/FQG/ZPD^Y8?[R>@"!?-C.?UA)]RP_WA,8SG]82?<L/]Y/
M0! OFQG/ZPD^Y8?[Q\V,Y_6$GW+#_>3T 0+YL9S^L)/N6'^\?-C.?UA)]RP_
MWD] $"^;&<_K"3[EA_O'S8SG]82?<L/]Y/0! OFQG/ZPD^Y8?[Q\V,Y_6$GW
M+#_>3T 0+YL9S^L)/N6'^\?-C.?UA)]RP_WD] $"^;&<_K"3[EA_O'S8SG]8
M2?<L/]Y/0! OFQG/ZPD^Y8?[Q\V,Y_6$GW+#_>3T 0+YL9S^L)/N6'^\?-C.
M?UA)]RP_WD] $"^;&<_K"3[EA_O'S8SC7\H*?<L/]Y/0! OFQG/ZPD^Y8?[Q
M\V,Y_6$GW+#_ 'D] $"^;&<_K"3[EA_O'S8SG]82?<L/]Y/0! OFQG/ZPD^Y
M8?[Q\V,Y_6$GW+#_ 'D] $"^;&<_K"3[EA_O'S8SG]82?<L/]Y/0! OFQG/Z
MPD^Y8?[Q\V,Y_6$GW+#_ 'D] $"^;&<_K"3[EA_O'S8SG]82?<L/]Y/0! DQ
MC.?UA)]RP_WCYL9S^L)/N6'^\GH @28QG/ZPD^Y8?[Q\V,Y_6$GW+#_>3T 0
M+YL9S^L)/N6'^\?-C.?UA)]RP_WD] $"^;&<_K"3[EA_O'S8SG]82?<L/]Y/
M0! OFQG/ZPD^Y8?[Q\V,Y_6$GW+#_>3T 0+YL9S^L)/N6'^\?-C.?UA)]RP_
MWD] $=Q:TW^W33NOV2)>8WM1(V>HQT_AKOJNVJNR1
M
M
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MJIU7S3:[,/A5<'6C#<GSJ^W"X5-%6323T_K<JO?ZM$KFLTG1$<Y57HB(GT=
M7&5IZ0$B5.%0V**..2NOE=!04R.;S<KE>BJ_[$1>OELZ:+$Z_.L/ANM^NM?;
M[Q<%CK*=:69S6T$>T<R-C$5$55;])R]=K\$0^RI\Y..D$.UDHL4H/$<J]?\
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M2)B+\>ZZ''67UC$J2Q1=:N]W&FHHFIW_ ,JU[G?4B,ZJ$6*
M
M
M
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MO(KD[*YO9VNZ;1=+U[F<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN
M
M
M
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M",#;5''/#H,L=8GSU7,V;U=U8D2> U^]:WO>M]-ZU]G4U_I5_P E;OZ=#_\
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MV5B1II7Q(J)S.UW]E9$VOYOP+Q"
M
M
M
M                                              %<.B^;?&E]9(G+
M09/1L@23R2K@WRM7W<T>]>]44L<P+Y:*.]VY]%<(N>%RH]JM56NC>U=M>UR=
M6N1>J*@&<Y51JJB*JHG9/,JFT6W(V\:*S)ZC'*B&U5=O90(JU-.LD:HYB\[F
MI(O3HO957^PM6)JLC8U7.>K41.9W=?BIR KGB[$N03V##Z?VY+C6,J:M$_\
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MBG3:>?OZ=\N.W++>(MER&\4,ELM-CC>M)33O8Z:>9_=[D8KFM:FFZ3>]H62
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MP3]&Z3]]_P#$/P18)^C=)^^_^("= @OX(\$_1ND_??\ Q#\$>"_HW2?OO_B
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MZ-TG[[_X@)T""_@CP3]&Z3]]_P#$/P1X+^CE)^^_^("= @OX(\$_1ND_??\
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MGZ-TG[[_ .(?@CP77_ARD_??_$!.@07\$>"?HW2?OO\ XA^"+!/T;I/WW_Q
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M@1[&,+Q[%YYYK!:X:*69J,D=&KEYD1=HG55)"
M
M
M                                       # O5WHK+2)4W&9(V.<D;&
MHBN?*]>S&-3JYR^Y$V9-;50T5'/554C8J>"-TLCW=FM:FU5?J1"!<.HI\HJ7
M9O>HU;ZPCFVBFD[4E+VY]?GR=U7W:1.@$_II5FIXI7120N>U'+')KF9OR72J
MF_J4["/6S-<;NE5<*>WWFCG?;V>)5.8_V(F]MJ_Z.NGO.=OS''[A;JVOI+K3
M.HZ)_AU$KE5B1NTBHB\VN^TU[]] -\#68]?K9D5 ZMLM6RKIFR.B<]J*G*]O
M=JHJ(J*GQ,&7-,=BNB6Y]VI_6EF2FTFU8DJ]HU>B<J/_ -%5W\ )"#2Y%E5C
MQQU,V^7.FHWU+D9"R1WM/7>NC4ZZ^/8^7#++%;[S36FLN=/%<:E[8HX%5557
MN^BU==&JODBZWY ;LZ:ZH2DHJBI=&^1(8W2*R/7,[2;TFU1-]/>1+B%Q"M&'
MTK6355'-=))8XHZ)U0UCO;<B<[^ZL8B;57*FNAK.*V5TZ\,ZV7':R"MGNCVV
MNC?32H]'RRKR*B*B]T3F7[ )+@>54V9X[%>J"EJJ:DFD>R)*E&HYZ-72NTBK
MTVBIW\B0D-LUWQG#:6R8C)=:6*MCCCI(H=^TY^NF]=&JY>O76]DR  &%>+M;
M[+0OK+M604=*U=+),]&IOR1/>OP3J!I.(.94V$VF"OK:&MK&33MIF,I4:J\[
MM\J+S.3OKRV2=BJYC5<U6JJ;5J^7P*CO-THL^XHXQ:;;-ZQ;;,C[O6[8YNI6
MKR0M<UR(J*BKS:5.REF7N^6NQ4J5%YN%+0P*ND?42HQ%7W)ON!L01BFSS'9[
M+<KO\I11VJ@J'4TM6_I&YZ:^@OY:>TB)KNILI,BM$=!;:Y]P@2DN4D<5)+OV
M9GR=6(GQ4#:@&+=+C26JWSUURJ8J:C@;SR2RNTUJ?$#*!I4RJQKC]/?$N4'R
M3.K6QU.UY7*YW*B>_?-T^'F9EXO%OLU,V>Z5<5-&YR,9SKU>Y>S6M3JY?@B*
MH&<# L=XH+[;8Z^TU3*JDD54;(S:=472HJ+U145.RFEN6?XS05K*)UWI9Z]]
M1'3)2TSTEEYWNY43E1=]%[^X"4GQ[E:QSD:KE1-\J=U^"&HJLFLM+D-+8I[C
M3LN]2U7Q4O-M[D1%7?PZ(O?OHYX_D5HR*.J?8[A!6LII5@E="NT:]/+?G]:=
M ,BR72EO5JIKA0/5]-.WF:JII4\E14\E145%3R5%,T@/">18ZK-*!%_$TM_J
M/"3R:V1&R*B?[SG?M)\
M
M
M
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MZ:ZK&[NQDBIR)^XUJ_:3\^,:UC&L8U&M:FD1$TB(?0
M
M
M
M
M                                         !4VBI[P (=B. T>/2QR
MS7.ZW>6!SEIEN51XJ4W-O?(FD3:HJIS+M=*J)I%4F(  AUAP"CM=TEK*FYW:
MZ)ZR^JIZ>NJ/$BII'+OF8W2=4VNE7>O+2[4F(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ+I-_$#9 (J.1%145%ZHJ
M
M
M
M
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MYJJZ1[O-RE;< +/DDW"VV/I<EBIK=4^,L</J"/FIT\5[5Y)%?KJJ*[VF+I5
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M?/HAD&-:Z5U#;:2D?/)4O@A9$LTJ[?(K41.9WQ76S)"
M
M
M
M
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M!I\1QZDQ>PT]JH'2R1Q<SG2S.YI)7N55<]Z^:JJJ;@
M
M
M
M
M
M
M
M
M
M                                                          '%
MTC&O:QSVHYW9%7JOU <@     'QCFO;MCD<GO1=GT
M    !>B=0 .,4C)6\T3VO;O6VKM-G(
M
M
M
M
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M);<6L]#-_E::CAA?];6(B_V ;4
M
M
M
M                                                         $!P
MQBTO%#B!!*FG5#J*KCW^4Q859M/J<Q4--=+;D=IXUU60T5BDO%!66MM'"]E1
M'&D#D<BJCE<O1-MWM$7Z73?8LB2TTS[Y!=D1S*V.!U,KFKI'QN5'<KD\]*FT
M]VU]ZF>!7?$JPWW*L:M&/R-C1M?6,6[3TR\L<,#%5ZM;S+M554:B+YJFU1-Z
M.W+K37WBWOPJU6N6WV1\4,4EQ:]B1MIT^G&QN^;F5&HWJFM*J^2;GX JG/\
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M1-][6=W>6^GD608]OHJ:W44-)001T]+"U&1Q1M1K6I[D1#(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>5Z:54ZHBJG=%\P-P
M
M
M
M
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M]JM<K514VJ=T\E"-X
M
M
M
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MB':
M
M
M
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M!)P".3YG9XLTIL5669UYFC65(TB=RM:C5=M7+TZHB]M]0)&
M         Z:ZJAH:.>JJ7*V"!BR2.1JN5&HFU72;5?L-3AN4VS,+0ZYV1\LE
M$DKH6OD8K.=6ZVJ(O777ST!O           !'+3FEGNV5W'':"6:2XV^-7U*
M+$YK6>TB:VNMKU3MM->9(P      ".9?FEGQ-]OCO$LS9J^5(:>..)SE>Y51
M._9.Z=U0D8    1R\9I9[3D]LQ^JEF6ZW%?Q$3(G*FNOM*[Z.NB^>_@2, ".
M7+,[/;\MMV-3RS+=Z]%=%$V)VD:C7+S*[MKV5[*JDC
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M6VU-U/-$YC6+O7+MVMK]2:^($C
M
M                         !5/"W^5CBG_ $FC_P"!Y+[IGF.V['JN\ON4
M,U%3S.IE6%>=TDR=/"8GY3M^[Z^W4B'"W^5CBG_2:/\ X'G'A]P;I<;R*JNE
MSKW7-L=3)/;J9S52*F5^MOY554632(F_@B]]:#"XX5U=<^ 5=6W6WK;:N=\+
MW4KG\[HVK.WE1R_G<NE5/)55"X*3_NL/\QO]A6?I,?R/7C_60?\ .:692?\
M=8?YC?[ .T  "(Q<2,3?>J^V.OMOBFHT9SR2U#&1N<[F]EJJOM*G+UUVVB=]
MDN*:X5VJWR\3^)L<M#2OCBK*=(VNA:J,VU^])KH!VY!54U#Z25KJ:R>*GIX\
M<>Y\LKT8UJ>+)U55Z(618,HL60NF;8[O0U[X?\HVGF:]6I[U1%[?$K;(**EK
M?28L;*RGBG9'8%D8V1B.1')++I=+YILY7:BI[?Z26.2T,+*=U;:I_6/#:C4E
MY>;2NUW7HG[$]P59]XO5LLT3)+M7TU&V1>5GC2(U7K[FIW5?J.RTW2@O%&VK
MM593UE,Y51)8)$>W:=TVGG\"J<7=6Y'Q8SB5MW=0UML?%1P1K3QRJR#2]6\Z
M=$<Y%5==]IOR)KA&&)C%ROM<MTJ:Z>[RLGF22-D;&O1%15:UJ(B*NTW]2!'1
MQI_DJRC^A/-;P_S;&+?A>+V^MR"UP5J6ZF:L,E2Q'-7PV]%Z]%^LV7&G^2K*
M/Z$\PL8QJTW_ (-V.V7*CIW4T]IAVJL3;'+$GMHODY%Z[ L!'M5G.CDY-;YM
M]->\T5/F6-U->RB@OMMDJGN5C(VU#55[D_);UTJ_!#S@F0W=GHV6NFFJ)F4]
M3=_DUU1M=^J^T[6_=M%;]2:+RXJX_;)N$MZH?5X8Z6AH'S4J-:B)$Z)BN8K?
M=]'7VJ!-JNI@HZ:2HJYHX((TYGR2N1K6I[U5>B&NL.2V7(%G2R76BKW0+J5*
M>5'JSW;1"M,<K[;=>'N WC-[A5>MQ+ST](U5>M=,U>5CEC1%=(Y$1')KS=M>
MYUXI4+5^D9>)VVVHMJ.L35?',C6OD7Q6:>J-5==-)UZ].J(!9=9EE@HJNJI:
MN\T$,])%XU0Q\S4\%FT3;_S>JIT7JIDI?;4MF9=OE*C2UO:CVU;IFI$J+Y\R
MKHJ:AQ^TW+TB\HBN%MHZF%;1%(L<T+7L5[E8BN5%37-K?7OU4[:=M'4<?:7'
M)8(H+18K3X]NHD:B1>,JMW(C>RJC7*B>[6_>!C9YD5GOO%KAHRSW&FK'T]74
M>*V%Z.5G,UFM^[>EU]1=Q47%6")O%[A?.V)B3OJ:ECI$3VG-1K%1%7S1-K^U
M2W0,*[7:WV>F2HNM;3T<*NY4?/(C$5?<F^Z_!#JLE^M5\CD?9[C2UK8EY9/
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MKW)M5 EUMN5#>+:VMM=7!64<J+R2PO1[7>2]4*W]&7^2NG_I=1_QJ='HW_\
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ME7ZWK[B7T-EMTO#J\7+)ZR2T-OTBW"OJ&2I"^.)SD\.)7*BZ1(T8Q4\U5WO
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M@IVHGAQM]S>KOK5.HP."*GX_\0F01LC8M-2O5K$TG,K&JJ_6JJJ@6Z
M
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MF2/B!BC<RQ^6S5%PJ:*CG5/'2!K%=(B*CD3;D775$[&RQJUS6:T04$]?-7I
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M^_*];5_*SD=ZM*OL0Z7?3KUUV3MI.G4EX
M
M                                 V@VGO  ;3W@
M
M
M
M
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M?$V.3D?K;7(U-+])/V+[](%H
M
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M2*D>YE%7VN-LL<D:N541RJY$;W7JJ]M(J=-K=8 Q+3+5SV^&6Y4S*6J>BN?
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M^PB^26B[WS!;)5IB605614-9!47&IKDW*_EWSMA1SN96JJHJ(QJ-1$]Z'I,
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MRL5UIX+E5K6TKG0I^,8U'>ST7HY>FD7WFOP.2[4F17_+,IQ>^RWVN=X--!#
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MZ4M@ 1#'[_D%=G-\M5QL#Z.RTC46DN"JNIUZ=/<N]JO3MK2DO
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUFL-9<K5:ZA]-4U$4K&O<YFO$6.->KT;OX;\MD\145$5.R@
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ME[IO2?L.BYX9C=SH:.BK[);YJ6C_ .[Q+"B-B]Z-UV1?-/,"MN&%0Y_&[/\
MUZY4M;5)!2L66!B1L=IJ(J-;S.^BNF]UZF3PJJ8*?BKQ2BGFCBD6J@E1KW(U
M58B/V[KY=4_:A8*8;C;;K2W)MCMS:ZF:C(96P-18T3MK2:Z>7N\CY<<,QRY7
MEMVK[)05%Q;K\?)"BN77;?OUY; J:S+CT'&;,[7G=';W55=-%4V^>OC:K7Q\
MFN1KG=.VD1/>BIY%KXK1XQ055?!B]+;()F\GK7J,36]5WRHY6IK?===TW\3(
MR/%K'DD<;+]:J2O2/Z"S1HKF?4O=#,L]IM]EH645HHJ>BI&=6Q01HQN_?I//
MX@:KB2BNX=Y2B(JJMJJD1$_U+S3\$JRGGX68PD,\;U2D;&J(Y-\S=HY/K31.
M7L;(QS'M1S')I6JFT5/<I';9@N+VOUKY/L%N@]::K)N6!/;:O=OU+[DZ 0GT
M<'MDQS)58Y%3Y?JEZ+[T8:'AQ!4UV&<6Z6UKS5LUSN#(48O57.9INOK7L6[;
ML4Q^V-J&VVQVVD;4QK%,D%,R-)&+W:[2=4^LY6?%[#9:EU19[+;J"=S>1TE-
M3,C<J>Y5:B;[ 53P?;P]O^!V]M=;;"VYT4"0UT55%&DB/8FE>[FZJBZWOXKY
MHI;]@2W)9J3Y$9#';/#1:=L#.2/D\N5-)T\S4UN!8I777Y2K,>MDU<KN9TKZ
M=JJYWO<G95^*DE1$:B(U$1$Z(B 0/),L2DXA4&,VNCHFWJLHUG6OK.C(XD5V
MFHB>U(NVJO+MJ>>R+<$ZA).(?$IU3<*:MJ5K*=JS1-1C9-)(GLMVNDWT[KV+
M+R#%;%D,M/+?+31UTE.OXIT\:.5OPW[OAV.MF'8XR[I=&6.WMKT9X:3-@:BH
MW6O=[NF_=T @?!E[7<0.*/*Y%_\ .K.R_P"L.&=S1TW'_A])4/;'&ZFJHT<Y
M=(KE8Y$3?OVJ)]I8-LQ'';56-J[98K91U3=ZF@I61OZII>J)OLJ_M.W(\9LN
M20PQ7ZV4M>R%RNC\9FU8J]]+W3?0"NO27EC=P[I7-D8K?E2G3:.36T5V_P!F
ME.KBQ=&XWQ5P._W;F2PQI44SYM;;!)(W7,ONZ*GV-7W%BU6'XW5TM+35=AM<
M]/2M5D$4M*QS8D7JJ-14TAES6.U36=+3-;J22V(WD2E=$U8D3W<NM =29)9G
M244<5RI9Y*QW)3L@D219.F]HC=]$1-JO9/,K/AMXE1F?%V*BD1*E]6QL:HO9
MW)(B+^TL.P8;CF/^,MELM#1NF:K)'1Q)S.:OY*KWU\.QVVK$\>M%8E7:K';*
M*J1%3QJ>F9&_2]^J)L"GN!D6#W3#(K9?;99F9!;G20UL-;$Q)7*CU7F7FZKT
MTB^Y44N?&&VAEE@;C<=+':T5Z1)2L1D7TEYE:B)I45V^J=%[F!=\%Q:\7)+A
M=+!;JJLVBK+) BN=_._.^W9(8HV0Q,CB8UD;$1K6M32-1.R(@%3^DVYK>'E,
MKE1$^4Z?NOQ<=GI-N;^"2OVJ=:B#7Q_&(6%>L<LM\=$Z]6F@N"Q(J,]:IVR\
MN^^N9%T=5;BN/U]'24E=9+;4TM(BMIX9J9CV1(NMHU%32=D[ 5WZ1DC8N'-J
MJ7=88;G22O<G5$:G-U.KTF+K0.X7HUE93O=4U4#H4;(BK(U';56Z[IKS+0?8
M;2^R+9W6VC6U*WE]4\)OA:WO7+K7?K]9IXN'>(Q6Y]#'CMN;2R/:][$B3VU:
MNTYE[JB+Y+T AOI)SPR<*%DCE8]CJRGY7-<BHOM>1W>DVYJ\(;@J*FG3T^OC
M^,0G-5A^-U5+34U3C]IFIJ9%2&)])&YD:*NUY6JFDVON.=9BF/UM%2T=;9+;
M44E*BI!#+3,>R)%[\K532=O("#^D,YB\#KNO,WVFTO+\?Q\?;[-FI](&>.+A
MEC-0]Z)"VYT;U=Y<J,>N_P!A9U3B>/U5OIJ"JLEMFHJ;:P4\E,QT<>^_*U4T
MAS?C-CDM,=KDL]O=;8W*]E*ZG8L357:;1NM(OM+^U0(MQRJJ-W"F],E5LRUL
M38:5C?:6:5SD\-&(GTEWI>GN*VR:CCQ2OX4NS:FCJ+'34#J"K\=GB1P3N8B;
M=W3IT^QJ^XNJTX;CMIJ(I[=9Z2&:+:1/1G,L6_S-[Y?LT;6Z6VBNU%)1W2D@
MK*23Z<,\:/:[[% C%HMN"4MVH)[/1V%MRFYEI9*2.-9%3E7F5JM3:)R[Z]NN
MO,B_"Y['<8.*2-<BN\>C[?!CT7^LGV.XE8,;\7Y"M%'0NE34CH8T1SD]RKWU
M\#C;\/QNW5K*RWV"UTM6Q=MGAI6,>B^_F1-@;TKMV6NK<\ON.V&*W6VIH(HY
MJZXUK=J_;4URQHK5?I%3VG.1$Z=%+$-%<\0QZZ7>*Z7&S4%5<(T1&SRPHYW3
MMO??7EOL!7WHS5$<N%79RU,<TLEXJ7N<W2<RJC.NO+:=3L]&)S7<.9^5R+JY
M5'9?BTG4.%8U#55U1%8K<V:N16U+O ;^-15VJ+T[*O5?>=]OQ3'[=3U4%OLE
MMI8*IGASQP4S&-E;[G(B=4ZKW IGA]!55_!;B+36A5?625]>V-L?57;8WHGQ
M5-HGUDVX%Y-:*_AA9XX:NGBEMU,D%5$]Z-=$YG15<B]D77-OXDSLN-6.QRR2
MV6SV^WR2-Y7NI:=D2N3OI>5$V8$V!8I/=UNDV/6Q]>KN=95IV[5WYRIV5?CW
M A'HQS1R8%7>'(UW_G6H7HN^GLK_ -4+1O#5=::YK4556!Z(B>?LJ8&/XI8<
M>DEELMIHZ.:7?B2QQISOVNU17=U3?ELW0%6>C35T[^$-FA;/&LL<L\;F<R;1
MWBO=K7OY51?J.C@F]KLQXG(UR+_Y[<O1?B\G%OP?&+?7U%;16&W0U4Z.221D
M"(JHY-.1/=M%7>NYD6O$\?M-2ZHM5CME%.YJL=)3TS(W.:O=%5$Z@5QPTYYL
M^XNQ4<C6U#JF%(U1>SN25$7]IH^!<.$W+$&6G(+99V9%;I)(:R*NB8DKE1[E
M1WM=5Z+I?<J?47%:\2QVU5K:RUV*V4=6F]304K(W]>B^TB;,>\8-B]ZN*5]U
ML%NJJSIN62!%<[7YWYWV[ SL799V6:)N-1TL=K1STB2E8C(E5'*CE;I-*G-O
MJG12N_24D;!AEGFE7EBBO5*][O)K4Y]JI:\,4<,3(H6-CC8B-:QB:1J)V1$\
MD,6\6NAO-OEH;M20UE'+KGAF8CFKKJG10*T](N1TO#^GJZ6-M;245QIJNLA8
MJ.22!%=T5/S556FQM]/PPK[737:EHL;DIWJQ8W>!&KT>JIIO+KFY]Z3EUO9,
M;+CMGLEO?0VFV4E)1R?3BCC1$?TU[7YW3IU,&T8+BUGN2W"UV"W4M;O:2QP-
M16_S?S?LT!"^--J^=\]%8<?5OSGHT=7LJFR*Q:.-$5-.<G5%D=RM1/@KOR>L
MCX2Y/1Y'B5.RGIF4%;;T2CK+>U.5::1GLJW7DWIT_9W13>4F+V*CK9ZRDLUO
M@JZAKFS31T[&OD1WTD<Y$VN_B<;5BF/VBL];M5DMM%5:5/&IZ9D;U1>^U1-J
M!7OHW54"8C>('31MFBO50U[%<B*BN5NNGQ\BVW(JM5$72ZZ*:&GPS&Z:^/O,
M%DH&71[E>M2V%.;F7N[X.ZKU[F_ IOT:)%H;-D-@N/XN]T-TE?4Q/^FY'(U$
M?\456KU^KWG/A_ M=QYSR\V_K:60Q4;Y6_0DJ$;'S(B^:MY7;]V_B6/>,4L5
MYK&U=RM=+/5M;R).K-2<OYO,FE5/AO1FTMHMU):UMM+0TT-O5BL6FCB1L:M7
MNG*G3J!6/H_N:ZHS_E<B_P#UQ5*]%\MEMFFM&*X_9JKUFT62VT-1I6K)34S(
MW*B_%J(;D"H.$53!3\2>*4,\T<<ORA'+RO<B+R>W[77RZI^U#MG<W_RG:9.9
M-_-U4UOS\55)W789CE?>FW>MLE!/<DU_VB2%%<JIV5?>J:32K[D.:XACBW/Y
M26PVOY1\7QO6O56>+S[WS<^M[WUWL"!WM[$])3'6\S>9;'*FO/Z;U_Z*1[&_
MF[#Q<S:T9U1V]:ZKJVU5!-7QM5)(E;I&-<[IT3ETGU^XMVIQ#'*FXNN%38;7
M+7N?SK4OI6+(KO?S:WLY9'BMBR5L:7ZTT=>L?T'31HKF_!'=T0#IQ6CQFAGK
MX,6I;; ]BL]:2AB:U.;2JU'*U-*NMKKNF_BA@\4LIHL/Q9;K<*!*]&SQQPPN
MTC?$7?*Y7*B\J)I>NB16BUT%GH8Z*U4=/1TD?T8H(T8U/L3S/MVME#>+?-0W
M6DAJZ.5-/AF8CFN\TZ*!3&65=;)QFX;)>;E;)'*ZID;!2-5&P<T:<NWJY5?S
M*FD73>W1#<YU+&O'?AO[;5W#6JG7WQ+K]I,G\/\ $GVZ"@=CML6D@?XD<?@)
MT=[]]U[)W[Z,FHPS&:FJ;4U&/6F6H:C4;*^D8KFHU$1NEUM-(B:^H"!<3G-3
MC-PP17(B^)5^?O8W1RXM/8WBAPN1SFH[UVH[_P UB$^N>)8]=:Y:VYV.V5E8
MJ(BSSTK'OZ=$]I4V?;IB>/7:K]:NECME95:1J35%,R1Z(G9$54V@%37N2R4/
M'ZXQ9S2T;Z"Z4$*6ZHK6-=$QS.BM17=&[7F^W7O0LW'*#$K?=YX\<I+1!<%A
MYIEHHF([PU7IS*U.B*J=$7OKX&QON.6>_43*.\VRDK::/Z#)HT<C/+V?=]AP
MMN+V*V6F6UT%HHH+?,FI8&0HC9/YR?E?:!7OHS.:[!KGRN1?_.]3V7^81SAS
M!55W"WBA36E5?6RW*X-A;'W<JQMTB?%>R%R6[%<?ML-5%;K);:2*J9X<[(*9
MD:2M]SD1.J=5[G*S8S8['/)-9;/;[?+(WD>^EIV1*Y-[TO*B;[ 0G@)DEIKN
M&-I@AJJ>&HMT/@54+WHUT3FJNW.1>R+WW\?K-?Z,T\4N'7E8Y&/1;S4N3E7>
MT5&*B_UDXJ<"Q2JNZW2HQZV25ZNYUE=3M57._.5-:5?BO4[+;A&,VV.J916*
MWQI5(YLZ^"CG2HJ[5'*O54VB+KL!!O1G>UV$77E<BZO%3V7X,/OHY/8ZPY5R
M.:O_ -<-6O3W*D>B?V_%,?ML-5%;K);:2*J9X<[(*9D:2M]SD1.J?6+;B>/6
MQM0VVV.V4C:B-8ID@IF1I(Q>[7:3JGU@5!PW@J:[!>+5+:UYJV:YW!D*,7JK
MG1Z;KZ_(S.$#>'M_P*W)76VPMN5%3MAKHZJ*-)$>Q-*]W-U5':WOXKYHI:MF
MQ>PV2H?/9K-;J"9[>1SZ6F9$KDWO2JU$WV0PJW L4K;K\I5>/6R:N5W.LKZ=
MJJYWO5-:5?BH%=\<G6UN#85\C-@BMOR[2.IVPMY&>'RR=6ITZ?WFP])=[&8#
M0J]R)_YUIM;^MW_0L*\8S8KU+')>+-;J]\3>1CJFG9(K4]R<R+HXW#%,?N4-
M+#<;);:N&E9X<#)Z9DC8F^YJ*G1.GD!7_I&S,I\?Q>HF<C88L@I9'O7LUJ)(
MJJI8M]R"UV*SU5UNE9'#0TS6NEE3;N5'*B-Z)M5VJIKZQ68[9ZVR)9ZJV4DM
MK1$1*5T2>&U$[:3RU\#&@Q#'H+#/98;-1,M4_P#E:9(DY7KTZN]Z]$Z]^B ;
M*T7&DN]LI;A;9FST=3&DL4C45$<U>R]>J?:99T4%'36^B@HZ&".GI8&)''%&
MWE:QJ=D1#O T>=6J6]X7?;93_P"7JZ*6&/R]I6*C?Z]$)]'K):2X8%16::5L
M-XM*.I*FDD7ED;RN72\J]=:TGUHJ%I$<ON#8Q?JOUJ[6.AJ:KSG6-&R+];DT
MJ_:!ILYK8;U?[!C5OD;45;:^&X5K8UYDIX('>(BOUV5ST8U$7OM?<:+BL]C>
M*_"Y'.1%];J>Z^]K$3^LL>Q6*U6"F6GLMNI:&%R[<V"-&\R^]53NOQ4QKIB>
M/7:M6LNECME95JB)XT],Q[^G;VE38$ XT.:W.N%_,Y$7Y77NO\P<5'M;Q>X6
M\SD3_M%7W7WM8B%@77%,?N]4E3=;);:VH:U&I+44S)'(B=D153:'"OP[&[A4
MI45]@M=34(UK4EFI6/<B-32(BJFTTB(!5%TDL=%Q_O,&<TM$^BNM%3K;9ZYC
M5C:K&HCFHKNC=NY_M1/>A-*^#A]9K==XV4=IA@FIVPUZT4345(97I&G.YO9N
MW;ZKV153L2N_8Y9L@HV4M[ME)701_0;-&CN3^:O=/L.%OQ>Q6^SRVFBM%##;
M9D5):9L+>23?YR:]K[0*NQJGO7#7/;#C$-T?>,5O*3)21S=9J/D;S=%3NWJG
MPZKT3SU.21S8K05/$OAU=E^2JR9L]QM%1UCF<Y_*[E3\E_,NE3NB[TNNA<ME
MQ6QV2?QK5:Z:FFY/#21K=N:S\U%7JC?@G0Z(L*QJ*O6LCLE"V=9?'VD2<OB?
MG\OT>;XZV!OJ>3QH(Y%8YBO:CN5W=NT[*4XZ^4^+^D-=ER.5M+27BW0QT%5,
MO+&G)K;.9>B;<COMU[T+F-9?[!:<AI$IKY;J6O@:NVMGC1W*OO15[+]0$8XF
M5L-[PW(+'8JR.IN\]NED9!3NYW*Q-;1==N;>DWK>^G93IX)7B@J>$UDFBFBC
MCH:7P*GF<B>$^/H_F]W;FZ^2[)9C^/6C':5U-8K;2T$+EVYL$:-YE]ZKW5?K
M,&LPC&:RMFJZFQT$D\R\TRK$B)*OO>G9WVHH%7<%Z.6GX7YK<%8Z&VW"HK*B
MB:Y-)X7(J(Y/@NM?823@:YOX"[2JN;RI35&U5>B?C)"PJ^TV^X6_U"NH::HH
M=(GJ\L2.CTG9.54UT,.GQ6P4UMJ+=3V2VQ6^H5%FIHZ9C8Y%3MS-1-+V0"M.
M"Z\_HZ(UGM.]5KFZ3OOGDZ&RX'72AAX(6B::1DL=/3S^+$FG.7E?(YS>7S7E
M3>O<3^RX_9[&R9EEM=#;V3:\1M+ V)'ZWK:-1-]U_:8=FPS&[)7RUMILE!25
M4N^:6*%$72]T3W(ON0"E.)F4U.3\"JRZTK[9:K-4/CAI[<Q/$GD1LZ)I7;1K
M%3E5W*C7=$[DJX^RPNX%S>%*Q[%]41JM=M%]MB_V=2=4V XG2LK&08[:V,K$
M5LZ)3MT]%\NW1/@AV-P;%DM]/0+CMJ?1P*YT4,E*Q[6J[6UTJ+U72=?@@$']
M)%[5X,U2HY-.DIN5=]_;:O0S/2&>Q>"=\7:*US:;E^/X^/6B95.(X[545+1U
M5BMD])2HJ00R4K',BVNUY6JFDVON.=5BN/U=OIJ"KLEMGHJ;?@4\M,QT<6^_
M*U4T@%3\89J>BBX:W>[4S:O&Z:;EKFN9XC$22)J,<J>>DYU3_P"J3JVV_A['
M5VVMME)CRU4TB>IRTT4;GN?W16<J;Z)UWY:VNB31V*U16=UICMM&VUJBM6D2
M%OA*BKM4Y-:[F#CV&XYCE1)/8[+0T4\B:=)%$B.U[M]T3X=@*R]'V[0VZOR_
M'+W*RGR!MWFJGMF7E=.UR-3F;OOU:J]/)R+YF9@=73S\?^(#H)XI&K34K45C
MT5%5&-14^Q>GUE@Y!AF.9#51U-[LM#6U#$1&RRQ(KM)Y*O=4^"G&CPG&:*[)
M<Z6Q6^*O1&HV9L*;8C41&\GDW2(G;0$A*GX:R,=QHXGHCD5>>CZ;]T:HI;!H
M[;B..VRM2LMMBME)5HBHD\%*QC^J:7VD3?5% @7#%[%XR<441R*Y9:/7V,>B
MGW"7L7T@>(;6N;S>K471/A$W9/;9B>/6JN2MMECME'6)M/'@IF,?U[^TB;%#
MB..T%P;7T-BME/7(JN2HBI6-DVO=>9$WY@;LJ+A-5P0<2^*,,\K(Y/7HI>5[
MD:O)I_M=?+M^U"W305^&8Y<+TV[UUDH*BY-U_P!HDA17+KLJ^]4TFE7W 0:J
MD9_Y35&WF3F^;JIK?GXSE_L.-^<U/26QI%<G,MEE36^OTI"?+B&.+<_E);%:
MUN'B>-ZUZJSQ>?>^;GUO>_B*G$,<JKBZX5-AM<U>YW.M2^E8Z3F]_,J; J+'
M?F[#Q>S:TYW1V]:ZLJF55!/7QM5)(E;I&-<[IT3ETGGI?<6SBM'C-#/7P8M2
MVV"1JL]:2AC:U-Z7E1RM32KK:Z[IOXH=^1XK8LD;&E^M-'7^']!TT:*YOU.[
MHAFVBUT%GH8Z*TT=/1TC/HQ01HQJ?'2>8&CXIM5W#3*D:BJJVNIZ)_JW$1QA
M7W3T=8*2SS-DKI;%)!$QCDYED2-6JU/COH6I)&R6-\<K6OC>BM<UR;147NBH
M:3'\0Q['JB6>QV:BH9I>CI(8D:Y4]R+Y)\$Z 5APB;P\O^!V[UVVV!MQHZ=L
M-=%511MD:]B:5[N;KI=;W\?>BDISWYOUG#R"QT%)3U$5X8VFM5'"WPT<Y>K9
M&IKV6,^FKM=$3XIO?5F!8I6W9;G5X];):Y7<ZRNIVJKG>]4UI5^*F?58U9*N
MZ17*JM%!-<(E:L=2^G:Z5G+VTY4VF@*^X*W&2S3W/!\@1C,AH)73^.KE5;A$
MY=I,BKU5432+[D1$\EUTXI40P>D7G<<TC(WR4-(YB.77,C8X]JGU;+!EQ#')
M;DMQEL-K?<%D\7UEU*Q9>?>^;FUO>SC>L.QV^7&*ON]EH:RLB1&MEFB1SM)V
M1?>GP4#>M<CVHYJHYJIM%1=HJ%-XT]UH](_*(KLOAON]%$^WR/Z)*UB-16-7
MWII>G^B7(UJ,:C6HC6HFD1$TB(:Z^6&U7V!D-YM]-6,C=S1^,Q'*Q?>U>[5^
M* 5AQ IW7;CM@=/:_:J[='+55KV?^JA76D<OEO3D3^=\3(MSVKZ3-T;S)S?-
M]B:WY^*Q2Q[+8K79&2MM-!3TOBKS2.C9ITB^]SN[E^M3$3#L;2X>OI8+4E=X
MGB^L>JL\3GWOFYM;WL#>E27V>*G])7'O'>V-)K))&Q7+I'.YWKI/CI"VS39%
MBMCR18%OMJI*YT"[B=-&BJS??2]]? "ON.4\2W;ARY)&*U<A@7:.Z:1=*?/2
M)<UM!AG,Y$_^N.E7JOEI^R>UF&XS6^#ZYC]IG\&-(HO%I(W>&Q.S6[3HGU'9
M<\4Q^Z>!\IV2VUGJ\:11>L4S)/#8G9K=HND^H"K.)TULMO&O':S,*:GFQVKM
MKZ..2J8CH89_$5W,N^B=.5-^Y?<A8-DMN%4-ZIW6.CLD=TEB<^-]'%'XBQ].
M9=M3:-ZHF^W71N:['[17VAMJK;91SVUB(UM-)$US&HG;2>6O@=6.8Q9,;ADC
ML-KI*!LB[>L$:-5_UKW7[0,G(:VFMMAN5=7Q+-24U-)--&C4<KV-:JN32]]H
MB]"@.+>2562\%8+GXUKMMHK9XFP6Z+\9*K6O_*?M$:J<NU:UJZUW/1KV-D8Y
MDC4<QR:<U4VBI[E(S3</\2IJ6KIH,=MC(*M-3,2G;IZ;WKX)O2Z0"$^DO-$_
MAI Z.2-S%N-/I6N147NO]AW^DVYJ<)ZO:IUJJ?E^/MI_T)HN#8LZBIZ.3';3
M)2TZ*D4<E*Q[6;[ZVB]5]YD5N*8_74E+25UDMM32TB*VGAFIF/9$B]T:BII.
MR=@(+Z23FKP8NB\R:<^GY>O?\:SL:7C--34%UX<7>]TS*O&8))(JQKX_$C:L
MD;48]R>>O:5/YI:E5B>/U=!2T578[;/1TN_ @EIF.9%OORM5-)]ADML5I;9E
MM+;91I:U16^J>"WPM*N]<FM=^H$;MENX?PUUMJ[51X^M9.__ +'+311ND<[2
MKMBM3?1$5=^1',->Q?2$X@-1S5=ZG1]-^Z-F_P#H3K'</Q[')I);%9J*AFD3
M3I(8D1RI[M]]?#L<Z'$L=H+BE?0V*V4]<BJJ5$5*QLFU[^TB;Z[ @&.O;_Y2
MF5-YDYOD>#IOKWC-;P%N\-MOF:8[>Y64]_\ E>6K5LSN5T[7:3;=_2[;^IR*
M6C!B..T]R2XP6*V1W!'K)ZRRE8DO,O=>;6]G#(,-QS(JB.HO=EH:VHC33998
MD5^O=ONJ?#L!7^%UE-/Z0N=+!412(M%2M16/1454:Q%3ZT7H=V'O8OI"Y\U'
M-5WJ5'TW[HV;_P"A-Z3",9H[JVY4UAMT=<U&(R5L#=Q\J(C>7R;I$3MH[J'$
M<=M]P;7T-BME-7-552HBI6-DVO1?:1-^8$ QMS?_ "DLM1')S?),'3?^K/MI
M>S_RF+XU'-YOD"/IOKOQ(_\ ZA/J?$L=IKDEQI[%;(K@CUD]992L27F7NO,B
M;V(\1QV.Y_*4=BMC;CXGB^M)2L27GWOFY];WOX@4YPOCQAV29=8<VH;8N0LN
MT]0Q]?&SFJ(GKM.57=_?KW.1?>3+-8,=I.$N:0XM!;X*9E-,R9**-K6++R)O
M:M32KI6I_42[(L.QW(YHYKY9J&NFC339)8D5Z)[N;OKX=C(J,:LE3:8;746B
MWRVV%46.E?3L6)BIOJC-:3NO[0(-1.;_ .3<Q>9O+\V53>_/U=4_M-30^WZ+
M#N3VO_,<G;KV1=EF)BN/I:5M:62VI;%D\5:1*9GA*_\ .Y-:W]AWVVPVBUT,
MU%;;914E'-OQ((8&LC?M-+MJ)I=IT CW"JX4OX+<9D9,R1([7%S(Q>9VV,1'
M(B)U545-:]YGX)FEHS>V35MD?-R02K#+'/'R/8Y.O5/J4[;)B5CQOUF;'+-0
M455*U4YF,Y.;S1JNTJHW>NB?L..'XY\AK=*JHDCEN5TJ5JZI\3.2-':1J-:G
MN1$[KU5555[Z [,XFM,6,5K,C3_S34<E+4+Y(DKTC157R1%<G7R[E;8G#?.'
M?$&RXBZZ/O.,W6*9U&DR;FH_#;S:54[M[)[NO1$UUMZXT-+<J*:CN%-#54DS
M>62&9B/8]/<J+W-?9,7LECF=-:K;3TTRL\/Q&MV]&?FHY>J-^'8"N^'=5!3\
M:N)T,\K(Y'K22M:]R)MK8UVOU)S)^TV[<O6XYKD-AL#+;:Y;:QDM=<:QO,LB
MN;T5L:*WF1$U[3G:3IT4DUUPW'+O=H[G<[)055>Q$1)I84<Y43MOWZ^)RN&'
MX[<;Q'=:ZRT%1<8T1&SR0HYW3MOWZ\M]@*X]'.9DW"^Y:G9--)753G<O=55$
MZZ^/1?M,GT<JF.;@Q;Z>FJ(VU;'U,2)S)MLBR/<B?7I47ZBPK1BUBL]RJKA:
M[314E;4[\6:*)&N=M=KU\MKU77<Z;5AF-VFZR7.VV2@IJ]ZJJS1PHCD5>ZI[
MM_ "H.!4.%W#%%L^1VRT,R2W32Q5D==$SQ7^VJ\WM=5UO2^[7U%TXNRS1V>-
MN-14D=L1[TC2D8C8E5'*CE;I-+U1>J=S!O6#8O>[@E==K#;JNL36Y9(45SM?
MG?G?;LD$$4<$+(8(V1Q,:C6,8B(UJ)V1$3L@%4>DTY(\!H)7KJ..[4SWN\FH
MG-U4E'%>I@EX792Z*:-Z+;)7;:Y%Z*Q=+]OD2>[VRAO%OEH;K20U='*FGPS,
M1S7==IT7XFHI\(Q>"U_)L=@MGJ'.DBP.IVN:KT32.5%1=KI=;4")6ES/_)N:
MKE;R_-IZ*J]O^[J07(FS.]&;%*J"#UJEHI*6HK(43:/A:YR.:J>[FY=EWMQ3
M'VVIUL;9+:EM=)XJTJ4S/"5_YW)K6_L,BU6&TVFDFI;7;**CIIO\I#! UC']
M-=6HFEZ 0JWT_"^X6BFNU-0XX^F?RJQ? C5Z/54TWEUOGWI.76]ECD;M."8M
M:+G\H6RP6VEK=[26.!J*U?\ 1_-^S1) *BIIHHO2?JVRR,8Z7'D8Q'+KF=XK
M5TGO72*OV*<^(%%\O\9<%I;:G/46A9:ZNE9_ZF)>7D:Y?>Y6JB)\=FKN5FM-
M_P#24JZ2]4T-7#'86R,9(OT9$E;I4TO?2K^TN"T6>W6:G=#:J*GI(W+S.2%B
M-YE]ZKYK\5"JR:YO_E//3F3?S=UK?GXN_P"PQ<\>MH](+"[Q<UY+1-1R4,<S
M_H1SKXG15[(J\[$__<61)AV-RW%U?)8+6ZN=)XKJE:5BR*_>^;FUO>S976V4
M-WHGT=UHZ>LI7_2BGC1[5^Q0BJ?2/@==;?BUEM_MWJJN\;Z9K/I-:UKN9_P:
MFVJJF3QMC?CURQO/:1CG/L]0E/7(Q.KZ67V5_8J]/BXL"RXO9++.Z>UVRFIZ
MAS>19D;M_+^;S+UU\-Z,^XT-+<J*:CN$$=12RIRR12)MKD[]4 T7#ZBEBLLE
MRK8U9<+Q,ZOJ&N^DSGUX<:_S(T8WZT4KCA#7T%!8>)M7=/;M\5[K'U"-3FW%
MI-]/--;+IJ((JFGD@J(V20R-5CV/3;7-5-*BI[C46_$<=MOK'R?8;72^L1K#
M,D-*QGB,7NUVDZHON4"J;=17/A?E>.4=BNKKKAM^J_5XJ*5>=]*K_:1T;O-O
MGOMK>^J[-PU[?_*=>G,F_FWRZWY^-O7[">6?$,?LU2RHMEHI*>>-%;&]K-K&
MB]T9OZ*+[DT<OFCCORI\I?(5L^4?$\;UKU5GB\^]\W/K>]_$"M>#4CK7Q+XC
M6>ZKX=TJ:_UZ'GZ+/ KGJBM]Z(CF_5OX'9X#KGZ33:NV>U!:[1X5PD9]%'N5
M_*Q5_.TYJZ_T?@67>\;LU\?#)=K;354L/^2E>SVX_P":Y.J?8ID6BT6^S4JT
MUJHJ>C@5RN5D+$:CG+W5==U^*]0*UX=/8O&_B:B.:J_]B\_=&J*<,/D:GI"Y
M]U15]2I5TG?HQFRP+;B6/6NN;6VVQ6RDK$WJ>"F8R3JFE]I$WU%'B..T5Q2X
M4=BMD%>CE<E3'2L;)M>Z\R)OS IF_LFPZ@=Q'X=759+'<)V3UUGGZQRND>C7
M<GYK^9=*G=%WUTFCT!&[G8UVE;M$72]T(_3X3C5/7)5P62A9.DOC(J1)RI)^
M>C>R.^*)LD(
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M1S9J>18Y&*C55%1R=4ZH1K@"]\G"/'I)7NDD>R5SG/7:JJS/ZJH%@
M          '750I44TT#GR,;*Q6*Z-ZL<W::VCDZHOQ0#L!4_HUOFDPJZK4U
M$U3*EXJ&NEG>KWOTC$VJKW7H6P     B^!UF4UD%R7,;;24$C*IS:1*>3F1\
M/DY?:7_I]2 2@%86%E-Q%R7*WWR/UNRVJK6UTM$YR^$KV)^-D<B+[3E541%7
MLB=.ZDEX?X;%A=-<*2BN%74T$]0LU/3SNYDI6Z^@U5ZJG_S=]JH2H   !M-Z
MWU  B]=692S/[?24EMI'XH^F<ZJK'2?C62^UI$3F^#/R5[KUZ$H
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M[+;
M                                T3L/QM]<M:ZP6I:Q9/%6=:1G.K][
MYN;6][\S>@
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M*JK7L?45"LWSI&JN5[FJY=ZTB)TTBZZ%3_BEEDMCR_&[=<;A46?'*ULJU%?
MU$594^A&KU1>1OFJIUZ]T1%.&9W6_P"(<,J^OH[L^[_]J8L%P;&R22&C>K=O
M5$1&O<WVM+K75%7S-A>+E4W2HDI,CQ"X5>-5](Q\<:T[)I89D<]'-D8URJFV
M\CD<G;X+VT."VO)<(PFDA^2:BMH'W69\EMYFR3T] ]JHQ.^E<CM.5J*N^94
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M/=RHB+U1&IL(M8$;X>7.^W?%Z>LRJUMM=T>YZ/IV[1-(O1=*JJFT\E4D@
M
M
M                                                57Q9MUZN6889
M56FQ5M=2V>M];J98Y(FHK5Y>C$<]%5WLK[D[=2T*:59J>*5T4D+GM1RQR:YF
M;3LNE5-I\%4[                  ('QFL]^O.*118RC9JB"KBJ)Z-ST8E7
M$U558E5>FE72Z7OHG@ @S,FO5[MDM)2X;<Z2LFC6-RW)8F4T:JFE551RN>WX
M(WK\#?X5C\.+8K;+)32.ECHX4C\1R:5[N[G:\MJJKHW0
M      *NR6/);'Q49D<5JJK]89*#U1L-*YOBT;E<BN<UCE3?-RIM4]_?HF]E
M=*&MSNJLR5MEJ;5:K?6QW!SZY6>/*^/?*QC&.=RIM>JJJ+I-(G7:3\ ##NUL
MH[O2+2W&'QZ97(YT2N5&OUY.1%]IO^BNT7W&8 /C&M8U&L1&M:FD1$TB(?0
M
M
M
M
M
M
M
M
M
M                             !@WVYT]ELU=<ZQW+34<+YY%^#45?V]
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MQOP3Y'?5HEPJ9)ITEF5Z*[?E[DZJ!Z*
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M.$W!.^_(KU==$IN:>M1-/DF<J,YD]R-YNB>7UJI">&KLQPZ2X5]7PXN=WO\
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M*\6?Y;^&7^LE_M0*NH !
M
M               13B;AE/G6+R6FHJ'TLK9&ST]0Q-K%(W>EUYII53[2#U>)
M<5KG;7V:XY;9H[=*SP9:J"G=ZR^-4TO3E1-JGN5/K+C &CPG&:+$,9HK);.9
M:>F:J<[_ *3W*NW.7XJJJ;P
M
M
M                                  CW$*PS9/AEVLM--'!-60^&V21%
M5K5VB[77U&AX58SE6+T;;=D%YH:^UT].V&DBIX.1T>E\W:15Z$_  I^3AWE]
MSXA63(<BO]MJZ:U5#GPPQ0*QR1JOT=HB(J]NY<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                          -1DUQN5LH8YK199;Q.
MZ1&N@CG9"K6Z7VMO5$[HB:^)&OG=EWZNZ[[SIOX@)X"!_.[+OU=UWWG3?Q#Y
MW9=^KNN^\Z;^("> @?SNR[]7==]YTW\0^=V7?J[KOO.F_B G@('\[LN_5W7?
M>=-_$/G=EWZNZ[[SIOX@)X"!_.[+OU=UWWG3?Q#YW9=^KNN^\Z;^("> @?SN
MR[]7==]YTW\0^=V7?J[KOO.F_B G@('\[LN_5W7?>=-_$/G=EWZNZ[[SIOX@
M)X"!_.[+OU=UWWG3?Q#YW9=^KNN^\Z;^("> @?SNR[]7==]YTW\0^=V7?J[K
MOO.F_B G@('\[LN_5W7?>=-_$/G=EWZNZ[[SIOX@)X"!_.[+OU=UWWG3?Q#Y
MW9=^KNN^\Z;^("> @?SNR[]7==]YTW\1G6/(\CKKI!3W'"ZNVTK]\]4^N@D2
M/2*J>RU=KM=)T]X$N
M
M
M
M
M   =-95T]#325-;/%3T\:;?+*]&-:GQ5>B&GAS+&9I4CAR*SOD5=(UM;&JJO
M[P&^ :J.:BM5%1>J*GF8UPKZ.VTSJBXU4%)3M[RSR(QJ?:JZ R01V/.,6?*V
M),AM2/?]%'53&\WU;7K]A(FJCD16JBHO5%0
M
M
M
M
M                                             ^2,;(Q62-:YB]%:
MY-HI37H_6ZWU>$9-2U]+32T2WJJ8^.5B*SDY6=%1>FM%S%+<"+107O#<BI;G
M#ZQ3?+U4KHE>Y&OZ,Z.1%1')\%V@&5Z/%=+%A]_\6:62PT-QG;;II%5?^SMZ
M^ROFU/[54Y\&VKG3JW.<A8E1/+4OAME/)[4=% U=>PWLCU7>W=^GQ+"IELE;
M1W"P6N>B1M-&M-/2TKF[IT<U41%:GT>F^A6GH]U;\>@N>!7S5/>;;4OEA8[H
ME1 [KSL]Z;VOU*GQ"K0R>P4&2V2KM5U@9-35#%9[3456*J='-]RIW13-MU.M
M';Z:F=(LBPQ-C5ZIKFTFMZ^)]KZRGM]%/65LS(*6!BR22/736M1-JJFOI<CM
M<T5I=+5Q4LUTB26DIZA[62R(K4=I&[VJHBIM$"-N
M
M
M
M
M                                                 Z*ZDBKJ26FJ
M.=8I$TY&2.C77\YJHJ?8II,:PNP8S,^2PT'J2R;5[8YI.1R^]6J[2K\539(@
M!IK/B]GL]WNETMM"R"ON;T?5RHYRK(J;ZZ5=)U55Z:[G+(,:L^0)%\L6^&I?
M"NXI516R1+[VO33F_8J&W $5J, L%6QD=QAKKA Q4<D-;<*BHCVG;V'O5J_:
MAL+IBUFNEXM=UKZ".6OMBJM)+M4\+?P1=+VZ;WHW0
M
M
M
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M]41>VT\B%XDWUJ."P44DM79:K(755/6S)^,JZ>%K9I'N=K\8GC(QG.OTD7X
M3FX<0J6BJJSFM=PEMEOF;35]QCY%AII5UM%17(YR-YDYE:U43?UF3=<R=2W^
MKM-NL-UNT])%%+.^D\)&1^)S<J*KWMZZ:J]/@5Y=Z^"AQ'/,4J%7YP7"X524
M=&K5\2I2H=N-[$_*;[75?+E79SRV'%:6X9.MRJKQ0Y.D,7JNJF2-T\C84;$^
ME8Q=/ZHB+M%7:+O2!5TPO62&-[F.C<YJ*K':VWX+KILYFMQE:YV.6MUX35R6
MEB6I37_K>1.?^O9L@@
M
M
M
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MJBJB*J=E]Q]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
.               ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g111069g99a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a02.jpg
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M P$  A$#$0 _ /ZI
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            (J*B*BY1>94               "*BHBH
MJ*B\45              93>QE,\^          !XEECB1%ED8Q%7"*Y<94#V
M   &4WL93//@                *J)C*HF>">D    "JB)E51$YN(
M            (J*JHBHN."^@            !XEECB:BRR,8BKA%<N.)[
M          >'RQQN:V21C7.7#4<J(J_8![
M       54:BJY41$XJJ@                       *J)SJB='$
M                     /$4L<K=Z*1CVYQEJY3('L        #*;V,IGGP
M            (J*B*BHJ+Q14                &4551%3*<Z
M                ?'N:QJN>Y&M3BJJN$0,>V1B/C<CFKQ147**!]
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MZJ\&\Z\WV_ Y]\I/YXS2UI6DN=72PSW2"FFAAW4;(CE5R*JJF<HK4PF<>5%
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M>M@1\L*PHZHRDBY?F-4X8PFZC><[T
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MT-\J8Y8)5F@=R2,1_P#K$;(JIG>3&,G5
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M\K9&HY.=,HO.9@
M
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MT5R\J][VN<YRJY57CCCS'Z:PV=0:HK++6UEYN--7VI,PU5*V*.1S^ERKN?\
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MO#X(\,3^SCRY=UOD3T)Y$\AD;$X(J36^TVDIF-BI8[HQ61-3#6YW\X3HYD_
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MI*^KK62U#ZA7U*HJM5R(F$Q]F?2JJI6!
M
M
M                                                         !J-
M66-NH[%56J6MJJ."J8L<SZ;<WWQJBHYN7M<B(J+SHF?2?AHO3;=*V:*UT]QK
M:VC@:C(&U7)YB:G[**QC<I]N3?
M                                  !XG8Z2"1D<KHGN:K6R,1%5BJG.
MF45,IZ45#V (W16@H=)7&X5=%>KK4I<)W5-5%4\BK)979R_Q8T5%X]"HGH+(
M                                 #G\>S5+9?;A<M+:ANED2X2K-54L
M+8Y87/7G<UKVKNJO_P"_ I[#IZFM$\]4L]377&H:C9JVK>CI7M3F:F$1K6IE
M5W6HB97.,FY
M
M
M
M
M
M
M
M
M
M
M
M
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M5^XY3\IJCIYM&6NIEA8ZH@ND"1R*GC-1RJCD1?(N$S]B>0#KP   !51$XJB
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MG'%./I,LY#1T=/3?*>JGT\,<;I]/\M(K$QOOY5&[R^G")^ '7@,IG&4SY
M   (J*F45%  &/05M-<*5M30SQST[E<C9(URU5:JM7"_:BH!D
M
M
M
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M\5/1A.*IA>)7A
M
M
M
M                                              A=LFEKMK/2,EBM
M#Z"%M0]KY9JJ1[59N.1R(U&M7.<<<JF/3GA= # L:7!MLA9=XJ6.K8FZY*65
MTC%QTHKFM7[L?>IG@
M
M
M
M
M
M
M
M
M
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M0(7PN:%ZQ4WJY.R/"YH7K%3>KD[(%T"%\+FA>L5-ZN3LCPN:%ZQ4WJY.R!=
MA?"YH7K%3>KD[(\+FA>L5-ZN3L@70(7PMZ&X?_U%3>KD[(\+FA>L5-ZN3L@7
M0(7PN:%ZQ4WJY.R/"YH7K%3>KD[(%T"%\+FA>L5-ZN3LCPN:%ZQ4WJY.R!=
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MQ4WJY.R/"YH7K%3>KD[(%T"(AVL:(FFCBCU#3.DD<C&IN2<55<(GT2W
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ML >.2C_AL_ <E'_#9^![ 'CDH_X;/P')1_PV?@>P!XY*/^&S\!R4?\-GX'L
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M')1_PV?@>P! ;;XV-V?5"M8U%^>4?%$__,QE^06W']7M1_.4?]3&7H
M                                                -7JK]&+Q_)S?
MY'&T-7JK]&+Q_)S?Y' :K93^K/2G]UTW_;:5)+;*?U9Z4_NNF_[;2I
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M4^W\:8G=GENK;1HRUT%U_P#7H(U;,N47>=O*JNX>7.?O*(
M             !!4WZ]*[_AZ'^H>7I!4WZ]*[_AZ'^H>!>@
M                                    "*VL6"XWC2E=-I^XW*AO5-"L
ME,M)521I(K>.XK6KA<IE$7&<XXDQI>.37VQ>CJ+-=KK27ME.]B3LN$V^E4WZ
M2/57<4<J(N%SA'<,'7#C.DU[P=M%UTX_^SLNI$6X4'0UDZ9WV)Y,X7\& :?3
M]\J=2;)K5;:*X72'5U3<4MTDBU\W*PS-XRRN\;.ZD35=N_115YLECM"M4E)8
MK'IZRW6\1W>X5K((:ONA,LK6(B.FE<N]XR(QB\%X(KN")DA]/U=#8_E$5=PC
MI%99K[+/0TM2Y?$^=MW.55O^\]%;GI5?(=0L")?M?7:].\:CM35M-&O0LF4=
M4/3[]QF?]AP5#;?Z*ITOHJW5MAO5]I*I*V*F=)W3G>LC'(]5WD<Y4SE$7/W<
MQ<WS1+[DEAHX;K<Z>W4,KZJ:5M=*M5+)N[K$21554;AS\\?(B)QX2?RI?U>4
M/]ZP?Y9#L+?HI]@'#]L=!-IN?2++/>;_  I7W:*DJ,W:H?OQN5,IQ>N/M0L=
M4[/%KK4^*T7N^T]3O,7$MVGDCD;O)O->CG.X*W*$Y\H?_P!;T!_?T/\ U0[$
M$<5VQ0U=%M!T+#;KS>:.GO-<Z&MA@KY6L>U'1_13>PS@Y4\7!V6E@934T4$:
MR.9&U&HLDCI'*B>5SE557TJN3C6WV*>?7&S&*CJ?FM0^XR)'/N(_DW;T.%W5
MX+]A=]P-5]=7>ZX0.?Q4=2OR@I+#W:OO<9MM^>I2]TY]W?RB8SO9QQSC/^'
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MKMU.#>"8QZ JJ  0
M   !!;<?U>U'\Y1_U,9>D%MQ_5[4?SE'_4QEZ
M                               #5ZJ_1B\?R<W^1QM#5ZJ_1B\?R<W^
M1P&JV4_JSTI_==-_VVE22VRG]6>E/[KIO^VTJ0
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M-AJ[D:-;S-5RHJ^5$Q]ML
M             @MN/ZO:C^<H_P"IC+T@MN/ZO:C^<H_ZF,O0
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M^LFGO=C_ ,PT=]K=HEIO5@MS[Y8977:=\#7I;GHD:MC<_*IRG'Z.#K)!:_\
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MW,VC]9-/>['_ )@[F;1^LFGO=C_S"] $%W,VC]9-/>['_F#N9M'ZR:>]V/\
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MJZ3E(J>A?$]W^D,QARO7''"\QVH@MN/ZO:C^<H_ZF,O0
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M*[=:BJZ?'$O:+5NG=5ZBCL=OFIKHD,/=!\D;]YL+XY8^3^_*YY^&[Z0BQ
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M_P!L: 7-NK(;C;Z:MI'[]/4Q-FC=Y6N3*+^"DOK+:%:M(U]+276DNBOJGI'
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M'*+]V.*$)L+<NG=1ZQT-,JHVW5BU=$CEXK!)C&/L\1?M<IM?E)HB[';YGH=
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M5+10MAIHDPR-O,U/(AD   !!;<?U>U'\Y1_U,9>D%MQ_5[4?SE'_ %,9>@
M                                                    U>JOT8O'
M\G-_D<;0U>JOT8O'\G-_D<!JME/ZL]*?W73?]MI4DMLI_5GI3^ZZ;_MM*D
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MB+Y%RG09YJM,Z?MNF;4VW66G^;TC7NDW5>YZJYRY55<Y555SY5-J
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MC43F1$Z$ ]           05-^O2N_P"'H?ZAY>D%3?KTKO\ AZ'^H>!>@
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M&ZVW*.-.+^&6+]O!/5H=O-;?['07^CBI;K D\$4\=2UJKS/8Y'-7\4X^5%5
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M55^U3:@  !!;<?U>U'\Y1_U,9>D%MQ_5[4?SE'_4QEZ
M                                     #5ZJ_1B\?R<W^1QM#5ZJ_1B
M\?R<W^1P$=LSU?IJDV>:9IZK4-G@J(K=3LDBDK8FN8Y(VHJ*BNRBIY"D[]]*
M=9['[PB[1H=F.FK%4;.M,35%EMDLTEMIW/D?2QN<Y5C;E554XJ4W>II[ZAM/
ML<?P Q^_?2G6>Q^\(NT._?2G6>Q^\(NT9'>II[ZAM/L<?P'>II[ZAM/L<?P
MQ^_?2G6>Q^\(NT._?2G6>Q^\(NT9'>II[ZAM/L<?P'>II[ZAM/L<?P Q^_?2
MG6>Q^\(NT._?2G6>Q^\(NT9'>II[ZAM/L<?P'>II[ZAM/L<?P Q^_?2G6>Q^
M\(NT._?2G6>Q^\(NT9'>II[ZAM/L<?P'>II[ZAM/L<?P Q^_?2G6>Q^\(NT.
M_?2G6>Q^\(NT9'>II[ZAM/L<?P'>II[ZAM/L<?P Q^_?2G6>Q^\(NT._?2G6
M>Q^\(NT9'>II[ZAM/L<?P'>II[ZAM/L<?P Q^_?2G6>Q^\(NT._?2G6>Q^\(
MNT9'>II[ZAM/L<?P'>II[ZAM/L<?P Q^_?2G6>Q^\(NT._?2G6>Q^\(NT9'>
MII[ZAM/L<?P'>II[ZAM/L<?P Q^_?2G6>Q^\(NT._?2G6>Q^\(NT9'>II[ZA
MM/L<?P'>II[ZAM/L<?P Q^_?2G6>Q^\(NT._?2G6>Q^\(NT9'>II[ZAM/L<?
MP'>II[ZAM/L<?P Q^_?2G6>Q^\(NT._?2G6>Q^\(NT9'>II[ZAM/L<?P'>II
M[ZAM/L<?P Q^_?2G6>Q^\(NT._?2G6>Q^\(NT9'>II[ZAM/L<?P'>II[ZAM/
ML<?P Q^_?2G6>Q^\(NT1.OM5Z>J=3:&EIK_:9HJ>Z.DF?'61N2-O(2)O.5'<
M$RJ)E?*7W>II[ZAM/L<?P(?:!IVRP:HT)'!9[=&R:Z/9*UE,Q$>WD)%PY$3B
MF41<*!8=^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@
M!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^
ME.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C
M]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H
M=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.
ML]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X
M1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.
M]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU
M#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X
M_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]3
M3WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:
M?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@
M!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^
ME.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C
M]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H
M=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.
ML]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X
M1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.
M]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU
M#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X
M_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]3
M3WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:
M?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@
M!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^
ME.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C
M]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H
MB:?5>G4VSUM8M_M*4;K%%$D_SR/DU>D[U5N]O8SA47'.7W>II[ZAM/L<?P(>
MGT[95VU5M*MGMRTR6&*1(OFS-Q'<N]-[&,9QPR!8=^^E.L]C]X1=H=^^E.L]
MC]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=
MHR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]3
M3WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:
M?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@
M.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33W
MU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8
MX_@!C]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C
M]^^E.L]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.
ML]C]X1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X
M1=H=^^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^
M^E.L]C]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=H=^^E.L]
MC]X1=HR.]33WU#:?8X_@.]33WU#:?8X_@!C]^^E.L]C]X1=HB=<:KT[4:RT)
M-3W^TRPT]=.^9[*R-S8VK3O1%<J.X)E43B7W>II[ZAM/L<?P(?76G;+#K304
M4-GMT<<U?.V5C*5B)(B4[U1')CBF>/$"P[]]*=9['[PB[0[]]*=9['[PB[1D
M=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGO
MJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^Q
MQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =Z
MFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&
MT^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_
M #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]
M]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9[
M'[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[
M0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*
M=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[
MPB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D
M=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGO
MJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^Q
MQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =Z
MFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&
MT^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_
M #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]
M]*=9['[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9[
M'[PB[0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[
M0[]]*=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*
M=9['[PB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[
MPB[1D=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D
M=ZFGOJ&T^QQ_ =ZFGOJ&T^QQ_ #'[]]*=9['[PB[0[]]*=9['[PB[1D=ZFGO
MJ&T^QQ_ =ZFGOJ&T^QQ_ "!T3JO3U/KC7D]1?K3%!45E.Z&1]9&ULJ)3L15:
MJNPJ(J*G#I+;OWTIUGL?O"+M$?H?3MEFUSKZ*:SVZ2*"LIFQ,=3,5L:+3L54
M:F.'%<\"X[U-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]
MCC^ [U-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]CC^ [
MU-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]CC^ [U-/?4
M-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]CC^ [U-/?4-I]CC
M^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]CC^ [U-/?4-I]CC^ &/W
M[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]CC^ [U-/?4-I]CC^ &/W[Z4ZS
MV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]CC^ [U-/?4-I]CC^ &/W[Z4ZSV/WA%
MVAW[Z4ZSV/WA%VC([U-/?4-I]CC^ [U-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z
M4ZSV/WA%VC([U-/?4-I]CC^ [U-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/
MWA%VC([U-/?4-I]CC^ [U-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC
M([U-/?4-I]CC^ [U-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/
M?4-I]CC^ [U-/?4-I]CC^ &/W[Z4ZSV/WA%VAW[Z4ZSV/WA%VC([U-/?4-I]
MCC^ [U-/?4-I]CC^ $'M@U18+GHB6EMM]M575/K*3=A@JXY'NQ41JN&HJJO!
M,G53E^V2P6>AT--44-IM]-4-K*3=EAIF,<F:B-%PJ)GF.H
M                                         U>JOT8O'\G-_D<;0U>J
MOT8O'\G-_D<!JME/ZL]*?W73?]MI4DMLI_5GI3^ZZ;_MM-+M\U14Z5V;7"KM
M\BQ5M2YM)#(G.Q7YRY/2C4=CTX _?5>US1NF*U]'<;NV2LC7#X*:-TKF+Y'*
MW@B^A5R9FB]I.E=93+3V.Z,DJT3>6FE8Z.3'2J(Y/&^[)KMD&@+5I72EO>M'
M#)=ZF%LU752,1TBO<F5:BKQ1J9QA/)GG4Q-I6RZ/45RM5YTW/3V2_P!%4)(M
M8R+Z;$_>1N-Y47&,]&4 Z8"-VC:]HM#6VD=5P35]SK'\E245,GCSOX9QSX3*
MIY5XISD?5[5M3Z>9#7:TT'4VZRRN1KJJGJFS.@RO#?:B?]<?CP [$"&VB;1*
M32.C[?J*FIFW.BK)XHV*R;DTW'M<Y'HNZN>#>;'22%VVP:AI+>M_@T'6.THB
MHJ5DU2C)7QJN$DY/"JB+E,9X>D#M .0U&UF\W:F?7:#T;6WJTPMWI:R65($<
MN,N:QBHJN5.9<9XHO H].[2*._;,Z[5U%1O3YE#,^:C?)A6R1MWE9O8Z4QA<
M<R\W0!=@XO;ML&H-26IE;H[0M5<8HF9JI'U*,8Q_.L;%5J+(J)CF3IYC]+1M
MIJ=36V%FCM*5MSOF%6KI'2I'%287";TJIA<]"<.9>; '9 <^V8;17ZNN%UM%
MVM$MFOUL5.7I7OWT5JKC>1<)Z/Q145<FLO&U2NJ]2UMBT#IJ;4-50NW*NH6=
M(8(G9QN[R\%7**G.G%%QD#J@.<Z'VF+>-22::U+9I]/ZB8SE&4\KTD9.U$RJ
ML?A,\$5?)A%PJX4U^H]KSK5KNZZ4H]-U=RN=.V+YJVGFXU#GQM>N4W?$:U'<
M797FYO('5@<ELVU:ZTVKK?I_76E9;%-<G;E).VH2:-[E7"-543'.J)E%7"JF
M43.3K0           ""VC_I9L^_O9_\ 3R%Z06T?]+-GW][/_IY 1>@$1M7U
MC)I6R106N/YSJ*YO^:VVF1,JZ1>&^J?NMRB_;A.D#=46KK+7:JK--TE:V6\4
M<7+3PM8[#&Y:G%V-W/C-X9SQ,V_WNVZ?MDMPO5;#1T<?TI95PF>A$Z57T)Q.
M";%]/3:7V[WRV5E4^LK6V=)JF=RYWY9'0O>N?)O.4WNTF)FJMN^D-+UZ)+:*
M2F?<)X'?1D?X^$<G2GB-3['+Y0+C2^U31NI[DVWVB]1R5CUPR*6)\2R?[N^B
M(J^A.)7UU73T%'-5UL\=/30M5\DLCD:UC4YU55YCE7RBM-T+]G<]XHZ:*FNE
MG?%/2U$+$8]B;[45J*G1A<X\J(3NUV]SZKTOLUM'*.CCU1/3R5>XN,MQ'E/L
MS)G_ )4 OK;MCT)<;HV@IK_%R[W;C'2121L<OD1[FHG^)T A=HFB++<=G%RM
M45MI8F4U(]])R<2(L+V-56JU>=.*)GRID_#8'>Y[]LKLM36/62IA:ZF>]5RK
MN3<K6JOIW4:!T$@+MMBT+:KH^WU=^B^<1NW'K%%)(QB\V%<UJI_CP/VVWWJ>
MP;+K_74<BQU/)-@C>U<*U9'HS*>E$<JF/LKT79[?LQM-#-;J69*ZCCFK.4B1
MRS/D:CG;V>?&<)Y$1 +FWUM+<J*&LH*B*II9FH^.6)R.:]/*BH26JMJ6C]+7
M%:"\WF..M;C?ABC?*YG^]N(N/L7B<ZV/W5^DJ?:=8T<Y])IR::JI&O7.&8D7
M=_\ V;5^U5-Q\FZP4LF@EO\ <((JJZWF>::HJ)F(][FH]6[N5Z%5JKC_ &@K
MJ&GK[;-1VR.X6.MAK:-ZX22->94YT5.=%]"\34:RV@:9T<Z*/4-UCIIY4WF0
MM:Z214\NZU%5$]*\#G6A8(](_*!U'IRVL2"T7.B;71T[>#(Y$QG=3H3B_@GH
M\AXV$TD&J=5:SUC=(F556^X.I*5TK4=R,;4SAN>;Q58F?1Z5".IZ1U?8M7T<
ME3IVY15D<:HDC6HK7L5>;>:Y$5/P-\</U/2P:,^4#I6NM$3*6GU!%)2UD,2;
MK)'HN$=A.&<K&OW>E3N &IU/J2T:7MJU]_KX:*ESNHZ3*JY?(UJ95R^A$4TN
MD-I>D]75JT=BN\<U8B*Y()(WQ/<B<ZM1R)O?=D@+Q3Q:Q^4E#:KFQM1;=/V[
MYRVFD3+'2.W5WE3IXR,_\*'Z_*2M,%LT];=6VJ"*FO-IK8G,GC:C5<Q55-UV
M.=,[O/Z?*H5U^[7.BL]NGK[I514M'"F])-*[=:U"/L&US1-^NK+=;KY&ZKD=
MNQMEBDB21?(U7-1%7T<ZD/M>J4U=K;9SIF17=R[@[NA4Q9X2-1,HU?N1Z?>4
M^W'2-JK]F%U=%0T\%1;*=:FDDBC1CH=SBJ-5.9%1%3'P".DSRQP0R33R,CBC
M:KGO>N&M1.=55>9" BVSZ!EN:4+=0P\HKMQ)'12)$J_[ZMW<>G./2<XVCZJK
M[YL(TA$V9R5FH)H:.HD1>+T;E'_BYK<_>=<N6@;!4Z(DTVRVTS:)*=8HL1IO
M,?NX21%Y][/'/.J@5C'->QKF.1S7)E%1<HJ'TY5\F>\U%VV84\-8]7RVVHDH
MD<Y<JK6X<U/N1Z)]B'50
M   $%3?KTKO^'H?ZAY>D%3?KTKO^'H?ZAX%Z
M          !!:_\ TYV>?WA4?TSR](+7_P"G.SS^\*C^F>!>@
M                                                         (+0
M7Z?[1/YZE_IF%Z06@OT_VB?SU+_3,+T
M      (+;C^KVH_G*/\ J8R](+;C^KVH_G*/^IC+T
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MSKG[0(G3&^GRF=><ECE.Y<.[]O)TY]^2?R7>#<G?_P":MSD^<[WTM[<9C/\
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MZQO_ %:OX'9#7:<LU%IZQT=IM<7)4=)&D<;<Y7TJJ]*JN55?*JFQ"
M                                    $%3?KTKO^'H?ZAY>D%3?KTKO
M^'H?ZAX%Z                                  !!:__ $YV>?WA4?TS
MR](+7_Z<[//[PJ/Z9X%Z
M                             @M!?I_M$_GJ7^F87I!:"_3_ &B?SU+_
M $S"]                                   ""VX_J]J/YRC_J8R](+;
MC^KVH_G*/^IC+T
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M[54_ECE=I_F>C/:JG\L"]!!<KM/\ST9[54_ECE=I_F>C/:JG\L"]!!<KM/\
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MCH:.>1F-YD;G)GRHBD+L,U5<M8Z$CNMZ=$ZK=421JL3-QN&XQP Z
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MIGG:OI1<HOI0V8
M(*F_7I7?\/0_U#R](*F_7I7?\/0_U#P+T
M       ""U_^G.SS^\*C^F>7I!:__3G9Y_>%1_3/ O0
M                                                   $%H+]/]HG
M\]2_TS"](+07Z?[1/YZE_IF%Z
M$%MQ_5[4?SE'_4QEZ06W']7M1_.4?]3&7H
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MW*AN4<];+#B&W-RM0Z54PC%9SIQX9YO2:_Y+*JNRJ)5Y_GDW_5 .N@ (
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M8AIRHTOLUM%OKHUCK7-=43,7G:Y[E=NKZ4141?2A=!
M                            (*F_7I7?\/0_U#R](*F_7I7?\/0_U#P+
MT                                  ""U_^G.SS^\*C^F>7I!:__3G9
MY_>%1_3/ O0
M                   $%H+]/]HG\]2_TS"](+07Z?[1/YZE_IF%Z
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MK?B!E Q>Z5#YY3>M;\1W2H?/*;UK?B!E Q>Z5#YY3>M;\1W2H?/*;UK?B!E
MQ>Z5#YY3>M;\1W2H?/*;UK?B!E Q>Z5#YY3>M;\1W2H?/*;UK?B!&;<?U>U'
M\Y1_U,9>G.MME;2S: G9%4P/>M91X:V1%5?])C.B@
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ML'))NI(L[VJ['EPB(=F(*F_7I7?\/0_U#P,KP6Z'ZKVOU*#P6Z'ZKVOU*%F
M(SP6Z'ZKVOU*#P6Z'ZKVOU*%F (SP6Z'ZKVOU*#P6Z'ZKVOU*%F (SP6Z'ZK
MVOU*#P6Z'ZKVOU*%F (SP6Z'ZKVOU*#P6Z'ZKVOU*%F (SP6Z'ZKVOU*#P6Z
M'ZKVOU*%F (SP6Z'ZKVOU*#P6Z'ZKVOU*%F (SP6Z'ZKVOU*#P6Z'ZKVOU*%
MF (SP6Z'ZKVOU*#P6Z'ZKVOU*%F (SP6Z'ZKVOU*#P6Z'ZKVOU*%F (SP6Z'
MZKVOU*#P6Z'ZKVOU*%F (SP6Z'ZKVOU*#P6Z'ZKVOU*%F (SP6Z'ZKVOU*#P
M6Z'ZKVOU*%F (SP6Z'ZKVOU*$;K39]I.CU?HBFI=/V^*"LK9HZAC8D1)&I ]
MR(OWHBG92"U_^G.SS^\*C^F>!E>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U
M^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_
M5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP
M!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5
M>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W
M0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0
MLP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0
M_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>
M"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^
MI0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"
MW0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!&>"W0_5>U^I
M0>"W0_5>U^I0LP!&>"W0_5>U^I0>"W0_5>U^I0LP!QK1NS_2=9K37%+5:?M\
MM/1U=.RGC=%E(FN@:Y43[555++P6Z'ZKVOU*&+H+]/\ :)_/4O\ 3,+T",\%
MNA^J]K]2@\%NA^J]K]2A9@",\%NA^J]K]2@\%NA^J]K]2A9@",\%NA^J]K]2
M@\%NA^J]K]2A9@",\%NA^J]K]2@\%NA^J]K]2A9@",\%NA^J]K]2@\%NA^J]
MK]2A9@",\%NA^J]K]2@\%NA^J]K]2A9@",\%NA^J]K]2@\%NA^J]K]2A9@",
M\%NA^J]K]2@\%NA^J]K]2A9@",\%NA^J]K]2@\%NA^J]K]2A9@",\%NA^J]K
M]2@\%NA^J]K]2A9@",\%NA^J]K]2@\%NA^J]K]2A9@",\%NA^J]K]2@\%NA^
MJ]K]2A9@",\%NA^J]K]2@\%NA^J]K]2A9@#CFU?0>EK)HZ2OM-AH*2LBK*1&
M311X<W-1&BX7[%5#L9!;<?U>U'\Y1_U,9>@
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M5S(IVYPK<^G=_P#$OH.['%=L'^D;9ME]/%QECJ))7(G/N[S%_P"C'':@@
M                                                  $%3?KTKO\
MAZ'^H>7I!4WZ]*[_ (>A_J'@7H
M$%K_ /3G9Y_>%1_3/+T@M?\ Z<[//[PJ/Z9X%Z
M                                               @M!?I_M$_GJ7^
MF87I!:"_3_:)_/4O],PO0                                   @MN/
MZO:C^<H_ZF,O2"VX_J]J/YRC_J8R]
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MFC:OW)_X43HRNFN6D-7:0UO==0;/HJ&X4-X<DE9;*J3D\2\5WVNRB<ZJO/\
MM*F%X8[  .5:'T9J*NUT_6NOW4C+E%"M/04%*[>93,7.55?+ASNE?I+Z$3JH
M                                                       (*F_7
MI7?\/0_U#R](*F_7I7?\/0_U#P+T
M  ""U_\ ISL\_O"H_IGEZ06O_P!.=GG]X5'],\"]
M                                                 06@OT_VB?SU
M+_3,+T@M!?I_M$_GJ7^F87H                                   06
MW']7M1_.4?\ 4QEZ06W']7M1_.4?]3&7H
M                           ,&_4\E98[C30(BS34TD;$5<9<K51/^IG
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MT=#1,DJ()'3K=HI-Q&2M>OB[J9X-\IU<
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M]RJ94;VR1M?&YKV.3+7-7**GE0#Z
M
M
M
M
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M@DMM$^AB^A3.@8L;.?F;C"<Z_B9%#14M!3I!04T%- BJJ1PQHQJ*O/P3@?N
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M0,65%1,)A^,\/M*'9K^KS3']V4W_ &FFNVT_JJU1_)/-CLU_5YIC^[*;_M-
MHP
M
M
M
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M:>DA9!'OKEVZUJ-3*^7" 9@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)QZ54_0
M
M
M
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MU3TO\U/_ )@KK(-9J9EWDL=7'IR2DBNKVHV"2JSR;%5>+E1$7*HF51,8SC/
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M]1+7RN29=Y,HZ/>W-U?(C41.@*Z%L\3&@=-8^K*;_M-* T&SW] =-?W93?\
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M<^:\EW+POT\<_DY^.]S]',!7@
M
M
M
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MUC8>07CE'-PKE^DO,B\R>7A3;VL?"5N[E%WF?-?I93E>5Q^.<_=CTE>
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!">%W0W#_P#J"'U,O9'A>T+UAA]3+V0+L$)X7M"]88?4R]D>%[0O6&'U,O9
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M%?(Y&-3DI$RJKA$^B7(
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M_=3\#Z /FXW]U/P&XW]U/P/H ^;C?W4_ ;C?W4_ ^@#YN-_=3\!N-_=3\#Z
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MW&_NI^ W&_NI^!] 'S<;^ZGX#<;^ZGX'T ?-QO[J?@-QO[J?@?0!\W&_NI^
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M=+/0W6&^5/SRJFN,LZ5.ZUG+,<C=UVZW@W@F,>@*J0 $
M                                06W']7M1_.4?]3&7I!;<?U>U'\Y1
M_P!3&7H
M -7JK]&+Q_)S?Y'&T-7JK]&+Q_)S?Y' :K93^K/2G]UTW_;:5)+;*?U9Z4_N
MNF_[;2I                            8MVM]/=;75V^M8DE+51.AE:O2
MUR*B_P#4R@!R_8OL_J]+V*YT^HW?.JB9[Z.-'N1R)1M<[<:GD1RO>['^TB=!
M]V+[/ZO1LM[=<I'2HD[J6V[ST=N4:/5Z8\F\YZJJ>5J'3P!K[]45M/;)76NA
M=75:INLB25L:95%XJYR\W-Y5(#8-I_4&D-,K8K_;61(R62=E3%4,D:J.QXJH
MBY1>?T'3P!.Z^;<ZC3-PH+-;5KJFMII:=%69D;8U<Q6HYRN7*IQZ$7F-%L5M
M5[TWHRAT_?K:E/)1-DW:B.=DC)-Z1SD3"+E%\;R8X<Y?@"4VGTEUN6B[I:['
M0)5U5P@?39=,V-L2.:J*Y57GY^9#&V1T%XLNC;?9;[;DI)Z"%(DE9.R1DO%>
M*87*<,9RA: #ENWO3NH-8:=ALFG[:R5.794/J9:AD;4W=Y-U$7BJ\4X\Q<+2
M=\FFIZ+4=K^;MJHUAJ*5TK9$PJ<51S5_!><W0 Y;HRRZJV=0OL]-2=\FFVO<
M^D=%,R*KIFJN58YKU:UZ9\CDZ?L3:ZEBU+K&VRV>FM\NGK=5-Y.KK*N6-\ZQ
M+])D4<;G(BJG#><Y,(J\%+T :_3UFHM/V6CM5JBY&BI8TCC;SKCI55Z55<JJ
M^53F5MTQJ?9]JV]5FE[?#?-.W>;YS)0I4-@FII55556*_P 54X\V>;'-C*]=
M '/;K3ZCUO3,M=PL_<"QR/:ZM6>I9+45$:+E8F-C54:CL85RNSC/ Z$B(B(B
M)A$YD0 #DNUJQ:HU)J#34UELK'4]DKTK%DFJXV<OAS51&IE53Z*\_P"!U*WS
M35%''+54KZ29R+O0O>URLX^5JJB^7@ID  <DU]8]4W;:7IF^6RQLDH+&^3/*
M5D;'3H[@JM3/#@G#/^!UL 8R5$ZV[EUHY$J.3W_FV^W>WL?0WL[N>C.<$7HB
MAOR:TU%>-0VGYM\_2**E>VI9*D,$:+B-<+G*N<YRXX9+T <XVZZ8N>K=*06Z
MR47+5[*EE3#.LS(VP.:O.N5RN4<[&/)Q/>IN^R][.*VU2:?1MYK:5U)*Y*R+
MDFJYN%D1<YPN5PF,_P#4Z( (?9C9[A2: I=.ZHM3(OFU-\U?_;,ECJ&+E%YN
M*<."HJ=).Z&TSJC9Q>JJV6ZF6^:-J9%E@1L[&5%$JKQ3#W-1R>7"^G@N47K0
M &EUK88=3:4NMFJ$3=K('1M5?V7\[7?<Y$7[C= "(V-Z6J-):#H:*Y(JW21.
M6JU<_>5'JB(C<].ZQK&^3Q3$I:34-?M/I[S=+(Z"TTM&^EI$^=1O=$][D5\K
MFHO2C4;PSP^WAT( 2FU.T3W_ $+=;124*UD]9$L;&\HUB,?SM>JN7F1R-7AQ
M-/H5^KK+H6DM=WL'SFY44"4\;XJR+<E:F4:JJJY3"(B+P7RG0P!QS8W:-9Z&
MTU-:+CIV&K:M0^>.6"OC3&\B9:J+Z4Y\]);6)^IKAJR6KO%"EJM%/2K%!3-J
MFRK/*YR*LC]W@FZC41$_VE^ZM '(Z/3&I] ZSO5RTI00WNP7F7YQ/0?.&P34
M\N557,5WBJG%>&>;"=&5W5VAU+K:C2TUMF73]EG5/GLD]2R6>:-%RL3&QJJ-
MWN97*O,J\#H0 T^IWUT-CGALUN6MJ)(W1,C25D369:J(JJY>;FYLKZ#G6R"V
M:QT1I%ECN.G(JI(I7R1RPW"-,HY<X5%].>DZZ (ZS2:IN6KFU5VH$M%DI:9S
M8X&U3975$SG)XS]W@B-:BX3RNS]EB                             @J
M;]>E=_P]#_4/+T@J;]>E=_P]#_4/ O0
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M6E+/98)73U<WSQDDD^&KN1HC>9JN5%7RHF/MM@
M                             $%MQ_5[4?SE'_4QEZ06W']7M1_.4?\
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M-HG633_NI_YH[F;1.LFG_=3_ ,TN@!"]S-HG633_ +J?^:.YFT3K)I_W4_\
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MM$ZR:?\ =3_S2Z $+W,VB=9-/^ZG_FCN9M$ZR:?]U/\ S2Z $+W,VB=9-/\
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MK)I_W4_\T=S-HG633_NI_P":70 A>YFT3K)I_P!U/_-'<S:)UDT_[J?^:70
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MU'\Y1_U,9>@
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MDIJF)T,K%_::Y%14_!3E'R>ZR>U17_0UR>JUE@JW)"J\-^G>JJUR>C.5^QZ
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MF&1LYFIY$/W   ""VX_J]J/YRC_J8R](+;C^KVH_G*/^IC+T
M                                          &KU5^C%X_DYO\ (XVA
MJ]5?HQ>/Y.;_ ". U6RG]6>E/[KIO^VTJ26V4_JSTI_==-_VVE2
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M[A,^#"<S5:KN+?\ 97*>@KH8V0Q,BA8V.-C4:UC4PC43F1$Z$ ]
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M.WMYOE3><O%.A6KTG9#0:CT?9-0U$%5<J)%KH/\ 4UD$CH9X_P#=D8J.^[.
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M<JN7'0F<)T&V         @M!?I_M$_GJ7^F87I!:"_3_ &B?SU+_ $S"]
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MKVH_G*/^IC+T@MN/ZO:C^<H_ZF,O0
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MOV2/X 8??WI'K58?>$/:'?WI'K58?>$/:,SO7L'U':_9(_@.]>P?4=K]DC^
M&'W]Z1ZU6'WA#VAW]Z1ZU6'WA#VC,[U[!]1VOV2/X#O7L'U':_9(_@!A]_>D
M>M5A]X0]H=_>D>M5A]X0]HS.]>P?4=K]DC^ [U[!]1VOV2/X 8??WI'K58?>
M$/:'?WI'K58?>$/:,SO7L'U':_9(_@.]>P?4=K]DC^ &'W]Z1ZU6'WA#VAW]
MZ1ZU6'WA#VC,[U[!]1VOV2/X#O7L'U':_9(_@!A]_>D>M5A]X0]H=_>D>M5A
M]X0]HS.]>P?4=K]DC^ [U[!]1VOV2/X 8??WI'K58?>$/:'?WI'K58?>$/:,
MSO7L'U':_9(_@.]>P?4=K]DC^ &'W]Z1ZU6'WA#VAW]Z1ZU6'WA#VC,[U[!]
M1VOV2/X#O7L'U':_9(_@!A]_>D>M5A]X0]H=_>D>M5A]X0]HS.]>P?4=K]DC
M^ [U[!]1VOV2/X 8??WI'K58?>$/:'?WI'K58?>$/:,SO7L'U':_9(_@.]>P
M?4=K]DC^ &'W]Z1ZU6'WA#VAW]Z1ZU6'WA#VC,[U[!]1VOV2/X#O7L'U':_9
M(_@!A]_>D>M5A]X0]HB:?5VFTVS5M:NH;.E&ZQ11)/\ /8^35Z3O56[V]C.%
M1<<YT+O7L'U':_9(_@0U-8+.NVJMIEM-O6F2PQ2)%\V9N([EWIO8QC..D"M[
M^](]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6J
MP^\(>T._O2/6JP^\(>T9G>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[TCUJL/O"'M
M#O[TCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]
M:K#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6JP^\(>T._O2/6JP^\(
M>T9G>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[TCUJL/O"'M#O[TCUJL/O"'M&9WK
MV#ZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7
M[)'\!WKV#ZCM?LD?P P^_O2/6JP^\(>T._O2/6JP^\(>T9G>O8/J.U^R1_ =
MZ]@^H[7[)'\ ,/O[TCUJL/O"'M#O[TCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.
MU^R1_ ##[^](]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P
M P^_O2/6JP^\(>T._O2/6JP^\(>T9G>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[T
MCUJL/O"'M#O[TCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[
MPA[0[^](]:K#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6JP^\(>T16
MN-7Z;J-9:$FI]0V>6&GKIWS2,K8W-B:M.]$5RH[@F51./2=![U[!]1VOV2/X
M$/KJP6>'6F@HX;3;XXYJ^=LC&TS$1Z)3O5$<F.*9X\0*SO[TCUJL/O"'M#O[
MTCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]:K#
M[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6JP^\(>T._O2/6JP^\(>T9
MG>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[TCUJL/O"'M#O[TCUJL/O"'M&9WKV#Z
MCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7[)'
M\!WKV#ZCM?LD?P P^_O2/6JP^\(>T._O2/6JP^\(>T9G>O8/J.U^R1_ =Z]@
M^H[7[)'\ ,/O[TCUJL/O"'M#O[TCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.U^R
M1_ ##[^](]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^
M_O2/6JP^\(>T._O2/6JP^\(>T9G>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[TCUJ
ML/O"'M#O[TCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[
M0[^](]:K#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6JP^\(>T._O2/
M6JP^\(>T9G>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[TCUJL/O"'M#O[TCUJL/O"
M'M&9WKV#ZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]:K#[PA[1F=Z
M]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6JP^\(>T._O2/6JP^\(>T9G>O8/J.U
M^R1_ =Z]@^H[7[)'\ ,/O[TCUJL/O"'M#O[TCUJL/O"'M&9WKV#ZCM?LD?P'
M>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7[)'\!WKV#ZC
MM?LD?P P^_O2/6JP^\(>T._O2/6JP^\(>T9G>O8/J.U^R1_ =Z]@^H[7[)'\
M ,/O[TCUJL/O"'M#O[TCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.U^R1_ ##[^]
M(]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6JP^
M\(>T._O2/6JP^\(>T9G>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[TCUJL/O"'M#O
M[TCUJL/O"'M&9WKV#ZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]:K
M#[PA[1F=Z]@^H[7[)'\!WKV#ZCM?LD?P P^_O2/6JP^\(>T._O2/6JP^\(>T
M9G>O8/J.U^R1_ =Z]@^H[7[)'\ ,/O[TCUJL/O"'M#O[TCUJL/O"'M&9WKV#
MZCM?LD?P'>O8/J.U^R1_ ##[^](]:K#[PA[0[^](]:K#[PA[1F=Z]@^H[7[)
M'\!WKV#ZCM?LD?P Y[HG5VFZ?7&O)ZC4-GB@J:RG=#(^MC:V5$IV(JM578<B
M*BIPZ2V[^](]:K#[PA[1)Z'L%GFUUKZ*:TV^2*&LIFQ,=3,5&(M.Q51J8X<>
M/ N.]>P?4=K]DC^ &'W]Z1ZU6'WA#VAW]Z1ZU6'WA#VC,[U[!]1VOV2/X#O7
ML'U':_9(_@!A]_>D>M5A]X0]H=_>D>M5A]X0]HS.]>P?4=K]DC^ [U[!]1VO
MV2/X 8??WI'K58?>$/:'?WI'K58?>$/:,SO7L'U':_9(_@.]>P?4=K]DC^ &
M'W]Z1ZU6'WA#VAW]Z1ZU6'WA#VC,[U[!]1VOV2/X#O7L'U':_9(_@!A]_>D>
MM5A]X0]H=_>D>M5A]X0]HS.]>P?4=K]DC^ [U[!]1VOV2/X 8??WI'K58?>$
M/:'?WI'K58?>$/:,SO7L'U':_9(_@.]>P?4=K]DC^ &'W]Z1ZU6'WA#VAW]Z
M1ZU6'WA#VC,[U[!]1VOV2/X#O7L'U':_9(_@!A]_>D>M5A]X0]H=_>D>M5A]
MX0]HS.]>P?4=K]DC^ [U[!]1VOV2/X 8??WI'K58?>$/:'?WI'K58?>$/:,S
MO7L'U':_9(_@.]>P?4=K]DC^ &'W]Z1ZU6'WA#VAW]Z1ZU6'WA#VC,[U[!]1
MVOV2/X#O7L'U':_9(_@!A]_>D>M5A]X0]H=_>D>M5A]X0]HS.]>P?4=K]DC^
M [U[!]1VOV2/X 8??WI'K58?>$/:'?WI'K58?>$/:,SO7L'U':_9(_@.]>P?
M4=K]DC^ &'W]Z1ZU6'WA#VAW]Z1ZU6'WA#VC,[U[!]1VOV2/X#O7L'U':_9(
M_@!S_;!JO3MST1+26V_VFLJGUE)N0T]9'(]V*B-5PU'*J\$R=7.8[9;%::'0
MLU116N@IYVUE)NR14[&.3-1&BX5$SS'3@
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M</F%DN[):U456PR1OB<]$Y]W>1,\./#B68           ""VC_I9L^_O9_\
M3R%Z06T?]+-GW][/_IY 1>GE7L:N%<U%]*GH_GB\:4M>L?E)WVV7V.:6D9;(
MYVMCE=&N\C8D1<IZ'*!_0Y\<YK?I.1/M4QUDI;=30QRS1P1-1(V+*]$SPPB9
M7G4D]JNCK1JO3\LMXBED?;X)IJ=8Y7,P[<Z<<_T4 M6JCDRU45/0#E/R855V
MR.WJJJJ\O/S_ /O%.K
M                          (*F_7I7?\ #T/]0\O2"IOUZ5W_  ]#_4/
MO0                                  (+7_ .G.SS^\*C^F>7I!:_\
MTYV>?WA4?TSP+T
M                      !!:"_3_:)_/4O],PO2"T%^G^T3^>I?Z9A>@
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M+CGQE?Q4[F<NVT:<NU]O6AIK31/J8J"ZMGJ7-<U.3C1S%WEROH7F.HA
M      ""VC_I9L^_O9_]/(7I!;1_TLV??WL_^GD!%Z<5LG_M5:A_N9G_ $A.
MU'%;)_[56H?[F9_TA!$-\J+3.J+GK*CK*.@KKA:5IFQP)31ND2)^5WD5K<X5
M>"YZ>'D.NZ$M]WM6Q&.CU&K^Z,5OG1S9%RYC51ZL:OI1NZGHQ@Z,:S5'Z,W?
M^3F_R."N>?)@_5%;_P"8G_[BG5CE/R8/U16_^8G_ .XIU8(
M                                                      05-^O2
MN_X>A_J'EZ05-^O2N_X>A_J'@7H
M $%K_P#3G9Y_>%1_3/+T@M?_ *<[//[PJ/Z9X%Z
M                                                @M!?I_M$_GJ7
M^F87I!:"_3_:)_/4O],PO0                                   @MN
M/ZO:C^<H_P"IC+T@MN/ZO:C^<H_ZF,O0
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MJ>P!= A>5VE^::/]IJ>P.5VE^::/]IJ>P!= A>5VE^::/]IJ>P.5VE^::/\
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MY7:7YIH_VFI[ Y7:7YIH_P!IJ>P!= A>5VE^::/]IJ>P.5VE^::/]IJ>P!=
MA>5VE^::/]IJ>P.5VE^::/\ ::GL 70(7E=I?FFC_::GL#E=I?FFC_::GL 7
M0(7E=I?FFC_::GL#E=I?FFC_ &FI[ %T"%Y7:7YIH_VFI[ Y7:7YIH_VFI[
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MDY1U%-,Z7_UAF,(YJ)SXSQYCM
M                    -7JK]&+Q_)S?Y'&T-7JK]&+Q_)S?Y' :K93^K/2G
M]UTW_;:5)+;*?U9Z4_NNF_[;3*UYJBFT;I:LOM=!-/3TJL1T<.-Y=YZ,3&51
M.=P&_!QF+;U231,DAT=J>2-Z(YKVTR*CD7F5%SQ0I=![6=/ZPNK[3#'6VZ[-
M17)25T21O?A,KNX54543CC@N.@#H(   &#?;K2V.SUMTN+UCI*2)TTKD3*[J
M)G@G2H&<#G.SO:7/K6Y)'3Z5NU#:WQNDBN-0W^R>B*B81<8RN>A5YE\AT8
M       #Q42I#!)*Y%5&-5RHGH0G-G6L:37.G&WFWT\]/ Z5\6Y/C>RWG7@J
MIT@4P          $%M'_ $LV??WL_P#IY"](+:/^EFS[^]G_ -/("+T D=H.
MT&RZ&IZ=UU=--5U*[M/1TS-^:5>;@F4PF>E5_$"N!S?3NUNV7&]4UHO5IO&G
M:^KX4S;G3\FR=>A&N\OVIZ.<JM:ZMM&C;*^YWVH6*!';C&-3>?*[H:U.E>'V
M>4#? Y10;;;4Z>E6]V&_6.WU;D;3U]=2[L#\\V7(O#[LH=68YKV-<QR.:Y,H
MJ+E%0#Z#\JJ>.EI9JB9=V*)BR/7R(B97_H<?@^4)IR>-)(+)J62->9S*1BHO
MWI(!V4$UH'6%'K2TS7"@HZ^DBBG6!65L21O54:UV41%7AXR?XDE==L]KANE;
M1V*R7R_LH7*VJJ;=3\I%&J<_C9X\R\>">10.I G]$:NM.M+(VYV.=TD.]N21
MR)NR1/3G:Y.A>;T$WJS:M;;)?Y+%;;9=;]>(F[TU/;8>4Y%/]I?+S<R+S\<
M=$!([/MH%HUO%5-MR5-+74CMVIHJMFY-$O-Q3*\,HJ?]<%< !(;0-H-HT4E)
M%7,JJRXUBXIJ&CCY2:7HRB93"9_^F35Z0VJVR^W]+%<+;=+%>7MWXJ6Y0\FL
MJ<_BKY<(O.B<W#('0P3VN=86G15F6Y7R9S8U=R<44;=Z29_[K4Z5X?81]HVS
M6R>[T=OOMDO>GUK51M+-<J?DXY57FXYX<Z>CCS@=1!KM17N@T[9JJZW>H;3T
M5,W>D>O'T(B)TJJX1$])S.+;K:6K3U-QT]J*@LM0Y&Q7.>DQ"[/,N47F^S*^
M@#KH/SIIXJFGBGIY&2PRM1['L7+7-5,HJ+THJ'Z
M                          @J;]>E=_P]#_4/+T@J;]>E=_P]#_4/ O0
M                                 (+7_P"G.SS^\*C^F>7I!:__ $YV
M>?WA4?TSP+T
M                   !!:"_3_:)_/4O],PO2"T%^G^T3^>I?Z9A>@
M                            !!;<?U>U'\Y1_P!3&7I!;<?U>U'\Y1_U
M,9>@                                                      U>
MJOT8O'\G-_D<;0U>JOT8O'\G-_D<!JME/ZL]*?W73?\ ;:3GRDOU-W[[:?\
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M9<Y4:OWHB+]YU (
M!!4WZ]*[_AZ'^H>7I!4WZ]*[_AZ'^H>!>@
M        06O_ -.=GG]X5'],\O2"U_\ ISL\_O"H_IG@7H
M                                                      ""T%^G
M^T3^>I?Z9A>D%H+]/]HG\]2_TS"]
M   ""VX_J]J/YRC_ *F,O2"VX_J]J/YRC_J8R]
M                                !J]5?HQ>/Y.;_(XVAJ]5?HQ>/Y.;
M_(X#5;*?U9Z4_NNF_P"VTS=:Z9HM7Z:J[)<WSQTE2K%>Z!R->FZ]')A514YV
MIT&JV65U(S9KI9KZJ!KDME.BHLB(J+R;?25'="B\[I_6M^('BR6Z&SV:@MM*
MY[H*.".GC5ZY<K6-1J9QTX0S#&[H47G=/ZUOQ'="B\[I_6M^(&BH]%VZEU[7
M:NCEJEN=93)2R,5R<DC4W.*)C.?$3I\IGZKTW:]56:6UWRE;4TDBHN%7#FN3
MF<U4XHJ>4SNZ%%YW3^M;\1W0HO.Z?UK?B!RMNPJTR1Q4E=J/4M99XE166Z:L
M_L4QS)A$YOLP= O&E;9<M(3Z:Y-U):Y($IT938:K&)C"-RBIT>0VG="B\[I_
M6M^([H47G=/ZUOQ PK/8*&V:8I; UBU%O@IDI=VHP[E(T3=P[AA<IS\#G<FP
MVT0OGCLVH-1VFW5#E66AI*S$2YYTPJ+_ (Y.H]T*+SNG]:WXCNA1>=T_K6_$
M#2Z6T99M+Z;DLEEIU@I)6N21^]F21SDPKG.7G7'W'O0FDZ#1>GHK-:I*B2EC
M>Z1'3N1S\N7*\41$_P #;]T*+SNG]:WXCNA1>=T_K6_$#1VS1ENMVN+MJJ"6
MI6XW*%L,S'.18T:U&HFZF,HOB)TKTF5K#2UIU?9GVR_4J5%,Y=]JHNZZ-R<S
MFJG,O%39=T*+SNG]:WXCNA1>=T_K6_$#EK-A=IEY&GNFH=27*U0N18[?4UF8
MDQS)A$YOLP='K]/VJNT^^QU5#"^TNB2#YLC<-1B<R)CFQA,*G-@R^Z%%YW3^
MM;\1W0HO.Z?UK?B!S"CV&V2%S*>>]:@J[+&_?9:IJS-.BYSA6HB90MM!:1H-
M$V!MHM,E1)2I*Z5'5#D<[+N?BB(F.'D-SW0HO.Z?UK?B.Z%%YW3^M;\0,D&-
MW0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z
M?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D@MH_Z6;/O[V?\
MT\A:=T*+SNG]:WXD'M$K:5^JM *VI@<C;L]7*DB+A.0DYP1T4D=?[/[/K9E*
M^XK4TU=2+O4U;22<G-%]BX7AE$Y_NP4O="B\[I_6M^([H47G=/ZUOQ A-+[)
MK19[[#>KE<;K?[K!_J)[I4<KR/I:F.?[<XZ"DUOI&TZSLKK9?('20[R21R,=
MNR1/3F<U>A>/V&W[H47G=/ZUOQ'="B\[I_6M^('-K=L6L[:^EJ+[>;[?XJ1R
M.IZ:Y57*1,QS>+CC]G-Y4*?:I;Z>Y[/;W154%;/%)"F(:%F]*]R.16M:F%YW
M(F>'-DHNZ%%YW3^M;\1W0HO.Z?UK?B!.:,TVV#9G:-/7^FCF1*!E/50/XMSN
M^,W[EZ4\A'+L)M#(Y*.EU%J6FLLCE<^VQUG]BN>=,8YOMROI.J=T*+SNG]:W
MXCNA1>=T_K6_$#%TW8;;INSP6NRTK*6BA3#6-XY7I557BJKY5(&[;%K//=*R
MLLMWO=A2M55JJ>VU/)Q2YY_%QPYUX<WH.D=T*+SNG]:WXCNA1>=T_K6_$#4Z
M)TE:=&65MLL4"Q0;RO>]Z[SY7KSN<O2O!";U;LHM-]OS[Y0W"Z6*\2-W9:FV
M3\DLJ?[28Y^;BF,].2Z[H47G=/ZUOQ'="B\[I_6M^($WL_T!9]$0U7<SYQ45
MM6[>J:VJ?RDTJ^E<)PRJ\WWY)V;3*R[?::^TE/6HV"W.^>5$K<0*YR(R-D:X
MXNQO*[BN.',=&[H47G=/ZUOQ'="B\[I_6M^($SK_ &?6;6S*5]Q^<4U?2+FG
MK:23DYHNG"+A<IGCQ^[!K=(;*K38+\E\K*^Z7R\L;N155SGY5T2<WB\.?"KQ
M7//PP7'="B\[I_6M^([H47G=/ZUOQ U&M](6C6EF6VWV!TD2.WXY&.W9(G_O
M-7H7C]A'V;8S:*6[T=?>;O>K\ZB5%I8;E4\I'%CF\7''&$X<WH.C]T*+SNG]
M:WXCNA1>=T_K6_$#'U#9;?J&SU-KO%,VIHJAN[)&[\45%YT5%XHJ<QS2'839
M,P4]=?-0UUGIW[\5LGJ\P-]&$1.'V8.I]T*+SNG]:WXCNA1>=T_K6_$#]J>&
M*G@C@IXV10QM1C&,3#6M1,(B)T(>S&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H4
M7G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZU
MOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B
M\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M
M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&
M[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=
M/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'
M="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&2#&[H47G=/ZUOQ'="B\[I
M_6M^(&2#&[H47G=/ZUOQ'="B\[I_6M^(&205-^O2N_X>A_J'EIW0HO.Z?UK?
MB0=-6TOAPKI/G,&YWOQ)O<HF,_.'\,@=%!C=T*+SNG]:WXCNA1>=T_K6_$#)
M!C=T*+SNG]:WXCNA1>=T_K6_$#)!C=T*+SNG]:WXCNA1>=T_K6_$#)!C=T*+
MSNG]:WXCNA1>=T_K6_$#)!C=T*+SNG]:WXCNA1>=T_K6_$#)!C=T*+SNG]:W
MXCNA1>=T_K6_$#)!C=T*+SNG]:WXCNA1>=T_K6_$#)!C=T*+SNG]:WXCNA1>
M=T_K6_$#)!C=T*+SNG]:WXCNA1>=T_K6_$#)!C=T*+SNG]:WXCNA1>=T_K6_
M$#)!C=T*+SNG]:WXCNA1>=T_K6_$#)!C=T*+SNG]:WXCNA1>=T_K6_$#)!C=
MT*+SNG]:WXCNA1>=T_K6_$#)(+7_ .G.SS^\*C^F>6G="B\[I_6M^)":]K:5
MVM]GSFU,"M;<)U<J2)P_T=_.!T0&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO
M.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?
MB.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%Y
MW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\
M0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W
M0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?
MUK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z
M%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^
MM;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D
M&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO
M.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?
MB.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%YW3^M;\0,D&-W0HO.Z?UK?B.Z%%Y
MW3^M;\0(O07Z?[1/YZE_IF%Z<ZT)6TK=>[0G.J8$:ZMIE:JR)A?]&9S%YW0H
MO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK
M?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!D@Q
MNZ%%YW3^M;\1W0HO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!D@QNZ%%YW
M3^M;\1W0HO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!D@QNZ%%YW3^M;\1
MW0HO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z
M?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!D@QNZ%%YW3^M;\1W0HO.Z?UK?B!
M%[<?U>U'\Y1_U,9>G.]ME932Z G9%40O>M91X:UZ*J_Z3&=$
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M6GV="Q $=X,-$=5K3[.@\&&B.JUI]G0L0!'>##1'5:T^SH/!AHCJM:?9T+$
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MOV*J'82"VX_J]J/YRC_J8R]
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MRL]1*C4=*_=1N51J(B8:UJ(B(G!/O V      06T?]+-GW][/_IY"](+:/\
MI9L^_O9_]/("+TX1?EU'J3;O>--6_5=RLU#!01U3$IEWD1=V-%3&4YU>JG=S
MBMD_]JK4/]S,_P"D(([/3L=%!'&]ZR.:U&J]>=RHG.1^U"RW2Z65:BT:BK;(
M^ABEF?\ -4SR^&Y1KN*8QC_$XC\J#5>JK3K.DHJ"X5UMM:4S9874LKHDF?E=
MY5<U4RJ<$QT</*=;T+<[O=]B,==J)']T9;?.KG/;ATC41Z,>J>56HU?3G(5Y
M^3W>+A?-F5%77BLFK*Q\TS733.WG*B/5$3/V'2#E/R8/U16_^8G_ .XIU8(
M
M      05-^O2N_X>A_J'EZ05-^O2N_X>A_J'@7H
M             $%K_P#3G9Y_>%1_3/+T@M?_ *<[//[PJ/Z9X%Z
M
M@M!?I_M$_GJ7^F87I!:"_3_:)_/4O],PO0
M         @MN/ZO:C^<H_P"IC+T@MN/ZO:C^<H_ZF,O0
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MS%\
M           @J;]>E=_P]#_4/+T@J;]>E=_P]#_4/ O0
M                  (+7_Z<[//[PJ/Z9Y>D%K_].=GG]X5'],\"]
M
M  06@OT_VB?SU+_3,+T@M!?I_M$_GJ7^F87H
M           06W']7M1_.4?]3&7I!;<?U>U'\Y1_U,9>@
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M#OBUUU$IO?4?8+H 0O?%KKJ)3>^H^P.^+7742F]]1]@N@!"]\6NNHE-[ZC[
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MW49*UZ^+NIGZ/E.K
M              #CM?'JO9Q>+Q=;)1MU'I.OJY*ZHI8UQ4TDCE_M%9^\W*<W
M'FZ.*KV(D*&P:CM;:^*VWVB?3U-3-41MJZ%SW4W*2.?AJMD;O(F]S*G/TXX
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M.D]11T\=YI8FU,,U.BMBJX%X;[6N55:J+P5N5]"@6@
M
M
M
M
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MR;O'G/QU-3Q;1=J.E4M$K*NQZ>>ZMJZR)=Z%TRJU61-<G!SLL151.9%4#"T
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MG=O;RQK^TUJ/<F\G#*)C('70
M
M
M
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MB(F$0^@#X]K7M5KVHYJ\%14RBGU$1J(B(B(G,B
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MSQ1.?I7F,;3>IM2:UM,]ZTRVUT%K61[*)M?#)+)5HQ5:KW*U[4C:JHJ)P<O
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M-K$KJ#;/LQJZ?*2S33TSU3I8JL;A?6. [*  @
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M M6CZI(GI&JN8B(C7*GC87&<9QE,G>%1%3"IE#SN,WVNW6[S4PBXXHG_ .Z
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M7[\<%0[58;K'>J!*VGIZF&G>Y4B6HC6-TC4YGHU>*-7HRB+TXYC8*B+C*(N
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MYMCLMTMCDJ;!IR![EK&<8IJE_,QCN9VZB-553@F,'7.<(B(F$3"(
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M,Y&3)#(C^3<O0[',OH,PY%L#I8**\;1*>DB9#!%?98XXV)AK&IG"(G0B'70
M,>XUU+;:.2KKYXZ>FCQOR2+A$RN$_P 51#(       "*CDRBHJ<W  >99&0Q
MNDE>UD;4RYSEPB)Y54Q[9<:*ZTC:NV54%72N<YK9H'H]BJU51<*G!<*BH8^I
MJ6"MT[<Z:LACFIY*:1'QO;E')NKT$)\FS]35A_WJC^HD Z: JX3*\QCV^MIK
MC1Q5=#.R>FE3>CE8N6N3RHH&0"6T':M06J.Z,U-?&7>2:J=+3JV/=Y&->9O_
M -.9"H14551%153G3R ?0       ?'O;&QSY'(UC4RKG+A$3RJ:2SZOT[>;A
M)0VF]V^LK&(KEAAG:YV$YU1$7BGI0DML5>]U;H[3V52GO-VC95-Z)((\.=&O
MH55;GT<.DMI+!:9+S37=UOINZ=-&L4-2C$1[&*F%1%\F,_BOE V9/LUKIA]V
M;;&7^V+7N=N)"E2W>5W-NIQY\]'.3>W6[U-NT;!1T,SX)[Q7P6WE6+AS&R*N
M\J+Y=UJI]Y07W0^GKW9Z&V7"VQ.HZ%S'4S8\L6+=YD:K<*B="^4#<7.ZV^UM
MB=<JVFI4E>D<?+2(S?<JX1K<\ZY7F0S#D/RAJ2G>FB*I\,:U++_31-E5OC(Q
MV55N?(JM1<>@M=<6K4%RELS].WQEJBIJI):Q'1[W+Q\/%_Z\.9<^@"I 54:F
M55$3T@    !+4MJU!'M!K+G/?&2:>EI4CAMG)\62)NY=G\5S_M8Z *D    Y
M4:U7.5$1$RJKT  &JCD16JBHO%%0    !J-7T5SN.FZ^DL-P2W7.6/=@JE;O
M)&N4S^*93/1G)JKG<*_2NS&JKKA5LN%SMUN<]]0C<)-*UG/CR*[ &=>M8Z<L
ME6VEN]\MU'4KC^SFG:UR9YLIGA]YO(9&31,EA>V2-[4<U[5RCD7F5%Z4(+9Y
MIR@N6RBW4MXIV5J7>E;5UKI4RZ:25-]SU7GWO&X+SIA,<Q8V*TTECL]':[;&
ML='21I%$U7*Y4:GI7BH&<  ,)UUM[;HRVK6TW=![5>VFY1.45J<Z[O/CBG$S
M3C\M+!3_ "GZ=\$,<;Y["Z256MQONWU;O+Y5PU$SZ$.P
M
M
M
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MY>;>7FSS*:ZYZ'U%8MH%=JK0E1;Y&7-J)<+=7N<QCW)^VUS47"]/'F55Y\X
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M@3W?SI/K18O>$7:'?SI/K18O>$7: H03W?SI/K18O>$7:/G?SI/K18O>$7:
MH@3W?SI/K18O>$7:'?SI/K18O>$7: H03W?SI/K18O>$7:'?SI/K18O>$7:
MH03W?SI/K18O>$7:/G?SI/K18O>$7: H@3W?SI/K18O>$7:'?SI/K18O>$7:
M H03W?SI/K18O>$7:/G?SI/K18O>$7: H@3O?SI/K18O>$7:/O?SI/K18O>$
M7: H03W?SI/K18O>$7:'?SI/K18O>$7: H03O?SI/K18O>$7:/O?SI/K18O>
M$7: H03W?SI/K18O>$7:'?SI/K18O>$7: H03W?SI/K18O>$7:'?SI/K18O>
M$7: H03O?SI/K18O>$7:/O?SI/K18O>$7: H03W?SI/K18O>$7:'?SI/K18O
M>$7: H03O?SI/K18O>$7:/O?SI/K18O>$7: H03O?SI/K18O>$7:/O?SI/K1
M8O>$7: H03W?QI/'Z46+WA%VAW\Z3ZT6+WA%V@*$$[W\Z3ZT6+WA%VC[W\Z3
MZT6+WA%V@*$$]W\:3ZT6+WA%VAW\Z3ZT6+WA%V@*$$]W\Z3ZT6+WA%VAW\Z3
MZT6+WA%V@*$$[W\Z3ZT6+WA%VC[W\Z3ZT6+WA%V@*$$]W\Z3ZT6+WA%VAW\Z
M3ZT6+WA%V@*$$]W\Z3ZT6+WA%VCYW\Z3ZT6+WA%V@*($]W\Z3ZT6+WA%VAW\
MZ3ZT6+WA%V@*$$]W\Z3ZT6+WA%VCYW\Z3ZT6+WA%V@*($]W\Z3ZT6+WA%VCY
MW\Z3ZT6+WA%V@*($]W\Z3ZT6+WA%VAW\Z3ZT6+WA%V@*$$]W\Z3ZT6+WA%VC
MYW\Z3ZT6+WA%V@*($]W\Z3ZT6+WA%VC.M.H;+>)GQ6B\6ZOE8W><REJ62N:G
M-E4:JX0#9@
M                  "\RXYR/T'IB[6BHK[CJB\I>;S5;L23MA2)L4#556L:
MU."<555\O#GQDL
M                   !SS6^D+[/K>UZNTG6427"DIG4<M)7[R0S1*JKP<U%
M5J\?)T)]^;/8K]JB.GI]7);*6V1RLGDHJ%[YEJ',<CFH^1[6X:CD151&Y7'/
MC.;8       BMKNF;IK#1]18;3)10I5N;RTU2]R;B->UR;J-:N<JF.*ICTEJ
M -9IJ&X4]FIJ>[LI&U4+&QJM+(Y['(B(F?&:BHJ^3C]ILP
M :VX6&T7&HY>X6J@JI\(WE)Z=CW83HRJ9-D -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L
M4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -+WI:<ZOVCV*/LGSO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'
ML4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -+WI:<ZOVCV*/LGSO2TYU?M
M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -+WI:<ZOVCV*/LGSO2TYU?
MM'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?
MM'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?
MM'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?
MM'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LCO2TYU?
MM'L4?9-V -)WI:<ZOVCV*/LCO2TYU?M'L4?9-V -)WI:<ZOVCV*/LF9;;+:K
M9(^2VVRAHY'INN=3P,C54\BJB)P,\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                   #S%(R5F_$
M]KV95-YJY3*+A?\ %% ] \R2,BC<^5[6,:F5<Y<(B>E364^H[)4U"4]/>;;+
M.JX2-E4QSL_8BY VH!CU%=24TFY454$3\9W9)$:N/+A5 R >(98YXTD@D9)&
M[F<QR*B_>A[  'B:6.")TDTC(XVIESGKA$3TJ![!K:*_V>NJ.0HKM;ZF?^'#
M4L>[\$7)^<FH[3'J.*PNK&=UY8UF;3(URNW$3.\JXPB<.E0-L
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MS(B(BJJ\%-JBY1%3I
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M3*KE,] &6#6Z>OMMU%;6W"RU3:NB<YS&RM:J-<K5PN,HF>/2;(
M   543&51,\P  U]1>K73U\5#/<:2.NE5$93NF;RCE7R-SD#8 Q)KG00OW)J
MVEC?G&ZZ5J+G\3*8]LC$<QR.:O%%1<HH'T
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M->7]_P#Z-T_)+;;=&[FB2-/[5[4_?>NZB+S\<!'2ZG4]CI;-'=I[O0,MLO\
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M3ZEEHN5'7.IG(R9*>9LG)JO,BX7AS+^"G*M'6^;76T+5M]K,][S)FVV%N?\
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MJ(X9&N="_P#=<B+P7GX+Y#-"
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M>D<Y55^51%5%7H0V%5IVAJ[[%=:I:F::%&\G"^=RP,>W.)$CSN[Z;R^-@W
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M(6R(N.#MQ4WDX<RGZ6"Q4VGK.VW6ET[:>)N["VHF?,D:(F$1-Y<[J83ADVH
ME:G3EVNL2PWW44JTKN$E/;(/FB2)Y'/5SWX_W7-*"V6ZCM=OAH+?314]'"W<
MCAC;AK4\F#* $>S9U8XZ6>A@6O@M,[U?);HJM[*=RJN7)NHN4:J\[45&KY#,
MU'HFR:@M$-JN$$S;7"U&-I*>=\$6$QA%:Q41<83&>8I !)4VSZRP4D=)RMXE
MHXVHQE/)=:E8T:G!&[N_A4]"\"AM5LH;/0MI+31T]'3,^C% Q&-S]B?]3, $
MII'2KK5?K[?JWYNVY7AT?*14J+R436(J-1%5$5[ERJJY43*]"%6
M
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MX)GFSQ-$^JJJ7Y,]#57ZLKDJ9(',@B9,YKIEE>YL".5/'<C6JUVZB\43CE.
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MXIP ZR#E^QB7E[UKE]M;R>G8[FD%#$S_ %;7,9B56)S(U5W5X<#J
M
M
M
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MKO*6X C*[0K8]/V2S::NM78:*W5+)G?-?I5#&Y5S'.RGTE7*JN>/.BEF
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
=                                   ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g111069g99a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a03.jpg
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M)$-45Y+!)C9T=9/A\/_$ !4! 0$                    !_\0 %1$! 0
M                  '_V@ , P$  A$#$0 _ /\ 5(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MFJB*9B(CBF.*IZ=9Y@%P
M
M
M
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MT111$Q/6.[$1Q//[".P
M
M
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MNF..*:?"9JYF9CIQ'BJ@
M
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MK%Q,>GYU7*KU$Q$?X4S/^ K0PICB(@$
M
M
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MTQ3313'RB ?<
M
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MB[7%,W*YGB*:>?&9_2#"U'"SYOQ@YF-DS8K]G=]C=IK]G5^E7$])_:0>H<[
MUW2=0RKF-@:I@Y63;_GM6<BBNNG^L1/,/1J.H86FX\W]1S,?$L1/'M+]VFW3
M_G,\ ](YMK7M(NZ9>U*SJF%=T^S$S<R;=^FJW1$=9YJB>(?/;^XM+U_!Q<K2
M\RS=HR;47J*._'?[LQSUIYY@'6'-S]?T?3LJC&U#5L#%R:_Y;5_(HHKJ_I$S
MRZ,UTQ1WYJB*(CGO<]./U!_1S+.OZ/?C&FSJN#7^*KJMV.,BB?;54S,511U_
M-,3$QT?W+U_1\/.HPLO5<"QFU\=VQ=R**;D\^'%,SR#I
M
M
M                                          ,IV!_KR[2O^9@_[IJS
M+M<[+M3RMXZON#1-Y9VBW=2]G[6UCX\5=**(ICF9JCGPF?#Y@U%FW\1W^IS<
M'_P/]_0\7^C7=W_YH:S_ -5I_P#$\6M=D&X-;TV]I^K=H^J9>%>X]I9N8M,T
MU<3$QS^?]8B0:OHO_$^!_P!!;_[L/8^6'8_#8EBQ%7>BU131SQQSQ''+Z@
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M4_EB(ZSS/,<1S&FB
M
M
M
M
M
M
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M\<\>,RU4
M
M
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M#]UF
M
M
M                                                           ^
M>3:]OCW;7M+EKOTS3W[<\54\QXQ/RE] 'AT;2L/1L&G$TZS[*S%55<\U3557
M75/-5554\S55,]9F9YE[@
M
M
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MKGBJBYQ'/AX<?_O$6
M
M
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M+Y; WM@T=I_:#J.5AZQ<_$W,6W:BUIM^Y7111153Q7333,T>$=)XY478S_\
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M,1/])Z3$\1X<@[(
M
M
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M?$ITZS=LV[M$Q-W,JKIBGFOB.E-,<Q$3,SS/RB.MF
M
M
M
M             FM6WYM71]0NX.J:_IV)F6N/:6;MZ*:J>8B8YC^DQ(*41_\
MI/V1YITG_K%)_I/V1YITG_K%(+ ?FW73=MTW+=45451%5,QX3$_-^@
M                    !Y\[-Q=/QYOY^39QK$3Q-R]7%%,?XR]  .11N?0:
M]5]V4:UIM6H][N_AHR:)N<_IW>>>?V!UP>?-S<7 M1=SLFSCVYJBB*KM<41-
M4](CF?G(/0
M
M
M                              Q?;6@Z1KG;AVBTZUI>%J%-JG"FW&58
MIN]R9M=>.]$\<\0VAE.P/]>7:5_S,'_= L/]'^S_ "KH7_4+7_A9_P!O>S]M
MZ7V4ZYF:;H&E8F7;]CW+UC$MT5T\WJ(GBJ(YCI,PV9FW\1W^IS<'_P #_?T
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M]04H
M
M
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MUNS;HO7>/:7*:8BJOB.(YGY\0#Z@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB.D=(F>O/Z0#21Y-(N9=[2L.YJ=BC'SZ[-%61:HJ[U-%R:8[U,3UYB)Y>L
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MYJFKN^/CT!IF%;NV<.Q;R;WM[]%NFFY=[O=]I5$=:N(\.9Z\/L
M
M
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M9\":QY_W+]CTP7@@_@36//\ N7['IGP)K'G_ '+]CTP7@@_@36//^Y?L>F?
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MM,3S\@>3=6]8T#=FWM$G2<W+][W)M_B;,?DL]8CF?U\>9\.(ZJX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
$  ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g111069g99a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a04.jpg
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M*"@H*"@H*"@H*"@H*/_  !$("94': ,!(@ "$0$#$0'_Q  <  $  @(# 0
M            !@<$!0(#" '_Q !F$  ! P0 ! (%!@D%"PD% !,  0(#! 4&
M$0<2(3$300@4(E%A%1<R5G&!%E61DI25T=+3(T)25*$S-U-B<G6"D[&RLQ@D
M-#8X5W-TP24U0Z+#X7:#PO!&H[3Q)B=CA(9$1TAFQ/_$ !4! 0$
M           !_\0 %Q$! 0$!                  %!$?_:  P# 0 "$0,1
M #\ ]4@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;*^@IKC32I_,F1K5>GW.TOV.0]JX)D=/EF)VV]4ND;51(Y[$7Z#TZ/;]SD5
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M32]6*J=/B!)  $
M
M
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M=5[_ )#QUQ7LV3YEGUVOE!B.0Q4E2L:1-EH)$?RLC:S:HB+WY=]_,$>RK/\
M^Z:'_P !G^ZAQENE#'=H;7)51-N$\3IHX%7VGL:J(JHGPV1SAODS[[:H:>IL
MMYM5524\394N%(Z)KG:TO(Y?I=47X]B$<?K-DL=YQG*\-I9JJNM+I&RQPMYW
M*Q=*GLIU<U?;143WA#BAP'LN1QU-?CC66J\+M_(Q-03.]RM_FJOO;]Z*>?\
M@_>[GAG%*W4Z^)"LM8VWUM,J]'(Y_(J*GO:O5/BAZ*M_'&WOMB.N&.9#!=VM
MTZB91.?S/]S7=.GVZ7X$#X7<-+[D?$>7-LLM[[72>N.KXZ65.62217*YJ<J]
M4:U=+M=;UVZJJ%>F0 $
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:5/-2T+1PMH<;XE6V_8W"M/;_59H:N%TSGHUZHG(YO,JKUZ[Z^2 6:
M   8EX2L6T5R6I8VW!8'^K+)]%)>5>3?PWH#+!7O!B+.(K+7)Q$>CJI9_P#F
MR.=&YZ,UUVK.FM]O/O\  L(  8EWN-+:+75W&OE2*DI8G32O7R:U-J!EF'+=
M;?%+X4M?2,D[<CIFHOY-E 8A7WOCCDUPFN%956S#*!R-]2I9%C6H5=\K'N3J
MO1-N]W1$UO9;+.%V$,H_5DQ>UK'K7,Z%%?\ GK[6_CL"8M<CFHYJHK5[*B]S
MZ5;PYP&7!>(5Z9;/6'8W6T;)8/$>KDAE1^ECZ]^B[1?<OP+2 &D?EEA;?Z>Q
M_*U(^[3JY&4K'\[]M:KEVB;Y>B+WT;L\QVRAIK?Z8*P44+(8>>23D8FDYGT3
MG.77Q<JK]X'IP   5KQDAX@RNLWS=R,:Q)'>M^U&B^7*J\_=OTMHG4L>'Q/!
MC\;E\7E3GY>V_/7P Y@
M
M
M
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MO[\<L%"LT<5/#,E*Z=S'\NGS?2ZIM=(J;\@-]Z/>:7^\7S)<>R2M^47VM_\
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MGA;E>J<WNVBHO4@OH<U=/&N3TTD\3*B5:=T<;G(CGHB2[5$\];0#TL  @
M
M
M
M
M               ,6YVZCNM%)1W*EAJJ632OBF8CFNTJ*FT7W*B*90 &+;K=
M1VR%\-OI8::)\CI7,B8C4<]R[<Y=>:J=E92T];324U;!%44\B:?%*Q'M<GQ1
M>BG< -138Q8:6=D]-9+7#,Q=MDCI(VN;Y=%1-H=7X'XUK7X.V?7;7J47[IO
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M.3;514WKH!] /B.155$5%5.Z>X#Z
M
M
M
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MWOR(O0%9\$+S=JV')K/?:Y]QGLESDHXZN1-/D8G;F]Z]%Z_$LP
M
M
M
M
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MT]XN#ZZ"59X7HQJJOLO1KU5'=4[(J=^I:
M
M
M
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MQ(X?7+#Z.*W7"LN'JTT-(Q(V2Q(K.95:G32-5R*ON7X 7P
M
M
M
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M5KD5-KU7S3?77<FMAM$-FH/5H9JFH<YRR2SU,BR2RO7NYR^_HB:32(B(B(B
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M6(F2>'9))&<[47E<DDFE3X]5/N24\5/Z1V(3P,;'+56ZI;,YJ:\1&M?K?O\
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M;"U-^TNW=51-(FTWOH!8A37&B&"HXH\+X:N*.6%]9.CF2-1S7?W/NB]^I<I
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M+$DO+SI'ORWO73>C?9/BL-\QM+'#7UMIH.1(E2W.9&Y8T37A[5JZ;V[:[:[
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M;)&YKV.1'-<U=HJ+V5%.1\8QL;&L8U&L:FD1.R(?0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_>+:             85!=:"X55;3457#//1/2*I9&[:Q.5-HCO<N@,T
M
M
M
M
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M32JNDWO>O@0C#\YXK9%@%176.@I*N2*:57U\ZLYWHG7DBB32>S[UWOLAMO3
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M_JD/K:QK4\C?%6/?+S:ZZWY;.T (
M
M
M
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MJ=P
M
M
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MY$VY>J] /5P!YL])R6Z8E7VFOL&07RD6YOG6>%M?+X:*WD5.5N_93VUZ)T[
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MTG=5[ 74"ON-?$)O#[&&5-/''-=*MZQ4D3_H[1-N>[WHG3I[U0KJ_7_B%BF
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MM?-')Y[4"T0
M
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MM-4G"JBRB[LU=\CO'KTR+W9$L4G@L3X(WJG^4;'-N%SJGT@J>V4\3FVF[O\
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M0+E/I.W6Z0IST./4R4ZR)V\56*SE^W;I/S0+U  0
M
M
M                         ".YYB5!F5A?;K@KXGM<DM/4Q])*>5/HO:O_
M .&T)$ -;CD=TBL]/%?I*>:X1IR234^T;+I=(_2I[*JFE5.J(JKI5-DJ(J*B
MHBHODH '&.-D:*D;&L1?Z*:.0 'SE3FYM)S=MZ/H    ?%:BN151-IV71]
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M7NNNY]  ^-:C4TU$1/@A] 'Q6H[6T1==4VA]  'Q6M5R.5J*J=ET?0
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M[_T3R_M62
M
M
M
M
M
M
M
M
M
M
M
M
M                        <97.;&]S&*]R(JHU%1%<ONZ@<@0"T\24N695
M>,18Y=V72C:CZE'N@1D3%Y=.5R2=4TYJ]-KU)^  (-:,TKJWBK=<3J+9%34U
M%1>M-J/&YW3;<Q&KK2(U-.7IU7: 3D      (+Q"S2NQ>_8O04ULBGI[Q6QT
MCJJ2;7A*KT14Y$3:KI=HN] 3H             !JLFR&UXQ:9+G?:MM)1,<U
MJR.:YW55TB(C455^Y#OK+O0T=DEN\]0Q+=% M2Z9.J>&C>;F3W] ,X%?)?\
M.*N&TW:U6&US6BM=&YU(^H<VKBA?K3U<NF;Y5VK4WKMU[E@@    (+Q1S6NP
M[Y#]4MD55%<JZ.B=/)-RI"YR]/91-NVB.\TUH"=
M         !B7BYT=GME3<;G.VGHJ9BR2RN151K4\])U7[$ RP85DNM%>[537
M*U5#:BAJ6<\4K45$<GV+U3[%,T    !ILHR>S8M2P5-_KXZ*">5((W/:Y>9Z
M[TG1%]R]>R>8&Y []@         !',GR.2WW.VV:UPQ5-ZN/.Z%DKU;'%&Q-
MOD>J(JZ3HB(G55773JJ=6(5N5RW&YTN66RWPPP\JTM;0RJL=0B[VG(Y5<U4T
MG?W@2@   07-LTKL>S+%K+#;(I:6]3^$M6^;Z&E3F:C$3OI45%5==>Q.@
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M,<UBR.:YW55TB(C455^Y#8TT\=33Q3P/22&5J/8]O9S53:*GW =@
M
M
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MCC:Q\ST1'2*B:5RHG3:]^@1W
M
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M]9A>^&56_P!%7L5%5/@JF=;;+;;9;%MUNHH:6B<CD6*)O*B\W=5UU55]_<V
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M5%"_2K'%M&]-]D[)W7L;0 ##O-JH;U;9[?=J6*KHITY9(9$VUW7:?VHB[,P
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MRBN]_-W)"
M
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M>X
M
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M#8UV^YM2&5TFTTUL:*JZUO;EUY:WUU)  *3SF[_(OI&8_5.H:ZM8MD=&YE%
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MR/3E;)MJ,VKE[_2URI[^I=M!4K64<50L$]/SIOPIV\KV_:FUT=X
M
M
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M1BEK6XW^L;24B.Y$>K7.5SE151$1$557HIN"N?2(1%X.Y'M$73(5_P#RS +
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M5%Z0^1V&KX77ZWT]YMD]PW#JF951NEVDS-Z:B[Z)OR+5LO\ [GH?_ C_ -U
M,P Q[A74ENI75-PJH*6G9]*6>1&,3[55= 9 ,6VW&BNE(VJME93UE*[HV:GE
M;(Q?L<BJAAR9-8XHYI);S;HXX9O5Y'OJ6-:R72+R*JKKFTJ=.X&V
M
M
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M=JF]=%Z]?ATT1H/2(LML@X-7-(*"EB2B6!:;DB1O@_RK&^SKMT54^\LZS?\
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M5=*3*VRU$]OII:VF2EJGQM=+ DB2>$]4ZMYDZ+I>FT[F0 @
M
M
M                 $?ILPL]3F=5BT50];S30)421>&O*C5TOTNV].:OW@2
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M*NDV!]! >%&77;*WY(V]4M)2RVRX.H6QTRN<U.5.NW+]+KYZ3["?
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MVU2-CITD<Z1N^5=JO;KVT2RW1U,-'''75#*FH;OGE9%X:.Z]/9VNNFO,R
M
M
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M-%0U5LH:"*6YW2Y,\6EI:=4171:VLKG.5$8SXKW\D4AN(W'A?>\3IKH^WXM
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M05W#3+\:I\9NS[GA^057@LM\KO$6GYDYO$B=YL1.JK[N^U78%Y  (
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MYVQ?%Z[Z)^55ZZ3H2AJHYJ.:J*BIM%3S ^@
M
M
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M:U$1J)I$3R/H
M
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M+I?-%+*QVT55J9.VLO=PNRR*BM6L2)%CUOMR,;WWY[[ ;<
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M^H];H*:IY>7QHFR:]VTWH[P
M
M
M
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M2*H<QJR1HNT:[75$7STIV@
M
M
M
M
M      (;<^(EBHLMM]B2NH7R3QRRU$ZU3&LIFL3HCE7NYSNG+M%[J<>(%/C]
M_;9;1=K\M%+-615--#3U#6252MWINNJJU=]T\T3J!- :BOR:R6^[TMJK;I20
MW*J<C8:5TB>(]5[>SWZGV+)+--?76:&YTC[JUJN=2MD17HB=]I[TVG3N!M@:
MBVY+9;G=:FVVZZ4E37T[>:6&*1'.:F]*O3W+T7W*=E\O]JL,+9;Q<*>C8_?+
MXK]*[2;72=UTG5==@-F#JHZF"LI8:FDFCFIYF))')&[F:]JIM%14[H=H
M
M
M
M
M
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M[WU5&IMZIM=<RJB>2(!+++;*6S6BCMMO9X=)21-AB:J[5&M32;7S4S
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       'QRHU
MJN7>D3?1-K^0^@"'0\2\5FKIJ**OJ'UL']UIVT%0LD?^4WP]IW3N9MLSC'[E
M>8;32ULB7&9CGQP34LT+G-:FU5.=J%<X[74=O])/.'UM53TS'6^G1%ED1B*O
M)#[RQ:6OL629)RTDD=766/DG;40O1S&+,V1G)M%ZKRM551?>U?L#:WR\45DH
MDJ;A*K&.>D4;6M5[Y7K]%C&IM7.7W(A%:CB=::6Y-MM=;[U2769$]5HYZ16O
MJU5=:C7?*O5>NU37GK1$<US.SP\<L=I;C<88Z"TTD\LBKM6LJ'HK41=)W1J?
M=LU^5Y_C==QEPFI;=8)+7;X*N22;E=RLD?&K4WT_Q4 LW',MJ;GD-99KECMS
MM-5!"D[9)^5\,K-HG21BJW?7M]ON)6:23*K)'9J:ZNN$:T-2[D@>UKE=,[:I
MRL8B<SEZ+T1%4YV+)K5?)ZFGMU2Y:JFUXU--$^&:-%[*Z-Z(Y$7WZT!N 1J\
M9SCUIFJ8JNO<]]-_TA*:GDJ$@_\ $6-KD9]^C6Y-Q0QFQ6>VW%]?'417%S/5
MFQ+U>QSN57_!K>JKOW:[@32HFBIX7S5$K(H6)S.>]R-:U/>JKV/L4C)8VR1/
M:^-R(YKFKM%1>RHI",DOF&93@MV6Z76%]@Z15,S7NCY7;1S41=;WO6D3>SMH
M<HQ+%</L+O7_ %*RRTL:44D['^U'RIR[771=>2]0)H#2W;*K-:+1!=+G6I34
M$^N2:2-Z)U[;Z;3?QT<J_)K304E'45-4K6UG_1XVQ/=+-TW[,:(KUZ?#H!N
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M&^!K+=?[5<KG76Z@N%/45U"Y&U,,;T5T2K[T^XV8
M
M
M
M
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M1JL5.7JO?:_$7? :.YY;39)+=;M%<Z5JLIW121HR%BHJ*U&JQ45%VO?:]?L
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ML7\0YPY_622L8N#Y8Q'.1O,ZFBTW?FO\IV G0
M
M
M
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M 5O@UTN]YXFYDYUTFJ,=MCV45/ YC$:DZHBR:5K45>145.J_SBR
M !6^'W.[WGBMEB)=9IL<M2,I8H%8Q&^L.1%>B*C45>32IU7^<!9    &HRZ_
MTV+XY77FNCGEIZ1B.<R!O,]VU1$1$^U4 VX,>VU25]NI:ML<L3:B)DJ1RMY7
ML1R(NG)Y*F^J&0     KB:Z7>OXXQ6BWW29++;[<E57TR,9R^*_F:QG-R\W5
M%:[6_("QP1K&[W/49+D5CKW(ZHM\L<T+T1$YZ>9%<SHGFU4>S[&HJ]54DH
M
M
M
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MJY(7=X(434,2_%K?]I/ @
M
M
M
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MU.MP>JJM5(WGEZ^2/=M43X(NC;  <)HHYF<DT;)&?T7M14.8 (B(B(B:1/(
M <8XHXU<L;&M5Z\SE:FMK[U/C8HVQK&V-B1KO;43IU[]#F .#H8W1I&Z-BQI
MK35:FDUVZ$"GX@4N0,N5FPYTT^01ROHU22![&4KD56K-(Y4TC4ZJB=W*B(B>
MZP#XUC6JY6M1%<NUTG=0-)A6,T.(XW26>VM7P8&^U([Z4KUZN>[XJO[/(W,4
M4<+.6&-D;=[TU-)LY@ :Z]UM)9+977BJA<K*6%TLKHH^:1S6IO2>:]C8@"J+
MI=*#BE<\6IL>F=5V2DJDN=PF\-S6L6-/Y.%VT^DYR]6^2-W[BUSXQC8VHUC6
MM:GDB:0^@<98HY41)6->B+S(CDWI?>',8YS7.:U7-7;55.J?8<@!Q\-GB>)R
MMY]<O-KKKW;#8V-<]S6-1S^KE1-*OVG( <6L:U7*UK45R[<J)W7XGQT4;I6R
M.C8LC4TURIU3[%.8 '!\4;WL<^-CG,7;55-JW[/<<P!Q>QDC=2-:Y-HNG)OJ
MG8.8QSFN<UJN;]%53JGV'( <98V2L5DK&O8O=KDVB_<<D1&HB(B(B=$1  /B
M-:CU>C4YE32KKJJ?_@H:UK5<K6HBN7:JB=SZ .+&-9S<C6MYEVNDUM?>&,8S
MFY&M;S+M=)K:^\Y #BUC6N<YK6HYWTE1.J_:.1OB*_E;SJFE=KKKW'( <)(H
MY5:LD;'JU>9O,F]+[T/LD;)6.9(QKV.Z*UR;13D .+HV.8C',:K4TJ(J=$UV
M(Y78Y)>KU'57Z:.6WT<J24EOC1?#5Z=I957Z;D\F_1;\5ZDE
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ,1K4TFU\]@20
M
M
M
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M -D
M
M
M
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MS762N@>KX'MN$K/ 55W_ ":(NF_<2RWTJ45'%3MEGF2--(^>19'N^UR]5.\
M:W([)09'9:NU7>!)Z.I9R/:O=/<J+Y*B]47WF90TS**BIZ6)7+'!&V)JN7:Z
M:FDW^0[@
M
M
M
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M57>^AJ\BSG/\>Q!URN-DMS*BWR^)<)%1Z1OA=.L;&PIOJY43F557HU6KK:]
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MFC\*62-KWL_HJJ;5/N [P
M
M
M
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MK\BCIN(EVLMFM*.?8+56K47-ZPNC9S0JK8Z=-HG-MVU771&HB^:%H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:]EZ<O7N2@KG&LDO=9QER;'[A/3K;*"CCEIHX8N7Z:M5%<J[57(BZ[Z^ %C
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M450C-
M
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M-M=IJLIXR19?ZK44MEM5"M)225$3HGU4CN;F<C'(CD8B/<FU1-KK6RU !16
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M972KI%U\4VM$LR>D-=;DZVW5MMGMC:".J=03)$Z9'L54YN72)[*^TO3IW+?
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MKTZEML:UC&M8B(UJ:1$\D/H
M
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MR.Z]%7W*!E@Z:NKIJ.'Q:RHAIXNW/*]&-_*ISBECEB;+%(Q\3DVCVKM%3W[
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M]6ZD950.JFIMT*2(KT3XMWLR
M
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M-,ZKTZK\2<4J3)31)5.C?4(U/$=&U6M5WFJ(JJJ)]ZA':
M
M
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M+\C\_JL$E"Z3FYVHC^=R2)OX:1-?$GP XQ(](F)*K72:3F5J:15\])UTAR
M
M                                         ([G>.U>36>.AHKY765?
M&1\DU'T?(S2HK-[32+O^SS-S;*&GMENI:&BC2.EIHFPQ,3^:UJ:1/R(9(
M
M
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M2U-QD\*EC?O<KMHFNB=.JHFUTG5#<!
M
M
M
M
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MC=(FUA5-=OS4[^Y#<@
M
M
M
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M;I_UTS+]8M_<)T .$,?A0QQ\[W\C4;S/7;G:\U7WG,
M
M
M
M
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MZ&IX<9CFN84%MN;+99(K8^LEAK'++)XB1M=K<;>W3MM57:^2(!:H
M
M
M
M
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M%E@
M
M
M
M
M
M
M
M
M
M
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MW^.W]H&> BHJ(J*BHO94,>JKJ2D<UM5500N=U:DDB-W]FP,@&#\KVW\8T?\
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M#4Q^)331S1[US1N1R;^U .P
M
M
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M/-$7S7K='#+.;?GF-QW&A5(ZEFF55,J[=!)KM\47NB^:?%%1,+_^^7_\N?\
M_25YQ)QFY<-<G=G^#1<U ]?_ &M;F]&*U5ZN1$[-7O\ XJ]>V]%27T@L8MET
MQNCJY:&F]=^4Z2-U0D:)(YCY$C5JN[JFG=M^2>XL^W4%';:1E+;J6"DIF?1B
M@C1C$^Q$Z%99GE%MR_AE;+O9YO$IY;I0(YJ_2B>E3'MCD\E3_P"SV4M8(
M
M
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MFJ/W1\YUJ_%&3_J:H_=)T .$,B30QR-1R(]J.1')I4W[T\E.8
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MR6-515:]J.1=+M.B_%-G,
M
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MJZ<WF:U7-<B_!4144V'#5$3AYC")V^3*;_A- D8
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M:VBJ:&2IYK8RG9IT46UZ.Z)Y<O?:[1>H$H
M
M
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M7<LQBS,Q^R4MK@JJFJIZ5B11.J58KVL1$1K=M:U%1$3S3?Q V@
M
M         **])USJ6X8#<9]_)M+<U6H5>V]QN3?^BQY>K51R(K5147JBIYFD
MS+&;=EV/55GO$:OIITZ.:NG1N3L]J^2I_P#8[*17%J?-,0H8K364D&36ZG:C
M*:K@G;!4I&G9LC)--543IM' 6*55;KG49WQ0R.T3U53!8,?;'$M-33.A6IG?
MO;GN:J.5J<KD1N]=E4W%Z;EV33T=#';&6*S^.R2MFGJVOJ)8VN1RQL;'S(WF
MUI55W95,&3%+QC/$BXY1C=/'<;?>(VMK[>LJ12-D;VDC5WLKY[153Z2_<&NI
M[C785QCMN--K:JKQZ^T[I*>*JF=,^DF:CE5&O<JNY5Y4Z*J_2^'7#I:&NNG'
MS);;/?KNRW1VV.5(8JCD5J/5BJQKDZL;OK[.E[=??)J#%KC>N(]/EV0P1T4=
MNIEI[=0-D21Z*[?-+(Y/91=.5$1%7RZ]#$L5AR.GXQ7?)*JVT[+77TK*-O+5
M(Z1B,Y=/5-==\J]-^85K<$;68YQIO>+172X5MFDMC;A%'6SNF="_G:U4:YW7
M75?[/<:R@L'RKQ_RJDJ+Q>XV0V^&2-T%<^-S4<K55FV_S$5RZ;V))26#(H^-
M55D[[93I:IJ)+<BI5IXB-1[7>)RZ^'T=[.NOL.367B_79-9;73W6W7.B932L
M=5-@="]O+I>J+M/93MONONZAOKQ9:R>X2?+EY6EQ*FI&QL9'62032R]-R33(
MK5TB(J:1W7>U(;PDRJ2WX-FU;5W">[6VQ5]4VCFEE61\D#&HYJ<Z]T7II?C[
MC8WC'\H^=".^OM5#?+7)1LBAIYZQ&,M\R:YGM1S5WM47VD;S:=Y:T8V!89?Z
M&',,?R.W4;K1>ZJHJ75U/5=DE9I6MC5N]IT[ZUU[Z38;7%<<?F&'T=WR:YW.
M2X7.!M4WU2MEIXZ5KTYFMC8QR-Z(J=7(Y57>R*\9K)/14?#NWS7NZU.[M34<
MLJU"M=+U_NBZ_P#B)Y.[H;3":+B/A5 S'4M5KOMMIU5E'7NKO5U9'OHCVJU5
M77N1.G;:FQXH8IDE\QW'9Z%])77VT7&.X/C5?!CETJKR-5>R)M$3:]43KU G
M>/V9EDI)((ZVXUB/?S\]=4NG>G1$TCG=43IV^TQL\_ZCY%_FZH_X3C*L%5<Z
MRA\:\VV.VSJO2!E2DZHFD^DY$1-[WT3?377R-?G\-TK,6N-!9***JJJVGEID
M66=(FQ\[%;S+T7>M]@B,\ (UEX+6"-)'QJ^&9O.Q=.;N:3JGQ(CP8L%1EV'W
MAU]R&_2I\J3Q-\*M=$Y%1&IS*YO5R]NBJK4UT0F?":UY#BN!4]DNEJ@=4T#'
M^"Z&K16SJY[G:[>S]+X]C&X-X_D&(XY=J&[VZG6:2JEK85AJD<DBO1/87IT[
M=_B%=' JLN5VPV]VV[W*JJI;=<ZBW1U:O7QEC:C=+S+UVG,NE^SW$;X!8]3I
M:;Y<9;G>(TH+Y4?R4=:]L4B,1B[D8BZ>J^>^Y*>$MBR3%:+(XKK:Z=7UM=-<
MH?!JT=MS^5/#7:)KM](Y\&\=OV-T5XH,@M],R*NKIJY)8:E)$3G1J<BMTB^2
M]0-=PQ\7B79[AD>0U5=X%1520T5'35<D$=-$W2(O\FY.9ZKO;EW\-&1PKOMT
M;EF683>JV>N=:7-DI*V5=S.A?V1[O-R(YO5?>IRP7',@X<NN5IMUN2]X_-4.
MJ:)T50R*:G5VMQO1ZHBIT3JBKY].NDVF#8G7V6XY)DUV;#/D%X?SK3PR?R<,
M;4TR)'JB;7MMVM=$]W4*^X68U<,OM>1?*&6Y%#ZGD$K&.@JN5TG(C.KW:VO3
M2(F])KHANL@I:^N](2DMC;[=*>WRV=U2Z&&;E1GM*Q6LZ>SOE15<GM=]*GEN
MN#6/Y!C#;W37NWT\<5PN,UQ;+#4I)R<Z-3D5-(O\WN<:BPY')QIILG;;*?Y)
MBHEMRJM6GB*U7J[Q>77Q^CO8$=;:[C9.,U/B]MR.],L=TM[JR:.6I6:1CFJY
M%2.1^U;O2;5.O5>O94S;?!58AQRMEEH+K<ZJT7>WRSRTU=5/J/#D9S+S-5RJ
MJ?13\J_#6UNUAR.;C-;LFI[;3NM5)1NH5W5(DCT<YR\Z-UY<R=-^1\R*P9%4
M\8++DE';*>2V6ZFDI5YJM&ODYT=MR)KIKF3HJ]= ;/(;1-65=XJ<QOK:#'T:
MUE#'25KZ7P^B\TDKT5O,Y5UI-JU-=E(UPHN-QO\ P.JY+A=*V2IB2ICCK&3*
MDRM8JJU>?OORWWT94>.Y11<3;Y=);70WNBK49\GU=75<J6]$1=M1BM54157K
MRIUTG7JNN?"'&,BQ_$:_%K[0TT5.U9TBKHJE'^+XB]-1ZVB=5[JGET]P87HZ
MV%CL L-Y=<KNZ9WCJM.ZM>M.J^(]O]SWKX_;U/O"JX3TF5<4)+G7UE;#;ZMB
M-?42<[F1M21>5/)$1/)-&QX.6S+,5QZGQR\6:D]6H72\E='6HOBM5SG(C6(W
M>^9====/CT./#K&;[;<IS&IOULIF6^_S^,GAU22+&B(Y.5R:3>T=W0#%X8P3
M<1L9FR7):ROYJZ>5M)34M9+!'21-<K41J,<FW;155R[7L=W"6_76JNV78??*
MZ>KJ;+-X=/7N5/&?"_FY5<OFY$1%W\?@<\!L.2<.Z2ML=+;6WRR^,^:@GBJ6
M121([JL<C7Z\^O,W?=>GDFSP+$Z_'%R*^W!L-7D5ZG]8EAADU'&U-\D37N3R
MVNW:_P!@1!^#%@J,MQ&].ON0WZ9/E6>)OA5KHG;:C$YE<WJY>W155J:Z(2?@
M%<;G78K>:*Z7":MFM=UJ+?%4S+S2.8Q&Z5RKW7:KW^"'/@WC^0XCCUWHKO;J
M=9I:N6MA6&J1R/5Z)_)KT37T>_Q.7!['\AQJ+(8+U0TT*7"X37&*2*I21&J_
ME3D5-(O37<*WO#6PW^P6BJI\IOKKU525+I8YE1?88J)IO7KW15UV3>D):1+A
MJN7K:*K\/4HTK_67>#ZMK7A:36]=.^]>>M;):$
M
M
M                                  #0Y3B-GRE*9+Y!-4-IGI)$UM3+
M$UKT[.TQR)S)Y+W0WP ZJ2!E+31P1ND<R-O*BRR.D<OVN<JJJ_%5-!6X59*S
M(V7Z>&K6[,;R,J&UL[%8W^BB(]$1O?V432[4D@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M -6TW[H$\! _P1RW_O$K_P!6TW[H_!'+?^\2O_5M-^Z!/ 0/\$<M_P"\2O\
MU;3?NC\$<M_[Q*_]6TW[H$\! _P1RW_O$K_U;3?NC\$<M_[Q*_\ 5M-^Z!/
M<(&N9#&R219'M:B.>J:YE]^CF
M
M
M
M
M          CV19;06:OIK:C*BNO%4BN@H*1J.E<U.[EVJ-8W_&<J(!(01.OO
MV24=*^J7$EGB8WF6*GN#'3Z_R5:C57X(Y?@;G&+U3Y%8*&[T<<L<%7&DC62H
MB/;\%1%7J@&S
M
M
M
M
M                        *:X#3K?,JS_(*WVZ^2X^J-5W58H6;Y6)[D[?
MFERE11V6Z<.>(%WO=KM]1<\6OCDEK(:1G//1S;5>=&)U>U5<[Z/7K\$V%NG5
M2TT-)"D-+$R*)%5R,8FD15557I\555^\C,_$#'XZ1TT-14U,J)M*6"DE=.Y?
MZ/A\O,B_;HVF)5EQN%@I:R\TOJ=94<TJTRIIT+%<JL:[_&1G+OX[ VX
M
M
M
M
M
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MS0X5^*9?TZH_?)Z /C&HQC6-336II/L/H
M
M
M
M
M
M
M
M
M
M
M
M
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M1S5]Z+U0Y@
M
M
M
M                                                     /G(W^BG
MY#Z /G(W^BGY!R-_HI^0^@#YR-_HI^0<C?Z*?D/H ^<C?Z*?D'(W^BGY#Z /
MG(W^BGY!R-_HI^0^@#YR-_HI^0<C?Z*?D/H ^<C?Z*?D'(W^BGY#Z /G(W^B
MGY!R-_HI^0^@#YR-_HI^0<C?Z*?D/H ^<C?Z*?D'(W^BGY#Z /G(W^BGY!R-
M_HI^0^@#YR-_HI^0<C?Z*?D/H
M
M
M
M
M           !2&=7BMPSC%:J]E=<%QMT427*"6KDDBC=4/F8V1&N<J-1%C1>
MG1-=$ZEWE<WJQ4V79'G5FK->'-:J&F1VM\CN:H>UWW.5J_<"+&1=IM.Q1]HO
M59EG'F:GEKKA%CS+:^:B@IZN2&.?PYO#\5R,<FT5R2:]Z(WR.>$9?<+K@K,0
MEE=%E\-2MDG7?MQ1M1>:H^Z-KM+YO1/>;"GI*:U>D/::&BC;#318OX$3&]D:
MV9=)^1 JW0 $
M
M
M
M
M                      B-@Q6X6O*;G>IKXM4ZY>&E1 M*UC=1M5K$8J.V
MW7-\=DN $:MN&6RWYQ=<H@9_[0N$$<#TUT;R_25/B[3-_P"3\345>!UE1Q A
MRU+^YE;# M+'"E(U8TA57+RK[6U7VN^_V$\
M                 P;W;8[O;)Z&6>JIV2ZW)2S+%(W2HOLN3JG;\AG ""_-
MG0?C_*_US-^T?-G0?C_*_P!<S?M)T (+\V=!^/\ *_US-^T?-G0?C_*_US-^
MTG0 @OS9T'X_RO\ 7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_
M "O]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\K_ %S-^TG0 @OS9T'X_P K_7,W
M[1\V=!^/\K_7,W[2= ""_-G0?C_*_P!<S?M'S9T'X_RO]<S?M)T (+\V=!^/
M\K_7,W[1\V=!^/\ *_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_RO\ 7,W[2= "
M"_-G0?C_ "O]<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_ %S-^T?-G0?C_*_U
MS-^TG0 @OS9T'X_RO]<S?M'S9T'X_P K_7,W[2= ""_-G0?C_*_US-^T?-G0
M?C_*_P!<S?M)T (+\V=!^/\ *_US-^T?-G0?C_*_US-^TG0 @OS9T'X_RO\
M7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_ "O]<S?M)T (+\V=
M!^/\K_7,W[1\V=!^/\K_ %S-^TG0 @OS9T'X_P K_7,W[1\V=!^/\K_7,W[2
M= ""_-G0?C_*_P!<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\
M*_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_RO\ 7,W[2= ""_-G0?C_ "O]<S?M
M'S9T'X_RO]<S?M)T (+\V=!^/\K_ %S-^T?-G0?C_*_US-^TG0 @OS9T'X_R
MO]<S?M'S9T'X_P K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_*_P!<S?M)T (+
M\V=!^/\ *_US-^T?-G0?C_*_US-^TG0 @OS9T'X_RO\ 7,W[1\V=!^/\K_7,
MW[2= ""_-G0?C_*_US-^T?-G0?C_ "O]<S?M)T (+\V=!^/\K_7,W[1\V=!^
M/\K_ %S-^TG0 @OS9T'X_P K_7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_P!<
MS?M'S9T'X_RO]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\ *_US-^TG0 @OS9T'
MX_RO]<S?M'S9T'X_RO\ 7,W[2= ""_-G0?C_ "O]<S?M'S9T'X_RO]<S?M)T
M (+\V=!^/\K_ %S-^T?-G0?C_*_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_P K
M_7,W[2= ""_-G0?C_*_US-^T?-G0?C_*_P!<S?M)T (+\V=!^/\ *_US-^T?
M-G0?C_*_US-^TG0 @OS9T'X_RO\ 7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_
MUS-^T?-G0?C_ "O]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\K_ %S-^TG0 @OS
M9T'X_P K_7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_P!<S?M'S9T'X_RO]<S?
MM)T (+\V=!^/\K_7,W[1\V=!^/\ *_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_
MRO\ 7,W[2= ""_-G0?C_ "O]<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_ %S-
M^T?-G0?C_*_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_P K_7,W[2= ""_-G0?C
M_*_US-^T?-G0?C_*_P!<S?M)T (+\V=!^/\ *_US-^T?-G0?C_*_US-^TG0
M@OS9T'X_RO\ 7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_ "O]
M<S?M)T (+\V=!^/\K_7,W[1\V=!^/\K_ %S-^TG0 @OS9T'X_P K_7,W[1\V
M=!^/\K_7,W[2= ""_-G0?C_*_P!<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_7
M,W[1\V=!^/\ *_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_RO\ 7,W[2= #XQO(
MQK455TFMJNU/H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MY_7S*/SX/X8_ .Y_7S*/SX/X9.@!!?P#N?U\RC\^#^&/P#N?U\RC\^#^&3H
M07\ [G]?,H_/@_AC\ [G]?,H_/@_ADZ $%_ .Y_7S*/SX/X8_ .Y_7S*/SX/
MX9.@!!?P#N?U\RC\^#^&/P#N?U\RC\^#^&3H 07\ [G]?,H_/@_AC\ [G]?,
MH_/@_ADZ $%_ .Y_7S*/SX/X8_ .Y_7S*/SX/X9.@!!?P#N?U\RC\^#^&/P#
MN?U\RC\^#^&3H 07\ [G]?,H_/@_AC\ [G]?,H_/@_ADZ 'QB<K&M5RN5$UM
M>ZGT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MG@_57"3.^(E'<;I6W!E'60Q0.J9.;D9_*+I$32)]R(6L
M
M
M
M
M                                                !&.*'][?*?\
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M_11=]5Z*H3A.W4!.P"
M
M
M
M
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M[E?>951=>2IYH3L
M
M
M
M
M
M
M
M
M
M
M
M
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MWF<K6SRJND]_0GF$Y-19?C5'>[8R>.EJ>;E9.U&O16N5JHJ(JIW1>R@;P
M
M
M
M
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MN)?]3Q#])J/W!XW$O^IXA^DU'[@$Z!!?&XE_U/$/TFH_<'C<2_ZGB'Z34?N
M3H$%\;B7_4\0_2:C]P>-Q+_J>(?I-1^X!.@07QN)?]3Q#])J/W!XW$O^IXA^
MDU'[@$Z!!?&XE_U/$/TFH_<'C<2_ZGB'Z34?N 3H$%\;B7_4\0_2:C]P>-Q+
M_J>(?I-1^X!.@07QN)?]3Q#])J/W!XW$O^IXA^DU'[@$Z!!?&XE_U/$/TFH_
M<'C<2_ZGB'Z34?N 3H$%\;B7_4\0_2:C]P>-Q+_J>(?I-1^X!.@07QN)?]3Q
M#])J/W!XW$O^IXA^DU'[@$Z!!?&XE_U/$/TFH_<'C<2_ZGB'Z34?N 3H$%\;
MB7_4\0_2:C]P>-Q+_J>(?I-1^X!.@07QN)?]3Q#])J/W!XW$O^IXA^DU'[@$
MZ!!?&XE_U/$/TFH_<'C<2_ZGB'Z34?N 3H$%\;B7_4\0_2:C]P>-Q+_J>(?I
M-1^X!.@07QN)?]3Q#])J/W!XW$O^IXA^DU'[@$Z!!?&XE_U/$/TFH_<'C<2_
MZGB'Z34?N 3H$%\;B7_4\0_2:C]P>-Q+_J>(?I-1^X!.@07QN)?]3Q#])J/W
M!XW$O^IXA^DU'[@$Z!!?&XE_U/$/TFH_<'C<2_ZGB'Z34?N 3H$%\;B7_4\0
M_2:C]P>-Q+_J>(?I-1^X!.@07QN)?]3Q#])J/W!XW$O^IXA^DU'[@$Z!!?&X
ME_U/$/TFH_<'C<2_ZGB'Z34?N 3H$%\;B7_4\0_2:C]P>-Q+_J>(?I-1^X!.
M@07QN)?]3Q#])J/W!XW$O^IXA^DU'[@$Z!!?&XE_U/$/TFH_<'C<2_ZGB'Z3
M4?N 3H$%\;B7_4\0_2:C]P>-Q+_J>(?I-1^X!.@07QN)?]3Q#])J/W!XW$O^
MIXA^DU'[@$Z!!?&XE_U/$/TFH_<'C<2_ZGB'Z34?N 3H$%\;B7_4\0_2:C]P
M>-Q+_J>(?I-1^X!.@07QN)?]3Q#])J/W!XW$O^IXA^DU'[@$Z!!?&XE_U/$/
MTFH_<'C<2_ZGB'Z34?N 3H$%\;B7_4\0_2:C]P>-Q+_J>(?I-1^X!.@07QN)
M?]3Q#])J/W!XW$O^IXA^DU'[@$Z!!?&XE_U/$/TFH_<'C<2_ZGB'Z34?N 3H
M$%\;B7_4\0_2:C]P>-Q+_J>(?I-1^X!.@07QN)?]3Q#])J/W#E#-Q'\5GC4F
M))'S)S<M14;UYZ]CN!.
M
M
M
M
M
M
M
M
M
M
M
M
M                                   .$\L<$,DTSVQQ1M5[WN72-1$V
MJJ!S!'Z3-L7K*J.EI,CM$]3([D9#%61N>YV]:Y47>]FXN-=26VCDJ[A4PTU+
M'KGEF>C6MVNNJKT3J!D U-FR:QWR9\5EO%ON$C&\[FTM0R56IVVO*JZ[H;8
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MVU$]9_DG-:Q=JG+M43:]/+H!(@
M                 -?1WF@K+O<+92U"25U D:U,2-7^2YTVW:ZUU1-Z10-@
M
M
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MR6RPTLE-9:"FH:>21971T\:,:KU[KI/L3\B&P
M
M
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M1D;&HUK432(B=$1"-4>%6^EX@U^71_\ 3JND92N9R]&JB]7[]ZHC$_T?B2@
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M=HG  A^2X7-?,HQR\_+E;2_)#N9]/"FF5"[15WUZ;UI>^TZ$P
M
M
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M32>?*Y=>\COX?Y)/Q.NV/T&->L06^E:]8EJXXWN5SD5)%<NTTJ*B(WOUZ^Y
MF%]S.TV3)K-8:Y\R5]U54IT9&KF]/Z2^6UZ?L)&0/*,Q=:<PQ"T5%BYJB[N5
M&U4DC5;3JB?RC6ZVJN3:>Y%VG539Y%F#+=D%%CUKHUN5^JXUF2G23PV0Q)WD
ME?I>5N^B:155?("4@A-#G,D&7P8SD]L;:[C5QK)12Q5'CT]2B=VM>K6JCDUV
M5O\ M3>)?>(=3;N(]/B=-CU75S34RU+)F2L1)$TNM;736HJ.15<J+TZ(NTV%
M@@@%@S^MGSI<5R3'W6>OEIUJ:5[*MM1'.Q._5&II>B]/@OPW/P!7W%S++SBJ
M8\ZTQ43J>X7&*AGDF1SGLYUZ<J)I.R.ZK\.AFU695U5DEYLN,VB"XU-HCC=5
MK45OJZ*Z1JN:QGL.YETG=>5$]Y"^.ER?687A%REH:F"62]T<[J1S?Y5B\CU5
MFEU[6^@%T K>^\1;IC=TMB9'BLE#9KA4-IF5K:UDKHGN[))&U-)Y]G+V7N2C
M+,HI\?6AI_#]9N5PD6*DI4>C.=43;G.<O1K6IU5?LTBJN@) "#VG/.?,Z?&;
MS24E-7U<#IZ62BK?6HI$;M7-5>1BM<B(J]M*B=SJFS^6KAKZO'Z"AK+=1O?&
MM157%M-X[F;1WA)R.VB*BIMRM15[=.H$]!4F:\5Y8>%U%E&+4#YFW!Z0MDF<
MU/5G\RM5'-WMR[1R)KITVO3O8>.W"[5[9UO-D6U*SE\-%JF3^)O>_H]M:3O[
MP-P#3Y;D=!BUEEN=U>](6.1C61MYGRO<NFL:GFJJ1I,[N%%FUHL&08_Z@R[M
M>M'4QUB3;<Q-JU[4:G*NM=E5.J=P)Z"!9AQ GQ_.+'CD-BJJUUS:][)HI&)S
M<K7>RUJJG7:)M7*B(B[ZG51\0;A3YU08WDV..M3[DQ[J&I96-J&2JU-JU=-3
ME77V]T]^P+"*]R?++S;.*V*X]%'1):+JV5[Y-.=,JL8Y5;[D3?+[_N-[D.61
MVZ]TEBMU(^Y7VJC69M,QZ,;%$BZ625Z[Y6[Z=E55[(5ED=9>:GCY@$5\M5/0
M^$RJ6&2GJUJ&3(L3M]V,5%32=%3S O( @.8<0:BP9Q9\<@L%57/N,<DD<L<K
M$YU:UR\K45>^T3:N5$1%WU GP()!GM33V"GJL@Q^>UW>KJW4=);'5#'OF5.O
M-S]$:W6U55Z(B>>TW]H\^=%E]NQZ^45'35-R8]U)+15WK3%<Q-JQ_L,5BZ[=
M%1?>!M[%F=IO>37FPT+YUK[2J)4<\:M;UZ>ROGI?_L;)&0?$\N;>.(&46-+-
MZC):TB\6=[FJ^H5V^551OERZ5-JJ]?+L?)<[EK'W!^.T-#64E#(^%]15W%*5
M)9&?2;$G([F1%Z<R\J;[*O<"<@@]!Q,LM9A%#DD;*A65LJ4T%&UJ.GDJ%<K?
M":F]*NT7KO6NID+D&407*W1UF(L]0JYFQ/FIK@DTE-O^=(SPT32>:M<J)[P)
M@"K*?/\ ):KB1?;%0XSZQ!;8(E6):R*-^W>TDBN7::5JIIJ=M=?A*+UE_J=V
MIK-14D51>9($J989JE(8J:/>MR2:7NNT1&M55TJ]$Z@2LQ;H^JCMM4^WMA?6
M-C<L+9E5&*[71'*G77V$4Q?B!272Y7VV72.GH*^S,2:I6.I2>!8E;S>(V33>
MB)W1414.B/+[U>K#-=L9QME7;',<Z!U76^K2U+4W[3&>&[2+Y<RM5?<@'9P9
MRFOS+!X;S=FP,JI9Y6JV!JM8U&N5$1-JJ_VDX*I]&'KPEH5[?\YG_P!]2SKC
M6TUNH*BMKIF04M/&LLLCUTC6HFU50,?(:BLI+%7U-LC@DK88721,G548YR)O
M2JG7R(]PAR.NRS +;>[JD*5=4LJN2%JM8B)*YJ(B*J^2)YFMN&67V[8A67:Q
M8RR>URT[WPK55W@3S1\J^VV-&.32IU1'.153R39K.!=TH[+P&M5RN<S8*.EC
MJ))9'>2)-)^5?<GFH%K KZ7.KTF-?A+#BCGV/P_6.5:U$J_ UOQ/"Y.7Z/M<
MO/O1NWYS8FX7'E*52OM4K$=&K&[>]RKRI&C>ZOYO9U[P),"%5>2Y53I25*X9
MXE%-*QCVQ7!'5,+7*B<SHT9R]-]41ZZ.RW9K)5<3:[#Y;6Z!U-1+7-JUG1R2
M,YV-3343IOG7NOD!,00R+-I5XG+A\]I="Y:-U;'5K.CDDC1=)IJ)TZ[[KY&!
M>.(E71<1TQ*DQRJJYW4BU,<K9F-23W+U736)[2*Y5WM.B+M-A80*THN)EP;E
M,^,WC$ZNEORQ)/204]4R>.H9U]I9%1J,1-+M5]R^>D7-Q[/JRISA^*Y)8'6>
MY/IUJJ5S*I*B.>-%TO5&II>B]/@OPV$^!$[QEZ17^:R6>GIJRXTT;9:IU35)
M3PTZ.WR(YW*Y5<J(JHB-7IU54Z;P<?XAQ7:V9(]MN>MTL*JE51T\[94?T546
M.1=(Y%1J]T1>G8"= JRR<2[_ 'W"69%9L+EJH_Y1SV.KF1(K6.<G\GMJJ]=)
MUZ)UVB;)+9<VBOO#MN56BWS5".A?)ZHLC6.1S%5'-5R].BHO7W>7D!+@5QPE
MS'(LKL=MK[G8FLI*M9G+7,JF(UJ(]Z-1(_I=-(W[MD^N<U33T$\M!2I5U+&[
M9 LGA^(ONYE1= 9((%A>?5.68M<[O061(I:*9T'J<M6C7N>WJ]'+RZ8J(J:W
MW^!SPS/W93@U9DU/;8J>GA;(K(I*M-KR;YN=4;['1-IWZ*G8#<YSE]KPJS-N
ME\=,VF=,V!/!CYW*YVU[>[2*OW$<XRY?=\4QNWW&PQT3V5-5'3R/J&N5S$?]
M%S6II%[+W^'13"RKB+46WAE!D]QQ5SV5+XUBI)9V.1C7)MCY-ITZ^2(J]NWE
MB^DFY7\/K:Y4TJW2E7_> W7%W++SBC,??:(Z)T%PN,5#.^9'.>SG7:<J)I.S
M7=5^'0L$J;TB?_=6'_\ VQTO^QY;(
M
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M
M
M                            .NIA94TTL$O-X<K%8[E<K5TJ:72IU1?B
MG4#FU[7*Y&N15:NETO9?<?2H_1E9X>%WEG,]W+>JEO,]RN<NFQIU5>ZEN
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MJ87PU,4<T+TTYDC4<UWVHIV  G1-(
M
M
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MW+TXDTU)#;J1V(+3*Z6K5R>(DNEZ=]]^5-:UI5781+P
M
M
M
M
M                                !$,TQZ?+:RAM=9$D5AIIXZRI>KD5
M:IS=JV%J)V;O2N5==D1.ZJDO             57DUIR*IXP6'(J.PR36RUP3
M4[U]:A:^7G1R<S6J[M[2=]*6H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
%   #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g111069g99a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a05.jpg
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MNU2RFHZ=O,^1Q_H \R>P ZE4!P]X_1U><76+)7&ELM?*#1/=VI-#E#7_ "<
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M>@+2_P#K<5Z4JY8Y^",\L)!B?CKG-UZ>[%4)[6]CDI,UM]X:P^[U]*(R[_\
M21D@C^:YG]*E_"#,H;WP,R&QSRCZ2M-LJF<A/5\!C>6.'R&^7Y:'JBJ@]GG]
MN+'/X<O_  7KU5C7[;N;?Q.W?U3+S7[,%DJKEQ1HZ^*-QI+9')--)KH"YCF-
M&_4EV]>@*]*8U^V[FW\3MW]4R%3I$6)6W&FHIJ2&>0":KE\*",=7/=HDZ'H
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M[=M3M>=?>@\C\"AKC!C@';WEW]AR]U+PIP(.^+N-D]S4._L.7NM%KRE[8/\
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M<B^VG_\ J>->U+)_X-0?Q>/^R$&8B(B"UN27NAQRQUEVNLOA45*SGD=K9/D
M!YDG0 ]2MDHQQ#Q&#-;)#::VHDAHO>HYIQ'T=(QNSR;\MG75!YVS#VB:N]T=
MSME/8*5EKK(9*<^-*XR\KFEN]C0!Z[UH_>H=[.7[<F/?;/\ \"1>J)>$N#26
MMU!^#5 R(MY1(UFI1\_$^MO[UYGX)445N]H&@H:>7QH::JJX62?GM;%* [[P
M-HJZ,-K_ *,XK<6:T4M35NA%*X04T9DDD/(=-:T>9/\ \JH?BM69[>:NKNV5
M6Z\6^URR@1T\T<C*>+OR- /3>M]>YZKT+PS_ &Z^)_\ "I/[#ET^U9^U9_\
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M_P"XY5_M*?\ JD4Q]J7]J>H_C</]94.]C;_N.5?[2G_JD1>/1JIWVK/VK/\
M[_A_J>KB5.^U9^U9_P#?\/\ 4]$B->QQ_P""Y-_&(?[+EZ'7GCV./_!<F_C$
M/]ER]#HM><_:NRR^6BJM=HM=QFI*&LIGOG;">5TAYM:+AUUKRWHK-X.XCAF?
M\)K3276FIJFYT/BQS20N\.HA+IGN:"1U((((WL?TJ?\ %WAE;^(5L9XDAI;M
M3-(I:H=0-]>5X\VD_>/+S!\T8)A^>V'BA]%6)KZ*[TA!GFWN 0G\IY[.81V'
M<^FQT">9SP8PG'9J2FCN]UDNMPD$5%0.J(6F5YZ;+BSX6#S<=^@V=!6QPCX7
M6OA_;^=H;5WJ9NIZQP[#\QGHW^D]SY ><./&#Y58L@FO5]JY+O2U3ARW%K>4
M-/DQS?\ T>O(=O3S"L;V;>*EVO%SBQ2^DUNH7/IZQSOQC0T;Y7_G#78]_7?D
M'HQ$1$$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%U5E-#64DU+51M
MEIYF.CDC<-AS2-$'[05VH@\,\8.'%?P_O[G1-EDLT[RZCJQY>?(X^3Q_3W'G
MK><&^*%GQF_5EQRNURUURJSUNS'<\S!H @M)UUUU<#L^>U[ NMNH[M0345SI
M8:NDF'+)%,P.:X?851^5>S79*Z=\V/72IM9<=^!*SQXQ\@=AP^\E%UE99Q4P
MV\7?"ZRBO<1AI+F9JCQ(WL=$SP)&[((]2!TWW6SR'V@L)MD3_<*BJNLX[,IX
M7,;OYN?KI]FU7$7LPW4RZER.A;'OZS:=Y/Z-C^M3S#O9XQBRS1U%YGGO<[#L
M,E:(X=_P!LG["XCY(>-3AM5DW&6]P7.^P?1F$44HECHF$ZK)&G;0XGZX!&R=
M!O30&]D6OQ(RBCQ+$JZY5\51*SD,;&01EQ<X@@;/9H^9T/OT#)((8Z>&.&"-
MD4,;0UC&-#6M [  =@OLT4<T3XIF-DC>"US'#8<#W!'F$1X&X2WHX]Q$LES%
M%45QBE+134XW)(7L<S31YGXNR]Z\YDHO$=&^-SH^8L?KF;L=CHD;^PJ <.N$
MMCPN\W&ZT[!/6U$TAIR]O2EA).F,^>NA=W\O7>RXJYS;\'QBHJZN1KJZ9CF4
M=,#\4LFNG3\T="3_ ,R$5Y#X(_MN8W_'/^17N&^4M96VJHIK;7"@J96EK:GP
MA*8]^8:2!O[5YH]G7A3=SD-%E5^@DH:*FW)30RCEDG>00'<O<-&][/?IY=5Z
ME0KQ7Q$X(Y-B$,E=3\MVMD?Q.GIFD/C'J]G<#Y@D#STI=P7X[RVSP++FLSYZ
M$:9#<#MSX?02>;F_/N/GY>IE4EXX$XU<L\9?GM\*@</$GML;>6.67?UMCLT^
M;1W/VE#6^;=*_.ZDQ6"HFH<7C?J:Z1DLEK2#U93GNUGD9//LWU4] T /3U7"
M"*."&.&"-D<4;0UC&#36@=@ .P7-$$1$$1XI8539WB53:9W-BJ ?%I9R-^%*
M-Z/V'9!^17B&YT-\PJ_U=#5MGM]PC8^"0 ZYXW@M.CV<UP)^17Z&*.9KA-AS
M.A%-D% RHY-^',WX98OX+AU'V=CYA%E49P9XR89CM@AM%;:I+)(.LM1 TS1S
M.\WN/5X/RT=>JE%CXHX;3<1,KNL]]@;05=)0M@D\.0\Y8)>8 !N^G,/+S4<O
M?LQ,=,Y]CR-S(B?ABJZ?F(_WVD;_ )JPK?[,%:Z4?2&2T\<?GX%*YY/Z7!#Q
M+,J]H[':*)T6-4=5=JL]&.>PPQ;^_P"(_9RC[5(.$=BR"OK9<SSQY^F*J/PJ
M.CY>5M% 3L@-_)<[0^>AU.R=9F <',5PV:.KIZ9]?<F=6U580\L/JQH :W[=
M;^:L9$>8/:ZM]?57NT5=/05DE'34KFRU+8'&)A+R0"[6MZ4/X8\<+YA\-);:
MZ.*XV.$<C82T,EB;O\AP[_8[?VA>SR X$. (/0@^:J#B'P(Q_**Z&MM>K-4F
M5IJ13L'AS,W\6F]FOUV(Z>H/=%UYXXD&7/\ BA=:S$:2JN<56(9(VP0N<X#P
MF \P';1!!WZ+VU9HWPVBABE:6R,@C:YI\B&C86)BV-6G%K5';K%114M,P=>4
M?$\_G.=W<?F5MT1Y$]JO):2\Y?0VVDBJ&R6N-\<KY8RP.<X@_"#U('+W['RW
MW4]]G#,X:'AA6PU=LN I;.9)7U<47B,EYG%W(T#J7#?;6@.I(5B<4^&]MX@P
M6R.N?[O)25 >Z>-H\1T6CS1@_,Z^S6_MEEDM-#8[73VZTTT=+14[>2.)@Z ?
M\R>Y)ZE%>!'7YGX?G(&0/,?TG[^(2=.(\7GY=^ODO3_'^YNO/ DW%]%54#JF
M6G?[O5-#9&;?Y@$_;_<I%1<(<?@XC5N5RP,D=(YLM/2<@$44NOBDUYDGJ/('
M9[ZU(N(^(T^;XE662JG?3^-ROCF:.8QO:=@Z\QZCT*#SQ[*.06FQ5&4&\7&F
MH_$B@?&)GAI>&E^^4?E'J.@Z]5ZDM]8VMM\-6(9X&2LYQ'.SDD:/FWN#\NZJ
M?A'P1M^&51N=YEBNEW:X^ \,U% /(M![N^9[>7J;A1*\-\?<DI<GXCUM7015
M$<$$;*7\?&8W.+-[/*>H'7SZ_8KWP[B%3T7 2.OKK3<H8J*D;;XR(N9M2X,Y
M>=A'9FQU<[0';9*E.>\*++FF5VF\7)O*VE:YM3'&-&K'3D:X^@^+?GHZ^R?1
MTM/%1MI(X(F4K6>&(0P!@9K7+KMK7DBO!/">^_@WQ"LMU]RGKC#*YHIX.LDA
M>QS--'F?B[>:O7VNY3-B>,R.BDA=)4/<8I-<S-L'0Z)&Q\B58. <)+%B&0W*
M\P1MFJZB=[J4.;\-'$XG3&#UT=<WIT]=Y/&/AW%Q$Q^"C%9[G64LIE@E+>9N
MR-%KAZ'IU';2"LO9?RFSV3A[=*>NK&"N^DW/CHV?%/,'11-:&1CJXDM(Z>G7
M2MGBU%45O#*_P4=)4U%544CHXX(8R^0N=Y:&UI^$7">UX!2>\2%E=?9&ZEK"
MWHP?FQ@]A\^Y_H%DH/S]Q+*<@X?7V:HM;G45;R^%/#40@\S=@\KFN&QU [:*
MLCB=Q8I>(?"^GH9Z84E]@N,3Y(&;<R5OAR#G9Y]R-@]1L=2O2F<8+8,TH'4]
M]H622 :CJ6 -FB^;7=_N.QZA13A3P<L^#.DJZ@LN=V,CO#JI8]>"S?PAC>NG
M:[GOUT.G<:COLHV*ZV;';T^[V^JHA4SQOA%1&6%[0T]0#UTIEQTR:DQSAW=F
MU<51+)<*>2CA$49(#GM+=N=V:!OS[^6U8*Z*ZDIZ^CGI*V&.>FF88Y(I!MKV
MGH00B/#_  &OSL>XD6^I9;JJXOF:ZF$%* 9#SCN >AUK?4CIYKU)[0)WP=R,
MD:_%1=#_ +9BY<+.%EGP%M3/3#WJY3N=NID'6./?2-OH-:V>Y/W 2?-,=ILK
MQ:XV.MD?'!61\A>SNP@AS7?/1 .D5Y:]E:]VRRYA=Y+O7TU#')0$,?42!C7$
M/:2 3YZ!.ODO6%MNL-PM+;C%%5,IWM+VB2%PD<T$Z<&:YNH&P-;T1T51<+>
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MTM9;ZFNIKB8^5M+HR-D;L !IUO?-Z^B]$<*,:O5-9K/49)+)2^Y1.;26V)Y
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M2L?XU3,]Q$;7:URQ,[,8!T]3Y_+SO[6F44=QNELL--%4>\6YSY)I)(RQA+P
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M]PX6/XNT530L-PRFJJ>3GIBYT,<NB.=VR&;Z>6^O76^JCGL:_P#=,L_ATO\
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MQQ1J64CVR,H*=E&]S>Q>TN<X?<7Z^T%;C,?:+R"\4,M)9*&"S,D'*Z9LAEF
M_P!5Q #?MUOT(5(O<Y[W.>XN<X[))V24)'Q>N_9&IG1<.:^9X($URD+?F!'&
M/ZP5Y)I:>6JJ8J>FC=+/*\,CC8-ESB=  >NU[[X7XS^"&"VFS/T9X8N:<CL9
M7$N?]VR1]@"%8?&F[NLG"[(ZR-W+*:8P,/F'2$1@CY_%M>"U[)]JF<P\*I&
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MG0[HL2# ,<FRS,+598 [_M,P$CA^1&.KW?<T$K]!H(8Z>".&%H9%&T,8T=@
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MS1&FFCK)JA]3(T.E#7 L:SD/P_%W)V?0()-Q4M=%+PJR2D=31"FI[9-)%&&
M-8Z.,N80/+1:%A< GNDX0XTY[BXB%[=GT$CP!^@!9^84>1WO *VVT]#;8KK<
M*>2DG:^L>8H6O:YI>UWA[<=$=-#OWZ=>CA!8[YB^(4MAOT-!JA:6Q5%+4.D\
M4.>YW5KF-Y=; [G?R1$W1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MI>*"...WP\S/&:Y[M1CX0T'9/R 46]F?%[E8<=NU;=*9]$RZ5(FIZ20:='&
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M=A 1"0.Y ^U?.=OYS?TH/J(OA<!W('VE!]1 01L'87PN:#HN'Z4'U$0D ;)
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M   *R$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M(X>1Z;!UY%,S:7W>%K1MSHF@?SBLO$:2EE<ZL,SY:MOUFN'U2?/Y_:NK)O\
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M;L#Y=3^E5][+^&X]D]DODU_M--72PU$;(W2@GE!:20.J#U#%(R6-DD3VOC>
MYKFG8<#V(/HN2X0Q1P0QQ0L:R*-H:UK1H- Z !<T01$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$00:YTHK,KEIW.+!(X#F WKX5LOP1B_P#NM_\
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M6%EG_C5%_!;_ &BL5]0;1=;I&.@D8X,^T]6_UH-9<Y355M34]V.D.C\NNOZ
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M)) USCKH-DC:Y4=JM]%,9J.@I*>4MY2^*%K'$>FP.R#Q/AMYO'!WB*]UTH)
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M%4F(\9&93Q(9C%'9:FCB8)O&EK'<LK7,!^'PQO74:ZDJVT!$1 1$0$1$!$1
M1$0$6/7UU);X#-7U4%+".[YI QH^\E:G',PL.2UM=2V&YPU\M$&&<P;<QO-O
MET_7*?JGL2@WR+'N%;36ZBGK*^>.GI8&E\DLCN5K&CN25 :_C9@%%L.R!DSA
M^3!!+)O[PW7]*"QD6#8KI3WNST=SHO$]UJXA-%XC"QQ:>H)![;"TN:YW8,.B
MC^FJS53+_D:2%OB3R^7PL']9T/F@E"**XSDMUN\=155N+U]JM[(C)$ZID89Y
M2/R?!;LM.M]SORTHC4<>,8@NQM;K?D!N/B"'W84.I.<G0;REP._EI!;"*MZW
MC!8[6YAOUJR.S1..A-76U[&?I&U-<=R"U9';VUUBKX*ZE)USQ.WRGT<.X/R.
MB@V:(B BT^69-:<3L\ESOM6VFI&$-!()<]Q[-:!U)Z*#57&*GI+4R\56)9/%
M8WZ+:YU,SEY3V<1S[#3Y$]]H+1185DN=->K/17.@<7TE7"V>(D:):X;&QY%9
MJ B(@(BU.3Y':<7M3KE?ZV.CHVN#/$<"[;CV  !)/0] /(H-LBP[+=**]6NF
MN-JJ65-%4-YXI6=G#[^H]-%9B B(@(B("+&N%PH[= 9KA5T]+"/RYY QOZ25
MJ\:RZQ9-4U\%@N4->^AY!.Z'98WGYN73M:=]4]B4&]1=574P4=-+4U<T<%/$
MTODED<&M8T=R2>P4,H.+&$U]PCHJ:_P>-([DC=)')'&]WHV1S0T_I03A$1 1
M0[(.)N(6"Y24%TO<3*N+_*QQ1R3&+^'R-(;Y=]*2VBZ4-YM\-=:JN&KHY1MD
ML+@YI_\ F]$&8BP;W=[?8[=+7WBLAHZ.(;?+*[0'R^9^0ZE0ZP<19LHJXSBV
M-7*MM1D#7W.I<VFAY=Z+F!VW/UZ ?H03]$1 1:Z_WRV8_;WUU[KH**D:=&29
MV@3Z#S)^0ZJ.V/BAAU[N3+?07N+WR30CBGBD@+]]N7Q&C>_+2"9HNNIGBIJ>
M6>HD9%!$PODD>=-:T#9)/D  H!7\:< HMB3(897#R@ADDW][6D?TH+#1:K%K
M]19-8J:[VLRFBJ0XQNEC+'$!Q;O1\MA:*_\ $[#[#<I*"YWN)E7%_E8XHY)O
M"_AEC2&^7?2"9(L2TW.BO%OAKK750U='*-LFA<'-=]ZRT!%ILJR>S8K;C77^
MX0T=/O32_JYY]&M'5Q^P*'T/%3Z6IC5V'#\GN-!^34LIF,;(/5G,\%WW(+)1
M03"^)]HRRON-OHJ*ZTUSH(733T=53AD@ (! ',>NR!HZ[K3/XYXQ!?66>NH[
MU15YF9 Z.II6L\-SB .;XN@Z@[]$%J(BA_$3B'9,!AH9+Z:D^^.>V)M.P/=\
M(&R02.G4?I03!%#<:X@T6162INUNL]]-%"SQ&/?1]:CKK40!)>1KR49H^.V-
MUUU^C*"UY%57#F<WW>&A#I-MWS#EYM]-'?3R06PBKRQ\8,4NEZ%HGGJ[7="\
M1BFN5.Z!W,>S=]0#\B1M6&@(A( ))T!YJ,W;/<6M59!25E\HA5SRMA9!%)XL
MA<XZ +6[(ZGN4$F1%HL@R_'L>C>^]7FAHRWNR28<Y^Q@^(_<$&]18MJKZ:ZV
MRDN%#)XE)5Q,GA?REO,QP!:='J.A'=:S*LNL.)T[)LANE/0L?]1KR7/?_!8T
M%Q^X(-ZBB^(9_C&7RR18]=X:N>-O,Z$M='(!Z\KP"1\PI0@(L>X5M+;J.6KK
MZB*FI86\TDLKPUK1ZDE0JAXP8'77)M#3Y'3>.YW(TOCD8PG^&YH;_2@GJ(H]
MGF54>'8U4W:N!DY-,A@:?BGE/U6-^9_H&SY()"BCL=VO;<+CNM19&F\>$)I+
M;'/U WLL#BWJ\-\M:+NF_-9>)Y';LJLD%UL\WBTTO0APTZ-P[L</)P]$&W1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 5&Y[4G+./V+XK(>:V6EOTA41GL^4-+QL
M>8T&#_>/JKR5!VMII?:VNGC]/>J &'?G^)C[?S'?H0C<>U!E]5CF%T]OMLKH
M:J[2.B=(TZ<V%HV_1\B>9H^PE9'LR8U2V?AQ2W-L3??[JYTTLNOBY XM8W?I
MH;^UQ6@]KNQ5%;B]HN].QSX[=.]DVOR6RANG'Y<S /\ >"E7LUWN"[<*[;3Q
MO::BW.?2S,WU:>8N:?L+7#^GT1>+$O=KI+U::NVW&)LU)51NBD8?,$?U^8/D
M5CV>BI<9QFCHG51%%;:5L7CU#@-,8W7,X]!V'4JGN.V79GP^DHZRW7REJ*.O
MFE:R"2A8'0 :('-OXNAUO0/11;B]?\CJN!E@K+M<6U)OE0R67P8!$V./D<YL
M1T?BV0#O_506\WC%A1J&,-TD;3R2>$RL=2RMIW/]!(6\OW]EOLLS?'<4I(ZB
M^W6GIFRMYXF \[Y1ZM:W9(^?95/8N&U=F_"JP44F:$V1T$4T=-%;8AX;P#MI
M>""2TEP.^Y[K2>TG8X+)POPZA9/[Z^AE%*RK<T<SF",].G8?".F_((+-J>-V
M"4T%')->-.J8VR^&R)TCH@X; ?R@AI]1O84_MMPI+G;H*^@J(ZBCG8)(YF';
M7-/FO/7$.TV]GLO6*HCHJ=D\<%'*V1L8#@Y^N8[]3L[]5CT-TK;=[(GBT4CV
MR/>^G<]IZLC?4EKOT@EOWH+8K^+^&4=1-&ZZ2310/$<U33TTLL$3CT ,C6EO
MZ"5(KGF&/6NQP7BOO%'#;9V\T,YD!$HUOX .KC\ALJC.$.&7#+>#S:"DR_W2
MUU3Y655#';XGECN?>C(3S;(#3]A [+,XKX=38?[/<MG;6?27N58Q\<\C #&7
MR=0!L\OUCY^903^EXT8/4,MY%WY'UTACBC=$XN&GE@<\#?("1TYM'1WI;W*\
M]QS%I?!O%Q:VJY#)[M"QTTH:/RBU@):/F=!5GP#P;&KYPTQZYW6STM17T\\T
MC)R"'$B9VN;1',!H=';"Z['<\<L/$7)*?$J6[9;EE>Z4UADDC9! T.VYGB.T
M T$@'H>P'R06MA>:6+,Z*6JQVN;4LA<&RM+2Q\9/;;2 >OKV[KSUP\Z>U9>-
M?_===_4]97L?!SKYE3P.5GA0@L'8$N?K^HK%X>?Z5EX_C==_4]!ZG7F[VRO\
MAB7\*J_JB7I%>;_;*_[OB7\*J_JB1(NGA;TX;8MK_P"=E/\ \,*23S1T\,DT
M\C(HHVESWO<&M:!W))[!1OA;^UMBW\F4_P#PVJ/\8+ABMPQZZ63([[46^*F9
M#4U;:3_*%A<>1GU2#S$?5[] >R#G6<9\&I*V.GEO#BV1Q:VH;3R.A)!T=/#=
M$;\QL+<Y/Q#Q?%YJ:.^W5M*:F(30N$,DC)&'>B'-:1Y>OIZKSCQDOE/=N%V,
MPV''JNAQJFJ/"HJZLD8))N5CFD!@).B027$]2%;=ZQ Y?[/-HMX;XEPAM5-4
MTA/4^*V($ ?PAMOWHJ0.XP8.RD;5.O3VTKCILQHJ@,)^3O#TLVAXF8I76:NN
MU)<Y);=1%HGG;23<K.8D#\C9[==;UYZ7G#A_D=7D_#.3AE3Q"2Z55:UE,^1I
MY(J?9ED<3Y<I8?YXUV75PWR2YQ8I?.&C621W6Y5K:2GV-^"'NY:CF] &M)^\
MH8])CB=B!QV2^_3#&VMDG@B9\,C.=^M\K&EH+C]@/GZ+GBW$7'<FNGT;;:FH
M;7F+QVPU-+)"Y\?YS>8 $=57?'?AM47K%;!;,2,4D]CB=RV[Q V26$AK>< ]
MR"W[]GSZ'5<%>(DF19I06;-+8UN2V^&:"CKN5T<@T/QD<C.V]-)WKR/0$[0>
MB%X_GK).+/M 4U%<9'/M$=5)'%#OX13Q!SB/M?R]3_K?(+V O&.* \.O:$BB
MO'XFGBK983(_H/"E#FL?OTTYI_2A'LN"*."%D4#&QQ1M#6,8-!H'0 #R"TCL
M7HOPVCR>/FCKQ1NHI T#4K"YK@7?,%O3[?DM\M3<,AM]!?[59IY'?2%R\0P1
MM&_AC;S.<[T'37VHCR_A-WM]B]I#(Z^\5D-'1Q5-?SRRNT!\3M#YGY#J5Z Q
M'BEB.679UMLET\2MT2R.2)\9D [EO,!OIUUWTJ'X<4E/5^U!>VU4$<S65E<]
MK9&AP#@YVCH^?5?;U304'M94L5#$RGC-;3NY(ARC;H6EW0>I)W]J*]*9-E%F
MQFGCFO=?%2B5W+$P[=)*?1C&[<X_8%J,-XDXQE]PGH+)<"^NA!<ZGFB?$_0.
MB0' ;U_0H+G=;BECXOT-UJWW>]9:Z-D-%::;E,<)<TM!.] ;V3U)UO>NRK[
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MH+\1$1!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M*P/O4SW%KXVU<=.(QKZQ+^_W*O\ (<2S/B)''1974T6/X]SA\M#02&>>?1V
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M=ZM%>]GB4T=72\QJAO0$8C+B3\EE6OB/0U66P8[<+5=[1<*ECGTOO\+6,J
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M0]#Z%!,%J+YDMGL57;J6[U\5+47&7P*5C][E?TZ#7;N.IZ=0HA=^)GN/$/\
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M2B1XE!'K)S<Y'R)TLRJP/&JJY0W">UQNK8 UL,PD>'1!HT W3OA&O(((7Q(
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M6W,\9N=?[E;L@M535[T(8JICG./R /7[E47M+7^)M[Q?&[E55%-8JIYJKD8
M2^2-KM!NAU/9W3UT?)1G,[QPAN&)U-)8K?)072&(NHJF"ADCD$K1MO,_6R"0
M 2[???=!ZB) !)( '<E1F7,L=K#5T-NO]LFN#8G\L,-4QS]@'L >I'R5(Y9F
M=WO? C$:8U$D5ROE6+;4SG8<YC'.82?X6F$^NR/-61=^#>(G$);;;[5#35D,
M),%>P:J&R@?"\O[GJ.H[?8B.KV;KI7W?AG!576MJ*VI-5,TRU$AD<0"-#9ZJ
M9W3,L:M5=[G<K_:Z6KWHPS53&N'V@GI]ZHO L@J<7]EZZ7*A>8ZQL\L,3QW8
MY\C6<P^8YB1\PM;@EYX26[%*>#(*&2Y7>HC#ZVHJ*%\KS([JX-=KH!O0(UO6
MT5ZABFBE@;-%(Q\+F\S7M<"TCU!]%I*G,L9IJ>GGJ,@M,<%0XLAD=5LY9".X
M!WUUYJG?9XOD/TKE^/6F>IGQZ$&KMIJ&N#HV$D.;UZ^;?O!/FM/[.W#?'\KP
MVLN>34CJ]_O+Z6G8^5[6PL: X\H:1U+GD_\ S%!Z(NE[M=JHV5=SN5'1TK_J
MRSS-8UWGT)/58MCRNP7Z5T5EO5NKI6C9CIZAKW >N@=Z57\0+1A5LX@-O?$&
M_P!+/2,I&PT-DD@<X0 :'-RM)+@=.[M V?/2KC+[YADV:8?<N'=NFH)XKE&R
M:HAI33P2M+F_"!TZZWOH.A.]H+7S>[7"FX]8-;Z>NJ8J"IIYG34[)7".0ALF
MBYN]'L._HK:5,9__ *1G#W^+3_V9%<Z(J'C#D5]GS+'<&QBO%JJ;LUTT]=KX
MF1CFZ-/D=,<>FB>@V-K$J^#=\HZ5]58^(60_2[&ES'5$SC'([T(WT!^>_L*E
MG%'AU1YRVBFCKYK7>Z EU+6P?69UWH@$$C>B"""#]^X,^FXU8DPO@J[=E-'$
M-\CP/%+1]O*XG[W?>BICPES2MNV#2UV9L;;:V@F-/4SU+? 9)K7+)UT!O>NG
M38Z=]+7\!L_ES"S5S[[<J)UW?7RB&D8YK'-A#&:Y6;V6CXNO7SZK9\/LNM7%
M7%JV"YVML<T$@@N%NJ!SM:X'8/4=1L>8V"TCR4)]E*QVQ^*5=W=04YND5PFA
M95%@\1K.2/X0?3J?TH+:JLRQJEIHJBHR"U1T\LAB9(ZK9RN>-;:#ON-C?IM;
M&MNUNH;>*^MKZ6GH2 X5$LS6QD'L>8G75><O9]X=6++;+>[CDM*ZO:RM?2T\
M3I7M;$  YS@&D=27#]"Z<WON.5'&>>VYH9_P7Q^F9!1T$,;GL?+RL^LUOEU/
MV\K1ZH8]$V+)K'?R\62[T%>YG5[:>=KRW[0#L+9U,\-+!)/4RQPPQCF?)(X-
M:T>I)Z!>4>(F48-"^V7OAK!+;,BH:AK@V"C?!'+%UYFN&@/3[02#M27CME-#
M<LSQ*R7Z>II\8?3,N5=' '%TO-S<K2&]?R=?+F)\@AB\+1F&.7BL-):K];*R
MJ'_HH*ECW'[ #U^Y1/CSFU1AV%S2VBMI8+S*]C(F2%KI.0DASVL)ZZ]=$*H.
M(-[X65^,2C%*.6V7ZE DH:BEHGPNYVG8#G ==^IZ@]5N.+D\.3^S]9,GN-)$
MZ]$0Q&I<P!X/,6OT?($M)T@OW&[M1WBTP5-!74]:T-:V22"5L@#^4$@D'H>O
M;YK9K2X=9;;8[%3P6>AIZ*&5K97LA8&ASRT N.O/H%ND1'>)%3-1\/LFJ:26
M2&HAMM1)'+&XM<QPC<001V(*I;AK@N39CA5MOTO$?(:1]6)"86R/>&\LCF=_
M$&_J[^]7'Q3_ &M,K_DJI_X3E2?".W\4YN'MHDQ:\6*GLQ$ON\53'N1OXU_-
MOX#^5S'OV16^M%PRKAUQ.L>-WV_S9%9;V"R&6H;^-B>.GF2>AY?,C1\B%>%;
M5TU#2R5-;40T]/&-OEF>&-:/F3T"\X4\M]Q+BW9KKQ;C%Q?5#W6W5]/*/=Z5
MQ.B?##1^=YZULGKKI(<\I?P\X[6W$;G)(;!;*/WV>F:XM$SSUZZ_A,'V<VM;
M06S9<NQZ]U+J>SWRVUM0WO%!4L>[7KH'>EM:VKIJ&EDJ:ZHAIJ>,;?+,\,:T
M?,GH%3?&CAQ8+=A%7?<;H(+-=[0&U,%11-\(D-<-@Z[G74'OL#KW6BXHU-UR
MKA]P_P CEMM1=+1&YE3=Z*GV#(=-ZD#\GI(-^7,B+JL^88Y>JKW:TWZV5E3_
M .JAJ6.>?L .RH1QKSV;%I\?H;7<:.GJ*NOB96![FF2. GJ[1/P@]1S$?8H
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M2S5#C'34T#"Y\[Q^2/(>74_TJMN"64Y'D?$_*_PF%12.92Q.CMKGNY*8$@M
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M*V4<K-D\@;S:Y.I^'6NI735</+//)<AXURBH[E*Z:LHHJM[8)WN^L2WN.;S
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MW^_55ZJ9J&430SS7&1\@([ .)^$#H?AUU 6UOV 6.^RVV2Y_2$K[=RFE/O\
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MO1!+547%:WUM5Q:X:U--25$U/3U$IFECB<YL8)9]8@:';S4@_"[+_P![FO\
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M_P#>YK_UG2_XD_"[+_WNJ_\ 6=+_ (D$]10+\+LO_>YK_P!9TO\ B3\+LO\
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M][FO_6=+_B03U% OPNR_][FO_6=+_B3\+LO_ 'N:_P#6=+_B03U% OPNR_\
M>ZK_ -9TO^)/PNR_][FO_6=+_B03U% OPNR_][FO_6=+_B3\+LO_ 'N:_P#6
M=+_B03U% OPNR_\ >YK_ -9TO^)/PNR_][FO_6=+_B03U% OPNR_][JO_6=+
M_B3\+LO_ 'N:_P#6=+_B03U% OPNR_\ >YK_ -9TO^)/PNR_][FO_6=+_B03
MU% OPNR_][JO_6=+_B3\+LO_ 'N:_P#6=+_B03U% OPNR_\ >ZK_ -9TO^)/
MPNR_][FO_6=+_B03U% OPNR_][FO_6=+_B09=E_[W5?^LZ7_ !()ZB@7X79?
M^]S7_K.E_P 2?A=E_P"]S7_K.E_Q()ZB@7X79?\ O<U_ZSI?\2?A=E_[W-?^
MLZ7_ !()ZB@7X79?^]S7_K.E_P 2?A=E_P"]U7_K.E_Q()ZB@7X79?\ O<U_
MZSI?\2?A=E_[W-?^LZ7_ !()ZB@7X79?^]S7_K.E_P 2?A=E_P"]U7_K.E_Q
M()ZB@7X79?\ O<U_ZSI?\2?A=E_[W5?^LZ7_ !()ZB@7X79?^]S7_K.E_P 2
M?A=E_P"]S7_K.E_Q()ZB@7X79?\ O<U_ZSI?\2?A=E_[W5?^LZ7_ !()ZB@7
MX79?^]S7_K.E_P 2?A=E_P"]U7_K.E_Q()ZB@7X79?\ O<U_ZSI?\2?A=E_[
MW-?^LZ7_ !()ZB@7X79?^]S7_K.E_P 2?A=E_P"]U7_K.E_Q()ZB@7X79?\
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MO-*U[W<K'.#=Z.B':\NW=:*R5=7AG!6KDI;744S;?0?]E\5I$\\[M\TCH^[
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MY!(X]7$%T;!T&W$^0.MEP^M%9CEMRC-<IA<R\W3GK9J9OQ.IX(VDLA^;@/\
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MZ>!D3IK'?K^]I#+Y=ZFNAV.IAYN5IU_ND_>@W?#7*KEE=MKJF[X_56.6"I=
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MR<HYB/3?==J("ZVT\+)GRLBC;*\:<\- <[[3YKL1!U14T$4?AQ0QL9O?*UH
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MZNFLJZ:AIW5%;40T\#/K22O#&C[2>B"$?@QG/[X0_4L/]Z?@QG/[X0_4L/\
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MX,WV*-L<7$S(V1L :UK7.  '8 >(I;^Q'@G[FZ3^>_\ Q)^Q'@G[FZ3^>_\
MQ(K8X9B<UCQNJM%YO%7D+:F1Y?+7;<XL<T-,?4GX>A_G%05O!NZ6V*IMV,YU
M=+78*ASBZA\(2%@=W#'\P(_1]NU*?V(\$_<W2?SW_P")/V(\%_<Y2?SW_P")
M$9=JP.ALF 5.+6&>6BCGA?&ZKUS2E[QITA[;=^C73795Y:. U?9J9U/:.(%[
MH8'.YS'3,,;2[UT'CKT'Z%./V(\$_<W2?SW_ .)/V(L$_<W2?SW_ .)%8V"<
M/;KC-\]_K\UO%ZA\)T?NM6YQ9LZ^+J\]1KT\UTY7PN%?DLF1XM?*O'+W,WEJ
M):=@DCG'JYA(Z]!\NF];ZK/_ &(\$_<W2?SW_P")/V(L$_<W2?SW_P")$8^#
M<,X[#D$V17R\55_R&1GABKJ6AHB;YAC=G73IW[=M;.["4%_8CP3]S=)_/?\
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M_P#Q()TB@O[$>"?N;I/Y[_\ $G[$>"?N;I/Y[_\ $@G2*"_L1X+^YRD_GO\
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M%5LD','.8.4\P/YPT?\ >48]G''+-7\)*5]=:J&I?52SMF=- UY>!(0 21V
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M\ 8]A<XN.W ]1LGR00WV<Y1?K!?,CN8;/>+C<965$CQMS6-#>6(>C0"=#YK
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MI!M41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MNVDI:>"D@9!2PQP0,&FQQM#6M^P#H%VH@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M]9):&WZ0W"OJ&2B%\<3G#PXBX@Z C#&$>9+O5!,J/+L>K;O]%4=[MT]QZ_\
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MVQNWS-.QL[YCUWZ>BFZ(*^RSAG'=<H;DMAO5;8+Z6".6HIFA[)FC0'.P]#T
M'IT'3HI/C-DGM,4SZ^[5EVKY^7Q:FHY6C3=Z#6- :P=3V&SOJ2MTB#5979(<
MCQVX6>JEDB@K8C$]\>N8 ]];Z;45M>!W2@QQN.C+*IUE9'X#0VE8VI;%VY!+
MO6M=-\NP.Q4_1!&[AA%AK<,_!:2A:RS-C$;(F'1CT=AP/?FWUWYG>][*TLN
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MH7N[N&@-_85-$00G \ AQ.W7*W?24]RMU>^26:"JB9U>\ /.P!T(&M=ECV;
M:['K?/:L<R:IHK+(YSHZ>2G;-)3<QV1%(2-#9.N8.TI\B"/67#[/9L1?C=%
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MU5(;5,VI@9##&1XS3]<[!WV'3LIHB"#YSP[I<JFM=P^D:JW9!;@!!<Z4 /\
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M"W8[&1S?BDU_K.UOKI35$%<U/#)U'E=9?\1R"KL%17GFK((X63PS.WLNY'=
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M7"FK2T^YRSF2&%PWLL!ZC>^O4JLJJV7BI]I"NBI,@DHZAUE\5DS*2-_)%XH
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MH"*N<B&7UUER.XR7&3&VT'BNM\4 AF\9D;21),7!W1Q'U6\NAWVN-!D]YNO
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M%H!.F-Z;[$DGJ?60SY;7WW);S043[U!:K1**-\UJHV2R5%0!N3;GAP8UNP-
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MYP9LM [:T>K>OJ%I+A41^-!)%SO9SM+>9ATYNQK8/D5"+3+?+EQ$O#8+W/\
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MTMIXFN&B& $?<NQ$!$1 5/8Y]+8GQ6S1]5CUVK:.]2PSTE31Q!\9Y6G;7.)
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M'A%W8A@^ML!WF-:'0[Z8V2<3W8_%37&XXQ=XL=F>UGTDXQCE#NSC%S<[1_"
M/RWT6H]I65HPFR3,!D;]-4KP&=2X:>>B"W45=9#Q+GQB:";)\6NENL\T@C%>
M)8IA&3V\1L;B6_I/RVI3?<FHK51T,K!)6SW!XCH:>ETY]2XCF^'9 UR]2XD
M#S0;Q%$*+-.3*Z3';[;9+9<:V)TU&?&;-',&]7-YAU#@.NB-?-1^;BUS7;([
M=;\5O==669S&.AAC!?)LNVX@;#6]!KJ2[F[="@L]%CVVH=66^EJ9*>6F?-$V
M1T,HT^,D \KOF.Q4?N^7LAN]59['037F\4L0FGIX9&1MA:[ZO.]Y !/D!L^9
MT$$H11;",TI<MQ>:\45'51O@?)#-1N ,K96=V#KHGJ-=1W\E&L=XJ5.36&JN
M6/8A=J[P)WQ.C$D<>@T ]2XC;NOU6AVO5!9RZJMTS*69U)&R6H:PF.-[^1KG
M:Z NT= G771^Q1_ LQM^9XTV\T+):>-KW1313Z#H7M^L'>7F#OT*P*?-JF[T
M4]=BM@JKO;HW.:RI,[(&U!:='P@[JX;!&R ">Q*#KX/Y?79KC-3=+E304LS*
MV6G;#"20UK0WN2>IV3UZ?8IPJC]F"0R\.ZN0L+"^Z5#N5W<;Y>A5H7JN=;+5
M55K:6>K,#"_P(.7G?KTYB!^DH,P]NG=0+ACF-TRFYY32W>AI:)]HK!2-C@>9
M.HYN8EYUS=1TZ!8O"W/[KF%LHJNIQNLBIJJ6;5;')%X#&->\-&B_G)  :3R]
M3U[*)<-KS6V[,>)<5JL=;=ZIUY>_DA?'$QHV_P"L][@ 3Y ;/R07HBB?#W-Z
M7,J>X".CJ;?<+=/[O64=1KGB?U\QT(Z']!77-F<U3'7U&/V6HNM!0N>R6J$[
M(F2.9]=L7,=OT01OH-C0)03!%J,2R&@RK'Z.\VE[GT=4TN;SC3FD$@M(]000
MHUQ=S>KPJS4LU!:Y:RHJZAE/')MOAL<X]CMP)) .O+U(\PGB*,PY9[O8Z^ZY
M%:JVQ4U)HGWIT;W2;Z#E$;G;.] #N20M;<L]DLIMU1D5BJK9;*Z=M-'4R31O
M=$]V^7Q6-.V@Z/8NUYZ03A%"J;/6NSZ/$ZVS5U%6R1NFBFF?%X4L;=_$PAQ+
MNW;6QUWK2R<;S":^Q7"HIK!<6T=*Z6-D_/"14O8[E(B^/X@2#IQTWIW02Q%6
M/#CB/=<L\>5V+5PHS<'TS*F.2+D@8-#\9M_,7#9)Y01UZ;5G("*(?AHZX7:X
MV_&+5+=Y+<[PZN83,AA9)_ZL.=]9X\P!H>97=B6;4.34ER]TIJJ&Y6UYBJ[=
M*UHGB>-_#WY3O1T=Z/R08E=D%WO%[N]HQ!UOBEM36-J:NN8^1AF>"X1-:T@]
M!HN=OIL#1ZZW6'3WVHL4+\KHZ6DNP<YLC*63GC(!Z.'4ZV.NM_W*H^">0W/Z
M7S$C'+E4>^9!*Z:5DD(;2[('*_;P3RCOR@_+:O8G0)T3KR" H%'F-T/&$XC/
M0TL5 *!U:R=LA?)*-AH] WKS=.O;NM3C_$V[7?*,AH:?$;E/36V:.G#8Y(1)
M$[XN8R<T@'770-WT'S6JR&X/MWM(4LL%#55\S\?Y(X*8-YG.,KCU+B&M'3N2
M @NA%!\8S_Z3RVHQF\V6LLMYC@]YCBGD9(R:/>MM>TZ/_P A]"MK<LG++U+9
M[+;Y;I<H(VRU#6R-CCIVNWR\[SV<[1TT G77H.J"1HHWAF74N3&YT[():2XV
MR?W:LI)2'&)_71#FDAS3HZ/R*V&37^W8S9Y[G>*@04D6@3HN<YQ.@UH'4DGR
M0;1%!XL^D@S&V6"]V"MM;[HU[J*>26.1LA8-EK@PGE.OF>X7S+N(D&.9C9\>
M?:+C53W%KG,EA:"TZ!^%HW\3M@ [T #LG2"<HJX/%$4&2QV3(\;NUKK:IA?0
MM')4>]'>N4>&2 [[3H>9"RJ+B(]F946.Y!CU?9:BX-<ZBEFECE9-RC9!+'$-
M/RV>X]0@GJ+07W)&6^Z4]IH:2:XWB>,S-IHG-:&1 Z,DCG=&MWT\R3V!ZK"L
M&:17&[W>S5=OJ*.]VR,32T8>V7Q8R-M=&X'3M]!HZ()""6(JRQSBG49-9JVO
MQ[$;M6NIJA\)B\2./0: >KG$?%U^JWF(\^X4GX?YE0YICOTM0QS4P9(Z&>&<
M .AD;K;3]Q!W\T$BJ72MII74T;))PPF-CW\C7.UT!.CH;\]'[%"N$&85^:X_
M7W"Z4M/230U\M*V&$EP:U@;W)[G9/7I]B[:?-JB\4M168I8:F[T$+G,;5&=D
M#*AS3IWA<W5P!&MD $]B5$O9IJ''A_>:DP2\QNU3)X('Q[Y6'EUZ^2"X458X
M[Q5J<FM%=6X]B%VK32U#X71^)''H- /5SB/B.S\#>8CS[A9-CXH-R6Q&NQ;'
M+M<ZF(EM33_! *=X[L+WN <[STWF.B-Z06*BC'#_ #.AS2P27.CBFI3!,ZGJ
M8*@ /AD;HEI^X@[6MJL_?]"U=]MMBJZW'Z5KY'5@F9&98V;YI(F..W-&CU/+
MO73:"<HH!F/%"VX]C=DO<%'5W"AN\C&02PMTUO,-_%Y@ZWIH!)+2.BZKWQ+?
M8;G;F7W&;I;[373MIXKA*^(@/=VYV-<2T>?7KK?3H@L1% N+><5F&4%N-OM4
MU9/75<5,R3;?#:YSNK>K@2XM#M>7J?(R?'+I676GEDK[+6VE['<K8ZI\;B\:
M[CD<X:^U!MD1$$=SK(IL6L4]V9;'U]+3,,E0(YFL<QHUU /?S_0OF!Y)-E=B
M@N[K9)04E2P24XDF:]SVDGJ0/J]A^E8G%X;X7Y5O_P"=TW]DKAP;_:MQ;^(1
M?U(.>?9A48C%33_0D]PI:B:.F:^"=C7"5Y(:TM=Y$ZZ_-2>@EGFI(Y*RG%-.
MX?%$) _E_P!X=U$N+#0['[;S#>KS;O\ ZJC"X9OQ"@Q3(['9YK57U4MU<6QR
MPM!;TZ%H'=SM\O30'Q [03=0+,,QNEEXA8I8(*&E=07A[PZI?(2\<@VYH:-
M=V]=GN>G1<8^(SZ;,+=8<@QVX6=US+FT51-+%(R5P_)/(XAI[=-GN%I>*7[;
MW"W^,5?]AB"V46@O>2LH;K!:*"CEN-XFB,XIHG-8(X@=>)(]W1K=]!W)/8'1
M6KMW$&@=-D%+>:>6UW"QP^\UD#W"0>%R\P>QS?K#7EH'9 T@F:*'67,JRXS6
M62;'JNFMEW&Z:K\9DG*"PO;XK&_4YFCIU/70.EBS\0))8[S562PU=TMUHJ'T
MU5/%*QKB]@!D$;#U?R[^6_+:"=HOD;P]C7M^JX A:#(,HI[5<J6UT]-/<;S5
M,,D5%3<O,(QT,CW.(:Q@/39/4] "4$@11>S9/73W>LH+Y8*JT"GIS4BK?*R6
MG>P'1_&#H".^CY E:VGSZHN5IGO&/XY77*RQ%W+4-E9&^=K20YT4;CMPZ'6^
M4G70()TBC-!FMKN>$RY1:145U!'"Z5T4+!XPY?K,Y21\0]-_IZ*+6_BI5W3#
MH\BM.'W6LI )'S%LL;0QK7.!Y>8ASSH;/*T@=M]"@L]%%:+-:.XX ,KM5)5U
ME*Z!TPIV!HE^$D.!VX#H0=]?+IM:7ACGMTRBRT-=<\?J:2FJ&RRNN DB%.UK
M7.UTY^?L -EO?KV06(M)F&56C$+2+E?ZDTU(96PAP8YY+CO0T 3V!/W*)7KB
MK3T%C;D-+9*^NQ@2^$^Y1OC:-<_)SMC)YBWFZ;('Z.JV'%?*+7CN%_2ETLQO
M="][.2'PV.9S'JQSN;ZHWKKHG9'1!-HI&31,DC<',>T.:X>8/8KDH?Q&S>+!
M\3%ZJ+;4UC"6L$<! :QSATYG'LW?38!\NBT^1\4),?IJ6Y7'%KO%C\SF-=<'
M&,<G-V<8N;G _A!I^6^B"R$6HR#(:*QVR*LJ#)-[Q(R&FA@;S25$C_JL8/,G
M] &R2 %I!FSZ+(K7:,BM,MKENO,VBE\=DS'O;HECN7ZKNHUW!]4$R4"Q/,KI
M=N).38Y<*&EI8+3'&Z-T4AD=)S]0XDZ ^$CIKH?,K:5.7MFO=9:,?M\UVKJ(
M#WMS)&Q0TY/9CI'=W'T:#KSTJ_X5UM5<.-^?5%?;Y+=4FGIFOII'AY:6M WS
M#H0=;!'D0@NE:&QY=9KY>[M:;95^-76IXCJH^1PY#LCH2-'J".BWR@^%9-;K
MQFN5VV@L1MU5;W1"KJ9(V,?4O=S:)Y>XTW8)/4'L$$X15U1<377')[]8K9C-
MVJ:ZU%K2S<;/$))V2YS@UC>C2"7;=OH.A6TP'.X<KK+M;I[;56J\6M[655'4
MD.+0[>G!PZ$=/ZO4()BB$Z!.B=>0566#B9=[ME.14%/B-RGIK;+% &QOA$D;
MCS<QDYI .NAH-WH ]>J#;MS&Z?LP?@E-0TL5O^CS7,J!(7R2C8:.G0-Z\PUU
M[#JIXJ:R2X/MOM&T4L-#55\S\>,<<%,&\SG&9QZEQ#6CIW) 4MQGB!])9=48
MQ>;+666\L@]YCBGD9(R:/>MM>TZ/_P A]$$X11RY9.67J6SV:@ENER@C;+4-
M9(V..G:[?+XCSV+M'30"=#?0=5\PS+J7)G7.G;3RT=RMD_N]922EKC&[R(<T
MD.:='1^1021%I,TOQQG&:^[BAGKA21.E=%"6@Z )))<1H#776SZ K0<-LRNF
M2V:W55UL%511STHG=7%\0IW'6_A >7@'RV/+J@G2*"U>?O%EJK[;[%5UF/TS
M72.K!,R-TL;=\TD4;CMS1H]3R[\MKHOO%"BM4=DJFVNMJ;3>#&VDN#'QMA+G
M@$!_,X%A^T>1]"@L%%&&Y5)+F-38*2S5E3[JV-]16LDC$,0>-@.V[?-Y\H&]
M:/8J*LXE76;B%>;#1XI<:J&W01ES(WPB7F=UYSS2!O(6D: )/KKL@M%%P@>Z
M2&-[XW1N<T$L=K;3Z'2CE]R^"@O]/8;?237.^3Q&?W6%S6B*('7B2/=T:W?0
M=R?1!)E&,ER*>FOENQZS,@?>:Z-\X=/LQT\+.AD> 07;)#0T$;/F-+'L><05
M>42XU=Z&>TWUL7CQ02O:]E1'^=&]O1VM'8(!Z'T.J[FO]QA]HFYS0X]<JU\%
ME%-'!&^%KS'XH/BCF>!RDD^>^O8(+,P^7+??+G3Y=!;##$YAHZNA+FB=IWL.
M8XDM(Z>?GY]U)UTT4KYZ."::!]/))&U[H9""Z,D;+202-CMT)"KO)>(ERMO$
M>BQJ@QRMK6NIGU,G(Z(/F;V:8^9X :"#OFT?0>9#.XD9C=,8O>+4=#0TLU+=
MZ^.CDJ)9#S1ES@" P:_)WH[[CLIXJ9XV7%Y9PYN%70U5,\7V"5]*0))6Z_)T
MPD$_($J2U?$B2U9%:[=D6-7*TTMTF%/25DLL4C3(>@:\,<>0G8\S_04%@HM)
MD>106::BI&P35MSKG.;2T<&N>3E&W.)) :UH[N)].Y("UUHS)L^5NQJ\6^2V
MW@T_O<+#*V6.:+9!+7#S!!V"!]Z"6(NNIGBI:>6HJ)&101,+Y)'G36M V23Y
M  *NKSQ6I[;::2_"QU\V+SRB+Z3#V#0+BT/$6^?EV#U(!^74;"R44/XG9S!@
M=@CN=1;ZFN9+*(6^#H-:X]N=W<#H>P*U&0\4/P<DI*J]XS=J*P5,@B;<I#&>
M4GL71-<7M'3?71^6^B"QT5<Y'Q/=CPI:ZZ8Q=H,?GD;'])/,8Y>;LYT0<7M'
M\( _+?12_(\@H[#0PSU(EFDJ)6P4U/  Z2HD=V8P; \B=D@  DE!MT4.CS9U
M)DMLLF0VJ6UU-T:\T4GCLF9(Y@!<QQ;]5VB/4'R*US.)?CYI><9H<<NM37VZ
M,.+6\C?$)UUVYP:UFBTASG G?0(+"10O!\\CR2\W6RUMJJ[/>K;RNFI*AS7[
M8[LYKF]".H_2.ZS*K+VRWRKLU@M\UVN%&&FK+)&QPTY=V:^1WY1_-:"?72#5
MXQF-TNG$[),:KZ&EIJ:UPLDC?'(7OEYR"UQ)T!MI'370^94\5,<,ZZJN''3.
M9[A;I+;4^YTS'T\CP\MTUHV'#H00-@^A4D_9,\;-;OC-!CEUJKA;XP[3>1GB
M$D==N<&M9H@ASG G?0(+#15S9.*+;E<;A97XW=H<FHS\=L'(XENA\?BDA@;U
M'4D=QK:V6%9ZS(;]=+%7VJKL][M[6R2TM0YK^:,ZTYKFG1'4?I'=!-$48JLI
MEFNM9;L?M<MUJ*(AM5()FPPQ/(V(^=W=^M'0!UL;(6LBXEVV7!KIDD-%72"U
MR/AK*-H:989&$!P/71 V#L$].OR03I%6,W%.J;B%+DL&'W:>U.@;/43-DC:(
M@1\7*UQ#W@?G<H'GO752&_9M3T/#YV66VCJ+C2.IA4QLCY6D-+=[?S$: \];
M/R*"6HH5PVRRZY+:;;/<\?K*,3T;*@UI=%X$KB ?@:'EX!V2-CL.JFJ BP;[
M=:6R6>MNEP>64E)$Z:5P&SR@;Z#S*CUFRZMKJRT"JQZKI*&ZL+Z:J\9D@;\!
M>T2-;]0EH.NI&^FT$O159;>)EWK\TR&U4N(W*II[8(6%D;X1*U[N8ES^:0-T
M1RZ )['??0E%TS%K+I66FQ6V>\W>CB;-4T\,K(VP!W5H<]Y YCY ;^>D$K11
M#%\ZILDPJ7(;=;ZUYA+V240#?&;(PZ<WJ0WY[V.GSZ+3<+.(%VS"VTE74XW5
MQ4M5--RUL;XO 8QKW!H(+^<D:#2>7J>O9!9"*(2YC/5>_P F/66>ZT="]\<U
M2)V0L>]GUVQ<W5Y'8GHW?3:V^(9'097CU)>;2][J2I:2T/&G-()!:X>1!!"#
M<*/<0;W6XYA]SO%MI(:R>BB,QBED+&\H^L=@'>AUUTWZK2<7\WJL(L$-50VR
M6KGJ9F4\<FV^%&XG\KX@22 =:&O4A8V<7:MNO"S,75]CKK08[?*&MJGQ.,FV
M.ZCD<[M\]=T$IP6[3W[#K+=JQL;*BMI(YY&Q@AH<YH) V2=?>MXJ9Q3.ZW'>
M%%@K6XI=:RTT=OA%15M?$S0#0"YK"[G<T>N@//MU5E?A5:!B+,F?4\EH?3MJ
M!*YIWRNUH:[\Q) UWWT0;Q%!KEGTEE;;ZK(;%5VVU5L[:=E3)-&Y\3G;Y?%C
M!VT'7D3KS4Y0$4 KN(Y@X@U.*4N/W.KJX*0U(=&6-\4[;KEYG !FB=N<1U&M
M%,>XDQ5F7_@Q?[-6V&\R,,E/'4O9(R=HV?A>TZ)T#\NAZ[Z()^BKV^<38[9F
M]3C,./W6MK8:,U3? 8"9NV@P;[=]N)&BW6B=+,/$&""Q66IKK3<::\7=[HJ6
MSN:/>7.!(.]D!K0 '%QUH$?8@FR*%G.Q;LBM]GRBU36B:XGEHJ@RMF@F?T^#
MG&N5W4=".N^Z^6W/!5Y]+B4]EKJ2OBA-2999(O#=%V#VZ<2[9(&@-]]]B@FJ
MT.(Y=9LMAK);#5^\LI)S3RGD<W3AZ;'4?-8M)EDE5F5?C\5FK2:%C9)JL/C,
M36O!+/RN;9UVUOS[+5\-LMM%ZMV15=OLXLE);ZV2.H#V-8Y[VM#GO>UO0'UZ
MD]$$\6ABRZS2YA-B[*O=ZB@%0^#D=H-Z'ZVM;T0=>A6EM&=U%SAM-PAQZL%C
MN<PB@K/%8YS0XZ:]\8ZM:3Y[.MC>E\I\FMLG%N?'X[$8[LR@,\ERDC8TOB!;
MIK2-N<W9\R-$=D$Y112NS%AR.HL-AH);M=*6,2U09(V.*F#OJA[S^4?)H!/V
M+[B>:TE^NUPLU12U%MOMOT:BAJ""[E.M/8YI(>T['4>H]0@E2*NZ7B8:[*[[
MC]NQJZU-=:PT<@,;/$))V27.#6MURD$NV>;H.BV6!YW%E-PNUKJ;956F\VMS
M14T=06N(#NSFN'0C^\>J"9(H'+Q"DFI[M76:PUERM5KJ'TU1412L:]SF:\0Q
MQGJ\-W\M^6U/ 00".Q0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!5IA[#;.->=4<O0W*FH[A!O\IC6N
MC<1_O%66HKF-@J:JXVR_V0,^F[67!L;SRMJH'?Y2%Q\M]"TGLX#U*" WT?@[
M[2-JNMP(CMUYMYHHIW]&-F'Y&_(GE;_.7?[0E']*U6$VZVCFOK[NR2#D^NR)
MH)D?\F@\A)^2M*YVRAOEN]VO%OAJ:>0!SH*F-KP#]G4;'J%CV7&K-997RVNV
MT]/.]O(Z5K=O+1V;S'KKY;T@AOM![J>'4EHBZU-WK:6BA;YN>96N_J858\+!
M%$R-O9K0T?<HK+8JJ\YM3W:[,$=NM',+=3\P<9)G#3IW:Z#0^%H[]R==%+$&
M@NN3TMJRJTV:OY8?I.*5U/.]^FNE86_B_M(=L=?+2KCVB;#2SP6"Y6R)L>6?
M24,5%)$-2R]22#KJ0W0._+7S5JWVQ6J_4HIKU;Z6NA:>9K9XP_E/J-]C\PL:
MT8I8[/5"IMULIXJD-Y!,07R-;Z!SMD#Y H*\S.:.F]H7 Y*E[8V/HJF-KG'0
M+BUX ^W9'Z5(<NS""W9E8K';J2CFO-S9)X5;4N#8H&-WS#8^)Q):1R CKYA2
M3(\8LN21PQWZV4M>V%Q='XS-EA/?1[C>A^A=%SPS&[G0T=%7V2WS4M'_ -WB
M,(#8O4-UV!\QYH*VX85#G\;L_P#?KE2UM4(*5AE@8(V.TT AK>9WU3IO<]5D
M\*JF"GXJ\4HIYHXI#502AKW!I+ '[=U\NH_2%8(PW&VW2EN3;';FUU,T,AF;
M T&,#MK0\O+T7RXX9CERO+;M<+)05%Q;K\?)"'..NV_77EM!4UF./0<9LSM>
M=T=O=55TT53;YZ^-I:^/DUR-<[IVT /4$>2M?%:/&*"JKX,7I;9!,WD]Z]QB
M:WJ=\H<6C6^YUW&_FLC(\6L>21QLOUJHZ\1_4,T8<YGV'N%F6>U6^RT+**T4
M5/14C.K8H(PQN_70\_F@U7$D%W#O*0 23:JH #_8O6GX)5E//PLQ@0SQO(I&
MQD!PWS-V'#[1I3E[&R,<Q[0YCAHM(V"/0J.VS!<7M?O7T?8+=![TTLFY8&_&
MT]V_8?0=$$)]G![9,<R4L<"/I^J/0^H8M#PX@J:[#.+=+:SS5LUSN#(0P]2Y
MS--U]I[*W;=BF/VQM2VVV.VTC:F,Q3""F9&)&'NUV@-C[5RL^+V&RU+JBSV6
MW4$[F\CI*:F9$XCT):!OL@JG@\WA[?L#M[:ZVV%MRHH!#715448D#V#1>[FZ
MD'6]_,^8*M^P"W"S4GT(R&.V>&#3M@9R1\GERC7;S6IK<"Q2NNOTE68];)JX
MNYG2OIVDN=ZN&M$_,J2@!H :  .@ 00/),L%)Q"H,9M='1-O591F<U]9T9'$
M"[30!\4AVTGEVT>>U%N"=0).(?$IU3<*:LJ364[3-$T,;)H2#X6[.AOIW/96
M7D&*V+(9:>6^6FCKI*<_BG3QAQ;\M^GR[+K9AV.,NXNC+';VUX9X8F; T.#=
M:]/3IOTZ(('P9>UW$#BCRN!_\ZL['_:+AG<T=-Q_X?25#VQQNIJJ,.<= N+'
M #?KL@?>K!MF(X[:JUM9;+%:Z.K;O4T%*R-_4:/4#?8G]*[<CQFRY)##%?K9
M2U[(7%T?C,V6$]]'N-Z""NO:7FC=P[I7-D86_2E.-APUL%V_T:*ZN+%T;C?%
M7 [_ ';F%AC%13/FUML$DC=<Q].A'W-/HK$JL/QNKI:6FJ[!:IZ>E:6012TK
M'-B!ZD-!&@LR:QVJ:SBTS6ZDDM@;R"E="TQ >G+K2#J&269TE%'%<J6>2L=R
M4[()!(9.F]@-WT &R>P\U6?#;Q*C,^+L5%(!4OJV-C(/9W)( ?TJP[!AN.8_
MXQLMEH:-TS2R1T<0YG-/Y)/?7R[+MM6)X]:*P5=JL=LHJH CQJ>F9&_1[]0-
MH*>X&18/=,-BME]MEF9D%N=)#6PUL3!*XAY/,>;J>F@?0@JY\8;:&66!N-QT
ML=K!>(A2L#(OK'F+0!H@NWU'0]U@7?!<6O%R%PNE@MU56;V99(&ESOX7YWW[
M4ABC9#$R.)C61L :UK1H- [ !!4_M-N:WAY3<Q 'TG3]S\W+L]IMS?V)*[9'
M6H@UU[_C K"O6.66^.B=>K307 Q AGO5.V7EWWUS Z756XKC]?1TE)762VU-
M+2 MIX9J9CV1 ZV&@C0[#L@KOVC)&Q<.;54NZPPW.DE>X=0&CFZKJ]IBZT#N
M%X:RLIWNJ:J!\(;("9&AVR6Z[C7FK0?8;2^R&SNMM&;46\ONGA-\+6]ZY=:[
M]?M6GBX=XC%;GT,>.VYM+(]KWL$0^,M.QS'N0#Y'H@AOM)SPR<*#)'*Q['5E
M/RN:X$'XO)=WM-N:>$-P((TZ>GU\_P 8%.:K#\;JJ6FIJG'[3-34P(AB?21N
M9&"=GE:1H;/HN=9BF/UM%2T=;9+;44E*"((9:9CV1 ]^5I&AV\D$']H9S#P.
MNYYFGF;2\O7O^/C[?=M:GV@9XXN&6,U#W@0MN=&\N\N4,>=_H5G5.)X_56^F
MH*JQVV:AIMF"GDIF.CBWWY6D:"YOQFQR6F.UR6>WOML;B]E*ZG88FD[&PW6@
M?B/Z2@BW'*JHW<*;TR4LF-;$V&E8WXC-*YP\,, ^L=Z/3T5;9-1QXI7\*79M
M31U%CIJ!U!5^.SQ(X)W, V[N.G3[FGT5UVG#L>M-1%/;K/1PS1;$3PS9B_@;
MWR_=I;2Z6VBNU%)1W2D@K*23Z\,\8>UWW%!&+1;<$I;M;Y[/1V%MRFYC2R4D
M<9D(Y3S%I:-@<N^O;KKS47X7/8[C!Q2#7 N\>C[?)CP?Z5/L=Q*P8WXOT%:*
M*A=*-2.AB <X>A=WU\EQM^'XW;JUE9;[!:Z6K8=MGAI6,>#Z\P&T&]5=NRUU
M;GE]QVPQ6ZVU-!%'-77&M;LOVT:Y8P6E^@1\3G #IT*L1:.YXACUTN\5TN-E
MH*JX1@!L\L(<[IVWOOKRWV05[[,U1'+A5V<:F.:62\5+W.;H<Q(9UUY;'5=G
MLQ.:[AS/RN!U<JCL?FU3J'"L:AJJZHBL5N;-7 MJ7> W\:"=D'IV)ZGU\UWV
M_%,?MU/506^R6VE@JF>'/'!3,8V5OHX =1U/=!3/#Z&JK^"W$6FM!+ZR2OKV
MQMCZEVV-Z#YD; ^U3;@7DMHK^&%GCAJZ>*6W4P@JHGO#71.9T)<#V!US;^:F
M=EQJQV.626RV>WV^21O*]U+3LB+AWT>4#:P)L"Q2>[FZ38];'UY=SF4T[=EW
MYQ&M$_/N@A'LQS1R8%7>'(UW_G6H/0[Z?"?^85HWAI=::YK023 \ #S^$K Q
M_%+#CTDLMEM-'1S2[\26.,<[]G9!=W(WY;6Z059[--73OX0V:%L\9ECEGC<S
MF&P[Q7NUKUY2#]BZ.";VNS'B<&N!/TVX]#\WJ<6_!\8M]=45M%8;=#53APDD
M9 T$APTX#TV"=Z[[61:\3QZTU+JBU6.V44[FECI*>F9&YS3W!('5!7'#3GFS
M[B[%1R-;4.J81&0>SN24 _I6CX%PX3<L09:<@MEG9D5NDDAK(JZ)@E<0]Q#O
MBZGH='T(^Q7%:\2QVU5K:RUV*V4=6-ZF@I61OZ]#\0&UCWC!L7O5Q%?=;!;J
MJLZ$RR0 N=K\[\[[]H,[%V6=EFB;C4=+':PYXB%*P,B)#B'%NAHCFWU'0JN_
M:4D;#AEGFE/+%%>J5[W>36CGV2K7ABCAB9%"QL<; &M8P:#0.P \@L6\6NAO
M-OEH;M20UE'+KGAF8'-.NHZ%!6GM%R.EX?TU72QMK:2BN--5UD+"'"2 %W0C
M\TDM6QM]/PPK[737:EHL;DIWEAC=X$9>'DC3>77-S[T.76]J8V7';/9+>^AM
M-LI*2DD^O%'& ']-?%^=TZ=5@VC!<6L]R-PM=@MM+6;V)8X&@M_@_F_=I!"^
M--J_"^>BL./EOX448=7LJFR%AHXP"-.<.H,CN5H'R+OR>LCX2Y/1Y'B5.RGI
MF4%;;P*.LM[1RFFD9\);KR;TZ?H[@K>4F+V&CK9ZRDLUO@JZAKFS31T[&OD#
MOK!S@-G?S7&U8IC]HK/>[59+;156B/&IZ9D;R#WV0-E!7OLW5< Q&\0.FC;-
M%>JAKV.< 07%NNGS\E;;@2T@'1UT*T-/AF-TU\?>8+)0,NCW%YJ6PCFYCW=\
MG=^O=;]!3?LT2&ALV0V"X_B[W0W25]3$_P"NX.#0'_,$M/7[/5=G#^!U=QYS
MR\V_K:60Q4;Y&_4DJ V/F /F6\KM^F_FK&O&*6*\5C:NY6NEGJVMY!.6:DY?
MS>8:)'RWI9M+:+=26LVVEH::&WEAC--'$&QEI[CE'3J@K'V?W-=49_RN!_\
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MAC33R_"T%XVX:.QV^:*P,WJ,MPS*\9=;\GFN,%[K!02P7&",QQ/=H![1&&Z
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M.@M]1<[#?8VBJ92 .FIIF]G<A(+FGKVV?B/H-AV4N0W;$^*E!BEWKY;I:+Q
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M.EKOT-AN,MHI+>ZADJ&^'U>7//, 7[+?B'7OWZ(J0W.@R6]55Z;57.7'K9
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MX'+5.YGT;_4'RT.O30(#NFP"KIO>466QUM+27>XPTD]4R22)LNP'-8-O.^P
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MI!/AL+M#ST-JC_9KL]'?+3=\PO,$5;>KA7R S3-#S&T '3=]NKCV\@!Y*]"
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M+;:,ILN/S^,^Y74N\%K&_"UK027./W:T-E!(U":#$*JS\2ZV_P!GEIV6J[0
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ML5FHK7;F%E)21-AC:3LZ \SYGS6<B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M8XV"6IE;&TN+>@V2!OH?T+;,<U[&O8X.:X;!!V"/5$?41$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MD%J%3-$;7X#>4OY6?C.?>]_+7DO0*"H\/XD93E&4UM%;\7I7VBAN)HJJL%8
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ML>.MU@OF.\.;I2;]WK;I3SL![@.;O1^8VI+G^17:V\7,$M-#6OAMU>9?>80
M1+KMLD;_ $(J4W#,Z*DS^V8EX,S[A6T[ZKQ!H,CC =KKW))81I2A>;<JQZ_3
M>T904D&5SP5M512U%-6"E832PETQ$(;O3@ ".8]>J]'4K'Q4T4<LIED8P-=(
M1KG('4Z\MHBNN+O$.XX57X_16BT17.JN\CXHXWRF,\X+ T#RZE_FM/\ AQQ1
M_>VC_P#;V?WK2>TM<([3EW#JXSQRR14E9).]D0V]P:^$D-'F>BW'_E!X]_\
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MM:_KKE<.@Z=]^04S4 X\6AEXX67UI'XVEB]\B<.[71GFV/N#A]ZW'#&^/R/
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MX]CMRN]4QSX:*!\[F-[NY1O0^WLJINV(\2;%9IKU0YY-<KI3QF>6AFIF^!*
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M6XU:*[(:&^U5&V2ZT+',IZ@O<#&T@@C0.C]8]QYH*OXU_MI<*OY0?_;B4?\
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M1S1U3VM&R6-)#C]P=O[ K"QFVFSXY:K8YXD=14D5,7CLXL8&[_H6Q<T.:6N
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MB93SW.7QZMP<YWBOV3L@D@?6/;7=1.JX+8%4W%U;)8(Q(YW,YC)I&1D_P X
M?8!I%5EP.98*?CWD]/B6OH:*VF.!WB.?SEKX ]P<2207<QW^CHI5P'_S\XJ?
MRN/[<RL>WX9CUMO45VMUJ@I:^*#W5DD&V 1?F\@/+K[EDV3&K18ZZYUEJHVT
M]3<I?'JWA[G>*_9.SLD#JYW;7=!1'%^RVH<=;149>^:"P72C$+:J.4Q".5NQ
MHN'8;Y=_PMK*X@X/PRP_'_I"Y3W.K$A:V*EAN)=)/L_D@GJ .N^WZ0KQR*P6
MK([<Z@OE#!6TCCODE;O1]0>X/S'512P<(,'L5QCKZ"QQFIC=S1NGE?,&$=B
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M[(#>W;>]:]4%HHJZJ.,V'1V*CN<-=-5>].<V*DIX2^H+F_6!9Y:]20/3:V^
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M$C?<_>.Z[N%6#W>T<)[MBM]BBIJJH-3%'(R02-+)&:#NGS)Z?)!A<+O]&?\
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M+<G];EM^&6#7FDRFYYEFU13RY!7Q^"RGI^L=-%T^$'UTT#IY ]3LJ/P8UGF
M9ED%;AULH;Y9KU4&I,,LXB?"\DGS([<Q'3>QKLBN[)?]*?%/Y)D_JJ%SIO\
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M=<G1.>!U<WQ(>A/I\3OTE1C)KG=7^TE<IJ/'7Y'-:**-M+2>.V+P061N,OQ
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M7%W95],0QQ>_W-]5!R2!_-&>Q.NWV+1<%\9S7!;E/C];04$V,/J)9Q7LF'B
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M=UN?%W#K_1PQNMMMCE;4O,@!:7!VM-[GN$X\XG=<PQ:W4-CACEJ(;C'4/#Y
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MMWNICV_;CU/D&^0[J4("(B B(@(B("(B B+69->8,>Q^X7>K9))!10NG>R,
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M(B@7$W-:W$[QB-)14U/,R\7!M',Z7FVQI<P;;HCK\1[[03U$1 1$0$1$!$1
M1$0$4"HLUK9^,E?A[J:G%#3V\5;9AS>(7'DZ'KK7Q'R4]0$1$!$1 1%%\<NF
M15>5W^CN]ICI;/2N:*"J;O=0#O>^I[=/(()0BIB3/LYR/-K[:<$M=H-OLLXI
MZB:O+N9[]D'6G#S:[0UY=3U4^P^Z9%<+OD,&0VF.AHZ2J,=OF9O=3%S.'.?B
M/D&GR[H)2B(@(B@60YK6VSBQC>*PTU.^CN=/)++,[F\1A:'D!O77Y [A!/41
M$!$1 1$0$1$!$42XK9/4X=@EROE###/44OA\L<V^0\TC6'>B#V<@EJ+7XY7/
MNF/6NX3-:R6KI8IW-;V!<P.('RZKMN\U33VFMFM\(GK(X'O@B/:1X:2UOWG0
M09:+18-7WFYXQ1U>36]ENNTG/XU,SLS3R&^9[M /?S6]0$1$!$1!6W$;AO<<
MTN[?$RNNHK!(QC:FV1,V)2TD[#N;0WT[@]MJP;=14]NH*:BHHFQ4M/&V**-O
M9K6C0'Z H569K6P<9*'#VTU.:&HMYJW3'F\0.'/T'76OA'DIZ@U\MFM\M[AO
M$M*Q]RAA,$4[MDL83L@#L-^O?R6P1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%5&/7JZ6SCS?L
M=NE?43VZX4;:ZW1S/)$>OK-9Z#_*?S0K75-<>W'&K]AV<Q1N<+95FEJN3NZ&
M0'_D'C[7(([=N(5YAX^Q,CK:@8M!7QV>2+G_ !1E<P@DCU#R3O\ U0IIF]YN
M==QBQ'&+/75%-3Q1ON%Q$+]<\8/PL=KR)9K7^N%6QQJHK?9OKK](#]+3W!U_
MY_R@1)RD_P SF=]ZF' 2HER_*LKSRJB+/>C%04P/Y+&-:7@?H9]^T5E877WC
M(.('$^R37JMA@A+(J1S'[-+S<XYHP>QZ#]"BWL^8Y6NR[*JD9#<6QVZ[/CG@
M!')6G;QS2?/S4DX1?MS\4/\ ;P_UO6#P%NUOHLQX@6VLK:>"OJ+U)X-/+(&O
ME^.3?*#];[D$9X=6/(<CSOB#06F_3V.U-NLDE7/2M_'R.\20,8UWY(US$D?+
MNI5B]5D6#<8[?B%SR"KOMGNU*^:"2M<72Q.:'GZQ)/\ Z,COH\PZ+*]G_P#S
MJXF_RT[^W*N&<?Z3.!?Q&;^S.@^7J[Y'Q!XEW3%<=O,UBL=E:!6UE,/QTLA_
M):[NWKL="/JDG?0+!R67)>#MQM5TER.X9!BU54-IJN&XN\26$G9YFO/7L''R
M'31'7:^X9<Z7!...:V[(9F44-^>RLHZF=W+&_P")[N7F/0?Y1P^UNO1/:+OU
M%DMNM&&X[4P7&\5]=&XQT[Q((F .ZN([=2#]@)02'+K[<J?CSA-KI:^=ELJZ
M29\U.Q_XN4ALI!(\^P_0LWVAKO<+'PSK*VSUD]'5MGA:V:%W*X OT1M13B?5
M4^-\;^'ESN<@@MD5-)3&H?T:TZ>WJ?+7.TG[5U>TYF-DJ<"^B+=<:6NK:F>.
M0LII1)X<;3LN<6D@#?*!OOM!@^TO;JNHP?'KN^[5?A.DIH'46_Q3I"R1WC'_
M %_+[%=N'V:JL5G%'77BLO$W.7^\U9!?H_D_8-?TJI?:/Z<',?<=\K*RE<X^
M@\&17/9;M;[S0BKM%=35M-OE\6GD#V[UVV//J.B"N_:*M%37\/:^L@NU71PT
M,#W2TT)^"J#BS0?\AKI]I41M=%=\8]GZKOE-DMSEEGM5/)31.=IM'\3>D9';
MH=?<K'XY?M39-_%?_B"B5SII:KV6(XH&%[_H2%^@.NFAKC_0"@L3AQ5U%?@.
M.5=9,^>IGM\$DLKSMSW%@))/J2J[X/9!=KI9^($EQN-34R45;/'3ND>28FAK
MM!OH!I;7AGGV,4G"FR5%9>Z&#W&ACAGC?,T2->QO*6\F^8DZZ:'7R4.]GJI]
M]Q+B'5!CHQ/5S2\CAHMYHW'1_2@UG"^TYYQ'QBGND^<W"UP4<KH8/"YG/J7!
MW,YTA#AO7,&C>_J]O7A#B%RE]H.NM;,LN\=2+=[Q[^TCQBW;?Q?\'J/T*P?9
M?_:CH/XQ/_;*T57=:"R^T_65%XK:>AIY+,UC):B01L+OAZ;/3\D_H0:G-*2^
M5WM(FAQJO;;JNHM;(Y:PLYS#%K;G-'YW0 ?;Y=UD9?39/PHNU@NT.7W6]VNL
MK64M72W%YD^MUVW9.M@.[:T0.ZW<)!]JB8CJ/H0?UA/:C_S7QS^6H?[$B#8<
M7\LO,>26+"\3JHZ&ZW8&6:M> ?=X1OJ-^9Y7_P WIU.Q'\KQ_)\"L<V26'/;
MG=YJ("6JHKE+XL4[-_%R@D\O3KKOKL5KN/=FM</%C%[SEU,^?%ZJ#W*I>'/:
M(W@O()+2"!\;3\PUWHN6;8QP9QC'7W1M%37&1P'N]-2W65SYR3Y:>=#S)0;?
MC)GM>WA7B^38W434DE;6P/<R-Y!<#'(71.([CF;H_8I+P]PO*[5?&WK)<RK+
MD:B%QGMVB(8Y7:UR[<1IO4=&M\E N-%)347!G"X:&VRVNF^DH'LHII#(^$.9
M*[E<X]=]?/[%Z'0<)G.9#(]D9D>UI(8" 7'TZ]%3%IP[.,MAJ[IFN57?''NE
M<(+=;9Q$V%@[%SFG3OZ^F]]>EK956U-MQB[UU!%XU734DLT,>M\SVL) UY]0
M%Y]X:8WBN<XS^$?$#)I[A<GR2&IIZFX>#'3@.( Y=@@$:/0@==#LB)9P=OUY
MI>(N187=;\<@HZ* 5--7/<'O[LVTNV2?K]=DZ+5B6ZIR/BSEE^;0Y%6V#%;3
M4&DC^CW<DU2\;V2\=?+?IH@:[E:/@A+83QYR-N)PMALHMQCI0TN(<&NA#G N
M.R"X..UN.!-UHL.ON78AD%5#05S+BZI@-0\,$['  %I/0]&M.O,.^116]QVR
MYS8LIK<=JKM<;OC-=1O\"\2N!GH92' ;<3MQV/GW:>G50[@;C5<[B1FCQD=R
M:+7<VMJ&@C5>>:4;E_FD_>59<'$>.Y\3Z;%L=@I[G1LIW35U=%+MM.1O301L
M..^4=^[OD5#>#-VM]OXH\2Z*OK:>FJZN[#W>&:0,=,?$FZ-!^L?B'0>J#;<-
M,GK7YCQ2=>KA43VZT57-"R1W,V"-IF+@T>71H_0M'AE#EG%FDJ,CN.4W.P6B
M29\=#16M_AGE:=<SG#OUZ==[(/8:7SAU;GW?)^-UMB(;)63/IVD^1?[PT?UK
M8^SMEMKI,'9C=WJX+=>+1--%-3U3Q$X@R.=L;[ZYB#Z:^80=^#7[(<6XF' \
MLN3KO!54YJ;;7R-U*X $EKO7HU_<D[;WT>D>LTV99CQ+S;'Z/)ZNV6>CJRZ2
M:/XI8V\S@V*([^ 'J21^:%FQW"#.?:/M=;87BJM>/T3VU%7'UC<]PD  =V/5
MX'SY7+8<%?VUN*_\>B_M3(,&U2Y)P\XMV+':[(ZZ_6.]QOY#7.+Y(G@'LXDG
MH0WL=$./3IM7JJ8XI_MY\-/X4W_)7.B*>XAY%D%_XC4N XC</HKEI_>KC<&-
MYI(V'KRM].A;VT27#J #O49G:<NX66UF36C+;I?K?32,%=0W60RAS'.#>9I)
M.NI Z=1O>SU"YWFNAP?VCWWB^/%/:;];A31U;^D<;V\@T3Y=8F[].<'LME[0
M696AW#^KLEMKJ>X76[&."GIZ602N(+P2XAN^FAH>I(16+QIS*[P6_ ;EA]7)
M$ZZU#7QQ<Q#9@]K"QKP.XV[J/M6%G6'YGC.,5F4P<0KO4W6B8*B>!WPTSP#\
M0;'OE 'H1HZ[!8W$FURV6W\%[94_]XI*VFAD^3V^$'?T[5H<9_VJ\H_B,B#:
MX%>Y,CPRS7>=C635E*R61K>P>1\6OEO:C''RUU%PX;7:6GN=51-I())I(X3T
MJ&AI_%O_ -59_!']JC&/XFW^LKNXPM+N%V4AH)/T?*>GR:416&+66JM_LZ7F
MNJ+S6UL%;9'NBI)B/#I0&OV&?;O^A8W"O"<HRKAY:JJHS.Y62A9$8Z"EMNX]
M-:XCGD((+B3LZ]-=?(;:PWBW5_LS5M)15U-/5TECE;40QR OB/*X?$WN.Q[J
M<<#/VI<9_BO_ ,3D5&^"F779]!E]LRZL][J,8J'1R5A'Q/C'/LGUUX;CL]=$
M;6@Q&+).*\%3D-RRZOQVT/F?'0T-LF\)W*TZYGNWUZ].N]D'L-+GPSM[[M?^
M-UNB<&R5E4^G:3Y%_O#1_6HIP:Q/AS>;)-;\QI(J;)Z":2*ICJ:V2!SP''1#
M><#H/A.OS>O=!8G#W(KW8.(]1@>3W47F.6F][MMP<!XCFC>V/]3IKNIV?A/D
M1JX51/#J@X?Q<6746$6"6::V0ND?=XJZ22"-SFEI: 7$.V':WZ[UVVKV1'G^
M:IS')N-&5XO:\AJ[;9XO"EFF8=O@C#&_!%^:7.=W^7W'+NTV0\),IL4M1D=P
MON*W2H%).RY2>)+3O/9P>?O/378C78K&QO*K;CWM'9K2WBIBI(K@R%D4TK@U
M@D:QA#23T&P3W\PN_CK=:+,KSBF&X_4Q5U=+<6U-0:=XD$$;002XCH.CG'7H
MWYA%2_B'1YM?<IMMFQ^IFLN/.B,E9=82TR%W7\6T;YAV'7IW^6C7?$:&_<*&
M4%[M6=W2[#WEL<]MN=1XID:022 3V^'70;&QU69Q!JGY-QM&)9)?*FS8W#2-
MEBCAF\ 5<A .BX]#U+AU_,('4J$\=K#P_P 7Q^GM^*MBJ+]+4-?-*VI=.Z.(
M!V^8[(:22WIH$H+0]H/([_9;AA3<7K)(*FMJI(_"#M,E<?## \>8V[LL"_\
M#?*+;A>2U5UXAWBN;[A+4/@ (8XMC>7,^)Q^ ]NFOL7=QT>),IX4/!!#KHT]
M/X<*L[B*TNX?9.UH)<;75  >?XIR" >S19:JEP*W726\UM135<+VQT$A'@TY
M$S@2SYG7]*M.^7*&S66ON=5OW>C@?42:[\K6DG7Z%7/LWWBW57"^RVZGKJ:2
MX4T<IFIFR R1CQGZ+F]P.HZ_-3;/+5+>\*OMLIO\O5T4L,?S>6$-_ITB*DPN
MSY=Q1M;LFO&772QT-3(_W&AM3S$&,:XC;B#\74'OU.M['9;'";WD=LS6[<.<
MJNTE9-+1NFMEV:WEF+2#W]2.IZ[(+#U(TN[V?LSLXX?TEFN-=34%UM)D@J*>
MJD$3AI[B':=KIHZ/H0=K56*NAS?VC_IFR.]XM%BMYIWU;.L<CW!XT#Y]9':]
M>0E%1[A]B%RJ.,.844>67>&:@="Z:J81XE6.AU)\EZ75,<,OV^N)/V0_U!7.
MB/-5RQ.XS^T.ZVQY5=H:B:WNJ6UK"/%C87./A#_5"S>(=->ZKVB[50XW7-HJ
M^>T-B=6/9SF&/<A>\#S=H=/F?+N-K?KI0V7VGJ6JN]9!14SK-RB:H>&,V2[0
MV>GD5EUKFO\ :FM;F$.:ZQD@CL1N1%:+.Z3*>$TEHR"FS&[7J@EK&4]927!Y
M>UP()VT$D $-<.FB.G4J9<9,NN]%=K#B6*3Q4MYO3SS5<@!%-".[@#Y]'=?1
MIUU(UJ_:N_:[H/Y4A_L2+1>T/:+='Q%Q&]Y12OJ,8D8:&L+7.:(SMQ!):01]
M??3OR%!GY/C&4878JC(K%Q!NETK*%GCU%)<)?%AG8.K^5I)Y>FSKOZ$*VL(R
M"+*<3M=[@9X;:R$2%F]\CNSF[\].!'W*ELPQ;@QCF-2W84M+7DMW3T]-=97/
MG<>P&I#T]3Y*WN&=+24>#6B.VVN:TTCHO%CHII3(^(/<7:+CUV=[Z]MZ00[V
MGJ^:BX3UK('%OO51%3O(_-)+B/OY=?>IS@-L@L^%6.@I&M;%#1Q#X1]8EH+G
M?:22?O6JXPXO+E_#VZVJE -86B:G!Z;D8>8#[]%OWJ+<'N*-EK<8HK3D%?!:
MK[;8Q25$%:\0EQ8.4.!=H$D#J.X.^G9$6+D^-6C**!E%?Z&.MI62B9L;R1IX
MV =@@^9_2H!Q>RF[VVY8[AN&/CIKO=SRBH<.;W:%O38!WUZ'KUT&GS(UK.*W
M%%TTE!C?#6X1UV25E0QOBTG+*R%H.SMQ!:=^?<  DZ6#Q5,^)\2^'^77F1U1
M14\/N%=5-9H->0X%Y [;YW.T/S2BLC)L)S'$+#49!8<\O5RKZ&,U$]+7N,D,
M[&C;@UA)#>@/3K]H75Q*X@UUQX$VO*;%4S6ZLJ:B)LG@/(+' O:]N_3F:?NT
MIAQ,X@X[;<!NE1%=Z&JEJJ22*EB@F;(Z5[VEHT >W79/DJBS"RU-B]EJR4M?
M&Z*I?6LJ'QN&BT/=(YH(\CRD=$%C8ABF80U+<JR#,:R8U%+)/+:6!P@B+F$M
M:W;M?#OR:.H[^L-X16S,>)&+BLO>97BWVVGD?# :*4LGJ'[V7OD[EHV&@?+R
M\[]J?\WY?XJ?["I;V8,SLL>!FRUUPI:.NHIY'\D\HCYXW'FYAL]>I(/II!NN
M&U^OMBXAW+ LKN+KKR4XJ[?7RC4DD?FUWJ=;[^;3U(UK36"HR7C!>KS64N1U
MV/XI0U!I:9EN=R35#AW<7CKV(/F.H&NY7;CE5#F_M#UE\L[_ ![/9K=[F:MG
M5DDCN8::?/Z[_P";OS"Z/9ZO-#B(R#"LAJH:"Z4=P?+&*AXC$S"UHVTGH?J[
M^8<"@S;9=,CX<<1[-CF07J>_8_?"8Z2JJ^L\,NP.4N[GJ6CJ?R@1K1!UF35F
M7Y!QNON(V+(*FV4#Z:&625I+O=HQ&PN,8!&G.<X#8([GJN_B#=*3.>,F#V?'
M9F5S;/4&MK9X'<\<8#F.US#I^1K[7 =ULL8_TI,N_D>/_P#9T&9=[+G^/X;;
MK#CMVJ;Q<JJL<VIO-26\U) 2 .CW$GIY_$1IWJ%'\]P^^X=C=7?:+B9?'W*D
M9XW@UM3N*?7=K6$ZWZ#KZ+8>T+>ZZ"]8G8/I6>RV2Z3N%;70NY#RAS1R\WD-
M.)/EU&^@46XF8APSQ+"[C/3S-N-^GA,=&9*XSREY_+Y6G6@-G9&NB#=<3ZBN
MS#V?:/(YKC44;VTC):JE@Z153G2,:>8>@(+@/FNV"ENV*>SU6W6GR*Y5%1/;
M:6>FYW:]S'P_!&1V&G:^Y=%4?&]D4>&.;5"SM\J@;_J*RKY>+==/9BGBMU=3
M5,M+:*6.HCBD#G1.^ <K@.K3MI[^B#*R3B!=K!P>Q&:WN-5DM\@IZ>"6;XCX
MCF ND.^YV0.OFX+E/PSS2"U.N%+Q%O4N1M9XGA/D)I'O[\@83H#?3>M?)13/
M*6HIN%'"O)H87SP6/W6>H8P;TPMC._LVP#_>"N.KXD8G3XVZ]_3E#)1B/Q&M
M9,TR/.M\@9O?-Y:UM! J;B)<,DX!7V]L>ZAOM QU/.^$\I;*TM^)OIL.'W["
MQ,2Q3,L[P^VWNZYU=;7+-3M]U@H26-#0-!\I#@7N=KF/V_<(YB=MJZ?V;\UN
M=="Z$W:62KB81K\7M@!^PD.U\M%77PA_:OQ;^3H?[(01O@!E%XOMDO%OR.<5
M5RLU:ZD=4><C1VWZD$.Z^8UYJS:RIBHZ2>IJ'<L,+'2/=Z- V3^@*FO9S_\
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M7+P$KKU?L>N61WVLJ)6W2LD?1T\CR600M<0 T>77F'V-"D_%']K;*?Y,J/\
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M@ ;UL:.NPVK5X=7V7)L'LMXJ6-945=.U\H;T'..CM?+8*QN+/[6.5?R94?\
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M1=J"GNM+;)JN%EPJFN?#3EWQO:WN0/0>J"*2\)L%EKC5OQF@\8GF( <&;_@
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MH#Z+IOH;_P"X^7\7];G[?PNJW2((;<>&&%W&N965F.T,E0P <P:6@@#0Y@"
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M!H\WIL=]+47<[]CV#KO\5%_]5A!<M3DUAQ?!:*[U<SJ2SLIHO #QS/+2P<C
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M+=5RTENDB]ZNDL1TYS-%W)]G*!T[$O&^RO%46XBT>U>7UA#67:V!M.YW8D,
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M=L<<CCXA+PYQUL:!_P!P+9Y[^R7F.+5MEK^']!''4 <LHN<+G1.!V'#;N_\
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M9Y"[S^J1KMU:1KJ%C!UXXK\0\BMS+Y7VC%;%**5T=!)X<E3+MP.W>FVN/78
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M[WU1^M40M#B"?4_!W/4APWU48P^BEXE6^3(\USFJMC:F1_NEMH:]E.VG8UQ
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MAPH[M2%CI;G6,<7L@8.W*YIT3Y>8VYH]57&"X'9LVR_BO%=X ZH;7O@IY_.
MODE/.T=M[8W[MCL2K_L&/6C'J=T%CME)01/.W"GB#.8^I([_ 'KOM]HMUNJ*
MN>WT--33U;_$J)(8@QTSNIYG$#J>IZGU*"K.!.45L$M=@64NY;[9#R0N<?\
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M%1OFYO=6ZWZZUK^A!5-<VD?[,]_K;?CC<=IZT"=M*)G2\X\2,"3;@"-@=!Z
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M[DEHZD=RX['3N24$Q15 .-H=2NND6%Y(_'AU-Q$ Y>3\_7;7SVI5?N(UJMV
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MJ&-TR-NP>1GRZ#R'0  #74+$/8ZZE4E[*S&3XWD=RJ '72INL@J7N^L=-:X
M_>YY^\J[54-9P]RC&,JN5ZX:W.WQ4]S?XM7;+BUWA<^R>9I:-]R>G36]=1T!
M&OXYL92<3N&%=1@-N,EP\!SF_6=%XD8T?E\;OYQ7?>?]*BP_R([^N9;+%^'E
M]K<T@RWB'=*6MN-(WEHJ.B:1!3]^NR 2>I\N_79T%MKAA5?4<9[;F#*BE%OI
MK<:1\1+O%+CXG4#6M?&//U14_5,<9_VU^%?\>D_M1*YU6_&#!;OE-3CUUQFO
MIJ.\66=TT/O(/([?*>N@>Q8.FM'91(C/'NEBK>(7"ZFJ6-DADN3FO8X;#ASP
M[!4PX]1LDX1Y*'M#@(&N&QV(>T@K57S!\ER"X\/[G=ZVV&OL=2Z>O,9>&R[>
MPCPQR^C//752_B18*G)\'N]EH9(8JFLB$;'S$A@/,#UT"?+T15!\4):J;@OP
MMHXPR2*H-.'MD=ICW",!@<?3J58KZ[BV^E=3.Q?%33N9X9C]X=RENM:US]M+
M;5_#2&]\)[7B-YG8RJHJ>)L=5 "X1S,;KG;O6QU(UTV">RCYQ_C!]$FR?3^/
MFE+/!^DBV3WGDUK?U=<VO/O\]]4&W]GW&[QBN'U=NOGN_6L?-3B"82M:QS6[
M&Q\P?TJ3\4+?+=>'>1T5,TNGEH9>1H[N<&D@??K2^<-L-H\%Q:"ST4CIG!QE
MGG<-&60ZV[7EV  ] %*$167LWW*"X<)+.R%S3)2&2GE:/R7!Y(W]K7-/WJ>9
M'>:3'[%77:Y/+:2CB=+)R]R!Y#U)/0#U*JNX\+LBQO(JV\<+KW3VZ.M=SU%L
MK&$P%W^KH'IUZ#0(ZZ.NBQ;AP[S_ #F6"FX@Y#04UDC>'OH[6T[E(]20/TDG
M7HBM7QSR"CR_#\&JZ0SML5RNS?%\9AC) );U'\_]&U?YIX33>[^$SP.3P_#Y
M1R\NM:UZ:\E$\UX?VG)\';C);[G2P-9[H^)N_=W,&FD#SZ$@^H)Z^:A?X/<7
MS:OH,Y!8/=.7POI/ED]Z\/MZ:YM>??Y[ZHB#X"?"X-\5J*G<76ZFGJ&TW78U
MRZZ?<&_I5O\  BEAIN$N.,AC:UKZ<R.T/K.<XDD_I6/1\-(;-PFN>(62=KJF
MLIY&OJI]M$DSQHO=K>AT T-Z '=23AY8ZC&L*L]FK9(I*BC@$3WQ$EA.SVV
M?Z$56?LGTL,6'7^:.-K9'7>2(N ZEK8XRT?=S._2NWANT,]H+B,U@TTQ0N('
MJ0T[_I*E/!;"J_!L<N-OND]+/-4W&2L:ZG<XM#7,C: >8#K\!_H3%<*K[1Q1
MRK):BHI7T5VCC;#&PN\1I:&@\P(UY>1*"(^S)31-CS6J#&^.^\/C<_74M;U
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M0&>CIZUQ;"Y^Y2YW<=1R@CYM"L?C)A5?F]GM-);*BE@DI+A'5O-07 %K6N!
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M-(GVYI#=?#H'HS?Q:T$'SV6:>FCX71U$(!J:FKF?4/\ RBX.T-G^"!^E:_B
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M&Y6VANE,:>YT=-64Y.S%41-D;O[""%I<1SK&\NYQCUVIZN1@YG1=62-'KR.
M.OGK2WU75TU&V,U=1% ))&Q,,CPWF>XZ:T;[DGH @Q+/8[596/99[914#7_6
M%- V/F^WE VLNMI*>NII*>MIX:BGD&GQ3,#VN'S!Z%=R(-12XQ8:2CDI*6RV
MR&ED<'OA92L#'$=B1K1*SJJ@HZMT#JNDIYW0.YXC)&'&-WJW8Z'H.RR4085V
MM%NO%.(+M04E="#L,J86R-!]0' KJIK#:*6W/H*:U4$5"\@OIV4[&QN(]6@:
M/9=639+:,8HX:N_5K*.GEE$#'N:YW,\@D#X0?(']"VZ#'DH*26A]REI8'T?(
M&> Z,&/E'8<NM:^2XVVVT-KIO=K914U'3[+O"IXFQMV>YTT ;64N,TL<,3Y9
MGMCB8"YSW'0:!W)/D$&F9B..,KO?66"TMK-\WC"CC#]^N];W\UMJNE@K*=]/
M5P13P/\ K1RL#FNZ[Z@]"J_K>-> 4E6:>3((WN!T70P2R,'^\UI!^[:F>/WV
MUY#;VUUCKZ>NI7'7B0NWH^A'<'Y'J@TV=Y%/AMBIJBUX[5W=GB" 4M SK$WE
M.CH-.F] .W384;X)8Y<Z1M]RC)J7W6]W^I\=T#A\4$(WR,/H>IZ>@;OJK/1
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M=C3B-A<;M:;=>(!!=J"DKH0=AE3"V1H/KIP*62ZT5[M=/<K5.*BBJ&\T4H!
M<-ZWH@'R6:@P;3:+;9X##:+?24,).RRFA;&"?4AH"RYX8JB%\-1&R6&0%KV/
M:'-<#W!![A<T0=5+304E.R"DAB@@8--CB:&M;]@'0+JN5NHKG3&FN5'3UE.3
MLQ3QMD:?N((64B#76>Q6FRM>VSVRBH _ZPIH&Q\WV\H&UDR4-))6QUDE+ ZL
MB;RLG=&#(P=>@=W ZG])60M1:,EM%WNESMMMK63UMM>(ZN(-<#$XD@ DC1^J
M>V^R#;/:U[',>T.:X:((V"/1:6DQ+'*.M%926"TP50.Q-'21M>#Z@@;"W:("
MTC,1QQE=[ZRP6EM9OF\84<8?OUWK>_FMVM1C.2VC)Z6HJ+%6LK(8)C!(YK7-
MY7@ EOQ >1"#;HB(-7=\=LMY<'7>T6^N<T:#JFG9(1]A(*[K3:+;9X3#:;?2
M4,1ZEE-"V,'[0T!9R(,:XV^CN5,:>XTE/5TY.S%/&)&D_800E-04=+0BBIJ2
MGAHVM+1!'&&Q@'N.4#6NI62B#3V[%[!;*LU5NLELI*H_^E@I6,?^D#:W"(@T
MT>*X_'<??X[%:VUV^;W@4D8DWZ\VM[^:V-=04E>QC*ZEIZEK'<[1-&'AKO4;
M'0_-9"$@ DG0'F@ZZF"&J@?!4Q1S0O'*^.1H<UP]"#W7&CI*>BIVT]%3Q4\#
M=\L<3 QHV=G0'1*.KIZVG;44<\51 [8;)$X.:=$@Z(Z=P0NY 6BKL/QJOJ34
M5N/VFHJ"=F26CC<XGYDCJMZB#JI::"DIV04D,<$#!IL<;0UK1\@.@528+C%0
M_BIQ%EOEG<^TU[X?!=54_-#.!O>N8:=I7 B#!M-HMMGIS!:*"DH82=EE-"V,
M$^I  7<:&D-<*TTL'O@;R"?PQXG+Z<W?7R7*NJX*"BJ*NKD$=-3QNEE>03RM
M:-D]/D%BV"\V_(+33W.SU+:J@GYO#E:T@.TXM/0@'N"$&1!04D%5-4P4M/'4
MS?Y65D8#Y/X1 V?O6/462U5-QCN%1;*&6OC(+*E].QTC2.VG$;&OM6P6HQS)
M+3DD-5+9*UE7'33&GF+6N;R2#1+>H'J$&=';Z**NDK8Z.G962#E?.V)HD<.G
M0NULCH/T!9*+%NMPI;5;:FON$PAI*:,RRR$$AK0-DZ'5!]]PH_?O??=*?WWE
MY/>/#'B<OIS:WI9*P[-=*.]6NGN-KG%115#>>*4 @.';>CU\EF(,6CMU%12S
M2T='34\DYYI7Q1-89#UZN('7N>_JNB\6*TWIC&WBV45>UGU14P-DY?LY@=+8
MH@QK=04=MI6TUNI*>DIV]HH(Q&T?<!I9*(@QWT-(^NCK7TL#JR-O(R<Q@R-;
MUZ!W<#J>GS*/H:1]<RM?2P.K&-Y&3F,&1K>O0.[@=3^E9"(.NH@BJ8'PU$3)
M87CE>R1H<UP]"#W6MM.-6.SSNFM-FMU%,[H9*>F9&X_>!M?*/)+36Y#76.EK
M6276B8)*BG#7 QM.M'9&C]8=CYK;H,:AH*.WL>R@I*>F8]W.YL,88'.]3H=2
ML"NQ:P7"M%97V.V5-7O?C34K'O\ TD;6X1!\#6A@8&@- UK737HM;2X]9:1M
M2VEM%N@;4CEG$=,QHE'H[0^+[ULT0==-3PTL#(*:*.&%@TR.-H:UH] !T"U)
MQ/'G7#WYUAM1K=\WCFDCY]^O-K>_FMTOCG!K2YQT -E!QJ(8JB!\-1$R6&0%
MKXWM#FN!\B#W"^4M/#20,@I88X8&#38XVAK6CY = M;C.16K)[;](6&L;64?
M.8_$:US1S#6QIP!\PML@QZ6AI*2:>6EI8(99W<TSXXPUTAZ]7$=SU/?U6NJL
M4QZKKS755BM<]83LSR4D;GD^O,1O:W*(,8V^B-;'6&DIS5QMY&3F)O.UO7H'
M:V!U/3YK[34-)2S3S4M+!#-4'FF?'&&ND/7JXCN>I[^JP(<DM,V2SX_%6L=>
M((1424W*[;8^GQ;UK\IOGYK;H"U-WQJQWB5LMWLUNKI6] ^HIF2. ^TC:^5^
M26FWWV@LU96MBN=>"ZF@+7$R ;WH@:'8]RMN@Z:*DIJ&F93T5/#34[.C8H6!
MC6_8!T"XT-#26^)T5!2P4T;G<[F0QA@+O4@>?0+(1!CBAI!7&M%+![X6\AG\
M,>)R^G-WU\EA7;&['>)V37:SVZNF9T:^IIF2. ]-D%;5$&$^T6U\=-&^WT;H
MZ4[@:86D1'U8-?#V'9=ON-)[][[[K![YR\GC^&/$Y?3FUO7R60B 1L:/9:2/
M$<<BKO?8[!:65F^;QFT<8?OUWK>_FM)=.*>'VS(18ZJ\-^D_%$!BBADD#9"=
M!I<UI&]]-;Z>:FR 1L:/9:-N(8VVM]\;C]I%7OF\84<?/OUWK>_FMXB B(@T
M8Q#&Q6^^#'[0*O?-XWN<?/OUWKO\UM:VCIJZG=3UM/#40.T3',P/:==NAZ+O
M1!\8QL;&LC:&L:-!K1H >@710T%);X714%+!2Q.=S%D,88TGUT//HLA$&EAQ
M3'H;A[]#8K5'6[YO';21A^_7FUO?S6QBH*.*MEK(J2G95RCEDG;& ]XZ="[6
MSV'Z%DH@PZ>UT%-22TM-0TL-+-OQ(8X6M8_8T=M T=CHN^DIH*.G9!20100,
MZ-CB8&M;Y] .@6MH<DM-=?Z^R4E:V2Z4+6OJ*<-<#&" 022-'N.Q\UMT'74T
M\-5 ^"IBCFA>-/CD:'-</0@]"M76XO8*YU.ZMLELJ'4[0R$RTK'>&T=@W8Z#
MY+<(@^,:UC&L8T-:T:  T /1:R\8[9;T]C[Q:+?7/8--=4T[)"!\B05M$0=%
M%1TU!3,IZ&GAIJ=G1L4+ QK?L Z!=Z(@QX*&D@JIJF"E@CJ9M>+*R,-?)K\X
MCJ?O6#=L9L5XG$UVLUMK9AT$E13,D=^DC:VRU$&26FHR6IQ^&M8Z\4\0GEIN
M5VVL/+H[UK\IOGYH-C1TM/14[*>C@BIX&#38XF!C6CY = M;<\6L%UJO>;G8
M[965'_K9Z5CW?I(VMPM179)::&_T%DJZUD=TKFN?3P%KB9 -DG8&AV/<H-G3
MP14T#(:>)D4+!IK(VAK6CT '9:VMQFQ5U>VNK;+;:BM:01/+2L>_IV^(C:VR
MU$V26F')8,?EK6-O$\)J(Z;E=MT?Q?%O6OR7>?D@SXJ&DAJY:J*E@94R@"29
ML8#W@=@7=RL>\62U7J-L=XMM%7L;]45,#9.7[.8'2V"(,2V6RAM5,*>UT5-1
MT^]^'3Q-C;OUT  OEUM=!=J;W>ZT-+6T^]^'41-D;OUT05F(@UM-8+/30TT-
M-:J"**F?XD+&4[&B)WYS0!T/0=0MDB(,>HH:2HJ8*BHI8)9X#N*1\8<Z/^"3
MU'W)[C2>_>^^ZP>^<O)X_ACQ.7TYM;U\ED(@QZZAI*^-D==2P5,;'![6S1AX
M#AY@'SZGJLA%TQ5=/-4ST\4\3YX.7Q8VO!='S;US#RWH]T'VKIH*RGDIZN"*
M>"0:?'*P.:X>A!Z%8,>/V:*A;116BWLHVR>*(&TS!&'ZUS!NM;UYKKLN26F]
M5]SHK76LJ*JV2^#5QAK@8G[(T=C1ZM=VWV6QIZNFJ99XZ>HBED@=R2M8\.,;
MM;T[78Z(.CZH.R1C)(W1R-:]C@6N:X;!!\B%UT5)34-.V"BIX:>!N^6.%@8T
M;ZG0'1:['<DM.1QU<EDK6U;*68T\Q:US>20=V]0%MT&FKL4QZOK??*ZQ6NIJ
M][,TM)&]Y/S)&UN&,;&QK(VAK&C0:T: 'HOJ("P;K9[;=XA%=K?1UT8[-J86
MR ?8' K&FR2TPY+!C\M:UMXGA,\=-RNVY@W\6]:_)/GY+;H-79\>LUE+C9[3
M04+G='&FIV1D_:0!M;0@$$$;!1$&E@Q+':>N]]@L-JCK >83,I(P\'UWK>UN
MD1!IIL5Q^>X>_P ]CM<E;OF]X?21F3?KS:WOYK<HB#2_@GCWO_OWT#:O?=\W
MC^Z1\^_7FUO?S6VJ((JF!\-3%'+"\<KXY&AS7#T(/==B(.NFIX:6!D%-%'#"
MP:9'&T-:T>@ Z!==+0TE)+/+2TL$$D[N>5\<8:9'=>KB.YZGOZK(1!J[KCME
MN\T<UVM%OK9H_J/J*9DCF_82"LN&WT4%4:F"CIXZ@L$1E9$T/Y!K3=@;UT'3
MY+)1 1'$-:2>PZE:G&,CM.46YU?8:QE92-D,1D:US0'  D?$ ?,(-LBZ*.KI
MJV(RT=1%41!SF%\3PX<S3HC8\P005WH"(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*BN+U-!6<=>'
ME/60Q3T\C7!\<K YKAS'H0>A5ZKS[QXLM)D7&+!;3<?$-)5Q/CD\-W*[7,>Q
M18N&;$,4$3S-CUC$>OB+J*(#7S^%4YP<CHJ/CSE]'A[@[&!2@O$3N:)LNV?5
M/R<9 /EO71<.(/L[VN"PSUF'OK'7&F'B"EJ) ]E0T=2P: (=Z=?E\Q-/9WN^
M.W/#',Q^UT]JK*=X97TL>R[Q-='%SB7.!ZZV3K1'D@S<OXH1VK)#CF.66LR*
M_,;SS4],X,9 /]=Y!T>H\M=1U7W$.)[+GD@QS)+)68[?9&\\,%2X/9..OU'@
M#9Z'RUT/55-PM_#F;*\[J<2^@#5.N;FUAN?B>(#SR<H;R]F_6_1\E(,HQGB#
M>\FQ6MR>MQ"DEMU:V:G,$\D4DGQ,+FCF!YOJCI\_F@LS'<ZBNN>WW%*B@DHZ
MZV-$K'.D#A41G7Q@:&NCF'77ZWR7W/<YBQ2XV"W1T,E?<+Q4^[PPLD#.4; +
MR='H"X?T^BA'%]AQ/B3A^<Q MI72_1EQ([>&_?*X_8"X_P"ZU?<<'X:<?[Q>
M'?';<7@%#3'R,[N8./W;D_\ =02G/.)=+C5YI[%;+95WW(:AO.VAI.G(WU>[
MKR^O8].IT%@6#BJ]V24EBS''*W&KA6G5(Z:02PS._-#P!U[#SZ^8V%6UB_#"
M?CAGTV*?0OTC'((WFZ<^Q#O3>3E\M-9O[EL>)&,\2<EMU!#DE=AE"RGJFS4\
M[)Y(7B4 Z <X'OWU\AZ(+ XC<5*+!LAH;776ZHJ35TSYV/A=LEP+@V,-UU+G
M #>_-8-#Q<=3XM=KUEN,W*PMHI(XHH)MN?5.>"0U@<UO7IU\OFM)Q IV5/M&
M</8ZAK7 4LDFO+F:)' _I *FW&'%Z#+L1-KN%SBMDOCLEI:B5P $PV -$C>P
MXC0Z]4$7J^+U\M-*VY9#P]NU!9"6\U4*AKWQM)T"YG*-=QW(4^O69V2SX>,F
MJZO_ ,U/B9+$]@VZ4/&VAH\R=]OTZT54MUN?%;#[54?A/:;1EM@AC)J)&ZYC
M&.Y<-#8T.I+'?-:?C9?8<GP3A[66&"&FM=;7=()V\L44C?A#'AOY(/..GEM!
M,SQ@O4= +Q4</+S'CNN<U@F:9!'^>8^7MKKO>OFK0QR]T&166DNMHG$]%4LY
MXWZT?0@CR((((]0JVDBXR20OBD&$.B<TM<TB?1'HLSV?,=KL8PRJH*ZOMM<T
MUKY87T$_C1L:6MVW>AH[!.OFB+ OWO?T%<?HS_O_ +M)[O\ [3E/+_3I>?\
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M-"ZV,O+!&*37AA_ARDC[=GK]JXX"*_!N,99Q%;!4W3(8&NI;J27".0]XFD]
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M]^5!-[SG,5LXCV/$74+Y);I ^=M2) &Q\H>=%NNO^3]?-0G'O]*;)_Y&C_\
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MB^(_5ZG\IP^J005%J_.LLQ6NMC.+&*6VLMIJ&LANE.UK_">?R@-D;T"=:8=
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M^[.K+FRGG/AM?SQD'8^('7VA:>OX!V./'Y/HFJKV9,QGB17-U2\.=,.H) Z
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M-!!X;1R/(AV>8#F/UW=SYJS5Y^X062JQWC[E5LK*V>N\"V-$51.[F>Z+FAY
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M#M/=$.;X ?L8[[21OLL+.>#]JQ?%ZN_8/47"U7NU0NJFS,J7.\9K!S.#@?4
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MBN-5S@QKB_@607421VJ!DS))FL+@TZ(\OX0.NZO5=55305<1BJH8IHR=\DC
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M<-@KZQK6-#6-#6@:  T $'FC@EQ%M6)5^46W)))*.AJ+I+-!6&-SH_$[.82
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M?VPJY8HV1,#(F-8P=FM&@%\9#$R1\C(V-D?]9P: 7?:4'-4QP&_SZXI_RO\
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M[SWF*1\;8_#+&ELG*'#R=K1/VZ\EZ$%JMXK??!04@J^_CB%O/_.UM9,T,4P
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M74B$@ DG0'FJ@I^*.2Y)/638%AINEHII70^^5%8V#QB._(T_=Z]^NNR"WR0
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ME,TM'44C9FL<=]6[^WIT'30)**AM92Y'1<?L&;F%YH[C7/CD>QM+ (V0L+9
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M16_%+3095<LBI8'MNMPC;'42&1Q#FM#0--[#ZH[+>H@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M[@C8*^H@XQQLB8&1L:Q@[!HT N2(@^/8V1A:]H<T]P1L%&-:QH:QH:T=  -
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M14.W&]@\V_%U/ERG:YY9#BU)7Y/])55YH<G$,7NI%3)&Z>1L(;&^F8PZ?\0
M(()V#O015TPO,D,;W,=&YS02QVMM^1UTVN:UN,FN=CEK=>!JY&EB-2/_ -+R
M#G_IVMDB"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@^$ D$
M@$CM\E]1$'PM!(V ==1\E](#AH@'[41 (!&B 1\U\<T.&G $>A7U$!" 001L
M%$0-#6M=/1  T -  'D$1!\: T:: !\D: T:: !\E]1!\#0-Z &^IUYKZ  2
M0!L]SZHB#YH<V]#?JOJ(@+X&@.) &SW*^H@^<HYN;0YM:VOJ(@( &CX0!]B(
M@$ C1 (^:(B 0""" 0?(KYRCIT'3H%]1 T-@Z&QYKX6@D$@$CL?1?40$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g111069g99a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a06.jpg
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M*"@H*"@H*"@H_\  $0@)E0=H P$B  (1 0,1 ?_$ !P  0$  P$! 0$
M       &! 4' P(!"/_$ & 0  $# P$#!0L'"04& P0'"0 ! @,$!081!Q(A
M$Q8Q5M(4%1<B05%489.4E0@R<8&1T=,V-T)24U5TDK0C=:&RLS-B<G:"L20E
MP30X<\(8-4-C9(.BH_#Q)N$G1*2E_\0 %0$! 0                    '_
MQ  5$0$!                     ?_:  P# 0 "$0,1 #\ _JD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M   BHJ(J+JB]"H               $5%1%1=47H5              :IKIJF
MO3H          /F21D2(LCVL15T3>7350/H   -4UTU37IT
M   "JB::JB:\$     JHB:JJ(G1Q                  !%155$5%TX+Z@
M           'S)(R)$61[6(JZ:N70^@            'R^6-CFM>]K7.X-15
MTU^@#Z                                 541%551$3I50
M              %5$Z51/(                             'S'(R5N]$
M]KTUTU:NH'T        !JFNFJ:].@             BHJ(J*BHO0J
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MA1U1JDBZOUC5.&FB;J-Z3O0
M   &'=JR>BHUFI;?4W"771(:=T;7+Z]7N:FGU^4YAL"M&18O;+C:\AL-12]U
M5\E:RH;/#)&U',:FZ[1^]KJWR(O2=; '+(\>O&&[3KQD5IM\MUL=]8U:N"G<
MU)Z>9O0]&N5$>U=7="Z^,OFXY5)CMRR3:A199=J*2VVZTTSH*"FG<U9I9':H
MZ1Z-54:FCE1$UUX(O Z2 !Q;%[=E^S&[72VVZP29#C%75.J:5]-4,9+3J[I:
MY'+QZ$]7#77CH=I '+=I=)E>3[-+I;4L/_F%R<Q(:6&HC7N9C7L=_:R.<B*Y
M='<&(J)P37RGOF-#>[IL;=9:2PU:W:HI&4BT[IH$Y-6HB*YSM_3=X+IHJKT<
M$.E@#C^2T.8R;.,5I;7;*Z"6WR4\-TM\53''-4P,8B.1DC'KXJJBITHOJ,&.
MRWFV;4+-DEJP=]-:>][Z):6GE@;-&]7*N_(B.1J:ZIQWG<$75=>!VX <LGMM
M^?MTI\A2P5?>=EN[V+/R\&NJR*[E-WE-=SCYM?5Y#\O=LOTNV^T9!3V"KEM%
M%1/HI)DF@17*Y7KOM:LFNZF\G3HO3P\_5 !PC+JUM+M>N$UZQB_SS-I&-M\^
M..?RLL.J[[IEC<UW3HU$7@F[Y>"E#B.38O=XZO!8;+=\>GK::9>YKC2K%).C
MVKOOU555SM-557<5T\I\VN'+,0SK)JN:QU&0VN\3MG@JJ6>-)8&IJC8G-D<W
MQ6HNB:+IP]?"DH[-77W+K;D=[H6VUMKAECHJ59&R3*Z5$1[Y'-\5-&IHC45>
ME55?(%1V 2YW@M W&*[%GWRBI7.917"EJXXVNC555$>CEU337ZDX:+IJO6[6
MM8ZWP.NC8&5JMUE9 JJQJ^9%7BNG1KPUZ=$Z#* 1S;;A8;O=K=C]=C]%W?56
MBZ15SJ9'HQTC&ZZHBKPUUT/C:6E^R[9E<K=08Q7Q5U?NQQPS3P-6-&O8Y7/_
M +31-=%1$157AQT.F #FF4T-[N.QAUEIK#5K=IZ)E$M.Z:!.3<UJ(KU=OZ;O
M#AHJKT<$-5D&'7[(=EV-04E,^U91CRT\M.RHDC5LDD4:-71S'.315XIKIQ3B
MB)Q.P "#QC),RNJT]-<L/[TS-<U*JJGJV/A1J+XW)M:N\Y5371.A->*KIQO
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M(KE1/M4YEL9MM_Q+9W4VR[8]6)702R2QQQSP.Y='NX(U>4T14\N]IZM>@ZL
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M535%1#GELV5U5=@V:V?DEM%'=JQ*JV44KT>M+N*BM5VZJHF\J(BHBKHGK.W
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MHX Y7LTMM^MF?YC<+IC]92T-\J(Y8)730.Y-&(_YZ-D54UU3HU.J
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MNJ[?DU7Q6\$1->E533RD/M^NEOO.S.WUUKK*>LI'7:GW)H'H]BJCG(NBI]:
M=C!-1YYBLEY9:H\@MSK@]_)MB29%WG=&ZB]&NO#3774WU=64U!22U5=414U-
M$F])+*]&-:GG55X(![@TUGRBRWFK?2VVY03U3&<HL.JM?N?K(U=%5OK3@;D
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MGU*!L08=JNEON],M1:JZEK:='K&LE/*V1J.3I35%5-3,
M
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M(Y?&8JNUT3I4\<WV;T.3W*AN\5PKK5?J-NY'<*)R->YO'@Y--%3BOFZ53HX
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M]FN%4^"6.>V4E?5UK):A]0KZE4545R(FB:?1KZU55*P(
M
M
M
M         -1EEC;D=BJK3+6U5'!5,6.9]-N;[HU14<W5[7(B+KTHFOK/#"\;
M;BMFBM=/<:VMHX&HR!M5R>L34_116,;JGTZF^
M                                             #XG8Z2"1D<KHGN:
MK6R,1%5BJG2FJ*FJ>M%0^P!&X5@4.)7&X55%>KK4I<)W5-5%4\BK)97:ZO\
M%C147CY%1/460                                 '/XMFK;9?;A<L7
MR&Z61+A*LU52PMCEA<]>ES6O:NZJZ_\ [H4]AQZFM$T]4LU36W&H:C9JVK>C
MI7M371O!$:UJ:JNZU$3CKIJ;D
M
M
M
M
M
M
M
M
M
M
M
M
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MI14 R
M
M
M
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M/.XTE:V2J5U#R#=.3BX\%\5/5HG%4T7B5X0
M
M
M
M
M       (7;)BUVS/$9+%:'T$+:A[7RS54CVJS<<CD1J-:NNNG'54T]>O"Z &
M!8TN#;9"R[Q4L=6Q-UR4LKI&+IY45S6K]6GUJ9X
M
M
M
M
M
M
M
M
M
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M= A?"Y@O6*F]G)V1X7,%ZQ4WLY.R!= A?"Y@O6*F]G)V1X7,%ZQ4WLY.R!=
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ML5-[.3L@70(B':QA$TT<4>0TSI)'(QJ;DG%571$^:6X
M                                     -7E7Y,7C^#F_P CC:&KRK\F
M+Q_!S?Y' :?95&Q=FF*JK&JJVRF\G_W;2IY*/]FS["9V4_FSQ3^ZZ;_3:5('
MQR4?[-GV#DH_V;/L/L ?')1_LV?8.2C_ &;/L/L ?')1_LV?8.2C_9L^P^P!
M\<E'^S9]@Y*/]FS[#[ 'QR4?[-GV#DH_V;/L/L ?')1_LV?8.2C_ &;/L/L
M?')1_LV?8.2C_9L^P^P!\<E'^S9]@Y*/]FS[#[ 'QR4?[-GV#DH_V;/L/L ?
M')1_LV?8.2C_ &;/L/L ?')1_LV?8.2C_9L^P^P!\<E'^S9]@Y*/]FS[#[ '
MQR4?[-GV#DH_V;/L/L ?')1_LV?8.2C_ &;/L/L ?')1_LV?8.2C_9L^P^P!
M\<E'^S9]@Y*/]FS[#[ 'QR4?[-GV#DH_V;/L/L ?')1_LV?8.2C_ &;/L/L
M?')1_LV?8.2C_9L^P^P!\<E'^S9]@Y*/]FS[#[ 'QR4?[-GV#DH_V;/L/L ?
M')1_LV?8.2C_ &;/L/L ?')1_LV?8.2C_9L^P^P!\<E'^S9]@Y*/]FS[#[ '
MQR4?[-GV#DH_V;/L/L ?')1_LV?8.2C_ &;/L/L ?')1_LV?8.2C_9L^P^P!
M\<E'^S9]@Y*/]FS[#[ 'QR4?[-GV#DH_V;/L/L ?')1_LV?8.2C_ &;/L/L
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M[4?QE'_4QEZ
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MUE6QM>Q)Z:UTE0^"&GA=Q8CE8J.D<J:*JN73CP1# S_'[MB5HJ,BP6YU\<E
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MGAA2MJYFU\JU$T[HFM1$>JKNLT=)JB*GD33BJE9M">V+ LE>]41K;;4JJ_\
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MW6P;=,?R"[V5;/1WR+O5/_XIDR2/_1<JMZ./)IQ\B*=2VK_FSRK^[:C_ ".
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M>T=P:GSM>@ZMBUXAR#'+;=J;3DJVG9,B(OS55-53ZEU3ZCF.PS\NMJ7]\?\
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M.SRTW2ST-UBOE3W75S7&:=*G=:SEF.1NZ[=3@W@FFGJ"JD !
M                                    $%MQ_-[4?QE'_4QEZ06W'\WM
M1_&4?]3&7H
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MZ5-VM_>BR4M,YL<"53)75,SG)XS]W@B-:BZ)YW:_18@
M           (*F_/I7?\O0_U#R](*F_/I7?\O0_U#P+T
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MM77IZ4^PL75.77;)+3$^T+9[+!(Z>KF6L9))/HU=R-&MZ&JY45?/II]-L
M                                                 @MN/YO:C^,H
M_P"IC+T@MN/YO:C^,H_ZF,O0
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MVT;K!CGPR7\4=[MHW6#'/ADOXI= "%[W;1NL&.?#)?Q1WNVC=8,<^&2_BET
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MXL0>^^7BRU- E72<I%34+XY%_P#$1Z:.6143CIY#M!!;<?S>U'\91_U,9>@
M                                                     U>5?DQ>
M/X.;_(XVAJ\J_)B\?P<W^1P&JV4_FSQ3^ZZ;_3:5)+;*?S9XI_==-_IM*D
M       2U\S2FM631V-+;=*ZK?2I5*M#3\JD;5<K4WN/BZJU>*^8J3QBI*>*
MJGJ8X6-J)T:V21$\9Z-UW45?5JOV@1DVTNVPWZ"R2VF^MNL\2SQTRT?C.8FN
MKD\;H\5?L/2;:%317BAMDECO\=76*](6RTFXU^XQSW:.5VBKHWHU\J$M?O\
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MF&JAY-S5553337R*U=?J*H_G&:=^$[0N?2*[O5<+U66FZ>9C4E5&/^I6JO\
MT>L_H"]72EL]FK+G6R(VEI8G3/<G'5$37AYU7R?2!/W;/[5;LN9C+8*^LO#H
MDFY&DAW]&KKTKJB)P37CYT\Y^9SM M6%,ADO=-<D@E5&MFAIE?'O+KHW>UTW
MN"\#EN$T%91_*!I*N[[R72ZV1]=5,5=4B<^1=V-/4QC6-_Z3?_*I5$V:0*O0
MERA7_!X575NT>SVN2G2_TMULL50Y&1SUU(YL2N7H17MU1J_2J%-=;DVWVV2M
M2GJ:N-B;VY2L21ZM\Z)KQ^HY%MOS7'[WA\V-4%7%+<KJ^..!U0U8(8M'M<LC
MI'HC41$1?+KJIU3&+>MJQ*U6YTZ5*TE%% LR+JDFZQ&[R>I=-0B<Q_:9;<BM
MZUUDM-]K:1'K'RL5'JF\G2GSO6ANL7RRBR*6Y0TM/7TU3;WM9405<"Q2-5R*
MK>"]**B'(ODYY?CUCV>34UWO%%1SMKIGK'-(C7;JHW1=/J.NX9<:#(;=SBM]
M.V/N_6/E-=5ECBDD:Q5^GBOJWM/(!HZ3:A:ZR^U=FH[5?9KG2-WYZ=*/==&W
MAQ5'.3AQ3[3:8WG5CO\ =:BU4TT]-=Z=-Z6AK('03-3S[KDXIT=&I XS/#3_
M "ELT6>6.)%ML"(KW(W7Q8?.+Y1)D^WS'+ACRMF@LU.[OE70KK&U5WMV%7)P
M5WC='2B.]05V8\ZF>*EIY)ZF5D,$;5>^21R-:UJ=*JJ]"'H<:VX7!]TS'"\)
MWW-H+G5-GKVHNG*Q-<FC/H71WUH@1<T^;1W&%9[!9+Q=Z/R54$<<43T\[%F>
MQ7IZVHJ+YS[QW.K/>[M+:4=4T%YB3>?;Z^)89M/.B+P<GK:JE/%&R&)D<3&L
MC8B-:UJ:(U$Z$1#CGRF[6L6*T65VYRT]XLE5&^.H9P<C'.W=-?-O*U?M\Z@=
M&S/*:/$K6MRN=-6R43/]K+31<HD2:HB*[CJB*JFLI<_IJNV0W&EL6134<T:3
M1R1T.]OL5-45$1VJZH:3:-=$OFP"X77=1O=MJCJ%:GZ*O1KE3ZM3\P//,6M.
MS"P=V9#:6STMJA22G[KCY5'-B35FYKKO:IIIIKJ!=XS>Z3(['27:W<KW)4HK
MF<JS==P<K5U3R<44][S=**RVNHN-TJ&4U%3MWY)7]")_ZJJ\$1.*J>6.=S.L
M='-0TZ4U/41]TMB3]%9/[1?KU<I'[=;'<[[L^J8K&Q9:ZEGBK&0(FO+)&[56
MZ>7SZ>54T R[IM!BM-!WRN>.W^FM/!5K'01JUC5_2<Q)%D:GTM0V.;9E08=0
M)77>FKG4":;U13PI(QBJNB([CJFJ^K3B3NS_ &DX]M$MTMKJFMIKI)$Z*KM=
M5P5W#1Z-U^<WI]:>5$//Y1K49L6R!K4T:U*9$3S?^(B M\:O4606F&XTU-5T
M]/,B/B[ICW'/:J(J.1-5X*B^4T.8[1+5B-QIJ.\4=T1U4](Z>2&GY1DSN'BM
M5%Z>*)H:W%=I&&T^,6>&;([;')'1PL<QTJ(K51B(J*A$;7\LL&19#L]@LEUI
M*^6.^P.>V%^\K6J]J:J!W2AJ%JJ2.=T$U.KTUY*9$1[?I1%4T]XRZTVG);/8
M:R9S;C=5=W.Q&ZIHU%75R^354T3SJ;\_GK:C03W>R73:'0:K5VBZQ+;W)Z+3
MO5CE3U.E5[_H1 /Z%(.#:?:ZF_U-DI;5?9KK3,Y2:F2CW7,9P\9=YR</&;]J
M%?8[E!>;-0W*D76GJX&3L7U.1%_]3E%FGAI_E-Y*Z>6.)'6:)$5[D;JNL7G
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M97;K4573HG$O:++<=RO(H[';YJ:Z)##WP?+$_>;"^.6/D_KU55Z>&[ZPBQ
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M>QSFN3543@I2FFL-PLF2PTM]L\]-6M2-\453'Q5K7*U7,7RHNK6ZHO'@AN0
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MV]#4\R&0   $%MQ_-[4?QE'_ %,9>D%MQ_-[4?QE'_4QEZ
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MZN2EN=3$CE]>[(FILK/A%DM-UGN=)%5NN$T"TSJF>MFFD2-5UW4<]RJG%$Z
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MZ$1/(@'T          !!4WY]*[_EZ'^H>7I!4WY]*[_EZ'^H>!>@
M   8MSH8KC1OIIWU#(WZ:NIYWPOX>9S%14^T#D_R=%19,\T5%_\ /IE.Q$GC
M&SW'<7K'U-AIJJDD>[>D:VMF<R1=%35[%>K7+Q7I12L XM\HJEIIKSL[?41L
M<JWJ.)RN3I8YS-Y/HX(=I)/)MGN.Y-7,J[Y3557-&[>BWJV=K8EX<6-1Z(WH
M3H1"CMU%'043*6%]0^-NNCIYWS/XKKQ>]5<OV@<BMT<4_P IW(8)VM?%+86L
M<QW%'(JQ:HOU'6K5:K?:*=8+50TM%"JZJRGB;&BKYU1$)>/9EC,=Z==XX+@V
MZNX.JTN53RKDTTT5W*:JFB(FA: <<R![4^5'C**Y$5;(]$^G6=?^QTZY4]MH
M:Q^15RL@DI*22*2H<NB-A56O=K]"L14^OSD[6[+,5KKJVYUE)6SW%NF[5/N-
M0LC=.C1V_JG3Y#VN&S?'KE3]SW%+K5T^J*L51=JJ1BZ>=KI%10*JWU4==04U
M7 CTBJ(VRL1[=UVCD14U3R+Q/<-1&M1K41$1-$1/(         !!9_\ ESL\
M_O"H_IGEZ06?_ESL\_O"H_IG@7H       !%;19VQ7K!6N5$5U\337^&G3_Y
MD+4F\BPFR9%<*>MNT59-44[D? K*V:-L3DZ',:UZ(UWK1-0/C:)A=NSC'9;9
M<4W)$\>GJ6IX\$GD<G_JGE0Y1@V0W[PDXWB&8P/6\6=:K=K-=6U4*PJC'Z^5
M>'3Y?+Q13O-'3LI:6*"-TKF1M1J.ED=(Y?I<Y555]:J8598[?67JWW:>G:MQ
MH$>V"9.#FM>U6N:OG3CT+Y0.;?*=I:B39S#6TL:O[VW&"L>B>1J;S=?M>ATZ
MR72DO5II+E;I6S4E5&V6-[5UU14_[^14\YDU$$533R05,3)89&JQ\;VHYKFK
MP5%1>E"(I]E>.T4DO>E]WM<$KMY]/0W.>&)R^7Q6NX?4!Z23MNVURECI7))%
M8[;-W2]O%&2U#X]UB^O=B<[3S*GG/K))VKM2PRFUX]S5\NG_ $QHG_=2DL%C
MMN/T/<=GI(Z:#>5[D;JJO<O2YSEXN<OG554T]PP.QU]];>JEE>MS9JD=0RX5
M#'1HO2UFCT1J<5X)H@'+\MK9ME6UR6\TM)+46?)X'-?3PIQ6L;\U$3SN<J>T
M=YC>;1;-+9-@>015KTEN51&E572I_P#:3OE:YZIZD7Q4]34.FW6S4%U?0/N%
M.R=U#4-JJ=7?H2M141W^*F)E6+VO*J)*.]QU$])^E"RIDB8_BB^,C'(CM%1%
M3770#PV<2<KL^QF1%UWK93+_ /LFG/\ Y.,K'Q9NQKD5R7Z=RIZETT7_  4Z
M+:<5MEIL<EHMW=L- YJ,1B5LRK&U/(QRNWF)_P *H:.U;*L4M$TLMII:^ADF
M_P!HZFN=3&LG_%NR)K]8$0VACM_RH:=N.-2."HMCIKM'"FC$<J/T5R)P155(
ME^E=?*9V:R,;\H_ T<J(O<51T^MDNATVP8[:;!',VT4,5,LSM^:1-722N\[W
MKJYR_2JD_=-E^+76ZMN=QI*RIN#%\2HDN%0KV<55$:N_XJ(JKHB= 51W"BM\
M5?'?*S<BFH:>5G+N=NHR)VZY^]ZO$1?5Q.5?*/N$%TV+0U]*KNYZN>FFBWV[
MJJUVKDU1>C@6UPV;X_<:5U+<.^U53.X.BFN]4]B_2BR:&3E&!X_E$4$-[I9Z
MBF@:UL=.E5+'$W=U1%W&N1NNBJFNFN@1S_:O@B4-KMN7X+0T]'?;)NU"QTL*
M,2HBT\9%:U$U5$U^E%<GF.C8!EM!FF,TMWMCTTD3=FBUU=#(GSF.^C_%-%\I
MM++:Z>SV^.BHEG6GC^:D\[YG(GFWGJJZ>K4TUJP6Q6>_3W>STTM!55"[T[*:
M=[(95\[HT7=\J^0#99;:&W_%[M:'/W.[:62!'_JJYJHB_4JHIS#Y-UW?1V*L
MPJ\-6EOEDGD1:>3@YT3G*[>;YTWG+Q3R*U?*=D)_(\.LF0U,%5<:/_Q\'^QK
M()'0SQ_1(Q4=IZM= -U75=/04<]76S,@IH&+))(]=&L:B:JJJ<EV"VFHJ;IE
MF:U4+X(K_6.?1,D31W<Z.<J.5/7O)_+KY2W=@UJJ%C2ZRW&ZQ1JCFPW"LDFB
MU3H58U7=<O\ Q(I2RPLDIWP>,R-S%9_9N5BHFFG!4XI]*= ''<#CBF^4)M$Y
M1C'Z04VF\B+IXC#J=#8Z"@O%;<Z.%L-361113(Q$1KDC5ZM71$Z?'5-?,B>8
MT-MV;8W;+S)=J&"NAN4JZRU"7&HWY>*+H]=_QDU1."ZH6('G4R\A3RR[KG\F
MQ7;K>E=$UT3UF@=!8-H6(T\E530W"TU\396-D356ZIY%3BUR<4X+JBZE&1U'
MLZLMN6=MHENMLIYW*^2FHZ^6*)7+TJC47Q=?]W0"1^3Y25%FJ<TQ]E1)4V>U
M7/D:*1ZZZ:ZJ]NOJT9JB>55\YY['$8[:MM7U1JKW;3Z:_3-J=0M=BMUJLZVN
MV4_<E&J.16PN<UVKNEV^B[V\O3O:ZZ^4T=CV<8W8KM)<[53UE/72OWYI4KYU
M69==?[1%?H_CQ\;4"GK8V=QSZL;IR;O)ZE.5_)95%V40:+T5<VOVH=.O5KIK
MS;Y**M6?N>3YZ0SOA<Y/-O,5%T\Z:\2>LFSK';'15%'9HJ^BI9_GQ07&H8U5
MU3BB(_@OBHFJ<=. $_:[);\^RK(+Y<NZGTE'-WIH%IZN6G\6+C*[6-S=4=(Y
M4XZ_,0E[]::/9IMEQ:[V[NB.U7MC[;5K/423+OJJ;JJ^1RKIKR?EZ&*=;Q3%
M;5BM(^EL<4\%*]=[DGU,DK&KJJJK4>Y=W55773I\IBY=@UARY\3LAIIZML6B
MQQ]U2LC:O'QD8UR)O<5XZ:@1ORH/S25_\1!_G-;M,P!C,;M.4X/0T]%D-F:R
MJ8E+"C.Z(T1%<U4:GC+IQ]::IY2\O6SO'[W0045XBKZVDA^9%/<:AS==55%5
M%?Q7BO%=5TX&^L5HI;';HZ&@Y?N:/YC9IWS*U-$1$17JJHB:<$Z$ U.SK,:#
M-\8IKM;W-:]R;E1!KJZ"5/G-7_NB^5-%('9@]J[<]IB;R;RK3Z)]"<2XBV>X
M_37FKNEN@J;=5UB*E2M#520-E]:M:Y$UXKQ31>)A4^RK$Z:Y2W&GI*Z*X2JJ
MR5,=RJ6RO55U75R2:KJ!O*Y]IQF2LNL_]C)<9X8I-WBLLJZ1L1K?*J\$^KU'
MW;KC;,HI+I2K$R>.GJ9:&KIIVH[QF.T\9O%%14T<GJ5#71[/["VZ45QFCKZJ
MJHI.5IW5=QJ*A(W^1R->]4U^H^JS!+/-?*F\4KJZW7*IT[HFH:N2'EM$T3?:
MB[J_3H!SS!K"S#-O%ULF.N>VQ5EJ2NFIMY7-IY-_=:G'Z%T]3O4=L-38,=MM
MB[I?;X7]T53D?45,TCI9IE3@F^]RJY=/(FNB>0VP        $%@7Y?[1/XZE
M_IF%Z06!?E_M$_CJ7^F87H   #BVSREIKAMDVI4M9#'44\KJ9KXI$1S7)HO!
M4\IV:>)L\$D3U>ULC5:JL<K7(BIIP5.*+ZT)&T;-L;M%X?=;=3UL%PD=ORSI
M<*A72KKKX^K_ !T5>E':HH%-145#::+D:&FIJ*DC17;D+&QL:GE71-$0YOAN
M,6S-8:_+;NVN66[5+G4W(UT]/NTK%W(D5(WM1=4:KN/ZZG0<@LE'?[>ZBN7=
M#J5^J/9#420[Z*BHJ.5CD54X]"\#\QRQ4..VQEOM39HZ./\ V<<D[Y=Q-$1&
MM5ZJJ)PZ$X <BQNB@V>;>Y[13+*RT9+1)+"DLKI%Y=FJKJ]RJJKP?TJJ^.AE
M_*2CCE9A$<[6/B??(6O:]-4<U>E%3RH760[/L>R&[17.[TU5/6PJCH9$K9F<
MBJ:<6(UZ(SH1>&G'B>5^V;XW?WT[KU!6UJTZ(D7+7"H<C-$1-43?X+P35>E?
M*! ;6<7=A5UMVT#"J"&!]N7<N5'31HQDU.O!7;J)IP3@J_0OZ)UO%[]09-8Z
M2[6B9)J2I9O-7RM7RM<GD5%X*AET5##24#*-BRRP-:K/_$2NF<Y%\CG/55=T
M^5318U@]DQFOJ*FPP34+:ARODIHIW\@YWGY-5W47Z$0"F.(;7*AVS_:78L[@
MADDH:R-UMN,<:<7\-6+]/!/9H=O-;?['07^CBI;K D\$4\=2UJKT/8Y'-7_#
MCYT54 UNSZU3VO&XG7!$[Z5SW5U<O_WTB[SD^AO!J>IJ$M1V:@S[,[]=;CW4
M^AM;TM-$M/5RT^KF^-.[6-S575[FMZ=/$.B7&BCN%')2SOG9')IJZ"9\+^G7
M@YBHY/J4U>*XG:<5@E@L<4\$$CMYT3ZF65F\JZJJ(]RHBKY53I Y)EEGHMFF
MU?$<@MO=$=LN3G6VN6>IDFT5VFZY72.5=.*+IKI_9E5\I1R-V.WS7RN@1/;,
M*K+\(L67\DF0TT]7%%HK(NZI61HJ:^-N-<B;W%4UTUT,6[;.\?N]MBM]TCN%
M711:;L,URJ'-X+JBJBOXJFO!5Z -WB[VR8S:'L5'-=1PJBIY4W$(_:J^/*=F
M.94-H5U1-2(Z%Z-3IDBW)7-;YU1.'#RZIY#:4>SJP45(REHUN]/2L3=;#%=Z
MMC&IYD:DFAO,;L-NQNTLMMGI^0I&.<]&J]SU5SE5557.55555?*H$]L9O=-?
M=FF/STLC7NAI(Z69J+Q9)&U&N14\G1K]"H?&;3MN&88A9*=4?4Q5JW2=$X\E
M#%&]J.=YMY[VM3S\?,)ME^-I<IZZVLK[14SKK,MLK9:9LB^MK%1/L0WV.8Q:
ML=;.MLIE;-4*BSU$LCI9IE3HWY'JKE^M> '/OE1*B;):Q%7IJ8$3^8Z+46VB
MOEAIZ:L8DM,]L4K=%TT5JM>U47Z4137Y;@]BRW=3((*FKB;HJ0]US,B14UT=
MN-<C=>*\=-3&IMGEBI:1M+2OO$-,UNZV*.\5;6-3S(B2:(@&_MMWH[E57""B
MEY5]!-W/.J)XK9-U'*U%\JHCDU\R\#/-5C&/6S&;9WOLM.M/2\HZ545[GJY[
MEU5RN<JJJKZU-J   $%MQ_-[4?QE'_4QEZ06W'\WM1_&4?\ 4QEZ
M                                              #5Y5^3%X_@YO\
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MC4557@FIU4Y?MDL%GH<&FJ*&TV^FJ&UE)NRPTS&.36HC1=%1->@Z@
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MNVS"GAK'J^6VU$E$CG+JJM;HYJ?4CD3Z$.J@
M                   (*F_/I7?\O0_U#R](*F_/I7?\O0_U#P+T
M                          ""S_\ +G9Y_>%1_3/+T@L__+G9Y_>%1_3/
M O0
M           $%@7Y?[1/XZE_IF%Z06!?E_M$_CJ7^F87H
M                    06W'\WM1_&4?]3&7I!;<?S>U'\91_P!3&7H
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M_EZ'^H>7I!4WY]*[_EZ'^H>!>@
M06?_ )<[//[PJ/Z9Y>D%G_Y<[//[PJ/Z9X%Z
M                                             @L"_+_:)_'4O],P
MO2"P+\O]HG\=2_TS"]                                   ""VX_F]
MJ/XRC_J8R](+;C^;VH_C*/\ J8R]
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M\,<KM/\ 0\,]ZJ?PP+T$%RNT_P!#PSWJI_#'*[3_ $/#/>JG\,"]!!<KM/\
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M'_4QEZ<5VI29T[$7ID%-C++;W72\HZBGG=*G_B&::(YB)TZ:ZKT:G:@
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MR]#_ %#R](*F_/I7?\O0_P!0\"]
M  @L_P#RYV>?WA4?TSR](+/_ ,N=GG]X5'],\"]
M                                                06!?E_M$_CJ7
M^F87I!8%^7^T3^.I?Z9A>@                                  !!;<
M?S>U'\91_P!3&7I!;<?S>U'\91_U,9>@
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M48OLUM%OKHUCK7-=/,Q>EKGN5VZOK1%1%]:%T$
M                        @J;\^E=_R]#_ %#R](*F_/I7?\O0_P!0\"]
M                                  @L_P#RYV>?WA4?TSR](+/_ ,N=
MGG]X5'],\"]
M                    06!?E_M$_CJ7^F87I!8%^7^T3^.I?Z9A>@
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M3![1!W;2^DP>T0#W!X=VTOI,'M$'=M+Z3![1 /<'AW;2^DP>T0=VTOI,'M$
MB=N/YO:C^,H_ZF,O3GFVRI@EP"H9%-$]ZUE'HUKT5?\ VF,Z&
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MU7M?L4+, 1G@MP?JO:_8H/!;@_5>U^Q0LP!&>"W!^J]K]B@\%N#]5[7[%"S
M$9X+<'ZKVOV*#P6X/U7M?L4+, 1G@MP?JO:_8H/!;@_5>U^Q0LP!&>"W!^J]
MK]B@\%N#]5[7[%"S $9X+<'ZKVOV*#P6X/U7M?L4+, 1G@MP?JO:_8H/!;@_
M5>U^Q0LP!&>"W!^J]K]B@\%N#]5[7[%"S $9X+<'ZKVOV*#P6X/U7M?L4+,
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M41HNB_0JH=C(+;C^;VH_C*/^IC+T
M                      &KRK\F+Q_!S?Y'&T-7E7Y,7C^#F_R. U6RG\V>
M*?W73?Z;2I);93^;/%/[KIO]-I4@
M""VC_E9L^_O9_P#3R%Z06T?\K-GW][/_ *>0$7IP+:_3VG)=M6.V7(YXH['0
M6Z6KJW2S<DUN]O:(KM4TXMC\OE.^G-KILRQ+(MH55?KK.MSKDC:U]ODF:Z*+
M=1&HJL1-[R=#E5-54$:;$-G6R>X7&*JQEU+65='(V=J07*21S'-<BHJMW^C5
M$Z4T,?; Z;+-IF+8 L\L5JG8M?<$C=NK*QN\J,5?_P M?K<B^1#1[>L5M>!T
MUFS+#Z>.TW*EKF1.93>)'*U6N7BU.'Z.BZ=**NIN:]ZL^5'8I9D5J5=E58T=
MY])%5/\ ]*A6)MAV?VG#<9CRW"*;O1=K-+')O0/=I+&KD:J.15X]*?2FJ+KJ
M9FV;*JN[X9A]LLLSJ6;+Y86.>U>+(G(U7-^V1J+ZD5/*5?R@)61;(,D6141'
M1,8FOG65J(<MR&%]%'L$FJ45(XW0L<J_HJO(*G_[^H"OS;8SC%'@E7)C]$ZB
MO%MIW5--6QRNY5TD:;WC+KQUT^K7AH66Q[))LKV=6:ZU;MZK?&L4[OUGL<K%
M=]>FOUF^RJ5D&,7B6542..CF<Y5\R,<JG/?DP0OBV1V]ST5$EGG>WZ.45/\
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MN_S+ZCNQQ7; G=&V;9?3Q<98ZB25R)T[N\Q?_D<=J"
M                                    05-^?2N_Y>A_J'EZ05-^?2N_
MY>A_J'@7H                                  $%G_Y<[//[PJ/Z9Y>
MD%G_ .7.SS^\*C^F>!>@
M                            (+ OR_VB?QU+_3,+T@L"_+_:)_'4O],P
MO0                                   @MN/YO:C^,H_P"IC+T@MN/Y
MO:C^,H_ZF,O0
M      :O*OR8O'\'-_D<;0U>5?DQ>/X.;_(X#5;*?S9XI_==-_IM*DEME/YL
M\4_NNF_TVE2                                 (+:/^5FS[^]G_P!/
M(7I!;1_RLV??WL_^GD!%Z<CRW",EL^T";--GSZ.:IK(DBK[=5NW&S::)JU>"
M?HM7I314UXZJAUP <7GP[,MH5_ME1M!BH+58;=*D[;92R<JZHD3HWW:JFGDZ
M>C5$3CJ4>U?![AD%19[[B]5%1Y)9Y%?3NE^9*Q>ECO\ ]].*IY=4Z* .(WO&
M]H>T9U%:LPI+;8\?BE;-5I2S\I)5*WR)HJZ)].FG3QT1"WVHX'%F.)1VRCF;
M0UE$]D]!,B<(GL31$X<=-.'#HX+QT+< <1O%OVMY38UQJZ4MFMU+.WD:RZ1S
M;SI8_P!+1B+JBJG3P377R'1)++48ULY=:<1?%#5T-'R=))4:;N^B:J]^O#BN
MJK])5&-<Z"FNEOJ*&OA;/25#%CEC=KHYJ]*< (O"5FS[9#2)D[DEENM+(RH<
MQB,U17.1'-1."<$14(ZR6S:QAUG7&[/2V:[4,.L=%<9IMQT+%7AO,545=/(F
MBZ=&JH=II:>&DIHJ>EB9#3Q-1D<;&[K6-1-$1$\B'J!#[*,%3#,;GIJ^=M==
M*^5U37U&FJ22.Z437I1/7TJJKPUT(JSXOGVS>IN%!A5+;;WCM3,Z>FAJIN2D
MI7+Y%U5-4X)T*NNFO!54[: .<;*<'N=EN5XR3+:F&JR:[N3E>1_V<$:=$;5^
MI/Y43R:KIKEB&78?F]UR#9]%0W"@O#DDK+952<EI+Q7?:[5$Z55>G])4T7@=
M@ '*L'PS(J[.GYKG[J1EQBA6GH*"E=O,IF+KJJKY]%=Y5^<OJ1.J@
M                                                @J;\^E=_R]#_
M %#R](*F_/I7?\O0_P!0\"]                                   @L
M_P#RYV>?WA4?TSR](+/_ ,N=GG]X5'],\"]
M                                            06!?E_M$_CJ7^F87
MI!8%^7^T3^.I?Z9A>@                                  !!;<?S>U
M'\91_P!3&7I!;<?S>U'\91_U,9>@
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MDN@!"\X\XZA1?&HNR.<><=0HOC479+H 0O./..H47QJ+LCG'G'4*+XU%V2Z
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MR70 A><><=0HOC479'./..H47QJ+LET (7G'G'4*+XU%V1SCSCJ%%\:B[)=
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MX\XZA1?&HNR70 Y1FG/;*['WI?AT-$R2H@D=.MVBDW$9*UZ^+NIKP;YSJX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                        !%UZ        #S@GAJ&N
M6"6.5&N5CE8Y':.3I1=/*!Z      !YU$\--"Z6IECAB;\Y\CD:U/I50/0
M         #\>]K&.>]R-8U-555T1$ _0?,,L<T3)87MDB>U'->Q=4<B]"HOE
M0^@ !\32QP1/EGD9'$Q-7/>J(C4\ZJH'V#%MUQHKE$Z6W5E-5Q-7=5\$K9$1
M?-JBJ90                 'G//#3M:Z>6.)KG(Q%>Y&HKE71$X^55/0
M
M
M
M
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M7Y^G3YNGCO=/DZ *\
M
M
M
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M&P\@O'5'-5%<OSEZ$7H]?"FWLQ\)6[N47,SN7YVJ<KRNGVZZ_5IZRO
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M (?PLX/UAIOY).R/"S@_6&F_DD[(%P"'\+.#]8:;^23LCPLX/UAIOY).R!<
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M>0TRO>Y&-3<?Q55T1/FEL
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MA4:G_ME'Y/\ \3&7Q!;<?S>U'\91_P!3&7H
M                             -7E7Y,7C^#F_P CC:&KRK\F+Q_!S?Y'
M :K93^;/%/[KIO\ 3:5)+;*?S9XI_==-_IM*D
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MQ.[/+;6VC#;7073_ -N@C5LRZHN\[>55=P\_3]91
M        (*F_/I7?\O0_U#R](*F_/I7?\O0_U#P+T
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MLYNW"V7B\44E9<XJ*>.FKI(XW1N1=?%1=$7Q>E/.9>U:GNF!XV_*,7O5R_\
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MAOE3W75S7&6=*G=:SEF.1NZ[=;P;P333U!52  @
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M6QIQ1>*N<O1_B0.P;'[_ (AC*V*_VUD2,EDG94Q5#)&JCM/%5$75%Z?)H=/
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M2"IOSZ5W_+T/]0\"]
M        YUMMPVNRK'Z*?'W<GD%LJF5%'*CD:J<41R:KT<-'?]"'10!S+:)L
M[6NV6TMEL"+WTM')3V^3>1KG3,Z5WEZ%=JY=?.J*6N'65N/8S;[6C^4?!$G*
MR+TR2KXSWKZW.5R_6;@ <LV\8]D67V2EL^/VMDC8JJ.J=4S5+&-7=1R;J-UU
MU\9.)T:SU%554$<EPH74-2O!T+I&R:?0YJZ*AF@#DVV&Q91D]TQ_O)9F.I[/
M<&UJRS5<;.6W5141J:JJ>7BNAU&W3SU%''+54CZ.9VN]"][7JWCYVJJ+YS(
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MXE: .>X4_+K3@=-;+M8>Z+I1TZ4\;XZR+<F1$5&JJJNJ:(B:\%]1A;!L>O\
MB.,R6/(+:R+2:2=E3%4,D:[>W?%5$XHO3ZCIX Y%18;D& 9O67+"Z5EQQJZ/
MWZNT\LV)\#_UXE>J-^K5."Z>1%3K4+W20L>^-\3G-15C?HKFKYET54U^A50^
MP!Y5E-#64D]+4L22"=CHY&+T.:J:*B_4ISG8?@-1A%LNC+BYTE3+5/C@5S][
M=I6.=R:)YM5<]^G^_P >)TL <]RJER&[9KCTB61S[!:JE]1(O=42/GEW5;&]
M&Z\&MU5W%=?5PXV=_A[HLE=3K1NK6S0NB=3M<UJR-<FZJ:N5$3@J])G@#E&Q
MNVY=AN*.L=[LG=,=.][Z22"KB5=UR[VXJ*J:+O*JZ^OU&!L[LV:8OE&5W&KQ
MR">EOE6M4UD=?&CX5WGJB+KP7@__  .S "-CGRJZ9/:TGM?>BRTJOFJ']V,D
M?4.W%:R/1O0W5V\NO3NI]<[D>(Y!8]H\N:87#3U_=L*07&V32I"LNB(B.8]?
M%1?%;T^9>G53J@ @JVY9ED%#);Z+'78^Z=JQR5];5Q2K"U>"K&R-55SM.C56
MIJ4U)1-QS&J6ALU%)5,HH600P->UKG(U$357.5$U\JJ;< <9V7V;-,1N&22U
MV.05$-VK75K>1KXT=$YRJJM77I3BG'U%@ZHRZ[9':8Y+3WGLL$KIZN7NQDDD
M^C5W(T1O0U7*BKYT33Z;8
M            !!;<?S>U'\91_P!3&7I!;<?S>U'\91_U,9>@
M                                          U>5?DQ>/X.;_(XVAJ\
MJ_)B\?P<W^1P'.-G=OSJ3 L=?;[_ &2&C=;X%ACEMKWO8S<31%=RB:KIIQT*
M'O9M$ZR8_P#"G_BFQV4_FSQ3^ZZ;_3:5($+WLVB=9,?^%/\ Q1WLVB=9,?\
MA3_Q2Z $+WLVB=9,?^%/_%'>S:)UDQ_X4_\ %+H 0O>S:)UDQ_X4_P#%'>S:
M)UDQ_P"%/_%+H 0O>S:)UDQ_X4_\4=[-HG63'_A3_P 4N@!"][-HG63'_A3_
M ,4=[-HG63'_ (4_\4N@!"][-HG63'_A3_Q1WLVB=9,?^%/_ !2Z $+WLVB=
M9,?^%/\ Q1WLVB=9,?\ A3_Q2Z $+WLVB=9,?^%/_%'>S:)UDQ_X4_\ %+H
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M63'_ (4_\4=[-HG63'_A3_Q2Z $+WLVB=9,?^%/_ !1WLVB=9,?^%/\ Q2Z
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M63'_ (4_\4N@!"][-HG63'_A3_Q1WLVB=9,?^%/_ !2Z $+WLVB=9,?^%/\
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M@Q%\E\O=HJJ!*NDY2*GH'Q/=_P"(9IHY9%TXZ+T':""VX_F]J/XRC_J8R]
M                                                    !J\J_)B\
M?P<W^1QM#5Y5^3%X_@YO\C@-5LI_-GBG]UTW^FTJ26V4_FSQ3^ZZ;_3:5(
M       EKWFE/:LGCL:6RZ5U4^E2J5:*#E4C:KE:F_Q\77=712I/&*DIXJJ>
MICA8VHG1J22(GC/1NNZBKZM5^T",FVEVR&_0666U7UMUGB6>.F6C\=S$UU<G
M'H\5?L/6?:#3Q7>@MC['?F5=:KTA26DW&NW&.>Y$<JZ*NC>C7RH2M^_]YS&O
M[CD_S3'5ZBDIZB:FEGB:^2F>LD+E3BQRM5JJG_2YR?6!)XUM&M.19'4V*AI+
MG'<:5%6I944_)\AI^MJOGT3AKTH;+,LMHL2I:>HN=-72P3R)"UU-%RFCUX-;
MIKKJODT1>@YUM9A?A.>63:'1,=W&YR6^\-8GSHG<&O7Z-$^MK$*RA6/,LT;<
M6/;-8K"JLI7(NK*BL<GC2)YTC:NZB_K.=Y@&0[3;7CRT*7BUWRF6M<C(4=2?
M.>O0W7>TWO49CMH%GI;C2T-YCK[-/5.W(%N%.L<<KOU4D35FOJ52+^4E_P"P
MX;_?T'_9QD?*9GI)=G;[2K4GN]=4PMH*=B;TKGH]%56M3C\W>37_ 'M/*!7Y
MUG5LPF&&>]T]>E)*J-2I@AY2-'KKHU5UU1>"KT'Q5YS%2T<E5-8,C2"-N^YR
M4"NT;TZZ(NISWY0$%52;";9!<G[];"^C9.]5UUD1NCEU^G4M:K:?BU/2TC**
MZTE?5SS0TT5/#+XSG/>UGF\F\J_4!7V6Y4]YM%%<J)7+2UD+)XE<FB[KD14U
M3SZ*9AX6^CI[?10TE%$V&FA:C(XV]#6IT(A[@        ""VC_E9L^_O9_\
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MV*UM3#50\FYJJJIIIKQT5JZ_451_.,\S\*V@\^FJ[O7<+U66FZ>9K.55&/\
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MN7_%54#W           @J;\^E=_R]#_4/+T@J;\^E=_R]#_4/ O0
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M *F,O2"VX_F]J/XRC_J8R]
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MBI=$1L,E5+,R-$UX,1[EW4X^30#86ZDCH+?2T<"N6*GB;"Q7+JNZU$1-5\_
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M-1$:B(B<$1/(         !!9_P#ESL\_O"H_IGEZ06?_ )<[//[PJ/Z9X%Z
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MT%_HXJ6ZP)/#%/'4M:J]#V.1S5^U./G150#7;/K5/:\:A=<$3OI6O=75R_\
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M@MN/YO:C^,H_ZF,O0
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MIU<Y=MCQZS4&#35%#:+=35#*RDW98:9C')K41HNBHFO0=1
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MYVR2WJY55>7GXJO_ -XIU4
M                             !!4WY]*[_EZ'^H>7I!4WY]*[_EZ'^H>
M!>@                                  06?_ESL\_O"H_IGEZ06?_ES
ML\_O"H_IG@7H
M                    ""P+\O\ :)_'4O\ 3,+T@L"_+_:)_'4O],PO0
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M.C&LRC\F;O\ P<W^1P5SSY,'YHK?_$3_ .HIU8Y3\F#\T5O_ (B?_44ZL$
M
M     (*F_/I7?\O0_P!0\O2"IOSZ5W_+T/\ 4/ O0
M               (+/\ \N=GG]X5'],\O2"S_P#+G9Y_>%1_3/ O0
M
M $%@7Y?[1/XZE_IF%Z06!?E_M$_CJ7^F87H
M          06W'\WM1_&4?\ 4QEZ06W'\WM1_&4?]3&7H
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MTOT3#_>:GL#E=I?HF'^\U/8 N@0O*[2_1,/]YJ>P.5VE^B8?[S4]@"Z(+/\
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MG37CT':
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M*U'L>Q=6N:J:HJ+Y45#T
M      !!4WY]*[_EZ'^H>7I!4WY]*[_EZ'^H>!>@
M              06?_ESL\_O"H_IGEZ06?\ Y<[//[PJ/Z9X%Z
M                                                           @
ML"_+_:)_'4O],PO2"P+\O]HG\=2_TS"]
M       ""VX_F]J/XRC_ *F,O2"VX_F]J/XRC_J8R]
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MA^;<JU:ED5'1S1-5%CF8UK-4?IHWYR=/!?-P"M[MI[@\%F2]].3Y#N-^YO\
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MM=JU/J143ZCJ!R_Y-=MEMVR6UK.U6/JGRU*(J?HN<J-7ZT1%^LZ@$
M                                       @J;\^E=_R]#_4/+T@J;\^
ME=_R]#_4/ O0                                  (+/_RYV>?WA4?T
MSR](+/\ \N=GG]X5'],\"]
M                               06!?E_M$_CJ7^F87I!8%^7^T3^.I?
MZ9A>@                                  !!;<?S>U'\91_U,9>D%MQ
M_-[4?QE'_4QEZ
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M]JW[P,D&-WPHO2Z?VK?O'?"B]+I_:M^\#)!C=\*+TNG]JW[QWPHO2Z?VK?O
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M:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6(
MCO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:
MT^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA
M'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6
M( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'
M5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!
MAA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[
MH6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!A
MA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H/!AA'5:T^[H6( CO!AA'5:T^[H
M/!AA'5:T^[H6( CO!AA'5:T^[H1E/@&*.VPUEN7'[<M"VR13M@Y%-Q)%G>U7
M:>?1$0[(05-^?2N_Y>A_J'@9G@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=
MT'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM
M:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1
MW@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:
M?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPC
MJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$
M 1W@PPCJM:?=T(S-< Q.DS#!Z>FQ^W105==-'.QL*(DK4@>Y$=YTU1%.R$%G
M_P"7.SS^\*C^F>!F>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JU
MI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'
M>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI
M]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".
MJUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0
M!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".J
MUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##
M".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0
ML0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##"
M.JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>
M##".JUI]W0L0!'>##".JUI]W0>##".JUI]W0L0!'>##".JUI]W0>##".JUI]
MW0L0!'>##".JUI]W0>##".JUI]W0L0!QO#,!Q2KS3.:6IQ^W2T]'5T[*>-T*
M*D35@:Y4:GDU557ZRS\&&$=5K3[NAAX%^7^T3^.I?Z9A>@1W@PPCJM:?=T'@
MPPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=
MT+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@P
MPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T
M'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:
M?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W@PPCJM:?=T'@PPCJM:?=T+$ 1W
M@PPCJM:?=T'@PPCJM:?=T+$ <>VLX)B]EPV2NM-AM])615E)N310HUS=:B-%
MT7Z%5#L)!;<?S>U'\91_U,9>@
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MGY,'YHK?_$3_ .HIU8(
M                          05-^?2N_Y>A_J'EZ05-^?2N_Y>A_J'@7H
M                                 $%G_P"7.SS^\*C^F>7I!9_^7.SS
M^\*C^F>!>@
M                  (+ OR_VB?QU+_3,+T@L"_+_:)_'4O],PO0
M                           @MN/YO:C^,H_ZF,O2"VX_F]J/XRC_ *F,
MO0                                                      :O*O
MR8O'\'-_D<;0U>5?DQ>/X.;_ ". U6RG\V>*?W73?Z;2I);93^;/%/[KIO\
M3:5(                                 @MH_P"5FS[^]G_T\A>D%M'_
M "LV??WL_P#IY 1>G%;)_P"]5D/]S,_[0G:CB>0X_G%JVRW3*\7L=)<J:IHV
M4K>7JF1I\UFJZ;R+TL!'9:NBI:UK6UE-#4-:N\U)8T>B+YTU\IAY0FF,W=$]
M#F_R*;"G61T$;IFHR56HKVHNJ(NG%"1VF392EI;2XC9Z6Y.JF2PU'+U"1<DU
M6Z(J:JFO2OV 37R8/S16_P#B)_\ 44ZL0&PS&[GBFSRCM5\@;!6QRRO<QLC7
MHB.>JIQ:JIT%^
M                     @J;\^E=_P O0_U#R](*F_/I7?\ +T/]0\"]
M                               @L_\ RYV>?WA4?TSR](+/_P N=GG]
MX5'],\"]
M                 06!?E_M$_CJ7^F87I!8%^7^T3^.I?Z9A>@
M                         !!;<?S>U'\91_U,9>D%MQ_-[4?QE'_4QEZ
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M[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[
MYQ9UU$IOC4?8+H 0O.+.NHE-\:C[!H,CY]7F[8_6\S::'O35K5;G?>-W*ZQN
M9NZ[J:?.UUX]!UD 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ Y
MQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9
MUU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU
M$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$I
MOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC
M4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?
M8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+
MH 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H
M0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O
M.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+
M.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.N
MHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE
M-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\
M:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C[ YQ9UU$IOC4?8+H 0O.+.NHE-\:C
M[!H(N?3,[GR/F;3+RMN90=S]]X^&[(Y^]O;O^]IIH=9 $+SBSKJ)3?&H^P.<
M6==1*;XU'V"Z $+SBSKJ)3?&H^P.<6==1*;XU'V"Z $+SBSKJ)3?&H^P.<6=
M=1*;XU'V"Z $+SBSKJ)3?&H^P.<6==1*;XU'V"Z $+SBSKJ)3?&H^P.<6==1
M*;XU'V"Z $+SBSKJ)3?&H^P.<6==1*;XU'V"Z $+SBSKJ)3?&H^P.<6==1*;
MXU'V"Z $+SBSKJ)3?&H^P.<6==1*;XU'V"Z $+SBSKJ)3?&H^P.<6==1*;XU
M'V"Z $+SBSKJ)3?&H^P.<6==1*;XU'V"Z $+SBSKJ)3?&H^P.<6==1*;XU'V
M"Z $+SBSKJ)3?&H^P.<6==1*;XU'V"Z $+SBSKJ)3?&H^P.<6==1*;XU'V"Z
M $+SBSKJ)3?&H^P:#(.?5WON.W'F;31=Z:B2?D^^\;N5WHW,TUW>&F]KY3K(
M A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A
M><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><
M6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6=
M=1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1
M*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;
MXU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU
M'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V
M!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!S
MBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBS
MKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ
M)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3
M?&H^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 A><6==1*;XU'V!SBSKJ)3?&
MH^P70 A><6==1*;XU'V!SBSKJ)3?&H^P70 Y-8.?5IR#(KGS.II>^\\4W)]]
MXV\EN1HS37=XZ[NODZ3?\XLZZB4WQJ/L%T (7G%G742F^-1]@<XLZZB4WQJ/
ML%T (7G%G742F^-1]@<XLZZB4WQJ/L%T (7G%G742F^-1]@<XLZZB4WQJ/L%
MT (7G%G742F^-1]@<XLZZB4WQJ/L%T (7G%G742F^-1]@<XLZZB4WQJ/L%T
M(7G%G742F^-1]@<XLZZB4WQJ/L%T (7G%G742F^-1]@<XLZZB4WQJ/L%T (7
MG%G742F^-1]@<XLZZB4WQJ/L%T (7G%G742F^-1]@<XLZZB4WQJ/L%T (7G%
MG742F^-1]@<XLZZB4WQJ/L%T (7G%G742F^-1]@<XLZZB4WQJ/L%T (7G%G7
M42F^-1]@<XLZZB4WQJ/L%T (7G%G742F^-1]@<XLZZB4WQJ/L%T .4YDW-\K
MLG>F7$*:BCDJ()'3]]HY-U&2M>OB[J:_-\YU8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MVR*"%%_1:O).73ZU5?K&UB9U!MHV8U=/JDLTL],_3RL56-T7^=P1V0
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MLG5>G<WM'*B<..FG'@JZ*8>TJFFK-GN2T]+&Z6>6W3M8QB:JY5C=HB)Y5*0
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M&*:I?P1C'=#MU-U55."::'7.D(B(FB)HB
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M/\I^GDIX8XWU%A=)*K6Z;[M]6[R^==&HFOJ0[
M
M
M
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MGJJ_XD7M"Q7(;]EF,W.TI:64MCG6H:VHJ)&OG5V[JU4;&J,3Q>G5W3T>0Z%
MLCH(UG8QDRM17M8Y7-:[3BB*J)JFOET3Z$".._*1M-+6T^(S5"3*]][IZ54;
M,]K>3=O;VC471'<$\;37UFKVX8;:<>QFV5EH[N@G==*>%ZNKIY$<QV]JBH]Z
MIY$+?:UBE]RUME@L[K;##;ZV*X+)532(Y[V;VC$:UBHB<?G:_5Y_/:KBV1YG
MC]LH*)MII)8:F.LG=+4R/1'LUT8W2)-4XZ[RZ='1Y0K7?*#_ /8L,_YCI/\
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M -L">Y\XGUHL7Q"+M#GSB?6BQ?$(NT!0@GN?.)]:+%\0B[0Y\XGUHL7Q"+M
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M0%"">Y\XGUHL7Q"+M#GSB?6BQ?$(NT!0@GN?.)]:+%\0B[0Y\XGUHL7Q"+M
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MG,I:EDKFIT:JC571 -F
M                            +T+ITD?@>,W:T5%?<<HO*7F\U6D23MA2
M)L4#556L:U."<555\_#S:E@
M                            .>9OB%]GS>UY=B=91)<*2F=1RTE?O)#-
M$JJO!S456KQ\WD3UZYU18K]D\=/3Y<ELI;9'*R>2CH7OF6H<QR.:CY'M;HU'
M(BJB-U71..FNMJ       16UW&;IF&'U%AM,E%"E6YG+35+W)N(U[7)NHUJZ
MZJFG%4T]9:@#68U#<*>S4U/=V4C:J%C8U6ED<]CD1$37QFHJ*OFX_2;,
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!MP     &JR3(K5C5 VMOE8RDIG/2-KW(JZN7H1$1%55X*;5%U1%3R@
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MG)T]73ROTUW62(Y?L10,D   :^EO=JJZMU+2W.AGJF],,=0QST_Z474V
M ##N-UM]M:CKE7TE(UW0L\S8]?M5 ,P&+;[E0W*-9+=6TU7&G2Z"5LB)]:*I
ME*J(BJJZ(GE  Q(KG02O:R*MI7O<NC6ME:JJOJXF6    &%<;O;;9N]\KA1T
M>]T=T3-CU^U4/J&YT,]#)64]93S4D;5<Z6*1'M1$35>*:@98-;CU]MN16UMP
MLM4VKHG.<QLK6JC7*U=%TU1->/E-D             *J)IJJ)KT  #7U%ZM=
M-<(J&>XTD==*J(RG=,U)'*OF;KJ!L 8DUSH(9-R:MI8WZZ;KI6HOV:F4Q[9&
M(YCD<U>**BZHH'Z
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M'CO;K^BCG;J>O0P.^%+1;6,MRN-$AL5CM"459)$FB5%2CM_=3R.<U-&^I=$
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M]M&'8J]D=_NVKWU+F[R4=.FN])IY7<'::^;Z"CQS#;-8HM8J9*JN?QFKZO\
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M4U0_3"M]TM]?/5P4%;35$U&_DJB.&1KG0O\ U7(B\%Z>"^8S0@
M
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M +F8 )3$<5=:K]?;]6]SMN5X='RD5,B\E$UB*C4151%>Y=557*B:KY$\M6
M
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MKO-U58VJJ+KP7CQU,:+&ZNCV<X/B2U%1WXJJR&LF5)%WHF-?RTSE7S-U1O\
MQ*WS@=G!Q26LO6TJKO3[=1+)98Y'T-O=42(RD16ZM?4R(B[TKM?F-TW4TXJB
M\3K6-6Q;+C]NMCJF6K=20,A6>5?&DW4TWE ]+I=:*U]R)73I$M74,I8$T55?
M([H:B)]"KKT(B*JD%MSB9=[+9L6:UKZF^W&*!%5-5CB8N_+(GT-33_J-9>;)
M097MKDAJ9*ON&R43):C=KIHT2JF7=C:W1Z;GB)KXNFJKQU,1>Z[[MGFMUC?)
M'2XY;FT25CW++W,Z719'M5RKO2JU$8F]K^DY==-%#LM/#'3P1P0,1D4;48QJ
M=#6HFB(?9P^UW&EQ++-H^20K4.LMHIH*-6R3ND6IJM$5VKG*OC;RM:J_[QG6
M'%\CR2KL=VOS9:&IAJ67"JJ9I/[553BVF@C:JI'"FNCE<J.=Y4 [$#A]EL+L
MCVC9K04]PN*VQK8J6X5?=#M^:1&N<K&KT-3><B*C=$1L>FGCZGQ:DNV2K5V:
MRTLU?8;&U+32/JYD933SQM1LD]1HN](C>&ZQ$5%Z5TX =GO%SH[-:ZFXW.=M
M/1TS%DED=KHU$]2<57U)Q4RXW(]C7MUW7(BIJFG^!Q++,4A=)L^P6HKJVM>W
M6:NF6ID8UU-#XSMYB.T3><J-:O2B(B(O VM6Q;MGE/@UFJ*N*P6^!+A=I%JY
M)))U>O\ 9P<HYRN1JZHY4UXIJ@'60<OV,S=T7O.7VUO)X['<T@H8F?[-KF,T
ME5B="(J[J\.!U
M
M
M
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MEDSNYN+JAC=5<QRZI\Y5U55UU7I12S
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
)         /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g111069g99a07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a07.jpg
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M                     ?_:  P# 0 "$0,1 #\ _P!4@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M"<U;=5O'USW)I>#D:IJ]-J+]VS9JIHIL6YGB*KE=4Q$<_*(YF?TXZOGM[==S
M4=?R]$U+1\S2]2Q[$9,4WJJ+EN[;FKN]ZBNF9YXGQZ1P"G''T'<VCZ_E:CC:
M/GVLJ]IUWV&531S_ &=?7IUCKX3UCITEV      0^I;US,3M4TC:7NNB,7.L
M7,B,VJ]S-44T53Q%$1TF*J>.L@N 0^B[US=0[4M7VGD:71BV,##_ !-.1-[O
MU7N:J(IF(B.*8XJGIUGF 7
M
M
M
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M54T?A:(HHB8GK'=B(XGG]A'8
M
M
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M9IMTQQQ33X3-7,S,=.(\54
M
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MN57J)B(_PIF?\!6AA3'$1 (
M
M
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MTAWNQG2]6T79>+C9NG?@XILS<JMWZHG)OY%<S5<KKXGBF.9XB)YGB.9X\&B
M,3[*<?<=_:.;@^Z]0TG6-4S;^1JFIYEKV<6YKJF.;,3^:NKNQ$1T[M,\SS/A
M/3[7M+RK.U]N;0VYHN=E:7D9-NWE48='/<QK4TS-,U3,13-4\?FJF/">6L@,
M=[2L#5,[,V-:U[2;V1HMG+NY.;B:58KR*:*J*?["U5$>,=9B:N(B>OA#G]H6
M)N36=S[/S<_;^=DXU.95DV].QN*J<>FW$31[:OGN1775,<SSQ333Q',\\[D
MR#M4L;CSXV7I>3I-_5K=W.G,U&C HXM1-O\ -;LS55TBCFKB:JN.8IYXYZ.=
MK^D;CRNU?0LJ_I%S4\O$QJ\KV\1-&%8O53--NWWY_N6XYJGCFJJJ?".D4[@
MQS%IW-=[9M4R\K1<C+KP]/M86G95='LL.F:HIJNW9JF9\9YZ4]ZKCI\N7Y[)
ML+7K.\MTY^?IF9.3F9_L[VI:A;]E1./:Z4Q9HYYF:IYZ?RTQ%/6KCB=E 8]V
M64[@R-S;BU&_H^5@WM2U2J[E96=9FB*<6W'=LV;<3UJJF.>:OY8C]9XAV*:*
MM]]H>-F4?FVSMNY5-JY_=R\[CB9I_6FW'S_VN?%;Z]I=6L8D8E>9D8V+7/\
M;TX\]RN[3_L=_P :8GY\<3^\/7@8>-IV%9Q,&Q;Q\6S3%%NU;IBFFBF/E$ ^
MX
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MT?W+U_1\/.HPLO5<"QFU\=VQ=R**;D\^'%,SR#I
M
M
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MBJ?Y>]5/Y8B)YGF>8XCF--$
M
M
M
M
M
M
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M4TQQ'3GCGCGCQF6J@
M
M
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M=KT?%T^K"NY5.F7YIBOFY/,1W>9C\T1S$?-MUNN+ENFNGGBJ(F.8F)_QB>L
MQZYK^^M4[3MV[:TC4=*QJ,'%MW<:Y=QYFFB*^[53S'69JXJXF9GB..>[U=+4
M-X:MBZM@;6NY-<ZKCX-&3JNH8.FW<ONU3TBBW;HIGNS5UGO51Q$?+F>(Y^U;
MU^WVZ[IU*]I>KVM.U#'Q\;&R:]/O1;KKHBBF>9[OY8YB?S3Q'3Q?C=L:UL?M
M7O;NQ-)S=7T'5<2C&SJ,*CVEVQ71Q$513\XXB/VZSX=!71T3>6X<:_NFWFZ;
MJ>H:?IV#5FX.=DZ;<PJK]5-/,V:J9IB)GGPF(CI$]'V[/-:US<^G:'KF'N+"
MU#'O3_YTT^FQ11&-WJ9_+1,?GBJFKB.*IGO1U=6K>F?GZ%GZEH6VM4N6L:U%
MRBG,LS9N9$]Z.]1;MS^:?R]Z>>D<\1'/7B)T_1,*OM4T#6^S[!S\"S?B[.MT
M58MS'QXH[OY8JIKB([\U3/Y:>>L1/3QDBFT+<FMY/;9KNW<[(QZM*P].IR,>
MU:M=V>:JK?$U3,S,U1$S'28C]GWTC<>I[TUW6L?0,NWINBZ3?G#KS(LQ=O9-
M^/YHHBK\M--/3K,3,\_)P-!N9$?Q ZWJ=>F:M1IN5I]&'9RJ\"]3;JNTS1S'
M>FGI'Y9_-/3IX^#E[(R-1[+-S;AT?6](U3*T/4,VK-P=0PL:O(IB:O&FN*8F
M8GB*8_7F)^4\BO5V:8VH8G;QOBSJ^=3GY=.%C\Y%-J+7?IXH[O-,=(F(XB>/
MT=.UOG+W%F:I7IV7JFGZ9B9%>+C7,+1+V;5DU4=*KDUQ151%//,13'7IS,QS
MPYFS=1OU=O&Z,^]H^L6,74,3&M6:[F'7Q$Q31'YYB)BCF(F?S3'$>/$]'EV-
MJNJ=EN?JFVM?T+5\S2+F9<R-.U# QJK]-5-<\]VJ*?"?GQX\S/3CB0=?,WKN
MVCL8U37\C ITK7L"NJBJ,S$KHB[1%41[2BW5,33S%4>/,<Q/^'QUK4]_8O9E
MB;LQ]<TVF[8P+69=POP,51>I[E,U35<FKGO<3,_EIICY1^KJ]J>=G:WV3ZQ:
MMZ'JEO+SZ?98F)3CU7;U4=ZF>]731$Q;\)GB9\./G/$?#6[UZ]V!?@;6FZI7
MJ%W2:-/C%C!N^UB]%J*9B:>[S$<Q/YO#]P>G?^YM6N]B=6Y=$R+6GY-_3[65
M5WK<W*J:;E,<TT3S'=JCO=*IB?#P^<=?LQQ=P6]!TO(UK6L;/Q+N!9FU:HPY
MM5T3--,Q-5<UU=[IS'A',]4QEX&=K'\.56DXNGYM&J6-)LXM6+?QZ[5R;ENF
MCO1335$35X3Q,<Q+O]G.XKNI[)P\;!TS/LZGA:=1;JMYV+<L6_;T413%'?JC
MKS,?W>>(\>/ 1>",[+-T:IN;2-0^(=.M8&K:=G7,'(MV9YMS53%,\TSS/^UQ
MXSX?NLP
M
M
M
M 'SR;7M\>[:]I<M=^F:>_;GBJGF/&)^4OH \.C:5AZ-@TXFG6?968JJKGFJ:
MJJZZIYJJJJGF:JIGK,S/,O<
M
M
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MVMB]35SQ51<XCGP\./\ ]XBP
M
M
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ML8U$7+F)',54TS$3_2>DQ/$>'(.R
M
M
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MS7MJSG]I>'N6[AX^)3IUF[9MW:)B;N9573%/-?$=*:8YB(F9GF?E$=;,
M
M
M
M                           !-:MOS:NCZA=P=4U_3L3,M<>TLW;T4U4\
MQ$QS'])B04HC_P#2?LCS3I/_ %BD_P!)^R/-.D_]8I!8#\VZZ;MNFY;JBJBJ
M(JIF/"8GYOT                           //G9N+I^/-_/R;.-8B>)N7
MJXHIC_&7H !R*-SZ#7JGNRC6M-JU'O=W\-&31-SG].[SSS^P.N#SYN;BX%J+
MN=DV<>W-4415=KBB)JGI$<S\Y!Z
M
M
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M5SCK%/>F>*8YXCCY1UZ@I0
M
M
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MB(BFF(_2F':MX]BW?NWK=FW1>N\>TN4TQ%5?$<1S/SX@'U
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MBY-,=ZF)Z\Q$\O6
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MHCK5Q'AS/7A]@
M
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M//\ N7['I@O!!_ FL>?]R_8],^!-8\_[E^QZ8+P0?P)K'G_<OV/3/@36//\
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M\39C\EGK$<S^OCS/AQ'57
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
;                                #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g111069g99a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g111069g99a08.jpg
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M$?_:  P# 0 "$0,1 #\ ]4@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MO,FG)U7KT(7Z)5]FH\XK;.KU]5N%,K^3R22-45%_-5Z?D]Q+?3'_ /=.,?\
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M(Y[$7Z#TZ/;]SD5 M1#C_G%5A&&1SVF=L-VJZAL5.YS$?RHGM/=RKT7HFO\
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M'4CG+#*K/Y6F<Y-.32]6*J=/B!)  $
M
M
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MQ7<JHBHB*GM.\T+-RSBOD+K/418U@&4QW"1BMCFJZ%R-B5?YVF\W,J>[I_Z
M7)%(R5JNB>UZ(JM56KO2IT5"J/2B_O2UO_F8/]\D/!2QU-@X;6BFN+9&U\S7
M550DJ*CT?(Y7Z=OKM$5$7?FA _2&O%?D&.U6,V/&<BJJEM4Q9*AM _P%:S:[
M:Y/I;779-=PC1^AM_P!&RO\ RZ;_ &2'I \O>CS4WC 9[Q!?L2R7PJ]85CE@
MMTCT8K>9%YDTG3VNZ;['J$+0\2>DG_?DOO\ DT__  &'LN_W5EEM4U=)25M6
MV+2>#10+-*[:HG1J=5[_ )#QUQ7LV3YEGUVOE!B.0Q4E2L:1-EH)$?RLC:S:
MHB+WY=]_,$>RK/\ ^Z:'_P !G^ZAQENE#'=H;7)51-N$\3IHX%7VGL:J(JHG
MPV1SAODS[[:H:>ILMYM5524\394N%(Z)KG:TO(Y?I=47X]B$<?K-DL=YQG*\
M-I9JJNM+I&RQPMYW*Q=*GLIU<U?;143WA#BAP'LN1QU-?CC66J\+M_(Q-03.
M]RM_FJOO;]Z*>?\ @_>[GAG%*W4Z^)"LM8VWUM,J]'(Y_(J*GO:O5/BAZ*M_
M'&WOMB.N&.9#!=VMTZB91.?S/]S7=.GVZ7X$#X7<-+[D?$>7-LLM[[72>N.K
MXZ65.62217*YJ<J]4:U=+M=;UVZJJ%>F0 $
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MPL945/)XSVII9.65$:J^]43I]FO<77Q9CRN3#YFX&Y&WCQ6>;$<L?7F1JO\
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MJ\_=OTMHG4L>'Q/!C\;E\7E3GY>V_/7P Y@
M
M
M
M                                                       !A7NV
M4UZL];;*]GB4M7$Z&1O^*Y-=/B9H \S>CY<JG!^)%\P*\OTV:1RP*O1%E8FT
M5/@^/2_<TC?')+7CO'.&ZTM/ZU!%+355P@Y?8\7?,K%\MN:Q':7S529^E'CU
M1:[C9<[LVXJJEE9#.]J=G-7FB>OY%:O^BAOTX<5&1<&;DVZL1^3WARWE[U32
MMJ%3<<:>Y$;[&O+F4*D/%V]NK\.MUHQ^='UF52,I*61OE"].:23_ "49W_RB
M;4%I2SXU#:K&L=/ZK3)!3.D9S-:J-TUSD14WUZKU3?4HGT7Z*XWMS;O>G.?2
MV&!ULMK7I]!SW<\B_:B*UOV+KR/0U1/#30/FJ98X86)MTDCD:UJ>]57L$47Z
M.^89%E6793^$ER?4K31QL9$U$;%&O.Y%Y6IT\N_<T<'_ &R'_?\ _F!C>BK7
MTC<URUCZF)KZEK70HYZ(LB)(Y5Y??W0ZX+K0?\KI];Z[3^I\ZQ^/XB<G-ZGR
M:YNWTNGVA6=Z4']\+"/M3_C-+$](7(<@Q?"6W/&ZV&D5)DAG<Z)'OT[HBL5>
MB:5.NT7OY:ZUCZ3UPI%XB8BC:F%RTR(Z;E>B^&GBHOM>[HBDW]*&Y44G"I61
MU=.]]350K"C)$7Q$1555;UZIT[@;?&<FO5'P/M%XI:*LO][EIV\D?M2/DD<Y
M4YGKWY4[K]FNA"^)E5G^+X-;LLJ<IJ(+HZ6-*FVM@B2"+G151C4TN^72(NU7
M?O,VVYK/BWHV6JZV%*>JK:>*.G=M>=L#G/5%5Z(OE[E\U0K/B'=J'(.$ELN]
MQR>HNV45-4U9:1U0B,IF^WS(D#=-:GT?:5.N^B]0/0M9D=XKN#*9+:GTU+=G
M6M*]?%C5[$5&<[T1-^>EUO?EO96?!JLS[B!BMWG7+_D]OKBM]86F2:97<C?8
M:BJC8V)T7V4WM5[><HM62V*3T>I((+K1.F@QQ898DF;SLD6!6\JMWM%5R*B)
MYFF]$6MIF8->8'U$+9HZ]TSV.>B*UGAQIS*GNZ+U^ &HX3Y=Q O>37O#*F]4
MJ5-$LOB7&>G262'PW\CD8G1';<J:YNW7[#(MV49CA7&RWXM?[\Z^6ZX.8B.D
MB:Q=2;1KD1/HJCD[;TJ?V:K@5<:-?2 S*1*J'PZMU9ZN[G34NZEJIR^_:=>A
M\XJ7.B3TF,9G6K@\&F=2,FDYTY8W)([:.7RUM-[[ >GR-\2_[W64_P":ZG_A
M.)'&]LC&OC<U[')MKFKM%3WH1+BU<*2@X<Y)ZY4PPK+;JB.-'O1JO<L;D1K4
M7NJJJ)]X11/HT3YA%CEW3%:*RU%,M6BRNKYI&.1_(G1.5%Z:T6?@M3E]7EN<
MPWYU%1W=E+2)1MB5TM-&BI+RN1%5%5%=W[+T(5Z(5UH8;%>Z">KIXJM]6Q[(
MGR(UST5B)T1>_5/(]"54]/1PRU55)%!$QNWRR.1J(B>]5"O+W#?)>)^>)E++
M1?Z9E7&V%5=4)RI'U>G)"B(K6;Z[<J;Z)U\RRY*WB/0VW&,;C@]9O%2WFN=]
M\)'PTL:R*B:WIKI$;[_<G1=[*]]$6X4D%YRF":IACEJ$@6%KWHU9-.DWRHO?
MZ2?E)=QZXB7G&LGL5AMU4EJH*Y&255R2-'O8Q9%:[DWM$Y43:]-]4[>8:ZXY
M%E."\;+%C]3D-3>[3=O!YF5<;.9OB/<SHK432HK=]-)KIHW'I,Y3DN*V2W3X
M_<HZ.EJY'4\W)%N;FTJHK7KV32+V1%^/NJ[*:C';9QZQ:JH+VZX6Z)U-)57"
MHK%J-R>(Y55TBKI$1.3:)I$]R=28>EA>;9<L-L/R=<*2KYZUSV^!,U^VHQS5
M5-+VWTV!F99#Q$I^&%+E,>8)3R4U%#.ZAIZ=$16*UO5TKE5SWZ7:[Z*N]?&;
M\*\]?>>$[<ER)[6R4;)?6Y6-1$?X>_:1$\U371/,U>:W2@?Z.<LC*RG5DMHA
MB8J2)[3^1J<J?'?D1'@]0IDOH[7NP6^>);E(M0C84>G-S>RYJ*GDBKI-_$"2
M8'7Y1Q3HZR^2WNIQVR+,Z&BI;>QGBOY>[WR.:JKUZ:36U1>WGNK729W8,-RE
MMTO5+7UU*KY;963Q([FB:SF7G:FNJZ5.JKI?>FBL_1^XH6C%;%/BV7R/MD])
M.]8I)8W<O5=N8[2;:Y';[].OP+7JL]L]_P 4R>JMTCEM-+1R,2X2IX<4TJL?
MMC.;2N5-)UUK;M(!&?1FR>\Y79K_ %V07":MJ$K&M:K](UB<B=&M3HU/L0CN
M#9E=.)5[OL-1F-1CE?')RVNWP-C:U4Z]7<R*LB]$VFT7OY=NCT4;G'18;E21
M.CEKHI/6&4ROTYZ)'TZ=]*J:V:;B18<-RS IN(&/5L-KO&FRU5&V5-.F54YF
M\O='[5514Z+WUUV!Z.POY8_!:W)D_+\LMBY:E6\NG/153F]GIU1$7I[R$^DK
M+-%P@O'@*J(]\#)%3^BLK?\ UTGWF]X-5ETK^&5@J;\LBW"2!>9TOTGM1RHQ
MR_%6(U=^>]F]RRQ4V38W<;-7;2GK(5B5R)U:ODY/BBZ7[@BJ?1(2+YMJU8]>
M(MRD\3[?#CU_86O?\CL^/1PR7RY4M R95;&ZHD1B.5.Z)L\X\,+K<."F6U]A
MS:"6&RW!Z+%7,8KHD>WHCT5.[53HJ=TTFT[GHIU]Q^OM4E0ZYVRHMSF*KWK.
MQT:MUY]=!6#0\0,2KZV"CH<BME153O2..**H:YSW+V1$0BWC9IF.37BC8^NQ
M3'J+FB@J6P,6>L>BZYD5Z+IG3?1$Z:Z^ZH_1(EI$SN^LW&DKZ-5@1>ZM21-Z
M_L)!2<09\JXGWRQ9;?WXY8*%9HXJ>&9*5T[F/Y=/F^EU3:Z14WY ;[T>\TO]
MXOF2X]DE;\HOM;_Y*I<U&NZ/5CD77=%TBIOKW(S'_P!LG\O_ .8*:WT9[U9+
M1FF6-J[A3T<4^FTJU,J,\1J2.Z(KEZKU;T[G;'=:#_E=^N^NT_J?.L?C^(G)
MS>I*S7-V^ET^T#;\9<ESC <KMB)E-4_';@_?B>ITRR0HCDYV(OA]51JHJ*O_
M *$_XFUU\C9BE#B.0ST]TN<Z0,=X$,K)8D;S23O1S%^BB(OLZ3VNQF<<L33+
M^'=PIH&<]=2IZW2Z[J]B+MJ?Y3>9/M5"&>C5#<;[:H,@OB\[;=2_)%MVG:-K
MN9[_ +5]AF_<Q0-1Z0^29CA5OLM%0Y'))35L<C9:E(61U+WM5%55<U$1J:>U
M$Y414UU52Q^-MZON.<.*J[XY5PT]12K'XKY8O$<K'.1GL[Z([;D7JB^95/IB
MU=/))C-+'-&ZHB]8=)&UR*YB+X>E5/+>ET6!Z0%WM\W!.Z.AK:>1*QD"4ZLD
M1?%U,Q5Y>O72(O8"+X)3\0\PX54]SILQ]2E_EWP(D'B2U*I(_P#NDKEVWKMJ
M(U-(B)W[&^]&K.[MF5@ND%_F]9K+=+&B5"M1KGL>BZ1VNBJBM7K\4.[T?+I0
MP<$*%\U93L;2)4>L*Z1$\+<KU3F]VT5%ZD%]#FKIXUR>FDGB942K3NCC<Y$<
M]$27:HGGK: >E@ $
M
M
M
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M'MVFETJ)M.BJAM3XUR.3;514WKH!] /B.155$5%5.Z>X#Z
M
M
M
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MDVJ=U:O1>V^IG6:>[XOQJI\:DOEPNUHN=N=5M;<)$DDAD:KOHNTG3V5Z?'X
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MYO>O1>OQ+,
M
M
M
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MB<_5R[1.ND\]^1\X.VJ_6!^5)>['44R7"XS7.!S9X7HY'ZU&O*_H_I]GQ0M
M 5?PCM%]LV0Y=->;)/1T]XN#ZZ"59X7HQJJOLO1KU5'=4[(J=^I:
M
M
M
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MR*ON7X 7P
M
M
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]*6V4ENXGJZB@9"M71LJ9N1-<\BO>BN^U>5#UIB/_52R_P#DH?\ <0#;
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M:V6I>V.L\>*.5RKR4ZO7^3;OLG*JIT/=-/-'401S0O1\4C4>QR=G(J;10.8
M            :3)LKL6,0>+?[K24**G,ULK_ &WI_BL3VG?<ANSSUZ8-NI/D
M&QW/P&>OI4K3>-_.6/E<[E7X;3?WK[P+HPK*K;F-E^5;*LSJ-97Q-=*SD5RM
M72JB>XWI4OHMIKA-2:\ZJ?\ WBV@            &%076@N%56TU%5PSST3T
MBJ61NVL3E3:([W+H#-
M
M
M
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M]_/OXYI$_A)DOBZ5GJVT^WF;R_VZ*.]#V*H7+K[*SF]5;0M;)[N=9&\O]B/
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M&1MVG,E5$JI\.1?V*#%_TGC^J0^MK&M3R-\58]\O-KKK?EL[0 @
M
M
M
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M18FRN1$YE=S<ZHFMZ14(A'P"OT>5IDC<LHUNJ5GKW.M"O*LG/S[US=M^1Z'
M%/\ %/A=D'$);;'7Y#04]-1QHJ,CHG;=*K6I([?/V5472>2+Y]S,Q' <JQG
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M33K#&V/Q9G<SWZ37,Y?-5[JIW
M
M
M                                                      K#C%E5
M?35UDP_&YU@OE^E1BU#?I4L&].D3XZYM+_BN\] 6<Q[7HJL<CD151=+O2IW0
M^D*R.[V7A5@'CI$OJM*U(H(4=[=1*[:]5\W.7;E=]JE;\-H<IXM,J+_D]\KK
M;CZ2K'36^V2K3I+KOMR>TK4[=5557?;0%^@J/,^$RQV6HJL)O5]MMX@8LD34
MN,SV3*G7E7F<JHJ]D5%[EA81+638=8Y+JV=MP=10^L).BI(DG(G-S(O7>][
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M8XG/1'O1.^D[KH[CRCPB@=3^DK<J9]34U*4LE;"R2IE6216MYFIMR]571ZN
M      #E1K5<Y41$3:JOD8MJN-'=J"*MMM3%54DN^26)VVNTJHNE^U% R@
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MQOU%4O\ I55-OV7N_P 9$5NU\T<GGM0+1
M
M
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M5575^%4.IY.54?S(Q>VT1=IW]X'K4\W^F5_T?$O\JJ_V1'I \O\ I676GO\
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M3/JT]82LEIHF\TD4N]N5&IU<QW7:)UZKY CTJ"L[#QJQ*MM[9+O6/LU>QO\
M+T=9$]KV.\T1=>TGNUU^"&LM&>5N8<1J6>SPW&EPRT4T]14UDD+XXZM_+RHG
M;JB;VB=^BKKH$5#B=/=JKTCL@@L%;!05LE77-]9FA\5(F\SMJC-HBN]V^A*,
M9S',L8XY1XCD%\=>J2:=L+U>Q&II[$<U[?-JIM-IV[_!31<,Z^*'TB:Z[2QU
M++=75=4V"=T#T:[Q'+R>73>T[^\XY1<H?^4K'?6LJ76F"L@22I;3O5J(R-K'
M+VVJ(J+^0*NK+KKF%TSRFQG':6JM=G:Q)*V^> CNBM5>2)7)R[[)V5=KY:ZP
M/AUF&2VWCE687=;W+>K<KY8VRSHWF:K8UD:Y%3STG*J=NIK.-V4W:+BA:Z*[
MSW*+")? D2.B5\:54;D17[5NE<NU5.7?1$36E4BV.5]OP[C]'<I+1<;?97OD
M]4A6DD23PWQJUCD8J<R[5?MZ@2WC5F&94/%>W8[;[TVDH9IJ:2G; SD^D_2)
M*J+MR<R+M-HBIY'#BW=.(_#6ZV^ZNRQ;K053U:C74K(XT<G56.C3::5.RHN^
MB]C0^D#=(J7C5C]UFBF;#%34=4Z-S.61&I(YRHK5[.TG;WDFXW7^'BG#8\=P
M&.:[R^/ZS/-'$YL</LJUJ.<Y$1/I*J[[:3S S>.F1W2\<';-D5INDM!07%(X
MZFAC8FY%>CE<BR=](K5379?,VG V"Y63AI;LCN62S/Q^FHZB=;8E)&B,1KGJ
MJ^)])>RKKWKHZ.-F)5%IX VZS4$;ZI;4^!TSHVJNT1'(]^O=S.W\$,+@[?:/
M+>$:X+#37!EP6DJ:62H2!5@BYN=S7N?V1/:1-=]^6NH&BM?$NY9C'>[E<,EN
M]B;"JMMM!:J!TK5<B;3Q)$8[F\D5%5/?T0E>)9_F-QX-9#=*R-E-?;.BN;4U
M5*K6SQHWF5>7HG/K:>[MM" <*<[KN#]9<L=R^RUZ4TLWBM\)B<[9-(U5;M41
M[51&]47R\]EK9EF4MXX49-6W&UU-IHZ^G?2VN*I8OK%2YS%ZN8F^5%7MU[(J
M^X"L\$N?%?.<6N-98,@8Z1EP1)?$<C)5VQO1JJG*UB=%Y41-[7N>HK:RICMU
M*ROD9+6-B8DSV)IKGZ3F5$]RKLH'T2KC3T5HNEGK%D@N,]5X\44D;DYV)&B*
MJ+K732GH8#79)_U=NO\ Y67_ '%//'H:_P#2,M_R*7_;*7CQ#R&W6''*WY1E
M>V2IIYF01LB>]TCN1>B<J+[T[GG_ -%BZTV-W.^4]\;44;Z]*=E.LE._E>YK
MGHJ;1-(OMIW!BZ.,F$W/.+'0T-HNL=NDIJI*I7N1WM.:U4;I6]4TKM__ *"C
MLCGXL\)E@K*Z]27*UJ]&>(^5:F)5\FN1Z<S=Z\M?!3U<][(VJZ1S6M3JJN72
M(4EQ\RRAR"P285B^KW?+A)&CHJ/^52!K7HY5<Y.B+MJ)\$5577F(P^)_$-<@
M]'A+S0L6FENDK**=B+OPUYE\1J+[E1BI]CC4<);3E<'!)*[ Z^CI*Z6HGJ)F
M2TZ223JU4:UC7+M$Z,7HK5ZKW0EE3PFJ/F&;B3)(WWB/_GB.W["U',KE:B^[
M2JS?WD6X$Y[18+C]QQK-VU-JK*.=\T#)H'[D:Y$VQ$1._,BJGOYN@$C]'SBQ
M<,VJ*VS9"V);G3Q>/'/$SD\5B*C7(YJ=$<BJG;NB]NG6L\B_[6$7^=:7_<C)
M7Z.F*5EINE^SB^TLMLM[X94IXYF*CO#5R/<_EUO2(U$3IUVNBO,HOC/GX=E=
M)25L]HBN$$_B)3O:KXV(Q'*B*B?T5UO0'M \9<7$6/TBJCY,Z3^OTCF<G^$Y
M8U_+L]!W+C%8/4'.QZ"YWRX.;_)4E+0S(Y7>2.56HB)[^_V*07A)PLO=;FLN
M<9[$D%6Z=U5!1KU=XBKM'.3^:C?)O?HF]:ZB/0@*,X\Y7GN&7RBO%FD@3%V<
MD;V<C'<\BJJJV3:<R(J)T5%1/O+MH:A*NBIZE&JQ)HVR(U>Z;3>@B"\9N',/
M$/'XJ=D[::YT;G24DSDVW:I[3'>?*NDZIV5$7KV7S?;,BS[@K>&6ZOCD2A5R
MN2DG7Q*>9N^JQN3Z*_9[^J>1>O$#,+E@G$VBN%=#75&(UU"V"H=$USV4TS7N
M7G1.R+I4WYJGOT17CMEEASW%J.QXCXE]O,M2R6%M+ ]RPM1%15553IM%UK[U
M[!8D/$/C-!:^&=IOV/QM=77G;:9DR;2%6])%<GFK5Z?%51>Q7]WSK(K1;[-<
M[!D]]OEXD<CKA0U-L<RF1%3:HU/#32(O3HO7NFCLXB<)+U1\'<8AI8G5ERM"
MS25=/#[:ZF<CG<J)]+E5$3IWZJ23 ^.ZUMHI+1+C=VK<FCC2%(J9C5CF>B:1
MSE545B>:]%1.H&9Q,XJ7:.[X]B^)1,I+W=V0/FFJ&<RTOBZY6<J].9-[7:=$
M\O=()L0S>TWNR5=HS&MNE+ZS&VY4U>V-&NBW[;F:;TZ;]GOU3J55QXQS)K-F
MMISNEH_%>V.GFJ5IT61E/41(FT7SY%TFE7XEEXCQFBS!:2CQ['+I-<Y'L2H2
M1$;3T[=ISO=*BKT1-ZZ;5=)H"H,ECR*N](NDL]5DT[ZVFJ6,IJWU=NH$=&C_
M &8M\OGKX]U+/XT7C,,"X=6^>BR)M95NJG05-9+1L9*]'HYS.1$]END:J+T5
M5VB[316_$ZJEQ'TDHK_<:2H6@6>"=KF,WXD?A-8Y6^]45%Z? EOI$Y-29-PX
MM\%MI;BVIGK63Q0S4CV/?$UKT\36NC=KI-Z5?=KJ!)++GTV,^C];,FNLDMQN
M,D2M9X[U5TTKI'HU'+WTB)O[&D<Q9^=9EPXN68KEM927!/&DHJ*FBC; K8][
M:Y.557:HY$Z]-)O9CTEAESGT;J*RVA'NO-I<DKJ:1BQJKT=)[/M(B;5CE5/C
MHQ^%7$2W8IPMN6.Y"RHH[W0^.V"CE@>CY^?:M1$UWYE5%W]H$SX!\3:_/+/<
MJ&Z>"R^4+$<V=&:9*UVT1RM1>Z*G5$TB[36BO>'.5\0<UXDW6U+DT5%+!2S-
M<[U9'Q1(V1C56.+:(KMZ1%=O2*IO/1IQ.LQ"TWK*LGBDM\$T+61,E8J/2-%Y
MG/5NMHBKRZ36^B_ B_H]U24?&6[5=;%44\%PAJ(Z=\D#T1[WS,>U.W3:-7N!
M(>%N:9=;N-%1A>2W9UV@5\T2R2-3V7,8KVO:NMIM&]NW7X'HX\E6B\4T/I*2
M9'(VH;97U4VJKU>3EY70N8COH[TJJAZU3J@&FS;_ *FW_P#S?4?\-Q1'H:_]
M'RW_ "Z7_9*7%Q1O]OLV)7.&OE>V>LHYXJ>-D3I'2.Y%32<J+KJY._O*-]%6
M[TV/5-\HKVVHHY[@^F;3>)3OU(Y%>BIM$TB[<WO[P8Q_3#EE7)L?A55\%M&]
M[4\N97Z7^QK2SN-T4:>CY6M1$Y&4U'R?#4L2(8?I,X%6Y7CE'<K- ZHN-L<]
M5@8FW2Q.US<J>:HK45$^WS(1F^=1Y;P?LN*6:"JJLFJ? IZJB9 _GC\+6U7I
MYN:U4^"KVT!,/1'EEDX;US)%561W.1L>_)%CC5?[54DOI%S2P\'K^L*JBN2%
MCM?T5F8B_P!AIJ2@NO"/@/*MLI65=[@:D\Z(U7M;(]Z<SE1.Z,;I/]'?8</+
ME=.+?"*\4V3P,@FJ724L50R-6MDTB*V1&_XKO=T]D#!]$1K4X<7)R?26ZR(O
MW11:*PX)U3K=QVN[H-K U*[G1/-C5<Y/[6M)+P:R9G"BCR;'\VAGH:J.3UJE
M:L;G)4NY>56L5$TN^5FE[=5]QL_1HP.X0U=URS(J5\#Z^-T-/%*U6N<U[N9[
MU1>J(ND1/>F_+6PA/H\1W').(61W>"J@CO2T<L\5141+*UDLDK45W*BIOV5<
MG?S^XE=IXJYCB/$Y,8SV:FKZ9\[(5GCA;&K$?KDD:K43;>J;14WW\T-#AU'5
M\$^+<ZW^"=N.U;'TK*]L:NC6-7(YCMHG=%:B*G=-KWZ;VF1VE>+/&ZWW#'89
M9<>H8X&U5Q6)S(G\CG/<C55$VJ[1J?9OMU D_$+/LYM'&"WV6SV]7V9[X6MC
M2FY_6FNUSNY];36U3HJ(FMJ7H4+Q=S//<(S^BKFK"_$)YHX8H6L8Y).B<[7+
MKG1_TE1=ZZ)WZE]!'FSTAL*R&'.Z#,\<HIZ]D:0N>V!BR/AEB7;55J=5:J(G
M5/<N_(ZO2%RV/)^%=EFEM5QM=5)<6KX%="L;O9B?S*S?TF[<B;^)Z*O=XMUC
MM\E=>*V"CI(TVZ29Z-3[$]Z_!.IY_KK)<^.><4MSGIZB@P:W>Q!),U6/JDWM
MRL3_ !M(F^R(B>?0*W&,X-=,I]'''[%35[+?/*_UISY6JJ.C6621J=.J=V.W
M\"$9-1<6^%M,ES?D$UQM4;D:^3QG5,;-KI$>R1-M1>VT]_<]4010TE-'#"UD
M,$3$8QJ=&M:B:1$^&BIN.6;6N7%Z[%K*]MXO]T;ZM'1T?\LYFUZN=R[UI.R=
M]Z\NH$=S#/7YQZ-MXNS(4IZQLD5)5QQJO*UR2QJJM\]*CFK]^NIL_1&:U.&U
M>Y-<RW.3?^KB-A@7"R2@X+7#%KL]K*^ZM?/-KVDAE<C>1/CR\C%7XHI ^#>4
MLX56[)L?S6">AK(95JJ6-T;E2I=R\JM8J)I=\K=+VZ_ #0>C\]T''JXQ4ZJD
M+TK(W:_HH[:?VHAZX7MT[GGWT8<%N5!57'+;]324T]8Q8J:*5JM>K7.1SY%1
M>J(JHB)]_EK?H(#QIZ/[_'X[4\MP7=2]]4_V^_B*Q^_O^D>RSS/Q1X:7_%<]
M9F^"TKZV%*CUN2FA:KGQ2;V].5.KF.Z]NJ;5.W4LZR<:L/K;>DMSKGVBM:G\
MM1UD3T?&[S1-)[7W?D0"RCSUDF*LSG,.+U!&Q'5L,=ODHU]TK(7:3[]*W_2)
M':>(%5E'$!EPHH[C0X19Z.:::KEA>R.LD734Z:ZHF]HG?HJZ--PERVWKQ4S>
M>J6JACO55 V@?)32(DR-5[4Z\OL[VWOH#3>C9Q%IK3B5\L]^F\-MHC?70<RZ
M58OY[$^*.ZHG^/\  BO%*TU2<*J+*+NS5WR.\>O3(O=D2Q2>"Q/@C>J?Y1L<
MVX7.J?2"I[93Q.;:;N_Y0D5J:1L>U69N_+VFKK_+:2?TJ[A25EAMV/VQLLUP
MI*MLLD$,#U2*/PG(G5$U_.;TV!:?!=W-PKQ==[_YBQ/R=#SABU7<:+TD[O/9
MK:ESK&U]=RTRSMAYT_E-^V[HFDZEV<$\JM=/PJH8ZV:6GFM%.C:QDD$B+$BO
M<C5UKVM_#926"7F"W\?:K)*Z"L@L\]962).ZFD]ELB/Y%5$3?7:?9L#*K:YW
M&7C+26K)T=8(*5KZ=M(U>>17,55?'S+I$>NG==:3E1-+Y^M*.FBHZ2"EIF)'
M!"QL<;$[-:U-(GY$/-?'_ ;K29-2YWAL$TR/5D\_JS%<^*5NE;*C4ZZ5$3?N
M5%WW+AX6\0J'.+2Q49)2W>&-%JZ22-S>1W95:JII6JO;KOW@3@\J\>?^T'CO
MV47_ !G'J>>5D$,DLKN6.-JN<ON1$VIY&XP7FGO7&6U7JU15=3;*3U5'SLII
M-+R2*YVD5NUTB@CUX>>_3%_]P8Y_YJ7_ '$+UL=XH;[0-K;5/X],KE:C^1S.
MJ=TTY$4\\^E7=Z6^0VFUVA)ZNLHJF7UEL<#U2-=(FE76E7>^V^P2+PX8?WML
M3_S32?\ !88.8LS>X5,]!BSK7:Z/PD7Y2J7++(YR[VUD:)INO>[??HAT<&[_
M &^Z8-9*"EED]=M]NIX:F&2)['1N:Q&K])$WU:O8Y8OQ2Q;([E<Z&CK_  )[
M>J^)ZVB1(]J+I7M55ZHB^_2_ "@,*R^Y\)N(-38\FME!,^>=&UM>U'.J)$>N
MTE215]IO7?*J)]RGK<\PW''Y.+_&M]TMD3UQ:@=%%+7JW3)TCZJUB_SE555.
MG9.ONW+N.?$S*<,RVT6^P6^*2DGB;(KI(72>L/5ZHL;53MI$3MU]I JV<HGO
M<%N9^#5%25=?)*C/^=S+''$U47<CM(JNUI/93JN_@>:N+,&:85E5ORW)G6?(
M$>[PJ=9('+#3.3;N1(]IRKW5'=5Z;WLO;(>)F/XWD%JLM]EFI*ZOB;*BJS<<
M*.543G=OIU14WY:ZZ0KSTCKHS*J6UX9B[4NMYFJFU,D=,J/2!C6N1.=4Z-WS
M;Z]D3KW0$26;B_0IPHI<J;"QE?6;IJ>B>_O4HJMUOI["*G,J^[XE5\5:*WV7
MA C&WRBN6272YQU5UF@J6O=*Y62+RZ:OT&KI$\O/ILNC#N&%DMN#6:QWZWT5
MUFHFOD<^>)'HDLB[?R[\NR?8U"IO2+L^(T%CCM>+66FAOT=8Q9DHZ)R.9%X;
ME7;D;K2\S.F_]@(L[T>[E0S<+L?HH:VFDK(H'K) V5JR,3Q7=5;O:=T_*0^]
MO6V^EE9G0=$N%!J9$_G?R<B=?]6W\ANO1MH\?;A]'+26^&#(X(715TCJ98YM
M.D<J(KE3JBHU.R^2&KLD"Y3Z3MUND*<]#CU,E.LB=O%5BLY?MVZ3\T"]0 $
M
M
M                                             CN>8E09E87VZX*^
M)[7)+3U,?22GE3Z+VK_^&T)$ -;CD=TBL]/%?I*>:X1IR234^T;+I=(_2I[*
MJFE5.J(JKI5-DJ(J*BHBHODH '&.-D:*D;&L1?Z*:.0 'SE3FYM)S=MZ/H
M  ?%:BN151-IV71]  'S2<V])OML^@#YI-JNDVOF?0      #XC6HWE1$1ON
MT?41$1$1-(GD  T-==^8 !4145%1%1?)0B(U$1$1$3R0    .#XHWJBO8URI
MV54WHY@    5$76T1==4V?%:BJBJB;3LON/H \D<<;O;9^/=GJ8JRGEI:-U(
MRID:]'-C5DRJ]'*GFB=T\CU?;JJDK:.*IMTT$]+*G,R6!R.8Y/>BIT4X.ME
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MR58EOUHI*]\72-\T>W-3W(O?7P,JQV&TV&G6"RVVDH(E[MIXFLYOMTG7[S9
M   -?D#;F^T5++$^FCN+TY8I*C?)'M=*]41%VJ)M43S5$3:&KP+$:+#;)ZC1
MO?//*]9JJKE_NE1*OTGN_P#1/+^U9(
M
M
M
M
M
M
M
M
M
M
M
M
M                                            !QE<YL;W,8KW(BJC
M45$5R^[J!R! +3Q)2Y9E5XQ%CEW9=*-J/J4>Z!&1,7ETY7))U33FKTVO4GX
M @UHS2NK>*MUQ.HMD5-345%ZTVH\;G=-MS$:NM(C4TY>G5=H!.0      @O$
M+-*[%[]B]!36R*>GO%;'2.JI)M>$JO1%3D1-JNEVB[T!.@             &
MJR;(;7C%IDN=]JVTE$QS6K(YKG=572(B-157[D.^LN]#1V26[SU#$MT4"U+I
MDZIX:-YN9/?T S@5\E_SBKAM-VM5AM<UHK71N=2/J'-JXH7ZT]7+IF^5=JU-
MZ[=>Y8(    ""\4<UKL.^0_5+9%517*NCHG3R3<J0N<O3V43;MHCO--: G0
M                             8EXN='9[94W&YSMIZ*F8LDLKD54:U//
M2=5^Q ,L&%9+K17NU4URM50VHH:EG/%*U%1')]B]4^Q3-     :;*,GLV+4L
M%3?Z^.B@GE2"-SVN7F>N])T1?<O7LGF!N0._8          1S)\CDM]SMMFM
M<,53>KCSNA9*]6QQ1L3;Y'JB*NDZ(B)U55UTZJG5B%;E<MQN=+EELM\,,/*M
M+6T,JK'4(N]IR.57-5-)W]X$H   $%S;-*['LRQ:RPVR*6EO4_A+5OF^AI4Y
MFHQ$[Z5%15777L3H               P;[=Z&Q6FIN=VJ&TU#3-YY97(JHU-
MZ[)M5ZJB:0[+3<:2[6VFN%NF;/1U,:2Q2M141S5[+UZ_E R@""T^:5TO%J;$
M)K9%!31T"UK:KQN=TJ<S6IIJ(G+U5R*B[[ 3H        !>B=2NY\JRF^6B>
M\8+;+75VZ.5\<+*R5S9:U&.5KG1ZTUJ;143F7KK?3L!8@.B@DFFH:>6K@]7J
M'QM=)#S([PW*G5NTZ+I>FSO            #C*KVQ/=&Q'O1JJUJKKF7R3?D
M0KA3F=7FE!>:FOM\=ODH;C)0I R3Q%3D:U5V[HBKMR]D0";@
M -5DV0VO&+2^Y7VL;243'-8LCFN=U5=(B(U%5?N0V--/'4T\4\#TDAE:CV/;
MV<U4VBI]P'8
M
M                                                  "GL1_[2V=?
MYNIO]R$N$IS$)&+Z3&<HCD5?DZGZ;]S(=EQ@"EYKK\E>D7>I&T597326.-D=
M/21\SWKSM7NJHUJ=.[E1/O5"Z"I[.J?\I6_)M-_(4?3_ .Z, DV'Y]29#?KA
M8I[=<+3>J)B2R4E:UJ*YBZ]IJM545.J?E3N;"X92V.[SVNT6ZKNU?3-:^I93
MJQC(.9-M1[WN:G,J=4:FUUU72$'9I/2>?K6UQSK_ *Y#1\.(;%5YWG-ERR&+
MY>6[2U,/CR*Q9H'?11O5-Z1$77N<@58E/Q#M4^)W>^MIZ[EM+WQ5U&D2+402
M,7VFJU%UT[[1=:VN^BF#BW$ZFR*LLD-'8;VD-SB=(E8M,OJ\2HBJK5D76]:U
MM.FUUU..16O'K1P[S>FQNGHZ?EHJCUMM/Y2>"J^U\=*GY3'P2.IFX 4,5KWZ
MZ^RO;!R]_$6-R)KX\P1MZK/8TH:VY6RS7*Y6>CY_&KJ?PD8Y&;YUC1ST=(C=
M+U1-+I=*I!N,5[H[FG#&\VQSZNCFO4,\7A-VYZ=%TB?TO+7O'!.WX7DO#R@A
MJ*.D?7TL7@5U/+(J.:YJJBN<U5[+WWVZK[E./%9+/0-X8?(RTT-FAOL2Q+"J
M>$UO-U5%[:WOJ%2VMXGTMHO%)1918[O8H:Q_AP5E6V-T#G>2.=&]R-7[?OT9
M]]S^GLV6V_'JFSW5]7<'*VDE8D7A3:3;E1RR)K7FBHB_#JFX_P"DE'#5<,:B
MB\/QJ^JJH(J&)$V]\RR)T:GOY>8Z.,%DK8.&EHNL"^)>L8=3US7IU5WAHB2)
MOW*GM+_DA$QOF8,M.36^QK9KI5U5<USX'TZ1*Q6MUSJJJ]%:C=IM51._39*"
M$X!,S)JVKS+D>V"LB;2VYLB:<VF:NW.UY*^17+]C6$V $3FS1M145L..V>X7
MSU)ZQ3RTJQLB;(G=B/D>WF<GFC=Z\R1W1L[[95MHUY:I87I$ON?I=?VZ*N]&
MZ^V^?A[36=960W>VR2QU=-(O+(CED<[F5%ZKW[^]%0"84^<4#L8IKS54EPI'
M5,RTT5#-!JI?,CE;X:,WU55:OGK7551-G&GS6-F14%EO5KK;167!KW4:U#HW
MLG5J;<WF8YVG(B]E^Y2O>,EXM;\KP.Z5[V5>+05M32UDC%58V2JUK6JJIWY5
MYEZ?T7(3ZEQ["J:X6NX4]+;5K'OU0SI)SN<[2K_)KM=]$5>@&GN'%F@I;_?;
M/!8[Y65EI8CI(Z>E5[Y-KW:GDW2HO,NM[36SAEG%"2SR8I%38_=))KVZ-WAR
M0HCV,5$5S$3F3<J;3IV3??R,#"51?2!XA]M^JT?_  VGSC-(R'/^%\DKD9&E
MT>U7+T1%7PT0#=YQE=H@X?U5URG&;C+;FRMC?0U=*QSE=OV7.3F5J-WI.95[
MFCX_W=8N"E3ZI13L970P-18FIX=.Q7QKIR]-(J>RFO>;/TC%3YG<@Z^4'_&8
M:KC>J?\ )YJ>O>GHO^)$%;;YQ66+$XZ^OQ7)(:"C@B2258(D1J*B(BHGB;5/
MCKIYF\NF;T]NPB'*)[9<74,C&RNC9X2RLC=]%RIXFE1=MZ-55]I.G?6S=;:>
M\X>EMJTYJ:LH4@D3_%<S2_[2H^%,M9?J"W87=(WK^"M:_P"47.1>65(G_P#-
MF?%%=[7V0I[PBZ;/6ON-N@JY:*IH72IS>KU*-21B>7,C55$]^M_;I3,  KO+
MN(\MCSRTXY36*XUKJEDDLKH8T5SV(Q53PD5R;TO=5[(BZVO:-<>[FE3B6'W"
M>DJZ)OR]3O=!41_RK$;XG=K57KTVB)ONAG9A(R+TB<%=*Y&-?0U3&JO3;N5_
M3[3[Z12I\E8CU3_K#2_['A6ZK^)M-:KQ;J6]V&]6RCN$R04]=4Q,2)SU[(Y$
M>KF;^*(OO1-*2;(,DHK+44='(DM3<JU7-I:*G1%EFY4VY4VJ(B(B;57*B?$@
M/I)JU,*M2NTFKS2JBK_ID@RW):2W9Q9+-16NFJLEKX9%IZBH5(V01)M7;?I7
M=>5?9:G7X!&9AV;TV27*[VQ]OK;;=;4YJ5-)5(WF1')MKFJU51477O\ =[R.
M6/BG/=,HO]OBQ>]2TUNDBA:L,#5D:]>;F61%>G*G1-(F^B+OW&KX7OJ).-?$
M-;C54M16-BI&.=3L5C.C-:1JN<O32(O7O[NQD\))8TXF\48G/1)/7X7\JKUY
M=/Z_8%6T  B+8_FM)>LMO6/145=35MJ:UT[JAK4:Y'?15NG*JHJ:7RZ*<;+F
M])=<UNF,-H*^FK[?%XTKYVL1CFJJ(U6JCE545'(O9/RD/PZ:./TAL\@D>C99
M:.D?&U>BN1L;=JGOUM#ABU3!-Z267)#-'(K;5"Q>5R+I46/:?:FP-[%Q/IZG
M*;W8:&PWFKK;6C>9D<*(LBJJ]N94:UNM*CG.3>^B*9F%\1+=DMZK;+)15]IO
ME(G/)0U\:,>K>GM-5%5%3JGY=]NI&<!>U./7$=BN1'NBHU1N^JHD:;7^U/RB
MX47RKZ1]MJ[:B*VT6IR7"5G9KG^(D<;E_I:<CM>X*F$^:137BNM=@MM9>JN@
MTE6M,Z-D<+E[,5[W-17_  3>O/1DX=F%MRJ&L]12>"LHI/!JZ*I9R34[^O1S
M=K[ETJ*J+I2O?1ID=36O*;1<5Y;W2W>62K8_Z:\R-1'?%%5KNO[3GA$#JGTA
MLYN%OZVV*DAIIWM^BZHU'T^U.5V_=]X1N[/Q5I;U/>:>SX]?*RIMLW@/@9 U
MK]IM%5W,Y&MZHJ:5>9=+T-]@&:T&:4-7-1055)4T4ZT]5253$;+"]/)415^/
MY%(AP/5JY%Q+TJ*OX0S?[5_^R<.#:I\X'%%$U_[T9_\ 4 MH^/<UC7.>J-:U
M-JJKI$0^D8XGPUE1P[R2&VHY:M]!,UC6?27V5VB?%4V!KZSB%!#:9[U366Z5
M>/P;<^X1)&C7,1=+(QCGH]S$]^NJ=4VAPO/$NVVNOLT+[?<IZ6\+&E#71)%Z
MO,KT143F<]%:O7LY$7W;(SPLMV"93P\MLKJ.@E?!2LBK8I9%_DWM:B.YFJO1
M%5%5%[:4W/$:CL-PX<TMAH:>&=MQ:R"S00+K4FMLD8ODUB>TKOZ*+[]*$BBR
MQD^7U6/TUIN4TM*D:SU;$B\"-'IM-N5^]_XNM^>M:4U=]XCT5!1W*MMMKN-Y
MH+9(Z.NJJ)(_#A<U$5R>TY%<K45-\J*B>:FHX(W5U/#=,5O;$ARBV3NDK'.<
MKEK6N7;:A%7J[::3X>SVZ(FBO&4I?^&.93XI1VVT6"DCJ::1\K/Y2=_)[7+&
MWE1G-S)ISE555?H@6/=<TMM!@R96V.JJK8M.RI:E/%S2*QVM+K::UOKM>A&I
M^+5/%C-'D'X-7Z6T2Q,EGJHX6\D'-K?TG(YR(JZYD3E]RJ:M_*WT7?9<BI^#
MZ=47S\/]IG2\J^C2W6M?@PW\OJR!6?=^*5%1V9+S062]W.QHWGDKZ:!&QM;Y
MJB/<USD3S5$U\3>7O(+--@%1?:FG?<K%+2>L/B9#XJR1*FUVQ?@O7?;2[[$3
ML?+_ ,FUO-KE_!R3_@..C&U3_DS;VFOD"?\ X;PB36;*K51<+J?):6US4MGB
MI/'91TL2.='&BKV:FDZ)U7R3KU-,G%J&3$X,BIL9OU5;71K+/+#$WEA:B]>K
MG(KM:ZJU%;WZ]#"L"I_R8WKM-?@[4)_^2>9>$<O_ ">*7FUR_(DN]]O[FX"7
M_AA9$P^+)Y:UL5FDA;,DST5%TO1$UWYM]-)UWT-1#Q!@9E=ML=TLMUMDES:Y
M:&>I;'R3*U-JGLO56KK71>O5-Z(3B>0VC&?1VQZYWV@;<:>-$;'3JQKN:597
M\OTNB:5-[\CCFM1=)N+/#+Y;EML?//421TU*KGK%[#=<TBJG/M>B::WLO<"5
MYAQ&FL6=V?'::Q7&M=5))+*^*)%<]C8U5$B17(CE1VN95Z(B+W7MQXB999*'
M%+9<<GQFLJHZBJ1L%'5TS'+%,BJC5?M5:S:;5%ZJJ&KS.5D7I!8 LCD:CJ2K
M8BKTVJL=I#[Z2SFI@-%M4_\ >M,G]K@J>Y5DUNQFD@FN#I'RU,J04U- WGEJ
M)%[,8WS7\B)YJ:>3/8+?>:"W9):J^RON#N2DGJ'1OAD?_05\;W<KO@OY2'<5
MI'6[C+PYNEQ75F:^6G21WT(YGHJ(JKV3>V?FK[CO])R)*S!*"WT[5DNE7<H6
M44;?IND]KJGW*O7XH$2O.N(-OPZZ6:AKZ.NFDNDR11OAA5S&]41>VU5W5/91
M%5=H8GSETU/E-NLMXL=YM*W)_AT=35QL2.5_]'V7*J*NTZ+UZIO1'^+Z.9F/
M"MLSD=(EUTY?>OL=?RG/CPJ)=^'"]-_A'3?DYD"K:  1'<@RVCM-VI+1#!47
M"]5;5DBHJ5&\_(G=[U<J-8WXJO7RV8UDS>CKLCDQZXT=7:;XV/QF4M7RJD\?
M]*-['*UR=%\]]%Z=%(-8Y'6_TFLA9=%Y'7*V1_)[W]GM:D?,UOWM>NO\53GQ
M/@=7\:N'$%M3FKZ9TU34JSNRG16]7>Y%T]$^*Z\PK7W+))H/2,ED^1;O5MI;
M(ZGCA@A:KW?RVUE:BN3V/+??X%UT,ZU5%!4.@FIW2L:]89D1'LVF^5R(JHBI
MY]2JXU3_ )3LO7_\7/\ ZR%M! K>Z<3):3B,_&J?'KK5L@I'SRN@B:LCUYVH
MUS$5R)R?2VJ]554TGOL@J2&1D?I/3MD<C72X\B,1?YR^*BZ3[D7\@&%QBN;6
M99PLN,]-5Q-]=DE6G6)73-VD?L<C=[=Y:3?4ED/$BGBRJ@L=ZL=WL\UQ56T4
MU6R/PYG)_-VQ[M+VZ?%-ZV:'C"J?.+PMZIUN4O\ LC.7&U6ID_#17:14O\75
M?=M/_L!4^R#(J>T5%)1I!45MRK.;U>CID19'HWZ3E5RHUK4VFW.5$ZHG?H:^
MTYM15-XN%HN=-46FZ4-/ZY)!4JQR.@_PC7,<J*B>?FGN*\R^6UTOI 4K<P8Q
M+97VA(*&:9RMC9*DBJJ;VB)OK^5OO)I66K!L<6OK)*2A@F?0R+4.9M\KJ;HC
MU7JJ\O5.H1V6O/X[@VU5<=CNC+/<YD@IJ]R1\BJY51KG,1_.UKE32*J>:;UL
MV=PRAL=VGM=IMU7=J^F:U]0RG5C&0<R;:CWO<U$<J=4:FUUU72=2L[13WOA7
ME./VBDN7RQAEZJO5::*7K-1N=U3E<G=OG[M;Z(O5<?AQ%8JO/,ZLN60P_+SK
MO+4P^/(K%F@=]!&]4WI$1=>YR!5L8?E-#E-%4S439H9Z2H?2U5-.U&R02M7J
MUR(JI]Z*J&^-#BMJQZT+7TV-4]' J2IZTVGZZDUOVOCI4_*;X(U.1Y!08_2P
MS7&54?42MIZ>%B<TD\KETUC&^:K^1//1I;!G4-RRVIQNNM5PM-VCI_6HXZOP
MU26+>N9KF.<G?R^WW*=?$;);=CU3C[*FV0W"ZUU8E/;DEY6MBD72*]9%1>1.
MJ=415^!#+=)7/])*%MXJ:&2ICL#M,I6N:V/<N^15<JJY=;7>DZ*G1 )1>N)]
M!:\PJ\<^2;Q55U-2+5:IZ97K-U;IL:)U=T55YETB<JIO9K\LXJOM&*6.ZT^/
M71L]VJ&0QP5,/(L:J]45KDYD]I6M<K4\]HJZ,:!6KZ3E1M4VF-IK[?';_P"A
MP](Y[8K+B<LCD;&S(*5SG+V:B(_JH5)K[E- _";Q<<BQNZMMM.W4]'5TK'.E
M;TZHU'*BM3S5536MF?8\BM%/P^M]^DCBM%F]3CG;&ND;!&J)RM1$^U$1$\^B
M&/Q<5/FPRKJG_NZ;_<4JO,YIJ3@)P]KTB?-;Z*:W5%=&Q-\T36]E^'-RI]JH
M$695YW44L=+52XE?TMD\C&)4I'$KFHY41'.B1_.UO7S1%3W$<_\ \G?_ .7/
M_K%A19-99;&V\1W.E=;7-1Z3M>BHN^R>_F\N7OOIK97FT_Y3O?\ _%S_ .L!
M.+AE+8[O/:K3;JN[7"G8U]0RG5C&0([JU'O>Y$1RIU1J;777HG4UD7$FQKB]
MRO4_K-.ENJ%HZJDD8GCQSHY&^%RHJHJJJII477QZ+JON',-BJL^SJRY9#%\N
MNNTM3!X\BL6:!WT$;U3>D1%U[G$MO^,8+/8ZS&(FTU"RZ5C:=SJ1?:;5HQ9&
M;7KIVF]E[[UY@2:S9+-67SY*N%DN%KJ74RU43IW1O9(Q'-:Y$<QRZ<BN;M%]
MY(RJN&UTR6S9O68-E58R[-@H4KJ.XHW4CHN=&<LGQVOGUZ+U7:%J@<99&0Q/
MEF>UD;&JYSW+I&HG=57W$(;Q#CJ;5/>+38+O<K'"KMUL#8T21K55'/C8YZ/>
MU-+UUUTNMF5Q>I:VMX99)3VQ'NJGT;^5K/I.;W<U/>JM14U\3&X.7*@J>$^/
M3T\L3:>GH613*JHB,?&W3^;W=45>OO YY%EM'7<+[E?[ LU?3RT4JPNIF[<U
M>5R;<BZY>5>^^VB/^C_>GR8%C]L2RW2*-E,Y?77Q,2G=[3EZ.YM]=^XC'"*D
MEI^!N;U'(Z.WU;J^:B:Y-?R7@\J*GPVU?R%@\"NO"3&=?U9?]]P5.S!OMWH+
M%:JFY7>I92T-.WFDE?V3R3[55=(B)U55,XBO$Z_VG&L0J;G?Z!+A1Q/9RTRQ
MM?SR*[V?I=$TO7?EH(P6<1*>+)K59[G9;K;?E;?J-34MC\.943>E1KU5J]4Z
M*B+U3:(=F9\0[?BN16>SUE%<)JBYJOA/AA5[.FTTFNKG;TG*B?SDWH@6>5-T
MJ.(_#!UYDML+)JV26*EI7.>L?LLTKI%5.;>T1--1/M-SQ25/G;X7(JI_TBK_
M -Q@5M9.*E!0Y!#:;_9;U9YZEJNI'5$"/2I5%URM2-SEYEVG3XIVVAD4_$BF
M;EE#8;O9+O:)[AS)135D;/#G5/YJ*URZ7MT7WIO6S1<758G$GA=S:W\H3?[&
M?^IQXTZ3->&&];^6D_VL")_?\CI[354E$RGJ*ZZ5:.6"CID:KW-;])ZJY4:U
MJ;3VG*B=43JO0P[%F--<;U<++5T57;[S11)4/I)N5ZR1+V>QS%5')OI[]^17
M&326NG]()(LQ9&EOK[2R&WS3/5L;7H_:MWM$3:\WWJWWH619;#BMGR!S[324
M,%XFIU571KN5T/,W:KU5>7?*!';%Q7I[_1W*:QXY?:Z2BJ'0.@CA:UVD1%YG
M*YR-1=[3E15=T[=228#F-NS6RON%L940K%,ZGGIZAG+)#(W6VN3:^]"$^CFJ
M+9\MUK_K#5?[&&IX<,JI<?XNQ6K?K[KK7I3HSOSJQ>77QV%6"W-VUZUBXU9K
MA?(*1[HI*BF=%'$KV]VL=(]O.J?XJ*GQ(9Z-E5ZQC^75:PS1>)?JF7P7M_E&
M[8Q>54_I)VU[S9>CA=[?7<+;924DD;:F@YX:J'>G1OYW+M4^*+O?V^XQ/1TD
M9);LS=&]KVNR*J<BM7:*BHS2_8!LK'Q8I[]2W*2QXW?JZ6BJ'0.ACA:UR(B)
M[3E<Y&HN]IR[5W3LAWV;BI;[]:'U6/V:]7*KB56U%%% C9*=R+K3W.<C=].B
M(JK\#3^CHJ+;,PU]8:K_ &,.7 /E]9X@(S6OPDJM:]VTT!,\!S*WYK:9JVW1
MU%.^GF=3U%-4LY989&]VN3:^\PJK/(_4JVX6NS7*YVFC5_C5M/X36.1F^=8T
M>]'2(W2]432Z72J03AO'4S-XR16U5]=?=*QL'+W\14>C=??H<$*##,EX>T,%
M11TC[C21K!74\KU1S7(J[<YN^RIUWVZJGDH$RRSB?9;!B%MR-L557V^X*UM.
M^GC]G:_TU7Z/9>G?HJ:.F]\4:.QU=$MVL5\I+35RMA9<IH&MB1SNRN;S<[4_
MRFHO?H17CC%:*;A19HK VF9:6W6G2!(->'KF?OE]Z;V;7TG.7YJ*OFUOUJGU
M^>!ON+.<R8-8HJJGML];4U$K8(E1NXFN5?YZ[1>V](G=?=W)#CMZDO,<[I+1
M<[8L2HB-KHVL5^_-O*YW8KSTD9&Q\/K;*]R)&RZ4KG.\D1.;J6-DE^H,=L57
M>+G*YM#3,1\CF-5ZZ541-(G?:J@1M :_'KU09#9J6ZVB=)Z&I9SQR(BIOKI4
M5%ZHJ*BHJ? V $/XKWFRV+#:FMR:TONMM:]B.IT@25O,J^RKN;HU-Z3:^:I[
MS"XBYVF&8#%>::URS/EA8D$;&IX4+G(G*DBHJ::FTZ)WUKIW3"](_P#O,Y%_
M_#__ )Q&:3CWUX"L5.J(VC7?PVT"R<8OTM[9*LMFNML6-K5W71-8DF]_1Y7.
MWK7]J&\.BAE9+1T[XGM>Q\;7-<U=HJ*G13O UF1WZWX[;EK;K.D4*O;$Q$17
M.DD=T:QC4ZN<ON0T%KSV&HS&/&KE9[E:;C/ ZHIO6O#<V=B;WI6/<B+T5=?
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M3ILFU##)3T5/#-.^HECC:Q\ST1'2*B:5RHG3:]^@1W
M
M
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MW1USDLM$ZX.?XBU*Q_RBN]_-W)"
M
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M5'M6-C51$1')I=]T]Q>X
M
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M\7=%Z'3FM'D%@XB4&=XY::F[4-50MH[A01-U.UN^9'(U>N_H]/>U476]I;X
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MD=I$[].B+Y=;1 $2I<X@="GKUBR.CJ43VH5M4TVE^#XVN8OV[(?P;LMTBO\
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M;\*=O*]OVIM='>
M
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MJJZYM*G3N!M@
M
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M6PP1R(G9S=JJZ4F5MEJ)[?32UM,E+5/C:Z6!)$D\)ZIU;S)T72]-IW,@!
M
M
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MUUTUYF0
M
M
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M=>::V=-OH*[AIE^-4^,W9]SP_(*KP66^5WB+3\R<WB1.\V(G55]W?:KL"\@
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M<W@I+#%SMB^+UWT3\JKUTG0E#51S4<U45%3:*GF!]
M
M
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MEY>3[][^!'^7B?\ X3#/S:G]I/0! N7B?_A,,_-J?VCEXG_X3#/S:G]I/0!
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M7JD@:U&M1K41&HFD1/(^@
M
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M4WT5.R+I?-%+*QVT55J9.VLO=PNRR*BM6L2)%CUOMR,;WWY[[ ;<
M           8%_EN,%FJY+)315-R1B^KQ3/Y&.?Y<R^Y._W%49W4Y!B-9A=Q
M?DM747&ON,%%74+E9ZO(U^^?PV(U%1$5-(O?JFUWW"Y@"J>,MPO]'E&#4UCO
M,E#!<+@E/-$D:*URHK51R]E5-*OL[TO0"U@4MGCLGPO*<8EM>55M=%>JQ+?/
M#<HV21L<[2(]K6(S6MJNDUV3KK9WYNZ_X1E&*7&GR:Y7*CN=SCM]925J1K&J
M/_G,1C6HW6E[?#X@7$85[N,-HLU=<JI=04D#YW_8UJJO^PS2O.-LKZO'+?CE
M.Y4J,@KX:#V>[8N;GD=]B-:J+]H&QX/PU[>']LJKQ/-/7UZ.KI72O5RIXKE>
MUJ;[(C5:FO(F1 .-M37V;A9=:JP5TEMGHV1\KX6IODYD8K45?H]%[IU31I+E
MCF4U&!4EXM>9W5EY@H&5+(>6/U>14C1W(K>7:[][E=U7J!;0(APERF7,L"M=
MYJHVQU4K71S(U--YV.5JJGP76_O(_P"D3=+O9N'KZVQ7.:WS-J(XWK$B;>UR
MZUS=V^2[32@6>"F.+#,GP_&&9;1997U%;22Q>/22QQI22M<Y&JU(T:BHFU3J
MKE77GOJ<N*L>3XUARY?1Y97NN%&L,DU'X<;:1[7O:U6MC1N];<G5SG+KSWU
MN4'1;ZCUN@IJGEY?&B;)KW;3>CO
M
M
M
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MTJ.5/-=(JHND[;718.,7:LN]&L]=9:RT.32)'5N8KG+YZ1KETB?'2K[C<
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MF?20/JHTBJ',:LD:+M&NUU1%\]*=H
M
M
M
M
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M3NAV@
M
M
M
M
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M-3,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJY/BFP-\#66Z_P!JN5SKK=07"GJ*ZA<C:F&-Z*Z)5]Z?<;,
M
M
M
M
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MA5GU$R[]%B_B#YPJSZB9=^BQ?Q )Z"!?.%6?43+OT6+^(/G"K/J)EWZ+%_$
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M]1,N_18OXASAS^LDE8Q<'RQB.<C>9U-%IN_-?Y3L!.@
M
M
M
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M?824 "M\&NEWO/$W,G.NDU1CML>RBIX',8C4G5$632M:BKR*BIU7^<60
M      *WP^YW>\\5LL1+K--CEJ1E+% K&(WUAR(KT14:BKR:5.J_S@+(
MU&77^FQ?'*Z\UT<\M/2,1SF0-YGNVJ(B(GVJ@&W!CVVJ2OMU+5MCEB;41,E2
M.5O*]B.1%TY/)4WU0R     %<372[U_'&*T6^Z3)9;?;DJJ^F1C.7Q7\S6,Y
MN7FZHK7:WY 6."-8W>YZC)<BL=>Y'5%OECFA>B(G/3S(KF=$\VJCV?8U%7JJ
MDE
M
M
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M\$*)J&)?BUO^TG@0
M
M
M
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M')+U>HZJ_31RV^CE22DM\:+X:O3M+*J_3<GDWZ+?BO4DH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB-:FDVOGL"2
M
M
M
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M(!L@
M
M
M
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M32;_ "'<
M
M
M
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M$LD]#3S31^%+)&U[V?T55-JGW =X
M
M
M
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M4MX 5?D4=-Q$NUELUI1S[!:JU:BYO6%T;.:%5;'3IM$YMNVJZZ(U$7S0M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              !\<BJU41=*J=%]
MQ] %/V.\Y;<.*N18G+D4;*:V4\<\<Z4,:O?SHQ=.3MTY_+W$QH*;*Z#+:-E;
M=8[G8YH)?$_YFV)\,J<O+M47JB[=[NQ7=MGNL'I(9JMEH*2ME6@IT>VHJE@1
MK?#AZHJ,?M=^6B?8U<LEJ\TO%+?J."@ABH8'TL<$ZSQ.57RHY_,K6KOHU%32
M=$3WA63A5YO>26JZ+>[+4X]41SR4\"JY'.<S721O,FMHJ^Y477F1KT?KC<[A
MAUWGN]=47*L9=:B-))G[<J-:Q$1-]$3IV3HFS-X,9'>LDI,DDR&>"6HHKM+1
M,2"/DC8UC6IIJ=];55ZJJ]34^CJDJX-?$IW,;-\L5?(KT56H[V=;1%3:;^(1
M-.'U\O&0622KR"Q2V.K;4/C;32.5RN8FM/ZHGO5/NWYDF*YX+Y)>\JQ&ZUMW
MGIWW%EPGIXE;%J*/E:WE1$3JK=JJ]5WU[F@X:7K/,YQ>Y5?RW;+=-%72P1RM
MH?%5>5&^RB*Y$:U%7NO,Y=_#J%R@K7AOGE;<N'E[O&2Q1K6V.>IIZI:=-)*L
M+$<JHGDJHNOM0T\639A6<+IL[@N5%%(D3ZQEK6E1T"0M<J<JOWSJ[E15VBHF
M^F@+B!&>'ETO5[QRDNM]BM\/KL$51!'2<^VL>U':?S>?5.Q)@(/G%ZJ'97C>
M)T%1)3275TLU540KJ2.GB;M4:O\ -5RZ3F3JB(NNNE,W&,.7'K_6UM+?+M4T
M%3$C4H*RI=.R)^]\[7/57=NFOBOPU7>94M\E](>PMH;I1T\K[9,M,Y]&LC8F
M>WM')SIS*O7KM/+I[Y-?\ON%NOE!BZ5:R7)*5:NX7&FMDL_ALYN5K60LYM.=
M[W*J(B>:JB 62"L<;S2YTUZOL%[BN%3C]#0K71W:IMDE&[V=<\3FN:U'+KJB
MHB=E-/)G.0W#&7WRWRW""NDC6HH[5%89YHGM[L8^;D]I7)KVFN:U-]-IU4+F
M!7UWOV:U-LQ&MQVP0HM<YCKK!5KROI6JC=II514[OZZ5>B=.I8(   :[(8JV
M6TS_ "97^HU3&J]LWA-E3HB]%:OE_:0#@%GE=FN/5WRZ]BWBDF3G:V-&;B>U
M'1N1/<OM?D)_DDWJ^.W295TD=+*_\C%4HRH:O#J]8#E\:<EHN5MI;3=M)T:J
M1-Y)%^Q$3[F+[P/0,TL<$,DLSVLBC:KGO<ND:B=555*CX0YE?<]R3(ZB2X)3
M6:WU+$IJ5*5J/DC>KE;SN7JGLM3MUZ]R6<0'NO$MOQ2E>N[JJR5KF+UCHF*G
MB=?+G56QI_EK[B*<&&,AXC<48(VM:QEPAY6M32(FI=(B 3:VWZ\U.>72SU-@
MFI[-30-D@NBO]F=Z\NVHFM>:^?3EZ]R4%<V/)+W4<;;YCM=/3K:J2W)4T\4,
M7*JJY\>E>J[57(BJG32=>QKFY#F%=QCO6,4==;:>WTU E1$]U,KUC1RLTY4Y
MD5S^JI])&^>O("UR+TE^O,N?UMEEL$T5EAIFRQ757^Q*]>7;$36O-4[[]GXD
M:PK(<CIN)EVP_)ZRFN21T3:^EK(H$A<K%<C5:YJ+KNO]GQZ=]!DM[DXY5V-U
M4]/\CQ6OUR&.*+3E57L1%>Y=JJI[7;2=>P%C JBJR++ZKC17XO;ZVVP6^.V>
MMQN?3*]8T5[$YU3F17/155$3:-T[:HNM'1:\@S>EXBUF%5E?:ZV62D2O@N;Z
M56+%%OE5%B:J(Y=]$3F3W[7L!;P*PQG(<DMG%2;$,FKJ6Z05%!Z_25<5.D#V
MHCM*US454\G?D3WF9:<CO3^-=TQJLJ*>2TPVOUZ!K(>5Z.61C41SMKO2*[W=
M^P%A@KJ'([Y%QN=C-54TTEHDMCJ^)K(.5[?;Y4:YVUWK2]4UW[&!=\BRY_&=
M,8MM7;8;<^V+6,=)3JY6(KD;S.3>W.145$1%:FG==ZZA:@*@I<AS>V\27896
M5]KN+JRD]=IKC)2K%X#$5R*BQ-7VUVW2)S)Y+OR,^QY!DUGXK18GD=?2W:DK
MZ)U92U45,D#XU:J[:K4545/97W^77N!: !CW%E5)0S,M\\4%6YNHY98UD:Q?
M>K45-_E0"NL<YN)?R]75M?<*:T05LE!00T-4^G]F/2+,YS%17.<Y5TB[1$1.
MG<D.(X[>;-BE9:KID=3<*E7RI35[FHLT4:IIFU=OF<G?:[[Z[(5?Z/E!E-3P
M\22T7ZWT=,M7-J.>W+,[FWU7F21O=?+1.>"F27?*,4N-9D$T,M7#<)J9%AC1
MC4:Q&]D^U5[A6#P#NUSN/"]]QN-147.X+45#D663;Y%:O1NU[=M)Y(2_ +S=
M;]CD==?[+)9:YTCVK2R*JKRHO1W5$5-_$@WHY)4+P@1*%T3:I:BI\)TK5<Q'
M\ZZYD1454WWTIL^#N37O+.&DMXKIZ=]VDEJ$B<Z+43%:NF(K6Z56I]N_B$60
M"FN&UWSW.L#==(KY;;?4NGE;$[U%)5?I>C5ZHC6IV[.7SWY&YP;B)4UW"6NR
MB^TS%K+:D[:AD'LI*Z/W=];Z??L"S 4Y69-F-/PL9G;+G0OE6)M8ML6E3P$A
M<Y$Y4?OGYD:J+O??IHL3"*V\7*PT]=?HZ".6I8R:)E'SZ:QS45$=S?SNJ]N@
M&_(+E]XGJ\YL>'T=3-2LJX):ZNF@?R2I"SHUC')U;S/[JG5$3HJ;V3HHZ]TE
M_F](^-E#=J*GJ'6-7PR/HED;'#XKDY%;XB<SM[7FVG?L!9&)XB[&[M<9X+W=
M:R@JD;X=%6SNG; Y-[5KW*KNON_V]-2DK6]YE74V10XQ%52>MTM(RHN5QI;9
M+4*CG?18R)B.1BNTKMNVB)TZKVZ<>SJY4,^3KD5/7SV2UTWK=/=)[<^C=,B)
M[4:L<B(KM]$5$3?N M %,UF;9+-C7RU0/N"W1[&SPV>.P5#X%:JHJ1NF5B*K
MM=WHY$WV31;5EJY+A9Z&LGII*2:H@9*^GE33HG.:BJQ?BF]?<!F%89CF=QKJ
M+-*;'&TT$%CIGQ5%9/S.>^=8U7PXFM5-*G1.=5[KV719Y0W%?$[]CESNE]Q2
M9E5;;[44\=PM+_I2RK(U&K&NN[EZ+[N9>Z=@L_"*F_LFKK3DE+3HZACA]7K*
M;G\.IC<CDVO,JJCT5G5-KW3WH:3B%GMUQ>^V2@AL"/I+G7PT3+A+4-Y-N<B+
MJ-OM;TJZWKMYFWX;YU09S:YYZ6&:CKJ23P:RBG34D#_<OO3HNEZ=EZ)HBG'W
M_I/#_P#^V2E_VJ!;#G(QJN<J(U$VJKV1"N[+EN19;07"\8I36QMI@E?%2-K&
MO62OY.BN1S7(D;57:)M'=NNC?\3ZB6EX<Y//3JJ2LMM0K53NB^&[K]QI> ,;
M(^$.-I&FD6%[E^U9'*O]J@;O#<QM^3XC'?XE6FIT:_UEDJ]:=S/IM=]FM[]V
ME(W;,OR>_P"-563V*WVY+2WQ'TE%4H_UBKB8JHKN=%Y8U=RKI.5WEM2JK-5S
MT?#?C/34RJD$-RE;'KLB/>K':_T40O'A+$R/AABS&(G*MNA54^*L15_M50K:
MX?D-%E6-T-ZMBJM-5,YD:[Z3'(NG-7XHJ*GW&X*:]%B5ZX5>:=57P:>[S,B3
MW-Y6+I/O5?RERA %8<3LCR6U9[AEJL=3114=VED8])8E<Y7,1-\R[^CIR+I-
M+M.^E-;G&2YEPZKK==KS<:*]XW4U#:>J9'1^KR4W-O2MTY=IT7NJ]M>>P+A!
M7N6YK+#EL>.6N2:%T=,E765D-!+6.B:Y=,8QC$73G=5YG=$3R55Z<,&R._W#
M(KS::J"LJ*&&!)J&[5EMDI$>Y=(L;V*C4<J*N^B)M$4"Q04IP^OG$;,;//64
M]SLM-ZM=WP3>)3JO/&WEYFLUV1-KK>U7?TDT76 !J\HN%;:[%55=JMLMTKF(
MB0TD;D:LCE5$3:KV1-[5?<BE?W^_99B^68@VXW&CK:&]U24=11LI$C]7>J)U
M8_F551-^:^7QZ!:@*QXIY-DEES+#;;89J)M+=JAT4C9HU5RN;K>W?T-.1=(B
M+T7KU,?,:C.\?X8Y+77*]6M]PA<Z2&:EI7)RP*B)RIM4Y7[7:*O-KX]T"TYG
M.9#(^-BR/:U5:Q%US+[B.\/KW=[_ &#UW(+'+9*WQGQ^K2.555J:T[JB+UZI
M]V_,UG#NGR9,6M]1<+U15C)K9$M.Q:)S',D5C5:LC_$57I[^B;[]#3<,,[K*
MSAG=<GRZ=CG4E14+)X,:-1K&:TQJ>?7MM=]>X%HE6<5*RYT7$+A\RCNM7#05
MM<L5121N1L<G*K515TFUWS:5%54Z)T]^TH6YID>.0W>FO%)9:BKB2HI:)*1)
MF,8Y-M;*]R[5514VK436^RZ([Q*2L3*^$B7585N'KR^L+!OP_$Y&<W+OKK>]
M; N$%?9AFDM-EL6-VQ\T$C*;UNLJX:"6L="U5TQC6,1?:=I5V[HB)V55/F Y
M)>Z[*KI:;C3U]5:HH6STETJ;;)1JY=HCHG-<UJ*O7:*B)T10+" ([DU=>VW*
MVVVPT2<M4KUJ+C*U'14C&I_1VBN<Y>B)V3NNP)$"N<%R"^_.'DF*7^L@N+:"
M&*JIZMD"0N5K];:YJ=.FT_(OO-7;+]FEXXHY=CD%QME+1VV.)8YO5%D\-'HC
MFZ:KDYGJCD155VDY>B=0+:!4.+Y#F]7F5_PNMK[6ZKMS63I=UI5VL;T:K42%
M'(BN]I.N])I?I&TX?Y'D"9_D&(914TUPEH8(ZNGK884A5\;M='-1=;]I/R+W
M LH%6+G51?;K=F6^LK[=;*"H=2134EGEK7U$C/IN5R,<QK$7HB)[2ZWM.AU)
MFF5OX0WV]ST+;?>[8^1K75E(^-M1&W2^*V-RHK55J]EVFT4"V 4[673/_FKH
M\L@O=MBFAML==)2+0H[QV>&CG*Z3?1RIM=-:B)V^))+CQ%AMO"VW9;4TJOJ*
MV"%8:-CM>)/(G1B+[M[Z^Y ,WB_/6TG#B^U=KN$]!5TU.LS)H-<WL]5;U3HB
M^]-+\3.X:SS5/#W&9ZF:2:>6VT[Y))'*YSW+&U5557JJ[(+Q6MN6.X77JKKK
M_3,E]4<^JH8:-O@JS^<QKU57[1.SM]==DWTS:/*VXCP7Q&JCA6HKJJBHJ.CA
MY7.YYGQMUM&HKE1$155$1576DZJ!: *EJ,MR*WW6S+1.NM]BJ:ID%=3NL,U*
MR"-W>6-ZM32-771RNVB]T[F]AR6XY/F-XL>.3Q4-#9N6.MKW1)+(^9V_Y.-J
MKRIK2[<N^O37F!J+?6W-GI$5MLGNM946WY&6JBI7N1(XG.D8G1J:1>R]5VO7
MN6H4GB]+<Z/TD:^*\7%MQE^0MQ3^"V)?#\5ND<UO3:+OJG?H78  (OQ/R.IQ
M/!;M>J&G;45-*QJL8Y%5J*YR-YG:ZZ3>U^P"4 A.(U%YKY*2XTN1T=\L=52N
M5TB0,8L4_LJU6\FMM^DBM=U3IU(=PUJLRO>49BZ3(J)K:*Z^JR1OH%>US6=/
MY-/$3PT5$_QNO554"YP5Y2Y/<\MS:^6/'JJ.W6ZR<L576^$DLLL[M^PQ'>RB
M-Y7;545=I]YPQO+KI0\1JC"<H?!4U#Z?UNWU\4?A^/'UVU[-JB.33NJ=/94"
MQBN?2!J[C;>&-SN%GN=5;JFF=&O/3JC5>UST8K576T^EO:*B[0[['>[QG+[E
M4V&X16FR4M0^DIYTITFFJGLZ.D]I>5K-]$32JNEZIV(UQ@@OU-P*R6'**RDK
M:QDT:1U%-&L:21>/'RJYO9'=]HG3L!:U@<Y]CMSGN<]RTT:JYR[55Y4ZJIG%
M<3WB\7!+'9L)KJ-*N&GB?<I9H?&CI8E8G+M4<G\HNETSS3:KI-;L"@BGAHXH
MZNH]9G:GMS<B,YU]_*G1 .\B]GOUYJ\WO%IK+!-2VBDB8^FN3G[;4.76T1-:
M\U[+TY>O<E!7.-9)>ZSC+DV/W">G6V4%''+31PQ<OTU:J*Y5VJN1%UWU\ +&
M!4U+D.8W/B[DF-4U?;::AHJ5DL4BTJO\-'\JHO+S(KGZ=KJY&]-Z\C-P/(\A
MCXC7S#\HJZ:XOI:5E=35L,"0JYBJU%:YJ+K^<GY%[[ LP$#MU^NN87F\P8_6
M0VVT6NH6B?6+"DTM1.U$5Z,1R\K6MVB;5%5?@=5YJLQQKA_D]=77&V5UPH6O
MGHJGU=6H^%K45>=B*B(_HY$TNNP%@@JO";MF=79K%D]]NMJ9CJ6UU571) OC
MNU&JH_F1-;Z<RHFD1.FE[FN_#N^W;&Y;Y;IKC2U,D;IZ&VPV&>>.1O56-DEY
M/:5R:]IBM1-^>MJ%R@@U)?\ )[U28_%1V:2U2U],L]?5U4?,VB5$5.1(U5%<
M]7)TWV14547L8G#C(;W49EEN,Y#505\EG= ^&KCA2)SV2M5VG-3IM$UV^(%B
M J/#LKR#-:6NKK3>J*EN5)7.C?8Y(&^S"U^M/<OM\RMW[2=-]-&VR/-II,QJ
M\>MDU32Q6^)DE;64]NEK9$>]-LC8UC7-;[/57.1?<B=U L8%34&>9!0V3-)Z
M^V5E9%9H4GM]=44$E)ZVU6KM',<B=6KW5$3:==(;G [C>KW%9;Q39%1WBU54
M2^O0M@9&M/(K-IR*WKT=IJM=M>NP+ ,&^W2FLEFKKI7.5M+1POGD5J;7E:BJ
MND]_0SC!OUJIKY9*^UUR*M-60O@DY5TO*Y%3:?'J!6=5>LQO==BM;:VVJE=5
MT]1<J>@E61VXTC:UJ2R-<B*JI,WHC=(OFNBQ;%<:NOQFCN%30205TM,DDE&O
MLN;)KJSVM>?3:E"4=TR#A-E5/3Y+$^_V&UT'@15E(G\I2TTTJ<JO1?C!I$W\
M-]D/0]LKJ:YVZFKJ"9LU)4QMEBD;V<U4VB@0?"LZN=_SV^X_<K(VU?)<#)%:
MZ=)9'JY45%VWV43E7>DW]IO\_P KI<.QN:Z543YW\[8:>G8NG3RNZ-8GV_[$
M4A>(?]H3._\ R-)_N-,#C^]S\IX9T;NM-+>FOD3R56OC1/['. D5YRR_XC!;
M;CET%K?::J9D%2ZB:]KZ!S_HJY7.5)&(O151&_8IN^(&718G9X*AL"UE?6SL
MI*&E:[E6>9ZZ:F_)/-5_::#TB8VR<'<BYTWRMA<GP5)F$!OE7/7Y+P+;6*JM
MDIHZEV_.18XEVOQVB?E"K&N>5WK$[C9DRYEMEMESG2D]:H6/C]5G<FVM>CW.
MYFKI4YO9UKL3\J?TH&-=PFK'KT?'4P/8OFB\^NGW*I9=CFDJ;+03S_W66GC>
M_P"U6HJA&:
M
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M(B;WKIO?NN0 0G+<PNU@_!IL6+U==+=)DBJ6T[^=*/?+W5&JBKU7W)[*]2;
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M8MDZY)(Z2DM-RI:!K-^L5T*P*]^_HM8OM*FM[=T3LB;ZZD0 %:<5KU>[9?\
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M].I;;&M8QK6(B-:FD1/)#Z
M
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M0.JFIMT*2(KT3XMWLR
M
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M[!$:P%UO;Q_OK+!12V^W2V5DCX%I74S9)$D8B/2-R)Y+WTF^OO,>'$K->_2
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M,ZKTZK\2<4J3)31)5.C?4(U/$=&U6M5WFJ(JJJ)]ZA':
M
M
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M\C\_JL$E"Z3FYVHC^=R2)OX:1-?$GP XQ(](F)*K72:3F5J:15\])UTAR
M
M                                        ([G>.U>36>.AHKY765?&
M1\DU'T?(S2HK-[32+O\ L\S<VRAI[9;J6AHHTCI::)L,3$_FM:FD3\B&2
M
M
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MAI:FXR>%2QOWN5VT371.G543:Z3JAN @
M
M
M
M
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MY'T;I$VL*IKM^:G?W(;D
M
M
M
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M9?K%O[A.@!PAC\*&./G>_D:C>9Z[<[7FJ^\Y@
M
M
M
M
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M,<US"@MMS9;+)%;'UDL-8Y99/$2-KM;C;VZ=MJJ[7R1 +5
M
M
M
M
M                                             IJIFNS..3<CCQJ]
M36=+7\GK*V!$=S<ZOYD:JHNO(N4 0RYY1=*BJH:.RV"[,DFJ8TGJJJF1D4$*
M+N1>^U<K45$3WK^6'9Q;;QE[JZ]4U%=+77V!6.L3%I_;GE545[W(F]M=I&<O
MDFU7OHN0 57DV29=5XQ8JJBL=VH)754<=Y@IX$?4QQ:]I8=[145?-.J=.W4U
M^'TM;9N+=UKUQZ_,METH88X*B?<[D<U4YEE<KW*WS72KO2=M]"Y !5_#".OH
MLISFJK[1<:6FN%9ZY2OEAUXC$;I4UY.[:1>I\X/,N%FH<M6[6>Y4KZB[U-RA
M8Z':R12<O*C=+]+HOLEH@"G.&M'=+/P@O-JN%EN45R_YSR4_@[63Q5=R<JHN
ME[]?=YG4RWW5/1U7'ULMR^6?5%HO5O!]KGWOFWO7+KS^[N70 *AX@45SNO 6
M&R4-GN,EUFI:6G]6\+3F.B=&KN;KI$]A=+Y]#MS>EOT-ZQ3-L=M-36NH8)*6
MMMCDY)UB?K:M1>ZHJ+T_R?+9;( C%CRBJNL$U4['+Q04<42N7UV)&3O?M/89
M$BJJ]-]5UY:WUU&^ 5'<+1A?R5>+;6T-9%42RJD\>FN:]ZJFG)T5>O8LL
M
M
M
M
M
M
M
M
M
M
M
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MHYH]ZYHW(Y-_:@'8
M
M
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MQ01HQB?8B="LLSRBVY?PRMEWL\WB4\MTH$<U?I1/2ICVQR>2I_\ 9[*6L$
M
M
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M]35'[H^<ZU?BC)_U-4?NDZ '"&1)H8Y&HY$>U'(CDTJ;]Z>2G,
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MLQ5^DO/S+T_I(7[+&R6-62L:]B]VN3:+]QTI0TC7(Y*6!%1=HJ1IT4"O>/\
M?+90\-;]0U5?31UU13HV&F=*GBOVY$33=[5.B]?@IQ]'N]6VNX9V*AI:ZFDK
MJ:G<DU,V1%ECT]4VK=[1.J=?BA8TM)3S/YYH(I'ZUS.8BKH0TM/"]7PP11O5
M-<S&(BZ]P'ROK:6WTDE57U,-+31Z5\TST8QNUTFU7HG54/// _)K,WB[Q DD
MN5+%%<JISZ-\DB,;.GC/^BJ]U5'(J)YGHN6*.:-63,;(Q>[7)M%^XZ?4*1%1
M?5:?:+M/Y-.G]@%9<>N'=5F%LH[G8%1F06IW/ F^7Q6[WRHODY%1%3?3NGGL
MV> <3K9>Z*.CO\K+-DD#495T-;_(.YT[N9S:VB]])U3^U;",*Y6FW71J-N=O
MI*QJ=DJ(6R(GY44",Y=G]NM5*^FLTC+S?Y6JVEM]$Y)7O>O97\OT&)W55UT-
M?P5P2;#+%537:1LU^NDOK-=(U=HUW548B^>MJJK[U7RT3BW6R@MD:QVVAI:.
M->[:>)L:+]R(AE@4[)F]@9Q];N\T'JGR#ZLM1ZPSPTF\?GY.;>M\O7N6^J15
M,"HJ,EAE;I4Z.:]JI_:BH=/R?1ZUZI3Z_P##;^PR41&HB(B(B=$1 /,'$' K
MA@.5T51CTDOX(7:Y4JU%,G5M/(V9KFHJ>[:>R[[6KY;]/G">&*HB6.>)DL:J
MBJU[4<BZ7:=%^*;.8
M
M                                *"RRCNF%\2KGD.'TZR6RVT5-+<;6
MQRZDAE=*CW,;V16^$U>GV]MHH7Z#1VJOLV;8S#5TWA5UJK&([E>F^J+V<GDY
M%3MY*A&^"5GI;=A_C0L5U3+5U4<DSU5SWM942,:BJO72(U + !CTM?25<DL=
M+503R1+J1L<B.5B_%$7H?)KA1PRRQS5=/')$SQ)&ND1%8S>N94WT3X@9(,7Y
M1H?4O7/7*;U/OX_BM\/\[>COIYHJB%DU/(R6)Z;:]CD<UR?!4 Y@QOE"B]=]
M3];I_6];\#Q6\^O\G>S)  QZJNI*1\;*NJ@@?*O*QLLB-5Z^Y-KU/M95TU%$
MV2LJ(H(W.:Q'2O1J*Y5TB=?-5Z(@'>#&BN%'-5OI8:NGDJ8_IPMD:KV_:W>T
M/LU=2P5+*>:IACG>USVQN>B.<UO=43OI/-0,@&/15U)7,<^AJH*EC5Y5=#(C
MT1?<NE.$USH('SMFK:6-T'*LJ/E:BQ\V^7FVO3>EUOOH#+!CUM;2T,22UM3!
M3Q*ND?-(C$W]JG+UJG\!DWCQ>"_Z,G.G*[[% [@=/K5/X7B^/%X>]<_.FM^[
M9QGKJ2GIO6:BJ@BI_P#"OD1K/RJN@.RIGAI8'S5,L<,+$VZ21R-:U/>JKV/E
M+40U=-%44LK)J>5J/CDC<CFO:J;145.Z*1'B[%2W#A7DJR-BJ(?D^6:-5TYO
M,UJN:Y%^"HBHIL.&J(G#S&$3M\F4W_":!(P
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M%Z<S7L<CFN3WHJ=SF:S&K#;L:LT%JLT'J]# KECCYW/Y>9RN7JY57NJFS
M       ZZ>HAJ8UDIY8Y8T<YG,QR.3F:JM<FT\T5%1?BA&\/ILK@NE_?E-;1
M5-#)4\UL93LTZ*+:]'=$\N7OM=HO4"4
M
M
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M%F9C]DI;7!55-53TK$BB=4JQ7M8B(C6[:UJ*B(GFF_B!M
M
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MVRG2U3426Y%2K3Q$:CVN\3EU\/H[V==?8<FLO%^NR:RVNGNMNN=$RFE8ZJ;
MZ%[>72]47:>RG;?=?=U#?7BRUD]PD^7+RM+B5-2-C8R.LD@FEEZ;DFF16KI$
M14TCNN]J0WA)E4EOP;-JVKN$]VMMBKZIM'-+*LCY(&-1S4YU[HO32_'W&QO&
M/Y1\Z$=]?:J&^6N2C9%#3SUB,9;YDUS/:CFKO:HOM(WFT[RUHQL"PR_T,.88
M_D=NHW6B]U514NKJ>J[)*S2M;&K=[3IWUKKWTFPVN*XX_,,/H[ODUSN<EPN<
M#:IOJE;+3QTK7IS-;&QCD;T14ZN1RJN]D5XS62>BH^'=OFO=UJ=W:FHY95J%
M:Z7K_=%U_P#$3R=W0VF$T7$?"J!F.I:K7?;;3JK*.O=7>KJR/?1'M5JJNO<B
M=.VU-CQ0Q3)+YCN.ST+Z2NOMHN,=P?&J^#'+I57D:J]D3:(FUZHG7J!.\?LS
M+)2201UMQK$>_GYZZI=.].B)I'.ZHG3M]IC9Y_U'R+_-U1_PG&58*JYUE#XU
MYML=MG5>D#*E)U1-)])R(B;WOHF^FNOD:_/X;I68M<:"R445555M/+3(LLZ1
M-CYV*WF7HN];[!$9X 1K+P6L$:2/C5\,S>=BZ<W<TG5/B1'@Q8*C+L/O+K]D
M-^E3Y4GB;X5:Z)R*B-3F5S>KE[=%56IKHA,^$UKR'%<"I[)=+5 ZIH&/\%T-
M6BMG5SW.UV]GZ7Q[&-P:Q_(<1QR[4-WMU.LTE5+6P^#5(Y)%>B>PO3I]'O\
M$*Z.!59<KMAM[MMWN5552VZYU%NCJU>OC+&U&Z7F7KM.9=+]GN(WP"QZG2TW
MRXRW.\1I07RH_DHZU[8I$8C%W(Q%T]5\]]R4\);%DF*T61Q76UTZOK:Z:Y0^
M#5H[;G\J>&NT37;Z1SX-X[?L;HKQ09!;Z9D5=735R2PU*2(G.C4Y%32+Y+U
MUW#'Q>)=GN&1Y#55W@5%5)#14=-5R01TT3=(B_R;DYGJN]N7?PT9'"N^W1N6
M99A-ZK9ZYUI<V2DK95W,Z%_9'N\W(CF]5]ZG+!<<R#ARZY6FW6Y+WC\U0ZIH
MG15#(IJ=7:W&]'JB*G1.J*OGTZZ3:8-B=?9;CDF379L,^07A_.M/#)_)PQM3
M3(D>J)M>VW:UT3W=0K[A9C5PR^UY%\H9;D4/J>02L8Z"JY72<B,ZO=K:]-(B
M;TFNB&ZR"EKZ[TA*2V-OMTI[?+9W5+H89N5&>TK%:SI[.^5%5R>UWTJ>6ZX-
M8_D&,-O=->[?3QQ7"XS7%LL-2DG)SHU.14TB_P WN<:BPY')QIILG;;*?Y)B
MHEMRJM6GB*U7J[Q>77Q^CO8$=;:[C9.,U/B]MR.],L=TM[JR:.6I6:1CFJY%
M2.1^U;O2;5.O5>O94S;?!58AQRMEEH+K<ZJT7>WRSRTU=5/J/#D9S+S-5RJJ
M?13\J_#6UNUAR.;C-;LFI[;3NM5)1NH5W5(DCT<YR\Z-UY<R=-^1\R*P9%4\
M8++DE';*>2V6ZFDI5YJM&ODYT=MR)KIKF3HJ]= ;/(;1-65=XJ<QOK:#'T:U
ME#'25KZ7P^B\TDKT5O,Y5UI-JU-=E(UPHN-QO_ ZKDN%TK9*F)*F..L9,J3*
MUBJK5Y^^_+??1E1X[E%%Q-OETEM=#>Z*M1GR?5U=5RI;T1%VU&*U51%5>O*G
M72=>JZY\(<8R+'\1K\6OM#314[5G2*NBJ4?XOB+TU'K:)U7NJ>73W!A>CK86
M.P"PWEURN[IG>.JT[JUZTZKXCV_W/>OC]O4^\*KA/295Q0DN=?65L-OJV(U]
M1)SN9&U)%Y4\D1$\DT;'@Y;,LQ7'J?'+Q9J3U:A=+R5T=:B^*U7.<B-8C=[Y
MEUUUT^/0X\.L9OMMRG,:F_6RF9;[_/XR>'5)(L:(CDY7)I-[1W= ,7AC!-Q&
MQF;)<EK*_FKIY6TE-2UDL$=)$URM1&HQR;=M%57+M>QW<);]=:J[9=A]\KIZ
MNILLWAT]>Y4\9\+^;E5R^;D1$7?Q^!SP&PY)P[I*VQTMM;?++XSYJ">*I9%)
M$CNJQR-?KSZ\S=]UZ>2;/ L3K\<7(K[<&PU>17J?UB6&&34<;4WR1->Y/+:[
M=K_8$0?@Q8*C+<1O3K[D-^F3Y5GB;X5:Z)VVHQ.97-ZN7MT55:FNB$GX!7&Y
MUV*WFBNEPFK9K7=:BWQ5,R\TCF,1NE<J]UVJ]_@ASX-X_D.(X]=Z*[VZG6:6
MKEK85AJD<CU>B?R:]$U]'O\ $Y<'L?R'&HLA@O5#30I<+A-<8I(JE)$:K^5.
M14TB]-=PK>\-;#?[!:*JGRF^NO55)4NECF5%]ABHFF]>O=%779-Z0EI$N&JY
M>MHJOP]2C2O]9=X/JVM>%I-;UT[[UYZULEH0
M
M
M                                -#E.(V?*4IDOD$U0VF>DD36U,L36
MO3L[3'(G,GDO=#? #JI(&4M-'!&Z1S(V\J++(Z1R_:YRJJK\54T%;A5DK,C9
M?IX:M;LQO(RH;6SL5C?Z*(CT1&]_91-+M22
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:YD,;))%D>UJ(YZIKF7WZ.8
M
M
M
M
M       "/9%EM!9J^FMJ,J*Z\52*Z"@I&HZ5S4[N7:HUC?\ &<J(!(01.OOV
M24=*^J7$EGB8WF6*GN#'3Z_R5:C57X(Y?@;G&+U3Y%8*&[T<<L<%7&DC62HB
M/;\%1%7J@&S
M
M
M
M
M                       *:X#3K?,JS_(*WVZ^2X^J-5W58H6;Y6)[D[?F
MERE11V6Z<.>(%WO=KM]1<\6OCDEK(:1G//1S;5>=&)U>U5<[Z/7K\$V%NG52
MTT-)"D-+$R*)%5R,8FD15557I\555^\C,_$#'XZ1TT-14U,J)M*6"DE=.Y?Z
M/A\O,B_;HVF)5EQN%@I:R\TOJ=94<TJTRIIT+%<JL:[_ !D9R[^.P-N
M
M
M
M
M
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M\T.%?BF7].J/WR>@#XQJ,8UC4TUJ:3[#Z
M
M
M
M
M
M
M
M
M
M
M
M
M     =574Q4=)/4U+^2"%CI)':WRM1-JO3X(0CYWL&_'\7^HE_= G@('\[V#
M?C^+_42_NCYWL&_'\7^HE_= G@('\[V#?C^+_42_NCYWL&_'\7^HE_= G@('
M\[V#?C^+_42_NCYWL&_'\7^HE_= G@('\[V#?C^+_42_NCYWL&_'\7^HE_=
MG@('\[V#?C^+_42_NCYWL&_'\7^HE_= G@('\[V#?C^+_42_NCYWL&_'\7^H
ME_= G@('\[V#?C^+_42_NCYWL&_'\7^HE_= G@('\[V#?C^+_42_NCYWL&_'
M\7^HE_= G@('\[V#?C^+_42_NCYWL&_'\7^HE_= G@('\[V#?C^+_42_NCYW
ML&_'\7^HE_= G@('\[V#?C^+_42_NCYWL&_'\7^HE_= G@.$$K)X8Y8G<T<C
M4<U?>B]4.8
M
M
M
M                                                     #YR-_HI
M^0^@#YR-_HI^0<C?Z*?D/H ^<C?Z*?D'(W^BGY#Z /G(W^BGY!R-_HI^0^@#
MYR-_HI^0<C?Z*?D/H ^<C?Z*?D'(W^BGY#Z /G(W^BGY!R-_HI^0^@#YR-_H
MI^0<C?Z*?D/H ^<C?Z*?D'(W^BGY#Z /G(W^BGY!R-_HI^0^@#YR-_HI^0<C
M?Z*?D/H ^<C?Z*?D'(W^BGY#Z
M
M
M
M
M            4AG5XK<,XQ6JO977!<;=%$ER@EJY)(HW5#YF-D1KG*C418T7
MIT371.I=Y7-ZL5-EV1YU9JS7AS6JAID=K?([FJ'M=]SE:OW BQD7:;3L4?:+
MU699QYFIY:ZX18\RVOFHH*>KDACG\.;P_%<C')M%<DFO>B-\CGA&7W"ZX*S$
M)9719?#4K9)UW[<4;47FJ/NC:[2^;T3WFPIZ2FM7I#VFAHHVPTT6+^!$QO9&
MMF72?D0*MT !
M
M
M
M
M                      (C8,5N%KRFYWJ:^+5.N7AI40+2M8W4;5:Q&*CM
MMUS?'9+@!&K;AELM^<77*(&?^T+A!' ]-=&\OTE3XNTS?^3\345>!UE1Q AR
MU+^YE;# M+'"E(U8TA57+RK[6U7VN^_V$\
M                P;W;8[O;)Z&6>JIV2ZW)2S+%(W2HOLN3JG;\AG ""_-G
M0?C_ "O]<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_ %S-^T?-G0?C_*_US-^T
MG0 @OS9T'X_RO]<S?M'S9T'X_P K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_*
M_P!<S?M)T (+\V=!^/\ *_US-^T?-G0?C_*_US-^TG0 @OS9T'X_RO\ 7,W[
M1\V=!^/\K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_ "O]<S?M)T (+\V=!^/\
MK_7,W[1\V=!^/\K_ %S-^TG0 @OS9T'X_P K_7,W[1\V=!^/\K_7,W[2= ""
M_-G0?C_*_P!<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\ *_US
M-^TG0 @OS9T'X_RO]<S?M'S9T'X_RO\ 7,W[2= ""_-G0?C_ "O]<S?M'S9T
M'X_RO]<S?M)T (+\V=!^/\K_ %S-^T?-G0?C_*_US-^TG0 @OS9T'X_RO]<S
M?M'S9T'X_P K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_*_P!<S?M)T (+\V=!
M^/\ *_US-^T?-G0?C_*_US-^TG0 @OS9T'X_RO\ 7,W[1\V=!^/\K_7,W[2=
M ""_-G0?C_*_US-^T?-G0?C_ "O]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\K_
M %S-^TG0 @OS9T'X_P K_7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_P!<S?M'
MS9T'X_RO]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\ *_US-^TG0 @OS9T'X_RO
M]<S?M'S9T'X_RO\ 7,W[2= ""_-G0?C_ "O]<S?M'S9T'X_RO]<S?M)T (+\
MV=!^/\K_ %S-^T?-G0?C_*_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_P K_7,W
M[2= ""_-G0?C_*_US-^T?-G0?C_*_P!<S?M)T (+\V=!^/\ *_US-^T?-G0?
MC_*_US-^TG0 @OS9T'X_RO\ 7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_US-^
MT?-G0?C_ "O]<S?M)T (+\V=!^/\K_7,W[1\V=!^/\K_ %S-^TG0 @OS9T'X
M_P K_7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_P!<S?M'S9T'X_RO]<S?M)T
M(+\V=!^/\K_7,W[1\V=!^/\ *_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_RO\
M7,W[2= ""_-G0?C_ "O]<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_ %S-^T?-
MG0?C_*_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_P K_7,W[2= ""_-G0?C_*_U
MS-^T?-G0?C_*_P!<S?M)T (+\V=!^/\ *_US-^T?-G0?C_*_US-^TG0 @OS9
MT'X_RO\ 7,W[1\V=!^/\K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_ "O]<S?M
M)T (+\V=!^/\K_7,W[1\V=!^/\K_ %S-^TG0 @OS9T'X_P K_7,W[1\V=!^/
M\K_7,W[2= ""_-G0?C_*_P!<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_7,W[1
M\V=!^/\ *_US-^TG0 @OS9T'X_RO]<S?M'S9T'X_RO\ 7,W[2= ""_-G0?C_
M "O]<S?M'S9T'X_RO]<S?M)T (+\V=!^/\K_ %S-^T?-G0?C_*_US-^TG0 @
MOS9T'X_RO]<S?M'S9T'X_P K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_*_P!<
MS?M)T (+\V=!^/\ *_US-^T?-G0?C_*_US-^TG0 @OS9T'X_RO\ 7,W[1\V=
M!^/\K_7,W[2= ""_-G0?C_*_US-^T?-G0?C_ "O]<S?M)T (+\V=!^/\K_7,
MW[1\V=!^/\K_ %S-^TG0 @OS9T'X_P K_7,W[1\V=!^/\K_7,W[2= #XQO(Q
MK455TFMJNU/H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZGT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@_57"3.^(E'<;I6W!E'60Q0.J9.;D9_*+I$32)]R(6L
M
M
M
M
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M%WU7HJA.$[=0$[ (
M
M
M
M
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M]YE5%UY*GFA.P
M
M
M
M
M
M
M
M
M
M
M
M
M                             ^.54:JM3:HG1/>?0!75OXD5E?EMRQNG
MQ6M6ZV^-)9V+50HU&KRZ5'*O7:.0V]+EU<W)K=9[MCE9;_7TD\"I=/'+&KF-
M5RM56*JHND7N5U;+S36;TD,UEJXJV5LE!3M1*6DEJ'(OAPKU2-KE1/BO0L;%
MLJI<IR"[4L-%-'%:FP.8^KIGPR^)(DG,J->B*B<J(B+I-[=Y 2T$#OG$B"UY
M[%BC;+=*JMDIUJ&/A8W4B:VB,VO7LY%<Y6HFEZF+1\4HDR*;'[QCMWM]\\-)
M::C1K)EJF]?H.:O*G9=JJHU-+UZ 6,"#8_Q!2NS%V,7FR5]ENKX5J*=M0YCV
MSL3NJ.8JIOHO3KV7J9]VS%D5SKK78;;47NZ4,;9*J"GD8Q(4=M6HYSU1.941
M=-3:^_0$EJJB*DI9JBH>D<,+%D>]>S6HFU7\B$<I,QI+WA=7D&)\ES9$R1T<
M<CG0(]S.[556JJ?D]WVG'%,SH,KPM]_HJ2J= C9$EI%8CI>9F^9FMZ55\NO7
M:=C581?K;D?#&MN%CM3+5;E94LBIFM:W2-YDYE1J:157KKK]J@;/A5DU3F&"
M6V^UT,,$]6LJK'#OE:C97L1.JJO9J$L*GX'W6GL?H_6RZ5J2+34<%7/(D;>9
MRM;/*JZ3W]">83DU%E^-4=[MC)XZ6IYN5D[4:]%:Y6JBHBJG=%[*!O
M
M
M
M
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M'\5GC4F))'S)S<M14;UYZ]CN!.
M
M
M
M
M
M
M
M
M
M
M
M
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MJ+I>O94 R   !'<4S*S955W."QU$E0MN>V.=ZQ.8U'+S=$YD15URKOH2(
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MFM=1)-6VU$]9_DG-:Q=JG+M43:]/+H!(@
M                        -?1WF@K+O<+92U"25U D:U,2-7^2YTVW:ZUU
M1-Z10-@
M
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M%(R:)DL3VOC>B.:]J[1R+V5%]QI69?CC[@E R_6MU8KO#2%*IG,KOZ*)OO\
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MJ?E,XU]CLELL-+)366@IJ&GDD65T=/&C&J]>ZZ3[$_(AL
M
M
M               "%YQP^H\ENE#>:6NJK1?Z%.6"X4NN;EZ^RYJ]'-ZKT^*^
M2G3+AU_NE,ZBR3,)ZRVO3EF@HZ%E(Z9OFU[T5RZ7S1O+M"= "*\0Z>&DX7Y'
M34L3(J>&T5$<<;$TUK4A<B(B>Y$(7PEQR_57"^S02Y3)';*JD14CAHVMGA8[
MNQLJN7WZWR[3RUT+&R^ROR''ZRTMKI**.KC=#-)&QKG+&Y%1S4YNB;1>YCX-
MCDF*V*"T_*4U=2TS$CI_&C:UT;4WTVU$W]X'&?"[%-ABXJM"QME\+PDA:NE3
MKM'(O?FW[6^^^IH6X%='XY^#=7E=1-8O#2!6I2M;5.A[>&LW-K6NF^3>O,L
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MS;ZNW]VB< "'Y+A<U\RC'+S\N5M+\D.YGT\*:94+M%7?7IO6E[[3H3
M
M
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M45%32W1'^J2T5?ZTWG:B*K)$Y&*U5WT7JB@3P B#<OJ+K=KC;\3ML=R6W/\
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M/9SKM.5$TG9KNJ_#H6"5-Z1/_NK#_P#[8Z7_ &/+9
M
M
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M$3L@'8
M
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M1,EAD3E?'(U'-<GN5%[G8B(B(B)I$
M      ==1!%4POAJ8HYH7IIS)&HYKOM13L !.B:0
M
M
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M;\T-O45N7IQ)IJ2&W4CL06F5TM6KD\1)=+T[[[\J:UK2JNPB7@
M
M
M
M
M                                       "(9ICT^6UE#:ZR)(K#33Q
MUE2]7(JU3F[5L+43LW>E<JZ[(B=U5)>             JO)K3D53Q@L.14=A
MDFMEK@FIWKZU"U\O.CDYFM5W;VD[Z4M0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
*          '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001193125-26-263731-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-263731-xbrl.zip
M4$L#!!0    (  "AR5PTD%7>M=T  -J(#@ 9    8VLP,# Q-S4U,C,W+3(P
M,C8P,S,Q+GAS9.R]6W/C2+(F^#YF^Q^TM0_;8S;9E;JGVDZ?,>I6K7.42:VD
MZCXS:VLT" Q2<0H$5+@HD[TV_WT\ B )$G$% H 3I8?N2DD1@?C\\[BY>WC\
MRW__L0@.WDF<T"C\ZT^'?_[\TP$)_6A*P_E??\K2V:<O/_WW?_TO__)_?OKT
M"PE)[*5D>O"R/+B^O?MV\!^7C_<'=V&2>J%/#JXC/UN0,#WX=/":IF]_^?GG
M[]^__WDZHV$2!5D*[2=_]J/%S_#WO^??.W@\_O-G^!'^]?GBT[]E(?ET]/GH
M[.#__7SZE^.3OYP<_7\'___#U__UZ=.__A__Y5\2_Y4LO(/4B^<D_>8M2/+F
M^>2O/Y6^Y2_]@,30,/\.:^KS\?$A  H(Z]AM%"^NR<S+@O2O/_V>>0&=43+]
MZ0 D$"9_\7_[_/GSX?GIZ='QN5&KO-I6R>_'?X[B.13Y?/CS?WR]?^(]7K4?
MT/"WK=(_7N)@5?[X9_;G%R\AJ^(_*N6+U@\O+BY^YG]=%X6&J*)I6C!4+C]-
MUQ7*A4]_SO^XZ86BW?^X+W4B2S[-/>]M77SF)2^\:/$')KC3M:RC+$SCY787
M$N+_>1Z]_US\<;M"%L>@EK(:Q5^WJDP)%9>&/VP5)#_\5W%)]I>MHJ%'_41<
MEO]IJW!"?7%1^,-609!0NGPCB5!V_"_;[:9OL:1A^,N.#-YBXK,Q*Z7QXF<O
M]N,H(/!5/_U$?KP%7NBE4;R\A9_7WXS3:N_@E]L=BU,9D/6?MKN7QCL5MGH'
M?_Z9_9G5.?GT^? 3C#J8"0X._L4+PRCUV)3"?V:_>7NCX2PJ?H1?L 'R%X;K
M&5HX8/_X]?%.,:ZY"*XBF D?O#D,%0HBV_RX;G?5\I3 O$9Y#PYAN,,D5IK^
M>+T#5O%??MXMO=M0EI#I./Q7_F\@*X$6.# VMHK:11%5S<T'[.KY7N!G@>:#
MQ6]7PFPLXW!*0O@"_ ,6!CIEZGGI!6R&>GHE)$U6PM>6T[!R!%0\@33)FI:B
MQ8-RDP=%FP=YHQ^,U6#LP8/Y-WTE*87NF=*W74G#Y7$=+@_^M/6-__K!K1FW
M:T$GX]GXC6WZV.9M%$*A!4CE%2K0=W(?):JA:M&(AOL3,^XW'SR(9@>;3QYX
M(2M9^N@!^^J',M@KPU,:^;^]1L$4]N\WOV<T71HJ@*"BAO33.J27/_-_'^0?
M^N#9GN<K+WF]#:+OIN-[4U[#ZED=5EGK![SY#RXK7'[STBPFX]EEEM"0K&;D
MRF\UO)RS#2Q-_"!*H![\D#? I+]JXD/V%=D_98N%%R]A>J/SD,Y@CQ&F(Y^?
M7VDX?P!U]BDI&#$LJ^'IRRY/1;-\\MLT?+!I^6#5] =_%?YN/1K_W0LR&"BW
M-(2-(_4"9LZ*^4&N($Y72,/8Q2YCK+T#WB C;=WD0:G-#ZHJ5(UA$Q_?A>\D
M29F(<FIV?ZFFXO#S+A6\_L&F@0^Y5^0.$TF<D>G-CS>V3+/M.Q?:%;>XI??4
M>Z$!(%G-<N;%-5P=[G)5M'RP:IKOZG,"B]8/2LU_,"G8]"T6E*MY?@CCJP,)
M-RN4JH"&K:-=MDIM%<>O4FL?Y%1W$J]>3"X]OL5>, 7G7W\(O'"U?5 4T)!S
M7-DSL+8^,6=#?BY>M7; F_M@I\(.,Q<\D)C++:=CZS<:^9_LRI]5/GB#B2MA
MU3_D79'W70C_),_>C]745/Z%1MJGN]+.ZQ[PRA^RKLCZFG65G^S3F+YDJUDE
ME[OLCQH.SG8Y*-HY*#?$9YL/0JJ3#?79!H=MG=[8=T?SF)#-GE?^9PTIE2-^
MT5*^D>)M':P;^^!%<-A_2<CO&>"\>=^<#BN_U; @.,"O&CC(6_@0?4T[2QU[
MBZ'=Y;!RBC>WNQS\:?6O#_^3M0GFV7L)B)DAIBBJ)O*H8@,P,,<<_"EO^X._
M!O:!,I.VE32<-K05?-!;ZUQ:)E1?3$-AQ8"@/J-^4&9V6"US)/B]AI2*X6#[
MX/I!@M$)MLQ!]=<:"BJV@_)I]H, <[?H-4D]&DB\HZL_:LBHF!:J3M*#/Q5M
M?7!2=QO_2. 8E)$'+P6!7$4)MT;?A2D!$:6KK4(^#+9(;:UUC594C!T61X-/
M!T5__MM!WJ,#WJ7_QC<LJUZ5=B_%Z/]0LJ9*5IJ(:RB1H+9&22K&%RLEV9[T
M/\BO>YK<HMJPK(;8BCW'Z#SY0:&IHW\TG?)^,VYF4;S@?=GBT::"ALR*E6<W
M0("=+=?M'Y0^\$&I"QO!%J_6M=3D'E<L/[96@@^&Z\06Z =PW<H:OBM6(65,
MPL?(KK79DMM]MK=5^G(:-JT-1!^LU6&-75F=9@'LB<2%BKG2E%S+YC0Z8!G(
MP@H4W^?;;%GAHA,?*M-89=CMB\(K[:?TG:;+&HHB;T2C'A5;F9UZL.^N_>#%
MES]THJE._(/0^6M*IJ-W$GMS,DJ2;,%EG/P*%>_"FR2E;*$-Y\^OI'0D@Y]*
MFF"\FK3V88WN54R#5KJWZNM!T=F#4F\/&(<'-#P@ZPX?P![U8,;.F>^K<R;[
M3<(U."JJ?6AN/<U=&8 >$\]Z$E/4U>A/U8BHU9^- >GQ:73@?<Q8=JZQS4P!
M9%(?3A[7-,A@$'XC:5&.'1BBD)?>4H'FS6BTH1JJM>UXVYX]^(?YB:;X] %\
M.Z_RP,ZR_/.Y0GUHA[5VW'AQ"'/N^B^%C"^7N5RO F_'N=2\&8UV5$R.<NT8
MSPY6'^:ZD"O!2DTNEROEX)__4 XSA^Z&5#8Q1V%^!1;&7%Z&L7%)9E%,UG5$
MIR:7#6H4IF+6W/(G;$\FFQZPG]A$4A3F2I9WHU3_X_!DISMZ:YAI837G)Q5K
MYP[G'\:N)C0^$C\*?1I0WH'Q3.9.M*NBH;1BT-RA=/L+;/C2O$#ZX3<TI_::
MS$@<DRG\ *<PDB8R_X1E'0VY%?OF#KFK3S R#SS^D8,_!9O/_-</?NTON6SQ
MJ2FCX:]BFY1>>?D@JL[E%_W"6:^JAM;JW3W%I9F/9;4.Y;LW:/1,6]70$%PU
MW.W>QSGXDYC4/]:,R_Z/6:,X 0%+^UGY(JOY2&8'/#?I7UCBQK_^E-#%6\ 2
MC_+?O<9D]M>?RHE6/ZW2J?[Y1S+]OTKI%XT=S^L:!S^WTB-]LD+CKNJ;Z@G#
M3OH^9X!VVNT.G4T"NR9H;;[3#WI1QC97B$5M]X.RE*_,%;A2DZU@JN;MJAG9
MWE+_3'-;.0W+;0F+-L^3F_#2EGI?27U4+Y*RI=Y9) AR'2[8VFRC2)33/""N
MK?&JRB#3W"_:4J^W,ZO4<-2TU*^M#"3V1J26>B7-U=',#-(6M_)$%DVM :VM
M>;LI'FJ>87M=DUM:F_M=HU>W*-VLU*O6^ET1+3%9M]OU.F.)QZ"EUM<<RRZ+
MJK:]_EAV45"SD_/+VD)7\QBSKM_CS%GGZJG3.;9.!WJ4E\CMZ50>H@_TL?K8
MHC-MKHOSHMJ>7N\LJ6ZSWU75%II]PUV?.ITP6+O]KG<1UC.)05-=8["]1M,<
MJNT7>Y2(XI:(4SDHOM,?>M?W(5Q*S'7?.I>R*G;?@:!4S;=^4JD9KU[C8%/S
M2QU*P"HFNY$$K+[4]DFP>>"Q_1FR^3?;EHJ3W9%Q>VVC,8DLM<=DTFK;R(P"
M*^VA&37;I37>%HNNF6YM\TY&4\W6.['I.P%HUV@#7*P;R>J97^&3RC^3($W8
M;UB3"<-^RG$3,EU4\52:X'!8V9]O?J0L7.4E(#=AMBAB6>YITM";(7K8-XCC
M_,,AF;.XBT_L'>)/AT>?#L]XWXM?WWLO1!*.M/V"<;FMHI*@Q[MQ=UM=)PS]
ME+\&OH9G$7Q6^M@Z8B[RM[X /[-GE17\[CY0S?ZQ(11^F/ OCEZ2-,[?9LX_
MQ!#S]B>5,I/#SX<_;<FBS>ZMGD N#0)N@Y;T5%9\<G%\+NYTF<)1O W B_W5
M=XH7K15/EZ_>O'[C$6J?_%<:K*F?Q=%"*<[BJY$IDBR!KN3WLED87!1/2?S7
MGZ A@),O7O>Y8*3=Y7T-<LWND<S5KT8_:&+.:;D6".0+&FK5K!FQ7,4F)OMH
M3\B^CA8>#37<YH4 [@5F*JO4R!DM(Q(3>(R<P)LPI>D2]B$@^X0?8M@_6""W
M8K"J*TTN3HXP$ZP<JR;0Q$R?(&>Z!$4Y6BOE /0Q&CY-^*FR*L$D)O(4.9$K
MSS<[^<'>XBM9O)!80J:P+( _04.HA)HJAPHH8A[/D/,HF)K@>$'N4K*PV"6M
MJX H/J-AU<$6:0>8F.-SY!SGT]4CF5-V$ C3;]Y"=JH1%85S ^JE=(<CV7(J
M B7F\XLMGRF)$W+?S\!E<Y9FH+(B@!?/^EF'Q"H8,7D7^T!>KI&W-"#QE9>2
M>10OE0-RJR2@QV-AJ#\>!9@DMH;/^T/IT\(+@LWE)@6E6R4!/FK+@B&E DP2
M2JWM1_U1>K,@\9R&\U_BZ'OZRAR)7J@>K<(:D\-#B3%SKRA68)-0;6T]ZH_J
M*Q!)S-P@4_+CWXF:Y)VR((*S = K1"4AUMJJU >Q(Y##E,GB-O#F,F-#N<SD
M\ CU"49+I "-A$!K8U%_(_/9^W$W!4P\V)KA^)8I# [*.B"2_=X)&Z"3$&YM
M5.J/<!8D$;]%N2.77VV_8N'U\?(JFJH/K\J:()[3 9!O@%&B M;VJ/Y4H##*
M%?]ADCE4$B\H#Z(8PJHL128AV=H@U3O)5_#/<?P<?9<Y!"2E00Q#.#A)<$GH
MW0O[U!8P/D6-XX<X>J>AKYZ_Q55 (*@=MG9$"\%)V-XC@U:![B%*4B_XG_1-
MNU:+*DP.C_=[ ZZ#)@FRV LK%YNA1C'Q%,R6BP#@_39Z5,%(V-L+@]8]M!$\
MO$8A41Z?=HL!\/UV (D!29C<(WO50TS9I9XGZAL<AW<+@[#V>VRJ8$FXQ1X(
M5805/(!&16%( H6G5E04L._WZ58.2D*HBWBG(G?H;H1U%R'8^J2:3A1/'7O/
M?K-1P^(7DW4ZP5(6 -C,\)L"BB!NF^J30UE,5S<0\RLW!F"V"T*W<9PY[66]
M/>)4\!R%?;M?&^L3721%,.9[ISS(!<<)5$6;BF A'D<1WSAX9FE/67X(^ ]+
MZ?KN!83=;TJOO#A>TG#.KWPK>#>J#W+#85,T8%>L#A8P'<63OY/X)4*@($62
M'G:EE #NEX!\(VDA.=5\H*@V.3S%<3BJK0YZ=(YBS7%,$@\Q>?/H*F6.GGQA
M>9 +KCV ->L*6(XBTG'0S?,A;4E'P76U\.3P#(>WN#;1,DR.XM5QL&Q*\*X<
M< 12UI^ZJW <A:BG4>H%O=/Z$$=O)$Z7+*< 2R'(MBMO[*0#*Y1RRI97FUR@
MW+Z9;./UL-#&L]>>N>^C</Y,XL4F?9\HK%97!88&#I^2/>EJ2&ACX.M/XMK9
M&Y!CW'N9'\1S ,Z"W5',U*7$-3 S51]7,;"ZF#8!FU0<-P==V=_L@..-J&^H
M-^;V.7DE$#,.#T@];K7Z(82+-_"^B8WFP5LR6X2Y=6:[ H@&U^9>QZ+:.","
MARHN7Y[$JOR729&P^!$H /$Q,^0U>2=!Q/>Q<JZMVX#QA.O<;D=_3;RH OWM
M-&(WA7557H9JH6\(9(7+D]-<-TQ!X[T8X&;S8+5I@'TXKHUDO25"!LS9#0 4
M!PSEHV1RCYZ\%@P('/%/+K>*6KRN;@Q@\>C5.FDJ98MVUUA;*71P\5XSJ.G?
MR_O,8>M<_H+2,-?B6A9T_$D=?&)D>.\9U%T7V!TX ZYWBX+T<%F%ZQ$MAH7W
MED$MH\ Z1_&#1Z=WX97W1F%74H*N,A!H*X/(<#F%ZFF"*5"\=QCJZ,8C2U4=
MPAFH>.X CD39(@M8,"U+3^Y3U59 7QDVT[CVB?5TPQ0HWEL1;K:'5MM"$ DN
M2T$][F7 7-V2P'%"U&V5&[B>0%RX@OP<NQ44H%U=O)#I".+;%P^<BE>24I]!
M'_95C'-GJ?8;092EW!<7A&YC.ZJ9REHV4U?A8<S WXAC_O!4\<:=),&WM@Z(
M!M>,+&).P[$8$\8<_+4.YB5TTES?\L(@#&Q;+R5MDK.Y!!>2//V&+KHG6#I)
MXL%"^4[BE+VRLVU<DF;_KM$*R =7!(>,0H53S@8IQCS^C6;W>T7Z<'EA$ 8V
M"XSU?+X#!F-B_^8&==@4CV,.><JMC:O')8UM[+(&0&BX(C9DO)J8V]4@!W7U
M8ALX1YF,LO0UBND_-R<RK5KL5@1)X?+$-5$',3A75S70JL%=DF36*I!7 @GA
M"O)N3G\9V* N:HC CK,T2;UP2D-1UEW#FI/#+]@<=$V5H()N4#<X2IZF&OL$
M@]H@,VS.&!N-,$:(]R6$AFIAL3]0U (A(;7^V*J!&-FP[GA4X&KW!9(:()Q]
M/B(H40WK$D<%JME^0%4-Q(34UE^/_ JTMJ]SX/*TK:67C&?CM^+%[CQH=0$]
M>&7/>;^3^RCI,PD:R[.^(.NN&CC;)#6 88EY"[E_[0*754XI7C.7VH4\;SH.
MTUP2IR5*X:<-G? #RP(PS?P4-H\D?J>^[(E<65$0 -(S58F?;2;54%#[R\RX
MY/$7.:Y$ZBI3EH<!@,-;IN9*RJL,T7[YR>ZA^[#.C>8QX1IMYA<3UP*!X3CB
M&+"D<(6IP&%**V;(\$,6^Z^>-<62:I,C)"^K-N-8B0Y3,C%#DL>\MY84"RN!
M"-!-RS4(5F ;E"NKJ0_[Z#-2XZ1T:Z4#@_'!ZWIW!-Y)F!&39,^[14%L2%G=
MX4K,K!B.(_\3&EX-^ 3@N#R*8F;4+.8@'/F,L-SA+<P_X7R=Q4 _2J5U8"S@
MBANPH5F#:EA>(7$^DP*Y<D KZL%>!M<HUU J&^Y:B,-R$?U"0A!3 'A'TP4-
M*1-12M^)7ALT-4'*N,Q=M?3!".2P/$@5.=DL!B"0 <P"$EC._$0H;NVM0>:F
M_=SAHV=Z4WIR=(AK?]Z,ZUU@SE)ZH6#[6Q1&VT@+(1EL^;1U06 XS&F--,$0
MYK R>?&D957DJIE 7 -VU[BV_X9T2F8%%4A4+WP;FE9_\6C(YK9;D-,32=.@
MN"Q9I+DLLESJ;*UFK< @P^6\KJ4*M8'C?1N\U@$!D(_#RRRA(4F2NQ!Z%6<<
MW%V89#&[M/U(_.B=Q*I[_A:M !>X8LT:3236P(>5$TPJNSK;#1#0 (Z4&GC.
MDH3AV':2U.AXL54.!($KX+ >SU5(SE*#H>!VE=!H%4!O<)*050'QX+I[7(MQ
M-3I7N;^P. ]VT5YZ"?4MN.?E84.-:[%7<VC&>PG9L))Z[0*]ID&6*N\32&K
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M-WU"!]7L]$C>29@1EH^1>]A!<O^@Z>M5EJ31@ODA3:<DNX9 DKA2XM:;A^J
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MG\NYLXP!.I):P??OGHS;&*"+(V0.>Q6%MC% '!R2>RY(0H NCG =T33DV80
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M<H3B!9?:Y*E0(;PV.8I\6L?OIQ^AC1H&>:$*=K8>P@[0(TS>6#6W.';AN_D
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M EHJK[.<-&@:A+;?+B8G^"5*LW,0[>79V:=LL?#B)<B$SD,ZHS[T>N3[S+[
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M\>P;;+9D+SH9UP78F*R\[A3$$+F$\)TS63\/ ;"W9RZ]A$ROH@7;>/%]]$,
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M%>1B0'CN'T*FM_,3)#<H%=37](/4%@="<\1 5 VI\:-WG4-M)7&<:NQDKRY
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M_@<T'IIBM\O)F<!US4_]DWE5)1 <'#_7;A6&?5!O)%4E2-Q4 G=D/XXX!8\
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ME<XS&GH-^$S^I2EB/\]776J%:-4RPU?KUX#G +.![2>MFC&JCH&K,QL,EH8
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M[YZU(<A</6>5;O%C\,7(5Z*LY?4Y*H4P \]-T=*(%C\-IX?&4 V\D60X3KY
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M23].-P(X7]]E97P7M\Y2RZ=5R^?K8RIA^D^,L=)HC>KRU2H"C*FR*Q@44V2
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MAH++4@&(^BS"J&X!E4V@J@U!0R?D>\794ZKI9K6D@4!H(-V@H-8 *3605AH
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M/<XQ5?@+[>HY?L5QNF.I!%B_AE8;=IIU;XXLJ4/#[*!68ZAJ#='F4*L];E
M+%064DM;!5FE F9JHZ8N%"MBDRB5M8#.DB@-><(0;H+<P:+,I_:$Z;H.\S.B
M4$ROZ6;H["AGOX]Z[B84%$5&GO8%2\7$LB:W ET*O-VE69 =4%2&?K%FV& C
MDKS;92G],9="DLYRM.,L1S&SXRS](OU-DF#Q$N=G4M :Z&F?DX2U0J?$)Y+P
M/G\[!F8_*]4?TS3Z3.)89$FD(\%T)/YDL@)5-@-H9:D65VO%6#5191LM&RG_
M[M]>6Y*]*0)_0ZD!XM%%FCF"/1$V2W,S:HH*D$A8BJ!'-U88SJTQ;6'X">;
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M""L6^83W'?0#NY=$T[2$+6%^-X&ACFL6)F[#LT4MT@3OA8FW"63;X-Y(Z7+
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M:DO2X^IB)WI;E"1_YHMR7E2*%<\4,84I74*H'$H7I1USP:4Y&!ZHZ,7<]+B
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M7:;G'4/0^NM:]@GT>CT#Y2[-$YS-N:MD(RI2DE%/0#E9[Q4]!K\D/,0,#A[
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M6*U"2=EZFF#W88A#[<C/.%([9SMQ]'9,-R+<WPL&.[&I5&[.)-*_FY)A3YH
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M!A-5JB9[1H=C*,=,R))\0S(UA(3>"#BJ S,.DU4 UR19NJKN25(O2O@LCDY
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M;W1!=%<Z]=@\U1<L?:<Z.#PIE<XI *[WK,9VS!>GJIQU^UO($$_SA=+\!#A
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MW[L_-U!WF=Z-[-[Q7V[WAM#_6HFHZI$A<]8R&3F=FSSOMPNDW]M2FW+V_-Q
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MP['H#.$DF<VS%C_J]P!&7B^\7UT9WO\UY[CA)7/GV-!J')0IQ7E_QVI\?5[
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MJXXK#-]8$:1^VPKG5Q U?\UA[H;NV X+]#X/,72OG)R#>.@B4:CH2Y0#Z(S
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MH"'0AF).FI;[$%\PQOYPN%0EM:QO^T*])&M3CJU46@*-ZXK99NNWJBO.K6#
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M)"ML-X[V'N\]8Z'@KLD*Z<?43C9EQ\P(]]<LH)R9ECK?'NK(E-_-#M!"L^[
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MS['F41+!JD-#V).3\P0SS,V602#G;[J+Q:*V#!+\8*+9ZOL]KCW)3]*+!53
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M3 PM[:&:4J]AK =9DL*F?$,5'VJ\F2W1+@B''<N*SSC[2&$X'NR/2XQ6E8/
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MZ<= :3< QQP)OSA\EU$G]N[2'N)SVW)SHBT,D[N,K I@("CVJ;ZZO\#T3P_
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M-@4QW63)6<XYF1&K<%)I6VA<DW:ZA97-D18.V.4,W3ZN)<W4(HC@Y[$;-54
MHU-3UF01%G&*KJ4?6ME\/5/&Q3UCCLATF5+89);&PX_.VG8JQEGBB2[19V"
M:P:&*^Q;4G\"D';)!9?:ENW%YH77.)>K:5!:"RT3L B@NB];UT#RE=!S/X?.
M;S*3QX'%Q8O;[?!A5_QL; VQ(O&YWZ(Q(<2MB,>5+WD2F&#,96^LZ-#R:]:5
M"FJZ?,94M'COQG'*+'9,2E9?0'8J0@FKV/WZ4UZPE[O%6B039L*T9=96O' O
M.'/'HI#T^!D8)9"5(!JT$1?_1^+AN=_N/F?CF$LOTZ[_"BDBSCB><,*TL\S2
M2MV0_,,R-TDD?A&ORR+IW3J)!+P*(TR0_;+Z>K>LM_'JX/4?QY8_$C3M'JBW
M3*HF*.&!,T,__NSO7/HA!9?*K?]0>K24Z[B/%LN/:XME;;&L+1:5S0>O3MZY
M<;Y^_^H1_='[P)\<G+[OGYPT/G[3/^X?_B(?1ZCU50U]I=M!34'M!!*23LX,
M\A'R6 TA.834E,,9I;Y[$<KN.=0/0"KOQRW$/;< >'\VFIO.YBK@W,]NB>;^
M8?NV#5SW?-M#7Z_7=XY!]TC5IWA CGC?[QSO_'KH3\FI/PX[1_U_G1[LZ5&)
M>GJH]N0S(AR\%EBW$%+WY8_6Q_-/[MOA\<F.CF97SOSAR=Y!__U>_X:#^;80
MX;O\S=U"+'>O;H!"7K@9;GQ#;,-' \PX]Q]=0D3.#>-OC_%_GWEE/"H?]4[F
M99QE<>]->G:.^3*KV-?W? Y_<PHW\M_]GKJ6,IW&N]V'[^-I<IM9#'?"*G;!
M;4?06(<[7X-3B!S=9@@+N!A7LQ[?:C21X94$I?$D&8)CI[CZXGLHO!B_Z_MF
MB4YCE( WHAF\!?57/W[[=F]ERLNM'UTK*&L%954*RC?8NVM5X+N9[^_KVO\J
M<^]3Q.ZC:_F/$W6:'X'3')Q@-_1X_6>Y4]I=OX?[_W8?OCE]]_;U_P!02P,$
M%     @  *')7):E>2SJ8@  @3D" !(   !D,3$Q,#8Y9&5X,3 S,"YH=&WM
M?6ESVUB2[7=&\#\@:MZ\D"9@E27O9;<C9(DN<UJ6/))<-?TFY@-(7DHH@P ;
M *7B_/J7VUT!+I)LTZI11W=;)+'<-6_FR9.9;SZ<?SQZ^^9#;__P;;?SYKQ_
M?M1[V_O/1[N/=YX\?O,S?X8??I8KHC?O3@[_$;W[]>#DZ.3T;S_]_J%_WOLI
M.CO_QU'O;S]E::X>7:KTXK+^Y;@H)TGV$]X3=3OPB .5UZI\^^:P_YN^_CH=
MU9>_O-QYEN8_14F67N3P##6NZ:XWG_1EDZ2\2/-'=3']Y?&T?AW)YT%1U\6$
MOQH7>?VH2O]'_;)K/X^329K-?SE/)ZJ*CM5U=%I,$GC3_E'_U^.__51B.W]Z
M^^;=V]Z?E^D@K2/J=?3FYW=OW_S\";O=UH3=O:_0AK?_]6__]F__'?TM.NB=
MGN_WCZ.#D^/W_</>\7E__RCJ'[\_.?VX?]X_H1_P@MXA?!N=?^B?18<G!Y\_
MPI5Q]''_]._PPSN8D-/]@[_WSL_BZ,/^6?2NUSN.3C[VS\_QU][!_N>S'MS;
M\QZ\U=^.X&G')^?PG//>*;YX__@0ON]O=SOP"]YP_H]/O>CDO7?C^8?]<_KQ
MM/=K_^S\=/_X/'IW<OXA.OA\=GX";>H?_8.>M']P_GG_"#Z<G_;VS\\B:-FG
MT_YO\#+ZV>WR3H0CWC[G>T^_XJ0/:172K'\ZVC_'7D4GG[!?W<[^KZ>]'HZL
M60+M#5JX FKU9_THS4?PCE^>_NL-5P2TZ/S-V4<8L+<PRV]^YC^C3_*=--9\
M?R+?4]O-M_ORK>Z)_H$ZI/_D?[N=K?_[+R_W]AZ_AC?O7Y1*3:#=>"%]O?MZ
M.TJKB(9+C:(TKXLHR4>1&H_5L$ZO5)1443&.3H9U,5#E_\T'U?3U[O,XVGN\
M]RS:JB]59!_?,S<=)K5RWQ%'@SD]-YD4^47T*2F3BR*/SB]5F4S5K$Z'51SU
M\^%.'"71H<J2ZZ14T; HIT69U"E<ZO1"[O:?CU]62?2AR$8IO.'HZ"#N=IQG
M9>DDK:&'69H,TBRMY_#TR33)Y^&3J\1_,+;Z[T59)7D2O4N+:IBJ?*ANT%RY
MV7WJCAX!TV[W+?BL)*N*J%1C5>*TP*3 2*DTAPD:I5?I:)9DV1RG)NEVO.;7
M<^<]<524T*HLXUGA._PIPUM25>%-.W+7!O;HJ2S:WD'_?/_([HK;RNB[[M#?
M]0[M@4@SS8FI.>^X63B,,G@T85,<>YRH^C*IHZ$JZP2F:S^OTT$QFD>':34L
MKE3)N^!D2HO$;,<X&B6X.&FO=3MG:EJKB=ENSQ;LMC_3JL:UOG]XLN^OV>FL
MK&9)7F-[KB_3X:596[#7Q[.<MHAN8ZDJE91P38*K)*4>P7T#%<&%>,T7E>/V
MU9L6.\"K-H;E.,QF]#1LVTC!(BNFV".4&=.RF):IJA/H]31+ZC'H"C UP\N\
MR(J+.<Q"*;=E*0Y-MP,WU58D1,D%/ F&=U@6%2_<0584HT>#$ML]2$IX.CZB
M+&87E]"/(8Q;43Z:J%%*PUF725X-YW51I=5K:O<&I/V2M03SW>W@PDF3#/9I
M7J4PWBP_<&RJ&4R*S%9L9O ZS;+H,D')G$?J3QC_"B5NP4L*)HZV%4OR(E<H
M B8%2A2]V"IX1'UIIA,NDWF+H?OY; S+8(;7PW"!B)RH<@C-@_["-[*8:5Q!
MU-71E8+5E2F2I06TM(I@XN!B7!'4_+8UT.W810 "%+J#S8#9A79/*GIQ-1O\
M 4*+]Q,^'@8!^U=%E:IQ<* #*=X$Z]GLHF7:Q3>;WF.9WI/?[8DK<N+<F7DX
MU'MMI_0[_O2S^1B3=(&^^>N!=P;V7%T4.+K34DW22O%PX4^363VC972E\@1G
M&1Z ^QOV@9P=>&6!^RNZ@%U$'Z^2;)8,: *=M\7T0-Q/Z;26^1B/4SKYYM@4
MEBDH]O#1 ]BYR?!+7EQG:G2A1GR["$>4$;5BB<-2)5,7='H-<,'$O"Y1\HWA
MH"JNJU\V</[LGY[W#XYZT>ZJ$^=K&B;.^P][[TGW!_W\X]FFU-+=G5U\LZM0
M[ __.4M1 ?E4%A=E,G%.F:BZ3+0@HN6GDIS790'Z":F2T1GJ'47.I]C>SM.M
MX?9&]NCNSAZ)V[!CT-YNIP=2S=.:J"NP;EW%B9?T^65:TMD')SWI9J@)CE@0
MX3$V3O-4[]:#RR2_4/07M*XL,ME'L&^<Q^ K=U^\!B$&^RO#4PM>S'L4] A^
M;C*=9NF0=JFBMDH+;OI:[X5@!IDW1NE$CDS8E2"M\5@6N9O!T0F3"H^C1S2>
MOJ'I?!).YXB/!Y!_IZ#-E%<P*^?P8E5W.P?%9)#F)-?NMGSWMI)-+=^G:_<W
MZOV)!W:ENIWC G0H=;<^/]G<EGUV@SD^0N/NKCW=V.P^7W]VCT#E=_K9[=QI
M&2/\-EUPRC5Z&KE=>SFM?WK+3UP\9-_BL-S5+4<MZ[#_&QR4@CA"9^B_T*.J
MGF?*GSTU:30%OYJ"B0'FA$J^/!HH5*Y^2;+K9%[]A$;>%+6 #Z?16?__0<>>
M_*2?2Z#H+__RBO[S4_1[__#\P]]^VGW\^%]-<P]ZQW"6WQX6_9; Z/<#);N=
MVZ"2T89 R:^R$VXZ<7>7'B_6EQX,.ZR6DV"4_I#'X,N;=M6<AM%[M<9)N*3?
M3W=V-]3I5[?O]+H:P(KY'FQJOG<?K]_WTY/WIVMWV)R/W<X/I?/L[B[NL/3S
MN)B(-AM]4J"KCVZF]B"X^*/H/;L-J^SP9#]J\U'<6)][LO.$._6]D6/H5<,X
MP5ZM*WJ7=6EW8UUJV!_:=FQV"/L1H5M%;-4A&XH9]&@PC\U'@C3!T"2(F7#&
M(M<_,CZ9B)F+"%-=[$3OB[+;P9&:SLII42F&Q-+*,8!CW41YD&[9EH&I8W[V
ML"A+E27DJI*!CQT$TG\*-UT_"]HL/[<UW?C4"$-@^SPM$<DL2O+=\-_7N2JK
MRW2*?2!PEHS]<3J&_DY!>". OO7L\;]N"^[7[5P5!/6GY*>K:O@C-LCNPIL%
M(5#_G.%,%&.ZA: ]](FCD9],IP4\<ZU&2$^*LJ(W)SGHS@+UQPP/N XPN(1Q
MC,&L2G-55;(@=E!(XR14=9(;SX'!->,(Y!$O>+RHVX'>3@4)5BD]D)9%[" F
M!I[@!3,JHKRHQ36A(M9V<?CKRKO)HBS.S8B6X(75;%"EHS0I"<+$;_DYO,CQ
M^0.$7F  1@)KTGK%X6! "1OE-QC.47X(/P].&?ZXL5W=L+!O*7EI M,25N44
M?0IE,KTTFS, YS?0RX9U+5Z,):)K4F1J.,N4Z]_:[%0UE'R+"1XEUTNZPJI"
MDN$.G9;)(_MYK!#NQQ]JV ^X0;)B"'I&EES#BB^A^_#/Q2P=)>CNQB6+F_%B
MEM$3"->/5(*[/JE@I- 7;1LE^*%VXTR2&GU2VE7!OM($]FA5S=2FM(^&-7%Z
MWM"@W[P'$Q@L>&VR7Z:U>E1-DZ'Z)2^N8:7_]/9@5C\Z&8_?_(R7O@V9#[="
MHC:G<+]J> !@4$BUOHVR^0-IUGL-4^+\-Z<S;]Z)V\[=/L:K*3Y]^%22RXU8
M%>1<JWZQYY7K;!4A0ZYTO!==9;19#ND,1;,%#E^7_Z+U^\#)[U[1(KF$GP(K
MAMN0.)0#>C&(8/^5[\AW?HX>W+0V .I67<"_>%BQ[H5"<);5*9Z]Z=AY-Y[4
ML)L=R1A':N=B)X[>#^G0A+-OQIY:?%(JAVMB[C..;3VX<<!(T4UKZ^W]Q2WW
M'G#+!]SR ;=T)7*(=;Q+\B_E;%H/Y]%!,;KA(1K@&B]VGF[JH E!#:=;O:L[
MPAJF6]]?!=T+88VV@V21(HH]JI&"HC7K:(N/!3:1+V<3]'7CHY#P2)PTYG)M
MTRD&YY,^9%T#:N!^MZGI#J&1=]K<%1+08;+,TA@E<]<0/4OJ60G?Q=$9G(SP
M;[=C[&BMN4>7109*^;S2IM?GG(BM9ZC&5YL:AM"6/$@R!3THH_^8@;*OR@5C
MP#PCLO 1BYF2DLDDR/H2>4%;3V22D: $2X<N&^J'3Z!AEX@LD(D&BOM')#(*
M7K8;1_\^RY5\>@QCZM,J\2M<1X>PUO#;Z,FF(/Z]YZ':W2!:M(^?P%D.1F*1
MMYC^-KPQY%;!(#GZ*AEH,)*HM(Y TRLJPR(A3E[)^ARR_IAMC%_RXY*J4K7%
M703J$XRE!?!R4#\+P5!SF0S3[1!&0NB:V=9;Z3:_#+DZTC9DD;O\&:0/BM[=
MU&"A>3[FXU%KD#TYF6;%'%;90.5J#%)LFL&W6_ P0@>)03JKZNT(!B>O"B1"
M$?*5:F(=-"<8@$7O78CS@6QS,3;X7_ZHF-4&'8/)+AGB$@APF$S3&L1 51?#
M+^M/P93!*;E.VP9H+]CYP"]!NHR@P7Q7-G>?@30H'BEDA-X&Q;QC[[82G[EN
MT3;?),)5E*;.,G>64 P;!XZJ4HRXBH2I7O<M0^F#>K2VBE+'2?!RTOO-+JY8
MRV;$1DB:#;-D!G]NZ59)$W&3>@L<E]"=6@@O9G8F':PPF:KDC7J;=>0].M;'
M-75J B?7 !&R-NX8/@HYH6N,.M&9[:K"%7>=+UY_L$(SE53U,IQZ=5?-FD *
MH$?K$X"\FI57Z17=ZV#:QIIM[1A,LMNSU<.5C!$46_+$*'Q@/O)0-^R*A1](
M=,*)<*ED'3(M/HF0PH>8'.I7R= NLTHANHT/L>+.7 (R8#"KF6!.6Q4E&T7P
MX'R!(@(S,((M/4[S)!\2CN_<+'M$E:BPE*HH+T"S_1]&#IGWG_RI'3F5XY_A
M 3.''\CC(?T!%_B^A5$Q@?62J6#A;F],/0X1VH.3@Z_%FAULHZC86,]"G/3
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M#*C>,0?O?006GS\ BP_ X@.PZ J.$++18*! -_4Z!4^6L-=>[NQM2B2&D(W
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M_]QA-CB!92 V+JSKFK;K-6:M*JE^G7V9)]88;U:F6)>DS\>*TR+0%I26]J:
M]&TF*I"#5E!>IOF;FF.+5F4CT"(\Z!J (J[Q->LCWF.T[ND#6O> UOU%T;I;
M&4NC;:E:Z_.AV\6%R4GE)4$AI WCQO !E$L*;4-"K=!R)3\]<M F4AF#=7 R
M9>@"#BX3"8E)&%NEHW>L1$)8*>=< C,!O9I*;% 4U10?C(I7B<?G'[-\Z.?Q
MU<TQ;966D*0%TSKG=V@E4SIKLNH@0,908BB!D0(0%DZN10'@MZJJ#IU@_%#B
M=)=RT%("SPI.SL)4#PE,!4?8$Z><LG_-/3"B26U/*W;AC/@"/*0TR2B.""9,
M= @26CNS"560OU+&,!NQ ]//FL:OQNE>]FX/+DVN0$&F@6<L-61';@+B>7/V
M$3;\V]Z;G_D/'QP+S&CL?3L\^[U0TK"\YYH@J=A&C%H,LZ1,I7HP;NMJ.3*\
MK9<&I045Q9/)N,NWKLF>5LSRFO:DKCJ*NV!I<XG!H0NP4+XML/=7N<Q-8!SE
M1'-BATT#6.?W\N(R<$/)(;VV4V%)LA3&R Y -<A4^L'@-''TNA:!3Y\R=$PM
M3XSGD[!B45-I"*LH*X:)Z/.M)@P;^@Y,(,'[6ZE$3Z:P!:^*(7$/"+#+#>^
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M_=CS3X/^H-?H#-AQ=W#&FI?]01?F%+0_4D^-YN"RT88/@Y[?&/09S.RB%WR
MP>AG>\D[#"EN[;E%3*1WA066J+]Q]+=XF,W?57JY^S%D3=CHX/R4]7O-]QO3
MO;V]W5=OI[NO=E_N[>Z]>;&__^K%SF_S*;+-X/U&NWO:E>SY>/-%P6L<MWW=
MUW&WU_)[VR!B[<9%WS_0?]S*4E7^VV"RF_<;NQO 9>WV1:/5"CJGYG/_HM'4
MGW\-6H.S]QM[N[L_;\CY]%B6+R(.'+HQ#Z=\>YCR\-.VB#,QY@?A=2+&JF%+
M/_SBYW)1@U;EQY<_;[ /2NZ *$8&I;0/D@/[&?LWYRF;X,PE,?M:D7S'*I/Z
M)4FS, [9L4BRD>#QB&<>"^*19%6:+_RKA__"S5NE+E9I+/45CG7P]N<':H_]
M_3W63'DV IW*^GG*>>ZQXT)$8Q%/V?YSC_4+D7-0:"_9+:KL#YG;KV&47X4S
MU$YL=__%R^=54?FC)]#(\_B _2.)0YA'O+[V021@F#Q@^NX/J7U$J>WY?T*I
M/;P\:G2;K,<S'J:C*];F.7@=K#$%&9F!M!P^NSQZF  _BKVO^!R->2HB27:0
MU?W=_5>W",GC.!PMH(<1"N\VK?!JQ7 Y_YP#+XV!B@<O'BJ4@RN1L4:<BV$R
M7K N^'H):R;Q;\4T!#VU"7NVM7K3V&:.C__MIS?[^[OOP&&SMO/XB+[>>[?%
MH GYF'S,1)PG+(S'C$\F?)2+:\["C"43EE_Q];4QC@D?HC#+609N9Y@7*6=#
M'B4W.!:WAO)-!RUXRA[/8\,%C3'D^0WG,;L(TW":Q*P=#I,TS)-4:)/AL9"U
M>!3>A##,*$GG^+N IIOE0.II=P3L?J4A6M7K^IK5K7H:N_54O]3KC<BO](P]
MQD,@>\B<V>0+:R[TS"B)(DF,:,%<,F%[6*X]^QTF-]WL8L;S#+@DA8'Q8=BI
M6:;ZC<<"9YZQ O@K93=78B0;J7YANE$$NPJM<.]"EFI>F:?)- UGM&WK:^6$
M##-=R 8.ITR249$!F\ .T$R V7%N8["HJ1B6/X1Y#H2!SZ!65)" "@0^J?](
M&6Z05JDP3I\CK>#9@>S=W5@1P\J1.X$<#'A5H%B)R0*VXCJ,"EHD4&;,@=;)
M'/Y6DI.@Y,3%*.))#L^LKXVT$,'T12I'A/YP+M495&=H2 32YTR/;<+8'FX5
M&T5A*G*85IRP!!Y/-;%@>X,8=PYMB^)F*5_X')\FX(EX]'%6Y$480=-K'L,Z
M,GPH#R%4'#/HCQ,EQJKS:9*,Z2,181AQ=P1/RB\LDPNP'M@P*R8306*QP/$E
MYZ! 8-\HH*-/<7(3\?&4CSV;I7 /<AZ3QP0$&W(6\6D8 6</DP*7'R+CHMJ8
M -LG-]G!E^AHVY-YL-*$/=HS6G%]37'RCHE0Z^=R'_W]8*<*I[*SAP.#5'-6
ME2Z670'I8+-F,U106GY<Y:EE/1=QP4'2<Q%1*^@I@@W)8?\.@/6VI%#A+ZBH
MU]? 8N52'*>P)60PFDF&_!RBS$Z(E4AY;[%Y*("74I;<X+["_FOM"5NL];/4
M,2"]?9P<JMQED7Y.(CT#QQI[XY]''.4*YG!< "?EK!G.:X;WV.9P"ZDPC[@M
M$2$209 B R6H=*"0-"I)&8%&L/I<7].=(MTV1XHN60%MI;1(R0*.)58=$[EP
MS;;BA%%N0(*1&B#5"T:/SWDJ$B4.-?I@ )K9U>2M(B4YL>>+K?0"J_P A!!J
MOF1:R)Q()0Z*ETGT [8$-7\QRA5G$-EHPWFIX"W:A1D::ZG@1(ZBN43-TBX@
M-5&#T8*7^!6US@ALYCA$=B5CF+O6:I6RQ&UR=?FFT&O5'$8+!<MT#9K+<" -
M(E=>S,>DL9&;T[&B[/J:HY"U21"P7LFQ-=SBSA&< 9"U%/6FJ\^!7J![49U:
MXF ,#7;2G4M_I(:EB?M$_1KC!(V6Z17"C2S!@19$X/$U45?Q"$BXF(6YYM.;
M*Q[+95?%^G%EF.9YJR#OF &D%KL*KR51R%O'49%G\0N;P,1<=;S/QJ6P*+)>
MD+PYU!7@IMT^_7V:OM)K:*O2F(1=CYLEL)_S MR^C&@\YNA1@8\$8P-QI;&&
M;?[,TY'(G&W&+<5NC%%7W>Q4E#ORF*0)F,<I&/"4&&-1D17)(Q7Y(;JCMD^3
MB.&CT&A!_LHD$B-22#C?>C6(^S3/M2,#A@M[K&LV!X'/@"A93@)%J[D1N!(5
MI+/#^7W10&;;Q#?W!16_.C*K!W/:K5.V_QS&]!'%00C^#YW$0U";QPE(YU*2
M<</".2]R,<IVP 3H?<,5MX(/(!(J<0!;2?^#_220PYT2GRW-"+^R4) A1[_T
M((QNPD6&H,2S.4; 9SW6#_X7%OA\0_=+N8V#G][2/R[,HN/XIM\9^+TOSV[\
MD?F-;Y=;6%_[DN0">Z+<PJ/H@8=NW-<[W?O&Z=8NG=3(CA\E8Q74[!4-N<I(
M*:]:A=6CJ !'!<)?8%*/S9(QV#D,W[(%RF<F,A.64A!6QFM5#]1RUL"V1&%.
M;@O,0\XTG.3*CW$C@QW614=!>X#*,Y7A?K3*'IG@'*QJ&9^S8S2;.[<!7"OU
MUU<A7+!9<JO@#VEF\=,.ZQ?#WV"IVI;5HA[D(;D653LZ*HR%/</0&3K1ODH(
M% ;C&L;91'HD;%-9S3!;7YNC*Y#GQG>\W=78(U\#?#WH(2HRW)9$.82NAUDN
MS/B6XU6A 6$(R@E&[P#83<]=('OD:/K1(4QQDU%)8V"S3 EDX1"]24DM:*O8
M'DE#'+6^MFE#4]6XQG'"EOQB08QLPD[2XQH_K. NS( M;"PR!#12B0 J8H7&
M^5GI&R*<4*0T9(DVD0LDLCLV:;\.93H\ 1T.)DC;G"N1\^UL'H[X09S<@&7=
M0#Q\N]5M'#[#ID=L>0L]](PA<%TF  -/C<<9?XJ5M=70R_,M_?59"!YEG8,+
M$B,YCYSA%"4AIF %M(P51:STU!7^A;@/-E#M<0)[K]]AW"8!*.!6"B]ESPZ\
MI/14S*>)Q"R)C:$%*NK-YXK8,W2 5#C.-G6T*G5KE,33&A6K&@\7,DY>CO.W
MJI3LJ#FL$()0QB2"M+&F5;GA2G/'!(J.B@RT9:C8WH1[2JUY&K@E'2<)H*-@
M7/[FGEJV\OE'(>T:* 9:MMH"A/'5EI)N!S'\4BZW8 @:3V)/#EA9AUP8Z (>
M2&9BI!8D9TJKTB;3 J(5.(U=3S@%9-V8LW,PL/A5"W@I3#.V^3][WN[N+OY_
M.;26@8^K@(%NZVMVU%Z*9\;1AP;66I+2S6Q+ J=9+D,Q!;GKAA4!Y1:K@U".
MHA"=B\W]K4TEID+]=TL**DUR3!Z"5@>47-31_C@IAKF4AF(^28'J9F0DC3.Z
M.QZ0@BP18E4VFB\9X/[;7YL@DGIN_XMXD+GJR&*L.B5I)U>(1&H#/2; B#<F
M$Q$)BE=M1," /.MK#5A*!2VX0X6^ML "S5A9,=Q2<^/D.JAL GAX85Q,P%<K
M4NYI[&V&RX4PY7>N@;0BHBC=1:6D-9;RK]S0C-TD:32^03'?)'51LO8#).D>
M0I[$?#L'QTMO<QUW ?^=H/PL2]Y+(WE VQI+XS"-DRS3KHE115_ B8ST_])8
MB@QAE"4(^ +=P9U+)<:)#H[D"F)!&^@S"KN6TW?8B9V[L<QE+1R4Q&!>$A3>
M5=9]AP43-WD"0CS'$A-MX)!3:.\]RKX4RBPD#&8JN8H(^9F/"DK@E4L =C?$
MF(-U2DO89R[<S-*R)2,M$VLO3L+,M$ST!KW;_0 D+W8L1TNL'E!^A0Y:-'QY
MO]DD*#E)!#M#^@3\Q#DNN!9OAJ7#[$8<W! G,P#]Z6BFI0?[0I6@D,-YBF$5
ML=%\'BU(T0='X%K [#-T,6!S1';X+#B2Y'"0/!@))B[11 TR<F7JB5[&+X+5
M((PX9G4,BDJ5\H%)EB,.J#4.\)[E2)10]TBDHV*6Y4BQ3"7:LYQ-H=-,Y?4-
MIVCU4D:F4M%\D2<J4="NL;_U_JZ46TD-G=P:DOJ!R!>>0E.8JGF2.EQ?TQ;!
MA+ 3= 9A#5I_P0,4Z)&&E>L@##JKRP"0.E[AQ1 F@ M.P6'$+?) 5ZJDG)5N
M8YN?76L(!H* UK"*MNJT25:N>%S#U'=AVF_PD_0,RLH,78Y! J.[ET9VL7)Z
M6J=-0A%EJW#NE9NW*OUSGSC%Z"A'(TAOW(DBO!5ZH]*(+.7O=RY4KR_[PQ>X
M,BI:T>D]$QE%[GKC.G)YH+FP%(HUT65=7/% 8L=$7)$BI60.\+$Q"$!N07J*
MS(?NV]0S:&V.%0B@XPL:S=+@UGQ0S8H1+4I:D?FM)+S/OM2Q$XF,/<#3 %_/
M-?!%"3R)>S6R2G4(\FHUD(9)3_"@ !*C]'96*3699>)*1[K2E"<F3/(D$'JG
MIW9G@_\4P"P\W1XNMM6?RJO3SMTPA!!K)0+F5?**!F-*N9@-BS3C3HR S\NM
M5$K )LXJDM #ZVN5B'] BE^RNMD2MZK,X#URR$H')UQFD!TO.$^F,JMHXLFE
M<:K0V]+@[PPBZ)5F9A9^%K-BME3?(<MR*!U<9H$]%3( R:7.M9+&2$:(13YI
MTH%L;^I4Z/>2#]0IIA%%^AM'^S\R8C\R8G^AC-B#-@Y"XH51DB#4$"7$/$(_
MF2H+0@@!# "7I-,P%K^'*J62ZD# .,'@;&RY$6:U/LT.& A+\>[R_S&-8165
MA+.DD)6NIBQ)*JGE*B\RW:H]1JQ##!)'& EAA<RJI H6?6")XD*752X#MDDE
M4G<U<EGVXH# 11SQS*J?T&CSRFHR3-F!D96217:PS%EA5G%]3?E7")J(^#I1
MT+OQVQ5=I?:&E1>$>EC;_0 KJ,A5>D-NY;0LQPI5\9L<T0GQ95ZRBNJK6>\P
M-VY;+@\*Q[\562X#>K2<5"T[ ]UJY3X)&D#7KU!)%!%/HM!4XZA@KXR#-2\0
MS4<TY7N"&29!F+.(8X6[<2JL@BRU0#G&#NLD.1(D(QR &.].GU165TE!HK(>
M$,=TX>9 K.);:>U-5C.T]KR$4N>POL]4) 8\?B(F^6*;L+S!55)D2"8+S'LI
MD;S\*DV*Z14[X<,4?+2%<IC?J&,5;A PXBE6'MNY1,D-NH3_'-E*Y42M'I9U
MA4=8"@4"140L4_$[+$;>%'G&HPDCCI>S_5+M!21,1?9)U]<N)R]LMI?L6N]L
MWBX)JH>Z?!>L6;.>D6K<V3'/*1(O.X800(H=:J4,=-R8V\5\&M&X)Z,9S.1.
MKSU.XNV43Z!_%"3MJB-A[O4HB 0P!SZZHY]]BI#JA0ZI+A0!953E(Q(]"K,K
M35@K;#(D@MV\W.GOL+&6EB7MGLWYB$I+M\R^4,B;)K$8,:0=>-^JMF!]#?H3
M,V!J(04SO(:=)B6E&B+6- SC3S(IH'2<K";1.)&N02[%8H>UT>8:_E X^&B4
M%ER"EHA13=)D1JQ.(-&XP+(/&&U.=B6&F($28/P_: IA'HJ)AXE2T0@.;Y.:
M07#9/ 1.P(S+1U,^!T-=6KK# &OAP'S)2CSVCZ3 NDN"1C>1JA[[%2;&TYCY
M4HEL@;1"4#)AX"_PU',C&A@NC,KET)!E;0:,&84W:E=E&&4V$=K/,7XF.H/$
M J&0@)A 2FYB^EGIHSS\K,T$>$<D1[45S?+8CRK3%WE9/00<7T@;0@K-[1?&
MI;U6]+%A<L-Z2\>WOX6$O-02TN,(J"@!<6WU#+0]:7Q=6J19M%";3T]ZX&8F
MR:?,LQF8L%6">%$.PI%4S+*!*7*B&I#ZDE@3I>I^EH)EZ@S]A=KZ;IUXN43<
M=EDA&T<A!>9'UJ*9Z4WEG^<RT5OZD;DIU[?GN;ZF:X&K135>A935<G8@$^H4
M<@"P EG3DM614@7Z43*2+L\-#H-?+0C^R_)$I;R6R]2!P%AB;D?Z"R=38"_G
M:>"O5YH3@PO6([S>0&#:L7 \\K+8J'(V(N72/<$_L1]0)B*/5([6*!%U8@K5
M+C2$+06= !P,SM8TQ:-+U)+*H5#W8$Z&4P; @7W<S46-<N]12W\MBBKIB-*5
MG5\M,C$*(U/AE:D#;58%_93'" ZN.."@?/M$93]7>5J80UL=TJUTE$KQE%GH
M&HKIW$LNCZG9E2'R&03IC58  Q66*_)0&8/3=,WI*(/4L$2].?I]Z#:!SD W
M+P8>@3V8X,H<C/INFMSB?GXSFE1+6")KQSV+1IXD4,D@]=W?34#<;T7!&I-7
M591%9J)&Y_#&JAS'EQ$!)L*58T;#67D.Z>\3A>#?L:KNP1.@J65JJQU(NL%:
MKL2<;4)W8**0^Y;H[=8]KC[^BKL-G)+5U]%1L"\=.3IB1:/H Y3T36:7S2FU
MLV24[J,\:OE934X^)#622?U@XE1#"1(S*8.W<3(JI/=(O8>?.#-GW'0QHK'<
MF899K%-*:#R%,3U9D:IH!F= O<B=KEV4S%R9-&:T<,ZG20I&8\?C=2.S$94]
ME3J<<?!1D@4!"!E/KX'%J4  S6YJZU;P63%NC#%[C\GPFZMDA>!0T(E!/F7_
M@32K2&_M/<I14N0VG=U$CC(87'*GD@78X?J3=M8 A@X790H5=UDELU85A:R"
MX*H>B@%FZ&24XD9,.R)(1[[K,!)3?9 8-3$6T,&N3@3N+5 Z(Y[SC-LH-_Q[
MS1P\_Y$Y^)$Y^/^;.>"QK,*9ASF7UPY@*%%%U:MJJ@0IC5TC=8(0K*I)H-"J
M'FHSAF64H*N@ZX)0LV:YC6S+8]BIK. EA80UH5A1J]40?KF^1IH([TT8J1'5
MJM2QR^7)VN%@=<X[S-<G1.RCD^X9:C>*C1,%<X,.UE5*JB0Q7MSN'9%&EZXL
M]$DY>^G+E2=*U7?+%7B4]Q$SJJ$@\_"T4,/KLKXAGLASV:"$Y 4ILEILY/YP
M?[@17  -,U+)VOI:93]@CS5L;>[/:3FG3Y0#6QI,=2]-.$O*LPME,0+^A%]F
M(3M+Y(UA[7;3TT$,[$<?>(3/ACR5LOJ2D/"7E+42L2Z]J[_BH>;\CIM_:E!M
MK)5YTMR ,.-75BK6Y3&<ZTBLRR66D#%TP-3AK+2\=@2F8N\Y"V)*1BT=EB^#
M-5S@%M(!&/"JC/F=X-O60.#I0.3L.>&);+Y:1[D3E-#(BDG63H37X(UCI 41
MGMI3Q 1L%B69.@&CN+J'N8#K\KM->7?0:E)07*9B'1DRY<D[X]CJ.A!AX@GP
MZGFF$JNJI _W1M<JITZ&:9S(EO:AI=I:L8=4RMVW&*L21]^UC^8&%[.1=Q67
M&C .-^BN;3;>]1,HR#=:0>JK0^3E3[87?]\;8CR=B[8*367):NJ93I;OD%E5
M9?G(^[YTJ=6FS@\N[?*6CC>MA6">Q<%X9%&N($%ZOJO4PQB\:F70%9!3R?;B
M23'\N+EG/U+?UC[G0B99)X[DB<LME+PJL"\3!(BZW7D^4]XE@:F_]36\T 5#
M:')NU ,JNUB[QE7KN'/*[KF[)^'XM\CE$*SH&^+(WQF4Q<M2" B\7^;-2IG@
M+2H@+/"\78Y(*MZYICG),U:\$OYB[;D"/LIHEX)OA0V2WT9@X6I\L11!.Y=/
M1\RQGD7G\O 6'E5!0"WM&U4&%9E,[<+N&B[2QXJD"VT5UZ0\H@'P1\F<E!+$
MCY$(AX*\K<1>K;0G6&$01M#=>*&2B@J66=B<3I>8E077",$ZDZ8K2VZ=N:=\
M#'U^CLQ:5G^J6RTK*])K!?K5G D1J9/;JSDN?F IJHS)]#CYFY>8-<8#>JI*
MR+6\<O%:E!SN(,A+$4DCQ^"(HH@]9!,1:U%<"!\P[8%5F5O>'8KUI32HMS=Z
M=9]&K[5IOK.HX*ULJ<AFB+FWB]^3)H.O]UZ4=PE\8_6"$U$Y)>AD%IM@PTH5
M5VIV5</)POAF[C%?@_&"H\9C0KK5 Y(.5Q ,K*]=A>G,R+XE*?<[NBA=/L\X
MU,HXNCQ=A2_E-7Y#71,#7J"6<7!'IQ#X9+ESY!!<THR.H(6S<(I_:$5 _JV*
M=3-]L)&JDDM0W\J<TGU_NKU,A(:P@VG,2_,[(30V3 5YP0B+TC' !1ZN$S,\
M!C<CGT6BS%Y9N$/' OA8U3S@$]9IG,K%1N592UQWY0Z\F$]!4J7/E%*:<%)$
M;(81H+P[34UH>?M75M#90@N>N'WZ7Q8ON#9?S;]F@*7>GD96]K2L4, "^X*%
M^B0L_VKZ%P,$M/Q_7?3\?K_]D?7] 3OI]@9GZVMG?L\/.A[S&\TS=M'H#3Y:
M[5I!O]EN!.=]UN@HG*S=9K\V>@BD!7X?X3;\Y9>@T_+T<ZS;8\'Y13OPX;N@
MTVQ?XNW-A,*Y3[;\?G *0Y_[O>89?-TX#MK!X".$#Y<]\W?Y8]MG_[QLR&]/
M@D$'AX)%L 9-.VA>MAL]=G'9N^CV?0^\DKN0ATZWLQUT3GHP.1\Q2G-L_D3!
MCP._W?8)%V07O>Z%C[3I!:=G@[YL$_1:<FB_[^&B&[V@CRL]Z77/85;-[F6O
M[\N%PK0[IQZ[[#=.?6PZZ#5:/O3::,+$_;[9)5Q/.U"+IT_'/=H9Z 5U-$P'
M84UYTAE^Q19 >_^\$YP$3<(\U]?4EEW"]SW[*:G8<4]8I\O\#S[2YPQW%/=0
M[OVQSQ#E'+3]%AMT6<]O=C] +[0DI$H7_M53;?&I_H7?#!IMVF@"2/'O9K?3
M]_]YJ1#B+NY*)Q@$'WS6:IP#!8!<.#H+3EC_$A=G=7K6:"',"U31&P'[V0\4
M1;KJ"=7/]W/#634O\>)'7N)'7N(OE)?X:OME[HUJ4 96G^;?@79"5P';?G:L
M@R4%M+NQGH'*,7M  (3)2RM+7AYR1X>&7 0'.4!LT3I)4'J!& =NRH/?NDT9
MJ0T1C[%2(-@_9L"],G1!M"_!^X&B<,''SF&PJ^0&8K!4H8'E+'$)*C&] K15
M5*!"@5HZ."NU7%J3,]%KD7<^&1_W=H#75-= F(25</(+RHUCH<(0,>A<'F]7
M*7YL/"S D:1:7 5A7&A_4-]Y[JP1HE]TMCUSH2<>_.#IE+"P,.)T\#C+D]$G
M\QFIQ='GU:ZHO YSH \LJ$("BU#N@9':NKH2)AX*B:P3<B7+(:AJ0M)BR&.@
ME^$<0QHY:%GXJHM*W*%W6"/6NZT8/?_20\?R2K-RWG@_S=-XI^9P["E=H$KY
MEO"F!$GKJ&S?M:J"_RRG\!P!F!K4 .N(#3F;R6R6Q#<<[_3$[\Z!I.#(%\ 7
MJMX?I8%N&J&X0E[$3->R9O*]"#<$)L8C,8]P6YZ";"\,P'8.7CV/HC#F2>%6
M^5I93WF6ABI2[$(P>>E$J*(D"GDAW,-9L3+>E*&B>T)<T,53X%K4Z<%%=>>\
MRN%8W$9UA4=67E0H<Q^>W$V1%[DZS$]GWCU3HZQNBRBO@EIUMFL)X)$R)^\;
MA"@.$P?J7)",L?$$'1]CR$T%O8+LB+R3G<_P]1%$8JD!= Y-U3SK*6A:*_P/
M"_>= 3$'AS=(BHE.W>(@\.2X7(##\\J6*6J!-M,R4%X0H=!()S$:LO(8"HJ&
ME!]CYNR<EU0KY>UO*%_0K9549C,\OR5/3FATTZI6Q0R$4$6+ZA0B72VC+F66
M15)4339*IC'P^%BGUX&T14J9BX1T-Y^%(M([950_)C_I)FV\ZUO?=3\>8P>;
M>.K'N@E<G4I$HBE01+:SC0E"GS#ZM8"]A%E9!S'H!%E-CL!.P"\I)>5$J(*\
ML:RZ+"A7"\.!0P"]3L)1)D"6":.X:)V4;U7)MCQS?9(T<96,(P(O\)282B%
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MAP&VV[FI!5; <(VV5_&SS*X_Y'XP2O[=9:\G&RY[I5D"8KHM;"FI2>DR/K#
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ML693I&-BV^ 66 ''"T"_W-51OE+?/0'":Y2M""!N\?.N\7,#@W8M_)1^P$K
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MDR!+#+AERTL-"1R*M%)&)K23.IP96K28J%Z0"Q#5TT;DUETV_"L.ZU.Q4\H
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M>JJS:BS^]((-::G4X$^XA$]J\@NP"TQRNM"TA(WIR;*^ ]@)X=3DBECWMU'
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MU.Q4A7UJ)Q&<P15B42D8(<$0BB!9-N2RM_[4V_M3]S;:GSHN3GZ3?*E[O5U
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ME:A6B2^PA$O*'ZCHH,8+C7S>M32P9:.:XB$'Q^9J_;4\6L&HPS?+32W1Z$$
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MS+@#?,(IQJ& S? 6322<*143YL8M4 AS\!",S,%K)#"D+["I(.@X?N"J**<
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M705,QN2;2,(T.*MA;]'O*:84$3'8TR2$D>QW:U"0"S#XX<VI.A<] *G4N'%
M-0;9N  *9[KV9?>(!L8?E#4L!NY 7:H1[NIG10HU7(DRA/61U%>H:,5UM%;D
M]R;<+<C_6:?)7U-6"^4#X9VA@9^1(2<TGQ>70>B08[F$2Y#@U4!%]ZP VB2W
MT1)5US E_7<X0)H2"@VSB,C,4&X;O2(]SHA-ES4.YUZX):NI9#;R); WCC3B
M;^&'0-[X$J'C +5:>##)*I6A.AWE-?#[2WR$+H)KB:K@[?YN3_GW0/G/NTSY
M>PHX^P=@NJN4CS00X=?(DUG-F(?HE%:9]FT #0'Q+8F\%&HJPC QS-7K"W<C
MF^^Z339@C8+<1NL;N,=N%J:78/2WL$^RIYU'0WF4&!O8VRQW@1$N5<2/$7O#
M)U%K,(PKQ!\LV.@EJINRFUWLXEY#O3O%??^(*&XO7X VBE*TC>;B/*I)@*+D
M9$]J(R@55IKVB+$YM/8FK**YY736:POC !U&YL4<OT)U-MB IZUZO"EJ)HSK
M:<$R-*BU>1&7\(ISQ>\HU'FB+B28R#I#VZ1QE=L_O K^IPY35#MV87$%SF0M
M\6/L?[DF]K]R4H%[5"\:-^#!4PATS'@[D!N',F1_\C,L1M(=8#'T_[ BHGS?
MT:86*U/!CYRK,26WV<LPO0@O2R3C;Y>HR+P_#DXF_P\6]NP;/2YE9+S\KQ_I
M__R[IZ>[-SXX'1___IR,KY&5\34R(H:#FZ9$!#!<:S)$\$?E0=S+S6"2_ M(
MAQ\>D70X9=Y^G3K24$%*A1%\X+RWTT6 3\."YEH3&?&P%/R0\?0[K'=BA;?W
M^LO=*?1%IRDTSV:PLJQ"5]<D(Q\ DM>JMQ?32YKAL?VDC-*\%)H.=!:*&\H:
M#JRK+K'C2^@9!$&"?HB8!V(2!#J%!Z9J'J8SX_.BUXM+01S-;3,Z5I%*SI&J
M5V:BXY+'*J6 -?N02]*28C4#:Q+>#N;CQ28K5%F&CCZ8"2E4#1<(!^@P1RB$
M04"]NL1?()$48@<H\FS;S97DJ2RO@C.5J0(VY#((S\,D)=^E+&U93T%=8X\@
MW,L%3A@_MSMMMR*?4D0P#*9UB?Y)V.08W8] M@&ZALA)!/,N8"C\S0:P 0DM
MQCE-Y'.67P3BD"EK4 *=$^)(Z3KZP'-QV8LX:3@2.!RH+Y@Y!3K@2 *6Y%B=
M_N:X3M?Y0+.07$7B7 7"6-822Z6CKRM0=<W783%-*LXK0WL_ L8'6P2O*Q+:
M*W@<'Z7PPS5'NA7L HG&817R43EKM6X%H$Z5$/71CJ+'EW(>AH-2,V<\5CE,
MX<U>,H7Q; 3GH'O%\@)\*U-%Q6\QP71VP&&<.* P,0R&A%8E58UA88ZBBPI>
MKCVNK?4'J;[PP;WLG6HWXO5F49:IRY??7R<(NACI<^F<;<Z*:+=*^)8)9\8K
M"53=8*_(T,1[RXP+&,L">1)PY2*OS^; 90),>D W<[X LU=81V.<S5>]GO'0
MM-?!0-\*[5V *$:9E"$+;-+:LDA0@\W14Z$2F,^LR!>K@A'%.;DJ_$% 4\:O
M#:>\*)*J(B<'N3UZ"GQX"NQ@K&V% A-7%VUA>$!2H:M3D2:!6D8(? TXX)G1
MCESE#]UBH%0,!_/P7,>Q4G4&DIA*5/!%H)&5^3KB#:ZC74IQ[^GW8>FW@Q&S
M-OI-0&-<8B0UPUP;3W=M4K,E7J!L4#]G":K+K(NC?<!5!J!U)NCY12&N%6OD
MO:,KU,V>&._J-OBQ>]3FN0TP(\OS$I#%Z6>%;8124P8B':GFNZ=_0UMLD1<F
MF>4\KSCO/*J!JZ$EB>8_FEB@,5Z 153.DR7E!A2JK$KC#^#7P+,;4WF'PUN7
M^84B58&S=>@S6! <C,Y?6.:@K2:J,5Y/M_>0S?BTRX3[-HR2M#6C!JE@)M^R
MIX135-@,9RXW2SC:AL\Z>6?6.N]3#.Z#@CIH)CL4M+_;3CR?LH2\]!7EZ[_%
M;$.4H_M%?1;LQHLD2\I*ET!21!6$;EE'D2I+8$BP=5ET&3 3&P[*>EI6(0E6
M*=PK0S#(9W5&#JS>,7\?=-9!D]C2V01$'M5NUJ!; 1_"S+H6MK4$:LLJ=K#R
MOS5G(CH9!4!SL<)<TE+'\>V7PP%]&V1 6_"HE,50YBG\*;X<^3+*EY=DK4A6
MK?[3&Y&^XKK90D^@C.8*U<*(_*!Q#5^ANKC(8T4IX-DYLE9Z]-HB'W0./)GG
M%R-=U,/S!^VA4!5-<H'NX@)LJ5E%E<=@39T5H?9 LUX!VD28G5%>)'R]+!)5
MA<6EY_)U'+:WU7$?87;#3I_=T&<W]-D-'111'?29.0@"9#2U):=3M0]HSB"[
M1IC=X,(_A.0Y$\L.5:$@! TH2LS750$RPC$#D?=6'!8NSL(L^8\\:7ETZ.;"
MBW5782P.%*PI3H3C#@6]C!4M*EC,9[T>=0]$VD''F(>M@4'8=IT]1N5<=&T,
M5M/?G#A>42D:$RO^B[Q@(0&CB,\ 'S::.M9-%(W?:X^<EZRI(V->@1 '-KBF
M&)/68W8TFV!Q3Z;W0*:=3EWWD[O:J35-2DIGP,0M*G2; 0_+I)Z>TB$PBYT9
M'V5#Q$!Q)4<>*'\75%TJ3 >C<\DT&Q4)Y> $H&U'\P UYJQ>P"<X1HJP./@B
MT)8=QYS]D<Y4(R  ^'3*[I&\B-G]!E^%4YCUG,KB:>[FM_ UOU-GL(7LARXY
M?V7F%0Z5\[Q.8XJI8(H;WQ4GX496I"N=,&M&EQ,-!YC=PJ'MPH>QP/OMI#5S
M+L4(:]<I&:;T\^WPUV *48D25N1AK1[Y$^%O"D52R!Q3/_!_S7BX(1BP 3EU
MJUO<U\:OJ8W?Z6YMO$$1ZPOC[W[4.UU,EQ',#LG%(NPLZR0NYYCEJ,%./ %O
M 4]<L!""'K'C&86!;$AD7<#$\B#F,@W*RE' _5K /S!5;TGR +DA\4AXRADY
M*2WG2PBZ34,B[O(BQHVI$,A)6,.FA95DM3EX)&8R+:E\Y&F9JK5(**&=]F3&
M>CA.+Q0D@#!..$=/P\R%/'.=.M3RLM"9..$#2$J2^1FY[+V?T?*J\#-M&PA*
M%*-!G:6818F_=7;"R^PK*X%4PH.J:(32'8*B8"0]T&T6VSF,2 Z0P(M"2;<<
M#IQ?,O%,%4M=/B;'M;924\Z)@?0J)_[0ZXEWYCH=] K#=?5*MOC*OG'S;XF@
MJ0KL4F>WJ@:V%]]7__:_H:'ZJ-7=R::#GAH7OJ7D#/W^F!\N1PAHH(LJBU%/
M%B&F V'>6:78@ID:5#)7M+#C TPQ<GV(HVS$-J9%=?/"XVB9HEF4#0>:L^R9
M@B-/?!OY92Q&K0;8KYIVFOM:D>^^[6O#].V"'J1JC']+94;CU_ANNRS#/#.%
MH5D,#"WRV-J!*_H>5GK 3[7MV8*FX;] WDCQ7/6%(W; EF<KO\1L6%(TG)WN
M!?R#7^$.RO_=QKW3Y5AXH\E6",A0"#V-/X,K&<9> 15=M;!A%XBQP4/0;1L.
MKKYNMB#KJ]RW4_,Z1T=^F/N&8#A\X9P]ZYTV=W?:/.NNTP8#L,>[>Z<8N]R#
M?3[:_=7#?^]+HNYP])W4B'0"*RH^1T7"8!TOM8-&O#BA4X2'S #L;:Y%C(.9
M4J;N*5P@6I5&4LZP,M#QLU Q9&NF8+-P=75"NF[5%&(ZWQ/G1Q?X''9&? 41
M%@-8!)#P^FR:M%XLGY3U0B?3& ?_$MY!6;E540MR5^G4E7L -RV30QF OBLJ
M+ PH$^+/E"WSK,^6Z;-E^FR9[HF:#FKNY&I;JJR41AN^D"E4LIC61:FLJ$&5
MUH *B.=<8*. ^2H9R\0SAP-38R' C__Q@YFF/,*+T*Y-8"?;?R-J_XU?L&_3
M;TZXJKZ\AM7W2M.-*;F;SL2/2:K**L\T+:\8DQH# K-F+LD<1'(FK[32=9&A
MP=J72+]6.A9Z]!%!DF9-/TN65\G,1-598H2S2M0S\VN*)47S1)VC:TF>7K5*
M">9,P_;-I>C=#H*^%SV*C@LE%<\!W>VVV0'._2(I6>N":\(3@X46IMB.XT$Y
M @U+H,V^2&\4(F%C-X6SC.<')G.J2Y=F85(@7$1MK%M0]1C=5>Z?=MPY(".F
M")!:+!AX;OMF695=@ 2Z+(?HXTKW>:<[F"5'@#V7NHO8UJH%Y!@];.B0W:,;
M4^E+8 J3DPPV)J)HE'<7A@-=LS_%Z!1B211A5LXX2XB$442HOP%?@28*RHK/
MM:RGBZ2R[[/A]?,D#-0B3##O%(NDD>V\U()IEY>UH(J)!58.M.(;Z^J<9CA\
MJOA',EJ+Y8/N-,13*3E-$#@9CM7<UA$G:UGY6X5?8!$;?$.!&V7R29ZU[3$"
MX+A0Y62."B".H.<DBZ6#IJ07J1QP:'G>R9LUWQDZ0",33W*>I[$$!"XM^A&.
M9[M-+0F.AG8&P]IB M.#)@\*/6TNZYPQ9]08/T(T!/-3)$#G8<JY5"A$Y-7-
M,+ICBO(9+92JF'^6>7K.#^@7/+QZ0G;67X"7=3"5$GC9 7*!\&(:1I]%0SFT
M-VK%@['4P'CK,,[#;)V.3&Z=QM6W]]%PF"N92[M7"$-?U_IMLCQ[$J&GAZ##
MM/>&,"!N\E-0+6!F^%-31N5?V :SY>=ITC=HU+0LU!.] WIXXIIXBTV(#S44
M@SO8:Q=WOY$=1$FVVD6PKV9AG8J6,6$>K\[IGLT(.@6D4%RK57W#;Y?5,IQI
METG)<@02@&,2J_^;9+%%45$KK8R(@)$7:HD6&B2 6&)L+%F\]YE(=>-SK7)3
M9Q!2H#W]AXV4!E*;5HC@36P9&''8&%PB<,F*$8-Q.E &ZH)XB,92#)"46#V[
MPLCW>HFBF,?<(&H7V,Q^<],5Q<Z7_K';&"OMK^[=KVX'(6PQ<RC+L/+XF$#
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M<D*)OL)O[31#ET9P-;X>T: +GAE-8(;PKVX)I3-M$V1PT"X3)Q,#&SI&U P
M'9(M_KX$5,FR8A\H.83YG<UZ$8F%_4)Z)%L+#HRC+LVBU*!*&K*L(-*1.]CS
M (MJR(]-CD2;XS_WW!J)R;I,$YR$;,?(_8,7)[B>5@*Z+_/PM-:^+13'+8DE
MKL+66*$</>2*%BT25Z!#M2=4TF>\^=89^^"PE<^($3,YV%$VZSB<S)>>*]V-
M*W4S&'FL!/<6B<EC2Y]0_[FY,M=48HU;6MMTH*HNN0['*)]:L_6(TP&A3Y-S
M45WU[7*4+E][Y)"/\R12M2C [*S(@I;7&90^_3.Z=CDCY]'3>$.J%H1QJNVR
M)NE5"N%P<'.-T"RT51$,#O(*&0SQ3#V6\4_XC,@$985IB0O +WJ[LEJ/#%L7
M]-O/>7%2Z;C02O+Z-2_I.X7> ]?HIHGKZC(B(JPNX\B-T@HC&_E;<?8XQ>3.
MK46SU89\+*1UB1"3D20B[8$<Y(@A?;#7R!/:WEQ]9C<+T\L2] B,*LYJF%W*
M]8N*,*(5!?FH![9Q9#E:%E7C[;0,>RH_Q%'EZN/-@D]++GDW*41MKY.*5^>-
M=NF;5-1BV:XX:K&LOYI3FVDY#.4=B+/WNO.3=06X_*?5,<L%GB8AEAL*F$19
M3M JU#(-(Q-<*U2C@-%QP#DQ?+<%YRRW25#<UGN!0.S<W)R6K1M[ZRDB;O&?
M)DCV0Q\DZX-D?9#LD03))'$C\7!)6LPSS,]*5<R)/8UTI3O$OOR@%V?3<$J?
M25!VD&"L.H89+%@*,AR@E],*AYO(8U,X?8KJ*%;KNW !%%GQ<OTRX-<PIYF3
M,F2$$.&ZBV2A7:/\6HTOEI7.=HU0I5[1<W7V,4B5R<'>(=RLCR>!& D,2JV[
MUP#3FZ)70GO,AP/?E](LX:^\U:WD!DLE;:./;"B>:7R)U)GKZ9E)E=J7CE(S
M+(H$<13@WS/$'YY3VL]%2!&[OK;DSO[='[KKWYV  /WP84Q\&WCUX1%(IU_[
MXI+[./@?.NKN/=3^1CSEWGWVD(W8@02Z2 3C+XC([GM0C!74TB-Q(Q%OEA$_
M(-4QH\6ZKJDBTN 334#E3=&HK,.4-!3V"K-R4=+/O/:.N2D@C;EWNY=?V?"M
M41<XQEHQ[=&]T(%)?]A8J4:8^$B+E'2>Z-7),[=86[!V::Y>=OWJO&=;U^>N
MQ7'9^W5;_5U^X+O<04_Y%;B\;@<56_-Q3HX?1[L>&8PSZV,UA#=RRYN' [D*
M-#Q9 HS[MU%N!@O2&RU#(<>QV"+M=P:[551*(%^HK+D=>O#*PA$+0]C^$E>C
ME@JA<XXKP)TBTXAXQB(OL!:/EK?9N&P($#8<-"_;!&OESKG^9P2_CVU] ,\)
MMC8Y7T'AG!Q1Y0K7(@8R.GSJZ/98&C$E/)KD+'/M*?XDV,!/-+ID@TU@IB ]
MM4E[0@L:2<4)PWY+=R$F 'FYZ\AWRE=&PX%D_-!ADFTDZ?FX(GRI8"# 5F!4
ME39:R$BR8W+IT^.B))!IA1%%[:*;C0($T,.T-O$3KNZ*GX*$)A=[5&3%I2DV
M0$2S*:/HZ,BO^T;M!39O\,Q!,^YP ..XB7U>QS]N(\@S/@,;K1(TC-:9K\-6
M"-T^CNQG)5/4+]&R^'=\@/YYM\2O<6Z-< D3"QY.H18UA>CQ*LTH.J*OPU;P
M5N-($>_4ONPXKZ>5$T83^6@P$# 8/S(4H.RNCW1E F:*S506C[C(@H]A#4](
MPV3!=G58L7O RY?LA=R#"[D.!G:N"2[>KWCATC5;,Z_50\'C9=A$&[-TM+&1
MHTQZ3R/>($'5DZ<'VWM6\SS&V^OT-W9%A&1B""_AD'*R=NQ6_$7XBK-Q4JR]
MU_UN"7U,8[W!$!R2P@J? JYHH3(W7&P34+2<V(ARVF@0:CBJBR3@3L&5C9["
MG93N?M$RT8?ELLW^?M_5[=!!+151[ID8@P^"%'2%]Z%W,MT7-]_IHOO!ZC.1
MB4B4%MC1!B%,+4L8L;(;:D/:V,F4.&U4$<NV%+LX9LC9"%M3 -V=VGET>U.O
M.F2%E*I=&]AXMT?(VOZWU@J2T4<WZUQK C*F<:U>%=?/?EGB6BG+6X+=3B(\
M]YINGZE6W[S<J(('=#*E?.<.)=)CT;?.8)PE1<E:=!35?ZJ^?"_ZJ'8?U>ZC
MVH].AG50H6DZ:\@)X/IJ5AQQ;=XU >/'W])/93"2>_3I"/BPJ2C4YG_;2.5-
M@%S:A0_8)4N%IA-8"46ASG/)Y2KRRS"M+I\@:,(-)9O.#<4!-E@$Z[>()Y#L
M#T)S=)LP/]_:86=\64]9%C)JUX8!J\+BT"4F(B1<1"H"T\K\%M^())B[!H<U
MV\0D'+G@I>+G<CX!D6[!<\ ,F\UT;EB(6U0J2BA&,=RL?_/0&=VZKY$NZ[(5
M72,A ;,:UED\E,GU!I8H**;?K@=VS<W,V+ED&OCVK>KOP<KJH)L$^UU;Y/%;
M&EK.Y+Y?HRC(1_BRES_\[7:*P^M)MNK(OQ*2?N1=&ZK_63 H("8C13DH\@4G
M%$FRC"YO9@AYS'-!+H*^FH6%AG*P6M#OC>P9X:M*@BBRFR<,!J\N5EAZKW0U
M\<G1ZOO9^6\GT"Q!X/X/KL$2FA).#3$H@U.-;03LA_LZ(1<UH/E8"%"%2;H5
M_.*VF#!^)),U)16L5)'+0(*VF >L*ULVM,0G&3 ?U;LL4B,W'-#F""=&!CM;
M"N :K.EBKL@J:QS3VNUJ'%=KDM/O&4B[N;3\-/L!]E"!SS<:%[#_FW 6A%8\
MT<'Q97>SVM]JBY,]C_D,3HISC&47K=S"S&7[*R\*7>G)II=ZFK8$BF9$&X_[
MK3"*TBQLT?&ZW.R:R7JK=%,N>%&38$S ^\ISFLS:D@>]V^;MH-1].&=Y[6;F
MA?Z57^'1F# ERX--G";_(;(VI.Y?0Z\)+F\$"N&ZU!7I" A6Q*:9G=8R="$*
MB\U>2-Y<2':PQR*=-$C*)WN@O(&0S)26E ;NLD'5OAIIB(X&<D;1Z9=^K8&#
M8M.">:D39#W0$Q0'>9'&8.,# T;:OKQ>_5Z&2?RD7AJMWM.D@W6*]&T]5DV'
M%>R-QLH=695Z$7Y6H^& E&F,:(XT=HD4;<#!N;4X!$OLQ!*<X[#A]E._,Z\Y
M-#<$L^YHW.0@/?.9$@?:,J^DR)4-'NHFI4.VI0)V 8P*3L!JSU3T8K["V&:2
M)1@2&0XL#L_&RGJL9O.[LW;Z#-LU&;8ONIMA>SP^.AZ?C ].R>MT0BZC7W:/
MT=TT&5\%K-!'06Y, 2^Z&.; J"C9Y"Q7QN@$.@HY)TDZ2#('N@@+]AZ1_F1J
MD+'M)78D =ZCOB1E9:TD%:3AA6:$P\%O=9&4<<(A;5"H6(^$GU]@AF=Q%F8(
MH.#4+R>L7I*S'S6G97Z!:6#L;Z XC.DI2)%KW9S6F#6MT9#<(*FC47!=!&5D
M:Z0;@R$(LWZITR10,J9";@P(XH4VAUX-UE'LHZ!)D@DCKDJ9"K?T"C9BLPME
ML\?(2D\TW:0MSV8@."J;8.,N+V%P':Z4SIVX%"?'_9DB*#_V$90^@M)'4+HG
M_SH8(L'JHFR&[FJC]&[9 O3U$G"D_1M3Q;XP9-0F46#D5MQI;WE[ IB#=6%Q
MS+3#84USJ5;\[W:AD,CBKLAP%D>*)(RZD-%]YLO=:;Z;'GACQ1]K&G= XW]A
M0D]4$V!Q[84P/F*\&L.!R4;,5,+M""H@1E,TXJ?Z)]EYGIY;+YNA\CGA%Q#P
MS#0L*,R%>=I7W[M$*W+4>2%VDXAI&-;JIHQB\RFC=)N3BB)Q;W7GUOVB/@MV
MXP48S&6E!T#?!T*4DH^;,E8L/)BN4Z5T;,JZGL.;PDC551*%5$@[33#)>)[E
M:7[&W5WIN;I .(Y*+XK2SY*(9S!VDL]W(UKL]H\_[OA91;9-'79B,QJQ.W"8
MA?#2O"Y)(7_EIG]>R\)<SZCA*>=)CEF=K-<G+D]97LM3) 2Z"DFK*0A- VR7
MC=O*P+T$2ANAPS:\""TT!B5AE]3GMJB,-Y3G!B?V2M=-Z<5*[33AW&+"N*E\
MMG5;KKO'C:^VV@;22,#"U'J_N&'/1%,7PJ?9A&];BP9]?5-%=F?Y+2%ZAGX/
M#+V#WF(L'6Q ]P#YW,ZB3RH#/;8^/829Q'#@YX:,./OO4@S/E2ZG;?GL5]NT
M&DK=P>3V5L+3\]@'W@>^1/P(9282WR"CVW". "E EYS!2R7'8RMXT_JY;GM)
M[<^(OY/@V#JA0)S"2J>]O"CJ)>:'(Z8!2JY=ALRV7-JYJ"A8@0J3*?(>8,C&
MBQOCVG'9Z >N*1ID^Z_)I#VLP94$E>VM9QO3M;[:'@[A5L[:'[OKK)T<[(\_
M'DS>3O;(PGT5?)B [<S6+OS_A\GNF\F'R>FOK\ ./OD$!N_>N/?@W@=9_-A1
M#^XIZ5?,]_98+=H5?R*K-FU Z:;<#>M[%AGR4,KNR]-X?;H:(Z5R8EBA,'NK
MI(0S8'OX+^DG306O9T;0H"I>IY7)/63?:#!+L- RP7]*ER9=J"E,,SY/2NQ@
MZ4'H,KXJFP]^V0[JW*EIN,&9^KP);O-CW59"IZ;KSI,;-OIFDU>P-1JL,5.7
M!BL70W)>[>V'O)3\)3.31I^(I@K,FBN&(N$\8VJ%2<[H@C,,*+FE]'$!\ ?>
M*QHXE-(&"HL$$*F]\"J*'6=]BS.YM2,?0\EYLF=52CO818ZC/+12RRCC!!SH
MZP2-)H<.GD#CC+FN+#9N>+729@.Q_J//>/29I&>T--UP2U2O?-]PX "-6C!H
ME.WG3#8,111S249;J9ZW2Y)BVC@Q6Y;!]$/(J2XP5@265&!RH?B&BA[O^/6=
M@CRV43R-X,>M'0E*KQ^A!.N52E"J.?6$<Y4?/<IV$.=<XH(]<MM60K%NPM4"
M2F0/U<4<*[&I>)?HGN_"7<Y/%GKEZ06K>3?7$O)ZI-5'&/S8?MI'/_KH1Q_]
MZ)[NV,WHQQ6ZHY:77E#D6MUQ!0A"./1PH%GTS10UD8LMNI1,\W>I0 W94)L:
M"%T\WDSN7)(_<%W3U99R2Z53=E&<.BUXK  CB>GU_Q'=CU_$@CQT6VPZRJD#
MXZBSQ/P>I;"(S9';DL'V0G4 +OF%V$7=BU+Y+;ILI:J9J.VCC;X(_&W3;8_%
MK'$MP)G&*26.\=;F1#<?_)6CH5XOUYWQ2#\-;JZ:WD35&+5HI</! ZDU]ZJ3
MLDJM3*, RHC4.-0+M]0(S@#KC;(X)0P+ 9L>N="@MG644TU4XB;F[9"FZ]'1
M3#JH:T$28G96%50K5!IUV@45=U,GA3GP721PC8R:>]&GTQ#AS?),-QNV308Q
M[SH&E@DC_587ER.&5X4Y-CZ.8<0YT;B)=5AD6<I5"I.T+BSY7Z[#NWD5/+1A
M8#A"JVFP_>H6IH$&W!L.F@;&_9H&#V74M3/$.U@&O<_LQGI/-R/@[;D0UM-R
M=X7'.A36*SSM2LYM%!PEI68VAZ4MZGIEYL<:N"%'HGN148H=82V/KM.R;[Z@
M@"VR PR+#@<$SD#-4>I*0X_Y5]"@^U"\IJ&=:6U!2EL$Q:Y<;7-O%!5@:=ZF
MZ9U$1D0]5K4 \(NF/("CYMKUNELA-EK6-!RL8R<CGZ8$&-OMDKY"9J.;TUE#
MKZ[F6.#+!'8'W^_5+W%H>3AX2&*^DH ;7;=L5UV-?[+NZ/N ^#WP]VX&Q/>1
MPG6YU$KH>$W0^,*M426.E*JPH$ZIW"\':3G0,+J@KOZFH\)-+<I-P!&5J0Q
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M^3MB5FP6"O.M,V< )**Y2F.B^ICL=.2E5FO9U YLBL=K U%/MLET2+N7+M'
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M+O(ZC;5;VPU@N;UW\8=TK5ENN3F8(\G6)#_U(JPJ$Y,S8<?6,)G"@J=(QX"
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MU4P&MO!P_U?X\/WIQP^O_S]02P,$%     @  :')7 R6]@]I @  :@4  !$
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M(/B:<5K,I:OB 79ZU?&/&5*Y81-?X2@OW^3%$&B:IST*\V\$_P!02P,$%
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MZ-COSOHQL>SWA/-*KV>B:&Q8MX;9J]M58V3ZAO6>\#\5!.^*%IRN"?H/J-G
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M52?J5=@K=I/>I4<%XR9[E>NFM\_H]CLWW,E. ]\]QS?/Z' $[;)FB>^>T24
M["\ _U]4,R_JNV<^ #6&?^(W-\&0NX;ON,\&_F0/^/22V\[0M%-[GAL!\4X^
M)A81@\)'\^D<NG,"M\L]\>> &SV@])\_PA>??X9_F.>/+=B[2(5[AF7>V^>L
MRS$T]--.K,&CV?,'Y^QT_\BT/S&]N<7[_B<V--Q[T]YSS?N!?\Z,P'?"9]A
M/HKWV0?JW^L;0],:G[/_^CMP_$]MV.8>N^&/K.D,#5L\_,2HI6?^A\,,1C":
MQ7V8XIXW,KH@+YVSXN@))N6,Q&\]TQM9QABVGP52%0XZL=Y%.UC.I[2,1TXP
MZC@6H&*R/9.3U?YE,S#%8H!,@' 2>!(M<LK1@X[C^\Y0/*-13!OYM%C7TF#P
M@D\3+Y\)S97 5)\+P\DL!<RSB6F-NR<'WG. 5_%8W[1XCSV:_H#Y \ZBJLS,
ML'NL]M0=8.T/AG**Z:&(P^"_7P.;L[,"0Z%B$99 ##A'0#3HC;//#@X.]LIG
M1R"%S@*E-MCADGCE;#!HXRVXN/_Z1^FX^&G&FK#MWD!BMS3OJH .7&"I\ME>
MU[$<%\CKOK-;+##\[T.RB1012CCE^!N:R#FC%*LT<.G+R)[ZP3Q3+V_*U%_$
M%DO'<VS+PTW9EF*V"Y+NW4V]7;MD4V?6:E?:M98"[@J/H;G@O3%L\%GP;M6J
M=\UZNUYKL<K-):O]6?U6N?E:8]7&]76]U:HW;E8+X?*;@G#Y&1#^P_ &T,YW
M[ *[W*_NP]E]='@V"ZHO52?6LC0VSX%Y_/K*17(VJSA.4[;!C 4)$-#:20T6
MAY0\<\JE?\7U:;6U8F??\<N.M8F/8\=:VL*7N/-/YMCYQZ]#*@MOGI/GJ #7
MM9M+^'^;W33V66FU;'8>8+_2OEP+L'TG!MX73'^9-J.5K9]UC.Z/>]<)[-XY
MLQT86/"2'N_*J\WDXSG6MX&3?/%>66P9S]PW.Y^_-)K7L8D]#DR?$SPXKNW1
M-4:+VUVT_O8\WMTSG_8&9@^VY[GX43H^*1X4#T].4J2]O<,XT%;"9^8#SAJ-
MI\W:UWJKW:RT49PE[0'Y[K(X@O;I!$7/,[M)246<PC9>YV/-OTU>0DC:N.B3
M-KL+V$Q?S0J^)=;W4NE%3&86^:R6*NYN+FO-'#Q9X&E_JS%=Q:ZV6>,+*YT=
M'"Q@<IQ;@UJJUI,A"2Q3C9I%)+F^%$&\/(^E)$M?6H+867Z.@>!G\^D<SB9R
M?)M=9AL8$!)=:='D]Z;GNX;MW\";'2;C'IJ\GUGH?X=<]^;3P]YQ\>3X;.=S
M]7OUJM;$@QWV6K-R6[MKUZNM JO?5/?)N1V-ORSA]EF@R+:5O)JG;&/<[FL;
M>K?V9'1]HD/F])D;TA\S/.:->!>CCWK,M)GI>ZP[,%SH_<-RS5PYD]YH)OTN
M4/K3SU3\#>!O62.CA[7A?MDI[M#?LEOZ>Q+K5.M/ 8$&E%$]"O[%XK\68%\G
M&KJZ>/7ZR(.GZK?P5;146 ],WL5_>HD@I(/#?WW:^1A[\\!=W^P:EJ(W@;1D
M*_5]>>)[M2A8TG.Z^OFCF*F;RNAFLO61<<_W.BXW?NR9MF?VX+GQX! 1ZV.F
M;:CD;($ZUJMRSSCYZS8HKR.IOU+$9A447-\=5YW>O(( 77?KHS#@HQT$2=/G
M(]=YP,&X'9,43HH[GZ\-SS.Z@\"#E7L9HH'\U^_-14;AUDJT?XL8N75-V-3C
MEMF%%AWN+BZ-G91V/I=/#P[?(6B7;>*;CJJV\527H=)=VD#/QEAYY_/IP5[I
M].SHX*0X'6\A]I[/U$Y6SM269OA]B=TW+LU(.\,29.WG^#V6)&L_9^A=8NO,
M<9GC#[C+_AVXIM<SZ<I*$+ZS+'FOCL)2CD(UM*F?TH1)]]ZPS?_0WQ\V@*^_
M.K'D^SW:[U*"8+#O[9[A]EC=[@58R,BP\LV^^?BCNZ1"D8*A(,Z$8)'O]'RG
MQW9Z?;^YW]IGM>'(<L:8.9?O[DW'65QA8#?._N2N)LD>_D'34-PHUK6XX8+Z
MXP\^#8TG!4UI^GH%B_8*_1POL&A/U]KDM=WRQQ5\65I08RL='K_2 LN'1^R+
MZ7H^'.XNYWZ!E4Y?T8SO#]@7RW%"QI/06]^94R/W+,UI-Y%;KPJ_-MRV\V@_
MPV)R (*2,>RX9N^>)PFOP%Z1"N9;.^GD#??6=1Y N5N)I?5PAJ5U\X%TZ\ "
MK?\S1PL8HW4('.U\+I9+A^45N9^WAD?L9J(#MVC%Y<8S$0#'Y.G121+\'Y8?
MBIDU_RL'E)G;@6/S9YMF3W8^'Y1/]DY/3D[3Z6CIP9LOBW5];P+UKF06!6:J
MZ[78?\P1(+K'"Y3"ZW.+CY &F$U$H+<T@+AETU@<PG_]X[1<.OGDL9$+C<V1
M83'^Q+N!;SY@Q +([]S+XQ'>4SS"N].E,L\$Z-?H^K?<]1S;YM;<(6-_700>
M] V"G^A!U/6!+F.'/E>:65B./<:.3W<^8[2:;;"OKA%8!78[V+]<58#9UISP
M[TT5NP4"HBI6= !4!R;OLUK(OQO$O]T<4QN J?!F8Z9?;5Q@=;N[GR-H+8:M
M%_/E$@K)N3TLMX?E)^$:[6%+$:?.WI\9[=EP6\3Z=CHKSG'S8;NX]6T9%'E:
MRHUVZS;:+05OY3=IZUO*T@]R$^%FFPC11%%@QO(,A<8]ZI9P(#"/NP^@3.:V
MP-P6^#JVP+6F45>=$1;&Q!U@6; =AL/ EJ$LL7T5?P.;!'8+X'EBVQ28-W "
MJ\<Z7#4ZSQ.R-RDQ['2)B6%'$R-/X_H+IX"]M.O#TP6GM\EI94N+^7N)E+JJ
MF+_G"/%_F)9E&D/VZSZ[-KL#;N/Y7O/^WO^YXWY\3>WB_PS,;QZS"RM *86F
MM.I SN<B=4H@9],9<4]PLO\RAB#7?W6-,;NZNB7XWKH!!3X:%FL[C]REAZ?%
M(KMPQI;G.[8TX-'S"\>C*HTQ!9J!5GAV1N]WCTLG*U L)L"]C%[/CDI[)\5B
M<0-"MU==W&ELV*P"NRMP]9UUX1I8LHY5]]D%=U%,"%]]-3L>5>,,;%NGG*H;
M^%U,55+4TP"1O#;L&&X7[T=P6)767&"M !#$RL< 7FS6@@E\@>&ZIM=U"JP*
MD !9PS8-=G98*I4$[1R6CE9&.Z]3%&G9BSDX.]@[/3@YF)9WN(SHY'<AR+U#
MQ4B5J#Q<6,[4*4 4PGWMBG65T<AUGLPA9E#V*(VR3\H-M[MTMQ'^#2U&CL>!
M.QL6-<!K!+SH&@' (SX9!1W0J<YCL*N ;N3 X6=@H)'110:.4K_1AS711[S?
MYUUR6JO1_8'IA8%*E$/@J8N6A!$#!X<77M_HJG3!1P-Z<)7:)M) NXXMKD'S
M6  ($\-=<_<>?JW<PUE,/?:XUW7-#BP.ON&FO9]IREH.UC<M".;UQ,+Z!!UU
M.*K6 O6 C![>0T'4\ 5D,#10R18.T(PKJN=T,4)'D$%XP85P8XCD7V:P 5"^
M5-E'ACU6- 2]0<_X$*1F(';Q_5<4FT&&J]M ?8'H^&N!P6'=_2$[MRSG$?OK
M.$__]8_3TMGAI__ZQ]G)X>&G&5;TG'Y60#^*.$QUS0GP(D5 : ^5]R#J5(;6
M&<,61(1X' 6N%QC"?M,,@#D='I=W.Q\TIJ'=F%+I^IG40)1EP= I'V4Q-&&'
M53P5I L+;[2+F&+&9[@&P0>IOI18R7Y.CAM$C@:#,]/?BU )J+)[ GM$J:ET
MU\OI[H5T5X=3OXNB1&<L 0;-?K#' 2>I &>O56,C1%G0#^"GV^467IL'N$$,
MN>@S27WZ1C1SV['WM.E+A(2+\(8@*P%$7#YR0+..3L@"2E2 ;P3N/;MWG4<X
M&.6[?: O3D#L\;YI2_D*R CCR<O%3UF@I->E3ZK9S ;9DU,-D>AEXXRYJI8@
M)M#^>AM8*Y4[>V6)*[D]PRNZ8$.GRJ?O0M'<2H]!Z7AII>".BTOKJG2VM*[6
M69\NT\IXA5Q)D)3&><0#8C\O-EA.:4^'XJ(#+#I,)<E0U[.B=+S*<MK$9/0N
MPSO@]H_PG:07V#BP5>Q?=LH[:VSXRA2YYD)N7Y DJD =]XX[?F8NKKB$FHBK
M*WM*Q@0>XG6',:%#$6-ZP;>5DNCQRC==2P@IXK-04A%_2AED=6N<@7&:FXK]
M6ASCYWWSB??V?#?@<10?:=!-(C5G",]F"/-5DUV42!;J=5$"K$FI6WPG1._-
MH'TULZ\TIZJ8S;/W0-^PO,0F.-9.P:Q-L+3R-KFA9NF&&M#K,W1&C/%*M1^8
M_:3I8&!X#(ZY+IYRMD-FG, 3NC&@C0/6>@Q;>J0DLQ$F@?7(@D)&YS$.3C9G
M-$K;L$@'U=T'TZ-3TT8OKV&A*HWUBK&Q)\O=H2O%>3!["1M22]C!Q5XZV34^
M[)8_[%Y\4$IDW"XTM\TFI[CE4-QH9 G?5X'!RRY'&OP331.(&S3B 09[W ,^
MA[2'#PWTS(U<$_]VT7Y!6*?[N5UNX>T!P0A^%TZ0'OHJ@$;(!$E4)YQCY^O%
MK&ZI>%-&EP.^=[AKRDIE;+?J.IZW=T&*/*M[7@ _VIP,LPVT>GY(W3XY>+/
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M00*&32ZKHT^I/PH,(TQ$@E*7HZ$7AADR8>$B4&JB QZ( TK9]-@U;&E,LY!
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M>$JS*?'.,MQ9M"]C\Y1^#D_^%0:OB^'"33X1D4X!Z6RAY>Y\GC9#4AU_ I'
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MI[22+;J>J@47%'6G5!X3LJ:8D-4Y,F $35<W>O\./%]PHCE4=:*R-Z_CM($
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M46ZII6&Q&V=?;/X#)-,9@^^S,&0#T2(.H>19M'(<M6,@]F!F"$28Y0.<#A[
MV7N$Q2-,^B[_.X Q #V&]P-6#G]YV!I:=9S )Z!=<_>>N_NLC6N7O178P'E$
M&!:B?AT;NO&"(2QGK*-OGWUQ7&:P(; =0.5P9'&? P:\$8S#)6K@%VULH(0^
M?@-'(#X!-&C]P9# ?CSLH@^$(E';!21X>_2(VUU8BIPIX21SCYRN8'?#WCUG
M?PP,GP&\(@#^ORGS.'[Y-$"</&<-FU5&KFD)BBT52#,IL.H8&+9+H/O-<3W#
M-@KLB^EZOIP::P4= GJ+PU;KZ4^).]&6D'"6[RKW+B?J+\!>-[L#9J@'[-$
M,@DZ7D1:>#9#'TY\=B=B>ONL E0Q&HOME3: :7>M (4A>A^=],@GN.\4$,Z&
M[QO= 0P"@\_B417;YD^LHK;JC-9J2]/Z9^S^=LK\%?<2M #0' H"1TB;@M[E
MRD/NI';<;>!Z@6&'[&L2-!-8?#2!@P[Q;_C5']!(A+L0\?18_D5S,^T 80N
M,P"7#O)JYQ&9+2+1[)FXG?&$5D1$?>)TO,!],!_PVZ[CCAQ7,&NY&'UF^^%X
M-#UX;:?.<8+\Y&PGR;+#%3E$DP" F'Y(1K%O)//"%L"#?!=8H"&X(CPEGH$T
M#C.8XWPQO!A7K-/Q9$LF2].-7FM;3RR].S!L6+;I>R',.+.!I'%PO+VA7/RD
M8'5A.E[71&;F@0IH=_?I?>G3*_$SV,<(.Z3A1X?XN&&;W)-42^AP!%85I\L^
M]Y;%[^(TJ0#7X98)9Q/,U<#=-^R8MJ*6^-0))7 0!9:/F#?DJ[$D2US:T*2E
MC<P1=&KS CSU?->!1W &@0;G#<P1;&IC2#/ '>/#AC7AQ.H:(V0AV+\3N(3$
MOM,-/,$(>S!!RQEAW[8#OQ(S@R\XG<M C4%7 +L3@*)(N\KF@>OT^#VW.6XU
M6&#/]/ @]-)/6"'/C/1-"0J APP'#U>=2N6!ZG$QICHZ&6PHU*\D8<[BE!'W
MFY>UTGTEY4]LSO8ANN=L+Z]#F;.U-^^LFZE0E%^K38KDL"EPDQMC-5";#QP=
M#GN=MB&*HJ"->JQT6"8HE0Y!1$%Q$*D.ML*X,*>D/9HA7*]6N"/F,3!&(]B=
ML&4C5F3V"T)Z!48B-EQ!/[U#_:1KP6&_#JDPFMH #B_3?@ Y&X]W4#]).T,!
M SZ3YW WP,.P0'_Q)X0VL20I*7!Q2D*C0JP#; G2/)ZFEN&+PS15IJG;]!S8
MG^UG@V7BX!P8P.\,9IE#$WLW.J:%A[T^,3I4<?+0L3/B0ASQB)>C*N-T4 HC
M22=2*_JF;=AH5P,IU,)V]^+XCD:_< RW!U@8,VX!+  N0^3^0DD%(K7O@;'#
M-$  Y<.1+V8D.;!ABV9P8@!,[LUN7/3H3UM_UBQ D(3CI@>\']$H%&;D_2!+
M*$X??B9WL@>'")QBW/.PJ6_\0+V7CV X#L>2A_(=S-HR_P[,'LHCT A.%L^Q
M'OBTODA?]SP.8(>E&.S!)&..88&,:XL#*F/A8J'&@V%:^ D0A2Y>]GB7]$F8
M4S@-'"N:(&):C!RC$R>P>F@41*76E +="$!&,.I+H<N&F0 # =P['<N\%T0B
MJ!V:0Y_0,PS/NMQ%>D'&Q%T -6WID8-&*CS=^X$?X&%K&>90?4XV#]@-. ?;
MP1D&L&HXQPU/;0<@G@#)LQ\*T;#SB"OV07@ -4HM4LDT  '?-3N!PFT(-!C(
M@^:\[TM B6:T/[T!B&H@R:-\PHP^X /AH&0@;=V3<CT P!?:  *A']@]L7(%
MAM?2IE&+9'681I<+:7_&^; .OOK="4@FGGM20!A= R1 -H8OB:-U.)P>)IIY
M@)$*[=70T9= 4*@JPK$#IR_101,4'> -ES"<H,.QG!;I0Y;8!@^.H SXSG4>
MA)0W1);E>D3S@&*0>)& 35LJ2ST05DE_E?1O>.=)F$8 .W['3I42])[M'5O$
M[T+"TG%F+Z6T7N8N/;<\E\V<V)@8S$ANC3AUDVJ$W,L!TC9]:FSR2*Z,6K9T
M_G;-N2^U3Z)RQYY*W9^VRD%4ROU#Z_,/Y3SKG?(L=7RGLBNGCUZ(7?.#6!,*
MFW2 )YI7G>$061<YG$"NY$_2%HCLC1L@^M%7^)&R8\4^T0U<+>@2^J^PV]!V
M*1KM1J;R: ZIW8%@'2A_&@^;S$Q*A@'WJA:9^U0!C"]*A?I0@/'-#R1N1^O^
MPW!!"$8=(;%F-6;80)N\>H?#?0G(>1#ULZJ9RZFG(4\"_&("X,E%34)=?MKB
M\$WB:QSU02,;9R2M;J"V!"[TBB:Y14E)C=L82<UF5Q\BZJ39NLO&";[$+Q<C
M:D ,\<=@Y&"_W.V:'H]_D(+%J41!DWC!+$#?0T=O4C&>@M#I\YJ.S0?S)7/5
M(?8\4I@^]Y BD)7LFD_/GRDJB5:*!"=H:OHLL(VPCF;(8;EZD1_5SSJJ22^V
M[8!\+F@.BQ.GC%,@RDSSV%&PBH'.4Z%/0#/+Y(&PU5"O\LW^;,I=>XC!4H[!
M==A,9KA+U3HFP@Y:O!NXIH_,]U8QQ,C%3OTHBYTP<$-'Y%B5=CG3UN((8D9<
M8(A?#-,EPUR!_<YM%QG>-VY8_J"+$EE5.O)N#=>WJ?U7<L%9K.);Z.SK%EB[
M^O7/ GKA.A1E\0=L?AC'AR5>PW+NI;>>6&K/B?HLL&8E[%]OV6S_ :#"=>#?
M,.3OYH,3??6K88,X^@W#*EP/!JFK)=,<N =XUQKOW^ZS:\>]!\JX,OL 2^E5
MAA/,?##TIJTF:Z"3LV783M]$8*"5$WK]S;#X(#"TEB,7/90M'U#@1X^1KPN;
M-[I'Q392JP#R40MD?0 X=#O2 AQ$& D902,,4E1)+^,8G"DGS[4;A'RI-D,H
MH @/#DP 9G"/0 HG,'+-+AW29$Q[,H?PUAJS?QZ<%O>+@EL"^5L4^=1:SV3E
MF3N*Q8L :PC=&S'[.SE4.EP*1[[:9C.% )QM].H%\RV0M[V+=DNRCX=LH*8D
MAB;:IT,;>3+N9:H1.BND;B%.51\"YS %8H4!/1G3(CPT:R+&%>@\PD1,_CVQ
MP>#,1",_4$^<KH].]D_^I>S.3N!C@$-"P^R*-8M@2MFR2G$7T'55QE3LH@&;
M]0/+&N_U3"O 83N&9WH?HO @A?"( 8P,E#+,D:'.Y.4!0+@4+<_1N R=.V([
M@*C*[TWR8)%LBX>OIYTYAG!?=D7W:ME+F5H*8\SP.Z8!FK8W+8GXIA![0BNJ
MJR\*X0TX-(2-31V@,QD!!=8@_0RX1='W:\-9WW6&PEF-+ Y_ZI!J!K"0P]*1
M",1;!690W@H#]P#FI X1(X#%>GW)8 '4CX;Y(-PW1"11K)\*5XU/3G(XPV./
M'+'GA<@0"(\ZV)\97+4<#CAG1-&RZ'TI 4CAYL2@E%@8PDK#:UISMIL48>>=
M4+BPYP<9+;BFJ;QOCMB>TU,1VW-6G".8)Q[^\_JA/2,9_.^%HA)ZEBAN3W+]
M&;ZH#!5S?8'@R<AA$7:<&6$=3\J(EC\,0-[I<.4V#GD]15B0EJ'[JLG]-C>
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M$67Q1,?UA=C69\PA?4^&)VJ' DMA@=%J(W/>4 2YHL1@/H&(ANX==$/">WR
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M)6Y(0BPKZX7?GR8H<P,76391 APVVP8&@(GDP+CH8?;'QB4X#BK\W6[@ 31
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MNKI6,L:6,[NZ@B58DLH^M]>2VGD6I>FZF>PH:G/A@*'2'(*O.?S/.U#)?WK
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M66)<:JAHE@(,8[Z -VI2"+4;V2/$XFH(:/WCMN$]=L4&(Q;\1[ 6T$"NJ H
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MU8</9\9WQ(]IAQ$>"I+%C,TDK)'AFJ+U&1,_VCW\,/B<!1\CT"9]Z)E0KZ+
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MBQU4Y1#^1YHBJX136Z("G5"%'@>]B]ZKQGRCEH0DTIQONJT=-+QV&.CF;H0
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M-X]_!HT85DG(D# J$D[PY F+E80"[=_AOM3((G_6 $!UZ78:<JO!D4H8^;K
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M_>:[KV>M-_5*&^<$!V\Z-<52Y)@4&/3\G(%<+&!U)R=A<')T\CSLD?\*>\H
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M3<7!NOB!%]3310Q^ZKP :G$)."(\*O[W_C>XT> RN<*XD2CE%G;:;HY7.\)
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MGHX9 -OK=;G LGX-(GX+VZW<3BRL<*U@(X]:IMY1[QO"$:-0O+^27X^%\X\
M+5$T2\C>-+LEZ9+0H.5/KP6$+/]TV$-NFLK">Z&<XXW*.>8BYVC5#E7.<1CM
MIHH4R/0#]A4!:_N[>V9A(6>C54?.0=MQ=(ZK7-9X!#%/+BR8RXB/ I-'4RL$
MZL3(A8OUOR$65]_$@ ?U$=KI9V"2_M!W-)G" >/5]J"2 D-<4IJD;RJV:D6_
MH%>-2- "#D5=V[0&BM@*/]H0D3Q \S]2?\%R3,++&J2':%1AD*0"%I57SV6^
MW]XCM1.A;VQ[LB'"\QOO%W,Y:BPUY5E_^8V?_G6^<#T:)&_2RKISB]O*QZHW
M.U, 7I5+/TA$-\;4<=J]&?3H, WN*LK2 (JC\;^YJP'\MW)1(_2]\BF8:>/:
M^-SI!4,I2D#^([KSN'K=4N_HW0@: _YYZ@2,2GJ355UL9=D #6-BP1E9OA%4
MFU:K6(2"V3OHF?U1X']WX^US!-[7;G428@($<&838=)B+9<<=S:0!>;^&%AQ
M/)RF#>O(:0'*%8)605L&N5^#I@+H&9;R/=7L+63-$&CDY(E-$T%.HZ9DP3LY
MF+\=&JJP";\.6:G))%64E/J/_^XP-.(K??_R]0\_OKYZ_O+GGY^]>O/CM_*/
M_89M: 7F(.C88"T!)':_,!F@/WA_9K7:P"JK;O[G#U_0S_Q)^!D?27-*)OU4
M8@+PV_RN+@OZ5!'G<)[XJ^NK=47J(T__\SNH/L)6YCR/'Z5AVH=DS9]^/7F5
M)ZFK3-_ZF#N:R9S%\S>;/G:.G(W1S:Q?I<4WTR0%L1.3R\#A@9Y<!^Z!]ZRX
MTYY[Z+Q;-6SGT9]W 8T.1 OX%:(MPR'R_VG@/[#Z+FOYLI;?<RUCE;7R807B
M";)QYU8V>^=VH1<\0N &6+ZTG9D/7M;J9:U^3+L[WR76'Q.(K#>N*T5H'9"^
M]I--#5A2")W%./M?^67;ME0OQW*BCS9A[5O'6=C!$,ZHE[,]G'1W]OK@,V5W
MV0J7K?"1S/:J;G%]@WW6%N?+4KLLM=,N-?9DVWRUKTAT67>7=7?:=2>9<6H!
MX-PW=Z$O0K[<-E-+EF ?VY,#:#%WB >>4ZAPP76 RNP[%G.]+.?+<C[=<O[P
MCJ4-K.7"/^(5_6O0L63SNI#6&Q&774^MZ<>)T/KJ@M!ZH BM#ZIQ! K+4.2B
M7&]4+\7" ECM!DL.142.9#+6>";<(M[<#R*EH_NJB?D1.0</-4G78+,9@V?\
M2T#70T_A'-4TA)5DWM1Y(6GH://A$02DIFFDA>U6V]<D\L)2;@8P-FU^ZH\.
M[SF!?\Y%QB<4N+2\D\7 &"+:Q%&2+C^D_LJ!L(BJ"Z8T!!5J[O_.;W+X@O3Q
MZC ]Q&J@K;12.:<=%5;3?,&58P3W5)4'N0R9 $[YYNI *!XZYC%W : J;GN
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M=HSN<:&9'.J11[P8=]9@2 X!)*=[0TG&Q+T4WJFO0XL'PC+'E1*FG;=-JF$
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M>%X1:F=ZY,855/]88!32JVY/TZ46'5/3*7K(WL/D]H=#=Z+339+@XRLBYE9
M_ C<S^XS$R'!/WD'"8.A#@LMJXU4$+C/7%\CNF64^O(C"TY?31.4N,FG#_/!
M2!%7Q=[)PG*$YD^.'%3>8'.LIA5$'<["\#M)#G5$B7OTCFD9B\T9Z#569Z0
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M1,"^:V]1T75T^M7 "M#J?BNK%I<#B@C%YQCW]B^8< .1,'?,_K##X'#KHD*
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MF=_53;#N P+JR-B;J H; ?FD9YD I9T?0WAM'=#;5X)G^:E#M0LW#IYE4
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MBO,E]'>5'6)^(H E5;490D*P&WPP[$L>W/BRIRY[ZK1[BKKCN/9L?6^[^KI
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MP&#%6.[$F!F16SY?X9+HT".W=CR7<KRG+C0E8SEW(8-' 5.YGO=-2Z1?9#_
MJ6=.K>BS*/Y9LF=E'R7H5BY $5K(*[P/'-0NNYJ5I9H;I3]-K.^6]HSA\CH?
M\>Q+/7M3)]M0WSGRI1)?B';:,$UB91@I6LMB 2JZ22J#$FAEI7>*1I7M2-KE
M60"N ^-!-2,_!?P4L_\F-D9B.S"ML3X,_9VU)&,7AK23Y%H4WH,X3MD,M8_8
MF4T_/%[&&D!_>_P=70M7LN0.4'4161<A\A*[JHE:ND^<O&+G24I:FBL/,CZ/
M0Q'G;/$=@$O_Q#/H?D/]L3N85P[741=.),Z\+:G@GL2Z,9MCJA 5 $0Q"_EB
M, M=%>TB9]I_UO0@3*D-=# Q7R.!/1DJN&N]6/A?<SXM>HN&NP&ME7F\J4<*
M=Z&0@\<%B"2TTCZ9G!&A'N42T-:-&<0M;7CK%F BEORAE,;>+YP_(CYTTK
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MBN:TT+99MC!:JU4^KZ73O0'/RY#\TB$N5YS(7 C6+IFJD*)L6!( +0G:MW1
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MH#%41^#$;^3G^L5P!1IR_9H+T +]\ =-42]Z&EQHGPFGIG12XO-/YG'0 V<
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M?L /@[PTF"=(;Y(L0$H8[!3:L7VX;,D_J.M\@*;U^ZIOQV3.F,8995$G9>I
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ME3-;8HZ=]Y,D]GDEMUST;V]1RHT*^DLZ#W$+:S]B1/  M+C ;]8X3GD<W+E
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M26%)&"BF]$ .27)@"U> BPJ[G10!H12&LG'^VB6ZO..GG[$"1T)(A4HN845
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MPF\:4DF5>[."F;U_E.6*NR/VW3$SBXGI<C6NV!*0^I9Y= R?*4>DD/QE=QK
M*X@FS]MDX'(]>UO3I7$(PFN0CQ0GY43R./X@KU0NY0MD6E4R2!Z6%(YQR8VE
M!Q E!8JXK!G;=>SY@"&)57O>.53=;>NJ<BOBGE-C/TK,?<+5'-08U 'V:UO6
M,(^-RCL@ZIP[(4ULE!D&5\P +\IFT:]AB04EMW'<F<^;.B^N!VYV522W%E*8
M<?>_@?Z@%XS:A&"._2D(\FAHN _&H^XWA-6I2/+!+S3NROV6(] >[B#?\^=:
M=T6JK7Y;E6Z;*9,-W:#EWUMJJ(R -+A 0,LJ7)?.C$A0@_BN%UW8D'[E-["]
M7YC7MY='PUF_$R_:VAS02\:VW4XDB(<M+CSK@<\(X02A*=0)"<&.K(%&@$-R
M.1.V)..@9Y5?1P'TY4-QY#.@=),T9X*8M$3F/<EV4]\E9P],50++7+ +UYLN
MN.#.4(2779!:!2.8DUW ZC*UG(Y)E BA)8TFPV^%OO5ZB05 O2NR IDL"C5_
M6'C;"W)D1-_-4"7+ DI-+:EV4F-H.)ZMSD_,(VM(H*@7(F/#U2IFR5HJYH;P
MKE6]<V!H6=!MC>X/:M93NDZ$R,B+B)\7&:EE+YJG1[-J*6YM=9\T;F6N#VY'
M"L6N_*K1G4B+#*?;>'Y=WU2",Z-*"EKK!%9&D##VY#U6!NG1%E3^?"FH/-""
MR@>=[*^,@SXX.#GINI&(+!N?80-. VM_5G5QPP5>!J-P BR;P6R%! HWS^(/
M&HS6$!#0,22'V!M$%)@[R $@9L(_4KU0PPCA<"&Y1!/)4,T\D--3VR!AD/'(
MW)/[K >5617GC:"@[?!!Q3_RH[="$>J>>_OVY:N-WZNQC4DR27DE0;WSZ=S"
MR.9SOW_.;T4>(@2K!$_FURI;S,3W<%8F,^@9:M!*[$Q"M9B]$/+DG(_H5N/I
M&0O7)J)J([RK \E%-#N: $?_C2-3$Y"QM#4FRL>*S!+BR1LS'Q/=MYVA\BZU
MHDZ\J+T5KQ$)O9C^(&\ <1_[RJPU)2N'(2#HI!T%?-J@@TK\F'(DU@BH75GV
MWMACLH0P1\"*J[JZ"N42N0OUE1NR39/Q;W6AU-"8F]%>6.RM!'XDP,.G9,FH
M=I'TA=(6&+$.ZZZT:4].&UK)Q$P%H4Q*<MI0U*0.V.F5?!&$[WUIQ-FH7M Y
M(?#Q"R!?@\Q\B%@ "D[(PVW>%.1/ W:2UX;<P20K(N=Y[7* KJ'0VUG; :SY
M3\YJ9/[!B,#\0-^D!-6;7G(=&O.RN##D11WE*32<SLC<1/$V[NHZI&^*$''Z
M<83CO<J;IM["F31QN*)'P$'B&)$'\/ZFD_P*)4J&LG5,&M<8TA!)J8 DC=5B
MDM<D87-XLRQ^?DK:F#>\GOVUH98DUF26 T$#8TTXPL]P"6[9)\PML FP<'D+
M32J(?,V[/D%>$=Z*Y,"!EM0;+TCFUO,[\&^$4NXHXTBI>J32$NMH7\6\)9]E
M.-226@LGCGT[I=OB48?!7<#VU91PQ&G"DY$JWA%/"F"1#;"//PC7P;6F#186
M\:9A,V9K).,,: 6H;4#@-'N)KETF;$W_>//J[<N,&@P*-/-E*_2,6'2CK"-3
MJASU N2/57$>+RQN@O5YUX6(ALH6X8;";!$&DLZ)94^R1:VW''@_1D]@+(JO
MVVOBP=8JV!T0Z<@;GEVJM/)2U]*,4&R:"_C=(?4)D6."4+H0OJW@=,AN26R/
M9R$.-^%T=.@PD((PB<;!W^=II[;MR"1-&YO(;11 .\^F34,P_PJP@RKD4CDK
M,&>,BUO1M.F,LWW53N3:<P.O;2F;-('A7(2S-7" S'<6OJET/R4"F_%=PEU%
M)-Y85*C5]'._7&=0N^FK1>BXI:25.B>W/KJE1."Z5@AVR.@WY9KR 7:VZH@3
MA[H88=,PLYP_YE>[MF,&)N#5P^JS-^"NO!.0LSP"^:\5[HD[],T/H+."3Z:-
MDP$FNUY#O=^'V^_.4V*4U"&!!]"84U$PLJZ\AB6$&-GB$HBNN-9&V^S7048S
M%/J(S#J'"J2LOE"OT]J<1J(-!SQA'Y'1 VP^P9J%?77K4K Z8P\I5XQ]<X0A
MW.9AJ1HSBLLC9[<$-O[0U\(FY\$XC8?I3XE3"SM$O"UO.P9E$^2EN<TW+5C:
M;&#"34#&/GTB!M?]:#A6/CV1TE[7326%IB!4P<,10[G$.&^_M_-)&HP?7!L?
MQQ<R+$K2,*U=&+H.0A>NE#+1-@(IHYT:"SRS<K=XY/><!K )7E:64)H@@A2V
M=//1!R>ZN:A)Z*R<'T="4"VR=!(3.2P,TQ -2]/B*:5G\&C0Y$OUP:0^3OY]
MU">2R-Z9ZA "JBR4LA[\+(PT7/_2!;BGX/Z8\_M?7O+[#S2_?S]!  ZN(S=Q
MTE9B($<(RK7%C"&;--;V>,.6,5[<Q"EB"01+$?F\(FMIV&GV5WN9$I_!3O4
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MH4+IL#'/8/=G&7T/,EK63DK#R+["2?D2&7=E7@O C/6%AFBO.J!=MD[]S+/
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M/6.1LD>S,R/QVXV"S0#&P*([0V$2@"4)_1X$M'<65>9K SA^%=,%[QYIOI/
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MRO1(A]9Q_N50Y/ Z>3"$/ ANS)#U??XT8V:E+R02]O,3>=(7PBF!SOJW9W6
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MV76+S[_Z#+_Q^5>?FUUX*:XNL^:AV9%4K21VGO[QJ]\#*1^4K2AZHGFLY5:
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MF16-EE8D(,*CT+\/;?T;).)C].77C13P?[%!(O1@@%6<]B[T[(:1"#:R75%
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M#!HXNJY(<" Y8;//G O:N -9 WV>=JF=4PH?NB,\+?9UD]</.OJJQ?BYO8=
M(Z(A$(BQ6I>LPX"9@XI26CPU!Z6 @^S"<"'_(^<Y#9,!VN)MS8B:R&?7\F>=
M>8L: ??#@-9085!WH)<N_SWX]H3A?*26:RZ*5H?CLVV;9B7(^/&;JWQO\8WJ
M*RAD'N-G'BB^"N,;C,P4"/^@>)W1C()\F6RI2E,Z/:!3]_$5/\+D[;=*&8!$
M48$],;CTX'+>UNC^NBTN7@AHN76Z?^?*S44R6I](@<[W)M#7/BA0Y] !@J9F
M9EQ'>!DO+(:SK%F3YS@T-K-G MR+I5#G51OIO-PKU 678-);DR O0O -Z"&
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M"<@14[ (S9;?P<2?^RG. GNO BMP*PG>7;3IY]GSL_R]9_FS]LDN4P(F_H/
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MY^N"$0S8?2;[K#;NBF]ES>?'IEX9 [755"([Z3H5Y)J@,].'N,A)0"J2"4?
M?9#F[BV<H'"E1 ,(MNEY]=^DP'8\TJ-GI1<ANSU1^!]O?GQ^\>2SKRQ+*(;"
M#E60*VX:00W)=X>*0G_\Q[)9(Y*CAZ3W=LGN05B]"_?P(OXEA"WXZ.+_M*#
M)*^+7;Y<//J^^$=!>O]Q%IT5>O2W99>7V-ZORX9V7KL.2$#T:_]1=D-=Y>.O
M5>7B>[H#ATL_99??Y.+W=3S3YP5*MF%&[[ 3>8R [=>?6:P]O&E6])1'\2_^
M3'>F9D$5!M,;LFNTA8PJ(WSTY;K,VP.]+EXODPW*PNX\7R[_LZ1?^($4S-ML
M\6->DX- _]PR47:U^.' -O)'BM27RVSQG\TA9W2NGW#(N&4=VQZZ?>7H+Y^O
MAAV>SR_%.8/G+Q8O=[NA+ISK1W+]@X;!@F27[&Y:]2X[%Z&K8N+[T8KN,O&T
M4#9!4! Q3&?!KO@@Z%TB+ ?=0P%[$CW 7/-]*9RUQ^N:(]8#/VG3%YWTO2AC
M;<)V%B T I?(/"G\O/X')I:?#59\JI;?N(57G3/1;\!/.3+3^[MD5MJ>KIR_
MEPK&IB!!*Z$Y\4AG(W6+T>U$:Y(5'+J^/8QP?S WBY@J[OFR".AD=:\CVM"
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M9E:'VF5'MT5>\3)XL/7L?)UOZ[W'4:M&Z-./Q$MWZKBV>,<&Q,[1PUF /Y@
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M;:1C%66'GEATI3>+FVV![_C)*MERAJJ1.F:B89*6\<E4%8S^%N-0\ET;:#4
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M11FN"T+0.9RF#Y]7&KDF=Y7-B'&:$&,HT&0\)\:(C_FJD)C!* D/>%RCB2Q
M\7?%8@:K<E6TB%IS27<D=8(Q_I[$A&%G$;K!V%NR,7,JAFQ!D??OP&4G@.)S
MCPC"<NJ+&I1&O+&PY!&<?[@R60)=I7<+N%IVE[3%="8Y1B'O:M6TO(5<+QBA
MFK%QIB\<FF$&UHQ4J&5@Q^Q2B0'EI<2CF\5<4WXT<S\3X$*]Q2D7VNW@7F-
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M^^@G:LVL!&^'@QJ;<.[G1GZ,F"@Z8FSXMX>.OA(KTMVJ+9=06!J-!;ZJCS#
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M?\:>43:/P*,L3M+"CXW5:DC']YI.E/4L=VCDU<8%<EFD!*O6!G%$88UJ&_,
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M?V,F61@K_E^VOL)?.P.E^1!%D+GN9@<->'<.>30,"48@7(RCRC,AW:R2LEN
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M7M*&(XD/K7/U#:P4XY\A@$*\&7K/X:<O&Q!A1"\-'!)#TG16!_>.:0&("\%
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M1E]3F+J)6^16RQNL5&GWP,/#'&'0P>NY O@;_S9]\R/[P?J:S5-"4LY,9[H
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MM8R<3@TP4:I[1RB$$)1V1.1]S6D&?KSRS;@?CQW;IGR7 *TN0<K4;T31&X+
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M+G NSNF^#)?1*K$G$ 1 ME0QUR4T[D%H4\).\=W$W[W^Z=T/KWY^^\/BY;+
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MFYU8:.RT2WX$8?Q(L+B]W)]?(RG "S+2$>E'- DXDY!-9.Q/RX=EG#?)[.&
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MQ!V/,.NIA7B@1CK/[:^,8#Q8V([@#9N4BURYQ3DS$AD%N$DC=E,TW170/R&
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MC]*RM-,SA[G;!^Y,5#"UQ,4*3*+]V>T9.-2-U8^C%L,,T77>..;-N/60.7
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M=VPTQ$U@90G8QCL\;'\70V0[99?HC"#I(G=8T%LZ-!$W'7-_ULH3VV;%Y15
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M1$+M6R5_E@WA.+;T4_! )4LHB !F&E= AG'<607?Z:>&S11.'8:;W&Z4^'F
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M%^%DC#LA?*?P_QFN#]07'&N)8SJGZPL7F^4=)3;S3;S&VE-(#N6P$[321$Z
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M)'R1_60NWWR77"S>4(!P!KBYFNS\3XL\5J#%QZ*C2\T[_K186]:1IAQZ"9T
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M,21: ";H VU9$3"?\E&LT?J:(SXX311^@U*>=;MB9QP@9-:H2PHV$7(IS!]
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MJ$K <+]HHWP73,5F=[!L:@DZQ@6D22=2VA57!IU-I_A.9#X8D'!TJ6)/6;
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M01UT0UY?18 + X>*[O>@"09EA:6MSIZ0$ZM7# %/J'HV0#@7;<V$G0(0T.,
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M<BQ!_38\@S61M-!=%C_I*%85;KCBP?)#8[\U85E& ;ZT1Q-Q?*2%6H%J5B[
MR<>W"7N$I3E!W^0N5S=^F*L;?XKJQOFIJ52^*G7U>6LR.#7&)SF2*UA3O![J
M;*>HG0[UFM-Z(=3CS:-<!'RA24QMF ,IFR'_K^O>15>.]8-N8!2<9,PMM)[(
MS*KDX/:8$CI*CB-6&[-ICD4#?BN)76IVH"<G(![Q0,EKTEU5)_0PDLRI0R\=
M>#6RA8VZ$7Z"@'%83[C95QZ#Q6!9R*)PK7*:9+/J9@EI%T26DG^EQ >V@6YH
M:CN57)]UCZV"!=X+6&>8+C>,2\4,S,MB4_!@JF[YP;M2'- :>)&C()AB4-HP
M"8H!K_7O)[U/H0<<Q;3ICGF[U.4BZG'SD7UCZ\BWJ7#E.E;Y8"XVG Z/H"CX
MEZ,*>X-M*'Z%23 DO819WAJAJ 53V?<$AIT$NJ]3Y2NS%30]8[!H V%LD6IA
M8+7 #&4WF&<?!'?:6UQ F 8\OT4 ZLZR[3M["LQEZO[$F"'\0DD>)^T<,+W5
M#C@-4;J.HO]@VH%"-,IVPC!L:?(3X\9D@BY*:V:]8RMF/9JNCHV5*- 1G5X?
MCYUACIFUB,]<!RE:O'%-W*?B3;BY,S@MA5UD&DRS 0+_)OL,#1G <=&RIEI0
M@P9B;C,H+)8<L&KDX7VBV5^] ][[OX61EW?+=AS[!!)ES&:(4 LX&4>Y/Q5Z
M^7AT;Z,Q#_Q0S:G:WB <,6*%*&/E<P?VZ8>C;"F;1,K#1CMB!J%24+SAI<+^
M?LI0Z1OS52MS4G=%IE18<(UPG*<BX'[!Y*(4+@Y%X9P:8LQL.$L2[\7-$$PL
MVV#GT!C##Q"\I8R@[@'OW?*HHC+O893QR<"(*L(&5)PHCN2D97Y#Y5!:SO81
M*X?$0?AMWW7W3F8+4N?#I,.V/=6PS%";Y!)Q%\:24C_C=1<ZA\B."/ -ML?*
M*NOW<:.HTJ-Q9,-:#]1%EY0Q+(EDHS.3,%U@[4$Y@-: 36NLDX/IL(7ISN%F
M>ZM>97W^ /? 851BGM"J"OXX(NR8Y^ 5XQ03;:.--YV1WU%N(.=DJ><ST7\9
MGCDU["H\0($'MHOW*S(+(0)(#&K<R0BS&IY*X8%#FJR8)/LP-#N> G%98CH[
M' 6[MFI>&1S+<!U >Q;&"C1Z=)X7#B I^DJPST?94Q"#P8R)C 3(GKE3*I0W
M= ;KH<C2$41E$T3WU/2G'DN;-=X]+& ,WFX53_9[_,15,+&"S.)^3>W?/&M0
M8A=A@Y]1PE<ZKF3Y0-O"0%AG+^%82ZECE]3*-&/31=A=R+EG($&'JZ@HWZE"
M'EJ]6UF85.4FJ'IQF:I5W7*2-UDN38E#L[F:KO:I]S1I$?<>NTOZZ;G(T0"@
MK-X)IMX9MY&!"\+&J( !Q:'.^51XT"O,T0>U)O.,%5MISYCL(Y)X>#$)WQ=?
MC0)]PU4!B#]P)7[%O$:G&D!?5@J(ARDHATV#S@D/</&*D[H!RQ#"F(73W^2$
M#Y2 P"A$'_FF\\@(C(O%UNAZ.N4-FYVC"@CH0 2LL%8<T9@MA>-\4!G4;[%#
MBN@$3+6R[EJ?X<<\^NBXH*$:L_.9(H_DT6\<?JHH:."N@VQT.%$5Q+R1RP:$
M"+CW?"/-+^8/C#\<\9ZJ*9!!U0TN&(5JNG#$,Z[(UB)[2F\KMR)T,L:DAN,/
MR.%<)D&UOS(/NE/4"Q55_5@Q.]BBLP()+TP&?X=.$^6]@@+.B/@0JVLQ,TWC
MJPZTN,6-=>,L@&/>-/4)&"L;\FSJHNH<-CB4$N$/[CR[;PC8*M%_VSMNF0))
M,QX-U4!0^5_:;6K)Q6 JG$GUZSUR*Z]9RY@2R1BLEXA+I[:>>+6M&5V#-G2O
M4N"*X TW#;[N>$4<G@DDM/8\$7G($--C$-SAXZV,R1?9\E-8_,>'=J[U[I4(
M.^1P'H>"_0.U1J1_R0:\9,JI,D[PUK7U50>)5/4;PEB7%0OAV[]D^TB?JRNY
MM@0<5Z>B,BVKK(-\@[79F-R,7KN#+CE_9G$8F6SL'2YO/'HXES?^%.6-"-B+
MQ'<2RB@^;':RK'JB9+,D)J)3S.HPU8S;H\V8Q"K==F-4YAR;3P=M<=;8K."P
M#8>V!ZB10SR2L#4. 5@8EBYT8X)[RFE>&/K!B*K<8_\"P9ZQ=T=O61A^-2O#
M<4Q]<D0]9D4=<@:@$1&6-MZ4E%XS+ZP084Z&7U0-&89>:^ CN[B\%@>9;#+E
MA/$A()&F;!7:3Y/KJ>H&$HA-6R!K5-TLBIPA"]< 9R/XA1RJC@ROY]]X!=X1
MW/\%U);?KJO"QH>0KP&+XDA)'C^.@@%3/=^;RE1I<7E+Y+"W=P-,=B>QVHIQ
MT)TYRG#*WS$# )G/SK%=K(;)._&L1&+B3O_'\<,GCOL GW>T1=1@BT:1#8]*
MS)?;R%MU(U#J ^WB!<.NP*_>W=9X2!"EX=+<PRO.%'B/LO1XMWAZ*.YO@Y<'
M]%W[<P-U"OBB7W:RM#L#,TJ)@.N]0;PO<"2#A]O1Z.!R8;K3(09_C9$E-!;S
MT5T*SP/LM)KS=!(L^)H@&KM.YO"(\6S+&3X>#JT6[2<H$L7Z,[[ O8L$1^%Q
M\#DG@1.3\E(FL!CZF"E;$O +3W1!IV-N5LS8A? 84[_%O&NLV2M&1RSE7D63
M$.!CNZP\-SKA (@4<K@(%]1R;B E]1."KY7)>\#[?L6D#A=/0%P?/( UNY"A
MIB$R3C>[&0H<^L!N*-?S1PS>8.F!#H20MZ/"*-E5.2XM!:N-@ VIADW\4T"Q
M, K<_0,X:$'7S[^D"+AT0RJD-4G7X^/>="H(R6K< CM0FLC;<6>'FQ2$<K]9
M(Q4,ZI7$$80(II0LM S%I6% .$ ==MD-6NZ>>C &$_72''&4_.NT*+VORA.0
M..R *2371<' I,*E'"2_]49G B7 M0^^_X3\Q+HNR/1FI4-R=/?2#<7^%NG$
MC.10HJ5CFAGJV6E$IJ[%5H8Q^47[-H2JKIN8[@LGOR"9@V.=X5*[YAV?$&RQ
M8V6HD:GK@)].!H?<Z%MC3K(F+[F^0P9Z#3C<J<]!>VYJ@KW!4XZ\5C"\Q!_"
M=_>D^I6.WI6(=)-]OI@02L-^7F.PHG8)<58T,LG"1G67BH@]GY3=AL)58$;(
MR@FYVCR'WKKKTDPE#3$OC1GK*G];5R>4'$8@DKL&DEP1+7(Q8B67O)O88H=
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M+A0TMD1MT4L"  N#(P%/AV3+F"(:!#@?J 7U6?(<EFU%B$?V*R]P$!]CD/E
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MLM*WS9U^.'U*)"[YKJ$LH\B<LZU]C.2]R>LUM-LO2=8V ]S(=V6&LOHB^!:
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M<) \X)"<ON<F%N'/ 3BQP\S$N2JZZ4TRQ%YT2YWFN<V;>I3\V^Z.K#]MS^3
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M(!-0&%VM$-Z(-%@H^!A3V%^4!=VJ&%F)H6D8;GO8T M C6Y<E NCQ"Y3<7W
M>59O'*$)/WA85F#FBP8G8C#.1J>'!X40T10?'%E^7D]XC@"JT Y>.>6@WAT&
M&3+F=X3#SS*2RZ+Q8NF5F@0 G;8ZWI6CJZ(;LK)2)$\ ?M4@FP!3Z7=YJ./)
M7 VXI4,=5XP$XZT''U.6\6BZ;/*D>$ 32*>,,?!N52!<!/BW;,!34E:D%0!R
MN11M$NAL#Y#Y6X5J]P.Y&)PG (FWXA#B"8*QSU30V2[KC<LV:C! >'!1EJF@
M =O_0N6:<N**IS- 'S<YKK11>LE4F6/191JPH^15WW0X3>#0#K[R+MB;L&D
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M#00!Q$&#7&<XW IB65CA>6?U6PO+;;YBV?^%0@YR^-Q^[Y75$LD;...OL8"
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MS8ZILI/<*^[39N%P3PO(VES  =D( TR((]<@-D#Y,X2BW_=]NO@".QAK5&N
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MG6+4GZMG4J5%EW)6C7$%P*3MX6 4<#_?.P)]Q)C*6]D=:.1!=M<4Z6#N[ZG
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M"N*T,*ODI2,->4OEMC1Y(UT;[T^MF<C@B\M/=>R"=(E7[IRX2\#UW\AC_</
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MAR[84)G[-H0@2/(Z^EHV'Z-$UX_V=7X'.QS#K.JNLZ.O,S#+ ^_!^0U# W]
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MT]<0-F,[82DF!L;@\KC=YGGEN:688<Y_)2_F+]>^!XO]-(BR:/!72=3CY83
M"1F.J+A);P@]?G\XV0 )K_-=V-)=_F>W BACAH*LVH&=(@\WPFNC'D(G,L(]
M@[7^8;^K2.&1E]N0=ZFCQES__5%6U,9T+#P*U;2AHN?U0=**CLQT_3)<B.;:
MV?"=7KY92A,;\Z.,W:W)J";<]LT?EH !%I/L:]RH^R15-%T@G>F@N='8GP]8
MJ5;*6( N/. D+GAA_SL:3WY&=M4952Q-)!'\A.7L4 '6_,560U0KGN[)??R'
M<CMQ[.6 TB2HD)."68M"AVIQ3N@ZB5C%FN\R^E]R7^:AS_X\MX\8IC*!3]0I
M3#9]$MV)"]N3U2>[B2R6 A"QC@T1R 8Q?\']""8-G,:BOBJ*4ZAN[7PGV"?C
M@^FW?2Z?;'9_6'\V?ZYJ1<-6B-.BAW5[1M79 A%5G#N%X[?,:9^G\7V+9[<K
MK,&MA-GT^;U4MD26>88>4X2V+MG D3'ED\")J>GRY8H)KF1B7/)[E4[L$&=!
MR+OTJ0OM[3FB%,QUDI-,(_R\DV=4JQC4L9^!X*9YF,W&M=BM*U5+#..9$\Z1
M8Q3-B=FT50NP=>,)[B#?R3 #^>QJPB!F;R?\K9I5Y=XQ^(%WG"IPI\;AX":'
MTU9G:S 6EAP(1VX5_!)BG$L;9MSQT3]R]MW!5TB8NTL96(8A 6I)]2U[WJ@'
MSM"/1?V^S&E]$+L74F('31[IX0/7@,_6OQ\ZO1)-57IEG@S,R[V0$9RO?BS(
M/N!!:+>A*7#UG8;&\-9S&7:29_P4BR)PG?*PCB#A;AXP*._"^MT#-#@_MO)<
MK0Q_[\$Y[9[9OKN[@@0*%?)."CKE7A4]S>5:D.RD5_*8B&6=OR>0\'_9)OR?
M3L+_;TM&(VC)=I)KJY]6E('=N"-]]-A0)<THD=H$ N>(&NW4S(3AXJ+F&]P:
M-=(($SDS,!%%%&+HXO >(Z2V1FRN5!,B&EX(%G? 6%=I^:OBI+WN#&W?1LE7
M1)()2R*%>3CCB1,'PC^)GKF!:2#Q1V$NG^+<'G)'7!\?$\LC,3+MM=^(K^D6
MLG2!%?&F/3;QIM@!7_V9QFJ<.?Q8?AFER7\-Z^X@GJ#]<*-WA!5B,HJ_"?EG
M_1I!PE'#J/TP$9:5OM#!@\VZCO'8>:()/_";OZ,<AB)=2OR&\[H4Q\BG0U#C
M>I> ='4T.GO4;TZ3SQH%7>4UA&@WV/02"+3M<,^FN:(NI6SP4SX1*<^S6K[/
MW#((4PF),!,+-Z"0!G<-E%"KY$86N&Y6%B,[8QIOH3[3Q!JKA(U5A[U.2(L4
M%<:R;@67KH*RT,,+':UNYK$M]6/XX%2/GS6=S_KNF%2/06HC(?N=MV_=1DZ?
M,/+0__V9CT@,;WS#8([$F^:+ D')AC$1A'/V(AIA3XR%[?J%"S5YN4X<5%&6
M;@DTI*^K-I#,B4]EHZ:5!Z<E>@S(EYRL!E\%X5]!_HR D[Z([W\!!8"VP2['
MN 11U#U.BM-O<B7BEW*ZP7OEFE_*ZB8_# IVH%5R3]SQQK.N5&BO>?&#'H/%
MMVW8[SNY11EHWEX_4-7FI*%NRL/MXT$SM+S"-.V8R!CGQE[7.+N6*#?,*.:T
MR<9?W(NEJ@RWM/+SN*?OGC7'/_^6]*BC]769IOJV9WDY[6,^3!>.^</R68,1
MJB6==/-LMUI.]MI0<40C#U88DK=QK:9,-'/W^4;_(9*S+\,5IJ.#.<BS^<GQ
M.!JK1*W)1=I9ZFHL#GID9:R\LFK49>$ZJ"B]*^ NCGGNNZ63,B,ZS7R,[C*5
M&,LNY):L<L7J63<N?1;(\06[8G Y'_J_(>0=$\0]YAOM4=<K\4C*H&G!%Y%J
MRL66,+&J A,1N.XJ&@V-I]0S]*7F"X6ZY!SPM30!>*U*&01R9@(/]]0@U*U.
M!Z[6W(/8 _T(^" $5#<"37.:4V>MS7?JK4<;[N?:U^F,U/2A7]M>9^,VS4US
M@ &X5XBE8R;VS=)8D8O6)54(1NWM/J,CU/D][E]-4=9Y0.Y5,BYB.!V26:"4
MTQ#>[]3#P@<\.'M9NJ!SX^PLDZ)I\K%WWH*8H^6GO53BA.J)T3ZS(5RV+6G:
M:_(<0?Q8#*<2K7@CEZB_<.W:W=DYE<Q[K4%M*$Y3\!&MKT&<&T@(1]XH?Q<5
MYL'^/\QZ:UW/%64R(.H;V4L4SKRX2B::JLV0IJ$4(&WG+M-V/H%\^ZLVW_Z$
M\NV6]39,%")A5[V_B#U]*Q093X:9QXFJ*+&DS]5\6:2-O"#+A6:&QRVIWL*S
MXVH#/E6<01/<XYSH<]0,7+,XI0;N9* W;GLM<D"Y\:HM(=2$X.J5E5ERI($U
M7A+W-QB[['4"'K1;2Z,+3?I;MM[UJ*I4C75"%=.:B>X=M"2Q^/QJDGR0]<NQ
M84W9Z_PKGG&2I>"RK^5',C7AVC[8,H"MX[,%B@R=#W,(%!Z/_C".D?UI1CJ$
MNIG)0O2Y.,7NLQEN%U]3'.37E"N]!:X&3]PZ@S*7HVKL81B88\O:QLOPY]RA
M4T]+)U2N+(>6'O$L*9S0!^;YWY78HW8L^#U^-7M;W=H\1C)$/'P,JZ+:2YQ>
MPE4-:9+&E$_P(0R3=ABLKB=3!>#$<J[X.G@+D!D#>RK,7E3:.?S"8I]J*_3"
MNK+>ZYAX4LR42O-ZA)Y<J'9*'FDH%1LR_>J65JC4>+1(K:&";4&NV*B/GR2.
MSLK%-JY9CA9E>ZP3+M'8[0FSG7&HN6V1 -?P778-I6GQU:)BY@7CM._FBE_C
M>-+!:)@^X_C]20G D3>.(\FE_5:"2?K12)*X',A%Q*P>Y\IYU$L7LU%'C-!Z
M>TPB1\X )TV\%O[P^ S_TBJ(,):._-&-GXSG<S(B83/49$?8*!5:/V(Z!*$\
M,YTU(N];5+MA$#9,_0Y\XPP%7(^#26UP/)/"P-V@D?+K")\CPA=<2,U3*4&3
MEPS\:2%RZ7W6_[K[Q\3@E-17Y7ZG2.\WXCT]A;\,= LR92%LREXY/GKL195%
MA-%HB$ART9+I*=IH&;;C#E (WQ<^*"[Q\EN,!K#SI\6F76!QDD:O:^)4_ICM
M#@E/CE,LCWAV^<J:0FU)WF=.4ZL8^<N&J=2T>![7JPP5S' S6)B>AO?![XB-
M.QZO)O/.NU-;0Y9(\3BD(7B7.6%F,;I&_!V.N)(I;MK>JKR.LV)J6<07NKR9
MQ!T6^$W&S?@Q-+>*/7QW-J0<&'>XTAJ-9D52-!T*ZS *Z1P2Q_&BA_[U U:@
M6\&O#*,D3XE,4H9NZ8F<XH>A4>F:)WYC&F//\8'V.N>-+\.1!]JGPPO<9/E7
MG[+?C2I-AC13QB(]T?6E#Y#.MVD0>> ]<R>OL]@>$U4:,GG4"8-8T2#HV,[D
MWX3.7JXZICX8PL94"PP!6=^X1+Z8ASBIM#DLQXNZ),:D49U6"C@%?*&TEJ/2
MB:YI9;WQT2&!JL2/:)"Z-<H)W=MM(!R>LRX#T(M*I;C23CH7&M)47?))3NO^
M:OPMX5EU_G"<KG7F*T96[N W;EOG<-JLJ-2L>T)^96DS1*$ZCW?.K;L^>L=R
M$DE0RJMG*(QRB,0?"(72&^_;/6KHS_6Z(VY?(#6J DX:-I<&>HE,R[1GH1R0
M3]N&+)UKE-ACA1]O0$!X^B&=9M3;<G6EIVBZLBAW:U$>!!OGMG[3FFI.G=P#
ML>YU3KD,,)>?(WRAN2QJF,[P1+NJWKJ!_)AS(8*2TWT"F?_G^VWF_PEE_GT;
MA*<9#WTWX"_2<$9$V1%S#JP+(P9IH4K"V5,QDIH(67<Y>1U$%'=@$JC1=S;!
M::A<J*660EK1N ID1AS<4?^*62]QU%1#C7$NRLQ8_=MX5D4<4[B--GD$+\:?
M S G:UTTV^ZK[*;&M5Z]K(FAK"K3+D>,T-O43 V+0Z^6TL!I4>8VRZ;/B*4U
M]C0@A#X.^@@N/;(P\MRD ILYYF5UR5VG$,%@@6?!5G8:E$BW/OT:]\!TOX=H
M'X?*^GJXL=%=>97#N37>6NINXY[/09/G$P)!W,L;$KB87S?"SX9/-9%IS>N_
M9I-,ZL"??]J/1GUL2JUXP%Z(1^G097LC*076E=8^*K;<ID,R*BJT3P3XA^\K
M9+;SS!W1OAS^JJ^-Z (7//=BU1MY>/)R[WFE/9*TB3OBWB;0I3$\[N?)1((M
M-:86ZS/]J;U/9>#>T<L*N1*^&OC;PWB1@1YV/P/5.#M)G..$Z/E-YV1 :[N3
MSF[@PTGJ$HYRG;F@NW1'R?U#?0*$2D3C]94$TD%-?K-M!9G)@26;&C1K=W>A
M7>9?V<.BR/H<HNJ<&@>^<ODB(5VD&B]PA'G]A"S]O' IS/Z-$QXW'Z[/4-"6
M#$I8':ZXI!(#FZH/L&IP-\H"7A9JHQLCR*A%>52NA64U,DM)B<+02\F8%IM'
MDS5*LH,7XQK^,82, [U[#OBHTR^!3:7D"OAQ2,+0-3W/DK!L$,FN65J6$S@B
MQV' N2Q.TH -/8.='3?0MS*..QTF5&Q$>""B,5B<),LX<W&]?=WX*5#?]HX#
M.CQ!T8787N9@AI?UC#I[$(87T6GADFR$@V-OEX_U\CK+)V<;'=+PL<47G?&1
MS:I)AP8<H:'9J \C#"NVNFOJ4M0U[[-C!XYBZ9?./:;3&!I @.._LC(W52P;
MSU>GV]HLL_$K>/.I-2(("W&4M^:Q-CL8Z[5QH+$8D:>">3V=Y,FH,O$AM,56
MII6B;8X7QM% 3[!ODB]CB09N:<PP,! #4<+)3<;4L_:3@[Z$X)=S4EXYRP1+
M#!;+N/$GM>G%>2/G0UU /VLVBD$V@5MVV?,Q9V@0]T?$3NKNMZ3AJ>Y^H(J+
M'S!ZLN'/=R[T.L!5TWY6\\4?7-N9II581'BJG; +^ ]\%MOU3&WXP@[H\;=C
MX8/!)7;?HKT;F&?[=Y0C]4[AS91<Z!,TTZ95+U,)/,/A'L<@/QL8E3D]X''#
MGL1BT*,0<8Q//YAQ]_PPNN:> 0T%<!\$NX*^:^U=-;[4#79N-2D< X>H=9LU
MOAF3J@XX:%V3_C0#%OR7)&8=2:8P-M)W#'4]"B+,^21U3@<3CTGKG]$"%FBB
M1=8!.#\;S+A;FJG0^!'=7D4C.:8W1 HQ=B+J_$7FG:GV87-B:NU(TZR4ML]Z
MM;R^NQN)6/09>+'4(8@,UJ33="HH?J465OX"JF.X#;XH&5##S;GYP!$RB[2P
MZHY&9D_.XT$V1C]%\%C^_!)J]\U,)F^9KUE79Y2PFVHPALH[\![K*7#?/S]H
M$_0;3-"OZ]76MZ%NHLY!TYBJN)+-YC-WTK P>GH,;]/I3\__<4N]\HXU?1^<
M=R:A0K<M]O)W551>HVE9V&Y>^Z8_?JO!S/KS5(+IF10,6(ZY O&-"VKNPP*[
MB<K#,X[P83UR9NNYAD>TA[DJ(FZ3'8(*P]VPS&2ZQDSQ68)!4]2_(O9MW6N!
M:33VA)??[3F^9FB?3, E=E7%51%U1G9QX1C=H O 81A&>@8PE(QTR35A)$^6
M#[C%S7)6)&-TK-'S^ZEZDMVQ/'$ZN%$E>RKX;_^<"B4)7>G73^>OWYSOGGUZ
M__[T\\6;G\P_YLMD52YZM'IRA&$;?MI7ZN[O$/^.1A.$"Z27_^?O^_RS?!)_
MIB59!:IT;4*;_!,XFLF /S7P%=8!7-T^VG00^LCA/WX&_X?X)42IP2Y5=1Q>
M!,3BI/$J!Z&K--]ZF3NJE]GQWU^G66,N^39J-ZLK3-,IK>DP)W%.,H:AQ@Z:
M)S!\Q=14WDPGRK. 6%LOHBM0' IJLHF4.HIYE^N:)FVA@Q):)2N:CCF*PF73
M,8!.$/)&65RDZ H>8ELCF>KZO>&.CR?K_<4+J84JFC\D"."G*<)I7(*35<Q
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MGZ[#LY1X\?#8O-QYWN#+%;@==1-=[;0[I]=:6("]*-=F;^AD(QR(%9O0)U(
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M,^=4V\D9X-SVXT&)DXG]2YNFV AA.<RV8NZ$)CZ.OZK%6>!B8B+/I6>)1T6
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M^Q[.A1.P8D,6'D]M/RHE8)SD23^>7P@94HQ+V7]*<]I.(BLAEJ6FX2+27DU
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MLH2O3:[A'AS'A,VO>LY4'J'A*'I%"_(_D&PLGLI;7>ZD:O]9'(&926#A*X)
MHL2^W,$UQ>XYD3S5L!6I79P7_GM1.GX7/T>/"7%*F6.]UN+U"F9Y]TC8#76:
MJ4IC<J[*>HG7Y#,EE21T4^5(:._EB_9KL#-X*G/?]SI.+]+K,OLK-U<5^FE>
M,FTH34!CWVGF#QJ<H0Q4+H@5*P^-V54[051 3;J0/UC9K-JVTHY5B(5F/-)A
MFBWS<>_53.!UH,0U[ H*'^),X3EM4VH1DQMLO=Z01$VS#/NR>7@4@4WA@(ZC
MKT;2*PS00<#.@]F(O__2L!M9BEZ[U44W5S36B\RE[,T &2Y]R>V&S"+N*YK6
MQ695GZ2]SKLI!&-\2F4=ZEU2HP&N1BJO\**3,?&K>32=7EP4YH9342#3WT+\
MI%1_%S3F,[8_>'>\+YTJ%M/ ;7AFGQ26BK) %'."KBHF >V3F["*5KZ3F%L8
M%\3JGK!.T0??!J.APVY^9T3&*0BK \%>)_$M+FGD!XMU<CC2S*EN6OK.@3S/
MC0EK;7(S!!KWDJ^PC26Q"=M);D0;YE#D.C[TE')#U0+>X*$LQ^5J\1V1ZQ&@
M8M"K">MV]6EA,9/EH1(*4-!\SI-KE);/HZ@O:\+7?E1=5N'6Y65X?4((;X%X
M?^2*P;00=LZ .\UQO*P$T55X;D'L'XUNJ8JU!X<?PT-.@P*,Y@E+I+DQZC,]
M9[0JZ[8R+#,W!<#)X#1*[Y,GY;85G02S,NT@-+@%P<) U=KK/VF3WVSK]SJG
M+#',<:)<JUKD(G)HUDQ<JWQ:?6%,U#&S><#YG5H&*(<<1W: W!R?P\D()E9R
MEN$.%10E'^:8!H6$" \N1>-L.YL\SWEW1;WI16Z+UXH5?:,3O=2FK442U9-4
M6OQ%4=Z15M:;L:4#N4BNP4G";@^EB;KDX.)[D5?4]&J\@U]]B,KZ,F]E$%D,
MDB&%6].*:YI+&*#%B *6T0Q=DD'<3X@04K)>M81 [@,KX_0R8E;3+*]R6RN1
MXT!&&[A!B%A/"RG1VJGA03I^3N/+;)J(,>_%TQN$9>CCT^!7<B4[%L(K?S(1
M8K[4+?!U5$2;'!1^9P^N+&W@P\E?\5'IR6*<40JA)--&P,,1WAO6\S4&RP*/
ME&;CI-]5[T"Q#3*.5BJ<E/#M"D>AF%L)ZC@>P&1W@[,'FHHZ0.%0(<L0J.(K
MRJ 79:^(_U,27L 1Y!9R R[ULY-$O[#A"I*8H3I4T7%-QU'<'K,D.09V>)GE
M9$#S3#A )QF'2&8X3$"!+<X"-;E.;FV,+V3=:"6!H/T,K^]D?9R(2?4!ZI.5
M:*WZ4J>4L4<%0+4+O;5>5F#3A^]=BMH:E!F&?N%W@'D2MFJ\R41FR6>43U"2
M(AA3\@GFQ:%8#NR1Y0F\:@*-(FWV>B?@<(&/<VE4R!6LJS K:8D]@M7KXPU1
MP&Y[\?J<3J^4HIS!LGDD+Q@PR;9A4N  VUD<Y9CSQ+S2:SC3F&KSLM?/Z8 '
M_W3\U,;>OFHK3"TM1ZNHUJ^H-#JDF@IV>&,<S8:I,(6P[+HH&&=T<Y>!:5?P
MU%R9ITEQQ8&UF&[-]^Y@&;IRHJ(*\/V*N 5MMA*P4@DX8V@/]^YXL!Q=Y@J#
M;S3$^;J:X?-XZ!P,2TIXE.6^B1']4GA"UBQ =@A:*RFMI#RDK>!>$JS=\"CJ
M434I8]+&F"S V#/2,#A7SQUAZ%YP5Z[I)#>Y!&D'XSD$*<N6:U!3?:H8Y?N!
M()BO&&%MK0"T K > 8@Z@SP:8@I_,NMZ"5.3C/501X<O!774F O?P=\*T.@U
M7;KZ$0,\:L'V[<%>HP^DX TZ;0&:6[+$7LI8P9#4%W4H4<O2J;S<8X#(+\Y)
M=A=#E' ;J.":(UI>4N4RR;H<(Q;,U/QQF9.8U@KF$\Y!,IP1*("<.4SO1OV9
M;"UWFAM[IW#V]L5T&?V-][TL(63+<JP91=^Z!B5BJ<-J[\4B"*0]?$!5*_&
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MQ"2X^:K<AY1=O\3XM=H3P4^0<G]-'^QX*NP*#9V6AFA!^XV!7=0=,@E&WM$
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M)+SL((]NJ.4A@;@]XCZN/F4S"]HK.NZ@BDDB45/GI&=060W!EX"_9+G;$VK
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MQC+A#BT&.*2%35JP1Y2D8/@:3AHNRQY)\H<PCXX'?)PFPYD]75+\Z*-RA\N
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M_#?]()MR>DW36NC?;T11"^@2M37]'A1^?1L[WRF]YT=C#FDS_I"VW/: W>:
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M(6M,"F-#5!&.T05FQSK7D+$)Y]CX&Z?5$F0$N[^@-K!!@8<SJOD.WDA2*Q*
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M2,@PF.-C$[N)QLC 9#+((''',9BY:'))6)L\+\UCL<&$+2*+K_R%5NC/1R(
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M+\C/,H%</ITY8O9 UP3I51Z>C%Y"_MKC3_P<".%J0/GT!&E5%JM<Y]%FQ!$
M6M6'?9^2MXJN3%RV1IY!V?:ZZE+3!CJRF;$!6T0&0I1I/$*M0R9+BN<"*.;4
M*JW=(G4?=,?PM4QA&L\KAOD\W6OS %XN#V!52PMMXT82'EVQ*^#$<Z+)OIL^
M"/LI$Y9+O1'9-K3<K;W"W/)&N%]Z99K4JH572W3!<!*LZLP-IX[H&"\)OJGM
M]\' Z6(W##=/=1/CA>NYVW8R6?/9+5J66P,^K<E NE%0H%EH\<>%S#1$'I=1
M8OAP$_SS?HS\(S#9Z :1*C/WKOR.Z#%L6]4YG51R$PI8 @$N@LC9%W47!MX'
MF?R*(\&Y_6Z=E7AHP>2'IP;>5N<H']3V6TL*/):.9UH%?+MXZWR#,*U9][L&
M UIW"$1/G+*Z?[G#]0L6'P]J5_>D>8QF/>85TT;II![#G9*HD9&' ?<:_/TV
MQ+,QX>/K4:'7I6OC+'8RRDF?@;7[SU#,:B,P7,W],1@+^NP!$9P<,$PMHHF2
M^]5\PC=]P1__\3O_XGN7<7?77>TL+RTW;'[E;9UN>]!:/JARW934027:+Y\S
MXLCE,)&^CA-C6-4)%#3=1^Q]E5>MIV!WX2S:B_7=V*]Z19C16]RF:&6%638Y
MVY/U0R5!U.XN&8](S;G[A'K@S?"F82^X>_CE3;=W5JU_8-UUQKKKUCD=KECA
M;Q%Q=S^,K4)KV+';#;Y&KBNA0P5=NR:%']X5<G7O/!B1;6Q/)'.%!JV:=+EH
MRC@GX,Z&]SDY!N"^/1Q%R5@I(81#PR]@O/:)SFC'D2[1<N\#/5BU*!F1>&EG
MHJ:NKM6G9<7/D0AAND8))/EQ_?N94E]TE4 ,MULL!I-_^W9T?/O @C 8I4:7
M,H)3'= 6,_*AUPL]4>(-Y01^C&[X-GN,L\1ZT,6QZFW[FB0+.U"A+G547L7*
M%1;*85+$N:VCXR&R4R& +_0*EB$1&,T4$C3;WVBY=(.,ZC@"@M@NN^ZJ=1V[
MWAE?,(B]KS^7++-\<M_M-0.4H[W;5842W5UP*>$7#5N,#!_C34L76+.WZ#*%
M/^9A7L!'W4N2<UY/.SXU/#H<\V0 P^K@0Z859R<ZS'YUTR\'[(2+W_WD>EQX
M[,DG]T.--=/H<F BNK&N(949\O64N7\T<1;7U4$AM^(N@R,>_UDBFY?G'1_&
M1%>R73AF67X?^*H,)WPL3D*S/N@7T$D;_O3VN..H"[1MA\I!)WI4C[?&%;Q%
MAQAL1"RNQ?Z ,!=IP*XRX3BI=\V8+M1\OJI4U@5"CN)B3."\07;J2JJ:]ABY
M+2<]'$D<C>W^PS6YLZ2B+&:6/I4\4'44JA[.EO%ASEJU1G% FAIT8$.3-)Z@
MA&0AK*1LP:)[.2W*VD.:8".,@EANB&#ZIX799XR$UQ(Q9A(F/"AY,Y6^8SU'
M^)(8SPF3F*;9(!P92QIGQ'Y5#Z)/=X&@#Z8AZE_88Y\2^PJ'/+M=K"HA!^98
M]'AF-GH8&R%MV+0;1Q78))HOR&I=T:R3+'^\W^=G\GN_/B:_61W\J&'A?MV]
MV?7>*_1&1GACPO/B-OB*#B8^$[JJ25/#5/Q2JT.%KY*]OB9<^N)93O9"!Z=:
MM^ +$JDZNLWQ)8;&WY?QASS^',9?\M&6 V!L",'I,++;"^>C=.TMT:$L<&QA
MU:-B8X]B:#C[J(8QNP&:HM)A/,$&$E /7:?Z!%.H_H-8]GC8-PU8+A*9MP7G
M"/Z(O# 86P4M.^;\HC[Q16-RD?"U47<;)U>?'F8+RY/D\ H$^;MY"1SON 3X
M81'4@TRC8^=%?%CU93HXZ:F 2W3E'$)+!Z[=&*9K2T.G)B8?S<Q+/FCSDN%C
M=VGRA2F951"1'DS1/M*":3-GX'86Q%_H#JWMT"[=>^DWMEKZG(E%>X#O2J1Y
MH,EA0489TDI^:Y6;IYTV8M-6;K8J:F4J"F8S\A2YFYVS&VO2LQR4"5CD!5\1
MG1^-:OII=A0)#NH=]14NFKE)EDGOX>7_!$9]W6/68(PM0U=*O[;5;JVT+U7:
MR8<!9C^G-():1K\SWAMUV'@$EC!Z=?2O=5+/3^WD@S0I[@=TDZ0 "OFT LZJ
MEXL\/'M3^0(8N0S(@R$<_2I:SM-L;C23M?-$Y\.-;8^\+<ZPTWG]Y'D*X^UV
M_[3[9ZG[1U\Q'P>)>\.4;&"1?4:6':C>/?J9,=;!H>1L',/C,""3\NF[Q0]N
MQH8)-J-7ZS[ER)3]O97K5JY7(M?L.B%W+EZG2-A )7,^?7?L53#6R#/1@_,D
M:$$G6I%<H4ARV"4:ZS@JF.?"\XQ! X]*$N"%+@704V^85!-M)3*ARS;2QE<H
M")J@)?X01(4RR(01N@BS!E+F5OA;X5\NI%KP=12,5>H2:9>Q_I91M95^@2'L
MX/^JO%*UA;D!!05-O;2(5'L3;25\Q99T745=.5[#V9$V44:*'FUH,QM2FI).
M\Z*WI!124D5N.'0D>9/[>_LVW:K'0?),-UMY]/"PW%Z?*S3Y>LI $Y7'G9;;
MW=/NGI7L'N=0H"P2V"OH-ZEJ[VJE#-4-Y(KB^_=IDF7:Z=*86E[9B@+<&7PA
ML'N,^?,7*:TLUEO(*7*TP1N3V:MW4EWB*>R9UGG3;II57G+IS+'9WZ5$HY(C
M!W/2>SUTX+@W#_'IH)>'4%!<%(L:YPW&UD/H=I"V?IQ6Q%<NXBC=9;26LOY&
MJTM]17"-C&HF,PJH9I*E+4E[K72VTKDRF]\40Y4\Z%.L_VJ.F!%?>"<9F6 J
M:=Y'_'M "#*8K!]HG[H.6<T!!81Q6W.SL%@FN<8.&45!J<EJEP(-?RXN*WTX
M2#XL7T?X[WG(.:DZ*3=K02+;S;=\G-.OHR G'!CV?R*:-&8 YO *;YTHB>]W
ML  $;P"8O9V;S-9?8PJ]WN2<;KT)&(\3F95W08:&EKU!<'HF7-"Q($@-,0:=
MC@7["J,:MUA%5<"?KCG)@Q&*TF181/=DM#GE)=0<OOI'T0OI'D.%EKUA&$O1
MXH/B%/014D4*APV&H9.^+PF=I?I8_FG7.T,8<)-Q+?G?96H/KF+4"==2TPC7
M+3!@\8:%."=YF@3:(<Y XO0K4UF32WLR9=?6+W.T?#)=U22FPKY-T:-2RD2%
M)E5-7?6(RU<E%WAJ[NJ6SAB0_!O,A0G[.;<L15P13&G,TXMS/2R&-!:I[ONH
M8#6(4P?_5DI7X(]M(R5<RB,)[4"H**"286OZ$"5=2L29?4C$2;R#[^KS08_L
MY>L'+OE23PD5%"6AP^=>0- P>,$NLD #\.A*B[E2GM&<S)I.9M\(6(Y$=T,I
M8N0*)^=+M&&P6(BL 'ZXTJ/:]ZB>P^1<@]A2?:FNH>>$96K;E&+J#:5;U1@V
MC4_@=W8]F,-Q4I"SO=2C\H29V]UD$LQXEMWMTP>R >U.J0?$/Z7LM>D]A!FF
MKY0)J_36K58;5%/LR\4'E%CN%*LM9%NMNQKF,L:=2K6L?@5:89IZ:IPMETJ+
MR\8++ONB3%A?<,QPU^12^H\[ .%^@FSV7*-F5B02T )5Z6+!(8H1,R[%4J_@
M5(E.;<UDW_L&%H]RGP(['T.+N,$-HGFI9#6S413FIO0L, 5F7=H_@G.&@X<I
M74^E4T56[>;&0H9*'5W*WA/48/?H(I1A416Y("6,L.@X-SDR\!*:T%3="K,8
M$3I ^63#<L>ARFHW3JIX$9TZ/ML!+J]UBS;<(Z56\' ,M)C<@A3(V7N*X$E8
M.)5*AZ3JS=2WY?JX_I2@=]>"S<*KE]<WWB#(&+X0B\NE,!A1#^%=]K#6B62I
MKK6A)JZA>$?4&7PE>*2C6./G86?$$.DE*(F>P<W@6LIT;$ O*OQ^E=7"XD$V
M?O2GLB+#I3>ECJ!#=5WR*TWTWV\3_5\NT7^AI7V&NJN9EIO;S^?__.7S![AP
MWW@WOWS^]<,[[_SSIYM?/]QZM[]<7%Y[MV?_ZYV]^^WRYC,\\?OE[2_>]<7-
MU<4Y_/X9'_'.KJX^7)Z?W5Y^_N1]?D]_XC+%"VCT[(-W^>G\\\<+:N?#V>\W
M\AJT?'5V?7MY_NN'LVOOYO+V5VKAQCN#KUQ\^(#_>_;I7_0:=NCB?WZ]^'1^
M<:,_<7UQ?G%Y=:O_>?ZO\P\7U]@%T [PYO7ES>6GG[U?/T$?)KMT<7-[=GOA
M?;[V?KY\?VN[!G^P;_!?WE,OZ'G?^_#Y'-Z&IV;:XI\^?RK9XO )[,\_?H6.
MO;L\Y\G27\,OR"R^_7#A3MCM]<79[;]>_E@\RQ#W6-_%X+#0032:1M:U.F)&
M981W<&CV^2I*==,S(^?A?/6-;<E?ZV9ZAILIP$LX5?]C29ZXE] 4T3ZE6I=2
M&VIHQ7#)A2ZFYL3;,E=VN:5K=5AR0;AOS*,GMTTS76D&/\/56_"/+2IU->W7
M/;.-MJYF5V!\D."QWN6J+P'LHQ*_HG:"O0L9EIR-JZ@8(N9=Z8I1&B@-#$=B
M=N0\PVUW:+M#EWU0B-OWD?S&(G-EUW>35+*'+")P9T:#R> &V%4_D=NV%=16
M4)<HJ%P,C$AB6QT-Y\J226X'0M$RH=]1&A*Z1U:,5/H0<D+0@^AW-U[$?A;R
M=G/[ 7FUE2E&H"^8A ZLR:$FBGR0I'2*)9Z4<U)\"4'*$%P.+P0]U:4OF\.$
MOP M;^W+",*<'$4!ECF$/4]%RB#YC:*@JP1':/+DX!XM& -< HC/;,R>:^M6
MK;C02L@S- H-S+,>])VS"-VZDC4P#')"SV=W8A^I>LB?UTN*NR9:'W0&Q@+L
MARM4=2O7! /*'KT:CS%YBI$?B$P,UV4^CWW@$CK4^.JMPU7;710GLO[)C-D$
MUN*/3O6Q8S90$8MO.1]3"""ICW%5/:0WCJ/=9S.-U]79MKT0.>XQ3LN.8YPH
M'3]P<.JX^DBR1<A-VQT$"#\'W\M 068VG[ N9N-X94M;N.KG-0!&=0C(CDEL
M\#LECC79$L.X.8Z+GKK+G:P6[;P@2U8_ Q\O%;ZZV?6S)&X73.0>,]SH+&-C
MVH(6CKOA*$*Y)!5+[F\29H[+X-+$N I]0?1#=H(@+U*UZYW99&D?@\:R,^&C
M62@PD>KKB)W^G+D<4GP:5J\;%2+N>@Z;1E&2H]GA/+I FP<,B.$6@YMNSXS@
MO763(W0\:$*D&@)2]M^.WDD5P\T-%+&Y$69/0RAR(<$C8XZ9+AIT-JY@D=XS
M6*^.HG(:V2)A5)ZI8<W\KSO\658CSYS]4A9_>1Z?NBX51A"G4:/0':7#0*&$
M/ES^&M<*",:NPF0[+;W] -:2Z])L&>8D,)RP"&K.I?H>U= 7Z!FS&2^V4S86
M.:E!^T0(0].&F1ZH"PS.I<E*S%T0Y[H>:54ZRYQA.PW6PP,5'(BAPG^<9)(Q
M^EE3GZ&:[7:+H:#7J"#%R".; M!F'Y>3*R\8LEE(SF9Z/>A8BR<P'NL\\H'@
MR">P5WBZ^ ^I CT;.]Q1VEF]^!QBTE>8:4S+QJP+D_,5C5W4/R3:LK%31GM/
M+=OF%(=Z=7.@39:JH>0]D<@VJJ\R>N[L:40V+BDKVSL]W7EW^9N>USSLCQVJ
M2E>;H79H1 _E+57K!3/R/-\); S9"IPU'K9#<55-V<'91!D=ZS6A'7GRU.2)
MGI/Z-?!G]BO,K UH+%L,:..^TO<^T@]F ]G ][2&Y1%*+D'7A5;>CS#] [#V
M5$J(T:30NG!H^\V;(+/A<&<-A0-<Y\_8E</L.AP-\8_,2!YRLP.#.[B_PE+/
MV(F:Y $%Q.Q*&L:@_&!9%D7+BOIOTOT5_8XO3NKU,"UI=F6RL832IKX=H^;O
MT1NK&QW7<!O:QE]SGL%!FV?P[>494/RXRH5&&]=>-.9U)1![1H%7(7O/T.#T
MG&W3:&@%E;VU5"NAV<8SJB7H_5%0EE-)"4T>@&5#PZ9IHVVDARP<J.QAYD1E
MME0QD1NO%0&1&Z%J??D;PB_)(SIP)/5V(NVVNGP3IYF;5FU>YYN5ON;N>I]C
M)=FXYN9KOA1J9(K*S-:=2*Y3L]XWD.WJB_]EW[.$2>*"1$^$/@GC&IFL<UU4
M#K2Z;KDKC;S88SV%31X,7W=24A#+4F0AZZ'%X:B8+"#8Y=%AL(.KLO4@*8O?
MMRW4W4'*33*\^U=NQQH,@4Q4TQ9]U*T)"S)=6X33A>.+V(H+OJ]M![ZJQ3&>
MTK2Q)I)>Y>*!&:9!N 8_WB631!I1U<;8C.MQG60T.;?F=(2&FD04%Z/)=).5
M%2*/Y!XCPFR?405"-E&S/WLLN]X[RHUW2/OFNTAGTXTIGZE,IZO>!<R^RE7*
M9(]&6'C!:=GY(Y&B+] ,:K69UF8VOUUH5DAOC]EWT89FYQO KO>^HK1KSM-Y
MCN$Z@=:WNNPI5VSM@:CAK_WNO0X36^D9OH9),V4N+\.92976=S7796C2U-G,
M6X+C5E2A>R?&K'UXC,C%N-/8TWKQM!?\>G\>=6?*AU_UP5+!\)H1!.DE79@
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M;9J4+BIHKU[>ZAY1@YR+1JB9J,8SY[TK27/#"T"*V 2_* 13G)@%]UHSM[5
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M;3//$<,93%DIK<U!L>FI$I_N.:.@4>L7Q';7"G,KS$L59L=ESLCPN;I/&V-
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M$*G"S%7RH>,FG5PW(4N+JS#31DBJA1ATG[$<:[-O[8BFYMY6MH**<[^T@6@
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M;0E'2HG\Z+SN\94P)5A=?/@1LX2P+C?LAB-BKVW<MYIM6B9_GG6GP>+2EK]
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M]66;T"*I\<II2ZBF1)+'^".#9(BB$R(4=BMB5L0.7X.(?<QD;27(URU2I.%
M5A$#-U!"(JA@"1":<@+/(?*+, D8B!+O3L6J'^:+,LNM!C3C4Y!B =,#88UL
M%H)&J1?G+AD%'CDU1"$]Q7BKBL$@#"Q&)INX K&!BV3?8+2G2>R:)H@-/KKY
M."3HB?K>,JN"G+]RS"-)@R'+M$1%:3(B1'*W%PS9EP]2A<HKI-51D1S8&OMF
M A.F- YH%RR388W26@B[@\"2^)A'NPJAJJ$S<\  (WF=DGI1/N7!>L!S&%HG
M;=J=L/.B)+[?P971>-GVC?+DO&:@O#<M4)ZT_"T!Y?WY[V(+O\5-PE &S.Q
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M=WM7]_CE[9TBIVL(3KL8>&+O!&05-%"EO&)FD!-##')R^#Q>D,/#Q7A!3I?
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M =EO8F8ZCE+6\^5E+BXA+8^ RK%)%_8@U15RV'O)!2\'ESW%9544[U9AX%H
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MTU(,::^MY+BXPDGFDLU<II!K"DLBS"4E-2T[@DO(Y0JX,S,BIP7%(DKDX!8
MF$6Y.=0)P^$J>8;&A5=5HGQ9@H! 6"_\$)?U0>+K=3,_]>X=XGHS$6]ADYQ<
MJ; M11]&UZ]OEBK60 H+V4?E17-3=PQ4ES)^5D9?A9Q1SK,(43"([Q$TV ZQ
M;))0# APC1@#>[*(3Q%P"G%577I.\&_ /U3_YD*(KU@DHE7D2+$WMO[AG#,#
M@N,3/]BO6]7[DU$E+9 9;LX<_K_JB5Y*1:8@B  =#9PB$E]4-K1-=!?6,'>
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M<UN4FWM(C5U+ O>WM8L0/1&3+LI2"#A,E@-V @@QI+E.2,XS*9LJV!K:MM!
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M0<>%RE[7#3<\5X=(?-I@%"0;G.L'+X.5%>JF)(*T99"9E_&\M)Y R!$I8BS
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M_$;;4O-=#PP14?$L(>*2?'?U5FEKF<L 3D81S>IOU"X3O&)!0D^J$N,@5OO
MAM:PNU8<@#+J^W1*I>_CA_*X($%D16]4@)ANL+-LE;O3-Q/8F=KJ?X^N&QYG
MK*P;;_QXX[<D^%IN=C/W+Z=L.*D1*\,9471,'CT:TEJ=;_7I*+M;D3R'EY6.
M;Z*&\O:5&EZ-?#'-6?'WN$Z 9SA9H=NGW:_T#A_HFX'SU&XO:^/,BAKRLC;\
M:W=_(1;2QD]GU8(<%M:FRJEFT[C5F53;0+" P/A9.(@CZ]LO_UC'?MD2!V:N
M*_]EY3LU'"9#.;#M5WG/Q5]NJG_-^*44"?6HS:KW1U8]LNJ[8]4=[B ""J!,
MZA13+KCI=IQZ%3C-*945$D*#[8C@5,,@F\AO4S9T2&V6J4^(75:UPSG)@!T;
M&4P#7?)D=>&;9@56:"61K;YYE[,[WIWQ[FS=OF\# +*C60Q(8 J2;/\E 'NL
M(?UP\(^<-'Q"2</M0"L]PI&@%>3;YP["<#UF,B_5;+W#.;8&"[7Q+HYW<;-W
M$8N"G#I858(QI71 71?;'0#30>Q*SBLJN?*8FL!2I2EXVQ!P3'X&P<K4ASQW
M8T=0@:RK4:.>Q]<"DH O!0N\NNI-6!-*\1XOS7AIMG5I,+=6FJ46<+R.\V[Z
M)CD72 I&J![(>#YM4W!!E)Q+UWI-'FFNVHLQ5VU[N6HC%WQZ7-"IFNB,2W !
MB(V!(;ZS/4PU;1C+,S <IHP1>U$B7]U%A3^5\R/&9S\SBOB1N.]8Q)L>9\CZ
M,..+,. LJ7H#G=F$M%,KHLU>(N4OUCYM5RF8"#14(6^C?7:0^X-@8EQ!#!+#
M5I,ML[F <'>)R5U49ZR*QQY"NR'+XW:NJA? OX5]H%7B8I=+KN%<B CO2]7D
M6?NP6DB1JP/_9^='.LC?X??CXC#Q?4E98(CJB;VQ,>]5[FM>+170,7OD9@QM
MA?6&SNJVGQQT,F]-C..$Y(X=[LR=LU.B3:EE)(\#\@FQVT/4F3?*.C%2N]#@
M:Y!1EA& Q!(Q!*CNTZWMXPD-R/9U4=U<Z_&>"+T^10:WF8DD6K4% "=810E)
M=?+V$VI(EO?XG!NOA.H=;U:8FH?J?,6!O6@B_W_&83;V--OYQ9N>(D"A0%:E
MW$" V"2@I@XJ<@\X#*ZOR(% :CW"/6N?G$[@\^ZQ6TP:W]D:32$LXZ_*Y4(=
M,*;DR>4CVT!JP-G3_F-)[[4"4F1>,Q$%(31!]+56^(D83J6[JK;)>A\.5>;R
M%*+41!PJ-Q.!'WQ%M)H_U%:V%YP8@(C0A6/SS@B^-X^DT$S$I3PPJ5<FB9"J
M9=%-#M8$0P"? $8,Y% XI?WV<)ZL$BHR+X3XRI!_^C"64(*?=G&U>X!7.,,=
M-LAR#R-W>]#EL21'UV,3D<3BFY$H#+]70+TAUAA$W)JQ2XRWWIG!-P*)V$#E
MA\,8Q W7V"DU$3VE)1U=7@] H8QF -L(=;.@PG)!>3-%0A?N=%3K/"AIB>M?
M9E@OB_JRM#VK*:DQ>5R@AIYA"7*5@ODY)>#+//Z6)5GE'*B\UPO,!X$G(-YZ
M:6)0G43A'JZ"\ PY P185_L!:1KP#P+G-\^F$& :&%,F2#Z !(A+/M+"P&WZ
METAU,?.<(/A6;!C0:],DBA=J>JCQ7F.E<,M\&Q5E5C0/4V$0XJ(PYS-'B[=C
MN&4U2>2Q377B(1I1V*O:X.7,*@B/RQO9YJ( )L$V@21.P441ZU(&1./EO:CB
MDOM34)!=8X75<0PM=RTX=&&@N6#W+:*/T.9.49#;5"SG.<GR5+25F7BU%%5[
MXH@Z2"!*+T&#D9=OD1I0(2?=8 :]UUB=,YF>_D^:G 47I98*5]01P[^**D?H
M$RDG%W&UD.<SB$62=24EF+@&6[;CC"99]K7@A#/"QI4?77*K&75H)-(]V:Y1
M;?M,)XA9ANH+(FM@"UDYKY6"\4',,0+QT=A*\@B7EC<^%Y=@Y1N8>4OC4I2B
M&*V:>4MESL/FMJJ/P$U8&\(A76+X'U0I.>J4=#;#-Z]$LFSAO272*Y\]'L&5
M/!XY)=T/W"94 E!(H45O,U':G+M&8RYJ5;6Z\-$2F0)2HU/JE(!I.HM8=TV@
M[TEEQ""2U<T$F\7;HE>)''F%Y;HDV<VB173)Q@&X  GL:!Y+.1?CWZMRI7N.
MS*V$H976NLUK6"/+TS '5-'\Y#V.DG+EFQ$@2#8M@BDSOT5<T)X01FQPF66(
M+@TEQ@!K+*\K5NAJ8 LHF8X+<#Y5=(T SA*>^!9G"J 8)B1/AY<0+PBY@EA5
M/.$*4\"FMR^8A8"$M73\MIT8A8XD@[.L=D/RBYRA]:VOZ8.D9L+EX\9V>#G&
MRQXHML/MO'JIY!9270/3O A;!9Y3X.H$;R9")T@#S4NM!& IYSJM$=04 .\F
M7VID\1-B'=?D"H7>1^@DXC<4@N/.'&'@(W &['HFX9$4-H.LB@JY,T@$#C--
M4-$IT0EE,P"RR:B(.0%\:E>-4Z"=!)G%GV-W.KC@B4&H:5NS\0?3-<:9WIK:
MIK,\(41\N3''Z24!A%J_WR%6I,X!-%X!I<(%NC_YP97.*74^L!M:]B]) ,45
M.;0@+C."!^(M(;V3((:=O6%WGPUN.,D14Y(8(W9N8G]?*I^\BI*Y?U]"K!U"
MY'#$@*7ZH1J&:U>AT=^\J70L:SB)OZ#PAY0V";J$$G3(5(ED]%*&Y-#_&EU\
M4W9"1:@]R/GN / %%LC"1ZT7=ED-A[0,5>0= X$G3I<&HC@?G$$$=%4PA4*'
M;M0,Q>P7=IQ#)WOH-:"Z,_H6F:/JL!18@XN;S_[L>1Y5,V4$2K4#B8+]U]#^
MJWZ4PRC<QP^0GDJL2]/=QW.=_$\N2>MC^"%:;ZZ).$[G0#L F?>!B >)F1$&
MS2OJ&GN)FYI:%HUZ>/?/-)K<TWF<+QC&E;ML&!V(8$^G5IQKJT$7Q]?9M$,T
M6W(Z>H!#"MMA]Y>]HD8CKW^5+(EL7*^$S4OQ45=!3(5D2I<8D@1MJ<;<M6;I
M G)B$E1%8./<C90Y".+Z*K/5>V)DA^,U /U5_L@V_C*3_U]^D8X+'T2N8./Z
M,N4"I<TK@/R?1]C43_T"5B,0T(#:"^#%T:&.NH$.P=RXY*LVS;'3SPDP+;XO
M2$V3[)OH!(>("R<B2'/&S]E,S[3WX%O)UC_OFR72W,"<=5?;O20^9@)&S$(:
M2DY V"(\=/L ,IX\&6R35"8@8%$7A\8WY*@@48YFA7:)J3G!9[S1GQ;BZ[!@
M:I4*<0X);M X@OH=^H:SO_R@S&02)%%29(.-9=<:GB?B>\P4SWC]D*%._I;T
M,J(:$^7&+5=+1<W*J6#9.]Q08($DK:90 Z<JKRC!@#TM]%4YEP0[8/*DJ.$*
M>T/A?"A"WU+L8GFN;Q8+(RZQEIM^+_@#5=\OT&'H) PN$/K[?_\90@7C$M9P
M<+#_T9^TH0#%?L?>LY'QIT[Q(W2PJC.;ZQQ E3?5TU,YF%>Z XW<]2MYG 2'
MA0B0L0'B+0S,O<[%")V^S;J8D#D%&*<4"D]L,H ;B8QF^W>A2Z@IDHNP(1%Z
MQ+1'C;I($:"^G[7!DC7YQR!D* H7?150[RD)9JHB&/8/<4K\A'TW_HNAR,5G
M*9E/Z4%#>XZU=D\UN'YY.QSN%@O+S<-*LM& ^0'C@ F#*WG^!?Q##B. #82V
M3P4);DJ2ONM^3-6U^* GCEV:D#.!:HSS+;Y*T1D" *C D6>Q4@>X[Q7F1R%L
M,[:1 A<)\W\PV:6>^R^5K($]4O6/)<QE^\3H]/KMD-K=@1FR+_!<P6)K\%J'
MP_)&4>QII@-/EL1$S8JZM /=0O,OY2O4G,:B93]_Z\R44'TD10EJ3%JV#=(2
MR]SV*7WFII+./MK2,EYPXQG>)L#&P&W2Y-@2J\?+:12:B:#XDNJ83.URD*%X
M,,0[MG@/*\50>Y3C]BF$9 8R-"^5G8.BRQD#D54JRO8@^2J9=I?P)=4CD/%[
MP><-BC_K9_4V 5UBU4H55-9G5NN"QW$,C18<*5-_^/9LOQ4M7\HS>=^*X(AK
M]<7,M$UY&,D/I&9/(U @0,&&YH@4&1L4WK=JC)-$>;3Y=K-;NO  (+:#!MC"
MQQD$821\.9<#(":]O 8+63R68*8SL.SF4AXU@E\?BI&S5D$HD$WPD;MNJ<).
MHJ6S(673JF#306M\I)&!5V-DX(%&!F['(H=!?FR?'W8R/.X&$M7P%"CW3SX?
M3^-$=.HW'&3'USE5 R,DA3PK]+"1?D1F%>@+AGTRF,A')\.X+;VPQ90G+V@=
MD<:)ZVOH&C_TY^ Q72":.IRE'P>W 67I9,.B=5$#CFQ\YJ)A0&L07YTF[L'Y
M4;5"V/L;TW+M;CXFJYL31WMA*._'[8,->+'Z$HE%I8L@2$%>:O\FY;XRII#=
MLX[.V20J$'U#B904J;DH5W"Z6-")9AB\T*"?T'<NH45*S2-P3LAW.BKU GJL
MJIYE$31*(W]T-+,JLEG% M<G3EINPK3224'P<;J#>ADS_03G.9-S0V\3:O.F
M%$>E*LSY]4([7TBK=J-7O74XG/_=P0.Q8V#[T#7GJEN ,)Q<WSMY0M[C4R4B
M5-][%+PW17"8I2^ B1F8+Q<O.ZR]_F[=U]O)QO<W13?-O^CI'UEP6D>ZR=FP
M3^M%K#>(*JF:NDMW6JQ9':>T@>9K.>SHU4U>^MSTIE[OHRI/3@DW4[EE!1M]
M+9R<^K.>V1TBX[D! %D8T#\^JW^<AL'Q=W1B!L_W#FQ\.>!5YD^'%.?6/S_?
MM5]\8?_P7(W]=_6/$V*,],-OK%Z'JF5>_$V@V3T $VW[EN@-L-*"6X.@W9?2
MIF\CL6=REF)Q1\&9F_XF [T"B/0*']/'K$J]K6Y.9=_>6CEAZTU'G4.<JV_7
M4T;]PB%>+,0,/!%)/P20G?=9VUU2&E#5^!^CF%Y<V8H2_7T57&)+0\5?:KTE
MM\5K3/?1F_-36J!:%NE7WN;SX. 'Y0G!RQ7^_554%>A[5K$&\)C8],1^6-8Y
M:#*.IMM&?'U*5=BI]X;*DP9Q'6F5S!I9#34=H ;.S\_R>6!:I*\TPWP&=2_X
M4,M^.LHG(FVWJ)XJC09BZ< _7'OEYMI"8]F6Z=.1_6RQK,.;UOC7*NT;E?@;
MQ0"PG!D-. ":[M_VE6, ,39R@MJHU=J_//@K>$"Z"NIIU;^H"G_YN&><%Z_A
M#UC@/01@(!B\6'1?.1_DY?)A'.SM@\>KR!(YZG_LX__5X0/4"AKMV7T^J\%>
ME -7O+]95[K[/MXJ;'0-??])*=ILPTNX\?X]M,URI:.+,L T[[G>#7IB#Z%4
M;N25S> &I___7Y[?#34?[#<^WPU?H7JJ61/K;79Y:B$V2^[Z09G'JE>FWJ2;
M;-'/ S;O\!XWCQ1*H]*UJV^-)MQU']BZ LA(:BG#]C9T6_M76%,2O?WA>MQ[
MMU(.]FY'4#_&G;.Z;CLFUQ.Z<^TW+2YL@P 2^HL"L%2N,\@"+ K.,N-](ZW>
M<:&C9PG00%R3G>-QMC6A8F9 O/SG&HJ> \=29J6#;L/&B@Z?KKVF&* C#]Z^
M_*7^'[C=H8X-=#S$4XARX9A)W([^*L*"IS2#"G%.G8/:"GR+[JS4"<-]^E]@
M!KMC=E0W^/1I^BW9=N-4[NL?YS^]I.ECHKC"+6S9,_4?.&H7(+0(U5'SKD76
MILEYR>_L2^UG_\#LX"^-'6P2T0V'WK/Q?VS\"6-%ET7[/NK^;ZF&0?UQ\!9?
MCU'B[>,MCN8J60JCO3K:JP_-7MV6WG9G?/XOO];4KB'ZB^JCZZ(>J^QTT*]F
M' ( V"[P(<)_X]3):B?\XKUN_U[0N]H;2<.#M7?IHM]MWJZ#MNV4ALJ@W'7^
M84=51)*SUG78:\57Y()4MM2&L-Q5AF,TAWHXJKO[EI4Z6\8*7$!QT+^HN)3_
M*!_$A-7LVL2]!^)<VG6C^#V:(: YQ%!OB>6F0M(2A$5;)E0VB2JD@A\;<YN7
M'JI2BD@/IVO2U)C8@9F3].M]M$O5WQ@+G-V8[<R*D<_C1"64LE&CTG(- '?=
M<MD@4_4Q ZOJ=!EA3G/'H<MMATQJX3MLJ#V)H!X 3H=1,%0K^V G2H.ZNFZ^
MK*$31Z<"1G_!_GM*CH0[%$B=/@K3;<ZP8"=*B;G]5 /3;[QG\YKMWB+O'HF0
M0D!CD[84F?8![8S;V3S.YE*,',0U\A'$;X#!D;W2J%CGBQA7@%^D H]6-A__
M889,-:7WN1R5@"828-<3J+\UF=8X#\6_3:TAS.*NV>H=DW0+Y$5D.R1MY&.=
MHTF1["ZOBO-B:%&PS[WQ.&G9MS=1GJ],8@B5K$X%"#^I/4'E,&@)(*Q+R!L@
M/SEK)PPK6_/RU$3@GJOZ/UWY]D7K-Z.(VP@_&&XJ6.+,YS!N*I_#[3?6]DV
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MLA+@_)J)D*/&^U TWA2 6FOGU:>/$5("%D8"9H,O"C6+BW_;M7FA"DI9J/+
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M[<2]FR?4VD[#$,5 \V[SE,H?."D227X%]8:T2:\UX-PX:!\5OJ#\BDU37=W
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MP>(B.LTE"@8OLMD 4V"!VBY?^#\>F@Z#:7 .Y3[&4@?4NC1%JJK[3V:K(FA
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M.?P/4W3O6DJ-6^J'+90(;NT<JX'/RW(*[,/N6" 9:UX@DS =N'*9%T0M4&4
M($WDX=IX$4049]3<"$CD^G>#K^K_/$V;%*&NN1=U2F (>$!(/3#< )%6,]"
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M-+Q\6IQ#)4#P^0%=4+(/D&;)H'0(47WEBX+GT'G!H>VDIV,E=R5\&?3U>8D
M/;(D!N<_7!L^;#9R/*Y(C!G4UD/:K@:O)7XI*B0I%,IWDE>3=@'F\20 PHAA
M_L;D5"P09#BLR4< LQQJ&HDXS?W1'=PJ=99%!0BPF-J84.QR3H%7-]X#Y02
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M$2^V^NE;<+1647,RD6\[QY.-=;7!N(?)0'E"$. I4FF*"L@7".$%@SR6R.#
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MP:W :GJ' '8PZG?!7'=*]??D E/=7(M2;R8B(2YRQ!RQ5SG 7A"OC/LRR(S
MQB\I(6O0F5> M2X ,X+A1>GGZ66:S]%. 1P!L),(Q0-"CX@\P7BQE(SE0ADG
M.F?V(?4%HFL(]1H:$W*4C=/5%=X%E,$G)*YT8\W2O!I1^3SXL(2[G1)68E$S
MN(^"+, OM)]_AJBB_@TP%PL#C)<A!5?=QKMOM(2/8AK_>&'LG171 ) UP#(&
M.,/S#&@_D$+&C0G),@[&UT0U!K16, >]IIH2ZSHME1 5'*T4D]*^TC0UK-:_
M!*_*JL"]X+^/D\>/'\/_U\A$1\(( QM0GL1B88%R6^*M1<^E@H3H;A 4Y%LM
MR:C-%@L"F62: 9#:F@.&7D08>],]-PJ%L]:[#+$ZCIRU\.CK@_&A>ILHMWZ&
MR-$KHJJ^>.?2\3J5U_PB_/N*\@5,7L:$FO0P5;'T1"QV$>"&=F\#YF,WMGN=
M$6S%@X;$>WJ\+SK8T:*#^PS;;0XSMSK,Q>$_QND)U,U@$!!:O($SD$(3=#OQ
M-<=PEERWAE=($@0-7W)ME.% ;*/89FO&C<@^0FU-:%<$H?;1AU!\;1=JE(YF
M4C)4$S.D;\-U2:TU #K.<&4<AE:P<GW.!Z=>Y]!6SP5[$.AFO74QK+(^(1RZ
M22@T-JFU@= PU-F+ND;"G01#Y#[I9V"[<<]D\ZAGXIL_A'FC'__<7FSSQ/-J
MOC+'Y.;6]=WZ"6P2 (OSKXRJMCTD<S5NUH*0>W0J(3, 2>J0)U5^;NYP5*4S
M&4;CMO&5EP;.FR"NK17G_DEAG"[U@CS^'0>G*KI^A/9'6^7V%5;[0O9;I%9/
ME&]$+P_4GTWZ@>#ZBUD.=^/YJ N-+\8SA"[8'UVZ2P\T/K$;$<HZ7(-X+0#9
MD00PP>6#/"UD9*FO0QD3F_*<(NWL$7G;/YJ7\2P:R":#UZ5Q(_>U,_OS\IG/
M2WU50A)F-LNGZ67.U&VI'B,4V#7GA0Q6)Z?N'I@R9+%)%@!V\/P2L;O<?0*4
MW8 T@$T9N8:])YR8(M*XJ[(%7L"EL#0%V=GP2,F]Q&03V62>>K!%OIALJLX0
MS>U/T_XT?>;39&@!1N=E"4/E6!M3/RL/XIEEK6717)3%59;.G52[ST+JN!NF
M#O!D!><$$Q47:=4$E"SK:.KV1V1_1#[S$4&W;BXLYTX N0Q#@PZ?Z$,D^,C9
M-6)UKS.O,+[2<+1 :;C6,LENV.&X/Q+[(_$I/HLRQU>9,YE:3EJ!]<3Y-<]:
MXW3X(I_D\VRM"B>++OSS !7?]BLKWPCL?#HN+S6T0'<5A FA_[V&)M?D!L$%
MRNW7-1QRRU4D$7!1/@DGD^JLNB1>L RN;!I2W/J%>M=QEA7.'40B1^+=[K'.
MR@").I>Q.P'XO'O/;X?6\P8A)-X1RIPY-6U8U=[.4_SURTYAA5/B-S-V[G\1
M7I<"T>JC7UU '(F&U=(U'@^"W8C"= =K($[<--.\=A-^1Z24VXEL"@XTE+.W
MU0KM1I+$1&222< 6^3DGEG5"S+(9RP,,!4RU; W/<UYSA58ZW\&=^P7K^MYZ
M%WM+6_<3<I#D"V)\S8&.P?//4B()(V@F1'"9NC^V-9<FFB@!-?W/TWRAN:*\
M7A5X@WB=!M\\H "6YUGN&.E!=N_Z>.VC<E])L7U;VU%SD(,PR!M(U1'-KU2M
MX B)^;EA]E:ZH)R.#[J1DE$^4_""S#+"8'8I@<C'?&JZ1 FD@N=KBOLRSQI\
M';!@$KF@H1:D-RBG1A$LT1%7.4E=L!ES8B:#[#!,6ZA/S-T52$_T"^6V%NC;
MX5'3;)85-;$?P;&=,TX%D%PGSN01B&OWU86R1Z.Y W7%ED&4DX4/NZ;@R;ZF
M8$=K"NY6*Y]"'G.B(?\7[ES/1[^8RK M<B"'QBGU;OFRT'$Y17NMQT=+8%1I
MY2E[P_8R*O6[EI#7")6+^T>320#7@VLZQ:PY7T!HZ8Q)\9OQ@4J>JE$U (YK
M,V%#AZ$(XR%VQ\4;EK=B9%/%&]"=8;RZP5)U-WSIQ*!"8COFSE(P"[T4D&-!
M),F6NQ>@F(T<%+BXP&)2GQ*^^166';I]Q"8R+:KD:R7<O=_;Z3D'!Y&!WCLS
MX?=XL,L*Z9F0'$[*V"<HY)*WNH[@\W5E*KI-I*O?KUL8KDUIBWG^ 6Y2;:C$
MNE59+UB!SG*UP61GJT3F$Z<Y1.D<?05WG:$M0H$FWU>)S0*YDTDD"Z;TQK@B
M1KBHJYG@*5M =5%8A^KG?L]32D9U.6(.2>H?\:.B@7)L'(9LW@LV_3(KL"!G
M5*1-6Q'O%GVQ0RT&_B2B\#:>)1Q?WZ)/EQEE'/?0W30V/0 ''4IW=?+9">G8
MB-A>)A#$\#,GFSF8NE#_8R^)2J16W'$LK?*C4I\R&,YALEZ%N).2P!J#$4>J
M&%A.(<"A\%SRFC5SU\Z'X;<E<665*.D;4"8BF _]>N$L2(CR-$*]ZL0*&FFD
MW\Q]E%V;\<W,WZ@5&H_P8IEA:#=(&6KR1;*%$VC6:%2^%EES-/H):0[ED?HB
MBDCSZ <".V;MJ:87;REHE*%J\4Y[Z27K>^RJS4+R-[O7%),FXD8T'KJ78S&;
M,[H&4*TR81P:W,%C<$CC[$<DZYB33\6<K)>9$(&Y-TD&%RJ]VP4]"7_+-8=Y
MH7XS6.WMO,F7<W"H%LXHI2I$/O3P)M2Y>'*;:\." TFH<^I.@#=^R/A0(R\@
M5,W5N']<+]&9LDXI'(JV/]%:):!0 +J-;%+:L?,*DLI$55NE+>&<&"$7PDXF
M-T':4!SCAYS/>1::<@(OD7@23+>!.!FWR+^W-24X>*N!$74R6I;N_UX/',^#
M]"JM:(3+%H[_)?7Q=]89+SRL-QQGQ/1((FI'$;SN$%(CR%T.#*QUC6S%&MJT
ME(1<+NK[41=YTV#/@\DX5E"96IG GVX*IS97:85G4I=.VAFJ:+"H-$>&&9^I
MA):J24.A@&E;!?VV]K[IAK!/NHOZ@@YEBK=0> /8.$..>2AV\,,(1)5Q58)<
MN-F\SJY@!EL( KT"A\F9SJ@.6)F]9;S+>W8A^G6ZX]+)+_K^:GR.LWF>76:U
MCZ!+4W5G'U=FOU?<M$Y(X?8'^N;Y-3LF>.Q337-PW$]ZYZAD&!2E--! X"*=
MHP3R</10=.MXV7P"B(VT((5&O:Z]<]1MR\ 0E/3Z(*8"5;TDD8+GR$+*0$!9
MS4:]2NV8PX"A)"03NT8+9*,J83=36#ZI$R;0/5B]PB+B#3:@^P&#>K7=6].<
M:M<1WPQ;=85M^3;C@J:5*R=@3FWC;I!V=+*0G6O9O-]SJ:$'XN8KD!YW>BY+
MK&_B6Z(; 7[+\=ZN"':_]TXS=F@,2+9H_3*A:=1WS;3@7G==8GLY:X"Z8XKT
MRO>EM-Y[]) )E+HKH:T=27>U?ZY<J';AE&78HUA3!AW>DC>0U0)RZIG3KKA.
M"W?? IQ"9?O$1]AA);Z%1707@V_@9D3S9*)3SIT5D4**FEOK!J2NG( ^QVZ\
M-7W.1YN=P8LT.(?4[^39XW4%$V@N!)E"_<#$VPG9+$ZI26.&<*9+EJ(4'/'A
M#DIV:<%HYU:V_L"#?<-6P!P:+B[+RD:]MY7%T /UNCP:?7/RX^A]./EPSG#+
M:7!9R<U77Q9Q;>ALD_#175CV7Y^_.&&:^G+9;'C6[_O._:V@2'TCR/ YHU=#
M1MP=P[S6LUS8;*Y 8A?IPOLPP 2%:HGKTSZZ^Q-D'A(R(#;<1EQE2_<_$*E%
M!YT\&LPZ@-:BCEC^J2*(K&FU^NG-.U;D@LK04#,.]1NL@0UB38S[M#9C_;"S
M!E_OLP9?9-8@U(+/40M2I0\7HBD)O*\$ZL#%W;&R=-+1*\[KJLR@FOH&%A+:
M7Z3SI]U()[J G*S4.020-L$T5X1C%MG"^1G%M%V@'U_7I5M1U2 (:#;G.(3Y
M&S\0JA1'7N_)A/6])XA:-/HUR]!Z1 @]LF9GSM_$. >4B/S1LFV0PHW-=4QJ
MW3'[39&!'P">.SO0_C7/P0@YQ/7",;/6(^" 3Y]D'!-,O6^X)>0[$P&PJB&+
MBT5+#6'XK#(>]I??;2Z_CG:0A0;=?Y]9*XDO>'$,3$NJ!W!F?N97#7TZ11_Q
M/PRJ= A+@F1]T3%.ASVPH]%9E@TO<:>*"89%Q^U=1JRP8N9EU7E&8&;'3YZ-
MSMHEX+V,_ \Z>S-VJJ<HV$.$:W1T_/WW&Y2/H,]"0!>^DU5V\JM/V,K;73CO
M_WXZ>O'O%[^<OGOUYO7H^9N3=R]'[TY?O/GUU]/7+\]&)Z-_OGE_*JOK)%2F
M?WKRXN^C-S^-WKY[\_;-V<DO9Z/7;\[ <!^=O'[I9!/_!QY^\O+-V_?P;/=E
M?-G)OW\]>>W>\?+-KZ=G[U^].,&_OCL]>_/+;_"?9P_;,OMF;YE]@9999*]'
M^=3-\>/Q\?'CIS_\?T^.G?'&9\$=A:/1MW!2'A\_>\3_"[+_\I4[6N_?O!N=
M_N+^%\1>?_()E0>W._@_,^S$UH/#SZ\QWBM%(3Y&%AH[<'T0-B=D@D  BY(J
M2)"4J7$RFIF0S$'V<9(YQ7!UD16<5@ K:99=$2J6_,+>7(<)VZH\@J)=C"G!
MYI_+%EI> "I^3<!-TTS^ 9$U2.E"D2/D4QEQ:89)I-_+"OF9N-I0']G $"&1
MC_&IH]'[R.1]A2$O (6M\X_^.0DB4F'^"1/@G+* DD(N$LD^+K&YO[N^9_;V
M9LN5AN$A\GSEH<U\%"5R+0E38W6I6;7.!'X<G5: 0OT<8$A&9V7[GS09O;TX
M>GF48'5^D8Y^/1K]7*7M7#]_"^60\/'?L\E%HQ__FD\NTFP^^GM^[G[GIGW6
M9)=N!4_=%\%L==_ [\%6OH0'_P,BQ#G__MY+?'X*$9ZA@<&9RL@?Q9* BYAE
M)IO1V7R-L2:C)20FH$Q&+1[_Y9=>$M[8 /L+3:S\C'7KD,^0:UQ35EK('$<)
MW0JG&0*%2TN'KA*!6R+-(LYR!*3E1!%:N!=V/3!8 ?I&*IEAY =M)^!<$6(V
MOXBP":5S0VGM$D);@4>@(Z<MT$#*<EX(15#E/"[GMY)S*F=Y2P9ZW##G) ?&
MU[%2+G'KR$D2BM?/K"D< J0ET5"<KH5N3^!,B4B.3@7S75T8W$:$-Y+Z87;N
M_782JI#UV'AD4DTL7RKK/'!?.^?']V(@.%+>M%K;-/0*#,JG2!$7)J!Y!.H6
M0'F(A1&5GZ_,\D12" (\+9<;J';GPX]AWZ8H9RF[FHK*ZVG$3XIIY7;_9R<_
M63W-05TD[F7'/WS[+/H_R>B]$Y1Z] _G+,_3#Z13L[FSZ]XZ_9!#,<[K?)'7
M%W U7+ JK;CN[G]*-Q2X0/^9EW/P]D_HVNG?['(%F:16E05%Z72"-)Z35R/9
MRV[ZQCP_84F!8RR5!?.R-H4'M FW<:IN74/KS] :K[\HE7A;BX]LY9VR)=SV
MQ-V_"O^BXS*?<5\T4YT'!@'5!0OH#%M7%6'& 80 Z4#%D*8O<*TVO8S4$,Q8
MVQV=&H3EFFJUH9T'H3]"X03J2!T(QQ2[>A5L8=5-J\3KR3?WXY)]<C0C<,Y>
MO_GUU>O3T[/1ZY-?3U^.7KT>K?;='G:\XMM]O.)/&:]XTHE7/(W$*TY^>_D*
M1/[=R?M7/TFD[D\7LCC9Q%^V78&H:-/Z \%"VB^#R9-BD1,;TZ6[_&R)9.H,
M.BITA@++;,BB/8 />PY@Y\=*P>$><EJYJY=TS/^3+I;/1O\N6W>/_O++6U#N
M?=,-U@H0/*GU3KO7N7P4[F(PT]T3 #9-[Y)97D/5.D(P9]2(\S*;H!7++ G'
MR>C)XR=/CU8-Z )32M4E);-N.S9G%SK[W4GT#UMH'\_R1GIX!@-?A59 4ULY
MC-P \514PLW C$::2)(ZG$VUO<[O=-.-V1)*:%>$+U)"W,IJ@MF.1/:PGOA&
MX^>D37"X0 J#->E4R9/1I,&09045S>"DOXK4M<W2?-XYKCJV=3/FO=#&+"H,
MTXXNM!$;@YZ/OC>MZ2E$LO+N7D)T 2>F^!:#[V9>#X KKLBO12L-#<*>TD$/
M5(H [>[C4]%A,P'-:5N)ETL@ZSC,:]^V3!-!(S(52)(KJ:MD.WB<U4U84FCF
M CC''95Y_X?VQ/L0*==>KI)$"!\9CW:<277 9G%6#YDL89 2$X]0YX\UE<B-
M8/$AW;)?H"-08ZE@3:@;I=,9T$BEQ8#(.Z(5A,L*,,)&> K1NT:7.QXGVDKQ
MG]/2^=+='2>D9:"8Y">)B9X!R>$DN_>BNC "3OA+*ANUZ;J?P4C';A-)!DRQ
M3?]BK$<$X!V]&+_%^;K_^ 8,@F&IB]6&+W4-4UW#WE::^3_Y5 BJ#A!4#RCJ
MLT)4D=7]W=._]L&J:+0_/A;K^K\0D>IO_Q6!@OKNR5_!C5B%]T23?J8055\1
M.E3W?S[',Q!%:1/XK-'&:X4^Y/JA;8Q^%7Z]]R/GP4% Y/_\Y:EN-V\/R\[Q
MT6-P<^L2"#__UV/\?UTT+EZMF-NU)B#SZNR%\S_^?7KBO/'7+T]?_N]Q]=7?
M7IZ^./WU^>D[/5#:0'^CN7J<JR]CAYYL8X= E=UB^1_RO+^YK=BQ'OML@D=(
M?^GD S4Z/N+HRV229;/9:I%$O+R;8M[96 @L-@2'[#7\2#Z\F56&=BY<M I&
M=PLI&>PIBDO"7_[VWY_^8RM&& [ZR]^^_OY;H#RZS8 ^SVGYHM;A#I3V\>-U
M6GO7CLBCBLL:MW94;ON$B)Q\]_B!'I<[6(OC!W!DOH#K!G+:&*WYDLX1%S=C
M%< W=S*X_9KLKR*(G "EY!=@J'WS[=Y0PW5X_#EO8')SM@$C[;V(T144/4)\
M;EF5LPR9_1"]BD.-!&9BZB0HT!ZM<R*F>@31*; Y3X.U-9/!7N8905I@Y#M?
MQ+_+A)]8,])_RQ\MDC0@G#1$B+%K_B=H1UN+DW#\^-'_588W7S9F,CK,C:<T
M[9ZX#N:OJV)H^0"L?W[M$90B^,8&-)D0H6M"6SMG4,]M!/?G<Y\JXTFMCN];
M7ME-8[<>'IC@RE'6UN[2LLH>2?>CPEET&_\Z^9YM</'A"%YHQFGMO-ZZ>9UP
MW:C,ZRWA'6T#W')EHE*[* 612;;_!KOG9PF%__@29(?8!,T$ORX_[RLC)PZW
M3-LF*V2=:OYYXA[8XR:"6^O8B0T3N:%Y%IP!G&8S+(H%A,'SLLJY"Q772;Z;
MT+_5F=5G8'HK_>@_:)=8'*=O(_9NT"R;B&5WPP@CIL8TWGD.N5C#P[WR(/K+
MH%,A74_*I::$O>Z33R)95\0J@6RH:;I((,GH]@6@H-?.;.T7)FGMC-'K1_"_
M&JYDA8.$T@8W-39 R'GB3##=)9T[V-/ &T.B]*F'1G=7^Z'GF&C#UY4$((<M
ME!OO"I=2)TA9&6"L, 8>7ZJ^'W36NJMB6%FDQ".+'0?UY"*;MI#\6TCSS#;8
M&E9K-@,NK@U. 6*;OP^Y9B4M.J=R."=)'W Z'.MT&P230S-@ ;"VJ><=CB4J
M(\I,VR<>:&'ETWUAY1=86-FW?]ZAXM@]4X:\#NYJ8OIR+L#"KX-O$_-"!HKY
MALU>/N2%N=G"FIZ;U3'<L IM YL.+O3*C3V7]JRDLR8P@UL/A6J^*GAO@<^>
MES4"5'K" AA76W!Y&GM3MWUK;O@LS67< R;IK(QI'V)4%":L[K V^T4::]$J
M,*-3+8QA81*R'QJE0(><^-&^06('0(/C&E:N7WW[XN3-<ZU5E1[(L],7-]_;
M53L ?YMG6 NH\#$W6VE=F?'UVE6 .<$CTVHJUUY@2.G%I]1>'=GP!$&#\P=<
M4JX7M;>F=C&&\OT)$Y:V&_/9P#W]G%JA%2+'&?8J6.NT%*/6Q<!T2%#47%FI
MMJ@I>T7\A/M"65V[IZ^U3B&X0FKK^/&C?XA]>E/]>/_&X',ZJ=V+BF7SN30?
MOHQVU\&A<[//VB:?.'OY53'YI G<:,#2TOT_1[ZK^\5%FE=W_N:AKO0[?W&T
M:7TK;L-GZU3L>KXG["V^LS79^V[$.^E&_.2U?A"M>2O[D+9S:I1'R^,FX+W"
MC& \#Z@R S1:)R3R@T0FQM]DK#?^ 1+<RC?TVG;&$!7'U](Y0+>=]#*@<#G7
M# KY)YF0HWL61J_</;;NF>?I."&P_.,?OOX:0_\IW<>)8-2??N1B?O?%1-L8
M%NE4"78 AE>A=)%'#3 E(*P'HZX,[@)^IM%%,XD<@7Z+\Q:@M'@&A)N'TWC8
ML8#O]K& +S 6L+[)\NM.D^5WD2;+L_=O7OQC]/:7DWUKY2U;*RU<-*-DC)[G
M93W),V(!0F,6^@\9<-#]&^[Z2^:HM5V5YEOP-_5/F?5% 2B$'XD!*#R'I$>A
M@.NB\[C155HKTND NN<(?9<5&![PS"3@B('G<W.@&F/B^\:X?&6$W #7'60>
MCM$\WKO4 U@Q1:EXITQ>(N@#YU6*YA#=1'TW#3HU1Z?.I6ZN._NSG8M^V59(
MEE4.KA%%718$<SE%40"Z,=0+:E)JNUNV6,[+ZPS$40#I-TCI0&Y0?BE&>,@5
M0!$FGS&2J+U$A"I+J1' TOB^.[O!8\GM@UCC7QZ-T<M'*J6B]F"R]&9GV"+(
ME=NRR!?I%)0HJOEE5@\M)]06P$EN&NC.Y.H);I+DYL'T,LWG>-]L<2FQ<$2A
M:A Z0^E&N/FNSIG/@%ORG(#DE]AXBNB[^1*B/YC06C;Y MBP&*QCEC>I^>EY
M55XU%X.;UUP@^PQ84G163)5&ES8I]@ ]>.<E8KL) )XSNCX8_\?2&" 146<2
MQ+JVC@7$2EA<,:;0;N>#T*@M<'T)(7;)!2KT3]!.F6 7,YN+A!7/3M[5HK6!
M<LSY>CDV:>)/^Y^,H./2__S=V6_FYR01]A2P5L.CHUIJ7!9M#0QPSOB:DZ0#
M:!L_\@1_(@_=0N7&&:AGS[7>7?JM=E=2R4R VQ]1M<@3 Q;F5 /4C."5B8.D
ML&W2"@U[XW3(M6>AXA_ Z ?>!?QRDW)Y;>F\0"FED.D%%VDMSG!19!]';X7$
M%0_(2EC@(WJ[7J_N]+;5N:!DI=/XBH0SW$'N\9/I(B\\GN#V.&U[!AB;(RD/
M4,IK1$+TANMC<70U<!_-+2&"2Y_TH0>$.&X;/@NO0QUD7%A51#$&(*1 ",8N
MV$VB@_Q^E #HQC$6B"#9OYB.]'%5.NESOM4%PI<&!B=?6!TFT-[PPAF0RG3_
MY71W$S<"W#=(6:JU""N9H<E(>'-2OD$:6)A/)?#8G\HX(X[#'3PB-/$SOZI]
MO;RM0Y,#V2#8/Q=(MEJ6<Q- &CA1JWR6O\H.-5 ?;O!U/31\V39*XCQ)E[!(
M?#_GBT4V!12#^;7MRE_IVHP.?+5K[ZPQNQ3; TL].VQ;(&YH]C&KG*1E&Y3O
M02W3#)9'BS>="(/X JZP.31"-9I.@0I2*G^I/.Q2&4PYXB8T%D,&%2]1_A]C
M9?-BHA4G<,5UW:K/M6+S,(8""SG!RC^#<ER,_B<M6F<]<$(,71DH^,+\EP?#
M=P-VS_Z.F5UQX9FQDSA&Y9'])X)#^_53"OUQ&=\H@]O<+=I&0C7-YZTWYW9C
MYR4^ '9J-@"(U%)B(ATYD4:^.L"'2?Q*Y4'Q%M\<H2(?O2GFUZL6R7 OK%J,
MC>4EK8W9&]CF]^^EGVTXM[63XLDS:!-?>?_A"AKG'M#O92FA<R"[S,NVAI,2
M_"V=^$J!V/&%_1K1CK+2J@B<6U68&PW>@,.C183:*V<O9DS<!QX90R5'].KJ
MI>D2#=.[H582+6Z:G+^#*3' 3J9/J#FG;99AAA[Z_X;X+CF&!X29 .1;+C+C
MTB.X)?I\@Q-W!@!3%!(DMJ;:F+(7K_SF @EP<5FNE1>ZP,P;'FNH0@2<VV5;
M.57K_PTS2S_2$]SUC0F4\3P_[^_,K:?QD!,:W^\3&CN:T+A=/!YTQ2919QOS
MQI-#5@L9BL,,/Q#V_N]5SP=.='Q(0M2Y7)/M'O ZK:?I'SMHOY^Z#950WW9,
M]1>,LTW-;)IJO8/P:!+&1[66[!-BS>VXSITY7UEDX@R7DO".-<#8J!7<OP%G
M#)(W:!?%P=FIVL/#MN%5MD2<Y 4Y&+IVQHY<);>>J7?M LM>'*Z$:%\;I5[U
MXUOD CYM*[:3FO$ ;%.WS<X-N4SG+:J?#/-''*H]&-OJ1+J6,4\W@PHS-[ /
M63/P4XI"4%7J)*TOPM!0F,J*690"[8GF$81!-F7;'MIZVXXI,QHK&#<8:\![
MX\:T4LLRDB,6B4";B_/VW$%V"XC.7.A<^U0GK-DS;?CL<4=P(C1X%)JH.>)!
MWG+:>54WH]_+O*C-G(%[QT_ECEZ=!P0, )P*E8G CQ@65%:C7R!.^S+ 7E^D
M3J6TBTU%=;6<L4%]N^FPDT-]<RNE9 ?OVO?72W)G.#RXG?LV&"4^:>H< '+>
M?D1E,'<Z52)[;\@OYJ%2^#+PF#?0(ZJ5X>@YOYMJT+76/14V$I_F,_DYB0_S
MR>VPD#= .U[[LB[X,?,GYW4WV8(YAYC;CP'OS213$S3:*FJ>,^# =F+.]KM=
MAX[_+1G4 S>P2P ]+<X/Z0?@=\O1E0?1 HD*]:VOK$QAC;'_V]H_1*R%)U:J
M82&+$X[4V1@5!'<VB)*K-.C;)1ZAD2C AR8'?0G&]11C %#&ZKZN<-%ZX202
M^P_CX<3:P/$DBAB&:XAW#);?V0T6(>TOTC@+>-@&[M6HM3$4A, ;122K>V]'
MQ\QKM4QS@B( )5KR8M%^+9Q\EZC UT33++,."+PSKB]+ZO6@7(X MJ>0'/D
MH@ VTK79'@Y?8J.)\XK2N2X!"S2$5/")=.81]M?+]-197^Y9F'XT02;B1Z4G
M)!KGD"B%'A;^-3T>BK-EJ>(9]R6L10,:P#T-N,EB941)1) P,SEM)UGD')([
M:,:.^7(08547$R@5F6_6&E]ECW#_M4<8XF4<(J<MIL?.\+FT]>FH<"I;8C48
M@L8 *ZJ$HCSLC/C^3=B;72,GMM;A'=8ZZ)4"M0YR N2<IG-NE"9@CM_;PB!S
M(%-@I9WM:7#4CT:_&:G!4P!O2+KW"K6!-WDSES0UMF%1?3P= . +1]5Z"[7
MS3\(00[VDNP:Z>9Z0/C@4S=H$'E(W=-P( .?7N/!R(MU:0&0HUCA"(K6!'^;
M,O\ZUCHG,M+@E&BFQB.R[\(Q=$OSV<\@//.+/(#OO R<:88("H2\34?FJ%OM
M7EF1Y733:#S]24/H;B>+VF?NN^?,7(SR>-\_"L?>?=K.T07C$'P+A(XS XOA
M312&[W%/=?.LX8]'.!?S$#QN/*1PW'JMTOC[0T5"/VH%&'RY>?% X8%E%,C"
M.8?VENW#=*/!A"2*>'0KH#_&S=2:>]PR:*L7Q5P,S+I=%<TW:-J@5#YZ;D(6
M*IEO!BO7W$ZPV+HA*H]K7M#%(%HR(54]C66;PJZ3IDS">(>&79 J4\C6286I
M_E^IA!]VCN2'?8[D2\R1;'HT??'Z<RH+U3-Y"FJJ4S6J!*"@<[6ETJI6\E<#
M;A"WD07<[Y3BM'IMG-E;0S1:&91ICR95CCUI(_=GMY=Y?3$81W_KLZC&O)NV
MQH'I3HB'@6UBUB-C]V6]'[:#\:>W9O5>R.IMKSZK[]C3I7NM14;1[68Q8> C
MO8ZEF>\DWK AES,($R.%F8=3]3@,X1)*C-'S#:2W#$-2@ Z,(4C\#XJK4% #
MOXK_M8,"\)[-HG2K"3\IC@PB16#3P7:Z>22!10DV.=ZW2!\^/8?8?5I#1)M[
M//V5[2:9D1W@/KZX7L)?)E*PFH:67J,H46-.&W'-/K*:00EK5D\0[(*P5IPM
M-FXIQH'%8:EWV]T/P7D(XUUTNX ]R<K!OIW#_N#;P4C=2.;Y+ ,?<0>%YH5;
M$:R(V:JTR'D.O(F).WS$*M6GNT9K3(;.J(""CSA4OWP@H4.E5U=VNQL^:AL-
M$NNKV7W))L9(4D@&<9WFBZ 4<TM[_6I%(6E8*SH4? FCGV#@E]5Y6O"O("#B
M-M)I#T$92()8B'J+TJ)3._^L@5\!^D\6?K@VY% OW=J4LUGBLUB8 *',GU$I
M3NZ\.O) N6ASR&]JCO^;8F8,YIN"X\Y)P=2<4T/77*O[<.P4(Y7NCP!QLH/B
MR",;E,-XZN(@/R2/3I"N%*"YKMN%-A#UMS5Q/Y7?8D6C9;I._5?D.TX=9O,,
MJ2*-_7R5YDC3=VU#+3Y2 $^X[#_ 1.;$<A!+&E[L?B4_(KH_]W@2:%LD#JV"
M?6%%.QHA)#A%9^C^W'@/+H?6BV)_<]_'N0ELZ,4C-P2#U-D?T#-?%Y!KGE9B
M3KA'8'7 YN=%2X:&WP<T5G#G"XI1#QY.++B$XH5KW!W.G5O3X0 O,6NC^CH0
M)^89UDNEDZ9%(,J+W(T9;\+UCLE.7DV V;$0<^N]J2W>GGNR27>3;S3"4!_B
MPT&A#$S'&8KS!@2I;NLE_KNLM&PZB]>E>[[2Q&.3BS>4%4[Z"#!%\5M26;C:
M6M'HM:Z*Q!^-7I?^MRA*,%;.")1#U4!:/>S^F_[#YN[IVL%W8VR7R%-EJ%!F
M[M8QK_Q2:3:91F>2!Q"0IP]]KXC33^X]YH 6I7RH+U>0NSS62Z4'HY;>PQI"
M@H9M%OTXY[Q5L@B"B(#69$_Y&\;8@;7D:GP+<PA?F%[R,<> )>R,Z+7X1=)/
MMU>VU!T*W]$/OL:! N4R1BT1P)Y=%.CASC)!S@U!_V!(R.?A!H:&CL>HZZ#L
M Q-R@<C5'#BYMM] ;8<W E4>@3A"%TA9H!TRSS] =2*,UKEO:(,5S1SX?7&7
M*,\V=F[A#/9&Y9]>Y:>;^ )^0=F1)^ . ##?. ,=/(4.'*R(U(HDB=M':U3"
M_B%_5M-:Y$$[NF<MWIUR\W(73)96S@<UQ_PFO9+)!I@97S]]T%'E[Q[OH\H[
M&E6^W07_4S9%!)Y7!9HV[]./L )>76RU.Q]2Z*,ZA _X[>CL:#3C4><T:FB=
M:9Q,48E,F)P;+ ?OQ'9JR#-I,0%;?<.E<4%Q;V0X&(V"NQ_K6.6+'J=G35<^
ME@_(S.,(!-G'B]09Z>073$?3,J.OI=,IUGZ!(>O1=>?9)<=#)9[60CVH#6[9
M*>6:2)V,)GDU:1=P13B!V$[)M:P$U[7!U2/39;A97-[N^O/]CTN<C!#G%@#@
ML9_<744;U0V"O(GGX1X,8OE[6^7UE%+#BE9WGL^:!%,:#98#8H6!Z0;%Z[N=
M9]WD\52Z0(/:6Q*\,Z*U(:7_S>,?3KS7.LT.M6N,YNHC$4-'Q'WO:/0\FSBQ
MR6R9?K#!&DQ/*%;:J;Q1= BF[F%A@<>C<02%&!X@&%/Z[D_.@)PKQK"OHUU;
M@;J#'H_/KP5UMEOR=]YL7,L;=ID.=-%*+@\<9ZMNQ$B-V:"AD#YY8F5T\V.V
MLCPW&%=7%:)QC,:D'1DZ2D[TV%C',Y 3[K.S8/_C[3MZ U%KV((O4Y",BTOI
M@V+-0V<8>G8''O6V/WH,YU4';PEKGK7>%OW/"T17ZKP+>6(JS)@T9$CC<V;B
MNH#K[;843&JH_K<O/AHQ$"V6C='-RN <3H/2ZB.JK/N7($PQ3@<G385;:IRY
MVSD)UPZ-<%V&T;PLSA]AP;-@*6"_:K3'GH-4$P3)G?DXF\GWNIM]CJNK"6HJ
M;940OQFRHN=R?ZWOF[Y$6 ;[]$[-&M;PBC='OSH:G8P&5V=43B:MNUMS@0'P
M?W&K:TJ3KTIF\>I@E;JALE=2F:]#^21VDOAOZT"I#)E@\V035XS/EOYR=&O%
M8@_420*^EJQAT1\.!OO<$L $#D>#FX;G4W8M&.2G[(N&#>1\I'7_U)6!B+JM
M!+M/6[A)(F'ERSHXP2IC=I2*4Q$*-/]<D0SU/$ X=:/-Z<JIV:98D@N#F]Y^
MH%.8S@"K%O:"NV^J0Y]+,(6R5"PA&FD*Q9M:O<P7-2YFV,?$;GI/[(/SRWN.
M$8EP&U8I7%@A+O\K>X>(:1BBC8(<+0LG=QV?73ZP-9L<FATT/UZ7A8<:VP4+
M9(-K5ML,LLP?+PW(?([^'<9YE)<XX16DY\[-U!'/1.I.0YD?O)@'+JT5ZC-V
M%475Z&57V0]JOT3=U_#^M6'4CLW6Q98(;+C0'\'S3JLS< 3O2@_=7J,P_2=Z
MT7Z7-@;4V4#,=DX?#'9I[*@ZP/./498EGWYNEP@+;58?V^%3"_4\X9'=Q.A<
M>7ZIMA(OBHT.\%AA74S\1TZPET8,^26Q2-2?_#0' 8<^NV^P\K;CYB%'UX_W
MT?4O,KJ^3GOW6GRVVF!^$FHA'PZ'0#B7.VP*[:5VNE?BF"$/[X8P&F)<30CT
M2$P+\,!,OKX4SI.^TT<T(DZC7HD3%33Q0,@2"SZHN3# SL[K#Y@=]-4U\W2)
MS<PWBE@,WB+AU2&5/?[F"%U@?B,:?^!=0V%B+S;1O3,7Z;5!QT" FE@<^?NO
M#\:'-D@'4Y*&I(@C;>]:N@]#4<!8(4&UK5^K]%,"#E0V9=9JO,E24<B!UXH=
M],A"X#JQI0\E$/U^TP%1-K$$D>:.\'D4 <JG-5PU]!!O8GM2J?6Y*R:QX*IY
MP@[:SCWM^UN!K;!#W6V)88;@YIHM:>J?I00_61N1[CO<U(PXB"U?VNP 0\M_
M/@.=VB0AN9DU*+CNKQ[:$DK]Z%U>3AGF!Q]K2F2]2&^H<R7FBA@(4)<G!9SF
M31G5[@J< XTQZ$"B.I8[MMI]+O.AJPJS#>:>T%+0^B+HD<]WL??F):V.KY\]
M5="U%S9ENQU-$-QHQT^?'"S"NWV>0WL_'8!@(G!%1G+$FJB"MFNN7PPRTW@V
M..#*":0)W,IN6P7\2:GF"G/U__?QT6.N-78"B<&45Q$\O.!=*IBU@L-TW]6+
M^:0;II9CC2GPM=XXW6N1P=6?$EQ3@WP=%BL.T$A [HY4\-K:$H]Q*[A9N#T;
MQ:]DD^<*P87F2 X!\SD4&]>C:8FQC)* EBAF 0PW =%*- ,18^S9PHF%O^%"
M/9>2P_M&OE28T8D3#F<93@@*<W[=P1#0FDB GEB!+L4B8;'318!YA[AL$;IO
M!2(Q*%Y:4:G$!1^!#2 %\G"/(: 4<@E)H68MA$C Q.V+TGDHW=K;&/W!@^&4
M7?-%T>H;,<^:1?<<J'_W<(71;S"'F3Y=F-U6\*:]+AO0>MJBL.%8$LF%^65"
MV65BFBF;$-Y9;D#)VEK8V/"#A!P&.[/5M_B>97=8W.(LNU&Y>N#<NA'ZR8<=
MPGVR#^%^@2'<]5RKWW2X5K^/<*V>GKU]NV=9O3>6U5/Q#5AQ"M="G&T5-N>S
M\*SB+N\NPRH.[Q;<JD.<J;K8V. <+K;6:?FV&JZB%)K63D%7C_-C=]A79?V(
M=Q5[6CU<^SJ/R4 Y=R#H$?&@B["C]" ^W1)]?)!R$4I.9[ZTBY8,-VQXXV[U
MNB.K/HSEF_JZ_)K8%RRCJ<V^)%V87JZGBE:N/_G:QB1,)^#Z5OQV_,C9H(IC
M3"[2M$2+<[ M;M7;M1#:@ ])9H7=-<1[%"\KV.,;=PP$FSVPB]NGY$31WDD>
M3CET=\O R:?A<W!O_M^[X-ZD5=BS;MZ(=9.NX[ODV[PSNLV;4&OB-./\F@#Y
M_D<+J69NNU'^RS1^T$ $^R $_3? ^.!Z-'28%3-=XFD<YQ28P$@)]*'9:X5N
MH?Y#&2%\CGP%@?ECDB/S]"K!8Q"07>=9+P"&SP?H"D(C7I1"&28N_\IA($@0
MMVL1O<TDF[;D]$-G-@1=I+Y<.L:1$30\ ;T%ALE,\-*>"I2 MMEU+[%Y.7'+
MB;U=U-TN8[!0.2@V,-:;WZ2SL@JO>T"] *M&&BV+G#*C;J2[6 G=(S#E6VQW
M64L#C02?0LR*0L)81+)G,.WS6$IES#J.R1WE.@TOH=UD.0U%\0OF/!TA+OH*
MQ_N3*%$C%_#H=MR@^$00*V[6'%L_T/"#0F&<\H.N6?G5XT#62K K8)ZM<PP,
MV\,:F'SA'"71<M=A\8AK,1 ,DM()]^_%OUJI+\F#\)T9T*32,5-&>*5?=ZJ\
M#[ 5<D;[#XV0AP$A0.]%[CYWB@CK#0.63BU"B6Q],B!6*!($U 76P,A]F,*P
MRTF@P&.O[(V+S$@G/(!2Y9[GUJR X)+S5\JZ1L<7[9EZ:"P&DH=C9HQ:ESWL
M,/[7^S#^CH;Q]PRC]VQ@;Y]A%!S8]3%6Y/R(!5BO!W]BU;BEE@1%=XB5[Q-G
M.+I!5&Y<HZNR^H!:&[U([-)^\GAT44(;+.SK59:1*>/_/L,^?#>W"]*U/9Y
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M_>K(0#D'\!N!Z\-><>!&$#3@R)/"WU_D3MS+Y07Q/(*KX=;=;5$Z;J&-+"^
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M",G,KW^ZK^Z^#P"H@^-(=J*MW:PED<!][./55]>U!-,=KX-XGP  Z*KIDDD
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MY>(1N=A. B_<U:2]8(#=:<TH7@'G2.(4#EV9(_WK"]9^WJ:GO*@J2=BB4NQ
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MGGJ  [8+L)8X\HY-*[C-0<NH\?:F3SJOV%,C@G0"9,%@M:!?*XVNU1JFFRB
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MXLN@B-M.%"0ILD]@DJ(O';^/TU% HVA9CIS;RVMN>([1[%S',AQ7)0T*OQ#
MQ08K?80+PT,&@[793@[<H63E:</'^T)'7<<?*OB.W2H1[8D1>1815LFH6U?Y
MM Y@,SCMC0!?8:WUD9>W?_:///]45X-V%@BN@509YE*8SO,+44E;")Q+6MN!
MZ'W>S(YXEKSCSSUWZ%9\[G5A5>;)"2+^TS4D\KOGKT_0$2_*#'316(:+"C/>
M#,:#=1_@M30\J#?$<%!&81*<,^A.'W-S_/$8CPPG'UNW)XO4&)U]U_93D&D
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M+SK(_^W.?9#_RP_R?T2LV^)_K V#(. =Q;A]W"<<ES2^"NZ^$+U7\I%Q,&I
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M])%<[;BV<.M&6/NP(;,JQ4V%C5S0GX_%.&*F.,GH^RX@FQ!*!:P+*2TLI(5
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M2JQ27] @QN(C1Y1%%H24UG$S"R46F12P_9K+R@,";HJ;[*UG#G4!P;' WL/
MCA1P:'AQ<\5C4,^(SJ/%K*K& Q4!W1I&'VY<5M*!$O:E<)EJ5R!N1!0EP4,>
M.D!4.R6- QPT]T7!]W+W-N7N#_#G.8:;YR0JV"Z(.ZA:0*]@#B6I7:M&K98+
M7&X_X-:&1,=-DR\4DBT ?8#B62;P)47T6Z,,++_Y<UR;M07ZJYB) NF+CXXD
M^I:!&7K"P8[RO7$[/E:G .#&.LE7(:@UVK?L@G9US!6D;><VVH".0QY/;<M%
MOM((JX%V)T4^'U_EJGVAL))O[V$EMP@KN;T6+^RO_:C-^7[&F7Z3"RS]U.RV
M-[V[?61LY[><'>F/Q/&N9W5@FZ$Y83GV/:LU28<.<E"&R;P25KVB]AP&4J1#
M(Q/L\;@@T^R'7*@4Q>""F"OE;76&!IMU3G)MQ&FQC@P4 U%^XL<%&44I9"WJ
M.D>E$IV\[>1@+C6A^ ;,TA$Z8PC#I7#K,;<M.!T=/WVV6?*F4EO0L/<J#4L-
MDII!NO&L"L'-@ZV(AC#-A1U4FUSA?1-PZ0K,P!;;BD$/CK[G;.9[>H' 4P<9
M[H^/@D*2Q;I:D45*^R%DO\P/R[U[*J!?#?3ZZL1_A?1+N2+EN&#_>TX;=Y8Q
MXB%89E?I=_HJ>-5/+3"MJTM&]E,X,E,8_7JEX(SNW=@$O+:P'Y*[?R/14RRF
M25./_O'55-H\3'=VLIW][5^7TZ^2;+[ZQU>OWO[X]JM8_#S9WB7S:I]$D(G-
M[4?\/T7)8O)C\"V_4X%<1=O\HI@R<&U74MY+3_'*3D+0\?V2S@M],MB8:_=V
MR_.!:/7<C8ZTE2\8$$[B\4E>8DHF#-^(9E9,5@;S9<?-!YE)6',9X5A#R#K5
M[>0%6U][.WL[+%28,%8 $5.^)O/PO1ESF3[9 9UKX\HD$RD<^M5!_)S D?X(
M7$ZM'+?\_.U=.=KZ.X:IV:(#3SO)E<HVXY)OSHNHX-2!HWL1$ZL)F2]=YG*:
MUT$5@M]I:][)PWZVXP<<4N62;[P41N;]O2<RLH6-[%1X4VO$ =7##[WB\(1=
M<JHT+T9JPG/(<MDZ<V.BU#[LN,Q=;F\?/7:BPSF3G>7\QSG]U)*#6'K<O6ZL
M>/#-Y8'(A!O);G.O+-86G/!)N5W(!;OG>SN[C[$JO<.FU-H3_K8U6G7^ G9X
M#!P+]Y"?\\E"MZE@.]W9*R5H0G;81-O7?_TM233>;]W=VU[C=R B#F+3(XM?
MCSREPKC(IF75N'SJM5@67 B;7U #V56?,YN)T![X[@EO3GP!B&1? ;<;6R@I
MJ#L-B8H;I>WWV:WXY:XUR7"3"PY^6<+4N'W#&!C3NQTI+08?*[M85T:Z-T:L
M@KB6R["2'*F6>:E4(X8J])ZI)-H6RKTQQ&.K7-'*<H7'FDN\6,XSUW9,FOD!
M%>6;G/G5E87TR\>/%8?PJJC^W?47OXZ[?,N&_,WQ%8CY_6&DN5$K(RMJ_..(
M$252*B7\'\N0Z"_: $5BG&/^".YFCF88M8"4XK72]B]HF_2Q4!.C9N*;]>5V
MV7NTLW,?$OD35=KX%*^JM<U9;(DFB/KUQKC5.Y-%4S7LS)R)!=P(@0G#.2K2
M#JS:2?^L<N;#CQB./K*UEW&^N[B"&AGY.&)'DR04L@:1K:5"HI?6B=,V%;J_
MSYT1/ E3VF+F".QFA.88.I]/TYOJ] W4[,=@\CX*:O1[H$+#I%&*(;C--D_P
M3<[R:Z"*[@)N?54XH-\V44..80-)G?3O,5R^O7'_G(W]''MM=08-0KU_0WUT
M%OG"BG2X6NP]Z W?%QRL[ 0F6?7#YW#>%;0R7;T:3'/<F!JELDVQ@'^<->_1
MSZ )6]6A+"OLT[%N+!*:NL&<E<RA;"1PFWOZ;&[8H]P0,_4YSW(NNT<DC_^
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MJCLT*8<CQ^)N?IQPT)W[5UWE>@.L\'.O\(SM82M81Y;^A4#5<EB(HU6I9K'
M"/F)]#C/*B.)_VYE5C8*YBY54#U)*Z@B]?;TEL !O(.X%Z&28TLN2N  2A?6
MNP95%ORQW#S0)(XF-[EV]78W.4$P[?M8L*'XVUX<69\*Z@A+GPB&O^_RU2J8
MZIK S:W]B(09TY9@TKZ\>XM1<ZV=VJ._%M9L Z!!DG**9)(+I!!#'S:D>U<
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M@MUN[*_[YA34:[VQ>C/R\W&@,5"/\>CCN*=-?C7.)^\P[&!"<LM9R^QP9)\
M9%33$XNNE9(_&:$G#R[>:[L\_2R-RAK+<IXF&(6_Q=HKK=B@4HK@A_PKXEH\
M[EL1TQP'8_@?GJ4\R]Q_CFCRR"@JFXG1KVT& .!%-;5J4.Z29PTO*?>REG25
MHIGS1;A[M!.9S7O1GX0->1B.36 7OQ!&-0U=[Z#D8)[+&WVE%+0OZY*"L&0T
M<-:%M#WWP2-22P/,CX-_<!!.$34^YX>Z>#+_@B_3[L8H_*Y>2VU=N.-OWH*7
M%B8;R9.DA\$3= ^>8:#P<PZ+1Q#J]U)*)S!\DE?Z+LD' _:Q*N;[I,'N<&S/
MSXD"D'EEK-8XIN72SXO\(CP?&4??NAH%L&J1SU0)W2GW; 1=E1+8J)%ES&I&
MFB#/ZHPD'8,C2P60\RL.=CZ[#W9^_<'.\.P.(Y,!^ZRE')DN97XXLHZ)*L1)
M \ 4^[PWZ)XMIIX'(R$K)KG:EIS-O/.AC9V.'OR'<+K^ATV'2FN&D.0ZL[M?
MC/+HNIS*@Z?'QXY!_<'AXP?/@P%[YZWQHQ2SY6"E@R 7A;;PSJ66ZU<1?4CA
M\=%:+%)B#K1[YB+BE;MB$-U#9EJJ 4JPZ*HA2.ZRL[&0DZT5H$ ?!62^:@4Z
M,LD)GB]+B?OLZ <L-!D:U'",F44Z@!/^5L+<0=%8<7TD*'8X>B, @S F9"Y\
M UC?,$WO:IUR&'=*)X2)8(@>RO1Y4JH?XP?N$9DY/GP,N+9^;5Z'J36=>76;
ML>75I@-#3$V'+;/?1@,]3KJ6:GLW[0>+TO\5-_DR;ZF%;]$#''U0O'*+/A_H
M\6P6M0_(02"W*ORO*'IR?3_3XZ.'SQ+6E>='1W<_>G)\V*<)<EI,_*L/I[,=
MU&<=-K%I09B\0;M:M$SD=;G5^,HKG@WN,<J(N4(EZHL](5V*1M@=?H5;)'@)
M7NA'-;Z.,"?IFR'='UHJ<>OP9""T&Z]T:J>QL 8<AXZO7QIP@*EA/MQWHM7$
M%ZG0_#(OYS#7$5#91OIU:-05%%_8[SO$0C\G;&7">I%Q0V?'H"&[%U3:PR<H
M&+%9Y!3 *A'?N7:%CYX=8-*VNF8.Q:;V6UA%;CH<\,FY%Z[CNT#-S#:N-:-A
M\Y7^B(D53-Y3HE>"L-CZ/42-$A7YC#=RZ7&'+.&EG@CEC7H%IFG0IHTE6!I<
M#+4IZ5VY'[P:;3"RY@2,XWL]7)-S'I)WQR"95#YV$'Y+.!!/V*97*M,$Y*X'
M>O 9F6B[;KYN9I/G]R&&.QIB^$18)JM#P>RVPHL/PE!K>=_E&?PH?K=<HP,=
M'/U@3^IV?7Y._$W&8>;+/'.[C8X?0[]W>(F*[BLF>KZ#LS&YX/!Y?$B/60GO
MZ/02Q7L^9-J'6^R?.V@?7].O^>'A\T=/TNSB\^</'SRY\_;QP\/13RHVL<9%
M]O*#Y5>N-G*$DKMM)#UP_G1=A3SR&.YD3T0Q%!%?)ZHW8C1_1+W"J?-1%0TF
MU#6?1O2X/5#T10L<4O_\HYM+=$A;W_FF%1K$21A>S#[:4AZ4ZB+]L#[**&%2
M/F>"F/!'?1=Y4ZF:)'>E5Q\1;&E'FV(5>2"'F(2R+>$/CG85]I4PC5F)RW:F
M*:-D,K!&<]? ?%>$Y$,;<*=!D92_"3<470!A)RC>'@X!\7,-SS5E<THFT"U#
MRJ1A \?.E'^7HS]YERLC$8&.UR8KMRWV<OMU3:<#2_5EV&"_C.LM'>F@G3]'
MK*T#D+@L^F<D4U&@<";,6<!#X8 ,21X7'9&C)F%48RKC\B9NE1G\C8TUV#L<
MG38EEVP5<ZEM4B[&;A.0%RZ,@'P]Y5G9/S=VV'^N:8(KIEGP9514, 6T9H]6
M(E;F((SI49E<M,6,M*RF9!FTKS8P"I)2ZCR9@[?I Z"L_ )Q=#.6>4K@BF 1
M0H&-R  WQ!N7-;RW)MV J$1O/->_8RT%V6%T)]<**U6DE=5EWJ*SHHHKNZU-
M/BUK,?4AL;EB+1)OG_ !,&ID7-KT;US$=N3DZ).5$ R;45!Y#'<)RU&?AU%<
M;$;?")'WV4]OA<;[VZ0PF&@2(S['0$,Q3J0\C*,@%578\@W5^&8$U2F%2$36
M:4Z=6*?%))\"2=K6<B5I%T;M(1OT/ FPXD-FP?,,(A>.03-Z>?0L<QY].PH[
M$L[K![/!'CU])&2P"=KS!Z*>6853N<H7];S_MK^7_Z*E_L37_?S3Z!>+G?R
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M3O_X]=>3LS<_?:\_[)Y:=QW&<)%0$Q%TQ?</7)3A?P:!F\^7A/JISO_?__F
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M26_=I&C7OH%#32K-K[V7YGMI_KS2[/N@ =DG54AD7% *]L!E-"[6X7,]@V1
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M! D1C'O%2C-?>K7'$EDR=O4 GQ?$J[:\D-=-J>%ZTP]*,B; ^# '3&X#&/>
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M? 2)G#!P.X1@@E:/0D1]=2=[5.T-[I46/"W0$;&IB7!)\)XH,=RR.#3\XE*
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MHX]42AVH<G,X^IMUN<PD2WG./(4::H[7N/4QT<Z1R*?DU\>KKOT ;>3!>'-
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M C5=D!/9K9W>M$/P7<VC $TR9@VD<"/+F<3LO+LL=YJ$4]X(R.22AE"F#-=
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M>[:6&BD2I&($O.20^G<$Q6F=+)T+=X D3"*>9 PYB->E=D>TU@.&Z@%.8/T
MJ2Z2WL<8\VN_Q<*AA3$B*>*"RHCV3%S'&[BV\-P29)J](Y&5<H#KB2U+).R7
MQJFD#(IER^34#WY^]3^/#E\].\U@DL8H:E1%6%R3@ET(NGSXM"*V0E1^5K"J
MU&I9[Y1@62[BY2+YE_YEW4[#J>>LSF6)MGO]QD,FPQ]X2B?,MN%9$86MBZ47
M,W>MW=(I\3K7#@LZOO>^,?;":Z:)'T''F T-3ZASH.&T7"T3V4%YP11+9'YK
M4S><IFK+X ]<*MJN&25:HMZ6O#9?GY.5@[N(N3C.++EAI+$ /C'F1V!"8=1A
MXTM^)(DQB,Q(,#;E;.WBC5[A]%:#VF8V?W! [+@A'\/51W(U2U7GEJ2\6F0]
MRE-SS$&*U,;D0M*_FEY-%30&#FMF+,4;(GTW7M<E8R:UZD5F/[GSO)[0\K(%
M$T]V3C=$QPX!Z*VF EQ-U#]HNT"+P!(S<ZBI9\[K&(?(LS-E@N;^,PHF$ TH
M$]RX*!<R;WSVA,NY\BFEYTBHFUT5@N&$G8^@841!0\8=^^X$NFH04!'TMFYH
M&\5B5ZG-_C'WU*F%<W<]QQCX;$Q)Y>T'A^X(CP>CS8E)>I.1"2NFN%!2!UR<
M))=@Q0C&)^UYW9.[;+_J]/Z3^_3^%YK>_[3>"U-C8BU?HE&>%8VX/6IQ0H#C
M?N^LPAP#Q1;K9&/8(, (C8N%<OKQX<D[>$ 4&5!U+>;QON6J0OX;-<OY4TO/
ML\P1M/@67JZ0AZ]3$,=^LZELQ),VV,6%< 32Q6SD",<<_2^1V+%E# /;?R)6
MK9QVK(G% .T*@'%J( 'MOEGJFV;9SA&"Z%A3,8X-1L+7BU(SA-K U[$KE)TL
MIX2A*2!FH3Z>2=8J2RRA?(0I-@%;"+10[T5]SV G1(E>\3?:\NDEH_ ;8TJ.
M0"4\,RT//HPTT_3T6YY%SIBZP\'>@@Q@^_'HLR1E^F5%I#'B(Q=T2M -A\-T
M@)EQ"(@,'C/H-TJ='E%>\.:6DO[QS_O#Z$'YD$\=JE0+[8CSN5?7NQJR:]9:
MOZ#P^'?[RA0T\17+3GKJ]D[PC^&9;O50^:;DN=3N$_]9$W'D_I7SL#'RJB"
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MQ,#^BZ>OXLL("A5^0\@)YA$GT(]%]?QQK>EMS)0I+E>OBS/8TC@Y,C_$(V#
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M%QC0)NKW>?/@K$#L.W^DT0./0[[V3&@:N6A35(39\FU984XFQ1ST5B0@B8R
M@8I-HTQP6QC,A-)AOO^7V@NN\I(4+>EF ">O6A5<G167R,P(R=9(&)BD*PIT
M^*U06^C5'_:P/NX1^<TA7Z+>?W]Y)8V(G2P>$?QLG.X0WI#V!1?OF.O3ON:G
M;5S/9H5JJC@A47M#]G;"JW*O1>:I;OPKZD.;RLHTGV4>-X]9$L>:+YJ,*$''
M!;,)";R\WL!JAFVH,YPS,"G-"%]_XT179FB5^CF@FZ6<-!0B4M-.ZC!+A5:C
M/F5H((M-&QEB,.X#(MD+FK=P"$P)4TLTZ8J@$7"4MF(JUA(+-X4X@Q'N&CK
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M.(-G.>+?K4<';J>ASHBGQ&"ON24\.)'9O(6\UO/W.^0*3'2#8O4F&C[62/Y
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MS,D!U503B0N7"A?]NO7AOK]OI)4K?VF-M']HBT:AWK)""RN)S0L*FW#+&YG
M4R#Z%6DDH&G3U-*8HXYV(1%^10S[$IH)5[JE6&2=^^,NZ]EE85*_#;.B$1B>
M.C\);$^T2 VIM*Y%24593WT'HO3.#&QW)KYO/A3$S# G1?6.?E1;=*:A7344
MSVL_;!B%,D*),KLJ0)E1L;[(R"P6.=!LEEC_'88&9"O45,O-NYB=S;H$48C
MF@SXQL7DSMEM7DWI]3L8/+U54MWN]%-NE%,0!>@5B75/5[/NMT@.3.4+FSY1
M;/^*.%' P$K3;GT%3/AG H.C:D5\I6A-+ML/X9@YGA'_" FCX2/2P'6C8$7X
M]NA%/@9%&C56'?R(7[6CD]ARJ&B5VXKKR>>E:RSCW@>6L_ZX'ID0SJ/P,Q$_
MK;9 LR7D>7%A3PKN.^5M.UFY=D3&FB\=#8U[H]HKXI#G">*\M=[A3U\*7O8Y
M;V,+"K6!*H.FRCOS-F0IP2M8%VJJ8A.'Q@P1]RV4_+1E[E[N'.L2$FM3SN\;
M]VY"WPK#!V@_^EZ;^HS5VM?<E\P:]STC01..%NP1^@5G:R8[-%U?U:%B$S+/
M/Q3V^J) A[5_>E)]M=K,]]>NN-,"1GV.AOZI6LJP'H(]YLU&HH6JEDYS$_[+
MG7UG>4M\:<JN;QI"81KR.+_:B@!2(+E8.F.9OH9%L11F2N#$QOF"!ZCW@SY<
MVQIEM>H)I1>S_DBGRFXO[>YWVDUFXR6M2]XUGD M3$)7-,=_-$\_>KV<S:V5
M:^A7M^L&EF_HV+J2-]P-:H@T^/+A $E'G8VFI&@4_@$=P%F6L!CY]E;SR1/G
MA=8N<=2J)"M6,"NZ[XX(U"%[23NQJ/$-MY+?PTO"/B"J VY*#^MI61A!(@8]
MV$Z;B4$9?!L=49\UWPV/IR)444PR7'#*["?<M\DSAS[_%>E\T8=XS"U$G\:P
M+];.3X25UXS$B5G<3K+GSU&N.@)%)HZ#P_A<QS7(W57:3?RJ]JX5K=Z*N[9B
M.3D6(LEG:Q@V>?]3D]TR_6%!6,+SY(]%;:12&RFI(13?QY9$?8N7A%W,' %X
M!@5S^ TP/!#/HKQAA+5C]&"C)3'.9-CKX9(+=&HJZ<#+P\-C;5O73C,FS8M2
MAR#(&1J->..@FV*7^T/DQB_L/=%,#:DJ2^!-3)8%FJ^+B1' X#AE:E):U24?
MAKH(\!YF=;MB25RG<[?I.TL];!+EPFOGVH(4/Z9(Q!J9<VSLPME'FPYOEMYI
MG =YR<'!"SXDK7%<K2F)^(X/+QSE9;U2T=3>K,$3.PL^0G')S@U%1'FPG*S5
MQZ.QM<:G.NPD_87/8-B,\*(P^-]6DW/IP#T#S2%-2]XPGPOUJU[S'G:AFKCB
M&B+=$&]T4D+@T:=9Z&A/YX$E"/FC\L[L*8EO0*6[=T='Q"),CH-;3\1$,X6=
MY8U@+T"'(CW$TCH??C)"=-,W_!".J&HKWK2\/WZA=-0M%L&^V7[SVU4-GVTT
MQ_KK7Q^4@/TZ4RX8HC@(5NH\<FV7'+/-P[$R&JNQ1:3$3$XA,J-X"L1;2F!,
MEX\,I-R[*U,>=XY,?CA.P77AQCGT0$1<B]"?[Y?H^+X)QRIX^F_RATZIG9C<
MEE-WNX&#0UR/[-9[?U3,VN**A"&_Q)CL]JI\\L,D/=5_11@P%8X3$:L'N4="
M,X8,*1TN4=RR8!,/$[+Q]JXC/E)DJ)MS7M<=/<^1]%'K)]1SH0^%#0SKA2&?
M!I?S2U@88;,R%<OO6B+7Y.?_''?J))X&;Z/GH<WKU&XZXDY3[JGDYO51TK>>
M_.K)7;M=[RXL$&=#%-O>W1%PNY>'(TIHY\)PR.9>%LQN/G #CITE]V8"HUR9
M4+EQ"NS9;?I_[+UI<]O6EC;Z/;\"E=>Y)5=!C$B-3M*ITO&0=K=CNRRGSGON
MEUL@N"DB!@$>#))Y?OU=PYXP<9!(2:1V5W=')@E@8^VUU[R>9= .+"O1@CS
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MBPT8@4V#Z4/T[S(:1<6<./]U,,,M]L +2LLLA&N[%W2V#<;[FGHCV UBATD
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M)B/.E0E:*[BV1K\R#V!^RYPR_#':4/2Y'7@%:LCT+3+K*$+;BX\,BF?VC%7
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MO\0E"QYI,@*A,J^C7M/X3.ESI5D%;Y$A%ML0L;-.Z*HJTG7/^X?!I". RDU
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M#VX4UKYOJQ;Y&GQ7+JXJ%JF^C\21>(1*'JI-D>.?J%S%KU:>9[; P$(#%05
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M153N;H5.97<5FB22H,I*P:19-SVQ98''QEM6CZQ5EYXR%CVI'D*Z_5A'4%6
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MFI^HWL?BT987J6[$.=NL5L]#5U^.0,NE76C96;,91IM"VY2T!!#*O:PI\J[
MH)';O<S9L(TCNJ8/5LL7:C?\8F)+ZK@L^X%6I6_ ODOAP,Y][XVI<N(3_KK1
MBJAN^]DB5:5UR:Z4DAEPM"EBD5PCHQ$YJ<<0R41-^;G*BU._ZM^R4H/Z9YG\
M*H K\R1RPZ00LMPEW*8((^_6UBW;)54;4]D7=5/*>];IM6KSEG(VJEW4JAB[
M54F.55$<Y@K:*OG4YG)Y08CU 59E!Y?=<@\GV"$8BI94).^1Q"?%2N$WJ '0
MT8C)O6EV9/MM96^DW]K*WN@0&D/Z49IQX>B3]:KZ^J(;H1KW@ES&SCO-4^;
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M$& VFW3"HE;W)LOQ6)P='?7IJJ.C@7=@UP. 2=Y_Z1WHJ@GD_FH3@;J)U4S
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M+PRLDQ+,7JY,C;AD.;UEH)IK+--EJQ1[A$:ZFQ2-_SP7:"(6M% $9$I+<S;
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MM@),D<6'QF3.2XRF1=)/1#9> )2!S7RR00_.E ARN.A6H"$@9Q]JR*&1=#V
M 4PAM$:(R D^I&(\#ED#BY%%/2#5E#F.; L[:=2])X&RNG@-RS$J?'C\M2#+
M2PHRT8$3]2?/050FGEKGTH#IYTP<OHY3%)PJ;OK.6%?M.R%8UEB=G4OVIH+
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M>$"D@S0_P'VFWE&U>\@R?(+,?@'1$W&=$LR9+&,O*.]&F+_2IC94UW=5-_W
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MTD(W ^.A<!@SPN@IZ%JJ+%%M)@B634C$3?6IGBBM35"B;]&091-3.:E$.)+
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M/ENSFH][9YZ5->MD@=LT^Z;;=^Q-\RG4[]F93#IJG.-1\BSH"--;L QR-.#
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M;Y>"X QT?[RNT%"7D%WSOJK9L6#,PK<C7[6:0^CD$J.GC5!0XL+NY906('O
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M[."T^DOD7!.)E4/3,3GEL]:+OFBV[#2CDUV5N@2/LVPHF1M5IL0NX>1XD\T
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M]T),]F]=_7Z:TO<<K:L4N6M(KI;>![\O8Z7PE<!-- KDQPQ =X"G]K>IQ3Q
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M#LJ"=(\"(\<L!Y=C"<JFF]^5<9K=]\,[]-QP$[80U%$9((?%@Q%8(1@SS_C
MR$E3%H8Q/B\X:D>DTB94V)WS>GAO)^/ >_!^.+=J-<1"]!FS;UM[L&:,$"B?
M-;O/6H-[4"\R$O_\=XX]R*,79W"HQ79YL?H1RUFX;@]C2D[K=UCQWS>G'YV+
M?]W8RTW;74,NN&N#RAY^HN:=J%;57I\6C;GWM/6D:Z(3@["#K>IT'"P(N<$!
M^_S .BS 3"V/T=-&6L>)%.9@R/TS[!D-S++S<''9J($D^3",DVWU96.N)CW
MF_N><SU*[M&X7JEH:1&-OBR#1E]! 8.>Q(/Q.\:2*Z;4[# HA3DKQX!3&<=9
MJP\_7:#)1\N1O7>U *];D7>-@]G1P*3O<>20:$-'&.7EIAUPZ5TBYX8#S^*=
MXG2OIC9Y>%5FX=;KE?IO"0Z#5LI%5J\5@>O9'D#V?<^26[AX1Z&^'@M_;$]@
M^IC3#!^4>6=!C+8+"*U<S/KLVP=IV9P ZU2X5S<JDSPU#T;@Y;Z!(05KF56^
MG;50^L!GV'\Q<+XEG1TE2;[\05EL3\JF?5+.98[J9,!#V6,R1B:EGV+>RG=I
M\GW(1>N<[USM_&$%2LX]OX\N I-O<\68*1-UO,3X(W.)-[/Z+?]@E2K'F(N?
MMVF*\JS3PMG2N%K(E)&I$H]9 2E%.3TY,GU%_Z7%"\WP ZM;:Y&'T^([,:U/
M_>D?T1/NQ5E#1=DFDJ72WN(<T]!**'?#+Y&9*QA60]A;[;0H-4Z!?]G1,^I)
MJ+J9R6T9UQ\-"Z#!)H1J<CBWN15U<=.;0P=B>RP\+2IP  %<U5?3JVQBXTA?
M8K,W1K9R+3KA +OPRJ$<B$RR\ZP+,C"*L7VSZN(KO]/"<J"^FJ?QY"Z,=]C\
M[\'OD)REE2.07P097+,$+/04G9L/S+4(^"6FY3/K.\B!V9[F)"3^ A")3W$B
MF2\)8N8 5@E&.*Q."-7SD68QX JDOMAO>-8K#J>\(G>.Y[WF:,IK>)A.";S4
MM12VJY3_X#8G_5TB0PFX9GF#,^T5CJOGR)0";"$OVG%N!"V!,YRF<21J!?Y5
M3J0GY&]\T@QHAN_&G*BE0QG3OI,AQEG?E*;S6=_UQ/,<*VXWX_/NS LKMCKK
MQH&/W:/%$'"UR#F@B]<&=4XD2>STO<>7>[/BCG*6W\N\Y,L8SA#/#.6[4>*,
ML*>P[K 9R)G(KX9)$WL2VU<E=W,6]SWTW\$Y#=5GY0\%>6,UY(#C_]2!'6<.
M;"?>=T%6HS_04Z=BE?\KY[)-W;>2LJ^MNLXJSG,R6BL@!DRHS(*>B75=#D]O
MHRP)[#J*<<($0^1QXC1K/ZO5P\B'T_!$%)ZC8M:]054S=K[D!@%&8N#YF)HN
M)Z_@B,M1 J8F!8@_.EO^!V;9I-1*\6=W@"U=V@61U^Z/4(/NLX?F(90SX>X%
M:;"DK\=81D&!.A0/#DV'FJY/>?%V.PRPR-F$DP&8J4E/5#;F.G'/8X3%JJ2D
MSP8#]16&RQQ%UK:U+LK29LLO.?LZQ][J5>QM16-O3ZM+,O1WS#A_HZ??T<S0
ML;02)55%J)/[[#B79,A$LF5<[VE.5$;6'V:E:_BHOQ2J)A.:!_$HULAC*,&
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M7G!OQ)$*U)KB=M>QRJ))1TG7O;=[N !U/I ]/M)KDMS-UGI3<KS*F\OK+C*
MGX\VV)%DE&0HTD;$4*6N_\P*7*L-?5H3G*M6\6DEM%8-@6U</K]H[,G=729N
M0!^>0MP:2#0*@!/?AAI#T)]A90]@(_NP3^$IDRR9&CLNR\Y<&B7B3EI Y5>F
M1Y#P]P_Y^]1;D+MG\)1#6LY8B+ID/?T&SA;]F"510V[[1D:5BJR4B'KW*\\
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MF+.]W6-OQ_F3)I%EGS>]\GW<L-^ECO/BP>N/<,H)-Y_OB ?1#X?8!YX@B++
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M:-A<CMW;@[4FS9$,;,D5[^F5=0^0%.]6B&EE"2HQXN)!3%Z\%:"BP,8=L&[
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MR<I=:J=H)!Y\\2C]TI(IH+MI--2OHTPD2K0T(<,(^]X&<2I8I.+IE-%-1^
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M9L5WMV0NLS<7A54\9JO[YGE,I>)4S.=YD<C=A6GO:PN$*DA0*3@5CWDQ\EI
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M*%\X;OLB:(O8A1.U=]1*9I7T?<O3^'BMTFD)J_: R0(T@=[P&?D.V."=CQQ
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MS%D)]A9F4HI\JO8Z)488OBB.\FG"FM%!D9@DDP6\F: 5:B>DJ!'^GEL(^XY
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MY96^2'T$S?58WW=?5#66O2 ?Y?B/CJ/]ND)<<@(TW\?+#M;@D\):*X^DQ%&
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M[Q]I'@CF]=?HCSB#;0;O)Q-@'3JY3R M/^4749K\)Q)XJ'<:>/]N$N;D-NB
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M.=>GP9J&99&D:.+6#[03G$X1T/?BTJ\8QQF)>ER]7WIC% N1=$F3L6T<\ P
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M'1CG%^Q%ZXA1*_1:H7>O0N_]-^#U FTM$ WE3$NY!LM44HRA\NHG)9AN8$?
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MEJ1+)(<KC M%>;@%+CK-L1:=,85 ?I54W>Y*)BX\;7B%A7.F912-^EU<DG!
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M,2K4;) J)'FT6(Q5UYRN2%U5!"/>WJ!K1IZ2UZ?<0^E*LK72EQ+>L=\[X Z
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M9Q-4OTL(=ROKLNV^NQ1L;64Q9'?>HK3I(:EJ!3]\UCJ-+EX;W/23<_CX"SF
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MA< #Z/2#IR8%6O:[-?LU<1_7P;?L]P#L=_C4V(]"@>NP(%R])C J\E[!E-[
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M=R_GY?B>^BUPT7SUA>>0/I2/Y<@\ 87.=R;Z^AOP'EC;]W.\1(SB(I,YC/O
M?LAFSFY,><UOE$WV#3GYG OX6N$MV9AFSI7 &Z'D38F%(YT+'78/F#$>*GRC
MSG,V^WX<);!X,AV7B ZG/L/A7,)U1N_K/XR!X\J.+6)P7"YZB8Z01'H1/:),
M%/.O')1U?N1AV!UME6X5W96/=&\R,,4'+N.)H2CU6E6+LU2<M7=-G&U6E$WT
M\4*FPO'3\@-@\<CW596KX'+$2CAKU P#)\5)_F<$A,H5KO\+BV.O1K5SVM;X
MJ>!G1^/G3*MMHLL5L.F(@=J?5[:(:W]S1DZDR'U^NW)%JI/<IWDH^=R9/ILR
M^'%JURWCC_N,1*8+4YV#A&5.J5%4GC?I-WQ8.IB DSE@\@5(LSD8D&R3HS/-
MON.B#0>;'ID_$086V7)A;HRB$DC(^.OXB2K259D7B9_Z=.XXH%-<UO?-P,8_
MTG1S^".W3#D&E28BLF!$5R7&,%<9 *NB /:OMD13'E$1'^%F<1DH:7%'B,YB
MWP@AO@XY]M!1=*RB=4T;$*N WR< 4'+1V'<!B>183!?QD] V/"EX,JW3HPFM
M-,\^R8I+<\),T+P=<A4 -M(,3!8\T9GP;+VQR\P0>'.Z=$"1T2)G._5 1= C
MOY8IV 4O%PV >M9/%E2,KZ;G,->X/S&^O<+;.2AZCW$(, =!,62V*5XR+YYB
M8D %00R+!!"@,BU,?APT-X\X*T:M53.^LBCPG73<W%>&G*D"S,L%@6?[1K=:
MK[:GRZB=#.8WJCJ8KX/Y:]1CNKNFQWPP/W)B%/G$_IC8LCI%NGE:J9VJ>H[%
M]9LP22/_T!</*;B[5>ET.]-NICSC9P?D$;Y^B2'96G.6&'>Z@QA7*X@&8X)!
MX%B(@TOA5TWV!]$XMK[2FNHN(-D]HUGQ<%&M@H[8+N'.Z;ZI,#6MPFQ.A5G;
MT4Z"H>"L#<>&/;[4:K5J^_1'$PC]]N[J^OSJMO?-N'^X.?_OWV^^ >NY-VXN
MC8??+XSSF^]?KJXOON(OM[WK/R=G0JLX45_'J.QYK7LO> [:,R:1&6AT.0-D
M("Z5'LEYVF!<N?XSFG(9-S-:5,#":0QWYANT?4W'4QS%X\!_>85E $M'&^E7
M^)LL/#"*;!]6C'5.CQA&8(.!8OC!95BW96,-%'KIA/@(QV @@\T86H'3YV^Y
MI2M-U[CV3Z9V&,YN?<'+.%-I)))H^E;$ W.#O]=^R ^9,Q*BD$5D!H,U;8%4
M,-'[KQQ1P![- *77S#JP<W_4IW,4 ;&D*"XCS9T1QB< 'H UY@"M;4" ,!Z)
M5XEG?6?!(QJS9@A?28_&] L-W[)B<KOY'C5[:7TN_(&3VNMMW.FGZ0/7VV^=
MM[X'"D5K1LXSOZ*QF,I!+L/VU*?4BI[ROG3K-ZDJ"QY&[F7DS.&YL.CEXATF
M, :63C<0F;+<MPFL@+T@X7.'U_DK2-M \D7I1>8.6W(M3I 9/IH\:52_B>.7
MER"YS]/T)XW\&OG?B_P)5G/D-1-G^#04U=BHL7%SV.C1L(E<FZ#IR(G\6".H
M1M 5(BB9/7/D=8*X2NLJKP!QI_>WFNHEV:!I\:7(.L#T8.RU,)(V7E'0,8A=
MEOCR[B_.1>U:'*99Q:&,VOI!/C.J*! X%=AI'8:,S5(S!UI#I=C$<3S+C6WJ
MRO":^"DQ&^MYZ%@R;BI[-> **1'JE2*AE#T,'V43O$1&5\%>X)9GH%$ZV_1M
MY 6=>(\,?I//0_6IYGRD\XVB$RRU"])#6,R:HU6)#+K"S:]J>12.S20V^'$$
M=K5GRT!^<:+#U)/!H"]Y#>) =GN!G8WC)'X.(@7]., 0)TU=V'+Z2$"8F [F
ME9:(OHD(^"<EP8>91;[YC8@%W&_"Q=R)\>"G)D1R,(HID7SVT_.?768_\EXW
M2D:#.1Z[P"51%.&!8@KL*WE0@'N^2E+@+(A\/K@77,*S$W* 6K3%/G/]YXI<
M/54&TDTR#9#+7W+L,.%KX'532!-*%@;]/9>JE5++_&EOQY/"]^12;$2!:>%1
M]LUPKH=B2@QD0K%1T4JF)4WWH9"7Y=&A](JLRTQ:GG-K/FX#=GSN^B$\0I9]
M7#H>\'!Y@&- 14H\+GR/"?B E::X@]3V+?+3\;Q7SFP7@U/LB<CGE  4S\CP
M8IG[.Q6!4B8_*Q"EJIL+,KB*>')R6KR"%U#$X6R /U[&QA $SV: Y2\\G20!
M4=$5N%@@B\FTKS<SGD'FUO -,F$25R4K)B$K((<\DR\<&>9&%F_)Q5/IC_,?
MHI7E=I!GQ)MF.5<Y[ZE*Z2EI"17G%;MQ,:XG8M:9<G="L(H7%068NG?8.#*U
MP']Q1G37+(I,G%+%1V")BBB!R<4(97Q EY@QB($HCVW'C4G&F*$3?N32"'W2
ML%"Y+24%4RFN+?<V%"$L?>WDY>:TK? *KED@?;@B'93*=W-R_YI%QKD9#L4A
M6YQ- ^(2'_XWJCWPKK_.VC2Q&8":!5*@CTH,+2DPJ::-L%Z6IRE+Y3%Y-+/1
M^4XIUE'R]F>L2Z9PD(,5!Q<OUM#T@$3OD.RR-@%GT%R0DC[!7R)TWDHB-A=4
M><0)"0+G0)FO7W(=)K],D"F$-)(7)/!<&*%2W$G),Y-@G-0 TI73\I KJQ*Q
M'-SIOB;V_$Q=%+&C',&\$(LK1DR'#%07.>/8I><\F6Z<63W\^M=ZNWO2Y)8Z
M,#17>KPSP,#K:M7,14K@)\%NO&P6G#GV"R6%;W(:[JEZL/VO6.J<*D>4>)P-
M,W%4)!D^BPXCN8RD!8OY^!A08TK4L2W&[- 8!/Z(9Z>:[M13S\0'%M+2,'>5
MV5))^Z?4$H0*OA*%3XB]'4V_J.OTBY*F7[Q+,_K#HP:G!48J9^VYBNM<C$UD
M7TL2^>+XH2CKYO6$*"@:QCD\!:&55JVY]B/HZ7]I_-KH_=J473=:U48%J,\%
M$382%6W-5B.G,"I;K+_5E3SAT,TY?%?J:N9(T6G_DG<Z\]5^JLK#I_SA@*<1
M3[ATV]U?$,OG-XR7%-+^1<XLGORQDH>L8<A"-S?*9**+^TD5^6*VD?N4Y1?P
MYX4IJY9EFMUE\YKXP&[D)XIW]^9Y1:.0@3.B</G[4?WHW6 J8F>SYX9?2Z?
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MLA8_C=, TZ2>$92F,;-88E:@K=[<RBG4C\XN_O?VXNYA\_!_$+40:/"1ZWW
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M"P#2@T=5$*-, Z1(A(+,@:6P)P<DA<6R2J)ACE :<:Z-^CFHT.*94[?%9:X
M):F5Z0*$%BL?7F2A&C$*5GP?R#[/&8!X 3#"2AT$, IW4"_[KXJ0KZ 2_<S
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M\Q%O]]YUWQ^'-\2AIDAUTB*T6K+=S^S'3#ZLP/E9Q :GO4P<-?_S6-$1P<#
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MONG:-UW[IBVV*16RLJ>SPW29K&85N\4J=HT)E"Y7-2G%&INOI:C#VGB%I(3
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MA6$\ATK+ON_Z>O9=^O/&X1FM6J7:Z,SG%(OS$G]@\'T;/02.W+DQSDISPR$
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MABFMTYVS"??@<#=@4N)<FVY^2(^.YAX('_Z->0Q[(B ;-NV1XSEAA&6?3^R
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MY+73&257V-22A9'@"(?L_D?&>.U[?M;FV%X0H%T].JNMV5]\ "& Y8YU_8&
M-M:%5;<2!M!ZVNXPYM],Q^-NN1!N=*D%!0YZP(E),?PZ-E^Q;_X!,FSK9[5:
MK75:K7JC\PG!A&ZA2X#4?0*HFT&/@^F60VF]3'Q*&Z9V?:-MF/:7E:_PP#?
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M7#T:LI"A#"3#P\1<T('CF9[EP$5A!!^@'R8\,;)G.;E[OJ?NHOIR ?R4)ZP
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M8)[%_"RP/X-PO<U$L%#5G:;@B7S0$*PMS(ETR P, 8;A<=_$:$?@OYHN=S+
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MK2?'>EQ?XEPQ!)S'WE](U7!=2H5-&0#EC8/"(OQP]"?J_Q$ F@Z6UH^I>W'
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MF=W+#V4\N1IC3HJ/.<3P['P/?;A%XIO2DL/W>V%.02^KMXK=,/P=*,,M6K%
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M%QI\PI*<,I=V:XT#D',\IPBY61B*0)CL*BT>^Y/Z!20:$&;C4*:2DL>>BQL
M3W,0$)P34A\\EO3!\WD?/!05OFRRR:_)OX7B'T$283N_^?H]3:<.0&%AS\7I
MOJE$<)3#([&5<>B0U.*CN!1XR!A 1J1.@@8T)M\R13^C$"03Q7+(YZ[</R>)
M06WB39?"#L4XL8#T%;Y%3+E#[;:R<B4>&,IQ G>!UNETQ=204#L"<QN0"GO7
ML!K4L9/!\YASR&>2H9H#KQ?A/KZ4U/4V.8YH%JL\3Q  'O4/,W!0J;NBVH(P
MNB"O-N>;[V67C=9AR38)2T,"TR!HY@79 25]268M*9D2#UPPYUP10$$EERO-
M8NJHF6%> I"@I-J,3W]@23 .<W%]-1C#._4_R6-([A;?PO7_N+HX,:X&N7O@
M\XF"'1()2N1/O(Q'GWAZ#"\[2 9'<Y6&5%MXG"!;8KE>3,-?L3;,M'A;B+04
MX8,C EL<"GQ*W%"4<8S]9T9%'S8YZD42#@U,2/5HC%DHN3\8=A3-"^%J6$IJ
MZ0,]^SB6.L-W/SAR!?1&/NI#W,/#"B8?/RO&TR-73$;52HT^TX&""N/2^Y)X
M"+\7WC=KRW[?I7@F]T:8_= /^M*U(60W+40=Z<C/(%)",>I!RS--,"AQ/<TY
M2X$7/+M "LUP;BX8GC[%R!V1]3<GC,</2E3ZP%]RG<*C%P)-VXQF+9@&6/(!
M?(L#R[G!.3OYA2^=3!)R<_39S/WR@TO7"SL)%P2CY\,A>8_"_S45H)./KW#"
MDO=R!I"G8&$)Y\C49KF3X=#GJ^ =^9,0\13 SI[L-TN4IEWQ5VQI-*N')3I3
M0&I1F61KHEJ>=AXE=U!^> &&A-&1AFU_3-MQ4_KDCE_,+.9%FAC)!U%1,> [
M;-$.;W,"7C(U0>%DO( T08[;#UGP1(_B%9J\\0HMAH; P LS&:6B^ID_ M.-
M*<$Y= "(IKH=R2Q#("B>Q1!D29NG;?  /)?7F;U3<V-U=Y,)0H+FE0VH_;*2
MYFY%*8_WY\:#/P9J;V"SIA0WPV/1-"I-W'T/]_@CQ"$;(1_^M5AURO+^IE8G
MRU@.3"?_@_M+$R@?+GN92.=>)/5]X?**F6V8TMH+ ?6T B,M?._U;I/D89$
M6NS94)*99'XH2PX7U<M_Q?;C*$WDPI)V11WF.<_H0):^ZXPW7G52BU%7(L]4
MP RW09Z=*?=$DRDT>M;S;N3(U)89]KR*X<^M)9JLM#IR^/."@Z67R<+I[N!@
MZ>Y2@Z6[.S98NKO48.FN'BR=-"7;T8Y+W:5F37=IUO22[Q L9#_[-,U59M*$
M#$7N)PY].VVAD.@'W'? 1USB$&N/A_OS7I<BS21UQ* +*-%/*HIR0M&EI.Z
M+ DU&IK5:4#;B'DGX20I8)G212S.4<88XM@0P+.*:CYE72, ')_[CQ+;AUR6
M&)B/S!>6ZZ62%HU@6.B9-,8!Y5F+/IEPE]"9,' 5,AH^Q9O.)I,WDP.II)J6
M1263U)'AN" 0@D\HR J1-F2?9I9FS@ ]LD,'F_.2=8JO#!PF@UKP)3J??+"/
M.0!4R),^B3G9?>8Z[(D#LZ^DSH@@EE*)RQV<Z&NE;])PFP@L*OB0I,-89A!0
M.@N=S P-%1-QN&-6O!!U7=NA_DVXUX 7[TB?:*AJRKSZA5\L]-EDGS@/,TF
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M> >>YSXAHAE''5 ^)-1)4!?-FI9X6N)IB7<Z$J\52;P_LT97+!)$G2\_^B!
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MGWP)=[ A+N,[(\?@CI.X$RQA!V7Z']U]?>"K$XGX%&\2,ZL9MW/0+SSRHT?
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M?I.GD.#674_600DU7P+OY'EB9.VLTB24#L,'6;0'"YE:I-21FU[X]0W$@Q0
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MN>^TM:8%"H;) 6B,WT"&C:W+-F<&_*Z3$MN/J?/$J1-76'I3+)R=6&QL?(R
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M6T1.14]]!HI2! <^P''LAS(VQE=,J\+(AQ]<Q?2J&1]A@V*B4,R+=AW(*YN
M1B. TAT]O JJK:!'1!^5,*CJ\I'XY@D.BKZ4647TK4@Q7N004%H<BLD_\$2$
MV N@VJ,#VW9YZ./+^&N$/']/O3K)>;"K=*9>N[Y' +W2*?./"12\0'1T$ 95
MH;4+=XS-&QL)>RT=%-RJNX/LPX%XO[[!U? EKBF-WU="_+Y^LPB_K[,]?-^Z
M0UPRAEGW<A&Q_@]DB/&!_ 1/WL\W63E2/KBLT^>WRT9@TYAYI[9C&C-/5Y7F
M\M)7F39-J:#LA=GN#!79RZD?C7#6N/W%1OGFF:@W7,GV^B:I.G!&[V.:BB'4
M_AIW#E@'[$&:#W\("W"5+O<;52@VL=70M:Y!/1:;M!4V:9>83?J5F^N\=)K2
MPTWI"V'+"^%WGK],]X$YPM19/_"H8^/1KX3CX!#M\EX0Q(7S/DB0M@Q'_KIR
MTVXTS^AJ.$5V2=X/)6:75KURTVGM$\U"0QV4"2/H_%=X"D '9:#3^:_PI/P;
MY9!PYV&=I0*H^[@VL<=E>Y^6E=[BU16L_6QQLW+3S6F[JS6C,T7%N8 EGH)N
M5 I"7< 25P>!V@3TZ7)*DWCR_A>167;D,J0'M:C$>";(E9%2VI+.?A))CSP%
M,X8\X/7:NV^-SIQ$:W3F3<D_B7EZA@MG#9XYHT0Y0DEP0X]G5E5EHM=(@C]8
M\%=(. 4\3Y;J?!"VA*7P>^!WT,V?>5HF/@>3QS#9RZ]%>Y8D$Q @21;,A60_
MF#>T?,I\@@? -.%@,)RL2)9$& 4!:V&*PB $-(!-^LZ"!*Z!"AHQ=*=34(Q$
M*1#_WDCTB:=9\4*B(I2$*"F3PX!07AQ^?#QF0\I85;[H>F-F8:D2?IP7W_/,
M1$YX_!XA3B#PAT1:$IM1%6F>\+48>42E9[QG5(G+IQ4W>U\MN3)?#22&%ALU
MX/@=\YVV(>YWTJ649YU%.3#\<#I%&)JH"DXB6PGJ)I(:%^<T6H32P),R?9W)
M&&4R7C>/ELG8*>Q$W-T^D_$TA]#Y;1>9+07W#4@LGDOICCF%Q$6BT]Y.:2/_
M16_+M-@!0I4\,_['!ZZ6B;_N42?3>WLF>_N534W+@8?R/V\%3!UH_?R%1[ >
M.$G?8.JT_U;O_"GM?&*O[V!O\7(=\C\)S0P+9?B?<;6,SG[5R4ZYN*IA #HY
MAW%> !"T4?;T&>2R%!0J>AY6U&*:R6_S#*+1  MGA;ZDD)=K50O1K[Y%99*Q
M[:ZFN-#(C_,9RTMJX1 MJ\%.+0[?M+#39J?:;I]3"[^#1^EVR#KRKA>27^IN
MI+7MCZ'^?'C_;<:\;S1+E:^:&W$5=N;M]&O7Y\14>Q9*!8X_W(^GY8SUM#9C
M18JCHC*BLMA<+5EO/69+H^"-0@_]9DFFZ51NVK5>%L'E5!GFE*50I&HN1_K=
M5NZLEH,PMGZPT=5?S'.33-/%+>LW&\UW.>B7_<9U>X?'7J?Q"\VV53;-]G<>
MF]**ZT;GGJCGWSD<?>-WS_7]U1+\RZ'"8I%7IUJO[[-=L;X[_+68: TM=@^\
MM6-MM@\,5FMU3Y*]=ISW5O;Q-)6TE^[$=1DI*R]6FT&!?^?[(1N]#Q%TF-\H
M),M]-=$E(M0QE)6B3B"%ALKU 0T5K:TLTU8D[Y1=85F7S1#L[@S8[)SN8TVE
MHVHM6A_94A^YY;TZ>8<YD2![QLK)F_WZ6C[&&<;RZBF5^K+($&XWL-:KVNWO
MW!1^JY67-927'!XJJ?JRD;^EW:S<--KU6GN?> OZ5M:ZRWYUETNL4"T#GL'Y
MK_ 4ZE/+0*?S7Z'F!,T)FA,T)YPLGD^Y?"^GFK&]$4+Y27AC2I2Q79)TEW8+
M,8U[U5[WG- KR^>$V7_&=JE\+IBQW;ZN]5IGQ%27GK&]C8-OE8SM-F5L7^N,
M[3)(H=4SMK>6.UME;+>/G[%]B9ZY4H!I7< 23\$.+P6A+F")FA<T+VA>T+QP
M% ^=]KWM)@];@AEJQ]L.[1:%MH=WO&V6^X159JUFM=7?)]:U-GA79YRS<+OU
M*S>-?J_6/*?:Q9-TNQ4S5I';K7$TMQOVKJK5M=MM.RFT&V9)NMW2/%$BOUOG
MD)4AVN]6*H/C I:H[6O-"YH7-"]H7M"\L++?[=<]]7(YZ]X(O"@_ZGW@+VY^
M@(U+$"6LFF@W(GN)^(E&+(%KS$)O. &M&[YGF,_/'GL6?3XT E*Q%P%[<Q0@
M(/&^*SYM0VE(N V2X+Y(V*S<=#K5?ONZB(15 W[,&+;_8/:\BB[A5^$H,$SN
M*>!LS5O3Q"UH?.I_(]J'\#8XP,]_/^1NI#P:].9[F.5'F&1>NDCI2P0[F 19
M:V0+!(G13X.VNSL%.Z9M&VG;SY$EZ@&H'::'5^ENO\<)@P/\BC\.XNF.2WP?
MW<"T%V9Y[8>U$EZG;L11W:RS$KCJ%70^GSE)ANH<*"JP$:UV*N*VIU6W<N.X
M.<& ]%F4.A.3($C&**F7K::6'?\8#Q:4-51%)SBE#1M=H%?DF,6^<!&S "&H
M$V[5<-BBIFX>L^E%T#6QA5WH8'<V_!O6(X9-*J439H^,IWE^7T#!+5R]4FBW
MBS: L-U7\@&B%P^V$EMRN44,S'O3Y9^LSZY8-O&S3Z=%??_6]8//;O!_#+A;
M4OYPGNU.P;E9?&OU*C?U6K;5-&<HX%F;NK<YO#=B1G.3O?G@3]'&+YB AB>8
M"NF.OPX%YSPQM3,@O+DP-+6W+>&R[J/KB9?P<T>+2G7ZE9M6K=[*F-)D),9M
M#M.WMM)#;*M^=_W=M+O+2$#A!I'=9K80@FLLZ2"J##(M^X$M,=G-QZL&Q^J7
M+R0=*/"&Z"%J\NLG\7;J7>(*;#SYP&Q&IW P SX>?6MT>_46G-3>MW8EZDDZ
M&@3+/MU)SK7($4491&GZLFDB1^J) 2]CCI3]:L[]R'N36GIZN1NLL+/6"KNI
M%4ZBP)EL2E2OPPTL'4\MW%BE[++1:54-^>,MO*5XK B?8M>KZZZUNE[Q_BW6
M&FK=7LZ>BI>S'9#7;Z_TJVE,/)23?P,Y&'69<D+;?I=0?[BGCSJJHFZ!F0"(
MT_/KSV;VH"P@]&+9DIR^V/A^K6.!8%$_COER$5$\OG[>6#.14$<O53;9W=ZR
M7(N<;K2J5JZ"=*+NS;5YWP^G_+5==J9M-]"\V)OB6C:9_:@H+U=2>?G--H??
MKV!77!M=?3&AC1#U6<N1RK"T#Y+]D?&5I,XKW;.@]M[.09AXR#>CC?R^W%36
M_6_I@<G^M[WNT?K?]GI%_6\[VW>>;9]2Y]E=)3Y%S0J[FS0K/&A/0>P#R:=/
M)YC_FCG&VV0V;YG9KAL*!Z?;L7+3K/C#[)C>J]1>;=3L43<+/?_REW^E762>
MY7^_&GN,@4() X%*:7AFL%$GZ5-*-]]UR"**"RH&T5<@[4>@[)T@[%>@ZXIF
M4=*5.@N3 <!VY$J]:J[N2^W6T977RX;"M]RIGS93M31_K,,?B=C?GOBC@?S1
MW3D\[T^'N#[TQ;!U7:0(A,#3@:Y@Y\\M9I\O(/P!S[DD[7M!V9W= U?-PH->
M4"[2;9:SD8AFDG689*W+8 ,F:1V]ID@;%"=W;XA42/CNU'AC.=R;_/;<[X\=
MEZTND@RK5Z>N%MKOMBLWG5J[% 6G>I-7V>24W%]IDSN5F^X^JXJU1E]ZR<RC
M@#-$4#!>7!O8U+:"^;E+YD,J;?^,J'IL'T\7 5\;M7I/>WE.DD<.X>?I 8\T
M&K7KO?*(KL3;5&Y_=+WUR_"B/-98P!NOIJ_D2X<^P<T[D>=?Y(A,++@?/-QD
M];OBS:$[G6)]$\\C&1NF@1;5#'_U+:"%Z5&ZMNE80 G*K:7$D%GX9%M#>VX$
MG@G3KQF/2I7@JV7;49X996S/9OA1F A<4NZ0^3[P/<P#GN:'X[$UM&"?#7,*
MIASE@"LSMAS.]7B&L:K0&\EDEN1:K, WW%<G<14^,9@Z9M:\F+ 08-/C9\T?
M+_M(;L[$C/.$AG#X34PSDNGJF$]-]':&,JL^K\A3%"<"V57V(2: =^4WL&+.
M#Y_^#6Q+W\X,#2L'[G4=V$OD8N>Y9KS?I!B"R@W6J.[9 D'FGY3KS;'/1!K=
MBN62]_'R^=?V@(2VJ$*EV]\WNLXZM$EFM>^2-L6%I NI<[UB_8Y@?9*$H@0%
M#I2)-7:A3<)+X7.%P\WAQ&(OO$UDK8!)A]_K]7JCU^DT6[T"%>4#+VS8-\NM
M"EJTB*2]>A'#;;_.7;'/3M;9J-Q\7H%UN/!:5@>E%CH%)$Z+13)>_TH]RUJ)
MGE5%>JY8'[KFC9C-\TY>DOV279)?X:2"VH"TIT1H@U?T'$9EZ):,&'LRGS[\
M)P1][<X!2H<D"K_@S?TX,9W<&NW5CG^\<;1O![\[>LU< 6!\?1C0$97:UCJ%
MGDF%6HY0[EU)7CZ'V)6%5G"O5;GIYJ-K<%K#_OCK;$J;;THR"1^+46D@L&V$
M='9H-#C,WUF0S-9/UZ$FC2_^O9$ 3J$]KQFWN;6REH.U*G+B;#Q&';NX>-9*
MW!-4+(G?0[,,C"S,DO=YC:.HITQ? HN<Y%$!9&K#^4T\P&L%F&NGI2--!/6]
M'.MM %;4%.9#=BX*%5,0%3=Y54>"Y>MBCI(5<W0[1<4<C?KVU1QKCZ'S_B\R
MEYS;Z[\^>3_?@'SA%.*RN[S5 'H?B_.^.6T$JA'?5E+?1+D09G[3BQC)X*]1
M/$.7$^@8<QX;_NG$7JXBO)>-:E$N.=*\U."*E.KE73;*8&EA$])NN]KH[3RU
M_.+0[??+3NN"WNV(TW8+=-?K(-!=I[M'7M,Y3^(^:I7M/OJ=N\+TC7-6CM?"
MUDX%">R]0S:CU:RU2];:$:;MSJ^BM5FPIVLH]*VUXJW%4R/.]M)Z<RS1PNE:
MNEMKH?;:K]QTZ]7Z]<[UU[?ZSMH38Y7USMK,?+HF\ZFIS:<+O(@^\K#P&=]%
MQY(8$65+=QL5*+#]0S86U-RU$^["=(ZR7D9K\U_CZ ;4)3:VA-7R\.39]BPK
MPPI/H7U=&>AT_BO4;IS+"H9O!**I=9_=!,./[MWI-RLW#3AU]5Y?A\)+S4Q;
MA<++XLOI4S^]SL[KO+7F7-9>N!>PQ%/0G4M!J M8HF[]O),*DG+TZJ,ZJ45]
M^486S")P/;^\#?/>BRGR"]_W@D<KP(XZ=P[!JH:FC;?^-NK!]CWU^FWLJ9<-
M\.B>>KF>T)UOZ2JP;?T.& JU[G5&C"7:[DE!E=/(+;_@2O?C.T),[:IQG=HN
M]2:CGP47\3:M[W;<:ZZ@@._TF[LM8\7]M6\KEH*FYP!G^2"T2 +NJC"VU>]7
M]HG94+:3UZ\9?[@^H19QI66-NN6X&5YZ-^ ^LH8#9_3>LD,$[-QEZ7+KNK''
MTN6RH4@0)4G1&'%:DN)HRRV3Y>^T<Q:5P\]"T;^.KEXL<(^^(73&C+KBD%=0
M!:,2Z%1AX ?P;!Q$J?(7VHTNABY7,30^>F^=[=8=XI)+H3?J@W<>);388,_X
M@"@*O$1V)[WU]ELD>_K\=L$EV^5NN:=W3#?>T\D!J_,2F1EF .0]8 ; CN-J
M91]/4TGGUI<VM_ZSM%2Q.4XP<4,?K,\2-,C90_;&DH(OH,2=@]C;Z)W9J%G"
M0F!6'V8(KZT1$.E6;EK53G/G.3G'++DJZ;8N[&^PXVWMX;;6=Y_^\E:K96>C
MEKUGCCNU'*V8:<5,*V:7J9AE6J*+"$&("2Z@JP$UAR$V$U'##7%,210I(;QO
M*II1,D7O.(G?J41:V?]!1,\XE.27.!:SD3J8S<XNA.I?K#$L;8)1L)K,,BBT
M==RU7*/VT^@WEK<>.-W,\Y-FZ86J\*[8X+JPS<9.6?HP:VE4;IK53B//3M,)
M[A=1+G?^*SR%]/8RT.G\5ZBC/^?C9OB\AMUP=$/A\*[#W!R[33W#*Q30K>U+
MO&XN4Z/22Q#:8*D6T<*D\L;^+8++\GNOQ;S+_-][V??VCIGW*(N@BHCF89E7
M*_^E*O>[@"6>@OI?"D)=P!)U=>NNNUNS']@8#QM9NU@,9)EV0;-JM4CUWF-C
MYGFR\6=5?"+J8^V(TM6QYTYYTW09,(#18-S<X@9N _@6M@'&[U#+/E]\PP^'
M$SFQ5S?$BE@&SPFL*QK+>F&U3:M7Q,W^V_R65GMKF[Z_7?6*[.0^&L MCD,]
M,)O13?RMT>W56_5.KYZ\R;M\4WB!!15>B":# 59=>,$DNSUQ:WEX'-JON!T)
MBJS3[4[VMOTE<Y R!4)J624MHFB%B\LZ=&7(WBI#VD65(:WM*T/6'>*2,_4O
MO#*$TX7*0_BONCQ$%QOH\A"]8[H\1 <(EO-2RL@X>@S@.)D5 U"VI4+_P(:A
M9P46\S]PJVWT$0RL6RH")W4\:]P,IL"FP6JP+A'!,W M#S \H0ARM$!\HNL@
M=,0>@2&O,5>YTZC66_L$Z]-,M#43)5S?96.B_B&82">REO4.(28T!)+II=X@
M='I%,EY" !!U!'$&SDCB=>%G\!T\B*L5(WV+4,KB$1-P7]O)G]_F^0.L@@>W
M65H==ORY[E5[W7TV_='LMSG[)2^=\V*_1KT.MU:K4VVW]XF)K>VCT[[;,,*B
MK[2]76F+T"M/39XTSA%C_YQ8+WF=G1/K87N';KO:Z+5U1<*%9&F?_PI/(26I
M#'0Z_Q66Q U4#MEU 1?ULB3U'=R8K<I-K].L]GO:[UU.'M@<L&5E'FA7;OJ=
M>K7;N=9:TZ7DME[ $D]!;RH%H2Y@B4M2N1/-.W:1W+TH.9B#=#V:/]Y;_M!V
M_7#;#@,K9 !W5)3[;KNYUSX$C7X!7QS+>7E=,SC1#: Z/&"3-@1\@-^HVT>\
M@_"/'U [@H_P.IR:G;8CZ+8[%]2. '/2AU&<'O/P,6/?XAOW!C/WWQJ\VXI\
M,3!_1'V/,)T_[AJ0PO[1301*D2JNFPB4(P=4IXKK5'&=>*Q3Q?6.Z51QG0JQ
M-F2M4/J/G@YQ>*B-&%^:!W_)[@2:?9EA;P5T;Z8,).9+:AT?9[Q1[VB<\7(R
MP>%0R1MU INO=_. 3,J/2JZ%]Y;"6[AICBZ[CQ.BVN#H"H+M-T0YMGZPT=5?
MS'.39[6'A"*8MIQNV?W&=7M/VZ Y8'4..$" $NMJ=&CR0I)<SG^%IQ"8+ .=
MSG^%VBUP/IKEHQN8]M'URI,P!S_\"#P3CJ+EF-[\+F!3_[/KH';AN390\_D.
M/8Q@,);!9W"M?0:GR20']"DTZKS3V5Z91&NII<HHNH EGH*>6@I"7< 2]XN%
MNB*6YGC,*&LZNB6^F@'[RD#^#RW;HGMDI_E7O4YKC_E7"Y!:!X:76!4F0\4Y
M3_",(=7=L9$1^@3@.6'&G[6'FC%FP#8(VQF801BXWMR ZY4ABBHA>'ILC)F!
MO*^:&]V]4=:4.09V,<P1QU;%IPX>_DP0(.^>6E=3!J*WKNK78O/A.29,#*YU
M?\:WEUHR^)SA\O.X+CJ#Z[IYM RN;J<H@ZN]?0;7#H;8 >3HNK.XY)2>1OMR
M,T0PD<SXD(]R7+[,D1WPVJZ")=ME(9Y$WM:FI#I5(FV4*E4>SM9I=L<2HKQD
M4J=&GM*>W3,/UUG>3=/;I8_8:>_9GH^8CC2>=J3QWF-8^885<3K>>&;QQD;C
MI..-.PXOE7V\M>_""SY$AXS'-@\0C]6':)7Q="9\6;6(/Q^,CR):]!!%B^"D
M&QA4.[I>L:_LZ)7D(D86$_&WZ.4/'&W@-^:PL14, D'!B(")R&09U G$]VKO
MM=;E7#AC28?F%6+/^V"'69ALXARSPU5S#39H5VZ:C5I]UWSPT[9^[E)Q0!ED
MPR&UI$[EIMO>><\!+1MV*!L6LL..9$-W_[)!>YS6TA5;9=,510D8!UPB;C^^
MY^F8]7.92T 0*'&FWUM *8_W43Y*^61#ET\>0]3OA1?2LAXE?(&P+^*&?CFY
MH:1\L)DRN.G>'U+MNZ[<:(.PU)+@ %I?LUZYJ9^HTG>FZMPN4JL_NPYL]RB$
MS7RRA1?/L-!9KS4U?B:!0C&!A,E^//S]9J-RT^GM7!R?H32^VEX<[VSK%XO@
MM6_D)K4MJNW<$W->WKF]G_;] YDT6Y6;ONZ*5KK#OH6^M?YA1U=\;>>=-K2W
M[7R\;1B$'7IL9&DO6[JX\\<MI\M1_&DP8BD]*">\T:N5]&ZUZ]M[SIK=<NY[
M27=\,\_9\ET^@'[6 T5<^\9*<JH/X07KHQ=LY\UBM1?L%-2LVXGI/&,O&>/%
MM'GO)\-$' 33&9YO MQ&PIF3ZLYYS\;,@U,+'QCX/@O\?TK*#23ACNA+P\!&
M;^<N[3.4WCLPK_?-$3NVNEOURDV[MG/7B_:P[8(1]J_8M=#-WNUJT7 BHN&0
M#KD6>M_[M<[AE<!+Q.XK ^KN^:_P%)#[RD"G\U_AGEU+9T"A\U^AE@::$PI0
M/,L<)2R'OG.XDNT5S:]DF=%1 F&M5CD#(J6VK#8QK/(*\X]81MAJ[SUI]*1!
M%W9Z@G?C%2DZP3J47;X3?(" 5ZM[I+3O2_1UE *X_0*6> KV32D(=0%+++>_
MHQ0DNH E:HF@>:'0Y_'K+CN7Y#>1Z&_=AJ*_FRX4F00@L;\21G6+]B5K+.D@
MZ3RHG;,?0SL<L9N/5TVNX\H7DD1)[7N";183C#]FR)5ZGC*$VC4VG'E@V%H%
M7OG6Z/;JK7JGU^&*/GR2C09!ZE.#&1B!H_BSWQK))10=/$K<2I.=31/^N"?"
M[OO%,.U7<^Y'W)JB2&HA*ZPL9\[KK+"96N$D,A$D"&^]_M,[0QZT%NZWXD!L
M=%I50_X (:*>4$*:V_7JFFNMKE6\?QG65CD+L^-2C8%JW5[.+HN750!A Q&$
M\T[<$H#A7TUCXJ%I^;? '48XRTYHV^\2:8)<UE%/)6P&A,8LO.[_^K.9/#1+
M2*\6N?*=[M<ZEK. #AY?'N][DT@CI)=6.88Y&[3.=K879$]NV?BI;)+S<<)@
M:Z<STYF33ZCWSA<H+]B,"3%?J(G4B"K7?6/LN5/J.)5J,C7S+%@43-<8A=1R
M*J(V017#S$UG1%^<FA8R$F: (%N9QA@X+R\+$YM#C40:"4W$I$22JN$Q/[0#
M;'UE.09ZMY3V6 ;C_C5TBM#C9B#EW5'-2+#L:BW',CDL V?TAV4^6;856,S?
M9;>Q3KW=.4ZWL>-PW?OLOAIO[)BV;Y&:ON4'R"*XC;Q)&>ZYZ>-KF;8[!M*7
MF P=:$9^ZS#=0,SH=8_60*S7+&H@UMV^==>Z0VP> 3W]IC,;]14RSJ*[ G;N
MXG2A]EW\U\OHX:5;>AR+Z39M):9W[(@[ME%?,]V!Y?RQTW-TUU\.6#%V3@T"
M-)5T&X53KB+]S +921LL4W1T&$/3\^9CUWLUO='Q$3P.GN>4\9E\D>3!?C.W
M*G%2'I.!_\79<Y%HJX^ :]5NXYQ@F$YUB_=4['<-6]RJ-OO[A-73&MQIB^T8
M8ZEDXOHXR8N9 QW!<QQ97K?KE9M&O=KJ[[P^\^(25'>PQ_L1V.V&V./6*0IL
M+8JW%,4/$],#TIH^0\?3%&-W% ;4HC@ZIO(U43EPJU!IX(Q$(8%/A/P-Z:A^
MX-;-]&0\A-QN5FZZU4Y=P[&<&C_L2<9C([IJH[ESD&.MDY_-17!KSJP R/47
M7 0>\YGI#2<4SA^Q%V:[L^F&/=%/6 @,O]?K]4:OTVFV>EE)H!#LJZ 7'/_W
M,;7PK!]#:6]7;OK5?K>GA7])]WU/0KX#BGRSVMHK")M6Y,LJO^^<P'2>$6]=
MNU'$2?W==4>OEFW#\8RIP]\Z@EC&3H]:(2_+)N^\J+M]R'Y_NLRW3, NY[_"
M4RCI*P.=SG^%VN0_GT2J1Q?LF+P2CZ,KD,>/J?_NN?XQM,0^&.^M:NOZG#3%
M$]C-/9GDU[2;C<X^P8^U+EBJBO<+6.(I:(.E(-0%+%$[!T]!T_OG!?586=(!
M:WU@_ .H?9WZOM2^<^Q_M=\=WH\JV&GL2Q5\JW7!DOI*SG^%IZ )EH%.Y[]"
M[1<\'VT1JZJT5S!/DP#*[$<Y+ @J=IIGC!1=^NW<>8RX<TCH?JT+ELI1<@%+
M/ 5ML!2$NH E'@SX]:QAVA1P0&-B^@;C,'V,(_G-7-\BE$!,TW;8LTE_L!?0
MF!&^[PE(B67QX<QUY.=]B]B"8?XJ=PBZ8\,*_#Q]KV9\,AU0Q3&GE9Y.D'#
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M#9F@O2&_;KN</?%T9T6>'H:>AS>G%*[RNE6928A@B]P'S["N5)I0OD9=&"0
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MD4C(WY>J$<YP;PK2%M)HQ^O223#V+A)1B]68Q>2YQG8']1Q>!^45#[ ]O]0
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MFE.BC1^7GR,T0YB7RY^7'4K-TZ+%1$N):R<4!Z\+I!&YG&@'43$U)1F8,\H
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M\#7%W'IBH(^@N66_FG,_/E.32!EXM4;!!*==_^F=(25#"Z>K..,;G5;5D#]
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M,*Q$0UENCJ:68_D!UA&\,"W.\X^SH!B<YD&"7L<7Z/W*3;/:[EUKD5Y2'CB
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M<;FKDH_'Y>CN3GY8;IABN^9#M6C58HOU-FO6 D1'L$6#!08+#!88+#!88+#
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MH:,:S :I[[_+1;RTR"#V@/0(;](-6@7A@OSR=[OD!*AW^R)\S*]5@/6RV?,
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MC?VY:6.OM)>(,>LS/#F*?QE$?[^V/@(7<@NQLR]1AS?;YG[_<;!C<%"\_M+
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MUB'5@]H)-BRP)+X&';8@&%Z=7*.#VM@5#7MX)7NXB]C$]EQI"MB]LVHO>(.
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M>:AP=>U+.@;,= I*Z/LTAK?C^ .+G<B;H#X':N=[._;BK\,[; P< *SAVP>
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MCN'*>A/4N12P/-&L>MTT:H+("\/_A[D<36_^=7/:[IPW^%]V((@7HL^3YZ9
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M?F7@N4>ZIHI[:1-RR!&W"M$,1ERNE+'E[Y_@E?S:BO59\/$9CAF&B@E*G,V
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M]'VX(XHQJH!9D0&DQ^.H^=!Q+<1?^\GV?#V>3^XC#$1X#_^1!_ BDR [3[F
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M=E*K6OA2:R0^A)&1/,S?9T"O1*Z-4Q(U[M_?6#JPRTP1JZ+39;MUVFXU..[
MRF6S;[AOPN#V]8F:##>M_A &5@?(N2&<(/"(V DGV&W<8;P?.35!![@#\Q&0
M>DP]OI$J5"WFW;ZJH^[E"^Y5B>Q4O$F%)*]77*85=K05HH*4'8[/3UUV_>FT
MVR/*+[]8T-%=^PU^$N2;2PQ(I2M)>#6A[T^ L;G9L]_;^1562>/DR2M"E8US
M3LT!@]N'3DW_V9[&F1RK;YC^T#>RQ,Y*UKS*#CN%'8Z4]5!F +9:0+^ELM#%
MX]2\L.U>MV')?T"SX(*[19([Y3*L>W>=E7;7K3Z_^1)@\_RBY$S%U[.<N^3Z
M+$A>_,6V0)H'Z>1O2>@ MZ(.VB 5W:#@0KY7^WH&_>= <C[)R*]/G.QEL^<!
MO= ?1\>TVG7$-\@[<N<\U_35R4N.K_LJD6EU2C8#=P#Q)KC9HO%6?N%E[/2T
MW3MM%]+3B;^B^'[H^[YHE&Q<%XL 5^G^" G02T@PM$%?B3RZ?TH"FY6*0/<.
MT\?18O')"<>@",,600]I%G]40N'(!J$P3H<@XGGX@Q KX4DN#S*AQH%F["4H
MT: <%J:@H;FNAS<+Y,4X16,//(Y:=29&QNED NH6"(%E$BPLS(Z2=&+!%S@C
M; !G JKM3_&W1T9*9&1[,4F,J,83]CQ[OF^AM\P#]4T73T&'\A*8%^:QW2>U
M=M ,'R-['./W"!,6\=7A%&1QB(@A-N:?T!(R><GQB;V]04&RTWKWS]N/]*G]
M[NVVI-LZW8NS-_;;"I( \ ,L^A.(-1[3)$36@Z?DZ.*X)DT#)*UQZ#(0RO\1
M/K,G5#Q 1-<1E0YN',(I:$@"N.7!"<,TA0.D122TBMAS/3O*E#$&BPC'H.Y/
M6$3.5CPP>,MR 0,=Q'G0NG!1A2$'H1VY-##^*/Y"0P4:3=!#&\.>8GP9+@.L
MRD?3TY\A:G--Z[TT5F7O O).PI@N71Y9BQHEZ"-AP$#FBQ*N<@HU+U/;*E<Z
M 6!&>!I(&^(1_ R[8XZ=QDSH< OA:P^'[/7P=4-:@KSG9&,":.%00!7PJ(5Q
M$'<)RVE:WVRN?^)O&73QG,:VRTK!;#T!HLF!RF"2HP\Z'#0Z@9!%> ET ,T6
M!LP/5J M=H!;2P//!XJ)FN54O&OASV(YV\)DT&J)#,%=]J<%O%), F3'Q=:"
M&:H(6"Q AF*XY0#(06.R+2 #HCH6+/7-X*UE#P S.2N"EP=P0&BX#3FNDBKM
M< (@8*-T:9CRX @F< $.'4$Y.[W3L[/W%71S%J9XW_',!FA7!S@NX&MH$DWA
M=/&5C-AFMZ&4Y-;(]CT+OBIL)A&+FZ!03 EU ]:8VYP!QW6\CI,HI5^4S /T
MR'8]/R.YQ.XS6W/3NB]8WSPR?:,OS+726#I0QEG@#] K& ID)[3.D5U,O9P)
M6PNFC3/K7V%/,+V8"RXPGC#<4Y_%,5$:I!]>1,^I-<(",B]'3 L*!S&+R'3/
M?266,[*#1R2Y_4 ?PP]A7+%?(%/_@=&\0%%N@5CH:83_\-'A.H= BNAN<^$.
M>5S$1BR($1PT(G  +M01,2 K/1)SN&H Z9SO@9O[T0C'7.Z6F/4E9;"!Y=,*
M2CQ7#6M^S-A'$I+ON>D5*/0?_)B^\5/ZH!U2%FJKX/0;;.HF':<^'7F?-C2W
MMOE+H\%.8^9@1-@SG"Q<YGPP6.?D.@AG(L%FCO/9UL^3.^@T6H+A\9'P "%J
MS0!9T'/">?N'-T['Z+2A>#K\B>:@>P<<)/43Z3:" 4+_B:G+1P.LF]#"QD]!
M6/%\#_%2$%4NL9=X@6;L195^H+[P6=UQEU6?.ZM^ ]4 ID)TZ0<N.3"TK[(P
MPQON 7N="RES#IW!C\?D'.J1/$/>P8^Z>Y%[C 1P+0WR5M%^6WFN-(0801N
M+&;K.ZZK.;DA6W%@;>^L^C-NW!D_L*\=E'#R(Y/B9&8(LFCXC)3_#3&:,(UA
MA/CMS\OX6'+RQ<N<+'R(5WM9_NL7BD.Q'.;[HB#<_SEIG=#?8E3Z>]:J2B84
MN6::3QA)A6'UXGQUA!%Q.P[ UI[$\+7\I'[*=LHC>:-<!)&<NO53,3!7V?%_
MJH[DYF_,_OO:,4P-W"H?WC$5:LR+>K\,HK]?D[QGJF_N\:'.E-16Y]HS-3E-
M?FD9QMU%X1"48.Z]&#)FRJ>MG#8E9#<=DI\ D$(\WH@^.S^[J7MR?75Y9O(\
M]PXQLB2ZS2#&V<EU^ZR[HZ2W(ZR663MJ_W$\\<,I8V1<!$633#@[I_@5@^SR
MZDI ?6/HF-(M5KLCZ]A MGUP5/U #G_3I/L<2/<>4VXCS6^%OI-=UM#SV2M-
M@+D'[(NFM:#E%W"=6X<GHA_ R6^:D&-9TDM3=\)4G3NH'>Y#=GD=X'3X.S2&
M@'T0%%?S-^]<HMP;TY_S5ZO5:E_T>IWNA;3_R>"+DEB7W0F@5R" -MJMJX,3
M08\/538LL5ZU %6N-J^K&)&U5C5BCF"+^R"TU@)01[#%Y4LBO:Y$TKRHRIMP
M//9XM#F6X:0HVT<6.+F@V$T75&GE"JKT>L<5,WO>M+13(*DX=P[SPRG7!I<5
MPE-%\)&X'J])\2D+..*C8RZIYU28FRWL](.1ISK@9G-TCB62]Y;G>?#S@/N6
M1C%E7 PPY87%<3X3AX+4,,B?,G*#!(4K46[+@0&1V&(^ ,-H/2N,'NW ^X^6
M(\(UMF3D1:[,_J,\%?4N)3)&;':L.$E=+Z?W868+E?_B[X1NZLBL%YZ8 D<\
M2:-)&#->GBQFVI(QN1#NB,CA<S ES?=YF2I1/ PX!]:L*J_R$XI:,3"U2'>D
M%#@$43ZOF8]+#X.H;/L\X7$[MW(5:K7+:WD+-VO,84: ^CH =BVPYG@OYM?
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MRT6Q2569F7VQD$!=IFIDU40D3Z_F^MH^XA3D,JS*P1/:]1H<5!C"YS5_E3#
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M "#'H0T_-JV'$9R,/83SR0_LQ1;(R"&\\N_4BSA,)_:4UI3-9P?  'PUW1A
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MZ^2[XO%U5SJ^LV/JV=O_BPT\VYBSI#GK?]* "29//+X]:\@2("O8LN8;L:K
MK.Q8)$"0C2(4&D*UG4I(^7)-\(88'A4NT!R$ B%&RNFK *QT"#(0*(KP!W/1
M86'9PZ'M1?&,T4LI*).1#=*7PU)R<&2Z)%XJ4%Q4-]_\8]A!&&.<K;^"\#E
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MD:*-?&P1">8X:21@CU@IH@\)K /4R_2K&(J74;ET*;Z3=)EB:(-^DVDEZQ8
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MU:3NOW[A)8X=YOL3M#$$C^2^PK_%J-RQ-8,-<0)\4:Z9YA,8E;O7*Z**Z*2
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M,W^FPEED,,>@Z+NS/+I<[,N@Q?6U4=1);FW=IFY(1/]/\9^LFRA0[3G^VYG
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MY:+7W\ ,+>L[9P6;=&[DM92MP]5]C-:S$V(816=KZ<K#H8>VC.-O/3T9VW'
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M>N1FA0^H%KO$+=5[=;;Q;I_5?;?/:K;;'T].^Z6#7$T'?1%DR9<7@9]I5\5
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M \:ETIR@S:<PCBV,#"J=) R:JXL<;449:5;!^M'FZHB!U:FKI&[^"HT^8GC
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M!PP6I^YX(9%A)O ]&#7Q*/7]F5P-KA<7GR#Q#_1XW@76%9#99P.![8.SHGU
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MEH(V)3UT[!B7TB\#=./7?>=R0#7H$,YPS Q;Y4!!4%24L* WD3LQ1-\$QB-
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M2YW[K-!5EN/B(RA8"4%,14$?\Q["^1&8S]HJ9%+F/7SUG,JH!,.2W23XWDC
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MSARSNJ1 XS9Y82;R\-_#$(5O"A_XC$)&S3L<G!_A"L"H?Z1(&6T20'%L*O,
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MV^\6JM#T?><=J'NWHTS78V5'VD<$+07:76:F3*,09@,*(1B%6!_NA9%2@$1
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MJF)S$4USB$7OZH>1B&$N[IC>-Q2/P@^G6-I"P[J,IV4]P/ HB F54SCP:UR
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M>21Q5784ASK]U*F.KA^X=M*)$$\)-\3=^Q/$&T;QT\%)_GI3G(M:0#9CXL'
MUW!.BFH95H2:&8?Z%)%="G!B/@:(0HP"%9V6Y/O3F6HP-T22PIGBMX&CTV ^
M^@(''*NB:2';#PE["!>K17 6VH-)Y\->*0B+#D"C'R)%,'M$85VXU(N>-E7\
M NN(T3_M2'R"#EO*0D>1E-8M!@;/CK<>RLK[YTM0.:EW$4C41YK-]?/#0E6!
M.T4F"5Y7.+ S#,C E?G*'9MC&H45@X')$'EOTX(:%@M;[\A(]7B9CP.2XN\
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MDIMB33]D+6+_)'95[^;Y'A5]"TIUS+!&.A?0P3T/'],"Y(+&L  G**/X =\
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MAS493>M3,:_3HJ(<^!(59: HB8]($9F$)4EV5N]0D18AW!@$NBKAB@DFVF1
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MB=TNB/ P2!Y&UN4D=#VK=49_[G';@ 'B'HL8([K.2'<OH!@.0RN[OO =5WA
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M9[WBULRA0X%],3I=7@3^+1>2[\MA$&)(WGL2TRB3G:/4Q:B,]%:S^?-[2]\
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M:\N>_)J*RURRJC<Y&]^ N<&R#,83X4]1]_.!+R-0#.'/B# 2RX=0>'1.\'S
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M1>B2T5 2*06!E8?%YWG#C)&B&2HW+ Y[U*#,ICM _$ YE<3*<Y /317V5#.
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M"6$ \T0U2 S^2#B;42<.P,%3P@TD(!]0V!DWMM4O6D>WD<G[L')M*+&6$;G
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M8;$]_+(Q[Y/=O(.K[AB;U$W^!X:6^W!1F"\XN'DHAS,/Y:1=#W>=:E?!7__
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M3TW[;=4RTF.VFN2KJK<;/E9M5?4U[=I\@<?B3^Q;+G>P*USGR5<*5+8=L'"
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M*O53&%Y#K07%#JI&84:)/#!/SL%4:A**KJG)&2!?$9%J^9U%1 <9O]#F4>*
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M:+;(=O@_?SON]T'H/\SWEJ9!]])=O=-M!YXP%IZD0C?:XG ^D6$B6#6=Q'[
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M@:[EW:YSG06[\_-)^MUN;V?_L%,I-VIOT&%*YWP7ML%>OT<3=O[*0-(/D0S
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M1Y@LY52WD#3[3EC9S 77#PYG, W$?6+Y[5^C0G7Y,D*M1-<?DV<=2YB17O.
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ME;[0;SQS\V2?.,-D;1 SH+>,F)W0[T!A+$('T-D-G-X7D)S @TM](HI@[L)
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M[*B'.B:5>F^]TGR-PS9?X^7R-585[$AG&E<*>Q,]*F4^S\T:!&5B9TB9 MJ
MUH_:7F?3L8#\MF 7@8?A['#:XXQP"1=JC>CY"<+\9[%.];"ZV'M:F:/> ; "
MNMRQ@R?X(78$3>\1@ZB %@@G%;L[5ICLR4-H@/J,Y:1X@K1!VVEH(K$3=&,1
M>BK&2Q%"B X#U4M!-98L;H JTX^OW%YA,AG58OF>>?4H&RJZJC4:A9IHJRZN
MK=305B[H0HOWT=/OT.XW]+@&+#[.4'' QVW/^%'^=5T&@GJ2Y&<SFJKT!V>K
MB.MB >HP4A6IDSG")_*;=Z?"X[5]4U::M^HPPBLZ=^(B4Z\[QG32'3I%ODJZ
M1T,'8;SS#]0XRMG2D?LAXRL%"M$SH1"^[L2,#8*C.!T1RHEI*V7\F &P%V;*
M#WQV(.?)$ 9GO C<1<A7A+?#L1QNR,:= 0G:?**;LYEPCWU)L6F;:AA%[<8U
MMCD#_1CW4Q&#:557_H,,_"2MLY\JBB:PL90BJO,QBL<.F(YE!BGZ52MS;LP6
M <*I#6B0S&XNSCN6PSZO^*+=IBTR/6YE>56&[4/U[#Q9!%Z'"'_YV UP'SL1
MIS+MJ):'^:Q]9(RMO>XV]X#FAN $*D=X@>8HPFFIR2@^*4(_8K47T7L!"E&E
MAWI8%@:$U>AE9.EREZY\5#Q,[#O$_:@[^H$X-U-)@@-U9>&YY$Q5?^.UN )>
M+.Y#&GO5! L8[58 "6GZR-FM[,[X[?Q3[:'YFT)*.X\029II0TAKS(P$XH8?
M8'NANTF^AOX\'SY].J]OX*1GXGS"E#A8<H/RGR-4K6Z3M#D(L%)AK.I^AH1M
M"!_]V,W&&*-T^>CQX(<@FHQ76)N>WR_"^)?@,>J9NO!4]V/ =/!0WX52065-
MZ8:!P-F%+EM[6WO;IKM66=;FC3SX=\L/Q6(=7X89IM$H%N,.(0ZZK%*AR3EB
M+9,3V'0"%KMS(YTE.>/HY3+;COJDS54LL24OY\Y ) I?#]0*948,HI Q_HJF
M@@A#M-[TKQS 0:60!#Y_NYWK);[VG^+;4:6DM-")F&)_">5V+[Z7B:_U)ON7
M' 91P<T3DJ.E4*O7HY8%VH9D>Z;CW EM&L%(_5BE NI6&];\)I@]8%USR[WI
MJ!&##(:DWJC;MM'."@GN0']%:P9_[*"LQ\?E/PSQL[2^"/PA3@0,6Z*']0@9
MLU\.IZ'>G_^*^8^(/9E_X['-EG\!6G=Q4#KNINJNJU@;KS*P[NJ.G->2#O&M
M)Q,W]@><,YAOF@&8CJ><#&J 5<W;U,,5+R>*F17,J?T*BY_M-2?XW.HJ\(4@
M'M"%((L0\'F!^<J*K!"D[( 8HU9"![Y$&0$J&LKGV^D$Z>WF^R3&KW-[0>4Q
M3TV;'[MI+0>9+9MBHC8B7,#;$$&/XSO=!QWKWM/,PT-<^==3;"C80510?XSV
M*K,[WTMOA(TN^=!0SU9]AX:@9F+J;BR'68);=8)<.*%X"UU"(F",<:JIL83,
M)!2$-8DZI8W)G'8E0Z<DQ@KWL317?:K5;9IDG;K+=9/?\@VY[".KJ/9^TD0G
MJ;X=AH=MGL!4(O64-$*2MP\^)$O,/.E"@PE1<2U(MT0JOY"-W%*>B!I\JIH>
M$;RYW8W=O&QE[?>+D+"9M4)V08BV#WI]C#P#K96T=(W]:V4K%$(HV,DTSB:I
M2PD2213<$1ZY]G# I;X<<C[T@/H4DH34!WV<*3\/*)%Y5P\'+48T+FR0;GS\
M'UG(B>WJL?@L"T:#C&H\LCS?8-V^TAC.41O#V=P8S@4HBFE]#V+7,BY+TAS.
M>=:][(M011-QJB57Z1:]P:U+.ES?A'TKK/M 0NJO V/C61? :_Z(X$ART$C*
MT+8%T4O]H],X2Y02BV\L#4!_K1\^T @\G8KWZ8MA,/PRUN35U]N8\Q7#T8N=
M9*5]!$G&./>I!;UJ-*OP^O-F:GQPINJP\SA91'ELDLQ%-]-*JTMW?ARIX,6"
MD0"0\K5L-I185!6@L42KB#FQ@6JW!\]@QX9]%(!.&V2:CI.\<3I0\#:#B6@U
M7L'.RWR\!988#R@-6?@QVB_Q$/18YUY03X(1E2GK3P&ND;X"C;]LH#]1&ITH
MQ R(Q1CT/I:C+)@]RJ2*%J$UX2>L/)(122IBDK<QD.C:RK\>.O\0_P6[,LH2
MT]PCZ11]8O9[R&(6839$6!?<)X3SDB14O.1A"B#J&\2=64+;!][)2B1P>TR*
M+ +*1Z0IDM:"R/+400Q(HOVP%8-:6=8E_\#9<$C-OBNU_>IPPX79K5I=4VYY
M<F%R3QSLVD*KIBK?D<YP]IAVBO1<\IWRTXA[16P*R!(Q-E!85GLWY,6)'J)(
M"D]@3[]I,KC?VP>-IZ.Z!(S)*[ 5:5]'WJ9\I9>G5F4TGJ7KW&%PR4K\C38%
M3._VH_W7X/+40#2+AOIK7(CD\LTK9PV\C:'&WJN@!E>5:CB<;/"HWN3EAZSJ
M9*N3O^L.22LK+]1N 3XM70IKW-.)UV&O#ADQV-/&!Z),\9(L1.&%9CVV@N76
MN'P <-<<%FE_  ,EGF\.T]R8MWKP5I[6UK,[^M@FIV L=GB\=GN;O.F-U1RH
MW GGKTPD_D[A6SN9_@%/0^$>+ =B"]R3*&SYK7"TA>Z4B:<S-P;P*)&1<0EZ
M)-_./82'U(47)TEMBI&DF)N$,\U4BB,\BC2_HI[7H81?].QZ).V5U-8N UB7
MV"(_'<=4,XX7#)7V0I5LVKT"I^Q ^292\9TFK&G"PEZW DID,-Q1ZD=$^0&6
M]FG1BT-@*^M7J$^366"C4%I.:L7N72RQHU"B1 \Q$/66]'0[?^=.@ )#&TAJ
M)P:NJ8=+:R4"H7G*E]G%%!WDVJ 0K2QF 7$Z&NJ7(B18BY$/1DQ1@^/$VCOA
M!SJ90^<3S%24/%!%HMK,(BJ$46)4*Z;<*4(^094M8*>N<K_!VF>O*K=4***U
M1@?;$()B'K?89XQ$&BCV%&PS6S2-OOLN>5A)Q\K0)RYBUP\CD"#X"[?GNB-!
M',=10G^"]%-.(K1B C$>TX?\10B>H3Z021F1."&]6D_!C*63]U*D1F8)<J\.
M<251X'O(XG]E/B6!C+"1O>GSG4>^<E.D8P=SV(G%S)DS0L'"0[:Q[9LJ4!<W
M1DC=R ]TFLHPUEW+=),OI.A$XGME-M:ME<C6F1M4&$QW]/6[1E-:30Z\N78>
M4M)^W[W9!7LI3G=N7!C9SG4$)(V<,SP7T'?A7(XILYU#-+DR>_@:U+=Z')G*
MJ@@J""[!92C!DWO+)S'FC!B$170-F5)\.^M&%R#CY:M+GXHFX56L8IUAA:9\
M1K6BS41!&:-<F2I!_J-0]#=348A*8D+W4:@Q+'Y!DL=/LU2[**S?4'3X8::?
M^^.([H4'P@+LH)+6*15/PZ3QX,3P.:9#*M^)%7..I[8?R#KGR:TBOPN= I60
M8CPN/,>^G&L\[E1T70<7T.D/YSYMRIH^CZP/9Z1LY0\H5%IVK!_R-.M$+:;Z
M)2GC8R^*L:&<VS8WZ1ZBIB2T8Q"\U4?Z"=3H,1+* V;V0_U)^W7-SQCD\_2'
MWZ\_F=NIQ2H: J,HL2(E"6BW\"9.:!_Z,B[P8;$&E8Y;NTR5,S/S2TPY$%XY
MBB*/.LAJ!RM!P</O*#XLDR*ODGV"-UM]-I-HF')257%?J1F[$89J(SYZ\8/*
MV>#\95TOI%&\=.]+##_!"8V*!!P$T1A33&$0ALJ)=&/JB3QW2_T)?^S<1O=Z
M%]5WGL\7"T.]L2]I)UF%Q;XMLG0X.-<^6-9H12>,4@52-;3R$HIM195E0T),
MOT>U1S9-<*U5-8IH37'R*PVZ';=!M\T-NEU>W]3KAX7-<LDG?$"E 6&&/CZ2
MWJNJX/P3! \ER%3[U:WNWV4'.S:61=R6S"#FD9<[_Y8RY#4X/>>!*I& X9$[
M-'*'I@-TQ>WSNM:CS.2;Z#$JW3#2;7M=T[8WO9WIZ%UZEZEJSO/J=$-G7S>S
M[Q2S$^H+'(PI!S12WB,<@:&T5D=4(W,L+49OE<*4L\H'A*G;IR8=]-.?YBGP
M G\\0>S*7>??%8.!\R+%=A]V=*E2G>WPDVF%L+NQZF#-5-<D-YEF5&V;C\*+
M@.LP\TUU*.<LG])*4N?QD/KRDKU\)_5GK@)FW'7SFX%A9ZM42@\;&$2Z4S'\
MZX<,4#,D/VDBC0U;.4%]:AD/$!S,6 JWNCV/EPF]:G.B[+NUG+HF.FL\OE9-
M#'H*6 ^6G#RH[8A.WG"<*4VY^'0]L%H49,;11N51=#=J49A^F:+O%I0?=+9E
M ;O<C"\#OJ$P9*R9AM$PE9]-AL(E/QN5TC..; 1J%L(MPP=_K P(Q3K&!P=;
M@:N_.3'[T4XXR]-:<[,NUX@5KB85APD$9:5.VP1OHYVXYKDKZZ_%FCO:*PA+
MEQ>]5=14NBJ(D;&'-O5':D%%//"-.W5BGC23S 'R !VQL8^F'?K,/>6=%^R.
M\ZGQ%#WV3JJ>]+"=<<_G3]VFE-^8[#<_1/[!&"^\)453TUB-!.V3/P]-3$(:
M<)&)!G&4J<1)2PSA8SW%-ZR;5;G\ZWVW1"1%BHC5XIPPH/B%,EA5)OC\_H$R
MCL^@W0OW-D.,V,1YGX'JC\>$7<=RACM^]=U=GX'=QMD8=5P"\Z!H-/((2: S
M0FZL[K;9.S XERL[.6Q.KS,7%HQ.UQ9\".W$&-M/Y;(+*['!DT,ZJ>'T+A=W
M'%%T:[_;[8$2:==ZK#3]\+"[T+-=D#H3.V-DR2J8_=[>EKOM6(D>2+42+?>[
MKY%Z_U;5(&=Y"<.RQ-0%)585Q%(51J^!<%6EY#5TBM4UG->84-&Y H2WT:8?
M+J.4NN0XKZ?5<6L%48UWHEL1M7!=;!)0A)6=.VK$NIB6WHNE4ZM-X4J:?LMK
M^9DZGT7\IUS90KTK#&K7*FA_9-Z(<R54\!N+[//4^%SU)N6<2Z"H0!$5=5ST
M+6VYZ@)Y@H?_*KBR7FDXL$%%L6Q?.YW1\S@B9<CZ.3<5+%02>JLJ; /-+B%#
MN' %NX75*RUP^EPE+V6^=(JZVNN*@E\II\6"I_:Y<6UH9:S:>Z/DHROX8IVR
M7 WUHMT *B\Q%7_*\ &G"N8]#[0JB$]!TQ$1+=7BT043D6 5)CZ3TG!G$S6M
ML3!.!WO2.3K$]W'\ADJ!PC284HVY*HBD&:24M\G(7@DU+:**DI6ONKVR\GN
M23^H(,,#C5MJ_$U%,!7+\;)-#CPF:QXP8\,DAU&Q4M[9:+)K",B.*6;!+YS_
M[^IUU9D9I1* !^Y@5X_R$M@O$@4X/16U*L&Z)=IU0*D<!-' Y;"A"C8:U @7
M<W]),.8!EID9EYQRMA.0D *G@;A/; \'[X?942'=307I3-9WF<R<$E=P6&H
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M]SQ^9CFE!&)'=;=1N(IF TK+_\104!HDG!::BA5\A7J+6?>$4%YH^*1KG'1
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MH%0LA,S,YAK[JEUEE56*_MH?H)-Q=FJ]C(A.;\VWVEEF'<B;#.Q $:,AC7^
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M%P((>&]9 ,6>BK[O;N*IK#'V31 =T:*9-5&(%LR^CW@Y'"0$Z<V&#+@C!\)
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ME!.NR* N963@3S?2W[:C$MR7KLX>**O7KF$Y"T*>'$<$7;-. /4SQD4%U@M
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MAZ\V!OD*$B9X[Y I6&5M"\;[1.N/[>8YII3SA%9R4M>?X3II;MW+>LM4@ [
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M;A_-\/X\>G;6=L?8&XR$#M<]F'_9JFJ$@<7@7CE47"A&.W3]<DLT#NF9CEI
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M7B!8P(63_">K4/$,1?>1"E4':F<$DLUF-A^HWDM2AR$J*2J">\(]?K#]<S8
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M(2.L$@J)HVR"4FB,N7*&.(2FJ9OCPW*BMUCPAW2X?KT*F;O,SF2,36&,C2-
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M\^9*Q%7>=E.OYLHB4"E5>,))<D$N $6R,"&LWI[YKI"ZL:R$L@B /U#?@N.
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M/)%V[_XNMMY%#N01!7N\>T*T:*EB!AVM5WM@]KPN6IPO'&U,,7'$H170Z:*
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MR7JR?%AFP@@+=SU^C ]MJ4PSB%Z5"W$>'.,F:G4L?:8W!,$A#?06V40WBQC
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MDZ'YF0-A+4E+*>3Y] '=D^)B<NQ*5X3FA"4A=B7"E]"?6OE3OK( E! >:FW
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M"-OZ&X^UPF4I7-6V(+!2E=[3)8BI)9"(_$DG(1N$&U.8U*MAI-(F+ >B@^'
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M.>M;H7_]5;=>'GX4H]?Q8RAJ G,'&$ 4%4_4R9N):3>F$*4./ZQX&AZMM$T
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M:SU!SN@0"(,BH)A7DH?(^;_[J3^ 0W^2O%LU,'=J R-S<ZE;\+KD:%)Z5BU
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M6:2 (#;>F-&##0*IF(W!B.LG?&%+(+;:D HK KBO&,?0%%&_/=SXO\@;T?J
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MX]@X/^+&N1MK-U.7_!+"$>_<5"2[8\)^,OH8=U)?(S^>?Q72\%LW%7+;RZO
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MF,BBXE5,_,=SV?H%85_TMB9]1A[M >5K-XYS2</[G>)+81'I!0'\3'&&21+
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M4IR<RD*9;$KWA< >Z[-@HP<0O-QP3L$G4*!WTKWF51&>MW#Q$7$YMR5#/^:
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M)]Y-EA2WMBJ> NB^G(?XS]-/IV]/1T%F\.G3YWF8K,0%*!P7@<.YD_!^Q]-
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M3XI<N>0\L<GI$9OM @KHS 7>Y@LX<^'0=_>_=D<OD +1_X^@8\S=%;3G$%Z
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MW^:+^HX_YLZ(EO_IGF.^(JK)!GWF$&;!'Y^ZI?(_ GA@'[K%@)')%->5_[$
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M]L=H 4>Y6^7%)JK7GD25CGR&G%NRO$VJ@3HSM7WM"S 4%3'_M?<F.2ND[N0
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MTZ9<VD1FYTCIR<4$<^4%'$)[[X[310T=J5'EU88#>1ND[_ 0$HSP;"LF_-+
M[CJEM+BE9U6/A47%UZ&V+;C$--TG7KQPFU,"WV^ZZO/\>]7G+U'UT>2=H;:-
M,$_N\,'%S^D[/+I9/!,V"\"1W&'78/" U6E+O:+X ;]%3<87>5EG^D447=2"
M"GS5<'!J4@X,D\W*'Y):MX> ,'U\I/<C&I1.>UO,42^PD@H80)N(+S1((L;/
MF_+!HR&GH3X2H"[(^%KJ.;-$#C9_,S%_2'B?<(2D&B6LW[&_E#YZ;FLF.$+M
M6N.T[.V,1W"9 74-YNMGF(QX"4)?=%WP%KDW\0(,7SX.6G-UF )T2CB@#SR
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M6@!:$NT</.VT?58"6_"PCQ3JQAN=Q?*(R'0/;WE;%R'2][0QK"84U()6UMR
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M#-+N&PJ2O@7 ,:Z#A3-W'_@0OH27W8A.!M(X1E".PM4RK?KQSTUU8;02L%:
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M?HAE7)D(M\F&6 ;7O-:X0L1>:4?7 FLDCDM3D'"LM<V/"B]I)Z5L^('+]''
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MD0UBZ[>BPV,#:[P*'<PJ^+$='8>>AHZ/:4X)V3=XZ<CU1(0!(;B6@72)?P8
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M\3[>27>WQE)_"I;ZR\$+]=XCOL&:I2%IA" &!Z8\)KE6&_+6_K-)/8R)<SK
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M8&S;#;<KAS^@K@7,,O1>G*P[L&ZL##;GE\7*=BNE7G3AX1+3F40PF!@58"X
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M0_4Z+NC&YNU0.+]O^5I(/\1RX+*\+*.=0\;,O 8B;W!EWH!2*Z?+[C%D"W,
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M;VJ;\ILWE='6J3U-UGE@M=]YJX%8F2>5W&Y"#V.4PA!!IH&,G*0!>;B!JK9
MVR.\SFJ\:@'11:YD$GJ7WH+/DDF*2Z>7-G4'#:YW(SM)5B=YL,JD,^$;2FL"
M!RVN*YT&,[(+5%8#0JC&Y7HT2G(P6!X959HN8DOXYG&]^%K/?,8Y,W+?<&9F
MAGCW.K7,^1BVWWHFN!?9?#&MEOEA4Y-*3V7.S6Q.][3E]1M=:45MAB=I/O$
MY8KVA025$>P,G>],J"Z<V&PV-@2\J,R):KX;C9*:A!2R5>4L&\?&/BS210)G
MBA6V.TO*(DXHZLYL9H6C'-2"3G*H(SA-300><9MHT9/O*]DRTA]?[9YQ2"MN
M+6LKZA7[6705;+"341X\6>:6 WH:C8VKD"& 1035AIE2HX;"BSJV!E!"EJ-V
M^_VOHCF)5O&DQ &GW^857<%=@8DP'F',K8:."$/UA;W:Z).TJ/L"$NJ,!Z'
MDFH4@!_.@G;,TX%XMKQ*P6:2((VL#;E+YB=(HVXC)\I+4@NKCOG=B_X7+2&9
M4^EP]$&"1L:PF6;VSN^ +_F*R68)G:K1;N!>]!H/%.9D.M*R$.PX*XTB-080
M,OJ!II P'Y@ML=AEZFC$7?".#,F#JQ7@$#]H>O?+_T<*S,M58S0-7%=&6!ZH
M>72("$GS-DJJ\TLO3OW&58<;*V_#HKL/5'/V'^5Y49=]16?W83*OKWX>-IF[
M&M"[A7'P?P/;",Q8T91W."@^UZ(7#B%(WC70-T:'_ASM/_['XX-_@+?67X5W
M3P/RAP\!^2T-R'_70KP7@D&'/V>9_'G_P))P4TG4\3:41+W]>/I;Y.C8/O_^
MZ=/'TR^J(>U#C=Z/+\ #!+(/*7[+ UG9Y?OCA[?OWABY?'?T_FX:=]_"H-]B
MXN0MY$NVIZ'VIZ-3.-[=!_[.?<#/S7Q>5@N52.KO;;VL)4Y/RUKPQSCJ-KE6
ME]WK]1I>=_A]_89ON=7VDA'T]-R6Z!%^$U""Z22$[$A'ZFM,6W6^ZND9+6Z\
M^F8L^00:G:"%UGTWL$Q?M=\:1\/:>JUX<I8&7;#[FR=+WPSNF&R#,A;U&#1-
MYL@S0;VX?W(B62<!AR[MHNQA*D=I7EXNK6ZX%;+L(9KI].3XW9>C]ZU*[.^N
MB;B+<XQ9O:8"@<I5NU'*?$MF89+F !RXLE$@"31Z=1$ Q/]^_>JO(954R[!F
M,YC>1NR]$Y3ZGD'=[J^E,Y:WM#<ZBZ $GJY?NR4['A&J$;,_9.";M-0 L"WD
MK?!#@$4@L$'::\+_AJTKZ5 N=/1PS<FO:- >>Z^D)@$>/#&LZ.DOHE'"W%'V
MX^I],/EM,:8+KQ;H.J+MUP7I=RX=:DLJ>-#M6B!*\OD#Y:(EN6OT;V**&;OM
M6[.HIZU[I<SH!@+0NEHVIC [FW/%X94MC3XIJH_A<!"!*@3WGS;Y@.*-@\>3
M1X\E6XEKXP?BC\:+79L-659UP)ASJC/ Q!GB@F@L@RW/.21RLV_1D==F:E.[
MD3AIY!,R:<:IAHK!.3)"WPG0*#68N$M\Y;8S2E8C]P#8H??;>PIT#=@< /_#
MQS]C))L_>?OQ]"2F5AD3QB49=8Z8!<BXE@T6 9Z[!B321!.;9B8U5R;>?5WU
MP?#&[L<,SWEC.T^Z#C5O(5T(X$R5$?=WAU.SK@ 3-5Y@?[J/.RS1FZ[-RW77
M!GJ+K^UL85<<&OCG) \:[N)<ZKA56(#WGC$$H9>TJJ1-H!K!.+"U>5#K-U2Y
MH'XDO\(#@HV["X9UCN$L(41& 3EL(<" )P]Z]+2!U#3FD<TUA55#]A7FVVS;
M^D^GNH&+SL>[M/UY.L&\@\W*JUEH*"7JBG.V%5+;=2W-Z$>8M<BOJ!&:_1=J
M=KFW!1(A26*<39757PGC 1=+?9[-[14@\[BQ[EE?.$=K"R=JT;I+(I7(=7;:
M]F^S8J+V!O3TPDJOUT);W<G6,&,\I5;H/?>\0POJE28\X&W<I?K(8!=)!J(D
MJQ=@3'>3.<?G5-7=,=$2#0,H3*HFL9TV_)ZG/6DJD;HYQ&$F$=4PC3,-3^[Q
M#UOJE:(:W^9T&-FJ/(%_DXT,>;%8+&"'&;U2<_7KY.Q96[;!>.!P>[P-I?7!
MLQ/J%NXN%O[$12;LC^L2PNA<=8@%63"S>7D)MIT3#BHZ+;]=[79M1[ -&ICB
M!+(]@>F"#;_;77X[OBNO>!>FP OZ<6XA^G:@ZB@X5#\ZO@D!I\SCSK(I%B^.
M >:%?_1JVZE"'/>UGN<9(HG0H*/RU0+%=9)!^>>HT3A,4AGWN83I^*&$:6L3
M3C>[ ,=K7X!?P%:8M@+"1O:O^:#*5M*O9>!1W4F%YHFS10"3:M:;C&4P^6(R
M;J;HSV/%36R[+,;1/#=6$6K(\ZLY*(LQJP.&NYU!?58,F$8+RH.FB!7S0IAY
MGA1CX\%6@-.%@HG4_-;:9;9P!5"![GN@5LQ?(&[A7H2Z!U\'?YKG"3N%H(*J
MIE[8;[:L8V719;5Q'&P_>]](5.I>5H0J,\P (62VP#@/.H4I5IEXFA J,TLC
M/ MCUA%ND33LA,I6!>?95 OZ8W!-C* HUT%&HSRYW!5T) J_V1P@@I8!X*HM
M./(>7%1$70"+A->8$0RL,[;W(BP2WT$<RK/-/@M\B;(YJ'VO_T!S)>$^T+V&
MUZ*/N;9;03<B_"L,G*!]ZP42J836#'*6?$TY<MD2T&%[&[OL2Z+HA%09,D@7
M)H2XR-]-&-"O)4H5-/W#CUS1NBX:$,#EW0<$#H=[TZ)"<$'^(./FE D8/-?Z
M2V NNV)',WL5V?12!+<64+B6TWSR;9S.L<K>'2-SA&;0JA$E<PN[TA_N3':M
M9W#WMGE'WJP=ZJ1H"1P")3TNMNR^:7'>GYG!Q95K%<!1!XI\4;O6KB!*X2/A
M"Y[Y=\?.[4HA"A;94]KNBUCBP[%$4.45IY834?E30M'#2D1_F7VO)W0"4<='
MOYK35N&=;/3C$56 RA6NMP8S",1+,9MEI(\P\(%U:4+ZA*>[=[,P7$B:/)9J
MTP7E^RSG#=X7JO29=L@XS7FG;^TO2L7> *ID*L\(OH^))BZ3EDO+O,FL=!RQ
M#L:@B)&F,[Y()4KNAV+_U'Z*G"4N*53Y$ 6.3VF_":WO1PXQXC!0#I:=&A4Z
MAHFQ2^FR<+:VB.H<R/;!]$V7/3?@V)%1U/E$Z[=&.V9;RC$9\69TE?WGKKO8
M06#-V:J*=/58H*@CQ0M7N7!4@,PS1JO,EXU@:1)]K/3UW+]$4!H$]_H86'C(
MG&F'XJPXP&/QKR(;:QP(#,GI\[!\&V!DT^2B#$E@M(S\1C6V&]!TXZW4=">X
MIW$K:&757" OQQSHC9GE*F8]Z(UWJ9W72;;3X239:XHC%+TF^*V;WC>SO.6D
MLDR"E@-KFN\)&[V6JR(QA\OH !K MSF5,(H)3D6UFI0#0VU$R7%E_2>]<1")
M3]"X8,^D*9"3 U>,23DBJ;KTSZS<6_:DNL?>QM4%(\=)+[VH6A/JN:G"[[F*
MMY57UIT?_<EN]*%<@-S;0V!F@70*49K7J6R5@P*8,U9U&!]&4+$\&/.LYC6Q
M.R6\R#:^/V*P@SV3G@\]*8VGSRL_NA)_>FS966B;??8", PRL^O6CR1?/&$6
M!-EM2\,:T7IT7)_F9W&4M?^<4>K9 CYBI,:PJ1@;J!:=A:"<UOO<<)(V6&"0
M-:4S!I(FZ[IVCJ;3+(=7P[JK6S'N24'M<HY-5(1_/<O]*F6,'3HQJ&@,#,"A
MJ[]S.\L_;)S?9X=V_;L1AL(!(> *</\"'A#DUY!\=:RRD!PY1SL&Q^+9^>=8
MAXDUQU2,F^1L"\6L^2.S3(D73:\=,XU^%I"J&6.:V4+<LL8V[2&UQ"':JTOJ
M-,3,C$F.,DQ-9J8?DP M EF=[Y-+/O!AH,M[<1(!(291JBX+J'40Q6&BH:R,
MVPEHXEQQ.UH:C7"*88*D@SU3Y4V\!)W.'6*\DA=[GESYCYZ;:\W1I_(;/ DB
M:J<K$!^@[7!KMB#6I%>#0QE",F!C#)J!&&2-<G".UN61V;88N$=I="KD+(>
M'!NB:2!V7F,L(-:DPVCT*'7AG?<YI?-0!+>M*9VU+*!_40>*KP@)**>I.0-X
M\AW>KO<(,,$7<XBI8!S9S'U!4L38 K[&>;N &UTDV+7%7$C4P&4L?.+>>4+H
M9A<YG#6]S/#QFLB-?$W@=4QT1YIC+SI2IK^QZH'J*KK(RMP^;2NCI(E$2<U$
MJK(Y.]_.8=I@+HO(""C=<Z*FPF+D9!01BFW+#/_ V&<? "AQZ'.\,3Q)I FR
M?],.Z4&.1"X\=9%ZO"C61V/TA://[47!W'URY?'PY(I;'#.G/\#O]+!/]S*I
M\KM117D/K >8GB#U,$M3BJZUK'B/F=_("VE&=,DM"+T_+A8#5S*\@G_+(5EY
M;3+YJVPH=D01D7IAGBFTPHH#$TB'Z!<N\ 2$9A=&JL SK2"250BAEDPCI-71
M13'M0.\(XP?X>_"^7)Q2XC*[K 1@Y< ED,,!MK@]"#*$("I%?7]6!-UWCIPG
M,3#PR-"LUP+,.DNRHB:'_@B.)&?&/U6E6=PDW]M$0N9=IVNXZ,#>Q[;B3*6:
MQ8<V:R%AZA82$(XMD2!AF OT-3.$"X$5AB+&B=!X><^VR$2 <!;\I#7$ 5^X
M.I;<IF,UR["%E^#CVRH:N%90^]TR_%G,_^B#GSGZ*2J[L&Z2AU!T.-,KCIB*
ML[BRS@-'\:B96V8ZB#A6X/#I01KIDKK*Q$:U1UG!_S ? SN6)2^$OV PU45*
M!*ZCBT0H/))G7U,Z 8"$MYTQ\#L")K(*C<D?L><%8S&H  /<W%21V->:ZQ.Q
MO/B1M]A49^3')^3D>"A;&QLG1#?_ ZV&2@*Y^M4<+Z<93TBWJG_PSRN?WYU*
M2AV(^^[MBB=KV!5T;9EA:[5E[*)D#"&ZCT5^U6MB&"7AX]M#,Z[,@?:91;U+
M!8WE/0C=;*N^MAI.=,PB]K/Z^!,&U Q[HU#%$:@6">3<(=P#DQ8M5(Y:D_!B
MPL]E^WK?).6;VEKM^^XTFS049YXT**HPNL(-J5(CG6Z,!^WI<+%ZYW*^<,5_
MZQ<B+AN"KW^%,%&I+TV^%ID&$+XQV;5Y9J1F%]9M[Y$)52,M2@B V"Q6F([3
M<!!/MQ.7+0?6%A85WD(6)%E>MS.VG3?J%E^FDF91D8O Z.ZV5M$NUL%4_QFW
M9?FZBP)C(@Y,<&4W%HW8 IF$@38PG035Y74+[4'93/C-S=O\"HK!'"MS<L92
M92RKNX/[/P5/W0(?,"8#G5[,QNQ2?H$N/QQ<D<P0#&M>0O6SBS3!AGNNT1V8
MV'R_(<\N[5=(\^BM]1*,A=!QN_YB:U2A;$1BP;.0#E[D]@C[J&4N-M9 S5+*
MN&%8 5@-% +L_I8)P%-U1_ O(3G=H0"ID^YB7MW^7M=FP(9S'P-WU+J^R([M
MFIL7BS@I-42M*HK:&$GB!<9;O<DMT"'='?94TR6!+EEPP]+I%NW E_>4[6]+
M@[WPB&YMF6?0@,(?0">N1;B6X0UMD#0\O#"3!M[\!3#B=* @I7367/?$><"W
MC4).\:0RD/!F;F4B*1P\!'88#%;" A3F]LRJ<3.#@!ST\W57:&2;=Q"I=]=;
MO-@S50';IB/Z!SN,9!.K&0UT8 I(K34&+!!H*KEBN4F:@/B956)S+(X8II/E
M.=5:0]:M3@K--*#SUIX=2 ZO0\6-R 7)J$M?5Q:0$?\$!A\3B\G89>8H_4N.
MGB\G\EP;'O<L7GT?;N'9>FFML(Y@+<\4Q9DZ/_14/+?E11\UDC[:"\BW0"IA
MC+D'NR4]@.&V;6C[DPB[B  &N<W#MRLJ[AW9OFEV&I\H*H(!X(4;6$P>)QP#
M\@[532QVWS3#;&BFS836=Q&:!JO@4L(HH^FX2A<>24>OR=LZ[O2Z@!1C.R,Q
M3T5+ TK,'/:B,T=N%DY$@S[VJ,H%!(LZ+.1=Z"99N,\9WL</&=X?(L,+TMGB
MJ?%O5'N+TM$ '051*+).-&RO [-$^G,+C[P+OO[988VR04QMQRI;BJRKR#OR
M"A!4AV_#I8VY!UO9W)F%4'<Q!^B&U>/;4>$[.#H$;A8CLY+B:QR-*G,I<$T6
M!MM[RU6"4/ZP2+Y%<O)"E0RE[[Y149[D-0PU9C_%LS?OPQ712<9Q2W4X:\>P
MG@V/87THH\_4!2U1:]9AI7B>2#<@4@.X!&6@JI)ZFE<D9P1WZ\152R\'E(CS
M;)0Y6K7D*R,!K3'*^\X[L_?$;_@0*++!7\XLZX]+$M )Q* ^FM2K6%]G#2QO
M'<'_FN4*$MH*'FT#A9S\\KHVZDB@_@WR+B7#IW3W OE\N$"^80"DXXA[Y]K4
M](HGZ2PJJL ?B?GIC.L>>  B$\UM59]+?F6<@^O,W9TL'I.\K_%Y.FGRM$;[
M>:),XI/CV-K0%*2!7F:(157UM/!HN"(M8%L+N:VVIH&I8H))2FZ%38TZ9;R\
MO:_E?!%2+V.(S.8Y"O 7U<DY1JCPO*,(LG4]V' ^H:RX6L"CV%%18EEMU_^F
M-V=A"T_H5]\=^+^V$+\8+L2G':U7__1:KP;+L#IST*,0MA7VLI/M=J720MA!
M92O:-5I\!9'/[1 )13O")LSD-NU@_,B2,8)-)>G=#MMK2FD"RZ&VA9:*HD?,
M,?9D8WL<539Z!E'VW8'8VL:"K[W@D 1 VCP(TH)#)I$HU%)YKHDM:K,[KK 4
MOJ0^C'33\6P&JSX)L/8M#+7W[*3*:C >2*^H?(YF2\)6EK,&@W/0O#$%%&B>
M7-:[W$K2HR35TF#;FX6&>YBK5VDF/P W@,H+?<': ]:O^)47<]D<E^7M596+
MC]"*87<$GT$=NO042IPM=X.DD^PE%.K%?IFDD5:C;LT&-@L;'>V(&P9"H<OF
M_&0*)32P2W0[#';D537+*VVF10'O )SGH4$%G,>Q_@1K1V,=]0QK?X-:R^ZB
M^=WK5(5WK;^M/W4<S!W%W#O>4= KLMNJ8KY)>3<W.>4G?;^R[IXQ<*EW.AGV
M@^XZ\-9J!I6Z_27R&RGH+FW_[P7TW]L$O.V+?\9 ++%1Z:3)Z1XR)RN;Y%=]
M90E=/(AP[+$OJ2SAI$FMXV$!99V<(_PXCN83Q^RN;5X)E8@)C8B 0AGG,5Q)
M>3NTEH*W-$Y1@ 6/VL)_MK$;H*)0L<4AE?6)/)"0/J2)P:HE8W4PFTK/TJ&N
MHGI@'$T7&P9WTY1'M1T$EY.QE>Y&X)I\(<EK""43(LXKU4 >)?:AIGDFI*IE
MI?8 V5>G"3R,[86"TCQBOD@1O=3!:N@6ZQ5*-G$!94_%GZ>-L:DV(131:_+P
MB5AQ2E!85P3?*OVDLA7X&M$8\UVAK!W($7J%]$%9Z2K51 V(L:&*R(Q[76"^
M83R,=B%V>Q"[A0?X%R\S#BA&,]]<\ U93Y5<G<F9D8,S(F;$ G3:[?[*>VK/
M#!@]XQEE&/Q,)@@;S:_6P+>QD XD4ME$<8IW'&-W%C&1J([8H+/)#6_1VW1G
MRI696 R*&"2QK_/PMJ1X#%HA@AZ)(71BB2.(',SU$2>4T]6]SH$]><B!_1 Y
ML#X.J2[-MNHTQ'P6Y"#84] Z .?81CKG:!GK9B80@5#B"/A ABA',;GQ!%M%
MV5:']U_UI>U0$Z)C$[(N2JP6)4>>@!'8;KD_P]ERPP".9/8W7W89@GL_/B_+
M&AD,^\8#UW_G<*P1!L\!U@-S164UI$C0Y31_0!'[9X/]QH+(OHO]]<1WVP-R
M)#Z<53!Z>@9N106W(H/:2\)JVJ$(V(D->0P7D4&&@3P_YHD]UD97'OA5@I.>
M;9%5NFT I8/"!UZD;7#G'2U,BV9Z1Y:A9V8H(;:1S+&VVVR,$:8!2!'0I*!(
M>DE)8(*N2Y(-?$$$*Y6" C1T_8G;7,*UYHWAD?'7HKQ$LEJ5=[+]?X*HL^NF
M4V,..BR9Z,JK%2!K&5HD%J;6M037,FDVH(:FNRW00!>BK^QNCF,6#0E*[ 51
M-W!=9,4%,':<.9NJ*L=IBE["/!5_$-V\&!T0?JO=O$Y@X>(<Z(530!+8'[>\
MKI7V/T=%.5I*WD"("B77?S<:Q)*E"*34/64V/:$[SEU8<B Z'. E]Y5S$\M*
MJD61!X!"%ZJ<"3'6[NA0%N;N4TXOUR"F=9A-E4SJJ#AW"$6')QUCII(R'NS5
M3IL*HQ+H_&.PB1E[K00;<S+/D&MZZD#[J,@F\G3L><9L@BT%H$@@, :CT*PK
MVJ196#Q\1@W,3BB(99[U!9FT=L;J*]B?30=,VCV,=+1U7F50]]9=V^&=(XS*
M<2R7\#<X#*9/Y*8DM99G'3WN5HK^ [-:G-4.?4*QIXF:*36;\[<]J_726E4K
M\UL636IW,+Q!N\$ "1MT++LV)<\J[$6\;H=#KID?^GC'JY% #&=WO;3<'68
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M; 3] -46UI4:X6L>B<::6?SY%,$4I=M^?M>(*\:PH/.D:*;U?JBSZHI)EG'
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M-EL4EC)I8.CNDV9CE)UBB[5R-M,LP9194MLK RTQ]C%G5US@(F$PO6_Y/?Y
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M=&2J-C+TD]^R6HKNON3=S]SM_,=W&&'4E;$K.E:%?LFZST9T;_>I4!0[F0C
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M8T:AB+R\F8&P&+$X8*8^I V/HY'9L$(A 4V)JX0;)1?1H!@9=[=*L*G'),^
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M^?TI<G[6FO>S]JOP7+-9I$NAE_W,RY(]7)>'NR-%DU1"!_H2P*R 4>#P;2B
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MN6 Z0@@-#BF/LGQCBKF#LV<W:7<K/OUMEW6#75C@E'!D%NE2R)\G'&%N?KP
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M6-/#=Y)>J=TO9!NZ<A"OTD,8'$?0E35"DJN:N:91LP@P##6*T_%9_[8.O&4
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MG]-*95*C"BT+!1\2"X4Z#Q5-H6XWE>4T2ZF65WEU;3"K7ZX*LP9C=-N3V91
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M27)&_1(,W[R:NFI!==VVY8-P.#)A[>(D(Y)V02G6,(M#6M&OH]_=^5YLM@[
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MUD3^2V 7ONTIW*,V)@\7N@%Y_E8"1,OC7)@?\R)X(^,!,,87@"RC!!Q6@I#
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M 'S6"1*;(2,:!I0*@/2@MP7&;\5*7)*R3R/:[ZU<V#$A,B6U<2P9>ZN%H^N
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MW7&,DK#(JOHRGSD92PE_\YZI8!K\>EJ<7LP4F2^&9?GI&5GLG;Q+44*T&3-
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MJ"XL+3<'7(\P_[3MKH>)!1YQ )7K("3 LT(H%9#CK.C0-G32!&,=5WG5S'5
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M*HEQY")* B4>;E2LF'QUBD%G D2P[K;MZ\J"RU9A9Q25D8"!K!=#K_7AG [
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MQ!:);3&,ODQPFWH6K@J78QC-(]T#SET?9F5U\>6*OW)M,)5Y0INDR[QK-S5
MZVV-,63] M<Y.O-<OT?4K%I4QC!]);]X_^*MQ&P+TIG>6#Y7C"$<F\&5-!D4
MB]AAH6Y\E9E'XOJS1=3^(X^JP *KU/M <,Z,),1\EFVQSELLR+,R)6?6D;O
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M'C'D!J[%\ZV=3M+M9!G_NHL;?%,(F]39,=&$+V:PHK2:EN <6])2SU++.K
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M\VDTE[6&AFL4C3"N%);!/ABN<"12"M0"X GE=?FF 5L[ZRX@?L-6[*XYY*7
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M!*,E.OKP[C41@)[^LGL"/([!OZI?U=]-';IO_\6='\AJ47:*IKR-F'I&.-4
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MX*P),V8\_'1Q6:+C37=$A09(HT^I)SNR89;,? $9 4 LC5-;KLY]'*"XFRH
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MR2F>VVBJ1]P=CF2 N$ 6>K6-;%FB$G:6W+4S33Y2=QNP>KDX"PT:R^6.3]O
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MMF/]NV?]>]_Z]X'U[T/KWT?FWP==Z]_6?0X.\#WEKRXXSJYRL%Z'AURC8SK
MWG&4UF<VSRM[WYTF9W85AU+;5+[*X[%3;]8NLYPM-&,O!F#TANS;&W*4TY:[
MA>YX"XPDLAV WK(C"1$A-&\XR&5^-*JX;C(C-(HM92XLJ[2O9<(\F8L=J=Z0
MJ<4Y_42(#6=*"^H+"8F)QB4S;Q1^95-D&/"DU"!O6:2.Q4+WOZ<TGLR[8&,K
MF(HM:_^2%K>"AZK)IXL86C0F$<,L>GZ??Y,$/.@/+A11(2:=Y@5/3@"V+![S
M? ?NVDBQ)_GR$>RR$_/4>OHY\C-)8%E$A9BZW<V_$0\&"B>38(@HHO&#27LS
MA"489%: M.R-0=9] 2H0O?O:VPG%RALC4HURNZ!U?0F$6>,T%#X&WVPG5+\B
M'6Z,-]#9)J?;H1B:G",K:AFF:Z;K5C),!7>XHSFU,I-34>K,T4MIEMR'%(75
M&Q[:KH$W#(<V,(KA0; $';##:]&Y*#&W=3#9/,5^-AR8?E4X?>MP1[G#G65*
MK$?0=78+@\#!# *2\>]NT?A'29@S^1N;$6SK,4_XG-2QB2R42=,&QL98,APU
M18M<2&@TQ%QU?ULM0Q[C-)?+B*TQ7$C6$LP"7Y!#"S*\] %S!#<H/^#KI^KS
MXV7)W&]ZUU7RHDQ&T#C>-!L3-1$:A5YFULD;^2-&&#L'2I7(7[F[^HMJCE#\
M';D- J7R(L:7F[LK68Z^%K8>WFSZ!/NE)VA&/CDF[A)&D!A/N5OO+'R'W:J'
MB:%3'D=[N4-I+UZUZZFT6YJ>>!*#_6%U7J%*=DE49QF;<@E+<L,":(!C+5,:
MU#4.@XS B!*#P]?1.6+KPS*QX 1:&<Z:!#>Q8W=1U!4L,]!::"Z#Z,M98&_P
M01M^_R%/9A_$D[X+P,@+ST:Y.*2IZIO>OP9N'CVZL(>;-[6[NS@UCI3"/176
M )?8O@3;BQA\!R,141%O@['_!4U36]-CD/*! S[Y0!=;X=J>ZUJV6N?@,&>K
MA5P'XDSKA'M3C+K*M50B8E$_S:4.=I!FOMWF#Z6WZ_WW57 7^.-@V/R?]4=R
M![O"1B[<6 V% *)&I].:KT&^?F1?SR,FU^R"X2K$=G=-2_2&--(+,U]SEMN@
M)U0%6C!O5ED*4.7,<VH)WIT#*,A&"5$6>+!3GMYI\1:\6C!-R^S].-%14QK&
M.3-BC*Z/PT#TZP4UXJP[%]PH#3^92052^R097-\$5ANE0#?;?;<'Z6*BRYE"
MZ23_AKL-;P<CXY3]NRE/PS:$T' @Y8-'J5@_X7^%&/E >4YS*C>0*!G.2I3<
M!8D<@Y]*&4GZ+*'E\Q$?& X,':XP'(_<+1.#\YN @E8'H4ID19A*KD7#]CC2
MI@L*IZ1P*@*[.<YJD&JAP@^VW 0:F%,F 4=R^'PPA#QZX%R'+7]4J ;3BEB\
M2.0>*_"4%46&.YLPM+CKO-P=%8R8!%@2Q?>2T/50_:@D7V&B)W;BFU,21; %
M2]0Y1V D<16X0^7;,<!:3+=7"'_WUBI$BO^Q; Q'$5>(UE3%*YX<:FNH&E18
M@<JYDWB!K9$M%_\@A]C3.P&_;V#@H[W\FHNJ),+?HCK+Y<+4H^6LV^U>_J Q
M#FPPFE*DH.I%'1(EH^PNZX_# 8H_?1[!&'Z1Q%$XH&A@E@P8?2B*K_#.56NA
MW3!C?W?)<D#U/A@ JTD:GTJ"@9[ 2KXS,B*=-KTS7\7C!&Y!ZZ(WB17DB!2F
MIB[%2#.0)7S ,B1,L;:SQ^S<<UA48YQ,,#U:-;#()R0.>.[JG90<6_2=WN02
M$QJ/)=LM+\O)J+Q- 9:T==RT9IG#C(?'Q*/1/C9=P3/Q%&DJ] ,XS!-OAVLS
M=\%!1G (8K9T2>90+#E_J@9/YYBKZ5WC'[)RY9&G&38@",G(1QGK(4(:?*W^
M^$$6DQ;>2$Z+RG HH%E(?PCZ0B)>]A<(8XF&$F?O/SR!T,#[Q"WZ2E*-*,>_
M0?-GNF)XEU9&6MH0E)U,+%XZKJ2*BX# U=7,T(21'X*$CQG)D@;HI2(VT*51
MG^>&AY&FO:;W#\;5MT5Y<OEH>4S1BDZOA(><7%;#BEKKO(45X2[J[QQ&DO$+
MEO V=WE"*D<!_US8((M3HT]Q<V^EYT$1&NAB^>*5BR(\V>BAB(-2:^?31X-4
MLP+;9E8.;KB+D8."S2UL..3.!OX,/C#;36((G]L'PVEB$=(* DJ/2CV>KQJ=
MB1:B+D8N!P@TW.RZ]6>W,2MB0EP1V4;+2C.3EII<._96!0$6Y? O99+H)><P
M.G4.XP7D,)86*7_@'*G#/F7^91[#/P>%0'==,;L+2M:!?^>].A7 4C[XRK'L
MVFY;SJ&T OZT,YO=NF=U+!^-.WE9/NBZ7-!KZY FV#!+'<4-L&OD24QVAJ&[
M8D5(5 2K&(-]+@(B[X=H-ESS8IJ%ZJ*9LH%V3_1RI^ AJ!7>,)S%YHU9$,29
MEE,I%E%6@'?C!B\61V63B>-!QK"!_,H!6.SDQ()/-./VQ.C+O%Q#N5-6.8[N
M);.PM5/NFCX]5& #>%Y^F,!^FTV&""JB ^<CA\H5FE,Q]>;YN:&TD,;6LNF1
M4XCYA-1JU UK1_!KAQ1S@*MTG'MS?H9L/L'^)*IO8R^?R?!B/DV"A4RO=>^0
M@Z)^1-"%3EBB4^XQXTOA!89E4E&OI<Y<B>%L9)NN<)#2!@5&=)]()D1DM_-2
MHEMW;&/F#QAF+)LY"I-TNA[EQ!J)EK(!!;7P6S;*=B\*""(U)K612FZ]X*PL
MXC781;$E\:69<K2\:J<845M/4 M-(&PW"QQU'VH<:VJZA"28S \IS>]^+)<J
MKO/ +8\L(*PC8;66]Z6O@\"^82_1"E5B6_$17F9K%@Z?@;'*)JM8D*KU"^Q2
MQ!G(4>)GPP:EG9-PXGLC'Q2J%R!#1:94!CZE1*>OBXE#V(9W<:+T-?=3D<*8
M4HN_K!['>8=&,0"[%J6#-L\H_$J;X0_O53;&3M+R;JI\O-O\KUV6)!ZJQJU&
MR-"^-RSAI&12R66;]RCR:6G]LB42EJR6*':NIY8E6 ^E+*#\&[FU/KE01^73
MZ83',8O4?@;V(R;G=1N"!Y _7\%&1/H9*BJC#D,V/B>WE&=!T.6+5>S4N5_1
M)F"GSP[I[Y*JIR_SP@A!+D691FZ6,IE-03&)3&P>7N9Q.&7\2MR6U4[/$;S"
MQ.Y"VQ0,V.E407$X_BWN>=X]T:9HZ9(4(7-["/CHV;I#<'_1J6H,D<(UZ2B4
M3IXBL+F=IGE7CGS8RM+T.F#M2VF>2.%#YI,-89X<ZTP[=\, +8/R7;1])7*(
M],K+NAQ8R P#';&>%:;TN 9%D :8Z_*CD T3U5P(=:"M5V;36_X+K'8W1K?/
M'@/J(P;X:?57^C0*:TV3C$\,W@G]5AW/XA8+XGHF4T$8<?Q."#,E;N%V^"8>
M10]\R?F%;IU?^";S"V4B,R5!5"B&5OI:H-4+.W9H [+D(@N ,7D:H"D:&WZ"
M8F5(M15.Y:(MV$;E@FT#,,Q@5Z,7BO&[C=A@B^YW0_7UL[J7%%$%#BC6MSOB
M#(L0/>6 A79SHUDN6X-,9VX13<K/NH+B?6R3]=&\'G,)\UTP#16 &E^WV":(
M]0=?K?P'Q]LM]@Y2:.I""+Q9,+NF=N4%M1*@[O'87U+B"P>;/W?K&&=ZR+IE
M%*%\>->'E=L.3_D]IB$3'$<UWQ R'JW H51EL+E-_3O)4L''X0IP2X:)_Z74
MC"Q%J0GO2S4M^;924CRB<+)N9[#"_,,S<NQ<!BP8?HX--Y\I&[QC> OLJL2B
MV;+9=[AVNRHFO^: O.5<Q2-#!;L-X\"5>?G+IS9LTPZ;^4HMNFRP?W,#'$UM
M^?.S(\KA4ZLU^F=VQU@^^C?GC9R>04!^P5=*)0]5!3 %LD9JN(SSI)V#W6'3
M?=SN+A\J==7@(V%WDQJMH$+ +W 7,=M!+!Q&TU@@8L3E0AOP?H-;>OO$5$:&
M4M7!$4H]SH$;S[EKZ^21ZKLJRZJQ2[BYC0* G4UOED9I3AR9EL0:-J\S-&5;
M[*1;DJ+/0:Z0$"E\HM-XZFP<MQ6+M''W2MWSS^A"E#5,G(^@LX(EQC.SEV&P
MH'T.&(=\<A:,T_8WU3O9MQCE(GD<J\]MV:YDX2S>5&S/@DJB/4I"5@;P<YI%
M23O=C,%F?PI]REDN:Z-691% X(4N:AA6%,9,V)(+?>" 9AF5L=F[0.-'*=NG
MT1WP*07V-V#5CG:YUS"'%,:J76?TH'9?;#)$^AJ%9LF9Y0S3-( K126P3SV5
M=B6:/"@209K-2L=:30W@JE*,@"0@^/[P*EH+R8 Z.3TUN0Z_U8:E4[*GWQF!
MEW@CY(YA!BK/=5&D6DV9CF@T<:9"?'^I183U\JXI(^T^*$LG2!5CF-BCC4B>
MP:\FIEM+BB::,(]M[IH?TA.8PTFX^4!50QW;4?W]SD?NR^K]YS=>DGT:%3?+
MA7<4Z+RPF4T:YEAV-@2E26/L:1E8G6S(.5"VQ$VQ7Y<>Z7.';?\E_JPJ16\#
M/U$U7WDJ3ZS)AHDJ5\2*-C\<JWU?W#:)AJZ@0P$,8E[YO$1' B P5",Y$TFA
M\-8P0"&V,P(IM1+ 95%%_8- I/S<">3&&,G&F2$^Z30M,F$_3J)@62+8@+BZ
MV?5.INX91NX9-BS?417RV"W8"KQ8AK4O].(E4X'QY3.\L*:,),5GH_NK^FZ5
M/M?(@&BN&)"FRV+'Z<:J?*I626TJE7>3<"IW<;[4(5&AR5)9*$6'"EF A&&I
MO@B#I!H-4^9<2D,T=AB4PA@!F:;<Z&YRISH]<@R6<7_NP>'F#4-R5?BYYNXB
M_BS;@&297=]OP4%6V+73!+55#G8&RD.EXU<(\N#W7J@.DPSS15N4E##,S)VG
M<(#!N]B6(=(IKF2Q$)&:H[;3MM(14YHP5_!LRN^#G;<",+G:?])PAVQJTF@S
M3PLLMYM0 X'5+1LF#56()REK6?O(NOO=:BE-F[95>R%O_1]M7N@$9^-(BRAP
M"LSJQ<V<6S\RNZM&\T5G+7IUUF)+LQ;+*?Y;4/PZ=L?"2NOUU%&P5=WG&Y4:
MRY@]B%[*!A(2*FOUFV1C(U(* 6J[#04J/[Y:ACH.J(G'#7!A0CY#J>Y$"X)3
MTJS@S!IG6S4EG?.UL!AG*=K'XM8%8]WTD:\',RIU0,5LLX/ZN)U(82/XP*"C
M'2=XE:F-^"8@?Y)V676);^@QKIPOPAE35L=;GD>E-T%EE=R]:&)S(AMH1)MJ
MOB^J/BIVQ2@6[4(F'8T2V+1[%)H(;:(QUC*LV?Q<FMR ZD0(%\57#7D:?8BR
M_2:.L6]4ABB 6YIBCO82=Y',]U7- =4:IHF^/JYUXQ9LC(1ZPIW_H(@(/_X]
M&]ZX,1ZDH#@C\_;?F0\^ C5/T34NL+F48)]Z^Z"Z[X6MWP5#&EMV%: ;']!F
MTAE06&K'Y:V48HKPDKNX9[!\$(1 LNCET<Z@_X=F+OYWF"6*A21XTP^F7] [
M7G(#<V6GRHF:LRU-]%ET+LD&*T=3CAWI#11CPI((2Q8N4^,E_T$C+6?FCJCO
M$>TP/!<[F35,)(2BU9K:G&,CIT F_UKD*EXK 3XUHZ;9!%_0L?&&(65\B/D5
MD]L'(FM*8V9Z/9:N2L916%L+@J*?JTTZ_3I3'G%"!\$O-=1C??F9 A/!$VMR
MA$Q@.2I.L&QPT0V@V>=Q1\/>PCN"RD656BKG'S6*(J>AKB;"3S"D; 2F=4<+
M;#<*N2E=22YUGC[EXAZ3X4HY!*;G$]HACD?%E"K;R51@ (3VS6:.LC$5=W ,
MSG)D@+K",:)X")D8D6*V58D&",G;25^Y.<Y,OO_0!L(AX:X5<5#.6R*M7//B
MJ(I_YFO@90\N%_(R^Z;F0U_*R@R2-.:XKP:(6[MO8L&<+V985L0S#=DK=0('
M%"FT0C%65AH8)5!U3 $F/ ?<.(OCV?Q]6HT_R/V2DCCT2W:"%]V>/N$A[+HB
M/5XKUL6[/+]O_23T.Y,0QP$5ZQNS4Q=]E<I7ELW^5SM[3QP8Y,X%)X$"(?P[
M"Z?VI$!G8%.)G*4TP3:)&(QP6")F6%38:B!31ME,M)RCE&D*'A[ICE? "#QT
MM81V5?L_>/4X4?O P7NYG>5H-'1Y*@Z'GXJ=IP&;:&1-,9C[H-E@%$A8D82"
M^D.O%)Z%_TZFJ3*]V<XB?".:8K[3ID8+%#*?+<>C:@@82E*), 75\^ ^5QP
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M24F+L1RY<S3,&F+-[@B/E "^3'&,L&_Z;N>&/BGZK>EVXW3;>Q%TNT2@'^%
M(_"BXR_I:S'LU$ +'L:!T\H]E))&$.>HV:)CO+U2*SR0,)-"=-O1U;,SN+N*
MIUI-E^N-1FXJ&^(CJ1Y6RBU=!21=K' T@YGPP!7Z?B3K)Q<:>\H,=ME;IMKX
MQ-X54R]FO;K]"HCN5&5Q>7L6AXB:ZEORSKE)!)>X6"])48"\DV*>2,/C[9GD
M>M 3O;+UIH3><GHASE\40_G@UV9FO;5._&6E@'FIH*]N#?K:'.BK5B E"F3_
MI2@02VGDY2(& ^PTRVM3$<NM$I3#;;O.VDNG ,'^KA=.L-8/A/P8[Q4,I&L9
M%9,ZMR-G)F'$^"0(3!E\F CXH] ,)9?=00=<L$V9!'6*>'_7US#JS2HMX=AK
M>[_!\K\?R'OZMBJC>:U.0K,R?,3-.4V7"%H<-\MGZ+6^#ZQ<FY>FJ2\[?.+L
MI8_S]O!7[>-NM_;Z:NMYW<+OX*4(OX6M9S+7TKN8QR5);PXNZ;&-+R469X7X
M5'C:&)FV^$3HEM=K>"#:^F"UMMLD*3$$*<8S/JRA#-XX"KQ^EF*A5(KCE#P>
M81>$=Z9H11;;4+.>TD"WD[$6.8P'&0M96.XH3+ _]-A/L:PG'#OC0BC-"*N?
MP#/(-<:J-'YG#.>FKC5J1VG-,UB<4N,K6)R1GTLE3<MFH<LA67)(7K^6 AN7
M H??HA1(,\IN+!H6&H_S[# ($M;:=N<,HQ*QQ2BU&J'0D3^0C(GT^;!T**>W
M99 <*5RQ7\@T&3K9E1E,1!V@L(-I,,"J,?T2VU!+>QZE\<BG1I-EA65V\9+"
M7U1:/^)1FSI6.,NR]O\RSWJ:Q&/*;"NO/">*<ODB!_7@=)RW.P4V\K?0C0;]
M(?Q 81;DP.([L&U,,-#*74G.L5B@*GV,))A#0P&H54[P%9$ 5IHSMSEL,S>8
MN/ ]L&>8#-;&4Z<6'"2?[W4G3I_+TD0%YJL6*QHJV7VY20G*M-=B-LZN"M55
M@A02"DFCEC3 4K/6W*,K.3G9!*N[X\*]&W=IGU7'*]70:M&E5'28G1$Q+I ,
MNA&ZHUN14K"T9!!G\"YC 790$TC3T9(*J6GESOK(+Z,@'(@1ZHL44Q,I:1E*
M4SWO$O3BW&F;^ S2K_1"]@#V/$WTL3;ZR52J_+$;+*VTIHZ,N#]VK@LK+P2#
M?K,FAG4>J^US.K>@DU=J#5AAI()AP,M]W5(A&8K))!R:&>[)?RM4,+_C&ZW\
M]TI!)RW\@A3!(H:%M_"K49S0>:"\G&Q]N]E"O4]3%[T_MNC_\M:'>H-"=4=9
M<+"(AG#B;%(GI08V]).]>;_XD$WZ&C,QU^#AM2IJJK*S'KT')2^\<.BU[=I2
M1\N6G90]_"W-6Z'N'*XY(21:PHT%@I!0*MCD>=JTO@%1A:P8_>6'SGH(M=TJ
M+*S$EBVK,/H_?SQJ'Q^_D?]TFFW"R/7>_+@B8BGK1&/"Q6'8;K=;!\?_:OL_
M_/5$=1,@67HI *GW-&&7/KH*XN3&C\+_E3X-0_(-?3)_3D#^CR7NUO ZK<Z!
M9&QHF ,H$3,6YQ-VF+@+,E@76!7GT:#9\$[!1.O'<:H>=YWUP:9)[BJ^.C]O
M>!<7IPVGU\9/89P.0O2CY;:J.RSKC!-0K5^]$\]XV%\?C*F[YT!XAW/KMG:;
M'%17)/O=$FQGXY2*I*I]J ]Q4Z@.#W9E)'Q0T_!W0\/=9GL3)'P[G=Z]WMO[
M\N5+$TSZ)MBH>R?)X!:\Z70O&-[XR1X0H[_7/MS?[W0/]T"- \'W#O:/V\>M
M]M%AI[7GMX]?'?:Z!_]J!U][PW;S=@HKN@KH_(=F$!F0\D>+R#U[N%T)X1*%
MS:03)#=5(MYK$J-=V?&"Z\<4UAZIPEJ.]L$OW_NP';RUG6/DO_:QM_,.OIU_
M.RT%NMWNJTZW==#>WT7JYB?45$Y4WME6*N^UN@=M.+5.[_#@:*^?W XZK=9^
MY_CHX%_!U^XK(72;OD_LU-H)-T,4^5["#>=.*V,6^>_]!P76)5'?S;%!%?UW
MF?Y/,>0 C[\B:/'B='_TZM<2NB\L94FJATU\U3TZ/#HT1%_3/-%\=^MI_N"@
MT]8TW]WO;83FC[>&YCLNS=LD[;WR#%'[WQ( J5<#D#8'0,+[?<M1N?V*J-S1
MD8[*_6&UXKD.R]5AN>_,CNAMJQTQRT/LB!%19BM(<_SE?,-JI[#STIS"VCXF
MNM[?5KH^[K8[^YV#-EC'AX=[0P[^#<$TWF>BOJ;>K^5V\*D[R<8UA:V>Q^7!
MMD7LX?T%R/T:S#Q-QA1;!.KEL*(Q=CVBS>-]>'>@S3I2P51Y\.*H\H"ITDC5
MI]/804UCZZ.QWO;&?!6-=3OPS[W!PR!Z!<K\7Q(1L(PS ;PK$,25*<"J+E;O
ME+0Z<BK4&0?>HUDD,F5D82. 4S!1E/GC?)"@W7KU:ZE2[[KD^J285TW:3-I;
M&^BM$I\]L53?23L<)3POD^#5NXQH\!]^0@BG51JDM?1\)(GM-]L_KC/M^]%
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M73,1_#GGE-K'WJE8)3THI)(DE%_+K/J'OUY:2H55TK^S,"%=F"K59^:$D<:
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MY/L2*'@TW"H/C.U?)=/RA!<V],T^WL&GDU0U<?#U2_FZ>ST&P+Q1ZPXN(BY
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M@7=E6XYD/W9M%T]UD6;DVD^QA_LY9MOJ]HL_[*^2H+KCV* 2C&5NA4*" L#
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M8W&$4)!]!RM)E=>8M1KM2^LW9U\>%:!BO])C9L:S4I=#/QHIRH:+JEDQ*F3
MGVX $^P3WH!*]8I)E_)S_3,^DL@S3MW->G'/X,%(M:XY%&B;5C$@JZ8T=Q?4
M\KA&0EI1XFF'!Z,.)B:1%1'GG=X\(W:A<-_)E/ #OC%+"WJGGG>O_&4=7434
M/3;]3FO>KXO*X9-6/;^"FISUZ.M=SF&;\+CAB_!1GG,6>H<>/Q.OSYXMN :,
MOGF_\:*RSW&1FK2?AI5!XD]%0Y7N7'S.BV?45\9UDWJRW0&>N A*\;X^G:QU
MSRX&"=0RGR<6=7(,BO-F++=)*?DJ(3!3'D6.J$[S,A7UM4DC$Z*^=!-=4[6R
M2ISQ9G+*Z\;D%*P_G?4ZR<N.*,JS_#1AP!K";B]&KV6%64:C PEFM[.28&<
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MCK[QC.%^[@@1!VBBZRJ2<^/EC19U%?29VU#9Y"9%6&8^,328;=W65V[PR#W
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M]A 'S6?RAJ[EB)3T9B$;Z3J\46>A&Q^;" PB(NK6T%A98+6Y:I?P*6N7=LH
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MD9X%2>+1DI/TXC?K;]'3OTEFHHR)^?Y]6*9W&/@<P'GG\N::\+G8AI0U<_C
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M</(S?W7PR=B0#%2"+J0OKK*<;TXA(CT"8%6!4V!^2B2?L('<MZ,S'6PU'*,
MI\,40E,6&UKECQ)ZFPJ]03C*RN98<CZ104DEZ@3E\]Z;D^;G'>&D'-]Y\6.U
M\TC"O^;EECL:MQ8,7(XX!Q+-V=($!Y&3<-995DS(Z[+=?7(A34H37-C4VP)\
M#L0$U)F_%V1(F..1>(9ZR>\5W6.U65FV,UE_>=^'][[/[!5-;4!X>+.[8F5
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M&+H7NJ6!YNITWFY[Q/T(P"G(04N_G?.Y;ZM%''8YP?!@L.B),G7C7'4I2OF
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MG09G53Z"_5QYXI9R QTP7C9=G B_9^W5 7 9:\%@R(3IN??3+A"WG&;L73N
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MZ5DITRK ;.S@5EQ@J*WO?S6*/QOQRRC^:J\$:N6)R?\<&D0!]2>%BF$A((\
MD%<(Q,<OQL,OQBO$P2,HQL\CP?T7SK_3 86!H% 7*1W]7R)3D OLXD)K"(%Y
M_HQ102X^+KX_:/F-]R]J-*%@1SN_OS&%3UB,3^2/IOR!\Z\Z4*D+; .W^6]I
M^2/O'_2@@E4,Y0&PERT$)B6+<LT#&SBM@J,GW-'%!0*CY1/DXJ%E-7)T T-]
M/-DDN/_$_F=S-#7%%*"V7C\SC:J"U*_Y%>4X1_ _PT0,+" J\( 7;/,SI?(
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MTC(PL["QL]VG ?( 67F86-E8?RI!P\;&QL7!O8N+>Y>5G)2<]7],5V\!1#B
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MYFK0LU.KX&[RU2NK:$(#QJ;Q'GK[)^%!")?N?6BX.4]=";@"E&M7<C#H(_I
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MBXD^"-"6'&\,FHSIE;0NRP0U\'?K16!,U>[YJ!IV4UWHW<M49B'QT:^E8L*
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M+9\&OA(<UAK *%NV(IV><0SOQJ5L^YIGY6Z/\58-KKK5U:GT,-"U6Q)+,A3
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M-$DHTGOOU=6_=^_>O<_=?7;WXWZ9WYEW/LV<>7YGSKSO3)'>5$"_8X_H'DW
M")8N3O$\R@D?\4TR%99,%C!]@O'98HBIAEMUL:_IXGX2=&\LC=!KS@],T4I,
M,J-P(AKYT UW_:;8U,2(=6V?!X(TZ_(_":I2[3\6E'^9O7%( KB-/!3*=='R
MJ'CT_;O%+LO@UP03B=%4JW+H$(]PXJ01A<QD5/#]#8LCUP:=@M *+?J$%ZU7
M[\2'Q:9XLJ<[;VZ4%#V.K][!+HFE?4&\=S+]%JXSEG9/3EOWT6D\%]UA?B3
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M#U=N;<9_$]@DC9#O06P ;(TW;.3E7>BJ,]T"'^PTKDIV ^TTO\NZQ(HPHB@
M_C6M.$29IU'HJT.E5YAIJ"NJ/I=4V?+Q^<'U*Q')O:&.3EYA$ZGP>P<,'$(F
M1=@ 3'<R0O,8-P7X1DKVHK:9F<1Y#L/'RL8V %9Y/?]PGXQQA:+8D5W:M'-4
MBQ<D\F-Y@>^6@-$G26_*TDIQ5,B$&]'X*+;H/9N6U;.4RMN4CS)-_T$U_@5D
M^)=EZU=I0>=L/PDTH)&>(T07%K_1:VC>?U8Y>B*_5W)]C,J5AA$!U_"C0/H<
MLTQ)1J:4&(+YTK<#1&ZR!)43EQ1-;/[Q4)]"&#TJ-^<K(9OMQ',,C1,@JTPN
M?0:\EW&="_T]^W)*+ @IH:#"M#%>2+D6)$E=H:,QJTN/,QZ7,+V\<ELHHOT_
M%)F,'E<O]OQ9W6EF;<4OW0/K9-;5$KUF^B-]R?]"^B#;30TC+YVLELMV7/*4
M^K8ZG)J$KS$&^N@H>9^4^F?ZI+@/>AD8X&<CU.43D^D_J6&8U(&\K*PV$ZUH
M\4;'<;KWV(JG-VSS N7?@RX^29(.9AX60XY@N*0-S5._"8Q=X],D#EZ5RMM3
MY]HF%N$"D@M!R[/R=-[,=BM;AD UG=,T+N<D2Y'AC;[G& [G/;5)2=AEVM12
M\L3433FSC[(%):[9MLWC%,)/5.^%4I6+XD:[0JYO=NE73[\'Q.:=P$501CLT
M(ZL_"21II.J!S>QH'O^@% .\K<S%7Q+HTT\GL&?S8D7:Z@5E4<Q\)R>1P<#]
MF'+4970 CA2O'8I2KW"8/"N9BPH9]7F=[7#@G0 61$5O7X^^@,GHK1FL%$U%
M--5JL.TPI7U8<O@!-*&+X6,7GA\J!<<#P'Y<@KS0DF9+6#F*93FKR$E=>L*O
M&#Z=K88-\!6/"&5*5Y>N[%:IOMUWKM-3O6&MG;,_HKZ'<[2'6C.GRRO/A=!Z
M29:^T"J!WB9(%)[99?.8@^^XUUI6=TRW:\^L"7(\(,SB*M1V!MJM8T=W($^^
M3>02I,W,A]B-H'>-FBK.V343N+2!-R#ZG:SKY)B$.0T3X?BA8?6C3K?%L"O*
MQG*-)FD*8+R*<O&]N(X;\[6KO5R!B%R3$4-0W7QM Z!TMO"M)&-?+R?QPA/#
M-KIU$7AT8"";.+(W,9MW,^DN9M74D6J/]FM13_*CHO?E25CS&>NNW0H_T<-L
M8-.5GNR2X''')F5#5R=KQ%/I.>C,&)K<<3E/O@Q9^W#WL0B1+Z[V16?]46D9
M4H.XVL@@;30T*C1$Q$<A2SUAZ&X'_T\"37AF5Q":K/NB_(M0V69Z3AO'J>K*
MN/!IUTAH!J%9<IAU/&95@<V[BA[%95L<7UR8MRL=(SXR()6"7/&&!VN:O:(M
M=U6]+ >IM)B*U7,<_CC4)9KU?0< 7J$1T9%332P%)Q-O0#&T(;02B].NJ&5F
M"J][1J';T^ZS%8PN\8P:*Q,80:9G_B?C\O0O4AA\9S7JB@IFTF5R$%)=EQ10
MMVX3YK5-/0_RR^(1<!*B$.&(B!AM9'"QIYC-58^^X#ZM4Q=[0+9U57J[CA\*
M@" NKSE5;[T'M)0J122G2AS#G0Y$SND>XDXXCGU?<E_LG(.:_EV1BRL[Z(?F
M^]2P+<="OMF-]7P9$Q,7O"O8UM=J+MUK%F$/-LAFD.9Z>&?W+MZE1I-GE3=N
MBR=$I]C,NXHZ/%_EC8F3BUS>#C0\#!ZV!+[!%6T\JFFA ;MAQJ0B=Z365MF/
M1<4J%2JFJN]\_E0]JG(SU/YIG(D#3NR/*ZW+Z=C4T-810;*N+\U=-(S])$"D
MW;O1V:_*+U(9)GUP.3EWXSAHSS"7\\AY_V':!+(Y(]2M.0X@9=N98'Y04EL8
M;J=.N$ I*Q0,[34SLZFV*'DCFE,<Z_Y-2:)@6D(8P8<64ODP$TSU[%U@P/C@
M4#(?1"2^=@ DD_Q*YNX>I-3LS*S'*K:.9>J/:.8:S89;"!^ 8GX21%/;5_%#
MRY>(JE*?7%L$C<=V<]CVU &&CBM(()GYV--VNQ\HL-GN1(RUH.WZG+'^:IJ"
MEKXN]_/[UE?4[</ED\)J*)(I'J(G2X0[ EGG)+-Z]'&] 2W+3D5I.O;9*7F4
MUFV$&%-CL6[B28/I8'^BMNM;^@'CV#M+= #X^YN/=O8J_(J-L_&3IPNLR,P8
M.:F&T#TJ>DM'M:;C!!09SC\O@3\W>O?N3"\E<4CV1O_\[-(B9T0LGB/19&1U
M><V!0C5>X];]YL>;\:,-EQ/7CZIKMWZP2?//Y6J0*+@YQRAPOM2#ON#L?3QZ
MD$^:=<!V^FR#O3-<<N_NTRLF&A>9U51&\APCMG$>_FI&IIGEW="W^F)_X[8I
M__ BWZXH6-JP+:Q18F?+Z##;?/J=T%ZL>&5>+18$TB"6I*XW[6,;^/'(%!\U
M<A"@,62.H'"NFNEE7N-2:8AV*<,B0@,PR4:&([(G8K*30G&A2,-*91F3C]MH
M(7);ZR> :_K&:.S5$R"3K;>$),_S63]X?-D*HWL"J532)#D'4#Z=O*F >NM!
MGD8:P G5JVW^<%3-4*C\4'JGO<M+)\F0=Y1&-YB"V,=>* :R>=3K[4^5VCX"
MDI^)<NAR 15\3PJ7 ^HN9G+Z@ B6EHKJS,103+9Z9WD%;EY)NT;*W0R>IO^-
MX/Z"YK\L)6A/,#+ORC^FW!A,Y(*\!G4YQ .2E0*U.!9EGKX)&6(2ARR9DF\D
M?EET=+XNAW9$%<S9V:Y"/<'Q^<A#!,+/PIS'A=A73!AP ED'ZRI1T*E!QH*$
MFM[5;RTH?B6A-O&>QKP('Y7]2C"4X-Y-6+E\:DF_5^O>=P5')>K8V:^[Z7@M
M)8K-W=)7,U=OX-?"SW>V+T2XBBLX6B.O4[=DYQQ-)N/,;71[!-H\7VW])-AQ
MAZ>,P$<8HU7,38]S ?UN' (+"9\5R2R7>XXT1^A#@E&[_6\M7_[I^PD$98E-
M"@*I_BG"_S\*//D3.,K-+"[TLU7@V979)0PA=-2A2UN>R[6K-N.K';GOH9G!
MPQ%8!!Q/1Q>MK=TJ;;G?:B"Q=2U\=N&.@$!63E[,-19F-AB% U$<R$PRZC9N
M;K??JIN:GN337\>#FRRHXD$IF*&$!Z3@:UF4579)T)2OQ@L"T83(0FUJ-]WW
MGJ[^D[S[A.LF7JS\6*\$5]0X;?]AJ/%Y9'W&9Z1B) "&BL%?"PU&R'!S2D:W
MFMC8L!4BWW&K-CJW:$-*Q8U']4G[N7HB\"52RR)>U/K8^Q[70ED ]*NBJ/$.
MNEIB86]<K[+/ZT$+Z+/\J"BK#4P7<F;H_<0A>XZ0C2>>.([&,Y2-! 8LAX@0
MO^ZGU8A!;I*7(9/J KGPL5F0H0#%[KPL"I2>"FU8_^1.Q/<'[87\2SP):)*[
MGTU*E)P;OUK7#:KHW8MESH0GJ0+>P"=\.+/7;,1N*M($?'"C+Y%J\RH6F_*T
M#W+W6.OZG>WPF5L>DYB*KH N2ICS<[V;N[RS%842%D3&>&CPU#*9XCN2)GW?
M=GAD1WS*P+L8:]Q<P90&4F'A%?7*1#-\!6&$?@;.G)JMVTOBT'O#2Z*U$>"%
M]3 7Q2C*-*R/$_%3\+)5R*0KQ:RQ+UD^4D/8S<$W.AE:5-WIB,/<.ED ]/G(
MPFOQ_+=J]#JT-">_6Q.6L+^&(-=@(72UDKWF61O@G/B*+1U>ZA,A\-%'K*5)
M")::#B$SF\&_.+6'T%HF5%CR2AZXLL+?4'#&PKT\6,QZ?RA)ZZ/1/MTSN? 8
M\&9'S83#I[*L)$1.PP!F<HQRP2LR&N7-@U(/@8W;I=1,6!?G(BG2I5U)K4M<
M84P$E"K!IZJPYH<:;@R*!]"L1OQ"5NV#\:=Q3ZM[;D6&:;-T5+)+V]:A(<KJ
MW/FQW;[/I@A:VPM%4=-\-%K!;T4\]9<;.#*M0S#3-V*5E+QLG<-KTXDT=CU8
MTH)7S#(:1_OZ?BP$0K^G)]9T<4#39#F'9<GS?]/*C8]%8L:=LZJ'PD7V!]MN
MSH]*D_>=07.:\+:?RF+;E?G>C\2KT?C)UC0N)J"W?TU9XJ\IYQ2<<2,58V!;
MLMDO7S%.F'-BX[O0J%>N$O.B4>_^6H[=O)#RUJXL)FL6%E(W8\9 >M0.=<R"
M&H6*>RQ[G9FJ/N^;I(E#[NRU',^.^S,\2]0?26QUR[6%:(\^\OW>'<M_VQVC
M7J/O/D,7:_9AS4SSG#O2SVTK7A5&R';S?&Y5597[OW@,TAZ=ZVC'TIU^@]LS
M0WVFXWQ)K2;)M2L_";*'U8:[JCX<T2OM(])G\RX3]6F%%^'+9()!*Y(@_:&8
MVW<6J,4[X<M'E*NMEK3JF/ ,NE[*Z#EB'Z0H[=V?!(4,XG[XV=F,0@:EHEE5
M2(_L6Y.#A^B#YQJGGZQ/FWE4>YA4_I=]M:MQGR\L:>JRRO$..@<B/,[<==3B
M[>+:,FP$9)\ZJ-U6(+NI"]1>%+];@FF!9OV;_U^A8.I2';4;QZ,_Z<??EZ&W
MB7Z._QM02P,$%     @  :')7 W47*<P?@  )0(! !$   !G,3$Q,#8Y9S P
M83 S+FIP9^R\!UB3V;8_'+N"#1!0BB!52J@)$.JH :1+"37 0$@@=))0!9FQ
M( F"4D()"$I/:(*T@(!*D2(@)2!-!.D( H("4CYP=,:9T?.=<^^Y_WOO<UG/
MHT_8>Z_UVZONM=^\L/ER\S7@N*::AAI@UR[ GO$]XP# Y@SCV4L.;C@WK(.;
M.[>TF 1 [KR&SMZ]@"UBI ?LT [MT [MT [MT [MT [MT [MT [MT [MT/\9
MVASZ2<X!AW.7%Q=WQ8K9V+G9(L40;B[B/C;NXI)B$N( 114?=QN$$Q+';8NT
M1[LJ\;PKK^+A1MLI\9B =21TW"\@'= 7_3!(0S]=(X2?$P)BQZ.B3*?H(^_C
MXNZ"Q-EP^[@XNV+E?91X/@N7W_J\/2S.P_UY"<Y)B>?<]@2WJ<XE[@MN&"2W
MC)@$$"$A(<4M"Q&3E &!Y.1$N:4DI"3$)63%)26 4E+R$C+R8&GN+\2C3+?U
MOR+&#B5O %7[ K?UDQ+/%[V\O;W%O*7%W##VXI(0"$1<0DI<2@JXM0*(]77%
MV?@ 7;&\OPGY*@>*Q"(P:'<<VLV5>_MG&ULW3YP2#P\=]S?T&Y =XG<<=T^,
M\V<4.X0XTAGI@G3%8;=L*"G^/;XMU7]G_*[AO\?D_HU6?V+:FMABDOX1DH[.
M/\9R<?DN)Q:GZH7[QYQ8(U]WI+@!$NOFB4$@5;VV=.;]OB@#Y _V_GU16\N_
M*\C]ZU/-'QCBZ_1O-E3^0X*B'4(>Y89QL<$IHUUL[)'B2'<L2E'\C]$_+T5@
MD#8X-XSRG[;P.3@,D1Y_'OTZX8Q6QF!D)*1!LA!%\2\#?V87_SO_YQW\'6Q[
M"S@TSAGYG0V<<\;]: /;1I)WMG&U5^+Q =HA43:>SC@>91TT N.&=4/AN$W<
M,';<0.Y+&#=') +'?<$&@[9U<\-N#1D"0=S6!M;JW%",#0IG+6;GAO#Y1UK\
M>1.?M?CK?A6W(D_^PK9J2.C6/^6M')8!2H" DC)&4M+R$M+RDC(B$F!Y:0E%
M\;^L_)X,-XR1FYNS\B7#SYD)%K-S=N8V1F*PVSD*%I,2D_I&RI>U?Q&CXV:'
M1OE^9RO2LEOEY-NM?+/RKS*V2I>=#<[FGY+R[=IOY&PEJ_R6!^P\$4B,\KDM
MU]C:X+BA:"P.[>R,Q'!+@<4DN,^:H%WMW+RQ0HKB?UK^Y^WHZ,A#W1">VY5&
M ZK\6WW=<AS:[H\TD9>RL[.5!8.10!LPR@X(D0*!@;82$@B@'<)6"H($V]K9
M@:4_[_?/POX&I.&*Q=FX(I!;<UL#8N@MD*WX MO)V<H 05+26_])@*2 <K9V
M8"!*"@F6 D/L;&6D?Q?]#?O?1%_<TMT-X_NOY=KGPNQN@\$BM^N&$L_7PL'S
M-X9MGL^E3-X&L5W2E1%NKEY(# YIIRC^I_$?,V[AV&R=6EOAIHS"N+EPV[B[
M.Z,1-MM<V_[AQKG]:<C+U>Y+3?K=#U^AOI'T-\6^FV[_%HVQ-E[_@K;HO[M:
M!B$M*6EK*PF4E9*3!-K:;461G,S6"2HMB92VDX,@Y% 0B:_RT=]S]5\QO!V0
MKG]-(!EYR=\3Z)M5/Q:R7=.\;3#(<_9;0:O\6QOQQ]=>4E)_3J3O\?Q8-L)A
MJXPB[93%OS)^'?C?Y#8P$B2)E 6!@%)@61301AHD#;2QD4,!$6#;K;8* D&@
M9,#_:;=]6_=VW/9OKR_?*2;;]>;;)N:_L[38(3'H?R5*O]GE[W;B_M^F]'\Z
M,?^YHW,G,?\R^M?>^4?]PY?&0@^#WKJRVCA_T]=X>FY97PZ$DI8%@6V $DAI
M,! D#48 (38@62!25@XL#9( RTJ#(%^%?T?&WYNPWW) ;3N*_[F@4OQ\(?K/
ME.R_L']/NMU_2.V_\7Y/M-M_RK(_E/%WWWYCVC_UT+_WMQ?<G-TP6PT[4AFD
M*/Z]X:\7>_&_W.Q_>VP@_N6Y@3+=%N+79Q;?"^-_/^V [(#L@.R [(#L@.R
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M-"F^-VJZDUCZ2=TU+P,TUW>_N*N?N>&<NJ%!C@[YL.X5J]1%3LB#G#H2C3\
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M32%X7A[:EG>CA=C2S/K$C-5>P"F\[9D)X:TT,^5JK4*FC:>H806Z/]N$VMR
M;3!4ALKYW&:^I'=3R+G8@1(1?<BG,R*'O<X^.6?4<31&\$Y//)/-]$Q!A*B>
M'@9I*6T@H_53_9H CUWPJ!_E?13!J0[%YMG7PG.ETMK4<3BVFJTWI?Q%&S*]
MJP(1B@UG8*UKA[4F/ NHBRD[?$$1!(LP;.^H0" 5];"(!FGHG+Z.5IA(:D9E
M6Y=-.0Z4;S"1!9OG/;T$-;($[NM--/33ZCJ<6RHSZI'ZB-\BG.7BO;#3_);1
MM 83E>P*_3'!TZ?:C'#//7U'I3,#./-.]5EE.Y_H%I L$FU@HS7$C4];B]D%
M'NKC#!*3C4^SD/*D/\6G25Y?:EM(]N5LN:[".HS.^VA, [.<3'&4DI$%M4&U
M'S:!&P+V1K*]Z149"!5R0%/.D(D,14<OFW=1,S-SF@2%\P2CLO7AVIH#C0("
M<@N1[7U3;QZ#F&6T[E;V6)BO&/N1I^1BJ.S"$Q-4B!<JWI^ F7=1='NRN& Y
M6]QW8XQ5[%;ADI#(0$+H**R7*BM:!6$K'+:PU.4@-.%M<SS!RDY[HQQHX<RM
M)@I@OY%$Z,N@NU.C/[N< !73:1*A,#.!G#!EV3I5;6+6I)X:5+6,G,752[-,
MIF _7N^^<4L=4]SU1,OU+MH\DS+^=-3I[G N3;6O*3P#+UVS+-.$:>O(RH"Y
MJ%U%42NAT'$KM96++2HUN-*P-YRJ'(9J=<G)J9G!C_#/LYYKE1ZGA)XI?^(>
MRJ4:R9%+9#"MA?IEB-4T:^E(ZTB;,.: :V&JBG4<RLSC88EO=%#I/4<J*#70
MK38V<BTQT8Y;78O!I&S<EYR-31@EZF,Q8^5L^$]AZ*+,#<AH\Y7 :#G _EL_
M ?;^\6WQA3O?7&E"6QMC5/.>ILI]^2KP>.GR3S5'"@W,8Z?!B54Z_'-9Z"Y5
M5W/%. AD$]! YT'/\Q$O$;J1&"J6;YT2G:0E-GY1GU5+_)WP^S,WIK"WCR;I
M&4&U[0^O,=(\<,M74ZB3@VO/^OO[>QHW 0(HY2/Y2KV3(>B9CW0-CF=1SJ1+
M%S]"XGG\TB]FQ0CS)#A+!L]$"PP,V<%N!V41AF'ZE)$V&*R]%S^ZP/'\F._5
M)WBR*]@Y^J*M!H,%(P\5EX(U)!HVCO XM-AS:;5AA()OK:>:&D2,[^NB1AOW
M3;Y\)KN^4**!9W$944^O:74,L"NC7; PM*6>"ZCH>*4/LGQ-\UBE"\YZ".H9
M63I>+B-:)!,Q><XKJ+PTBXM]D4QJD00Q;0(PHTT;:@/QS$-9S$=<P 6D24%<
M,FHU")JK'8[I)22,F>9Q<>D(409;K@P<I7=,4KWF<7@>'';9JIF3KY6_S;(R
M\O2>"N-A-J><LH^*12^\01VR8; KUTBU1EO!+S,C%RO"<LE,U%N8;0J=;EY2
M9'@NQT@M65A<.'V@_ C!7^_F6R]2_8,!I08G1_.)+LVN9Y'F(VUP(B&D7D_5
M"LLE%!(UK+BFY;9?DO=)]P=9Q0@[:.L:G?]<P";@FMLF8"CR@SW7 5MS>I?B
MRJOSG!9#9$N@L)TCE3,EPJ>IH7 UWU;+D]+A?=\.YN9B4'$&DX*%&D^D1[^R
M\@]9I(VO2T^G>ZCTGOM5A.O<DXHQGSCV5.<%AZP.)>9A4N;(:@?OJZ-Y)>S3
M>8NR?F3'28,>Q5MA)B+A87/Z('T3U,6L:5X9N);&A6NN+'C;NS1FQHJ9R_H@
M!A:0ZP!U(4/RYJYA.F<E$VQT@5"J"^QP5/;%<&;]%N.1+%)Z\W4=:FS2(LFU
M@^GTE78G#L^HEU(5+]$%_$^*%O)G;["&7FR767"8:5*LS&Z5A!<QN6,O3D^/
M>/:(,# (,_O,' 5BFCE+1-^OC8U&YT9T7TO++M7RO.^BBDUH<-&].(8U!ADY
M$3'-$!,Q_S"7#WWG JLC7P%+V >TR#1<Q+2T51E0^P,R2=[7]_FP8):*CBTB
MA6$A]Z=+WNK5+5DC@'W;J227-.=[=1,P'>A\'?+-VP+$P+MB(=:Y51N?+ORR
M/]=]*YL.I&]P?MH$N*RAQ+LO)+J84]@UL*GD<&:SP\_#ZU_!H!BQ5GUF?Z#Z
M<^ CA,RQM"J+*7'\Y0#<)<F)1AS>%L/;3Q56<!,+C"48V?+5*'*;V5WE(X31
MQ7)GN(81YETBG[1KTZ0;O$8?O'D3/ZJT,7E$AP]35_?32R(_5+698W1!^/W]
MIGS8,[>*2\::83C<$D/CB)MP"IQ ];OE4!3\?*TL:XF)%KRLMWR^UL3"B]_9
MN/&FOF2V*L:0^KS#4E# M<%K/.+T&[DT2NE0[TNA%')>9MI6J_)!))Z72*'D
M0GNIY&-ULL'B)FG9:7;9H1;1!CP\RRW6/'D0;KB;9E,0%_EJHML&YXG#X:<[
MYXBA#9B&P>GPBR62VMKJ1'(Y$WQ)[WIN-PN/RQ3><9Z_^"0H]NX3/?B(H^!'
M%O"2G5K>[7L/YH@Z8!T%ZXL#I_B=S$,2_<Q&XH^ON&P"#CZ[XC)TQVH05C<_
MS1%Z ]'>"M9^V"JZ\?"N5\V'U;?(?;1%11<F_<QEP=#<5M$/#N/1%K[U)3IF
M[[DTJ#!.N?0K'8YUK\9(YO'\J]'CYW-4M0)@YHWC 7"+P(V76#F)$@^\?VY;
M<E E2U&;_'V<&5,AD=FW[6A /,.0PI'62J]@-RWC@>PPK]I:^^>9--4F=$-U
M:7X4*_O5KL<%ETQR#>OJQC+[:?XG8$U$_U15YC7UZ\TX6P%[Z:B-/BU]_LK1
M_:(U7B&W&'GE"F=GP6][*67R\"3:T@G2PEL!3+][ ">_9B]9C,B,0:8,'AS"
MLE%70":@EUD;4#")#5V'=EC!^>J(=DB.F:T2)F-KI0KDE#<!3TQO=^BLOA-Q
MQ3S/MW4^A2XT[GL3<KQ2OE+\%C;^*/H>A1P]F/W+*^.^@7;OF'*%$-1-SXGY
M!'RBGP($N];#X*;4D. C,CD#M6_ZZ?.WUP# [C_>7=G_Q^L9<:_6^$LRUN]<
M.TM'WS'7DA<'V$L! $XG[N6S\-$1G7[BOPF8V=W-+W#Y\NT+>BN#ZWT0S"9
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MV/CNSYHQ^['#=+_?'^B.UO[8>?]MY?NI^[=&%-S"FIBSL<FL?BE#Z#,!*W9
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M$&6R2-2,&!LL\QC+O0I3#Q=GL8<-2F5D_<O4A_DYJ%IO?&+$##SD<,>:T"9
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M-]4X\W6U1]$S=#.&5Y;.[5C70YK(L>N.#K87!EM;6U/ (\4DASV,0-!]-^&
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M:8^*P$9_5*AKK":5E^.P_7WY6&DJ/<#8,S=SX4J>A1[@Z <!XQ!;_I2='2J
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M.#H4I?J#_7?.T$UF:B&MG_CE8([SPTE5>H4'NH_,U-<<JK7-2H@Y(8HF52G
M(MH7/%/K/6$.0DMI89455I>">Q)7,X^$. 2S/-MJ;8W4@3(>II*A?>:&.A*&
MZW0GZ-$'P,9#I-FWM>;&C%=&DZ9,5?@Z^/X=N[=RR[9=SGPBP_*U4Z^VH+X
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M=#!P\ %P7E5)10E 1 0X/G-\!@ XP-/7W+*#N\)=[.!.3,)  8"X@HHZ,3&
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M)3U]FI22_-R9\U24U-14E)<OTS*P,=+2L=!?OLS$R\3"SL'%S47#R"? QRG
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M^1=6(4%XF,])Z]0'LH?",V%%[[()TD./F[[AV]('M0RX?&8EV!5J,O31:B/
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M$0,^9W:E'@;?QWA-\\TG9=<O&K&< M1"_Y$6$2#HL''^WQ UX/CM_Q'#A.E
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MFF9^X4E:7-6B*L5'M/(],^U6B1Y\L6N?B2X&S#8=PR^_/C3S/H5?6'5!_0"
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MN9:![-8!=MS>;L:EV0.ZH=G3=:%2 <N,VGB8?EI!IE8%L@/(%3" /0"4,A\
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M:R=T+UQP]U;K.=L6Q/BXDN".9+V-:;/^ 4 QM?1-11:RC7UM:=*W?I?G-:*
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M8'X .%EM_H4PW1>L=$IN-SEK1Y:P]GS1K"KX)(7FQOK:TM,>JR=,8[%K;F>
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M$65(GC8^\J9Q]UQ&(0U9MC'YX:J(\GI'?C<>KUP1;HZ3K%;5UX:]\R.K/N9
MW%T*J(#LSXH#$9F,Y6+YZ*<8:,?<N!NNR#DL62 &NSX<"MT9QZ*5*/>][ZM=
M[AND?5ZJ:5A37Y;*-8+B;#*S.>8M^@&I41;*((G.E$MNO.<I>V\!;83.ATGY
MA(:(:>7#MN)#.Z>@_F<P&Z;/-*\-7][HS6S0 MJ_+3'CWU)-O\O]@HYCUCP@
MMXTJE">9*Y_N\[JAU;(-!$!T_#AQI& &(+;2VI_MO( F+\*.<'7F_.F7+ E)
M@+M,IX@/ *ZD3!2 .]^_X5QUYQHRFI;UU*2JX;(D5 ^E^4F%)5\,*QRLS3OR
M>NQV9<N4M_9;YDLLH"?%Z3JBD!SW\9O>0D3,=> ]%-YVI98L@O%)5F4RF=6<
M2,#2-$89]+"K869)V _C,+"((<5(:IF]KT2-^RZ5=6R\R#!0*T>Z+*S$2]A2
MB_$_7',7AO&D8>?[[[VC'!.>AY;KVI62QJB:&8+$+$W3=8?+XH"?Q_=RX1()
M.N>&S.*J\CU,:9.L*C9,5C_ZWC>+E,.#8-SQA961XDH\B<D+8EI9&VYM$RI*
MZ;(!QWJK1%/*KS2AP(AB-QQO>3]'YX6AX4YX=3*#:%Q;>7)S>P=Q9D3/@W+W
M!FW=;22[SV:M7(R/3MGG2JZL_CG^O8<;+B[/S71[09X@%X[T5.PB?KYX%V.S
M,ZS7G<%A%NO\T&U5TI$\H.3$)*.M_G)8C..%6:]Z&ZA,TS#:Q2!6NU-NT=X.
MK_ZI(K>K&/O)9)?72#-4_+58B6A[T^@ HJC[*<Y+\:QR@2*5.4D5/KUDKM^
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M I6,\Z9:M],I2U;EVJ*3>]'>XH$V'C4RUXU3,6:[Q.69U&#0!=JKS9FCY'6
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MN#4L)A]W:=*[;#&M!,<=5V4R'A4K",]%^13D!K337)F?"U@5-;DS\'RW(.<
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M<VM\V7HE52D0O= FMG'!K4CRZ0$]7C[<%.F(1E('V>7&D=RZ2'&]"#;'%P>
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MU:K?->D]K[-:FG94I3(2F>5)Z6HS=.B7#)JJ\ AB@59D:V4G.<^RT1E?B_1
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MXJ6.QR![\<L'#+?$/%[*OHC8'%KCLU\<#,O@MTJAK+,3B!DQE6'R2>8UG38
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M^PR=@JL2F#U@4-[1PA1$6AU>@WK*GX:@-21^!OCD'M[9R!D2&2W.L+R7=ER
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MN"PGUVHXVNKR?ZWQL0A6E+ [Q4E(9.0[D4,_ERPHFYG34!]*<%DFL(@E9]B
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M@44SC)X9F,0(T\NGCO=49D'T:>Q%0&B)0$_G!9'F 7U<*5U)C ?,"DY1#GP
M]@M("!L VC_S#-U0,?:&=<>MF"SPFSP2"=W?I^/S'A^R5!L&=TESO<4_=L_G
MUA_(Y=%N0#=U7VD>V0U,+(%9^K/=F^KF=(+!-(ZJ07A*IZ28#FWX6(*8N+R@
M^U)L+)R%H?M=+<C&M@)'AZ?CWM@ZR*U?"^=M4.ZK#%5)B&.@4G#8''[DO, "
MP8GR:BQLMB[TEYSF8PABJ^*14RH;]PQ5\HM"U9R^@IT-8.PM<$OEJ;E<FF/M
M8:@R_>!&AOH+89.(@8ZFP_QKK9!4J]O*?L#B(^Y#MM^2:D&S:%!AY-<#WOYE
MY(+WFW&VV]$8A3:%#SYQ=KO:V_*_'<.\^S *S0I!*J>1MBOX$.W9JK!R&N"K
M6/,0\4"C]&=963W@:-V9H9\!%H^:DWPI\M*4^C""9EQQH@L:9=N:<C5U3KOP
M;;+F=V> _L@TPI5?FT>45$617W>9_8N(]W<<^CMR!3:.I0YI*!7&._U6Y7TB
M'\D;^3)"LF/U@P5PC+*4]P>TU?LB%=\N'MS_TT>[ED!2STOSHQ5;5>;W1GQC
M?4G..X](6R4HEB='4K5*I+ZL)OT'U[^<&RBG^ ?K&K' ZO:C,?*"J;^%:D16
MO*RF>G4Z^VO]F$BM1H_/G^N>/_RDN>4/7\S>_[D&51Y%KDK(*7(:^49OWR:V
M%KTM/SGF#R\8@$&!PPISO-*;LCZ&4I84[RQQ2^7G"\V7"N6U&&[7H?9)^$9Y
M?%8T3MP-S8.-ALU!X/.Y#N0@-H(/J5HTF6BIB]MY8F*$.RA8MQW.O5\0&!K>
M@WO5NZ<I(R><3T>2?U_'%>VK91SHFJT+G(],5 B+#LV2FK)"FM@F0E:'W'#5
MV;6N\[%.5:J/S JJ4KK*L]SWEUX)!KTOY/N)AH8:%F=="Q-],:8=;@_.$H_C
M# RW1*^8@I[B"&:V^0&:>"3U&>!*B]=X_9!2N7,T*&#J99:[51:P.GPV(XYI
M>,Z3SS8QQA1#8@\^:5%%"*IV]+A6>)D&\-+&2T'(JU_S2+(F]Z.-7-9R?.93
MT[M^.B3$&YF.,P.+9G+*K1)O"IIT"<H_13]=' 7![?H32S"T^.E^8>:V!A.D
MLA X)X/&=X;MBEHQ)=F\(39 5K<P_&F4\?)(MX&NK6Z<RG(-^6^CTNO8K,H<
M=P9<T80"2Q%'\3+O8H5 -=9I6LGB,VRMA#.GF6[YP$1G[@LL<=U=>YB)/SV/
M@R&H.Y\]O#R[MVQL-]Y=6XO67C"H)*YF/8#+CC'O2JM(4Y%[TG).VQK81%]D
M;G2+.C0NG&UZ,,GG6X3D8$]U:3)3N79T0PM'K5#66T9A/=T]*DU/'[?R,\ F
MV]1BK5DI02 XYA.OV=_\OT#EC!<S5MD2=Y;\OLDW],.WB>EXU"=>/HL_Q<)&
MI_7],TI=U)C4CLX/A6YC?7IV0 $W-2V6PUE\>Y"#0[CX:GB08K+^#I6KZQD@
M7W^'@1+8YCY@9#=55.^;)/)%LZ6^NX1!SV1/#72XXZ^ML&#@ZU6;7;!Y=;O%
M/L\;:;%#./W&UOO=E%-_AUZLG(9V=CTPWECOD%FB+;T/C!Y:8I#5?)NI^D&8
MMYUOB0U#5N^<@.+<\N/,X0OD><TQ=YJG[H@DG"K(WB<@_Q*1MDI/3(BJ=>MM
MX^N4G4=C I)+0T2%%I!YXG4&0,6?WFU4TC:FTC*?QQQ^WJ/2.ARHU89-LYB\
MR?8._HL2"1>;S#??$1F/!PD7/-NCT3S<.=?8TW:U9K4$J]K/<Q*\YS=&I01.
M!WG9)?V3IR7XF$:)<[Y.$CEF.48$#A)M /CU.[P*_Q/&Y^784_"]/-P+G#-7
M86W(7V!@(#5_S^IM:TTF'_P,\&% Q/J_3)M^5M!5QQQCG!H+TORB%"AP1]U*
M _GB'TV,VWDII\1@'CCNIAH[4E=Q6HN*Q=$]^UQ=ZI9>7B/1@9F\H5W##'C+
M5HH<* W='[;8QLN7L"D^-SY:ZCZ:L#F=J^@A\\50<I@>% >U\Z)U%)?:BPES
MX6?K+,480^E/\(7:^$Z.H9S%;2RE @:K6V;]W7[!MF)WN!HE()E<E<HY%,6%
M?+[F5;P(6ZK9R8/CH]\/^\9I5/H"A3LL=9#L<_WP56G5\$'+1\=C!3$O5GR9
MXB,S^Y$DTW8^<PI*JF7+FP0W*TX7!7]Z[V4)3'-<NGESAKKN3&9?>^OWPHUV
M5#TT0E#4$(22J+ [;?.N-'5>#=>-/>1/=#QH,M)S::&B"LZ7%.RO+,$I/.OU
M@SW%_VX9,W6L/!0DJBY!^GT-![4@I2R9([3VKH*&W'>5YO$AVR4Z)X'9I/1C
M':LE2YA_U$+%$)^DZ#P7K@1[.R?TEUVRLW'J[,C$ $0P)%(,\?;W\JI7BR_5
MBVC=US4>'$ZKWFJ>2)/>#+H6[N(0XKQTA+,Y#B8UKF(C5Q@Z8FL*VZ_,WDO5
M8.E@0V.7L7Q?],OB5"3Q' I%[Z232G(2?B6\. /(^^-:]QB>'N[4Z@@\_X9:
M%?Q"'*Z9\DW]"M5.N':#B_^"P%,:^UDX@P<7=T)M30Y(5-$UPY ;9="($D7A
M.6-)D/D<YC!THE3CW4RPH*J07"3D]FWSP/:0HE7'U,@LXYTK1<5_Q)#>X1/4
M,?D%=M4]E2AB:7^3;VU7A](AU5W]I]7F./K._LD#M-^W]IA8>JNWQ4NWQFDL
M?VDA'?5JM1.,&32=%@=/5%T>?YL"A3QIW51#\%4<F!R6YYA-VWT^=*O5X1C3
M%#T7K%*%#XQPW>K&OM-J?]P?8OQQQH!?J*/@3-^_TN3:392FPI&*BV2(L@2;
MH7RBV-$\_2-3 FG;S'1"<+%S!"JX:RTQH?]A&I+ZW]&^_L^:_P9]X7MAYWGH
M=@Y[0W4_T4(-A!Q_-CVU7X0#? 7<.3\:K^_\:#S$?SD:3TZ=HS%:Z58KV4VG
MA/GY]XBWP@L7^&^^_WPIST[=(KUWB(D6R9_=Y&^)??M=_;[6DSL.M\$/$NR^
M*5U0YI6+)ZF[0_(X/6$.<.562Y+^@W_[$ETNY*3C+JZ_1S:!LN(></[@' 8-
M-=5V0=%)%?>&5/25%4ZO1\1PA2+>'X4"/LIC^>V5#9JU>-N09P ^\;*M,T"D
MT/XF6Z*&IU[TK+? -@IT'735>K!+C%TC)O_VE=*^MG=(37ZV]'<ODY8FPW#]
M'P$A@!L +9$'_^7$TMD*NO&]$\7SQ7T?X.[1:>IYI$ZME3_(R.^Q=>HC\L+:
M+(PBNRCH:^UC&KKXAR8?[YN\\ZE@/S]5,"Y,X?'Y?_584AC>-EZ0-B!/ Y#6
M0^^IM0,NM.892(5M_O.(BQ<NX&M+]&\L=M*-)GKVQ6C)A=H-&(W0;6;@MN'.
M.YM8$9V)9W/6JV*([H#9=:WZ7)?6HEYIX;PB'J)9A8OK3EO.RAI(-2CVAKD&
M2VZELD\\U2^V%%B9A]C=&[;^7@+!#0G:R'H;N2\A=,I=Y,:2JJLB#*T*G\Z\
MC[FS]?WBJP>7+WHJ/!8#4"/XH\X=:=D?OGG2_.S<:^2BY;2;R1G@ZM^8Y?)3
M2M"/[_J[H#Y<[9#_JN%M".0_\CR -W=FHQ_S6'T"S$XP<(3X6?Z8OJ; .0NT
M,>3[ROHAB0,WIUWWM;"<Y0<+Q&6=,S>:5.WZ!XEA$<+#FV_?_<N3[++7VWX7
M&'F(HZ@A'U-@N(RS<T9\590C*4<M@_R,Y\%KX=G#H?X2-,6&$A(#3ERD-R<8
M]:&VHP8H%2:$>+EW0+\V_7_;:2)MS+)ZWXL:02+K<4LN^XR'KG8-"RW7K!]$
M2)]6QO:7WIYI8:Z8(K-/ ,K?[+S2PV:ZLA*C3$'Q^]T_,>X7^*,O X +/]ZH
M P"W+NHKDSZFI;">/0.0YKSL<)PAIKEW6AQ2\5 _SK \8HH^?=$LU$>%OK#S
M_&WJ)<3;1@ @DKI.>*-.SN#QY0MO2#A=.:1];P!8#&_=NT#J&4/W"?#ZS5]J
M24UOL4%'W<S>A\SU0LJ1O*+PZ#IX\&QM04"'\1E N#]2WM?+7U$2Q)M93NW%
M-XQ#2B3 6"FV-4K[6GABQQX^3[DF_E'0RK0,>3=SI VKN[&E']S6H)EL739X
MTR)-]3SNV[E;>@,_?T+#F&L:^PU5IT)]&%9XG2K9<2FJ\>*=B_\^ T_CKVLK
M"8#S&^#_)> /23<O7Y"V#/Y$PEFL=@=@\S_=_RYOU@%(9Z5O *:G&'[3LE==
M?P@3OQR]$/B0C.+/<'^(OS5K^W#.U73":+BNC5#,H_*Z]??F"#1!;VQ?8"T;
MEQK[T@S)?G@CN![*E\9*PP1P'3-]AGV?W&G0_VXCINYW1EEQ"%:*AT#+J9B3
MKA1GJM0L"HZD-7MQD/DB;T\PRLZ\HJPVC>Q+,TO4RU\=SALL78G>(9*T<1I>
M4:AKO<AN7[2A0=>#BK( GO;_C[+W#FNJZ?J%HZ)@ 07I5:5WI'=N04 2 0F]
M!%1J0I/>005$J5)S2Q5"@! ZA-ZK]!("TJ5#(""]PP?>SW/.^[WG><]UG?RQ
M9]::F;VS9J_?[%G35D8L7E2N?^Y9>_P+7%;VK62VDL2MR_\-N'-^?)Y:?7KW
MNA##\K'[YG8"V=3?%X#3JT-_$_U><O2<)Y>=?NX-!5S_3ZL?KW[$ORY;$947
M-][J[[.+?.FD@867=RC*JODILC:F-0H_N!<>H_@H[NF6Y'!,MH9V;#.(/S'-
MS;WC#<*V"(O"1EA-,VBF6S! ?=6:%H8$J<Z_.7I0?1[Y&&.JBI:M^JIQ2YZC
M?J8N:W4"\EM*$6.6FZE=5C^=MR$P#YP;!(>G2F:.Y6O5DDM:R;P8L1?C%Z8I
MXVD;<IJSE_]4/.579K!R'$[@7VFOG=O:,92.J.MES(#9)TTP?:K+:1["2$[T
M:;)(?<L_&6>JGW!%#605P'"&H6%,RD<%OI_HQ?JMZY"#DQ5B]AM<:.]B3ZW8
MI;[>@#)I=YG$&6 %<KHKL]("NR(]6'2,^-(<-+G:KNYB*RG#HDCDG2Q L6%]
MR/15>N-JSJ=(7UR[=4]P;\P2K^=NAKUL/BQ3'_W;H1Z YHGSOWV]FK,!2!?^
MJV8M#U^V+41_-JI?U[I&0M>$E<DE3[N+HA+DBY/_>1 [?N*?E[\4CUUD$5G&
MT]?O#Z_SX'<+;'E>>;6S*('M_$(3.RB6(J5$^]_X?1\=S1DNQG&VN1$'PWLF
M#UO8/^JK>.5.#6:STZESG+.;E4T-E+=/5E:%Q^3">U5[RZOW=R;C-MSN\B9V
MQ4O$Q?0_^2'?%!@6J:W)2:.7;,K.EM8Z4/=Y_TM 0("^V@BL:E)YULE--;"L
MZV1<YE, &W!^[&C^D^"MZOOI9QD)3NUU&N^2K=+N:OZ6%QB5T#L8'#VUG+(!
M2<[&M$A(6$B?5_ 7&UT C)(76XC96T&?I\1XM1%]>0BJ+4KT4/XI-\K_WA$(
M/"V#]G2@+T_4-2I#M:OS"7X95/78R(\O!*>C)W53I.1AH!LYQR-YLRJ,;E8(
MEB_-P;V\05/TT3&'(G^Y!]9A2('Y\0E)[U8/AN-29<<6QJ3/BS,<&>PE7E7'
M&VE'/7SIQJ(\7(E0,4"#GSKVIGQ!L<UMIRDIK=5\N@"8$:B'NC7RV1V3U92W
M)2*"V(%]$5*U?4_52D6]2=@? -HW!'_G9KUHWV#YG9MQS[WKW+1ASJ!KZ9^P
MW>S/2IT'_QDZMU^\)]*(X_&37-@>QN:H;W\A/)=8@(PLN?OF!73JU*.F5)J#
MQ5+)K$ME(P73?;1/OP4,288N!'J9_&@4[MM/M@AAIYQ8B02E&Q*(];Q5IBOS
MZ=[UMF5VI\]-0M*A]$P>*AAOYYSJ C8?\9%MK,0M*J2G=-1I[HNCJ-+\*NV
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MU?"HI+JX:.5;J_SW]Q[@8TZU*=!*4LO*OP^[!=Y[U"Q"5,OF-&=JT^*0[<-
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M*].F%?0B:5R80%MW'[)-1VTS"@N^?,MM6G].^M)?2.XCOKB3% (]%9+8VLC
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M,1_X*J8KINFG\#,4AM"0"Z7O!9U)R%)X0>^F=!2:#N[#1)?I.M^5SP?: 7E
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M,78>%]@"U432-%;FBI8T>-Q7(JW@DM2:BUFRUE>:]P\_2$ASV9X?)1UEOI1
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MO1;XG""WGSUY0\/]EO>1"U(=EZAEV&F%M?=+C7&4LMF&BINPR+_H9NWN3KT
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M6:J^>SI2/9+F(G]'7R>YVIQ#[4U>5B+]@_M4TRA+FRW3N6266 M#_(B$(Z4
MM/.(0U2N<<=T>F(,["8 :R<_+$6HC_!A&$_X;=0OTX0!O\U@Y>6Z"&#="U1W
M1B<A6PR<;,T, W$%)BKU/")B)O5)3=+_+;<<"+D D*(.J>]I=)Y3]2_Q(6TM
M+@!WUG:HM5YXEB9X79JB)$07 .?;#.0Q+MU$%*&W9U^KYJR(+#R[.DL!P/Y
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M/"4.5F^)<\XF'7[IS+ADDY'93CXU;V)N"A<H[V^?'H&6JN3YCB(VIIH^\)\
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MY@\ZMJSKB8IZBC* 9CC_F_2P++T:#)_W4*(\(XN4JU;VX%C*8F&^>QKD=MX
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M;]MT1<!U!NWG.\-MO*<_;SVSM WQ/0*= 7*C;;2B=7[]6JN 'H90-^I/6Q0
MKC[];Z":,?K;Y_<2#Q+6:]+)EP[!?? PP1]#$J.-P@DZ=+6[O63F95W@W4!Y
ME/;;@M$E4>O*+Z/:$?E@!'M21]E(^_[*;KU,1AW=M"$Z_U6D T["NT+]MZY$
MR,MMOTG2%G0D9D8%G"E7]F(76(/2F]<47.>ZN8I$0#YT2Y8[=VWXM;_T\VVL
MO&'R?"X:5$+@9.2I\;O;:H.XL0X,D_%.E30U617LCV+;V(I:D373F:$7MQ:L
M"T\46B@5/1(=[M;CZ=<4B8/*OW=:X;3L'ZME-[3\..B-3Y;SR[ XRND4%5DR
MQ.0;J%,(?):LDVD()6KNE7?NZ2; N)M2HS"K.V-BW^NMC(UQ:-"V1IQF^Y%T
M$*XT33TGSPCO07KLD[6<9@8>W;9?7C6_\<2&^^Z@?;).!,0QE=XQIM/7XN,)
M.EVDTV;R##!<N\VC4S' ;P7RP-R B=GT$%T#AQ9* _A100',\.$Q,QO5?2?A
MVEXK3_.@ZO+\-JH9TL2WN6&Y46R5BZ!%M8<MVK5M.-['31N9!P-)Y^&G@J.H
MH8M/3NIA=;[I0VX)KY#D2235=DS7KO.@#;8)K(=@'U6P%%H@Z<!<'6MW%LM7
M1 T[.HG\?.H=#*$39@VW++2T<&R9)MJM,<I57/BT4M=8/0.\[XO^);7'3I-Q
M60>(YK?+9C 8O8;$(CUJD#X1(>?6L_0S"[0,-88$JN<:R4FJ=@EN" VEI:P>
M@KC/ +/W?H<9A<P&XXI=!*R4G@6YU$LZB23:2\7Q# 4%FE.A.>E$[UFO&*JG
MR<._Q^/'U#:"H9$4!J:5" K+<E"NM<C;7$4-;](;KL1=@B"DI-]*U\542C)F
MW8ZURMZF-G)X<.G7T<NY:^FJFP(-Z.6N0ZD=?NB+,/L[D]I1O\TJ]2QK@S".
MD"/03XZM0 &T1K-JFNPSG0&$AH5>S!K7D+6D=_?&K\8B*'C$T4TH#J5AQI\<
M=&1I,Z2YIU85,-;0IB? WC>>EKQ"J'*A=^'8DE01.GYIOD!=UEHH>%Q;]-NK
ME[+FE$EO_8E</D6I7[#S0=@3@V&6/Q#\\[\A^'^,%SF)"Y$JR9N;:>4F)@;M
MVO7@[1KY5+!]?N>Y(4"T4IQX5KL+^!*RUEYA#(Z'1:(84GQ,- $K;%'(R'MT
M)':J0V0.>-UO1L5=9($_2K[LV2(RE4N1-PZLV2?6D/<H3O.';ASS&Z(E@/;P
M)ZRV(+$;$TM'5(KJ\C)ID)*7THYT< C;E'6MDI%$Z\SI)')$NK$L>T@VB72-
M0B5VI6M@MF.^FT'YR49"[J0G(Y$K:_8X[B$<:5%G[5[G' ENUS4L%U%M;SQ(
M[X &JB<E#,LFP1@LK"NDGL0C3LW2:KV7^&H]W<3FD:5B#6E>H=[NX::1J>MF
MID7 B12>W0JL $L2&Y*03BZW3AQ*R=",0"W?\_=XOL*$M:P263 @MO$X>?>'
MF$EY-P]'UC'%-@J",31JE%J,1O5:\E:U18U'IP'EY8L*G?(J&2%-58GF4LJ3
M-6Y,>%.#'4O^I&&3J*K\[TW.=(0H5?J5*RG/*PZ$K77"9K@,9TXEY"QQ,_R]
MQ%$S'>%7OIQ#\?/*V/KYIDRN]:G?P'+F'I%N5N,$M'*JUQS)DB'3 9>[1ZW+
MK62J2$9O67&RDV?G8WT'I9Q?J6^OGEG_J%KO44.=6'I*#79&\S3 @OC=P*(I
M;S!YS>80-/LS.9RTBM8*;&UG9RV6O;O;V( HR -&B(PFLIJ^6N95"YQ@C#/F
MFPL@&KK!]:W$3+I-E45^$^1#++3II9JLJX@<FZZ'6/I/E5U0Z9R;<#O93'U[
M68ZTR.1! SQT9MUB8KPA!<:0N!>?JV#D_J+02C9D?I=&K>(;J]XM;K*XC&OR
MPUW/J@=<Z\?P1L;@[+)ILR/$(!H!#@JV'4ES2T@DV?-*0\#@DJK*T(!'Q3'<
MXG7D(WL@"LAL:7+V9M89X,XHS&<EFY\G)T*MWATFY8'IBI415QN71JL>L"P3
M:&XE;7/L#X-3$CJT8U[EW__8RW3S:N]RX8A*W6[8\/>&%R?7IJ4IGB!;>D [
M57D=;IW(29*8X/)BSN)B=:]3QL_-[P9)HVG1??B*&XG4(#-%46:+^J[*;N)N
MBG6;=F7HE,V]F WVKC=M@A=O7V\)_F_IA?SU7G5\,:9]$'/]><'C'Q<]_A6P
M=/&IFL+M%W?>^WM$OG[*OOW@+Q+WC/GX3$*C\1TG.VU5W[>)11ZZ<(^R((Q7
M2^KKGXPYLR,6&VW3LW.$Z#'(+(*ARU(=_O,=(E;K?N<$\D',A;NU3'&+:HPX
M#RE_]\L;GTL'V6E"MH5U>97S.JW0'%[E1S7 9(UC' T-.BR]EP='<C*FS/?(
M*P9J<9I)0ID/7&/HGMR\,;Y,!$O'Q*#]-#0$+*OLYUU3?)LA^KA7Z&GSU(RD
MMBV!=J69>H&5.>4"9S(^$9#K&< R63,L7_U511;2H')K/Y'E4IS)<R19K=A*
M^F2I:Q5^?V$NLQ5FE\)?9B[M=</Z=FP7WS6:G]?#YOI:[<>8EI*5#-EUZJ8V
MA(UI6,-FOQ8L1R#M*E9X=#*#I:*$$J0^GZP-[T3.8,F#X@3>U&A=^<49Q$Z_
M9K%K;O9EG#>O.M^1YG/7CU_=F^WO6W\^&JUD [QU^C_;ID_^K#J?IM0?HYA2
M6 _M>S=9)0YI9:-/Q"T/[J3Z7#E\#KA^"<!Q"?#I,N!%7\"+==8'%[@XM $Q
M,M<O//SQZ?P;>7[Y<J.IQP5F%),>"'3#R6Z+AP":@2!C+?2,BA*_9HB\[H53
MTJ<@6JFB+EX8)#S]YVRVVX!KOR\H6RK76QOC,UA%N92SW2WB8K=XJ+=6%[DY
M(,N+;N6Q)BJQ&;?<&$O;3>I@ P%R_NJ_HWNT-4P+OMR9<_9(BZ^BH7&F%)2[
M5\FM](:,S=F*=/C)(>*&4^*] .>Y#R4%:!JJ/JW+&"H/E)D=MZ-: ,,Q.BM-
MHD4B *C>S'<O^MLUNA91:G8JPK>/.N'4#V*.*;V?.SWPUN+WD2)66 WEJPEA
MF".0N$_7Z'!H8,;EK%0I4V37.;H;&71&*=Y)V6A>OO)K:VQAE^"^FZR=+F5^
M?42[LLHA4T/!K)DY/!JZ+W0,R%^./SK1.\U20M,J&;[U8_@+O:R-;SR_J,?1
MT2PB\2&G8NS&K;T*5I:V6.790+])4'C351%I!8G]-) -[DL9V)J7]$/Z DYQ
M=;RN3:HD=E^X&G !<#VD\W'DVP&5=*D(9.(M/TI!OO<+K9?;,"K<,T+L6V8)
MZXEA )E;?!7D^KWOA_P329Z97#V2'SH!@!< "L!Y]P?D4DPZDQ=]_6Y#8SV>
M<&^V>V-R@IOQ0/BSF5,AUE!7]\TDI=/Y5R@Z ];HF(F&9.=I=,(EI7J+6@_F
M6 C?9D_HG+1=;EX:V&+-^,1Y^?H7P",MX\ 5=4C8G!SCMHQ9D0Z=J5 R=C*^
M_5?# B&Z)B?91F+>2\)L!^QW,0PUICE4;^(+0U06T>/Q6;AI[W1?AG;7([^4
M=">S_)V1?B>)*;EK' JSGHK>DED7'\S=#YQ^UAY"][J.DBJ#K8'LZX_.!Y'W
MIQNNJWH(/DMX 5!4E<F.W7_T]&JLT8!?*!E[/_O^ _+B;Y[K;4U??2^X7+?5
M>A]%D&^U3KK$@CT#! W>-MV5[SNWX*D%MGZ9B(,P*:H/B\W\MY]>]I]_RGXG
M!L#\$,#)^.[U4S:7BX\?:RH_#;_H$7P&<#COL'>#/UQ\[#)&B+BAJ8692%5A
M=X;4.!?\SN@6#Y(N')7QV<2U(AQYMN*RC[7DA1.NWGJ9[&/[-O;%TXOE?]Z,
M UP,81?^>+T3IA<9KT1]0"VA'LI=:,XA-.G1*]2!-'+$:<<>M#._]"NB62!M
ME9NS3L70L0E_^/H.\(SU =7_L^W^[G_M$L;]R11-I?7Q6''^A] U_S7]XG+W
MZAKTM>GA5L>)!GGEFFJHVIU.40OB@,WJTN+@ZN+I@DRVO4(%%I$FMZ@F(K#0
M8Z*:="7X)VZD"#XT<A?M9JJ=VYYB('85-R3;!!^H+3AUBGS;\?KGF,D(1"5T
MMAQ6%$)"5HO4XGZC/52[NCC*\+SCJ]@.R$ <L1+%)^-!QV_SQHLRC3>%)P*<
M4X9GM6P-<B"%:<A3/=:6%B$L3BBBXG$G*_=_-@3>(9A42+M+@I,#],*D':S3
M^W;J\M,@],8%^Q+96;]HS@#NY2@Y%CM4VWX2N5>RN A^7E<G*EETU$LFN*-A
M*O<$'2QCL"%CR*)3.[!#)(+P^Y.4+V ,QLX2/6IW[+7($+8S-RLR@M2@5M(1
ML*'[7(:-/ -&$B977?(U*I$P9XANKE[ ;&T;,_*EJRJD0J/=@!!KKPV_.3I;
MT >X^>[2GW-/+GM4W.B,*$]:F$_Z,)3O^.P#R4#6>::K4#0$JXU/L5W:8'ZP
MAI4SV07<^/ @08'ZSQ+1Y*?;=&/T:S$!22GG,U5E"AKTNM)00RW5[U*"]MKQ
M<4JRVP.:1R]5,FDY+Q=F/BYA?'@^$45?3E7MN'+SK4-,T-/(.RWGW>[WT'7)
M1DNJCP  AR#FW004IY<1URL0_G6M:2&_MU-?<CEJH4[^1_C4_.M=E>VQC&EE
MQVV:A=L.16 JKAZ4<MRCTN&?\XU5$6,HM;N'POIO/U#(CF4WEZ]B-O=3J3<&
M'D]4Z.P\OB\M5HZ15*U:!+M%#N*VU;621_.UXH")(37LR@,X<8H@I*0BL=R2
M??IGX,P8N90FJDV_1=9I&%O',8+@QV@>-NI:NX3)'.T!L1B;N.W:N]8\1D)?
M\31T< UN\.\UTI!C6ZRT::XA%*A3B:4/.1#*5"D;$Y\>I_MN?!0UT!MB,$*#
M<%V=2\\ >V1/W'P9T5@21/G$0_4@RTG)3)3?ODLS-J+;2N%8ZUHCO4K@H+Q.
MON.*%/V@GA0VYY3=_JAL3*YS +'8G=MF?CP%5../J[*/!V:%VV-FCE]V2R?K
M5('B"*Y#.B)B$WUR.J,"8M[&;=S.'F)7#_&67^;C^.;%V[@FG^2&GYRNX/@6
M':0_JAG3O]R!>05KX2$1#!\=FS:GD<O=B?!<_>][.MVJ@W/X3?NQ*W;)VT7E
M"Q(M0ET&ZWR?[+)N:N+QC;H#W'KP.9%2\Y W[RX]TA1.O,DV\5[N^F*M>U7*
M/@U+-AB^Z!8_W?M$V".N;%;E_78VWO/)=;8@^A?_YX32 VK^&^C[<HQ;O#F&
MS](%6!E3#RPV+.7#+BUV&%^:9^U;/W9@4930?$I9S/+J?YSTA,^W'0NVU-1_
M.TGHGE*= 2XV&_PZ [0/^M+<Y5?2,?-[DN^'?U$A]R4D)&A,:E"600-CT)06
M^>)G@7MR5<51@='(R,8;(:--(Y4P=5Q%0[]4HN:L;F[5EF[&>X+;,P@Q.8*N
MISS_%3PY)!Y7%4\AJ%Y955X9[Z%,IMJ:(=QO6;=]8CTK1HPORQII(4U;$\,B
M^"$L#[_O9CD>)'D<4UBM(HP)^7J!\1Z*XZDE^.JU))W*80+SSX'@6QQOZI@S
M[Z/!>:=Q!].QI^',1=DV7O8\JS2:+LCN[.[@LAWW)7ICJ9KNE][+:76U,469
M1LV%)>:LI?0XD""7>"=%MF!CQ)?H>]9/X%G/&X,_&.7-PT"+*@5OS"%K;O;D
M8RIZ!\)JJ4BV#6Z!8./OW4/S!ITS)K,%8(>D$.)A!3:G*M=X[ U(^'/[SY*A
M%99;>\D^)DO?]:?A^U%:EI"5&<\=6P2E.##Y.S2$0*2>Q:HUR,IKQL7#&EF2
M+5T;?'B!]JO=[!!U(8-YFVY0KNL'#<(,Y5:"WUV%N&*BU-A@53F^WA'#'I<B
MO=OSN[Z_(@267#^C,^?P72NSC!]%]BK@"^':#9$)*S?=A.6*U612A%*J+WO?
M:+^UJJJ+56Q'-FBM_%#']XD*)G4M-(:,-??NA^L/)$#)@9+BOT--RER61LLS
MNI52#(I&1]1)P#QQ[DZMMHQG&QM^AT4I1S5^Q]\L^6X[R:7,/+CG?_'RW:?Z
M?SI*!J72![MQ<;E9C2W>'SNP"F.&W Y&R?65"$]Y>?96KL;& $9^=+N&O'"Z
M9!G)H(C%T[C[2]SC._<?(&@!5Z_^J>$QX": W>5!G,+SLF:L7S#H^):7#'WO
M/@+^52'HO,\I+FU1.Y64G 9.S/(M??D1,F^&,+;H59_<K2U!M^$XE![5U8HU
M4'CJCED0KGW[)+LQ\*1G,2-WK^L%G'E0"U\(6B9^3V5$<V0U<C36]V&,;39*
M<'&I9@)TJC+(G)SHIN55C'%?!$0(^,% @[:NH3<',A3/0Q"9DMB$-08L5#:Q
MVNVW $\9)<MTK9(9Q05(>'.(EK^PN\=^C$9$>E7DIXDMEY.7/1D^BJ>)'G:B
M$O)4KY##J/!:C=.LF:KM9$^EK$R-3:/PB?OQS]\R\O;Z!\SM@%_(0-++S-'/
MQ$&9--/#H57C$&-(/66]V61"MP>7[NA1);;B)Q&I"55!AUB-&C)H(5&Z^7":
M&W&D<>=U44PVE#]_H"8[[U5R*DNHI?4L4;3J+3'-,P^;9N"HG-(B]GP4UJ(3
MJ\J>H,&;M;L:$4\&*A*E+1+NS5ZL)*8:8;.S$V-%$V'T.W9*H++BKD"^F@X/
M.H'O9<O"71VV#%P7/CS2IF._+2)EO\BCRP#' +$"4C'PG[U+\1)67/&S/<<Z
MW8U1,ZT]/RZQ<EJ6 "YR_9TMN #O[U"\W5MP8QI$)!*B)R6U9\"W2"]SIB2G
MZO7,>RFNUC"!8Z>0-.O2WK=$D[T-15W>/7YL?OG%VT<AZP\R+EX_[P&7_EI$
MP)]<0_\_"4_(YOQIE5^WK_)R06$T5.SL][FF^/"&;B9>.L#J*D>WVSURIGXK
MG$",:=:@K@D[U\YCGW2[?,-\0;MZ?PPPJ\=@P/CY:S?P@E<,ED'*P74CD6/6
MI,#6#&6+IG<&6F>(-5UB:JS$QKG4)KKV_<[7,!<QVXU$F9P!K(U'=&-CT5<#
M=RD;._1\,..#,;,C8G8[$CU#!?33_05U;/8)2 ^-35B9I4E7T%!!AH#QRT'K
MB"1YB_&J[:EMP_:3[CKFH!1B/:@J/1.8#B7O%?SV8^DHS*02;PVL1(%PQH_#
ML$CK@^2,<CLI,<]442Y0:.I;5"NIUX) V,E/22B"Z;[2:J-E>E8_RM#CFGC7
M/H"MAK*6#D34%*FB@>E$!=\PN:9BN6NC-Y1O'9_7'NHWLZ&TF8X;.(FM7@4_
MME&/ERVIETZ1E.A/+6F!(FUM#E&RG)IIJAW<#HW,/AKP;%A%Q6$B)&W5F)-Z
MBMKL2&&H4 #A"=YY*/D*'2)2_Q)%L6%CEZTV$)&:5?U81,8GN4W%W:A-0%6&
MX5V?M+CC,ZU1A+TQ)[M.PIWZ;:_Y1;&2@BQ2Q@=V_9TL!YZV/"='[XT?N<:C
MUHL%\9+J=#,_?E1E'P?1J>ZFP9?4^[PTJW90\R("OWR?W?J1??27DT4;'@YL
MT],8""9W]N3MYPLSKR(*Y-,$GUWR,@2O0:E0\W R=.SVF++[HX)\ZR:#PWOC
MB^>4"2KWMOQBT?AB([S/K;8H99N\(O5^Y![HL/</.^0;(%86_C\\\9Q_%V_)
M?M_WZ-^\/P/DS:D3WZ%N=6[1^_RZ,3UYU;EUX5J-[Z78 S5C[_ 9YHRN1&QP
M=[A07*%H$YEZ7Y35T&E] R7$Y_Y(DDRGBA_VQ,/SS@K]!"$QTT5@W_?YY &5
M'^R/RK7R)3\3DW<FCX\_MG(SX_[HW?HKN!HX<=/T@.J?BLC6=IJ*!!4R75MI
M?94XB:)_F']J$[%S;=TDD[\;^P\[#(<:(,S:)<W6Z6D$LD40Q)J]QVMR"9)I
M19C+_T"XNMY.RT3EUV[_>-^,_X9PC[W^Q_LFWWZZ?N&V0W4!=@4-]E/FY</M
M<.JYK)[>G"6&Q[8#]X@<V<LN]!M:=S'4T?[+L>JZ6$XOT23\AL7<QT:BH6+G
M=Y$%-B3MMBA3J1[3EU%)YV\$'<=N"PKY>YHZB:6N[Z%1B8Q#EY%.*O-MWA3B
M]:3<-758>WY>T^AH.>&G5NO5Y+&8W8@5N":YC"BUCRIGWBAU*;#R@X]#))YD
M<X)C<A7VQUFK/6Z9C@[&G2SN=AJOP-8=^3;7.8*(QA2.Q(0R"2 :/2+>!HUM
M]@N8T<2%YL_1SC0MPT9H\02WG_LC\5*B\D<"CW:&9X,IA%]&*"?Z:#O;-N\V
MP< H7L]UC98,\0]F RAZ[5=1;%'4%<H#I"$7N/E],CYODI\RN>D2-<*%W%VJ
M.'R*&59V@=A88;L]/AN.E%1/Y.S;&ORE=P?+4ZO4>X5.ID"8I687+X)]A%)?
MV!A5=;+;3_E8N:NGW:488#@=[8AQ5 YK4XL.VR_-'XZH0WT!QNIW"M7VA*ZA
MXSG")_(ZO!!%(\_P7@CT.<4>83C/7??VVI@CE<4K42,KON/,:*6=DZ(R5;?U
MG<<F"UTK+)A!MPH61\YQ\:B0 K9AIKMU57:GNW+97J J8CN^67>D1]@F8H=U
M;&YG>#L[ZKEE0][(RAO9PG/RNF'<SSAZ=>MPV9I7=L7U#&##HOWWU[U+JT>'
MRU[UIW5,;X3'"?#=$N8_Y+'<6E-A>]W:4DGN/Z4[?XMW_E7>>U[NV>MEW'1^
MVW]H,W_]:7WP7X%]6>.@W7D]?\BYOOP_^I@S@-Z0%W&%<%KNH^4;[6/'4-UX
MR(Q26EDPBQO^-"#V$^W0Z/6D@Q,LO/]+;L*:L)&Y&**WVV1W2Q?<@/>S.E&I
MC3I__JVF0G+!*N))O:S*7ZH-V=,^0>XP+\J7^V:#8L\;C<B,_$M1SF.2/LCS
MQOA#!0+_'Q'\;R'S>8NR+XKPI4_8[/;M,/^EO+Y_FCEW3Q,*$]3.?+M[!*T,
MQOQ+E+Z@?JXOBTLDRK_B%[$!8GM2\4V7*N:N\CX;F$%C.#GYDI05KM&'[0&/
M*55N9+0D_GY08 N?14 /0_QJ;'S4"K]#-^BK3IXWC58T9D5?35_)2D7E$JLW
M9SXX9(41?<.DEVY9H6AXX@AL81';KK9V1>9:RDA(-M6B;FBB\"VBYD1E:=GN
MT8L]Q(.M'[NV&H-P+<U [/:4,HJ]=6O\IJ65U#'"JEVKV&?-?>/SEL")B@72
M#7A45AMI5T7+RCY\$U\>HN0N8%E)>.HT'#F@?I]=P]SO#;H$8;72K3S;N>/F
MX/3-J(9FF8'7N?N94K6=D[9%]7(G"7P&X!Y5%C#B+P_O.1Y+&!3I@ QKBEJ#
M](T$.8O*^.\383XK[J(\7?PBJM.T-H5]J[F$5%G_\N+C*./*V6J"B->\)A$E
M0'L&2*()60!'5,ZWR[^_]?(+=A&'UGQ",EH/J1;YWM:WL$@\Z2P\M9-T5OY5
M/R+E8TC7MPJ6<$RE'X^ U$%=C31=1JU B7I]3>/V*U+I&3S%19HZDYVAT794
M%$BPI]QZ=2F*<\S1 16#:Q)+7=L7Y'N;Z4CIL<5[1-U9B*U91=!_BH/-A?(C
MQ1M$T]1?#-K-48\A$]A*NJY,("]8^M7DM@\+RQG%59O<.)W$%7+94(O"K=T2
M[W-4-VB4P.M<AO5Y-C$J48Q3)&W^A:$QAC(B%?OR=DZJB22-F8U5WVIY)V][
M(/-X-C#T_)DV]66(X3::0]9#1J*.':F+#?IFYV:MCJDK,:P'^FZ7J7NO]^CA
M@SK3<*'89>F4M8Q=UE]NXA/RR\:L3VKFC@(:V4W3*=HMJZN!&+>N]<=JO<:3
MIU:'$\E+--]/G$:'FI95@;NR;FLJ@F\(OMN>KIO;^=!<GO2VPI-Y+^JZO<PR
M%&1C/]H_?QFR-_[QCR)TERDRWN9KL\ZNK//:\R/F<YU?"^#ZF_>US,XK4"E9
M:O(\5["5['=/A7[+]3J7%QW=8Y!U"_%KVS^X._:]N!U4LUW59D>S+NLN.IYH
M62.;Y&#B='S+NF1TPMLWN&TF8P7J%GH&R#9>/PYBB7[QYP';YV6#G4XV#AFW
M%^LF#VX*12\;IJQ%]7E1SQY-;3,I3=SZP=:I4F(/;Y17^"OII\Q:"YY^?!SZ
M?Q?V61EOK'/>^H$\HOSS,>;6FL;]DZN!4[=^G)M+/],_=__PI^58OO35?0*5
M>VFXTD2[51FYU(/)@3 ^D:<^MRC+_NRLR?Y<7V*9W/&[</6>F4O=<1OJOEW4
MP-H6]7O?=T_3U83@7V\$6]6.#&QC%%/:(!DJ26'+K<\GJQ*0+M5Y0]ZP\M=N
M6 \;PTIBATS++0I6&YA823ENOB]455%"<(.9:4RR%3Y6J^V4>(LM0K:"VT:3
MU%2,T8Y7Z0&&U(O>V.8R[!@MQTRE:Z;Q#^/1[99?2<=O#%Q$$:OH&M<3_<&Z
M@L4^J/KU7W7JABCL0G]!.F=4ZL=Q/$QW)#%M6J_/HGZYG>B3H1-8D&PS3V/X
M ;ZY=9_*4J/MA :/=V/>Y2G[721CF<CZ)(LPA-U..4R.5U7]GFX69Z$%@HQN
M) 16GQ1IY**YN^8493U3=QJ6,&/#TG[F^:H:;X!6J\M# ^E%V#$CJ.^FXVRL
MF$4^DFALH!NPT,8GVC>1<4=_N4XK$VXV\;W $H*6-$WO/BKRHL@OK_0&+1Z/
MFUSAM!W%#[A=.<&6V:>R="L+;1[N2D>B!@=1D!+@3X\GEEG]SYZZ>KU9W9RQ
M(*'$$\X E_I_+4V68?;+R+%KTG58 2R9 2B G=$<_>/[KENUS2^]P!NN6ZD6
M!^5!]0QX9ZF5Z45@>'*K#;N;?L70HHD:6$^&JIZ:TKKL;K3R+G]WQIS\LE;Q
M*K31[U<)W9A?!NL5?,L2V#!:7;C^#% 2"O8\ XR? 98])>:B, >;L5>:;IK&
MWS(CG.Z= 4R7_R6$:YX,'=^\_[^+1=P,UQ_KRD9!CR9.@DN6S@!>9X#B_C'X
MU^97N[)^:WZ[S.U%)VNGK2J(IDM7GOW:.0,TG %^>3$W[34=43 -K=YIT?7Y
MCP^K<#G%3.LT1#GX+)TV&ZS>+-HO.KI[K)YB#S-PS<<L3EH1/(T39G;]4CRB
MEKUDPYQ/]D[;4P2+8CO\AMU;-\^A(.NO*O$)O^5SD<_>Z7?/XKK)\'\&5=/N
MOT0B@K1_X#/RZ'R,K9T$%Z_"&\__KUJ:</E'#L>A\O_BO2C_2-_5FQ[<E'\4
M]6?Z:=K],[".S@!OR+^S?&K=Y#K]%WM^+P'?X8QE;;=KP2\"!Z5=BBS;Y85'
MU0 7 4__E6SK?^VMQ7S<8+][8^APP#S/:C!3PR(KZE%\697,MH1:ES92(M=)
MHU!Y9%*3K]7:R[/U58(-SF#_42?749,[OW+'\,(V6E)W9@O\LM>R]N9R.4SZ
M(PF![!86-ZUT6:+;>(7J]D"*4L6T?"?_!:O!UQ+K\DAU*'$[H ]PQK^U:*WS
M_G9>7,&D."3;(49I0AN'K;@N,:H@ND\[8HQ"C0R"'FH)&1UD6UIA=XV1>E^6
MH&/-F*$M,0:D:N7,=?EE)2[%.*K7,>H_IH=="VNTT2T# 4#?%WC#F.]K"J,#
M>(Q.7&Z/@3>O3$1+#;+7S5QM-270BIMS-J1$&]6TW! ;Y:_FON"?:6GG7%OU
MK%X737_'PTC]:K.7\,NIJ=6#'6$PM2Z?59[KNK;Z;X.$Z"EL%9\ ?9HUCTZ+
M@8Q4Y!#.U-3DU9?J.!-R$2AKQ',TF;)ZK#X#./X71)9^)(=T?[YQ5=*&:]1U
M:+TR!].O]D0EN5>UHKR(!_^P57PP?=/VGMF=#?6^B[9/;N4U7'VXH_?EDNE'
M']#\'Q8@\$WMB:-[Z#8O?84<_1@UN>)CX@[CLPB&EO-1@F0B?9WZ[0^]K*5(
M&966O;GY+/'K.ZKVWT_V 12T^P^[.@"7-S>?LZ\_%7]W.]*BYA$.U3?YI33:
ML"(L32DPP<CN$5*9][<9ORPTD<7NI2YP/N2@">1Y5:%[]0D+^_R?Z\*E(+D7
M#H)L5Y^>$PFSZ8:K^A<^'@@JG%]/ :G/.CQOGE^W__YUI_5<'W#O1S >0(Y\
M+/TW("5IIO\ST]Z)N,>!^K5_[Q+>9/YQFE)V_+%'SO_D-N !P;@06%.-ME0;
M3YU-75\/ W=6NB93W'"*NIFH:\'3CS9DFM9I?YF:%0>^JTICEG#/HFSEED)-
MX(ZLVG>*'L&0W\,^4F0H(&V,AO=SI$'_Q,["0D_X\M*1HG[OM9"Y87K1(206
M/RAZ796SFYOAX0*U4R(#BEF@X9:&E .:F59)A?E%9:2^QA3YY?7VCKL)=ZZJ
M1!DX0T2G_.VMXXH3T^D*CWAP2^W INH:)%>-#)K-[B:W$L99PUG%F%YD?JXV
M--)SDCZ=<G3&A==KXB76#]4]4C6N)/.ZU/+3-*Y74>MJWDA*XY)RY:[Z$63+
M83J#7,8ST.MD,J_?/Q.<5L">D%WR@UA1/J(>G#001?/;S1#27Z6/OE[43(-@
MHE>*L^7C'L&I<B&)J8D*44\U,#%.']_>=NH@&#AJQ^PS'E_<>%D] >;>>_4[
MG^TP#59 )VL1=45/I$:8VH?1?G9L8Y>3R_SV'9",?S,M+?EYYZ S>7XQ)_)Y
M%N"ND.-E8_;'4@ Z84\*SG0Q4UB[4+,-#N8&[DH4<YJM;>N5GAH8^;%N]NWU
M^AG Z(WP!ME!R;MH%;XLALVW-V\+;Y!OT/H^;\\%R"@#;BT+ 3C8Y"\"&'G.
M )30]W].<W Z)K]B^<_"LOI)E\XB2$Q\ZP]D#C.D\G>7Z+R3:DX?]N1MU$4%
M$'Y7+-X+ O)"TW5E<'YH4AXF6B2!0&AU86,&#SZ/UY7+CTLB]7F)LSA<!202
M90V5[W;B>Q SKUO>'88B@D!, MR<78+LI>$/E9,#[FH;DUWY-3WQB&&Z^"D#
M;;?E\])!C,/8 -#7W"G#LE;7>D-"M4TN5>D7191 FBG<5 %8Z1\ ;&>-S,\Q
MM'9AXJWF;O^Z>]$6F&A9"_6>^;KOC/M8!H-HY"2IZE3D9$6Y"WS;G%4T5I!\
M$-[TKFL?8!P$_1IW^$GM09']9]])><9XE\8K4X:9X\2NWZ7 <\<PXX-<U727
MLU;4D>.0I@2 F1!LR@:P9;W\SHZ6EHV"0?DJV27EONC..S\'3$Q=9"'FG.#%
M)^H<PEWZ0]6SFP,3V:W^1/GWJP;MSPK',ZYP%;W_N6\P-F.S+>.^\_WYW#K=
M\77:QT3G_9N?$CP!DHYW,KZ&/S8.Z?TMO'_G?9""Y#'9W'2DA)7Y^ZZ,&+IC
M2DF FLVW8/R#R^E,EL=R5;^]SIWE/ZB*CY8_:ALN_\2:9X1A?MSW39]@/]=B
M=0)7+^,XY<1[VNGCD*O9(T2$YPAIL<%:YU7X.(/RB ]EK>MVIKA$&[<\(^-Q
M5TGH*-%F4,1S^\&&I$JL<NE(;65F16'>R/@K+#C9/4R[HQK7/%M=DNE\#''T
M8R13+APU3-YR!.[RDEOC\0>JU9,T_.^_-+"\U,QVA-C,T2W9B0V-&Z TN0]^
M[Q8:B):T^M\J /M=ZLV%G'LW%8Q\&J^W[Z7F%+^&?>['BP75 "NDA#%P[:U7
M!M,6%11'P'/_'UN0GQ>CK_7NUP[_ C@,9$HG&"I3OIVBYDR*X)I;%^7A2DM?
M60I&Z&GC6;?RMKY%!&P?P7QX7L'7I:=H6R1"5=U?SS%;&57F#:WBK!HH%[2_
MI.XS/P[M-:>WS52TG_T0'COS+2(:S*-M;81;1/2C;LBWAH;N/[)U;4]\,"%T
MX?(FNX@CVTVYR2 8-YO>5F1@'3 K;Z1B6G>VVIQ]NE>%IGW@. G.)#$37DQ9
M9!)>D@ 0,0\OOH#D,W]'06?&![#JHGM]2:$SE)2;^(T4!0J4D]I0SQ""AL3'
M@+*^)Z-M:YR;QQA?!Y1<;KST==-PB33CYIJ:&?>48UCSU<SZ YHW/M<>7;A<
M<._#QZX_47Z29GR4^K1_;G:+[F^^W]O7+TRH_^=Q5!ML04(OV/Q?* 9)WM94
M>/#NA:#_G0>W*;4M;Z<#YGX[-/-_TG[P-YS^;QSA!80,,8T=3%1O8XYAU-&0
MO]N5W6D/>YE/0U9^F'IS%_TZW?+^S^9.1OX<U_C-@\?54",%KOL!%QV>GJ..
M]UQ["[OVY67L/Q(J_N0>V9[?K8?6M[/*I%/?:1D/MVH-XEJ6-*P:F&K-[LO@
M>'H.85!$RNU2(O'E$AYS#>2DW2ND6J54=?,U038>3JA; *5\IRH.BUP87)B'
M:-@0QQZ4B@A].3@L@N-9(0Z!-.PTD0;\3!FN15HN2R[+9LK:4QM6#<K#U]A*
MAV_-YHQ,6RH^?FQCCY-6+R-NCTF)/N093>3LZW%%U(S/#OCD&3LD8<GMKU*8
M$E6LEN#CN.+2**9NI?A("VE35Q2_%B@R#:/PO7ZBN_>1E3T +#X^BZIRD2)H
MJC>HSR+SRQKLUXQQ/GDK;X0-HAX2NL-> ][5"E\Z!W Y:_+<Z<9T[R?\<'_"
M-YW__?IX\[\W:P7[S]OJ J"9C4/HU>GO1^#K%)\ EU4!F?@8L@?O_3VN]5U?
M5"7'2#Y]!KC ^^7!S.\'&Q-]H%QY$="B4HN='*J#O5N8/%]_"_&@AKGPYES[
M2]X;4F2B]WNC9_+=;L!FD(/8.A6T_+VP9&.#CUA,Y83;CTW-W8*M!&O'07TF
M_<+2Y[P??=Z"S2'P?$OF71-;PGX;NC$,JLJ(%"%P)($C8!YEE6EC+[8_G0%H
MRQ[&7E+7SLWH\0Z/:%CF$8!?%1"[!>N2*49@,"ZP]# UH7R1&'?AC92IX6SB
MWJ!N\G08XR*P$M4&5'MLPK>^5RY21P<JP)O>3QC>:K<=P];B\_5A=UMZ)+)Z
MF3W<&B4LW: O1D;[JS7!.ZPB]4F_IC-I. 9,; ?. &5@M'/NO)MP7>[L?J+>
MNE2=Y\K%)44,A;A&!H5U]6RD'K5AJ%1:2HI_#;I])I; DL:(CO-^[XA:8]!X
M)+55D_N;0%=U='-BCR&H:UB4/E3OCK?,X:8@='[T,CJRX?K\<.&1Y;CP"/T5
M+8ODB)^$;HNWOQJZ=,H"1CF=557=)9F3G0.FVL@X:4A1D;;S]BO.6M4$[E'=
M5UIA+'MBB:8IATNOIG (ZU00IBO0?$L@=QQAW1+CA&&G+:+V6%@$(RR;-6=3
M4;@;RD$K46XV.SOZ"Q 1GI:[B>0Q+[_84!]56?9G8@@UZ>Q;Q;\^1Q6S3=%N
MJ&9'L8E*TPVN(ITU\#T2.K,P%:+HX!G $L'[W;TV7+(+3]C$YL'*MT_,C;1"
MJ]98>D0'HK#60VC%V#35W&:$[:1B \\&"0D4CDHUR';;7:^N(4+,*VX4$05?
MQ[;.VD;^W#Y,,'Q#:')"&('=FRZ)W[&1 )TR-ETJ\::L;5*$OO_,*\UPD&9X
MFJ64_RWOSY(8_#"$NNGNP.6[ZPK_Y87PN #%C4N%Y: 7:H)M5-@WPWTU[E#1
MQ'!6N@+][Z0PF+-*_I;3=I>6X"+I#, A':HO.?0!+4Z=;/4[JD1@=H*R*V(0
M\"#KZ07 ;0X\X&UVBJ9#^-!(6BVF7:H8J$5K.V2<O6I@)?5\#LZGYQU=8"L@
M'KB:HJ=?522JEM)SAW3"F&XM>P:("AHA-OX((QF$=3X\UA#\I64E+K7"4RF%
MU>3]K$XNJS'0&^]]>#BOWRO$ T8K28*20[<L,[2;,G.&\=4UJ:;7"^U?'F14
M"A!X1H=V9:G1%"(;'!G?2N&_#_TC( C6-C5K]=^.\9ZO$MB!/%!J&]^6'=XT
M%3LU%'X4-3NLO,(Y<;^:<Q.D%AHL8^JM6O1[8G4Q;&:\%3^GF6W1Y,9&^+I/
M@([6=3V/.@;AD7Q3@3OB-&]K5ROXBPQ?#::FA M5)Y)L4 P)%=WTO*)SM()A
MDJ]JD,:^L]F6^\(S%,\0]F,SU3R_%G9X%%/?;@1N2%$OC4G3&"/M<@FQ <D]
M*FIRE5B3--H:T)^W9BQOT.@*Z-VG+TX^ Y!Z,^J>C2<>8M5YR>E[;E1P=4SN
MEW67BC;H/1T7J[4;@ZE%O-CH$%.-0,[75E%Q=2AC];]K9=DN:X@DP] D*UE+
MP[I1XVS(L,%@8AFZ-W!S&NYU0S,PC=YI=HHJB:]OS?@Z)YO0A:FA,T#KXNFU
MXHTEO\D=OXO-_K^:E+>V_L3G^D;,S?$_^N2C?RO_,@!P;A@N B]??'_9_[+J
M@Q@K2NUY!W:AYDYCRLMST8"+%Q 7/:ZV/XR?O@B5XI>_B\DWW!._RZ^^(0/!
MHOU4.P3<I1QG\K9]?363///V+YK3T$ET.#_8EBNH2P%< 0!> 9X"J !1.HD"
MMU,<C3WHQB@)M^HM!+Y'^>F1N2>,0)Z@%-B<>LX S%JX#DSN#%[N??1OCPF1
M"_?>/7CDH/!\__8%P%W NQ=_<AH! )=_O[L >,>T72O\90W5G]PZ'W)N.U?/
MC6C@U4M7GQ<&W*V]_0KP7[*ODRFX7#"R5@D1ON^#=DN*HZ9+I/ F%\*E>SMS
M+Z:!QW6G<2\7O</LO-QUH=)7Q::TLAK#HPF,E1N6!\O[S4%>EC"J ]4[#,_/
M #\;U(>[CA&3TMS-O7'@E_&\-^ +JG32AO0B!SE) AJ3S38TECF:[G$$5FD;
M91%D0.2/]D!3QL207CB<A:J5]/0RXHV;;+>7,7.#NNX8B":<==KG!&5O_(8X
M!QQD%X63B<35L%AH*&M/GCM3&N8C8_0NNTSVJW="2>OZHA';KYK,/U?K#T7%
MK9OX6=FI#(N!ONG&Q'*SE.YMGL]"DF5UP!%P74S;B+&18H(WV[KA#HN(J[-?
M!7:91QV*Y(E_>XB<%_AINQO?_0TNPDY+")U.F7UM6W>__V'FD,]4*IY!4Z(Y
MS^MQ3=$7UR0&'E&V^8V*\&-UE5]Y^O K@A6R*L#B$80UC$=S<M.(E[UQW&>F
MGD>NU$ 2C[J1'^08CISN[X92KADW%7K)=T+P,VUBJ. -N?"3#+!K0<SA1ZSO
M0%\XWY/+,2W3">3RRSLG@KV+2-1^A%L3DE^^?$DZA6@/7I"S<WI"1.A;^Z"(
M>L4Y@UQS KS1VW*+PX>N,Y.[\R1M?6#H[*L]S;!L5Z\OA.J2.82 -NF[*E<>
M/.QPI,C38$&LNR> +5-;(+44CJU#/U,?L%N!M2GI^$>QSC7D@U9.J,\ CB8%
MHV![%-^QDMS GBA*S6W/2;/%3I[9_YA%+?O9$VE#<&09TG"\]0P Y"X3'&0<
M_,>5MCYWI7?Z/U/\IRO=?II:=ASDN$TS_W^=\?#OG\N%J2'&UU\\"J*DN8>^
M(;1&_UV*48"W)9PA=A:\!F>'(&?W-4>-P(=#3\*&9H\ZW)B$]&S4[+9LRS5Y
M/'I#HFIQ^-@XK<P@H/OVFV;TK,(\UHY+_,>\H]423_4GS:LW_-D"0E0;W^O@
M9^A$#J/IG>!DS%TV9+HQ=J9WAZ^OX/('UX!S_GM9;CX#<$8EBW$BE1[[S]T1
M<#R=N9Q*2HQ;<OC<\MN]H&@=2/\B!.@>5^_\07$W<[@M<F183]R>KM:I]YZ'
M7$AQ8X05BO/G^6Q2;LD?Z+B/;!V:<ME:@)XDE&Z3-[7YE6B<9/,)6*TNJ;>3
MJ?FK\PN\J#GM@N+V_)+\2JQ6+%_U/=04\UQF<)[-3E2$#X%23I:R\<O?XTLQ
M&H,15V@H#7HHH+_8CQM._7.(:*F(W^76*9QV!O.B"&FO&:[J#>6,NX_/H<9L
M-$]=ZPA,8>]V[OKIU:8/2V);^QG"IX-NPI# "+93&W7./AJ&J)<HK^4= 5@>
M=BJ8(_ DMX#'2+>L(2<UMXV#^"1JT.1(I#SG2-C?03^>8T+P/4I:/'?>M00<
M)Y2U*L5@6-;0;:I>9D(WJA.^@&LG]SZDKRL-4TN.@B'@& $>[:+4HE5KUL6(
M9VJE<>P(:7>U FJ=R;G8F71"E0 F;S$&M]B?RC?%R5AM:L:Q,B2MAQ,Y:6;B
MF4V=Y!2XQNWR.*U2KZ](#.05*LHEM1EIUAH>X_ZDS@]FN&B<@L_,41.NB6,&
M>G##%0CV/HD:U6AVQ8G9RJ$[;T\2>(UUJQHC-#G5>1F5\2M:NE4#8FTCX:8,
M(0KKDZ;)O_I'[,<6#2N)@7A<)<ZRNZJ#S8<IQX:H8<E@8U@KH$ZFI,KR9*BB
M%E>YO>9 6IM*9(TWI+-;L!+?K5B4BI^@(MP>:L=[IE>8YDP15V$ZO9K<;$YE
M>#L$N8?F0(-4/LN,AQRTJ:9Z["BLN@$KT7(K@<W0BZD>BU[UT=,(GY$2F;C1
MU9&.M/D?+/+MST*#5-5WDE()73[CT_\6IF8>$&+T[MT0F&Q11>'J/;T!D#WW
M@'X,SPY&+2XYQN9J2ZR^QV-(9X5CK)VD]ZW,@X/-C"6H](ZOM^W*?6]+3%L/
M]_%L%#4*7"$IMR!^C\R$5%_V+3NJ))@%5M5>I:?.6Z0I/V>"9H&A=OIUXF8/
M*U6HZH=QQT_,#9&0E 4V5Z5S2!RWKYD-Y18>MG-V0G6(J;?86;S8'A[6K4[6
MUMJ0\91)4T[KG#9Q&504(;B0O,\ N [WXRCH[.09@'VWT?(DZ\T*PM +T5\1
M"UL.N\%;5AOZ_Q'V%6!-O7W#4RQLZ4;I1KI!44"&,&D8I2(2<_2H$1:BI+2T
M,,88 R8Q.@0%'"W-1C>CN^$;^G^>]_W>][F^[UP7Y[[&+\[OG/O^U9U/PKDU
ME)3/4VPG?4O&7:9W$*T,,;7Y8;/,S+ -,PN?2(RQ=QZO?;,AWCZ]Y)<KUL28
MW9,2UI]2Z] [KS9QW2E*^7M(JZMOV$!*[HJ"%M936TY//T#.73F[LD](:$'
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MBG4ZI-K<W'5K"O-^J(HF3L@8T\?=I5;VW-KTK_)A+<[=#-'RP4KQUZF#)I[
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M.#C21-:)J?3Z?F54_+97IZBA6;6>P>SU0LU<+V;Y(.L#G[!^?_3TK&P3QPD
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M>D*?WK\1Y82G>F :&I]8=R&ASZ':-H#8&2_;G7;CJ T/U7Q2$BC5)7B>5YM
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MRF062M"&E<:\@='^RVT>X6_2#6KR5V.\_7GQP^$$0;8>I51V=2J[D1- ,:O
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M&FS("_K@U!8W0LO;QG/,5<L2;3TS;%6T5)?IT(^3]*0%SICZ)O@O>EJ;+YT
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MTUWGL[[L;J%=$S_>/G6SX.;"X V^ZC&9UMD5&F!%Q+/*&2#$(WMP;I$3^P+
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M6#E; II6D>8K'OGKTPL+S61M73Q6>BT9.GI+_.0#S$R-:/PX<_=M4>T)]>)
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MNA'*3-M:#S?HX#TF?IFGB O#B"V;8.<:8H[?'&%_(C '#3NX'A"G^CUS\.S
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M5+>:&@@BTH^&J_19_R(1WQ/2P%J#+) HJ^ =T:$N62M@04@@6[B^I!)V;HZ
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M;'<_7V#5TWC *H]"PUE%>?F!,'Y^058Q"5X!46%A<?';K(+\@OQ\_&)\ OQ
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M0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y
MCD".0(Y CD".0(Y CD".0(Y CD".0(Y _L,@E+_](@"XO84,FRN;G.S! $ >
M<.K$R5,G3YPZ=?+4Z=.GSE!^1TEY]BPE[86+Y[ZCI[URA9[V\F4&YILL#(SL
M3)<OL]YF9>?@Y.+FNLH"Y ?>XK]YB^O69R7'3I\^37F&DH:2DN86PV6&6_\V
M'?P,H#Y#<>;4$L4Q-L!QZF,4U,<.:@',@&. X\<ICAW[[?<=G#I]XN2QXQ1G
MSAY>-OP.<(R"XMB)$V?.4)TX?>@$!>#PTHF3U*=.7[HN0',7Y'B&EDU0S"PT
MCXY>1%L7\WWN97:A>V"TDW-R=;M.6/C(C9O"\A#S" Y1\2<URYP*L(Z5*]"4
M?(O7HX?*&8Y]I=^PCQ\[5'[J\)H8]>'QX;?C%*<I3AP_M!!P"$Q-<0AZXBZ-
M((CMGIEC<F[U]Z'+)]G;1VB%M%?HP/+HL(-^P#F*0SEJ"FJ '& G[;__2Q]&
M-#7I7]*>(A<F8 N&RK.*#+1CNFA7\J"D=IZ$TO+M\?)LZ"EC(*USKGMX;1_-
MPKT758;LY78=&ZB8$MO-UC82B%_=Y:*3UX[&9FSZ 4"-I+YCE;)6PW>2[RH?
MR]C41OX^TT)^V)ZT3]P!(-JN$*FZQV69;N?'[MR1/DM #I0_K\LP*FYS+.X3
MV2G2MO:G2FB'&6"+BKI%%S-/UK,5DP6)Z55(P]@4 G/8]UW\4M@.J8!(J5<J
MA4*.3SMS<08[Z;7"*RKL9:$Z,&R]W2>^K>&5F_N$LI)&.;ZUG<%'BAD7DZ;Q
MHM\7[">.6.3X-\(M<$W..JMI]2N"=@SYNM9 +50NTO6-Z5V]\6"&;@XZ>O&Q
MS0^:4IZF<DHF*E*[? [:96Y=/?CS2^H$?QNQ]% G"G?U<GY_9 Z#)R(DS7NE
M9]9M,BA!['GMD-Y866]:8[D'H<L$"LW0(*]/?+A7H)OOD][E\>1[+NTK=F'K
MMR:,\#T$G7?60'FW_LLML]V23T$FL5-W\D7$V</#QHJS"T$9)$4E4NDV82.4
M<!*F7?7D )"&XZ/3/*WNMC]8SY?YT6AU?$AP;., D-@LT?]V/@YM'ZU\=UF[
M<_WE^]6UDD3WA8W+<6XLHDB/@82+/PJ6OE'OCXN/:/6_+.'P'']-++HKOF5/
M0[Y@D$6--RUQ5\N85JU*1$A_G"39$F8D4%2$FLRY38H,0]7/[]#2;9A43A?J
MEN:)4W=@;NV'X#W%>9IE4JW[ZX9/[D1#0)VBR17L7*GJJ6 L_2F,<9]W3,_M
M*,_*'T_0P(OL5 SE]56R@:N=/=IJQ7W=,MV:0YDB'A]I"E<Y6B$P5\"QH/]^
MO?XCH@]+DD08$V:E1-_-3D<6M.5KDP6Y!"XML1N_3GP4NFZP"IZ,MEGOBJVR
MP9Q)"I[NNZW6NXG#,?J^G"H;4D'-QT^N=)4.AF]YL],,W% /?:E;0@WR!*E.
MV4EVEZD9V(SFWM J?;LW25H84JI[CINHTR#6+U5=G&:T6.7;41#8+F_L#K:Z
M(%M3T17HD]S%T+\Z#DDA/9#U/SFK+Q#-[:GDMCYAU>FZ^Z@-=JXHL'(+O'L
MJ'>.R6L>-$EI%QU(:#PL^KYH/,W9ME=1=%&-O/S]HB)W3;6+GR8F=$C-7\=
MRN[T>[29P@Y+V-+"O]^5VUW[X4QCR&Z,RBC[.=*/18/K9V[%Z>+)L:?!AO,>
M_?<7+\_6WW#HSN7/JJPJ.J4[)"(S6>W3B8?%*NI?2YI>F!"<<" O<::6]W@3
MX?U+_78N3-PCJI?7,EVR9J'#+#Z9P=9]'=N!&A^>Q[MZTL;.QT%ZYHRII<FJ
M#?:.^ ]._2\57,&OX/7S S(Q0G%ANX6TI:T;ANK9'>T=I-R.3E&KM_@W3>6A
M-*_>+5PT,)[W5.P4]3A])P+2Y"<HXT\TY6&BEZ;,^$$5T>>2[UA8G:777 X2
MU4<L%WLAWS#.BPTX9>$*[4XKM]*:2!B>L!LT=YAAJ?C45>X8-[8UO)<'MQT?
M+IH963='GSSK]6I!D\'=F2(GHC6*8[WY+J.;",V:)VV\[99QHT_?^%930W@=
M]LI^3/8X$>GTZ7[Q'&/4)W?;9G=UYZF:UZ?;+ELA!]-? X=ZLK! '3^>U."8
M<J/G =V:FS8.W<)%"/RU5ZEA;B,*>KR@6BR37R^^F6/=]-'M[;#MY7S "<G_
M? G_'9VF:AD?N9-N<P!8N0G=N'P 8+^TY[1=WN\]B:5Q>3JE,/NT*.QV0]*X
MIGD[W?G^^'XL(N:=BN:+=<9X$)C)*0D46F!,I95M;(MINS^H\J"/J:QDR-S)
M1F^HMZVF><_U -!ONQ3Y*7L_:3+40TJ*8'BA1$WR449/1V5>L@=Y:6R+F\%8
M2DL$^H/.2J=5VHH[\^M<YLC]DV6XVV_+9OP'="[:\DA3T1AA(U#GT"(#,AUM
MG0:BB8V&[-REHB4Y:+$SXQ"3*V(\9*%/SCDS^6<['3Z)%094[^=%95JZ-,S$
MOPT[/SV!X*-U\6C(_-%.082N%#% $3OWPVP_0>ECJ\:X$%\<(RZS1$?7NFQ/
M(Z[.N.(VL"E_?O1II_Q\%)5BM]3;GXJUW,K% BSB6LTW4^C*T6_1ADL5$G-<
MOF/AR]:%;^CW"OO6T>YZ60I&6P4EO%4WR?MOAM$O]MQ3N$4XTCI[Q!%]%,!P
M3# L)M(#+LXV]8S-!DK9IB)\JPS/3E<RW\2TNO2F<ZELI[21J+&+>,3M6NWY
M-+J"X]%'\FZ(G=\!8#C(?:-#*T^#&I0"%.F*%%''&?C[QM!E#]; H@4E]//P
M!-ZBJ*U,THD"G0VAM W:W9+AL4A-K^ B+G<Y*I'=1Z^?BO?5;S>CYAY-9$92
M>W'!FM!I!X ]N&\A2NDP-7CL#]L4.F6&]CD&=9BSIQ7?V3N^G5QT2AI7$6D-
M-E9.Y]5]";]O@0MPS-%I$IN7L!H.N2J3N682LS;PT:=I24E7?[KP_/T]-<9A
M! ;1&$J \M(U]RI;%ZH8C[X8=/'$XUC3LQ JC-<FU,5B.< ?HXB1[:&&Z[22
MB/GL;-\KV:&@LJQQ2!M;933,==<6?RJ:O!&A2X;H^/89#TF'4SXSRHL.Y^&+
M3@JA$L^M:Z..RPLRQ<I1S:T'$[V<(9B68;@:M="/FFK!WA--0PHL5IXR:1U4
M()V=&/QBI)X^+M.HQ/N^)DWHU3[GG-E*"<NM/<"Q"X__\]T#4K6MH'9I)8+
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M^(78\-;]2\94!6J7\Y4%>QYL0@3$TC)BRG)0&[MGP]"W$O1M,]IW$9W1C.K
MC"?CXT_=QM1%($W8YEZ3QH8!/(?> 2"68Z)X'."NT]+OQG([X&FN8!IV&O?<
M'U=^7().D*S(LYL^BBLQ(7OV413;BW%%;"2ZS!&,C^>RA2[Z52T.OJ&X?$N
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MC-Z+9>G2*AX0$8UQM?4 _-8Y_Y2.,Y.VC4'Y90-76UFAGA>9_57["F$/=3?
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M@XE&!AX",;UV=0X]H^F%'CP Y#[8-=[3I+<M"GSTY:-:^.]<.MFIJ^X5@CH
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MHUJTLX+=QC]* 2H/=(6UB'-M<7RV2N@LC1)A6<]L^,D3O71VS3,WXGN1>X#
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M<RSJKJC65;3)5[=G=HR>D67"8_;*O&YU["7;N5Z&*+8'!J/:=FQ/$NOJ]U\
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MR/5A@!S@SJ>_P!3\F-W*C&ERO2["SR<KPV5-_0//,L/[& JH@_4[V=E^%2B
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M&D3*)0XY3>)>W&&A__=D#O_"_JTT_:</O$:#K3LAC?7H63-:"M(&,Q>DA=5
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M@/C&!607L<>M:R=*T7=:V,>;<++^W2N<OQD*[7D*&6@%4^6D%^X)ZF915X_
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M*1^6=/$G:$ NVGG ?]GO)9JQG5+")%PK%ZU'55AH$= )E6/ZV1N30*.F(&!
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MM PTN^2Z#A-F*X4-LS-&:1!\PA<VV\S6SGN9C*I[@Q-X\?8_DX7ZBE,G1DD
M8IE#2/RSMN:MKP<M4 X\*&%#H135/[)EW9MM>;Q">S"I$&?L PP"<"8_GYJ!
MN]">N2QE))4S]!#F2=0+90CC9G'@U"L!A-TPMF5YP<AR;S JO37.DKS\T24@
ML P5#N(=]M@"NE&U2(E=#ZX(>80U=BD:9\\5LX3UF=A&?(UIT<ITJV"T]T+G
M7+73BU3V:-0GUS+[$Q5Y!/(3I,%WW7*<C3/1)H'5ZY_;OUO'D?$DCVW%=<.Q
M?I# KF"S%(59A/UC"(5^W)]);4X@^!SSL,H4WAU)>"B'B3[4P;(+XJ)DI<CL
MG=-O?@<7GB2XEO!'PUF+MB9!&H19$"F-ZT:>1<#048?S8N9:FM_/G;N2:?&0
M9VW[T?6+S ,\R V[HZ\IK_BBE^_!'D%7FD=5DL:'8B7)P?IN7A\2MLJ>2H%1
M7@W)"Y%JQY]^8?L<7]]=NJ.//.>U\$)[R9Y_VJZ)-3NG[D6;L0 .Q<_4+ISZ
M7PV5_R]PDOU74FN8O<VKADG#$]L7!K*2]R1H;+<X!M3.O8:-O=!@V<Y[2F/1
M6/*Y%.XKB.<\\87!E:&\.^1?7PV(4+'G,SCB+$(S)82G$#'[J Z5C8/&M9YT
M@'>V';::=$7R7 Z\='#I9\O54D9DU<Q\[K+/YLHQQT]Q%%A]NFF6)BJM2JP2
MWK9R@H]$&)*99&A'#=6<L#-&5S"A@\TQ2FKLKKL)Q#LMOW7V$IMP2$P?W!;!
MG[B,HN;7KZH).)+7?*;V5;ZPU3Z=%I";:3-2_[3OID"#GWIA/,HGY>'G/<&/
MKK50<L*F@+Z;26]OV]LKFOIT2[+4VO9$;)$T-,<2W9KV<V^?<EJQK,B*J&0_
M3$E)K'QXIG["C!%>!XD0P@ G&4EPGR]L=N%-]IKD\OG.'M4SV64?L7@K -QF
MKF$*_X4M4'_,F6Y,E]IJ@/)SL+>VO/G\ Y#:CUD'XZ0XJTZ3.&B27VDAO/TY
ME8<0V"[Q:A,YPN]>V[Y0+-?^O)(K7#^@=<,&U[V/=U3TJXK!;GRZ6AL)T*9L
MP(,FAF9?]"#5&7*HZN- >ZZ+$=%1"B9A P!OF?7#5(QRR,8<2)/>+%&PI_]0
MC@)\BYQW(I'CBMYQPE=]DT^]?*'FMR0VMA(7O9D6.89WP[NL*_4 TVT*^UVM
M>PT$.$5U%W)T $)R ETT2%%!EVZ^XD9ED'PZ!6X+-:BP\EHBI'PHF8]^W,XK
MP\4"KYZ6\K 2'B8O0J?"%7"N ;%DV<*8Q43#&!W]8OT9)@PAPYGB/&^-'I6R
MQ#Q>/OSI/$QQ=<Q,3F!&W-$'-H5-1^C5) ?8*^=..?.I/?ZD:N-6'':5L/"Y
M F71NIB)G5Z&CCB&,(<CJ4KMI6?U'I139F :QK")FG'3!-PZ&.!.-L&ET,NL
MG3SLBK4([M*NR'<BT9_E:>^-#TF%0ZO<?<%>(-7WTV'NH0AI'P>UF/?Y?UO=
M_ZWJ<0^__2\>=P0U95)L)2!W3\9&X3NAF%NO GP3Z&Q"^S$?*OT=!$U:&UD0
MVNF?ZG$F)M"'O *@8/VF//4E]'/\\4^MAT:?..C<R29M5+H%2FBF)1-+([C[
M'3++3^V*3*@%[Q_>]?CQ=RV=9R?V]C/UC'JLA#9&9O7'V%UJC]LGU:_R,3&>
MU#L\:B=RAIB^Y )?*3J@YC[*06YP2TJ:LS3TZSD@!T>"7*I0>SY)L=S^PI;T
M($X5H]36+*^=,SA=GXTSN4/VI[1_3,ZK6)B3!AK<O-)=W@$WUH3890S]C7Y^
M84N627T1%B9M]4;"^H?2Q:HSF!&JE@<,E:/J8*A1E__LG9ZU 5P_27&S6>1,
MRKAKPLG4U+ZY!O\$'.A##1#XA6VW;6#;@C9[\=LKM@]*<47E@%&7MRVB]G67
MT_@ICIQ[$G(QVOKOPSQ=!VM,+"O!"@E\8FH9XZW1&\O_UU!=51#O+ G$81)Z
M9^6V4GE8)F2>C^K/2T:9:K2D96+GO%HQ"\7N<V37+0'U6EFB8XD2_'/K;F#T
ML3*+$A9$M_T9Y7*O1%CK_"P,M>O/(2G6RC(>^CQ NU6,8"Y*].-S?0=:VQS4
M]@2Q4(/1;9G&_)Y!RO=9!7E)FTVS)-P^SBN-O?Q*S.Q!A^=^Q0>*917+3+!3
MR5<OBT2^>MN+3$1G<;:DFP2JO86<6;(/:<*;( '2NSBR+&; #WB]+CVV4PJJ
M,'; ),=:+G/\A:#J6?R5KS[+_I/B1,=X:Q$_@4TDH8"6T>D##M@;1>U.UGZ7
M$=.?^XT_&-Y&TL/(-I%$@CI5?MB2*LJ-H\484EL(=2[0>4F;W-X0$JE15 CF
M0HH4R0!@"J=W*U:(%8<+ZDO%/CNU(RLOG:4Q+@6(-Z8.,<XRRQ9"8<MQ83N5
M4 !C@OZLJ-CB^@"X]_;M8]?TG30SS)2W7OE0VW=(3BS)$-X"@Q*U@L7'9X\;
M]8\@U7"Y\<<WX:-!AR3S@^O%\"&_$J2/QXR[52^\K0M;Z$.Y&3D@A3,?+1]>
M.J@T]  91J0>C;6^9IO\>_#,[RK _YVI7D'^207X?REP[S^#@&AD/!4I;-)A
MXURCN]UE^'X+T4UJ%M=@3-=UQ[-)MI&BG@D+@-4+4>)*<Y^PF^'Y$F-M.Q]J
M[4>>VEJ\.1:(\Y"']C<?&R.?BWHE:YJ0.&VF"!75@$$!#I>GX<:]#SRJ>@?$
M)S-?;!>-7CJW]OL"]XLK!J.PVN^OBB[*)&R,GS&@982U>Q'\-A/ +(\Y-S+<
MX?@7MD.AI*5W1"' 3/J>Y%5NL9WB@JF9=%R$0CWO6.QDI,9-S<W%^S8G/XQ=
MZ&^K%NN6QF:?LMFW:MH%$=_Q-TZ3EY2??PCVIJH/CE84QSGMW0)2AL*[0OFY
M7A^MGUTSB=>Y8V.YO"(\%'LO9WBV7SJD6D_'J:C1=)^47)ZKH\!7F\NRPN :
M2Z-**:]=29P!V20E/<F0X>J:F!I;^Z@$<MG67 94?>WU[A&WLLGFV/"VAC&1
M7HH5AACW%]ED@ !JIY? -N]O=;]UYVV.H"=Q TYV4M<\A7MZ2,HO-$6MB67'
M?*H7ST8W2<Y(&1)3>G.XE1T(- N5"7%89=#&4CI-R7ZNGJ.L6KH<8J,X4]9=
ME'\!2N6?K>2R8AW)P%G0!<OR=D26$[HWGT#VYYYVM^_K-)M*V3#N*14UCJSI
M&2&1<\CAMSGF=X F?$G-%N'SY[E"NH?/K!TXW <F U[W9J=SD%Y&O9J*M>@#
MR9YG[N><=9*B[Z!+M)=MS4:G"MS="HN;!CQ(^FBR/)[(I1+RH8,OE*ZF,'S)
MTH<%6Y@7BRNJI/B0O<CO6,O*2-#(4\S.@.G2$$"$H*><$Q<G9IDI9W)JT4"3
MOO/N?#@E0ZO\EQW)C.E-<\9L+575GA$L4B=;C?&]\JSB\UA7_N5*0[RH)*OV
MGI)U\*>1 B:K<\-'ZD2PE-:R(9=VO^N#4X4[U@(> 9^+8679)8&)WLHQ F/!
MZQM;,Q/W76@S??VU"6I'DMP[H8$7!M-_L-/A-*<W6+Y\F9%3"7CXVV+['VI<
M_%]Q$@$49+C&<?%@)=AI2 <JK(P2%2S<&13A^8E3(;>HS)S)'ZTCU_H,?,S6
MOK)XRB@)IC?RCG7D^.&I]?79XH$\,(!T:^8CD;%H"G6IT/'"Z5VN\/'R#;UT
M[N,?FN%POY?MCL6<#'H??MY2/$[=Y87X ]0E@:.SN.0"<K%FY<+5X[[V(2N5
M/&BO%<V\1<W0$0<2RLAR?PX8<J8,:+GL!4;=@^Y=A1S>Q(S6"B)*7BAI5&77
MSI)J!DJ+ S1(I/G5GRU18GZ)\#,%]E:5HX%F9X;.=T:3<6_H.XO8N15H(P"T
M&)EV%9H9X^,]9-_UC#&R6 J2(TBZ+!&'-$0^8,5Q)AU6*>*S0$I7T)\/EG9
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M!'$>)F.8D^T#X.).& RO#>%A+$5@JC;OS(15E\@LR=?$05.N&H@W8@;<Z/T
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MLB)OR9K9D'+>%\!-U('#P9)#L^7L=.)@_2?7,+MT4'\5ZM3JNW=O!!W"$JH
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M\9H(B3Y?*&/_E>.D-]+KL_N-D9V3)<MRI=2Q)4 9;,/+5APOI*E]J5V;WC
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M7+E:NQMB<MP4R9,R(6)P-+GG!G9$V @.[2(CC<8O+(14+<'XS 'H;.'M(+Y
MR+7D%96F7\N=K"YCMC];X _S9E(Z"IF"Q0.3_I/>2Q[DV&60W6>IV/2(!B@
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MS<*?I%%65B=-Q3*+VG1%QH!%R7WM_*A\' ]!O@H/V)G22;WD^5CT<JA?[(Y
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M_Y%&-?\C_!OWX#X!+V%1*.X6^, ]!R37&/?,+*O9^#7SW2U5S3SIG<>E\"K
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M&Z3M;M8I1S"GV[8]FC^9D'W!]7O;BX$)I=F;40U#M4D@F/*Q>9V14]!C+>7
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MC978Y'$FY@1C?C,[E/-_M(H_&_'K*OYJK_3ASI.\]WUI:/G#']G#'!8%"8J
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M&$U\JFF*_'6$Z^OO@I\'376SB[ARLE.*UK=>^J>MNV^H4@MO><I_@85Z$@\
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M*25VF,:1;-JEIS!4V(L\OL3HCUQY/K*QF&;6N5[/;.#?N.7Q-$5GME]-./4
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MJ2KZ(7HM6FS%\6TZSZ4S<=WZMR8*=#GQV*%)W?C:^;K% (?E4G 32@SI!13
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M4C_$VTA?D(BIW.B/EQBRJ8I0=+\R$U#W5?)RO/C <A,7!2&74GK#>3.^,OH
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M8E+<R'? O8>\R^.CXD_3W\XI7:J--&%2;#0BEPG2WJ54%T)B]OL@TB29;E+
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M1"'?O!4:"KNL['O8BWR_V8R-WS+'<(&72\S2OIX-%G#'E3"%+^_)+EJ@".:
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M%!?KY.5%QYLQ%AB(JXH9@&)I^U_S(4OU5H;F)SL,$\3#7O+G/MM0ZW ZSC(
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M%]F"B VSP]P7]C4%",$'68(T&+'Q/BQA=(#.Y*2ET"9%BA<3"+6\'+S,^FW
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M3C4H(9%J'_4PHC0K+'>0JCP)+X5<)[Y>8FEC7?'3V_<']9R?89:!# O^PA-
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M)]--';$CV5ZTJ;OW=FJ>"2X580I\>UQM(1*,,KI5"-#;[1@IOP>KFHJZD_A
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MJ?ZFUYXUTUA?(SCL/2"%J/-[/OYPLR=CIOO.'U-V,G2H5<-!@YY^61%:_>'
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MQ6KYPUM?5"7\.>I"G&8C^!;2+5OA)/HPN<#ZZ;+9XOQSA61K69MO)A$H'NP
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M":2 ?UC>G\YV)3GY]DV+1_DY84&99 7L^3;E52[=_S.A^4\D3BY[7)P$07X
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MXS!6NUEM."MCXB:?[B\A/3GYW'K;1HC^L=Q>LAMZ.:17KMZ"6 I%,M;6#5/
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M6F#:?%;QSV&^5?E&9^.DII4U2S[XEHN,CQS7GNPX70DL39IY[Z#QY%2C^\S
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M-![AA_+=50_,VM3D7\W5XNQ&<6 5?+9K!0(N/@ZOB$8N!9R(,/5VN'C^O-A
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M0:5XI.)E:N&X:G/^&R%0)L#9X0. ]-S@'A8^ M)>AY\=N>K600B>8%Q D@X
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MQ!O2T^-I0O)C;=(GNK>5_,?H\]9-^-23?:/! L4.-+:\Y5.-.A5N_?Z?XP\
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M?+\UY&"LD;+-: #(H-H1UB5_A7/20^;^>]7V#F?UW7JI?8=]+^AKA [DTMK
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M[J06)7?G:W<+9D>G]]8-V8&38])8V3EV''*$VX<-HC^!;&$^36DC*WNTD /
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M*YV:0IIRQ&K;U+Y5T!MUZ[K>5->L_''X0AXZ1QUJ:4E)=J7(=R!ZJNLWE@\
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M%'5F"7CP)MR=,S34 -XM<)9WADK#D_EI??VHCJ;V(V1!7'1:B0?V%BYVON'
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M8GV(R4";L_%2:;+G%?M'%>82]MMBX)4*TT9010UKF?2:R"$?A@Z/5PH$AZM
M!QV9\*?;X;WX<NV(H"RR6K>OW]0'5O/-G%H61&^9$;3F96:[0J&[#J0+:;ZL
MD9/ _2RRAED9Q9-![D5 U@2Q^OR(]R6K,:75 3!Y>@?,8V>$V16(G\%J+($C
M&EQ9H.L\06E=B%LXARR<\BA]J!6/8D@!*=QDD&TSG:!Q36)UH+9RJ,=;,/75
M(?O9)%%$NG:P^^A"MT380?D$"L'*.J@M0%KHATVV3)GOQO5NRW&'D"767OY,
MKM TI<1ZTCG4T-)S*&L/UA3+0Y]/B%Y*5:]$!N6]FTHW,0D*OG>R;^MRWQ I
M1O73%&&(6PS:+UX@N'QTNHPN)6(YS757F5[/UH8-5L_W84KF9MQ@)-/2TP:0
M&<Y$H(NL%_,5X"2SKA5((77AM4V[HJ@;K^>$&X_F<EU[18/N8#DP-=N>'>%D
M&XOHO![><_$,LA?+J#+$./-T 21#(6*)",T>4=D$<7NNR;!Y*P]\T?_HFBFR
M,3;PRL?1LQ-GQ,-'_U*;T;RCZT55EX6%*U]C4^Z='TZ_N:P(M;U_HK3 8Y$]
MWOF N4>'NQ#*+Y+5D23S@I'<;39?C/D*<(-4^[MUZNYBP-4O=,80AUTV A+Q
M.#5_/?N,3F25\4QQ"#'>N%]TO:2P:G,GU5[#)N4KH/M 3T^H4N@KH'!_XNW0
M;'72,V63?(S[558Z\$0'$21Y\_0J]*G=ID:O2L3 =(9)H]DDN^8;[%AET8OU
MWKK-[3XDWY03M<3ZSPVWO4C&FA4,O+385_<)ECHRC8V*?(Y=>RT])IVS)535
M]*?F?_(XHWGW6U\LG9.'/2.BB.+0*D2V]NWHYL#3,+'#A5ND/A:>D;!E%E'H
M5*^F!4SBN<92LS7L&25\2[9 !W^[SV\ :I0Y>'T9MIF=[-X3!9'4H9)$%KYN
MN<K%_>PM'TRS=@C<9%#>"Y*"*R%S:ZY-*B&2>@X2"X#J*<SUV"A$L J'B:QJ
MQ,=F"RJQL'0-^,]L,R= C_^[=S@QL:4C'Y]DOP%H:[X[S60U SCY,OW-WP:E
M6ORN,&##X]$RRJ/:%R53,WD IQ-^!+L,RQU7.08[OH./Z,VUF\Z? ^R:W@&<
MDO< 0NW(_'JNCK"X8'MJDRI%MU2419_7%B%N'!C(;#J+-FUA,LWA<#2_OR4N
M->.8BWL?:\*3C0BGDQ&N#!>V#&8O7_E8SOKN_I!>B8A(DZE:YR3?!1OY<P<!
MC@[L>"R_@]ZY<-Y'\I]*MQO,/Q2CL30/'[:IQ,H_,=K)+;7Y"O@5^P&[8_FG
MH2D/+Y(*S^N9]@HN=AW(-FU*7N,RF,_G]5A_!N3TG(/X5>2!?6Z@)P8'6E<*
M*PS/+$2FK,AZLE!E"FGMPH;</-%NO$+, GKR)<+P=]W:- H.S J.<>)NWTX,
M6"QL8J-3L\OP0W:Y*:@$?PL%?3YCA3Z^P%U-E+0>=#D%5',R=_D:$4*I%Z@L
M7/&Y5B.\\SV6+A69;/X@M/)%P8,X9QAB]QKFHY9/.R?.""/+4S"#4,I+C..V
MU:;UQ2VV?3L@I6S(KUU<)6M=8T)76>@?G^KJ/G'X_'WUH*+9;H:A^L7E<)_7
MI>(R?&,OT-3GG\^#R\JH^X(ZC,3@4LJCRLM-S$HI(WQB93"91'V=G";IZY%)
MW'/7.YO[/(R3M9WQU6!)*&>J5[VA#X2*S3OY4%$&=*>:-VR8PTF#SR1%408\
M3%,ZL%,_>D]38^[ .D(4BA!]'196\<7E(*='1 3:Q>4=U)Q:N9]HD9T-<;U-
M!8RHVQ6^)WF#S08FF=!78A#V&'#_+QGSM,D52IWJU&!-4]9[7AZK76-!^+B"
MUUE(J_=FF]C4+1'.ZH?W=-BIS\V5T+A(?KFD)M512SL@?HEL:FS^</'V1X4"
MBP(.<T$VI[3%W ;#M"]/!\N3VF&6+CA]/%X5EE(8J\='?5%7*RTX7Z8B0G[]
M)MR^C&K5-I*L=AZQTZ+1^0@=/2S[ #G.4"$C?ATT#]=^-^20H145E[-RNU=*
M-=%@ 9*:S6/SM#<6QTQ2I!/8%C\5_22AY&ZL#H=F2'ILR=3Y[7.I339LXEV4
M:1K-MAZR*L=JX]O!@[IK@%N!C9^J8TR<-*7Y'L7Q R\ J0YS'NEENF20M%+*
M_3@3PB\,V*<7CK'T@'SJ9%67+P:NDY6M*SI-W3+>XAM'<%WFFXS^HA'KSQUA
M9HY]) >38=O:37VO]A?\IQUZZE(%!>A\:62:\AOVHQTNA;OIM)<00'5L#FG$
M*T_F(_PR.D95/67>UDO+4I10I+^>TM^N$I:[%@/**_EP2"Q4%,7:$/'YNQ]7
M-E-&T%Q\_N/:SP/7ZI:'8+EOV_(7EAE"0Z5#8);^$*_!#R+36E;FOA5'R8K:
MRHCR#S*Z$G#G:QJ@#[Y[E$_Q0GE@AC/B\;JT!?M7BL]=3^,:@:QM3'R([P5Z
MPHS)RCR'/;GYQGHV(Q,BO96THYM;I_WI>&3X@P)VA?.HK3@\TNRM)TV0#V*V
M=+V #C1U.5*I>B(J*0"VX7@4G=)""J9-!>O F#K624??_KF+G>_C!,^?W_T+
M:HXX6+\"--6_*!X]/[-5U&_BE)2!XZ<N),8KTMF@T@]DY@XU$:KA'TOK)BVO
MC/RZ@=+RNWZT&/A[:O'.4*[.L,<HQF@8_>!F>'@;C2_./_9B+6XIZP.YI#6?
M$5L)TT3:X!RD=N2>2HJ<9F=.T%^WK5*P<?TEI=&6WK<BRP63VN*&"=M'7.V-
MY7VG4?@::GNN/FX]*[(DV):\6K69.EY"6--UVGY34  5OAZ[!.6.I6INF^*J
M+C%-7=H(X</2E1N_5#<2$)4F5/)B\Q!H-<_$T52.E]NX:5^;_+$!BX!28E^I
M&!NNR]#PN8+8BP+AY-7'1$_F#('X4AQXPM5-Z M%)]K\GD'M<KYE\$_VC&3[
M1K9A[D+/S@-#59KV!3V0<[ZB:L\ F+T,SYE8,S2$TL3K#B\5J0K2+'\.D1?G
M>YD2A>G5L:?DTU8@*.OCI%7'HYW\MOA,R5%VXH)JHZ3DT)!H)5Q'#QWG2EF@
M&C[)E01/U_0@!_ET3+ADN7E<I#)W3B[$;,^XZ^9D,4TJ+D^;>1F_A*B; AU9
MYJ2I%F;;:;8/1F\-5FSQDW/]D3[&%$;3(+^Y5G>'FB %&(TLR._8@FGW6!JH
M,YG14M&%I1K92&BM3-B]-"MAFG3_4N]7<>A9NWSZ3!H>6*HGG"+MMY?[/H<[
M%FE$E8.-4@2!%$CUNE6#,%F]>[:%M:.QX$6/8!B7'[9>*>D^A5*CHF0+J_G6
M.V &+JWEDEG62N2K$XJ__/=/>?]IFM#28NZY^\:;3Y<4J%P\FN\1=1]?>N8K
MP'%[9Z^_*L1L26JL&\F_+=6IA- Q[>*YJNSB.6_@1V-1N8)!AI88M4&IF"_3
MW2X0>.%\SFLWL4/#C$IH<NM6Q-&R3;5!L3=K6DSW;I)?20IA?&)B/6;4;%&3
MLWASE$W3I;8;2)$>%6=GMB1$UYY_B*75+[7GM:O3\6S!-M:5UDBVTSM,V2]N
M)NH27.K/VX,Z,E^#7VF?56N#BD8I"/K5W^)E:B5"#NH:^_! K&T2%3 L=4@2
M_?R;N<1_%W!B^H3?+2JR/8J_6JN'T[,7C"W,?"]30-V/NV 6G:RS FSBY>LS
MMDFT+!V(I:'5O\]7NTRH'/6__;(<3'C8(TE/(4UWVZDEN3M^6!7'F*RLS71M
MR)<M0E0)&Y7KQG83GFCA4"GC&T /':8=F& :YGY4IF. +GEHM#!\6D93*=<H
M(V!Q3)_E6@+&F!)3@FY_H)NN%MYS;BO&;8<7OJ9XVC2QLR .7*'L@XJG!,U]
MK/&$9T2"[>W11+.F=2&F?LNA*DR>414A8R.QG&QLD\Y^6>L%)GHBG]_S#HZI
MY1>BHO:],ZLQ5:7Q=]6/7^PV6OO8 Y @#T_&^(K6 VO*:U@/$_5!MN92('5G
M] MD#QP(GX$R2)$-KY7WM8Y%NYN,79N95D+XVS?GEU'ONN4#N;6J7H]3A4R4
MZZO?JZPP,(N(5J&"R+G]'&#WV1HHZJ(0UJ=$<-"1?G5 0Z@8A8]"\)A.BU+6
M"^UJ?JU@WBK+5$Y2"_;;R]?!T\@2\_@DY]3YAJ?C\P[U*SUX'6>GE(CHS%OL
M']4_,.H4HH8$Y92Z4O_@*\6RW?EA5_G?C>(IA9.-R(AF)NN'?P9VV-0; 07A
MVD<V+3<QTB+K/8A X> -,4G*XL\%7P%WBO:J,TLW3*#&RO=T=-ARA+GX^N6L
M@#MV/!EH;[$%Q#(EI$6E]D[.AH+W_8YQ:13:W]O5G_G]7GRIHK9DU*I'N;+S
M\#SW1"-6VY %-3/WM%JZ BOE%).UKU1\ 5\T-\-*ML->%"C"TW;JP#QIQDXE
M<6YCYF>+_7C2%'[1D['V&4$6U0C:O<$I@\S=JD8F0T9T](CRMZ,T/-<Z^VLB
MU2U"Y%>-I;:)U[>+_02YXF$]A*QX(S \AXG?9'P 7]D^5\SQ;GK(5*#:7VL[
M\1;*%6TVEKU(-$&D,_3BY:-M/7V.E1-&/E<:S+[:Z%PY?+AZJ)-AB=PZW6%P
MI&)G'1IG0-\B:XSG84T[F]E2Y"D73R2D>AMWG'9W"'Q?RC$QB\*?C7=.Y$^;
M0?Y<["<,3<)^6L-(Q'\,J'S763S"SZFH-!VHQSGI)I):(D)4[6WVF/0FN^X?
M1JEL"$D,3FP>%"=A=*XQWU!4,8@D,J1(IX@^_AMC=<J/O-+"PC[LM3,50[6C
M]^&234'$W1/6/X*=G-'QM,Z49TB,]M=+8B3LO]8T7[V_K[[0)VA7M)KD5YDA
MI;G8S#)N$J%-@+-4;68A-,"%Z=$N+\8/Y1\4$-N.BH<:Q'MIM3&RW"2]RR9^
MQU!\CC?>7U[89Y8KV HB[M6_*@UT79#7?>TWU1N4+V3\Z,R58.U/"UORJ.WB
MSLV0^,48U?V$#_TL\5L\$</G[CS;#WJAC3@TQP8YY]W.^E[?KT\=N/><%;\I
M%:A-.D1M!-ZTVO]6WYVMEKQ#-8N*]Q=O'&5EXTG!$+)YV@(%]_?Z7GQO%$W%
ME4=G-P\O9>GM-T"_C*L8RGVO3_9[H]!OGYV3+YCWV,\B'D!F]^^W?:_OT?=&
M-<&>7[_WK9>$?ZB3;CSRNND)"P=E@J+G0=><HI!5'ZH3+#9U1X=C(HOVU0("
M*TOM[1;(NN+5<A_)^X>Y$$M=;\L<78"DP.YO8^%2P'WI*^ A+WIHV)N4VHKQ
MNM#<,WY#BX4C^/)5WU6;8C_._1CGSZ5C^<K]+5>#8>F3"AJV'%<'#?4<QE')
M**RNGBX!&&#(LJ2TV3)@YEI7[$Q-\]US=M_UL#!:KZ&'_FAZ*VH,#?.*&+75
M@6<91]+V90VNH?9<_/R2@\;M[42CTY^.GBWU8Y-2#G*O1:J^FJHM)VDTMICQ
M-J<KS.66>IR0^BGR&Z])3#B[7:+=N=EZ,OKXWG7EN$!K^EQ8QI7I[_WXKZ[/
M_&6Z=*QMID^8VU-BX?C4^JG@T&K[O"*(#3<;FSA?W"^2OW#9V+!QQW;9(CFK
M]L7X85:P"K\V>TO5JXH>=A&HF)LI>+&P(C#4P>.R^]23VELS)/C#<REAJ2WG
M%1HUF@I>GKW@=DZ-M=!#'T+6=*XVX>,,E+VZUJ+\_//4EQE.LD*S3)C[8S9O
MRSBAAEMB#<.1-I@DJ0)U(&67Z(2UJ7256?A(@ ?+H+$'5GW1IC!SSLU;D 'A
M31TK_2KK\\^I0P[7GQN5P-:Y[YZ@^%L]^P>=<->_"Z3&X'/B5\ IP;Q^Y8\H
M%OR,<<]/S@_B0S<EI;6% ( ?#S2<>/\[W^FK]ZA[.\D)E"WP=&\GQV]X'D8>
M*>QSWCCY>.OGWZ'3'_-0]@PS:Z**U_7ON>194T/N8$F%L\'9CR/M/#<=E5H0
M1GT%"JJ0?48F"C#>8# $9E ^:S2WJ%HEOR453!.<[41.#%TLV"3IC/,%N*%9
M4$.V,N$^W+4IX<^5TA6FM1[_B6W^G/Z9&*V/ ?_5=&[KN_E6\5TA+A>$,G5J
M7WO\4_N/8&>H(5^NU,>+/0(&OZ-8 /9L\+:4[X$W[Z9]FIZHNZ2%_W@7</Y'
M')>Z:Y5>4Y.+<G&)5W^GN?MA_O27T6"+KX!8N7 5P&=9@]\'YGD#*1(8FH$W
M%;ARMV]+T8WW\+%-5UQ[Z^NYUNT2!-&DZGXTP7^1J;0Z6648RC?;=56+U:(A
MW,!AJ,[7:$AUZS;QF@?1+=<B,O(%_28=)@,MQ"2<C^6CWQ4\-*U)-=<6(J_-
M@HC<*I_-! +;$9_:8=&8H#+\,DXND:>A',Q.-3C]8!/<:K\8* .$B*&;L^?C
M;#1RV)!6V,);]NA-\M.(<Y_#ZQB:)\Z_SK>P?)E3YF#A\X"0 =!Z_..9K7]]
MP\I?)JI.;X@L3=2&;FM)6V-X H<5Q$U.0'XAN\$F+,.H<2M@M-2FFN[U/ :O
M9[JVTG9V!CB^U7;QOL?9O&6/KX#;,K:UBT&^AX;![0X-BW&7O]^O/Y;.D.\X
M^W_C'W3,<&5U)WA 9'*U*$CWN5G(AO4N5SSIT\R!5B+:H>RZUV$XRG_LP%WD
M'1G ]"+[CY16QHQ]<9V4K?RF<E@]9>[,0GWR +0/?QR0.ZD-GT,V4\K.HX[.
MF:MB8E+ L@7ME3FGQEYP4\Z[>65:   _QC@[&3*?7U/)2F>XF5"8G).T/!)@
M:MNKET46Y)Y=/*#[$KZI=O?L"=(OOT(S<RM+T>7*EF)=%X _'5B@RQT84CM=
MH3BP<1)$MCA\$"K.1QCAE-GR> 6^.P]]$VV7T6;(KM/:8 ],R:_(IHU"+K47
M#T<]JHPI4'&,U'1.SBGUZ17GW8<@GJ[&Q4D^PA>'D/UIL^^@30IT-5%BQAKF
M9@L+GSWKT7ZJ9SFT!T!^W?9;(16WDI+JC;$TTE63EHDFVTC?R":4.!KN&AYN
M"RP'$\.Z'I6!NY\A@A -3Q;:BON8MS+[=N>!L"2H;6-84X!=O9:AONX"GN'I
M,YUA1E.'1(X"[]L%P2YUW($XKN0HXNQ'0,:)'QVO_^+13JLS#VG&%I<5Q5[D
MA9<H,X,"NCX\@EB>'\OK_6"T&)4:4;*D).63QH:52='X_#H\E>SV66/2I?4D
M<T"-KB%_?']_>RR^<02)G-J^ICGUGD6_R-TQ25Q?#^C:PH:!9+V.:!QR/9<2
MT6S]]C-JN]\;EEJ=?0MJX4G9PC+'MNZV%REFR,BDY4^D0FL@]R+-RK2O\O@T
MG UXFE3M?+H+O@C2SO/83%;S@_!9I_%%FPYP#3L7VV'S.1:O:<.+X&;TG^-1
M^HI<EAQC;"XIS]X%X/!#_)XT1&VE)@I0.[+JCK]KX2)0,:I?JIVKMX4CXA4;
M+Q*7J<QC\'*.*2ECH%OT^_I8Q+)R4\NA**?";WK!>@-%VO/WWMW93%3YII:V
M+E_Z:ZTRX4?7F?PY51MU/_3/0N(/^0#Q'S"3WG\P!) H_H&)8TSK=J<:_9V^
MR8@<R>?11\*:"N#VFQ\K_M/$(&+SIWG"E%6XR%\[T5GA_/'DP/AIFBS3^#W.
M[Q_268K?IU\=047^T:K=ZNZ\ ODA,^W._FW!/>KYA,>73A(?_PI]H8KD,^I9
MB6WOA^CF%' J)M8V$+;4NGJYRR0F%342F+M_ABX*T !Y$"R-2<JRC+_4EN):
M=$PWPKD];.ABD'U? ?T+P1'C)-I%YT._Y%WT4?Z%S,M NRSZ\2_ HP*>SQO@
MAJ/9X-7^_>3!8K _>+Y*,.E0,.#)FNG5T8?]GA!9W(%;8#DL@OASA512(]I(
MT:]FH(XIK#XNY2O@16I7\%[&5\ '<Y(QHT/>>.[FNK$UVJB%G3B: Y=_)%$$
M=K442WGYWN2_;[*@65Z&&L]$1\=E:7RJQE2C28WZ4*1(EX$RR%EF0F1,22I*
M:I29T[O\X4,SH*SQ7'6_2JTK<H9=:\K!P[9)6G[7[BO@I[15]$Y(LGR>JYM=
M=X17\&K/T9DU&)K^*V!Q6]>>IL[O8]!\']D.>0B#P=_D5>4SBUA-IDBX-V>,
M:HR][@5'R=N%AL9%7*(%4G6!V5#)3$0W56&(=$F^YZ5"H^N.XMS&$^%,I;@X
M/E#'M,;-!",+,<OTXC+:#,3,!92?72&/MT#;GMA+ZZ9UH+6U?#!=\FERD;D>
M[7-<_>W==AV<K_=JZIY-Z%QY:@8?T!J;N(0,O@!><T5);K7O::;D9::NV5N5
M\*IJ@FCU<$:%QKH-@Q%][BV+;9K2P?[0GFA6+>C4NZY;>O>4V8 (F1A0HFLG
MA(_P"VQGFW&Q,"=78<U;:2:1L8<N,G8(5MNW;U9?(LK9F\&_Y0R1XOD*V-X8
MS5)->6MP<X@LZ%-O!HU#DG73=37WNLRBM(>,^L/+25^$HGTSVINX;:MWY^3B
MDSL\>;F)4JGCN;!NLV[9.H?4>F)XSS4LS,-E>/Y&'APJ=MW@)93-]PIB>X(-
MO^\W@_:4[I-*B^PSJ1D6DSF@S9ZSV02O^6QLHMT,).KV(P_'NYK/#;Z.7I;X
M[H>3UA$9<YM@R5J)()V1UA[C$:PH%*!=N*IFG]9(%.;DXN*^6JNA80,X<?X<
M9CK )!A_7U_1FWURZBB5<=M<JKXXN3(X)EA5/_S3J?G+#U<__Y5&N$27'3 8
M=#YOO_R6];RYF/E3>SGT)0@V .A=%S+5D"?[YF3$YN,_8/R?8S+F&^/\<0_R
M>7M'[YU$+4=VE-G*T6PD>3ZH>N0?WTK4,Q6SZ3^3/4JQU3?=W,G)$:W2\V47
M$HD0Q1!+9-B$([LZ19C<KVP/[)"J&2HJ00;YN7#_MW'8:"AW >>BLGLNLD+9
M_-J2D7)9N2K(9<1[^N5R9GI.@SW# &G"(>L:='<\&J8/[-<TP6J5E.C,#[-5
M2_"DUPO)^?*Y/U<\"IEBB!4R:&P95.W*Y+?_J#U^6#3Z8?R"FJ1UA;U*7ST.
M\H3#62QGKX20LC0TSII_%:8V:&PH&K&I*K6*F!S.R"VUOS59F!)N[*'041"?
M"@P^T&LUE&BY;VN3F-H?T"W_.0JE15B.CM9[<_X3O>@?B?BO1H&Z=CG$N=:Q
MP6!RNB?KVM)7P$3N5\#D7>]Q!=.M#'YL$OC]W-TMR';,Q+1!M5N2$05E?5PN
M<_F54O$IN Y%7S!6J/M6_4&?9<%RU#++YY[Y%SK[N<IZMT&"G\GLS?0+G%ZD
M>0%1'9!N^R#;MS %J$RU%"&&195/#A1,%8MQO&P;5E&D%N^$**4^)\Z8:]4.
M#V4))JOAXF>D<31P+B&G6_46[F;GY9]W]H7*\M'4+5LNPN,/Q-AFVMI\X\FH
M_,R8>X;92$558ZV1G#U)FOJ80;_VM'1QF*];X'LD4-%1QE!!WYQW3[WYUC U
M0S,;N]%K!6TVND;=>(/TCUV@CV,]CA9L=Y;J+G@;:%5ON-B)CE(G;G<XU-K@
M%CJ1T_-$?NG]?LY,% $NK#9CD:?I_S;=+(X/:R0%$X(A4J>W.[PQL=:(6#J>
MS.D-&O@B3%NP01 ?T;^ZU")?*=__E'6"KT4S%Y9 ('_.7TL2&I&EHLZA;H+#
MMRH#;K5^,2=LO7\D1+YL5MM+&*IX!ZQ MW=Q*@LKD/JY$U#Q*LNVB#9XG6[V
MUF7FF*A'TF8?P[X8>>'G1+)R;%>'*F>H#LI8*-W4R!=GY64CN?V4ZAV3AC58
M(O$>U<;:>*/YTJ)P29P?;@PD4F@.[G'0>%_M*F3Z&=#I\O^:^2 '#-I.GB_^
M_+#^4A;CEGF_]+$V"=+'FIZ*<@9!<QB.M8@XG[8Y)M$H*-;"6@/CI;.P%"\3
M::_%[[@1XLDN^M(SM(74U)56-;4IP!MSFN0S;%G3U<<-W4_GJVVT0/)/(^%Q
MYZ<@BFPN.(GXU.MHH0)QB 9>_71FXJ-HB"N.:H%0QU>&39FBVM'='HIH5#[?
MC:=$*DX+.P2S;+IO"WP%"-.=Z<?DF$I$HN+I6( DW#3$TJ,+'#GK^KSQU/P%
M@3]V_5_=$271DO[S-$#B72L@# #(I@9\_YG^C43_[\T=A2YA-"Y*6UR5;^U;
MS3E[IRAH&D:@:Y+!%B<XY(# .[W-I?H=3!I:T#D<U07AK7J:'<D,S9S;[J &
M"=4\* JRS7T?.Z(FZ_PPP=.H/D?% I7(R'3K2/. HE\++\0DG$<"BW13=("=
MP:]+MF/UM+!;_--1+U+9]@BO8%ZH- /[+9RVYF1[*9].IM,Z,,?+7,/HQE,X
MG+N?(%FXY;&KKZC?S<'/"[6SSW'T6*N0P.<:O;YO:U$BU*QCB(5S/Y=#? +\
M&.CFG_<LNC9F@K3+7;G] O/<L"MJR3F2KO&?X^0W1K?3FJ,M)0/P0ZX2[T&-
M&0O;T1PKVN41VS%?=@)SRX/G:LC,+4WF?M'AD*O>!4,2\75RO7Q#W_"B>[X"
M,E?*O5FIQW)S_B/,QIW"^<1O3\T-E\:3V>J.IQG9<3LRZ][R@;+KFBQ)BM-$
M=2S+;E)K\T"E^-A2[?8>DE8^\J_O&0G0_I]\IJ+W31V/J54$^9/7MZKAU :R
M766R-.V(QM#1+'4&;/I&P&%QN6*YX/7IQ]QWJ=_(4K?^E<0 )'[7F]G)OPF/
MI!EQE3BV31=]]&K[\26^WC]B_!_C"[V</H\))SM7@)$W"U.?OG-Y"]U//32U
M1E8;]T%DF?IK0M!ME7-=/FR90*NU4B7!;]M]-&WL886*.?RF*2!&6+$'4XD7
M[0 /^>HF6(U@@0N4TSL_P2[J_J[ ZJF22E.AHB)TYCP&-63*7\BTP'H_(5']
M*Z!.>PFR-*]OU& #5/P)V&<T*.#QJB9:PBK(+"(S;@W:N6@_^MTUH4N,V@MM
M'Z;^"KB4OP\_.IO7G\:U9>9XR?I2>4G'9:NPKEXN0869Q'4ZLWA"Q:$>%/8>
MS]MV,IE>OYFNRBB^?B1>O274I^QG[KO_=:E2<JC;_ I0G9.E&=L/SMO(\O1Y
MD!Q\+84>4 I7NGLB]A7 R@I 3P\X\X>,A@!FE_D8ZV)/"''\I/S"37A,]/7M
M&-ZQL*L>)Z1.5FS<^"M.^M^L? & .X#K!]C44:\GGT;L/A=&^>4.1 2(CCY]
MIJTC%4>\\. GG.DO&<+6OX0WSTO\J1,4GS8@8/Q#W7IXA<_G @OK7I4EMB!\
M6W"]\9+H950U43CS#!S495;_S* RTA6U%<@XB>WMO)1EN>MORU8 S2D12[\G
M0D6?1.PA-$%.<L-C2S^P^[S>QNBTC;T85*D8F!"EB61JF*'?9>$?)D;FE2=L
MQ;+QJ_>7A=,$(+6*O+U>1^L]M]<:4=BR74Z-ZX;&LN-,%NPSZQ@YPB+\T,E&
MC.D\_/68"Z_[<W/])"EA/<;BQAC^3 S4H4Z!0K\N3P/JBJ%KQ\W[;%U*J%TZ
MW ]==*[2U+,G,_1;MZ<HDB(R**6K&Y>,7&\?=&AHHNA#B<]:;-'14X[PHA"W
MMESE O*# 5LA(8FD6"&AUX!3'/]=3'D\^(]_&,@S=)" BU\!>:%V[TDK3[(V
M7^&56R[Z*W^SQ:0 &2>&??\Z /=9BD_UC@VG>@.-K@EO"J8)OA/- K_@&ZIG
MJ!E[OS;>R_+I1)/?W3]@_*/KKW]RM:;]R?.:.K^7:#D4@/*[H3GOYC+V@MM^
M]@;@U(_MES"+,*YQ7?/,4E4+]^-Q(K<T]05R2A[UK@<Y-90$MV8IY %<6(I^
M?!( P'(7\-(AD/%>$<\;>'6U.5WX_-$9 8G:CEF^R^<<%"GCG>;GR1XE>GJE
M'@H.U"R*@M;S>BS7S*\BO@(:N3_GV5X/6Z3H98.E+,C;:V]W3-+$?.&3_^GM
M*CS1U+%,=\;'_&%$H>&!]=J%EB.:K">07=WW",=20HX _<,P) QUI&"[$;0D
M6IN5O%3E$27-XS%:?;V'JNA)8=:C\ZLO\F%*HV#)@8]:R@5+W RZ5EE:P_G0
MG-PW%C/?OF7.@B@_<#?HMQ3&7<\J[S"7UNN7KS[,8A2*SBH3+-T21 [[LT^W
MXVXH=)-U'>][F:40AF%6#CTZX%,F@GEI#(M[%5NVV3/-)SO-C37OG8079;Q2
MR##;>L\2)U3EI\5O6V!3W@WBY.-P$[1GU '=P<U;L]+&?W ?2$4VQ80@Y,-"
MZY9'/?D_^(M^) "I"$J15_ER3>#^BM,JP1,5XU\!.I#@\PT$S-:ER!</G. 9
M%7I]'09MG!&@.*55I""+T%$H(:)Q.4D\S3) _*>_Y-KKE?_FVG^(:P& ]6L-
M(0PY=LB XJ^ 0NT=@9!Y'PRXG2^=AZ8YCN%UK/L'/JJVK"$E\<;-1!0LB=K1
M=YZ/=1<<=$;>1[0&"XY&Y#U)!^D4VU_U_92"OT<C>C$T4ZR)FCJD"/J(2J:%
MJ [M]K5_/0M/WIYDSS7PD%OIFX^T, 0J5F0O:M2E:RE-#&BSS?AF\BLBBHT;
M G,JAF_91GR*8T_F?\_&M@'2LUX6H]!LFS\(J8C+7^BQ#F=J(+T8&W7,J6@:
M?*A[3Y,AV(N+7>^04KHU9;C<V7KTHT)O&:XS-3QIT13(I!IZCT&(^M.+MS=$
M4C[.&C4J*-T 7'GU3R\6G*#'[. /N=,W(?X+1_%=@<2)2Z9?CNTGWA\)>=W4
M=%7D*(X^EP)5?R:X]X$F*Y,0F054=X5C_B>/L[#9NS\B )@$[^^5?J%6W;)[
MV/$;+S$50W>A*_X4+<$J_G?/TBS\$>,?W#%WD:MX]V8@E^-[Z%? 4[I>A]Q9
M4(S].GK^B7AVVP<_IHR"UX\!?Q65=.)WON'E_'W5:>Y O6VO^JCI*X M\.JK
M$[_X_9VH/_\F[[_)^V_R_IN\_R;OO\G[;_+^F[S_)N^_R?M_-WDOOOGNI/WG
M#XZ>LJD9U][,=.\Q72G8UY;<@3R7]/ZVM/5743<>>7K_TKVO8O-2 +-+?_PV
M2RD:X-)2[@O>O!O_YOPGYLJ4OVZ42QW%;,>J)C<Q^\'OM':K0TV@ZI8$F0]O
MD@%,D+P_8OR?LH?MC^DG>0R67RX13Q272IA4P5,ZS_'<T(U:S4?Z&?![P+RN
M0I]/:JUS<=GP,<V=?ZEDXWNS7/\@%H<.[(TH*==7F5DJ/>JDD1D@^<&&4,8P
MS)N<2BB"$02+G>^7#4SF-"N<_/+)XV+% I_I;94HAQO.'-I"9U=C*H51=SND
M2FC5?!DVO22SL5AVM6$AUA<2CS0EB1A"]^1K(U%W87BJ9(Y)J5)N;$![8%AH
M+Z1ZHK+/<-JD[F<%T.;5]>K$@?+^G'VOH2(#P#63OW2V61W+H>+6!IXEJ(.U
M\0=_VY[2^'WF4IM/W\X+M[8"A(5_XQ"\2;\/?D]0K_N7Y1DYTNH+@2,>ETLC
MEY9UCO.W4872+M(XY9,U"9?>D(\+F"XM/Y1Z5GF</RZ^2_H-[N0_"(;XU7V<
M_MG;[;6I28O?RR-U\BN\\L=0V=SC@09D !1,/'1"EO4J-N@![W=N'5_")T*6
MCTL>6IVD&,FE&'G3>H8.IT2'N_?JHJ#;2T&W9S>NF\T<7V?NWJEK/[XN/G[D
MGW!\_8[^YS7A%^]W> (,<48(JF"EK"?MV\6AF*^ MP'>FR_*+[Y,/V;9[V0!
M7'SY^'<:'6>>L-3XK[6$[9BFHL!+-Z>.&YX%^\[ ^03F*N:1W">C[:;*#[V.
MRZ//>M]BOC=\7"#!//+&\ZS3<?ZX^,GO<&?_03"]/_%_QC<B:9JU^+VJ34;
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M75'*W(P(UJ(ZWG"Z3E"\-[)%YH:+<R@V)R7>[#8_C$&P[.C=4C=9=W.8;/T
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MLI^ZY"^Y(NBPH^+]L_CMXA^<'X&U;_6X)S;<SO%)=W[YC768=Y2-520&#'Y
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MO2M*?W> 5E(U/2%^/+S'5S&Q-S6& NZD@D\!C4Y7BK9KA XE&'4)E I)UO6
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MPB0%_8]M\GGU/"R_][+$/T&I^-M=GSM/Y<86+5ZT>-JR1<O4G(Y]M#SUY$5
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M!WX?$D#;+$$:07[E, #MOTQD !LFX9OX:M&-K)M)O?WKJT4W?MS-T;4OV,S
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M__*<OL0J[NTVXK]OY7]O$_Z_A_K8CM(G&$#?KD!#3J=YCBHG[K'ZCP$"[KN
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M&33G?'D5*YS=6CKJ4B%H 'D E=(?.>T0,A[AC/ V<R35_,1FOGAS6\5I Z8
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MHJZ"4FEM:5!$*W,S*Y 23WG?)^6JG9T G$YQ%!/Z-+RS*/VG[M&H Q'PR,/
M@".%?X*6J?ONQOO01Q/1G6,HHRZVSG"7;P?,E!3N.VW^3>KJ$U;HUZ\E"^6
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MF#6C2$W>/1C;=JXNCQN+G#8M&W?CD2:8,(_RBKI#>?0@A=&EICVMJ]:VR.8
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M-N";)"]CNCL%9G,D*E%8, ]B^1\"1O*B#H+JF/RY4RM<S!(C.B22BGRR["9
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MIAWX3S5FVO1D4LE&98;TM(.P(XW5X(SL':EBTN6:8B/)+%KJ_N7T=WB3=M?
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M=,KF_.%I/JN>W)_4M-WE9J)LX(OS5-)S-88\)[LB4O,+5@+%+U XM) ,5^B
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MK,*DTB\6\+;2,,#QC?X*_UK N2^9B$Z?+D@"7,M\+>Y(1C1(WV+GVV^Z8=W
M O6WS<?KX>USCQ/9V4)&]#YZ+?NK:):$>7A@IJG%D_99!><NL;NVW^46=*_]
M,85Y/*LULXX?W729F;+ H&M&R#^QMI5-!_)L0]E-UL(J;E=:.K'JQ*VQ=K,F
M]--8C[F>GY#*V<1/EOM=+7;78*6?PB+$K&-#;</G.E)U]<,]=/0 -SV25>SL
M/$_/T+AUJ[T8^AI7-#ER$Q1]6^V5A[.5#TO4I^DC=3,]X]R$+,^X"CAX*)C$
MH4FHURPOZ6B5)V^9IQ$_5UOT&I7JIJ62]+_$%'493]M??-A$F2YH. ?J7&AH
M'WLNS<(!];N5Y7<3Y2(&.<J!1(<W9.@B=4SS/W#V^2C_IJL?9[ ;P5?H&_>8
M=RQ0<NCO&<]X.HHF>)M):6NPS\ S9$:2>CWB!FT\:(^GP^MBC:Q'ZXFXN*-:
M[_OM,V+'].$H_D(>_H$&[[%-Z5FT8NECHXJ&K@C!Q:*3)E].-Y(]IUMC$]W]
MQ/_F2^&Y270W$1TVMZ,(^P+,J[C3E0.MSET=&NI5-.R<A^[*P;-G]P\?CV?D
MO_[ I75OIUW6-\5EPAXR5]_9LRS M=ZENK>^Y0CC1)-G^6H03]"U3\W$I"\3
MPH!5CS% Y'8FKY'M3KIQWL*QJ9JT/\O#?!%5:E%#K1D]-XOB'645U4P/Y1UV
M]H$@/%*XM_2% .&5-37"^#6R[;WQH <RPTNW)%"!>%5GDO!TGRTDT8FR',CI
MY-1^6Z*==SC%M10 0>KY1P*DPE3G+-<.ACE$K>DO(MP/=6FW5BXYKO:N#O!5
M7"_MF(Q$C$]O",D",-R@'IULGLY7+=_O;.3DIX)ELW]9<SR&5Y]^5!D=ZC])
MKN%'M1MC [JU'LVS#V\.3<"O7(AK&_\<VMZ!.<N6MIQ;Y6$"0WPG 6#H+=K1
MEIGE>02,C&3$A)>+=>(?\#@ :7O<.T?5'N"7S; .ZN6FX=]T#%.&73^Q2!B(
MOC<LO[X:=RO^E;"1:?*4EI&GZ?;87:$^$:9!KZD#5S<XW\PNRR9_NF*NU6NZ
MOWZQL[]?G"KSIL]'+WT[T!^.A,BTB2(/$M G8,O-?--H@K)F08[3C$1M'>^#
MP0P1(W+32+SOU?8GV8C%8O@N[N&=(U"G61C!3A/HIC=4$U,V^ [WLV5/M67#
MA]&T:7R%?WT_J<1JFQBR7DLH0A4]-10AFO'Y.C7P/S$*5,P6!7%=SNRO+J %
MJTZMGQQS^JZ,*]KC#5=.F8E$?_X4*P=<TF\ZW]-VA,VVI&LG-#$>CQJE)>X)
M0Y2(S3_.RH1B8B$\="@3/_8 (V )D&N(I(PVSS8A+;BJEV;SS:QZ<:R+_':P
MHJS7JLBWM*O>,L[5!VDJDGH.=O,%$^9,R/H;J4KOT7N$$W2)P;":!RA.1F7W
MWEF1V.O"]S:U1@<82./%']."'%QEF55,';C$^N B+M#>M"\@?'P]J1ADK?K3
M.4^HQPQ52/'!M.Q8"9U$O@27H$V31ATG&R>GWU>"K&B^O^G2K;(@LH(,AX<@
M%.DWW=?BP&'FABWTRWB-(O)JZZ?%JK__#OX?OZ_/49-$AE>N(QN'<K1!MW:O
MS@32,]N7C& .9<7UOZ)W7GNF(C%O;+V<9;>ME(,]J5&6_-"$Z$<KG^IZOA<F
M$N% L;26.9YB@+W?GK.*J<6F+.\_C*8T<4UA-,7R35X0X1.6DXUD'%GSN;;$
M-.XV?Y)P(\4 S"QPY#$&\>OQ%/4UA;-]["RYBV8HX*-8@F/WDV>[T0]_X 66
M6B+&AW,'$I?)O_!W\C[PVW/'KX[&\W\(&C77:F#H@&V"/U:N1H,/#P*4E#[,
M\24'2O!.DWO,53/> Y,K0Z\/FG@%EN?GA^RNE0OYD(388W\E\749E%!*XUN.
M[Y7!*VXC-A$TLUCJK>[)3@7NU$Y:N]P#V["+<:S]H3W**F[OJE@\J-+"P]P<
ML.,MPYH78B),P!9^[]1-@6@D!)DWC7'N&9!C2@8)ENR<66VP']C-*?YKH[VH
M8:GA'"KAINV]V,@8H-4:6T__VH[<]Z[RQ+VI? =U_I;>%J+G13%C!T)H.(&[
MQS\V?5W.X?9$NGY!U%X^W7WT0VAA/];]6I2M,5\2J6W0IRIR3#?_% 95CP2E
M%N<M?+<:X??E3Y-;4>]E\DHC\!Q=E+-*"F\:D'EH?,BM%@']N2W[]__\=S =
MW=T'K"7&J!P')_"VC82$Q9ZXLC*( GZ>ZZF*H.&;1@@PU3=;PC+!F/R0 6Q=
MXIK"8 'O\ DZS0=V^%([RX8@[Z?2+;A>]3ES.=+M\$G"[GW3'DFCW@X',Q]4
M\-W4Z\S4.RZ9>T)57!4( \C"SRK>DI'UR9#L-;/$]'27=*/7_<FQ+'E"TBU6
M4\(M,Q,NQY3.13#&[OOLQL&PAB/ 3?@5O ; DGD@'JT^X-J<U,\X1$Y85-+[
M%>U5,**R.FT32BK$>XOSO] J7TJL2Y->.49()"ZY@;&CD>E 6SA$!:R)/LQ@
MY)*><()$N+H0?M,%CA51ZT@B_.),L65#]Z:<_,"G6PDV+X2"">2$+?KP@KCW
M9BG+D;!-MP.>;;T+5>RN]EL^1N >PM<*AUTG"9;D5@Z6O<)(_S<1!6(UO?M%
M_L9O-'L\:_BT5=>Q!!Z/W; F'8]!)@%L_19 ,7#"LU\NEBG/,9N:TFOH6 ^3
M#= GAE)4T?VUQ6HF6Q,EK;81T+3(Q7&8SRVMZ(Q\]Y-<^^5)MR?)Y*D!N0VU
MST%\[M:&:TU-!M!H(__^O0NW+.**(4FQP/ &1/&5Y[RNZR)OJ;(8H>5^&,9]
M)P25XI'&7D<4+-7I63^!\DJ6;@]PW/]5SO:6%UO?#7-998#EO?"D"H6B-I9@
M?-E%:_*K?!,32_5S%\G[D5IJ:@*J7"JY;YH[FN--1 PU.%<.-S!5$(/8 ""E
M<C7XV_1:J[3T3(T67X1CEDT19-):&M$16KYM()A 70'5.KD.!PY%[HO*-51&
M&!Q* J53.EH%7@ADNZZ[N<EVJV9FBEODI UDM"Y$,+$L/HWE2;*R-E]@F6E;
MB?6D*M@"JN1JS? ?-%XO_C!K59SB+*#71[R@J!A B?0UR_>7]?I-5OMVN-"&
M^@!3'W&G&ZACA<ERA1H5*R$A@=,X'E[7LW*KIV3=DC=4B!XO[9-;FOBUS([4
MG=QA,C+^,8;J=X:F_J 4+ND\YW:'+G0DI;]?MBTL7Q3K(!T _>)\>- ]]'?-
MN(U,Y[B26RQK+K$TKGWX90@LKV+2-9K.@NA3<#)ZHC(?EA&R*_L.5 6#>!/+
MBO2G)2 *<K$0?_I=(G\X_4>?:$D%KE]$(6%&;-;1#CY:?I#A?\!F4C)BITH9
ML;EW9#3X><IIX+MNIRA]7W=3A;SUI >CD-!J6GW:9C/UKM(O6D_9.HZ@L($L
MV24DW;2[NDFLK EC5N2TD+58Z64Y:"UIWUW6;BDN9>B]D^QC-FR=#;=XE7A<
MV.3P5.&!YRU_$6-WQG:1R%,W98NWF/YYG4G)VN46H!OK2+1Q?LH:+XL'")]Y
M\/#Y<GFUW.1LA3?_>_.BZAF;0NF.,FR)@6JF. D4??W([9%>$R(\[CLO6VCR
MVU^8HNE6TH_&/2#@)Z;@9^CN?MY/0S(P<E6 =V+\Y)A+&E7UW9*HERJ_DDS*
M%9ZR-L74R>]8BE>6Z4C>"]KLVG9R@N&Z+4)"C"IOI1;D;7<KUCV2J,@6-;$9
MF9'M0.]9Y-A7C::.;'S/EEKD2XH(<VT+6TGAO-9P&^?/L5(SG&E=DM%2NQ0K
M*.KKU?,I3/!F0072,UY84*&=]]N,2*=%E<4=U4)3RD3 B?<*SGU%2]01D%6L
M%97T<RQNXSO]< I&MEMYVAVD3+*/*,ZS[9Y:I[@:=Y;Q0C56C:ID)K9+0>%(
M1\]!V>B^9.]8TG5H]<*TGQAUQ<9YW,-2308@,0*2U.S6',G%[ZZ0 [.&#\4-
M%.O@L5";Y!V8;/MH:SMB-O5&LI&!)90AO]A6I+PY0IG\+3XYA:^M)3.KP:79
M"#J_X$&"41]6#(>=,I;S(3,\FR=5Y6-DF1AE>79>N%<^D-AWZ;K_8V'W,>MC
MO6;3RS7IW!S#&$PA!2(S*UCD=RBH&V"<1)NKKQK!CV2LFMA];+7H-O6(%0TX
M=<BFRHHKC>IZT')ZS =JG>)&]"2O),<W06!"/, B:_U_:+XE'0T.-<.>*35"
M^KWL#L6Q]Z5 )M'0QI9GXR\3>NO;GMD/&D_-]@UX,MT :MO)WZ<W7A1WPQ'R
M;G6$$:4%@-+#M1M- W:>!'AG;@.+I_!P@LGK[?[HUL0VM8OE BM1R3C]'IMM
MP%%F7OX,#F_X.#EL(*N7[:G?WGV=*XC4^3UK2OB6+D0&MK4KGJ2^2@J.JSM9
M'5^K0KH4_5"ZG!2RUBH@'\I>7I',@UD.*9B?=9G9W-YX,CC>(*<"J5,2U?>G
M=);S".8@]=$K4=V[.FDUX2TUW$_;>9=?-(_=MA,'@G!";HN?:,Q3G@/NMUO$
M[W+0 T3 #=3D/NP3LR75U<(502A4X:9/3[E,5>O#HG7C@ME/O)]1=65-U+3!
MS,PL*'EEA[T<$9K+VZ06@[!@H.>-BQR9$\HSF%@TK%20,RDVPE0I#%DG\93%
MO78?P4M@L4_B9+97O:GU\ARW!)4*E@W^@5IU;0&[K?P2$S$AH=/AY05<0-SZ
M,/D3%Q) ;,G:6+?@*,"*DY=24-OP%EXOPNR6CKAWCIF%0R=;L-5DQ[>E4BI[
M#]!2]41FA[/<L%FG_,9EN9&1\_:B59L^C*P'3Q*HFPB1D[R^IA___+"2>&2D
M_27AM;- 8V@+"1U6.M-CHPSMK\8O364?7E=>1 X&JN_65/6\92K#%]X,L1WX
MT2K.U/S+2-BDIEUYM\"JWY1\(0_*X7; ^C5&>=+);W2E;O<%D?YU!Z+"3<7&
M388)I7Z0*;Y5ZE;:8*/CG445\8#W=]H_)C;A'%848A6=XWJ!A>4RMO,I[CSR
M/$,+3*&):='<$3V0WW0LZ-89B;-^Y?)P8;G$A+4NUH5P\!=\A5M+M4KW((1]
M21[YEG#H(W3@GW.>OJR?G)HY[7I3?</0:4]J'V GIP*^(ELP7:*G9K@P_,2B
MT^&- R4TOK3=HI3[O#!EU<U5/H"PPWZB)-5R7:7*>2<U<+P=F0!=:-O2G4R-
M+ZFQ6+UH);;0/%U(=A?(&?!2 /*YSCYF_"Y,1K22S OFRGVNI^$;IS O<QX]
M.7S7%&O#:QG3KS(1^00]8T'8! =4F(F:.L7[=.?]'-P8%+3B=_Q24F'7\(\/
MT#RE*O#U?+&K=:H.U'%G8U=.%2"N!GPA7TO0I1:=JN^*+31$W],_DJB*;'O-
M'=T\E8+R+*!5OX&##PH;9T X'[F,=P!V.Z*W\R.ZJP;_9P/7HY'WPL#I]TW.
M\6SLQ;Z<*5G1/IE)?S,I<.7P]#&TY9A_7&WN6MT4*B]M*YTK/V"&(=[40"L,
MXV4SD21?3I3*T:N@05W;98<18.4Q<)KP1KYX#IK<0HA-K<FSV>;F2E_PDD*E
MAG-<+-?.QQS<W8,3$DK:YW5TQ:J/=N8J=XR_792EH[OR=$6MHAW8HG;S\;1>
ME0_#E(<6-XL7(?,$'6N=\=[*4_ZCM@M0##)L:4,:P(=SQR!4A%5,!9KF?4O$
MI-3@_>,#)RD".9T.U"3/JOQ)3HKF">WX;5AX36&,D\=K;5-KTUT>!P#QR""M
MCZ#0ZHB'3.'XXHH-(<9.RJ%-8X=Y93G6OC=-2K]+Y_<;N:T;N8F\4YI=F29@
M4HNN#SL.)3<3< UOQU+$2AL^>"!3P"B@KAY>#2^?[(L3:$J R8E!'?-XFKY[
M/U2EFN[)?PCW (= _^%(=9!#K;J7$&2@&MGKB>P'%PO,.&== V6::;P<C1_K
M"WJ9/"]_B@)U/OW\DM,5&R,AFXF5%6NNNU;9D\R#O0N&?Y4'(E*_S4BP163C
M8$:LT=*"N5VA*>("F8>#NTQJNP"[*UI&'(6/F<HV2]:*0H@L&#<H:O;:7.KR
M=*3#,[A=_UN$OZ_VK^QU5 WWQ?@TFB 1.5LR E?CT:F \HVQY'QMD@[\:U:A
MQR.?=I<?LBGZM[OVVJ2*%7#=?=3('E4X['D"/=O 5$B8W.&BC=&.!"VM LA<
M%MUW:?VS \QNUX1DF7B+QU:^;R+ ]JKG125*/[UP!#2$IRVN]ECF[PP %!2?
MLYFQS^*J?(G[<2P!]6-A5^![[UBJF)ZZ.,,G2PQA&I;\G'ZNN))%-&[30.G9
MPYPO3;T=/\9L,"_M%.L>RWCP5!3[72O9VPA03K]RJ[3?*T+U@FAT#^@WW9Y,
M$4\6C]U">SZ1D9%E!'?$7 0*KG.5D'9DCU3>X7%RF"S;/];6NOOX"Y-Q(3Y;
M>T*%[Z^JTMI^84VW[FFAY+V2*Z=]X2=:)H#\LG?V0FH7-WNN-PO;V93)!Y'<
M/ ST/J^AK*I#X^"5)-4N3Z]'ZU1GLR0!7('MT?IW=K\YL=&];<%B[2%G2([$
M$WRET/2$$].4^A#ZUGSH8$:.V 6)H/[UZ8V-H>ZF*NB%$1>RZ3S%/"PLI2:W
M3?-8,#]P,2)P?_\WW3]BAZ4BAG*G$G>=&A)\')>,ZZ<:_KE2N',+39H8NRB;
M:(4#C"AX>W%O\L%6P\G+1QJ!'W<83G2C?M-Q<Z]S7UOD/LSB/E54^L5HVFSO
M^INN7^*7)Y]IE@J- &"69;N#U6S>5F GK"Q:Y.[9!R:QZE!,CL)F6=1LQ,1,
M6PQ)RT:H5.@$C.J8'&&8Z6X QE@\JMW'&G=4"KON :?4J2V$DO;93$AG.R.P
M--R#[N5_MUV[T+RHOZT<$30<IL$9:2VN/B=TR"@S6BODHN_F<[^\YL$AFW:J
M_>B4;R;*1IVRJ@).\1#@DB!Y2CBLECBL6'[L6+RVPZQY=,^1U[12F%@"B41K
M-?-LCB"74Q6NFI&A"\4-.59'J-.+8'1 =M-KB=H%J4I]Q9RWOTQN;[^-,JSB
M:)#:7E;_+WS^C6@W'1Z3]YM(V%P#^3NRC"+7A6J)6F'-2S(57#[RK*--[<<C
M[-/&@@9+)&GJB&]_^7]-!B ?!KNI8E$E^"N6@]T$942U'9#M<C3R-% &?\UQ
MY!*L/'[#_^6T\AWWKG/#5I/Y]0%AC1]J0&8]LP/ZZLR@]99JVTE58$?82C2C
M$C[HRR?.6$!^E T=W>Q?/DM;DK*'Z(89O7>4CKYPWL@JS586=RL9Y5,F*L*
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MI/'%W[Y[<=M39305@++R/@OT-4<<2?1SOTRZ]>8G^EO 8N75>/F',NR'2"K
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M=_R&*669#)Y]'-5@=2TS6<U5<XCOE]/X) @74U.)XJ%=OR%GM"JQ3BR7?H"
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M9_#+*FP3V]8/'NZ1<#LN$U&OIOF;*!5A/-=UN/\!_0/Z!_0/Z!_0/Z!_0/^
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M"!!CH>!WS6YZ^F;U%3H(W,^N<-$.]$JD]J%FLJP<CGX\ GXYNB0!7SX4=1P
MFEFMU%R58G5Q*6\*I3"[,F /C<;>\-KE>\$KVX:]##Q'')6G/P 4[OZ(QG98
M;II^M^U6T_O2MFE>9(:NI@#(?[X<NWW(5!EC['JR:3CZ)E/5$9Y.*5 T3_95
MB'.G5,D)SL:8[:#:#GI6"&M!^KB) ;EVN"]I63Y!ZZV1C;Y1O;2_FJ+'J&4
MDH"H8+;TWZNQGYR_JDYD9OY.!S@[_)B6!0J$!=URU_K4GZ6QVM(Q.C,Q$)TO
M"_0VF!4*2.\?U*)\1<L71O]8@N]_+\'.(LBQN1EB1MX% J?JMY5&BTJ"2A6&
MBM8>\:>1;.T[Q_(30MQ]1-3'D(NS1Q#8H49%4-\ (;!68WK7:I2SU7ZG'E(O
MP#![\O,"D_K;OVGP?)!=4:[+QKZPU*4L'E1;<.@K[T"VN+5Z%OW^ZX*= >U6
M6UES\DFWT-@\5+E,T)D[,S-9B7.^E/MJ^[QXPXBH,BOM!7'HB!FJ6WAY]K"R
M_0+5*J')>MA#?93^JG>??2N@[*2/8#MEO(;$R[E^3J_9;#-C)+M4S[/,):\#
M $MS?T??LZMHB;, HD2_=>0\A?A*[D?5;<\%CR[U'*A#O;A]CG.M@@TJ"34.
MAH7'-/#++!,"#MC88.<\OZ1\MT;G()'-DI^@;.=P0]:>P*)3"B])F@JNK2DL
M9GRD1DX+9PUB[K6TU;75%:$C,Z1CW/@%/K\'N-C_W^&'&N67GP2=/#XR672N
MDN,U7IG#/!)C;M5DZF0V3<OJY;+<\-A&>S.?Q;O66VG,?ZAHUZSB)-YP-)+#
M5*F%([J4\_TGY?*"I;=./HRT^56A0818;&]-U#*W:DREAZ2XI/F@+VA1M7SN
M^1GE=?_X,:G5\R@*O*#]:0'>4I_7C294<)*898&/3":Y]8*LN>5) ?G!7\T]
M:]\?%&-=X+'/5F"3P?JD.L./.V!?(Q?O;$1!!QK'>U]SQ#S673TTI,D/][UV
MN>^,\B(+=2^;<B7\O'SX$Z8(?1(0KA&TU[V+X[>5 ]YZ)F?FHV6$G]9/$P,
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M.#(F<F(C4'%Y@QIP9%RW[^3#<F,L:@JV$%U/3M]N1_"3KM!XW>9^_!N<H7C
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M%LXT2<GV<P#3 TMJ.#I9N?1X-JILN8D\?%QZ/*=:J9I/.JZ8Z?\<K@_-X-U
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MQ[[/#EQKUBM'R*W1/+U:5%$TN-7+F$>$LQ=W[=!TKXR-6ZBKS\$W$W(*4%L
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M!?KCW<%<?6!A%++?YM%/K?8\N19H(0WTQ]^#0Y2<6<*>;$M"MLSG?P>LS
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MI9JC>?E_CVN<)$ZZMU>969>,A$\>90UO VB_*_S-$Q$4>342RZ\Q. Y]\1M
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MD)RI$A:>U6L&72_BH WY./5-;LZ.I!0R\0MM7$7DM3:W0LW$4N1P\!$7L)O
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M5WD*&[B^/;6A7>42$:Y"BB.R5HA-(E[^AB,;BBK*4%;6CX'#[$;.Y0*>&<E
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MQ?,_"Q#^!:_Y#4 +:R_Y7=^T4A3,81LDC4QQ;'?N$H*=:F"7F%:!:?@IE]^
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MAD23[)!HF47?$Z%CK-B>.^VZ2Q$W/.[8>_I@\C8^I_[A^%77Q**\S^ RFV?
ME]$3S,E6;XAW\PTPJ)C&Y2.6&1S-']8V*T]'KAC7KB*39]+?M3-_ND^G]RM#
M^%]7JPNW\6-R86XTO8,\2)P(.RTZOY_?\VCMM9'-_2.L85[,&H)\%%7.TU5R
M!TM:O]LRKPN1^/:NQON.XU!$",/[GR=<IKF9=TF(5#[E9RB.$,M1:>G&_*\/
M9#$Z,2&%ZE/.&.1D]LF77#'VHAJ1%M\2<L!71\12(OFDY;-(M19%O'X#9S(2
M-5Z4Y%3/?])_\T@\/AV%BK&'EYY2\3'/V\AYQYK:Z# =(X8HU=\9JI]T^PS
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M(9>02\@EY!)R";F$7$(N(9>02\@EY!+R;X80_?7W D#@-C*LGJQRLN=8@"*
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M3ADHWO;%@C/!/-#E$&5!_;K*81XY[EY04XT<UJ1Z[GF]_4[DX"G6TC(]\1Q
M,GRP >)/R1!KFYX:/>SC6W38)%93\^RW/#!M]1K&AC_+F@6]!3._59] J.M,
MCA3GRO*ZN724BM(."'=9G0-"'.W6>\X!HIT50S9,]7WANWK^Q%AE@_5O^$T:
M3/A1L,$]$_;N5FO.8D;OGQI%9".&:1IS/NJ[9:4^2&)+X;"4?GE=2,N?@\K
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MNL*7":+,'RW,NQLQ-^R_@M -:WS 5YV_>7M$0>9!6 GY7+54+1N]$0=JZN.
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MGGIH^;)GN]3E<7Z2SR2$8\?]H>Q607N:\0O>__Q]O%4P;O5F LF7H>OWOIM
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MEGIX,5.R$:^4:0[VR8H.YN;P=Q9KO^#FFF*6^Y$% RDS%[[?=A#K4(6-S.&
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M4R,6AJWM\$)9#>6PHFFE*<E8=M>YL<_W6H68+N_]+S7M-3M^I%]@?P!>K<Y
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MQ!3NT7LJ&%/^7E>KTO')^%IKJL6C [80CIN[$E7$#*7ESP:Q;E$_-+RNG?\
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MS^YYWXT !4KWY"D@02J(\D_C)OMGH<B4^@8Y<OYB)[>2@!OCRH;8XA]7D#^
MAM8+W-X/QK:[0+H&72L>O[WLHDW_G/<0P, '!HY- !%>3?L/ /N.Y@OOP:.
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MI&5468AWSPEGIQ2^_=$6\,X95:@F%^WRGTK<_7\8WL!.GM40H9Z^F)<7$MD
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MA:)Q<ZBTW;^XU6,M&50<4Y4IO7%KX\Z[!KLI/2:_R4 ->1.W^(0Y?Z7.803
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MOHB)9SIGI7[Y_ZT;]_\O1-2>6A1>ND#U_7H.(/#-):92-7+?B(L#V)M IG.
MK9:R8#X\%KUP?-HI:#':J-XS:!3^]!D[/99%;^'N3@8\_S\O=1/DL-(8[/H(
MV/J=)T6PY? (B,&*R,L9SMW'*_4 I=?. .V-ZPP/7M,>+!COR3UGI-3=ZE/&
MZR,PXR4*E;<[).1/;>@5&\\"UV;%NBNWA(8U_X2K^3NJ_%; "R)D>T>@X3^I
M]L^]*94P\#2VM"M*U .^1@8/>H6Z]L\KX?]S3QP1E^ZW9>B\J4;)>]T_L_;]
MT_5/S=Z?LL1C:,;'XT,.34!?'ULFX,$V'X!8KAN74_L1,* B]K-"X"?+H1-9
M^*PGG'=R^?!#MH8ZA6%O4@R5+:8@*W1EY[YB[=+H F9@$KCW.LSK@@\%]!^/
MDHME/XW?>(7OH:>!1^*72>O/>&0A:WEBHUQJN^4;V@]$/;#57?!^>_$U*"R6
MDFT"A(KYPO4__.'=7_X0T,Y4&B:"9Q^O6?LBX7^LM/5FW,*GZ$Q9OO\6X/D_
M]WX@V?[FLI51NH)+V/;+&0I"<#M2?PBX$Z<5N=(S3[&52#%K7<E.,^E)MZ@%
MO/5#(!7]<3N=VT\@IS."GA,ST*4XA&M%O=8WR7>8>1EM)YM$>Z@YG!T>.[!Y
M1T_)!N5.2\3:W>X#5V8 O1,D)>\J<!17B&X98A@DO@6?L[_>TQP@TSBPOTT9
M^$*6LX7Z4(K4*F:?)R,W_K%BLSF^J6SRG6. XZQIL.G;T9$^8R?[VMA7FZOP
M]U.+=%V?]=["R;YV?#?&?;[S,'-9 V\D/Z:<(ST\Q$X^'C_W/@$%R*IH:%(-
M]SYGAG*(6^T=B]9]"57.290XYMYR*IR#D!R:;RHHJWI_6&F2]_UR=VWY", 0
M_U#&Z&@6@_D(F+4Y"T/3@BQZNXV--3GO<OFI<0@RT97Z1^%4IFIX\#DU:0_)
M_4X-[S;^$W5Z: )N@Z+LNJ;*EB7YH'*+4;;OCD:/SMD?MH+XNF@Z@VP^CL\4
MKF$V6W'>23,0;!&T> V+J\\0).ETTDK;E\7P4IY>N:W\_N*(FF?YLN'*+G]]
M\OD/U96WQ5[D-Q4W^*Y=Z6N),O=9T=Y;L4T:-Y%^TG3<RC1*:X,WX>NTZ='>
MZW6S_'H"..+/8UXK]<(O3@NAB0USZ2U4JI(_/IZ8-ESJ_G473@+G1F=T 1G1
M@MFL'C>'@X&3@V=L]17^\>E-!P_TL$> 7$$=S[>W<K65X;8EQB<J8 K<K 'P
M[=I?OZZ3O:].7F1;#7@$V%&BWQ5QW@D042X;[>AI0)9(N>>VF[TFRP+N:H,^
MO^:<M7%0@H%K89NW&+]<&SX).CW;!G/!)W4 E6OND6=OT2_?P6+$1_O"[>F,
M&C:'QHXI6G(WZ$I_1YD,J-H)E4'!F)L+V6>&HO1;J).IQT(E&Y4A2M&;^U]_
M&(O2[]%.0O?+?F2*-!EW%CTP0YR6S*3XRH[UC+X<C,&@(22XCX U99XSIKWH
MV[^A-"CK\##:E^Y,E]&T/OSA*LZ84SU:NU,N#KSF$J_<&6=P;JIO2+>)/U$W
MC,P/9$4&Q>#=0LNH">O\1(AT"!E^Z<S$F$X.10WU<9A<T*0K37@WS8W03Y>,
MX:>%Q_'DA&9O5CNG8MWKS!7;"<,I11"I CT4*W@26LGJ]UE1F_J.TU[S"1UY
MB58^0",=>$A;Z'ND]1AYC@M]7G?BQMN#%+K9QN64'G!::LLO;J[O[3^QN+EV
M-9]JQ2\NU&RE\B*4=QF/L9,RW7@KW]$T_333^FT>-"NF5 XZC&4/,;0;^I7B
MQ($(>M%&>C!Z;K2M$;JX4*WL871@7).Q1,HC[P#^N4'8]<_'<.A<= 1I)2^S
M;M%) _928'F?!(F/R[[7T"*NK=Y*3W>:'^U4 ^X,$3]+>9>(.<//>FPU!RQA
MQ?8XZ3_T/G$2D[1/*^83]%-LID!]8$;VR^345H^K.H[D?(VH/^MA><XA+A>J
M:53)UYANRW[^ T8B=]<<UK(S\57#F8CO73_ZO=9L0O3-?<87T::AKHWDWF/L
MKQ:US$%,DP<9GCWALZ("I+\:<.D:5J2.W$Y9.(ZY2D>BB%%C'@'1OC6)JFHV
M'X<POOW!?$S@Y%"<9KKR3_](W<P:,]N3&A4S?4NHDU?&@'L=DG59Q\!9YUJ<
MK[&\[]DZ>;L-3TXNLR_-%8C^2TV37H#/ZQ=#2U?UE650-.?-?NBO[D< S#?5
ME/T:,TN$DIWM+B67A]L5RSVN_;9BD^&MS<<^4CGV!WH3.3-;R^$M!LB&UV2E
MJ/[,(X#D]:6:IN-KQQ:C_%+'N8*8O68B*NI ] H%#3D\Z\UO?&#VI9^6>W^<
MTZ0+6/OW2U/M@PJEVS0S2A]L]R';'Y 8[#,#(D>Q$N;*9+C.'*1[(.3JEW16
MXCX+*#KQ2I5DQ,WM%@)IX&X^+KJ@6>J<\FJ>E;@S40SGKX[ Y4E+RN&>_%55
M^L#Y#IE=[KEEH$5)+[*;O%'Q^FV:D4 =EW5&9D;3.?.7)0/.;[+TRGTO,]I@
M);R%O&ZJI_Y8 LK+U.-^Y[,2V]"687=VK54_!&MT@K$]727,?YJJ ]T<B]3^
MCY^KT]W]I=,K^O7.79R1/E8NHU,GJW[6,P#FU>J3Q2:#TKP'P7.6W6>'C!2]
M/]<P5M;?@SPC@SR9VC<5^S*7GF\(?)H@6M-;3W</B=8OB$:\S8DB"6C))BU*
M*3QI:Q?%'@G,G'&9ZZ6[W)GBZV[V5AZ7SW.Z#( =NH(SEV#>U)\B[B]')P9K
M'2#[R"7:4O8XI]Y)(6="VJ,5EP$VW8/?$RI^JCY0BB$.<5G7?^DP!6YT@CT]
M7@#VG_\Z(I,IY;-WWOI'A:]M/O8L?_&'[4#&CK'3P)K*$0&8:WT!:C^#'P':
MEQW3_'X=G;4&'"ERMIFCO*Z9ORFN"5EEWXN/](7;N?XQAD8SH-4(^G-ZM6W)
MJO0@=1T3.^N""BYXQZ*%/_58]P5:U+.TF=%L ?%U9>E@VAXS.,MWV5=7JJ2*
M8RWN$YH6QZ(UT='*\8FO9^>64_I3_V'=;RVB?#:)+"U&\Q_^T\><__&@/NU@
MIX?WQ7BVEM]P$I4Z;6,GOYD!IW5Z.BW8M5U'WGB]:*N#\(Q]<!@O]LT(L(!9
MI^H]EW@F3VP!R5+PQ#*^P^DK1QOW%/V$,I,U7=#&'6++/AOBG4/*'8*Z).?#
M1D'%;DWAV@%C0ZA83EMEPI9EAEX25_I(_CO$9O];1/TFYQ/8VD+7C=*P*>%/
M85^RKVFQ-[3N<GZ#U%HTS;QFY*4,@PS#[^I;;FD? :7Z2HQY;'R->G/I4R2O
MPIU.1,0$ZBY*/VY<Z0IM3O?C:]\\E!]=92MLSPRK@YH?(FEH+E0!T1VSZ9<S
M#=P:BTOSXCRM-ZO</ _[#S .S[[KW_H/@,]3.,LV6T_:+@U^YTD21OG'-K5]
M3IFG[BOU1AD_R'33?S(D??OZ5S2F>.CDZV"0,R+M@OVV@'VI\M0Y+QP,+N3&
M,"3I/PG]1!3 T='1R^0!'N#A&8LWWSM[D[\M6S2]%()U_SR=X>O.A^^)25GP
M2_;I%R]]=&9ZY97Y5-['QF%\-;UN*S!\IFCV#EE1CV"QVXE7&Z"DIU7$!LLY
M*_Q<=1_T??%:"E:%P/O%+GTW^: )6VOMK/@UU,6[5FKG2=38:<>B?U Y^]'6
M G0GMTYQ"WK#&WUR+?@(L/*^J+N%L4:>7'; #3O/BY<%Z[4C91;6SE#&Q9CP
MJC7\$>;+? ]Q%>%(ZJJBB51$]T#P+FW3=&=(C<G^:6H)!]&B=S(<N_[BS57H
MBA2JV']#G12"X?4M P!W>LE+2GBOG: K?K>-FM"ID8J6)\Z'PN!%UX?)N GN
MJ*L*FK8) 8/L1\#/@1N,R$J?]3<R$N@<%K"$Q;<GT.]\5A/QN5[VVCX$.I !
ML#[B>SVMGZ6%:0^6,3?&L7&%7(I?CJWUE3_D!0]BUG'N_377B+]V" T3Q]]E
MTF+]T.[C2S[ZMA42!,-IX#/=)N4UV:MT'QD&#O)K%U7W$59&S4"\E4< *.E&
M*=:AZJZQZ:IWWS30^#RNCHKN$8#U_K0O_-6T&JMQ<50MS5N)]7\'HO^_1_S1
MK+!ORV(5LW$4-0X\_Z37VM<6Y*G[T/<(&-;A%@ZU[>1S4XBUQ4(X(BY[6N7:
M94C;PK=(5R<FBY"=BPK?(:)Q@X\ I"[FQI6JHN6TG!;HC^4=7Q72QNLP?=/<
MNGW3SIIMD5?BITJQL")YOE[E&>_V<%)VG_00TH$_(>[C]Z70+VJ(#MQ::?(C
MOL@EM_HO!.%7) [OKL(VT0<]R+_[](:+@RNL-(\@/T(*KMU_C^E.)TM3B]AD
M_7! (BU<@=X6SRG[>EEW="XYEKN(]=[.Q=^$W  EM<*&__I[M[0K6Z)@(.OG
MMZYLT=4GN$<U+68B5;GW8UVA F9K[_;MWGSQ?$D _B]6VBHZ5S*<BT0*73,Y
MO]WK.OXC6;G&"\6QG2C2:V(98K4SXXTHW18)J=?);,V\SP1Z6HO&>\2[9RNZ
MQRFRPF@F?_8\Q2A\BA$-,+W@K2HK<=# AKQ.]*XG%D%-8_&$.H:$?Q7;.CW#
MSN$\44>0'_QHKZW<$@]/2_:HZ1Z/I?0;OI8EGS.,6/75H.0"EB?EBEZC!Q(!
MC<0<TJA#R(MZ9!()J?EV-]C:%5D9WAYF;1:FVQBIJ/Y$F^JW5:-FW!$XQ#PE
M%_UM.M\GY C.'Y'=4Q'54>>V\R&G4R/%!0ZR3EG[1JTQT="\\M:K)66R(]5V
M5=U?H1,:2(H+[*N")S<.&_IDV+IX.(',(FRRB1L+?[]N>3AF/$LA6S2[=G0^
MCIAL_]VB.2=-->LH[C>%B,?W5=Q>.> ;<&<8C.Q _?P'8]$QLT;R,WJQ:GP0
MN>_2^M=R\W+=-_0#>I9GMCN7*17-9E>0(E)*JW7E];X%4?,A??_O]9G^>9[L
M;#FZ23\$LQN?MZH4K:T$8$:_S;LT]JUZ+[Q%X$^ZA0;NQY4V?>;CT[+-)#YT
M&8:\*SOAU1,>Y^-][V,A0,858>Z!11^NPWK"[QMIK/D(@$BMR\@F-O]1)P$Q
M\/;"=I"Y(#R^QYXE-,9O'&$A<2P&K5*S2S%@-=.![K/"N+ZGIPKEM I95N.'
M><4IL:@5\!A\W%YO+3"/;IXRDDW2L5<J<R!PA.:&H+<39PY>HZ,D+:"+9\_&
M-MYK@."NAF/99=]&Q[V#P)29%I12K=_8D7BE&3/?+'R(F8E"V'63RM+;5(V0
ML)PNT1ITL85^I:7R=*C<3[^4SS+J"K(F=NSYPO'&1O4(G#=O4V%,T&SI0;YQ
M0'CP\MX[FAJ='72"C%.><(6Q!JKUR.CPX'\A5:?CU/9,LAZ3G4=2;M53HU=#
M@_G(E10;==0W)]&49$= @V<(+#@[6/M2GC^8?9>21_V>?_&U&Z[3>FS> .G>
M8'E ^EA@CAH$F:HT_, :3F<.1!QMX]ML("SJ?_NQ'BE-O?S/UIC_]]W6?RF>
MER96PY790MDLL#)%NK&F/B*Z6LN"/CX"=ECJ/(E&)(W!?+=.EY(@3XFF'@LN
MI].=X)9QUPO"5IV3_R09RO&++3LY*A1)R-/;NJHE$HM0#3:7_;);M']YL5HB
ML9&[UJHKM5O,$\'X;,H?T1MNIY\#6,/00GS_3(65+VB>.-::]9#%(R;.^8R4
MBA??;J#)G^S=I%>D,(5+\B__:FU^J \:)1Y11IHT!7)4OJMX?8YV-AWR=R$F
M\63V[MJWC*K3G L^_ZO.S]?\#]B((/]'0%Y)"/MW&<W_:<D@'4!1$(7 6<=$
M@ SXQBLYD/2U5'+Y!(=LG$A:V8P7CY&F1=2:MPWUGMBARH'4%^V2'WL"0D*<
MD<U24.:%R!=/9>NKC2C-M+'"J6T$J!X!W![L&$(=)8L'RJ;7=\;'V^( L4Y/
M%N-_?N1"""!"_&IP\*,_N)DOAM0]7H)(9?%XL[]&+C',KZ77KFE(BXLBG&QM
MW,M<NZ^GUO!VR,Z.LH-V7&G);GGYE)BX)<ZE*'XH%MK6-:T;ZX@Q+6Z_)#SA
MG;WPH&W;$&L\TUC3[0I,W CK+2%YIQFJ,:>FK+Z8FSCF+7IS>5$FW IF6;+Y
MIH[8%5G<,_2E9)=7T:3W6^,$CA@^!(,V1S"^%;M99%J0V71$V$(.1=.@39#O
MJB;DH4W&A9/'\>KOCQ<\X'1>[D\_WV,]]]/445$4L2[^NT%:RI=4@4< :@%N
M&P-]@["<,\)"ZQ&0O/;[U;WBM?[LZQV!H*==FCD'CB8X@[7I32]UU@&G0PF/
M *FB+XQ@K'(Q-2_,5-N3<".S6J;;"BA2> E8:C,]7<O\U<(OC:*P_F6(/'V4
MS;Q>V5--:2=XB@YVRO()CS2M@IB0.6OK#<_!4<.YU.8B;?")?<0''$%6Z;J1
M%)/A\(K+NE8;;@DRDP7.]I46C]6;N(U?I?.B5)5L9#GN0P;O<,JVP%UWY7;Q
M9QE=(6:EXH=D!;^+3]<A2#W#M_(- [=B:N^J1W;?Y?,M.77Z986'M%;BH6=[
M&]%N?B/_?.6^V\C4JFKY8O #8)C,"[45?S$E="=+.6SH'%149X>#6@[C2"VQ
MY-TY\==JR#AB\])M<69J_*;L4>2)6U'/;6? 2?5A%R\S)#"L95I$%]RF.>8P
M^U)3O=OKZ[QY>,/Z!<@7=:+*;F(IBR@.E%91FFRT:&R0[M5C2.=^Q]4VZXNK
M.^,VD$/@PQ4KI]4K+DK*,BVMUJ4Z)IX:1Z0Q3+&'42M:#@I=Z@R:/.E\IZ<W
M#81R"R\ET6)7/@(.JD7H2KM:EGO$CF?\EE>Q(J_=X4&XXV)&G7V5"T:22V@S
MB:/R#.]B:=HXICSSF$&(I .OR7F[+@I0$*@@&W;#I_;9ZLB+<,+BBVO[]+RO
M_'#Y??XJC&[1O'5RC)[W7!X[>*JYOLGO:4P8T;72(\ "VF48] A(;4P?"KO#
M*D10,I<.7;AI?)\3:AB#*&ZE&KOZT]_'-GYG19X(B\2::?')K-C@W!@;NV:?
MY0NPSHYE>!-=Z<U$O\:(;4>A7OD65ACC<3CFS(]BHK+I/]EJNTS'(]A1Z?(4
M=93P^8];O^PU6EA^8FWW;3%?%7!0I.99CBT+[>O?+8(G'__ L?=+MB-)FWO3
M2BF?_&>]F30@BW*6TMB9MR/)X,#'K\ */EA_<,6'5I$HG:?<&MDBG==4//$"
M'/J&:QY?'P&.-=GC%%T*NIV0=&8/JX8:A8%FH\U!^^"!U1XU6GWS?E$NWYBH
MKMN)#%["_$O/&2VX?AD.GSW)GK@DM;4A!0HIE3\K%H)@GCM4K5$:4B\J>)V)
M7<'1LQ-'F;OR?IHO]-L.E<; 3H-SQS2=</:@Y"!'0H@8BCVS0$DTYV?-Z6&S
MZU(.4)[UUT45]L%/!P:J<U*]4]-4$J\%G$OU?'WA%9<(WNM4,\O"R/;(Y7X_
MLDT1LKDSU+ITQ#%9NL$5,]!?LJ]:G)1NP,)E=_MVA>B+=:L"$D>0L7B64)LC
MZL0A>:H-)6N@2HK(18G3_;0+BV]P1S1Q8%9/.5^^M@+H21;N^+;4U H6TU*C
M=!K6OK)3>'6V7]':+ZZDN(C59.E.0>8>0T'!HB9]<"S,-RMZX5ML>%<D6NF>
M[X&+MOT$+UD.#\KRT_@VC% D:K[ S7LIJ6MW(JFR\<N,\!FYI^R'@(U+; O&
M3?P(8A]&ORJ:*B6[ "WSQ>7<#P*LO_R:3+JZ!MLJU8S1C.R:,*X.)0XP[&4=
MA>A7/I%O&+3IS28=C'&R.#K9PQ@A(4//*$A<%,6SE:&LR5>R'%"&;*Z!)<6F
M ;0 ^?S+G=5HY93^>[&GBW2R?,H+\J7M(8L. GHF3L1V97Q+19?O+57! H->
MF1AO+,0*TO2%S>0G8$?O.Y&.&IK %8IK3L4?@,-VQ9W]GIDC/!?[V^"7]-EX
M# =BBYCP4BG@N1E'&-<*MV29WN;)>'J9EAV+2K$Q<X7.+(=KJ<<++0AXM-DI
M1@!*XR:*]*M#B)4>$1N.Q,%:5-AI@2--.(J)18O'5.8$A*-XRR<40GY;.4GI
MG9ZR; VMOALJS[QKI7:;* ]%X4L%!*V%]M#03"C_&LZ4K-9*@^ET [TQ*.-S
MO8=ZUD8;;8$]:0ZC2/L0*[&)GCT[TY*1[/ QSP(/&Y_Z\+KI:ECAI:#8H4TU
MUA@A[, CM^7]L$$QSLIFUDHJ&,O-S^?BHC)[G_P8;7C'J2 W6S@"SM>OU^\5
MJEP3O@TZNR4:B4%DK_68'ZS[&'?AW_P>056W6_38'6/B(/]M]/E'32+QC8$/
MQ9 Z%E7VO&_JY.'YV[KO>SL_OMNXOP\=1:=.R6I(!Q8NAD.R.;<(J-M^[7./
M&Y@*OU5H_%EDWJR%O&W5_SJJC&\2_)Q2CKLN)(;KQ.2T9\Q-R'*H9EG1>_Y,
M@5^G[ 0RZ-2(U?X9P9SO':TU]#VF?OLZ-,ZNL*)^U:"JK]&PYW"JU/)C0:2/
MZ!:Z7Y5;/4C#LEH65EQ9AQ3BT'&(W=1'H*9E)D)>R8M_D*U2?7E\&9?XK8(8
M0Y$Q 15'KW_&3=GNI$XTT:T/76#-1'&WTG%/S2&FL;)3RR-J#*_$LK!Y9RUK
MULK!;LO 93*%D'!62UN5+N$YG8_KMLCP];)Q3)*-9V7LF)]WS"X\<=8>1/JK
MK?2^O$MJ]S!LZ+*N(I!2*MK?D36+.F#VVG[6"@9WS3J?V2:U3FB6ZO9)S,X:
M@6M[;]0=]M&E"+0@9>4L[9LK_5ZWRITKFQR\9EEPP,D]S$B*U\#Z^5O9\23U
M%UD0_-T]5IG;<:JP]CC?LXM3]C:U@5W5!MV::ZB$O%]LKO9,=R\6QB">"]6W
M%+T#(ZJ6V8O^&\(K.VNA[WU=(DM4DGOA<1(VD%(G4)*LF-R@ W[/O+"P=[['
MUR.T7"L%D%"IHSCUM):*D=K3BP_':6!1WN!V!2_Q'HR] WWY1P 5(Q.'PP'D
MP7B8E)*EMKT.::+(,7U\(>"[N 46#N_E94L(%XPY'U"UW^\[U]83]NM?6J_(
M=_$43<GE6LL$].M-P](;C+PKL?:-[/S7J%\24Z_^-[-?&GJQY4@F/ARKQI"0
M5'>"\3C^1L:6$\#UDRJ=<[&0VNQ0AVGMN3$*@I^SPR:TXX#MDR)/H 6IDYN>
MPL:<JL92/G*1.L-^*?TSUS4Y*DU\ H/"=KQXB$Y>[F4L455CJZ_N5^B7)[;&
M;OI!)1IC!8=B[/RI55 ^C]GS$5)+C;Z(K*W)O3I*)/N)$S13Q]2.4U;(@@17
MB-@RQ4>*^_M>D[V<]]DX::K87=);7C,A U!&&1()8P+&A\^I"GJLRZR]V<NH
M61X1TTDL<":^D\MJ6VG86NW7$G3BK7:V&)4W!@,,U%28/&W7J&I)7S]/96$A
M@QC8=]B[E B;$L&G90*QO"1LCT80,S>IO<J.W)>.,[$UA_HD\ZV2I!D>?%-)
MDYEN[.>EO@9%B$#*;78G_EOA@/N^Z>BJ91"L#5ARM#NF2?TC]"W^(.[XR:[P
MK=*4B*8CJN9RQP6\OA//*2P4DMC%C#K\ALHFVP=-_V"'J=10,34;QI44QC\?
M#,HOYY>O9\F2UQ"#7?7S;^$K+]+*G;Y '7VY(!5C=URP5IXA494?(BE&P>TD
MK]8LFF\T:%.E600LWMY8#9W=4C<02?.9$9OZQKK O5N?(#).Z%X78!,X([ $
M4^YKJ9_YV6\\'VDZFKE5JM^*66>BYE66I(7>)\5LPF.XOX3BM1T<EP6ELJI:
MN*IN-VL0<V0?SP-+4\B./>%ORO;_9O!QF=3#0V-O3=!3;\78%A9;Y(BY)1T8
MKP;4SZ#O3HVB9U^C'B@@$_;H5\NR/2&K,]U/CP8V\+KH3*GZXL /R,?V Z)K
MX$J*[UZ=S?:PP_P] _JF0,UP0\<&PMF)#;@$XKJ-M-N0':ML?79*3TU>]5<N
M-($K;"_C/-O[:#_OSK 947E+E;H!O5FT8QY-R>C+#<]"3(6X9^[E1SB\MPO"
M=FX_!M:Y+F]\;@F%B)__B2P%\;]OKS&XSS2D27*\.\V[4&*ILKT=T) LR:T^
M\!6H!6( 2_R-L[<6IGT (DI?UAJH)B^,#FPZU)Y6CRO@B%0!:4L$=PEIBY/!
M.VY ,6/S):AR>]=+*3X.:*D(*T1]62UTIC.;V6#$SZ7E^*G[18J!H>=JZPS_
M3V6K*+BV-&1"?7 9+((N+GW 0@U-A@<P6<Y*X<AE--A,1I8<6\'XXE+XF0]9
M0]/TL,QXK8EBYV.<FZ %.[I%9X\ 0J*XTH[O[B3%6_++H_&,2U)1'Y*!E[4_
M9N2,($H"90:E9=L-!W=A'CCV1="P:5Z1/-H."1![B?-MNG*6XVJ)HCPN353P
M)Q^;M%V1<'$=[OFU8$@.(N>"R?O*<N&[V]77S$VM&2/3V92^S7"XFJ;!CV9.
MA?LU5<SAN^+#G+/3/[1UN/X/IR&J8&2?FO=ZCR9M@;TAWP'W$[K1:;!=RLYH
M,R[=MUW3M<FZBUF-0!7/K!RM44]2IBR8Z!4 ,X^POWMBY92J>'P!5T4,6495
M^;G&O.*6&M3 *3I4N'#,%\K MZDH<;7D$EQWHUCQ[X4,E^E7B:A4UMT] E1W
MO7$/$O@J8JQ"ZWG/J=UZGQ8WN4!&3X9*XP1J,X)H;F2?+,JU"7>&V)99.'BQ
M.+@*/".[RHZC7 T3,U#%Q7.(K=F.4RB5SY75=7QGRS?7ULY/R8=OV:+82LEP
M<@-TW9Z+NWS=C,S*M6V"Z]@Q2.K(\K0T#0F^RTB]$.^K]Y@&J\6]9RS[;*2-
M\ Q$VXU^'3@SGF$]*W G,NK,NZD_\HD^XLT+^>&R -9*OD9HTY!3;1_%_#/!
M3KLA5,.%!1<R=&OW/SR:A)YN38G!MT1*2;1-[YL_37Y]XR0?7Y4A?.%2XU6C
MP;+JC]U/NT(#*-]Z2\;%E+P:'%T\ EJ?3<L-.1'*1/;><A6411XC7QGZE#)=
MUE!JTZ,+]'DR*I1BJ>P!'1N;U,4%815][7H2/R;WY(03ID8#6&FMR$XN2_D*
M+QHN46;DF.DLC3X1K<=@QZUK=_""G>;1+,J_V+'S62,+#)$85]%LY8W5RZ)O
M9 ?6NT0Z[A"$Z:5V'5:^UO,9UH[2HJ@]W_TR&?:\*'\-(QS;=$SJ1_DA!DB9
M9UX*=".H=;$KGA=EREC)!03@>CTJ3XQQ-\?"$3%"&KYGDY>$*1 1-NSBW'!J
MB%7;.5$\<S=5^_D@^U7_Y0ZH.+46X;/B:8S]BENWR<NGY=M3KS@E,'R8RZWA
MF[?=!C,37&^R_J4VV9YMDP_?NR_IX@S"):)R!Y&X'%ZVI-N 4\.#R[B&*6(6
M.>3^9EENSANB$[!KS$9OO1<AJPI_IW-;>Y3]FPSM Z]KXA"FSJHYWE0<IK=L
M3P(YG4,',IU;$#R[E+"Z1C-^2(DM7<?2*%L^$+1M5$[>[8E 3QN0U3=/3CWY
MLFO&4,R9.O,'81>R@$7==E Y-#MU _]#R_16D%="@E?P@H\[)JKODFY!XV%9
M!38>(:>\!ML+K1\#QJEU4)[0>*6O!WO,@M?YM;-;,01W:;[&N^#T93U1]K54
M)M,K =(A0 (!OM52YTVI?=EFQ_*R,@57PU2SS*[S*]>E:EY'ZR8'K])+(0_U
M/KF;#WBQ[6LA<ER(N"_D'X5K3TLJO10JX;6ZTOC&W0M+*Z^.0&B!(P[T4_,^
MJFL@!4\]?Z)-%A%#QU<W'Y?H90E>N9;0^$D48Y,&&@K9D"+UXJ!=C@PC[T=F
M@S#38T\ ,MT#&.>3@NXWVNQL66XM](?F5>&'I7[YT;8!^B,GL8Z[U?S$,O._
MY(2?K!:R#%-ZEC=47-F9,"P<F$<2;T$8]@ M _5GVX2T(9J.'@6*R \$.4;[
M9AB=_K-^DG.IC+(.+2X'3B_=/4;MC1?3?:E.$TU3,:-8CI+Y\-M\#3Y8K+C.
M)(YQ?TCE+;P;ZBN),Q LFIR0D8UJ_N^_^9FEK9*>:IOM97A%E+2"T7.AWZ3U
MQ>0#I??;!\TR 0W'U) 6%K[TCWV*UIZ*!:4\/[V\:B7[>>*R4SK4<5(Z3L%[
MG=<B3\2A[S*AA_&++=1)*J12(GJB06R'5Y_IXS68QHUR*!X!*!;&76VP1X#E
M(R"W/.5?V;2V.-J]T!]QQ%@0?]H#8R:VER_>4$9&OL / #^\T X\"DJ#+>IP
M# 5AV+T#O1N==626X7[>N-8W.W)9\&#>:6BF>=SVT]/MWO81\/5M:C(AUF?C
M7(S(3V_SQ/Z5[+\Y#D _<?Q-VOIP\PB0UGAJ5!)9^#^I*,/_I(1J%-#"'Y)\
MDF =Q!"/S-4</+!T7W7;HP#7GLR"=><ZY;--R$1">@S[-#:1/**U-V\B7RJ.
M/_&"?GR#\I+LN0MJ&A.>+YD!"]* 0)K#]88PU+D@+CJM^KNPI]B.^<&AEJWY
M*X5W2U1"CX!6D52$#:--5=&WQ8II9$]E8W")=RVY(^W#%?QZ'A>^4DBV] @X
ME24)1WV8YSP+0E BH7Z9URT3=,V98#^=GP/MY_>EY4MM))ZG@C*RI><;?RD3
M%'MB&>NG2H$KJ1< +IH%I1ML_W*V>9>G=85EW&2?[#'EAIZ1=5-QS')0%)P\
M\[/W12_)Y&3MX(3?PF0Z0GP+3^/)(=H@[RL5T4\HMT5R5V;D6TVZ422[24R_
MI"FC#5Q*'.G15&1BWUIJM.P4U*-DLH.^=DCZ0M,-[;PD%E;)) ?$3:UVK#Y3
MU>*[_584-F6<W<J< [MJ;#1,!+?(R.Y34+]\07C2L&A5ICD_9$9Q-CDW-"[/
MB<ZWUUY_=4M@FO3!]?FYGH]?/GJAJWGB 2.X-=&94DX!]GXW-0D[>X]*1254
M;5+?87/9_DO8,UQ%(?<HBA4UH$8%?EVS1\,5;(^P7PFB.L_;OQ\J,31A7+K$
M-J?(NE=:UO<,7IF% 9KRX#6<2L9);[G(QC"5._IPM[S<Z7I3YC+V[OTQ*V5T
M2:NOABKSRFF(,:#?O\])0T11,_9'A!7.N,X(4LMAP9.']3EQ:1]M/#]&MROE
MXCC1;:@5_Z%327[;,G([G$5S>NGCV%$"IR+(?:)*UH)F"LDM7CXL_)[KX!5C
M/3N^<OE^Z59VW@4<WOQUQ\*KA2HW7EW?B'^25JZUIK]]EBP!Q1G/ ]MW9H=0
MQ.!XT9\,],+]F!6<U^Z@FEIYR*Y".:WD3>_C$SN%3K2]ESC!QS"W+/Y%>_G8
MH\[8$OJ#R F]\<WF@X3E.<D^%*/\?-M19%\#Z$HWZ\GG 5*RK3\"V>6R &5$
MB4^QG9MN68;;/JI[:\<UFMI 0Z3'!7CH<(]"N"L)-+#A8<<!RI;PK4$P>%_Z
M@BBX<?]*X=9+O+A1(V)&@=-U96J!X-M+34UW+UH%*<&Y!9BL5SWEUVED6Y+3
MRSEQ<)D'UX/<N2FZ]"XK0ZCU!==^$I059EGR)=K:8<S6XNL68OX14 NUK5I6
M37;.RVG;6MDQKLW+72A_,6R@XP\#1W@+=O>?G-[Z;"TTI>M9:R_9:[>>.C</
MT]"O:[:^D;#H8O03VAG)2=-7*$)R*VI9613U$:6;8#X"3NS1XTVY[W88\7NP
M?^.^Z'>%"VD=F/7&GGX3R<W$G5TDI!=2:O(BZZ7XX*>GM0<;9G]9WD!0%;ZA
M8UG^%:*T6$#!?72^J_#-T*1HJ?X^E=6J3DV[L3'763P?U"[:G/DL)L[D=T@S
MW[.AB^/-1J6*Q0.&!/ C -T%D+0<@F'">S7$>YQ?D_*6D+"6<R<_K[N>ZC<
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MRZ1:B("J+D)@()*RLID6LD@B6C&U;O_5! Y/4N7'(T&!N?ZPOM6]3;-B@\#
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M(/Y0;O;O_X4F0"$)Y*K+BF'PU>7PQX.N$,C#5<D]/CY[4\)DE:_2<Y+ER&S
M9;2OO*O;';MHK<E ,4M"V4C9FV(/*BH[YW_'I]OJ6;CE'=R4,E$5I*>TOX6P
MNHTZ/]MYD/B@6TMPS$09!$U[D21]O\I)\]D.^_*7GQ2,89?"$:^V9&D5"K<L
MJ=ES994:A8:_X_FF4W1LZ+TS'9'9*-?L84FC$<?P)7R(OI_W?_VB0E'[K+;[
MQYJ#)PNI&7;T[70Y7]M7:^_ '><T?X>NCX_$&Z2;]BCHUI"GIC8#_*&I&;9=
M9)]SJ,6RIM=E.8=2&P:2#RBL%YVM&RG8$4>2W*-(6-@HO@I@#:"D*Y/4>Z#Y
MJHM,(R_\$2_#_WZCMO]2A?/Q^.-:$[$:EY&OG$C<NOUM,BLGOA:,>G/T4OPW
M0;@ZHDJL?-. 5"DPXDV+-KNOY+!<>(-3_$PC3$#$FIY'T-^R6>HF/W$=I^$1
M-]5#>4[*LGZS8'S-?4/PFC\P[<+;>"_WE'K>G55&>H55XR^IN/&=_VAT>Y^8
MI*TOE)CWN>_SP0GG\K37G]]1LS;G;CC6IQ30WY[S_;:S?C7V&_#44N!)6?W<
M#TQ3R'^HQGGOO%/N!-#R1?3*TXZ&_'>M>,3_K!6G@5^4[=6+$RZX&.!&V!_&
MAZ8$F^LPOM/IK<\MXDQVL["!''JY.ERJZ07:CD=N:W'73W3I4VUMP9GN1@M3
M_=T7)+]9>Q(W*]6[+<3JGDV#5=[\N;IQ1['TB8@/H^8%8TRXE)^*^C[W)X)C
M0@SN3*I.1]N]7 (B7:,ZW4WQ!J^XLBRSMMPQ,X.9?[RQ]="]C^.\FJ#_X4,\
MMG"2VUX/W9KD31B$';1*7GL9=VZS$WFC)0<RGR\>GE9HP1W*V9P_J<T\\ANP
MP":\N$Q4.T4@J[#'A-U^N-?KHQ+'9RR=5<7?W.S'RD(>>S]I;]V"O*XL=7Y&
MUO35=QSU5L^DK,KKWB>%IQM,6B?,L]@^D/-D^OX@AW2(L;='79)D#82;)X13
MK:]^K#8R,:'ND[]J2V6*[I!M*:-#X;,7GB9\06\N"ULJQZ%PF'K7;7'@NUC"
M45'BY( 9E0/YF\OEL]\ ;_DI07?/Z&P/]3Z^B#%JC?@$W YG:>\FVX<HS;\\
M(5JNSPF^;]'OZ#YXXAFO$G<J0-R$ICNS6U*&7)@[?CFYQ?/03? WP.^"SSQ/
M-!\) #P%[+V<Q- A<<_TL#'/WM(?RA;;"OIKS)S-"O!B;>86K]XI&4H-_3_%
M:.-,WPE3/L@*H(__B8V"Q(8"'L2+$UXUHJS/[/1R2IW-T]<<_M+"SMDS8,\3
M^"Z7NS":PRB:@W$=W<&EI+P-=U/L?7VJW#7+TB.Z1-!%@$=7[S3TW..SU(BZ
M&:LIDRGA-KD_L[PLY8OB.]789@Y$W<[6(<N/MI</4P8>,,G<]5\5')&Q;S(E
M-2LG^45D)V&ADNM8]D[)A)$AQ_('=^!-?^BEBZ74GM"^VZC[RP4O_V1-1S8_
MC^5OF85^*/SMA?/J G3H<L[A!<_G]28CZ>?CN-FN^3,(RC 'RT_AI4=1T\OA
M[M1F0&@WU2NM,/.&E?[SUBN8$[FG8@E?&7*HN*+)? ?\F9J<4;Q(X.=J$H#%
MH[01;6Z+!>]=:SD2Y[+DU9B;$ZBSIR"[%%DHLREW9RNC&3-H,>RZ8@V/_)$)
MF:"#2<J(^)>/201A4Z=I%=C*B<F=:X%E%5M;SD!\<W8BO7$2HK'4FK',JBP#
MH<UV!!SF% S>VHAR=B42;TB4B7_U9C_LR">MSN^QT&Z6$T=B1ZL2B]:1G#/^
M,?6;\B?.,\.8"4.*XU>MX)]"&8T_#,D(BBCM^\-RYL3>0RKC=0UZ9R#(>O4<
MLHFDQ*[$H6Y?-X^ ^%1(]\0J5*(J%[A#[%S2?_%UE()E96M__M &ER=UJ#TQ
M+3ORX.X]L @Z86*>!=P:QQZ=K;:/]_7SHTPCD[,6&$E)KKG)S4[P,T\X_ZKO
M.S#.^N9I6-?%"^/Q!3$0 ?3V'ASF.&O?PTZA&'EDM/[\E\63"=87EUWZ.ECP
MS;#74QWSB-GD)8D%:AU$$%Y[KS_A9SA1P)5<UF_ $]J=^'P\Q*14P4+1O@6S
ME]<[V6^/"SXVCVN<](H6HDHGQ+#Y46U)N3K;NT-14DVW=0R,NA<9X0'B MPL
MZ.'I+?X&H#<BZL@'A@5SVI!CRA*;KM& V%$W8J8C7 0=3AP4FK?_Z\<.C_-L
MTE?\Z1GFKN7A42WQL"WMRCQ^9AOD8Y&N;4AQ5$']II$:(K_([F?M:EF/O,QF
MTM3+\X\@$__P"7_4_)[HF>1WO]U5 "@NOPK"+F=KN=3ZHQ&ZF#H9C91%!%1(
MFZMR&CYADFR)GAY5Z]@_H]Y',<L&)TZJ.)'[RH^M($5B(@</V->9W[I_.1W)
MP+-R1(:JVK2HVA<V3"T*'MA3XU+X*3SI%[^IX:^;[K),0!N@YHJ(KYA5H%>I
MS0*_(1FYR#IR<<%7SI^9N-=T*/L;<_7^+88I$>->JR2V  P9$]5&WWE$)8ZR
MR!?C"B(F)=>''G^\"(A_>-UT9HMGO8VT5@_%T>XJR\H<@1S2%?G6NG?[]ETH
MQUO9)KSJG,J1_&SIAMBQ>C26R84FS679<SA8@ZC6F'!?&T+5G/SS6=6"[/QE
ME8,CH^Y!)*ZRV"_HT[3-Q^F]D.\2ETQW&:_CQO.@X^61'3;-EDMJ^_T?'].-
M]RY<-@^SW=\"QSY#"F"B9L"&*EQ1 4SUY4D^+B#2L&'BY]K*NLY:"Y5\(FBU
M6L>L8*([]78X+!!ZK[?/M^E0VL_[5& Q!04$HIC-]=TG1"Z<1EHC>6<= P.7
MG>W)^=U]@,)OL)*;&_(N LW61<VS$=[Q6I:"( <N'^P7;$>//_?MRTB#.M N
M6/0W -@76EC&W_"%N5N8'$OEVDG!_.[Q5-,BW;<9P]+N4=+!.-_L0VKCES./
MIZMP])I3=^>&U 1<;0@W+FKP[#X[BZW@5Y'7+.9:.5V0X^0E9-VS[0/I]SMA
M2]X1L($2F]9)(Y'1P4D,/FO*=D,;L16SNFF.M/YKNUXH=N)#KBVT)M((;H5Z
MZDJIY2'+6S8;82"*:N:OQ'8M.C'N/)_),09X\HPD=WIFM"C0W5Z5O4LC[5-,
M+I(H=U/R!.845$4.A9J!5E[#P7-%L'B-&KJ-UEA/8L^_"ICOP*?JF<'?8@<=
M<WP=HP:W:G1^ _PQ(O"AJ>3L"SX^%85EC,8 H$ST%:]$.O>S],&PI^3[4YXN
M <LGQ,1BH\\9KY_?.,:O\2J4BYXQP[[/R5(3!&\<-7T-YL3'SV&4)OW(1FEB
M2A[Z8VGF-P!1>'GGXW:Y+- 0C<Q3L/L\-EL1]$B2J3^32KKX/9$;*HT,0'SY
MXM8 UO0JZLQ2M#: =\YVAXM>YA;Z39)LZ[YDQ_:T49?B#@8$MA+74+-#V' F
MT3_*8CQJ>G^;Z?Z&'-H4-WU -HM(2S-PDN+-:GEX6%)4@I82![+*[C451<9+
MPPI^ P+3[!N0^29EEU+;C((T]6^2MKG=/OXXE89+A]_J04/E!L!6S8N;KT]]
M!H*!98WC87X'K.EX')MI_9_,T0X0&ZCYDN;2?GWR;\#N2;N$C2P)( UO^PXY
M:E]6##8S_+Y!?[C?H>S@;F;Y1YLE&X[GL*-9_+:(QQ-BH-<B0QT7"[X.MH5A
MA\3^=3'$1X/'(2%*MTO ^X38(F1]<P38MJRP48W^ >J'6P<]Q>X@J]"WJ>I'
MF5->318"M'R<;9%B_7953J:<3G7AHR2R.5(G=Q 3DU<!P7BU5Q(5K2=%T*_A
M4LFD^=_J MD.I-/7X\HGY@@F9^Q&S^XM"L1B%#AJ%)D9XW9?)S3W]>T!8JX2
M& )RD%^!*G.Q%C#<71/S<$'*B!99[-CTXB(^KKCAQL:A%I)>C=9/&QVF;U\1
M:<+2_J1!^215"!0VF^?DF*]]!I8(&*V WG=ISG#Y,WT:; :P#,8@H?H-(HM?
M-BI[6IWA>,_<CY4BN;[W73*%P<S/!X"O&Z1J+Q&NDS_F\4I6OXSUG."WAKF/
M$-TQ+D5_1738-4Q-9?BEKK21 AE]-S*& 9'HPK*-!\ %<4YV,6/3V=I%=D2,
M/*7YS_. VOS9]31:**U=>-(*06,?=&7< *?0'5N7..B2))GPDDAN-*QFJSY+
M:_;*T5SA5<M+9?TO;D/FC'ZN[EOBF5K"FV !\ZK2TYO^S"D":NCDH4X7AY>!
M)D7(\LXW=0"EN@YY,>1&X^891T"7!=BZ7NYE]PG_E^;0P#[R!7<?SWF:D,*:
M#J^I!T2@G?>S9SF<^+Y9G'PY3-_]97K9*!K7*%0=UL)@V]!@]8!6N2&P2Z/)
M(7E\S*S&!F"S[B13@>UG^:MR)R/$A \YQ*[6*1-H:-UT6)NYHICP755&LHB,
M4K4?F4+@[SV+K']O8'9ZZC,7:SL;\TGHC@\1_4 F\]K)&D"FKW-FFSQ8H=0%
M3?,1PB?@6^YSQ)&/_!-70B7NJK&/&@ 5I=Y!5RW$C%7XYOM#[G)GN)(W=3JV
M,2UN03GZ;V%-R)FJ*A9VIC^$".^RKQ.3IRVX) 4BQV></EFX&$[NO.\2,1B$
M=)FZ?TYR#P^@:($MZ>X3QHV U:'A"VY-%CN/[I,&L^,7V4C/J[>?I3Z8-M-D
MJ(/<.XA[V.R2O,'X&V!Z,3KL#/:8>F;D49ETQ[>=>8YXV'V7?3HL>=L\4#6X
MR<!TYS$?TCC=Y(N(:"5Y8-;BGPT,SJA+R;'<' PMK2@.=[37QZF#^(5M_*NM
M.[:TB^7K8_SF'$;=1FTGQCYR9(O7DF]LRKFHSJ)FXWX#+L1P#,?PYYP7ICYF
M D/XG%CI9\TL[UVR_1-HR*LA8@%SAL>[PG9%Z-D=9DU'V^Z] PC; <##_\UQ
M1*6T411QEHD[EO:*4;+CHO,E8Q>Y+).\='M "BV$P:,0Z&RC ;9)_?2=;SD)
M Z%OFVR=X1QFSI.)3]0XG#1W\!H*2C/W=H#FC;<,_XF8W5OO4&O'H;X>M[0K
MSR,<QNNC#<=+0A#AJWPV40[$ @!4HW3ULS?3Z/O[=E%156E+3M0[2]"*!%6"
MS@+ (W]9:0]9:V/::UM.N8%SJ")!UY(C:[#<A6%[$)/1_8<LBI=A4IZ[,647
M&/58:=[J7A:E&MAEG,:ML=MWB3?N/+E#^3/U^=[<Z1.O?WNUA$#.#.,0Q]<&
MM%*^\W1NUD3PP#=;VNG4/.*C[SDP=5X?HDB(U1PX$@ ;ZLH1P;_6&D,.N8]3
M" V$>D1>J5GTL<LR=24$.V'>.+,?&=K<F(1NRFKQ\5H5%L,054:*VO>!2^S#
M#*-2209HK0]:$_#2BB-TCES(%:3ZT5QVX#<'UN7IG_N_#O42C!VO#9F]DS+&
MY8P6F4R ,O)2W'>%P_>.096QO0F/1G=:#5VPM]XNL4BO595"1:@ZAS8E-X<2
M^ZQV0,'V-6813?O(ZL:#0RG8DM;VFM6A&S,55Y^'&NQ1/ 1DXX#;\$-BU?K[
M0_>W=FR>:=/N/CTQ)1&K*_GYJ!R>"=\WU@?Q%60RF KS96#<S-S\Q66+Q6K%
MG]QK5Z;!9>Y@K<O#XWR,)N;M[*E1!@8'F58CPP+,MS;5G;+D2BK*"@M$#:;N
MN&= ^!X^'1Q;P@3>R]7SY2O0B6(,GA6%87UAD[U5XKP_5.PC%S2V!]EO]KPL
M9K4=: 0,?<H:9HHS3<J^.8]+CAV@;KG'!1U3ZKZ;O4IL,K_W12<+@>7W\B79
MVK9N6K MD483SJGM1'8&9J_T4K=BK^!CH:BV56BES79!;\KG7B\E;TJB](<\
M24493<J6TDY&9'(.VZYZ<R_5O+NEB##I #?SS_/2N(TE,,B](+PVTDX;)*RX
MFOC^8?MY(<C[COJI[.)&3<2(FY-\'\<R -,EHE\70D+/[AE3TQ[_:GQWI+WB
M\$#O-X#'X->@=R,V4T@C &AH/EZ&IH2IO)@B_#(HWN_Y5DN*NO)I4T<?W6L<
MOZ=NFL83G&X.9:6#MRW"M-\GT[?=U_[CIHQPS-D^2ZC01Z-]_\B MW;8LRE>
M.@I6@T[3L4TY]?;35%*R.8A@!+R0Z571$AD*OE%3_ ^HCC^@ DA,_@4JTF#'
ME%F_+G#=N[%1O+W$:=5MH\=%.M'P(*QEPL1'P0,>&1=09FG,$>H__(H@]G@8
M;XVZ\ WJITL44)^NC[/?<:#7$$OO]Z+@_A/0T%%N8N 3N!@WB*!+YZLLM*"^
MH$CMDF DZM=]8A=?LV?AP=SH8(I",;E^L'-]KO 0\X1J,J]5T/#'9)5M\,2;
M]L: )*ETSL2QKR*NB9])D&X< 2\0*,O5;[\!5W6APD8^L<VF!9,!R/,*:D47
MD?V,8QE#*6WB1UI6XKY]?9NS2'YJ;(>PQ(Y+=9SI%0UJPN![HQCD6VQ/7F [
MW_3=95(UMI/;3]*R3&]4JRH<G]"0IOK[KZLR53MM-[U)CMS$'Y6J2-/?[0<)
MZX/LZL'E@KZ$*F/+G^ZGS\69L-W/MH$]&-'\-FY6^VQG561=\![WAP(I;G-=
M1W^N8J][.F8KO\:37-\1^:T)'_,X+4Y/;[9V5#KT<>>1DBA_Q4KE2PRY1"^O
M4UM;HAL9C250,WPN!@\V[QOV)'3;-"S#+9(>I#C1.7F]2]M_KG:=;//#8.6G
M>+C4V]X39K>J[T/>*NXXFU3LED:B,6Y.#SU0R-G6=S?.8:GSNYR@F>6T<-S8
MB(3ID GRH&YO=>DQ?ZI!5;539D\/CWNXC$=*PJ+\5;-DV4NN!=%CWC.)<=1A
MM(!8HX1M$14VT:R\\%4F#.%$^\88O/.J"!%[PIA2)2,IN7;"SM3*-UOH])U^
M(VGI574E^L7^C%-&PN25RC8KSQT+>&"VWI:2]\OY!W,5 @]T'?<A2D-48L4-
MGR;UNT?] N?><W84W7\;+E00ZD,X!(FK?:MM- %#88I45KM*-MS3#FSR1A0F
MC"3L!3^TH.E6NT*%)I09L;/=,_[8>Q;3)^0B EP^GS-BX@J'\T=FCQY.&%S9
MK0H4%VTT<(C3=X=0R)9^&@8584@<GWWE6M+#)JDH=5Y:3#[U]HP#J!7'V1%U
MGO=VC0U)$KSPYLJO6ZQW<L.(T4Z!@8 DO(<?O[R/YX#[279NVON"08+#D(.G
M\E!8;V/U2M^SE$]$S7*Z@.P$_\=[BW.7H_O)\+EOE5D%Y4OH<XSJB&J)(#4-
M3-I[HO!AX6?8-LN$B$MY?MDX-4/X;!!OYF-+P0U?+5,ATX#EHD_#LCIQA4R'
M3EMJ5(9/H9%2%;IE!=BS5%$RCB$R+4%G3=:4S4B/_;T]?0&2BJVS".29@;.7
MT)?]OGSW/FM9R?-PQ$M[ H\7##'^S,I)2KKD%9:O/SDT1RA134GY=F^H<G(H
M;W!;76KU=+!X1]0)&&H;U^TXSD4[0=CS$5:E9=4?NF>>SJ>A>U;$A^MF=X;$
M^0K\HMKBG0*\NR4YP@_)VU1=:E<%2.<T _&6#O1_%+VNJ57+9F5L]S3#)BCL
MJV3N:$!.I1]A'1?4%8JA%$WFFN&IM6)"-BY'!#V ,R98 VBWV2ZO$L;+$!C-
M]EK%W426KS!<Y1:>@/]:0+%<H0>&TR'O'M2BG95]&=%BJ-/];6H*.]IZ.M2C
M_U?4K'0DU<5N_.#+$TND9>ST;<E9_ W8CFM:2QG5TYSI/>_ND5,5_>,V?RQI
MILS.&5O]<3^028@)FQ#L6#P)!M68BW@O$J]@]+L,@1Q>9]XBKG$D.6_#IN!*
MJ3D%:.7/&L[):KB%V]V\L*_JK"19/<'MJS(]@LI:/<J^%?QKIJW:0458'XT*
M9,_'9=3^8BAY\W"W>R]_X$$Y:KK2?:$J5>:.B:*F54SK>M=#I,.&1I2 P^*C
M#]L+>:9/?%7F_,1)O8-BEZ)(8_GRO)"'=@&5.?I(J)0+@D&C^DYYHZ9X86'!
MNR'AK,NYPAJQMK<>%1REA5)@L*DWLP'.JXT:Z/;.52ZN_CY91^MU28UZ8CG)
MDGS+C(AVZI&0D91*$!?1+?#V'5;_65#<G ]\[H$O8ZKM\U_6L"MC[?8;#ZG'
M50,N*&-DF1/#M?-^)LPTP&,JSKQZ36$KJ-\'4RM>403NS9N2+9DN/: 6\?ID
M+AA?+(VF;-"3\GGQYRG7IU:)2<+ZUUP?*H 9]U>*1U)R%EGD:,X#K)6%#)+%
M=HNPROCB&XF)=1*+@6$L$P!&,'8=X0X,$!M<76(-7%J>'A9ON&X%2CM,8%Q*
ME(6J?@.ZRVL'^+5MRM0'/LHIT+'##/:#UUP,.T24Z2<"9H>*'?=/IS)>OYM\
MGPZG;UGBIB=JD.D&$/$1CJ&RF+O/R,N.YAUXR_%$?K&J;3'*/7\*+Q>K:?+B
M^E 84&=J<OH%=7I!P@W#E%S?D7H94Z>^Y6#:;(<3N>D\483$&"MZ5OC'=SCR
M#.HIR7,/$"'D3Q!3.!=SDLY'C_G_YY9RACI142;YW+=4:.R;V>_4&=,D.D@E
M.;]Q+KP&YA8\OTI]AY*RU!+JW$EF5D2L$KYMF;>AOYJ\= \4OOT=4AC_"%']
M5P,8R?Q<7?X$GYQ0^9H#RX4)R]K04:,7WQM%,.'%2'HN;KQCZD5W5NGF%>K.
MO:/WC2QY5?D*5A\^W&)3NCWW7PG]5.U:E?LAY7XL:B5LN<#W.&3$OSK!_"NG
M#]R)1:ML[FUL-Y(LS+N?ND8<8_YI!_/?4OP_VB(OQ%56BET\[OJ:F\K+_K#Q
M/"T@KD^D4O_/QO&T)BS_[1%46RQV6&4.\,E&]X,?=E0DEJ3?]K _>ZSH905E
M=TJ]-R#:K"G3=5_]=:KBBO19X/L<([%F@4-]0UE<RIEA;?*ZFL=A2IE1GPC)
MA.%P>2-Z'RT?5"#I;GZ9=\.W#?8F$*A/3<$]..K #W@6VZZGRRUH<O)@CF?B
MF3S'][L_8PY$9WQ["Y'>)QKSBIE. A.:LOYUOP'CM#.DYH&UX$,O5T33>(^,
M"]WQ^V=;LA]?[WWGA>;NQW?:1;[5%XT)_#0YT9# ?;,RLVVLY.H<\V=KXLDD
M1"QY^TG&>4:=%%)H<PJLE"I6X)]M.Q80M.B=6 LMTK:NB)OS2QV?+7J8?\"1
M3NEWXI_ (]HEEZ0\#G?888MS8)EYE)@_%*BE^&;KQ4%>HYGL?FQ<8*^3J9#Z
M'FDJ</_"_ ?Y0^QDV?MWP\]GX5U#,3^7U/=/V-BRG*=<<&F^8.0Q:T 9B_R"
M3+'?SJ&J1V6BV[OL L&[3%6TC\-6/*+<:Z'47%4XJH_31TXETF?W\'I7C_$.
M'Y-^GK]1U%7.H]M)6.;E]AI[.]W)0(2B?ETMY6>#")=@L[&)$HNL0=(!*-X$
MW'^3/$8L4[[Q %<[>/B6$1A?IF?L>%EE>(S#2:3)'#-W?>*3.RISYKJ3R>."
M0J;N\;-)2\@E]AE4 R3;):OHUS:RP]%?_"QF/$JK5M\IF<*)_\,KF%<^GFA,
MKT(\Y]T ^T8'"36U(ZX$^RS4CPD5%S9,F>$OQ1D/4VUD"F^BU?9^KLN\'#;N
ME(N>"9"-KL\U'GWT:/#\Q2.VIX?";; QL"[)+;7\P%FUD:<DI,!\P3/? -X,
M/K,IR23"!N_&]0@T+O?MQ?.%HE]ZA6"^7_O(FT]7M!E9')/-3/=72CJVOO70
M%O2)-8$\0(E4 ?;9?WLMW<4=M=TM7H=-02H#I2VXJ9O;LD)/;F;[N&E(,G![
M1UH4C95*2BVNR<AF.B;AS@#X7@A@V!Z)M\*GJZXZ9\I*XARJ4!243BMN#BEQ
M6:M$$F=/@JT+!!@0IHZ92W>*&_5#K<V5GT7Z]3A0,L-3N95N S4<2%6RFX">
MK]$7?*C8E<SK5(72=.$3Q7B%+8O,J1<FZ)CSOFK^C)&&@:_1[[XOK,X?J+*G
M:6GH?2!SBB#@[%X2)?>6\1P;[&)*:&URR@PDUB'<\^ED?]!VZ7@?,@RJG,]=
M+O*E\>Y!FA"'Q>Q []OC&.P8R8[D8'-D,4D2V\3Q7I_6\'IC E)28\EL3*7P
M(OK91*4*M>9$90O T(-4M$C\PVF.\"F*. A3!_.*,D^]KAWU7;EM+QQM.IM?
M$B\X]>O)BQZ*=\)IVE*?=/&8)JZ$1LJ72Z##]/2R? UE.V5%ST!XOP'N726%
M!9/38JX.:/-OF G#A6IC.H6[VCZ5WL \HJH-?P)1I=O&1EM %41E)"9_(D5<
M MS$[-WF>7OE<U:+5+Q&Q>KX*8.-ZY7>':();8[3U'LC^L;/8)"EQI66"Y9B
M2^#74]1AF:WB\L<)LMMB>NUFHX%X.W>IR)7KP (;5Z[/<.8"QJJQ,XY0;Y>2
MH,*F+]Y;K:CN$7Y3>QV0'ZH6(556UL(@?^G;U7U^%/CQ.+IOGQ,XAD?8XMP]
M9.E;VC0Z:<&?BI;9X4!-8K)B N<)%?A<$5[07-!L>2G4K;6-ML71D<,_"-L8
M0RN[F2$W(I3X"%^[R&N?)?43=E:@*@/WR=YM<'G34W)#GO5%YSA&< *QY8+R
M>@79/O#6,\0)%7<L-RT3X87)P,T?I-ZE[CJ71&1?*'&U"(UO2T2.SVY&">UM
M7C_7SM%\8NHX%E##*-H=3@^=>Q/[GHX,'['--*LB>;=^*ZR:YUS=YEZ[("WC
MS604$=%7!;=&*4<[*FSOB2^UM6@^DMP!+\\*;[I)B3!N'_'8)3-RS+_,ZUO5
MM(45F1N9=!>1GTUN/\UG(P=2L>)&1?><"13M2W!C_VZP0CAT\=L*+B" YQ7;
MHTQ]!9/3=:\&XAP3-TR_N+FE>S9.NWF>*8#RQ2GNBF&@[$E]8.LP#[.Q4^@]
MYA[ U,EMHAA/0,QJ4G(!/N&E0U[;[&:#>9E->6%.<W7L:N)5?/9C83%9*WY;
M6?,>':/9:05H/6+M0I_,ZUC2Z[2"^2Y5*[!0P#1<6LD;!"-&>HH%.&Q'OQP%
M]Y)97<I@R 0B$9_ : %8P81_R?VQ8<(3#X7;3.]O2893.LX^NM7LTKNGAVV#
M[[M]MN"Y('T4N>H6-/@6)M1]#(@;?!M1,2M W:SJO#-E7XK"6:!V[>,RB\=[
M-5$U(9IAZ,(L]]YCH\Y==D9VICZ&J6==!%7TM]GD7DWY#/%X?.J"CC=DU9>U
M&,HFZBO+.I5_)15>O[L8L_9LR%(\F-X!Q^ 8A0TI@BKR%%K%+L/:N"-7_>.8
M.L#]0"@YX_R5%*\#RT%5%!<J5^M6O[P\<HZ_%CL/J1 4O6C&EIFQ:C-/-DU0
M=:Z,HDOPTW+YH!6GRH4&0T!]\(I! X-95, .?<S]+Y0Z3-*RDGI>\HJHR1$!
M,> G3)^^9[,YPS"3MZ]&@X$Z8Z"B^IJ<\C,E>=WZ&W:7"<974RKU&OV.Y?;Z
M&'A5E*^B",>7^8/&4$/;;69*^_$3;7VEV<R*6%6>BET[80,-Z>@1^W1KM4)$
MN&11IL2KU^,VP?L.%"%2K\^K#6Z' B%\(9G(E@GPDLZV()J%^CGU2OOSW(YV
M.J:?N[3&#G\Y<4E5J;<M^7BVRU=+U^P.:?#LPI\59%!VE\J<,U^ P:XV8(O9
MQ-PKVZ7/TBU[1#KKLKDG[Y2K:M3'W-BO;K[JJ'\GVBQ;39$)WW+P+LNSP=?V
M3,U_!M/Y1IM3;\S)MFV#F$%,^_-)/(2*X>'"-N?,W?K:'CA1,42"<JU3\@)P
M(&_^@"75IN"69"D*6GX)@I3D).EW.&?4856!S8RFIL3X='):E H1AY6G7RFJ
M/@TY8*1\QOL5LZW<G)K\>Y^_6'R$7ZE)I=0[ES,9-I8KM/=O9;E_7EE9WB>5
M[EUS9+X'UQ]<QVCEQWGJ=(N6?%C-7CZGU-)HH(*0)4647F2\[B*+E11\0T5C
MEV]M&=HDR-K<][/8KIJAE\"0X_2 $PD35U';P;L=:G";W9HUJIEU9^ W0'(7
M?^'!5>3><*E^MBCVR\S'[:;6$3GG%0>;:7(.T/Q[0XMO,?9D-F'XH[<RM_;A
M8]O7!-UCQN:&OL5(=R$_.^8P>3I6+B-8\H*=NGJ/DY+;W'DR9_S[0U@,S93^
M0=C#-#?EYJWNIX50[-F#0"I;98'NJ&U]6^1%=Z8CMT0W0\_ZT.TP?[(R)Q]5
M1K;O=&>@RWJ+R*7N8_%0<5FWDE,CQSM\[% 1U&!<F)+UBHC' CO1>A^HS^L.
M^1F?M*Q9P(FC"'4B;,BI!KR:_OHU0T:8V]F;^)>\TGG?)E,9XE_VE?#N/1TZ
M3/XJWZC*CF +8GU[*6%4-2)B2/&AWE!W;@,62IP]?,F)'Y@.$$^SPK-R#,[1
M,S]4.7)IFN=O$&_P4=^R8/S2 UJ9U??8$L.T'?/9U.T0G[>Z-#H")[,OONBI
M,VX[W(Z!.7QR4V-/I^C1GZ[UH22#5DW6$<:Q5U5!?--M@2)V$?E80[0Q[83A
M?-49B R&J9D;IXGKF)<*BN96@? &\U_7E97;9L_SQNK_""/O#"24INK35^H6
M$.G-GNHA#PR.5]JV^[- Q22J#+&3;B\7+8"$YYXQ7@"O?5-R4<Z5ZV#!SU%T
MN^:./J^*_-UL?+/"OLGWZ4O_&F:OQE&+1RN?;]M4ECLIJQ?XW7+VXF"9F.RK
M8_3.TM>S?+R[:PYF<HGSU5P^T6WQ '[<G(:5QM;6X5LU>D?=<*S^!MSS_E;8
MV?=#>;XFU_A,MYEK3=ID5KKRNL :*LB86]R#S7XB]7[[N@K9-B267SG:D%ZR
MC/OBF''?<1;PY6T@8',H>6ZVMIX34NS2A+O@>PH'/R%/&9WHI^"UH##[OOJ]
MZ>V0-M#6V$.4D0$Q)>10:EF\B_IBX)*ZOE\6I2]^7^:B=_]7="""'XM=0%><
M08][5XRU.L#4C:T%1%Z4;FYK:IT)4WOUZ6;E%2)GQ[O6WQM<1ZA)VV,W4:LU
M:B)5,>CM.1"(3"!8MX)S0M^ ^6)86^];?A]-#,-*ZM>XI6K40AR<5*0>:HBX
M;1]!+R/)3"@ISF$5$U+[J1X2TK##S TR=FRHG\,WVXIE-V68SL8.Y0$(A3=T
M:VK=M?IXH 'E-PH0_^=[SS0EK%CR?,)* CSZE$LJ3\\'7IM)O21DH!32AG"C
M4N]!"JPR[;A:?MYI^[7^Y#B5]$).D6Y,5'N!<=Q0MDIV6;3Q2J/&U8 ,,\OW
MF#,PO3\]AS1[,4_"YJ$C2@[V5MTDQZ6X%%8@KK'MNP9@2B"4#*!>%:F1N)C)
MKFG(T&YZ5#_]U<QG9]_34,SOP1>-Y<6@3%MN_%':UK:+0-R5SZ%'@SJD9B;D
M\HM#=(@]\Z+_EE!@?Q9$EE*YQ+ZEM_^C8Y8G>U2?Z5.BU(&T76I6Q/0Z_$Y/
MB[$Q)G9X4:1Y^>EE?,#"6O?:VB]5H:[,IS'&(RU1>R5'X,K? /LG/Y/J&7E^
M:EO^!EB$7D+U!:3K=H#,\!/HGR@<+-L79].0.=_3,CX?KWO.GR-: '$V-:KO
M(3<;[S*P,&=OIW Y4?2W&2WPS[LP#E1:Q0Y+0[U 5.9A'RDBJN\R 5<HYV^@
M8Q$?G0IFZUP,NC%(1(+:XN.EMUF>(WDCRG*C&+U<-=.B_#\SDQ^?TF_.!E@+
M>S8P6N0DN0%>&]?Z"7+?7K*GZT--O>4QI_[QX_.ORJ5!W(SXJJ51@-UO0'9)
M?0XE$#KIC8F3:EK2-6!AOA^VX')$E.;Z"O+GA!6N07J0VG- P-W?RQ4@VCR\
MN!Y15*> :%.G[[J-C0X>JJ6JR^VA*;W)^IQ1_EQ=O937!UEF76O.5C^%@5#<
MR!,%9RVJT4/V>LK 1LRT(/L)8\8U0WUU42>@.>.?^ZC)- ?2"-;.K-?I&PLU
M8;65S<8P=B5LM)12J7#IW+?JU &0/0N>AJGKQ!SA?/0#J0/XM5\KN((K6B!;
M2<V?L0@O;%0ZY<2BWMAAH+=D\5NF_<'!V18Z4UP>?#JDO[-:5EY1X=:1Y+LY
MC:!TLN@179:LHF,[CXC33!.YFOKN9=U53R%@^'/O<M?.9\C$$K$N%:BC,SHF
MIDK"EIK7R#(>]+;WRC"Z-IC'N @Z]="MJJ"LI-3SM4W9/! <YIG]9N-E W."
MJ2.?'3QJQ5R!Z4O3]\X5C.<-S1&&(HZ<4S0\O+8\DSXG@XMB,;!E_IJFR5,%
M4G3U,^;I,EPLRZPZ]UPNM*T/D@P><2LI3+WR,\)C<^5JAIO':PO'K8=";P4$
M(-,7N H\F8&<+*?*.>+N Z1HFC"TWM:VU]%B$HG0IN9&[,W)I45"ZYZI&'RF
MF%?DYX3GI*X&TZAMNR?#09[-NF9&OI13\Q69E'^'^O/+)X5L]>Y\K2/H%UDR
M6J2_*,U<+RT&2W^-[%W5;Q9^_FZN[%J$3F9GU>93 2>/^!VPM 94\*GL[41K
M&H[P&YX9Z@PP%BR#8MLI+8#ZAC5SP)WB8.;N%55MGD5O&1?&8A.[\/GJBK8(
MBUSVV=V"*A2$>WPB$_S:-"ZSO@I67"<GR>XM_=&!<7]$YT'RZ[LJ"RD*:_%M
M]?DCZ[C#1L\S0(/K&,U1H3TVY7B$6J3=54/KY)B)PO^*)B0-^VG[1I@:1K(&
MHYL]_\@"<%]TEX6GIAR7*51L[,VQ$)&4F$&K]2JG)SA%0\)Q*=XGQ#RVZ37C
M$LO"?4R_#*M*:IT8"9),]FC+I9$1;]8'*9T3#VYYD%I(^K<;1::,&ET3P%:<
MO&J-QB<;,0K"JCY_'*>P>GJB+GB_I-DLO\B]K\2IPT4:5B$CKKY$N69],//@
M445*B\,4SM'8,3C*PI$#$9>I)O]QZ(/U>TK7I]*R=YYYO#Z8IB[J9+*!V@PV
M_ERX6)V+<!LHV"]4U2YY?+%=QNG"=+[\6;I][0(.7-*&:/"II-J^69O4#?M^
M(*QBQJ0NR8(VS*0R\YLIQ+[.^JG]2S14^IE7!*CZ(/#%N1R5JRW=O1,Z%NT4
MRFK>TIEF;H;[YKVC*_);S)T'BPL^[CL+^CQBXA#A1D7/QJ\JJ\F:4['8#7U]
MQ)9),>+36%U'Z5K$Z'K8:U<R6O_^N'$JK9PY[MH^L>Q4O= ^D@NY]HX"7DN,
M,">PJ\D;KW#7U-6S)-FX;%:.V$N"I8DZN4"DA4%K<-=;0 E-E4&6=0R@4&-J
M"J"A>3?V //"*28%[8EC&.]<8</W]0U$/#=1JOUZ>#EQG^Q>=(_3\0+\&O33
M<NDWP"MTM,+<QT)V)"#(MC.C\YW!P:]X=LD3>V^S*4=B%UA_.4.>)C45AGNU
MBK@S:AN)IPW!ID[R7J?:+L[H==RWKNBX^XD"Y)K5@/L4K;:3 K:;,JA]^P6<
M94M%ZI87(DD^.M050Y$S;<H<(5=\_:R.H?98D3@^M)J,E7LB1L!)3)FT,"ZJ
M0M^2U[F2G6:;BTEV;*SH[*&)0<J1GKZR-HC1)IPK\EDL';D#'> QE%.-8Z[>
MZ-<6XOW>K$]S?MD[UF\F@;K.N#D:3.VB.-"!;E#$RSZ)^3> PB#:'.(GZATQ
M65[^$;+J%9,<\I1D0,M]R$7F'K>.']/0O?97*Y+5]!0N3Q58WFDE48C-Z$.D
M! JE->8($"N%<\XBE<NH+IYC\0 F,OO/(ZEDC6!>9"!O)CP0W;8J?WTJF#TW
MOTKV+.W>AB<^?BA3:OP%9QSA ,AI@G8NN%SUW@Z='9,,"Y*Y [A]&@LGY_):
MY6& VK'?+Y09J!MLS!T>D;FH.%!#= _93104A Q6QV8K+W<FP+S:V9=7I\MC
M#11]J.NF&E>0C7KW B/WHEQNXO5'5#D)7 I;#<'X0.NB3/FM;Q)K03].RI@R
M[TSIYI6=%GL6EQ:$B]4D91.%+\8Q?WT!N?=MW:[!5:B'9L#53#7RL ;I$JCN
MME:(>>M]_6(FQKOKYIV\.<MO0(>PV_!A]</&,X%8HYZR*IJRQRY742=N5B[K
MDJ4)$O(R0UO:Q4!OKK@&1W)9D&.5T!M-.JO2F(.^^[-/F;#3NB*-Y.)]FQ5+
M)6R8:;O/2JR6*V#8\>BWHX?,6:WIAVL5=XC/S%6FSA*QJ6(O^>@[(1?]XDW=
M3/[26:TYOXKEL('2D3.!D?O>+?/5J:A]@9)@SZYW;&<+S+^\DRM%J%GRFQ2\
M2I"5J(45EU6GQSF8X\5-WP*(&S Z*"$@2ZP\9!0U85?2!DDO7TGX\*WH7BUD
MM7?1]=E@@#]?SLR"Q&X$Q;@I86:/=](NV+VJ92%[F*Z\RLTS?7$C[JN087*M
M56FE[(@UG-M(RGPI*,=2LG*D:VGQ9]7B;X!C/*1;F1 SF]N2?L^/Y<0OM/A+
MCJRC=>!,JJCY 6+;OF5^SYO:7O3%QQ5DUK@TI46(=U:!3R!TG!8<"\7X+ZW4
MU(K7FK% 1U+A1=DG_?7K [P%/RP(*^8/9JUKL]01"T*2XQG#DAD2<<,7N71G
MUJJH0;'M@V:#HK*R!_7TG.1)NGV)K4,/UWP\UHJ\K_G?+MW!1)/_VG\5B9P[
MP>K*$,\?C!.]2H8LL$-J()?\IY_<>>PH5C."2C3-GGX[F=60%+3\H!O$/6]4
MWP_*@U00R(@L'N\,"3/A1PY^6 N6<$V2C*%JG@EO.7\;E(=CI"BN1NM&,>@;
MDA(\=G#X4*])$R9I135=1#[S.)Q65]>Q^48T>\T/GXOQ34F%YQ1I:."HT4!<
MS%N0?IN&%)U9S]-N/-\DSQ'9F[(F$T9;$-50 ?:K+EHVI]:."%U5ZG?;)ZR3
M%K[8SL+5*RG;4"KOMH,G@YL]*U[&_-F,;9A^M,F<^++2/2INV0:0O*2%H\<-
MKLKJ:_3U^5GPC/KKW=JEAUVM1UY%<';8TVI&;=],[2_I,RR3[>65/+"]4?)C
MG/O\LZ&U@M%!LXCQU>@3*_O(M$'6^'<FC>ZIL:BR/6_3\[CP,WWC$KZ"DF^Z
MENSI*CV;%23L^$Q7\"6IT1D!&@RR8OO$NL7 D2%*CE.Y<V-;(H]\?+(AR%^V
M%<\(^'G-L.TP(_31H][I?R^7J'$IBC:WOAW^T/]V2)D)D&6M1]VEW ;/<^'^
M+&"?@UHS-S&MYS*19,9Y?(AS()IOZ0V+>+:6W+W<QUI#^ZGU%_/D4)&$]Y$N
MAS'VC#-7!C-N@8^$XI)XG>"A%=+!I:L"!MD![C=WE92W6?R-=\DI#?@X*U J
M7)&JKG3@[^E!"RO*0> 6RM\ !.XWX!;<<<A_V5!(S_1E'V?,09NQIX-LNT_I
MY_BTSO_%VGN_-=5M_=X@4J0ITDM *=)1>D>0WFM 2D":$$*OT@1!02D!@O0B
MO80FD%!"44!Z)Z$%0J^A*55 ]+WOO:^]]W/.<]YS?CCG#UC7M>9<8\RYOG/,
M\?T8+A?])KY=;"ZQN;Z&_;1BR/B8@^'O)^9_7H;=*-A];?UQ?'GE^H?@S1W)
MUR*V2B*5OXD/]$N]@/=CI);%_2X-60M"9H*2,L;1FK\HL!FNTN]+J3_V",I;
M629<3?@:GMKF>42]&4T9#3<K%U/L4/C*3XX!YYPI7KT=)Q!*B;VO82CUJ=(#
MDR9Z*&%DXRK AY_C+L^+D4:<1SWI!$^'\F,8L@?#CTK#^]ZW?-^(S:G_?1(2
MU9E=F2]@%>Q2D5+?0ZN[=,%&@J"$ 2G@3;-VPC;UX#G.F+22F%'QH-P?R]!O
MQ!%K&F4_H6U;<:]2*E]SU5X6-2\'X"Q^"]S-_D. "I\-L/M9H03YC2>34.)V
M\_H@V.E:_H$E9TWN*%LP_ (T';%6<%EW78X+ OXAB(O>^G(8V?O9O=\4Y#9/
MEW[)5\@[E%W@&0/]%2"X"WKL4().UPEU)O*A4\U)LF@Y\SE-4W\N-1U25N72
M^;W+0L> C0G7_V:)_(M[LX[N: /YM7^W&SBG??:NJY)W,#_WZ+_J7F#DNV.
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M443VD8C)GMRF7R\Z=V1H;G?#SS^>E0=''0@IR&D2S/J2\HZ/.C[W!S5J>1C
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MH)!/0#[_ D2P(6'+DF(%1=2X?U'[PFHM<EH=J,TWS),X3_Q28-@A$'ZMBY0
MGDFYW(&,=,/F3?N<N<:",C5(=L?MS=V(6#;M=-T+LQM6%?Q//S<''VMYL] ;
M(T#%X.&9* R=!-!4*KABZ:&X:>>CH=#,;0+ \">>QH5ZOP-S<K 87SGJZU#^
MP6(NT=88@^?"#E_9O/I!JB:KI2%!&"_1@+<WKC\HJ,:6W]OET:46=O>Z@SC5
M)=!MK\;,'S-2&/LXN%^Q:R H+0F"]<QLF=74&9H';WP\['.K7*9P4ASUB[P-
M7WC>V:GAW@"-(]>)_&G-Q5D=[/XXK;[97R;A\IIAV37P!APVE686- 1XJ*HF
MK04/=T^X=T^#C6UK)2@$<P#:\ SO385+@C[IJ=/6T3OP#OG0Z8/#8*^K-,7J
M)6;:/KL)H#6]JD(AJKKM[$6\J@^]7D$BN?F$KPT7]SQ1.GLO.RU+,:=2Y[$F
MAD]"W0A=EU):ME2V@CYW[)ZIZXM\;I2V<_WIZFDZO(()>LX^;]F^'SD1DK#-
M=GW%AZW(.QQ4SU=4DDH+#F>;%OF2;4Z>N7B7JO[(ERO#YG(6,C8E,5VVSD.E
M[M0PSL@?QDXZ,O?E.>+>LM6'26TAZQ<S#:91+YWS:E\ :F^O8QMOQI--VUQ\
MQE&S9IAQ0;C-RAV_YO</_A#@='6K'FKC."U?S)CK_FR5F[1<%6J.R5J: 2PR
M'-VZZ_5P#@'%CJ5^EX$[UE1D2R>N=Y6F;$;??"=-W3/VR$:;3"XW51(3N)8[
M&^,H=Z:LCI5/V=ZUSQ$32["*%@A]R*IX'%;N'^S4<G:D2??!))77O&JT<P\,
MW5:QH,/<!;_*E!_\NI>_SU=\7E,R;^+X?3>/*7"WTD,BAF9;C+ M20EH<1L]
MZ<YKH:FF!1%!*Y-XLS*G%%R1T&U-LJ-8W+*AZ;TE((\ >:L9EJP@F^ZER5;H
M!R2G=-/SJ27A22O%4U@3H>?BVBN-GXNXHZ$:9--?,[:LL>Q:*>CDWC"E-0>2
MN)N8RN;OF$L05*GL&7C59COLD0['7H<#.RYP\P"ORG55.LTAF@S?/D"^K7?-
M0>V"\/%^]PG=Q+<Y\*YN88]F\NKWH-"V%/5'TK*//*1<?K:A.:X]GOYJJN1,
MW!__$53V]!P;<>EAHJZ)F5*\Q<G'_3_9#R"S81>JY0>TBYYI0F5E22DI*\EL
MP83#8Y'S145-DD$-(,<<(ULDE=-5%)&BOII(1>H[.N7TZ)Z?,KBM:KQB>.F>
M)^)\2'=:8GJ:@&GUY0^1@?% 4I$S%X:X/G 5]TXQ(RZBM!K821K8,64Z3:VA
MN+:&7@Q2Z:_QJFDFU\WC$JB9?H)!/UT9I.W)#K=7%_,0YZ&STB_8E3G<FKL^
M(ZNAQ@DM;^8?'$5_LAI/ EIRUV.6F+W?+_#G;NDK 6(8<FG0"G&F#(E30HYV
M>L)+''U>;[ZW+-JP>3K*7C(FTF_AK%V<9[(;>*WSQQY4\ ;D=%S*?#72S]HI
M"KPIWJ5X]]78Q&[GDXD!D6Z\BI*#,NFF=<[T[UDG6$J&V]PNR/R$34%O]1"@
M$:KH!DYQW7N%3K?&),".P(6U*=%4 6I4R4D:S^;07?02E#'Y4NJT)'O/NR(G
M%V]!K0-^I[6"U)MB+C4EP8$["3*)ZXMW-@P+:GKQ/[SJ)U -1Y94/.(A@X*?
M%8G:+Z-,=VA!QOGQFF5(CUC3._HQNX96#EOG?5I^FJ^IJ17V1,9#FY9 Y@O.
MU@( ;?XH[PF5Q/4J Y-,Q&B<<'CMF1?JKSW?J]+]>&*XJP*B<KWPAT ")G?%
MT*7R\/\9AICP70!BX?#T]]V HK+JZ#KJ5ST+Q_2C\&D5US*Z<Y1 B)S/E P7
MI=< @\.#@O_9-YRBK\G14%-AE"!SW>^K8LOM.N?XP-_XFIOX/P0?X?H8:_6"
M6FUQS>( NHM9X(=5J B9I_2=[=P;';TJW,<(L-_I7QK%Y',&8\/QN%2Z^,!!
MV]\(XW0^!\S0/;.T"#7&1+\1?^!=^YX<UO=*WN3GSR\>'^*_S#_=$9R0,<QW
M\@E+\FN%:?-X0_%_TP>A%F3O;]U6N[WGY-O:#&]Y<PP@^<'NO9I44F5IML#]
MZT'%S>+?]CP-I?<&S.?+89]<@DQIFW5[F+0.19CM!!Y7!N+^32;4(7^KINS=
MJMY-E'9JV-I7I"V1&/9/F&KP&T=MCL=3G8%VST)S(D@\OW1&3&!4&-8X^;G_
M<7Z55F]=@P2FYJK?]DSI'R$4Y >^WI%?J+ERH A[C$M'/0-$7U+MG4:^E=8J
MV@HWJ)SV]!FLJ*O<W%IZ.O&X=C]]QT,J3H[<_CUXS=WCC/CDJ/5WUQ&T%+8M
MZ$=%=NPKUQZ=E!+.7E+-^$I-G;C['U]B I(HJUUY^NM4LD2<W<;W=V(/,LS'
MU^56K9OW]Q^TP](YDW.*P.OFCE=X,H-/2-TV8[Y1O02%N:6^*YW+]3K;"L$<
MLOBWW)R;WI&;C&21F[;RMR:$*T(#>+#".YD1\UQ!D"\*5_)T7$XA_%>HWS('
MWDWH>Y>XI'>+RU97W=!T%H'GE96.[M[?)OHDBY,)R133FXUM^??-/^SAQU.8
MCJWD.G"1PF\;Q/APW% J1PV;]0GBD['),R=4#/[GF@_#3T ;K<I/NR,.G5M/
M(]HP2X>I%N9?0K3O/IR;G"/-@D1Q$J7UT=;31;8"?%O42([' X)HDLW:A!6B
MDQP^F>X*MH^Y>BBQ>*L.QX@NP5^>;7063I&HE@G'N/^0H1H+9^N(&_)@#_1Z
M^6)8&/?4<5AG]V?UQY+[W)41/1&G[,[M:D#/OT3W>IS /;/D?T_G]Q93J=J8
MHJQ#8:=)E-CJ'%F?>9N^Y<,&TU%ZA;%,K8,U$-2F?JY!DD;XLTV\]FW3P:BG
M9A5+P_D7"U6ZB]LT?'B_N1:QC:CI;NJG'\H-OQ[VW^D0VBK]:6KS*E5-#;1-
M]J^THW.Q 4OAR[!65SWZ*_35U4Q)$1%!QR$)(699]X@9T2SJ3<+Z%754U?Z'
M[=IL,5SL1Q0^;2UC!GYXD[?*ZOZ/DEZF!NPT(*=M+\U1B"W%,69OHJ#*<8.J
MQ.*=.("?PW?R08"A,>O;C]-ZGG9$77@2S:E2U\CN!A.S"2R8'U*E(%7$U,-A
MW+.X1H.U3HW>LQ)\E.1<9[.$9*KQKVU5&Q@A42"[" UJ'-\P*5&F8S@H%.29
MI<8T*:HJPL%K3I+>Y"_UYN?0R6)'T;B448,40IOP,1'S!61WN;8;?I@'$-97
M5)1LW&N$.\%\_K*R&0(&9)KNAD.,*UP/S](>P\M6, UU1TEI&U%.8DY^ VSU
M[^R+;O$VXEA& <13C\Q1=3WP97/M)#^_T..0W"LSAE9$D$?%<C'Z C_*6\F?
MQ19@HL14%H-27.9939+AIJ2LRG*59$]$HV :VN&-4^8#73&=&L'*04Y^RD!K
M":0:KGD)7NF9N@30]Z QGQU.ZAR[0*P0#A:0K!,59<ZZ+Q5EWX ")[&P1D-#
MV]\\9D)OTNX-G$Q?)VVPA6+&!IV;YBK>\>3'D<OY7-YK].<P#)E[P,G"^PP-
M1N'W2O7#@3.7M@25M95?18@*()J/DL3Z)E'WBW7L(-O-=N4!L-H@3([U[GS,
MP HAI^$[*$@N7,#[/27K 3S]PJ6ZR8;)3A?('*=,37W7Y\B(A2I[Z6%SPRBP
MUC,5/#??[4'G/ZG^F-+?/I?J6'2X,8/G)><M9/-^K9QP+@@19A&4+=??.JGS
MXKB ^'JN[R(-EZ_C8NI,NZMI*;-9$\ ;]:,Y^!< M^\RG]:L=OO^IY>!S?M+
M29JXE["&[$SG-"$V?I;O:ZH+(RL)ES/0DP9(VN]1X3IC""2M.S$!5YJ %A-E
M;0,\VB6Q\>W3VJ*O?4\IR$. G-]QO1UCK$OT\"X7ZT(-D<S^#A*UK+V ?/=Q
MH397(Z9=GW*B+5#+"<".7AZIN7H@*)>8#?+\H:D*1];T'3DY9F\;OQ+R9O;V
MO0V3'O(VQC4]YQ<)Z7=A<' N+_5/_=:O?#"K#F78!1^Q)56"ANV\&Q9JI<E9
M\%BMK:I"OSQ]0=0W S'- 26UVX\ V=,6BQ7P &A%+>:>T0!W66D831>3]XY=
MZ_>!KUOFQ]O%\Z"Z?>RG'DK/9A7N6YF:R3??-8(:AYD/_XIHE2H)'M6 >4R3
M]>GY[%B?IK4>_[R@&\NL"[/"PB[;;.*R2QH51C*C@ZL"CC@+>*T@6EWNK&::
M,KF0M $8K[O!W-RC$:8MXC\=.9LEC\/GE!Y^(8%W%A..]RO/0/5=#X$&?:?O
MIE"]?JV[.%-+A\K\=6-Z559#@)IO3%L*+J(KD%J,<0)R:_AE\SR_G3ZX!)I.
M.K!K,W#%V):EA"!)U=JQ-L]MFC65C@<I?DL% 4V"2BIY99?V^\4'^'#L(R*!
M6J5%4R$SF^#&H;5U#;PK7"88SQ7:VHRIWE!6/;!Z%J_K.G3M 6^H9>:Y;R@9
MNF@GOZF >\C%K)3P.#Q3W2=6%;L04E%96;/(<XQIR6*_(R,RR"O3_;&(R!2.
MN*$N;S"$H$3'RC-(A63\V&1C)<[OF=T_:-C+.QP7AE_7B-#/?!\Q[08[OER/
M[?(;UA)S;$D9M>(KU:Y]9V.*5_.2NQ_UH]2CR6VP[+[U/$>TN>J&-NO<$W:Y
M]7+UTLIY9/<)FUE(L\7B8X97^;-Q#PW9V)ZA![3.+PW9TYPXTQY%QSFI6KBZ
M00Z<.]?50:;@M@6LI;Z%'B$._"M#XMC[1$B BM!"\3!JNTJ2!W3N1OJ#WR%
MP?^'Z U4R,5$'O.#SM/1#:]>@:CRN!H[J'RG6Q;@+&@OT?U$%.4W.+_]Z5FM
MQ%N)H$"0VVE@9<T4HC:ONVE!0E2[Y7#V2<LE,]NE8)=&[16M[I)@F-BF8U%%
M)>\C3?';5S[3EKK?8CEN$7W>TQ?O:X8M2$Q9X?<4V,FSM$-+<6#JY-19GOFS
M*D95\,PN2%S3Q5D;[B'#%6?9VI&:G_549]'8Q'1BJE]?_;:W:=^3N757B/(I
M\7[AT&!"8-'#,@0/H-P0M#_=&+JJ[5N9':Q:O/@U^<3+%-T!?C'?NQ7W'GN
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M^-RX_B'(?)S^D?Z?(^I\^Q_V9=4V\I3WWQ=EU&@\.3EASTXJLQ"GQZ,/>[C
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M@.4NFW6A_C@N.R&4I+6D<Z0_-[:BN+3RPW<C0H-OVAKL5EYO7Z+$EEZA\:$
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M@MKCPI%BQVI X+V=+'V/H(HSKGGAK6F88<E7/0,-FH+%SJEA5@V_HR19FY;
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M?!"WO'<D"YZO^.Y).?Q9R']L\;S[5;=EZ,N"6;?IBLY30J8'?NIQ>S\"[)O
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MUC>F( ?A!"$29BMW3G^Z%-#G9V:[J%-!HJ)AVZ0_LUK?H\;2GOCM"53Z^/P
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MJT;2DK)!.:4EM(M812W7IBY%I0?PU+OWUN+9(I!D^*,9=^(GQ&65*I!+,>+
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M:$Z8*V9]\^NF!K@XBYOUW)B9,/M+;._:QH=8WERE/& !^!>7O65M>5?R#M,
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M]E!BO17;6&-"!FR&('^?F!"$F1MQ ?M// T.+F5(KA?Y690A]PH-=GE<&,2
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M80OK@I!JWE/]ZLQ:2]C.Z"U@75QYXZ3B4Z]7XNQF>JC1NM#/_F&H:6+G&D5
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M^+XN)#M8;J^ROGX:11$W?3\SIT'#@Y0#RZ=(2_W<@<B]%0<O\@@D:?U[>DY
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M(XWH.@'9Q/)FIXJR3L+7LZ^FDOVO/@DN=7U7OZ)H[L^OFO0ZNO)53<:6JDC
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MT@E3X3W?]1XV9UP_QI9/+ZB?+.YRA:13"%D:0VI1VYGV^[;9<I=6V#ZPPQ8
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MDEJV^GB7'33 .8'4J6\HD^84Y^>Z&?WH'V_V>]8H@4""28&(-PX+ES0W8TA
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MTCG7YM+QB/H->[_@:'>9#E][TY\#S)K2]ZH(EE[J6J%R#=K?6;V$_;1GXX9
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MDA<<7XG[4N7E*$WMQ-#]:($VI+[/DV5L9Y?,'G$#JNOMM13I]"(@&UMQ26;
M;'OFQ&(J$QPYC'*6,](<0K-B72AY7]PRNFD$U2T**84YEM4GN;JI."48K(EX
M9W\&W3&2;[U#DFAPJ8F8(:#4R-E6L;>1<7HI$F&AEIN/N]DW/(ZU\P8H2&YT
M^2JL?=EF-=)I6H%SN44U^X;,D$*^AIN]_<3+2R,F6I#DZ@+--RP9<<M/CNZK
M'TRF+O>^E;2NO[9JH&)&%@A;D+Z2S"S;M/Y9[2LO?K2LR )-Y<ZZL;&-RQQ%
MVPNI7KK:JYIAYA5V#8<E9F5B _XH7Q!BESBXA+^RDW*KLH!6Y4I>((9K@(*Y
M,4RLSHQRZM).X4?3.O^8*J=3@ PO5DG:S<CK4J3UI3F#-DY'!L>T,,8T&ANF
M[M&&4MM<VE1Z[P)KOXVRSKLN$T["UP6RV01D,T.4OGHZJ\U%41.XT$(Z/(@:
M5TQ2HV=*1'-,\/K*UJ-2/::&&6;;UDMKS.Q0-I\O5K29PI*Z[H*/N%6]O3'@
MT>D249UEU;$01ZIR]R.JI.3:=*,,;='BM#*FDDW 4DU4G*NI%D@L;V,M0UL;
M1WX-Q-Z@9L+(GN20/D^\SS/T,N>S^4/!B+P':W&DJ'8-NP?+DJ3O_&ZJ @CD
M7*E"%1IN= Z]7S'CNFCM36=UR"51U(,&/I)^QD>W+%>&\'9,V ;LT7#X5O2Z
M83"X;'=_5S@#CYQ&9T9W\@3O0COS KN[D8BH4Q,[#9O1[O0IX(0:"(?E0Y,R
MJQ[I5(%C^?@/EF=&EN>KW<:BCP5C^?J-OFH7O4J8'CNX2Y-B(O4 :]=R/VLX
MB4-[4XD0Z.=;W.&R!_$+&;,N:MR5PJV?Y*U009^^N.*? 2$KW]4P6NT:<44@
MDO:6IU1H>+D[^OB^WEG:0:P-[GI@T%GIO=8%#C=H18!^032;+3$KBR3/GV&-
M:H G>:)8 O\KY469&$NOW/%]L&(S=(;EWM?]F\7AS:1V&7X?V^ PSP%.84;H
MQX%^E668KP2V+ X3$WF'=9FOQ5=7%X5YRK9+8^#1>#?0BARE+[\0S?=ZOL[
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M?EGL_!NLAGK-J+Y8-L@[ ^36#PU%/$RN#63+ND2]<#=%E<*GZD9A(>O]W/1
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MF1R:$(<?GWZOL(%*.#H*</'R"0J+<?[VX$=SSK_:_^+!7\F^N8" (FP@/W%
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M/3;(ZCR,0L 2G-\-OS_X?VK8A+G-A+A!_$!S;F$!H(4 '^_Y"@7Q 86%> 7
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M&P@:%A86]A5L0FQLPML4)!2W_V/Y6@\@N((^=+D/'8T.<(D #9T [6L3@ J
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MRHMGUG!5N/ +6+>N%6W68DL'1FA)JR!OV82=:'O/D;IF,W6(6FUH:;ZM9K2
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M:47E%H?#*K-'<'GK4V^;3RC='K;%EXM;PHPZ9;UMQKI4!.A1U,M46 9I*FI
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MI(=_X$X<?&!'D9^</W=J%Y$&\9:V',\V<<"0T.SSO)0#[R=VM.WPJE;39,B
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MQ11=XW/9QZ?5]Z 6=.TC%R SJ[H/KFAFL+7IHG*]DP:!F3R\OMD:Z-O,2Y(
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M3E/.W,>P(7_8M_P!IY:PIE _\VG$"9K8Z.RK%H*L_\62FR5H*TEKY_\)>4'
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MR,1W<'V:MCRTH/!FO J?L78B<+$R?=@P!PT"":-&8KZ@VYQWF1SN"$'1!NN
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M&^C($]C1>O4U"\"9\DVT!7\XUF&&9ZG7X4]V%T&1K)I1G2 VP?F):F\C3^!
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M4,[V?=&^6VYN/@KO'78>#59YB]/F@N9$=4$]_NR4Y<\$WZ?$0//61W&3]O=
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M00P/X-P_93-)N'<X.8&NQSU^3&MA2D[N/UTL\._&\B?V8[(X/ZJ6]O&:T8
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M,)G+[KN=$JW3HRG*]*W:&++'EX%T$&>T=H;@BW.'O<!YNCK64!\[*>1G,\O
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MB4??CJQ2\6 >I>7'@BJN':-E/PD#YLPOL%!4I5#*DO2VH[IQ7=E>"_Y0%X=
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MEFU(M$F#C4MJ8=SW%%FKP+/V7,@LFP_^RQ@3ZOCE=+H@!L +X,18(J*N]7D
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M9I=<2#:3)](R7?CC#,*H4>'"38DK*&&#-$?C^7R]&VCCCR_D')Z72H374/<
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M61D'ZH)[&8&H*E[WMUK?Q'SR4BA3S<!IA["** -:(U8G3HS.5@%W=$8T,X
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M'D64*I/*%6\TU0/ ['YW9/4GUJGG?53LU4\F*V^U2,][*R,'2\&MF9/<3P^
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M\W3O"7F(L(Z]J:W;IO*4FMR]7?2O $%'+$J:C!JB(DK.,9P&#N*DVLJ;_0<
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MT3[7YE/^J)\R1:[[8A:@H1=D/(\N.;K/X_/?/O,*<S1>&)N8AKG'(32M_,!
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M?XNQ]B_!U(ZO)COOMA]Y^KS7U5Q*GS?D_'.[U[/SLM'7J>' VIH/TZ,T^L\
M_1UQC\C[6NVCJ"E,2'VQKH*^90/\M9JA$@$(["2TU.\4ZNVU!/=*@> P#C?Y
MB79I?5Y<ZBM54O\LNP3<)J](W;(SS5)W]UE-Y8W*+\RS@?5C^ (-NZ"7+EQO
MOW];$A0>7&W]BC=@I*D/M2H'*X5_TNKR_,UA$>[G6A GW9-620'L J/FHZJ
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M5>UDU\4$"X0O2&'3>.0<Y3FH)OZIO(6)<9B_-(5&KZ8H>WK@ %I>K1:"]N[
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MN2P*ULJBOI9=@Z81^Q#^I&:CHR!^K.^,'^9<%;!?5=M67(J_JLCVD+(EWCH
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M)W+XU>- /=0?4!J\<F GA4Q$Y&8CK*I2VW025^]2E5C^HQ4.G&,_]2*EPOG
MQL\M]!X!P'A$7(><BYSBT$"SC%=BE_=4RJ-<I9K24\O'MLE+GP&)A@.0L%5
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M:5=J8!QW2OZT#RBPZZ2J4/PDZ&[Y)D>*CP@5]^(F2\JAQV%SA03G>,((Q=F
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M468?5Q]CXZ:Z@MG#4ATA1J$5TWJW&F 55P39L"0"D"\X+.W9\U^!&C$U_=[
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M[+#4S3/&*Q:!;9RXLLK93URP\_?.$B^P7MMM%=HC3_C>"-9^?AK*9A$3X;V
M>\M_?5,]HXO%*PEST-%-CS0<3 :7"^YRU[!/O;B=*Z&,L7=I/A R!QJN(A^-
MZ7CI";_+:9[4TL2RZW]#HZ*YZ+X1Z$7=0J8S$&];;KR)$5A?#SD:Y9_LLZX=
MJ!)^9RV<6[$G)CHH=?X,YN>4D%T[VH?7& Z^>:N)_<%#MF(M>YE$2,6MQ")0
M*GK?F:88>"&--&1UKT]H9>?BF6LCA.0.X:+FH\1B $@"T+K,(5=%!M%-,8J^
MG&']U!V.()$OLSL]/S%.@*Y5&O?)'5_Z#@-D:-;OQ4#7(I_WK1&RDC_;YV^"
MP^N-RR\VM8'+Z;^-]'C2L+G4.0@6^8@F1NQ!P$7IZ4HM4- ^?O>/MU/;QQA:
M"G-"$#7Y983O3'5=$%Y.78-S+40>.63S@#)I5<'J?"'<IL3+3V^W$KT<$_'6
M^,D!!L;P5W*M^/.%'=9B.Z<$S;F2K" :KE',Y:0HY+O&A-Y]8FRC!9'L^_<'
MM;*+S\R#W&(PO-ZR"+7*K_1'3H?OM^;=/>Y87;%"P*5_KAY>BE@F"LP4HZT4
M0>)?.;NAT%Y];]>UM>I.@_&^>=HV^'3.CZ<&'+SNV&]1-3Q34 N0[3&HVD8+
MJCW-KA%J=BTI*K;_C@#GMUIY]S.OSJVN#SW>[%+6+5_?,PA>^;JV#K/RNK#:
MG2P)EO->(#4M6>H6>B\N_SVXW25W(ETC)=*43J]*]L,8I1"\[#RM[CK7WGS!
MC<\Z(Z%_ E[8</SC-K.^\G1C B*B[*/$%A:IR_4_L_O@3^ Q5K*#7%P'*V."
M<\]+\SEL0\DM0"GC85B$^M_4??[/'@_TCT(,"-N<!7:LW=6VB/\L8118P-I=
M4V&>>I0<%RB"5':P,[:U@?-=#]HJMEC!OQVX<.*Q=,\79TDZ9V<-O(1Y??*=
M'8:9^8!E>]I#^0*).8W-.$TR+.ER9=3[&O0VH@(I142PRLM.;O[S@",["$&E
M>7D%R7FYRY5=\WF*DX[)2NOFY;IXC]+2-EZ*D8OT]8#(QSSJVVTA/GR'60WQ
M0@3#1#&^*GYUG5:UE]Q\:&)!0>0BQ("LP:Q+[BZ1$X."H1D23U%^66BQ6WVW
MI$WP+ =]5(<+6J6#J >1^&-ZYFTZ>PVN]T\J(E70B?LP;9E)R9Y)H>!FCU\8
M&*C($*Q!LX7TA@V5YIZL-S/WTY"D=+@0I'M0[WJ:L9QY)(/W&!L@-7%(N5^W
M]7%1<7839=DXNS*1<[BM%=@F!J-K:<E_V6UO(R]^V;V\##'W^J=YMK6$9<5T
M OK^H5'4TGN?I"9^+R6"W.Q1.UOQKP[$\!-O,<_01^4;[H%"(?"4YRAD##!Q
MFW7R/34FUFD<>W1'M[?F)UL&>*HFQ37\#=9O)ZO1.QDTWPLY'A\N?#8H*7F)
MX\#F-M&S^HEY.E9408ATCTQ/:;^J+*<8 G% =^E7IP1>,<PX[D=_<](#-LOA
M1"&!:U9,>10H!%FYG8U"JXU4BE2E_$[B-OS\V@DJ?&3N?K@;04_G$V*PJ3W\
M?3? CC^.3U1>Q7LPBSL6- B1 .9]8E>7$&*R8D$%L/ "4%&=WNM-J/FTL&/_
M>1=VI*I T^50EFOF3,.>9E>WRH!6DQ->H'A)0.9ZO\_Q4^>F\6EH3HM Y2TR
M=WA $]>84O"3&B7^5?D@*R6@DELO^H.Q%UJZ@T\X?#8 -[H @*=E.Z-T]DI0
M78#)\7+#J<%4OW-YJ>DJ+!79[&N,S+8;+(04A@#)I]EJ0T);K;_%QCS1F)XI
MAZ_W3I!/S/YD<"NV]H*+/:! W+Z5(&K'8*T&;L1D)AC!Z)E<OC%F$P.F#>H*
M*GKS$5M/09])V9VW#2?*1HT7*&M6N,]N'U"2A[''*49TW4PD%VHX.AT$/YV?
MQ@H1T6/+9W7-Z1:,CNF;UE@,@D?8E-%X@ZA'MOJ"9PT6/)=5]C-1#QL$2SY^
MO8@R$9=.5);NKP[=5F&X31EMB ^LB7%VX4&+A93^UW.):NAU?)JT#]@ATM(
MMW\J,<!BA)U2%0&Z)B>X#P%?_8R4#;+%FNV $>QZ<#O=[O@IV( "LH:?(W "
M$4*Z1]YOA]J64-EQ[Z,S7R@L76)J,?,=,_VCM!RK+9MQ?IUOEGV\+/Y@8YMU
MDJ405&_1!%K>9&4P"XP>>D#Y$8##[#Q,(LSQ+M$N_;JORI_N^]+PQX5@]RT/
M&H;Q6%V=04YB8%"EZ"=1ER_,R]>PFL*]Z+P\^V.<TI*0L07O@RV->]T#=X$[
M5@TI[9[-XC);L)!1ZWW^>'#4:@3 57E[6I7CJJH+QTWZ-#MN\G)44N=QA=YV
MJ.SQ3.0'>\EO0<W-M.?/:SR#&ELE?RG-X+[*)(&2K%HE#3B:GIKDS@X]3/**
MY<-"WI[ E\+R^&21S[6T;CTV(*]XL7G%_J2G,+IM*ISH8QV1!#K?IDL.GQ4*
M\"=?@%NV [3#T\-LB2ZE%@?D6#U9Z\1\?V&Y63=MWQ"D,5VN37<BI2OL_^+M
M6S\&AL,W_H[;6.#,<=_\=W%JA"_ZW^[6PY.4A6W$Q<U#W]TT3(6-)1*HZ_TL
M*>>R'UCTFQ_<'U2S$7IIS4F.2+^SJ)JW3!8PL5E[/BXK2_EV*!@<=U,FO"%H
M\[]X>^NH-MNW2S1]*:5%7UH< FTI%;2X4\'=+<$=@@7W(L4A+>ZA.$$"!'>'
M(L%)(+A#L.+2TL[[S?SFG+-FSCIG?3/S??]<ZWG6_>>SKO7LO:][[RO''CL"
MEM&#H)],>>]03OEYX;:34B'A8YEE])S54L(RVT-H!>G,J8>O/J5(>YBT9*G-
M(;U:' S@$%.XEW1[&-W@7(=G5+VIR[:3I-*(%='24'LE=$^$26*$7K9&55&0
M"S,]7I>$UAM,;4;N#JV"Y[3FN?B/O4QIR2+>E!8W(K"7VF1LNN5/:V;1%D.-
M#1]M29G_%AF24N&DR9E. 6&V7*V+[5:Y[!-.AD]%!VT+@+9^W=*ESEZ_@U)7
MH(B2XK2NA(3OTJ:3;9S)E YD@@9#^6C@>YL)5U9Q;J: -6O#J*CMY2PP<!VS
MF1X-7SE&?X7OD!7'@?!.DOOZ))<O2V&JE16>Y"R9N$R_PV]/&SX8."#Z54@)
M%R^E1X(W:GLYE%'^6ZK4*M 6^>FAWY#,T9UAU])NBX1J=2Z9UN>O1T:\@I=F
M.Z.U56H4%^5FT#URH%/<M&GRE5+]=F=QKH98IR+]GJV_,EOZJM..U_M3SO%G
M#!8K@9D;WFWU*;6R3ZT<4Q9,*.FY64M@5,QA"D8. D6JMR WG,AX\&&O^$GN
M<Y03X?"*8TG3>^N0I$;'@ZUF^D5Y _VX)+"[":4C5<>;WHA;^,*QI 1C0:H3
MM1VL6]NW*"0Y1>,@E-6.+.D5DYA$V4+BD0J7H)@;?"?P\\R( ;I!1O&OE^>N
MZ^K4E:UGVM@]!FS'AJ!J3N$C1HE6 ]%=HD]SC=YLN.%IZ-2Y  P!@Z-B7O9R
MNC4)B]"1._N$MD#')#*$>9%?^*.J*'M=%U,:;B_2?\1[R7C\M-[$)O-:9!RE
M]GNS9KQRM1Q;NSDZ"Y=8$'.X_;&J2JAW4MM=\BZ_R^U,"5<)),3%'WA@\!%*
M\W2KKH\&6;AIO%HN7+*2<,J5HW\-(=*O<2(9)-Z >BSW1F!+;R(F>[98,1[=
MGG$S:*]BZ6_2=?GWMHB5:,G3JJ)R#^I.'2&<,VGY94M!/=-C<7<PYMYJ@V!1
M?7R^7;,H##$T-DC>C^3,/FFW[^\SBQ-*CY79\_D?L=5_AI?JOT?R%8'?'N9-
M(6=%YQL9(Y72/W;[M'/T6_V'I#3]?Y7G.'RPLMSP  4Y:Z177:G80OW?J'RX
M@A6]Y0#QK#>[_ 1&^7Z!O]H&AL;K"VU>]^:2[ZONS"G!D*K$E)U[RT\DVMFU
MZNOX.AZ!7]A2V'_G, /CP?K*3*/7O3YX]FK;XI(,MZ@8@W^;8/'4'S;@'!QR
M3^B\ MJ)[V0\?^7;[3JAI:A.(\6WPVERI%4$8I>?:V:Y7HA-2AK+^>ZU\<-?
MP.\YJJD>'#7.^V_GI9=52.P/K=];I7JI9&M4E=IJ9?5 <EU1"J*W'IV74!__
M;S$)2/:+!;5WG/T6'8&?(B=6OXFMC^)*C,(A!M_+GU/*&JW5+Q_A6;\Q=\Q*
MF?)8FF %#\GM%S\L$^_Z<ANUN9DBG.JV??8,78-=* J]YEF_A?3=I!+#;DH]
M#I!%CV>FM-O^,BNU ;^R86H)N<3%2L!*48FWCCX>W%(4*9'K\#&B&B-%5;M9
MH>V.LE2&)O+WCVM[S%?E#5Y'"@V6V;$S TW?XS\^,.6B[)+2 ZY8Y/(KA8 5
M%MA45:@?.]+J"?9'R+_KZ7;V8R@45I/SV++VT)YFB%$(ZT[-@>&LXF_$K^)N
M=.$EWR)EU E[NET3IJ*E ]5*D[+CPIJ^^C3>>WS=[ ;QI'TUHNSJ9)#[P+#,
MR"LLTFP=E1R0.I4F/"LVSVYQ/2G8RO7/5SF6WH]<*B<C6ZKNU3E+-V66-OV]
M=,=ZICWQX4-PC3TC=4)3 VYO38*D@6]CAT-B@N'M R(-DWR7P$E*RJG[,C)M
M'(9N87)<PK?^Y0^>E5\B6L):B.='2"JXXEL-V!&+$SL'M/PU7<XZ[=[D<%J>
MLJ$GDB6%]4EL0NWR\JZ6[<6V#ZT)(BB4YCGTWF8>"K,:\7(Z/85]W:X,*2X/
MU*B9G'F2UO*6R5]NO690BD(YIDJA,4VV^+]A%YU& _\!'GB^TJG9U1,N@F._
M\>R5CRFOD2%7[;9C+GE*J?4'9SZY_0F4U.G_SC8(V0*-I[ ;2P.-](D?W<?,
M9?*KB41ZP&=1,ZR&^S$0LKX%A\.IT1>13HG9CJ)+RDR_VI+08IX_C'XW2!K[
ME@S%%&ZIP>&164T+#D\K+!^,2'$T.F]T0W#@%*ER3. =8I^1C,K63B L=+*[
M@-@<6N>-3&["<RR_K"R-B[&#70[6";/41FIA4T&9XGKIS;.ZVJ@R5&%#9HRP
M[;.%T\,E<%J.O\EES+*?]Q_ PLK:R5H13P#OH==BX$4GCQ!_<E:;.N;)S!S^
MY D8+7<MUP5Y*S<^WZPC#":D>#FP),NXU8YI1R)2T%UF1.*LM5-EQN=%+[,S
MAP5?))+?N@3H"H;U6%(\()^JJ+N,:L+[;I77#Y(!Z[[+N.DJ,0#& 3XI=MN+
MYWA\="]^O_G2TCC@'#XT'(\'.PD2HE)JVJM13Z6]HKL(O#Y&.%2R!>5_8X =
M8?IN$5!T0F3B!]%!><*H1J,J#,F2+%L94NW78[I:FI&1J'=47S^Q'>55=NK-
M1'ERZ=KYB(,%Z>][;;A55@I]<?9^R<PR:R*I(R-S=9;:M;FA:1]UF$7+""YS
M/OD9X;B%!,8<ZSE\Y\&2>#:?_Q41"C>[P75GW[S'D]R#3F%BU9+K3>HN]FJ-
MUI/%]'E_GGK'D;.2< UUE-9,Z"V"RYY]'3+\ ^A762I.F**PW]=L]>AOER;1
M9JGOFWHYS2)YO,;B)9XB;I.#:%^(#YG0EA80UVX/\_(;\2,_(F:>=R ELSJ3
MTIH,-G(/%B%,G'&;U,.+X6.52>S@OSXN[G0#371K/#"?ZQQ4:;KE-79Y?K0Z
M33TY4I=6N)$L%XVU;<,@HT9,*,AL7^[L+$O9><';C8]FOMKORZJH6L'F* &8
MM..QLRG$?@PQ7EC# 'G^55NO>0U=1GZE\B)^T\-VHL#S<L^)(2(?OL=9YZDA
MDB AWN6SZNWA2^UG+#,2WU-<KCND;2Q2M(W8=+X'B6P>-Z/_J=/G('YAFH;;
M*93G"4K !GVBVM?6-S['A ?EM%0KRW,8+M=K9M?WBG9)/K,L[C2Z"(Q9*/:X
M U"=>ZRJ:AQ?QB4:G\AMT;0N<:?%B(D)ST@Y*-E0DKYW=C%-1I@D537OD5%K
M@N^3PA?<HD\D-V)9VMO\>'/%IAIC?V5?=>,A3TJSCDM2=P9W"N4F'9Y\O)H9
M>L7'!-JNK2W2_%84LI4X=D/_A)UA:,2GOJ0P,-9ROO1;G=T"\"=I2K&\4%ZV
M=&/.X##5$VT9,F/5P)94!W]9G?Z:1^0?6(/XIS$UZ9GC^B82'2@;UD:G7Y8%
M_,-D96GJ8$/"+&WB:P[>,2W!A5Z?4#GH#!+AR>_L=2=JW]S8;N?479'0RTU!
MSTQ)4,*8*I_ ]0AXVHPMKS7DZLCH3_BHWOK)#D^O[TD3^,Z]&1^-%-1<0*QZ
M];^)VR ?&F 0^4(4Z8";K>M3\8B&#ACIUFTT' J<7(^K4] LQNKOE1X>9(K7
M,]JG$[RG6%X.YNU78'4W9309)&",F'!=E0=MWG$YPLY*2P_=9X4H^6-])Q:S
M/8_WP8YNVB88=ZY9:@MR1BE:BI<86C5F5JX-J/%O%XZ8<V^*T$FP]<QXMLNY
M0CVRI01%5WIH(1Z.L8U /5SZN@A/I&J)4;0N"%5*OT' NTR9W5'KPN'4D[]R
M00(S^?F\;+JN?P FCCY2'R:*F76G8W@PV%N)W\]=^V3?7F#CKG^;J&M2.FS]
MIP9__#\B0!XMU+*FL/GJ+3;:D1.C3?[G96[_FY:$_]]"90I>\,6;&_[-"'4.
M(J*Y0'R\28A/%.9=I6GZ6QX4'5\).U.6S2O]ZZN]<G",O-9P &UV]>4%I_5Z
MR.7^YVH)X%>W0<]P&ZPHC-R^-].-0FND%IL>E^)8A$?5Z0DUQ(A^^-'5.ZBI
M7V82,%"B]?PY!=6#/X#7I9@LP*9V_^7CDGT0?^_LE3<\$H#PUB<!.KU[ $G"
M!_W$"#,T,L48?%8%%OX!N* =3[HA2(4'<^TJWLVS -O1AM>K=?U'3=<WR_9?
MN(*^,*]BTD2")]L2Z_7?2)1T2]N5QJJHX6*V6\U/'P#3(\DJ$D(;F L;_:HL
MD=\>TRU)R(9T)81-;AN-692BC#:+JTH8-9.H?C2WPGN;OH@L4R38;:@U/]MZ
MON-5>D&^>;V#_"KZ0T?E,#OD1.W!V4S#7<SBOM,_-,/9SYYY[T70V)@B'@@D
M23$LYO:XS<R=>7NEW?SKCLU0Q#Z.^<4Y91=,U%BZZ/CYH?1AESR8-DQ YIAH
MRY?87LWOS.VXG UJ+9,L2);O;XG@=(T?6P7&#QZ"+LO&"7'3K*(%*_$OE*SI
M@U84QK<I"%$SMKK@[8@WR-32.?S @-<&]!D*(&Q%GM!,:[<P>C2]5JLK.9K(
M7T\:?Z7FL[O4%=;'U3^4VE*$$;I:BR"^=;U_(EYRUUM="8%^$P8;JWB+YF@Y
M?!%G#>FU_$I!> "DDY!7&-.K1^DOU<$*(_R\.MAWC>[%D4:#_,0_[!K/KMYE
M1.="VGPE1ORD<=$5_I(EZ/GW6S12O4;[*<4PE,*+DH 3P:,8N8/F0MA]SM U
M/XM_6^G,QXMI-Z%BL'D=S_;[Y/W)ZB/E3''BD5.[*Z&8-86-A/L_VR+_ #8K
MZ^FV;]Y7_$-]<H?\OYF @]JE)Y1-;_X /$> G%?'$M<V092<RU57G_]-O?D'
M ?7\@X"4%6W#%E7J*-KWI=P#B77R6XB6+W)%.\+90=A:]/HG&AD9/;-_1R_R
MT);RSE[Y.3#@_ Q'PG:N7I#U#J. ))1E7(?(^I&(GP'2SL(>1^O4[3$7ZO@G
MKZI*8<R0+O=-+Q%?O0!<0U%G>:P6E\E=4>X+@.(J3?0L;0R7<N568:O2+<2?
M_SY?8Q YM'Z33?G"Y;5'\8J^JCG, :%,HK+VF4_B:!PT.8,I#Y\VU-*TDI4$
MWS-/<F45&5=:6W>74XS1+L>=VQ*)K,^[_904\QWL%\)&:NZAW^%EAWI0F*O&
M]K*0,2+]2W;^H852B" K.X][36HK6.4GN=3A$H \.^6B/*\#5.C9</9B?!ME
MZ5CEGOY^%0P/CY[0PRNG3(DXZTKNJ?/.[\1Z$UEZ;S<W7P7N-V;-%K^NHA"'
MWWE3W@;H_RK$OQ'$((/!J_X/&-5)K>*2DK9U\/:OZCY(4G_'3NM^G'@67D)Z
M=ORKIW^12ST/LURBJ=.O_[J4LO\%]^*ZV@%U[FRJTP?[HN/8RON5<2+"V3YC
M%,EL-]O>10@\ F09'17O<69=+_R26HCLC6IIY=4CMK+XBDR;.K,ZRIQO/D<B
MF@=8?,LMW8H>!WL1Q  [!JW%3/D37Y>6-_<3V-L>HXS0)R+9J0EP("OQH-S,
MA-;R1LRU@Z%THCH?D0B%'%]JXSNE@4Y^((\2NLK9?A\Q_4RWN-S.19<&VP$7
M"^:#OIYC;/F'V"H;4SJ1R9SH=(U*5L4&O[",!B :O@:EI&E@.VYOP-)_ +V/
M2,)@OW/@_1?#QCV]&K=^7+SJ:F\LG!>V+5UWFLZMCI\2FACKN33=#6\W5B+?
M5(RKW>YBSF==ZF< \B+=V&[U2J;\2=SQQ"+73#UOGP%FYD,KN<B]N97I?B4G
M?8CQ=.+-+COC?<\ZWD/S+NM#^F4Q#,(S$041-"F O7[C5/E5GL2T:7@=&D&0
MO1$-DO7U=+@XT89G;,^BC1T\SW ;I@YB@;)^I:6-TXJ,;$'8!K/6H6:;<Z*7
M*;<-\;/<< 9VNF7#QOB2YF7U=TJQ]M-,NM87]Q\!6\E=/FPT*U7ZP?8+RR'V
MA]0U[OQF3D?^\IKT2RF@Y1JG93&!$9640?RU[\RU$UA.:]K^+F#?:6TTE6Z%
MC4=LK97[/I'E'X"1KGC.@#)-]@S#Q[I6.'6EAW2LEWO2+M%8]2U,K&D_5]-8
M0E#P29V:Z9->E.(X91-U:+,.6I_3?5;A2FEM34R>5ISI@5L^'\0SZMW@11(]
ME_@>BP'\Y$KQV"5F09JP9<5#4"<\/E&/- *EXK(Q.%J-!??KY3G^?>"N0\7K
MV$L@+%C"N(13?ZSGM<"=Z?6UN:&Q@W CTS6XSD:8.7XCZ!/;57%689D'YPE6
M1RKQCGD>$F8DD_N".5PPNF'[I5@!G'<0-(KWWQ_OCYW*C-ESV+%_S4U1&&I!
MTJ!VS).B?L,YJ0/ZBC'B/AT2@"K7HL."3[TW4\KS&MLOO?4'KOD9>XUZGU(
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MS('#41UU0KFE9;4=$&H<'7[+WFHF/*^H]X+9^O5F&2C6<_C$OHFFYL?:3U$
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MQ+><U13F][;1Y.0(O]C8Y8 OZ"-J4+]GQS'NQC$C4\.9;QB#IM+R::GJO9>
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M_3]IP/^,H*]ML=Q!/C$T64" X25.='(G!T1%Y;T5YW4B2ZC9N-L?<-0J":C
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MX_80+O;^47SU7:#,NT?T^]Q1M#OC.(_.P(UZF9!./7X'<*[X!L%.;L?;D'O
M*,QPK_$4Q)6DRV6(%$/-8.M+%$T.2U[*]@+-/YEA#US\)#4P+%FAVA1Z5-\Z
M]P#;X_]0],V99*>0;-]AL;]?K17$'3.-]AMSX%+$Q;V)F WN6IAF].@M$O=&
M+_#:-EKM,W5T#D<FW7GXB/#6- T)W;:'N:I,P>X(]GT[E'(,C"!5W02]N0B_
MK5O]V7'*/9>@UM\GMUI?-\N'+ZR9[.1"L+G:@N-MQ1_+>!7@,G:?(]IE4(A[
M96"PUP".2,-3$<]/E"_D1\M_ >C":^-:0(,DL)V^D,L0]3W#')O2MC ;^D6
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M%>JC*5VY)5UH6%VZ( F*]?XN9.>9K^/JVFU=8 @S-YN;"#U^IL7YL^#1+)O
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M1O.^Q20,*WS>:"1L_;"Y:[WM\[%-Y919DCP>QO2SLHB>Y;]KY;* _]L<H=5
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M8O(AE\MG1<JALHDW>[/H!GZ65/B\1?X>:JSI090H7+HPS;% U&OM(-Y!"^!
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M1N"(<TXMJ)0CRC0A>36M">*RW:&!>0'7?4BY5>VJW9]80.5.75#B,'$3:3C
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M=TAH86#%';$\I')N/#*B>J:F/L4KZ&PK2%(HF^C=RKL550#K'\1S<)9D=G#
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M<1PE>03Y%6,IYWZR-%]T$?(VOC^3YKFH7Q+Q!!7=/VI">]2'ER%U$9ZQX<T
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M6V9YD>8,Q2R6&<N4O$L0=Z%R^,./\E:NG2#;G,N+ZH<4P"J\=D49[[?<9!5
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MV^451MNP-BFS(P5_U?GR2M[6[LI^<(3Y=DGF@].48#1;B!+PB733PVTU>-,
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M2[)E_%[]2)O&.A#D6E"UVHO,#!H5\&!MC8\0X_91EA^DW\+6Z:\W(*>TUZ.
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M"-(]+.1;Z&OY^\]T+4-3AO<I%#\5-S]G4UAZ<_" DOVE7LG/&0#:;22WX[
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M2G[2FE3NS3YHNJ=A8']!T?AQZ>I^M;U@N?)Y$%:7^B*J=:5>!G>@DJ&2A;T
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MC*8R691[W"F>(*.8J6N=\>'7^P!4%?Y+I/6O[A% WA51^<ABL6GRKM=+U06
M2NN*Y@^FZL4&YSFIEHZ@\S(B^5-^FA]X=5R9*_VB./2%[O[H57/;-QL]'99P
M.?5&$F>;0P[=R*6 8CT62KZ+\,97^4#Q[(,:=U0F'4K=@LP.;U2N(L$?'J[V
MJNI[CP*[-W82-<J_LH!*>^5H;S -PAX>PR'*X&\$6J9-^4^,NB97C26H/$N2
M#5YU/D6ZBCA7'Y5*O99VM>>*X-[[F'1L >]<HVVF]-#0<_AHJ#CJ5G^O=051
MY8%'2DFD,!>3&694(*4["Y) K@GL=#W=*8OF1*@7" <M0_V8.SC*>(V^\GM
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MI=36 0+M=)2G-329%:=*_I#)A)M^'O+92M3U'XKAU2&6.!M8!W%__6(M20=
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M),7?HCB(J4KIH:!-LX[4>.P= ?8/KW977_03N;VDTZYMF^NV.#P%15!KA*F
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M55HH-K$5H%%UW*C#Y,MI,%FNG*/%(<+VF06\Z)YO6J%'X@*QJ@=E&GP;9X<
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M8C[GJ,[/-<)<&< M]=A, C4#^9?V7$1OG3[;+5ANCVM(Y"4N&#_'+FQ)6>K
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M?KV1'S%'1<.PB_59:?KBUZ</ ,OS0M@V&YW@7=;AN+Z><SA/(.6'FQ]-9X[
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MF7?6J?<6UB2C/7C+/!X94]R_+XQ+38T["##'O%31+VP=XKP/2FI[4@"#A=1
M/Y4.CW4*A97"4"+_G+SG3)QJ%88)C79?SK.PHNH=-(N7%?C/C'_;-#BVH #L
M!#F]QAXO( OG%Y^!VG,+)[Z59OIK*S^WZV4["VYCNP7C8F<_F*OY,11(XE)'
M-C>UP.O#?1_\8&;<*RU3=9;&G#%__$D-X#R8/\27KU?K04R8X?S9,Y;L J8D
M0+G+U:_W?_-O!6)_/2M7<X\_O1,F@LC:_-*+)-IH<*CK<>/JRMQ=,@E'00'[
MC\_,M5^'9!REDWB6<$1L5[+VIB2%%['W$VRJRZS@SO-:H)^AT?6#7,Q:"7Q]
M[TPE4&#92&UBF1,"P6;5GC(M?KU"$]&\;*9Q-T\AR#G.:4;JAL[*<9N^"8M7
M*_-#P KJD_+5(W0AF5:VO_:<*J* %=@V9.B><16.8: X$F;L6/%;)++3-# *
MLIJG0F?[N2!B8-#\<+]Y>HJ/@V\'TS%"'QE*8[@XU]BFLL.J-GY%]:$(9/O!
M1[IE*RW5DT!;+N(%8!3&HSTF3"#] LCE3"LY9V/I##:^0G"2%S/M#V16@D?5
MB7?*\=UUZD#YL, -6K5MPJFDWB*F5?MMF"I,9RR#M/$^-W>Z<F;C&?2!_?:.
MZG?/(V@=1?6DS8R!##9]/J2#(9U#%Y3$6B-MN+1D72W0IS@UF> 8V2_!M(9E
MQ?.K*74P\,Q(3Z=]N2BH_>N" ^0S*.X"'P$!8"D6C5*:U"0[U;5SA].^-8LM
M#>F"+/&1WLD-_)Q8VF])Z-NW[QHA1,2S$#"Q';,GE>7;S9P[)5-9C?*:_[9&
M/+!4!M@9'W<URU_I/!OFED&&[4G;M2L,,_C%[$!KLAL&O?(0&#Q@6<&)+[V0
M0\,ZCHXTHLSR-'*X9'#9'T!- $+H)IGI6::8UI;YS6*+>^&LK80#JKRZL9=8
MVW+2S3C]]^NA?6Z-XTUW?KMVA;H4ATO=FBD6+50:T7H EPA'Z'PZY18(5J3G
M,W<?CUJPO^X\8KX(_X8RC-+3E.J[Y$3E%<J^-Q5CXV+/S9H81,37-!7QZF")
ME=^OE*^BS&P*HT04"T@SJ"G<;[?ZVS/-&)')4U/;.CF?R&PIZ"$/LZ_&Q8\P
M>&JW(\MR"I*(V4RTOV"ED_J/Y; ;XF]EK6.Q; OIP]#+!ZO<BK7O<I?/&5S#
M'C#]G=]X%6[HA!DWS!=)X+/[]&NL^U9)> 65#I!%T"[:,%(W:G]0C@)?3=BQ
M'7=V^+-_[177?*\5HF7/F7I6T1X7?GU89X(Z13Q&EW_K#&60RB*-]T]BQQ4_
M=@]*(#=0P4)WT/3++:E^%&(CL]BR K]:?N0A>)!H6ZS##%DQH9,E[-ZO@$G@
M68J=0;4W+:WXG*8C-7AS #4=/E7Y=*W/V\Q+C%GL^=O^83$5KWZBBE]7/U*.
M^W]:SKYT&  W#(QO1%<C-/G>$,%FMC 6EMWJ''=W\-WB)@?K-6HF/VA7";&&
MBM@W;MH5M3);66EJ"N!5L(3(A!< ,'[;5KG!5L%#8\$"!RMQ'9L9,/J\,1VK
MSZ8K0_*)\&.0=04)D21M?7+\]P"2Z/4B9C\W/-+9Q5+8[YX^=RJ2L9_GP3Y_
M[;2?;FZIL( [MW5R4JVET*+WT7H,J2OFU;CG9L6#,CQ8J>J'N>:YT9D(4'C?
MM@.^C9N"5>LU6N0I&JI6Z &SRB[HE1+@JL]:Y>TN%J?"#>[7\(-G#%2EO>]]
M]?GF2DDSFF?$)==TO9*+SW;5:$8E:4AF^)@AS^G)0[X+S,,C>EJU6 MW!)T<
ME!!_>B0K_N3?%M@^ULZ\(?X/+YEM^^R["I)"C_@(7(K4>.!/LKG[  M/=BM:
M*IP!LA$C+,,-"+ P+C=G Z(8/&RTYGM)@I[4OSA53X8X,%AKR&/*6=36C22A
MS9)M[7S807^59D8.N;P\T RQ>@\P,09C;CU ?@S>ARJLK/<T(;J%WVWIEW_>
M>4]](/1'N-/[C>*I.U5:40$-F/9W&M&N>>/&WR6/GK[9:Q3-XF?0FM_^-?6!
M!$=^0SCEKSM5=IM3MVPB+I3!C.QK@(6166R''9T+1*'MEZMKBNH<A&C.UJ;.
MC/<:E[N*^G]VE'SM/Y5!BF\TL4V_HS+Z=W6D TQB\UIT+$QJ8H<WSYB-*GDV
MRC;XN'T1@/IT"L%9%SLJNU:33=*C[J4OP5J%1*=F@>/7WK-5R7:>3VY,6"(E
MSJRX05<.\05=>HQWP[8AXDX8JWFRL^GBKE345Z9&4[C=*9J3PJN7F@\_1P\X
M?XUHU/VQVC%^=ZL=\],/<.W: #W>R_*@G;VYXJ%C<OPT3\R0VA>PW&@M^10:
MK\(8_4P';N7%>ZQE3NW<>J^"158]IUG[-&=!S]0G5_TSV5UPY?A&29?X;^7T
MN\H45M CB;R^!Z=,*;$G[7@Z=-@[#ZF=@^*F"&C3,4K."8R7CQEFJ1_K?$64
MM^09PNP=4KYJD.W OJ+!,Y8EY4TN6M7HDG)ZEYX\V17B..(..?B6Z<:#P9+N
M\81%3FZTYT7"P7\3KYB^@V6SK!I\@;@V&RV^YK T7-9.P&GZ%N:@FJWJ:J^]
M7"W*;8!AF>IN$1WKZ!G2?)TWMX,04_!H3>L;WWIMW(DOMP6%"(M&POE/PR$R
MK>)P)C78EWJ*=//CFX@>V8]8ITED7[RZ$F ^L4F30VX39'=ZWZQ\<](_'+<>
M[ SI:@KR<KF1/I0$YHS,3-5+:\CX0CL.RULZL@K@_>XSKCWB'O+=LACYR4?E
M"\YHR]N#9U/>W:6/#K%WR+F76Z\OMLHXN\U? %T6AS?.F@K#L?93J^.)!4WK
M)PA9)]:BC&([F<&-[A+?,4=T&B!_-OFGYO/%SD"0RB;7PV::]%Q7RAC&GQH?
MU_J3B:^W!@-Y];Y%U>U(OXDTW(I$UNVN:Q]?]4[:\#^#+&6B6QIO$X"*5%MD
M[L^=I<HKR2H/]XG#YTTKAZOC,8=IM/M/0)"5L4F4.XQD%;5X!>I[X';Y,%?J
MOR&,JBFL7N$H25K?QUDTNB)Q?(":=#KI(500,+;#26 "%K^ZDX933X1O6#R;
M*^CH*&;5+^0L^(7PG;.SG^M^PJ@-!:<\4"OK?!P8T*)K7-5:=[+YGCNBSN*1
M'9P1YBCTX,;[?"B;Z5*1QVWZ62&/^@I<C]-OP_F[&4NNQ:L'9\.H:+^5T;"&
M)Z.4>2U5:^W8T0?J2_MPX7!W]\RDD5^5($=QB,&K)?9U;JG(I):V?O;ML#VO
M9U];O2JV+.OJ1SE9WH4=SU?!H(\[_[6O+_Q'EO)(0? W.>@L$QW[3"HL=[^O
M4IT*6XO*GNBUGYO["\#R>GI1_"EIYL^TMG@!,TY3&NW\Z^K4I@BKE9(GLZRS
MQMI0JZW%M1W2S=ADU*HC1J+@-1A.ZJP\>+NHV,@_&;<=XP$K7_>1V26?>IE[
MP6RH9R_ZD'JRAG6V;8'*J=JI#</05+=;C5$U=SYT42CQWAI =G71"JM  2IO
M<FK(.#[3>^S^;LBN:3T['*K7$[5J>3VBN5@^$IV6P[AFHTN+J2AA=.ND0?2$
M%C9L\;U<CNSU)Y1;CHJLQ #7IV<K/K[3+MD6[;26WHI[KC--A0DQB\4G#'DB
MLY"Q=[9C.L=1#,@D?=6(MSND7V?MR-DCB$E4/8.-TIHC.&H0 !^YM:?0/FV+
MJIQZH<C>VLLZRO!C]D;5(W7TH*IK^FO_]30VU;T0 IHD2RARVMS >]04VRF[
MX@\"B;27+<\!*14B"OAQ#9#[A'O4%X"5?3H_E.!8F:4< ;FFN"3_==#"A^=0
M2Z=F1K^UTL_Z75K=& 06A6TZVYJGDL,F^3:U2.;X3T #G->[KD]#LL6W>C^G
MKV7K$AF6H)-Q[X7*JEVS^OS!Y)N2>G818MTA2GJ-\-+GU[@1!$PFSI@I?4;4
MQC=9[@W-5,-:PYH D&= 21YV^;T>DR.1*%/";9."!#H5#DH4EORN*_1B6;):
M OV,6'._<8"FP0XCF;K=G>Q42-6K?ER]1+<__-FEN)O'^LR:M"[C"IT)'WOH
M;9W4U0G/O3#U]"YUJ4H>!DC*B.=8K<NU4!(E)^38@ORH>T'&Y_Z"'7YYXY>3
MXE)]%('U:>Z=2: %$:7MI:2!E@S;Z]-J6PG3;;A: !C3V@% ##D7SI#G9DW)
MRK>;-&*K>B*%.\0Y,5-5_#-&1I0Y6R)T$&;@9"U3%3K!G=E$N?!N1Y@5 _61
M W<DW%H6:=/A6;8!<K4LQL?^F&@I7[.ZI76D]MJN>CORFG6AINF[D2[ 2O*U
M;5W:H$3V)88G?YX#80)X1!"*QAIY#*BSK_N<??9IFC83,;*^;B3X7<HR1DGK
M=]M )D^8,/@S*G]Y;W2=CK^R;9CSD42/@ ,P,#@V\E8U>)]<D?<AI*[>-5-_
MPJEDKL1!BZ6"XG>CN(]XETTC\XA1-GMC%1F3\?P7B^6HJJQYSQZU"#S8&?[J
M!-6$Z3UCIQOW@;)F\O>M8F6_UHP-%HVB081YHI'#Y&>$4-G74ATJL?D1_HC<
M0^9J@V NF8YREW/*SZ=+N)T3_1*FRW U#:!_,OK?3?7TM7HSO**B6!_#2KP=
MJ1S)B!Q/BI$=>IF5)]9N%YV2)6\#9T"(?%_D3\6(J9\Z\]2./SV!VXW<?:<[
M%?&KYB 2X#Z]6$GK%D&V%MOYNCZH55>X^V-M[^"=\OQ1-49:<9;A'&9??\17
M/!T")'M#2*4'0M/:46XC.?L:<OD@O+VKO!F;EF>I$?FK<^GMM"!P3"E*Z,_
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MJZL>RM_K\4W=K-:"TD,V\NP*6(UPB_A<Z1Q__O3KN9J\O(A-]/0!-UMT54;
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M]HQV?C(N+3B$VD)\]1$IXT/>K.N]5/C$999!\PH&L;N*:?216RPMA>06_9Q
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MM##1I12HK)[LU+TVCZP6% 408=HU3NI;,F,%]Q)F[Y[0AT\D<-D^P]9T1JB
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M-N[N?:U%&2[GHIK7 _ +6UXM@6$LVA>*I>98V2_$=TP+;)R0VU:7$#1U!7'
M.,HHUR)?\"3SJ4^[L6AS06G>T#T@W*5\RTWJU>CB3A=-5DZ(9^RS4G3,,-K8
MH%5-;O6V6 :<J[4]9 @)[N#$IQ\3)Y'KTI\L/I?AWKR=B21$5"RE@AL#LC*(
M27]XD>]E8\COE _?W2Y<5:@1"GT+?O ]F,RP\U@[A)QO[*<^M7>#)^Z"DG')
MUB"=O8$B<^P3L3JW5%=Z*PJZL_-X053S'LC+J#FL /?[B 5<I2SQ:9%%YX>!
M,KME^P<W&S_=,24T<DLUH@D@JL&;Y& %O:7$/TP'9PN^<^>;M;I$%!UFO%ZW
MRHJ%?,.(0^8J]9JERO0Z+!X2+!@5Y9N.E-B?H&HJ"!E6);J-X]2=\FD[>I/Y
M)]&$<]FQ=L%\7[-[-&7M,B>HEGL=-@\A?$8<:K'KF)F7TJQ[4BFZ18"X8*91
M-%4.(9/P!#R=AIVK$;KGVNT0:'A<)X(U ZM#H:6+8\M 1P2G<LA29Q(V4L^/
M$RX9U/:/V'@(RQMM=5Q'.$S 8@7A%O'8T$67<H]Q5$O<0L7=?,FU?NY%"H7Q
M)%6JJT[UE7K=*P*7@4$4 F=09^$5>M^P(4=9:^)SCS"FNIM=/PKK2S]G.'2&
MY\=3+"^7BGVN3<72%U_GZ_A3NWJZZ $X<TA&$&[H)5R[5I"<L;A2MV#;-LS/
M]H\/<J&55P$L<.'=P\_#T7$S#$K@;?2DETM0X1_=KC6J$4.3NI6MMY<DWF%]
M;<O9?Y:VS.PD]X)*E4.C_,88"1N*,U+V"U:CQ,_L+MBY'V_#A9C):?+=X]7)
MZ.\!Y+N)+:]J%*<#YN2%M!!Y2>/4"=V?HC2133^,\((SBDA0(:(D;<O>9YCT
MAOB3?Y17L\VI5D9)X<DM1K9>Z@VW0,Q(N/&BR$+^/< 4N;O]XDUY^;1E\1\;
M[^Z'.WQ(K^B#XJY8*\9*F?>NP@L^41VFY"SYMF*(^)RUB9JQ"[W/1\_< L*9
M(N26AO6]8E559<UL)>DB)BAMIZ_GWSJ M:4%55=CV1Y4NNH#7T;FGK "53 )
MYW\<5ZM=!#K<!XZ3S0GN0A8JM?GK^N(G7Y;C*(R4.'EZW^BFBB88I&B'":ER
M2?4Q74BOJ\Q!9A0KSU]-Z),T;!5W&/)^5R7+";%O[W^"\:4IO8E^YDSNJ)-2
M+L,;76:SKB2XA79S&E3U0:^U(LWM]!7*<DS'KB"MWP^_OU@AK9\)8T+)Q]T:
M.C8%,A_+<ZS(A@UPC02F&E+/)*S[M^E4*N7%_I+MO+QF*H[E^JS\I@HQ6UM2
M*TQ]*,Q*_'ZT\C:<6Q$89UVI^2+IHVR<]'^N.K4PRG=23M?7WJTG_=6:#IT+
M*QO$K?4#]X#/93*N_-/5'QC_LZ84CWZ+R1;U;TO(<5AVQ?2BRCCK9F(E'M9]
M4:4]J-8QG'GM,5=N@R'=+I/LS4W-]7I-U)OUX;\IY98'OP&,E(RWZZ9RYT(0
ME%+&&&9PB(,38%'._(W&T,A(NOJ[F/>Z#]!7;*(+#MUW80PAO6FJSW96W\]-
M.IL:$R?;PP+UQY=*(;6BDUHNGFRVR78WDG6!P8 >TF%*&G0B.%R%7<11=O_
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MZRWX=*.Y*#VRFLZL9\8]/5P)'YQNDN.P!-'=9DT9/YZ#8I-U75_W?( \HRJ
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M=<R%A$FG/#-?L &S %5R*_ JFG#6WI77%YA:B?= -O)^K6\5UER=N"B.[J7
M=5 @4EJ=>BXN-5)O&QKU:2(O)(]YD0[7"-C<(\*-?7/T!="*H;U,&H*/B!J(
M_?-I'!WF:9E1W3J4^5:,]N!=RC[[">G^<51-;>=7R+J96H_BYSS)#HK/7)UM
M#P!TX-.F ;6N!X!//I[N N'YCA(1)@,$7'9>^O[+>,^W;GG-+MK,<_F8$K0Y
MM.P%I^4!Y[JA75:?EL1IF0)#"_BL412%3CBM),G6OB2I)]ED*0J06'MEE,0S
MO;%PN'("UV1/C6?P^U7JU :;& <3ECFUE2C<@X?,HS]A()Z0^3!93WGJK,:7
MX.S[54I"JA(Z$X=Z!A59L#3J > <[KLHYY9=P&C!Q$754Y]+H60R5TKB@N7)
M%YA9 S$7P'<)M*]/ETCU@5#AR06VC'*A9UM&U?1W7Z<'J?#"J5,F6+"U&)6G
MK[Y-RX<?%(BC X,;!D])IT>B4M"0/A]8#WY=X)>.PT.<N]$49@N^10::TMC'
M:GV6#'DGWNX.<92;/]PJHQ/!S1S>@>O=4?*51D] 7XS+XN&P:;AL>VJBN"S"
M!"V*:)R"UY8.W\?VZW-^M?;-TZ\H8I#F-8YZI*JT:26+2?(SXK9'9*>V2<^Y
M1%PUO5_&*W;3HA'O]/7^]DO-=01(I0%B8&=OQ@R*2I(0[[$>'#UHB.A&ODFU
M).+.J5D3Y-=W\B%DD*.\KMZ/D21NF^PIM_R)E-C7:D;#=;K$?C/BF<0CO)>
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MF.ITT3,34PN29E6<=BSW^%HI/A,/!DU"00%T?ERNO%0V2YNNT5D\>IN)B@^
M 4O?Y/X.>YJ"%I.NE,"$;UW313_8RQMN[9)I,D0&UC OEJV;UW,N^_;2><-Z
M5)JC!U4_U^0[_MPFK>2>Q$+23V?E:5X2VUG7/W%D39K-F.X=76U]MU>AGO0
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MN!CHF[/\M+D%M4J)IZNM?@(NGY;VK6GXB/>M#^!% !]U3!P)6XU)M+ ,JCP
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MHE&I'OB?W[V:B2_-]5"?PU:M.QQ#:=%LBGS5/#LX[!33[YLV7NLKUM+H4U-
M'/J#ULN%B.,)".:H\'J;\%LQ]L_#^O6^L@? E//5 (M:7@JE:M0VJ\V>[@\C
M7Q1^V\O',T<:I))8%/9>,N[FYG9HD(VFKL(7@:P,O#TNAY,LQL6-_@46$I*:
M.YNN2EM@(]09IT4)4&"O*GBT%_S-EW,OR=J4H7<:7MPWV](U2%:/0BG6(2^7
M:QQ!\/Y[&5-DIYP=&&=H"N5;F-^*^$JIZ_\5A.U?_>RU[+FOKCL.#_[L@-ZG
M L/UC4H3O%]FN6.KP1P<,.Q#]_^;T?N>$OT-2A$:<ULB%,8C?V#S 'C;6/0
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M;."Y&C-D@B1T^VX[B?S<."7:J;<9)NE[X;N'/X.J9)U_Q3XR_F[U=7[LHO?
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M3Z]CG;1A0@45R:&%%<&U_835>^A&H@S78QU'*$Z*(GO2'+>*!K'%JG,/L,A
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M-[4HM;@.IF4149CBHIU?8OZ [:+VRK=V;B51L4S3Y9OR#X!,MV?6D9FBH1H
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MSB*G-OQSS FB:>-6N2OYX\.VA!S)ZD3L#I;>SU09X1/!1T_7[&;5DU$A^47
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MBNT;G)^YBD 6;YR^&V1Y@>68!(((')/[O?$>HIP-^F)8.-8OG&[]8HRV@5P
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MD+I; S"7,896Q>WS0J<Y:A70OHY9P@0Z/ZR&)=?9^DUGWMN#W!ZEA/HR.93
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M8P:0FMB_EP24+#6 6;$X:2NK<YUZW!>S3Z=M)Z$VV3!H>-N"-"[1LGSLO#L
MPD#B+4#WO5[W_^"WE9;C"Z@SDP,1N$T:5]#.#T<:+F&?T'G%-S1B*:\>)Q5?
M>ZA4_DQB :?++&(%_QY'&GH(NA="@\<)+3WE=OD[X_>&64JTJAC'XJ5='&Z)
M.)1^'8UL&[PY;^NE'L9:$DR08+]ZAE@K;DS]G0Z+SFS(/P3W$6=S3YW>&P"3
M^OI6#?B^Z*9!8Z 4$4!>CQ[(M_PRWLT^F"B_:-4ME?%&*_-O5/>21V23?4UC
MRJ?I08WQ$6Q/D@K'NE2">]8/'LH9#K1M?M%6A1=>XC,Q+M;-/]012(3G8LJ!
M:XOW[;0M/FCTN&)H_<87<U]+EW^,9,Y383)^^5(Z3 K*S[9.[_-LR!PL<EVX
MD3?N:'KBBC.JV),4GC8N] .LCR,SX^ZB^9JW5)6RS,[,TF2%9""(!:[FJ5/?
M )\A:NJUE(M/N7^V6K-;MP:OQO<M++)/*M:2#SCL.>9/>?QB0+,GE<H+'N18
MHH]K4.7Q8=1Y-D-D5%C&4SH-M82(]U,J_<V*QLYC&'>UGC"M[)TW1DU)),_7
M$@!]+SC U-N]O*WI9OR6LT D?0RD^@4!3W_;?G8\S(68H\MK#13NN$J!,K49
M4F*D=&D8$KRU 3M-U5(?GF-\%C0S[G)0C&-E$SD'OG'_6>9)^LGG!P1*B[9D
M- 59>S%$]9LZ7,'$?X*!; J1(67Q'(21H"8_L?62#@N122]KV$2#E\110/W;
M&-)LSF.>N,&9IQC(,I42,CG],07^TSU&,EAMAF\K"H*D1'Q:QDF%8B"==EH=
MNGG( VH4/4_X%-.')5DHV:6,MW?[7'8'/B+C^K=%:IXY)O:KV9RX\M-Q-?W<
M@]*9:O=W#,HY^K:O.6MF*+Z@XTKN0#@9'O097+BHXHVS3F9CJBZ!)BE,(G+J
M;#[*7GZ]\L:C-4IJ9:D%K_97]HQJ+L:2(=0L=_A+^L-MB;1#A=8XN.K]GCTN
MA"F\W[G>3IK),RP9L,B<X1?I,-_'OT]QTMNU3.B"'[OU,H(R&Y3CFBD;(U1<
M@'<[C(?3H)O*FB.S_5LMDF5_E"LMSL*QWJ&'V*BHSY1,9A),7(ZC P\;?)0V
M+MSY1M;F!QC1?'!Q,[$0B<]3;3G;\6T2/U)!QH2U9 8K=&1%UEP\UD7<:K@F
MDTVV Z7^J%8V:J&[EV)D]O#"#HB_"KUFV]!*;=)8VUB9*T5<_N(HX*4B;?XV
MYOR]9KDUY\<# !_] /#%Q=V]\5*E2ZG*3^F\A5&?%ZP'5#397LDE3AU<@/-(
M!QF3>_3'W;1G@VD'0'1.JCV&"T)S=PWG5#KHZ^DJ7EY^TTGYOB^S1>8X+B ,
M_/"GOHO3#HV#VTIU!UNV;$Y[-V_$.PG,N$7B.2A+[U6.L26G.4G68UL[(7<O
M?52NL9[PI0A:J1K\Z+ ]K!CK]JBY<:8.+2O>LM5YC=N-9\EB7X(1SOH=1\3_
MJI5Q=MQ[IZ_P69DVD_9F0T4U+W%] \((%8LJ9GY73?]V:OT3)][*NZ:)!P"5
M?OV ]UOH1+%Z\U XEN.^"=#M8-:",QZ\-7?[)9Y%J0Z<06><+M'4N$^F=T!>
MC"64=6PSD<#C+BUTI%!\^VM-Y3-]J$(CEN\:.B$B9;D\<U#NJ?Y-Y;>3#]BZ
M1U47,_NR-QZVLY\G-<S3 \I";SR#AP=_2LM27 Z9=&==<M6#P]C7-]8WD'9_
MC=E90],]U.05F+Q5CD<UEE9%PNBPO@9IB[;=;KN;2#P\426C)KRMB+)<,'@F
M14/][/#&$7)M.^[<5I$UPX>?T/3)[*,<]JLL&_J7NL]FG+55-$H7]X8T]-JV
MRJRW-E173&'42BPQD1@0*O9A@C\4^IM8T>4N]@2?O-17/TU=<:5,)<HX0B3#
M"_5J:>,[!C*P4(*OIL=M)T:V+95>IA3>OQQ^#+I_LN28;GMUU5"G&6OA8,U5
MN*=3B:<[J#[%:C@[@/3^ZY"15I<.#P56%M<,>K/F0/CL8PU+#;H$M$RY1SE[
MN&]+(R@? +E-D:,W/\_1-P+#S^%:<4/)+GQCE,/5;E@J51D=,"4(]CL<NN*+
M/\&W_-S/VV.$LLLA+6)==?X?YVSU2"GJEB&']*3/C.Y?8Y0C1YU4--JH54E-
MU[<^5]\'E97PX5?&<GG_M:F7^\0$BR6 B;_WO\I%S _;M<L),O(%+CNZ(HE,
M*P=LMZTEZ4LW' P=9EY=L-U'C8\9PLWS8J #W!KSMEF9$1^TGR(.]7C%DA,4
M*1J2.Q@OG1&S=BS0=7SZ/9\W 6PL%:[;=\D.EW"(-]D#0"H_'*("?OF35*1F
MCB^O'#/S%T+8PQ#SEES(/5*E"/4XKMS]1A$H/S+A.J>1RR7/_:,F-A+RC_)E
MN_-LUF(."5Q"U&'',[/R-7D0S/^'N;>.BJO;O@4A)"$)'A)< X'@P:4H2$*P
M8 D$MT#A#@6%0P+!'4+A#D$+=W=W+:C"W0IW2</WW?ONO:]_[XW^O=%C=/]W
M!M2857NNN>9:>Y]S]I[>Q4FDF"\17UF<2VM*:C,J<XFK1"VOXQ'PX4IY"[>]
M.Q+)TF* KG0$F8O)!8T4F]V 81(:-Z?#7ML:,\6R:E,"97;+5;.E76UK=F36
M'\QEW36C/NTHSWM]C3>.$0QQACN<L8C);$Z_G8:)NTA/L]A!-?5",/2;R2L[
MS$Q,GM3CJ&HR 8QAB<5&T]X@_.TJW<\N.9EYU8K7GH:VSC"P9\I&4<49+LLW
M)V=7%DFF</=Y7'X-^[&8TFX.JX7RX[UQEJY'?]!J3)S_H*$-'?JHK3K9YA["
MF8HOV+27E^&3@3O[&%HH1;X#"J%J-(!+O@(E.NQ#_2-DYYN95G<(.?.JK=EY
M)&>NM@T7 0%8Z.??K__MF,^(S4SA.<V:69E>JCP%D^AY%K@3+>*3P"^;,/*Z
M,689.8Z29K^MV.UEF)1^BFRD]-N'[51N^Z%)M#_ B\305.7_,-@")>OR%+_M
MT62H%K :?7+&9EG_&DNX8Y^W4'30N%3E2:MFSN[!V=SDWC'U. V]J,L"Y?4D
M,.%!%N, YWQ$78KSEP'^&+<:THSBPX_K<0D7U!\?%K]Z^.[C(=DKG_Y?E;<O
M[1[WOX>2&*X:^,T1P[2I)2HT>#.@UH^S,DQ#Z"VT5_"JF80L@ 2FQ<B)'G]?
M+:2Z9,.:209G1=, ^9FH65MR@P7&85QDGXI!L89.]_0@*H'G\8^53'*\CW"7
MAP_%/NJEX!3X&JV"'P4=@KD8W=],[QTS#EAN?V/F8@U6/)+O.R3NIX?O52.L
MR]*1%D!"@X<BOEZ=$Q44I0IVX[:42[[.@AEA.UA@54P-<G4FI#9MO:>/^>5W
M/H0>:MK2P,; "MP8)+&JIU=*L/J&:P7')O"#LW-=."XB]=7NXAP/KBJB@5[.
MQMY61'N:JLO]NQ)?^>,=8=\^C?XZW1S#]G-Y/(,'GH0>/Y]+S.?J*^2:=^1M
M+R (4W@*..R_'UNUN4?9&(+VBT?:Y3[<)>FO[G4IJ;79E4A/C8.2WR;3S6V!
M,8EM3Z@H0@# 3 C-99%YC6];?'YP("'K&$_W$FXK'QY7K<'1A,DJ$ZB*2[/\
M)H'<,UX8^9DD5HY)%8<5N@P=0-1GP2+[$]OQWF_D7U6?:D+'>?<O<KCXGC[^
M?:6,)SK$OEN,@B%47N7K2.\(2Q*B@Q.7X:P4N/JLC6_G0D)#'ZS;Q5#M4IEA
MJ+*'Y9LK+)LH\(S(2'_G<J+L78!LEYP5PK6I95Y&6,)W-.*[@SO7^V_U%Z0
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MRR5%B1NS_"[]]39*X,G>IY9>]!TM=.0CNP9?0Q7UH%P:_*?DR6T.1),NK3B
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M.<$9]D2*-%@ Y)&M(09'P;5QDK2EYG*FM+H6=@] 6<PM@%"TS]=VY#'%D2
MA8)72NZNZX0C!\?A["\HA:5VBNGH]L!HZ %]HU4Z)ZTVX[4:ZLWY:."%D:>"
MQ5J- F.["_XYR2O(4QRN>>5R<P;Y$(-106M(0D='N X\%P+W+>G3G%9.I0P:
M@@]\A'WZN!C<\,I-]QBI\E"N.=Z@81)7G-7UXWA;8J+->N&HJ(<A8M=4!_[
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M:&IM;<=JMAW'5G,R*6ST.%VS$6FFJN%#/6T*?YM;2M9>DR5V+R$K<X6>O@T
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MM_LBNG>E_YGVNBMTT89WG4YI+%2Q68TF.B#,%<XY+E?&BQM13ZSC/QR9-O0
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M%L>Y9=\B/4S4A1Z'F]3)I$'"7!4,/3!NA+8GQV/&TT;%J7W<Z8*ZJKXCZ4=
M[#5CTA\TXKB,9M2KAGR25)2)Q7F%'(DQ^05,3LAL:4DTU8*1H,5'&^82!%D.
MRLZ'P24[_8Z,25]F\-8IV' \L$>FQ  PA\.U8G4A! Q_>HX!>],21UL@@-QY
MG64*BX8CF3PDW_#S[17IDWMJ84S&K.HSVC)*4'2A_?K&QTI%,YJ\2GH'E8R
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M7]B*+J;O,D7'\,QX>3(%CX0>[$(2[]FA_Z<4(/^[_*]+LC^+_P%02P,$%
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M;ENMT,4_0DO$90V?3G+)?(%8(@43[N*5,7V0,T,!A6*(WJ.5T/%!BXG'1\@
M)O'@XL0T11FNRM_/$#HB8?5%]5"92;V]@ <B+/]@."DQ C.C*K#!1\6W!1,E
MH"-26(@W\H?GH_8:,+1408*C/)[/8(:[D%=E@QF>&T*B$Y YP)%?]Y,! -7]
MAJZX])="IS8A]7^B4;*:>@-=DAKK+&-0\J$-0X8&6N4)H):00 4'BOP/9X^_
MO$%F^>.?F>KEC0VZX')#R0DY;OJ_<%ME4BK 1^J0%M^U'+K_LUI7CV,$HP1T
M,7)#:"%C3#6SH;[B8H-JB#GN8<NAE*OGEH0=<F.@2$<7"!\.6HZ*.C%Z^1RB
M>Y$?Y.R?>2[E!L M<?NV:3L6 93+&'T3D7$R[N>5S(2<C-PI<A 5]UZA.Y\_
MKO>=T 'NH4FIF,V5_#TQ[EX=NVV#KM2P,ISE]M)'SWY'9D1$,)@MD1U"TD5<
MQ/E.TBN8)(JLD))[YZY0"/"4";0I7V/RV'HRB#NN]Z/0]T('<,%VY(PPY>U%
MD^U/ZOP?J&ZK/>9 YLN#Q<0DH- )@X-_6+?M4"1'&(G*$MK6@0O*@MAF)6LX
M8D/$0*OM:D*;*QQB86RY39C+;99$I3K60:QV1?R64\LF=G=^+"[]WEIT//Y0
MY5/P7[/A-PG#.*S(V)#'Y2<B(NM^_'# CNPQR3M(/0Q CAFQ[0O:@G[X+;>W
M]>J8I#K;8FA)\UH9@B])_^.\T!<35\*.FEU9Z("W=#^=S4/@VX)^3U64/@J"
MDV4\.G3UG  (A*AI@G]*2M!-93E3"Z[O@ *A!IDI-VS88Z]Q99?375[42M\]
M![JP<IQLC,ZI4&4PPDP\NJY"3R2Y6GRNY@VNWC;3NYX\[4VT8TS)WX.,.QH/
M8@[/UX Z#/6C>HE(O6P59Z=5H7_$2^GIA4'+DT@Q<9URO_"7<3>#@M(9$;D/
M#!XO$L2;!\?<ED_B&#*,E*C7,/-JC8]3@+34.(D+/?=E*VT>;#?UE!XO>QIX
M6>[EN(,WIG]Y96[/*%AJ<4*__].@-&^E<$%H5W7>OT)W.6T/!/U@< DR?JW'
M2J$H)C/_<_F*YPNP+D09B=.]HYA; Y&]>L>__M/YD9[%D62L$:Y"EN)[<MFL
M6+H*S9@WO9I^3R7/VYH5<S5=3/*-@,*81<)0@.0%'D6!VLD_>V9:_H5G'P3K
MLW1'\IH,/FH=/!IW1X%3\> #;4E6]RASZFH3+?]BGPR]RU:8^0*ML_NRNTU5
M=XZQ_MX(IOG<TO'X:R-UE^6)$N8-IV@WL<B#784N.<Y-DX<>+.!-Q!VI9*_Z
M!L7G&:  A4X>Z%U*Y*+AI/^T[I2S-_3V?N,VB/]($XOK&+OS!7[9,[1[8-]"
MYG=O&"BVF&4N7Y\%(SE^E$P7NZ*7X'$,6VK8-$5Z/8*%&@7"XT05O$M&^&DQ
MK<EICW?;O\E!+T.BJI\6J+,G+TB2:@<BJ)J^K4F]4S'Z</_\O(7G846]VJKK
MJ0:K/F6GGH_+H&4HG; 57VZ 8\<A[5E^CSW)_BK*\P8Y&6&=%\LW7$DGI]<:
M;6LN4I1N*VK')8=(Q4(]'^'81Y@;0LBY"1OQ?OZ>-M?8U\2'(XPI?5-[=3"_
M)/:\DGT=$H88TVFXJ8 BPC0XUBT-MQJ^WQ!:MUJ[$/NJA9'?/<-IQB<:%2=:
M6/$<21;W,CY*Y\TLCC9M"-ETF@1K=VF"&S>$@" "[;K>(SCN28BJ69*<.[+]
M42[.>+>R& P)#_@HX7 H_WE?42:U!Q/'0 J?EB_PG\+K%@T/FN_@LXR*R,Y!
MN5Q;9A\/:?DI<'CMG>&RP.?&*KEO0=<QH6%;F<,835>JXAKTC'KN\C5R/_V*
M25[(J5@@'Z\&BED;?!RX(00]T^_V'66.@ASFMD]ZT/N7RZ<&0HZ&TFEM&GR/
M' H]]>TQ%T]%'AK!%ZXOJ)#N8J;'X'"C:&&1Q^;Q^8PRKP=[2O/$/S 4<%+U
M9K-UC@(0,2ED@"IQK4=^6/1[_S".K+<>AU%,A/D%GP97+9I0\Q/J<RFT,QM"
M1;<<6&E+EF86W\/2D).YY6A+,E5&.F]?1?<$(R]YAM*W[02I*?J^7P4>0-L!
MEW]]?_B)[/?GD\4Y_3Y%U),3L1#_CSD,%AK$ <?O;:4RM)P6]UW;I2Q#5;[%
M6 ZYR7<5F^H6B<^*A"?G(MYDC CH,14>#/Z&D/';@TT"I&7(AM"]JU-4\:7G
M=D>I,Q5%<[9X<D+I3GW;TSKL5H'N R@H[3 UJ^0GB;U)]Z+SRK7N+>G@QK*#
M*!GY02WH7*QF?X"4F:X4(IB=GKX F'Z2(5?@'6P1=M?JJJD3J ?6Q$!FQ9/I
M%SNA4 A:&%63<RB%;2"L_ER\SE)KN-Y9NWV%SZFNG2OT5CY2^2RLI,[\I5UN
M#Y@#@@Z1Z<\NC8W"I.BL"F5PAZ84^8[[LB2;RI,J#>)0/M[",Z#OKL$S?$03
M+J$05N81"<^78GK]7STU?<[(/O0Y$^TE@$-MVPWT;498+XIGDE?/)R6O$9,S
MX-8U1C):54?>4R1/J7LJBVIT^!]LJ=?]E>&81GC)G.\+R^%CXSTP\17E,^:Z
M^6]BSO>5R9.I9'!3FK@[@\QR&#UZ+#^EEPG4U6V<]$&TTW(Q6%X![.Q'?@IU
MIC1X;0!G93?I0L\(G"T$)Y969S]\M_=V\8D>[T'[Q%63B!/)2G"85J(OJ?-9
M-^QI1XI8_:CA+T4UC^<,&^4_)L^^@S@N5UD M5P'!^#M*LL\Y[3!-K+;[5-(
M]#+^7B]=/(?5/1I.KQJ-G%C"!7#V:6K%]A?I-,IYBWXJF2\.:T7)D&"D2>5/
MNQ4$I9-(6:.[?0KN4T<J"D_CZ?[51X>-BH_H!.\K="E9-/>DIQTL)S< <LBY
M51*CBC$P&Z9V:@121T>6H9H2F>X[EN^=IMWD(Z?&M3]:*9+$&"\_LKD:)'YZ
M?=F;\J-A'2%A^BR\V;//8QM"=,]KRXX[;J(HCI=+92VAUGD/8_./7Q06\;/G
MTLO[QN"$(I[]&0%R#ZP9Y!H_ QGTCZ+*/JJ;KK0TEXF6J>SN9E2U"](#?>%@
M)>6 >IH+BJ+U8\$,F@%FO9/?2Y2H<B& 2X,/XX29V9GI1WASC'=*0*;Y-.ME
M'IMGIT,U-YY:UT%6(;H'IQ\]TSQWOA3B*7_*4[)IDA5+P+'>173R-!H.#*C?
M()&@Q-3UPL.?.P5K;CU <A)/:X]GPLYEB\A&P.D[%Y QPWS%V,+%THB#0=VM
M*R"'&(Z!U>ON9*S?TP%/Q97R:K#Y![&)<3;(7$?^R@3:HKXIO]!.L_+N)>Z&
M4+$HWG E,3#U*5H5@6S3IF8 *Q.A"+.9EN$U5/) VJC$8?G#,._+B]*%U>W!
MH,K&M@AFFSN^U#Z<7-YYW\Z-VQ;)BITT[U4V=G5+'9V-\R!V6"(5->X12V5K
MNW)BWY 93\$EBX:$8 P('R/6]GK0O%=V:G(=05%VZ,V1CZ@S\^3V=K/<4UO5
MAPKR*K6:E$6]&-FEC!\7>;%)D](+_ERX;;PS*L__8E] 5L+V^+Z\:[H.U?GP
MZZ_N[^2X)>-V87J.O&J4M+0ZDTZ9IJFGM?]ZR]LZ#I1=+[FCR\YD&J&$JPC,
M[H @'/?[AE?#D,C(VFNF2A,3U$A&>OO*BWW)JL4!W)G>H41[@/\%I&1\;'!V
MTI$*GXFJETA1;=#GTO<H'"W;"&4%4.0L1*3E5B],U!<IY/6)Y5<TVHP[G/"*
M:"R#(P80D+<YMT)>K?LR*['\BKY;S2"S7U0=ER"PP)7H,^6$"!;]G2TZ34N>
M#7%5/V:Q^N/AXJK4KJ:H&WUE<C\-HLKG#%DQXPCS>V\PF$##<_%US7;Y<PD'
MNJHMHR]_2U?HO1H6<M4HK/C9I7A[FQ6KA8N=8^9^_ =(K0]/1ZN;=],>T\+V
M43KKJ6HLBTNCN,"0L*+)2L*97J;P_4S%'L8(Q]SMV!H'[1*X'QK;$8R;_#&?
M9AXD$ZPO^9:;4EP*N@$IW<U\W#4@RH;7U]PC4<!:2&:=2);?R=;(R:*T5GWD
MH&3S,-FP(G UGL0/& &E[:U$(=]JG<S-)7;$B-W%14X)2S).C)<'5P@LEI21
M&:#* /KG88/=6B<:9JU-&^"SHDU-91-C];Q!)!3)A>U;M <V/\HV2>[E':(S
M0"ZXLQ^"&ET;,BR3O;^E3H:E<?TT5#TE,R,RY".?Z4)*YTWO56KXA8+%BHX<
MRH%X*^3@@F^-0\U[_(+)](S8PQ&6GJ90TIJY=NK;YJGQ8+().;C,JGUO?">[
M+THR+3L^Q.[@QWW)H^R2UDQ=UV$'"M54P68NU72;IUHO<+5>-<SHF;HX3+[\
M=':E&$S,4N_LJ^37@JB4=@M"W4+FN7E5+>=(RQ;'CS2P&(Y1IRZE1M'8//V:
MM;GJR>S'/^WV"5RW@Z,G3^8DP:WGB&!=]VK97TJ6.?M14B1@X\%DG'8_?1]4
M5X/7ZVODSY9_P<65LU(8C@K+0P-$,S=>]3-9.JTY'W[)ZC$:+@N-W7%U2)_D
M>&3Q8$:!:5#5J'4WR_^V/?-DI Q9O"T!/S4;1H)I4X[>7WMH\_F'3*BB=]$:
M V.P,ZR(,E4W\?:M,I3A7[+D.Q\>)MM6=-OA!-4>,Z"79WLDAB O$X*K>ND\
MD@+;$)(*EZV\I*.-VA JC#5BZ\F'-Y9%9PX[4TLZ>FEV 4B9C),QD$%.A?N#
MSJ5'Y1;7NF'>L-;^$@$M6($'YC&?F4QV.O3DE$?4MDD@'Q67(2M<B<))NS!%
M_<I)D::XQPDYV GG*Q !8_&@;DY+42569(KA39ZP26L;>>3)$ZF)L.U3]_1M
MC44-3A[BL4()9JSQH71A ]AW.T%LYGJ.R7V4?MFA,?/G/M_Q!#F9Y]L]"16T
MGEIGL9 ]FI.TWI:QW/8#VS&'ZV9[%-G"/9/E ;]&% '*)3=;A&Z_FL:#[:#6
MY27LR8N,<?V)*"J1<=H@?<^Q5RLV2:NR1HAX-6G;Z&NR;:[SCLZZZ>,HRJ>B
M41>3VT5=[*M)(Y;T[NRRH+7AWOZT1*CV&VB4I:L24CVU237N)[#T.9,DS3YB
MAGE5Q\419]UG!>"\E[[-+'U=YRI+8[-Q7UPYR+-J-\GQ57Y9$K6TK[ Y?Q\C
M67LQV!2@VL:%:? ?<L=_>>S?=.KVRI4L1J5EX4FC%PI(!WI'Y!N%;"02+J)=
MNR&45*:AP859'FXQ.ON]U8>VPV&;E:7W#%H1AA8WDE>E++/A"L=[9DU_>F3'
MC*FVRJA.' J^&/-NLL5"):[9Y-.)>_?V4]EV]MU=S5-'<ZI0<?=^4?UP*DZH
MTJIK\*>J9LE31LW2Y!A>Q>QT!ZP51D*^;6%G4T<-P/7$MY_!Y2^DZGU6I5BQ
M[=!3AN,N(V^Z/B #)2M+6XJ8:)DIG'<E1Q5$>"'C@C ?C+"1%*ZQ.WM*88;(
M+QJX+//Z42P!A!33EI=_Q]NWYIO>]LP(,;UC=L\CJ[);?EX\TH9075!X,(7.
M\GA[[*RH'8>#?L*,'L_1#@9WQ"902QDZN(N709"HBNYN"H.NE(;M\=+(3/&C
M-PV !KQB-C/T !C<O8-V#5"#XC^/9M$"3E?0<X:34"'73Y36);Y(!395 M@&
MUSOD#5)E<0#U+)&:3>\L$5QS;4!;+"67S&R7SCRF!6[<&]_R2Z-DG[S25"&<
MK.QY_K)%L6(1M3^IL'>@42$@GA4LP]-S)+RLM 4F5>++&K>]I7SO;'(_6SH6
M&H(RCXN':?:\MQ_8Z7UJ1T7^8N=BM#,[#[)DCACD724JXY%$48[TX:$7E98^
M%$:E>D2ZH>1,YB[NC+@V+8;35%_/!S52J5.7=AEY[QP]]=K9 ZWCH=@2V<Y]
M[#=$TXZ1]L>U(Z:' !6^'0=AZ2%!19]./$XJ#;6:CQ\GM11?JG$MBLD=?^<I
M.971QOPUWQ\O&&M^=SLY^;7:-#OG_06O4H0.1>)<<W4KA-=<16_O?8,)\.RK
M;]>3K6_P9^*3,0F/&WUUNS26'P]%O@,U9SM&5?$<%VC;>F_N>>J@V%+!>56!
MTRH_P@>]9#"8-"TPR0+QJ<RIF#= "C.[4K[VT8.94B6Z[K4\LF90^^C)^8@B
M;MW):.C8H+GS:;ACNQ+XQ1E.'V6UK:4>P3(*?ZW:&^S!ZO00D9?PUY>.13IV
M179X>_<I-GM.VNI9UV*D_E%XS0+&;(]^GO<*G?4.0^HQI@*3]2T=JD?&@0I)
M2AA;N#'ZVDM@UZ%APX+C<3 4=*A"62>53Q@5%E8_C,*U,A/5S<P:: /&K_,D
M](++Y5B=<;2T&V6.9^:^74PV[V3=[ZW:W[>CZ]G1'2+82%NKWGOQCKD-[FF;
M9^D<YH+D',349@V8C+9;6: _BNP@DX,%#?U%K7/O-H2\1WT#>D-T<O10L#BL
MA$=.(.0\U4SV\S04V*2SJ]$823N9AR!4.OI\7]OZQ(LO__"A75.4?;EX6=#+
MANSTSCFJ+Y#O.*6Z'M['G$#2K7H#NQOD/2L8%3C,S!Z9\LLG*KD###0B7L&!
MKR^"&.0C1'++BT%#J@?)I&37"N^6-EQT^<CALGI-A8$F3=EHK%D^1 #0-Y,9
M$$EIME6-_%7HY-?G"-]WU5:_$KQ>"Q*]D9@?&9+5]W1Y00XY%X!J]'DPR'T?
M5\GX=9?!])<'C-^>8C\@3O.KY(  >]L5@^J0Y\EVGWW?(Z\-\!;NR_R\/[SQ
M"Q[P]04"8.0^T%)B0RCZ@<>!W>F 8I7>C&7MI=LWY)-LQ[DW A)K7((EPXKZ
M:_8^\-AC6*S1,!.$L!97L(=;+84N@,),I:O@02$X3Q\^4H+1':OMHVA''<N,
M\]".SK(W:IWPE82KIL,*2Q]'CXRD/EB7HQEY-SD'2Z879"ZN2H0U18RB?)%H
M>.2A/M?C:SM_G Y7=YC:O:+ Z5\K&$>L-9[-8J[WM57UY:]%,B@8F+H%^0RK
MO L*>M=PYBJKSYN158'L>!R;*KB!,F*TT%E1-/?78[#2<4F%Y-5)62Y"[52R
MECZ]I@XW#PNVM-"%.;;/E>M#V5WU#811!THSXV0L=)@ZW>:A.7JMPOY,ZD\W
M^IL4$(W9KLY3":"S0QG4"H\<SQR*7$\2&X6P9S&3O.'-=U /L@:;+^B?:A+H
M"7=:0T9<O(F6R'30VP*35(L^L;"C:QW\J&^M.(2JM)6D@.X!$I_L_FB;FX3#
M?2G2B@*PQHZQPV*)8\.H@TSRLTS5;N(^E/X8_?@ED+GMT=+N\4+ISM6@5T6"
M\CX&G88S:/)"1[!AHKS"LTH'KPLH9LY%;RW0T9WP&EL_D]L_4K2J<J3KO$Q#
M6B?3EV7HN8G<@S@*;7^=P;43E7V:N\[]E$.KL@5Y'[VP@A:OR/:#65J&0-J=
MNM=AQ=_E/VDX&'SU#7G"<II&ARSIA9BR<N#^E,V"77J-I2A7B PN>"WUY)U/
M:1+^<8O*6KKXN*9)96C%.W-@2!!W#.QK:8D4TT"\R275-ZFVQ-9=J<Q?OPO4
M)R9[VRHM9/,"WW%+X*NQ)Z=@M"5AUD@6B^X&6 >GR91_AO(,SCUFG:'DCZNV
MZDS[.>2D/:EM/_#A7-2*VST-;>O64TU3],.6ES4<F &)L>0*4&[U3L93I_;'
M6?3<J>>Z"3$='HWO)\@Y*T#$U5_EK V (R>&,H6#E[2<*1Z9(GHP@\Q*$:1?
MPZ'(E*NI*&,V+-.!EOE:3+\I,<37?BJ)!>%I.%[5J[7 B&"L3>PSFM;U3R.&
M"*6'7#D.$9U\Z^D.YHN1D])W\/"HR_VS^T;!_%JK5'(/*NBE*[7TU\FI4QDO
MN]@Z6N7\DAMD@&NE;>TYPDBM?74T#^SX0?H5H-TGR=\^(WDGMT9+G\GZZ$/;
M)R8&_O#^;LLNL=*<;I9X[ZU8G-V.T'C#SV>6)F Z)/['@WUA0)J+34N26$)1
MB,!4&R1!+C@/N,;3&#\N>;+,>F3MQX01-CXG=#=;W:3-CQ<B^BX%+BR,1ERA
M[9U.I>1SB#%!'X%GU,MQ_G=DE4_%U"3P$U\3?+D!:*0&U_Q&9A\PA]R>@7SF
M@Y$)G_%B2FK+2-'K1$H<--9@14A7IALY1I#4;D?*A\ "RDL$[Y-V=L^OYH%)
M42#3*5N;073"V2(N6DSB5W.*I@\$(W6V,2^C$JZJ:Y,9=O:1Z.MAF[#W)XUT
M.#^N4G$316#+/#Z;0=GV<!GK5S*H>:7EJB[3.V GM; IUO I6N '"UK21\TB
M?=*Y!_8GMVHQ>QC7!(C+I4&)-I-'D9=]+IN613T0Z8#@ A85SUXX#V@,Y@D'
MJL]IH<RN@0LQ2R7+S1GZO?$")-$M;AWBDVZI(W&=M@@"E%(_Q,+XLF.YU7MJ
M%_HKM11YJ9&K^J5>=?DP86'5]^<O%U=1EM"$_(>EY1X#2#5VA_[AJK3IEJBV
M"RS_CTRT5TG2.X/=$7PCU4EJEAO<;:4I)G=6,]_>:+*.9D*"#/0;^:S7]WF)
MIRCI(GZ!7XSH0FIJ-M/VP<.NSN[H'&!1J)15C+*^/Y /X?NXJ6H/L0IG=IU\
MRGT,K>A=NAY8:BP5O=D65HV)&Y,="]EXZS,NUV-G+O> KB*4O,NQ 5(>0&NF
M:.:]F'F%_F40B",!P7F^T?^E\E;/YQ96)W_]5+)HB!5: VT)@K[+NH53\JIK
MC.AYL%!$2LZA%YNU=5X+5T!%.LJI?L 3K6AP+,=>P3&*53W<\2S\-7YYTC,?
MX<#6P.6.XZF^$!Z)G\[6=,EOU$0&-8PB;'-7#1O>() ^#Y0>%;M.6T0YVZQ7
ML,624!)@2^:&$':(6@U#U-9KUZZ+>$*A1!C\;"EFNK%->_W&\+5RX [&@V2&
M)[)IP%(#,CZ4XR<N$<:J0MC+G4$#D3J32M/Q=G5SE2GEO^P-4S5M\PQ@^,RH
MZ,^$HSZG7V8$^EU %7Y*[D.?NYK%8F%WU-<$-/6DC^ 8NH_% G$95%PG<BTG
MHL70(.\,A[/F4:Z=VL[]C%SGNH+1I4D\D3ZM81RN*CHF'CYR7CPWET&FR!.S
M.GPQX*0;R5D?!,N;;6=.;E/I5(VH(R83;\; ]A:6?5<N7X/L9VIPC3P;KF.C
MBHG@E <)^<@(=C2DH?WS9<62=SQT[N34@_+M1>PX_PIWGJ,"W77$_E#!;2W$
ML-^K_LG5#A#"DZ/;W/+84O*H3._+WO'J9BJ(SF DC[7.ZRTGN\*,U//O,:D,
M9/ CQ/S9]=K7#/=UCK6!.Q<."Z(R9*\]>8<LTT7[L?QN#QN#-.@;0H>/Y#JL
MG2CLRTO!.MJ2<K"07C!'AD+.]PRQ6V1D/>WUO_!3E"B]S%%!3H$U&VE7&U[!
MO/RJ2O=8^LOGN$D/3753E.6WB L6YI/BH#%B/.I.6Y#/(&/T20M&_;-CWQ$<
MT#'=W/?P:BBGRUNS\=HO_ Y7:YIE*<Q^M^;IB[%0\]U1M!WG\XO>2C"7%'G6
M)OX\N&H3Y5&,D7MZ;UGZDRM>Y$2/Y+7\G/=>M/ 9UT7/@T10T/VJW,>^Q5&C
MCD<S#6YKU@2>RO# 1M(9E4;NL>8;0L8951PQJ'!DW($= <Y*,#&'=*Z>NG#D
MDJ'BH=;>=5_*;?[%59P3U/8(L[*2.EF'J*NQDY^Y?_B,CR)&'@,9Q#C&#O#+
MLKBK-R=_R2.LA)9<8G3QY'6@.,_L^[<7EN/WH_(8E%(6CD'+2VQ9"NFOEG_<
MI8P, 06>X7E,<FOAZ;S%%VW**[;#I^]-9!3;3A?8M-Y.X)E\)-^Y6#?@3 P.
M'V*^(I9<GBVNMY#KJ+S\TC/O$'!;?H(B',$$V IKL[7\T :8?89ACR7UNMR'
M'F")GO=WG(C_R59<WVBR,J.Z)<<\2(;PVW.2%PV^IC50"S@H)^ET[(/UNM<0
M[KA21K3CM%J>SY)WC0G;#!,@/&>NR\*]@S>\>B_BD9IX?E#Q-LU7=X)"Z\=8
M;W833+VW24=,_7@0KGJQ]=50,:C/CGA+FX$ YD.;7 J%F;YH!/!?"6HWW=FN
M9B^0Q.4OC]H%Y.2'%ESD-/;!S/)>ZU</CC^QG\*)=.S1R78RI+K'("$P4['X
M<52H3Z2"O*![:9O= +\\0"H?\H8<U?IK&_.^7(YLGB&2X]KJ9P9/C=@0&B3?
MEWVA_(0K>6HPG ,9'3 ^,D+T$^!N]?81JLLP28AXF^$PNLVB7T".L)A("'G6
M8R51\)!]JKNE/]\K0$(U>D-HI#AU*G;\P@77]:/,4&,##JHT[1Z$=VSJ^0=N
M'3,)*J)-(;ZASWP(GYISSQS'/QIU?\N37B0 <C)FB1ZP+P>OP:3X/QV\>-UF
MGY-Z6INR(0& U9.<H/N&TRO"K0EN$I6E02\=Y+MPP=4"# )B.$&F9V6@9EVK
MTZ_R2!YY0S'EZ9TTQHF$S( 7ND>E\M!\U<VCUG*<FG>I>ZHXQX=^! !@.N1F
M5'<<#,YEXE*8S!>$&/)89J3:F_(#\(EI6WSH723CI'R=D0)[[$UZ/73<[3"4
M&LY+2N83]L'&%2V,F/":R!:'^R$":]U"3S^_IQ#ZB'-D'()/#*%]/!)S"XO2
M'86U]01FX(8N=AB63U!R*JBTG^=7HBK5'66$@7?\BLO$Q]S4=ZO=B*6^11T%
MB2IG!DD8%D8RZ$!FSU5[4T.VFAUO<PM8%QF6O\R4]P4>C<>4E(!=+>$B]M6P
M2Q].;-[QW]!JSNZ'F=Y?,AR/[QU]&#]K[-'A/Q'CZ&*QZUM/GKFK7,/^7#:5
MYBI;-?_@P(YM'B76 S[Q?;E9J*Z+C*[ZT8&AS(/G]K>I1;*(EXR\".V[0>W(
M8!D11SRRQ897<@^Q%E0*\PFU(#].ST[6DDD,@4+'WDE+^K4H=>4E9_9Y,NQL
MLL.+]6TBF?V,"L_WAT."IQER5'"]S8H]R1*)D@TTUY:ONB]1.0Q7TVV5?(-:
M5N('L=[)7SEKTW4ZN%%ZI/A5C6M9)G1)T6+]_G62P"2+[QW[RD&>(_YX4H37
M2V+,:\6PK>U+4?B'#;A)=WF7F#1NRP@NF*6$0$["I9>L:]TR?=?59S76C"-2
M>R+:5Q8N'9:5N%H_9.S3>8 LA@8;,O0K/EPJ\3]Z\QFPE#H75%:G/@)9I#1F
M)\(DD-RR J\$FUP&^@[:&^P]]MHA0;4_L4<W(/%.^O-NL?JBD*-#"52_A".'
MK;1%($O[.%<)E673K %+CG<,J$(9KM[D'&AQ:T,(1W@;_OIXHZU[0HPDVI(Y
M%!>F78:<5)OT]TA"=")>'"T,H/.-F(\@/M6/'!,#BJ<'ZE?9GJ$K=O<1)@T&
MFN66(H8Y5=H']8O<^$PEFS4DP_^9A120N&ZB]+%< FV:,SJ06W:H31KGU9U&
M],\;UD;Z[[5Z?XU)H? @JP_VE+F@+8_4">3?2WK6M"PPD2)3C/S*5X7_?!YC
MXH\V<+*,[>KH=GJ4DQ627L!*U4)*54U%<;/<O=J260F4MS#?EW(%Z@!V4W>2
M5+QGP0['U9@!*,ELX4V[Q:,R?QGP\/#;32<;G%+,M((C?<HHXHA+A1HWP_R@
MP<I'+W%&NO:P=$OD<;17ZO[4LGN/(J4C$@"Z-Z[,&+<]8X%,K];TB2,7;QT(
M&8Z"<!@%XR<"TD:;IMDZ)B'A\)S;"4/1X8R(M,CJUE\C&.65UD%.(+B/HF5L
MT(;0Z\5U[Z(: 9I86K'BCF49UB]B#NN8UFP>TQD #\[[^)F [2^+#@5Y8LMG
M;U(W.RG<!S%371]1LR?C@6PIYB.B0LK<SO<@]>6^1/Y027(E.OSS/4PWH\ 3
MCNYZ!SGG(["$BEI*N50ZIY831GO2#0T(.00SPY68V?S!&Q=M9CU$>)MMF$&W
MZI[6S[>I13R31/@SQD7!(DS;L^5Q7[']HY[!;23J2U)NJ/S$*A(F9FG/4 [?
M>^U"[RD#W1#S_1<94IE'?Z"P05R8;:P*6<-_FI5N-L,3>?^&"5S3:&(*!'DT
M=F4\,: W+AC49KZ@?%#.UE1?S.S>DJ_!X6$TOW"22DTN;7M?.<KU4%%CY%\V
M1<JD_#*1EH\_JO'NR!QDKVI=QK2D)>.C/[B7Q&+6ED:QUV#DCUA8L^98.[M,
M_;EOG9WX[!YB#7>F8]3B@E,L8W#,]*DU^TR=LT+@QPSMR;?R@ VAGCM/JL<'
MQ]?D0>IDS)WH(_*NC'&1V(.TPD^&[Z\]S,UC6RUT+DX_BMV\C]VN:O(2?+%\
MXB KLVO6V+XJ8B7;@3X(';+]?$=K(3#_[4? ;"LK:M!#JN=S0&BY0/[0%(.W
MR%8#1^V/K.B:YUJDL)A\32;9=\W:DE9<#.&K4Y*@6,5%I!4<6?O!+2; L2&'
M3 Y,ODS=+VOT@%&82_YHTR_00:%\%2YP?:HK *R"H]-7V\JSLUG>UA3[KK9<
M 2\:5P>'U/N:8P?>T%]#AXAM^J[T7P2& ][Y/@D7;+JF:;MDJ\3TSMB7^XUE
M'^NYJDY\='GI."6UZ<&RSS#;(FGO='[F?94'DDUY'Q4+S1H:J?/6).K*JZY>
MEG?M^+WQ3V5:^5Q_CY[/B*$P8?U"JBQW_AX$IF_4=U8ZT@62T$KU>/:I(:=[
MG3O_8-V@1ZO7U0E7-P"Y;X^B=7D+VO:A!_1.<A%<S3$9O5-B7)AEL'RZH1,B
M^&B\A#H=:K$A!'6\MELRS>[T^/=6%-FTMK633]W  _=/51L;>Q7E[VV-="QR
M[^2!QMY @)<? 2VBYXJP(!B2#S+45LDANY?YR*77<Z\]$%AYH4Y1NILA8JKU
M,>BE)#LFP[,7#OA06DV=::).]9ZDY4;&D7P(@ HMK0S0)%2O>-EKG6!\7S8T
MTI=3.9'6ZT';[S-_I%4ST26G[MA/+QX2H#+BH. ROSS<^\D",:0*-;K.H"TU
M<JIHM#'',XI=RVT0'F+YYLFOQ]>O C64DL594TWC,H<+PBU";[JMGKJ=Q-.2
M)"9D5-^++Y>.>3=A'[C#K^!$#QM$SGR7S/A0XKGB$'.UXGU.U02M3Q"G4S0,
MNG</N5B&.^595FZS(<3KYY)/>RV:Y^06N/I*A3I>Y' TAW);WHT?6@./'$.*
MB5G"H>8D ^FQDB__.27;<[]L;=>+PZ,ZGT;VI89<^R54-1->T&K^=+6AL7KF
M00"J]6!O0[E@;E"BB0#F2]JLZ%>O/5\U-U)^%5*^6E7-G,.,"!T(L?G76W J
MED&AI7V_1-7I>WO]  ,\]8L+!A30K1ZQ!^2])5)F10\JG"9#B4B)!W%:39Z+
M/R)AN3FX3";S*0@.,T#].+;4/186#N^L>6MJ&G#[5+)L#<1(IF2H;D[I]LYV
M?&D3+('/0?#A==9C+9$BF1&C_+3KANX9V;/AZ"Y-?_47X,NOW?"]7O/UDEY6
M:\B8UQXLDE+'Q8RIM%?+B^S0,PZ2"$8#4<]\SV,Q/XV BX=KNOL7C<JK%1&"
M>Q<YNM"D'C*#/'SK>5IP))6<W^)Z*L#KO>HO@X7'&D/+;0^J5D:'\/T*<,1@
MUIT3Q27.*3M5'9HK"[QS27N>2EZ^Q#,LN YNNVH  ! !8FUIT3,\U8,5&:X
MS<G(E%$%GX*39:YKB(>,O&0=>^#^6%S+B#G<#PE'A^"J!K(5/-,NYD\MBG:S
M>>\Z7DA\C+O>F#W(J-8?X8[+_8(]$NSL''KBUM1T#T//E:A6K'FMI+G5 &[,
MF\Y;TIP$Q1HVC0SXT)^]!CS0Y(!$"$]F/RS5Q=KE+B9YC [Q3^\+]'^5OY-"
M%!&7(R\/WSS<R==<SW ('%=LG$UZ7U_8CD;*2&04)#5%+> <2:G[54L<'&/O
M )B+,=Z2*2MSFT?Y$7-YGB/)ZN?=E/>)A!94W/>W;#N1GN!AD;937H(XE3+T
MVX<-,U:@3HTY7(UK 1TY!C%?("8[*J/)-O,7O47+R!?]HHRQL:[9_4L6"$&(
M&_"!AGF'&/)Q9,Z9R+=[)OA(&)'@+.LV4:4<>+O=WH=%O_%NU?.@EGX:+V*4
MN(C6TS-#IXXFV\=**IU(:)QT[^=K@M,%PJU(/BQ8;+<;1'!BL;ER+(/"2'4:
M7/;LI:;$/NU[Z#57ZW_9IX!)K?0S+\VJ4(U89MXOH6BE@L:M;C]!-J+1EBB#
M]+QVVZ,T;S,7B+D+Q""UCUVHK@Y.105O")5$Y,@(2Q^PLWUM"A>=OU8NPA'P
M2Z/H5QU\#F5R?2NTT#[&7@4Y,#2SEP\B<>#0<2CX@SS@_<-R3[Q(NIDXOC67
MXJHN\F8B.G@UTEZE<H#:[M#I97FQS2J JI,U53>4,>M\K'"FH^><9WX#08)
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MVK)BWMUZ8W]D^7Q+@K-WCP-!Y>)QNLZ+08RXL**_) U;RSC&I&6$B%$J2@(
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MCU]*T^/(XZF)-E97W8&HSL,36?!.!$B[029+T <&] "&"UV;D8&. M9R8:B
MYF+ARG[S6 :#H('2FHVR>ZESCZ?GA5P)4B97V*=#RM9+\/@=0+$@-]04TL4
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M0BV3)%M)0EP(/] F;1;T.?\>]"8,[+@D/QD&&/X,=H9OVP\OOOHZ\0O?A=:
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M%',[WM:QS4LT+DBH1^31MR/N,)]64BF+H];V8IW-0'\-O31.B\^]3VT]I@Q
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MR1G3Y&[@%,"*EKG.+#(BCB$LX0/5N!P;UA(-91=]"'8BGEMW'$TD/$UJ%=*
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MENG1:]#@\[Q\U^:Q->M/G'?IM(N"4=,W>,5)J#@LE5SLN9U57UN7-;[KT;S
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M?_J_B51.=%>HRLK/A5LU+_BG0W^5'_]*70WI5/R40WB[C'%]P $ 3[B387_
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M H_NQGSV#2TN/QF'-[EAJ"QS3Z_J?BQ_ZH^68!+NVN+>9-G7E=HXLE[K*([
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M\@@N^$2E9H?[%@!X_%/K9&VVU@_@#_K),:HIFN&X<C2A@$1Q3M-(O4_L*%"
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M<388DRN!@!A .U.C8K"V>H-;\53RUDNOQ++3]8GQB%O^Y,A;5I=U+.!Q'Q6
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MZI&B:&:?N%A"L1VF"%TK$?=N]>$SCJI&3G5WNQV77_]?9X5T[MO5J[Z5&KN
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M>;\*-9[.2'J9,"A+C#?6F,^-$Z%GML04[-:]_L^!Z;_]#//?UFN!3KEY)&H
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MEH7]];5KFF=^KG[-!S'S^WWN2K)X",AYV-E3S.'JVHP-I*)HDWPT?+_MF;"
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M:/<3&40=(CR)5@(JJ=G4V4?.2M?%H_P+-&_*/7&U^+DVQMFV1\X3\4GW+2@
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MN@B$?$LVH0N;V)0IDO"^\(GK+]$Q;9Q?_EIB\#\H7\RU?77M3O86A$&=^Y2
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MGV&0VQCY,N+M\\7/RO/<L]+=CAV[>\U4ZMXE!88ZVK<@,$']_YL 4$L#!!0
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M=?@-]3M/_S2P/SUN_RLCQI@X_S=&B_BSI18RX^,7$ 6!3>$6('Y1(2&0*)^
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MC(+K!;CT+ Q2+UC7S#I*<D(W@>QRJ/#^N^4NE[XC](VN839GA.(3A_"DD,9
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M"Y[,)*6=0AZ!2F.9<Q41^$D!5<E5ZXF"B0.YFJ$\KOZU0V#,-_'EE?GJ=\<
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MK!<=<@8%;-#'_4$4;M$)V,+U?=QZMYJZD=<]A=D?#EF>LSP_'Q!W^2< Q4\
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M663&#^'5<J-I9635X:\2OANI)FU8QIICP*/,'>5BS7+9 5C=Y0DIV:4F3'Q
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M!:ISA,3G)+(4O!G0!M(%C?3N'0,*]#"M)4Y[@J1+Z@KI)<%5_?3SK5.RV(+
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MK]^H'R^E9>XI9 26;HTX=S7"U?,J,W"2)=8:Q)C=G67K@T:0&;$[/6;$#EN
M1CO4S[_JP"VR>2A^X_IK]FK/(6(U?$QTIIFB+LTOY3?E$/DQ+/U16S*:4T\+
M;CV$BKIL8V,K$AZE]/3V\@2^MK=6S*A-BZS[*LJ=64872S2/RJWACJ 1%9W]
MD,F$^BM\M*X^0;KW>9YH=88D\.1U[6M*9-D:U)8;B6DGN'F8H,6XWKP7GA"6
M&#&A>,E#IN#3)_YD;5PN8@E#Z^Q^F- BN<M5NX<,+E_.T$)Z>)!\Y5TOUSX;
M=&M[]^777VF3=?5QC,9I^@ZUS%45DNCD/LPS"D?&&7MNW!+^T/>)LZ7 Y 7
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MM,O-_I=6J$B=4S?M6(LRMI]L\$E7V,* ;FW6#24I@F3A_%"U7D]W;PQL?TN
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MG@ZX6%'_X&R$NL[,2<<7_=FX .GGVWB]C+)LB5_E3 D0 Z'&[MY]%)/UJ74
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M;;MO"4UY\"UE$&7%)B_?T&X]R65 ^3Q>+F+*R'W)H;WRU@8Y>)&PQ3[Q&1/
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M;IH<6<,AN5ZL#<5GZ@+G%8I@KK6$#4KAH()X<NG V+/AJH**W,P!O39.O=U
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MX8 ?"6W9&R\$Z'*7RB>$'K)IFIV[#<AG9#9([#ZMAS&X=@?5YRY/ED<H R\
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MLMU",>1>LS!Z10J5#[^@YW(6D2[)?K)[TKTMYZX[N+C-$.Z7ZJ#6PRB>V9+
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MC=[ VZ;6X/2&%WQ'P$N'KS'L6]X.:4]S_$7>!VC5#A;4R14SIIR$V5[GVO
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MZQ%S)=S? JN#,*]',PQVV(=F?'4)-=30OO,C%)GN".H)@$)N!7_U%;=1*#H
MU1TZ!\%JJ--")62O13W]B/*X>@%\:OW=K.=91SX"T08U223/5U'/!*(R!9HA
MKQHKE6Q0\*Z^_8A*SA?3F# X=DTS5).J69S[F:!]V%UF,K!@G@<XQ7[_;]6Z
MTE*FP:X\?+V',047,FR\DW^\=64^^_1.3.T@V7S$100]A2V8MD1-?.J3VMR\
MA=\X 8P$]"'2U28;S TEY=I"#8,WN)/:V%_[^A&^0*X74UWY46MVNPI5UM%C
M\\D<BS/!.R0MT&*TB9Z0< V83[4@VSP2;)YU43)W211>W54-MCZ 6Q7CL:_0
M#RS-+J2)MAMV3#153\*%[]E9>DB^_E;QQJR,&K"=JP?J@CA9:?]?!O3_&7[@
M\FCXK0&ZN)A? HW"24O576UKK[[.F/\:38Y_P,H"!+%*#12X(R=&RMGR&62C
M4 WKI59CL'!%XL3'T:'W9PJ<$#@69,32_945S10J#7DHZPMJ]X.+V</8V-*W
M>G6N_<CO$K%N%)3UT__WTT.[9U</+T?56T_I=QKH[I9]LYAQ.RL&'AX.)P6(
MF>(G':TO1ZN^00O^ON4Y";47OP%F3J1UR LQ9>91V"A7-<9QQC$!6?PEB6#O
M"C?>E%=K!7[CF4\W00\$=3\.<\V+&4M'KJ/8$D#T^C>UUFZ4"@8JRMGQJKJI
MP]%EV!NSY^-ZKV)?[271S]L9^Z0Z:=5WU=/P(2J(Y%XG(;%!6&Q8BX_Y(*/L
MF\>$LE*G3=ZN_UI>'L828U&J.:.Q!>XU;2[Y"IFJ\'<:"(CTI-0,/6X5, 'S
M'^;%U4G$61=BEQ%,0K;#453Q(:XRO! 5Q>@ W/Z3D_X%M^^<7_T60^:*>>#1
MU8":X.P5%59',#3D:S.L7-RWV4Q$O5I:P]5,.&TIH$XP6]>1R:B>5P88LP"5
M?!0J*5=!W@U;Y14[2"YX_68N-.YX?70UD;Q3Z[N=:*3YX!1;'Y@A_!OW@K*?
M;0'9!+I4J_#+'$W!.K4YY-H2E0B"B9N?3:Y0^]:4T2GHBQE@XT ?UYDF%+K:
MY^2]0J5&=-A#I8J-3C\,U\VLW@NOQ!WX;O=_&@4H?OF[X&($ER"J@88!:[&K
MT<?65@A:Z<7QA:TM/I.0%2[]@X(O#K\9;S5HE;PM />!V]5E;_N#0#JLO*6/
M2ZPCONL9GID_$WKS0HLKZ6'=UNNS^(SBH*:[XOZ];7L,ML:Z]U&QD74&JT/
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M%T>J6&_/D(W>4?QU/P'/((.)O;R58@E4K:+,D><J#6&-4D/91TI6D-"XE1.
M_DK=9IZV_=.[I;=1,3$QFD3,UXBPCXJ<?[U+_XZSN;4)!F=I4!V1LO&**'V'
MKW+3O?"<5].>F!RLO>K%B#$N6L-MS$N1P+G?SX/,ENOC8AVZ9;'![K19&?ZD
MA4X3%47I(N=\U:MMUNX,/P:<9$9JO7,%2NSU 5T7V<$.U RYR*ILTW0AZ)$"
M.VD+"X*&YXYMRJ=)PIC!(-EWR2,&:CF^C]R$@AV254K>W2/FFLC%PHD$@3[G
M\2\5G+>+:P\#LLL:D:.M&3&FMKHMIN*?+N[XT189H=<JHZ?"1]C<3;_:ELAZ
M5=E!OJ*B(5*0(<64E_9!Q;# #L#M,AZ,&FY7LG7B  MNZ,@:BIYHJ=V.MO(N
MT.VZ&.48\*,!5^Y4F_>[-NUVUXHPGH8&LU'[6AT(\8Z9EY* \Q65>47.8%NG
M$-7\RCSUP%+@>[?!\9W2C3/*@?DQ&&GA?,YJN\^:/$E$"I*2!W,/P"7*GE[O
M*>4SU7ZCQ8=^A6#<>3,@[9)UK5BKC6%6C=?/R=G[R:ET>>R7>AN!XO(A ^B:
M-3Y>2(JWAY MG<)7)INZ_JY/G&7Z?!-U9^EXT-7.=0KU2JF@HQ1M>#;P^-E7
M/8/3?5-)US/7]%*B"A*)APY/1^@Z5[\,]5I)"P>#)2O\55@_OV+800=%>!)[
M:*2@U:U]9N%="]68RU%T3O7L0M/\YT=<C;NN"Z!_).S VOUQ_H7WL/5_RD!Y
MP'XL)B ]8^6!.'6*3WH]RT\O5)N&EO8E.2BI'SYQ)987G@"@,X:-YP3D>@?K
M#"S!>OGB40U@Z[G=/L,0EOEC.ZF1H@G>S,%["']RY"S8Y5T/+$B" X?L/5^1
M*53O_+4_)D9I/7FS)"7E<'?V7&FF<X-<.^OHHG5Q[$N9ML*JV46!XOJ1FDZQ
MJ2K;*0@B,#DR3K("L>?\^;5'07GK4S)$Z-DU=>WZ4O2D<J1T7H?OAHI--7]"
M[=P)@/F;L%$7S2\ I>\^HM 1^:()<$5D^^^^4%FE]+(&I@\>\DOC&17OET5L
M/B07C0]8+-U.;7',IN^3K%=ESZ:CI_QJ:-M)Q,X!L!)Z=5\G- 9VG2IUEUK
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MNZ;J*BTGSX"S2>CWM7KCEC1+W92R$/<47V$AZA B(,[]:P'9O,7 N*LZ^9K
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M3T2:VQ^P/V=:]".,6]1T1:[^-1Z*E$@0>ZE/+V00][M\\DO-O:QVZ15FZP^
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ML -M+]P(1N5'630V,< E>JG3580]:&-_78P'7=*SW#,DUPX'4.USAEZ8F4X
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M.QAG!Q506HB!T(%BP/U.#M&X&-^:/GGQ?LZ?,^)+WMZ\W)N-\:?[CB[(KKR
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M]HO8\;B\-4DCD,J5/#@MT=XCR8E]^07.K:1B=#E %AHBE:*?#"V0%0-]MBY
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MXK)R%994]@I<;NOJM)7A^ODSM+=,"L23]1D<-AE5&MN6TM6CML<]G?:N32,
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M-EB%1?B8'%"^]5B./QS-E5 G.))&L!XM]8&O]5/7*!"M\]U)!+%*0@&ZI"A
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M6=BYN(&\0#IFD!"(1XB3!\CS ^34^?/GR2Z072,CN\9#3T//\Q_+T1L Q05
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M%4A/*HZ3P4 "+5V6K(F5X:R%U-<KI89\5.\MB=/#WT)V7NFE.Y$3"IMY&:!
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M^]A++ILBI_69D%@)3==[_#EYJ51W^.ZI97S:^B36<:@:07E.EQ[A(->\:SM
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M=RB7SP4XYDM*9APA-Z]0!05BBKT5Z7]/Y!IL,DV/>,.9D?/&TKI!&-KCXQ4
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M'N;M'2O9:(%MH<2SB>1"M4W"HKRB-@II5*AGE O5=/0PKC8=HLR]B54&;0E
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M\'9T#B-3_@2T8V:&NQ'<9[%$-JA_V< /T@6L@_&[EZ5;D.(RFW4Z8D<R=63
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MW:WMZKLP'$K3HS64_!16ZUH9Y$M^R@OCQ_.DQ<Z-R;M^;N792&;)E0:*^<.
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M7+QM.>:38US8%QC9!S*N\#+KQ[S]K#8VWFD'' _%W83,=Y<93XIS9/)-AM\
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MV;_*$(+$@.K=/SR"];>5T0PUVJ0BYL@EJCLP;I[.S:,]FCKEEH+/;?AB%0=
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MY%5Q -<N[SWW4]9L!VF_WCP^WO5>W>;)MP??Y+=(3P[L7?W5Z; ?Y?-D;P$
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MV_68[ZO5=BUQ[*M62/Q\(]E"647 KJ/:S*-=16-7M[HM1YY&?E^9JC<M J=
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MUED4K'4Z/X6N#->DK&G'J$0%OI8GS0LLHZJ6BM"YQ0G+&W4%=I\RM&;>S-5
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M14^^N;E!;!:B;8?';$ETOR-/:LR\=V'PG%D9;45_H"GG515MQ3J!\\7G/K<
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M9EC&6M-&%6V]\?<-0+!DW+]3'I_M7D12WC!Z4ZQ4+[@61"']":"9'G<GK?J
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M3P %<AT.GCRG1EM)9I]+92NIH#!*>=2GKK[\A3?"%'N=(NZEZVG,Z=7W9^A
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MK<"66&*X?IC<-[ZGQ<.Y:U$:C ^<\D8)1H2U0K-74LXTU>?1<PA(61<+GJ6
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M"PI8_(DP$7)Z!K0.1_B866SOOKA7XLZ.,:Y9]YV9BO+U,B/Q/E[9A=GD@G6
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MZ/&RX?&"V-&/='@0&L1(E>KFIM TE3:0E4^N*A+"C&.BBSV%)%**;LF*A[E
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ME#-M)[.C'=EWG,H9BZ<UOB5GC:N+[M]A=C7O@$*GR<Z;KV^8XA4<4](/BI?
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MCF>Z/#GQ^+^;*6N:NUC-W8'+:$[C7"\O,.OE8NZD;*)_,HM%6$*:18ZM<,U
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MX #!9*'-*#J#DVDN:3'4_((Y6[;1#K(EIK]9XK:3#(J^@_]9N[78P86299/
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ML,K\@C06_\FK5$F?]O2=]C1B1P#,ANC$E7J?#4C"/0'<%<$^^_GMJ4_GW54
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M']LQTLF/'YZ)^ A+]+@K"<>$KH$Q$C%[MQI9GP5TC&/IP*$]=(J4'&CD5G8
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M$U@&L30#(^6*D<QPN%&+7/&\[)?F;FC<1^@@LI[U:%7I6\+4V5H# \'LR6/
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MN0.;V[JRZ6:\[L00(^BSQ*!"PK.'U^\,IUN[5I A7A5W9>5T"5/(D"1P3&[
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M&&M18)=&J_%<K&__T \P7UF-HZ.3H_6$B9?WZTW(UZ%7Q:=T+%UO16=L/%(
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M*XBI+Q]  !7BGR7A966A%_6ADF4%:5VV)HKW7S!!D0'REU:&O$BB0+ :IY4
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MUI[&?%0*E+*K9BHL"C?U-XQ!&!JG@^),&"(OW<%YZFLQB'-!7E4W.&Q5W#5
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MC94WNH[![Y$+2(C4R AK)9^8,=LC76\]/ YAMAHZ6Q=( @N5HP76LX'&QGE
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M\9';S/1ASW*4T;6ID^<W+D[4/7GAX'B5G-C@JZ *.&<L%/3;5SGY(I(9+P"
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MG(62UI[$FJ>%-(2AV*^IEF8IC)@)3:,X!""*3HI-X);Z4^M()1\)*Q %9$9
M2DQXC/$I!W<42&ACW['9H.\:7?//4)7CB)L I\>]$=%;2&$YZJ:>Z?*65,5
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M^97C2W6\IG2^J&O1:]L_+.^4?B!1]7C]I=DK>[*)WMT]5YAZ0?&_'.K2> 8
M?%'D0C[OMVY&SD'5-DOPX]8::57*^#=(J>?/&U3X;WP*[_@I<>;%%L4WB_O6
MT*.'V(2VU"G]<<^M-!G:B&Q*E<J=Z&)5+=3=^S5=SQ@=9E ^A?1DP@9G CA
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M)"E*[2_)5!&NF79&3)V3>C;G7\<57*:XI6LU-V2TMCWN]AGPV,L=SDF&]:R
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M@43Q42$1IJUP>+-:1:H5E1D:CD-W%D7S=3#SU".B,D5]H ZCE-J*38F1L\!
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M7Q/[:WP_VK2U -:?_==0WGW*L$BOD4C'L1S>:]]0M\*?5;?_9KN\Z4*A>V#
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M/F^I$"C,@PJ-3_);;1>=#%JSKW%[<Y70ZM"[$K,2F7QWS!.NF:Z<KF4T +<
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M&.83'W '5D]%K1>:$( N+1F"]!+9\/9#?\2M7!; [P%<-E#%+=.;]"N$N3T
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M;W4+_<*7-:<H")]K2#Q/'S5U=1DV&BRB?X3<,I<N%\*$ @G%<>^5HQ69?GN
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M?8C!IK[H2PE\$TBHPS_E<&PFJD +@K#HWY&WT>8S 5VBUD N/)[?)*\H6OL
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MD:6=K-LKDUJP6>X>H%\B+0A)08$J2C2RUJR\-IG([JN@1Q%VZ#[%,V1IXJ+
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M8+X^116SD1]:]1M<K7>9Y)(9]TKKN=)Q3U9F+UBY^S-XFNKG?^,#"AWO-MQ
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M]?MA(;2&ZF!*($#4%@TF%PR+TWMB']0Y>$?R8G946\I<&GL[<"VGLZ#X8C5
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MO>M*"0VM]6+.."+DL8BKN0U8D4G$7-]45COS:<!%C#2)DI8U%X.$I(ZJI>@
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MEG9G$*PL?'4G[O-JWK\]\F]02P,$%     @  :')7&G7)5#R#P$ #XH! !$
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M1T",$09!+]0;6SH7]"<@/;U#WYX? KY-&*YD;2D4WYNM2-=,/P1,Y;-H,<F
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M^)2: +R&F@(_BEMJ WMXZFCD.<OE:.N6D@(^.U[?1D_W:[6K*W,!3CC_9_;
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M_N\V"&SH,OH)X"OD;.R0SN\$QU3?E[;Y^-=7)#Z^B:KE])&5:K4QOYU?1FB
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MV8HSNIFQM.CB+1&;$]6P;Q38=)OK36/JIPYXI7';E4V->0*K6;W+C($36VP
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M^_G5U2J/1R(RP=5PC]?9*05-5C S]XI,]QU81'C2#_,KM.WBG2XN?ZDQZ)Q
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MZ^#L;'8, *GI&0 N2#[_AZK]JV*]_PPP8M['.&(-F/EB^YWX14<NI45/"H*
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M41)KWGHB^WP:P1D_P%&'7&+!P%ZZ/I'JTVCAKZD?.'?[K#\ T.Q8,5PG:%T
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MPW/E^@!4J5G9WDA U-T(TVU%R7M^IRZZ=5D5:9 B.K>-22L>\7%1DB_%*LL
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M]-&'8M T0%5/A@"$4TJ%:B/KC) D_4'")I7$OUF@^D]>6/@O)$UUO7U.&O2
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M9ER73?5JYG4FQQS7(6K$4RM3 :D--3W9B70>I3U3R3G!J=ZSKO6L_ONN"D.
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MID2[)6&N'CDQRBPD/+3.=B<F5:,DTM6&4H/+82G=\E<\ K+;HGU_(- S=2!
M#9.LE4!CAGQ*<21E>RS4)W\B$'XI2'6_G=46>LK$)<AI1\]/A\]49KUC[?IX
MX%LI9F'EL,EA1>#U<B#90N5]T>?LM5\E30%!3^"P$<'D5'J+MIXV(=5)A[:]
M$=K?V-TDET;6RJZVH4T/8)4.XGJ1]>P:?#5]WMZA LFKT665.,>ANFB?\1,Q
MV'%X%>WCX$_-KS<$XZ:7&J\RD&T\;50]K8X%HQ:K&5G%($%WM6.,ZLO**]3Q
MOL!GQ'A$JD9<6\]H(SG&"%4ITN_%7<//Z\ZP'A"4%IM@7MHU#*:@YJS7$0]3
MN4V7QQD_Y;!CA$06U,A>^U,6;*AYBZ$ZN;>E+&;Z+P:2<]MF,_>*Z\7<!9'%
M54Q>H9)<%,\Y9)^X#Y*$!Q?O%\4.C**9F*Z7I70+(INM2 V,G_"L'5A+RXUK
M%'\9<"-&D>_-QZ&M$K,LKN8X_WQWR8D&3.";\I(14Y-T+T!I(K-U<1&18W)>
MD?@YZ?IJ>T'Q"D+Y%FJ@V<0+?Q]=(X4%6C0@YYL\#(R@"H(C_=6/%KSD]_OJ
M?'1(\.P@*LN3+X]6E>^7'6>^ _<; ^,!C.>?VYGL@54G<1P,6WPM^>5)K0Z%
M>;=C ,48X%+1PK6OU>.Y=;MXZ:]MDQ8,;UV+70';<DX0-[)!W>\=KQLC&?$Q
M)6TS!3E+T44LLEV^+>KN95\8.PY^7_"X>_VPO$_"A&U<**&2Q$I&95K:-GWQ
MDW_&EH^90;#>=IXI==TBL*45@%^(8@#I.87B+^;$X_83\D#O"FHFDE'@Q*9U
M-2 KN >\J2K0X-FU/2/L4)%0)6O;VMW+!(B"= [8G_V4'?& 2U44H>O$^ 7!
MUH!9+OD@,E7JLHB&BN$L>\B]1:6RYTN$]#2WHDG[\*D[)7K+$YR(5K4!=74Z
M(3*]FX,8&+P7]^2_:RQ3XD$BQ7N1;8-2 (C@:O@'C\''DU5YOAPC*+L'"'\^
M&TC*_?HI"<[6SL3<%NO7A@M>HIUF+G2RZ+)MO[VC=E%JG5=^0?G8]JBW#UU>
M%Y<_QX(A:+-)8@QKO)/,!O 5V%F'ME%1_).-1(H6WL%PV53@*!UQHD<M^=&K
M A&HDDMR"S7.;$ @V;NY<&>:=9H75&_A/OG%YCWH 6_K.NN)) G1B=INM8+@
MMH*@FM^7=!];IWU ",WN:*_.OXW:]$<&D&BR^4,S"J(OJ-;O]\A,EOY0JN[8
MH;I?^7\5\+\"+BQGKC2Q\8YG+/$4T=5A[#MRCW2E%4Z,NBT*=+TP'6:K8\!*
MU^=DG(S^%)PYY+0LMNYVP[F)%KJ0 @N9/>9<4]K(P9Q=4#E>4!GK-_QO,93_
M-<+7_V3X$YF #W71#=9:2)A4UPC3(O\B*UN&1;P=MK/@T##SCA&Y8@PZD*&U
M0W4C;Y&)H&D5W9">07,*87IZCRPG4?FE]]5V?->^1@R,@-!==+N:&;+)<T8^
MN>4PWA9Q(&:$;6^8B* /2:'^NK9@DUK7D4;KQNE8,RI=J<D2KV1(=!I,QVZ"
M-R\3IL]2$V06BQ_4+C3[N $C;)>P;I,W"B:HH;G]3G)_$.+F,CY'K"*BB*3"
M.H@[EQFNVBZ<O)]-%%HH0$;-F+SUM]C)%&']86Z4U24IYM:=GJBKO#E?LD;*
MK'CR![.:U.025' ..)^+2BOP-90]4"\XE4ZUJ#GVA)\N@?A)^/PA6B@P9=E:
M)N">0^C8N@?NL9VK!?OUT102G*==TC\03(65J2%Z ,($T56GS_:LK#DF>=8V
M2%]\5@Y;+Z@TQ&;X[SY:T:P8L_='FQ36_NRE6\483/L%74VQD/U4"C-Q:.3K
M\B3.+5=2KFJFZ07U29--(XMB=)(ZBZ(/@/SG-9LK!58U-\]TA ^]7!WWYFHR
M^.##<7>^VVR.!>_T8KW8=4P2OUOAY6>#!8,G'[LOBRXU+%V3PF[IV1X>COH+
MIQ\.E-[YJ=T*V^@G>@**JIW>-:OKC)R9>9/J?7+%V_D!\@=+X6F)]O73YYRF
M$&>8<*"1C:'QJBI1,3)CXOE^ZJ\%2>9D7%S[5-7GS+(-:A=EG]+ _9TKU$U+
MW/:$GWH WY;F$=3<2IF+X@ -L,_8UA#4\?L%E3[CG7P2>8>PJJOK9-XZFXZU
M,2" 8AXNH4;[F8TR"%GTSCWM2+,9C*'5[I5+K6HY?B)ISGJT12:%X9D#7,SC
M:QUR3$]G/(2+QV/4^*2%&&EEK55UST[O54F%IKXW<-+RDY>0DW%10Z+')M,$
MW@TH2#0M>N4#J#VVLV>'$>\:F1SP>E2%?KA<2>-N9F0;5,>=-\$K0"(-+KZ^
MO4'Q1.?A[EZ5">'MP8\IW+J@<M"W4[XD[O\;1U>/#;?WTJ0Q>=O+H>LY[G7E
MQS/.B/[!U79>[4!$ #A$@SXX:O=M^H")@BW\UD1*\=,E(3T?2]L1@Z3L^Z)4
MXEW3S?Q"X-)V[BF."RH4=LF:YY<;EUFT!@PRA;!!+NO8'K(>!5!#.#5O!SV"
M&B!*O]/K14/Y80\X=#32\@I*!F'^LF8,CBQ8,'@L1!_>X<L<V[GESGU'_86G
MS6ZNV&)H)+:GI&@<N\?(3_]8U721EE&IF^#\8VB'6&X5_6SZ5W%)R_ ,F9E/
MO*A,"CM"?W3IE</JK]WS-% -(E)!^Q%R%3.! 5WI-S5GCZ9W^.B$%=_RY"H0
MX^<J.+G?=3WJ74Q2TLWX4C[=FPS^&<I@R@<NW:LV_AF6PBV:"C89-60-.=?Y
MU<NU?<9H$PX&#RX65RM"7P\NKY.,:FE#]Y/+F$"_25:?!,JU:C$4^@L!VP5W
M"KX9;DRU?9[V.I>_^R&67HUHHA&]>J30WPJK;-L4NRLUDA7;9IFC_V-#T2^K
MW&+U"FTC4#O1*L(DV0#NJ5NJPA4(V<;K@>_UG&2P1/S8=XD8- F('\R= BT+
M^US1#FIL+K5!=\R!+;$P7$#28*"CA<#UN'Y,$SFA3S7&DY Q17Z"/>LM+16C
M).$QZI@J+A2_Y<X-70'[&;'?<XJCQN02N^<WIGP9>R)(^-WB$68A[67&.;00
MH98!I$C#:49=Y,D2 VA_/#@[L@6/]QY1^L1MN;#BS12*?VE;RIO,$^ BZ:4N
M-=XY^?+0USX#JT1I%U]W'D9RR7:M0]P'PB=UKB$[K B,Z@(%KHJ4,:E4LK-Y
M?>Y>',@S_S+>0BNK8SJ[(MG$=!C=:2<=&!E%?M(0"7C3D"[*'7)P(T0_"7F7
M!&>I3.I>+ ,O!I;9%9A,#OD"L"</?L]PNN6D).%TIC8Q!N(;TBM;7\"# 4 K
M*Y5FW4:_J.:.7N":N-_S"2Y9N>PV[/+II_+JM[FH%1&E5;MV=J995F%8^:QX
M>X/AL>'6ZZDG/W\.%*L UY$[**&Y$/CJ&VVDM,ZG_ZX93RHJ\+A/RW@\<V2W
MS1>O[1F1RL99:[=YAYBII_=F[C)ZP)/4-4+[7?%*-CP1E[^/H(0 &^/UZ2T$
M!K;PPKJE?#GL%0:CT5%,+(;AXP75I/1C(%]URQK!4[5I$5Y+LF!EX&#;G&6]
M[M-E.$8-2%FWS,A)\GZ0;(:=@3 )+8B3V@^H[W2G2(X6QBF'W%TPAT>!9KT9
M[C[K@FA)$9"GD:@,@V&XN S*.-)CH&4HILZ'K]O6J>RA7P,EK5>*+RM?@*VF
M[LL5Z3?_LE23YMNEZO_;(<E__X=7I^G?\6._N/G]LY8:IOKCH**%<?<,7VNA
M87?FH)I6%(\V92FI%"1)/!H;'P38JE3\QU+^>;J$&#"!'RI(%2/PH_=9N_++
M7SV8X63"3720NN7O1KC$N#P:(A06-:@N3YHI+=_,NGM;XB9KI3J*Z^0V[HI
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M[<P[.!A)VV=+,?4.6@A#Q0L'L[FX7,+#'OP#R_>[51BM:%EVLO)(2)DNR *
MP$WY-_>D0\:GP_&?XGI81=SO#Z%034WJ_&"><<"ORKMJYF8]<=J("ZJ;!:J'
M2DTB?]S009',T"(!M]4;N<%8Z(&@@.JB8O<PVD1@=<:3<6NK8QX<$1X9T8 ,
MIA):O_\:1_-%WL01O3J94(LM%0P4J8UO*_E/;-S^]XA-</7&@]D4A9^>_*F7
MVF060(]E_[<8=QAT#:JI9!:&N:NN_ NV\J@&CM]Y0G7I!^'W>:9_>[C"-.1K
MA^BO/U_ P[.O92_]->S*!Q_*C7\QWS6+-U11U7\FQ'Z#7?9^\O<P-L\ JCDV
MKG78O\;_Z--9PO8FX[]8H+\3]_'B):7<;Z 8-#*-73@R,O$A6!U@MT='=;W:
MN9YEH:(RL<V>WM3.1<3(TT?S@!]@I=C3S?SC=#"W[W"U9L6EF-J-)[Y<G>#O
MNSD%ZYZM6BA7/.4Y 8&NATC+!9RB=83\4T<#^91<,,\GPW=+1EQ9>>[?9E0:
MQ&065^0OF$SQ"Q6?\EB")^!'@?-AUF>FSK=]BAOIYRV-^]1SP"MS:0<)G#4B
M]&E:%U09[GN/MP)RZ'KS' =:ZYA=!].1L@9>ZF*B'4:$>LG!X</'R1,Q[$)[
MYOUVA2I.^'RB22([J53.4%VLFS#F<P85%ZYR4;%4W%],6!HX-LSUQMTHQ5?D
MG7;BIN(5KPJ]&K220X/;TK#MO_QEW'/M9H*3WPMAMAE7G[+ %8U?)96KJAT0
MQGQ11>+&R2F]HM -;6U[V6TK;]?O;O=2BTG== =* &YDL)?20J8,MU>\(K*T
M;AVV&JZG(%(D_6FFQ4IKJ/QQ,MY:@Y['%R &-&C&E&D/CK^H>M/IP!S1GUP!
M1#+:1C@$3^@Q!=>!U1;L ?"6YPW4#KG3@:3.65Q=5PX<$U955ZHY)!AT*T#/
M5ZH*['CVL&#+O=-1T8#=I0[4@D<'E?D0_5PL J4&[@X< U@3$FAY4[+NVI[Q
M6'S6L6&.^6#J&:$Q7EM4<\#Q:'N7!RT2:E&\Q&5IPJ-AD(">0S>H]+M?4%$#
MUL6&G0$W=\$(^Y1P"8A]F$ZC/X7R4QFYH[5BQ<.%G^R-&\P8CMAIM'LT![6*
MS4Q(%A97UN3/B3_B^ CC<JMKJ84B!,_I%K>8,5*P#NO\DF%AHT2@+U!?HZ6V
M1XLW!+2L0%, 3A*MW=&<C$2>!".)Z6Y[Z4*,R3T'SSL&M!=$7.$2MDX8Q/YJ
MG_V.^WSE8AT[04?YC?'5%E2KYX,4-]"I?D^=U6)5Q=JORB\=#0R%C\^-'$PZ
M7F4NS00D>7OZ6%0=_=16XZ=OB]*U$>^&6G3.+LFR^NR94NK:A0LGSA,4?Q^)
M](LSMK-%"KK%.%<!04ZH5+7ZZ %?41QM.=-LCY)OX$U;+Q>H6[V\2U8;_M J
MU_Z; TZ>.@.'[$NT'OFTO\(3[1LZR3Y9UE\0/GO*)26IH)PDZ^I6/$O#9FV'
MEKS=@?4JC)-B'?5UF=_98ZR0D#!.X]%UGOW7G:@J9N7F@&\Z+86ORR2&OHQC
M5_2SM6LGLE$XX"9(K]2OXX]91TB!65KIVPA6V23O$7I;BAHWK'SH**Y<?C^V
M_L7'K?JF/1GWA-3B/A5)/:(20,@\B_K[B^[-<Q,^DK$3'[)/DU(,4>RL0:W-
MY%^)54Z[W5#:,.!ME)?2MAG ;J!K]B[CR*EEL%<"Q<U:]</0$+A22CM>E:]$
M5WN 7LJ*<W*7CRH0LW/GU656-M)()1\S@%P8N3/Y.J]&QP'XEA;DO:S2OPR%
MUBKD:6#(<@C[#CRQZX(*-#8M%A^P+_OKVB!XB"7L1E2[QJ<?:CU]Q'%489KH
M!&#_@HJ+]#R]"21F(UO;P@<_@>#']AQ;1RW*:?PNJ$PA.09'D2:WDF9,!$S>
M-2J;_J4JL?2C^!KM9#!I14WI"$J%C2^O3/*B5.1DFIBJE8EH'YPK!@"V@:7+
M#+S0B(&NP7(K$X$!3.VT\F=$6E/[4LFAC4C70.TFKY-?O1ZQD.Z/A#<%,6V-
M5PJJ!T>ABK)IG+AV:GXF6!T%V:W?9,1EJ+J(:)L#[W]5V3I1G\DJ*C&Y(1WR
MO'W,->!6G)<1EQ__N^/.)*!3<7#"]V9$D[31H,YDA-#1D#>E#FBM?%>RE\]A
M2[R?T\@?8M,8(*06F6U)L*PA$GB1K U]!49Y[7S<5T(>K-?'4N>.=>O=DG_R
M>D;TH4U6D7?&6"5/S8'<_9P4XVBWLUN#DEF_6?:'QSX.BY1E%?=05E'7G^O"
MR*?C7&""$JH3\OM+>3^P:GAP1WBF8'[YPN/N"8'F(-YG6OUFS3X=%7$.GG)\
M&V3BV=7&:(A$:IB)]6-=KEF*NET=AL"]5!MQ%K6^D!"YE^) +Q[07:,JDNSI
MUUZ,\8,]GGK%Y-9=+F6QZQ9 :A;_]$N4)KFU/8KP*4QXT"V1T=O286U^3?X0
M@H(=T=Q(S7-3!Z4UY7[*24)G=&0P#>;9<].+DQQ3NE3W3"&2,J/Z/+[N9.S>
MNDL<'M4@4;0:::_9% AR'J[K@:Y'0C,_MBZ)J%OT#,FBNP<DGL\GE&LOC9*G
MOON,'27=N%G1W T(>3!J4G,D I#N*1Y(L8T#^.VMCRV*R/DM*JNJY?N'"$EK
MF+$R;,MBH+XH;%M83*(#JP\X)N.XO"UC+<:(8+  %!#EMU4ZKOXT(>XIR\%Y
MXQE/:N>$A%JY; B0(5#;+?MG#3=S5.)Z#%EOH'-(=Q @^A2W:+A2.980CIA8
M@27D.\B7#),-XCA_(%1$"WY6=R7D <L6T+PP/P*J$+T3%_C.Q)N5)GM!NJ]4
MGS>D6=V5!"$3F")RN_SXXAMH18DCIO>D=U<2T!L3HVV(J66#]83CJK_4ZM"F
MH'&2(EM66_;L=#UM0 ";_@!IN%-[#\;C2Y264D RV7$G,WN8&D09U\"YQ46Z
M+# IC[6XZC!@*Z5Y,4U@@:^"R92^$[W+ZX^Q+3IV-M0)_0,>*?=?:JQ+5=&R
MI7?;+T_-?40;.1:KCKQ$QJGN3N"LUR,S\Z168FN4[W5;O:U!9%5VCKE(-S"3
MS$A*M_R8%JB9S*@C,3'9L9KD860IQ[K=B,) L6HP&\B\8R2K*7DY_*BN@WA_
MQ;_6#I C,B?X9&]=@\\9<E3$,7NM*^$.Q_SJ*T;5FN%SZIS#;IUC5&#SM:\>
M@=(]!E!HX/Q>I[R=K[MD#E2TO;ZSK"#XG"MAJNN0J7)=80S,MO4GW&8=/DP
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MO!%DPF:7'K>_QQXFQ[L%"E"O*1A.*6@;^]1="8;7! 7!\-^BHI>#?$9ZVSG
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MG$?4"R83HP_:XOHXOF7J2[#TV.M9E(P2S@1D D=*Y2S4 KMDZY/R\7#1>8(
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M)EVS1_=L_* 8-/$XGD3AR0H,R?0LS_PZD1V\%%1=P2($<0_FR LX]F*D=^X
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M<?5/I\'W#"0$VGYM+! EL&V_&:X):<OI19@D06+93<W^OM/*=@SA%B2K82W
M9S04T$#IF+0;FQ@*@EJ,-!J?)J92'B,^L(!8Q".9UJ/EE$UK7%0;4F#NVL'_
M]M+QK_#C3HAH]W,/1@]0<+5'%/Z0)S:_<U^Y,P;ZT5>"D(*W.XWZJ^&$QA2@
M]U@'0YW XQ?(?>UK@%2":(7QB*B!Z2:8H>V65VRS;!'-3?74%Y5N58^2^$1/
MF ;B@6Z,ET ZX-5BG8-<8,&C5J'/QIEEZ)VL-X>%_1A\:;ON@04>NUNF&[-;
MP;Y[K(GCLLF=<[<)>6/7-I*K>11J%W6.6A<*Y'A)/VQ%X_5LK%S?%<P;=X"[
M-@+03XJ;]5YN(Q=:DU[\;+J[=:N.P-C.KI!^F(3VEHH?E.O#R*H$6!#M1NZ=
M]]9X_OFLG"[A)_=LMYURLM7^V @4;JDZ/-65K<TQ3\NB/5 SDY5/@:"+BSMJ
M;%(C&P4*>BH=:9?"Y4V A(;]=%],_F(N@7DT/)5V]-CDTR:"M%6P<?;&[*Z:
MRDX6V.:@IU3P^6H0.Y-YJ%XCV))OL9^ ?QHF:)K)@*0,P@LSKHZ?#6<%]7DZ
MY@B.O ]:'%,?I_R>$,"UUL3+^%Y<M4Q:V5Z3U\Y.:W4K7/&Y%?T%5R73TWQ]
MK0.YZ'J!=Q^>Q!\*UOJ6VYQ?=R;E%FH/%U9E2(C-\8W?*F.C)-L^C1Q)KAT_
MMGA:?&B"3NXJ3E@' ORD8Z4S8FK$GN M"-HGN0>40UA@QTAFK6=N?EH.^]O>
MF<% YD/JE1>Q2JL/3./!>$# [&A$9*&KV[F# YA2-5"W,\N;* I([;US2DK8
MKXYOUXGFA"K]@.L]G]GLP=T05.W^F)= -1)[1FTC7,/#>9-_%LJ(":%T5%$O
MD91EZ3E2=7@*>7R[R/^2.M:!:XL!YNY<!G1>]+/NOJ//356TJT0FENU8EB0M
M-I/\LZ?H(5Y+YME&$O;]KH2X4]K='T9VA1EB6@>1@13' #E@V6XN2+;?8PGV
M*/^RR'WR*=3[89DN!W5 >T(GZH]!+ E#, 'U>;J%.U)[LMFQPWEOAOL,^.#Y
MJ?@8*($FENM#G7\MBH_INM:*5M QTTOR-GN_AW<:F[O"-M3=F#PAP ]^6=(M
M-XU>30#FEG^!JHP?C_*3! UB8>(9N1M.>\8W$3'I9ML2+J?; S&K]+CN'MIZ
M;LIO%9U6"2UW%Z9 8;JZIUPC$(WL+>I<!^KUJ[T)5KX*:W$E(JC>)E5S)T U
MSV5$UIQ?VOKC\OSGI#P?$WOA>O']M!0M4:1S D(M ];\P_13 C#XC4&D+S>N
MHAY^[C^ZY,5$!:"3+'[RTI3/L7<,'T_''P?T18JC]5<[!QY%&R_;XJ5CKH[2
M#=[]8GY"XKW+)_6C''OO;@<3YUHW>TEV,0/T-4!5VDT\YI 3V"KP)U5EDZL0
MRB0" H9ZY31DG(PT\;7T^+(EA]9<GU&X_NFVEM.?P,B?RROCF8M[SO9=O&CU
M @R.6,C<($3-VES1.G9/=E]R#Z:[O8J93FS@8C,9N<R[C0GA*V>JSIJ(5>;?
MH3<G%S.GE4)X9B*O_B 8-(?5:):SW4)MNLBST:X9)8F>Q]6E@SM<A6CK4DF#
M(:"O2XGE:!.[#F,BL*,XX77X+6;1]:HC,^W*K8_[%G@;BC<FWF=F9?^IY5TY
M/9!NIV3'+8)]:;J*882*B 3#-D6='IX%:6+H.@:^RN+5"@D*L_^40([-?1;\
M>9B)CUJGBLQ$J5DU:;R?R'N8&""$5\[UU\2Y4V@7TW!<XCZR+!%0E?H&L/P0
MF(X[1=3[^;/ANJ'*-?(,*^DP7"U6'2U0D7A;6-=#3F@- ZH\T^P3E>H/RV^7
MT0P*JB'$B>7M#IWL\H*(S_#Y33]D1*?+.JR$TJ75OA\XEJ6!Z_U^@*S8,4V=
M0=/#E&K/#FGF140(AG "6D;D;V;]CF@9IHB5I_*("%,:,+=LF7=S!D0W-#1<
M2NB?!=SEDY1M-;^TG%39^$2$R2 #"&*T]1?+/H_;H$N^Q<3A2 06S,+XS&ZN
M1M6Y5"2)Q\WT/ARDV(@6YR'OX+OE !X][:-=KDK:VJU(A5JF,&H6N3KT@PP\
MJ+Y[!<?HA!$$8+V8B7M1QEGK:&#M$)6#L.800*RZ(ZR6@[;PN+'IZ\6U-?SZ
ME')07 /0F2&:^?N[7FN'NNGYY$:(4RIM+OZNLKA6J^OI>T;C9O*)<&P7%X94
M).F[02X8X38O?^.5'?>H7"C)P*YF?MO=YGE<'G1W$!K$L^TX;"AL;?S5IA?D
MHLO&G_RU@N^(I?M&<]'>Z>]2U>0.U.10[3/L938*JZMOK&9F1/)C72K.*I@4
M5%)^>T+*=7Y+K79'\KC*(2?.3_EMC7M<I;25.G&J-43$FL*!4LJ<OX'.FCN=
MYD,9[C(8,VI::.Q)6+)6,(O> 0W?5LU"_W49;(#T54K[D+K_;^L"WO$RG>>L
M2M%>3[(/!SK1CH]5C52?<XN!SF(1[2<^:1!:#CF?N9OVP;L7)=KTC:2)^9:1
M8AX)V@ 9.>2CQ.4M*(,Z%T+/W\<]G]J2!/L/%ZP\)S,9:6> 6$5VO'O ,+D3
MM2#R3-HY. (E.<3^RN((M4;M*UK(<FH,!<YC-<;H<[YAOMR03W;I2AO6],#P
M#%89=I)1WT.;+#1SJ3HHVG?_/<YYK>#U;9@7R&M[)"4E2R=2@"TI>AM@JOF,
MS 3H!L+683IY+N+J@G'I1.C6E5T-R()!_M3P>4?/)>/E$W,$-Y/0E*R2IL.,
M8,#UBC=O4)&7\0.5];]6L@G=U06$8$P6<7&L:DE]7>[B)+$#(VUEDVJSH!I^
M/":$^^4N^,JS#O3IHB(H52Z\ !^$.2^A];QB1^LR\C13N_<?'Y52^$?U2*.B
M^^BC],=28N7 U1%P$!8Q>-??$=)RB^ &[W69E*@F6.E&Z7OQ^6E4C'G^=,=R
MD%BCX1%Q,ZP9)7)F?R<SJI6L:V!ZJS&'3B+5F"EY5SM0>U88J39(?8@$)E13
M 1XS@;I0T19A+<-&[SS-">,)%LB7+/\;B#H<H41_;4(I+KG3==V[^ZV]2YC1
M:)"%+==VR_M#_];;%D21\X9R-ZAV)G.>EJIVTWM[O*B4Y071CX@1/%=8_+;E
MBO14G]5XWCX58!\X46&Z9^Z241X(^W"U#U78 =+H1+W.*']KV<UT(^779I+X
M7CUI0_=H=G*UG0-U=(4WCFU5%/P,@-7P,;7>A<*= VWGD.4D?=<*SN%)TO[P
MI#G?;5%.#)9ARM,8M5]T@I5$Z//H63>B;:5]R7!-269)PGP_BP<175+Z])'6
M7GR/!3&!LRKS38=L9Z&6Z3OE1;3K^XLJ)O V%A=>4O3##[?.74@Z)$OIYS04
M.M5?EM"&6'5MVKU_DF2[/J%C1')&.P8Z>K/NZ7E'\HS'#\DZC=2;U': (O42
M<F3(1Z@=NZBZ&?%LJ&O,&K1M&CN$GUJ5\A=#-UA:%*9\+K=T( :L'GX25R73
M=<Q\#E-ZX\*!D__SJ[[_F_CE^^B_ %!+ P04    "  !H<E<(.#VL+FB P#!
M8 0 $0   &<Q,3$P-CEG-35A,#$N:G!G[+P'6-/9MC><F;&,.LH@((H4I:@$
M0VBA!T8A- D(28CT@22T4!-"+U=G4 $!Z=*5$B A("5@0&!$I0I(";V(]-"5
MWO(Q,V?.F3EGSOGN^]Y[GO>[W\OO"3S)_N^U?GNMO=?::V]XPNYC?P!\JZ>E
MJP7XX@O 5]-?30, [(4+^[<=W#S=B YN[I=D):4 BC=UX4>.  YP80QPB$,<
MXA"'.,0A#G&(0QSB$(<XQ"$.<8A#'.(0ASC$(0YQB/]A8(]IG77P]'17!H-=
MB9(V6#=;G"3&S07L8^,.EI:4 @-4U7W<;3!XG.<E6YR]HRM4>*FJ5OB2(Q8J
MC(; I>#N&C@'1QT_ @[A9X#$^.$Q2EAA=;63JC[*/B[N+CA/FTL^+LZN1&4?
MJ/ ORI4/WO_<#!:^]$L73SQ4^,;/#R[=@=^^I.%&P%V2EY0"8:2D9"XI*$E*
MR\O)*2I>OR0C)2,%EE( 2TN!9&24I>25(;*7_@)AM9,'OU4)6#ME8TVMO] =
M?((*_\4N;V]O26]923>"/5A:24D)+"4#EI$!'?0 $7U=/6U\0*Y$D5^5_*9'
M$T?$$!S=/1W=7"_]_-G&UHWD"146/GGI=_B5R/UW1']PX,&# P?*@O],"(OY
MJXP[B>#\R]"P&##.&>>"<_4D'LA)_ZG<@4Z??\KF\T_I#MS\YU*_3?(_$8+#
M_[68B\N?2A(]85Z>_UJ2B/1UQX&-<40W$@&#@WD=6"WRYZJ,<?_$OW^NZJ#[
MGRIR_^U/G/_$?;\]_M4=:G_3H'K@6>7;!#<L"8,CJ-T@NKL1<9*W#]:9G1OA
MDJ0!#'E)1D[R8,6J@O_0\7<*L!CE@[XN-IYJCBXV]C@PSIUHIPK^6^L?N7R4
MC;7A-IZ>!SJD90Z"0!8D)27]J_;?/?J=S,$\*6L0<#:>.,V#'S5I)2DID)3T
MP0LI!5&6DCIXF:F"_Z[3WXG#W;".=KZ_/#F(,WF0E!Q(6A$I):T,45"64Y X
MT",K]:N.W_7\LR&X$9!N;LY_\=*EVYZ^E_0]L9*_H_]+A[_G/\@'6!M/F__4
M"'[?]X]ZX'!E33<,Z><0TM54^S7;8-TPCMB_S;ZRG+R=$LY6R18$P4AA07+R
M<EB0C9V-#4A!&B*'4Y"34[*%8'XA^J.R?R#2=25ZVKAB< ?/#AHD'0](E!2D
MI:05;7$@K!36%F2'D5,"*<G:04!*BE@%68@=Y""/2?VF^G?B_Z#:D.!XD&=M
MG']'3R(=Z,?(2\O@;!3D00?*I$%R6)P"2!$BCP')V=DHVLG8V6'L,+*_Z?\3
M'?_ H^-(/)@/7[4_1,LOZ0^!\_ACZV\/G!U_28?N-@0B[N>P@PK_%G?"_R#P
ML\POF4#9!O-S(E7#N+EZX0B>.*PJ^ _M_USP@,?F8*_ $8AJ=@0WETLV[N[.
MCAB;GZ5^CH=+GFY_:/)RQ?XEI/\ZW[]1_4[3/Q@&_M6R?X/%6!S!T>M_S]Z_
M.NO2/UC^)V;^[(E?DXN3.\[^_ZS11)O_%9,=_S&.,%+RMO(X>060#-96%J2(
ME9,#V=A <"!I&QDI:8PM1%8:HO";?L<_BZ._Y_!VP+G^-:T<Y$7I@YPBJRPE
M_5M:^5VO?ZZ$Z&;GZ6U#P-VP/P@GM5\KEK_]WXR,C*34I6MH1U>LFS=1_#>5
M?Y3YY[HQ#C:N]CBL&O@WP=\:_B=-&TX)*XN5EY('V6 5Y4"*-G*V(%N<# 0$
MD5?$V4KC9!2E(++_^]/VM]U ZG#:_EN3ZM_RQO]%^?1_D-'_Y<"$R$*P2K*R
M4J"#I H!V<C*28-LI.6E00HX!25%>5LY#$;Q,##_OS=M=A"(+ :+LP')V!R4
MJ[:R!]N@[<^%JZV\@JRBK,U!N:> _>^8-H7#:?NW%:G_LE3[]1SX_X]\^C_(
MZ/]R8/[GSGF'@?EWK7\\5/YV4/W'0^AO)_E?UZ;6SZOK/S?9JK]<%OU74NG?
MB?^9=NS?#M0_:\?^+^RO?R?^9]K=_DM'_W^JXQ_=_COO_N'^Z:_W)/HX>QN,
MK^YMI(:FHSV.Z*D&4]22AFAHR<IH:4A+*]Z0OB&C<%->X8:F!D1>3A-R\X8J
M^%\(_RF%AINS&P'NAL6I2?]>^&_-?RJEJZ%QF^!FY^B, __URA;\=W>VOUX(
M@_]R(ZQV\L#JWVZC_VR5__?CD.20Y)#DD.20Y)#DD.20Y)#DD.20Y)#DD.20
MY)#DD.20Y)#DD.20Y)#DD.20Y)#DD.20Y)#DD.20Y)#DD.20Y)#DD.20Y)#D
MD.20Y)#DD.20Y)#DD.20Y)#DD.2_F>3DW[[?!>>*A0I["ZNKL0<!&H!C1XX>
M.WKDV+&CQXX?/_;UR6]/GCQQXB3W&8YOON7E/G^>E_O<.3X!,2&^BR+\Y\Y=
MNGY)Y,I5<:#X!2&0%.B:E-@U\6OLGP"GOCX1?]SABR\X >PW  ' %X OO_SJ
MBR_^]MTSQXX?.?KE5U]_<>+@L<.W@"^^^NJK+[\Z<N3XUZ>_/@[@ GQQ\.$H
MY[&SEX]+<PG?^)K;R(9'QB/ZG,C-N\^*.WB-49ZQ<:_&1&7EY!60)K8$8DGI
MLM@5"(9T[X?.\QJ:B!]CZJY>4X1A,U>T7N.RRKH^:MO%9X^S!P!?_SP$=<":
MSO^Y+]TYQ/^-D%KLK.13J'[2WCZ/> 5F%>;J#M\?_!RU-\@&?!9"4 9RU(4'
MH];<V(!WZB1+HYU![T^_OG<QRLAWW8>S 5N1+JPVBIN=>7!L\+ZM?79U-CB!
M87KZ8WJHHT?[78-)[Q,_+K(!H;-MZ?@YDPIZ>6%?_#>O$Q1$WVD53N M7F@2
M5J9N6OU;3#MV=&D_*GC73WRK8&GQ0> #%U5C9+>VX9=VIOR/;#%**(O+8FYP
M$OY)% Y\B@U 7-W7"-_VH#Y),E, ]Q^IW3J-"TJJ-1LH+"PWF3= M>8&<7VF
MWF;2O7$\/)14"72(!MAP!+]*[Z^X=3TBT@O2VO(D:GL(?-)_AYP\\H-Y7YK[
M4_\NY\((3**M>G-H&]_D^+M;__%O,C/L.!O0D)F1O+0_X]WGZGF5;^KM;E#&
MWKAAA[G]!G=PQEI^S/<C(#GO,"5Q5\[KSW52++H)%>*I&[ M08WU^[.:RKHM
MOL^[&'%WT.]ZLF-\,ZYPO9M$&LP8P[TFVHORW7; +#;@5;6ED8;)!(DK7]1/
M >269LUG+]&.M>)P_G?8!/CFU.C&5VS >(=AJWVPI\J\@AGOSE9QL% N&^#3
MM6K2O_?VG%HP3?^Q9B75P65#$VT^\L9/9Z;W9-+\JO6,NIJ3C1D^POG,^.NT
M!<TM88K NG+%;:O,/$P\Y84=8HRA;K-]2P/9W&S7>DZ^"IJHENOS[[#A8&)V
M[K(!*S.Y4Z6UE0+K%VDG]G;[:J.ZV("7CML2SOMCX9_WZ3(WHMQ#K^3X\R?!
M&N;4%4F(LU"TI^T5KA$<&^!27Z@M@0U!U#X<[0EZ-'-!X,H3,I&):I[>8 -T
M=;_^]P_:\F#0I_Y\T-970_0VP&1UTZVWE.&/3M2LV%T[Z_4A)[)^#;_W"E]0
M^.H6CQQ=1DFJ*F._,T;JWS'6_]=%\EIH>L\)>P_<797BO*U60E\T*5?02M+?
MKN;J6E"'XJ]LI*0%;&VOG04&>0-3:<@V6M5K@S<MT6:[ 24/9D&4B&L.25_Y
M0U!!:TT)OZ/]BEQ"!BKK4IP$RL\G%_F-*VH"J^&]:0+V2<LRU>WI"DI1^/R<
M.J"DRH*4BV 'GS+%I)S"L(59+>0D!:IW7)5WS7*D-NP)68IF.'.XD0-OQ[^2
MO1H5@$_8=<<75MX;=HJP-I?-<@HX/^UGWZ&F?5HAW\4O,HE^+G18S@!& -9/
MN8?3_7/?'LOI]EI0TN\OC+T.]U,RO:_4/SA:$O!^L:O7Q\UKAIK/2Y*C:6O-
M W%*JU:!IQ\?C%M1V82^PQ/0U_3 KZJCWZ&3,@YL.,FXP. KG#1"EP2&!998
MYBUYK9L,9IN*IU,B"'3S9DG>$-G_^,WN,T4^46]U-GR9'H\$GO[<X)YLHL$U
M$>U>3T;IK)6:FBTF^M)6N:['OKH: KSNZMI+9.6'S.L"CKBR 06T<V8S>50@
M_T"^&!9D?W\21HQM3M)\59L3;W>W!"@,G*X8\#I@>OUR:-9YO3D\I X6F9!6
M->$'L?QQAROFJAV+'/,2+FJR\V,,-+)OPLSW8LCN#%Q\"KLBKY-XG2"<.2[0
M]M,7]:87N0VCY^[3>5!!6I6W%K[Q)$$,X@-.8F'Q@[S-X74>K)N)M.0+DF=O
M[TF 7]9O:$WM9+]4DDWW&G^?@K*:<70!,># \NA&IO8\:FSXQ1+K)@CJT%%A
MWMY1YGU!2(W'O:PDUW67ZFX(YM4SAUU]V:M3_#:-H45EU!7E]I&/Q7?'^25$
MQ"<T;,;%"%,%:2:4L4%TR'2E^,O?5L[XT"-,ZF)CDK'T,3H=-9)-[WA7@M+J
MJ5ZX,_3$:3R5@F&>^.Y?+ODO[OKO?_AE3RM<6DP,O#]]\^KN[Y;\X-Y;WI^7
M_ \M@EW#!KF%V8EPTYSAVA/RFT.](N.)J9(>4>"?/@>X- R\+!HPJWFW;5F9
M8M8.N85R3-*^PE.H:=FXN<?#^]'_X>\HC]7>MCC;BRNDC7M^JV8R*9.$1_GN
M1,FRPM&WMVD^Z(X<U7/7A"8"07H_;13//*R*MF!LAT=^S7N[TAJ>RUHP&7"<
MLZONS7XXA=3O+7UC-SRT8*!DC9"WMH<;@2@))8.G+*^_ET&+S)U_&$D0+E1<
M:+*TDFLC=WY6HG<U?9F[S\I5HZ2'?Y(:Z^&=06 5E.D[]@=EQMO9A+O,RG7:
MU0(:Q=R/0&E>*/S$X/3Q"N0QO&V]6NK9#@=>\YR/!0XZ4JZ$Z6;#%RV@,Y%(
MS697Z\3CB9ZTCRO4RB3;"B?QH9Y.BTM.)2<$'H@,#64NHF#ZPH(C%48:;EEA
M"4DOPN0&NL<KIF0.G' 2;+IF7/Z9VJ7CH-5E:+'J+QAO5/TD1D')ZN%"XY.!
M.H^;90-7WM.]FY-SHI?T%[W#0AE</S:T<G]^@*;2RTL]8^AE';=E\6P IT26
M-5#2!PU^\\"SI:!BX9NWV60SIS"<4Z9_%S8:(=F\[B=8.;-?]F+NEHHD3X=Q
MB;C(R-N02%>4(&V^T/JNS6^S<D2=LDV&BF=)HIKGD:(<GM=H:&&&FB)R,]GJ
MX3#B=I^E5XQVC=_]!HD.(IV25XOBC3-L,_UY;7WU*$*[?@I($8E&B ]]$BH3
MVS">#6?61YZ(!E4H"7WC9FI1I)6I$/<Z]E3[3R_V4@J6C1V<G-8"2E'H&]]T
MUMB+)'KQEHRKU<H,2EVIZH01(^\N>K]L;.?,KWA$G-N*:P>"'>PM%RJ#3J7=
M-YR/S\<:X">0=JTQP$).1&JF7[Q0J?E4+U2SJ-*:'/^I/.**L[-?@<.4[D4C
M(X$,S<UTAJ:FOK#PU<:#<7ZZ6F;"8%A"/,T\.N7Y^/R2/A!>,:+\ S),O6W\
M \ZTU-Z4H,I%),QELO"C:)1FTY0N]>+% &UA\'DG22DJRVJ8I]CJ.I^KF?E.
M/%,EZ5'K1_='FE9!W<:OCA)[(W!JCSJ"/M\:VV3&*$=3UAE]:*TU?1O$J80-
MU7RG I9 >QW#Z%V#C/>5;A*B0Y5:4<X&A%V\!1DT'2&U9AF,3#M+T;#(M5-P
ME8Y!42(Q! VT/[4,&GB11J%_PW?EPC2.TBN21[T2NG/59%^/FOA $F/EL;(9
M[U;&J^M0IH$I>HZRP#VH,[4+1&E83!!JW<X[!>@&EPI4!J)SJ2D^!04!G-V;
M#J$RA9PB3KEGFAXP)>_"8:*)("X(GBD_R>1Q=@-2"N>[+;R N%ZSL,^GSZ0S
MNH41);1X05&WX(>4&@N)^.8GKQ,?!7#XS)K#0#%-AAHW(Y<QPR%>"H1)5!LG
M%#GXEZ3^)=D(\=$7/R#)!N3)H586Z<V1%4CIN)E2G4F"4BNAD)/_R79UDW=)
M?+K03WU%7"VJ:UV;Q= N)<$GNHKU"+50EM6'7_2@ZH!%SWZX1<K)I^7EA+:9
M/D7B.\Q_A%F-YK4=*X]<TS8UV7807(LO)/Y<.^<2L7^>W'Y7>U3]7# )=!-K
M8@J!>1[C-]<;AX?(1H2DG=#7?K64P5/"FN7S]FYOJM07^"V9K<B)!9=]V.A6
MQ.DE4VLWCQKE)>+RR!/KTV'AH^IGU;E=(E!&OH1) G9@@8YNGGA605=%"U<1
M.[Q6FC\]S*U1UGV&>9_LT3,%M9K6WR+6^OE&U[PP'(G]C]\-38@G[T73L;ES
MM'#=F:JXQEZ015PL2#V>?[C5;9*02D@+P_=C# ,5@FN=6DK8 #LU'\HS'<O[
M4YJ)7D:(Z97+U1HLDZQRDLPL3"=.D!]%EVZH$4,-] N&ION/G0ICS464C#LF
MS>D7M]]L2@^-MVQK=XNV1SCB_6J44UL_2G!]BA7*>YP<:%\?5<,&?)NQ-QAU
MSK-C="_%D=G\,)20/;W_23"!M8%VV;X2:>;S@9H\+B&J8\D/BKE2G3=:- 5K
M2%+7O>V955A!3:@A/ZMZ"U^$=$&;'[]ZD"DB.+&XR*L(M8'+.HEGIJMFB=I"
M94=/)EVJ-F"!KD22\6;]=E0"9":Z6# %A5(/2%WV'<Q-"ZR\S:)59J:E3ZTS
M(O2<G-4)#'G*HI_'T!J3/ TGY>B%:>/"*$]0^BOKXLE?W/1'SN7>*5LM/\\7
MF5!S3"^LH/E*?VSE=!1U6:62%_\ MMI#7C.J7J(DQ8<]LAP=-.7SL@@($H/D
MD'!NM[>KE]#9H=2CW\3-ZUPH;>ZEQJH6J9&@TGK=5B5,B#^(QK5:UOQRM?ZU
MU\N2:1/6FWS,D]5^H AA9 @S 1?_Z/QMN;P]WA\[CZK#^7-'E7&@$K6--> N
M!R66,I1O^DV4K81%M\56M#\P9B2*="S*W#',M\-2 'D]4KQC <^)71XH-"%/
M?II$IB/;!GQ>:F?%,QH28]^8[=#\(K,0.]U2"*WHUQ\^FI%@8VUL@&(5R=NT
MQS55;- 0H4_G,F!YBRX+9\KB/]>I?'R("N2=<ZD/VUI,;,PDJ0X*1PU_^"R2
MNKJ4Z#4QNO:Z8 ,?N!97GNPS"(<KCS&YY^+A>2^!*AG&;3,5)M<@I+"8!!TG
M<\_01]BY,4@Q=;CJ8D#SBP\9<^9=9?L)M,KB2/^G6D (;8B:2*\NR>!J\$QS
MKKE-^A(?CY2;O<7].1-RR7('3;AZ<BGY7*)Y)</T7-I=SS7EK<ZK#*=+S:Z6
M_?-+S[M6A6@H2?\%WL;DJ1)Q>QCYP:>2(4+A5GX62\&\R'-@+()\[YSYQP P
M,B$M0-^&9S0^*I+CQFI+OM>>ATNDDR+%% QD \[*TZ6KS=)2:[_\">*7O@'/
M+4!5Z+WQ?Y83@25B--&4@&B4[$9ZX&R19<)"-U\+J5[,A7^-Z%]2SHV/D:<O
MPEE%2W5>4)%;1@+(;Y)Y19ZL9\6>2I^->;2>P *UZ,%.US!/64L,\@]FAU@-
M 1O#DF & 7DPY=,]^:FCSXH\7$T:1"/,'!!S$BF1J&&&M087S?(FTR1"^RB6
M\_W>N:8L3X<9BQ(<7]C\YR@8Z$S\6F%O@;BXH]T]6@5.4Q=U&6\[- V\HLHZ
M&#US.R@%-4NIPME6"U-".RC%@^A3G^O2+U0:-W6E4UN.TLRF.GJ@Q9O4VON3
M2@OITQ02C(K$NYQPV3YY"XLPU/YJ=,E\("41GW@>-L[X[HXR+6^;F"]:;G5!
M0TQ%2"1[PP>UB":T\5B,R'2]K\R$(FCSIX.2 TO.&VM-2A@M>!GQJJ-X-YJV
M]81@),3M&9 I3^1NL\)/"P6M<L#)=U%.&\38+K4'SVD*7[O&<3*[1#JO3E_L
MX/1!&1H^GZNQ="SHJ4QF-0!A1_ BT2^&\D+;.%$RN7%^B;TI+1 DN*Q+*Z'9
M5ZC8COQ9PJ?AVJYXL&=BWOHPT39D=58.Y0[C IXUH3^<Y4FR?!AI)1-FR#3B
M K[D*2^=NY+6:5RI$@)MLX=PHH<S,3L,!'-V6;7?<.$T1=SM#.5^<NRK.^4V
MW=34:?5:T82V6A;4B)A%-WZKV= J>WXR)LTLQ6+"S=-O?PO*@7"L5$X^!8%"
M"&]8]UV'BH%47P(%HRZFT;S?RP:LQE,WWXS./W\)S5!_E9.RF:V>KV_%6#LV
MG4E3$TNX-HR<$DDNU2RR#9+F8]3E9N9/&40[4<*"R!6W>[1K\BUO4_J2XC[3
M^\?5><'Y"Y8BON8+-*93@^Q9":FI!2M.WG+T1TV_S1<=G&P G^$&@=NZN*RC
M:W21T/@"XU("G SBDDHE915Q]I$3VG-G<\VF1)*NQW//S"02.<WI1EN[A3Z*
M.RHDKW'*W!PHL7%L1639]&S7:[K,PE8S-?'#@V?_<52L=[^@5+L+!G..6'HA
M0U;G; \5XJN?&5KD)4@&%<V*0KE9$,G2KCBJ)*9H4&2BQ:P>*$KI;DA"*[ZR
M17?GB!V%ZV4RGM?/2G4W%W*BHUXL!]^1;')G6=!/8P9& ^(;(UUY4P/:=1PB
MG^5<B>_JAI/S4"[<^JAE0JHTU)M7@+\&*LIE@WB#L0[9(AN\QTLFF)G'/6\R
M+G&];](\7-B05!WA9N1VNL2AA8DPHTI<<Q(22A1G%#,0JKG'H_VN>B6P <Q<
M"U9TOMQ:620!(I6J(L#8Y*W5/]_-*J^Q(E0<"V+ T?2LV.6;.9Q-&=YN%Z9W
MB'#>DIZ>U;8MQ@)L&_82.,X&F-2-SV*2-F5-NOU1(VO ,=Z)!Q&DBDWC@],*
M^OB.?<T,&\ 8W&(#3+.9R97#9'$A(P_=]![I=I.Z".+S[N9E2FJZ$RNQ3)49
M[UG0B21*7PH(!=<:YUZK\AK']WY@[-:7_#" -T*\;^"!0<$/Z[-\<BR"RZTL
MSU9:KL%/+56$Y&C&:":(AE!&1?H9,N'I :-G>R6L"M8,!I_-8)VCN^'&54:J
MYP?6MTKW"0$<J@Y1#M16"N[6$'(IUX0BC$!,]C<'6*4G76=%.;HH00M];#*K
M: $K-8KJQ4G%HDBDZU*]_85Z7?3-_"5F$Z$[D9ZIIT+%D*Z[9Z6(>$DD+\SD
M_SC_I"X??TM"V'56L">WU=TWJM"20.+YB-=*#FF"RF;?LV=^%_;6WSK$A*+.
M6JYY8!"UGAKZ6$9  RZ;;2M"O*4_Y#Z:FL&E?H=$R; R-VG*G'4:?\$PE]S>
MY!1^C?*^<F=#TA]S;Z+K3(:NX['"S #))%$TN+(0<3+)D!9U+V[)!/IT)@DF
M(/@DJU!OO3$RFNG9>F== EW>.ZW4,'O)1-T1"K]Q@YLG;M7'%GP]QQJ%6O/%
M>UK?89W)'F;A68%OXSR--82%M0K\Z,WSVQ3@UJGY_.WQ[DVYP'0_X/F)Y,]R
M+@'G(T0CI(5%HD>P%F,",\A P;DU&*3>"83X<M.X<2NXV+&#ET56*^UB<J [
MD=HH@Z9G!*4H38(-<9@#M(,#?YR)90/J,MD [\NJZRZT^\R./@FGU'1^@WP_
M.B4EGF\#_'7-2YX,X\!,5ZXA9K)=DG#V/4UBX';*F4&Z&L=2:N*#FZ1WE:-Z
M,G[E(OC+$>&2/2ZVU/@]AO5(<M +DHL<5,+F:41;8;1@!/I-E)W95.;TN_!^
MY&//\+Q5LT]OO^F0L4/5]V@K0R-LKZ?S*0T:\;_T?A7:TY;=\'3AZ^?%;85!
M#17264ETB[S:N/#T;R0?KMEE6';NT/4),I-) G$1%P3KQW<G+3Z9BP:;LB@"
M$KC\%VB?*&=I-?CC3*41$VH5,/>G3X&] X(SE3U^<\[2\NWCT@O.JVQ 9-_#
MI#:A1\LU.=&X]8RN%IVHRH[A<YJ::!_N=PV%'DEG%B[D2^X9])9Y^VNZO_J^
MH@6H,_"B1VFHB6^)PY6GD5IG'[<[N<MTEI)]2S2+<!*F%'[[V=#"KQ_]I9A@
M?"Y:ZR'3GR*^<665V.%.\W[%IZ?,V>,$1QL,HEIC&KPU8U#^MOC+?6'=FLW5
M:-7=4V_Y#S;2YH HE1TMDOP*EORB'^3^^H-!;Y?^[#/4)V5)+XI*;<J'[Z#)
M).+J;@5#@&LBYD/9SKHV@\LM]+-^(*:W)[DHJ-P898.H#RVQ.5A^^NG^ZV&L
MP)&N(PDI^M*B9R52)')#T EZ3^JRJMQO!*9#,/,MIJHKNJ*Q/2TJ+Z]M7+'D
MLV=R?&_.@K+2Q.K(0>)1&M6+^(N)#+X,'@MN7NO*EC-)&3-X56.UR8O1V!B=
MZ&6JQ3LRCV!X.D+UV\!3"Q+0TZK<R9&G9]YHMHK)!&VA_*NAW/&C>T]!R@E=
MT%A#HR'C.4N^5UPL\<$QR-P@@<[*RWA26@EU>&DNMWTK,/!B#B7LPL7%YOFK
MB:F37!\-_^P2YJMCGQK40F;>H+R;U/2"?*HT61D^WKOA!%1#,/%@$8NW+%]%
ML@%?#@4G-;$!<5N;/)3@NZ[J[R;8@&;U+^F&RZ"6K=2,+8--Y4"J$__#%DNL
M[][>]7PVX+W!JG?I(KFZ6L@]X?XUKJHKIEF$E;C=J-#9Q>35SI9GL^<3MMW.
MY/-83&>W^TG$YT5NC]JH_'Y@QU.AI78!7N%?74@KPIFI1,5I?>Y7(XNOYNA[
M%%IR<].\U:JL=S@42=:[X.'2P5$6&S"BX^=MQ@8X/P_NCP[6=>]D XBP_7M!
M6<^[YM27U'9V;P9ON*I*DZ\Y%4+19LI*(K;MIG"^@C1&W=7,]/*]-A?Y81&"
MB^;7+-9#:83(E:!>BOW)I(71#[Y7M;IDH@I'%L[:7J.R,$[VBIJZG!QXIQ.N
MCQV.Q!HV-Q;"[W&<6+);-3"O>@2>F'Z_$F4@J7!RA%II'A<1D_/\W3OZPQ$%
M,%D-F#.X<+EK$/XQ1B7^K&;EW<7[ E25^!%! 3: JK^22KQW8[[WZ6+RS?H2
M2^MCT^5:(A>J^9/\)%'\W>/W6(#EZ;)JIVZ2I&@&L-'$I^M'@[/:Z8GW[N!F
MJJN_M\ARR.?T;5?!J*:\SUC.4 O>D-TO@_IK[_,!@^??[+E<__9V4$>@24%G
M80[=-$T.PG-"E0"UP0Q0'K96;^WFK,K,5-J[] Y#*DR&,IT3PUCGKZZDR?8-
M+VDQ6'DC7*HK/[2@3^&LPEFB<9YGWS3E3Z?+*\FL9T*LVIL-[PD],[%76O?C
MA1*F;_!1=M>?3;HYLWQZ5G2-HNISY*ZW!2HTFXZT=W//S[R,Q/#PS"+?3OH#
M\Z?X_$E0=71>?O+;Y124[H]#-84VLT).%UU4M@/ADQ^38FO499:KU'6/K<O2
M$4C0>J&)G8^UWE05@<R[4I/Q9,UQS-!Q0%%\^\?1$Y1044-_!JJYH$0PL<ST
MFMTLU?&LV++E[28>GKFUE_*?8YN'O\JZ'Y13@("@(NZVZ0-SQ45.V0\*#QH,
M. $GW,8G\O'\58DEFDN&[]R@40[?A^OMC//EJW94%WFAXW33(M6E27/4.<^I
MN$I+BQB58?%1&1&^L!ID^]<O!7UGT_-IK)J"%R4;PBU.83F/PGBEBZ'%U?R4
ML(*U3[GYG.MAL[!S,<X5_K>$PXY3<_Q-' 4GAX'"@:[J$A]-K1HV@ ,T$32/
M/LW3I9!H]K#;X.SYE1GS-'UR&!6>33J-EFVP'>/E'S.\L"-O] K=#2HMMH@@
M$[OB#8QUVI$[WW6\16?B5F+5+E[Q]T5.O_:8!F,IYX&D>,U8:=3R)MAV$G'J
MY7K_A\7GP?=92^.?@TH'E65WWA<'<_ZP-VAXAK2EOB/&4&=9[J\CAOR,I!W<
M!O>^]AD<4#G5@S6$KV;,/YLS2*S@XPL5&2-*RJZL\/MB!NY/YN&8MS2\*&'F
M2)*DRW7G4#X:#..-Z]/?8UGX:>N;D< WY[M[R721L*%'$9UZQ?0\:AN*=R($
MU1D9;?F195Z(C"1'=MRP%-:NQK:,6\XPG19>QYZ?OEJ4$!USNR39<Z@;;^1>
M^V5(YX!)BS:5XE*Q[:T5VP*Y9;5E>5&^T*.9XI>9<!IML.JB?Y;ZO2[_(Q2<
M[FK56'M<\+O95)<'E+)W4?<7'T3MZK2__ZJQIG?V((&9U3Z"[[><>MW_>9>O
MOS9,8SMND!2[*V#IL?)@;XY#:D>2#0CI9@,LT?L+AHX\M=;J+Q^R 1%7=Q@<
M,OX0QV8:W#\AHN2GN$>YIE<P3"-+H;!N@G"F]T3-=O73>:_]M!YM#?V9?FUM
ME*A.*=2]BG\)-1T3O:ZGC]<[4%KP QO0*=@#> ;-JBPF=I"DS K.ZA[UWQ6W
ME'@:J=.CX 8SE$<K::ZJ%$#EZ?C(= 33^GO=10G12-.S]O6C0 9MK/:ZGR F
MOPPYDY[786X3 Q;D:\:BI5&MGR4$,TQE60^J/34_HQS]+E!2HY(:%]HTZ\!I
M#1';B[5["5A#-H C@PW(7C\.5W^UF,(&E'Y@ VQ.7#J6B&8I"X!QZ>.$6*P^
M/IZ+:&21Q_3B(F0"M] _M)AM%+ETQ_&>5-;#QUX#/@V0WBQ;R?1-HO<3E ()
MFM T^?T9]_GMFJU;^P.)(_$OY-L+_)+,'AL:J9***Z_-#E:SJG)@KP/]TP-8
MP^,FHT7>)ZEK4'UY,ESXN_Z975YYL6A4'I4N.]NFLY_FE8<K\79LM(N)$#7D
M>DTV#>@SM*1&2OEI]%?H6>?;!+(6$'HS1+E;%XU:8X$]VRZ:>V*G"ZV*6&G*
M!W7\J_V.I63PHMU^< ^BVJ8SCN#D#_I(2?K\'=TE)NLUL>21W;OI#D78FFC"
MPL5,5^3C;HVSPOK=!&FFZU"&DTB4C+]A'\CKU!JWET^"O%Z3Q6YC47-6ET#W
M:E1IPZ92>3#/035/Z.(=D#"UE N*B"EL KY&U5S7*88L:**!0-\P[:?<YP1P
MUR.846%Z^>=04\''U='\PKEO=4T*9DQB2B7(^0GW$A3(C8.0.JW"76 N:>NB
M0:BGWJ@;[8?;0P*Z:#Y;/30"V5B%PZ8"EQ_F)^RV:PJJKD?W]N:RM/LO&C]Z
M%NGW$%48DDKG>?*Z../F3YV!P [EP5RO_/YOB%8"&L<?K=*"+@+IA5YFO9)0
MGU='N]/./B_/!R7@(](J>,D3K:\6!T,L&_.;IT-6P6VQGCW]ST"4 9WD^+/J
M;XC]LB/,%K/PM=H.Q34JO&2+;/8HI%.O^>'("W2@25;-L11-QS0![Q*93)^.
M6$:;4XE>#OYY>.1@V.<!O+;CCN#C;&KI3[0$75%\:BQC)B^:LDW9?E:^KKB_
M46C-.EAC3L8#+)K+Q^',1929GPG,DM^AF-&QI&G9:M </AO;!#V3EU<TMP="
MC07H3:-1E=Z0*J)P Y#A4:^$ K65>9Z!?K=:V-E*)N>9D-D WV142SR+\D+3
M.S/!6TN.I/6PH\FI(( CR=ZS><9BTNU:]VXV;%6<P_GE?&9#L%_XWM!]M]+T
M$+MG7<BUC=J3?L<8B_?DH>_\L<Y/FL>X(O?)'/3"Q HS&C>/IY&$6()W5CR6
M,,VYRYVX<_GJ;@>5#4 =WS&.=L/O'*V)3MB)^Y9!=W/^)+%!V8J?;Q>H1@[M
MB,R&F_795U\_LZT%_-%$]Z/*B4INV+CB;H[BSO>F>5,EVJ08B%E?"C<H:&V,
MLE$H/<C4J2W12JTP8>Y)&)VL++XH9UY!\34RG>U;$\RAQ8QB"O-#!#XV'(ET
MRB*&:%$R]W]X4ZF"4+<@ :_.\3V9""-GIA6A!D^"DQY9F3_RO56+]KRJW0/9
M,)/+#HM*$KH>_\G%)),8TIR;N?UX^/+[*N@T<K,;8M*< N&?-_T85JY=_<YB
MC-.(-YV7R6%L2HLK]\>!CGYU3MG,(>D('"WQO)[<K5\D47?YNQW389( 3Z;.
M-:=GN(C5%>5,L5">MN"(NJSRE?X:,F\)ZC2T0</"T:FO,)?4ILO#B5(=X;;*
M^PZ<=C$Y*+,D1:<R<69SD+\%'"I:T*SR+B6:VN[*8=MW3<BEO"09+=WF1)FD
MO)@,PADN(%^\U_WLS 8L=C_TYV8#.@9B]_BL>Z5G[T6M%Z,,TGHR_4K4-U:B
M#3&/ D^A5S:VU(>>K_9/63O!??U*>Y0[W/)T9BO>4")#(@UE!=)1,LK23SV]
M*F:9ZITK)9FKZ3*,BR93$@&+>)19K_N3AF>YS$".+J\&,7Z>\CQ7689MI,*0
M$*,(.0ZR"D2\IU>*=>*](BKD*2:O0778B,6$$R-3U.3"Z5-1HP&GW/_T.G_S
MX4/&FMJC2W]L-1IA)EQ8'# ^^4(X1NL]@JFSAN&?QUT8%:@IRC?Q%YV3-W.#
M>#DU73B+5KL"P?J;1CR*#O2]O+W8:^0_AR-!:A3>;<U1><*Y>+;@GU0>>8]Q
MZ.![*D_N\'/ M&4&+Z)XI$/TG[D;_U;1\LT1<^@_->&OA)V##O*5Z#R"68!/
M9%B==LW-<[&Z7VTH*%]Y+^N\Q3HF=IOCPFK[K@(B>  9O'!Y@:;-!GS7RP90
M/,8B9#+VGA^THX(I&D-E0XXLZS7._6S5T]]7R;=T)U.J*?,^K77 J][@-^OR
M*1U=%I(%-4ZZ@Z:WBWU<X.%G,Z_PO%0X<7!R"-N@AR8R:(;)'R"-4YETH\::
M/(;:#_6"O<I^>J?1<,N+_#.3H9^5&IFO49U%I 76'0$>)O?&8C3Z-M.DZRWZ
MFY4;W#(Z;_R3Z[486F0>1,A.&+6_U! YO)V&$KD@XFC.HW&.%-'\AB"!OEAE
MG]Z0ZR);GE5 ,K1WR_(85:-=)UJC?3)S"N[%KTGYORD1=?QY>P:NCS,F@O$_
MUA>5[D[E[1D))LX>WU3HLE['*>R4J3HR#9=?6>ZZ4O<F'E3-9ZQ"CJ_XL ']
M&BWI_;6K(>#MA\$#<67;7^P?1>\!BWIRG]3NTXW8 +XL-L#Q079@[N;LIP/W
M9>S=XYI'[[W.VQ^P9@/T_ *6>^G@38T'&7L:M2.-?K&&P3X>]FR 3_LZGR_X
MH/*XUK2\<?#YI8WK#O;@;%2^-.ZX/UL_UW]\Y^T/>R?41U6+E0<R]AZ1A%8N
MU/:K+LS'[BT/!S]ZM9U^1ZUW+H*?#5B#LP&!%^[.N^W-F00+!>\\:2G*"Q[9
M#BYT8R'J:]ZIC_&P 6\%]C_),BV]]C\YU3+A^PL-:=#'M34#;,"J#1O@8NB0
MSC%W?-.U<%]=80Y:G*5>?4IHY;SZ<-GR]($)=>:UW55[\[D,N8J];T<KMK]=
M*2ISV[0W7)U5[]?HV9-L^( ZH^(:NS<>);MC#J75OI>(O39002$'M]HHSDQX
M@_!9+NL])N47H=S?W,],Z\C<?.?E_G!"/Y>YF;B0/&CH6/%*5Z\U^NU%C&9S
MT6G]JT0Q^U"^Z>O%668O4.@KG$'V*9XNK*"<-1F?Q:*5:[,94&%IHXMQ$19Y
M#-NK2^$VGH%M8>(9&IYAHLM,'E70:,'*$IRSB>D7.,<8?#;-!IR5705\ M/9
M@#TQIWUIA9WK8 [[]F6\W;XX!POATF.X3"+M'/C [_4[M9;:,9)Z+XH-J$(,
MZ.6%QB,UM^(KK'W?K_SERC2XV&VCQ?V@6,K8WPI9ZV$#EK[\O'N3NM<5);<C
MQ@8$Q8_.73KPZ /Z=ZK^"^%[V\;CM56OMB>@7)U"R][P_;C1A1>?P";JK[N"
M(SN"BSD7X$?W9LWW&]B \O$&J#<;<$HF6.B7JHQ#GPWX75DF# 3C8#N RU"#
M]_.]\MO*)YM,%]V9\M[U$P1737QR?@(%B.//MEOK@)[6SIK[>/]==)/A+=G,
M:*=I)*:<8314FPI^\YD-T%I8&:A\)<8CDS5VOS*:\QT*.4D<_9R8J[]>11E8
MBD.YO*I.K)!)KL5;+]W,W:P*'I7K])<(_N'6Q^T]X=$-9TFU)T6[@U1\XIF-
M?!^KO<<K">7-)+V,1T&20NN/-X:%-E2"U>?$SU3C0V=)9S*ZY+<"Q%Z8^,?K
M;0DD-!4KP?1S.:SZC&UP[]ON=[D$GD8:&31V!:2@&B=7+8![N<G0? ?\-;?5
MZT54G!XC9L&D^")=X=D,&V ?M4QTWI> [T]F)^:9R8S2"@S++3YJUT]#AJH7
MMJD934C$V^W$W.W<W,J.LIYS3!.] OP@",*5K45OLY+*6^R[&=QK*58DF>R7
M,.99F,Z*H+BMJ\HO%$7AA:8M(Q:&E<9C$>_5BD>O;Z18/:FZ)08K-TV"']'E
M-]J43,"B"(7#S>FD,73W.E$PRE:)$A;."H^)F-O0=EB#<A6NQ^% =4+G3%$!
MNN?LH:;]C#K,J5D6,O#;IRR!(@0<6])NZOK4+%<;HI_0'6"*%W@@D?JV3E)-
M+5L[[UR:>2;$?Y'8KLQ4PA),0.=ZA)468=NM@^VKZ1'K7BRZ55EN8,U\5 (]
MBB"/Z^O6@CP:QQM!4;YB KX]1(?A\_%QLB)..93(-+,4GD&KR.DSL/%[ZEVG
MA2LLA8[ZDS&N9^(7/)O#6XQ\X-4U@C_*#A#:"?09BBCUA;;1\5!A2$3HQ:BW
M#'0L;MYC;\FB]J!B[LX9I:E7AS_8/K'?*:@TL\0&>&(SUG.\=\ZFC]IWN_6Y
M1V9>$"I1RB+6G"8 T\W6F_=[85$K>;7#C7=JFD<_U(3O'62O)>Y0?QP;X)]0
M-'XVN$J^IM%Z),1Z.T]]((ZY@PM^W].^=K!/55RH6=?:7\:K]Y;N=7VCCJ^0
M758X.955\;K>=WM19*0A>$AB/XX-H#T@X_.33+6A<DU/IB(Z&#+Y<4BDU:CC
MN$'9J@E5NU=^A8SJ1+3(&I_4N1R#KJ?92A(H\Y.-M;XBS_NWH_*4M1%P(_>\
M>S'*)U#7<.7"ND @@R?"\N%\T6@3TB'0C:*,#DI.*LS+R0THV*AT%'_2J_>H
MC:N-:;*'6XB<9GA>>>J:TW5N,-:,1H)=EV50)E P?\X^B\ <PP7'D/>D&4K&
MP$%P!G6^6'=D##N!XN6AZG?B$$U&8C>;B^618]&99![>#P]RR[P2,KN0XJ>O
M.T0-34M$MUE,UY(0027UO2YHNL R:B)GCW*0^T4/HC-XPTDS,$Q]9D%W/P(\
M]V2UDL%5F<D=3$_<5*%9;[]@ T;K88&1ZC-ZM>.?@ADVLSE$1&5F$.'YG*'>
MPC:KZWH'_;'E^8EH>_]LKZGB2$W7;@O[N-55U?:N*LGJSN216UYI9GWQ^]R$
M[I+AC[*85";*LM5"V#Y^ZP+4H\NL[BUU-+"(FEQCURU:0(U\@#\_)4VM92W4
M8>8_E :F5M:Z5^NN"FRU4Y**[I_'O?'(0@U^>H%'0!^O/O[S_VSX(Z0@1TM4
M6F,J!]5&3U)X;RXTQ=61E33JAHW>HT?26&'A:4>(#7IT+K63#S_V]?5%U@&!
ME.6\C[".H*S9'=!;^D#,?;[P2KWIDAK3]4K5^KPE0Q1JI\4P+_"[S@V5X=.6
MIUEA#IW1?)/8I(&%-@MP>YQH97CAMG&K?OU[DTY+42V(_&OC"(OQ>>L'LY>3
MO>"F/0*Z2VN@PA+'/+-^V_N>*UF>[PX.[D"72:,VT")YZ$.7W[&YL2Z13)*
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M<ECYJG7WV]VM2?\I8 B9;9U5P>$_/Y^C8X$O_DKH^P"2&3$/\!OGMZ:YZ.@
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M)+Z6;M-:?S?Q^77)(T!="NX&_O/RVT(<'> M\4'W?_A>_5^XXV'>\K\2S?R
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MZ*95@JL]+T/6('PW[,/-3$XIMK8Q&$RA4T)Q59&*-Y6G67[KX"_:G?ZXG-J
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MK5619QMM4>/5 2G @!",7*[&GQ_XWX9=*;4R1HP&-!<?_1F3'K69P#NP-W2
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M1X]XR5^<&C-T&T?3,,R,>O""@9OQ)L:7LXM9X56#B+MQ(VBU>F3OBDD)6P:
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M?+]/_G*P.W]"F=^7=3K1^_(A^/%:^TG#>4N0K "==:-%98458&1D606*?')
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M,#<0LFAQ8U>WP(0\C@:)!W?A22Y (6V)^!M!T5+!,_6P(3YD+O%*V>C%UKB
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M?,>#H(F:GOGT/^,#(JO@$9ZMG?<:)AS)Y@AVB501+>ISEO$AJZZ?4'!ZJR&
M6E:BFZ,/UF>N:/HN7'SG$UCL_2_^9GBU_J5U"3H;6]/?L6B2G;P6'!(E[>H+
MY(_W_?4W/HD)@R_'=URS$:1=AH+- 1\ X8T.G=:\U:NMUR^ZSC:-FF[G2N>\
MLALL=J%/ I"UL1)6;XP0P[7'O/J#<\^^CVJ=DRU2,CSQS,BOPJ54@N0\FR9#
M)> .V2%=7?L?.%QLU2O;-'3UQM'=A-$YX.39^E!O6<)')8@A2?,-<_><ZT:N
MZ#@K!*!&P@,;N/:T@^[,KB1:^E%+7$+_SZD%2C8R#1;[Y07M4A[<_Y;?9\:.
MY<Q#F,&J:+^$],)0(ARBDVY;^"R FLL617P5XWP5^WA9&K_6A!OX2ZL79.KM
M)YAA(#%)]/7W4'C@*%(F6X/":H*;+6.EN8\^=0 UHF+Y7;'C<NIAWB@4"DAU
M3PS)-#?KS5T@?I(Q+NN7'QHVSHRJJ84IZ&O!C:1$ST>@_&%MWV_Z *.YY"_+
M.NP"%-!H NIL<*2; %+=EZZ!(4MNK"X>_>)N[E(:4^EK9%M#%WS^]NS]F35I
M;H^I;N1YSG:*M_8RW./7!)0+?I*9U2_GMM,I4]0'6D^O;C?)#YPDNIOA5U5S
MC<8W3.$LV?U)F06KM9E:DB\]8>.=^G,Z*E#5!\]\Y(LN2$.U\EKHA*TR!-_Z
M?MWNRY[S;Y9G:WA%P&N%%:5@8=-2SJ,K^V]F#'@<A^IPX5*6,6TCRT&1DJ7$
MQ] 6;G-#':^JJGU4TS%6#O97=XMWD;D [[6L0D3,J@Z[SDYXA(E,=_<4IQ+U
M!R'1E.1-3(T"#/D^;]7@L##&"+ _&!7K< \ONFC)5HRE).%I^6Z^,1C?N=V6
MEW9PE]Z*89(.QB)UX>8\(=XLU&&*Q@(![H.7;UN?E]]:GAQ<5=Z7<67 >B5%
MI8ZTI,*BO,W2@L_VQ=X*[T:)WYC>>]0/0$]P $NH&U:)-/@8^^/J#?=/78"Y
MI/:K^0)/N9#\9NU;]"HZFC1;XU9M#X>^:__.@>6;J:H8DFAIL9Q/S6%>?)DF
MGF(+<PNNX3=M&P)XU#1::^[5-GULL;KZ*9>^]8I1)0C6(,_^XJ9BK7Z,[,RB
M2NI?TV.Y^6T'+M/5/41D1<#<O-K2<&"O.7P3-7%<:6;]<Z'$(VS,YR]F]<T.
M?>L_9$,05D)B/RPW-%]"B_LX5PARN?#ITT(F8>5 L?O 2/: GAOZ4^D(6ECL
M3(U43OEYI--LK-YL:H,-IR51"<; J'7NP#I#_3;@_._C?5V'@#C(+Z)99;C<
MST2).:!^%]?DIQG_TR7';9;8M$8^?!@Y,JA(B-.1+IS9@\/=/AZ)&]5.0Z-:
M9O+6LW?T#/9)F.WTP:50D^_(/,U1Z%<QY6\PD 4G*.[F:/YR>0F=-S'=2D_P
M",LBS5>B5%40YLT#X_Y7D28G%D;X17??MJ;9L,S Q8FD<6OY$W\@,&RPK^9_
MJ/)_."%'^^&TRP"=)0+<<F&X&77@"0UW^%=S;1DSLN-M-=>7LKB7)V?]6O5Y
M;.G405?1Q\&\TON<=#*ZO&LN["F7>EJDF\%PK]?EIBPNW%HU=L/$"2Z'Y#>P
MOXIYOL;$ESN)9 0@@C3/I:#S68=E>=RB. HGKV17DE1%8I3.D?-'Q\PVO"RV
M8'#4LC;U(X0F\TY4H&>8?1"Y^)'Z1"1X,?;I3#.D;S9AD#6Y?TG_GDED[<B]
MI=<Y5)D2X[/'9[7[OXI9FA]^%7,I$(]OK"1_%6L_^FO(P#B%,.B1S*;A#S2Y
M3S^%BQY:5/(*ECTH!+,LC.8K0'QLX<GY]@]PSR/^B16Z*9:Z+3A=$AMH\GQV
M[Q]A#U:_BL7."\$;DHZOR/G;(G[:B &5T\Q972)SCMRS.K>Q-@D^8<TY>A>C
M@Q>7N;1+]>N,KM[H)T^65KM[*H."8T=49^=+>.WG Z,QX&'# @Z*#3#^H#6Z
MO7G@L*AZHC@QO XRJS6 2\1N?LE4J HZD*:CK.V<7:5BB'I</?[@9!:9I+*A
MC[##A(M<%::EP95S\JO?PK]]WBC4T+_65.$F90][\>IUW7VT^EB,S_E7KF[=
M,S/LZE*4LNJDME7$+'/!_#:30:?G,V$P:_)<\OSJ_GG3[PY._M[>_2LU8K3@
MLK&Q;NF0'5$" H'>J QF;/97-7.O ZL]]G3D<9:)9#T23E)=ZPY G*F81FV%
M]FTH(8E;%DW))Y/!DR=L.:4WGUC9:Q8H'/Y&F:]"X=F\0H^II^9<THGW(W(U
M\^50O]K:,C7CBP)1A*?0DE)X\1B%J@#:N@@8-_#HK1FQN^WG0H/CGE/JB3MR
M4,_K<:_Z'"QAOB;.7&KIS*[3]K;ZR3WKW8.3<PZE3[Z*U54HW']P-)<L?R1T
M+*SA;MM<D((E4UIW>OY[MOPN??\YWW&Z&MMD&,L\H(IRE+L(X5$*>8WF'A(0
M#%PZ<Q/+$!H!$EV-Y-5_EE28S9Z5-HQ2&= 9?+YOP\^<8AM%DBH_P]5^K6$B
M-0P>!STL[F5-.29\6)-)\X%'2FV3R1B2V0EE@]/*NUC6:ICR34*_B1QW33#,
M-[S\*;>J,&W2?:[EH@5EZ-= )L&M>MT5J>.)E*+JT@0X3-<"P.AV>^4]Z&2A
M]7U1"ML,Q*.,Z2'ERZ6W>(/XV)Y!=@([&''&^09-))\FV-%YY5U?HR.%;U&>
ML,-=1-2G^W>Y99U5E!+4LMU%U9GF]C-' *3EO+- @SP^P]H3A-\?L1,WB] D
M^E3!X!T-WH)H]Y9<XG@%(I]=7'(2%)O#A=@*$=(W%I/3X5WZ\O+ 1=DXVJ/U
M*3V[DSLON4\_0VF7FP43CR,/WWL46PLR XT3AQ'#O&I6,.!J8A(S!(+08ZEO
M=K"H]R."&US3VF@'F#K'>3AJ":7>V5_X$P-5#L6MGFZ^4:H3-EPLQX]3Q5:7
MD/'4L55'WAN"S=.0-,5OD);.C.K0O 6<*Q(%J$V]:S[X/8.=(8 <ORQ^B*9]
MOAZ>_ZQA_5$&I1$J.)%[X7R#NMH<&-,*CR.S"Z_YI#HM^HT##5PZS6#NW1L[
M/3X&$ ;<HSMZGH%K$M+ E'X=\0YF9N*9?*H'+W#N#5$;7UA8I!GZA_=>Z._3
M*DT@!TS]*SFY@4Q"1@GHMBW!VFVU:]Q@T,P<"00NAP_ !#$:Z,*$ 17=Y;FH
M,:# IO9>\E75J3&S/A  #I'DM<3R*_8Z"273?"=*>4R.\F@TGI8\Z[8]$>-@
M$7 V))N127MBV6395:.Q KH%-]]U^'@_[XKO/EX@V<M20Q1<*J=FSCY,_G#W
M,PEHH(#Y!F#SP;(?U]E3JX]?3)53:H<AW- @&N'/GZC-_H/+:RXE/> LH;@Z
M_ X43!?&_N2-VO+08W&?;G@?>T*M"@)52=64A*&NKD]AK2[C?C!;UEQ TZE1
ME+CGZ%3^%IQMU?9Y)=@,G96T&$73W,:WDUZ,\]>M-V_.A=QWO*ZZ,BFUA0)N
M>V$'#&7: XSD?L2W:=/ZX1#I)M*E%WT6>4Z"^:QT1%D$=!T\[?!RXR(8GRSG
M"17WL<O_8#1H*=_+AG1SS.VH"8.GG(=#R:&[38F;#QO,*;YT,HH]KEP?>@H:
M@^G$+0,>EF+.QV<$VL4%B4#FD>9-+NY&<$=NVZUU[_>%T@KODZ5-&HQ>(.*@
MI$S[>C@4W$3UHC"I[K2]-X&<WL0JDN1<2X#T60=[JB8LBS=%H5)'$]F<F142
MC:849SU>V[KR".P,AV)I!0AN6*9N)K+)W,SJ78=RY"OK@/6TT6JYWR.0N*/N
MM84*Z\R?5L/+D5J;MILXFO\Y#^M2=F).W91Z-K&^"8S2[W&71?&B+\M ;BNS
MEDBX,M\8@\YM=\F&CE6#9#6 VLR<,+_2MFS5+BPH W<T;;,NFK=OD([.</M,
M4\B\O6"(RQP,,!*WJ:S&&G[S1V7;$_SIH^)N5<]$22F']ZS WJ1"!BY0]Z"W
M.-*,@?_Q36WK=03(1? :/MD1FY3[TLC._:*+>Z"OKPVE0%3AE&,^M8QV2Z+-
M+-Z^UKQ?-)8+3D-?**E%\+6)_&';[1_]N2N6K0"M; <S[<@O!#[2W< &-7KD
M1R T2=?S&78R[Q+]==!9J';,(PS#S;])^>],E"%HOW!RA5"*$(Q#/81Q(F<X
M*A;)>2Q;;6D$F+2CS3M^O]%9+F3'@5:%]V@)#J>*WV\L#YH?3>[>-1891'AZ
ME)77(6"5AAJ:Z:\M-] 9U Z@_FF1F_'(A?U9,!HP17KD#!$_ZUY#S\9P-@:L
M_%_^F-B <E4/#O:>F_R-8B$/2H.Y=:4,0%=PO!*E5PY2MD<U[$NE7DJ__/W?
M2G_PONEUBVHK:LG^O9= A;Q-6@J7VE#Y8NXR4G+>\R%"WS #I5W<=ODF+I%K
MJ:Y:"4=H%U.6HPS<>V>*I^=ELS.JG:;9DD^Y9>(B6,9QB];.N^@=5DB<?:L+
MP:^DH=Z!R;YE[@&_!?V.2=@Q#R0P2Y@U7J^+=IW?IZ'\@<FE&8U#=77$ZLCP
M)>?UV^FX5@Z"B92EQ:;:_:M$J9QML049,3*Y=ZE6P$B,(F,5!Y#*\6'[<63U
M=T37*A&MJ"3PRJ1$],;RW<Y:C0#7]/3=:[3Q^5U=S_7IHR)SW_092L"Z]\(%
M#V3#3^V/RWIZ=^G,O49+D/Q<RKZ2T:-=/1RTV"1L\:L88OY+^;8#P&AK ]_R
MJ>>K&#\J4B7,O_#DPN/ZQ+DG*%2,<K)GP]_F(5'Z&*QM6$\9-C>12C?*:6,J
M^:,JSBZ0XZ(7EQZ,S&KDJ-)50LX<>F''%%:)'AQ,U2ODBH/J#*&>3].\(MGN
M^-=6J;?0)M<D<W"L8FT4#; 0\CIAY@[*CW>'G@4>VW4P<ZQ54*)W?I^#\<'4
M22/M"#<%RNA>/ZW)8,]VDGV!.J>D37^Z]TES[A[[35_F*YG)9R _%/;PUI"S
MVCBX,%R1S& 00'"SH/!-L]6%S#M5#*0T.%_.&8E4!4B>5IO.:I^R3E6=/P%
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M5"=^LJ4QHVUC"4W-P=OW[XV-6_YPGT3ZHF2+*46QWA#'G-Y2V,<%QA9L@)O
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M3%4N_?/%_1J#:+A&T>'(CQQ4V,5WJM*[-P \].=^L8Z_[%'WR1]1MAV!&GE
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M$2AM_ZB:KV=EY9$"UW3XL6M]@)V+O[GE789B/$/U=?27$\/BU(3%->4!("R
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M,F0PQ 6EP><$>$W]-(8^5IV27M'OE+(1B,V?,78'S-YGO]62-H#)X2S2'#;
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MGP=I#Y>:CUC5:] <O$\$*S7VXY[,.W#'6&TAVY]#%RT\>)'TZM':)U6]1NX
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M^7G5!^S0/<?7Y(!7%"&>2H^*<P<WXML&A'2X]#4O!0L@,+K\_"G@!/+V_*O
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MK!HR@_A(C @$LAX5E3Z7^K< L0'Q=,GU9X&]2EZ<-O?U5JLQ'T"B9H+M0G:
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M&\A&>UT%FJ?,C0-BU3:/4YLK+%K<?(%4>8O#;VE/,M=_ZG -&Y%KO4)A3]A
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M/#X*EC03DT :,HN #BCW#X)??<LR)1N#&OAEF#D.DTO70C13@8Y<M@>SU?P
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MN/G$G/Y#97*_LOVJW-/0:AIJ"3:M_LQK8O:Z+.:K!)O.@T2,KAJ]AMB=*LL
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M50_"BY+S1;62(UJ^MTN;$,//\B!EQ>0+Y.23^]<P\X;,"D6)9/&Q",_R"=E
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M!S&)A0T83?((920]T>':25[K,(4N=(RBZEQ%O0]82L,ZW+>SP1?A&TT2O*P
M&RX!D:8WK/?!>:[J.MB,EB3#\>2U?7<.]%R\;$G5-G?1_;,S^F<)'W-E@T$V
M(V"C4'_]#J^HAX:WW+),>*-$OIRS-?W./L$7$5QSQ#(_"%+VIPNT9WQ:$;AU
MEBG:/$Z<P&X<=&+5:"19D&$F<)P%WW)5@_(4@EBW4/6^2C>IH$1>5'\Z:%+)
M8G^(SJ8DC44(S_ F17-=8"J)&L-0_M"FE-90R8(X7^79<6+S"F(FOH_CW0&S
MHC!)<\NA%<UWG@K-;.0IPF/]B2#UK: >_MC3N4--_;X2_ASR]/PQK="Z:0V;
M[XI;]7*B*Q__$5 Z>&3#DBJV/QY76F.W$B4')#4JEMV>"OTJ\28R%2).8)O\
M,.EQV/0UD93_&H+U"GTZ-J4W2F)&H,L&ZW/=3I,?IJD\]/V3Z?+WPHC+T6.<
MKM9+\)CK@YEUC;1K.(I)&&#[PS5.A;%L351FM=,O"P34;<Z";>21'#R16^<G
M^_0F/[6;T#!X];L29HQ;MB/V4-AL[N\QHMO>3G@+TP(G27JI4"YYO"/OF&/R
M@K18*[ ;S'I7@JY+G*;]MKE]QC=!*,2P(P)!D=$.!BEQ74M_ X2=@79,:5R3
MFNSH'%)G*\;+[/=?(!9/^GE=5J;+E^I]$]I /L"@SGG$^K:L>>8&NGH%\*#A
M+: &'T3*WL'%R8%&!(#=R1U>YK<=:+]_=>2R9&2O0\Y7B;X/7R5>W%V0N+^R
M?X=#%,"^2C3/[4$IL94E7R5NU1^YW]:7O#-DLP/D[S%XHJ\2XGK?W3NRD[?#
MVIP\/@?L3[>X22%M.90LA92Q MEQ;,OWJM1ZC=$X^$53*R1'P$RR'=<YEF=R
M:*2>5'>0\RE$T#H(BJ3]6&*WT_1#Z8#T<\3U_2T-#Q4X59\*Q+8:0PT^D4-3
M8DD*)UQ7*$GH=OV44ZR\M.P9] C>D@WK(I1Y."/ZEID(<12GM9ON1<@T42$:
MLJZX>J'JP^\ 0LR=O/CLF_C83]JUF8Y^=/_H2/^98GI,].'2"?XTEC->GCQ^
M>+,#T."@,(O0\2Q9#887\%N7E'0*2DFA_AP"83]WD.T/.]6G]C(A_]E:/D>*
MW&!;"/\J(?W[7DUN0TPA,& &_ZP1YW5SH9A6 $<@F@,A[D9?)<8_.UECC]2K
M5\4)%@ZJ.UGI=X_E\E-PF[WMU+U\^E>)(_AJ*G_P*(?OOJ1IHT VM,I82\Z?
M4&/,?_COINF_6:SOW ]N<"&Q?15W2\F7#%.TKTR>J*KB^'1L"C33T_FZB"E)
M>;FH@<, =/P*CX0VB3/EC*K@W]LJ'%,CZA/!GNW=K.:EN;AUM?&(AR;H@&.=
MRG"ZC^",QO,\F4&=X(F$FS*6,[N->47L-(2']B) 5?,%A3N5CZ:K.7^5:+F=
M\E7"\0'/<4= S[WP8L[H0\%7B<CFYT6"S#VMPL9T;-/\4(;16"NL,(\-MX#8
MTRZ/\C@AD3OQX\6*];=1QLM>5U253MMS39?&APA?1 C>&7)Q;=^8;_ K^ =U
M="W"@V/N&TWYPEX%Q$&G3>+[[&Q3,BR1%014!;01N87 +=N'ZZ[D7G,-K#K=
M_;PCC.)T&$(TX);B@""4*BZQ,U+>Y"J]?PP,<2 U$M^+LD"_##>,LY+- ]F+
M<W)J!9YN"\.!-4XNRC#[H31IK[CZO.6[S;$X*C_7IGZH)"CL#9TH2)Q-],]^
MKXTZUOK D%$ICH#.]0MVT$_/.<]V?Z_[1?MTT\+<^R8E(1.!#:'2&'4A6*JQ
ME'Y[S]TVJDQ/DM@-$3NP<<:NV%ZGV!O'A%ZPK ]%F!]K"]S)9N=MJ-0E+=U+
M"H>W'3BF\X+KDYAB8=%Z'[+G:\+R#6WH"@\F1W*J-*TTBA+9-KK)A*3LYYWJ
MA\7=")_6[A+O.DX'>L@;!7I^&U.O]^CSJWZW@!^>]HT$IWDR2-74T>_>!VH&
M[(+I+T#4SS%'C2+SS1KW[V%A5"["2M\.%,710,CD3$GCGKJ?J([!A_%T\#YY
M;-4^SL+)?MO6W=:9Y25&OHZZV!5$%P# E!39N?K%PC!HPPSQNZ/Q2BG-TFRM
M*(BD$D"9Z$QBCG>(5B\OYOY,+^%O1-[^O,5ZF2P'?3,T,N2AM%J#!:AE OO5
M58W.^R%I&[TW=(DW!\!5(L7M^T[,MI*12)/DUVCKF"GH[:%LOM0AIOAG,+&,
MVSK27GH' ;-QW$CTR<N53IJ)E8;>GX+5C'CY.Q9T1/61MRRK'\B0*M05ZE2I
MP-+^&HK3<FG,""@8/&=E%U6M2?#&!_^&WD&NM$1]2&"D]OA >,D]!?V7W?4'
M?.-861,@)WL^KH)>7Y[(-?^^T %_/*.IY!(65$Q64(:9G9VMJ 15]%HX<%NC
M7UR0RP?P=V*DT%69/_II%,$#[_9SW E8JO;]:6%'%KON"0R;;<7Z'GRW<EL$
M/3LOPP[F>]Y?>Q$38O\4GGNM812?2QM_X*)@$Q;&_DVI)""\@H5H(=_MY2^1
M7$KQ8Z<!BEV0%$B%BVQ^\F?:Y;)IC1Q::([B)D2=_:(KXK-:C:Y0&0?K^+GC
M4JO7D89M"$9-^2-]SY;9/UCGZJ.!/1-]9\KEN_,)[%Z '7,\>](Y> 2&JN,_
M6 64LBK:OF/XC[!L%%) P-)T8U1NF?C <C</%&6VJD(B5K(/VT9 ''G!6TP<
M(&R3*PLDL8+8SRK'YEGI'?IDCJZ)\@?*8*&\L'49ESB[+2.KY@RH<%&N"W[+
M&E=P]P*SU"EI')@Q K.)B3Z&T+D!EIX=9=">;Q-(PV@QLE!$ 6HCU0XE<.VC
M;3)M.(\H==TN*DX)(W4FY&*RBM=-8),#""T@2V2/W]!A]2[8)0@#.XV'FR_)
M%M^6=Q2L\>UQA$]Y#].^R&E'I;GMC[7<PD0?KD$&)#=?QFJ6\_H&KF]WQ(BS
M=&<5?=IS/X$I"U $UC&EY5X!ZC)(!$B+-"3E'UG55/I(54@5,7E+\UYG.Z:V
M#M2T$YV.Y'(]W)KZ;>I@L;5#8;:8LDI.4#EL@*GD)7E^5N-.=N@C=Y'89ZRN
M!.7D!&X%V27/H[G>]L4!15&86FQ-7E1)&964Z\"F%M!H\4DFB=I2S1TC[4.#
M #@TI\:X5^$[]DL<;XFO5?C"NL-OW/:Y$O7W0\0>2>E16'Z:V[ZKXFZK4B$-
MCS%?'/%)@[X%-^2\<H>:^WP1G09%M*^C K%<**-S^AT278\>?U]2BQBYP"BF
M5;>*D^+H-*=6R\2<R_<A[F<:C[:#1\4F"(.2QZ]7?RU$)TJU!&^X1QD:K>LW
M& EV'L,P]$D]U:!&^$2CBJY>9RG*,-WI.:]_/@@%K,18U4)5X.K7#N#MST8?
M>FI96+U&^'0!7+V0*-XA_Y ]:HK>.8@ U:D6XE)#H^;,'\OL!4%#7_0&#CAY
MR!A%ATB_"9B&.\XG9<V!\N*)TW?KQO6]1?2TB0\"VQG<ZRDJ>]"KS^QX8S:V
MSD&C;U2.')BUUK.3\#[0FN\VH<$W0ES7365(L^I<"@$:FR2;+I)RE=<+5;BR
M,O=HMUO+P7[0O=(5LZ7VV 8]XX5Y&@J-.:-PZ]*@B4C0-7Z,2%@I9+,"D^4=
M[&3^,/35X'9RA9)0(W?$L>)JRG-G420E8#1+(Q\4% KSPO!&Z'3Z_F[JD-Z,
M8$$&,@];^;ZR>\1V'&HVT-?;<6"&4!*7@Y8S*N4LMV+-R1>$<@GY!?#*EU91
M-[ 'KY7,+R*WMCD1WI3L9H*D.#E^2MJTY($%R%9&FZ&=F.K8HGF4 Q^H5DGD
M!7=>-E6L;^D\Z>%K"MR 8N4OWT<0A6!/ S!.Z6RCC/;RMD>'QR]NBPW?!Q;S
MEBT^%G]A24+O[:11',NO^GHPUF8YYH]\M3$/%MQOX>_?'=3<C-C4'OM\9TQV
M3P7JI% 57.[ZJI18L%X5E!J:EIU;>451<5IC]&';H*'994A4I<&'U+R&#:.2
M0-T:S2>II>,=:]OI#<7+V6C\>5ND<;1MN^#B:J;.B>GSM.Q"Y)X/ B\XVE^3
M#6[TJ>4JQ]<O<$?SAPV,[\TIT_(M)H!( A;@&RX<"&H^2PLX9V-2F";-'LL.
M5V,[63GKM13%Y3=XN6Y=$#KY-7WH<_@JX7O]RVH;4^&*9FQ;EZS'+A^GF/LX
MWZST0=VZX2KWJP3\=G[IT%Y;J<;^ ?'U7J#R'N*KQ++3_@GRN5;^TI\A,92K
M+Q>^2NP?'G8N)OK"RI#9Q],SZF]<@YH=\?%"I&]/<E'$92>!L\GY#9Z9DS\]
MVQ;#VES0-;"OGOX[N'.]=1%T>;P/)K>C?FH>=W42/-C@( U!O1M'?KJ%J>@0
MMEXU^'&R4A]:27R_J9;[MN;*5PG!E12D@14^^V9EYFX!GV6IJD>>>YN[:PB'
M'%AP&^!UMB^XX; FAER9.6/)3RVH)RYE,]3,LDC4_*=SRMW%@-5BI.GQEK6D
MA!?G?R_LK;N6MRN[DZH>Y?S@$>7J^_('U6OO-Q_W#V!94DY.C@14/U+%(PN3
M8V LU7=FZ[6&'4LA=)[VM'S +KO!#</C2S)=T[U)MKPN*"['^,6[=4/+19V!
M7-,J5U^LP3U7Q:N':V=17%.J#D/_OWUI/X5\6)+1R\_LYUEND]BV62-EV!KU
MV;G\<LY7B<-!*2]4ZB(I]["(9$4#FQ$^\F./=.@\+++7J8GN9AT@.CLO>D<C
M>LBCV9Y,>0(WY-S'DSUU3M(^9L1AJ1'Q8[<+ 4\'%;GT6:XN8U*NX&J_@;!*
M)+95TT8J1QC!ES<\/*I&@2G=AE23#=TII;H^FDI\$M7:WSNWTK85X#3LEGEK
M:G-XQGOGZ^Y=:G3Q?GC0P$ 5TT3P];X@4_&QZVU=?#4QXLT36*S*V?K!^)T(
M?1/J("[[E]>Q!44,<D6OW)'K<MK13"+BLYKGF_ZZZC[ EP+(RL/Q6HD(="4
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M^[@55(]&'';4[MJB-IFRV(PUB)Y7VMTW:R_%"JLS'CK!%*8SWB=SY;]O">X
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M8?!FXI@1\)!TO'[O'@]_@RX L&8*T]0]E="16-$J&=YFC2 +-\19XCWC$QD
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MI+6EGWH2TDY5_.RU5(<;'J8]69V5NC$>-2RJ!VK&[>Y21(3GS245G\M6[9I
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MNO7-/F"<52'^;3Y@@.(JKPB^M@N%E6+"90Z==X]OW-X+0>FZPE,M7[5"NC;
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M%3=7AR&P=ON&@O!Y])O9ZPM%K;1E+C"00N( ]4[3L>'0IUX?M+6OSDHWD=5
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MP//$9_V_+I]? 7V(2( #>E0/M557U0(-/#EEY;$*C'%E?.;49DT0DEJ\R-Z
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M<8E4(Z/8@8!W,%IS#T7BJ>>'IC>LNX?2$MDD*.+9>^F69J]OKD;>=A==FP@
MQ;N';[1ML\$3Q(".4J\C6*]Q5*V_!C*<=5U.O1RDG_@<:A6';)TFC8S"O+IA
M/[)%X4<(-,BN>@P_41,5I/48,[8OH=^BNI?\*F<V<ZLHE13Z4_BX2$ +G#U'
MQJ0L>$7X'\TNA"]C?K$C+=%K.-'?]%(HM\;G)AKL7DI)[:@F$ <RX-$$G7X'
M6UZ2O=G&-B#J"7)^N4035]7R>5G\ MWI6FI.7&,V_LYX9<M+D_N?ES<(Y3W1
M#YT<3."&/>R'3]\GD$+/BE18--HVT,,:/^ P)ADA_6XT7*]AKSW0KO\(*2&0
M4)NT'?WBL^[5_EU^^K;,HGX,S&8!O3RG%:OB_(!N$O;3IHKN(YM>T\;P5=6[
M[G?H@ZZ*)8/[&Y%%Z<63EZV+W>_3H4AO*8\%?[JK3@F5^T/4RO#[YA6;V>UM
M#T=-V!X+)4>BM!L>\$;$JQ)9]]#U2:J?Y),T;\L]1B51?FR23/W15V0\CXHW
ML2$#U"H/*(Z\H(B(V9A&(?!DY?3-!# I0(!\-$J>OO**@[B;OVI1]\+?XGW$
MJ.;D-7Q16>Z5J#XYJR\ZZY/C@(0;13O'%2?V0^DL50EV_<2.A=8BX'0Z^"E"
MDZ%"'(<(2NAU4#Z4A$P6JL>(_9QGL201"XJCU0\J[W.A73#5Y0B9YJ6&-H\Z
M!=NJSQPX;XE^RZRJY>8W467WRD84M:$M8MXTM_]*[0K:A9?61S>]94X]Z1G?
M T1H[":FUO+>+#N%^">O;]>&^X=/:X#!( -O0:_B\B-\C[2@=PKF+U<Y/;GQ
M12C4FJZ',LDHU50C5->ZB[$8S5XD:!Z&O3;QM>]FHF>S[C,_+GT-T.QW4VJQ
M@Z*6K6K\ T)\^U^VP^KG?FAY&<888E&FR6B%.;N:A/ACD]C3Y#5:V[S.^U1J
MC6N%_9A,W80SX(.DX]!J'/=#=,AS6=@R4M#&(X#^3WJIGM2HY(\D7D?^A]>O
M*R;2GQ'Z+,R<OM H/_*KO' X/R0U!W^*OY,.^MS,PQDF4\P^49,E-ALC-YX]
M)/EGUBK'A&8&H$P_LI0+8>[+F@7W^J',#OPYY;J#X.(T+8O*IPX5[^.C$D7V
M?X=,:>* B;1X)F30Q+*G:F9<]H>0Z!W>'^'ZL)7Q.58J/?0P/5@>+'7[(?G-
MXG59(ZM!G\):?'-?F*1K,WD4!U<:_YSFUW/]#UK9YF<X<%E*H]3HLN+J=K%+
MTO(IJB!7S*[1=G34>%&YEI8-.)D<!O5B8DM\=\-^@N(:O]V=F+=)'6LB&OP2
M^]SZ0^! ^>"63/D9&4=$7M4:E4K#L3Z]&-R)>C8=EUXU+F_U$ ^WT'"W;VGH
MX+"D.:]7+A8@=N6KSE'M/<FDOUZ;[EE5OX"Z_5"Z3)93N>$]GD"T5QRXQ@;I
M=5P_M7/Z;&&(>7&:MI8YM9-^T+.)1W=IQ4)=HM0^#L)#<Q-70$"OGL>(D1]M
M<F5?XF%TE*15A9U28!11X,3T.U]<(@&0.:XJR00U1K*"  +[=KX5$HG8;8,?
M<P21'&"EU9VX;NV1$CXCV$L<T$3DLM;%PIOCKRQM2^Y1 SN>U!_>D/[<K)UL
M[7K99P[W^=[JO>'>BJT !R+D^EFCQ+?+ 6<=BKVVIJK5&\CKVP&/:+CQJE>%
MOR@E$Z,>K8'*/5H^-_9FTO^*L<!--*":'DSYNN6/U4R5IF_?XS'(,0+\)=7K
M@2)@>$I,TM__Y57&_V\[UW=?LQH8AJL]G.!@JDJ:&IS9P)[UPN6+^&7<@&XX
MOD]XA.>H31.BTJ%PD$L3-:876^RSQ,"59X;0P.5F)%6'$T]640'AENJ@ [^S
M/0C[+%>+=8T+:U.(INYK__/_=C6CH6_NZ;V16W[,GK4*[6'&.W#=E4J2Y"F8
M2HM%U#RY? ?*FBMZ./Q^ PK47"(GWPI\#%] OSACNC.9&V0_$?C9XAIOV5F.
MTMQ=T%CY CJ[HN3Q?Z\MP@(SO2\R&HS@CGN!Z"L)AE<7-K&H(\7#]N<FDC-$
M3U0#W8$ %#$X%_&_@=7_MOVKN!ZY!@K,>U_1/+X\O]AU:PWYM6V3ZG$JO6RW
MA>9^FR^L.;[6,#  NMICY!<R7"5OI7'4)>R"M6: (7.Q?%>GS>VCNWU/%JY+
M=U+3UFVZL=_$?Y,&AH7NI)AQ[:148&W*DR\@!?K]G'NC#]*J3-=[D?-7%OCX
MVK-FS$2,'F011:T79<'H'1.86]?SFV>(5"J_>98EI3A1<S9D\L6=@.Q&KT%#
MT^%!V$.8H;",7EU<Q]_MZ;-FTG:-!E31OLR@Q J;4;>NU%ZO_^LT,_K]@VV'
MWFF5'1^[\^?;9*24D&]ICX]\BW%O3+JE,Q<K)X*S3(TG!W3*@]KAO\"DO8#^
M?O)27WL_NE*7)K#&[G]-\>D">,M+LTX $E94<1XT8E2KY*09D*[(6$7)%.<V
MF)CH\%U4!Z69+G;.^4GDP $S0A=S+<>0[5'V'!/U#C)V9,ZUU??U177SSCRF
MF:SS.*!>E[RB1'MDH:2(]1G&?$(!I#-LI(1H"]&.'ZUI^?7&=^UA$.['=/L>
MJ7ZJEQ3+Z\KZCW,8@'H\8+U04U(8A)#.S"IWRV0(69>%#_NC5+D'2J__G^AA
MP$]*2+EW291$'4_7,K_\5W3W9[$+E@" #&'^ JP>7 KQS:)>CT11Y:('4;.M
MU]^P^69EQZ4"T\UD'3EP'7:]L?&NKJ^R+TV"7D)&/R;1I-">?/]YDRJLAA,P
M"0-?4>E [<M(KX:X=32CL7X9-RFC]X]"N=P_S,228)I/6 6-^%6%N%]N*J()
MFNGG)67%,#TN12,_5GB"=_PG8>O37I66@LNBJI#P%Q(_@AE5&U2:J^/<-H_M
M"ZGGNY0:[>&!WY=%<-C4/6/@:YZR/K=E47  L^M<&ZF"$QD]>##V7Q/XD@)D
MF;_Y*2?Z!0S>Y5N,9A)$*Q]8")^K@'XK.1"./Y%N/>5E'#Z+_W9/B8--[2ZN
MV0[DC&59> 88!Z]9&GOSTU::XWXA:()<&+4*/7JXOJ]2.;"N5CY60)@&5?_G
MWO8\0)Y&KV7XPM&10;WCE_U#:0L5>:/)B[?1+3&Q$V+6,1W<P]]"TBC9JK\>
MH=$Y)EWPX]\MX*+9I>G/RG>JU.$Z+A][P5?7!??-D KD9086T5"@N8$YQJ^O
M?_-(2FN_Q@WGH+S_0?%=@8/EZR&[[G;1S1T.D.[(4H]_3+_6=67V]1U9<73
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M+3/TM-L+/F%XC 1:4 +%2T"HB^#X%=>$2[6LE S^"P:]>,GM>LG7S'*4LX2
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MC!9G@ O])N,@]\G4@H6@H8GIB'BP<,\G%#Y], ^-@BC43?- O=D2D\F&'\M
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M[_72#/TFJ;!9JR]Z;6-]X>Z.;G0(-LB)%;-9:!<L,-8M*%LRF91-$(%]F^8
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M@F^HSU".=Y+M96^O93)*WZ+6X*Q&!B@BDT"15W,M8"@WGB?7JW;5,^>?;>1
M%[2EULF1]^T O%QR8R+/*KB@Q *]=)KR5HW4^YK_P\%H#7M8MIVI$A39,AB^
M<8I(H$Q2%"RZU/JFAQDO;[E+([<Z+8+^>%6_$L!;(Y1SA. XZ-QH#/T*5J;?
MA)_,CZX^STCR^1(%71MA1:57*,[3I.S5\VG-BQ,#UW*1?V6EO3W#]ZMEOG?O
M'&4JYW9Y!#1@#!#&&%V6P?FTL_\*"\L[]HP"NVG7\3Y9K':9.B2($F.$I^=N
MUW\PRL8-ZT^T2A"OQ+%1SDCOY9IFI-;AH2_&!\8@\[AV4?RQU1[+EF6P\M'#
M6CW]5R<>MWK[O&LV<+=*2J0'0,["1@HV(FAUF="T=R]*=+@CO.P.EGI=W41$
M&4>CE@]UP!/%*F-<'W]D]P@X6/AX0,MZD-6SG/!4DW+=Z03SZU4[<@OJN[;W
M"?:5L$<?V&2,",^B)M#DV+;XQ.\%K -00Q_@XNOP:V.O9IX>><6-S5- I4I^
M>"@#MBTB'_KJQ[;KLWXXO8_.04E8<W9V'N2?ELI;LKR?H8X/];FA[,8^Q0F9
M+='-USCNKP$GOKUG[.5='Y&TY80G0D"2FRB)^ E/K4[<Z#?9/7==^H*P9$G'
M,<*\G P'7>;P05-M?]^][R0S? VQ.J_D#,ZTS(GW&919X=R8'=<>PV\R>%FZ
M:\:3G-YWB&?*[C(B^O,AG?%^:PO+O63N.S%$$;;?2A8]/9N^;>TKC.BX5H%7
M"4].+'A:$U$H=Z,Z2;39\/(%#A;'1K/*=GYJ.S_:3%@]#$W>:'AFWPE5MPFY
MKW)M=?RCO^*@/*67D7("LBV'%#C+?;M"/L6)<J)T@*V&!:<,I"VA:Z;M'R-9
MX>W>S8+*25\54*)Z2X-AI-=O5\4R):+;89"6UF6835D@FIB^.-A3 >8KMAMU
M.AY-J$RNE7Y5*S*5N7SU^P:(\P=7UL&-FVLYIYWTB+%;PHE#G9M[*B^R7,K?
M+@[;>EP!\U4I&:T%CYM%V"& 2'"&4"T!Q_A1/+/0,*W\2+9A388$1^,V2E<.
MD._9I N[E1[B:0)3L):E:N(\M@;Y3A1X4WBSW:%&']X#=SC1:+226#2JARE"
M"$'?-$O=UN[X#OF$FXJ=QT/+P%4_$3XP%K03P7O*_>W"+ \7E(;:.]8PM?Y&
M?.RFEOD9ILT \[YM# _9Y:;A/28A,U5 :XA9<"G7Y.DY\41'28^GT)YEPUFS
MUT!OK47,O064\CSH@KL4Y1*"?,SQ?9$[[B1T0@3$&77=0NC$@YM>O4( UJSY
MCA<)U(0WM77)7@6#?FY:0 .O:3?>*K&$&/$:.L7\:.O/2:ATHH4C0.N5Y51+
M@:.TA-S6"I$6N=9-X W54 5/L<[+-4V-4W2Z$WF-X"V:8M^=8KZ^T[XMVKL/
M6CN)T0<^'W)P[M2XBM30F)&\-0?'[P;>Q_?!'.A,:LPZKKK$+J/623DSD\'*
M2MW_KDP)-BW_<7$YU;0_NKQ[@LUK#\9ME8&L8;G4W>1'D_I  V)BC!35*4KY
M1(-_E\Z*$$1R[[.0$C? 35\MB(\+[&,@"!1LRX=D&^:X=G.0VSPAMJ$<?>\W
MO;<ECH"FO07KB>_ISFMMPCLU$..1V!*:<]'K$]EUM7B-21Y@UM-_5+X-$1[!
M<)&7;^" "W3<VLSXOY 05ZSV3DT$LX:P^*N\GC .:4G5HX(P(8KB&>5HFRR_
M_F:47F8;^_>L#X$_B'@UZO7;^O'$(4U"\[D,R5MXJL6,[*,/_#II?&=DLFIC
MWEM<YU"O4JJ3E$P''ZN&BT(FB1^GM>,?PVL_=)(B)'M32>W,LQQI&P+)4GD9
MEWA[,C 5K/D\A#$"5J=ALW52YBJ0!+OJI1A!^?A\WO32@N,8)['XG45&ZEKQ
M,Z*A0VS;+!*JV7P*?]RT[*6#S4F>@D(Z4ZB>Y.(ZC.\]L"GE[:\BS2R6E(.Z
M9[[D:BD=YM6\,NA\L' B=($:%6"!P^N9E!H6*QZ5V@5+K;>NL%%+T@MX)*GD
M1E'+[P2R\ES$S<YD1*'4F@ +IR7J,O L,([0O./J #:DP565&7MEZQ/*^]'5
M->7@28_;/=ZK+$EB*='/D%XG%Q!SGZ&$=:7 IWW/(^H1EI>.>Y=T\LPDQHP,
M*2.,>P#]NZN .];5XW:T56<'/TI;^71SA_YUG1T^!((MDVT^;#]I#*2B%]2Y
M,(7HKCT[ @<M;'$8.R?EU+LVNF'5;.:-U/*CS[11E,0,@F8KRF_/'X6*)WE+
MK2=J4"^(I]AW$]3]%:Q_S YIB_>E[24'D/6!CZ^@*@4^&EG=V0Y@%IMRP:/<
MQ5T_/#(EA];.?TFD_'AC)>,#3Y7Y?I=<PJVQ&??[;?V5BQ8D^F0(Q8RG_#+(
M0K966H"5M\4O,J7>16&#378>M\&!7$)"49WXY? F<H+'B#46K>,U\KZ31$;\
M?4]>7GQJ;73\?"'+8I4W^)<T-3:@Z3P-IF#&52K]^P[=2X9;G/:!_4YK1(F
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ML<1WOL%7NYI:^1CN!-)']!-Y/R1 TC.RZR*F*'1D+<)<'WM5$'JN*E?*U,R
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M*K\?*<9Y\%Z>B\E*RP-J0"^PO(PNM_WCP$'#<)]W;OY-/V<X]\4?_=M?@ Q
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MN0I&/ZDIH/1'B$XKWYQ_U.+$9,5:#5[IQB;:$(G-[\.8[G3SG$1ZVMP0^X,
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MUSE7EBWYMY-56.S/'P<DFH'\WNYSGD>A^U;$X,]NU!_L'U,<S4X2F4$H(^[
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M4\^- ^,]_;H'6GJNQPF46$DJ[;1R8UOWR*C4^;'>6<SU3'V9S+TQ&D]K&&V
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MZ"4*Q#'4D2\<.,Z<%Z=09-X0@3U$*=R!R;D#FE?BJ5@_SL CCNM,>7I&IRT
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M(+XK+\=F!5O.S_Y7<U-'?9/8^_;&'#.N/R)\#U47CCXT;Y'JARV<O& (#M+
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M\46VHQT&H4\D& 2/4HP8?O,A#L-DBK@:!KM 1$388%NI(L;I .A5_,-],Y^
MA<Q74Q-.$][,S\U7-+X"P9E$\"(O@X?E"G_E7F_R9K6$>M60<\9I*Z$-8[QZ
MY&?6 _QV;^7-_30AQ$_T+F8WJD/C.NR\XES_"M;T/:7CF3II.F>0>@2&.%*W
M#FZJV4^INH?@>7L]4!EL=6L7-5"D,%_*5S)\VOQTR1L1[+\R!44*$YE80!F%
M@G.2D5J_H[R?U=2QM=#S9M<JU]^_:"[PDURCJ48%>.BVSFV6(\U;_8MM_WQS
MQ6FTF>^YJ<GRB8C'=YE"[Z2&,;WZEP+]6*!LD+LHT)'>H\=+'/B)+"_F,QGG
MZ4U.C1T_^Z-A75'2C<9LN.,<GWV#;JUU_I/B:DN.YRSC".!,4FY!V-7J'&"R
MKWU2!@DW>!;G9C-6(L[TSM?8'TJDPE,W&H5J9LV[T\Q\CQ#HEZ_U\!-P[8N8
MP0I/3P7WP'*^'G0 G_%N49&QN4VX^-?_=;?VTV#RI$F.O8=\PB5'&S4OK1)4
M.&I \VAMY2/ \;'P<9=3^5ORO5HDMS[EN+ B0G"XY9OV=T<\ZG$I?#>SBGU\
MT?EA>69Z\>+5_?KNT6.UZ9"I&@T,0G:L_]([>*SL[?)D7V73N*? _1?L1U##
M"4^\M$PN57K_0UM2U;\>?]M:7['ZVK-0LQ^?4.\6P^!1?5Y!YRL66S1:RD]&
M79HPG)!_4<?'YR"JK+Q92K[SF>P\!BZN.@];BNUT3[)7J9WX9:;>XRG3 -T!
M>/ZI1>-YUT>,"8H&U"YPG(#<?RK4<FI]1V-!V4.\)1#^]J:]06 %?)Z39UY=
ML$Y92E(($>:Q!X_J_=8B5K\0R\U*ZV#?3S5G5GR;J#R!7FLT$T;[?IN:TZ_X
M)H/X-C!H3GTI)N+%\8,V]R$(1X//$--25R:^K]'8(ST]?0'L[.H[=KXJ9-"3
M]L'N=V::RQ=7HW,I=7_ZW4 )4<:(D].?W5IKRA^_BQ/#WH%DFN\\VI"=1P].
MA5&95N$RS_,M<NRN-VD3"D<I3:DOJE&UH46\F"@$+#A/1E$Y> <FJ-.=:*L-
M1JFSQYI+A ^$;S3UD<S!/ESO54GOC6T/9KU8^P?CY4U1EVM0++J\N=9V;[U%
MN[[) %B[Y<"\LBX*22/P^@*0.AY,#%1.2EQB&2C8\#(*IZ^CT2GQUIQ'LK%,
M.=S&1U4B?Y\7%,TC!@$] 9HA;IG%3M*HY3N<UU"U V^HYX:LPF_.3RO;;GOW
MT8CLI7>U;,DO]ZK:[C<WQ]:%_)R+IU]3P-LN+/S9,D4?&,49=F].KFY_Z[!,
M$MI+@<+S6TU=.AJ:I&'VC<?5>=?JX)_]S8+/O+[30HMN&M=]$9VB4F[IK! R
M>9QB[E,7\1L"V7:VU>FAZ9$CS*!<4PR"]W470MH"L$ S"FU?<]%<,7\X@)[X
MVUC<H>P/> ^1>Y?>>=3:9_3*L;GBP*F.^MEX7@EBV'9VH6[AKCL6WI)@*39R
MK5+_^N\AV=M'[[XDI3RJ!JKM9%'CJU;N9SYU7ZX.VA?J#:&5@>5Y<IT_/R44
M(3;"DFJ9>[\U_5UX_ QQL5E[=,MQ<[-L+371J6W%%)!4PPBG#.,<8]$T(S&-
M.3QIET2E*A]!''GCFWEYP[A6)_'0:MI<M6#.6U1^NM]G\F)?0WUJ*\+ZM28Y
M\:C28)_R$FK'MU"2'LS7>)'1%IG!DIW[LH4"!;<C3)UFUJML1Z\BG%6P67/2
M"3NVNIP6M]EJ(E];+:,N+U,0Y1>O"<B#=20'Y<(]ZB^?+UPOMTA(TGRM%O!\
MAEI&ZXCCHO"'IN^]+A6:V'(KQ-H,=)VOM?.UO9Y-G>^GO!+[TAJ]34/D4'QK
M6L,;;5,%/&_1#*YS K6!^/K12*TF2%>N M</;G-#,;,8<5AU+9(5<_9U%4"G
M.4S.V=-TM2[??0&;TN@7X,V<9L!W%MLC_Y5@,0&?Y4SC@;B,W".3 .ONS Q<
M'[?#C#H\5?54?0_9R#J,&E\ _+.=9-2['ACC9S@6,X8F1,\H)S!AC9&X72-O
MO1=_NNP=>\SJ*+3?]W2\)2^T"E^V5@\<5E0$58?N-ID<W/'2.% =$SH=W("%
M0^_U7M'EZNP5.'G,;VV1<*COI_ 7C!)@KOHMU*-P(@*KM[\6C%Y\&)UU\O/P
MM+75B_6Z,TX"_[S=]JI[C^_X1A^CT#@C\O73'81A;=,U=]F@C*'8%0QL%);S
M7W.[F#\6%+3Y(N/[8X2J.3/I&OTV<Q4\I807NP5>W_:HKS;(YA<]U-J[7$AC
MC5DJK)9B)A*^\A@.BRC%R[)M4-&@W1C7_T9%6$+@D3+*'J^%@<J<M^J13?Y'
M_10S-;_:!MT*N&S-'[AT+F^4II)G<74J^09M@MFTFMKA(^'HR!]E<@@MM3"F
M2[-U379401\#OK01=R@?GC,K9GX;04YSFKM[0<+PF8L 6'&MS]1A:4XJO[L\
MK 3*_O:6LOVMY%=1S/Z!#4-SRY"R7ELQ5X-SI3*C8K?"'X*WNRZR)1ZO*/*<
MN6B\ML'&:8=;MGGTZ@&W92>9@K"ZF_[M"=9"2[<UO\SXJ\4_,($YV;:F6C#=
MR'=$^#4.+2/-"^UJ@MXI:THBDJ54JA^_[W18^^J88B.!G.R(ZC]\3FY2F8.P
MWL2(F?\F4:+&C$(HKQHBVU5ICDEUDB;1&.4&)K9ONN]JX>+MZ9U14?MP!:3K
M\$%;=_R#?7PNZ^GC?GG(-V'$L:;-4;EB>$-T:=1#S^I7O8_U+R8S[M,+:\?D
M@QJ[CX*<@T-? 5D7D"R>I!5L!1X6'LJR.FD5-G2#;9>0*WFNWT_Y5TNB#[VI
M>T51Y0LWB6G4ID&P-I+8[!CQ"31F[U9Q(0,W(YO.& (]^//=MPE$P0U:=54&
M#",9M2C[?FJ[]B0UO%9HTB6!R#*K"GLF1QEXQ3YB5I=FW/"[=_D#GK7<<I%V
M45SWT7-&J4X*;_6P5).LF;%N&W\NA)0[M5<?A1@J)+"8B*Y/'R S3UM$H=J9
MY^M@+*^7C=,"M.;7LL#H?,-;9) CDGS__?=3NVG.S@A8M;>#U^</EM]&M??O
MY9CZ9 D0>@W7#I -\]%S<]1C^V%R7-M*\TE<J_O2BT+K64V/#/B$L7'/0[#1
M'K+<D[E7K>O6Q&<_ESSQ>)L8DMH&8I\<=/>)RZ#U39X(6,7EK$W)U=8-1+ZW
ML9#^#Y)?R]\<;PW_!.@4/#1$7O>*0ZPOXC8Z@<X:=JLS<+2R!P0.&/=, +QP
MAS1=X>&UO&IRH)H6_%/P&QQE?*WC[$_USQO@>W%@L/(]9@UUR+Q7@RHH[(NQ
M\#4H9[*' XU&3!_(2XZ(^N3$RL#C.^Y4P%$(R( QV4V4G7VG_+%3\0IQX. ,
MTUO_DUBO<R$PXNIF.A\A02_(6+HO(> VL]/"WM=^?_6/"!I<$O00JMJ.HQY,
M'1O-J'*^+K9P_5N-P/!V."NV..R5ZF:&[[9#E%!:=K)'UES3P>01.49[C59X
MXNS6/"ERI?*'^LI6ZTN8F[.)W]05F.2Q^ LHKR!^PQQ:5U86!E%&6O?_;B<[
M9%-U#_J M_19_DJ,4C)E U?%Z=!\B- .QU%_DB5Z]5%HF?3A$CM?.]\OEN-3
M&QNC9M93Y1>!U-1%-;]]KZ].YORCV!Q37..V/)>E/RNJBH)"%9[AYHN_GP*"
MG&UFYAM=]0;FHHYXU?4-(@]XHS?0DID%M3/ 7PJMFF:XR^.\0'*<R/D%_?*)
M)&>Z0/[:2EC+&$Q_[GTHIO:)IXX0WGMSQ>$C1'D4+[]=-1X[4^NO R_D/?2S
M"YB29\K3B;*H9ZZFCD)"%L(L/H*R&RT*(Z'O?/ ($0; <88M[P[\-XR(IM>*
M1X2%1\<_PZ;-'L<@'!ZNIV_3A+N'FK)IK#=7MLIF$/W#8R.DI,<LASNLC8L5
ME28FA.L 35W(3Q.-$NQ@_J)HOJSJS^J_IJ5E!=LD6H9/*VIQN\!LJ=/B/_$O
M88U=WQJFUF</7!MG^V8^Z*Q8N04@5OY)[/QIQ3)V]R*7.K/^Y;&'$@A&S?<A
M[NX/T3/1@Q8.C9J16_)"!]U59\O1)GGLTY5*2>%1(?OW&*VSS"#I66!'J]EH
M=9B^K\GCF(:[VX"(B^]RL(N1<QWMWZHQ] C?-"7#VE=MVLS4Q6U[2JEGPY7]
M QXS\?NIGPJ)@IR7N\P"<(,T&JJ>,H1<T0,0J:N\Y!/0;P-ID"V6M^$8"J#X
MO-/6?0X4P*#B78T  3_*OS3;E\Z+1#.X;L[Q.0,"36L]C8G7N'':8]\!'G?A
MQE)NQGII#&V4:L @N24MS:K6^KWN1%OX56F&+\)4\S/+GT='PBPKSE^948A:
M^+78DO4.T_$*FBSXM:>Z$8?6[3VM(?$_69S^?DIRX_LISO."8[/'3TXLOI_J
M?GS<G:(MF%3PE%R]EQE!&7BK_^#SQXQ<%I!33H@?JP-C*G.2,F?5Z[QY$[2H
M(;%3H:43 \5(-7CS.65'/2J*NDUH@XFL0T0:FPW=JSV,!/\$[]1[L$'\ET2I
MM*EC9Z_=^;_HM>W]3H<K=>[%+T%>Z4)<ACAC".H8S )9BC@!O=VMV(GN!6Z]
M)NX76HQCQ=W&!4O'X"35>GRZR"^JHBC8K"K_V[/[I4URVF#@OKUO)&=$6V<Z
M1-9+@)ANU[QW>[B;&?^GS0W<!$K)*"C>9(:B%J9T=T@R["]-*4&3I.E?>N/
MN[J>X=DOW8^,06J)^.^G;(30/_!.*1)W,UKQ=&MOS!Y R52 0193*(WKF>B,
M2CM$;M+0S_'TDMZS$^I7(MZPZ>OGQFB$3[%L/PLE3-!.E<Z"_HV'P^]><@OK
MHJ-$@)3QL"U:3 ])#0Q'2KP[B@\+Y,^73D9SP[;V0@D-PE<SJJ0$M3PF[NJ;
MQG3<_S/(2^?F?? ;1_6WO&MB.BWLI<>KN+8%$=ELTUJ#K.^G/E#O[/YCU#E*
M;-W)H,PVP@10;GIF,:^&R[^N>GOA?@E$HE#C:]>=+YPP[N.^:DB^'C+*U.%8
MWL7L<OXN"ME3J3"0^$_W:[2 AD/3J5U+9S>C/@)R2&*:!$9;IVE^(*<PJJW5
M_Y1O>,#E$>F?U.;<FL%1&V]_@]'W#2><OI_27'KN>D>"@/R<R]^<>14S_@\:
M2_HVLG7VA_H@-F.$FRHV?M>5WF&78F.YC[QDFYN)R%T;DO0?'7&#IHES14/<
MP6R3 J1CI1^_@>^>-!X?0P[(4CA81'':0-]/Z04=&XD2FLM8WN.?U&Z=2$;Z
M+_ZQ%RLMO[EVLW@K=6;:FF3OE+,0E!*YSZFX3GPXTKT?U>#JT02"1U;U%:!,
M@K6*L2M^N2LS3]FCA01OT$2IL!FWPRE:/Q/P9C;'>PBYUJBLR"VF^J51Y)I9
M;*L6<J+NMX8T4HT?*,>_@UYP]E&OS=A=XDC\H.'W4YCZFIF9 Z8!R/05?_SX
M#II#;:&+ZL< ,AHY 04<_V7[^#6'OOC.2K4GTKD'\:RE9T>9EIS7OIY&R-T*
MCBH H$41V$%CZ_77U+5C8L9-/CNIY3S4^DN"?Z6RY+_D!90U74FV^&FD7(,U
MX;Z;:%!D<U=<R#O0[%Z)BJ3W:L*NC0E=41O:M^Z7GJL-&R\M_+@RFYXUO.9[
M=UF@9-;HLSMKZ-$+;\R_S&4D.F-\TX+-)+ZY?[^(2:G*UR'=5[I^J4";M."N
MIA4>E1<0I=A 6WF0XOO.BXMN@*I;,\=76:Y77CR]P?UGSIO 7,6ESM/_$<MV
M1(U@]BY1%LX2/.)C-977,+Z7]3N+=P/!'40^O_5DCCT[Z4-;!GO1@!8OF*"\
M78ER"/KXU8$)>8'\YUD*8Z89*,GY?JHL>T.CO-ID@1+XJLHX\%6M20V5+<VT
M%2*D]8;Q9^1>*?V,D,MBS3\&.3K><MN-T[;"?"P&'YNKT,8U(39NT>#QO#'5
MO8G"+XS9TL0VO6=6*BV4JPB)NA_!@=:\NM)+#M#RO7\V3,7IN1S(>;<ZL!;7
M+W73, QK/ B>S5K@R%YWX13 'HNXWHT+$*>!@.3?H!UNLHT_Y,[@5>-O/7/X
M%A6Y_ E$%">"48\'PK:'OU')W@#YX:"!V.[>KXU;20FV&)U&!@JRZT@ PTE?
ME3,0@XL#[$#PVK>=HVMY7-&T5+!C!)*#9(?,1-#0QE]0A\5[/@\^FZWPCS)D
M2" '5K#!+I+4#/1EI"S,072G@@8=G:O1 5U<H<.3X864KL6Y5F7O\]]Z-Y#D
M5+6OGMNR)>##A^1:G<Y9W=ZW%NYKN4$F)@D=.+:G9CG <_?YYW!<)-NZI[RO
MMN.8?G0K/(C A4VAM7_#;N?_NF"PD/U91Y$FD+3QWWLG20L\,"XPB&%IV&OF
M1Z$/W@'ST(;V(.5+X?]]C?*?3!GU\J.HFKW3$6ZU J/A7^;NK]">JEJS<R8E
M,P^GT[G'R[NW2HN%G9=>KR:7KTON5 (1O*?_Z&X6A>6K)!IROY_*3B@YM!?L
MAMQ+,!713H#5(@T=V^X\'%Y6H6T< =_*6+\37TH"GJMFP$T(D^.0.[X/:MU+
M%914,Q3M+IIJM)R9>M#?$)O'$>PE#U*J<8R:0C:_+]=&9;352=3R:V?9!&9.
MG18=Q*X3FMP3;)%HU/S&*L.&S_8K"+@#T/V9KU%HF0&R8%SISD0L%UH74'-D
M/MD(?L_.?1KH/[EYC_).5\=A)?G&1(V)SEJ$<.)"S>1P]1S,E("SJ5JZYH.@
M'O5M1I?_(0*%.9YC[?*G2'E[&DK:IN3'&<I+FDR_Y#W]$K5R5;Y)UR<:.@;9
M0JG,UPA!YN5U3X U0?5^5?18Y; NTXGW/KUE>^9I[8B8;U++VKFS"MB:$@3T
M<+H[UZ(@M]\7-IHB_:-<&)L<W&L/\QL!@RR)K;%0Q=S>Y24AR/%R92Z%\!/<
M&04!JCDR27;J'T4:<P89;!X./"!#G%KN%VWE"#R&?2SK@/E_-WWZX\@@%[-8
M=*;(B(>SZO%I7]X%6<;!>((M!OSDET*+TT!2V01P.LV90S"$6$\JYN*VL56:
MQE!I]]Q^9UAP3=-^O?AR\XM.-/"I:9(L7/;C6ZWPITB.$4ON9G;7":(K^'TX
MY_6+" &A@?#&UAR/URJ=%^=[[X"^*7@VR,_12G;JKSI\M%Z,<.$41562ZV/,
M+CW/9%3,4\O_L1N?;%\M)RS;WS4Z\1R)BY\>_/W<Q;O++3/Y!,1G6KA5[UF<
MI)=YCD0;*S+I((L4GFD'MXVY)\TCX'$3GQ,;-L3AW!=-)TG?3Y'K*IM93(I]
M\?4T%?P_A5[[8%> D"NW.YB3^3#<D >R/.>O%D77O&S(N<'Z@C:2*@J$\4<?
M_7>2#7MC[DZMQH?.\1&K'MLUVL"%I[D[['\*IWA+(^W<,N6/)KJDZB[2N&/7
M]U/U?QU/*,E"ZZ+Y)58O:Q$&,E\@@+(,=M]L$MSKQ+7RY>P13HV@).>\V-TT
MJI]1 +&E7OC [S@I@>\<]/X]'[T&7F"87/>89LY+;<F9YL-5/MA\0;<1:.TL
M.8YNP(WD(0*VTU%4^A8X>"4?@DUD3.<<T7K4:>JO;2ON&GA/OZD38W3.X7['
M.F4\2T[D%6\)# ]P>C$%S#A D^WP ^*4K FMNK$C:&WG@>B3"F' 3KQ5@6DK
MI(WFNR9=]5V\NRZ=2WQ\+AO-EJ6]M4(@=8SW+',*FC%SCQC:<3--@LAI"2L/
M82B?[OW;3-R-92OK>ZA^<>=/YFW6WBL;37&%S18/PM[FKUT8$EA]/V5TK4(F
M0G*UEAF?,9[FD9?YTD;3%&N<0->;DGM/JJ?,F74BW0TZ7C38V2FM#M\GUZ!Y
M];[ZI(G%]+>\>UM;=V(207?%0828YNA,3;<:_VN\3)05,\&8!W!KQ[H?39 1
M1V3R[L<1#A'P%@A1MQ& )$'CRI^>H3_CG>]*F=/$W _ES>[7I3 ^K87!(_1[
M2-.!9]XEPQKK;BQO'3I]?>XRL<W.3GMK[ISE^T*-:W_5#+G+9NU!$3)142M?
M#C0GE029CD;NE8@1K=]2[H]9C[']X,F(R).2WM(.*?6I>ENOZ'*E3T4!N3V4
M@V3_N11D3<G1H'.&?XR4<R?\_C&. ,1==\VV<E=D1!1:M^&M$%\+ACR0WG%\
M0E9*ZE.#!$W-&J+Q[[71#=4P7DD4(:OLUM[%\[GW':%^8K[.4:&]\?31&?D<
MDLTG]I255P.5N/JFTD-30F:]!0>^;J@Y7Y.7T9*,K?<[8IF?C10'Y;3/QG//
MC6<T'%=![&E,F^!S,\1!^.Z7<I#36'RUP\:T!%.[X$#UO'7=I1M3BW^'PRTJ
M-$#E!GI5?3B]3. \A6\TT_OOY]$(J5LJB3J92!9OKH^2W9.8(8[/Z;_X)K@R
MHS]-_S(0MFFE<:UM_9CQ_11E_.Q&E+_'PYL5"L*^K</'KVE$BGO\@LT;^JZ#
MH7T/R_T+F0:8[1Z ?<C(?\J:C2_@%]>\:NFB9-HP++WMK!M9THF4S!6_J&7)
M_F4Y!\[CQR\:D'#?X,I\D;;!"&N$O2Y ],Q6-=Q>>O]'B,Z<P]BE@A"",).:
MXU^=8V\"S#>(+EOQJ@/WEA+/1#@<W7M(XLL3:2(U^=F8T]R0"<Q\<5R)#!8
M0\=*\DWY$F!R<YO;_8WGIE3F^<S"J_ZX^8O**CNT/;2.63]/F3"G=XTMXLY+
M0EKTF*G,VOZ?/I"BZS J*.7P* *Q(MR1[!AM2'^Q :)#Q>ICCHK]4).Z<_$
M5]OE+DV M#1V:TIV.LXE^OLIV@,O2<-#0:-+F_FV LE[.&_A\E*C.G6*%FU-
M$O50DZM&LAP&$O]J+K^'['C4N'UKXNQ;AT"J.(F_[QTCT'8\/;VAK7KYBVI.
MT%NH3&61%E;Y8W9OZ%(^>.)\N9=X^Z5X4$O\<,O%GE<R'@SB[7=W3^/\@#!S
MJR\!]4"$NHM)D6-8V*!R*-PY.B>T:2@#H?3,*\QOY2%(@X^);BX_X_^B7%J-
M3,(H9A!%^SO(CA$3IS5*?;,&@^'7^&L@YD"EC48R!3HFTT8GT!VD=<X7S^MM
MHY,ECIHTT[0JNV_A(!A;?3^7+YS.)37,2' 8VD6FW"*45VS=!LI#"0CK\E<E
M1UC->$:')HC7.DS[.O+DV#JD+;6Z.:3OQ^H*QP=VOFS%#F_Z1[#*''*LY0CW
M4PTZ[-J%SLF50D;?*IM'*R.-5Z, O8&O=[8A#-8%YVC)V(P:$#0OE%HKUZR,
M0FQYW;LB\%M)Y!;][,1IH7"V4D':R+Q>Q7<':*IZC5LU]H!G?(66L;+]YRA'
MP=F&M"OL>$(A&L!';?19O%7Z=#>:%LR_>?=HA:\V84@>#G53Z0#FO;G$NLAM
MJ)86KX"MJSZOQE7"$>ADVOS-_"&Z#$9^MZ GZ6RS=D:/?O;0HR\R SU/VSTY
M0 AY.4E+^ EICC*132AA#19<V5G;*1CY:S?UC>?]]3K#3 $:J0ITA%MY!0[G
MP3C*1^3*,Z+8)YP[41,?D36..2+[/C_$?$:%(9:V4$&RW2_G<]*<G1G12Y5S
MSE%Y>7>_?(@J2=W:6D'KUD?WMX[)7_YTAZ^4$%K2</PV:NEC9&[7XCP[/'G9
M-7A30MK877DJ.CUX);>PLCY<$!<0#H*>W3DF =,<8T".$PZ<DO&ILJ,,Y4RC
M8<T!E;),2N8[_U_G]8/NGX 8,?.DF ,8Q'K:\(^7ANH]ZX'S$\I5BU>S[Z$$
MDHWF[ Y+!C4F$*^<IUI'PKU#@W94W&9I]%B:<F#YCCTGXV>3ZIHHE&]-COP7
M#<W5C *+UUBN_"Y:)0GU['W6L5K(H4@[!J79*E2 _:R3,1\PI/CUP.%:QLW<
M$&]@,HW6C'8T>L\ -_YBP_)8XR*VK3\*T%4?5[8P,<Q<KICN34=,S2B95[YX
M\?2)$G*BY4/]&VE:9D5VG,5+G#=9; '7Z/REQBV$,DM5*6S$CY!6H_8(;V%C
M)KH.HR&F1J/-/0"-KS:0E/A.?,\CWY=/?PAQ^L2NE@$?[_8;D'V;WX8U%5=?
M(Z9W7C)*LN WOJJ)=--)%R8*A 8[U0BHGLKR7I=FY/83>[N@":4;G5Z^Y$(B
M!!R=/EGU5 YN.WZKT33JMJ_)$553E%,H-)+\(0'3U&H.'MWX-'41.&J/P^J>
MG4LO&0+9%MP'MD!8@=,0C#]Q(:J.T*#@^!,9J\SN$R"B8%(I3M).B'A?;Z_X
ME#MT77WHNX;1A[_95L6#ZA#Q58!8Y> A]G+!GJD=&J=1=[7.0/%Y0[7H:D0B
M%LBW&R@[T)G++-YI*?M+VXZT-^RR!4=YIOU[VOE1IE6FF^^E]+J=%>@5ZHPY
MF1D"=?U'U?=3O6I7)QA2C^HZ/(#693$F\!G-RVS1C0/C 7D]#QP:"$5I;;;V
M2W<*8A0HTTC._,&=GQTR%%RF:2BKQG#?OC=R!^W[6\\*E7ZGRM3N-L46\>]$
MM4 MG4M&9Q BEBS4D$:+['AF_BE2?*.IL=,.H5<'GGZ;[P',47/#RVVHW,K5
M5<3&2]7&.QK$X@/;^KD[#[<G#XR- !Y9<]*/5;,3;$7B$[O*]?N2, PYD&=<
MA#5.I"JF<_.2;_J9DK&^1R"[P/K0Y!.(JO"_:-Q-3.!7/SW4&;RS4:AL4D<]
M-=YGA//[Y:LJ2!-\_AO;M:XL?7IC/5)YT<P)I8AUBDYS9,8ZE6#D)C@$B$0\
M^:4V6B>>-8P)L#Y$4',4R_\2]%?I2HT2VGPF3R2[>M89:4LWJ17]P^MJJ*T2
M"WBTWP#&*M/T!$@J)&C<R-O,R$'K>9<IUU<=R0[4S\$\'[_GF5QXF";]QHBM
M^S0[-QO0'&SN<UO'";=N'!WTG%#(NI<49K4#-Q[A#D64,X:CG;!9ZZBD*R(6
MKU\PDQ(H?,GX21*>093O-%?/DC] 5OG_VD%&')"*['/ORV=)3/XH;"K,L5;!
M'[?CLN*6E]I0@M*]3B=QYG*+=Q,._-LM3]4D+QS%QGAX&H>LEI;?9'JTZX#.
M,I<L7$P*E'0JZC'*?JOR9($KY\I<FR*K[ZW7HV2?E"RJ)ZWI<EJCQRZGFV70
M]%LF(A1P"[$Y/:\_NW1U5UM;'>J.JJT3&CDD?!6X]$-3)5_]&F1GXZ.(YRB:
M]?>YIKY4@Z33V@U77MEX37FSE?82C65&Y3ZD'E<5$NC7'3;'Q;MH^)NE".NU
M']&L'@W>I*XCY8?!WALFHI#VOR?'4P&U9D,(FS5,HMDW)PNU)#M4$[*L%0TX
MK678W!#@KP:>S?'9N&:J_/72B'BK>#;"VVR,97">]*/VWV^ZXRBSFC#*B)7/
MV:E&F85O/3-DB@02Z!\$;_IO.GY HM8NNJ]3[AM6#U7VX/7CZ#>.\) D\R/[
MWJ[#VJ(>;/<*G-= X8Z"/.+V%.QA&TI M48J9=FFYMV ,#W7RDL'5@$;VL_L
MJ+TO_TM(BEMP1I\DM[;F!Z/5[*$ T@^&S61 OY/V;A2-MFPP!@6?%\(-I]YG
MA'BLJ019Q;Z-0E"?+?[0[!O/ZGA+]\0QHP$FV?9Z8AL_6>-=ONUH_HW]%<ET
ML3-]ZM+6&"$",1]]_N5(41H_+./Y+G*"KMA'Z#&>:;$(1_RSYW.*0?S=%8&C
MYF$T0UE/]2F8]#2Z!O4'+L-P9R\((:O0M516V;*.3!>81'D,:Q^&+ ?"5BE1
M+VR6=)Q+85(5EO8;2([(<9PD=9<_&%(R7'+U1^S\J)WUQE$RN9K!^<ZCDM-4
M]79OEG5=8<8>HEFD+;%M:>AK(S 0X=T.CU#$U2*28;GS"\Z?[A$4G&IEHEY#
M/3EE.-QKE798)C@D9G?>/<I2ZKKRJ</V6L_:!P9<DYD:4HK/0F%HA%T_L*>:
MYMMG<3<%1:!1B\3R'/I64>OPN 00Z^_6!.<+.> WC>FKFNHD"[N?A/)QR.AC
MJJS1L:4?,8=&JF)Y.LN0'R]Y[5=I B*STF[ ;M1[BD"/&.'P@YFFYQ&95RZ6
M--0X!Q3/KJGCK^;ROA3@0JIUA"?^M1R^H45,6/,5/$*IO*]]/]S"[M5^RE@+
MR!*(&U]M&$Q=^HW),TZD3 0WZG;/Q:0YH^8-?KI)R<MR&1\LV^K5PJH'(/94
M0OCV \-6!A+V-RE=0TI0?OD82.(?B#+VH)5BJ3,I=V5D^=2F?=9H28KWJ[F+
M =6(M KOXULY">_;XHUKMN1]^G7'=F!V[LB^@+Q_1>&-JE%QL21C5SM&])XA
MC1\3&[^Z1:8@ 07Q+6*N8AD9-/(YC#IG)4+E!M>ZH6^NX85A!_8HIXRVOG1F
ME$R9=5G2LXGJ.6"[!PW NER9GP]IVHT:"W\R[ QXR=BA0T$7B,,<<PEY+V:<
MN3HYIG%_S%!B$S<OW$,G2JU_#J*\0C/TQJD1ADTYD+!5CA$OKUNDF(V3)X:V
MG#L:F'(D.^RFS!=0Y0;F_/U#@0?7XYT4<[K8&[P?GWUU%X89G].+YF(DZMYA
MU@_A?\$-P5CC2*:3J7)EAI#Q'X];'8,$TUB/VUOC&Z'P,'?\!H_>\NC'_[DX
M_N!W(_L.4LRU<JT\<V+A93]P3)A*)9I=%KGL5[]R#3^V_[QQVMVZ-)&)>H1
M&!_;7O?B)$#KM 4Q2/(? RD=$0D8<D*>K(=PYAD&!2B+A-\2Q@ 0T-<UZ,N7
M5? AXMK"O'<9FP6Y@-&2S7;F?ST7FV?-WC=()1(&U&0BFFU5HVJB&XUS\A T
M(3K4BRPU]U_9$_ ]@+>G#)BW_ON3S3"@ _Y23J8ZQ\Q4.UX/=34X,;Y20VSC
M! @Q<1LX5Y['@(A"\FNQ!RR^WKM9AC>M=>?3Z[!YSRW"C1MP4JR-#$+AT^(%
M]>AP$7U72&1RNNL*9\54%;</9/>:3[+RM$Y4LS0(\F>-AY3+N%@JE3Z>/SH
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MP]]+?C2WA^64"+%'(MS%9L'4%P/>DF,0JZ^PS3+GI;]2P.P<6R&-;^UZXK(
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M%^";V+:09"&1/$@\ QLO'6HSX+SNL^X?\F^@0IN$%D#92XW*9)6\#U:?2KY
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MNY*TM93U23.IDI6& _!/B[\/_W_M9_D3F*.>TU:K+<,VV2HR'%BR62//U<S
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MJGY%U#;.@R/J,IPD:+[;--Z*-.>\KO<%'_J0EKWUPM@?[[+6%G(;=A&D2M7
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M>?F/6K/^G='4@+CS;FM4X^%(A%I5A*3L1Y[%&58\PAL4&/4(<)E'BL7;6/V
M(<5)%UX.:#Y8%X1TE??%#I8(<$<_G(>5!6^O<X>22(TP@;:V4J=V'CNJ/Q0X
M?U!#K8A&"V7&5O=/_ 8<?+<D+20-SZ:G8Z,K=T+E7$.#!& Z.UR$-)_R:7..
M6,';!+:^<$0ZKQ5W#3&!3/=5,T\<=VH?UC4TGG"A-\IE&CY=_IM1"I(9??";
M_1=/KYW'EGNB,GV';?=C7_G[NB:W#:WPYNP)^/Q]9_2GRZD),*79N:&AIR-Q
M7Q[]M6,#'+Q>)[%ZQT-WPTXD-G<[3^J@ >RPG$.B-V%0U4">/0%1A>QZ*MSK
M]SC'-<_DP$8^S)VZ_<PZLB+G#N1<H%<C:=E!<)+2/I,I_>V0E00ZY!AIU:1=
MRFA],_-Z.^_AW:;+OTRQ-2^*$5[T$JV+Q5V.3M/E@4?5_ DTI:A$H_Y*V='
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MSQNC1_Q5UU3E17Q/;:7 &TPJD%%/#-H@B)XH@>/@+Q[7#/KEBW9GN%'>/ Y
M_U)M51@OG :/WD?@$S!47[I_MO*M[+I")!B6_,-W-73/HF$_E< I>U__)@[]
M;ZK1-1,3B/=2?.]GVTCW_5Y*C.!Z12WH5[FWD56TP@^0C]P6-"5\=16@?QGQ
M^MPP&,%& S.8/*7X>:L:I/L"G7B]?D))3^-!6KT\)E*('#H'_QXA2]WS2J"2
MALVQ2U$USXGODWS8X$]FW])/'Q/_-/V)?YF]R6,QRU<"&O;6S1GQJ_4>3R84
M!3C@"^8'F,4P&/QD7M?'K;<$)BN+P:-UB%CM^"1MS['_X!=96D>@&#TNA*,O
MUL^,Y6DV#-CZ#^<7UH&&:D*+=4<JAYZ<J%WFU?+U8,I#D[>#DU]ZG]Z<LFQN
M=//4C')#4%K;=*92ND"M4<J<K4<8[DS]VPKFF?RK=$.WL=W0A$2=895%2&\!
MNBY1I2BJEB=E.2>4O6Q&>J(]7"[_\SH2\;?L--.;GE9<5!B5+7_\*77HSNG2
M0-XF5-IM'+:S?*&2X?>+FU;/+(/Z/];[:NGA<*RKA#K:AW,ZE1KPL)"H<":#
MC&:=ZG^,X0\G[+A @([E7J ?1X@MIPRJPD=AUMP-M\)K=REU$88VK7..^M4J
MD,HQSV3*G+%3"_U"']30T0+U^R2^;>Y*F_=?]#KP7:XII:^0)!T8:RCZ^;(A
MXE;+S+DL- .&5$= NICWRA':8&/QVY]>-MG#8-_K\F!QQ>1%,KKSU]ZK7?YF
MN_]**'?'@3]%7+078=Y"F,_B>:Y&O7BGI+L5.2"GI:77YA^28(]N>:S)HX;I
M+); 7M,'J6N]G&,]1CF,[@+"8')8\H2=PCRM*%6$HT#5:]9P30@ (<=!JW*U
MD%+H#$LG#+I\/?:G?W2N'Q?C&;^[=A9-A?K\_+A/V77=F("UN!;FY!\14?C7
MHZ$=YU=CWM1RS,@DFM7<EK4TO6 O8%)JUP$&<:LQ@G56#!5E([&OJHQYCLA4
MV$):FE88%J."+B1^CC"G\CS9%@DX?'<0A>4]4>\[:5LQT\-NLP7*46H+$<;Q
M#QB*)[S>4MZ2C05)8)R/HXZ;9\&N R$A]R33O30;_M!"HHV26C9_4&2F\"XQ
MD?(F/S$4IMQ4Y9(?W*Y_0MM_.*S[(Y+OZ$->Q;8\R#2,NV=X[7[BBJI!__V^
M+ F0AM$>SG-I'GG?A (F@;UJLGX/\*K$9"N,][X&6^1P]&A&SM%'P!3Q $C%
M"7/&J9)<J)9S%^BU.U91+(LJ=X$L9';S#H-"RLS;!S,Z.V;5<XPW_G2?Q OG
M8N,>?'?4,.T5_2+,\7P]A?),4-93XROF0"_>+IOWF&L;(-A"3E;9C04Q*0O^
M40+4.9U?S(=HVIGZ32S+/>GI9#-D/;#B\Y2L\_S<_ 5]RY07?XF33O%KF$6%
M?_C[0)R^Z;#L,R_Q_J"2L)>82!6<V&ZAMTS)C'-%IX X,J'\%\#PUV,!:I2Z
M\XC,>SV.\E4J-H\\)@!WZ36.@8%GCD370/):7X_)T=%MR"O%*  YX][#[U%C
M"<)/:[O2L@(6ZD/WL\JR](U5>R5J/H69GO)_:5%-1;Y#JWJ%"8UE6>)=2&6\
M5-MP[.W5I0952NW14L&APJ%M<72\NOD4-[9_L2I00Z_,<D;=Q$AWJ!K.+0Z&
M.E;KKO)1R@K9>:Y>%:EHOJ9GY\R5"07V9D:/RDYV/*%MIDY"2<X9:;&??X$,
M':STBX,,\9#?UC_A]#1^R2^VR?%&\"AOB"NGKIX( VL4-FB9DGHR.  U"QV"
MV:[R6HX,G>08YZBP-@'N$(LT,!YP-1.(C1&@=J"VE6.QYO?WWZ-3:\3PRM)]
MC.-EE+6]DA!?O]GFE3?=CKH6I)H2L=I"62FG /X@OZC-T1KF["#\3UEOG)_-
MNLGA)_FU)I]&C#=!\AMDFD /H%C"<$BE>G.E&)4,P+S9VI-8:#P;&?W*Y0YW
MFU(<.'C&__QZG5TY3+T@E8D?8T22NP(HX9ZD><6FXA<.2H7^@;RGXY,S"=HJ
MZ2EZ\1X"Y&@]JVM,?**&:T8$NDFXZ^/">* %H$XG(])?ID[=G*H+J8DN;4@8
M&+&I*YL%."R7]>IM ^480CEJGK0O_?E^G[L$\N,C;P\Q#:=P*E%";F/K#-=7
MH%11H#9(E/?3SHLO9V7:5"X+"'M[%U?/&^USFLQS0Z@K8DH6]EO]9G;V_FE'
M>> 4J+=&1\0#!KBJBMH$G?FR^H[OK]FV77E*50J\UYZQKW-5W(GX<UCD8GL#
M*LWD4%S^ZY_71HDV9@/]J'"%;QIZ+%-3"J)Z4@@'5C<HQBEKES#5H;_6DC-O
M!V#*?-Z'E(G$OM*H*JAQ%.A*EE.-V1]@-[&3DE;9U>=5^S9""^2'D6Y#C;KN
M;!5F*]+[FW)5LAUFGM ]\X<MT$P38OMK3(%A%<0Q\5P%IJ,"N:*DG:BF=[^O
M5&)&0ZM]B*PJ*K/_*R<XP',9>5'9NWU+B:%@ZG]REKNR[4YJH1<R(T7XHA,%
M&@.>_ X()C<A\9FOT<')(#(.Q"TR%VK2<SHJ_D.\?G: DS;767([*?)^;\5^
M5,W.@54XV(G>U)=42LD9'7,[:'J/B&>VW0&SQS-[55Y6,G*KAT,&PL)>1<_,
MG:0;\=3%.K7/F,>S395AOHP8><":X^^U*G;A>:3*ZM1LOO( (MQ=]"?Q=!"8
M4H@V.D%YM?WZ^R;9(_CD2K$)=50QWLN;TY#PUO_:\>=HD@134D_"4KA.=;B;
M$5Q+^O#R5)BFOV3%0P5R&:D[=2O#"8R4,TH9"E^X"8Z*;!^NFVO.;>L-$>0?
M3)J?C>@M&&"^FD-EY-!_IQKS"JK^$= 1D9YAR<:T5**L.'MSKP -%DP+T9]O
MR-.*NAA^5<%2GX-EWPN2;YZ#\9+Q_.:VY[ =*72T&$R9>R[DIFD:1^!S/%N&
M=1V1DG&"#Z6C<.JS#) 6WT>MP<X$&V=N8KXY%O6,P_)"EE#--B.QOZ#&LQZ'
MRR0./<]_Z),1-4><*N%A@TYV81]7_C^N@A?]T">K8EZPAD-\#"<P8D#(%UMX
MUY= #S7*9_;GS-UL02"4.V!/.E\S2])[V?4V[4B-RQ0M?#UF^LOGW7Q%"$A)
M3" BNS6]*ML,0Q:BPV.6-(*Y3DL$PP75OKQ;1E8PKHF)1H.MA?<JECQ?MZJV
M8Z?^]=A(O&BW>0]#YY3K:]R<*S]4>^%6[5L F=I1+OOG]0U3E.P][WU:N)QO
M^4?@J%X$?_!,4X3D0_. 7VB^M#_4_&])PK) XT&F&T/"X7T]MGC)^9D+\L>1
MK\? 9[\>.Q\.OXQ^V[7J]^3=6#1IB@XPYN%L"FM;#4&M[WF?%57#3>,/'S?:
M+1_4K>6"NPX2BXJ6F\+\R<+TJ&WU\=KVEACOQ-^AJM QOT.N\==CV^S?Q4^+
M#N 3 -?\WEHZ+>IB\$Y:96)(RE9<<%GHQD32F2<K8"L8W;@G?30?WP8 Z)UM
MG4(IJ[2'UF9B*[+O$3?KR*(PS;! JK-7B(>\?V+TL*&U=8]WAK7WX1L_AGWI
M?\&..JZ/(56T7GX0ZP<MW?)>4:M("6\ -]@K/BW.)C_N@9=!3Q7QN.#_NI G
M-2Z .OZ52=E15_W'NG +'$E9MT9\$<X-9P8&\XJP15Y(UDGO,N49\:6%V3DU
MN\6=R=*#;1FH;)@1'QS?Y+2+L7?-\G,*M;(@(4SN2AOZ/[YU)H,Z2M$O9VGM
M<8(-V:4T37IE+IG66)G)/ 3I9V3KC:GM=GC73$>*H+\UX5*7M(CD5A--&C(A
MA'^<,5FZMYXAKYHE^B5,\.^<%>RKRP6_1Q6F6^]&"B$N]';L_M*'L0,C@&['
M=NWT@S[>=<F5R03U6Z.]UN)JZS=E#AY*2Z1OBHBO6[2")V^$[$OJRJW:B*H_
M6"!+ '4IJK]<;PP-@5%ETS+ZK!\K.P"UN>#MF$$FBW7!++WVY:6IXI/H!0K=
MXXO)'$="GEV:EH:U7[<=#5^?,[U^SU%FA)B4]W"%B0Z!+K4RM1%*@UVUG3 @
M>"?\3B"UZS:JDPS'Q52X<R=TRLG+*\LZX,TS=DM$5:XWPR(9BY0<3P/;E./]
MC"R)-=[ZE@3-9"ZWZ?-R.N1:9/U+3:_L<VE=@82A%<.F!5CO*AFIK)2FY$&%
MHV/6=6XBH8A2LY8;\F7C*E#UR/0N+7O!C^6^O.!T8P/>]-B YIFKUGYO*TR8
M'CT),::3-N\$IL."O]+N.>Q5M]H:=Z:/UX/]3@,5B9R:-],)&O"; PKQQ'JF
MQKZOGXG9$4_NF(CK^S-2_]2++$Q'6BT2<W5>AZB5W'?+J\"!]OYS_H*4V+"7
M>'#-N@<U-Y[E,W'*M ET&";!H(LU 7-I*9")L]>?#T\MR\"]E*(U+PU>!CV@
M2?SUV"^)[R3I+24UKZ%?S%W@WK*.PG*W&>HE=$BI?GO"^V2UOOP]GB+6_YS+
MJV71EM=!9[="C\O9AOSF!J7[&B[&F38.Q;D?TSD?)P\\X5/3[Y9*U78677NR
MVP:VU!,#!Q77P2>#OQXCU79RC0[S@'K-8A_]H)I4(+V,L!/M\<E.I)G<R^00
MQJ4^U(FX+T(4]V0JFU'/62'BA<$5DU^/O>UXH3I+:5M-$Q%-X_V<7='K00-&
M-V >*F<^=-]J:C37EW.#)#XMANNDN#01/MC7F2=$E %+2?/D)J8ZML'>T.K$
MS6GJ*VI[RM#78_AX^6JEH@FR5* +I10!;*JNZ2491P@^KH7#"KN"SB$DR[;Q
MP@I)44<_2"%P3#G0.]N@_OWN-13H- ([9ZJ="(B5Z7#;,8*3]J4^@6WH]),*
M2D/W:^TJ=HU^>9)H6![2.ZEZ^!OI0S;2?2;;LQA^)@*O'9@&4.<ER9< XI59
MZ1=A22/5OR>PFJ>72[*6WG$16WJFB88!(EU3U9)E&5JS3V^C(X=.CTB9J\0L
M^0BX+Y.*/Q(L\\8U L(PL\ZKE/@C@V^^"P/5U8\QEPGHGMK:CII"X^\U"*_'
MS@?[(RCXM3=I'MVY&^N0WD7M9(Y4NC:ZGUKAKX*4-I6I;RS: L^W7[=$#.-.
M==H<_'L*!>W]R#/O)CH\ ##N%@#W_\63JIT3C.VW(>5\FVM(#+/]C<*RX6$;
MUHJSF3M>R'(EU?4?#V/30E[@M)[\[1_Q>(4%\B)<:>T#\A#1GQ.N"9[CM4PN
M2>#J2FE=2?[(U9?4764@DD,/C52'SW6_'T*[?':,_WK,YO>OQ^(R4G$^4:L"
M92.A)UH!\?48^WSHA*ZQ\:2)>1R99.<##'!3C\1+TOJ\#S2 N3;6;Y"?AT<I
MIJ,6'UIQ[$]%_=5Z2)!1LZ*F,56),J]G8P;[UV:L,QJTHF\*A=T=V5&N @DR
M)HQQQP?>\7JPM6U"!8L_)ZK$,LO\%9#NK-L4936O1;P=OB&$0&QV( @7$U-M
M4JRVZO#O572^ %Q;/6%LU!!;D=LXVM_W1*+7<_1KR,)XB5>%M<N3PL=UM>;I
M#AY-@7@+"2%U)]K+1_U31>'!A65^!DGB*P?KW_E'M7I:)NR']APPBX1HDOVS
MS%#B+^I13_P;M$EUT[=]SIH<@$(T_+-OQU3:=*H06\NUGT<K@(BE>@%86Q>I
MT9U:#YC7;E-6U([0\MR@ X:!5+I;8Q^R#SVS;^LU+G*U<6W!G 99KY7_NO R
MA/PBJ-%"S6YJ[O#T4WKOB4* CUKYX4/S9T/O('\KE?\@&&^(OP&!VHZ(.[_3
M FEZQG:B_8',5^1'JTR(<U,LI_/'-(L(D)/M?!XT8_YZ"2':I[Z;-Y5S0TG[
MRQ-]XJL'*^?[?E[FG:VMM1VJ#J(%WNPZG/EN#OE4R@D"-S[$W!YN<>@@O8WF
M\B?(X=E<.$=\?VYF#TD1T 3M/+E7\]SQ98=+ #9)EB?[5WU0:K,BT[O0C:%8
M7RSY\4RDS*MFI(M+0.)N4B=+*'OW08=1=Z ,5G*.Z1M!*!%EV6$U['9FRK]%
M34M.I\+I@>!FV7;SUV,_RB[VA'P]-N5J?^.O&JZ/17X^/2/*O\R^*.ONPG0&
MPL6O$!J=Y67K+RKM=_)>= =4M/ JH8DEM*PH8FT:07%@X[+?W5,@S=_RPH[H
M!Y2U;&J K=%OT!PVN2"H3 Y\DK9)QYL\$!G=DJ2UZ6UM[969AQP62.34IOF)
M&SR^2:F&,"8LM^7U+WQFIF[=CC&M+/BO?4C=WQGQ+8,9&Q9J7RSR+SIIU95#
M@6M4 #=NT'I#$=ARJE>:;=F*#@,&5=;@-X)('=YN#).&'-1JU 4:EKG<CBIW
M.7CK5;<BDX07T;TR4X5!+7&&0%+237 FE""8D&<%0C5?;VI;Q]]3+NGXM,-K
M1GXA!F6T-Y3_&L!^I?1SPG7;DSF:+?3ZM(S[,4+P"9OWV=W#R=6V$>B$!I<3
M@27J\/B_.O9U;4.@\LY347]$!1 4G3/"C;13IY<6$:I#?<KF%=X<ISA5L"?%
M]+'@Z[%S8 N/P[[K^[\=.MSW([T;PRE[TH(S>\IS3Y3OVJQ/C.2?Z*C!F%'\
M QH:3J! @TY4I'SGLE4-Y5;7(#M$Y[RR*\KWS_YLLUB#OU+X-^+H*V6D?26/
M>3IA23ME3K]0 7G8MJM6[.-7(=-=$[KL^M^GOK !>?:A*S82VP;A[TL"9-"'
M9VKJO6Z'E@']JS/3M S:3UD/6@85)I%/FX'8QCAGZYJ=8,4!3E!"?R\%89(R
M\AO^6W6'%*MUF+R;KOD6'TZ47PO8\L%<-&U<?!CHB P1Q&0K,80*B?:=--;S
MS!!P<;C<<&-H6!/JT%GN*M$!56EL_GJ;O#0JSV])O&?N-LHPDC4OE3<]DW;;
M(JVXNWH[Q2M346'PA1R".W9/E1ZS@ I?PW=^?['ZU[2DY^N$<8$HL6[KFZVM
MV)EDI'X]YL/=WW$7 RH8H3S=.V\ZPMH++"OS]RI /RYN_5K4(T/>4$<^2T+X
M BAJ>_ GVLG0.CCY#_+V4V)C#Y\:3"[!+PQ9%$6PZ6#)ML#L3,*4\AH-<R&]
MBU)OQ]0L\.DGS3JJ^/0UFSW/,:7H?YI06K/5,^)@7ZFLU"C7F/])*U;AZ27O
MV+I\8JI]/IS%%!Q_Q8AJ%XXWQ2N&5SZJDAY_IV[#=85;6ML<XCY/<?(Z<O,I
M!3<PLQ7>NWS1SCVE^<TBCZ.^#7B+]<S%[PR\6SQ,*=K".%@ %Z='M9F2+GQ>
M=HG$;S?<M:Y -[B<@DUMMDI* OY;2IIB!(HDP"8!]&V37ID;]2]O4]::3+/T
MZG##ZUI<0 OU4S-I[L::+&^SFYB)?UJ(7=O2FM:[NH8.&I[LMO.[2_N@H, O
MAEI-BG0N3?YCY&\!0GJWV0+:1PF.%TFL;;P,U^Y)C?X2 Y1<KN]VY;M\LK_6
MD331#3^!Y\E\A9S?@0<&(UU%^\T5_HEA/*B <*_MUT'Z@R> *A=:_BZR,QS^
M$[]*CM7)B,_Q6KGFP&V^V4G8,KNR>#MJ^[SJAZ;M<5GRX[+"EU5].^]>H4"M
M\8?>@<GSL+'QG$:4M.S$6&4&SL?*F[_Y#'4C)X@O-@_>O^BC?/N.AG&VB:4E
M)2Z[^E]_X\YGQC8RY<N>[ICP(FPH^UK+K5H"^+";)(A$1S!-[<) 92LN#4$W
M/K7?T7J06**'8'@D\^.UCO.]Q\,]\>_X%<J:/@ZV2F;)E/G?5I]VWE\>+)L-
MVT^'0B(;NR\8$[(E-CV2OCQO_:M65F/%S(>C-1]S89ZB<$+V6IBF\=I41UAZ
M*C.R%2G9X]S=BA]35/D^RC&&R&@(F8TJ\%<GVUJ/?VY_60S/$$(CG,R6G[AF
MK_4?=NE.'&CJ^MWU/($.4]VQDE=J?.VT=^79=(?29I5_S0*ENI;_P 8X93K*
M.Y&9&4E=<CIZ^&[;-;70&/S)3@[_]5B5<'K!Q>_$Y6S=_W*)J-K.H 46UAN4
M6P,HUM/:_+LN#H@'4?U'^*.* 9;_%UV<__]\2U5=5/I;VJ[^6)W+ZJ4'X\\*
M#@R&1T=#'*>S;=Y$#X^:0ZQ[A)-'7X_=KU[^4=-HGTH3GST;-^R+EB/TZA +
MKEZ=J A(YFYGG7KZ_K4;-0OYYLNSCB&_.4^J"GORP781[D"WX?A=1FV95AR4
M5+NAD "$K7+T%TUNB1>Y8J76?0_2E'J^267+R:2;!KZ#5Q%N,;:)A\=5ZOE!
MLDVNY-^Y;]U:/,.&WTL&(?W@Y/>G[U?<.8":3<EY%]R-VOMGPHWZ]9@TH^&R
M'8,(!#:38O?K#./E?NSPK1![XM^DB^+6<?0G"5AIN$H>Y,N:>1+MO#6GE>(U
M5R5HNF>BK79_.ZYN4'%.1BB];Z70RY ZM?V;_^FU4D4 =':?CW4\I-S)9#DZ
M<S7"/'*^'G-<E,WE%/WV?)DY=K8X;"QU19IT5(8KK1U/M ],N)K9WJ*E>&E:
M_T55\XJ/2^6*)$\ '54H.!$2:/>Q%<4C:3A#^BMM)+&DFKH7(EV0'S2Z'H:Z
MI>[E>"UX=S@]K_?=%OWMV?9)6Q>K6N5/KB8)CVX''-VEFMAG)+;>[-O&5ST_
M?*>',;ZG\>M.#!-YU6:7UG6F:B:>4WZ7T^*=;\O67\5<@W DGXNS!J8[XG\8
M:ZR)7NZI@/<6/#Z +L%DE[_Q.:N!E +\*WOEU^S+Q?+H>@Z%FC)_JL<RT!8R
MRC;B>:E8/A_ML_(OJHBGWJ[9(+8C_5U,O,J\RGKR67VUYF:4:)(>C=H^M89+
MEJ\= =7X>[[74WR_2EK;_?.B&,YH(=!%>+Q"&0!/%N*,/-O<EBZH?0[%Y>>/
M\1U5PK3(;=,Z80Z+I*%;LW(9UO' Q'8V4JF\Y,W*P$GZ-@;$BB<RLI8IR-#!
M<.XD ?$_(:GLJ(H_UCHY4PH'T:U=XM*S#@B7$C[U?3U6X5M$^,&-B?M-KF\#
M\6S&,W1_([KR'QC/NS@HW\Q=0MUM9D:Q[Y7!.Z!?CT&CP6?,S0]O^-2JEP+#
M1N#,H1J_U4 LV'0^%KQ%L)!#>YY*&!6'O6P04J)3#&_75XP<5SF9[,#HTGMP
M(S8:Y3:%\R'5;Z\XN9')^28(>(.?G*<,,H="QW3E7_G?+VN^RQ2M0]>X;&@M
MMT!&R58K>M$DLBB2?IYM/^=-(46-O_+FN@&3%*[<_WK,7MHEJ\0%QD^"UY<+
MZ8,I2GQ0QL:%1<H>+&&N\[NHX5/*R(HF-NC4'0=^SX0<;/<+66$&?W._>#1A
MM13>C&8;$Z-H!2?N4]4R)?ZP;(W@0F\218]G@AF=(MJZABGEV]U-\W)C*OP*
M"1_[7,HW@WMQDPM]EYG76+G6"%3"PD@?' 0VFCH9F-V_YY@W=.)5B7G4J/)A
M/Q(F#G^.G-:D/$\847+H;8X!JO:J56-;K5')CS"COY7PW9E(G$_7+V<)GFF5
M&(U)6G='W?'*.QNCI2&DM2V]1XSV,:_ ]U3H!=$/]NJ\6#U!'T?--,=CQ+)T
MIE8O"GW*)[:--UV5PNU8]Y02E;A1WGSUAE=[R.OF!7_:H%4+IS&LX=^J,W,/
M*H BB@(\?-K@?+GWD4-^64>]$4P$)-)7IYD&H2X 0,VE5T&K.H,$:?Y\C2QT
MYV2[MEVMN'0M6:]7[2WSW;,NAGS>1ZE29(E<<J6'%E?)U_-$-/:=Z-S"5,;G
M3L-?2*Q #Y>1)R(6B].>=-.M@]Q@%'[4]WCNWL/O?\H3TS4N6ILD"*$G=Y,<
M5^  PMP[<F>#6H&MO51![\E+^,@;JJ:C^[8EJF>,_:X!F LH1R?U1B";%O;+
MH8@I4=&..?H^J?]>WO1T?%Z&CZ58K[SI=4@];Z;<\5J(\@RGNE$ *T>A(V2<
MP[?UHX0BUW%IE8^F8*V.TGX9!YJ1*7NO*QYG3+]:\YFABMU @FM\3X#H5I%:
MM<3K!ER=<E$>H'SRG! );9TNS?Y7B;2\>L?B\J9OQ(Y7)K1/DG/]IZIW7T#O
MRHG$U;8K^T:CQ:EYI-8&9BYH=&3@A/KV#K9%I6 AS%SA!28ZC%V/,G%K[THP
MT)KU,(T'%'$.?T8JHO0]*=2W8124E0:E'9E^(>SN:C66G%KW0J[=$[SCXPO<
M1]4" RB)]1U"JYM4YY[;G7@,,68-TGUT=>F3-6U[G[A"*/)LK_+!#0,HX,6B
MV/"=^R9ZBR3*UF!"XN]_N8+>5Z74.9F=XR)V]4X *:7&;%MRB,P$GU,?#KOQ
M,0XQ&.IA"^8(!7F^G&!]%:,Q5L_H&1:A>?T,K31]3;^TP0#&+N^O+T/DRQ1K
M6J".*B2;;D-'%[\SZS94U"FT_MOD@ *&TLTZ=_=@G4O%ZN6G;KYK-R@)0\@0
MNZ7Y ]I(Z+".M+M8F]TQ"W/*] Z?/MR5]0KEPE1&<%_^JVU"/[*-*0_7,-YZ
MUV-IIQ ;Z#%TLC]YX4\@R;S4ND\J4PF3C07X?:?41+-V_Y29B!];G[^4]CIP
M<C\"CA:E<-XS93C9CF(W#%C=L_T._Q8;=.T0N:3UX&9TBF_FJ**2TO:[">VZ
M)"M7IZ 3/=_2YCJ"$&Q9C)HT+T#%4D+[;$$_Y'$84RUZWW8FZ?C,<U$U902U
MQ(T^<GRTO(2Y'6V\V?R3#4\X9&VK;68%M(YN/H0POAX['N'*1R(0CB<&Q4^8
M*ZEF;#Z VGUK4.P"C9#&D\+L7V#6G"BTW!Y*967VGP'X-V@#AD]?WK[@(-"9
M4;H,OHWEY15(PK#M_VG>.VMW:;%4,_-@<B$JN6%.GA-FWC8*8$V56E8.UY7A
M9;9*%>HO;-XT@M<04=-?2$N8TCX_[WTX'?<@!4ZN9E6^[/FGTG5P B9QQK;%
MOD6M@6VM3K^&N)S>(9BTK#DIN'C%WSGT[/$.&WD_E8?MV6[68BK GJ[>)\+Y
M/R@8N\! N!^X1?F4K?#,C*AG:8B<.$*/"25\M9;B(&&;L!JK$";'Q2MALN9Q
M+7?-E %[C00B)RW/6QM05JG),B*W'%>N"<?.N+V7[MRGE+L39I7;J<6=Y2\[
MXN]7DJ-3RZM?5%FCFH]7$ _D&/'UK9QYU@XHR6T8I\08!=SRIBQCY#+\59QJ
M"9^LD0COFNI;5>)HE*OL1V5: ;.]>9HP0_R=BN'WR^#H3F[32KQ9,.W#["-"
MJ7\F#TKU*/X^-MQ&TG/B=9$+Y4C^\A"CDY4VV+^2WV9*]>EBPA\$0/Q:6R^K
M6 865!/-PWA1WEJ>\4^GX!;P-\C<&$O)^$V=#YD&5./,L+"&SY/\B1>9&971
M6VK,:QS&)!<[WQ8I^,.S.,E:=]#W+?HO*@O^'!VJF/G7"NWW'/Q*I.?C@'<\
M_ZDV<8E:W5N+?P20T5+_2MPI'S\7,8-X!I1KC]*](-]\/,>V#7[.5BM2T.J7
M<]HW)YHCM$V(J1X#\7@%,4QI_5M/.M%5TQI[>P)I;0O</7#NR)4N"JM9?\/B
MZ/9?%$<L?_!0:.6T49?;I"8J<2*9+ZVZA3<Q%E!710F[&6<!ZV=2"<AOYQB_
M\X+I3!V)=["0XLKMIE8$,-,T8 !62]:#]/G\.E!\"@R.< PW.3>\ @.?^0<D
MK]S0]F6FNI$4;T.U"]D9<:O,S'Z?>>5+4'_[QTXC=7J\;XW;L@61DE87O:41
MS+UK)"02?%<( ZX6#.-32;.53J,?#(.0&F?>3Q;'!N+?[W@GV]^&>6FF]JH
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MAI_F:2"/\PW>L0O.N_Y^3S38.JSX2\4'G"*Z/<E1 -> (4Q^,K$%D*KE^DI
M](6BZ/Z*SY[!U;7<WW.:.^[V*55YAR84$7H4KVTOI$!'!4DD0$!+\&3_0->'
M;0E:T_%V 'K-6QJ^(#Q3*IVJDFT?0$?J;OGIX10Q[ MY#0><"H$SA3+&9G"$
M,+DSCZ>;_%R-!V98Y5#4K%Z,B*?4I^*676F7)B!W\I#)G^Z-))<,5#]O]PT?
MS"?M1;E3-))N@D:L](N35?$42CL?6&Y55XE*/_2E\:+Y(92:*OP&[ S0F",-
M"&9,9D)\Y1]_;'7PJO Q;PV!6L&]//N*>EF!T(-[BXC>P+W?GD=O=FQP6_Q>
M;$PY_&/=:]8>LX=42(I:MC5_%$9J6]FG#/Q<*_[(3;[@NP6YF7YBURZM16_^
M$K4E8_\?L!4DVO=%L*Q# *QA)QG\G!9>!HF_*1F82N'4Z&2]8L4_>J&G] 06
M#,R .<R2*)KY,?5>J>'N&R5U>^GCV3*4(U?L7#(V0596IVBD9%B'&U*RT/N,
MZ]^\;S\!&;U,;1HM!&)&\G/.MLE1I)\%2@S%JU^(,G4$V((W^<BN_\?-I5CF
M]!^E+U\W!"3DGR7=AL5&XBFO$C-_8 ')2F5:'DPEGXKF!NN"WB1X *?E,92R
M_I"\#%6H)D>7XBV0WY'^T]NV7/LF0L^[[KBM^="+Z[\93]^#P(Q!>2?V*0%I
MM=^R/3[3J2[\7A]LZAOP4FE9HP6*@F5)6-KMC6($/XZ>'*O6$OL^)W@MW_MR
MT?>>X^7KIRV%T M7WAVVES]^,/1E8<TEWNH;F3:7AZEXVF79W;Y[,4-(Z]IV
M!3Z/C_5 C\7BIS(,+5,90CBRP8?2J[X3YATT__#B-S4V#RN&G'\N9O!B.!E<
M^U_AS<='4 #2'JR/:,,L*>[(CFY8J9)-M_270L+@LW;+"K(3/%]O7@\,F73R
MD]M:FL19S+M9WA!]U)'KNU),RRC\HWVX^3@Q9@YY+JW73"J[TK0$#3][8 H+
M*>MK\=.IP%^0"#TGY D/!IT7LBKV]>H<W8$A@!%$XG 7=[;%$H'P[=\""70^
M@"8CW-%>1"_-4"3_/-H?%=;%Y!R-^VW]LT(2'2:"PUO$N("9I5_A]8,^[5AI
MKFK;ETJ#?>2W4%O$-_)!%QK=CC9L'&@Y'Y6=I+A@T_0 "M++XC/?/\<W4%VX
MM\S+HQ;\W0GQ+=AO+6'TY/(=KI2/6BYU04A^F]PO3K(Z_]MN5>CQ-PA(5+9<
MWX13L;9=W7M^C \TFMK*0U1%(Q5^+95@;3*P4:43OO^:P@&K=_)E:D-DZ2N<
MPN^>-5QD@ZF),01:#$-=HN[9C&7=\"[GLO7)Z#^)Z2[S_8A"=(6?!OH9<A!%
M-#ZT%J4LSI(OUC9=YM%HV [4J*O9R^9O$29[$,F)8@J.;+0R1&%?C]V:G7LE
M.^TI4OG>QSD/EQ5F'7&7Y]:&%7ZIT;^HYD,QUL4-4:_,?@H@._3#@S<%[;$:
M^'5"@D[S2G@>A3>9/&IOW:>ZCZ&!PFW\Q<PZR!K[U3N;^+]'5V2!S7BJRW2X
M,?.E0P,=;/ST30QW3@%; B E+3A,C4K":.%CBRN5K:\A5H9VW**80;XP\5TM
MP\_::O@L,, $ ]9D%:B>,CIM<KMVQO(-L*P^FC>9_7+F,LCH@]^EHH6_I6$8
M#2R[CQTK5% ,7_?%5F$47<P?T;0(0U1,'2+&.B)%C56E&5ILYC\MZ">BU,X^
M0.XG]W<Z%]Y^Z6IR 6EK5.S<TXAE4O!"9WEPFK93*#QD0$>AHTHUQP35.92Q
MV:F.J[TL+9B"0GY,-.@_0XN")\A-*7C2IY]VD(G7YFKC48SHTINCRR?9FUY8
M@/KMFEH[]3O^V+G:A34A/'9T)A^-8:ZE2K@6S,D789LFI!,.(E<2>&(+9"CL
M@2GG^/,8SZJ?$PBB&DI0LX_D'CO$-8WN7[($2':#GWA:7LD@&VO#F('>9^GP
M>QU>],L0@OT(76,#1LYG#\QRJ$6SK_)PL=6FIV[V!YPY";/0T?T\<OF;J;F9
M33-0K(67\>DU-9TBNS#I\M=C<@WU*RWGYRAEG2&_C2;I;L1#H-41JNK:->0<
M"BA!:0ETE$0IF5,<F*Z;(+%*PZU?#B/]M)HHN^'4G3>0R:_'&.VQ^X')GWCU
MTHEMR2\PS+?:61%6Y/Q(QFJGM[U;M3!;*W3"(EV7!ZM?*SB7A;84]5\C?]1$
M$-.ZKR=FSNZ?S*W8/PV6NY.=#ER@T>T6R!Y*3R7+^!)*[/ITV7__GU^XN*CA
M'^!?J.ZY:'9EL<T07_XC@ X;1I\<V*P601)9'L+:F+WS$6YO^+?EY*\ZWTLY
MX$Y*#ZJ:!U10,'<B3A'05\+?E65B*OVS+^!K5X. [3FO_[_>U/@W;LE)E\61
MJ"3A?*P-#3(RE94]R:F4;[A;:/E_3YDS3K[L?(=2G72KN]F33%\K_6#S)G'D
M<A;60 [9+T#"V\J^(P$ @, S-%FO7=@DZ?-*'LKA .+87%%ZHQF$!5UY2LV8
MY^Z1]F^$C<86>"^U\7TH1/=%%EM9K7[ NR+[7IZO?,[_Z[=Q_]NX/T2/;T2V
M^WE*UW+#E*O(58FMI=XSGDM!>5CM ./&6[)R%^L",S*-D"(G!^/]%OL@?U.T
MO,W.\A4Q6^\G(HBKW>IN6LI9$.1N+O -X^&PCW'<[(7?$Z*F+O$0U^8K60.1
MU>(J)&%]3>0" ^M>4U:+9_BUF/F,N] _ZZM6^E0SHX]D4<_'&U\[-=BR%>!F
MLJX7I[;C>7Q=CY!V:(R=W&=[9:\Y-=)M3PJ;9\^;0GF&(>M=D?UJ4#4 4^E]
MS<4CJX1?:45:]DI"AC4V"8]9+^  =;5?\>T6TK&F[XH+ +&3# 3? 5%;@65=
MH]YWTKOU'L$!J"9W8 YXZ8PT?Z).1SJCU77D/Q2^V2[6MGWS94G[Q_B?KP6\
M""V:.4Q<B6ZN]7*40CKFP!J<IXN=IVPE7VCZ 5*]4U;D,%:R<5*/+;,5LFD:
MRSB5\F.T@I0,<Q)&HPN=JL&&"!:0@BPJ(.M_\RA]UL$CL5R??)%DN;:4-]Y[
M_3M;4C HS+*!4?:%8]QDGJU\^BV@[4AO<<=IN\>^:F0)&EJ94TT79]OPHIJK
M4<<+_;C1XQ%Y* ZBMH4]F FWO"OQ%9=_B/%E<//C=0#4LL4W;S@2I[IHY]F2
M^;NOAF=T7$EIXOIO\3GW)"?P5-IIL2^3]&$RQK$J@4>S;39^@S[R*8DLO_WO
M*;U#/[$N6__LI*.RCJ<,'9:]H><QF_+@?:YTB6;JH *W?"8^J?,7)273YB!/
M/R8@H8@.B1$ZA=U/\EX[LSUIAJ:4T/%:9FM=@9%IQ$.;LV5<MX,O6$N!^G1&
M%V-;LEZ27&4RF.!9B"4IF:L@,716A^"'.L]\NV6BPC/HP.#]+YSP5S814V7W
M<HLH:H&HXSC:>[M2K75U&!(Q/(5+J9Z/RGE8Y'&69 S!FCUSOD=X8*XLPZIA
M:X/UE<KR<U+7=B\62E:GI5'8PBY*$OOIS\Y,WJS/,.:XSI3]NLG^TT_5W=YO
M$"@+"Z)W1^;>!2&5%^]7$U\VEQ2HY-903ZBRFZE#OQ&=FS4%[_G!*RI*K7+J
MK*89DR^&Z^^TLDH[OK_0X9.!F$,F(1U=2<P<#S&%7&!Q)Z&X' ]"U"25@@:F
MW/I=IQK@),.?P=>TVLQLF6#OSM/<5^)V'Q)%*7["-Z=?S9J+,5KTG:5-#7-[
M4<Y]S[U[I!R5WEQ]5J<O.KQ:L&I^.W\G@=U5G6-,',QZ.B,3QLZ+F_I>]8V!
M3X;E?ST66=V@JVE(NFYD[L)HE^=D+17\&2\M]K)B-+UOL2->E[_5-/0&_68Z
MP[\@!7FXUY$+\YK >455/GA5(;=KLY&R5XHZA(766VI-:R2XV58HUQ>WP4-N
M>)S" 0$Z@F=EA1!?<.3](;+Y/'S6_!D+[ERE9.N(7!L!MMBLFYNJAHW[]B_[
M&B/[JJ4IW]<-3>F"+X>5>BQMJ:FC+JI"4U+W((G5T=L[;</,R/9B9D) /YV6
M2E#(C[W=UGOA6;,C3V6Q<.L#NU_9MY[29K+Y-/U0&ZI5T<(37(Q(M:4[GO\$
M ,;UJG:6_M9^5-OL7IE6\(LJWT[J'],8"PB[!)AC5!%(I1.9HKRADY^OK)N*
ME:W_L?7< 8T&W1U;:C;:YQ3IXJ)K5VS*&]^NK832\JE YM0V,\OMR TL_Z'=
M(8A1ZM(F4BX%YT)[[75GT#'("@ )V]B-8E/:;+4MG=_\%"/+=6@1X?>]U$8/
M4=H92QN"R.*#N3/-K%AN/IK]/>H^-,WK!_GW=+N2L=N%O2?:I"[PWTE@6SJ_
M3"H>&P6II\?'&;25Y]-EV"^_"'?@7J$1*<Q-,!5(I$\*IFN^'LN;\%KYLZX"
M7UTX1<IN+Z)V?>QES^A<;CKMA@(/I%X+GRST1<JW3-:<A(AS-JS%Q0F\][9A
M6UJ*5R&2;1WX 7@%TTS=D;(JSQ&J[YIV8W)3*PP$_1NNPIW:?%R*2@$IZ%'K
M_P^#_S^/WS5DF\)[#;+DMQZW[?+;F@PK$N]2BU,2AN-<LGNV>*HUAV<SBRRL
M7FQ6GW?4<G292#UI[:DY"XE;[MC0\S+*1JEZ?RY_UL1T4;J[_L4Y8OO"?7T;
MD1+TMF7[QBMK>HO7"-KI.B81F3D5&TDAY]U$58("=BS_63FEXU=/=%-.C!:W
MQS#7L.T6*#,_ZF<KO^>,1A$C8P7-\2G;'OO/[H[6XM)5X=7=XK52J>I <KVE
MB.)G0='S HP*M-U(&IFV#)A7+W#K"NM\9#%4G)!*H$[N*^$+*>KNHWHV]28M
M>MY1PEVE\ SI8H&WR;Q'0A1[  A0L^E6J]]#DVI(->1FD6Z;>=+8R2I")HQ[
MN2GN*'!&,IA_;:OW/ZV >&J-:(T<D0 \&YC@D<\LQJ[Z;QX%8B1&UF+Q*2,R
MO90^"O64YI:=R_"5,RS_IZ/60<_\Q==C^V:V]_O!8B\O+9LY"R'8:$N=K9%?
M8QO=#A.W;9OM_)C*EDMK7YD?OG>P-J&N\H=(V$G&*19O5T>W?Z(GJ#F$7+NN
MGANKD[*DMUL8[YN[H[7RJ_E]2HY'#2F'":-^<F0?%)4P9JZEO584C?UWB^V8
MAR[NI.%_^KW$\@$E:Q"G*,*;T4K<R #/QWG"1!*6,CAW?>BVO*@CMX9?"N?F
M\4%86"_TS+/, Y4, ^IR![[:R<1]/VR, U!6HDQ1PXTWP%HQ.Q(T,V'N2@?.
M:*FQC\>H\PG6U_,/,S'?4[-.<S-#YH3+NDAUGW(_VK!ZGR_O/Z"ONC28K3@L
M:V3W&1<+!)YE3^/7G=N3'HY_/3;K^J;S2$W59[L,R\,YYSSTU1G#_V(T@<UZ
M0%Y1TZV5TO/G?:29;[<TAL&-:B:("%WGJWXO7T1PX;@@&A^H:_6L7Y.!CB\)
M]/]&-?6JA=!W5,Y\RXMN"AC<(NW8JZZ;M!]9-)N%N1*Q<86?>7A![=-RQ5B_
MOX>HI_MH:P(#NY@&+^:US8%.3C$QNSTC2+5:VXT%"QM1 K%(XZ+DW,KJM*$-
MS>FWV>L8E52)\[45 O2)-UB<_[";MCQVS=7KCXH$/R(RBHB,+*U?W,T9"DZZ
MV2,]>IA:/("Z+!U$=@%CVA0MVX86@1TOG8L,^T.'T?C]N)4)&*#Q/:67.=%=
M<&$N^:<LV+!T<\IZPOCMV<JPP;_=2 H4-[/B2?RB4 Y+;C^_I\QX[DN-2%(>
M-AP<Z_6 *7C:$>YR!Z7674F/'T&C\:]-;=4[N+J>@H 7T4-N [OL96J&ULP;
M>(42-D?9F=VFG[;N-EGK]9.*<,M,XEUM]C$W^,1.>V72S:)$O7Z.-O'ZBIKQ
MT9! HPES\M18Q[[H<W]&-NB/XCOS_A?*<X^PQ<X%)HW6F.+JC,(/'7\WMXDG
M:?VE;>.]A??V,WY[PF]T";%@^F</)N9%]4QKW1^$@SM^@#N8WO19I;'0+,<O
M!0F/+O256M/L&@AN+<>I>=#:\G*-G>=*> O?AE<3E[DR: ,+'1R23S+VD*-V
M6I2D$\3L+!=5G9JQ>\OA;>@3D_CXHF>N6S[JQ=#3=D<^ZG$0Q&Y.4BR_*-/^
M+RIS7!)[G'+7C:J"M'GZ#<BQ0D^9;]_GM5ATICY6--0X\+_:N_.@IK+]0>"^
M]]IN4;$;$5$0[68G+#Z$0 ,&%PA[B)&$L 1I!10" 64)=EC\N8 0)#1+0+8@
M$++<0&+0@$D$NF4/BT(29 LT2V3?E$T0G>Y7,U5OIN:/J7KOU53-\/GSU+>^
M]3WWG'N^=:MNU?&#('.JD=*1\DIH:G<<@I/*3!+I65TK%BA?]#$B[-VJ>3:B
M<5MFI##6_G@YE7\62-V6K/W@<UU.Y5VT_<@QB#@SC!U\RL<Q6EKE?E5CW9L_
M:,U >XG9#-5TRP!:57@A.PR)V&Y4NNXTPB!U9-XJX@]_F/[)-UJG'A[LFV[C
MB:25\L\_ZJ2$@6Z,O0Y(!NJ&P-\@0A<*6M3:<=:$&@(H\$FHKUXR*<HC$AA#
MMXW<7C,-"?>$&$C2C&/A3!/F8:CAI.M]=<U-4L#@B\&Z&J;)+"2_H+:RQC .
M'1;E]2EV$2\=R7*J3Z'#KYC'".D%"H_$]983H/*XNK'MCY%6JCWG" _*NIY4
MJ7T+DV)SC>TXAX@^X=JRD\.&V2(&I1)^F2Y&*VH!\:Z+PHJ7';>J(AZLU6JI
MGR+CZ8=BEQ#GK+1FP@%:+X&.@M*9+/7 Y&,[0R,!CD[I[NC(L@D!\\7,^D/>
MFB]ZMJ./YKVB8G_F<H4Y1:T,<DH8>?7.[5'_5$:/&F309O#B:_C?^F<-Y@Q?
M'D&S*(_"(LMC;Q:-75KCNJQET-\:OJ/1)#Z>[.&.E^;IY0Y]+@M"RSJ1T$?J
M+UH\WX"7!5TOOBI%_@*'I6=L[+<$C27NG]*CN>I*;0OZBHU?> YX^ZN8A0"8
MMEE,7QNQCZ^"4F.UN#P<&.Q0*7>;Q=FI =+FL-S@3+_<I71,E2B@QH="VZ#Y
MF53,>H2"KU3'D3>\ALQ\H:#6)!$ODBAMW4<!$MXH(U=?LV*LKXQP!5W1G##$
M$NR]EA:TQ:]%M6LF^^M[77\<$\*H^Y>L4K'/AD$S2M^C2-#PP*%N%97(OJE:
MIKE8IBH('GF"D#U/@AW F;9JBD0#E(^YCEJ%+<<?7?6=6S$H5I7J!H/V#]I@
M+E<-NK3KH-L/VVH04X@EWJI6$;^N6MI9^\B^O4C..SY.65]O5QYU/5-_2K$;
MZA;$X+\O#?N7&OI?Y"3N2'Z%M?3J2T\Q\C5,Y6!7Y/E.-F:J+!8)]T\UBGU>
M4T#*5,NUV9;QU).;#W,BUI+I WJNP\$3C'K/VM^(3O(*)VIHH6YLR_R8Q[$Q
MUVVD/+IY=!]0/V6I,#=YRV[;M%4+W,*-SG1J\C+@\H'\Q9_B7*>=C=MUJ6)N
MC76JS'RM(Z^M.B!\6+.L+#;VU]]Z+%*7=O9*E2ST*EJ\#'J =2!H 'I%>7Y3
M_7/)FH#403\ZFE@K\X?PN+T\]8.XX4=8,(H?":)Y" K^O#LNYA#U12BH7Z:B
M W&3S!.O&T6RKA06,%(>(S_$MANN^X<.T,)A\1$W/M&13/Z+"5%(R 0YX<DB
M8Y/J55%]QM)$^JJLK9/F/+&E*'X[[(V9,V)=;N5-+R44"F^1+ -Z%'0KQ=$=
MXE I:?1H6TD$XYXNOQMCV+]T!2V@P,615TP&26ETJ4UNE@*DM>MH?X_2N<14
MX<DK.Z]1?N91P!9&9J!>&EKHK'+&L&B! HU@FV48.$3?\+\@YB\1XA"7,!KF
MY%[KXV6I5>G'FH9D(JD_J_4;')%+H/?-QC7J V,\NPLZFA7(.)4KS5'5Q&':
MV9G9 %^3=AIA3@?:32GMC"GM*7_<J8MY&=OZ:W]TXO%L@%"Q1+3']I]( :3V
MJ-%3W\0^B[[<*M6X5 W54E\T'<-([:]X!:R!#/S?RBRD1,>+VR_UY0YLTTV.
M1Y7A+,%?VM$<@X/8KPME<7(X/@/?XL!ND>.5SM7H!6UF)KZ8"^;1>$]U!%G5
M!>2<I8"==Q9EY\A()!+U^UI]$4Q Z"O9[Y7]94_3Q9+UK#>7_7%WW'Q]7E/+
MHTW+R5?J'5AD#ZPFG?-K;TA#"$@M-#:)::PZ8-@C B9IJ2E5JV[A<(ECR!+A
M/FL'2G'5NE$[,]VGE@R]27>P\I$](F@5D$3 (G*J]M<N(=JU=Y'GMQA6P4PH
MF#"&6%OLVV#YI%\31A4_L!_[&6J]55$U)!E:+'H:(K">1GRHIY3YI&0&-!4J
M 6PL'_$C'CDX&V<W7[!$K9%<JW<YAOV>O"+O0H6YN95QZ">IG,$+6<Z]![),
M,^)R*27)-/1V](W0Y\_6'CH?#R: @8WS7_:TL HHGKP$*P/;;#$F9H2_9;O<
M:G3)80V:!4YO2$.V&L/SS==+>GF71AA@%WN>>0;SGFKC7ZUZR\!L%,KMJG+'
MJ"WCIQ'>NU3?:-2ZL4U<4"]3U!;)V'!8%9EB1I5NBS37/5@L,+C6O2AZ"V K
M]#'GD-7@:X.3?@OV(KWP[VI7R>8\C7U46BA*-Z&NRQZ)F3)9-3A4(%,/I<T:
M9]$HI:!95GE@^% R4.TXU7#NB6QUEN1-L),<\U<>G!I!($X0\V$K!JEO#M$N
M3^]8QM3Z!YN8%+@^RC[C8-_'/<Y-M^\@6W4@.V>R0WF4.@%VJS\H2&UPBAJJ
MFQZ0'74KZ96NZ<<N?P?<9?_GZ;U97E?>-CJ?K1HA#K-O/FZ-F6R9&2GO64\W
M4"Q$SLPUY=D$PK.\U83'-5G#DPZ:=2IH;%G /J^=;QL:$-@#0Y6K,3E'K6/%
M56=1F5=%S:,YCE$41$+"I;IOC:*K*?;KR0U.FX$..S8W&\E :D8+I914H#^)
MYKZ(! "VR_U!D65[;ZR%KM7BQO1M;- =_07Q4<M1:QL=K4+>0I:WTJD<N1JC
MN+ZW:"9=[#8S9%-)>-4:75"3R<D/2O>TL(FJ3AGF ZRDS:/?.L88<@0C$T=+
M2ME/N!<SK751344\E*6F31$[:C9D(9U<WU.[ZD5=IO+%'VN6F;P$IQT,TMJ.
MI7;/SP-765DK8\<HMSQO8SRZ9C7W+I)U)WY$1/O<6HD3KQV20DMQL2!]:B!+
M^QE7^QKDV)J(/16@_]C"XX*V;8_%#0O+L3Y+UG *4/C2^0Q^V]]1:Q5S\DA$
M7-WX*6#XRYZE YH?@WRGX%@FBEG'-$IW!-'UWVKBM^%GH[MG:-$+Q7V0JP$"
MF*]#J\N,%BH]8U@>J17Y#F"K0!0:W-G,*BP/E]MNYWWA.B7S!SHN\#:,(P)%
MN $?2E!@B+7TZ6JAYVR<XE:RX+:<001Y&Y3#%952=CKXLU+D!WI38\\6I=QS
M&SH *J]@$8G[ 5F:N;YD<'IR*,EMJII 89]]+=U;MSK'R!DD#@[HE&]\E=1)
M>]B<N-&N9QO8\O?46=RB;2\!#T@17^&-SS^#J9?9.P6@H$ADM^4Z^.3K+7>Y
M:WG,WD4F4]T0QS/OO+L0%>2HR0$1BU^8UWW'",S50%< WQ>HK0_* S1 N&L"
MOZ%;LPW>$,4&5^O'LK_8(6@\#8WXCM!4KNF;5Y* /)!\D.T);+B_LTU)YC!V
M_+,1S0>?KPL3",[JH')/2"?AM-13KCK[R2U.9R3Q<0QV1:>/0O/%]<I1E]/@
M)Q%5G86Q5OVOY.T#L!U'3[ N=W:O8H-=G+2^]RGDF7&0U@DI62@K;B.] N$F
MM.W*=RRJY]11429'#B=\/]A^3EV[VE2(.-ZBE BJ?S W(/9'V5(2S!+N584C
MHS^@ZU%)E>F=CI:*[AW"KF6C+B6)+Y[]LF\H.)CUI"!7.[^;$8H B(S';E8_
M3Q;\U[_2YO>M4WOPBD[KMAL1+O0_*HKW/OZ@^XY.^VS(3S,G4^X%YAJJ6=BO
M;3#SONRI+.*FI[^X=O4K;HU7R8G47(@*&TXT8/.\JFJ _%E]@Y<&='MGC;KN
MX=0A 3/O5AG]Q9LN1]]3:3 S?%T^4I3 ;,\(JAZ:?VJM'G3NKCHW9V0*OR!#
MOKE""*4N@=N]HYY3UPR*SHWH1,2(EDGV:]I/?6>>4(.,$+B[C)3T8=8#^U=1
M15L:%FG@O91O[,+IRP%1?5#8(AY3]Y;L?_>W&L/0\(P7-84JG'1-;TMA[M2/
M+;>FDSM/&]RW@U&-HM\RV6\NE8<?;A^O]U>9RXOJ5KDU6Y^\F3Y;_"T]QJ-_
M;H</&FY9P&[VFBD4?7;-E@QZS4N.@DY%\3RVZRP6ABSYPV/*0C*Z^@=.0W"'
MXN<J$%NB@+#6U+1ISGRI%ZXV"?<P>0@?T@=5,*@5R^]RSRDLCL@[$D]PVK;#
MGOH:QV2C+HEO>W1* D;KND5Z[>B3*?$L<9] ^ @L/2*<+2,XM6Z2W*Q,DUZ9
M0+ZC6M_;"7)F59"VH5$2@0NMS/_0/=E%8+H4.L:.\TGK]DV2?31L+Z7WYL%B
M*W&'B(U1W)"MH_7%(>'(7E-4(::RD5ND1S;+%D<?F7&V@[L/XY(M6AY_U#VT
M)O^[_>EB<&_LX'- ,'BY+/J55MVXY_I"(R9UUJER';"!'(S&]\>K!7_@%9+[
M10 '!-1)W5D[1-F=LAB=D<(1@V$2]EE<X2N::BYP.@@\Z&\?LF!2794\G$,Q
MD7W90\K\.%24<.-T,RP=19*A;M+8#-HHRIWM55+7SO,;?8 Y/643G@L85BE/
MSXVMA(RDD*[+PQ$J*E90Z&)*;._E1N?]4/>N3)J2,JCAM(=OL-@B#>H*&$M"
M#G9W^XU#9-L;* OR=XZ( ^/YPG*"(2:_!7%;T[,^/T3=KZ=6[<!%J!<I- M^
MFSS,0W@D1=++U+>[2+*?EQ.SZ"N?5% 9W>_&T,?GF<MV9XBY:B"O&:9W]3&Q
M8CCJ9@FV0"%:MRAW?JXH5^(S!>DUJC<O\1X03> AZ#?]'B%S?F 5F/818<CL
MJ7&7UTH=_.&H(KF-7@ </].2(_2H5#W@ CL,F(R>]'Q?$O#++T,+T?@ME?+R
MAXTTS$=+T,:2B.T69U)2XQV;<-SU]Z"_U\?:/)J2(B6SAR@SZ1=N;@PU5X%
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M0H$8!G;/HSII9J%( JL3?6#,"X<&2 J*1H/<8F-9^B&@G\JBW:+JQH0H'VD
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MYUEMGE=(7MP<>)LS]X2IYC;#+9OPL/W+=FC>CMB>60U\'7H5F]=K16#"R7U
MCK[50_'['P]O3UU<9N5BA.,4(9[D:?^8$ 1@7"8H7U ?0+A(/[I89>@N8&P9
M067?Y8IA<LACV(D/>DE#H/?NNT.%YM"6MQYM^8 S%.XKV^MYY0:^Q\1_@JN
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MFOT):?P.=M01LJ_>W:,]2^<, AY=Y"\ 51\C]5K(Z#8$36$FZ*L"N,'=JL4
M*?B8ISNT&.>8C:TI8N"FO)?Q2E,.$B%9KSP*.C%IPC'#0(Z'L+ X>0/$E<9
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M:&15LB&1-N97S$\H3!M4 "9_N*!WYO;CMF!V"V#F$G4,]?:<CY[U@O80W5&
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M!D _: 45E:QW)DNND4GFVP8O&8AC%IK,AY>E;RCA77U]#N+<VH/>T*75$>?
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MCS1$)35LZ/2UM(90Q206$3.7VV6MRZQ'P(?(E>XZ4_UWR;T*DEO]+64^-E-
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M33'U.&J^6>:E+-B3]K:D3#)"B% %Q$U=U!Y1L+? 5YYN.@B-#$#8-&UN%3-
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M]I=5+8XN;F6,,5NODANJR!Q%8$&!^]+'#8^GJ/T"C-!=^TKIB.P@(VI@)/L
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M>!6K]M"57%V.IY<?'$F1SJ+7@2EAQ<-/M&]7F^?V\$^N&?UH))CT6IX(JU
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M-D$EC3\4W[0#.[.()H'>JCNE)(P+7DZ(H5A?ZN +1WLNO@EJ^MAA(\:H(6+
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M2\(?>]S@F:;O*]_L#C'1+_.#)&''GVX-@^VW+^ +,1[-ELQCXVW+R6-VI;,
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M7'?[!0_HT1_!IB00) AB75"%L=?B#BIJ (1[7GT28W"I_?4I777DTH5 C.D
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M6NTKJ]82Q[*SA\T.-=RZW P_9*_CG[5N^+JI,*X<2S^X;-_?_,^P+*A"-VJ
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MK%:MI??0;O?+;$J^'5[FPH($;]*N@52=4*0H#5LZK1$.O^)W0<PC$_+5N3M
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MHM'CMX<, VET:KI$%<X4Y)>F:<W<O:V]+W#X<PI [!OCS NA!+47-U\9DE9
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M]:.!S\OR)8>3!*F0ELU2*Q]I36&(J.1+&*[6+0 ]-,7INF!YJVE6YT7E]\(
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MU_[<$J;!IF[0=,#P<&"P!ZQY[KHV11IN**ZI.FRH/.'F*6X3$=(Q>IMA> 3
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MD+9\LGLSBWOPS0%\=:*HFD)+8Z9[\CL&!R>G%I\)LT1=:65Z"4$+P,W4MVH
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M3=_S/N%->5=:RU>CGUDPO@1)K?^^H2!WEE<YLZJ-Q8"&("5U]YJ&]+$'0H(
MMV::,T_4-$B.4<W7C:6J%HDW@KI,<,AX+ W7KPB0="UK![)\94'\?F"6S--
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MX(ERQX5?E#KUF@2=^BXZ%<T$2)^( 9Y%N@BZ=!4HH5#SY47O3SA8,(@]U)R
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ML??=44VEZ]Z<&1T510<!48J,(""A#4JH J,2D&Z $ @!1I 6>D?JT1&$0&!
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M-/@+^!ISJ#LW$1EXP]H 3XB<47-L[]D(L/"JZIF+X<)&+@W>GTE4$C%@'5?
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M83R\[#&T?*YB$+EPT#\_OZB &*K&?:WYL)F]:<?^\9BDM^:R,4D2:OLU=6>
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MY**>H9VJ0H>+OJ,O2 U%/BRQ JI)YR?T,'0'!OA6DUJ(#6$_XHGWF[FW#'I
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M7T@<-S;B?C[_9*"TMP!1#B6QS[;4<S?//%LA,R7:\6?1/$>"PVIF<P]MW^G
M]9Q02$RY9PHQUR>X!NQQK+X@-7M6I;@D*;/'K2.W-*\J.A.^KN4HQG[?(+/$
MB:YYOW0:9GZ1UN;BJSI<Z^XEG&]#L;L\Z0/F&\I# JO"AZD"7@&\-N I17],
MKCV;3%(TLEM]/*VBLCDTI+<:9S^%/R20^@>*ZWNA9JGS-*ZJ*J@(F9Y,N/#'
MG-Q@K#NI#=BF)2@\8J GL,J2>Z?7MV^2 ^S=Y6N'4'U6U#RO'9%LHW1^Y1?^
MFU'W+FMHG[YQ_OZS033UMI[@"L_J=JK)W%J3N1 DETKT&5\:;Y/<6G!JHN36
MV;]HC3<N>XFG7FJ(W%X("P2;W_6[=N>RB9!XR7@&D29_PD5QT:&.Q@S:OD0M
M05G#SWHDDWUUY.3GML3#XVV4G.E8&J(_,)JL61R+!#?CP?A:,2@C#D^F)U&V
M_\<F/9.8$XBXH=#\6LB51Y@:J7642Q!]NO/L2D18-"Q9ZY6K0,#3^)['SWZ.
M$+!QD<T$*0??5WGXE9UD]C<_L= 2E>X?IUG=GQ5C8[QO))%;<L/FP5"*V:\D
MI:*A"$\A = =399O'X<@_/YAVTOZ,?$E27%60W/9R&$1W&DY6CQXM>2R;'2:
M3\QUYLHV=!V/X :SCMG]9U,.VA;'R5O6[ 2JL,.8?QX+6H\$*OY]V -N63'"
M.G&%%, .1E9I SGB,GB<FGI]H/8CG69+;EA8RC.NFO9^YZ:9Y[JH6" <\W-F
M[LBXI<.,9[S(K6L''^"M_O(#O#P#26H#="Y[L!P_AL:C@927EP,QEE,?1@%!
MLM&)YWD[QE&:<B+H.@$FA4U^?M15L'ZK"Z;7,716X.C=N]J\KERO3$-#+[!8
M*[B+\&/;'85X@<0M22M.E7Q,K-TF$U=0TKUTFJ=$9)VB2#=^)U>@\N+ C".J
MX@F)F_U:F(C<M7J7:GD]+M@,$[^;VQR&IOI->^-\)>>Q(ZOQ?U0/& W"VWRA
M,?;^O(NS,D!0A$J61,Y*]=&T4EV-BX7+DMJM8IO+Y76"-KU.9U:AN9,SW.!O
M*"[$5K&59FQ3+B;*;EOJ@J76EEK<4B+!'/CZ.2ZLG\Z\.?+DK&=E#Q$] UU"
M^_!M<6+"VX#,YZT*?EK%]C<D8A\46F.' L$FE>*GE:N8DE[>+!Z9HVRPT[#K
MU4=8S]^0/U=F:B,2H2IS=#BHR_!::9.65FUS(Z6@<KYU#'O[? GJ>[MBBQ3/
M3%A:>+DY;:]LM!6EGMQH,>'J353IQPAH.W#6;#CL,E3Z3SOMUQD8UQ'$M;PH
M2.:-""W!,86>]>,WTNV+NR^6#_N \5N7?!7/%VGXO;;$@Y<:H@J)UDN>25WU
MW[:'#U^5*SCG:WQQ(-CL1,*PI\%A-T69@OHV%R0TQ+Q043)79Y?A&Y"60U!$
MB)WER'B?JKQ+%JRKR$<TY\7TM R.-C3<,!HO=#=CQ6KZ(M"S5,,URT]&<TU@
M!4+<J\L83&UO*'S5[EII=R^HFP#E![(W"&R5FY&GFH[&5&:OD(\FW;R$&B)2
MNS#[I2S(F4S'9N.*-?)!G=_&:V">< PFQR;5*I[J/#2K5K=0M*DQ,LS$A.A=
M_NEQ\ZER 3;WLD8HE])1>FB7X?7,=9+ +H-@\OH,>E)]E^&BJG91FS* HALN
MW+MEO92G6RL KZA6.F<+FDTS[.FK*9')6Z]/O&OZY'Z=WY6-\'4/'UO4P)&8
MN%SJN=:6I! ELY<X8:<FK6^5B1M'N]PJ:JA&)-63/ETSE0(<L7IN5M,*JR(
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MRDXV&5]@+[_![^$4B@O9$':6O57"H7(_S^\09R\Y7D#D_K2G?+NQ#Y1Q)'+
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M:HMNND?-V16%O7QB[Y88T9DG1D>+82.$?F[B2XIH2T%KB4]&#V?/:99DVGC
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MR53N!5O4'/J@&R*XJ^'K))ASO!'1B%G=-3V/Z(%WBMME1#BOE(A^I*Y*F=*
M#[^F=G\$H+?!U?\C@#/A7F?5''0YVXERC#_#O#17\F?,G7_!W!&V4*;7Z[T*
MG[C9_V?ZUO+_NC)PR"XL>W2BO-$-^+>5V+]?^5>:_XKRZ3]A;/,?B/@K=.W_
M9Y#^S:0SU']/D"=HV+_(Y'T_ZN\Y^T>P[_O_JI[_,:L;_SZK+OGU;<F' M_]
M*R3Q5Y+7<'^;]&>27_G&^-PSIG /!=:AWQP*5"FK\'L_?%Y>FHJXFO:5A-?_
MCES^IG'W_T P_T-R_PD@EZ^3;GW\;^CH/R#EXE_]C/47UUN[Q$[FBNYSZN?6
M4=]&2P]K?G6J!EY=@/0C>_1.H:NG.U-E"DS-@E._9C[[?UTN5\T%!?\Q1OT'
MM/VF]8N' H_^*,5/_U;=K__BEW\AJ^3?=?__-V7]3US^OVED?V/OG](D]=^Q
MI'M? XS3P?]]_M]BQIG_(NJ_&?'NOX/Z*Q>+1PVM4V@%\/?P"1D-T<53LOS%
M0"S]Y\EK[$B7,SG7<I&--U9WXVY]E03T/\<T_%]@\I_$D7\2;/]+2FSU^N^%
MLG^THIO_S/G_PHT_0WVOR@[BH.#&O-LN"3)WC2#FG$QR/#58W.Y,Q!XMR<;O
M3B35(NGA[(F_2R/T+US$8RHJX-MW8[G\?6];WU>O F\4[&G;W/&@$NK?J-)3
MU:<=*7'-KZ\?[?RQKOM.\G; WK7 ZT"I\]/1U\^K3$(->S"^@QK:GLZI)E/&
MVB3JA\+EKK:-KY.T+S8GY<=+\.X$U=@IT^FU5<%Y="- )6B&M>&OOQ1R\A3G
M;,>\'>YIF'WF32%,#,]FR&;(7.^UL[$X=&7-ME!8\>!XO)>Y-ST;$?K)_-LP
M4Y%[4_5Q^,[AEZ9'<7-^338:)7$%#P/!W2V7^>\?'#PUO?+$]O%O:*]%XVY-
M_RS]E*)U*)!ZQDS"/2UY]X?I>WM:!^?U)=*7(8;>]M#.VQ+B/(Y/61U$_V*T
MHO&YUS/3ZPTDWLQ!T[=&?,7H$F+0AK<ASTNB86#E\]+4G@3+Q\LGTR[R#V6'
M I[V!:=L4]YGS.D]^%G]3V E'CL9]!N>7K\9)0PZ+Y'X6^>8C.B VL#O4XRR
M7GE;'!AI'V^.RX^_-.V\)Q?^FV"^=LX872>X$QZE),QGS3__/P/_DX&8OXB7
MV*&MX;)]%_,/BOBQJWW#8N-_V\!7\\@3JKCU,^[V'[D(^]\BS_^?#<3\J7/)
MC@B9$A?=N8(S^E\OSHO3TK]UW"J,.#TNSM?1P+-_5PPC<+9/- &TZB9ZI&%$
MCD"JLF 7!UE.9+M&X)'4-W$-,?+V*M3AC4TN*UP9*/%&WS-,B\M(ZD"E3SV]
MCBC]J,Z0[+'S;% /VA;+L4@%7>[0N:#MT%CGJ&WPOOTL<Z(<)GXAN]9868R-
M')B\M 8%AP0DL?D+FBI[E$72#Z7%E?K9XHD>M A*5HQV3Z+OE"+N%&?$<V+3
M<J_;.T;Q4*!]UD7:(,53&NG?&M0@Z598Y&73/'!^.4("YP75A!.5#5L/7#71
M9TO9P%PNV;@YVR3'AGI!N /=4+X3]-/[2,GRUSME7,'NB_/CLG <V[K/)2)P
M> 3;+ 0,'%P '"FU8*)?Q3N):CEW?/[2QJ@40X<L50Z;<: _K[UNG^H\I?CI
MP.KHAP-)X)ZDHKMK8I0%U6*[CPVCWTP$J(0/DZ;I-74(,O9HX8(8%]S39=N5
M,JO.0ZJLSRD.C(393 */EH)'76O[?[^')F6X7U5&K2@C@Z;*O]O*:N1YK*XR
M>3-%AP+>@7QGNZ'CB7P67>LCOWL9N#7++UU@>2H0Z1AE6U=\;7)(%4C[_8B'
MX^I>_6BQ1P$*6#6%X1:9T9+&&RC#+L7"+Z8<:7 [( H7D;[A.^.KON1HBAK+
MNV3U2DXSZH[#>D=5I=5\!L_:@GL[R0\7NX-'X;]<E;*(K"IU@H8P>XV86[[=
MZKZ&090)71*[0ZT]O*])MN,HAYMDJ.L*62M)23*8A(9?O^TN&55Z6W>67,]A
MHY;4QNT-+64(0=C3(0IX1PDA$1T1G1Y<2G_4594<"4(%92G(7<+ZGYT>_D_:
MT0=WBJYKS%_(CZ]/U7$'4*I.-L)+XZOG)C1LS9CQ6DN6#S/>6]Y-8WK*IO2^
MQUN=RF=8T8GW]PG7$8^LQCVO0S>P(AO]*:MX(;MA-_A%(X;.B[QO=JOX.4^>
M6MTU!JDY>4U.!.)'D%/$IQQN*#(XP/[\%J#WEJVY:0!A$FM0J9B;J@TFQ;,A
M$'Z(35#>>$=6[812R_=U4-O7HT0TU$795"(^(;U5NO0\_V4+09TAAW^>GQVO
M45'9=#5X\>T27>B6[I9$D@+12QF^JP+EG%^OZY'63(.[B:T\GC?0;CZK>&US
M*7,?9*FL9TTT@WKA^S [73,+AE9%\CKQ_9:1#&M#N!@H]6:O 5S1G\*Q*A\S
M#(I);?"D!#TGTHK=R+G23X20-$-,W81J22BEW'Z;K*X*AX^O! _?.3J6LH*7
M3^F#3"(#>!_R4$^?]+@?"D@-;6O=#SK3")?6WA1?-5+*8M&%B>6%9PS;[H>(
M#3MD(.J!")-SYUEU.L(2-YXZ09>V=#?[QA%?C#.)16:N@?D;[[+F#=YS0Q=[
M\_LCJ0_?>V9G9R^<![>F6<P!?#6U+>[9EK_8YF9K+).7(.IX;'4YN;3,QZRI
MBX8F +L?MP;M=):4OEEWO%)ETOV#CX^@%X GD[NDPJ??B,T#21KE!!UU'8M?
M#:"32O"9YUU<C:@I4)HOO_3(^[87FU5+7\S$G]PVE=6EI=;=^F98-R) K4UK
M;]_Z[+&S<V[*#Q2LUUVOAZ^+]T_R($BY@'V=UYZ6I\*&:BBEX.&!RGY;M=F,
M/"'DMG9@?1ULYF9;H;EL+.F5X8*!JL"Q4_:3"]6;,10FH>0:2AA!;MXBT)%Q
M;1%;Z<JE=LM6S9\;\<C!L8GR0)$,KB)8BQKIFEPEZ591OKDA!AL_@FGJJP-5
M #HO?VCI8+ECX42%$<PJ@K5(5+G;22Z.@JJON"IE7'S&]6N(EULGAJ>\/=/Q
M9G-&(Q=A9B<[648B^>AHR+K@XZ=9BBGPAT$2=9M10Y9./NSP5'?3HUA(4(79
M2':'3"ZY'4G*O5&<=;JB7]@UQLA4O);XK,[PR]6S,*_@ER3:6'C_W0(%F+[=
M=E;MUJO9>_ H+0IV4RR8YF7ORU77"0&;;)++9B0E*!W&EQ<1,WN9Q52V#[_)
M8PL=CP(YYT37$[+0-B8#J3>%)*8ACOC^,VV.+VGN)=P3I< C.Q0$ECSCR#7J
M??M>F!PXQ([B6WK:RI5E6ME)2G/;A %2,A='+]4VZC,6(/R;I9MMA5QHMO/^
M75QYJ;<GBW(S,:6?!R.&B\#/&G2<NOBOB@S?]H5I7^/L4Y:P5RXF.-J[6<Y3
M24Z7 YK'2A0#1W-3P]&Q:&=3SV*<1V;A6IU$PN>[&^KT84"$F\PL.4/CG@AB
MN$FLO-/&]<U0>+SB--X2IV)ZA==*'1C?[3=>U_W#Q8B4Q,#,0G+:H])-:/.N
M@[*LQ,9JMM:N\<TTQHH!2PXJO%4X^2="CLBC=42 [=EHJ235/%=GM:C7<)>S
MQEA L,BWOMF=+GN4A[CMP.Q#@5(GBP6)%!N-XU..2BXP2\Z''%*3GF54N2]/
M8\C7=<='G?FLA(?Y:#@17GK.ZR/9R]9P].J[9)]9$<-#@0T,'AMEL4TK;-W/
MP5\>B[T<N\'[NC[O(E^IY8EPG:YC)IX:)U.[6K5%#+T@QYI+);IOV=^'VDN>
MH\S<W%VYUB2?7?[8Y^50G9IE,,DD)=3?T9:X*]G4PMKS*?6,?R9Z0-#1U@1K
ME8N$7S_[ ;/UHSICWY% H4)GLHS5A"2>(0.V\G/\4SR#*6/9V$,!CYU$G]8
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MUVR4YS33[^_#B=I6>I8D&D-,"KU]ZA5$)7O8]O<L&/7!=^SP.CJT7VK UJC
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MIJ!^%3B;J?L*PP@EG*>W8VE[AP)E@.5M"OE^O(Z\1>P6L%E57]WJL56I0K#
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M\6671,*>3P\"JJ\C?C!-H5$F9O"(&8-=<L.GZ.94\ZJF*/W2H1J-YKB/2)^
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M.)N&A?0WE_?4WZQ_MK!\U<&PG,STB%AV.WEKZGMPCXP(C@?! *$BYRE;]TC
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M7.8@RV\'!V?@4]%D$IC#7GGHBO2M&V>1Q]-^II8/BVGSC+V8W;8J?-VH-%^
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MV!B<T.U8V^BLBXM08^)- #=07.>APA/C8RWP^CEI)IY#I9L _EU_,>;8K&"
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M,7:QY$40R_'21'W"C/L"/U/]6^=.AUJU_5#C#7[Y8-@+$-LQ>U<-A<5'IVI
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MB E^@%\&G>/=+4P>416>^FAQ2.[+KX1VU![+!QCKZ 0(0QCA&M17_@)G-LR
MSIBEHI*HG?#'&7%S2V&:NF?!WE[M[+;KTRY,S$>W1$AO)";L6:6\WL0R0[C>
M!E.,()3M+PX7BS7*P;RT,V$R4YFWCMS3565FPL4>[F() ,K674)=D 6;V#09
MM6M42@B!6<MM0'=BVR]%S5-\MWR]IK;V*,]([!P2M3(8;H&S>GZWJMM8U5PX
M=B1-QHHJ$/)LAT+$7:6Z9./07,UZ8JK'/Z>!!XL7"M,FA0#(I*3<+?4^$!D$
M9JM[_GJ/I1IKA,FZ"2:F:':AU*PH/6F1:0Z@9$@[#Z#!Q1H !(6 %9ZD'<O_
M[GIMN(U75%W-%JN.X-[[T!87XL<JQ=$7K."4\<Z^LF,4LX@MN-SN41@-2P*:
MW-B'P7QLU2QH-]7R:)^ =FM-RN>OS=D^7QF+,: [%#5#W =\02'!6U1?A!DH
M!K9#<GXUS$]V"K*"+/A.EZSOZ@]];*LZ(+WSL8I9:;B#PZ= 0?//"Q]9O8#<
M _0BO_:097>F4,FK2XU77T6\&#YA\OY&]T==EW7%4^;-!98(-E\NEI(E3N3:
MD?2,A:^]! J[ 51PLC'!%$>A"<LFH]S<%>Y7 ;3VR?R\=W"LE7NL%U5F_4%U
MV\6/8W>WVNB/H\# ;23KM(+<VPF$>_%5A2PG(-9DXWF<@SCCQ V4X5()4JDJ
M.A/E!F*5%FP1XM!WCTBZN$7Q4AJB'7ZSR_TY/636_DGBXPWV,-YKI2^&VS@(
M!,)!5\PR;-WB;:=];32I9Z,/B'C*_?"Z2=9^MR/+\9")\_-(/M0-&Q3HRZ@$
MDPJZC#-OBB5[QQQ'>WLV[,JH?A*HM.&T3J@+!QE>GHI/VTW0?!@"$>A(VY W
MZ>K7-CBH7N'!(K 1CE<N-*I>N_]LUW4)+0O.QC>A7E\L0+% XV0DV/!E:B""
MJ/%&II%.%KVVG5K7EV>D_B]4Q@P;U'7W=G8>#X,;%+5KG1ROC?79>6WV2+TI
MTM8VI,9;VJ(4K4%EX&^O(T2X/,T$;4I09XL>/4Q<D;!QWXRPL7UTD-9WO271
MC16H%)]&N]#,/\MY*A<_Q^9I:'\_CJ44RT.="--[\[!S^JUQ^)@^@DY01@Q2
MHY?9(B;V3<Z#XV),49&>T8@JO>\"[4)]LY<FTS<SA@'Z ^UV(B.3\D#V2B),
M$F"P60\9AVL1>J(J39%.:3@D2?^**69+1K*GG%QHWTH11UMM*-B'M/JD\2]'
M>)R9>:$VWL#?T1%_8UJC6.+S56!(&*<T*BDO*4^@P7M5$P""A<# 5X-X7!.,
M>R@^<#Q$ *G$*"H%JZ&])8UKL#*0=H<?WHB<TS;,CX>H7@D,OR+ML<>RQY(R
M"(<8M3&DWB%R.%&A[]Y&TVZI?MHMRZ=8&*";RPZ#'Y1?52]Z_,Q$_L81JYY(
M")YVRZ(>KV1%9Z7"%UZHTXOK:'2X1Z!7(2YUE)XDZ)OAUWMKOL](??F=#R8B
M;SQW6&*JD@F/!\3DO[4)Y,8Y+.UH"DOECI$X,D\$XMTHKH^?H9)RGZTJ(I&X
MN>7'(L\+4;<T%)Q,KW*UU4IK[*S/)]R,BTX3S&7Q?5,KP+]168D!0:HYG^;W
M^G_M\.AP#H 4R%^?5_FC;TH09E*.+?9?/>_ ?XC?]WP;IN]1F&M6/=P&)-V9
M.21/X<<S#<ZWFR$1(%P,18]; -S7:(+?A@F!5'/J$?P+&.% OYVO)087;2*E
M[9@D901432AJ)UJA%$C[@X')&&QJ2R)"\3A?NL9W#X?7/PMVC-R68,]?"OG7
M?WU9_'S4Z'MM%X2H^30%.G2VM^$R,NNZUJ ([6#^S/*9[DQF>"O89&T)7^$S
M+",;%,#>7#^HH!*[7$QB/8\I3@MQ*?3U:@!L';B7PR3]Z>C.9/NT@*<<48"2
MAHJ0@.1+>1?449J5Y1ZJR8)V9ZX&2Z!"&@&9D'SW9O(T$/%[<4B:3@"/55S&
MJ_*P.-_?Z.BNTD_6XYZ;EL TN#'VOWXD30MM^_8K\:22L:D-T&X6F3^^?QWY
M 1W=+1B,:7BD5[H_6H*PO/6*:5.LKGI6+-E\+5^!TG&BW[/V(7-Q[ M+4DM/
M%S&G7HV[:G.*-\"WME5[N"C@Y=X7JYM#7&]+'#9#L*2.">#L"JDG+D-O[QO=
MYRN/K<9 K&R1!_F_T3UD90T$WJ01!%-;!Z=T^?R!W&!T=GI!E<QKU4[2E+^1
MC7[/#Y,Z*7&?,F?LB@,VVL.BH?TP",-C.X[NV;5,'_LS>>\3E A+>IZO',=+
M]/[\:GZ!$B8NB/7C;]TO]W(H,$.BG&P&Q=8S]WRN?CFJZ/-(&P?*H [$&M')
MB+-QE<"RYP@X?_]7+O]8F#3S?YU4>S$).H1*T'^_\C_]%O7_&\YS+"'L^V)B
M1PE&$9> 9CI3XH)'3/9V-Q"@];T8LV.(OY*0@SI4HXA%*-7ZZ->U;O#E^)@5
M9/_X&'?,QL/DNRF5+[DP2Q 17+0Z%&4RC<N$NJ ]'P%O^WPR,J'.Q"SUKA&?
M+("E29?P_E@O3!DZGPU;D716HWRS<C%".9(R8LRNG&$/<?OH7J260SPR18=Z
MX-Y[D]T]=DNGOXHNM<40;J=Z<93Z-#'U$!QT8FS]WR5KC/G.#ZI!&/&/^IJJ
M.^KURF_E7*9%56[<+>WA[8NUB'_\9G5:7-KX:"&:X%"YRTT$PYBQARGP5SI9
M &(GH0+85).!P'QXU1)6M&J+>[R4'>HL;?Z-CBVQ<T[O"T5!S,<LTQLC,%K2
M+A"[&=W3:?6Z8 TQ;7EF;8,[2X-4;D/J;8ZI;]-^9Y0&M"QR>1]7ON=1D2B<
M\T$]^]S"<<:-K;$!9LOQ"C7(JV7OHCJC,G5HF9TS2MZ@>C*- , E:?&Z3+;$
MQ86%VG LICI$!%U57=#&Q*I<XKGY>5"-,4M HTI&0\0I<U:37^*S(:BT6*V/
M<C_V\UH(J&<%FX4KHSTJB9^[_1EL+^J0E'5SV7T5V&FAQ!PGQ'X(>M4C$R3%
M,_B^CUF<=6@M+66XZL;TD042P0^#>7H[U*L'5!D7$0)S[Z;L\IIOZ_&\P&5V
M&VNM#)0%3-E;4H\C74(60FR76D6^$+U:6EHF*/JMLH91W^B<GCXU1.5<+H->
M'-C/XW4T.#C^_3-*0V=F;7:LCD1,7A[IH.X4VH2/W3X8XTD6A4*W5*^&F&2&
MH/'[Y5=C-GY'>_9B8>\T^7727>K2^HDU1;D5+J9@Z*'#[/P36&)!<*-VU-/[
M$V7[E$\ OTPJ.'!B.2 [5=U@J#1^:Q&BZT)J'&/.R =$5>QDY\4R5ZB MW2K
MOTJ$5YHAW)-UDGLUF7,2<!H[QIB*JY,$S7#FT<8@Z5 QR_=MC3>FGOIQ-V=L
MAH2=+-485/5[H,X/,.>DBL]84@8/E%M?18B0.U'&&E)WF8-Z,I6O$7*M$K07
MX,#%BWN]GT0J.Z9[#DC*I+8/?82 >?:[.D1*HNH$FU#*FG 8NR,E):MA7U9[
M*_$Y%,WT0CM3KN+*#1%9BBI@?K>+>CP=$XS!%(/!D(V[RUER+V>U1D^H;7EF
M8H8IRS<;1EJ:,TX<LT8A_-N(ASN-=WT70CSJO#B;LXG=\F]#90)SMBCHS'>S
MJN)I<F-7T4CKLIXGUDXLGQC*'J&=U]=:)9-)?>MS"^X8Q;N0BCB.)Z5E(XH*
MZ#J\T(S9RNN9#;]91Q;ODH=L$VGYI(VRJ^=>?9+A);I6ODQ.O=EV:V7/S_,^
M9>1Z,/LY5%KD^*HHIZ*LK<]<2SNP1:5CG7='N,Y(P[$ZZ&I)3Y=MV)9["/S<
M!8(3WOS#XQ=#.EM'RH:I\"M#K,M5UB)Y(K7*QLJ0 ,6FWAS_M_O_'P^;_P:K
MQM@^S)YOTW#]<\@4_4QAWDTN8;#Y@CO0:]T@=>VVN?/PB[9BT?U!'TLX*[NQ
M)JB_<54X.U7MW8(9B"4=,,-G'XEJC4X[5_#(:C+J%0$+B?-<$]X"\1J7U4#,
MW-;*ZGK=0X=)_<VK.DT]Y>KOWN8PBOZ#]YC+=&S2_:-:I<+DITKS-MGI ]OX
MRO'F*]M9+V;<S("U1_=$1.JU=15IQSW,8O0]D%N64QD(4+Q5_V#CTKQY@C=X
M0\&Q2H>$A\96'6[6)SCXY%(\C-@Z2EW1#8E'A S(QS3D2(V?N0-%2H=JI;/)
M?]?/<$1^C!XP=4 5$O'(8L%DF8Z70:$6LF&0./X(T*4SPL -4)18-#;D-A;W
M:*2WKT07VV?/.7*$"W4#(&:R-Q1"<E$FV5J5F@Q8;^]$> N,%:)D\>O'R4(_
MJN+O87<A:I.PPJ>BWH%SB@S=ASF?.Y4,\J=8U?/&>%UKH/WZ.H>SV4-+2ZXA
MZ\TMH?#8!DFJTTRUNJI3DHSY-NO>"WF4_B?WP\R%%BYY0[+CZD"]R4+#EJ8.
MA (4\=&4 7/@6A!!;@>I-:.;ZHS*@/QK2.8@GS?O7[R9M&0U2*XW>V^LS8/L
M]8@$:=_U@_D?P!G:.<^.(8ZKEJ_C'7)K!UB E9H/RE-C</A4=;V])55;RNM1
M0QP).GS/W60\KA?KW1!8_(GCNC^A7H%<+,[&'WJL($]@C@ZL1 4<L_(/./J3
M\1X!#$V3!_K,UZ_+=OA(-5-GN[<+L)7! J;[QF2GM5L]RSKUIBQ)8B:O%3QR
M@K:\8]W2$)_+U#Y0K  QA_:/)I#9P]SR'/F=AI8M(Z$^#M?7EWT"1M/2[WIU
MPE@VYS8P$UU/BL-2RU$$]=@@S<-W.R,,(Y^ON+4;;L0*"=D4$+$Z!U#0KEYE
M@ZW)X2%^86_UW)2K3F$!4CBOF[(SZ\-\L1G.-1_Y<FPT"+BVKPX;+D]#F 7?
MY"^*%+ QF47[-I'D6 \>M\!'78GF(][H0E_C]P>NU2O+?+ A#Q;5;$V[I H[
MN'F9!;IQ45_7X-B1! -0O3&*0F-_I$^!6@:I+R8_UU1)4&7J\0^1Y@!;^LKJ
M@N!P[WS0L>UR6,X0V"]+B  $\F26Q_;%C!*XYP-]EZ';7]A->]_M:H0C0WM/
MC#1)<O)AXL+>L<CEQ<\HX;*$]6 S4;3RS@7Z"1PB.<B*D.F:9/OT&QT"H"A;
M5J]_KP:*RQ+09F6X#G+QC&E*\OU&]ZAOH@5COH^U%!W4FA.14-WQ<S!#PK2E
M<GSW;C=4A^A;$5]L;"J-.EE-^59"C(C>%!?PX#I4K^*U:D,UIRJL9$^Y/*NA
M5]B-S3"V PV2JH_K$C"0&ADN$1M.WX(5"1,S(7H;::.EKE"D9\(K,58FA5";
MV8D9OLEX QGV+Q\,S?L: MXB2$W-=S*@!GR.I"U[DQD7W6*\!;IKXO=05 CS
M%9<1^I@6^05;!(OS<S%CAJ+DCKB0)ZZYJ)WIM:DHJ-Z>^)E'%5LUC=DPUY-5
MGENC,T3KYC'%*VJ:&K-R:R<7UM@9\[(&U/J"C0F@4A>Y!G@!O>P\2)T3-CE=
MY6=$\%W\2%G8NM_+B=4WV=PB)*!K&^TM/PG7-W@VJ\1*'*J*^0=IE*_#2H9V
MO7(;=<T-:O'.1;&E?FY2,(Y,JZ=V!X=:H6XI"FY.2\B<,G*"_[%C]$8.H[V#
M)<@2*T8QM$40REUUTN5A/2NDW@3N/5_VQDTCXVD_=V0MI5C4CWI-_<&R#8@U
MKA(S/V,IW+'H'*+>-F6I8^:K7JEJJLC6 8,AF3YGA"L7+N8)K(W;NCZHD@D=
M!0'R*^G/V/O!-DEU;6 1@RB;W'&7P+WR*XB9E43CQKF*^30GXW.IJ;]*H6.9
M@\!E<+&['KGMFRIJ9MQ+3EF#1O)WB(L2WE%\M>PM?1.EICOC?(07AB)@B1JR
M/7D9W[JJ6,!<4O%H:G3XMVR^S&._+1U[;'ZR9E.86895JM[^TM-^[ RX,B0<
MZXHN&D0]&JG<6)Z9&UI;Y-0D*9/=8<' .>>HWG/!Y'8N41%]K>D54E-?;J"%
MF)Q?P;1]LM%00#7<; //G;@04[V+;@@H-"Z'-2O(%:QCW;5K0C9+*GS"!73&
MAEO%+J/M'-B")(Y:Y9&.)7;D*2577\G.OE"/$N!2.[I_-!_<'55EZ<]U_W@,
M-,Q+94C[8/"T %LH'7;Y,V-)O095IWZ>2)-_?;\EOUS$607?1D(MM0K)IZK+
M<Q/N%:=U7;.2-7/HW-<<_3YS_J)RPDCJ]<E&N=D.&#$4W6#.77ZG[)6G0?)*
M+[YX5%$UNMMD9??ZA".6Z,Y$%!X?V[$IX?"0NNOUQ^J ??&(RD5=EI0R_T6<
M QH29-$ S53H/Y,)*Y^\:Q8%Q(>+3$5T!HDTI<S"B=7D!*\MD7_^WURG_S#=
M2K\'160("F]=ZS;TJ]VMB-0$#4)]/LEA(8+-[*-/SL"<M]P"R>L>N8@B7'&)
M'?W[V(IY5E;),C4/S5\,RWQ'L<WKNN9EDJU)P0I:SDO1.GX^LTM=%K&-S5?<
MPN->=I8*@CA)0U%OWM2B=W:O^$QORP>P0+N9W[N::>@;EN)G?EM1P,AT?,+P
MY#0A84-GO^([:D"6C)VBOU8;ZN\X_S,Y!3H]!R<QP?V8P(&$M^5E(2IE+2Z
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MLI)L3L%>2*0??E\5+^I'\:$8&4->/^M:MTI LS%ZZ."14CAG$",S$,?1_>J
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MNFY-V43SJ+'V2VZ3HB'1T.:44_#1HUKA>S[23D&W3DWQFTOTQ/=CV_"Z]0U
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M\M86]VF*1;FZ9<+\ ZT1GM?8Y2-[-F%1Y=*K#0]/#15Z1NXOT-V<FZ+<+&^
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MEPLH :A?/;[86S48XM=8 6.#FER U6O.[IN+,P#_1Y6P-2U)^4)DYIW!IZ
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MIQR-7/<%?N %%G==PT84BM91*3Z#30>Y8Q&V.1_3TO&AJ "N>^<-F+?0;3U
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M2+< Q57KE"U ]=4MP.<?1,9(UUR_=F'']!QP(>9;R5(V_6M?U67F^WMP:9E
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M,J'6BAR]ZCUQO(4<HU;=F4W7.[I)^6?2[XW6X9H;]C4\93^!2@D^@M+Q.EA
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M8/!):L''L"@$@^$\_ZB+J0: @%%+NLF%$?K2]:.FOA.VOQM2=^1B3YM(?0R
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M]3?YN5%9W=5&@Y&^S\QGQL*&$8DP1>-6(YE/AF#'$T9HSQ=S3QX@WU)0:JO
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M',_8[-\VX5*MAZ4E_53S/8F9XA]8,R)I-MUG= ';Z7JJ"1C,,L&E7^CNG5V
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M-^$.[M3B);N8Y11]W;8'G2 !T?=:?"U_7G+-MLZ]O@]'*-:"KT7'JZ< X0"
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MC'X8R6_5H0NG-:A?X;9>VC"@SOF-TFIH?D2XVLD<-.5C[E[2KXJ,)Z(8H!^
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MP'F)E5%NO=10%MLJ67 !THHJ!B&&(# WSW8/QPU@"2A!2P5#DX^,3D_K,1@
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M:_;P@9"06Z)3%D7U.259$ TE@YL,ZQ$TVVQRBJ+R'#DI:7K50O%0HE>5_((
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M00N/4^Q^IU9$^./R*<[T,R:<,">-QED<,&8!:SQA-YK8Y'01HE1V"K(+J25
M7GE:&YU?C6!-7Z"$P:V9:A #<Y8O.43L!/++UEZ B0FJ.[P3!^#)(-B0L#XX
M0\-Y$@C*$GRDYWPN(Z06-K\>#VV^K,0[^S&![3!9,>859_/GX')EY96(A+":
M/\)+\];BF5>V>^Y;GX6YJX?G+&JFF%57!SE557*:;)L3EC/2]J9"5(<N:N>3
ML]Q=@JLQXTX&IA<U\B"JK-28?NO]WIQCJ!9JT^DO($3('UOZ3O C%]7Y]H@J
MJ&VQPH#=\_ZLR_Y-Z_GM_I*'WLO TKY/,SGQC*<AA]+ WQ4%17>]#R%8A MW
M5S]HSM[M4@U(^?&.[]A9>I2I/[!"(Z+:AXN2SV,+C @,O:4:<^%I6>C:8'1^
MR4#LPQ2<U3C,?IN0*>G3B1Z.>UG% 4E41RV-.V^(!1_3*T-37PZ[RAJ1B_9<
M#(-'81HA)6JF^A8<:(,&Y-8!FU=95,^UK>)/Q($7#!<C?W^8,$^N'2F,/IP;
MWJ*MHN86U63WH!!_YB>+Y+@*^>84XDZ9;-P?CT*Q4<A72RV'>BPY@1F;\]SY
M2,D7@S,'/6"2I6#]YMT&C?=9FX\E,9(O1_=+E19,8<T-P%N.:,WT[$G2Q\Z8
M@29*@:2OSBU@D=9L1Q_L_>&QCX=&P P<@#@D7!)Y>L!2-#B0&1[X-F/II)'0
MM^S*2&?Z@WY%XHZ24IT'JUB6<RRVP2>AR:R!K.PZI5]*HS]$M!PB2"L.N] Q
MAB3$8: W)I9I;J><GL&-VQ$8?X2.$:2L8]'"(D7TD:V*TY6@T&CB<H[[V@ P
MZW.AN?=F_B#*Q0F0O', J5OVXY$"#@*M;=5+*-FJL*,@_E[> K!#(546_-".
M^>D[%DO#*UH#GN !B#+QCR%-P>YVU8[.L^CH5[\M?ZT8CM@K9[&Y_=.,# G
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M%AQ%H\]&-XG!.H^3[KL':?IC::Y)@))WOD-W=.EI]M_I8'ZY3?&68TV.%FH
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M"(P:[3Q8O4?#'VM3W5:0.-77=9FC2Q!AC\AZ=K!+EG>K S6;_0E@'-73?&$
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M;,LA":5H;-2A47SXON"*CF$+ASJ1 ]XM"'S"?N.5T!4T-((RO"*G-_A^D3&
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M$D4#\S92"#C$Z+X9TBZD).3>[</P]OF(A)% VQA.N-DP>+;9V,:"AN#:*7[
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M 8%+G"?' S+V-Y[:D/OHXR,PC O(-F<3="H?Z6656+^D'_=@TAN4IV(UQ <
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MYFMV1,,K57^"K6_Y T#/;B)LNVFMW9=TAW?6K]7Z5SCXC6YTYW@QWGZ//CG
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MB$;+Z]O*@D/-.OL1ZY!+9?PA]PVRHJ71?^F2*.HWF==AS?]C6H'>ED\,.ZB
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M[8\3M,X$\PY)OKOL?BP[2C'J&KEY](^)\>D99V^(CF_:W??LE"<F=#37BJT
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MG0MK\XN4:K_A\ 6VR@U77Q$O<J;?=!?E:#&?USG?_/SASULY?=W=<XVQ_J4
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M4JM!CZ][^)QVSLO(7@J!6V$8K0.JLI7;FFW/3N^F-L/LA(P%<D@J_#+>K*;
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M* 0XUV/Y<1Z9\!C%J+\/"QS/DXU$0@%'[3X/>]P66Z_>2=Q,QXQ>G_E7XFD
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MIHS#1HGH7H9%3-)SF.;1_FZ:-Z"+F1^]/O2O_8 ;UL?1A7CK#%!"P<D1?;0
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M6\3@JCTM,*.-HLUL:_)4@ 13?-W:AKM)=GDZ;CBM]R^DJQ=\9:OMW.LC'11
MFBE76R060\TG%W4-/249"C++6/CE C6\D;9#@5JAUH7^4-=4&X6@>N_((*2
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MO3O\F6U$\*Y^[[C:>@C9_^K8!77X]'/*7X^. 7^>X[S:NBN\<I5N]+?Z=#F
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M ZQ>3I\7]WL=QS-^<&GSLOA'F'\V&<<.N?]Q^%'IL7E8^K/6YR5Z'(->?/.
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M/Z%W66F=S.IV)68CAWVOW85]?F_VW7H\Q8[=#T;AU/O:]%,J/>H=EX\,8C#
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M1'QR$$HO*+:9=&B9Y&7MQNRCJZI.S,P3D+@%8='"HG/CXJ]NU+YOQLXO 6E
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M;RI*D/S;2Y!:46/(%3XVL9&8H )7J;!W6 33<20PC V9K@J9) _E6CD!<O'
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M!% 7D.IGP:8;H7'YN^@<W5M=04PDTC>J6QJ)?)=A9G7^UC_S,^LN7<C;S:0
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MN&DP^I"7[ZYHD!+H-JA#'7\,]R8"$:]2J-ZP;CSLT.EM(+@M!O%5]W=NU!]
M]3^%_OO@\1\HZ1[Y\D('WEM3"J-@?4!%W3XK"Y(0;7= 3LK?X*;'J'N\\6DJ
M0"^H79(5)*84?8CD5F*X*0CN"\:+1;T6K=*#,B\3>:3T3]V7]-0@D<H$S=Z
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M* GJ!+LH;A+Q.>MNQ>Q@+E[UBGZD%HQ=7;&QXB*<R&XF58K]TZ\[-W6WPG-
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MNJEJ'0<-]F!>UV<_OE?^)48;'(!4@"Y#:3^1*VZ9AP='8AU5:_B@])Y9>39
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MYFVA*TT9@K(M7I5[Y9Q58.G,+AE334@8)PC!1Y$8$'')-I PU_2+]A87[3!
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ME^3[T!SW/_NZ\/V7)[)I9]6\0C&(  J@A+QP*3F'C)RID?:=TMWDYGM<[FZ
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MT*<%-K(A<.K F & )6+<%#U'88X**V']9HV&^.G$JKR&'*?XZ Z!4TR[.,E
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M9Y?$(7*@J(0/_\WA/R]1-9>T2I,(5B-YZ#AE7@Z7TH8M7')'5O(>3##RTWR
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M)D=#!P3H"TV9LSN9H#N9\'W$'8YL*F51%K%&][6N?1;4QVFJ:\YK!/!RX?=
M_AR.Q +M12IC9&U0!H38[6J#RJUDTF(-.3O'O5C6TH8.2#%)>Y&-F,_*>[37
M"HY@L'$<H6@TR85QG/ KV]2H9,=CB[9I.,:T)_N9<3K\DM,!\@Y'ZMGQ)/K
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MB#*HSJH)R>2-O;$+"H#TV/R?ON?_:_UK_5^S0!@Q(IGGL-E->D 0;/Q&H8+
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MC]SF>4<-KEO:]801>2.3#*F[%JP,T7 @',>X<V40RW-XI;/:MG//244N43"
MA)AVZ'^8;=)[)R[I/A%&(9*(64PWL3H3"-KI65B/J9U)4-; YL="U1;:I4V?
M:_L^ZN(F.R\SG/S?72^6C)-1[<7T,\E6Y*3-G97[R6G7$]VT_0)&2F 6"-^\
MO@ V<2C,>S:A_7Y2L_ND2[^/5DOI+A*#":JN/R[6EK@=>^R)#?7!CTVWTI(R
M74ZJ;@ T0"G%;S(CJE#H5K+GK_Q[KM.)S8JBW?/7U)L>^SH%3Z?BO&!N$]WV
M8^2]WE,'!'#=F:I9@W1)'_Q %P] :5V['&S$J+X1S-3K,O8UKZ.^LZCI@<E
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MXA6<_4-$%H"=R<F%O/ ,$0>7YP3_34$X2-5WCT19_U7D?'=C:TQ?8=H9^S+
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M>@.ZF= D/Z5I2]&F9<HC5]\3J.8<6P (IB$.>&=2^(Y#?G?6SK"TZ,:[F4'
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M@0$X)@QL>P1W5NM[-WD>3[8$UFEO4>\0D46LC,C$/>0$5L9Y6 SEZ)A"N;U
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M"R"R^AE::\%8G9%\]*3Q4$>0CGYM@9^(F;;<2L(C3E_0_LL!:-O/@T2@6!F
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MQ*2^CK\0U#C( /6V391['4!ZZT_?? _OX X8C\.!S9^<WPP.@4F"\G)N8^J
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M_Z=G9 4]V33ETC=JXHX(P!'BOFU$,]R\D)=%H9:P'1KU_;&R#->>9&B@P/L
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M#ABP*_G#_TD4P>>U\,9%W#$<4;>N&*SXPQW$L@46W]5T@%JY,=,B#'*X/:[
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M=*?QPQXNC"&+@+, JV"))RHW-P94+[V^O?LKMK0CT@MNHQ&+TPG@0[-'C!
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M)\\.C8!=^F"+AU@XK?*-0RH%C!F7_%N'EIL1G^5BAF,XM8C&5<]+L1M^::U
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M1CVQ7;O#[1Q=:V'-$._]S&[RC>GS6(R(T7][>;#2UHI+-I H*/!S/8^[]LS
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MFIV6H:L@2!GH*%,.ZAW>RKVT(6<$4KX$8'@18@'0&V60#E2J([J4@'K-^E@
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MLJSUN%S9DXK%&8%LAVN;--L':GIDD1MZW8-M6TRK5A82R%HV.RS$TZ9;YEF
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M9M@&+BI5HMG1FQ103/9 I\HUABDUFZVX3=>AFXED7)L^HA,TE%PU 3N4Q(Q
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M*IH,RUFXJ 0)D:OI-LZ,A8G7"QHDGU7'$3L5DI4 1[A^7M+R N-9":'<"6I
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MS\[_Y="8/8 W6_X3>LEJ('/,;,S6[;\<&[/MUIO,;KP8G\3G&#!>Y_!D]@&
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M=<^0DAO 15A7#ZQ@=[A#I8?N2)'GW??A< @4!">HH?NO<?3C8C<=&(:#APC
MNG'^KYA@^C<OM8J.\4'OT4NE0D&F$G.#6_BC^3>#L-#!O(_JFV%[-C=4PB*]
MP8I4*9=D2_B2M+&B)<)V"M*M.D.-K)J#OPDL3IUL4)Q&0$Y#:^V$Q'O@Z[LO
M>I4L:J@4CL,<\]66*QE46<HQJO]2:IS[MY-TQJM]C*LN>?).>81T$ZT$+3'X
MD(/AXRA8&48_678[L-)IR>=4WD_+$:G& DD%/:5[DG=^$4W0"=IU^PD5^,YP
M:Z>RK+>54O8P:8Q!!TL!CSR>3#5\<BA<5K @]G;!9?6+LF4(U4;-F3V,%6BA
MA,J[4G_L. ^0Y>G<BNBFJT,GFYOTHCSBIE#1EED0;7Z52B+M(FL*:1;NY>HE
M]YRCDR.&FPE@$?'KI.(L3D7-UC=D\-[%*]6H<,L%B+GR'5"T@CT;#IO7#_ZL
MVQJ?)/:>32RMPF;$8F53C578WVQ=$(B#.W2=Q=[PFZXW?S+MA,0X;Q)JRS/2
MYYL0'?(VC&4+:B_,,X(]-/:U;//IN"SY8ID51JTL0P1I\6JCQU2**4*-*PI$
MX([-2"3JSAWV>,[Z0#T/,&L5_9D,RW=?M^,!QK[S ,Z?'^.4)K</XWI"]D*T
M.3W?X4;S.-.I0$K_K-2&WM<Q8#4I&&ZM$7OX2_ZG+[(+SP/NU!S@"R\9VHZM
MK.8,&&30Z %D9\7ODX=M*=$FSX^%A>B_&:0X2.Z3H]O])%2J7"HUM>0GD-C6
MQN_6%HG!8G.%<V]&R*KHPJS0MB&/^-RQD/D;RKV7>^'^Y4!LV-#EAUA/D;X"
M@D'A*DN417R?N6]_0M82JZ=_DF@-= P4="HZ7C,UEE?5O3.[83:UDRO@@QZ=
M_.9X?_,1O1)IU?!OBZ5/7@$!/1\KPHZ\LV 2US HK4N'C.Z'?+^'^R1Q,W<S
MJ>-![%4E(6R:_'3;O4W$$8<4;3EWX1QR;&5W8BI=V47=--"H*B,UB]I/F<!6
MZDIMS03\IP6T:;3UJ](?9S?B':W*?MAPI=>D3^2[L]X2%%)(&^CVFJO8Y[2-
M/OK[WZ8PWSP)2]<,FU$'P?E44R'(0]IX<T<Q6V338NPTA./2Y=3 U78-,NU(
M&DYV76QL;I([9I)X@/N.F!]%N[<AKTQ!RT<I;)L&: A1CL1@FWZ;-]FF9L[%
MC,;%ML9D\6OWEN01"$9<6;R=*+_CK$Y03.P(XH[.J?9A[\G,OOS4-Q<8[0\O
MY<Y^:BH"VS.O=.SX'-!=EX;P\XU@.>P[LHN=<@+1BJ')N!P0AEV)*PG)W"?>
M?/MI<U5_QW_B",,_5]#X00\ZD;IBD\!VNM??G54XA=3Y!J5JHX1+M[B]G[@T
MSS4EF]'AXCW8Q&V^:ZGE5,.D1H(H&T='H%3KI>Y<U/=WZ/YUN,T5\?&W9,\%
M5VR)CQBU\4XVMAY-70G@\NMM*=*,\U3\;_,Y9SM$UA%!'0CH4E2?XIW)@7_R
M;ES+<(TPK>X(J(;?[QI4]FJ=M[\^W%!([(#[JE=^0\.AQ15C*%WAL%N"L"N?
M"E[7!]J5O*Z]WY(CD&<[Z:MKI29"I>/D@PWG$W:"T5GSWRZLS12/60VA RUE
M4>?HAR@\DW(-@>X\G(FVC[#^T$2%Z>V;.JX[JH]#_$M<TJY05-YG_.[IN!DH
M!3><_Y:EE;@R(J@5A[N42A*I\J JN"9ZR&+!R493@8[LQ4+*R$4PSID'R/!/
MVMK@ ;Y^-SKQ\5K)9W8#$;:-\D5P3LND"<MTN @KY3N<B3B 5\7=[<J>A;C_
MF(9&=E.!]C<4W8*26Y= E(+H#0_ZIS3NZ5!Z9=X5>&*%P[M0L^?U''/+M1Z"
M9=&.?'3T)\4^0/&GBYE(]QMW."/I(DAKN&XJLO$-126#(\V8J@KP!G.W18YO
M^)LEG2OMA&#?Q^XIQ?7&"7$7SGH+HJ1"##DN:%K9^CP_]G'MN+! 4<TM!E[_
M5<5KD>R/1K23.MN)1VZ37=<1BQ.S_,JOC<#(3J1DF]77J=Q\+*F9#H=[L?4S
MXCE>RQP_^;>43[(-@_<F"*E#M-R"9I)OV;<.BN'R=D3DTH$UV<L% -*Y"<$V
M*JL/TXF$[N[&K&&F(RNC=WEZ]]JT^6S>!7,53]GNUIG;GDYAE@ZSOAH2]9B\
M(Y4]SFA\3P7FK^TS^BM>FUD554*'M$2VL595D>82'KE#T/3Q?Q'_YT2JJSNS
M_]*L<Z.R#\9^+=_"K&'LNY%\-RH(@8 ;[JCZQ]=(2FPW-MTTEK;M'7HSW2V%
M[]U@70UK\$OM05[X><!FZ-QH$1(7JY6 *]B3QB@?XW8.<\(D8D^+?[D ^I)<
MSB=A+1.T4_OBV;O(5,2A< M]-P2CZA_V#VA3.#,RLK'V<5RQPGPA(M:JF1-U
MJ1H'00]M(\E!"BR3>PO*'^WG%1:%JFB1)6($6!B.(=C*U'&"+AED%1TPAO_=
M5YO2YH-H&96%'7W;_-C"EQ>IF'MH3S+@!E;J%G.V3S?1?NJ!:,Q?Y\ZD_M;3
M(N.-?Y?BV$4M8-.*,RU&SFIWB^JU>0L-4-[;5%5[4] O.T)P)%T(ZD"M8+MW
MKI83'5)-$8;6;OA^XB"[OK,;P!"^C-;4QNK5-TM<*K.B"Q=^=99X=%5=]"EI
M*-I,*606MT:.[8R4SK6 ]-2FZ:50LW/SB#W==4HO:W]K;JSL,G!L1T#7BZN\
M]7X:_,EP;>C%9I^9;N8%!?@ 75VJ"00W+^\F9TCML>;W#6R%/^B_>X8S02N7
M=?6XE,\M=SAY IVC_P62]TWSO=*V!:Z"_^3ZKM;V)#ESTD86;.<\N[5+Q#B5
M@OS-3'SH?/9M_^B?%;X>@)>;GEMV30LKJ&BCJDQE\.SY;ZZ#&NFX:C0/L.]!
M?/)_URX\ISB)Z'/XUSZNV#Z<GU^/7EK@<6J#/C.]P@.\Y:@>L7F X9L^_QGA
M?  /,((Y:II[RT?_QLI,8QW_Z\C:0?( ?GN5>!Y@#M3& P1'[TB2_A$YW"5]
M6:?.2GNJ5==7;YCI@ Z"\Y3.F7=MJ-28-8T,G4XE( >#EDUE.%\23B+;OUOT
M.W\GS+?._-?39A2OIVYT0DUI7V<^D;L,DZOXD>/3\N&G_[=9_/SOYI>LI7HE
M/Q"R+KD2/;5#<PZ0/S3#/+W+A3@EK]0I -]BJ\Q=[P*) BPY8N+1FV;6 VF^
M+CF23IBW'5_PQ%U_@EB.@S0<<^SK/XO6Y & E<:;G)1.R,-&40D$PIE.E"ZH
MEK82U@F*U0MMS5F1HD9Z]$HYFC,0F!LC>,;0I!V0NFQ^SAN&*RYG_;+, C!Q
MH2?HREQE[>.C#VWNM"@NSOR2SUR=R:*5Q7''20=;4*#0F5N-E3Q )I8'Z&4=
M7)Y%(6%WC4$(EZXO4#[!=7,I[GML*,):@NK6.R"7%3-3;A^,D^XQBRD:@Z_?
MUU?[0HN$<&*UL"+F3[:Y[D$)6X7\^D;:7Z.U50Z %1[QT\P]B6_Y7]4.HA20
M3@45=^<%^2L_YO:D;P#)2&8;&S7+6)KN7Q?^[SVV.H.]WPTR6/U"-?)??N$(
ME>3M($[4&H:=44//-LU/-,Q[*OCX..4%PAF.?4'KAAL[)W9YF!SW2?JPV#FZ
MQV".7.W" \CQ )3;Z&L_O!$07U$E!*BGQ1*A;$A/MA,K#APN,<!2F6WQW:K/
MRO%/+$>]?5Q53*V!$'&9AX/#$K4FO8N;%M3E09C7Z"O)L\O)=F$)[L7DO&#7
MNW*!4F2OKFR9)*_7O3/HF#??H/1DB8YZM;@X^Q;52J7%XA;@U5:N2$Y<7A+K
MW[.J;N2,G8"M^S:9C_I/VYR.K\V>1,E"O*V3/1\8+U\1QD!B5W:J.\F?2OXY
MP?VUM'QE.%',EA('0;B"E-34P,U%)SGM]6HSW[&D\\O5Z:>63E&ZL]KH%1NK
M)YL5)2VF&4,KYYWVF9% HV(>8(E )9&7*W/ZS'=OI]_%_W"[ZYP-WS/K>4AU
MEZ(C/Y<P;:=VY?:B1&!AB-MS&X<ESCF=:<?FG0AG3.NR]]&%D:,4":_-!Z4(
MQT^YQIC+/O;F+@%0S8RYN!F=!.@!&\7$$V!F__O>G\FWKA K1+ *E&O9AJ;4
MZ=6W";J5R]U4+K@YADJ;BN&WW+_C;\3]%T<L;X*=17#N<,$^,*^OABB\TB)M
M#47^<N^%QIF/[H[BY5H\P*G\]Y] 7G+%$!Z@3&F>FBVONX0([C'O06G:C+Z.
MWLV4/'[& ^RVL1[EM&AI' GS *]^T$5F=S=6WTR,NY.+(CK?$6J(RK[/IH<L
MFZL@**#O*'ZP<?9FFR]^N#B0,HE H*AT8+"^-??BX8<I3&?\L?E%;+]!N\W*
M7-<)"?Q#!^&<ZD1]PX8[G*V0/>U->B@$?T=WY)NV W/M+L(+],4A2WNV<8>!
MNA=K4BS+;*A'\I#[(IJ2<RPGA,F57+_MQ0.@# XYIY)4NKKOFC;>N/[#22M;
M=,/)&=0E0A0Q/(K!.707)/Z^ZR"SWLB!0I$"$R%5# 2"=F 9_6'C<;2* 0]
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M11E+[7Y+T-R;Z#Y6S6S187!:! >7H4MEFN6M5ZX7K1K#3$_Q$QI$@_H8^@1
MG[N@W_WQBM:X2KO+2J3,]!64O U0?@EU;>*"@.O+<;N.VATD3!:B?WW;I)G-
M/UR,92"T1ZSQG/3E(6;!2'BNO3GS/"A8O?@0&),I';K238Z.M3:>.WBAH>50
M458>A 67,P8_-@RN^*!KLI@Y4?L+;Z5<?5GPF9*[<B"9S1!YTDWSE$D;4^T<
M&>6 H!U%MF96)F/^I:]9!"GQW]]2)"."+Q9]JM)6:Q'9?>@E8PRDI9&HZPNF
MG([@V> &T6NQA/K&4BTI4!'64R1V@!_<F*;5I!!0@QYW+W(6:WW]ID^'R[H
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M]IE\A$MV(1EK<H=C_PI4A*KLRP9R79&_.&H]SC"U'9@M3G!.0 X&@(H1<%A
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M,*XGH3H&3!2] W6E2'$F9L375V,RFNT1!FD4(R)"#*';'JEC=^;-[:K2ZNC
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M9?V^VT.= 60'C=>2:^I1<);]*#$^61>'QZ=32<&%,66@ <$/]%L9ZJ-[PEW
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M26\8C0.CK7B!G>549'E;(>EDE3IQHLJZ(3S'.\$-;,!$FB#$(GNQJ.F;5]N
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M&&--D<D:Z$SX]CQ^I0']93>$Q-*MB<WNX')$OWW_NG'%H"SQN0JQ3UF)/G.
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MJ,:4F5>=STF/)9ON*YH)H3!#I/F2](Y;=R_*Z-8YQ;\DBX165]KD$$]^P\<
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MZPCPX6"BX+LK313,/&7VHGCEA#^*W*'%,1(0;I)Y_->Q='Z.T:@U(BG"PM0
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MN#;.%).T'E<V6>07^^O85R? )U=Z\7/9F!,51URF7%!E#[85<NN=_0)_)C.
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M7C#BI$M2C856BE4GSMIL)W,:$IJER^175?]U-&_<\]<EF5M5C=I\T I%.0O
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MFG-!92#MH[Q\G.!I%A=GQM6QC-%^ .XCM=!ZPR%^[*XVZ6$ZNZ\2""+);&V
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M>^^P)M.N7Y29T1D;SM!$ 74,(!+:B!1IEC&A&A!(""V@5$D(*%4"R.@,"$'
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MP98VU\D!+$/GD]]#88-R#0H3;OJ<]LR+<[TNVE*:J;;SI7@'(^>&W0-QUWP
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MD$T)J;3$1U/<\QW;2X,2;[QZ3['57<E,00&1^ (%J%,O)TKA]385KE.9+T,
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ME]=N7V6-\C [$A__2,Z=&_Q]Y0T84_?3;=,G"ZEE.7"0X-&0 D.,,<*6D=A
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M*+6D;C+#Y3@4;#LD3Z*UGUI0.C?6Z(1"5_,0Y8;.BI(Q>BE3F=\!](UP#?.
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MS%M\^OL&!/+L;M1>-7:;5XXIHJ1HX6W#-1=!D\V:2*&%LA*IQ-9G<D<BAK'
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MZ>S=%V9LXUAF1 PHB,Z$IJ&-2$":Y6="-2"0;P*!@%($$@-*J*'81H1 4,#
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M8-%:N^?8)TQ9T1P(T4B7X92V:B#7[*DZJX:T4[Q?=B8SPK_$9";>N(""E_H
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M+%BI9T<<H[F195\E+*HJ0(8/7TK BS-\2^W?&M2TUFD?ZV[_(U_0"1\!"RH
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MB\%\#9DB"*-(M[O"R5Z:TNDK<)8M 4GN.$4W%4Q/&.<-S%ZJWWH@;>:59Y^
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MM@\1OWF/J/'VXUAW"@;# \Z;[>N"_A2WU#@.PUU)YHB%MGR5]#(+QBA%/'3
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MESR]R+'\4V+8\ +2.*]-3HD2(I@W 7\F$R7NDW6NR[E&45SEVF6[.E1ZCNN
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MJ\CB)%NO _G<\9P'%4UC:1/9,,O(NWC6GZ_I:5P^ZCIBK[P:W\@O!J<L1,_
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M,L0EV3<5006!E+YNV@[N1ND@>7E:8?+^U&&?;)EF>RYK0.J1>*X6C'289?L
M4%7EV[L_*-+DJTJY*%%%)QQ14YJ@F<L($5Q44Z,1 52ECS%3Z\KNM"Z(M1N
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M\X:+0Y>,?Q=ZB&:O0R[-]&D[@Z9SE$DAO83<\L PZA\_?GG](M.@V9VMRMK
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M!DKC:TB%CHQU=#<8%0Z D5?RU7B<E-]\PVLQ>;N:GJ1A9F?4$AI#X%/E8QX
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MB#XV3JYS.;?+>T'S[W=0)M_5UB<KD1]]Y%DI5!@;S)B39Z@)8&?J\>.F"0X
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M*VL0T-Z0]GLH7F/(E1_/K)-,A$Z,4'?>I+WQG^@^D5%_%TGYH\G5C39OP,
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M^-6_4]*]Y2 Q5_J+$15&@[-(OE#4C^0G?O*NT=RD?A.SGT]5;<GDGF-J%KH
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M]XT/\/$/6^\7H;L5U7!5S=A*O6O _$YFZLU1!@A1-('WZY$3"#.G@2,ZZU9
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MJCFHC5)2R)L/:SQO1SQ?-[@<T2F8>ZEU(/;I^M=3U&]B8U.'Z[/_SX-5T^6
MV=.&MS+.OK^#OMTP1"[#UDLW/\',G]^PC$E#;$ $06Z][O_K)RJ:U^TRIN)7
M#RM_V>W2ZG#9+[_^(7+KR+^/J8)WS(S-/Z?(+OJ9AI1E)B'N&.?92/8N\K \
MZSJ 7(J G4@ERR/*W-^(-'YW9&UF]G8%)=J[V0'+P4VY'^#66TY%$O=8KD*-
M)S7'YPMM%\P,.P; CHN);:+1L[;TR%2=76\:(V(4&EHP;6B(*;5)7XW/D6Z
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MR"R@?:H>LO%# F5D1U-I30\"#UH=SP6^.I(X((PP"&N^8=#;!5&ME(2=9$(
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MCD]:Y[8A67UH9Z6. "]:)GZ?D7I^CR4C!F'PW*XTJ_WH4DQ4X\VO,:(&=/M
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M&OC.@T _MRAS.J\O8,4Z?QBC\>/H*OI;%.3X@^HV?!3=P<C+V=D]PJ^BM#!
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M]*64I0F]U!;F<%K)(E-4>"]_GQRDD#VT%EV (W.3."YC!C#[K48M[Z"=2JB
M*1E!.30L^DS&_"/ZR)0[,7@XS5^,U@Y\_C[1J60Q"L#1PP^#X6CC\/&"U]G[
M*C^WRBS5WWD,K,1,%:'^%N?"E(FA?[V?=FS![0FFANFKE#*//.U/4LEQ:ZC$
MX4E\BX[3V!2GX1TC5\/G0I7C=[+QA(UX)IGL"#*MU!Y^J%%<3R@!P8V V$%
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M#L<@;;F0[7#/VKD?]F0EGY/*Q ;1+_V5XA?=W:45!,;_> .[Q=9-X\&[H;1
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M4K2_]5#V,AH8;I][#;F?6G$I[USS@GJHT>GR(ZYG-Y8&*=8TFDO5R$.A=X4
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M[T;\"IQD[*[&X;QF6!:P3W6EMAV@ \+H\9$],\5J>"'D@&Z=;A(QCJXE+EL
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ME;:4X;.]D:]<B ,1Q':_'\T,#I+)C\H<HX\B%W_#_/;$OYR#YF8K_Y#>]78
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M<M\@AMPG7%476_D2A%Y!%>TPI:TCY!E5!Y>AVD_Y_H*.:10.#H9&W/PM,L\
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MOJPP:Z8/X]J+JCJ#2S/&TOM^5[ SRRJ<C7E)(&^F&O)#@NG\X;MT0U;ZC^W
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M=L[L.4I:MDIK0= 3"MV9[6?OG"^N#"WVA'^&%NU^1[)#9#CZ<< <QRD<OJ3
M9?F^5J$IB(A"6PN2.32<"! 8UTS]0S^6=;Z^T^'4=ASN-:Q]T0EIS2<FS:3.
M1^72I_M/=B/;_3_*2E=<K)DY&EKM5*&:PNO(TIQ3#/#]Z2E&GN07,X6BDV!Q
MN<0#V<YV;<HNELZ#DTAR3VA)/)4++K?",/E0+42W<XW"!I02"#/*J:P#5<>Z
M(H\NRVN=Z^X0;YI8."U<1 <H"6U.F,3_1:;E'?^R6+\[#VK3&X:[#.3]3NRI
M(A3"$RY/I5CR],,3YQ$>B;,4[ A#%&+3\!MU7R6>NRJ%=1IB&9OY<0G9C=RZ
MOO?E-HB!59M>!8J):4T/&#Q 3LQ&#$Z8=3=J=;.,M%#OW7',MJ$LI-/W+A7\
M&^N(*72-K,(@!8<*B:NTO+BZ6R^5.X"8P"<S.MJ][ =')\.&V5EF]H*P@1 4
MK<8L8JNH7G!S:ONJC&Z-<DH[++IUI3O%C6NMQ*<6DTYR04A6!'Y>B#(DO-;#
MI2W>J9B^4OL,@6(,P"P"\^D^L2Y*3^Z;:HF2NI*7%@,'O#@-'PL3OAWR>F?F
MAVH EG)LI,UYCM>AQP(50NL6MYO#$#VBXC2*^F[XXA7Z6R_FD& ,.0EZ7@:U
MW=8L.3NC R\WH;WL 4=HG<XQH['RH#C!W9Y<B<^'/6<Z,:4NT_2B[V.!^".]
M$%G706B>&:PK&!. ^,?WY+7:0J_\ O.<"YA?#-7T"<?Z/K7.CQ$#*G+&IGAA
M0(WX]GP8R=GW=*[/WS7#RHAHU**B%<K* &#-70PF*OQ?[+UG5)-9^/;KV,8!
M41$C"MBH&@1&)" @H",= 0,)@4""TH2$&GK3T1D0 @0#!B0T#2T$2*2$0""@
MTJM2DD!HTDOH$*KBZ[SG76>M<[[^USJ?SOU][V<]N_SNZ[K7WFOWVY" -%:X
M5_B*/=;^MIG&;Q3/H"(O1(U\CM%-E" APK#.U;]60X:@60T(Y]-\9.S"RQW<
MLH7JX:MQ-5<\2URXXOW523;===W[+.2F@<'"M,5\C]@'LY":P%;WVY[GHUN"
M!5KH3'M2BERL%-NF");640$UUYY;$@WL;VX'EMU5U&[,WD@JXWNQ8'(BYDH.
M8.E;#N28&0R(R=FFO<KJCC!Z*0CN_-.,<%PC("F+_6B!DCM\?88^]\55IXYJ
M >4I6,:.->U)-O5=^YQ?,< O>D)W<*;]DEL2TK< ZOTS&*\1\0*?F(MVW@\P
MQ1,EZ<+O2Y(&34"21134$\.=<FE%O(Q3-4!R,X@2RPI/""PK5XK#;I^T2;_F
M64D),W20!+E*NA%*8*"BL]64[H->$I5K>%J<_RY.O8FBHFY6H[08NVX]K.3!
M;"1#'!NIJ>[]WL/D=-YWT:$O#?[%?_USU?3<NWI[;T8LG%U4VZ=#HX0%H*'+
M4&1ZKX*^^?=[X&GQFY65:];FEPTN9:44;@;$NKO<F"C2TC)B\>E0Q'QAKOX*
M:S/%ETF3I;1<3DN0?>UPC1SA5P=Q=KQKDH<>CH>BM"DD_O"]M;>J61<<?<X/
ME/(ZMFXA;/:8)F0I=LJQYT'5E,)E2TS Z-YFAB,?PXN_7,=DFQMXU((B;*\5
MAYFTB050$B%;X(68Y:%?MF7CL-N].RO^S,&0IP'5 T4C#Z /2RFM')F,&<VY
M)GWHGN*2])+6INP=P$3!U8:;7-3.62%*NYNYK)>!O@%D.7T=.;]JI=D"%\Z<
M?063!"4-@1WM'4KIA6?I$HV>"6%%A&[S !]S3QD'NL9WBPY8FHNF#%5]KL0<
M Q]Z.#"0K**BG$V'\OO07-[81S:,Z]8[B1_V*G7I=4E$RWOJBMQV#Z, 6UJI
M,U.<GDMU/CJ[9_E-6,^.J$!U(!$5YPKICX^2M(JM;&U$T6$$**"V-=.ZP^V5
M4-N&?22%V!#^N6B6V=O\6K52,\?4 UR8&SY:M+BI/UJ=.CX%J"AJ7>865_X#
M8+2MFYMY=56-/$7;R[[V]SA[8;=RU(L& P+1I;6EDURTS0,YLS)3?A3)&%!D
M!.?H=*:F,<.1'!+?H8V6N/BOFXU#SI4)@+P/SCXMV&1NR"CP7=1W*D:>1=X>
M*T,S]_4N)^TKFX4S92A33?RE_C/-U(! TR]VF0?F"3%+TL%0&# <?_=KC.5O
M\B4%XU0#)0J!'KC(9!>?T=)W,OYQVYB*;"O-MIF^0SBO%$YN=4N:A#H>4PID
MI.A!,<98FJ=[@I$'0 T'A6X,]C3$(1&NXU1KK_R*_B&?]2]@._W=%(U;PW,C
MTD!-ZW32MGF0#&/_V,)2]*3 ]TGJT[$2>H5  TCAE@H 0ET;N2@JK)HR/5H1
MDZD61XVRW,E+,7/N6*L);!X'/VU1M ?VPS[V&]A9SQG2($C#74H!DM4C:G$Q
MD_/S4(QO>UT=;G&__D=AW+%/I64FUW+"&#X0?4-6UU8%DPN!;JB+QQ',>TFF
M#Q//5$$GH9OQ$7XEVO(I%_%?C-0-0>V%E>N:4IEUPD,/7O+6'63^R'TU1<3R
M?A]QBT@9=6O3T3G"(S>NY&&T+6Q(U%W"(<)CJMF_'0%EKM;(8M"YX5K"*?14
M= "DEY0#MO:"#B$& _M&<KYU<;;#7JEAUX)2\JE)2TI2(&%)L(PA2!10O'>#
M2ZWW[L[X72(R7:^5QK$W<*5)D4EHJZA%XQ$=4Q75:CQP_WH,-I85B.&_^[8D
M-]&DZ[3/>CGYD,"]2(7LKXYTMP ],B_7C34P&J4U/@D?FZ"F*L'OEDW>PSM2
MG,(,S"U^'@+,)0S'=3?U4OM('EI!LL/RK=X1:9-E<;6,$\6I%Q][KAMR@ 9G
ME;D$<DRZ_L W^J^/G <#9AI\<^%#F0;=QQQ%6F<T)?/#51Q]"KS'Q*Y$<R0S
MDM<._THXKE1&KPN  ! UDVXN'#?I'(5.8^9YP=YC9TJ:;W9P@A-:(HOK8(,3
M-",3(Q.?5=YK([JAXO ,A=4>2U^(Y<+5;QB];;)TKE#ZK,DK5&B'59;&$R32
MISS]@$!_%7TH!&(.W+Z6H5OE=@= ?TN?%:/56O=J=I)H#!V<)YY"(>FE6:?:
M+U,RM=#Y7&VM(&>EE@OD8CJ[WS9CWF;>J[QKIQ$Z]B]7VPM&DL[?)+,ACDI'
M75>WYH,*)MSLXF"(V9I'X <B!G?9U]DIH##Y@5^N#WFP(JT=]=5%_)G"T[6(
ME:H^$P,YM1NR :O:F1DT&P9A$8+20&^"->A07MH= ^HL;LU-8-NI2\7VA!2\
M>#-*>;UNO3XO538_7()<1@!I->&JBWCDFH7B#."L,T,RH6YG3BZO,,=0$=R)
M(N6PNU$:\RK0[=!%Q2?/:Y W=OAQO'1__$TVQ+][0;U4 KM5.L_XI3ZTE5-)
M0*FAUPZJHW*(M1K7@,HA@R1Y)9?-N3$)TM,M)\W6VA*+&HCYDO;;4!VY"21H
MDD%!BWQ&0YE$>"CEXKC OZ<5VP]; JNG[X<GOEZN>@I0'KQTK(XT^Z2NN9_B
M*BV3GY_&RFRE8&=HR"%'C\BV#XMYK=X#V8#KM\Q8$0PS@XG?S>Y;/^+D?C4>
M6=;0),=LSH]8/^N->*A6W+8LY<>R=6K-S:<W>7GI>^&.*Y*,-#,E*VR*&/4>
MK<OIYH'J2A^XTQE@^A2[__;0XI;MY7;C!;PDZ.&7T>%B R@:#-">#\J,#P?)
MC6<$,,?D2V$M[I1W7D<#E5<W<6AB;7O,CW5J*I4Q].[*GQV$K:ZFCJQK@;5?
M0AEUPZE"'A3;_A2Y6<,B*#P&FPG;DJ?WT[$D+>W/?LMFZP/4*S+,D74GR(&*
MPX'\KN!+G26.L:KDBVVXR'((B<)/>5AB*)7.6T3"^ZB*B)*4?,C8[>%M:0I(
MRT,,L9?QH39KZ7YC.O7T:[;2)^<7BDJ"+\YVLGCERC91<@PE?3DF?=HQ-"J&
MIUQ[IT/U#F?0#M.\+%"TM]01.VO4UUHSXSPYIL[\M?+V%5B!I4VE0U$-L<$/
M)]:,Y$XB*6_4]S0!YWU$M)A&)& .%!;FO<T.?D=FQ?H[Y"A-'"-E_QDI["7X
ML^5HFS%7$5Z[D(#R$BVD+F3USFMM]HX$W#(3 =R%WB[17TPH27)%@5PP\@2>
M12R=3RH9)\A-C#5*=3.G'U?U@I$+SBE$C[L@PQS1_5G],(J/!W7Z@^AO20+?
MMO(.JK8[-;)RS TK1Z5$E03T=@"!E>J*>'")(8E")03W@(;;7 L46MZQ++V8
M7U[OX&_W7Z<*-3-O!)&G[<!B7KTD?KVYJ'97N=SG.^D!;6O[^JD=<@MW>IE)
MF7/)!C)BQC.D[0W';8(XXMRHXW)UWL;IVJ[$P;PR]AY33A(XVE2(_][62>Z'
MHL62T\30=*@%;T'B87NY;"/-%NJ2=LG @:O]KQIH\ZRJWF_@GX=,G/51BF!Q
M=RRE: @]%IKAQIPZO_C/'P4?$"Q3R82V-WV&I3+$Z1D4J3H(9[,]!+9V4=UU
M8=H\>L+%GI1?XE=2=H#>5NSJQ&*R#<5?!NI \P_"L@(RK4W&K+H5'H37(3^$
M#7F# I*TO<(5*<3I**EF+YWL=2+, Q#(BOB+66X:G_Q'>RE\QH6=JAW)F;Y4
M1\51KN-CNUE2W88%RLSO80K0!5/5C&AFCGKE^!8PNA=J^7!AK[U;/_S=BTOM
M,<W4H>[9 !Z)I("XD3,) DRL@6/RB"T(.$\X0QSXZI8S"A0/'=(I4*"O+JUI
MA?SCVCI_VTP^/-8^$W$7DE6(\,3/M5T1HM04(/P5-!# >7CFWK^F3N7#?OS<
MU-"R]"A$DH3'%9@)G&-<H\_3243#2SBI[G]=]]E5MHQO"W]Y,RN+6IB8,B92
MI^52$,N*T/4.'$[O521$\G/_>G(_H&8&DOR5[0RMM$?HGWT E?O49>* <V*D
MJ(.@X=3=S-Q>M%G=ZX/+L!G;2ZRJDLES_S>(6=B69@HEYL!5WYLQ M4*X)J3
MGZPY45;L&QPN1Z3@KZ^<8O7N=5XOS,6$Q-9A"]FBXDA[C8CPGX?J?/=_'N*8
M.B[=\</](U,_<(N'0I]D U8=GE1!U%,,;_K=JCUHN9TQ^M3#NL-(5Z5WU*=O
MO!=^:Y_PUW]%2XC"!+'8&1K43=M[?FKLC'SP0)EDU(&0T,7S(TZKYTWC_E5V
MZM<UI\AZHO&M_5PHAK2?K._X+R.<Y3JF_F'8N]?!_FF1IQJ]#%2DH-@S<BFW
MCU!;.#WV')R83KVO&_B4F/\EN/I);\^!:G1L%SK=BE(_G=Z9T:7?ZX'HV->:
M\,T:"FSVSZ 2B\Y3WK]G]K> S>3T_JU8-8Q9<6W'Z1N8%QB2!&.IC_Z\HV?T
MK&:T7*BPK"/N/'%G1\[I_I&D]S)]UNEIV)(ML)AYKW20+"0XO.7@$30('O<F
MB2?I!J_R ,<TEW;(2'(1#BQQRGY7L,@X:\+.V]ZKI,4;>FY;NYSO@?;8/7_9
MB!9<W6V!D$]%P)CH,?RQ2^-WMD&[GAI'R^N&_@_TI+6S'?:GYL?L=XZY#/BD
MGMQ7:;MQ0QETOD,DR27'$C)M@LKG=TZ'D=;IH![)DB4 K'47.\5 &YU3](UX
M6<J]D)LO&/+RC$>[VH2V* "E@?F92QZZB<@?M_PZ=+BOTKI-;BO183>]=_6H
MJG#YW"2K+CH,U+.2!J_M8&L,ZLH_T\,-JTA94;JH_9A'5GT]>2+,%%?+BVUT
MF.FF <2G%R/M$QDV)Z)\"_S&,20]<["@'7CU':-8).'K?0GC9I;4##VCM<3'
M  )3A,),V"+9PLO<]@B^4N,*PVB$5"E[VQIJVEQI82)9!_/0VK;D[R47O8+
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M'9:^N]Z0^HC,UB'O5'Q/X'<WP5A]&JNC/,)?])>I03S."8BM-"33\&TKAB
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MN_K8446=+\(TW>_R/ ?QVPPHUR9H3,6N.+X,E+FP#?A0_'*J(Y+RXR@A29N
M;Y.<F'7TAR[I0W>NBCUV]TE+>-GD*Y!D]0J9TF#P.A/U;*PYJ2:,&T2SF+6Y
MD3Y9C1!!N&)G+QF I!>"JW&Q,G-%]%G]7@]Q\MD_8?SFA\>4=7.K+VG$=75T
MC;>-K_QXJJ)<I]US-SHD_T5R@Z)LU))1I6$U@(H2&!ALW-/^S7%XI^V%/?J2
MF37^WCR\EKKJE.1&^GE(,P%R4.;XF#6$$?8,%E;R!%7X(&3QVAX5RW$S<:O(
M=Y[WC]2LA1^K&'9\8/_Z'N%6M>TF]H8<&JI-JO[?+5UK'B&7>F \X'AQ3NJ<
MF7 UL6YS[^"0VTL ?LWR9(NW\KL:Q\>XDKCVG4GG:1N5ZN$$A,HG$Z7H;:]6
MI4Y:&>>3O?%!K*PRSV>X;GI'Y9'ZH<F;"5B--NGUTA@J9A\OI"@R0:^KB=L]
MHKA^+C+%YH&EAU-.DH8FM,:0I! (11;]^!OYC70S3:3^RN27,WP5QHFY.>?\
M%YKYS\V+G.?Z-W[-Q,T,R]@+67;P!6V1&0EBA4'PRQE=A6HQ)DE'[/GCL]_0
MJHH_BJ086LQ=QV, H(K*72J'.QP[ OL6_<^%B6>7DF%Y(L1?^/6>:\UUGO _
M$)G5GW$D__'Z>-F/YY6V,GE):[;M-I!NGCMTKNB+#"-_T_+EB_*CIVAQ.W)R
M/9S==: +&5TM5>(\(J'2K(]B[+5!>?N>%8-70JILF@"E"6A.043G-(8$LK;G
M 2E!VR_*?C<7@0#Z(8* )-D*MFBE;59F!E>^YUF_-=2]O3@USBOP\Z OCH2+
M6G'5+S&2-IS12&NML91%O*@Y*C'=5'QYQ, $"GUMO0,UAS6,-^]*S>00:FSH
M%'*Z@04Y,[Z]3F9"[>VF>-M*1:Q79OM K@%,<]EB+EY_AA>:S_Q-Z>CS,YW%
M%Z/4RIU3KQ?9GR49]QO=6ASSHK=BT[F1@-]/888,E=+]3(MDJEM,+-?+5/5$
MH>W3L^DY\'3H_AGA[Z*=#S1:5+=,JY8X$BWZZ1'N.&?>_TGI%^TLK%V:W-.A
MKQW>O8_JR _!4F9I1% A/7C@;^_[8HU5<5A7NG+^!^3CPD)]Z*H#5U^@OTSF
MDH _HINW"0.+@9N;L/ WYPBWFW=S7&HLW&X!NH,$N?KZT(7CBZ*UVG=:RJ_
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M!425[UFM=RKDG[#ZR?-/'8O%&;)TB*^.I)KJ$M2A?V.!BHQA7<KCX"WB$FC
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M4N6V;8F_P^L<UNB79T..F-](3>6>TGU/<$TQ$\$9N M#XTSWDH0PB';7%XP
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M?[*J#L2OAOX.5@TL0WI$M+V6D:+-[6P[I=KF.3UA0O8G/''&,@KIK!L2H5'
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MT^D%ADD1?D^2K/3#JL!0U"8+&7/N!;EC>*=_LAAI&UCI1O1)S=;$@[O3#>%
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M[!XW -J:441' R&, QB8QO "X: INZ#'AZ5!6P2\KI&HE'D(3;J"GPO]L=_
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MDS7J *>"7,"J[2:(\NEL@- @RB!5%(Z"[RJ?YMMA+_)_)DM/-H'D"$RZ"<>
MM28(C1P1'*8(">CZ3!B+%LXP0BK.C3;C 3>&1,HH@C"IQ^-"Y*G!C1%/HI7*
MQ%F*5D5$U&^(K)!J2(;A3ZV*6#H.I9H\F]M$!_(JY@:;NCK,\2K>D*UHJ3J-
M\B#PU(G#Z0!$L$7K4XVU*Z)G18NO/;7X4G59"Z<\*=^W Y#-.LV("V!O'!H^
M->"D$;8FJ2JW"#H#S<G!E-5L1<%C/!,* \ 4&BFT*W&-R+@'I(K&B10H5PBO
M'PUV0^;*!!'/;@O&2)2Z4AP>2^'$6;+@0<D8./S ]FD\U/D!6I*J8CM>*L43
M'=C6]$HK[21]Q&.YF,JXYI3[U[:RK#B6!K81"^UDAT?JC, ;W$0H3%T>0%'/
MS"@\%[N2- !$+[ HBDWBLH#V2YP@I225-2MJ>>A6DU*H>PZAT):4:N7P;#&-
M)$6K[5;T@9F=A+<^)250)4FS$CTF"Y[,52J('6)9L\IGTC37SLHM01_7$2G)
M307D;-#/$ZEAUP2*J:H@:BQK#V*1>F[QD;0G&KOK1@*$0"0*%>%HAK;X'OF\
M<$Y0 =<&0RK"7.2=;ZPPS#)Y=<HOY[,DW>:U0)P(I=OFZ[5$0AXV2U%D1&2C
M*!U\'4P*.=KG.T8@<C"5=AV*"?G.1&,#4 G28E..=W.D.9'O _<C)D$?+&?K
M4W$%8$GC2! -%M2[17 J3N"J(IB<40%NUP%FDC]4HTB!:PVB]@++T'28ZO*Z
M9N"E$NA3(4D,5"!RRUY'0[QN3KPOJ5M/2O&:93)XN6GW"AY3$BH5+71J A O
M9QHX%\UD;"K'$2,L ?"KQ"#K^RHU;)0CSR17<QB^,*KBS>)PQ$^\+\\OIP>Q
M7+4M5/N2T,L(/44I$+5*EV\E=)+(>(5"(BWS="K02N-@R.,9LL)26$[6HQBC
MFW*&4 QMDNU8I"HGZ;YF*1M:>I>KPP"4HZHCP#0)JVOR/%FA\"AP;G>P"M_:
MV,M7^YAFN'F9748Z4#U$'0ZJF$X]*7NRK,LML@;E\'+6;N:MT.BFBVK+U1R6
M 6BU!/FZT2<59M :C0H3'!(P2$A.0Y<-)U3SH\J8;Z;Z69>=JCX.6::JL/EX
MMEZLY-00+'A6J5D%TI'7WV].!<8ED%!UF R1 3XHUR?*H0I![GB *GI<DHN&
M/[;3=3)11^HQJ>ET1T@A;62K%@AU9:-8)HDV;9:JD=?;=SA+ 0BKQZI$0P=9
M)"5ML,N *::8OI450-W@L&IHC]IAM*K+6T2A4Y$JY@Z@OCT R48N"N-Z..AJ
MDY(H%(:'8#HJF?1PJMC>5#&_C8HOE[PRLPG51,JOT>IK,]M4,@EOWV#/'*1*
M>>5BMBR/:JD6X01V&: R(S[2]+&)E*<!XZE!:*7#.-^NJ%P.97U5HZAB%T"#
M=B\)Z6HC-N+9P.<A!VIS 5H W&!($IZ;C&+E(M>IRKFLTY]X7[( V%);SC$H
MT1:+="+AQG)HD<T2E)LF.;1ME*.PUY+Y9KPID8A?ELCD6!Z/!=TIMP.T9S/=
ML(E'X/<2]B0'&V:ZB7:%(^*1)YZJ*16I*_<3S'A0@'V;*S<98DBUXF4 %P0'
MJ(\P'36X<C[P1@6>[//-F&CQ^0;0DVH](CZ<F "24%$BCI1Z?)'J:C33B0*;
M,-8PY1%9:--,C3*0.H?W[4;9&A=< BL$(4$X%51JP>4D%SE097A #3MRDIL$
MX%1?*Z LZ_"E'.>BS72N@1/E3N R"2WO%3IU,A^/B7G JM@ G4<K6:LPJJC)
M)EP!$VVCJE(Q6VRIF J0'N%,,T1AM] 39$L+T!(^((8(622 ?FD4N?T9MU,P
M(R>.]]TP#*S(J_*SDD+818<VAVVIYQ!NC=9<JQ7$3#V(@I%)1*_'B;B>YP;#
M6 DHC=PR. "Q(E"@FCA3'&-B*I;T:;O79^BL6$HY\;RBCPMBK%BH\'I 6%R;
M]6I! DT3^6"29M%@36*AELJ-RM42)';IEDK'9;-*,"35*(XR<<Y3$H5A7<6%
M4='M^!"7[!5149"]!N DV:$H4CV:,E2WK4YP*-@47&K%(L26H"0#^&VZ&U3I
MH)ERQDQ)8Z!\S: 5B\DQU "5RH5DI>W[@Q8NL(UJ7(JEF9 !&N4@Q]"CSB2B
M;^5!G"QYDIJ*AEHV"QDB5/DJT1'U/M2"^FQOS,<AE*G1F&!51SZG<T/'+WA2
M32!Z3";,9'49K;D<F@$'$T,?'_'T@ S&@2O$=-\O$[2)>D/29T5/TQLRWT[8
M_58L5HB6Q4:_1B@I8IN%BVR[900D36IBH^LEQ.:&+'$<\!@,3_F!FL?Z:$^K
MP0RA-_DFJ$:Q0Y7/95&HU[#S74[-3SU[2)ATF4_H3,X TCY4BS,FBLF\2"+<
MAE254J>M.(0@/N$C9AMTJB.)Q$O=3*(U\L8RI>!4QF=5G,O#J,MW70.6-$1I
M)1'%<1D[5V0B%T2.<8WRD)TP!"-/H#5$DUW*5!R%Y6&!%]M4P 7E/$?T?,RG
MK#K1L88I5&XQA@8:K!7]9_5X,Y-ITODJU7%HKMY(=-I@<9+'[DF6IQIHLPLT
ME5)]6*%:R<!7RMUJ)*2<FD+*S$#H1M*HDP ?ZX6#L4Y48 E&*VA[$-G?#*"
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M PBORN!- 0(,O;6A,"7,>?24M_G/@8:MY/&&\; 5A[>5:IC&P\ONP3\')'8
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M2_[)4*%TU4NI\<C0NJ3>YFT,)XY"X "2K<))R<34]AYJWQI]"=KTS [@S1U
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M@OF*9DP1?]=AC+U0Q#Z'\+9V5D A8?]D'Y?$JOFX[FE!42]A!)'*WZ=3HK*
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M<)G2/*<6U9<'A1+2)Y['429;CEJ*!2-0MZ.XOBY">Q]Q^S$ZS?U,/\\+E4*
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MXP_Z>Q;VMY_4?=RU[%I"P1*9*1< ++==! OJFMU0CDB,TJ]P9N@F%K/##*4
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M\*67.NE$\K$VI3^39RC?O*DIS:7DD2&W-%L!_/+38F!^W,DSQ <=O*S%]XU
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M<U[$G8R_)E<(:\SL7+BUM-$CR=LLG9Q_Q>YYU:KCO H=8AC]:V0O;]#M09Z
M91(<1IWUE[(G93JIO M*8?W^RU9SGJ R3N5UE??AMZJ.+PT81:#;BX;@?+^
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MG&AZWH A%HQP/=RP?N1UZ:*\BO$4"<#:@]Y?U!14)8^!(H7FN?KK>G<?D5.
M>>/;&N]8D9'B[4NSM2X4UUG)EC$">]JQREI*2L*HFNXA%NSGXE8R'-/MX\<1
M4N/%'ZQ:(#9;2B>&*R$UYYFQFY6J+>2@1I)/(8O=JS64WP\-6E3Q3DO:_I%Z
MC9I'J6;J[MW0/V"-C8J>Y2_\?!K&T$4Y6+SUT_/KET+N1EE;4<HWZIM\^V8=
MM[;<.U*[DR0B-FQLH1KEU;HG[&OE*DCYF (X#H&Z=$A"NAD#9=;,HKLDGT3@
M9NO%"#+1W[SV\-SKJO&0)A-JZ,K-$4+QVYNK?A^XG>9:"3A!LU;-Z(\C'B&1
ME7=PD*T#1&Y%M7D9T8]7=O<Y#!\NB,@>1T'>MT_+A0<'-1!_/WJ]5QIG/?&5
M7KH((=T=-O P RR,C:*R4]R"*Q^$T8_GPIPNM,]4<7OA016"'CZM6$KS^@4)
M _L9M/,G5%/9$-R7=&=>)>]Q6:U;DGVVT[8H.#T'VU=X7X[IL37\S%-H'B)H
M:+,++2A(,W-8\I*7J; =G0U=&M[EV"Z#FY^FNQO)C9X&#Z8+7?CI^QP(WSF
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M$'%6N: )>W<6DY^D@;I:A796H/]UZF-$FNEMR1G*BILO/#A[]K\O9 #S/41
M(5/5I8!>B[SN/1!Z=J+1PUE1KN;2+N1Q75$NQ#X"#W%SNV<B>)AL'"CD2$+
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M+FX_,05K&Y[S]/&B7/VN'SO0*X>LO.,YARO6"/18D+4/"I**6BN)N'IE;%/
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M&0UB.Q,@C<-?/LA7"_3.F[Z"[YO0GNE!]2XVN=[L<*XX.&3 %JO'2_GF=]B
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M&3C!6\5DJ&>497P9%0ZW_5>, QBX_Z.HJL_TKM_CK @N3C:^CG&3B=7[9E$
M%<U^>O1(1A052#S0(GYV1>^@?[/5AH'&Z)3I-E].N4O#X."0?Y:9F?=GS8NR
MN56 ,X:^=V7]EK:^H($4T'1NV*QP5V^0H<3<**"Q<19C:MA^#FELEEQ\T+]
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M\![QE%7!-+94DZ8D8(28OCP"WUZ1+]'\4NT%1"OB7M:[@(H]NC<,@>1_/ )
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M2 >SP9 >T:0_W$0*=$E>/-^5W/-6!G:"*%[7P3'3PV!#%]@>Q3NEU]AC'X(
MHV<^XO+58J_)NQUV#AA,?<53?H1-Y6;\L+-4@.;I4=19C?0ZLQ+R9#J1*LHR
MIA.$JDCAGTPPLC_2\O0^GL'G$IM5MB_ROD8NEZV]'S!"7V+?V&4LE=B[HC1R
M(IX-HCE_3@JNA#);I;*%# D3[K)W5VB>NN6VE2CK]&RS?E\Z4%;!+B0JX--
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M[F3@=9_CA3XY8"SYCAU2>2^&.^$C&"C4;'>\--/QA/(?WI/SON7W,[^P8X\
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M:!)60F\ EU5W::3$U?JK&PZZ+35\@(9_B'O3PER:MG:JO##A\Q,C8?IF/:E
M&7A:@-!>6S\"B*7>G=DPJW$!F\4@!W]$:"S1\G@Q_13'J_E:VO!#M8?69U[_
MBM"JL7@?Y&OGA")X]#L]LK9/1\2<-MLET)J_?UODM; ICZGGV7PKFH9^ZN#8
M_I4SWT=2EC2:S?S2)Z*)N&H\A-,NB0%A0*#@KU!Y(;;$BQU+ZY(@,I6Q]AW]
MHAQ?AAU=2 B=F'(H][7_CAE82025-B_EM@95N%N9P+W("?;$#>9]E+)(<8R,
MRYC#J&(O/8'H#;JGGP4B,W4=M,-65)WIKP=:C&"N&:=_]Q:-G3 =14:Z4'WS
M7DH^6H:UR;Y+E/F!=O846:X\6\$H]- V868KO2+C[:[+S89@! L^\KY 5^2)
M:#=C/D^F8H"Y[O)3(B&D=C6KD"E\/MZ)%V9@$1X,^;"SIN=O7-<R7=VM9Q>&
MF;*?!VI.;1:^B4K#NRD[I4P//(#4--[TR;NCN(-*\GB8:*CW"O&:G=]M3V^H
M/R# ;>ZX_ !]+2P9GX*7 8L.@6^D?,VPK/\X_H\9E&_^92DG7_"OZSK_>9R2
M^_B\>T-_2V[8H)KFM#*YX-.+QVEO8; OMV>. +(02(;K?6C<YB8G5-+&TG_'
M6A#9/OC.ET:53AL; #-KM-.5@6K;=!YCSC7$]ODYI75<&2EWHZ9]T+@=-%F2
MR)DY>*R=U[G]T+ V/3+/FQUFAU!C[%K!$>J!DTF1=:'_EP.8$#5SM--.W\+^
M$'+1ORQ^ZWP*ZS6Y8,, -Y<T2>-_K8?]NX]%_%N47PHJHM'OG-I5QZ$=]$O0
MV.D*IPK[?8C.2U1Q&3$> >*$YXF"=N%"WX=O>Y(\FG56Q45.3KB\Y"6BJ7SG
MIVW L5W8*\E?:H_C4:>8^K!(3V 'KLZ$&,,JB)L/623HU254[26PD-]F9J9#
MI%><I>[#_2:*JAQP17&9!14C7@0&NV[.T0RIU]HP08UI*WX0J/U\^0O9X,Z^
MLT80F0$[ F@VU"TB;#+A..(R7$KDJCT; CE&FT)(Q)P .W^WB2/*<-Y$A;D\
MEK&3[VN*2!T'"U48,X6$A+]+_$=O_>AT!-B<\RZ:!%[CZC;_Q#P""'IZ#9I
M!J3P_V2+WUKWDQZ$%9P>ILEL;35L1W /:?%58$HM) /J++\8V _OUKN5]DE!
MP2NE2EL[OXTYGQ)6)OQ3Q*A,<KU?RBVEZIF\=-E4&]O!M?<9Q9U'@-R0XLY:
MXV<O& .U;6E#-_2"+GG#%?QN9O%N/]>^_&6S\EQL8:$<.:J$['E=\9ZQP+EC
M-,7$0JH4_?<<(FT/;@GJDFBIW@IJM+'F-=R3&O@^X_?<8:;3;"4!*)(3>7MV
M2G[4*3$4<S9  7C0W?#28=,Z@;2!^=Q\KN !V]:U0CU;(:0B-YVFGJ7)Q&1^
M;4 :!A1AF?M$DDI./_TT1U$-[/!Y<A#CS'M/H33-&]DM55KWFZF@W<*8+Q7J
MBVP,T867\YOU%5Q>KQS?3 ^=J&-92"BDFY:'CK2@M]>,+>[-[UQN*7B7OQ0!
M/.^4'LH8K/74"/\RV>(<UR4J>P K>>ZPS(Y]/!L::2IXAOA[$05KQ35,NZNU
MQPU$HU(:?&Y)Q.S6T[(0%=TYI@M7'E(\2B!S?C<VC<G ]T]O:\=65.1Y1CEG
M;5A8*$'R[/Z:;2F\^)&98B/R/1]#T/-H2MCPR7+T;SP^J&JO5SU.D]J="/F:
M#$U:[SK-T2*%Y\G%E,=6[!&*<N4S[*N"&G9",1.VL/J.0*'@CP! 5;!]-G,A
M5[JDN1T*EI68=[23MHR[Z';E\HS)?:AJ_OOSK[W6T8WZ7#7)N<@1RQ>'G62#
M72U.>VO%NV%)E@J79=?7\.H(\*C@$K=,*2M/.BLIK/?^,PSTR9N*''L-LJ$X
M8](]CDWQ64:"!K(2R[*X%FZ&TE.++E9H:LJ#(T $4M)[]=C/<A[U7RB^8V31
MM-=Z55R7DO@;;] EGQA&[W&T-)51EN FLSPYB&-P1RK_R0LUBK5^EL7OI'?J
MRZ27XMVU]UHM:V[%^@HKIR,B7+>Z\E^@J 8A([%9[ DDIF' 'C9^N>6Z4?;I
M^"@M&A$<]@7V]_D -^ 2KW!3P.@P3G<'J9A,R&\L8"<GCC%B=TK>0#;%Z?QK
M#Q\)JGS\!/ I37IAKD_]&)LV[-F9Z1IX@OG::R]VVGP!^1A+HQ:\[+<*HT6)
M+$,R3EI3^B+C8(;?:K(=%^2?^2$E=. 6XE83',D5<,?X!_C-Y/=21<MN=Z^?
M98S1-Y7.ZDEL=S;>JQIXE6S^I&I:DDG)@5D>4!@V/_?7Q=%]P(R<LL8QUZ=I
MFEZ/M4/49 ?<#XH^XI(& A3KV'[@%AW0]0+?Z3UYW=6<CD*K.1I#[XKZ4,49
M]UJWN<810=DS&L5%,&)U:^2'+GZ(3R.]IQG@S_0LKC]0#:W5'DM$6ES7,=B!
M=\,@^P2H]?WUP,86?*LCL?*L$Y*?'B'D._-^SFA.H3Z/;S6G<G'>OM)LY/L#
MDY+RW 32:3KAVE[(M06_G]+Z>J^-2 $E4HT?GEQ@,PH?X2/9G3DGU!4=I=,6
M$ZJHK7#83./)VD&X"]:+28O_U!I7CJ'D2-Z?TC31AG(*\\F'XIM9B\4!X#.B
M+IX-$\04:'?"!T?I?D]M@@=\ GT$:,+9=IV1)D=?O2F% 1:-L!PH3]M/6,MO
MDV^(1]UIOS@E9T5$)WNLG=#03!.Y*G6NS-#C67'3T+C@9U.4GR1./NW)DV%I
MU!;J@TXTUG)72#<A8:PF0-._R2RT^!%;+).>@[HP#7VA<M%9+^S+ X[LB4[W
M4W-V*C_;*#8RXF1:0Q<CAK_/ERWMTSESKB\D19< ZQM7 J]IV&L8<>KE^ZBM
M#&OYE^BD]&1\R0@O:U(PYI,E\"<7<';E*8M\W'7T!@TLTMJ[KW7,9&;7#.I%
M&V+'$"[ 1I81^L8X$T9P)CP*,_]:+7& SM?U#\*&5C!C U8+N=-K>;(VS'<5
M0W2=T>7,(X!Z"0RM<!^3N]18,#;?.-:U/](3:261ZBT:V!J:/H<BE9,9A/UU
M#F'C?['WWG%-95O?.&-OZ" @2M&1)H0F)2 @H-([(0F1$ABE24+O170L* 0!
M*0$)34)+(4%*Z&4L=&DI]"*=  'I @*O]WWO.-Z9][;?>Y_?<Y_[F?U7^'#6
M=WWW.FNOL\X^>Z]->%_1L1Y>\/;3TE+10;C)8EO.2,/"V+2Z$7_*1!&N2NP!
M1Q!A2ONS&7.#" =.C8AP(SI6@M0QFJJC/O'-U?7:C5E7]>=$VWU9T2AL= =W
M*+?D'IN)F#3P!((,1@EJ//R$2S:Y,OK^P ZYV:.GGVAF)VVG$BK"/]3\TBJX
MPN7SS?*6^8:IQ2_!.H]_YX#(XCI&#>.69 AG#5;[5]$$W(B6L\+) 0RP'W19
M&981SYRZG>9AX&)M@<X.E8H6_Y 3O.AMBH^S 'X)]/00-!\:VJZ\902'9^:K
M5"RIFM%,+7I?%3:NX"WY8#'/GB%CE<H+^!V.C* /S\;5;89KM"-+DU^>'5)R
M8:B<1Z5'FO5A6G)%),4Z4F4YN-L@B,!6:CJDQ3<I@)3&W!XZP 4+)\ZY7-SB
M,/;"^?B@(=#63P7<8Q4VGDK=$MI2T4,"['5)FR7WKQ>;;*+QC[6T8 2"H/U#
MGQ]XHU+G> 4\<L7)])-(!\@@[I&R[^D\*F*/C<&3<_FZZVO6Q^F2=\/&DU9W
M+_6F&H:7AN0Q"X !AK[<BK.5)1"\%2_^!]=:--(F(OV>>-C8+?!\GC[-)J><
M1H5I>Z*A#OCH2?,^6V*]]T2\Q',E=$<),UE"NGB/S5ZD(?!V? "J%3"F*&1-
M);Y67[R^,.1=BD 9Y@#>-8_GX1.?D#'^6=5.TI>GEHR4+T^L GAGUN_?,LSA
M?G-G;I: RYYT&8)YX7!Z(YT3R&%\1OF:9:;DBAU AHL(]ZB C$]SFC&:3TD]
M?N-!X?&[-_A=AP+P 4;>0\E0.LUGX#:)(N)+'VB9HC6WN%,T7GO-!+QD/<E]
MG>=6*I-:.W*\U@LR$:JM156QS(5\2.GP)B8)?!DWUTO_O*CF^/5[&2S.S5D[
MY@O;YU;'5_?8[F1TF.^Q&;U9_9(PUI<&&1K;E1KCS;LUN;6O$HUZZ@6%,!-O
M/D*8JD MX_2C@L$UI%@"PT+-:D+;R!,R%LF\H=/U91C?J5:?<\\C/1P5VIC\
MYCU @#NHJT][7SHJ^@E-NZD+# :9ZZ!833=[>^E,&U&.DVY9OO7%5F_MB.XL
M\J0[0]I/20BNILZ21%:<!NBL8R=YR>/;L[X"UQVRZ@:&M+TWW^+M$D(NXN($
M5B$0B'=A$^&%K>.'N[1$@("JJV,MO2\K*V;'QMMD,X#S2 KIBZ-<.NGPX?!%
M6H*9ZXJ'3[^XQ4T6;V*$R%,TFBHC_9XPN0"%VIZ:AMH)G.A(B!="8P25^QO?
M;4](A=@FZP*#NL YQTF:Q2PUG'OGX,(J ]S],V[&P: ON8E@'\E1H.4L)W/"
M:^P>C)7"K-IF#@4_+*6X=)V6MAHUFW#BX!1+^<SST#&H)_L(>SXSX$X5J>H.
M+^#A6>$RZ<F6Z'0%>]$\VV,LNI&GR;&ZV[O-W:LU6X_ -_'2W1%Q"(-$#V"P
M58V4MR] YJ"F-.H)K\$A4*%CXB&*]6ZL1*Y/;##_-(%8L07I<JDYY4!3.H8B
MGN T*\ULV73!IGU^E#8YP0@ W7MW33SZ(J7_J>L>FXN%0- !.7U-&!^I3&S<
M1&8T46;@M9J50'7WR+POS]85O/LKX8_:5_VD$ 7RO1,^L"43=0CT&K!*G6**
MI'FI?(@8,IBNK*RX_]F%)ZAMF_?%[6#>QR0!S$@!)6UWSFN3-N/F86A\FL9H
M-4U2:DCKBVJ#M@YVKXR_4Y%J0*F&\2<4U_KKBLJ],OIDUY%^\G96_ (8EJ.0
MEF?P6O+,E;R'1P6J9S+ DOG#T!:"T" .50-(_>!M;.V,[<MEE#QY6?IY3-6Q
MN;VT1W)-SCC,7\F&'-M2/A;Y;'Q;CC@I-N'>Z)',]#V27A%F4=!U1LJN630S
M-YTL]BH_<OK_3)F5_VG*#-(N'WU(:L Y^-ZBVY,1W^A1F/9IT7EY&P+_\/$$
MJ/9];J./T*G] 3GI?0IMF?,0'[CN,6R>@?O%"Q18(\'?/A_G=FPV M?56<.;
MNJQ;(8$9 6 ]M[W3#E%CG"V. 73,NTC#Z>B(RM[;58S"*%-!H/#K:IH_GW\*
M16[ .6]"_.RT&F^!#\-F$NI-3"40"$3J2U-7IPWCT+Z<A\&65AO7]04DV[3'
MFH40P"9\5UM&H=D2R=GM7@%5T<!9:-:>9)UV0RE&Y "HAJ-]V4.-I;6\M'RT
MU"Z7.JD62D&OHY)[Y*6*2JV<FFH3"T$:!Y3Z?8RL2N:<K1WE2ET89X(C''R+
MC?!M=4(,F[K@!QVU$(.((JMWT&G\ \X]-HXNA%0)K)5=#6A_VLJY5-PZK/$,
M08T0N8X5+V!@SM<3 \!FU\$P3D_\J?8I!SU\JO2X350']_BS%_2!JX7F5,5$
M=$^X"V:HNUY@C)2/".(X;?0C^T[IHJXWH?RZM@Q@ZVBMAPHVD!3OQT_29D)T
M1>^F-@01:+S!?;EN:1U%-)*:C!@3RKT07+%@0_S?A<8HQK@O;T/?5-5A_BL+
M 7,,R#.V$/'.&*=THEG?!QQJR*19,*Y4M"):KQ^%0LUC\YYG+XX8^*4W+AZI
MTGGJI(*H!Q639(':B7V25&N7P<T+AGRIDS<'T%#(6(Y2,"9DEL^TL/'C_@MU
MH>+=(1>J!5DG=U;S+.?O?8PL<0C Y]5FEFSSW_]N.#=]ZPEMWNLS6^-7=,VO
M(N<$9ET6<6[JC1=^_BK")KN]04US+MQ^(]WY*R'=KQI_%3EQ[ZM&U5]$NF*_
M:CS\!\G_2I(<*MM0YFR:<69.;EV_$RI]ABEZUR^V0LCCHJ"',FB0$Q"!7DX:
M^JKB:?^AM*+7! 5A3TM65Q$RJT_"TNB=;MGS6,\)K;%D+1NQ,P+;3)/BWIU1
MGCL!BSDJ'?8;C^%90C7&:FOL>;WCGTZN*6S0%3/L8SX<TKBW!<Y?UPC4[O]5
MI&D1;!JJZ;)^97?_5Y'O8D9J$^;48H8Y_)]^%9%3I=-&S/I#HS5^^BK"9K_Q
MB\;,KR+/HK]J_%7D[,X?)/\@^0?)_WB2$7F,8#_%#NN;9=L&H,IZ+GV-#J$)
M!E.585U3\VP4Y-5N]S7,[CN?8=('<X.6$)W+I.1NWHX5W"Q6XABLHH6<;?!Z
M^\/-@/]0$_U!\E_F;#V\!29TI-11H-HN35)AC5;K7%2DI*A(4NWB;HG^D PQ
M$=GX^@B^N-:=5O26I,!EUL?J:@3>9:&?Y=P6#D]8_))C7LD-7-KW]G]6'O$'
MR3](_D'ROY'D#[XF1!I]:]S6%'2OI/Z@MJ-J9NQ:+*4("R[DMB+, P2Q>2?C
M!G[-^[<NF/0Y]:ALB>>O,P4?%B47RM+?6S1$FM1#$/9/N3OVC?\1VO\@^;=)
M7F<]@MR4#A:TLG9;9\ @6RW&O3\2HW6KN#D(HS@"\;6<'SB)%??:.;.3!C'K
M=UMEL.=G#R7R.LDV8\*[/'')4RK_\'3(/UUQF,I:@4"8\!0; &M9$DJ1=A.6
MNZ3*O=D:3XW2M:?]I!$*H[3QY4K8Z7I5E1HT]9QZB%$RF)*);1D^4AMFDXR1
M<5&!61J5K*MF"1.UAJU<;LY,-!I@E:]Z5(E6.?#N8^3XYM3,Z9Y("GYA#81#
MGNGJ%7@[6J&J0?C46U>3I\&<+M;2,2 ;$BQ-24TM;H]-VRQ.REYPR]5T6&<\
M".3U;-61C?E35+]B#;:SNU\7^AH8VE[X&2W"+1>X4O?$J^-Q2QXZ,$_Y HSB
M9IJ7S.Y?TNFG."=)UJDDI..+54X4L*]C[_=<B&%3_?YB:42)@;%0%FL+A4DN
M4P$TCT6AFBL4!D-L)H*E9Z<?!152]>"EKW$N4G/W'UWO5C40Q.8X,,2:[7C)
MITU,C^$B$QH"@Z^QV": ?);50_@,^,M5-[=9VO& G/Q$R /^\E9, P!0 4[V
M2A>K/J:F6H)277\_1_'CYJ--F;W?Q(V(<A?I#$TZK:N S]KXR"A=X_EQ;)WU
M"L&NCW!TC^ZDP,YBG1#9H0:RS^ZK--1;8)MP+Z9,TNU72]QR\\#6MYRBJ>@R
MU2EN!%, H,LMRG.T!I#+HW;T;7+0J\,.A]7[GG39$<D\UMK]75*8'5?()--V
M9]6",![$<W3F,P@$$RU:HAC,UAA:W^Y40;AI0F^P6BK#TBX^O.3,5]7Z&B:&
M;T\%>3U7>:G<_K3_]C!0&(,T[\NC;44\FSQG*D'5,:$;$0H_&7W4MA/E\"2&
M ;=BD.T49!4Y(8OF%R"1IGI[D^@R-6XVW=!#!@>\0X(&X>BIJ>7#%H=%BMVL
MYHR)I*W[<!=+5[!-6H6^*N+TG>%)&R$H2+8=EZQM \@%R<>3OKKO#Z4Q6Y;%
MBXO.>VRF%X.ONUU8+78>&>[83;^F/7- A['V#&/1S'6F?-<'1_;8))4F<P*8
M/$^V\A;*Q.K<.;/9&6?(13T(0IN2OE6?!Y>7-^U-M^H)=ZM4>-3@I[;1U"5Y
MCXTJ]XQ20\\:B[>ZNA>HB= WSIF<.;#.5).CA:%JBDD#-<M]EE\&:'<?%9$\
M6#&2J'MC@WPWI1T<4O(BF5"ZF*U0$RQ<BC)P'KST8$1']],GW4L&@5&FA:V3
M^\8-66"=V9!XM_5(NK>%FF=33L229,;"(E:P(/,*>HWAN\KE ^WN$%!3D((U
M2T;K4*),_*"V]NB[V)*AX^L!:F/1&  R)VW)U!!TG"/FM@>%&X?O"FN_BGN\
MT./A,ULC4VRM*S8SSN"D-</*RUN]SH/GWR?OL:'9:DM9,3=LW*->YM;5M]8,
M//.-U>?CK]4*P43L7KIVT3\"*UDFD&I# EF[W'8$"HWH-[\+?U43!450@F@H
MT;OX^(^] @LAZRWS%&",)> 6$I^^9D.L4)*P(C*'=!YTZATO[2V1(LQLA\*W
M9%)U6(WY('VAL]6]," A8_SGG=*1X/3717,[?OR1 J;"O4(AL&.,V)GW>3D<
M+;GJ+:OP])%B/N,3W;.6<971RD1EO=A6^0F$\D#?=(-GNI;6OJD1:T-O[).B
MAU@ QA(3$WTS-1I):T$]3B3T)\90>[A?5@_;1U/*1YZ(C4@D[ZZ/2:O7C_F0
M8H;LLO'K:?:ZRJL8;Q<"GG>M_5P$3\ >6Q_E'@/LM>S^RKSY9>(>F^=# )$T
M%92+PR6';U3@UMP78)E00OD>VQT)G,L<JQ@T(%1^<^X6*2MX5#@J"*W<!4[C
MZ:PVUBGJ/Y3<U8Y2T_2+Q@2!@YY3R'':IM)S("@GM?JD7^:/,7J?7_J=3RTM
M_*'$9B8%+J :**?,>6[(Y/'8[M&9Y?.*G/J'\ RKCIM#@HY0ZX63V3F^)%UO
M68K\D^F4>@O1T//H([/!NK!>2B@_6L5_DMO!BR <A9"PK;=UFZK@ ']4:CQ%
M7WUUIR/A))I<HM5B%7J=*X'R_%U*?NQ,N>ZM*\X2O#O#:-6?>--,\5*\MOV4
MC:U/=_ ^E='Q +*=D%4R3":3PUCZ>;]M/(-!U+U=U0B\+5CQ0YS2NPU!'R*H
M*67$7^]X_56KQDD1=L)4 ]W:=Z=J6BHW5JY1C\48AC#'A30^9FY]SB9=ME98
M*[/H?XG"K+B0(MZG*V9!WT,A0_[*--7JW0Q F-\VI1W5X9Y>RX1R2_&+UPA3
MJ_Q(-]1?4]HX[U46#;G7ZLQ6"%3Q.:+TXK27@39T;3M=E>?;MGAC.*G4)]<!
M%B#]86$&4I]^&L@IQMB.96XD;'M1%0D[+^!P;O:KW&=:_/#9<6)=T4]]4%E0
MY5@0M^S'(TSY5O[OFQ66Y:YD(2H6@T=)6G\J;7)CGU3QS#EWEQM#FJ?$R(/Z
M EP1IPNV9X<&@WUB]-L58PC$Q90C5 Y%9Q&GEQA>E0B.P!J^A/MC4V4:03W2
M5H=>@['"--=2FF*$>+=8(:^'[':Y/D?01G'CU=F7%K)M(;Q3ROP]HB"0-^HI
M#7TW>1'(X_8"_/;FVMW2_@BQV'8; J7<![R@BPT-]S/[>\_G ]Q*<]2JW?-/
MMYXF9?_Z^\'?V&+R;<W Y=5OM\I_^,<_DWS3'G;:Y6UK[08G;3GQ9)]YN*/1
M?VF%7D>[7//71?X+J]_^184RC4D-!&:RB)#\(Z+B#N(VP?N2^JR'+&Q!=WI!
M4O'7+33F#' ]U%A*S<@U\>C-_#BE7*LIPBT0N EW*./&L,O:H><E-DQAY#@N
MUS[I^"K\F3*1J:UM6M[M)F]KO<J..;;]V!Q2&31PP/<C03BF'0KEN!N>,99N
M+E!UL999V9^LZ)>/D.("U]B6 &6]NPI#S[4$7RF[JDQOHU4)XN+-P;/L(3AG
M>@"OHR[XW93[]=/829Z O..-1\*3I[7WFQ)%##(2HA\FCG*.Y812J)K\3>G"
M+?'2/%E!/#Z+KZFEV0FMQ:&@E:%AS0K:=,A&&4_ XG"#FJ@H=?7@^7)L]@@!
M,^*;&8_&DA\QWRP(\,NE<@1U>4>\BR'W/7E%?U7OWHV99/CK*'.OKB9$A:U@
M90Z$Q.^QJ2TVAL/D&425SPD*>>T^-4.G>*YNIS#XZD8?U; 0HMI%;H9<;CH-
MK:Y12- 50:' LR$&?=6\Q9IFS!0W(W\"0CGKKD&L=WAW831"Z9SI\'3'==-\
MUTB<;T[W^SYJ&M(E8Y\!:7APV,CYG-'N#R;SHHJZ1<8*W4#>2",RQ!10TT+\
MA&_UUW_[8XA6XQ+QBW^Z#"J(//"MC:7T"9BA);1YA(N%E)0^$:;/V?ALZJM=
M+%9B[F3,JBG,93G[#:V=,GC\R$]PTEXG5&"R73;=]\C&LG]4['R(J3N0K[8O
M==ZW0')7>*0Y7506,\1"""6N"7E'=*8V[TI\2KO@;.72KZEC[6I*,"@#45B6
ML2DI QT^%47E6S>G@55RG0M=1K7 -5;^ MIGCI/#W3MDI+B]8OM:!(V/N9S<
MDYJH;#+YMFI]V7=Z).Z^R#![\\@>&Z9,6=VG9K6L[-RS/;;M34-K]:=^=8B
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MVDZRZ0E?IDE3ENN1H7=1O.%T#T79MICKF]8SXE(ES:;N.7G9>=I0O9=10@C
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MBN2D>LU@H$VBMIF N9CO9T>I(;:R)9LX6<\6=U!L9;N;-*!/U$)/72WSQH+
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MG6)T!69Q,)'[ ^XS+1#>\K!13ZX;JCJE"KCA7Y]G;KTU"'FG+WOI54I6)ZF
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M#D>UO&;"Y39.QL2<689>,=IS@>'I]/'N_1V?-!US'81&ALR,QO?'TY9E3#F
M>N,\H&Q,3'89J7LWPD^'=O;&^L,A_$I]VXOJ=]54==6;,4.WT@F6"S+A)X6S
M4\Y5D#%4\W"$C*.NS)O.E4(H,JWUQ#IQ\'>A 8\4V7O%%6(!&;:55Z&##]N?
ML!'IZ.>^(RV^TRZ]X<.C]Y>)Q(KE[?$VV;WL=A5Y7A[]1M[8Y ET#\)/CO/8
MMY\XD+QP]Y(+Y=;HKZX6Z=;"X>3J@-;.=B\>0XA02:@E?>:3+F!.YN7UL>I6
MA>P 8J%W8-RA&$O3DX#%MMM?]$LQ2'X9+&K'3?NI_FRW_\<3E36%-1-*?(RH
MJ EFM8VTO=&;=@UXHC<-#+7MK.[14Q-+\733*R5YJKGA"PD->N==+9Q)QD/-
M">JZ)$EUP@F3:)M-8<MCG9O+)1#+"F:.R8<E\Z%15WL>@(R]S<B-A D0;OZ]
M-W]MR]QL.[%RH<NE_! <%)%4U3>IQ.XO8$8J88G2,X6)XU]@/JUZ)F">#*'0
M[X^G+Q[RA0RG_^BVX@?NM?^1Z.G,\[-?EK!&^BM=M2\=Y:G.;;'1YDURJAS4
MK= '@[4:-994]2<Q,L\J#I)(5CX.E2B0R2T'R9,V$0.)/ >7?N?*')GA-]#\
MT3VWO@^D!],SYE.>\<NO;6L!UH[HZ!B1Y"]INVE7RES\NJ/OC(J2L!CHMU!&
M+#K.S5A;7W%\#Y,_:7+^;9#OPMO>WX6B9+7)4MLY]X@+2LNT"M/*'3777(J[
M%B)COVU.CB.R-N\@WZJ%;27^. 9\4H0JY*LTO9\RHT/VEGKQ$K'^JE4EKDXQ
MJ8A++;MQ8.^I\LM"VI.LUS&SH]><"XOR40\>(VGS#8HV*S<K&I_G'U3^FK\E
M/E%KRF'=2?8/*1S"N!>QT^QY^]1@^\ ('@Q?6.RT_(TS!#"7OEO<X6/?=#7Y
M(0-!X!UC:)@1V2!-,D!5%,HMT#*'@4)#-,6VNSU",%T4FFW+(B)*789M*.F8
M1W9G?0>\^;8=H\;P$U;E4H-4?"W*'\5-+,L68O:]24YNWD4DLJYX[=EF[K@X
M(F[.HA!VMC4NR_P80]G0F1FB833N0=N&6^U*L].S\8 A&H"/\TK'2V%PSJ96
M6(BW\P/K^2-7UGE-TH)G]):/P6[N0U(Z)2/<+V&ZN35_X>=++J6U5W/[!0QJ
M6(&539SDHA32#5TB"4O^7)LY ?@\-PL<T^A-=54R*1P0*,0 @KS*3=5-3][7
MKV6(@GFNF<B:=P=7"_L?:U?2T3#H'YKW7P:E,U'Y!=ZBAGZH0+&AEAR]\%<P
M.9ZVV+>W%Q2V<P@TX#KAX8X6-J5T*.Z#.\?%O_V\<ZC:Z! 5JMC3'.2LUOV:
M:S;TYS>(BV!]0F[YV&-D'^R!;]H3DOM/Q7I/E#[2[>X<M$Y7V-Z,J)[<_%K>
MWT6(?S3F.,/&$Y/>IP.[K1HR%3*Z347FLGY"_7#Z^O#V(8HLVK]UL7^SPKN2
M)5*,/4E7T).;A:DU 07[WD*#-GR4QTQ+.9[Z6LE8EENA'GQQBF[RLE@'Y,=_
M: T+?#GVZ[<H21E>$GAN#EFH7MK^(%0!_#Q>:$5*[Y3AGAPAG&2LS<UJ+4<U
M%Z%L4]H-72K?,@:&WOEDI)#<P7'O [?=GMF4H'NZ?E_XY9)]A;%DD5>@^ZF2
M?J*I(5$VP1\)'FQ/,>8I?\5L?U<P85K0'?<"O$".*:E^..)=:2!XA_LV8][*
M G>E^\#GVS+H+CC0# VFQ_6>5AA!__K("AA +:D=^SDF9<L<![Z%,@YI1:_R
M?0NB"1.IL)&MYV#X]G.R/+^ATT^]DS=Y/A23W%F7)89%O"54YS2%6DVXD!05
M1R8<Y@JGXC%]QKX5DP KJ+#!D/*->T%LH7&9U 5Y!7F%X""(M_O-L]:UR;:S
M8<,+SFIVL)L8OQW'_O_&^_]?^+\7-[.,U@8@'7=6=1_P\*TB-X$\@,:/I^?/
M*(UN/S-G(*[Q:>\H;)LV\%?(6S[>4MB^6WM",GKY_-"U<*/ZQ*G0^ULQ-R'R
M3N??W ^RZZU__'RP8^3&_RC1P/]J!_X2_1\DJA5DWYO6&O;()4<HH?XW^6-G
M_R[U=Y'OEK[/_F>%>O^L[3>YM_\S14W_?G6W[A_^V_U+]!],E'7QW1$7Y\Q_
M%W?_BT65-."]&\9"8,X9OG6U:X,S^48D*K=6+/+?78HP.25]\:WK?I&)+;W_
M<OT[0ME\Z(MB?P,@<MM61>^(*Z:?[-M8D_-4_L\<0OF7,]"'@P>GIB-1VL?G
MC\_^,1ZKGF29_K['M?NWT4ME!_)9ZQ>MOXV"?PA??OW7I/]9D[X[E4;YO&"3
M0<3LY,X?<6U<EF_[TQ^K-_X(JU_&O5<('\.YPOXVJ@CN$[_<O'OS;^/%EJ^<
MB-.]I[O^&(__+08WC_TUZ:])_WB3OM?P<8>XT,ZA30^1+_..N#I;[+__S^)\
M^U>'G!+_32TW&K#J'#6WPK!.C$Y3S?4<G@%,D&8<QI1NHEFN1*[RY+=8N&B(
MJAWJ:L_?7B#)\3AO4N=8:XG<[2E?VENE5B3=U*Y.2)%N#5C2MDA E'.<OR?$
MND=69O@2:)\/JCT'G3]N2P X]UO#&S_00+.+8,_L6.90.V>%1ZTXEKM#5"N%
M#ZQ27<([L_%._$;/\LN\?NA>O-EXB5"6HP39 \A_G2FUP"_GR-.Z][!3;J<?
M9'?NE6@$V#NO<<1_F=%ARCK'",KQ[X U[\8(-C;.0_UX;ABOZOL6>0W6]/<4
M>BI7>9MQ3GA"[TMJ2$V_FT%,9\B-O_SJO'[2<6G?$&HQGY,]*9?*+J$#F;=I
M7K0S%:6-,H*"SS?R I%D7#?2U$-"L/+UB',36_;3%"R,O-M\2V%HJ$L,[*.#
M6 &0?.S46L(E/9"B#N8($1&5,R^0IMA6#O[R[.P1%^E85?5\>KAFKMQYTY!!
ML\$^ZQE_/ZWE1Z_\1*$@W;R^HC2=J02!^I<CJ1 /1H]_[03P!&[+&.>4EHJ(
MD3]K-]@DNM89VVN_6-*;]>"0!3[B\GQ?TCZYI4;0'L_X>O"+.^W2*\K OGCC
M>BJ93#67+:9$U:CO6LLD 6:1<7$9B]5#>#8?#^;BT'O'%..L43D@CKE%H_6*
ME7? H&(,<FHX+Y($U.ITB4%Z5);LE3$C6;B;V^,Z2YA6(D+9D\#&,U?S"\,5
M;OF(U_"ON^&FZNI@JV<VUE.Q90-YN76C<JF&X7X _%.+E#++#[, ;:EB/:\Y
MU>F$SW/R*[2AP]-YB,5%27(Z-D8\- ?\:+<@<;PMHP=J0V>\B,WT53WB8BCW
M1>2-;(C7(%QLB VA5Y#G'_#>\5F2VPCZO,Y[Q 6P)"0Y;<G]&IJ$H?(;OQQG
M$&[NXG*MPP41U8A]H.:^)92)AY5*$FC]@UIGI*<"KXI6\0F+XGXB46U\/\;^
M>MI^88R:5#Z(D#V-I,; 3Q5O766D/Q^$F.MDVL?40^$S)FH(PFT_/&"*VC<$
M($%!,?!K-N/^$I]\]NEH7/N/UB@XU''V(&G7:,-KRN_K,1ZXR<Z]"L^+^K[1
M3/,^ILH5Y>R"-?T+:!NUVB5SN_-?"E6Y;TH0+&R5F.%#:Z@:&QE':@J.#+&^
ME> N,!315!NH!IU.R'G9#CC[::3 )DDD'V+C%*:V@%!0)A'RI!JCTFZ*%YBL
MR77V)'34S<^LRRT]MMA_A \W>5$W"+& @8? ?5W@$Q4XL_M%VZ4V:2QS/<E+
MSNW:WGU _GB)1/\=<KGT5+0,8M;P60=8:266HJ-'(M%>^:?IDOPE5$FXC/NA
MCKUPW*JY;N68&8E\Q%7CFU;P87ZS*_>ED5J%#YZ0&/B]*';9"Q.N'=J[.931
MM7>-"K,P8XJP$,(,7:H#P-FN>LY.RA*!S@G[^K28-E'RF\F(HU^:[%"P".[%
MYJ3CZ)P<V+HNQ^LLI?YKDD?/_K;\QINENY<D*^+@Z9YO7$<%0IG;@N'L#5FH
M$DSZ0[-%(200U5Z3&9QT]O?EYS=&GR]6/=%>'3SBPAV[F=U/5=%,'?ZPJCQ&
M"7?&D$HK4"E["RPP>@:JI[O#GJ]VKX$J_DI$Q-<%"&OZU!BP-@NB^X&QW3L1
M'9!^\C/3BL1!]1N-EISSGA8D4H%S]HA*]P^5_:(Y'0\SNU/T1)QY=L#$[CI3
M#:-B*KG!;9\//\E2LY9' 1;H 4WQ%^2,W\,T8JY"':8)OG<'EFYL!<,IX$*:
MLR%'/H71;=43RASK:TM;"S]#S+FO=@Y=,L XS)D@2\N0YQ'S;L[$&+A!:E-M
M%X+*CX)(OTLS\?2KMJWX.K[Y]76=5>A+_=!X.N03,2G_Y6$J@,8C%*P5$4,<
M_)9\Y4Q[%NWFC(]YQ//^+8'G3Y3C?P7>P!?6,\W$&C4,\]<EI>A-Q5[(4NOY
MUMNE'R1*Z)Q#8;#L#FI'X%Q57[LB_ 5V)0\J_&PJ1_#\2\G\J/A'[IJWWV3P
MM7SH\$AY7XC&ME_PWNVZ8V+C70A#0>]4-P$(%YP6QQ0J/U#2 :-=4J1]F[[\
M)5Q'*H/ZB1KR=3M(/NG:U"]2<KR^PWV&QHIS3D@)OEZC+]E9=VXTZTF.$VZ.
MB-&&* 1.O6*1U[#!7LV3RM!0SJ)S8@G!?ALZ1IH!N0BY:+2ZJDZ,.T2\&MRS
M=N5-"%@^L0#R89G($2*"OW;6:PTKB4PB:&Z@W)7+:*:^E8BR@/*W1+Y^\]'6
M>"QWI[E]_@S#[S$OHV\(YI:E(>@5J#[*J6P:MH!:0/4!,HE\-D48J&Y53H80
MMV(2[-&7+:U>J1^CEU.&':)I_6K\LMA""]+]G/76AB.NW=&PT2U;@X7JXI1J
M6[!O?6<RN&F$.V[^#34M,#5-39FNV$N]*[(-(\OS+-]?!A4YI\X.<Y1M/<$/
MV>]]V&/%.O-0!S;D$*>^O#XFW,\25RJ'_AZ7T2XN:_@Q%'8^>L(!O[DA?_E>
MTW:Y=7@%:S/[#6E VHU0.IBOT"[L+C'Q] OHR2*8CT>P+6=5^%#,:9!XRT2O
M9=L;V-Y91'Q[=R92HJ"8/K_KK1)?T#UEQR'^K&<^U"$JT+(RQ1VW/#YWQS?[
MSIP%O;?9-P^;'@P0==QEF6I,A81C'/"$3\A)[!RG.3(GYRM%_:.0^\PX+=50
M=G0NL-;6B\_'QCD?C2 [)Z+1%)<EF2IH4 F?4>K^PUR4';JVXZ2MI[BMK-C
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MMJD)K^]&\7<&RV<W,Z:E:K]TJPUDW&FUY[H$J;JH201"/#93SILC6[VI&/I
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MJ]\9&BT+,(MHXL9Q,9@%X18<'\(*;)*X+I53GQKLVY7MKPSOL>AS$X"'9."
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M9S2:I.X&4U0G5I.U%RMX ,[Q6C=115)[5U9%!%R':5%OD'CYC6L!(?3!(+$
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M>;(=/GPKR[?$=/%KYD;%V]'1K5R1;@@YWDV^^IN!I>('M:S,=$+/HK,85I3
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MCM^KCB:@3E);@5J*L7-@I-@ +SUSY."96?UMSP+2HT**U6T)$?&D6X7=3SV
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M1W-A9>1>)/QH >;&*-M!>%]+$V*VHV]&,[(NB!^L3Z(*QEU+2*+E9:C!X6%
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M(MLI1&CL(_-UNWC/[S2HT1)@');VQX626GMN]URGM9(,H;*']<*=7H!DTPM
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MU!1\KJ5[E5\=F!L$<1UBU"Y]UETD36F>&3+D#3^O_TD+T3X/5PF7:"_V-S;
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MSVN1_B"NBO](Q%#!T@?$4GE1/O')I3X-/#P?!L=1=J /JCT0G3H]='IK8.V
M%0.&(B\SKF98S68W-)W$CK?/:1G^ 0VD)6.,\'<A5+2>/GY:A+U=NUBSXU"S
M@MDH.2B]Z<56U!A:?Y^H<3P?MRH1Z$*NL&Q1('_N<<I.QSGI:"I5_X$]C;+]
M;UR[?^ &7IX% !A>H^1BRGTY->H\4N8$93U\1^9NK[S2F'M)>>)FX8!BQ\ZT
M7O';8[/BJNH&51-+WO)5M"M^8B)_"#."6E_X7/L\/=CPX7N^YHY&3%)Q7D)"
MFE*&^#@F=;)IY75QCPBP?$"Y):RHA.6HK. U!8-K[L#U,D:53X8!5Y'K'U[[
M_M&E#2I[SL2XW[7SW#IB?$K[GN;9Y4'Q^^__R2P,!RLNN^57=_>/>FU3UPL)
M9Y)$")9RHC8SJ[Y-9RU$1Q_E;O_!'R[<&O3<C>B$H&L@Z@6X%]5T@_<- *%,
M@! .Z"?:(_9X\/(A'>SZK7[;^;%7 'I(S:]C!@*"3P<?D?\(M46*  9)/,Q2
MUS_A::#RS Q4K%<O+O/3^;8_QG/G1W^DZ]S%QM\\\F_Z/FRD\D=EQ?\;">)/
MP'\&E/R72B7IMUP5=<3<SG2\GF69\9HY^LFXEBU]>?WIAV:QT_]H*/R?'EO_
M>P'^JTF&[K\!/4_;JB#PQEP[/,V.]0W+?(WT&;K=8QU']/[["_0GX/\VP*.U
MOWL1ZU?\G9W)2&BYC%;!0335G4"A2POMG\MHF/UO&BS^/P,4^MV4VHSWGH3$
MGKGO!@%ZRB%]X/'B$&#)KIFKWC\\2D)MPN<:)O\R26W2[5_^O[NH[EU6^Z-C
MV;X&W(ZDF,#I]'YH[!(F2PM-4J=02@A0XH?;1*UB]RU_5?5_V>P98BDC=2)>
M'CGE!!M N<"_ZSH8^XA?@(NV+,OY[7(0PALVACV3D?.*)UT.[>5 ]5KFS@GV
M(=Q&)!!3\/>KH0@*!<>QE"G@C8<R[%#BI"ID(=F5 ); N_.:=.4?UP-7V1^^
M#7T=$;G ( UV!5WJ%K,NW],26<B\X9I/P8+,>0^%(VKCBJR@*C1#7>V8>AJF
M"BEC<?J30K]T7=HLQ#:@@@NY 1.7+%^(<;GJ%EG8(E9#KHNL@3_5\KD..G]"
MS1!6?*WCT6_X8[V.Q0"HH'6OO:Q+[I.A>(L67I%3#3[ )[KABER<5U4W\H5_
MWP(KI#!MVBG[1.2&H8P6D&1Y^MW!IK\77,4NG .RTV/-\]R7+_7V@!ML1>G@
MYFVE/4(U-0I\Q2G[$S_^ 5=PX71-+[Q7_U XD;$!*?H>KB].%,]-H3:H1C<(
MX;[Y^)N\WQ\6EJ#T9;O>M"O:;/>*Y?;->77UMA<L3/KE4W RZB928VC$O% P
MN*TU#@ 6//?);=%+X_ "55],DF/J126E!5)?^&7OIS7%]$MT7ZHA71,Z.]\L
M_/ZOH#?>O='#(GJ7YFY5;*.PK<QV)ECQ'NR:1T)E(ML7.M*!B;P'T$IK,-E6
M+=CT?-).N(@QAC92C&K:D"4]&WX/\G\3^3<VGT0)%(#$)L+OW^M-GJXLF_$Q
MA!B4?ZC%DY\L%):L9BUY4;PH3IG!O^[7G'7#4Q'AF4?^2MZ+EW0D#93<.MLA
M15S1.4T^J.1LX8$/ 8GNS\IS 2*9HT<SP,&E3>KIMP8I+RA):<LWU*#%8YG=
M')460=_,V=M!,B=]U!S^7J>;YD6RWKQ[\9-.-4/N=B"(A"%,4ZQF%"*27MU<
MN,VX"G6X"GG I'$JM(Y8\!;;6:E=FD4$*;*3IH:V=N%2R2%[;F,8[G#"WYO@
M:<:VR?$PE59'.W/ST]DW>MA]N56N$?#8D[JW=V_U6\'?TKM@-R"GE#3&X\ZG
M[H&O)_V!ILAOM?\>],S%H[]IY:?+]G/\<OID-;/3:?=&3H "-?2USQT3-^DP
MT!\))*A&OO(=_%?'F!YV_7L35+@N,/KW9)3R&?Z]3?WT]ANQWRS@ZE\U<OR'
M@X%_POU?#O?BG&6.6F[%&ULO>UTOQ)E!\<R7&+FJ>(7WJ.KS2/$?!W_W%??
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M)O$>D#(NUE'%)I:<&+_,.!3_WK8\'!2:3RK 'JH0CBP8RT1L8PHYK78L\IO
M?(BFXB^B,XM.W !S+*;._>PR=P,>H4=(Q)9I2>%MAJH&A:?TQZN?O9C9+  I
M7LM]N9#N7!YXO%;Q:B)AHZ?V-MXM+^"S1(!0(+;US=6YJ*RK^Q>_.?Y"(7 H
MH(@;:-J@<U!M._AVDOKK6_.B#<YN;4HVD>3Y\0;-Z)P_*.?"^<;F!C0/CUHG
M%H M<[Z/0=MPT +"G'>148]OSO$%.WO$:C]#8YA(:=4Z2!=?,%[=8&1@H*_
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MC0#]5S)K)?[Y9!:XSE$<I,\1M81@XR*6MEK<:TID#-4%SF3EBV3ILR-3T=T
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M<J\0_O1F$B QEZCUL"?O:STJ3D2RUHO6M_HLJ\*R0)T=Y[R&+AWED''@BI*
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ME(2<9GG\R]5X#X,TI:&&!*]:O/XFXC%FMAG^O;6I6"E<Q>\Y72?(P//)XV.
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M&U#]JS)BF)<.FL)@IG9'"/T&\H[]]N:V0035Z@J'(<OL=+T9,V6W!EZ='0D
MW"UDROQ9*V0S_E[#@X%2KK\'U5(FW6K>,%R"SNK-#Y\SA6U(-K@VZ<1_OPA1
MLM$2N-.\J=GOFLX+PECUV[QHF8<?Q>U>%OAS5\R>F>.PFC>=_ K"V>EF"K4D
MU.-$DP#F&IBI2XSYZ06?SY%Y&' F59P@"PO\V\& RO1U)LPJ%B0J(,Y:2A7
M8G1)4W(WBFXM+>N,J6@W'6HG^%]F3,CZ3F@Y.E803-].SN<<=GW[5<RWLM0R
MDCLP<*7E^J7L4E1(.P+2*]*/M]%&REJSZQT0.A"UU"J+<HLA$=]*$)N33YI]
MSV2CU&PV"XC$06EY3^I,W2)S02'U)@0"SK%CBA8]]D*&UMCZ>N0GZS)X5EOD
M8_ /?G8J_PQ/K^WDG+9)WPPM+O3\@N=;#0?%9R-T_!2*B]/-H_Y^WA8Z4T@O
M.*A?T\T0;0=FLOG.1+U%97YYIHD5\$8>@I[3//Q!4AP5/ \ \P>>HM7/+(4?
MA_BS& S1!4)7,4FBO%]'FF9\=MX$X8;EZ+ 7$9,J7K6!K&%&9>UC4[MPU)VC
MQ,>9?F2\5>]M9KCJ4(3LX4?FSBM_>[[X\_&=G7+3S\NW)>)2_[3WPY7F'*YW
M6\O IE?.HZ#M1*+9FH)/WL3?[W.[V^ +3[8VG\HGN+K0WE;=B,C<#O*N]'9L
M<Q"-IW72F7@">OTY93-:O%00]L[!@!F37%3B'SFE-9W\(HB$;M00Z1EOVAH,
M%&[-D;)O=4]MGS.'"!"GM>%O+7=1V5=3LM17]'F-G<F9I_@WZ#LT<QK%T:#U
MMZ?$I@%H:-=\Q"FY#\[#[[M$S[=^EAYVF:K</5CEM'I:4&&Z332_#C(^.[N
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M(,9I:]W:^/F;;MXV!C)F>PI2;.H6QE-_?^YC\ ="D3? /QVQY[I8JYF$SZZ
MRJ1W-M#+;&Y+24;#$9T),O#8V0DW6F/Y0TL/&G' IDF.PFP&[*W44W<)/DWK
M*P\M1V5G',85XA?+&D6-^8KZ6T5UG_%2-RPQU;[RN;TR@XBXP5>_L!E?>J\-
M2CW@L>JB>,+^:QD#GPJVFHRS?G%9$A8E&N9UG:ET<M V5_!"5] ;%_B!:S]6
M;]:F%+AZ5XF<[[ P4/'G8-3MJ&+54!/S^-&@29H9P8^>;6LUTG8,'!K<SC;E
M0?7)>7JF1SKUV:\")2?"L'+,QY$J(^ (US-R:W$#Z 91*U$*3F]&SQ2+S*CD
MRC&Z:+7:8G3Q:>*=EX(V!;@SVXS"9:;V/0G]CIECY[=B:4Y;HH,HX4KBIN'5
MH4-F4P(SRFH1H/]8#QTCWM9_TUDU_"8"S0X+XT@R%4.LM9SGO8.?P-Q(;W9R
M ]NN)2[MO%Q8*4^/-PQ\2IPYI#7-MHI^E3=:-=#8DB!A\KG]T4O22 [TX'A-
M\P]Q>V:ND(O?UJ_>%(D[Y21]EI"-4<3:*$NVWS0@3*\%5B&48./U9*(46F'^
M/V^Q96MS?A(,P>#65W ('C\NU.Q;@R&PH5!H!BIM6WGR([Y-P_PJ],]/:R>5
MTI.(/L+-5@NB(P0$:_7$C>C??<!Z)B%Y)$(66I/9ZU=4,S$S*U(!!6CHZK<Z
M/[$S_OD&5AV8]&@>UXX@Q2JTN%;N\KD-7>9VV=./Y=5>+]_IVCD=@S,;*X7[
M@+V8[+OG6(M?Q6KHV5/@^8:'D[F2A4>LCC3[;Y"Y7<&O.1%FGYZY]LR::YPG
M;+UGNU<IV8VJ(9RTQ8=7K'&,6KZ#*?O^2P7I!',PE!!JS.8%@7&W?QD?#RNI
M'V&R:\<M//#4-R=N-E6T$TPG4>#RD^$1+@6[-Z<[2P."G*08,B 6:7)4U*5?
M.!'\='"XC;^+$DQAGG18+1+MC*SF*!L!9D71=1^ *')>[?0KK[$F 9_78ER&
MN8F ZD\ILAI:!PG3[G5'>Q/'L-L#[N&)+J*B^'&AU@+I(B84N1S*:6@T0K-W
M0OKO&:R7#-;0M9O3:B8B1SNQ6V6$#?";9DC<'? >"AS@!Q%A)HX-\<V^."OF
MZ\R?#//O65:7"_E%TPY7K6H=0A><:9(HH7W@##>EPE'.R41GL%<?FC_W"@U6
MCJ[[MK^*Y%+M.S:O9>13G=?..$\@U2FH!#YVTKSH[ASFR[%#7PH&=5SDP.-6
MRI8WOXIM<\(OC/=K;G$W#/'E[Z./JMZ&659]5B]=TXDJ\HY_:Z9SI)!P+@7=
M_J*=(YD7*>A?V+,*@^3%J[)?P5V#LQ\Y("J\,LW+#W-..E5_8(6K-0WL87@-
MK%-E<TSSJON&SOC1_#*WC% NG#74D"_FN""H](, #RU4^^YGZ?F17U"%Y'2+
M3T'&G9/S^#45V^#RHIHA ^H,<$C),.I*5><#3/S2/\+(5-OC$7FTRPSG-)?J
MJ2N[J03KD>B^-%%]6]JGQ>TI' F5]Y-@$AI@-[ ]_G;%CA0N6$F7%:\Q*QH\
M$LG5:7+JS=*'H]= ''HC_+3!-O.KF'_]H( _L>1!)J??N:[=E>'IQH>%!JD?
M,N6%V-"*AWT_AW@*"#E<(.U*1:^BY?'9.Y>W/"MX"G!>0^H#"ON([.?Z/\V6
MU61M;@X.3[[Q]WWS4/SN7MRD%/Q:M-1JZ)ULB1]YFS00I66YU<KIK(!=9<P1
MA$M0S^B=?1+#C3EE+M08?!IF:UT6L)<@Q-8*!+]P2)RCQ\R[H2S)2*!;8:-1
M)KD@ 7%XNGX=^_2I=S@V_LKIH/;902N^9U7O_7ZYK=_FKBKE;]>D<K#/9<P=
M)D#X(;N.%\0/;>A\(WS*?13$.1G?=)3T.ODWT7@LN[[)73UX>' "F[%]RAD[
MN+K692UY=:3^C-K9CB; *!Q VAWY/=Q\T1KR<ZW-1\XQ6$BH)F'),.2F<,XL
M9)T[]*3K:8/+JA0T8TNJ6J UT*1 )_Y;8]Q(-)USN_O/K/.$S4L'MZWSCX;"
MNN01\MVJB,9H%<:;:60"*AO8@#02<7#IOW0=AL9]!FB9)<.8RR)7!+=;G]N#
M;U_EH(:(X2( < ,??CV[9T*FO*EILKT6M@J-Z-;6>"8'2+**L*:,K-7:[*M\
MY)S(X#ZO1C:\GEG#F,C8&C#PDY_UAP.H=[\>_VT+H7NC["VGCMT"](;E7/NB
MT(C\J N77COP;N),81$E?\2W7C"%'682/BRQ?!4>1Y<&'>YH?@$$;F9!%CQH
MEH^KIBX6"K;&']IP W'*FY[L3+;EI #YG"K7#/F[V=3MT@TD# :SH>0B3)]_
M=+4;7HWQR\G,P#5[C#Y^$6X:W.3E" INWZ,$?Q7K%&^**"P;D<E_<Z<*[8H9
MW&'HRY+Z+A4ITG/>2Q@GX"]9/W[X.$_KI?9GO,"CV"* ?Q-ANJH6YI=ET=(X
MC^/&@YDT@]'FG H@P*TO"P,&CRI[<1#U5)TFB55<6A]O$PP"W7GI'Z$;G]E:
M8=T[739H,'4#BLQ<=0* E[JR!)LMR$:RU./"*Q%E-SCQ(?'AE2E;VNF:(\>N
MB#LV.U)]8JA7V=,=Y^-4UC"/VJJ2R\:KK-LS)#0K]0)/7XUZ!/SZ2>BHO0X7
M$4^:PF8ZE-1>! PZU03Y6>668?T=FTNZ^T1*KE],<B&(5:6=W*]B1\CY LHR
M:Q,O8T!U=&,6S<B)!X:<V=5L"FTTD#X/^R?B#%.?/CN'Y%VP@<0/OG(W1I_^
MED*2\)9T.O&<S/RO7\6F0D'OW!*.SVK]^C]]:/:'; K1M^!T3T":,7-$HRLC
M5-T '%:X\!W$O+!L9^Z*3LP$IX8 H.:J!8$6.?GQPPV&*0N!)U:N%2^/)TP
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M5G@831>X\M]DF#Z/UJ2.?E=*K7@YM'BL>T(A=!)3Z&TXBR-%>GHPBYSSCI(
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M>$U@)I,:_#W"RO?XF:Q8^0 \HS>E+]PH7$J=E#$Q-CW[K;;AOM6V?,B+29>
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MK%%L^<;DEOVQ18-\#\(1-6E();+,B@C_RW=EIP =P* YW&.N?V&-0;7TG9L
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M ^NJ/6K+"6H\+I>5YZ+<9#R+QM"^S0+=7W:5:?/O02;6YX:$C.0-(R;\!]R
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M.AHP .RE]D&7J('XX60P; T9%"@8 %W%:2[XLJ6J7W*U%G05GZ0MG_B^=-R
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M4!C*,GV_3IDKL^R,VUN;K\J)X]5B)U*2N^_=S$E*?O?(*83WEY^KJE%E)/!
MI>C=UOB2:HBH+,,L-7(L97[G%[?"BWKG_M1+"ZV+FT^_0Y.ESJ>'G WT<IO_
M9,?'-_[>+$EWVM<+7Y_SP8GC@NEA_Z^RROL7"@UJ;8T2/_Y0V5TW[P(Q_4.5
MUXZ;\ZV\Q@6QS;J;J(LEPV8C*5$^12I*4.-055UMFKQ?U:%OPDS-BCA2+QBQ
M!(9\7GWMYOB['6?,;P5G)<[)9XN,)[(S_F1"J:MO?GAH_[ZC/"?2WZNO%DSS
M0K[*BAM8. :Y?@;6N$7>>R[.;'%>EW3+M*&VJ*!OJMN(.W )MK"O/*^EVRQV
M4D. ;,68'(965=6X3 %#&NZ/G_OBNB;\749SC:RZ/6YOF<TC(;9^9_^_P::O
M'.OVMI@.7B\NF$ZV'TDM C3O!]QZ4)I8< F*ZTG/ZKA5D5E2DI2T59(5HQV]
M5:C[*?>G/\ S[E3)9TZWF\YMGGIH$]+7+#\\_?'YQWH:K3-3-<8)^@M_HP!7
MD3W0<68@)8)\:?(DG]H(U6AKPSYS(N8O[)EG7("DDR9)7U+]"K?*LS1;&NJ-
MQ57"ZP-Z>E_LUU/)%A[KW5$?P"_4PT656ZG[^A&\*=5<P\)6O'WW+$*2.-X2
M(.NY476KO_*8DG/I\ S\[!$PKG77?&H6+2YGT';W1&932)O?]M8F^T_3H] 5
M-L*W$=#KQT(F4JD/"9 %_.RZCLL7N.22J1VP;7F:8QR<.DB6=2XU1YDKK8:
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M?N[L_Y<<A'*,UP2&)6%VFA[2?H,-J\\[S<\P7(YE>D18AEY@.8DK=5L'8DY
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MOSB9ICB'HK1Y<O\4CLU[#GVN:-7%/.H N8=+S3.,7H=K,' Z^AF.B:2CR!'
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MM(E'0HAN J@NB9C#>09&HA\$=-F/#ZV"P54%YWJC*):12O*JFLU1XFILYOE
M#;V'3,JO_N$S%>52BC\EXM7 D#MJ]&4_&_>"G?5I\=0:3*9M=6U%-NW(P;(8
M&B7S\,V_S/GUG6^J'Y=RJ\NC\QQG<M<->;D+(X_9_.)N-!69$VEV;]#+_D;M
M@G*MVF\@U>9NZ$[ _,K2A%'ML[,,)UBF?]#ZY3,/9S]4MS3C*A:LOU^:FH]V
M8?#>/\0G2R>50G7E0I#O<L7C([]15_\%H8*G;G<ABE>+NQ3(5C2=/RL$$31+
M!*50!MZ9$+:,L52J6*\VW>@F2(E"73T?#ND?CJ'II,<48%A0C^WNPN>?/2(>
MN9Z<,3%AU8*&-2-J].>2OWVA?:QUX0,FIU)T#O>H?J&A=*.B:G?H_;K[!#C_
M0N:"]U65(%BDEK"[D$S<E-]^?YI; ,&R5TXME3_WH_=O\VM<U"0C.G38X\T\
M?;>ZB(8KQ:#T<RQV;F&E-NB!Z ]W0O?,'NSKFVJ7W?9O=LN-H?3,FJW>?_S1
M@9$E)ZJ]W166$9$AD9*<,*ATZW]V_T,U_M[64#%C<],KO3EXV?ML]#&8P_39
M+\S>1?!7;=:2B!$M&"XVP+#TMLZYB+^O2F:9E.^R?IJ52GN?<JT)#Z].J^BU
MA6Q]>C $-N1$VWP1\'][A_X^/DU*3?$[SU?=3.E<B$NTN@]A?\^:N!+#6LI
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M.>7(FL"(8C<5ZQ66,&"8%&@KU@$ NY\V=*A#O3/VS(ZF5[!1,PK:\5S/ 8A
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M6R$UET;(9 V'OSL8,!98P*EN(E[/2'VGXC8EM1,^FY&0YEAK^QWO2D<AG1H
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MH#4% [(CZ ^E=:F:@=7H4QP;,.2),"0P(A^)R %9B%E($*Y"J,8+TIA&-GJ
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MUKWVG6"B\ EI"I77M6AD95"7$?G3:U1EF.(OMW/1I#U8FFI,O]#I"@AT5AD
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M7'$^QE1]Y^]YE52XH\6XWUV=24DSYFB.#$\8](?5)82?9])KK)(?G4%/9AR
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MZ7%>]()/EP&GY[D)4#:USS)S!*8J<L)G/G@RS5^F*WFHR*T<X9-L<$,X*]U
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MYW.\M#)/G'4^.^O/77('YNL6_-R.(L$P1]GO Z?V03K9*&QO/N"<J07^YX.
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MUS)>.Q4[%IUS"Y+4$\S-Y(8R\=X]/8UY-&V=EE5C&/75\$=H450,DA[3XQ@
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MP_S(%M]NP["_! 5&-XH'=WX-VT(S=$@[$\_)71,N,;W18=OOV9<+:8)_!Z*
MDL*N;'L7<:RR+KB-RZ$I5@Z3U2E\[\=]Z<NTU[MC_/]YLY^>W""\J01L>U'
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MQ(!AQ50H!+H"=TY?%CXE+WK'_6OLU.:3=318-E'!W&[,ZH@I%S!\2ED.A1(
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M6.R#3EQ&/&^47B=N=*!YN(S(NAY<.MP5\CPIM].?0M,V4<]*#&.)Z9UY_6O
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M04Q^G$;X].0%,G[QA ![T\^'&:GJ_Z<0<I>VC9ST[7&@<\$ZN<#(>SINN=%
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M]1^0$L=$8T\Y"NPY%8)*!0;@:A\>^J6'N2A=DX75*5M8N#HA<2EZ0EEFM;"
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M#Z::MTUGOD@RCPW-CL-3,V'3.0)ZI4]F7 _4$P0*A-X"\";.L-*O%#\]NGM
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M?HB&GNUVCZ^;?NAVZIJF:3:05W-&\(5_E<K1GL>L;EO5$<SS+CTP1.Z]X_T
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M'#3+!8\GRG6UY RO^>?;C. 93NJO>^\.)]4JIIZKYO*%OHG)3:[J3N""I1\
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MZEG!FNM^O?T!6?[+=LB;,CNJ#R8\[=Z7[JI,,Z=^@U0Q&OMO<UCD#?R2W@^
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MT3LSBG.(B\OM)G8:DQ8\VEDAEBTA_=44WWJ[\^CD?@8&7$VT1\!.'^Z_,IA
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M_SBF$?S:[0!P,E.@UI4FK2191AG]8PKD7X#'9WIZZZE$X8H#/ZXF[ZWHROP
M?/H!^-[@EIH<%7JDT9*<F(_=T?ZBEOU@5UV<4EJ)HY4YXS!!7$B\\L9JF(-X
MUDD8NSC]EIC"[:Y38<U%>@<X\(5@<"#RO82;2735M\H)&KN3\ ?#ZRX4%E!
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MM8I:[-"?N92D7;9B**D (GDXD'.T.5L'0_[W7MS(NSJ[)BYQM)M!+.0PWA\
M$X7&X'F82G9:LQG0&=N96@8\7[<].=SS"@!([AX-%1M.3;BK:\W5K 30S'T;
MT)OTK=W_//[IO(.F@CUOJ+<;ODRJ;["C:<9W<#9&UH/UEE_(G&U[F(3;S4QC
MAG83F35 AJ V@XJG+"H]E@"-!0/?,5N7T:K>ZMA"5=MV64:C5/W(8,N[/O70
M77W*7 4"\<\$S&9,J#-OI3';U_\8)&,D^Y? HIP>M+EVC$4/T1^FH4QJAR=)
MRS71/=BLB,FK+O6(.R:A+!Z:]S$3?T41YA4%F=MF!T[[ &3E+"\ZL] PM,FM
MW/*C:(*%5G+&$FC#6)6/IJR[\Q[V2TC<:XW]DW_-8HU?5_H.HCU],5PS7O4]
MX921*WP#&]':&C> />"35*,=2]302/X8= \Z K3=!497,6+_F:OB?O!]6YR?
MGP@J*DXL@S:MX^PRH3MQ(8\!\4ZAOG%./KA'[+[+4S1_,4]DQW"*J$%+CD2W
MNA^P1_]5P>^/-J54\LQPX\:7P VYLA!]D X3UVY<+O/A:K8=R3SA4&9:TEM1
M&Y,%[!+4R$^@H9L7+P%,W-]E^\?.+A,OD3+EGM;F>)ZMB$BO1X\XO6]O7<HR
M0OS1IK];)RL,OMG@[")4Q2[ 8#"K&GCUS[K:)Q*M/&+[#3/3S ]G,[Q.P*Q7
M-"HG9L6:T)E:)-$1F&1M)Z*QK/$>M-4!&\HPOM1MM[7^!^#V18 Q/<3 ]WFO
MM%&ENW?:N'^EMC?&A\=015(7X'//CY^WQ\(]R35\Y*:,W.?Y:M159(ENW7]P
M2SA)<OTYUQ6=='WL(=Z-_)HOO%Z3T_%JWN1XIN*YG.PX,ANUD?$8 '!GOC!N
M?%6HT[[>AU.X.Q&HZ5]#3\349?-ARU8W%4FU!YM4OQ;&,EM-M+1HX\^2'I;+
M>F-($>O4VOG:?3!)C!QO7M!:?8?U1JV]Y+'.'E6&^5^5&F+M=1<M_>T<DNEY
M9I\+/17?[B=^JMGC@8[A)J %)XF46P?=Y(]*/UVQ"GK:#),(E, YIVC[@T#!
MZ\A^-%R9B(PZN>WWSU)"XIHOI-?3@VX)-;DKW@X7?QX2#:6R-1^8[_M0XKB-
MM@[!X2_&>^%]"BW^/2W+QWEM'NU9U$W=N''O_AG:I8ETNPC@4=77+TS'3;=,
M6N+;VX8[4+P@:+\* -&WI^O1<F,CSTAD*2HH=%5\$Z <:?F@U#2)5]929^J0
ME@ _E$GT$ >^Y'VD8VK*JAPZ'>?]-]!.X6N0P#.6.K?]+)X!T_!'QD-TDEI6
MUYS"&4%*%]Q]-I_AQ?L2;TYN7>+XVFO'35?K'P"88R,,M0G.Z!U0K^SWL@]B
MXV7M5!0)#^+?D]\/\8/XZ*C=CL<'[KA\6MI6@*X(U5&K 99\%T8\$#C-V5C8
MAJ4?;YX+6J!5V%$HX'&AD0T!T342M;VW$KEOA.<]CYJ/4FIIG5[^3_CX^1!]
M H(>PK&M0SNQ)%C&ZBX4SNV0W($#\X_ :N@C"9\[E%,=QP4$-L D_6BS]=HR
M6^BQAYI:,L0Q_ILYKO9_^@Q/![-7W_W)+J*AW3#7,QCH80$AZA5:N 8=05^Z
M<)BF>>*JN?W=M!:O5Y3;BCR3C_,/%8DZ-'$P.0NKXB+,R'NR?N)EG?%W<-XX
M/3H&S=N,V-89&.T; 6BI?5K:G/,MO\:W'$ .=<Z@8(O\Z([US> ;S<^^E?7G
MN2=UWQUP'OE78+HO^ 'XZP+ Y-O'I;XY1L6U?9']R)@>43(2XE0>TQ?P_.2[
M.\XI'1+TG+0:A<];UJ0"SWJW'X!WPX\5N:,W!H/!6=?55A-9*+#:*_+(7V@]
M$BE,8TML\/G7Q:[C48<,Y<JVK'[YM8# J$C&I595U;EN P/O B1G]V221D27
M/>B]F6&C;T5WXRO5KA3 (79D<HY4\8<3Q$TCR"-283Z-R>VP,,>__+CN72H4
MHZ6&J=3:!;[9R0.VF/LL:]M[7-O;AV LV43S,/O.'JAX9&CAJOJ9*'RWK0(6
MR*EC2:$)\']9$!*1#YRA]FPJ)RX>N!.Q?_QBKZ#T!#3$%>4>UWH)AG:KSY_?
M?K9PHGDA];;Z,-_*5DG"&"I".)1"Q8P0H>]C^0OQKQ9-CL$GDK3S9;.&"5*F
M 0 )] ^ 0L6XY,?VCH,0QZ,U8Q&5R?'#ZS5:DXP^<B33N3)+*;75*]\%V<60
M#M'E62C7*N9.8, JC?!W/^O-J<@'#0G0%<B=@JD5FI635,0(;WAO# KX^29A
M-'3=S!YN&\'ZA$;?S2Z[2YWD4#BSWBAAD&-"-S4%<-"G_E 3;K(XC=ENHO9J
M#G<1[?9>>;_:/\O(IZGX^@V%?RK;'H)*#=%0:P&W>KRLB,"V!DOA;+=8YQ\)
MR(8TTXGF9\_0%H:WW4"<TC;/LO;0RJ;/)S"TD.>:GSD'J[JBZ_AN^<4%5$\F
MR<C2]RPULYL_@%$FAH._IYP\&-X5:Z.V]B?J3_O,5HJP] G/]'OD04<\(9^/
MB*/L*LA?>R$GV^;V?QT/CZE"BIZV^N)CN2:'%.1CC"_;)'I&",2;&6]^(K>6
MU1I9W1+J[QZ$5(C#37M;*ZQKA_&9**<R..J];H-K6I))W^7WYO "2V.JIN..
MT,EW5WWCG@T@J?ZWYO.A0?Q>O.^K[+T@RNP8>"%JH[ZZST5;U6T_.-9MP("N
M<GSYLI8<[1PB4(^T\V<_0-'O?E]/,+I"N^MNY42XZ32V2G$PO@ #I@]U%Z.1
M?WDWTZ0'[J:Q5:,,K/MUNN#MU7R@%J6-HT7.27SSLZ+;*/V\*UO[FU?S])M2
M7$V&,G$P8<$33(5$-]S17]14^(Z;B$GQJ$,M&5C9\3:S!T:B?@ >/K@%2)PX
MHPUYU2$OV#94=UDJ5G7U5W5BA%Q' Y%?0RR>._/Z%)EZ7-.TZNP4$\LF__S]
MR('/08Q\\XV1B@3P;:\.H%/,)BIY2@%=!6D/.;QVD(I+P#!U KH,S_H3(!FV
M>,S1$Q^?X_ZLCCD?]BUQP06IR5EB(9*VN6:W#F#]RP8TK"LJ>[EWU#F2LJ]V
MV&X$K?B"94&Z\[._S[.<%XV.JA]#_5EO7M98X0M?MVP=BI"[!?CT7DCVM>X7
M;WC:4*>++6TO$K0%0<(83]#<9\"=H4]JD-YI=VPRM_0D1^G!ML,T96!@1&>(
M<S;H];FKMHB#:]KF9LI/:"Y6UO1O.(2D9#V7!PI6>B,A,;L?QX*XO?OXY ?Y
MD10O$8 .'<$3V-7MY/1L_?,<]!UD, N)[CJ**#-"H:U!P0+'/(]Z@ =CDY5Z
ML;+Q=D1E=R^OD2'!+.)GPB,TYG,,VP+['@U&?_"FO"FWHXBN>"+3W)H2.D X
MQ^ZJSQS!YY''6MI>-\\SM2F5^RXOBRJSO?8'?CC0<7NW6/6XXE_-,X5DIE T
M742$*+Z%64;7SB[H/#Y,#)%8.C);.T^T/J+2RPG+W4-#"9'\#MA$\,YZ0GD=
M]XFS=IBJ2Z7PPE/SSA@%,<:[96V (!,E]353Z1\)B:P3S7/QJ+0$M*$L^JIS
MQD68KYYFU-[P5+NV0G*_$CF*Q+<RGHE5\R^]3)N"+=1QHKNC 5R;LJ.'8IGF
M)1!J;A()BHH8@\%B!A:V.X*Z8U\']<[-$J,-[T!P.9T;RU3%H84 1.#$-L+L
MT0&3R(92G3[*6*V0XCE6[*MVM:7+36M3ARGO4_WLJ?B.&2R U<V_QRM6NVJ.
MGRPS:D1& KI[G;4]!Z.\@H(WW2I$<C-=,&L22 R9S'0<_B:=+)N_7[2=#LUA
MQLJTQ0V;#4XXO^>PUK/'H>CN:''1NNEC68/S\G]+-4Y[]3#52HMP-076RRN<
M3HQNT'@6FA>F<B<4(%OZ]SXU_FER:/FI[+2SHUOS-6]RW6Y4L\PWZY!O"V5&
M(P=HQWU!O!KM#M_PS:"9W 5%'T"W\PU6^IGB2&VY2)17-&&02@\@Z!1@=-&!
M65CE+6]X"P!W3?400ZE2;R22A*],[#0)]5=QM6S;=Y*(-:NP@JS8OD@N@FEQ
M2+90L8;D#\JOFOH\CJUE1EVZYP H\*V4PV[PC(ZHYNA96!UZPFQJ,IWF)WM1
MX\BE*!0/G#:1UNC%9*)8W.8#1:A !KQF&1R,,0R>BIHI.EAM"5'G"G35*BRK
M=?= /:4Q;:J<G:'6__VMPT\DFZC*OT"9X$A47XOUGU9/5QVC!AA\3% Q+RWG
MGS<+2B.DWOFC6;\/AS1-0N-LIPK@8HS/]<V8[*%IW[-N^CE60)C;S2.]X:N(
M? //0$M7?Y8>2&3',=Q:%CZK..*FEJ]<-[; X>I?+*Q&0<N_(! #9[9<?(C.
MN.%U:GT&I$HQ,R=<Q9+99I'T5UA^\^AWG7%7:I&M3U#2>(#(,8Y,:)8C1A4Z
MUOJ#09J93_0.>7^R'Q+U-SF_&)Y7#4SB39^W0FUFR&<S(=BV>2@4&SC+B!E2
M8 D>9DB[YO:[7[,S/Y_J^J1BF1U_OD400(50ZK*L"B8F'>-I/P4]+7KO"JS8
M^2._43/L=)I-]-TDTUD27ED]R)R>(S850"C<P![H[%3_43G9V"FX:W'L-AKH
M^M'(K14A%78/->F(\2>!0"5AP?'=$0?<CE.++"YIE181+V9TH%SPG8$/OFM4
M9FT?\7WBU:IY&J-?Z&BEFO_=S85<'*3DLU2#B*OCK7F"0<JI)-P;N>/RK=;#
M6GY'\$6CMK:'KGND_=)CSC EB#$E=CD$26R!($6ZU=1Y-<1\7G=)5@[-K6PJ
M#8Q6$S]AMN^V:KV87$=V>9+K[#92SLF-,):F^HTN$@;E@NP#_5#=UIOJ\?/.
M7!EBRW!>IU5+/4#MJ[4NZGMV==&=R*B(LE9OD59/H%_S,9$:HLI=Y$">I_-6
M/8O8OFX:V!1'W"8@ ZC@[+UQUGNIZSHI428K0U(^4;BM/\P-I\:X2_]ST4"]
M:OC*4HDAO&UG:\O6^XM:8&>A2[1T']_*6Z_6K)L1/=[W$]+/SISMH[SX[9]J
M:Q,+C-WF9*$7]65]*A'1UC-?Q]O8N/BWW]V4T>9^\:M^U>G1IYTS<;I7SJPW
M-;?U6/O7!)9P]RTE&H_\=E#F\/(>\(.$RSV'+%M50T_WJ/2;:5J8$EG*DN._
M?SD-_+F@12/,4B;G06E)B_22.X>_]>J+E86\Y;/9 I.K-G'LV?ZHX0A1S>?E
MF>J5(PX/N+,$SA7KRDIJ4GKO)3PD1-6FB:J*:*L=R,;'94Y3.3]_/!3R]Q#3
M9!+=.S.#8UD:5+1"#*/:B"_-6Q$(:<B$<3X!@48$)GPI _Q<U*K1?Z=ZU+>9
MMO':PYLHW8QF)=Q-'I^9I#)0D\']%2/0$5>! ZYP0_6?@(%#EY:7TP?#O]^D
M0I:[KUWQ*$1#+4NA,#@U:D!,(SO<HC!GFS K'5[-7AMX3_,C[8%$"1/>9JX4
M01X_ 2=Q@H>*4= 1%#9H(K#EFE?(XL.3F;-6_FV,ZRU)U>P<V98+GM22'2V>
M;LN02#\0N_.'X!"RX>C01NSGRN&)VA['.2NR-R3*T &A1,BOHB@&>OG63E,U
M [=KAAA5LYK22]M1KJ)E9YFBEIF8[^]-:1F2:!!F66Q7ZY/.%NNMHG_N5CSC
MW:U8+7!2;)GCVGN(J&EZ9\^J7.N!"82.)?.>"\710\>.'$G@M\=MN(OHO.OG
M*IG*9K\^.;724_.^7?9F>B2Y\0$#*][M,#GB?W1(<+'K"B,HWJZ2/5Y4[.57
MX&U<?!-JE93*9@@/9<)F-#+D_@_>OOR;K33^WW1JVNDR,TK:VKI8JF(;2RBJ
MG4Z#HJ%DLR4ZEB(16H+:NLTPQ%945(A6$'(C44N"$+JHM:@E2<76JC6$4KMJ
MOYWO^9SS_0>^YW-_OL^Y]S[/ZWDM[^><^[Y]'T8@=<LOE_:79XZ@G (SUP;"
MFQ^<X<SP5T\UFG<8*'+V(E>'_H2//RT?#4^[XAWD_&?F7-^<VT1(5O56CGB6
MMS*",<@I.S=_HW)[YPZTK+8#*7F3I-38GA92LP@L,FH6GOR2MZ=3]M8OMJ%=
MM^.CVLHYO5SWA11O%/)EZX5 ^IW5UK BBI!.Y4PAQ5&JIOD%2]<G4EQO7$:O
M9.NU4G$$3F]J92<IOW-VTH8&B38<=9;O&G^K^Q9!%%WE3;5ZII](V)*%<,E)
M65!6L:V%1C0'G@TB5LRS_0DFU*PXHT^68Y>M7Q^</OD0<V3ID FLHH1)/$2"
MXNK+6*$0N8O4W2>JI]Q/E<X9X0L<R'X1-KZ];4L(D'["T.7WKSN,Y:QR57M>
MAVWE $5($XK+2,DRW]W ;7)Y2[YE<ON\>/Z_*LM>KZ2HH'..JI@8LH'B)YK1
M\=J*([;Z%%+3$F13+6.>=<;?+KYIYRAT8_PT?:WC[%&* 2(B[\VLLWDL=*[&
M-FSI[COY0YWK;T) #5A?G-59QKB1X=W\22>_YNBY"RORP<\+.PWS-,?FB0V7
M'W:K("LJZ,P8%9&YG*2U&M?B'7(EL< K>-73NGVRFZ\*5 S*:RJ$_2E@_)UQ
M@HWJ3 V3ZQHRSXH1"DP<ZWR"&UQ\N/5LLS;T@-VE??&.-94M#W<.(];S!*,6
MX7M\?[#SN35U+%C?7R&E<Y+N$:/MC<^S5A:7AWFNXB"=9:,Z.17AX]=,:T6"
M5W/RJ2]S#K1=&_28S@U4!6_J1D.D8K-:!'2GZSJ]^C%^ZN/T:1"7#8XN=9^Q
M+LLTD,^VX@-F :0FZ>I.C.)@3E".XL34$Y4&K' -QX=W:SA2"LX5/[@BGC%
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MFD4?UMK:H/1!((4AA4AQ:F .G*=&L+Q_7J;$-5>O*_U85Y"BY9RB75#00V;
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MF0=L_7G"$AMR9$B_G(.\UG899#]@ &X7&>.: L:21>\]KA^H3029S6[^C7]
M?[#FEM!AS]"(2&C(%2A[+0*O;4/Q&-/$AODF>E'\-=1$/=GO,$HGG%94Y]@)
M6"?LS3P#%?*CD-W($#/$NC,R@J?_4!;^XJR^R;'S+W(<K%OC]<T"%TV6RN+=
M139KLZ0FQ\VCSV3@*E%I2^%U'YW?E1]S^)ME=A3U9O/# $BYQ(;3-8I^[P@V
M#E2$;A6^KG+3L@%S?X5#D5X16S7_-/YP%<,T/DE>_J?CK $$I40!9?(.6H)4
M.DMU<EYENY8MVM X_+YCF,C!G9<XBX6PBUV!@"$^NREM_CR\WRH#\M96V7GW
MQ'H%V*"&*H>,K)J60;C=D+M9-B'5)-2S"6EK5U,:YQIPF[_@*:0FSVV?"SUA
MV3,_UUFFW!KL@W2W+B[;HHDXLW?$P1[K5%",EA'S&#8@?9/\;L_I/%03>-M>
MN20!SX5X[$T!7+4Q+K,EUKCJW%0Q$VG.H^EG_]9WTTD5:/LF\[.;"HCX>,T:
M9X<K88KME$T:YSOY[B1>OP$V#SOU6 8$XM?NO[U!Y-OY\4J F##" F/-#U6>
MN!Z^L;+J%5#[!^C,W>#V6TV:SC<VI57XURHU=PIOT?XN;TR4%CTNN-LMW3V9
MUO^7=^>\?E\7:@&W'/(T03.,S-7P7;D82*]20")A(3C>BG!;@I(IWO3[R<G_
MPR+&ULZ?5=C<@81C_LR^-I<^8[,RARXU[8LVV-G?ZA#4@/T4 \)YUVMB+UUR
MD[7NI-63JAIR8J7Q[ @!,&4-]7&6DS,;7'V\IWCB2Z1#=XY<L[MNCO;7JPVO
M,) CKX GAP%^K D2L^I(W:8/U%=/P.*PMB^'6XX.'YX7,G,EG^!=L"ZU=:Q?
M\+IP8]L=2VT(;I>Q_G3;*N1?84-<3P)-UF\O$6FRYKRBWV^"S\(&\*,S3ASP
M-L,?$AU? C9>X,@>X44MP3F"[UM'KE^K.3=*?O?PT6=[\AKAD^=.*@0/J59U
MN<6V+66TS3M?JRVXK>D="%(<C?UZ0D04>9P\QD>-*T.@Z^[#2"5U%P7V@%;&
M:%2M$GB%8X''<^;[+-FK,F"EZ9'*)@O1N$;EJ([43,='.]=*UJ+[0[L@Q%8M
M[F31:-S<LJ!1IJQZZ1'SW)._,=KE9E$!T@N6DK'..\%.1TUI:H%(%<9,5\V.
M8X_.Y9O,WD\XWD&KGBIR'V)+,O5 -LQ=5 2IF#.P%I\.NJ>]4)5SZO6YO$V\
M=[4 2S"S,(5[GIT;_M*(&PVM5QR-5KO[66T^H%CR.DN(N5[&RE+E#<^>3LX]
M4F5"N%HQWN=[%N")*  !:4(=S+H'?F(KP:?2.HC<,3VS P>2V/)"0_]XYV3E
M>H@T8MQZ%F?(,#IQS->LRW=3VK^1*A)>X*8!0\=2-K-WQ=.['>,89Z194T[
MGN:>IXU^(SKM@1]K'&S=D >V61H5N#?K- Z<*E_DR?/RQT]QQOH@W#JP<9I"
M1PK*75](JLA2O+J%9PC/F-Y0=X9PAK-R&\1:(:&K>J=D__K;]UA0S,&2JK'E
MAJZ*B'87LBG<A>>*<V;0S:NUGB66)37YP<)-/8^U@)</V7T:1283V8RX<+AK
M _[$KA;8H""#L;%0<.^">90[LP1S9AMT\7!1W>77NL*FJNZPDL+&"_M<>JTL
M.$!&Y7\^?9S<Y?N#RX?4NM>M0=PY9S_>I6">]5Z$X,@  $&9JAF8Y3D3>4BU
M<!,W?;ND*=.%(M4F3Z,<"]3 !>A48>J3;M>(R1L#%0CKT-7YQ=7?]\B_W+#X
M\*J!4#7C7T%;BSX^BSO-_OOE,DBQ4ZJVAEI=*EY:SU@\Z&WF(0OKU)G@KW)S
M_6J'OMC,Q6%ZEU758K;X_VR&@H_6[<GG#TR>TU)@U^NQO^/SF9=:$O@#+>3\
M)SMEY[+)D/"%YE\#H^E9$:8&,:PF4_>D\FPNH(%W,?#Z#Z&1=7WH;,8 P!95
M.$'&[LE>M%TAF[4=JEKR\.7!?'F7G120CQ[U4.667RN%X^4PK,]GUD8/WOO!
MO=]UWB@-?&TJFQCVUIVEP'Z0E*T[2:&A/ZL7HPQ0'#DQ-"(GD"_7:./Y;WQM
M#)]<H<P;JY0 ;8*W@F&UY2=*5M$<Z;B3_O9\TRQ?_[TLLJ7+U#K'FSS,IX](
M#D[1WW?%@U16(+X9J8Z]_2N<3GY4!%_>0[PZXF/>/;%9L]KS<BE"TG.CQ&'^
M<0:\973'7E2!7AW+4!:$\[5<HF4817ZOXTZ=O.T!Z=;3"=HR!/,Q4>>=CN7=
MG;R;.KPHN57_^B;VHL>2;C7F).[!B&2?P)2*+%#C=]5\1JTYEG!E0$\4*X='
M?3>G[4@OQ4S6@\*5$C5VX^VQ5%O.!0O<&7XG;Y[V1N92Y8)P_BZ9<B#VPAHA
M&SON1IXY<OG0U7%.9\-T1GB?G#QOK5^NX.1;SW/^4>UZD/7A>$P"KU(P"*GY
MKF-3:#6U-O7CI&DV98PGLM;[).OS[SN\I"[]H7^DN_;L4W)N#5$ATVPK$CJ(
MX]E"+,',:+-F;)GWS82#J4=]J C/H T+BYB24$%_Q_D#0GXB>[9I2D)5X/X!
M,CMPNL[%?ZL;&4>9L7.(!'Q7LYP<67A*RYV-79"$8JT"\7OYA&3^.MR/,N=@
M'97Y?7MW.[)PQ5>C_\M]-<(NWX\Z7\Z-?45;9H.(@^**=_><&XW;A_PG#.3F
M_+FC@#I%4F$W.SM9YH,$=70N0I&XBIR<T+]2WC&U>I;<NB<R<=AH:-%3&F(Z
M]UFM.&PD=2Q_RC'5L2Q9Q&!^T#6SO/-7KEUHY4C9W-(Q$%!"<1W(R1)ONR.G
ML../N#*,<U:J+T51/7X\M^!'&2/!82.!5$V+G5L 0"-^C0Q.,#BL*Q#8M3CX
M30M":R_?*6=0?J;?=Q>0H*B-E4@.7SOTGO8=E4G%"XJX?Q7:EP\*B(\L$\B\
MX2,.A_J6AJ9# ?7P81R?4W.Y.0GEF3<UXF11XYY)F\'CB\HYKPTLR5I+ :)
M\VRY'NO^2 1"?/KFO;-->F/Z4<&6Z:P*N0[7&A$E.M?#V;9]=2HH#V>,FUI:
MY706?"T9ON3">70+H2L_\)G^17NX<WV7P>D;^U^NKLB$(Q$O['Z<85+.GO+O
MST2KNX_K WP9Z4_\G ;$HY5!V[!"XF^ 1J;F95 Y<C8/,V>V;&Y]FPN#0:!H
M);.!5[M"5(\ ?[$3,W?AD_']GR9@JGG@EFRM3A?!)2>7CB<>=@@A79R\H%-;
M,:,V/Y;J<BG3%]6([9L7D5I?.9*$$,_)Z8Q.'A3ZV>N;S!75K<,KPVGBDGHL
M,&1G?;1^*A0\'Y=UA00T_S7L6S^ )2A$@O>9#V;?,@W(GV8BW2?%^CFU?VJ_
M!DMTT@^&OJ8!= "OM_)9UP4R*YA"PN:B(RQNWWKHQLH_WQ+(1L>$:UXE=]ZY
M H#=E$>_4"*L$<@]L7OT!P+?R<A(@+*$3.IG 4SE-YN\V$QS)6$I'QE]2O7I
MRYI1EBA1U8KVP0YS$--9Y?)FR#UY<1@)]T?DS$-=A+9Z_4GI-#S&)8W*>*]>
MV]7+68_LY.\^#[K_+YYW#</@WQ!@'#!.35Y'*3<Z1W>X L2YT9"C75!8IO16
M46'J*!5NZ6V] ^J\AR]7C,LZU> IY48/ HS:T!(G'954;Z!>SI11XN47H[Q2
M\ &"T8P\?BX'&5SV@$Y&%H5IWI]=O_@N0@"R,,#D[)>Y1;:Q5B[.EOH28/4]
M&#4M/J+O8WU<\NFDD[AZ.*Q;-\.P2=VY%V7NC&2-"8[9ES4%#O[ZN-7+MQ,<
M_/L[I@LK0$7H.%W9/AA66VR-F%]%5S9KCQU%OW4/TS\[.(*;"V#T+PZZ^6=4
M5EYX0@&T&KF$V@.65!T<BT-<>]0S.Q0X&93B5>F,E.GXB3MWMUKLEZ;#$H];
M:U!=.RED*'M'KC//5#<,V\I/LS7LJ$%@:$]/.B;'$R \$JYS[F-I23RPI9DQ
MPO*!=R.6P 60T>N$'=E* >*UJJ;?4#:($-,GYY/D[*S:/,W,MOPF _U9X[Q=
MVV@LC8/@-9'H]<[:JF[6NH?*D LI813J=J2(N)%G^?WC:KQ80GO)H)_P_23!
MRM)UQGP8"6-G7:$> QBMO(^D$5R ,@;CQR@C131E:%*TZJLC<-7X)D(%+/RT
MBCL>G?1%#XD+$0$6\U]<GW-_.-15_@@4E69(9+7[U_;:@KD'SO2D$#RH7\:P
M\\O"[2.D+NIAD+4)*/OA)2N'+^?4,Z&V]DMA<-[N<[^_/2[?K1:)[*PO1=0.
M"FTYL;\-5JZ88==ITD/)U,X$T57.,0LQSH*(N<TYPC5=&JT%GU+\HX4[,JO_
M:,ZJBDNNDL7<?K3"M5F26B.,GLN-9!ERWIW40&J[P9T5[I@\ZX-?*%RV%0W?
M!1N B=CML1S,HX?\;A]D+P+O; HPBZ%@[$^^"FC3*?0!8-O+J\[KA@WDLQFU
MCU,>!,.%X!*IOQU45VH:7G'0@XB[+Z9?OD:J;,YVYX.<G9VC:31:834$69NG
MFN1-9]=[Z %+B[=@EJ?'O3203L:^5:T/R[O4CVB$F%G4FX<OC=?]<EWDOB1,
MKJFRQ?'>HNU.HKF4PDSFA4$<.S51)C:4 .2)'+].J+X<UI-]T.%E'=RNU53)
MJ;)PF\[5="U@!7\41_S7669JC^]A:*X5R<(-*.%[^- 3D _LGKBT5E:IJ3%!
MG3PQP4)9R0*(E@1( DI)M +HL&;2[+JYU2RC[X]%F;8Z5/]P&9U9448J(!]E
M3I*_$]N@$P3Y(Q4)13P:0"#:W[V/3]9(C[S!D<<Q-TX#+2LQ*+<0,N^5"P=Q
MZ\WL>:PM1&7Z>UP.(#$$%OF5(^2!C&L#"#'S>BY8S2[OF&4L%/=-QJY!'/EG
MY>K=!O?R?*ORS/F;M-J6>8X]1&#,/0-(^7*>9;)O?@'<'X/G/I854\S?9YCG
M:CC:0CJ6K!U)UP63INX6ZV^%&.E;%-]9V4G/05EMB4MA/C.]+B/SDC?*$B8>
MB>&\S$P 832RC4W/ #O<J<M-!X!H$@H)[U6HZ0VQ]//I>Q,6-\L8\/K-\CX]
M2Z=MHBB-C9]B@]U.S Z99%_%GYAFYR=.8?2S01:*QY2EM&$8R+IS_I*=DU&P
MN7^9+^'N.Z",]%.+BO8TB?83S$E=,P%J:[@0:LZV7BACC!XF8.U\:&Q[<%<W
MMZ 2*7>*S$C)0,;$@!M^Q/U"X?&BSQV-[DR\'F_9H=/'<N)'JSJ$%=K_A-8C
M&#"LRJ8';[,^C20/.0_W/U6\WDKZ8 O9@WJ%=M(\PL%F'\XX>@&QV#@L3(VM
MQUX\#(% -[H\?T?0WV>ZTPVKZ&M<H *Q(S/R-PW@4C*3UK*1<I<=E,U'C<<2
M6T+X:&[J#;-';BM@,"X/&2NOL;"L>-+B=G[36O#ZO>![,C\ 5S-;:T]F]:\%
MN7\-]D*MT6\W;(0NQ>RD[E,,,:B\V7NJ/,$WH4A /DOM+IF.7M$R:&-_?7\!
M<YN:*IY) M/+U^S.K!$K_#322I;-V%X@^>SH'2[UV$CQ(.GFEC#W68,JCQP-
M?E3ZM-06VL9U1-J8 :7-=\7VSX\?C"AQ^$@X+^$D.W(LH+,IMNK1%<WXX??%
ME]-R\*DY"2)PE\,T"4$,(@?<Y5G+%R1N0&)S'%A;(;ZH\7^]%5F=*^0K#&5H
M%T8]8)[AGJP15C]@[CN];;_ZU2D/SQ$^.OA4Q<?6U+1H],TDU#J"P]G(O_?_
M=%P5&?Y[7W\W'*GN_>"H;J;5*&40!E2,1-PS>4>'X3JE_>AW.!0]-<OBUV,9
MW;;FO#%N(F]^9.11;5'WA,CO0TUO@V< :]EB[IK0@A[1DBSX#[V>-9S?! -M
M5KI]W7N3WG2H?P?&?_\LOV;Y ROSFXQ_VNRP;PX^)E@?8YHMT+5#+]S8V/W7
M(J^;32X97#,#G_4/SO#)C.!T-(V"(@</??I+B"$,PKE*G=OV4?F)+-]J2!H"
MV0]6JVA,<5]XI)#OQ!M5?-AKU5J543;O0+<.TL55FO=1^TR3*E:H2WMN'/JY
MPK0=KUE,^7"E\[&WVU12/T=5)08Z'1I"(\"!)P2S/+\)LXZ []FD36F%/UC-
M1>!VLMV93XWOLQN\6$<C;8;YP@?Q_7%[@3)?^Z7J7/@-POE/@R\[ J?27 OR
M\.\F0[^31]F^OTH[J_ VVGB/U*^5-8\2%Z'1G![T=\V4DY-#HFEY#^I7$Z'8
M7R9CH!@CT#>9E3=[GA<":5Q2 2"+3+@]K .".W1.BHD["HMJ=3UV/J2^&[5=
MT5PC?N!I'-R"D02N4"-.CGV3>98-IJD!@)I6^#49H4?504@/8(\GC(VCX4J$
MY4LN'2?&.7+(:](&K![Y]I"F^*/M9641+/RJ-$FE63;TJ>+S5D*<\NR1>@YQ
MD8;ZO/WR2O))@^:\:%&+J"O;Y],+!Y.-+E]#).2DXQSN<4LV<\B#(WER7?FA
M4MFD-8Y&6[-V^EWF>*0'2Y9.U:H77K([F)^"+XDVR^WDV=!W@)V';5=)G;47
MLUR6@SW2UB1--;W'[BS"EG9DQ#^RZ30EUY-65RM?'90/R;3]3JH;0 74D&46
M0YC8!PNH<Q:]%(76KU:;HFC_3?[@H;>7#2TU9:M-.R2,%:7O<A^6JSMXQ#'=
M'CK,62@-,8'-TP(R,16H!DNE'7XGZ7[:MCY K53;S?]NB);?-'5D>@834?:#
M3,H(BV#/2;.I[/D>@<"ER/7O[@1\XO!@O_"65M*:B?P+9Y@>4B=7U\"V<I:5
M!7R7P))&&9G_UZ[[WH]NA/:@6GN&-BLG)MSO:F#MZ^_V],3WMX<@K^V$-KOK
M9<O!1]@U"F%=NST6I 2;F=U$@/0TZ+[B!(Q&WOI7^%8TIE'MTI"]5.[+.*D&
M:><CD?(.%5'U549GRP</E3+B$(=+4Q6O;819H(K@3LC/2,>&S?OQY*FCL?:B
ME81+KF)[;+!-O?N,#K4$BX!:([$D L/?#V9B_+KY%Y3Z<$W_'#P @7VXI9I0
M$2^:C[.:'K)Z=5.2F^W,PQ2_&:,D-R4UJPFJOLDL1I_\LO^;S.@?QC*&BZ!!
ML@2-& $_+2GU[R='R:4X<9#$G_XP)-0JZ92HXUC9C]8>L6>'&%/_.;-V($$E
M%Y)V=CK3HYMW[D.>8#)&XBJLPJBM@('Y/'NJY7WN_W;VL #FGI;3,PN X],/
M;)A>*JFVD/8F>U+$?X>$B8C+"7#_QYHP7<B15T8.^ 04K<0!#%)4/A;7IS(=
M(O6Z]?EGX,GQEE#VR:L/F[8<4(\0CB@US<M@M',[8SIUN*!I$A9UE#6\[VG]
MK9^ZL]\PYE&2J--7MB(RP;O[P-]DDM]\D^'#1W1ND@ZPU=_Z+2'6>/:V QJQ
MS7:=35T;2S;U<QNE=6#>ZOU6*?G"S_"WU_JA[Z2?G[=CVO/;&Z;":I="0_ S
MU7_-F=G"]#5O4-P#O(R#!Y<UTKQU,M)FAB/''8K%L3_?5;A97]V@3#@8[A"G
MU)[IT 6;L)((AHG 9']<5_/]-LN7?F^>U2V(=$K_Q:BD4+/?ONA,4D<2EW[-
MC<V&S\7>D?%9!O<1:C[5ZA. <5OHD-YGG7[*T=8TA/=\;%F>&O$=E534UZV9
M*;"I9OTK.A_R\WDGT.D9V\^18P/CPZ7>?L37!ALI%[A=$1V%9%SK;6.$T5@J
M-/6[IV/-S$Z-H\% 3,;><WXO]57T-7+J! 7E-79H";8?SC0WCXI:ZZZ8N>O_
MV#9RGT3C2?R[-YPC.N,20QJ_2W2%(FGVEM_#][0@"UX.+:>0N/09G"_L :28
M'J8U9:O&*4M!AQF8-F98[9H2-N&!=>\VX_QJL04;Z$M'BOH6IU%J]<ARY 8'
M2-T@[D%=-KZB>VORJ$?"Y= \XI<Y.QQT6=D93*__HO!?#>,8O2'RC*^R\0M)
MA3DA3[-J[,Y5WG!1K'(F52OMRBB?5IMKTM2_-O[D^?[2GU4/UC6W(&DTRJ@]
MJSBTOT/)IFS*N\*HTC($V-EE\Z]B57S(T05&M[3!>C591@4X/Y*YFNU_;>T\
MRP1S'*^+I)U!LFO=W="J&;-##_+.9*)&AD]6O+)2!_774^6SV\M28$1A=OA,
M$R,C\;K@W5>OZ&98;%KE1CP>>&]O<-BT!>&O]KE"OW:&_TTF .&?8()8#S9>
M/C(<E%0C7/73Z"Y--6FM?R,&M'PE4PMA[U6A44C0!I@'R3:+9O[S,.Q*?I?3
M06>@/;>9-C@][O@U1N/VXJ]> 3V+]2:U[R2^/'4WN)/$,W7*A]B#G$%:P[20
M8]L4\1U%T;LJC_B!GSM4_>EUS:^!IY0,\&FT%)V;R XQ"-_ES?Y4$:] '%3Q
MF0BW4I![\:/7E<DTTQ4.Z$U8CMTZ4#'F*1N5^/Z8Y4\AT<W-ZNY<S%%(@:*V
M4GI6!L\I$"3'1Q(3Q\0[#H?4?UES<'(+9):6/P GGI2O+\I.G&Z@;]-6L:^1
MLWU^G.8$5$R6M,:QKKA:PKB.ZWS2:7ZAH':X-/1]1I*Z2ML9\63_;GS,JY$#
MTGAX1W!1ATN,ND:F>W3@V;R>UQ';YE]&W9,%SG*@N-F](?%D![^VQ$:'LKIK
M<&27:K>Z=Z_2Q8QC3Z*MI=75_UR[[-.S67HI)/E5;3\"WGO8V )"6K\RHP[O
MBH;N/'STX;A5A.%#+_WT)J/:J:38Z,?D]%?0#/.:<D3TG!6[J[EFZ_O:;7[U
MB&YRB$NK#/D5/W_*71^*]#97;&^<[V*'6"WM_%G8J%&+J6H\@Q=C"065T61_
MU.9Z[PG8Y_I&TE2&Z2#N3!Y+#4S499_PT6\QM-!19Q\9.9*3JVR2,H5%A@)F
M'M@DOI;+:>N7\P66T:RR%RL=Y4+Q$,J-M>+,I9O6QS#-LR%;5J-HZV2_I^'<
M4563['!(%7UDF_0O8<4<C>-;J!&BU=34M*#[N[79QN[2-17[#]7 V4 _=\J<
M#]7K(&:"(T?!<POZSXAH.=H_=3^+'LG1K,)\;#)*GXQ"X5SCG%H<PZ>F9[#$
M:>NI!<J>DZ]3[O3BNS8)>E6"R];J2QF<'OK]2ITL L8 ?&:[L'JB=Z/G0\C7
MZ-)=H7+C^+XZ/S/+P][C/D7A!3>0?PJ=P]2G882>X:_I3D6[0&S7)WR:=89K
M\/P=$MG#6.A^>_CR&Y&5<Z-$VL'Y[VG]!N&+()6);MW#$^,')7GR1^CVC(^Q
MB04#E$%O#BBNG1TY!5=.6:<<^*K]20">\\D2@L^0_!#SZLJ=DWB^5-Q0^CIN
MLO;W%VS%$P[>C9KK8/100=4 ]-%Y*;I>N8>-C"8<RZG"8[_)&#Z^+M@ZZNS+
M-]I155]8=-/VMM<GHLV5WU3\SSU>XKWP)*X'(2]QQ)1=XPQ_B^@(=0]4A2G9
M]BH5Q67WG]D&EXZ5GE]DD O,?2+/4YWKQAD7E.RF8*]DW9G9R+$K4S@MY&9,
MCDOYS#Y6IP'9,B6R]5I)@2^C-.GL%\= TSPTF&]*A12+GKB8/1Z8!)U'<+_N
MQ\[Z-<(]\K.)X94ZC+DBM-8*HP2)'VLL2Z02J:L_Z1LFB8WT?_=55#FZ65II
M=-SEYRVD&H4% N;41;;X''M^-C(FQQR.]%6Y]#J$J]$Q]%>=6#^\[ZWYX*&,
MS)=;9IW?N<Z1U!37F.RKSJ87* %1IX $\Z<9@*A-W;D[U("(P)+BM69W<1QC
MA79]%_'W!%S4B-0UXE&3U>52O3E*4@)DBB8I]UUQZ>RTRSW\9^W5C.7-5-R.
MH &VF_>GZJNK)Y@_E[**M_ZJ/6#!&$>L7\AZ%6W_%8&T51>8QQ6(/R_NU?E'
MV,"%_^T0Y2"H;>/;&3-C8[S2M<PL\]K9;O($&UH@K_\,[WBN)IFI_.^_L1>V
M_-MH $#M'Q1<>M/A<A%WCGK2*,PXMSV_<0RV\[/>OH/LVU,35;'JNI3>H/)L
M/_*XGC+8QR>']]V?>V5UF#*+;N7<'$O7:CTKS1:!URJ*LG':BZ15MR$C &CH
M, &:K4V2BH4U]S'ZS]D0\W#2+N9.Z;*>I]27&#'Y]VN?+/LVRY:(X4^Z>Q23
M/RJJ*JPN=1@?2&Y$=-45DK(?M:\),WS#D)[?9*H#\I:J;LBUN@Z9.)%0D&4^
M(()TU/PWGV #F\X ^0/MVK%G],RZD,ZW<7DA!CKR.5@I40]H==QV\[#3.5V&
M HQLVWJ$%7R/FO&AFM/G+[Q@?FKPZR>1=U3A^#-Q<"^]HV3S_$328KIDW']V
M=>>/?[8M/AZU?X/:T20 :27C.@AX:?I!WZE4.0HN3&W.8DLYQ/8G3;T<<.U+
MMKV]Y=K5WPW1L2F.&+4C^JK7U^J0[)G+LM+L%&;VFBZQ)I:IT@.U#IW[.A"M
M53T@-;\YOA]XI<DK6M*KNW2K+,XW)5P-.OU&2G!NGUHG4CD;.YUY#\<,^P<$
M-U]IKCU6RWM92'']8J->?R(%8VXV!!^[FGKG,BYAYSOT@/SI%QZ.VY'U3^S*
MI@'"!>UGB4]^*N?R/']4JJ!S^RYC]+@GC]#.*0V=Y-+8(TD<\<-O,K;EH=TW
M7^D/C.@]"@]S"F4D+16<:0=:$.OPP#[+5:<HXY>&NG\K5AH-+A0HU6D7?@K8
M8LT6*(70FH>':ZAR<O"/E:\:3S3\7#6B-RBJDPPYJTO48VNB74M"SPB(WV0"
M^?)#<^OW93X0.F/Q_RA.UAR8B4WW\A2;-HBO]+%PM8O6F*_P0-('R-"O!P,#
M/>)JHZECJ=6(*]SF(_X7H--A5+4NJ94*4PJ.=-([$OOKO_T^"NB\.((@QX,@
MM/,O2[!W.HQ<45/?+8[> 2?R(3,C I]&HZ:)Q<QDY6[)G.XOT?4UH7VVQA^L
M,8#A(O9)WG)_O.NY4:Z#U8-Q H5MWZ%]RE?'62VP/Y1>G_/Q[3NJ@D)W$>U!
M;B9,Q]O;\*2Q8"DBRR,L!ZAH6=I?H5/8.AL:,S__!/EP3,<'[Q5RQ:4D\"\H
MQI %'81AI%'9ICR)[>:^O<C& ^[1=?TXMZ.L H6D-_FDF1B+C4@-A1&KBMH;
M9L.<//5,$FE]NJDJ3^"AD3AI#6M3SX$M\L6\\2>7TT"O=KA::6C762.4W1]K
M=P&-FOTS?Z1'C+XI6YW!;B_D(3$&U]6^IF]22?,OQ/XC!$2XBU!72K:CV?*=
M-<*<Y=! H#R]<7OCPO;YCZ8QS0<*,Y>"Z17DJ#/Q2PSO*Y.I;%21.U-05C I
M0B(783?/@YM_>57RS!G[,9>%UM-=<5Z+]YQ"$^2^CB/GAKWD9WZ]25G0.5K0
M91V31K_@?X'B%K#]<D9_!$C\OK1F0Q;XL4)DZ:\&'*&!3=<486^Z.^5GG!H]
M=,TU YM(>N)O4??L=DCRT/QMN\ BH"0!T*$>U&+&IMI:!/J%&(^QL8 4F(NA
M9XU$O#]O&6R8,F(HF4_6%U)>9WBI/!I3YJX.]"%5&JQW3 L^QV?M;_JX[J:+
M.D_-&.+3GW,4L'HP8Q4 $%Y)MV%S>6@(4?96/'(0PU<UMM"IYM\B/V+2Z63$
M]+I/JDH/<UJ +5@LF, [.,DZ%04%E9',71_/6$"DUM#0/X#D=1I]W5[ZV*I@
MZ$$WR;E-7:\:WK$W#1UL^YE65,!DLS%+M>MR#G</KQSP-&(>RS$DDDOHF12J
MXI_"*\)ZD!P[NCYB</Q[2$3,U?SXZ\F2!]5]26I 4F;;BDJO#=\T<9JSB-LM
M*R,]43#\_8O]*^3LKD*V*6#G3QG0Z*$NJQ?/V-0[MZ])*!A\!>Q(LLV/H;4W
MQSSMC"X>,3\5#D98)#5WM$R&FK-PYA8[&! RG-WJ]^1P!>?3\KL:L[JQI(,,
M&C/\9$U[/HE$&HO3X;%S2G.L]R=\O.K7U7<+]4$9C+*T<JENQ5W,=LU4!WWG
M"[N2E3[U]^%DT;Y?EAO^.2H^.S])"[%R.(6SEVX,9Y@V[, 2M/[6R]GSY BK
M7B^<_\GA:H?ROGAU]:R\7%!4-BBNI'_NPN?TP\O*K>K!#X;0#[D?\27X7*<#
MSEPM-;#4_,D;@#<.PTM7]@2AFAYNB.?W'=*9X;1OXL ::;DWO.?Z.%U2L$$.
M5/A5\Q%N)>;P3["_RFLP-+< 26[GJG5_*:8H(S8;) =?V*/W\ /7_)P3W#\M
M\Z?^2R%A[S.4\GQ3O>NK:-]D' (Y7A>:5KAL=H[F*CRN<TL>C'\?[Z8*?6-[
M\5V9C7H?&C  !Z)[&=[&^YKU?Z][LP7W\G/EN_G9JZ)TE43_3H0Q[Z0[!L-F
MNSN?G6/7:=S.IE>2\^QMWF%3_WX=6@FD0:W19W("!>B8=ZBV'ZL]]-Y)V3%Q
M7!(YJJQP6>/!3Y6]ZW)Q)5#QVD;F963R," U=<<=D+R;QSBVMG3D[OL':.7(
MF6?E#F.I UY_<?:WL,E)2WY-G+^BA8;2H",TL/V@4Z )?]L <5YZYYG@YM>K
M>48OP..7+@?QC IBW.LQ>Y=#H6FSS/&6C(Y/CF*11Z_1:UK'7X4(-K,6?<UI
MWH1#!!(WQTMPM.\7QQD).E8OU_;,8IA%=PV=S[ZZZC)2RLR\?\I7^QK#,CLM
M&XYC(?"83HKCZ*ILQJ5KV423-3U<Y9G4*G4TCV!68MF>O9/HNG@QC#P:6L9,
MHVO@ZBNO.>DX@TPI8<?+^,<Z8'=[ID_O!G_89C,WKSM=VK,UTG*1-7(1*;A[
M*';1^Z1P\20@:4[8N_J; ?7-Y>W15VL8]*>V_Y]#%FD3!3H>;K)Z5LC0[O.I
M28GS! =GSZE^ LI*"[GX%/;<0F<(KJE17EA@$9US)E<WXW\\TE?$GIQ58INN
M2.67#Y!6D2U:5W0@L6#K0Q"I'!9C!:>%8Q-];RK]$JP\=;2E#G;) 48LIR>4
MI$/#36)9$D$D5"B(W,A<_$_"822NR"$FC6U>L$7[O_H6P666[L#FADO%^,J>
M8TV"E$E3I8:/3+V-$K(=4MM%6YT,A:(A[5,PXC;XR=U&X)L,R;&M\$4ESQ-+
MH95H!Q/?)"P^#&1_9_8F(]KMM%"ZP*-&+'_BPE!FP3CNS6R@3^:'=*$M7/]Q
M'OD77UM.W/9L\]ZAUMI_-O!IQRZEBZ:6P@B9-MO[7O_9"DD^:;.9] ;859LS
M86TN5!9RNN#I#H1F1-7$=N*3P]#4>+6@Q$D$PH;&SG)@2_8ZDG3N$*@#6#<5
M"&I83SW.W1H'OD"+X%I[K?I,BNI]O4Q,;H]J*#1ENOTY\++]B\?YT.9LR)NU
M[[Z10W2LBR+!/]RF@C+)3HJG;"WLLAN9ZB, ,.6TL"-WV*IA7YW+K:,5>N'K
MYII O'9)R9J>\0MK:QO:9ZGJ0BFV*6[/Z?7&.P/HN=.9)<@FR@U--O@[DQ0]
MK@)7@B2"6>;RSD[N\=$F<M><^NWBFA>JFIJP),Z1%P>=4]S.H[3,P$1KX3<9
M\$X'K'I?!6U"[X;KSD)H%_H(W,%!XEG^*<NS3/ ]:3LBYD6]A2NZ2DT7-#IR
MOC0H=6N<*)-XN:S'>>6J=G7W-@4G26.^-#XH?$SM>?#J]=65\XNN@4RFAN\C
M8Q0^T_UBH%P*<HX5"&*,.L?VP=)_> 9X8%1;UZRJ!=.,.H1=L)LK*]/"-O!X
M/G,X@,3STOR=I3 49X//05X7#<,(7/L:7\&Q<_EK:3=*7=51D7BYCD5'GF.#
MR^4DWZ@X_9A- \HE_),V6K@?Q*_^Q" "_ST,J.=\_+2RU'3?-UM4?'&#VOY-
MIOW?K\8'%=[Z/QYTNZ/MY5U6%F>"#&@AEN/,NVWX[-GDKXY-GQ)+/NY[AJV#
MJ9H(.\\5#'OX)=S^@/=22#K:USX)VUA:FJ^JI7?HUP;_]FE]V,O]6<GTC 0$
M@D.PF7]VJ @Y<S5(V\ R/CQ ,"]P<'QRJ/UDBK%RG9^<76"0MOW6]<)/DN)_
M/1N3U=JG2ZO[/%/&QP=[.NLB?=I_+S/,@4KLP0A<_X5?2QRG:31SLW'>4MQZ
M4]R?G/ O5O6>(<=WPS';F089@/)Y/1JG^,!TJ75Z7@L& J=S:):O)GE346?\
MHA[,7Y;U/69'Z$ZC_RT\>4ANU<>]23W*O0&)@$H:L$TN;WSD.@*\8* =","[
M-F#.3CL^Y_;CY)1D,!.*#,L:RX-M ?2^\ VLHO!2#LK7%6L+2:CB1WH<&#"E
M*8[NZB,1_6O(SQ(FB_ G9,,3]+AW_V<2N'-Z9(*11N>GN!-)YTYVO$EL)1 3
MIVFE=2^JO%%*Z;8)71 @T_[?(567:IZ&6RPTR3-M!MM@#15A$RD+COJW_P][
M;Q[59+;MB\:V+!6K$ &E48M60E<J 0&Q36@-"$D(! (E?1)"- 203M12I#$@
M("!!4$.3#H(@H0D$2J5'P 1"('2"A%;Z5AJ][G/.._O<^\9X8YPW[CG[OO'V
M[Z\U1[ZUYK?6G&O.^5OC&RODAMI?*IQI33YIS)$$;[3_\L1,<9O$L5%!VT4!
MAYH;8W'06:1SWI$G#J%C2]844_Y"&2(*3Y3VR%;_P 82@Q0/5=&JS\V;AP+/
MP1[7^%;.K8 #A,%<+%/E#ABL,4IX5-&_G@:">J=]$J]KV;OLSO[IP6B D#2'
ML0\KNO/@R?YP 3&:0CM2;'->)Z*@^K*,&V,&5&01J*)/@@CN@,^<^_S0\SO
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M^D<[JS?BM_YHTW5>D7W3K3UU#$E@5EYI!"VP@II^&";+("9[&3Y[3TXY,\9
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MYY^M="+B:CUHC=24^R^74\AZ/9SL^DNQ9H.?B?%"%8^9 >G^CG60=%B15V]
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M7;'=N_V/F!M=-T^;;"M7!K,Z!XIB;\Q_!UQXU3IT,W<%%8\?Z?]FS=U?&-C
M*XO+DC4)V694I.^8/NFR)NVWY1C6JM_YH7BN2*727MYMA@.-+!/91XZ(?BV2
MV_,=0(EX6M;0=3HR%BLD3\2/%4H$F^F7859+O;[E2+1.<)3[&\'MYT([EI>V
MR=F(Z0,(^0QI>QBV$ *?K!ES'][.]P_H""XOPY:[R2=')\60TY K8]@94E=
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MU<C>,9XB!<+?U9@XEB'!]!FJ64R649\?,W-)R9%5AL+=#GG2R_ATS7R F-Z
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MH2E]-HV1K,#U3E(S9\ZEMH61 I$V(NKR5 RBFW%KFG#LC79 ),3?.>!,/2*
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MV[J\9!-]!_ABY:'= B!KYX&_2S^UZ1U;9T9URUZLVTG:I_]WZ81!A>\(XSO
M"?X=\.O/'T_6_D<YXM\'OJ1YZ3^HN6*7T(/OF:GM\I\WV>\6E)(DJ(&,N4V7
M,XO2JZ4RW(>1$5FW[R7WE&CY34UJ?4Y@)X?Y$->O);6;-\PE9-;PP@C8N(=W
M;_3IDAS+K,7[@Z]^-O-.;18*S,(KV]W8[G%T)78;,Y)=G#9>8C)^9?G>')13
M0BP"%KT/.[\47+<8_AUP@(47]J3">W%N"?1*$1R\9AVK;_B*6(F<H&H"B>66
M/$28?BY UDAF)J2_X^%U]3W)U+1)*$SJRG6XE8+ELF\DT!C61HJC<VW[T'*'
M3@<75/$+5KI1K5=3+).$E7'C^ME);+1*!(DU:P0 [%;)>7@[$KS8!F+[6JFF
MSKJ[TZ%,MHAJN;O_5W>*Z]F%'TM5 (R*N8"YV5$/^_::\>VDS,O+=_XN?<U[
M?U'6;N,=;?VN[;T]?Y?^'$L_N(6X.+W_Q<@.D]WR?Y=^^0^C[I[X3RL)6%HG
MP(;+_8HQYTT[7\'S@_GRF9'VLF$J3/R/7,<\PIM6K$%ZKA<&R<DXMN8Q:[+9
MGW6O+=2P"S]LN+*1VL^%Z*)2!IL"#:Y8*#AQHH'UPMF;FKS_44.Q<3LS#<U!
MR*/"4TVI06IW+R]JC]U0#OZ]3.E644Y!AL-HJATAUN9XISMD R)!ZG5FEM4,
MZ,O.B%JSG1_!G;^ @KK*PD99]-3D=W6!D2^\8]:HS&6WB=@^!@8 K-%WT4_/
M;%?6I;QW=I9E#RN_>S63)H>A,\HTS_(1 Q?:!VQ=/<K="45U-9#7W8@\J98#
M65?67[])*AS\O)H+K2U*MXO% '[+B!S7R2MLB-KK;]\E$'Z():ZDJUR@@"23
M?#%$4,4,U.@;K^&!NIG3-/E"H?"(P)#O4VXYH4$,UV=D]+-%/77?!$1 4<5W
MP/;$&;NMH]\!(Z_?E@SIKR4H\_L*GPG?)8^#=FGUV3M.]-K)?39?K^YO&=?@
M4E5#))V599^A99/AP]LM'9[E-FAG5[)GJ!>9G&B'2W4M(H:JK [!PA]PBT]G
M1LAKDU8WF'ZJ]Q:LUX<X.&G9-D?CYL(Y%\$6(!;IHK]U?CB5*;KK<J,:*6AJ
M&O4?D&Z2!.:FN#8/M&09\>4_D6YU=T8VW[0L- PW$ 8M-1\1W X$]XQ(T$SM
M[%'$FD;2G9&/ $<EWY<\R?DS+HCL]\[J[SC\RH\U3BY36XFX]"Q'Z(]",!4Y
M>V'!(WHM>3[;!<I^BYK.PGG@7D:\+O]K-(F-"*^&ZO%9;(1[0ORY'3N:]#+P
MY8^>RGP^NA8?D?@NVAK8>+JE@8II7SU!"P)W9_6&2*B!YE]?6.V:RK%D*C44
M)%%G%&:"P.YF6N)_=*S_+\%.Q< 1];AXW?*>9.[#13NEDBY;SC6<%J5N(@$Q
M.VY*T^.',QICCJQO;Y>Y0,1;I0YMSK)0 X,5*:]4ZX%)[A13.$1: D_M_J@0
MMT5I)E0)Q*R IT_ZF<_)T:D"S9@5M\&..[2>$AL#D<CY5:7@PE0W*\NZ5]HM
M)FLU>UE,FMW;HQ ?8.-=.8#%ETWGJ4,C34/SHK6DV[$$:YY9*S^R)=A=?Y5U
M4#=MX28MQW.M=:36>D9#9#5 RD*B[_;^R4S(W]_BA,5H)&!#GR5;J 6,X<2,
M4CA\]I'?/WIE_UMP*&Y=&7'5WK;9_4 >F9];L'$- ;'U6J?=!-H>=1#KA[K9
M)SO"/JX;*4C*42,1^,[/]U@?QC2X2T!@T5<@L5A<6)YMU!]@\!'<<CZRYJ?'
M$G$;^@R^^0,/<;1.8KY*@/JEW1Q_%/Q!)?H<@\9@,SWE#+NZJG"*LOTM37V]
M9*2>4(:[AI@(^N/YN9?UWFE4U%1KGE?J881:JJVMH_5W0.YJL8EJJDF@GLCE
M1YJ'[U1\^M%PK2%,4?V^1N>%^S_KR>^?Z"MOU!$3SE2&\X[Q,S?.3] I 8^Q
M+C#B!3T$2L<_Z/C%!+[ZP<XKS/@VE27K[JK:F&U5V8'E1/2,O0WL:/WD%] :
M=^S#!F6:@^KJ,(B)H0]^((.VNFG@S0_^!*G[[^.18HRV+XHY#M6%O+=,KL&$
M5)KU0?-KZG9*W;6[J@=]-M:?]-:KK),K"O#"@PDL&,V C8V"N,865?_UKB#T
M>)!/84V_+ZW\SJ^JE(U28JN]K)Q0T6X7B1PK:U2.1R!""E<TUE\<+#0\Z$/]
ML!''7>VP4I<9RVJ*:\H=,E4%0T_+(A 1PB .6J/RC_4#Q4PL$)NYW3!I=;F4
M2DM55+HY%XE0R S+%[FVT+,M[]KHE+6X@*@)?03?1U96,C=BF54_^(X59PGV
M^S_:T_Z)?^*?^"?^?X2?&H$@IF0PR8AO6/MD _#H:EVU(W:23BVB1_J?&,#T
M7;Y>8O$-%F%&(\WZ])U]?$<2&MUIXZ+BZN/Y0DG&H>W \^Y\(2R+CCPW$Z1<
M*[ [%XE'F)U5)M# SE[F*D5J%Q;K\XJ*O3(T==62A-U.7S7Q8'V+T_%GO7PU
M^&%%V@B$_*!P<Q<NHMK>^51R_C"P."$,HH@2ADO"MN5.,SB!Z?TQ$.RY+$Q>
MI6$?FL!S0/N 5U#&D[)%+ 0:"QH"KKA5P479I>! U_:.7Y2*Q2[DAJ,3N@8I
MK2IL80$]3-M>WFI X45PVQWDB\]!_=[OL"Y!]VW0-?LKU3)3^PN2%EBPR(OU
MEW3Z W49E:.@-%R::6"I\/)^VUY-2<29-WY9:AZL$%%YWZRZ3_(U9K,RA3(U
M_0!WU6'6\GAW)?IL&:.E0270.$P?#(%EQ6MPW#49M')X)9;!^0R#R@Q3#-Q:
M)@9C1B%KTY<"=BA4^YY;R<<^8T[WKW5&"0Y3LJT?_/D=(.V)2WIQAQP K3_H
M4^];UN_NK@Q&RI\59AY>"5>:142]+9QBU097W3.@4X"WW4'@@C@YS;/9:_]Z
MIZSG%X<S3GUJ=KC/1%7*&)MO'P[4VM>L_\P'=G\@;3+HX>JA)/@'$?<"$J_4
M!>E>XV%DPDW]B(]M9-]_T5OY#G H:;51L+<R/3%CT?*\"DU"A^I?U[@K&"AA
M@:C\/8)QU-,NF>EDC&J8IEO?9.E0HP5PB])YV<K"'@8OQ/MN'S>L6[,Q@FZ>
MIFJ+:.]?*M[%%AR38G]K><A!J!71HAZ=M_/,29,/SVY4,6:MON+L.K1T,ZX3
MRRRB)V!^RR=[A_]!=EL!S^73 EWN2XY4)IR%1I2_-S#@'$I2]1);3"8&&G(1
MMM55L]@2US6EW#)7_DI'ZI/B!1N0F<$;B&(IHV7RJ!"'O&/-D]+/R7T<_Z><
ML7JXL^+A5^V!Z98Q*58<Q,ZVW6Z)%QIP^J152GB.,MHA;D*AF%>0);.E*#1V
M7P,^JXPZ?/H+:HW <9U62 VRZQ1G1>PE,I=JT4FDF-@A]N:.,WNS#V:WFCT4
MT6=_,'IUC34'B22 '\2N"9\L IG@C8,HD\2O%RCYEM.IV=I:4YA16L3C;RF'
MS3FN+X[T*'["Z8HV$2WCZ("7%; NY/5*1=A! H1D7;.\27[VC][X_T4X)%/L
M'6W9ISH22"FT.L;VF3'-Y\,P"Y"=::_[)@(N)(=6A^RWQN8;#MF.E=VF+$-&
M'S%57GF]Q11[G$7/W3IS(,@,;!_68E[GA1EF\97(V$CU<5&CU=K$R6%HV<%D
MZG> U-Q)[[%7QMY,/$RZPS8V#^S#X9O@T+]V% QOF[T+,QH@E$\_,'A3DE?:
MV77V77A/==LXSNEY<^F7EQ;Z)U937D<]\_X.B%F*1GX'^'U0W1I ?!M]0*T%
MY!1\.)9B,A.2,*TH=RI+*6G10F&NQYPE:QQ6%%E4AYY7,/U!O)-M@JH@@7G8
MDBR^E<(9.2!0VYY9#X&(U\0KFX!'H[\$M0KV)_<ZDPK*<@V](WE=TPK:N8'?
M 4]%IJZ9CAP8E7#-R.@#I&+4^9"[16 5<O1T[WBTIM"R'HQ#%4%!CPF^*EI5
M';\?,/036_1O^V1SR:&,:8S:_%A\1TYI#::&T=DT5S^_@5,<.+^FF#?"\71R
MR!^W_VQ<@( X<G[P BYTTI +94Y(6>Q\<=7H@([#=>.B\5BTP\Q,>Q8B A)"
M*3+<W-HW?OR/_#S.'_,?ZP\:+(P^;?._R5'HWC:CJI!LJXR.]/]6VL<.DC4\
MT'[9BT:/.M_EN-%Q2%[_K3$"-NN6C3)R-OK%/WW+D?+V+%8+H^7MO[P(:V9X
M)AG-+.FM2L:"A<%,)FN(KG2NH2ODP)FG1!4:W9H':Y-YE?^J8:3UW$_^)3S%
M-IC/G^^(WP&&<#+;XQM1<S5SJE_#-%K?+.%S!$]X^3HW&Z/A&Z\=Q(:X056C
MFL&();>Q/MEB2(*SU@R)@T <Z9IX_!#K*C)^# :;JU UP:)LT<@>E[M#RG6*
MCKJ^A1!2=]#"W&F>R?IK?36=D*]VWV#? 95,Y:=-FQTGB!0@BQ=9EI]\/^/I
M\8)B:HTLU@0=6#S40=2'!D_WY24EC*SVWZE9<0X@NX#$K.XIV:#ETMC<=4+&
M'9$6O?U<H&\K:U(/=%CD,KO,:)6*K"'L]Z&Y90IF3(H:F?=2'@\;."I%2\*\
MWTG0Q(J&IO%DMJ-IQC$^UYS#X,N8UR8@%?J0^TL46)[9+4\?%N?T\E$B7B&1
M5M5+7%DT>E:C;_?'@MI*W\,6KF/.">>;63ZIJ"Q*/%]A@,E.DBF*S S;L [;
MT)K4ON&U_*;8,TTS7[S*Q-A?BKLQW]?YH+MGII#LA\80@"!I^[Y$\5 ] AFE
M_$1/8>MN#9ET\6&GCB/49GI_LAESU#H=4]-86H762*E9MB[8TBQW'J'GEKL3
M3^G*! :(Q0-7G@_P917;8U=-B[([RMIEG!F_HYX[4+F3SK@LF5Z*([5N]LX=
MO^4NP5+0]&L5U\L54&+K^HUFG^RA*^GFW*R50UC+,:H1+5J(P.+00OG!F("*
M!/ISS' <NR:5L*5FB.C7+!<)4)G.=YI\V)RFWE/3+^#"-&4<55-?,SE((IXT
MS._4&=[>:Z6<L6)T(,OLW<=O8:AU#7"6;!"/R;$/R5W\UGX7<OL]K*/N^'$7
M;9SO2TX7O$.E8S]'%JA09UF3K!V<$$*),OUD?1&@Y=VL:U1%GEIR=_$/[$X%
MJL<>'21U<L\8SOG%?CVT]6AGJ=?M5IWR<:&H.&'A&,*@MI6S'9E+_+$TI;&%
MH<I.9;N@'O3[V'CAXOP4?N--0- =[9-H'!ZKHK',S$0S\4$O#1VO8=]B:]'L
M8(JE"A=IK.RB>IP=F!JV D$;A0^!H6M&H[!C;_'/9F%W:J^W.6VTOO\Z[E6B
M^JQ>S%S,+Q_XP9U[#RH\WF KQ'I<4]5..BK!FCWEL]!YW9U?;5MVC_ZJ_QS8
M0<\(F2B.^C5BV#$2W%H+B5^_^[?+NMX5;,2FWXF77_BI7=:WZUK5LE-MS-^N
M]_IGAW]V^&>'?W;X?]MA_%"4LUJ!QZ>OGM+MYDLF%%VC.[@MVA^:E_[1]>7_
M,^(&%H&4S*7B+YABFUMDAKHW/+9-ZH!R7X9T)$-YJQMO-D7/&EW^0KINH93,
M]>7019;+8"13,P@,AA:]E0:,_>LH.URO!E;U5PS#\*^X;8M2S'O)W3#58ZW3
MA_%'VP/<"#FT%;?)V9V-__)L ]>Q'E\F%,%5NQ7\W,_RR6-$#IW)M0,)=B1+
MV:I'/%)O]",<Z5HY\E'XILX+(67.D\%FV<N&3V/FX89_[7"=3YNY7=N_V$H.
M:D>UG@^1Y_<Y3?34F9NS/HQ*P&(]OC2R/_?;,%)YSQZHUX0D+EO3^IOYDFGJ
MOZB8^.FVP?K#;THOE*C5@LZNSLN.PG!5!A8T$2.!,E6*(O$FJW C  "4H;LZ
M1';&!I3'/;B?D%45F&K(Y"71L[$L_J]2ST[*ZXPM^3>*?JOPZ(ANJO-/-A))
M8S_'(LS*K[:V]MHCJC>O(!!/Q(Q;M>E3VJH)G9\,:=W*O4ZC$(@=:+#3:B#D
MI>%+-NXVV>5JXEF-@@;)G\>0;P*M'&+A/=FC.&^GT*!6H4G@G U/3NT'5?W;
M'SN9+UN FGOMPT\IW3UY'L_K]W]V-?=UMY5-*(,9G9;XWE.IQ'(-EV(+^48X
MLSS-![S8)2?<O=S=8@F<4H;!CNAXO:F4EK-04=%.=UN9\OY7@ST8G%LI/\]_
MEFUVD66U^V=$(-M<=<!.87M?3P*$$#.["8>#I_-V^N_KEB?4]J&#[W\'!'ZU
MSNPN)U# 6)M/+'O2-T<J7A[3U_I%[>4.ET\B&]YX;&5*%HF2HUQF]A0^;_S8
M/'<JI@2#ZD*,PN%3M>TZ=__-X61K3@16#=XN3%-!^V0J<52U/.XYU1$*C*7=
M8N@_'A;0$-]NRET" /;FZ-5V>JQ+@L:XQA):KH?QAWO5'<%":6F9&?BN@(/A
M> =D'P/;IU1L2-6P3FH91!8KQ7")H4 "\]C?U&C'LM/#OIVK]RL?T+#1K>E/
M12PW-1#7B\9PQ]I:VX2R[.ZMN\5O%1KF KN\*F43>$U3\1'%;0?XTL:38Y!
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MHGNUF7N3YW@%^G>2?(&=N^V;7,S^9;&9>">/$*@8"HTRZ8T>V^XP"GTW['L
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M>7UL8&LY6 F_E?5=2^3O6E(AP:$\BO6\]=^ QV&6W/F <=>,AD&D-6;T_5
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M;O>][\N1_;W:^P> U_S?SD[T[:7(-Y5@VS9U;>Z=VIAM,NPS3N"Z8<L*LDR
MXC6[H.VGKH?^3,Q6,+]E]"(/';PMV_OM?>U$-?H)9M')UT*D%!ZTEQO3$%?V
MX.2AQ+$'F>\=VF45=#LXL(31C@@V%P1FU=XU_^''O:,T6AD;JS$4.XFZX4M[
MQJISN>/<'E,0-SF:F.]W UM?-O*EP>LSSRU0X*F0=E$)8;"<-B 3%Y'4XL![
M8P* 8!?]_#E3B;]OZ=YE]RY,5PQ-^]U"P#>AG(U100FS?'-&Y96!PU]%Q9$+
M,DERM +G7#E(,D7[JYMQ'S5,,R?BI T\UO_'C\TE)\F"\Q6ZMH^BRI/MKB2
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M;2\27HFT%+M]!1&1/+I^OO,;WF-/YV25^O\<DG_B3O?PS-^R%'17A+6+*/0
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M2J"W^$&V6M>P7O.E9X=I%ZT?Q_^H17VD#4\TP 3HB'_A:&;<>3_B?9Y@AN[
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M5\3W$OU03;Y)8)%<+OD D$#,O?B0/\:?^Z%UW-P,QALT\^)XZ4*M%%>,:UU
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MUF3XB%D]<[2VEQ'@2@UG;'JU4#O.!NM\BIH/FXH0?TH[QQB(HY6FC ;$=V4
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M)X$GDA?,[:NCH-!Y1FGK+^JB/G^4 [P^7\R0'-/+3YUQQ:62/*NA$4Z!V3W
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M93@Y:8W7"1B)C&UECHW\5O8[^@(=A?KG/1J>A/SPV<U&UP7V2]GG&&U%2SD
M+\%W&M/%0JL[L\(@;\MVO:I 0*(NP+BQ4Z[?'D\U?3[A/44-*TESX"&A<WTO
MP^YKSX=E<Q['VC5/"+J EJ?C\L5!H)YEJYOO#<Y36LDGB"RI*$+8!]V:,^X+
M8#3?;3KN/<L[QD<#![I<[!#RU#ADRN1DF&%CBK6J91,/*IU#ZUV2!=W'!,>"
MLT>3Q]W,>0"SM\!2.';9<4:Z87HOF2S*[!CA>>MI5XT=CFM0';649A^4[37+
MWE;#@<ZY6MGEU]LI458AB72%6P'*U5U:!="J^\?TZH=<$\T:GO_GQGQ,<E6.
MJ$*K1VYGS1W&:HXT-<U;*FRW%'G-B&OZ@(0YT.3 *3^C]?3&Q90$;MZR;5T?
MTDT@/S)DG#_A>D,&]+.>T<C%:+VZC8&RR-G9"P'TV:*JUL81-;G<IE;6=)X"
M8T8!LU.RL"Q[.:G%I*/7^4X<?^Z46)RJ2"#0;VOZA<0HMOM]!W1G_PAF$2;6
M-1!:H54$Z1W_3O'\_@72BQ3Z=Z9VRCI=AYR<Z-+BBKO69@:K_CT6";DCO,/1
M:L1E)NNU5Y\6H*S$*>*'>;?&PW=YTWFN5-68C3R*@A_36 0,;P6DZNA&73_I
M;K_C<0+CN-GC-&78U%H. ?D&[^KPID010RDR[#M$!:^M\\?-+2#ID'CUO0)S
M+-WOD6],H1O.-#NW::I2*C>L=#/3PJO)@3CQO&U=WVURI^9H9Z?P+D,MQ#I,
M8!;9%5(%7S#7^"##.%_S^(_2QI7G3!J[\H3$3Q]/&%"+^,P-KBDW7:$*Z&N$
M"L9"!).5;75:&!23E)7C[E/CRE]0/HJ.O:M!YHP'DMUL%J(CF;S)R&Z&?N;+
MZ/MGE;,3#F5PW\;7L11TG&(I=W;&<449Q\LO;HG/4VAUV'B'F+"(N7[C33OV
MGODGWNP.G[A;<C[>S\$HW5"7Z^J@%.V*<];_)A,NU.^&M<O\+9D$>!?6,;T#
M),\)ZJ,/WV2T7/=QL8F#:W;19W8<FNL & 87R^MY[,-7-//2OS;TYP&LU.$P
M3)<91>I9O>S<QAGO9!&TJEII0J?&?+3+C,S^KWB]V>QWO.NMIWEW2K.UXU!9
M2G-RA=VU/N UF-N2]S%UF0-8]J;Q543.55C*L :'\_)A_RD]F&H]V2!ATX"X
M&7,8ZKXY@LUSC;E2^U8WF?C7<:;CZE;'RQ+KQ@U5]M#0('W(%2O\/!^L?5:;
M-E66G:_NQPLKZJ[&UBQ90Q)%\76^KJ6OF_;EUC*+;BFM)A?QJUO=!BB6%L=X
MY]!@Q081K9ZAW\\OV91(G?*:%!1#L8./55XRN?6IPT$2\J"V+]!'+/,J&TGE
MP)R)9V[<!SNI]<%K'6_FG&B89ANVA69K<.+@ZL_X1$W!Z44\056'WP/%@I?H
M>746UL5K%WA]RL5XV$T#5^5REXH9N%,N;<-D#V<HW%5HK;@$4I&C#,)+*L8R
M/#S&J:DLBHE9-M']#YR%[G#_ C48!DPGB0(Y3L7\>MZ3P.N))&R G,6SG?^S
M$ZCOSX^_!O>.^SOTBLDGX5J/SF?<G-6:4:"TB).+85V[K31-(E6SY:<G&5J:
MWSU'F5@@>\GT;\681Z<LH7>00'>=1<$5DT92N+@6D.;.SM*G1]VQ4\3]9$3-
MJD@Q!^C2[/OTRQTS*OUA0#%1FQI;#E9_$M@)Y"Q4KII?VO=Z3&(9<S<>+T"'
M1.E$5-[Y7!3!"3QI4)E8T]+2UH^J>$;YC\C\Q[=Y F70U+,+8!C?9#0_F-RG
M&[JK?;(*I?1@MAFZ;@%=0U>M.<BD#OA6ZG>H+,7)VXO(CF+E(8:>Y]6F92PC
M":M]6]H\%SA)$,T_F!Z^+6F1(!AKT!&O_SQD:'=CGX4:3Z5ZA]!FJSU![*J!
M .5-=81U+<S=%'$O1T".KB[U,[;0%$GJR/[7<<TE'J7]8,59NY(PH8WK1:;'
ME %*AZ#9-YS_G^X'O!O2QL[.TG%Q(N&XF4WU8 ^<\14*]CHQ0/UD?!&3[J]M
MM#J(U< I!^ADIU^# "S;2G$+G\@8GQ7)5+T%EM]#:#<UTJ^2G7:R!UVB_\N/
M,J@R0GS6\7PS9J"3-L8A/-\S;<C)_>O@L_&N#HW)Q1D-8J3C).N@*:6<?\K@
M51)K;4E<O6]0%OX@]/C+08T:S!(Q#6.XGIU1C"HEJ0?,@[_)4/C4O<C0VE %
MOYH+"9_Q#/H](*+4X^.B7E9;G/G0 I0\$Y>A&K:KW4E8>GW\XQGE$RW^K:\.
M'*3<%,419PDLS2HULQ O--Q@&/ZO8B ;X5\Y1,-%'7SR^R SM[>[&[QH9TI!
M*%#,J#B0L<A,NP (I191R$"OZV7=@LNIS;W,[STRZZ;LG51P8= @DR+6:G8Q
MR<'@2_3O\R^3G+UM$ CU8^L1JQTJW:14M=P1GESDXXBNAI^<,J)/*N/@@J4P
M5=58X-+D$8;'<_!H4$^%C87^_-9@"O8+\;'#8L2AE>VY /1_IB?U)[!W@[T:
M%T6@N.:?KYMA9V=HHRN!X#.ER546'&N357J[MF^&9LNQ)[%.\$)I-<SYWK^3
MASS,2:# ?*E9,_;Q^9DB%][L2)7#AV:9'SH1[G XQ ("^KU.[RKE6?D2-"(%
M"B"Q!O@N\-KF#\,!C+!D/6.8PU\98_N\P%&C79#H(J0UDT\K@)EZ,'F=KTHX
MA8QLVP#&S&3&Q9+&<1O3-UC5-?!@K[%6D<F181+6LD="8_<!T 1X/"_^[/&/
M9D.(@[>"]+.-L@8F? 2FF5[C5F;4XZV-&*. \U^304VMBSG3!3=.O:AG<0I?
M6NOA,);G+",DV=";?:.\<XJ3(MHD^'_3?I@4_,-:;;5G ,MX9HZ97]Y])9$3
M!O&D\[HBG)@2QXJ.=%YZ%@NR:/$0H(F_'KU\2:KMAW%QU8 &E-B(-*6IJM5H
M8.2:Y<_[OYXB59UX.&KG#!CUR .Z:YWVFY8!4A96]_84F%&5I4Q?[/>Z=6SS
M8/S)9>AVY!3BZAT:+88V0:8?P];C3#UZ2[JE7R/[2N_H_WF[@KEK&'ME@1"#
MF+/YL<@755'03WL32/G]_MC'F*78\\3/& "YQQ^UFUL93+UE;.L?$ST6:"0,
ME#-UI9@%WD#?H-'N%NML'=3T!EM7V?IX1)EX-?=\#E.=&ZRVF1LLE3XQ7;[#
MZWL^.]O]9\KC"9!@J]T=8W:^ULT $Q85HLGC_*'WK_562.J]XZ/'DZ4\5D:)
MRH3'<),:X/$EUI2,7U:_'VC0-X<CGA@7]-P-5&78*)V842<CC&O*L#IY14M%
MTQ$^6? <W1>IW+<>4IH:V2?M8[AR@U9:]C@,MIOHI!.&ZR9MY\SZ^_"[[> P
MQY2P -H7,3P6:,S9E1^\;C^ >TD!'4B/T,UW/AI@^3S5AO,Y5V0L,J>=_'?T
MITXDM#]@W*_<U+BOO''<N_S:3,8H[%B:C1[&7/U!DCHK@@0C,?O;X6NPKO5K
MYRZOFO"M(2L"Y09-Z22[TW7X\0>9>MP[TGJRK508!6@!C]1AA/A"41X%^-/E
MR@RCA+@_9VC54K%GM^?(ASL)UZ>2N._5U$DS?%%R)7*3F@>* BN:*C8W2[%1
MU=-\=X\Z[W+0I7^%XQMH>&]"_YW7;T'UO 5_2^---<EW-$3.)E5Z,;M?"L!6
MAN<@GU0.%EOSO*I,2LVT,#&G3!;U+NA,SX+5'^:S\]W'=D*YT/"<#:K^AT//
M9&1\N4+R>G"1/_(( XO[RT[.*VG);>E6S&"OH>>FFD<2#\"H_E J\#^.QDT2
M.]&A#\WS?,FO7):R;98(_]NUD\!Q2A@OV<ITOXRNRU=HNNKJ@%##SJ+57I(Y
M2*?K:T3ZYC>9@-#&C?H&*QM(&1;G.='U?4%VLVZER:RY'KS^9PRC[UH7];/M
M(K$:Z=14P@&ZE%)SV['3.G<'WMO1P-K8T\G7FU0.D0A4]8 BP)D7#T[S?-B@
M9QW^=*A/D_;B89Z*0E/BEW/ES421("V0HV=@7<(;_/4.1++9@I?M&@EF,E+,
MI.L$UUJF9(^$,KVW/S&OK\/V]EVR?]Q&F^TKO\]C*RX]7*H]S8MDIYCC!//R
M^^Q]CY^7_NO= [1>A@ A)X]E^"(&S\X!,S"4\[6RZ:4#T'B#@>+IGVW-L%CZ
M3(V!>_[96%11Z-93Z\^"&(C)$&HPE"A,]2CMA@$_SE[/B86300N[KC&7SATY
M9TFVGE$/OUZO*F@/FY&3%S(*-#,NJ$:DV3:.87$=A!DY*W"IXG<G_<^.?I-X
M%]/_O9\DNQ\.!YNF>IRS9127H^HPAXW$/Z5>Y?E<M!7:1'H1\UQOXYK3.D>?
M$'-,4HQY3X)A+KT\>A$4&DP^&"1C%)TGI([=8*2D+F "*63!#$2Q7)E!PJ@R
MLT4FBUU[MIF%/  6]>L" *EH0;CJ4H[$<D5>4P9/OC*8DDO<R\!P8$%F:/*R
MO9V?PZG\Y#Z=OTBS/?2LP9HGA%( J]8IG6>*YL<.>XPJ>_,_:GMMC&WNH*P4
M;UEZ2K$9.-3[D<Y LGR_4\XUO1O KZ@M?-U 76KYTCW+IZ[E*O9]3'>$JU9N
M]HYMSR04NR8-FKKQVBYI)2'(DMNXJ]>5I#.M2I[])N-&9HS'!@&S)*1O'KMI
M7);V@XO/:D-MT&>=[(4VA ^W-6/'#$(H<B*;?+(?AVWD5<Z(&\5?7Z!O,+>B
M(VF5*TH:;QE8#5I1,8G2V^>X'M-_D%S3^=D L&:2Y>/P%;_\L'PW*ZJ)$U6+
M!TJR>;V[.+5\^K$@'U6A%]*+$W4>E2.,O*3WGYNRKKC'Q2\Z6 7/S'BI&ZY>
MF=:^'MY+F6GM%;1(HA%H2=PWF1^]WX/OWLV$136M6K>X'H9[IF_LX,EM_KJ'
MNE3+Y5R= 6"@>FUUWX@L[FWN0SYK6Q,214]E5YUFX\]C-3#BVR#,J*!E<@$2
M^>8OO_M&VU;.-^NF!X#XUV]A!R6(?-5=9^1JH"LS<_[J7VB,W55%*S[CP$WP
MS"FCQ%I@$X=D6FIVG=Q";N<TJ6I@S L) 3'5:-CNL8,XA=O$O/033SB%]@DN
M>A@S0 ?A B*;]GTY-=_R_USWCP)D#A',I!Z]HA[\GTA(<O,$$1H/WLV\XC%K
M6QI[3G*I*4N%.&D&M8'D])TK30UI/70_8D=RD5'L_%2!J1.]YQ4Q/K&YQ'^D
M 5CZ:>LIKS@?7;.I70N/!_\P>.CZHI$+($PU:[XE,:G1HS#6=M&BK$LRA@'!
M1D"8V,R^.7K\Z0S?U&,B1)HHDFG^!0X ENJX..3*E0;3$RGDZ1X4>$;.9)+9
M^?ON84?Y)MT[;<>>)D7[!9XFEGF'42-_K/SQ-)>?D<3"^R./3:]WN[G+Y7B'
M!1VZ'QLN[=49'+=6Q7DR.^6'_V))!Y^]/3>H?13\SZ"!>TZ+UK:.^,V=DR]&
M=3OK.,>MS\<)<I,J/O5<(1<E&\42A3;AFI1['\Q_J#<]J19=&.,U$H.Z'9MM
M_?Y0J@AQHIY)037]OG\#GNN[U3WN/RSPC<79V),OJP_+H[AOR,S&Y(DV5DZU
M?YQ>UX@S)CB/<HQRR$Z5DEP9CN)2&F1F"VO^PRN -V$0X).PA%K,Z19LK(>
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M#E!.SRT'JI1T-3@ Q3X)KAEI/7LBHIIMS$Y@VZP.?/-ENSPJ*_P/B+Z),9^
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MO4$5RXP+4-_GE0_(XB.=H_N7XC;"XQ6RN(Y>+U^@,##9;WG9K,!9DR*+QK%
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M@2"IS^N/6J>^\FWEY QO:4>]<NR?VAX0,CVQ(Y"GG1]8MA#E"PERR@4  *,
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MG!E%1B&-:F6;FTTYF0Z#ZY!%K<U+F4UF8<@7BCC@DTQ%E'\NK!1"ZDVR<6$
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M@K>(IZWO"2U>^>/]HJ9*@F,))J%'0%I>I,&)*E57TY[G"(/M=;T[1*V^_6#
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M;\";TQ1#I=+29I,WK&ZSOOK5+)DCO.):FS"<'5VX0YE\1\I<8W;\&1MCAE7
MP^0TQC*F+B]BRMUWNX95+EXI]MI_YQ?S@48N&2GM60X'!:^?J/H5HZGSJW5+
M^VA^Z]?'+.X (MPAFAQ\EW?7J /UC\,D7?RHQ7"$V6[!5328-VY_PI4,G@%N
M+K )LP<G?Y_3EZ?E5 V1G?YQ?,#T@:@\W3J8YN*%7\B\_L40JIZKF8Y>,_M\
M+\6N<8%WZ4IB1*/TCF.MA\NKB4CR.X@5H*.<3Z4J1VXL+%]^YAYD!DU5*W/"
MYNHCAQ'VE-.RE;67\NM<T;DO24\NY.D1"O]LU 9(ZV#BJ\ER")5$QUZF^EIB
M (\Y*8XDA5#@ Y/._V@/')(&8_-<R3L<4(8&W^[8DT;*)'D'[;A"]0,@HOY^
M^D#J6G;;8??#!JF#<MA7@N92F W ,MG./FZ8'<%E)D%#'+_OXQK'18\K0*MC
MUS]3C,!(I&%?AWU;AJ:D"E2'R^UU(29!D$!=V]AJZ,,'OQSZYQ([U]0-J=(R
M[%N<1L'XH=MY?99F4O5PC%^$KMV#+\:7]B&'W#ITSS,]WY4WF<]'/FP&GI[,
MD)\IHT3@J7YFRE7%#2^R$!E(A%=ZEH[![0<3#K>3C!%L2""+6F7!RFR./#Z-
M4B=,F6\]J3-URW5^.":C<1OS5YK-L/QR?M ]LL<:&)&)BG2=/?1>8F2WT95F
M',Q3LR2V7?-Y!3?*(+/97IRXY<44BSY^^"9^$SV9I]6NL;KQHO#C5Y^I.R2/
M_ ++/!.!5$!0=JVLL!#A7G:=6;7_\B_@P@LSG7.K65VJJJ!HM^,Y:=; 41>B
M>8"@"S'IP6V-90U:QPW-9UU*X\CNU,0\>%0Z;+'UGQ,DI'O#EGUZ1D[@S6X3
MB5EX+B R>/[@.D -VQ1^:XP@#8N_>=%GZ,P3GE5VWX;O)TV$_/!21SE>K2I8
MO+YR:Z+B"#?2U[6+A+-^YWY,FI'Z.6OD6S+.SVSW]= !N[3)X%/<-%>*8.6Z
MTZ2GLUQXKN90%58V!\.T2#5[!?,1QA^^DKSSC\Y21$]?BU,JKA/*0O=A\)R]
M<#8MO*/^_+Z/_.5<Q7=:89-&0*;(3;Q5>CO?(PC/'>EP85)"XOY[H%+@45=>
M.<S 3XU DTS[=E//S,NF.1J]2&$Y8 2]#F3"YI9=S.N7Q"WU#EVC=YH>K]9A
M/:K4^0'TMN',#6:S":)N$KJV^VTB\LD4:; X.$V3H+R,%-.%/KUZL\U-)W32
MK-#54P$[(0C$XD-ODA"-"=O^&Q+%=7C_^0;3R:N0Y?+H1KQ4Q7 "',X/AG_:
MO[;O[VGY*_27OM)1^".'$$'+>FTJ^!9-*8J+2%<3AJSK,>+ S2&C-]5?/[B2
MT]?;KS%?>C0F$C7"8?<%I[7 ]58R'(J-+YEC"5P$.C9NIGQ4?&&[QWMS,6(;
M8@EUP'L.[VG=4+:>6Z.XY%L#()XS#) 9.3S2E"$.# =--US=%M;QZ63Y59:K
MJ+"T+L+]6W/;Z9\;UZ9'SM]_ZL3OFM=WX>M*AU8R=QZ&;"-@=6Y5<#%S8VTQ
M*MTLK63KYXER0]#3I_H79?H00_9D55*N58FZ<B5)IE!_C;8+W-J/_P7\LY06
M]QGDN)4<$$ N+3 \B<.8A@,![:._,FJ!2S*<#0[MZN1I<QG-8,*S>/!5CD_C
M-H/SJ^'3P6_!"1][#',P(J!ZS:]_ ]NCON]398Y#-INN)>PT2O<K(>*P2HF[
MH>4IFNE^!1A:)H4K&CM7Z_VM,(16!K.'P,)3#C+23C/M3S'R1BI4,M$+Y>98
M!-*Z5HI^HDQZ=H>^Q+6KX,D(C8RUM#,0IS@B<WPA*OI?!YGQ0ZK\J6@>2KGP
M>7&9GAK#:=X^3%HUT#AVP' DEM(# QR/7=L5S#> !D\W#R#]@^1G%9"N\_P^
MKO&27HY<>?Q4)QNQ]8="]NEV[">M,W)= R_UF<Y3&-YAEE,?EBPIA6%]S?_
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M7F&Z=?;J5:$9>HEZ.AF+%F![Y/?R#A '^.WY;XD8$%U(5889QE*>[/QOT:=
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MNY_?XI!!DO?'H-&-0X8UU>V][:-X&[DIZ00_841R.<P+P=).J5YW[.JSDX&
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M(#&D.^$B991X$N#(>K3 N-/J 7E9:-<XOLL*@9E2FS;NW1J/8]TU4Q B$HE
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MLX>MSG78MK0E]&AGO=&/UE,)A[LKI3KX#F4+3+5?D\=C1)Z9RT3-DMOAJ62
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M\7-=)Z,K<:(3'=MX2PGV]J%SPS[:E#J>ERCUX0L18YMI!(WH6?NDB*345D=
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MOB[*+#8B5GST 9N4_?4!3S#[\"^9^MEZ-O#*5:^53;X:B@OCD.?6F R'I8J
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MUVTW?D5>&XO6[+[.)$J452\C.()+^!NC,L@9QSX.SR0*;=ZB\> )HN*[ .^
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M,;;)BMX$%F!?\&/#2CP"-#@\F\ O+8:X=WRT]\%K:-)]&;#=9?7P4$:&:_Y
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MR> D+S$LO,XH(@TR(=C2/#*5#^".E9\^9)$Q*/%UZ1B>?9WTJA9-(),UFYE
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M<L4'0)N0[@,(IDDNGJ@2RHP*MK[MC&. T 960'T*CCPQU3@:GH&I1TC>N?"
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M%F$Z0<^ 1<.$-4N;&_',RT< T:OD_E,EL1^2]LG?OZA88:'(;;VQ*]9ADFY
M =)$\9WT(Z.HU SQ3+\5AW X*,YM'6U"NG;S74H]BV61\,M%<+FF9M?W>&(9
MH5<,Y\=\ZX+ZB)])7"\]-<7I2[1Y;: GCO9#V ]5&^1F<;05!J&IR8D>#H"(
M+$V,L_6*H'[J&4? .9J&TV#AQ7.U1,F82PH#)#R46:7XHLN6SAH7T37/<U]>
MYR:CS&-\3]D<;6[;.["/%9+WL4,9:,Z'<.>DMH^:UHVV;I_-BI O*B3;:?8_
M ER&([I&7K?V1UX]1#[';R<4?:WV';8E+<Q?=717&K0U#(N%%-58# @\;*,1
MA'4Y]==-\S;!G ;5IF7K1&ET8Z2[[%/ZR1"C#56>^/MX#$:]?"NT=JN&2*EQ
M,1OHI%U#!+,?;-81S$X)][,M#2 >PBX+.PS6WV-F\G1'M*E\(&/=KU$_ A",
M=BD,]QX!MI.9#NO@BTS*KN_A!6C9!_E'@%4U3U+UA$2/9S[FTJ]?]]O#FI_Z
M]-QIEX[CNZ,1@DA+<'/%>\>36] A*_]V.SHKDSHD]@/V)@,']D#]$6"7[P@
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M1WU=':L5#.Y F'HY4B2=CB> I_//SI>N >TV-R)Q-?<L)/0RUB&7,'?/NF?
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M2%I$&K9OGV1>40'CQWB3\O-!";QPI@]8-GAL(3 I^<@>-_LI88^V3)^FQ$P
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M/U1NIAXJJ,CUUNO8!6T(K"?..]XA$U)@F7^D*Q3:4]$G=5G==1/G7>IY!9B
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MK$M>O10FNGYZ"XIESX?!Z*<ZR CH&F'\&Y]X\D;X?[362CCGARHKL[#1\LK
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ML]2_;LL):CDFI<!*$",TW72.\.&5/]S+(</IK" C)2^H-#"I&20*OPNUR"V
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M+3=!BV!4_'+K5Q0I*=\FO2-$7]3\Y*FP&HA-KUG$OVE\IOBAZUL%68>Y//<
M2CO[WU?+BXQ6W0ETXM($B"5@'+RF)B6]%B?LIU!Q7&"4W'*>J.F>]617$@6-
M;'&B#<YJ!4YD5B$+DKF+Q[G3'?^<2M7K*UE^E2"Q ;A,2T-M4H&MECQ&\;5F
M&1*\@EG_PIK1Z"H=/Z6K;.W,>V#>0!*H 8)&PFFR$'FN+V%^+I(A[:)_5.5B
M"3%>.S /.A7K"^(>'<LIT3VYP?,#JTR3HEM^RC*OV4E_T  URY&_F8L$$E8!
M0ZL\W?7,V]D/)U>T=K+S8N\HGIG!#7=?99(_VWG]L:OSN^4]P"^G:NHG$C6N
MV4V''YX(X\/G%Z@+! !5I(CU.=YW=V>[QC451WZI_R<_!DJ?/X<'C9QU%MC1
M1E>+V/7LN%PRIR_Q_LQ&S(H2GCE8TW>'/XMW,B#J8EG_550,S[*!.@\R4[O^
M>;5QCM&+W^<M(2R=TUZ1RF< N9*D0E@8"4!9JW ,N[P$\_+%;.8R_[]:T_[?
M(C\ORHUW*K_7(9Z<4V69>4-8/V/G#&(,K4+[8ENNUU=*W7F+S?0[@ZNSQ3$R
M'QW[$QHZJ8"+O6X-#E1UGJ*7,@KGRG[O9L!:Q6B;:,-'+>MVWVI]-V2;Z(=D
M%X16(^A\HF\2HY.$6'+.U+L+MW9T?)R7SH44I$H./*/ZS)P<V:[)US+664?U
MR%ZKQ.D\D?EMN/XJ$["GA;%3*<&@U?>^NPT'S&K3R/2,?.TB[=PORM)?GG;"
MBK"<47.6QNXJ1!,74DA_B!T\_UG<VM]*^.<&GXX]:\;2I9%A50U..Y$;%YZ5
M%/F:L'&FP"-0/TO+UYI4_YWU=CG?P0PX3/L".\:/-;V]KG8XW9/M^V@4/&)&
MXVE!3EC9@([2N_21*)-7BC%V\WD@@TM\*:T>]_H1?2:&$J16FYP<U23,*KC*
M+T,L;DR?^[O7MHL%,FZQ<)/<A/)5&SU>O%>9[,C N9U.<K6TQ74T,9L?^0:8
MME95J)E01"RJ:]"=OZ=_+F:D##HF[?!>F7+^O4(Z#+&?4)6J)5OX10-M0+B&
M]5*POF<[1QH6FN6CWC1@WL9J\M'_.-W4#A<'Y/(A+S;EFL_H;NNY0[@[X^I%
ML%J:QC%YN- 9CFOD'C-S3V1'WLB0:_0]P)6U"Z.EDJG-C@1&.*"CC.K&-J7>
M.#P7(/A992C8 ^9RUZ4;Q+0K^<7SB]#J:]3'.<(*=VCE^*G:/<#29GK7[.T?
M>\XYHY3RP6A?P205UBH1P=26\Q'MCGL 4^6412!%[J>H7XZ*JB"*7)BX<$SG
MHR5L1!5R-QFWB+YL4EN/E4Q+N95>A28W-QIW"\7[F\ KZBM+6YC)5P'0RTY/
M^QKDL27LJ]KDQZ&C^!UL\VB)8>#9'E[-\S13G>_>])U[T!W3@,@Z$M&2'.=&
MQ:DV66]HYNZ3L_WAT_D1HHS*-;/HI5FF[PM[52?VOK8=Y76)LHL'IR_L9T%#
M\AL=1]Y\&A^W^OV6<=V$C7J7R:C+K@3SI'P7M>9[7_,4+U95*^:%:@[HL9HG
MQKM\ ,P]\L7.&W!US()16+WQ")&0H/B4?;"<V/II3#*:%8G/40K=E#9#&>V>
MJ8!GKOJJS7E<2RJK?\D9]3[[@,0<OPG1LEB>!;574"2.G*7.?:AN& [8=55Q
M.K'VH+B.?Y3\W;_:0L];?PDMX")',3(FT[7)FEA-+";WEK@_[@D?3E-%%AU0
MT?_%-P24DZ-+(TL?] L)96*[R68K_SPB_5;")>^G;>,\5;CR0HF#N)O0U.Y6
M!:*VP>[7Q$G"8 VY/B[/Q2A<^\:H13[WXE"/'3U]UN=48GU>&""M>I<.OSC;
MKZS7KC[B4VA#7JQ8>P,A'NQTG^Z8LOB(*4XK[@$V),+2YFX\6/59[H'DGLK1
MON[4I_J8[3<\$DYI"YLB\P$[4>  AMS!:5Q3*L,;QJU=T&WR[P_ JD<83^0C
M;QX\R"GA7W=^RSJ+&^7P9I2TQ@LHOT8795GU@+D?_0*.!!!; CWL15U><<>T
M[+''"#S0D=1E^7QH7;#LSY8@XLKS=(IB3W8S>WW$GJL?3=&]-< 0=PPRT*0[
M-'K-B0Z2 &2,@C:U0JJ!R*B@KR>JJJ.M*K@BKESMW5/DI/-R0OCBQ?WS)75K
M1+Y(-'@QJC N7(^._3NN ,^V/_M&YJKG0/FUM&N\5B(!A,[A0XQ&^^4"A:_Q
MU,S2R-FF+=?V;1'MS_,^H*^(&]^EPI+[Y;\VY(E,KGG5V@=)1V?##B%[+@-J
M.L)1"W3M40[MWO#(NQ];V>3NK+N@QPSY'JXZ5V+DA4]<P5"VD%3CQA$'_VWA
MB<?EC@/E,R\"*1BT9A(2!3'33-?O 6\GRQJ3\2WQU%HB%!Y-M]_PK7M9_ JA
MSH$A0<Y<04F\>T>XGI0Y&>QO"AL&V'F(X..DJ2SY?V&"[(@4F?HO(4V!?CH"
MGK&]\W=!(^[7FFH:7=]U[9W:.W7&YFBC!&=XSJJJUPU.T/I^*UI_0T/#^;^8
M&:HN_::Z.;X';$_@8,X\];C16%SA\ZMM%>,ZN"NS"O\SZF=$+V8Y"<+ZY*9"
M6->$PPA+'ZHG#C,=]A8#JHW;$K;4ZWOLX9J7&S$B-5K9E>:="B#;#*YC=5XN
MPEO1[+BT18/L=W-I7/< .\[3:@.403IN5M@I5+X.S)PZW,/=)C-DBJH7#?^Y
MM+ [W49U-GH/,-!<9JN:6NRQTU.6AOIRLW]W82Y83R[..P26F?3*S-X"<:FH
M@[C)!LL;4YJS@GM<P[,J, ;H'T='_G4P6'7$BLK./S5(;1H-'/AXU5=B_MJU
M^&JT_Z S&C:4T:,N)C=J=)M7S*L]Q6+Z?6;EI:B-U6^K"XNQ+XZ/!W;X2WLN
MV?O=%'M\LUEV:T7DY*(-VL==][?&N&_>6Z!2O_R0'!//>NM**=O!BCC07VS@
MK9[ >OHYY=GG0[G=7N-AO#L%)__N7;XG;2?5MHZBGZ74 ";T.=!5,PF7YK\5
M'-H1OH/Z@ARO'<?E0._@Z4?\ELS85CR71,J.MRB?TE#/N?FX0R60#DCOQ-4N
M)6(>^/H%!RXNP^XJ5J#L,9TU^W<H4Z6Y\0%:Q(41EA8\\ R2#:/U=N'Z+>"[
M:*_E;[YXZT9%,&CDW*UD85 0R;H8'EG&M7,TGP;-SCY__(F:)7$F^BRW^(X;
M^RRAJM#$AG,&5GG13S7SD9ZOL8^RXA-Q843N4J# <FU;_Q 9PKN:]$)28EJ,
M^K7!= 9)O:X3NMIN-/E$$:D95K!)3^[J],55]FC^V@N0,_F"A BY2.Q15+YM
M6 (+?KG^W+)Z):ESZ!W&[YOS:B/'7S8[G)'0XN="]5O%,G0B/,YU#;\O*.C<
M-D<Z\L8WLA!%=W+67>UB"J@.Y<LA-C4WU[B,4]UAP_TZHNAH2S[*0(2-@E:G
M("L-15R*#)(Y1431 6/F<E,KC:C 7:7#Y^[:593!XO5 5@[DZH+@N)MG03FV
MMK;@U$ATK)^/S,FV>5**Q$MH ;/=2I(.1R'(:$OT)>_&4N!*RPIQHQ^I></D
M^XQ._Y!7/,;_)''RD C<?BE6X# U;1S3&9)P#NV2> C%#U,VE,0^^KT[P/%^
M<_=-9];D9_?NM+)PNEG-L6L4"F<I/W/+F/3 ?2T Y47_DD\FY"-?3B-/3WGQ
MEM#V;DIJ:UUW]R:"H)>7SM,S C/DLR@C>-XL#Q9 JHW@7IQ 4>1^J/72UV5:
MM752X4DA$N%;?P<I$^%?GU-"0-%&B%$.*,4W7MZF 3S;HP]/Z@C+2]5]ONP5
MBED)"8%9N%M>PDF.YG,@GDEXP4/B2(0;-O59VH.CYMGVC8ON^I4''7^?U%9_
MNB78=?R(I:]F?6JB<YT(B9-JAHBW9[(QC4M_4#6 [.2Q+]H@=7<+;5HKBCPV
M>$Q$)T1FZ6&]D'DJ(HQ7V'P67:4Q*V#D5.PM"6%'1/U*,1WIAPI@@UI4519*
MI0M;4#UQWN\5G!JX*K7D(+91+N@*<S!*;,:MZ6;DU?-!%M-X[2VAF;[3#VI:
MG0QAWQ"NW_+*V:PYK*_%U;V!2PN^-9*.E1,=>M*<XS"Z,K=9G^CN?(<GMI-K
MCK .0%8>E[9:C7QP4NLKP39[CM/]M:SFOMAP;SPU.4+:Y][]Q9$Y^_%/JOR[
MJ9&QA%@DD>7O\T)X3^)P:PJSXAZ)2!::85_Q_?SPO"3Q5=][#LK9%;$SN70M
M.Y=[P$FLL%3 .7&#"?\5<RVI^:,.RR_W@!OIHT!VKSL1Q#U@437#NLA("X9L
M:V=E%=NM"4LEDJ5*)!3A/YIF%V.\B=4![JTK659ISQ8M+(Z.2FWF0*]**#:/
MC1VJU+1;NVY8=CW6+$;/L5#/EIWN ;1O>E(I)2_8(-CH:FLCCO$TZ3JSR0AS
M.#M<-[MQ-G3G,_;A.^&US2?=)]_S%PAFZ<Y^_ 9NRZ_=99#Z#SQ%%A4QEYS$
M3>AH2BLI$:SY5#1RE;S)@0> ;-,D.O:AV>":N478<I84GMF4,6"AK1\ 56[B
M'RM<3)\J(2';)5$,WV0 /L[R]R(4M>S"BGN$HYC6AJARY1-.T%X_;_ ]_W[#
MGS("E%C)]W SV%QX]=9^1MPL#5N BD2M_!"Z%8HLO7Q<2A7(;'_Z/>^56%M8
M"H</XL2,'"?-3YQH+'*5SR=FHF9(;[E/]F]O:#K%<APM-'.M\1%_]NI*T>![
M= 6KNT;4VM0J_NA 987L>B8%QXH'=5.FVWS8@X46WX@L&<2),;N1JC'F@!$W
M!Q^K*3(5>2(5\$%'+S%&1ERJ]F&-59AV.NW?E>-T*B#MIM\36WUVPT'BJ#MP
M/$\959,L J6/(_VJ<"_!47WL$788:YL$8]F;G"N\HJ$+=]EW$(B 4P<%9P D
MO@>+:)<BT%*D_08T9G_5EK]9QEMM:U[C_9A8SJ:7$P4=>X]^%AP%]YR9PIQ]
MRHE+9^^);80?(U'6R9WFPEB2GUT^1UM0E$<1]ZA+YBQRVP<!B*T0BE:M.8^H
M;N[[^$]X]^!@-BR2%TL68K9G;Q(8Y9QS&JY5#&QVRS1;R:H:93<W%S R)/X*
M8 ,4W'HQ4"LWL*7P@F3.*JW!\/4"YO*9)\W!Z;?Z#/XTKLB;Q:&2V]"WL#VZ
MI5J<=N)"[TIIGY5_' SM>X=:9F]Q,6<$XG0<M@!>FYBU,<W-#>]66$U>C+3>
MGDUP-K0COHX_<4&-M*GQ4F9Y09L:7%6HXL=6"OHB@;P.U=)T-G_#W;NL7Y;)
M#O]%X=D)@_KM'H>8+FG3^#7@6!1>JH@X3=E*(TS]#Q2^X%W7U-3S:9AW;"ZE
M4M=K#(,XVBTU)E:@PT 5IVDMT9$J1TEH*T=9Y]3>BX:NI^G9RNQ30HQ#4J[7
M*H6SWBKEB$7@[_I,V+BXODKL.N95F(29C@E[/+&:.Z(D&#ZC.RVRI-$[KP.)
M/SV=,G1"WU;2U5Z?1I4GQ/OL17=\HB;!^VO+QO39? K+279X8\$6UT5VBKJ]
M:,@2"=4ZT-6HT)&ZS"WX+CN_0[]MMC/SK,3A)9>08([Y>? 3:<X@^IUPT)^N
M?T,(;#QNW3FK>EC!R+DP&!9%TW^9ZP$1OY8_7@/&43Z9%7#KP.'_!D[J>4'R
M)+*5^\V2"M<)NKELBX_O24U.\DXUB3WWDFXU@RU/?+RK<MW'MR%=47)?/.QG
M# 4C]/](+$A6A)>SZTT*N]9+.^36!4\J"OX,]S#_TB^B-S@R=&YG<XS'9.;1
M=+8 1B ")K1>.2MC!6E^7V6$*U]M9V*[-)58ZK2E#FKQEIS[E"-K-6L*J: U
M-?S8T:?U/<^%VZ\\C+KF@2'29"_YC'VK?(RNKS++4]M?J$WJ%U5RCN/5C@FW
MQ9DRBA_QD7_H"\46=V-5"SZT(NX!6\O6:Z@;LM)S@239,ON:G2>#CAT!V^MK
M-1]4<_*L<-\'5\#?5AD44@(^ 7WXW:ZU$Z>O8&D'/RCB6PD3VV*.C_#L+DJ/
MI>0</)M%S(MA<8N.$XIL+Y4HW_5P_P3OK!_Q'.$O@NW9^5F$FY#PYFG5WA2A
MX.,.5KRVP*RM4OXH@O5DH-O>!&\748NV-ZIE+!+Y2&[,Z,S!,,]@LG6/:" $
M1[!S(Z=3ZO,(MQ&O6$BSD4C'NO@IU:MH%8XYWAS2#\K-/9&?2-!5V# O+RL/
MY9/8!1S\X[37_M-K,[UX1/H,DUNLC?(]*R+SYXT;/]8\)4&S#1>W<@P.3YUE
M?V+5EU5HE,K(=V5L@(UN\)(K#S+(O)]2JP>[GD(B5$Z^$L!))U*Q@2YIZMQ]
M$AI%W[FB"WN>FJ61?ZBAOP?,/9^NF +;:=6R3)(H&3DF]?%*(3GI*LVP>R(!
M -&QV01E,S6AVIFVM_DAQ9I5[/A0V V37NFHR@;+1C<GCS:.XCE%?#/P@V09
MA<NL%V_D&WM&<8S9^-<P)["=6-4\'6\<%Y&1(JU7*^GDS(N 0?<FW:?7@<TV
M!8M% 0=:DI3#C>"1[N&UAEWLGZK]..0%=O/+L!6U)PN(R!?F%%-9OZC4"?R%
M,SE$K:ZLGC+M$0^KHSWN >W/]9][%&Q.8TG'=@Y/UJ;&=HF[;\F7U=7[)Y(M
M#IQM*B[U)OT]6'3<0S4&\[;M<"S,9MZ(W@-D$33W )*@:ZZ2\RHC^H0TZA8^
M L.-KQH$8KP551D;T]>Q>A^PJKML%[6^<K5\+PR=Z+T'\",_&E5NN8I?!X8Z
M^A5/7;3 /Q/"]?%?SS)GW23UL*_A4G'1B:7DW0 ?A%Y+[(WWN[9]J*ED56R4
MR"ZP?6O!AG*T@J-L3-W#WG%W(-^@]!;E]Q4_K^#@'F#=-R>COP_-:5 '$3VV
M;5F9&B8[V.^VRWFU(K[@6S)HT[ER\_E/<A1LB#=YJ+!NXH][]T\HLZV]XV8M
M8)=_!+TCOZC;:\]I"4UE\%&TYXY2I(WAP>!5DEO#5MGKY$]8T)$ZF49)D.5D
MUQ\HA/)%^#+85M?97>5\I$TMRHR)F3LYI@!/7;7Y\O$%C3#]% QVT?O4$.&+
M1^??V-A)?[CQ=U8$.I:!RCLIGJ6B;5RX/42E&2/:* WAS_+32[D=O#< JY,A
M_IK2GKL:UK7P-Z++>YI_FJIC\3T) VBP! B,2F)+.6-.=(!E&'8YF&5A&>-$
M6KMJUYI]-\Y4V\[5)2T7;IS7;_W5GX=$D#VM.L2;$!DCJI_?J7K]7A 1G-@>
M5MG]%R>,+AY6#F\2C,\+,51L/SJ_3HC2D-,?:7&"T[Q. 9Y@T,Q<OLPK_'86
M6S:F;\/56-&%PURZBY3&YJ&+'Y1U"7!OB-$KN1(&]1#Y*%"\#3OL[6SF#T3Q
MMIG^/L=BX9NSRZKQ5D>RNM&_+A<=-G=U+.-J;+=.QX-+&(?#Q#8UQ6+52(A\
M\ M^Y@<*KN3YE-='IHBXR,A2"SC\ZG*+L*A0U2L>GLEGGNIE2N[IEKF\56@1
M@*_ 5TK"OZ]-8TTB/>S./- :,;/\0%S!'?Q5^0?H3<]FB ;52V@>O)P^<2 6
MB%"!4,+T/?MI(J\B_4/WM*/_1CF6=E#\YA*R%:.R:(:#5-3H^D_=5*B(I :W
MUC,N\:D?Q?U?L/3YOT BG"BPJ]?=20SL!US>M VIJ%&AOMUECWM%BPU+^9,)
M[K%+ Q&;=GD]!9\P8G34)_C(^K!-Z>B'&8U-%_*0%6J//6.&+>I+7NUJ2!!S
M6Z8Y:\DMUWC5FXE,_5X(^!+U-?$5JB)1CVW<8U(,MZ)+=E)CM-W@Q8>9-9&K
MAG'X@ZG/#\Q97.-,T/.(C5VPAVT]&3%Y0[E(9,6]V29'ET>]ME_*<,S=^;XO
M@\A6CQ>)%M]B%7"UC9*?UQGGG?W=L$4P'[6+JJ@E?*S5 :>:YT09B&J%:4E+
M_D#KDU/0-3\S&#\ZAAA0#@)E0IVP%<RB)IQHMZX\'":WE:*(11#P7V2-G@S6
MPNR1Z?IS9PSM&V^";-JE'NM8N#?^.4]9/L>TK$WE38$.SI@YCJW'5%7'405)
M)M91<4_H,WV9@P7*1"&_R;80#( %6D7!UM5HFKS\[Y)J,E?']>A><N4V'OP_
M8^OCK/4$.E7<EC41JQ/'>@;NU3KU"00@H#=6O .;M0\H0[PRZ26.KXHRDE2
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ML0,740M-P3?5:\YU86T[X7G,-6M3%DH,''(OV*,0"?MOF4]XQ)TP?47?(*<
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MLYSJ&,,O+->>5&)L,@33U?-)CO3'U,7-W3E>R%WKU!Y$['CR,8 ;.TJT-6I
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M^I0E%!1EX9&:R>&6:YTGJ[W>KRPZ.UO= Q@W &P?S-J7&28VZMJZY^L3KB^
MC?"]@C5:YR0?4+^/MQ=T.LZG^(+0KD6ANU:;9R9YP,'3V2>\TB5H&4M]WE/2
MA8%?R"MS1/,..K_/AQ&^.:YY<FJP<P)>/Z81WV:!E_Y0R[6O[>J4#&?P\[>;
M0)<1W.X5\2?^&;^(!1Z]7;IL5PX-8%&NP];':J)@O+V!8BO39]RYJI),SOEG
MCI%C:4/OZ]HF??9=GGKKM_?621UIGW7??=^4NP:6]1BJ8!K?P?J5VPPR^Z1;
MC?L;<BAX1WL^]VW +:H&G3>C2_&:CCIJ2N"U9F7S.0XNU?W$M<"/Q.JET:-
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M]%WY0^7W]:[^J*F C0[;]WAV()4Y6)4C4M2T"?>&$UW,_<%9[+7I&3VU=D7
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MSS1HX++\9?M[IC>AS)E*05J%(:M%LZ9(9I<-P<>0?C!#D5C.N>C ^H7X=Z_
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M2S^TO\>2*<34;53QA1<JKYVESJ8'7-..C.CG6L7=+ELT2J[?'Y'79G!0$S[
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MKCEJ_<1\]FP!L7. N@'8:X2W?6MM[4N5/Q(+R</> !2^L@N3-TA&+#I.M[.
M_*ON]%&][Y4'ZGI\W(3UFA>$FWQ8;)YQ2W%;3@ ?[J5D&:;_[_NCU__,4"#R
M.#LDM%XZ.R%C(TY*B^(&P.K#SY-2<ZCYV6^%+SC_7>14C$XJ3%J#QCJS*#O4
M'<H#%Q9I+#9LI!<YAR_1SQE3GEMZ>$?V=0YJ"+?Q1$7< *)RHXX-/5?<;I6Y
M@92"L<JADF#W;K;4\\_+#$00F6N*2!=#'W$QS4V <,WF"7L.RWS'ZUB]Y[58
M5AR;R8/?0./]3\)0EP@"8LC9X=Q%(;L)04FO%0:^J&2=./Y![L7OO5H<WD5
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M9=G.56^%S=MMX2Y-K!*$!L>M*F!'],;+29K71!]^LG_,L*N91"[0TI'K@*@
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MLJ)+P_>XS+TAX["M9$'70R;*-S[3NM;/GUD N1OCAEY?BL2,\C<LB4G'\Z6
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M$1#"Z*-(^_BLY1TG</I/_^J"*IK9H"Q>R+[7X)IBV[G/9/A;!6+EQ*7S=IM
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MIQPCX,J-X2;EM[P\R$'"*(P<5I!RW:'T D(Q+ZW]@+UR\2\:;<WL)GS"01<
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M!-/_53?&H]$U&:HH1PSKYD=FH5P!<V<DFN.L&YK=>@;L_A)TOI7]T]#"V#B
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M245?$HD0<*M)HU!' _A]RX@(T'MWI-1YU*9,W*C7*0<L$P6^E3Z:67],#>)
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MFN.Q$XN4RM3X<#ZUSY_(^OW\U1&/YCS#;I<$YTN@= _L9/J"G0!S0> X,0Z
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M1?:WQ:_[;6P+!^HX9A$]1I+;(-_]@B"G"UM-[?)(7'ISU_8;<_.*P&?NP8+
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M->QOU@F%R^"[S'LLUM]IWRTPDC.&0[^W-"J+OLPC9&9\)$Z:.V/QW.?:V]8
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MOT1,HA1L;D/]+-6?;SB3=&U9HP+6=S3SX_IL,KG0Q&S,59,G*+W.OOUB0E'
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MY:$Z%!,G3S>N\Y)7WVR,=$1KLFT\J==GQ4_H7U61OY5OT.K4[#L;7@A*OZX
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MF*IVD[#I1SP-J%#%&D.K3'^$60RZ?"^?))4I6K/NJ$D-8'_IX$)'RY!0C^4
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M'CFODT4KGD=&0. @+ZS09R2"S$?.7.?ND*5R-O;C8<3"*U&24YFZLCE&FZ3
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MD__CM_[PR?3VW\;1N=LM]'08_?\92LT_'CB@EF %?20K$JK+U]YO*5_!JR-
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M3 ".UR3-.C6456@G.D54VXF<Y.$B KV']DK(U;/1!C6BU=5CT2,@$@QP&@1
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MX,;OT'187E(,_<9>-ZUGS6]T:CS&EI*\_T%@RGP2]:PX:@O?CU[+X#F,5B3
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M- @G?%RN-+D2:X!5=?NI:L^*#G98OVV"G(NEL>DZP!X\(Q$:.1'P*=(3E4_
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M4:C<EG^@9'.(I*-Y6>(F5+XWI6PQTW%.D%Y6$3?=]- O\Z0WV-IEDVQ#3B;
MJ @<G5:UH,@)AD%H"Z-1.IBD)-(-MC=/Q>;VBE'#/F"BP#JH AZN5DET_N#
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MHHOI K@'_46S%6@E-E0M126G1-$22_$>WB6'5Y@'Y!U)4NG_Z@>8F/.2N6E
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M\^5+!IV[<R(AP=5",?0!^Y_Y(#AB0_@D/MG_C<N)N31T-/(OEFK><FP))EK
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MPKJAP!D:HL'JTO6?E^Q7O"2]RQJTXHDM9=OA,U@%4.7)I;]Z^LQC3.BK!!D
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M-#7:CIDBLN?0( JB,J=KSBR\H6P^E</+^]:6IH*L4\83$0Y<3W@R!S;85,^
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M5BS'.LT.=;PE:2SJP3)344,KH/26HR?(0F;!]IHHZ+KP!Z-.)A=!D&PR=0
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MMJ=% Q9"X5D-\?;E9H2:?MK:R36/)\%[G#8&^@0++"6'W]'TK=FCV=##J_.
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M/1;BTGW>#]E](E=R@WG[ 2!]F90!\24P>W7LX[OLO\,D"[-O=(;>_BC1M<#
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MG6X=<FE&5D(2'*>8V,-O>+&J'?\.6O_7]9.+\$"MDRJ_ T7^N5,#U8O1YF8
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M*]RP1[HA]'*(53*:C^;D30'R2\]DV3;U=WP?5=J&/!\QBN:CUQ#GR(DD>Q%
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M9T9EJ+H6S"$6UK5,[=S1CF*QZ\]OD;NV>7\0JOO_W6$Y;T\AXE-%\;.Q8K-
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M2>.%E.C/7]"R\WG%6Y1=UXD6UZ\RN-M1+TY^#"8;&AM.&[4KZ0+L=/M9T)\
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MRA[@O=MHXRL['_)=W)R)I5@<A_Y1U8KYI2A<[3EZCMD>*Z[M-^ TP^!;^+Q
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MWF1<A4MM&Y[^Q?(<?ID2L.D4.,R?5+[T*\?.;-;1]K/@)DMF4H4[!+NZ2O4
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MOIZCE1Z;5?#.SK[.\<TMQ'@3.GM,E]Z^ K)AW ^5J?_@#'F7 3QW"\C-+3M
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M@Z1IWGQ#;[FFS22A7M(^*&KTB%P]7M:H'*O4UMZ<.2ZZ]GP?_B-)PQ5["S%
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M,%&W>.O".>SGU4-AGIO4$HU?AG1PK.FRT]<(5&5!D3ZF)1!76#-*CE5_(A5
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M9-*<+WW<J4^"BU1CTI($U1W1.C3=7%?&S9B[ Y\!1(ZOO =MST&I_+"&_OR
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M0D'D3_K(^ R :">%LV=%+^3!9C9."C?*?+_+W\J.^0T\ _;-NX^!, S'IV>
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M5 GDJ*7.)_'HC_3*&*,%.TR=MK0-&0=UW>->J+W?".+%$*8X#5G]<7ZP^J3
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M\$_'KK"E&:QPD<=TYJ<M+,F\759<-5/PI,_QM-S_B:E*%TAVM2+4,BPM2_>
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M31RZ>RRTHW#MWCQZ8OCU<Q^Z4G@[**O[5CLQO2Z GEL-L7U,I8^%EL[S?7@
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MH)B[.J->9:%SG!)II]+A48/,QCHLG.;=)=FT7+QU+GZ: I?RKJ1/@#6.R"=
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M)NQ$R3D #AMO.MIYFJOTJRBC,)V9C,]BOZF%?2W44/UJ,$950#\5@.(6HYA
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M %C['N*3^RSE7KBS_$39F;@L<DQ8Y.DKN6U77R0QZ.]L_,QT#]7\N1$FN-[
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M0WBQ8\WA+(+3=K5'3=96R0HC7Q<BP$2QXPH_G2[=_%J_&W-[B+"*=Y=&2@6
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MO<H4.FOFEMUW2N&!1_0N(<J?A-_)$,, /2UXM/?)YMW<7:)33?R*X\1MPDK
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M-6V_J?UH_^KHU05[H$7#O;=*_TV?\H%:*&7Q-8H%,_).5*.P8LL[D<+VZ2.
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M#+'0L(]O-RG7/: DI_@9H;2>"R97AHI^8SLU;'1A7[7&I77LX6JB:9)*#TS
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M:1S\.N&WT\(S1@'0O,OI?E]>V'P@Q3G5782=)JK,(-2ZJ%-:)K]L-\(O@H7
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M\250+@(=B- 6B8EXCI$*_>QO;$1%G3$+ OS_ '[F!7=J2+!TM-"OHY-IU61
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MK4E]-Z^:W=/>4-7;?IN38\9ESP/D(_8(S+/.1EF\U@JEY1&X]<S.]&O6G=X
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M02^(C%COB%C%OXF*@X8-]L@/^5: ,<!Z UON,67L5J1.I>D?<].HY]X-AP,
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M4CS-Q3JS=[".SO3_JOGJIDVY89&41L5KKHU;B3G9PE\_,&&/S(_2*A<XW(6
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MZS^="I,J@_59*URM+,.Z%DSP.^X^._Y>1XHZ\O^:Q? DW5+7GTH[E18\"WH
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MY"Y^.6A&\0;4UE/9NG3G-RMW]+YZJQDXQ$W!MG@]#RF!Z>=#.>/%.CT[MQX
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MJ,Q/"/U73'0 B0^L_;$"AA8>G#-_;/^P-:T[&=@A=H'JA@QED9]/:>H:OA[
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M2RT:-(V[700K?GZW^D%)2<EG(FAZQ#=O]#@XJ..=*?/Q;5*5$6V2PZJ!6(9
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M/2I2"-27$'VI"R6L]MCV&"KW<[.!4QN%[*R#LH:W!<HLMB2_)=,%J21G2*2
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M\NU,A7V(B 47/^1]!XKC/C@LLO1-B;FK_5@'V1][4&MU;RNINIZGAC*^D?.
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M!):'!=SVR#?,I"Z7+VH5)DT9Z9'GT;VL:)![-@IV><6\Q7A H(915C!+99K
M\JCJ)-(QSFBI2ZLLRM4$C<^$"_6X/0"(%Q0D+R[:6(=082>9>T9&OIV5ON3^
MJIQ7#A/B9YHJ.\ML<Y+<Y0P[P>M_U_9R&_3&#H ^-:AU0Z[.0=H%9[%F0?%K
MRXSRY1!4)NI,FO.7S4'S"?$#(+I'WM(Z]XW(6>/=>XF%'8(X0'D 5XHQ,MUP
M\"0U28O0'TF5'S1L\?SY[TYOV'E Y>G3\M59"I/>?43L<10#O9SHDV9GO>O!
M-H2WC>@U9A.90?EFGON&I$;0'E)KR@X^CXUDG9W6/$^9"%,HY%V!*S)59$M9
M<$Q^:GX F#FBG"J^ZT<++H;MN529.?A/^AA]6^;A:$Q=MI@+T&?X2J+JCN?I
M;'I[.\JIL4[Y!U9/W>L_K+ZNI?@[->6)!) U;D?!-(MDS"YJ5\9QOB%WS3V!
MV/J57^+Y6"D\OTTZABA!%6<X@7[G;T0FZW?3?1&3JFJ2P<*6-;[@A3E0J>R?
MS+#W^/5H?P&,;$:QJ458:JQ=DT[3<=@]Y22_R\S=\#]%3K.Q7.T^\./]([IY
MSD*0'Z]KL!G"TV(*KC/2F42@H^3P]PX_3PO4OF_X3\2SU1$%](5T9^PI5:_I
MO!"VQ -NDXYQDPOL%X-LZG6-::2BNUK@'>6P$%^"-J>0J;<E4#NQS</E=]]Y
M40,E'.RE78:]_5M5"J3+NLTX14*VE3NUC5?$%<);;"8)$]LBSZZP5/=;>@,:
MQ?F @Y%G]-H@'QJFH4\\M>C/9T#Q"L>Z6;C0);LGSYK):%2PKMC28[LV4R-R
M?C4B7$$]G.%CL0#%\0M&IX10H3T(3+F &.*?Q@YCXABNQ3N?DC+B3:(?D*A3
MO$##B<:(^%2B>%>M>R_(N5XF7XIZ[5K$%,2W'-AM$*0L6UU<AR\6"7]#1T8[
M!ANGIK(;#:6@?GYAJ(3-[_!O_W,]=M@J4/8\<^25@!SGI+3&"Y#I ),SZ.<J
MU02N.Y[5AM!0C>F0QUV^GM*6\>*<-P+S^81W\58LX I3Y*;S-S*^:#7CBK5W
MM=64SVA#Z#;58UH&R+\,E.#EPNA3B9[O/,&EOSE=_6<M>_/MOC!%;Z_2AH4E
MEG>^=\,/@&\*(Q5I"T_.9B<HO[#SD:WV'+'WE;B(A_/WLQVYGSPMQF-18-8>
M<<(0L&9]?(+SPQT]XNF$OQZOO24R0ZSCDEF'#-.WF,I_\TXZOF 8:A/N$C*.
M2^D0MIK2Y.)7RE[3(V\>V2?&UJP@9:,'/UZO8#QVTRR-$6K%8.W][+-/UMQ,
M.;DW_?S:8399KX5^^>ME"K-&4)[P\4FIK]"<"XR$?"S]>U<T\ #PVCVY-TMV
M"1Y9O;1VZ>=K7A@Q'K29-$"\(N?]_DT\V)2$E_D("VOG>.)=1-7GV"A%)1PN
M+>=;5KW0LB]9I\0TQ-_VHHL*'? )NQ8P.N0MH^R^6D3%BV&1N-UTZSN*]E4A
M/[V&Q?RFR[X$>JNUT^"&8"-;XS4:EZ7-$D_DP=RQC,('24N U%8DVS?-X35J
M;^HU>90X4>#CC!V\HH&-A%">^A5G\"#BPN$JK,<,5%8.D78EOKP$5>ZN&,T#
M/\W)^K#)-)2FRP2M?_R-M=7557];5%!HC_[.B'MQ R Y)Q'@+DI,Z*"=$$L5
MH::;PCZ>^RS);SXCTBJD3HXL^(%V>!JD\^GJW-X)UR5ALS4\()LAJH^5!FM.
MOB9NDV;Y\[.4WTH':_'*'5:YTY%1^2=A!NH,>LO'6"NNH*?RA$OBTY;C[9YY
ML*#[5,E":'UDRB%G!YUSL+8ZK3^]T0?U-VW".R+_N\&"@';1IA$-.R IRQQ2
MJ7B> SADX\*T]PH;(Y;[I*>?B[XNVFD^@S:,](!3KR0P7)E=41@LD0 +D,7(
M?J.8Z711W;F<+OMJ?!9V!DZ.1-*?L ]91+$F,/9"K7HHF[4%O4O>S %<<>;@
M*](G=&DTS&9O2VC#D!?=:NR+SAR0+>1(['PNJ-0ZUY.YNM_]^,S;<[;)CWGG
MW."<RD;GFXWN=U[?\M&+F.FVKH;)18?4,[7EK&A[CQ;/XY@_HF(+A/[DY&NF
M#97=G,$8HE/46*1^P95M7=!?VL3W!^T'RVF@IGT @6H&,@W#0TLS -9Y9^8H
M!%;:U&1CMS]\?EU1Y/RGL&E_?H=@AN$H1]H_-^<Z10\^Z[P\$6N)'BP%ZUQF
M,W-Y<\8T3R;WOVIQ/:W^<'4PS67[G/>N_LGO.FL*6N2-L<1)W,R4,;NX[C#M
MD_E]@>/XZ1=H\QB&<\,89_8;G1CS^K2>EDI1!(S^.2^'HH483C&NSVVQ^BL7
ML>'Z8="SGCT@M*)5N-6GU]_+ CCDUS'N/#=Q[=Z*8.TQI36N-*5? I6EJ![6
MT3\67%5T2NNQ.DD&&$]4A+;OW)ROF&DBRX@/-/R[.),-9WL74A<^;<?)/[9S
M37TRSGQ^-\OSHF+&JY? JQF31HC8?4T2K3*Y]6*8X//CBPL3\=?W9;QF&SM2
MORC:8J5JZ93_F+2=4$>$K]<OOUO9=Q,R? I67@*]?J&P]D2F41T"L^ZM^&[0
M^L*[7JX[BNN7P9[UL9Q[X^BT[?1!7[T_J:!0^:[#.VZ>UHX@@]W_B[2WC(KR
MB]^]1T%1&A40A@$44+J''@21<J2[6V* H3L4E&80) =IJ0&&'AJ4[H:AN[L[
M'G__<]9ZSO.\/6_NMSO6WM?UN;Y[KWLSM3BQAC!OOFS1>D$7YH&SC>>&[3.9
MVTMH%/<%VI?K&-FU6Z-:*UW'GE7V,S[D!QP_Z$B?ZP+2OVY@?,)@EB>MYMC"
M43VI^"["+"YZ>D\PR8=![Q5 [?V31].0*,.[2)'M;,JF)8X.=@W!0K-0=ZKB
M$T?J8(&<I2XSU"J0@WT^M1:G[Q[ +YNNHES3J.;1*20:91G/BD**]/CL(,M2
M4RUYA27\&2.=)2^2>\=30#>,^6?^R7]ABV!#!4G.2 V@@8P[MC46,%#O#+\=
M#O ("VI<T=K!":R>?5F<ZH,Z9]!FA>7PBCR[!X3$&"J-$9MYG8"PW;^(16!J
MVWE"V8Y^RNT> 9Z<=MQ=],!5]KE+^<W1M)(S2=_764P#:*IWY9%S%U.A+%S\
M12^.%3X= []%1J<]AWI%5OXY.64K#Q+2E/0.INW=K_'%SM%VKK_@:6A^^QZO
MN8/6OO[/PV5TG>CD5L"^])H8:V942"56_OC7VJ9E/:;H4!(65*'*2Q$)BQ6R
M[O &B=Q W(I20<HKU=F-U[1Z;I10" N?LJ8\B\\:*8W!P#E 5FU]]3<%-9?P
MDD)"F&UA)^]./VI XG(61(0.JZFX U+[E5?-7-I&ICQOL.+XAU%E^#?PT/Z_
MV\7KKRHUU:B37<UC0BTBOLA']N/N9QE</:">^V& *EHB(>5R^$QJ,L&$2:V]
MN?#Q7,MWR\PQ.06"7+,:+A'?4MCDU7RD6GE[M$B)75O.1C0U%119MIDMZ3TB
M <3)#&8*E@H!!+*^Z2UU\QY-P8-='@VJVEP"G7BA:N1O^<PC VOPI*K0*>@K
M384Z_JH9#Z^;VN@8^??=+&P@4JS0P=32F9<MQ8\"2L=&F\>U@2&)"OU8PC]M
MC%^_']:391U4"YHUF:Z^[N/09,,^8EMI+3!/+Y>2A;B\'MU_]-.IXQ5//:Q
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MWU1>8)S/I5W8HH=@+0P,I9(WW!238K?G!7ABW-Y1/-GR/A\FB*-,J-9!K-)
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MB^PTB,NDP^G4G^[CK9OPR4;]H)A,&X*\&.8W,?&R,GH,GV'ZNI(3Q+@@GY.
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MGRF[*$ DS!JIPZA:(5QLO?<$TLS0+\R4B:F:["&HU3-Q.9I, \&6<;PC*/%
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MHJ\;R</I\^DR64C)HD)NR\M:5D,7]U)C\*N2+/Q_0CTQ<PU=(/)M!5AZ-H;
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MO"Y/MY0,OX!UA>/Z!UIM21C+EJITH9'.^033-,^<00$T@W[#@^*G3;=1)?>
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MNY;:GS0LM%$B'J,^9#V)MVQAG!OZX(@<&RCSLD%I>COH03B;HO>,G/?SG?R
M77W\UZW?VT0I!2:ZNB!T@Y"::!V'+%JCDU'K'G9>JWL\KTQE2E@EOMK!@?\0
MMY]28VUNG98H\8:'&36A?3.:I)QU7O"&PK"("*$,!W[ F);3068,!<B/_ZXL
M5<N;#7&IQ./88EC#'&&7RC/Q#%A@(EGFXCV@DO9NP7TW 0# ]?#PY!WPXU*V
M,Y3+D);EQ&Z]G;RU?V(N;O'%<M@SK*TMFRJ[[X8X4+OEX9_/5HXBLC@D;BV/
M'^DE;WPLAXK7^=X<N6L,A6=!T_;IU%2U./LPD@1UE%57<@)6LBWWA _*%0 =
MTUNQR"6)9E5-(&,^)TQ5I2Z4T7]E_-MK$>7=E7%%PK(.9(RJH^"NW$]$]W5B
MPYOA(,N4SWU\B"F%:,D*;@\0',A@3K#G+%]VA<UK+ODC)V37O9>;P$G@+'!L
M[/LVOG0K2*VL"#5ISOD>JOA32S=CN H-"MZD(A_=PY0>!V9MZ-%"9I#>;*,U
M+67 O4N_^D'WW%+3&)@TO%\.R^A<2$:J=S/8E;;J?">P-BPA5O/^\\D94S!Z
MWWOO-%H3&W:'IZ0@MQ(TQ2"M9?>R".0;9?DA9GTN&6YEYS898G3_(0 <B;/)
M>$>KD*9M/%BM4)&6+U$?(\BQ<<MV!/<9 SP._2H:V[,4R=RKP'>.#,8(C'[5
MR6ZZXW(KT_!889"H?JB%OID>&3DDI<%?3;H(I"=:'K/274:WUF_9FFILOWQ'
MQ'6&P6(=LD28UX!T^=P1G,6_X?K):UH]LVGGP%>+<S4&DVHUQE%T7P+3ILDL
M:U!\I\?8=:BD,T[$Y89,,D3Y/4%E1 K_>/5'W4551JN\U'J"LR;;W,.7ECT3
M(7AGQ_":R/[OZQ4+*ZS$9<L! 4$C)\45N6"9&=E1BWTC;GSAOOJ.T'?"A!^?
M 1_U#_!Q"J"40G[+)@?)N!<BQ4\H8G?5BE6BI,N.693(IK9$%]6&S;U F4_Z
M1P&ROTS^W$AWE,G-/LQ.SO0D"P7B(8C34MKL7\!:/'V:*_S"34V"?W^422Y6
MYL8?H0L,FI,]O/ 1>^"M%#FY@ECY_5AZLN*C?@.?YK-]@'.]V7B85)\<#W%4
MROJ[I41E?@0,4_@>,>=&'4'>[.M7S $H758=]PKTF1 ]U5^9+L$&V<HZ"H9:
MW#^EM]\8>]L868>AK$\I7>X%8'</9=%-&/%:5)>A\;&6]*Q+L<0WB2I]EW.N
M.ZZH 35ZL_>=#;$QK=9@!<?!I;"'DI,\/9G 1O2H&5#D/,U_=Q642/]CZ)PP
M_L+)XFA:1Y_!MEK-3G\8XQ5('$DF5JPW/[$0=](:,L,_T[?K.P!E;3&%2SX#
M+$I,7 86JSQ(SW:$0\0!*,#/?T3 +8ER7LR<\1L>E$,YZ$ FNQJ,Y-9]2AXH
MX/'(XWZH54-2IV<IGV0(J@4E6SH\55M:79]99&-U"QJO\4C3Y5O*RN1I=Z5\
M0?8D4)V0H80(<B7!;AIT.*'8>C276I?F]C4D[\S0\ME^9&(1&P _-2<-$R.0
M5XW<@:SKE)-)#1NR*[I,@A]B4<5\6VGP/;/9'D$N1 N((*UIQZS%%*Z\!+W=
MBK[84_QC@J:;3/'9^M-H,77U1S4*\\?Z&ZT'3^7#+U!7O=- U%8D#_\EG+2R
M*+]-Q]QEXGY &+S*N)_C1823!IO_$CI.M?N]8IT8LQ2B/?\N;G.K'4R.0W%R
M0,BQ,6T3_\N#P4ORIS^4G#+42Y99P[OK3#]@H^<^<Z5ASOK E2VKK<^ G&VE
M6YAS>.>O&51]HM-F<O*F.C;+C2.!6+_'JS[')\'E$'%Y?78A]<W[6Q+$#O.D
M <PQ^+Z$&W$8NV"R1/O"OW^J5)-YOZGA3DM-B+A742@5D?*(6"ILF:T?7U2P
M->R1M??^6+_.ESHW!&%R3Z=4!S3)?"*'@H[U*&7AB@%>#+?]-UT7<C4^8M%I
MJN/HN^_G1;;C=5=GX+QM]P_7,VBK\]?D;=^;?( MMT>/UM0\_ '&S+K]/*WD
MU!Q^\O&GGU=9X2$>E(2?%(J3@@VDP4<.EC0^=Y.W/3:\T:B].;4PV=T,"K,L
M-VQ24\'%>N0<0 2@^DO*[&#5*0#1K2#TSOEK0K"\AZX8?==FU&.%L_)*<2KE
M5CQUM180JLQ:D!\V.3B\Y+\I(B<"N&0J:SII?=]WQK38CUGI<K6S#QQ7L2DW
MYB#V*\OQ=-WA?K6?#XT@0O2T/0,$DC#L:#:Y"69E5ZCNA/24D+33,6)R'PU"
M*PPISC"$.W&[(+M8A]7ZT-%3[Q\D@X"D2^KQ1W*MV^)?4UZ=O\91XGM.;F78
MV>HK/*T'OYP;4"\X>5,V#=HW3_Z>]<I?MWM<'B&S1!G/I;D+\+PM,5R[)AXM
MV_D4HRTRE=Q]IYRD['ER[VF=;N#SY+47&KCVL7MME;"D= EH5Y256[<,XAF&
M9CO8[VH^ _YA-"Y"L/$/F%CKWCG3UHG69JS+B16:P$XFR?E>0]V#XD M1359
MTAT0GSJY3WT1RQ4[+BB2G@ W524J[3W.<J;Q'Q5QC$P,:W@BI_C:2N.V/_UR
M"77N/T[V$%'ZI?$OS%.ZQ;U?$TQJX!^661XYGFQUMYL8MV"CY0E4Y/R\CEZ*
M+?045RA,U%UV8N.T8=^BK" \PT?*3+;GQE_',Q*50V4D^(!^]Y:PN^R00F6H
M1C<\7 L&S(^JZNL^QBO,S3G_AP>Y*?\JNI:>6S&:!X)E#[[OV7"^G*YO%W]D
M$ROT_F-)XU9/9<88U7:JE^^,TU'J;/3RL>7C1:G?*P?( U?:(^507I*)0U,'
M5,R-3;C"@0S=R'5W,XF%J6.U#RN$)2TO<9J83'9W/:QPA5D?1D+?HPO_[?5V
MB2;"D3ZW8T)8P)W, _PC?DLZ<^I.>1<HS&QBS7_ZQW/HA-)0:4ORA1NHMT;0
M9R3ZHM17+TAKQ3T];--EAJ \OXY7@MN)^#7U"$ZS^$N/VYCZYDI<>W0NTF!4
ME^+&56J28 A&43RJFCC*^@0=)=JM!\H$.+?LJBP8=VXOK7K!S(S'6SI- M;U
M1\B(NLK^<:*^[7.HUFEMT'H'Q[;@6^8%&62C'77N;];\&X^D+;=%'T-\*&@U
M[_#L=5Z#'MF1G('PBKY89]'OV:%89).BST;839&<HLI?<ZM@,)_OX1"[M AG
M $2+<;VQ%BG*-[D1 SFGO3:M.[(4E>FU6-WY.W='-'*]+ 69\5+H#QQU&?J]
M99^$<3KZ;=.RR" A7[8ZG"316:(<_[+3D+S8N9)5^QJ]G2)G(+V(L$-38S6K
M!;HA6VB4DENR3C6Y*2'IVRQ&)B1!?A([7D'3VV+O.EQ7[($;W%\K67OANE81
M^L<W@3OT2+M'#WU,\7N FLTQ0>-6RHQBVA[%NV0ET\@[F+"/5N.66 &^\(RQ
MW9^;]B@UWF6S01LXN8MD'+H6QTVDQ>$MW<7%%@-'M1P7%=FI[E0(?*6H?<[N
M5&!ZRR>5AD9(=UYP;_D-3JC0CN9L]B,34V<L^F6]K0,5.9"1*S]I6RMIA0N/
M-/S%6P_C(LN75 :! [$3 %ZO^'I8EI&.>MN7$+:NHZ0]JWY5#+G\"DM:@WQ%
MT$,[3V4:LT8@9WW'9&J[E#M.64%A5$+7:DPW+;E]L>)?VU:174_)P]W&5)KE
ML.I>7!IT<72.RX84%.MB>\1DYT<@5RH_%@R?[!>*-'X XV%+_K!T(51$T04%
M/Z*;S+>'+DS/.MQSC=FIHX<1*^B#= 5>=B];6U\*]6\3@\XIQS^[5ARB_?42
MDPWX';J%!K:-:AM*>!XC'^+XLQM3H\0<M#Z8VU?K5]^%<O5-IHL[4S.6QO>8
MR#H@Z1?)]G-7QPVL!'IQJ%N9S: =X\ +30E+OS I=?(&\"I*2+'$/K0=9T!%
MK^/MGZ\+)*P"]>O#"L8V43Z2ME$>2<4)!R@CW&(EE)24-%&._HUO>\N)6 @O
MGN[N3?)RDS,$>3F[I<]#7.>PZ']?'FXU^HZ>32Z4.0G;'<O/?2+S3);3$@:S
MQ57\NG!PW!/_>/#N]VTB6^L:SZ=32?P!UC-5"<N:2=&$J3C$APBJV> H:\D4
M-]J:G7497"BQ3=%PXG="ESI25)0>,U<)!W >6R=FLX1H?N.W#7B.A!DD/4Q
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MIK8G),?^0^@1V?+C"J2[J\G6+8+53B_;(-6MXT\/);=#X[>I@%=S.[PNRD:
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M/*H;*Z^?59/6I>9FCRI<]F>EK=Q5P<$ROIP3)1@6F?2TW",7CCO_]^D+\%G
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MBX:'!0AXO=@27RQT<;U#Q+,=DDH9S=5DVL;7\FU*SDEXIF'OJK4K\?YC"E&
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M[;[X8BT5G:W!HRWL(/SGR>HCD9/]FL8SX)LF_*6?5:3)3;I?><G1QQZ]BNQ
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M-6/B:(B2S%70,*W'_ 3N6"B^#F?*XYTX2K?NT+-6NKLZ4)>_#G.4Y&@@IU(
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MLWL%$F>E]%,*V\^M?X](QK6V(2XKDDO03W49A$K&R9G8Y8=EBJ+9&Z:MOIL
MH)=H[X%S1NA 6K%J)_FOP C.DID^)*MX,",]ZK)G5KM"6]]=ID=9K^IL.:9
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M'5Z(&>EE-,_K[3G"OZ\<'O45%FVOGQW_7G0;[A1Q!DFP?/F"YRWVNG$=;A.
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M*]\TI3K\K=IBZNT]9J&2GBG@Q"UP"@02A.N?34 7*9NY3!PBIG0^]^->;-J
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MQT?JJ)F>Y8$U\;L/O<.-YYA%'*W.,?.FU]]]^\U:#*W9'-@(">_=%I1;WU7
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M_S.(+7I$R.6R$WUFP'KW4E]?Z\_5PY'@(9_W'@Z2X6"ODTRJU"#\H GQR&=
M]W\_2M2L23&_(),1U[5I[*(K*#&U%;/W^I&Q([F'K]F+<0H\7G78%Q[L%B%A
MJ?W$:&OB[0WFB/R<('?0@Y+KB]JZ1^A$O$1OA5S_93D^6U5FOY4.7F"95;"3
MHR.C'/(%9RS?S;T$08]#&M "V9*0)TCFG^DQLB3Z5D&VM,=]_!NR7<LJ43Z
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M!F7UQ.24I*(U7 I-N=EFO=!<G[T1;((.;@698ZFV8[X/Y9,E=, V)^5!A,P
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MZ:MOR<O7 O-,BB[K%&K\L 72S)XB!&^B%BDA%\$Q^O(;&\X@@1NRL9+HEF>
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M1 SZ8(O<],(F_7UT+J([T"G1Y4VRZUE80.^5"$1-+H2JUA33:W[H&=">&?[
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M6*RI-4@EI,0$XSACSCUZ+AA9XX,($B@)M3RZ6:?@3/V://Q61E]32MD 5=?
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MBSFDS%>)\S(7P72@)[+68JK'<M+Y,BQXPC*\(RO[-YA<9FXF@6$PND*Q0(<
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M ,=W(M^O_P,39]..O+5KYMBK6P?8.GV]8VIQ96RQC7CO/P6[.@%>Y.04KB+
MX<9P\CRLX\F:/6CT@W:2AZ7D2<"3 Q=VX]7HC-5^>BT>FF30">(4NB;Y0=^E
M5\>Q^+-PM?N8O8/P$.L+;T=,E!CHAALS# ]-.>)DFSIK!,K1A'TM(ZZN][>_
M07LV9,VS>A+WS1EZK<>_ ,GOKY.,-OF=4Z=_5F?:/#XX,]'=[RDK32)0]RHL
MI]/_ 0RI0FR =$_Q ZKC]P\KZ;N/VD>B1L&K/(;#SINF^GX=C]NPL1TWI^FH
M//];:QU]&PK)WGP+*R[5-UU8+2_;.'NLX;@B1B,9 M-7" *QPSD0IQ!E[C,@
M=0U^ Z7Q)^=<WGWO)N.81%M^=I!GYJL>._O1WMVS9@1FX$&OR@_L=]Q*.>"C
M4A*C/5#W:$5;@P3/L]2PC"_O2QAU^&@7&EK0F$;8?!' 7A#]$=L?R/P ]JM)
M(L*S[RG,B6J>$5O7UW@&^)WSA5K"IQO#'EUO\Z>R4-<TN&V(+-T^UXB,42Z@
M[.W*)!+ASSI2[V_!KOZ3:5DJV:A1'6R\3U.5M5VG-=":4)$"D3!B;CZZ7_(2
MABR@E[ 4XEW#YI>PU!":CZ+P2E@F1\H-*6/HRM TDJ&7;L/WN!!5(-V3//_C
MOWF]'=#'H]1-.NM?=51X&1DK\6D<+K5C<-M20#QN6U'Y?J@Q3.^2J]0QHJKJ
M57.H=</M!=-?"4*OUR="26@%43Y%U+FEW7_FA)<3RNRE9^K_GN,CTF(GC-UE
M1R7$)"10_Y</2?"V?VT@Q?<?;YGWS(J)[OZ1A)7@+41)&I4K33'45]_\8A12
M+D>1_B>UY^=H7$KA?K@+; *W?36_K/YWW?0T&$Q1:@;W&YSAJT.9\,)NN,L'
MOZN#RW6$X W4>2AK6A;7-(>E4@''P<JDMN;8V,*ND1,UM6,6S>E6-45;M"$_
ME+N8F1$3XU+/@.[&&*F=U".EY07TD0:FS=6E\ \5$].8E;1W]EHAF-J_I&BF
M;[UI6ZY$OQRN^2NS 7UUCV,F3R='OI*04H319->OIJ? 1K>6FRXW*FT7-68"
MM9$V%1P_5$54V=_U[^*P RCS-D:+D.;W6%A>V!:(*=:(:1T727[+7US.4=TS
MED["Z&G&4LA ?OGII3;B#:?;!7D8#,BR)M5-0;8+I.))/ QU!S?$&_(23Z]I
MD/7?SN\5-I#01PY/N"SOS,O,6&^7J4VKARS8C?PHBCZTC$74J8RIC:S);A]N
MCMGH' A<83!CK32GO6\K4;^5-.FOV=<4QU]/6L:09,9 IR59GH?"D!Y.P<V:
M;^C#A)VCV)-V^,-J\EMPMKBOPK W"35EEB!LPD(G8KNZ,K90LF_C;OM_]C=P
M^B3*YK^BT%=Y\'8>Y,3.H=DY( FJPWZKU)K&EF =P&8@_I>(%.G+]TP,/UUH
M&3F+MD@EW6!'79CO"^?4;OD7NQ^$QHXW1ZZL\B!3!SY_>CF:.MA&COX@4-1E
M+'*JO)FM.<N$N[;/M%^+N %;Z5+\$+W(+DH*G:&KPF> 3-0\X^*$IB+=2][J
M[/WO/UM%[G>1$E:6Y]B4FT[)XXVLJR7=J4R))\)G/MG8,M+GJ*' ?0]'$ ,8
M$8?("N'7$!C#>7>BV6/C@AF'B'"0G)E\M]5XL/6Z*(N\<0)YP'-?3?2X7/-*
MX>_1"I\->$N099W%$$0:Z2,^R>OA]:7PIC&MRVB5CO>W@O,\F[6),,%8[9?/
M*VNZZ)$O$&1GHH;>RH8/'Z+Z)V"#OVXQ?^/$[1X?G9*S-<2%S://F&X%7E2L
MW!J%#EE&L><L 1ATU,#8-PGZ.*_M"QON<A>M^?934+D5A-IMCR+Y>T;6SL\!
M+@AGG->'6M:,<A$_+@FOY:;F:51^P.225JH?OY&A*W12-E**F:,=U0E\F[TJ
M'V<OA?^(SE2GUU2..4GSTZ(:AY,4/9!V\I@OGMU^ZVF,<3B KE+ADHL8U<3_
M8&_#H)\ASRL=L&#CQ?1I(!KA-BI,!N(O\N;> FWTB>X]>MFZNF5(R>6RW;Z-
M+=;M,!G]X@TI 6J8_D(R&Y?&=;_)*8R)NOX"&F78X)=^P@-Z*SVAGNR%\[>3
MZ\1-:ZJ/M@E%*(_QP#GXNJ^V4V!L;';W 6D1KB;9?"_'7PL'ZAI'1O(F@JM#
M#VN!:. 3ZS>G(LR;LVJ$L?ASC.9S6E_[D(.&2)K1B]T/X:4?F36]UR/LXG8]
M^LY)"PNM(C4$HI!B?2D4=NSIP <&MXFD!1U!AC[4;9I^MHMDYZ[R>=<6'6$K
MS$I%=/^)X9.Y0*'Y+2KEYO"H2LUDJ]FDLF> .84*$LU$7;UD,KI/8CX@ON$5
M2>[B]S3JP\@'^IT-@EI">XKZIF\]IY8*E\#R>#).&L>8@\B,E7X907/A/^B2
M40=&OS'-'5TV"\%A0QXH %'SDTG3W[48?J7ALWY6J;/[.>X:UR3Y\T_BC!]L
M77?VQ:*O68KC0_G]10FD#CO.K?$;.X(M$BM7'5R)[;U%SO!4PG!-XXN&KJZ#
MM]1.)".T6VCI4.03D@ I3N?FLT<4 EC,\L>65FR10U"PO8*WNN*KDX%JX-YQ
MHHFZ6J6>S5>*XFQ;=SL)1U<^1\'-[V1TYED%\R4%-GPS>)SDAUYX%7CRIEGY
M7%<+JH5?OSJ :#L%]A<@;E&*$2_0\V:WFC,&:8:$ P71//2@Y<L'WT3Q#PC^
M )\!NYC6EPR-ZCH/#LSFV73<I=;W,-O;"UNDE>SIV0/G//:^>>2P526#+Y+Q
MI^CKA$8VE.-3 ??YP ;-'C[NG&%J+CA#GRJ_;]J?T[6V\,YM<B=1G''NC+R,
MB)WJO)EG /B:+S],W*-BFT*E1<F4%'VLKCGVZ7\X>\NP**.V_7<0$:6[AE)
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MI*=6^.SE87GQV(==%NH5.UDJ%GT@WQW]^5_ P%/>MX:"P,YTXUCDC]3IKPM
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M^?X1%+^;I&U#@V@;HR \ZQXAE+RP:FYN+B920%T SPC48=D;Q/W($V((WZ-
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MA:EDC.NT[8WSY^?VE0YK,INBOC0LZH#+*--R#$S#B>!:SJG.#T9!C#R="XD
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M5"&3+"H4=V["C "<J^1;<[XT6HF#ZI0LO4=U8R^7*BXCDNM9@N!EU2U#ZU/
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M:-#M&M9+BM5P$(4\:X+GZ]C8"BO)TN<=X: @Z7P^3KTY6"V'71*\V/@OSWJ
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MP!,SLU@,^E4MB-LQ;D;Y-:1HK2#0V>0K%N3!?^=/[X9K&U!8'YH1YP"=AL#
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M\08W*!*R;4Y+PQZQUY:;OLQ;W]@R=7H2:3G*8EZ02-4TA2'8%)JD?WQ"F4F
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M?Y[/(AYK<.5\$_&O#ZKRC \)U.[5$*VBM5M9,_\%T$0_J):Y (^LJNRH.U-
M;-C-X)&0I>./3?@?(JR0;N9[=QXTO =@(X/*;B(;CXW(2(^QI>V:%R?ULPZV
M..907]I+VKO,BVNME-.%A*2-KLIAAO._ /7M*GA,77H*8X58!Z[-6X1/GB5_
M8_1R9L_OEF#8]+>A1WMG#?7%7?+"#7,VAV[ .<YW*N$PYLV<FL7"'XXUZD1Q
MY^T'HA]T^VEJ?*N5U4F?!3<821(L[<MUFX^D/./BWJ5M2W %IXSPE =>30HA
M% M7@:.7IP&$#29GZ* _C9)JH+?1GVGUWOM1^0&A2J,&I\BR"8VF<@H,N?VT
ME1^?)RZ>3X$ZJGV#8$?[R@IP<.I_SQX:8:_N[04F#E?Z&EOL#K68[:=!0K"#
M@2XFY4E@Y"6K];TS_1W;U7 T68!=_^PB\W9QXR!U9GTH-<.GF,GRO2R$'FU&
MPFR)@B(:O0$Q*Z<$]<T@$%5V%Y.:1;&)N5N+N"TF7K9E-"AKY^G("CW]+P#M
MH#+:="0HT34-V\NSK"R6,5)0U-P8@+_I..&TU<I2$=+&>&@3Y4K9QC&I_ICZ
M%Z"5TF5=?ZXJ#S8I98V/],!U;K DOHJ$4E!T_+] GEGD4,KW#M84$$'BX53_
M-C=Y4B165:P$W;@_LL$[O?7U<:.'D(K4$H*]M#=9AQKO='Y/V-M*_@-=B5M3
MFJ?7_6Z]E\::/K1^B1*A-3$U*]"N/HII(+OPNRH[,D9F?AVLW1?YJ@:"<OZ:
M7Z-CJ%BG:.LO@)&%"MC6Q>U3IBS,,+Q[:TC<CSFVRE"GJYLX+*]^FVJ<SN?F
MCW+Q\F2G?,T=&ZREK+)$AX^84IN5P>G^$2&,VQ!(9"72?ZV^(0+;,0HVV]#>
M -W,#9*#3>.NIETNL/96Q3.D:S+_ KZ$)Y[3/C?,]BN]5#^M8W9-)E*D@))-
M3(AVD$YB?09_B$QGHMC9HD1>(G$L8!L:8UC0\%L2"2<"60N_7Y_DX5U_IK.%
MVP-QFDMFG334)+3P8<5D^1%IYW(=:_<8&$+\C:HK_(-=S?%M2B11Q8RCA)>R
M7/HS5-197[QR_P+,%W=._TTAHA=<EY#61LJ*C_O:0N2C)^K6;C,#3"!)AX7B
MFOK(=O[#!VJFC5FG5.&U8VE)&]*W8/]T7?BG,3M6]JA/1_6RX#^ QU2EV,.&
MG<=W/_CO%YUB)]7L'7W"ZE/4I((_"_*LOO)=M<==J/6JS2K#AJ!D0E#F6?F/
M2.8/L$'.][P:A.WDO[G%[I#(US<8X%(R?4J$$$-;OX;RU['LK) N,,KA_R&!
MEO3Q5Q)12V7$4J'0[YXXMD"V;0H<FH^.WEO54M2>:^-X8F *<- 917I^Z*1(
M5U1CC*!<7FA#!GNN91H>KF1.-HDL/G_AR%C@>LLG*].N'0/=0>;UR$G>US<S
MA[O1GQT!P(-:=TV5:<WN-<WI;A52[_^"IQ8%IA=5&Q<5&H,("Z[J/!B*\N K
MK;JDTW-"DJKTIGFB*?_"KO>'R2S#F&/LM^7:<>>Q0<H1FN]B#(T-9QNXUH+[
MPZ:@62T!NAF2,]2>?%5!GF5NP1LA,;824R-I\WII;8OU^JE/A3?)OVN$_P):
MR[*%KSG='\$+#F]-5Q@E#0U9H"9A&]^BX=J^.-2RBN@&>E/-_*8/H/750<?5
M4WBN?=^@]O^W32P'%'/</)'8$ H -@#/+<<?)/V/'>ZDZ^ECOPA2A.=62VB#
M'7+.A 0"?1T=*63_ AKEK&:/UJ,IROA2Z-6$*/K?.1]0=_6-<M5G+E\=Z]UP
MWP<U__%FU+'*'"HZA\J9:+AHC1,YL4(7Z7@FD?O$E?\*=J*. I(#>Q_)$U/#
MDW.(0OQ9FP/O]%?8@N)[Y<&B0RUDM&=.!7ZB#%4]P71Y>X+$Y1:U++0DM!&-
M@]2>TH>TVU-W'\.B;P[$$FAMJ<)M"37!?7=2LXM=\ER>@#&@CPW"5\)LKM)$
MYW[JM<O.R<L*Z<S.#X:SG<22O.*[?$GT=/#$5/D7L&GV%W"U>9W+TXU;>VN<
MN^!UUR[_T#YWVE)_OO)PN<K<B,5)'IC/2RX^X?-A&W4:^@N)J/R/1UC+?CW_
M%E]\UM!53R)Z6-%?9_>X?C^)BIB2Z/);@K<+MR]HI_X[]N'A2?9.9\.RX2'"
M.SOOU9=?:)[40)GEL=WE_ /$.DV> 3=O$P:ZR P1=\V8S]S'KCE2KR;,=V3&
MOOA87R,(J\@F>%7423'.#Q2'_1*%G=-=GCBLJS7;LM%EUH96^R A4-D#OLLR
M*UX.O;@'UH6L6ID]Z&Z^U[_%L)JR'_U ZWD'DJ,V,7=G%L20RTN0*S)?H,\,
MHYSOX*#A*B]I^K! B/H.K-VY4$:!@J^&=#T)%0*::B#+=15R58+';3X*#S"@
MENA-RU88R]WMR3;80!HIZ<($]-?C+^TW5=35)5\&?+.4B/TI=\FPB?MS%=Z<
M5[.85TILO[A'\[\AW8B#)%SW#Z;<)'JEA.X#W_-T LUS]%\ U8%LU\GB8IB/
M)?,6C%>J8R!I[J,S5,;7D!SK:\SY/X<B^V3VRE?_.HYREK/#YN( YC/T%_#H
MP))F&T66[;!,:0E.=UZ?\P5Y>Q<R9?P%"%;\!:B6@YR>?M^J/1:?''64*[WB
M /:>+JP?@!YS4@Q2Y-_"9#FG9/H;0ZS8(0P%6[L!8YZ?G;):O.S6(3\W##97
M<SS%+]!Y4UK_R7/9NLW.<!M<Y9G/X$SPT0"#FD;G#S=W[5=XW9J\])I4=P%/
M3.)YE+%"_8W;G7MZ4W!L&PU&4P)&4GV;? ZN]7-7S*1J[Q>F['R_N(T:Q8A7
MN,U5[#FIXK^EDVVO-RRCX[?+DT335@QH*2?3GC*]>M6$7\4V\X]"*DA#5][U
MEEG6]]#L"&S;<-Z=7]@<:[83G(.BJ8)CL=1(X1<,"M2=]-_>UHQ38&]#J&0-
M51:\_JR\Y:4*EE:P>WMCT:BO!3IU:33<:A<!H"]6;_O;%T7]ZPD9PJS/6G\!
M&T&@@\"?O2Q)>W3@I>ZZ1&Z"Z?-+*34WV7M5H[^ 08*_ (W/1]>E3R5B#_<T
M^^[U(YSD*4R1P9J1Z E1WT5GX&0[9O2353(VGA60M^@:S7\!N/E_ 2:K^QKH
MM31W%5$^;))/(26ICA28@1.]'U] %FC1OPO\A^'SO'+-2(8K<"N<6'\N'B&<
MAY6O^3PS!?F\8\F.O,+!\#-19@LL]RMY"30$:J/(F99Z4]JQIZZ=C285@!?7
M#A$7_;$L>0V6S2@M;)G Z.A /?''>T+K]9[Y>OZ-ZY^PN'NZ+BC .CJAF?9\
ME5@,'#Y*1;M6*Q:6,*Y"T_P)010#+1]T<*00U06B;]7N8THR@VM59 W.&,!&
MX!^NASO!4>![YX8)9-DE@< E-U'<N,^<X\?:P*=<M"3_^O5M(YW0F86MLII.
M_;!9X6[[^$ER&MP"Q0/9=F67;.&N M=B5QNWK'Q*_H*S3X/[=#<_=-=CV9P6
MMJT#9(<E/1 )B&*#OH'^3S(AG-W2Y<"7K%^ &DW^LJ+!_K')Q_=CP22_,VI\
M_>/6-7@0>"._1Z[+TRUV/Q0N2CI_Y$NJ7K-US##:<1FV0ATU/0.&WUZMXI;6
M&/,0ZI_P0?3_)\EI^5.3:(G3D9[V[5E?8UZ<UA\%/0O-:/+?S:B)ZC)C?'$S
MO,H@8C-R08KO!XQ3:O3G][JBA>CL7YTH@XRX ,X4-V\,UMICG-NVWFYL95T_
MMI./_JC%;,WVRX=O?#4F".Y1"+4SW_5N;DKW#;XO:8,8)V=5RPQ2X'1X2 !!
M R\A5Z__%=>O'4\.6(\A3)NUWF-+'"LOVRK7)O79=9,*/5-(U*!XLXMIGZE2
MP=)I;I_%5"4\75?PO;TT9JH\&^K)P05R/*]&KXB92H2A+>K-\HI<%A3D/?5J
MS@)C& DD*Q^T1;V4LH:W+:L.[69_7\S=PL$!N*7QI[D=*+Q*B9KON5UD)KL/
M64WMZ#2WQ/W4Y+T4D%\[NM.V*@I;U(ZL4^:MF>.%Q6E27X2FK-/<U-80,:+K
MT[6F<VE]>QT'/W^ZO\5&SJ_=+*[P':X:-X'K=MFY)-;)U^++7=8]S0524>7H
MHS*<QV-;=)0PZ1PM8;Q]1Q?<W "752/[_W^WDM@^W'_H;(DF+BD/AI-5V'=L
MO%2O.0FV$Z!Y[?(!6\2IRIG4Z8!@L/@IHS+Y1W V= MN!T*Z^)N>2J8-+;O,
MFYLCO+!=M!Z=/4R<O&^HFB+C]58CYO\;:T(%B%5F['8(^)L/S(M-G98G+83,
M@YXY(LLC&'7G'F^>ADA[+2*"JP/G336_SWTZ$=EFH@&"3X<I]!@_V)X[UR@M
M5C#L2EC4PU8]B8C\*]JCWMJ(7=36_N+F_ J \\JAS.- !$4+(W'Q#I4&;<-G
MTTE?C6I]W992DA@3K/=A\RW" 6ZFBM:"8Q8:_,!UBY^ WS^.L;#YC26A3BYB
MT:=!/4Y6RQ&Y)%1.Y:L&UZ)-P0EY(_?Y$-UST=% 8I=7QW%W)+)NC0N<0AH%
MP$!7;HW)R5 +9IR^OO[/*X'I:;R32\24:[P*5GT-)6GS%:KRBK9-*^&%\[NI
M4JGC/Z,R'><=Y!BSD.WS?7U]E9'88)D \0D4QV%I!38%9H9\ORNL^ZJFCZ#5
MWS>O/Y03+Z(=O-W0+QO?)*ZMFG;PMA$J!K;O?<.WPU@( /?CCM,PP/<L8F5J
M1@E3!W,<AOW,(:(FCZ'_*'K$MI<P?7<#3'E13U+S8N/B2I_X&@GTA51DYQ=C
M[:]2O&\W_-'%'-?#;+HN!MP889N9[H_2,:=24%1CP119VQ2F5O9!\C_Z B<%
M=99PGZKY*Q[SQX_&RK5S3%3J^)/F.',4_Y4'#6V;+)9*ZW$4+^>XD!U4G%U,
M3%V:LR?CTG\-\2#@<QL_TR!*EL%BXFGI&'E?SO8R^G<Y1/BAES7.V'NB#K-T
M0E&$WCE=-Z&K:X?WW9YD1L65._^C__'Z*AY;\K$(-8W?(,/*CG/"QPM*)>C;
MR H<AMX.:"'P$KC2LL77XKZG<O3&J+5?DNX(3W?U9:V( ,4YPZW21<B>IB)Q
M7;#O  2R5Q018O.Q9\[!JXE*Q<![P[2-A6<XQ'DI=*;]5798W)4,N[667 >P
M_OSJ$/T_R4GE;;C'VE_ 'Y&YV>X2$2JG(0M[$S@L]"]@(<M\VS/Z9_UW"/[J
MJ+MH]NMB(T<-_$_:J=S;(EFC8A"6_*AE:6G,K.R<_(*@59T8J3GNI\R7>&.$
MG0JN?V:#8VT7BBS8LM,U[_"S^W$/,"([RQ*%RJ&F:[.3Y5[MI(WJ<R,;5R:1
M>?DBT9_7O?=(LQU2>OO)?G\JH>[/:_WZ'A\N:&9/4A-"<):?WH,#OU")^D=3
M[KHIQQH):G7I3UY)PIVM<%>]*YWS!Q&*Y2LD)H^Z]TQ[K8CL68-/:8F=+?S#
M]G^5S67+0^(U3#:*YB:=^"^ N?O)K@3]?Z*QSX;[JH.TL&]*!._%?AZUC*+'
M/;:2\E56?:R2"?D8B2?3*8'^Q^9(,>(OX-^%Z\SV#7U],AT#R/_I$:"?^/@H
M^'C_=X,F2&*]Q/9Q+IK&">X1L+\;)/4^[2%6'G136?GJ8*2^[?&!YF.UBNH5
M);@%K&6A[1H4IF!2/X=.9F%<2!B3->\KF)XS$7EMR"&L/UCZ4]JM^;N&>D-/
M-%1:<E]OH[9<A'(;NL8X<5"AF-FD(G4A?#T.6U<Q/*#WG)G%-FOJQ[O=Q^Q#
M ML3]>_0T O7O:%6]4\\KFM+I]KB.QX;I= "F-B8 T_;2J;G@(3]NX!-8<FL
M[+7 QKSTMW8Y^)5G/89KB0YR9!*"@K2_VI-4>,^TF)L7@Q"$'?O0(RPSKOWW
MA?C)<C2DP:-6'521OB[EW568,40*(<G+S=P]D==IY;E1C +QG%_7;D.X7QQE
M<&;C/.'&!JN=J=$-FA:E +JVFI!,*SHGM3QL!83XJS$%#X-7*&@=,$S_,PSA
MID4G4Y$Z"];@>4P+-B?V+0?#G"&!VBMYBI4F=^<568SJT(LE:X70W!N*) L:
M)1'.7ZE]:]F"NRXOW=PSD]\%*>_@--A];B;(RB3HEOC"6%)VYDAV4?:13U^I
M9U7,4)I'7%H=Y%KDT+BI,6=-#58U7!4__E+<R(C7T>]$F9G^)'$!G)SKUZCJ
MY$^P<2.ZG9,U2^^.Z1G'4_MR>OUU<B9!*/_>"9$IR"@K89Q=^,GZHZ9>-<L8
M&Z0OOTE_3Y_07(<H]W9I!-<A5< ;;T(V>>4Q/B! _]AEQ#Z]Z0[BE=YX[&$H
M=T-*<MX0>86J-_?< ]Q4]F;9.3M]7K8L2P]?R2PNM>(.E!\R-G^9&!7BCEHO
M35RRGJ"O8/5(FP(HM.:L(.SEL;KQ(WW^W5_F5][TG.8D8?=O\U(E<^I/>^_R
M\FERF03H/.U(;TV7IE[A?8L*I3]T#\KL:<CP'OJ$\6KQ-[(R4J.ECSU6N ;[
M!>C)_B#QN]_!/JX421-S; X, 5W>;UKM+M6_F8<8KHWKLTD:A:1,YMX\B3DW
ME8WC-L0NP6ZTHE?9N.:KOFA>M$69.=3)/#M09;7]>0KYGE[(2J^!W1]^5392
MP5^60@;?<LM+DOXZL(^J0^>HL'(NDP0\O3_QZAKOYT\V6&K*(!^SN]&V=@([
MVM?9<7-EC.)01:^X7^Y-&YEE^]D1ADZNWS #V<H71 [HRBDGE#N.]?DJ>FX@
MNXZB!K+N5)HP'"8#2Q<+BF_OC"LJIQ!R[X+;*!+&,0T\>.Z/[KV/+#/K$LGI
M352:Y WF9#I ._R[ *%8#:]>@_?2W?L/1!J\.W,2]F>-&91P!^&/HZ_J99,:
M6G#6),Y'#GB;_^BP:CR*%6;E.]$%;,>6_.H..O1>+>!V(#DHI'*/\D/;LJK(
M;9R4UK$NC,I/T$]0(&R$G[X!HH]8$L<6BE)L)[\2Z30R>-3JJ4?N)=V^YXFD
MONZF"UBBH%!P<VEK$R_)(&[MC-EP7NSEZ,8VP4[B\]BD=S(7S3ST&N ME /$
M.J+#@VP7^9VM'S9GKL_0JH)_3ZG-W+:L7)0=(2>V*+9$QN?N6%?>:RY!/C:G
MUH4;-<X(,G).A 6"2MG>CB]<4CEM!SC).V>6U0_K2VMA*]*;KDUU'3L?!88
M9+WP/%A!2O2U6\[.^JQ._T3BQ %UQ-I,,XTZ"E ,74#NN/X*KEK,KR([K)S6
MD"<>7Z'PU!$86UB[H5I&/!G")T[Y>-HG_ZCHG#ZJ>LQJ"$_)JPC_XB4#;SLC
M)Y3FG)L.P"?2[E9$J$&/TN3QTE.+=K6CD+9%2J":/%UC<-A<Y\0%5>VV8%J9
MZ06,%",UO9ZFPVZ0XZJ&,:$\:SKT>] B76+2C=!+%RJ)N<O0FA@M5UD"AF:3
M6+" = +TE=3\H_8?3W^Y?3*A!&&70Z4,,")+\]V+#S(":4U;/0K7#(8V1$Z:
MUV\R?RJ,,1L+WM9FE4?9?&L=SW[HP=J;;]V@K)G4Z^W:<BLZU<%/[,;_C8<Y
M.+G+*R9Q*<$K#?HA+%]4O^7C/Y\7#+VZJWR3_SU)F@B;#IS</R[ECAOJM# U
MN]A0X%ZWY=Q,[0%K&CE(]6?6+;20^L_;["B(;YLX3[R";IF_6<Y+%%\IV?07
M%X.&RSRH&(0-@*$>NF\8D[!QBSWBF]7[[)YCM4G/F-JKF9,7N0+T>A7:J(Y1
M(C-SK+1:;YMWYB/.SZ$%=]\>SB6XI3'716UMD1'NO!,8[7G0%-EJ#L:@*E'V
M?J\'1T/^7ST87]GBU ]STG?<&L1BHU:5KC9%ZI3TL7\*T52W^5O ,E/^'];>
M,BK*Z&T?'01%I51":@"EI$4Z!D1:I+M5:N@88&@4I$M ND&ZI'- NCN'F*$;
M!H88AOS[>]]UWG7BPUGK?\Z7_?5YUG[N*_:]]OU<X9YT(ES\V#LJYI()M1/Z
MMBFM>N<GH*8%R5;Z]]X<[E3Z_)\27]:=P')&("I=WP\^$"O44O7JVG?Q[J)>
MAC1*41':4@IB3;QY\Z9W;O]F,1M+AF%;=9"%K*O3AW]<+H,Z_U MTONYC#@:
M["^B3J6<^R_Z:+(8 _7&E=+7LP&G[+@QSA#2?A>/,AVOYO#4 :.MJL/OG4(N
MM8V[?4/OSPV6IH02,9T&::- >]_9Q/I$CY(G*7_:HC)I A$KT.HI+&-[W,0U
M[^RRRBN'G"0:>X&<*F5^J+/8DZ+X7L9??XB_+'=9G4J N:>-+&)C9;#,3N9V
M#T>=10'$&R7!\>'ZW"I[*<>T7!B.3R\H@^RU#3^_B$4F%)K.^GD=!*S(FA[W
MA?;Q5#8;."2FE&'V+6%K<?*G 4]F%_X1BXF93-&2D7GCDB,TC0(4IF54J240
M-U4OJ/6H9[6JIXT#\9X(#J2YE<AQ>5WF9,(RNX3&\GZJ[V .OUZERG$,9XJV
M_%Z3=_' ZP5QC$F$;?!V=)ME$PO?O](DOPAY,*(\AGI..K$"MLWY,F=:\4Q%
M_4,-Y^HL9P-U'QC\T-=W38-6W$3UP:OR?B_@V9;H[OG'U.PP*Q_I/B=_J/U=
MU7!F-BG9<SES[V^[,.*N0\.RKUCY.+UB[HNN5WDEUJZ6<A3"WQ3V2(;)M^WB
M,'$CA[CV9?%$I$:[12:#MI!2,PG^ST/%@?U3WID95QSX7&N;<KS^N55#4<J@
MP9)%<BVM<>7A4S4,Q24UT<%C,>A0-?NBK&Y/]]6B'(FQWZ@S_&"J0XTM^S?)
MEJ_FD+N(^Z,0OQ903$%B=4L8U2U1'2:UC3;YGRL(/T$=\KT#V376$D41M^OF
MOEZ7?5F]3>&=^6BXH<<-5/K7=9(*OX>>[=4( U0,SQ4U\;[8(S_9!&S>:N8C
MF5GR=[DI;D1G5ID/'RJ0"C_<',%D-]JPAJ<^82E*B)6F4<IBBB:R?7^D" J8
MT]T0;.9T4+J9419,_,!.)/.YE7+,BLB-\4 +\^)T/>E8KGHUQF C,^ZW*,'W
M.,NJZ8<5UGN2/.91MOV!:/UD=T6G@A5?63GY<!E[]T4CNJ.!/2I&;E[T3MPR
MG=1$H0Q].5K* <[]*ZE4F7EP^55B= DOIRH7UY;U@:M74&JV%GPDM:<SS4%9
M7V'('G96U4S-_IDX(J2+]-&WNYSLCQ&9K%L'];<BK,2%%,2FSUJ0^-&,J+&!
M\GUC;]\[,+>66J'S4Z1VU\?6WN$N7>6'8@7'="BBCI&C/N@$O3^"3"(B@DI"
MUC:\G:C#JE%#D*79<ZOX>4/W.$_TV_<\FV(TP/Z#@$U9PM5H?_D,/78.N"KS
M0V7:8.IFZXP:@F](OS3J4P9WB7!6Y1[Q&);$"A/ZU7^UOKO)ZWW^#PEV%4"L
M@1]*DO>/&$/#; QP\)"*W'<A>DICMX0+X@TS_.3@R'BQ6AX[5ZIJ0;V:]3PC
MT9@[T; NUU;@;@&W,#_V9J4V X*;LR>IP)!1U "0''-@\^>X!YP/_#16^/'M
M">M[SY* K' 1;D60^3P%M4-BN+4Q29N6CB )9?1-E"2TTJ_Y( #)!% \$"UG
MH4\P>'>M>23X-$E+0U#SB6?4\.4WO"AAW"V*B&#L&54=T:3(&]9ZX_)J#X%?
MFG1F-,W[\M)F.< 0M6(5G"W=(7<:=<ON*D\4]-%,6ZXUD.]+ $53.='#OI88
MMMTIE-0>O_8VX>7/FY)#2)6)_0MX-0%$>BO?&]N5]D<DU15DB!%^]K$#=B*Z
MJ?G+B/>&A#KN5M]1O,Z-I,CN;??14@MHM /8I^8&8ZA5UYZ/(:T0$/FM5V 1
MK6C6,BUG7@"Q?-'W%I#YPR?U*#LSS_BEG&T/O.H 44.9U[?59/10C%YNWIQY
M:O"03F,<^>-1T@MWO\JQSUP_M$L]TD!I#U+O >EZVS7:]=E3TA^ 8\S2=7\,
M__"3F)I$L=HJJW<?3,*EST90(?%3\^^W8T]F!4Z[Q_['J#OGAB"%0\SKCF^;
MO,U]E>OU%G9H*"\W(=&!_-[  ^#%Q)E:,X)EZZ+4&H;P\+JT>_^$;F<_=3?W
MRTVAD.$M@\]9P(9L95_%6=(U,_D_^KKZV)C&;QX%I'\M'GJ@2YB*E8J:W^?&
M6+>RL^M 8'_MLA@ ITP[.'MJ=A.:KDNJ(P[NIUXU3D>>!Z+;9AMEME8)6>FS
MMKXP'.R+ LKM9^5-+/BF<0MZ&._T=VTV^JH<Z[&1W)S.^\A"4VD,0^KKO(-T
MZW;SV(F1J,\SVF>K(Q9V4<EH&?2A2]T2S!6AH=+L6-^<UH%#[IQRPI*[G"#T
MLL=.T[1R[17_1+TZF1/_^<-1"2_&<3>@NVN=%JTF; &=9IP$Z@%:7JE($7%I
M";P&#PT <"LR^I'&4=&A7-W:A:3"!4OT+/4&OVN53%'3J(1@*@D^UFXJ2D<V
M)%^@'&;*-WQ6N8<S>N8'HK*)FXJY^2/5%W.U 34#UA=B\C(-A3RJQJB!AZWA
M9=W"";X#:%&YR2_GZF;DLIUB995<M.76XALN^[]B<RXP:+U89Y5[0)SV;#3=
M5^*6Q6+FM\UMN<5_WLD3WWS#H$&87,$'!)[DT"X_)L5X)+?>+7I$((DA^W/<
M1ZN!-8'A>1I\Z=,TS#,I#GE)2EN+0<?DY23RHB8$V,:8\'F/,*$WM8)KG'#4
M6]RAJ0K,$D/C<^UD?](C ?UTCP*KZ+8>:%'DP*?5MW$BW_#V_<V,<Y_L"8R7
MW=P#PGBJS,D:$2)6B=>QTWS_O#.ROU]_P^2H^1R].QT[]>7KZ]^.K=:PKUN9
M$>Q=S#G-8QR&S\BEQI6H=K8%5NBRT3<@;PP=!,&T/:TG"V2(2_4.FFQ6?1H>
MD+4_?)25[8;K!>K[$/ U/*MX+5$U^I(\9?0Y5_T0W\(_3M."#],<CD[< P8P
MF>&+OXO"*Q*I4ZUI.$G?*M(LN--."C[&/@L,ZFU.7912-S3E8_A=^"5.W\25
M<EQ04>V&(UQOULHS%?XEL\0@=-VUNRUCV/HSPXLGV$:H.LJ:(VHV*61FNI8B
M4->Q.#2\N4-,_R@;E-[^9._((:_08JXS,M.;AS"W?*",LPIN7[]#__!S1AQU
M;^*YDZW<@I&G2HR&2<"RK/+DB31_BUK:2$A(_+2>5[/0D-X_V9$4*9N]![R'
M]B?P]@@'V@\Z-2_>EHB(%*W_'%-DV_1QX<U?"FGW9[P'##[[-*%>[R" K!;U
MTC])IRA9)56PMTWCW0C;['XDL 13Y>$(FU.^V*WS)-IQS'EO\"F+O7:=!<$C
MP/UM;I2M^)PF:^35@2AN96U1 ;0[Q0[+1#G*:Y%X&ZM$'WY)Q1#UDZ\?AC 6
MQ;HR5JJ59')8S-G"D"2UYI<'LTIUH 6JOR<R?T:HG&B'/4[Q&_<OLL^(IMAK
M%] T%M'U^1-+%5*]J:]H0OUY_++![J>&=29;5$1MR!Y"N2G-+[_+RBOL@@E^
MI+<Q<W]'<B^HFL82T'.N@7H)F^U,"?NR?%NF9. VZ;O=O.\?XSU87]J)X46.
M500,RAJL+BF6EP_U<B29H?4JXV0L"Q]\X=>L?:#*$=(O-NW#6@2B:&%8.U=^
M!'7K+D^>QHB5/6+1$&0[8^'^[!UQP=];2W<M"76B6&"O'^G>SZ#3E8W9GE^M
MTEHBX0)^<GL MH Z&$?WF1-O%]/@VMIW^S%JK@G\HBBA<9-=?U6YKRREXJJP
M)Y+NZBI*SSA_@0MF#2UY(ESNU[MOC?^<]PGGQ4)A*-Q850,.IXGY?"SFEW$F
M^O"C1U163YBL;4!X@"$,L<\:(BV/V^6CLN@,-2;..[O]C0>WYO'4+ACRK%VH
M$. .;]X[!3+B.4#%@K_O/0IQ7M;5=-9\W;M?)/_L[:EU_>S'5_;V($-+.P=0
MT[=;4,>XZ$-'R$TPTG;T.,W7(CAN7=,YXZ"P+"DI,S)@+"S-&N0N]AR.MU:P
M*:MLK"BKKDWHEF#1^=CHF)Z'0REC4"P#H&AP':QMW; Q>^!7D3_<O$2Y/=6S
MVA@2'*#:_2AD!C286S.$D"6I50[/3:/DF]70'",G$H)5M5V_Y.SJWCH8#>J3
MK^PZU1% LA2$A"5;5&]'3M+ >F,GPP=HYY0^',F_E)L:A$X__R/O2J'!OBVZ
M9E8&I]4;%;#,O ?$P@+D-;N/>S],"A(LSQGS^S0_KQ:D:)OK$4MH8<RI/B&@
MCNO@\FYBLX$+I^*W-+ Q-FC@0Y8<I4L(],DAW7YO9'^8SZ89RU9XS>IV8JEW
M@$T$O5V,M@(G+\6D&V>GW3=[AI-H4A,K^3H*ZO7VS)^'A^ZE<:PAMP%B.^[B
M1=P_C+[&QLL,O';R<01#C,2>>9/GCKH,.5#%J'JT@CH?]YLQ?E[<]#R8C=&L
M''\BU6YD[OTZ:E)AJRKJX2@D^AMN$WN&/^FI!U>[BI;3GON\B,^'53W"PYAV
M$<N&<K=##+8\T3Y-R7N52W:=N+YM7]%825P;;WC>6&Z,J /E) :WOHE%#CP:
M ZYML<::G\R7G;N1"\0UC9CUB/UPV+1VGHI)_+Y7N!=W85[>G/YA69I;<,%6
M^FNJWE&G.ZDZ:[A<!& +V ^_&4NM0Y?L)]3WJ6N;U='4=02U 2F39=?L_]*'
MGE'C937A:=1$7$8):BSYUM5H&1$>YDO@$7O3L$%YV* .V\:"9>1;]P!+VZ#5
MZJ6O,51V9P)016-=5P'"1QD=WT*QCQ=KW:;]O);53GI/?<+!)Y$L!>N&2ARW
MN['#1OWK^,KB'>WZ"U#5I*Q8W6KV*;8U>^7J3;L_\!/X48JR!9^->;9Y1V0^
MGEU(OWR2Z2N,'9>F1ZG_'Z1]K<C=:WNRAB<R;V>EM.#)<Z25$<;B5^>(YIU<
M;CPU!+/5M!Z(G#5""=2Y;<P:)"N-/Y>R++%,G.W.:NZJ=E7!OM&XN&M3T\JN
M9)Q8($4/FYH1-/NOPR16PO @8*ZB25U-21EH;_1649LA^!%H150W:P!\I#I?
MAQDNF3)K6>!*8D^2-73[V:/009.Q)DP1(/@H9!9XJTW3:[B\<P(AB(OK0#V?
M5-E>I%VHQW'>>AY?.3RQ.]><N4FEI=6$3\+0OO8KIL4XW\FV(+9:8I%E'<G8
MI#*Z)!H@420%?OW-F23L^?I+ PY@P1P(Q5CFR*_U5BPI >;'VB(OG8,^>"(*
MU E*UVF=YZ[5:I7KH3?[7>X1S7YI0R.N[(SV:_'+N/EI6%1ZQ.;,3?B@K0.H
MC;NW6^&0+*&0==)+-5"AL[_&FF4PK^[=3E$]A,>[7$U,/SVQ/N9M8(DI: 9W
MB#X<F9-&B^Y/@;E_J7]J$*]9]]#R%%!"@L@.HJ:'0WTTDZ+^$%U%MS,\#9P]
M893,JY<XE216XB*TBCRV7;"T\X([@VF HK<FH5Q*MXCP+JN29F-F7G6-FDS=
MX"27J/T_>[IB H.)IS:_FPPWWJG/R,!S/:T=^8P$B6/42HU0+'E#MUDHH1:P
M-]L>>*R#==8LL,MHZN*95N$/T[I@CIL,_(L'3VS>7/@FJJWJC2AO;<"9PE]3
M]N==3<+ZE,%W_Z1.V].X^P QX2!4BB0Q?1@*P+2);C6#D_W91OX)H0(]B*$:
MO90Y$V9 -'JKMN?U]J+7A!%RQSAOG9W%W!!U&"<("[%W(L;?T&8^)'?_W7;\
M(77?P=.7V5A6?"*.W]6S^?F&_->6K![.RAT=!&<CD;**$*'4W3E((5K?#+<L
M*D8F>+_BS,M-RC4W;!XR!%K$N>$F\:&8_8"U)*$GLT@C=@B!5.7L5^WE\!LI
MC:"F)3^NTTKZ7%C9]7 I0QCC+ .7^*X;_AT18S]X6'<_M5OKT=<'DM4*U+ZC
MM"EF%N-M)3H3I0'>?)\'D?O:K"><OLH.MS/%+VD<HE@VF-^$I#V&$X&=''6?
M"2V.C3P\"F\<$4[BRCQ7C)ZWBS>I#EM[T1;-)JVO\AC9>^L/5?D=%;6Z()P%
MR1EX8Y?^OC?K2^;*T<>/!2HL ?(7FTSN8@Q04._Y\L."<)RLDZ>V#Z\"@7T'
MDP@T^_SP<(%=+HL\Y?P6).98=>=(U%'3>LUM+82M?AZR9#RK6.%PO,O^M=AN
M0N'V&[7;8C%NTY&HVP*!MC6WOG;!8IRAG4 "M\7DVISH?T3=PP%S@I,SC^%P
M+^(60JSW"8\$+EL69N;7GDW9/*9IZ-^&")2#SYF^!=S*JLR<F#+U6>27CKY-
M*7<73<%]:"2@G#'NV"#V_FY]MV9"L4;BE1!5^]K9I/J[W F?GS+<1&D?6%\(
M'._+/-O*.'!%YCY9XZ)PBY,*^PKEV-04E].0'9['-OG(QQ<T^!DZX]JVD#1/
M(WDC["?K(]7&]'&M^%=O;KXO&PCES!F ?EHN<_.[EU#9.KBI36K("&(M/6P-
M,0F5@^@(%3;+*QVLQN><;5MQN=[M<ZA#%!Z6/62AMWEC6",U7$S?M_BTCV/_
MYK,(,^V*_,#2@=M"W[KO(,IUQ7:[G[-@1&?Q!Z>]2)'=TC!N'C9MJF),-8[@
MBK5>8>$"6/=7F#[6*('SB,W"_T/]B<5?&QOGQM<DF)0]&9<A2J#)_)F"0S-*
MOE#[\[H(K. ZL(;=/#AUZ;5/C0=L=6/>0Q252^)P"U+[^%RSUD=]R.4Q4]-7
M2K*9>A;A8%5UG7GS=-Q<O:D+3PA;.S$DG'!M@DN;5E-C1E-Q969B5(#IA1>]
M.E)^P_O9AR<&_YOQD/^/A5V5(RK.6VOUYI!XLQ;4Y9>'<-6>S]']1#;GK#.1
M<LM R77F\!NCBN]S?>+'[>>0M>D-OL!F!WE_DAOXTIG"*)VZ/VW/$+V">:IT
M2(RS<B%;U1[PS[RN)M>+*W6,VG!^-GKX<B)AI.P>P+CFD=X>?Q[<ABBUZ!8'
M;UZZ#7:SP\9G!:).6B5)XQ,.H3/SR)DY5VW&5'1R(PEJX4HH,:UGZZIUJ?9J
MZRYKUR2T\9)>?L9[F[7Y4N7$\ZZ2)4;PSF AU-0#8M]^?+$889SO?=N929E3
M&NH"BY/[V\$ =&N#B9Y)>H5I'?<)-1G>!;4ZO[ ND_%P$105K/<TNYF3]-X3
M.\C*G""O%UB[!VSD)4!./2052/#]4]:D[@$2CKLFX:NUGP)#&KN=^05RX<KC
M/FO6DI-UNG= ->WC3B/V,9Z):0<SR@$E\0\BYB3<C&;F/Z'34(U(]^4S4 #<
M[L3'T24_/*U[<W-[X[/#^9SAG+ENAI,I5?KSM>0\/&&=Z2BA@?2H?U*]O+#D
ME+O8'>;A:^''Y]?'4-O\^DNT 53D\#+FK3,1:@16RA%"B><15(*1TM0;^B7T
ML8G=!(C/0.0MK?1X2VQ'[&9:)SY(GX67ZY/P(VOFZBFQH=O!DI2:T+";2>CM
M^ZNXP,(0O9&MP B,89M4[/IYDGY1*WLS^\O$0<D!=-/$#MBZ?/^4KO01W)B$
M\'(B06,FZ^F05ZXO@EZ*Z<N8!WVN25:'YBBUTU$64>*J4TFCJGN[D<I>Z;9#
M1#,J(<]*VI\/1O*>W/^01UHZ3N?+183K0=P]0%OO2ZC<BM)GCZFE0T_'7[??
MD?PO2*R4S%%]W)[:(^W8OM=EOIIAZ$CAX)@:BPV?4)V$KIXKB<+E>\"0A\K&
M'45T>[YSK>%*G<'.X9G=1D%^T,]>I%PM0++8XC5;I04][H5 5M=<Z^TKGE8_
MJ&!:^>V"WI+^YFV&L.V1 >8.>MG:;MBQ!;PS./'/MS\2YVPV0+-?]Y&X6,V;
MFAQYE8@PD+['./K\I5M61(O")W!SYU=:^=W2&--8!ASY3-&*5*OU!0K==M]_
M@X.%*IKM' L_N#X:9!<(^-#G_7%[LBF[?U#88&J'X OR_*%;D7$@OF FD[F(
MZ>0#=?=P8=A<Q^9QD[0<MJGYUE1J6?DY67OM<:%@I((.^KH8)L.R=3@P>&1_
MNZBSO+V<9EF!&55U)4.=>+95LK(A[@RT4'7FA"6])R6>0@-<\$CWEIVJOV6#
M;106=;62[V=/'A1\,C,*YG$#%_E(WP/D=H5JI@I&^X8&R(W@,EWPUYAUB(=E
MPXG8S1@=-Q(%X4#T$*RLG!.Z7Z"'%TG%GR%N[O!5=XT])4F**GSXX@GK/G'5
M^M$Z][&&K+D$MXK'"0HJXEOYCD[G=CE>L?<Y-'AD\C1KRJNNN:!/T?Q"7FA$
MRVL.'HMV]]NP75]D4@^F&+9NC,4V.]XB9,O&L)+HV+^W0R;71Y,>-[ ;D&+Y
M[=*^E>33B@NQ&3=_XNJ0^=4*_S 0X?1AZC.43N#BV7\N3(M+KI8Z[V_J2/NV
MJ/H.L!OV[PVD],\O8LL<1EML_3( 0'<MJZ /:1<N:U_\>6 AW8Q(/Y76A6NL
M9([3Q<^)RK\TRI7Y1*N9J,KR\@:O>X!WK.S!):SS'M"[=%70XY,YY)Z=*B0E
M1LED%AB<WO<'@R]]YL[>TW-I93!<09LFU-YV#X 6.'(QXKU^8WWW):_I.L0$
MIA+Z]&)3-6[&6\G<KG>_?%J79;QOI:WMW45RJW ])0 $;;_=K%Z38\LRX4UY
M<TI;^:*PKEF'_H5.\S,ZDJY"BC-0WZ[FW>MCA'C!KJQWG3%KM;FK="+U#LW(
M,**=8+&J:AJ+_>DN^N;T4M-O@)M,PYF4RVUM69XA]A?9V4B "*TX0MY?97%"
M]-6CI/!?O[>,7A:4)8H6"N9I?.P:'C":4FW W7I"H^-/(6G+68H5]#\@CTC]
MW/XC18X1:N'TVSX ^HGAV:G'WT0ZXP.7_?AQ#)9-4,HV&/.UT: D(NVAO=@N
M8@N#,\(0>[H7&N3T-9HFY*&=EIO="\UI=0DV2G^V"LAW^NR2S*Y$K14?OM&3
MC\7&9^6YQ=._6*L@5DP"(]<2K/> 5O*JSM;7)P'2(.8^UBN5X7XLFS42/V3%
MQQ"!C?'-#&\?K-JW-#QDL[. C62RBX+WCEI_B*2?Q/=/G4I&X'F1:5=V1H*_
M>CS,G-X*GG[WG%E^5/=&Y19O_P#'H3KKU!)UH^)X(&(WIZU%6)*?FJGVR>5/
M[PKH\<1=K:SBP3W@6KKGAKK]$.;NS=G;ZY29,0)^> X1Z?;,^-X^_J!_=8[0
MX=)V'ZR?(%%#GTBE3TZP6[?:='6)&5ER.QP_N-#PH_C2][ [IYH:Y7>\Z9,I
M%+2*2D89M4C.AG]?_=NP8"KV_-N3A@_OT4C.IP1_;3B/2@8\X\E;X.![P&G@
M[9'HCA$VLK5\3\%Z=_>46-<W#5\0P6KJ<@_XC1>P_6G0W^W8;14=VOL/$[>J
M4LORE49<C1H6Y$V/<&('/I=6B,^X'GU3QJN ,R\55L%9J_94:@-$M,,W(2<<
MI$T66)VW'$6;6P&9K[^F>F#;6.KR\]*&?3=-G]9V>5BH2R?<D6UBX(Z8+;ZN
M[[VOR+36BRX-Q,]4L_>\'$NJ)\CZJ/*$*WQ#MIT"YAFS=A:_TU\5HF1NO[6C
MB#Z]]Z-V_J=N/\5.$I?<7]GG2<AI_L&0W .>W&R5,H)ZK4\)/ZZ;E<1WVFMY
MF;>V(F@Z%HTKTB9P"WIG\0F<DITXM1-#2WR/K#YBMXMYT50FZTA#T2EI>0@<
MCWH["7'4*@O3;[2-@?O>_7A\)&2SA3[XMYT.Z:YRS:BJW0EIX2SYI,E-88)3
MPYGZJLGEO&,V</:&G8&/S^@6@S &MZ3*T>A=J\96 I:;((Y 0+OO#JLJ\#95
M!(CM\I> M<3GS2F90E=Z.C':4E"8Q;E "A'7)XA@[D?U%=Y(IDN[L K:=HHP
M,?3A#'F?\#U D9/@\A<2GN#3VT\W#=<#+8,C8[(4R":Q@6F%+\JHK"8?O++Y
M?GQ=&=C^,EG<,2VM<.X,E)@GL9IOO,U1,.AL>Y H=J/^V)3U!U.T3M1^LF^(
ML3MQB$J:5/9%5$+ ?M=\1$CH_A M?K_(MWN G@$=H[1/T<7/VKZO9;F_&V^I
M[@%F<4U!$Q?QR0"<_?/IZ,I J%A/[QQTX!WVZ&6):&/A"? 3GG)82%JG&>XW
MA]$PZ%!UDC-/R*^44K"-OB&HXMP1"F+V%5[,$T.$SL\C359B3*X?TT&BG.DV
MPY?>H'T*28/'. Q8X_0R2 U$ON,G-Q1V/ZAMA,HRMSRJ4E?25S7:\U)8(^='
M;4?+U8(ILGC+V2\:@CQ5E(_.4F8=KH-27X8TQR7&_DFI6TSINHY97C:<=AV?
MT)!24J+Y6O@]*EIX@?\_8S!80&C^;3[6Q^XETO^XO8 &)8[4-27QQWC^)V?*
MQ>72X43$4^ $XCXW JY)5UE,6:^!HPB= S[0#5"Z7F:*B11.V]UV!QE+!NL/
MUR.SM]<X*_XD7LH\?<OJZMM$@&E;EFC ,$0<.UZDK^FVH';N 2\:EF$"*YZ^
M2R4]%VZW!2=C*V/W #I96'8GUVPF_<S7Q*_6Q06_$[-Z/;:=7:,8^H\6Q<30
M9SLOH<3.@2%?$O>?E&*ZY.C$_4FZMK=BQZY:1*\64!N!MC]U)PW*=*FO?Q+G
M%A3ZU @EI:5$63/9CID-:";[[H=Z&J>*MG+/1*[K'53ZMSQ)7D.+A'(3@3=1
M[0- Z+(1)L(-A)C1=ZBP G$9\03H!);7_0V\?:A-04=EF;Q,5;../2ZHPA?N
MA7,=Q(%3%9GXXT_/@5X[#./'?C11DO0U;QR3*"MT6=3>JFJ3?1"$(<-VJ$6)
MB(2.#%6M^N&7UCU4(O(BK2*M"*\3EIV&RY=/&;L@-FGGY%NY%:(ET@]EM#]M
MQRD2I&XKF"-=ME &IQS.74MD:T*1!8U+#TVGW HJXSLVCMVW,XU/Z1PKD87F
M6D+O<.\!;*VT^\4-GX3N#O9#R/0OZ7N6E-[%K.160"=T\8D#*V><KZ/O 5>4
MFK:CQ Y&*E462(7'/=49Q][_X$#Z#PY9_PV'D 6)W$D/?;?@3?&OV<V2;I^=
MMOE"B,"^:<@AL("/L/70Y4"B176T%X?I'3B;M6C^ZHA^TO_J==,OOL#&@1YA
M;^N&X<Z%OAH$>P.RQ[][Q<\LSW]9DU^6U^L_4T@D:,;V"HO.4U*FBY(JD4.\
M/DO(8COCY6K[^,<TG96MPO!:JJQ)G-S$'Q/7A8%M]J<W1C?+$NWVGLPZQ%9K
MY7169]_ A3G\?KLKJ#2?>\!+22'5\D43!8$;F\&=JC0N6#S<&J7+OA=+])#I
M@-@Q KLL-5N/K]+"V.!&U<]V66D89<SNJ&OD,O1A0=$\E5W/F#/]^X^F%O>_
MNU5_M!;#]<@E/,'YWV?B%O=W"DYVV=<=>:/N ;Q5?[P\ _^0.=^(#*+.<I%I
MENC9!7Z\7[7\986N5X>C)W,F><;JVMX^_C<_8[ZWJ7K?.+3S(?S;$[S$GF+\
M_^Z_;'*YKFSL6'6YV#SN;<^1?^L E/J\>OA/KTLM%H*M/A*TTA.L^!O;)I_C
MFP.OO-[ 6 E..01(RRY1SRP+_@#K8D<4YD8(2#;JKI$[7-<_W9TIVJG*5N[L
MZ9C>!#*()WQ-I"?T0#!"1\;MSE SW,B=9N0&I?^?&>9ZI\$)AU68PRMEIL[,
M:J$G>]&1,;$+-U_0NSE3XX!:=SI*DYUC6P27V^"(+Y$QGW710/Y<,S_I/,0-
MT:=\-OET6V3S-NQ2%I5U:=6J>3UZ5]$D_]\DX.6$1@/WDXRABQ_)>8@/9V[X
M\[HJ7S27/+5QEUE(%(I=/0 R@??ST/M+0<_%WXV:VE\1J[P>M!-O>_X@TF-+
M8BG]&NF097C]\_TQT*_32!.C>B.$*,38^QJ[-#0L]U=D/N[M;U2/%!0,#I2;
M WO%*4K^3ABZ$&_0<)JL(:Y1L&8K87"5RSD\H34Z0@N[PB6AA7'+JSJ2'64:
M<Y8"=*=':H+T-/'Q629>\+E=*0TGF^JX.;>U0PLGNG4EESA]PZ&J_BE>I[DL
M*;A+5V6ZU! 746G'(>6L4+0BXRVRSRQB2204$J@GXHU"RQMC-(U40Y[I%PSW
MV(,K\@=8?:JE5SW\:(!C]?\\0][UV4&>#AWEEL<(1[GPEA=;F=&1JUTB8H#Y
MA_!!<)Q_HV-% !'^D^RF*6\9"R=DA;K1D5W==] G]<<+ZXW\N/+V1"1-#L(X
M=][.2EC3>T#%IX9DH2?P4*L7&V30DO JS8\[['DE5N+Q"MOXHM(L-TOC;I4P
M!P__@/2/F 0CHK_:MR+Z*!/ZP(&5&U7QEBUQI&F[2C^+IJB@-&,!Q/"9-0^W
M*, S'JT%S,(?XMW2FG4*X6K0G6?)0 N&N\S]$?/B(I[ B\+Y8[A8TIXY"XLV
M^PLQXI?:>ZQUR_,4_>EK056ZY'!4Q8PF6]*2C36-V%?64T7D4+\[#?/SM,ZR
MO3:,5[L9'!27.1.G]E9)_>@>H*'F-M>T?\*/$2,VJ#1O7$!0SXJ4XXPU*0W[
M^CV>;@DQ EFR@28W32&I*/^FK&MMU^'->;2M84T.!DN\@ ,]3L(7?L3+E;WT
MT!^DM">N3A)4\7FB'$(_@FKG?]:B0'11!'.)@N@;J+3> P8X;74,XRU>7A\8
M<?^9?\,U?<["GI9@2V"LSH#L*7!C;=HCD9Z.VE6U=H+@D]OR\?S&#9)]EH=1
MQ3=JWKQL^N?,3!9.U?4:#7^N-RQFF. F"LY(.?\:X0+*,EK:TD)G6JZ]7('\
M3]X4V5MPR\OV'5 U!6U%KQM=;GC3* &B?OZI?X__6:4?]#%VO'L 5.I ["WE
MZNZT1;KAJ2=T]>26PTRI8R&T^II;7?.7MJY),>N[F1%- %>1PS=",^EOD3C#
M^/[EZ,GXJ<\%=!S:EOX*#UASR3)W5VZ-7?Y1'7+O8B[UZ?Z"<5VU^0TH.@[,
M0%SN'\+\?DDY*95;XV3W'L!5OMD[U)-B?ZX^9YY<V2S!*NC@!7V$?N99[^EM
M:^/<S?EN,7T=5;?L.8_[X\\8_=Q_LIW]XAZ?/L71[.+<6K475"I\;I[:NW7I
M\F@"1SSVSC8+=@XD'L >/JKO"8++XYK&F*<8YTQKZ(B<-; ;)";GQ?N,@+G'
M67VN'7,D;59UE7J&J>%\4=J5'-6:,DKK&>U1QZFB*)_?9_3I*)@>5(5*S[81
M2D<[OQ&,)) *UOEI;OXM?LUQI#N^W3AV0F9CM=Y;TT[PX^CKI@M=O@Y_+@(?
M:%^Y2Y*CK[SR*3T,#Q/<!!(T#5Y$\6LA=FE'(,:JFS2I:W, >>>JJ8ULNAF$
MT($925 [P2ZEC[V?(\?U/0 V6':@1)?3X[S'(5!<8<_,(6)@XK[]0I&;=3I.
M%='RSI:<6/%K6:UQ[@EX+Z7_(C!7O ._/P"'_FWH4/UU^\1TV_K042:I.)W)
M4NJE&WHV*:O1?P"5[HP!^@*;FD3\*@4+$>U8&%EB4K (K!IYQI46&B_U%3=.
M<$!N3I7,/W4.Y8N?0\_%%BS0->0@%*"[[IY"A_0-UE'5?;/E$P<*RM]P/9R2
MWL3DUF:.O*WF)M%/[_UFX8-R/I?@ZSL'E)U3K=9S.K4*!G3:W!Y/7F;%'-](
M.%C3W@-*:RK+*^X^?@HM<(#[[FUW>_<D!<_?)B\5)5,YM^@*)55N'38[3U#O
MM_45!$]SA+MZ!G%+!PRD(LKK+ UK_8B8R6BC8E2M^)I"B4%_]\J\48059]AR
M=^5 \X 172> CI2 <"H;21$2WK:,^6>P#;U6>GIO0>23F&0M'7/^F>>#@R&3
M,0\$^>-7JUD:;1TF6/V,8XV-9(+BKV6=SJMK17*?F."<@W\&7KTWC+%N7PC8
MOUL@N2PWO+XC=EB2[ZNN_(UG*M-]>;O8L77B&1B,;6KV=92&6SB+/1=IH]?]
M2MZV8>7C>-+*0YJ4T('4-6N#J5GHY?^N^TR!+<3YQ9_8CS@I_T[S%>_L^D')
M\4V@^)!]9>E?SD:$6+2$52B]1M<HFCC]2,<5<7T#NAE-&'A8\CQ&'EPR?7:W
MQV8^/Q>*4-&\L&.O[NF\Z7H9;&C)D?%4B68# B<[(TQ4</="QV]?/;K:?4ZW
M"@,M)"W(G1-+NP9O0^P+3Z:ZGH7!?%Y04X-P<!P:.4A)*"Y+V< G-(8TTC <
MG^Z8VXDKBFVB50YGN\,F9H&+@G+TE 1U[TS?&+-,M-@[R(%MD:,RW?)5^1%I
M8+H5QQ"/W J[7T:1^1W)/XI&)V4X)I_Z^DO!R0G60G&CEP2<Z)_S/? SO>EQ
M.]X)OI8YP:E;P&Q+406F-46L'*+G7J=;"(NT;7N,RG$_P+'DD4"MG'HL(?<A
MQ*;C6M)"M7KO1EF>BAFC&X"C]N/X[TK>W%&M,3P3J!K+1JFY_7''?]]S4>(F
MM#(J#!?Q/5C.X_6#\C VW1VB_3],G=APS,C7"G*1)Y9$Q]7LH,&;Y5]<7UVG
MI9G)K\TY9B8&1ESZR@+'7A:V;))[TJD;.T6_6;@(722DF=B,)!UJH#@_G>LO
M[0KSD<P=90,O714?SAF\O/SE=G8/,'GI"FJVL\-= D8'X9'R]GDD.?5R\Z=0
MJ(?+6B=R&X0QA4W4E2/]OB(RW&;T;K@;VF:^Z>TP5>0W4GLY4Q;G^XMK\),.
M#?KTUDILXE:N.AC'R1*U\XUNE%?SCD!V=XMI2+<G=FA7_].5Q9:Z+,JJVC=,
MJ8UWSUM;K]NIRR%&;.6^W3X.E:1OMR%,NHV07*O2I=4_:4>;]=S0.9)T9)_4
M83-?7C9ICW43.FTV^H[^5^>9M^RD5<)/65AL[\"QH60OY%EN4LC9?,:B=JWS
M>)\L(]:3 $L-\* 1+_S\'"G[:*WOG]!]&/>.X6GV;O4C875041^J3*PMBJ9#
M^Y$Z5RX)G/G]OFK7[9Y>G$,._R9+YQTIYV<9^;I&.WW!12$'!R]@<[[<)+9[
MW^+YU!90)I'8-]:_-/Y<-_#*U\[E:?B /-]&["'7%N.X)PGV(#?O;MBIFOO9
M(EWOMUW+#)1$80_$OSC'()RGB_/3JK ;,'36>[?0-?KD1I(D+643J6ME@&@I
M_O Z?M6RW:J"*7S9&[-VP^UP1WS39G!\#\B!7,3:2[:N./CSP"*FOTJ:*$<[
M[F[<!3&->=@S[[\N''!.ZZ[GC*/PL,R)#:EV]\1O&"M4/M\M#\PIVH0^0@GM
M9]2C?EF^FUL&EY@EI/XF"JJJ/:@JPP/'/5I&'X1?=[<O8H+O 1UI5^$6R=H6
M79)-R$O[) TU\Z^"\DYYD#1&+R)B)Y$FZ*"H2&$14I9OX _$>^RD-6D7YW%-
M2 STV+/5Q/Y.]^TF:D<GC7,UPQ7KVJ1"]7/@2ZN6'&.Q]0\ELA6P7>T%"#_V
ML"VDY/$=*'W37?QH+.:$9<B1;PE*!!R--W3&GH,$W\^FE0?FPW\\-3ODRDP1
M\=U1[UAU;.=A$E^X!RP;MCH&)Y$F:I@W]<I<'PZ&Y=?&OL,A?$N*-0".F4K-
MS4EKGS6.6,H>/D]IGO#,'''-"7BRNY<+]H"'LR3""O?Y Q>OKAGBO#7!ZQZ+
MUO> $SZ/F.6Z\[;2ALKV^*N7!&#'.VVHY&^!L3-IW[&T2UY4TCV@T_\C0D_8
MS#F++:^_9BD,<[5'5^OT[Z'/6DZ;Y"';\VZXWN.&#HS'6[3UU0&'4LZ9(S_'
M70LJOT&>(0H3NLS,BD]/01V3A*K@&/?;4,<[S%"%7BL(LWUB.%29=0]@#YM;
M^X4U>=Y5+_8Z>BA90TV6"S;J<<)T8ZA(FT8LJ0:,7@#-3IJ0FZ(-!E7AI#R^
MB,6/)XQ@MN(T7":G4T_J:S''XHFG2MW1P"F+XT76W(K$,6A=2VIX=4;+\;4/
M<PL-$#]Y;A>/(PVAU-U&KR&OG3:^\$X)SZ6N6JN;FND+Z_L+:LEW4W-C)?,G
M*A7L=ZQ.T17I\0]E4(GOY-I>>LCX2^G/I',/NCA"?X^>6AEQ3BC @8I*"O.$
MW>Y;3G/G](WG&F4U#RQ.V;H=QG7JHSG]Y$&U:W1?WH@W@\6[DHS:@O DN>\!
MBC<T6$'_2[<GF?> WU"2]O"QVQ2MP+!TX=)!Q]FT\^AKYL13![,\\TZ>9Q09
M-[TQW2CC@&K6U5MM2XO0#3=,K(!Q7/SR%AVJTLO3+'4;E;8*=S_/#6#LY#:%
M=X6U82O]3_17(;Z.^"G+_X#2G@/UUKVDKX+Q2,#V=REA2%/#M(3KN>7V'0W:
M_>"85O-8\_F1+5MB>1H\QZ)H7D96,#7.X>ENSA8_OG1VW2R"PNC(DYQ\.]23
M X7*AH*X:)T>?S9K.7TF=H[;[RAM'AW*#U^R-!%S&JBS)_ZI"1O%/^TR@EY]
M0'BK #RD(?.'_-3W@-WO"N\X:1'"(=$6] J/97-BK%H\Q!$\;QGW(430,PZ.
ML,NPD>.KTF?E&$:Q=?^H58_432?HS#RJ4HO&2 9%7AV/7,JY^ZLM6=O  ULQ
MP5;FWB4YMI[Z&MO#_F%@^R[!67_G+KIV0AURF7F(^VI[MJG)X-'Y)MSFM$QE
M,=6L!HXB\O_^BL0\4M1'%9@YM2?HM_:!T>M.E0C!RL/2QNVP@*T4/;:Z2%Z3
M_Z_N#47#\JW "C$2RO[K/QV?V2FSXO^CX\/P/QV?JGM 7(;:*L6^+LF>LQ(O
M_W2-QI#J6B.DL5GNISG4P:RFG4<EM)R^IO)0*-K_D>,EFH-*7A@2F2Y&5#^O
M;-I&_?9D_=*/7I(_VG\&/C<[Y\_,**-)-R2YE2E[TR!T(SQG6EW&Z<#Z\Q.U
MN/SRIFW&'BY5SBWK67'[TV-(@ $WO]P*!PS==)Y^1Q(R,#P;;0P!WIK< _A7
M=8B=Q+A\<1J?HKS*?4TE U?1IP)Y249]_KKM(WCRK$-'=>+*Y7^<3NEKQ_SR
M"Q\U[QHAU'J?30W5[W:[6:7L;T[9/.S=$Y_-7(X9244<:C\?@$3*RDKC<QC\
MVX_1%5I74=M;"ZM-<?ZF=J$TSDXT?8Y#'6]H25X<#K\F ("(<8CZ9QCR?"FR
M&%=@8^R%T:7,PR7LJ%B%.:FW^;;6*Y_W#.:_ Q7G>MI?39#/I>U<?UI9:S#9
M/WKG(8[4[9E&3K69[N@DFJF;_>XK*1SL8:OIU;/$)+<JW/TA6G2%GM@.6'M$
M?9O<FKVBIZXV((#AWA@H!0E/Y?@KGR'5%/ -\;/W<MUH.0=<1-BL:Y8F,$H"
MX@&JD,)\.SH18-.2)-;/X"C0N!M>;".<T4E5WA,<KDAW26B_Z1CL\WJ9Y%4Y
M9P7_W<(2VQV(YR)'PX3U>!/N7#6]P%U1O50VQOT[5;AI 6=SMSS*-J'YNK>Y
MHB6&>/]HYA+4>>B/"3]PEU?B;SN\!W@S#TMF'/LJ>V*D*+N;_-$YPZ!KDY,S
M5[_#$6SZ'U32/[7-&G& %< 6+QB:K\=X(M8Z5AS;)<.7][>'QFXYK+I5:&I8
M6M1-[3"*!RG,I)ZORX-:.T;VCV'_F$LUZZO4_$ZM\JKR_JMF=:T3&@[?H^BH
M-84BA@*[YR!$Y9S_1'OJX\IG>7&&63AP$X1U9*Q'SIW#/: :Y>]5W8C&6:7[
M^!AYFU'XC\0%H-MZK*MR2J'+AB9L#P.*ICTD2"2C&N0\H<,B_@-7=/< YH8Q
M9U1GZX=M,W*)/5NSYY=+Z3=9S\0VYY&.6K)FD,$BY\RGJQ+GEH4PW5E-36EI
M13'<9(OCOFYWXKJJQ4KUQ>8CF.;)UQ;ZQFD3A^3-Z*#::D5^U_%F:UQ<18BJ
MX.*BV9<A_WBGBLSKKFL*$/.@ D?91"^;P_.^7+K>X(,&W^B&\C,&MYT_P*ZR
M^NM/7-@*9V:+K/>*RK(*\T U_/@-H-N>^(2:G>KM"P?DWZR[=XV7LM=Z7]L'
MQOT_OSF/":I>]-"$=&9YVHV40(;=_ Z'5D.>N1J.S15)F#6GK5$X=AR8S%CQ
M7?<U3KW+ZMG8W-ZD1M2[7=@_BHBH-V21"AZQZS_Z:;"2*G=)_JY_%OU)T+#B
M*V[KE6?4;4E3>>':%I%=!JJDSL+](S@L3F3Q<NQ)7@5F4%5J#P4SI+ICE$HS
MTZ;PSO%F]'PAS^EOP(9O13(I/_RB=-?#/G-F$6A>L<;QN[HIDP +-F#U\6U2
M:FC+*\#&( +$>FE3TW@N/');)S2]RR SW5/X_D0CD(6M&/5_A\5*EAY:C[]!
MD0]8)M"/]K-I4R>#+8PX<IN=1N,):V=IW)CYYB^&+V]TA0,4F>QABLYBFNO*
M+9[YV_> "0^?!:RMEXR:#T.[856[E<%BQE9L0JW3]" 1QP(MBS-$VD!J?K8?
MO;OL6+7;6/X3OE/"%;LN/%( 3MT#_U")TUMC7)WR:JAO=KU^L*PGK*PHV[G0
MRKYMLM?/SN3:=DIK0IJ\)IWZ'GY@('Y5[E89HC_"5<W!U/K!V\[Y[0?D@Z#R
MHN-OX^"?&0V%R@>[Y#D7CO^^RIJ834F:OG#E= (1&)RRF.0(<*4!N9T:.II?
MIM 3;'A3X_ZN3!B5^"T0>!7P\W@L6/VSMCX@NTDT%PGAY.U@,J6E;>TJQ;;Q
ME.^(<64]?9OW_6N[-/6)Z25F9-W#Y.7LG++=E5=V09DKW,*4]G0U8LG^ERY+
M*R3U<FAH=7YS8QP$V$ NU1LI=4/21DK":8>XNXO9S$KL?GZ\ Y.$X];B1GCO
M^TJ8,DN,"5ON(^0?*44A+/]L./-UN7VR(S$?P7T/:J'9G?+UPOGC2E$1$P2U
M[962<EMC4=G?MT>=L!7E%C[K!(X?_H4>B-I6-&>X2IV&7H+[(=0$T;P)F@L0
M+W834X)TX8&7)OEY1?14^[F/&7/'55.WA046IEZ^.'1O2:C(S98"COXB=A?'
M1B.,W0:7=\YW"FX^K':A:<Z)93^W*IOU[\!7!4N$NZ-B,_Q>-ICYCBVY2NV6
M*TL2H))*EYO;0_7585(.OY1591]R? YM=8?4(0_FD.79]=I<W<XJ*+ *,/S/
M%'T0FZ.0@W],/&IKLEG;OGN4HD9D@$M(D8=TL0>/V\P0SS]RFRD15HGL-#BD
M6W;;"*-JA?*O_TCA:7.Y]#L2\6R7S&C-\A?\Q7X:.6V>.3R;_-LVJC<<2>0F
MM.U#-(^[9<;DNVK'+JP=:ZY-5HO=LN9:&/IX?"+_[XWX8A>[&>\!OS 3P)DJ
MIE^_R+['M3WU L.SZ:0-9G%.=[.?>:)>]2_W<$")JHI,C/93R)-,-*<%@777
MV!?PQ]?4,,I>04&!2+"M 3\ "- BJ3'AD[V43=B8)G*N]Q[^)=@G=@_0'AM>
MDS#8H,\WW2F!+E1>5#BB?TA.G_<M^%]DT_<6WP.V"L55NEZ-GH@<U,R(QHYZ
M6X2[-V3%'A[6']B!8Y>@ZF)9A#Q0!*U2Y(;(E_)B ;M,T3F-@VK!6AQZGK?(
M%,3-! 7CUVCQSQ]Z<4C!6%RW<<"(M6?NJ U^M?+B,N8>X#N=>C-&#:I4I[9?
M'.&1O(OHVIH;,IP,7J$5*^AUHCHQC%)RJ$T@3NIQCN@DMKV.@@!]6Z2>=-K[
MJ/G1F[O%O^K5M^-WIK9,M7HQZQ*%>XPYQQ[:"8M%+7%1S>H:N_5S0JGWQI$^
M!0T*GKF_A,^]^46\6U <020$-80N3[CF_;R9F6-'6839BVDX5O#.B9SO 4D\
M-]-]P1X/B0D<2\P%^'2-;,U/;#D*KT[%*A=SIC.WBT'JFDPR,O\?IO;_S\M+
M;>U/9#^;;8KS@EDP/M%$X.M!XFF],^W:N@FJ-S:?BR-=MX+?GUQ]**>*-99$
M!Z=V[^U*A-@7(D#S^[\DS=;.I:QS>_*:U.9 ![GE!46N_D:R'":&%SMG^MQ.
M9DKIT@:/!EC?,UQ%/$I$V9>F=RDZY65^00@7VJ9+K.B8Q_U/DD1YE@QMK%F7
ML:+ I]KQ&2EF&=/-UW;?FK+ 1R^?+F80$20O+"P86$GNA>7;$K2-_**R(0D]
MKJ'HX8DW/N3GP6!%FLQ3/]P#",4:/X,>73NV-;.U&-&.;_TTD.N@LRE<<=<V
M=<L=8NT_\N-TA<IWD"40VQK2X%NB"F4H!KE3/Y9X]<M,0WK$Y6O6/""JB)<+
M)<ELKUQG-.4)E8^PM-03F%_ HN8W^VRE7T[ ):^*(AK$54D<=Y_6MIH+Z?GF
ME+E3EIK;YWHK%<8EVR:,+2%?VM\I^7\@4'RI;*P-HF6Q&5@K#(7Z5!+^V]G2
MQO)?NN,62R+!?2Z<.4U+G[0E"%*W1D<]@AOF"KN]O;+3-^<3"CD#HFF62%)%
M%7L^256+I'K@X8Z?H^".27VPJJHQ[T"]B6K%<1PSM26P+?:VMSJU,#ZOE<K@
MSK1!]I$&-T^B\-(L[-#:>4I*%([E3K79^UC,')U8\B3K^69L53^MGN]CX$_S
MUYU"MDYE&&FGW^2&<X'K0EG^'8A9&R+R++):.)J@;B\ OWK5E4M ]9U(Q]5A
MMA=)DZ,61R2&)BHO&#IXS80JK"R,BHG6L;6G8_2,,3UW+[654T\82G=JCK:-
M4BKFKD_4FI63=N/#FD/2O?P<7]T^YMF0>2\C0_ER7YGK8L30MK%J['=IV,3'
MV1:9VBOZU[6-= \_=Q3;O.K;!9*6/.939AS:\&MYH/I/X,CR_]^+6&K_4C_"
MB$_>@GR:)W-KN_H#_2M>2%VVP%)&0T%,7/K_]O7$T*T;T=Y3D2^9V _&^@2>
M9L7!TK3E-(AZL>C"MK/\_H#G(4X-Y-U'D@J&;TRY^F0$2TIT/UX$8EMV),8%
M"W;^[\D3!+*./5S\5-I#K_._'S8O,=JYO:"BE4X='^='=.U%#WG][R9:_'>L
M!4_F2KW15EQ<ZCV ;"PZ59K)DHW@,1/X=E M]"VGH!?!PX)4.+C 0H!(S-,L
MK$VZ:<\K3E5#5:-FXO\'!OF_+B\S&N= 1)(4AXYKY )N<I1OSC_->[:^$AP=
M:E)@NOH^9]2F-,%>,'9:,JPJ2-;D5LT>25&=_GC/+/_=I<O9?+QYX#1=ZL$J
M4O;QU,K\$95VNB%/^ML!MAVSL&CR^GJ1(P'..]PE6J1$,\.SIU-;R5/OVJUY
M<DML;!ARXF;[9A[3Z>U^!?J 8EY[0M$&$9%ZH_K=D08J+Q;-@PM2RVOF9J<T
MVQXSAHH4EBH @/B>1"ACZ"24%'@/2. ?W11O_V#KM;OT.H_6N/.05JBD!_V)
MF\T^0;FQ3YF1BF\);B %\@Q#6^.Y,Y3B1B:OM#>/G<U**UMW[V[R-$IS(IX4
M2\8A'!#&;>88'&M84?+V6N.QF5*=9\@?Y(9";3K4G+]5L^<_E\=E3<C)F.,$
M(GFBXE_<)N'< \9'6[L4]G.?25]6TC\%.\\I!<R^(XQ+.?#E*S)/69P*$5QR
MG\BI)L;\(6N/F9EQ6Z+JW!\.09:P@[=YZ*_ZWF\[GB64KB5J1YM<^D-JG69[
MUO\:#'#8['+=X?&?\*XN*X(7PW +"V9-*<S)?9ZNKJ\\7._-P9?V>HW_0&+M
ML10[)7E$4#U!HJG<0FK+.7F;QNX>,\^+X16)U^+U1QGB8:AEG4:F5IY&>-14
MV,NLWV@#]"Z[LE31C:IF0<-/V_JVD1U7@@GX2,QQ/$FK?F 7O?ZGR^1U>.5<
MI^J0EU8(28V=U?,_\M$G=/V+]GL+A$:GAC=2:G]5V?#X#_8+KH$/2+2H6A_V
M%^T*?_?M+A/2=T@>"T0E[C)M+8EN;D5" &XG]%NHX7*2AQ[^=L,.*<8J<E8E
M#1I+&W9:KZW>,;YB:CHB8HBO4),X-W.*/C>-WWCI72<H*6O3DXHD1K+E/=<:
M];([Q<W]SV^=^FE$.0P/QOL$T_BVK&E@"G*]K3]M>6WY*?%KQ3@IK[>"A]SJ
MJ9,TFC]L575E&2!-@OERO7:[N5N F=S<SF)L18-,J=Y$P7E+.SLTC"DTZ;1;
M24#@G13K\"G.O+5#91GT3FM^OTGU3;6PH['8:.VTD)"3?Y@^7_73CY4=$3=W
MF(<^O"^KJ9XX<[FW!\NUG.$;O!'U"(N9/ ZX_3SHM"Y WI9;50M]BL.105;.
MD+$3OS'G&R+C@VE GA7U2<;2WT+**>Q]K*A0LS2/&%6U0='15750@LA84>&_
MN 8T^VT:1R%-C/TO&C"S+?< =CNWI<)?^K1"%1G;4@6U^KN753V1%48ID]-P
MWMT@<BY [$AD>\H(MZC841]]9M_/R>D37-R<+H^\KEU.%K"]0)(./<0UVOO5
M+T6ZI>7XBB^56[<1SD1#%Z_6HI74_0J*;RC[\\G5=66IO+\D.3C;?L/"EL5N
M-??+)9S3>M).6$/0>KLVRU]_-_?.S@X1),,WW_$E\],U@W&QR*^$HWP;[HL-
MY&^JC')1S#5D.=_KR*,B6^XFV&A'K#?Q]F7;K7JV\ZE']QN=S1LZO%?=UG=N
MHH/E1(6S3[ V5,.XJ4?.%<O>YX! 6'$#V1NF;N$JI70M^+)[7\EN$%='V8^/
MGQG DO*%EO^KO?L,:D+9%P >BA25)N4(!$6!HP(!02+2 APPE( 1%2D:0 %#
M2 )(;PI20N\($B'22T* A X2+T5!D%Y"$%!:#+THB"C7>\[<._/>QS?S[KQS
MWGOY\MO9G=E/.[/[GVW_FL@=.>=[OHNA9MT;PR/O ^^E#,^JCJMK")U@E!=X
M'&2O"=4^BKE)RS,231&O7?3_N\3$G24_!<N1![0+)X.[EN](Q'[7RHS_">@\
M:B'-T[/JQ4>B$;*B;NX3+H0F(W4LHFG)(-[&_)'.A4>ZVPZ!5F+O$E['+XNZ
MB*TM)0JS GIUG],ZA^UU#8BTH7G-HY4W^-Q5MFH@YUWO!0;RS@,X+Z][.FJ<
M\N^J:-(+[2IHH/>L7H.RN%R)Y'2H5KW4RM;Z#OIY57)+D*JQUQ[C)K)SO0[<
MB)LMQNE=;A((K&2 ?A2U"0AL5CT%^\^?/D[%A+:J4#W/;#7_6B*F@C5)(@LS
M ,OTAFG(/;-].9D^_H^OK?VOPF],_ U9%9_6N5T9I2$\<ZHK=:&HNC*"WCQT
M8WI]5PR\10TVQYU<BCLDC$Z+Q[Y[/-;;BKWI=D]<8C)1+(6K4BU5ROY#5OBQ
M7XZ\K=CYX9#\U02NIR&N,$>Y!@@)<F#*L-)F6N\L&OY;5Y+_S83^\U=1N%<H
M?<RPXWQ1="Y%K=*S"!K!C VGZ9%#8 Y#3$*42(W-F.&;*PQ1+KE__7+J;6QP
M5P%WH7[^33=KS4=#1L7MC]!A88I>5[\NB-K@FU1:D5T 8N*>I%$JG=:D-#@7
M8R,7)ADG[?=B-+YR8\3^E9Q!!L!EH%H>WG3U^/7-CJ1$IHXNF0N-_SVH$:SE
MAEI=B,,9,GX4A97X_[O><;!APX8-&S9LV+!APX8-&S9LV+!AP^:_R)@+7?HI
M%:=%EK#S%&TQH!L"UZ+J6_0E9@TV /1^Z*MCU,W9C=;=/,W]5+B(P4_ ?]0S
MMEI5#C=67]F-AL5Q;XL)_:>J_O^_7EE^*7(]JU6I-Z>]6EJQ2E\';QVPY$58
M)R 2>7EY@H1RA9[_QHGK_S422JE5!!S>',^8+RM+Q.[T;KVI"WW+DB  ^R3Q
M5D M\;P=T?R)B3=F^@.&-&.4H!M(-G),A$FI$O_B/X6\==<]O[C,,PB9JE:T
M><Y4W<K$>4 -V3N),W(7"AL7)#H'T?H)K[S3-&( ]H:\Y6?^ COT?W%XN_^9
MOD/CRYE.)R*:<3#C2>I0=[<_L$>Y):U4I"3?YARX=MM7]LO$TW<5'MSVYU4#
M/:["?&)F+] (1)78MO9JUD R('QN1X=/O8V@5)(@]&J_%J: PRWH8$=-S7X"
M:ANK.T*G]"N?#D9BM49)EW*C(PJ#W!T%J 1XO/9Y*;\MP?;%38_-46:EHK,+
MN:C)%N0SS#,*1965E/@$7 .. $"G;4H/%$<9&^3]7;U!3IH[X3.V(K2&,G/$
M6'!UH/^K-.,[W[="\G%"NV$Z0W'=QE82##8Z!ODUPM:4Q3P0F19_[E&FX7_@
MCC1UN=@UV==#OXQKK,9_=[2#>Q82J T/#&%<Q]--/Y?6YV/2Z[\TRU2YD56R
MJA3MJM+X41=63DW 9$&"0QY[IMP8;NC,GSY>?W5XK_K)6X^EC][R>58L%2"?
MG+BZ;RF;TD3^%1P]J9;S0@$7.9WX7!7C8]:SL&*/*'SL@C5-X\$/)C#6OH:4
MC+S_K4=IPU.(E*G5U0,]8.4)%A/PLW3E2,E:%T[54M#6&$VTJ42VP32%Y*#!
M/.P"M<C&CSE)'&U0UTD$T_E.&D6!&X_&Q^[IA H%H;YW3"+4T."1;70+?<@$
M]*@FPTRE9ZMQA]>DT7(3YONGSX3_HT16V<?>3[\,T\"$QEB@<SD>?A,"G^JY
M!+/,.G2G]E_ ?_+*2Z7RM;1<7%_>_#'Q99E6UD>Q7O^R<'$QJ&80%;4[0M,O
MLF5]*\UZT>$IAX(_#A-]L9(:5&>>B?2"ZG,R774*LV S9S*ZN+J6@7@AN6:9
MUDQI](8#EOX964"9WAA/+'6]1?LTQR$-_ 1N50T)3N]DA+:X;A17%!<44^^2
M-D9OQ+]U*U#C'84&/U8;"/3X6@,XYR+CNU+0W.JUYQJPK*Z=0*8Q5TP?S<*#
MTR4LI.C>^(>2P$UT'+=,'B'2I#(X.:=FMD(I\/G#ZL;++9VP_78KA4N.5I)A
MEQR8PJ$&0)D^6DEWP9DC=%3;\'1E7394:^S++DC0K>*4-!Y^S89K,I)2DN+4
MP]K8:R:]679*)KK?0'IYO@8F)^9MVBN4F1?76QY;40NFG7L"(D_$Y5B"1O2Z
M%P(_9?8 -11\.2&'\-?,NC&QO5?M%L$WK6%&,($.%NI.<-&EZVVE 8"WS;'*
M&=DK&?15V3;U2CP]@5'<C"#> 0(>@\@KW_+(N)K'5OJJC=3VRG>H_!J&TEPA
MD5CQLD'?NR F^W7:(!(2)Z_!4W?"3%O*ZJ5%.Z)])>XJ4>IRNZ5MKW]-"Q2]
M'=D5]6K^N-<*;P'=-<+5E<CH:%T*2;S=JPCG*;T/.6E15U 9TB;=L(K,9QI>
MD#SDHUK:@01\E.;)$O0[Q^S=!<R&,<[S2SK<5W2>WVWS;S8A#'6[MXQ-LTAN
M2J!T$_&KW$EHIFJ&@S!2+L%QP!00^2%DXFF(M1*R[1;3BK?U] ,SN&;R29B%
M<O%%[8>C)*Z9W38.I=-J]]XJJ>OB^L!&:T/64Y&D\^T*ZT\V?4>,32863W!1
M:&1(+$D6F?DE,\"N>H^41(#Y'B\/O5F?+GERQW[6!/H)/* "?-DZ*:^< '66
ML709"T C_/"4S-+Z-.M]Y.LH&:U^91_<>TI#GD@-*2X'796B5$RUF:FZDH!-
M@RO76!PT&MDR@IY$CXB^,[(_Q8Q<U!W(YIN!F*3!$0I,"WP\[K6-@'$#WHHK
M3$J*^^'Z  ^2IXG0IC%<P)2 J.7 'L43BA?H[L<P6R%]2NZ)9R&_S3J98J([
MG1=;,$&[X)&6]]+K 5+:2M6:P^/U'!':9,Z-\"O-S]U4/"]*<]C4:>P16Z.K
M/G3&'S 6B UCG3Y)N^KFDY-.H-C>4Z8N$=>N X;IFI;*W[$3^)\ [%Q_^MC\
M:CVUD)]4\<W4[V1$WEI@ZF-XEQ'T^V;AV3FLL4K>T&6W=_W2:C&"3GI^,R;8
M9G+I\K.QA:QE2TMK\*4R@MM!5P>]OA3BJ2EXKT8G:-=Z +!V7QOC?G1*2V$@
MQW;![F.M=6)N]C[58B/J=6%(.M_2D*+;5.#R?J=Y;Z"=F*/!.]\WN"3\L[?K
M!]<QE5KDTL/TNY5[.9:P\K.8]+%+E<;- YY*B&_&WKMR9=E>M\5K]4O)Y,;Z
M/=)3<,.23D6YAR@X0FN1HTOP^H9_#$]K9G-1,.)RCUS)_/B(MIL=4)ER V<B
M;62O?UK30.>(:*NCFSKPN403@XC."XO_V,.DW/KQ6Y9^7(;>MG]2OT=/1MB#
MO0B72P>>84Z/B/-]L-7'R:[#_4[1HY^].?KZ!WL16Y]W5L-42,X92Q-KP9]<
M&\<#TV\CW._ CUL!8(:RO[0.YZ="1H=M@L8/<-^M#!5HA33=TAF?^//*HGZ8
M%)<I=8A*?F-J=IQF/D!V35FWY<-3JYEE%? >"6&)<# TOU?^"V^$G'/>Q\Z^
MN5"!%3,=?9%S)C7'$F1;1VPQXP&PA.DI^P<^KS*QW3T W;?R #WS<5OU-],>
MUA*K253JH%=\KG4L^CBR*RK/)T9M0$;H-_[)2=N[MJ45I+G#@$BN);SDA947
MQXURFREP8 H@Z =(WWWBCLHM2:0HBK2688+ %-99"EPUXEE0S3+M<SY'"5 "
MFNY\N'4">%.]?DGS6)L>W@0NWKQ-&>?ZD5ORMQ?AWYZ0/2D[4UW-R+T$!&XA
MH.EENZ7E3; R:-)GY84(* #W03_V2EB+V9"]N_D^92TE3I-#](Z .%B^,HD\
MI%NW<29?J$9 N?>]'/;N:5)Q15+Z[5$[HM8BZ,BL4N'#U,BEQE\>9TJ'9-G)
M*#0,@L$T:@MU;0)O?T7+:( Q ,N=EQKB]88O(QX^J/.^'P!CE!#C)CZ9"5P%
MYO/;7=(.1/"CY+-8$8;,8PC0W^/[8IQ]OP8IEK-(K!RN#;53T!NM'=P^KW;X
M5SC6*8L%SU*_EG^LL3(#(?"D,W[6>IC.[:>^6_6U/5]U'!-/7736&IS@78QX
MZ#4O#A*WON=7-:= _:"#(FVH[9Q$E6A/RC9IM;_L?%9?+'!(^G4U1SOK)\ &
MU6CKT8A:/AMO]\%LCL=DWL<[PF%O=]1L><=Z:99V%&BB^UJ1_X=LTUW%:!E)
MU+;B5:-&Z4G=]]M^D+ME:(*=(,C,,>-0P3JHX&V76DB%N#IT>1%SAD++2=0.
MZP+(1O@+?A&QL5!5-Y*>[H9^TCC1C<9^D_&=8M8WO:WRUT+[?71?1-T'R_T$
MC.P(ABU/,<[^%8*!/QN(,#]WN.GZCJ.5<"B(.RG<;RPT>X0+%\N[;FP@*U+(
M<1J\W2\HY<4=++XK+!QNR(T1,Q800"/TA %#7 : (&[CTU)<4#S@M+R;@)0;
M(#1[S'!+0X#%02MS0+, )PRD]0:)9X7PP/=#'X@'L>$TGO#YW]MZ#V(AWLD>
M6$$L&KUREA,@!1'FG8P--Y SYH2X_5[^D36VISJWJ,QP--_1BLO(B84)JH[.
M3S7E3NX>?F3,_<?%<C9LV/R)&/YD_ -02P,$%     @  :')7&[E_FY:;0(
M% \$ !$   !G,3$Q,#8Y9SDY83 V+FIP9^R]";P<59D^'(P2C0[*Q  #(C%
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MB*K)6JD>;UJ<Z>:\,@L) M(--QR'ZV4ET@FIE(:33ABS;*JIP9$"[]8TMJ-
MJ51P#%"L58 BV])I3-9M&HZ[:3:;<0R@+@&85NMYJ9)"$)8#:GVG6O, O4^E
M#12PJI$\74B!I)9( W2Q%"N'='48I\2C1-MW'+[.1 ,"SN@0@EE5+YT)%HQ8
MWU>;03T,)$N=;I:)#R"%B+J0EROBMAZSFI6RF?'%E91JY0C*5:S$4'#FO!#
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M""&T@-*+@'3145^^S_.6Z_GE_0O.N?9>^UZ?^UY[D^TOR?:L%@?&J(*J 2T
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MX5TM$.): 7?<<<'^E/84D\I:K3A1U4W_E_2X9$E6#MA4W;.<8+WDH[1=KS!
M!T&^ZN_ME1^*JK^@L]L>CNE^B'#U'ZP98DV[G#0&FRT?JVK9&^Z#8\>48E#8
M!$G \I8D<^0:==>86#6)(%!8A9I;5F!XEMOL1_$N?=V% 6*TIU3$N_# B154
MU='C\Y$92S>;1$UO2%FU,DXV=GS:K2J?J "0VV39?''MZU_MS#]8R_U#UMU#
M^OI&HB;/+8Y5.3ZRX%<U^@*4@$:8;81>L;AB;A1T%IRO^M>9+SKVQ[B1#GUD
MTI;&MX@VS:J\Q,B20R"A:XPR1IY,70TXCKF4X]E'__'1YW\*EC)TLE7I7XX;
MP_!$!!+"#UC\P>'8'>UFY)!O4';TB9JZ*5@VYERHQYP(^7_289GFFYUO"H4I
M2RL&]5ZX(83CB/$I213?-BJ5W[\&SO=ZOHN([?PN-6O:M42T)8#=3N<S*@07
MY#);\/D#C%-+$+,-O*#<_N[3 ]">&EUB#9=?"OQ&3UFW8PGY_8#7Q_-&%[HB
MXL>Q1=[+[<NU>5G/&DHRZUB<];#+I>1R9\U&JTB<",#@"I1^WAJR048^>Y$Y
M6=OYT&&)4M1/X9),&*=$8S8.?%9#$QL@"!W37)3_4#+T-<[U]$D52/!G[#\=
M+YQ7>ZRHBF\H(H?AQ#I<9FJ+K%P+;$U;(J4T.WWDH'8E?HI#C2IAX-6]7^GF
M@BO%@#+M4SMS^EWCV==G0W$+DJ+NJ/*54K_F%@1& Z)TS-#NL<%,\KR7)FE9
MIU&!E)R<3X2Z7ZD2NYIH9/>-&@*8?S!J[Z@LN8<4C0SK$[-:/6ATV,K-^;VT
M]P'T7[UA<\N'S@D#ZLRR+^&>N=4@'#+<*Q>K,0I'XB#2=QKS H#D@4_Y5-.T
MGW2S,#V>9]^G>WYLC.$^'W;1-4 *NP"KU)=4K0JE[=-@:N.RA:JAC-7YBH.:
MQ9PZEPC)A;^2ODNYA]>,ZJ\Y65O[<K)Z[20$9U U>)%V<[.<[:1'*O[M<8BQ
MB?WE7;,BMF:)'(X%>J]Y .P&T)\+X'1T_VNF);7X?"JB?L6L9OC4Z?D0\9&F
MPJ4+&G\:-77'/6COQK2$J=Y<C?G/6,LH@"O:N3ZPIA032_;CB_T8*:[[U?/O
M9_T4HUI&B8D:87&3DYGYJ"L6C\RV]D9T_/(EQV@EO0/IW0IZ=/N6DON<%* ]
M:,(N0_?;++Y*20WD3Y_T/*TQ__"DI:ZNRXZ_Y3C@ #&6GNR@4[*4ODNIUGNF
M3@M^EAF0UI357XAS'OZ77O!PNS3UOZ9:(:H@?@)D'(-AY8I1OZHRGHG'3IU:
MJJI,ZN3$+N(F8R+_Y*8V*/DSF=1R2*1C@<*I8W]-Y^GQQ;7^)[GFUA.TE: :
M_H_:-UCIZNEY2T XY#\QQ:8_\7!*KM.^3/NEP4E<4]<,# &<_V)^_"6K(5-C
M&&J!L'J3M-)Q6M@Y_RM?LB3K,0UXJH2?^X%5%Z32??8"-KR\=@2GF6%QV.+'
M:(AO8%AM_ IL+%R$C,+SJ00%;+*J"[OF$6\S$S!)FMEV0)F>5,<K3&,L>_B_
M8?P/0FJPE7%5)S,V.H\69 %E<34;M:*K+8B]1$^GOTMMS[5S,8S',-C9RM%R
M]4J?.JO<',)PP (]#C-,58:LZJ+L_KV.YZ?M=#6T)=(">F4'5H*Y?H7U Q$7
M-3I^CQ$:^0DHF7");0RO]\7+J6:'^X)S>DF%BGV\V**'BVS9R!R$&8BG4^?X
M."=!"W  <HM=Y2>'Z4,<60CB4<)QO_Z@'N?>R&1NC.$V5A& Q94'U==K\><Z
M*I4*^CJPD5/C7WE_LO^-[*]/GHU)ER\N3M0ZK\Q4<K#(^"YU/_!S=[JK42P9
M,1PIK$$7=%,5N("%H@)],0H,:&#\=.Y25LUP_F.5%T&.C X_M_G=@N\V1B_=
MU?#9SI)%-J(0XZIT/O=)Q'\R%=/?7G((T8@#  $L5*@K9A4_SK0/<)D6(,O^
M;Z9"\ZWP6L0O/<P.\"FNL>,2X[W-S2.@<BV^=DP66.Z04R1W[^=3::]C@877
M82$T539Q(F7VN]1^<\^WP<!&@W-G:,X8&#S Q_F#UXCH%+T'3<,A9Z*M\C&)
M&_Z%30078N%\Y'!S[^\YNDW/%^2OOAZZYH)\Z\U;M@'U</TP+,&&1N#R[_0M
MG_$+>JN??D5XI>$80<:MHW!E*<^03%/%"]:M4OOX.X?#<WQKC_!,)'\LX@UX
MRKN SLS:""AV*?<-F0!3V+QW? ,F*?\GQV]BOP8D?Q(-"$<^#-B=^%PK-%>$
M7GXKM%G9X"63GIG" <<'%O[F#B$YETUQ V7!->^184_'5<-97L[,'18]F%][
M"^$A>B\$/W6T)2Z2=HR.)(T%U]CX9E4/U+A=+:IXW8K_Q?P#W 9'DOSO$6,A
M]OP'J:DZ,G;B18W;!T?NMGLDSRG0X1\9;MA9%VPS61@M"W4JF%J/C_>7,H\X
M'<D=/H[*H'GHS.D=CZ&\3]31-M?6T4!$3L4*6X7W]L%ADZ__?5VIR"G&R>LI
M;&+U7Q9LL-R#RG+ELFVB739A@N&H81UZLZ%*X9ZER]5#K7UKL=B) \!0V<_"
M%\KJK*9CF?:4\)+P&"4F68*(,9MOL1\](U=S;>LS25'M!B4C0'(E_9).DQHF
M8*)JEQ3GS#6[3P]W=I<$*9CXBL$;PH'G:=F0N\I(T([_S$5D%D ++HYQW/C_
M7>"0DCJ@/%P9HP.E9H^C;N9@?U&(M!$;EF/J60SQM'G2<\[)XX:!=<-KBM)P
M0R*FPZTSZ>W1=)Y2*WVQ.F&+7]N>VD=\>E O3:7Q6H-CHZ]S7ERMN_(FV:U.
M>[2_L/#ZAK7"-"P6@R$8-!OMU$U?]:G5R\0=<_4;)CD$\867YTYI,\*= WPC
MF/,J9,"&3D'#Q)Z'&F4RI)3<Y6O]OIQNP.K7+.[+E3F-02]0,4+TZ0PAF^\V
M%;8ZYX21)DX6#9]7J@T@Y'HZ53F4\O3.[=SM>&,7<(U)CLTEQRI_+:.$J=83
M(@^HTFXBXAC-/A=C^8%! VX.TFX24/ND7?4R==^4B)G,#:_=D+SC^X--2C_/
M_R5S+J-WQBAP$E+*&]%]DCVN867J$ ><;H->/NJMEIYQ>G$"I#'L#9DO*%W1
M-4%_=F>X/8T4NL6.?=8H960?Z%84=3:LJ9HK4!?R(PM>R /B.R.WE2IC@W:^
M$!CM5U]@QB+<&P:KUC[BP7;NM&DT(M)LA[<9_5.7I/*KP<C2R?W6B5QW.$1N
MKB17\PZD<SIFA<?6;& U%E@8.OUT#BUU\SZ?5]W@68>(:35<?S-L8S)^UFQV
MK?(5N,+W(W='.I)AGC\V3+\KE5'+]-Z.6OCH$E@;%Q,S')!3SS5F'\LL'FY8
M$0% CQ  (B'"SKCA]UVGCRYJLJEMR ?#*W(U43JL&V2-.RS01,O$UK0%9Y!"
MFW\E?IE!Z<;&=W'JE9?OU@P,O\^VT '2*R]SLV15=I3&(<8X?S+<,POP^@T=
ML<<@,K'7] 2WY7$<K30\%WZSE$TQX4,!M&UQ#EKHQ3+SY^.:@@=XE-KGB\5_
M^>%J75U_ "O8,W!/789-(W1>8''TB6QWS?MK#1+.X->(<W#)IG-J"=!#MRU6
M5E/D,DF-4/'%R8" A*X:O[#:*SZ050QFN4WIC-->9V/\X'3X=ZEJ 52 E(5@
M[BG+/)*:R45(+T]6W',-*(/B(PI3'CHXSC]Q1'3C5)NPS^@K,@HZY;;[H*X'
ME!/:([#D"Y<N?W%&INE;57]@9D #,^ *4$*XTI0 0\(SCDTDYSL^E_J[U>AR
MYT+UAECO7-,9:+<]R%H8_(1D-IMJ#G#7LU!8N2+H!)NA^%QJNH8=]-FZ;C3L
MQT!(Z-""OV)(X*+Q828G'!/OEH'G-[ 7Y]XEZ/._OA?G6[]CNYO&-@QUK?7B
MR[6;.I?7J,OQ[F/EO_<_5RI<#7DVV>#'ZEC:TDGMID^'^*FS'-2#,N1Y*$I:
M&*Y0)YHP*7Q%@?+3=#Y.:EY$W6_O(FRU(E=,Z- II&<J.PN0]<AC@Z:Q"!2I
MX)\]G7.<G)FE/K9JQ@OG+JN!J5KU16.%XO2ER%.<2U#)^XW/:>*1D#'EO >E
MB9S [MK(JIQ+3\2>J-B'DFGHZ.?=0I6A2TU'ZOKM? DO:J<]!9K?(D+<PQF7
MGL QNF/+2(5*?,.D5GE_G-.%!RXU0F*'6@5Z5(_8C^S3G?<E^_I0[V.7VLPA
M*#3ZN]2O#/9M\]&HS5=:P]!:K0;!64EPU<NM*WUO9O@!?K<.VFW@0"B3ZD\%
M%ZC<@GU+])&<P'&=9I.WW@D7[F/! G?%@%G?,*'=2C[5/(KQ9W0U#(LB*3_:
ML^=1K5ISX-BV_9?C.8KWG1@,6A+-U.)X/56M-#:?#(@!K(0@DDN#F.09)+Z_
M^(^;?DYLX :$<*P"9:T>%V++=DMI%/D4O+J7 ]=Y?@+3%6B:IQ]?R?;\L[+0
M/AIB@2S'\0A?',.KZ%-1!J;=#06)E?.C!C%7!JZ<U:#0H&'ULB,KN HD@"(%
M,#YM_G'0^$6H>[8N>2I280'@MH<0C8"W#G9;<RTQW ]!X2)F0T,GR-_!(.*:
M&P[R/$^_.9[=DE#]%HZRGU?NM'!YK)0\KS0E&8WALLJS?IY[+NWI6&LSN;G<
M-J+(Y9"QESN,);%"$I3XOJUXT;SINB60OG10OIT9VLG>[W>,DC$+6+2. 0W\
ML$MUT].0*/H6-6!Z3?GFGJ[3B\3/RM5C*YMF7SU,4N^J$]+?S#\!O*LB6\.O
MPK$B00S4DW)P6KKFZW&);J76Y&;*#69M*:\JK!='RC@]2JM]* YO\?)BMQ//
M'_S9X0 2BWV$]#5;7('P0G)KV%D(&-X!<83*?(T' !<6MUF7"'B>#3]WO*1]
M?DL+(#NEBFT)I"3< >CUOR,PUBK)&\"M;@0*\#JW#_54ZK>(T.L<Q*,7]Z=,
M.DD_>M/<M&M+R/.JYDJD,F?S,?@:C;!S*6[/SMB/YT>]&^3CUTBY/4&0E]F@
MF< ' & QUE$!Y2(!;2[BKWW6 ^!W*67 V+0QP;(INY+LBMFO8(1.C)_&0BIU
M= <Y:$3<DA@FOBCO8\;S-,0WMB'WSC$7#8S0@BMG8;&L(JPL)XP&XO@$56YA
M/-'BYQ^T M&Y&M?E]5S"IQT2+[?9M?M-E62K6"[Y? H&/TZ"!LDETB];(N^=
M>17F;O C5$.ZZ;H?7%?C'K]P_F1#\W<I1;C0,\<<B%HLVC5D#.TG[7B3*I)7
M0$5GA_Y G1^E:-[J$%A9@6J!IT.08"-16$3H_S*L7/G5O?K#V:6@I\" ^P=*
MKK"SXTF(=B>4-:%62.('M&%WC^.4J\&Y]$GWJYG0EB7)I^(Z84WAY/DA=R6.
M! 8+-\V![W"^2QU;6WA4?]C/%$%_7W_4)3[VU)P:T_8U[^<U5K-$@IT,-BTU
M1BQAX._NW9!*. VXB,(C=RLXFN).'0FI62IW66O 4F-Y]=G;5]"VE[?4*\#Z
M'EO_;56=J([I-4/FPE\R3CR%HZ2O-U_A] <E'BF!=?";+,>Y.Z9NJ>NRP#R[
M^G,3+F:)*HYO]VX9\JL T!S(RR,/%ZK^?.UMBO69^&8X.?5^T>+1WH=!!UYD
MT#$^/16'5=PF$9>K>=G\%(4VA\,@=WE-IS;:-*<(0X*BL,:ZJ_B!"]$%E1X5
M;:ZGAEO&[<&D#KVT-35DOBRK#8A4(<MUHJ4.'AS4_]:<*'X@:*%X++Y;:;DX
MP2IUJ85T-;"5F[?F6#2#)J5XV_"RK(]7N_30:^CV5K#F1!9SMCP7TIE2WL>\
M9S)(I'^EC 1G?TCL@BKT8[JQ2O-61K;%VW%P24Q#;.*.\>:=;=QKP^J(?WN^
M*#V]D#/^B'NW+&)=&UGFW**R1B<QJ;@E8[&3J4I\S.LUA^:W08(JZ5PC'9U'
M.%UP4<<[;I/4LBN'[/QI.""&.],(FHR-O_9F+.'2U+I"1_9%-'KSM$CO(7&"
M+N1>9Y,ST:9 M%,^G_919+58OI?5ZZ2!4 ]'.$#5*8Y_O.%@JM)RB#TA@V#L
M[8/Z0S4'72G7Z_?Q9#Q77US9T?OX47+#@+QK(8),W5Y_EV+W,*Y*A96]''_@
M4-U^@U,I\C7+G.LS\R^BFK1!;%CL:?(RWNN%?"H/9GMS(LF@<VGG@$94ES9[
M-2"CD,^W_Z1.HT)2%)A@>FUT]V1OR@LY!E:.47[;/.D51[X!4K-]\5:5TY\+
M[']$@O8JN!JD7 (+(6UBIP1QU)ANYX[YM3)5L>O]_@D1)*[ H_*JV!8E%S#6
M9L L!R+6$^C@ZMR[B/,'98>2?HUC#@T@4GT'<H.ZZQ%(/2)>34GB2;:9ZXZL
MT]UU,2^DLX^$OUT= 4S,(UXKAV:GI#@YA2;5F%Q4#WHG2FA$P804*A@-G5^\
M+1->S>9BKZ4JUKDMG/KU)\(KQ$V:75U_LRWTV9#. C.E+6E7A+$R][V= FF%
MD_L)&X(.C*,HT,@:ZK(Y+Q$787KR"4;/I:1:ZYWTH?O6A'W=&%WWB1>'>4J;
MZZKUR+,B\^S6H-I_'6X03;IJK%VR>AW4*]J4/EKFV#8D0J,1LJBN)@;;\V^V
ME#G]^8?M?/R/26VW=F4>Z:2>H<[6<R+/S>*2\\H!<5K6V<I%=<I[$^MP2I>N
M-_\LU::O?7G7WF-%V/@8Q9\/KI,793O*W8U)Z8-Q_\[0"\WQNFQ<<0:.A\\"
MU&+J/9C\11H;*9>(<PV*2%-[<_,+PKK\!-?/#0-W54>ASX\ARL;>L3OCID7&
M0D]E"\.]7"GSA%']R#?E/R0-^5:('%R1>N'6:=3C88=:1,C.<@%P2R*R]BOH
M(5FE2I?1&JYVP)7]=">HVB+2' ^. -S ,>53S&:?&/@LX:3US'NX/Z_TF)G$
M/3*8:!!6^N>9V%8?.:^^D%1N:E^3PI[2P:#L68?;PE&#\.)ET<,RTL%VR56=
MJ&'67L+N82G_+E4V^"%C)=U#.Z0ZVK=:!&1W_<WZI3(W>>!R\D!#HJHJCCK?
M6QC\\.K[_E6+K(!:TVO.8;$<K$213M4L4+)J:^$G98_8*FLT%^K@_(4V;7)(
MCA-3VC&: L_VEG=0Z@N[Y'I\T5>(;:,54Y>LF!28>H4#!7/M%>L#L:X%"RPD
M[BME%)ZDN;D*6/PVMFB.@Y"%PH,;S7[O>ZY$'?_;XS2"-+K:J1!@(,Y[>*8F
M^,('GZL!CS@8W/8N)JNA>OB$T/= 98P[N?8 SZW\^-"<SISVT-X^V]:M=F:!
MOK/YZ-F"PQ_W-0M9Y9M1T(&C-GY)&S.F#\(][H?1UT+4/!IE.R5(^;<S\^;P
M2>6FGC=&*_@7# 95@%6&Q_HR4T1$G;R&GK$Q(.:FIT&8X;'W#+EGM\U-!,PP
MW3'DWZ-!GT3X]]7]'.Q5?;B%CEIMG,VBEKQF:GGF&W:?;U#84'RCY].=P $=
M:CLG\M RY*=+1=[!M%7OW2;"?;]!"+5(_N'70)/!D#S=9B,.EQ&K?1PT3L@3
M=+X>Q]T$$$3$V.$F73K]U8WCU"[/,_MR&&NU_"4=]A1ZHI*--$U(XBF,?[ZL
MN%2KWC2#[B?J%:5*WQ&(K+O#RC:-JE)]PO TJ HY[.,$6>BI<_?IW@P7_S ]
M%,[U+NKT0EY6S>=/UQ/IA?[#@Z.OT8(O/7#8:DX:Y/T+>13GMCE7L@2%#D[3
M:WIG*K]<(- S[F V2L(%><]LCP&;QK6MG-.#'PC9G\8J]1 #E[!"/1(XVQ0?
M',;.F=?2'QC-F,U_ZYYAE*2K46G+ 74B=0MT\_-8>M1R!Q<NS%')L]GW:BL7
M\P*A5W%!X^*@*/P:V8T2LY,9C81^!GZ647S*WB0VYYPJ256N%S^O!7/:4/85
MP6PQ$4(9CR6@!?*>E+,T?G?5#INUKO,AW14B/.7]2OUF0[SV[S:Z:MZ6&_DI
M-'!#AZ9B^7.U5\6P98OTMPZHPH#']7(*H?"DFLVS2!N#15'[\I$IX0#AH]FW
MO>Z/O9WK3N?1-1>K_(7I)75"9YOV<84XR==E;=I-,8(@3&JR)#,E54>DD[HC
MJOO=Z^TTR3F'U<E8B6/Z!V\C#4]KG68_S\>:]^Q.ZP0]!(!^49:QH N% %]N
MTQNIY?8\"]GX^-_\\KM.MQIL?2UU#[\?EM.L6+T(O_D$/]RAGDI)(WLP2:Q7
MB6!<_SI+>%[IE7K%:,V=S,DTL 8]_,$DAK*<A8>DZ%]FT1<56NN'H<83((O;
M^)-2Y4A"3N"CK]_25,I GMM\:>*EDU;2A%0U#VH%-UT>-N988/7,"Y!2X--T
M: Q6W#W+D1I+8OO3SJ@/QO, %NXEC?]KS*8LN7L*#?=4^#3\U18F%7YYX857
M]=)CM, ID%F!J;1!7S6IM#%W=J9M+.M6XV@@7MB&M?HN5>N0[1KS$A?(O@^@
MO!;FLS,"IK,-ILD>$K%]FBT(^H/,9$E<856IE+&9IOEQC>01O9N7.FLH^N)+
M]+P5 &,^' T- S-BK[]:WA8]'3_MER(>@=CW7SS*E00N 3@V<?=_6$+&?D\M
M>ZE0:= AYX:B9<;X 0@6[E+U<EY1'^8H0DJ.VH#LS($&5E'=L.:Y#$_AR:[3
MG9"2]@^5UK$20!>:;7HS'.@.JP5@ZQOF4;0"CSTG*5YK>2.309X&B\>"X-.E
M;)8OR*;-#0Z/Z;;!1<.:R8WR5^4-GGJNIRH7'O[@C4_PN61EN1T_EW?,KBUJ
M#;H4L4YEM9QD[/=R9@1)A;WY-I+ &4[X-:+6!;>P- #/O9&5>5Z4F>6ME4Q)
MAQ"$%+Z"=:E(XZR(L^X9VM""EA58-HE,Y"WY4Q&LSI!E<V6^A  3.REZ6GQ<
MFM5EEG96%##&RM/=--L#Q2[7*&=G"\A4\HG'IQ4V81( 8[A_C;9Q^T5X?C!E
M7<5:YES"4\RHRD[NN-N-TYMA 2#8U(,Q[V(XY+RA;OSJ;EHSSC0AYXXN9RN
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M8^ 7H_;2DAHTMJ*K_^M 2TFX.<X5  "N3[[$C;]!*__SY*<QTU#N,+S-M$G
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MO&;6:(1!;-(*_F#!30$W"#2&\/F+G("H0..-3$2Z^X0?ZA>[]#7_)=$<$.)
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M ]!+20;27T'I'*60Q7SQKF?24D\@MLL8LA3[7GKM=N0Q0_P]'4IB_-"X!A[
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M4U\Z7;$$0EF/FBMPPQ:L[6F\Y$G0ZI *(S$VV#C&>N1C.UIS;@R(]%+USC^
M!X/C,DJ5VD7&ZF QY*:B8?6GNX/*(FG_5$W=K8K\\@IW[=L+Q6H%^C7\0QCK
M"_8A2Y2JI1FK2J]Z+\NW),&[ZFD[RW0P1K%(*7IT4_=1R.'^2QW3XL!0=0O[
MP0V(/-ZVP.#ZE#AYVMGZQPO-Y2J78PLFYRU(R4;1RF4"]-%JC$GZ=9%E,5%!
M] ZKDSS]VXTR^4?YF/%82UES:5AZ([U(()^,R,+/5^@L*$+GQL3S^Q[T!=)'
M85E+QQ\6WZDGC[VS*U;\='8#OUS]JJ#DO>ZCUKX\!?CT(*RXU-^OE#3;%' 9
MIC(<O2&VRM^[J>0>MON5YUPTC]'@C2T1M<_-YUSIJ\: @ ]SHI>2TINZ/U]Y
M\<[4WVR!V[-?ULSS*LGC!A#E4_!V#)&YF3MIV"P[T>C.0=5=U>**U2KTZ:R=
M;J/S)[ EP<]-\+/2#9V&'PNZELK[;UTYFB^?DRR?OZ[@8J+ 2&NQI)*DD%D8
M/ !CC<4);:Z)4%->-H!P4NGP;/H7Q*',)2;%K2%ZJ*ZM/J6X9NZ;7()SI5_3
M7 @!M5C=98%&FP>R:ARYZ3$!2/&Q)43T_311&/.1?N;B_!@"^Z>0>Z.H5\0.
MZSWJAX01(MU)*1O&BJ&5BW"\>H87>[QM>6]X+?SVN!]I7Z!L!3H%]R[G4*.I
M;0"OL8*_Y\_@5;#HM&HI,0'<;M>%V.7EYR9"S]6O*"75PTTDQ:D72ZL6J4*5
M-HEJ.U_(N;R";AS=WS<-1C,C_MH/+RAT5ZQ#E2/<V5%H;/(:LLDAOH01(E Q
M7_8S2J)@SO\Y%#I=E!E5C^U+UY:OF(I)5.GW]R?82U#B5A87*5- (Y'B^IN'
M:AE=2]NFEF$";11FWV!0P#KUMZ>Q]B,OD5!45-VPQ7=).,%>(#R;XW_(V[0"
M&GGO^O/2#2^3*;K-DS %]P=83<)'Y5)B[Y4'^L*NPAANI12#=^)>\IS/03LW
M-[FH: [4@]UL4QAY)E+1K^7D JFG.DSI%CI.-#CGW7O1[LJF((F+\6IDY79!
MD# %M+/ZKEFUE".EC-OMQTW]W]YMS?J(UM!7N+E<B5*%EC"!P5N=O[(3S7\?
MXD;K;-*KW9KJ1XZ50GQ9)76+GT21T5.'4Y82Z&-6>V'(AZ?-5<\HPLY: TGU
MWU7YF_NRE6MSQ/;0Z&WC+7N.(=FM6U-UGR!I>ODIQAV8BE8GOG_W!N0?3'@C
M"2T.(A)6*T Y)0#)X0A-O^]!6%(C835_L_#DQY3I4>,JESJDUXS0J\CQ$.5L
M(>=8TIQWLJ9WDJB6!>018!;[AO@[@J#I ROXD643P>%J?=;$G?(PR(R&9G:S
M'T<@MD"N=FZ&VV0,L<)6O?6YZ'G39;L;=#QX.?S8 9@)<KPQC.I,D0OR/WLY
MZC)C[J%#-)_/KWG9RIP:5#S"ZC1#1YF"P1 8>(/MXJ&J79*3?HKO5T[$92 1
M3BG^Z1Y9#@O+6_N;XA_8]]"YK;E<:"_Q^SORI*WZJ/#ET8FJN%(#@7";_9:3
M17%0%66\[*E]]7Z6 G41_'!VY$4)\>GD-SG#=M*>X1N,>T)W3 UI:9,C.[]X
M]^>VD7TQ0OA%5Y$+W%?KO5OK-[FCW:T5M4H^G&Z1AN[!^]=J+I^%E882S$ #
M=7A]ZD.9*7@(;02PN%C0PC3FLJI;5WYJH]#*]9-7<#6JM:*1K$$)@FS,N5=+
MW!+4$%(EU7(C5Q(S.,J"B.]?JM[K93M,#(DMRWWEXAI6?7\D8!'W32YJ\_:/
MF*\E35.<G^@5X[+#7MHPF#+!O(M6KE3AHCG\?F0*#]+/+L:<C3$!9\GG5S3=
M0TX<4E[(#5T3O,+E]:%6P?-3L>#H\TXQL7#"VO4?#6J\%T)O:W$(63.-9J]>
M,M-M;[@USXU0)A:VGVZHARWY54E#"N*<_%(:''#(U,3K4OL-G*2'E+04_]FE
M+.X?U0,WVB(\ 5IN*771?5#>\XP;&.7-(C4+8M%(U'B>R6]7^R=?/3&R6BR8
M_1P7F;X<&!#/U_QDY!6-&3Y+P#'E+YDW"'LC7MV"'?[(5EJI'ZB>9^GX&/O8
MVFEHW'Y#DF[0C\=PQ_G7^_(KOLF1:[FLEF#-^@[1\.U5K[8R^X9S^O[4]@*,
MQXQE9\6H TXH>7/E0NO)N0E[>C+[&1<B_D5R]0BQ\I<JE!?W04\!G>&979QV
M=H6_^\N>X9XO>Y3,'GC/F=[)& S/;$WW"C6!I9OX6*!>2]$:'R?("N=RY%&D
MDQ/;3I-.JBJ=G[3"HN:#Z^M65WU]?UC9^7+VMXY]GJ%>'3\::K7/$("&]OI;
M_Q(_M;G2 _\=5OIZ_G15HW>A+USEHH%SB%5&$11JOVZ+3:+IJA,W_N7@&5KE
M^IEA7-'FM&.2TJG6B?(S6I"]PM9:Q][H[4GP"AZC;SM[JSJHG@B%W='..4+3
M'&T7F%&M/FHH$8XH7G\ORN,:1^OIS_M/:B=WWD\GV+-8G0HTNLY\1*^/^HD:
M1:]"2T.GJ9;& ZFU/89],48V<7'IDDB,=>S"P@_&"OS++MCMH1@#E!%M2HM(
MH,(O;(O?W)SM^PQ!A>7O(>5%HZ6APE/_>H%[7._-<[L9C#5"JY!([E-WV=;6
M9SZ8@C'@,#8_A2]_*\/A:I6OT38%X_O/::/BJL;J##81I0E"R6 NZN4K$4-8
M?;CR/ 0)0<20T=.FPX^-C*G><^&'B%G;H+$R)M,Q1F,8#X;#ZQ69O2W.UB>5
M_._Z'0XYW6^X^[SSK%YISK58"SMK5'M2OOX\Q(7U6&L3=Q?Q-LM\*9.Z02S+
M*MK8]Y$*1:(U=)*98CX7A2S;\W_',9+_G$D#LTPGHT"<RP(!\@;JE'_.^F#N
M,AD.[Y0MX36,&D[2/G;]9*P:IA]$ZG6)X'*+[[!:55%M"XJ(=;A[\WRA,^/#
M?\+I.5W_DD1;.WUZ'(T;\@""\@,(#!8;B!5?^21G.^9^Z"RU>0P%C15)2Y]'
M(V501"M'FSHP_TWNL G2YQP4LG'XPO\1\S^ZQOLYH=F#=SN46\.R(#6.E2C7
MYWU3=[M\LL%\[#*P\$UN^:[U_6.,*IBU:R?"*X*%-<4.5!>7QB$PJL\4N%@L
M1R2%3/!HN0__\W/ZM_UM<G_U3!Y8YBW3YEY<.?]=O%7'F@F69 @W'ALP2OEZ
M,N&7FN57ISX%"M+<)-$)D;( -CO=[IL<3C\;;:[:4(Q ^>S]:JVEW/9>33"Z
MZM4$G<[!Z9"6K'Z*KVA E=FV%"-2[90^75ANW>0,O<3KTY( VBHL]OSBK?0/
M;L<=DJ4C62,ST> $FR"*64.7>YHF#E7W&H6"3>*9N9A]_Y1K"0T]PQF]U#_A
M*;3-L#CD>_0(P*(@WX/H3&G /SYL@<EHZ]8>.A;@T#6.] R2E5[_" OE)/(.
M-_A[_)IV3(HG,-@OD-;ZP7H+K.F2LKL9DLM-%/L2F.<F<)W%GC:_UA9WKVWN
M-JGP\Y_$O];1CH,SD44"Q-J617NL/5%R*T8AB3,M0Y=\ KB,DBP:*&>"Y)AC
M?M)S2AQP:[X.\IY'1GVD(-9HQ<S<GP32COWJ\%W=.RG0\ =2/&"N$-]!QWY7
M,O_H_>=?S;CS]1_+82L )VJ4Y8W2<C=AXHR!8Q_(>WB2/))P?F.-4%C3 'Z>
M>JQ:XL/Q\,63M (V#,*2-26EA!W7Y>1N]L@D5R3GZ$*Z2FR4#B\=7:PBW0#>
MV?3-?(K_7LOVF]H,_]8">K'/2:46/!1K;H*/R29] 78-:T/ F4^DW>UM[&D_
M![4'F.\#QY)2IJ VTC<A6VL_JGQ=9'R3<V!LO[85>$]!L#H 9W+'^DY,[ ]_
M_<PB]^/+I;BW:4\:CFK26"T 3B2Z@;$J6>X*K5YP.S_4CQFQ%+3IQ-7>'!0E
M-4ELUW4:4;-K<Y,_9,K)[40BWXJ^OSTFE\$N8.R+F4C'7BO6\4>CR.U2O,9V
M-A3Z\=4___WM:= 9+-%CN?]H=K[Z7FZW;OQLW'36\B+3<\.O;:A- Y^;S. -
MSTE($1LYUTX4%S,9VRZH<P5')@@?OM>7((')Z&U0SXHQWY;9]Z//7PW1;_Y%
M_-<#L![+G9K5#^8=XK*+"LSGAGBV;2I_M><2$'Q+E>1:_ZM6V_^<G=UJBUL[
M_>G+%ORK_6M.5/J8N@J77I!%YV 4J&=$.L$S(SCOQC"5A&O6?8TGTL<.$84+
M3V.QP:#Y4?=*"=+AJ6J>%(H]Y0]!RM@?'1B<[MWR!>S()4Z@B?(UZTV#&$WF
MO3]BO-2ZG\;%.BB<NY5+@4#?TICR+D>8N;L&,<"+T"Q42_AZ5RS<>GY3<ODE
M?N'84[ R\2SA9L<TS$S@3NQIJ0*]XA_R=.B/)&O6# (![FG+,)-TLV),<0T!
M%(-./7;4])5CXUAA2_;D<*<25-NB>W VN*#"="<FNF +,(M9J&?3=9)2IO;=
M:XFP#)2$>0P;XGO;#OW2W6BM/^.?YO,2)>N,!3$XSY0(+B<BT_I9/5.(<_XQ
M=TZ5W,E<=YMY-9NF3@^W7AZ!IBV\26YQ*>F%I4P=)@.8-:<=AL1,Y=B;=!JH
M=E2Q*%*%;*>S@ %N]+H8B6Y($-/>B)/T@?PPATM9N60PT>"&69U6G/HE+L0.
M?YWLJX12(D!AQ'%V=]'8VHVR+*9\'42 0(J[,?-ZL\-GJ*_MX4>X,#2EX/07
M9DM;W'L7I\_(;W+3ITUQ#Z8^!!HNWQ'WXQX75'CV@0[3[;/LGA)-(N&486>5
M=7YNJF-(E"')YT:91TAVP5MJ6ONV7T'6M5I,O0C0]WXI<3G'X;/V#=%H,Q[^
M'&:Y6]/%&U16WWQ):J9]S6K4"I70Z^)S_W!'>F= UQ-P<QB?MOXI0\_HX&GN
M6MDJ+VD9C0;AFFX25C=T\A'!?5^B$'\,&VP"KR?*V/[P= Y5@8 '"=KS"'@-
M^A<M^8G]KY8/?[YT,SABWN)!%,,\Y^)/?/MI"00U.KQJ<0ZKL0XL3.[I&%#%
M[!X4$CXP\ME(@9Y)/*?6+,QNG#<MPDT8J^^6G9@T95?&C-&*4E >6I&G=*)U
MUOW 7ASPL,PLFU* \*\R<-&H'SIE=>_50J2QT./8EL1)<_NHJH:&.>L+>(Q!
M W1$"R\>]TSU-48^G*PAS^!;G#]=7KL\CZ39G1(M$]KJ.%2XDHDM72=?G^5V
M6!:2&:U>^?LO,A%7[*;MZMB#<GRYJ@D-6U[(B.RM8S1B7!J>#NAQ+0V+'E>7
MK?XY6*;*T>JBS@(S1G5=*-1X(\KL$[0)OS__F]S!UK+]%SY1J6L&5;*#YFGM
MZ6#6)"Y-"5$4B^B8?[,Z$&5,G7XDV"4ZNU@ED&<'>K\F7B;U<)0(_K<K9<-Z
MG)H$N<M++2JE+\M9ISF[H,\+/D'1!P0N95EVSI0H4NH(GL[\)O>B^ Y4P-G
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M/]?NRUM-FL6CD3(RWM(Y"[ >4KYO]TAV97'PM[#.E;/Q7>7E()\YRYFGFM,
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MTM$1,[.0!1T7(&-R[:WF(_D78X8$*Y6><E-5K\>9L1;ZXF9H6'R(;H&![5U
M%O^!QI#@P81&I&%B)-)5;;:"Z^,5E"S+A831<M/L;IQK42QI&7W>A\W9#UJQ
M7/CU9H;Y0(^4%G ZGT:]S4;#>YWOZ@=/:7_\4ZOKUUK/[8:W!:W8TY2<DG2&
M7E0F5@R%=%/K>M:$5=4/I2S4&CJS+U'!#V-1W:-7M+)EN>[EDO>__+#P7=_M
M/EUD'=G=]WYJF$U06CA%_N1;'#6/RJ3)\FC.F[RWL^M??F+T$'O"10*'8ZWC
MF[XP*:V%:&^OFG9L<K1^C85, 8%Z>S(\TPSYOGSA"!H_2JY94I:C\B25+:RE
M+61B4</4=B22BXP7AJO[7,[\N*/1AIR16*A^*ICTIF0D,T0?QOH#4<C@KZF(
MF0K"IC^K@L:[*[N]9)<^M[G,X(WFO/9,7W;F(1"U3D)%"-?#TQ-I7EK/<J71
M"0N/;IA]:U QHR2 ;&9 I%&I4G=H7F6#3H)QQOML? :F:;1OI9F:Q.$BQ3O<
M"DW^I(S-$8AX?8R_5UE>=\M@6W]875HAE=Q^1T1P"7 D?7[8IF*I_JW/3F"-
MKG5"ZCJFFI:*+Y1[B:14G_KIM?LG@_='I$"J+E$1&K(46,_JCN:^WD[]+F&I
MI3H3';&5'@T![A?E 6=^K:_2BE*"V3<SQ'J?O)36?(R61",'PG/-V/:;W_5O
M+S\>7W]K+Y* ?^#;9&'?^]17D"?S>SC*UK"/*L1'$A0V0TW6L;VK^7I5#$L\
M+01<3R_/MJ_5M*0[+%1#)GFVZD3_ZB\#.,##T=2B#]9U>Z[A:O6UY^<J5IS$
M?+QJ.-I8"!N+M97&X(K<I#-'-,%9@=,;2$SC$'/W$>)F+7O%3@9T(3L69F\!
MEBU*D.2]1,)B!P'^X2XG]755L74(A>#A:PM\VI[68D [24&+$WQ73$:F@ZIM
M=.8A3M#:: G/H:$,8V![BC#F(8#96=,><O9->7EWP':Q7333<>I814[R9CV!
M:[9CH3B.VW7E1&5+IWZH/DUZ= -@%63_SN3Z?730V2S-JJ):35M=I50/[4.
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M(S9VN*F8;O O:#KL@9:0*\E;[ :"%.8"MZ82OX!I09HA?[GL4BY:+%#'<R=
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M:FP;O]3_BI!<9W TU2=6+P;6&K%_ZU2A?[\?74K\8L8MM%_ [ .N6$-#MD?
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MU3[ &Q6'][\>\&959[TFM)G7/I!HUII23TJ._WH)\^) ?@?/P'E(/+:7-/7
M$8L*^8< #R'%*Q6(0B(""L@XFL#TCZ"Z01?0"EA'YR,N[J\>F/WL8OH")_B%
M)WP)Z0ZZUQ><-OL5X1"!/ 3X>X3#T_:'M+X^FN^E=$\0X+1<L]6LJX(8;V1=
M?%C%7BZEI!H[RESAEG>6*'EHMDJ3O_[4$:UZ2L4!_:=CV JD651G*_1UQ:PU
M4ET1,C,3S.C.'T>"V;>,P_DR2)Y("R0N4*M10WTV?(I8JH.A&DMV4X9P%O$%
MZ-OH)V/#<[5^^-SF'-LB"W=)(0]M['PV/7!))D@'P88CN:P.DJHURMWH4Z-M
MVL?)K9#3SR8G*CFYAIA;"*6U(:)",-QV+U$2JH=-A45%N.'OZB?VH/OOO*TP
M0Z U+Q._/#;0$%F^,CN\=$QAW1YI$./_/D1.')F^),2HU]N5_SSDK.N4XD38
MYJO1SXK&"F?+FSEO\.YN'Y,IM74?)*RAPW&%2LC@)NCW;(.*V-&*=$4D#RN[
M R*=M;VK7U[$#6Z-+[M\4[->)WNPO %X4Z@0F)32<@*31&9JXCQG+M.[&M),
M]-VV?.03TGT;$<;QSC&Y9@Z@7?$2VB'@QNY VO6ZP.#[>XT$J]@YM"NYFKKZ
MX$:[+?XT,O%Q@?A]88'H'!3/KXUS6>;QS]'49%O&TG@.U874 EB"7XD+/#F^
MI"J[86Q HW#L?8+IQ4R&^KDWW!B-S3 MUD8ZZLNLP:2Q#ZG&Q;.$F$.UBOZL
M#5*-&/#P)X)E!4B6SH+N&>U:\[F;PVUX2 !AE@N4[":+I?@TLR:#(G@R7A_)
MI93_?;(.#):XM15SRG_]$3E#D,+VD&A8W\D7V, ZCL2ZR)Q/B\!O@($4ZI<.
MJ,F[P*S+?<K9/)$;-LN+"HW#EB=MW:^JI#!3-A5D7"2T,;4<*!QB.^\PD)3!
MY=Q<)*4;]2ERT20:VOB:Q?*-,;G,/R1=7&V'0>I>$?UAG[A23(Y[M:EW71_T
M6)_79X&&]\4SKV%^]S(4:B01$3=3MM;T\APT GK)0QD[<F:;%+8(R#LY;3IE
M!HPWB\0E5S 7$F;.3;1(E:Y8&V(\R\W,&Z0PY7DUQ("723N:PM!UOQ]>35C*
M'6LGX(^%==B)>W@T8]'#%<G4W<_GHF0$RLRU@$8DJ-8EHWOD/#.8-I*TS'4W
M(%))!Z @45WX8WXM[APE!-%G%'HSTVRN>V'J;/+@7#,5E](U<%QSU]S#82%T
M]+),@/V?BHW](C.4/SLB>JO-B8:VV5 8+#;:?S!8]YO;-12H\FFO00E[&I?N
MY9O79^1,&J.@[/YR'OLF-1&-(OF+YS/@#1]02A^3%P=G,73<[+H^#&DT9^Z2
M-+K.]UNL'GP'M^G@I0?9I-?TS8<[SEJ 8L"\:\:WA\V;'J0Z#U,U3IXHN+I?
MK]\^E7%EU>4*6IIK?:!.+X+.%1K*/A^<X8@2&>6F_LY)C_&8/!5S!96DX=7F
M*#BG0-3<KNYCU(4F"Y>$<@JU2!F2XCQ*&,E]) &N-L-\LKV03):/LV[K\WRC
MKDQT/^BEN$#,IM1)V5%2I$%:VR88JN3R:Z?,'T$UR\WZ!8\4!*N%5F 4%!BE
M#YU4[X+J;,FD%'WGV=R>O'.T&6&2W+T793)_BR;.+EF<.5C=85KY_(U3;A41
MD9\T8!?C%?F5X$_?9BXM\6[IHWI>"2YY\&0]WJ\>O#Y?E9&^[%;8$49#+? 2
M3/XR=;(,:D2WV^]J@(=P.0U*=9T4.3-H.OG%:"@+%KWP8MK=>3L4[UQ]9B+H
M$\HT-&^,;9M[XD$$C=YN4KW6M+MEHJ8;D&KO[K!U%-C? JK8<A['2%B03IWZ
MNR5^>@\<N#CT68:/&,:5.WYJO6_K@/?52K:\>H.!ZB[\:3.X.MVZL)T:_4N/
M)(+UAZ_\(4#[0;#%[XS9G&8-7N\%VH5)9F68ZHU=(/ *<8^=?!56%WB'VB]'
M;-;$.G2SI'O]Z7":F!C6C)V(4\U$1_RX^;J*$]66Z5BU56E)%E9R/O5RW+(<
MG5.(NY*\^4LKHZG$=\JNX#/-]O<V:Y#ZE.F7?2]"<0(W60/46UR*X+<%W="T
M,8J,=<@J0^,RW+SCV"3EL5W)&>A)PLG3LL2:\2JQL5TKD<QAJP:[RX*(@0\=
M;@)4P$NC5LDDZ3;Z!UV;1F!USOQ)F\KRBOCZ+3+!!!B '$?U3LK"HA/B[:!)
MP[SQ2*<TQ,3X#I)Y#+IS,%\C2^[2*G8H1;FKK4H,?.PG!AVMFZ!JI++./(S[
MJ_H1UD"Z"A4:LD^E%A&9YTH?JD!$9&1M,.!*C%^JV8*9G<)W__@)Y?]57@&<
M:S0X1]<)J2C<.IFZAQ'&3(E\CBGH@-C5G[);CT X7>X'2AX"3/)LWUC.R!AW
MA<9V<4;\J12EN,:R@ "?<"4T$!P'%/*T@(L0=<#TU 6JLW^UH6&"66!8E?!*
M =TV1__MI%WI?;FRS)Z&./PL]RVM'8Y$]LLT$B>K"JN2HT,]80NI"[9_W<!/
M0.2.B:O]D6 Z$\PTB)FZ_)G>ZK:%TN(?5VBT.'L(4!M_^!.?UZ'QH#)<KD,6
M5X-)V9+#<#&-?+5A$:2HQED0DZ8V'>A'FT>8*<^,YER66^1%OV_2%:Z<HEEG
MVX%FV5#@> 65H*#RX)EL^"]Q<('%8V*SF$/WIAW)B?>UR[89/N87()^.4O\E
M(R/C9ADY;"'U ;(Z\L6-&J#)"WU#E]JW#DSA6*&W<N".Q&(+8C_U1O>$@4[D
M5PI[UI@NH]=%1WQY%VI=A38ATX 0/M5<LRB2"8%\3YU"RF&/@5U_W,01=7O?
MQ$6A2].!8#N%->/7,&E. $Q,3,?,[I?_6*QOWF*NH='73^2O>8+%8\5?73]N
M[+\JW?.]%_OW&R!!$I$=L2^=!68H=W%HXL/"J[M/&"KK%U5ZTEW5EH)9#E"8
M[6S\B=[1TD!;VT?:5;&*Z"4SSNE4XA^1'V?D<D9#H3WB720*)OJ3Y6Q8HK (
MH6\N^F2J56DF^J'GD>$U7^<J?C\V"*%^HE2^.CLZ8C>^%6:[86';Z^SX+'6H
M.9TAC<^QN"G8<Q4@D5O4I\@<PP1OX51D42$M])E%PT^9?Q)X#.>YZL(KFUI9
MIX+6"\O)F;Z_#0]U5J\&=9[H(L9(Y_?SEF/E#'HBRMJ<_34=%EW RHB@'#T&
ME@N\NCJ+V,@#_PR!VRD!M2\Y>F%JUMK(<\VTE]\$_E82:=3-$*+4MI@PR3M*
MGTPP%AV(]@C;C7=H><0Y7I;9L,SH=5QTS8!X-O1/:(6<]6*<3L.F+$TD#[#?
M4N9-:BWY+?:OU1@SX]SUQ4. C5_QCGW&2\^&F4WC+M\R/$%4$)?.I+;U#<WK
M1S?WS2.1.CLG3W6Y)P0)R[.7PGTH<J::P),1?FT:/FEFF%"WGXC?]:WS1QN0
MC)X0G?H,CM-ZM"R/_:K H>8%6,QH)8Q4'_5T,DBB7R/S]YBCR&K+8*18.3*"
M<@C@V^XZSU-CT^,16^!3^=BZ6VCW:_L/#%6QHJ88"G>J1!T&D_L*\O!V;*L&
M$:T,Q['B0W>R+E(R5*[BM!X_#E.L1T"@V,'3H@66O1_WI=(ET4O>EPX!^RH%
MAX#9&75YB>#.9F#/G<+>HG(VY!!PS$"#!&QP#@QSUI@8$SU">&RN'-A;PS!Z
M'-82DWP(.%%2R@BDG:V'7FP@..])J1P"_(0!A38!J@<NM2HO',5$2_!3ZR6D
MX"L<_(D4SXH6BQ-^;\)*-U$*MR'(F[F+Z/B*R !%F?6TO[%ZD]HZ8.PE+Z:<
M[DL\/U#L[1CD)*+O<N-<.C@BHV5@ATX/^P(J^\+V_LP8_F9"G1FU%>\[UD!*
M30CUT0ZD&.W%-!%$3RK\#A%U0CT>N3:EKJ= >%CD$+82*;RD&MR\/UDM)LE]
M(W"_L/^7)#3%U-V*OA+;O%B1DM!"K8JD0V&Q5R1XHODS.](H^W'#9:3-RBE<
M0!M\Y(7518*4OOGQ-('8==&5G%B<G_1PEVVV?9=X%-8,W=DL0\=1Z(0%L7?;
MU?>51>ECN>_K=3:CQE26;W19G] &*; [(0$P, )Z)PNE^G1AY >7ZP1/G<8X
M3[:E>*0?@SO87:R/W[O:H>.N5E_+7_RX_7F!G(,EI<V5;;3[*L0T%E&9L0R=
MX4J)#M\7=E%U;.OKR%LM[%I"5*T4:F"!%15/FSWBG<.72>Q8&7YT-;S%W^N>
M_!YUCJKPQ8I,^FU7#SUEX5'YJEK4V460$2/F/_M^WFQ>O3%_'CJO=79='=4;
M>2-1\75EGJ@-$"5]]2!>_F/ +^F#[^19BD"Y;RX@8 *%9 _"WJ%<+O]2<2]%
M*<,X(D ZF4JE]$2*^),I3.^\*H36??4OGL5F/>(640;ZO7C$UJKJ^I) 8^)/
M9ZJ$#K,OE-DA79HO^JK6DL@U 'HB)\(. 6]P]GTB2J3X\Y<5PX'%H\V.9(+_
M2S@N06WPN-S?9G A62HL?7/MO>O0BG6%Q>G?A!&Z!B=$.H(&\!*OX4YG83:/
MS<R;%5$TE)EML1S<_9+JT\&QR*#4,:U+:/+O](<"T)+&#5>,GF ZI927V F%
M7=$D.]Z;AVO]:G>QA9ZHTA&Y%(LRXYEM$8Y?_YTOH6BGC-31$X'&0[-3T\$.
MPB*(K498J*T(5;-<2LZBCJ;1[!M$=*FJ+8I2GZTHK<ZYD-TW1.:X2[KO1'QO
M,;MK"?.A]&MO(RSAO@S776FU\\Q%.G5[2<@B$&.0\?-%76)X?@-WRYRZ$V1"
M^'(9@Q5!XR8P=57T4;OQ+ P>$J@9CJ8QT>TI;:UMAOREZBS6R'9HZ@A]R'49
ML96U-?3BCK]].]8I%YU8#[F3-M/5R3D1.S(Z'B[L7.QIZ1'"LP]RD)+>/_NU
M <,#MDO8U0[,@/YV*Q"WN'EV=_'DZH,!.]T-H*2=0<";HMK );D:%@(V2JPF
MEA?/=QSK+$E%<J\0%3]KX9*IH>R[XMLMRB],>FM%!'W,8DN+_\7>>X UF6T+
MPXQB&3L#B%+4H6H0&('0D5$2$##$F(30 J/TT 1";R.."$% 2D!"D]!2($@)
M2&B#2N^$@ 0"2N\(4J3)YWQGQG'.^>?<<^__W7+.=3U/GOUF[>R5M=:[]]KK
M???>:RG[V9],HYD&GY25KS >Y,"Z5>%1-9>^]E_-B;9-MJFCK2U,1;'\K>;I
MCIJ@.-E-B@NE6A<P72 U/G4[U96OSMDX7VS:R0VZ3[K//S;P>FPAE4*APA;0
M'"0*K1:0(_O+(^KDR[E0@E]I';'AK*=^([LRP-K*/+RJSF>:Q%,#.-XF$;QT
M(CBE=UZ!R^I2A2'\7B>SRUK)MH@<;G!(@2$& GL@!=/DIQMZ";GQE55.BV>K
M.J^ ?7#5I;%GD_C6!1\HHY$P)/\V"K>$1AGNWZRSSRX<R,QX,KY%T'K<GQO0
MW-/%P\,_0PDCW#'\:2^\.*_^GG+]!5KO.K# W05QA48+06RT66X1-^#@<UX_
MK-$&UQXG-U52H<3 KU\^B[![M@.<H$V[A.1P4,8XO+0V4OQH8F^^8PQPI!(.
M'KD%GZ/RYI0;N.5FT7!O )0FN$AS=E$5TA-M'HMAW*VD!>:>CBV:U5J3-[<+
MO:#LDU=$BRD4' 84<&]6Z7(8HT[-%V3CJ;Q246DYIH(,!W;4TN-Y#=LE,!@B
MG):MC3[3,2?#@)G;1E53*#A#HU26MR#NI\@/NF(6JY"@S)EB[N*V '+E30:#
MXTYF,B0SJ+%GS$!=RNP(1HWACQZM@L];%5P%S"35)DOK3##ZT^0R?%MN7+ G
MN6$*K6FX*O*TY]6E ><(AJ7K_9TNQ%@@^'JWFDD.XG7RHCLU$2KJ2/0]^NMA
MQ!/& N,?NK2BLC\DW9_>=S?(<I[W_8SE].-?0D^HE'9<<* )6;/Q,M:7>N#-
M,[;5%WB$^R0C:N'-7@XC3F_U>%F_O+6B%#;WB0)^,0%R^5\+Z;055H#?K)MY
M:CH)?"U2<W'Z#@FESY@=G=GE$N'W@[&)=R%@L+8#<<S>@4PBBX&]QBXZ.6%\
M4:"N$Q/O72XYM=TJ:'&9IYFXL&0]E<70FI?GI07<Q1&1\V"6(&UT<P8K'-*D
M&US&P(USCF4'D=:T8>+J4R02:=PJ!OG1Y]C[3KCPQFAIO=D\A*"FLLO5WR"^
MF.BF"-*A6U!(*6J\/PI'"!'OV27[IW5=+RKJBNT2?YI5Q "/]U-H!>X4RMM@
M?<K[*9OMK,PHHUL\[;V7I8:_=62OL(19TV H0,#D6$?A7.@\?_LB!*GI!(@*
M!>4GI>!R4HPC_<34>'P<&L+'@_JKE8,#U0MN&/7FJXF"6\P!P@^[>("@X=>5
MO,AIR_,GA$SJ./?1S@/?/R=]>W=M?+ <QM1Y:-TS6XMFA.=ROZ:NR$VEN@K4
MW+#N53.@$ZT)L=G);98?;7V?5 S,!W :B_BN^X9\9,3%IT!*QS:(EM0.7E;M
M0**P&X@N*V/-N-,%)/+36N!AC'!!+.'"<*/J4! $Y2DP!=KS>$3(G.35L99X
MN_UUJ-YY1S'/TE%AA[IMX.T=#=[^C($VYP\-5X(S<0FS>Z#<\(:;O905S2A=
M8/"+Z%3^&T==.O+A[*5GJ7= B]D>'+1YS<Y*1.78IE M>0;S38\7YLB60@W:
M1;-G4\BLFPDJ675GSDR\9WZT/"RTQ419+O3$5*+@^04^]YOM&_W"!,R49(#<
M=-^]QZ2QS7C6R+/47/X0XXMN4.YOU'V[+N>8F%1^-#=B@R1<-=+PD:JDB1VQ
M/X>U)!PRP.$9D#7T+"VW(\<Z\[-=RM%B>.Q(1 XCV!89D"T<^6K^G:7T$]!:
M*Z!H6[0N<5GO$1.*XC.5%ET@FP@"'$==@']YAX8^8E;:OK1552H=V*U^'\UG
MZO("V)S1]II!I$B_ISC6HIX<'9)=:WK(/E.G"^RY0P'XPMT.[E"J-7)M5?%'
M,] PH*B:0"8\YUJ9A(?9),)06(.1^X@-FYNI!5]K-@56,+L+E<V.H/Q*+Y$G
M=+((0JTN+USJYR^6]D]O'-)1[="A#JZB5)%(9/O'#W*9Q#MPNHIIZ>40W6$@
M9C'E():=1*HT$7?6*>?72!7<.?2@WEG=Y73HM]:YB,#K2"HVE3=:X@BLBC3Y
MT<-8HVML!SQW3AQU<$]CL)NWP-=G\UJ<\A.2BN3R\Q#0PJ-KJ@]-"WO;2YMM
MG%B'(C1!1;^8@JGAF!F:9;[/5QW5"/WP(M.7R&GR7=Z-J B8,[':V&&:>BJ6
MJ5FHSQ& \%/ZZ+"@>#!PP^7X[19O^+F0')KD%/FX9VMC#!PM\JQ/S'.D$MM3
MG],_CDN(*2DIJ-2^WKM0>GZ1W]D*WAH6:Q^V_\. =V8YTOP<,1$?R,WI4"/Z
MY,=Y"N>#EREB<9;R;Q7:C"Y%FUU*MO.?*YF%&C2K(<'^:33_1*1[>3.%4DU7
M^OB<^OF:2]8?5F/^T068/XT(+U*L42.8U3^A $4^ZG]-PG$,FT1C2R7+HZZQ
M<3C</ S>>M-CF&]6,WJ$QROR6*L;E5^GO3"<<K&TR39VP'"R<=-X<!)0ST$B
MX;CXP9Z&FCOLP':M9T>"_$=2[0JWK\IV3E9?Z/4_^U)T_K3PIVH/^)F=%P[K
M*A]>7]I8Q'FF-2P=K-!.>Y]K,A=\(J+$^E/UF[;K_NM'<P='MWYL^$3GV&^D
MNV(^53\ 7EH<5$KWB%[8>_83'=7?2.OH?JH6_L+B?Q*+7;SI-CZKAI![!I#@
MDC9^S:[NZ^]GQ=QUAJZ"AMPSGTE2PBD;+0L8J^%GSI<GSPYJS^\5*:J-_R&F
MUJY,IXD6;9UOH\!S9N@JN*LQO X(0O,=/O9/)/P7%K^P^(7%?R46NWBA^%%R
MJ1^[KH9],[+W/%%OJ^@RQ"*N"EDQP'8D$J>[+3]Q-'(F7:2(QJ8Z&'6XF%H_
MK1,%#[8.ZKHO0N85F6@5S+X'FDN&Q:\^?"M@_VDJ?1CUR1*JDJ.#WI1LI03?
M.;6]7J?68?7^)W1&1P \;TTK#,R6_[UZ(D=S*Y2YX+;SL]6[W^C\3KKQ4_4+
MPN/U!2%H></Z5]&?Z C_1CI3[%/UL4\\[-?ZPN)_"XM$*97F)?;#%FY"VBZ7
M0X*@W_2P0K^)4+*04>H4;ESW#@3)&Q[XJ4>'!<R*%+T@_ #3MBO3%6:]*S62
MQX?%BL*K8,($-XC/TIX7_XI#\0N+7UC\PN+_*Q;/W4DI.)/;KM T(]?[^ DI
M+Q<K?[E(J12A[R5*1:*)1 #@SG+"X"?[I'6@P:G83G4%;C+?#=YGHW#;BOPX
M/_)D*H[4PWS WW?7[7^"3/\$:O_?R.*>XTZGP2&3/QD8.%>S*3/I)GH51_C=
M&M<=8(*T2##2XFLRR]"RU&!?VH/]!&(HTS6'Y&PC.?>4>2D*@A$#=\& 4VH_
M_J/O-_Z]43T4*P*: 6[H9'/ _/)%)%W665Q>RH!_<V9L-1/&]EO9.RS-'A)Z
M:'0Y:M3;"1]#BPY)BL*W6BK@*WD"]1E)CRVZW<R;;7(+.:<E3"67F?H-NI)I
M2)"[S[!13H7UJ7U4_CJ915,5FXJ>Y_V4F:S;:F#_."1&U2<3CE:$*E4!;CM+
MVQ2.H:21DT)I:4W!1))3A'%CM3^O94HDTQ>&95I*D@Y<YW;I*IX1%N1<FVFT
MI97W:L5F$7.@9[S?]AFF\B*A:DN&AW19\V92#4E'O1SN]@SD%94+SE#\<EJG
M/"V$YD&[7-7IKESJ)[XM#2_1OZY[O&P,T=-6WF4$Y7,R@C3EC+(GQ;J\419'
MIYC-U]"EM8^ZS7IWN?8?,)Z#\?-+2Y!U]-^SL'JJFOPP 0330A@>)O)$&)?K
MJ)Q,EYY]JZ%4NNIPGS3M*($_IRM+*,^[3:3BU00@/L2WYPLY6;#A4CMT(@Q6
MI8X[G0X4&NLR$W<>,G)U&(<HHM7X57RY*@X(E#G?.]<D<SW_Q5-3ZD.8@BGY
M[,V'5F>["PN1I"* 9.K7XU/O-DV5F/ XLUNV9W%&@XL$ *M;#1$%@ B AO!P
M<%]CBII YO?JYU376I5PVXSJ6?L*4XEBRWQ<2I7T<#6.A5:.P4)1;!R.06BI
M9TE3EDT'3NZ-;'O$ND$;1UYM?U3+2V=Z^_H 9G"I%SH9F .( ZJU:X_+'L9>
M=Y0HAD:/7;<[W^QK$2OO1<10&HB2E3RH-J(LCG&AH'&M<M;(V[/N_!*C M^>
M6N@M[3#!P@B_9Z^RE -TZ")U[ )=W<=J3U5EDC%]IDZ,X>A)X[S2TPN&@UFI
M]*\57=UI82P$1 W)BT!V(8&@/GC^IT[\][;,<NNPWEVX9';QANGH0@INXL-X
M*5,40XOQ<:4$43W!FUCH>2'*148+&M]KA<7G)RSI"LAHR%B56'EBW+R2&>_;
MWM JKP_L+ Q$#T@\LZ!^FYD9/6D F")L\&A0JK-&[D B1IFWM[RKS:0!Z2:F
M VH0N'HB>L,:*^<W.S'DGLS)>ME*=7D5*F<1+D.,35K_^K5W6\R'RV%CR[EA
M/9O"U7=D+P52;I5K-I5N@6=4I<\PY"_<#C"0VE:?"J/.&$K<]T1K[A-F(8L;
MH)##R&4#L9A\*W@V$O5D7.M\GLO]+?6T)5T(/["]_7UN-NE^6$,ASSP8 _!5
M1&/?$7DKS*LZ\"-;P!+WJ"@-HI\O8%T 8I;EE]N51]CEZKZ+ZN44ODX4RG1>
MZ7M?[EWA%A5[0<PJL37: U8S@MTC8.\#CATMCL!3I)TO7L_)\I]658DY*5!(
MR3<JT'<#];43TH3V5G4$]:,3<@IG):Y?]%08HE(JXMSIE.JJ'GO=*^=D!V[5
M.J-T!V86N[Q!+H/!$GRQER*ZB.7YB%VN,P=*!Q;AKY30P;3,&"OR6#*W*V8J
MW^3,0Y:F?13RTAKJ?O^4DI5#1MJ @;(WK %H=^$;59N 2%W9Y0)#PE2:-6C/
MQ+"9@3LQM"B$"""8$**CC%.B')GMN)\2D/2+6B>?Y>^;>"?LF<\,.I490+/;
M-@MC!!Y^.6EVEE'S32[;,U)XLMLJ#H*\UD=C*.@)>.]R]=.#\'"W99>G-YON
MRGQXPXU$F?6\@\!@"CR+'K 9#@?52&&AM88.S9Q:7>N/&1![9CQ[*S_3;RI6
MI^I0ZGER=\2,A62F?,=2BFJ7PK>,!H@&N;+1M$]/-#?=DT0)K_4IV)OZPU/=
ML.TG[AKN[)>A71Z9SECL_.O&,0B0 Q5U"^9>]8V._*G[2ORX29H5-AR/='VF
M%HOOIHLTUO?TZ<QVC5!Y+5'Y5]72Q!)?%6VJ MP&XI$Q]:18("G?G]]/F3 &
MACX=%M:2S+YW9./[$7IO6)(!]!%80L;ZDN2LN)]LV#QO*(,!W*S">',!52_K
MV=?-4RV#"T)QB>@>+(%2'M"&P= L;XH2S+4=?-+0IB5>TI4>1J* K&]TWJ>-
M&>(QJKS^,^?D^)9LM2Z<=T8I*1$_CH>*[))NR3QL% <]#I4[?7J;Y+>=E:^X
MUNHWD,!^@B.\<\@/;TU3RD2V(A$<K]0+M$5H07L&.FC>@U@\D%O 0((-= ^Y
MZBG2.(XWHI\Z>WQ=@S9Q*;,4]32/XD06U8GKB6X0:!C1 FKVM< "1(Y9LM/D
MZ1CT4,6]K3?PDY42&$D2:S-F>C5^P.VE,W+K.X8:0- '((.=A>N)PS)%CDWR
MZU"PHD2 PSHWECP>==":X'M:&$8W7Z_".L+4D*C&G[C-['ZV*<\^['[*%^DU
M<FTJZQI]ERO2K"*W *UII\*^C+0,>*7S+:^MNY$UK[8N3%1.(--3=X?FZ+G9
M.9MX<4\M_">]R**!ZVSQ7&-BM^*0U3I6C\?/FSY:H$_B?^AA45\>I0MLH@!D
M2:2@%.I8AR^IPNEYFF #=;RT1P\4Y3Y#Z9V:R/WE7-V)F2=_/D'_!?X#(:-#
M.G:Y9+U\=][ =A1:NC\["/^/QIG^ W"?W+<17 (=)0?GW/*[\H-EXA;H@UKB
MINWOVP'_%OX3EU\HGX69S0IN#F(!6VR0\C^SW#M[ZA!CAJD]0[<+>J+[9BXJ
M_9[+P  )Y4<JEJQ>*C*6N%UT;8A ;T-TP>"MI/WI^RJ98Z?N$R?UQ"Q%P K"
M#+DV+X(J=1;,NIQI5M*Z//QC_Y."9V )@]S4I[K00[GG=SR1"/ [T6"<;Z/M
M7.A69&^/7G%>/;$+K,Z:U88+R CQ![!GTF@R?0_TDYXM-%+$FQR6CZQ_FR[V
MC E02Y-2<#^(%T"@AV4C&D @B)_G7FB"/E[KPL5#9C]!<00#Q_0C'J(^<8#K
M#+DX7P&/V<YILYOZ-OW5,$Y%Y0/_W#[_U3(![]DA)M0DO*1R3[0*,6N80AC&
M9L3AB;1[D\\7SA@*YG);Q*-A*C&K ]^URAO?+K--:J',/727GIZ^(,0[";(X
MN"[UH6+8'J708N2Y<?YV:C>U:OBX@$5JVTSD\-O.17_3\!BG9 F<4J:53:D.
MG93"PU-Y1#/;:>A(\?Z,>F?Z)3:9-!&Y!  WBYG6JY(X0&CO=%\C?$()W.AF
MD)]4G*W6R[S,C3>K*J\D..:0"]C<"\^MK/W%ZPGUF3 '?'/X_STQQ%)U:5)Q
M.FY/"&+7;'JEON!^*BL7QIZ+(NGCB1&Q)C')R=M(3R:2F=NN-R*D$*15O!TM
MZ-E5S%C8?)!]]0HCQKTP\[++\FP.8>6)[G 36TFW<,[?C<19:YUT&+<PV=:K
MB=.X;J7@32=%F?5$LG@;4[_^(+V6>M;.F%EX1'[@=N!-)".R -/Z<'!HR#^U
MBS+]KF0:6"%?R[DO_[ZOK[2X&MF1!Q$='%NOT<WVW/P^O%Z9.:Z0YJ[FGCK[
MP'MZ;+IC.-9/N_5P["[7!\S@V$+J8BIM5+%OEVNXW;3_K;?96FY@Z\FJ(OE)
M Q&UF\NF%_WS(X%#?=%;6LKQ:0PGQJQSDV-!LD;3R09@[< J-O;GN"MBJ\@A
MD$44@-I9)4TDWCG4XYSLIE17M)K)K#Z,&$OTGG177UK9+!G7>KE5)VKU 5&>
M%861[G=ZX(EJHEY8/7\G-:G-N6DXWB:1[-K_37$<#J434V?(@O"?ZED%Y,:H
M%!Q32S:X?&PVJ&>Q/*2O5,><;)6K;V$ CO8LS*E@+^URV4TLWSV]_!/&(]JV
MG5EOP.01^/#LPV@)CQFX=CAQT(V0@RJ-N;C:EF>49[9-P[$XTY#+KM SL3WG
M?A_PGSROJRLA;*UQVXZ:JO0=C1\CF!O/#_?"#>B'JPU\?W8M<\A$W1SXYOS@
MJ^D,,(+%*/1$227V5@>=[7I]?+Q"R</W@0NJA?D=M9+..KEV=<O,<SP#XV[)
M5J^;6H(W;5XS'ZYY>Q9PT8L8?!*P!2=:)68&?F-Q%LJ]=:.T]/5B)IL^<,ET
MK0K? \GZ13S;E/3(JH*S:X&"OM#\G!\0_71^P6SKWEEZM:$ICL''ZJQX$!=*
M8HBNY/)]GV_7+$A3@SP:$\Z,.6FDR\O;/AY3>;D--:-:;:4G$1MQBX6WS\/A
MKHFFHE^XF3\J.#ON_0KU7J:Q2#IR;VEX@L10O[:H@<A13?FK32FIAT5S"#LX
M!F )8C"X?J+,]EG/FB-1-483MF1P)KFS,?68*YN\ GARVB35''OJ_@+%3LPJ
M%&=7CNII.%$CZ:=WP0OLB"616UH4V\#O+N+"/\"1\*+6^B7MHW'B'6>14?7Y
MN@W\ 'F'5ZS7?5JY3>.H0+OOFV5*>N?34 -3TEMU>A!0(=BH#K%@!*P4)@#D
MN*&7,WC3S[/UI)6N!%Z+,9\J/UT"5;#!%+PB%/0@G18H:H/'14CW&R?T7._Z
M^ K$@1";B0C% 9EL,L.)P(3&N:^Z]][4!*CG-T\V-Y2S70%+(W57]1-MD@)Q
ML?Z7I5(O1Y_!MQN]T 3H*1YU7]+1RIT%NZ;GAO&^LA%/'*@?F+G 8REB8)-Y
MOVTD.FBNZ<4N%W,MT5*2_6RF](J-DPL8>XP@0/3EEW"?7E,5F 4H^3\P>_O1
M8$'HEJ*N%XNA4AT$\+3[3EA8&@CT[5B_YX=:[V>(N=D+!L"CS\$)F-/3L?:C
M?BOEA-G<_@D(ZD>CHX<D7HS#+-YKV [D'^Q'JO$T1[[9Y9K57A]KV.7ZZ4G+
M/.\="K&RJ5FY.8P4"5VRBH DO?[NUAT45!-;9L"J-S0JK;;NZI83X>%%=JD4
M)$;57)5,ENK/;Y*?>9B^KR8_:MJHQ]D:>E\B)%!+S[3J\*K<&0V5&4$(=9=K
M0LBM/[MZWQ A=1E91>Y^R!*PW.6R'J4++]IMJ1$:'AE9)\F\66^-S4Y)Q*HI
M1CXJ7C4>EF*^>'!5DDJ3U!WF&Z!=9 NQX*1A/859&;>J)J%3O=<B\5,1N0_7
MZ;R(:5>2F-['YYR6:J3RR_2ZQ=14ZK&:;$8,UE]J)]2[.38[QHF&\43;4/)"
MSP^,NQ.ISP(A-Q\XJ&O:FL%=&&8N-_N7A3"4[CX09YYWU3P%"*WR\T0H&LT_
M'EHHEV LEFC@Y?2<O2\8Z!Y5TSZDU3@IZE# !YY:EA)1V0>=X&LOG(^PX67Y
M%$J(=KK*Z9Z/-')8:V1F.>-H:C*)-M^TCCD:A1C'6?;ZN1 #:=I]#J? QSRL
M;(Z:=W?WU(I"#5 "'2&@Y=Q4C>E=+AO03<%,FR0CG9)XU7;[63PN:=ZOF\D4
M-R1QIH;=@W>"ALY];X.]R5[[MFAS,Y0"UD4+=P<S^OF[17?"TAUV5)%(?DT^
MUDU-,C<LCQ94R4,B4'9"J>?KYI,DY6 _%#SP&K[H(&1V)M*X#,LQVL#S\T*?
M3$#[;1TT,YZ-&P5-CIX/%RPL"8MCB.]RS;'8LSDI:DA-TSM[^\;(4#$E#Q12
M#"EDXDXP<AQWF17:Y?(J>.6EC8XR(17.BHCD_)(N1T]05\B3%8BACB/12%0[
MQ>GJO^E"\2M/=E=\L'BP^2 QZ_?KNW_'&_HWM_7_NV#/X3W;-6RII9X:YG=5
MYYY^%FGWS]M\GDF@^P\Y!O[AO_T]M51]YV?^W(^LSU-+C:FK)]J'WQTE.V6]
MY&@/O5?=1R*3]/B3PRLJP]J42YAH%3X-&G/G^)%U2OJ+/2LGS#]]$?Z"_@OZ
MLPGW'IX=G/$F;17^WMK+53*@_.3IX4/F:/K7[M[NXOR\5"-#\.8RH1CALE E
M2&-\-7!W7_.\5N?;#C_R]J5/5]_)7?EWH:%)I_K%/,0=+1HDHQSC$(AW@!,I
M_WG";@S>OE8D9E9-9M"8N-QDR_QKABB'#P]"_5G0-U&?KN[Z'93]@OY707]V
M"FW<*WW*QZX*\>&T"'?2+M?]9KJSK-RPQ7)#)8N4'C/F:V=/JD@>&&"_94(4
M]Y;M.?QI/%A]NOK!(N0+^F_0CTQVN<;;.[0J 5HYGVGY;))>.LWLOHRGK"Q>
MSTS971S(2^7?OK<ZSF]"D5Q@.!2(<,T_"?GT^U._7PE\07]!_\?11_X0?FG$
M."!IV=:$TMD],FM,1^R\BD,8QF1N[%]8QCQDP;TAGLRH[ ?2);M<VB\T9W+?
M_ES%+?#[MX8O%?^ABL_>XN7RL^.3F(4".5<@#XL&.-C*3%)N:G?NAV\)]E&W
MI0P),U6"J:1_U"_\ZO?W>4+:OR]#[D46I;>E7=CI@WQ(UH\U^WT=\G'%[<;9
M0LTTM)P2/ES:(4'<#L"9>-]-IU("#STQN1=N0EGK\"[N'"0#+KE,YMW%\V2R
M5[QFV5$0N&$J7U.]5T2\J0?C(MQ^C7U>\IG4AV.ED2BWA671&2J-0O#E%S 4
M]MQ;])$M^^**F5&5P*'EQEB[+CC#2(=*5.4<C)CI^U[YR7CR.5+'XO7,FK%U
M,ZLY?,^L(N+.U<@8RKPR/\H[$X*:E'LT\\.OTHV:B65DINDX5#8.CO6UAV4I
MO2BJ2+ ):?"JNBAM-!,N:@%.CNQB.+RX(??SKPHY^'F*)XM'9KK;>?WKZ\6[
M7+F/>/R^:O5**CF<7RQ1=MO8AAO8+^&HBL3.5.(U @+L[,EC8(NT@VEH[-[<
MO9&L"9/JKTRN*'6.E/2]PHP[':>5B1%F4 4ZRP#)_-?54"G#RI.)CNK?!PEI
MN^26=&77;WDEQF3D]-6YOX6,,[.!'G"H;-4YRWL1@T4BI#>E/376/:7JV=FX
MJ+QLXI!3SQQRA$2MQ2YO+Q:']UTL4S-K(T:-N\;%9U'#BT&+ZN:$G.JG"E_=
M]R^PH;59WDF$-.O[2GE5V]+1NUP9=6[7*QPWP*$)2QBZE0$87EF85S'GGFF>
M;R'T 7M#_9G$4T9KK/H^&\-@_M)8VFGA%5-E0/VC3)AW(M)";3'PV@.-$IL*
M<$>2B=?SC&(SITOZ4]-&K_O4]/-9(Y5 YK:BA2 -]\3KYRM.Z6JD%H<%A#)%
M<F!9Z/K@?4\%5%U?5)0K=%]7 +6+6?<UXV'?=ZU%5'J!W44ZT\Q9WATH %CQ
MB-7SF>D5=7R!L!1=<:1@P@[<.J#07^_AD]<L>RK451>B]ZA;)ZY.1KY  BDP
MJVPIQV=9%F*?>YWKF$V)QL2[_2;:#WY8B:<K;X:5^TY0D&/DV^_*>5O&-YDA
M,X[GB\UK>%KRC9PSP<ZD)Q5:,=GEG6*$7H-:G@(PLYF4^C631B5.B?QX0MVH
MG>)F9#I?"I TEU>OK(P44>_3D;HJS:E3D22/0^7.'-)#%\UGS.WT>%\<$=+L
M.$LPJH-+E-.<XBD+]T?"*8$&!3IDRE?LVK,E*1-Q1U[TKCS4;Y(T:M ]C-JI
MC(:8-;01 3L'KY@O;IDV.+7$<J;F@%[OV7%(LQ]T2^VMIBV%VL.9=6S?^&/L
MH[:7_+,:Y_@$_#WP#HZB>B8%^H[=K%7B3,2LMNT_,, _2^ZTO/)YIJ=/V1O^
M%@Y^'J2WZMS'SM^2FA;L@PB^_O=:_3E\OE21]?D:QI\W^:^)VV48D%6CX+V8
MD[[CQ>?_>P2OE V](-O%88C6YMP>[>,#I:H.+_,29B+0.^]NWGAAN [6KW-,
M:62SC&B;&$+N7L$T_YP^I=Q(SNLBE.E2!6\YEI1G.YKMM:P.6I:E].:$48D8
MQE+GG+K2]M#M72X.MF9:,7/OQH!41I6-65"U%5]B\VP@!7,^BS)FC3;C-1&D
M7 )V\;<;$0OR_7R($Y-%O7,=IPIOE1[>N6ID,6LQM-'74I\@8AI!I$SU0,9&
MTNP ]A2GI5VNG1EYUP6?7:[YKZ*7$XH=X!'6[P9Z1S'T'FE9Q:T*]O-QS QY
M8LF<L,':0U=.43]38B)5;J6N3[J>0  F%3=Y1T[?6,NIH+E4'<X)K_/SF?$;
MIT>R+_\L%(]"&L%1G7#]V!<0.2F^;C%"GVL9]+2 IW#XV)"F7)D,[L:H/.>\
M\YK^S/U(HT,J[$KJ<.Y^JI]90S921<BQ%6+7Q%B4=CHQNL.\-KT5(@7(5$XA
M &;"2)2PB-Q'1RV4"IWZ;E](A/4.8JA4F4XE-;_RC6NB,9MBWJ>)]F%4&F%%
M,O2D5KBQ7*F:?ZEE23@GAE4?5[Z$'HV\8#[&$HSL"R5,D6LUV$(5[>JHN(#'
M^5BC*8Z,M=<,)HSHRN]7R(,D3R)=&%+IVM"?>N>\:GBSR54W^NU=;ESM-8+W
M%)J)7NOI:NY=J4!"?!R9DWN#BX2KWW@4V[S?&1IKP3M'!#X:M/)39X@B_( #
MC95(9;] AW'(M=28'_J<B2/?H>62T"-I +WTH[SG\)X0D<K)<J0GDM4</MY%
M?EG6#X309F\U+R0(&Q(:'#W$0Q+(.-)F/5"DSI3\PE#D4"42WF@7D%BC&&_Y
MLN/#'5%:0G([NLR<>C)TY\Z3HFP-7L3RS7+TLU>9("M/-*]O!RM@TZWGE1T+
M^.IHNN#/>;Y'WO:@,6>*.;.V72MO77V%J9D^<G%0 L.>XORT9F?"H^/UN5TN
M\?T'FI68(I>U<3:HP^Z#>8B;,IKU(IPQ)Q<O$B7=K+K$->6HA3;NU:79HY#1
MXVR-Z1C8R^+,[ I= %(:CKQ=; %@W#&\;-,S..X/?]91:"8RTAX9NN6/+Y$Q
MRMVZP&/>+]QC:>;C6Q;7^H-UG\Q#LTMD%Z46YZAQXXG@-Z0WF.5833^>MNG;
MOJN@+6@;<72UV,E5N()=.#4/5"+D#*8[WD4.IF HE*J#C.T^@,.+Z,='JPP;
M,/->7].4\BCOYVCGC5 (/5@5OW87T$@5EP[T4Z&L+/4]:=V0_H"Y_4'>=2NC
MD#:@)#H'7@<(I7CTMAS*4IJ8H1_#PT&WB[-5WO9E]N;4C!51*@#AJ-P*R5TN
MQE=]OR5WW_-Y/IN/IJEKETM:*7!G;I=K>HS;(N6L[+.ZN]L9YQH7\_TO)F*X
MLYTM9LJ?5O&0&-.[7'L<9[RJ/2J%7SB8X"7B9.C]\EL0X6?X9HG>4N)E6%X2
M<,F<!09!DQMVY@-P!Q]N@.;WU/K]/%ELM5J(QM@&>.C/6(K$+P$;*]K=[T#0
M#([6T*7B:<K%H:^+<8T2I-*NF]\WLQR]$X!8)_2\QBRU9)7.VQPT#R@[56GJ
M\!22"#>SI54B=.C0,M"0H<KC^?G)*G(#&&2![^()-%T1R1YS^=GI\;:\Z>V"
M>O.U&X/B,90/5\5UZ-2*3@91/;<Y+.U&OA'3*R.B][6 J;I$LU#^\W$]"0V^
MDL:"X"@6V"-N!4:FT!A8(6C<3P6)5J7[8I#(R@H>5&M<U8FH=G?S_4P<JFMN
MD\"$/[(@FIX7H__,BML"<=!(,M4'\/;=](NV3K>$FTX-UFMKP^+&;TJ9=$RJ
M$')3<Y'%%L6^[^@\DOJ4.4A5<@[**KK9@K*$'SC7>'NC75>59_@#WJW]4HJK
M8^FVVH!(T;1MJ5)L:CZN=XJGW5T4>VT=B/4KX._"LOQN5+<N1V2NV<XE<N/4
MFHPD$?5-;SSP;PO:$1B +"DE*!NX!BE^P_+)4C;=:@,"]:]&I44V5Q9;,^L=
M3;H7- ^E<"5!,GILMOC;1-#7XU$#SHHE^*=E"! 2[+(LN@0)L&8VDK*K7YRS
MN=Q4F* 3%E92,;M2WCR^R\4/3W-*/IG75.B<P9F]P-%II2^OB[M+XAY:P$QW
MN3+]H+M<AM5PY=M;X"+CMPE6&S8!1A%5>$NH(K_C,QI&%<E?D\>0)4B=.5.R
M]]W9&/L@^.F*'S9B3874":F'5IP$Y=X7L&VVXZV@^_$*!:?MGK5N"%<!*O*@
M.\=E'E[:,.I\=W'IVUAU&Y?YHX>S7"(N.G/ 7FG.8G:]E#0P,%FH469 F=9X
M)Z^(IF[U.C\0(KPJ72[<I<K# VMYD4&J,=WXL7\R^+UK?,(!#7-Q0I2Q92Z>
M8<#<'G[ME1EJ+'V;+3DL6M._GO-TM,?1D)W/TC%0B)D>F66^ZYMQJ4:HA4PD
M6+?%\8UG+S;7M;@'Q"XL+"P&+$3]&.56W+$-;9:V!\HO)0CZ9-A6ZTP+!B]G
MK"_GWU:VB^>704N&3!]^/#8-'GSTO*)/NSBU&CGDJMYI[*ZF4X_WI^3A;!=R
MHA"[7/=VN?H*8JX[TX;SM_0KK7QL+R!%6H+H=$\ZWVR-\"4@/S^RJ=9'M655
M%$LR"ER:-5E^4G=:ZV2M/38//#5DU-:PRS7<:CP_<A):I($O$@5(J&D"W]'G
M/U+F$_>JJPIW5CC1/GPDF@ZG]_"W1U8,QJ$K(]USN\1J$J& ,V88]M'D<R]0
M0B\=B946<JY1!S.RT*N.WEW-M'=8!^+2:$',]XE-DH'/FYYB3/%#H;ZO]7B"
M#3Q_P 2'%+"#0=8WBC+/EM<"'(7CBPJ;)L&WB2G>3J?RT=%VSVP"2R4HZ3P)
M:7J"+UGF]9G>G.U63 $5N2STL,7)./.I8',RI!M O6^C0,S)M#L=JTN'?329
M+KA*SW=W^GX\'CNXF&C=D^='*14DO^($# P,K[NGVM]_%:H*BYCK[7*E15KE
M>Z U6BT2RA=0+@7Y/#"!WON=_X"G]L4Y_#O.(0S5=7/P@B7$$G(4J; RA+/O
MFO.*H& B:GURLDI; -/]Q>8F!:3[- ,;-8!T%[] G .<4U(==Z#D>\USH0 ?
ML= T)? 19QUY):!@+YT7! )-@2YW')O/7GFL2?RU^.IMB_,1[].R1S)SG ,B
M!P/U03TQ;6]JT3F4%-X'Y".)] *KQVN9A+$N&!R!T/ O3>S^82U,_2_%_K3$
M0W73CK&ER2(E8*.(RCCY*$5WN50!P\.SRDCL4R.X'M2$&\YL)%R^8!SE&-=*
MJN3;6&!;ZMUCG_NU.(OM>=O-;-AW$?:"VUFG2(4=Z0A3X^%1$14TBQ**-*<:
M%;V)9F,H>$^3G*S(!>0J)?=LWL"ZLUQ6[?P)[[\4QTOA+T34X$7G!_8HNXGI
M$(%"73FI@G[1TH'[)$J3+LSWE*S$3U'(?#Q9SN"/4Q.O]FR%0Z#D<?M[?RE^
M# "[$$.K,5.DZ20S!5A1CY)D5C2("?(H8<%#L!N/&A.4#(0R\9$!+I"^7[9Q
M^>*/R_Y1@;D9+RX1#HWE$QOR^5;M*YH4$6[TQFHLPO LK$9#_8\*HR5^T^ @
M:W G^RG[#0W9QQ#+LK(LP'O' 'OZS?)7O-A!DV4WX=U7*!5Q(8J1C +]J?",
MU;_<T2N_W=C:-___$8V?OV$P^U61]]@2B./-3_<Y+:D*>?F5PZ884M]*71,Y
M4E<^0*+%1V>7=S%[X5J38)C@M;I-O.+EK3^*QA\M4FP,F[8NZ31;_^#'_/X5
M:UB?Z*;$_YTVDOL1HDZXLS&Y($KG8T]Z!Y#;=_FO]%+4$3[::YJ(8%_T:A9\
M@&V!ZC=R5C#AM <+-B[DBMOK@$.G2-ED4KA5I+19U3> @G9W>\9T=XH:[&BB
M5_?F]3-=!_Y2<-6^G.L:?=5&Z^"+D#Y/[C]PGIRS25=$.8RQ?!X7OS&N7)U%
M7U:WCRU$^=IZ"F/&+=5HJ9>+W?Y*/5T\I+ >$.AU6&C"$LYJG9+0PYGS:IX)
M?:N'N9 D5O(.0Z:E9=K]L='EZ=<XPGYM**]HJ"+'VHTNV)N;Q*-V-'#Q3+$E
MH7YH'J','3WA??UHG/<42^5TU8#!]'?^()&_%'LG!EPSZ=WR"0-Z4+WK'<D?
M^ZH3-(-'4=*FSH;,=KZL)P]K@.CJ3'U[+6FGI$@+Y)'EE0[,=XDTU)3N&B?]
MU8@24/?D[XY9*5-3\VM&;4]1Q/1.U>@#[*V,EV8U[T<[Q[*T79W2M<J?./D/
M&X:_;/VKUI[?:</WOB;C5#-BE"V%(W6!31,(BSBD;9W;EH0!Y>*:@?.1A==%
M<*:\LL,$BQ>MJ=/RQ]'D3Q$E$HD?[S!8$>'C!02[+6Q>#V+N<ZEHTL#&T*=^
M&1:'9Y4X?Q1_\(S(%\2_#_'YM#GP%]W_) )$:CTX-*WJ4Z9:P^M=QH3X9VP#
M]V;<>_%7M^A?"?'Y.I6O\U_&XE5>34JNEVOQI)(//O^9(0WA9Y_^WGOE;N?=
M_P>F\POBOP$A>N?W32K,M!_P-Y0UV;RI&M?ZC)C22 N"W(?3J?LF?YT!U@\\
M^..4\*^$"!^(GEC+?-^L-6,E9^A;VOQ8XF? :;XNS5D3W4S3%>0N%]M*[=0_
MZH#^R9FO Y?[Z]OO;(5^%65D-%HZ/9-;5GNQJ%K&?%V:!XGJI<!\9&HW"QS7
MSMM\OF_G8,>^9UK(^:"Z R&#9REK-;?O/]ZC4.MRG.5O67CE==F!F:J"5QFV
M7 _?FMU;M>B;N_$;$9,?Q31.OMY!T;?XSAR^$T1E[^!._O!/0.S@X*S=^]23
M>O>OZ$4/C(06C4U13KTJT3O=V#C/6L6$U<#ZKWWN8^U'_?KG]W[]YZNM#7FT
M+.+@0C/IPOHJ9]Q:Q]6!F4/ASOWKW\4D4LVC'<7*NU07T(*][75(2WDW!9N8
M&)UI"7\3(3A*M84HZLOZ/NJOV8>9R94FYT5']6&?Y <$:Y:PCL28K60BL4KG
M='[[R6_BG;_@?AB(=B1-RZY-SPK5_H#+CHK1F@;W]-\]_:M^GOQ&O1B(3]I'
M""TLP9?Y!VJ:,;Y-R'[HM\O5327Q?OA52<=_U=!A130<,1):/>U/-S6OY[A@
M%0WC)B0@VF*H0*%FPEW5OR;]--1X,CRV5DP\?)IJ4<<23L,B+M&\#0(IW(1I
MM 'X$"UL,SQ9"!F4"/CJTE^WS<O(SR[(<0;ONP[\3GVBZ4C86D$G^>?U_VF=
MYG\OL:M*Z7:ODDMK39S-@X9*CA2!;[Q2E>,7-QEB>:4%\IR8^WP?)/YO.AW7
MWW39BS_SI/UU?_N.V^YO!ME7?]N#_QF(Z4PD7WXYM;PM2D@\6U:WS\:IJ^=2
MH7TL\)Q_C, L"%[TA]TYIRW^9S'_A=A_ ;'ZIYST$<^D'#<#Y ]E+5!=E&&S
M#^<DF1>]UYR4KD\AV_PV>B,^"\OY_V'/_Z?(\Y]-S*V-^MJ''G<LMIIYZTE6
M'HX6<UH1-C4Q"Q.4C5@!9+QJE'GVP16C]3#S0X[\/WPN[M^[<P5_[L\H_=TM
M'W=D"IAL=S3=JM0\RB>SL-,LFTK%%KM#7-;6PF@LQ9%7V]7PZA3V=/%% U$V
M/W)S5FUP-E:)OK8AZ4B,\.0A45Y"%J6T\7#D#9WD$_V]30L"IRB%B3=[D5V-
M_>Q'YEDQK1[F.%S^\!2+-UOQTMK/TT5M.;=?[>FX:$1^15_GCAR@2@M5DNHL
M=[ED@LI$-TYTS<_RTU]C>YU:CN=&,=VS:=:&-LKAPOE&Y3YTE:"HB%Q]P(R+
MXU#>!NQ5=A(_&66#C!29[ 8C=KE62$:2K[R"'5ZX/5X>%$VN$G!4+&RJVLO)
M*J3&4*+ %IH75G)(C!E;YV0 M>+-X\"B%@6R;<OX_2A_5(2H.]!\N%2'N!D#
M;T9N/Y&P-CO7=!(,T@752U9[XDD/9!IO!?+Y<Q.R^<4B.PN;:XC41D#PUN:/
M!6VE"@]AK_'N5BN&Q$HS!PX<8B9,&T>+.U2-RE9Z,F?Z0N\G-!3I%56EFM#H
M+D/4 $>^A1V[PN8Z[[Z<&I/JYFSK4W4C)LAO5*8F// !C0V E/6QVL,C_2)5
M'6!0@N_0<&;\1]$8Y_G-C!JSZ[P"_2OA (GK)Q:>4PC38H,/,3OZ8Y:DD/Z%
MAB5JPCY=5&R7VAN?BN_9#%R3C3>@[UIR$X/Q%@&&9GOVP;V7X^\OS_FM%!)I
MHZ_]8S0&BR\OMW#CXVZ=6BF4S0NL3FVLID$RA!MN)_%#$EH(QG*\3<BV"UEC
MXW[OV^_R;$JQFFAIUNY2C_KF//:7VAD)YC6H9!O0FQ<U<.TF[1R<9+EI)$;T
M[4A$;A*/8F>?U=/JZITR[VXB%<W]5#(-M=!*""35.'16&]XL0D>]4N;7 "5%
M0>6S.@ZE].OKW9^W%/UY),WD8OM=V9-K^O/C#]"<">)&I<T'B!\2XO6U-9%-
M\\1;FR ,+%V>4$P/>XH-5L8)<CS1O-E8CF5VRPS33M!;MYF&#/=<<%1>8_@"
M0?,E 8E:A4]M^&+OI!UN)8L%D$?H6@NLO<<2AH^U*@W;E[[JO>8VF"  7,&L
M>HBF,J;R^_HJMEMFU OKO'Y.[2IU3F36U1O/B.,;4]4K6BT_Z(J0_G2$_37\
MFVDM_@:X3P9O>!1W+!Z*GD[[X_[8OW?X]4_A\X,7W9^?R/CS)GO^</#B\R,9
M?^?DQA]A_^_/><Z?+4 <-?H]M = S_FSM'(__BG_?QYL8;IQ>5!,HGA^CQ/3
MKB.3D%,DCJOF&,W7M^6$4U$A01&H;$5$7Q3E@3F7F^_;N19[U):-3N?M)W1C
MY^ZL^=*;3<T,(FAJV(M"\%7S X(,U>+]4;4+I_>!T[8B6&#=6),Q%)-AF20M
MD!VUR[7.Q.4F(J:>'!/SKU][4&(',RT^9. <?19GU&847[P<BY0.""?2PE>F
M<Z$B/(<#2:_=;%7BO9I5D[5-0&O0*_)2!]->=O$^$%%\\R(S9*FSC,M-J*[&
MT1<2Z4;-EB%P#-1]!5NR/%S5C'>Y#'1$9W!D9BVPKQ&K=Y%^JK<=[?#2D@^(
M50Q(%<<+NBP2,05!E2HT2HT>PLI\Z@(M81,G^-Y,4T+[I*J5%T.5VIW"%?'\
MHYFW5@R/*Y=(F#40 PC7BP'!'C'"/89?U_+<B"HR4RI\8-(G5-S=3^OY;E:$
MO]ZA3.0POX_K)20_=EDR(E>'\L A.S<TE@#P,TXZJ@'1T1428O0">4$@J.B9
M)]ISF?NN*PBE$:J]^M#2XYZ00!U"5JQZ-J]%/-12GU)P%"N:][XZL-@O^?Y^
M?@/GJE&Z@IJ?/29G+"O;?4, "8&'8 &S.97\B/DGQ]R*4LY,VI1;R%\OS1',
M(RR,C?N>7;NCD\I##\KZ@(!*4G/*;Y_V.IO,<3^:#M:^\Z1253RO%*G7Y"#'
M/^Q(!TTC+=*[$5T^(C]^U?PT0$&4UIY.F%S(LJD_;Y06$H(?:,VY/4NA;*R@
M?%&3<F1>RI_VL[^!_[TKAD>$5C7P">J1B@<C%'NZ=5XBF2AI).^'B3M[$T<\
MR]L>G"IAB_RDK=;9W7"]*'M$<G$!*$1+IN8PA%S<)D6N1HS"O R><,NIO(O*
M "^1*L12?!MN$-_WH&.GOCK<KC%*@@5@9!LGS[CUG*\&"E@SN*Z^BU:9X;,4
MC"A2;4CQ/"07">Z7_?%$Y6B[VGV!>N)<U#\W4?$/U^8FWGDU4.&'0_E*6/DW
M"UV6U/&]R@K>Z*&SZFB?%1'[_^$2?"'ZSTRT28NW.,<N;BR@Y;Z93'F\\(/
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M^Q#EU,IP1JH(8!S9%ZU[9H)K?$NWH<@,/WRT:2Z>CVD^UWUM>KZ##-(M!6$
M2F 0!,8#M[1,U$833#T"[@&>+WYG;/\$QX*)=\/5JB@3L^6TK74L!,;/(Q@U
MA;2\].I[X0X'XP]@5-RM))G0T+122ON&?TXXYAO-_\/>>T<UN75[H_&U;NM&
M""A%]Z9*:(*$7K9;0C5@2$* $-C2A(0BD-#!;4,)@AND:&@2(*201$HHH6U%
MNB 00@<5""4(2!>D?+[G.]_WON-^Y]Y[_CGWG'/'7G]ES)7?7,]XUEQS_N88
MSYIS*ID)&8M*%L'WC*+LE XVXL2O%VF^9:Z)A48Z@GI9!M6P=2HS\1RKA[2X
M'"PDS;TV$A(N']4>44CXZ=TKRP6=&C]5!C4YI;.=#Y8Z/<GA88S\8RSZ8QYC
M2K'1H=\"/,5W<MIT-<1$K1JDX^F!YC,< PF"-L:(GN,J(W_@W2I:YVJY(50M
MB<L?-_28]JS\H9"6A*HKQD3H)1.Y0FYXUQC/]J%)*.W)^!+PZ[.@>7^CU'3K
MK[BL4D1!5)ODET0:>4NT8.[/'_R$I/GP/UD(,?$-YIM/UMM><5;#?0DQ1")]
M\2'/3<E*/MVO]ZD'8E! (9)RMJ35\IS2:;IH\1SM1(1MFNVQ' @F^I$#(.1Z
MZ, SQQ*&B:%'"1SM>S/Z.I49@_,,OA(ACLH7J75=DBK*A\/\6JX8YPHD'DVD
M;QLNZN-I!+=@*T3J"MQR,1LXJCUKITZ-[Q%\_N6T;^XG5/'J,>>HU#Z\1"L6
M[60V*#UC<9!$DI/>!8=R62PS*!!NAM$3KCCXGU$8&NMM"FJ^Y%YE8]=F4)AQ
M1.46 C'1+'L;R5O+>IS[D?#ET.+[WZI[)L2Y4F-B> (>OPP/L#"PJ7WB@:ZC
MR\IBJ;5ZN_(;@\6ZW\;4TOJ/O4#;63D.,9A/<Y/]_:R*'K-<CV=)W/LR*>B>
M_>WT57'3=)B_R7VE@A;_XKR8RKH.BU,XIU%:0VU2\")9XZ*<2'C$3O5:NE&*
M3)F#U^GR-Q5ML_:CC]/\!2(B"ZYPJ($1\A.KZ 8@Q&@?<+%5JCP:I]KB(UM=
M$7?>EZXL<V/0A1FI\63 \-&<QM"\4<7]^*F,R,]WU%K05A:ISCV=!.DRE0F2
M$F@?X,WNT9ME3-N=#_\",7C\-YMS5=X2Y_-3=CWSRN!O^:BW[>6TE##?UY+4
MQ_VZK@9T^I:QYT:77X1,ID[[HBX:H=GC!G(RE)%!N\Z*4/=.0_7FZ7@9/8 ^
MO&0G)P.+BBJO(!DNU-.2"^O)=.:Y] 719C-W,AU;!^KCXVV-$,*7IV&E:'74
M(P]=*;68]/18ZPCO>V10/P>D.TJ2U84Z9ZLPRC\5';ZBHWNS]?)G\2AD[\@)
MX<>TU5^3D6"TSO8\A1O.C>Q*!TQ'G7\U=2[V9[1?#?HFX=JM%,H%<QK+"CD<
M3IJ;8)_.N7_PUG.U8>F+\LU:)#W:)RX4=N564;;\F$"$&D^);Z*3YGO^G/_M
MM-6#:^7%SF.G#6'>'(RO,KJU=[2_)@7G89=9WPGL(/MVQ[_67G\19==2BA.8
M*XQO6SNW.*O<9-.R>?)J:9_G<,Y<.H[7%([-5OJ^,\:O'+5.DI]=B'OO_[ #
M@CG5[$6B%?<X)O5K?^2R+^3<;_&I>KCWZ4[+JA&R?-E39W!+WX?NN:R82.!G
MSC4BQH,C,EQ3NX6_G ;GCJP6EQJYYE75J4DM5%HRY.\&7$_N&N43!LRPNFVO
MD>%KMW5J[$JFAN2_%J3/0[4,!MQ.M>-CW&55GC=\'JZIC<T^_1(PC79]Y7D>
M8J(KDS-R(CVN7BJU PQW(I?([))N8U!/[:Y^JS@A?BUMR"^U(LK/J-#83_>'
M:BR%(UEL<<<[2P*YS(W4D[E\H&,C(7Y*UY!S7Z/)/B=#OD*SI\T"KEA,4L(5
M8Z<^"<(R9_!DLE@XOU&CRG(HL,):RDA$LWW6R2'M;->NGBQ(%IRXLHQT3;I7
M?N!=A<=OK:HO0C%N816-I]2$-!#944A:?PI= K85943HO1Q:3Y#E^)]0K1E3
M^Z/Q6DR*4HD38H![ <HR&_]N9G53LP8^!],\'(P8P&%Q%,S*AU(U')BF2DLJ
MQ$F=^:F68 &&N33H1XI$&D<K5Y9=_ %=D^KR;M$MFQY<R\H-X.XZ1[;_]R4!
M?XW__XZ#712?.9H@)RQ?-IZ^61V=:,9'[0#6#FGYXXX@^%H@+[NO\I]SZ\5O
MQ[[BW9'/_D/]P)E/MX[.G])=L1JZ\)?T+^E?TO]DJ:F1VL?AN2X0)A(_>L?S
MQ!_7OCJ]WFZ$[J2$6CS,NEBL_:%-R?/$[W])_Z]2N_<G]$P=:0TIMJT2/SWZ
M4G9_/2YS2_[ST[]+??]%"OA+^I?TWR?]L@_8^B_P&/^=I/$)V,'KI2UB$:>T
MZA;-P;H7FY!XLZW"5_]NYO)_T^LSWPL:>-\(U62WQZ"LW-GT!U5*;=,VSG[[
M1U5*VL'5H 9Z[F^C@<*BP=C?377__H=3S7OTF$>S?TW]-?5_3/VHW1GXR'IJ
M#*I?=^;9/N"M4<-/M :3M \K:Z9]1B<Z_PZ\_W?4S6W SK\ _P5U\>69OZ;^
MFOIO.W5,I@I,*QM^:%ZT-V0QM0]8ULQX^Q_7][#02NV?[IO^\6^IT5P42QZ
M=4"OS'@&*Q)G%:/M[#2.EL#:UI5;*FZ-I>^2!55Q4$*-P_NV@OZM(G8FJK<Z
M?/%KZ^,I?KU6$%_F[8*2[$@3$$**$H_!)F*<W+//(_K7.JS7>UH;?J47[6+K
M?P%_'4-4Y?0';JB25PG42CLSX8CG>M@/:<7Q(AURL:%$:N8HBA@<*22E.A[F
MK(4GAD)21MG2V1Z*##^PQ'G^I3D)E&;\Y,Z4=T+=:C+J'N5!8+OF6MB\CF%P
M*6_S36F.TAC0L=;POOG2TG86R]UW>GP]X_RIX0SM<@^=3'0E3>O4,/V!;3JL
M)7\*.]?#J)3;!]"B7SM^/:V)1-U7(VS,QR[.)URT;V;VYHFGZV)G!\<N]B:.
M\5'( 8S5PL.FL%8==% U-+P*^0'TC9Q^'H?SBH;=-L,N8FFOP^<I]67E?;(Z
M*0BLK*PF3,3DH;YIF\<J[.ARR)TQP,CHJ^>:.V<_EF\6$YU)4M%)2;?&;D&E
M6_DP&#,8+(JPE?3!5IAZNV1ZAT85CJ_^876;[L>0?U># !.L7/MZ1+;QLA&G
M[V;'FDV9CO$OSE6E;1GNW=)\_U5Q'^#Z"WCHM";ZZ>>4W797%JNZN]#+#]@S
M8#WDDMD5H@^!0-='<;#O0V\V8$-!NM1OL2>HF,5F,MEW%7.<N31%) 8UG9\&
MHZWYLC/@'IP[G>FHW2'87N;C[.3!%>?$3(^5'J_W!908+=7;"ER)%5_ZEW%7
ME?4'L=&% F;YIR_CQ9OH[/KJ--B?#*B3O%\(\")=162$.U\D _[HAL$QOUZ0
M0KDY&;OTI6JJC&X3'W6J)LV:C4?2A2R$V621Z-.=?'^);>-<+33E^GR:;NC;
MK'O=36=D9,A+ND_/:-JM%!(C=.SL9\%3DXR'/-]M$CWH^YXY ZL:_<.DZSOM
M8CN$PN&TSU9S"WC.F7O'P[.;'B\T65@*H$!D1]&%8Z1SY_>,"6^+U\^+_Q#,
M(CH?*5X7;R<]ZN/UF8UK]+"1#M6B24S$K/IM8A7NU;P,$D1N5#NI'I!C-FI[
MI'GZ#V8%$U2^& O9H=1)<=4;/HKHQH]30Q/NV[O<)""U"=!><UY?_?F?DQGY
MF?5-D(\-6-\_B5LZ!MRY)P,8MBZZ\ TGK9>GB<5Y14DV<W)?LL8&D*X&6(^=
ME)<Y:B2DE18( FZV:&2G45N'Z;G.&H,4N[:@V2I@ERDO:<E WZB#VW2\8OBA
MJ/!R0B<$[$60\9*1YO]H8X64!SW% =M80K*^'EZ]8/<($!9>.J%.V@SU,KI<
MZ._2676=(]HU2^HSBZ0OEEE8T<'P5E(04D7GP4;374]V)!E<,9R&W >L9'F[
M?\:'\_.>0J6'+6'P=S6/1=IT.! 3TZC7<TS=S!U-E\7B0CJ$VV>8FNCR%L%W
MY>+98JK!,;EJA!-H;)W;3]EEYC-:Z.(5B*K/V@>/X1E#A,-23*0H.FJ',I2[
M^=EMYN;@[])PGSX^HN9FHP^-C6JE:FB\P-+RJ]XUJPNQF=0D:-]D-TGI("<K
M"GLQ9^SY/J %OH<X%.VO.!DR%!.3M!K '>@?% I[DTH_8 SIVN,0!#XPE@WI
M87VB4[@R%I=J6FZVL"2LT/6IK[CF)0:N2SW82#[>;-M*^M%1]KO@$UX.<*1U
MAW%IP.R]$<ND.VJR> ,GZ7A6+CUQA2VZZDM(XX2-QC;Y5C+;S3L^6+?C7Y3@
M3H(R'[/"3HDCW><$HS>T1X[6C6/@J1Y._G"A1GI[E]/[J,W*_&3P\ITQ"#3&
M<@JD\]KN2L6=R.)\%CN/D5>80CGO"W([O@2F<]6%%%ICGFT@O@H3M,N=W#H\
M_*Z":#B%$>;N \3:4BSV$M+0/2W/YE; MOG?#UX.<G<$]MUM__S  ZA_^IWJ
M^N?6%4DT'RIK,^8;\F*N7>-7KJZ^,W/=M]M/YX?G+BL[!A&!->RJ;F1]DM7W
MS<X@2%(71./J=1**,ONO0O[P#F]^XX>2\@R=4XN'2BFDB!MC?2>"Y^I)+"$]
M8JT'"(\C94=Y.XP RXY7M!#I]0/:OH8*P4LFR#!@R,!Z;<(TSU;R\ V72Y-L
M<GKZK:YF2Y+*RQ<]QB:/.#"X$/[=WV"_.?!*:V_]7(-1$<XY#RTL,8J3%V(,
MV$)&);(UZ98,>*O%1V]\5"Y6X]G$R"\%[HO=MJFH0]@@@N'ZW#8X,D;=!U+/
MQWY+.%IEHLM7\'L\Z#-B8_@I>?T,IC59N@FRU06%YYO!5<Z4UIQO\?#OFD-C
M' :=M]OI[30%2+ L(TVDG=J_MN;[6A0#Q5R;;-NX>^VDAE]%AY@:*[F56V']
MPIEV_ [OPK=]P+SO%D?(36N>*$7_3( T;VK!+$YXFNOW^+!>A&7D?].I!J^H
M_'&L,TU0&;^1&TIN]4I39I?[<8?)R1T%MX4+_;(10$<N/6*XR*5^Q(.+]J*D
M8ZM$X(B4]+POQ@SR+'4:I-%7:VQQ<ICOM=@3_K;L^!-??\2&=>H]7[GB)/_9
MB^2 @$JB8F;;/@#V(<4<"FTWF\('>J^Z9!\G9HF=MEK!$?QY9])7P[FCB\!%
M>OHA M2S5+,X8/'Q$U3 /*L6/Q#/#\!KNO@44'*L'P_N9<"[OKKF7GM.I6UD
M54Y5;Y6X3<[L VILJXY*;>ER*^:\:ER6)'#,-ZP3#\J3F5 _MH<'#KU]?(&/
M08;3L:X+B@_YX?[CCJ!Y7]"<KV+.#S20YT/GC1(D> PQ#H7IJ5-_C7X.%!5M
ME7,]X[6(#XFF333CHP4+3X^W7E@WP_FO'Z?7FTV-'EH@MI9]KDA3JAZ70<,"
MD^C6G*K.]H(.<6Y^)<>,'XN]O9JG^6K$[X5MEP\KHZ9IC\QU\L(5V'"NZ8&%
M\:_99K/7\IPDI_U6[GYW/R,('VH]9.H/P1VE$<@VVRO5'JUU"_T17Y;_L_4Y
MP2AF'4H( TZ^/9T7Y\CP0^H^GN'VNS!7WPWYC#G=F"N(UX5)=\Y$Z#Y#;$?O
M:K]=?*_&J7BB,W 5OP\8>9F(UA(FU"X(D&%G3.WZ8?\F@?JG=*/NGU./?]^%
M>9$HU"N7P'-,_.!NL^!:).6A)\79FB9G!=1C )D8"01?! F&\.(U$BP48THB
M]3]OXC@*BP9A)4I>S?YK], N"WI-LP5(=I8[F_0I;^ TF*AQ.;2'T')Q-SM#
M'E)U(T*RC8?94,K$2'QVC_B%-[G9GO7,<R/3"_AF_C0&'F03G<*,WBF^ B:D
MH\*W%PLL66-;5,9KL*K.0VQ*2IM[2W$&^EU8U$/<SW'L^BL&#B4B,MHLS-)Y
MD2>N)UX#1T7 /R]O<Z4NME]@?9)1%)"^J:YI<]3=1+DCU>V,.Q.1*H05^E92
MWF]F#;<JHWBU6!NX \^L'O(,0;C&VV,VX_8F[^55[ ,LX F?'(0CIX3?K!!I
M)?9<VZVN]>0D"_J27 Z-14U@\[M=QK]DC*8T6ISJG[$+>)FV?L5R>,Z![J0;
MYIA%IE=+Y>>R+VK)!GU26BG<&;^Q#XA\O>=T^LT'4NXOTG:XM2L>G'!\: )_
M[\BH^K(]8IY C=T)0/#UZO#;-UCM&]&5)] 3Y>/L\G7#SY@A];)Z9:G:S'>1
M^EU\(#?/>.7N=Q<@D[,/>/?CG;'3]2)-H2VG,.+=MWW4!C+Y,L;3U=T.C8??
M>)<L6%BLPJ/,;X<\:^K^7/Y*BT2Z).<DW3J<"$GY3BG,5JO;Z8QY9-\D.B:.
M'#WIK0GKVU2P6=22#UF4V](-O)9?B;JW>]PE)$IMOG$/"/CQ=B^"W7X<?7R<
MS?#VKZQ)R:@/65PAD7U9>QM9!)[;%\.@1DVN];9&*L<,A2:-"@U;V.JO="Y*
M1' 5Y\,COFYW31\]O_5KH5=99N4)KXEEB()7%TAYDL)*T1N32B8LP_"0Y4AX
ME]>"<\[<W<GO1#B*W[$/.*@:PX-@$-O46XGOS7UWR0P2MUJ/7'3*[DPJ>Q^
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MNXADL'=]H;V&0&$?\.I3PX?N.T/-%NW>D5:AH=^L.4HU X@WP\=#%==8D<9
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MG]M1+HZN81XNAUY$><QL\Y00T-/D13O\/8^V>Z0VA[@;U/..ON6-. Q#UMI
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M=U+PK/A(/1?CN%7>%VD!G"LQK"CL%#XTFPKC,QL%VE-)I1Z=4'7VN):=24]
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M,.=UQ>90H35PDT.A95#2.GFRN&\RCY-3&YK.W'3X<G@C9^E2LTZ OVU.N$Z
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MG>)<WE;(F=Y[-R)'</$USK&LXXZVG^K\)STJ[-$19?)N(D\S6*@QQMXLDH<
MD!A[-1FY7746F\<ZC=QA+KI>;E.L.TM7WMW>N$(1MP$HY2:44EFLW-2-9WV2
MBM>#[M,VK%('R"PY67!S)<\^C8*P/@TFUP_#8N)G7JO>G]KE. IW@3]?1FG"
M9:?-\@:U=$49=<B(;(7VY(0%_,+EPNO<ULI]8%S+W])3>LBRV"N=_D96C7VV
MD^]>(D(*HCD-\O:U\O*L$D?Y<Q<B@CGC\XY5-H$!18UBGR0S@4T\<U:E?XWM
MV+'&JAO*@LTO./F*HP_M+Y16OJHDKOP*%R!>;F?W>GF0KT]MVM:/(1X#>O3&
M&IZL;_:FMG7I3ZB^3\-+NH7T&79,?,N\VP,\G)D\@))7*/[Y8'^*M_'G6[JU
MN&(GKVF2:IUI(+W$VFIJ2E@1R>R6C\IML_]I?E5M!T!HLU3&(SF#R/K7M]<R
M:KHE>I/>/$OR3B\:M.?>R@#7U 4FL;WE@N6+>SL5%'/<<HR4;8^^8V:31E,6
MK1=Y/;-(S^-XM<??O1AY&'UZF'/U'QHL>?E#XI6Y0,ZIM%[?<'7B#J.L@S&?
MM&65T&P?4STY.U618M* W:7N 3_W]\2P5VP.LWL!0GP/_L<F^OEE"(S0$7+N
MMP-V9:T4T65-OU::66S VEC&/$VKX>=WWV2T+5J[_"O'@L6"5G>\QK,.0(E$
M>SFD'N>60N/*DO ?MP_._KK7[%5X![<6S[;<<Z#./#N(L#?R-"583]>#>HJ2
MC28!\EA$")O[\&/N\;H/F]Y1NN>)<. D[(@4,'2=TTB3_#0#O$N91IC]MJOP
MPQDW-TF6ZVQ!1<;K?D$174E;$<;F$3+B9YO'KP;EO(@HZ9BOK$^%#%YUJG)E
M>DY]DPF0CI1[M;==:;Z:,FWN@D  0K,+$_5$?M_%1[_)=\!"^SRA;*85C:MY
M"!:]V%]L.76F]L&'L[!GW?Y=_F2Q(VH7K"(7>S5#=WA-Y&S,W2-$IT;//T>+
M!@^VX/6I-/V"Z#O/YSA1UO_DZ^8]<CB5NR]YDE%*[,906<G?9#Z(2=$@&^UI
M040 JT_R[@DX7RH_')NGM,[?L[*LR>JV4X8UCA8$6]=%,6(@"O?ST8TRIE;"
MLW:6J&KP<Z3QM9'"X?F#$1=#[[86<F)I!B=[<D+H(+@@;Z@5V18:8OYG_3'X
M*1:\$T(/U5;6+5B_H01"PR3(E2][$W;RQ"!$L1=V- ,AT;A#LG8G095KG^^^
M)^EZB[I@1L[L;'F+]@);BVKCG!>)3I-&NNY+-<%6Y?\\8/;8:B#?QGX$WK%H
M] (+00".6I[9H?;U3@!L[@8E">5$.P*H2 ZLM,X$@O#X>@%L#?^#7U65>5IM
M9NWN\,OH_5K^*P'U' 1&/(?._:?$_93)]/F(H$-=J*!&M&A@)7C,V4JR@%LC
M:@_>QY*-D KJ*16^00B"VX#P7Z5L[TH,[C>J\CJMHIICFZ+[SF^,>J/[@('+
MF^1TG"B2&FHPM_;1\X?>J5UQ3\M;*AE.5Z7 )CZVQL<G\IL,=,Q1]8L(Y0A?
M =7R?+P7YUHY<W-C:OOG+'^?>'+R<YF:?>_)DK(\WD&0G1CMKLC%MHH +$T[
M"V6RW6OP2';QK2O%YUR;4^>]A.&BRD,:6"Y4LA:QY@ UV%4C8]+3%X*>X'^%
M/^F[J->FYF;\6M24;3RH9=HYF34K0F\15XK]@H?AM"_6:"-8)_M%,2,SZM1-
M2Y/A"CS;9<94H35\-CF9W(0SU/L>"@U(3BYZ>KZ(<-3O:HE:1Z2[QY]C(21A
MU=2-.]LEM$@VK$OIF\R-^C8 IP"(3)9QE/ZMBH<5<QP::_# 6.O641N-\/*(
M@9"Y2EUT8KOX(Z(?0.+@JYL(/!2D06%KW )=1P#B"+>_M\ON;F\$Z\6'?J\)
MET5N69I(+R(*."Z@SA4A5QD95[K+IGG.JITO_)GL)3BE2;N)4(5(#S\'[]-B
M9[B)WA4 2C/:%_L3=W *>N?O#8!4YQ[93'4:&!!KU%E.DO:S\W98>Y#7SD%-
MBE& X;L4!DMNPJ*R_[E&?V-EBPJP%)>[$Q(>9(S]SXQAK]S0GD6SV H&ZM*8
MM")S!GN31A>Z\:XN9X-CJHY8Q/N92V<M.B:[(\W1[F@2A]VH44%"567N/5.4
MHJ*MMF8U3T\N\)R:$!9_N7(K8*?E%<0F_!:6(, %&M3KU8X%A20$"Z@S#M>V
MH#XU5X8I2$^=U^1)5/QTB CL-QV:US<Y)5FEBMSW/*](H7SMCP"<Z:R6#@Z8
MTI94:*86@4 (%>X_AD*UDJF_J"XI#R^:/[RX&R/+R5SYHOS9)["HVNKKO?]W
MTO%WE$ZCN_3KM3?_K Y4/EJK'7I:Y"<.UU%K8HK-BY5*%BY70Z$P$(IO_.7[
M,-2U27?/S/</9DR:@O>HKM>"1Z9*N;ZR8T3'YK6U;;&([6C!P,E<F8B[_*?O
MJM6K6WCR[":P>K4SJLK,GP:;5R]*3@8;#%'8=*MD\.%G:,-KFYHOQ3!,Y:'W
MV/U2R# - T_+BG%AK]9(WT7Z[J0AO]/:Y RJ[5IVUP?V^OG9*>HF]FNJBS%!
M<ZTP\[!8)0?'^]X=)4.WXK)'(GYP0 4T8)NF+H==*?B4[;5*!9/9W&X'YR(_
MI/E_Q"B/'MRK.0P.W!@Q8C%?LN88)%D,0.R)A[UDCXXWY.-*"E*X>? ==#0Z
MLO%F>:3[0%!*MN2K\V+3ZV%7-3.[*?Q-2;]7'X! 2%]++R.0@!#N=5+UQCE!
M_T1]^$LNML7-W#>G(Q#GM :D9<(:HP"TU*'FT\B7Q<3JXRW..3=L.?7]@^KN
M*G5\Q25:1SV]OJG9X.$"++GQ)%DF;1B7I#IQ@[3VR""HRFX?1FC;(O[L_.D5
MQLO+JLD/O<O'@=O@@M9I:GW ET#)A@ZB)*W%NMFQV [M+X'39C\B$"AYPPLF
M1KWA<\&/Q9ZG+::TGZ;7E[&><HCV\8!\(TF*-SAN,,@4P,(6%/<W8 7'%LH2
MZ; ;YYRT,8C*\@J4!1'_J5TT06>2!00ZF5P/^=>3RH3??@2IFIT[%7JBNJ_#
M;7Y/2W95OQ65_PJ)%"ETT7B69<"*LAIW04&U<^-\#*7-51.)2+OGM>_"E]G;
M/&^NS@NKM4"00VY4+GRS10R* [@^'B(< (&C+DRZ>KZ>K)DX$C\8F_0\D)OQ
M2%2'O5"EJ:RN\EJ$,LX%QIG,?/9SU![R*H&W("6 ^MA]9-B\\0D[=[<V+K&K
M$PZH+SM"3/23!_IQ1*GY"@T6P"3?18B4=DRPS+CDR].6IFMY!^JVZLE%4R%W
M=/PSV/6ZU#0D'J9MSVR^\3KF+3=]Z*MX_HP=#XZNC$^D*)IQ3#P:N]65DY/7
M^C'OR() ;MH<QAS_[_Q&6^YW%AC0*.,POD6J/DE,K]1# @I'*&X]2.'?'& K
M#0O5S>T40&DQ6'1H1 6][IH#%G?V%WJ*H,F:DYSLNX/=VA=V4>+S0XA$=_U,
MLXX1!TT(HFK ".=66=DCXF"\H(Q'14/!S04CRJ].#]LXF1<"P-5*I%9Y>$D=
MA"SX2@8#65]^E)DR/]NSH/C@^\21#(S14$P-NDQC8_L/26'G2TG(A)E70S(U
M9+X%Y=E;:5?1[,-/90=,)4W$!_MY$&V+S.67P=/D)^4"8NSK!3<MID"+-243
M(9OH9Y2?])-/#1H(Q9V4\F'DX+901 6 ''M/@V[!I0-2@/2KL-_.$="%)FJQ
MWZJ+$7AM6["(^;]#&'''^(PUA*T?U%^K'35.K[>1=VM(+#',^G=>KCW3L2VU
M$D\O9$:V2@W@D%<V\NZ-WTM+4[BSVSVO9-[GZR;HK4>6!9#+U'.6;I8GG.%#
MZI>O4/!7WIJ%K<2F45JK8@^@]Z<K=\U!JR0+!W.,7S@O.N1X-WJ(V[B]R+'^
M%G')X'WO?<D"?,H.YEM7F>GHV>5/*^582I!Q'+?DH]=$/OF[/+Z(^>P6R"C#
MVN&@Z^J*7P7#XSN]GJSP)EA*:8*YT&W-IQ T1ZZ$V6M[RMS$4?T/UY\EM<GU
M\./BGK)SW)3;+LT@T2H2[AZ\@1K)BVN_[S[^3XE/XS7-8 O(K_V-G1EZ"()*
M*9YX3KG!4:D#A&X19XWV_2?FZ2<GYUSG-JQC@D\99'\@GC$M1P'*0VY@\R5M
MA6%I_L1F8YXG/EBL:*=2T9N*$VME6FJK^\R.?T%/,Q1H?_QOU0L_EX>;#8S\
MZ7O,0)6VDZ/=[@^WF+.3P*TTC%1$0BETL<[_X2=ZW-O1JLS6/ OC*KZ,\Z=G
M<( [QZ]].;9!3Z7/S7^3^8ANDCE?<*;^2U50[HV\74N;^WF[X>!<I_2ZL]-?
M4U:+//D**SA)C!F?1(R#C@NVGX-S ^.,6!26FH.=83_F/&GX4H?*L8DG+UJ0
MZX5<DC%1:+@:<.M.FU$_J>2^R="XI>\WF;\]XFC%;F36 8(@>2;P]9/PPB2=
MHZ>",HW5'Z]9P]L%--J:SIK,RWJ/V8K#AP8EL.+2TA1X?!5?>>";S/8V)>[!
M,+Y*\C1B;-Y.3Z^6O(=>C;87!5&0XEO%"YYZ8R)'^6@IC4/5JA,9N0<#G2KW
M %F+]3_K(G7*O$V%R^(6<7'T&D/!0@X55S8=.>R>+:)5M<04+\($90Z'J)&+
MBV;(+XK@:1;X48PC6FHE6:P&11+**CO0O[7IC$V5WSA"9]W>[:/V>F%  F#>
M40-(/0^3DZD[3/-_^SO\'S0'9RX'E"3@^JJ**'E/S%PGK>"6O#/4R0C';HPS
MB"<7H3/_84I_R_>#1W0="*46T900ZR%@"[8$BUS!DYFDV- O10:?T%__^N_^
M0>7/DKDAG])%=G>"GJRE0'U.PPJZTY.D7DXJNZC7>?'OAGN"SWEK9 R-.(26
M^F1ATE0I1#!E)B(#[G4&&B/3N*,6L4!Q<&B>-1^H"J:<.J0^ A+IK*GUHZVU
M;;Z\-][4_><@YPY'=,ZEJ-^K9\YPJ/4.+-F',M^#6E10JT%A<">&7<=H BH5
MS*'&3/@AT07MZL!RJ3//0Z#-DL<<-"\<?$OP#>4[]SL96:L?J;[RX&WXCF'G
MVLY/7OYUXIO,R3D7M<O)@.#((-U\P2(H-ZJ5@&L )?&=%7CIW.4__\T1!J71
M:#"#/<A=<F])3Y]UH=6::JFLM1ZKJP_;TR='&XB1A?OGSLHA_S2[<I+S&4$O
M37GX'++A,I&64N(R($8@5J!J1)G3B_"!VF%3V/P,I8AZSG@R@X@0$1V6,9=_
M^6];?F2R0)A!UN^[IEV/'@C)Q/(R>/"( @%4NQ#35NL1L/@H#:P%+F)M9TPK
M<I1*WH B#&ZGG9#)298.-@XXRJB4?8(2&Z-3:MVF3K+6FMOZT2OKQC3^Q3<9
MB/7ZH>_Z979ZO^?=8V_=46$E9$Y2I ,*%FJMJ^3,MYA]ZON]UVZ>K^*SQ0<=
MW ?U-G!T&<.YK;[]9:/LSH&/V?<'!MAA$31CX'_.S]Z)L3=O9AK;!^%P+&PV
MN8ADF!/?K-;HH5%<,[:PGIU!XU]/C&P<UK:E09<=W ZY^W CYF_^$P<LQG4/
M&@'&&P^M2PI:UF%LTCK^7O7R9[LE0_$-=VG]#$J%1BX[DKP!1R-1\<.$#6Z!
M;)[E*_'1A*':5J\%RC/3D93O,=4Q.*%@ASQQ&F.2D'7%4:-]9CI/=F_&SNHU
ML)6L3U?!ED"#)R3PB>O%^.?+\Q):TI!7<,K (WT?5OZQ<I>Z6'F0"M,NM'@:
MHH]UV^_N3>JLI69KQEH?UX.>3>@4J*,]LT6Q/[\R/=BI3"F4_O'OH2C+W0[(
MA]6U6ID"@& KVRV5P:SM7G#=T^ENOCPRH>>(!C1XR;.;_.AGT<V;[Z?$C-\A
M,C":%LA,F?]WM32EP:Z[XRZ6\QWB?1]_J&&I*O8X6)]!2$3#7]B<YC+&PWV_
M[YS?;&41%@;5A@ K,M]!5).93&:#X[5_M5JB3^./A@FV[63C@L6F/I)$5O?8
M%3%&?+\"CHJGSN$7H_;]@_4' +%RK8=^Y'S$$\U+Q@BJ<S7#X4S]A;-<TR13
MW_)@S;&MD!(6[GP5M;@BG/ :).^HAKZH<]3P:HY2[7]_L,P&396*'>.9%SYL
MJM2-;CB&E#7T5_'TURK8%?$L-CT3\S9")#$?C3:P#: 2%9UU 4U*KW50;6NE
ML,\J R$V]6 .K',ANTQD?E#AU,@*S@SS:B0?XQ2M^L-3.G7195&QQ/&"JR_2
MNVSVG.^\560;[9.VKJAD ^,)0NL3W!N:2$(F=?OAA__[NT3^?WS)A?(^)-52
MZB&M"]D.M">_<"8UP31B_#6>>_.S)FO];:A!5DK?C[CR=U7^D?/QM<,#3YO<
M&+94Y5RM"L(G6$FC;05^?@8A_7[OE-(]E^#ZL\QGUZYIP =6+Z68G>O<DN^Q
MXFR#8#,#AP4&I$. @-9D[LYHJ!JYSABTNPMWD5R3*) *Z"LAQC@@_LMNRYBT
MX/V&S[6K1FEM@7-J&K;<Q$"UKA ^!$N&GK9H+F73J2<JN\-.@9N6FL3TAI7!
MH6EBUD@9%5F6CT%8JV=3E[12Z17ON7(4S8"-H'EWHXY'PY7\P:OA!!]MXH&,
MGM1L+!SBRLUP[&HQ"3MS4Q!P6K;&USF6[[=HVZDH'BEE%BY=*4%^'33$PK9(
M7L5)/1+RU(#*-6:':-#F'=_I#)6N$?]@T1=?-WW3$WTW%AL%>/[Q>GNX24_1
M(??Z:^39]VS?K K;5H%I0)UA-@3=/N5\]IO,JVOPR ;O=Q_V:S9-%/;+SGWL
M\*M%5#=_DSEHS_Z2[T+!*<^<-N:MZ&:8!-P*2JI6;)"<+ QEL*K\G-O5('^_
MU5\];J;KJ#HS_[7?.J"^:P*ZME:HKE<L&'C#M_"G*]L].--RR@)D>\>>GF6K
MU$4O\IFL%SVH/N\ZW2)A,-]O.C-Q1'./QB,IY-2\^9SJ&D:TZ&QLQ8,0[77;
MVN5O39=0*W!$3'_B;'/@\UJ?>ZZ$C3LU)B"-'7>2(Z]AYOQ*-)X.C&%N<7'Q
MG(&E,[H9%!<AYU:J@(*3QPX*])]<[ZE-2/6-/-"L(? 8"<C,V;HV?+^VB(Y,
ML)PS1R!<,HZO9IBYSZQ_IPU0D DC7ZV#RKG\VB2"NE]\&-#(GCB77($48T(:
MHM!)39P?4+XGNXLGS.&E8+G_N<NA)#\G,[\I_!HVI'63GBH@)X,I-'U!S,_%
MM)85?'"YV(_<93X[QW*_./I%!+W2+ES ?8G1@XSIUS>J$L=6\EQ;(>ZX'+<S
MHWA:T?X%/GL_C24Z =XCB2@8I#/WP8(24KJ^QS982^N#^)=6@V=_FU&2JO@U
M2OOC[3VM(NO)ID=?4Q#680Y8KI>$[IY3%^*B:2;&/I?%P"U*KK,BY(V/+.73
M/I&9(+E"2%R9?TFO]ZX+:OTFX\ONA-**><-:B\Q9%H-T&=1VH,XTN@Q8U;U*
M%LP)BEP]=3-&-W)_:Y]U#[ U-_?U@5+IB$S?#($I]HI(F<7=O2PX%__CPXYE
M,)Y >):M:.H:5NOX=L0"6+Z,69]R,K0FL+,!"*D?@T.W,^FXKVVH>\%W?\Q5
M24"=PN9I,SAW1 <SLM3==BQD9T-\Z$<'SQI^DVX&;N,NQ6LAK693+\/7V=H1
MK>YU_N2 -:$4_Z#?_KAY[]SYB ]8:)/_X^[QP9R<?I?)^ J_'2L9/[>&-U7:
M"2NE_GGTVI>+N,/CYA?_O"8Q^B:3W.^\B7['IC'C*VQ9[C0>I3_*6FOF$CZM
MWTMGQ+6A/&0;:FY_,A6$?M$V'_Y!)Z&\YW0#^PAI-\^YUNY C2C3S*B]C<;8
M"U=""KLF5XE_I%0T#NM4/ O1#'I*_-A?]<5^T-2/F!ZR>5)04@0*YAK@ Q]'
MCL&M[_</G8D/M^VT:\":G,CQ S.13!^>2&,L?(FH/5RFWU=YE?%KK0MK8DGC
MD-#9^F9V3Q%.T4JW)HW5P:D0HEL!)"!NN:R._U1[.6]B<(3TO1M+@T(SX[^%
M(RB(./BR2NFM,_AF4Z*GVG<N([:"4<+9H"CYVO#X0E^G0:!RW8$^]>8E)BB^
M1'D&NF-,:=J'47#$P'9;V/[U:O-2@=/%@&I7T[TMKA>1P*F*PF']B4UG(YYJ
M*N-8(=QRX]X?GF>L798&R0)W>_= K!G<6N!R3"3UKB=!T.+Z*4P_A;ZD&$(X
MAW":<G)EG4A1<M%KWU*,"J3I%GR3H0Y(A7  9R(%=0[7P6JON8-L+:2+=#R^
M!R$5,L'F#=-;714#GR^\[-?J>I,+2WU454Y<X3LK7QG>/%V>1IU-'9_C;'5Q
M;42P$Q1:D8LVWE+'K3P.6^R(1EY^=#WZ%N%W&W1@VTRUY#1?BU@CQ9W*0*$:
M^XIT <CYQ89H_-/K'Q3?C@T9I8;R3-47XUZ^[C<+]DP30E0:V["!+SS-6.=K
M87;!=W>[D?,_LZN';4JR=;T+.V#G?,?SDZ>NO$D#$/8_/;<HN[7_WE0D^*!/
M-PTE.&G ._NJ$[S1J)FR9 T]5RYT5 "0XPMH!QU:EG],@F<G_4590F)N9M:C
MX*OV&3ULS*WMT$\L0?-2=*> J'W%^<64.E+-4\&7R22.TD8#Q\.-;O#(Z>(X
M9]HL^[DA#NYPHGI8X?K0H,(9[X(*.&FP:M^1:2:8B4GI!5!?/#D2(7,Q73^5
M-NM[XTV1==Z'1>5]C)$ [FL,$E!&JK^56[4@3X4TD(#9]\]-UO)BM'1(O;_B
MZ^U=AO<G$$29Z*8DZ\X,V['[(%^E'Z3/$:%<R(K\4_Z[&(5ZB=%Y&_]J#RG^
MJ.[B3^%%,0Q\_/05]J'0DH;Z3H:G:<]9ZYIG[Y(D\9P_-2W<3HM/'K*!:7C'
M/)ZT6H+=ROQH7WAX]J^(H*IN0GQ=WL:=V"1:)LLX>.#*)G+T \+SE ^./0F,
M<X2 X?L7=\J'9)' Q&\'W+8[&9TUZXZUD9W3G6F$HC3AK&"."M5^[3OR<90N
MRI^"#V0.PP*6*&-^P6Z-HL-I0G38D90)./R=9-+^I[;V6Q\^'^X*>_ #]RC5
M7$.JX$?)#)G-:*!=F0(B^K-P$N/<1 )W]_L^R-DJ#V7QHP^>;_46;>?RRH(O
MEX2+V@?NQ+B:5#+K=[X1!&$@]YCJ@0(#DV>N3:B&<3!;E+WV(/.(UQEV=L]4
MCLEFPRR5,7#O5O=R^5WYH?X@!2,1VM4V/=@PC9E1V=&T:1KU3:9:) B-D2?U
MM^,_=N<[]P?5UO_8\1:I>8KYU99.L>8/\^?6 ,)CJBZ.QH"(15,'\1Z*HLBA
M>7R58@>Q'GB]>56T:CN5H1%AW%R-B[>B<7>'I-".>VGUOA+=_PI+G],XO4Q0
M?/WAS?8$2>$-;/;$O4#IXL'X!K9/OQ6MC::>K7"_QZ$,Q6DYW;6HG>0T9/#J
MJ55_:+D]/;LW?*FQ%Q-9@4 9-Y"?!D>R;#LK"B93U,M"M4.+G,N=!/"QH!",
MR(T%X@OW/X\O;?V[D@ 8'4SW/$$ITYTN61[E.;$M@DE"\L+ ]L/9HYH\@__#
MWIU&-77]#Z.GK=I6Q18Q11FT992$H0)A%*V2, <,Y! A!"J3D# HA!ELI14A
M"!H@H&%0PI#D!!(9 A(&:Y59D) !F94YA$%F<;S^GO7<>_]WW3?/_;][[N+S
M\KMV=G:R]]G?[UDG*]M\<T!2$QF"<](W_41;7JG&<>Y[GJ@]8.N;.47:PM69
M>O[2\.];Z6PJ'25]"U:K%A2K7Q7@IPS?ERB?S5DDM/6]3A+V=ODRKFO2L&>0
M1+0RK1$+X!7+!(M__=@P,58HG-!^A!UXDE1\[TZ/)U2]E(1(I*J2MT/HA!F\
MR6O&X9Z@.(X=&95SIK&>_#=?W',U\Q<6Q4PK\DUF=,;L9[F6 5J2>/"FI&?5
M^R:D0#/Z18M[O0RGWU;T JU=2?TL]Y$F.]'[62ZQ_'3/--0FX*Y(J6)& ML,
M:Y\*KL4'EI269X.VU;>0/C ^D^.31<6XJFM7//4'!BY>&H;4?$E/!4%G\3J1
M]5CV:"=%M2F-/;WJ+@/6"S[2_(9^,H[N6@A/#\F#M07D[W%,2(>3[:"<N:-"
MC]6=,5W&>=G3%W)/N7G$92PZ*;""H)H2B['O3DA7G>>-HWK5E#4HZ&$B2")=
M_=KW:.WX^BVSQ]@#8<6M_(4N+7(-?<88[TB>L:W7-M6RWS9QI2T![@ >LW!7
M?^_X4/I(<(UCIXSST+:21H<##B:1RQPP#6QJXH,;',:99ZL'M[])DA2&UW1%
M=JC![COG*]EWA5!Z0 :YT/V3K".5X5[W%.L:D6I%=2?(%""!]ZK+PB)!<%["
M.*_-UX'@%>" SR^J$R';-/[SSW(*_[+ H+)2OL4F9.#\IO]T^I>MDM+5IC#"
M00IOGV..0 XF6M:/U#RW+EJAY7',02D]L@Q^U0J/7IP'Q(KMTLE6^M/@MRA;
M&]_ EI<+DZ6=>@-KN2_N@=6.XAW!XR_)=\[5<N?YZ0*EULO)B_2N!PTCH74\
M>9"50BL7'P9:^/.]P"U;8[)L@+VP_^X(G)8BJY,O=/I2P)FVLE;MT]$:20@B
M1(&9M:IT&Q).;G7G7 P5>:@DH'&>,%U!]T?->VM-@'2U&'P\B5PZ .F,& HR
MCJHK+\^MMY"45#&9%&X1OHD-J"B7*K9)Q6/6QVU*?JNQ_$X2<RH'AO:16'A+
MFEQ.DIFTBE:\XOQO659KE+H!B7#2&*/9O3TNE0(JQL/CJ)&18;@2(G;/:MV@
MA+#U.G7XZF+0D&?P\KQ.]$"Q$IO-H*AV1!#(MQ,8E /)57[YH[SZBWK+]4_E
M6^MA*5V 2=I<2\'P*64)5/WJSO!'GS^LP<FAXY=OCYP\61!2EJ=\5Z9#XAE9
M*RP.VIK9YV"F.&M2@6!F_V#2@\]R6WK&G_S+/LO-GOYTX5>0HV!\F1FT^8GV
M;?N0-Z6% \3>&K^!\= FMZ@FS;X(>53OE._NOSI@],)1EAR _=[#B^6=12V8
M&&JP;XTX4<@W9-\\,<;P&]+&_60Y_-.P;MZ8IWR[CU>%781C[Q^UX92K_VD$
M_03&VSBMD<N3%O_=@?+YL:BDE'OQND"5H)O=7#6/5>=!(.XW%;\AOAW3UC U
MRYY:DPCQB2M[309:.9[Q<1,MX-GD'F[O>XAC$6.R\;C7Z-63*L$5N+  LV,_
M$>XI)7@0/Q:0;L^N[O30N0LEV[PDW,_/PWY*L(I-8!6A  BIKYB.=$&G/?XR
MZ+<-[5]:O9G_#6Z%YU*C%H_W1!4[AOJUAEA5=6[ZZU 4WYL73W]4([WN;QHO
M]3UC+AIQTGL[]N]46,UV+9]S9&N8@51U6X%Y/C&'XY^F%J(ASA\YV^\(HRXF
MO.&57[M@DM(3I.%M!%,LF-^&P_T5 ,!;A,##D6*3]O#+L4]^N;Z=7.!^<='8
MI7.6V>"!5$=P\ I]_LJTCS#&IS]C$"@%1;)TS@)2 \^8@4=%Z)^^%9U!M76
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M0L_WA'80F@;Q?HE:]1A#M0ZSS>9F$A)8KVA../(KZR'[HRDVH'%(JE</)81
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MSI-,<"+5#62_(+)M5[B]:^IP<SB8_L[;AA%HT7+_>/O JON%P0X]YSR:_'1
M[8J4GTFL\[%DN-JI)<@+#>I^:+!L@;$\TM/ =W_?8ZN0I.)AZ3^S5H@\0<SP
M\5,VGJ-%2[S?9+VA?00+2/KD;\]\H;!1,'/MC> 'E;^(D9EE8L_0RH:!H6HF
MG2IP:;// S%84V0ZL^!].B<3(&@\6O@65=X9NNG1N(S9=M35?P,KT'=T'G>!
MN^1&\00FKX5S1E6QRC#>'J"^FTF8GT%ZH X(%F,RZ/,L&>H0NLA?^/JE'I9H
MC<C7988_;_661*.(/+$F@'B5EL9DIC]18,W8@,.Z\]*J5:UZ&M0K!'Y/(\O$
MC[ Y#@A.@U]*VH=P3XYOZ+,P5_:CYVWY'O70  I+DQ/5@%8FMRAO<,^KZUKQ
M1H27_\$C UBI">R-Q3KA&:72839TN27:U1C]6>X<:UAQ*=::=?'D<EB%XP%]
MXV7>@/VSF#5P[8J= .2L@:5Q7]*"HG8YLW/K2?##EY0Z#]E>#9!0<8,Y?M[A
MK3K<1*#ID21>BX U_TDBJB6GCFAI&YZ[6NK5#8UI'S9]+J96^J/-&_ ))D8K
M2N^15#^GEKZL],"=]-.]?DU9M JV0&:1[&R"47'F\-%"4YB!4A#%A\)XP:2"
MF^&MP/1;D,-FY_CD=!QZ9N"99:'6 >6FF',7AKLKW$$^X6YK$NF]C*&CZ.ZJ
MP 2;L?'P"U:.5UWVU6]?JWM9&I!?0-4Z<&+=@^Y1F_BB @SJU23E9CM^EOOI
MZ$4._G0FXOV=V1$#!J/G*F$Q0R/+,KT&VW-""_HFBZHZ:[1O)\>6_8@$@AO7
M^PV4$J/Y-Z@\\89HX[8P,D3+EC>\$=R*3Z*1R,2V^@KQA+G!D1I< R###.&Z
MZ#J.["^3OU;(56:65SXW*LR3-LG_]:.=U]+#D,ES7;7OL?1K]6EI&4+Z?,C2
MH>B<WP>=QM8R:SR\%V8?"02=8].APJ:8$XHE<:"UHJNOXU>#,SU7WU:^&2MO
MP0V%W@.J,?P2EHH8@D:SN6H0I4736D#XQ'Z!-4>V]&A(%EK/W[+=$6-3BVO_
MFCC%\/HU-!9R[V+/S'9D%A9:D6N"EFJ^9_?3U DS'W4LL"4*A__UG.S<8MC=
MMJV*3GEZ3BV13ECHFHVDVW"+JB)N%;<H=?[IZQD1TS-ZN/?R(S=)FZ+$C/^]
MPGR'#H4T[SXY=L?+ *@=P"V3HH$+VAO5-L8^L]I\ C-#P/VA;$[%@8B+K9NZ
M6&FRL1F/MUG@0.2I_C,/TM,XJ"TZ&,&01UO"UQ="!Y5Y4S$CXW:4+I3/O+[,
MI6X501&Z"]N;I*ZJ"=R]D=I-W2";L6?^FV3""SVETUDS@0SN=1[)S4C?%Z:@
M$U7 H;P=;L3U-YOK4@H")<]MA5J!W4%Z+#[%73/303NJB)\F M:_7 O:X%5B
MT?7^T//BH#"]\&XCVMN%2>*QTE+JFF960D@;LW,XC3TMXKYX/^);=XLP%KT<
M75HCM)1=H7FHL\5G:Z\7*8-L<4]3!S[N9S4W<DTQOZA6(+)!'WBD\3K!&F0)
MV\R/FQ&K]M*+=/@>PH'S'-O26<K1K,@-=>) :YF1KNZKBNO5;D]5?V0<"0BU
M52=VE%@>0M[&TQ\%W*N(_^-:_>@UAS#)_)C@L.W]X1;6NQ7@2YY8[3^4[Y[S
M4EHIP#.:^HU&#-];YKN(OMRY8&V;\) XPSU33^S5,D:7&JWUQU?Q.*1[0DN7
M9C9ZK3?IH=NI[LY)#R((5XA^Y]M1EGMQ^2??G%O/*S-BEOY@1OU^O:LM"\Q'
M$'0HL1"LS"K&^G)%C>=\L*Z_/\[)I9L4Y94&9A)T3CP\2&QI%]Z8',#T409P
M^AOOC+2#BV&X)_\YUN4IPF9$Y?%()(P$Y(',(/^7@RVWJ%R2X_1@]+P8KUJ,
MV?S1RK=A(."8MD[FMHD1X V-)]P#TCB!JL>M1KCSI47\XI:#A]ZZ"<+\];NG
M$*EM_G5:D "*=CK:+6MBS%6C4"1H+1?(+6RK%.VM,76(K*HHRUP>)3*HU:5%
MLT@ A1DTUG_(_Z=GA%-7[>6SF<ES;\KV+\SRF"<OP2?%PA<#A8=L<K$.!D>Z
MPG]$XN[-2-7@IPW#WP?_7$3R5_2EI8UA^^;4N6IB800/%U93\'7[Z@A<W_I?
MD!Y7A5%%=V;:Z4"7515(F>@^*6IF\[KX4M,(@^\4FLJG.?V-+AMP-T5X*K?-
M1S:4*Y*3F8F#DH$1Y@R;RTREY6F.9WL6W_)W[P.;?QR8NIO)Z7*C"GX;,ECY
MB\+D8 3K"TO;L.9"?(<H+:U0X<>"$7I;[[[S+W'6 _R8D:K53GZU3D';Q-C\
M.#%6#'&_J6;Y6VW8NX%WQ&2;<$S&WB=2-<U",+QO!HFQ-:1^60-&!F;*L$ C
MD3=;5_HS4IA;[-$^EC0,SD<E5M4,N:(SA]6CW'I3JPT L?*53,$SE@KD#WRT
M)^1TY_W*OV?F-.Q>;5H $BHO7R93VYLWNE66[K0G:S0S%GM3#=T7*X7R6@.^
MX;A/2V@%6O\N.7D,56W H"AC-)I937Q,YSIJ9[29&Q9F#9GD;EG?=Z!,PX]L
M&(TO!/!%/5:"S CHTD4:]SUS3%$2$CD2:IIYU_\1I)ANAO%>4.=UOO7.X*<U
M;1J^WK#Z4M/&?1QNT\_[]-RMQ_9M0.J4^BFM"0DTX>CI^+*@9F4PDQC[@?44
M;VE3Z1150M[O.5/)"(!'!)!62&GIL/OK7N(U<$?!TK6G:B!5Z#1FYMB=8 \?
MFZ A_* [.3[4356Z55F\RZ"^%%I3H-+Q*J"N,J=M!@P2W^$L;!#&@'0A7?U3
M_@^P/=BD3SO7'M>WTE(F(,YYX/>C&9IU GBLS_Q=/KS&'BRV!$&2^E<O@V&Z
MG"-7Q/TO($B]7KL./1<[^'PK!B.U[CUD",GJ<-VG?QEDS(3UFWFY>*H9'WU<
M-BV=9'/X\:@WJA/!\_F+4PIM G3(U+U!VO2:YH4WF4JBN2979GWM1)490U0C
MB"SE1!M3<K1.]^;D /-(01S)\"4#^K1J_3+.IB>"1UN/SS$=48S^+#=\[Q"S
M<G#+<1-K<=8!4"Q1S:#G27'$CJA"?O<S,EN]L8U0!U-$V+]D*P9$"*? !,'7
M37^8+[9L._DF!R=.<D8=PSV;*[9HRU*N2R%):GVY!?=SDW"XXI%;S<P%,0G#
MH;)@ @4 4.'P@S.V5/-_KFZSB1[J.Q" >D>VE/@0&:Z%F1EXZ?'6>%7.U-RK
M@'-JY:9-"2VMIAT1[:SM$Z;D'9TJYN224GGWK3$_LRY0/3[%\JF!B6LEJRS0
M^P#@W-YEXJ >\6R0R.>XY"(%"4D=;5J2"2PAK(]63\-%W:W1<@I WHZVQ":6
M(@0NN.NC@D=A[TUH]W.;IGF16OI&4-@$GWWD1YW[*#'@:P1R]YA(1O3;MIM,
MOPI/5ID_!7ZW(,LNQW>A '4V#7PVN<4#O&\!!"@7\NK/&.CI[![/<!:WO.E"
M#](9S.D;&FD\3"=.6>$54^BKZ_=#._5_*"FI#.S+#(&5A9K4:E:-W5L>M.5%
M3[+I;UQ//3=NVON3\9_>.C.^\8_'H<,O+]]'#2W,NJ"R;'7(:>T+52Z6(7.3
MH=#%(WKA6AENX)F;1TFQECNTPJ/5IT8+L!_G&KLW78V!)!:3!.M='@RX7NMC
M<*0.W83YLL$=:V% A#Y%/W[(WB%DU9.SG*@:!)D7M^)&4/B'7B'>B[:*,E^X
M^<O3T$%\R3 Q\D +R<0D?[OUI\J$UI*ZX!F"NRV[U \Y%MGH'H_GWNGJ7'T'
M*Q8OQGTLICZT"6^HW!0KR%H[J:R#5S7X[L_LX H0DPFLSA'1H=J0)MSRFQXX
M6%]<<[*,9)AT6$/ =<D#&52X:]WS1%J[Q8M(>!4* $@(&_RE:IS>D?4G0?34
MK.]GHVVFTDT(+</JG&*7[PH5;WY]>"6AO+-&5@5)ZASU5;6-]5<B>P"/,_PP
MKH42Z?I9AX5T^OS>JB:=&F].T7+]J)0-W8$P/82/<Q%^%LH@)[S*!59!YA?\
ME;>(RMT^%M'H_B EN^*SW 5N104!S@G3/#M437*U7 !;]H.I*Z&>\CYG;QHF
MW.\:78:?PK$"/A;,X,U:<PD6[H,/CCA0AO+61L[C@_-F^72WLMX9"!J.&1O$
MH\WG#3S5\H8\U;3:939.@'9!M9.QUXR8Y+*_&>[S'2K X_WQ$ZFQ_UH>)4!/
M\3VA(< 'G^Q&,GG;T(7K0_6ABEW"KM6+T(N169*/1*,/PW0=E,;;EN7$;"2P
M#K^%B+@'%QV2^<8UX$"FE"V3LA9@)[J$;7K,0><58W0<N$&*?W%R[<#IAX,]
MD+[,U0O6_F!4$*', #&9A8\S9,[BD+P::9WJ^:<1ES\%W/+JYB_?^SE%FWUT
MVE> GVMQ=U'YDF1M):<*U$I_"JMX0BA+E=[Q:#OW=:E9 Z27>$)=?2-$10EP
MM>0Z<DJ2;P1Y)/T[" FDEY/G>#YU+RB%=2'-3/*L.H<F!8G3&%.E@B6PLW,L
M]M$ 6I.V'+E6:E8G%2@Q7 WOSO(DCY2(;V_L3=5N<[TU4AY-$C!ZTQ='R3I0
M$CC/$221P>#*6.YGN3N1+67C[M1'^&PO7( +RN-D;)YYB5_"!,@ILB1\&_S(
M-\Q#AC, MJ&6B8G; -7HN:1]::6@E$KZ4D:?N#*V)!S3JK?!H[3^/3D0HEN@
MKG?+;\,"-Y#>=D9D7N'I%\T-B/,Q!NS4@LY=?!M\*<OG=-[[;(=K?R/")QO-
MZ5#IS$FC ]%:Y)W ZI=_U'9'5/.5>VJN4'-[@>R0I,XYPWT[CT*>,/\D'4AU
M]V^0V-D!I/*P@!P[E^&8Q]=\T+)2],4Q .X+K2B.VO]9KL"SLJ$)#U9PBHBP
MP"A(<ZU*)[P2"YL W[A\ESX#^'Q[MMK.OR7,@Z)/$M5M.7O<CX3>0$20Q*(K
MX5D^AJ_(S&:@#Q^W0&XT-?7D)N([.=0WZ%;EP,!LLADB:V8.,:,3LUP(L.FP
MYO0!YM[BBW4-T)&]JIYG$Q;4/+H?O4H)*I7=%0$7WT5[&#I*P2MF9O^9G/8S
M*U?+Z:'_<W(F^40A(W?VT4>MBJEZ8M70+49J<;^X06C=,X7QL&A:AP%QG.G@
M6V/S!")=71DFO^*MHC\,S%AXR>[#'$+3/\2;HWM4T:?.CE\#ERQ)HD-"S_AZ
MM%?VG.>5LI31*KMRYQRX!L;GAAV1+IM>+X98Z&?G/[*J6+)1BEVNTOZPY()7
M6P<*X^@+]T,ZC)I,\L)N^5T<0RD2C:#C+A.NBF_Y6I38<J'/]WR11T0\?)T0
M:KB5X#%SL=50L[]18)W/[O6O(X0CFNX@:!\D$1R9YS3"A2K&6#E41;\;&!'J
M+3>BR\5+V/J<O @H,YW3Q)<)G@VI7LJ+,PKCCJN7WLB5.)U6O1&Z^I93')*?
M2RT8L^1D$O-]Y D-J=MR"YAXK3P>KZ^LZ8+S\(F/K.=%X)V-#YN#-\]O[.1V
MUHY5;=,TV742H62 32VL_,&N 2-%N7=?^1!$+W94?1R,-3]V_*SJB&0!08!3
MY:];F$-P G[&NGMI?/=CNMBT/J&[V4FN^B63H!'C2_&PT/KCVUB3 :GF@$5K
MW,O9-^O2Z6\8XS4%:I07@7TRISV]8Q*UC]*DRQJXLA!V/A"ILV?M7FC3R/W8
M;%'WPF7OJ=MYR5#[#)CGN^[Q7!?=K<(;&_56>8)%#ZND"]M<53L\C*,8S+9V
M;,KQTV.W]4V(@>A)%F/^7F.R=8/"<)9%'%F+6%;6^,)3QSEG7M*B@"U/"K3E
MG2Y4D%O8@(@:OKNO)>\,5ZBQ0\PA-B+A2WA5L;";3(,>5V+WUG?8C6%I[[R4
MPZ8C=-%06S$PC\)V$TR)_ODGG@:?E"E8-<XOT*K.AFE05UQ9WJQ-Q<3S7AG7
M^JNM;C@?Y%0/KN4YTN*5;X=&W$/W7LMXFC6;L8 Z_0 S>RR9<:1:2S)C=.9;
MB\QTB@6XTU"85D #U1EJT8.EZ0WUH\&<W"YT6"6#S0"$N2D>G5^*53JHVO%+
M'8[S_O?VI2.Y)L]37[A..';4F"!7W7,8MWW5U1>:6I05ZP:EIU[&E!<.3Q+#
M>(I/G<((VI075F=K2,RB_6/;1&X^\IM:\<32D5AS?3'6TIPXBPDEK=QC:5 3
M%%0XS:37<TI-'^EM*B?B&P7]O,]R<((VT:PU$S.7=_"0E^.!9 ]/7\6!\4_O
M47LMV47N&)'X,LTN>&[^,9R9EOX$CC^8F>_F/G,W,_"SG!;9DG:+N@87./)+
M=2E]H5?,1&GBV$-4X()N5(<;=HC%M'@QKDN<2Z_;_/&YI,OL5D;CB2.#B2E7
MUG<<]&L"ZY<=Q\C"<::4T2@QS7NM0^)QRBM<E?$S@\\ E#)-R@']Q2.5V_*U
M_4A5DW[TU!U$C?W,CMA->^:T_&")L@BK@7L*#*+B[M7E"GRWUJ/N"4YMO/Q8
M8_D'C5PDL%R!?K0J_)H=RC,O'Z87;7D5  'U<8WF>30/A]'*1+0)2JD-:2O=
M5!E)#H.WDY7Y^]/ D*#PC<AGTU$^Q22,U+Q\DGS_QQ<KF+L?+8T<*_W,_3(?
M6Q)84+4CX9$[WB ??$=U:2$/37:L-@72]XYGD8ON:#SV]*+!6GE3FW]?FKT7
MQOVQOL,S)A^1[6&CZNRQTN(][?+=#$( %V-]OB.'+8DW8J%!HA%0NB =Y6L^
MM+]-^!C,5^W;B: _#FL=1*F9J.1Y!38.HA[16B_'W:GNDZZB(9U%>S[>_'EV
MS*#?6!E*BI8?GE&#T^Z=]@"<Q_QGE.^#<P8@:R#S@A5$]G.=IP86OXS)33@U
MH!%$59Z#,T%0LL%)R^B_.;6F@D#C-(NG4%][-R1FUI[-(2U,(Q%$/!U<=5$F
M/IL:2JXG5] [;F L83?&YS##/9M]MO3E&DT'S?"U#^/*&EZ%RF)7"2I6Q:4T
M9:?HDB3#Y&IL4L_8@*2CM,@5==CBZ"SW"&*< IB\XA"C18=*(K[44\; TXBJ
M"E9>MHMC"<4^Z^+]=QQAB6M/[^1(0.ER4ULR7-Z4.>Y&Q_A'^VJS9TY5+Q($
M6=NN\<%^9<M4OYY&;E85 0X^=DLF@.PV3,J(5DWVQ\3VZF6D9E632",HD8JE
ME-Z(=XAU+P%GQE#NY/FT%CE2OO<\SM?U_$+GX1HZ/.]H/&*"DE[!(<2CX2XZ
M;0.K83Q-(NF1&WHMH]0BGM:[N:[-[EBPJ'>/??#@,7:VQO8V;\K$L*3"XXTC
MC:6:-GLJJ5=0.=@W=PW,&:*:&5YN\ =ZLQI.=5].;U#./Z4VBB9V6U0-SO)N
M(;_L/=W+5+%-69#G#?V?GLO6< '-=6YN$8*S5W'=9UQ_.@M!*V443NB<V[EY
M+O2?*\2]%3*\$U+#/\!WQ%$26=L2G6#F0\5:.!0NXZ*OV=SPSQ6ZUW39CG\$
MK+DN#KFBI0%];.E5[\>O+LT^'%K&86OU'1L:JZZ4+[32\=Y5PF>,&[35< X0
M,ZESB]T/?HNC\?.4NQ,<P$M98(GJPW_GZ&<0!,*22(J'HTBG(LQD*,JMZ,D9
MA_-#9RZ3'"41(<(*]K1%N%:"4UYL;N#@IF-<6+5#>(-;8U>KI'W<(UJX*6P;
MQ\SCW7V^\[_TJ%=H^= AKE/VH.*F>JRNT6_@0KHN!?!T'C1(/Q*<#I:BNY>A
MX)\Q[8VJHBA 58Q"NY.ABL=L0F3<EQ\/1&)Q, W6<EE)*B:46DD$ #)MH?(5
MV PQ0;YC_4XV_SGKJ-<MLFFILF@>@1#\.&,>K<^9X[W?W-)^HDH*C^9D]L5P
M64SAM9)W7,@8ZF@Q@A!,^UGM%\.\\N8SHI%,]=$AY>X%#+6Y]"(MKGLL&C&9
M\B*)-]Y4VJ*D[#@^=VVZY07,]]&*T3SCEVJO^8A$FQY.X=^8N[SREJ>G,U%6
MK.= =E#CF$'XNX5-0-PIH2^0IW5C-)2!D95C\K;3T8/#Q8N.)(R=C2.MI@@L
M1HP10$/JD4.Y=G-FQ\#8:ED )ZN"_BT*=Z&/YH@1JT[[:DS0>8\WK390]9?N
M"*=,'6 ,_PJJ]QVAN_&<R'E&0&F0L+>TV=._A!\-#'M\I-,0JY>U!!D'L[WX
MLVY=*I>P]? !TX6VF"FTF?OM\\2G%XS.N/:E3E3C5#>-[/;H!ZP[:&;9\E@]
M]GR0>S[8ZTG.Q;FPQOZQ>9]\2"1ZN4^\G#E>U'?&E!9_*.(V!NUY#26"-)S4
M*%8F1F*,=!4]SN!G2,&L_E;+AI0"M<)7>3+;7P(?!>12JKI3M46E,Y_E/MB6
MJDTF?W<[L;!(91E8T[Z.<BH<@M9T59ILUKTH/NJI4>XP](B;V( [?'7U_E.\
MHGA.I6YSY+< T0ZL2$M>I936>Y!9)>[[+$?40$</EBABUI.O6BFG]*)#&WV(
M#\JR7L<4XVJ,<Q#16@9;B][HTZX0/N,(,,GJYQ.NL(L>'_MW776VN+@8"DY'
MH[34KT2%W&5#+!LMDV(),Y$?EJ(G'T2_S[(+JA]\8G.%+W#W<)D.O=)C[+4-
MW5!7Y^9WS6D8ESG_%1*7:I[^>.^!HJ1*5R.[R?/W<>)K3R^E3DIVKHP$*+VE
M/_*&[EB58W)6DWBGU1[+;,%2]\ZTM*(]-_[2*:/'Q!<#+=EG8GOVUD-\C(0#
M#;$>.[0Y+F0=_$ILD/\>64%73BSJR\J.IQXVG[U7&<7#*R* ]3?O4/<ZKGQ0
M;OTLYT=G]1!?81I;K8H"+A"D1#QXQM1!7=JDHN"5KN*.$,ZII1U"-2A#O<GK
M-R9?,,B>RTJ'?+!LM$]W<$X" BE%H?_XY\7(S2O#IH#O.;N(\G%VU,E@5H$B
MFJ67P2>+A @,:@;I>NHUV=#"=#!G'-M15NW>$5SAJW,2Y%+=)1F3'_V-?:XN
MW59\:-917F?[7HQ+<(\_;1^]6?KHXWZ(C0.A[G<K"QJ\K&(9E_PUG_'>Y+/<
M,]@QD/THKGMFD-$7_,GU;8MUOES#8(_=GE@KFGY 35EPEFTGOYK9<E(4OO)#
MV<[(LQ><FJ%5K\ML@I'*WQB.(*Y,/_*,7;*7V8)[J6V=R+FBG#AYP\3^=:9W
M.@BW5"[&*WQM=(C8,/+WUJ)I%N#0)))1K0PR#C6-=7+P&Z\[D!B"X7W\:88C
MW$2<]SRK6(;(S +WQ]^WP1[)1!(:E<FSH*%C\/0W@*G%[8#<N(]A>S N927,
MK/ILK^ 1/E.$%Q$8YPE,?D)FVXN?Z[P6'E0T>L]+"3H8^TE:$*]/3$(I8+N;
MS^1DOKS\!O_'L!J$M^::-<+4:#SGO W++HZ5-?W4BHC\F*">G'C+9@^GQ9.I
MTP-[%1MKWU,>\.N7&2Q#VE5K44@#I@21_3!-.WWJI)KM2FR#)RN;OH1'V>WG
MI.U,VZIS[\&E[MIY=&5^,*@;F$6(][J=93^:11QF@5 HB5[HJUC*7U)I'=+;
M_NZD_O;W 26E]_BM<2$*W6T!]GQ3,^MH\2<C[AX$ZL=%4UR8/DUH%];0T37@
MAGCI1^#PX2SZU;7K\G7-G"GY+<%-/VY [/MZ;K)307,N2<K9H,7CGPP39]_M
M/QTE7WN1+H$&@)P_CK$7/LO5,^^- U%C'0LNWT^?/YQB,+.#&BWCOAZ+L=W>
MWU32F>5GK2);]7YL6^[RTL#=\U>5JN&\.?<(9FDZ_L #6X,/61BB\G0B'HR
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M%)X?8_CG8JKLEUZ.Z6UG9#H-QO=1I/PVRD?HYE@4%5O^HW@T\J5O&O:R4D(
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M!29H8X.$IW-9>JRC.>?$FXXG/#;[6I=WLZ(\V[HZ,MLV(>(=Z;R,KGI8J@_
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MPU^^!E:6"2*_/8LJ80P\._4GND<QJP@K?IG*6-BP$I$!.X7@+)?'_#!0I4*
M&6/@^7/7)EE6I^M3;8(Y ''A8:Y(IZ+DFC:[+0H5M;ZC9H((=9/T,UT($?=]
MXUGGW]4L@>!":X70QIJ_[8UP25RN@O)]D*G[\,>J5L\A>^FN2ALD*=NFCT:A
MI#CRJ1,::15,Q3.<]9%&GFI0NY*+K[; C_9T'S&0J+6&)''S-V1L%I62,<0B
M5#JK%+9?+3Q\ H[Y"&(-@?.WLWW>T0?M@5YN'3"+Q,$10SAUW/GD@)?O+4<4
MN#TGNSV<3G+*RIB4T[LB=$#PG5F"GI++%BKX>W<]WE[+ZW3 7K_7@G%4P,*#
MLVW)V(2:968,].@<U J5,LI<"'DE-;UKF%>P@@MU-%K-;GH1-ADN(<!E2(_3
M11H "G[Q3Q4+4D)K/;4WKM[3TOM-8ULB/L1%(S=9+KTV)K-=$IT:/7IG7,5H
MT1J5/9]Y<4I@L6P^A.I>OOH,5BK2_UP)QOZCLBXMZVAZOZC3V'LE17S1:9SG
MV52X9Y%VZI>[+17"9IRULN5?>^@ZL)5Z^5/[0T.WZ9K.O5'GGFTUSHMZ17\1
M_3XJRQ[=W)4NO JXVT: S(C(I7?)KN6M-I3W\8>*]T S)R4 C-Z/6:FA#L?^
M3?I'A>QF?%NW+B0W=G"BX@<>)PO!N,6 .[;"$8$UV'E+"_&'P:'.;1;H9UM1
MCN;6HS2";_'.].*=.^Z?.'O3QR2?6MB<7#EH2QF.]L"L/]G#0X[3JP 9@0%)
M4#P#AL[=>](R6K%HL9_5A%!4!JY,N>@\)Y+"FT$FY_#--SM,1NIM/.X(/Q?@
MCO(=)Z!E(1>0%S\5&.H0FK0#:!C@,U<^&^A;?/CS+=\3WB\:_X[25A-_&M,Z
MJ_$Q_#F>U4!QIT'4/>Y]['QO^3HIL\E87%U6+L5D9!$%IW\'<*=+P[9G/<GT
M,\XE/G'O5AX,,XA#84]R\ASUPFE8&X""AI 0(FO^/J-]AC>\EZ(]6NGB1_1Q
M9S5V^8IEL8X0=)2:WI("$C0\$,KX^3OM:*M,[]ID1G?FK@!EPQR;C'3\^JI=
MHO-1@&V/<<5GB)YYHFJM'+;QVM9)3"C^=9XP^1;ZQ2IA>.M;+;T3$$20?JOS
M)/CYCZGU,0;\VCN1BX^/NZQKNJ"PAR;!DE.H3/ #+@GS]5%0O=U?N1<#JDD"
M'@L@GS'NFPX3$I[=]TR]&J"CDM,16?GG_*Y'EA62\.",7"\V'T&+_KCZ)9$1
ML(K_C 92*D@V[[)*OC,JF.TJQ;<N!*2Q-C;)-;AJM:- 554=@5@^9-5KOW?Y
MAACK[)6$_>M3DY/9D2>>2!E&8KUZ0L7F^HO8I!1>UGS^N %?JE>9[2X/=9NB
MK581:XWLJS'C2^@4(=3./77]Z+/($4-VVE@L)_G8+#MD]3V;?GGZ]7-,-%5F
M@8)XWJAY,&(RO.M Z<,ARSR&!B:#!Q"N_\O([Y8_N(@W,D"E<$#:>TY.UH%M
MO5K&<RZ2Q/\_&0"WM\^>FK8G#?S8];I!*UWSO$)'CHF,!# $SRXFCSOS)O+Q
MYCC]I_.:VR939ZY&701$-4N.L]# ?2NZ@])H$,KA#J-_/;I\_G3?GU-1#Z2#
M"WY:55Y(]P6WN%@R2C;^V_9'5[SE9&2]+]7&/U>'8_2\^(MS;?AM'^LY/9Z2
MT,+EGU/>O+HYJ&%;#3;D11O@V6WH]V/(=T>@TS=].V/,#EJ\$9XX@)3 $3BX
M@^@.0#/_<JM@-=-D-"0(-IW45.UE1>81;%5)RZNKBL'R0YN#=1\O?=UFGX*Q
M\.L-;&.8>^B7I:2O 7'D@-]Q2>H>=7\]O^IF:DQ?KV%<)#J_>R(#3A3\@%^M
MMR#./@\TS0 _8RI4OFMQ^*YF$OTB#X^UC&#T&JPX*PSBN2![1:@>8&N4P3^<
M_><FN\/:X9G[[FIF'2^(++X=(G2MU%^7 /W851 $E8^^:+X:/Q/5,5]U[^&0
MP8'Y(9P_/TZBJ@KIQP%8!&*R=6?&0-K II-)3Z.L"B7PX5;ICN&+CZX7^_G!
MM'?7#7D)=(5,3L7(M)?K^52IB7!2F37-@-36:DYH'),@D00&2*W&!!R+?*SV
MX(V7=97%,";4<YXTU'Z*M"QN<V1U" 5MYOQ,ON[X;]<2&\Y2ZH;'"%;#3)[&
M$],I!D]&A)I2BW4.O%!!^7U(AC0? #NC5C-1T>#-@;[NUD0G5@,9"&@!2&]7
MK\Z>COAP/NGN@<K.'QL$]<([@\<+V^3)HHTZ K@M(-.H*"&<>>#-WNU6&;Y+
M7[ ."(9YJ\@ 9H]R>)>?XYZF7R045$XC1'O)^6&?9.PGV"NI62X1T'MD"^ZI
M?OJ<&LB;\N=.LD%N*6FJDY-Q2:7D^8>O7F;J?C&NE2&1$;L-N14I+T,B!CJX
M^>TQ6]_(U%,3:1+R2<+Q$$Y*CJ.43?T4XCU^UR&'>LVI<?.5 T^-7W&5LI"H
MD..8F=-A;3P7K74>LQ7='ZC]AX>+G/ XLOX%U6\>^MINSEP_M,1545(KL!#Q
MD$069^M;)?2Q&B5R<R_YT9.D:G*[%$HF/H$1WL7H\UW-5$?AUJMZFNNW+DHH
MCWP6(4LNAE'E 74\.41+0C0"*^6S#DDJZNIOO<;_ F0F*](Q& QRL%(,[-:^
M@IF-NR-L2!Y.SYP[_EC]_;,J6HU_U+XRG^/1QQ;>;^CO<O^&/;RKQUMN?B'\
M(+(8"+I#XVMF:,>X%OQ;?]B_]4?^G_J7/!%O+J@8U+26>)N-=GI$IW'(AJ2E
MLR9N$WOV4]Q*:5@R=VXHT,=712LE4ULP;<QQ*[9M\[VRG+O2L8ZTV+=2,X^)
MNUX^)8=C]VR7Q*=9GY!HP 06,2Z:VT+]\NRG9P$":?P?%>[%#;/6M>3FY8 -
MKQ">^VP@P!@"YI9(O/X0"H*V]4R]=M?EC_Q+\>?K$T+;:FNOG^WZ5!H54E-K
M=52A[SN-H/#+*E6<I>^_O+S*7B#<1"K! @ R\))<D7R$0^_#SDZO':^YK5[7
MF=]L&++?#1PLUSISC>*G92K43U)%S:I$U!J'2?\T.;GPDYTPPI_/J4QS0EJ8
M!C""1RLJYU"DP.--*JZ82WFCBN/%"5PA3M,#%D:%"CN-PS_RJH%@DE/XHRIJ
MU.7.BA^%,AZZ'E'=U-'%81C@IH.UA>*@;[==^?NARJA?M789NTK=@GB": \+
M^)(06LDI&$39PJQ.14 H^>UO2F)^Y'P(O,6VV\:H6S,IISI/3[CFE_&\)4!Z
M+:&%A@0P^/#T%L]SKS=UU1(,#R/K8-N/./2@1XTM%H1B"FQ=9Z2H^0%[W=4.
MB%M3X+#])*XA-;5/MH]%F[-WH*^(4?IE>:'N.WG)#("T?/1<HNH>6(#F98'L
M+NG^/><%\U_J*GQ"XB:>>6@"O:UKR@N;K++>'C2^/G]5Z%<A;8,/N5C\Z\GB
M^3A_FO0=BU_(04AQ>PB6+XT/9E8CR3IPV[X+@FLOOOPA+,XY :'_5W3B[#>Z
M&;[%!T)-.Y65K'2<\0]CA^IUS4!+@PB,L6H/(U#(OXNPO+2)W1,+[BFY$<[K
M]5(ZZ0F6'#P-3.@:[OM>8\;==7<E!7^$1B;UCY'+ARQ+C!:>CF;<-7=,9^H9
M+<\)F4?WHBHV>Y7J-.."O&.:]F2Z+JB=C?RM20VQ8J.<>>3QR7\P=22Z5##V
M]EZ#)Q+EM)NBGV8Y.\PI=#BVZ7!?L7=I>4G:-G[JD-WKSR8BH#5W 6O*0XEQ
M:+#5!.G(O_.BZT.AT=GPM*&KJ6&CDWBSNMR5MIUU* LD :)*$EE([Y6IN%Q\
M_ZUWFP&IJ'K2UWKT5NBI?%\&3:MXKVQ"Y"ENV:4-\-)>GAMU0^G:ZYX\'7G!
M[)#L^N__J#3=4<E]'HOUY4O'UF+BZN4)I)0R3%=++BH("E<%5 /D$L"_@LFG
MGQ)<^N\^)&QZ^;'T>DGJ4H:/?E7V!"JIF@2'TYO)\\&^5+I@@L4GLO!%GEEI
MW8VIHI#ZPINLMK:2[,-HV/%I'M,+H_?0$2]MZ@;MLEHT%.8G=<+Z[DX1_>:*
M<CRYDJ"*&UV\-"^P(9$[@Y1 3N?:#!\MPIGI>)BS>MA^Q6$F)X\KE) 4?!G]
M3 W^,UF*PG*0RPKP#\*.PP^GL&,W0TO^SA:Z[AB;7J21_9?U^F!T[M^_1^*Y
M01P$((%0BCD'I!F%MWU&!'N\>&MT%^  UJJY580T4@X\ELYVPFUMG& 41B]_
M&^)-D<KLNETUI#I\4$C*D,35YVV?!6N=YTEXO6N[A*MZ>N =G^ 3@Q=^?AW@
M>@P<9I\&UL)!\1^!1Q#N^1&BM:+)1T?N=<=W*?$9W(FSE^[1KB1)7\CPY4O!
M"$Q2-&^2,*D ^;H>B?/V:V,FO-0281M^3SP#.D-;VT>*;>VBI9K )?UO9KC%
MW/R7'!7; >N_=?MUGKYEA/CL;OCP=7=Y>5DI4:&S2!/VGAQ:S;^OS=\J+0TP
MRE@#,(^,DK2:UT*)F.XM!5O/%_21>HVS(G?*/73[" !/AIRD38%7M[3]ECJ=
MI\5;>IL@1PCVMO@?386&7P3<UP<?IRN./$GH91FMY/?(-RXA>4#-Y^.5PS_U
M0&UML?XQTJ/+F -[XC/U6WC$;YGJY=A_5&2GYN\P0N.T/0MD1DW HPY?5XI0
MR_J1+#(*@U7,)#4'FJLVHD[8UK>6R+C3#%Y]M.\Q29:,9+S4(.%. UYSX/7:
M@E>X:T\E]78?CT[8CC'NU^WA938;^I2QDYHJJB8"H)FMO$SEFE+7=6<P)\WZ
M$JVF71M]*U@=@3^Z%>&AIT;QLW1+6JA4_Y'Y/'W&,D_K&"LG%5H:""N1C ,*
M6;12SY0)+L&ZJM*F G-,4+</%-(S@33A(KN*X_Z'D\9<[_3;)R6 ]-=#S=_W
M1/N$'5)R)XR^*'V;CDV<BI)%?F4FS&8\Z^7LT]GC^K7?R6AD_M6\?4]AZ]XR
M<@_;.H(2$ADN)QR::>J78J.7$#'[?XRZY1UNQM4U9(OV&SJ=EPT;"4&^:Q.V
M!]PXJ])&SGRCY(6-^+6$*PG9,N?%;^^VRB3V[L2YU7NZ%EO>^6CN\<C&"N@U
MD/ZX? 3"G7'A].UT=E8(L5W_,(U8,\9#BKH',^>L%U Y9\E/%CZ'3B951-YV
M&AH)_Z'@@VWY%ZX?3$+-(C9U@32IHP NPE)3Y)9YE\>V3YO"R1%^75R.,SL.
MY^ECNS1!3.A')#-(_[L?'OZ6&I*GU19]N7&C'TQ:_#FINYPO8H]>]70HG::3
M LQG,UKDLUB8WQ-K:4@#(<^GR"W]%2B_)_"[,\+'[L0U'[W%K-\I^P*M;/<O
M0L-78K>/*NYWZ69.NM.RW>(;ZWT@GD!6R8$)1O<['$0]T/?^T*'A&EJPJM8P
M.SUC(#UV/G? EY?LU!U3[ZT&0[;>$@R 4&[(]71%""H)(%VAR9'2'G)F7>Z'
MT3G#:KIHL%9#B!4HVPFJ( ]#A$)-F4M(B<JG<J$(P,&BQ"MEC%P43:+*.O$Q
M>1:484LWDOX0!W5J-FX.8J#Q=\,$/^IF$8.:91="U+^>LBA9Q*7,XTNO/W2K
MG0L5]OXFF=$(K8HB*>Q'O+]\SG=.B7;AX1\Y?4IGPNC8VQY;?/ZXZ"[[TW]Y
M3T%H6EH"&'V;31BV\NHSXLD-,#C*=8)O'PEGE8]#?V_WRCJT;2;EX>7&TQ '
MV6# G.(@6.\,X=K;FX)R J!,EYHNF^EP)V?;6(M7K,MQ66U+Q&KGRN0W-?5V
M*6I"QY\[]%@VBX%W88)__]I!-K]1U79Z! P!KVJ:+7JW#7^],)L=S^9Q;F2T
M&M/^44G4?@)?YK4Y.!4.#D0.RJYV5Z$JR<.\G?.YJ[<9@3I#3=^,LY"3,ZM*
ML 4-.76/_%,LK \D[$,];$Z!G 1"&8Q>3R(/"[9Y^TI\F&WAGV:'5XT6]QTM
M7Z82LEY'*(P%@'LC&MUMCPJIA8VX]9K.H357U./M*9[NIG2=^?D#^P;WJ6>4
M0FM3WO&R03 'PDJ^5,WU&:_%$/<2N]+7<)0B^49?"DO1%7?M,*-O#U0U1 :\
MC6]U YP<?(S7;[+30FD^6QIKMS>75V^P@F=]DIW"['NZ_YV0ZE*=_!V'.2O8
M.9=J63)V+NLZCTF!5O6CR'%T2$\'3ZCO^\@FP7/"!"[P.;C[2E5%\7HW5/-J
MH0MP,2UKZS\J84Q3ZHQI^LQJT^AG"\2^T7TNR2VRVK]ZYB(>#KCYA#V$GM6W
M"4G;116@@*/7FWNUU5>UJ+R DNU_A#>NU+0R7]4HFVG7KCVMK:D3G773Z^BT
M7XYI]15/5@PK.TKSR59TX-23\?.P\F'J<%T&SA:A;!ISVQS^?Y6BK0R%D6L0
M<*@ T8,Q?X&Y&X5#E,U-9SD1275+[+D?:&?0_3@),#D/#S1/QKW/U0P8E5/9
MKOUO:]'FKC>C2"(6<%[H.#R[^GI)/5 #!20H=P3L,*)F,1_A)0EK?PMH"X>.
M$ZK,ZT'$X#&1&D(:J-GS-QF+!YG*EN_G]B.];+3D>#"<6N+A?>3>FU=II@7D
M>+*+;K]<]^9:)LK056PSB$%I6U$:&$FJ/>N@$0WG7;RS(@EM.!>^JK&M8;!K
M[@0M1O#2QS1WJ6-"5>*.-UT=@K(66.PYDD)ZP31^"O,J/I98YEQH#W0'-PP^
M?U1NP7-L\/"-I8@Q4P?3(P^MU0^Y<?21[EVJI,]CE2S^(+=SSF8>I1$_K[V_
MPR816FG&/- H<8,J:WN;N\_Q H<_O_SRHC#+!74MZMM,H!_<2#,D[DWR/89(
M*(S_ZQ\573#K-1Z$JX*%_8 4@U)1&.=9=1M$TK-2\.D?2^F D%T))EH?JF^N
MADB%PQ.VYW,%^\H9: W'+IE5(;BJX.?T@HG['+(\D;?>0Q>O"=?]\#PSVS>5
MLHOUF'%1G8B8/GT]74RS30&OC)KU[-D12I2*I?['>0=63Y4G3U73@9#XVW%:
M4AOO3IL>VKAC::,R$U3N./>@]J]\[5Y^ML@V0_+=^$=/UJ*E[AD4=I7QRYJ5
MTX_WZEW^>&\FT6 J&]G3Q5?YCCW3>1$&*+\=QWDK9( &5@@_!)PBF[$ZE+,?
MXWZ;=$.C)ZA@%\$(0Z>P@@-[S\L#3Y(=_U%Y7KUR8^1)NV%5:Q24M_J5K-8=
MFN4T,"9#ZYG3(4+!FKF>Z2I/^LX*)1ZBLI9LA^&1?J9GHNMMV;X-%W_N\DK$
M=N20+<8OV)OF^\("B88DA9I$;)ZW500$Z@NUTN^>X[7N3 ?+#KZ>#!WO#6MG
M#K>QO\92MP(H+^L[S<M==QT\/;[00M]UGV7,\YSQ(=P%;4-UPPH9CVGA6ID?
M;]G@Q)Y)9WX2XKF=GJK)O*_UB=7#5MVZIC;146I>]KTGXFQQ!YT$_MQ6J$ U
MHY6OL"$/(??U>NPA?7#:NL<1N:'H>!*\@JEWY,I^P>N(6..'X9\-8!?F3%C,
M7?#('"&R$A1!1IMZVBR7!>"C1<UAG4#];NA["F$E]'YE6GG^+K"@[)L$L*YG
M[AP%Z4^9LW)B:;'\9[OOK:_E/7U_.WRD>IO]T\GZCGJHW\U DMWU"%4>L88[
M(!XGZI62$)%)$5/*%-_L^>QJ'+/7#7XMK4-<-WB:%Q)JL=(ACLP1AS</ZB=$
MUZBBD[#N*O')[?U9?83*QM<S41O&^Z!+2+P0KBXN JZYM)]O?'T[.$!&\4^O
M!".^[5#K-7/&&;U\X$M5CDH;?+ALWX)#4D^'*;O$]'GUQ!X:?I6EIW=B"\&K
MO?E*[B<XD\6#;6O;VH@K\VTRR"8G_:-R9<>QF0T/"]IX!AP'-PV?[?UXTHH4
ML)(_YM<]5?-Z<->A@F]]O& +QL;84INYSVZ(_[N._G\,U(>3V*)$J*)*<ZM)
MO<>IG-I=7PR+Q0O)C'Y'^]J3:<O@['1 SKZUA[M@>;K$A^5/[PO6UE"\DNF/
MI=/7SD&A-KY,(Z5>. VEJCYONW-S?*8N>*WDK<OU%K'_#.]&1#G]T"OO#AC0
M9A#QA#L%!7E@VS555?BK[=I^M_QFP[G$79DT^):#MMY^NR->#?-: M)!/@8I
M@N/4.2C2Q1>;=F=%+FB'H>);_4W)&IHP0K&?KMWH+:H&"0ZH \E,F2H$BU @
MD)-)P8=V^9K#6B>%\YY7F6T"289:C7X6?,A1CX7GRV*V2DCNN8@ PP=;BH8B
MVZOJ>X-+WBO,,F!'O)4'SS89-+^<F"[+3Z3<R5K61V/O8TJ[8EV392^/Y+$P
M4=M8H951ZL&H$0/'A0Y0^,$1#V9P&*=>AS]6M;JUOVUDBJC5W.H6,>*8&^&@
MKEI1/3Y.-"X^EH6##R$Q;WE%NR^IT/PMV;)<W(D[?8/0[Z+3^^<YE>6^Z24?
M62QGL5.-[SR$/%G1%CQY>TL4A/_#@I_ D[A[""L\L4LL]YVWB)[R1!!\B_<B
MW\XLY]W;.=:A3^8_"Z\Z\!F(@I7>_+&2YRQ:$<^F,Q>A2EG"')L[IY"Z>3RL
MHNX.\7H5]_5WBSU!"/K9LUM]3Y8Z-E50QP]C;"]M\237 ]VAH6W= 7E]PP:H
M?+K<OT.?A!(#".3LI'"5I-57%$2\G+ :'])83C: RF_VW]!/@A7-V"6BL<F9
M+=UKC!]VIIQNQ^V+S0Z<=@7MR$]J:J$V<BQW?*+8O %PU/N B'%G*C,&T/+X
MFX^"L6ZNF+;\YH@)CUXSN%>,'EN8F)2TMV)+ON1]L>20/&NT:>N<)R%[6ZB;
MXLZT\^0LC3XG%&/U_<'F'E LQ8C4LJ9^'Y+VW;9DUR;.S@.FU2F>_ZB$*RM7
MEPZO$[Y >3A5B\ETIEZXUZ]Z,=Y:LI7&Y5W<=K?CI:4+%JR,=)DO;YSR<8.1
M-YEL:N4SG/7A X6GO'GY#2@*XV-F-8$+'BO8939H@U;/21&"PM-'X*JM4"K(
M9(W_JO<3ZF[G+0P& _C/-)W_4@!>=NJ@=^XN"]1$5P[*/302@82K*%4L;CPV
M*,>HW=3+FXL[)Z@ANMGYM%7CP1@C)GM##X?D5K_NA!8S17WI)C>B(2<B%V_
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M^ _^@__@/_@/_K_%/R/_"U!+ P04    "  !H<E<3-L-X+-Q  !2? $ $0
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MN2U9'-:?&]/GV46$_LB8:"]HS4" ;U6]*.Q0B@V-RV>3A ZDB(AP!H6T*&]
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M&.OM@B1X,"ABA,P#[@NGAY&P^$@BP]_*R\49Y(/UIGH@Z-)0/$M"7VJR!S,
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M7E"Z/UK@-[7!2DA"2I@KGRN*>,'ZO/B)N U]L9C%FCC GWC5;4^*W[94_I/
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MV=OZW@UQ]&#=35N3HC+;]^KB"X)4,+R$C857KZN?(O0KK'MIUMWIE:EG)WH
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M7;VC^2N-6^:&N1[J!WD4^H#4NM4JYNOAD$K$NI9Y8WJ*T$2:2/_\E:_5DWD
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M _W\^YE47D4ET<42$UD;!WLZ5W\+Z"#9!GSG:W'>?<Y@=S%)9;OBQOYA!IV
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M"_!( VNN0="EI7F9H/!S4^',T!(;RY_/#R>@>[QMXM2\.]=17JD<K")^CI<
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M5!75E,E4LC8Q FFBF!4V&7&M:+"%(]\^-0.VN':&IVPUD7'HRBK![W?H LV
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M2%]S]&I/&G-'2WE %N2@O1P+<VZGV5OV)%R@*,(@S<FA@DRJ*CDG01>*52=
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MM6=29*08C$#V5(6*2@9]W%GBU!@' '2US-JL'K%L N*A2HH@+!+HQ^T\@4L
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M;XR=\>]"3:-C*IY-''CD$H8!YR-^R#K&=_#EW8P[VS>B8O2=>Y#=Y.+6MJ0
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M^]A[P1O/<[KFM[;=2 #'AM$02H5E+3_435P4$Q1L .;^RZ/(MH8"0X+=9,1
MZJR),MHG*H6-#<KBT^@JWT_ 1U4'!1,2 >+R@DD1;.H$%BO)=K#[NH/B C>-
M:_0BE':C)73=*Q?3HF7[!IP615P"*-<=VDID*<D?"BE#RCFRTB7<+1<?:SP(
M0_6N_!V@^.M2AJA2< =%S:XOR\K11;5%O&0NWG4&AP6B0:S0"D,+LB*J=OW3
MM^:BPX=9P-A]]]R4*N5L[N6BU8F41,SFHCZ)7S]Z,P4V:?_MS%2R=H;?92>
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MR$;P2:6\72B<5%-B4H24?XG:544!%>M2M2>QJ&1[FPY OUJO3\6=0Y$32OU
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MPT/&4I[2(A,7EA8S^0*I/D#^Y0MU4:S7I7 :FWP-FY)O>.Z\3UEK4D !7!#
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M$V(:!P\9L9IC_BSV*82&L_0XF&V/9T<)8/A496"45+ R0.L%M$4Z,]<G09P
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M^G=30/N,1K"KVE?G*]]*>C3D__D2%P\QU;6*0P0S%ZFUD1_EM!;0.]8(Y02
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M5E'J;F>NJJYH\(9"H0_P)Z!"UN6=X)^S:\9Z7/<O+K?2?#5]=:C7?. XS9D
M9DTG>(OJ*P3K7@NZTZG4\K)-&F^,C2'Q+F.@CO4(;_]P&/5ETK[#]2_^]0WS
M7_G9578\V,?&II\1N>'=5V^D$1MUO3:$)4V_UR]49C*H4>T-42!B*MJY5B>>
M(#3O^6 +M7[Z!^! :L(W-S)"ZK%^%&DD\5J=5]5Z&X"UG&QZ/X?.'J8BTR;[
M:F5E'-$Y;N$OX6Z.,1WS0.KFM#N_$@NHT"AL!387VZ"H_&^S*$4:3>$!;A?4
M&Z.5YF:;GU+@+WG*:Z;4H*-Q)(S5S7&1*47>_3@IIT 0HN/M:.FUQ=UPE]JO
MOUF?++KT[W#<70=#_S(<<FOYBUQ*@3Y<KWF$"*JPB!%\P#_QT,8DV8X[W_SP
MR3C1J=!50380'7MR:<XZ +E=#>9O![JTINGHQ$OT#%QMZO^CV?>XL<R,[>WH
MDAS*\,LI4^U0'<%(73Z)@-<-K+QCXY(9S!X$J?&.Y.(E?!)>Q"2 A7FM?< P
MRTDJ;>DKP@V;51?U\J5T&WUIZ'UZG.\>9^82(F[E1F8A*'1]KHX)0SJ:[_39
M+_1W+/2E$>8ZK6TES)'6HE6)65K6]ZE35 V=X@A?3.V,=8*?(-%IH9Q&WQC'
ME0X(W-_;W/G6C6I9DY;KIDQILQ<SD\(,+H].W&E?O'"*L1E0WH+#.*&L[Q0)
MTDE:1.(DE8F?S"0P2#IBR.\5^@.Z.?E.?N5R[Z@>*(OZ%R[O<S(:J16NW1#$
M;NP_SU_K%/C-MD&-)<2='F;'.7/1>J6KVGK<X74$8GAO _-^6+K[P1I/.5P7
M--LFBVZF80LG K%38%/L8$WG=-IL'8F0-J![/-4M_/7&G0_ [ ^&K8**!H-0
M)_8TCQ;4NZN_%]RKC&B@14AY#H*RL5I&N:TS<NXR,<UQ&#<!-(CCI1]^NE/K
MDX1#TTF:7%P1==OC50@=JF=/':J(%/)SXW>_H)7IC2U(6?[,[0&UY)&CZO^T
MG)@10_+C6A=6\K=)=UXT_?(<5.6(P:@C+;Q4<3H$NYZ0*WVMQ-C.FFXJ=<TJ
MD_V36*0*4!&P9;]P>=^G4/?@Q4,U#>VZY\Y7<>2 O"&89)=+TZ'(O=</KRGH
M.%EZ.<;&854[>4"HI:L5W5QJ_S+7UG$N%P54A._&&0J?O55#.F 8J9!9]*X[
M30M_?)0Y,%W8VNLK1V!*AE-ID]GVSI *=[N:/A7>&6+6@H*") 7)'Q1BW2:7
M=;H"6.2Y.I_86K'P+XK,D>4[LAOQ8=#XS3 (HT=Z+R-Z':D]/6%'5<GB+  D
MG;H?=CSO;0@IK'+$*<=)K/LUG;)1!I)*:=*M_5J3N^H\O%7LHK[B:):!T6_M
M5H\4(IC$4AW(XY46$)7:UE&<QW15Q?<QO\H]:WN^6(WRYO*\$X5V<PA+=.'X
M1$%<S71A=R@0 D=YV49$3^H=45LCMO&G<^#;:IF!=*N#)AOC%WX[EL8SZ:ZO
M7=767C,P,S/H?.M3U!$R@X/=08& #):B571 K=\V*;5X%,+8]"]S=G^B1#5T
MD OP?!#$-Z1&UXH7NS0?\8U^55_C,YJFXMV3R 0 "GFPRW$5@)(!9J,EH.WW
MY"1!M4P7C1B%![LOX'!5VA.U6K$]K'6(3BCCZ#&H87Q)A?Y<!*=3@%=U!_%N
M4($&J3)I0=NVNQ%3'G:R, 6/\E'K!&=R-:Q!7HT:]H  O[IHJNS^$*1K1DGK
M*SNF>&*%>)TA2G?D9Z+K;FEZ+;[NVC&7LX6BMO/+8Z9Z7,SRZSB@$=4O_P8W
M]C"=M\[J/P,?Q,I#</L=_/UZFGC#C/_(:X5X+RJ-H4F'HN#\2=(.)Q -E(/I
M X'2+:/QY.-_9NFTG(RS,XR'YJ05YD&L_<3"\)PS::RP H/P(Q_*\<&)0&.F
MW,4XG6WLGGRY?C8@UE:>^5ML#Q1)!>Y/#^U/=DURCGS0_]@VU%'9ED4MGYB8
M;@C6J$]<6<T-6QE>[R'H]ALIGUJ5MI317B]/.PV.L1F<-!'$B;M<Y-+R-Q88
M_/EC\8XAE?^$Y*<.#ZMB*,MNKI.#('MJ=*$P)K;NG\PEJP\43V)0U5>S%BF>
M,L!^ FX*G+$M2 .!0("X&[\^R,N)3TZYUC&:'Q<CXV\:8,*, _^@?DTRICES
MW$[*.U@F]X-3;LJG@CC[?G=X8#R.2JU%.B*520A"\%WE/<N#KZF\@]LO]QO?
MN+SRTQ?M.BVTMMZFLS?/WA%>SLEJPC[F%BJ7+2V7M[,^R,<":]IP=!,-6KT%
MWKW=IXR+!J=!M<6]\K82G9,;;B4ZH.G(D+,$_:B5VFH.>1,"68&C0%=^?VG6
M&G7KL^BX,[MW[N0=:UT]#_2,T80M*L&.]ZTD_!?1)QT%A36F #8Y;]XTY&JI
M3FYTKTM&6^WEC<P6_7M>2,,2G"@W8C*Q'VAI";W[C3\B5IC/AF!@[CA%[-HF
M.?U.EWB%H.QWV\%S(9[YJ4P)+EPXD9P%GY]42]F%W3WQ3_2U?YWEUZ\W'4E&
M7WN0!B+LADT@FVRE&#4[PL<+? P*JY(_EV*+A)S6C(?Q.&SY,"H:P[F(I#(&
M6EJIM6*2C\6IX7_R'"A(Q5H[%Z7I/.]E&_:5T1B.[C0;[/8?8]TP^TCS*1-U
MU47,0R,HU!CJ4HPR-97+?:"97\X SPT6_P"NC53VH<@;N4.1F O>Q1YSQ3%'
M<T<'O#X<QP5-I!2@\I\I"0(2WR8L \DKN"U'\(8M%;_U1!_TTMP2PBY^CM ]
M_@"-*E1XWNOY  U/X&C7T.&SU1"7MZ>VSR&&+?^%H^<@VJI0I 90(S_X=KVU
M]J2)7N0/S"2\!5"K4(5J57AW[0^PNOI<<D&<@Z75H<C,#,+.M" I,]=:WNJ[
MN:K2W626%OU0)&]+9;FN36#EN]!O[Y>T.^5O>2AB^.MNZ3GZ'=_D+/NQU"6S
M#9J3LAB@'6$U3?S/$^J_#[H^7QZO.M6Z;!Y9W0'#D13H[@<_EWI Y\A@XDAN
M'>3N<6PK.[G_%LS)+_/UVJNKKO+%*#G'+'?+2^5&PDCGUMVS/45^+&4/K:%S
MB4=G9RZQ.3=8AR(0EM6N0<B3)Y_2==) N]PQ8G)FB]R];%("DP-<N"BP U$+
MH'@.9O@1*,3PJ+/ET:"':78V5;;U!90JN9P$-A:'PT-^[HR;3]9ID4[;T!/K
M"$ ^HM22)";"W:2EI1JUI1KS$\1+_US[K_ZK^K_UO_7_+YTDS/(=?SN+GGWC
ME8UD1F^[O+!ZJ):6[JJ- &N<.4<P]F"F+/YAUV!M"UN!LGSM"M"&X3?.:5F+
M-6=65:7413Q:?WFZ])C@&C1KB0N)@!K8H4+-LMIZ5A-N)OQX^7U;U",0 Q\T
M2ZCT8.2:Z)./5?O$R#)]-4)];WH^+5R+K1 @98R250Q!PX4P5F6A3*%R?RNK
MCT7U92E^&<162MY*<*J,L+1.83UV-;]84AJ\:BZ#TG,4;&[.3!"CC_XM\K/L
M&W]UB?H?M+VX1.C15U41'>NHPS'K3/=5SZ;CG?$;.^AFO410=+JR7I)EZP0$
MND?(,ES+*[=QJLQBD)^\HJ.D09X3T(#F8H(RFRLP[GOS<A]>>B@RD7THXB\R
M\#^,Q)U(/5HLQ33W9]LUF)IT$C>WBQ.!B@C7IWAE:N2-^[XL'6+V)LC* VP^
MJQ1JGSY/XSI'L]=OYZ^]8%N&CJVSOBASL1N;GZ0:ZCQ<@<S.X('6R8)!ET'(
MJ)U!%IP#'TJ''47HXT)Z&1B9C<>W!B#\L)J>^[:5P_WG>8T3 3+1=)Q:M^WP
M\QYJ?!I(WTS):Z#EI(JWM\]F/E,K9OOW;0?;4[(RZPAUL^]/=2WE>!\<>_G%
M$S?C->TXGQ#6EMIWKO;VKLI?U9N.3R+I+,(765:TG#^6,E+W._9L<]LP'H5A
M;D7+8_%(T(HMC;>M(RS%40N,A[1636%' FZOA=MH7VQ2? C,[[XY^3_#QDO#
MF]'PXM;8R&+9ZRN%[7VMAR+8F0-E<7[P8-3\*B__%"MI0EJVZ^/#XCR+GI"1
M3OMMYT7$%E9WL[A&-.=$*[TJ+D7@!&J?U28M:W,^)#C342!R6-R,S8YJ?B74
MO%B_\%!D6/7=_[G<>;BDH^@S!%8;X*S9!5XCYB548\1).M%"W/3)K_\+L^7_
M6_VL6Q\>\R9?+*2F"B9?\"1<PE4/-5]R0^]NHH1O[E'C4F>:V$<EEXGUV62N
MW8JZ77TZ^* ^803WTZFV]_(%:U@FKXHRERNNT)<]Q^TTYXHUU[G9&1Z*O/*-
M^+WTQD5N2-/#R!$HT.XFL:X]*&W-^BE(^S%'(8EPX[[ZD^52@UB (X5'&$@A
MA:=8?EVM.Z&6="_<-2>^=EC:C1K!*C&XG+$(06S)E0DKE?NN.[8N7G.Y9#C)
MPW@T?*VEDRZIR]U'KTW!%R<F!=#+U<+F;/].#?]S0N\696S?I+-[##!8"P9L
MNMDPQ2_7VLBB"1$HW+I:YXW'A),IAR)'WR[;(R*C:DN[#D6>'8K,/BG;TQ^[
M7B.9\@=>]90V7)UTF4J)<R/=MP*[C;]TIE(9."PA3*D["'GP<CVT \N3H];G
M,;L<-, [_6H, HV+F"42AZG5D\,'OV:'S.W/X'SW*@Y%(CE9:SKP];W":F@1
M?#9FL_DD=.M3O7>Q2)-WL1.*A6ZMA)$ E$V5J[T8'XP;'U0 @2-<*T>6Q.58
M[GN&'GV'(H@Y  [>'@MD%H'1ZN#_D%6NYO^\MBXCY-;<I95'-3LO=>F$VL?/
MVT;227Q>_>G93C67TKU^_\@+/=TK):BQ(64QEUY,9!*_=W[H!V:'\0.-@:-!
M8\D*R=\*%S]TN\Y72%7.O-62B)%J:E]0ZV8)4%@8TNLKS5#"5R)H^$\XI\\P
MH<75[/W-3;7RM0!4VR99?3B:L)A/EK)':<.[OXCB*YHG,+:8W-DZP"_-P\DC
M(QI)>_V2>^;6%K<BLALKL9!@5G-)-V<@.XRK3]T]!48KIE&IP'#XJFM>\69[
M[J&(#N10Y*S-Y[6G%L^^J_[S<7(I82U2IRYGU,!I*P#W ^1E*Y/OUY]6^.+'
M<N/VO0CJM@9^$7T8VYB(! )G6FN3+-+A8&&W9.';CXMJO0(N?L,[$13""/37
M]^R]U9U80HU>R.=9I$-FNFU;M/L TW-1]_KCE6P&.JJ82*K#8!*0:]%@S[-H
MPC&;TQ8S:V)Q(\^7=I]S YR]"I6P3&5+4!4'WB*7*0H[!S'1:RL#@X>3[MF]
M$4JL=,I/:9][8<,>N)<=K]LF.ON'>2Z)#K=JZW:N'DYR!+OLS'GX4?>3D,XX
M@\N>K0^=L>+@OE[;QB+OY68N/+BZ+4+,("M\S/0W1@A-]O7H.L;A'MB"XOED
MMK_P32ULR( I9LNW8BW&#);72H7$!+0M\*0]=B 4>D6.3&N>-=I^J*RG=I:8
MN;>YQ'_69QN.'M?TH_:6?BLDTVMI,(Y*M?UWTP@).&0@HY#G9$5\>Q]W47(,
MG&BS_%FHVD6(%XX9I.])ZBM'+D)_5BOJW&T(EY/.;U%#2D/Q^E4Q"/#KZ!CK
MCGY 2QY\. $9P3785,Q0'P.'WVJ@H>EE)5_"<GU5RG#-E"XQ6*ADJA@RH35S
MO8RSN2H<3P,?G'5GJY&RZ&6[H>EM^ZPK0N-O5$DU=FNG+P(KZJ18G>GNJ[XA
M][$X)&INKK+6<:[Z47JD8S/"Z6?JYY<]>F( PIQS;9?3]Y%KRH'I2[RE"-6#
M$UN/%;>R%&/:TT9TK5 !$3O7&QKJ=F\C'V<H/1YZL?'N9_H:L=82\D]IQTWA
M?MYCB@?[G-"R5;#!F^]+/TCUNAC>JMH[B!C_,H^/)VVH1":TZ/Y[X.*%= *[
M*DP&V!Z*5%',B 3H*/S;_@=Q6H4V^Z@AR'$"/L-\$'"U;1E5MR+Y:TZR^=:M
M+R>.61R@?QC@9+H+RZ=*<A50N*D$&/OUIV66MXX0X19?I0;O7<PZ37AN*$.W
M\O!)87<#C%:.3J<DAF>F]GV;C,QF&7=(@0Y%EMWX!0)TW<H?SDXUA#'M39$<
M<D06#ZJE'?:0T;F.,U5$"":@($92V ^4E#O3&4)/N < ].F?L*@"IB$BPF<[
M@\GX":(\)\QH?7CWS_*UCX<BA7:NJ\\/1:"3J]UNN[VW#D72T_<I1T2C9'!M
MO@A&*=2KH!8U*Q8!7<#9YB#$$,.**2 @: WLDK8Z\YRTC(EY8^+<ZITE&BR7
M<-G"?LSZA!D78?B<O!H*PB,X!7"@4=RED?B!0Y'GL$.1X_4I/ZI05?^-CD.1
M?=,G,ZZ?,0%7C[DS-8IT&G*QZ*HA?@-:3]SE@,6KH90X3UT;B_!HS0%0R]W*
M'76WO!/SY;,<G O+()"9 0L6N&^O4P9J\6S-N6RG0A<(NQO"/XA*/109P;T2
MF@Q:GFB;W]1W?OKD1Z:&;G>?R[?GWK,C7TY@@%%ZLG5,P^DCAR+_R#A43NA!
M?)1>EY)X%OB$/ZEY4 V/N, )^$(MD KR HA7L,7J%W4\X1=0B*C$*%'C0K18
MO!GW<AJ<#_)JFR?K 21S@GM9*M>O?_(7W0=X,(:LC8-2LO0](N#Q 3Q2:$)<
M& _35CMCX+VJ*W4H4K?0="BB^P.%3_\%>=D@LTG<:H?ST.D1[&YT&M@-^#(Q
MKP-'INJ8JF<E$)AB^N?>'@MX/O4-HX;_2^/$-P^\MK'<"+!63!([@@+I2;J@
MS)KR7#=IP0>$2P=;W3LJ*C.?BYYYZ<XI.>D^*YX)N3JW&_BKCW]C6*;=PXMR
M7Z@6Z+1-Z]G.HK<^#V/V)A[X.OJD^* *(#.3[WW-6"?'HMH>W2E?-0ZL:-&G
MG<O*!-KG"UQBNP&V3IS]VM^)!+V^6^:-HIISSG$.UQ^]F=HVFQZ,V:2N[;;%
M_O!GOL.-_[Q4G+UV'ZG[KT2;=.@P29SF5(L-K?8N8CC[=M "^ 90PU(IW5M^
MV.O)WV3B$X/EMNT4+1;(6 )63/1&MW_P9T?K9_!#$:&$JNY^OOBA2/F/PA[_
MSBHDJ9X!NI]","^6Z&.!]#-9YX%NGG'-0UA&Y'9Y.G3=:O\XX*%82,SK^Z[J
MHV_V50%'8%6<+BUZL@/@+?3!@S4!!+)(I#&BSN3K'@@:ZU;%'[,XKA\?"W_]
M$>;_( ]%SMW5,GI9X\SR1*)I%TV^N=/<E6%'[]R9F +#3;6;,W47@.3\:B7@
MN"F@_RE=NY0+E<4>T"G3XPD1T6FTW !F'HJJEN35CXS<T>RVWIU5/##QW2BK
M'^])OR2K/$*(6_DJ7]89H%/8\:N<3G0A;P=5LW$T)T,0;CZZGC\47C.L$GR>
M>MDLKZ(T4WJ4RD3EXKP06ERHD#Q7=;5YZZWMF>-* <Y!G-9&B[CEG#07>/YL
M$8[!JK,&^R2A-G#D[\)3/EIW$=W]<I3\U!AY&XUR/":MEB19_]=6^BUWII_X
M'Q5C,[]@7[?;\YL]',1>F@]T$@4(U*IOV-T_G#7&?,]^N""<\2*_*Z:8U!<%
MMK[JZ5:LZ)9>RV*L#+!PZU>7U;0]S['_A-SOE"M(U.4JR,^;I37U5*%R Q"U
M #&$9)=7_YTNXQLY*?MEC_<?L,>*][-I-SKA=8N-1P]%9HZ^\G@SJ:0=I#,+
M(AQCTBG4 !+Z/.,Q2![+ P5;>R$C%S >MZ;7+X>ILK=UI.:T7B1FQU,C.MR1
M53L(OG+8)FJ^<E_A4*1F?>I'AW][H/G;P^R>!.\+TD$9+8BSU' ]R8TK5Q]S
M0@X*S]"+,+;-(P"W$74=UERDD\'-W_ZKQ^/_M_I28XI2+<U.COE>4!R /_FA
ML?0JC3W;"Q\1*+7ZB'O^]?!T6\I?[Y+7)NQ6+7T1#[2=VEKC)J?39KY6?SR/
M/\G YYM]SSKFG S > :B2W)9.Q9#PI0(?%W-ZH;Q]&IHLSJ^(BP>!IECXD)*
M0^"@OM5P\;?9TU^/&D=\_# PK*"FAVO#VG9;-)K*M_GB[DPR83  C+\"993?
M6ZK^MU_W#$/3$MN,3;+ALK2H1$==:E4<8D>YHYL?P):U?/\3K=7[]?9% _\/
M?7H=3\LE;T_I5@=ERKR50*D/WGWS\F?-DP\.=FA&KI:^,2VCK!"Y@-PPW7XW
M'&Y;$6_;_?U$0'3-E;I)K<!S+:64 TNR(- 2=J<4;G: TELQE(FF,8,2Q+1B
M<X(_RYS=?-)MCJ'5P@95VKKD@%A0J4FSP'>U*J6?HPX-MFD6"9W27\-Y8/E.
M49<"B$_D'\?,DDX%R_L,[S^O0,<L0@,WT_=N_!O<Y9";$GT!A5I,3EA(5L9!
MY;XC*Z9IW$,1<_&AXKKFJH\2%T,_[OVC4\=>"&V]8O/X%-#M?G: 8Q^02HZX
M04Q&I)REI?^:+M4^.^.SMABCQ-^Z9X_\C(%)LVD+Y/SM)!=P\T^3Z+>FENO4
MY3G[9)BL@=CCI$1(XH4W68N>0.&N[J+*"]M_2[X.J+4ENJ"%P=69,J\UD%:"
MX'_$^11ZG R5'<8O1H7B57\_36F-E/:7&B(B'KS6@Y+#)+I91R+ ZN8Y,0.F
M5W_D(0!  #$J>L"\?Z]KD4>Y5/(5M*R#'\V.#K&H($FFA-,QA!EQS!1SY%N,
MD<B)#[$U,N53/>7C1RT&BE4?7'UH$E#J6> >1L!;-5-J:_>UO?Z^TO;R5$A,
M1*/2<M@DPLM2Q3DN\/WG36OE"VNP 3"D+ZFK18=J'Z(F:OQT;'7@:@.81J)N
M(GHK4MU3'#%9,<4>^F%7"GLBT=0[(A=#ZOQ.[(>WH-77^U%2SOFI'Y1SLN%H
M/6VZX@UWCF26[JDQT>#+Q@ZF#HXO705>]^S3Z#-TIG-M6/K-8RFJ>>P^)Z=S
MFKC<"@1MOXJJU.=NXA5)Q(J'\2*R'?W&GZ4:B3^F5MY*ZD8TN6I><NFGD%PU
MY$A(JTF^7F@F;[@6%NC\[I25-32(5L:6B2Q/)C([P<OH>PYI<:M6J +7LG<+
M1O'!Z1!.FL"GK? [(Y^D0#3I+BZ=0!V*6+H&NW%NGG U'(V\G_D5UCVR0G-]
M8@EL'OEY<)*62<=&U.&*L<$Z&3<^:F0H XI+!U:4 ^,(JYP6!=$*T<&)2<3&
M?JX P@D%"2MN]XJ$KI[\KKTJUCRC'E1$CD%_G]SP(/\@A@D[JGK%(D*G!O9]
M2'BC119';Y[^_O1R$?Q]:=R >W@K)=[%A\:C'HK<#Q;!G_CB+S5[4G6K$^%D
M&O+.[&RR?'SF ]>CT@QDF"5S(0^J/FS+LS:5KF6OSH4$F<M>QP9K6>JSE<C6
MP09BP1MKABHB17ZG+]BYK5J&L%T+V.[#OY#S"VG(%H!:SS9%P-]#>O440 N/
M-5<>C6S&Z:<OM"GG.+U8T3%5"03%0=# RTGII< _I_V.(NM]+@DN-.K=>E3<
MC/W:<#&7&ABH=N (1WK9#FS8DFP+:@&1O_RS=XV]M&%>&.F20__0!6Q3N4@I
M2GJ;8D8/UK7JX./G'?\^(1K-?EF(K[,,J??Q=WJ89GUA;54N(2XI#'FU8W:X
M%L^([;<MX:8L!>BVE,QAM4?^BA<X'9FN22*7GL\1P)' ' 3G!F&6-?/AZTU9
M^)[>:+GUOPX39'+;:+*JV=:,JR\DIK1*3(\T.#@;0Y\!_/9O^,]UIJ1\L\'2
M.)]"A[G!N=LU-,4;1NL= Y&FV1\E#D4DME"O_(]C2W@36A)KO?[D'#ERT!"(
M62A7T=6/D#2?B)T:;*_WDZ%=^#B[3+U.Y$\:8/-3>]4&H80J]Y$*+C*]H+H8
M]\/3AR*_?O\1/Z)U7X(_>&@9E3:R='4<)?48Z$W(QL%GWX9%\8'*9Q+:HG?+
M)(E!.%.;O@#MA>%ME^%T*'4FN(R_J?+JUPS_K*.>=E.J$JG5T]Z+KCZ@X_D#
M/1UZ2!*%)IS;3#[M]@7=.@],%VM@:"6G2YFV&'@4.'B08-,+JP&7RPN9,SR/
M-)&":]:?8X5GU! XV(060@L?!Z;$K/E <,SB";A+9%H :[?'W6?[H_+ZG$+6
MH8@3J3NOTRM=GZ4/,,E)<N0$A'J=,?[[S^UCBDB2WPKM8@MM-+D\+RT"I0)J
MS$D[\-0[3ZTM&\K?65\HS?]T[5+J@TV'$>,WG["YF6))^G'Q81/HH WGZ%X7
M6AY_[B'YIJR6UD$AQ-KJ U3_B[3;LF>PYD@N3S.E \DJ'/RO;KC_3SKQY84#
M(D(;GW2F<<I>/64&%GMW),_RV-J,^#@#J[[%6/UZ+N BCTR3B0<C(!RA1>;7
MG=NE!K4IS^Q_C4]0IW*8P*<2P14PY?):9$<GJ@JU4>BTQ)<IB+U#J9O8;)WS
M,4HL"NS;=:=9)<ZQ![,X3 ,\ H':^"HY#;K>]6^;;#*9=KS6%5L1?;X4W%O9
MOG&G\ =09%")M0FPL.1S8JKNW_#QEK2'V$^]=W<^6Q$3Y3-B.MIC>6'#'X?^
MQQ?(:B!LFVP!UY/J6V."2NJGR'H[LRRKN9PJVT>44--GKXR2.#[E">O:VN90
M;7>5Y'Q$(@3C. &M(A3?-'3^:;++O,7G#2DBG_WIE:O2N<GMOA G5_4HXC#$
MRD[8;XTE*%I])-SY/>N,TPCT*9]&]=&5VJF.4]'6-'>PV2Z;TB6@]2)>STU
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M81X0K,TUDW+<P7#.H0B10HW=#B<F_9N*__+L%31V^?0 RMC7FQ&ABKL] WQ
MW85.^G0[TK@ W3S$R$<:>K7ANGZ;JS: OU3&O&K8795HTYX)"V2Y0$'AMH\>
MK;+_XJO:G^3-X^"5;?(MYM NB1</6BDTYB08@0:"UE8YV!-U'.25#YZO*]<O
M*R%6F'";ULWR9%T]1V(<V&J(:UOQ<<C3'CH@OQ;6,/:N@JLQY^7F'B%1HJR
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MEEJ_E'G=HR2KM*QZWWU%2[)U+, V3RE;5T<@2Q!0S6V'@@5N=//'GKR?W]Q
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M*_IKWNKPKV>8VG!:OI95ZS!K.J\REQ\7.1H5O!BQV?/T2/4MI'.@8%TWO6]
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MS$P,YDW)/_OJB3E&SK# _#)*&'$7&1CBZBEF:J3B'1>?/_T0<*5%5A%B\7F
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M\1"TF9'^Q"#';&DHV*8^^GEI:;%?\(!CN#\;AG)6G/0EBND3E6T\)\* "@K
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M^H)0O9S>O<F5@,) YFAU$.IZ:M]*8+G9@)90SO#T\(#@$E?9L]2]^ CO7=:
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M5G HS#:5^)MSF>56! ZA!]2'RI78JW%\R3NX$B@$9:'0];!Q(@S1A?WIF).
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M:%8DWZT8ED$Z]"/,!O-:(0B:(*$W"C]>L!A*LM>UNH5'WFJ?L)[O-G95J>P
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M])OOC;"PB;T2<)/.3PZ(IOGULH^-MCW&H5XH-=C5K:DTU6#SE&"TK44A-)Q
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ME&-:E%$@^'*.(%9MZ/*3NP=7[SNO2VI]D=+^<.P)^"T].WRV-/;G'V?/N%]
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MTYP$*)N6F .I1J1K9@"]I*)5=[K0B5'3?(:_I$((^B!PR]L'^4JV9,GTL;'
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MS8$O%V_<?TWW_'IS+G39"(P??3:H4'&OBJ!U7^,$7D,OWK/,D+MA"?3&G;;
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M&T$5X2MCHMCOV88Q"482QH<.ZW3KETO7.C^&#K-"N]J_#C*ZC"#BV@0Y[^;
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M_T&H?M4HQ6LS4 7QGGA:]P\2(.O4!3_6P3?/DE ,MZLG7?6T]JD)I[ADF-(
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M'4=VN!PH3S HZ@DO:A?YQ?Z+'2^(Z:8:UEX;BIE\\I:*D6*;^[R!X<XDF0"
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M_N.2C1:<]^N@[\<2Z !..$)9)UZ;[-_)>'0@M7IX,KOW=[]V+Z[931M/O';
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M9Q<N1N0-B"']L$RD=TE)EFLHP=O]D:<L/>_+_-SIJ0>U+,Q#"K%D]"P$4M*
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M)M:=XU+7();+UZY1/R@?+9B8Q"AN#:1>W)<!"^I>BUVI2S%[E4I#7TS+<B1
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M-*QM7[-S?.U$6@M"AW$5 OP'.5,B7^' )"OIO8U:#KF'>'N0RDP-/J0KG39
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MH/IJHT+/8"$ E 2C903%YZT=FOK#9LD'C1DUK9[;K8[USE(O^23QW['X[4W
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M&U9%1G:WCQ86:<H5TK0_PBMP3"=?$QCH<L"-.WQL3DXGJ6RW'C(]R9TNN]A
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MIEWH=ILQU(]B+]<'V71X\>\>@O_Y'/ASL=[\X(NV.O9ET7RL7:H^* <OR/=
M(#_',VL +98;*R%]\(2#7"+/JO <,<BRSUI#E<>)UM$>R(M=:\K@2\F/M:S-
M\U?.\F(  VD#"T5H=H2CTLG%L4"6%U:9!4>-9;I\!WSQZ_CZBBKM!O3Y,D<&
MD\['15E97A&O!\T!A1% P)]V=AG+J<5$LN?H+SFEWP$+Y[VKF)%3TM%$RN/N
M5F7TI\J, L/>Q5W?#4^\A&.IYMAP +NX>,Y:8X/MX>Z)O=$U?'8.UCFFF2I=
M;ANG?+/;_H"5J=-L)>_+:7%FJYE!OHA:ZAH?+?4[ #C>+5[ %:^6*G1LMW7'
MV+3'T<NZU5$;8'^WA]1Q7=WI"0W53F)"U.S-<W2FPL>2>H]T%@R(DLI%9_'\
MUAE%8R'G<'9*[A5<ZX=@11/N[K"!>1O";Y!EV0@O>4)GB8X[;L+D*EUNZ%M!
MF=,$TPHS)46"?>7D5['4E1/*<RJ1UFQ6>=F[J7=NR)2U3V$?/!RX/J2NHWD"
M#\E1Z7-$Q0H?K<OO6E"$\)PH0K5[%"XWN>[9RSFT%-?#2;=C$@Q\;S2MY;]O
M#IA\- 5X3L77PG3#5X\ABX>[KC\6.GS%GV'OYE-Z/"1@HL0HZ@5;34[ @!SU
MFAR1EPTQ 9^#7J.&#WI2WKXM^FS9#BM-(!YY@[8&NUJ:ZIHH02R56U%O"VWO
ME_)<';*(SX"2X3)35-Y<*)A,TGMXT%,Z4=$=+2 25BLM&_YZQEX^/_0&-U!/
MU=*&N_Y4ZJ!PW;#]VG6=54)<WWGU,]\!><,265TA7P7>W KRD/X.L*RY:4C:
M^S#BI;2=?G';1']^G^;/D)\A/T-^AOSW"*E^>=5+HO9!K&&D5%!C:[.Y.>OQ
MS)?Y@U__[H7_)__U./#G<OU!99.KO>+F#.0&TR=6UX1,$O\@D=5:$-A$FG)5
MUM)=4]:*?U%K+98^X6DS!AE8]U!4[4KB:8#G@;]V6M33'KL$JE)Y,V2Z[O3A
MWU35W CU02E+UIY".W_&>&JE&M]MA.7UHILHM$GW)_]3\Q;=SJS QK7?6E[=
M<.Y.XL?@IO383SGHTNSUW<Y@M?Z<;<_?36^=:UC1$M+"Z00SNY=[9?3RE>O%
MLI8T$MT[0(]S*P?,H86%47PD9H)&IEOLN(DB7BWU0-G_<0M/[R9'6$7SP=A&
MV#0W0=-12GHXOJ/VSOQT7*@3%&)"=+=T99V)=G<3E@M6\!7;-;)YE:IBUI%[
M53R"5(YDX0$- ,!!?\&6_!X8HNW8.5W\,0^L8]J,P*LNS(J/J1,$@:%MG[GP
M#Z7WK/Y)MY=R<$P:Z'F*)$H2UA8_CU"-1;G;C2$;(LCZU.NWB^&CL_6YN4Q;
MCXXK3N&BV\[1]2@0F2),5M*U;V!_E0'@&E.L4U,@T=(Z_8$)JOC[!FDYJF*M
M#$Q.>6Z%4\0_&W707[DE_TNPMDII4Z2D3=[U2R+BIM@L?]/(K [_%>A^W2/S
MMBG6!?J?]1^3@KSA1B\Z]1I>C\4WD=+:5=(ZR]^" /O.E;OXH3TL/>K!8*DM
M9%7^KVJR2D792&>_XLA9>OK[^/\P1 R3QX1>Z[7-I&V_[5J-&'70*&!.3RBN
M1D1$#]K?+WY#QI6$IY//>_(%],II)!KGRG2&OCRY>&0N\6H1<EDK+:''7(K3
M/=IO%&"*OE?)&^/-H*O\S2+.7#@R%ZU<9(\12R-P?WB4=)E9?S-L10NC7E=
M3>AFBD\,G@#^+Z&ZZD_@:V9][#&^FP"_*X6V/*,:FC!A4HJF^NH.Q/_V-UTH
MG5.&/>ZV^N<PJ%"-F"4X'16Y)U, 7Z9;C%VN5--KWS9X(,@X7X-_>=?DY'=
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M2+N.D.20R.S1]6+V)X\Z%UEC,_.IHQGL !!^-BM33^X+SFI>QM-VYS2XI7"
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MV[GIR)#W8Y^8L6VCZ&]J*57+(3)<J:+.P5GA8R8.H:TSOP<I(MQM6PB\(//
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M2$;.Q?' #;#ZTZ(P%-@!GK89WV#=FGN\0!HZNC:UM_F[5_0;LC=I :,#X\G
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M<H:<K[:\)FPEPBG JM=L*#B?WUV:-F3G9&??E7]8/O_H$R^M"^ 4"+HEQ6]
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MB6LIWYBII26Z*..VIP9UDXOO;#'MT>J)M9\E%7W-98.ZX2Z*RI;"E#B-'NV
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M4$L! A0#%     @  *')7 24+.XZB@  #R8# !(              ( ![-T
M &0Q,3$P-CED97@Q,#(X+FAT;5!+ 0(4 Q0    (  "AR5R6I7DLZF(  ($Y
M @ 2              "  59H 0!D,3$Q,#8Y9&5X,3 S,"YH=&U02P$"% ,4
M    "   H<E<,^)UM5<@  #ZC0  $@              @ %PRP$ 9#$Q,3 V
M.61E>#$P,S$N:'1M4$L! A0#%     @  *')7(1,H&%_-0  ^U\! !(
M         ( !]^L! &0Q,3$P-CED97@Q,#,R+FAT;5!+ 0(4 Q0    (  "A
MR5PYI+X3OPP  !E    2              "  :8A @!D,3$Q,#8Y9&5X,3 S
M,RYH=&U02P$"% ,4    "   H<E<2A8^(^M<  #DL@( $@
M@ &5+@( 9#$Q,3 V.61E>#$P,S0N:'1M4$L! A0#%     @  :')7 R6]@]I
M @  :@4  !$              ( !L(L" &0Q,3$P-CED97@R,S$N:'1M4$L!
M A0#%     @  :')7$!XR$R' @  S 4  !$              ( !2(X" &0Q
M,3$P-CED97@R,S(N:'1M4$L! A0#%     @  :')7"%A\A1P!   & P  !$
M             ( !_I " &0Q,3$P-CED97@Y.38N:'1M4$L! A0#%     @
M :')7-"Z_'41< T J+!M  \              ( !G94" &0Q,3$P-CED<S1A
M+FAT;5!+ 0(4 Q0    (  &AR5S3$2Y*RT<  ,NA   1              "
M =L%$ !G,3$Q,#8Y9S P83 Q+FIP9U!+ 0(4 Q0    (  &AR5R=E(,2LU@
M /2N   1              "  =5-$ !G,3$Q,#8Y9S P83 R+FIP9U!+ 0(4
M Q0    (  &AR5P-U%RG,'X  "4" 0 1              "  ;>F$ !G,3$Q
M,#8Y9S P83 S+FIP9U!+ 0(4 Q0    (  &AR5RWJ/! V7 ! "+N 0 1
M          "  18E$0!G,3$Q,#8Y9S P83 T+FIP9U!+ 0(4 Q0    (  &A
MR5PK'RQ)S"<! -&I 0 1              "  1Z6$@!G,3$Q,#8Y9S P83 U
M+FIP9U!+ 0(4 Q0    (  &AR5STL^UQX2L! .NK 0 1              "
M 1F^$P!G,3$Q,#8Y9S P83 V+FIP9U!+ 0(4 Q0    (  &AR5P<T!I*8,@
M *I0 0 1              "  2GJ% !G,3$Q,#8Y9S P83 W+FIP9U!+ 0(4
M Q0    (  &AR5Q.*\V:K4D! /W1 0 1              "  ;BR%0!G,3$Q
M,#8Y9S P83 X+FIP9U!+ 0(4 Q0    (  &AR5SD[:/VMT," '+1 @ 1
M          "  93\%@!G,3$Q,#8Y9S P83 Y+FIP9U!+ 0(4 Q0    (  &A
MR5S&)?L+?^P! ->- @ 1              "  7I &0!G,3$Q,#8Y9S P83$P
M+FIP9U!+ 0(4 Q0    (  &AR5PRW^1K<>8! )MP @ 1              "
M 2@M&P!G,3$Q,#8Y9S P83$Q+FIP9U!+ 0(4 Q0    (  &AR5S(XK@EEDD!
M $OS 0 1              "  <@3'0!G,3$Q,#8Y9S P83$R+FIP9U!+ 0(4
M Q0    (  &AR5R1=:%8B/   (-C 0 1              "  8U='@!G,3$Q
M,#8Y9S P83$S+FIP9U!+ 0(4 Q0    (  &AR5SGU'EX-5\  -V^   1
M          "  41.'P!G,3$Q,#8Y9S P83$T+FIP9U!+ 0(4 Q0    (  &A
MR5R+K)B6ZV$! ,," @ 1              "  :BM'P!G,3$Q,#8Y9S P83$U
M+FIP9U!+ 0(4 Q0    (  &AR5QIUR50\@\!  ^* 0 1              "
M <(/(0!G,3$Q,#8Y9S P83$V+FIP9U!+ 0(4 Q0    (  &AR5P@X/:PN:(#
M ,%@!  1              "  >,?(@!G,3$Q,#8Y9S4U83 Q+FIP9U!+ 0(4
M Q0    (  &AR5P[6\16%DX"  9> P 1              "  <O")0!G,3$Q
M,#8Y9S4U83 R+FIP9U!+ 0(4 Q0    (  &AR5Q:GS%O!&4  &W^   1
M          "  1 1* !G,3$Q,#8Y9S4U83 S+FIP9U!+ 0(4 Q0    (  &A
MR5R(S[+77F\" 'HR P 1              "  4-V* !G,3$Q,#8Y9S4U>C T
M+FIP9U!+ 0(4 Q0    (  &AR5RV]N$T]2,# &Q2!  1              "
M =#E*@!G,3$Q,#8Y9SDY83 Q+FIP9U!+ 0(4 Q0    (  &AR5S@@+31F*0"
M .1#!  1              "  ?0)+@!G,3$Q,#8Y9SDY83 R+FIP9U!+ 0(4
M Q0    (  &AR5Q5CW_=?7,  &A\ 0 1              "  ;NN, !G,3$Q
M,#8Y9SDY83 S+FIP9U!+ 0(4 Q0    (  &AR5R&<L'Q;<$" ,OY P 1
M          "  6<B,0!G,3$Q,#8Y9SDY83 T+FIP9U!+ 0(4 Q0    (  &A
MR5RH[]VN[-H% 'P4!P 1              "  0/D,P!G,3$Q,#8Y9SDY83 U
M+FIP9U!+ 0(4 Q0    (  &AR5QNY?YN6FT" !0/!  1              "
M 1Z_.0!G,3$Q,#8Y9SDY83 V+FIP9U!+ 0(4 Q0    (  &AR5Q,VPW@LW$
M %)\ 0 1              "  :<L/ !G,3$Q,#8Y9SDY83 W+FIP9U!+ 0(4
M Q0    (  &AR5RH"4).<,$" /WY P 1              "  8F>/ !G,3$Q
C,#8Y9SDY83 X+FIP9U!+!08     )P G *4)   H8#\    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>d111069ds4a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001755237="http://www.cyclerion.com/20260331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ck0001755237-20260331.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P08_01_2024To08_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="P05_01_2024To05_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="P07_28_2023To07_28_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2023-07-28</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="P07_22_2024To07_22_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2024-07-22</startDate>
            <endDate>2024-07-22</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn02_04_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2025-02-04</instant>
        </period>
    </context>
    <context id="P05_07_2025To05_07_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_LicenseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_OptionAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PurchaseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ck0001755237:InterestAndOtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:CyclerionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_LicenseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_OptionAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PurchaseAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ck0001755237:InterestAndOtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaMaterialPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:CyclerionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-13</startDate>
            <endDate>2024-12-13</endDate>
        </period>
    </context>
    <context id="P12_01_2025To12_01_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-01</endDate>
        </period>
    </context>
    <context id="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ck0001755237:TisentoTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MinimumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:WeightedAverageInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MinimumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TerminalDeclineRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_TreasuryRateMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TreasuryRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MaximumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:TerminalDeclineRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn07_28_2023_MaximumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ck0001755237:WeightedAverageInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_OptionAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaMaterialPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001755237:TwoThousandTwentyFiveEquityPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="PAsOn05_07_2025_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-07</instant>
        </period>
    </context>
    <context id="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-19</startDate>
            <endDate>2025-09-19</endDate>
        </period>
    </context>
    <context id="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-03</startDate>
            <endDate>2021-06-03</endDate>
        </period>
    </context>
    <context id="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-03</startDate>
            <endDate>2021-06-03</endDate>
        </period>
    </context>
    <context id="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AmendmentAkebiaResearchLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-03</startDate>
            <endDate>2026-01-03</endDate>
        </period>
    </context>
    <context id="P01_03_2026To01_03_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:MedsteerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-03</startDate>
            <endDate>2026-01-03</endDate>
        </period>
    </context>
    <context id="PAsOn01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-06</instant>
        </period>
    </context>
    <context id="P01_06_2026To01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-06</startDate>
            <endDate>2026-01-06</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_OptionAgreementMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ck0001755237:OptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:MedsteerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_PerformanceSharesMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaMaterialPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_SalesAgreementMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001755237:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:PatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2026To03_31_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ck0001755237:AkebiaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesSeedPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001755237:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-01</instant>
        </period>
    </context>
    <context id="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-01</instant>
        </period>
    </context>
    <context id="PAsOn04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-01</instant>
        </period>
    </context>
    <context id="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-01</instant>
        </period>
    </context>
    <context id="P04_01_2026To04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_CyclerionTherapeuticsIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:CyclerionTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="P04_01_2026To04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ck0001755237:KorsanaBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001755237</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="P01_01_2026To03_31_2026" id="hidden167030477">S-4/A</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="P01_01_2026To03_31_2026" id="ixv-59443">0001755237</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="P01_01_2026To03_31_2026" id="ixv-59444">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P01_01_2026To03_31_2026" id="ixv-60769">CYCLERION THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2026To03_31_2026" id="ixv-60770">MA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2026To03_31_2026" id="ixv-60771">2834</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2026To03_31_2026" id="ixv-60772">83-1895370</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2026To03_31_2026" id="ixv-146">245 First Street, 18th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2026To03_31_2026" id="ixv-60773">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2026To03_31_2026" id="ixv-60774">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2026To03_31_2026" id="ixv-60775">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2026To03_31_2026" id="ixv-60776">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2026To03_31_2026" id="ixv-60777">327-8778</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-60778">Regina Graul, Ph.D.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-177">245 First Street, 18th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-60779">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-60780">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-60781">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-60782">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2026To03_31_2026_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-60783">327-8778</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2026To03_31_2026" id="ixv-60784">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2026To03_31_2026" id="ixv-60785">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2026To03_31_2026" id="ixv-60786">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:DefinedContributionPlanTypeExtensibleList contextRef="P01_01_2025To12_31_2025" id="hidden167030863">http://fasb.org/us-gaap/2025#QualifiedPlanMember</us-gaap:DefinedContributionPlanTypeExtensibleList>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60792"
      unitRef="Unit_USD">3240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60793"
      unitRef="Unit_USD">3232000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60794"
      unitRef="Unit_USD">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60795"
      unitRef="Unit_USD">556000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60796"
      unitRef="Unit_USD">384000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60797"
      unitRef="Unit_USD">421000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60798"
      unitRef="Unit_USD">11000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60799"
      unitRef="Unit_USD">16000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60800"
      unitRef="Unit_USD">4635000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60801"
      unitRef="Unit_USD">4225000</us-gaap:AssetsCurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60802"
      unitRef="Unit_USD">5350000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60803"
      unitRef="Unit_USD">5350000</us-gaap:OtherLongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60804"
      unitRef="Unit_USD">9985000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60805"
      unitRef="Unit_USD">9575000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60806"
      unitRef="Unit_USD">508000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60807"
      unitRef="Unit_USD">390000</us-gaap:AccountsPayableCurrent>
    <ck0001755237:AccruedResearchAndDevelopmentCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60808"
      unitRef="Unit_USD">198000</ck0001755237:AccruedResearchAndDevelopmentCurrent>
    <ck0001755237:AccruedResearchAndDevelopmentCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60809"
      unitRef="Unit_USD">52000</ck0001755237:AccruedResearchAndDevelopmentCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60810"
      unitRef="Unit_USD">194000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60811"
      unitRef="Unit_USD">283000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60812"
      unitRef="Unit_USD">900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60813"
      unitRef="Unit_USD">725000</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60814"
      unitRef="Unit_USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60815"
      unitRef="Unit_USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-60816"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-60817"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-60818"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-60819"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-60820"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-60821"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-60822"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-60823"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60824"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60825"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-60826"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-60827"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-60828"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-60829"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-60830"
      unitRef="Unit_shares">3925314</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-60831"
      unitRef="Unit_shares">2710096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-60832"
      unitRef="Unit_shares">3821236</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-60833"
      unitRef="Unit_shares">2545922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60834"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60835"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60836"
      unitRef="Unit_USD">280105000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60837"
      unitRef="Unit_USD">276342000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60838"
      unitRef="Unit_USD">-271020000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60839"
      unitRef="Unit_USD">-267492000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60840"
      unitRef="Unit_USD">9085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60841"
      unitRef="Unit_USD">8850000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60842"
      unitRef="Unit_USD">9985000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60843"
      unitRef="Unit_USD">9575000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_LicenseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-60844"
      unitRef="Unit_USD">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024_LicenseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-60845"
      unitRef="Unit_USD">1750000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_PurchaseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-60846"
      unitRef="Unit_USD">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024_PurchaseAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-60847"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_OptionAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-60848"
      unitRef="Unit_USD">274000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024_OptionAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-60849"
      unitRef="Unit_USD">250000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60850"
      unitRef="Unit_USD">2074000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60851"
      unitRef="Unit_USD">2000000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60852"
      unitRef="Unit_USD">959000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60853"
      unitRef="Unit_USD">286000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60854"
      unitRef="Unit_USD">6088000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60855"
      unitRef="Unit_USD">5342000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60856"
      unitRef="Unit_USD">7047000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60857"
      unitRef="Unit_USD">5628000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60858"
      unitRef="Unit_USD">-4973000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60859"
      unitRef="Unit_USD">-3628000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60860"
      unitRef="Unit_USD">128000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60861"
      unitRef="Unit_USD">208000</us-gaap:OtherNonoperatingIncome>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60862"
      unitRef="Unit_USD">0</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60863"
      unitRef="Unit_USD">363000</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60864"
      unitRef="Unit_USD">1317000</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60865"
      unitRef="Unit_USD">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60866"
      unitRef="Unit_USD">1445000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60867"
      unitRef="Unit_USD">571000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60868"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60869"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-60870"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-60871"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-60872"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-60873"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60874"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60875"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60876"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60877"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60878"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60879"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60880"
      unitRef="Unit_USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60881"
      unitRef="Unit_USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60882"
      unitRef="Unit_USD">-3528000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60883"
      unitRef="Unit_USD">-3063000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60884"
      unitRef="Unit_shares">2474159</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60885"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60886"
      unitRef="Unit_USD">275717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60887"
      unitRef="Unit_USD">-264417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60888"
      unitRef="Unit_USD">-12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-60889"
      unitRef="Unit_USD">11288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60890"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60891"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2024To12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60892"
      unitRef="Unit_shares">71763</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60893"
      unitRef="Unit_USD">625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60894"
      unitRef="Unit_USD">625000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60895"
      unitRef="Unit_USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60896"
      unitRef="Unit_USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment
      contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60897"
      unitRef="Unit_USD">-18000</ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment>
    <ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment
      contextRef="P01_01_2024To12_31_2024_AociIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60898"
      unitRef="Unit_USD">18000</ck0001755237:ReleaseOfForeignCurrencyTranslationAdjustment>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60899"
      unitRef="Unit_shares">2545922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60900"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60901"
      unitRef="Unit_USD">276342000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60902"
      unitRef="Unit_USD">-267492000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60903"
      unitRef="Unit_USD">8850000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare
      contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60904"
      unitRef="Unit_shares">499998</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue
      contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60905"
      unitRef="Unit_USD">1245000</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60906"
      unitRef="Unit_USD">1245000</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60907"
      unitRef="Unit_shares">715220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60908"
      unitRef="Unit_USD">2077000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60909"
      unitRef="Unit_USD">2077000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60910"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60911"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2025To12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60912"
      unitRef="Unit_shares">60096</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2025To12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60913"
      unitRef="Unit_USD">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60914"
      unitRef="Unit_USD">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60915"
      unitRef="Unit_shares">3821236</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-60916"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60917"
      unitRef="Unit_USD">280105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-60918"
      unitRef="Unit_USD">-271020000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60919"
      unitRef="Unit_USD">9085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60920"
      unitRef="Unit_USD">-3528000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60921"
      unitRef="Unit_USD">-3057000</us-gaap:ProfitLoss>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60922"
      unitRef="Unit_USD">0</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <ck0001755237:GainLossFromSettlementOfAccountPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60923"
      unitRef="Unit_USD">363000</ck0001755237:GainLossFromSettlementOfAccountPayable>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60924"
      unitRef="Unit_USD">441000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60925"
      unitRef="Unit_USD">625000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60926"
      unitRef="Unit_USD">444000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60927"
      unitRef="Unit_USD">556000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60928"
      unitRef="Unit_USD">-37000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60929"
      unitRef="Unit_USD">-21000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60930"
      unitRef="Unit_USD">-5000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60931"
      unitRef="Unit_USD">5000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60932"
      unitRef="Unit_USD">118000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60933"
      unitRef="Unit_USD">-445000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60934"
      unitRef="Unit_USD">146000</ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60935"
      unitRef="Unit_USD">-38000</ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60936"
      unitRef="Unit_USD">-89000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60937"
      unitRef="Unit_USD">-515000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60938"
      unitRef="Unit_USD">-3314000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60939"
      unitRef="Unit_USD">-4333000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ck0001755237:ProceedsFromAtTheOffer
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60940"
      unitRef="Unit_USD">2077000</ck0001755237:ProceedsFromAtTheOffer>
    <ck0001755237:ProceedsFromAtTheOffer
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60941"
      unitRef="Unit_USD">0</ck0001755237:ProceedsFromAtTheOffer>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60942"
      unitRef="Unit_USD">1375000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60943"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001755237:IssuanceCostsPaidForPrivatePlacement
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60944"
      unitRef="Unit_USD">-130000</ck0001755237:IssuanceCostsPaidForPrivatePlacement>
    <ck0001755237:IssuanceCostsPaidForPrivatePlacement
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60945"
      unitRef="Unit_USD">0</ck0001755237:IssuanceCostsPaidForPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60946"
      unitRef="Unit_USD">3322000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60947"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60948"
      unitRef="Unit_USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60949"
      unitRef="Unit_USD">-6000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-60950"
      unitRef="Unit_USD">8000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-60951"
      unitRef="Unit_USD">-4339000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60952"
      unitRef="Unit_USD">3232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-60953"
      unitRef="Unit_USD">7571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-60954"
      unitRef="Unit_USD">3240000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-60955"
      unitRef="Unit_USD">3232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-32792"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1. Nature of Business &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Nature of Operations &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Cyclerion Therapeutics, Inc. (&#x201c;Cyclerion&#x201d;, the &#x201c;Company&#x201d; or &#x201c;we&#x201d;) became an independent public company on April&#160;1, 2019 after Ironwood Pharmaceuticals, Inc. completed a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;tax-free&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;spin-off&lt;/div&gt; of their sGC business. Cyclerion has one employee as of December&#160;31, 2025 and also relies on a team of specialist consultants for its operations. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Cyclerion is focused on building a new pipeline of innovative therapeutics to address serious neuropsychiatric diseases. The Company&#x2019;s current strategic focus is centered on the development of a novel therapeutic approach for treatment-resistant depression (&#x201c;TRD&#x201d;), which represents a substantial clinical and commercial opportunity. Over the past year, the Company has refined its strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CYC-126,&lt;/div&gt; an individualized therapy for TRD as its foundational development program. In September 2025, the Company entered into a license agreement with the Massachusetts Institute of Technology (&#x201c;MIT&#x201d;) for intellectual property supporting this program (see Note 11), and in January 2026 entered into a collaboration and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;option-to-license&lt;/div&gt;&lt;/div&gt; agreement with Medsteer SAS (&#x201c;Medsteer&#x201d;) to access certain technology, data assets, and technical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;know-how&lt;/div&gt; related to drug delivery and physiological monitoring. The Company is advancing development planning, regulatory strategy, and commercial positioning for this program and intends to initiate a Phase 2 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;proof-of-concept&lt;/div&gt;&lt;/div&gt; study in Australia in the second half of 2026. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In parallel with the advancement of its neuropsychiatric strategy, Cyclerion continues to evaluate opportunities related to its legacy soluble guanylate cyclase (&#x201c;sGC&#x201d;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions designed to maximize shareholder value. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. (&#x201c;Akebia&#x201d;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a&#160;$3.0 million&#160;upfront payment to the Company upon signing of the license agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&#160;13, 2024, Cyclerion announced that Cyclerion and Akebia have &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-negotiated&lt;/div&gt; a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator.&#160;Under this new license amendment, Cyclerion will receive&#160;$1.75 million&#160;in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was received in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated (defined as first patient dosed) Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis&#160;(&#x201c;FSGS&#x201d;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to us and it was received in February 2026. The Company is eligible to receive additional milestone cash payments of up to approximately&#160;$557.5 million&#160;in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher-tiered sales-based royalties ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single-digits&lt;/div&gt; to twenty percent. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#x201c;Option Agreement&#x201d;) with a third party (the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;Optionee&#x201d;), pursuant to which the Optionee had an option (the &#x201c;Option&#x201d;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company is currently exploring potential license opportunities for olinciguat. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Zagociguat is a clinical-stage &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CNS-penetrant&lt;/div&gt; sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CNS-targeted&lt;/div&gt; sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. On July&#160;28, 2023, the Company sold &lt;div style="display:inline;"&gt;z&lt;/div&gt;agociguat and CY3018 to Tisento Therapeutics, Inc. (&#x201c;Tisento&#x201d;), a newly formed private company focused on their development, in exchange for $8.0&#160;million in cash consideration, $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and 10% of all of Tisento&#x2019;s parent&#x2019;s outstanding equity securities (&#x201c;Tisento Parent&#x201d;). &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Cyclerion GmbH, a wholly owned subsidiary, was incorporated in Zug, Switzerland on May&#160;3, 2019. The functional currency is the Swiss franc. Cyclerion GmbH was liquidated and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;de-registered&lt;/div&gt; in May 2024. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cyclerion Securities Corporation, a wholly owned subsidiary, was incorporated in Massachusetts on November&#160;15, 2019 and was granted securities corporation status in Massachusetts. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In March 2023, the Company entered into a stock purchase agreement with the Company&#x2019;s former Chief Executive Officer (the &#x201c;CEO&#x201d;) pursuant to which he invested $5&#160;million in cash for 225,000 shares of common stock and 351,037 shares of Series A Convertible Preferred Stock of the Company at a price of $8.68 per share (after giving effect to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;1-for-20&lt;/div&gt;&lt;/div&gt; reverse stock split the Company implemented on May&#160;15, 2023). The Series A Convertible Preferred Stock is convertible into shares of the Company&#x2019;s common stock on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;one-to-one&lt;/div&gt;&lt;/div&gt; basis. The closing of the equity investment took place on May&#160;19, 2023, and (to comply with Nasdaq listing requirements) the Company&#x2019;s shareholders approved such convertibility on July&#160;19, 2023. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2025 Equity Private Placement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On March&#160;21, 2025, the Company entered into a Stock Purchase Agreement (the &#x201c;2025 Equity Private Placement&#x201d;) for a private placement of 499,998 shares of the Company&#x2019;s common stock, at a purchase price of $2.75 per share for total gross proceeds of approximately $1.375&#160;million. The closing of the 2025 Equity Private Placement occurred on March&#160;25, 2025. The Company incurred transaction costs of $0.1&#160;million for the 2025 Equity Private Placement. The Shares issued were not registered under the Securities Act of 1933, as amended, or any state securities laws and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act as a transaction not involving a public offering. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the 2025 Equity Private Placement, the Company entered into a Registration Rights Agreement with the investors, dated March&#160;21, 2025, pursuant to which the Company agreed to register the resale of the Shares pursuant to a registration statement which was filed with the SEC and declared effective by the SEC on May&#160;15, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;At-the-Market&lt;/div&gt;&lt;/div&gt; Offering &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On February&#160;4, 2025, the Company filed a Registration Statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt; (the &#x201c;Shelf&#x201d;) with the Securities and Exchange &lt;div style="display:inline;"&gt;Commission&lt;/div&gt; (the &#x201c;SEC&#x201d;) in relation to the registration of common stock, preferred &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $25.0&#160;million.&#160;The Registration Statement was declared effective by the SEC in February 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On May&#160;7, 2025, the Company and Guggenheim Securities, LLC (&#x201c;Guggenheim Securities&#x201d;) entered into a Sales Agreement (the &#x201c;Sales Agreement&#x201d;), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the &#x201c;Shares&#x201d;), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company&#x2019;s agent, subject to the application of General Instruction I.B.6 of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Form&#160;S-3&#160;(&#x201c;Instruction&lt;/div&gt; I.B.6&#x201d;) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company will pay Guggenheim Securities cash commission of 3.0% of the gross proceeds of the Shares sold under the Sales Agreement. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2025, the Company sold 715,220 shares of its common stock for net proceeds of $2.1&#160;million under the Sales Agreement, after deducting commissions paid to Guggenheim Securities of $0.1&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#x2019;s financial position and the results of its operations for the fiscal years presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation and Cyclerion GmbH which was dissolved in May 2024. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At each reporting period, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company&#x2019;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#x2019;s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;205-40,&lt;/div&gt; the future receipt of potential funding from future partnerships, equity or debt issuances, certain cost reduction measures and the potential milestones from the Akebia agreement cannot be considered probable at this time because these plans are not entirely within the Company&#x2019;s control and/or have not been approved by the Board of Directors as of the date of these consolidated financial statements. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company expects that its cash and cash equivalents as of December&#160;31, 2025, will be sufficient to fund operations through &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-2026,&lt;/div&gt; however the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;have &lt;/div&gt;been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-60956"
      unitRef="Unit_USD">3000000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-60957"
      unitRef="Unit_USD">1750000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-60958"
      unitRef="Unit_USD">1250000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:RemainingAdditionalUpFrontPayment
      contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-60959"
      unitRef="Unit_USD">500000</ck0001755237:RemainingAdditionalUpFrontPayment>
    <ck0001755237:DevelopmentMilestonePayment
      contextRef="P12_01_2025To12_01_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-60960"
      unitRef="Unit_USD">1000000</ck0001755237:DevelopmentMilestonePayment>
    <ck0001755237:PaymentOfCashMilestone
      contextRef="P01_01_2025To12_31_2025_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-60961"
      unitRef="Unit_USD">557500000</ck0001755237:PaymentOfCashMilestone>
    <ck0001755237:OptionFee
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-60963"
      unitRef="Unit_USD">150000</ck0001755237:OptionFee>
    <ck0001755237:SubsequentFees
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-60964"
      unitRef="Unit_USD">80000</ck0001755237:SubsequentFees>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-60965"
      unitRef="Unit_USD">8000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:OperatingExpenses
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-60966"
      unitRef="Unit_USD">2400000</us-gaap:OperatingExpenses>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      id="ixv-60967"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="PAsOn03_31_2023"
      decimals="-6"
      id="ixv-60968"
      unitRef="Unit_USD">5000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-60969"
      unitRef="Unit_shares">225000</us-gaap:SharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-60970"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-60971"
      unitRef="Unit_USD_per_Share">8.68</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-60972"
      unitRef="Unit_shares">499998</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-60973"
      unitRef="Unit_USD_per_Share">2.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-60974"
      unitRef="Unit_USD">1375000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001755237:TransactionCostsSaleOfTransferredAssets
      contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-60975"
      unitRef="Unit_USD">100000</ck0001755237:TransactionCostsSaleOfTransferredAssets>
    <ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice
      contextRef="PAsOn02_04_2025"
      decimals="-5"
      id="ixv-60976"
      unitRef="Unit_USD">25000000</ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice>
    <ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice
      contextRef="PAsOn05_07_2025_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-60977"
      unitRef="Unit_USD">20000000</ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice>
    <ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock
      contextRef="P05_07_2025To05_07_2025"
      decimals="3"
      id="ixv-60978"
      unitRef="Unit_pure">0.03</ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-60979"
      unitRef="Unit_shares">715220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-60980"
      unitRef="Unit_USD">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-60981"
      unitRef="Unit_USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-32892"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#x2019;s financial position and the results of its operations for the fiscal years presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation and Cyclerion GmbH which was dissolved in May 2024. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-32926"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.&#160;The Company&#x2019;s president and chief executive officer, who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews the Company&#x2019;s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews net loss, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-operating&lt;/div&gt; expenses and operating expenses excluding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cash&lt;/div&gt; stock based compensation expense. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Variable Interest Entities &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii)&#160;the parties&#x2019; contractual rights and responsibilities pursuant to any contractual agreements and (iii)&#160;which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements at the time that determination is made. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Investment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for an identical or a similar investment of the same issuer, the Company will measure the equity security at fair value as of the date that the observable transaction occurred in accordance with ASC Topic 321, Investments-Equity Securities. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of consolidated financial statements in accordance with U.S. generally accepted &lt;div style="display:inline;"&gt;accounting&lt;/div&gt; principles (&#x201c;GAAP&#x201d;) requires the Company&#x2019;s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period &lt;div style="display:inline;"&gt;in&lt;/div&gt; which they become known. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair Value of Investment Instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1 &#x2014; Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2 &#x2014; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3 &#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign Currency Translation Adjustment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The functional currency of the Company&#x2019;s former foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company&#x2019;s former foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company&#x2019;s former foreign subsidiary was included as a foreign currency translation adjustment in the consolidated statements of stockholders&#x2019; equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measurement&lt;/div&gt; of intercompany balances are recorded in the consolidated statements of operations. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;significant outstanding invoices. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had &lt;div style="display:inline;"&gt;significant&lt;/div&gt; write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December&#160;31, 2025 or 2024. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 606&#x201d;), it performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1)&#160;license agreement, (2)&#160;purchase agreement and (3)&#160;option to license agreement which are fully described in Note 11, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License and Option Agreement&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and Administrative Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel and outside consultants providing the Company&#x2019;s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company&#x2019;s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company is primarily subject to U.S. Federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;more-likely-than-not&#x201d;&lt;/div&gt; of being sustained by the applicable tax authority. Tax positions not deemed to meet a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion&#x2019;s income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December&#160;31, 2025, and 2024. The Company&#x2019;s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December&#160;31, 2025 and 2024, the Company has no accruals for interest or penalties related to income tax matters. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $0.3&#160;million and $0.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Interest and Other Income, Net &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the year ended December&#160;31, 2025 and 2024, interest and other income, net consisted of a $0.1&#160;million and $0.2&#160;million of interest income related to interest generated from the Company&#x2019;s cash and cash equivalents balances, respectively. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company considers events or transactions that have occurred after the balance sheet date of December&#160;31, 2025, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K.&lt;/div&gt; See Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December&#160;31, 2025 and 2024, that had a material effect on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2025, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2025-05,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326), which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with its annual report for fiscal 2027. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with its annual report for fiscal 2025 and interim periods thereafter on a retrospective basis. The adoption did not have a material effect on the consolidated financial statements. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09,&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09&lt;/div&gt; requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than PBEs, the requirements will be effective for annual periods beginning after December&#160;15, 2025. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December&#160;31, 2025 and continuing to provide the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-ASU&lt;/div&gt; disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December&#160;31, 2025, the Company adopted this new ASU and it only impacts the Company&#x2019;s income tax disclosures with no impact to its operations, cash flows, or financial condition. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-32929"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.&#160;The Company&#x2019;s president and chief executive officer, who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews the Company&#x2019;s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews net loss, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-operating&lt;/div&gt; expenses and operating expenses excluding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cash&lt;/div&gt; stock based compensation expense. &lt;/div&gt; </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="P01_01_2025To12_31_2025" id="ixv-32935"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Variable Interest Entities &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance, (ii)&#160;the parties&#x2019; contractual rights and responsibilities pursuant to any contractual agreements and (iii)&#160;which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements at the time that determination is made. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made. &lt;/div&gt;&lt;/div&gt; </us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-32940"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Investment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for an identical or a similar investment of the same issuer, the Company will measure the equity security at fair value as of the date that the observable transaction occurred in accordance with ASC Topic 321, Investments-Equity Securities. &lt;/div&gt;&lt;/div&gt; </us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2025To12_31_2025" id="ixv-32945"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The preparation of consolidated financial statements in accordance with U.S. generally accepted &lt;div style="display:inline;"&gt;accounting&lt;/div&gt; principles (&#x201c;GAAP&#x201d;) requires the Company&#x2019;s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period &lt;div style="display:inline;"&gt;in&lt;/div&gt; which they become known. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-32974"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value. &lt;/div&gt;&lt;/div&gt; </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2025To12_31_2025" id="ixv-32979"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair Value of Investment Instruments &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1 &#x2014; Quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2 &#x2014; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; text-align: left; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: top;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3 &#x2014; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33017"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign Currency Translation Adjustment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The functional currency of the Company&#x2019;s former foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company&#x2019;s former foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company&#x2019;s former foreign subsidiary was included as a foreign currency translation adjustment in the consolidated statements of stockholders&#x2019; equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measurement&lt;/div&gt; of intercompany balances are recorded in the consolidated statements of operations. &lt;/div&gt; </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <ck0001755237:RelatedPartyAccountsReceivablePolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33024"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;significant outstanding invoices. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had &lt;div style="display:inline;"&gt;significant&lt;/div&gt; write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December&#160;31, 2025 or 2024. &lt;/div&gt;&lt;/div&gt;</ck0001755237:RelatedPartyAccountsReceivablePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33052"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 606&#x201d;), it performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1)&#160;license agreement, (2)&#160;purchase agreement and (3)&#160;option to license agreement which are fully described in Note 11, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License and Option Agreement&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2025To12_31_2025" id="ixv-33060"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses. &lt;/div&gt;&lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33067"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and Administrative Expenses &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel and outside consultants providing the Company&#x2019;s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company&#x2019;s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. &lt;/div&gt;&lt;/div&gt; </us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33072"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company is primarily subject to U.S. Federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;more-likely-than-not&#x201d;&lt;/div&gt; of being sustained by the applicable tax authority. Tax positions not deemed to meet a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;more-likely-than-not&lt;/div&gt; threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion&#x2019;s income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December&#160;31, 2025, and 2024. The Company&#x2019;s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December&#160;31, 2025 and 2024, the Company has no accruals for interest or penalties related to income tax matters. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2024"
      decimals="-6"
      id="ixv-60986"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2025"
      decimals="-6"
      id="ixv-60987"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <ck0001755237:PatentCostsPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33102"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $0.3&#160;million and $0.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;/div&gt; </ck0001755237:PatentCostsPolicyTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2025To12_31_2025_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      id="ixv-60988"
      unitRef="Unit_USD">300000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2024To12_31_2024_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      id="ixv-60989"
      unitRef="Unit_USD">600000</us-gaap:ProfessionalFees>
    <ck0001755237:InterestAndOtherIncomePolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33107"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Interest and Other Income, Net &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the year ended December&#160;31, 2025 and 2024, interest and other income, net consisted of a $0.1&#160;million and $0.2&#160;million of interest income related to interest generated from the Company&#x2019;s cash and cash equivalents balances, respectively. &lt;/div&gt;&lt;/div&gt; </ck0001755237:InterestAndOtherIncomePolicyPolicyTextBlock>
    <us-gaap:InterestAndOtherIncome
      contextRef="P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-60990"
      unitRef="Unit_USD">100000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="P01_01_2024To12_31_2024_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-60991"
      unitRef="Unit_USD">200000</us-gaap:InterestAndOtherIncome>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33112"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company considers events or transactions that have occurred after the balance sheet date of December&#160;31, 2025, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K.&lt;/div&gt; See Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt; </us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33119"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December&#160;31, 2025 and 2024, that had a material effect on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2025, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2025-05,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326), which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with its annual report for fiscal 2027. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-07,&lt;/div&gt; Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with its annual report for fiscal 2025 and interim periods thereafter on a retrospective basis. The adoption did not have a material effect on the consolidated financial statements. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09,&lt;/div&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2023-09&lt;/div&gt; requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than PBEs, the requirements will be effective for annual periods beginning after December&#160;15, 2025. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December&#160;31, 2025 and continuing to provide the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-ASU&lt;/div&gt; disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December&#160;31, 2025, the Company adopted this new ASU and it only impacts the Company&#x2019;s income tax disclosures with no impact to its operations, cash flows, or financial condition. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#x2019;s consolidated financial statements upon adoption. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33156"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3. Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December&#160;31, 2025 and December&#160;31, 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2024:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2025 and 2024, there were no transfers between levels. The fair value of the Company&#x2019;s cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company believes the carrying amounts of its accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair value due to the &lt;div style="display:inline;"&gt;short-term &lt;/div&gt;nature of these amounts. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33159"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December&#160;31, 2025 and December&#160;31, 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 60%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2024:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;3,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-60993"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-60994"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-60995"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-60996"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-60997"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-60998"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-60999"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2024_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-61000"
      unitRef="Unit_USD">3025000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33528"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;4. Other Investment &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On July&#160;28, 2023, the Company closed the transactions contemplated by the Asset Purchase Agreement receiving proceeds of $8.0&#160;million as cash consideration, approximately $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 programs for the period between signing and closing of the transaction, and 10% of all of Tisento Parent&#x2019;s outstanding equity securities which fair value was determined to be $5.3&#160;million at the time of closing. The Company&#x2019;s investment in Tisento Parent does not provide it with significant influence over Tisento Parent. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company has determined that the Company&#x2019;s investment in Tisento Parent is an equity security, whereby such investment does not give the Company a controlling financial interest or significant influence over the investee.&#160;Further, the Company assessed the accounting for its investment in Tisento Parent in accordance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;with&#160;ASC&#160;810-10,&#160;Consolidation&#x2014;Overall.&#160;After&lt;/div&gt; determining that no scope exception applies under the guidance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;of&#160;ASC&#160;810-10-15-12&#160;and&#160;ASC&#160;810-10-15-17,&#160;the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; Company&#160;concluded that it has a variable interest in Tisento Parent through its investment in Tisento Parent common stock. Tisento Parent does not have sufficient equity to finance its activities without additional subordinated financial support as Tisento Parent is a startup entity in its early stages of raising funds and will require significant capital to advance its programs to commercial stage. Therefore, the Company concluded that its investment in Tisento Parent is a variable interest entity (&#x201c;VIE&#x201d;) in accordance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;with&#160;ASC&#160;810-10-15-14(a)&#160;and&#160;is&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; subject to potential consolidation under the VIE model. However, all activities that most significantly impact Tisento Parent and its subsidiary&#x2019;s economic performance are directed by the Tisento Parent board and the board approves decisions by a simple majority. Based on the board composition, the Company determined that no one party has control over the Tisento Parent board and power is not shared because the activities that most significantly affect Tisento Parent and its subsidiary&#x2019;s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Tisento Parent board. Therefore, because the Company controls no director of Tisento Parent, the Company cannot unilaterally direct any of the activities that most significantly impact Tisento Parent and its subsidiary&#x2019;s economic performance. Accordingly, the Company does not hold a controlling financial interest in Tisento Parent. Because both criteria (a)&#160;and (b)&#160;above have to be met for the application of the guidance &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in&#160;ASC&#160;810-10-25-44B&#160;and&#160;criteria&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; (a)&#160;has not been met, The Company concluded that it should not consolidate Tisento under the VIE model. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Accordingly, the Company has accounted for the investment as a financial instrument without a readily determinable fair value. Such investment is recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment is measured at cost less any impairment recorded or adjustments for observable price changes. An impairment loss is recognized in the consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of December&#160;31, 2025, no impairment loss was recognized. The Company considers the cost of the investment to be the maximum exposure to loss as a result of its involvement with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-affiliated&lt;/div&gt; entity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The initial fair value of the investment in Tisento Parent was determined by reference to the risk-adjusted net assets value using the discounted cash flow method. The estimated net assets value of Tisento Parent includes the cash generated/used from the operations and the proceeds from equity financing. Valuations were derived by reference to observable valuation measures for comparable companies or transactions, including weighted &lt;div style="display:inline;"&gt;average&lt;/div&gt; cost of capital (21% to 23%), terminal decline rate (25% to 75%) and the discount rate referenced by a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-year&lt;/div&gt; treasury rate of 4.01%. &lt;/div&gt; </us-gaap:InvestmentTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-61002"
      unitRef="Unit_USD">8000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:OperatingExpenses
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-61003"
      unitRef="Unit_USD">2400000</us-gaap:OperatingExpenses>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      id="ixv-61004"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ck0001755237:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1
      contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="-5"
      id="ixv-61005"
      unitRef="Unit_USD">5300000</ck0001755237:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61006"
      unitRef="Unit_USD">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MinimumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-61007"
      unitRef="Unit_pure">0.21</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MaximumMembersrtRangeAxis_WeightedAverageInvestmentMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-61008"
      unitRef="Unit_pure">0.23</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MinimumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-61009"
      unitRef="Unit_pure">0.25</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_MaximumMembersrtRangeAxis_TerminalDeclineRateMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-61010"
      unitRef="Unit_pure">0.75</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="PAsOn07_28_2023_TreasuryRateMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-61011"
      unitRef="Unit_pure">0.0401</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33563"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;5. Accrued Expenses and Other Current Liabilities &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33566"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 66%;"&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;143&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61012"
      unitRef="Unit_USD">143000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61013"
      unitRef="Unit_USD">220000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61014"
      unitRef="Unit_USD">13000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61015"
      unitRef="Unit_USD">33000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61016"
      unitRef="Unit_USD">38000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61017"
      unitRef="Unit_USD">30000</us-gaap:OtherSundryLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61018"
      unitRef="Unit_USD">194000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61019"
      unitRef="Unit_USD">283000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33691"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Funding Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company may enter into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company&#x2019;s option and do not have any significant cancellation penalties. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Guarantees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#x2019;s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December&#160;31, 2025 or December&#160;31, 2024. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Separation Benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As part of the separation benefit of the former Chief Financial Officer, the Company paid $0.1&#160;million each in May 2024 and August 2024. The Company has no further separation benefits obligation as of December&#160;31, 2025 and 2024. &lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-61020"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2025"
      decimals="0"
      id="ixv-61021"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SeveranceCosts1
      contextRef="P08_01_2024To08_31_2024"
      decimals="-5"
      id="ixv-61022"
      unitRef="Unit_USD">100000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="P05_01_2024To05_31_2024"
      decimals="-5"
      id="ixv-61023"
      unitRef="Unit_USD">100000</us-gaap:SeveranceCosts1>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-61024"
      unitRef="Unit_USD">0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61025"
      unitRef="Unit_USD">0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33711"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;7. Share-based Compensation Plans &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (&#x201c;2019 ESPP&#x201d;) and the 2019 Equity Incentive Plan (&#x201c;2019 Equity Plan&#x201d;). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options, restricted stock awards (&#x201c;RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cyclerion also mirrored two of Ironwood Pharmaceuticals, Inc. (&#x201c;Ironwood&#x201d;) existing plans, the &lt;div style="display:inline;"&gt;Amended&lt;/div&gt; and Restated 2005 Stock Incentive Plan (&#x201c;2005 Equity Plan&#x201d;) and the Amended and Restated 2010 Employee, &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Director and Consultant Equity Incentive Plan (&#x201c;2010 Equity Plan&#x201d;). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pro-rata&lt;/div&gt; share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table provides share-based compensation reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;534&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Stock options granted under the Company&#x2019;s equity plans generally have a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ten-year&lt;/div&gt; term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of stock option activity for the year ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Average&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&lt;br/&gt; thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;158.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(62,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;140.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;149.73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;232,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;187.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the years ended December&#160;31, 2025 and 2024, the Company granted stock options to purchase an aggregate of 25,000 shares and 55,849 shares, respectively, at weighted average grant date fair values per option share of $2.14 and $2.80 respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;There were no options exercised during the year ended December&#160;31, 2025 and 2024. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options held by the Company&#x2019;s employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employees&lt;/div&gt; is $0.1&#160;million and the weighted average period over which that expense is expected to be recognized is 3.03 years. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion during the years ended December&#160;31, 2025 and 2024 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected option term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;141.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;111.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;For the years ended December&#160;31, 2025 and 2024, expected volatility was estimated using an average of the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has granted certain employees performance-based options to purchase shares of common stock. These options are subject to performance-based milestone vesting. During the year ended December&#160;31, 2025 and 2024, there were no shares that vested as a result of performance milestone achievements. No&#160;share-based compensation expense related to these performance-based options was recognized during the years ended December&#160;31, 2025, and 2024, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted Stock Awards &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No RSA was granted during the year ended December&#160;31, 2025. The Company granted 65,000&#160;RSAs during the year ended December&#160;31, 2024. The fair value of all RSAs is based on the market value of the Company&#x2019;s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of RSA activity for the years ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(60,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested RSAs held by the Company&#x2019;s directors is $0.2&#160;million and the weighted average period over which that expense is expected to be recognized is 1.69 years. &lt;/div&gt;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33740"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table provides share-based compensation reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 82%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;29&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;91&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;534&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;625&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61027"
      unitRef="Unit_USD">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61028"
      unitRef="Unit_USD">91000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61029"
      unitRef="Unit_USD">412000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61030"
      unitRef="Unit_USD">534000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61031"
      unitRef="Unit_USD">441000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61032"
      unitRef="Unit_USD">625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-33851"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of stock option activity for the year ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Average&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&lt;br/&gt; thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;158.98&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;25,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(62,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;140.44&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;149.73&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;232,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;187.20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;4.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61033"
      unitRef="Unit_shares">335448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61034"
      unitRef="Unit_USD_per_Share">158.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61035">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61036"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61037"
      unitRef="Unit_shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61038"
      unitRef="Unit_USD_per_Share">2.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61039"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61040"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61041"
      unitRef="Unit_shares">62686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61042"
      unitRef="Unit_USD_per_Share">140.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61043"
      unitRef="Unit_shares">297762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61044"
      unitRef="Unit_USD_per_Share">149.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61045">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61046"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61047"
      unitRef="Unit_shares">232385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61048"
      unitRef="Unit_USD_per_Share">187.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61049">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61050"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61051"
      unitRef="Unit_shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61052"
      unitRef="Unit_shares">55849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61053"
      unitRef="Unit_USD_per_Share">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61054"
      unitRef="Unit_USD_per_Share">2.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-6"
      id="ixv-61055"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-6"
      id="ixv-61056"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-61057"
      unitRef="Unit_USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61058">P3Y10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-34155"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion during the years ended December&#160;31, 2025 and 2024 were as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 77%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.79&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected option term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;5.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;141.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;111.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="4"
      id="ixv-61060"
      unitRef="Unit_pure">0.0379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-61061"
      unitRef="Unit_pure">0.0364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="-2"
      id="ixv-61062"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="-2"
      id="ixv-61063"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2025To12_31_2025" id="ixv-61064">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-61065">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="4"
      id="ixv-61066"
      unitRef="Unit_pure">1.4107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-61067"
      unitRef="Unit_pure">1.1197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61068"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61069"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <ck0001755237:ShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61070"
      unitRef="Unit_USD">0</ck0001755237:ShareBasedCompensationExpense>
    <ck0001755237:ShareBasedCompensationExpense
      contextRef="P01_01_2025To12_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61071"
      unitRef="Unit_USD">0</ck0001755237:ShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61072"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61073"
      unitRef="Unit_shares">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-34247"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of RSA activity for the years ended December&#160;31, 2025 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(60,096&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2.57&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61074"
      unitRef="Unit_shares">164174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61075"
      unitRef="Unit_USD_per_Share">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61076"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61077"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61078"
      unitRef="Unit_shares">60096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61079"
      unitRef="Unit_USD_per_Share">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61080"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61081"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61082"
      unitRef="Unit_shares">104078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61083"
      unitRef="Unit_USD_per_Share">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-61084"
      unitRef="Unit_USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2025To12_31_2025_DirectorMembersrtTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      id="ixv-61085">P1Y8M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-34388"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8. Loss per share &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,057&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average shares used in calculating net loss per share &#x2014; basic and diluted (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,518&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share &#x2014; basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company excludes potential shares of common stock related to Preferred Stock, stock options and RSAs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. The following table sets forth potential shares that were considered anti-dilutive for the years ended December&#160;31, 2025 and 2024: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;RSAs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;752,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;850,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-34391"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,057&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average shares used in calculating net loss per share &#x2014; basic and diluted (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3,181&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;2,518&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share &#x2014; basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61086"
      unitRef="Unit_USD">-3528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61087"
      unitRef="Unit_USD">-3057000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61088"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61089"
      unitRef="Unit_shares">3181000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61090"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61091"
      unitRef="Unit_shares">2518000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-61092"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To12_31_2025"
      decimals="2"
      id="ixv-61093"
      unitRef="Unit_USD_per_Share">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-61094"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-61095"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-61096">The following table sets forth potential shares that were considered anti-dilutive for the years ended December&#160;31, 2025 and 2024: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;351,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;297,762&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;335,448&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;RSAs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;104,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;164,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;752,877&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;850,659&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-61097"
      unitRef="Unit_shares">351037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-61098"
      unitRef="Unit_shares">351037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To12_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61099"
      unitRef="Unit_USD">297762000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61100"
      unitRef="Unit_USD">335448000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To12_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61101"
      unitRef="Unit_USD">104078000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61102"
      unitRef="Unit_USD">164174000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61103"
      unitRef="Unit_USD">752877000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61104"
      unitRef="Unit_USD">850659000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-34642"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9. Income Taxes &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of net income (loss) before income tax expense are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows after adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on a retrospective basis&#160;(in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pretax loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;US Federal Statutory Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign tax effects&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-deductible&lt;/div&gt; items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;571&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-16.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-2.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-4.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-18.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s effective tax rate differs from the statutory rate primarily due to continued losses and the maintenance of a full valuation allowance on deferred tax assets, resulting in zero income tax expense for the period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets (liabilities) consist of the following as of December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;57,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;53,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Capitalized research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has evaluated the positive and negative evidence bearing upon the possible realization of its deferred tax assets. Management has considered the Company&#x2019;s history of operating losses, in addition to the expected timing of the reversal of existing temporary differences and concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company will not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved at December&#160;31, 2025 and December&#160;31, 2024. Management reevaluates the positive and negative evidence on a quarterly basis. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The valuation allowance increased by approximately $0.2&#160;million during the year ended December&#160;31, 2025 primarily due to increases in capitalized research and development expenses, net operating losses, tax credit carryforwards and deferred tax assets related to share-based compensation. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;At December&#160;31, 2025 and 2024, Cyclerion has federal net operating loss carryforwards of approximately $211&#160;million and $195&#160;million, respectively, to offset future federal taxable income that will be carried forward indefinitely until utilized. As of December&#160;31, 2025 and 2024, Cyclerion had state net operating loss carryforwards of approximately $212&#160;million and $196&#160;million, respectively, to offset future state taxable income, which will begin to expire in 2039 and will continue to expire through 2045. Cyclerion also had tax credit carryforwards of approximately $10.8&#160;million as of December&#160;31, 2025, to offset future federal and state income taxes. Federal credits begin to expire in 2039 and will continue to expire through 2044. State credits begin to expire in 2034 and continue through 2039. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s ability to use its operating loss carryforwards and tax credits to offset future taxable income could be subject to restrictions under Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (the &#x201c;Internal Revenue Code&#x201d;). These potential restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Changes in stock ownership may occur that would create these limitations on the Company&#x2019;s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has not as yet conducted a study of its research and development credit carry forwards. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are &lt;div style="display:inline;"&gt;being&lt;/div&gt; presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits, &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="margin-top: 1em; margin-bottom: 1em"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Upon audit, taxing authorities may challenge all or part of an uncertain income tax position. While Cyclerion has no history of tax audits since its inception on a standalone basis, it may be subject to tax audits by federal and state taxing authorities in the future. Accordingly, Cyclerion regularly assesses the outcome of potential examinations in each of the taxing jurisdictions when determining the adequacy of the amount of unrecognized tax benefit recorded. Cyclerion had no unrecognized tax benefits as of December&#160;31, 2025 and 2024. Cyclerion will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December&#160;31, 2025 and 2024, no interest or penalties have been accrued. There are no current federal or state income tax audits in progress. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-34645"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The components of net income (loss) before income tax expense are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61105"
      unitRef="Unit_USD">-3528000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61106"
      unitRef="Unit_USD">-3061000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61107"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61108"
      unitRef="Unit_USD">3000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61109"
      unitRef="Unit_USD">-3528000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61110"
      unitRef="Unit_USD">-3058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-34753"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows after adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09&lt;/div&gt; on a retrospective basis&#160;(in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Percent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pretax loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,528&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(3,058&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;US Federal Statutory Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(741&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Foreign tax effects&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-deductible&lt;/div&gt; items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;571&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-16.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-2.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-4.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;-18.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61111"
      unitRef="Unit_USD">-3528000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61112"
      unitRef="Unit_USD">-3058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61113"
      unitRef="Unit_USD">-741000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-61114"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61115"
      unitRef="Unit_USD">-642000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-61116"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61117"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2025To12_31_2025"
      decimals="-2"
      id="ixv-61118"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61119"
      unitRef="Unit_USD">-1000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-61120"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61121"
      unitRef="Unit_USD">571000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-61122"
      unitRef="Unit_pure">-0.162</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61123"
      unitRef="Unit_USD">88000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-61124"
      unitRef="Unit_pure">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61125"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2025To12_31_2025"
      decimals="-2"
      id="ixv-61126"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61127"
      unitRef="Unit_USD">11000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-61128"
      unitRef="Unit_pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61129"
      unitRef="Unit_USD">170000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-61130"
      unitRef="Unit_pure">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61131"
      unitRef="Unit_USD">566000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-61132"
      unitRef="Unit_pure">-0.185</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2025To12_31_2025"
      decimals="-3"
      id="ixv-61133"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2025To12_31_2025"
      decimals="3"
      id="ixv-61134"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-61135"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-61136"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-35045"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets (liabilities) consist of the following as of December&#160;31, 2025 and 2024 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bolder;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;57,618&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;53,281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,385&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;10,383&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;6,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;7,122&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Capitalized research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;8,867&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;12,370&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;20&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;(83,156&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61138"
      unitRef="Unit_USD">57618000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61139"
      unitRef="Unit_USD">53281000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61140"
      unitRef="Unit_USD">10385000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61141"
      unitRef="Unit_USD">10383000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61142"
      unitRef="Unit_USD">6500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61143"
      unitRef="Unit_USD">7122000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61144"
      unitRef="Unit_USD">8867000</ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61145"
      unitRef="Unit_USD">12370000</ck0001755237:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61146"
      unitRef="Unit_USD">20000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61147"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61148"
      unitRef="Unit_USD">83390000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61149"
      unitRef="Unit_USD">83156000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61150"
      unitRef="Unit_USD">83390000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61151"
      unitRef="Unit_USD">83156000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61152"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61153"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2025To12_31_2025"
      decimals="-5"
      id="ixv-61154"
      unitRef="Unit_USD">200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-61155"
      unitRef="Unit_USD">211000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-61156"
      unitRef="Unit_USD">195000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-61157"
      unitRef="Unit_USD">212000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-6"
      id="ixv-61158"
      unitRef="Unit_USD">196000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OtherInformationPertainingToIncomeTaxes
      contextRef="P01_01_2025To12_31_2025_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-61159">begin to expire in 2039 and will continue to expire through 2045</us-gaap:OtherInformationPertainingToIncomeTaxes>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2025"
      decimals="-5"
      id="ixv-61160"
      unitRef="Unit_USD">10800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OtherInformationPertainingToIncomeTaxes
      contextRef="P01_01_2025To12_31_2025_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-61161">Federal credits begin to expire in 2039 and will continue to expire through 2044. State credits begin to expire in 2034 and continue through 2039</us-gaap:OtherInformationPertainingToIncomeTaxes>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-61162"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61163"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-61164"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61165"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-35298"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;10. Defined Contribution Plan &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has established a defined contribution &lt;div style="-sec-ix-hidden:hidden167030863;display:inline;"&gt;401(k) Savings Plan&lt;/div&gt; which allows eligible employees to contribute from 1% to 100% of their compensation, subject to certain IRS limits. The Company&#x2019;s contributions to the plan are at the sole discretion of the board of directors. Currently, the Company provides a matching contribution of 75% of the employee&#x2019;s contributions, up to $6,000 annually. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Included in compensation expense is de minimis related to the defined contribution 401(k) Savings Plan for the years ended December&#160;31, 2025 and 2024, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="P01_01_2025To12_31_2025_MinimumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-61166"
      unitRef="Unit_pure">0.01</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-61167"
      unitRef="Unit_pure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2025To12_31_2025"
      decimals="INF"
      id="ixv-61168"
      unitRef="Unit_pure">0.75</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <ck0001755237:DefinedContributionPlanEmployerMatchingContributionMaximum
      contextRef="P01_01_2025To12_31_2025"
      decimals="INF"
      id="ixv-61169"
      unitRef="Unit_USD">6000</ck0001755237:DefinedContributionPlanEmployerMatchingContributionMaximum>
    <ck0001755237:LicenseAgreementsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-35306"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;11. License and Option Agreement &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent License Agreement &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;19, 2025, the Company and MIT entered into a Patent License Agreement (the &#x201c;MIT License Agreement&#x201d;) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, the Company paid a nominal upfront license fee and patent reimbursement fee. Thereafter, the Company is also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $4.4&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, the Company is required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company recorded research and development expense of $0.1&#160;million for the year ended December&#160;31, 2025, which consisted of upfront fees, patent reimbursement fees and transaction costs related to the license. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Akebia License Agreement &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On June&#160;3, 2021, the Company and Akebia entered into a License Agreement (the &#x201c;Akebia License Agreement&#x201d;) relating to the exclusive worldwide license by the Company to Akebia of its rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the &#x201c;Products&#x201d;). Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Akebia paid a $3.0&#160;million &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;up-front&lt;/div&gt; payment to the Company upon signing of the License Agreement. On December&#160;13, 2024, the Company and Akebia entered into Amendment #1 to the License Agreement (the &#x201c;2024 Amendment&#x201d;) to the original License Agreement between the parties dated June&#160;3, 2021. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under the terms of the 2024 Amendment, Akebia paid $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was paid in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#x201c;FSGS&#x201d;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to the Company and which was received in February 2026. Pursuant to the terms of the Akebia License Agreement, as amended, Cyclerion is eligible to receive additional potential future development, regulatory, and commercialization milestone payments up to $557.5&#160;million in total, and Akebia will pay Cyclerion tiered royalties ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single&lt;/div&gt; digit to twenty percent of net sales. Cyclerion&#x2019;s obligations to deliver certain drug products have also ceased. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Akebia License Agreement, the Company determined the Akebia License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the Akebia License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company determined that the grant of license to its patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-evaluate&lt;/div&gt; the probability of achievement of the milestones and any related constraints each reporting period. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Akebia Material Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;3, 2025, the Company and Akebia entered into a Material Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) relating to the purchase of additional development materials (the &#x201c;Additional Development Materials&#x201d;) by Akebia for Akebia&#x2019;s use pursuant to the Akebia License Agreement. Akebia paid $0.8&#160;million to the Company for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company determined the Purchase Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the Akebia License Agreement or the Amendment. The delivery of the Additional Development Materials by the Company represents a single performance obligation and consideration was recognized upon delivery. The Company recognized revenue of $0.8&#160;million during the year ended December&#160;31, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Option Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#x201c;Option Agreement&#x201d;) with a third party (the &#x201c;Optionee&#x201d;), pursuant to which the Optionee had an option (the &#x201c;Option&#x201d;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. &lt;/div&gt;&lt;/div&gt;</ck0001755237:LicenseAgreementsTextBlock>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61170"
      unitRef="Unit_USD">4400000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61171"
      unitRef="Unit_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61173"
      unitRef="Unit_USD">3000000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-61174"
      unitRef="Unit_USD">1750000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-61175"
      unitRef="Unit_USD">1250000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:AdditionalUpFrontPayment
      contextRef="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61176"
      unitRef="Unit_USD">500000</ck0001755237:AdditionalUpFrontPayment>
    <ck0001755237:DevelopmentMilestonePayment
      contextRef="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-61177"
      unitRef="Unit_USD">1000000</ck0001755237:DevelopmentMilestonePayment>
    <ck0001755237:CommercializationMilestonePayments
      contextRef="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61178"
      unitRef="Unit_USD">557500000</ck0001755237:CommercializationMilestonePayments>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61179"
      unitRef="Unit_USD">800000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:Revenues
      contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61180"
      unitRef="Unit_USD">800000</us-gaap:Revenues>
    <ck0001755237:OptionFee
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-61182"
      unitRef="Unit_USD">150000</ck0001755237:OptionFee>
    <ck0001755237:OptionAdditionalFee
      contextRef="P07_22_2024To07_22_2024"
      decimals="0"
      id="ixv-61183"
      unitRef="Unit_USD">80000</ck0001755237:OptionAdditionalFee>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2025To12_31_2025" id="ixv-35377"> &lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;12. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On January&#160;6, 2026, the Company sold 405,000 shares of common stock under the Sales Agreement for net proceeds of approximately $0.8&#160;million. The Company exhausted all sales under the 2025 Shelf. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;3, 2026, the Company and the Medsteer, SAS (&#x201c;Medsteer&#x201d;) entered into a Collaboration and Option Agreement (the &#x201c;Collaboration Agreement&#x201d;) pursuant to which Medsteer granted to the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(i)&#160;a&#160;non-exclusive,&#160;worldwide,&lt;/div&gt; royalty-free, sublicensable license of certain of Medsteer&#x2019;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#x201c;Option&#x201d;), exercisable at the Company&#x2019;s sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#x2019;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;in&#160;multi-bed&#160;or&lt;/div&gt; intensive unit wards, or in the context of medical transport. The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an addition two years at the Company&#x2019;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Under the terms of the Collaboration Agreement, the Company will pay to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $3.7&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-61184"
      unitRef="Unit_shares">405000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_06_2026To01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-61185"
      unitRef="Unit_USD">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001755237:DebtInstrumentsOptionsExercisePeriod
      contextRef="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-61186">The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an addition two years at the Company&#x2019;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer.</ck0001755237:DebtInstrumentsOptionsExercisePeriod>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_03_2026To01_03_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-61187"
      unitRef="Unit_USD">3700000</ck0001755237:UpFrontPaymentReceived>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61188"
      unitRef="Unit_USD">2823000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61189"
      unitRef="Unit_USD">3240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61190"
      unitRef="Unit_USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61191"
      unitRef="Unit_USD">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61192"
      unitRef="Unit_USD">255000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61193"
      unitRef="Unit_USD">384000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61194"
      unitRef="Unit_USD">11000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61195"
      unitRef="Unit_USD">11000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61196"
      unitRef="Unit_USD">3089000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61197"
      unitRef="Unit_USD">4635000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61198"
      unitRef="Unit_USD">66000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61199"
      unitRef="Unit_USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherLongTermInvestments
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61200"
      unitRef="Unit_USD">5350000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61201"
      unitRef="Unit_USD">5350000</us-gaap:OtherLongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61202"
      unitRef="Unit_USD">8505000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61203"
      unitRef="Unit_USD">9985000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61204"
      unitRef="Unit_USD">457000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61205"
      unitRef="Unit_USD">508000</us-gaap:AccountsPayableCurrent>
    <ck0001755237:AccruedResearchAndDevelopmentCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61206"
      unitRef="Unit_USD">148000</ck0001755237:AccruedResearchAndDevelopmentCurrent>
    <ck0001755237:AccruedResearchAndDevelopmentCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61207"
      unitRef="Unit_USD">198000</ck0001755237:AccruedResearchAndDevelopmentCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61208"
      unitRef="Unit_USD">1109000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61209"
      unitRef="Unit_USD">194000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61210"
      unitRef="Unit_USD">1714000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61211"
      unitRef="Unit_USD">900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61212"
      unitRef="Unit_USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61213"
      unitRef="Unit_USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61214"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2026"
      decimals="INF"
      id="ixv-61215"
      unitRef="Unit_USD_per_Share">0</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2026"
      decimals="INF"
      id="ixv-61216"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61217"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-61218"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2026_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-61219"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2026_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-61220"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2025_SeriesaConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-61221"
      unitRef="Unit_shares">351037</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61222"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61223"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2026"
      decimals="INF"
      id="ixv-61224"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61225"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61226"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2026"
      decimals="INF"
      id="ixv-61227"
      unitRef="Unit_shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2026"
      decimals="INF"
      id="ixv-61228"
      unitRef="Unit_shares">4330314</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61229"
      unitRef="Unit_shares">3925314</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2026"
      decimals="INF"
      id="ixv-61230"
      unitRef="Unit_shares">4241260</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025"
      decimals="INF"
      id="ixv-61231"
      unitRef="Unit_shares">3821236</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61232"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61233"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61234"
      unitRef="Unit_USD">280988000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61235"
      unitRef="Unit_USD">280105000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61236"
      unitRef="Unit_USD">-274197000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61237"
      unitRef="Unit_USD">-271020000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61238"
      unitRef="Unit_USD">6791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61239"
      unitRef="Unit_USD">9085000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61240"
      unitRef="Unit_USD">8505000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61241"
      unitRef="Unit_USD">9985000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2026To03_31_2026_OptionAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-61242"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To03_31_2025_OptionAgreementMembersrtProductOrServiceAxis"
      decimals="-3"
      id="ixv-61243"
      unitRef="Unit_USD">81000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61244"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61245"
      unitRef="Unit_USD">81000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61246"
      unitRef="Unit_USD">730000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61247"
      unitRef="Unit_USD">36000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61248"
      unitRef="Unit_USD">2479000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61249"
      unitRef="Unit_USD">1502000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61250"
      unitRef="Unit_USD">3209000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61251"
      unitRef="Unit_USD">1538000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61252"
      unitRef="Unit_USD">-3209000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61253"
      unitRef="Unit_USD">-1457000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61254"
      unitRef="Unit_USD">32000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61255"
      unitRef="Unit_USD">28000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61256"
      unitRef="Unit_USD">32000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61257"
      unitRef="Unit_USD">28000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61258"
      unitRef="Unit_USD">-3177000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61259"
      unitRef="Unit_USD">-1429000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2026To03_31_2026"
      decimals="2"
      id="ixv-61260"
      unitRef="Unit_USD_per_Share">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2026To03_31_2026"
      decimals="2"
      id="ixv-61261"
      unitRef="Unit_USD_per_Share">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-61262"
      unitRef="Unit_USD_per_Share">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-61263"
      unitRef="Unit_USD_per_Share">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61264"
      unitRef="Unit_shares">4205000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61265"
      unitRef="Unit_shares">4205000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61266"
      unitRef="Unit_shares">2556000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61267"
      unitRef="Unit_shares">2556000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61268"
      unitRef="Unit_shares">2545922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61269"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61270"
      unitRef="Unit_USD">276342000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61271"
      unitRef="Unit_USD">-267492000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61272"
      unitRef="Unit_USD">8850000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61273"
      unitRef="Unit_USD">-1429000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61274"
      unitRef="Unit_USD">-1429000</us-gaap:NetIncomeLoss>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare
      contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61275"
      unitRef="Unit_shares">499998</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue
      contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61276"
      unitRef="Unit_USD">1245000</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue>
    <ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61277"
      unitRef="Unit_USD">1245000</ck0001755237:StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2025To03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61278"
      unitRef="Unit_shares">15024</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2025To03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61279"
      unitRef="Unit_USD">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61280"
      unitRef="Unit_USD">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61281"
      unitRef="Unit_shares">3060944</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61282"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61283"
      unitRef="Unit_USD">277701000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61284"
      unitRef="Unit_USD">-268921000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-61285"
      unitRef="Unit_USD">8780000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61286"
      unitRef="Unit_shares">3821236</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61287"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61288"
      unitRef="Unit_USD">280105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61289"
      unitRef="Unit_USD">-271020000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61290"
      unitRef="Unit_USD">9085000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2026To03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61291"
      unitRef="Unit_shares">405000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2026To03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61292"
      unitRef="Unit_USD">825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61293"
      unitRef="Unit_USD">825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2026To03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61294"
      unitRef="Unit_USD">-3177000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61295"
      unitRef="Unit_USD">-3177000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="P01_01_2026To03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61296"
      unitRef="Unit_shares">15024</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2026To03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61297"
      unitRef="Unit_USD">58000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61298"
      unitRef="Unit_USD">58000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2026_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61299"
      unitRef="Unit_shares">4241260</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-61300"
      unitRef="Unit_shares">351037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2026_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61301"
      unitRef="Unit_USD">280988000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2026_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-61302"
      unitRef="Unit_USD">-274197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61303"
      unitRef="Unit_USD">6791000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61304"
      unitRef="Unit_USD">-3177000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61305"
      unitRef="Unit_USD">-1429000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61306"
      unitRef="Unit_USD">58000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61307"
      unitRef="Unit_USD">114000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61308"
      unitRef="Unit_USD">-1000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61309"
      unitRef="Unit_USD">25000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61310"
      unitRef="Unit_USD">-129000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61311"
      unitRef="Unit_USD">-165000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61312"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61313"
      unitRef="Unit_USD">5000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61314"
      unitRef="Unit_USD">-51000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61315"
      unitRef="Unit_USD">93000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61316"
      unitRef="Unit_USD">-50000</ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61317"
      unitRef="Unit_USD">-2000</ck0001755237:IncreaseDecreaseInAccruedResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61318"
      unitRef="Unit_USD">915000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61319"
      unitRef="Unit_USD">121000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61320"
      unitRef="Unit_USD">-1176000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61321"
      unitRef="Unit_USD">-968000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61322"
      unitRef="Unit_USD">66000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61323"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61324"
      unitRef="Unit_USD">-66000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61325"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ck0001755237:ProceedsFromAtTheOffer
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61326"
      unitRef="Unit_USD">825000</ck0001755237:ProceedsFromAtTheOffer>
    <ck0001755237:ProceedsFromAtTheOffer
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61327"
      unitRef="Unit_USD">0</ck0001755237:ProceedsFromAtTheOffer>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61328"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61329"
      unitRef="Unit_USD">1375000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61330"
      unitRef="Unit_USD">825000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61331"
      unitRef="Unit_USD">1375000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61332"
      unitRef="Unit_USD">-417000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61333"
      unitRef="Unit_USD">407000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61334"
      unitRef="Unit_USD">3240000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-61335"
      unitRef="Unit_USD">3232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61336"
      unitRef="Unit_USD">2823000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2025"
      decimals="-3"
      id="ixv-61337"
      unitRef="Unit_USD">3639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-37770">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1. Nature of Business &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Nature of Operations &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Cyclerion Therapeutics, Inc. (&#x201c;Cyclerion&#x201d;, the &#x201c;Company&#x201d; or &#x201c;we&#x201d;) became an independent public company on April&#160;1, 2019 after Ironwood Pharmaceuticals, Inc. completed a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;tax-free&lt;/div&gt;&lt;/div&gt; &lt;div style="display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;spin-off&lt;/div&gt; of their sGC business. Cyclerion has one employee as of March&#160;31, 2026 and also relies on a team of specialist consultants for its operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Cyclerion has historically focused on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Prior to the proposed Merger, its&#160;strategic focus was centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression (&#x201c;TRD&#x201d;), which it believes represents a substantial clinical and commercial opportunity. Over the past year, the Company has refined our strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, The Company has evaluated multiple opportunities and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;prioritized&#160;CYC-126,&#160;an&lt;/div&gt; individualized therapy for TRD as its foundational development program. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;In September 2025, the Company entered into a license agreement with the Massachusetts Institute of Technology (&#x201c;MIT&#x201d;) for intellectual property supporting this TRD program. In January 2026, the Company also entered into a collaboration &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;and&#160;option-to-license&#160;agreement&lt;/div&gt;&lt;/div&gt; with Medsteer SAS (&#x201c;Medsteer&#x201d;), a developer of anesthesia delivery and monitoring technologies. This agreement provides the Company with access to Medsteer&#x2019;s technical expertise, data assets, and intellectual property relating to technology-enabled drug delivery and physiological monitoring, and grants the Company the right, but not the obligation, to obtain additional rights under specified conditions. The Company intends to evaluate these capabilities as part of our broader development strategy for our TRD program. Given the substantial unmet medical need in TRD, the stage of clinical development, and the potential commercial opportunity, the Company believe this program is well positioned to serve as the foundation of our future development efforts. The program team is currently advancing an integrated clinical, regulatory, and commercial strategy for this TRD program. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In parallel with the advancement of our neuropsychiatric strategy, the Company continues to evaluate opportunities related to potentially monetizing its legacy soluble guanylate cyclase (&#x201c;sGC&#x201d;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions intended to maximize shareholder value. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. (&#x201c;Akebia&#x201d;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a $3.0&#160;million upfront payment to the Company upon signing of the license agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On December&#160;13, 2024, Cyclerion announced that Cyclerion and Akebia had &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-negotiated&lt;/div&gt; a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under this new license amendment, Cyclerion received $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and the remaining additional payment of $0.5&#160;million was received in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated (defined as first patient dosed) Phase&#160;2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#x201c;FSGS&#x201d;) using praliciguat. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment was received in February 2026. The Company is eligible to receive additional milestone cash payments of up to approximately $557.5&#160;million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher-tiered sales-based royalties ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single-digits&lt;/div&gt; to twenty percent. Payment of these sums are reserved for Cyclerion stockholders under the &#x201c;Cyclerion CVR Agreement&#x201d; described below. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#x201c;Option Agreement&#x201d;) with a third party (the &#x201c;Optionee&#x201d;), pursuant to which the Optionee had an option (the &#x201c;Option&#x201d;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company is currently exploring potential license opportunities for olinciguat. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Zagociguat is a clinical-stage &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CNS-penetrant&lt;/div&gt; sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;CNS-targeted&lt;/div&gt; sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. On July&#160;28, 2023, the Company sold Zagociguat and CY3018 to Tisento Therapeutics, Inc. (&#x201c;Tisento&#x201d;), a newly formed private company focused on their development, in exchange for $8.0&#160;million in cash consideration, $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and 10% of all of Tisento&#x2019;s parent&#x2019;s outstanding equity securities (&#x201c;Tisento Parent&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2025 Equity Private Placement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On March&#160;21, 2025, the Company entered into a Stock Purchase Agreement (the &#x201c;2025 Equity Private Placement&#x201d;) for a private placement of 499,998 shares of the Company&#x2019;s common stock, at a purchase price of $2.75 per share for total gross proceeds of approximately $1.375&#160;million. The closing of the 2025 Equity Private Placement occurred on March&#160;25, 2025. The Company incurred transaction costs of $0.1&#160;million for the 2025 Equity Private Placement. The Shares issued were not registered under the Securities Act of 1933, as amended, or any state securities laws and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act as a transaction not involving a public offering. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In connection with the 2025 Equity Private Placement, the Company entered into a Registration Rights Agreement with the investors, dated March&#160;21, 2025, pursuant to which the Company agreed to register the resale of the Shares pursuant to a registration statement which was filed with the SEC and declared effective by the SEC on May&#160;15, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;At-the-Market&lt;/div&gt;&lt;/div&gt; Offering &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On February&#160;4, 2025, the Company filed a Registration Statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt; (the &#x201c;Shelf&#x201d;) with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) in relation to the registration of common stock, preferred stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $25.0&#160;million. The Registration Statement was declared effective by the SEC in February 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On May&#160;7, 2025, the Company and Guggenheim Securities, LLC (&#x201c;Guggenheim Securities&#x201d;) entered into a Sales Agreement (the &#x201c;Sales Agreement&#x201d;), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the &#x201c;Shares&#x201d;), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company&#x2019;s agent, subject to the application of General Instruction I.B.6 of Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-3&lt;/div&gt; (&#x201c;Instruction I.B.6&#x201d;) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company will pay Guggenheim Securities cash commission of 3.0% of the gross proceeds of the Shares sold under the Sales Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the year ended December&#160;31, 2025, the Company sold 715,220 shares of its common stock for net proceeds of $2.1&#160;million under the Sales Agreement, after deducting commissions paid to Guggenheim Securities of $0.1&#160;million. During the three months ended March&#160;31, 2026, the Company sold 405,000 shares of common stock under the Sales Agreement for net proceeds of approximately $0.8&#160;million. The Company exhausted all sales under the 2025 Shelf. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Merger Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On April&#160;1, 2026, Cyclerion entered into a Plan of Merger and Reorganization (as amended, the &#x201c;Merger Agreement&#x201d;) with Korsana, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, pursuant to which among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp., a Delaware corporation (&#x201c;First Merger Sub&#x201d;), will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;), and Korsana will merge with and into Cariboos Merger Sub II, LLC, a Delaware limited liability company (&#x201c;Second Merger Sub&#x201d; and together with First Merger Sub, &#x201c;Merger Subs&#x201d;), with Second Merger Sub being the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and, together with the First Merger, the &#x201c;Merger&#x201d;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#x201c;Korsana Biosciences Operating Company, LLC&#x201d; and Cyclerion will change its name to &#x201c;Korsana Biosciences, Inc.&#x201d;. Cyclerion anticipates that the Merger will close in the third quarter of 2026, subject to certain closing conditions, along with&#160;the concurrent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Korsana&#160;Pre-Closing&#160;Financing&lt;/div&gt; described below. Following the Merger, the current business of Korsana will become the primary business of Cyclerion. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;At the closing of the First Merger (the &#x201c;First Effective Time&#x201d;, and the date on which the closing of the Merger occurs, the &#x201c;Closing Date&#x201d;), upon the terms and subject to the conditions set forth in the Merger Agreement: (i)&#160;each then-outstanding share of common stock, $0.0001 par value per share, of Korsana (the &#x201c;Korsana Common Stock&#x201d;) and Series A Preferred Stock, $0.0001 par value per share of Korsana (&#x201c;Korsana Series A Preferred Stock&#x201d;) (including shares of Korsana Common Stock issued in the Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Closing&lt;/div&gt; Financing described below), excluding any shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares, will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock, no par value per share (the &#x201c;Cyclerion Common Stock&#x201d;), equal to the exchange ratio as described in the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;); provided, that in the event the aggregate number of shares of Cyclerion Common Stock issuable to a holder of Korsana capital stock (when aggregated with all of the&#160;shares of the Cyclerion Common Stock outstanding then beneficially owned by such person and its affiliates (as calculated pursuant to Section&#160;13(d) of the Securities Exchange Act of 1934, as amended, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Rule&#160;13d-3&lt;/div&gt; promulgated&#160;thereunder) immediately after giving effect to the issuance of the merger consideration) would result in the issuance of shares of Cyclerion Common Stock to a holder in excess of a specified percentage (initially set at a percentage up to 9.99%) of the total outstanding shares of Cyclerion Common Stock (such specified percentage, a &#x201c;Beneficial Ownership Limitation&#x201d;), then Cyclerion will issue to any such holder (x)&#160;shares of Cyclerion Common Stock up to such holder&#x2019;s Beneficial Ownership Limitation and (y)&#160;in lieu of any shares in excess of such holder&#x2019;s Beneficial Ownership &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Limitation,&#160;pre-funded&#160;warrants&lt;/div&gt; (&#x201c;Cyclerion &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants&#x201d;) to purchase a number of shares of Cyclerion Common Stock upon exercise of such Cyclerion &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants equal to such excess shares; (ii)&#160;each then-outstanding share of Korsana Series &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Seed Preferred Stock, $0.0001 par value per share (&#x201c;Korsana Series Seed Preferred Stock&#x201d; and, together with the Korsana Series A Preferred Stock, the &#x201c;Korsana Preferred Stock&#x201d;), excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;B&#160;non-voting&#160;convertible&lt;/div&gt; preferred stock, no par value per share (&#x201c;Cyclerion Series B Preferred Stock&#x201d;), equal to the Exchange Ratio divided by 1,000; (iii) each then-outstanding option (a &#x201c;Korsana Option&#x201d;) to purchase shares of Korsana Common Stock will be converted into and become an option to purchase shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement; (iv)&#160;each then-outstanding restricted stock unit for shares of Korsana Common Stock will be converted into and become a restricted stock unit for shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement; and (v)&#160;each then-outstanding warrant to purchase shares of Korsana Common Stock will be converted into a warrant to purchase shares of Cyclerion Common Stock on the existing terms and conditions, subject to adjustment as set forth in the Merger Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Each share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock that is issued and outstanding at the First Effective Time will remain issued and outstanding and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Prior to the First Effective Time, the Cyclerion board of directors will accelerate the vesting of all options to purchase shares of Cyclerion Common Stock (&#x201c;Cyclerion Options&#x201d;) and all restricted stock awards (&#x201c;Cyclerion RSAs&#x201d;). Each outstanding Cyclerion Option with an exercise price per share equal to or less than the volume weighted average closing trading price of a share of Cyclerion Common Stock on The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) for the five consecutive trading days ending three trading days prior to the Calculation Date (as defined in the Merger Agreement), as reported by Bloomberg L.P. (the &#x201c;Cyclerion Closing Price&#x201d;), will be cancelled at the First Effective Time and such holder thereof will receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying the excess of the Cyclerion Closing Price over the exercise price per share of the Cyclerion Common Stock underlying such Cyclerion Option by the number of shares of the Cyclerion Common Stock underlying such Cyclerion Option. Each Cyclerion Option with an exercise price greater than the Cyclerion Closing Price will be cancelled for no consideration. The vesting of each Cyclerion RSA will be accelerated in full. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Based on Cyclerion&#x2019;s capitalization as of December&#160;31, 2025 and Korsana&#x2019;s capitalization as of March&#160;31, 2026 and assuming Cyclerion&#x2019;s net cash as of closing being equal to $0, each share of Korsana Common Stock and Korsana Series A Preferred Stock is currently estimated to be entitled to receive approximately 1.1009 shares of Cyclerion Common Stock. Each share of Korsana Series Seed Preferred Stock will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock, equal to the Exchange Ratio divided by 1,000. The estimated Exchange Ratio does not give effect to the proposed Cyclerion reverse stock split and is subject to adjustment based on Cyclerion&#x2019;s estimated net cash at the closing of the First Merger. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;In connection with the Merger, on April&#160;1, 2026, Korsana entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with certain institutional and accredited investors for the purchase of shares of Korsana Common Stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants to purchase shares of Korsana Common Stock (the &#x201c;Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants&#x201d;) for an aggregate purchase price of approximately $380.0&#160;million, immediately prior to the closing of the Merger (referred to herein as the &#x201c;Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Closing&lt;/div&gt; Financing&#x201d;). The shares of Korsana Common Stock and Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants that are issued in the Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Closing&lt;/div&gt; Financing will be converted into the right to receive a number of shares of Cyclerion Common Stock and Cyclerion &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Funded&lt;/div&gt; Warrants, respectively, equal to the Exchange Ratio. Korsana and the investors participating in the Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Closing&lt;/div&gt; Financing have also agreed to enter into a registration rights agreement at the closing of the Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Closing&lt;/div&gt; Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Korsana Common Stock that are held by the investors participating in the Korsana &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pre-Closing&lt;/div&gt; Financing from time to time pursuant to Rule 415 under the Securities Act. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Based on its current operating plan, Cyclerion expects that its current cash and cash equivalents will fund its operations until the closing of the contemplated Merger, which is subject to approval by its shareholders and the shareholders of Korsana and other customary closing conditions; however, Cyclerion has based this estimate on assumptions that may prove to be wrong, and Cyclerion could use its capital resources sooner than Cyclerion expects. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cyclerion CVR Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;At or prior to the first merger, Cyclerion will enter into a Contingent Value Rights Agreement (the &#x201c;CVR Agreement&#x201d;) with a designated rights agent (the &#x201c;Rights Agent&#x201d;), pursuant to which Cyclerion&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-merger&lt;/div&gt; shareholders will receive one CVR for each outstanding share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock held by such shareholder on such date. Each CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of Cyclerion&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-Merger&lt;/div&gt; legacy assets, net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of all &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-merger&lt;/div&gt; legacy assets other than those &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-merger&lt;/div&gt; legacy assets described in the following clauses (ii)&#160;and (iii), upon the second (2nd) anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#x2019;s right to receive payments under the Akebia License Agreement, the earlier of (A)&#160;the fifteenth (15th) anniversary of the date of entry into the CVR Agreement and (B)&#160;the expiration or earlier termination by Akebia Therapeutics, Inc. of the Akebia License Agreement pursuant to its terms, and (iii)&#160;with respect to the sale, transfer or other disposition of the equity interests of Tisento that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement, dated May&#160;13, 2023, by and among Cyclerion, Tisento and JW Cycle, Inc., the earliest of (A)&#160;nine (9)&#160;months following the date of the consummation of Tisento&#x2019;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any holders of CVRs will receive any payments with respect thereto. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The condensed consolidated financial statements and the related disclosures are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. Additionally, certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the fiscal year ended December&#160;31, 2025, which was filed with the SEC on March&#160;30, 2026. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#x2019;s financial position and the results of its operations for the interim periods presented. The results of operations for the three months ended March&#160;31, 2026 and 2025 are not necessarily indicative of the results that may be expected for the full year or any other subsequent interim period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation, Cyclerion Australia Pty Ltd., Cariboos Merger Sub Corp. and Cariboos Merger Sub II, LLC. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;At each reporting period, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;205-40,&lt;/div&gt; Going Concern, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company&#x2019;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#x2019;s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;205-40,&lt;/div&gt; the future receipt of potential funding from future partnerships, license payments, equity or debt issuances, certain cost reduction measures and the achievement of potential milestone payments from Akebia cannot be considered probable at this time because these plans are not entirely within the Company&#x2019;s control and/or have not been approved by the Board of Directors as of the date of these condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company expects that its cash and cash equivalents as of March&#160;31, 2026, will be sufficient to fund operations into the third quarter of 2026, however the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. If the Merger is not consummated, the Company believes that its cash and cash equivalents as of March&#160;31, 2026 would be adequate to fund its operating expenses into the third quarter of 2026. However, in order to continue development of its programs, the Company would need to secure substantial additional funding in the future, from one or more equity or debt financings, collaborations, or other sources. Additional funding may not be available to the Company on acceptable terms, or at all. The Company&#x2019;s Board of Directors may also decide to pursue a dissolution and liquidation in lieu of continuing program development in the event the Merger is not consummated. &lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2021To12_31_2021_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61338"
      unitRef="Unit_USD">3000000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P12_13_2024To12_13_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-61339"
      unitRef="Unit_USD">1750000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-61340"
      unitRef="Unit_USD">1250000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:RemainingAdditionalUpFrontPayment
      contextRef="P01_01_2024To12_31_2024_CyclerionLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61341"
      unitRef="Unit_USD">500000</ck0001755237:RemainingAdditionalUpFrontPayment>
    <ck0001755237:DevelopmentMilestonePayment
      contextRef="P01_01_2023To12_31_2023_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61343"
      unitRef="Unit_USD">1000000</ck0001755237:DevelopmentMilestonePayment>
    <ck0001755237:PaymentOfCashMilestone
      contextRef="P01_01_2026To03_31_2026_AkebiaLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61344"
      unitRef="Unit_USD">557500000</ck0001755237:PaymentOfCashMilestone>
    <ck0001755237:OptionFee
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-61345"
      unitRef="Unit_USD">150000</ck0001755237:OptionFee>
    <ck0001755237:SubsequentFees
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-61346"
      unitRef="Unit_USD">80000</ck0001755237:SubsequentFees>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-61347"
      unitRef="Unit_USD">8000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:OperatingExpenses
      contextRef="P07_28_2023To07_28_2023"
      decimals="-5"
      id="ixv-61348"
      unitRef="Unit_USD">2400000</us-gaap:OperatingExpenses>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_28_2023_TisentoTherapeuticsHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="2"
      id="ixv-61349"
      unitRef="Unit_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-61350"
      unitRef="Unit_shares">499998</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-61351"
      unitRef="Unit_USD_per_Share">2.75</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P03_21_2025To03_21_2025_CommonStockMemberusgaapStatementEquityComponentsAxis_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-61352"
      unitRef="Unit_USD">1375000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001755237:TransactionCostsSaleOfTransferredAssets
      contextRef="P01_01_2025To03_31_2025_TwoThousandTwentyFiveEquityPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-61353"
      unitRef="Unit_USD">100000</ck0001755237:TransactionCostsSaleOfTransferredAssets>
    <ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice
      contextRef="PAsOn02_04_2025"
      decimals="-5"
      id="ixv-61354"
      unitRef="Unit_USD">25000000</ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice>
    <ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice
      contextRef="PAsOn05_07_2025_MaximumMembersrtRangeAxis"
      decimals="0"
      id="ixv-61356"
      unitRef="Unit_USD">20000000</ck0001755237:MaximumAmountOfAggregateInitialOfferingPrice>
    <ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock
      contextRef="P05_07_2025To05_07_2025"
      decimals="3"
      id="ixv-61357"
      unitRef="Unit_pure">0.03</ck0001755237:CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-61358"
      unitRef="Unit_shares">715220</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2025To12_31_2025_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-61359"
      unitRef="Unit_USD">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2025To12_31_2025_MaximumMembersrtRangeAxis_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-61360"
      unitRef="Unit_USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2026To03_31_2026_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      id="ixv-61361"
      unitRef="Unit_shares">405000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2026To03_31_2026_SalesAgreementMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      id="ixv-61362"
      unitRef="Unit_USD">800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-61363"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-61364"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ck0001755237:DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares
      contextRef="P04_01_2026To04_01_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_CyclerionTherapeuticsIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      id="ixv-61365"
      unitRef="Unit_pure">0.0999</ck0001755237:DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SeriesSeedPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      id="ixv-61367"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <ck0001755237:NetCashOnCapitalization
      contextRef="P01_01_2026To03_31_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      id="ixv-61368"
      unitRef="Unit_USD">0</ck0001755237:NetCashOnCapitalization>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      id="ixv-61369"
      unitRef="Unit_pure">1.1009</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="P04_01_2026To04_01_2026_KorsanaBiosciencesIncMembersrtConsolidatedEntitiesAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-61370"
      unitRef="Unit_USD">380000000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-37937">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The condensed consolidated financial statements and the related disclosures are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. Additionally, certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the fiscal year ended December&#160;31, 2025, which was filed with the SEC on March&#160;30, 2026. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-37989">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The accounting policies of the Company are set forth in Note 2. &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of Significant Accounting Policies&lt;/div&gt;&lt;/div&gt; to the consolidated financial statements contained in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&lt;/div&gt; for the fiscal year ended December&#160;31, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the interim condensed consolidated financial statements, the Company did not adopt any new accounting pronouncements during the three months ended March&#160;31, 2026 that had a material effect on its condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements upon adoption. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-37997">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;New Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the interim condensed consolidated financial statements, the Company did not adopt any new accounting pronouncements during the three months ended March&#160;31, 2026 that had a material effect on its condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements upon adoption. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38004">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3. Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 61%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;March&#160;31,&#160;2026:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;During the three months ended March&#160;31, 2026 and 2025, there were no transfers between levels. The fair value of the Company&#x2019;s cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company believes the carrying amounts of its accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these amounts. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38007">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company&#x2019;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 61%;"&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;March&#160;31,&#160;2026:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;2,610&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;3,072&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-61373"
      unitRef="Unit_USD">2610000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-61374"
      unitRef="Unit_USD">2610000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2026_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-61375"
      unitRef="Unit_USD">2610000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-61376"
      unitRef="Unit_USD">2610000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-61377"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      id="ixv-61378"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-61379"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2025_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-61380"
      unitRef="Unit_USD">3072000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38385">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;4. Other Investment &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The Company has determined that the Company&#x2019;s investment in Tisento Parent is an equity security, whereby such investment does not give the Company a controlling financial interest or significant influence over the investee. Further, the Company assessed the accounting for its investment in Tisento Parent in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;810-10,&lt;/div&gt; Consolidation&#x2014;Overall. After determining that no scope exception applies under the guidance &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;of ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;810-10-15-12&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;810-10-15-17,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; the Company concluded that it has a variable interest in Tisento Parent through its investment in Tisento Parent common stock. Tisento Parent does not have sufficient equity to finance its activities without additional subordinated financial support as Tisento Parent is a startup entity in its early stages of raising funds and will require significant capital to advance its programs to commercial stage. Therefore, the Company concluded that its investment in Tisento Parent is a variable interest entity (&#x201c;VIE&#x201d;) in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;810-10-15-14(a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and is subject to potential consolidation under the VIE model. However, all activities that most significantly impact Tisento Parent and its subsidiary&#x2019;s economic performance are directed by the Tisento Parent board and the board approves decisions by a simple majority. Based on the board composition, the Company determined that no one party has control over the Tisento Parent board and power is not shared because the activities that most significantly affect Tisento Parent and its subsidiary&#x2019;s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Tisento Parent board. Therefore, because the Company controls no director of Tisento Parent, the Company cannot unilaterally direct any of the activities that most significantly impact Tisento Parent and its subsidiary&#x2019;s economic performance. Accordingly, the Company does not hold a controlling financial interest in Tisento Parent. Because both criteria (a)&#160;and (b) above have to be met for the application of the guidance in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;810-10-25-44B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; and criteria (a)&#160;has not been met, the Company concluded that it should not consolidate Tisento under the VIE model. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Accordingly, the Company has accounted for the investment as a financial instrument without a readily determinable fair value. Such investment is recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment is measured at cost less any impairment recorded or adjustments for observable price changes. An impairment loss is recognized in the consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of March&#160;31, 2026, no impairment loss was recognized. The Company considers the cost of the investment to be the maximum exposure to loss as a result of its involvement with the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-affiliated&lt;/div&gt; entity. &lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61382"
      unitRef="Unit_USD">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38426">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;5. Accrued Expenses and Other Current Liabilities &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;984&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;143&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;21&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;104&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;38&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;1,109&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;194&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38429">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 70%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;March&#160;31,&lt;br/&gt; 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;984&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;143&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;21&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;104&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;38&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;1,109&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;194&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61383"
      unitRef="Unit_USD">984000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61384"
      unitRef="Unit_USD">143000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61385"
      unitRef="Unit_USD">21000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61386"
      unitRef="Unit_USD">13000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61387"
      unitRef="Unit_USD">104000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61388"
      unitRef="Unit_USD">38000</us-gaap:OtherSundryLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2026"
      decimals="-3"
      id="ixv-61389"
      unitRef="Unit_USD">1109000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="PAsOn12_31_2025"
      decimals="-3"
      id="ixv-61390"
      unitRef="Unit_USD">194000</ck0001755237:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38556">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-style:italic;display:inline;"&gt;Other Funding Commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In the normal course of business, the Company enters into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company&#x2019;s option and do not have any significant cancellation penalties. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-style:italic;display:inline;"&gt;Indemnification Obligations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#x2019;s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is &lt;div style="display:inline;"&gt;unlimited&lt;/div&gt;. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of March&#160;31, 2026 and December&#160;31, 2025. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38593">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;7. Share-based Compensation Plans &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (&#x201c;2019 ESPP&#x201d;) and the 2019 Equity Incentive Plan (&#x201c;2019 Equity Plan&#x201d;). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options, restricted stock awards (&#x201c;RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Cyclerion also mirrored two of Ironwood Pharmaceuticals, Inc. (&#x201c;Ironwood&#x201d;) existing plans, the Amended and Restated 2005 Stock Incentive Plan (&#x201c;2005 Equity Plan&#x201d;) and the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (&#x201c;2010 Equity Plan&#x201d;). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pro-rata&lt;/div&gt; share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table provides share-based compensation reflected in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2026 and 2025 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 79%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;102&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;114&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Stock options granted under the Company&#x2019;s equity plans generally have a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ten-year&lt;/div&gt; term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of stock option activity for the three months ended March&#160;31, 2026, is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Average&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&lt;br/&gt; thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;297,762&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;149.73&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(17,355&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;203.65&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of March&#160;31, 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;280,407&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;146.39&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at March&#160;31, 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;220,760&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;181.20&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;There were no options exercised during the three months ended March&#160;31, 2026 and 2025. As of March&#160;31, 2026, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options is $0.1&#160;million and the weighted average period over which that expense is expected to be recognized is 2.86 years. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company has granted certain former employees performance-based options to purchase shares of common stock. These options are subject to performance-based milestone vesting. During the three months ended March&#160;31, 2026 and 2025, there were&#160;no shares that vested as a result of performance milestone achievements. No share-based compensation expense related to these performance-based options was recognized during the three months ended March&#160;31, 2026 and 2025, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted Stock Awards &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No RSA was granted during the three months ended March&#160;31, 2026 and 2025. The fair value of all RSAs is&#160;based on the market value of the Company&#x2019;s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of RSA activity for the three months ended March&#160;31, 2026 is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;104,078&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2.57&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(15,024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2.52&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of March&#160;31, 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;89,054&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2.59&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;As of March&#160;31, 2026, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested RSAs is $0.2&#160;million and the weighted average period over which that expense is expected to be recognized is 1.45 years. &lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38601">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The following table provides share-based compensation reflected in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2026 and 2025 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 79%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 8%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;12&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;102&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;114&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2026To03_31_2026_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61392"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To03_31_2025_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61393"
      unitRef="Unit_USD">12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2026To03_31_2026_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61394"
      unitRef="Unit_USD">58000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To03_31_2025_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-61395"
      unitRef="Unit_USD">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61396"
      unitRef="Unit_USD">58000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61397"
      unitRef="Unit_USD">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-38741">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of stock option activity for the three months ended March&#160;31, 2026, is as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 56%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Average&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&lt;br/&gt; thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;297,762&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;149.73&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cancelled or forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(17,355&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;203.65&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Outstanding as of March&#160;31, 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;280,407&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;146.39&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4.9&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Exercisable at March&#160;31, 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;220,760&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;181.20&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4.2&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61399"
      unitRef="Unit_shares">297762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61400"
      unitRef="Unit_USD_per_Share">149.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61401">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61402"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61403"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61404"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61405"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61406"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61407"
      unitRef="Unit_shares">17355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61408"
      unitRef="Unit_USD_per_Share">203.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61409"
      unitRef="Unit_shares">280407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61410"
      unitRef="Unit_USD_per_Share">146.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61411">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61412"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61413"
      unitRef="Unit_shares">220760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61414"
      unitRef="Unit_USD_per_Share">181.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61415">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61416"
      unitRef="Unit_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61417"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61418"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-61419"
      unitRef="Unit_USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-61420">P2Y10M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2025To03_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61421"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2026To03_31_2026_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61422"
      unitRef="Unit_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <ck0001755237:ShareBasedCompensationExpense
      contextRef="P01_01_2025To03_31_2025_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61423"
      unitRef="Unit_USD">0</ck0001755237:ShareBasedCompensationExpense>
    <ck0001755237:ShareBasedCompensationExpense
      contextRef="P01_01_2026To03_31_2026_PerformanceSharesMemberusgaapAwardTypeAxis"
      decimals="-3"
      id="ixv-61424"
      unitRef="Unit_USD">0</ck0001755237:ShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61425"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61426"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-39057">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;A summary of RSA activity for the three months ended March&#160;31, 2026 is as follows:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 65%;"&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Number&lt;br/&gt; of&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of December&#160;31, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;104,078&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2.57&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(15,024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2.52&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#x2002;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Unvested as of March&#160;31, 2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;89,054&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2.59&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61427"
      unitRef="Unit_shares">104078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61428"
      unitRef="Unit_USD_per_Share">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-61429"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61430"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61431"
      unitRef="Unit_shares">15024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61432"
      unitRef="Unit_USD_per_Share">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61433"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61434"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-61435"
      unitRef="Unit_shares">89054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-61436"
      unitRef="Unit_USD_per_Share">2.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-61437"
      unitRef="Unit_USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis"
      id="ixv-61438">P1Y5M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-39212">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8. Loss per share &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(3,177&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(1,429&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average shares used in calculating net loss per share &#x2014; basic and diluted (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4,205&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2,556&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share &#x2014; basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(0.76&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(0.56&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company excludes shares of common stock related to Preferred Stock, stock options and RSAs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. The following table sets forth potential shares that were considered anti-dilutive for the three months ended March&#160;31, 2026 and 2025: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;351,037&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;351,037&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;280,407&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;329,458&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;RSAs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;89,054&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;149,150&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;720,498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;829,645&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-39215">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 76%;"&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(3,177&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(1,429&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Weighted average shares used in calculating net loss per share &#x2014; basic and diluted (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;4,205&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;2,556&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Net loss per share &#x2014; basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(0.76&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;(0.56&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61439"
      unitRef="Unit_USD">-3177000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61440"
      unitRef="Unit_USD">-1429000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61441"
      unitRef="Unit_shares">4205000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61442"
      unitRef="Unit_shares">4205000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61443"
      unitRef="Unit_shares">2556000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61444"
      unitRef="Unit_shares">2556000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2026To03_31_2026"
      decimals="2"
      id="ixv-61445"
      unitRef="Unit_USD_per_Share">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2026To03_31_2026"
      decimals="2"
      id="ixv-61446"
      unitRef="Unit_USD_per_Share">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-61447"
      unitRef="Unit_USD_per_Share">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2025To03_31_2025"
      decimals="2"
      id="ixv-61448"
      unitRef="Unit_USD_per_Share">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-61449">The following table sets forth potential shares that were considered anti-dilutive for the three months ended March&#160;31, 2026 and 2025: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;"&gt;
&lt;tr&gt;
&lt;td style="width: 74%;"&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;Three Months Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;font-weight:bolder;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;351,037&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;351,037&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;280,407&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;329,458&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;RSAs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;89,054&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;149,150&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;720,498&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;829,645&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2026To03_31_2026_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-61450"
      unitRef="Unit_shares">351037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2025To03_31_2025_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-61451"
      unitRef="Unit_shares">351037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61452"
      unitRef="Unit_USD">280407000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To03_31_2025_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61453"
      unitRef="Unit_USD">329458000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61454"
      unitRef="Unit_USD">89054000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To03_31_2025_RestrictedStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      id="ixv-61455"
      unitRef="Unit_USD">149150000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2026To03_31_2026"
      decimals="-3"
      id="ixv-61456"
      unitRef="Unit_USD">720498000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
      contextRef="P01_01_2025To03_31_2025"
      decimals="-3"
      id="ixv-61457"
      unitRef="Unit_USD">829645000</us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits>
    <ck0001755237:LicenseAgreementsTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-39489">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9. Option/License Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent License Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;19, 2025, the Company and MIT entered into a Patent License Agreement (the &#x201c;MIT License Agreement&#x201d;) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, the Company paid a nominal upfront license fee and patent reimbursement fee. Thereafter, the Company is also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $4.4&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, the Company is required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;No expense was recognized for the three months ended March&#160;31, 2026 and 2025 related to the license. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Akebia License Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On June&#160;3, 2021, the Company and Akebia entered into a License Agreement (the &#x201c;Akebia License Agreement&#x201d;) relating to the exclusive worldwide license by the Company to Akebia of its rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the &#x201c;Products&#x201d;). Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Akebia paid a $3.0&#160;million &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;up-front&lt;/div&gt; payment to the Company upon signing of the License Agreement. On December&#160;13, 2024, the Company and Akebia entered into Amendment #1 to the License Agreement (the &#x201c;2024 Amendment&#x201d;) to the original License Agreement between the parties dated June&#160;3, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Under the terms of the 2024 Amendment, Akebia paid $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was paid in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of&#160;certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#x201c;FSGS&#x201d;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to the Company and which was received in February 2026. Pursuant to the terms of the Akebia License Agreement, as amended, Cyclerion is eligible to receive additional potential future development, regulatory, and commercialization milestone payments up to $557.5&#160;million in total, and Akebia will pay Cyclerion tiered royalties ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;mid-single&lt;/div&gt; digit to twenty percent of net sales. Cyclerion&#x2019;s obligations to deliver certain drug products have also ceased. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Pursuant to the Akebia License Agreement, the Company determined the Akebia License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the Akebia License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company determined that the grant of license to its patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-evaluate&lt;/div&gt; the probability of achievement of the milestones and any related constraints each reporting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Akebia Material Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On September&#160;3, 2025, the Company and Akebia entered into a Material Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) relating to the purchase of additional development materials (the &#x201c;Additional Development Materials&#x201d;) by Akebia for Akebia&#x2019;s use pursuant to the Akebia License Agreement. Akebia paid $0.8&#160;million to the Company for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;The Company determined the Purchase Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the Akebia License Agreement or the Amendment. The delivery of the Additional Development Materials by the Company represents a single performance obligation and consideration was recognized upon delivery. No revenue was recognized under the Purchase Agreement during three months ended March&#160;31, 2026 and 2025. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Option Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#x201c;Option Agreement&#x201d;) with a third party (the &#x201c;Optionee&#x201d;), pursuant to which the Optionee had an option (the &#x201c;Option&#x201d;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company recognized revenue of $0.1&#160;million related to the extension fee payment and expense reimbursement for the three months ended March&#160;31, 2025.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Medsteer Collaboration Agreement &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On January&#160;3, 2026, the Company and the Medsteer, SAS (&#x201c;Medsteer&#x201d;) entered into a Collaboration and Option Agreement (the &#x201c;Collaboration Agreement&#x201d;) pursuant to which Medsteer granted to the Company (i)&#160;a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-exclusive,&lt;/div&gt; worldwide, royalty-free, sublicensable license of certain of Medsteer&#x2019;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#x201c;Option&#x201d;), exercisable at the Company&#x2019;s sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#x2019;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;multi-bed&lt;/div&gt; or intensive unit wards, or in the context of medical transport. The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an additional two years at the Company&#x2019;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer. Under the terms of the Collaboration Agreement, the Company recognized $0.1&#160;million research and development expense during the three months ended March&#160;31, 2026, which is related to the upfront payment paid to Medsteer and other transaction costs. Medsteer will be eligible to receive up to $3.7&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and&#160;royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. &lt;/div&gt;&lt;/div&gt;</ck0001755237:LicenseAgreementsTextBlock>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="P09_19_2025To09_19_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61458"
      unitRef="Unit_USD">4400000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:CostsAndExpenses
      contextRef="P01_01_2025To12_31_2025_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-61459"
      unitRef="Unit_USD">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="P01_01_2026To03_31_2026_PatentLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-61460"
      unitRef="Unit_USD">0</us-gaap:CostsAndExpenses>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P06_03_2021To06_03_2021_AkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61462"
      unitRef="Unit_USD">3000000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P06_03_2021To06_03_2021_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-61463"
      unitRef="Unit_USD">1750000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:UpFrontPaymentReceived
      contextRef="P01_01_2024To12_31_2024_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-4"
      id="ixv-61464"
      unitRef="Unit_USD">1250000</ck0001755237:UpFrontPaymentReceived>
    <ck0001755237:AdditionalUpFrontPayment
      contextRef="P01_01_2025To09_30_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61465"
      unitRef="Unit_USD">500000</ck0001755237:AdditionalUpFrontPayment>
    <ck0001755237:DevelopmentMilestonePayment
      contextRef="P02_01_2026To02_28_2026_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-61466"
      unitRef="Unit_USD">1000000</ck0001755237:DevelopmentMilestonePayment>
    <ck0001755237:CommercializationMilestonePayments
      contextRef="P01_01_2025To12_31_2025_AmendmentAkebiaResearchLicenseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61467"
      unitRef="Unit_USD">557500000</ck0001755237:CommercializationMilestonePayments>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="P01_01_2025To12_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61468"
      unitRef="Unit_USD">800000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:Revenues
      contextRef="P01_01_2025To03_31_2025_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      id="ixv-61470"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2026To03_31_2026_AkebiaMaterialPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      id="ixv-61471"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <ck0001755237:OptionFee
      contextRef="P08_01_2024To08_31_2024"
      decimals="0"
      id="ixv-61472"
      unitRef="Unit_USD">150000</ck0001755237:OptionFee>
    <ck0001755237:OptionAdditionalFee
      contextRef="P07_22_2024To07_22_2024"
      decimals="0"
      id="ixv-61473"
      unitRef="Unit_USD">80000</ck0001755237:OptionAdditionalFee>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="P01_01_2025To03_31_2025"
      decimals="-5"
      id="ixv-61474"
      unitRef="Unit_USD">100000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2026To03_31_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61475"
      unitRef="Unit_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="P01_03_2026To01_03_2026_MedsteerCollaborationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-61476"
      unitRef="Unit_USD">3700000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2026To03_31_2026" id="ixv-39567">&lt;div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;10. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;As described above, on April&#160;1, 2026, the Company entered into the Merger Agreement (which was subsequently amended on April&#160;17, 2026) with Korsana, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, pursuant to which Korsana will become a wholly owned subsidiary of the Company and the Company will operate under the name Korsana Biosciences, Inc. following the merger. The Company anticipates that the merger will close in the third quarter of 2026, subject to certain closing conditions, along with the concurrent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Korsana&#160;pre-closing&#160;financing.&lt;/div&gt; Following the merger, the current business of Korsana will become the primary business of the Company. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CYCLERION THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001755237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1895370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street, 18th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-8778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street, 18th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-8778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Regina Graul, Ph.D.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,823<span></span>
</td>
<td class="nump">$ 3,240<span></span>
</td>
<td class="nump">$ 3,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,089<span></span>
</td>
<td class="nump">4,635<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other investment</a></td>
<td class="nump">5,350<span></span>
</td>
<td class="nump">5,350<span></span>
</td>
<td class="nump">5,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,505<span></span>
</td>
<td class="nump">9,985<span></span>
</td>
<td class="nump">9,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,714<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at March 31, 2026 and December 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, no par value, 400,000,000 shares authorized at March 31, 2026 and December 31, 2025; 4,330,314 and 3,925,314 shares issued at March 31, 2026 and December 31, 2025, respectively; 4,241,260 and 3,821,236 shares outstanding at March 31, 2026 and December 31, 2025, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Paid-in capital</a></td>
<td class="nump">280,988<span></span>
</td>
<td class="nump">280,105<span></span>
</td>
<td class="nump">276,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(274,197)<span></span>
</td>
<td class="num">(271,020)<span></span>
</td>
<td class="num">(267,492)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">6,791<span></span>
</td>
<td class="nump">9,085<span></span>
</td>
<td class="nump">8,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,505<span></span>
</td>
<td class="nump">$ 9,985<span></span>
</td>
<td class="nump">$ 9,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">4,330,314<span></span>
</td>
<td class="nump">3,925,314<span></span>
</td>
<td class="nump">2,710,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">4,241,260<span></span>
</td>
<td class="nump">3,821,236<span></span>
</td>
<td class="nump">2,545,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ck0001755237_SeriesaConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">351,037<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shared outstanding</a></td>
<td class="nump">351,037<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ck0001755237_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ck0001755237_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 2,074<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">6,088<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total cost and expenses</a></td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">7,047<span></span>
</td>
<td class="nump">5,628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,209)<span></span>
</td>
<td class="num">(1,457)<span></span>
</td>
<td class="num">(4,973)<span></span>
</td>
<td class="num">(3,628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_GainLossFromSettlementOfAccountPayable', window );">Gain from settlement of account payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery', window );">Gain from insurance recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,177)<span></span>
</td>
<td class="num">$ (1,429)<span></span>
</td>
<td class="num">$ (3,528)<span></span>
</td>
<td class="num">$ (3,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - Basic</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - Diluted</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract', window );"><strong>Weighted average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares</a></td>
<td class="nump">4,205<span></span>
</td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">3,181<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">4,205<span></span>
</td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">3,181<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,177)<span></span>
</td>
<td class="num">$ (1,429)<span></span>
</td>
<td class="num">$ (3,528)<span></span>
</td>
<td class="num">$ (3,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,528)<span></span>
</td>
<td class="num">(3,063)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ck0001755237_LicenseAgreementMember', window );">Revenue from license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ck0001755237_PurchaseAgreementMember', window );">Revenue from purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ck0001755237_OptionAgreementMember', window );">Revenue from option agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings per share basic and diluted other disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_GainLossFromSettlementOfAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from settlement of account payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_GainLossFromSettlementOfAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483605/220-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnBusinessInterruptionInsuranceRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ck0001755237_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ck0001755237_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ck0001755237_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ck0001755237_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ck0001755237_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ck0001755237_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Paid-in capital</div></th>
<th class="th"><div>Accumulated deflicit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 11,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,717<span></span>
</td>
<td class="num">$ (264,417)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,474,159<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense related to issuance of stock options and restricted stock awards</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment', window );">Release of foreign currency translation adjustment upon liquidation of a subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 8,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,342<span></span>
</td>
<td class="num">(267,492)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">2,545,922<span></span>
</td>
<td class="nump">2,545,922<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare', window );">Issuance of common stock - private placement, net of issuance cost (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue', window );">Issuance of common stock - private placement, net of issuance cost</a></td>
<td class="nump">$ 1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense related to issuance of stock options and restricted stock awards</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">8,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,701<span></span>
</td>
<td class="num">(268,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,060,944<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 8,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,342<span></span>
</td>
<td class="num">(267,492)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">2,545,922<span></span>
</td>
<td class="nump">2,545,922<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare', window );">Issuance of common stock - private placement, net of issuance cost (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue', window );">Issuance of common stock - private placement, net of issuance cost</a></td>
<td class="nump">$ 1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - ATM (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - ATM</a></td>
<td class="nump">2,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense related to issuance of stock options and restricted stock awards</a></td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 9,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,105<span></span>
</td>
<td class="num">(271,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">3,821,236<span></span>
</td>
<td class="nump">3,821,236<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - ATM (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - ATM</a></td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense related to issuance of stock options and restricted stock awards</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">$ 6,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,988<span></span>
</td>
<td class="num">$ (274,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="nump">4,241,260<span></span>
</td>
<td class="nump">4,241,260<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release of foreign currency translation adjustment..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period issuance of common stock net of nssuance cost, share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period issuance of common stock net of issuance cost, value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (3,177)<span></span>
</td>
<td class="num">$ (1,429)<span></span>
</td>
<td class="num">$ (3,528)<span></span>
</td>
<td class="num">$ (3,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_GainLossFromSettlementOfAccountPayable', window );">Gain from settlement of account payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(51)<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment', window );">Accrued research and development costs</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,176)<span></span>
</td>
<td class="num">(968)<span></span>
</td>
<td class="num">(3,314)<span></span>
</td>
<td class="num">(4,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_ProceedsFromAtTheOffer', window );">Proceeds from ATM</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,077<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_IssuanceCostsPaidForPrivatePlacement', window );">Issuance costs paid for private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(417)<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(4,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">3,240<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
<td class="nump">7,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 2,823<span></span>
</td>
<td class="nump">$ 3,639<span></span>
</td>
<td class="nump">$ 3,240<span></span>
</td>
<td class="nump">$ 3,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_GainLossFromSettlementOfAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from settlement of account payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_GainLossFromSettlementOfAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in accrued research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_IssuanceCostsPaidForPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs paid for private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_IssuanceCostsPaidForPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_ProceedsFromAtTheOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from at the offer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_ProceedsFromAtTheOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Nature of Business </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nature of Operations </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion Therapeutics, Inc. (&#8220;Cyclerion&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221;) became an independent public company on April&#160;1, 2019 after Ironwood Pharmaceuticals, Inc. completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">tax-free</div></div> <div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">spin-off</div> of their sGC business. Cyclerion has one employee as of March&#160;31, 2026 and also relies on a team of specialist consultants for its operations. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion has historically focused on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical need. Prior to the proposed Merger, its&#160;strategic focus was centered on the development of a novel therapeutic approach for neuropsychiatric conditions, with the lead indication being treatment-resistant depression (&#8220;TRD&#8221;), which it believes represents a substantial clinical and commercial opportunity. Over the past year, the Company has refined our strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, The Company has evaluated multiple opportunities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">prioritized&#160;CYC-126,&#160;an</div> individualized therapy for TRD as its foundational development program. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In September 2025, the Company entered into a license agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) for intellectual property supporting this TRD program. In January 2026, the Company also entered into a collaboration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">and&#160;option-to-license&#160;agreement</div></div> with Medsteer SAS (&#8220;Medsteer&#8221;), a developer of anesthesia delivery and monitoring technologies. This agreement provides the Company with access to Medsteer&#8217;s technical expertise, data assets, and intellectual property relating to technology-enabled drug delivery and physiological monitoring, and grants the Company the right, but not the obligation, to obtain additional rights under specified conditions. The Company intends to evaluate these capabilities as part of our broader development strategy for our TRD program. Given the substantial unmet medical need in TRD, the stage of clinical development, and the potential commercial opportunity, the Company believe this program is well positioned to serve as the foundation of our future development efforts. The program team is currently advancing an integrated clinical, regulatory, and commercial strategy for this TRD program. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In parallel with the advancement of our neuropsychiatric strategy, the Company continues to evaluate opportunities related to potentially monetizing its legacy soluble guanylate cyclase (&#8220;sGC&#8221;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions intended to maximize shareholder value. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. (&#8220;Akebia&#8221;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a $3.0&#160;million upfront payment to the Company upon signing of the license agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">On December&#160;13, 2024, Cyclerion announced that Cyclerion and Akebia had <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-negotiated</div> a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under this new license amendment, Cyclerion received $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and the remaining additional payment of $0.5&#160;million was received in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated (defined as first patient dosed) Phase&#160;2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using praliciguat. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment was received in February 2026. The Company is eligible to receive additional milestone cash payments of up to approximately $557.5&#160;million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher-tiered sales-based royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single-digits</div> to twenty percent. Payment of these sums are reserved for Cyclerion stockholders under the &#8220;Cyclerion CVR Agreement&#8221; described below. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company is currently exploring potential license opportunities for olinciguat. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Zagociguat is a clinical-stage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-penetrant</div> sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-targeted</div> sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. On July&#160;28, 2023, the Company sold Zagociguat and CY3018 to Tisento Therapeutics, Inc. (&#8220;Tisento&#8221;), a newly formed private company focused on their development, in exchange for $8.0&#160;million in cash consideration, $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and 10% of all of Tisento&#8217;s parent&#8217;s outstanding equity securities (&#8220;Tisento Parent&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025 Equity Private Placement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;21, 2025, the Company entered into a Stock Purchase Agreement (the &#8220;2025 Equity Private Placement&#8221;) for a private placement of 499,998 shares of the Company&#8217;s common stock, at a purchase price of $2.75 per share for total gross proceeds of approximately $1.375&#160;million. The closing of the 2025 Equity Private Placement occurred on March&#160;25, 2025. The Company incurred transaction costs of $0.1&#160;million for the 2025 Equity Private Placement. The Shares issued were not registered under the Securities Act of 1933, as amended, or any state securities laws and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act as a transaction not involving a public offering. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the 2025 Equity Private Placement, the Company entered into a Registration Rights Agreement with the investors, dated March&#160;21, 2025, pursuant to which the Company agreed to register the resale of the Shares pursuant to a registration statement which was filed with the SEC and declared effective by the SEC on May&#160;15, 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">At-the-Market</div></div> Offering </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On February&#160;4, 2025, the Company filed a Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $25.0&#160;million. The Registration Statement was declared effective by the SEC in February 2025. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">On May&#160;7, 2025, the Company and Guggenheim Securities, LLC (&#8220;Guggenheim Securities&#8221;) entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the &#8220;Shares&#8221;), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company&#8217;s agent, subject to the application of General Instruction I.B.6 of Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> (&#8220;Instruction I.B.6&#8221;) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company will pay Guggenheim Securities cash commission of 3.0% of the gross proceeds of the Shares sold under the Sales Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2025, the Company sold 715,220 shares of its common stock for net proceeds of $2.1&#160;million under the Sales Agreement, after deducting commissions paid to Guggenheim Securities of $0.1&#160;million. During the three months ended March&#160;31, 2026, the Company sold 405,000 shares of common stock under the Sales Agreement for net proceeds of approximately $0.8&#160;million. The Company exhausted all sales under the 2025 Shelf. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Merger Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On April&#160;1, 2026, Cyclerion entered into a Plan of Merger and Reorganization (as amended, the &#8220;Merger Agreement&#8221;) with Korsana, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, pursuant to which among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Cariboos Merger Sub Corp., a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Korsana, with Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Korsana will merge with and into Cariboos Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Korsana Biosciences Operating Company, LLC&#8221; and Cyclerion will change its name to &#8220;Korsana Biosciences, Inc.&#8221;. Cyclerion anticipates that the Merger will close in the third quarter of 2026, subject to certain closing conditions, along with&#160;the concurrent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Korsana&#160;Pre-Closing&#160;Financing</div> described below. Following the Merger, the current business of Korsana will become the primary business of Cyclerion. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">At the closing of the First Merger (the &#8220;First Effective Time&#8221;, and the date on which the closing of the Merger occurs, the &#8220;Closing Date&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement: (i)&#160;each then-outstanding share of common stock, $0.0001 par value per share, of Korsana (the &#8220;Korsana Common Stock&#8221;) and Series A Preferred Stock, $0.0001 par value per share of Korsana (&#8220;Korsana Series A Preferred Stock&#8221;) (including shares of Korsana Common Stock issued in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing described below), excluding any shares to be cancelled pursuant to the Merger Agreement and excluding dissenting shares, will be automatically converted solely into the right to receive a number of shares of Cyclerion common stock, no par value per share (the &#8220;Cyclerion Common Stock&#8221;), equal to the exchange ratio as described in the Merger Agreement (the &#8220;Exchange Ratio&#8221;); provided, that in the event the aggregate number of shares of Cyclerion Common Stock issuable to a holder of Korsana capital stock (when aggregated with all of the&#160;shares of the Cyclerion Common Stock outstanding then beneficially owned by such person and its affiliates (as calculated pursuant to Section&#160;13(d) of the Securities Exchange Act of 1934, as amended, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;13d-3</div> promulgated&#160;thereunder) immediately after giving effect to the issuance of the merger consideration) would result in the issuance of shares of Cyclerion Common Stock to a holder in excess of a specified percentage (initially set at a percentage up to 9.99%) of the total outstanding shares of Cyclerion Common Stock (such specified percentage, a &#8220;Beneficial Ownership Limitation&#8221;), then Cyclerion will issue to any such holder (x)&#160;shares of Cyclerion Common Stock up to such holder&#8217;s Beneficial Ownership Limitation and (y)&#160;in lieu of any shares in excess of such holder&#8217;s Beneficial Ownership <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Limitation,&#160;pre-funded&#160;warrants</div> (&#8220;Cyclerion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) to purchase a number of shares of Cyclerion Common Stock upon exercise of such Cyclerion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants equal to such excess shares; (ii)&#160;each then-outstanding share of Korsana Series </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">Seed Preferred Stock, $0.0001 par value per share (&#8220;Korsana Series Seed Preferred Stock&#8221; and, together with the Korsana Series A Preferred Stock, the &#8220;Korsana Preferred Stock&#8221;), excluding any shares of Korsana Series Seed Preferred Stock to be cancelled pursuant to the Merger Agreement and any dissenting shares, will be converted into the right to receive a number of shares of Cyclerion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">B&#160;non-voting&#160;convertible</div> preferred stock, no par value per share (&#8220;Cyclerion Series B Preferred Stock&#8221;), equal to the Exchange Ratio divided by 1,000; (iii) each then-outstanding option (a &#8220;Korsana Option&#8221;) to purchase shares of Korsana Common Stock will be converted into and become an option to purchase shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement; (iv)&#160;each then-outstanding restricted stock unit for shares of Korsana Common Stock will be converted into and become a restricted stock unit for shares of Cyclerion Common Stock on the existing terms and conditions (including with respect to vesting and accelerated vesting), subject to adjustment as set forth in the Merger Agreement; and (v)&#160;each then-outstanding warrant to purchase shares of Korsana Common Stock will be converted into a warrant to purchase shares of Cyclerion Common Stock on the existing terms and conditions, subject to adjustment as set forth in the Merger Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Each share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock that is issued and outstanding at the First Effective Time will remain issued and outstanding and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Prior to the First Effective Time, the Cyclerion board of directors will accelerate the vesting of all options to purchase shares of Cyclerion Common Stock (&#8220;Cyclerion Options&#8221;) and all restricted stock awards (&#8220;Cyclerion RSAs&#8221;). Each outstanding Cyclerion Option with an exercise price per share equal to or less than the volume weighted average closing trading price of a share of Cyclerion Common Stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five consecutive trading days ending three trading days prior to the Calculation Date (as defined in the Merger Agreement), as reported by Bloomberg L.P. (the &#8220;Cyclerion Closing Price&#8221;), will be cancelled at the First Effective Time and such holder thereof will receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying the excess of the Cyclerion Closing Price over the exercise price per share of the Cyclerion Common Stock underlying such Cyclerion Option by the number of shares of the Cyclerion Common Stock underlying such Cyclerion Option. Each Cyclerion Option with an exercise price greater than the Cyclerion Closing Price will be cancelled for no consideration. The vesting of each Cyclerion RSA will be accelerated in full. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Based on Cyclerion&#8217;s capitalization as of December&#160;31, 2025 and Korsana&#8217;s capitalization as of March&#160;31, 2026 and assuming Cyclerion&#8217;s net cash as of closing being equal to $0, each share of Korsana Common Stock and Korsana Series A Preferred Stock is currently estimated to be entitled to receive approximately 1.1009 shares of Cyclerion Common Stock. Each share of Korsana Series Seed Preferred Stock will be converted into the right to receive a number of shares of Cyclerion Series B Preferred Stock, equal to the Exchange Ratio divided by 1,000. The estimated Exchange Ratio does not give effect to the proposed Cyclerion reverse stock split and is subject to adjustment based on Cyclerion&#8217;s estimated net cash at the closing of the First Merger. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">In connection with the Merger, on April&#160;1, 2026, Korsana entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional and accredited investors for the purchase of shares of Korsana Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants to purchase shares of Korsana Common Stock (the &#8220;Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants&#8221;) for an aggregate purchase price of approximately $380.0&#160;million, immediately prior to the closing of the Merger (referred to herein as the &#8220;Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing&#8221;). The shares of Korsana Common Stock and Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants that are issued in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing will be converted into the right to receive a number of shares of Cyclerion Common Stock and Cyclerion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Funded</div> Warrants, respectively, equal to the Exchange Ratio. Korsana and the investors participating in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing have also agreed to enter into a registration rights agreement at the closing of the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Korsana Common Stock that are held by the investors participating in the Korsana <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Pre-Closing</div> Financing from time to time pursuant to Rule 415 under the Securities Act. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Based on its current operating plan, Cyclerion expects that its current cash and cash equivalents will fund its operations until the closing of the contemplated Merger, which is subject to approval by its shareholders and the shareholders of Korsana and other customary closing conditions; however, Cyclerion has based this estimate on assumptions that may prove to be wrong, and Cyclerion could use its capital resources sooner than Cyclerion expects. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion CVR Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">At or prior to the first merger, Cyclerion will enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a designated rights agent (the &#8220;Rights Agent&#8221;), pursuant to which Cyclerion&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> shareholders will receive one CVR for each outstanding share of Cyclerion Common Stock and Cyclerion Series A Preferred Stock held by such shareholder on such date. Each CVR will represent the contractual right to receive certain net proceeds, if any, derived from any consideration that is paid to Cyclerion as a result of the disposition of Cyclerion&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-Merger</div> legacy assets, net of any indemnity obligations, transaction costs and certain other expenses, during the period beginning on the date of the closing of the merger and ending (i)&#160;with respect to the sale, transfer, license or other disposition of all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> legacy assets other than those <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-merger</div> legacy assets described in the following clauses (ii)&#160;and (iii), upon the second (2nd) anniversary of the Closing Date, (ii)&#160;with respect to Cyclerion&#8217;s right to receive payments under the Akebia License Agreement, the earlier of (A)&#160;the fifteenth (15th) anniversary of the date of entry into the CVR Agreement and (B)&#160;the expiration or earlier termination by Akebia Therapeutics, Inc. of the Akebia License Agreement pursuant to its terms, and (iii)&#160;with respect to the sale, transfer or other disposition of the equity interests of Tisento that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement, dated May&#160;13, 2023, by and among Cyclerion, Tisento and JW Cycle, Inc., the earliest of (A)&#160;nine (9)&#160;months following the date of the consummation of Tisento&#8217;s initial public offering pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission pursuant to the Securities Act, (B)&#160;the sale of Tisento, and (C)&#160;the seventh (7th) anniversary of the Closing Date. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that any holders of CVRs will receive any payments with respect thereto. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The condensed consolidated financial statements and the related disclosures are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. Additionally, certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2025, which was filed with the SEC on March&#160;30, 2026. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#8217;s financial position and the results of its operations for the interim periods presented. The results of operations for the three months ended March&#160;31, 2026 and 2025 are not necessarily indicative of the results that may be expected for the full year or any other subsequent interim period. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation, Cyclerion Australia Pty Ltd., Cariboos Merger Sub Corp. and Cariboos Merger Sub II, LLC. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">At each reporting period, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> Going Concern, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> the future receipt of potential funding from future partnerships, license payments, equity or debt issuances, certain cost reduction measures and the achievement of potential milestone payments from Akebia cannot be considered probable at this time because these plans are not entirely within the Company&#8217;s control and/or have not been approved by the Board of Directors as of the date of these condensed consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expects that its cash and cash equivalents as of March&#160;31, 2026, will be sufficient to fund operations into the third quarter of 2026, however the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. If the Merger is not consummated, the Company believes that its cash and cash equivalents as of March&#160;31, 2026 would be adequate to fund its operating expenses into the third quarter of 2026. However, in order to continue development of its programs, the Company would need to secure substantial additional funding in the future, from one or more equity or debt financings, collaborations, or other sources. Additional funding may not be available to the Company on acceptable terms, or at all. The Company&#8217;s Board of Directors may also decide to pursue a dissolution and liquidation in lieu of continuing program development in the event the Merger is not consummated. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1. Nature of Business </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Nature of Operations </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Cyclerion Therapeutics, Inc. (&#8220;Cyclerion&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221;) became an independent public company on April&#160;1, 2019 after Ironwood Pharmaceuticals, Inc. completed a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">tax-free</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">spin-off</div> of their sGC business. Cyclerion has one employee as of December&#160;31, 2025 and also relies on a team of specialist consultants for its operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion is focused on building a new pipeline of innovative therapeutics to address serious neuropsychiatric diseases. The Company&#8217;s current strategic focus is centered on the development of a novel therapeutic approach for treatment-resistant depression (&#8220;TRD&#8221;), which represents a substantial clinical and commercial opportunity. Over the past year, the Company has refined its strategic direction toward programs that combine established pharmacologic agents with enabling technologies designed to improve precision, reproducibility, and patient outcomes. As part of this strategy, Cyclerion has evaluated multiple opportunities and prioritized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CYC-126,</div> an individualized therapy for TRD as its foundational development program. In September 2025, the Company entered into a license agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) for intellectual property supporting this program (see Note 11), and in January 2026 entered into a collaboration and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">option-to-license</div></div> agreement with Medsteer SAS (&#8220;Medsteer&#8221;) to access certain technology, data assets, and technical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">know-how</div> related to drug delivery and physiological monitoring. The Company is advancing development planning, regulatory strategy, and commercial positioning for this program and intends to initiate a Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">proof-of-concept</div></div> study in Australia in the second half of 2026. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In parallel with the advancement of its neuropsychiatric strategy, Cyclerion continues to evaluate opportunities related to its legacy soluble guanylate cyclase (&#8220;sGC&#8221;) stimulator assets, including potential collaborations, monetization opportunities, or other strategic transactions designed to maximize shareholder value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June&#160;3, 2021, Cyclerion entered into a license agreement with Akebia Therapeutics Inc. (&#8220;Akebia&#8221;) relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement. In 2021, Akebia paid a&#160;$3.0 million&#160;upfront payment to the Company upon signing of the license agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;13, 2024, Cyclerion announced that Cyclerion and Akebia have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-negotiated</div> a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator.&#160;Under this new license amendment, Cyclerion will receive&#160;$1.75 million&#160;in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was received in September 2025. In addition, Akebia is responsible for all intellectual property expenses associated with praliciguat. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated (defined as first patient dosed) Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis&#160;(&#8220;FSGS&#8221;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to us and it was received in February 2026. The Company is eligible to receive additional milestone cash payments of up to approximately&#160;$557.5 million&#160;in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher-tiered sales-based royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single-digits</div> to twenty percent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company is currently exploring potential license opportunities for olinciguat. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Zagociguat is a clinical-stage <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-penetrant</div> sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">CNS-targeted</div> sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. On July&#160;28, 2023, the Company sold <div style="display:inline;">z</div>agociguat and CY3018 to Tisento Therapeutics, Inc. (&#8220;Tisento&#8221;), a newly formed private company focused on their development, in exchange for $8.0&#160;million in cash consideration, $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 for the period between signing and closing of the transaction, and 10% of all of Tisento&#8217;s parent&#8217;s outstanding equity securities (&#8220;Tisento Parent&#8221;). </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Cyclerion GmbH, a wholly owned subsidiary, was incorporated in Zug, Switzerland on May&#160;3, 2019. The functional currency is the Swiss franc. Cyclerion GmbH was liquidated and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">de-registered</div> in May 2024. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion Securities Corporation, a wholly owned subsidiary, was incorporated in Massachusetts on November&#160;15, 2019 and was granted securities corporation status in Massachusetts. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Purchase Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2023, the Company entered into a stock purchase agreement with the Company&#8217;s former Chief Executive Officer (the &#8220;CEO&#8221;) pursuant to which he invested $5&#160;million in cash for 225,000 shares of common stock and 351,037 shares of Series A Convertible Preferred Stock of the Company at a price of $8.68 per share (after giving effect to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">1-for-20</div></div> reverse stock split the Company implemented on May&#160;15, 2023). The Series A Convertible Preferred Stock is convertible into shares of the Company&#8217;s common stock on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">one-to-one</div></div> basis. The closing of the equity investment took place on May&#160;19, 2023, and (to comply with Nasdaq listing requirements) the Company&#8217;s shareholders approved such convertibility on July&#160;19, 2023. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2025 Equity Private Placement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On March&#160;21, 2025, the Company entered into a Stock Purchase Agreement (the &#8220;2025 Equity Private Placement&#8221;) for a private placement of 499,998 shares of the Company&#8217;s common stock, at a purchase price of $2.75 per share for total gross proceeds of approximately $1.375&#160;million. The closing of the 2025 Equity Private Placement occurred on March&#160;25, 2025. The Company incurred transaction costs of $0.1&#160;million for the 2025 Equity Private Placement. The Shares issued were not registered under the Securities Act of 1933, as amended, or any state securities laws and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act as a transaction not involving a public offering. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In connection with the 2025 Equity Private Placement, the Company entered into a Registration Rights Agreement with the investors, dated March&#160;21, 2025, pursuant to which the Company agreed to register the resale of the Shares pursuant to a registration statement which was filed with the SEC and declared effective by the SEC on May&#160;15, 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">At-the-Market</div></div> Offering </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On February&#160;4, 2025, the Company filed a Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-3</div> (the &#8220;Shelf&#8221;) with the Securities and Exchange <div style="display:inline;">Commission</div> (the &#8220;SEC&#8221;) in relation to the registration of common stock, preferred </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="margin-top: 1em; margin-bottom: 1em"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">stock, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $25.0&#160;million.&#160;The Registration Statement was declared effective by the SEC in February 2025. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On May&#160;7, 2025, the Company and Guggenheim Securities, LLC (&#8220;Guggenheim Securities&#8221;) entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the &#8220;Shares&#8221;), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company&#8217;s agent, subject to the application of General Instruction I.B.6 of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Form&#160;S-3&#160;(&#8220;Instruction</div> I.B.6&#8221;) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company will pay Guggenheim Securities cash commission of 3.0% of the gross proceeds of the Shares sold under the Sales Agreement. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2025, the Company sold 715,220 shares of its common stock for net proceeds of $2.1&#160;million under the Sales Agreement, after deducting commissions paid to Guggenheim Securities of $0.1&#160;million. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#8217;s financial position and the results of its operations for the fiscal years presented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation and Cyclerion GmbH which was dissolved in May 2024. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At each reporting period, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> Going Concern, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company&#8217;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company&#8217;s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1)&#160;it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2)&#160;it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">205-40,</div> the future receipt of potential funding from future partnerships, equity or debt issuances, certain cost reduction measures and the potential milestones from the Akebia agreement cannot be considered probable at this time because these plans are not entirely within the Company&#8217;s control and/or have not been approved by the Board of Directors as of the date of these consolidated financial statements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company expects that its cash and cash equivalents as of December&#160;31, 2025, will be sufficient to fund operations through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-2026,</div> however the Company will need to obtain additional funding to sustain operations as it expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements <div style="letter-spacing: 0px; top: 0px;display:inline;">have </div>been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Summary of Significant Accounting Policies </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The accounting policies of the Company are set forth in Note 2. <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies</div></div> to the consolidated financial statements contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">New Accounting Pronouncements </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the interim condensed consolidated financial statements, the Company did not adopt any new accounting pronouncements during the three months ended March&#160;31, 2026 that had a material effect on its condensed consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#8217;s condensed consolidated financial statements upon adoption. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">2. Summary of Significant Accounting Policies </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Segment Information </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.&#160;The Company&#8217;s president and chief executive officer, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews the Company&#8217;s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews net loss, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-operating</div> expenses and operating expenses excluding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> stock based compensation expense. </div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Variable Interest Entities </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii)&#160;the parties&#8217; contractual rights and responsibilities pursuant to any contractual agreements and (iii)&#160;which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements at the time that determination is made. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Investment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for an identical or a similar investment of the same issuer, the Company will measure the equity security at fair value as of the date that the observable transaction occurred in accordance with ASC Topic 321, Investments-Equity Securities. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of consolidated financial statements in accordance with U.S. generally accepted <div style="display:inline;">accounting</div> principles (&#8220;GAAP&#8221;) requires the Company&#8217;s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company&#8217;s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period <div style="display:inline;">in</div> which they become known. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and Cash Equivalents </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair Value of Investment Instruments </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1 &#8212; Quoted prices in active markets for identical assets or liabilities. </div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2 &#8212; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </div></div></td></tr></table>  <div style="clear:both;max-height:0pt;"></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign Currency Translation Adjustment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The functional currency of the Company&#8217;s former foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company&#8217;s former foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company&#8217;s former foreign subsidiary was included as a foreign currency translation adjustment in the consolidated statements of stockholders&#8217; equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measurement</div> of intercompany balances are recorded in the consolidated statements of operations. </div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts Receivable </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">significant outstanding invoices. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had <div style="display:inline;">significant</div> write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December&#160;31, 2025 or 2024. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenue </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (&#8220;ASC 606&#8221;), it performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1)&#160;license agreement, (2)&#160;purchase agreement and (3)&#160;option to license agreement which are fully described in Note 11, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">License and Option Agreement</div></div>. </div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Costs </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and Administrative Expenses </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel and outside consultants providing the Company&#8217;s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company&#8217;s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income taxes </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is primarily subject to U.S. Federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;more-likely-than-not&#8221;</div> of being sustained by the applicable tax authority. Tax positions not deemed to meet a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion&#8217;s income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December&#160;31, 2025, and 2024. The Company&#8217;s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December&#160;31, 2025 and 2024, the Company has no accruals for interest or penalties related to income tax matters. </div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent Costs </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $0.3&#160;million and $0.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest and Other Income, Net </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the year ended December&#160;31, 2025 and 2024, interest and other income, net consisted of a $0.1&#160;million and $0.2&#160;million of interest income related to interest generated from the Company&#8217;s cash and cash equivalents balances, respectively. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Subsequent Events </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company considers events or transactions that have occurred after the balance sheet date of December&#160;31, 2025, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K.</div> See Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events</div></div>. </div>  <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December&#160;31, 2025 and 2024, that had a material effect on its consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2025, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2025-05,</div> Financial Instruments&#8212;Credit Losses (Topic 326), which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with its annual report for fiscal 2027. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Adopted Accounting Pronouncements </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with its annual report for fiscal 2025 and interim periods thereafter on a retrospective basis. The adoption did not have a material effect on the consolidated financial statements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09,</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09</div> requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than PBEs, the requirements will be effective for annual periods beginning after December&#160;15, 2025. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December&#160;31, 2025 and continuing to provide the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-ASU</div> disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December&#160;31, 2025, the Company adopted this new ASU and it only impacts the Company&#8217;s income tax disclosures with no impact to its operations, cash flows, or financial condition. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Fair Value of Financial Instruments </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 61%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;March&#160;31,&#160;2026:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the three months ended March&#160;31, 2026 and 2025, there were no transfers between levels. The fair value of the Company&#8217;s cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company believes the carrying amounts of its accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these amounts. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3. Fair Value of Financial Instruments </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December&#160;31, 2025 and December&#160;31, 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 60%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2024:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the year ended December&#160;31, 2025 and 2024, there were no transfers between levels. The fair value of the Company&#8217;s cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company believes the carrying amounts of its accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair value due to the <div style="display:inline;">short-term </div>nature of these amounts. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Other Investment</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Other Investment </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company has determined that the Company&#8217;s investment in Tisento Parent is an equity security, whereby such investment does not give the Company a controlling financial interest or significant influence over the investee. Further, the Company assessed the accounting for its investment in Tisento Parent in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10,</div> Consolidation&#8212;Overall. After determining that no scope exception applies under the guidance </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10-15-12</div></div></div> and ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10-15-17,</div></div></div> the Company concluded that it has a variable interest in Tisento Parent through its investment in Tisento Parent common stock. Tisento Parent does not have sufficient equity to finance its activities without additional subordinated financial support as Tisento Parent is a startup entity in its early stages of raising funds and will require significant capital to advance its programs to commercial stage. Therefore, the Company concluded that its investment in Tisento Parent is a variable interest entity (&#8220;VIE&#8221;) in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">810-10-15-14(a)</div></div></div> and is subject to potential consolidation under the VIE model. However, all activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance are directed by the Tisento Parent board and the board approves decisions by a simple majority. Based on the board composition, the Company determined that no one party has control over the Tisento Parent board and power is not shared because the activities that most significantly affect Tisento Parent and its subsidiary&#8217;s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Tisento Parent board. Therefore, because the Company controls no director of Tisento Parent, the Company cannot unilaterally direct any of the activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance. Accordingly, the Company does not hold a controlling financial interest in Tisento Parent. Because both criteria (a)&#160;and (b) above have to be met for the application of the guidance in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;810-10-25-44B</div></div></div> and criteria (a)&#160;has not been met, the Company concluded that it should not consolidate Tisento under the VIE model. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Accordingly, the Company has accounted for the investment as a financial instrument without a readily determinable fair value. Such investment is recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment is measured at cost less any impairment recorded or adjustments for observable price changes. An impairment loss is recognized in the consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of March&#160;31, 2026, no impairment loss was recognized. The Company considers the cost of the investment to be the maximum exposure to loss as a result of its involvement with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-affiliated</div> entity. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">4. Other Investment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;28, 2023, the Company closed the transactions contemplated by the Asset Purchase Agreement receiving proceeds of $8.0&#160;million as cash consideration, approximately $2.4&#160;million as reimbursement for certain operating expenses related to zagociguat and CY3018 programs for the period between signing and closing of the transaction, and 10% of all of Tisento Parent&#8217;s outstanding equity securities which fair value was determined to be $5.3&#160;million at the time of closing. The Company&#8217;s investment in Tisento Parent does not provide it with significant influence over Tisento Parent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has determined that the Company&#8217;s investment in Tisento Parent is an equity security, whereby such investment does not give the Company a controlling financial interest or significant influence over the investee.&#160;Further, the Company assessed the accounting for its investment in Tisento Parent in accordance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">with&#160;ASC&#160;810-10,&#160;Consolidation&#8212;Overall.&#160;After</div> determining that no scope exception applies under the guidance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;">of&#160;ASC&#160;810-10-15-12&#160;and&#160;ASC&#160;810-10-15-17,&#160;the</div></div></div></div></div></div> Company&#160;concluded that it has a variable interest in Tisento Parent through its investment in Tisento Parent common stock. Tisento Parent does not have sufficient equity to finance its activities without additional subordinated financial support as Tisento Parent is a startup entity in its early stages of raising funds and will require significant capital to advance its programs to commercial stage. Therefore, the Company concluded that its investment in Tisento Parent is a variable interest entity (&#8220;VIE&#8221;) in accordance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">with&#160;ASC&#160;810-10-15-14(a)&#160;and&#160;is</div></div></div> subject to potential consolidation under the VIE model. However, all activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance are directed by the Tisento Parent board and the board approves decisions by a simple majority. Based on the board composition, the Company determined that no one party has control over the Tisento Parent board and power is not shared because the activities that most significantly affect Tisento Parent and its subsidiary&#8217;s economic performance do not require the consent of all of the parties. Rather, all decisions are made by a simple majority vote of the Tisento Parent board. Therefore, because the Company controls no director of Tisento Parent, the Company cannot unilaterally direct any of the activities that most significantly impact Tisento Parent and its subsidiary&#8217;s economic performance. Accordingly, the Company does not hold a controlling financial interest in Tisento Parent. Because both criteria (a)&#160;and (b)&#160;above have to be met for the application of the guidance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in&#160;ASC&#160;810-10-25-44B&#160;and&#160;criteria</div></div></div> (a)&#160;has not been met, The Company concluded that it should not consolidate Tisento under the VIE model. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, the Company has accounted for the investment as a financial instrument without a readily determinable fair value. Such investment is recorded using the measurement alternative for investments without readily determinable fair values, whereby the investment is measured at cost less any impairment recorded or adjustments for observable price changes. An impairment loss is recognized in the consolidated statements of operations and comprehensive loss equal to the amount by which the carrying value exceeds the fair value of the investment. As of December&#160;31, 2025, no impairment loss was recognized. The Company considers the cost of the investment to be the maximum exposure to loss as a result of its involvement with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-affiliated</div> entity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The initial fair value of the investment in Tisento Parent was determined by reference to the risk-adjusted net assets value using the discounted cash flow method. The estimated net assets value of Tisento Parent includes the cash generated/used from the operations and the proceeds from equity financing. Valuations were derived by reference to observable valuation measures for comparable companies or transactions, including weighted <div style="display:inline;">average</div> cost of capital (21% to 23%), terminal decline rate (25% to 75%) and the discount rate referenced by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-year</div> treasury rate of 4.01%. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Accrued Expenses and Other Current Liabilities </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,<br/> 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">984</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">143</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">104</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">38</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,109</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">194</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">5. Accrued Expenses and Other Current Liabilities </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 66%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. Commitments and Contingencies </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Other Funding Commitments </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In the normal course of business, the Company enters into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have any significant cancellation penalties. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-style:italic;display:inline;">Indemnification Obligations </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is <div style="display:inline;">unlimited</div>. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of March&#160;31, 2026 and December&#160;31, 2025. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6. Commitments and Contingencies </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Other Funding Commitments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company may enter into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company&#8217;s option and do not have any significant cancellation penalties. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Guarantees </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company&#8217;s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December&#160;31, 2025 or December&#160;31, 2024. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Separation Benefits </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As part of the separation benefit of the former Chief Financial Officer, the Company paid $0.1&#160;million each in May 2024 and August 2024. The Company has no further separation benefits obligation as of December&#160;31, 2025 and 2024. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation Plans</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. Share-based Compensation Plans </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;) and the 2019 Equity Incentive Plan (&#8220;2019 Equity Plan&#8221;). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options, restricted stock awards (&#8220;RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;). </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Cyclerion also mirrored two of Ironwood Pharmaceuticals, Inc. (&#8220;Ironwood&#8221;) existing plans, the Amended and Restated 2005 Stock Incentive Plan (&#8220;2005 Equity Plan&#8221;) and the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (&#8220;2010 Equity Plan&#8221;). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pro-rata</div> share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table provides share-based compensation reflected in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2026 and 2025 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 79%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">12</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">102</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">114</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Stock options granted under the Company&#8217;s equity plans generally have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ten-year</div> term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of stock option activity for the three months ended March&#160;31, 2026, is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number<br/> of&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Average<br/> Intrinsic<br/> Value (in<br/> thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">297,762</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149.73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled or forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(17,355</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">203.65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">280,407</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">146.39</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">220,760</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">181.20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4.2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">There were no options exercised during the three months ended March&#160;31, 2026 and 2025. As of March&#160;31, 2026, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options is $0.1&#160;million and the weighted average period over which that expense is expected to be recognized is 2.86 years. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has granted certain former employees performance-based options to purchase shares of common stock. These options are subject to performance-based milestone vesting. During the three months ended March&#160;31, 2026 and 2025, there were&#160;no shares that vested as a result of performance milestone achievements. No share-based compensation expense related to these performance-based options was recognized during the three months ended March&#160;31, 2026 and 2025, respectively. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted Stock Awards </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No RSA was granted during the three months ended March&#160;31, 2026 and 2025. The fair value of all RSAs is&#160;based on the market value of the Company&#8217;s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of RSA activity for the three months ended March&#160;31, 2026 is as follows:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number<br/> of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">104,078</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2.57</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(15,024</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2.52</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">89,054</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2.59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of March&#160;31, 2026, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested RSAs is $0.2&#160;million and the weighted average period over which that expense is expected to be recognized is 1.45 years. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">7. Share-based Compensation Plans </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;) and the 2019 Equity Incentive Plan (&#8220;2019 Equity Plan&#8221;). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options, restricted stock awards (&#8220;RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cyclerion also mirrored two of Ironwood Pharmaceuticals, Inc. (&#8220;Ironwood&#8221;) existing plans, the <div style="display:inline;">Amended</div> and Restated 2005 Stock Incentive Plan (&#8220;2005 Equity Plan&#8221;) and the Amended and Restated 2010 Employee, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Director and Consultant Equity Incentive Plan (&#8220;2010 Equity Plan&#8221;). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pro-rata</div> share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table provides share-based compensation reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">534</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">625</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Stock options granted under the Company&#8217;s equity plans generally have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ten-year</div> term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. </div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of stock option activity for the year ended December&#160;31, 2025 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number<br/> of&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Average<br/> Intrinsic<br/> Value (in<br/> thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">335,448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">158.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled or forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(62,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">140.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">297,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">149.73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">232,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">187.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">During the years ended December&#160;31, 2025 and 2024, the Company granted stock options to purchase an aggregate of 25,000 shares and 55,849 shares, respectively, at weighted average grant date fair values per option share of $2.14 and $2.80 respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">There were no options exercised during the year ended December&#160;31, 2025 and 2024. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options held by the Company&#8217;s employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> is $0.1&#160;million and the weighted average period over which that expense is expected to be recognized is 3.03 years. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion during the years ended December&#160;31, 2025 and 2024 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 77%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected option term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected stock price volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">141.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">111.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the years ended December&#160;31, 2025 and 2024, expected volatility was estimated using an average of the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has granted certain employees performance-based options to purchase shares of common stock. These options are subject to performance-based milestone vesting. During the year ended December&#160;31, 2025 and 2024, there were no shares that vested as a result of performance milestone achievements. No&#160;share-based compensation expense related to these performance-based options was recognized during the years ended December&#160;31, 2025, and 2024, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Restricted Stock Awards </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No RSA was granted during the year ended December&#160;31, 2025. The Company granted 65,000&#160;RSAs during the year ended December&#160;31, 2024. The fair value of all RSAs is based on the market value of the Company&#8217;s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of RSA activity for the years ended December&#160;31, 2025 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number<br/> of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">164,174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(60,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">104,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">As of December&#160;31, 2025, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested RSAs held by the Company&#8217;s directors is $0.2&#160;million and the weighted average period over which that expense is expected to be recognized is 1.69 years. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per share</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Loss per share </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(3,177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(1,429</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating net loss per share &#8212; basic and diluted (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4,205</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,556</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(0.76</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(0.56</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company excludes shares of common stock related to Preferred Stock, stock options and RSAs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. The following table sets forth potential shares that were considered anti-dilutive for the three months ended March&#160;31, 2026 and 2025: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">351,037</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">351,037</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">280,407</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">329,458</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">89,054</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149,150</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">720,498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">829,645</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8. Loss per share </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating net loss per share &#8212; basic and diluted (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,518</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company excludes potential shares of common stock related to Preferred Stock, stock options and RSAs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. The following table sets forth potential shares that were considered anti-dilutive for the years ended December&#160;31, 2025 and 2024: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">351,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">351,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">297,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">335,448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">104,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">164,174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">752,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">850,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. Income Taxes </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of net income (loss) before income tax expense are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Domestic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows after adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on a retrospective basis&#160;(in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pretax loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">US Federal Statutory Tax Rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(741</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign tax effects</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-deductible</div> items</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">571</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-16.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-2.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-4.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-18.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s effective tax rate differs from the statutory rate primarily due to continued losses and the maintenance of a full valuation allowance on deferred tax assets, resulting in zero income tax expense for the period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets (liabilities) consist of the following as of December&#160;31, 2025 and 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">57,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">53,281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,383</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Capitalized research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,867</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12,370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangibles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">83,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">83,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(83,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(83,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has evaluated the positive and negative evidence bearing upon the possible realization of its deferred tax assets. Management has considered the Company&#8217;s history of operating losses, in addition to the expected timing of the reversal of existing temporary differences and concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company will not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved at December&#160;31, 2025 and December&#160;31, 2024. Management reevaluates the positive and negative evidence on a quarterly basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The valuation allowance increased by approximately $0.2&#160;million during the year ended December&#160;31, 2025 primarily due to increases in capitalized research and development expenses, net operating losses, tax credit carryforwards and deferred tax assets related to share-based compensation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">At December&#160;31, 2025 and 2024, Cyclerion has federal net operating loss carryforwards of approximately $211&#160;million and $195&#160;million, respectively, to offset future federal taxable income that will be carried forward indefinitely until utilized. As of December&#160;31, 2025 and 2024, Cyclerion had state net operating loss carryforwards of approximately $212&#160;million and $196&#160;million, respectively, to offset future state taxable income, which will begin to expire in 2039 and will continue to expire through 2045. Cyclerion also had tax credit carryforwards of approximately $10.8&#160;million as of December&#160;31, 2025, to offset future federal and state income taxes. Federal credits begin to expire in 2039 and will continue to expire through 2044. State credits begin to expire in 2034 and continue through 2039. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s ability to use its operating loss carryforwards and tax credits to offset future taxable income could be subject to restrictions under Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Internal Revenue Code&#8221;). These potential restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Changes in stock ownership may occur that would create these limitations on the Company&#8217;s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has not as yet conducted a study of its research and development credit carry forwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are <div style="display:inline;">being</div> presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="margin-top: 1em; margin-bottom: 1em"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Upon audit, taxing authorities may challenge all or part of an uncertain income tax position. While Cyclerion has no history of tax audits since its inception on a standalone basis, it may be subject to tax audits by federal and state taxing authorities in the future. Accordingly, Cyclerion regularly assesses the outcome of potential examinations in each of the taxing jurisdictions when determining the adequacy of the amount of unrecognized tax benefit recorded. Cyclerion had no unrecognized tax benefits as of December&#160;31, 2025 and 2024. Cyclerion will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December&#160;31, 2025 and 2024, no interest or penalties have been accrued. There are no current federal or state income tax audits in progress. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Defined Contribution Plan </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company has established a defined contribution <div style="-sec-ix-hidden:hidden167030863;display:inline;">401(k) Savings Plan</div> which allows eligible employees to contribute from 1% to 100% of their compensation, subject to certain IRS limits. The Company&#8217;s contributions to the plan are at the sole discretion of the board of directors. Currently, the Company provides a matching contribution of 75% of the employee&#8217;s contributions, up to $6,000 annually. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Included in compensation expense is de minimis related to the defined contribution 401(k) Savings Plan for the years ended December&#160;31, 2025 and 2024, respectively. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Option Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_LicenseAgreementsTextBlock', window );">License and Option Agreement</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9. Option/License Agreement </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent License Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2025, the Company and MIT entered into a Patent License Agreement (the &#8220;MIT License Agreement&#8221;) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, the Company paid a nominal upfront license fee and patent reimbursement fee. Thereafter, the Company is also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $4.4&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, the Company is required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No expense was recognized for the three months ended March&#160;31, 2026 and 2025 related to the license. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia License Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;3, 2021, the Company and Akebia entered into a License Agreement (the &#8220;Akebia License Agreement&#8221;) relating to the exclusive worldwide license by the Company to Akebia of its rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the &#8220;Products&#8221;). Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Akebia paid a $3.0&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> payment to the Company upon signing of the License Agreement. On December&#160;13, 2024, the Company and Akebia entered into Amendment #1 to the License Agreement (the &#8220;2024 Amendment&#8221;) to the original License Agreement between the parties dated June&#160;3, 2021. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Under the terms of the 2024 Amendment, Akebia paid $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was paid in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of&#160;certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to the Company and which was received in February 2026. Pursuant to the terms of the Akebia License Agreement, as amended, Cyclerion is eligible to receive additional potential future development, regulatory, and commercialization milestone payments up to $557.5&#160;million in total, and Akebia will pay Cyclerion tiered royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit to twenty percent of net sales. Cyclerion&#8217;s obligations to deliver certain drug products have also ceased. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Akebia License Agreement, the Company determined the Akebia License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the Akebia License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined that the grant of license to its patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-evaluate</div> the probability of achievement of the milestones and any related constraints each reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia Material Purchase Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;3, 2025, the Company and Akebia entered into a Material Purchase Agreement (the &#8220;Purchase Agreement&#8221;) relating to the purchase of additional development materials (the &#8220;Additional Development Materials&#8221;) by Akebia for Akebia&#8217;s use pursuant to the Akebia License Agreement. Akebia paid $0.8&#160;million to the Company for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined the Purchase Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the Akebia License Agreement or the Amendment. The delivery of the Additional Development Materials by the Company represents a single performance obligation and consideration was recognized upon delivery. No revenue was recognized under the Purchase Agreement during three months ended March&#160;31, 2026 and 2025. </div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Option Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. The Company recognized revenue of $0.1&#160;million related to the extension fee payment and expense reimbursement for the three months ended March&#160;31, 2025.</div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Medsteer Collaboration Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On January&#160;3, 2026, the Company and the Medsteer, SAS (&#8220;Medsteer&#8221;) entered into a Collaboration and Option Agreement (the &#8220;Collaboration Agreement&#8221;) pursuant to which Medsteer granted to the Company (i)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-exclusive,</div> worldwide, royalty-free, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#8220;Option&#8221;), exercisable at the Company&#8217;s sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">multi-bed</div> or intensive unit wards, or in the context of medical transport. The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an additional two years at the Company&#8217;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer. Under the terms of the Collaboration Agreement, the Company recognized $0.1&#160;million research and development expense during the three months ended March&#160;31, 2026, which is related to the upfront payment paid to Medsteer and other transaction costs. Medsteer will be eligible to receive up to $3.7&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and&#160;royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">11. License and Option Agreement </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent License Agreement </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;19, 2025, the Company and MIT entered into a Patent License Agreement (the &#8220;MIT License Agreement&#8221;) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the MIT License Agreement, the Company paid a nominal upfront license fee and patent reimbursement fee. Thereafter, the Company is also required to pay MIT a nominal annual license maintenance fee. This annual license maintenance fee is nonrefundable; however, the license maintenance fee may be credited to royalties earned during the same calendar year, if any. License maintenance fees paid in excess of royalties due in such calendar year shall not be creditable to amounts due for future years. Under the terms of the MIT License Agreement, MIT will be eligible to receive up to $4.4&#160;million upon the achievement of certain development, regulatory and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products as set forth in the MIT License Agreement. Further, the Company is required to pay MIT varying percentages of income received as consideration for any sublicenses granted pursuant to the MIT License Agreement depending on the circumstances of the sublicense and the development milestones of sublicensed products. The term of the MIT License Agreement will expire in its entirety upon the expiration of certain patent rights for the licensed patents, unless earlier terminated by the parties in accordance with the terms of the MIT License Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company recorded research and development expense of $0.1&#160;million for the year ended December&#160;31, 2025, which consisted of upfront fees, patent reimbursement fees and transaction costs related to the license. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia License Agreement </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On June&#160;3, 2021, the Company and Akebia entered into a License Agreement (the &#8220;Akebia License Agreement&#8221;) relating to the exclusive worldwide license by the Company to Akebia of its rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the &#8220;Products&#8221;). Pursuant to the Akebia License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Akebia paid a $3.0&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">up-front</div> payment to the Company upon signing of the License Agreement. On December&#160;13, 2024, the Company and Akebia entered into Amendment #1 to the License Agreement (the &#8220;2024 Amendment&#8221;) to the original License Agreement between the parties dated June&#160;3, 2021. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the 2024 Amendment, Akebia paid $1.75&#160;million in amendment payments, of which $1.25&#160;million was paid in December 2024 and an additional payment of $0.5&#160;million was paid in September 2025. In addition, Akebia has agreed to assume control of the preparation, filing, prosecution and maintenance of certain Cyclerion patents, and the expenses associated therewith, at an earlier date than as originally agreed between the parties. The parties have agreed to the reduction of certain development milestones and the increase of certain royalty rates on net sales and sublicense income. On December&#160;1, 2025, Akebia publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (&#8220;FSGS&#8221;) using praliciguat. Pursuant to the terms of amendment, upon initiation of a Phase 2 clinical trial in the U.S. for a product, a $1.0&#160;million development milestone payment would be due to the Company and which was received in February 2026. Pursuant to the terms of the Akebia License Agreement, as amended, Cyclerion is eligible to receive additional potential future development, regulatory, and commercialization milestone payments up to $557.5&#160;million in total, and Akebia will pay Cyclerion tiered royalties ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">mid-single</div> digit to twenty percent of net sales. Cyclerion&#8217;s obligations to deliver certain drug products have also ceased. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pursuant to the Akebia License Agreement, the Company determined the Akebia License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the Akebia License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined that the grant of license to its patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-evaluate</div> the probability of achievement of the milestones and any related constraints each reporting period. </div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Akebia Material Purchase Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On September&#160;3, 2025, the Company and Akebia entered into a Material Purchase Agreement (the &#8220;Purchase Agreement&#8221;) relating to the purchase of additional development materials (the &#8220;Additional Development Materials&#8221;) by Akebia for Akebia&#8217;s use pursuant to the Akebia License Agreement. Akebia paid $0.8&#160;million to the Company for the purchase during the year ended December&#160;31, 2025 and the Additional Development Materials were delivered to Akebia as of December&#160;31, 2025. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company determined the Purchase Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the Akebia License Agreement or the Amendment. The delivery of the Additional Development Materials by the Company represents a single performance obligation and consideration was recognized upon delivery. The Company recognized revenue of $0.8&#160;million during the year ended December&#160;31, 2025. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Option Agreement </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On July&#160;22, 2024, the Company entered into an Option to License Agreement (the &#8220;Option Agreement&#8221;) with a third party (the &#8220;Optionee&#8221;), pursuant to which the Optionee had an option (the &#8220;Option&#8221;) to enter into an exclusive license to olinciguat for human therapeutics, subject to certain carveouts. Under the terms of the Option Agreement, the Optionee paid the Company an Option fee of $150,000 in August 2024 and subsequent fees totaling $80,000 to extend the term of the Option Agreement. The Optionee originally could exercise the Option on or before March&#160;20, 2025, which option period was ultimately extended through August&#160;22, 2025. Thereafter, the parties had an additional 60 days to negotiate the terms of a definitive license agreement. The parties were unable to agree upon the terms of a license agreement and the Company provided notice on October&#160;23, 2025 that it was terminating the Option Agreement. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">10. Subsequent Events </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">As described above, on April&#160;1, 2026, the Company entered into the Merger Agreement (which was subsequently amended on April&#160;17, 2026) with Korsana, a privately held biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, pursuant to which Korsana will become a wholly owned subsidiary of the Company and the Company will operate under the name Korsana Biosciences, Inc. following the merger. The Company anticipates that the merger will close in the third quarter of 2026, subject to certain closing conditions, along with the concurrent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Korsana&#160;pre-closing&#160;financing.</div> Following the merger, the current business of Korsana will become the primary business of the Company. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12. Subsequent Events </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">On January&#160;6, 2026, the Company sold 405,000 shares of common stock under the Sales Agreement for net proceeds of approximately $0.8&#160;million. The Company exhausted all sales under the 2025 Shelf. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;3, 2026, the Company and the Medsteer, SAS (&#8220;Medsteer&#8221;) entered into a Collaboration and Option Agreement (the &#8220;Collaboration Agreement&#8221;) pursuant to which Medsteer granted to the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(i)&#160;a&#160;non-exclusive,&#160;worldwide,</div> royalty-free, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii)&#160;an exclusive option (the &#8220;Option&#8221;), exercisable at the Company&#8217;s sole discretion, to obtain an exclusive, worldwide, royalty-bearing, sublicensable license of certain of Medsteer&#8217;s technology, software and intellectual property to develop or commercialize licensed products in any field of use except for sedation regulation for patients undergoing major surgery, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">in&#160;multi-bed&#160;or</div> intensive unit wards, or in the context of medical transport. The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an addition two years at the Company&#8217;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Under the terms of the Collaboration Agreement, the Company will pay to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $3.7&#160;million upon the achievement of certain development, regulatory and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products, subject to certain adjustments as set forth in the Collaboration Agreement. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The condensed consolidated financial statements and the related disclosures are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. Additionally, certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2025, which was filed with the SEC on March&#160;30, 2026. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company&#8217;s financial position and the results of its operations for the fiscal years presented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion Securities Corporation and Cyclerion GmbH which was dissolved in May 2024. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Segment Information </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.&#160;The Company&#8217;s president and chief executive officer, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews the Company&#8217;s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews net loss, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-operating</div> expenses and operating expenses excluding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> stock based compensation expense. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Variable Interest Entities </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company reviews each legal entity in which it has a financial interest to determine whether or not the entity is a variable interest entity or VIE. If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that VIE based on a number of factors, including (i)&#160;which party has the power to direct the activities that most significantly affect the VIE&#8217;s economic performance, (ii)&#160;the parties&#8217; contractual rights and responsibilities pursuant to any contractual agreements and (iii)&#160;which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines that it is the primary beneficiary of a VIE, it consolidates the financial statements of the VIE into its consolidated financial statements at the time that determination is made. On a quarterly basis, the Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, the Company deconsolidates the VIE in the period that the determination is made. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Investment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company accounts for investments in equity securities without a readily determinable fair value at cost, minus impairment. If the Company identifies observable price changes in orderly transactions for an identical or a similar investment of the same issuer, the Company will measure the equity security at fair value as of the date that the observable transaction occurred in accordance with ASC Topic 321, Investments-Equity Securities. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The preparation of consolidated financial statements in accordance with U.S. generally accepted <div style="display:inline;">accounting</div> principles (&#8220;GAAP&#8221;) requires the Company&#8217;s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company&#8217;s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, fair value determination of other investment, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period <div style="display:inline;">in</div> which they become known. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash and Cash Equivalents </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Investment Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair Value of Investment Instruments </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1 &#8212; Quoted prices in active markets for identical assets or liabilities. </div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2 &#8212; Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div></div></td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; text-align: left; vertical-align: top;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="text-align: left; vertical-align: top;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </div></div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign Currency Translation Adjustment </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The functional currency of the Company&#8217;s former foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company&#8217;s former foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company&#8217;s former foreign subsidiary was included as a foreign currency translation adjustment in the consolidated statements of stockholders&#8217; equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measurement</div> of intercompany balances are recorded in the consolidated statements of operations. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accounts Receivable </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">significant outstanding invoices. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had <div style="display:inline;">significant</div> write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December&#160;31, 2025 or 2024. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Revenue </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div> (&#8220;ASC 606&#8221;), it performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1)&#160;license agreement, (2)&#160;purchase agreement and (3)&#160;option to license agreement which are fully described in Note 11, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">License and Option Agreement</div></div>. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Costs </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and Administrative Expenses </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel and outside consultants providing the Company&#8217;s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company&#8217;s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Income taxes </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company is primarily subject to U.S. Federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;more-likely-than-not&#8221;</div> of being sustained by the applicable tax authority. Tax positions not deemed to meet a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion&#8217;s income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December&#160;31, 2025, and 2024. The Company&#8217;s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December&#160;31, 2025 and 2024, the Company has no accruals for interest or penalties related to income tax matters. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent Costs </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $0.3&#160;million and $0.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock', window );">Interest and Other Income, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Interest and Other Income, Net </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">For the year ended December&#160;31, 2025 and 2024, interest and other income, net consisted of a $0.1&#160;million and $0.2&#160;million of interest income related to interest generated from the Company&#8217;s cash and cash equivalents balances, respectively. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Subsequent Events </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company considers events or transactions that have occurred after the balance sheet date of December&#160;31, 2025, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K.</div> See Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events</div></div>. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued/Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">New Accounting Pronouncements </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the interim condensed consolidated financial statements, the Company did not adopt any new accounting pronouncements during the three months ended March&#160;31, 2026 that had a material effect on its condensed consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#8217;s condensed consolidated financial statements upon adoption. </div></div><span></span>
</td>
<td class="text"> <div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December&#160;31, 2025 and 2024, that had a material effect on its consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2025, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2025-05,</div> Financial Instruments&#8212;Credit Losses (Topic 326), which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with its annual report for fiscal 2027. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Recently Adopted Accounting Pronouncements </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-07,</div> Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with its annual report for fiscal 2025 and interim periods thereafter on a retrospective basis. The adoption did not have a material effect on the consolidated financial statements. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09,</div> Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which focuses on the rate reconciliation and income taxes paid. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2023-09</div> requires a public business entity (PBE) to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. For PBEs, the new standard is effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. For entities other than PBEs, the requirements will be effective for annual periods beginning after December&#160;15, 2025. An entity may apply the amendments in this ASU prospectively by providing the revised disclosures for the period ending December&#160;31, 2025 and continuing to provide the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-ASU</div> disclosures for the prior periods, or may apply the amendments retrospectively by providing the revised disclosures for all period presented. As of December&#160;31, 2025, the Company adopted this new ASU and it only impacts the Company&#8217;s income tax disclosures with no impact to its operations, cash flows, or financial condition. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company&#8217;s consolidated financial statements upon adoption. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest and other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for related party accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of March&#160;31, 2026 and December&#160;31, 2025 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 61%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;March&#160;31,&#160;2026:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">2,610</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom;"><div style="display:inline;">3,072</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The Company&#8217;s cash equivalents are generally classified within Level&#160;1 of the fair value hierarchy. The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December&#160;31, 2025 and December&#160;31, 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 60%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2025:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2024:</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 11pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="text-align: right; vertical-align: bottom;">3,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 70%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">March&#160;31,<br/> 2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">December&#160;31,<br/> 2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">984</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">143</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">104</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">38</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">1,109</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">194</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 66%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Professional fees</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Employee compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">13</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Accrued expenses and other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table provides share-based compensation reflected in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2026 and 2025 (in thousands): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 79%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">12</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">102</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">114</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The following table provides share-based compensation reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 82%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">412</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">534</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">625</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of stock option activity for the three months ended March&#160;31, 2026, is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number<br/> of&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Average<br/> Intrinsic<br/> Value (in<br/> thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">297,762</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149.73</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled or forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(17,355</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">203.65</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">280,407</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">146.39</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4.9</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">220,760</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">181.20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4.2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of stock option activity for the year ended December&#160;31, 2025 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 56%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number<br/> of&#160;Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Average<br/> Intrinsic<br/> Value (in<br/> thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">335,448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">158.98</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Cancelled or forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(62,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">140.44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Outstanding as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">297,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">149.73</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Exercisable at December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">232,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">187.20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">4.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used in estimating the fair value of the stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion during the years ended December&#160;31, 2025 and 2024 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 77%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.79</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected option term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">5.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Expected stock price volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">141.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">111.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of RSA activity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of RSA activity for the three months ended March&#160;31, 2026 is as follows:</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Number<br/> of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">104,078</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2.57</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(15,024</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2.52</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#8212;&#8194;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of March&#160;31, 2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">89,054</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2.59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">A summary of RSA activity for the years ended December&#160;31, 2025 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Number<br/> of&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Weighted&#160;Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">164,174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(60,096</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Unvested as of December&#160;31, 2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">104,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2.57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(3,177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(1,429</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating net loss per share &#8212; basic and diluted (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">4,205</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">2,556</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(0.76</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">(0.56</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Weighted average shares used in calculating net loss per share &#8212; basic and diluted (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">2,518</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1.11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of earnings per share diluted by common class</a></td>
<td class="text">The following table sets forth potential shares that were considered anti-dilutive for the three months ended March&#160;31, 2026 and 2025: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">351,037</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">351,037</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">280,407</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">329,458</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">89,054</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">149,150</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">720,498</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">829,645</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">The following table sets forth potential shares that were considered anti-dilutive for the years ended December&#160;31, 2025 and 2024: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 74%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">351,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">351,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Stock Options</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">297,762</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">335,448</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">RSAs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">104,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">164,174</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">752,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">850,659</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Net Income Loss Before Income Tax Expense</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The components of net income (loss) before income tax expense are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Domestic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of reconciliation of income taxes computed using the U.S. federal statutory rate</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows after adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09</div> on a retrospective basis&#160;(in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 65%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Percent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Pretax loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,528</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(3,058</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">US Federal Statutory Tax Rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(741</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(642</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Foreign tax effects</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-deductible</div> items</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">571</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-16.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-2.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-4.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">-18.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of deferred tax assets (liabilities)</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets (liabilities) consist of the following as of December&#160;31, 2025 and 2024 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse; border-spacing: 0;">
<tr>
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bolder;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">57,618</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">53,281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,385</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">10,383</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">6,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">7,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Capitalized research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">8,867</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">12,370</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Intangibles</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">20</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">83,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">83,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(83,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">(83,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Net deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="text-align: right; vertical-align: bottom; white-space: nowrap;">&#8212;&#8194;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2026 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 06, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 07, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 04, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_OptionFee', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_SubsequentFees', window );">Subsequent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cash consideration transferrred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,209,000<span></span>
</td>
<td class="nump">$ 1,538,000<span></span>
</td>
<td class="nump">$ 7,047,000<span></span>
</td>
<td class="nump">$ 5,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity investment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="nump">$ 1,375,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice', window );">Maximum amount of aggregate initial offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock', window );">Cash commission of gross proceeds of sales of common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_CyclerionLicenseAgreementMember', window );">Cyclerion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_UpFrontPaymentReceived', window );">Up front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_RemainingAdditionalUpFrontPayment', window );">Remaining additional up front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaLicenseAgreementMember', window );">Akebia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_PaymentOfCashMilestone', window );">Additional milestone cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_UpFrontPaymentReceived', window );">Up front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_DevelopmentMilestonePayment', window );">Development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001755237_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice', window );">Maximum amount of aggregate initial offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Commissions paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_UpFrontPaymentReceived', window );">Up front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember', window );">2025 Equity Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_TransactionCostsSaleOfTransferredAssets', window );">Transaction costs associated with sale of transferred assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember', window );">2025 Equity Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock share purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ck0001755237_KorsanaBiosciencesIncMember', window );">Korsana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_NetCashOnCapitalization', window );">Net cash on capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ck0001755237_KorsanaBiosciencesIncMember', window );">Korsana | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Number of common shares</a></td>
<td class="nump">1.1009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Aggregate purchase price</a></td>
<td class="nump">$ 380,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ck0001755237_KorsanaBiosciencesIncMember', window );">Korsana | Series A Preferred Stock | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ck0001755237_KorsanaBiosciencesIncMember', window );">Korsana | Series Seed Preferred Stock | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ck0001755237_KorsanaBiosciencesIncMember', window );">Korsana | Common Stock | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ck0001755237_CyclerionTherapeuticsIncMember', window );">Cyclerion | Common Stock | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ck0001755237_TisentoTherapeuticsHoldingsIncMember', window );">Tisento Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Outstanding equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash commission percentage of gross proceeds of sales of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument convertible threshold percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_DevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_DevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of Aggregate initial offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_NetCashOnCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash on capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_NetCashOnCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_OptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_OptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_PaymentOfCashMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of cash milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_PaymentOfCashMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_RemainingAdditionalUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining additional up front payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_RemainingAdditionalUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_SubsequentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>subsequent fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_SubsequentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_TransactionCostsSaleOfTransferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs sale of transferred assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_TransactionCostsSaleOfTransferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_UpFrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up Front Payment Received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_UpFrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ck0001755237_CyclerionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ck0001755237_CyclerionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001755237_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001755237_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ck0001755237_KorsanaBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ck0001755237_KorsanaBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ck0001755237_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ck0001755237_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ck0001755237_CyclerionTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ck0001755237_CyclerionTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ck0001755237_TisentoTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ck0001755237_TisentoTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ck0001755237_InterestAndOtherIncomeMember', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income generated from cash and cash equivalents balances</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Legal and other fees</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ck0001755237_InterestAndOtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ck0001755237_InterestAndOtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax, penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 2,610<span></span>
</td>
<td class="nump">$ 3,072<span></span>
</td>
<td class="nump">$ 3,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="nump">3,072<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="nump">3,072<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 2,610<span></span>
</td>
<td class="nump">$ 3,072<span></span>
</td>
<td class="nump">$ 3,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Investment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems', window );"><strong>Investment Holdings, Other than Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cash consideration transferrred</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 3,209<span></span>
</td>
<td class="nump">$ 1,538<span></span>
</td>
<td class="nump">$ 7,047<span></span>
</td>
<td class="nump">$ 5,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount', window );">Impairment loss on other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ck0001755237_TisentoTherapeuticsHoldingsIncMember', window );">Tisento Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems', window );"><strong>Investment Holdings, Other than Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Outstanding equity securities</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1', window );">Fair value of outstanding equity securities</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=ck0001755237_TreasuryRateMember', window );">Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems', window );"><strong>Investment Holdings, Other than Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Net assets percentage</a></td>
<td class="nump">4.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Weighted average investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems', window );"><strong>Investment Holdings, Other than Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Net assets percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Terminal decline rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems', window );"><strong>Investment Holdings, Other than Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Net assets percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Weighted average investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems', window );"><strong>Investment Holdings, Other than Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Net assets percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Terminal decline rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems', window );"><strong>Investment Holdings, Other than Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Net assets percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale securities, continuous unrealized loss position, fair value 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment owned to net assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ck0001755237_TisentoTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ck0001755237_TisentoTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ck0001755237_TreasuryRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ck0001755237_TreasuryRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ck0001755237_WeightedAverageInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ck0001755237_WeightedAverageInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ck0001755237_TerminalDeclineRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ck0001755237_TerminalDeclineRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,109<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Payment to former chief financial officer</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Separation benefits obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Liabilities recorded for indemnification provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period to recognize the expense</a></td>
<td class="text">1 year 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period to recognize the expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_ShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period to recognize the expense</a></td>
<td class="text">2 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per option share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">55,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_ShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_ShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Schedule of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Schedule of Stock Option Activity (Details) - Employee Stock Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of the year (in shares)</a></td>
<td class="nump">297,762<span></span>
</td>
<td class="nump">335,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">55,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(17,355)<span></span>
</td>
<td class="num">(62,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of the year (in shares)</a></td>
<td class="nump">280,407<span></span>
</td>
<td class="nump">297,762<span></span>
</td>
<td class="nump">335,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">220,760<span></span>
</td>
<td class="nump">232,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of the year (in dollars per share)</a></td>
<td class="nump">$ 149.73<span></span>
</td>
<td class="nump">$ 158.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">203.65<span></span>
</td>
<td class="nump">140.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December&#160;31, 2025</a></td>
<td class="nump">146.39<span></span>
</td>
<td class="nump">149.73<span></span>
</td>
<td class="nump">$ 158.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 181.2<span></span>
</td>
<td class="nump">$ 187.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">3.79%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">141.07%<span></span>
</td>
<td class="nump">111.97%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation Plans - Summary of RSA activity (Details) - Restricted Stock Awards - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at the beginning of the period (in shares)</a></td>
<td class="nump">104,078<span></span>
</td>
<td class="nump">164,174<span></span>
</td>
<td class="nump">164,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(15,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,096)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested the end of the period (in shares)</a></td>
<td class="nump">89,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,078<span></span>
</td>
<td class="nump">164,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Schedule of Basic and Diluted Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,177)<span></span>
</td>
<td class="num">$ (1,429)<span></span>
</td>
<td class="num">$ (3,528)<span></span>
</td>
<td class="num">$ (3,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in calculating net loss per share - basic</a></td>
<td class="nump">4,205<span></span>
</td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">3,181<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in calculating net loss per share - Diluted</a></td>
<td class="nump">4,205<span></span>
</td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">3,181<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - Basic</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - Diluted</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_EarningsPerShareBasicAndDiluted1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings per share basic and diluted1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_EarningsPerShareBasicAndDiluted1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Schedule Of Earnings Per Share Diluted By Common Class (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits', window );">Dilutive securities, effect on basic earnings per share, options and restrictive stock units</a></td>
<td class="nump">$ 720,498<span></span>
</td>
<td class="nump">$ 829,645<span></span>
</td>
<td class="nump">$ 752,877<span></span>
</td>
<td class="nump">$ 850,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the calculation of diluted loss per share</a></td>
<td class="nump">351,037<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
<td class="nump">351,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits', window );">Dilutive securities, effect on basic earnings per share, options and restrictive stock units</a></td>
<td class="nump">$ 280,407<span></span>
</td>
<td class="nump">$ 329,458<span></span>
</td>
<td class="nump">$ 297,762<span></span>
</td>
<td class="nump">$ 335,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits', window );">Dilutive securities, effect on basic earnings per share, options and restrictive stock units</a></td>
<td class="nump">$ 89,054<span></span>
</td>
<td class="nump">$ 149,150<span></span>
</td>
<td class="nump">$ 104,078<span></span>
</td>
<td class="nump">$ 164,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Net Income Loss Before Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (3,528)<span></span>
</td>
<td class="num">$ (3,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (3,528)<span></span>
</td>
<td class="num">$ (3,058)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="nump">$ 566,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 211,000,000<span></span>
</td>
<td class="nump">195,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInformationPertainingToIncomeTaxes', window );">Income tax credit expiration description</a></td>
<td class="text">Federal credits begin to expire in 2039 and will continue to expire through 2044. State credits begin to expire in 2034 and continue through 2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 212,000,000<span></span>
</td>
<td class="nump">$ 196,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInformationPertainingToIncomeTaxes', window );">Income tax credit expiration description</a></td>
<td class="text">begin to expire in 2039 and will continue to expire through 2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInformationPertainingToIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of events or transactions pertaining to income taxes classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInformationPertainingToIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pretax loss</a></td>
<td class="num">$ (3,528)<span></span>
</td>
<td class="num">$ (3,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">US Federal Statutory Tax Rate</a></td>
<td class="num">(741)<span></span>
</td>
<td class="num">(642)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US Federal Statutory Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects, Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items, Percent</a></td>
<td class="nump">16.20%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits, Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Percent</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income Tax Expense (Benefit), Percent, Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets (liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 57,618<span></span>
</td>
<td class="nump">$ 53,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">10,385<span></span>
</td>
<td class="nump">10,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">7,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development</a></td>
<td class="nump">8,867<span></span>
</td>
<td class="nump">12,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">83,390<span></span>
</td>
<td class="nump">83,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(83,390)<span></span>
</td>
<td class="num">(83,156)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTypeExtensibleList', window );">401 (k) Savings Plan</a></td>
<td class="text">Qualified Plan [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contribution (as a percent of employee's contributions)</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum', window );">Maximum amount of employer matching contribution</a></td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percent of compensation eligible employees may elect to contribute</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percent of compensation eligible employees may elect to contribute</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount per employee of the employer's matching contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTypeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of defined contribution plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTypeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Option Agreement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2026</div></th>
<th class="th"><div>Sep. 19, 2025</div></th>
<th class="th"><div>Jul. 22, 2024</div></th>
<th class="th"><div>Jun. 03, 2021</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 730,000<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 959,000<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_OptionFee', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_OptionAdditionalFee', window );">Option additional fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_UpFrontPaymentReceived', window );">Up front payment received</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_PatentLicenseAgreementMember', window );">Patent License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaResearchLicenseAgreementMember', window );">Akebia Research License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_UpFrontPaymentReceived', window );">Up front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember', window );">Amendment Akebia Research License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_UpFrontPaymentReceived', window );">Up front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_AdditionalUpFrontPayment', window );">Additional up front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_CommercializationMilestonePayments', window );">Commercialization milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember', window );">Amendment Akebia Research License Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_DevelopmentMilestonePayment', window );">Development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaMaterialPurchaseAgreementMember', window );">Akebia Material Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment of additional development materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ck0001755237_MedsteerCollaborationAgreementMember', window );">Medsteer Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_AdditionalUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional up front payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_AdditionalUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_CommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercialization milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_CommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_DevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_DevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_OptionAdditionalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option additional fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_OptionAdditionalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_OptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_OptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_UpFrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up Front Payment Received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_UpFrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ck0001755237_PatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ck0001755237_PatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaResearchLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaResearchLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaMaterialPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ck0001755237_AkebiaMaterialPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ck0001755237_MedsteerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ck0001755237_MedsteerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 06, 2026</div></th>
<th class="th"><div>Jan. 03, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,330,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,925,314<span></span>
</td>
<td class="nump">2,710,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,375<span></span>
</td>
<td class="nump">$ 1,375<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock purchase agreement</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_DebtInstrumentsOptionsExercisePeriod', window );">Exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may exercise the Option at any time until the earlier of the second anniversary of the effective date of the Collaboration Agreement, which period may be extended for an addition two years at the Company&#8217;s option and upon payment of a nominal fee or by mutual agreement of the Company and Medsteer.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001755237_UpFrontPaymentReceived', window );">Up front payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_DebtInstrumentsOptionsExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instruments, options, exercise period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_DebtInstrumentsOptionsExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001755237_UpFrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up Front Payment Received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001755237_UpFrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001755237_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>172</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Other Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/OtherInvestment</Role>
      <ShortName>Other Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Share-based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/ShareBasedCompensationPlans</Role>
      <ShortName>Share-based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/LossPerShare</Role>
      <ShortName>Loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - License and Option Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/LicenseAndOptionAgreement</Role>
      <ShortName>License and Option Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Share-based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/ShareBasedCompensationPlansTables</Role>
      <ShortName>Share-based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/ShareBasedCompensationPlans</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/LossPerShareTables</Role>
      <ShortName>Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/LossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/NatureOfBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/NatureOfBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Other Investment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails</Role>
      <ShortName>Other Investment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Share-based Compensation Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails</Role>
      <ShortName>Share-based Compensation Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/ShareBasedCompensationPlansTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Share-based Compensation Plans - Schedule of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation Plans - Schedule of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Share-based Compensation Plans - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Share-based Compensation Plans - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails</Role>
      <ShortName>Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Share-based Compensation Plans - Summary of RSA activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails</Role>
      <ShortName>Share-based Compensation Plans - Summary of RSA activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Loss per share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Loss per share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Loss per share - Schedule Of Earnings Per Share Diluted By Common Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails</Role>
      <ShortName>Loss per share - Schedule Of Earnings Per Share Diluted By Common Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Income Taxes - Schedule of Components of Net Income Loss Before Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Net Income Loss Before Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Income Taxes - Reconciliation of income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Income Taxes - Deferred tax assets (liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets (liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/DefinedContributionPlanDetails</Role>
      <ShortName>Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/DefinedContributionPlan</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - License and Option Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails</Role>
      <ShortName>License and Option Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d111069ds4a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Subsequent Events (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclerion.com/role/SubsequentEvents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ck0001755237-20260331.xsd</File>
    <File doctype="S-4/A" isDefinitelyFs="true" isUsgaap="true" original="d111069ds4a.htm">d111069ds4a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g111069g00a01.jpg</File>
    <File>g111069g00a02.jpg</File>
    <File>g111069g00a03.jpg</File>
    <File>g111069g00a04.jpg</File>
    <File>g111069g00a05.jpg</File>
    <File>g111069g00a06.jpg</File>
    <File>g111069g00a07.jpg</File>
    <File>g111069g00a08.jpg</File>
    <File>g111069g00a09.jpg</File>
    <File>g111069g00a10.jpg</File>
    <File>g111069g00a11.jpg</File>
    <File>g111069g00a12.jpg</File>
    <File>g111069g00a13.jpg</File>
    <File>g111069g00a14.jpg</File>
    <File>g111069g00a15.jpg</File>
    <File>g111069g00a16.jpg</File>
    <File>g111069g55a01.jpg</File>
    <File>g111069g55a02.jpg</File>
    <File>g111069g55a03.jpg</File>
    <File>g111069g55z04.jpg</File>
    <File>g111069g99a01.jpg</File>
    <File>g111069g99a02.jpg</File>
    <File>g111069g99a03.jpg</File>
    <File>g111069g99a04.jpg</File>
    <File>g111069g99a05.jpg</File>
    <File>g111069g99a06.jpg</File>
    <File>g111069g99a07.jpg</File>
    <File>g111069g99a08.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="630">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>145
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d111069ds4a.htm": {
   "nsprefix": "ck0001755237",
   "nsuri": "http://www.cyclerion.com/20260331",
   "dts": {
    "schema": {
     "local": [
      "ck0001755237-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "inline": {
     "local": [
      "d111069ds4a.htm"
     ]
    }
   },
   "keyStandard": 201,
   "keyCustom": 32,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 21,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 3,
    "http://fasb.org/us-gaap/2025": 1
   },
   "contextCount": 172,
   "entityCount": 1,
   "segmentCount": 45,
   "elementCount": 400,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 630,
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.cyclerion.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "longName": "1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "1006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cyclerion.com/role/NatureOfBusiness",
     "longName": "1007 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cyclerion.com/role/FairValueOfFinancialInstruments",
     "longName": "1009 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cyclerion.com/role/OtherInvestment",
     "longName": "1010 - Disclosure - Other Investment",
     "shortName": "Other Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "1011 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cyclerion.com/role/CommitmentsAndContingencies",
     "longName": "1012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cyclerion.com/role/ShareBasedCompensationPlans",
     "longName": "1013 - Disclosure - Share-based Compensation Plans",
     "shortName": "Share-based Compensation Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cyclerion.com/role/LossPerShare",
     "longName": "1014 - Disclosure - Loss per share",
     "shortName": "Loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cyclerion.com/role/IncomeTaxes",
     "longName": "1015 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cyclerion.com/role/DefinedContributionPlan",
     "longName": "1016 - Disclosure - Defined Contribution Plan",
     "shortName": "Defined Contribution Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cyclerion.com/role/LicenseAndOptionAgreement",
     "longName": "1017 - Disclosure - License and Option Agreement",
     "shortName": "License and Option Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "ck0001755237:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "ck0001755237:LicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cyclerion.com/role/SubsequentEvents",
     "longName": "1018 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1019 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsTables",
     "longName": "1020 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "1021 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cyclerion.com/role/ShareBasedCompensationPlansTables",
     "longName": "1022 - Disclosure - Share-based Compensation Plans (Tables)",
     "shortName": "Share-based Compensation Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cyclerion.com/role/LossPerShareTables",
     "longName": "1023 - Disclosure - Loss per share (Tables)",
     "shortName": "Loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cyclerion.com/role/IncomeTaxesTables",
     "longName": "1024 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cyclerion.com/role/NatureOfBusinessDetails",
     "longName": "1025 - Disclosure - Nature of Business (Details)",
     "shortName": "Nature of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P08_01_2024To08_31_2024",
      "name": "ck0001755237:OptionFee",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P08_01_2024To08_31_2024",
      "name": "ck0001755237:SubsequentFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails",
     "longName": "1026 - Disclosure - Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details)",
     "shortName": "Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis",
      "name": "us-gaap:InterestAndOtherIncome",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "ck0001755237:InterestAndOtherIncomePolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025_InterestAndOtherIncomeMemberusgaapIncomeStatementLocationAxis",
      "name": "us-gaap:InterestAndOtherIncome",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "ck0001755237:InterestAndOtherIncomePolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails",
     "longName": "1027 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)",
     "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2025",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2025",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails",
     "longName": "1028 - Disclosure - Fair Value of Financial Instruments (Details)",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2026_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails",
     "longName": "1029 - Disclosure - Other Investment - Additional Information (Details)",
     "shortName": "Other Investment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P07_28_2023To07_28_2023",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "1030 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "1031 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P08_01_2024To08_31_2024",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P08_01_2024To08_31_2024",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
     "longName": "1032 - Disclosure - Share-based Compensation Plans (Details)",
     "shortName": "Share-based Compensation Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails",
     "longName": "1033 - Disclosure - Share-based Compensation Plans - Schedule of Share-based Compensation Expense (Details)",
     "shortName": "Share-based Compensation Plans - Schedule of Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails",
     "longName": "1034 - Disclosure - Share-based Compensation Plans - Schedule of Stock Option Activity (Details)",
     "shortName": "Share-based Compensation Plans - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2025_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails",
     "longName": "1035 - Disclosure - Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)",
     "shortName": "Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails",
     "longName": "1036 - Disclosure - Share-based Compensation Plans - Summary of RSA activity (Details)",
     "shortName": "Share-based Compensation Plans - Summary of RSA activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2025_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails",
     "longName": "1037 - Disclosure - Loss per share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)",
     "shortName": "Loss per share - Schedule of Basic and Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails",
     "longName": "1038 - Disclosure - Loss per share - Schedule Of Earnings Per Share Diluted By Common Class (Details)",
     "shortName": "Loss per share - Schedule Of Earnings Per Share Diluted By Common Class (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails",
     "longName": "1039 - Disclosure - Income Taxes - Schedule of Components of Net Income Loss Before Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Components of Net Income Loss Before Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "1040 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2025",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails",
     "longName": "1041 - Disclosure - Income Taxes - Reconciliation of income taxes (Details)",
     "shortName": "Income Taxes - Reconciliation of income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails",
     "longName": "1042 - Disclosure - Income Taxes - Deferred tax assets (liabilities) (Details)",
     "shortName": "Income Taxes - Deferred tax assets (liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2025",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2025",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cyclerion.com/role/DefinedContributionPlanDetails",
     "longName": "1043 - Disclosure - Defined Contribution Plan (Details)",
     "shortName": "Defined Contribution Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To12_31_2025",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
     "longName": "1044 - Disclosure - License and Option Agreement - Additional Information (Details)",
     "shortName": "License and Option Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "P01_01_2026To03_31_2026",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_22_2024To07_22_2024",
      "name": "ck0001755237:OptionAdditionalFee",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1045 - Disclosure - Subsequent Events (Additional Information) (Details)",
     "shortName": "Subsequent Events (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "PAsOn03_31_2026",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn01_06_2026_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d111069ds4a.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r706"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses And Other Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of accrued expenses and other liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ck0001755237_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Current",
        "terseLabel": "Accrued research and development costs",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r798",
      "r799",
      "r800",
      "r801",
      "r884",
      "r943"
     ]
    },
    "ck0001755237_AdditionalUpFrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AdditionalUpFrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Up Front Payment",
        "terseLabel": "Additional up front payment",
        "documentation": "Additional up front payment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense related to issuance of stock options and restricted stock awards",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_AkebiaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AkebiaLicenseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Akebia License Agreement [Member]",
        "terseLabel": "Akebia",
        "documentation": "Akebia license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_AkebiaMaterialPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AkebiaMaterialPurchaseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Akebia Material Purchase Agreement [Member]",
        "terseLabel": "Akebia Material Purchase Agreement [Member]",
        "documentation": "Akebia Material Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_AkebiaResearchLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AkebiaResearchLicenseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Akebia Research License Agreement [Member]",
        "terseLabel": "Akebia Research License Agreement [Member]",
        "documentation": "Akebia Research License Agreement Member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r332",
      "r333"
     ]
    },
    "ck0001755237_AmendmentAkebiaResearchLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AmendmentAkebiaResearchLicenseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Akebia Research License Agreement [Member]",
        "terseLabel": "Amendment Akebia Research License Agreement [Member]",
        "documentation": "Amendment Akebia Research License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units",
        "terseLabel": "Dilutive securities, effect on basic earnings per share, options and restrictive stock units",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs)."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from the calculation of diluted loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r13",
      "r743",
      "r744",
      "r745"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Cash consideration transferrred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r77",
      "r94",
      "r120",
      "r122",
      "r123",
      "r159",
      "r167",
      "r179",
      "r180",
      "r190",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r385",
      "r390",
      "r438",
      "r474",
      "r475",
      "r483",
      "r567",
      "r639",
      "r640",
      "r648",
      "r706",
      "r711",
      "r712",
      "r726",
      "r832",
      "r833",
      "r897"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r101",
      "r120",
      "r122",
      "r123",
      "r190",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r385",
      "r390",
      "r438",
      "r706",
      "r832",
      "r833",
      "r897"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Securities, Continuous Unrealized Loss Position, Fair Value 1",
        "terseLabel": "Fair value of outstanding equity securities",
        "documentation": "Available-for-sale securities, continuous unrealized loss position, fair value 1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "us-gaap_AwardTypeAxis",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r788"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r93",
      "r627"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r885",
      "r886"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r55",
      "r117"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r55"
     ]
    },
    "ck0001755237_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Commission Percentage Of Gross Proceeds Of Sales Of Common Stock",
        "terseLabel": "Cash commission of gross proceeds of sales of common stock, percentage",
        "documentation": "Cash commission percentage of gross proceeds of sales of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r96",
      "r97",
      "r98",
      "r120",
      "r123",
      "r149",
      "r150",
      "r152",
      "r154",
      "r161",
      "r162",
      "r190",
      "r215",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r251",
      "r253",
      "r254",
      "r257",
      "r258",
      "r260",
      "r438",
      "r522",
      "r523",
      "r524",
      "r525",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r555",
      "r575",
      "r593",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r730",
      "r791",
      "r793",
      "r803"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Nature of Business",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r161",
      "r245",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r401",
      "r522",
      "r523",
      "r524",
      "r525",
      "r649",
      "r730",
      "r789",
      "r791"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ck0001755237_CommercializationMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "CommercializationMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercialization Milestone Payments",
        "terseLabel": "Commercialization milestone payments",
        "documentation": "Commercialization milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r70",
      "r484",
      "r554"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r208",
      "r209",
      "r618",
      "r823",
      "r828"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r722",
      "r723",
      "r798",
      "r799",
      "r801",
      "r884",
      "r937",
      "r943"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r555"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r555",
      "r573",
      "r943",
      "r944"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, no par value, 400,000,000 shares authorized at March 31, 2026 and December 31, 2025; 4,330,314 and 3,925,314 shares issued at March 31, 2026 and December 31, 2025, respectively; 4,241,260 and 3,821,236 shares outstanding at March 31, 2026 and December 31, 2025, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r243",
      "r250",
      "r486",
      "r706"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r66",
      "r103",
      "r105",
      "r111",
      "r472",
      "r494"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r128",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r458",
      "r477",
      "r619",
      "r831",
      "r834",
      "r835"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r128",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r458",
      "r477",
      "r619",
      "r831",
      "r834",
      "r835"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r32",
      "r33"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditDerivativesByContractTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditDerivativesByContractTypeAxis",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Derivatives Contract Type [Axis]",
        "terseLabel": "Credit Derivatives Contract Type",
        "documentation": "Information by major type of contract of credit derivatives."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ]
    },
    "us-gaap_CreditDerivativesContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditDerivativesContractTypeDomain",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Derivatives Contract Type [Domain]",
        "terseLabel": "Credit Derivatives Contract Type",
        "documentation": "Represents major types of credit derivative contracts."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ]
    },
    "ck0001755237_CyclerionLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "CyclerionLicenseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cyclerion License Agreement [Member]",
        "terseLabel": "Cyclerion",
        "documentation": "Cyclerion license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_CyclerionTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "CyclerionTherapeuticsIncMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cyclerion Therapeutics Inc [Member]",
        "terseLabel": "Cyclerion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r37",
      "r38",
      "r68",
      "r69",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r705",
      "r789",
      "r790",
      "r792",
      "r797",
      "r824",
      "r825",
      "r826",
      "r893",
      "r894",
      "r906"
     ]
    },
    "ck0001755237_DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfOutstandingShares",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Convertible Threshold Percentage of Outstanding Shares",
        "terseLabel": "Percentage of outstanding shares",
        "documentation": "Debt instrument convertible threshold percentage of outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r705",
      "r789",
      "r790",
      "r792",
      "r797",
      "r824",
      "r825",
      "r826",
      "r893",
      "r894",
      "r906"
     ]
    },
    "ck0001755237_DebtInstrumentsOptionsExercisePeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "DebtInstrumentsOptionsExercisePeriod",
     "presentation": [
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments, Options, Exercise Period",
        "terseLabel": "Exercise period",
        "documentation": "Debt instruments, options, exercise period."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Capitalized Research And Development Costs",
        "terseLabel": "Capitalized research and development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Benefit Obligation",
        "terseLabel": "Separation benefits obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r286"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ck0001755237_DefinedContributionPlanEmployerMatchingContributionMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "DefinedContributionPlanEmployerMatchingContributionMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Employer Matching Contribution Maximum",
        "terseLabel": "Maximum amount of employer matching contribution",
        "documentation": "The maximum amount per employee of the employer's matching contributions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Matching contribution (as a percent of employee's contributions)",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percent of compensation eligible employees may elect to contribute",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_DefinedContributionPlanTypeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanTypeExtensibleList",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Type [Extensible Enumeration]",
        "terseLabel": "401 (k) Savings Plan",
        "documentation": "Indicates type of defined contribution plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ck0001755237_DevelopmentMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "DevelopmentMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Milestone Payment",
        "terseLabel": "Development milestone payment",
        "documentation": "Development milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r939"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r298",
      "r327",
      "r328",
      "r330",
      "r658"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r112",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r147",
      "r149",
      "r152",
      "r153",
      "r154",
      "r158",
      "r241",
      "r331",
      "r379",
      "r382",
      "r413",
      "r414",
      "r473",
      "r495",
      "r634"
     ]
    },
    "ck0001755237_EarningsPerShareBasicAndDiluted1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "EarningsPerShareBasicAndDiluted1Abstract",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic and Diluted1 [Abstract]",
        "terseLabel": "Denominator:",
        "documentation": "Earnings per share basic and diluted1."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosureAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic and Diluted Other Disclosure [Abstract]",
        "terseLabel": "Weighted average shares used in calculating:",
        "documentation": "Earnings per share basic and diluted other disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r112",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r149",
      "r152",
      "r153",
      "r154",
      "r158",
      "r241",
      "r331",
      "r379",
      "r382",
      "r413",
      "r414",
      "r473",
      "r495",
      "r634"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r154"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r155",
      "r156",
      "r157"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Income Tax Expense (Benefit), Percent, Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r660"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "US Federal Statutory Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r344",
      "r369",
      "r660"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in valuation allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r660",
      "r789",
      "r796",
      "r870"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax effects, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r347",
      "r660",
      "r789",
      "r796",
      "r870"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r660"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "negatedLabel": "Non-deductible items, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r789",
      "r796",
      "r870"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r660"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "verboseLabel": "Tax credits, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r351",
      "r789",
      "r796",
      "r870"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected period to recognize the expense",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "definitionGuidance": "Employee Stock Option",
        "verboseLabel": "Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r84",
      "r86",
      "r87",
      "r107",
      "r108",
      "r109",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r160",
      "r191",
      "r192",
      "r204",
      "r240",
      "r261",
      "r331",
      "r367",
      "r368",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r453",
      "r455",
      "r493",
      "r509",
      "r510",
      "r511",
      "r530",
      "r593"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r375",
      "r438",
      "r732",
      "r733",
      "r734",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Outstanding equity securities",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r438"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity investment in cash",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r416",
      "r434",
      "r435",
      "r436",
      "r437",
      "r480",
      "r481",
      "r698",
      "r713",
      "r715",
      "r887",
      "r888",
      "r889"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount",
        "terseLabel": "Impairment loss on other investments",
        "documentation": "Amount of cumulative impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r427",
      "r698"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r427",
      "r698"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r287",
      "r288",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r426",
      "r427",
      "r429",
      "r435",
      "r462",
      "r463",
      "r464",
      "r624",
      "r644",
      "r645",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r698",
      "r700",
      "r704"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r420",
      "r698",
      "r888",
      "r890"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r422",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r471",
      "r698",
      "r701"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r274",
      "r279",
      "r287",
      "r417",
      "r427",
      "r435",
      "r462",
      "r624",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r698",
      "r704"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r420",
      "r698",
      "r888",
      "r890"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r287",
      "r288",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r426",
      "r427",
      "r429",
      "r435",
      "r462",
      "r463",
      "r464",
      "r624",
      "r644",
      "r645",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r698",
      "r700",
      "r704"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Investment Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r469",
      "r470",
      "r516",
      "r622",
      "r626",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r200",
      "r201",
      "r202",
      "r203",
      "r469",
      "r622",
      "r626",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r516",
      "r622",
      "r626",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation Adjustment",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ck0001755237_GainLossFromSettlementOfAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "GainLossFromSettlementOfAccountPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Loss from Settlement of Account Payable",
        "terseLabel": "Gain from settlement of account payable",
        "negatedLabel": "Gain from settlement of account payable",
        "documentation": "Gain (loss) from settlement of account payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainOnBusinessInterruptionInsuranceRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainOnBusinessInterruptionInsuranceRecovery",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on Business Interruption Insurance Recovery",
        "terseLabel": "Gain from insurance recovery",
        "documentation": "The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r577"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r124",
      "r343"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails",
      "http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total",
        "terseLabel": "Pretax loss",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r72",
      "r76",
      "r474",
      "r476",
      "r490",
      "r630",
      "r632",
      "r633",
      "r636",
      "r639",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesScheduleOfComponentsOfNetIncomeLossBeforeIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r124",
      "r343"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails",
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r392",
      "r393",
      "r394",
      "r395",
      "r421",
      "r423",
      "r428",
      "r439",
      "r440",
      "r441",
      "r506",
      "r508",
      "r578",
      "r622",
      "r624",
      "r661",
      "r662",
      "r696",
      "r697",
      "r699",
      "r704",
      "r879",
      "r880",
      "r908"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails",
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r392",
      "r393",
      "r394",
      "r395",
      "r421",
      "r423",
      "r428",
      "r439",
      "r440",
      "r441",
      "r506",
      "r508",
      "r578",
      "r622",
      "r624",
      "r661",
      "r662",
      "r696",
      "r697",
      "r699",
      "r704",
      "r879",
      "r880",
      "r908"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r344",
      "r345",
      "r356",
      "r364",
      "r660",
      "r873"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r344",
      "r345",
      "r356",
      "r364",
      "r660",
      "r873"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r125",
      "r338",
      "r344",
      "r352",
      "r353",
      "r354",
      "r358",
      "r363",
      "r370",
      "r372",
      "r373",
      "r374",
      "r479",
      "r515",
      "r527",
      "r660"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Income tax, penalties and interest accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r81",
      "r120",
      "r143",
      "r144",
      "r159",
      "r170",
      "r180",
      "r342",
      "r344",
      "r371",
      "r497",
      "r630",
      "r632",
      "r633",
      "r660"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r340",
      "r341",
      "r358",
      "r359",
      "r362",
      "r366",
      "r521"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "verboseLabel": "Deferred tax assets, valuation allowance",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r660",
      "r870"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax effects",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r347",
      "r660",
      "r870"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "US Federal Statutory Tax Rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r660"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r870"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r351",
      "r870"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ck0001755237_IncreaseDecreaseInAccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Accrued Research And Development",
        "terseLabel": "Accrued research and development costs",
        "documentation": "The increase (decrease) during the reporting period in accrued research and development expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest income generated from cash and cash equivalents balances",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_InterestAndOtherIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "InterestAndOtherIncomeMember",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest And Other Income [Member]",
        "terseLabel": "Interest and other income, net",
        "documentation": "Represents information pertaining to transactions recorded in interest and other income."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_InterestAndOtherIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "InterestAndOtherIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest And Other Income Policy Policy [Text Block]",
        "terseLabel": "Interest and Other Income, Net",
        "documentation": "Disclosure of accounting policy for interest and other income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentHoldingsOtherThanSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentHoldingsOtherThanSecuritiesLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Holdings, Other than Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Owned, Net Assets, Percentage",
        "terseLabel": "Net assets percentage",
        "documentation": "Percentage of investment owned to net assets."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r597",
      "r603",
      "r604",
      "r605",
      "r607",
      "r718",
      "r938"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investment",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r517",
      "r518",
      "r519",
      "r520",
      "r598",
      "r599"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment [Text Block]",
        "terseLabel": "Other Investment",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r738",
      "r813"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_IssuanceCostsPaidForPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "IssuanceCostsPaidForPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Costs Paid for Private Placement",
        "terseLabel": "Issuance costs paid for private placement",
        "documentation": "Issuance costs paid for private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_KorsanaBiosciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "KorsanaBiosciencesIncMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Korsana Biosciences Inc [Member]",
        "terseLabel": "Korsana"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r71",
      "r488",
      "r706",
      "r711",
      "r712",
      "r789",
      "r794",
      "r814",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r92",
      "r120",
      "r122",
      "r123",
      "r190",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r386",
      "r390",
      "r391",
      "r438",
      "r706",
      "r832",
      "r897",
      "r898"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_LicenseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "LicenseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Abstract]",
        "documentation": "License agreement abstract."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "terseLabel": "Revenue from license agreement",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_LicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "LicenseAgreementsTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Text Block]",
        "terseLabel": "License and Option Agreement",
        "documentation": "The entire disclosure for license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cyclerion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual",
        "terseLabel": "Liabilities recorded for indemnification provisions",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r731"
     ]
    },
    "ck0001755237_MaximumAmountOfAggregateInitialOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "MaximumAmountOfAggregateInitialOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Amount Of Aggregate Initial Offering Price",
        "verboseLabel": "Maximum amount of aggregate initial offering price",
        "documentation": "Maximum amount of Aggregate initial offering price."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r211",
      "r212",
      "r213",
      "r214",
      "r292",
      "r322",
      "r323",
      "r324",
      "r334",
      "r420",
      "r467",
      "r505",
      "r507",
      "r514",
      "r546",
      "r547",
      "r596",
      "r600",
      "r601",
      "r602",
      "r606",
      "r614",
      "r615",
      "r616",
      "r617",
      "r620",
      "r621",
      "r642",
      "r649",
      "r657",
      "r661",
      "r663",
      "r664",
      "r700",
      "r701",
      "r702",
      "r703",
      "r708",
      "r836",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "ck0001755237_MedsteerCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "MedsteerCollaborationAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medsteer Collaboration Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r211",
      "r212",
      "r213",
      "r214",
      "r292",
      "r322",
      "r323",
      "r324",
      "r334",
      "r420",
      "r467",
      "r505",
      "r507",
      "r514",
      "r546",
      "r547",
      "r596",
      "r600",
      "r601",
      "r602",
      "r606",
      "r614",
      "r615",
      "r616",
      "r617",
      "r620",
      "r621",
      "r642",
      "r649",
      "r657",
      "r661",
      "r663",
      "r664",
      "r700",
      "r701",
      "r702",
      "r708",
      "r836",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840"
     ]
    },
    "ck0001755237_NetCashOnCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "NetCashOnCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash On Capitalization",
        "terseLabel": "Net cash on capitalization",
        "documentation": "Net cash on capitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r57",
      "r73",
      "r87",
      "r90",
      "r102",
      "r104",
      "r109",
      "r120",
      "r122",
      "r123",
      "r127",
      "r132",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r151",
      "r190",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r241",
      "r244",
      "r247",
      "r252",
      "r331",
      "r379",
      "r382",
      "r414",
      "r438",
      "r492",
      "r574",
      "r591",
      "r592",
      "r630",
      "r632",
      "r633",
      "r724",
      "r832"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued/Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of RSA activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ck0001755237_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Not Found During Migration Deprecated Concept Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]",
        "documentation": "Not Found During Migration Deprecated Concept Defined Contribution Pension And Other Postretirement Plans Disclosure Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total cost and expenses",
        "terseLabel": "Operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Cost and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r630",
      "r633",
      "r636",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income Taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "ck0001755237_OptionAdditionalFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "OptionAdditionalFee",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Additional Fee",
        "terseLabel": "Option additional fee",
        "documentation": "Option additional fee."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_OptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "OptionAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreement [Member]",
        "terseLabel": "Revenue from option agreement",
        "documentation": "Option Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_OptionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "OptionFee",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Fee",
        "terseLabel": "Option fee",
        "documentation": "Option fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r706"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment loss",
        "verboseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r493"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInformationPertainingToIncomeTaxes": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherInformationPertainingToIncomeTaxes",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information Pertaining to Income Taxes",
        "terseLabel": "Income tax credit expiration description",
        "documentation": "Description of events or transactions pertaining to income taxes classified as other."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_OtherLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Long-Term Investments",
        "terseLabel": "Other investment",
        "documentation": "Amount of long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482",
      "r740"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "Interest income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "ck0001755237_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r38"
     ]
    },
    "ck0001755237_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs",
        "documentation": "Disclosure of accounting policy for patent costs."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_PatentLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "PatentLicenseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent License Agreement [Member]",
        "terseLabel": "Patent License Agreement [Member]",
        "documentation": "Patent license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "terseLabel": "Patents",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "ck0001755237_PaymentOfCashMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "PaymentOfCashMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Cash Milestone",
        "terseLabel": "Additional milestone cash payment",
        "documentation": "Payment of cash milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Commissions paid",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Payment of additional development materials",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r272",
      "r273",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290",
      "r291",
      "r656"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock options",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Number of common shares",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r717",
      "r720",
      "r721",
      "r722",
      "r723",
      "r937",
      "r943"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r253"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r555"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r253"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shared outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r555",
      "r573",
      "r943",
      "r944"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at March 31, 2026 and December 31, 2025",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r243",
      "r249",
      "r485",
      "r706"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r193",
      "r194",
      "r628"
     ]
    },
    "ck0001755237_ProceedsFromAtTheOffer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "ProceedsFromAtTheOffer",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from at the Offer",
        "terseLabel": "Proceeds from ATM",
        "documentation": "Proceeds from at the offer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from private placement",
        "verboseLabel": "Proceeds from stock purchase agreement",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r468",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r625",
      "r629",
      "r632",
      "r633",
      "r650",
      "r651",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r736",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r829",
      "r830",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r468",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r625",
      "r629",
      "r632",
      "r633",
      "r650",
      "r651",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r736",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r829",
      "r830",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Legal and other fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r639",
      "r724",
      "r941",
      "r942"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r90",
      "r102",
      "r104",
      "r114",
      "r120",
      "r122",
      "r123",
      "r127",
      "r132",
      "r140",
      "r143",
      "r144",
      "r190",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r241",
      "r331",
      "r379",
      "r382",
      "r384",
      "r387",
      "r388",
      "r414",
      "r438",
      "r474",
      "r476",
      "r491",
      "r529",
      "r574",
      "r591",
      "r592",
      "r693",
      "r694",
      "r725",
      "r745",
      "r832"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r454",
      "r478",
      "r489",
      "r706"
     ]
    },
    "ck0001755237_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Revenue from purchase agreement",
        "documentation": "Purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r211",
      "r212",
      "r213",
      "r214",
      "r272",
      "r292",
      "r322",
      "r323",
      "r324",
      "r330",
      "r334",
      "r420",
      "r465",
      "r466",
      "r467",
      "r505",
      "r507",
      "r514",
      "r546",
      "r547",
      "r596",
      "r600",
      "r601",
      "r602",
      "r606",
      "r614",
      "r615",
      "r616",
      "r617",
      "r620",
      "r621",
      "r642",
      "r649",
      "r657",
      "r661",
      "r663",
      "r664",
      "r700",
      "r701",
      "r702",
      "r703",
      "r708",
      "r718",
      "r827",
      "r836",
      "r888",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cyclerion.com/role/DefinedContributionPlanDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r211",
      "r212",
      "r213",
      "r214",
      "r272",
      "r292",
      "r322",
      "r323",
      "r324",
      "r330",
      "r334",
      "r420",
      "r465",
      "r466",
      "r467",
      "r505",
      "r507",
      "r514",
      "r546",
      "r547",
      "r596",
      "r600",
      "r601",
      "r602",
      "r606",
      "r614",
      "r615",
      "r616",
      "r617",
      "r620",
      "r621",
      "r642",
      "r649",
      "r657",
      "r661",
      "r663",
      "r664",
      "r700",
      "r701",
      "r702",
      "r703",
      "r708",
      "r718",
      "r827",
      "r836",
      "r888",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "ck0001755237_RelatedPartyAccountsReceivablePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "RelatedPartyAccountsReceivablePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Accounts Receivable Policy Policy [Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for related party accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r126",
      "r127",
      "r456",
      "r457",
      "r896"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r126",
      "r127",
      "r896"
     ]
    },
    "ck0001755237_ReleaseOfForeignCurrencyTranslationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "ReleaseOfForeignCurrencyTranslationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Release Of Foreign Currency Translation Adjustment",
        "terseLabel": "Release of foreign currency translation adjustment upon liquidation of a subsidiary",
        "documentation": "Release of foreign currency translation adjustment.."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_RemainingAdditionalUpFrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "RemainingAdditionalUpFrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Additional Up Front Payment",
        "terseLabel": "Remaining additional up front payment",
        "documentation": "Remaining additional up front payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r622",
      "r630",
      "r631",
      "r639",
      "r905"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cyclerion.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted Stock Awards",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r62",
      "r487",
      "r512",
      "r513",
      "r526",
      "r556",
      "r706"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deflicit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r86",
      "r87",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r191",
      "r192",
      "r204",
      "r240",
      "r331",
      "r367",
      "r368",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r402",
      "r404",
      "r405",
      "r407",
      "r412",
      "r451",
      "r453",
      "r509",
      "r511",
      "r530",
      "r943"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r623"
     ]
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Total revenues",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r110",
      "r120",
      "r122",
      "r123",
      "r159",
      "r168",
      "r169",
      "r178",
      "r180",
      "r182",
      "r183",
      "r184",
      "r190",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r438",
      "r474",
      "r476",
      "r639",
      "r695",
      "r711",
      "r712",
      "r832"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]",
        "documentation": "Sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r145",
      "r293",
      "r731"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of deferred tax assets (liabilities)",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Common Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r154"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of earnings per share diluted by common class",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r802"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of reconciliation of income taxes computed using the U.S. federal statutory rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r660",
      "r870"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r375",
      "r438",
      "r732",
      "r733",
      "r734",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r120",
      "r123",
      "r187",
      "r188",
      "r189",
      "r190",
      "r438"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r200",
      "r201",
      "r202",
      "r203",
      "r469",
      "r622",
      "r626",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components of Net Income Loss Before Income Tax Expense",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r795"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r330"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumptions used in estimating the fair value of the stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r60",
      "r61",
      "r62",
      "r96",
      "r97",
      "r98",
      "r161",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r401",
      "r522",
      "r523",
      "r524",
      "r525",
      "r649",
      "r730",
      "r789",
      "r791"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r181",
      "r183",
      "r637",
      "r638",
      "r641"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742",
      "r837",
      "r838"
     ]
    },
    "ck0001755237_SeriesSeedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "SeriesSeedPreferredStockMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Seed Preferred Stock [Member]",
        "terseLabel": "Series Seed Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_SeriesaConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "SeriesaConvertiblePreferredStockMember",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "SeriesA convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Payment to former chief financial officer",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Unvested at the beginning of the period (in shares)",
        "periodEndLabel": "Unvested the end of the period (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Unvested at the beginning of the period (in dollars per share)",
        "periodEndLabel": "Unvested restricted common stock at the end of the period (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted average risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfShareBasedCompensationExpenseDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Plans",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per option share",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Outstanding at beginning of the year (in shares)",
        "periodEndLabel": "Outstanding at end of the year (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Outstanding at beginning of the year (in dollars per share)",
        "periodEndLabel": "Outstanding as of December\u00a031, 2025",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails",
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansSummaryOfRsaActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ck0001755237_ShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "ShareBasedCompensationExpense",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Expense",
        "verboseLabel": "Share based compensation expense",
        "documentation": "Share based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of shares vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "terseLabel": "Common stock shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock share purchase price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r96",
      "r97",
      "r98",
      "r120",
      "r123",
      "r149",
      "r150",
      "r152",
      "r154",
      "r161",
      "r162",
      "r190",
      "r215",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r251",
      "r253",
      "r254",
      "r257",
      "r258",
      "r260",
      "r438",
      "r522",
      "r523",
      "r524",
      "r525",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r555",
      "r575",
      "r593",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r730",
      "r791",
      "r793",
      "r803"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r45",
      "r46",
      "r84",
      "r86",
      "r87",
      "r107",
      "r108",
      "r109",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r144",
      "r160",
      "r191",
      "r192",
      "r204",
      "r240",
      "r261",
      "r331",
      "r367",
      "r368",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r453",
      "r455",
      "r493",
      "r509",
      "r510",
      "r511",
      "r530",
      "r593"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r160",
      "r242",
      "r243",
      "r245",
      "r248",
      "r453",
      "r468",
      "r517",
      "r531",
      "r542",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r632",
      "r633",
      "r719",
      "r940"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r145",
      "r293",
      "r731",
      "r735"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r160",
      "r185",
      "r242",
      "r243",
      "r245",
      "r248",
      "r453",
      "r468",
      "r517",
      "r531",
      "r542",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r593",
      "r632",
      "r633",
      "r719",
      "r940"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Aggregate purchase price",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostShare",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Issuance of Common Stock Net of Issuance Cost, Share",
        "terseLabel": "Issuance of common stock - private placement, net of issuance cost (in share)",
        "documentation": "Stock issued during period issuance of common stock net of nssuance cost, share."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockNetOfIssuanceCostValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Issuance of Common Stock Net of Issuance Cost, Value",
        "terseLabel": "Issuance of common stock - private placement, net of issuance cost",
        "documentation": "Stock issued during period issuance of common stock net of issuance cost, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock - ATM (in shares)",
        "verboseLabel": "Sale of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r42",
      "r62",
      "r522",
      "r593",
      "r609"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock awards (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r42",
      "r62"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r42",
      "r62",
      "r307"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock - ATM",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r42",
      "r62",
      "r530",
      "r593",
      "r609",
      "r725"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r58",
      "r557",
      "r573",
      "r594",
      "r595",
      "r706",
      "r726",
      "r789",
      "r793",
      "r794",
      "r814",
      "r892",
      "r943"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r34",
      "r84",
      "r85",
      "r86",
      "r87",
      "r108",
      "r129",
      "r130",
      "r131",
      "r133",
      "r140",
      "r142",
      "r191",
      "r192",
      "r204",
      "r240",
      "r261",
      "r331",
      "r367",
      "r368",
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r412",
      "r444",
      "r445",
      "r449",
      "r452",
      "r455",
      "r510",
      "r511",
      "r528",
      "r557",
      "r573",
      "r594",
      "r595",
      "r613",
      "r711",
      "r712",
      "r725",
      "r789",
      "r793",
      "r794",
      "r814",
      "r892",
      "r943"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cyclerion.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r461"
     ]
    },
    "ck0001755237_SubsequentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "SubsequentFees",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Fees",
        "terseLabel": "Subsequent fees",
        "documentation": "subsequent fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "ck0001755237_TerminalDeclineRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "TerminalDeclineRateMember",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Terminal Decline Rate [Member]",
        "terseLabel": "Terminal decline rate",
        "documentation": "Terminal decline rate."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_TisentoTherapeuticsHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "TisentoTherapeuticsHoldingsIncMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tisento Therapeutics Holdings Inc [Member]",
        "terseLabel": "Tisento Therapeutics Holdings Inc",
        "documentation": "Tisento therapeutics holdings inc."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r895"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_TransactionCostsSaleOfTransferredAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "TransactionCostsSaleOfTransferredAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Costs Sale of Transferred Assets",
        "verboseLabel": "Transaction costs associated with sale of transferred assets",
        "documentation": "Transaction costs sale of transferred assets."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_TreasuryRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "TreasuryRateMember",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Rate [Member]",
        "terseLabel": "Treasury rate",
        "documentation": "Treasury rate."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001755237_TwoThousandTwentyFiveEquityPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "TwoThousandTwentyFiveEquityPrivatePlacementMember",
     "presentation": [
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Five Equity Private Placement [Member]",
        "terseLabel": "2025 Equity Private Placement",
        "documentation": "Two thousand twenty five equity private placement member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r357",
      "r659"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cyclerion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r659"
     ]
    },
    "ck0001755237_UpFrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "UpFrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.cyclerion.com/role/LicenseAndOptionAgreementAdditionalInformationDetails",
      "http://www.cyclerion.com/role/NatureOfBusinessDetails",
      "http://www.cyclerion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Up Front Payment Received",
        "terseLabel": "Up front payment received",
        "documentation": "Up Front Payment Received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cyclerion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r163",
      "r164",
      "r165",
      "r166",
      "r474",
      "r476",
      "r635"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r661",
      "r664",
      "r700",
      "r889"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r661",
      "r664",
      "r700",
      "r889"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.cyclerion.com/role/ShareBasedCompensationPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "ck0001755237_WeightedAverageInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cyclerion.com/20260331",
     "localname": "WeightedAverageInvestmentMember",
     "presentation": [
      "http://www.cyclerion.com/role/OtherInvestmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Investment [Member]",
        "terseLabel": "Weighted average investment",
        "documentation": "Weighted average investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares",
        "verboseLabel": "Weighted average shares used in calculating net loss per share - Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r154"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.cyclerion.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cyclerion.com/role/LossPerShareScheduleOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic shares",
        "terseLabel": "Weighted average shares used in calculating net loss per share - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r154"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483605/220-30-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4L",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4L"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
